<?xml version="1.0" encoding="UTF-8"?>
<DataElementsList>
  <DataElement num="1">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>36</PUBLICID>
    <LONGNAME>RT Administered Total Dose</LONGNAME>
    <PREFERREDNAME>RT_ADM_TTL_DOSE</PREFERREDNAME>
    <PREFERREDDEFINITION>a numeric value for the total dose volume of radiation therapy given to a patient.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013998</PublicId>
      <PreferredName>RT_ADM</PreferredName>
      <PreferredDefinition>information related to radiation therapy administered to a patient.</PreferredDefinition>
      <LongName>Radiation Therapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015807</PublicId>
      <PreferredName>RT_ADM_TTL_DOSE</PreferredName>
      <PreferredDefinition>the numeric value for the total dose volume of radiation therapy.</PreferredDefinition>
      <LongName>RT Administered Total Dose</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>Gray</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207921</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Total Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Dose of Radiation Thera</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Dose of Radiation Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RT Total Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>2-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on Melanoma Template form: (Gy)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instructions on Gyn Treatment forms (for each RT site): to Location 1.  
to Location 2.  
to Location 3.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total cGy administered
</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation Therapy Total Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose of radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total daily dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose of radiation therapy to Node</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose of radiation therapy to Primary</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total Dose (eGy)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose to regional nodes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose to internal mammary nodes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, total dose:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Breast-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation Total Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total dose (cGy)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811789</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811827</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811829</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Local-Reg Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SPOREs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Radiation </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000158</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Albert Einstein Medical Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke 500</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812580</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 02452</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812584</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 03058</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812585</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 04251</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AE_104_085</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UNMC 284-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811942</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000209</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000609</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2976812</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>GO Trial</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GO Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2976834</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3590028</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Initial Treatment and Followup Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3590029</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3590028</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Enrollment Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3590030</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1201</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104994</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1010</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0534</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171063</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0815</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4631580</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Exceptional Responder CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exceptional Responder CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5242953</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Bladder Ca Advocacy Network</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC-GENOME</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5242975</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506112</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Breast</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation Therapy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6643185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLGSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5655940</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Initial Treatment and Followup Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000268</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Enrollment Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000269</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_DOSE</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0002602</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0002969</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0003281</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0058475</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0061458</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0062962</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0064988</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065260</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPOREs</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_ADM_TTL_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>RT_ADM_TTL_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_ADM_TTL_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_ADM_TTL_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_ADM_TTL_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PR_PRDOSE</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="2">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>834</PUBLICID>
    <LONGNAME>Specimen Lab Submitted Date</LONGNAME>
    <PREFERREDNAME>SPEC_LAB_SUBM_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date the specimen is submitted to the lab.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014070</PublicId>
      <PreferredName>SPEC_LAB_SUBM</PreferredName>
      <PreferredDefinition>information related to the submission of a sample of blood, urine, or other substance from the body for laboratory analysis.</PreferredDefinition>
      <LongName>Specimen Laboratory Procedure Submission</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2728371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294:C25695</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Submitted</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25695</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2203811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date specimen submitted</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date specimen submitted</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date Specimen Shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date biology specimens shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date biology specimens submitted:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specimen Submit Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of tissue submission</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date Specimen Shipped:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date shipped:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG- 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date specimen shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, date of submission to Adaptive by Nationwide:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of submission to Adaptive by Nationwide:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Ship Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shipping Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date Shipped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3298557</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3298577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3152820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NOS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811864</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neuroblastoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811874</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment trials</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2017-09-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0250</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPEC_LAB_SUBM_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_LAB_SUBM_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_LAB_SUBM_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_LAB_SUBM_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BE_BEDAT_SHIPPED</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="3">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>905</PUBLICID>
    <LONGNAME>Patient Medical Record Number</LONGNAME>
    <PREFERREDNAME>PT_MED_REC_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The unique numeric or alphanumeric designation used by the facility to identify the patient.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188725</PublicId>
      <PreferredName>PT_MED_REC</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s medical record.</PreferredDefinition>
      <LongName>Patient Medical Record</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207595</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25261:C25198</PreferredName>
        <Version>1</Version>
        <LongName>Medical Record</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25261</PREFERRED_NAME>
            <LONG_NAME>Medical</LONG_NAME>
            <CON_ID>2202452</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25198</PREFERRED_NAME>
            <LONG_NAME>Record</LONG_NAME>
            <CON_ID>2203775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018390</PublicId>
      <PreferredName>PT_NUM</PreferredName>
      <PreferredDefinition>the number identifying a particular patient.</PreferredDefinition>
      <LongName>Patient Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient Medical Record Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>CDE and values comply with Clinical Data Update System v. 3.0 May 2002</DocumentText>
        <URL>www.cancer.gov</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>added info merged from (duplicate) CDE #2001560 </DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient Hospital No.</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient Hospital No.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EORTC SAE Form</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Internal ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCR Immunotherapy Migration</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>MRN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Medical Record No.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Hospital Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3298557</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811951</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cytogenetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811952</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>APL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811786</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811789</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811797</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HCL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811802</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDS Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811806</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811827</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811829</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Localized Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Non-local Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811921</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>APL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CML Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811925</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HCL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811926</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Local-Reg Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDS Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811928</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3298577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000449</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Reporting Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC SAE Report</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NOS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811864</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neuroblastoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811874</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment trials</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000000</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000524</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104880</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0227G</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104881</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0265</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0230D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104893</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0231D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104894</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0238</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104895</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0250</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104903</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0254</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0264</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104939</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0268</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104940</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0269</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104995</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000081</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000082</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000162</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000281</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000282</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000284</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000426</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000427</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000430</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000501</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000591</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000592</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0001546</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0001586</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0002693</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0058390</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0061372</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0062877</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0064921</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065197</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>2001560</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_MED_REC_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PT_MED_REC_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_MED_REC_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="4">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>1264</PUBLICID>
    <LONGNAME>EKG Result</LONGNAME>
    <PREFERREDNAME>EKG_RESULT</PREFERREDNAME>
    <PREFERREDDEFINITION>The result of a electrocardiogram which helps determine abnormal cardiac rhythm and myocardial damage.</PREFERREDDEFINITION>
    <VERSION>2.31</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009090</PublicId>
      <PreferredName>EKG_RSLT</PreferredName>
      <PreferredDefinition>information related to the result or outcome of a procedure that records the electrical current in the heart in the form of a continuous strip graph.</PreferredDefinition>
      <LongName>Electrocardiography Result</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2486907</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38053</PreferredName>
        <Version>1</Version>
        <LongName>Electrocardiography</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38053</PREFERRED_NAME>
            <LONG_NAME>Electrocardiography</LONG_NAME>
            <CON_ID>2202414</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224045</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183345</PublicId>
      <PreferredName>ASSESS_RESULTS_TXT</PreferredName>
      <PreferredDefinition>the text field to describe the results of evaluations of the patient and the patient&#39;s disease.</PreferredDefinition>
      <LongName>Assessment Results Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>EKG Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EKG Result</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>EKG Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>EKG Results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Result in number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EKG_RESULT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EKG_RESULT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="5">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>1710</PUBLICID>
    <LONGNAME>Specimen Gleason Score Type</LONGNAME>
    <PREFERREDNAME>SPEC_GLEASONSC_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>procedure used to obtain tissue for pathological review and diagnosis.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188810</PublicId>
      <PreferredName>SPEC_GLEASONSC_DESC</PreferredName>
      <PreferredDefinition>information related to the Gleason score description for a specimen.</PreferredDefinition>
      <LongName>Specimen Gleason Score Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206585</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C28084</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Gleason Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28084</PREFERRED_NAME>
            <LONG_NAME>Gleason Score for Prostate Cancer</LONG_NAME>
            <CON_ID>2202653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177536</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Description</PreferredName>
        <Version>1</Version>
        <LongName>Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018645</PublicId>
      <PreferredName>GLEASONSC_TP</PreferredName>
      <PreferredDefinition>a question related to the patient&#39;s Gleason Score.</PreferredDefinition>
      <LongName>Gleason Score Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy (including TURP)</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metastasis specimen</VALIDVALUE>
          <VALUEMEANING>METASTATIC SITE</VALUEMEANING>
          <MEANINGDESCRIPTION>METASTATIC SITE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical specimen</VALIDVALUE>
          <VALUEMEANING>SURGICAL SPECIMEN</VALUEMEANING>
          <MEANINGDESCRIPTION>SURGICAL SPECIMEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine Needle Aspirate</VALIDVALUE>
          <VALUEMEANING>FINE NEEDLE ASPIRATION BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy by a fine needle aspiration technique</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Gleason Score Based on Specim</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Gleason Score Based on Specimen Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Gleason Score, Specimen Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Localized Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Non-local Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_GLEASONSC_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="6">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2236</PUBLICID>
    <LONGNAME>Breast Biopsy Count</LONGNAME>
    <PREFERREDNAME>BRST_BX_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the numeric count of surgical samples of breast tissue, removed and examined under a microscope.</PREFERREDDEFINITION>
    <VERSION>2.31</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>Breast CDE Disease Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201882</PublicId>
      <PreferredName>BRST_BX</PreferredName>
      <PreferredDefinition>Removal of a sample of breast tissue, which is then examined under a microscope.</PreferredDefinition>
      <LongName>Breast Biopsy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2185529</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Breast</PreferredName>
        <Version>1</Version>
        <LongName>Breast</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177647</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Biopsy</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018392</PublicId>
      <PreferredName>CT</PreferredName>
      <PreferredDefinition>The quantity of the specified item.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Breast Biopsy Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Breast Biopsy Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Breast Biopsy Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>No. of prior breast biopsies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How many of these breast procedures have you had in total?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How many of these breast procedures have you had in total?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BRST_BX_NUM</AlternateName>
        <AlternateNameType>DCP Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="7">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3015</PUBLICID>
    <LONGNAME>Non-protocol Therapy Other Administered Name</LONGNAME>
    <PREFERREDNAME>NPROT_TX_O_ADM_NAME</PREFERREDNAME>
    <PREFERREDDEFINITION>the name of the type of non-protocol therapy the patient received that is not previously listed.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2189778</PublicId>
      <PreferredName>NPROT_TX_OTHER_ADM</PreferredName>
      <PreferredDefinition>information related to other nonprotocol treatment administered.</PreferredDefinition>
      <LongName>Non-protocol Therapy Other Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206588</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25590:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Non-Protocol Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25590</PREFERRED_NAME>
            <LONG_NAME>Non-Protocol</LONG_NAME>
            <CON_ID>2206325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207818</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Other Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018280</PublicId>
      <PreferredName>TX_NAME</PreferredName>
      <PreferredDefinition>the name of the type of therapy.</PreferredDefinition>
      <LongName>Therapy Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COMMENT_BREAST_23</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction to template form: If yes,</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other Non-Protocol Therapy Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Name of Other Non-Protocol Th</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Name of Other Non-Protocol Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>2-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>#62664 appears to match this CDE - may need to be merged into this CDE or change #62664</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Localized Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Non-local Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000311</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Superficial Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000312</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment trials</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000000</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0250</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0003024</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0003256</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0003457</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0058446</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0061360</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0062860</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NPROT_TX_O_ADM_NAME</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NPROT_TX_O_ADM_NAME</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="8">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5698</PUBLICID>
    <LONGNAME>Cigarette Use Current Status</LONGNAME>
    <PREFERREDNAME>CIG_CURR_ST</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify current status of the participant&#39;s habitual use of  cigarettes.</PREFERREDDEFINITION>
    <VERSION>2.31</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014295</PublicId>
      <PreferredName>CIGARETTE_USE</PreferredName>
      <PreferredDefinition>Cigarette Use</PreferredDefinition>
      <LongName>Cigarette Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177134</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Cigarettes</PreferredName>
        <Version>1</Version>
        <LongName>Cigarettes</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1802</PREFERRED_NAME>
            <LONG_NAME>Cigarette</LONG_NAME>
            <CON_ID>2202497</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177321</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Use</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015874</PublicId>
      <PreferredName>YES_NO_UN_NA_IND</PreferredName>
      <PreferredDefinition>Yes, no, unknown or not applicable responses to a question or condition.</PreferredDefinition>
      <LongName>Yes/ No/ Unknown/ Not Applicable Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Current smoker?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Current smoker?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP CRF Label</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current smoker?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you currently smoke cigarettes regularly?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you currently smoke cigarettes?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient currently smoking?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the participant currently smoking?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008590</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>STANDARD FORMS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TOBACCO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000022</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180156</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>NEW CDEs PER STUDY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Iloprost 01279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811713</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate Reuse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2992453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193113</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCEG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGEMS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614828</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Virtual Colonoscopy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812772</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2931931</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Iloprost Trial</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Iloprost 12079</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2931952</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PS&amp;CC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CIG_CURR_ST</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CIG_CURR_ST</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CIG_CURR_ST</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SU_SUYN_CURRENT</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="9">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>58209</PUBLICID>
    <LONGNAME>Lymphadenopathy Image Documented Ind</LONGNAME>
    <PREFERREDNAME>LYMPHA_IMAGE_DOC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to determine if lymphadenopathy has been diagnosed by diagnostic imaging methods.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009608</PublicId>
      <PreferredName>LYMPHADENOPATH_IMAGE</PreferredName>
      <PreferredDefinition>information regarding diagnostic imaging of lymphadenopathy.</PreferredDefinition>
      <LongName>Lymphadenopathy Image</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187601</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymphadenopathy</PreferredName>
        <Version>1</Version>
        <LongName>Lymphadenopathy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3206</PREFERRED_NAME>
            <LONG_NAME>Lymphadenopathy</LONG_NAME>
            <CON_ID>2202609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Image</PreferredName>
        <Version>1</Version>
        <LongName>Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015794</PublicId>
      <PreferredName>LYMPHADENOPA_DOC_IND</PreferredName>
      <PreferredDefinition>the yes/no indicator to determine if enlargement of the lymph nodes and/or adenoids have been documented.</PreferredDefinition>
      <LongName>Lymphadenopathy Documented Ind</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207998</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25356:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Documented Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25356</PREFERRED_NAME>
            <LONG_NAME>Documented</LONG_NAME>
            <CON_ID>2203901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>EXAMINATION PERFORMED AND LYMPHADENOPATHY PRESENT</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination performed and lymphadenopathy present</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>EXAMINATION PERFORMED AND LYMPHADENOPATHY ABSENT</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination performed and lymphadenopathy absent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not examined</VALIDVALUE>
          <VALUEMEANING>EXAMINATION OF LYMPH NODES NOT PERFORMED</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination of lymph nodes and adenoids not performed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lymphadenopathy by scan</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lymphadenopathy by scan</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lymphadenopathy Imaging</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on template form for Leukemia: or x-ray</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HCL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811802</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDS Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811806</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811921</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HCL Relapse/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811926</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALL Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000449</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1010</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMPHA_IMAGE_DOC_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="10">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>61345</PUBLICID>
    <LONGNAME>Non-Protocol Immunotherapy Administered Text</LONGNAME>
    <PREFERREDNAME>NPROT_ITX_ADM_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to describe an immunotherapy regimen given to a patient that is not specified per protocol.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2189780</PublicId>
      <PreferredName>NPROT_ITX_ADM</PreferredName>
      <PreferredDefinition>information related to nonprotocol immunotherapy administered.</PreferredDefinition>
      <LongName>Non-Protocol Immunotherapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25590:C15262</PreferredName>
        <Version>1</Version>
        <LongName>Non-Protocol Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25590</PREFERRED_NAME>
            <LONG_NAME>Non-Protocol</LONG_NAME>
            <CON_ID>2206325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180739</PublicId>
      <PreferredName>TX_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to treatment or therapy.</PreferredDefinition>
      <LongName>Therapy Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Yes specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Yes specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Non-Protocol Immunotherapy Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0064894</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NPROT_ITX_ADM_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="11">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>62728</PUBLICID>
    <LONGNAME>RT Field Fractions Total Count</LONGNAME>
    <PREFERREDNAME>RT_FIELD_FRAC_TTL_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the value indicating the total number of radiation therapy fraction doses administered to each treatment field or site per protocol.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190129</PublicId>
      <PreferredName>RT_FIELD_FRACS</PreferredName>
      <PreferredDefinition>information related to radiation therapy field fractions.</PreferredDefinition>
      <LongName>RT Field Fractions</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176998</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RT</PreferredName>
        <Version>1</Version>
        <LongName>RT</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25507:C25514</PreferredName>
        <Version>1</Version>
        <LongName>Field Fractions</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25507</PREFERRED_NAME>
            <LONG_NAME>Data Field</LONG_NAME>
            <CON_ID>2202635</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25514</PREFERRED_NAME>
            <LONG_NAME>Fraction</LONG_NAME>
            <CON_ID>2203814</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180122</PublicId>
      <PreferredName>RT_FIELD_FRAC_TTL_CT</PreferredName>
      <PreferredDefinition>the value indicating the total number of radiation therapy fraction doses administered to each treatment field or site.</PreferredDefinition>
      <LongName>RT Field Fractions Total Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Total Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RT Total Fractions per Field</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total No. of Fractions of RT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total No. of Fractions of RT administered to each field</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065266</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="12">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>62742</PUBLICID>
    <LONGNAME>Protocol Surgical Procedure Normal Complete Indicator</LONGNAME>
    <PREFERREDNAME>PRO_SXPR_NL_COMP_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no question to ask if an operative procedure was performed and completed as described in a clinical trial protocol.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010729</PublicId>
      <PreferredName>PROT_SXPROC_NL_COMP</PreferredName>
      <PreferredDefinition>related to the routine or expected conclusion following the treatment plan established for an operative procedure used to treat or remove disease in an clinical investigational trial.</PreferredDefinition>
      <LongName>Protocol Surgical Procedure Normal Complete</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2479466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C15329</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2479467</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14165:C25250</PreferredName>
        <Version>1</Version>
        <LongName>Normal Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015403</PublicId>
      <PreferredName>PRO_SXPR_NL_COMP_IND</PreferredName>
      <PreferredDefinition>a yes/no question to ask if an operative procedure was performed and completed as described in a clinical trial protocol.</PreferredDefinition>
      <LongName>Protocol Surgical Procedure Normal Complete Indicator</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>65</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTEP CDE Committee</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, surgical treatment was modified from protocol specification</VALIDVALUE>
          <VALUEMEANING>SURGICAL TREATMENT WAS MODIFIED</VALUEMEANING>
          <MEANINGDESCRIPTION>SURGICAL TREATMENT WAS MODIFIED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, surgical treatment was not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the surgical treatment co</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the surgical treatment completed as specified per protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COMMENT_354</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on template form: (check one)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Surgical Treatment Completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811789</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811827</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811829</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Local-Reg Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000311</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Superficial Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000312</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065009</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065285</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="13">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64511</PUBLICID>
    <LONGNAME>Specimen Coefficient of Variation Percentage Value</LONGNAME>
    <PREFERREDNAME>SPEC_COEFFVA_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the percentage value for the coefficient of variation.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2191343</PublicId>
      <PreferredName>SPEC_COEFFVAR</PreferredName>
      <PreferredDefinition>the percentage value for the coefficient of variation.</PreferredDefinition>
      <LongName>Specimen Coefficient of Variation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2191344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Coefficient of Variation</PreferredName>
        <Version>1</Version>
        <LongName>coefficient of variation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0681921</PREFERRED_NAME>
            <LONG_NAME>coefficient of variation</LONG_NAME>
            <CON_ID>2204268</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019194</PublicId>
      <PreferredName>SPEC_COEVAR_PTG_VAL</PreferredName>
      <PreferredDefinition>the percentage value for the coefficient of variation of a specimen or sample.</PreferredDefinition>
      <LongName>Specimen Coefficient of Variation Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>% Coefficient of Variation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>% Coefficient of Variation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Coefficient of Variation Percentage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Immunophenotype</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811956</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="14">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64563</PUBLICID>
    <LONGNAME>Cytogenetics Culture Mitogen Use Indicator</LONGNAME>
    <PREFERREDNAME>CYTOG_CX_MTG_USE_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if a soluble substance (protein) was used to stimulate mitosis as part of a laboratory culture procedure to study cell genetics and perform molecular analysis of chromosomes.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009675</PublicId>
      <PreferredName>CYTOGEN_CX_MTGN_USE</PreferredName>
      <PreferredDefinition>related to the stimulation of mitosis with a soluble substance (protein) as part of a laboratory culture procedure to study cell genetics and perform molecular analysis of chromosomes.</PreferredDefinition>
      <LongName>Cytogenetics Culture Mitogen Use</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2497369</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16487:C16478:C660</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetics Culture Mitogen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16487</PREFERRED_NAME>
            <LONG_NAME>Cytogenetics</LONG_NAME>
            <CON_ID>2202727</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16478</PREFERRED_NAME>
            <LONG_NAME>Culture</LONG_NAME>
            <CON_ID>2202719</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C660</PREFERRED_NAME>
            <LONG_NAME>Mitogen</LONG_NAME>
            <CON_ID>2202749</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015494</PublicId>
      <PreferredName>CYTOG_CX_MTG_USE_IND</PreferredName>
      <PreferredDefinition>a yes/no indicator to ask if a soluble substance (protein) was used to stimulate mitosis as part of a laboratory culture procedure to study cell genetics and perform molecular analysis of chromosomes.</PreferredDefinition>
      <LongName>Cytogenetics Culture Mitogen Use Indicator</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTEP CDE Committee</Origin>
      <Representation>
        <PublicId>2188676</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No (not used)</VALIDVALUE>
          <VALUEMEANING>NO (NOT USED)</VALUEMEANING>
          <MEANINGDESCRIPTION>NO (NOT USED)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mitogen Use</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mitogen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mitogen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cytogenetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811952</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="15">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64694</PUBLICID>
    <LONGNAME>FISH Assessment Amplification Value</LONGNAME>
    <PREFERREDNAME>FISH_ASSESS_AMP_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the amplification cutpoint value used during analysis with FISH (fluorescence in situ hybridization).</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192063</PublicId>
      <PreferredName>FISH_ASSESS_AMP</PreferredName>
      <PreferredDefinition>information related to FISH amplification assessment.</PreferredDefinition>
      <LongName>FISH Assessment Amplification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660558</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17563:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Fluorescence in situ Hybridization Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17563</PREFERRED_NAME>
            <LONG_NAME>Fluorescence In Situ Hybridization</LONG_NAME>
            <CON_ID>2221360</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177624</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Amplification</PreferredName>
        <Version>1</Version>
        <LongName>Amplification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20589</PREFERRED_NAME>
            <LONG_NAME>Gene Amplification Technique</LONG_NAME>
            <CON_ID>2204035</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019300</PublicId>
      <PreferredName>FISH_ASSESS_AMP_VAL</PreferredName>
      <PreferredDefinition>the amplification cutpoint value assessment via FISH (fluorescence in situ hybridization).</PreferredDefinition>
      <LongName>FISH Assessment Amplification Value</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184351</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Value</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FISH Amplification Cutpoint</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Amplification Cutpoint</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Amplification Cutpoint</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cut Point</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tumor Markers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811932</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="16">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2001524</PUBLICID>
    <LONGNAME>Professional Organization Medicare Identifier Number</LONGNAME>
    <PREFERREDNAME>ORG_MEDICARE_ID_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Medicare Idenification  number of institution.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2011217</PublicId>
      <PreferredName>ORG_MEDICARE_ID</PreferredName>
      <PreferredDefinition>information related to the medicare identifier, the unique number or code assigned by the program under the U.S. Social Security Administration to hospitals and physicians for medical care provided to qualifying people over 65 years old.</PreferredDefinition>
      <LongName>Professional Organization Medicare Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19711</PreferredName>
        <Version>1</Version>
        <LongName>Organization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19711</PREFERRED_NAME>
            <LONG_NAME>Professional Organization or Group</LONG_NAME>
            <CON_ID>2202773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2744492</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16665:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Medicare Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16665</PREFERRED_NAME>
            <LONG_NAME>Medicare</LONG_NAME>
            <CON_ID>2204823</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016764</PublicId>
      <PreferredName>INST_ID_NUM</PreferredName>
      <PreferredDefinition>the numeric identifier assigned to a clinical facility or other institution working on a clinical trial.</PreferredDefinition>
      <LongName>Institution Identifier Number</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Medicare ID number of institution where surgical resection was performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Institution Medicare ID Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="17">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2003608</PUBLICID>
    <LONGNAME>Best Response Date</LONGNAME>
    <PREFERREDNAME>BEST_RESP_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Date of the evaluation used to determine the patient&#39;s maximum improvement in disease status within a period of protocol time.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012690</PublicId>
      <PreferredName>BEST_RSPNS_ONSET_DT</PreferredName>
      <PreferredDefinition>First date of the best response to intervention or treatment.</PreferredDefinition>
      <LongName>Best Response Onset Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25432:C25755</PreferredName>
        <Version>1</Version>
        <LongName>Best Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25432</PREFERRED_NAME>
            <LONG_NAME>Best</LONG_NAME>
            <CON_ID>2206164</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25755</PREFERRED_NAME>
            <LONG_NAME>Response</LONG_NAME>
            <CON_ID>2202805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207409</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25279:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Onset Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25279</PREFERRED_NAME>
            <LONG_NAME>Onset</LONG_NAME>
            <CON_ID>2202391</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Best Response</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Best Response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Best Response Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of best response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date Onset of Best Response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Outcome Measures CRF Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date for determining Best Response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OHSU Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Assessment Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AECC Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date Best Response First Observed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMSv3.02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811686</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Off Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Albert Einstein Medical Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 0404</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812578</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Panvec</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812583</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 02452</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812584</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 03058</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812585</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 04251</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AE_104_085</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UNMC 284-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rembrandt</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2812349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3234177</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Patient Outcomes Data System</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PODS Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3234178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BEST_RSPNS_ONSET_DT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>BEST_RESP_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BEST_RESP_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BEST_RESP_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BEST_RESP_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BEST_RESP_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="18">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2003717</PUBLICID>
    <LONGNAME>Adverse Event Infection Outcome</LONGNAME>
    <PREFERREDNAME>INFECT_OUTCOME_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of the outcome of an infecious episode or event.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2180324</PublicId>
      <PreferredName>AE_INFEC</PreferredName>
      <PreferredDefinition>information relating to an infection as an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Infection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184272</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Adverse Event</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177458</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Infection</PreferredName>
        <Version>1</Version>
        <LongName>Infection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26726</PREFERRED_NAME>
            <LONG_NAME>Infectious Disorder</LONG_NAME>
            <CON_ID>2203837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017115</PublicId>
      <PreferredName>AE_OUTCOME_TXT</PreferredName>
      <PreferredDefinition>Text description of the result or outcome of an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Outcome Text</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>24</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>(Infection) Outcome</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>(Infection) Outcome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Outcome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMSv3.02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811686</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OUTCOME</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="19">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2004557</PUBLICID>
    <LONGNAME>Laboratory Procedure Hemoglobin Result Ind-3</LONGNAME>
    <PREFERREDNAME>LAB_HMG_RSLT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if a blood test for hemoglobin count was performed on a patient&#39;s peripheral blood.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188767</PublicId>
      <PreferredName>LAB_HGB_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of the medical procedure that involves testing a sample of blood for hemoglobin, red respiratory protein of erythrocytes, to help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.</PreferredDefinition>
      <LongName>Laboratory Procedure Hemoglobin Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738863</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16676:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Hemoglobin Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16676</PREFERRED_NAME>
            <LONG_NAME>Hemoglobin</LONG_NAME>
            <CON_ID>2203742</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hemoglobin done</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Hemoglobin done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment trials</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0204</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0250</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_HMG_RSLT_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="20">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2004603</PUBLICID>
    <LONGNAME>Non-Protocol Raloxifene Therapy</LONGNAME>
    <PREFERREDNAME>NPROT_RALOXIFENE_TX</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if therapy using raloxifene was given outside of protocol specified therapy.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCIC CRF:National Cancer Institute of Canada Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013343</PublicId>
      <PreferredName>3147339v1.0:3147340v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) that binds to and interacts with estrogen receptors (ER) as a mixed estrogen agonist/antagonist, that is not part of planned protocol treatment.</PreferredDefinition>
      <LongName>Non-Protocol Raloxifene Administered</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3147339</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25590</PreferredName>
        <Version>1</Version>
        <LongName>Non-Protocol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25590</PREFERRED_NAME>
            <LONG_NAME>Non-Protocol</LONG_NAME>
            <CON_ID>2206325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3147340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1518:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Raloxifene Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1518</PREFERRED_NAME>
            <LONG_NAME>Raloxifene</LONG_NAME>
            <CON_ID>2204929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCIC CRF:National Cancer Institute of Canada Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Raloxifene Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Non-Protocol Raloxifene thera</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Non-Protocol Raloxifene therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="21">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2004856</PUBLICID>
    <LONGNAME>Adverse Event Hemorrhage Symptom Status</LONGNAME>
    <PREFERREDNAME>AE_HEM_SYM_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>a condition or state as related to the adverse event symptom of hemorrhage._a condition or state at a particular time related to bleeding symptom.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195579</PublicId>
      <PreferredName>AE_HEMOR_SM</PreferredName>
      <PreferredDefinition>information related to the adverse event symptom of hemorrhage.</PreferredDefinition>
      <LongName>Adverse Event Hemorrhage Symptom</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184272</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Adverse Event</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207256</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26791:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Hemorrhage Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26791</PREFERRED_NAME>
            <LONG_NAME>Hemorrhage</LONG_NAME>
            <CON_ID>2203751</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017955</PublicId>
      <PreferredName>AE_HEM_SYM_STAT</PreferredName>
      <PreferredDefinition>a condition or state at a particular time related to bleeding symptom.</PreferredDefinition>
      <LongName>Adverse Event Hemorrhage Symptom Status</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Cancer Family Registry Data Committee</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild, not requiring transfusion</VALIDVALUE>
          <VALUEMEANING>MILD, NOT REQUIRING TRANSFUSION</VALUEMEANING>
          <MEANINGDESCRIPTION>MILD, NOT REQUIRING TRANSFUSION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Active, requiring transfusion</VALIDVALUE>
          <VALUEMEANING>ACTIVE, REQUIRING TRANSFUSION</VALUEMEANING>
          <MEANINGDESCRIPTION>ACTIVE, REQUIRING TRANSFUSION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Active not requiring transfusion</VALIDVALUE>
          <VALUEMEANING>Active Negation Requirement Blood Transfusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Exerting influence or producing an effect; taking part in an activity.: An operation in which a term denies or inverts the meaning of another term or construction.: Something that is a necessary condition; something that is obligatory.: The infusion of components of blood or whole blood into the bloodstream. The blood may be donated from another person, or it may have been taken from the person earlier and stored until needed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15192, C25652, C25594, C45329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5615621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Petechiae Or ecchymoses</VALIDVALUE>
          <VALUEMEANING>Petechia Or Ecchymosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Pinpoint, unraised, round red spots under the skin caused by bleeding.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A small bruise caused by blood leaking from broken blood vessels into the tissues of the skin or mucous membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26758, C37998, C3323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5615622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bleeding/Hemorrhage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bleeding/Hemorrhage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Baseline bleeding</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="22">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005270</PUBLICID>
    <LONGNAME>Patient Follow-up Assessment Report Date</LONGNAME>
    <PREFERREDNAME>PT_FU_ASSESS_REP_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date of follow-up report.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013726</PublicId>
      <PreferredName>PT_FU_ASSESS_REP</PreferredName>
      <PreferredDefinition>information related to the short account of the examination of the body by auscultation, palpation, percussion, inspection, and olfaction obtained after a study has officially closed about a patient/participant.</PreferredDefinition>
      <LongName>Patient Follow-up Assessment Report</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2400062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16033:C20989:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Follow-up Assessment Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of follow-up report</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of follow-up report</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_FU_ASSESS_REP_DT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="23">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005483</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Myositis Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_MYOSITIS_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of a myositis (inflammation/damage of muscle) adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192622</PublicId>
      <PreferredName>CTC_AE_MYOSITIS</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of myositis.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Events Myositis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192620</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Myositis</PreferredName>
        <Version>1</Version>
        <LongName>Myositis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0027121</PREFERRED_NAME>
            <LONG_NAME>Myositis</LONG_NAME>
            <CON_ID>2204180</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017683</PublicId>
      <PreferredName>CTC_AE_MYOSITIS_GD</PreferredName>
      <PreferredDefinition>in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of a myositis (inflammation/damage of muscle) adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Myositis Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Disabling</VALUEMEANING>
          <MEANINGDESCRIPTION>Disabling</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Pain interfering with ADL</VALUEMEANING>
          <MEANINGDESCRIPTION>Pain interfering with ADL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Pain interfering with function but not interfering with ADL</VALUEMEANING>
          <MEANINGDESCRIPTION>Pain interfering with function but not interfering with ADL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>mild pain, not interfering with function</VALUEMEANING>
          <MEANINGDESCRIPTION>mild pain, not interfering with function</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>(inflammation/damage of muscle)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Myositis Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Myositis (i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Myositis (inflammation/damage of muscle) Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="24">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005580</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Myocarditis Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_MYOCD_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Cardiac General, assessment of the severity of a myocarditis adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2193173</PublicId>
      <PreferredName>CTC_AE_MYOCARDITIS</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of myocarditis.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Myocarditis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2193171</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Myocarditis</PreferredName>
        <Version>1</Version>
        <LongName>Myocarditis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C34831</PREFERRED_NAME>
            <LONG_NAME>Myocarditis</LONG_NAME>
            <CON_ID>2203671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017780</PublicId>
      <PreferredName>CTC_AE_MYOCD_GD</PreferredName>
      <PreferredDefinition>in CTC category Cardiac General, assessment of the severity of a myocarditis adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Myocarditis Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>CHF responsive to intervention</VALUEMEANING>
          <MEANINGDESCRIPTION>CHF responsive to intervention</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>severe or refractory CHF</VALUEMEANING>
          <MEANINGDESCRIPTION>severe or refractory CHF</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Myocarditis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Myocarditis Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Myocarditis Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="25">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005662</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Hypomagnesemia Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_HYPOMAGNES_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Metabolic/Laboratory, assessment of the severity of a serum-low magnesium (hypomagnesemia) adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2194779</PublicId>
      <PreferredName>CTC_AE_HYPOMAGNESEM</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of hypomagnesemia.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Hypomagnesemia</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2194777</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Hypomagnesemia</PreferredName>
        <Version>1</Version>
        <LongName>Hypomagnesemia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37975</PREFERRED_NAME>
            <LONG_NAME>Hypomagnesemia</LONG_NAME>
            <CON_ID>2203715</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017862</PublicId>
      <PreferredName>CTC_AE_HYPOMAGNES_GD</PreferredName>
      <PreferredDefinition>in CTC category Metabolic/Laboratory, assessment of the severity of a serum-low magnesium (hypomagnesemia) adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Hypomagnesemia Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>&lt; LLN - 1.2 mg/dL; &lt; LLN - 0.5 mmol/L</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt; LLN - 1.2 mg/dL; &lt; LLN - 0.5 mmol/L</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>&lt;1.2 - 0.9 mg/dL; &lt;0.5 - 0.4 mmol/L</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;1.2 - 0.9 mg/dL; &lt;0.5 - 0.4 mmol/L</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>&lt;0.9 - 0.7 mg/dL; &lt;0.4 - 0.3 mmol/L</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;0.9 - 0.7 mg/dL; &lt;0.4 - 0.3 mmol/L</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>&lt;0.7 mg/dL; &lt;0.3 mmol/L</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;0.7 mg/dL; &lt;0.3 mmol/L</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>WITHIN NORMAL LIMITS</VALUEMEANING>
          <MEANINGDESCRIPTION>a reported laboratory value that is within the institutional range of values for normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Hypomagnesemia Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Magnesium s</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Magnesium serum-low (hypomagnesemia) Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="26">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005732</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Other Visual Specify</LONGNAME>
    <PREFERREDNAME>CTC_AE_OTH_VISU_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Ocular/Visual, text description of an unlisted adverse event type.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2193315</PublicId>
      <PreferredName>CTC_AE_O_VISUAL</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of other visual.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Other Visual</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207567</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C38059</PreferredName>
        <Version>1</Version>
        <LongName>Other Visual</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38059</PREFERRED_NAME>
            <LONG_NAME>Visual</LONG_NAME>
            <CON_ID>2203689</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018370</PublicId>
      <PreferredName>AE_SPEC</PreferredName>
      <PreferredDefinition>the free text field to specify an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Ocular/Visu</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Ocular/Visual-Other (Specify)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDUS_SOURCE</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Use CTC v2.0 or CTCAE v3.0 (as determined by CTEP) for reporting to Clinical Data Update System (CDUS) v3.0 Release 2</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTCAE_SOURCE</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="27">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006084</PUBLICID>
    <LONGNAME>Quality of Life Complete Assessment Ind-2</LONGNAME>
    <PREFERREDNAME>QOL_COMP_ASSES_IND-2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator checking completion of Quality of Life assessment for a given time point.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2736453</PublicId>
      <PreferredName>QOL_COMP_ASSESS</PreferredName>
      <PreferredDefinition>information related to the the completion of a quality of life evaluation, an assessment of the overall condition of a human life.</PreferredDefinition>
      <LongName>Quality of Life Complete Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2736450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2736451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Complete Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was QoL Questionnaire complet</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was QoL Questionnaire completed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Quality of Life questionnaires completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient completed a baseline Quality of Life assessment and Smoking Questionnaire</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the S1007 Health-Related Quality of Life Questionnaire Randomized Study form completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the participant complete the PRO/QOL assessment(s)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was PRO-CTCAE completed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the questionnaire been completed for this time point?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0204</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QOL_COMP_ASSES_IND-2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="28">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006114</PUBLICID>
    <LONGNAME>Treatment Reporting Period Week Number</LONGNAME>
    <PREFERREDNAME>TX_REP_PD_WK_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>a question to determine the week number of the reporting period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014012</PublicId>
      <PreferredName>TX_REPORT_PD</PreferredName>
      <PreferredDefinition>information related toa phase or cycle of treatment or other reporting period.</PreferredDefinition>
      <LongName>Treatment Reporting Period</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207238</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25651:C25616</PreferredName>
        <Version>1</Version>
        <LongName>Reporting Period</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25651</PREFERRED_NAME>
            <LONG_NAME>Reporting</LONG_NAME>
            <CON_ID>2206359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25616</PREFERRED_NAME>
            <LONG_NAME>Period</LONG_NAME>
            <CON_ID>2202575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018374</PublicId>
      <PreferredName>TX_REP_PD_WK_NUM</PreferredName>
      <PreferredDefinition>the week number of the reporting period.</PreferredDefinition>
      <LongName>Treatment Reporting Period Week Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Week</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Week</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Study week</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify week</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Panvec</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812583</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unresect Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000000</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TX_REP_PD_WK_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TX_REP_PD_WK_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="29">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006249</PUBLICID>
    <LONGNAME>Bowel Patient Routine Activity Assessment Quality of Life Scale</LONGNAME>
    <PREFERREDNAME>B_PT_R_ACT_ASS_QO_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>a description of perceived changes in usual or habitual behavior or level of being active using a quality of life scale to evaluate the function of the digestive tract.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014133</PublicId>
      <PreferredName>B_PT_ROUT_ACT_ASSESS</PreferredName>
      <PreferredDefinition>related to the examination of an individual to evaluate the function of the digestive tract with regard to perceived changes in usual or habitual behavior or level of being active.</PreferredDefinition>
      <LongName>Bowel Patient Routine Activity Assessment</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2442491</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12736:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Bowel Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12736</PREFERRED_NAME>
            <LONG_NAME>Intestine</LONG_NAME>
            <CON_ID>2202700</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2442501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47893:C43431:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Routine Activity Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47893</PREFERRED_NAME>
            <LONG_NAME>Routine</LONG_NAME>
            <CON_ID>2425538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016847</PublicId>
      <PreferredName>FACT_QOL_SCALE</PreferredName>
      <PreferredDefinition>the scale used on FACT Quality of Life questionnaires to assess patient responses.</PreferredDefinition>
      <LongName>FACT Quality of Life Scale</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rarely</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>SOMETIMES</VALUEMEANING>
          <MEANINGDESCRIPTION>SOMETIMES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Often</VALIDVALUE>
          <VALUEMEANING>OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>Slightly</VALUEMEANING>
          <MEANINGDESCRIPTION>Slightly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not bothered at all</VALIDVALUE>
          <VALUEMEANING>Not bothered at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not bothered at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered somewhat</VALIDVALUE>
          <VALUEMEANING>Bothered somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered somewhat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little</VALIDVALUE>
          <VALUEMEANING>Bothered a little</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered a little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little difficult</VALIDVALUE>
          <VALUEMEANING>A little difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A little difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not difficult at all</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not difficult at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted totally</VALIDVALUE>
          <VALUEMEANING>Disrupted totally</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was totally disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted quite a bit</VALIDVALUE>
          <VALUEMEANING>Disrupted quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted somewhat</VALIDVALUE>
          <VALUEMEANING>Disrupted somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted a little</VALIDVALUE>
          <VALUEMEANING>Disrupted a little</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was a little disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not disrupted at all</VALIDVALUE>
          <VALUEMEANING>Not disrupted at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not at all disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to do</VALIDVALUE>
          <VALUEMEANING>UNABLE To Do</VALUEMEANING>
          <MEANINGDESCRIPTION>UNABLE To Do (Health Activity Questionnaire)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very difficult</VALIDVALUE>
          <VALUEMEANING>Very difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Very difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat difficult</VALIDVALUE>
          <VALUEMEANING>Somewhat difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had no pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have to limit my physical a</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have to limit my physical activity because of diarrhea</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000209</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="30">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006513</PUBLICID>
    <LONGNAME>Quality of Life Embarrassment Ostomy Assessment Scale</LONGNAME>
    <PREFERREDNAME>2014362v3.0:2016847v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale to evaluate the unpleasant emotional state experienced upon having a surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent as a subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014362</PublicId>
      <PreferredName>2736450v1.0:2856309v1.0</PreferredName>
      <PreferredDefinition>information related to an unpleasant emotional state experienced upon having a surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent as a subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.</PreferredDefinition>
      <LongName>Quality of Life Embarrassment Ostomy Assessment</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2736450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2856309</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62187:C15290:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Embarrassment Ostomy Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62187</PREFERRED_NAME>
            <LONG_NAME>Embarrassment</LONG_NAME>
            <CON_ID>2503472</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15290</PREFERRED_NAME>
            <LONG_NAME>Ostomy</LONG_NAME>
            <CON_ID>2602209</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016847</PublicId>
      <PreferredName>FACT_QOL_SCALE</PreferredName>
      <PreferredDefinition>the scale used on FACT Quality of Life questionnaires to assess patient responses.</PreferredDefinition>
      <LongName>FACT Quality of Life Scale</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rarely</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>SOMETIMES</VALUEMEANING>
          <MEANINGDESCRIPTION>SOMETIMES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Often</VALIDVALUE>
          <VALUEMEANING>OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>Slightly</VALUEMEANING>
          <MEANINGDESCRIPTION>Slightly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not bothered at all</VALIDVALUE>
          <VALUEMEANING>Not bothered at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not bothered at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered somewhat</VALIDVALUE>
          <VALUEMEANING>Bothered somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered somewhat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little</VALIDVALUE>
          <VALUEMEANING>Bothered a little</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered a little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little difficult</VALIDVALUE>
          <VALUEMEANING>A little difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A little difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not difficult at all</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not difficult at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted totally</VALIDVALUE>
          <VALUEMEANING>Disrupted totally</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was totally disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted quite a bit</VALIDVALUE>
          <VALUEMEANING>Disrupted quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted somewhat</VALIDVALUE>
          <VALUEMEANING>Disrupted somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted a little</VALIDVALUE>
          <VALUEMEANING>Disrupted a little</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was a little disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not disrupted at all</VALIDVALUE>
          <VALUEMEANING>Not disrupted at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not at all disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to do</VALIDVALUE>
          <VALUEMEANING>UNABLE To Do</VALUEMEANING>
          <MEANINGDESCRIPTION>UNABLE To Do (Health Activity Questionnaire)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very difficult</VALIDVALUE>
          <VALUEMEANING>Very difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Very difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat difficult</VALIDVALUE>
          <VALUEMEANING>Somewhat difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had no pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am embarrassed by my ostomy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am embarrassed by my ostomy appliance</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="31">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006897</PUBLICID>
    <LONGNAME>Institution Shipping Company Identifier Number</LONGNAME>
    <PREFERREDNAME>INST_COURIER_ID_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>the numeric identifier assigned to a clinical facility or other institution working on a clinical trial for courier company.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3029875</PublicId>
      <PreferredName>2513353v1.0:3029838v1.0</PreferredName>
      <PreferredDefinition>information related to the institution&#39;s identifier for courier company.</PreferredDefinition>
      <LongName>Institution Shipping Company Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513353</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41206</PreferredName>
        <Version>1</Version>
        <LongName>Institution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41206</PREFERRED_NAME>
            <LONG_NAME>Institution</LONG_NAME>
            <CON_ID>2228359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3029838</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40353:C54131:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Shipping Company Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40353</PREFERRED_NAME>
            <LONG_NAME>Shipping</LONG_NAME>
            <CON_ID>2204003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54131</PREFERRED_NAME>
            <LONG_NAME>Company</LONG_NAME>
            <CON_ID>2456442</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016764</PublicId>
      <PreferredName>INST_ID_NUM</PreferredName>
      <PreferredDefinition>the numeric identifier assigned to a clinical facility or other institution working on a clinical trial.</PreferredDefinition>
      <LongName>Institution Identifier Number</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Courier Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Courier Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Courier Account #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Account Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If expedited shipping is required, enter express courier account number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Provide Courier Account Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neuroblastoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811874</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0912</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000081</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000082</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>INST_COURIER_ID_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="32">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2007107</PUBLICID>
    <LONGNAME>Tissue Specimen Radiation Field Taken Ind-2</LONGNAME>
    <PREFERREDNAME>TIS_SPEC_RTFLD_TK_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether a specimen was obtained from radiation therapy treatment site.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2761964</PublicId>
      <PreferredName>TISS_SPEC_RADFLD_TKN</PreferredName>
      <PreferredDefinition>information related to the bit of tissue that is taken from the area of the body exposed to radiation during radiation therapy for research purposes.</PreferredDefinition>
      <LongName>Tissue Specimen Radiation Field Taken</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206399</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12801:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2761962</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54648:C25701</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Field Taken</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54648</PREFERRED_NAME>
            <LONG_NAME>Radiation Field</LONG_NAME>
            <CON_ID>2479357</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was sample from radiation por</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was sample from radiation port?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="33">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2007321</PUBLICID>
    <LONGNAME>Assessment Performed Date</LONGNAME>
    <PREFERREDNAME>ASSESS_PERF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on which the assessment of the patient/participant was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014686</PublicId>
      <PreferredName>ASSESS_PERF</PreferredName>
      <PreferredDefinition>the performance of an assessment of the patient or the patient&#39;s disease.</PreferredDefinition>
      <LongName>Assessment Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of evaluation</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of evaluation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Assessment date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Assessment Date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Assessment Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of  evaluation:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of PFT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CE7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of recording</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Performance status assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of surgical assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date HPV status determined:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-TEXT-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Last Stability Assessment by Transplant Specialist</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Most Recent Prostate Volume Measurement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2670694</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Relapse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma Relapse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812926</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2670694</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Relapse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Solid Tumor Relapse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812928</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Superficial Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811939</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000524</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Restorative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812086</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3835419</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pharmacovigilance</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3902524</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Research</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952294</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1010</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0534</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171063</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0815</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>DATE_ASSESSMENT_FORM_C</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESSDT</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDA</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDA</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB_MBDAT_HPV</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="34">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008091</PUBLICID>
    <LONGNAME>American Joint Committee on Cancer Lung N Stage Code</LONGNAME>
    <PREFERREDNAME>AJCC_LUNG_N_STG_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Pathologic N (nodal) stage of Lung cancer, using the AJCC TNM system of numbered categories for representation of data.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188580</PublicId>
      <PreferredName>LUNG_TUMOR_PATH_NST</PreferredName>
      <PreferredDefinition>Information related to pathologic N stage for a lung tumor.</PreferredDefinition>
      <LongName>Lung Tumor Pathologic N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206550</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Lung Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019182</PublicId>
      <PreferredName>AJCC_LUNG_N_STG_CD</PreferredName>
      <PreferredDefinition>A system for describing the extent of cancer in a patient&#39;s body. N describes lymph nodes that are involved,  in the AJCC TNM system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>American Joint Committee on Cancer Lung N Stage Code</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>No regional lymph nodes metastasis</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with no evidence of metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>REGIONAL LYMPH NODES CANNOT BE ASSESSED</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Metastasis to ipsilateral peribronchial and/or ipsilateral hilar nodes, intrapulmonary nodes, and direct extension of the primary tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, including intrapulmonary nodes involved by direct extension of the primary tumor. (from CAP Lung Cancer Protocol--January 2005 Revision)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N2</VALIDVALUE>
          <VALUEMEANING>Metastasis to ipsilateral mediastinal and/or subcarinal node(s)</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes. (from AJCC 6th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N3</VALIDVALUE>
          <VALUEMEANING>Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular node(s)</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes. (from AJCC 6th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>N Stage, pathologic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>N Stage, pathologic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>American Joint Committee on Cancer Lung N Stage Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic Spread: Regional Nodes (N)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathologic Spread: Regional Nodes (N)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008609</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DC Lung Study Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC Lung Study CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811966</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183534</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Integrative Cancer Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Dir Chall Lung Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="35">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008208</PUBLICID>
    <LONGNAME>Gadolinium Injected Material Volume Milliliter Value</LONGNAME>
    <PREFERREDNAME>GADO_INJ_VOL_ML_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the total volume of Gadolinium injected. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014981</PublicId>
      <PreferredName>6987698v1.00:2821068v1.00</PreferredName>
      <PreferredDefinition>An element with atomic symbol Gd, atomic number 64, and atomic weight 157.25.:No value exists.</PreferredDefinition>
      <LongName>Gadolinium Injected material</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6987698</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39765</PreferredName>
        <Version>1</Version>
        <LongName>Gadolinium</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39765</PREFERRED_NAME>
            <LONG_NAME>Gadolinium</LONG_NAME>
            <CON_ID>2735018</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2821068</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0940886</PreferredName>
        <Version>1</Version>
        <LongName>Injected material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0940886</PREFERRED_NAME>
            <LONG_NAME>Injected material</LONG_NAME>
            <CON_ID>2204461</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2823505</PublicId>
      <PreferredName>VOL_ML_VAL</PreferredName>
      <PreferredDefinition>The amount of three dimensional space occupied by an object or the capacity of a space or container._A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Volume Milliliter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>ml</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2823504</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25335:C28254:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Volume Milliliter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28254</PREFERRED_NAME>
            <LONG_NAME>Milliliter</LONG_NAME>
            <CON_ID>2204829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total volume of contrast inje</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total volume of contrast injection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>scenpro test RDName</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>ACRIN 6657 Study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180156</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>NEW CDEs PER STUDY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ACRIN_CALGB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MGH New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813098</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="36">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008265</PUBLICID>
    <LONGNAME>Disease Stage Code</LONGNAME>
    <PREFERREDNAME>DZ_STG_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Code to signify the extent of a disease, especially whether the disease has spread from the original site to other parts of the body.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012407</PublicId>
      <PreferredName>DZ_STG</PreferredName>
      <PreferredDefinition>Quantification of disease extent in the body.</PreferredDefinition>
      <LongName>Disease Stage</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2192176</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Diseases and Disorders</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177372</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Stage</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018862</PublicId>
      <PreferredName>DZ_STG_CD</PreferredName>
      <PreferredDefinition>The extent of a disease, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Disease Stage Code</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2538206</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C16899:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders Stage Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IA</VALIDVALUE>
          <VALUEMEANING>Stage IA</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>Stage I</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer confined to the original anatomic site of growth without lymph node involvement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27966</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IB</VALIDVALUE>
          <VALUEMEANING>Stage IB</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>II</VALIDVALUE>
          <VALUEMEANING>Stage II</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>III</VALIDVALUE>
          <VALUEMEANING>Stage III</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IV</VALIDVALUE>
          <VALUEMEANING>Stage IV</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread to distant anatomic sites beyond its original site of growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D0</VALIDVALUE>
          <VALUEMEANING>Stage D0</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage D0</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D1</VALIDVALUE>
          <VALUEMEANING>Stage D1</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer that has spread to local lymph nodes only.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D2</VALIDVALUE>
          <VALUEMEANING>Stage D2</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer that has spread to distant lymph nodes or other organs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D3</VALIDVALUE>
          <VALUEMEANING>Stage D3</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage D3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIA</VALIDVALUE>
          <VALUEMEANING>Stage IIA</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVA</VALIDVALUE>
          <VALUEMEANING>Stage IVA</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27979</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVB</VALIDVALUE>
          <VALUEMEANING>Stage IVB</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>Stage A</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer confined to the original anatomic site of growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B</VALIDVALUE>
          <VALUEMEANING>Stage B</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is confined to the original anatomic site of growth but is clinically palpable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>Stage C</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has reached the muscularis propria of the colon, or cancer that has invaded the prostatic gland capsule but is confined to the periprostatic area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D</VALIDVALUE>
          <VALUEMEANING>Stage D</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread to other anatomic sites beyond the site of its original growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Stage 0</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer confined to the epithelium without invasion of the basement membrane.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28051</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIB</VALIDVALUE>
          <VALUEMEANING>Stage IIB</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIA</VALIDVALUE>
          <VALUEMEANING>Stage IIIA</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIB</VALIDVALUE>
          <VALUEMEANING>Stage IIIB</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIC</VALIDVALUE>
          <VALUEMEANING>IIIC</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIE</VALIDVALUE>
          <VALUEMEANING>Stage IIE (extranodal)</VALUEMEANING>
          <MEANINGDESCRIPTION>A stage term referring to Hodgkin or non-Hodgkin lymphoma with contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2635234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IE</VALIDVALUE>
          <VALUEMEANING>Stage IE (extranodal)</VALUEMEANING>
          <MEANINGDESCRIPTION>A stage term referring to Hodgkin or non-Hodgkin lymphoma involving a single extralymphatic site in the absence of nodal involvement. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2635235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IC</VALIDVALUE>
          <VALUEMEANING>Stage IC</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer stage generally indicating the local invasion of tissues by cancer at the primary site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2698093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIC</VALIDVALUE>
          <VALUEMEANING>Stage IIC</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer stage generally indicating the invasion of adjacent structures by cancer without distant metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2698095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVC</VALIDVALUE>
          <VALUEMEANING>Stage IVC</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread to distant anatomic sites beyound its original site of growth.  The definition of stage IVC depends on the particular type of cancer that it refers to; for example, for head and neck carcinomas (lip and oral cavity carcinoma, laryngeal carcinoma, nasal cavity and paranasal sinus carcinoma, pharynx carcinoma, thyroid gland carcinoma, and mjor salivery gland carcinoma) and head and neck mucosal melanoma, stage IVC is defined as follows: any T, any N, M1; for appendix carcinoma, stage IVC is defined as follow: any T, any N, M1b, any G. M1: Distant metastasis. M1b: Nonperitoneal metastasis. G: Grade (celllar differentiation).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Disease Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Disease Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease Stage Numeric</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stage</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Disease Stage of Entry</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease Stage of Entry</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stage of Disease</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stage of Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease stage at initial diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease stage at study entry</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical stage at diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stage of disease at randomization</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stage of disease at randomization</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCR - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease Stage at Entry</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the patients Disease Stage at diagnosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Enrollment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248627</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Report</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248635</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 0404</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812578</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke 500</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812580</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 02452</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812584</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 03058</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812585</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 04251</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UNMC 284-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2548333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>I-SPY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C911/C1000</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2931931</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Iloprost Trial</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Iloprost 12079</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2931952</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2964591</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Eligibility Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Structured Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2965104</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2964591</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Eligibility Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3070842</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2012-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3694151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DISEAS_STG</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPOREs</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DZ_STG_CD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DZ_STG_CD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="37">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008504</PUBLICID>
    <LONGNAME>TEST CODE PUSH</LONGNAME>
    <PREFERREDNAME>TEST CODE PUSH</PREFERREDNAME>
    <PREFERREDDEFINITION>TEST</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>TEST</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014141</PublicId>
      <PreferredName>Apic_test_Anti_test_tp_Bloo</PreferredName>
      <PreferredDefinition>Testing definition field for leading blanks    _The &quot;circulating tissue&quot; of the body; the fluid and its suspended formed elements that are circulated through the heart, arteries, capillaries, and veins; blood is the means by which 1) oxygen and nutritive materials are transported to the tissues, and 2) carbon dioxide and various metabolic products are removed for excretion. The blood consists of a pale yellow or gray-yellow fluid, plasma, in which are suspended red blood cells (erythrocytes), white blood cells (leukocytes), and platelets. (STED98)fdn</PreferredDefinition>
      <LongName>Apical test Antiemetic test Blood</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>TEST</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008506</PublicId>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>TEST</PreferredName>
        <Version>1</Version>
        <LongName>TEST</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206437</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25423:C12434</PreferredName>
        <Version>1</Version>
        <LongName>Apical Blood</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25423</PREFERRED_NAME>
            <LONG_NAME>Apical</LONG_NAME>
            <CON_ID>2206158</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2429680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0017337</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0017337</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2203117</CON_ID>
            <DEFINITION_SOURCE>Medical Subject Headings (MeSH). Bethesda (MD): National Library of Medicine, 2003</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SEER:Surveillance Epidemiology and End Results, NCI</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015097</PublicId>
      <PreferredName>TEST_VD</PreferredName>
      <PreferredDefinition>TEST VD</PreferredDefinition>
      <LongName>TEST_VD</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>TEST</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008506</PublicId>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>TEST</PreferredName>
        <Version>1</Version>
        <LongName>TEST</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TEST</VALIDVALUE>
          <VALUEMEANING>IDH1 R172 Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>IDH1 R172 Not Tested</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-03-24</PVBEGINDATE>
          <PVENDDATE>2007-03-24</PVENDDATE>
          <VMPUBLICID>3121609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEANING</VALIDVALUE>
          <VALUEMEANING>K</VALUEMEANING>
          <MEANINGDESCRIPTION>Definition not available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0439112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-03-15</PVBEGINDATE>
          <PVENDDATE>2006-03-15</PVENDDATE>
          <VMPUBLICID>2561813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>new tp doc text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>new tp doc text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008604</PublicId>
          <ContextName>TEST</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TEST MIXED CASE TEST_CSCXZC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TEST ADD CSI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811720</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="38">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2177984</PUBLICID>
    <LONGNAME>LVEF Assessment Result Ind-2</LONGNAME>
    <PREFERREDNAME>LVE_ASS_RESULT_IND-2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the LVEF assessment result was equal to or greater than the lower limit of normal.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014620</PublicId>
      <PreferredName>ASSESS_RESULT</PreferredName>
      <PreferredDefinition>the result of a patient assessment.</PreferredDefinition>
      <LongName>Assessment Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176954</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177339</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Result</PreferredName>
        <Version>1</Version>
        <LongName>Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>was the LVEF equal to or grea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>was the LVEF equal to or greater than the lower limit of normal for the facility performing the procedure?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is LVEF greater than or equal to 55% regardless of the cardiac imaging facility&#39;s lower limit of normal?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="39">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2178146</PUBLICID>
    <LONGNAME>Quality of Life Bed Rest Assessment Scale</LONGNAME>
    <PREFERREDNAME>QOL_BEDREST_ASS_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale used to assess or evaluate whether an individual is confined to bed for therapeutic reasons as a measure of well-being and ability to enjoy life.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2742815</PublicId>
      <PreferredName>QOL_BEDREST_ASS</PreferredName>
      <PreferredDefinition>information related to the assessment or evaluation of an whether an individual is confined to bed for therapeutic reasons as a measure of well-being and ability to enjoy life.</PreferredDefinition>
      <LongName>Quality of Life Bed Rest Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2736450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2742813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45985:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Bed Rest Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45985</PREFERRED_NAME>
            <LONG_NAME>Bed Rest</LONG_NAME>
            <CON_ID>2233193</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194224</PublicId>
      <PreferredName>PT_ASSESS_SCALE</PreferredName>
      <PreferredDefinition>the scale of patient assessment.</PreferredDefinition>
      <LongName>Patient Assessment Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>75</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not relevant</VALIDVALUE>
          <VALUEMEANING>Not relevant</VALUEMEANING>
          <MEANINGDESCRIPTION>Not relevant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A lot</VALIDVALUE>
          <VALUEMEANING>A LOT</VALUEMEANING>
          <MEANINGDESCRIPTION>A LOT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, more than once</VALIDVALUE>
          <VALUEMEANING>Yes, more than once</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, more than once</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, once</VALIDVALUE>
          <VALUEMEANING>Yes, once</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, once</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily</VALIDVALUE>
          <VALUEMEANING>About once a day</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Several times a week</VALIDVALUE>
          <VALUEMEANING>Several times a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Several times a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About once a week</VALIDVALUE>
          <VALUEMEANING>ABOUT ONCE A WEEK</VALUEMEANING>
          <MEANINGDESCRIPTION>About once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than once a week</VALIDVALUE>
          <VALUEMEANING>Less than once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3120272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, not limited at all</VALIDVALUE>
          <VALUEMEANING>No, not limited at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No, not limited at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a little</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Little</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a lot</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Lot</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Lot</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>Slightly</VALUEMEANING>
          <MEANINGDESCRIPTION>Slightly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered somewhat</VALIDVALUE>
          <VALUEMEANING>Bothered somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered somewhat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little</VALIDVALUE>
          <VALUEMEANING>Bothered a little</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered a little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not bothered at all</VALIDVALUE>
          <VALUEMEANING>Not bothered at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not bothered at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not well</VALIDVALUE>
          <VALUEMEANING>Not well</VALUEMEANING>
          <MEANINGDESCRIPTION>Not well</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5290195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very well</VALIDVALUE>
          <VALUEMEANING>Very Well</VALUEMEANING>
          <MEANINGDESCRIPTION>Existing to a great degree.: A cavity or vessel used to contain liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70592, C116076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5290196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Well</VALIDVALUE>
          <VALUEMEANING>Well</VALUEMEANING>
          <MEANINGDESCRIPTION>Well</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4975879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable to me</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Very Much</VALIDVALUE>
          <VALUEMEANING>Not Very Much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of disagreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5806311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prefer not to answer</VALIDVALUE>
          <VALUEMEANING>Prefer Not to Answer</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual prefers or preferred not to answer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5684650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am forced to spend time in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am forced to spend time in bed.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you need to stay in bed or a chair during the day</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QOL_BEDREST_ASS_SC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="40">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179669</PUBLICID>
    <LONGNAME>Relevant Laboratory Test Names</LONGNAME>
    <PREFERREDNAME>REL_LAB_TEST_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of a laboratory test relevant to the event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2179525</PublicId>
      <PreferredName>LAB_TEST</PreferredName>
      <PreferredDefinition>The name of the laboratory test.</PreferredDefinition>
      <LongName>Lab Test</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2179409</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>FINDINGS</PreferredName>
        <Version>1</Version>
        <LongName>Findings</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322104</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0022885</PreferredName>
        <Version>1</Version>
        <LongName>laboratory test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0022885</PREFERRED_NAME>
            <LONG_NAME>laboratory test</LONG_NAME>
            <CON_ID>2203066</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179456</PublicId>
      <PreferredName>RELEV_LAB_TEST_NM</PreferredName>
      <PreferredDefinition>The name of a laboratory test relevant to the event.</PreferredDefinition>
      <LongName>Relevant Laboratory Test Names</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2179409</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>FINDINGS</PreferredName>
        <Version>1</Version>
        <LongName>Findings</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>70</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Test Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Test Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Test</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Relevant Laboratory Test Names</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Review Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812969</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CIAF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>REL_LAB_TEST_NM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="41">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179759</PUBLICID>
    <LONGNAME>Off-Treatment CAM Administered Text</LONGNAME>
    <PREFERREDNAME>OTX_CAM_ADM_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to describe a complementary or alternative medicine treatment administered to a patient during the follow-up period after protocol-specified treatment regimens were completed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195137</PublicId>
      <PreferredName>OTX_CAM_ADM</PreferredName>
      <PreferredDefinition>information related to the off-treatment CAM being administered.</PreferredDefinition>
      <LongName>Off-Treatment CAM Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206850</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25601:C15178</PreferredName>
        <Version>1</Version>
        <LongName>Off-Treatment CAM</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15178</PREFERRED_NAME>
            <LONG_NAME>Complementary and Alternative Medicine</LONG_NAME>
            <CON_ID>2202703</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180739</PublicId>
      <PreferredName>TX_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to treatment or therapy.</PreferredDefinition>
      <LongName>Therapy Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Yes specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="42">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179780</PUBLICID>
    <LONGNAME>Gavage Prior Administration Duration</LONGNAME>
    <PREFERREDNAME>GAVAGE_PR_ADM_DUR</PREFERREDNAME>
    <PREFERREDDEFINITION>the length of time prior to study entry during which a patient required a feeding tube to meet their nutritional needs.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195387</PublicId>
      <PreferredName>GAVAGE_PRIOR_ADMIN</PreferredName>
      <PreferredDefinition>information related to the prior administration of gavage.</PreferredDefinition>
      <LongName>Gavage Prior Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2737044</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73430</PreferredName>
        <Version>1</Version>
        <LongName>Gavage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73430</PREFERRED_NAME>
            <LONG_NAME>Gavage</LONG_NAME>
            <CON_ID>2737019</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207229</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Prior Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179778</PublicId>
      <PreferredName>GAVAGE_DUR</PreferredName>
      <PreferredDefinition>the length of time a patient required a feeding tube to meet their nutritional needs.</PreferredDefinition>
      <LongName>Gavage Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184292</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Duration</PreferredName>
        <Version>1</Version>
        <LongName>Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than 1 month</VALIDVALUE>
          <VALUEMEANING>Less than 1 month</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than 1 month</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 to &lt;7 months</VALIDVALUE>
          <VALUEMEANING>1 to &lt;7 months</VALUEMEANING>
          <MEANINGDESCRIPTION>1 to &lt;7 months</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7 to &lt;13 months</VALIDVALUE>
          <VALUEMEANING>7 to &lt;13 months</VALUEMEANING>
          <MEANINGDESCRIPTION>7 to &lt;13 months</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13 to &lt;19 months</VALIDVALUE>
          <VALUEMEANING>13 to &lt;19 months</VALUEMEANING>
          <MEANINGDESCRIPTION>13 to &lt;19 months</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19 to &lt;24 months</VALIDVALUE>
          <VALUEMEANING>19 to &lt;24 months</VALUEMEANING>
          <MEANINGDESCRIPTION>19 to &lt;24 months</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 years or longer</VALIDVALUE>
          <VALUEMEANING>2 years or longer</VALUEMEANING>
          <MEANINGDESCRIPTION>2 years or longer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How long were tube feedings given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="43">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180037</PUBLICID>
    <LONGNAME>Patient Relative Adopted Ind-3</LONGNAME>
    <PREFERREDNAME>PT_RELTV_ADPT_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if the relative of a patient is adopted (not biologically related).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195399</PublicId>
      <PreferredName>PT_RELTV_ADPT</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s relative being adopted.</PreferredDefinition>
      <LongName>Patient Relative Adopted</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207529</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21480:C25290</PreferredName>
        <Version>1</Version>
        <LongName>Relative Adopted</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21480</PREFERRED_NAME>
            <LONG_NAME>Relative</LONG_NAME>
            <CON_ID>2202798</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25290</PREFERRED_NAME>
            <LONG_NAME>Adopted</LONG_NAME>
            <CON_ID>2203584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is this relative adopted</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is this relative adopted</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="44">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180364</PUBLICID>
    <LONGNAME>LVEF Heart Exercise Test Ind-3</LONGNAME>
    <PREFERREDNAME>LVEF_HRT_EX_TST_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if the ejection fraction measurement of the left ventricle of the heart improves when a patient exercises.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195655</PublicId>
      <PreferredName>LVEF_HRT_EX_TST</PreferredName>
      <PreferredDefinition>information related to the LVEF heart exercise test.</PreferredDefinition>
      <LongName>LVEF Heart Exercise Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206889</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37946:C12727</PreferredName>
        <Version>1</Version>
        <LongName>Ejection Fraction Heart</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37946</PREFERRED_NAME>
            <LONG_NAME>Measurement of Left Ventricular Ejection Fraction</LONG_NAME>
            <CON_ID>2202616</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12727</PREFERRED_NAME>
            <LONG_NAME>Heart</LONG_NAME>
            <CON_ID>2202646</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660667</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16567:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Exercise Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16567</PREFERRED_NAME>
            <LONG_NAME>Exercise</LONG_NAME>
            <CON_ID>2606079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does ejection fraction percen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does ejection fraction percent improve with exercise</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="45">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180573</PUBLICID>
    <LONGNAME>Kidney Disease Present Ind-3</LONGNAME>
    <PREFERREDNAME>KIDNEY_DZ_PRES_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if disease is present in the kidney.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195806</PublicId>
      <PreferredName>KIDNEY_DZ_PRES</PreferredName>
      <PreferredDefinition>information related to kidney disease being present.</PreferredDefinition>
      <LongName>Kidney Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12415:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Kidney Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12415</PREFERRED_NAME>
            <LONG_NAME>Kidney</LONG_NAME>
            <CON_ID>2204911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Kidney</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Kidney</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you have kidney disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the reason for visit Urine and bladder changes/Proteinuria/Kidney problems?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5242953</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Bladder Ca Advocacy Network</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC-GENOME</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5242975</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="46">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180700</PUBLICID>
    <LONGNAME>Dose Received Number</LONGNAME>
    <PREFERREDNAME>DOSE_RECD_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>the number of doses the subject or individual took.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2180699</PublicId>
      <PreferredName>DOSE_RECD</PreferredName>
      <PreferredDefinition>information related to the dose received.</PreferredDefinition>
      <LongName>Dose Received</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177152</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dose</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184327</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Received</PreferredName>
        <Version>1</Version>
        <LongName>Received</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180698</PublicId>
      <PreferredName>DOSE_RECD_NUM</PreferredName>
      <PreferredDefinition>the number of doses a subject or individual took.</PreferredDefinition>
      <LongName>Dose Received Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of doses received</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of doses received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OHSU Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total doses taken this cycle (up to 28)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify number of doses given</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify number of doses given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of doses of agent received prior to start of protocol therapy:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of doses received during this reporting period:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of doses received during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How many doses of LMP-TCs did the patient receive?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Average # of doses per day taken during this 7 day period</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total number of product doses administered in this reporting period:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total number of asparaginase type dose received during this reporting period:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How many busulfan doses were administered at this dose:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of courses of Erwinia administered:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DOSE_RECD_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>XLPpre_assess_diag_prep_mult_tota_dose_given_count</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECDOS_CYCNUM_ERW</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="47">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180758</PUBLICID>
    <LONGNAME>Heart Shortening Fraction Assessment Percentage Value</LONGNAME>
    <PREFERREDNAME>HRT_SH_ASS_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the value in percentage measuring the shortening fraction of left ventricle, measures and ratios the change in the diameter of the left ventricle between the contracted and relaxed states: the difference between LV end-diastolic diameter and LV end-systolic diameter over LV end-diastolic diameter.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195900</PublicId>
      <PreferredName>HRT_SHORT_TST</PreferredName>
      <PreferredDefinition>information related examination of left ventricle shortening fraction, measures and ratios the change in the diameter of the left ventricle between the contracted and relaxed states: the difference between LV end-diastolic diameter and LV end-systolic diameter over LV end-diastolic diameter.</PreferredDefinition>
      <LongName>Heart Shortening Fraction Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2519953</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12727</PreferredName>
        <Version>1</Version>
        <LongName>Heart</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12727</PREFERRED_NAME>
            <LONG_NAME>Heart</LONG_NAME>
            <CON_ID>2202646</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2627862</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38020:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Shortening Fraction Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38020</PREFERRED_NAME>
            <LONG_NAME>Left Ventricular Fractional Shortening</LONG_NAME>
            <CON_ID>2202816</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180234</PublicId>
      <PreferredName>LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the value as a percentage of 100.</PreferredDefinition>
      <LongName>Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Shortening Fraction</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Shortening Fraction</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction: %</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>LVSF</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the percentage of the shortening fraction result?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the percentage of the shortening fraction result?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Shortening fraction:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shortening fraction:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shortening Fraction Result Percentage Value</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shortening Fraction Value:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2180758</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value WHERE PerformedClinicalResult &gt; Performed Observation &gt; DefinedObservation.nameCode = &quot;Perform Heart Shortening Fraction&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Percentage Shortening Fraction:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shortening fraction result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Fractional Shortening (FS) result:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shortening Fraction Result Percentage Value:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Percentage Shortening Fraction (SF):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2038r1: Mucopolysaccharidosis and Other Storage Diseases Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>muc_base_short_fraction</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>HRT_SH_ASS_PTG_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HRT_SH_ASS_PTG_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="48">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180833</PUBLICID>
    <LONGNAME>Bone Marrow Biopsy Ind</LONGNAME>
    <PREFERREDNAME>BM_BX_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if a bone marrow biopsy procedure was performed.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014582</PublicId>
      <PreferredName>BM_BX</PreferredName>
      <PreferredDefinition>a biopsy of the patient&#39;s bone marrow.</PreferredDefinition>
      <LongName>Bone Marrow Biopsy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176966</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Bone Marrow</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177647</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Biopsy</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180832</PublicId>
      <PreferredName>BM_BX_IND</PreferredName>
      <PreferredDefinition>information about a bone marrow biopsy.</PreferredDefinition>
      <LongName>Bone Marrow Biopsy Ind</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>17</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2188676</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>no</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>inadequate sample</VALIDVALUE>
          <VALUEMEANING>inadequate sample</VALUEMEANING>
          <MEANINGDESCRIPTION>Not meeting a quantitative or qualitative measure necessary for a requirement.: Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69177, C70699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was bone marrow biopsy done</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was bone marrow biopsy done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bone marrow biopsy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a bone marrow biopsy performed?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a bone marrow biopsy performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a bone marrow biopsy done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was bone marrow biopsy/aspirate done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bone marrow assessment done</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was bone marrow assessment done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was bone marrow biopsied?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a repeat bone marrow biopsy done during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a bone marrow core biopsy performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was bone marrow biopsy provided?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>58059</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>BMBiopsyPerformedIND</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="49">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181450</PUBLICID>
    <LONGNAME>Peripheral Neuropathy EMG Diagnosis Ind-2</LONGNAME>
    <PREFERREDNAME>PERI_NEU_EMG_DX_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if a patient has been diagnosed with peripheral neuropathy based on EMG test results.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2196146</PublicId>
      <PreferredName>PERI_NEURO_EMG_DX</PreferredName>
      <PreferredDefinition>information related to the diagnosis of peripheral neuropathy EMG.</PreferredDefinition>
      <LongName>Peripheral Neuropathy EMG Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206578</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25233:C4731</PreferredName>
        <Version>1</Version>
        <LongName>Peripheral Neuropathy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25233</PREFERRED_NAME>
            <LONG_NAME>Peripheral</LONG_NAME>
            <CON_ID>2206343</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4731</PREFERRED_NAME>
            <LONG_NAME>Neuropathy</LONG_NAME>
            <CON_ID>2202754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38056:C15220</PreferredName>
        <Version>1</Version>
        <LongName>EMG Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38056</PREFERRED_NAME>
            <LONG_NAME>Electromyography</LONG_NAME>
            <CON_ID>2616004</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction: (Note: If yes, submit EMG report)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EMG</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>EMG</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="50">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181474</PUBLICID>
    <LONGNAME>Soft Tissue Plasmacytoma Second Dimension Measurement</LONGNAME>
    <PREFERREDNAME>ST_PLSC_SEC_DIM_MSRT</PREFERREDNAME>
    <PREFERREDDEFINITION>the measurement in centimeters of a pendicular plane to the largest dimension of a soft tissue plasmacytoma in multiple myeloma disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2196171</PublicId>
      <PreferredName>ST_PLSC_SEC_DIM</PreferredName>
      <PreferredDefinition>information related to the second dimension of a soft tissue plasmacytoma.</PreferredDefinition>
      <LongName>Soft Tissue Plasmacytoma Second Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2659323</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12471:C9349</PreferredName>
        <Version>1</Version>
        <LongName>Soft Tissue Plasmacytoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12471</PREFERRED_NAME>
            <LONG_NAME>Soft Tissue</LONG_NAME>
            <CON_ID>2202889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9349</PREFERRED_NAME>
            <LONG_NAME>Plasmacytoma</LONG_NAME>
            <CON_ID>2202851</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C25483</PreferredName>
        <Version>1</Version>
        <LongName>Second Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180417</PublicId>
      <PreferredName>LES_DIM_MSRMT</PreferredName>
      <PreferredDefinition>information related to the dimension of a lesion.</PreferredDefinition>
      <LongName>Lesion Dimension Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction: cm</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Greatest Perpendicular Measur</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Greatest Perpendicular Measurement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dimension 2</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ST_PLSC_SEC_DIM_MSRT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="51">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181888</PUBLICID>
    <LONGNAME>Lesion Longest Bidimensional Dimension Measurement</LONGNAME>
    <PREFERREDNAME>LES_LGST_2D_DIM_MSRMT</PREFERREDNAME>
    <PREFERREDDEFINITION>a numeric value quantifying the largest of 2 measures of magnitude for a malignant tumor or cancer lesion in 2 linear directions (length or width, regardless of anatomical plane).</PREFERREDDEFINITION>
    <VERSION>1.5</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>Brain CDE Disease Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2533262</PublicId>
      <PreferredName>LES_LGST_2D_DIM</PreferredName>
      <PreferredDefinition>information related to the two greatest measures of magnitude for a malignant tumor in 2 linear directions (length and width, regardless of anatomical plane).</PreferredDefinition>
      <LongName>Lesion Longest 2-Dimensional Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2465192</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2533260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C48282:C25483</PreferredName>
        <Version>1</Version>
        <LongName>Longest 2-Dimensional Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48282</PREFERRED_NAME>
            <LONG_NAME>2-Dimensional</LONG_NAME>
            <CON_ID>2422614</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180417</PublicId>
      <PreferredName>LES_DIM_MSRMT</PreferredName>
      <PreferredDefinition>information related to the dimension of a lesion.</PreferredDefinition>
      <LongName>Lesion Dimension Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Longest Bidimensional Measure</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Longest Bidimensional Measurements of Lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest measurement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="52">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181958</PUBLICID>
    <LONGNAME>Patient Medical Condition Current Specify</LONGNAME>
    <PREFERREDNAME>PT_MED_COND_CUR_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field to specify other medical conditions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197460</PublicId>
      <PreferredName>PT_MED_COND</PreferredName>
      <PreferredDefinition>information related to the medical condition of the patient.</PreferredDefinition>
      <LongName>Patient Medical Condition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207472</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25261:C25457</PreferredName>
        <Version>1</Version>
        <LongName>Medical Condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25261</PREFERRED_NAME>
            <LONG_NAME>Medical</LONG_NAME>
            <CON_ID>2202452</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2197571</PublicId>
      <PreferredName>ASSESS_CUR_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to current specified assessment.</PreferredDefinition>
      <LongName>Assessment Current Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208066</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Current Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="53">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182352</PUBLICID>
    <LONGNAME>Surgery Reconstruction Type</LONGNAME>
    <PREFERREDNAME>SX_RCNSTCT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the field to indicate the type of reconstructive procedure performed on the patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182220</PublicId>
      <PreferredName>SX_RCNSTCT</PreferredName>
      <PreferredDefinition>information related to reconstruction surgery received by a patient.</PreferredDefinition>
      <LongName>Surgery Reconstruction</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176917</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Surgery</PreferredName>
        <Version>1</Version>
        <LongName>Surgery</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177398</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Reconstruction</PreferredName>
        <Version>1</Version>
        <LongName>Reconstruction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25351</PREFERRED_NAME>
            <LONG_NAME>Reconstructive Surgery</LONG_NAME>
            <CON_ID>2203958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182351</PublicId>
      <PreferredName>SX_RCNSTCT_TP</PreferredName>
      <PreferredDefinition>information related to the type of surgical reconstruction a patient received or requires.</PreferredDefinition>
      <LongName>Surgery Reconstruction Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myocutaneous flap</VALIDVALUE>
          <VALUEMEANING>Myocutaneous flap</VALUEMEANING>
          <MEANINGDESCRIPTION>Myocutaneous flap</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesh (chest wall)</VALIDVALUE>
          <VALUEMEANING>Mesh (chest wall)</VALUEMEANING>
          <MEANINGDESCRIPTION>Mesh (chest wall)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite (allograft and prosthesis)</VALIDVALUE>
          <VALUEMEANING>Composite (allograft and prosthesis)</VALUEMEANING>
          <MEANINGDESCRIPTION>Composite (allograft and prosthesis)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoprosthesis</VALIDVALUE>
          <VALUEMEANING>Endoprosthesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoprosthesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metallic prosthesis</VALIDVALUE>
          <VALUEMEANING>Metallic prosthesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Metallic prosthesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arthrodesis</VALIDVALUE>
          <VALUEMEANING>Arthrodesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Arthrodesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allograft arthrodesis</VALIDVALUE>
          <VALUEMEANING>Allograft arthrodesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Allograft arthrodesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autograft arthrodesis</VALIDVALUE>
          <VALUEMEANING>Autograft arthrodesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Autograft arthrodesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteoarticular allograft</VALIDVALUE>
          <VALUEMEANING>Osteoarticular allograft</VALUEMEANING>
          <MEANINGDESCRIPTION>Osteoarticular allograft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Free tissue transfer</VALIDVALUE>
          <VALUEMEANING>Free tissue transfer</VALUEMEANING>
          <MEANINGDESCRIPTION>Free tissue transfer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excision without amputation</VALIDVALUE>
          <VALUEMEANING>Excision without amputation</VALUEMEANING>
          <MEANINGDESCRIPTION>Excision without amputation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intercalary autograft</VALIDVALUE>
          <VALUEMEANING>Intercalary autograft</VALUEMEANING>
          <MEANINGDESCRIPTION>Intercalary autograft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intercalary allograft</VALIDVALUE>
          <VALUEMEANING>Intercalary allograft</VALUEMEANING>
          <MEANINGDESCRIPTION>Intercalary allograft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascularized fibular autograft</VALIDVALUE>
          <VALUEMEANING>Vascularized fibular autograft</VALUEMEANING>
          <MEANINGDESCRIPTION>Vascularized fibular autograft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascularized fibular autograft and allograft</VALIDVALUE>
          <VALUEMEANING>Vascularized fibular autograft and allograft</VALUEMEANING>
          <MEANINGDESCRIPTION>Vascularized fibular autograft and allograft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rotationplasty</VALIDVALUE>
          <VALUEMEANING>Rotationplasty</VALUEMEANING>
          <MEANINGDESCRIPTION>Rotationplasty</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arthroscopy</VALIDVALUE>
          <VALUEMEANING>Arthroscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of a joint space.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38033</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No bony reconstruction</VALIDVALUE>
          <VALUEMEANING>No bony reconstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>No bony reconstruction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small bowel-to-small bowel </VALIDVALUE>
          <VALUEMEANING>Small bowel-to-small bowel </VALUEMEANING>
          <MEANINGDESCRIPTION>Small bowel-to-small bowel </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small bowel-to-rectum </VALIDVALUE>
          <VALUEMEANING>Small bowel-to-rectum </VALUEMEANING>
          <MEANINGDESCRIPTION>Small bowel-to-rectum </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileostomy </VALIDVALUE>
          <VALUEMEANING>Ileostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>(il-ee-AHS-toe-mee) An opening into the ileum, part of the small intestine, from the outside of the body. An ileostomy provides a new path for waste material to leave the body after part of the intestine has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tube jejunostomy</VALIDVALUE>
          <VALUEMEANING>Tube jejunostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Tube jejunostomy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tube gastrostomy </VALIDVALUE>
          <VALUEMEANING>Tube gastrostomy </VALUEMEANING>
          <MEANINGDESCRIPTION>Tube gastrostomy </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small bowel-to-colon </VALIDVALUE>
          <VALUEMEANING>Small bowel-to-colon </VALUEMEANING>
          <MEANINGDESCRIPTION>Small bowel-to-colon </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrojejunostomy</VALIDVALUE>
          <VALUEMEANING>Gastrojejunostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Gastrojejunostomy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colo-colostomy</VALIDVALUE>
          <VALUEMEANING>Colo-colostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Colo-colostomy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colostomy </VALIDVALUE>
          <VALUEMEANING>Colostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>An opening into the colon from the outside of the body. A colostomy provides a new path for waste material to leave the body after part of the colon has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneal drainage tube(s) </VALIDVALUE>
          <VALUEMEANING>Peritoneal drainage tube(s) </VALUEMEANING>
          <MEANINGDESCRIPTION>Peritoneal drainage tube(s) </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Continent Catheterizable Reservoir</VALIDVALUE>
          <VALUEMEANING>Continent Catheterizable Reservoir</VALUEMEANING>
          <MEANINGDESCRIPTION>Continent Catheterizable Reservoir</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3157786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neobladder</VALIDVALUE>
          <VALUEMEANING>NEOBLADDER</VALUEMEANING>
          <MEANINGDESCRIPTION>NEOBLADDER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal Conduit</VALIDVALUE>
          <VALUEMEANING>Ileal Conduit</VALUEMEANING>
          <MEANINGDESCRIPTION>Ileal Conduit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3157787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bioprosthetic Material Reconstruction</VALIDVALUE>
          <VALUEMEANING>Bioprosthetic Material Reconstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>Bioprosthetic Material Reconstruction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5845184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound remain open at this time</VALIDVALUE>
          <VALUEMEANING>Wound remain open at this time</VALUEMEANING>
          <MEANINGDESCRIPTION>Wound remain open at this time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5845183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complex Layered Closure</VALIDVALUE>
          <VALUEMEANING>Complex Layered Closure</VALUEMEANING>
          <MEANINGDESCRIPTION>Complex Layered Closure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5845185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complex Sutures/Staples</VALIDVALUE>
          <VALUEMEANING>Complex Sutures/Staples</VALUEMEANING>
          <MEANINGDESCRIPTION>Complex Sutures/Staples</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5845186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound Vacuum-Assisted Closure</VALIDVALUE>
          <VALUEMEANING>Wound Vacuum-Assisted Closure</VALUEMEANING>
          <MEANINGDESCRIPTION>Wound Vacuum-Assisted Closure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5845187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Free flap with microvascular anastomosis</VALIDVALUE>
          <VALUEMEANING>Free flap with microvascular anastomosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Free flap with microvascular anastomosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5832536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin thickness skin flap</VALIDVALUE>
          <VALUEMEANING>Skin thickness skin flap</VALUEMEANING>
          <MEANINGDESCRIPTION>Skin thickness skin flap</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5832537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pedicled myocutaneous flap or muscle flap</VALIDVALUE>
          <VALUEMEANING>Pedicled myocutaneous flap or muscle flap</VALUEMEANING>
          <MEANINGDESCRIPTION>Pedicled myocutaneous flap or muscle flap</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5832538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Use of local muscle flaps</VALIDVALUE>
          <VALUEMEANING>Use of local muscle flaps</VALUEMEANING>
          <MEANINGDESCRIPTION>Use of local muscle flaps</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5832539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simple skin closure</VALIDVALUE>
          <VALUEMEANING>Simple Skin Closure</VALUEMEANING>
          <MEANINGDESCRIPTION>Easy, not involved or complicated, not elaborate, having few parts.: An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.: Closure; refers to the closing of a study to enrollment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25366, C12470, C47880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5832540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Surgical Reconstruction</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Surgical Reconstruction</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Reconstructions/Diversions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bowel reconstruction</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of bladder reconstruction</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Method of reconstruction</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="54">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182372</PUBLICID>
    <LONGNAME>Lymph Node Assessment Type</LONGNAME>
    <PREFERREDNAME>LN_ASSESS_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the field to indicate the type of lymph node assessment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182371</PublicId>
      <PreferredName>LN_ASSESS</PreferredName>
      <PreferredDefinition>information related to a lymph node assessment.</PreferredDefinition>
      <LongName>Lymph Node Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177119</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymph Node</PreferredName>
        <Version>1</Version>
        <LongName>Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177637</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182368</PublicId>
      <PreferredName>LN_ASSESS_TP</PreferredName>
      <PreferredDefinition>information related to the type of lymph node assessment.</PreferredDefinition>
      <LongName>Lymph Node Assessment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Random biopsy</VALIDVALUE>
          <VALUEMEANING>Random biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Random biopsy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sentinel node</VALIDVALUE>
          <VALUEMEANING>Sentinel node</VALUEMEANING>
          <MEANINGDESCRIPTION>Sentinel node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sampling</VALIDVALUE>
          <VALUEMEANING>Sampling</VALUEMEANING>
          <MEANINGDESCRIPTION>Sampling</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dissection</VALIDVALUE>
          <VALUEMEANING>Dissection</VALUEMEANING>
          <MEANINGDESCRIPTION>The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure. (MedicineNet.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph nodes attached to primary tumor</VALIDVALUE>
          <VALUEMEANING>Lymph nodes attached to primary tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Lymph nodes attached to primary tumor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of Lymph Node Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of Lymph Node Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of lymph node biopsy:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="55">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182582</PUBLICID>
    <LONGNAME>Prior RT History Specify</LONGNAME>
    <PREFERREDNAME>PRIOR_RT_HX_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to describe the prior radiation therapy history.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197694</PublicId>
      <PreferredName>PRIOR_RT_HX</PreferredName>
      <PreferredDefinition>information related to the prior radiation therapy history.</PreferredDefinition>
      <LongName>Prior RT History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206566</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Prior Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>History</PreferredName>
        <Version>1</Version>
        <LongName>History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, Specify</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other, Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Radiation </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="56">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182938</PUBLICID>
    <LONGNAME>Adverse Event Outcome Code</LONGNAME>
    <PREFERREDNAME>AE_OUTCOME_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The code that represents the outcome of an adverse event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2179537</PublicId>
      <PreferredName>AE OUTCOME</PreferredName>
      <PreferredDefinition>The descriptive outcome of the adverse event.</PreferredDefinition>
      <LongName>Adverse Event Outcome</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184272</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Adverse Event</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177438</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Outcome</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCR:Center for Cancer Research</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182936</PublicId>
      <PreferredName>AE_OUTCOME_CD</PreferredName>
      <PreferredDefinition>All codes that represents the outcome of an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Outcome Code</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Fatal</VALUEMEANING>
          <MEANINGDESCRIPTION>Fatal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Resolving</VALUEMEANING>
          <MEANINGDESCRIPTION>Resolving</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Not Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Not Resolved</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Resolved with Sequelae</VALUEMEANING>
          <MEANINGDESCRIPTION>Resolved with Sequelae</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Ongoing at Death</VALUEMEANING>
          <MEANINGDESCRIPTION>Ongoing at Death</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Outcome</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Outcome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse Event Outcome Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Review Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SeriousAdverseEvents</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812325</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke 500</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812580</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CIAF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imiquimod for Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exp. PK Formulations of SR13668</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett&#39;s Patients</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2813043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3152820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_OUTCOME_CD</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_OUTCOME_CD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="57">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183219</PUBLICID>
    <LONGNAME>Alpha DVG Blood Pressure, Systolic</LONGNAME>
    <PREFERREDNAME>ALPHA_DVG_BPS</PREFERREDNAME>
    <PREFERREDDEFINITION>Oracle&quot;s Discrete Value Group (DVG) for a Systolic Blood Pressure that may not be obtained.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2181673</PublicId>
      <PreferredName>ALPHA_DVG_NOT_OBTAINED_IND</PreferredName>
      <PreferredDefinition>The DEC of the Alpha DVG Not Obtained Indicator.</PreferredDefinition>
      <LongName>Alpha DVG Not Obtained Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008583</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>RESPONSE</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236773</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2415348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183217</PublicId>
      <PreferredName>ALPHA_DVG_BPS</PreferredName>
      <PreferredDefinition>Oracle&#39;s Discrete Value Group (DVG) for a Systolic Blood Pressure that may not be obtained.</PreferredDefinition>
      <LongName>Alpha DVG Blood Pressure, Systolic</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>Numeric Alpha DVG</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Obtained</VALIDVALUE>
          <VALUEMEANING>Not Obtained</VALUEMEANING>
          <MEANINGDESCRIPTION>Not Obtained</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alpha DVG Blood Pressure, Sys</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Alpha DVG Blood Pressure, Systolic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Systolic Blood Pressure Not Obtained</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Systolic Blood Pressure Not Obtained</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Blood Pressure Systolic, not obtained</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imiquimod for Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exp. PK Formulations of SR13668</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett&#39;s Patients</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2813043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3152820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261112</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-08-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2017-09-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5981652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6046252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>COMPOUND</DerivationType>
      <DerivationTypeDescription>COMPOUND</DerivationTypeDescription>
      <Methods/>
      <Rule>Combines Alpha DVG Blood Pressure, Systolic 2183219 with Not Obtained Indicator 2182879 that could be used for Oracle Clinical.</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>2183219</PublicId>
          <LongName>Alpha DVG Blood Pressure, Systolic</LongName>
          <PreferredName>ALPHA_DVG_BPS</PreferredName>
          <PreferredDefinition>Oracle&quot;s Discrete Value Group (DVG) for a Systolic Blood Pressure that may not be obtained.</PreferredDefinition>
          <Version>2</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>DCP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2182879</PublicId>
          <LongName>Not Obtained Indicator</LongName>
          <PreferredName>NOT_OBTAINED_IND</PreferredName>
          <PreferredDefinition>The indicator that represents that a specific test, exam, or specimen was not obtained, not examined, not applicable, unknown or not required, etc.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>DCP</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="58">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183219</PUBLICID>
    <LONGNAME>Alpha DVG Blood Pressure, Systolic</LONGNAME>
    <PREFERREDNAME>ALPHA_DVG_BPS</PREFERREDNAME>
    <PREFERREDDEFINITION>Oracle&quot;s Discrete Value Group (DVG) for a Systolic Blood Pressure that may not be obtained.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>COMPOUND</DerivationType>
      <DerivationTypeDescription>COMPOUND</DerivationTypeDescription>
      <Methods/>
      <Rule>Combines Alpha DVG Blood Pressure, Systolic 2183219 with Not Obtained Indicator 2182879 that could be used for Oracle Clinical.</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="59">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182879</PUBLICID>
    <LONGNAME>Not Obtained Indicator</LONGNAME>
    <PREFERREDNAME>NOT_OBTAINED_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that represents that a specific test, exam, or specimen was not obtained, not examined, not applicable, unknown or not required, etc.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="60">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183468</PUBLICID>
    <LONGNAME>FACIT-Sp Emotional Well-Being Subcategory Score</LONGNAME>
    <PREFERREDNAME>FACITSP_EMOTW_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric score for the Emotional Well-Being subcategory of the FACIT Spiritual Well-being tool.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183466</PublicId>
      <PreferredName>FACITSP_EMOTW_SUBCAT</PreferredName>
      <PreferredDefinition>Emotional Well-Being subcategory of the FACIT Spiritual Well-being tool.</PreferredDefinition>
      <LongName>FACIT-Sp Emotional Well-Being Subcategory</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2191308</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Spiritual assessment</PreferredName>
        <Version>1</Version>
        <LongName>Spiritual assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL269984</PREFERRED_NAME>
            <LONG_NAME>Spiritual assessment</LONG_NAME>
            <CON_ID>2203512</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207531</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25495:C25692</PreferredName>
        <Version>1</Version>
        <LongName>Emotional Subcategory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25495</PREFERRED_NAME>
            <LONG_NAME>Emotional</LONG_NAME>
            <CON_ID>2206201</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25692</PREFERRED_NAME>
            <LONG_NAME>Subcategory</LONG_NAME>
            <CON_ID>2203589</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183451</PublicId>
      <PreferredName>PSYCM_QUEST_NUM_SC</PreferredName>
      <PreferredDefinition>Numeric score on a psychometric questionnaire or survey.</PreferredDefinition>
      <LongName>Psychometric Questionnaire Number Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>500</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2665189</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17034:C25337:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Psychometrics Number Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17034</PREFERRED_NAME>
            <LONG_NAME>Psychometrics</LONG_NAME>
            <CON_ID>2520620</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Emotional Well-Being Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Emotional Well-Being Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="61">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183585</PUBLICID>
    <LONGNAME>Breast First Progression Local-Regional Site</LONGNAME>
    <PREFERREDNAME>BRS_FIR_PROG_LOC_SIT</PREFERREDNAME>
    <PREFERREDDEFINITION>an anatomic location of the spread of breast cancer within the vicinity of the original site.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197850</PublicId>
      <PreferredName>BRST_FIRST_PROG</PreferredName>
      <PreferredDefinition>information related to the first progression of a breast cancer</PreferredDefinition>
      <LongName>Breast First Progression</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176971</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Breast</PreferredName>
        <Version>1</Version>
        <LongName>Breast</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207358</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25331</PreferredName>
        <Version>1</Version>
        <LongName>First Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25331</PREFERRED_NAME>
            <LONG_NAME>Progression</LONG_NAME>
            <CON_ID>2202788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183583</PublicId>
      <PreferredName>BRS_FIR_PROG_LOC_SIT</PreferredName>
      <PreferredDefinition>an anatomic location of the spread of breast cancer within the vicinity of the original site.</PreferredDefinition>
      <LongName>Breast First Progression Local-Regional Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral breast</VALIDVALUE>
          <VALUEMEANING>IPSILATERAL BREAST</VALUEMEANING>
          <MEANINGDESCRIPTION>IPSILATERAL BREAST</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axillary nodes</VALIDVALUE>
          <VALUEMEANING>Axillary Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supraclavicular nodes</VALIDVALUE>
          <VALUEMEANING>Supraclavicular Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node which is located above the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest wall</VALIDVALUE>
          <VALUEMEANING>Chest Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.: The muscles, bones, and joints that make up the area of the body between the neck and the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL035093, C62484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Internal mammary nodes</VALIDVALUE>
          <VALUEMEANING>Internal Mammary Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the lymph nodes of the breast located under the ribcage, near the sternum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infraclavicular nodes</VALIDVALUE>
          <VALUEMEANING>Infraclavicular Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the area below the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axilla</VALIDVALUE>
          <VALUEMEANING>Axilla</VALUEMEANING>
          <MEANINGDESCRIPTION>Axilla; the hollow under the arm where it is joined to the shoulder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regional nodes/axilla</VALIDVALUE>
          <VALUEMEANING>Regional nodes/axilla</VALUEMEANING>
          <MEANINGDESCRIPTION>Regional nodes/axilla</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3027256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Progression Site(s) First Local-Regional</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on template form (make Site plural): (s)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>2-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on template form: mark all that apply</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Site of First Local-Regional</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Site of First Local-Regional Progression</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Sites (progression or relapse)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461588</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imaging Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886753</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>General Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902138</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886754</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imaging</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BOLD</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BOLD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="62">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183716</PUBLICID>
    <LONGNAME>Gynecologic Examined Site</LONGNAME>
    <PREFERREDNAME>GYN_EXM_SITE</PREFERREDNAME>
    <PREFERREDDEFINITION>the examined gynecologic site.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183715</PublicId>
      <PreferredName>GYN_EXM</PreferredName>
      <PreferredDefinition>information related to an examined gynecologic site.</PreferredDefinition>
      <LongName>Gynecologic Examined</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184301</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Gynecologic</PreferredName>
        <Version>1</Version>
        <LongName>Gynecologic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28016</PREFERRED_NAME>
            <LONG_NAME>Gynecologic</LONG_NAME>
            <CON_ID>2202649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Examined</PreferredName>
        <Version>1</Version>
        <LongName>Examined</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25500</PREFERRED_NAME>
            <LONG_NAME>Examined</LONG_NAME>
            <CON_ID>2203928</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183714</PublicId>
      <PreferredName>GYN_EXM_SITE</PreferredName>
      <PreferredDefinition>the examined gynecologic site.</PreferredDefinition>
      <LongName>Gynecologic Examined Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor present</VALIDVALUE>
          <VALUEMEANING>Tumor present</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor present</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No tumor</VALIDVALUE>
          <VALUEMEANING>No tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>No tumor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suspicious</VALIDVALUE>
          <VALUEMEANING>SUSPICIOUS</VALUEMEANING>
          <MEANINGDESCRIPTION>SUSPICIOUS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0750493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Organ absent</VALIDVALUE>
          <VALUEMEANING>Organ absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Organ absent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not examined</VALIDVALUE>
          <VALUEMEANING>NOT EXAMINED</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Having been subjected to inspection or evaluation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25500, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Exam</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Exam</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000079</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0218</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000080</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GYN_EXM_SITE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="63">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183785</PUBLICID>
    <LONGNAME>Granulocyte Colony Stimulating Factor Filgrastim Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>GCSF_ADM_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether there was administration of the colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3534084</PublicId>
      <PreferredName>GCSF_FILG_ADM</PreferredName>
      <PreferredDefinition>information related to administration of the colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents.</PreferredDefinition>
      <LongName>Granulocyte Colony Stimulating Factor Filgrastim Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3534081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26078</PreferredName>
        <Version>1</Version>
        <LongName>Colony Stimulating Factor 3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26078</PREFERRED_NAME>
            <LONG_NAME>Granulocyte Colony-Stimulating Factor</LONG_NAME>
            <CON_ID>2717412</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3534082</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1474:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Filgrastim Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1474</PREFERRED_NAME>
            <LONG_NAME>Filgrastim</LONG_NAME>
            <CON_ID>2427132</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Filgrastim (Neupogen)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Filgrastim (Neupogen)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was GCSF administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ThermoDox Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812723</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>GCSF_ADM_IND2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="64">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183795</PUBLICID>
    <LONGNAME>Interview Start Time</LONGNAME>
    <PREFERREDNAME>INTVW_START_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>Clock time at the beginning of an interview, using a 24 hour clock.  Expressed in hours and minutes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183793</PublicId>
      <PreferredName>INTVW_PROC</PreferredName>
      <PreferredDefinition>Sequence of events that occur during an interview with a subject or person._A conversation with an individual regarding his or her background and other personal and professional details, opinions on specific subjects posed by the interviewer, etc.</PreferredDefinition>
      <LongName>Interview Process</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2596195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16751</PreferredName>
        <Version>1</Version>
        <LongName>Interview</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16751</PREFERRED_NAME>
            <LONG_NAME>Interview</LONG_NAME>
            <CON_ID>2425737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2183791</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29862</PreferredName>
        <Version>1</Version>
        <LongName>Process</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29862</PREFERRED_NAME>
            <LONG_NAME>Process</LONG_NAME>
            <CON_ID>2202628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019249</PublicId>
      <PreferredName>TM</PreferredName>
      <PreferredDefinition>the time at which an event was observed or occurred.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Started Time</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Started Time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>LCC Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Time of Assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DFMO/Sul Colon III UCI 02_06</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 97_05</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>INTVW_START_TM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="65">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183880</PUBLICID>
    <LONGNAME>Multivitamin Name Code</LONGNAME>
    <PREFERREDNAME>MVI_NM_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Codes to represent the type of multivitamin taken by the participant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183801</PublicId>
      <PreferredName>MVI_USE_HX</PreferredName>
      <PreferredDefinition>History or a person&#39;s recall of their use of multivitamins.</PreferredDefinition>
      <LongName>Multivitamin Use History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2183798</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0351716</PreferredName>
        <Version>1</Version>
        <LongName>Multivitamin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0351716</PREFERRED_NAME>
            <LONG_NAME>Multivitamin</LONG_NAME>
            <CON_ID>2202933</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207513</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340:C0262926</PreferredName>
        <Version>1</Version>
        <LongName>Use Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0262926</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2203171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183878</PublicId>
      <PreferredName>MVI_NM_CD</PreferredName>
      <PreferredDefinition>Codes to represent the type of multivitamin taken by the participant.</PreferredDefinition>
      <LongName>Multivitamin Name Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Multivitamins (No Minerals)</VALUEMEANING>
          <MEANINGDESCRIPTION>Multivitamins (No Minerals)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Multivitamins with Minerals</VALUEMEANING>
          <MEANINGDESCRIPTION>Multivitamins with Minerals</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>B-complex multi-supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>B-complex multi-supplement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Stress multi-supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>Stress multi-supplement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Anti-oxidant multi-supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>Anti-oxidant multi-supplement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Other mixture</VALUEMEANING>
          <MEANINGDESCRIPTION>Other mixture</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Multivitamin Code</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Multivitamin Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DFMO/Sul Colon III UCI 02_06</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 97_05</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="66">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2185857</PUBLICID>
    <LONGNAME>Internal Dental Tooth Treatment Text</LONGNAME>
    <PREFERREDNAME>INT_DENTAL_TO_TX_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field regarding internal dental tooth (endodontic) treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2185856</PublicId>
      <PreferredName>DENTAL_TX</PreferredName>
      <PreferredDefinition>information related to dental treatment.</PreferredDefinition>
      <LongName>Dental Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2185709</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dental</PreferredName>
        <Version>1</Version>
        <LongName>Dental</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0226984</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2203108</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180739</PublicId>
      <PreferredName>TX_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to treatment or therapy.</PreferredDefinition>
      <LongName>Therapy Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Endodontically treated teeth</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Endodontically treated teeth</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="67">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2185883</PUBLICID>
    <LONGNAME>Dentist Signature Text</LONGNAME>
    <PREFERREDNAME>DENTIST_SIG_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field for the dentist&#39;s signature.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2185882</PublicId>
      <PreferredName>DENTIST_SIG</PreferredName>
      <PreferredDefinition>information related to a dentist&#39;s signature.</PreferredDefinition>
      <LongName>Dentist Signature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dentist</PreferredName>
        <Version>1</Version>
        <LongName>Dentists</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0011441</PREFERRED_NAME>
            <LONG_NAME>Dentists</LONG_NAME>
            <CON_ID>2203215</CON_ID>
            <DEFINITION_SOURCE>Medical Subject Headings (MeSH). Bethesda (MD): National Library of Medicine.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177359</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Signature</PreferredName>
        <Version>1</Version>
        <LongName>Signature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018289</PublicId>
      <PreferredName>INDS_TXT</PreferredName>
      <PreferredDefinition>the free-text field to describe a specific person.</PreferredDefinition>
      <LongName>Individuals Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Signature of examining dentist</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Signature of examining dentist</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I have reviewed these data and certify that they are accurate to the best of my knowledge</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="68">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2187959</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Decubitus Ulcer Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_DECUBITUS_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Dermatology/Skin, assessment of the severity of a skin breakdown or decubitus ulcer adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2198302</PublicId>
      <PreferredName>CTC_AE_DECUBITUSULC</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of decubitus ulcer.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Decubitus Ulcer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2198300</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Decubitus ulcer</PreferredName>
        <Version>1</Version>
        <LongName>Decubitus ulcer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0011127</PREFERRED_NAME>
            <LONG_NAME>Decubitus ulcer</LONG_NAME>
            <CON_ID>2204422</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2187958</PublicId>
      <PreferredName>CTC_AE_DECUBITUS_GD</PreferredName>
      <PreferredDefinition>in CTC category Dermatology/Skin, assessment of the severity of a skin breakdown or decubitus ulcer adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Decubitus Ulcer Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Local wound care; medical intervention indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Local wound care; medical intervention indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Operative debridement or other invasive intervention indicated (e.g., hyperbaric oxygen)</VALUEMEANING>
          <MEANINGDESCRIPTION>Operative debridement or other invasive intervention indicated (e.g., hyperbaric oxygen)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Life-threatening consequences; major invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening consequences; major invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Skin breakd</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Skin breakdown/decubitus ulcer Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Skin breakdown/decubitus ulcer Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="69">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188168</PUBLICID>
    <LONGNAME>Serious Adverse Event Treatment Date</LONGNAME>
    <PREFERREDNAME>SAE_TX_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date of the serious adverse event treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013053</PublicId>
      <PreferredName>AE_SERIOUS</PreferredName>
      <PreferredDefinition>Any expected or unexpected adverse event, related or unrelated to the intervention, occurring at any agent dose, any phase of product or procedure testing, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect. Important medical events that may not result in the listed outcomes may be considered as serious when, based upon appropriate medical judgment, they represent significant hazards or potentially serious harm to the research subject or others and may require medical intervention to prevent one of the outcomes listed in this definition._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Serious Adverse Event Occurrence</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2717046</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41335</PreferredName>
        <Version>1</Version>
        <LongName>Serious Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41335</PREFERRED_NAME>
            <LONG_NAME>Serious Adverse Event</LONG_NAME>
            <CON_ID>2202356</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188166</PublicId>
      <PreferredName>TX_DT</PreferredName>
      <PreferredDefinition>A particular day specified as the time something has, or will, happen.</PreferredDefinition>
      <LongName>Treatment Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SAE Treatment Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>SAE Treatment Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SeriousAdverseEvents</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812325</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="70">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188449</PUBLICID>
    <LONGNAME>Agent Bicalutamide Administered Status</LONGNAME>
    <PREFERREDNAME>AGT_BICALUT_ADM_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>administration status for the agent bicalutamide.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2762100</PublicId>
      <PreferredName>AGT_BICAL_ADM</PreferredName>
      <PreferredDefinition>the administration of bicalutamide, a synthetic, nonsteroidal antiandrogen that competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens.</PreferredDefinition>
      <LongName>Agent Bicalutamide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2762098</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1599:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Bicalutamide Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1599</PREFERRED_NAME>
            <LONG_NAME>Bicalutamide</LONG_NAME>
            <CON_ID>2451677</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188448</PublicId>
      <PreferredName>BICALUT_AGT_ADM_STAT</PreferredName>
      <PreferredDefinition>administration status for the agent bicalutamide.</PreferredDefinition>
      <LongName>Bicalutamide Agent Administered Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2184340</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Status</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not taken</VALIDVALUE>
          <VALUEMEANING>Not taken</VALUEMEANING>
          <MEANINGDESCRIPTION>Not taken</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Initial</VALIDVALUE>
          <VALUEMEANING>Initial</VALUEMEANING>
          <MEANINGDESCRIPTION>Preceding all others in time or space or degree.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Second line</VALIDVALUE>
          <VALUEMEANING>Second line</VALUEMEANING>
          <MEANINGDESCRIPTION>Second line</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Third line</VALIDVALUE>
          <VALUEMEANING>Third line</VALUEMEANING>
          <MEANINGDESCRIPTION>Third line</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bicalutamide</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Localized Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000455</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="71">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188527</PUBLICID>
    <LONGNAME>Form Name</LONGNAME>
    <PREFERREDNAME>FORM_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name or title of a form.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188525</PublicId>
      <PreferredName>FORM_NM</PreferredName>
      <PreferredDefinition>The name of the form.</PreferredDefinition>
      <LongName>Form Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2458985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19464</PreferredName>
        <Version>1</Version>
        <LongName>Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178066</PublicId>
      <PreferredName>FORM_NAME</PreferredName>
      <PreferredDefinition>the name or title of a form.</PreferredDefinition>
      <LongName>Form Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184314</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Name</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Form Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Form Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Template Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Field Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imiquimod for Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett&#39;s Patients</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2813043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="72">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188593</PUBLICID>
    <LONGNAME>Lymph Node Clinical Involvement Type</LONGNAME>
    <PREFERREDNAME>LN_C_INVLT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the reporting of presence or absence of disease in a lymph node based on clinical assessment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188590</PublicId>
      <PreferredName>LN_C_INVLT</PreferredName>
      <PreferredDefinition>the involvement of the lymph node in cancer as determined by clinical examination.</PreferredDefinition>
      <LongName>Lymph Node Clinical Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177119</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymph Node</PreferredName>
        <Version>1</Version>
        <LongName>Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015384</PublicId>
      <PreferredName>LN_INVLT_TP</PreferredName>
      <PreferredDefinition>a description of the presence or absence of disease in the lymph nodes upon evaluation.</PreferredDefinition>
      <LongName>Lymph Node Involvement Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>clinically negative</VALIDVALUE>
          <VALUEMEANING>NEGATIVE BASED ON CLINICAL EVALUATION</VALUEMEANING>
          <MEANINGDESCRIPTION>NEGATIVE BASED ON CLINICAL EVALUATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>clinically positive</VALIDVALUE>
          <VALUEMEANING>POSITIVE BASED ON CLINICAL EVALUATION</VALUEMEANING>
          <MEANINGDESCRIPTION>POSITIVE BASED ON CLINICAL EVALUATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pathologically negative</VALIDVALUE>
          <VALUEMEANING>NEGATIVE BASED ON PATHOLOGIC EVALUATION</VALUEMEANING>
          <MEANINGDESCRIPTION>NEGATIVE BASED ON PATHOLOGIC EVALUATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pathologically positive</VALIDVALUE>
          <VALUEMEANING>POSITIVE BASED ON PATHOLOGIC EVALUATION</VALUEMEANING>
          <MEANINGDESCRIPTION>POSITIVE BASED ON PATHOLOGIC EVALUATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Involving advantage or good.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>INVOLVED</VALUEMEANING>
          <MEANINGDESCRIPTION>INVOLVED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not involved</VALIDVALUE>
          <VALUEMEANING>NOT INVOLVED</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT INVOLVED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1-3</VALIDVALUE>
          <VALUEMEANING>1-3</VALUEMEANING>
          <MEANINGDESCRIPTION>1-3 lymph nodes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;=4</VALIDVALUE>
          <VALUEMEANING>&gt;=4</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;=4 lymph nodes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Node negative, no neoadjuvant chemotherapy</VALIDVALUE>
          <VALUEMEANING>Node negative, no neoadjuvant chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Node negative, no neoadjuvant chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2667379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1-3 positive nodes, no neoadjuvant chemotherapy</VALIDVALUE>
          <VALUEMEANING>1-3 positive nodes, no neoadjuvant chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>1-3 positive nodes, no neoadjuvant chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2667380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;= 4 positive nodes, no neoadjuvant chemotherapy</VALIDVALUE>
          <VALUEMEANING>&gt;= 4 positive nodes, no neoadjuvant chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;= 4 positive nodes, no neoadjuvant chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2667381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not sampled</VALIDVALUE>
          <VALUEMEANING>Not sampled</VALUEMEANING>
          <MEANINGDESCRIPTION>Not sampled</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-11-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2626108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt; 4 sites</VALIDVALUE>
          <VALUEMEANING>&gt; 4 sites</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt; 4 sites</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;= 4 sites</VALIDVALUE>
          <VALUEMEANING>&lt;= 4 sites</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;= 4 sites</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>N/A</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not dissected</VALIDVALUE>
          <VALUEMEANING>Not dissected</VALUEMEANING>
          <MEANINGDESCRIPTION>Not dissected</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than or equal to 6</VALIDVALUE>
          <VALUEMEANING>Less than or equal to 6</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than or equal to 6 measurable nodes at baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7 or more</VALIDVALUE>
          <VALUEMEANING>7 or more</VALUEMEANING>
          <MEANINGDESCRIPTION>7 or more measurable nodes at baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;4</VALIDVALUE>
          <VALUEMEANING>&lt;4</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;4</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4488271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multiple nodes</VALIDVALUE>
          <VALUEMEANING>Multiple nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple nodes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6664649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Single node</VALIDVALUE>
          <VALUEMEANING>Single node</VALUEMEANING>
          <MEANINGDESCRIPTION>Single node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6664650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not apparent</VALIDVALUE>
          <VALUEMEANING>Not apparent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not apparent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7797517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apparent</VALIDVALUE>
          <VALUEMEANING>Apparent</VALUEMEANING>
          <MEANINGDESCRIPTION>Apparent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7797518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Clinical Lymph Node Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Clinical Lymph Node Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical lymph node status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiologic lymph node involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180933</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>LIDC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>QIN Breast Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6788757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LN_C_INVLT_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LN_C_INVLT_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>LN Assessment</AlternateName>
        <AlternateNameType>QIN Breast Study</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="73">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2190450</PUBLICID>
    <LONGNAME>Lung Cancer Pathological Attribute Text Name</LONGNAME>
    <PREFERREDNAME>LUNG_CA_PATH_ATTR_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name to describe pathological properties of lung carcinomas.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Director&#39;s Challenge Lung Study</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190447</PublicId>
      <PreferredName>LUNG_CA_PATH_ATTR</PreferredName>
      <PreferredDefinition>Pathological properties of lung carcinomas that distinguish them from other malignancies.</PreferredDefinition>
      <LongName>Lung Cancer Pathological Attribute</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2190444</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4878</PreferredName>
        <Version>1</Version>
        <LongName>Lung Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4878</PREFERRED_NAME>
            <LONG_NAME>Lung Carcinoma</LONG_NAME>
            <CON_ID>2202892</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207808</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C20189</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic Property or Attribute</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20189</PREFERRED_NAME>
            <LONG_NAME>Property or Attribute</LONG_NAME>
            <CON_ID>2204011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2190448</PublicId>
      <PreferredName>LUNG_CA_PATH_ATTR_NM</PreferredName>
      <PreferredDefinition>Text name to describe a pathological property of lung carcinoma.</PreferredDefinition>
      <LongName>Lung Cancer Pathological Attribute Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural invasion</VALIDVALUE>
          <VALUEMEANING>Pleural invasion</VALUEMEANING>
          <MEANINGDESCRIPTION>Pleural invasion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular invasion</VALIDVALUE>
          <VALUEMEANING>Vascular invasion</VALUEMEANING>
          <MEANINGDESCRIPTION>Vascular invasion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphatic invasion</VALIDVALUE>
          <VALUEMEANING>Lymphatic invasion</VALUEMEANING>
          <MEANINGDESCRIPTION>Lymphatic invasion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural surface involvement</VALIDVALUE>
          <VALUEMEANING>Pleural surface involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>Pleural surface involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive bronchial margins</VALIDVALUE>
          <VALUEMEANING>Positive bronchial margins</VALUEMEANING>
          <MEANINGDESCRIPTION>Positive bronchial margins</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive lymph nodes</VALIDVALUE>
          <VALUEMEANING>Positive lymph nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>Positive lymph nodes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inflammatory response</VALIDVALUE>
          <VALUEMEANING>Inflammatory response</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammatory response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Desmoplastic response</VALIDVALUE>
          <VALUEMEANING>Desmoplastic response</VALUEMEANING>
          <MEANINGDESCRIPTION>Desmoplastic response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Necrosis</VALIDVALUE>
          <VALUEMEANING>Necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The pathologic localized death of living cells, as from infection or interruption of the blood supply, generally associated with severe cellular trauma caused by progressive degradation by enzymes. Characterized by mitochondrial swelling, nuclear flocculation, and uncontrolled cell lysis, it is unprogrammed death of living tissue and cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathological Attribute</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathological Attributes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathological Attributes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183534</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Integrative Cancer Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Dir Chall Lung Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="74">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2190504</PUBLICID>
    <LONGNAME>Medication Administration Route Specify</LONGNAME>
    <PREFERREDNAME>MEDS_ADM_RTE_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the specified route of administration of a medication.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190499</PublicId>
      <PreferredName>MEDS_ADM_RTE</PreferredName>
      <PreferredDefinition>information related to the route of administration for a medication.</PreferredDefinition>
      <LongName>Medication Administration Route</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206749</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C459:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Medication Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Route</PreferredName>
        <Version>1</Version>
        <LongName>Route</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25169</PREFERRED_NAME>
            <LONG_NAME>Route</LONG_NAME>
            <CON_ID>2203782</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other route</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of Tumor Injection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000609</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MEDS_ADM_RTE_SPEC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="75">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2192791</PUBLICID>
    <LONGNAME>Protocol Study Description Text</LONGNAME>
    <PREFERREDNAME>PROT_STUDY_DESC_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field of the type of study being conducted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192789</PublicId>
      <PreferredName>PROT_STUDY_DESC</PreferredName>
      <PreferredDefinition>information related to the description or type of protocol study.</PreferredDefinition>
      <LongName>Protocol Study Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C15206</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Clinical Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177536</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Description</PreferredName>
        <Version>1</Version>
        <LongName>Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2411350</PublicId>
      <PreferredName>PROT_ADMIN_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to protocol administration.</PreferredDefinition>
      <LongName>Protocol Administration Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of Study</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of Study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Protocol Description</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Protocol Description</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000210</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876594</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Theradex</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Theradex - CTMS 3.14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3876603</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PROT_STUDY_DESC_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="76">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2192852</PUBLICID>
    <LONGNAME>Adverse Drug Event Expedited Reporting System Lab Category</LONGNAME>
    <PREFERREDNAME>ADEERS_LAB_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the lab category associated with Adverse Drug Event Expedited Reporting System (ADEERS).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4280814</PublicId>
      <PreferredName>ADEERS_LAB_DESC</PreferredName>
      <PreferredDefinition>a statement or description related to a scientific test, investigation or observation associated with reporting data to a Web application developed for electronic submission of Expedited Reports to the NCI for serious and/or unexpected Adverse Events.</PreferredDefinition>
      <LongName>Adverse Drug Event Expedited Reporting System Lab Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4280811</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17443</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Drug Experience Reporting System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17443</PREFERRED_NAME>
            <LONG_NAME>Adverse Drug Event Reporting System</LONG_NAME>
            <CON_ID>2493687</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4280812</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37984:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ADEERS:NCI/CTEP Adverse Event Expedited Report System</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2192853</PublicId>
      <PreferredName>ADEERS_LAB_CAT</PreferredName>
      <PreferredDefinition>the lab category associated with Adverse Drug Event Expedited Reporting System (ADEERS).</PreferredDefinition>
      <LongName>Adverse Drug Event Expedited Reporting System Lab Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ADEERS:NCI/CTEP Adverse Event Expedited Report System</Origin>
      <Representation>
        <PublicId>2184279</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Category</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemistry</VALIDVALUE>
          <VALUEMEANING>Chemistry</VALUEMEANING>
          <MEANINGDESCRIPTION>Chemistry</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coagulation</VALIDVALUE>
          <VALUEMEANING>COAGULATION</VALUEMEANING>
          <MEANINGDESCRIPTION>COAGULATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematologic</VALIDVALUE>
          <VALUEMEANING>Hematologic System</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to or related to the blood and blood-forming organs.: The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12909, C62780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microbiology</VALIDVALUE>
          <VALUEMEANING>Microbiology</VALUEMEANING>
          <MEANINGDESCRIPTION>Microbiology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Respiratory</VALIDVALUE>
          <VALUEMEANING>RESPIRATORY</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to respiration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow</VALIDVALUE>
          <VALUEMEANING>Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lab Category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lab Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Alternate Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lab category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000210</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858965</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="77">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2192888</PUBLICID>
    <LONGNAME>Medical Device Brand Name</LONGNAME>
    <PREFERREDNAME>MEDDEV_BRANDNAME</PREFERREDNAME>
    <PREFERREDDEFINITION>the brand name of a medical device.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192887</PublicId>
      <PreferredName>MEDDEV_BRANDNAME</PreferredName>
      <PreferredDefinition>information related to the brand name of a medical device.</PreferredDefinition>
      <LongName>Medical Device Brand Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2192884</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Medical Device</PreferredName>
        <Version>1</Version>
        <LongName>Medical Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0025080</PREFERRED_NAME>
            <LONG_NAME>Medical Device</LONG_NAME>
            <CON_ID>2203284</CON_ID>
            <DEFINITION_SOURCE>NCI04</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192885</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>brand name</PreferredName>
        <Version>1</Version>
        <LongName>brand name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0592503</PREFERRED_NAME>
            <LONG_NAME>brand name</LONG_NAME>
            <CON_ID>2204271</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2192889</PublicId>
      <PreferredName>MEDDEV_NAME</PreferredName>
      <PreferredDefinition>the name of a medical device.</PreferredDefinition>
      <LongName>Medical Device Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ADEERS:NCI/CTEP Adverse Event Expedited Report System</Origin>
      <Representation>
        <PublicId>2184314</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Name</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Brand name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Brand name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Brand Name</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Brand Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000210</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4272090</PublicId>
          <ContextName>ONC SDC Project</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MedWatch Form FDA 3500A</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Suspect medical device</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4382695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382692</PublicId>
          <ContextName>ONC SDC Project</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MedWatch Form FDA 3500</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Suspect Medical Device</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4633601</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382692</PublicId>
          <ContextName>ONC SDC Project</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MedWatch Form FDA 3500</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>All Sections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4940571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SDC Pilot Project</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="78">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2194402</PUBLICID>
    <LONGNAME>Head and Neck Progression Distant Location Solid Specify</LONGNAME>
    <PREFERREDNAME>HN_PR_DIS_LCT_SO_SPE</PREFERREDNAME>
    <PREFERREDDEFINITION>the specified solid site of a distant head and neck progression.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2194385</PublicId>
      <PreferredName>HN_PROG_DIST_LCTN</PreferredName>
      <PreferredDefinition>the site or location of head and neck distant progression.</PreferredDefinition>
      <LongName>Head and Neck Progression Distant Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12418:C25331</PreferredName>
        <Version>1</Version>
        <LongName>Head and Neck Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12418</PREFERRED_NAME>
            <LONG_NAME>Head and Neck</LONG_NAME>
            <CON_ID>2203706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25331</PREFERRED_NAME>
            <LONG_NAME>Progression</LONG_NAME>
            <CON_ID>2202788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207139</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25321:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Distant Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25321</PREFERRED_NAME>
            <LONG_NAME>Distant</LONG_NAME>
            <CON_ID>2204917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194416</PublicId>
      <PreferredName>ANAT_SITE_SOLID_SPEC</PreferredName>
      <PreferredDefinition>the free-text field to specify solid anatomic site.</PreferredDefinition>
      <LongName>Anatomic Sites Solid Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240753</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45300:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Solid Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45300</PREFERRED_NAME>
            <LONG_NAME>Solid</LONG_NAME>
            <CON_ID>2240752</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other solid, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HN_PR_DIS_LCT_SO_SPE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="79">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2194505</PUBLICID>
    <LONGNAME>Laboratory Procedure Calcium Electrolytes Outcome Value</LONGNAME>
    <PREFERREDNAME>LAB_CA_ELE_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the serum calcium lab value in mg/dl.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2189860</PublicId>
      <PreferredName>LAB_CA_ELECT_OC</PreferredName>
      <PreferredDefinition>information related to the medical procedure that involves testing a sample of blood for calcium electrolytes, substances that break up into ions (electrically charged particles) when they are dissolved in body fluids and are primarily responsible for the movement of nutrients into cells and the movement of wastes out of cells.</PreferredDefinition>
      <LongName>Laboratory Procedure Calcium Electrolytes Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2766644</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C331:C464:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Calcium Electrolytes Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C331</PREFERRED_NAME>
            <LONG_NAME>Calcium</LONG_NAME>
            <CON_ID>2204986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C464</PREFERRED_NAME>
            <LONG_NAME>Electrolytes</LONG_NAME>
            <CON_ID>2202615</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194504</PublicId>
      <PreferredName>HMT_SERUMCAL_LAB_VAL</PreferredName>
      <PreferredDefinition>the serum calcium lab value in mg/dl.</PreferredDefinition>
      <LongName>Hematology Serum Calcium Lab Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/dL</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184351</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Value</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serum calcium</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Serum calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FBPP  Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Calcium in mg/dL</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total serum calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2539469</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FBPP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FBPP Pooled Database </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812242</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000209</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ELECT_CA_LAB_SPE_VAL</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_CA_ELE_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_CA_ELE_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="80">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200276</PUBLICID>
    <LONGNAME>Clinical Data Update System Report Submitted Person Phone Number</LONGNAME>
    <PREFERREDNAME>CD_REP_SU_PER_PH_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>the telephone number where the person completing/submitting the report can be reached.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CDUS:Clinical Data Update System</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200274</PublicId>
      <PreferredName>CDUS_REP_SUB_PERSON</PreferredName>
      <PreferredDefinition>information related to the person submitting the CDUS report.</PreferredDefinition>
      <LongName>Clinical Data Update System Report Submitted Person</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480146</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19992:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Data Update System Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19992</PREFERRED_NAME>
            <LONG_NAME>Clinical Data Update System</LONG_NAME>
            <CON_ID>2202434</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207515</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25695:C0027361</PreferredName>
        <Version>1</Version>
        <LongName>Submitted Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25695</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2203811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0027361</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2203279</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015979</PublicId>
      <PreferredName>TELEPHONE_NUM</PreferredName>
      <PreferredDefinition>the telephone number for a person or organization.</PreferredDefinition>
      <LongName>Telephone Number</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008544</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TELECOMMUNICATIONS</PreferredName>
        <Version>1</Version>
        <LongName>Telecommunications</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>7</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208005</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25395:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Telephone Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25395</PREFERRED_NAME>
            <LONG_NAME>Telephone</LONG_NAME>
            <CON_ID>2202574</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Person completing report tele</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Person completing report telephone number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2 </DocumentText>
        <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Submitter Telephone Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Phone</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Administrative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812610</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000130</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261112</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5416571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2017-09-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2017-09-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5981652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6046252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="81">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200337</PUBLICID>
    <LONGNAME>Right Brachytherapy Second Reference Point Dose Total Dose</LONGNAME>
    <PREFERREDNAME>RT_BRT_SE_REFP_TT_DS</PREFERREDNAME>
    <PREFERREDDEFINITION>a quantity in Grays for the total radiation treatment administered to tissues at the standard cervical Point B anatomic location on the right side using a brachytherapy technique.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200128</PublicId>
      <PreferredName>RT_BRT_SEC_REFPTDOSE</PreferredName>
      <PreferredDefinition>the radiation treatment administered to tissues at the standard cervical Point B anatomic location on the right side using a brachytherapy technique.</PreferredDefinition>
      <LongName>Right Brachytherapy Second Reference Point Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25228:C15195</PreferredName>
        <Version>1</Version>
        <LongName>Right Brachytherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15195</PREFERRED_NAME>
            <LONG_NAME>Brachytherapy</LONG_NAME>
            <CON_ID>2202699</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207895</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:CL220834</PreferredName>
        <Version>1</Version>
        <LongName>Second Reference point dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL220834</PREFERRED_NAME>
            <LONG_NAME>Reference point dose</LONG_NAME>
            <CON_ID>2204485</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200299</PublicId>
      <PreferredName>BRT_LCTN_TTL_DOSE</PreferredName>
      <PreferredDefinition>a quantity in Grays for the complete radiation treatment administered using the brachytherapy technique.</PreferredDefinition>
      <LongName>Brachytherapy Location Total Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>999.99</DisplayFormat>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207921</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Total Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Dose to point B - Right</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Dose to point B - Right</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total Dose to point B - Rt</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_BRT_SE_REFP_TT_DS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="82">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200609</PUBLICID>
    <LONGNAME>Data Unknown Text</LONGNAME>
    <PREFERREDNAME>DATA_UNKNOWN_TEXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to record if data are unknown or not available.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200607</PublicId>
      <PreferredName>DATA_UNKNOWN</PreferredName>
      <PreferredDefinition>information related to unknown data.</PreferredDefinition>
      <LongName>Data Unknown</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177146</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Data</PreferredName>
        <Version>1</Version>
        <LongName>Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2200605</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Unknown</PreferredName>
        <Version>1</Version>
        <LongName>Unknown</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200608</PublicId>
      <PreferredName>DATA_UNKNOWN_TEXT</PreferredName>
      <PreferredDefinition>a single character text field to record data.</PreferredDefinition>
      <LongName>Data Unknown Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mark an &#39;X&#39; if N/A</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mark an &#39;X&#39; if unknown</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mark an &#39;X&#39; if unknown</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Not Done</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mark an &#39;X&#39; if not done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I do not know</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mark an &#39;X&#39; if not assessed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF1 Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Not Applicable</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Unknown</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text  2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Check box if number of lymph nodes examined is unknown</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Check box if number of positive lymph nodes is unknown</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Check box if Breslow Thickness unknown</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Report not available</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I don&#39;t know</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DATA_UNKNOWN_TEXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="83">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201077</PUBLICID>
    <LONGNAME>Patient Pre-Existing Condition Name</LONGNAME>
    <PREFERREDNAME>PT_PEC_NAME</PREFERREDNAME>
    <PREFERREDDEFINITION>the name of the pre-existing condition.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201074</PublicId>
      <PreferredName>PT_PEC</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s pre-existing condition.</PreferredDefinition>
      <LongName>Patient Pre-Existing Condition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2201072</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Pre-existing condition</PreferredName>
        <Version>1</Version>
        <LongName>Pre-existing condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL232826</PREFERRED_NAME>
            <LONG_NAME>Pre-existing condition</LONG_NAME>
            <CON_ID>2204482</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201076</PublicId>
      <PreferredName>PEC_NAME</PreferredName>
      <PreferredDefinition>the name of the pre-existing condition.</PreferredDefinition>
      <LongName>Pre-Existing Condition Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ADEERS:NCI/CTEP Adverse Event Expedited Report System</Origin>
      <Representation>
        <PublicId>2184314</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Name</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anemia</VALIDVALUE>
          <VALUEMEANING>Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2869</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thrombocytopenia</VALIDVALUE>
          <VALUEMEANING>Thrombocytopenia</VALUEMEANING>
          <MEANINGDESCRIPTION>A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thrombotic Disorder</VALIDVALUE>
          <VALUEMEANING>Thrombotic Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Thrombotic Disorder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arrhythmia</VALIDVALUE>
          <VALUEMEANING>Arrhythmia</VALUEMEANING>
          <MEANINGDESCRIPTION>Arrhythmia; an abnormal rate of muscle contractions in the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac Failure Congestive</VALIDVALUE>
          <VALUEMEANING>Cardiac Failure Congestive</VALUEMEANING>
          <MEANINGDESCRIPTION>Cardiac Failure Congestive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coronary Artery Disease</VALIDVALUE>
          <VALUEMEANING>CORONARY ARTERY DISEASE</VALUEMEANING>
          <MEANINGDESCRIPTION>Coronary artery disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypertension</VALIDVALUE>
          <VALUEMEANING>Hypertension</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormally high blood pressure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3117</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prior Anthracycline</VALIDVALUE>
          <VALUEMEANING>Prior Anthracycline</VALUEMEANING>
          <MEANINGDESCRIPTION>Prior Anthracycline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diabetes Mellitus</VALIDVALUE>
          <VALUEMEANING>Diabetes Mellitus</VALUEMEANING>
          <MEANINGDESCRIPTION>(dye-a-BEE-teez) A disease in which the body does not properly control the amount of sugar in the blood. As a result, the level of sugar in the blood is too high. This disease occurs when the body does not produce enough insulin or does not use it properly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endocrine Disorders</VALIDVALUE>
          <VALUEMEANING>Endocrine Disorders</VALUEMEANING>
          <MEANINGDESCRIPTION>Endocrine Disorders</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroid Disorder</VALIDVALUE>
          <VALUEMEANING>Thyroid Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Thyroid Disorder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inflammatory Bowel Disease</VALIDVALUE>
          <VALUEMEANING>Inflammatory Bowel Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Chronic, non-specific disorders of unknown etiology. Includes Crohn disease and ulcerative colitis. Extracolonic manifestations are often associated with Inflammatory Bowel Disease (IBD) and involve the liver, joints and skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peptic Ulcer</VALIDVALUE>
          <VALUEMEANING>Peptic Ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>Ulcer that occurs in those portions of the alimentary tract which come into contact with gastric juice containing pepsin and acid. It occurs when the amount of acid and pepsin is sufficient to overcome the gastric mucosal barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic Disorder</VALIDVALUE>
          <VALUEMEANING>Hepatic Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Hepatic Disorder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis</VALIDVALUE>
          <VALUEMEANING>Hepatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatocellular Damage</VALIDVALUE>
          <VALUEMEANING>Hepatocellular Damage</VALUEMEANING>
          <MEANINGDESCRIPTION>Hepatocellular Damage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatitis</VALIDVALUE>
          <VALUEMEANING>Pancreatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammation of the pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autoimmune Disorder</VALIDVALUE>
          <VALUEMEANING>Autoimmune Disorders</VALUEMEANING>
          <MEANINGDESCRIPTION>Autoimmune Disorders</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bacterial Infection</VALIDVALUE>
          <VALUEMEANING>Bacterial Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fungal Infection</VALIDVALUE>
          <VALUEMEANING>Fungal Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>An infection caused by a fungus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Viral Infection</VALIDVALUE>
          <VALUEMEANING>Viral Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>Any disease caused by a virus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteoarthritis</VALIDVALUE>
          <VALUEMEANING>Osteoarthritis</VALUEMEANING>
          <MEANINGDESCRIPTION>Osteoarthritis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rheumatoid Arthritis</VALIDVALUE>
          <VALUEMEANING>Rheumatoid Arthritis</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrovascular Accident</VALIDVALUE>
          <VALUEMEANING>Cerebrovascular Accident</VALUEMEANING>
          <MEANINGDESCRIPTION>A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Convulsions</VALIDVALUE>
          <VALUEMEANING>Convulsions</VALUEMEANING>
          <MEANINGDESCRIPTION>Convulsions</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral Neuropathy</VALIDVALUE>
          <VALUEMEANING>Peripheral Neuropathy</VALUEMEANING>
          <MEANINGDESCRIPTION>Peripheral Neuropathy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Pre-Existing Condition</VALIDVALUE>
          <VALUEMEANING>Other Pre-Existing Condition</VALUEMEANING>
          <MEANINGDESCRIPTION>Other Pre-Existing Condition</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electrolyte Depletion</VALIDVALUE>
          <VALUEMEANING>Electrolyte Depletion</VALUEMEANING>
          <MEANINGDESCRIPTION>Electrolyte Depletion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal Impairment</VALIDVALUE>
          <VALUEMEANING>Renal Impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>Diminished kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asthma</VALIDVALUE>
          <VALUEMEANING>Asthma</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchospasm</VALIDVALUE>
          <VALUEMEANING>Bronchospasm, wheezing</VALUEMEANING>
          <MEANINGDESCRIPTION>Bronchospasm, wheezing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic Obstructive Airways Disease</VALIDVALUE>
          <VALUEMEANING>Chronic Obstructive Airways Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cigarette Smoker</VALIDVALUE>
          <VALUEMEANING>Cigarette Smoker</VALUEMEANING>
          <MEANINGDESCRIPTION>Cigarette Smoker</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eczema</VALIDVALUE>
          <VALUEMEANING>Eczema</VALUEMEANING>
          <MEANINGDESCRIPTION>Eczema</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin Disorder</VALIDVALUE>
          <VALUEMEANING>Skin Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central Line Management</VALIDVALUE>
          <VALUEMEANING>Central Line Management</VALUEMEANING>
          <MEANINGDESCRIPTION>Central Line Management</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coagulation Disorder</VALIDVALUE>
          <VALUEMEANING>Coagulation Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Coagulation Disorder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Angina</VALIDVALUE>
          <VALUEMEANING>Angina</VALUEMEANING>
          <MEANINGDESCRIPTION>A heart condition marked by paroxysms of chest pain due to reduced oxygen to the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51221</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myocardial infarction</VALIDVALUE>
          <VALUEMEANING>Myocardial infarction</VALUEMEANING>
          <MEANINGDESCRIPTION>Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area. (Dorland, 27th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral vascular disease</VALIDVALUE>
          <VALUEMEANING>Peripheral vascular disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Peripheral vascular disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transient Ischemic Attack</VALIDVALUE>
          <VALUEMEANING>Transient ischemic attack</VALUEMEANING>
          <MEANINGDESCRIPTION>Transient ischemic attack</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Respiratory Tract Infections</VALIDVALUE>
          <VALUEMEANING>Upper Respiratory Tract Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>An infectious process affecting the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea). Symptoms include congestion, sneezing, coughing, fever, and sore throat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2944013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rheumatologic disease</VALIDVALUE>
          <VALUEMEANING>Rheumatologic Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2971319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diabetes mellitus without complications</VALIDVALUE>
          <VALUEMEANING>Diabetes Mellitus No Complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.: An indication that no complication occurred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124832, C2985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diabetes mellitus with complications</VALIDVALUE>
          <VALUEMEANING>Diabetes Complication</VALUEMEANING>
          <MEANINGDESCRIPTION>Organ or tissue damage due to diabetes mellitus. It includes heart disease and stroke, renal disease and renal failure, retinopathy, neuropathies, and erectile dysfunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3185651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deep vein thrombosis, pulmonary embolism, venous thromboembolism</VALIDVALUE>
          <VALUEMEANING>Deep Vein Thrombosis Pulmonary Embolism Venous Thromboembolism</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.: The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.: Occlusion of the lumen of a vein by a thrombus that has migrated from a distal site via the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99537, C50713, C49343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Depression</VALIDVALUE>
          <VALUEMEANING>Depression</VALUEMEANING>
          <MEANINGDESCRIPTION>A melancholy feeling of sadness and despair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coronary artery disease or ischemic heart disease</VALIDVALUE>
          <VALUEMEANING>Coronary Artery Disease Or Ischemic Heart Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>An imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50625, C37998, C26732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac impairment</VALIDVALUE>
          <VALUEMEANING>Heart Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3181118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone pain, bone fracture</VALIDVALUE>
          <VALUEMEANING>Bone Pain Fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>Painful sensation in the bones.: A traumatic injury to the bone in which the continuity of the bone is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3046, C38644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrovascular disease/History of stroke or transient ischemic attack</VALIDVALUE>
          <VALUEMEANING>Cerebrovascular Disorder Or Transient Ischemic Attack</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad category of disorders characterized by impairment of blood flow in the arteries and veins which supply the brain. These include CEREBRAL INFARCTION; BRAIN ISCHEMIA; HYPOXIA, BRAIN; INTRACRANIAL EMBOLISM AND THROMBOSIS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; and VASCULITIS, CENTRAL NERVOUS SYSTEM. In common usage, the term cerebrovascular disorders is not limited to conditions that affect the cerebrum, but refers to vascular disorders of the entire brain including the DIENCEPHALON; BRAIN STEM; and CEREBELLUM.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50781, C37998, C2938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone loss or erosion</VALIDVALUE>
          <VALUEMEANING>Osteopenia Or Bone Erosion</VALUEMEANING>
          <MEANINGDESCRIPTION>Decreased calcification or density of bone tissue.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Connective tissue that forms the skeletal components of the body.: An eating away or breakdown of any type of external or internal human tissue including but not limited to skin, teeth, mucosa, or somatic, which involves only the outer tissue layer. When tissue surrounds an implanted device, the tissue breakdown may result in migration and loss of the implant material and may result in further complications such as infection or abscess.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50443, C12366, C37998, C50910</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arthritis</VALIDVALUE>
          <VALUEMEANING>Arthritis</VALUEMEANING>
          <MEANINGDESCRIPTION>An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3292693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anxiety</VALIDVALUE>
          <VALUEMEANING>Anxiety</VALUEMEANING>
          <MEANINGDESCRIPTION>Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2746213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alzheimer&#39;s dementia/Dementia</VALIDVALUE>
          <VALUEMEANING>Alzheimer&#39;s Disease Dementia</VALUEMEANING>
          <MEANINGDESCRIPTION>A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.: Loss of intellectual abilities interfering with an individual&#39;s social and occupational functions. Causes include Alzheimer&#39;s disease, brain injuries, brain tumors, and vascular disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4786, C2866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alcohol misuse, abuse or dependence</VALIDVALUE>
          <VALUEMEANING>Alcohol Abuse Alcohol Dependence</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of alcoholic beverages to excess, either on individual occasions (&quot;binge drinking&quot;) or as a regular practice.: A chronic disease in which a person craves drinks that contain alcohol and is unable to control his or her drinking.  A person with this disease also needs to drink greater amounts to get the same effect and has withdrawal symptoms after stopping alcohol use. Alcoholism affects physical and mental health, and can cause problems with family, friends, and work.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93040, C20701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infections related to immunodeficiency</VALIDVALUE>
          <VALUEMEANING>Infection Connect With Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>The invasion of an organism&#39;s body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.: To become joined or linked.: Used to indicate the presence of something or someone.: A disorder in which the immune system is unable to mount an adequate immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39725, C62355, C94560, C128320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperlipidemia</VALIDVALUE>
          <VALUEMEANING>Hyperlipidemia</VALUEMEANING>
          <MEANINGDESCRIPTION>An excess of lipids in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2751390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIV Infection/AIDS</VALIDVALUE>
          <VALUEMEANING>HIV Infection Acquired Immunodeficiency Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>any state accompanied by evidence of HIV in the body (positive test for HIV genome, cDNA, proteins, antigens, or antibodies); may be medically asymptomatic or symptomatic; prefer AIDS when appropriate.: A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections (usually pneumocystis carinii pneumonia, cytomegalovirus (CMV) infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2851, C3108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis C</VALIDVALUE>
          <VALUEMEANING>Hepatitis C Virus</VALUEMEANING>
          <MEANINGDESCRIPTION>A small, enveloped, positive sense single strand RNA virus in the family Flaviviridae. The genome consists of a single RNA molecule with a single open reading frame.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3781475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis B</VALIDVALUE>
          <VALUEMEANING>Hepatitis B Virus</VALUEMEANING>
          <MEANINGDESCRIPTION>Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5&#39; extremity of the long strand. (from http://www.genetique.uvsq.fr/RC/virologie/hepatiteB_2_uk.html)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemiplegia or paraplegia</VALIDVALUE>
          <VALUEMEANING>Hemiplegia Or Paraplegia</VALUEMEANING>
          <MEANINGDESCRIPTION>Paralysis of one side of the body.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Complete paralysis of the lower half of the body including both legs, often caused by damage to the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50687, C37998, C64329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal disease</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-neoplastic or neoplastic disorder that affects the gastrointestinal tract, anus, liver, biliary system, and pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6424136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None of the Above</VALUEMEANING>
          <MEANINGDESCRIPTION>None of the choices above are suitable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5913672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary Tract Infections</VALIDVALUE>
          <VALUEMEANING>Urinary Tract Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4395783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Substance abuse or dependence</VALIDVALUE>
          <VALUEMEANING>Substance Abuse Or Drug Dependence</VALUEMEANING>
          <MEANINGDESCRIPTION>Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Drug dependence - replaced the term &quot;drug addiction&quot; and is defined as a state, psychic and sometimes also physical, resulting from the interaction between a living organism and a drug, characterized by behavioral and other responses that always include a compulsion to take the drug on a continuous or periodic basis in order to experience its psychic effects, and sometimes to avoid the discomfort of its absence. Tolerance may or may not be present. A person may be dependent on more than one drug.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3894, C37998, C18272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal disease or impairment</VALIDVALUE>
          <VALUEMEANING>Kidney Disorder Or Renal Impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Diminished kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114592, C37998, C3149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteoporosis</VALIDVALUE>
          <VALUEMEANING>Osteoporosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obstructive sleep apnea</VALIDVALUE>
          <VALUEMEANING>Obstructive Sleep Apnea</VALUEMEANING>
          <MEANINGDESCRIPTION>Cessation of air flow during sleep due to upper airway obstruction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obesity</VALIDVALUE>
          <VALUEMEANING>Obesity</VALUEMEANING>
          <MEANINGDESCRIPTION>Having a high amount of body fat (body mass index [BMI] of 30 or more).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metastatic solid tumors</VALIDVALUE>
          <VALUEMEANING>Metastatic Malignant Solid Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant solid neoplasm that has spread from its original site of growth to another anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mental illness</VALIDVALUE>
          <VALUEMEANING>Psychiatric Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Any deviation from the normal structure or function of the brain and a psychiatric condition, that results in an impairment of an individual&#39;s normal cognitive, emotional, or behavioral functioning, and is caused by physiological or psychosocial factors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Malignancies</VALIDVALUE>
          <VALUEMEANING>Malignant Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas, leukemias, melanomas, and sarcomas. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung impairment</VALIDVALUE>
          <VALUEMEANING>Lung Impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.: Loss or abnormality of psychological, physiological, or anatomic structure or function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C21055, C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver disease</VALIDVALUE>
          <VALUEMEANING>Liver Disease or Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392, C2991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5251422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pre-existing condition</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Comorbid Condition</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current Comorbidity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="84">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201189</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Reporting Category</LONGNAME>
    <PREFERREDNAME>CTC_AE_REP_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>an anatomic system or grouping associated with an adverse event in the protocol-specified version of the Common Terminology Criteria for Adverse Events. </PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201184</PublicId>
      <PreferredName>CTC_AE_REP_CLASS</PreferredName>
      <PreferredDefinition>the anatomic location or grouping of an unwanted effect caused by a drug or therapy as defined in the version of the Common Terminology Criteria for Adverse Events (CTCAE) used for reporting per protocol.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Reporting Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207697</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25651:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Reporting Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25651</PREFERRED_NAME>
            <LONG_NAME>Reporting</LONG_NAME>
            <CON_ID>2206359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016506</PublicId>
      <PreferredName>AE_CAT</PreferredName>
      <PreferredDefinition>pathophysiological and/or anatomical category of an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Category</LongName>
      <Version>5</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184279</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Category</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Constitutional Symptoms</VALIDVALUE>
          <VALUEMEANING>CONSTITUTIONAL SYMPTOMS</VALUEMEANING>
          <MEANINGDESCRIPTION>CONSTITUTIONAL SYMPTOMS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary/Upper Respiratory</VALIDVALUE>
          <VALUEMEANING>PULMONARY/UPPER RESPIRATORY</VALUEMEANING>
          <MEANINGDESCRIPTION>a pulmonary or upper respiratory tract related anatomical location</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dermatology/Skin</VALIDVALUE>
          <VALUEMEANING>DERMATOLOGY/SKIN</VALUEMEANING>
          <MEANINGDESCRIPTION>DERMATOLOGY/SKIN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal</VALUEMEANING>
          <MEANINGDESCRIPTION>The system that includes the esophagus, stomach, small and large intestine, anus, liver, biliary tract, and pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain</VALIDVALUE>
          <VALUEMEANING>PAIN</VALUEMEANING>
          <MEANINGDESCRIPTION>PAIN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infection</VALIDVALUE>
          <VALUEMEANING>Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>general term for invasion and growth of microorganisms in bodily tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0021311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allergy/Immunology</VALIDVALUE>
          <VALUEMEANING>ALLERGY / IMMUNOLOGY</VALUEMEANING>
          <MEANINGDESCRIPTION>ALLERGY / IMMUNOLOGY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Auditory/Ear</VALIDVALUE>
          <VALUEMEANING>AUDITORY/EAR</VALUEMEANING>
          <MEANINGDESCRIPTION>an auditory, ear or hearing related anatomical location</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood/Bone Marrow</VALIDVALUE>
          <VALUEMEANING>BLOOD/BONE MARROW</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL324677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac Arrhythmia</VALIDVALUE>
          <VALUEMEANING>CARDIAC ARRHYTHMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>a cardiac arrhythmia related event
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac General</VALIDVALUE>
          <VALUEMEANING>CARDIAC GENERAL</VALUEMEANING>
          <MEANINGDESCRIPTION>a general cardiac or cardiovascular related event</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coagulation</VALIDVALUE>
          <VALUEMEANING>COAGULATION</VALUEMEANING>
          <MEANINGDESCRIPTION>COAGULATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endocrine</VALIDVALUE>
          <VALUEMEANING>ENDOCRINE</VALUEMEANING>
          <MEANINGDESCRIPTION>ENDOCRINE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0521425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemorrhage/Bleeding</VALIDVALUE>
          <VALUEMEANING>HEMORRHAGE/BLEEDING</VALUEMEANING>
          <MEANINGDESCRIPTION>a hemorrhage or bleeding related event</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatobiliary/Pancreas</VALIDVALUE>
          <VALUEMEANING>HEPATOBILIARY/PANCREAS</VALUEMEANING>
          <MEANINGDESCRIPTION>a hepatobiliary, liver, or pancreas related anatomic location</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphatics</VALIDVALUE>
          <VALUEMEANING>LYMPHATICS</VALUEMEANING>
          <MEANINGDESCRIPTION>LYMPHATICS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metabolic/Laboratory</VALIDVALUE>
          <VALUEMEANING>METABOLIC/LABORATORY</VALUEMEANING>
          <MEANINGDESCRIPTION>METABOLIC/LABORATORY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Musculoskeletal/Soft Tissue</VALIDVALUE>
          <VALUEMEANING>MUSCULOSKELETAL/SOFT TISSUE</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL327736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neurology</VALIDVALUE>
          <VALUEMEANING>NEUROLOGY</VALUEMEANING>
          <MEANINGDESCRIPTION>A branch of medicine concerned with the development, anatomy, function, and dysfunction of the nervous system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ocular/Visual</VALIDVALUE>
          <VALUEMEANING>OCULAR/VISUAL</VALUEMEANING>
          <MEANINGDESCRIPTION>OCULAR/VISUAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal/Genitourinary</VALIDVALUE>
          <VALUEMEANING>RENAL/GENITOURINARY</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL328688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secondary Malignancy</VALIDVALUE>
          <VALUEMEANING>SECOND MALIGNANCY</VALUEMEANING>
          <MEANINGDESCRIPTION>SECOND MALIGNANCY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sexual/Reproductive Function</VALIDVALUE>
          <VALUEMEANING>SEXUAL/REPRODUCTIVE FUNCTIONS</VALUEMEANING>
          <MEANINGDESCRIPTION>SEXUAL/REPRODUCTIVE FUNCTIONS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syndromes</VALIDVALUE>
          <VALUEMEANING>SYNDROMES</VALUEMEANING>
          <MEANINGDESCRIPTION>SYNDROMES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Growth and Development</VALIDVALUE>
          <VALUEMEANING>GROWTH AND DEVELOPMENT</VALUEMEANING>
          <MEANINGDESCRIPTION>a growth and development related event, especially pediatric</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery/Intra-operative Injury</VALIDVALUE>
          <VALUEMEANING>SURGERY/INTRA-OPERATIVE INJURY</VALUEMEANING>
          <MEANINGDESCRIPTION>an event related to surgery or injury occurring during a surgical procedure (intra-operative)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular</VALIDVALUE>
          <VALUEMEANING>VASCULAR</VALUEMEANING>
          <MEANINGDESCRIPTION>a vascular or blood vessel related anatomic location</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Currently associated with the CTCAE version 3.0 value domain - a reference value domain will be created when caDSR 3.0 becomes available </DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCIP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AE Category (2-character internal code for Toxicity Category per CTCAE 3)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000210</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ae_category</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="85">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201836</PUBLICID>
    <LONGNAME>Patient Physical Examination Head and Neck Status</LONGNAME>
    <PREFERREDNAME>PT_PHYS_HEA_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of a physical examination related to the head and neck.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201749</PublicId>
      <PreferredName>PT_PE</PreferredName>
      <PreferredDefinition>information related to a physical examination, a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment, being performed on a patient/participant.</PreferredDefinition>
      <LongName>Patient Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2261670</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20989</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201818</PublicId>
      <PreferredName>PHYS_HEAD_STAT</PreferredName>
      <PreferredDefinition>the status of a physical examination related to the head and neck.</PreferredDefinition>
      <LongName>Physical Examination Head and Neck Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>6</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184340</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Status</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Head, eyes, ears, nose, throat</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="86">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201914</PUBLICID>
    <LONGNAME>Cardiac Disease Assessment Uncertain Diagnosis Status</LONGNAME>
    <PREFERREDNAME>CARD_DZ_ASS_UNC_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of a cardiac disease assessment where the diagnosis is uncertain based on the New York Heart Association.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201913</PublicId>
      <PreferredName>CARD_DX_ASSESS</PreferredName>
      <PreferredDefinition>information related to the cardiac disease assessment.</PreferredDefinition>
      <LongName>Cardiac Disease Assessent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2207060</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13306:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Cardiac Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13306</PREFERRED_NAME>
            <LONG_NAME>Cardiac</LONG_NAME>
            <CON_ID>2204960</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177637</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201919</PublicId>
      <PreferredName>CARD_UNC_STAT</PreferredName>
      <PreferredDefinition>the status of a cardiac disease assessment where the diagnosis is uncertain based on the New York Heart Association.</PreferredDefinition>
      <LongName>Cardiac Uncertain Diagnosis Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>47</MaximumLength>
      <MinimumLength>43</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184340</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Status</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No heart disease</VALIDVALUE>
          <VALUEMEANING>reasonable uncertainty that the symptoms or signs are not of cardiac origin</VALUEMEANING>
          <MEANINGDESCRIPTION>reasonable uncertainty that the symptoms or signs are not of cardiac origin</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Heart Disease: Predisposing Etiologic Factor</VALIDVALUE>
          <VALUEMEANING>includes patients in whom no cardiac disease is evident but whose course should be followed by periodic examinations because of a history of an etiologic factor that might cause heart disease.</VALUEMEANING>
          <MEANINGDESCRIPTION>includes patients in whom no cardiac disease is evident but whose course should be followed by periodic examinations because of a history of an etiologic factor that might cause heart disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Heart Disease: Unexplained Manifestation</VALIDVALUE>
          <VALUEMEANING>includes patients with symptoms or signs referable to the heart but in whom a diagnosis of cardiac disease is uncertain at the time of examination.</VALUEMEANING>
          <MEANINGDESCRIPTION>includes patients with symptoms or signs referable to the heart but in whom a diagnosis of cardiac disease is uncertain at the time of examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Uncertain diagnosis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Uncertain diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Reference: The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown &amp; Co; 1994:253-256.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="87">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223541</PUBLICID>
    <LONGNAME>User Email Address java.lang.String</LONGNAME>
    <PREFERREDNAME>2223489v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An individual who uses a computer, program, network, or related service for work or entertainment. (from http://www.computeruser.com/resources/dictionary/index.html)_An e-mail address identifies a location to which e-mail can be delivered. A modern Internet e-mail address (using SMTP) is a string of the form jsmith@domain.example. (from Wikipedia)_Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223489</PublicId>
      <PreferredName>2223465v1.0:2223457v1.0</PreferredName>
      <PreferredDefinition>An individual who uses a computer, program, network, or related service for work or entertainment. (from http://www.computeruser.com/resources/dictionary/index.html)_An e-mail address identifies a location to which e-mail can be delivered. A modern Internet e-mail address (using SMTP) is a string of the form jsmith@domain.example. (from Wikipedia)</PreferredDefinition>
      <LongName>User Email Address</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42745</PreferredName>
        <Version>1</Version>
        <LongName>User</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42745</PREFERRED_NAME>
            <LONG_NAME>System User</LONG_NAME>
            <CON_ID>2203603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223457</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42775</PreferredName>
        <Version>1</Version>
        <LongName>Email Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42775</PREFERRED_NAME>
            <LONG_NAME>E-mail Address</LONG_NAME>
            <CON_ID>2223429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element User Email Address java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element User Email Address java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812253</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.security.authorization.domainobjects</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000217</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.ucdavis.caelmir.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2629622</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TrAPSS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TrAPSS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2629622</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TrAPSS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.uiowa.clcg.trapss.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2680967</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000633</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Security Module (CSM)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812424</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.security.authorization.domainobjects</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.uiowa.clcg.trapss.domain.User.email</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>User:email</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.ucdavis.caelmir.domain.common.User.emailAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.User.emailAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.User.emailAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>User:emailAddress</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.security.authorization.domainobjects.User.emailId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>User:emailId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.User.emailAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="88">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223871</PUBLICID>
    <LONGNAME>Agent Name</LONGNAME>
    <PREFERREDNAME>2223713v3.0:2018334v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known._The name of the agent or drug that has been administered to the patient.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223713</PublicId>
      <PreferredName>2223333v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Agent Name</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018334</PublicId>
      <PreferredName>AGT_NAME</PreferredName>
      <PreferredDefinition>the name of the agent or drug that has been administered to the patient.</PreferredDefinition>
      <LongName>Agent Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2738661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Agent Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Agent name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Agent name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Agent.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Agent:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="89">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223872</PUBLICID>
    <LONGNAME>Population Frequency Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2223714v3.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the relative rate of occurrence of specific alleles, traits, or other factors within a population of organisms._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Value Domain for java language Long datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223714</PublicId>
      <PreferredName>2223334v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A description of the relative rate of occurrence of specific alleles, traits, or other factors within a population of organisms._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Population Frequency Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223334</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45373</PreferredName>
        <Version>1</Version>
        <LongName>Population Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45373</PREFERRED_NAME>
            <LONG_NAME>Population Frequency</LONG_NAME>
            <CON_ID>2223222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Population Frequency Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Population Frequency Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Representation is Integer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>VD REFERENCE</DocumentType>
        <DocumentText>NCICB Database Primary Key</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.PopulationFrequency.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PopulationFrequency:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@id</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="90">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2225394</PUBLICID>
    <LONGNAME>Institutional Review Board Name/Number</LONGNAME>
    <PREFERREDNAME>IRB_NAME_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>A unique alphanumeric identifier for a Institutional Review Board.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2225392</PublicId>
      <PreferredName>IRB_ID</PreferredName>
      <PreferredDefinition>A means of identifying a group of scientists, doctors, clergy, and consumers at each health care facility that participates in a clinical trial.  IRBs are designed to protect study participants.  They review and must approve the action plan for every clinical trial.  They check to see that the trial is well designed, does not involve undue risks, and includes safeguards for patients_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Institutional Review Board Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177101</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>IRB</PreferredName>
        <Version>1</Version>
        <LongName>IRB</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16741</PREFERRED_NAME>
            <LONG_NAME>Institutional Review Board</LONG_NAME>
            <CON_ID>2202674</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2225390</PublicId>
      <PreferredName>IRB_NAME_NUM</PreferredName>
      <PreferredDefinition>The unique idenfitifer for the Institutional Review Board.</PreferredDefinition>
      <LongName>IRB Name/Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177869</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Identifier</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>IRB Name/Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>IRB Name/Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Office for Human Research Prot</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText/>
        <URL>http://ohrp.cit.nih.gov/search/asearch.asp#ASUR</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Firebird</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2812347</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="91">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2227358</PUBLICID>
    <LONGNAME>Second-Look Surgical Procedure Text Name</LONGNAME>
    <PREFERREDNAME>SEC_LK_SURG_PROC_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name for a surgical procedure used during second-look operation</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2227355</PublicId>
      <PreferredName>SEC_LK_SURG_PERF</PreferredName>
      <PreferredDefinition>Surgery performed after cancer treatment to assess the results of prior treatment and to plan possible future treatment.</PreferredDefinition>
      <LongName>Second-Look Surgery Performance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2190057</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Second-Look Surgery</PreferredName>
        <Version>1</Version>
        <LongName>Second-Look Surgery</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15317</PREFERRED_NAME>
            <LONG_NAME>Second-Look Surgery</LONG_NAME>
            <CON_ID>2202886</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2199504</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Performance</PreferredName>
        <Version>1</Version>
        <LongName>Performance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25361</PREFERRED_NAME>
            <LONG_NAME>Performance</LONG_NAME>
            <CON_ID>2202787</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2227356</PublicId>
      <PreferredName>SEC_LK_SURG_PROC_NM</PreferredName>
      <PreferredDefinition>Text names of surgical procedures used during second-look procedures.</PreferredDefinition>
      <LongName>Second Look Surgical Procedure Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparotomy</VALIDVALUE>
          <VALUEMEANING>LAPAROTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>LAPAROTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparoscopy</VALIDVALUE>
          <VALUEMEANING>Laparoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(lap-a-RAHS-ko-pee) The insertion of a thin, lighted tube (called a laparoscope) through the abdominal wall to inspect the inside of the abdomen and remove tissue samples.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Procedure</VALIDVALUE>
          <VALUEMEANING>No Second-Look Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>No Second-Look Procedure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What second-look procedure wa</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What second-look procedure was performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="92">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2230153</PUBLICID>
    <LONGNAME>Test Result Value</LONGNAME>
    <PREFERREDNAME>TST_RSLT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The measure that describes the result.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2179526</PublicId>
      <PreferredName>TST_RESULT</PreferredName>
      <PreferredDefinition>the result of a test.</PreferredDefinition>
      <LongName>Test Result</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177214</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Laboratory</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177339</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Result</PreferredName>
        <Version>1</Version>
        <LongName>Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CTEP:Cancer Therapy Evaluation Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2230151</PublicId>
      <PreferredName>TST_RSLT_VAL</PreferredName>
      <PreferredDefinition>The measure that describes the result.</PreferredDefinition>
      <LongName>Test Result Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>9</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>5</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Result</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Analyte Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="93">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2230261</PUBLICID>
    <LONGNAME>Physical Activity Readiness Questionnaire Reduced Activity Heart Condition Indicator</LONGNAME>
    <PREFERREDNAME>PAR_Q_R_ACT_HRT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indicator of whether or not an individual diagnosed with a heart condition limits physical activity to activities recommended by a physician as described in the Physical Activity Readiness Questionnaire (PAR-Q).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2230230</PublicId>
      <PreferredName>PAR_Q_R_ACT_HRT_COND</PreferredName>
      <PreferredDefinition>The diagnosis of a heart condition that limits physical activity to activities recommended by a physician as described in the Physical Activity Readiness Questionnaire.</PreferredDefinition>
      <LongName>Physical Activity Readiness Questionnaire Reduced Activity Heart Condition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2739336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17708:CL315230:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Physical Activity Readiness Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17708</PREFERRED_NAME>
            <LONG_NAME>Physical Activity</LONG_NAME>
            <CON_ID>2202366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL315230</PREFERRED_NAME>
            <LONG_NAME>Readiness</LONG_NAME>
            <CON_ID>2203424</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2739337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25640:C43431:C12727:C25457</PreferredName>
        <Version>1</Version>
        <LongName>Reduced Activity Heart Condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12727</PREFERRED_NAME>
            <LONG_NAME>Heart</LONG_NAME>
            <CON_ID>2202646</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2230220</PublicId>
      <PreferredName>PAR_Q_IND</PreferredName>
      <PreferredDefinition>An indicator of whether or not an individual is ready for physical activity as described by the Physical Activity Readiness Questionnaire.</PreferredDefinition>
      <LongName>Physical Activity Readiness Questionnaire Ind-2</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has your doctor ever said tha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Person Diagnosed Heart Disorder Physical Activity Readiness Indicator</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Minnesota</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812655</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MN_0708M15062</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812999</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="94">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2230381</PUBLICID>
    <LONGNAME>Tissue Bank Diagnosis Text Name</LONGNAME>
    <PREFERREDNAME>TISS_BK_DX_TXT_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text terms to represent the principal diagnosis assigned within a Tissue Bank.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2230339</PublicId>
      <PreferredName>TISS_BK_MAIN_DX_CAT</PreferredName>
      <PreferredDefinition>Principal diagnosis assigned within a Tissue Bank.</PreferredDefinition>
      <LongName>Tissue Banking Main Diagnosis Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2230337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0087095:C25562:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking Main Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0087095</PREFERRED_NAME>
            <LONG_NAME>Tissue Banking</LONG_NAME>
            <CON_ID>2230196</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25562</PREFERRED_NAME>
            <LONG_NAME>Main</LONG_NAME>
            <CON_ID>2206300</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Category</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2230340</PublicId>
      <PreferredName>TISS_BK_DX_TXT_NM</PreferredName>
      <PreferredDefinition>Text terms to represent the diagnosis assigned to a tissue sample by a Tissue Bank.</PreferredDefinition>
      <LongName>Tissue Bank Diagnosis Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>18</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acanthoma</VALIDVALUE>
          <VALUEMEANING>Acanthoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Acanthoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adamantinoma</VALIDVALUE>
          <VALUEMEANING>Adamantinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Adamantinoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoma</VALIDVALUE>
          <VALUEMEANING>Adenoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Astrocytoma</VALIDVALUE>
          <VALUEMEANING>Astrocytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Astrocytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blastoma</VALIDVALUE>
          <VALUEMEANING>Blastoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant neoplasm composed of undifferentiated cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carcinoid</VALIDVALUE>
          <VALUEMEANING>Carcinoid</VALUEMEANING>
          <MEANINGDESCRIPTION>Carcinoid</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carcinoma</VALIDVALUE>
          <VALUEMEANING>Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Carcinoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervicitis</VALIDVALUE>
          <VALUEMEANING>Cervicitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Cervicitis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemodectoma</VALIDVALUE>
          <VALUEMEANING>Chemodectoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Chemodectoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chondroma</VALIDVALUE>
          <VALUEMEANING>Chondroma</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chordoma</VALIDVALUE>
          <VALUEMEANING>Chordoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Chordoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Choristoma</VALIDVALUE>
          <VALUEMEANING>Choristoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Choristoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Condyloma</VALIDVALUE>
          <VALUEMEANING>Condyloma</VALUEMEANING>
          <MEANINGDESCRIPTION>Condyloma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cylindroma</VALIDVALUE>
          <VALUEMEANING>Cylindroma</VALUEMEANING>
          <MEANINGDESCRIPTION>Cylindroma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyst</VALIDVALUE>
          <VALUEMEANING>Cyst</VALUEMEANING>
          <MEANINGDESCRIPTION>Cyst</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disease</VALIDVALUE>
          <VALUEMEANING>disease</VALUEMEANING>
          <MEANINGDESCRIPTION>disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysgerminoma</VALIDVALUE>
          <VALUEMEANING>Dysgerminoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Dysgerminoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysplasia</VALIDVALUE>
          <VALUEMEANING>Dysplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>Dysplasia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endothelioma</VALIDVALUE>
          <VALUEMEANING>Endothelioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Endothelioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epithelioma</VALIDVALUE>
          <VALUEMEANING>Epithelioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Epithelioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibroma</VALIDVALUE>
          <VALUEMEANING>FIBROMA</VALUEMEANING>
          <MEANINGDESCRIPTION>FIBROMA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibromatosis</VALIDVALUE>
          <VALUEMEANING>Fibromatosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A poorly circumscribed neoplasm arising from the soft tissues. It is characterized by the presence of spindle-shaped fibroblasts and an infiltrative growth pattern.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folliculoma</VALIDVALUE>
          <VALUEMEANING>Folliculoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Folliculoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganglioma</VALIDVALUE>
          <VALUEMEANING>Ganglioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Ganglioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glioma</VALIDVALUE>
          <VALUEMEANING>Glioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Glioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Granuloma</VALIDVALUE>
          <VALUEMEANING>Granuloma</VALUEMEANING>
          <MEANINGDESCRIPTION>An inflammatory reaction usually caused by infectious organisms, foreign bodies, or cholesterol deposits. It is characterized by the presence of epithelioid histiocytes and chronic inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Granulomatosis</VALIDVALUE>
          <VALUEMEANING>Granulomatosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Granulomatosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hamartoma</VALIDVALUE>
          <VALUEMEANING>Hamartoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Hamartoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemangioma</VALIDVALUE>
          <VALUEMEANING>Hemangioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Hemangioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histiocytoma</VALIDVALUE>
          <VALUEMEANING>Histiocytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Histiocytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperplasia</VALIDVALUE>
          <VALUEMEANING>Hyperplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Insulinoma</VALIDVALUE>
          <VALUEMEANING>Insulinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Insulinoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Keratosis</VALIDVALUE>
          <VALUEMEANING>Keratosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Keratosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lesion</VALIDVALUE>
          <VALUEMEANING>Lesion</VALUEMEANING>
          <MEANINGDESCRIPTION>Lesion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipoma</VALIDVALUE>
          <VALUEMEANING>Lipoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Lipoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphoma</VALIDVALUE>
          <VALUEMEANING>Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melanoma</VALIDVALUE>
          <VALUEMEANING>Melanoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Meningioma</VALIDVALUE>
          <VALUEMEANING>Meningioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Meningiomas (mostly WHO grade I, with some WHO grade II or III) are generally slow growing, benign tumors attached to the dura mater and are composed of neoplastic meningothelial (arachnoidal) cells. They typically occur in adults, often women. Meningiomas have a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesenchymoma</VALIDVALUE>
          <VALUEMEANING>Mesenchymoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Mesenchymoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesothelioma</VALIDVALUE>
          <VALUEMEANING>Mesothelioma</VALUEMEANING>
          <MEANINGDESCRIPTION>Mesothelioma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metaplasia</VALIDVALUE>
          <VALUEMEANING>Metaplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>Metaplasia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myeloma</VALIDVALUE>
          <VALUEMEANING>Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>Myeloma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myoma</VALIDVALUE>
          <VALUEMEANING>Myoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Myoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myomatosis</VALIDVALUE>
          <VALUEMEANING>Myomatosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Myomatosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myxoma</VALIDVALUE>
          <VALUEMEANING>Myxoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Myxoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Necrosis</VALIDVALUE>
          <VALUEMEANING>Necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The pathologic localized death of living cells, as from infection or interruption of the blood supply, generally associated with severe cellular trauma caused by progressive degradation by enzymes. Characterized by mitochondrial swelling, nuclear flocculation, and uncontrolled cell lysis, it is unprogrammed death of living tissue and cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoplasm</VALIDVALUE>
          <VALUEMEANING>Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neuroma</VALIDVALUE>
          <VALUEMEANING>Neuroma</VALUEMEANING>
          <MEANINGDESCRIPTION>Neuroma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nevus</VALIDVALUE>
          <VALUEMEANING>Nevus</VALUEMEANING>
          <MEANINGDESCRIPTION>Nevus</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Diagnosis</VALIDVALUE>
          <VALUEMEANING>No Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>No Diagnosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Tumor</VALIDVALUE>
          <VALUEMEANING>No tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>No tumor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodule(s)</VALIDVALUE>
          <VALUEMEANING>Nodule(s)</VALUEMEANING>
          <MEANINGDESCRIPTION>Nodule(s)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncocytoma</VALIDVALUE>
          <VALUEMEANING>Oncocytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Oncocytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Odontoma</VALIDVALUE>
          <VALUEMEANING>Odontoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Odontoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Papilloma</VALIDVALUE>
          <VALUEMEANING>Papilloma</VALUEMEANING>
          <MEANINGDESCRIPTION>Papilloma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Papillomatosis</VALIDVALUE>
          <VALUEMEANING>Papillomatosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Papillomatosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericytoma</VALIDVALUE>
          <VALUEMEANING>Pericytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Pericytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pheochromocytoma</VALIDVALUE>
          <VALUEMEANING>Pheochromocytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Pheochromocytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pilomatricoma</VALIDVALUE>
          <VALUEMEANING>Pilomatricoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Pilomatricoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plasmacytoma</VALIDVALUE>
          <VALUEMEANING>plasmacytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>plasmacytoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyp(s)</VALIDVALUE>
          <VALUEMEANING>Polyp(s)</VALUEMEANING>
          <MEANINGDESCRIPTION>Polyp(s)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ranula</VALIDVALUE>
          <VALUEMEANING>Ranula</VALUEMEANING>
          <MEANINGDESCRIPTION>Ranula</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sarcoma</VALIDVALUE>
          <VALUEMEANING>Sarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Schwannoma</VALIDVALUE>
          <VALUEMEANING>Schwannoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor of the peripheral nervous system that arises in the nerve sheath (protective covering).  It is almost always benign, but rare malignant schwannomas have been reported.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seminoma</VALIDVALUE>
          <VALUEMEANING>Seminoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sialadenitis</VALIDVALUE>
          <VALUEMEANING>Sialadenitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Sialadenitis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sialadenosis</VALIDVALUE>
          <VALUEMEANING>Sialadenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Sialadenosis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syringoma</VALIDVALUE>
          <VALUEMEANING>Syringoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Syringoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teratoma</VALIDVALUE>
          <VALUEMEANING>Teratoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as mature or immature. Mature teratomas are composed of well differentiated, adult-type tissues. Immature teratomas are composed of immature, fetal-type tissues. Testicular teratomas in children follow a benign clinical course. Mature ovarian teratomas without a fetal-type component have an excellent outcome. The prognosis of immature ovarian teratomas is related to the grade and stage of the tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thymoma</VALIDVALUE>
          <VALUEMEANING>Thymoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Thymoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroiditis</VALIDVALUE>
          <VALUEMEANING>Thyroiditis</VALUEMEANING>
          <MEANINGDESCRIPTION>Thyroiditis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trichilemmoma</VALIDVALUE>
          <VALUEMEANING>Trichilemmoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Trichilemmoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor</VALIDVALUE>
          <VALUEMEANING>TUMOR</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xanthoma</VALIDVALUE>
          <VALUEMEANING>Xanthoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Xanthoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Diagnosis Category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Diagnosis Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SPOREs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2201036</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Head and Neck SPOREs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Bank</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>TISS_BK_DX_TXT_NM</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="95">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2231213</PUBLICID>
    <LONGNAME>SF-36 Questionnaire Physical Component Summary Score</LONGNAME>
    <PREFERREDNAME>SF36_PHYS_SUMM_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric Physical Component Summary (PCS)score on the SF-36 Health Survey, a 36-question survey for measuring health status and outcomes from the patient&#39;s point of view.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2231205</PublicId>
      <PreferredName>SF36_PHYS_COMP_SUMM</PreferredName>
      <PreferredDefinition>Reference to the Physical Component Summary of the SF-36 Health Survey, a 36-question survey for measuring health status and outcomes from the patient&#39;s point of view.</PreferredDefinition>
      <LongName>SF-36 Questionnaire Physical Component Summary</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25618:CL111010:CL016027</PreferredName>
        <Version>1</Version>
        <LongName>Physical Component SF-36</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25618</PREFERRED_NAME>
            <LONG_NAME>Physical</LONG_NAME>
            <CON_ID>2203948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL111010</PREFERRED_NAME>
            <LONG_NAME>Component</LONG_NAME>
            <CON_ID>2204549</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL016027</PREFERRED_NAME>
            <LONG_NAME>SF-36</LONG_NAME>
            <CON_ID>2203549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL316498</PreferredName>
        <Version>1</Version>
        <LongName>Summary of needs</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL316498</PREFERRED_NAME>
            <LONG_NAME>Summary of needs</LONG_NAME>
            <CON_ID>2231202</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2427038</PublicId>
      <PreferredName>PSYCM_QUEST_2DEC_SC</PreferredName>
      <PreferredDefinition>Numeric score on a psychometric questionnaire or survey formatted to two decimal places.</PreferredDefinition>
      <LongName>Psychometrics Questionnaire Two Decimal Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>500</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PCS Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>PCS Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="96">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232430</PUBLICID>
    <LONGNAME>Data Element Derivation Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2231829v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The data element component(s) used for a derived data element._Indicates the person or authoritative body who changed an item._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2231829</PublicId>
      <PreferredName>2231673v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>The data element component(s) used for a derived data element._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Data Element Derivation Modified By</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231673</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41089</PreferredName>
        <Version>1</Version>
        <LongName>Data Element Derivation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41089</PREFERRED_NAME>
            <LONG_NAME>Data Element Derivation</LONG_NAME>
            <CON_ID>2231585</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Data Element Derivation Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Data Element Derivation Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.DataElementDerivation.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DataElementDerivation:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@modifiedBy</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="97">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232580</PUBLICID>
    <LONGNAME>Classification Scheme Administered Item Unresolved Issue java.lang.String</LONGNAME>
    <PREFERREDNAME>2231979v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The descriptive information for an arrangement or division of objects into groups based on characteristics that the objects have in common.  (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_Any problem that remains unresolved regarding proper documentation of the Administered Item. (ISO 11179)_Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2231979</PublicId>
      <PreferredName>2231652v1.0:2231608v1.0</PreferredName>
      <PreferredDefinition>The descriptive information for an arrangement or division of objects into groups based on characteristics that the objects have in common.  (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_Any problem that remains unresolved regarding proper documentation of the Administered Item. (ISO 11179)</PreferredDefinition>
      <LongName>Classification Scheme Administered Item Unresolved Issue</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231652</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41079:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Classification Scheme Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41079</PREFERRED_NAME>
            <LONG_NAME>Classification Scheme</LONG_NAME>
            <CON_ID>2231557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231608</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42869</PreferredName>
        <Version>1</Version>
        <LongName>Unresolved Issue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42869</PREFERRED_NAME>
            <LONG_NAME>Unresolved Issue</LONG_NAME>
            <CON_ID>2231549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Classification Scheme Administered Item Unresolved Issue java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Classification Scheme Administered Item Unresolved Issue java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ClassificationScheme.unresolvedIssue</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ClassificationScheme:unresolvedIssue</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.unresolvedIssue</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:unresolvedIssue</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="98">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232608</PUBLICID>
    <LONGNAME>Object Class Administered Item Preferred Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2232007v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of ideas, abstractions, or things in the real world that can be identified with explicit boundaries and meaning and whose properties and behavior follow the same rules. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_Designated as more desirable.:The words or language units by which a thing is known._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2232007</PublicId>
      <PreferredName>2231657v1.0:2231599v1.0</PreferredName>
      <PreferredDefinition>A set of ideas, abstractions, or things in the real world that can be identified with explicit boundaries and meaning and whose properties and behavior follow the same rules. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_Designated as more desirable.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Object Class Administered Item Preferred Name</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231657</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41106:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Object Class Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41106</PREFERRED_NAME>
            <LONG_NAME>Object Class</LONG_NAME>
            <CON_ID>2223438</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231599</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42711:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Preferred Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42711</PREFERRED_NAME>
            <LONG_NAME>Preferred</LONG_NAME>
            <CON_ID>2231546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Object Class Administered Item Preferred Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Object Class Administered Item Preferred Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ObjectClass.preferredName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ObjectClass:preferredName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.preferredName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:preferredName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="99">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232630</PUBLICID>
    <LONGNAME>Property Administered Item Version java.lang.Float</LONGNAME>
    <PREFERREDNAME>2232029v3.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A characteristic or attribute common to all members of a group or class. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_A form or variant of a type or original._Value Domain for java language Float datatype</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2232029</PublicId>
      <PreferredName>2231658v1.0:2231602v1.0</PreferredName>
      <PreferredDefinition>A characteristic or attribute common to all members of a group or class. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_A form or variant of a type or original.</PreferredDefinition>
      <LongName>Property Administered Item Version</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42605:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Property Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42605</PREFERRED_NAME>
            <LONG_NAME>Property</LONG_NAME>
            <CON_ID>2231569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231602</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25714</PreferredName>
        <Version>1</Version>
        <LongName>Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Property Administered Item Version java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Property Administered Item Version java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Property.version</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Property:version</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.version</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:version</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="100">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2233171</PUBLICID>
    <LONGNAME>Occupation Average Weekly Day Number</LONGNAME>
    <PREFERREDNAME>OCCUP_AVG_DAY_WK_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Average number of days per week spent in a person&#39;s normal or routine occupation schedule.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2233118</PublicId>
      <PreferredName>NL_OCCUP_SCHD</PreferredName>
      <PreferredDefinition>Standard or expected schedule of events in reference to an individual&#39;s job.</PreferredDefinition>
      <LongName>Normal Occupation Schedule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233115</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14165:C25193</PreferredName>
        <Version>1</Version>
        <LongName>Normal Occupation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25193</PREFERRED_NAME>
            <LONG_NAME>Occupation</LONG_NAME>
            <CON_ID>2202912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25211</PreferredName>
        <Version>1</Version>
        <LongName>Schedule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2233200</PublicId>
      <PreferredName>ACT_AVG_WK_DAY_NUM</PreferredName>
      <PreferredDefinition>Numeric value to signify average number of days per week spent in a specified activity.</PreferredDefinition>
      <LongName>Activity Average Weekly Day Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177868</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Days/Wk</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Days/Wk</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="101">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2233820</PUBLICID>
    <LONGNAME>Arterial Thrombosis Prior Event Specify</LONGNAME>
    <PREFERREDNAME>ART_THRMB_P_EVT_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field to specify the other prior arterial thrombotic event that occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2233816</PublicId>
      <PreferredName>ART_THROMB_PRIR_EVNT</PreferredName>
      <PreferredDefinition>information relating to arterial thrombosis prior event.</PreferredDefinition>
      <LongName>Arterial Thrombosis Prior Event</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0221464:C26891</PreferredName>
        <Version>1</Version>
        <LongName>Arterial Thrombosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0221464</PREFERRED_NAME>
            <LONG_NAME>Arterial</LONG_NAME>
            <CON_ID>2217583</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26891</PREFERRED_NAME>
            <LONG_NAME>Thrombosis</LONG_NAME>
            <CON_ID>2203713</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233814</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C25499</PreferredName>
        <Version>1</Version>
        <LongName>Prior Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182309</PublicId>
      <PreferredName>CHR_ASS_DZ_EXP_SPEC</PreferredName>
      <PreferredDefinition>the text field to specify chronic or associated diseases and exposures.</PreferredDefinition>
      <LongName>Chronic Associated Disease Exposure Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000104</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="102">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2237991</PUBLICID>
    <LONGNAME>DNA Microarray First Array Feature X-Coordinate java.lang.Float</LONGNAME>
    <PREFERREDNAME>2236840v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Generally speaking, this term describes an experimental format in which probes representing genes that one wants to study are affixed to a substrate (e.g., a glass slide) and then exposed to target molecules (sometimes referred to as the sample). The level of hybridization between a specific probe and a target (typically indicated through fluorescence and measured through image analysis) indicates the level of the gene corresponding to that probe in a test solution. (From CHI Outlook Microarrays report)_Preceding all others in time or space or degree.:A specific position on a microarray.:A horizontal coordinate that is used together with a vertical coordinate to specify an exact point in space._Value Domain for java language Float datatype</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2236840</PublicId>
      <PreferredName>2236696v1.0:2236637v1.0</PreferredName>
      <PreferredDefinition>Generally speaking, this term describes an experimental format in which probes representing genes that one wants to study are affixed to a substrate (e.g., a glass slide) and then exposed to target molecules (sometimes referred to as the sample). The level of hybridization between a specific probe and a target (typically indicated through fluorescence and measured through image analysis) indicates the level of the gene corresponding to that probe in a test solution. (From CHI Outlook Microarrays report)_Preceding all others in time or space or degree.:A specific position on a microarray.:A horizontal coordinate that is used together with a vertical coordinate to specify an exact point in space.</PreferredDefinition>
      <LongName>DNA Microarray First Array Feature X-Coordinate</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25922</PreferredName>
        <Version>1</Version>
        <LongName>DNA Microarray</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25922</PREFERRED_NAME>
            <LONG_NAME>DNA Microarray Analysis</LONG_NAME>
            <CON_ID>2236507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236637</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C44283:C44477</PreferredName>
        <Version>1</Version>
        <LongName>First Array Feature X-Coordinate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44283</PREFERRED_NAME>
            <LONG_NAME>Array Feature</LONG_NAME>
            <CON_ID>2236508</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44477</PREFERRED_NAME>
            <LONG_NAME>X-Coordinate</LONG_NAME>
            <CON_ID>2236519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element DNA Microarray First Array Feature X-Coordinate java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element DNA Microarray First Array Feature X-Coordinate java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2321254</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Mage-OM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812454</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2321254</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Mage-OM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.Array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812455</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mageom 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.Array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000468</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.mageom.domain.Array.Array.arrayXOrigin</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Array:arrayXOrigin</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="103">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2240978</PUBLICID>
    <LONGNAME>Increased Tumor Size Confirmed Ind-2</LONGNAME>
    <PREFERREDNAME>INC_TUMR_SZ_CNF_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether an increase of &gt;25% in tumor size was confirmed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2240977</PublicId>
      <PreferredName>INCRS_TUMR_SZ_CNFRMD</PreferredName>
      <PreferredDefinition>information relating to increased tumor size confirmed.</PreferredDefinition>
      <LongName>Increased Tumor Size Confirmed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2240852</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL124321:CL228347</PreferredName>
        <Version>1</Version>
        <LongName>Increased Tumor size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL124321</PREFERRED_NAME>
            <LONG_NAME>Increased</LONG_NAME>
            <CON_ID>2240803</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL228347</PREFERRED_NAME>
            <LONG_NAME>Tumor size</LONG_NAME>
            <CON_ID>2240663</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240805</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25458</PreferredName>
        <Version>1</Version>
        <LongName>Confirmed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Increase of &gt;25% in tumor siz</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Increase of &gt;25% in tumor size confirmed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="104">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2261656</PUBLICID>
    <LONGNAME>Left Lymph Node Positive Total Count</LONGNAME>
    <PREFERREDNAME>LT_LN_POS_TTL_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the total quantity of lymph nodes located on the left side of the body where disease presence has been detected by examination.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2261645</PublicId>
      <PreferredName>LT_LN_POS</PreferredName>
      <PreferredDefinition>the presence of disease in a lymph node located on the left side of the body as determined by examination.</PreferredDefinition>
      <LongName>Left Lymph Node Positive</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2261643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25229:C12745</PreferredName>
        <Version>1</Version>
        <LongName>Left Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25229</PREFERRED_NAME>
            <LONG_NAME>Left</LONG_NAME>
            <CON_ID>2204810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177453</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Positive</PreferredName>
        <Version>1</Version>
        <LongName>Positive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25246</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2202905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2261642</PublicId>
      <PreferredName>LN_TTL_CT</PreferredName>
      <PreferredDefinition>the total quantity of lymph nodes that have been identified.</PreferredDefinition>
      <LongName>Lymph Node Total Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Total Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Nodes Positive Left</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Nodes Positive Left</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number positive</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811942</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LT_LN_POS_TTL_CT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="105">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2342548</PUBLICID>
    <LONGNAME>Induced Mutation Site Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2342371v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A mutation triggered by outside influences (e.g., radiation, chemicals or other means) as opposed to those created by the inherent infidelity of DNA polymerase.:Position in relation to the surroundings._A statement or an account describing something._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2342371</PublicId>
      <PreferredName>2342241v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A mutation triggered by outside influences (e.g., radiation, chemicals or other means) as opposed to those created by the inherent infidelity of DNA polymerase.:Position in relation to the surroundings._A statement or an account describing something.</PreferredDefinition>
      <LongName>Induced Mutation Site Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2342241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40987:C37901</PreferredName>
        <Version>1</Version>
        <LongName>Induced Mutation Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40987</PREFERRED_NAME>
            <LONG_NAME>Induced Mutation</LONG_NAME>
            <CON_ID>2224006</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37901</PREFERRED_NAME>
            <LONG_NAME>Site</LONG_NAME>
            <CON_ID>2202394</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Induced Mutation Site Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Induced Mutation Site Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2496586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812496</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716603</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.MutagenesisSite.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MutagenesisSite:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.ProteinFeature.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProteinFeature:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="106">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2388900</PUBLICID>
    <LONGNAME>Pathology Report Accession Number java.lang.String</LONGNAME>
    <PREFERREDNAME>2388863v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A pathology report provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. Report defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread. Essential information to be included in a pathology report: the date and name of the report, slide number, the source of the specimen, the primary tumor size, he histologic diagnosis including the grade or degree of differentiation, the extent of disease within and beyond the primary site._A control number unique to an object, used to identify it among the other objects in a collection._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2388863</PublicId>
      <PreferredName>2388855v1.0:2223255v1.0</PreferredName>
      <PreferredDefinition>A pathology report provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. Report defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread. Essential information to be included in a pathology report: the date and name of the report, slide number, the source of the specimen, the primary tumor size, he histologic diagnosis including the grade or degree of differentiation, the extent of disease within and beyond the primary site._A control number unique to an object, used to identify it among the other objects in a collection.</PreferredDefinition>
      <LongName>Pathology Report Accession Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2388855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28277</PreferredName>
        <Version>1</Version>
        <LongName>Pathology Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28277</PREFERRED_NAME>
            <LONG_NAME>Pathology Report</LONG_NAME>
            <CON_ID>2202705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223255</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25402</PreferredName>
        <Version>1</Version>
        <LongName>Accession Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Pathology Report Accession Number java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Pathology Report Accession Number java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2388918</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 1.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.cabig.caties.document.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812489</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.cabig.caties.document.domain.PathologyReport.accessionNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PathologyReport:accessionNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="107">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2404909</PUBLICID>
    <LONGNAME>Dentition Number System National Dentition Code</LONGNAME>
    <PREFERREDNAME>DNTN_NUM_SYS_NLT_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The values and value meanings for tooth designation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2404905</PublicId>
      <PreferredName>DNTN_NUM_SYS</PreferredName>
      <PreferredDefinition>A numbering system for identifying a participant&#39;s teeth.</PreferredDefinition>
      <LongName>Dentition Number System</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404902</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13072</PreferredName>
        <Version>1</Version>
        <LongName>Dentition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2404903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337:C25700</PreferredName>
        <Version>1</Version>
        <LongName>Number System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2404907</PublicId>
      <PreferredName>NLT_DNTN_CD</PreferredName>
      <PreferredDefinition>The values and value meanings for tooth designation.</PreferredDefinition>
      <LongName>National Dentition Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2407197</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13072:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Dentition Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch  lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch  lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>J</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Q</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ES</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>QS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tooth Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tooth Number</DocumentText>
        <URL>http://www.ada.org/public/topics/tooth_number.asp</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Tooth #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Restorative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812086</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjunctive General Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="108">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2405474</PUBLICID>
    <LONGNAME>Cheek Cell Specimen Frozen Collected Ind-2</LONGNAME>
    <PREFERREDNAME>CHK_C_SPC_F_COL_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the buccal cell sample was stored at -20 degrees C.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2405473</PublicId>
      <PreferredName>CHK_CEL_SPC_FRZ_COLL</PreferredName>
      <PreferredDefinition>information relating to cheek cell specimens collected and frozen.</PreferredDefinition>
      <LongName>Cheek Cell Specimen Frozen Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2405464</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13070:C12508:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Cheek Cell Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13070</PREFERRED_NAME>
            <LONG_NAME>Cheek</LONG_NAME>
            <CON_ID>2405463</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2405470</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL267638:C25452</PreferredName>
        <Version>1</Version>
        <LongName>Frozen Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL267638</PREFERRED_NAME>
            <LONG_NAME>Frozen</LONG_NAME>
            <CON_ID>2204514</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was buccal cell sample stored</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was buccal cell sample stored at -20 degrees C</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="109">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2407022</PUBLICID>
    <LONGNAME>Nipple Aspirate Fluid Result Number</LONGNAME>
    <PREFERREDNAME>NPPL_ASPR_FL_RSL_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The results of the tests performed on the nipple aspirate.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192062</PublicId>
      <PreferredName>NIPPLE_ASPR_RESULT</PreferredName>
      <PreferredDefinition>information related to nipple aspirate result.</PreferredDefinition>
      <LongName>Nipple Aspirate Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206510</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12299:C13347</PreferredName>
        <Version>1</Version>
        <LongName>Nipple Aspirate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12299</PREFERRED_NAME>
            <LONG_NAME>Nipple</LONG_NAME>
            <CON_ID>2202753</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13347</PREFERRED_NAME>
            <LONG_NAME>Aspirate</LONG_NAME>
            <CON_ID>2202569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177339</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Result</PreferredName>
        <Version>1</Version>
        <LongName>Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2407020</PublicId>
      <PreferredName>NPPL_ASPR_FL_RSL_NUM</PreferredName>
      <PreferredDefinition>The results of the tests performed on the nipple aspirate.</PreferredDefinition>
      <LongName>Nipple Aspirate Fluid Result Number</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2407019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Result Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Result in pg/ml</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Result in pg/ml</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="110">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2414588</PUBLICID>
    <LONGNAME>Concomitant Breast Medication Received Text</LONGNAME>
    <PREFERREDNAME>CN_BRST_MED_RECD_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to capture whether concomitant medication is continuing in a breast cancer treatment trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>IBCSG CRF:International Breast Cancer Study Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2414579</PublicId>
      <PreferredName>CONCOM_BRST_MED_RECD</PreferredName>
      <PreferredDefinition>information relating to concomitant medication received in a breast cancer treatment trial.</PreferredDefinition>
      <LongName>Concomitant Breast Medication Received</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2414577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C12971:C459</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Breast Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639</PreferredName>
        <Version>1</Version>
        <LongName>Received</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200608</PublicId>
      <PreferredName>DATA_UNKNOWN_TEXT</PreferredName>
      <PreferredDefinition>a single character text field to record data.</PreferredDefinition>
      <LongName>Data Unknown Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Continuing</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Continuing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="111">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2423046</PUBLICID>
    <LONGNAME>Category Specimen Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2422845v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>This term is used informally to mean a class of things.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodil_A statement or an account describing something._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2422845</PublicId>
      <PreferredName>2422756v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>This term is used informally to mean a class of things.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodil_A statement or an account describing something.</PreferredDefinition>
      <LongName>Category Specimen Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Category Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Category Specimen Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Category Specimen Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ProteomicsLIMS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.fccc.lims.protlims.domain.class.sampledata</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.fccc.lims.protlims.domain.class.sampledata.SampleCategory.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SampleCategory:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="112">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2426141</PUBLICID>
    <LONGNAME>Quality-of-Life Assessment Medical Staff Unavailable Incomplete Ind-2</LONGNAME>
    <PREFERREDNAME>QOL_AS_M_S_UA_I_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator related to whether the quality-of-life assessment was not completed or finished because the specific group of workers relating to the study or practice of medicine where unavailable.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2425474</PublicId>
      <PreferredName>QOL_ASS_MED_ST_NA_I</PreferredName>
      <PreferredDefinition>information related to a person who requires medical care not finishing the evaluation of the quality of patient life and function assessment because there was no member of the group of workers relating to the study or practice of medicine obtainable or accessible.</PreferredDefinition>
      <LongName>Quality-of-Life Assessment Medical Staff Not Available Incomplete</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2424965</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15584</PreferredName>
        <Version>1</Version>
        <LongName>Quality-of-Life Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15584</PREFERRED_NAME>
            <LONG_NAME>Quality-of-Life Assessment</LONG_NAME>
            <CON_ID>2424964</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2427391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0025106:C25594:C25429:C49160</PreferredName>
        <Version>1</Version>
        <LongName>Medical Staff Not Available Incomplete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0025106</PREFERRED_NAME>
            <LONG_NAME>Medical Staff</LONG_NAME>
            <CON_ID>2426910</CON_ID>
            <DEFINITION_SOURCE>MSH2005_2004_10_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25429</PREFERRED_NAME>
            <LONG_NAME>Availability</LONG_NAME>
            <CON_ID>2204038</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49160</PREFERRED_NAME>
            <LONG_NAME>Incomplete</LONG_NAME>
            <CON_ID>2427335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Staff unavailable</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Staff unavailable</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="113">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2429529</PUBLICID>
    <LONGNAME>Hemoglobin Decrease Symptom Post Surgery Present Ind-3</LONGNAME>
    <PREFERREDNAME>SM_P_SX_RD_HE_PR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator related to the low levels of the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), after surgery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2429452</PublicId>
      <PreferredName>SM_P_SX_RD_HEM_PRES</PreferredName>
      <PreferredDefinition>information related to the low levels of the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), after surgery.</PreferredDefinition>
      <LongName>Hemoglobin Decrease Symptom Post Surgery Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2429450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16676:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Hemoglobin Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16676</PREFERRED_NAME>
            <LONG_NAME>Hemoglobin</LONG_NAME>
            <CON_ID>2203742</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2429422</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C17173:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Post Surgery Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17173</PREFERRED_NAME>
            <LONG_NAME>Surgery</LONG_NAME>
            <CON_ID>2203602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Low hemoglobin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Low hemoglobin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="114">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2429665</PUBLICID>
    <LONGNAME>Surgical Procedure Kidney Performed Type</LONGNAME>
    <PREFERREDNAME>SX_KIDNEY_PERF_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of surgical procedure that was carried out on the kidney.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2429661</PublicId>
      <PreferredName>SX_KIDNEY_PERF</PreferredName>
      <PreferredDefinition>information related to surgical procedure that was carried out on the kidneys (bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae).</PreferredDefinition>
      <LongName>Surgical Procedure Kidney Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2746349</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12415:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Kidney Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12415</PREFERRED_NAME>
            <LONG_NAME>Kidney</LONG_NAME>
            <CON_ID>2204911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2429663</PublicId>
      <PreferredName>SX_KID_PER_TYPE</PreferredName>
      <PreferredDefinition>an enumerated list of types of sugical procedures of the kidney.</PreferredDefinition>
      <LongName>Surgical Procedure Kidney Performed Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>radical nephrectomy</VALIDVALUE>
          <VALUEMEANING>radical nephrectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of a kidney, the adrenal gland, adjacent lymph nodes, and other surrounding tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>partial nephrectomy</VALIDVALUE>
          <VALUEMEANING>partial nephrectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The surgical removal of a portion of a kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of surgery</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of surgery</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Extent of surgical resection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of nephrectomy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCIP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of Nephrectomy (Radical vs Partial)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>nephrectomy_type</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="115">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2429685</PUBLICID>
    <LONGNAME>Renal Cell Carcinoma Hilar Node Status</LONGNAME>
    <PREFERREDNAME>RCC_HILAR_NODE_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of hilar nodes in renal cell carcinoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2429684</PublicId>
      <PreferredName>RCC_HILAR_NODE</PreferredName>
      <PreferredDefinition>information relating to hilar nodes in renal cell carcinoma.</PreferredDefinition>
      <LongName>Renal Cell Carcinoma Hilar Node</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2428360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9385</PreferredName>
        <Version>1</Version>
        <LongName>Renal Cell Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9385</PREFERRED_NAME>
            <LONG_NAME>Renal Cell Carcinoma</LONG_NAME>
            <CON_ID>2428359</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2429682</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25724:C0746922</PreferredName>
        <Version>1</Version>
        <LongName>Hilar NODE</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25724</PREFERRED_NAME>
            <LONG_NAME>Hilar</LONG_NAME>
            <CON_ID>2205418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0746922</PREFERRED_NAME>
            <LONG_NAME>NODE</LONG_NAME>
            <CON_ID>2204389</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2429525</PublicId>
      <PreferredName>TUMOR_STATUS</PreferredName>
      <PreferredDefinition>the status of a tumor or a tumor-related feature.</PreferredDefinition>
      <LongName>Tumor Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cannot be assessed</VALIDVALUE>
          <VALUEMEANING>Cannot be assessed</VALUEMEANING>
          <MEANINGDESCRIPTION>Aspects of the context prevent the evaluation needed to determine a value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No extrarenal tissues sampled</VALIDVALUE>
          <VALUEMEANING>No extrarenal tissues sampled</VALUEMEANING>
          <MEANINGDESCRIPTION>No extrarenal tissues sampled</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not sampled</VALIDVALUE>
          <VALUEMEANING>Not sampled</VALUEMEANING>
          <MEANINGDESCRIPTION>Not sampled</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hilar nodes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Hilar nodes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="116">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2429770</PUBLICID>
    <LONGNAME>Renal Cell Carcinoma Histologic Subtype Classification Specify</LONGNAME>
    <PREFERREDNAME>RCC_H_SUB_CLASS_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field to specify the other histologic classification category subtype of cancer cells used to define a diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2429765</PublicId>
      <PreferredName>RCC_HIST_SUBTP_CLASS</PreferredName>
      <PreferredDefinition>information relating to the histologic subtype classification of  renal cell carcinoma.</PreferredDefinition>
      <LongName>Renal Cell Carcinoma Histologic Subtype Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2428360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9385</PreferredName>
        <Version>1</Version>
        <LongName>Renal Cell Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9385</PREFERRED_NAME>
            <LONG_NAME>Renal Cell Carcinoma</LONG_NAME>
            <CON_ID>2428359</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2429763</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C25696:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Subtype Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25696</PREFERRED_NAME>
            <LONG_NAME>Subtype</LONG_NAME>
            <CON_ID>2203810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018432</PublicId>
      <PreferredName>DX_SPEC</PreferredName>
      <PreferredDefinition>the specified free-text field related to an aspect of patient/participant&#39;s diagnosis</PreferredDefinition>
      <LongName>Diagnosis Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oregon Health &amp; Sciences University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OHSU_2683</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812946</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="117">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2432081</PUBLICID>
    <LONGNAME>Thrombosis Adverse Event Observed Date</LONGNAME>
    <PREFERREDNAME>THROMB_AE_OBS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date a thrombotic event was observed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2432063</PublicId>
      <PreferredName>THROMB_AE_OBS</PreferredName>
      <PreferredDefinition>information related to the formation or presence of a blood clot inside a blood vessel as an  unfavorable and unintended sign, symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure, having been observed or determined.</PreferredDefinition>
      <LongName>Thrombosis Adverse Event Observed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2432061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26891:C41331</PreferredName>
        <Version>1</Version>
        <LongName>Thrombosis Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26891</PREFERRED_NAME>
            <LONG_NAME>Thrombosis</LONG_NAME>
            <CON_ID>2203713</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2419892</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25599</PreferredName>
        <Version>1</Version>
        <LongName>Observed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25599</PREFERRED_NAME>
            <LONG_NAME>Observed</LONG_NAME>
            <CON_ID>2203942</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of thrombotic event</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of thrombotic event</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of last event</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>THROMB_AE_OBS_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="118">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2432586</PUBLICID>
    <LONGNAME>Breast Neoplasm Other Detected Diagnosis Ind-2</LONGNAME>
    <PREFERREDNAME>BRST_NEO_O_DET_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to perceived, discerned, discovered or identified abnormal and uncontrolled cell growth in breast by a means different than the ones previously specified or mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2432580</PublicId>
      <PreferredName>BRST_TUMOR_O_DET</PreferredName>
      <PreferredDefinition>information related to perceived, discerned, discovered or identified abnormal and uncontrolled cell growth in breast by a means different than the ones previously specified or mentioned.</PreferredDefinition>
      <LongName>Breast Neoplasm Other Detected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2432578</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C3262:C17649</PreferredName>
        <Version>1</Version>
        <LongName>Breast Neoplasm Other</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2432572</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25481</PreferredName>
        <Version>1</Version>
        <LongName>Detected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25481</PREFERRED_NAME>
            <LONG_NAME>Detected</LONG_NAME>
            <CON_ID>2203891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="119">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2433395</PUBLICID>
    <LONGNAME>Gene Version Entrez Gene Version java.lang.String</LONGNAME>
    <PREFERREDNAME>2433362v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).:A form or variant of a type or original._NCBI&#39;s database for gene-specific information. It focuses on the genomes that have been completely sequenced, that have an active research community to contribute gene-specific information, or that are scheduled for intense sequence analysis. The content of Entrez Gene represents the result of curation and automated integration of data from NCBI&#39;s Reference Sequence project (RefSeq), from collaborating model organism databases, and from many other databases available from NCBI. (from Nucleic Acids Res. 2005; 33(Database Issue): D54-D58):A form or variant of a type or original._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2433362</PublicId>
      <PreferredName>2433350v1.0:2433335v1.0</PreferredName>
      <PreferredDefinition>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).:A form or variant of a type or original._NCBI&#39;s database for gene-specific information. It focuses on the genomes that have been completely sequenced, that have an active research community to contribute gene-specific information, or that are scheduled for intense sequence analysis. The content of Entrez Gene represents the result of curation and automated integration of data from NCBI&#39;s Reference Sequence project (RefSeq), from collaborating model organism databases, and from many other databases available from NCBI. (from Nucleic Acids Res. 2005; 33(Database Issue): D54-D58):A form or variant of a type or original.</PreferredDefinition>
      <LongName>Gene Version Entrez Gene Version</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2433350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612:C25714</PreferredName>
        <Version>1</Version>
        <LongName>Gene Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16612</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2202483</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2433335</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45765:C25714</PreferredName>
        <Version>1</Version>
        <LongName>Entrez Gene Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45765</PREFERRED_NAME>
            <LONG_NAME>Entrez Gene</LONG_NAME>
            <CON_ID>2322220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Version Entrez Gene Version java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Version Entrez Gene Version java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2514015</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000306</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557869</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857188</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server 1.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812071</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.GeneVersion.entrezGeneVersion</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneVersion:entrezGeneVersion</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.GeneVersion.entrezgeneVersion</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneVersion:entrezgeneVersion</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="120">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2434825</PUBLICID>
    <LONGNAME>Cervical Tumor Pathologic N Stage</LONGNAME>
    <PREFERREDNAME>CERVICL_TUMOR_P_N_ST</PREFERREDNAME>
    <PREFERREDDEFINITION>the pathologic N (nodal) stage of a cervical tumor, as defined by the AJCC Cancer Staging Manual, 6th Ed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2434812</PublicId>
      <PreferredName>CERVICAL_TUMOR_P_N_S</PreferredName>
      <PreferredDefinition>Information related to pathologic N stage of a cervical tumor (or cancer of the uterine cervix).</PreferredDefinition>
      <LongName>Cervical Tumor Pathologic N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2434808</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12844:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Cervical Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12844</PREFERRED_NAME>
            <LONG_NAME>Cervical</LONG_NAME>
            <CON_ID>2205294</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2434820</PublicId>
      <PreferredName>CERVICL_TUMOR_N_ST</PreferredName>
      <PreferredDefinition>the pathologic or clinical N (nodal) stage of a cervical tumor, as defined by the AJCC Cancer Staging Manual, 6th Ed.</PreferredDefinition>
      <LongName>Cervical Tumor N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</Origin>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>NO REGIONAL LYMPH NODE METASTASIS</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer with no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Regional lymph node metastasis</VALUEMEANING>
          <MEANINGDESCRIPTION>Regional lymph node metastasis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>REGIONAL LYMPH NODES CANNOT BE ASSESSED</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic N Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic N Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>AJCC Cancer Staging Manual, 6th Edition</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000209</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="121">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2434980</PUBLICID>
    <LONGNAME>Person Geographic Birth Place Code</LONGNAME>
    <PREFERREDNAME>PRSN_GEO_BRTH_PL_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>A system of numbered categories that represents the geographic location where a person was born.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2434962</PublicId>
      <PreferredName>PRSN_GEO_BRTH_PL</PreferredName>
      <PreferredDefinition>The geographical location where a person was born.</PreferredDefinition>
      <LongName>Person Geographic Birth Place</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008506</PublicId>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>INDIVIDUALS</PreferredName>
        <Version>2</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2434960</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37957:C25319:C25155</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Place Birth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37957</PREFERRED_NAME>
            <LONG_NAME>Geographic</LONG_NAME>
            <CON_ID>2434959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2434978</PublicId>
      <PreferredName>GEO_LCTN_CD</PreferredName>
      <PreferredDefinition>A system of numbered categories that represents a place determined by geography.</PreferredDefinition>
      <LongName>Geographic Location Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008524</PublicId>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>GEOGRAPHIC LOCATIONS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2434977</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37957:C25341:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Location Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37957</PREFERRED_NAME>
            <LONG_NAME>Geographic</LONG_NAME>
            <CON_ID>2434959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>00</VALIDVALUE>
          <VALUEMEANING>Foreign Country</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL024888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>01</VALIDVALUE>
          <VALUEMEANING>Alabama</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the southeast United States. Its capital is Montgomery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>02</VALIDVALUE>
          <VALUEMEANING>Alaska</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the far northwestern United States. Its capital is Juneau.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>04</VALIDVALUE>
          <VALUEMEANING>Arizona</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the southwestern United States. Its capital is Phoenix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>05</VALIDVALUE>
          <VALUEMEANING>Arkansas</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the southern midwest United States. Its capital is Little Rock.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>06</VALIDVALUE>
          <VALUEMEANING>California</VALUEMEANING>
          <MEANINGDESCRIPTION>A state on the western coast of the United States. Its capital is Sacramento.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>08</VALIDVALUE>
          <VALUEMEANING>Connecticut</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the northeastern United States. Its capital is Hartford.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Delaware</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the mid-atlantic United States. Its capital is Dover.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In what state or foreign coun</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In what state or foreign country were you born?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193113</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCEG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGEMS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="122">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2435009</PUBLICID>
    <LONGNAME>Protocol Deviation Notification Date</LONGNAME>
    <PREFERREDNAME>PROT_DEV_NOTIF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date when DCP was notified regarding the protocol deviation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2435007</PublicId>
      <PreferredName>PROT_DEV_NOTIF</PreferredName>
      <PreferredDefinition>Information related to the protocol deviation notification.</PreferredDefinition>
      <LongName>Protocol Deviation Notification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2434994</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C50996</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Deviation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50996</PREFERRED_NAME>
            <LONG_NAME>Protocol Deviation</LONG_NAME>
            <CON_ID>2434968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2435005</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25297</PreferredName>
        <Version>1</Version>
        <LongName>Notification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date DCP Notified</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date DCP Notified</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="123">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2438068</PUBLICID>
    <LONGNAME>Type Cloning Vector Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2437865v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Something distinguishable as an identifiable class based on common qualities.:Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain genetic markers to facilitate their selective recognition._The words or language units by which a thing is known._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2437865</PublicId>
      <PreferredName>2437786v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.:Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain genetic markers to facilitate their selective recognition._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Type Cloning Vector Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284:C1329</PreferredName>
        <Version>1</Version>
        <LongName>Type Cloning Vector</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1329</PREFERRED_NAME>
            <LONG_NAME>Cloning Vector</LONG_NAME>
            <CON_ID>2223199</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Type Cloning Vector Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Type Cloning Vector Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857162</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Models Database 2.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000545</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.SegmentType.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SegmentType:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="124">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2438205</PUBLICID>
    <LONGNAME>Genomic Segment Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2438001v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Genomic segment extracted from a library e.g. BAC or YAC library to be used in the genetic manipulation of the animal model. (caBIO)_The words or language units by which a thing is known._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2438001</PublicId>
      <PreferredName>2224119v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>Genomic segment extracted from a library e.g. BAC or YAC library to be used in the genetic manipulation of the animal model. (caBIO)_The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Genomic Segment Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41097</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Segment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41097</PREFERRED_NAME>
            <LONG_NAME>Genomic Segment</LONG_NAME>
            <CON_ID>2224009</CON_ID>
            <DEFINITION_SOURCE>CABIO</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Genomic Segment Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Genomic Segment Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857162</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Models Database 2.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000545</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.EngineeredGene.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EngineeredGene:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Transgene.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Transgene:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.TargetedModification.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TargetedModification:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.GenomicSegment.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GenomicSegment:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="125">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2444997</PUBLICID>
    <LONGNAME>Dental Professional Practice Full Time Employment Office Manager Yes No Indicator</LONGNAME>
    <PREFERREDNAME>DNT_PRF_FTE_OMN_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator that asks whether a dental professional practice employs a full-time office manager and/or receptionist.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2443434</PublicId>
      <PreferredName>DENT_PROF_FTE_OFFMAN</PreferredName>
      <PreferredDefinition>information related to the employee charged with the general administrative responsibilities of any given office of a corporation or business, responsible for all paperwork, including its filing and retention over time, and the supervision of office staff employed for a standard number of hours of working time, at least 50% or 20 hours per week for a health care professional business directed towards treatment and care of patients pertaining to a tooth or teeth, or to odontology.</PreferredDefinition>
      <LongName>Dental Professional Practice Full Time Employment Office Manager</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2443432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52658:C52663</PreferredName>
        <Version>1</Version>
        <LongName>Full Time Employment Office Manager</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52658</PREFERRED_NAME>
            <LONG_NAME>Full Time Employment</LONG_NAME>
            <CON_ID>2443136</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52663</PREFERRED_NAME>
            <LONG_NAME>Office Manager</LONG_NAME>
            <CON_ID>2443144</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does your practice employ a f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does your practice employ a full time office manager and/or receptionist</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="126">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2452214</PUBLICID>
    <LONGNAME>Homology Modeling Protein Structure Protein Data Bank Title java.lang.String</LONGNAME>
    <PREFERREDNAME>2452071v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An approach to modeling a protein structure based on an initial sequence alignment to a protein with a known 3D structure.  After evaluating and resolving structural irregularities in the initial model, it may be further refined using energy minimization and other procedures.:The amino acids and their 3-D arrangement in constituting a protein. The four levels of protein structuring in a water environment are primary (amino acid sequence), secondary (alpha helices and beta sheets), tertiary (formation of globular domains), and quaternary (interchain interactions)._worldwide repository for the processing and distribution of 3-D biological macromolecular structure data.:A general or descriptive designator for an object, work of art, or literary composition._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2452071</PublicId>
      <PreferredName>2451979v1.0:2451969v1.0</PreferredName>
      <PreferredDefinition>An approach to modeling a protein structure based on an initial sequence alignment to a protein with a known 3D structure.  After evaluating and resolving structural irregularities in the initial model, it may be further refined using energy minimization and other procedures.:The amino acids and their 3-D arrangement in constituting a protein. The four levels of protein structuring in a water environment are primary (amino acid sequence), secondary (alpha helices and beta sheets), tertiary (formation of globular domains), and quaternary (interchain interactions)._worldwide repository for the processing and distribution of 3-D biological macromolecular structure data.:A general or descriptive designator for an object, work of art, or literary composition.</PreferredDefinition>
      <LongName>Homology Modeling Protein Structure Protein Data Bank Title</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2451979</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19234:C13303</PreferredName>
        <Version>1</Version>
        <LongName>Homology Modeling Protein Structure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19234</PREFERRED_NAME>
            <LONG_NAME>Homology Modeling</LONG_NAME>
            <CON_ID>2451929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13303</PREFERRED_NAME>
            <LONG_NAME>Protein Structure</LONG_NAME>
            <CON_ID>2342178</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2451969</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49039:C42774</PreferredName>
        <Version>1</Version>
        <LongName>Protein Data Bank Title</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49039</PREFERRED_NAME>
            <LONG_NAME>Protein Data Bank</LONG_NAME>
            <CON_ID>2451938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42774</PREFERRED_NAME>
            <LONG_NAME>Title</LONG_NAME>
            <CON_ID>2223215</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Homology Modeling Protein Structure Protein Data Bank Title java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Homology Modeling Protein Structure Protein Data Bank Title java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Molecular Pages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812107</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerMoleculePages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812108</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CancerMoleculePages.ModelStructure.pdbTitle</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ModelStructure:pdbTitle</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="127">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2452331</PUBLICID>
    <LONGNAME>Patient Blood Bank Specimen Consent Ind-2</LONGNAME>
    <PREFERREDNAME>PT_BL_BA_SPE_CON_IN2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the patient has consented to blood banking as described in section 13.3 of the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCIC CRF:National Cancer Institute of Canada Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2011932</PublicId>
      <PreferredName>PT_BL_BANK_SPEC_CONS</PreferredName>
      <PreferredDefinition>information related to permission obtained from an individual to collect a sample of blood and submit it to an establishment that collects, tests, processes, and stores blood and its components.</PreferredDefinition>
      <LongName>Patient Blood Bank Specimen Consent</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2451896</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C51963:C19157:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Blood Bank Specimen Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51963</PREFERRED_NAME>
            <LONG_NAME>Blood Bank</LONG_NAME>
            <CON_ID>2451895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient has consented to bloo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient has consented to blood banking as described in section 13.3 of the protocol</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was consent signed for banking of Peripheral Blood Stem Cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was consent signed for data collection regarding Peripheral Blood Stem Cell mobilization and collection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PT_BL_BA_SPE_CON_IN2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="128">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2452758</PUBLICID>
    <LONGNAME>Lung Nodule Number</LONGNAME>
    <PREFERREDNAME>LUNG_NDUL_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The number that indicates the number of the nodule for analyzing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182206</PublicId>
      <PreferredName>LUNG_NDUL</PreferredName>
      <PreferredDefinition>information related to a lung nodule.</PreferredDefinition>
      <LongName>Lung Nodule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177118</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lung</PreferredName>
        <Version>1</Version>
        <LongName>Lung</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177426</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Nodule</PreferredName>
        <Version>1</Version>
        <LongName>Nodule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3280</PREFERRED_NAME>
            <LONG_NAME>Nodule</LONG_NAME>
            <CON_ID>2202765</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2452756</PublicId>
      <PreferredName>NDUL_NUM</PreferredName>
      <PreferredDefinition>The number that indicates the number of the nodule for analyzing.</PreferredDefinition>
      <LongName>Nodule Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Nodule Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Nodule Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of Nodule(s)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of Nodule(s)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506115</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vanderbilt Image Archive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5983666</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="129">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2459758</PUBLICID>
    <LONGNAME>Myelodysplastic Syndrome Assessment Date</LONGNAME>
    <PREFERREDNAME>MDS_ASSESS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date of the assessment of myelodysplastic syndrome (MDS; a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2466257</PublicId>
      <PreferredName>MDS_ASSESS</PreferredName>
      <PreferredDefinition>information related to assessment of myelodysplastic syndrome (MDS; a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines).</PreferredDefinition>
      <LongName>Myelodysplastic Syndrome Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008536</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2459218</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3247</PreferredName>
        <Version>1</Version>
        <LongName>MDS</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3247</PREFERRED_NAME>
            <LONG_NAME>Myelodysplastic Syndrome</LONG_NAME>
            <CON_ID>2202745</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Assessment Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Assessment Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="130">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2460632</PUBLICID>
    <LONGNAME>Brachytherapy Isotope Specify</LONGNAME>
    <PREFERREDNAME>BRT_ISOTOPE_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>a text field to describe atoms of equal atomic number but differing mass used in interstitial or intracavity therapy where radioactive material is placed in or near tumor in sealed catheters or wires.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCIC CRF:National Cancer Institute of Canada Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182129</PublicId>
      <PreferredName>BRT_ISOTOPE</PreferredName>
      <PreferredDefinition>related to atoms of equal proton number (atomic number) but differing neutrons (mass) used in interstitial/intracavity therapy where radioactive material is placed in/near tumor in sealed catheters.</PreferredDefinition>
      <LongName>Brachytherapy Isotope</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176969</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Brachytherapy</PreferredName>
        <Version>1</Version>
        <LongName>Brachytherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15195</PREFERRED_NAME>
            <LONG_NAME>Brachytherapy</LONG_NAME>
            <CON_ID>2202699</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2187548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Isotope</PreferredName>
        <Version>1</Version>
        <LongName>Isotopes</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0022262</PREFERRED_NAME>
            <LONG_NAME>Isotopes</LONG_NAME>
            <CON_ID>2204235</CON_ID>
            <DEFINITION_SOURCE>Medical Subject Headings (MeSH). Bethesda (MD): National Library of Medicine.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="131">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2466086</PUBLICID>
    <LONGNAME>Patient Acute Promyelocytic Leukemia Risk Category</LONGNAME>
    <PREFERREDNAME>PT_APL_RISK_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the patient&#39;s/participant&#39;s acute promyelocytic leukemia risk classification.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2466080</PublicId>
      <PreferredName>PT_APL_RISK_CLASS</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s/participant&#39;s Acute Promyelocytic Leukemia (APL), acute myeloid leukemia (AML) in which abnormal promyelocytes predominate, risk classification, the potential future harm or risk of progression of APL.</PreferredDefinition>
      <LongName>Patient Acute Promyelocytic Leukemia Risk Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2466078</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3182:C17102:C25161</PreferredName>
        <Version>1</Version>
        <LongName>APL Risk Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3182</PREFERRED_NAME>
            <LONG_NAME>Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA</LONG_NAME>
            <CON_ID>2202299</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17102</PREFERRED_NAME>
            <LONG_NAME>Risk</LONG_NAME>
            <CON_ID>2412275</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2466085</PublicId>
      <PreferredName>DZ_RISK_CAT</PreferredName>
      <PreferredDefinition>the level or category of the extent or aggressive nature of a disease for a patient.</PreferredDefinition>
      <LongName>Disease Risk Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intermediate</VALIDVALUE>
          <VALUEMEANING>Intermediate risk</VALUEMEANING>
          <MEANINGDESCRIPTION>Intermediate risk</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low risk</VALUEMEANING>
          <MEANINGDESCRIPTION>The potential future harm that may arise from some present action or attribute or condition is small.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>HIGH</VALUEMEANING>
          <MEANINGDESCRIPTION>HIGH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>APL risk group</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>APL risk group</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="132">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2466378</PUBLICID>
    <LONGNAME>Gemtuzumab Ozogamicin Agent Second Prescription Administered Dose</LONGNAME>
    <PREFERREDNAME>GO_AGT_SE_RX_ADM_DOS</PREFERREDNAME>
    <PREFERREDDEFINITION>the second dose, in milligrams, of Gemtuzumab Ozogamicin administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2466318</PublicId>
      <PreferredName>GO_AGT_SEC_RX_ADM</PreferredName>
      <PreferredDefinition>information related to the second prescribed administration of Gemtuzumab Ozogamicin, a recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.</PreferredDefinition>
      <LongName>Gemtuzumab Ozogamicin Agent Second Prescription Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2466312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1806:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Gemtuzumab Ozogamicin Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1806</PREFERRED_NAME>
            <LONG_NAME>Gemtuzumab Ozogamicin</LONG_NAME>
            <CON_ID>2466311</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2466316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C28180:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Second Prescription Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28180</PREFERRED_NAME>
            <LONG_NAME>Prescription</LONG_NAME>
            <CON_ID>2230250</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222463</PublicId>
      <PreferredName>AGT_ADM_DOSE</PreferredName>
      <PreferredDefinition>the dose of the agent administered.</PreferredDefinition>
      <LongName>Agent Administered Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184291</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dose</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose given</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Relaps/Refract</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811785</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="133">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2468926</PUBLICID>
    <LONGNAME>Patient Disease Body Surface Area Number Category</LONGNAME>
    <PREFERREDNAME>PT_DZ_BSA_NUM_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the category that signifies the amount of body surface area involvement by disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2467200</PublicId>
      <PreferredName>PT_DZ_BSA</PreferredName>
      <PreferredDefinition>The surface area of the body of the patient that is affected by the disease under investigation or study.</PreferredDefinition>
      <LongName>Patient Disease Body Surface Area</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2467197</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Patient Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2467198</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25157</PreferredName>
        <Version>1</Version>
        <LongName>BSA</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25157</PREFERRED_NAME>
            <LONG_NAME>Body Surface Area</LONG_NAME>
            <CON_ID>2203871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2468923</PublicId>
      <PreferredName>PT_DZ_BSA_NUM_CAT</PreferredName>
      <PreferredDefinition>Numeric values to represent categories that signify the amount of body surface area involvement by disease.</PreferredDefinition>
      <LongName>Patient Disease Body Surface Area Number Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2468922</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Number Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>0-10%</VALUEMEANING>
          <MEANINGDESCRIPTION>0-10% of BSA involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>11-50%</VALUEMEANING>
          <MEANINGDESCRIPTION>11-50% of BSA involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>&gt;50%</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::50: A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570, C45255::50, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="134">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2479040</PUBLICID>
    <LONGNAME>Patient Protocol Repeat Enrollment Indicator</LONGNAME>
    <PREFERREDNAME>PT_PROT_REENRLL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify a person&#39;s repeat enrollment into a protocol&#39;s arm or study group.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2479038</PublicId>
      <PreferredName>PT_PROT_REENRLL</PreferredName>
      <PreferredDefinition>A person&#39;s repeat enrollment into a protocol&#39;s arm or study group.</PreferredDefinition>
      <LongName>Patient Protocol Repeat Enrollment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2479036</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25320:C47886:C37948</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Repeat Enrollment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37948</PREFERRED_NAME>
            <LONG_NAME>Enrollment</LONG_NAME>
            <CON_ID>2203918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Repeat Enrollment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Repeat Enrollment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="135">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2481660</PUBLICID>
    <LONGNAME>Prior Cancer Diagnosis Text Type</LONGNAME>
    <PREFERREDNAME>PRIOR_CA_DX_TXT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>The text that describes the type of prior tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues the participant has experienced.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010134</PublicId>
      <PreferredName>PRIOR_CA_DX</PreferredName>
      <PreferredDefinition>information related to a prior cancer diagnosis.</PreferredDefinition>
      <LongName>Prior Cancer Diagnosis</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Prior Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Diagnosis</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2481658</PublicId>
      <PreferredName>PRIOR_CA_DX_TXT_TP</PreferredName>
      <PreferredDefinition>The text that describes the type of prior tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues the participant has experienced.</PreferredDefinition>
      <LongName>Prior Cancer Diagnosis Text Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Text Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invasive Breast Cancer</VALIDVALUE>
          <VALUEMEANING>Invasive breast cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unilateral DCIS</VALIDVALUE>
          <VALUEMEANING>Unilateral DCIS</VALUEMEANING>
          <MEANINGDESCRIPTION>Unilateral DCIS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atypical Hyperplasia</VALIDVALUE>
          <VALUEMEANING>Atypical Hyperplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign (noncancerous) condition in which tissue has certain abnormal features.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRCA 1</VALIDVALUE>
          <VALUEMEANING>BRCA1</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast Cancer 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unilateral LCIS</VALIDVALUE>
          <VALUEMEANING>Unilateral LCIS</VALUEMEANING>
          <MEANINGDESCRIPTION>Unilateral LCIS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2626420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRCA 2</VALIDVALUE>
          <VALUEMEANING>BRCA2</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast Cancer 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Diagnosis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior Diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="136">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2481698</PUBLICID>
    <LONGNAME>Visit Reason Text</LONGNAME>
    <PREFERREDNAME>VST_RSN_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field used to describe the reason for the visit.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2185496</PublicId>
      <PreferredName>VST_PURP</PreferredName>
      <PreferredDefinition>Intended reason for a visit to a healthcare setting.</PreferredDefinition>
      <LongName>Visit Purpose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2181693</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Visit</PreferredName>
        <Version>1</Version>
        <LongName>Visit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25716</PREFERRED_NAME>
            <LONG_NAME>Visit</LONG_NAME>
            <CON_ID>2202626</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177388</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Purpose</PreferredName>
        <Version>1</Version>
        <LongName>Purpose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25634</PREFERRED_NAME>
            <LONG_NAME>Purpose</LONG_NAME>
            <CON_ID>2202870</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2481693</PublicId>
      <PreferredName>VST_RSN_TXT</PreferredName>
      <PreferredDefinition>The free-text field used to describe the reason for the visit.</PreferredDefinition>
      <LongName>Visit Reason Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason for visit</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason for visit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="137">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2482403</PUBLICID>
    <LONGNAME>Site Location Description Identifier Name</LONGNAME>
    <PREFERREDNAME>SITE_LCTN_DESC_ID_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Detailed spatial description of an anatomic site or location.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014618</PublicId>
      <PreferredName>ANAT_LOCN_DESCR</PreferredName>
      <PreferredDefinition>Detailed description to locate an anatomic site.</PreferredDefinition>
      <LongName>Anatomic Location Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206444</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25421:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25421</PREFERRED_NAME>
            <LONG_NAME>Anatomic</LONG_NAME>
            <CON_ID>2202601</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2482401</PublicId>
      <PreferredName>LOC_ID_TXT_NM</PreferredName>
      <PreferredDefinition>An enumerated set of modifiers to support the identification of an exacting location of an item.</PreferredDefinition>
      <LongName>Location Identifier Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Text Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper Right</VALIDVALUE>
          <VALUEMEANING>Upper Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Upper Right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medial Right</VALIDVALUE>
          <VALUEMEANING>Medial Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Medial Right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower Right</VALIDVALUE>
          <VALUEMEANING>Lower Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Lower Right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper Left</VALIDVALUE>
          <VALUEMEANING>Upper Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Upper Left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower Left</VALIDVALUE>
          <VALUEMEANING>Lower Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Lower Left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medial Left</VALIDVALUE>
          <VALUEMEANING>Medial Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Medial Left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left</VALIDVALUE>
          <VALUEMEANING>Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the west when facing north.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right</VALIDVALUE>
          <VALUEMEANING>Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Location</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Location</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Abdomen Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Arm Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="138">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2495640</PUBLICID>
    <LONGNAME>Patient Height Weight Assessment Ind-2</LONGNAME>
    <PREFERREDNAME>PT_HT_WT_ASSESS_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator for evaluating the height and weight of a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2495638</PublicId>
      <PreferredName>PT_HT_WGT_ASSESS</PreferredName>
      <PreferredDefinition>information related to both patient&#39;s height (the vertical measurement or distance from the base to the top of an object; the vertical dimension of extension) and weight (the vertical force exerted by a mass as a result of gravity) determination.</PreferredDefinition>
      <LongName>Patient Height Weight Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2495636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25347:C25208:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Height Weight Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25347</PREFERRED_NAME>
            <LONG_NAME>Height</LONG_NAME>
            <CON_ID>2202568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was height and weight measured</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was height and weight measured</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were measurements taken during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="139">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2500195</PUBLICID>
    <LONGNAME>Dysplastic Morphology Number Count</LONGNAME>
    <PREFERREDNAME>DYSPL_MORPH_NUM_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>The absolute numeric value of the number of aberrant crypt foci visualized during endoscopy with morphologic features of dysplasia.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2497198</PublicId>
      <PreferredName>ACF_LES_MORPH</PreferredName>
      <PreferredDefinition>Information pertaining to a larger than normal, microscopically elevated colonic crypt that may contain dysplastic epithelium lesion morphology.</PreferredDefinition>
      <LongName>Aberrant Crypt Focus Lesion Morphology</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480785</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60536</PreferredName>
        <Version>1</Version>
        <LongName>Aberrant Crypt Focus</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60536</PREFERRED_NAME>
            <LONG_NAME>Aberrant Crypt Focus</LONG_NAME>
            <CON_ID>2480655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2497196</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824:C17943</PreferredName>
        <Version>1</Version>
        <LongName>Lesion Morphology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17943</PREFERRED_NAME>
            <LONG_NAME>Morphology</LONG_NAME>
            <CON_ID>2202748</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2500193</PublicId>
      <PreferredName>DYSPL_MORPH_NUM_CT</PreferredName>
      <PreferredDefinition>The absolute numeric value of the number of aberrant crypt foci visualized during endoscopy with morphologic features of dysplasia.</PreferredDefinition>
      <LongName>Dysplastic Morphology Number Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2480313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Number Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dysplastic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dysplastic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="140">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2505997</PUBLICID>
    <LONGNAME>Participant Health Care Provider Communication Sun Exposure Protective Clothing Indicator</LONGNAME>
    <PREFERREDNAME>HCP_SUNPR_CLTH_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify an exchange of information with health care providers on the importance of wearing clothing designed to protect the individual against sun exposure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2505995</PublicId>
      <PreferredName>HCP_COMM_SUNPR_CLTH</PreferredName>
      <PreferredDefinition>Exchange of information with health care providers on the importance of wearing clothing designed to protect the individual against sun exposure.</PreferredDefinition>
      <LongName>Participant Health Care Provider Communication Sun Exposure Protective Clothing</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2505966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16666:C16452</PreferredName>
        <Version>1</Version>
        <LongName>Health Care Provider Communication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16666</PREFERRED_NAME>
            <LONG_NAME>Health Care Provider</LONG_NAME>
            <CON_ID>2479788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16452</PREFERRED_NAME>
            <LONG_NAME>Communication</LONG_NAME>
            <CON_ID>2435936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2505993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17725:C0033611</PreferredName>
        <Version>1</Version>
        <LongName>Sun Exposure Protective Clothing</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17725</PREFERRED_NAME>
            <LONG_NAME>Sun Exposure</LONG_NAME>
            <CON_ID>2505976</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0033611</PREFERRED_NAME>
            <LONG_NAME>Protective Clothing</LONG_NAME>
            <CON_ID>2505992</CON_ID>
            <DEFINITION_SOURCE>MSH2005_2004_10_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017177</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2179965</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sun-protective clothing</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sun-protective clothing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="141">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513700</PUBLICID>
    <LONGNAME>Storage Unit First Dimension Position java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2513434v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A physical structure or device capable of holding objects or samples._Preceding all others in time or space or degree.:The magnitude of something in a particular direction, especially length or width or height.:The particular portion of space occupied by a physical object._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513434</PublicId>
      <PreferredName>2422775v1.0:2513286v1.0</PreferredName>
      <PreferredDefinition>A physical structure or device capable of holding objects or samples._Preceding all others in time or space or degree.:The magnitude of something in a particular direction, especially length or width or height.:The particular portion of space occupied by a physical object.</PreferredDefinition>
      <LongName>Storage Unit First Dimension Position</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422775</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45322</PreferredName>
        <Version>1</Version>
        <LongName>Storage Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45322</PREFERRED_NAME>
            <LONG_NAME>Storage Unit</LONG_NAME>
            <CON_ID>2240763</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2513286</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25483:C25339</PreferredName>
        <Version>1</Version>
        <LongName>First Dimension Position</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25339</PREFERRED_NAME>
            <LONG_NAME>Position</LONG_NAME>
            <CON_ID>2203955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Storage Unit First Dimension Position java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Storage Unit First Dimension Position java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2680967</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000633</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.StorageContainer.positionDimensionOne</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.StorageContainer.positionDimensionOne</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StorageContainer:positionDimensionOne</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="142">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513774</PUBLICID>
    <LONGNAME>Event Parameter Object Date and Time java.util.Date</LONGNAME>
    <PREFERREDNAME>2513508v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Something that happens at a given place and time.:Any factor that defines a system and determines (or limits) its performance._An expression of both date and time that an event has happened or will happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513508</PublicId>
      <PreferredName>2513375v1.0:2437776v1.0</PreferredName>
      <PreferredDefinition>Something that happens at a given place and time.:Any factor that defines a system and determines (or limits) its performance._An expression of both date and time that an event has happened or will happened.</PreferredDefinition>
      <LongName>Event Parameter Object Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513375</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C44175</PreferredName>
        <Version>1</Version>
        <LongName>Event Parameter Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2437776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Event Parameter Object Date and Time java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Event Parameter Object Date and Time java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.general</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000135</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTRIP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.general</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.general.EventParameters.timeStamp</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EventParameters:timeStamp</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EventParameters:timestamp</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.EventParameters.timestamp</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="143">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513866</PUBLICID>
    <LONGNAME>Fluid Specimen Review Parameter Object Date and Time java.util.Date</LONGNAME>
    <PREFERREDNAME>2513600v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of appraisal, evaluation, or analysis.:Any factor that defines a system and determines (or limits) its performance._An expression of both date and time that an event has happened or will happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513600</PublicId>
      <PreferredName>2513362v1.0:2437776v1.0</PreferredName>
      <PreferredDefinition>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of appraisal, evaluation, or analysis.:Any factor that defines a system and determines (or limits) its performance._An expression of both date and time that an event has happened or will happened.</PreferredDefinition>
      <LongName>Fluid Specimen Review Parameter Object Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513362</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25278:C19157:C42729:C44175</PreferredName>
        <Version>1</Version>
        <LongName>Fluid Specimen Review Parameter Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25278</PREFERRED_NAME>
            <LONG_NAME>Fluid</LONG_NAME>
            <CON_ID>2202644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42729</PREFERRED_NAME>
            <LONG_NAME>Review</LONG_NAME>
            <CON_ID>2202331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2437776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Fluid Specimen Review Parameter Object Date and Time java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Fluid Specimen Review Parameter Object Date and Time java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.FluidSpecimenReviewEventParameters.timestamp</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FluidSpecimenReviewEventParameters:timestamp</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="144">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513900</PUBLICID>
    <LONGNAME>Fluid Specimen Requirement Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2513634v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that is necessary; condition, something that is obligatory._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513634</PublicId>
      <PreferredName>2513377v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that is necessary; condition, something that is obligatory._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Fluid Specimen Requirement Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513377</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25278:C19157:C38015</PreferredName>
        <Version>1</Version>
        <LongName>Fluid Specimen Requirement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25278</PREFERRED_NAME>
            <LONG_NAME>Fluid</LONG_NAME>
            <CON_ID>2202644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38015</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2203776</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Fluid Specimen Requirement Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Fluid Specimen Requirement Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FluidSpecimenRequirement:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.FluidSpecimenRequirement.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="145">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2514052</PUBLICID>
    <LONGNAME>Orthologous Gene Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2514038v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A gene from one species which corresponds to a gene in another species that is related via a common ancestral species (a homologous gene), but which has evolved to become different from the gene of the other species. (http://biotech.icmb.utexas.edu)_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2514038</PublicId>
      <PreferredName>2514027v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A gene from one species which corresponds to a gene in another species that is related via a common ancestral species (a homologous gene), but which has evolved to become different from the gene of the other species. (http://biotech.icmb.utexas.edu)_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Orthologous Gene Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2514027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28708</PreferredName>
        <Version>1</Version>
        <LongName>Orthologous Gene</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28708</PREFERRED_NAME>
            <LONG_NAME>Orthologous Gene</LONG_NAME>
            <CON_ID>2514017</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Orthologous Gene Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Orthologous Gene Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2514015</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000306</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557869</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.OrthologousGene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OrthologousGene:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.OrthologusGene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OrthologusGene:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="146">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2516062</PUBLICID>
    <LONGNAME>Non-Target Axilla Lesion Present Count</LONGNAME>
    <PREFERREDNAME>NTAR_AXIL_LES_PRE_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the quantity present non-target axilla lesions or area of abnormal tissue change that are not in an object fixed as a goal or point of examination in the axilla (the hollow under the arm where it is joined to the shoulder).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2516060</PublicId>
      <PreferredName>NTAR_AXIL_LES_PRES</PreferredName>
      <PreferredDefinition>information related to presence of the patient&#39;s area of abnormal tissue change that are not in an object fixed as a goal or point of examination in the axilla (the hollow under the arm where it is joined to the shoulder).</PreferredDefinition>
      <LongName>Non-Target Axilla Lesion Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2739011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25592:C12674:C3824</PreferredName>
        <Version>1</Version>
        <LongName>Non-Target Axilla Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25592</PREFERRED_NAME>
            <LONG_NAME>Non-Target</LONG_NAME>
            <CON_ID>2206327</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12674</PREFERRED_NAME>
            <LONG_NAME>Axilla</LONG_NAME>
            <CON_ID>2202318</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018596</PublicId>
      <PreferredName>LES_CT</PreferredName>
      <PreferredDefinition>the quantity of specified lesions.</PreferredDefinition>
      <LongName>Lesion Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184284</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Count</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of Nontarget Lesions [</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of Nontarget Lesions [in] Axilla</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="147">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2519862</PUBLICID>
    <LONGNAME>Tooth Cold Sensitivity Assessment Yes No Indicator</LONGNAME>
    <PREFERREDNAME>T_C_SENS_ASSESS_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator of the ability to register small physical amounts or differences of cold in tooth.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2519690</PublicId>
      <PreferredName>TOOTH_C_SENS_ASSESS</PreferredName>
      <PreferredDefinition>information related to assessment of ability to register small physical amounts or differences of cold in tooth.</PreferredDefinition>
      <LongName>Tooth Cold Sensitivity Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2514269</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12506</PreferredName>
        <Version>1</Version>
        <LongName>Tooth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2519688</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62180:C25201:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Cold Sensitivity Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62180</PREFERRED_NAME>
            <LONG_NAME>Cold</LONG_NAME>
            <CON_ID>2503466</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25201</PREFERRED_NAME>
            <LONG_NAME>Sensitivity</LONG_NAME>
            <CON_ID>2203788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sensitivity to cold</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sensitivity to cold</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the tooth respond to the cold testing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Restorative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812086</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DPBRN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="148">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2519990</PUBLICID>
    <LONGNAME>Patient Dentist Visit Date</LONGNAME>
    <PREFERREDNAME>PT_DNT_VS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on relating to the patient&quot;s visit to a dentist.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2585397</PublicId>
      <PreferredName>PT_DENT_VISIT</PreferredName>
      <PreferredDefinition>information relating to the patient&#39;s visit to a dentist.</PreferredDefinition>
      <LongName>Patient Dentist Visit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2585395</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654:C25716</PreferredName>
        <Version>1</Version>
        <LongName>Dentist Visit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25716</PREFERRED_NAME>
            <LONG_NAME>Visit</LONG_NAME>
            <CON_ID>2202626</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient visit date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of visit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the date of the patie</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the date of the patient&#39;s visit?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of treatment/baseline visit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Restorative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812086</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DPBRN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="149">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2520644</PUBLICID>
    <LONGNAME>Wechsler Intelligence Scale for Children IV Raw Score</LONGNAME>
    <PREFERREDNAME>WISCIV_TEST_RAW_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Number of items correctly answered, that has not been transformed, on the Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV).  Raw scores range from a maximum score of 0 to 136 depending on the area being assessed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527419</PublicId>
      <PreferredName>PRSN_WISCIV_TEST_RSL</PreferredName>
      <PreferredDefinition>Outcomes from testing a person/subject using the Wechsler Intelligence Scale for Children Edition 4 (WISC-IV), measuring a child&#39;s current cognitive abilities in  both verbal and nonverbal areas, including verbal comprehension, perceptual reasoning, working memory, and processing  speed.</PreferredDefinition>
      <LongName>Person Wechsler Intelligence Scale for Children IV Test Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2527417</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C62715</PreferredName>
        <Version>1</Version>
        <LongName>Person Wechsler Intelligence Scale for Children, Fourth Edition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62715</PREFERRED_NAME>
            <LONG_NAME>Wechsler Intelligence Scale for Children</LONG_NAME>
            <CON_ID>2527141</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2527278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15336:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Testing Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15336</PREFERRED_NAME>
            <LONG_NAME>Testing</LONG_NAME>
            <CON_ID>2204718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2526966</PublicId>
      <PreferredName>WISCIV_RAW_SC</PreferredName>
      <PreferredDefinition>Number of items correctly answered, that has not been transformed, on the Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV).  Raw scores range from a maximum score of 0 to 136 depending on the area being assessed.</PreferredDefinition>
      <LongName>Wechsler Intelligence Scale for Children IV Raw Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>136</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2527426</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62715:C48188:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Wechsler Intelligence Scale for Children, Fourth Edition Raw Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62715</PREFERRED_NAME>
            <LONG_NAME>Wechsler Intelligence Scale for Children</LONG_NAME>
            <CON_ID>2527141</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48188</PREFERRED_NAME>
            <LONG_NAME>Raw</LONG_NAME>
            <CON_ID>2422622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Raw Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Raw Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857168</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR CRF Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neuropsych Testing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="150">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2528401</PUBLICID>
    <LONGNAME>Malignant Neoplasm Disease Diagnosis Specify</LONGNAME>
    <PREFERREDNAME>MALIGNEO_DZ_DX_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify the type of tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person diagnosed during the indicated period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Transplant CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528404</PublicId>
      <PreferredName>MALIGNEO_DIS_DX</PreferredName>
      <PreferredDefinition>information related to the diagnosis or detection of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PreferredDefinition>
      <LongName>Malignant Neoplasm Disease Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528402</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018432</PublicId>
      <PreferredName>DX_SPEC</PreferredName>
      <PreferredDefinition>the specified free-text field related to an aspect of patient/participant&#39;s diagnosis</PreferredDefinition>
      <LongName>Diagnosis Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Malignancy, Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Malignancy, Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical diagnosis for the malignancy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Evaluations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MHEVDTYP</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="151">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2529265</PUBLICID>
    <LONGNAME>Class Comparison Analysis Finding Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2528969v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A type of analysis that determine the significance and/or magnitude of the difference between groups.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528969</PublicId>
      <PreferredName>2528760v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A type of analysis that determine the significance and/or magnitude of the difference between groups.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Class Comparison Analysis Finding Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528760</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61038:C25391:C3367</PreferredName>
        <Version>1</Version>
        <LongName>Class Comparison Analysis Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61038</PREFERRED_NAME>
            <LONG_NAME>Class Comparison</LONG_NAME>
            <CON_ID>2528582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Class Comparison Analysis Finding Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Class Comparison Analysis Finding Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528519</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.analysis.classComparison</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812212</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.analysis.classComparison.ClassComparisonAnalysisFinding.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ClassComparisonAnalysisFinding:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="152">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2534606</PUBLICID>
    <LONGNAME>Person Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2009983v2.31:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a means of uniquely identifying an individual._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009983</PublicId>
      <PreferredName>PERSON_ID</PreferredName>
      <PreferredDefinition>a means of uniquely identifying an individual.</PreferredDefinition>
      <LongName>Person Identifier</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Person Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Person Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812743</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000253</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5527905</PublicId>
          <ContextName>TEST</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ModelTest</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mctest</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>6058375</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Person.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.Person.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.contact.Person.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.Person.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TEST</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mctest.Person.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="153">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2534620</PUBLICID>
    <LONGNAME>Radical Prostatectomy Gleason Score for Prostate Cancer Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534375v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy and perineal prostatectomy.:The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score d_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534375</PublicId>
      <PreferredName>2534231v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy and perineal prostatectomy.:The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score d_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Radical Prostatectomy Gleason Score for Prostate Cancer Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534231</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15399:C28084</PreferredName>
        <Version>1</Version>
        <LongName>Radical Prostatectomy Gleason Score for Prostate Cancer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15399</PREFERRED_NAME>
            <LONG_NAME>Radical Prostatectomy</LONG_NAME>
            <CON_ID>2431187</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28084</PREFERRED_NAME>
            <LONG_NAME>Gleason Score for Prostate Cancer</LONG_NAME>
            <CON_ID>2202653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Radical Prostatectomy Gleason Score for Prostate Cancer Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Radical Prostatectomy Gleason Score for Prostate Cancer Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.prostate.radical_prostatectomy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812227</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.prostate.radical_prostatectomy.RadicalProstatectomyGleasonHistologicGrade.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RadicalProstatectomyGleasonHistologicGrade:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="154">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2534641</PUBLICID>
    <LONGNAME>Specimen Item Collection Cutaneous Melanoma Characteristic Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534388v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid ta:A group of items of the same type, gathered for display or study.:A malignant neoplasm derived from cells that are capable of forming melanin.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534388</PublicId>
      <PreferredName>2534195v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid ta:A group of items of the same type, gathered for display or study.:A malignant neoplasm derived from cells that are capable of forming melanin.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Specimen Item Collection Cutaneous Melanoma Characteristic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C45261:C3510:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Item Collection Cutaneous Melanoma Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45261</PREFERRED_NAME>
            <LONG_NAME>Item Collection</LONG_NAME>
            <CON_ID>2512704</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3510</PREFERRED_NAME>
            <LONG_NAME>Cutaneous Melanoma</LONG_NAME>
            <CON_ID>2431169</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Item Collection Cutaneous Melanoma Characteristic Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Item Collection Cutaneous Melanoma Characteristic Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.cutaneousmelanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CutaneousMelanomaAccessionCharacteristics:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.cutaneousmelanoma.CutaneousMelanomaAccessionCharacteristics.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="155">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2534804</PUBLICID>
    <LONGNAME>Transgene Recombinant DNA DNA Sequence java.lang.String</LONGNAME>
    <PREFERREDNAME>2534736v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A transgene is an engineered gene consisting at least of a regulatory element and a coding sequence; regulatory element and coding sequence can come from different species. (caBIO)_Biologically active DNA which has been formed by the in vitro joining of segments of DNA from different sources usually for the purpose of genetic manipulation.:The sequence of nucleotide residues along a DNA chain._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534736</PublicId>
      <PreferredName>2224095v1.0:2534703v1.0</PreferredName>
      <PreferredDefinition>A transgene is an engineered gene consisting at least of a regulatory element and a coding sequence; regulatory element and coding sequence can come from different species. (caBIO)_Biologically active DNA which has been formed by the in vitro joining of segments of DNA from different sources usually for the purpose of genetic manipulation.:The sequence of nucleotide residues along a DNA chain.</PreferredDefinition>
      <LongName>Transgene Recombinant DNA DNA Sequence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224095</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C22190</PreferredName>
        <Version>1</Version>
        <LongName>Transgene</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C22190</PREFERRED_NAME>
            <LONG_NAME>Transgene</LONG_NAME>
            <CON_ID>2223976</CON_ID>
            <DEFINITION_SOURCE>CABIO</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2534703</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C453:C13299</PreferredName>
        <Version>1</Version>
        <LongName>Recombinant DNA DNA Sequence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C453</PREFERRED_NAME>
            <LONG_NAME>Recombinant DNA</LONG_NAME>
            <CON_ID>2534692</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13299</PREFERRED_NAME>
            <LONG_NAME>DNA Sequence</LONG_NAME>
            <CON_ID>2423567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Transgene Recombinant DNA DNA Sequence java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Transgene Recombinant DNA DNA Sequence java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Transgene.constructSequence</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Transgene:constructSequence</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="156">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2534855</PUBLICID>
    <LONGNAME>Inherited Induced Mutation Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534783v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Transmitted through genes from parents to offspring. (genome.gov):A mutation triggered by outside influences (e.g., radiation, chemicals or other means) as opposed to those created by the inherent infidelity of DNA polymerase._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534783</PublicId>
      <PreferredName>2437787v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Transmitted through genes from parents to offspring. (genome.gov):A mutation triggered by outside influences (e.g., radiation, chemicals or other means) as opposed to those created by the inherent infidelity of DNA polymerase._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Inherited Induced Mutation Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437787</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28018:C40987</PreferredName>
        <Version>1</Version>
        <LongName>Inherited Induced Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28018</PREFERRED_NAME>
            <LONG_NAME>Inherited</LONG_NAME>
            <CON_ID>2437674</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40987</PREFERRED_NAME>
            <LONG_NAME>Induced Mutation</LONG_NAME>
            <CON_ID>2224006</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Inherited Induced Mutation Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Inherited Induced Mutation Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.InducedMutation.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InducedMutation:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="157">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2535265</PUBLICID>
    <LONGNAME>Bioassay Class Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2535049v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An abstract class which represents both physical and computational groupings of arrays and biomaterials._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2535049</PublicId>
      <PreferredName>2236720v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>An abstract class which represents both physical and computational groupings of arrays and biomaterials._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Bioassay Class Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236720</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42886</PreferredName>
        <Version>1</Version>
        <LongName>Bioassay Class</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42886</PREFERRED_NAME>
            <LONG_NAME>Bioassay Class</LONG_NAME>
            <CON_ID>2236542</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Bioassay Class Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Bioassay Class Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mageom 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000223</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gridExtensions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812798</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000221</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2632574</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Bioconductor</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000222</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BioAssay:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.mageom.domain.BioAssay.BioAssay.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="158">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2535295</PUBLICID>
    <LONGNAME>Physical Bioassay Object Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2535079v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A bioAssay created by the bioAssayCreation event (e.g. in gene expression analysis this event is represented by the hybridization event)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2535079</PublicId>
      <PreferredName>2236718v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A bioAssay created by the bioAssayCreation event (e.g. in gene expression analysis this event is represented by the hybridization event)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Physical Bioassay Object Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44181</PreferredName>
        <Version>1</Version>
        <LongName>Physical Bioassay Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44181</PREFERRED_NAME>
            <LONG_NAME>Physical Bioassay Object</LONG_NAME>
            <CON_ID>2236545</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Physical Bioassay Object Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Physical Bioassay Object Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mageom 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000223</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gridExtensions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812798</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000221</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2632574</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Bioconductor</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.BioAssay</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000222</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhysicalBioAssay:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.mageom.domain.BioAssay.PhysicalBioAssay.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="159">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2538781</PUBLICID>
    <LONGNAME>Re-Excision Cutaneous Melanoma Specimen Characteristic Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534406v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A surgical procedure to remove the remaining abnormal tissues from the body, not completely removed in an earlier attempt.:A malignant neoplasm derived from cells that are capable of forming melanin.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid ta:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534406</PublicId>
      <PreferredName>2534193v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A surgical procedure to remove the remaining abnormal tissues from the body, not completely removed in an earlier attempt.:A malignant neoplasm derived from cells that are capable of forming melanin.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid ta:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Re-Excision Cutaneous Melanoma Specimen Characteristic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534193</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48600:C3510:C19157:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Re-Excision Cutaneous Melanoma Specimen Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48600</PREFERRED_NAME>
            <LONG_NAME>Re-Excision</LONG_NAME>
            <CON_ID>2431178</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3510</PREFERRED_NAME>
            <LONG_NAME>Cutaneous Melanoma</LONG_NAME>
            <CON_ID>2431169</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Re-Excision Cutaneous Melanoma Specimen Characteristic Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Re-Excision Cutaneous Melanoma Specimen Characteristic Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.cutaneousmelanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.cutaneousmelanoma.ReexcisionCutaneousMelanomaSpecimenCharacteristics.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReexcisionCutaneousMelanomaSpecimenCharacteristics:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="160">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2538807</PUBLICID>
    <LONGNAME>Fuhrman Nuclear Grade Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534434v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A 4-point scale that indicates the level of protein synthesis activity in malignant cells based on the appearance of the nuclei. The grading ranges from I (best prognosis) to IV (worst prognosis)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534434</PublicId>
      <PreferredName>2534208v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A 4-point scale that indicates the level of protein synthesis activity in malignant cells based on the appearance of the nuclei. The grading ranges from I (best prognosis) to IV (worst prognosis)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Fuhrman Nuclear Grade Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534208</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62411</PreferredName>
        <Version>1</Version>
        <LongName>Fuhrman Nuclear Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62411</PREFERRED_NAME>
            <LONG_NAME>Fuhrman Nuclear Grade</LONG_NAME>
            <CON_ID>2534092</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Fuhrman Nuclear Grade Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Fuhrman Nuclear Grade Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.kidney</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812221</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FuhrmanNuclearGrade:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.kidney.FuhrmanNuclearGrade.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="161">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2538828</PUBLICID>
    <LONGNAME>Invasive Pancreatic Carcinoma Histologic Type Other Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2534455v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>User entered text indicating a subclassification of pancreatic carcinoma</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534455</PublicId>
      <PreferredName>2534225v1.0:2431195v1.0</PreferredName>
      <PreferredDefinition>Marked by a tendency to spread, especially into healthy surrounding tissue.:A carcinoma arising from the exocrine pancreas.  The overwhelming majority of pancreatic carcinomas are adenocarcinomas.:Refers to the type of tissue in which a tumor originated._Different than the one(s) previously specified or mentioned.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Invasive Pancreatic Carcinoma Histologic Type Other Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534225</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14159:C3850:C4741</PreferredName>
        <Version>1</Version>
        <LongName>Invasive Pancreatic Carcinoma Histologic Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14159</PREFERRED_NAME>
            <LONG_NAME>Invasive</LONG_NAME>
            <CON_ID>2203841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3850</PREFERRED_NAME>
            <LONG_NAME>Exocrine Pancreas Carcinoma</LONG_NAME>
            <CON_ID>2534097</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4741</PREFERRED_NAME>
            <LONG_NAME>Neoplasm by Morphology</LONG_NAME>
            <CON_ID>2431145</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Other Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If type is not listed, please</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If type is not listed, please specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.pancreas</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812223</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InvasiveExocrinePancreaticCarcinomaNeoplasmHistologicType:otherName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.pancreas.InvasiveExocrinePancreaticCarcinomaNeoplasmHistologicType.otherName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="162">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2538830</PUBLICID>
    <LONGNAME>Invasive Prostate Carcinoma Neoplasm by Morphology Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2534457v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>definition pending:definition pending_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2534457</PublicId>
      <PreferredName>2431293v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>definition pending:definition pending_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Invasive Prostate Carcinoma Neoplasm by Morphology Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48596:C4741</PreferredName>
        <Version>1</Version>
        <LongName>Invasive Prostate Carcinoma Neoplasm by Morphology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48596</PREFERRED_NAME>
            <LONG_NAME>Invasive Prostate Carcinoma</LONG_NAME>
            <CON_ID>2431179</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4741</PREFERRED_NAME>
            <LONG_NAME>Neoplasm by Morphology</LONG_NAME>
            <CON_ID>2431145</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Invasive Prostate Carcinoma Neoplasm by Morphology Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Invasive Prostate Carcinoma Neoplasm by Morphology Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812224</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.prostate.InvasiveProstateCarcinomaNeoplasmHistologicType.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InvasiveProstateCarcinomaNeoplasmHistologicType:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="163">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2539792</PUBLICID>
    <LONGNAME>Administered Item Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2539597v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2539597</PublicId>
      <PreferredName>2231648v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Administered Item Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231648</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42613</PreferredName>
        <Version>1</Version>
        <LongName>Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Administered Item Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Administered Item Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@dateModified</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="164">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2542051</PUBLICID>
    <LONGNAME>Record Identification NAACCR Cancer Registry Record Version Code</LONGNAME>
    <PREFERREDNAME>2542046v1.0:2542049v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The system of numbers, letters and words that represents the NAACCR record version used to create the record.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2542046</PublicId>
      <PreferredName>2608610v1.0:2633549v1.0</PreferredName>
      <PreferredDefinition>The North American Association of Central Cancer Registries record version used to create the record.</PreferredDefinition>
      <LongName>Record Identification NAACCR Cancer Registry Record Version</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2608610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25198:C25737</PreferredName>
        <Version>1</Version>
        <LongName>Record Identified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25198</PREFERRED_NAME>
            <LONG_NAME>Record</LONG_NAME>
            <CON_ID>2203775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2633549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1613951:C25198:C25714</PreferredName>
        <Version>1</Version>
        <LongName>NAACCR Cancer Registry Record Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1613951</PREFERRED_NAME>
            <LONG_NAME>NAACCR Cancer Registry</LONG_NAME>
            <CON_ID>2542043</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25198</PREFERRED_NAME>
            <LONG_NAME>Record</LONG_NAME>
            <CON_ID>2203775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2542049</PublicId>
      <PreferredName>2542049v1.0</PreferredName>
      <PreferredDefinition>The system of numbers, letters and words that represents the NAACCR record version used to create the record._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Record Version Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2660164</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25714:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Version Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1992-1994 Version 2 and Version 3</VALUEMEANING>
          <MEANINGDESCRIPTION>1992-1994 Version 2 and Version 3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>1995 Version 4.0</VALUEMEANING>
          <MEANINGDESCRIPTION>1995 Version 4.0</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>1996 and 1997 Version 5.0 or Version 5.1</VALUEMEANING>
          <MEANINGDESCRIPTION>1996 and 1997 Version 5.0 or Version 5.1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>1998 Version 6</VALUEMEANING>
          <MEANINGDESCRIPTION>1998 Version 6</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>1999 Version 7</VALUEMEANING>
          <MEANINGDESCRIPTION>1999 Version 7</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>2000 Version 8</VALUEMEANING>
          <MEANINGDESCRIPTION>2000 Version 8</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>2001 and 2002 Version 9 and 9.1</VALUEMEANING>
          <MEANINGDESCRIPTION>2001 and 2002 Version 9 and 9.1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>2003, 2004, and 2005 Version 10, 10.1, and 10.2</VALUEMEANING>
          <MEANINGDESCRIPTION>2003, 2004, and 2005 Version 10, 10.1, and 10.2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B</VALIDVALUE>
          <VALUEMEANING>2006 Version 11</VALUEMEANING>
          <MEANINGDESCRIPTION>2006 Version 11</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blank</VALIDVALUE>
          <VALUEMEANING>September 1989 Version</VALUEMEANING>
          <MEANINGDESCRIPTION>September 1989 Version</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR Record Version</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>NAACCR Record Version</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RecordID11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242098</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>50</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NAACCR Record Version</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="165">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2543457</PUBLICID>
    <LONGNAME>Laboratory Procedure T-Lymphocyte CD3 Complex Outcome Percentage Value</LONGNAME>
    <PREFERREDNAME>LAB_CD3_T_OC_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the value in percentage estimating the portion of T-lymphocytes positive for CD3 present in a sample of peripheral blood in a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2543444</PublicId>
      <PreferredName>LAB_TLYMPH_CD3_OC</PreferredName>
      <PreferredDefinition>information related to the results of the medical procedure that involves testing a sample of blood for CD3 complex (Consisting of cell surface type I membrane Delta, Epsilon, Gamma, Zeta, and Eta protein subunits with ITAM domains and noncovalently associated with the disulfide bound heterodimeric alpha/beta and gamma/delta TCR, the CD3 complex couples receptor antigen recognition to signal transduction pathways during T-cell activation) in T-lymphocytes (a type of white blood cell that helps stimulate immune system reactions).</PreferredDefinition>
      <LongName>Laboratory Procedure T-Lymphocyte CD3 Complex Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2779801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12476:C38897:C20200</PreferredName>
        <Version>1</Version>
        <LongName>T-Lymphocyte CD3 Complex Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12476</PREFERRED_NAME>
            <LONG_NAME>T-Lymphocyte</LONG_NAME>
            <CON_ID>2529672</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38897</PREFERRED_NAME>
            <LONG_NAME>CD3 Complex</LONG_NAME>
            <CON_ID>2593496</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019101</PublicId>
      <PreferredName>HMT_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>a percentage for a hematologic laboratory value.</PreferredDefinition>
      <LongName>Blood Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>T-Cell CD3+ %</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>T-Cell CD3+ %</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CD3+ percentage:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_CD3_VAL</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="166">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2547784</PUBLICID>
    <LONGNAME>Prostatic Atypical Adenomatous Hyperplasia Indicator</LONGNAME>
    <PREFERREDNAME>PRS_AAH_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator to ask if there is presence of prostatic hyperplasia characterized by the presence of crowded adenomatous epithelial nodules.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2547782</PublicId>
      <PreferredName>2547780v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Information pertaining to prostatic hyperplasia characterized by the presence of crowded adenomatous epithelial nodules.</PreferredDefinition>
      <LongName>Prostatic Atypical Adenomatous Hyperplasia Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2547780</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C5595</PreferredName>
        <Version>1</Version>
        <LongName>Prostatic Atypical Adenomatous Hyperplasia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C5595</PREFERRED_NAME>
            <LONG_NAME>Prostatic Atypical Adenomatous Hyperplasia</LONG_NAME>
            <CON_ID>2434294</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015873</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>A choice of Yes and No answer.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008509</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPORES</PreferredName>
        <Version>2.31</Version>
        <LongName>SPOREs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YES</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AAH</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>AAH</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="167">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2551893</PUBLICID>
    <LONGNAME>Residual Tumor Burden Value</LONGNAME>
    <PREFERREDNAME>RES_TUM_BRDN_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value calculated for a subject&#39;s residual tumor burden in resection specimen after treatment, based on fraction of cellularity attributable to the invasive cancer component, max diameter of invasive cancer, max diameter in a second dimension, diameter of largest node metastatis, numer of positive lymph nodes, and a decay constant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2551883</PublicId>
      <PreferredName>RESID_CA_BRDN</PreferredName>
      <PreferredDefinition>Reference to the residual tumor or cancer burden left after intervention.</PreferredDefinition>
      <LongName>Residual Cancer Burden Tumor Burden</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2551879</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37895:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Residual Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37895</PREFERRED_NAME>
            <LONG_NAME>Residual</LONG_NAME>
            <CON_ID>2206361</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2551887</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28384</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Burden</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28384</PREFERRED_NAME>
            <LONG_NAME>Tumor Burden</LONG_NAME>
            <CON_ID>2551884</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2551886</PublicId>
      <PreferredName>RESID_CA_BRDN_VAL</PreferredName>
      <PreferredDefinition>Numeric value calculated as the residual tumor burden, based on cellularity, max diameter of invasive cancer, max diameter in a second dimension, diameter of largest node metastatis, numer of positive lymph nodes, and a decay constant.  </PreferredDefinition>
      <LongName>Residual Tumor Burden Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2551885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37895:C28384:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Residual Tumor Burden Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37895</PREFERRED_NAME>
            <LONG_NAME>Residual</LONG_NAME>
            <CON_ID>2206361</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28384</PREFERRED_NAME>
            <LONG_NAME>Tumor Burden</LONG_NAME>
            <CON_ID>2551884</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Residual Cancer Burden Index</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Residual Cancer Burden Index</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2548333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>I-SPY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C911/C1000</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2956164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Transcend</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transcend CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2956165</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preoperative Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886755</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Preoperative Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preoperative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902140</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BOLD</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BOLD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RES_TUM_BRDN_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="168">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552293</PUBLICID>
    <LONGNAME>Patient McGill Pain Questionnaire Score</LONGNAME>
    <PREFERREDNAME>PT_MCGILL_ASSESS_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term(s) to capture a patient&#39;s self assessment of pain using the McGill Pain Questionnaire.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MPQ:McGill Pain Questionnaire Short Form, Melzack R, 1987.</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200785</PublicId>
      <PreferredName>PT_PN_ASSESS</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s pain assessment.</PreferredDefinition>
      <LongName>Patient Pain Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207484</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Pain Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2552262</PublicId>
      <PreferredName>MCGILL_QUEST_PN_SC</PreferredName>
      <PreferredDefinition>Text terms to capture a patient/person self assessment of pain using the McGill Pain Questionnaire.</PreferredDefinition>
      <LongName>McGill Pain Questionnaire Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MPQ:McGill Pain Questionnaire Short Form, Melzack R, 1987.</Origin>
      <Representation>
        <PublicId>2552261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21135:C25338</PreferredName>
        <Version>1</Version>
        <LongName>McGill Pain Questionnaire Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21135</PREFERRED_NAME>
            <LONG_NAME>McGill Pain Questionnaire</LONG_NAME>
            <CON_ID>2552225</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Severe</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rank of your pain</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Rank of your pain</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ThermoDox Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812723</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="169">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552770</PUBLICID>
    <LONGNAME>Question Repeat Administered Item Preferred Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2552573v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Designated as more desirable.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552573</PublicId>
      <PreferredName>2539534v1.0:2231599v1.0</PreferredName>
      <PreferredDefinition>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Designated as more desirable.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Question Repeat Administered Item Preferred Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C47886:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Question Repeat Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231599</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42711:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Preferred Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42711</PREFERRED_NAME>
            <LONG_NAME>Preferred</LONG_NAME>
            <CON_ID>2231546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Question Repeat Administered Item Preferred Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Question Repeat Administered Item Preferred Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.QuestionRepetition.preferredName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QuestionRepetition:preferredName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="170">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552773</PUBLICID>
    <LONGNAME>Question Repeat Administered Item Unresolved Issue java.lang.String</LONGNAME>
    <PREFERREDNAME>2552577v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Any problem that remains unresolved regarding proper documentation of the Administered Item. (ISO 11179)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552577</PublicId>
      <PreferredName>2539534v1.0:2231608v1.0</PreferredName>
      <PreferredDefinition>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Any problem that remains unresolved regarding proper documentation of the Administered Item. (ISO 11179)</PreferredDefinition>
      <LongName>Question Repeat Administered Item Unresolved Issue</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C47886:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Question Repeat Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231608</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42869</PreferredName>
        <Version>1</Version>
        <LongName>Unresolved Issue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42869</PREFERRED_NAME>
            <LONG_NAME>Unresolved Issue</LONG_NAME>
            <CON_ID>2231549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Question Repeat Administered Item Unresolved Issue java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Question Repeat Administered Item Unresolved Issue java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.QuestionRepetition.unresolvedIssue</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QuestionRepetition:unresolvedIssue</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="171">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552801</PUBLICID>
    <LONGNAME>Form Administered Item Unique Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2552601v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A printed or electronic document with spaces to be filled out.:A registry item for which administrative information is recorded in an Administration Record._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552601</PublicId>
      <PreferredName>2539536v1.0:2231610v1.0</PreferredName>
      <PreferredDefinition>A printed or electronic document with spaces to be filled out.:A registry item for which administrative information is recorded in an Administration Record._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Form Administered Item Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539536</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19464:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Form Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45282:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45282</PREFERRED_NAME>
            <LONG_NAME>Unique</LONG_NAME>
            <CON_ID>2231550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Form Administered Item Unique Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Form Administered Item Unique Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Form.publicID</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Form:publicID</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="172">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2553378</PUBLICID>
    <LONGNAME>Status Present Removed Parameter Object Timestamp java.util.Date</LONGNAME>
    <PREFERREDNAME>2553235v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A condition or state at a particular time.:Being or existing in a specified place or at the specified time.:Taken out of, separated from, or eliminated.:Any factor that defines a system and determines (or limits) its performance._A variation of the Date datatype that&#39;s useful for storing very precise datetime values, down to small fractions of seconds. The Timestamp datatype stores all the information that the Date datatype stores, but also includes fractional seconds._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2553235</PublicId>
      <PreferredName>2513387v1.0:2553105v1.0</PreferredName>
      <PreferredDefinition>A condition or state at a particular time.:Being or existing in a specified place or at the specified time.:Taken out of, separated from, or eliminated.:Any factor that defines a system and determines (or limits) its performance._A variation of the Date datatype that&#39;s useful for storing very precise datetime values, down to small fractions of seconds. The Timestamp datatype stores all the information that the Date datatype stores, but also includes fractional seconds.</PreferredDefinition>
      <LongName>Status Present Removed Parameter Object Timestamp</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513387</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C25626:C25650:C44175</PreferredName>
        <Version>1</Version>
        <LongName>Status Present Removed Parameter Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25650</PREFERRED_NAME>
            <LONG_NAME>Removed</LONG_NAME>
            <CON_ID>2203778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54086</PreferredName>
        <Version>1</Version>
        <LongName>Timestamp</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54086</PREFERRED_NAME>
            <LONG_NAME>Timestamp Data Type</LONG_NAME>
            <CON_ID>2553062</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Status Present Removed Parameter Object Timestamp java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Status Present Removed Parameter Object Timestamp java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2680967</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000633</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CheckInCheckOutEventParameter:timestamp</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.CheckInCheckOutEventParameter.timestamp</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="173">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2553385</PUBLICID>
    <LONGNAME>Container Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2553242v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An object that can be used to hold things._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2553242</PublicId>
      <PreferredName>2553166v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>An object that can be used to hold things._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Container Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2553166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43186</PreferredName>
        <Version>1</Version>
        <LongName>Container</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43186</PREFERRED_NAME>
            <LONG_NAME>Container</LONG_NAME>
            <CON_ID>2513272</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Container Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Container Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2680967</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000633</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Container:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.Container.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Container.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="174">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2555092</PUBLICID>
    <LONGNAME>Pharmacokinetics Collection Status Type</LONGNAME>
    <PREFERREDNAME>PK_COLL_STAT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to identify the status of pharmacokinetic collection for a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2180561</PublicId>
      <PreferredName>PK_COLL_PLAN</PreferredName>
      <PreferredDefinition>A prescribed outline for the collection of pharmacokinetic data.</PreferredDefinition>
      <LongName>Pharmacokinetics Collection Plan</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2555088</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15299:C25453</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacokinetics Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15299</PREFERRED_NAME>
            <LONG_NAME>Pharmacokinetics</LONG_NAME>
            <CON_ID>2204958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2475238</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25619</PreferredName>
        <Version>1</Version>
        <LongName>Planned</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2555090</PublicId>
      <PreferredName>PK_COLL_STAT_TP</PreferredName>
      <PreferredDefinition>Text terms for the status of a pharmacokinetic collection process.</PreferredDefinition>
      <LongName>Pharmacokinetics Collection Status Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>22</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2555089</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15299:C25453:C25688:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacokinetics Collection Status Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15299</PREFERRED_NAME>
            <LONG_NAME>Pharmacokinetics</LONG_NAME>
            <CON_ID>2204958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Collected on time</VALIDVALUE>
          <VALUEMEANING>Collected on time</VALUEMEANING>
          <MEANINGDESCRIPTION>Collected on time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Collected not on time</VALIDVALUE>
          <VALUEMEANING>Collected not on time</VALUEMEANING>
          <MEANINGDESCRIPTION>Collected not on time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not collected</VALIDVALUE>
          <VALUEMEANING>Not collected</VALUEMEANING>
          <MEANINGDESCRIPTION>Not collected</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Collection Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Collection Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ThermoDox Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812723</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="175">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2555581</PUBLICID>
    <LONGNAME>Participant Initials java.lang.String</LONGNAME>
    <PREFERREDNAME>2555505v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Someone who takes part in an activity._The first letter of a word, especially the first letter of each word in a proper name._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2555505</PublicId>
      <PreferredName>2407061v1.0:2555350v1.0</PreferredName>
      <PreferredDefinition>Someone who takes part in an activity._The first letter of a word, especially the first letter of each word in a proper name.</PreferredDefinition>
      <LongName>Participant Initials</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867</PreferredName>
        <Version>1</Version>
        <LongName>Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2555350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25536</PreferredName>
        <Version>1</Version>
        <LongName>Initials</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25536</PREFERRED_NAME>
            <LONG_NAME>Initials</LONG_NAME>
            <CON_ID>2206246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Participant Initials java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Participant Initials java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2555333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trials Lab Model</PreferredName>
          <Version>0.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lab Hub Model</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2555333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trials Lab Model</PreferredName>
          <Version>0.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2555333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trials Lab Model</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000317</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2964508</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabViewer</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000318</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5527905</PublicId>
          <ContextName>TEST</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ModelTest</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mctest</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>6058375</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.labhub.domain.Participant.initials</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant:initials</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.Participant.initials</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TEST</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mctest.Participant.initial</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant:initial</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="176">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2557954</PUBLICID>
    <LONGNAME>Data Service Instance Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2557907v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Work, or a product of that work, done by one person or group that benefits another.:An occurrence of something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2557907</PublicId>
      <PreferredName>2557896v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Work, or a product of that work, done by one person or group that benefits another.:An occurrence of something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Data Service Instance Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2557896</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C47920:C48364</PreferredName>
        <Version>1</Version>
        <LongName>Data Service Instance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47920</PREFERRED_NAME>
            <LONG_NAME>Service</LONG_NAME>
            <CON_ID>2414569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48364</PREFERRED_NAME>
            <LONG_NAME>Instance</LONG_NAME>
            <CON_ID>2413213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Data Service Instance Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Data Service Instance Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557869</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.DataServiceInstance.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DataServiceInstance:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.DataServiceInstance.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="177">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2583379</PUBLICID>
    <LONGNAME>DICOM First Name Person Name</LONGNAME>
    <PREFERREDNAME>DICOM_FIRST_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The DICOM Person Name (PN) value representation.  A character string encoded using 5 component convention, each of 64 characters.  Components order is: Family name, Given Name, Middle Name, Prefix, Suffix.  &quot;^&quot; used to identify a null component.  Excludes Control characters (LF&lt; FF, and CR), but allows ESC. [Standard-based]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2583255</PublicId>
      <PreferredName>DICOM_FIRST_NM</PreferredName>
      <PreferredDefinition>A comprehensive set of standards for communications between medical imaging devices, including handling, storing and transmitting information in medical imaging. It includes a file format definition and a network communication protocol._A word or group of words indicating a person&#39;s first (personal) name. (NCI)_A taxonomic category between Order and Genus. It consists of a group of organisms among which the differences are quite minor, e.g. Equiidae - horses and their relatives. [System-generated]</PreferredDefinition>
      <LongName>DICOM First Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2583253</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49059:C40974</PreferredName>
        <Version>1</Version>
        <LongName>DICOM First Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49059</PREFERRED_NAME>
            <LONG_NAME>DICOM</LONG_NAME>
            <CON_ID>2553610</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40974</PREFERRED_NAME>
            <LONG_NAME>First Name</LONG_NAME>
            <CON_ID>2203651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2186630</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25191</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2583160</PublicId>
      <PreferredName>DICOM_PERS_NM</PreferredName>
      <PreferredDefinition>A comprehensive set of standards for communications between medical imaging devices, including handling, storing and transmitting information in medical imaging. It includes a file format definition and a network communication protocol._Person; a human being._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>DICOM Person Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>64</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2730956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49059:C25190:C42614</PreferredName>
        <Version>1</Version>
        <LongName>DICOM Person Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49059</PREFERRED_NAME>
            <LONG_NAME>DICOM</LONG_NAME>
            <CON_ID>2553610</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DICOM First Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>DICOM First Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>2006 DICOM Standard</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>2006 DICOM Standard - Sections 5</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DICOM Tag CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2960572</PublicId>
          <ContextName>TEST</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Eligibility Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LABS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000458</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="178">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2585028</PUBLICID>
    <LONGNAME>Other Neoplasm Excision Specify</LONGNAME>
    <PREFERREDNAME>O_NEO_EX_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify other tumor removal by sugery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP:Phase II Breast CDE Disease Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2585026</PublicId>
      <PreferredName>O_NEO_EX</PreferredName>
      <PreferredDefinition>information related to other group of abnormal mass of tissue that results from excessive cell division being removed by surgery.</PreferredDefinition>
      <LongName>Other Neoplasm Excision</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2585024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Other Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2439990</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15232</PreferredName>
        <Version>1</Version>
        <LongName>Resection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="179">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2590543</PUBLICID>
    <LONGNAME>Hospital Transplant Failure Discharge Diagnosis Status</LONGNAME>
    <PREFERREDNAME>HO_TSP_FLR_DI_DX_STA</PREFERREDNAME>
    <PREFERREDDEFINITION>the status whether transplant failure, rejection of healthy skin, bone, or other tissue taken from a different person (donor) or form another part of the body and used to replace diseased or injured tissue in another part of the body, was an identified reason for hospitalization at the time of discharge, the end point of an inpatient hospital contact which consists of one or several days of care.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Transplant CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2590464</PublicId>
      <PreferredName>HOSP_TSPL_FLR_DIS_DX</PreferredName>
      <PreferredDefinition>information related to transplant failure, rejection of healthy skin, bone, or other tissue taken from a different person (donor) or form another part of the body and used to replace diseased or injured tissue in another part of the body, as an identified reason for hospitalization at the time of discharge, the end point of an inpatient hospital contact which consists of one or several days of care.</PreferredDefinition>
      <LongName>Hospital Transplant Failure Discharge Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16696</PreferredName>
        <Version>1</Version>
        <LongName>Hospital</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16696</PREFERRED_NAME>
            <LONG_NAME>Hospital</LONG_NAME>
            <CON_ID>2202656</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2590462</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12981:C25745:C25166:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Transplant Failure Discharge Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12981</PREFERRED_NAME>
            <LONG_NAME>Graft</LONG_NAME>
            <CON_ID>2202844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25745</PREFERRED_NAME>
            <LONG_NAME>Failure</LONG_NAME>
            <CON_ID>2203812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25166</PREFERRED_NAME>
            <LONG_NAME>Patient Discharge</LONG_NAME>
            <CON_ID>2203907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2590538</PublicId>
      <PreferredName>DIS_DX_STAT</PreferredName>
      <PreferredDefinition>the status of discharge diagnosis.</PreferredDefinition>
      <LongName>Discharge Diagnosis Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary</VALIDVALUE>
          <VALUEMEANING>Primary</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring first in time or sequence; original; of greatest rank or importance or value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2590540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contributory</VALIDVALUE>
          <VALUEMEANING>Contributory</VALUEMEANING>
          <MEANINGDESCRIPTION>Contributory</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Noncontributory</VALIDVALUE>
          <VALUEMEANING>Noncontributory</VALUEMEANING>
          <MEANINGDESCRIPTION>Noncontributory</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2590541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Graft Failure</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Graft Failure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Graft failure type:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GftFlrRp</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="180">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2594799</PUBLICID>
    <LONGNAME>Mandible Tooth Present Year Date</LONGNAME>
    <PREFERREDNAME>MAND_TOOTH_PRES_YDT</PREFERREDNAME>
    <PREFERREDDEFINITION>the year date realted to present teeth in the lower jawbone.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2594796</PublicId>
      <PreferredName>MANDIBLE_TOOTH_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of teeth in the lower jawbone.</PreferredDefinition>
      <LongName>Mandible Tooth Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2594794</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12290:C12506</PreferredName>
        <Version>1</Version>
        <LongName>Mandible Tooth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12290</PREFERRED_NAME>
            <LONG_NAME>Mandible</LONG_NAME>
            <CON_ID>2202585</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2195353</PublicId>
      <PreferredName>YR_DT</PreferredName>
      <PreferredDefinition>the numeric representation of the calendar year. </PreferredDefinition>
      <LongName>Year Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208026</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29848:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Year Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Year</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="181">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2596708</PUBLICID>
    <LONGNAME>Patient Day Personal Medical History Alcohol Consumption Frequency Amount</LONGNAME>
    <PREFERREDNAME>PT_D_PMH_AL_CON_F_A</PREFERREDNAME>
    <PREFERREDDEFINITION>the total number occurrences related to patient&#39;s daily alcohol consumption.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2593545</PublicId>
      <PreferredName>PT_D_PMH_ALCOCONS</PreferredName>
      <PreferredDefinition>information related to patient&#39;s daily alcohol consumption.</PreferredDefinition>
      <LongName>Patient Day Personal Medical History Alcohol Consumption</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2593543</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C18772:C16273</PreferredName>
        <Version>1</Version>
        <LongName>Day Personal Medical History Alcohol Consumption</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16273</PREFERRED_NAME>
            <LONG_NAME>Alcohol Consumption</LONG_NAME>
            <CON_ID>2204017</CON_ID>
            <DEFINITION_SOURCE>NCIt</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2596705</PublicId>
      <PreferredName>D_ALCO_CON_FREQ_AMT</PreferredName>
      <PreferredDefinition>the total number occurrences of alcohol consumption in a day.</PreferredDefinition>
      <LongName>Day Alcohol Consumption Frequency Amount</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2596697</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25515:C25417</PreferredName>
        <Version>1</Version>
        <LongName>Frequency Amount</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25417</PREFERRED_NAME>
            <LONG_NAME>Amount</LONG_NAME>
            <CON_ID>2202462</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5 to 6</VALIDVALUE>
          <VALUEMEANING>5 to 6</VALUEMEANING>
          <MEANINGDESCRIPTION>5 to 6</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 or 2</VALIDVALUE>
          <VALUEMEANING>1 or 2</VALUEMEANING>
          <MEANINGDESCRIPTION>1 or 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7 to 9</VALIDVALUE>
          <VALUEMEANING>7 to 9</VALUEMEANING>
          <MEANINGDESCRIPTION>7 to 9</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10 or more</VALIDVALUE>
          <VALUEMEANING>10 or more</VALUEMEANING>
          <MEANINGDESCRIPTION>10 or more</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3 to 4</VALIDVALUE>
          <VALUEMEANING>3 to 4</VALUEMEANING>
          <MEANINGDESCRIPTION>3 to 4</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In a typical year before the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In a typical year before the year 2000, how many drinks containing alcohol did you have on a typical day when you were drinking</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How many drinks containing alcohol did you have</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="182">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2598180</PUBLICID>
    <LONGNAME>Treating Physician Signature Date</LONGNAME>
    <PREFERREDNAME>TREATDR_SIG_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date of the signature of the physician who directly administers medical aid to a patient or study subject, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2598178</PublicId>
      <PreferredName>TREATDR_SIG</PreferredName>
      <PreferredDefinition>information related to the signature of the physician who directly administers medical aid to a patient or study subject, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions.</PreferredDefinition>
      <LongName>Treating Physician Signature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2598176</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C51883</PreferredName>
        <Version>1</Version>
        <LongName>Treating Physician</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51883</PREFERRED_NAME>
            <LONG_NAME>Treating Physician</LONG_NAME>
            <CON_ID>2479861</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2436718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25678</PreferredName>
        <Version>1</Version>
        <LongName>Signature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Signature:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2012-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3694151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="183">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2600824</PUBLICID>
    <LONGNAME>Dental Implant Performed Indicator</LONGNAME>
    <PREFERREDNAME>DENT_IMPL_PERF_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown/not available  indicator related to materials placed into (endosseous) or onto (subperiosteal) the jawbone; commonly used to support a crown, bridge, artificial tooth, stabilize a diseased tooth, or to use as anchorage in orthodontic therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2597306</PublicId>
      <PreferredName>DENT_IMP_PERF</PreferredName>
      <PreferredDefinition>information related to materials placed into (endosseous) or onto (subperiosteal) the jawbone; commonly used to support a crown, bridge, artificial tooth, stabilize a diseased tooth, or to use as anchorage in orthodontic therapy.</PreferredDefinition>
      <LongName>Dental Implant Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2597304</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63718</PreferredName>
        <Version>1</Version>
        <LongName>Dental Implant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63718</PREFERRED_NAME>
            <LONG_NAME>Dental Implant</LONG_NAME>
            <CON_ID>2547874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2713491</PublicId>
      <PreferredName>ASSRSLT_IND</PreferredName>
      <PreferredDefinition>a yes/no/unknown/not available/not applicable indicator related to the result of an assessment.</PreferredDefinition>
      <LongName>Assessment Results Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCIC CRF:National Cancer Institute of Canada Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient received any</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient received any implants since the year 2000</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient received any implants within 3 years prior to ONJ</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="184">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2603124</PUBLICID>
    <LONGNAME>Responsible Person Occupation Specify</LONGNAME>
    <PREFERREDNAME>RES_PER_OCC_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field related to occupation of responsible person.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190356</PublicId>
      <PreferredName>RSPB_PER_OCC</PreferredName>
      <PreferredDefinition>information related to occupation of responsible person.</PreferredDefinition>
      <LongName>Responsible Person Occupation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206597</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25657:C25190</PreferredName>
        <Version>1</Version>
        <LongName>Responsible Person Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25657</PREFERRED_NAME>
            <LONG_NAME>Responsible Person</LONG_NAME>
            <CON_ID>2202516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177431</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Occupation</PreferredName>
        <Version>1</Version>
        <LongName>Occupation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25193</PREFERRED_NAME>
            <LONG_NAME>Occupation</LONG_NAME>
            <CON_ID>2202912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188481</PublicId>
      <PreferredName>INDS_SPEC</PreferredName>
      <PreferredDefinition>the free-text field to related to a specified attribute of an individual.</PreferredDefinition>
      <LongName>Individual Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="185">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608124</PUBLICID>
    <LONGNAME>Qualitative Evaluation Survival Status Description Text java.lang.String</LONGNAME>
    <PREFERREDNAME>2607749v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary)_Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.:A condition or state at a particular time.:A written or verbal account, representation, statement, or explanation of something.:The words of something written._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607749</PublicId>
      <PreferredName>2607684v1.0:2607543v1.0</PreferredName>
      <PreferredDefinition>A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary)_Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.:A condition or state at a particular time.:A written or verbal account, representation, statement, or explanation of something.:The words of something written.</PreferredDefinition>
      <LongName>Qualitative Evaluation Survival Status Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607684</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49143</PreferredName>
        <Version>1</Version>
        <LongName>Qualitative Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49143</PREFERRED_NAME>
            <LONG_NAME>Qualitative Evaluation</LONG_NAME>
            <CON_ID>2607495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607543</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17177:C25688:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Survival Status Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17177</PREFERRED_NAME>
            <LONG_NAME>Survival</LONG_NAME>
            <CON_ID>2202477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Qualitative Evaluation Survival Status Description Text java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Qualitative Evaluation Survival Status Description Text java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.QualitativeEvaluation.survivalStatusDescriptionText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QualitativeEvaluation:survivalStatusDescriptionText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="186">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608160</PUBLICID>
    <LONGNAME>Observation Relationship Comment Text java.lang.String</LONGNAME>
    <PREFERREDNAME>2607785v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Watching something and taking note of what happens.:A state of connectedness between people, objects, or events; to be associated or connected with something._A written explanation or criticism or illustration that is added to a book or other textual material.:The words of something written._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607785</PublicId>
      <PreferredName>2607688v1.0:2607544v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:A state of connectedness between people, objects, or events; to be associated or connected with something._A written explanation or criticism or illustration that is added to a book or other textual material.:The words of something written.</PreferredDefinition>
      <LongName>Observation Relationship Comment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607688</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Observation Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Comment Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Relationship Comment Text java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Relationship Comment Text java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ObservationRelationship:commentText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.ObservationRelationship.commentText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="187">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608327</PUBLICID>
    <LONGNAME>Death Summary Death Etiology Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2607948v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The absence of life or state of being dead.:A shortened version of a speech or written text, containing only the main points._The absence of life or state of being dead.:The cause of a disease.:A system, often of numbered categories, for representation of data._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607948</PublicId>
      <PreferredName>2607702v1.0:2607676v1.0</PreferredName>
      <PreferredDefinition>The absence of life or state of being dead.:A shortened version of a speech or written text, containing only the main points._The absence of life or state of being dead.:The cause of a disease.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Death Summary Death Etiology Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607702</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28554:C42581</PreferredName>
        <Version>1</Version>
        <LongName>Death Summary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28554</PREFERRED_NAME>
            <LONG_NAME>Dead</LONG_NAME>
            <CON_ID>2202731</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42581</PREFERRED_NAME>
            <LONG_NAME>Summary</LONG_NAME>
            <CON_ID>2203701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28554:C16390:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Death Etiology Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28554</PREFERRED_NAME>
            <LONG_NAME>Dead</LONG_NAME>
            <CON_ID>2202731</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16390</PREFERRED_NAME>
            <LONG_NAME>Etiology</LONG_NAME>
            <CON_ID>2497372</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Death Summary Death Etiology Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Death Summary Death Etiology Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.DeathSummary.deathCauseCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DeathSummary:deathCauseCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="188">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608390</PUBLICID>
    <LONGNAME>Healthcare Facility Site City java.lang.String</LONGNAME>
    <PREFERREDNAME>2608007v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The buildings and organizations where healthcare services are provided.:A position in relation to its surroundings._A large and densely populated urban area._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2608007</PublicId>
      <PreferredName>2607685v1.0:2224078v1.0</PreferredName>
      <PreferredDefinition>The buildings and organizations where healthcare services are provided.:A position in relation to its surroundings._A large and densely populated urban area.</PreferredDefinition>
      <LongName>Healthcare Facility Site City</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21541:C37901</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Facility Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21541</PREFERRED_NAME>
            <LONG_NAME>Healthcare Facility</LONG_NAME>
            <CON_ID>2202668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37901</PREFERRED_NAME>
            <LONG_NAME>Site</LONG_NAME>
            <CON_ID>2202394</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224078</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25160</PreferredName>
        <Version>1</Version>
        <LongName>City</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25160</PREFERRED_NAME>
            <LONG_NAME>City</LONG_NAME>
            <CON_ID>2203881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Healthcare Facility Site City java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Healthcare Facility Site City java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3253737</PublicId>
          <ContextName>CDC/PHIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CSTE Position Statements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Possible CDEs for Reuse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3262077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.HealthcareSite.city</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HealthcareSite:city</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="189">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2611890</PUBLICID>
    <LONGNAME>DNA Sequence Assembly National Center for Biotechnology Information Assembly Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2611801v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequence of nucleotide residues along a DNA chain.:A group of parts that fit together to form a self-contained unit._Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease.:A group of parts that fit together to form a self-contained unit.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2611801</PublicId>
      <PreferredName>2611785v1.0:2611735v1.0</PreferredName>
      <PreferredDefinition>The sequence of nucleotide residues along a DNA chain.:A group of parts that fit together to form a self-contained unit._Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease.:A group of parts that fit together to form a self-contained unit.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>DNA Sequence Assembly National Center for Biotechnology Information Assembly Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611785</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13299:C63548</PreferredName>
        <Version>1</Version>
        <LongName>DNA Sequence Assembly</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13299</PREFERRED_NAME>
            <LONG_NAME>DNA Sequence</LONG_NAME>
            <CON_ID>2423567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63548</PREFERRED_NAME>
            <LONG_NAME>Assembly</LONG_NAME>
            <CON_ID>2611722</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2611735</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45799:C63548:C42614</PreferredName>
        <Version>1</Version>
        <LongName>National Center for Biotechnology Information Assembly Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45799</PREFERRED_NAME>
            <LONG_NAME>National Center for Biotechnology Information</LONG_NAME>
            <CON_ID>2342205</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63548</PREFERRED_NAME>
            <LONG_NAME>Assembly</LONG_NAME>
            <CON_ID>2611722</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element DNA Sequence Assembly National Center for Biotechnology Information Assembly Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element DNA Sequence Assembly National Center for Biotechnology Information Assembly Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812759</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Assembly:ncbiAssemblyName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.Assembly.ncbiAssemblyName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="190">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2611899</PUBLICID>
    <LONGNAME>Oligonucleotide Primer Genomic Orientation java.lang.String</LONGNAME>
    <PREFERREDNAME>2611810v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._The orientation of a genomic element on the double stranded molecule._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2611810</PublicId>
      <PreferredName>2611786v1.0:2423577v1.0</PreferredName>
      <PreferredDefinition>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._The orientation of a genomic element on the double stranded molecule.</PreferredDefinition>
      <LongName>Oligonucleotide Primer Genomic Orientation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1451</PreferredName>
        <Version>1</Version>
        <LongName>Oligonucleotide Primer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1451</PREFERRED_NAME>
            <LONG_NAME>Oligonucleotide Primer</LONG_NAME>
            <CON_ID>2611725</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48673</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Orientation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48673</PREFERRED_NAME>
            <LONG_NAME>Genomic Orientation</LONG_NAME>
            <CON_ID>2423569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Oligonucleotide Primer Genomic Orientation java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Oligonucleotide Primer Genomic Orientation java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812759</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Primer:chrOrientation</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.Primer.chrOrientation</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="191">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2611922</PUBLICID>
    <LONGNAME>Project Single Nucleotide Polymorphism Relationship Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2611832v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any piece of work that is undertaken or attempted.:A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:A state of connectedness between people, objects, or events; to be associated or connected with something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2611832</PublicId>
      <PreferredName>2611791v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Any piece of work that is undertaken or attempted.:A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:A state of connectedness between people, objects, or events; to be associated or connected with something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Project Single Nucleotide Polymorphism Relationship Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611791</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47885:C18279:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Project Single Nucleotide Polymorphism Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47885</PREFERRED_NAME>
            <LONG_NAME>Project</LONG_NAME>
            <CON_ID>2422635</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18279</PREFERRED_NAME>
            <LONG_NAME>Single Nucleotide Polymorphism</LONG_NAME>
            <CON_ID>2433334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Project Single Nucleotide Polymorphism Relationship Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Project Single Nucleotide Polymorphism Relationship Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812759</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Project2SNP:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.Project2SNP.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="192">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2611947</PUBLICID>
    <LONGNAME>Sequence Chromatogram Genotype Relationship Genomic Orientation java.lang.String</LONGNAME>
    <PREFERREDNAME>2611856v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The output of an automated sequencing run represented as peak intensities plotted against nucleotide position along a DNA strand.:The genetic constitution of an organism or cell, as distinct from its expressed features or phenotype.:A state of connectedness between people, objects, or events; to be associated or connected with something._The orientation of a genomic element on the double stranded molecule._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2611856</PublicId>
      <PreferredName>2611794v1.0:2423577v1.0</PreferredName>
      <PreferredDefinition>The output of an automated sequencing run represented as peak intensities plotted against nucleotide position along a DNA strand.:The genetic constitution of an organism or cell, as distinct from its expressed features or phenotype.:A state of connectedness between people, objects, or events; to be associated or connected with something._The orientation of a genomic element on the double stranded molecule.</PreferredDefinition>
      <LongName>Sequence Chromatogram Genotype Relationship Genomic Orientation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611794</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63580:C16631:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Sequence Chromatogram Genotype Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63580</PREFERRED_NAME>
            <LONG_NAME>Sequence Chromatogram</LONG_NAME>
            <CON_ID>2611732</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16631</PREFERRED_NAME>
            <LONG_NAME>Genotype</LONG_NAME>
            <CON_ID>2221799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48673</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Orientation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48673</PREFERRED_NAME>
            <LONG_NAME>Genomic Orientation</LONG_NAME>
            <CON_ID>2423569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Sequence Chromatogram Genotype Relationship Genomic Orientation java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Sequence Chromatogram Genotype Relationship Genomic Orientation java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812759</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Trace2Genotype:traceOrientation</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.Trace2Genotype.traceOrientation</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="193">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2613471</PUBLICID>
    <LONGNAME>Molecular Weight Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2612822v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sum of the relative atomic masses of the constituent atoms of a molecule._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2612822</PublicId>
      <PreferredName>2612280v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>The sum of the relative atomic masses of the constituent atoms of a molecule._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Molecular Weight Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612280</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43521</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Weight</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43521</PREFERRED_NAME>
            <LONG_NAME>Molecular Weight</LONG_NAME>
            <CON_ID>2223226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Molecular Weight Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Molecular Weight Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calab.domain.nano.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812764</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813021</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MolecularWeight:createdDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calab.domain.nano.characterization.physical.MolecularWeight.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.characterization.physical.MolecularWeight.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.physical.MolecularWeight.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="194">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2624846</PUBLICID>
    <LONGNAME>Dental Restoration Required Replacement Reason</LONGNAME>
    <PREFERREDNAME>DNTLRS_REQ_REPL_RSN</PREFERREDNAME>
    <PREFERREDDEFINITION>an explanation of the cause of necessary removal and putting another in its place of an already replaced or reconstructed tooth structure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2615495</PublicId>
      <PreferredName>DENTREST_REQ_REPLACE</PreferredName>
      <PreferredDefinition>information related to necessary removal and putting another in its place of an already replaced or reconstructed tooth structure.</PreferredDefinition>
      <LongName>Dental Restoration Required Replacement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2514540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60718</PreferredName>
        <Version>1</Version>
        <LongName>Dental Restoration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60718</PREFERRED_NAME>
            <LONG_NAME>Dental Restoration</LONG_NAME>
            <CON_ID>2481613</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2615493</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25652:C53610</PreferredName>
        <Version>1</Version>
        <LongName>Required Replacement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25652</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2204014</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53610</PREFERRED_NAME>
            <LONG_NAME>Replacement</LONG_NAME>
            <CON_ID>2504929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2624843</PublicId>
      <PreferredName>DNTLRES_REPL_RSN</PreferredName>
      <PreferredDefinition>an explanation of the cause of replacement of dental restoration.</PreferredDefinition>
      <LongName>Dental Restoration Replacement Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mobile</VALIDVALUE>
          <VALUEMEANING>MOBILE</VALUEMEANING>
          <MEANINGDESCRIPTION>MOBILE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fractured</VALIDVALUE>
          <VALUEMEANING>FRACTURE</VALUEMEANING>
          <MEANINGDESCRIPTION>FRACTURE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secondary Caries</VALIDVALUE>
          <VALUEMEANING>Secondary Caries</VALUEMEANING>
          <MEANINGDESCRIPTION>A carious lesion adjacent to an existing restoration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2624844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Margin stain or breakdown</VALIDVALUE>
          <VALUEMEANING>Margin stain or breakdown</VALUEMEANING>
          <MEANINGDESCRIPTION>Margin stain or breakdown</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3182639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sensitivity</VALIDVALUE>
          <VALUEMEANING>Sensitivity</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the minimum change in an input signal that an instrument can detect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Primary reason</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Primary reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Please indicate reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="195">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2625807</PUBLICID>
    <LONGNAME>Endodontic Treatment Patient Occupation Disruption Oral Health Impact Profile Assessment Scale</LONGNAME>
    <PREFERREDNAME>ET_PT_OC_DI_OH_AS_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>a scaled index of the social impact of oral disorders which draws on a theoretical heirarchy of  oral health outcomes (Oral Health Impact Profile) for the measure of a person&#39;s perceptions of the social impact of oral disorders on their well-being, of a patient&#39;s interruption in the principal activity that a person does to earn money from dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2625764</PublicId>
      <PreferredName>ET_PT_OCC_DIS_OH_ASS</PreferredName>
      <PreferredDefinition>information related to the Oral Health Impact Profile assessment, a measure of a person&#39;s perceptions of the social impact of oral disorders on their well-being, of a patient&#39;s interruption in the principal activity that a person does to earn money from dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.</PreferredDefinition>
      <LongName>Endodontic Treatment Patient Occupation Disruption Oral Health Impact Profile Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2625738</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52575:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Endodontic Treatment Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52575</PREFERRED_NAME>
            <LONG_NAME>Endodontic Treatment</LONG_NAME>
            <CON_ID>2443135</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2516913</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25193:C25486:C62359:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Occupation Disruption Oral Health Impact Profile Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25193</PREFERRED_NAME>
            <LONG_NAME>Occupation</LONG_NAME>
            <CON_ID>2202912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25486</PREFERRED_NAME>
            <LONG_NAME>Disruption</LONG_NAME>
            <CON_ID>2203904</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62359</PREFERRED_NAME>
            <LONG_NAME>Oral Health Impact Profile</LONG_NAME>
            <CON_ID>2511485</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2504090</PublicId>
      <PreferredName>OHIP_SCALE</PreferredName>
      <PreferredDefinition>a scaled index of the social impact of oral disorders which draws on a theoretical heirarchy of  oral health outcomes (Oral Health Impact Profile).</PreferredDefinition>
      <LongName>Oral Health Impact Profile Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hardly ever</VALIDVALUE>
          <VALUEMEANING>Hardly ever</VALUEMEANING>
          <MEANINGDESCRIPTION>Hardly ever</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fairly often</VALIDVALUE>
          <VALUEMEANING>Fairly often</VALUEMEANING>
          <MEANINGDESCRIPTION>Fairly often</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very often</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you had difficulty doing</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you had difficulty doing your usual jobs because of problems with your tooth that had root canal treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="196">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2625972</PUBLICID>
    <LONGNAME>Post Endodontic Treatment Diseases Diagnosis Yes No Indicator</LONGNAME>
    <PREFERREDNAME>P_ENDOTX_DS_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to disease after dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2624999</PublicId>
      <PreferredName>P_ENDOTX_DS_DX</PreferredName>
      <PreferredDefinition>information related to disease after dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.</PreferredDefinition>
      <LongName>Post Endodontic Treatment Diseases Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2624997</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C52575:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Post Endodontic Treatment Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52575</PREFERRED_NAME>
            <LONG_NAME>Endodontic Treatment</LONG_NAME>
            <CON_ID>2443135</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has there been evidence of di</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has there been evidence of disease since the initial endodontic procedure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="197">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2626204</PUBLICID>
    <LONGNAME>Placebo Bevacizumab Agent Discontinued Ind-2</LONGNAME>
    <PREFERREDNAME>PBO_BEV_AGT_DXD_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether bevacizumab/ placebo treatment was discontinued.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2626203</PublicId>
      <PreferredName>PBO_BEV_AGT_DXD</PreferredName>
      <PreferredDefinition>information related to the discontinuation of bevacizumab, a monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor, or placebo.</PreferredDefinition>
      <LongName>Placebo Bevacizumab Agent Discontinued</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2626201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C753:C2039:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Placebo Bevacizumab Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C753</PREFERRED_NAME>
            <LONG_NAME>Placebo</LONG_NAME>
            <CON_ID>2202783</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2039</PREFERRED_NAME>
            <LONG_NAME>Bevacizumab</LONG_NAME>
            <CON_ID>2202398</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2433916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25484</PreferredName>
        <Version>1</Version>
        <LongName>Discontinued</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25484</PREFERRED_NAME>
            <LONG_NAME>Discontinue</LONG_NAME>
            <CON_ID>2203906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was bevacizumab/placebo treat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was bevacizumab/placebo treatment discontinued</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="198">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2641814</PUBLICID>
    <LONGNAME>Object Property Description Object Property Uniform Resource Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2640438v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A named data value associated with an object.:A written or verbal account, representation, statement, or explanation of something._A named data value associated with an object.:A character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640438</PublicId>
      <PreferredName>2640414v1.0:2640385v1.0</PreferredName>
      <PreferredDefinition>A named data value associated with an object.:A written or verbal account, representation, statement, or explanation of something._A named data value associated with an object.:A character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL.</PreferredDefinition>
      <LongName>Object Property Description Object Property Uniform Resource Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640414</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62498:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Object Property Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62498</PREFERRED_NAME>
            <LONG_NAME>Computer Programming Object Property</LONG_NAME>
            <CON_ID>2640374</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2640385</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62498:C42778</PreferredName>
        <Version>1</Version>
        <LongName>Object Property Uniform Resource Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62498</PREFERRED_NAME>
            <LONG_NAME>Computer Programming Object Property</LONG_NAME>
            <CON_ID>2640374</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42778</PREFERRED_NAME>
            <LONG_NAME>Uniform Resource Identifier</LONG_NAME>
            <CON_ID>2236546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Object Property Description Object Property Uniform Resource Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Object Property Description Object Property Uniform Resource Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.PropertyDescriptor.propertyUri</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PropertyDescriptor:propertyUri</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="199">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2646059</PUBLICID>
    <LONGNAME>Agent Reduced Quantity Ind-2</LONGNAME>
    <PREFERREDNAME>AGT_RED_QUAN_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to decrease in amount taken of an active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2646057</PublicId>
      <PreferredName>AGT_DOSE_REDUC</PreferredName>
      <PreferredDefinition>information related to decrease in amount taken of an active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.</PreferredDefinition>
      <LongName>Agent Reduced Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2728379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25640:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Reduced Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was dose reduced</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was dose reduced</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Medication dose reduced</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose reduction needed (for each drug) Yes/No</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose reduction needed (for each drug) Yes/No</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was dose tapered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were there any dose reductions due to toxicity during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were there any dose modifications due to toxicity during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Question Texyt</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Indication for dose reduction from previous inoculation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose Reduced?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose Reduced?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was Eflornithine dose reduced due to toxicity during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the anthracycline or anthracenedione (AC) dose reduced?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were there any dose modifications for Gilteritinib?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were there any dose modifications?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient require dose reduction of non-olaparib PARP inhibitors for hematologic adverse events?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716207</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ASCO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colon Adjuvant Treatment Summary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812709</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716207</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ASCO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer Adjuvant Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812713</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716207</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ASCO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2898482</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjunctive General Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="200">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2646435</PUBLICID>
    <LONGNAME>Kaposi Sarcoma Number Malignant Neoplasm Cutaneous Assessment Status</LONGNAME>
    <PREFERREDNAME>KS_N_MN_C_ASESS_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of the number of cutaneous (skin) malignant neoplasms of Kaposi Sarcoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640354</PublicId>
      <PreferredName>KS_N_MN_CUT_ASSESS</PreferredName>
      <PreferredDefinition>information relating to an assessment of the number of cutaneous (skin) malignant neoplasms of Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells).</PreferredDefinition>
      <LongName>Kaposi Sarcoma Number Malignant Neoplasm Cutaneous Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9087:C25337:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Kaposi Sarcoma Number Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9087</PREFERRED_NAME>
            <LONG_NAME>Kaposi Sarcoma</LONG_NAME>
            <CON_ID>2637488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2646195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13316:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Cutaneous Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13316</PREFERRED_NAME>
            <LONG_NAME>Cutaneous</LONG_NAME>
            <CON_ID>2483537</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2646434</PublicId>
      <PreferredName>KS_N_MN_C_ASESS_STAT</PreferredName>
      <PreferredDefinition>the status of the number of cutaneous (skin) malignant neoplasms of Kaposi Sarcoma.</PreferredDefinition>
      <LongName>Kaposi Sarcoma Number Malignant Neoplasm Cutaneous Assessment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2184340</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Status</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete resolution</VALIDVALUE>
          <VALUEMEANING>Complete resolution</VALUEMEANING>
          <MEANINGDESCRIPTION>Complete resolution</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2646436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;=50% decrease in the number of lesions since baseline</VALIDVALUE>
          <VALUEMEANING>&gt;=50% decrease in the number of lesions since baseline</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;=50% decrease in the number of lesions since baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2646437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;=25% increase in the number of lesions since baseline or since best response</VALIDVALUE>
          <VALUEMEANING>&gt;=25% increase in the number of lesions since baseline or since best response</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;=25% increase in the number of lesions since baseline or since best response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2646438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None of the above</VALUEMEANING>
          <MEANINGDESCRIPTION>None of the choices above are suitable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Greater than or equal to 50%  decrease in number of lesions since baseline</VALIDVALUE>
          <VALUEMEANING>Greater than or equal to 50%  decrease in number of lesions since baseline</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than or equal to 50%  decrease in number of lesions since baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5838510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Greater than or equal to 25% increase in the number of lesions since baseline</VALIDVALUE>
          <VALUEMEANING>Greater than or equal to 25% increase in the number of lesions since baseline</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than or equal to 25% increase in the number of lesions since baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5839435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5 or more new lesions in area(s) with no previous cutaneous disease if participant had greater than 50 lesions at baseline</VALIDVALUE>
          <VALUEMEANING>5 or more new lesions in area(s) with no previous cutaneous disease if participant had greater than 50 lesions at baseline</VALUEMEANING>
          <MEANINGDESCRIPTION>5 or more new lesions in area(s) with no previous cutaneous disease if participant had greater than 50 lesions at baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;=25% increase in the number of lesions or a minimum of 5 new lesions, whichever is greater, either whole body, or in the case of participants with &gt; 50 lesions at entry, in the combined representative areas</VALIDVALUE>
          <VALUEMEANING>&gt;=25% increase in the number of lesions or a minimum of 5 new lesions, whichever is greater, either whole body, or in the case of participants with &gt; 50 lesions at entry, in the combined representative areas</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;=25% increase in the number of lesions or a minimum of 5 new lesions, whichever is greater, either whole body, or in the case of participants with &gt; 50 lesions at entry, in the combined representative areas</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;25% increase in the number of lesions compared to baseline or best response</VALIDVALUE>
          <VALUEMEANING>&lt;25% increase in the number of lesions compared to baseline or best response</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;25% increase in the number of lesions compared to baseline or best response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;50% decrease in the number of lesions present</VALIDVALUE>
          <VALUEMEANING>&lt;50% decrease in the number of lesions present</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt;50% decrease in the number of lesions present</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;=50% decrease in the number of lesions</VALIDVALUE>
          <VALUEMEANING>&gt;=50% decrease in the number of lesions</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;=50% decrease in the number of lesions</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete resolution of any detectable residual disease</VALIDVALUE>
          <VALUEMEANING>Complete resolution of any detectable residual disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Complete resolution of any detectable residual disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7372078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of cutaneous lesions</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of cutaneous lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Evaluation of cutaneous lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7312662</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TRORRES_NCUTLES</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="201">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669787</PUBLICID>
    <LONGNAME>Laboratory Procedure Bone Marrow Metamyelocyte Result Value</LONGNAME>
    <PREFERREDNAME>LAB_BM_MT_RS_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the percentage value related to bone marrow metamyelocyte (a cell derived from a promyelocyte that differentiates into a neutrophil) hematology laboratory procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669285</PublicId>
      <PreferredName>LAB_BM_METM_RSLT</PreferredName>
      <PreferredDefinition>information relating to the result of the medical procedure that involves testing a sample of bone marrow for metamyelocytes, a cell derived from a promyelocyte that differentiates into a neutrophil.</PreferredDefinition>
      <LongName>Laboratory Procedure Bone Marrow Metamyelocyte Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738837</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12431:C13116:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Metamyelocyte Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13116</PREFERRED_NAME>
            <LONG_NAME>Metamyelocyte</LONG_NAME>
            <CON_ID>2669282</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019101</PublicId>
      <PreferredName>HMT_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>a percentage for a hematologic laboratory value.</PreferredDefinition>
      <LongName>Blood Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Marrow metamyelocytes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Marrow metamyelocytes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Metamyelocytes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical laml</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787540</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Lab Procedure Bone Marrow Metamyelocyte Result Value</AlternateName>
        <AlternateNameType>TCGA_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lab_procedure_bone_marrow_metamyelocyte_result_value</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="202">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2671973</PUBLICID>
    <LONGNAME>Peptide Decimal Ratio java.lang.Float</LONGNAME>
    <PREFERREDNAME>2671680v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A compound of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. Peptides are smaller than proteins and the dividing line is around 50 amino acids._A ratio expressed in base 10 notation._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2671680</PublicId>
      <PreferredName>2612311v1.0:2671551v1.0</PreferredName>
      <PreferredDefinition>A compound of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. Peptides are smaller than proteins and the dividing line is around 50 amino acids._A ratio expressed in base 10 notation.</PreferredDefinition>
      <LongName>Peptide Decimal Ratio</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C735</PreferredName>
        <Version>1</Version>
        <LongName>Peptide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C735</PREFERRED_NAME>
            <LONG_NAME>Peptide</LONG_NAME>
            <CON_ID>2342173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2671551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67272</PreferredName>
        <Version>1</Version>
        <LongName>Decimal Ratio</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67272</PREFERRED_NAME>
            <LONG_NAME>Decimal Ratio</LONG_NAME>
            <CON_ID>2671507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Peptide Decimal Ratio java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Peptide Decimal Ratio java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.PeptidesBase.decimalRatio</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PeptidesBase:decimalRatio</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="203">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2671991</PUBLICID>
    <LONGNAME>Peptide Next Amino Acid java.lang.String</LONGNAME>
    <PREFERREDNAME>2671698v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A compound of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. Peptides are smaller than proteins and the dividing line is around 50 amino acids._Subsequent; immediately following in time or order.:Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2671698</PublicId>
      <PreferredName>2612311v1.0:2671568v1.0</PreferredName>
      <PreferredDefinition>A compound of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. Peptides are smaller than proteins and the dividing line is around 50 amino acids._Subsequent; immediately following in time or order.:Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins.</PreferredDefinition>
      <LongName>Peptide Next Amino Acid</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C735</PreferredName>
        <Version>1</Version>
        <LongName>Peptide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C735</PREFERRED_NAME>
            <LONG_NAME>Peptide</LONG_NAME>
            <CON_ID>2342173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2671568</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53286:C231</PreferredName>
        <Version>1</Version>
        <LongName>Next Amino Acid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53286</PREFERRED_NAME>
            <LONG_NAME>Next</LONG_NAME>
            <CON_ID>2443959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C231</PREFERRED_NAME>
            <LONG_NAME>Amino Acid</LONG_NAME>
            <CON_ID>2342175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Peptide Next Amino Acid java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Peptide Next Amino Acid java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.PeptidesBase.nextAA</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PeptidesBase:nextAA</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="204">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2672046</PUBLICID>
    <LONGNAME>Sequest Scoring Engine Score Group Normalize Correlation Delta Score java.lang.Float</LONGNAME>
    <PREFERREDNAME>2671752v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A proprietary scoring engine from Thermo Fisher Scientific that can match tandem mass spectra with peptide sequences.:A number or range of numeric values measuring performance, function, quality, or ability.:Any number of entities (members) considered as a unit._To make something conform to a standard; to remove useless or extraneous entries from a data set.:The degree to which two or more quantities or events are linearly associated, a statistical relation between two or more variables such that systematic changes in the value of one variable are accompanied by systematic changes in the others.:A change in or difference between; usually represented by the 4th letter of the greek alphabet.:A number or range of numeric values measuring performance, function, quality, or ability._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2671752</PublicId>
      <PreferredName>2671641v1.0:2671609v1.0</PreferredName>
      <PreferredDefinition>A proprietary scoring engine from Thermo Fisher Scientific that can match tandem mass spectra with peptide sequences.:A number or range of numeric values measuring performance, function, quality, or ability.:Any number of entities (members) considered as a unit._To make something conform to a standard; to remove useless or extraneous entries from a data set.:The degree to which two or more quantities or events are linearly associated, a statistical relation between two or more variables such that systematic changes in the value of one variable are accompanied by systematic changes in the others.:A change in or difference between; usually represented by the 4th letter of the greek alphabet.:A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Sequest Scoring Engine Score Group Normalize Correlation Delta Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2671641</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68825:C25338:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Sequest Scoring Engine Score Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68825</PREFERRED_NAME>
            <LONG_NAME>Sequest Scoring Engine</LONG_NAME>
            <CON_ID>2671519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2671609</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62007:C48834:C54126:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Normalize Correlation Delta Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62007</PREFERRED_NAME>
            <LONG_NAME>Normalize</LONG_NAME>
            <CON_ID>2528556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48834</PREFERRED_NAME>
            <LONG_NAME>Correlation</LONG_NAME>
            <CON_ID>2433331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54126</PREFERRED_NAME>
            <LONG_NAME>Delta</LONG_NAME>
            <CON_ID>2528551</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Sequest Scoring Engine Score Group Normalize Correlation Delta Score java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Sequest Scoring Engine Score Group Normalize Correlation Delta Score java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.SequestScores.deltaCn</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SequestScores:deltaCn</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="205">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2672277</PUBLICID>
    <LONGNAME>Sequest Scoring Engine Score Group Light Mass java.lang.Float</LONGNAME>
    <PREFERREDNAME>2671918v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A proprietary scoring engine from Thermo Fisher Scientific that can match tandem mass spectra with peptide sequences.:A number or range of numeric values measuring performance, function, quality, or ability.:Any number of entities (members) considered as a unit._Of comparatively little physical weight or density.:The amount of matter in an object._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2671918</PublicId>
      <PreferredName>2671641v1.0:2671567v1.0</PreferredName>
      <PreferredDefinition>A proprietary scoring engine from Thermo Fisher Scientific that can match tandem mass spectra with peptide sequences.:A number or range of numeric values measuring performance, function, quality, or ability.:Any number of entities (members) considered as a unit._Of comparatively little physical weight or density.:The amount of matter in an object.</PreferredDefinition>
      <LongName>Sequest Scoring Engine Score Group Light Mass</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2671641</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68825:C25338:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Sequest Scoring Engine Score Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68825</PREFERRED_NAME>
            <LONG_NAME>Sequest Scoring Engine</LONG_NAME>
            <CON_ID>2671519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2671567</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68808:C43246</PreferredName>
        <Version>1</Version>
        <LongName>Light Mass</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68808</PREFERRED_NAME>
            <LONG_NAME>Light</LONG_NAME>
            <CON_ID>2671510</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43246</PREFERRED_NAME>
            <LONG_NAME>Mass</LONG_NAME>
            <CON_ID>2444528</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Sequest Scoring Engine Score Group Light Mass java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Sequest Scoring Engine Score Group Light Mass java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.SequestScores.lightMass</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SequestScores:lightMass</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="206">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2672816</PUBLICID>
    <LONGNAME>Schedule Protocol Treatment Arm Begin Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2672790v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An ordered list of times at which things are planned to occur.:A specific treatment protocol used in a clinical trial._Have a beginning, in a temporal, spatial, or evaluative sense.:a particular day specified as the time something has, or will, happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2672790</PublicId>
      <PreferredName>2672777v1.0:2207412v1.0</PreferredName>
      <PreferredDefinition>An ordered list of times at which things are planned to occur.:A specific treatment protocol used in a clinical trial._Have a beginning, in a temporal, spatial, or evaluative sense.:a particular day specified as the time something has, or will, happen.</PreferredDefinition>
      <LongName>Schedule Protocol Treatment Arm Begin Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2672777</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25211:C15538</PreferredName>
        <Version>1</Version>
        <LongName>Schedule Protocol Treatment Arm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15538</PREFERRED_NAME>
            <LONG_NAME>Protocol Treatment Arm</LONG_NAME>
            <CON_ID>2206366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207412</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Begin Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Schedule Protocol Treatment Arm Begin Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Schedule Protocol Treatment Arm Begin Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812978</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ScheduledArm:startDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.bioinformatics.studycalendar.domain.ScheduledArm.startDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.ScheduledArm.startDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="207">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2677711</PUBLICID>
    <LONGNAME>Ovary Present Ind-2</LONGNAME>
    <PREFERREDNAME>OV_PRES_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether one of the paired female reproductive glands containing the ova or germ cells is present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2677682</PublicId>
      <PreferredName>OV_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of one of the paired female reproductive glands containing the ova or germ cells.</PreferredDefinition>
      <LongName>Ovary Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2677680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12404</PreferredName>
        <Version>1</Version>
        <LongName>Ovary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12404</PREFERRED_NAME>
            <LONG_NAME>Ovary</LONG_NAME>
            <CON_ID>2202769</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have at least on</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have at least one ovary?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the participant still have at least one ovary?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the participant have at least one ovary?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-01-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="208">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2677716</PUBLICID>
    <LONGNAME>Main Reason Death Other Type Diagnosis Specify</LONGNAME>
    <PREFERREDNAME>MN_RS_DT_TY_DI_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>Most important; principal._An explanation of the cause of some phenomenon or action._The absence of life or state of being dead._Different than the one(s) previously specified or mentioned._Something distinguishable as an identifiable class based on common qualities._the specified free-text field related to an aspect of patient/participant&#39;s diagnosis</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2768365</PublicId>
      <PreferredName>MN_RSN_DTH_OTH_TYP</PreferredName>
      <PreferredDefinition>Most important; principal._An explanation of the cause of some phenomenon or action._The absence of life or state of being dead._Different than the one(s) previously specified or mentioned._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Main Reason Death Other Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2768644</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25562:C25638:C28554</PreferredName>
        <Version>1</Version>
        <LongName>Main Reason Death</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25562</PREFERRED_NAME>
            <LONG_NAME>Main</LONG_NAME>
            <CON_ID>2206300</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28554</PREFERRED_NAME>
            <LONG_NAME>Dead</LONG_NAME>
            <CON_ID>2202731</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236666</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Other Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018432</PublicId>
      <PreferredName>DX_SPEC</PreferredName>
      <PreferredDefinition>the specified free-text field related to an aspect of patient/participant&#39;s diagnosis</PreferredDefinition>
      <LongName>Diagnosis Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Main cause of death: Other,sp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Main cause of death: Other,specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2677716</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedMedicalConditionResult [death] &gt; AssessedResultRelationship &gt; PerformedObservation [primary etiology] &gt; PerformedClinicalInterpretation.value(ANY=&gt;CD).originalText WHERE PerformedMedicalConditionResult.value = &quot;death&quot; AND AssessedResultRelationship.typeCode = &quot;primary etiology&quot; AND PerformedClinicalInterpretation.value(ANY=&gt;CD).nullFlavor = &quot;OTH&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2681516</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>New Content T Joshua</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Post_TED Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2681516</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>New Content T Joshua</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Data Element</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2450r1: Post-TED</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964925</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2455: Selective Post-Transplant Essential Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3160397</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>post_ted_oth_cod_oth_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalInterpretation:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="209">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2680075</PUBLICID>
    <LONGNAME>RET Oncogene Mutation Status Codon Identifier</LONGNAME>
    <PREFERREDNAME>RET_ONCOG_CODON_ID</PREFERREDNAME>
    <PREFERREDDEFINITION>Identifier to represent a germline mutation of the RET (REarranged during Transfection) proto-oncogene, which codes for a receptor tyrosine kinase, to cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2680071</PublicId>
      <PreferredName>RET_ONCOG_MUT_STAT</PreferredName>
      <PreferredDefinition>Reference to the state of a germline alteration of the RET (REarranged during Transfection) proto-oncogene, which codes for a receptor tyrosine kinase. [Manually-curated]</PreferredDefinition>
      <LongName>RET Oncogene Mutation Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2680069</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16936:C16885</PreferredName>
        <Version>1</Version>
        <LongName>Oncogene Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16936</PREFERRED_NAME>
            <LONG_NAME>Oncogene</LONG_NAME>
            <CON_ID>2680068</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16885</PREFERRED_NAME>
            <LONG_NAME>Mutation</LONG_NAME>
            <CON_ID>2224010</CON_ID>
            <DEFINITION_SOURCE>CABIO</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2680073</PublicId>
      <PreferredName>CODON_ID</PreferredName>
      <PreferredDefinition>One or more characters used to identify a specific sequence of three adjacent bases on a strand of DNA or RNA that provides genetic code information for a particular amino acid. [Manually-curated]</PreferredDefinition>
      <LongName>Codon Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2680072</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62019:C0600091</PreferredName>
        <Version>1</Version>
        <LongName>Codon Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62019</PREFERRED_NAME>
            <LONG_NAME>Codon</LONG_NAME>
            <CON_ID>2528558</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0600091</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2203051</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mutation Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mutation Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RET mutation Codon</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="210">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2680562</PUBLICID>
    <LONGNAME>Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria 40601 Type</LONGNAME>
    <PREFERREDNAME>C_PT_IN_CTE_40601_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the elgibility criteria for CALGB 40601, the element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2625931</PublicId>
      <PreferredName>CALGB_PT_INCL_CTEC</PreferredName>
      <PreferredDefinition>information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.</PreferredDefinition>
      <LongName>Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2625929</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25442:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Cancer and Leukemia Group B Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25442</PREFERRED_NAME>
            <LONG_NAME>Cancer and Leukemia Group B</LONG_NAME>
            <CON_ID>2205049</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2518229</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25532:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Inclusion Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25532</PREFERRED_NAME>
            <LONG_NAME>Inclusion Criteria</LONG_NAME>
            <CON_ID>2202445</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2680561</PublicId>
      <PreferredName>40601_INCL_CTEC_TP</PreferredName>
      <PreferredDefinition>the type of clinical trial eligibility inclusion criteria for a Cancer and Leukemia Group B protocol 40601.</PreferredDefinition>
      <LongName>40601 Inclusion Clinical Trial Eligibility Criteria Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>255</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Women or men at least 18 years of age</VALIDVALUE>
          <VALUEMEANING>&gt;= 18 years of age</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt;= 18 years of age</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2625936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invasive breast cancer</VALIDVALUE>
          <VALUEMEANING>Invasive breast cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum Beta-HCG negative</VALIDVALUE>
          <VALUEMEANING>Beta-Hcg negative (in premenopausal women)</VALUEMEANING>
          <MEANINGDESCRIPTION>Beta-Hcg negative (in premenopausal women)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2626074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Bilirubin &lt;= 1.5 x ULN unless due to Gilbert&#39;s Syndrome</VALIDVALUE>
          <VALUEMEANING>Bilirubin &lt;= 1.5 x ULN unless due to Gilbert&#39;s Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>Bilirubin &lt;= 1.5 x ULN unless due to Gilbert&#39;s Syndrome</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2626070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy</VALIDVALUE>
          <VALUEMEANING>Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria</VALIDVALUE>
          <VALUEMEANING>Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria</VALUEMEANING>
          <MEANINGDESCRIPTION>Multicentric or bilateral disease is eligible if target lesion meets eligibility criteria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ECOG (Zubrod) Performance Status 0-1</VALIDVALUE>
          <VALUEMEANING>ECOG (Zubrod) PS &lt;= 1; life expectancy &gt;=12 wk</VALUEMEANING>
          <MEANINGDESCRIPTION>ECOG (Zubrod) PS &lt;= 1; life expectancy &gt;=12 wk</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2625937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumors are HER2 positive as defined in section 4.3</VALIDVALUE>
          <VALUEMEANING>Tumors are HER2 positive as defined in section 4.3</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumors are HER2 positive as defined in section 4.3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER/PgR status is known</VALIDVALUE>
          <VALUEMEANING>ER/PgR status is known</VALUEMEANING>
          <MEANINGDESCRIPTION>ER/PgR status is known</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Target lesion in breast is &gt; 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate</VALIDVALUE>
          <VALUEMEANING>Target lesion in breast is &gt; 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate</VALUEMEANING>
          <MEANINGDESCRIPTION>Target lesion in breast is &gt; 1 cm by either clinical or radiographic measurement. Patients with axillary disease as only site are not eligible to participate</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery</VALIDVALUE>
          <VALUEMEANING>Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient consents to undergo pretreatment biopsy and to acquisition of tissue obtained at the time of surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer</VALIDVALUE>
          <VALUEMEANING>No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>No prior chemotherapy, hormone therapy, biologic or radiation therapy with therapeutic intent for this cancer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry</VALIDVALUE>
          <VALUEMEANING>No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry</VALUEMEANING>
          <MEANINGDESCRIPTION>No medication with known potential for interaction with lapatinib for at least 7 days prior to study entry</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac ejection fraction &gt; 50% by echocardiogram or MUGA scan</VALIDVALUE>
          <VALUEMEANING>Cardiac ejection fraction &gt; 50% by echocardiogram or MUGA scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Cardiac ejection fraction &gt; 50% by echocardiogram or MUGA scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients not pregnant or nursing</VALIDVALUE>
          <VALUEMEANING>Patients not pregnant or nursing</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients not pregnant or nursing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AST &lt;= 2.5 x ULN</VALIDVALUE>
          <VALUEMEANING>AST &lt;= 2.5 x ULN</VALUEMEANING>
          <MEANINGDESCRIPTION>AST &lt;= 2.5 x ULN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALT &lt;= 2.5 x ULN</VALIDVALUE>
          <VALUEMEANING>ALT &lt;= 2.5 x ULN</VALUEMEANING>
          <MEANINGDESCRIPTION>ALT &lt;= 2.5 x ULN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ANC &gt;= 1,000/mcl</VALIDVALUE>
          <VALUEMEANING>ANC &gt;= 1,000/mcl</VALUEMEANING>
          <MEANINGDESCRIPTION>ANC &gt;= 1,000/mcl</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platelet count &gt;= 100,000/mm^3</VALIDVALUE>
          <VALUEMEANING>Platelet count &gt;= 100,000/mm^3</VALUEMEANING>
          <MEANINGDESCRIPTION>Platelet count &gt;= 100,000/mm^3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2680576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Eligibility criteria</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Eligibility criteria</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="211">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2685099</PUBLICID>
    <LONGNAME>Anal Surrounding Anus Biopsy Performed Indicator</LONGNAME>
    <PREFERREDNAME>A_SUR_A_BX_PERF_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the indicator relating to whether an anal or perianal biopsy was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2685102</PublicId>
      <PreferredName>ANL_SUR_AN_BX_PERF</PreferredName>
      <PreferredDefinition>information relating to an anal (having to do with the anus, which is the posterior opening of the large bowel) or perianal (encircling the opening of the rectum to the outside of the body) biopsy (removal and pathologic examination of specimens in the form of small pieces of tissue from the living body) being performed.</PreferredDefinition>
      <LongName>Anal Surrounding Anus Biopsy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685100</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28048:C52247:C43362:C15189</PreferredName>
        <Version>1</Version>
        <LongName>Anal Surrounding Anus Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28048</PREFERRED_NAME>
            <LONG_NAME>Anal</LONG_NAME>
            <CON_ID>2615799</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52247</PREFERRED_NAME>
            <LONG_NAME>Surrounding</LONG_NAME>
            <CON_ID>2443939</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43362</PREFERRED_NAME>
            <LONG_NAME>Anus</LONG_NAME>
            <CON_ID>2494283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2682430</PublicId>
      <PreferredName>ANAL_EVAL_IND</PreferredName>
      <PreferredDefinition>the indicator relating to whether the patient/participant has had an anal evaluation.</PreferredDefinition>
      <LongName>Anal Evaluation Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2188676</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Participant does not recall</VALIDVALUE>
          <VALUEMEANING>Participant does not recall</VALUEMEANING>
          <MEANINGDESCRIPTION>Participant does not recall</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2684394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anal or perianal biopsy perfo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Anal or perianal biopsy performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="212">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2685112</PUBLICID>
    <LONGNAME>Surrounding Anus Biopsy Performed Indicator</LONGNAME>
    <PREFERREDNAME>SUR_ANU_BX_PERF_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the indicator relating to whether a perianal biopsy was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2685108</PublicId>
      <PreferredName>SUR_ANUS_BX_PERF</PreferredName>
      <PreferredDefinition>information relating to a perianal (having to do with the anus, encircling the opening of the rectum to the outside of the body) biopsy (removal and pathologic examination of specimens in the form of small pieces of tissue from the living body) being performed.</PreferredDefinition>
      <LongName>Surrounding Anus Biopsy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685106</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52247:C43362:C15189</PreferredName>
        <Version>1</Version>
        <LongName>Surrounding Anus Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52247</PREFERRED_NAME>
            <LONG_NAME>Surrounding</LONG_NAME>
            <CON_ID>2443939</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43362</PREFERRED_NAME>
            <LONG_NAME>Anus</LONG_NAME>
            <CON_ID>2494283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2682430</PublicId>
      <PreferredName>ANAL_EVAL_IND</PreferredName>
      <PreferredDefinition>the indicator relating to whether the patient/participant has had an anal evaluation.</PreferredDefinition>
      <LongName>Anal Evaluation Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2188676</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Participant does not recall</VALIDVALUE>
          <VALUEMEANING>Participant does not recall</VALUEMEANING>
          <MEANINGDESCRIPTION>Participant does not recall</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2684394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Perianal biopsy performed</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Perianal biopsy performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="213">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2686228</PUBLICID>
    <LONGNAME>Laboratory Procedure Anal Human Papillomavirus-18 Polymerase Chain Reaction Result Type</LONGNAME>
    <PREFERREDNAME>LA_A_HPB18_PCR_R_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type or outcome for human papillomavirus type 18 (a strain of the human papillomavirus virus that has been directly linked to cervical cancer and is significantly associated with invasiveness) from anal tissue determined through a PCR (polymerase chain reaction) laboratory procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2686215</PublicId>
      <PreferredName>LAB_A_HPV18_PCR_RSLT</PreferredName>
      <PreferredDefinition>information relating the result of the medical procedure that involves testing a anal tissue sample, tissue from the anus, which is the posterior opening of the large bowel, for human papillomavirus type 18 (HPV-18), a species of PAPILLOMAVIRUS causing warts, benign, squamous epithelial tumors, and is directly linked to cervical cancer and is significantly associated with invasiveness, by polymerase chain reaction (PCR), q method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.</PreferredDefinition>
      <LongName>Laboratory Procedure Anal Human Papillomavirus-18 Polymerase Chain Reaction Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28048:C14377:C17003:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Anal Human Papillomavirus-18 Polymerase Chain Reaction Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28048</PREFERRED_NAME>
            <LONG_NAME>Anal</LONG_NAME>
            <CON_ID>2615799</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14377</PREFERRED_NAME>
            <LONG_NAME>Human Papillomavirus-18</LONG_NAME>
            <CON_ID>2686212</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17003</PREFERRED_NAME>
            <LONG_NAME>Polymerase Chain Reaction</LONG_NAME>
            <CON_ID>2202449</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2686220</PublicId>
      <PreferredName>HPV_PCR_LAB_TP</PreferredName>
      <PreferredDefinition>the type or  outcome for human papillomavirus (HPV) obtained through a PCR (polymerase chain reaction) laboratory procedure.</PreferredDefinition>
      <LongName>Human Papillomavirus Polymerase Chain Reaction Laboratory Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Involving advantage or good.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Results not available</VALIDVALUE>
          <VALUEMEANING>Results not available</VALUEMEANING>
          <MEANINGDESCRIPTION>Results not available</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2693093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HPV Type 18 Results</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>HPV Type 18 Results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="214">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2688017</PUBLICID>
    <LONGNAME>Hospital Specific Radiation Therapy Type Number Code</LONGNAME>
    <PREFERREDNAME>2688010v1.0:2645150v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Defines the type of radiation therapy the patient received as a part of the initial treatment for the reportable tumor at the reporting facility.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2688010</PublicId>
      <PreferredName>2685312v1.0:2688008v1.0</PreferredName>
      <PreferredDefinition>The type of radiation therapy the patient received as a part of the initial treatment for the reportable tumor at the reporting facility.</PreferredDefinition>
      <LongName>Hospital Specific Radiation Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16696:C38024</PreferredName>
        <Version>1</Version>
        <LongName>Hospital Specified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16696</PREFERRED_NAME>
            <LONG_NAME>Hospital</LONG_NAME>
            <CON_ID>2202656</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38024</PREFERRED_NAME>
            <LONG_NAME>Specified</LONG_NAME>
            <CON_ID>2211671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2688008</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2645150</PublicId>
      <PreferredName>2645150v1.0</PreferredName>
      <PreferredDefinition>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Something distinguishable as an identifiable class based on common qualities._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Radiation Therapy Type Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2661633</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313:C25284:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy Type Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Unknown if radiation therapy adminstered</VALUEMEANING>
          <MEANINGDESCRIPTION>Unknown if radiation therapy adminstered</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Radiation, NOS - method or source not specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation, NOS - method or source not specified</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Combination of 1 with 2 or 3</VALUEMEANING>
          <MEANINGDESCRIPTION>Combination of 1 with 2 or 3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Radioisotopes</VALUEMEANING>
          <MEANINGDESCRIPTION>Radioisotopes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Radioactive implants</VALUEMEANING>
          <MEANINGDESCRIPTION>Radioactive implants</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Beam radiation</VALUEMEANING>
          <MEANINGDESCRIPTION>Beam radiation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Hospital Radiation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RX Hospital Radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Note</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>This data item is no longer supported by CoC (as of January 1, 2003).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103542</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242104</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>690</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Radiation at this Facility (COC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX HOSP--RADIATION</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="215">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2688036</PUBLICID>
    <LONGNAME>Hospital Specific Other Therapeutic Procedure Number Code</LONGNAME>
    <PREFERREDNAME>2688034v1.0:2645274v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2688034</PublicId>
      <PreferredName>2685312v1.0:2688032v1.0</PreferredName>
      <PreferredDefinition>Other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.</PreferredDefinition>
      <LongName>Hospital Specific Other Therapeutic Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16696:C38024</PreferredName>
        <Version>1</Version>
        <LongName>Hospital Specified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16696</PREFERRED_NAME>
            <LONG_NAME>Hospital</LONG_NAME>
            <CON_ID>2202656</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38024</PREFERRED_NAME>
            <LONG_NAME>Specified</LONG_NAME>
            <CON_ID>2211671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2688032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Other Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2645274</PublicId>
      <PreferredName>2645274v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned. (NCI)_An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Other Therapeutic Procedure Number Code</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2661644</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C49236:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Other Therapeutic Procedure Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Recommended, unknown if administered; other treatment was recommended, but it is unknown whether it was administered.</VALUEMEANING>
          <MEANINGDESCRIPTION>Recommended, unknown if administered; other treatment was recommended, but it is unknown whether it was administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Refusal; other treatment was not administered. Treatment listed in code 1, 2 or 3 was recommended by the patient&quot;s physician but was refused by the patient or the patient&quot;s family or guardian. The refusal was noted in the patient record.</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal; other treatment was not administered. Treatment listed in code 1, 2 or 3 was recommended by the patient&quot;s physician but was refused by the patient or the patient&quot;s family or guardian. The refusal was noted in the patient record.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>It is unknown whether other treatment was recommended or administered because it is not stated in the patient record. Death certificate only case.</VALUEMEANING>
          <MEANINGDESCRIPTION>It is unknown whether other treatment was recommended or administered because it is not stated in the patient record. Death certificate only case.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Other unproven; Cancer treatments administered by nonmedical personnel.</VALUEMEANING>
          <MEANINGDESCRIPTION>Other unproven; Cancer treatments administered by nonmedical personnel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Cancer treatment that cannot be assigned to specified treatment data items.</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer treatment that cannot be assigned to specified treatment data items.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None; all cancer treatment was coded in other treatment fields. Patient received no cancer treatment. Diagnosed at autopsy.</VALUEMEANING>
          <MEANINGDESCRIPTION>None; all cancer treatment was coded in other treatment fields. Patient received no cancer treatment. Diagnosed at autopsy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Other-Experimental; this code is not defined. It may be used to record participation in institution-based clinical trials.</VALUEMEANING>
          <MEANINGDESCRIPTION>Other-Experimental; this code is not defined. It may be used to record participation in institution-based clinical trials.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Hosp--Other</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Treatment for reportable hematopoietic diseases can be supportive care, observation, or any treatment that does not meet the usual definition in which treatment modifies, controls, removes, or destroys proliferating cancer tissue. Such treatments include phlebotomy, transfusions, and aspirin.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Hospital Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RX Hospital Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899839</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464313</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX HOSP--OTHER</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>730</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Other Treatment at this Facility (CoC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Hosp--Other</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="216">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2689272</PUBLICID>
    <LONGNAME>Immune System Disorder Classification Type</LONGNAME>
    <PREFERREDNAME>2689239v1.00:2689266v2.20</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the immune system disorder classification.</PREFERREDDEFINITION>
    <VERSION>5</VERSION>
    <WORKFLOWSTATUS>DRAFT MOD</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2689239</PublicId>
      <PreferredName>IMNE_DZ_CLS</PreferredName>
      <PreferredDefinition>A disorder resulting from an abnormality in the immune system. -- 2003_A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Immune System Disorder Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2716886</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3507</PreferredName>
        <Version>1</Version>
        <LongName>Immune System Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3507</PREFERRED_NAME>
            <LONG_NAME>Immune System Disorder</LONG_NAME>
            <CON_ID>2469349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2321361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25161</PreferredName>
        <Version>1</Version>
        <LongName>Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2689266</PublicId>
      <PreferredName>IMNE_DZ_TP</PreferredName>
      <PreferredDefinition>A disorder resulting from an abnormality in the immune system. -- 2003_Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Immune System Disorder Type</LongName>
      <Version>2.2</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2486864</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3507:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Immune System Disorder Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3507</PREFERRED_NAME>
            <LONG_NAME>Immune System Disorder</LONG_NAME>
            <CON_ID>2469349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B- NK-, Adenosine deaminase (ADA) deficiency</VALIDVALUE>
          <VALUEMEANING>Adenosine Deaminase Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive deficiency of the purine salvage enzyme adenosine deaminase which results in Severe Combined Immunodeficiency Disease (SCID).  The most common form of SCID, accounting for about 50% of autosomal recessive cases.  The first disease for which gene therapy was applied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B- NK-, Reticular dysgenesis</VALIDVALUE>
          <VALUEMEANING>Reticular Dysgenesis</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare severe combined immunodeficiency disorder characterized by congenital agranulocytosis, lymphoid tissue and thymic tissue hypoplasia, and lymphopenia. Both cellular and humoral immunities are absent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3326327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cartilage-hair hypoplasia</VALIDVALUE>
          <VALUEMEANING>Cartilage Hair Hypoplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare autosomal recessive inherited disorder caused by mutation in the gene for RNAase RMRP. It is characterized by short-limb dwarfism, presence of fine sparse hair, and T-and B-cell immunodeficiency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3322411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B- NK+, RAG 1/2 deficiency</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency due to RAG Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare severe combined immunodeficiency disorder caused by null mutations in recombination activating gene (RAG) 1 or RAG2. It is associated with a lack of T and B cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B- NK+, DCLRE1C (Artemis) deficiency</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency, Athabascan Type</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive condition caused by mutation(s) in the DCLRE1C gene, encoding protein artemis. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell negative, NK-cell positive. Sensitivity to ionizing radiation and a high incidence of occurrence amongst the Athabascan Indians are also characteristic of this disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B- NK-, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency with Absence of T, B, and NK Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A severe combined immunodeficiency disorder that is associated with a lack of T, B, and NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Severe Combined Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3472, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other SCID</VALIDVALUE>
          <VALUEMEANING>Other Severe Combined Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3472, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD40 ligand deficiency</VALIDVALUE>
          <VALUEMEANING>CD40 Ligand Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with the X-linked hyper IgM syndrome have a deficiency of a protein, CD40 ligand that is found on the surface of T-lymphocytes. As a consequence of the deficiency of this protein, their T-lymphocytes are unable to instruct B-lymphocytes to switch their production of gamma globulins from IgM to IgG and IgA. As a result, patients have decreased levels of IgG and IgA and normal or elevated levels of IgM. In addition, since CD40 ligand is important to other functions of T-lymphocytes, they also have a defect in some of the protective functions of their T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61244</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DOCK8 Deficiency</VALIDVALUE>
          <VALUEMEANING>DOCK8 Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition of decreased or absent presence or activity of dedicator of cytokinesis protein 8. Deficiency of this protein is associated with autosomal recessive hyper-IgE recurrent infection syndrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5207250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MHC Class II Deficiency (Bare lymphocyte syndrome)</VALIDVALUE>
          <VALUEMEANING>Bare Lymphocyte Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A hereditary immunodeficiency disorder caused by the absence of major histocompatibility complex class II expression. Signs and symptoms include upper and lower respiratory tract bacterial infections, malabsorption, diarrhea, and mucocutaneous candidiasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3322393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omenn syndrome</VALIDVALUE>
          <VALUEMEANING>Omenn Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3323722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ZAP-70 deficiency</VALIDVALUE>
          <VALUEMEANING>Immunodeficiency 48; Selective T-Cell Defect; STCD</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive immunodeficiency caused by mutation(s) in the ZAP70 gene, encoding tyrosine-protein kinase ZAP-70. It is characterized by absent CD8+ cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ataxia telangiectasia</VALIDVALUE>
          <VALUEMEANING>Ataxia Telangiectasia Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DiGeorge anomaly</VALIDVALUE>
          <VALUEMEANING>DiGeorge Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2989</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEMO Deficiency Syndrome</VALIDVALUE>
          <VALUEMEANING>Ectodermal Dysplasia and Immunodeficiency 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An X-linked recessive condition caused by mutation(s) in the IKBKG gene, encoding NF-kappa-B essential modulator (NEMO). It is characterized by the onset of recurrent severe infections due to immunodeficiency in early infancy or in the first years of life. Affected individuals may present with ectodermal dysplasia, including conical incisors, hypo/anhidrosis, and thin skin or hair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wiskott-Aldrich syndrome</VALIDVALUE>
          <VALUEMEANING>Wiskott-Aldrich syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Common variable immunodeficiency</VALIDVALUE>
          <VALUEMEANING>Common Variable Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Activated PI3 Kinase Delta Deficiency Syndrome (APDS1 or PIK3CD)</VALIDVALUE>
          <VALUEMEANING>Activated PI3K Delta Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare, autosomal dominant inherited primary immunodeficiency disorder caused by mutations in either PIK3CD gene or PIK3R1 gene. Clinical manifestations include the following: recurrent respiratory tract infections; non-malignant lymphoproliferation that results in generalized lymphadenopathy and hepatosplenomegaly; chronic infections with Epstein-Barr virus, cytomegalovirus, and herpes simplex virus; cytopenia; and glomerulonephritis. Patients are at an increased risk of developing non-Hodgkin or Hodgkin lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autoimmune Lymphoproliferative Syndrome (ALPS)</VALIDVALUE>
          <VALUEMEANING>Autoimmune Lymphoproliferative Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CTLA4 deficiency</VALIDVALUE>
          <VALUEMEANING>CTLA4 Haploinsufficiency; CHAI; ALPS5</VALUEMEANING>
          <MEANINGDESCRIPTION>A somatic mutation in the CTLA4 gene resulting in only a single functional gene. Haploinsufficiency for CTLA4 is associated with autoimmune lymphoproliferative syndrome, type V.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5207234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IPEX, Immune Dysregulation Polyendocrinopathy, enteropathy X-linked (FOXP3 deficiency)</VALIDVALUE>
          <VALUEMEANING>Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An X-linked recessive autoimmune condition caused by mutation(s) in the FOXP3 gene, encoding the forkhead box P3 transcription factor. The condition is characterized by infantile onset of severe diarrhea due to enteropathy, type 1 diabetes mellitus, and dermatitis. Associated features may include hypothyroidism, autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatitis, and nephritis. The condition is usually fatal before age 2 years if not treated with bone marrow transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LRBA Deficiency</VALIDVALUE>
          <VALUEMEANING>Immunodeficiency, Common Variable, 8, with Autoimmunity</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive common variable immunodeficiency caused by mutation(s) in the LRBA gene, encoding lipopolysaccharide-responsive and beige-like anchor protein. It is characterized by recurrent infections and the development of autoimmune disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Gain of Function</VALIDVALUE>
          <VALUEMEANING>STAT3 Gain of Function</VALUEMEANING>
          <MEANINGDESCRIPTION>A mutation in the STAT3 gene that results in an increase in cytokine-related function. STAT3 mutations of this type are associated with infantile-onset multisystem autoimmune disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5207241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic granulomatous disease</VALIDVALUE>
          <VALUEMEANING>chronic granulomatous disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A recessive X-linked defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GATA2 deficiency</VALIDVALUE>
          <VALUEMEANING>GATA2 Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition of decreased or absent presence or activity of endothelial transcription factor GATA-2 protein. Deficiency of this protein is associated with immunodeficiency 21 and autosomal dominant and sporadic monocytopenia and mycobacterial infection syndrome (MonoMAC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5207249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leukocyte adhesion deficiencies</VALIDVALUE>
          <VALUEMEANING>Leukocyte Adhesion Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare autosomal recessive immunodeficiency disorder caused by deficiency of CD18 expression. It is characterized by defects in neutrophil adhesion and bacterial infections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3323201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutropenia with combined immune deficiency (MKL1 deficiency, Actin deficiency)</VALIDVALUE>
          <VALUEMEANING>Immunodeficiency 66</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive combined immunodeficiency caused by mutation(s) in the MRTFA (MKL1) gene, encoding myocardin-related transcription factor A. It is characterized by neutropenia and recurrent bacterial infections in infancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT1 Gain of Function</VALIDVALUE>
          <VALUEMEANING>STAT1 Gain of Function</VALUEMEANING>
          <MEANINGDESCRIPTION>A mutation in the STAT1 gene that results in an increase in cytokine-related functions associated with IFN-alpha/beta, IFN-gamma, IFN-delta, and IL-27. STAT1 mutations of this type are associated with autosomal dominant immunodeficiency 31C.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5207240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other immunodeficiencies</VALIDVALUE>
          <VALUEMEANING>Other Immunodeficiency Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: A deficiency of immune response or a disorder characterized by deficient immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3131, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3929631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIV infection</VALIDVALUE>
          <VALUEMEANING>HIV infection</VALUEMEANING>
          <MEANINGDESCRIPTION>An infection caused by the human immunodeficiency virus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immune deficiency, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Immunodeficiency Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: A deficiency of immune response or a disorder characterized by deficient immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3131, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B+ NK-, JAK3 mutation</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B-Cell Positive, NK-Cell Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive severe combined immunodeficiency caused by mutation(s) in the JAK3 gene, encoding tyrosine-protein kinase JAK3. It is characterized by decreased concentrations of T-cells and NK-cells and normal concentrations of B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T- B+ NK-, IL2RG mutations, X-linked SCID</VALIDVALUE>
          <VALUEMEANING>X-Linked Severe Combined Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>Rare congenital disorder inherited as an X-linked defect characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7515583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID,T- B+ NK+, ILR alpha deficiency</VALIDVALUE>
          <VALUEMEANING>IL-7R-Alpha-deficient Severe Combined Immunodeficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive form of severe combined immunodeficiency characterized as t-cell negative, b-cell positive, NK cell positive, and with mutations in the gene encoding interleukin-7 receptor alpha chain protein. This class of SCID accounts for approximately 10% of all SCID cases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14741328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEXAS Syndrome</VALIDVALUE>
          <VALUEMEANING>VEXAS Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An X-linked inherited condition caused by somatic mutation(s) in the UBA1 gene, encoding ubiquitin-like modifier-activating enzyme 1. It is characterized by the adult onset of rheumatologic symptoms in males, including recurrent fevers, pulmonary and dermatologic inflammatory manifestations, vasculitis, arthralgias, facial chondritis and hematologic abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C181924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15232293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyper IGE</VALIDVALUE>
          <VALUEMEANING>Hyperimmunoglobulin E Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition that is characterized by elevated serum IgE, dermatitis, and respiratory infections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3144</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7519097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T-B-NK+ (RAG mutation) without Omenn Syndrome</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency due to RAG Deficiency without Omenn Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare severe combined immunodeficiency disorder caused by null mutations in recombination activating gene RAG1 or RAG2. Phenotypically, it is toward the more severe end of the clinical spectrum due to complete arrest of T and B-cell development, without the clinical features of Omenn Syndrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C212081</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15354872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SCID, T-B-NK+ (RAG mutation) with Omenn Syndrome</VALIDVALUE>
          <VALUEMEANING>Severe Combined Immunodeficiency due to RAG Deficiency with Omenn Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>T-cell negative (T-), B-cell negative (B-) severe combined immunodeficiency (SCID) caused by missense mutation(s) in the RAG1 and/or RAG2 genes, from which proteins encoded for by these gene(s) retain partial biologic activity that result in a less severe form of classical T-B-SCID, along with clinical features of Omenn Syndrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C212080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15354871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the classification of the immune deficiency?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the immune deficiency phenotype?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the immune deficiency phenotype?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify disorder of immune system classification</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify disorder of immune system classification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify disorder of immune system classification</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify disorder of immune system classification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify inborn error of immunity classification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r1: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_who_immune_defic</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_prime_dis_hct_immune_sys_class</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_base_imun_def_phenotyp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_ICT_immune_sys_class</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_DIS_immune_sys_class</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="217">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2689906</PUBLICID>
    <LONGNAME>Physical Entity Accession Number Database java.lang.String</LONGNAME>
    <PREFERREDNAME>2689854v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:An independently existing thing (living or nonliving).:A control number unique to an object, used to identify it among the other objects in a collection._An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2689854</PublicId>
      <PreferredName>2689838v1.0:2689831v1.0</PreferredName>
      <PreferredDefinition>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:An independently existing thing (living or nonliving).:A control number unique to an object, used to identify it among the other objects in a collection._An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.</PreferredDefinition>
      <LongName>Physical Entity Accession Number Database</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2689838</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25618:C51070:C25402</PreferredName>
        <Version>1</Version>
        <LongName>Physical Entity Accession Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25618</PREFERRED_NAME>
            <LONG_NAME>Physical</LONG_NAME>
            <CON_ID>2203948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2689831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15426</PreferredName>
        <Version>1</Version>
        <LongName>Database</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15426</PREFERRED_NAME>
            <LONG_NAME>Database</LONG_NAME>
            <CON_ID>2228339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Physical Entity Accession Number Database java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Physical Entity Accession Number Database java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2689825</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PathwayInteractionDatabase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PID</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812660</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000687</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2860261</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EntityAccession:database</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PID.EntityAccession.database</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.pathways.EntityAccession.database</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@database</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="218">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2691464</PUBLICID>
    <LONGNAME>Hematopoietic Cell Transplantation Institution Department Name Specify</LONGNAME>
    <PREFERREDNAME>HSCT_INST_DPT_SPC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the hematopoietic cell transplantation institution department name.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527677</PublicId>
      <PreferredName>2531883v1.0:2230198v1.0</PreferredName>
      <PreferredDefinition>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_The grafting of tissues from one individual to another or place to place within a single individual._An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization.</PreferredDefinition>
      <LongName>Hematopoietic Cell Transplantation Institution</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2531883</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12551:C15342</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Stem Cell Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2230198</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41206</PreferredName>
        <Version>1</Version>
        <LongName>Institution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41206</PREFERRED_NAME>
            <LONG_NAME>Institution</LONG_NAME>
            <CON_ID>2228359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2691461</PublicId>
      <PreferredName>DPT_SPC</PreferredName>
      <PreferredDefinition>A specialized division of a large organization._The words or language units by which a thing is known._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Department Name Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2691460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42671:C42614:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Department Name Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42671</PREFERRED_NAME>
            <LONG_NAME>Department</LONG_NAME>
            <CON_ID>2223425</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2691464</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>Organization.name [unit] WHERE Organization [hospital] &gt; OrganizationRelationship &gt; Organization [unit] &gt; Performer &gt; PerformedProcedure AND PerformedProcedure &gt; DefinedProcedure.nameCode = &quot;Perform Overall Hematopoetic Stem Call Transplantation&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the transplant hospit</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the transplant hospital unit name:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other unit name:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the other unit name:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:name</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="219">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2691556</PUBLICID>
    <LONGNAME>Clinical Study Document Revision Letter Sent Investigator Date</LONGNAME>
    <PREFERREDNAME>CS_D_REV_LTR_INVS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date revise and resubmit letter was sent to the investigator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2691554</PublicId>
      <PreferredName>CSDY_DOC_LTR_S_INVST</PreferredName>
      <PreferredDefinition>Information pertaining to a writing that contains information about a type of research study that tests how well new medical treatments or other interventions work in people and an act of alteration involving reconsideration and modification of a a written message transmitted to an individual who conducts scientific research.</PreferredDefinition>
      <LongName>Clinical Study Document Revision Letter Sent Investigator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2689665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Document Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2691552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54087:C70805:C25672:C25936</PreferredName>
        <Version>1</Version>
        <LongName>Revision Letter Sent Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54087</PREFERRED_NAME>
            <LONG_NAME>Revision</LONG_NAME>
            <CON_ID>2475253</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70805</PREFERRED_NAME>
            <LONG_NAME>Letter</LONG_NAME>
            <CON_ID>2691050</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25672</PREFERRED_NAME>
            <LONG_NAME>Send</LONG_NAME>
            <CON_ID>2206250</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25936</PREFERRED_NAME>
            <LONG_NAME>Investigator</LONG_NAME>
            <CON_ID>2202869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Revise and Resubmit Letter Se</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Revise and Resubmit Letter Sent to Investigator Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2487057</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DESK</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DESK Database</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="220">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2691613</PUBLICID>
    <LONGNAME>Clinical Study Document Amendment Review Received Protocol Information Office Date</LONGNAME>
    <PREFERREDNAME>CS_DOC_A_RCVD_PIO_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date the Protocol Information Office (PIO) received the amendment review.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2691611</PublicId>
      <PreferredName>CS_DOC_AMND_RCVD_PIO</PreferredName>
      <PreferredDefinition>Information pertaining to a writing that contains information about a type of research study that tests how well new medical treatments or other interventions work in people that was received and evaluated in the Protocol Information Office (PIO).</PreferredDefinition>
      <LongName>Clinical Study Document Amendment Review Received Protocol Information Office</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2689665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Document Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2691609</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41200:C42729:C25639:C70829</PreferredName>
        <Version>1</Version>
        <LongName>Amendment Review Received Protocol Information Office</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41200</PREFERRED_NAME>
            <LONG_NAME>Amendment</LONG_NAME>
            <CON_ID>2551428</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42729</PREFERRED_NAME>
            <LONG_NAME>Review</LONG_NAME>
            <CON_ID>2202331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70829</PREFERRED_NAME>
            <LONG_NAME>Protocol Information Office</LONG_NAME>
            <CON_ID>2691102</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Amendment Review Received in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Amendment Review Received in PIO Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2487057</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DESK</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DESK Database</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="221">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2691680</PUBLICID>
    <LONGNAME>Prior Chemotherapy Lapatinib Administered Ind-2</LONGNAME>
    <PREFERREDNAME>P_CT_INN_ADM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether there was prior administration of the anticancer drug lapatinib, ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties that reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2691679</PublicId>
      <PreferredName>P_CT_INN_ADMIN</PreferredName>
      <PreferredDefinition>information related to earlier in time or order administration of treatment with anticancer drug lapatinib, ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties that reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases).</PreferredDefinition>
      <LongName>Prior Chemotherapy Lapatinib Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Prior Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2691677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26653:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Lapatinib Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26653</PREFERRED_NAME>
            <LONG_NAME>Lapatinib</LONG_NAME>
            <CON_ID>2646202</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Lapatinib Therapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior Lapatinib Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lapatinib</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="222">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2692983</PUBLICID>
    <LONGNAME>Treatment First Course Systemic Therapy Number Code</LONGNAME>
    <PREFERREDNAME>2692981v1.0:2654171v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Identifies systemic therapeutic procedures administered as part of the first course of treatment at this and all other facilities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2692981</PublicId>
      <PreferredName>2691043v1.0:2692979v1.0</PreferredName>
      <PreferredDefinition>Systemic therapeutic procedures administered as part of the first course of treatment at this and all other facilities.</PreferredDefinition>
      <LongName>Treatment First Course Systemic Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2691043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25509:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure First Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2692979</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15698</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15698</PREFERRED_NAME>
            <LONG_NAME>Systemic Therapy</LONG_NAME>
            <CON_ID>2202843</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2654171</PublicId>
      <PreferredName>2654171v1.0</PreferredName>
      <PreferredDefinition>(sis-TEM-ik) Affecting the entire body._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data. [Explanatory Comment: refer to FORDS for addtional instructions.]</PreferredDefinition>
      <LongName>Systemic Therapy Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2662278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13310:C15368:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Therapy Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13310</PREFERRED_NAME>
            <LONG_NAME>Systemic</LONG_NAME>
            <CON_ID>2204930</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record; death certificate-only cases.</VALUEMEANING>
          <MEANINGDESCRIPTION>It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record; death certificate-only cases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>85</VALIDVALUE>
          <VALUEMEANING>Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Combination of endocrine surgery and/or radiation with a transplant procedure.</VALUEMEANING>
          <MEANINGDESCRIPTION>Combination of endocrine surgery and/or radiation with a transplant procedure. (combination of codes 30 and 10, 11, 12 or 20).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Endocrine surgery and/or endocrine radiation therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Endocrine surgery and/or endocrine radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Stem cell harvest and infusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Stem cell harvest and infusion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Bone marrow transplant procedure was administered, but the type was not specified.</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow transplant procedure was administered, but the type was not specified.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>00</VALIDVALUE>
          <VALUEMEANING>No transplant procedure or endocrine therapy was administered as part of first course therapy; diagnosed at autopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>No transplant procedure or endocrine therapy was administered as part of first course therapy;
diagnosed at autopsy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>87</VALIDVALUE>
          <VALUEMEANING>Hematologic transplant and/or endocrine surgery/radiation was not administered; it was recommended by the patient&#39;s physician, but this treatment was refused by the patient, the patient&#39;s family member, or the patient&#39;s guardian.</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic transplant and/or endocrine surgery/radiation was not administered; it was recommended by the patient&#39;s physician, but this treatment was refused by the patient, the patient&#39;s family member, or the patient&#39;s guardian; refusal noted in patient record.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Bone marrow transplant - autologous</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow transplant - autologous</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Bone marrow transplant - allogeneic</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow transplant - allogeneic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>86</VALIDVALUE>
          <VALUEMEANING>Hematologic transplant and/or endocrine surgery/radiation was not administered.</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient&#39;s physician, but was not administered as part of first-course therapy. No reason was stated in the patient record.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Summary Transplant/Endocri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RX Summary Transplant/Endocrine</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Summ--Transplnt/Endocr Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>If none of these procedures were administered then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FORDS Manual, Revised 2009</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>See FORDS Manual for specifications of codes and data entry rules.</DocumentText>
        <URL>http://www.facs.org/cancer/coc/fords/2009/fords2009.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hematologic Transplant &amp; Endocrine Procedures</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Hematologic Transplant &amp; Endocrine Procedures</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899849</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Caris Registry</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060676</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3595692</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Miraca Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Miraca Registry</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3595693</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3250</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Hematologic Transplant and Endocrine Procedures</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX SUMM--TRANSPLNT/ENDOCR </AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Summ--Transplnt/Endocr</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="223">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2695308</PUBLICID>
    <LONGNAME>HLA-DR Antigen First Antigen Name</LONGNAME>
    <PREFERREDNAME>HLA_DR_1ST_ANTGN_NME</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the 1st HLA-DR antigen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2695306</PublicId>
      <PreferredName>HLA_DR_1ST_ANTGN</PreferredName>
      <PreferredDefinition>Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants._Preceding all others in time or space or degree._Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.</PreferredDefinition>
      <LongName>HLA-DR Antigen First Antigen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2695299</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16692</PreferredName>
        <Version>1</Version>
        <LongName>HLA-DR Antigen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16692</PREFERRED_NAME>
            <LONG_NAME>HLA-DR Antigen</LONG_NAME>
            <CON_ID>2206236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2695121</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C268</PreferredName>
        <Version>1</Version>
        <LongName>First Antigen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C268</PREFERRED_NAME>
            <LONG_NAME>Antigen</LONG_NAME>
            <CON_ID>2202300</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2695232</PublicId>
      <PreferredName>HLA_DR_ANTGN_NME</PreferredName>
      <PreferredDefinition>Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>HLA-DR Antigen Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2695231</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16692:C42614</PreferredName>
        <Version>1</Version>
        <LongName>HLA-DR Antigen Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16692</PREFERRED_NAME>
            <LONG_NAME>HLA-DR Antigen</LONG_NAME>
            <CON_ID>2206236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR1</VALIDVALUE>
          <VALUEMEANING>DR1 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR1 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR10</VALIDVALUE>
          <VALUEMEANING>DR10 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR10 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR103</VALIDVALUE>
          <VALUEMEANING>DR103 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR103 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR11(5)</VALIDVALUE>
          <VALUEMEANING>DR11(5) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR11(5) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR12(5)</VALIDVALUE>
          <VALUEMEANING>DR12(5) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR12(5) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR13(6)</VALIDVALUE>
          <VALUEMEANING>DR13(6) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR13(6) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR14(6)</VALIDVALUE>
          <VALUEMEANING>DR14(6) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR14(6) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR1403</VALIDVALUE>
          <VALUEMEANING>DR1403 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR1403 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR1404</VALIDVALUE>
          <VALUEMEANING>DR1404 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR1404 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR15(2)</VALIDVALUE>
          <VALUEMEANING>DR15(2) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR15(2) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR16(2)</VALIDVALUE>
          <VALUEMEANING>DR16(2) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR16(2) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR17(3)</VALIDVALUE>
          <VALUEMEANING>DR17(3) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR17(3) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR18(3)</VALIDVALUE>
          <VALUEMEANING>DR18(3) Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR18(3) Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR2</VALIDVALUE>
          <VALUEMEANING>DR2 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR2 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR3</VALIDVALUE>
          <VALUEMEANING>DR3 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR3 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR4</VALIDVALUE>
          <VALUEMEANING>DR4 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR4 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR5</VALIDVALUE>
          <VALUEMEANING>DR5 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR5 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR6</VALIDVALUE>
          <VALUEMEANING>DR6 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR6 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR7</VALIDVALUE>
          <VALUEMEANING>DR7 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR7  Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR8</VALIDVALUE>
          <VALUEMEANING>DR8 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR8 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR9</VALIDVALUE>
          <VALUEMEANING>DR9 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DR9 Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRX</VALIDVALUE>
          <VALUEMEANING>DRX Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>DRX Antigen by Serologic Typing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2695254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>First DR  antigen specificity:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>First DR  antigen specificity:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2695308</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value(ANY=&gt;CD) WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;test for HLA-DR Antigen&quot;  AND PerformedClinicalResult.targetBiomarkerCode = &quot;HLA-DR First Antigen&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specificity - 1st antigen</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specificity - 1st antigen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specificity - 1st antigen</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specificity - 1st antigen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2681512</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>New Content R Aley</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2005-HLA Typing Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812690</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2005r1: Confirmation of HLA Typing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HLA Typing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859958</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>hla_srlgy_num_1_dr_atg_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>hla_option_DR_1st_antigen_name</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="224">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2704351</PUBLICID>
    <LONGNAME>Patient Confidential Maiden Name</LONGNAME>
    <PREFERREDNAME>2704349v1.0:2658676v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Maiden name of female patients who are or have been married.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2704349</PublicId>
      <PreferredName>2704319v1.0:2590010v1.0</PreferredName>
      <PreferredDefinition>Maiden name of female patients who are or have been married.</PreferredDefinition>
      <LongName>Patient Confidential Maiden Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2704319</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C16466</PreferredName>
        <Version>1</Version>
        <LongName>Patient Confidentiality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16466</PREFERRED_NAME>
            <LONG_NAME>Confidentiality</LONG_NAME>
            <CON_ID>2493174</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2590010</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25381</PreferredName>
        <Version>1</Version>
        <LongName>Maiden Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25381</PREFERRED_NAME>
            <LONG_NAME>Maiden Name</LONG_NAME>
            <CON_ID>2202915</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2658676</PublicId>
      <PreferredName>2658676v1.1</PreferredName>
      <PreferredDefinition>A woman&#39;s surname before marriage._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Maiden Name Name</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2704318</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25381:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Maiden Name Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25381</PREFERRED_NAME>
            <LONG_NAME>Maiden Name</LONG_NAME>
            <CON_ID>2202915</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Name Maiden</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Name Maiden</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PatientConfidential16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899842</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PatientConfidential18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464315</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NAME--MAIDEN</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2390</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Maiden Name (COC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Maiden Name (CoC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Name--Maiden</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="225">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2704391</PUBLICID>
    <LONGNAME>Patient Confidential Current Address Additional Text</LONGNAME>
    <PREFERREDNAME>2704389v1.0:2658757v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2704389</PublicId>
      <PreferredName>2704319v1.0:2704387v1.0</PreferredName>
      <PreferredDefinition>Additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.</PreferredDefinition>
      <LongName>Patient Confidential Current Address Additional</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2704319</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C16466</PreferredName>
        <Version>1</Version>
        <LongName>Patient Confidentiality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16466</PREFERRED_NAME>
            <LONG_NAME>Confidentiality</LONG_NAME>
            <CON_ID>2493174</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2704387</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25407:C25406</PreferredName>
        <Version>1</Version>
        <LongName>Current Address Additional</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2658757</PublicId>
      <PreferredName>2658757v1.0</PreferredName>
      <PreferredDefinition>The location at which an organization or person can be reached. (from American Heritage Dictionary)_Added; extra. (from American Heritage Dictionary)_Text; the words of something written.</PreferredDefinition>
      <LongName>Address Additional Text</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2658756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25407:C25406:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Address Additional Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Address Current Supplemental</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Address Current Supplemental</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Addr Current--Supplementl Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>This can be used to generate a follow-up inquiry, and must correspond to other fields in the current address. If the patient has multiple tumors, the current address should be the same.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PatientConfidential16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899842</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PatientConfidential18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464315</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Patient Address (Number and Street) Current--Supplemental (COC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2355</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ADDR CURRENT-SUPPLEMENTL</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Patient Address (Number and Street) Current--Supplemental (CoC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Addr Current--Supplementl</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="226">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2705223</PUBLICID>
    <LONGNAME>Thalidomide Dose Clinical Trial Protocol Modification Ind-2</LONGNAME>
    <PREFERREDNAME>THA_DOS_PROT_MOD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether there was a change, addition, or omission, aas part of the action plan for a clinical trial, in the administered amount of Thalidomide, a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties that acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2705222</PublicId>
      <PreferredName>THAL_DOSE_PROT_MOD</PreferredName>
      <PreferredDefinition>information related to the change, addition, or omission, as part of the action plan for a clinical trial, in the administered amount of Thalidomide, a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties that acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.</PreferredDefinition>
      <LongName>Thalidomide Dose Clinical Trial Protocol Modification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2705073</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C870:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Thalidomide Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C870</PREFERRED_NAME>
            <LONG_NAME>Thalidomide</LONG_NAME>
            <CON_ID>2205408</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2666439</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25320:C25572</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Protocol Modification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25572</PREFERRED_NAME>
            <LONG_NAME>Modification</LONG_NAME>
            <CON_ID>2203850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was treatment modification to</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was treatment modification to Thalidomide planned (per protocol)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="227">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2707835</PUBLICID>
    <LONGNAME>Analgesic Agent Use Dose</LONGNAME>
    <PREFERREDNAME>ANALAG_USE_DS</PREFERREDNAME>
    <PREFERREDDEFINITION>the dose in milligrams related to use of compounds that alleviate pain without loss of consciousness.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2717533</PublicId>
      <PreferredName>ANAL_AGT_USE</PreferredName>
      <PreferredDefinition>information related to use of compounds that alleviate pain without loss of consciousness.</PreferredDefinition>
      <LongName>Analgesic Agent Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2705028</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C241</PreferredName>
        <Version>1</Version>
        <LongName>Analgesics</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C241</PREFERRED_NAME>
            <LONG_NAME>Analgesic Agent</LONG_NAME>
            <CON_ID>2202311</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2432128</PublicId>
      <PreferredName>DOSE</PreferredName>
      <PreferredDefinition>the dose in milligrams.</PreferredDefinition>
      <LongName>Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2432127</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How much did you take of this</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much did you take of this medication since treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjunctive General Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="228">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708037</PUBLICID>
    <LONGNAME>Finding Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2707967v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2707967</PublicId>
      <PreferredName>2528734v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Objective evidence of disease perceptible to the examining physician (sign) and subjective evidence of disease perceived by the patient (symptom)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Finding Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528734</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3367</PreferredName>
        <Version>1</Version>
        <LongName>Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Finding Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Finding Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.finding</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000475</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.finding.Finding.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Finding:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="229">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708052</PUBLICID>
    <LONGNAME>Gene Expression Reporter Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2528820v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528820</PublicId>
      <PreferredName>2528722v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Gene Expression Reporter Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528722</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16608:C44255</PreferredName>
        <Version>1</Version>
        <LongName>Gene Expression Reporter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16608</PREFERRED_NAME>
            <LONG_NAME>Gene Expression</LONG_NAME>
            <CON_ID>2203923</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44255</PREFERRED_NAME>
            <LONG_NAME>Reporter Substance</LONG_NAME>
            <CON_ID>2236612</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Expression Reporter Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Expression Reporter Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.gene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000474</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.annotation.gene.GeneExprReporter.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneExprReporter:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="230">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708065</PUBLICID>
    <LONGNAME>Bacterial Artificial Chromosome Reporter Technology Platform java.lang.String</LONGNAME>
    <PREFERREDNAME>2707980v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Based upon the natural F plasmid of E. coli.  Inserts up to 300 Kb can be cloned and stably maintained as circular molecules.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2707980</PublicId>
      <PreferredName>2707928v1.0:2223310v1.0</PreferredName>
      <PreferredDefinition>Based upon the natural F plasmid of E. coli.  Inserts up to 300 Kb can be cloned and stably maintained as circular molecules.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment.</PreferredDefinition>
      <LongName>Bacterial Artificial Chromosome Reporter Technology Platform</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2707928</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1860:C44255</PreferredName>
        <Version>1</Version>
        <LongName>Bacterial Artificial Chromosome Reporter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1860</PREFERRED_NAME>
            <LONG_NAME>Bacterial Artificial Chromosome</LONG_NAME>
            <CON_ID>2528533</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44255</PREFERRED_NAME>
            <LONG_NAME>Reporter Substance</LONG_NAME>
            <CON_ID>2236612</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223310</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45378</PreferredName>
        <Version>1</Version>
        <LongName>Technology Platform</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45378</PREFERRED_NAME>
            <LONG_NAME>Technology Platform Version</LONG_NAME>
            <CON_ID>2223238</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Bacterial Artificial Chromosome Reporter Technology Platform java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Bacterial Artificial Chromosome Reporter Technology Platform java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.snp</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000401</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.annotation.snp.BACCloneReporter.platform</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BACCloneReporter:platform</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="231">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708075</PUBLICID>
    <LONGNAME>DNA Specimen Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2529035v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2529035</PublicId>
      <PreferredName>2528719v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>DNA Specimen Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528719</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C449:C19157</PreferredName>
        <Version>1</Version>
        <LongName>DNA Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C449</PREFERRED_NAME>
            <LONG_NAME>DNA</LONG_NAME>
            <CON_ID>2202485</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element DNA Specimen Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element DNA Specimen Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.study.DNASpecimen.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DNASpecimen:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="232">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711610</PUBLICID>
    <LONGNAME>Peak Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2710853v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The most extreme possible amount or value; the highest point._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2710853</PublicId>
      <PreferredName>2710713v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The most extreme possible amount or value; the highest point._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Peak Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48054</PreferredName>
        <Version>1</Version>
        <LongName>Peak</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48054</PREFERRED_NAME>
            <LONG_NAME>Peak</LONG_NAME>
            <CON_ID>2483456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Peak Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Peak Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Peak.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Peak:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="233">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711736</PUBLICID>
    <LONGNAME>Protein Microarray Microplate Reader Experiment Upload Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2710979v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._To transfer a file or program to a central computer from a smaller computer or a computer at a remote location.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2710979</PublicId>
      <PreferredName>2710728v1.0:2629674v1.0</PreferredName>
      <PreferredDefinition>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._To transfer a file or program to a central computer from a smaller computer or a computer at a remote location.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Protein Microarray Microplate Reader Experiment Upload Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25867:C70661:C42790</PreferredName>
        <Version>1</Version>
        <LongName>Protein Microarray Microplate Reader Experiment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25867</PREFERRED_NAME>
            <LONG_NAME>Protein Microarray</LONG_NAME>
            <CON_ID>2710229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70661</PREFERRED_NAME>
            <LONG_NAME>Microplate Reader</LONG_NAME>
            <CON_ID>2710228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2629674</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48914:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Upload Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48914</PREFERRED_NAME>
            <LONG_NAME>Upload</LONG_NAME>
            <CON_ID>2629623</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Microarray Microplate Reader Experiment Upload Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Microarray Microplate Reader Experiment Upload Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.A2Experiment.uploadDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>A2Experiment:uploadDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="234">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711739</PUBLICID>
    <LONGNAME>Differential In-Gel Electrophoresis Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2710982v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A form of gel electrophoresis where up to three different protein samples can be labeled with fluorescent dyes prior to two-dimensional electrophoresis in the same gel. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye and the imges are superimposed, allowing detection of changes in protein abundance between samples._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2710982</PublicId>
      <PreferredName>2710729v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>A form of gel electrophoresis where up to three different protein samples can be labeled with fluorescent dyes prior to two-dimensional electrophoresis in the same gel. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye and the imges are superimposed, allowing detection of changes in protein abundance between samples._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Differential In-Gel Electrophoresis Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710729</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70654</PreferredName>
        <Version>1</Version>
        <LongName>Differential In-Gel Electrophoresis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70654</PREFERRED_NAME>
            <LONG_NAME>Differential In-Gel Electrophoresis</LONG_NAME>
            <CON_ID>2710244</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Differential In-Gel Electrophoresis Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Differential In-Gel Electrophoresis Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Dige.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Dige:comment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="235">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711797</PUBLICID>
    <LONGNAME>Database Search Programming Parameter Taxon Filter java.lang.String</LONGNAME>
    <PREFERREDNAME>2711040v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.:The activity of looking thoroughly in order to find something or someone; an operation that determines whether one or more of a set of items has a specified property.:A value that is passed to a routine._Ranked categories for the classification of organisms according to their suspected evolutionary relationships.:A higher-order function which takes a predicate and a list and returns those elements of the list for which the predicate is true. It is a means of narrowing the scope of a report by specifying ranges or types of data to include or exclude._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711040</PublicId>
      <PreferredName>2710735v1.0:2710438v1.0</PreferredName>
      <PreferredDefinition>An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.:The activity of looking thoroughly in order to find something or someone; an operation that determines whether one or more of a set of items has a specified property.:A value that is passed to a routine._Ranked categories for the classification of organisms according to their suspected evolutionary relationships.:A higher-order function which takes a predicate and a list and returns those elements of the list for which the predicate is true. It is a means of narrowing the scope of a report by specifying ranges or types of data to include or exclude.</PreferredDefinition>
      <LongName>Database Search Programming Parameter Taxon Filter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710735</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15426:C54117:C48913</PreferredName>
        <Version>1</Version>
        <LongName>Database Search Programming Parameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15426</PREFERRED_NAME>
            <LONG_NAME>Database</LONG_NAME>
            <CON_ID>2228339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54117</PREFERRED_NAME>
            <LONG_NAME>Search</LONG_NAME>
            <CON_ID>2505702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48913</PREFERRED_NAME>
            <LONG_NAME>Programming Parameter</LONG_NAME>
            <CON_ID>2451932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710438</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40098:C45801</PreferredName>
        <Version>1</Version>
        <LongName>Taxon Filter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40098</PREFERRED_NAME>
            <LONG_NAME>Taxon</LONG_NAME>
            <CON_ID>2342211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45801</PREFERRED_NAME>
            <LONG_NAME>Filter</LONG_NAME>
            <CON_ID>2521484</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Database Search Programming Parameter Taxon Filter java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Database Search Programming Parameter Taxon Filter java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.DatabaseSearchParameters.taxonomicalFilters</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DatabaseSearchParameters:taxonomicalFilters</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="236">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711997</PUBLICID>
    <LONGNAME>Protein Data Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711242v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711242</PublicId>
      <PreferredName>2710771v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Protein Data Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710771</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17021:C25474</PreferredName>
        <Version>1</Version>
        <LongName>Protein Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Data Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Data Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Proteins.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Proteins:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="237">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2712035</PUBLICID>
    <LONGNAME>Spot Second Dimension java.lang.Double</LONGNAME>
    <PREFERREDNAME>2711280v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A mark on a substance or body made by foreign matter; a blot; a place discolored._coming next after the first in position in space or time or degree or magnitude.:Dimension; the magnitude of something in a particular direction, especially length or width or height._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711280</PublicId>
      <PreferredName>2710776v1.0:2207728v1.0</PreferredName>
      <PreferredDefinition>A mark on a substance or body made by foreign matter; a blot; a place discolored._coming next after the first in position in space or time or degree or magnitude.:Dimension; the magnitude of something in a particular direction, especially length or width or height.</PreferredDefinition>
      <LongName>Spot Second Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48039</PreferredName>
        <Version>1</Version>
        <LongName>Spot</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48039</PREFERRED_NAME>
            <LONG_NAME>Spot</LONG_NAME>
            <CON_ID>2422621</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C25483</PreferredName>
        <Version>1</Version>
        <LongName>Second Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Spot Second Dimension java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Spot Second Dimension java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Spot.secondDimension</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Spot:secondDimension</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="238">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2712088</PUBLICID>
    <LONGNAME>Specimen Origin Tracer Process Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711333v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The place where something begins or comes from in either the sense of a physical location or a metaphysical source._A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.:A sequence of events which produces some outcome.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711333</PublicId>
      <PreferredName>2710782v1.0:2710602v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The place where something begins or comes from in either the sense of a physical location or a metaphysical source._A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.:A sequence of events which produces some outcome.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Specimen Origin Tracer Process Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C42703</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Origin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42703</PREFERRED_NAME>
            <LONG_NAME>Origin</LONG_NAME>
            <CON_ID>2204026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710602</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2480:C29862:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Tracer Process Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2480</PREFERRED_NAME>
            <LONG_NAME>Tracer</LONG_NAME>
            <CON_ID>2203969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29862</PREFERRED_NAME>
            <LONG_NAME>Process</LONG_NAME>
            <CON_ID>2202628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Origin Tracer Process Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Origin Tracer Process Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.SampleOrigin.taggingProcessIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SampleOrigin:taggingProcessIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="239">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2713393</PUBLICID>
    <LONGNAME>Diagnosis Text Endoscopic Examination Diagnostic Procedure Text</LONGNAME>
    <PREFERREDNAME>2713391v1.0:2644975v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text area for manual documentation from endoscopic examinations that provide information for staging and treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2713391</PublicId>
      <PreferredName>2704295v1.0:2713389v1.0</PreferredName>
      <PreferredDefinition>Manual documentation from all X-rays, scan, and/or other imaging examinations that provide information about staging.</PreferredDefinition>
      <LongName>Diagnosis Text Endoscopic Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2704295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2713389</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16546:C25305</PreferredName>
        <Version>1</Version>
        <LongName>Endoscopy Exam</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16546</PREFERRED_NAME>
            <LONG_NAME>Endoscopic Procedure</LONG_NAME>
            <CON_ID>2204779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2644975</PublicId>
      <PreferredName>2644975v1.0</PreferredName>
      <PreferredDefinition>Methods, procedures, and tests performed to diagnose disease, disordered function, or disability._Text; the words of something written.</PreferredDefinition>
      <LongName>Diagnostic Procedure Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>250</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3015291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18020:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Procedure Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18020</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Procedure</LONG_NAME>
            <CON_ID>2488312</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Text Diagnosis Procedure Scop</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Text Diagnosis Procedure Scopes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242106</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2540</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TEXT--DX PROC--SCOPES</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="240">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2713745</PUBLICID>
    <LONGNAME>Diagnosis Text Neoplasm Primary Site Neoplasm Text</LONGNAME>
    <PREFERREDNAME>2713743v1.0:2644983v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Text area for manual documentation of information regarding the primary site and laterality of the tumor being reported.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2713743</PublicId>
      <PreferredName>2704295v1.0:2713741v1.0</PreferredName>
      <PreferredDefinition>Information that is given only in coded form elsewhere or for which the abstract provides no other place.</PreferredDefinition>
      <LongName>Diagnosis Text Neoplasm Primary Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2704295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2713741</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262:C25251:C37901</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm Primary Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37901</PREFERRED_NAME>
            <LONG_NAME>Site</LONG_NAME>
            <CON_ID>2202394</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2644983</PublicId>
      <PreferredName>2644983v1.1</PreferredName>
      <PreferredDefinition>(TOO-mer) An abnormal mass of tissue that results from excessive cell division. Tumors perform no useful body function. They may be benign (not cancerous) or malignant (cancerous)._Text; the words of something written.</PreferredDefinition>
      <LongName>Neoplasm Text</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3015293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Text Diagnosis Primary Site T</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Text Diagnosis Primary Site Title</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Version 12 Updated Instructions</Name>
        <OrganizationName/>
        <DocumentType>Coding Instructions</DocumentType>
        <DocumentText>The rationale and instructional text for NAACCR elements was significantly updated for Version 12.  Please refer to the documentation for new usage information.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899846</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464320</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>DZ_PRM_SITE_TXT</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Text--Primary Site Title</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2580</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="241">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2714679</PUBLICID>
    <LONGNAME>Nodule Change Previous Computed Tomography Diameter Measurement Percent Number</LONGNAME>
    <PREFERREDNAME>NDUL_C_P_CT_DIAM_PTG</PREFERREDNAME>
    <PREFERREDDEFINITION>Percentage value from the previous CT scan diameter of any dimension of a nodule.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2714675</PublicId>
      <PreferredName>NDUL_C_P_CT_DM_MSRMT</PreferredName>
      <PreferredDefinition>Measurement defining the alteration or modification of the diameter of any dimension of a nodule.</PreferredDefinition>
      <LongName>Nodule Change Previous Computed Tomography Diameter Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2453620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3280</PreferredName>
        <Version>1</Version>
        <LongName>Nodule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3280</PREFERRED_NAME>
            <LONG_NAME>Nodule</LONG_NAME>
            <CON_ID>2202765</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2714673</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25627:C17204:C25285:C2</PreferredName>
        <Version>1</Version>
        <LongName>Change Previous Computed Tomography Diameter Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25627</PREFERRED_NAME>
            <LONG_NAME>Previous</LONG_NAME>
            <CON_ID>2206349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17204</PREFERRED_NAME>
            <LONG_NAME>Computed Tomography</LONG_NAME>
            <CON_ID>2202436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2475074</PublicId>
      <PreferredName>PCT_NUM</PreferredName>
      <PreferredDefinition>Numeric value representing a percentage.</PreferredDefinition>
      <LongName>Percent Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2475073</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48570:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Percent Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48570</PREFERRED_NAME>
            <LONG_NAME>Percent Unit</LONG_NAME>
            <CON_ID>2475072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Change from previous CT scan</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Change from previous CT scan (%)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="242">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2714892</PUBLICID>
    <LONGNAME>PET Blood Glucose Prior To Injection Value</LONGNAME>
    <PREFERREDNAME>PET_BLOOD_GLUCOSE</PREFERREDNAME>
    <PREFERREDDEFINITION>Record blood glucose value measured before administration of imaging agent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACRIN:American College of Radiology Imaging Network</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2714884</PublicId>
      <PreferredName>PET_BLOOD_GLUCOSE</PreferredName>
      <PreferredDefinition>A simple sugar found in the blood prior to a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG) used in an imaging event.</PreferredDefinition>
      <LongName>Positron Emission Tomography (PET)  Blood Glucose Prior To Injection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2230940</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17007</PreferredName>
        <Version>1</Version>
        <LongName>Positron Emission Tomography</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17007</PREFERRED_NAME>
            <LONG_NAME>Positron Emission Tomography</LONG_NAME>
            <CON_ID>2224887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2714888</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12434:C2831:C25629:C28160</PreferredName>
        <Version>1</Version>
        <LongName>Blood Glucose Prior Injection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2831</PREFERRED_NAME>
            <LONG_NAME>Glucose</LONG_NAME>
            <CON_ID>2206226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28160</PREFERRED_NAME>
            <LONG_NAME>Injection Route of Administration</LONG_NAME>
            <CON_ID>2202407</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2685196</PublicId>
      <PreferredName>BLD_GLUCOSE_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity which captures the amount of a simple sugar monosaccharide with a chemical structure of C6H12O6 found circulating in the blood throughout the body.</PreferredDefinition>
      <LongName>Blood Glucose Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>999.9</DisplayFormat>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
      <Representation>
        <PublicId>2685195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12434:C2831:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Blood Glucose Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2831</PREFERRED_NAME>
            <LONG_NAME>Glucose</LONG_NAME>
            <CON_ID>2206226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Blood glucose before injectio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Blood glucose before injection of imaging agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ACRIN FDG PET Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Blood glucose before injection of FDG</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>PET Blood Glucose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Blood glucose measured prior to FDG injection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812731</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FES Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FMISO Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812733</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Virginia Commonwealth University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2879403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>VCU FLT 8029</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2972035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Patient Prep CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3162439</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314439</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging Modality</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Positron Emission Tomography (PET)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3314449</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Patient Prep</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000580</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="243">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2716285</PUBLICID>
    <LONGNAME>Gene Expression Microarray Reporter Nucleotide Sequence Type java.lang.String</LONGNAME>
    <PREFERREDNAME>2716184v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.:A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._The sequence of nucleotide residues along an RNA or DNA chain.:Something distinguishable as an identifiable class based on common qualities._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2716184</PublicId>
      <PreferredName>2716124v1.0:2716109v1.0</PreferredName>
      <PreferredDefinition>Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.:A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._The sequence of nucleotide residues along an RNA or DNA chain.:Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Gene Expression Microarray Reporter Nucleotide Sequence Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2716124</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16608:C44282:C44255</PreferredName>
        <Version>1</Version>
        <LongName>Gene Expression Microarray Reporter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16608</PREFERRED_NAME>
            <LONG_NAME>Gene Expression</LONG_NAME>
            <CON_ID>2203923</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44255</PREFERRED_NAME>
            <LONG_NAME>Reporter Substance</LONG_NAME>
            <CON_ID>2236612</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2716109</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45374:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Nucleotide Sequence Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45374</PREFERRED_NAME>
            <LONG_NAME>Nucleotide Sequence</LONG_NAME>
            <CON_ID>2223191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Expression Microarray Reporter Nucleotide Sequence Type java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Expression Microarray Reporter Nucleotide Sequence Type java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000536</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000541</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000542</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExpressionArrayReporter:sequenceType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.ExpressionArrayReporter.sequenceType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@sequenceType</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="244">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2716313</PUBLICID>
    <LONGNAME>Single Nucleotide Polymorphism Amino Acid Coding Status CodingStatus</LONGNAME>
    <PREFERREDNAME>2716229v1.0:2716253v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population._Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins.:The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis.:A condition or state at a particular time._Coding status</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2716229</PublicId>
      <PreferredName>2514028v1.0:2716118v1.0</PreferredName>
      <PreferredDefinition>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population._Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins.:The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis.:A condition or state at a particular time.</PreferredDefinition>
      <LongName>Single Nucleotide Polymorphism Amino Acid Coding Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2514028</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18279</PreferredName>
        <Version>1</Version>
        <LongName>Single Nucleotide Polymorphism</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18279</PREFERRED_NAME>
            <LONG_NAME>Single Nucleotide Polymorphism</LONG_NAME>
            <CON_ID>2433334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2716118</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C231:C45971:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Amino Acid Coding Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C231</PREFERRED_NAME>
            <LONG_NAME>Amino Acid</LONG_NAME>
            <CON_ID>2342175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45971</PREFERRED_NAME>
            <LONG_NAME>Coding</LONG_NAME>
            <CON_ID>2492757</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2716253</PublicId>
      <PreferredName>2716253v1.0</PreferredName>
      <PreferredDefinition>Coding status</PreferredDefinition>
      <LongName>CodingStatus</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177848</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0332307</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2203010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[Complex]</VALIDVALUE>
          <VALUEMEANING>Complex Single Nucleotide Polymorphism in Coding Sequence</VALUEMEANING>
          <MEANINGDESCRIPTION>Single Nucleotide Polymorphisms in Coding Sequences consist of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that may or may not cause an amino acid change in the protein product and a detectable phenotypic effect.:Hard, involved or complicated, elaborate, having many parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47881, C18518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2716254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NONSYN</VALIDVALUE>
          <VALUEMEANING>Non-synonymous Coding SNP</VALUEMEANING>
          <MEANINGDESCRIPTION>A Non-synonymous Coding SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that causes an alteration of the translation of the affected codon into a different amino acid in the protein product. A missense non-synonymous SNP results in an amino acid change in the protein product due to a codon change, while a nonsense non-synonymous SNP results in a termination codon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2716255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SYNON</VALIDVALUE>
          <VALUEMEANING>Synonymous Coding SNP</VALUEMEANING>
          <MEANINGDESCRIPTION>Synonymous Coding SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that causes no amino acid change in the protein product and no detectable phenotypic effect; a silent mutation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2716256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Single Nucleotide Polymorphism Amino Acid Coding Status CodingStatus does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Single Nucleotide Polymorphism Amino Acid Coding Status CodingStatus does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.SNP.codingStatus</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SNP:codingStatus</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@codingStatus</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="245">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2717505</PUBLICID>
    <LONGNAME>Post Procedure Analgesics Lesser Quantity Patient Compliance Yes No Indicator</LONGNAME>
    <PREFERREDNAME>P_P_A_L_Q_PT_CO_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to patient taking lesser quantity of prescribed analgesic agent.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2705018</PublicId>
      <PreferredName>PP_ANA_L_Q_PTCOMP</PreferredName>
      <PreferredDefinition>information regarding patient lesser quantity taken of prescribed analgesic agent.</PreferredDefinition>
      <LongName>Post Procedure Analgesics Lesser Quantity Patient Compliance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2705006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C25218:C241</PreferredName>
        <Version>1</Version>
        <LongName>Post Procedure Analgesics</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C241</PREFERRED_NAME>
            <LONG_NAME>Analgesic Agent</LONG_NAME>
            <CON_ID>2202311</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2705016</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61422:C25256:C39490</PreferredName>
        <Version>1</Version>
        <LongName>Lesser Quantity Patient Compliance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61422</PREFERRED_NAME>
            <LONG_NAME>Lesser</LONG_NAME>
            <CON_ID>2537013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39490</PREFERRED_NAME>
            <LONG_NAME>Patient Compliance</LONG_NAME>
            <CON_ID>2493492</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you take the medication l</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you take the medication less often than prescribed or recommended</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="246">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2717608</PUBLICID>
    <LONGNAME>Dentist Analgesics Failure Notification Yes No Indicator</LONGNAME>
    <PREFERREDNAME>D_AN_FAIL_NT_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to informing of dentist of lack of effect as the unfavorable and unintended sign associated with the use of an analgesic agent.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2705037</PublicId>
      <PreferredName>DENT_ANA_F_NOT</PreferredName>
      <PreferredDefinition>information regarding informing of dentist of lack of effect as the unfavorable and unintended sign associated with the use of an analgesic agent.</PreferredDefinition>
      <LongName>Dentist Analgesics Failure Notification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443308</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654</PreferredName>
        <Version>1</Version>
        <LongName>Dentist</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2705035</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C241:C25745:C25297</PreferredName>
        <Version>1</Version>
        <LongName>Analgesics Failure Notification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C241</PREFERRED_NAME>
            <LONG_NAME>Analgesic Agent</LONG_NAME>
            <CON_ID>2202311</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25745</PREFERRED_NAME>
            <LONG_NAME>Failure</LONG_NAME>
            <CON_ID>2203812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you have to contact your</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you have to contact your dentist because any pain medication you took was not effective</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjunctive General Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="247">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2721620</PUBLICID>
    <LONGNAME>Patient Person Gender Code</LONGNAME>
    <PREFERREDNAME>PRSN_GENDER_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Text code to specify the classfication of the gender role of a person. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009919</PublicId>
      <PreferredName>PT_GENDER</PreferredName>
      <PreferredDefinition>the classfication of the sex or gender role of the patient.</PreferredDefinition>
      <LongName>Patient Gender</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17357</PreferredName>
        <Version>1</Version>
        <LongName>Gender</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17357</PREFERRED_NAME>
            <LONG_NAME>Gender</LONG_NAME>
            <CON_ID>2202402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2721618</PublicId>
      <PreferredName>PRSN_GENDER_CD</PreferredName>
      <PreferredDefinition>All codes representing the gender of a person._Gender is the assemblage of properties that distinguish people on the basis of their societal roles.</PreferredDefinition>
      <LongName>Person Gender Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2721617</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17357:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Gender Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17357</PREFERRED_NAME>
            <LONG_NAME>Gender</LONG_NAME>
            <CON_ID>2202402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M</VALIDVALUE>
          <VALUEMEANING>Male</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>Female</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Gender</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Gender</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGCI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGCI DLBCL </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179564</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRSN_GENDER_CD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="248">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2724792</PUBLICID>
    <LONGNAME>Investigator Signature Indicator java.lang.String</LONGNAME>
    <PREFERREDNAME>2724672v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a researcher in a clinical trial or clinical study._Individual&#39;s name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions; having a handwritten signature.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether or not certain stated circumstances exist or criteria are satisfied._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2724672</PublicId>
      <PreferredName>2528490v1.0:2724652v1.0</PreferredName>
      <PreferredDefinition>a researcher in a clinical trial or clinical study._Individual&#39;s name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions; having a handwritten signature.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether or not certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Investigator Signature Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528490</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25936</PreferredName>
        <Version>1</Version>
        <LongName>Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25936</PREFERRED_NAME>
            <LONG_NAME>Investigator</LONG_NAME>
            <CON_ID>2202869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2724652</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25678:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Signature Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Investigator Signature Indicator java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Investigator Signature Indicator java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.StudyInvestigator.signatureIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyInvestigator:signatureIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="249">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2724975</PUBLICID>
    <LONGNAME>Person Pregnancy Outcome Type</LONGNAME>
    <PREFERREDNAME>PRSN_PREG_OUTC_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Final result of a pregnancy in a female, regardless of the outcome. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2724964</PublicId>
      <PreferredName>PRSN_PREG_RSL</PreferredName>
      <PreferredDefinition>Person; a human being._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Person Pregnancy Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2724962</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C25742</PreferredName>
        <Version>1</Version>
        <LongName>Person Pregnancy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224045</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2724966</PublicId>
      <PreferredName>PREG_OUTC_TP</PreferredName>
      <PreferredDefinition>The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_The result of an action._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Pregnancy Outcome Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>23</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2724965</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25742:C20200:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Pregnancy Result Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other (specify)</VALIDVALUE>
          <VALUEMEANING>Other (specify)</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Induced Abortion</VALIDVALUE>
          <VALUEMEANING>Induced Abortion</VALUEMEANING>
          <MEANINGDESCRIPTION>Induced Abortion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Live birth</VALIDVALUE>
          <VALUEMEANING>Live birth</VALUEMEANING>
          <MEANINGDESCRIPTION>The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114091</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Currently pregnant</VALIDVALUE>
          <VALUEMEANING>Currently pregnant</VALUEMEANING>
          <MEANINGDESCRIPTION>The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stillbirth</VALIDVALUE>
          <VALUEMEANING>Stillbirth</VALUEMEANING>
          <MEANINGDESCRIPTION>A fetus of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, that is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spontaneous Abortion</VALIDVALUE>
          <VALUEMEANING>Spontaneous Abortion</VALUEMEANING>
          <MEANINGDESCRIPTION>Expulsion of the products of conception before the completion of gestation without deliberate interference.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ectopic</VALIDVALUE>
          <VALUEMEANING>Ectopic Pregnancy</VALUEMEANING>
          <MEANINGDESCRIPTION>A potentially life-threatening condition in which the embryo implants outside the uterine endometrial cavity. Most ectopic pregnancies (&gt;96%) occur in the fallopian tube (PREGNANCY, TUBAL), but they can be in the uterine cornua, cervix, ovary, and abdominal cavity (PREGNANCY, ABDOMINAL).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Does Not Know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multiple Birth</VALIDVALUE>
          <VALUEMEANING>Multiple Birth</VALUEMEANING>
          <MEANINGDESCRIPTION>A single birthing event that produces two or more offspring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3610257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Single live birth</VALIDVALUE>
          <VALUEMEANING>Single Live Birth</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others; exclusive of anyone or anything else.: The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114091, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3610258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Outcome</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Outcome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the outcome of your first pregnancy?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the outcome of your first pregnancy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Northwestern University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812693</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Northwestern U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812694</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NU 0943_011</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="250">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2725493</PUBLICID>
    <LONGNAME>Dyspepsia Adverse Event Present Yes No Indicator</LONGNAME>
    <PREFERREDNAME>DYSP_AE_PRES_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to presence of upset stomach as the unfavorable symptom temporally associated with the use of a medical product or procedure.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2725464</PublicId>
      <PreferredName>DYSP_AE_PRES</PreferredName>
      <PreferredDefinition>information related to presence of upset stomach as the unfavorable symptom temporally associated with the use of a medical product or procedure.</PreferredDefinition>
      <LongName>Dyspepsia Adverse Event Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2725462</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26756:C41331</PreferredName>
        <Version>1</Version>
        <LongName>Dyspepsia Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26756</PREFERRED_NAME>
            <LONG_NAME>Dyspepsia</LONG_NAME>
            <CON_ID>2203694</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Indigestion</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Indigestion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjunctive General Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="251">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2727113</PUBLICID>
    <LONGNAME>Exon Probe Annotation Universal Protein Resource Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2726769v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._UniProt (Universal Protein Resource) is the world&#39;s most comprehensive catalog of information on proteins. It is a central repository of protein sequence and function created by joining the information contained in Swiss-Prot, TrEMBL, and PIR.  The UniProt Knowledgebase (UniProt) is the central access point for extensive curated protein information, including function, classification, and cross-reference.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2726769</PublicId>
      <PreferredName>2726705v1.0:2726679v1.0</PreferredName>
      <PreferredDefinition>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._UniProt (Universal Protein Resource) is the world&#39;s most comprehensive catalog of information on proteins. It is a central repository of protein sequence and function created by joining the information contained in Swiss-Prot, TrEMBL, and PIR.  The UniProt Knowledgebase (UniProt) is the central access point for extensive curated protein information, including function, classification, and cross-reference.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Exon Probe Annotation Universal Protein Resource Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2726705</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13231:C43523:C44272</PreferredName>
        <Version>1</Version>
        <LongName>Exon Probe Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13231</PREFERRED_NAME>
            <LONG_NAME>Exon</LONG_NAME>
            <CON_ID>2240634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43523</PREFERRED_NAME>
            <LONG_NAME>Probe</LONG_NAME>
            <CON_ID>2433326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2726679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43579:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Universal Protein Resource Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43579</PREFERRED_NAME>
            <LONG_NAME>Universal Protein Resource</LONG_NAME>
            <CON_ID>2223223</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exon Probe Annotation Universal Protein Resource Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exon Probe Annotation Universal Protein Resource Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000647</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812742</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000649</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.array.ExonProbeAnnotation.uniprotId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExonProbeAnnotation:uniprotId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="252">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2727152</PUBLICID>
    <LONGNAME>Protocol Application Note java.lang.String</LONGNAME>
    <PREFERREDNAME>2726808v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The use of a protocol with the requisite Parameters and ParameterValues._A brief written record._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2726808</PublicId>
      <PreferredName>2236762v1.0:2423574v1.0</PreferredName>
      <PreferredDefinition>The use of a protocol with the requisite Parameters and ParameterValues._A brief written record.</PreferredDefinition>
      <LongName>Protocol Application Note</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44184</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Application</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44184</PREFERRED_NAME>
            <LONG_NAME>Protocol Application Object</LONG_NAME>
            <CON_ID>2236570</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423574</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42619</PreferredName>
        <Version>1</Version>
        <LongName>Note</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42619</PREFERRED_NAME>
            <LONG_NAME>Note</LONG_NAME>
            <CON_ID>2223997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protocol Application Note java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protocol Application Note java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000255</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812748</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2837741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>protExpress</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>protExpress 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2837744</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2837741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>protExpress</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.protexpress.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2837747</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.protocol.ProtocolApplication.notes</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProtocolApplication:notes</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.protexpress.domain.protocol.ProtocolApplication.notes</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="253">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2728975</PUBLICID>
    <LONGNAME>Menstrual Cycle Flow Type</LONGNAME>
    <PREFERREDNAME>MENCYC_FLOW_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to describe the character of a woman&#39;s menstrual cycle flow. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2728960</PublicId>
      <PreferredName>MENCYC_FLOW_DESC</PreferredName>
      <PreferredDefinition>information related to menstrual cycle description._The motion characteristic of fluids and gases; the amount of fluid that flows in a given time, e.g. through an body organ or part, expressed as volume per unit of time (called also flow rate)._Description; a statement that represents something in words.</PreferredDefinition>
      <LongName>Menstrual Cycle Flow Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2442660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16838</PreferredName>
        <Version>1</Version>
        <LongName>Menstrual Cycle</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16838</PREFERRED_NAME>
            <LONG_NAME>Menstrual Cycle</LONG_NAME>
            <CON_ID>2202740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2728958</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41141:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Flow Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41141</PREFERRED_NAME>
            <LONG_NAME>Flow</LONG_NAME>
            <CON_ID>2203767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2728966</PublicId>
      <PreferredName>MENCYC_FLOW_TP</PreferredName>
      <PreferredDefinition>Regularly recurring physiologic changes in the endometrium during the reproductive period in human females, and some primates, and culminating in partial sloughing of the endometrium (menstruation) in the absence of fertilization. The hormonal changes that lead up to a woman&#39;s having a period. For most women, one cycle takes 28 days._The motion characteristic of fluids and gases; the amount of fluid that flows in a given time, e.g. through an body organ or part, expressed as volume per unit of time (called also flow rate)._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Menstrual Cycle Flow Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2728965</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16838:C41141:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Menstrual Cycle Flow Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16838</PREFERRED_NAME>
            <LONG_NAME>Menstrual Cycle</LONG_NAME>
            <CON_ID>2202740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41141</PREFERRED_NAME>
            <LONG_NAME>Flow</LONG_NAME>
            <CON_ID>2203767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Varies (from cycle to cycle)</VALIDVALUE>
          <VALUEMEANING>Varies from menstrual cycle to cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>Varies from menstrual cycle to cycle</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2728967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pregnant</VALIDVALUE>
          <VALUEMEANING>Pregnant</VALUEMEANING>
          <MEANINGDESCRIPTION>Pregnant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2728968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heavy</VALIDVALUE>
          <VALUEMEANING>Heavy Flow</VALUEMEANING>
          <MEANINGDESCRIPTION>Of comparatively great physical weight or density.: The motion characteristic of fluids and gases; the amount of fluid that flows in a given time, e.g. through an body organ or part, expressed as volume per unit of time (called also flow rate).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41141, C68807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2728969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate Flow</VALUEMEANING>
          <MEANINGDESCRIPTION>Moderate Flow</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2728970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Light</VALIDVALUE>
          <VALUEMEANING>Light Flow</VALUEMEANING>
          <MEANINGDESCRIPTION>Of comparatively little physical weight or density.: The motion characteristic of fluids and gases; the amount of fluid that flows in a given time, e.g. through an body organ or part, expressed as volume per unit of time (called also flow rate).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41141, C68808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2728971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Thinking of the last year, ho</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Thinking of the last year, how would you describe the flow of your period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Northwestern University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812693</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Northwestern U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812694</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NU 0943_011</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="254">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2729085</PUBLICID>
    <LONGNAME>Tissue Donor Research Specimen Identification Number</LONGNAME>
    <PREFERREDNAME>DNR_RSCH_SPCM_ID_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>A unique numeric identifier assigned to the donor&#39;s research sample.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2729078</PublicId>
      <PreferredName>DNR_RSCH_SPCMN</PreferredName>
      <PreferredDefinition>Someone who gives blood or tissue or an organ to be used in another person._Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</PreferredDefinition>
      <LongName>Tissue Donor Research Specimen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512816</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25168</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Donor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25168</PREFERRED_NAME>
            <LONG_NAME>Tissue Donor</LONG_NAME>
            <CON_ID>2202520</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2729068</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15319:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Research Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15319</PREFERRED_NAME>
            <LONG_NAME>Research</LONG_NAME>
            <CON_ID>2202802</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2527837</PublicId>
      <PreferredName>ID_NUMBER</PreferredName>
      <PreferredDefinition>The procedure of having an identity established._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Identification Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2527836</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25737:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Identified Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Research sample donor ID:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Research sample donor ID:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2729085</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>SubjectIdentifier.identifier WHERE SubjectIdentifier &gt; StudySubject [donor] &gt; PerformedSpecimenCollection &gt; Specimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Research sample donor ID:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Research sample donor ID:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2006r1: HSCT Infusion</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_demo_dnr_rsch_smpl_id</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SubjectIdentifier:identifier</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_donor_infant_demo_donor_research_specimen_id</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_dnr_researc_specimen_id</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="255">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2734756</PUBLICID>
    <LONGNAME>Past Integer::4 Week Adult Pain Life Satisfaction Psychometrics Assessment Score</LONGNAME>
    <PREFERREDNAME>PAST_4WK_SAT_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the response to a QLAC question posed to an adult about being content with life over the past four weeks. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2733813</PublicId>
      <PreferredName>PAST_4WK_ADT_SAT</PreferredName>
      <PreferredDefinition>Past; before the present time._A number with no fractional part, including the negative and positive numbers as well as zero.::4_Any period of seven consecutive days._A human who has reached reproductive age._A form of physical intimacy that can be directed to reproduction (one possible goal of sexual intercourse) and/or to enjoying the body of someone else; activities associated with sexual intercourse.__The organic phenomenon that distinguishes living organisms from nonliving ones; showing characteristics of life._The feeling of being pleased and content.</PreferredDefinition>
      <LongName>Past Integer::4 Week Adult Pain Life Satisfaction</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2732119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25609:C45255::4:C29844:C17600</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::4 Week Adult</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::4</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17600</PREFERRED_NAME>
            <LONG_NAME>Adult</LONG_NAME>
            <CON_ID>2204022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2733811</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37987:C62186</PreferredName>
        <Version>1</Version>
        <LongName>Life Self-conscious</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37987</PREFERRED_NAME>
            <LONG_NAME>Alive</LONG_NAME>
            <CON_ID>2210813</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62186</PREFERRED_NAME>
            <LONG_NAME>Self-conscious</LONG_NAME>
            <CON_ID>2503471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>QLAC:Quality of Life in Adult Cancer Survivors Scale</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2734610</PublicId>
      <PreferredName>PSYCH_ASSESS_SC</PreferredName>
      <PreferredDefinition>The science of measuring &quot;psychological&quot; aspects of a person such as knowledge, skills, abilities, or personality. Measurement of these unobservable phenomena is difficult and much of the research and accumulated art of this discipline is designed to reliably define and then quantify._The final result of a determination of the value, significance, or extent of._A number or range of numeric values measuring performance, function, quality, or ability._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Psychometrics Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2732885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17034:C25217:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Psychometrics Assessed Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17034</PREFERRED_NAME>
            <LONG_NAME>Psychometrics</LONG_NAME>
            <CON_ID>2520620</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Frequently</VALUEMEANING>
          <MEANINGDESCRIPTION>Frequently</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>About as often as not</VALUEMEANING>
          <MEANINGDESCRIPTION>About as often as not</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2734611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>SOMETIMES</VALUEMEANING>
          <MEANINGDESCRIPTION>SOMETIMES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Seldom</VALUEMEANING>
          <MEANINGDESCRIPTION>Seldom</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2734612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>I NEVER had an erection when I wanted one </VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>You were content with your li</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>You were content with your life.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="256">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2743711</PUBLICID>
    <LONGNAME>Assessment Disease or Disorder Status Current Chromosome Banding Disease or Disorder Finding Yes No Character Indicator</LONGNAME>
    <PREFERREDNAME>DS_ST_CU_CH_BA_FD_YN</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the current conventional cytogenetic assessment used to assess the disease status show evidence of disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2743700</PublicId>
      <PreferredName>AS_DS_ST_CU_CH_BA_FD</PreferredName>
      <PreferredDefinition>The act of judging the value, significance, or extent of something._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time._Occurring in or belonging to the present time._The treatment of chromosomes to reveal characteristic patterns of horizontal bands.  The banding patterns lend each chromosome a distinctive appearance so the 22 pairs of human nonsex chromosomes and the X and Y chromosomes can be identified and distinguished without ambiguity. Banding also permits the recognition of chromosome deletions (lost segments), chromosome duplications (surplus segments) and other types of structural rearrangements of chromosomes. (MedicineNet.com)._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Clinical, laboratory or molecular evidence, or absence of evidence of disease.</PreferredDefinition>
      <LongName>Assessment Disease or Disorder Status Current Chromosome Banding Disease or Disorder Finding</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2777687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217:C2991:C25688:C25471:C16</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Disease or Disorder Status Current Chromosome Banding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16437</PREFERRED_NAME>
            <LONG_NAME>Chromosome Banding</LONG_NAME>
            <CON_ID>2777686</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2739620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C3367</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the current conventional</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the current conventional cytogenetic assessment used to assess the disease status show evidence of disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was there evidence of disease?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was there evidence of disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="257">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2743833</PUBLICID>
    <LONGNAME>Toothpaste Use Daily Count</LONGNAME>
    <PREFERREDNAME>TOOHPAS_U_DAI_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>to determine the number or amount of treatment every day as related to the use of a substance in paste form containing abrasives used to clean the tooth surface.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2743792</PublicId>
      <PreferredName>TOOTHPASTE_USE</PreferredName>
      <PreferredDefinition>information related to the use of a substance in paste form containing abrasives used to clean the tooth surface.</PreferredDefinition>
      <LongName>Toothpaste Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2743271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73516</PreferredName>
        <Version>1</Version>
        <LongName>Toothpaste</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73516</PREFERRED_NAME>
            <LONG_NAME>Toothpaste</LONG_NAME>
            <CON_ID>2740980</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2743831</PublicId>
      <PreferredName>TX_DAILY_CT</PreferredName>
      <PreferredDefinition>to determine the number or amount of treatment every day.</PreferredDefinition>
      <LongName>Therapy Daily Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2207951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25473:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Daily Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25473</PREFERRED_NAME>
            <LONG_NAME>Daily</LONG_NAME>
            <CON_ID>2204015</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often did the patient sta</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often did the patient state they used the protocol toothpaste per day</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="258">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2747056</PUBLICID>
    <LONGNAME>Concomitant Medication Antiemetic Agent Administered Ind-2</LONGNAME>
    <PREFERREDNAME>CNMD_ANTIE_AD_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the concomitant antiemetic agent (drugs that prevent or reduce nausea and vomiting) being administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2746360</PublicId>
      <PreferredName>CONCOM_MEDS_ANTA_ADM</PreferredName>
      <PreferredDefinition>information related to the concomitant antiemetic agent (drugs that prevent or reduce nausea and vomiting) being administered.</PreferredDefinition>
      <LongName>Concomitant Medication Antiemetic Agent Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206481</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C459</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2746358</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C267:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Antiemetic Agent Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C267</PREFERRED_NAME>
            <LONG_NAME>Antiemetic Agent</LONG_NAME>
            <CON_ID>2206157</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Antiemetics</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Antiemetics</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="259">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2747131</PUBLICID>
    <LONGNAME>Concomitant Medication Granisetron Administered Ind-2</LONGNAME>
    <PREFERREDNAME>CNMD_GRANIS_AD_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the concomitant medication granisetron (a drug that prevents or reduces nausea and vomiting) being administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2746368</PublicId>
      <PreferredName>CONCOM_MEDS_GRAN_ADM</PreferredName>
      <PreferredDefinition>information related to the concomitant medication granisetron (a drug that prevents or reduces nausea and vomiting) being administered.</PreferredDefinition>
      <LongName>Concomitant Medication Granisetron Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206481</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C459</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2746366</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62031:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Granisetron Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62031</PREFERRED_NAME>
            <LONG_NAME>Granisetron</LONG_NAME>
            <CON_ID>2746365</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Granisetron</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Granisetron</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="260">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2747980</PUBLICID>
    <LONGNAME>Course Protocol Agent Duration And Schedule java.lang.String</LONGNAME>
    <PREFERREDNAME>2747719v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.:A medical product, practice, or application that is tested in a clinical trial._The period of time during which something continues.:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:An ordered list of times at which things are planned to occur._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747719</PublicId>
      <PreferredName>2747592v1.0:2747506v1.0</PreferredName>
      <PreferredDefinition>Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.:A medical product, practice, or application that is tested in a clinical trial._The period of time during which something continues.:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:An ordered list of times at which things are planned to occur.</PreferredDefinition>
      <LongName>Course Protocol Agent Duration And Schedule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747592</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25379:C41161</PreferredName>
        <Version>1</Version>
        <LongName>Course Protocol Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41161</PREFERRED_NAME>
            <LONG_NAME>Protocol Agent</LONG_NAME>
            <CON_ID>2390873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2747506</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25330:C37912:C25211</PreferredName>
        <Version>1</Version>
        <LongName>Duration And Schedule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Course Protocol Agent Duration And Schedule java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Course Protocol Agent Duration And Schedule java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813011</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.CourseAgent.durationAndSchedule</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CourseAgent:durationAndSchedule</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="261">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2747999</PUBLICID>
    <LONGNAME>Common Terminology Criteria for Adverse Events Severity/Intensity Scale for Adverse Events Severity Grade Text java.lang.String</LONGNAME>
    <PREFERREDNAME>2747737v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The description of the adverse events, from the Common Terminology Criteria for Adverse Events (CTCAE), used in reporting adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747737</PublicId>
      <PreferredName>2747598v1.0:2228365v1.0</PreferredName>
      <PreferredDefinition>A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.:A scale that defines the degree or state of disease existing in a patient as a result of the occurrence of an adverse event.:Used of the degree of something undesirable e.g. pain or weather; also, strictness.:A position on a scale of intensity or amount or quality._The words of something written.</PreferredDefinition>
      <LongName>Common Terminology Criteria for Adverse Events Severity/Intensity Scale for Adverse Events Severity Grade Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747598</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704:C49705:C25676:C48309</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events Severity/Intensity Scale for Adverse Events Severity Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49705</PREFERRED_NAME>
            <LONG_NAME>Severity/Intensity Scale for Adverse Events</LONG_NAME>
            <CON_ID>2480698</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2228365</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Common Terminology Criteria for Adverse Events Severity/Intensity Scale for Adverse Events Severity Grade Text java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Common Terminology Criteria for Adverse Events Severity/Intensity Scale for Adverse Events Severity Grade Text java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event (grade) grade description (first 120 characters)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Question Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event (grade) grade description (full description)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Question Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event grade description</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event grade description  (first 120 characters):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813011</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4861354</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RAVE Integrations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CtcGrade:displayName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.CtcGrade.text</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CtcGrade:text</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.CtcGrade.displayName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTCAE_SEV_GD_TXT</AlternateName>
        <AlternateNameType>SAE Rave Integration</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AETOX1</AlternateName>
        <AlternateNameType>OID, NRDS Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_AETOX</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPAE_QVAL_AEGRDESC</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="262">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2748002</PUBLICID>
    <LONGNAME>Site Investigator Status Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2747740v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An investigator designated to a specific study location._A condition or state at a particular time.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747740</PublicId>
      <PreferredName>2747600v1.0:2223293v1.0</PreferredName>
      <PreferredDefinition>An investigator designated to a specific study location._A condition or state at a particular time.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Site Investigator Status Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C51873</PreferredName>
        <Version>1</Version>
        <LongName>Site Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51873</PREFERRED_NAME>
            <LONG_NAME>Site Investigator</LONG_NAME>
            <CON_ID>2479855</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Status Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Site Investigator Status Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Site Investigator Status Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813011</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.SiteInvestigator.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SiteInvestigator:statusDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="263">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2748008</PUBLICID>
    <LONGNAME>Severe Adverse Event Report Prior Therapy Verbatim Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2747745v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.:A short textual account; having provided a short account.:An indicator that a person has been previously treated for the same condition or with the same therapy._In precisely the same words used by a writer or speaker.:A written or verbal account, representation, statement, or explanation of something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747745</PublicId>
      <PreferredName>2747603v1.0:2747511v1.0</PreferredName>
      <PreferredDefinition>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.:A short textual account; having provided a short account.:An indicator that a person has been previously treated for the same condition or with the same therapy._In precisely the same words used by a writer or speaker.:A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Severe Adverse Event Report Prior Therapy Verbatim Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747603</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41340:C25375:C16124</PreferredName>
        <Version>1</Version>
        <LongName>Severe Adverse Event Report Prior Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41340</PREFERRED_NAME>
            <LONG_NAME>Severe Adverse Event</LONG_NAME>
            <CON_ID>2389416</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16124</PREFERRED_NAME>
            <LONG_NAME>Prior Therapy</LONG_NAME>
            <CON_ID>2202433</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2747511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54032:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Verbatim Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54032</PREFERRED_NAME>
            <LONG_NAME>Verbatim</LONG_NAME>
            <CON_ID>2653844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Severe Adverse Event Report Prior Therapy Verbatim Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Severe Adverse Event Report Prior Therapy Verbatim Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813011</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.SAEReportPriorTherapy.other</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SAEReportPriorTherapy:other</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="264">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2748064</PUBLICID>
    <LONGNAME>Meddra High Level Group Term Hoechst Adverse Reaction Terminology System Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2747800v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A superordinate descriptor for one or more high level terms (HLT). It is subordinate to System Organ Class (SOC)._A terminology for coding of adverse reactions, developed by Hoechst in 1991.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747800</PublicId>
      <PreferredName>2747549v1.0:2747455v1.0</PreferredName>
      <PreferredDefinition>A superordinate descriptor for one or more high level terms (HLT). It is subordinate to System Organ Class (SOC)._A terminology for coding of adverse reactions, developed by Hoechst in 1991.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Meddra High Level Group Term Hoechst Adverse Reaction Terminology System Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71889</PreferredName>
        <Version>1</Version>
        <LongName>Meddra High Level Group Term</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71889</PREFERRED_NAME>
            <LONG_NAME>MedDRA High Level Group Term</LONG_NAME>
            <CON_ID>2747441</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2747455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71884:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Hoechst Adverse Reaction Terminology System Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71884</PREFERRED_NAME>
            <LONG_NAME>Hoechst Adverse Reaction Terminology System</LONG_NAME>
            <CON_ID>2747432</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Meddra High Level Group Term Hoechst Adverse Reaction Terminology System Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Meddra High Level Group Term Hoechst Adverse Reaction Terminology System Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.meddra</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813009</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.meddra</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HighLevelGroupTerm:hartsCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.meddra.HighLevelGroupTerm.hartsCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="265">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2748120</PUBLICID>
    <LONGNAME>Meddra System Organ Class Hoechst Adverse Reaction Terminology System Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2747856v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Highest level of the terminology, and distinguished by anatomical or physiological system, etiology, or purpose._A terminology for coding of adverse reactions, developed by Hoechst in 1991.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2747856</PublicId>
      <PreferredName>2747548v1.0:2747455v1.0</PreferredName>
      <PreferredDefinition>Highest level of the terminology, and distinguished by anatomical or physiological system, etiology, or purpose._A terminology for coding of adverse reactions, developed by Hoechst in 1991.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Meddra System Organ Class Hoechst Adverse Reaction Terminology System Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747548</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71888</PreferredName>
        <Version>1</Version>
        <LongName>Meddra System Organ Class</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71888</PREFERRED_NAME>
            <LONG_NAME>MedDRA System Organ Class</LONG_NAME>
            <CON_ID>2747440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2747455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71884:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Hoechst Adverse Reaction Terminology System Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71884</PREFERRED_NAME>
            <LONG_NAME>Hoechst Adverse Reaction Terminology System</LONG_NAME>
            <CON_ID>2747432</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Meddra System Organ Class Hoechst Adverse Reaction Terminology System Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Meddra System Organ Class Hoechst Adverse Reaction Terminology System Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.meddra</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813009</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.meddra</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.meddra.SystemOrganClass.hartsCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SystemOrganClass:hartsCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="266">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2750540</PUBLICID>
    <LONGNAME>Psoriatic Arthritis Psoriasis Involvement Occurrence Yes No Character Indicator</LONGNAME>
    <PREFERREDNAME>PS_AR_PS_IN_OC_YNCI</PREFERREDNAME>
    <PREFERREDDEFINITION>Joint inflammation associated with psoriasis._A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Psoriatic lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region; the pathology involves an accelerated epidermopoiesis. Psoriasis is associated with increased risk for melanoma, squamous cell carcinoma, and basal cell carcinoma. --2004_To have a connection by participation or association or use; sharing in an activity or process._An instance of something happening, such as an event or incident._Indicator of Yes or No to a question.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750538</PublicId>
      <PreferredName>PSO_ARTH_PSO_INV_OCC</PreferredName>
      <PreferredDefinition>Joint inflammation associated with psoriasis._A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Psoriatic lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region; the pathology involves an accelerated epidermopoiesis. Psoriasis is associated with increased risk for melanoma, squamous cell carcinoma, and basal cell carcinoma. --2004_To have a connection by participation or association or use; sharing in an activity or process._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Psoriatic Arthritis Psoriasis Involvement Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750536</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61277:C3346:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Psoriatic Arthritis Psoriasis Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61277</PREFERRED_NAME>
            <LONG_NAME>Psoriatic Arthritis</LONG_NAME>
            <CON_ID>2593530</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3346</PREFERRED_NAME>
            <LONG_NAME>Psoriasis</LONG_NAME>
            <CON_ID>2202355</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the psoriatic arthritis /</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the psoriatic arthritis / psoriasis have a particular involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2750540</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>&quot;[IF EXISTS THEN &quot;&quot;true&quot;&quot; ELSE &quot;&quot;false&quot;&quot;] PerformedDiagnosis [primary] &gt; AssessedResultRelationship &gt; PerformedObservation [assessment] &gt; AssessedResultRelationship &gt; PerformedDiagnosis.resultClassificationCode(ANY=&gt;CD).originalText [secondary] {specified involvement}WHERE  PerformedDiagnosis.value [primary] IN( &quot;&quot;psoriatic arthritis &quot;&quot;, &quot;&quot;psoriasis&quot;&quot;) AND PerformedDiagnosis.resultClassificationCode [secondary] = {specified disorder} AND PerformedDiagnosis [primary] &gt; PerformedProcedure [overall HCT process] AND PerformedObservation [assessment] &gt; PerformedClinicalInterpretation.value = &quot;&quot;Involvement&quot;&quot;  AND PerformedObservation [assessment] &gt; DefinedObservation.nameCode = &quot;&quot;Assess Involvement&quot;&quot;&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_ps_dstrct_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_ps_other_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_ps_psoris_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:resultClassificationCode </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="267">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752653</PUBLICID>
    <LONGNAME>Concomitant Intervention or Procedure Complete Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2752137v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._To possess every necessary or normal part or component or step; having come or been brought to a conclusion.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752137</PublicId>
      <PreferredName>2751997v1.0:2475300v1.0</PreferredName>
      <PreferredDefinition>Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._To possess every necessary or normal part or component or step; having come or been brought to a conclusion.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Concomitant Intervention or Procedure Complete Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2751997</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C25218</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Intervention or Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2475300</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Complete Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Concomitant Intervention or Procedure Complete Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Concomitant Intervention or Procedure Complete Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.ConcomitantProcedure.dateComplete</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ConcomitantProcedure:dateComplete</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="268">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752791</PUBLICID>
    <LONGNAME>Disease or Disorder Evaluation Details Other Lymph Node Anatomic Site java.lang.String</LONGNAME>
    <PREFERREDNAME>2752275v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:Particulars considered individually and in relation to a whole._Different than the one(s) previously specified or mentioned.:A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. The lymph nodes consist of special cells that can trap bacteria or cancer cells traveling through the body in lymph.:Named locations of or within the body._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752275</PublicId>
      <PreferredName>2752003v1.0:2751870v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:Particulars considered individually and in relation to a whole._Different than the one(s) previously specified or mentioned.:A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. The lymph nodes consist of special cells that can trap bacteria or cancer cells traveling through the body in lymph.:Named locations of or within the body.</PreferredDefinition>
      <LongName>Disease or Disorder Evaluation Details Other Lymph Node Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2752003</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C25214:C25480</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Evaluation Details</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25480</PREFERRED_NAME>
            <LONG_NAME>Details</LONG_NAME>
            <CON_ID>2203578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751870</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C12745:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Other Lymph Node Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Disease or Disorder Evaluation Details Other Lymph Node Anatomic Site java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Disease or Disorder Evaluation Details Other Lymph Node Anatomic Site java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.DiseaseEvaluationDetail.otherNodalSite</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DiseaseEvaluationDetail:otherNodalSite</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="269">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752845</PUBLICID>
    <LONGNAME>Assessment Head, Ears, Eyes, Nose and Throat Physical Examination java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2752329v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Examination of the body by auscultation, palpation, percussion, inspection, and olfaction.  (Taber&#39;s)_HEENT is the Head, Ears, Eyes, Nose and Throat, and is referred to as a body system on a physical or medical examination.  The term is typically used as &#39;HEENT&#39; in a physician or caregiver notes.:A systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752329</PublicId>
      <PreferredName>2411342v1.0:2751901v1.0</PreferredName>
      <PreferredDefinition>Examination of the body by auscultation, palpation, percussion, inspection, and olfaction.  (Taber&#39;s)_HEENT is the Head, Ears, Eyes, Nose and Throat, and is referred to as a body system on a physical or medical examination.  The term is typically used as &#39;HEENT&#39; in a physician or caregiver notes.:A systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment.</PreferredDefinition>
      <LongName>Assessment Head, Ears, Eyes, Nose and Throat Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411342</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20989</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751901</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42300:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Head, Ears, Eyes, Nose and Throat Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42300</PREFERRED_NAME>
            <LONG_NAME>Head, Ears, Eyes, Nose and Throat</LONG_NAME>
            <CON_ID>2202540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Assessment Head, Ears, Eyes, Nose and Throat Physical Examination java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Assessment Head, Ears, Eyes, Nose and Throat Physical Examination java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.PhysicalExam.HEENT</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhysicalExam:HEENT</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="270">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752847</PUBLICID>
    <LONGNAME>Assessment Height java.lang.Float</LONGNAME>
    <PREFERREDNAME>2752331v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Examination of the body by auscultation, palpation, percussion, inspection, and olfaction.  (Taber&#39;s)_The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752331</PublicId>
      <PreferredName>2411342v1.0:2236635v1.0</PreferredName>
      <PreferredDefinition>Examination of the body by auscultation, palpation, percussion, inspection, and olfaction.  (Taber&#39;s)_The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension.</PreferredDefinition>
      <LongName>Assessment Height</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411342</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20989</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25347</PreferredName>
        <Version>1</Version>
        <LongName>Height</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25347</PREFERRED_NAME>
            <LONG_NAME>Height</LONG_NAME>
            <CON_ID>2202568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Assessment Height java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Assessment Height java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.PhysicalExam.height</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhysicalExam:height</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="271">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752878</PUBLICID>
    <LONGNAME>Radiation Therapy Clinical Study Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2752362v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752362</PublicId>
      <PreferredName>2403872v1.0:2555361v1.0</PreferredName>
      <PreferredDefinition>use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Radiation Therapy Clinical Study Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2555361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Radiation Therapy Clinical Study Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Radiation Therapy Clinical Study Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.RadiationTherapy.studyID</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RadiationTherapy:studyID</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="272">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2753000</PUBLICID>
    <LONGNAME>Hematology Test Chemistry Test Patient Initials java.lang.String</LONGNAME>
    <PREFERREDNAME>2752483v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A laboratory test that has blood as its specimen.:A laboratory test designed for the quantification of a simple organic or inorganic chemical within a biological specimen._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The first letter of a word, especially the first letter of each word in a proper name._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752483</PublicId>
      <PreferredName>2752013v1.0:2751724v1.0</PreferredName>
      <PreferredDefinition>A laboratory test that has blood as its specimen.:A laboratory test designed for the quantification of a simple organic or inorganic chemical within a biological specimen._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The first letter of a word, especially the first letter of each word in a proper name.</PreferredDefinition>
      <LongName>Hematology Test Chemistry Test Patient Initials</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2752013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49286:C49237</PreferredName>
        <Version>1</Version>
        <LongName>Hematology Test Chemistry Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49286</PREFERRED_NAME>
            <LONG_NAME>Hematology Test</LONG_NAME>
            <CON_ID>2751689</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49237</PREFERRED_NAME>
            <LONG_NAME>Chemistry Test</LONG_NAME>
            <CON_ID>2751688</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C25536</PreferredName>
        <Version>1</Version>
        <LongName>Patient Initials</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25536</PREFERRED_NAME>
            <LONG_NAME>Initials</LONG_NAME>
            <CON_ID>2206246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Hematology Test Chemistry Test Patient Initials java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Hematology Test Chemistry Test Patient Initials java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.HematologyChemistry.patientInitial</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HematologyChemistry:patientInitial</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="273">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2753044</PUBLICID>
    <LONGNAME>Therapeutic Procedure Clinical Study Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2752526v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752526</PublicId>
      <PreferredName>2512834v1.0:2555361v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Therapeutic Procedure Clinical Study Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2555361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Therapeutic Procedure Clinical Study Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Therapeutic Procedure Clinical Study Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.Therapy.studyID</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Therapy:studyID</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="274">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756095</PUBLICID>
    <LONGNAME>Immune Cell Function Assay Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2753985v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of laboratory assays that examine the responses of lymphoid or myeloid cells after exposure to an experimental material._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2753985</PublicId>
      <PreferredName>2753772v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A set of laboratory assays that examine the responses of lymphoid or myeloid cells after exposure to an experimental material._A statement or an account describing something.</PreferredDefinition>
      <LongName>Immune Cell Function Assay Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2753772</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73490</PreferredName>
        <Version>1</Version>
        <LongName>Immune Cell Function Assay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73490</PREFERRED_NAME>
            <LONG_NAME>Immune Cell Function Assay</LONG_NAME>
            <CON_ID>2753701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Immune Cell Function Assay Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Immune Cell Function Assay Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.characterization.invitro</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813020</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.invitro</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.characterization.invitro.ImmuneCellFunction.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImmuneCellFunction:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.invitro.ImmuneCellFunction.designMethodsDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImmuneCellFunction:designMethodsDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="275">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756173</PUBLICID>
    <LONGNAME>Polymer Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2754063v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A molecule made up of a linked series of repeated monomers._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2754063</PublicId>
      <PreferredName>2638569v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>A molecule made up of a linked series of repeated monomers._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Polymer Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2638569</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48803</PreferredName>
        <Version>1</Version>
        <LongName>Polymer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48803</PREFERRED_NAME>
            <LONG_NAME>Polymer</LONG_NAME>
            <CON_ID>2612121</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Polymer Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Polymer Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.samplecomposition.base</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813023</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.nanomaterial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.samplecomposition.base.Polymer.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Polymer:createdDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.nanomaterial.Polymer.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="276">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756199</PUBLICID>
    <LONGNAME>Other Target Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2754089v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Different than the one(s) previously specified or mentioned.:An object fixed as a goal or point of examination; something to point at; a destination._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2754089</PublicId>
      <PreferredName>2753800v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned.:An object fixed as a goal or point of examination; something to point at; a destination._A statement or an account describing something.</PreferredDefinition>
      <LongName>Other Target Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2753800</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25702</PreferredName>
        <Version>1</Version>
        <LongName>Other Target</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Other Target Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Other Target Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.samplecomposition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813026</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.function</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915887</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.samplecomposition.OtherTarget.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OtherTarget:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.function.OtherTarget.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="277">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756231</PUBLICID>
    <LONGNAME>Imaging Technology Function Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2754121v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any of a number of technologies that permits the visualization and acquisition of images into a physical or electronic record.:The normal action performed by a structure or device._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2754121</PublicId>
      <PreferredName>2753799v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Any of a number of technologies that permits the visualization and acquisition of images into a physical or electronic record.:The normal action performed by a structure or device._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Imaging Technology Function Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2753799</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18843:C25518</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technology Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18843</PREFERRED_NAME>
            <LONG_NAME>Imaging Technology</LONG_NAME>
            <CON_ID>2615877</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Imaging Technology Function Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Imaging Technology Function Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.samplecomposition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813026</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.function</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915887</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.samplecomposition.ImagingFunction.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagingFunction:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.function.ImagingFunction.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="278">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2760788</PUBLICID>
    <LONGNAME>Gastrointestinal Disorder Diagnosis Indicator</LONGNAME>
    <PREFERREDNAME>2760733v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Diseases of the digestive tract (oral cavity to anus) and associated organs (salivary glands, liver, pancreas)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Indicator of Yes, No, Unknown, Not Done, or Not Applicable to a question.[manually curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760733</PublicId>
      <PreferredName>2970272v1.0:2239981v1.0</PreferredName>
      <PreferredDefinition>Diseases of the digestive tract (oral cavity to anus) and associated organs (salivary glands, liver, pancreas)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Gastrointestinal Disorder Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2970272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2990</PreferredName>
        <Version>1</Version>
        <LongName>Gastrointestinal Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2990</PREFERRED_NAME>
            <LONG_NAME>Digestive System Disorder</LONG_NAME>
            <CON_ID>2469346</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the gastrointestinal diso</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the gastrointestinal disorder have a specific diagnosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2000r1: Recipient Baseline Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964872</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coex_dis_gi_crohns_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coex_dis_gi_gerd_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coex_dis_gi_othr_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coex_dis_gi_pud_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coex_dis_gi_ulcer_col_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="279">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2761453</PUBLICID>
    <LONGNAME>Vaginal Brachytherapy Intracavitary Perpendicular Axis Middle Administered Dose</LONGNAME>
    <PREFERREDNAME>V_BRT_I_P_M_ADM_DOSE</PREFERREDNAME>
    <PREFERREDDEFINITION>the intracavitary vaginal brachytherapy dose at 0.5 cm from the surface of the applicator. </PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2761307</PublicId>
      <PreferredName>VAG_BRT_IC_PA_M_ADM</PreferredName>
      <PreferredDefinition>information relating to intracavitary (administration of a drug within any natural, nonpathologic cavity, such as that of cervix, uterus, or penis) vaginal brachytherapy administered to the axis perpendicular (a straight line through a body or figure that is at a right angle to a given line or plane) to the midpoint (an area that is approximately central within some larger region) of the applicator.</PreferredDefinition>
      <LongName>Vaginal Brachytherapy Intracavitary Perpendicular Axis Middle Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206688</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13309:C15195</PreferredName>
        <Version>1</Version>
        <LongName>Vaginal Brachytherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13309</PREFERRED_NAME>
            <LONG_NAME>Vaginal</LONG_NAME>
            <CON_ID>2206267</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15195</PREFERRED_NAME>
            <LONG_NAME>Brachytherapy</LONG_NAME>
            <CON_ID>2202699</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2761328</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38231:C54649:C25569:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Intracavitary Route of Administration Perpendicular Axis Middle Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38231</PREFERRED_NAME>
            <LONG_NAME>Intracavitary Route of Administration</LONG_NAME>
            <CON_ID>2452908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54649</PREFERRED_NAME>
            <LONG_NAME>Perpendicular Axis</LONG_NAME>
            <CON_ID>2479358</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25569</PREFERRED_NAME>
            <LONG_NAME>Middle</LONG_NAME>
            <CON_ID>2204826</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201467</PublicId>
      <PreferredName>BRT_PRESC_DOSE</PreferredName>
      <PreferredDefinition>the prescribed dose of brachytherapy.</PreferredDefinition>
      <LongName>Brachytherapy Prescribed Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>2</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184291</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dose</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Vaginal dose at 0.5 cm</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Vaginal dose at 0.5 cm</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total vaginal dose at  0.5 cm</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total vaginal dose at  0.5 cm</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>V_BRT_I_P_M_ADM_DOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="280">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2761459</PUBLICID>
    <LONGNAME>Radiation Oncologist Person E-mail Address Text</LONGNAME>
    <PREFERREDNAME>RO_PERSON_EMAIL_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field for the telecommunications location to which electronic mail can be delivered to the radiation oncologist involved in clinical study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2761313</PublicId>
      <PreferredName>RO_PERS_EMAILAD</PreferredName>
      <PreferredDefinition>informaton relating to the telecommunications location to which electronic mail can be delivered to the radiation oncologist (a doctor who specializes in using radiation to treat cancer) involved in clinical study.</PreferredDefinition>
      <LongName>Radiation Oncologist Person E-mail Address</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008544</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TELECOMMUNICATIONS</PreferredName>
        <Version>1</Version>
        <LongName>Telecommunications</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2761311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17833:C25190</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Oncologist Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17833</PREFERRED_NAME>
            <LONG_NAME>Radiation Oncologist</LONG_NAME>
            <CON_ID>2405366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223457</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42775</PreferredName>
        <Version>1</Version>
        <LongName>Email Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42775</PREFERRED_NAME>
            <LONG_NAME>E-mail Address</LONG_NAME>
            <CON_ID>2223429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2484074</PublicId>
      <PreferredName>EMAIL_ADDR_TXT</PreferredName>
      <PreferredDefinition>The string of characters that represents an electronic mail address. [Explanatory comment:  The format for this value domain is the SMTP standard local-part@domain]</PreferredDefinition>
      <LongName>Email Address Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008544</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TELECOMMUNICATIONS</PreferredName>
        <Version>1</Version>
        <LongName>Telecommunications</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>320</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radiation Oncologist&#39;s E-mail</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Radiation Oncologist&#39;s E-mail address</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RO_PERSON_EMAIL_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="281">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2768504</PUBLICID>
    <LONGNAME>Mini-Mental Status Exam Outcome</LONGNAME>
    <PREFERREDNAME>MMSE_OUTC</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to describe the final result of the Folstein Mini-Mental State Exam (MMSE). [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2768464</PublicId>
      <PreferredName>MMSE_OUTC</PreferredName>
      <PreferredDefinition>Conceptual functions or thinking in all its forms. (NCI)_A condition or state at a particular time._An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s)_Outcome; a phenomenon that follows and is caused by some previous phenomenon._A brief quantitative test used for assessing cognitive function in adults.</PreferredDefinition>
      <LongName>Mini-Mental Status Exam Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2774533</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74982</PreferredName>
        <Version>1</Version>
        <LongName>Mini-Mental Status Exam</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74982</PREFERRED_NAME>
            <LONG_NAME>Mini-Mental Status Exam</LONG_NAME>
            <CON_ID>2768589</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224045</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2768466</PublicId>
      <PreferredName>PSYCH_EXAM_OUTC</PreferredName>
      <PreferredDefinition>The science of measuring &quot;psychological&quot; aspects of a person such as knowledge, skills, abilities, or personality. Measurement of these unobservable phenomena is difficult and much of the research and accumulated art of this discipline is designed to reliably define and then quantify._An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s)_Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Psychometrics Exam Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2768465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17034:C25305:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Psychometrics Exam Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17034</PREFERRED_NAME>
            <LONG_NAME>Psychometrics</LONG_NAME>
            <CON_ID>2520620</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Assessed</VALIDVALUE>
          <VALUEMEANING>No Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Having determined the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2768467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MMSE Mental Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>MMSE Mental Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="282">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2769129</PUBLICID>
    <LONGNAME>Contributing Cause of Death Reason Assessment Other Specify</LONGNAME>
    <PREFERREDNAME>2769112v1.5:2194376v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the contributing cause of death.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2769112</PublicId>
      <PreferredName>4731571v1.0:2390595v1.0</PreferredName>
      <PreferredDefinition>The part played by somebody or something in bringing about an end or result._The circumstance or condition that results in the death of a living being._An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Contributing Cause of Death Reason</LongName>
      <Version>1.5</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4731571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61412:C81239</PreferredName>
        <Version>1</Version>
        <LongName>Contribution Cause of Death</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61412</PREFERRED_NAME>
            <LONG_NAME>Contribution</LONG_NAME>
            <CON_ID>2512710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81239</PREFERRED_NAME>
            <LONG_NAME>Cause of Death</LONG_NAME>
            <CON_ID>2958299</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2390595</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194376</PublicId>
      <PreferredName>ASSESS_OTHER_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to other specified assessment.</PreferredDefinition>
      <LongName>Assessment Other Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify contributing cause of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify contributing cause of death:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2900r1: Recipient Death Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964926</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_CODM_contrb_cause_dth_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_CODM_contrb_cause_dth_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_SRV_contrb_cause_dth_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>death_mul_cod_contrb_cod_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>death_ccod_contr_cause_dth_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_SRV_contrb_cause_dth_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalInterpretation:value</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="283">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2769791</PUBLICID>
    <LONGNAME>Caries Proximal Width Physical Examination Maximum Measurement</LONGNAME>
    <PREFERREDNAME>CA_PROCX_WID_PE_M_MS</PREFERREDNAME>
    <PREFERREDDEFINITION>the determination of the size or magnitude of the largest possible quantity as related to width of the proximal (area in mesial or distal surface of a tooth) to the axial wall (near pulpal wall parallel with long axis of the tooth) that has the decay of a tooth, in which it becomes softened, discolored, and/or porous.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2769771</PublicId>
      <PreferredName>CAR_PROX_WTH_PE</PreferredName>
      <PreferredDefinition>information related to width of the proximal (area in mesial or distal surface of a tooth) to the axial wall (near pulpal wall parallel with long axis of the tooth) that has the decay of a tooth, in which it becomes softened, discolored, and/or porous.</PreferredDefinition>
      <LongName>Caries Proximal Width Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52593</PreferredName>
        <Version>1</Version>
        <LongName>Caries</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52593</PREFERRED_NAME>
            <LONG_NAME>Caries</LONG_NAME>
            <CON_ID>2443118</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2769769</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25236:C25345:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Proximal Width Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25236</PREFERRED_NAME>
            <LONG_NAME>Proximal</LONG_NAME>
            <CON_ID>2205253</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25345</PREFERRED_NAME>
            <LONG_NAME>Width</LONG_NAME>
            <CON_ID>2203977</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2520484</PublicId>
      <PreferredName>CAR_MAX_DPTH_MEASUR</PreferredName>
      <PreferredDefinition>the determination of the size or magnitude of the largest possible quantity to the extent downward or inward of decay of a tooth, in which it becomes softened, discolored, and/or porous.</PreferredDefinition>
      <LongName>Caries Maximum Depth Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat>9999999</DisplayFormat>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2520483</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C25333:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Depth Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25333</PREFERRED_NAME>
            <LONG_NAME>Depth</LONG_NAME>
            <CON_ID>2203893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Greatest proximal width</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Greatest proximal width</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="284">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2770783</PUBLICID>
    <LONGNAME>Physician Person Verification Identifier Name</LONGNAME>
    <PREFERREDNAME>DR_PER_VERIF_ID_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>the name of the doctor, a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon, responsible for verifying, supported or established by evidence or proof, of clinical data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2770772</PublicId>
      <PreferredName>DR_PERS_VER_ID</PreferredName>
      <PreferredDefinition>information related to the name or identifier of the doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon, responsible for verifying, supported or established by evidence or proof, of clinical data.</PreferredDefinition>
      <LongName>Physician Person Verification Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2525300</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25741:C25190</PreferredName>
        <Version>1</Version>
        <LongName>Physician Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25741</PREFERRED_NAME>
            <LONG_NAME>Physician</LONG_NAME>
            <CON_ID>2202785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2770770</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45513:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Verification Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45513</PREFERRED_NAME>
            <LONG_NAME>Verification</LONG_NAME>
            <CON_ID>2673245</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018284</PublicId>
      <PreferredName>INDS_NAME</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Individuals Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other Physician</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Verifying physician</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Verifying physician</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Name of MD who verified response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104880</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0227G</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104881</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0237</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104882</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0265</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0230D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104893</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0231D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104894</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0238</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104895</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0250</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104903</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0273</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-9923</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0254</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0264</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104939</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0268</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104940</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1201</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104994</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0269</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104995</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1008</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0912</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0839</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0937</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1106</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171058</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0724</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171059</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1010</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0534</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171063</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0815</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0926</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171066</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1119</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1114</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1122</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171135</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4471913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE2</ClassificationSchemeItemType>
        <CsiPublicId>4514847</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000081</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000082</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000162</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0267</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0273</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000164</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0273</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000165</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000281</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0280</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000282</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000284</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0235</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000287</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0213</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000288</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000345</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000346</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000426</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000427</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000430</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0257</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000501</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000591</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0255</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000592</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-9923</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000692</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-9923</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000693</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DR_PER_VERIF_ID_NM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VERIFYING_MD_NAME</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="285">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771279</PUBLICID>
    <LONGNAME>Exon Probe Annotation DNA Sequence End java.lang.Long</LONGNAME>
    <PREFERREDNAME>2771097v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._The sequence of nucleotide residues along a DNA chain.:The point or place at which something terminates in time, space, or extent._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771097</PublicId>
      <PreferredName>2726705v1.0:2771062v1.0</PreferredName>
      <PreferredDefinition>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._The sequence of nucleotide residues along a DNA chain.:The point or place at which something terminates in time, space, or extent.</PreferredDefinition>
      <LongName>Exon Probe Annotation DNA Sequence End</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2726705</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13231:C43523:C44272</PreferredName>
        <Version>1</Version>
        <LongName>Exon Probe Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13231</PREFERRED_NAME>
            <LONG_NAME>Exon</LONG_NAME>
            <CON_ID>2240634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43523</PREFERRED_NAME>
            <LONG_NAME>Probe</LONG_NAME>
            <CON_ID>2433326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13299:C25496</PreferredName>
        <Version>1</Version>
        <LongName>DNA Sequence End</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13299</PREFERRED_NAME>
            <LONG_NAME>DNA Sequence</LONG_NAME>
            <CON_ID>2423567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exon Probe Annotation DNA Sequence End java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exon Probe Annotation DNA Sequence End java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812742</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000649</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.array.ExonProbeAnnotation.stop</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExonProbeAnnotation:stop</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="286">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771391</PUBLICID>
    <LONGNAME>Microarray Data Quantitation Type Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2771209v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A method for calculating a single datum of the matrix (e.g. raw intensity, background, error)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771209</PublicId>
      <PreferredName>2771083v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A method for calculating a single datum of the matrix (e.g. raw intensity, background, error)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Microarray Data Quantitation Type Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2771083</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C25474:C43447</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Data Quantitation Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43447</PREFERRED_NAME>
            <LONG_NAME>Quantitation Type</LONG_NAME>
            <CON_ID>2236561</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Data Quantitation Type Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Data Quantitation Type Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812744</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000406</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000410</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.data.QuantitationType.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QuantitationType:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="287">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771440</PUBLICID>
    <LONGNAME>Address Part Life Sciences Identifier Entity Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2771251v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The location at which an organization or person can be reached. (from American Heritage Dictionary)_One of the portions into which something is regarded as divided and which together constitute a whole.:A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771251</PublicId>
      <PreferredName>2341906v1.0:2771057v1.0</PreferredName>
      <PreferredDefinition>The location at which an organization or person can be reached. (from American Heritage Dictionary)_One of the portions into which something is regarded as divided and which together constitute a whole.:A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Address Part Life Sciences Identifier Entity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2341906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25407</PreferredName>
        <Version>1</Version>
        <LongName>Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771057</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45313:C47841:C51070:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Part Life Sciences Identifier Entity Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45313</PREFERRED_NAME>
            <LONG_NAME>Part</LONG_NAME>
            <CON_ID>2405237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Address Part Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Address Part Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812743</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.contact.Address.lsidObjectId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address:lsidObjectId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="288">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771444</PUBLICID>
    <LONGNAME>Microarray Image CaBIG Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2771255v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:Any record of an imaging event whether physical or electronic._A globally unique identifier deployed by systems that are compatible with the caGrid._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771255</PublicId>
      <PreferredName>2771076v1.0:2726661v1.0</PreferredName>
      <PreferredDefinition>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:Any record of an imaging event whether physical or electronic._A globally unique identifier deployed by systems that are compatible with the caGrid.</PreferredDefinition>
      <LongName>Microarray Image CaBIG Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2771076</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C48179</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2726661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63540</PreferredName>
        <Version>1</Version>
        <LongName>CaBIG Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63540</PREFERRED_NAME>
            <LONG_NAME>caBIG Identifier</LONG_NAME>
            <CON_ID>2542033</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Image CaBIG Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Image CaBIG Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812744</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000406</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000410</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.data.Image.caBigId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Image:caBigId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="289">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771455</PUBLICID>
    <LONGNAME>Microarray Design Part Life Sciences Identifier Namespace java.lang.String</LONGNAME>
    <PREFERREDNAME>2771266v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:The act of working out the form of something (as by making a sketch or outline or plan) or the result of this activity._One of the portions into which something is regarded as divided and which together constitute a whole.:A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771266</PublicId>
      <PreferredName>2726696v1.0:2771056v1.0</PreferredName>
      <PreferredDefinition>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:The act of working out the form of something (as by making a sketch or outline or plan) or the result of this activity._One of the portions into which something is regarded as divided and which together constitute a whole.:A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)</PreferredDefinition>
      <LongName>Microarray Design Part Life Sciences Identifier Namespace</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2726696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C43358</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Design</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43358</PREFERRED_NAME>
            <LONG_NAME>Design</LONG_NAME>
            <CON_ID>2220104</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45313:C47841:C42699</PreferredName>
        <Version>1</Version>
        <LongName>Part Life Sciences Identifier Namespace</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45313</PREFERRED_NAME>
            <LONG_NAME>Part</LONG_NAME>
            <CON_ID>2405237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42699</PREFERRED_NAME>
            <LONG_NAME>Namespace</LONG_NAME>
            <CON_ID>2222837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Design Part Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Design Part Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812742</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.array.ArrayDesign.lsidNamespace</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ArrayDesign:lsidNamespace</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="290">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771612</PUBLICID>
    <LONGNAME>Scientific Publication Digital Object Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2771595v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._A unique code used by publishers in the identification and exchange of the content of a digital object, such as a journal article, web document, or other item of intellectual property. The DOI consists of two parts: a prefix assigned to each publisher by the administrative DOI agency and a suffix assigned by the publisher that may be any code the publisher chooses._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771595</PublicId>
      <PreferredName>2224105v1.0:2726691v1.0</PreferredName>
      <PreferredDefinition>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._A unique code used by publishers in the identification and exchange of the content of a digital object, such as a journal article, web document, or other item of intellectual property. The DOI consists of two parts: a prefix assigned to each publisher by the administrative DOI agency and a suffix assigned by the publisher that may be any code the publisher chooses.</PreferredDefinition>
      <LongName>Scientific Publication Digital Object Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19026</PreferredName>
        <Version>1</Version>
        <LongName>Scientific Publication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19026</PREFERRED_NAME>
            <LONG_NAME>Scientific Publication</LONG_NAME>
            <CON_ID>2223990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2726691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71462</PreferredName>
        <Version>1</Version>
        <LongName>Digital Object Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71462</PREFERRED_NAME>
            <LONG_NAME>Digital Object Identifier</LONG_NAME>
            <CON_ID>2726659</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Scientific Publication Digital Object Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Scientific Publication Digital Object Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813019</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.common.Publication.digitalObjectId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Publication:digitalObjectId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="291">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2772928</PUBLICID>
    <LONGNAME>Term Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2772284v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A word or expression used for some particular thing._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772284</PublicId>
      <PreferredName>2726734v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>A word or expression used for some particular thing._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Term Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2726734</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45559</PreferredName>
        <Version>1</Version>
        <LongName>Term</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Term Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Term Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Word:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.Word.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="292">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2772975</PUBLICID>
    <LONGNAME>Contact Information Status java.lang.String</LONGNAME>
    <PREFERREDNAME>2772330v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information regarding the means of contacting a person or group._A condition or state at a particular time._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772330</PublicId>
      <PreferredName>2772232v1.0:2320064v1.0</PreferredName>
      <PreferredDefinition>Information regarding the means of contacting a person or group._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Contact Information Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772232</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60776</PreferredName>
        <Version>1</Version>
        <LongName>Contact Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60776</PREFERRED_NAME>
            <LONG_NAME>Contact Information</LONG_NAME>
            <CON_ID>2751571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Contact Information Status java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Contact Information Status java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ContactInformation:status</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.ContactInformation.status</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="293">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773163</PUBLICID>
    <LONGNAME>Cell Specimen Cell Culture Growth Medium Supplement java.lang.String</LONGNAME>
    <PREFERREDNAME>2772513v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._General term referring to the maintenance of cell strains or lines in the laboratory.:A process of becoming larger or longer or more numerous.:A substance holding another substance in solution or suspension.:Something added to complete a thing, make up for a deficiency, or extend or strengthen the whole; serving to complete or make an addition._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772513</PublicId>
      <PreferredName>2206545v1.0:2772215v1.0</PreferredName>
      <PreferredDefinition>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._General term referring to the maintenance of cell strains or lines in the laboratory.:A process of becoming larger or longer or more numerous.:A substance holding another substance in solution or suspension.:Something added to complete a thing, make up for a deficiency, or extend or strengthen the whole; serving to complete or make an addition.</PreferredDefinition>
      <LongName>Cell Specimen Cell Culture Growth Medium Supplement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206545</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12508:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Cell Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2772215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16396:C64379:C48164:C68641</PreferredName>
        <Version>1</Version>
        <LongName>Cell Culture Growth Medium Supplement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16396</PREFERRED_NAME>
            <LONG_NAME>Cell Culture</LONG_NAME>
            <CON_ID>2523384</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64379</PREFERRED_NAME>
            <LONG_NAME>Growth</LONG_NAME>
            <CON_ID>2612128</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48164</PREFERRED_NAME>
            <LONG_NAME>Medium</LONG_NAME>
            <CON_ID>2513277</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68641</PREFERRED_NAME>
            <LONG_NAME>Supplement</LONG_NAME>
            <CON_ID>2660075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cell Specimen Cell Culture Growth Medium Supplement java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cell Specimen Cell Culture Growth Medium Supplement java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.CellSpecimen.cellCultureGrowthMediumSupplement</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CellSpecimen:cellCultureGrowthMediumSupplement</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="294">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773263</PUBLICID>
    <LONGNAME>Standard Operating Procedure Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2772613v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An established procedure to be followed in carrying out a given operation or in a given situation._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772613</PublicId>
      <PreferredName>2772260v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>An established procedure to be followed in carrying out a given operation or in a given situation._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Standard Operating Procedure Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48443</PreferredName>
        <Version>1</Version>
        <LongName>Standard Operating Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48443</PREFERRED_NAME>
            <LONG_NAME>Standard Operating Procedure</LONG_NAME>
            <CON_ID>2612106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Standard Operating Procedure Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Standard Operating Procedure Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.SOP.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SOP:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="295">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773267</PUBLICID>
    <LONGNAME>Note Content java.lang.String</LONGNAME>
    <PREFERREDNAME>2772617v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A brief written record._Everything that is included in a collection, container, or communication._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772617</PublicId>
      <PreferredName>2772261v1.0:2516606v1.0</PreferredName>
      <PreferredDefinition>A brief written record._Everything that is included in a collection, container, or communication.</PreferredDefinition>
      <LongName>Note Content</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42619</PreferredName>
        <Version>1</Version>
        <LongName>Note</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42619</PREFERRED_NAME>
            <LONG_NAME>Note</LONG_NAME>
            <CON_ID>2223997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2516606</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44476</PreferredName>
        <Version>1</Version>
        <LongName>Content</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44476</PREFERRED_NAME>
            <LONG_NAME>Content</LONG_NAME>
            <CON_ID>2236544</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Note Content java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Note Content java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.Notes.content</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Notes:content</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="296">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773281</PUBLICID>
    <LONGNAME>Electronic Document Suffix Display Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2772631v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Material recorded in a format that requires an electronic device to view or modify the content.:An affix occurring at the end of a word, word base, phrase, or name._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772631</PublicId>
      <PreferredName>2772262v1.0:2231629v1.0</PreferredName>
      <PreferredDefinition>Material recorded in a format that requires an electronic device to view or modify the content.:An affix occurring at the end of a word, word base, phrase, or name._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Electronic Document Suffix Display Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772262</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73620:C49106</PreferredName>
        <Version>1</Version>
        <LongName>Electronic Document Suffix</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73620</PREFERRED_NAME>
            <LONG_NAME>Electronic Document</LONG_NAME>
            <CON_ID>2772172</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49106</PREFERRED_NAME>
            <LONG_NAME>Suffix</LONG_NAME>
            <CON_ID>2493180</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25485:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Display Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25485</PREFERRED_NAME>
            <LONG_NAME>Display</LONG_NAME>
            <CON_ID>2203905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Electronic Document Suffix Display Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Electronic Document Suffix Display Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.FileExtension.displayName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FileExtension:displayName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="297">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773341</PUBLICID>
    <LONGNAME>Biologically-Derived Material Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2772688v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Important substances derived from living organisms such as cells, tissues, proteins, and DNA._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772688</PublicId>
      <PreferredName>2236707v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>Important substances derived from living organisms such as cells, tissues, proteins, and DNA._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Biologically-Derived Material Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236707</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43376</PreferredName>
        <Version>1</Version>
        <LongName>Biologically-Derived Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43376</PREFERRED_NAME>
            <LONG_NAME>Biologically-Derived Material</LONG_NAME>
            <CON_ID>2236534</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biologically-Derived Material Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biologically-Derived Material Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BioSpecimen:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.BioSpecimen.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="298">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773353</PUBLICID>
    <LONGNAME>Molecule Specimen Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2772699v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An aggregate of two or more atoms in a defined arrangement held together by chemical bonds.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772699</PublicId>
      <PreferredName>2772243v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>An aggregate of two or more atoms in a defined arrangement held together by chemical bonds.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._A statement or an account describing something.</PreferredDefinition>
      <LongName>Molecule Specimen Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63816:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Molecule Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63816</PREFERRED_NAME>
            <LONG_NAME>Molecule</LONG_NAME>
            <CON_ID>2612116</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Molecule Specimen Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Molecule Specimen Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MolecularSpecimen:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.MolecularSpecimen.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="299">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773365</PUBLICID>
    <LONGNAME>Protein Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2772711v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Proteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772711</PublicId>
      <PreferredName>2223335v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>Proteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Protein Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223335</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17021</PreferredName>
        <Version>1</Version>
        <LongName>Protein</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Protein.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Protein:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="300">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773438</PUBLICID>
    <LONGNAME>Physical Characteristic Value java.lang.String</LONGNAME>
    <PREFERREDNAME>2772784v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._The information contained in a data field._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772784</PublicId>
      <PreferredName>2772245v1.0:2528693v1.0</PreferredName>
      <PreferredDefinition>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._The information contained in a data field.</PreferredDefinition>
      <LongName>Physical Characteristic Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772245</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25618:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Physical Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25618</PREFERRED_NAME>
            <LONG_NAME>Physical</LONG_NAME>
            <CON_ID>2203948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49100</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Physical Characteristic Value java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Physical Characteristic Value java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhysicalCharacteristics:value</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.PhysicalCharacteristics.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="301">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2779085</PUBLICID>
    <LONGNAME>Registration Specialist Person Identifier Initials Name</LONGNAME>
    <PREFERREDNAME>REGSPEC_PER_ID_IN_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>the initials of the user who, on behalf of a sponsor, will manage and process the Investigator registrations.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2779084</PublicId>
      <PreferredName>REGSPEC_PERS_ID</PreferredName>
      <PreferredDefinition>information related to the identfier or name of a user who, on behalf of a sponsor, will manage and process the Investigator registrations.</PreferredDefinition>
      <LongName>Registration Specialist Person Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2779082</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54632:C25190</PreferredName>
        <Version>1</Version>
        <LongName>Registration Specialist Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54632</PREFERRED_NAME>
            <LONG_NAME>Registration Specialist</LONG_NAME>
            <CON_ID>2779081</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018271</PublicId>
      <PreferredName>INITIALS_NAME</PreferredName>
      <PreferredDefinition>the initial letters of the first, middle, and last names of a person.</PreferredDefinition>
      <LongName>Initials Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2238450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25191</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Registration office specialist</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Registration Office specialist initials</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2012-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3694151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="302">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2782511</PUBLICID>
    <LONGNAME>Engraftment Syndrome Symptom Present Type</LONGNAME>
    <PREFERREDNAME>ENGF_SYND_SYMP_PR_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of engraftment syndrome symptom(s) that were present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2782507</PublicId>
      <PreferredName>ENGF_SYND_SYMP_PRSNT</PreferredName>
      <PreferredDefinition>A toxicity of hematopoietic stem cell transplantation that manifests as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment. It occurs unexpectedly and is occasionally fatal. It can occur after an autogeneic or an allogeneic hematopoietic cell transplantation._Subjective evidence of disease perceived by the patient._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Engraftment Syndrome Symptom Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782505</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63324:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Engraftment Syndrome Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63324</PREFERRED_NAME>
            <LONG_NAME>Engraftment Syndrome</LONG_NAME>
            <CON_ID>2531990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2780141</PublicId>
      <PreferredName>ENGR_SYND_SYMP_TP</PreferredName>
      <PreferredDefinition>A toxicity of hematopoietic stem cell transplantation that manifests as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment. It occurs unexpectedly and is occasionally fatal. It can occur after an autogeneic or an allogeneic hematopoietic cell transplantation._Subjective evidence of disease perceived by the patient._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Engraftment Syndrome Symptom Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2780140</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63324:C4876:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Engraftment Syndrome Symptom Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63324</PREFERRED_NAME>
            <LONG_NAME>Engraftment Syndrome</LONG_NAME>
            <CON_ID>2531990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin rash</VALIDVALUE>
          <VALUEMEANING>Skin Rash</VALUEMEANING>
          <MEANINGDESCRIPTION>Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fever</VALIDVALUE>
          <VALUEMEANING>Fever</VALUEMEANING>
          <MEANINGDESCRIPTION>Fever, also known as pyrexia, is the elevation of the body&#39;s temperature above the upper limit of normal, usually taken as 37.7 degrees C.  Most fevers are caused by infections and almost all infectious diseases cause fever. (Wikipedia)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capillary leak syndrome</VALIDVALUE>
          <VALUEMEANING>Capillary Leak Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A syndrome characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2780142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other symptom</VALIDVALUE>
          <VALUEMEANING>Other Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: Subjective evidence of disease perceived by the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C4876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5084332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transient encephalopathy</VALIDVALUE>
          <VALUEMEANING>Temporary Encephalopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not permanent; not lasting; lacking continuity or regularity.: A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26920, C53288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5084333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Weight gain</VALIDVALUE>
          <VALUEMEANING>Weight Gain</VALUEMEANING>
          <MEANINGDESCRIPTION>An increase in total body weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5084334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diarrhea</VALIDVALUE>
          <VALUEMEANING>Diarrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>Watery bowel movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4395762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-cardiogenic pulmonary edema</VALIDVALUE>
          <VALUEMEANING>Noncardiogenic Pulmonary Edema</VALUEMEANING>
          <MEANINGDESCRIPTION>Pulmonary edema that is not a result of cardiac dysfunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erythrodermic rash</VALIDVALUE>
          <VALUEMEANING>Erythroderma</VALUEMEANING>
          <MEANINGDESCRIPTION>A generalized inflammatory cutaneous disorder characterized by erythema and desquamation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5095791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Development of renal insufficiency</VALIDVALUE>
          <VALUEMEANING>Renal Failure</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5095719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Development of hepatic dysfunction</VALIDVALUE>
          <VALUEMEANING>Liver Dysfunction</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding that indicates abnormal liver function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4291760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the symptoms of engra</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the symptoms of engraftment syndrome:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2782511</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedMedicalConditionResult.value(ANY-&gt;CD) WHERE PerformedObservation &gt; DeinfedObservation.nameCode = &quot;examine for Engraftment Syndrome&quot;&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the symptoms of engraftment syndrome</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the symptoms of engraftment syndrome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the symptoms of engraftment syndrome</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify the symptoms of engraftment syndrome</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedMedicalConditionResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_ES_engraft_syn_symp_typ</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="303">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783660</PUBLICID>
    <LONGNAME>Specimen Integrity Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2782897v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The state of being complete or undivided, of being sound or undamaged._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2782897</PublicId>
      <PreferredName>2782753v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The state of being complete or undivided, of being sound or undamaged._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Specimen Integrity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782753</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C62446</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Integrity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62446</PREFERRED_NAME>
            <LONG_NAME>Integrity</LONG_NAME>
            <CON_ID>2534086</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Integrity Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Integrity Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000322</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_SCG.SpecimenIntegrity.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenIntegrity:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="304">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783741</PUBLICID>
    <LONGNAME>Histopathologic Grade Grade java.lang.String</LONGNAME>
    <PREFERREDNAME>2782977v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior_Describes how closely a cancer resembles normal tissue of its same type, and the cancer&#39;s probable rate of growth_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2782977</PublicId>
      <PreferredName>2431271v1.0:2427327v1.0</PreferredName>
      <PreferredDefinition>The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior_Describes how closely a cancer resembles normal tissue of its same type, and the cancer&#39;s probable rate of growth</PreferredDefinition>
      <LongName>Histopathologic Grade Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18000</PreferredName>
        <Version>1</Version>
        <LongName>Histopathologic Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2427327</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18000</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Histopathologic Grade Grade java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Histopathologic Grade Grade java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000322</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_SCG.HistologicGrade.grade</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HistologicGrade:grade</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="305">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783947</PUBLICID>
    <LONGNAME>Lung Pathology Other Surgical Procedure java.lang.String</LONGNAME>
    <PREFERREDNAME>2783180v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Different than the one(s) previously specified or mentioned.:Surgical Procedure is a diagnostic or treatment medical procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783180</PublicId>
      <PreferredName>2782776v1.0:2431225v1.0</PreferredName>
      <PreferredDefinition>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Different than the one(s) previously specified or mentioned.:Surgical Procedure is a diagnostic or treatment medical procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.</PreferredDefinition>
      <LongName>Lung Pathology Other Surgical Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Lung Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431225</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C15329</PreferredName>
        <Version>1</Version>
        <LongName>Other Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Lung Pathology Other Surgical Procedure java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Lung Pathology Other Surgical Procedure java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000322</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_SCG.LungPathologyAnnotation.otherSpecimenProcedure</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LungPathologyAnnotation:otherSpecimenProcedure</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="306">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784008</PUBLICID>
    <LONGNAME>Specimen Event Parameter Object Computer Time Stamp java.util.Date</LONGNAME>
    <PREFERREDNAME>2783240v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that happens at a given place and time.:Any factor that defines a system and determines (or limits) its performance._The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783240</PublicId>
      <PreferredName>2513358v1.0:2782728v1.0</PreferredName>
      <PreferredDefinition>A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that happens at a given place and time.:Any factor that defines a system and determines (or limits) its performance._The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events.</PreferredDefinition>
      <LongName>Specimen Event Parameter Object Computer Time Stamp</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513358</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C25499:C44175</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Event Parameter Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2782728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C72669</PreferredName>
        <Version>1</Version>
        <LongName>Computer Time Stamp</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72669</PREFERRED_NAME>
            <LONG_NAME>Computer Time Stamp</LONG_NAME>
            <CON_ID>2782652</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Event Parameter Object Computer Time Stamp java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Event Parameter Object Computer Time Stamp java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.SpecimenEventParameters.timestamp</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenEventParameters:timestamp</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="307">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2787149</PUBLICID>
    <LONGNAME>Movie Title java.lang.String</LONGNAME>
    <PREFERREDNAME>2787074v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of images displayed in succession giving the illusion of continuous movement._The name of a work of art or literary composition etc._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2787074</PublicId>
      <PreferredName>2787019v1.0:2223286v1.0</PreferredName>
      <PreferredDefinition>A sequence of images displayed in succession giving the illusion of continuous movement._The name of a work of art or literary composition etc.</PreferredDefinition>
      <LongName>Movie Title</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2787019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75001</PreferredName>
        <Version>1</Version>
        <LongName>Movie</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75001</PREFERRED_NAME>
            <LONG_NAME>Movie</LONG_NAME>
            <CON_ID>2786999</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223286</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42774</PreferredName>
        <Version>1</Version>
        <LongName>Title</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42774</PREFERRED_NAME>
            <LONG_NAME>Title</LONG_NAME>
            <CON_ID>2223215</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Movie Title java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Movie Title java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2786997</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DMR</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.cvit.cabig.dmr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.cvit.cabig.dmr.domain.Movie.title</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Movie:title</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="308">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2787152</PUBLICID>
    <LONGNAME>Movie Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2787077v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of images displayed in succession giving the illusion of continuous movement._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2787077</PublicId>
      <PreferredName>2787019v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>A sequence of images displayed in succession giving the illusion of continuous movement._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Movie Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2787019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75001</PreferredName>
        <Version>1</Version>
        <LongName>Movie</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75001</PREFERRED_NAME>
            <LONG_NAME>Movie</LONG_NAME>
            <CON_ID>2786999</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Movie Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Movie Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2786997</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DMR</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.cvit.cabig.dmr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.cvit.cabig.dmr.domain.Movie.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Movie:comment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="309">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2787453</PUBLICID>
    <LONGNAME>Tacrolimus Administered Indicator</LONGNAME>
    <PREFERREDNAME>FK506_ADMIN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not tacrolimus was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2787451</PublicId>
      <PreferredName>FK506_ADMIN</PreferredName>
      <PreferredDefinition>A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.__The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Tacrolimus Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2861801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1311</PreferredName>
        <Version>1</Version>
        <LongName>Tacrolimus</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1311</PREFERRED_NAME>
            <LONG_NAME>Tacrolimus</LONG_NAME>
            <CON_ID>2590816</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was FK 506 administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was FK 506 administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FK 506 (Tacrolimus, Prograf)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FK 506 (Tacrolimus, Prograf)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FK 506</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FK 506</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842912</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapy</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2842918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cgvhd_trt_fk506_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>agvhd_prevent_fk506_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>agvhd_trt_fk506_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="310">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2791147</PUBLICID>
    <LONGNAME>FLT3 Ligand Mutation Abnormality Present Indicator</LONGNAME>
    <PREFERREDNAME>FLT3_LM_PRS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a FLT3 ligand mutation abnormality was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2790168</PublicId>
      <PreferredName>FLT3_LG_MT_DG_TPT_PR</PreferredName>
      <PreferredDefinition>Flt3 ligand is a novel hematopoietic growth factor ligand for the FLT3 tyrosine kinase receptor.  This growth factor stimulates the proliferation of hematopoietic progenitor cells.  FLT3 (FLK2) is a tyrosine kinase receptor structurally related to CSF1 and KIT.  (from OMIM 600007 and NCI)_Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>FLT3 Ligand Mutation Abnormality Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3234297</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20492:C45576</PreferredName>
        <Version>1</Version>
        <LongName>FLT3 Ligand Mutation Abnormality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20492</PREFERRED_NAME>
            <LONG_NAME>Fms-Related Tyrosine Kinase 3 Ligand</LONG_NAME>
            <CON_ID>2790161</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45576</PREFERRED_NAME>
            <LONG_NAME>Mutation Abnormality</LONG_NAME>
            <CON_ID>2532673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a flt-3 ligand mutation p</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a flt-3 ligand mutation present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2010r1: Acute Myelogenous Leukemia Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_base_diag_flt3_mut_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="311">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2793688</PUBLICID>
    <LONGNAME>Other Organ Clinical Involvement Occurrence Indicator</LONGNAME>
    <PREFERREDNAME>OT_OR_CL_IN_OC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not there was other clinical organ involvement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2793685</PublicId>
      <PreferredName>OT_OR_CL_INV_OC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._A unique macroscopic (gross) anatomic structure that performs specific functions.  It is composed of various tissues.  An organ is part of an anatomic system or a body region.  Representative examples include the heart, lung, liver, spleen, and uterus._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._To have a connection by participation or association or use; sharing in an activity or process._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Other Organ Clinical Involvement Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2813544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C13018:C25398:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Other Organ Clinical Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13018</PREFERRED_NAME>
            <LONG_NAME>Organ</LONG_NAME>
            <CON_ID>2202464</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was there other clinical orga</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was there other clinical organ involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other clinical organ involvement?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other clinical organ involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2793688</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>[IF EXISTS THEN &quot;true&quot; ELSE &quot;false&quot;]  PerformedDiagnosis.targetAnatomicSite WHERE PerformedDiagnosis AND PerfornedDiagnosis.value = &quot;GVHD&quot; AND PerformedDiagnosis.diseaseStatusCode = &quot;Acute&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the recipient display any other clinical organ involvement?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Did the recipient display any other clinical organ involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the recipient display any other clinical organ involvement?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the recipient display any other clinical organ involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other site(s) involved with acute GVHD</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other site(s) involved with acute GVHD</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other organ</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other organ</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>agvhd_othr_svrty_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_AGHD_dx_agvhd_oth_site_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_artho_pre_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_lung_prep_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_org_arthr_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_org_lung_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_org_tngue_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_org_tssue_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_tong_prep_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_tssue_pre_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_othr_org_invl_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_othr_prep_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_oth_orgn_prep_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:targetAnatomicSite</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_oth_clin_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_arthropathy_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_lung_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_oth_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_soft_tissue_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_diag_tongue_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_AGHD_agvhd_oth_site_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_GVHD_agvhd_oth_site_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VOD_DX_oth_organ_involve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_GVHD_agvhd_oth_site_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="312">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2794460</PUBLICID>
    <LONGNAME>Actual Follow-up Occurrence Date</LONGNAME>
    <PREFERREDNAME>AC_FU_OC_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The month, day, and year the actual follow-up occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2794458</PublicId>
      <PreferredName>AC_FL_OCRS</PreferredName>
      <PreferredDefinition>Existing in fact; real._The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Actual Follow-up Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2794455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C16033</PreferredName>
        <Version>1</Version>
        <LongName>Actual Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2532012</PublicId>
      <PreferredName>DATE</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY-MM-DD</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Actual date of follow-up:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Actual date of follow-up:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of actual contact with the recipient to determine the medical status for this follow-up report:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of actual contact with the recipient to determine the medical status for this follow-up report:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of actual contact with the patient to determine the medical status for this follow-up report:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Date of actual contact with the patient to determine the medical status for this follow-up report:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of actual contact with the patient to determine the medical status for this follow-up report:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of actual contact with the patient to determine the medical status for this follow-up report:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of actual contact with the recipient to determine medical status for this follow-up report:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of actual contact with the recipient to determine medical status for this follow-up report:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2451:Chimerism Studies</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3160396</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>contact_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_VS_contact_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_SRV_contact_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNfup_vital_contact_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_SRV_contact_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedObservation:nameCode</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="313">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2799820</PUBLICID>
    <LONGNAME>Susceptibility Arrhythmia Agent Administered Ind-2</LONGNAME>
    <PREFERREDNAME>S_ARHY_AGT_ADM_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether agents with proarrhythmic potential were administered to the patient/participant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2799780</PublicId>
      <PreferredName>SUSC_ARHY_AGT_ADMIN</PreferredName>
      <PreferredDefinition>information relating to the administration of an agent that increases the susceptibility (the likelihood or occurrence of) of arrhythmia (an abnormal rate of muscle contractions in the heart).</PreferredDefinition>
      <LongName>Susceptibility Arrhythmia Agent Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2799777</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16505:C2881:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Susceptibility Arrhythmia Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16505</PREFERRED_NAME>
            <LONG_NAME>Susceptibility</LONG_NAME>
            <CON_ID>2434932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2881</PREFERRED_NAME>
            <LONG_NAME>Arrhythmia</LONG_NAME>
            <CON_ID>2202296</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Agents with proarrhythmic pot</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Agents with proarrhythmic potential</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient require medication having proarrhythmic potential, for example terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="314">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2802830</PUBLICID>
    <LONGNAME>Cluster of Differentiation Laboratory Procedure Performed Missing Value Reason Indicator</LONGNAME>
    <PREFERREDNAME>CD_LP_PF_MS_VAL_IN</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes the reason the cluster of differentiation value is missing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2802724</PublicId>
      <PreferredName>CD_LP_PF</PreferredName>
      <PreferredDefinition>A designation for cell surface molecules present on leukocytes._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Cluster of Differentiation Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2802721</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78347:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Cluster of Differentiation Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78347</PREFERRED_NAME>
            <LONG_NAME>Cluster of Differentiation</LONG_NAME>
            <CON_ID>2801986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2756825</PublicId>
      <PreferredName>MISS_IND</PreferredName>
      <PreferredDefinition>A specific reason explaining why a meaningful value is not available.  A meaningful value answers the question posed by a Data Element Concept.  In contrast, a Missing Value Reason answers the implicit question &quot;Why is there no &#39;meaningful&#39; value?&quot;, when there is none._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Missing Value Reason Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2756824</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48655:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Missing Value Reason Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48655</PREFERRED_NAME>
            <LONG_NAME>Missing Value Reason</LONG_NAME>
            <CON_ID>2431146</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-quantitative</VALIDVALUE>
          <VALUEMEANING>Negation Quantitative</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of being estimated or expressed with numeric values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70766, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2777712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Negation Test</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47891, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown/not applicable</VALIDVALUE>
          <VALUEMEANING>Unknown Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.: Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660, C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested / unknown</VALIDVALUE>
          <VALUEMEANING>Negation Test Or Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998, C37998, C47891, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3262968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not measurable</VALIDVALUE>
          <VALUEMEANING>Non-Measurable</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-Measurable; not possible to be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2678954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the reason for the cl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the reason for the cluster of differentiation missing value?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2802830</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.valueNullFlavorReason WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Determine Cluster of Differentiation&quot; AND PerformedObservation.negationIndicator = &quot;true&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2131r2: Immune Deficiencies Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3234637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r2: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3638517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>imm_recon_lymph_cd20_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>imm_recon_lymph_cd56_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>immun_recon_lymph_cd3_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>immun_recon_lymph_cd4_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>immun_recon_lymph_cd8_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd20_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd3_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd45ra_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd45ro_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd4_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd56_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_lym_cd8_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_45ra_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_45ro_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_cd20_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_cd3_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_cd4_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_cd56_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_lymph_cd8_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="315">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2807193</PUBLICID>
    <LONGNAME>Protocol Treatment First Treatment Step Protocol Treatment Arm Assignment Type</LONGNAME>
    <PREFERREDNAME>PR_TX_F_TXS_AR_AS_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of treatment assigned during the specific treatment protocol used in the first arm or stage of progression through a sequential treatment protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2807191</PublicId>
      <PreferredName>PRO_TX_F_TXS_ARM_ASS</PreferredName>
      <PreferredDefinition>information related to the assignment the specific treatment protocol used in the first arm or stage of progression through a sequential treatment protocol.</PreferredDefinition>
      <LongName>Protocol Treatment First Treatment Step Protocol Treatment Arm Assignment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2425177</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2807189</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C16154:C15538:C25426</PreferredName>
        <Version>1</Version>
        <LongName>First Step Protocol Treatment Arm Assignment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16154</PREFERRED_NAME>
            <LONG_NAME>Treatment Step</LONG_NAME>
            <CON_ID>2203804</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15538</PREFERRED_NAME>
            <LONG_NAME>Protocol Treatment Arm</LONG_NAME>
            <CON_ID>2206366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25426</PREFERRED_NAME>
            <LONG_NAME>Assignment</LONG_NAME>
            <CON_ID>2204040</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2807192</PublicId>
      <PreferredName>F_TXST_ARM_ASS_TP</PreferredName>
      <PreferredDefinition>Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>First Treatment Step Protocol Treatment Arm Assignment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AC-T</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Cyclophosphamide + Placebo + Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>Doxorubicin Cyclophosphamide + Placebo + Paclitaxel</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2807431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAC-BT</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Cyclophosphamide Bevacizumab + Paclitaxel + Bevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>Doxorubicin Cyclophosphamide Bevacizumab + Paclitaxel + Bevacizumab</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2807432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAC-BT-B</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Cyclophosphamide Bevacizumab + Paclitaxel + Bevacizumab + Bevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>Doxorubicin Cyclophosphamide Bevacizumab + Paclitaxel + Bevacizumab + Bevacizumab</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2807433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A:  Lenalidomide Monotherapy</VALIDVALUE>
          <VALUEMEANING>A:  Lenalidomide Monotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A:  Lenalidomide Monotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3012880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B:  Lenalidomide + Epoetin Alfa</VALIDVALUE>
          <VALUEMEANING>B:  Lenalidomide + Epoetin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>B:  Lenalidomide + Epoetin Alfa</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3012881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm C - Cabozantinib and Erlotinib</VALIDVALUE>
          <VALUEMEANING>Arm C - Cabozantinib and Erlotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>Arm C - Cabozantinib and Erlotinib</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3687471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm B - Cabozantinib</VALIDVALUE>
          <VALUEMEANING>Arm B - Cabozantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>Arm B - Cabozantinib</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3687472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm A - Erlotinib</VALIDVALUE>
          <VALUEMEANING>Arm A - Erlotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>Arm A - Erlotinib</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3687473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm B: Dabrafenib + Trametinib</VALIDVALUE>
          <VALUEMEANING>Arm B: Dabrafenib + Trametinib</VALUEMEANING>
          <MEANINGDESCRIPTION>Arm B: Dabrafenib + Trametinib</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4736491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm A: Nivolumab + Ipilimumab</VALIDVALUE>
          <VALUEMEANING>Arm A: Nivolumab + Ipilimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>Arm A: Nivolumab + Ipilimumab</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4736492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Which treatment did the patient receive (on step 1)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Which treatment arm did the patient receive on step 1 of treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="316">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2807559</PUBLICID>
    <LONGNAME>Person Integer::6 Minute Walking Distance International Foot Value</LONGNAME>
    <PREFERREDNAME>PERS_6_MIN_DIST_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the number of feet walked by an individual in 6 minutes.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2807554</PublicId>
      <PreferredName>PERS_6_MIN_WLK_DIST</PreferredName>
      <PreferredDefinition>Person; a human being._A number with no fractional part, including the negative and positive numbers as well as zero.::6_A unit measure of time equal to 60 seconds._The act of traveling by foot._The space separating two objects or points.</PreferredDefinition>
      <LongName>Person Integer::6 Minute Walking Distance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2807552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C45255::6:C48154:C73554</PreferredName>
        <Version>1</Version>
        <LongName>Person Integer::6 Minute Walking</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::6</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48154</PREFERRED_NAME>
            <LONG_NAME>Minute</LONG_NAME>
            <CON_ID>2513263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73554</PREFERRED_NAME>
            <LONG_NAME>Walking</LONG_NAME>
            <CON_ID>2743260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2436194</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25167</PreferredName>
        <Version>1</Version>
        <LongName>Distance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25167</PREFERRED_NAME>
            <LONG_NAME>Distance</LONG_NAME>
            <CON_ID>2203902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2807557</PublicId>
      <PreferredName>DIST_FT_VAL</PreferredName>
      <PreferredDefinition>The space separating two objects or points._A unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.(NCI)_A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Distance International Foot Value</LongName>
      <Version>2.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2807556</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25167:C71253:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Distance International Foot Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25167</PREFERRED_NAME>
            <LONG_NAME>Distance</LONG_NAME>
            <CON_ID>2203902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71253</PREFERRED_NAME>
            <LONG_NAME>International Foot</LONG_NAME>
            <CON_ID>2807555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name># Feet walked in 6 minutes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText># Feet walked in 6 minutes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="317">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2816287</PUBLICID>
    <LONGNAME>Magnetic Resonance Imaging (MRI) Receive Coil Type</LONGNAME>
    <PREFERREDNAME>MRI_REC_COIL_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Differentiation of the coil of the RF receiver;&quot;picks up&quot; the NMR signal. [Manually_curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2749658</PublicId>
      <PreferredName>2730326v1.0:2749656v1.0</PreferredName>
      <PreferredDefinition>Coil of the RF receiver;&quot;picks up&quot; the NMR signal. [Manually_curated]</PreferredDefinition>
      <LongName>Magnetic Resonance Imaging (MRI) Receive Coil Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2730326</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16809</PreferredName>
        <Version>1</Version>
        <LongName>Magnetic Resonance Imaging</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16809</PREFERRED_NAME>
            <LONG_NAME>Magnetic Resonance Imaging</LONG_NAME>
            <CON_ID>2202506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2749656</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639:C49877:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Received Coil Device Component Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49877</PREFERRED_NAME>
            <LONG_NAME>Coil Device</LONG_NAME>
            <CON_ID>2749655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2816283</PublicId>
      <PreferredName>IMAG_TECH_COIL_TP</PreferredName>
      <PreferredDefinition>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._A structure consisting of something wound in a continuous series of loops._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Imaging Technique Coil Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2816282</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17369:C49877:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technique Coil Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17369</PREFERRED_NAME>
            <LONG_NAME>Imaging Procedure</LONG_NAME>
            <CON_ID>2713347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49877</PREFERRED_NAME>
            <LONG_NAME>Coil Device</LONG_NAME>
            <CON_ID>2749655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>Coil type 32</VALUEMEANING>
          <MEANINGDESCRIPTION>Coil type 32</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-12-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Coil type 12</VALUEMEANING>
          <MEANINGDESCRIPTION>Coil type 12</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-12-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Coil Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Coil Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MGH New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813098</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="318">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2830262</PUBLICID>
    <LONGNAME>Race Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2551698v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Major living subspecies of man differentiated by genetic and physical characteristics. There are four racial groups: Australoid, Caucasoid, Mongoloid, and Negroid._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2551698</PublicId>
      <PreferredName>2389400v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Major living subspecies of man differentiated by genetic and physical characteristics. There are four racial groups: Australoid, Caucasoid, Mongoloid, and Negroid._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Race Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2389400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17049</PreferredName>
        <Version>1</Version>
        <LongName>Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Race Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Race Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.Race.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Race:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Race.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="319">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2833148</PUBLICID>
    <LONGNAME>Laboratory Procedure Performed Upper Limit of Normal Value</LONGNAME>
    <PREFERREDNAME>2188501v1.0:2833144v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188501</PublicId>
      <PreferredName>LAB_PERF</PreferredName>
      <PreferredDefinition>information related to a laboratory test that was performed.</PreferredDefinition>
      <LongName>Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2833144</PublicId>
      <PreferredName>2833144v1.0</PreferredName>
      <PreferredDefinition>The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</PreferredDefinition>
      <LongName>Upper Limit of Normal Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2500946</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25706:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Upper Limit of Normal Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25706</PREFERRED_NAME>
            <LONG_NAME>Upper Limit of Normal</LONG_NAME>
            <CON_ID>2203609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ULN</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2188501v1.0:2833144v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="320">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2834557</PUBLICID>
    <LONGNAME>Gene Expression Occurrence Date</LONGNAME>
    <PREFERREDNAME>GEN_EXP_PROF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Calendar date on which a genetic expression profile is completed for an individual.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2800335</PublicId>
      <PreferredName>GEN_EXP_PROF_OCC</PreferredName>
      <PreferredDefinition>Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein._The transcription of genetic information into a message and the subsequent translation into a functional protein._A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of an enzyme or other protein. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of an enzyme or other protein. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins)._A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of an enzyme or other protein. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).</PreferredDefinition>
      <LongName>Gene Expression Profile Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3812756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612:C18477</PreferredName>
        <Version>1</Version>
        <LongName>Gene Microarray Analysis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16612</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2202483</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18477</PREFERRED_NAME>
            <LONG_NAME>Microarray Analysis</LONG_NAME>
            <CON_ID>2557754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Genomic Profile</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Genomic Profile</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of GEP</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="321">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2840156</PUBLICID>
    <LONGNAME>Surgery Procedure Post-Operative Fever Intravenous Antibiotic Complication Ind-2</LONGNAME>
    <PREFERREDNAME>S_P_F_IV_ANT_C_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to post-operative surgery complication of an abnormal elevation of body temperature, usually as a result of a pathologic process which requires administration within or into a vein or veins of a drug used to treat infections caused by bacteria and other microorganisms.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2840123</PublicId>
      <PreferredName>SX_PO_FEVER_IV_AN_CM</PreferredName>
      <PreferredDefinition>information related to post-operative surgery complication of an abnormal elevation of body temperature, usually as a result of a pathologic process which requires administration within or into a vein or veins of a drug used to treat infections caused by bacteria and other microorganisms.</PreferredDefinition>
      <LongName>Surgery Procedure Post-Operative Fever Intravenous Antibiotic Complication</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2840121</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25623:C3038:C38276:C258:C2959</PreferredName>
        <Version>1</Version>
        <LongName>Post-Operative Fever Intravenous Route of Administration Antibiotic Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25623</PREFERRED_NAME>
            <LONG_NAME>Post-Operative</LONG_NAME>
            <CON_ID>2205402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3038</PREFERRED_NAME>
            <LONG_NAME>Fever</LONG_NAME>
            <CON_ID>2202636</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38276</PREFERRED_NAME>
            <LONG_NAME>Intravenous Route of Administration</LONG_NAME>
            <CON_ID>2453314</CON_ID>
            <DEFINITION_SOURCE>FDA</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C258</PREFERRED_NAME>
            <LONG_NAME>Antibiotic</LONG_NAME>
            <CON_ID>2202302</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2959</PREFERRED_NAME>
            <LONG_NAME>Complication</LONG_NAME>
            <CON_ID>2203884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Post-op fever requiring IV an</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Post-op fever requiring IV antibiotics</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>S_P_F_IV_ANT_C_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="322">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2842658</PUBLICID>
    <LONGNAME>Specimen Tissue Microarray Prostatectomy Submission Type</LONGNAME>
    <PREFERREDNAME>2842652v1.0:2842655v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of specimen submitted for use on tissue microarrays, a device for use in high-throughput molecular analysis/screening of clinical tissue specimens that spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array, following prostatectomy, an operation to remove part or all of the prostate.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2842652</PublicId>
      <PreferredName>2241613v1.0:2842650v1.0</PreferredName>
      <PreferredDefinition>information related to the submission of tissue microarrays, a device for use in high-throughput molecular analysis/screening of clinical tissue specimens that spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array, following prostatectomy, an operation to remove part or all of the prostate.</PreferredDefinition>
      <LongName>Specimen Tissue Microarray Prostatectomy Submission</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2842650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19922:C15307:C25694</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Microarray Prostatectomy Submission</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19922</PREFERRED_NAME>
            <LONG_NAME>Tissue Microarray</LONG_NAME>
            <CON_ID>2842644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15307</PREFERRED_NAME>
            <LONG_NAME>Prostatectomy</LONG_NAME>
            <CON_ID>2202793</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25694</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2202488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2842655</PublicId>
      <PreferredName>2842655v1.0</PreferredName>
      <PreferredDefinition>the type of specimen submitted for tissue microarray.</PreferredDefinition>
      <LongName>Tissue Microarray SubmissionType</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cores</VALIDVALUE>
          <VALUEMEANING>Core Needle Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parraffin block</VALIDVALUE>
          <VALUEMEANING>Paraffin Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>Paraffin is a common name for a group of high molecular weight alkane hydrocarbons with the general formula CnH2n+2, where n is between 22 and 27. Paraffin is also a technical name for an alkane in general, but in most cases it refers specifically to a linear, or normal alkane. It is mostly found as a white, odorless, tasteless, waxy solid, with a melting point between 47C and 65C. It is insoluble in water, but soluble in ether, benzene, and certain esters. Paraffin is unaffected by most common chemical reagents but oxidizes readily. (from Wikipedia): Blocks; refers to preserved specimens embedded in support material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C727, C25436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sample type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sample type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="323">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2848671</PUBLICID>
    <LONGNAME>Long Form Brief Pain Inventory Complete Indicator</LONGNAME>
    <PREFERREDNAME>LONG_BPI_COM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to signify whether the Brief Pain Inventory long form, consisting of 32 questions, has been completed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2848667</PublicId>
      <PreferredName>LNG_BPI_COMP</PreferredName>
      <PreferredDefinition>Of relatively great or greater than average spatial extension or temporal duration._A printed or electronic document with spaces to be filled out._A brief, simple, and easy to use tool for the assessment of pain in both clinical and research settings. The BPI uses simple numeric rating scales from 0 to10 that are easy to understand and easy to translate into other languages. On the BPI, mild pain is defined as a worst pain score of 1 - 4, moderate pain is defined as a worst pain score of 5 - 6, and severe pain is defined as a worst pain score of 7-10._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._</PreferredDefinition>
      <LongName>Long Form Brief Pain Inventory Complete</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2848665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25248:C19464:C18203</PreferredName>
        <Version>1</Version>
        <LongName>Long Form Brief Pain Inventory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25248</PREFERRED_NAME>
            <LONG_NAME>Long</LONG_NAME>
            <CON_ID>2206292</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18203</PREFERRED_NAME>
            <LONG_NAME>Brief Pain Inventory</LONG_NAME>
            <CON_ID>2848661</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2405014</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250</PreferredName>
        <Version>1</Version>
        <LongName>Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015874</PublicId>
      <PreferredName>YES_NO_UN_NA_IND</PreferredName>
      <PreferredDefinition>Yes, no, unknown or not applicable responses to a question or condition.</PreferredDefinition>
      <LongName>Yes/ No/ Unknown/ Not Applicable Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BPI long form completed?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>BPI long form completed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="324">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2854466</PUBLICID>
    <LONGNAME>Head and Neck Tumor Pathology N Stage</LONGNAME>
    <PREFERREDNAME>2854464v1.0:2854442v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the pathologic N stage, the extent of lymph node invasion of a malignant neoplasm based on pathologic evaluation of a tissue specimen, of a malignant neoplasm originating in the head and neck.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2854464</PublicId>
      <PreferredName>2228482v1.0:2673290v1.0</PreferredName>
      <PreferredDefinition>information related to the pathologic N stage, the extent of lymph node invasion of a malignant neoplasm based on pathologic evaluation of a tissue specimen, of a malignant neoplasm originating in the head and neck.</PreferredDefinition>
      <LongName>Head and Neck Tumor Pathology N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12418:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Head and Neck Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12418</PREFERRED_NAME>
            <LONG_NAME>Head and Neck</LONG_NAME>
            <CON_ID>2203706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2673290</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18189:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Pathology N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2854442</PublicId>
      <PreferredName>2854442v1.0</PreferredName>
      <PreferredDefinition>the extent of lymph node involvement of head and neck cancer as determined prior to treatment based on evidence from clinical assessment parameters (e.g., physical exam, imaging, endoscopy, biopsy).</PreferredDefinition>
      <LongName>Head and Neck Tumor Pathologic N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN0</VALIDVALUE>
          <VALUEMEANING>pN0, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pN0, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN1</VALIDVALUE>
          <VALUEMEANING>pN1, ACCORDING TO AJCC CRITERIA</VALUEMEANING>
          <MEANINGDESCRIPTION>pN1, ACCORDING TO AJCC CRITERIA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN2</VALIDVALUE>
          <VALUEMEANING>pN2, ACCORDING TO AJCC CRITERIA</VALUEMEANING>
          <MEANINGDESCRIPTION>pN2, ACCORDING TO AJCC CRITERIA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN2a</VALIDVALUE>
          <VALUEMEANING>pN2A, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pN2A, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN2b</VALIDVALUE>
          <VALUEMEANING>pN2B, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pN2B, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN2c</VALIDVALUE>
          <VALUEMEANING>pN2C, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pN2C, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN3</VALIDVALUE>
          <VALUEMEANING>pN3, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pN3, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pNX</VALIDVALUE>
          <VALUEMEANING>pNX, ACCORDING TO AJCC GUIDELINES</VALUEMEANING>
          <MEANINGDESCRIPTION>pNX, ACCORDING TO AJCC GUIDELINES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN3b</VALIDVALUE>
          <VALUEMEANING>pN3b, ACCORDING TO AJCC CRITERIA</VALUEMEANING>
          <MEANINGDESCRIPTION>pN3b, ACCORDING TO AJCC CRITERIA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6620840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN3a</VALIDVALUE>
          <VALUEMEANING>pN3a, ACCORDING TO AJCC CRITERIA</VALUEMEANING>
          <MEANINGDESCRIPTION>pN3a, ACCORDING TO AJCC CRITERIA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6620841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic N stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic N stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>HDNCK_TUMOR_P_N_STG</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2854464v1.0:2854442v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="325">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2855082</PUBLICID>
    <LONGNAME>Past Month Chronic Graft Versus Host Disease Severity Global Rating Score</LONGNAME>
    <PREFERREDNAME>MON_CGVHD_GLOB_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Health Care Provider global rating score to describe the status of an individual with chronic Graft vs. Host Disease (GVHD) as compared to the previous month.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2855069</PublicId>
      <PreferredName>PAST_MON_CGVHD_SVRTY</PreferredName>
      <PreferredDefinition>information related to the severity of graft versus host disease following transplant._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Used of the degree of something undesirable e.g. pain or weather; also, strictness._The final result of a determination of the value, significance, or extent of._Before the present time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</PreferredDefinition>
      <LongName>Past Month Chronic Graft Versus Host Disease Severity Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2855067</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25609:C29846:C4981</PreferredName>
        <Version>1</Version>
        <LongName>Past Month Chronic Graft Versus Host Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4981</PREFERRED_NAME>
            <LONG_NAME>Chronic Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202365</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2855048</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25676:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Severity Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2855073</PublicId>
      <PreferredName>CGVHD_GLOB_RAT_SC</PreferredName>
      <PreferredDefinition>An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Used of the degree of something undesirable e.g. pain or weather; also, strictness._Type; a subdivision of a particular kind of thing._Category; used informally to mean a class of things._A number or range of numeric values measuring performance, function, quality, or ability._Covering or affecting the whole of a system._The act of ascertaining or fixing the value or worth of something._Persons who provides health care as part of their job responsibilities: or a person or organization who is licensed to supply health care._Covering or affecting the whole of a system._The act of ascertaining or fixing the value or worth of something._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.</PreferredDefinition>
      <LongName>Chronic Graft Versus Host Disease Global Rating Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2855168</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68846:C77538:C4981:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Global Rating Chronic Graft Versus Host Disease Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68846</PREFERRED_NAME>
            <LONG_NAME>Global</LONG_NAME>
            <CON_ID>2679978</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77538</PREFERRED_NAME>
            <LONG_NAME>Rating</LONG_NAME>
            <CON_ID>2793832</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4981</PREFERRED_NAME>
            <LONG_NAME>Chronic Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202365</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>+2</VALIDVALUE>
          <VALUEMEANING>Moderately Better</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is moderately better.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>+3</VALIDVALUE>
          <VALUEMEANING>Very Much Better</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is very much better.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>-3</VALIDVALUE>
          <VALUEMEANING>Very Much Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is very much worse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>-2</VALIDVALUE>
          <VALUEMEANING>Moderately Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is moderately worse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>-1</VALIDVALUE>
          <VALUEMEANING>A Little Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is a little worse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>About the Same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>+1</VALIDVALUE>
          <VALUEMEANING>A Little Better</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is a little better.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2855078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Clinician Global Rating - Pas</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Clinician Global Rating - Past Month Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="326">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2859402</PUBLICID>
    <LONGNAME>Surgical Procedure Target Chemotherapy Temperature Value</LONGNAME>
    <PREFERREDNAME>SUR_TAR_CHE_TEMP_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>a numerical quantity for temperature (degrees Celsius) related to the goal temperature of chemotherapy during a medical procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2859397</PublicId>
      <PreferredName>SURPOR_T_CTX_TEMP</PreferredName>
      <PreferredDefinition>information related to the goal temperature of chemotherapy during a medical procedure.</PreferredDefinition>
      <LongName>Surgical Procedure Target Chemotherapy Temperature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2859395</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25702:C15632:C25206</PreferredName>
        <Version>1</Version>
        <LongName>Target Chemotherapy Temperature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25206</PREFERRED_NAME>
            <LONG_NAME>Temperature</LONG_NAME>
            <CON_ID>2202772</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2859398</PublicId>
      <PreferredName>TEMP_VAL</PreferredName>
      <PreferredDefinition>a numerical quantity for temperature.</PreferredDefinition>
      <LongName>Temperature Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>99.9</MaximumValue>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Target inflow temperature</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Target inflow temperature</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="327">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2859987</PUBLICID>
    <LONGNAME>Analysis of Variance Outcome Group Name Item Collection java.lang.StringArray</LONGNAME>
    <PREFERREDNAME>2859982v1.0:2425588v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A statistical technique which helps in making inference whether three or more samples might come from populations having the same mean; specifically, whether the differences among the samples might be caused by chance variation.:The result of an action._Any number of entities (members) considered as a unit.:The words or language units by which a thing is known.:A group of items of the same type, gathered for display or study._Generic value domain for a java datatype that is an array of strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2859982</PublicId>
      <PreferredName>2829722v1.0:2859977v1.0</PreferredName>
      <PreferredDefinition>A statistical technique which helps in making inference whether three or more samples might come from populations having the same mean; specifically, whether the differences among the samples might be caused by chance variation.:The result of an action._Any number of entities (members) considered as a unit.:The words or language units by which a thing is known.:A group of items of the same type, gathered for display or study.</PreferredDefinition>
      <LongName>Analysis of Variance Outcome Group Name Item Collection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2829722</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53241:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Analysis of Variance Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53241</PREFERRED_NAME>
            <LONG_NAME>Analysis of Variance</LONG_NAME>
            <CON_ID>2710291</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2859977</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43359:C42614:C45261</PreferredName>
        <Version>1</Version>
        <LongName>Group Name Item Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45261</PREFERRED_NAME>
            <LONG_NAME>Item Collection</LONG_NAME>
            <CON_ID>2512704</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2425588</PublicId>
      <PreferredName>java.lang.StringArray</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is an array of strings.</PreferredDefinition>
      <LongName>java.lang.StringArray</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String[]</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2707839</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26358</PreferredName>
        <Version>1</Version>
        <LongName>Array</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26358</PREFERRED_NAME>
            <LONG_NAME>Array</LONG_NAME>
            <CON_ID>2236563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Analysis of Variance Outcome Group Name Item Collection java.lang.StringArray does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Analysis of Variance Outcome Group Name Item Collection java.lang.StringArray does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.columbia.geworkbench.cagrid.anova</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2829708</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnovaResult:groupNameCollection</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.columbia.geworkbench.cagrid.anova.AnovaResult.groupNameCollection</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="328">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2861514</PUBLICID>
    <LONGNAME>Decitabine Administered Indicator</LONGNAME>
    <PREFERREDNAME>2861512v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not decitabine was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2861512</PublicId>
      <PreferredName>2861510v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)_The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Decitabine Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2861510</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C981</PreferredName>
        <Version>1</Version>
        <LongName>Decitabine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C981</PREFERRED_NAME>
            <LONG_NAME>Decitabine</LONG_NAME>
            <CON_ID>2451847</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Decitabine</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Decitabine</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was decitabine administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was decitabine administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Decitabine (Dacogen)</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Decitabine (Dacogen)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2014r1: MDS Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842912</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapy</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Systemic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2842916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mds_base_tx_decitabne_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpost_rel_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpost_therapy_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpre_therapy_multi_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MDSpre_therapy_multi_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_PHCT_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_RP_decitabine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="329">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2862229</PUBLICID>
    <LONGNAME>3-Dimensional Neoplasm Volume Volume Milliliter Value</LONGNAME>
    <PREFERREDNAME>DIM3_VOL_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the volume (length x width x height) in cubic centimeters of a lesion.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2862227</PublicId>
      <PreferredName>DIM3_TUM_VOL</PreferredName>
      <PreferredDefinition>Volume value for a nodule detected through medical imaging._An abnormal tissue growth resulted from uncontrolled cell proliferation._The property of being measured and described using three orthogonal directions.</PreferredDefinition>
      <LongName>3-Dimensional Neoplasm Volume</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2862225</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18005:C3262</PreferredName>
        <Version>1</Version>
        <LongName>3-Dimensional Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18005</PREFERRED_NAME>
            <LONG_NAME>3-Dimensional</LONG_NAME>
            <CON_ID>2534952</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43320</PreferredName>
        <Version>1</Version>
        <LongName>Volume</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43320</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2223991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2823505</PublicId>
      <PreferredName>VOL_ML_VAL</PreferredName>
      <PreferredDefinition>The amount of three dimensional space occupied by an object or the capacity of a space or container._A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Volume Milliliter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>ml</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2823504</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25335:C28254:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Volume Milliliter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28254</PREFERRED_NAME>
            <LONG_NAME>Milliliter</LONG_NAME>
            <CON_ID>2204829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>3-D Tumor Volume (mL)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>3-D Tumor Volume (mL)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="330">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869785</PUBLICID>
    <LONGNAME>Study Site Accrual Status Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868112v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the phase in the lifecycle of a participating site relative to the enrollment of additional subjects in the given study. EXAMPLE(S): Open to accrual; Closed to accrual; Temporarily closed to accrual; Pending accrual.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868112</PublicId>
      <PreferredName>2867638v1.0:2867818v1.0</PreferredName>
      <PreferredDefinition>A facility in which study/protocol activities are conducted._The process of obtaining subjects for a study.:A condition or state at a particular time.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Study Site Accrual Status Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867638</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80403</PreferredName>
        <Version>1</Version>
        <LongName>Study Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80403</PREFERRED_NAME>
            <LONG_NAME>Study Site</LONG_NAME>
            <CON_ID>2866824</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867818</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25403:C25688:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Accrual Status Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25403</PREFERRED_NAME>
            <LONG_NAME>Accrual</LONG_NAME>
            <CON_ID>2203570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Site Accrual Status Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Site Accrual Status Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudySite.accrualStatusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySite:accrualStatusCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="331">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869793</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Observation Plan Study Activity Criterion Name ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>2868120v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To devise, contrive, or formed in design.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.:The words or language units by which a thing is known._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868120</PublicId>
      <PreferredName>2867641v1.0:2867823v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To devise, contrive, or formed in design.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Observation Plan Study Activity Criterion Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867641</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867641v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria Observation Plan Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867823</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25466:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Criterion Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25466</PREFERRED_NAME>
            <LONG_NAME>Criterion</LONG_NAME>
            <CON_ID>2203889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Eligibility Criteria Observation Plan Study Activity Criterion Name ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Eligibility Criteria Observation Plan Study Activity Criterion Name ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PlannedEligibilityCriterion:criterionName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PlannedEligibilityCriterion.criterionName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.PlannedEligibilityCriterion.criterionName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="332">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869820</PUBLICID>
    <LONGNAME>Product Investigation Performed Observation Outcome Evaluation Conclusion Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868147v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the relevant fact within the context of the evaluation final results for a reported suspect medical device. NOTE(S): Based on FDA CDRH Conclusion Codes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868147</PublicId>
      <PreferredName>2867645v1.0:2867833v1.0</PreferredName>
      <PreferredDefinition>The end result of a manufacturing process; anything that is produced.:The act or process of a systematic and thorough examination; research, study; the process of inquiring into or following up, intended to develop facts.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A position or opinion or judgment reached after consideration.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Product Investigation Performed Observation Outcome Evaluation Conclusion Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867645</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867645v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Product Investigation Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41198</PREFERRED_NAME>
            <LONG_NAME>Investigation</LONG_NAME>
            <CON_ID>2469351</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867833</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25214:C54033:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation Conclusion Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54033</PREFERRED_NAME>
            <LONG_NAME>Conclusion</LONG_NAME>
            <CON_ID>2787001</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Product Investigation Performed Observation Outcome Evaluation Conclusion Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Product Investigation Performed Observation Outcome Evaluation Conclusion Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedProductInvestigationResult.evaluationConclusionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProductInvestigationResult:evaluationConclusionCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain.PerformedProductInvestigationResult.evaluationConclusionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProductInvestigation.evaluationConclusionCode</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProductInvestigationResult.evaluationConclusionCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="333">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869908</PUBLICID>
    <LONGNAME>Place Identifier ISO21090.DSET.II.1.0</LONGNAME>
    <PREFERREDNAME>2868233v1.0:2803345v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A unique symbol that establishes identity of the place. EXAMPLE(S): The license plate number of an ambulance, an identifier for a bed in a hospital ward</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868233</PublicId>
      <PreferredName>2493216v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The particular portion of space occupied by a physical object._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Place Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2493216</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25319</PreferredName>
        <Version>1</Version>
        <LongName>Place</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803345</PublicId>
      <PreferredName>2803345v1.0</PreferredName>
      <PreferredDefinition>A collection containing unordered distinct/discrete values of the type II.</PreferredDefinition>
      <LongName>ISO21090.DSET.II.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090DSETv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Place Identifier ISO21090.DSET.II.1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Place Identifier ISO21090.DSET.II.1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.CommonSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Place.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Place:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.CommonSubDomain.Place.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Model Integrity</AlternateName>
        <AlternateNameType>Map:BRIDGSCC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Place.identifier</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Place.identifier</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="334">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2870101</PUBLICID>
    <LONGNAME>Performed Study Activity Status Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868424v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the phase in the lifecycle of a performed activity. EXAMPLE(S): For a lab test, this would be the condition or stage in the lifecycle of the test (e.g., &quot;completed&quot;, &quot;canceled&quot;, etc.).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868424</PublicId>
      <PreferredName>2867719v1.0:2607549v1.0</PreferredName>
      <PreferredDefinition>Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._A condition or state at a particular time.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Performed Study Activity Status Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867719</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Status Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Performed Study Activity Status Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Performed Study Activity Status Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedActivity.statusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedActivity:statusCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedActivity.statusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SubstanceAdministration.statusCode</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LabTest.status</AlternateName>
        <AlternateNameType>Map:Lab</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Activity.statusCode</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProductInvestigation.manufacturerEvaluationStatus</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedActivity.ongoingPerformanceIndicator</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RelatedInvestigation.statusCode (in IndividualCaseSafetyReport)</AlternateName>
        <AlternateNameType>Map:ICSRr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Observation.statusCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ClinicalResult.statusCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Base Test.Test Status</AlternateName>
        <AlternateNameType>Map:CDISCLabv1.0.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EligibilityCriterion.statusCode</AlternateName>
        <AlternateNameType>Map:HL7SD</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SECTION VII FIRST COURSE OF THERAPY - TREATMENT STATUS</AlternateName>
        <AlternateNameType>Map:SEER 2015</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedActivity.statusCode</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Histopathology.statusCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LaboratoryTest.status</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Activity.statusCode</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedActivity.statusCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InvestigativeEvent.statusCode (in IndividualCaseSafetyReport)</AlternateName>
        <AlternateNameType>Map:ICSRr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="335">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2870263</PUBLICID>
    <LONGNAME>Performed Observation Outcome Target Anatomic Site Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868586v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the anatomic location that is the focus of an observation result. EXAMPLE(S): Arm for skin rash. NOTE(S): The target site of the result may be different than the target site of the activity (PerformedObservation) that generated it. A chest x-ray (observation) has the target site of chest while the result might show an infiltration in the left lower lobe of the lung (target site of result), or a dermatological exam may check the skin across the whole body (target site of observation) while the result might identify a rash on the right leg (target site of result).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868586</PublicId>
      <PreferredName>2867619v1.0:2867757v1.0</PreferredName>
      <PreferredDefinition>Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._An object fixed as a goal or point of examination; something to point at; a destination.:Named locations of or within the body.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Performed Observation Outcome Target Anatomic Site Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867757</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25702:C13717:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Target Anatomic Site Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Performed Observation Outcome Target Anatomic Site Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Performed Observation Outcome Target Anatomic Site Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedObservationResult.targetSiteCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult:targetSiteCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedObservationResult.targetAnatomicSiteCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult:targetAnatomicSiteCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="336">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2874074</PUBLICID>
    <LONGNAME>Laboratory Procedure Prior Radiation Therapy Performed Date</LONGNAME>
    <PREFERREDNAME>2874062v1.0:2018550v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the date of the medical procedure that involves testing a sample of blood, urine, or other substance from the body performed prior to radiation therapy, the use of high-energy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2874062</PublicId>
      <PreferredName>2543047v1.0:2874060v1.0</PreferredName>
      <PreferredDefinition>information related to the a medical procedure that involves testing a sample of blood, urine, or other substance from the body performed prior to radiation therapy, the use of high-energy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors.</PreferredDefinition>
      <LongName>Laboratory Procedure Prior Radiation Therapy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2874060</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15313:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Prior Radiation Therapy Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date prior RT ended</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="337">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2889211</PUBLICID>
    <LONGNAME>Laboratory Procedure CD4-Positive T-Lymphocyte Outcome Date</LONGNAME>
    <PREFERREDNAME>LAB_CD4_OC_PTG_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on which an observation was made or an event occurred related to the result of the medical procedure that involves testing a sample of blood for CD4+ T-lymphocyte, a type of white blood cell that helps stimulate immune system reactions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195883</PublicId>
      <PreferredName>LAB_CD4_OC</PreferredName>
      <PreferredDefinition>information related to the result of the medical procedure that involves testing a sample of blood for CD4+ T-lymphocyte, a type of white blood cell that helps stimulate immune system reactions.</PreferredDefinition>
      <LongName>Laboratory Procedure CD4-Positive T-Lymphocyte Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2775202</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12537:C20200</PreferredName>
        <Version>1</Version>
        <LongName>CD4-Positive T-Lymphocyte Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12537</PREFERRED_NAME>
            <LONG_NAME>CD4-Positive T-Lymphocyte</LONG_NAME>
            <CON_ID>2542052</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of CD4 count</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of CD4 count</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date drawn</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC Question Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date most recent CD4 count obtained</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date CD4 count collected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of CD4 result:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Checklist</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283432</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Evaluations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_CD4_OC_PTG_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CD4_LBDAT</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CD4CNTDAT</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="338">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2896996</PUBLICID>
    <LONGNAME>Per Probe Copy Number Analysis Outcome Chromosome Number java.lang.String</LONGNAME>
    <PREFERREDNAME>2896992v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>For each, generally denoting a ratio.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:The result of an action._One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.:A numeral or string of numerals expressing value, quantity, or identification._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2896992</PublicId>
      <PreferredName>2896988v1.0:2771061v1.0</PreferredName>
      <PreferredDefinition>For each, generally denoting a ratio.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:The result of an action._One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.:A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Per Probe Copy Number Analysis Outcome Chromosome Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2896988</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2896988v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Per Probe Copy Number Analysis Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43523</PREFERRED_NAME>
            <LONG_NAME>Probe</LONG_NAME>
            <CON_ID>2433326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49142</PREFERRED_NAME>
            <LONG_NAME>Copy Number</LONG_NAME>
            <CON_ID>2528506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13202:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Chromosome Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13202</PREFERRED_NAME>
            <LONG_NAME>Chromosome</LONG_NAME>
            <CON_ID>2203872</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Per Probe Copy Number Analysis Outcome Chromosome Number java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Per Probe Copy Number Analysis Outcome Chromosome Number java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2804620</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern CN Analy Serv</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.icr.asrv1.cnstate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000373</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2819751</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Copy Number Analysis Tool</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.icr.asrv1.cnstate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000374</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2828532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DNA Copy Analytical Service</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.icr.asrv1.cnstate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProbeCopyNumberState:chromosome</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.icr.asrv1.cnstate.ProbeCopyNumberState.chromosome</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="339">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2897074</PUBLICID>
    <LONGNAME>Month Immunotherapy Start Number</LONGNAME>
    <PREFERREDNAME>MON_IMMURX_ST_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the month in which immunotherapy began.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2554413</PublicId>
      <PreferredName>2554222v1.0:2207412v1.0</PreferredName>
      <PreferredDefinition>Therapy that designed to induce changes of patient&#39;s immune status in treatment of disease. The concept encompassing various treatment modalities including active and passive immunization, treatment with immunopotentiators, immunosuppressants and nonspecific systemic immunostimulators and adjuvants, desensitization to any allergens, bone marrow transplantation, thymus implantation._Have a beginning, in a temporal, spatial, or evaluative sense.:a particular day specified as the time something has, or will, happen.</PreferredDefinition>
      <LongName>Immunotherapy Begin Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2554222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15262</PreferredName>
        <Version>1</Version>
        <LongName>Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207412</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Begin Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2895904</PublicId>
      <PreferredName>EVT_MON_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Event Month Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2895903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29846:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Month Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>One of ten equal parts; a quantity corresponding to one tenth of the whole.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C81010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::12: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::9: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::7: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the third position in an ordering or series; coming next after the third and just before the fifth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3rd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the second position in an ordering or series.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Coming next after the first in position in space or time or degree or magnitude.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1st month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Preceding all others in time or space or degree.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2896404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Month of Immunotherapy start</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Month of Immunotherapy start</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="340">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2897082</PUBLICID>
    <LONGNAME>Day Immunotherapy End Number</LONGNAME>
    <PREFERREDNAME>DAY_IMMRX_END_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the day of the end of immunotherapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2554409</PublicId>
      <PreferredName>2554222v1.0:2231605v1.0</PreferredName>
      <PreferredDefinition>Therapy that designed to induce changes of patient&#39;s immune status in treatment of disease. The concept encompassing various treatment modalities including active and passive immunization, treatment with immunopotentiators, immunosuppressants and nonspecific systemic immunostimulators and adjuvants, desensitization to any allergens, bone marrow transplantation, thymus implantation._The point or place at which something terminates in time, space, or extent.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Immunotherapy End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2554222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15262</PreferredName>
        <Version>1</Version>
        <LongName>Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496:C25164</PreferredName>
        <Version>1</Version>
        <LongName>End Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2896868</PublicId>
      <PreferredName>EVT_DAY_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._time for Earth to make a complete rotation on its axis._A numeral or string of numerals expressing value, quantity, or identification</PreferredDefinition>
      <LongName>Event Day Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2896867</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C0439228:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Day Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0439228</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2204684</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>22nd day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::22: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::22</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>21st day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>20th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::20: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::20</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>19th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::19: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::19</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>18th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::18: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::18</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>17th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::17: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::17</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>16th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::16: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::16</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>15th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::15: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::15</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>14th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::14: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::14</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>13th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::13: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::13</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1st day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::1: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::1</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2896392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::10: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::10</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::12: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::2: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3rd day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::3: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::3</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::4: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::4</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::5: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::5</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::6: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::7: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::9: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>31st day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::31: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::31</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>30th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::30: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::30</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>29th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::29: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::29</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>28th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::28: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::28</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>27th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::27: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::27</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>26th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::26: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::26</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>25th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::25: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::25</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>24th day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::24: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::24</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>23rd day of a calendar month</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::23: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C29846, C19459, C45255::23</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Day of Immunotherapy end</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Day of Immunotherapy end</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="341">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2897104</PUBLICID>
    <LONGNAME>Year Radiation Therapy Start Number</LONGNAME>
    <PREFERREDNAME>YR_RT_ST_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the year of the start of radiation therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188786</PublicId>
      <PreferredName>RT_BEG_OCUR</PreferredName>
      <PreferredDefinition>information related to begin date or occurrence for radiation therapy.</PreferredDefinition>
      <LongName>RT Begin Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176998</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RT</PreferredName>
        <Version>1</Version>
        <LongName>RT</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207746</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Begin Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2896906</PublicId>
      <PreferredName>EVT_YR_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Event Year Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY </DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2896905</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29848:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Year Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year of Radiation Therapy sta</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Year of Radiation Therapy start</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year Radiation Therapy Started</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Year Radiation Therapy Started</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TCGA Application Question</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Year Radiation Therapy Started for the Other Malignancy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BRCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CESC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>COAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787503</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GBM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787504</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KICH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787508</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787513</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OV</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787514</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PAAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>READ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SKCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787519</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>STAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787520</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>THCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCEC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical radiation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787542</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLGSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5655940</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>year_of_radiation_therapy_start</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="342">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898800</PUBLICID>
    <LONGNAME>Organizational Unit Life Sciences Identifier Organizational Unit java.lang.String</LONGNAME>
    <PREFERREDNAME>2898634v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Organizational unit like a laboratory, institute or consortium. (caBIO)_A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898634</PublicId>
      <PreferredName>2224111v1.0:2898544v1.0</PreferredName>
      <PreferredDefinition>Organizational unit like a laboratory, institute or consortium. (caBIO)_A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium.</PreferredDefinition>
      <LongName>Organizational Unit Life Sciences Identifier Organizational Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224111</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41167</PreferredName>
        <Version>1</Version>
        <LongName>Organizational Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41167</PREFERRED_NAME>
            <LONG_NAME>Organizational Unit</LONG_NAME>
            <CON_ID>2223214</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C41167</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Organizational Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41167</PREFERRED_NAME>
            <LONG_NAME>Organizational Unit</LONG_NAME>
            <CON_ID>2223214</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Organizational Unit Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Organizational Unit Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000253</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.contact</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.contact.Organization.lsidAuthority</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:lsidAuthority</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="343">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898855</PUBLICID>
    <LONGNAME>Controlled Vocabulary Term Parameter Value Life Sciences Identifier Organizational Unit java.lang.String</LONGNAME>
    <PREFERREDNAME>2898689v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A specified list of terms with a fixed and unalterable meaning, and from which a selection is made when cataloging, indexing, or searching books, journals, and other documents. The control is intended to avoid the scattering of related subjects under different headings.:A word or expression used for some particular thing.:Any factor that defines a system and determines (or limits) its performance.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898689</PublicId>
      <PreferredName>2898540v1.0:2898544v1.0</PreferredName>
      <PreferredDefinition>A specified list of terms with a fixed and unalterable meaning, and from which a selection is made when cataloging, indexing, or searching books, journals, and other documents. The control is intended to avoid the scattering of related subjects under different headings.:A word or expression used for some particular thing.:Any factor that defines a system and determines (or limits) its performance.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium.</PreferredDefinition>
      <LongName>Controlled Vocabulary Term Parameter Value Life Sciences Identifier Organizational Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2898540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48697:C45559:C44175:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Controlled Vocabulary Term Parameter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48697</PREFERRED_NAME>
            <LONG_NAME>Controlled Vocabulary</LONG_NAME>
            <CON_ID>2519067</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C41167</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Organizational Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41167</PREFERRED_NAME>
            <LONG_NAME>Organizational Unit</LONG_NAME>
            <CON_ID>2223214</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Controlled Vocabulary Term Parameter Value Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Controlled Vocabulary Term Parameter Value Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TermBasedParameterValue:lsidAuthority</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.protocol.TermBasedParameterValue.lsidAuthority</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="344">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900005</PUBLICID>
    <LONGNAME>Image Feature Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2899747v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899747</PublicId>
      <PreferredName>2899645v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Image Feature Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899645</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70838</PreferredName>
        <Version>1</Version>
        <LongName>Image Feature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70838</PREFERRED_NAME>
            <LONG_NAME>Image Feature</LONG_NAME>
            <CON_ID>2710233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Feature Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Feature Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.analysis.featureextraction</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GenericFeature:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.analysis.featureextraction.GenericFeature.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="345">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900128</PUBLICID>
    <LONGNAME>Tissue Microarray Data Field Group Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2899870v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:An area of database record, or graphical user interface form, into which a particular item of data is entered.:Any number of entities (members) considered as a unit._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899870</PublicId>
      <PreferredName>2899676v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:An area of database record, or graphical user interface form, into which a particular item of data is entered.:Any number of entities (members) considered as a unit._A statement or an account describing something.</PreferredDefinition>
      <LongName>Tissue Microarray Data Field Group Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19922:C25507:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Microarray Data Field Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19922</PREFERRED_NAME>
            <LONG_NAME>Tissue Microarray</LONG_NAME>
            <CON_ID>2842644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25507</PREFERRED_NAME>
            <LONG_NAME>Data Field</LONG_NAME>
            <CON_ID>2202635</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tissue Microarray Data Field Group Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tissue Microarray Data Field Group Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma.dynamic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899635</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TmaDataPanel:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.dynamic.TmaDataPanel.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="346">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900146</PUBLICID>
    <LONGNAME>Evaluation Question Set Instruction java.lang.String</LONGNAME>
    <PREFERREDNAME>2899888v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A group of things of the same kind that belong together and are so used._A message describing how something is to be done._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899888</PublicId>
      <PreferredName>2899681v1.0:2518557v1.0</PreferredName>
      <PreferredDefinition>Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A group of things of the same kind that belong together and are so used._A message describing how something is to be done.</PreferredDefinition>
      <LongName>Evaluation Question Set Instruction</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899681</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25214:C41116:C47894</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation Question Set</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47894</PREFERRED_NAME>
            <LONG_NAME>Set</LONG_NAME>
            <CON_ID>2425537</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2518557</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42688</PreferredName>
        <Version>1</Version>
        <LongName>Instruction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42688</PREFERRED_NAME>
            <LONG_NAME>Instruction</LONG_NAME>
            <CON_ID>2231589</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Evaluation Question Set Instruction java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Evaluation Question Set Instruction java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma.evaluation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Question:instruction</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.evaluation.Question.instruction</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="347">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900166</PUBLICID>
    <LONGNAME>Tissue Microarray Row Quantity java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2899908v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes._An arrangement of objects side by side in a line.:How much there is of something that you can measure; the total amount or number._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899908</PublicId>
      <PreferredName>2899683v1.0:2553656v1.0</PreferredName>
      <PreferredDefinition>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes._An arrangement of objects side by side in a line.:How much there is of something that you can measure; the total amount or number.</PreferredDefinition>
      <LongName>Tissue Microarray Row Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899683</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19922</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Microarray</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19922</PREFERRED_NAME>
            <LONG_NAME>Tissue Microarray</LONG_NAME>
            <CON_ID>2842644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553656</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43378:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Row Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43378</PREFERRED_NAME>
            <LONG_NAME>Row</LONG_NAME>
            <CON_ID>2236514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tissue Microarray Row Quantity java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tissue Microarray Row Quantity java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TissueMicroarray:numberOfRow</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.TissueMicroarray.numberOfRow</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="348">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900231</PUBLICID>
    <LONGNAME>Image Feature Data Extraction Algorithm Implementation Author java.lang.String</LONGNAME>
    <PREFERREDNAME>2899973v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A process whereby specific data is taken out of a larger set of data and presented in a usable format.:A defined procedure for solving a problem.  Applied to a problem-solving procedure implemented in software to be executed by a computer._The act of carrying into effect.:The writer of a book, article, or other text._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899973</PublicId>
      <PreferredName>2899646v1.0:2899693v1.0</PreferredName>
      <PreferredDefinition>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A process whereby specific data is taken out of a larger set of data and presented in a usable format.:A defined procedure for solving a problem.  Applied to a problem-solving procedure implemented in software to be executed by a computer._The act of carrying into effect.:The writer of a book, article, or other text.</PreferredDefinition>
      <LongName>Image Feature Data Extraction Algorithm Implementation Author</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70838:C44285:C16275</PreferredName>
        <Version>1</Version>
        <LongName>Image Feature Data Extraction Algorithm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70838</PREFERRED_NAME>
            <LONG_NAME>Image Feature</LONG_NAME>
            <CON_ID>2710233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44285</PREFERRED_NAME>
            <LONG_NAME>Data Extraction</LONG_NAME>
            <CON_ID>2236550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16275</PREFERRED_NAME>
            <LONG_NAME>Algorithm</LONG_NAME>
            <CON_ID>2553061</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47899:C42781</PreferredName>
        <Version>1</Version>
        <LongName>Implementation Author</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47899</PREFERRED_NAME>
            <LONG_NAME>Implementation</LONG_NAME>
            <CON_ID>2427515</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42781</PREFERRED_NAME>
            <LONG_NAME>Author</LONG_NAME>
            <CON_ID>2223995</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Feature Data Extraction Algorithm Implementation Author java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Feature Data Extraction Algorithm Implementation Author java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.analysis.featureextraction</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FeatureExtraction:author</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.analysis.featureextraction.FeatureExtraction.author</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="349">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2903302</PUBLICID>
    <LONGNAME>Image Series Protocol Name 64 Character Text</LONGNAME>
    <PREFERREDNAME>2902818v1.0:2584117v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text which defines a users description of the conditions under which the (imaging) Series was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2902818</PublicId>
      <PreferredName>2436196v1.0:2553635v1.0</PreferredName>
      <PreferredDefinition>User-defined description of the conditions under which the (imaging) Series was performed.</PreferredDefinition>
      <LongName>Image Series Protocol Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2436196</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179:C25674</PreferredName>
        <Version>1</Version>
        <LongName>Image Series</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25674</PREFERRED_NAME>
            <LONG_NAME>Series</LONG_NAME>
            <CON_ID>2202620</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2584117</PublicId>
      <PreferredName>2584117v1.0</PreferredName>
      <PreferredDefinition>LO: A 64-character string with leading or trailing spaces being non-significant; NO CONTROL characters. [Standard-based]</PreferredDefinition>
      <LongName>64 Character Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>64</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2637360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45253:C25704</PreferredName>
        <Version>1</Version>
        <LongName>String Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45253</PREFERRED_NAME>
            <LONG_NAME>String</LONG_NAME>
            <CON_ID>2539471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Image Protocol Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Image Protocol Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DICOM Tag CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2693115</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA_Model</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Silver Review Modified CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2838921</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2944977</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NBIA</PreferredName>
          <Version>5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ncia.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000240</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ncia.domain.ImageSeries.protocolName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImageSeries:protocolName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="350">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2903584</PUBLICID>
    <LONGNAME>Temporomandibular Joint Disorder Pain Other Symptom Specify</LONGNAME>
    <PREFERREDNAME>TMJD_P_OTH_SYM_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field related to the other indication of discomfort from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2903345</PublicId>
      <PreferredName>TEMDJD_PA_P_O_SYM</PreferredName>
      <PreferredDefinition>information related to the other indication of discomfort from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.</PreferredDefinition>
      <LongName>Temporomandibular Joint Disorder Pain Other Symptom</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2903323</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63709:C3303</PreferredName>
        <Version>1</Version>
        <LongName>Temporomandibular Joint Disorder Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63709</PREFERRED_NAME>
            <LONG_NAME>Temporomandibular Joint Disorder</LONG_NAME>
            <CON_ID>2547865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Other Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2228479</PublicId>
      <PreferredName>SM_SPEC</PreferredName>
      <PreferredDefinition>the free-text field related to a symptom.</PreferredDefinition>
      <LongName>Symptom Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Orthodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="351">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2903755</PUBLICID>
    <LONGNAME>Temporomandibular Joint Disorder Pain Treatment Muscle Relaxant Administered Frequency</LONGNAME>
    <PREFERREDNAME>TMJD_P_TX_MR_AD_FR</PREFERREDNAME>
    <PREFERREDDEFINITION>the number of occurrences of muscle relaxant treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2903432</PublicId>
      <PreferredName>TMJD_PAI_TX_MR_AD</PreferredName>
      <PreferredDefinition>information related to muscle relaxant treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.</PreferredDefinition>
      <LongName>Temporomandibular Joint Disorder Pain Treatment Muscle Relaxant Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2862211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63709:C3303:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Temporomandibular Joint Disorder Pain Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63709</PREFERRED_NAME>
            <LONG_NAME>Temporomandibular Joint Disorder</LONG_NAME>
            <CON_ID>2547865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2903430</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29891:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Muscle Relaxant Preparation Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29891</PREFERRED_NAME>
            <LONG_NAME>Muscle Relaxant Preparation</LONG_NAME>
            <CON_ID>2903429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2902259</PublicId>
      <PreferredName>DNTL_QUEST_FREQ</PreferredName>
      <PreferredDefinition>the number of occurrences of something used in dental questionnaire.</PreferredDefinition>
      <LongName>Dental Questionnaire Frequency</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2443080</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25515</PreferredName>
        <Version>1</Version>
        <LongName>Temporal Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Usually</VALIDVALUE>
          <VALUEMEANING>Usually</VALUEMEANING>
          <MEANINGDESCRIPTION>That which is considered customary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Half of time</VALIDVALUE>
          <VALUEMEANING>Half of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>Half of the time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2902260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2889147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2889148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Muscle relaxant</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Muscle relaxant</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Orthodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="352">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2908019</PUBLICID>
    <LONGNAME>Person Quality of Life Clinical Study Refuse Consent Specify</LONGNAME>
    <PREFERREDNAME>2907014v1.0:2018806v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify the reason a person refusing to agree to participate in a Quality of Life study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2907014</PublicId>
      <PreferredName>2236731v1.0:2906985v1.0</PreferredName>
      <PreferredDefinition>information related to a person refusing to agree to participate in a Quality of Life study.</PreferredDefinition>
      <LongName>Person Quality of Life Clinical Study Refuse Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2906985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047:C15206:C49161:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life Clinical Study Refuse Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49161</PREFERRED_NAME>
            <LONG_NAME>Refuse</LONG_NAME>
            <CON_ID>2427336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018806</PublicId>
      <PreferredName>ASSESS_SPEC</PreferredName>
      <PreferredDefinition>The free text field to specify the assessment performed.</PreferredDefinition>
      <LongName>Assessment Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If response is &quot;5) Other reason&quot;, specify the reason the patient will not participate in the quality of life component of the study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If response is: 5) Other reason, specify the reason the patient will not participate in the net clinical benefit component of the study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1008</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1010</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1114</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PRSN_QOL_REFUSE_CNST_SPECIFY</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PR_QOL_REF_CNST_SP</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2907014v1.0:2018806v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="353">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2911999</PUBLICID>
    <LONGNAME>Aplastic Anemia Classification Anemia Hemoglobinopathy Type</LONGNAME>
    <PREFERREDNAME>2911995v1.0:2689128v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the classification of aplastic anemia.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2911995</PublicId>
      <PreferredName>2934401v1.0:2321361v1.0</PreferredName>
      <PreferredDefinition>Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow).  The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well.  Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors. -- 2004 _A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Aplastic Anemia Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2934401</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2870</PreferredName>
        <Version>1</Version>
        <LongName>Aplastic Anemia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2870</PREFERRED_NAME>
            <LONG_NAME>Aplastic Anemia</LONG_NAME>
            <CON_ID>2486851</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2321361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25161</PreferredName>
        <Version>1</Version>
        <LongName>Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2689128</PublicId>
      <PreferredName>ANM_HMGLBN_TP</PreferredName>
      <PreferredDefinition>A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability._A group of inherited disorders characterized by structural alterations within the hemoglobin molecule._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Anemia Hemoglobinopathy Type</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2689127</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2869:C3092:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Anemia Hemoglobinopathy Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2869</PREFERRED_NAME>
            <LONG_NAME>Anemia</LONG_NAME>
            <CON_ID>2419896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3092</PREFERRED_NAME>
            <LONG_NAME>Hemoglobinopathy</LONG_NAME>
            <CON_ID>2593294</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thalassemia, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Thalassemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35069, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fanconi anemia</VALIDVALUE>
          <VALUEMEANING>Fanconi anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diamond-Blackfan anemia (pure red cell aplasia)</VALIDVALUE>
          <VALUEMEANING>Diamond-Blackfan Anemia PT: Congenital Pure Red Cell Aplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3322760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shwachman-Diamond</VALIDVALUE>
          <VALUEMEANING>Schwachmann-Diamond Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3326330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other hemoglobinopathy</VALIDVALUE>
          <VALUEMEANING>Other Hemoglobinopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3092, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other constitutional anemia</VALIDVALUE>
          <VALUEMEANING>Other Genetic Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Not otherwise specified.: Having to do with information that is passed from parents to offspring through genes in sperm and egg cells; inherited.: A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2869, C17938, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sickle cell disease</VALIDVALUE>
          <VALUEMEANING>sickle cell disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sickle thalassemia</VALIDVALUE>
          <VALUEMEANING>Sickle Cell-Thalassemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Hemolytic anemia, in which patients are heterozygous for both the sickle cell gene and a thalassemia gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3326333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acquired Severe Aplastic Anemia (SAA), NOS</VALIDVALUE>
          <VALUEMEANING>Severe Aplastic Anemia Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening anemia associated with a high risk of infection or bleeding._Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C61229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acquired SAA, secondary to toxin / other drug</VALIDVALUE>
          <VALUEMEANING>Drug-Induced Aplastic Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A state of bone marrow suppression and failure that is caused by a cytotoxic or adverse immunologic response to a drug treatment, leading to a failure of production of red blood cells, white cells and platelets.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acquired SAA, secondary to hepatitis</VALIDVALUE>
          <VALUEMEANING>Aplastic Anemia due to Hepatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow failure defined as pancytopenia, secondary to hepatitis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acquired Pure Red Cell Aplasia (PRCA) (not congenital)</VALIDVALUE>
          <VALUEMEANING>acquired pure red cell aplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disease characterized by normocytic, normochromic anemia, low hematocrit, reticulocytopenia and selective erythroid hypoplasia. It can occur as a chronic or acute form; the former is predominantly seen in adults and the latter in children. Pathogenesis involves immune dysfunction with antibodies directed against erythroid precursor cells or erythropoietin, or due to T-cell mediated suppression of erythropoiesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acquired amegakaryocytosis (not congenital)</VALIDVALUE>
          <VALUEMEANING>Not Genetic Amegakaryocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction._Having to do with information that is passed from parents to offspring through genes in sperm and egg cells._A non-neoplastic, congenital or non-congenital disorder charcaterized by marked reduction or absence of megakaryocytes and thrombocytopenia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61248, C17938, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other acquired cytopenic syndrome</VALIDVALUE>
          <VALUEMEANING>Other Not Genetic Cytopenia</VALUEMEANING>
          <MEANINGDESCRIPTION>Not otherwise specified.: An operation in which a term denies or inverts the meaning of another term or construction.: Having to do with information that is passed from parents to offspring through genes in sperm and egg cells; inherited.: A reduction in the number of blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2979, C17938, C25594, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2689230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta thalassemia major</VALIDVALUE>
          <VALUEMEANING>Thalassemia Major</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive disorder that affects the production of beta polypeptide chains which are necessary for the hemoglobin synthesis. Anemia and failure to thrive are characteristic features.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paroxysmal nocturnal hemoglobinuria (PNH)</VALIDVALUE>
          <VALUEMEANING>Paroxysmal Nocturnal Hemoglobinuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the classification o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the classification of the aplastic anemia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Classification:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Classification:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2911999</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis.value(ANY=&gt;CD).code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2400r1: Pre-TED</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_who_anemia_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="354">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919262</PUBLICID>
    <LONGNAME>Additional Information Pathology Report Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2919232v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Added; extra; further.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication._A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919232</PublicId>
      <PreferredName>2747619v1.0:2919203v1.0</PreferredName>
      <PreferredDefinition>Added; extra; further.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication._A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Additional Information Pathology Report Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C48191</PreferredName>
        <Version>1</Version>
        <LongName>Additional Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2919203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28277:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Pathology Report Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28277</PREFERRED_NAME>
            <LONG_NAME>Pathology Report</LONG_NAME>
            <CON_ID>2202705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Additional Information Pathology Report Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Additional Information Pathology Report Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813011</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.AdditionalInformation.pathologyReport</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdditionalInformation:pathologyReport</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="355">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919562</PUBLICID>
    <LONGNAME>Abstract Specimen Class Specimen Class Text Type</LONGNAME>
    <PREFERREDNAME>2919414v1.0:2615469v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A concept or idea not associated with any specific instance.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Class; a collection of things sharing a common attribute._Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._Class; a collection of things sharing a common attribute._Text; the words of something written._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919414</PublicId>
      <PreferredName>2919356v1.0:2430993v1.0</PreferredName>
      <PreferredDefinition>A concept or idea not associated with any specific instance.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Class; a collection of things sharing a common attribute.</PreferredDefinition>
      <LongName>Abstract Specimen Class</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2919356</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42874:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Abstract Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42874</PREFERRED_NAME>
            <LONG_NAME>Abstract</LONG_NAME>
            <CON_ID>2224028</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2430993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25346</PreferredName>
        <Version>1</Version>
        <LongName>Class</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25346</PREFERRED_NAME>
            <LONG_NAME>Class</LONG_NAME>
            <CON_ID>2203880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2615469</PublicId>
      <PreferredName>2615469v1.0</PreferredName>
      <PreferredDefinition>Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._Class; a collection of things sharing a common attribute._Text; the words of something written._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Specimen Class Text Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Text Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid</VALIDVALUE>
          <VALUEMEANING>Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Fluid</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular</VALIDVALUE>
          <VALUEMEANING>Molecular</VALUEMEANING>
          <MEANINGDESCRIPTION>relating to or produced by or consisting of molecules.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tissue</VALIDVALUE>
          <VALUEMEANING>Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell</VALIDVALUE>
          <VALUEMEANING>Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2615470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Abstract Specimen Class Specimen Class Text Type does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Abstract Specimen Class Specimen Class Text Type does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AbstractSpecimen:specimenClass</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.AbstractSpecimen.specimenClass</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="356">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919566</PUBLICID>
    <LONGNAME>Report Problem Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2919418v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A short textual account; having provided a short account.:A difficulty, disorder, or condition needing resolution._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919418</PublicId>
      <PreferredName>2919357v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>A short textual account; having provided a short account.:A difficulty, disorder, or condition needing resolution._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Report Problem Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2919357</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25375:C28020</PreferredName>
        <Version>1</Version>
        <LongName>Report Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Report Problem Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Report Problem Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.ReportedProblem.comments</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReportedProblem:comments</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="357">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919631</PUBLICID>
    <LONGNAME>Cell Specimen Requirement Lineage Specimen Lineage Text Type</LONGNAME>
    <PREFERREDNAME>2919483v1.0:2584018v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that is necessary; condition, something that is obligatory._Descent in a line from a common progenitor or source._Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._Descent in a line from a common progenitor or source._Text; the words of something written._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919483</PublicId>
      <PreferredName>2513391v1.0:2553142v1.0</PreferredName>
      <PreferredDefinition>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Something that is necessary; condition, something that is obligatory._Descent in a line from a common progenitor or source.</PreferredDefinition>
      <LongName>Cell Specimen Requirement Lineage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12508:C19157:C38015</PreferredName>
        <Version>1</Version>
        <LongName>Cell Specimen Requirement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38015</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2203776</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553142</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60792</PreferredName>
        <Version>1</Version>
        <LongName>Lineage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60792</PREFERRED_NAME>
            <LONG_NAME>Lineage</LONG_NAME>
            <CON_ID>2496587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2584018</PublicId>
      <PreferredName>2584018v1.0</PreferredName>
      <PreferredDefinition>Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._Descent in a line from a common progenitor or source._Text; the words of something written._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Specimen Lineage Text Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Text Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>New</VALIDVALUE>
          <VALUEMEANING>NEW</VALUEMEANING>
          <MEANINGDESCRIPTION>New; having no previous example or precedent or parallel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Derived</VALIDVALUE>
          <VALUEMEANING>Derived</VALUEMEANING>
          <MEANINGDESCRIPTION>To take, obtain, or receive from a source; having been determined by mathematical computation. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2584019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aliquot</VALIDVALUE>
          <VALUEMEANING>Aliquot</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to a portion of the whole; any one of two or more samples of something, of the same volume or weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2584020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cell Specimen Requirement Lineage Specimen Lineage Text Type does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cell Specimen Requirement Lineage Specimen Lineage Text Type does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CellSpecimenRequirement:lineage</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.CellSpecimenRequirement.lineage</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="358">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2927765</PUBLICID>
    <LONGNAME>Software Service Application Context Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2927693v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A software system providing a public need.:A designation or description of the application environment or discipline in which a name is applied or from which it originates._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2927693</PublicId>
      <PreferredName>2927620v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A software system providing a public need.:A designation or description of the application environment or discipline in which a name is applied or from which it originates._A statement or an account describing something.</PreferredDefinition>
      <LongName>Software Service Application Context Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2927620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80736:C41086</PreferredName>
        <Version>1</Version>
        <LongName>Software Service Application Context</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80736</PREFERRED_NAME>
            <LONG_NAME>Software Service</LONG_NAME>
            <CON_ID>2927597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41086</PREFERRED_NAME>
            <LONG_NAME>Application Context</LONG_NAME>
            <CON_ID>2223418</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Software Service Application Context Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Software Service Application Context Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caGrid_1.x</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2927590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cagrid.metadata.service</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2927595</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cagrid.metadata.service.ServiceContext.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ServiceContext:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@description</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="359">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2927766</PUBLICID>
    <LONGNAME>Software Service Application Context Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2927694v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A software system providing a public need.:A designation or description of the application environment or discipline in which a name is applied or from which it originates._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2927694</PublicId>
      <PreferredName>2927620v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>A software system providing a public need.:A designation or description of the application environment or discipline in which a name is applied or from which it originates._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Software Service Application Context Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2927620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80736:C41086</PreferredName>
        <Version>1</Version>
        <LongName>Software Service Application Context</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80736</PREFERRED_NAME>
            <LONG_NAME>Software Service</LONG_NAME>
            <CON_ID>2927597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41086</PREFERRED_NAME>
            <LONG_NAME>Application Context</LONG_NAME>
            <CON_ID>2223418</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Software Service Application Context Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Software Service Application Context Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caGrid_1.x</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2927590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cagrid.metadata.service</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2927595</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cagrid.metadata.service.ServiceContext.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@name</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ServiceContext:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="360">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2927774</PUBLICID>
    <LONGNAME>Input Programming Parameter Qualifier Name Qualified Name Text</LONGNAME>
    <PREFERREDNAME>2927702v1.0:2904830v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Anything added into a sytem.:A value that is passed to a routine._A term that helps define and render a concept unique.:The words or language units by which a thing is known._A first-in first-out data structure used to sequence objects and to line up requests for a resource.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2927702</PublicId>
      <PreferredName>2927622v1.0:2927648v1.0</PreferredName>
      <PreferredDefinition>Anything added into a sytem.:A value that is passed to a routine._A term that helps define and render a concept unique.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Input Programming Parameter Qualifier Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2927622</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47905:C48913</PreferredName>
        <Version>1</Version>
        <LongName>Input Programming Parameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47905</PREFERRED_NAME>
            <LONG_NAME>Input</LONG_NAME>
            <CON_ID>2422639</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48913</PREFERRED_NAME>
            <LONG_NAME>Programming Parameter</LONG_NAME>
            <CON_ID>2451932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2927648</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41009:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Qualifier Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41009</PREFERRED_NAME>
            <LONG_NAME>Qualifier</LONG_NAME>
            <CON_ID>2231576</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2904830</PublicId>
      <PreferredName>2904830v1.0</PreferredName>
      <PreferredDefinition>A first-in first-out data structure used to sequence objects and to line up requests for a resource.</PreferredDefinition>
      <LongName>Qualified Name Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Input Programming Parameter Qualifier Name Qualified Name Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Input Programming Parameter Qualifier Name Qualified Name Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caGrid_1.x</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2927590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2927589</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caGrid_Metadata_Models</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cagrid.metadata.service</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2927595</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cagrid.metadata.service.InputParameter.qName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InputParameter:qName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@qName</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="361">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2930682</PUBLICID>
    <LONGNAME>Ratio Original Text ISO21090.ED.TEXT.v1.0</LONGNAME>
    <PREFERREDNAME>2929182v1.0:2846976v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The relative magnitudes of two quantities (usually expressed as a quotient)._Preceding all others in time or being as first made or performed.:The words of something written._Constrains ED so that it may only contain plain text.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2929182</PublicId>
      <PreferredName>2236798v1.0:2928440v1.0</PreferredName>
      <PreferredDefinition>The relative magnitudes of two quantities (usually expressed as a quotient)._Preceding all others in time or being as first made or performed.:The words of something written.</PreferredDefinition>
      <LongName>Ratio Original Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236798</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44256</PreferredName>
        <Version>1</Version>
        <LongName>Ratio</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2928440</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25604:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Original Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25604</PREFERRED_NAME>
            <LONG_NAME>Original</LONG_NAME>
            <CON_ID>2206332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2846976</PublicId>
      <PreferredName>2846976v1.0</PreferredName>
      <PreferredDefinition>Constrains ED so that it may only contain plain text.</PreferredDefinition>
      <LongName>ISO21090.ED.TEXT.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090EDTEXTv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Ratio Original Text ISO21090.ED.TEXT.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Ratio Original Text ISO21090.ED.TEXT.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2928087</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ISO21090v1_0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISO21090v1_0.ISODatatypes</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2928092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>coppa_datatypes.iso21090.isodatatype</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958967</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RTO:originalText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ISO21090v1_0.ISODatatypes.RTO.originalText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coppa_datatypes.iso21090.isodatatype.RTO.originalText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="362">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2931042</PUBLICID>
    <LONGNAME>Text Encapsulation Data Restriction Character Set ISO21090.Code.v1.0</LONGNAME>
    <PREFERREDNAME>2929542v1.0:2862119v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The words of something written.:The process or condition of being enclosed.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Anything that limits; a limitation._A defined list of characters recognized by the computer hardware and software. Each character is represented by a number._A string that is an identifier, and therefore must be either a string representation of an OID, a UUID, or a simple token taken from a lsit of controlled names for the context in which the Uid is used.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2929542</PublicId>
      <PreferredName>2928185v1.0:2772185v1.0</PreferredName>
      <PreferredDefinition>The words of something written.:The process or condition of being enclosed.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Anything that limits; a limitation._A defined list of characters recognized by the computer hardware and software. Each character is represented by a number.</PreferredDefinition>
      <LongName>Text Encapsulation Data Restriction Character Set</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2928185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C73476:C25474:C53452</PreferredName>
        <Version>1</Version>
        <LongName>Text Encapsulation Data Restriction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73476</PREFERRED_NAME>
            <LONG_NAME>Encapsulation</LONG_NAME>
            <CON_ID>2753712</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53452</PREFERRED_NAME>
            <LONG_NAME>Restriction</LONG_NAME>
            <CON_ID>2726208</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2772185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42631</PreferredName>
        <Version>1</Version>
        <LongName>Character Set</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42631</PREFERRED_NAME>
            <LONG_NAME>Character Set</LONG_NAME>
            <CON_ID>2231561</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2862119</PublicId>
      <PreferredName>2862119v1.0</PreferredName>
      <PreferredDefinition>A string that is an identifier, and therefore must be either a string representation of an OID, a UUID, or a simple token taken from a lsit of controlled names for the context in which the Uid is used.</PreferredDefinition>
      <LongName>ISO21090.Code.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>UMLCodev1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Text Encapsulation Data Restriction Character Set ISO21090.Code.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Text Encapsulation Data Restriction Character Set ISO21090.Code.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2928087</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ISO21090v1_0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISO21090v1_0.Constraint</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2928088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>coppa_datatypes.iso21090.constraint</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958965</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EDTEXT:charset</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ISO21090v1_0.Constraint.EDTEXT.charset</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coppa_datatypes.iso21090.constraint.EDTEXT.charset</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="363">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2934415</PUBLICID>
    <LONGNAME>Data Value Type DatumConditionValueType</LONGNAME>
    <PREFERREDNAME>2915609v1.0:2934411v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A collection of facts from which conclusions may be drawn._The information contained in a data field; may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state depending on the nature of the attribute.:Something distinguishable as an identifiable class based on common qualities._The list of values for value types of data and conditions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2915609</PublicId>
      <PreferredName>2423506v1.0:2640411v1.0</PreferredName>
      <PreferredDefinition>A collection of facts from which conclusions may be drawn._The information contained in a data field; may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state depending on the nature of the attribute.:Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Data Value Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2423506</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474</PreferredName>
        <Version>1</Version>
        <LongName>Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2640411</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49100:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Value Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2934411</PublicId>
      <PreferredName>2934411v1.0</PreferredName>
      <PreferredDefinition>The list of values for value types of data and conditions.</PreferredDefinition>
      <LongName>DatumConditionValueType</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>boolean</VALIDVALUE>
          <VALUEMEANING>Boolean</VALUEMEANING>
          <MEANINGDESCRIPTION>The type of an expression with two possible values, &quot;true&quot; and &quot;false&quot;. Also, a variable of Boolean type or a function with Boolean arguments or result. The most common Boolean functions are AND, OR and NOT. (http://foldoc.doc.ic.ac.uk/foldoc/foldoc.cgi?Boolean)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2915867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mean</VALIDVALUE>
          <VALUEMEANING>Mean</VALUEMEANING>
          <MEANINGDESCRIPTION>The sum of a set of values divided by the number of values in the set.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>median</VALIDVALUE>
          <VALUEMEANING>Median</VALUEMEANING>
          <MEANINGDESCRIPTION>The value which has an equal number of values greater and less than it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2915728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mode</VALIDVALUE>
          <VALUEMEANING>Mode</VALUEMEANING>
          <MEANINGDESCRIPTION>The value which occurs most often in a set of values. If no value is repeated, there is no mode. If more than one value occurs with the same greatest frequency, each value is a mode.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>observed</VALIDVALUE>
          <VALUEMEANING>Observed</VALUEMEANING>
          <MEANINGDESCRIPTION>Ascertained or determined through monitoring or observation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2915729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>root mean square</VALIDVALUE>
          <VALUEMEANING>Root Mean Square</VALUEMEANING>
          <MEANINGDESCRIPTION>A statistical measure of the magnitude of a set of variable values. The root mean square is the square root of the mean value for the squares of the original values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2934403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>standard deviation</VALIDVALUE>
          <VALUEMEANING>Standard deviation</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the range of values in a set of numbers. Standard deviation is a statistic used as a measure of the dispersion or variation in a distribution, equal to the square root of the arithmetic mean of the squares of the deviations from the arithmetic mean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2572278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Z-average</VALIDVALUE>
          <VALUEMEANING>Z-Average</VALUEMEANING>
          <MEANINGDESCRIPTION>A parameter used for calculations involving mechanical properties. The parameter is measured by using dynamic light scattering to obtain the intensity weighted mean hydrodynamic size of a collection of particles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2754201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Z-score</VALIDVALUE>
          <VALUEMEANING>Z-Score</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates how far and in what direction an item deviates from its distribution&#39;s mean, expressed in units of its distribution&#39;s standard deviation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2915866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Data Value Type DatumConditionValueType does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Data Value Type DatumConditionValueType does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Datum:valueType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.common.Datum.valueType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="364">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2936577</PUBLICID>
    <LONGNAME>Patient Lobectomy Non-Small Cell Lung Carcinoma Clinical Trial Eligibility Criteria Eligibility Ind-2</LONGNAME>
    <PREFERREDNAME>2936573v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether a patient received lobectomy, removal of a lobe of the lung, as treatment for non-small cell lung cancer, a group of at least three distinct histological types of lung cancer, as criteria to allow an individual to participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2936573</PublicId>
      <PreferredName>2233604v1.0:2936571v1.0</PreferredName>
      <PreferredDefinition>information relating to patient having received lobectomy, removal of a lobe of the lung, as treatment for non-small cell lung cancer, a group of at least three distinct histological types of lung cancer, as criteria to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Patient Lobectomy Non-Small Cell Lung Carcinoma Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2936571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15272:C2926:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Lobectomy NSCLC Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15272</PREFERRED_NAME>
            <LONG_NAME>Lobectomy</LONG_NAME>
            <CON_ID>2204812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2926</PREFERRED_NAME>
            <LONG_NAME>Lung Non-Small Cell Carcinoma</LONG_NAME>
            <CON_ID>2202762</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lobectomy vs. limited resecti</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lobectomy vs. limited resection for &lt;2cm NSCLC tumors</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="365">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2939045</PUBLICID>
    <LONGNAME>Person Type Food Disease Or Therapy Restriction EORTC Quality of Life Scale Score</LONGNAME>
    <PREFERREDNAME>TP_FD_RSTCT_QOL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent a person&quot;s reported restriction in the types of food to eat as a result of disease or treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-Pan26: EORTC Quality of Life Questionnaire Pancreas 26</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2939044</PublicId>
      <PreferredName>PER_TP_FD_RSTCT</PreferredName>
      <PreferredDefinition>Person; a human being._Type; a subdivision of a particular kind of thing._Processed or unprocessed substances obtained from animal, plant, microorganism and mining source that provide nutrients for living organisms to maintain biological processes or functions._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Anything that limits; a limitation.</PreferredDefinition>
      <LongName>Person Type Food Disease or Disorder Or Therapy Restriction</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939041</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C25284:C1949</PreferredName>
        <Version>1</Version>
        <LongName>Person Type Food or Food Substance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1949</PREFERRED_NAME>
            <LONG_NAME>Food or Food Product</LONG_NAME>
            <CON_ID>2717948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2939042</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C37998:C15368:C53452</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Or Therapy Restriction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53452</PREFERRED_NAME>
            <LONG_NAME>Restriction</LONG_NAME>
            <CON_ID>2726208</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2927907</PublicId>
      <PreferredName>EORTC_QOL_SCL_SC</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._The subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._an ordered reference standard._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Scale Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2927906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C17047:C25664:C25338</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Scale Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were you restricted in the ty</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were you restricted in the types of food you could eat as a result of your disease or treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="366">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2939074</PUBLICID>
    <LONGNAME>Person Skin Jaundice Occurrence EORTC Quality of Life Scale Score</LONGNAME>
    <PREFERREDNAME>SKN_JND_OCC_QOL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent a person&quot;s report of yellow skin.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-Pan26: EORTC Quality of Life Questionnaire Pancreas 26</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2939073</PublicId>
      <PreferredName>PER_SKN_JND_OCC</PreferredName>
      <PreferredDefinition>Person; a human being._1. An organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands. Subdivisions of the skin surround various body parts; as a whole, the skin constitutes the external surface of the body. 2. The rind, capsule, or covering of any body or part._(JAWN-dis) A condition in which the skin and the whites of the eyes become yellow, urine darkens, and the color of stool becomes lighter than normal. Jaundice occurs when the liver is not working properly or when a bile duct is blocked._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Person Skin Jaundice Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C12470:C3143</PreferredName>
        <Version>1</Version>
        <LongName>Person Skin Jaundice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3143</PREFERRED_NAME>
            <LONG_NAME>Jaundice</LONG_NAME>
            <CON_ID>2205318</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2927907</PublicId>
      <PreferredName>EORTC_QOL_SCL_SC</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._The subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._an ordered reference standard._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Scale Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2927906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C17047:C25664:C25338</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Scale Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>To what extent was your skin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>To what extent was your skin yellow?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="367">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2939263</PUBLICID>
    <LONGNAME>Pharmacologic Substance Biological Absorption Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2939217v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._The process of penetration of a substance into a living organism. This process could involve specialized and/or non-specialized mechanisms, active transport or passive movement, and carrier system(s). The common ways of absorption in mammals include organs of respiratory and gastrointestinal systems, and skin.:A written or verbal account, representation, statement, or explanation of something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2939217</PublicId>
      <PreferredName>2437803v1.0:2939203v1.0</PreferredName>
      <PreferredDefinition>A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._The process of penetration of a substance into a living organism. This process could involve specialized and/or non-specialized mechanisms, active transport or passive movement, and carrier system(s). The common ways of absorption in mammals include organs of respiratory and gastrointestinal systems, and skin.:A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Pharmacologic Substance Biological Absorption Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437803</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1909</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacologic Substance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2939203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71733:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Biological Absorption Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71733</PREFERRED_NAME>
            <LONG_NAME>Biological Absorption</LONG_NAME>
            <CON_ID>2939187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Pharmacologic Substance Biological Absorption Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Pharmacologic Substance Biological Absorption Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Agent:absorption</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Agent.absorption</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@absorption</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="368">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2940128</PUBLICID>
    <LONGNAME>Patient Satisfaction Dentist Behavior Assessment Scale</LONGNAME>
    <PREFERREDNAME>PT_SA_D_BE_ASS_SCA</PREFERREDNAME>
    <PREFERREDDEFINITION>an ordered reference standard related to the patient&#39;s assessment of satisfaction in dentist&#39;s behavior or respect toward them.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2940060</PublicId>
      <PreferredName>PT_SAT_DE_BEH_ASSE</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s assessment of satisfaction in dentist&#39;s behavior or respect toward them.</PreferredDefinition>
      <LongName>Patient Satisfaction Dentist Behavior Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939807</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C62185</PreferredName>
        <Version>1</Version>
        <LongName>Patient Satisfaction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62185</PREFERRED_NAME>
            <LONG_NAME>Satisfaction</LONG_NAME>
            <CON_ID>2585226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2940058</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654:C16326:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Dentist Behavior Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16326</PREFERRED_NAME>
            <LONG_NAME>Behavior</LONG_NAME>
            <CON_ID>2203709</CON_ID>
            <DEFINITION_SOURCE>CSP2000</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2940115</PublicId>
      <PreferredName>PT_ASSESS_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard of the patient assessment.</PreferredDefinition>
      <LongName>Patient Assessment Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly agree</VALIDVALUE>
          <VALUEMEANING>STRONGLY AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agree</VALIDVALUE>
          <VALUEMEANING>AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neither Agree or Disagree</VALIDVALUE>
          <VALUEMEANING>Neither Agree or Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Neither Agree or Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2940116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disagree</VALIDVALUE>
          <VALUEMEANING>DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly disagree</VALIDVALUE>
          <VALUEMEANING>STRONGLY DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutral</VALIDVALUE>
          <VALUEMEANING>Neutral</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person has a neutral opinion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2902512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am satisfied that my dentis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am satisfied that my dentist respects me as a person</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DPBRN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="369">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2940152</PUBLICID>
    <LONGNAME>Patient Satisfaction Dentist Reduced Anxiety Assessment Scale</LONGNAME>
    <PREFERREDNAME>PT_S_DEC_RE_A_AS_SCA</PREFERREDNAME>
    <PREFERREDDEFINITION>an ordered reference standard related to the patient&#39;s assessment of satisfaction that dentist had reduced fear and anxiety.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2940096</PublicId>
      <PreferredName>PT_SAT_DE_R_A_ASSESS</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s assessment of satisfaction that dentist had reduced fear and anxiety.</PreferredDefinition>
      <LongName>Patient Satisfaction Dentist Reduced Anxiety Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939807</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C62185</PreferredName>
        <Version>1</Version>
        <LongName>Patient Satisfaction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62185</PREFERRED_NAME>
            <LONG_NAME>Satisfaction</LONG_NAME>
            <CON_ID>2585226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2940094</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654:C25640:C26696:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Dentist Reduced Anxiety Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26696</PREFERRED_NAME>
            <LONG_NAME>Anxiety</LONG_NAME>
            <CON_ID>2206376</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2940115</PublicId>
      <PreferredName>PT_ASSESS_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard of the patient assessment.</PreferredDefinition>
      <LongName>Patient Assessment Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly agree</VALIDVALUE>
          <VALUEMEANING>STRONGLY AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agree</VALIDVALUE>
          <VALUEMEANING>AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neither Agree or Disagree</VALIDVALUE>
          <VALUEMEANING>Neither Agree or Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Neither Agree or Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2940116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disagree</VALIDVALUE>
          <VALUEMEANING>DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly disagree</VALIDVALUE>
          <VALUEMEANING>STRONGLY DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutral</VALIDVALUE>
          <VALUEMEANING>Neutral</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person has a neutral opinion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2902512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>My dentist tried to limit my</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>My dentist tried to limit my fear and anxiety</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DPBRN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="370">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2953109</PUBLICID>
    <LONGNAME>Laboratory Procedure Cytogenetic Analysis Cell Line Outcome Ind-2</LONGNAME>
    <PREFERREDNAME>LP_CGA_CL_OUTCM_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether all cell lines are maturing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2953107</PublicId>
      <PreferredName>LAB_CGA_CEL_OUTCOME</PreferredName>
      <PreferredDefinition>information relating to a laboratory procedure that involves cell lines maturing using techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.</PreferredDefinition>
      <LongName>Laboratory Procedure Cytogenetic Analysis Cell Line Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2953105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18280:C16403:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetic Analysis Cell Line Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18280</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Analysis</LONG_NAME>
            <CON_ID>2528326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16403</PREFERRED_NAME>
            <LONG_NAME>Cell Line</LONG_NAME>
            <CON_ID>2223178</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are all cell lines maturing</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are all cell lines maturing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="371">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2953612</PUBLICID>
    <LONGNAME>Microarray Data Quantitation Type Data Type</LONGNAME>
    <PREFERREDNAME>2771110v1.0:2953590v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A method for calculating a single datum of the matrix (e.g. raw intensity, background, error)._An indication of the form that a value will have.  Examples include string, integer, and character.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771110</PublicId>
      <PreferredName>2771083v1.0:2771063v1.0</PreferredName>
      <PreferredDefinition>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A method for calculating a single datum of the matrix (e.g. raw intensity, background, error)._An indication of the form that a value will have.  Examples include string, integer, and character.</PreferredDefinition>
      <LongName>Microarray Data Quantitation Type Data Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2771083</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C25474:C43447</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Data Quantitation Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43447</PREFERRED_NAME>
            <LONG_NAME>Quantitation Type</LONG_NAME>
            <CON_ID>2236561</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771063</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42645</PreferredName>
        <Version>1</Version>
        <LongName>Data Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42645</PREFERRED_NAME>
            <LONG_NAME>Data Type</LONG_NAME>
            <CON_ID>2231560</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2953590</PublicId>
      <PreferredName>2953590v1.0</PreferredName>
      <PreferredDefinition>The type of a piece of data.</PreferredDefinition>
      <LongName>DataType</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTEGER</VALIDVALUE>
          <VALUEMEANING>integer</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2570865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LONG</VALIDVALUE>
          <VALUEMEANING>Long</VALUEMEANING>
          <MEANINGDESCRIPTION>A variable that is stored as a signed 64-bit (8-byte) integer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2953591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHORT</VALIDVALUE>
          <VALUEMEANING>Short</VALUEMEANING>
          <MEANINGDESCRIPTION>A variable that is stored as a signed 16-bit (2-byte) integer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2953592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DOUBLE</VALIDVALUE>
          <VALUEMEANING>Double</VALUEMEANING>
          <MEANINGDESCRIPTION>A 64-bit floating point primitive. When wrapped in an immutable Object, it is called a Double.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2953593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STRING</VALIDVALUE>
          <VALUEMEANING>String</VALUEMEANING>
          <MEANINGDESCRIPTION>An expression consisting of a linear sequence of symbols (characters or words or phrases).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2953594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BOOLEAN</VALIDVALUE>
          <VALUEMEANING>Boolean</VALUEMEANING>
          <MEANINGDESCRIPTION>The type of an expression with two possible values, &quot;true&quot; and &quot;false&quot;. Also, a variable of Boolean type or a function with Boolean arguments or result. The most common Boolean functions are AND, OR and NOT. (http://foldoc.doc.ic.ac.uk/foldoc/foldoc.cgi?Boolean)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2915867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLOAT</VALIDVALUE>
          <VALUEMEANING>Float</VALUEMEANING>
          <MEANINGDESCRIPTION>A number that can have its decimal point in any position.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48150</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2953595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Data Quantitation Type Data Type does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Data Quantitation Type Data Type does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2953481</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Service</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Service 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2953482</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2953481</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Service</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.external.v1_0.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2953485</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QuantitationType:dataType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.external.v1_0.data.QuantitationType.dataType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="372">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2954255</PUBLICID>
    <LONGNAME>Acute Myeloid Leukemia Disease Secondary Diagnosis Type</LONGNAME>
    <PREFERREDNAME>AML_DZ_SECNDRY_DX_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of secondary cause for acute myeloid leukemia.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2954175</PublicId>
      <PreferredName>AML_DZ_SECNDRY_DX</PreferredName>
      <PreferredDefinition>information relating to a secondary (derived as a result of a primary condition) diagnosis (the investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms) and acute myeloid leukemia (AML; a clonal expansion of myeloid blasts in the bone marrow, blood or other tissues).</PreferredDefinition>
      <LongName>Acute Myeloid Leukemia Disease Secondary Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2593592</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3171:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Acute Myeloid Leukemia Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3171</PREFERRED_NAME>
            <LONG_NAME>Acute Myeloid Leukemia</LONG_NAME>
            <CON_ID>2320062</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2954173</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25667:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Secondary Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25667</PREFERRED_NAME>
            <LONG_NAME>Secondary</LONG_NAME>
            <CON_ID>2206365</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954249</PublicId>
      <PreferredName>SECNDRY_DX_TP</PreferredName>
      <PreferredDefinition>the type of secondary diagnosis.</PreferredDefinition>
      <LongName>Secondary Diagnosis Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>70</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prior treatment for other malignancy</VALIDVALUE>
          <VALUEMEANING>Prior treatment for other malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Prior treatment for other malignancy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2954250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unexplained cytopenia</VALIDVALUE>
          <VALUEMEANING>Unexplained cytopenia</VALUEMEANING>
          <MEANINGDESCRIPTION>Unexplained cytopenia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2954251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prior hematologic disorder (myeloproliferative disorders)</VALIDVALUE>
          <VALUEMEANING>Prior hematologic disorder (myeloproliferative disorders)</VALUEMEANING>
          <MEANINGDESCRIPTION>Prior hematologic disorder (myeloproliferative disorders)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2954252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prior hematologic disorder (MDS)</VALIDVALUE>
          <VALUEMEANING>Prior hematologic disorder (MDS)</VALUEMEANING>
          <MEANINGDESCRIPTION>Prior hematologic disorder (MDS)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2954253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If secondary, choose one</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If secondary, choose one</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="373">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2954787</PUBLICID>
    <LONGNAME>Surgical Procedure Other Anatomic Site Performed Specify Text</LONGNAME>
    <PREFERREDNAME>2954772v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe other site(s) of surgery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2954772</PublicId>
      <PreferredName>2322305v1.0:2953799v1.0</PreferredName>
      <PreferredDefinition>Information related to executed and carried through to completion the use of an operative procedure on organs, regions, or tissues in the treatment of diseases, including tissue section by lasers._Different than the one(s) previously specified or mentioned._Named locations of or within the body._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Surgical Procedure Other Anatomic Site Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2953799</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C13717:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Other Anatomic Site Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other surgery site(s)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify other surgery site(s)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>specify other site(s):</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>specify other site(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other site(s):</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other site(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2954787</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedProcedure [1] &gt; Subject &gt; PerformedProcedure.targetAnatomicSiteCode [2] WHERE PerformedProcedure [1] &gt; DefinedProcedure.categoryCode = &quot;Surgery&quot; AND PerformedProcedure [2] &gt; DefinedProcedure.categoryCode = &quot;Surgery&quot; AND PerformedProcedure.targetAnatomicSiteCode [1] IS NOT EQUAL TO performedProcedure.targetAnatomicSiteCode [2]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other site(s):</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other site(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other site:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other site:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Other, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2018r1: Lymphoma Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2013r1: CLL Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lym_base_tx_surg_oth_spc</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cll_base_tx_surg_oth_spc</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>neu_base_surg_oth_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure:targetAnatomicSiteCode</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CLLP_LTHM_surgery_oth_site_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_therapy_multi_surgery_oth_site_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_thrpym_surg_oth_site_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="374">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2959902</PUBLICID>
    <LONGNAME>Observation Study Protocol Document Sampling Method Code SamplingMethodType</LONGNAME>
    <PREFERREDNAME>2868286v1.0:2959655v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Watching something and taking note of what happens.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._The selection and obtaining of small representative quantities of biological material for the purpose of analysis; also, in biomedical statistics, sampling is the selection and implementation of statistical observations in order to estimate properties of an underlying population; also, in environmental science, the collection of representative specimens analyzed to characterize site conditions.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._The code that describes the type of process used to select study participants.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868286</PublicId>
      <PreferredName>2867687v1.0:2867904v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._The selection and obtaining of small representative quantities of biological material for the purpose of analysis; also, in biomedical statistics, sampling is the selection and implementation of statistical observations in order to estimate properties of an underlying population; also, in environmental science, the collection of representative specimens analyzed to characterize site conditions.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Observation Study Protocol Document Sampling Method Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598:C63536:C42651:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Observation Study Protocol Document</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867904</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25662:C71460:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Sampling Method Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25662</PREFERRED_NAME>
            <LONG_NAME>Sampling</LONG_NAME>
            <CON_ID>2203793</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2959655</PublicId>
      <PreferredName>2959655v1.0</PreferredName>
      <PreferredDefinition>The code that describes the type of process used to select study participants.</PreferredDefinition>
      <LongName>SamplingMethodType</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Probability Sample</VALIDVALUE>
          <VALUEMEANING>Nonrandom Sampling</VALUEMEANING>
          <MEANINGDESCRIPTION>Any method of selecting a sample in which cases are not chosen by random sampling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Probability Sample</VALIDVALUE>
          <VALUEMEANING>Random Sampling</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of selecting a sample from a population in such a way that every sample that could be selected has an equal chance of being selected.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Study Protocol Document Sampling Method Code SamplingMethodType does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Study Protocol Document Sampling Method Code SamplingMethodType does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ObservationalStudyProtocol:samplingMethodCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.ObservationalStudyProtocol.samplingMethodCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="375">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2959937</PUBLICID>
    <LONGNAME>Study Protocol Investigational New Drug Or Investigational Medical Device Exemption Flag National Institutes of Health Holder Code NihInstituteHolderCode</LONGNAME>
    <PREFERREDNAME>2959237v1.0:2959554v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A device that is the subject of clinical investigation or research to determine the safety or effectiveness of the device. Investigational devices include transitional devices (21 CFR 812.3(r)) that are objects of investigations. An investigational device may be an approved device that is being studied for an unapproved use or efficacy.:Immunity from an obligation or duty.:An indicator that can be set or unset in order to signal whether a particular condition is true._An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research.:A person who has physical possession or legal rights to something.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._The code that identifes the name of the NIH Institute.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2959237</PublicId>
      <PreferredName>2959119v1.0:2959152v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A device that is the subject of clinical investigation or research to determine the safety or effectiveness of the device. Investigational devices include transitional devices (21 CFR 812.3(r)) that are objects of investigations. An investigational device may be an approved device that is being studied for an unapproved use or efficacy.:Immunity from an obligation or duty.:An indicator that can be set or unset in order to signal whether a particular condition is true._An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research.:A person who has physical possession or legal rights to something.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Study Protocol Investigational New Drug Or Investigational Medical Device Exemption Flag National Institutes of Health Holder Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2959119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2959119v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Study Protocol Investigational New Drug Or Investigational Medical Device Exemption Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49135</PREFERRED_NAME>
            <LONG_NAME>Investigational New Drug</LONG_NAME>
            <CON_ID>2480875</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72968</PREFERRED_NAME>
            <LONG_NAME>Investigational Medical Device</LONG_NAME>
            <CON_ID>2958971</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73530</PREFERRED_NAME>
            <LONG_NAME>Exemption</LONG_NAME>
            <CON_ID>2958970</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2959152</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16895:C53299:C25162</PreferredName>
        <Version>1</Version>
        <LongName>National Institutes of Health Holder Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16895</PREFERRED_NAME>
            <LONG_NAME>National Institutes of Health</LONG_NAME>
            <CON_ID>2202459</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53299</PREFERRED_NAME>
            <LONG_NAME>Holder</LONG_NAME>
            <CON_ID>2512709</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2959554</PublicId>
      <PreferredName>2959554v1.0</PreferredName>
      <PreferredDefinition>The code that identifes the name of the NIH Institute.</PreferredDefinition>
      <LongName>NihInstituteHolderCode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CC</VALIDVALUE>
          <VALUEMEANING>Clinical Center</VALUEMEANING>
          <MEANINGDESCRIPTION>The research hospital for the NIH, the Federal Government&#39;s principal agency for biomedical research. The NIH Clinical Center is actually made up of two centers: the Warren Grant Magnuson Clinical Center and the Mark O. Hatfield Clinical Research Center. The Clinical Center as a whole promotes translational research, that is, the transformation of scientific laboratory research into applications that benefit patient health and medical care. At the Center, patient care units are in close proximity to cutting-edge technologies and laboratories doing related research. This &quot;bench-to-bedside&quot; approach facilitates interaction and collaboration among clinicians and researchers. The Clinical Center supports clinical trials conducted by the 27 Institutes and Centers of the NIH, including the National Cancer Institute (NCI).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSR</VALIDVALUE>
          <VALUEMEANING>NIH Center for Scientific Review</VALUEMEANING>
          <MEANINGDESCRIPTION>The Center for Scientific Review (CSR) provides staff support to the Office of the Director, NIH, in the formulation of grant application review policies and procedures. In addition, CSR provides central receipt of all PHS applications for research and review.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FIC</VALIDVALUE>
          <VALUEMEANING>Fogarty International Center</VALUEMEANING>
          <MEANINGDESCRIPTION>The international component of the National Institutes of Health (NIH) dedicated to advancing the mission of NIH by supporting and facilitating global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the U.S. and abroad, and training the next generation of scientists to address global health needs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NHLBI</VALIDVALUE>
          <VALUEMEANING>National Heart, Lung, and Blood Institute</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIAID</VALIDVALUE>
          <VALUEMEANING>National Institute of Allergy and Infectious Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19753</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIEHS</VALIDVALUE>
          <VALUEMEANING>National Institute of Environmental Health Sciences</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIMH</VALIDVALUE>
          <VALUEMEANING>National Institute of Mental Health</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NLM</VALIDVALUE>
          <VALUEMEANING>National Library of Medicine</VALUEMEANING>
          <MEANINGDESCRIPTION>A division of the National Institutes of Health, it is the world&#39;s largest biomedical library. The Library is involved in development of electronic sevices.  Its mission is to enable biomedical research, support health care and public health, and promote healthy behavior.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OD</VALIDVALUE>
          <VALUEMEANING>Office of the Director</VALUEMEANING>
          <MEANINGDESCRIPTION>Office of the NCI Director serves as the focal point for the National Cancer Program; develops a National Cancer Plan and monitors implementation of the plan; directs and coordinates the Institute&#39;s programs and activities; and develops and provides policy guidance and staff direction to the Institute&#39;s programs in areas such as program coordination, program planning, clinical care and administrative management.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NICHD</VALIDVALUE>
          <VALUEMEANING>National Institute of Child Health and Human Development</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that conducts and supports research on all stages of human development from preconception to adulthood, to better understand the health of children, adults, families, and communities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIBIB</VALIDVALUE>
          <VALUEMEANING>National Institute of Biomedical Imaging and Bioengineering</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences, to advance basic research and medical care.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82609</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIAMS</VALIDVALUE>
          <VALUEMEANING>National Institute of Arthritis and Musculoskeletal and Skin Diseases</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIAAA</VALIDVALUE>
          <VALUEMEANING>National Institute on Alcohol Abuse and Alcoholism</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that provides leadership in the national effort to reduce alcohol-related problems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIDA</VALIDVALUE>
          <VALUEMEANING>National Institute on Drug Abuse</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to lead the nation in bringing the power of science to bear on drug abuse and addiction. This charge has two critical components, the strategic support and conduct of research across a broad range of disciplines and the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIDDK</VALIDVALUE>
          <VALUEMEANING>National Institute of Diabetes and Digestive and Kidney Diseases</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that conducts and supports much of the clinical research on the diseases of internal medicine and related subspecialty fields, as well as many basic science disciplines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIDCR</VALIDVALUE>
          <VALUEMEANING>National Institute of Dental and Craniofacial Research</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the institutes that comprise the National Institutes of Health. The mission of the NIDCR is to improve oral, dental and craniofacial health through research, research training, and the dissemination of health information.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIDCD</VALIDVALUE>
          <VALUEMEANING>National Institute on Deafness and Other Communication Disorders</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that is mandated to conduct and support biomedical and behavioral research and research training in the normal and disordered processes of hearing, balance, smell, taste, voice, speech, and language.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIA</VALIDVALUE>
          <VALUEMEANING>National Institute on Aging</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health that leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82604</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NHGRI</VALIDVALUE>
          <VALUEMEANING>National Human Genome Research Institute</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health (NIH) that led NIH&#39;s contribution to the International Human Genome Project. Since the completion of this project its mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. To that end it supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of its mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEI</VALIDVALUE>
          <VALUEMEANING>National Eye Institute</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82611</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CIT</VALIDVALUE>
          <VALUEMEANING>Center for Information Technology</VALUEMEANING>
          <MEANINGDESCRIPTION>A center within the National Institutes of Health that provides, coordinates, and manages information technology, and advances computational science within NIH.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NINR</VALIDVALUE>
          <VALUEMEANING>National Institute of Nursing Research</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to promote and improve the health of individuals, families, communities, and populations. It supports and conducts clinical and basic research and research training on health and illness across the lifespan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NINDS</VALIDVALUE>
          <VALUEMEANING>National Institute of Neurological Disorders and Stroke</VALUEMEANING>
          <MEANINGDESCRIPTION>An institute within the National Institutes of Health with the mission to reduce the burden of neurological disease by conducting and funding research on brain and nervous system disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NIGMS</VALIDVALUE>
          <VALUEMEANING>National Institute of General Medical Sciences</VALUEMEANING>
          <MEANINGDESCRIPTION>The National Institute of General Medical Sciences (NIGMS) primarily supports basic biomedical research that is not targeted to specific diseases or disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20131</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NCRR</VALIDVALUE>
          <VALUEMEANING>National Center for Research Resources</VALUEMEANING>
          <MEANINGDESCRIPTION>A center within the National Institutes of Health that provides laboratory scientists and clinical researchers with the tools and training they need to understand, detect, treat, and prevent a wide range of diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20016</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NCMHD</VALIDVALUE>
          <VALUEMEANING>National Center on Minority Health and Health Disparities</VALUEMEANING>
          <MEANINGDESCRIPTION>A center within the National Institutes of Health with the mission to promote minority health and to lead, coordinate, support, and assess the NIH effort to reduce and ultimately eliminate health disparities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NCCAM</VALIDVALUE>
          <VALUEMEANING>National Center for Complementary and Alternative Medicine</VALUEMEANING>
          <MEANINGDESCRIPTION>A center within the National Institutes of Health that acts as the Federal Government&#39;s lead agency for scientific research on the diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Protocol Investigational New Drug Or Investigational Medical Device Exemption Flag National Institutes of Health Holder Code NihInstituteHolderCode does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Protocol Investigational New Drug Or Investigational Medical Device Exemption Flag National Institutes of Health Holder Code NihInstituteHolderCode does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.StudyInvestigationalNewDrugInvestigationalNewDevice.nihInstituteholderCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyInvestigationalNewDrugInvestigationalNewDevice:nihInstituteholderCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="376">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2960085</PUBLICID>
    <LONGNAME>Observation Plan Study Activity Category Code Category</LONGNAME>
    <PREFERREDNAME>2868880v1.0:2959443v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Watching something and taking note of what happens.:To devise, contrive, or formed in design.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._This term is used informally to mean a class of things.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._The code that identifies the kind of activity, drawn from a controlled list of possible values, which groups similar or related activities together.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868880</PublicId>
      <PreferredName>2867659v1.0:2867794v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:To devise, contrive, or formed in design.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._This term is used informally to mean a class of things.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Observation Plan Study Activity Category Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867659</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598:C25619:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Observation Plan Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867794</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Category Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2959443</PublicId>
      <PreferredName>2959443v1.0</PreferredName>
      <PreferredDefinition>The code that identifies the kind of activity, drawn from a controlled list of possible values, which groups similar or related activities together.</PreferredDefinition>
      <LongName>Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eligibility Criterion</VALIDVALUE>
          <VALUEMEANING>Inclusion</VALUEMEANING>
          <MEANINGDESCRIPTION>The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2579170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intervention</VALIDVALUE>
          <VALUEMEANING>Interventions</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or ministration that produces an effect or that is intended to alter the course of a pathologic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Plan Study Activity Category Code Category does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Plan Study Activity Category Code Category does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PlannedObservation:categoryCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.PlannedObservation.categoryCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="377">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2964597</PUBLICID>
    <LONGNAME>Laboratory Test Result Unit of Measure Identifier java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2964540v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of a laboratory test.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2964540</PublicId>
      <PreferredName>2964513v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Laboratory Test Result Unit of Measure Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2964513</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C25709</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Unit of Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Laboratory Test Result Unit of Measure Identifier java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Laboratory Test Result Unit of Measure Identifier java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2964508</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabViewer</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000318</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.labhub.domain.LabResultUnitOfMeasure.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LabResultUnitOfMeasure:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="378">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2964622</PUBLICID>
    <LONGNAME>Specimen Material Type Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2964565v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The tangible substance that goes into the makeup of a physical object.:Something distinguishable as an identifiable class based on common qualities._A system of numbered categories for representation of data._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2964565</PublicId>
      <PreferredName>2964509v1.0:2222855v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The tangible substance that goes into the makeup of a physical object.:Something distinguishable as an identifiable class based on common qualities._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Specimen Material Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2964509</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C48187:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Material Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Material Type Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Material Type Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2964508</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabViewer</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000318</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.labhub.domain.SpecimenMaterialType.code</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenMaterialType:code</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="379">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2965215</PUBLICID>
    <LONGNAME>Maternal Engraftment Present Indicator</LONGNAME>
    <PREFERREDNAME>2965213v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not maternal engraftment was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2965213</PublicId>
      <PreferredName>3148113v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>A designation that has some relationship to motherhood._The establishment of viable, functional grafted tissue within the body of a host._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Maternal Engraftment Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3148113</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C89336:C37947</PreferredName>
        <Version>1</Version>
        <LongName>Maternal Engraftment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89336</PREFERRED_NAME>
            <LONG_NAME>Maternal</LONG_NAME>
            <CON_ID>3148112</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37947</PREFERRED_NAME>
            <LONG_NAME>Engraftment</LONG_NAME>
            <CON_ID>2203995</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was maternal engraftment pres</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was maternal engraftment present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2965215</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Assessed Maternal Engraftment&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r1: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964897</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_base_matrnl_engftmt_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="380">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2965899</PUBLICID>
    <LONGNAME>IgG Level Immune Function Status</LONGNAME>
    <PREFERREDNAME>IGG_LEVL_FUNCT_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the IgG immune function level.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2965888</PublicId>
      <PreferredName>IGG_LEVEL</PreferredName>
      <PreferredDefinition>An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli._A position on a scale measuring intensity, quality, or amount.</PreferredDefinition>
      <LongName>IgG Level</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2965886</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C568</PreferredName>
        <Version>1</Version>
        <LongName>IgG</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C568</PREFERRED_NAME>
            <LONG_NAME>IgG</LONG_NAME>
            <CON_ID>2206239</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2238473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25554</PreferredName>
        <Version>1</Version>
        <LongName>Level</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2964767</PublicId>
      <PreferredName>IMMU_FUNCT_STAT</PreferredName>
      <PreferredDefinition>Any multicellular process of immune cells effecting or involved with the immune response or immune maintenance. _A condition or state at a particular time.</PreferredDefinition>
      <LongName>Immune Function Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2964766</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17937:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Immune Function Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17937</PREFERRED_NAME>
            <LONG_NAME>Immune System Process</LONG_NAME>
            <CON_ID>2964765</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Less Than or Equal To Integer::10% Normal Response</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.: A number with no fractional part.::10%: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI): Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25755, C14165, C45255::10%, C61586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3148142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial</VALIDVALUE>
          <VALUEMEANING>Partial</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial; being or affecting only a part; not total</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2785808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>No testing done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Between 11% And 50% Normal Response</VALUEMEANING>
          <MEANINGDESCRIPTION>The space or interval separating two things.: A number with no fractional part, including the negative and positive numbers as well as zero.::11%: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A number with no fractional part, including the negative and positive numbers as well as zero.::50%: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25755, C14165, C45255::50%, C37912, C45255::11%, C94545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7595788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the current IgG level?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the current IgG level?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the IgG level?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the IgG level?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2965899</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value(ANY=&gt;CD) WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Determine IgG Level&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2131r1: Immune Deficiencies Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_igg_level</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="381">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2966467</PUBLICID>
    <LONGNAME>Person Fluoride Use Text</LONGNAME>
    <PREFERREDNAME>Pers_Fluoride_Use_T</PREFERREDNAME>
    <PREFERREDDEFINITION>Person; a human being._Considered a trace element, fluoride is any combination of elements containing the fluorine atom in the -1 oxidation state (fluoride ion).  Due to its reactivity, fluorine is found in nature as fluorine compounds or fluorides.  Fluoride inhibits various enzyme systems, erythrocyte glycolysis and binds Ca++, causing anticoagulation and other toxic effects.  In addition, fluoride is a mitogen for osteoblasts and stimulates bone formation. (NCI)_Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2966465</PublicId>
      <PreferredName>Pers_Fluo_Use</PreferredName>
      <PreferredDefinition>Person; a human being._Considered a trace element, fluoride is any combination of elements containing the fluorine atom in the -1 oxidation state (fluoride ion).  Due to its reactivity, fluorine is found in nature as fluorine compounds or fluorides.  Fluoride inhibits various enzyme systems, erythrocyte glycolysis and binds Ca++, causing anticoagulation and other toxic effects.  In addition, fluoride is a mitogen for osteoblasts and stimulates bone formation. (NCI)_Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Person Fluoride Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2966463</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28149:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Fluoride Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28149</PREFERRED_NAME>
            <LONG_NAME>Fluoride Ion</LONG_NAME>
            <CON_ID>2478956</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does anyone in the family use</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does anyone in the family use toothpaste with fluoride?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Health</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2936665</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="382">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2967995</PUBLICID>
    <LONGNAME>Registration Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2967517v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Registration; the act of enrolling._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967517</PublicId>
      <PreferredName>2404664v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>Registration; the act of enrolling._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Registration Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404664</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25646</PreferredName>
        <Version>1</Version>
        <LongName>Registration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Registration Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Registration Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Registration.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@modifiedBy</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Registration:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="383">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2967996</PUBLICID>
    <LONGNAME>Registration Origin java.lang.String</LONGNAME>
    <PREFERREDNAME>2967518v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Registration; the act of enrolling._The place where something begins or comes from in either the sense of a physical location or a metaphysical source._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967518</PublicId>
      <PreferredName>2404664v1.0:2231609v1.0</PreferredName>
      <PreferredDefinition>Registration; the act of enrolling._The place where something begins or comes from in either the sense of a physical location or a metaphysical source.</PreferredDefinition>
      <LongName>Registration Origin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404664</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25646</PreferredName>
        <Version>1</Version>
        <LongName>Registration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231609</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42703</PreferredName>
        <Version>1</Version>
        <LongName>Origin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42703</PREFERRED_NAME>
            <LONG_NAME>Origin</LONG_NAME>
            <CON_ID>2204026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Registration Origin java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Registration Origin java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Registration:origin</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Registration.origin</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@origin</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="384">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2968048</PUBLICID>
    <LONGNAME>Unified Modeling Language Class Object Class Relationship Administered Item Metadata Source Class High Cardinality java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2967566v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A non-proprietary, third generation modelling language. The Unified Modeling Language is an open method used to specify, visualise, construct and document the artifacts of an object-oriented software-intensive system under development. The UML represents a compilation of &quot;best engineering practices&quot; which have proven successful in modelling large, complex systems.:A grouping of things based on shared common attributes.:A description of the affiliation between two occurrences of Object Classes.:A registry item for which administrative information is recorded in an Administration Record.:Data about data; information that describes another set of data._Where something is available or from where it originates.:A grouping of things based on shared common attributes.:An elevated level or position or degree; greater than normal in degree or intensity or amount.:The number of elements in a set._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967566</PublicId>
      <PreferredName>2967440v1.0:2967463v1.0</PreferredName>
      <PreferredDefinition>A non-proprietary, third generation modelling language. The Unified Modeling Language is an open method used to specify, visualise, construct and document the artifacts of an object-oriented software-intensive system under development. The UML represents a compilation of &quot;best engineering practices&quot; which have proven successful in modelling large, complex systems.:A grouping of things based on shared common attributes.:A description of the affiliation between two occurrences of Object Classes.:A registry item for which administrative information is recorded in an Administration Record.:Data about data; information that describes another set of data._Where something is available or from where it originates.:A grouping of things based on shared common attributes.:An elevated level or position or degree; greater than normal in degree or intensity or amount.:The number of elements in a set.</PreferredDefinition>
      <LongName>Unified Modeling Language Class Object Class Relationship Administered Item Metadata Source Class High Cardinality</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2967440</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2967440v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Unified Modeling Language Class Object Class Relationship Administered Item Metadata</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54193</PREFERRED_NAME>
            <LONG_NAME>Unified Modeling Language</LONG_NAME>
            <CON_ID>2539475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25346</PREFERRED_NAME>
            <LONG_NAME>Class</LONG_NAME>
            <CON_ID>2203880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42702</PREFERRED_NAME>
            <LONG_NAME>Object Class Relationship</LONG_NAME>
            <CON_ID>2464022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52095</PREFERRED_NAME>
            <LONG_NAME>Metadata</LONG_NAME>
            <CON_ID>2521487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2967463</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25683:C25346:C25227:C54199</PreferredName>
        <Version>1</Version>
        <LongName>Source Class High Cardinality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25346</PREFERRED_NAME>
            <LONG_NAME>Class</LONG_NAME>
            <CON_ID>2203880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25227</PREFERRED_NAME>
            <LONG_NAME>High</LONG_NAME>
            <CON_ID>2204796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54199</PREFERRED_NAME>
            <LONG_NAME>Cardinality</LONG_NAME>
            <CON_ID>2539477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Unified Modeling Language Class Object Class Relationship Administered Item Metadata Source Class High Cardinality java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Unified Modeling Language Class Object Class Relationship Administered Item Metadata Source Class High Cardinality java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.umlproject.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000238</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UMLAssociationMetadata:sourceHighCardinality</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@sourceHighCardinality</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.umlproject.domain.UMLAssociationMetadata.sourceHighCardinality</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="385">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2968193</PUBLICID>
    <LONGNAME>Valid Value Form Element Administered Item Workflow Status Name Administered Component Workflow Status Name</LONGNAME>
    <PREFERREDNAME>2967704v1.0:2463565v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The allowable values for a given data element (question) on a Case Report Form.:A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Workflow is the operational aspect of a work procedure: how tasks are structured, who performs them, what their relative order is, how they are synchronized, how information flows to support the tasks and how tasks are being tracked. (from Wikipedia):A condition or state at a particular time.:The words or language units by which a thing is known._A name of a designation of the status in the administrative life-cycle of a Context Owner for handling new administered items.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967704</PublicId>
      <PreferredName>2967421v1.0:2539494v1.0</PreferredName>
      <PreferredDefinition>The allowable values for a given data element (question) on a Case Report Form.:A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Workflow is the operational aspect of a work procedure: how tasks are structured, who performs them, what their relative order is, how they are synchronized, how information flows to support the tasks and how tasks are being tracked. (from Wikipedia):A condition or state at a particular time.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Valid Value Form Element Administered Item Workflow Status Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2967421</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41124:C19464:C48792:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Valid Value Form Element Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41124</PREFERRED_NAME>
            <LONG_NAME>Valid Value</LONG_NAME>
            <CON_ID>2231578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48792</PREFERRED_NAME>
            <LONG_NAME>Element</LONG_NAME>
            <CON_ID>2513271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539494</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42753:C25688:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Workflow Status Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42753</PREFERRED_NAME>
            <LONG_NAME>Workflow</LONG_NAME>
            <CON_ID>2231547</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2463565</PublicId>
      <PreferredName>2463565v1.0</PreferredName>
      <PreferredDefinition>A name of a designation of the status in the administrative life-cycle of a Context Owner for handling new administered items.</PreferredDefinition>
      <LongName>Administered Component Workflow Status Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2422682</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42753:C25688:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Workflow Status Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42753</PREFERRED_NAME>
            <LONG_NAME>Workflow</LONG_NAME>
            <CON_ID>2231547</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>APPRVD FOR TRIAL USE</VALIDVALUE>
          <VALUEMEANING>Approved for trial use</VALUEMEANING>
          <MEANINGDESCRIPTION>Status assigned to Draft New Data Elements included on Common Data Element-compliant forms, as well as their associated Administered Components.  Promotion to this status occurs when the Administered Component has been fully specified and Case Report Forms with which the Data Element is associated are deemed Common Data Element-compliant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE APPROVED</VALIDVALUE>
          <VALUEMEANING>Committee Approved</VALUEMEANING>
          <MEANINGDESCRIPTION>Admistered component approved by a committee.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE SUBMTD</VALIDVALUE>
          <VALUEMEANING>Committee Submitted</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component submitted to a review committee</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE SUBMTD USED</VALIDVALUE>
          <VALUEMEANING>Committee Submitted Used</VALUEMEANING>
          <MEANINGDESCRIPTION>Trial use approved, committee submitted administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRAFT MOD</VALIDVALUE>
          <VALUEMEANING>Draft Modified</VALUEMEANING>
          <MEANINGDESCRIPTION>New version of an existing administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRAFT NEW</VALIDVALUE>
          <VALUEMEANING>Draft New</VALUEMEANING>
          <MEANINGDESCRIPTION>Newly created administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RELEASED</VALIDVALUE>
          <VALUEMEANING>Released</VALUEMEANING>
          <MEANINGDESCRIPTION>Reviewed and approved administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RELEASED-NON-CMPLNT</VALIDVALUE>
          <VALUEMEANING>Released Non-Compliant</VALUEMEANING>
          <MEANINGDESCRIPTION>Status for short-term use only, to be replaced long term</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED ARCHIVED</VALIDVALUE>
          <VALUEMEANING>Retired Archived</VALUEMEANING>
          <MEANINGDESCRIPTION>Old version administered component replaced with new version</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED DELETED</VALIDVALUE>
          <VALUEMEANING>Retired Deleted</VALUEMEANING>
          <MEANINGDESCRIPTION>Erroneous administered component to be removed from database</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED PHASED OUT</VALIDVALUE>
          <VALUEMEANING>Retired Phased Out</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component rejected for general release</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED WITHDRAWN</VALIDVALUE>
          <VALUEMEANING>Retired Withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component removed from general release</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Valid Value Form Element Administered Item Workflow Status Name Administered Component Workflow Status Name does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Valid Value Form Element Administered Item Workflow Status Name Administered Component Workflow Status Name does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ValidValue:workflowStatusName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ValidValue.workflowStatusName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="386">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2970366</PUBLICID>
    <LONGNAME>Assessment Additional Method Type</LONGNAME>
    <PREFERREDNAME>2970343v1.0:2970357v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of additional method used in assessment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2970343</PublicId>
      <PreferredName>2228487v1.0:2970341v1.0</PreferredName>
      <PreferredDefinition>information related to the additional method of assessment.</PreferredDefinition>
      <LongName>Assessment Additional Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2970341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C16847</PreferredName>
        <Version>1</Version>
        <LongName>Additional Technique</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16847</PREFERRED_NAME>
            <LONG_NAME>Technique</LONG_NAME>
            <CON_ID>2203854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2970357</PublicId>
      <PreferredName>2970357v1.0</PreferredName>
      <PreferredDefinition>the additional method type used in assessment.</PreferredDefinition>
      <LongName>Assessment Additional Method Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Additional Method</VALIDVALUE>
          <VALUEMEANING>No Additional Method</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Added; extra. (from American Heritage Dictionary): A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71460, C25406, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palpation</VALIDVALUE>
          <VALUEMEANING>Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination by pressing on the surface of the body to feel the organs or tissues underneath.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2832987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain X-Ray</VALIDVALUE>
          <VALUEMEANING>X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-energy radiation.  In low doses, x-rays are used to diagnose diseases by making pictures of the inside of the body.  In high doses, x-rays are used to treat cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT Scan</VALIDVALUE>
          <VALUEMEANING>CT</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI</VALIDVALUE>
          <VALUEMEANING>Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiral CT</VALIDVALUE>
          <VALUEMEANING>Spiral CT</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest X-Ray</VALIDVALUE>
          <VALUEMEANING>Chest X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>Chest X-Ray</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caliper measurement by clinical exam</VALIDVALUE>
          <VALUEMEANING>Caliper measurement by clinical exam</VALUEMEANING>
          <MEANINGDESCRIPTION>Caliper measurement by clinical exam</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3179023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What additional method of eva</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What additional method of evaluation is used to obtain tumor measurements</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0240</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0254</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2970343v1.0:2970357v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="387">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2974120</PUBLICID>
    <LONGNAME>Viral Hepatitis Etiology Specify Text</LONGNAME>
    <PREFERREDNAME>V_H_T_S_T</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the viral hepatitis etiology.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2974118</PublicId>
      <PreferredName>V_H_T</PreferredName>
      <PreferredDefinition>An acute or chronic inflammation of the liver parenchyma caused by viruses. Representative examples include hepatitis A, B, and C, cytomegalovirus hepatitis, and herpes simplex hepatitis._The cause of a disease.</PreferredDefinition>
      <LongName>Viral Hepatitis Etiology</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2974116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C35124</PreferredName>
        <Version>1</Version>
        <LongName>Viral Hepatitis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35124</PREFERRED_NAME>
            <LONG_NAME>Viral Hepatitis</LONG_NAME>
            <CON_ID>2203605</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2512801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16390</PreferredName>
        <Version>1</Version>
        <LongName>Etiology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16390</PREFERRED_NAME>
            <LONG_NAME>Etiology</LONG_NAME>
            <CON_ID>2497372</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify viral hepatitis type:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify viral hepatitis type:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify type:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify type:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2974120</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis [first] &gt; AssessedResultRelationship &gt; PerformedObservation &gt; PerformedDiagnosis.value(ANY=&gt;CD).originalText [second] WHERE PerformedDiagnosis.value [first] = &quot;Viral Hepatitis&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2028r1: Aplastic Anemia Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>apl_base_diag_dx_hep_type</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:value </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="388">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2974237</PUBLICID>
    <LONGNAME>Grooved Pegboard Test Assessment Left Hand Result Time Sum Value</LONGNAME>
    <PREFERREDNAME>GRV_PGB_LHD_SUM_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Total sum of time measured in seconds for the completion of tasks that are part of the Grooved Pegboard Test using the left hand.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Grooved Pegboard Test, Lezak, 1995</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2972018</PublicId>
      <PreferredName>GRV_PGB_LHD_RSL</PreferredName>
      <PreferredDefinition>A manipulative dexterity test using a pegboard device wiht five rows of five holes.  It features 25 key-style pegs with holes in various positions in space, and is especially good for testing lateralized brain damage._Having determined the value, significance, or extent of._Left; being or located on or directed toward the side of the body to the west when facing north._The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Grooved Pegboard Test Assessment Left Hand Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2971999</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85394</PreferredName>
        <Version>1</Version>
        <LongName>Grooved Pegboard Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85394</PREFERRED_NAME>
            <LONG_NAME>Grooved Pegboard Test</LONG_NAME>
            <CON_ID>2971767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2972016</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217:C25229:C32712:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Left Hand Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25229</PREFERRED_NAME>
            <LONG_NAME>Left</LONG_NAME>
            <CON_ID>2204810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32712</PREFERRED_NAME>
            <LONG_NAME>Hand</LONG_NAME>
            <CON_ID>2202677</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Grooved Pegboard Test, Lezak, 1995</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2974229</PublicId>
      <PreferredName>GRV_PGB_TM_SUM_VAL</PreferredName>
      <PreferredDefinition>A manipulative dexterity test using a pegboard device wiht five rows of five holes.  It features 25 key-style pegs with holes in various positions in space, and is especially good for testing lateralized brain damage._The result of an action._The continuum of experience in which events pass from the future through the present to the past.__The final aggregate amount._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Grooved Pegboard Test Outcome Time Sum Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>seconds</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2974228</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85394:C20200:C25207:C25697:C2</PreferredName>
        <Version>1</Version>
        <LongName>Grooved Pegboard Test Outcome Time Sum Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85394</PREFERRED_NAME>
            <LONG_NAME>Grooved Pegboard Test</LONG_NAME>
            <CON_ID>2971767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25697</PREFERRED_NAME>
            <LONG_NAME>Sum</LONG_NAME>
            <CON_ID>2203808</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sum Left Hand Time (seconds)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sum Left Hand Time (seconds)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="389">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2980444</PUBLICID>
    <LONGNAME>Autonomic Nervous System Involved Ind-2</LONGNAME>
    <PREFERREDNAME>2980442v1.0:2018320v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to involvement of the enteric, parasympathetic, and sympathetic nervous systems taken together.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2980442</PublicId>
      <PreferredName>2980440v1.0:2493153v1.0</PreferredName>
      <PreferredDefinition>information related to involvement of the enteric, parasympathetic, and sympathetic nervous systems taken together.</PreferredDefinition>
      <LongName>Autonomic Nervous System Involved</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2980440</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12673</PreferredName>
        <Version>1</Version>
        <LongName>Autonomic Nervous System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12673</PREFERRED_NAME>
            <LONG_NAME>Autonomic Nervous System</LONG_NAME>
            <CON_ID>2205912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2493153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25547</PreferredName>
        <Version>1</Version>
        <LongName>Involved</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25547</PREFERRED_NAME>
            <LONG_NAME>Involved</LONG_NAME>
            <CON_ID>2203840</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have clinically</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have clinically evident autonomic nerve involvement per the protocol criteria</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Recurrent laryngeal or phrenic nerve paralysis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>REC_NERVE_PARALYSIS</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="390">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2982573</PUBLICID>
    <LONGNAME>Bone Marrow Laboratory Procedure Performed Laboratory Finding Result</LONGNAME>
    <PREFERREDNAME>2761384v1.0:2676304v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the bone marrow laboratory procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2761384</PublicId>
      <PreferredName>BM_LBPCD_PERF</PreferredName>
      <PreferredDefinition>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Bone Marrow Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2769785</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12431:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the result of the bo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the result of the bone marrow laboratory procedure?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the result of the bone marrow examination?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2020r1: Breast Cancer Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_bm_30day_cyt_rst</AlternateName>
        <AlternateNameType>NINDS Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_bm_30day_hist_rs</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_bm_30day_imm_rst</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_bm_30day_oth_rst</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>BMLabRslt</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BM_BX_RESULT_TYPE</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="391">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2986453</PUBLICID>
    <LONGNAME>Testicular Non-Seminomatous Germ Cell Tumor Present Indicator</LONGNAME>
    <PREFERREDNAME>2986438v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a testicular non-seminomatous germ cell tumor was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2986438</PublicId>
      <PreferredName>2986436v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>A testicular germ cell tumor characterized by the absence of a seminomatous component. It includes embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed forms._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Testicular Non-Seminomatous Germ Cell Tumor Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2986436</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9313</PreferredName>
        <Version>1</Version>
        <LongName>Testicular Non-Seminomatous Germ Cell Tumor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9313</PREFERRED_NAME>
            <LONG_NAME>Testicular Non-Seminomatous Germ Cell Tumor</LONG_NAME>
            <CON_ID>2986279</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was testicular non-seminomato</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was testicular non-seminomatous germ cell tumor present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Non-seminoma</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Non-seminoma</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2986453</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>[if exists then true else false]  PerformedObservation &gt; PerformedClinicalResult.value WHERE  DefinedObservation.nameCode = &quot;Test for Testicular Non-Seminomatous Germ Cell Tumor&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>tc_base_non_seminoma_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="392">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2990833</PUBLICID>
    <LONGNAME>Schedule Clinical Trial Epoch Clinical Trial Epoch Off Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2990621v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An ordered list of times at which things are planned to occur.:A portion of the study containing one or more study segments with a consistent objective such as screening subjects or treating disease._A portion of a study containing one or more study segments with a consistent objective such as screening subjects or treating disease.:No longer planned or scheduled (said of events).:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2990621</PublicId>
      <PreferredName>2867686v1.0:2990537v1.0</PreferredName>
      <PreferredDefinition>An ordered list of times at which things are planned to occur.:A portion of the study containing one or more study segments with a consistent objective such as screening subjects or treating disease._A portion of a study containing one or more study segments with a consistent objective such as screening subjects or treating disease.:No longer planned or scheduled (said of events).:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Schedule Clinical Trial Epoch Clinical Trial Epoch Off Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867686</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25211:C71738</PreferredName>
        <Version>1</Version>
        <LongName>Schedule Clinical Trial Epoch</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71738</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Epoch</LONG_NAME>
            <CON_ID>2732738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2990537</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71738:C40450:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Epoch Off Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71738</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Epoch</LONG_NAME>
            <CON_ID>2732738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40450</PREFERRED_NAME>
            <LONG_NAME>Off</LONG_NAME>
            <CON_ID>2615912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Schedule Clinical Trial Epoch Clinical Trial Epoch Off Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Schedule Clinical Trial Epoch Clinical Trial Epoch Off Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.ScheduledEpoch.offEpochDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ScheduledEpoch:offEpochDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="393">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998095</PUBLICID>
    <LONGNAME>Adverse Event Report Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2992775v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._A short textual account; having provided a short account.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992775</PublicId>
      <PreferredName>2235992v1.0:2992646v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._A short textual account; having provided a short account.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Adverse Event Report Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2235992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25375:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Report Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Report Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Report Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.AdverseEvent.reported</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent:reported</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="394">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998129</PUBLICID>
    <LONGNAME>User Password Last Computer Time Stamp java.sql.Timestamp</LONGNAME>
    <PREFERREDNAME>2992806v1.0:2238377v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An individual who uses a computer, program, network, or related service for work or entertainment. (from http://www.computeruser.com/resources/dictionary/index.html)_A secret set of characters, numbers, or symbols used as a form of authentication.:Coming after all others in time or space or degree or being the only one remaining.:The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events._Generic value domain for a java SQL datatype that is a thin wrapper around java.util.Date that allows the JDBC API to identify this as a SQL TIMESTAMP value.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992806</PublicId>
      <PreferredName>2223465v1.0:2992657v1.0</PreferredName>
      <PreferredDefinition>An individual who uses a computer, program, network, or related service for work or entertainment. (from http://www.computeruser.com/resources/dictionary/index.html)_A secret set of characters, numbers, or symbols used as a form of authentication.:Coming after all others in time or space or degree or being the only one remaining.:The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events.</PreferredDefinition>
      <LongName>User Password Last Computer Time Stamp</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42745</PreferredName>
        <Version>1</Version>
        <LongName>User</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42745</PREFERRED_NAME>
            <LONG_NAME>System User</LONG_NAME>
            <CON_ID>2203603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992657</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42710:C25551:C72669</PreferredName>
        <Version>1</Version>
        <LongName>Password Last Computer Time Stamp</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42710</PREFERRED_NAME>
            <LONG_NAME>Password</LONG_NAME>
            <CON_ID>2223427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72669</PREFERRED_NAME>
            <LONG_NAME>Computer Time Stamp</LONG_NAME>
            <CON_ID>2782652</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2238377</PublicId>
      <PreferredName>java.sql.Timestamp</PreferredName>
      <PreferredDefinition>Generic value domain for a java SQL datatype that is a thin wrapper around java.util.Date that allows the JDBC API to identify this as a SQL TIMESTAMP value.</PreferredDefinition>
      <LongName>java.sql.Timestamp</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.sql.Timestamp</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element User Password Last Computer Time Stamp java.sql.Timestamp does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element User Password Last Computer Time Stamp java.sql.Timestamp does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>User:passwordLastSet</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.User.passwordLastSet</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="395">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998131</PUBLICID>
    <LONGNAME>Clinical Trial Epoch Sequence java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2992807v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A portion of the study containing one or more study segments with a consistent objective such as screening subjects or treating disease._Serial arrangement in which things follow in logical order or a recurrent pattern._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992807</PublicId>
      <PreferredName>2732749v1.0:2236676v1.0</PreferredName>
      <PreferredDefinition>A portion of the study containing one or more study segments with a consistent objective such as screening subjects or treating disease._Serial arrangement in which things follow in logical order or a recurrent pattern.</PreferredDefinition>
      <LongName>Clinical Trial Epoch Sequence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2732749</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71738</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Epoch</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71738</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Epoch</LONG_NAME>
            <CON_ID>2732738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25673</PreferredName>
        <Version>1</Version>
        <LongName>Sequence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25673</PREFERRED_NAME>
            <LONG_NAME>Sequence</LONG_NAME>
            <CON_ID>2203798</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Epoch Sequence java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Epoch Sequence java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.Epoch.order</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Epoch:order</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="396">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998231</PUBLICID>
    <LONGNAME>Distant Research Personnel Staff Last Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2992905v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Far apart in space, time, or relevance from a point of origin.:People engaged in research.:The employees of an organization; personnel who assist their superior in carrying out an assigned task._A word or group of words indicating a person&#39;s last (family) name. (NCI)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992905</PublicId>
      <PreferredName>2992561v1.0:2223451v1.0</PreferredName>
      <PreferredDefinition>Far apart in space, time, or relevance from a point of origin.:People engaged in research.:The employees of an organization; personnel who assist their superior in carrying out an assigned task._A word or group of words indicating a person&#39;s last (family) name. (NCI)</PreferredDefinition>
      <LongName>Distant Research Personnel Staff Last Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2992561</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25321:C17089:C63612</PreferredName>
        <Version>1</Version>
        <LongName>Distant Research Personnel Staff</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25321</PREFERRED_NAME>
            <LONG_NAME>Distant</LONG_NAME>
            <CON_ID>2204917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17089</PREFERRED_NAME>
            <LONG_NAME>Research Personnel</LONG_NAME>
            <CON_ID>2202675</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63612</PREFERRED_NAME>
            <LONG_NAME>Staff</LONG_NAME>
            <CON_ID>2667911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40975</PreferredName>
        <Version>1</Version>
        <LongName>Last Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40975</PREFERRED_NAME>
            <LONG_NAME>Last Name</LONG_NAME>
            <CON_ID>2222026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Distant Research Personnel Staff Last Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Distant Research Personnel Staff Last Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RemoteResearchStaff:lastName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.RemoteResearchStaff.lastName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="397">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998258</PUBLICID>
    <LONGNAME>Submitter Identifier java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2992932v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who presents or submits something (e.g., a proposal or protocol) for formal consideration or review by others._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992932</PublicId>
      <PreferredName>2992564v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A person who presents or submits something (e.g., a proposal or protocol) for formal consideration or review by others._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Submitter Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2992564</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54269</PreferredName>
        <Version>1</Version>
        <LongName>Submitter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54269</PREFERRED_NAME>
            <LONG_NAME>Submitter</LONG_NAME>
            <CON_ID>2523383</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Submitter Identifier java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Submitter Identifier java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submitter:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.Submitter.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="398">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3007034</PUBLICID>
    <LONGNAME>Clinical Study Site Relationship Provider Software Service java.lang.String</LONGNAME>
    <PREFERREDNAME>3007020v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A healthcare organization, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study._A state of connectedness between people, objects, or events; to be associated or connected with something.:One that makes something available.:A software system providing a public need._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3007020</PublicId>
      <PreferredName>2715172v1.0:3007008v1.0</PreferredName>
      <PreferredDefinition>A healthcare organization, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study._A state of connectedness between people, objects, or events; to be associated or connected with something.:One that makes something available.:A software system providing a public need.</PreferredDefinition>
      <LongName>Clinical Study Site Relationship Provider Software Service</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2715172</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70777</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70777</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Site</LONG_NAME>
            <CON_ID>2714955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3007008</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25648:C37900:C80736</PreferredName>
        <Version>1</Version>
        <LongName>Relationship Provider Software Service</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37900</PREFERRED_NAME>
            <LONG_NAME>Provider</LONG_NAME>
            <CON_ID>2202411</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80736</PREFERRED_NAME>
            <LONG_NAME>Software Service</LONG_NAME>
            <CON_ID>2927597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Study Site Relationship Provider Software Service java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Study Site Relationship Provider Software Service java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2672769</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PSC</PreferredName>
          <Version>2.6</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.bioinformatics.studycalendar.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000049</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.bioinformatics.studycalendar.domain.StudySite.provider</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySite:provider</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="399">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3008835</PUBLICID>
    <LONGNAME>Disease or Disorder Status Amyloidosis Neuropathy Status Type</LONGNAME>
    <PREFERREDNAME>2512861v1.0:3008813v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the peripheral neuropathy status of amyloidosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2512861</PublicId>
      <PreferredName>2404658v1.0:2320064v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Disease or Disorder Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3008813</PublicId>
      <PreferredName>3008813v1.0</PreferredName>
      <PreferredDefinition>A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._A disorder affecting the cranial nerves or the peripheral nervous system. It is manifested with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Amyloidosis Neuropathy Status Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3008812</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2868:C4731:C25688:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Amyloidosis Neuropathy Status Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2868</PREFERRED_NAME>
            <LONG_NAME>Amyloidosis</LONG_NAME>
            <CON_ID>2443944</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4731</PREFERRED_NAME>
            <LONG_NAME>Neuropathy</LONG_NAME>
            <CON_ID>2202754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease</VALIDVALUE>
          <VALUEMEANING>Progressive disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Requires any of the following: 1) worsening of physical findings 2) worsening of EMG and/or NCV findings</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4241892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No response / stable disease</VALIDVALUE>
          <VALUEMEANING>No response/stable disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Does not meet criteria for peripheral neuropathy response nor progressive disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4241891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral neuropathy response</VALIDVALUE>
          <VALUEMEANING>Peripheral neuropathy response</VALUEMEANING>
          <MEANINGDESCRIPTION>Requires any of the following: 1) resolution of abnormal physical findings 2) resolution or improvement of abnormal EMG and/or NCV findings</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4873951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of amyloid</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of amyloidosis peripheral neuropathy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:3008835</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = &quot;peripheral neuropathy&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the status of peripheral neuropathy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the status of peripheral neuropathy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the current status of peripheral neuropathy</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify the current status of peripheral neuropathy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2117r1: Amyloidosis Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_post_crnt_pneuro_rsp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:diseaseStatusCode </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpost_amy_neuropathy_stat</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="400">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3008933</PUBLICID>
    <LONGNAME>HDL Cholesterol Median Baseline Laboratory Result Value in mg/dL</LONGNAME>
    <PREFERREDNAME>3008574v1.0:2655757v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A laboratory result using the metric measure of milligrams per deciliter (mg/dL) to capture the median imaginary standard against which the measurement of smallest and densest lipoproteins is compared.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>eMERGE:Electronic Medical Records and Genomics Network</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3008574</PublicId>
      <PreferredName>3008552v1.0:3009017v1.0</PreferredName>
      <PreferredDefinition>The imaginary standard against which the measurement of smallest and densest lipoproteins is compared.</PreferredDefinition>
      <LongName>HDL Cholesterol Median Baseline</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3008552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25186:C369</PreferredName>
        <Version>1</Version>
        <LongName>High Density Lipoprotein Cholesterol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25186</PREFERRED_NAME>
            <LONG_NAME>High Density Lipoprotein</LONG_NAME>
            <CON_ID>2206231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C369</PREFERRED_NAME>
            <LONG_NAME>Cholesterol</LONG_NAME>
            <CON_ID>2203873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3009017</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28007:C25213</PreferredName>
        <Version>1</Version>
        <LongName>Median Baseline</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28007</PREFERRED_NAME>
            <LONG_NAME>Median</LONG_NAME>
            <CON_ID>2528579</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25213</PREFERRED_NAME>
            <LONG_NAME>Baseline</LONG_NAME>
            <CON_ID>2202304</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>eMERGE:Electronic Medical Records and Genomics Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2655757</PublicId>
      <PreferredName>2655757v1.0</PreferredName>
      <PreferredDefinition>A laboratory result using the metric measure of milligrams per deciliter (mg/dL).</PreferredDefinition>
      <LongName>Laboratory Result Value in mg/dL</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/dL</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NHLBI FBPP:Family Blood Pressure Program</Origin>
      <Representation>
        <PublicId>2655756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37984:C20200:C28253:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Result Milligram Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28253</PREFERRED_NAME>
            <LONG_NAME>Milligram</LONG_NAME>
            <CON_ID>2204828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Median HDL Cholesterol Measur</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Median HDL Cholesterol Measurement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3006612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>eMERGE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>eMERGE Data Variables</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3006613</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Median_HDL_Choleserol_Measurement</AlternateName>
        <AlternateNameType>eMERGE Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="401">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3012453</PUBLICID>
    <LONGNAME>First Electrocardiography Left Bundle Branch Block Status</LONGNAME>
    <PREFERREDNAME>3010220v1.0:3010619v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>A condition or state of the initial measurement and interpretation of the electrical signals along the fibers of the left bundle branch during the first electrocardiogram.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>eMERGE:Electronic Medical Records and Genomics Network</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3010220</PublicId>
      <PreferredName>3012432v1.0:3010218v1.0</PreferredName>
      <PreferredDefinition>The initial measurement and interpretation of electrical manifestations along the fibers of the left main bundle branch, or both the left anterior fascicle and left posterior fascicle.</PreferredDefinition>
      <LongName>First Electrocardiography Left Bundle Branch Block</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3012432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C38053</PreferredName>
        <Version>1</Version>
        <LongName>First Electrocardiography</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38053</PREFERRED_NAME>
            <LONG_NAME>Electrocardiography</LONG_NAME>
            <CON_ID>2202414</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3010218</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62269</PreferredName>
        <Version>1</Version>
        <LongName>Left Bundle Branch Block</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62269</PREFERRED_NAME>
            <LONG_NAME>Left Bundle Branch Block by ECG Finding</LONG_NAME>
            <CON_ID>3010216</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>eMERGE:Electronic Medical Records and Genomics Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3010619</PublicId>
      <PreferredName>3010619v1.0</PreferredName>
      <PreferredDefinition>A condition or state of electrical signals at a particular time.</PreferredDefinition>
      <LongName>Electrocardiogram Characteristic Status</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>eMERGE:Electronic Medical Records and Genomics Network</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>possible</VALIDVALUE>
          <VALUEMEANING>possible</VALUEMEANING>
          <MEANINGDESCRIPTION>Capable of existing or occurring, or of being conceived or thought of</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>asserted</VALIDVALUE>
          <VALUEMEANING>asserted</VALUEMEANING>
          <MEANINGDESCRIPTION>To affirm; to declare with assurance, or plainly and strongly; to state positively</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>at risk for</VALIDVALUE>
          <VALUEMEANING>At-Risk Population</VALUEMEANING>
          <MEANINGDESCRIPTION>Population groups with an increased likelihood of a disease or other health issue, eg smoking, drug use, teen pregnancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>not recorded</VALIDVALUE>
          <VALUEMEANING>Not Recorded</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Record; anything, e.g. a document, providing permanent evidence of or information about past events.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25198, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>negated</VALIDVALUE>
          <VALUEMEANING>Negation</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3049796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>other experiencer</VALIDVALUE>
          <VALUEMEANING>Other Experiencer</VALUEMEANING>
          <MEANINGDESCRIPTION>A reference to someone other than the subject as being the one who has had an episode of the condition of interest, such as a disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3010621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Left bundle branch block char</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Left bundle branch block characteristic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3006612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>eMERGE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>eMERGE Data Variables</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3006613</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Left_Bundle_Branch_Block</AlternateName>
        <AlternateNameType>eMERGE Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="402">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3014793</PUBLICID>
    <LONGNAME>Prior Cranial Radiation Therapy Administered Ind-2</LONGNAME>
    <PREFERREDNAME>3014789v1.0:2018279v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to prior crianial radiotherapy being administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3014789</PublicId>
      <PreferredName>3014786v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>information related to prior crianial radiotherapy being administered.</PreferredDefinition>
      <LongName>Prior Cranial Radiation Therapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3014786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C37936:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Prior Cranial Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37936</PREFERRED_NAME>
            <LONG_NAME>Cranial</LONG_NAME>
            <CON_ID>2205421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior cranial RT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior cranial RT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABTC Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive prior Radiation Therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cranial RT for CNS leukostasis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive cranial radiation therapy during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive prior cranial radiation therapy or radiotherapy to the head and neck where potential field overlaps would exist?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Cohort B, has the patient received radiation therapy, interstitial brachytherapy or radiosurgery?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient already received cranial radiation greater than or equal to 30 Gy to the hypothalamus, inclusive of any total body irradiation (TBI)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_CRANIAL_RT_ADM</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PtRcvRadCrnmGt30GyHPTIncTBI</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="403">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3014799</PUBLICID>
    <LONGNAME>Quality of Life Diarrhea 7 Days Prior Assessment Score</LONGNAME>
    <PREFERREDNAME>2786950v1.0:3014717v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text response to indicate a person&#39;s report of having diarrhea during the past seven days.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2786950</PublicId>
      <PreferredName>QOL_DIAR_EVAL</PreferredName>
      <PreferredDefinition>information related to the condition of frequent and watery bowel movements difficult as a subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.</PreferredDefinition>
      <LongName>Quality of Life Diarrhea Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2736450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2786948</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2987:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Diarrhea Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2987</PREFERRED_NAME>
            <LONG_NAME>Diarrhea</LONG_NAME>
            <CON_ID>2203759</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3014717</PublicId>
      <PreferredName>QOL_7D_PR_ASSMT_SC</PreferredName>
      <PreferredDefinition>A number with no fractional part.::7_The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._Earlier in time or order._The final result of a determination of the value, significance, or extent of._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Quality of Life Scale 7 Days Prior Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3014716</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047:C45255::7:C25301:C25629</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life Integer::7 Day Prior Assessment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3014718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3013155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have diarrhea.</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have diarrhea.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HOW Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2988352</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>My Health as of Today</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="404">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3015030</PUBLICID>
    <LONGNAME>Person Circulating Tumor Cell Collection Off Treatment Reason</LONGNAME>
    <PREFERREDNAME>3014976v1.0:3015025v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the reason a person is off-treatment, the phase of a protocol during treatment is not received, and collection of circulating tumor cells, metastatic cancer cell found in the peripheral blood is is no longer being performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3014976</PublicId>
      <PreferredName>2236731v1.0:3014974v1.0</PreferredName>
      <PreferredDefinition>information related to a person being off-treatment, the phase of a protocol during treatment is not received, collecting circulating tumor cells, metastatic cancer cell found in the peripheral blood.</PreferredDefinition>
      <LongName>Person Circulating Tumor Cell Collection Off Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3014974</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63797:C25453:C25601</PreferredName>
        <Version>1</Version>
        <LongName>Circulating Tumor Cell Collection Off Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63797</PREFERRED_NAME>
            <LONG_NAME>Circulating Tumor Cell</LONG_NAME>
            <CON_ID>2547860</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3015025</PublicId>
      <PreferredName>3015025v1.0</PreferredName>
      <PreferredDefinition>the reason is off-treatment and collection of circulating tumor cells is no longer being performed.</PreferredDefinition>
      <LongName>Person Circulating Tumor Cell Collection Off Treatment Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient withdrew consent for all future blood draws</VALIDVALUE>
          <VALUEMEANING>Patient withdrew consent for all future blood draws</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient withdrew consent for all future blood draws</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3015027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progression or relapse</VALIDVALUE>
          <VALUEMEANING>Progression or relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>Progression or relapse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3015026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Day 253 blood draw completed per protocol criteria</VALIDVALUE>
          <VALUEMEANING>Day 253 blood draw completed per protocol criteria</VALUEMEANING>
          <MEANINGDESCRIPTION>Day 253 blood draw completed per protocol criteria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3015028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2839905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Off treatment reason</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Off treatment reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="405">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3019975</PUBLICID>
    <LONGNAME>Clinical Study Estrogen Receptor Status Progesterone Receptor Status Stratification Code</LONGNAME>
    <PREFERREDNAME>3019925v1.0:3019958v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the coded value related to the presence of estrogen and progesterone receptors, estrogen and progesterone receptor levels measured in a primary tumor or in metastases, as a stratification point, classifying patients into strata as part of the randomization process or for purposes of data analysis, for participation in research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3019925</PublicId>
      <PreferredName>2430995v1.0:3019923v1.0</PreferredName>
      <PreferredDefinition>information related to the presence of estrogen and progesterone receptors, estrogen and progesterone receptor levels measured in a primary tumor or in metastases, as a stratification point, classifying patients into strata as part of the randomization process or for purposes of data analysis, for participation in research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects.</PreferredDefinition>
      <LongName>Clinical Study Estrogen Receptor Status Progesterone Receptor Status Stratification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2430995</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206</PreferredName>
        <Version>1</Version>
        <LongName>Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3019923</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16150:C16149:C25689</PreferredName>
        <Version>1</Version>
        <LongName>Estrogen Receptor Status Progesterone Receptor Status Stratification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16150</PREFERRED_NAME>
            <LONG_NAME>Estrogen Receptor Status</LONG_NAME>
            <CON_ID>2534076</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16149</PREFERRED_NAME>
            <LONG_NAME>Progesterone Receptor Status</LONG_NAME>
            <CON_ID>2534077</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25689</PREFERRED_NAME>
            <LONG_NAME>Stratification</LONG_NAME>
            <CON_ID>2203803</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3019958</PublicId>
      <PreferredName>3019958v1.0</PreferredName>
      <PreferredDefinition>A numbered system to stratify estrogen receptor and progesterone receptor status for participation on a clinical trial.</PreferredDefinition>
      <LongName>Clinical Study Estrogen Receptor Status Progesterone Receptor Status Stratification Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>ER- and PgR-</VALUEMEANING>
          <MEANINGDESCRIPTION>estrogen receptor negative and progesterone receptor negative</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3019959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>ER+ and/or PgR+</VALUEMEANING>
          <MEANINGDESCRIPTION>estrogen receptor positive and/or progesterone receptor positive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3019960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Receptor status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Receptor status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3019925v1.0:3019958v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EST_PROG_REC_STATUS</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="406">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3025063</PUBLICID>
    <LONGNAME>Questionnaire Request Type</LONGNAME>
    <PREFERREDNAME>3025054v1.0:3025059v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type as related to being administered a predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCIC CRF:National Cancer Institute of Canada Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3025054</PublicId>
      <PreferredName>3025052v1.0:2517608v1.0</PreferredName>
      <PreferredDefinition>information related to being administered a predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc.</PreferredDefinition>
      <LongName>Questionnaire Request</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3025052</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17048</PreferredName>
        <Version>1</Version>
        <LongName>Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2517608</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48312</PreferredName>
        <Version>1</Version>
        <LongName>Request</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48312</PREFERRED_NAME>
            <LONG_NAME>Request</LONG_NAME>
            <CON_ID>2437671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCIC CRF:National Cancer Institute of Canada Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3025059</PublicId>
      <PreferredName>3025059v1.0</PreferredName>
      <PreferredDefinition>the type of questionnaire that is requested.</PreferredDefinition>
      <LongName>Questionnaire Request Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>75</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCIC CRF:National Cancer Institute of Canada Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LASA</VALIDVALUE>
          <VALUEMEANING>Linear Analogue Self Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>Linear Analogue Self Assessment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3180144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UCSD Shortness of Breath</VALIDVALUE>
          <VALUEMEANING>UCSD Shortness of Breath</VALUEMEANING>
          <MEANINGDESCRIPTION>UCSD Shortness of Breath</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3180143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LCSS</VALIDVALUE>
          <VALUEMEANING>Lung Cancer Symptom Scale</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung Cancer Symptom Scale</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3180145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EQ-5D</VALIDVALUE>
          <VALUEMEANING>EQ-5D</VALUEMEANING>
          <MEANINGDESCRIPTION>EQ-5D</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3180146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Block Alive screener</VALIDVALUE>
          <VALUEMEANING>Block Alive screener</VALUEMEANING>
          <MEANINGDESCRIPTION>Block Alive screener</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NHS II - Physical Activity</VALIDVALUE>
          <VALUEMEANING>NHS II - Physical Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>NHS II - Physical Activity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quality of Life</VALIDVALUE>
          <VALUEMEANING>Quality of Life</VALUEMEANING>
          <MEANINGDESCRIPTION>The subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17047</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3772693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Timed Up and Go</VALIDVALUE>
          <VALUEMEANING>Timed Up and Go</VALUEMEANING>
          <MEANINGDESCRIPTION>Timed Up and Go</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Karnofsky Performance Status (Healthcare Professional Rated)</VALIDVALUE>
          <VALUEMEANING>Karnofsky Performance Status Scale Questionnaire</VALUEMEANING>
          <MEANINGDESCRIPTION>A standardized rating scale originally developed by David A. Karnofsky and Joseph H. Burchenal in 1949 which is used to evaluate the degree to which a patient is functionally impaired. This instrument consists of 3 sections, no special care needed, unable to work, and unable to care for one&#39;s self and is completed by a clinician based on their observations. There are a total of eleven levels ranging from 0-100 where 0 indicates that the patient is dead and 100 indicates that the patient is normal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blessed Orientation-Memory-Concentration Test</VALIDVALUE>
          <VALUEMEANING>6-Item Orientation-Memory-Concentration Test</VALUEMEANING>
          <MEANINGDESCRIPTION>A screening test for cognitive impairment that is administered by a non-physician. This test is designed to discriminate between mild, moderate, and severe cognitive deficits.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Social Support</VALIDVALUE>
          <VALUEMEANING>Social Support</VALUEMEANING>
          <MEANINGDESCRIPTION>Social Support</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Social Activity</VALIDVALUE>
          <VALUEMEANING>Social Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>Social Activity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945655</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Your Mood</VALIDVALUE>
          <VALUEMEANING>Your Mood</VALUEMEANING>
          <MEANINGDESCRIPTION>Your Mood</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Your Health.  1. Your general health</VALIDVALUE>
          <VALUEMEANING>Your Health.  1. Your general health</VALUEMEANING>
          <MEANINGDESCRIPTION>Your Health.  1. Your general health</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Your Health. 2. Medications</VALIDVALUE>
          <VALUEMEANING>Your Health. 2. Medications</VALUEMEANING>
          <MEANINGDESCRIPTION>Your Health. 2. Medications</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Falls</VALIDVALUE>
          <VALUEMEANING>Falls</VALUEMEANING>
          <MEANINGDESCRIPTION>Falls</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Current Health Rating</VALIDVALUE>
          <VALUEMEANING>Current Health Rating</VALUEMEANING>
          <MEANINGDESCRIPTION>Current Health Rating</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical activities</VALIDVALUE>
          <VALUEMEANING>Physical activities</VALUEMEANING>
          <MEANINGDESCRIPTION>Physical activities</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily Activities</VALIDVALUE>
          <VALUEMEANING>Daily Activities</VALUEMEANING>
          <MEANINGDESCRIPTION>Daily Activities</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Background Information</VALIDVALUE>
          <VALUEMEANING>Background Information</VALUEMEANING>
          <MEANINGDESCRIPTION>Background Information</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spirituality/Religion</VALIDVALUE>
          <VALUEMEANING>Spirituality/Religion</VALUEMEANING>
          <MEANINGDESCRIPTION>Spirituality/Religion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3952152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Your Feelings</VALIDVALUE>
          <VALUEMEANING>Your Feelings</VALUEMEANING>
          <MEANINGDESCRIPTION>Your Feelings</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3952153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mental Health</VALIDVALUE>
          <VALUEMEANING>Mental health</VALUEMEANING>
          <MEANINGDESCRIPTION>Mental health</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2914011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Your Health</VALIDVALUE>
          <VALUEMEANING>Your Health</VALUEMEANING>
          <MEANINGDESCRIPTION>Your Health</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3952154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Questionnaire</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Questionnaire</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="407">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3028663</PUBLICID>
    <LONGNAME>Prostate Malignant Neoplasm Extracapsular Invasion Indicator</LONGNAME>
    <PREFERREDNAME>PROS_EXTC_INV_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator of the presence of extracapsular involvement of a prostate tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527498</PublicId>
      <PreferredName>PRS_MALNE_EXTCP_INV</PreferredName>
      <PreferredDefinition>related to the local spread of a tumor composed of atypical neoplastic cells from the prostate gland in the male reproductive system into or through the connective tissue layer surrounding the organ.</PreferredDefinition>
      <LongName>Prostate Malignant Neoplasm Extracapsular Invasion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12410:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2527495</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25502:C20625</PreferredName>
        <Version>1</Version>
        <LongName>Extracapsular Invasion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25502</PREFERRED_NAME>
            <LONG_NAME>Extracapsular</LONG_NAME>
            <CON_ID>2206208</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20625</PREFERRED_NAME>
            <LONG_NAME>Tumor Cell Invasion</LONG_NAME>
            <CON_ID>2203828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Extracapsular Extension</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Extracapsular Extension</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Extraprostatic or Extracapsular Extension Present</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="408">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3029959</PUBLICID>
    <LONGNAME>Diastolic Dysfunction Present Indicator</LONGNAME>
    <PREFERREDNAME>3029957v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a diastolic dysfunction was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3029957</PublicId>
      <PreferredName>3029955v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>Impairment in the filling of the ventricles during diastole. Causes include hypertrophic and restrictive cardiomyopathies, coronary artery disease, chronic high blood pressure, aortic stenosis, and aging._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Diastolic Dysfunction Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3029955</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C79547</PreferredName>
        <Version>1</Version>
        <LongName>Diastolic Dysfunction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79547</PREFERRED_NAME>
            <LONG_NAME>Diastolic Dysfunction</LONG_NAME>
            <CON_ID>3029954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was diastolic dysfunction pre</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was diastolic dysfunction present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was diastolic dysfunction present?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was diastolic dysfunction present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2017r1: Amyloidosis Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_diastl_dysfnc_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_organ_inv_diag_diastolic_dysfunc_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_organ_invol_prep_diastolic_dysfunc_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="409">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3030069</PUBLICID>
    <LONGNAME>Nerve Biopsy Performed Indicator</LONGNAME>
    <PREFERREDNAME>3030022v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a nerve biopsy was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3030022</PublicId>
      <PreferredName>3030020v1.0:2828214v1.0</PreferredName>
      <PreferredDefinition>Part of the peripheral nervous system composed of bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another._The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Nerve Biopsy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3030020</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12466:C15189</PreferredName>
        <Version>1</Version>
        <LongName>Nerve Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12466</PREFERRED_NAME>
            <LONG_NAME>Nerve</LONG_NAME>
            <CON_ID>2202756</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a nerve biopsy performed?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a nerve biopsy performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a nerve biopsy performed?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was a nerve biopsy performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2017r1: Amyloidosis Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>amy_base_nerve_bx_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_amy_organ_inv_diag_nerve_biopsy_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="410">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3030312</PUBLICID>
    <LONGNAME>Diffusion Weighted Magnetic Resonance Imaging Method Cateogry</LONGNAME>
    <PREFERREDNAME>DIFF_WT_MRI_METH_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Categorization of in vivo images of biological tissues weighted with local microstructural characteristics of water diffusion.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3030304</PublicId>
      <PreferredName>DIFF_WT_MRI_METH</PreferredName>
      <PreferredDefinition>The movement of chemical species under the influence of a concentration difference and as a result of random thermal agitation.  The species will move from the high concentration area to the low concentration area till the concentration is uniform in the whole phase._The vertical force exerted by a mass as a result of gravity._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. _A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Diffusion Weighted Magnetic Resonance Imaging Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3030302</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82333:C25208:C16809</PreferredName>
        <Version>1</Version>
        <LongName>Diffusion Weight Magnetic Resonance Imaging</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82333</PREFERRED_NAME>
            <LONG_NAME>Diffusion</LONG_NAME>
            <CON_ID>2904845</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16809</PREFERRED_NAME>
            <LONG_NAME>Magnetic Resonance Imaging</LONG_NAME>
            <CON_ID>2202506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2730351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460</PreferredName>
        <Version>1</Version>
        <LongName>Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3030309</PublicId>
      <PreferredName>DIFF_WT_MRI_CAT</PreferredName>
      <PreferredDefinition>The movement of chemical species under the influence of a concentration difference and as a result of random thermal agitation.  The species will move from the high concentration area to the low concentration area till the concentration is uniform in the whole phase._The vertical force exerted by a mass as a result of gravity._(mag-NET-ik REZ-o-nans IM-a-jing) MRI. A procedure in which a magnet linked to a computer is used to create detailed pictures of areas inside the body.  Also called nuclear magnetic resonance imaging._Category; used informally to mean a class of things.</PreferredDefinition>
      <LongName>Diffusion Weighted Magnetic Resonance Imaging Cateogry</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3030308</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82333:C25208:C16809:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Diffusion Weight Magnetic Resonance Imaging Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82333</PREFERRED_NAME>
            <LONG_NAME>Diffusion</LONG_NAME>
            <CON_ID>2904845</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16809</PREFERRED_NAME>
            <LONG_NAME>Magnetic Resonance Imaging</LONG_NAME>
            <CON_ID>2202506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Restricted</VALIDVALUE>
          <VALUEMEANING>Restricted</VALUEMEANING>
          <MEANINGDESCRIPTION>Restricted</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3030310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DWI (Diffusion weighted MRI)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>DWI (Diffusion weighted MRI)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MGH 09 364</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3030983</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="411">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3087902</PUBLICID>
    <LONGNAME>HER2/neu And Centromere 17 Copy Number Analysis Input Total Number Count</LONGNAME>
    <PREFERREDNAME>3087900v1.0:2528510v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the total number of Cells Counted for HER2 &amp; Centromere 17 copy number.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3087900</PublicId>
      <PreferredName>3087898v1.0:2423582v1.0</PreferredName>
      <PreferredDefinition>The ERBB2 Gene at 17q21.1 encodes ERRB2 Receptor Protein Tyrosine Kinase, a 185 kD type I membrane glycoprotein that controls cell growth with features similar to EGFR. Ligand binding increases phosphorylation of tyrosine residues. A potential heterodimer with ERBB3 and ERBB4 receptors, p185ERBB2 is an essential component of the heregulin/neuregulin receptor complex. ERBB2 homodimers do not bind heregulin but ERBB2/ERBB3 heterodimers do. Neuregulins do not interact with ERBB2 alone. The IL6 cytokine induces tyrosine phosphorylation of ERBB2 and ERBB3, but not EGFR. ERBB2 forms an IL6-dependent complex with the IL6R gp130 subunit resulting in MAPK activation. Expressed in fetal kidney and liver, herstatin is a 68 kD secreted product of an alternative ERBB2 transcript that retains intron 8. Herstatin binds p185ERBB2 as an inhibitor by disrupting ERBB2 dimers and reducing p185 tyrosine phosphorylation.  (from SWISS-PROT, OMIM and NCI)_The act of joining or combining or uniting with others; increasing the quality, quantity, size or scope of._The nonstaining primary constriction of a chromosome which is the point of attachment of the spindle fiber; provides the mechanism of chromosome movement during cell division; the centromere divides the chromosome into two arms, and its position is constant for a specific chromosome: near one end (acrocentric), near the center (metacentric), or between (submetacentric)._A number with no fractional part.::17_The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium._Analysis; examination and interpretation._Anything added into a sytem._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.</PreferredDefinition>
      <LongName>HER2/neu Add Centromere Integer::17 Copy Number Analysis Input Total</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3087898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17756:C64911:C13198:C45255::1</PreferredName>
        <Version>1</Version>
        <LongName>HER2/neu Add Centromere Integer::17 Copy Number Analysis Input</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17756</PREFERRED_NAME>
            <LONG_NAME>ERBB2 Gene</LONG_NAME>
            <CON_ID>2202658</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64911</PREFERRED_NAME>
            <LONG_NAME>Add</LONG_NAME>
            <CON_ID>2710231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13198</PREFERRED_NAME>
            <LONG_NAME>Centromere</LONG_NAME>
            <CON_ID>2523774</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::17</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49142</PREFERRED_NAME>
            <LONG_NAME>Copy Number</LONG_NAME>
            <CON_ID>2528506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47905</PREFERRED_NAME>
            <LONG_NAME>Input</LONG_NAME>
            <CON_ID>2422639</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423582</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304</PreferredName>
        <Version>1</Version>
        <LongName>Total</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2528510</PublicId>
      <PreferredName>DNA_CPYNUM_CT</PreferredName>
      <PreferredDefinition>the numeric amount of DNA molecules per microllter.</PreferredDefinition>
      <LongName>DNA Copy Number Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>ul</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of Cells Counted for H</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of Cells Counted for HER2 &amp; Centromere 17 Copy Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Average HER2 copies per cell</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Average centromere 17 copies per cell</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HCMI Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of cells counted for HER2 and chromosome 17 centromere copy numbers</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BRCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical brca shared</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787529</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000009</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Stomach</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000454</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>her2_neu_and_centromere_17_copy_number_analysis_input_total_number_count</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cells_counted_copy_number</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="412">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3099389</PUBLICID>
    <LONGNAME>Small Intestine Liver Disease or Disorder Small Volume Ind-2</LONGNAME>
    <PREFERREDNAME>3099387v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to disease in gastro-hepatic region that is small in volume.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099387</PublicId>
      <PreferredName>3099384v1.0:3099385v1.0</PreferredName>
      <PreferredDefinition>information related to disease in gastro-hepatic region that is small in volume.</PreferredDefinition>
      <LongName>Small Intestine Liver Disease or Disorder Small Volume</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099384</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12386:C12392:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Small Bowel Liver Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12386</PREFERRED_NAME>
            <LONG_NAME>Small Intestine</LONG_NAME>
            <CON_ID>2202819</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3099385</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25376:C25335</PreferredName>
        <Version>1</Version>
        <LongName>Small Volume</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25376</PREFERRED_NAME>
            <LONG_NAME>Small</LONG_NAME>
            <CON_ID>2206253</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Small volume of disease in th</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Small volume of disease in the gastro-hepatic ligament defined by a &lt;5 cm mass in the epigastric region on cross-sectional imaging</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="413">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3100899</PUBLICID>
    <LONGNAME>Financial Account Number Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3099674v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A formal relationship established to provide for regular banking and business services.:A numeral or string of numerals expressing value, quantity, or identification._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099674</PublicId>
      <PreferredName>3099519v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>A formal relationship established to provide for regular banking and business services.:A numeral or string of numerals expressing value, quantity, or identification._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Financial Account Number Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099519</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88186:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Financial Account Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88186</PREFERRED_NAME>
            <LONG_NAME>Financial Account</LONG_NAME>
            <CON_ID>3099482</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Financial Account Number Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Financial Account Number Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration.customerservice</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099475</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.customerservice.AccountNumber.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AccountNumber:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="414">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3100956</PUBLICID>
    <LONGNAME>Cost Per Unit Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3099731v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments.:For each, generally denoting a ratio.:A single undivided thing occurring in the composition of something else._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099731</PublicId>
      <PreferredName>3099525v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments.:For each, generally denoting a ratio.:A single undivided thing occurring in the composition of something else._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Cost Per Unit Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099525</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C69088:C65039:C44278</PreferredName>
        <Version>1</Version>
        <LongName>Cost Per Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C69088</PREFERRED_NAME>
            <LONG_NAME>Cost</LONG_NAME>
            <CON_ID>2742960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44278</PREFERRED_NAME>
            <LONG_NAME>Unit</LONG_NAME>
            <CON_ID>2236581</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cost Per Unit Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cost Per Unit Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration.customerservice</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099475</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.customerservice.Rate.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Rate:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="415">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3100958</PUBLICID>
    <LONGNAME>Cost Per Unit Description java.lang.String</LONGNAME>
    <PREFERREDNAME>3099733v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments.:For each, generally denoting a ratio.:A single undivided thing occurring in the composition of something else._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099733</PublicId>
      <PreferredName>3099525v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments.:For each, generally denoting a ratio.:A single undivided thing occurring in the composition of something else._A statement or an account describing something.</PreferredDefinition>
      <LongName>Cost Per Unit Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099525</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C69088:C65039:C44278</PreferredName>
        <Version>1</Version>
        <LongName>Cost Per Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C69088</PREFERRED_NAME>
            <LONG_NAME>Cost</LONG_NAME>
            <CON_ID>2742960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44278</PREFERRED_NAME>
            <LONG_NAME>Unit</LONG_NAME>
            <CON_ID>2236581</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cost Per Unit Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cost Per Unit Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration.customerservice</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099475</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.customerservice.Rate.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Rate:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="416">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3100980</PUBLICID>
    <LONGNAME>Quotation Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3099755v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A statement of the current price for goods or services._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099755</PublicId>
      <PreferredName>3099527v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>A statement of the current price for goods or services._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Quotation Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099527</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88193</PreferredName>
        <Version>1</Version>
        <LongName>Quotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88193</PREFERRED_NAME>
            <LONG_NAME>Quotation</LONG_NAME>
            <CON_ID>3099489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Quotation Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Quotation Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration.customerservice</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099475</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.customerservice.Quotation.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Quotation:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="417">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3100996</PUBLICID>
    <LONGNAME>Telephone Number Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>3099771v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of decimal digits (0-9) that is used for identifying a destination telephone line or other device in a telephone network._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099771</PublicId>
      <PreferredName>2958326v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>A sequence of decimal digits (0-9) that is used for identifying a destination telephone line or other device in a telephone network._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Telephone Number Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2958326</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40978</PreferredName>
        <Version>1</Version>
        <LongName>Telephone Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40978</PREFERRED_NAME>
            <LONG_NAME>Telephone Number</LONG_NAME>
            <CON_ID>2223426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Telephone Number Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Telephone Number Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TelephoneNumber:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.TelephoneNumber.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="418">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101295</PUBLICID>
    <LONGNAME>Development Stage Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100054v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100054</PublicId>
      <PreferredName>3099579v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Development Stage Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17770:C48308</PreferredName>
        <Version>1</Version>
        <LongName>Development Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17770</PREFERRED_NAME>
            <LONG_NAME>Maturation</LONG_NAME>
            <CON_ID>2237044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48308</PREFERRED_NAME>
            <LONG_NAME>Stage</LONG_NAME>
            <CON_ID>2676538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Development Stage Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Development Stage Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DevelopmentalStage:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.DevelopmentalStage.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="419">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101301</PUBLICID>
    <LONGNAME>Development Stage Modified By java.lang.Long</LONGNAME>
    <PREFERREDNAME>3100060v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._Indicates the person or authoritative body who changed an item._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100060</PublicId>
      <PreferredName>3099579v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Development Stage Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17770:C48308</PreferredName>
        <Version>1</Version>
        <LongName>Development Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17770</PREFERRED_NAME>
            <LONG_NAME>Maturation</LONG_NAME>
            <CON_ID>2237044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48308</PREFERRED_NAME>
            <LONG_NAME>Stage</LONG_NAME>
            <CON_ID>2676538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Development Stage Modified By java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Development Stage Modified By java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DevelopmentalStage:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.DevelopmentalStage.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="420">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101377</PUBLICID>
    <LONGNAME>Disease or Disorder Stage Modified By java.lang.Long</LONGNAME>
    <PREFERREDNAME>3100134v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Any distinct time period in a sequence of events._Indicates the person or authoritative body who changed an item._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100134</PublicId>
      <PreferredName>3099566v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Any distinct time period in a sequence of events._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Disease or Disorder Stage Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099566</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C48308</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48308</PREFERRED_NAME>
            <LONG_NAME>Stage</LONG_NAME>
            <CON_ID>2676538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Disease or Disorder Stage Modified By java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Disease or Disorder Stage Modified By java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DiseaseStage:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.DiseaseStage.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="421">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101832</PUBLICID>
    <LONGNAME>Minimum Reservation Quantity Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>3100592v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The smallest possible quantity.:The act of keeping back or setting aside for some future occasion.:How much there is of something that you can measure; the total amount or number._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100592</PublicId>
      <PreferredName>3099529v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The smallest possible quantity.:The act of keeping back or setting aside for some future occasion.:How much there is of something that you can measure; the total amount or number._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Minimum Reservation Quantity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099529</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25570:C71729:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Minimum Reservation Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71729</PREFERRED_NAME>
            <LONG_NAME>Reservation</LONG_NAME>
            <CON_ID>2734796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Minimum Reservation Quantity Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Minimum Reservation Quantity Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MinimumReserveQuantity:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.MinimumReserveQuantity.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="422">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101882</PUBLICID>
    <LONGNAME>Nutritional Required Name java.lang.String</LONGNAME>
    <PREFERREDNAME>3100642v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Of or relating to or providing nutrition.:Necessary, not optional._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100642</PublicId>
      <PreferredName>3099561v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>Of or relating to or providing nutrition.:Necessary, not optional._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Nutritional Required Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099561</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25597:C25652</PreferredName>
        <Version>1</Version>
        <LongName>Nutritional Required</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25597</PREFERRED_NAME>
            <LONG_NAME>Nutritional</LONG_NAME>
            <CON_ID>2206329</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25652</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2204014</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Nutritional Required Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Nutritional Required Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.NutritionalRequirement.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NutritionalRequirement:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="423">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101901</PUBLICID>
    <LONGNAME>Stage Description java.lang.String</LONGNAME>
    <PREFERREDNAME>3100661v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100661</PublicId>
      <PreferredName>3099583v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body._A statement or an account describing something.</PreferredDefinition>
      <LongName>Stage Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099583</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Stage Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Stage Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TumorStage:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.TumorStage.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="424">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102099</PUBLICID>
    <LONGNAME>Race Description java.lang.String</LONGNAME>
    <PREFERREDNAME>3100858v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Major living subspecies of man differentiated by genetic and physical characteristics. There are four racial groups: Australoid, Caucasoid, Mongoloid, and Negroid._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100858</PublicId>
      <PreferredName>2389400v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>Major living subspecies of man differentiated by genetic and physical characteristics. There are four racial groups: Australoid, Caucasoid, Mongoloid, and Negroid._A statement or an account describing something.</PreferredDefinition>
      <LongName>Race Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2389400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17049</PreferredName>
        <Version>1</Version>
        <LongName>Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Race Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Race Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Race.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Race:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="425">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102114</PUBLICID>
    <LONGNAME>Coat Color Name java.lang.String</LONGNAME>
    <PREFERREDNAME>3100872v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The covering of hair, wool, or fur on the body of an animal.:The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100872</PublicId>
      <PreferredName>3099577v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>The covering of hair, wool, or fur on the body of an animal.:The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Coat Color Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88212:C37927</PreferredName>
        <Version>1</Version>
        <LongName>Coat Color</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88212</PREFERRED_NAME>
            <LONG_NAME>Coat</LONG_NAME>
            <CON_ID>3099501</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37927</PREFERRED_NAME>
            <LONG_NAME>Color</LONG_NAME>
            <CON_ID>2710268</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Coat Color Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Coat Color Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CoatColor:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.CoatColor.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="426">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102118</PUBLICID>
    <LONGNAME>Preservation Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100876v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The activity of protecting something from loss or danger; a process that saves organic substances from decay; to maintain or keep intact._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100876</PublicId>
      <PreferredName>3099574v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>The activity of protecting something from loss or danger; a process that saves organic substances from decay; to maintain or keep intact._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Preservation Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099574</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52243</PreferredName>
        <Version>1</Version>
        <LongName>Preservation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52243</PREFERRED_NAME>
            <LONG_NAME>Preservation</LONG_NAME>
            <CON_ID>2443938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Preservation Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Preservation Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Preservation:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Preservation.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="427">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102912</PUBLICID>
    <LONGNAME>Fibromyalgia Medication Use Ind-2</LONGNAME>
    <PREFERREDNAME>3102910v1.0:2018279v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to medication use for chronic disorder of unknown etiology charaterized by pain, stiffness, and tenderness in the muscles of the neck, shoulders, back, hips, arms, and legs.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3102910</PublicId>
      <PreferredName>3102908v1.0:2234899v1.0</PreferredName>
      <PreferredDefinition>information related to medication use for chronic disorder of unknown etiology charaterized by pain, stiffness, and tenderness in the muscles of the neck, shoulders, back, hips, arms, and legs.</PreferredDefinition>
      <LongName>Fibromyalgia Medication Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3102908</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C87497:C459</PreferredName>
        <Version>1</Version>
        <LongName>Fibromyalgia Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87497</PREFERRED_NAME>
            <LONG_NAME>Fibromyalgia</LONG_NAME>
            <CON_ID>3014943</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fibromyalgia</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Fibromyalgia</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="428">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3107563</PUBLICID>
    <LONGNAME>Carcinoembryonic Antigen Specimen Collection Ind-2</LONGNAME>
    <PREFERREDNAME>2011695v3.0:2181518v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to collection of a CEA specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2011695</PublicId>
      <PreferredName>CEA_SPECIMEN_COLLECT</PreferredName>
      <PreferredDefinition>information related to collection of a CEA specimen.</PreferredDefinition>
      <LongName>Carcinoembryonic Antigen Specimen Collection</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206382</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25159:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Carcinoembryonic Antigen Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25159</PREFERRED_NAME>
            <LONG_NAME>Carcinoembryonic Antigen</LONG_NAME>
            <CON_ID>2206173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177591</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Collection</PreferredName>
        <Version>1</Version>
        <LongName>Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the CEA level of the pati</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the CEA level of the patient been determined</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HCMI Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the CEA level of the patient been determined?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5777527</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HCC and Bile Duct Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6403794</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>carcinoembryonic_antigen_test_ind</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="429">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3107602</PUBLICID>
    <LONGNAME>Prior Epidermal Growth Factor Receptor Therapy Performed Specify</LONGNAME>
    <PREFERREDNAME>P_EGFR_TX_PERF_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field to specify the other growth factor/TKI administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2228854</PublicId>
      <PreferredName>PRIREGFR_TX_PERFORMD</PreferredName>
      <PreferredDefinition>information relating to prior EGFR therapy performed.</PreferredDefinition>
      <LongName>Prior Epidermal Growth Factor Receptor Therapy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228852</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C17068:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Prior Epidermal Growth Factor Receptor Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17068</PREFERRED_NAME>
            <LONG_NAME>Epidermal Growth Factor Receptor</LONG_NAME>
            <CON_ID>2202420</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184322</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Performed</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179878</PublicId>
      <PreferredName>TX_ADM_SPEC</PreferredName>
      <PreferredDefinition>the free-text field to specify the therapy administered.</PreferredDefinition>
      <LongName>Therapy Administered Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208052</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Administered Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="430">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3108205</PUBLICID>
    <LONGNAME>Patient Breast Reconstruction Consent Ind-2</LONGNAME>
    <PREFERREDNAME>3108181v1.0:2018303v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes no indicator related to consent from a person to participate in a clinical trial involving surgery to rebuild a breast&#39;s shape after a mastectomy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3108181</PublicId>
      <PreferredName>2233604v1.0:3108179v1.0</PreferredName>
      <PreferredDefinition>information related to consent from a person to participate in a clinical trial involving surgery to rebuild a breast&#39;s shape after a mastectomy.</PreferredDefinition>
      <LongName>Patient Breast Reconstruction Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3108179</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15354:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Breast Reconstruction Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15354</PREFERRED_NAME>
            <LONG_NAME>Mammoplasty</LONG_NAME>
            <CON_ID>2716449</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient has consented to part</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient has consented to participate in the cosmesis study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3108181v1.0:2018303v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="431">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3108931</PUBLICID>
    <LONGNAME>Surgery Liver Not Performed Reason</LONGNAME>
    <PREFERREDNAME>3108928v1.0:2538261v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the reason relating to the not having diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of the liver, the large organ located in the upper abdomen that cleanses the blood and aids in digestion by secreting bile.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3108928</PublicId>
      <PreferredName>2322305v1.0:3108926v1.0</PreferredName>
      <PreferredDefinition>information relating to the not having diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of the liver, the large organ located in the upper abdomen that cleanses the blood and aids in digestion by secreting bile.</PreferredDefinition>
      <LongName>Surgery Liver Not Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3108929</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C25594:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Liver Negation Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018700</PublicId>
      <PreferredName>N_PERF_RSN_1</PreferredName>
      <PreferredDefinition>the reason an action was not performed.</PreferredDefinition>
      <LongName>Not Performed Reason</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>55</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient refused</VALIDVALUE>
          <VALUEMEANING>PATIENT REFUSED</VALUEMEANING>
          <MEANINGDESCRIPTION>PATIENT REFUSED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-05-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Local regional tumor growth</VALIDVALUE>
          <VALUEMEANING>LOCAL REGIONAL TUMOR GROWTH</VALUEMEANING>
          <MEANINGDESCRIPTION>LOCAL REGIONAL TUMOR GROWTH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metastatic disease</VALIDVALUE>
          <VALUEMEANING>METASTATIC DISEASE</VALUEMEANING>
          <MEANINGDESCRIPTION>METASTATIC DISEASE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Second primary cancer</VALIDVALUE>
          <VALUEMEANING>SECOND PRIMARY CANCER</VALUEMEANING>
          <MEANINGDESCRIPTION>SECOND PRIMARY CANCER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adverse event/toxicity</VALIDVALUE>
          <VALUEMEANING>Toxicity Adverse Event</VALUEMEANING>
          <MEANINGDESCRIPTION>Toxicity; the degree to which something is poisonous.: Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41331, C27990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progression of hepatic metastases</VALIDVALUE>
          <VALUEMEANING>Hepatic Progression Metastasis</VALUEMEANING>
          <MEANINGDESCRIPTION>Refers to the liver.: advancement in extent or severity.: Cancer that has spread from the organ in which it first appeared to another organ. For example, breast cancer cells may spread (metastasize) to the lungs and cause the growth of a new tumor. When this happens, the disease is called metastatic breast cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19151, CL101509, C13308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interoperative complication/adverse event</VALIDVALUE>
          <VALUEMEANING>Interoperative complication/adverse event</VALUEMEANING>
          <MEANINGDESCRIPTION>Interoperative complication/adverse event</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3685150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adhesions or other complicating factor</VALIDVALUE>
          <VALUEMEANING>Adhesions or other complicating factor</VALUEMEANING>
          <MEANINGDESCRIPTION>Adhesions or other complicating factor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metastases discovered during surgery</VALIDVALUE>
          <VALUEMEANING>Metastases discovered during surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Metastases discovered during surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3685151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Locally advanced disease discovered during surgery</VALIDVALUE>
          <VALUEMEANING>Locally advanced disease discovered during surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced disease discovered during surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3685152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unresectable due to metastases discovered during surgery</VALIDVALUE>
          <VALUEMEANING>Unresectable Due To Metastasis Discover During Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be removed with surgery.: Caused by or resulting from.: The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.: See for the first time; identify.: At some point in a given period of time.: The branch of medical science that treats disease or injury by operative procedures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173, C25490, C62262, C19151, C89272, C14151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5427673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unresectable due to locally advanced disease discovered during surgery</VALIDVALUE>
          <VALUEMEANING>Unresectable Due To Locally Advanced Malignant Neoplasm Discover During Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be removed with surgery.: Caused by or resulting from.: Cancer that has spread from where it started to nearby tissue or lymph nodes.: See for the first time; identify.: At some point in a given period of time.: The branch of medical science that treats disease or injury by operative procedures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173, C25490, C62262, C8524, C89272, C14151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5427674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical risk outweighs clinical benefit</VALIDVALUE>
          <VALUEMEANING>Surgical risk outweighs clinical benefit</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical risk outweighs clinical benefit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6851647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete Response</VALIDVALUE>
          <VALUEMEANING>Complete Remission</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer in response to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3854972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upfront Resection</VALIDVALUE>
          <VALUEMEANING>Upfront Resection</VALUEMEANING>
          <MEANINGDESCRIPTION>Upfront Resection</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6851648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason surgery was not initia</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason surgery was not initiated</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="432">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3109721</PUBLICID>
    <LONGNAME>Extrahepatic Metastasis Medical Imaging Diagnosis Ind-2</LONGNAME>
    <PREFERREDNAME>Extr_Meta_Medi_Diag_DX_IND-2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to identification of cancer that has spread to locations or occurring outside to the liver through tests that produce pictures of areas inside the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3109719</PublicId>
      <PreferredName>Extr_Meta_Medi_Diag</PreferredName>
      <PreferredDefinition>information related to identification of cancer that has spread to locations or occurring outside to the liver through tests that produce pictures of areas inside the body.</PreferredDefinition>
      <LongName>Extrahepatic Metastasis Medical Imaging Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3108904</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28358:C19151</PreferredName>
        <Version>1</Version>
        <LongName>Extrahepatic Metastasis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28358</PREFERRED_NAME>
            <LONG_NAME>Extrahepatic</LONG_NAME>
            <CON_ID>2322314</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19151</PREFERRED_NAME>
            <LONG_NAME>Metastasis</LONG_NAME>
            <CON_ID>2202751</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3109712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16831:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16831</PREFERRED_NAME>
            <LONG_NAME>Medical Imaging</LONG_NAME>
            <CON_ID>2224877</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were extrahepatic metastases</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were extrahepatic metastases evident on one or more scans?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have extrahepatic disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="433">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3113185</PUBLICID>
    <LONGNAME>Image Slice Thickness Float or Fixed-point Millimeter Number</LONGNAME>
    <PREFERREDNAME>IMG_SLICE_THICKNESS</PREFERREDNAME>
    <PREFERREDDEFINITION>A string of characters representing either a fixed point number or a floating point number capturing the nominal slice thickness of an image, expressed in millimeters.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2413319</PublicId>
      <PreferredName>2423453v1.0:2553654v1.0</PreferredName>
      <PreferredDefinition>Nominal slice thickness.</PreferredDefinition>
      <LongName>Image Slice Thickness</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2423453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179</PreferredName>
        <Version>1</Version>
        <LongName>Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553654</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25682:C41145</PreferredName>
        <Version>1</Version>
        <LongName>Slice Thickness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25682</PREFERRED_NAME>
            <LONG_NAME>Slice</LONG_NAME>
            <CON_ID>2202619</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41145</PREFERRED_NAME>
            <LONG_NAME>Thickness</LONG_NAME>
            <CON_ID>2413316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3113181</PublicId>
      <PreferredName>FLOAT_FIXEDPT_MM_NUM</PreferredName>
      <PreferredDefinition>DS MM: A string of characters representing either a fixed point number or a floating point number measured in millimeters.</PreferredDefinition>
      <LongName>Float or Fixed-point Millimeter Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>16</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>3113180</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48150:C89579:C28251:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Float Fixed-point Value Millimeter Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48150</PREFERRED_NAME>
            <LONG_NAME>Float</LONG_NAME>
            <CON_ID>2433734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89579</PREFERRED_NAME>
            <LONG_NAME>Fixed-Point Number</LONG_NAME>
            <CON_ID>3108413</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28251</PREFERRED_NAME>
            <LONG_NAME>Millimeter</LONG_NAME>
            <CON_ID>2204830</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Slice Thickness</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Slice Thickness</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ACRIN Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Slice thickness of reconstructed images</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imaging Data Standards</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000331</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DICOM Tag CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314514</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>E2410</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3428274</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>(0018,0050)</AlternateName>
        <AlternateNameType>DICOM_TAG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Slice Thickness</AlternateName>
        <AlternateNameType>DICOM Attribute Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="434">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3113330</PUBLICID>
    <LONGNAME>Soft Tissue Sarcoma Necrosis Score</LONGNAME>
    <PREFERREDNAME>SAR_NECR_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the amount of dying tissue (necrosis) present in a sample of tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3113323</PublicId>
      <PreferredName>SAR_NECR</PreferredName>
      <PreferredDefinition>A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones._The pathologic localized death of living cells, as from infection or interruption of the blood supply, generally associated with severe cellular trauma caused by progressive degradation by enzymes. Characterized by mitochondrial swelling, nuclear flocculation, and uncontrolled cell lysis, it is unprogrammed death of living tissue and cells.</PreferredDefinition>
      <LongName>Soft Tissue Sarcoma Necrosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2963681</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9306</PreferredName>
        <Version>1</Version>
        <LongName>Soft Tissue Sarcoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9306</PREFERRED_NAME>
            <LONG_NAME>Soft Tissue Sarcoma</LONG_NAME>
            <CON_ID>2202826</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2448417</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16897</PreferredName>
        <Version>1</Version>
        <LongName>Necrosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16897</PREFERRED_NAME>
            <LONG_NAME>Necrotic Process</LONG_NAME>
            <CON_ID>2202853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3113325</PublicId>
      <PreferredName>SAR_NECR_SC</PreferredName>
      <PreferredDefinition>A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones._The pathologic localized death of living cells, as from infection or interruption of the blood supply, generally associated with severe cellular trauma caused by progressive degradation by enzymes. Characterized by mitochondrial swelling, nuclear flocculation, and uncontrolled cell lysis, it is unprogrammed death of living tissue and cells._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Soft Tissue Sarcoma Necrosis Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3113324</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9306:C16897:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Soft Tissue Sarcoma Necrosis Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9306</PREFERRED_NAME>
            <LONG_NAME>Soft Tissue Sarcoma</LONG_NAME>
            <CON_ID>2202826</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16897</PREFERRED_NAME>
            <LONG_NAME>Necrotic Process</LONG_NAME>
            <CON_ID>2202853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Tumor necrosis score of 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor necrosis score of 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Tumor necrosis score of 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor necrosis score of 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Tumor necrosis score of 0</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor necrosis score of 0</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tumor Necrosis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tumor Necrosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812731</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FMISO Soft Tissue Sarcoma Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3113297</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="435">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3117240</PUBLICID>
    <LONGNAME>Recurrent Disease Lung Tissue Present Indicator</LONGNAME>
    <PREFERREDNAME>3117238v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not recurrent disease was present in the lung tissue.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3117238</PublicId>
      <PreferredName>2678101v1.0:3130962v1.0</PreferredName>
      <PreferredDefinition>The return of a disease after a period of remission._Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Recurrent Disease Lung Tissue Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2678101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38155</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3130962</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C33024:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Lung Tissue Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C33024</PREFERRED_NAME>
            <LONG_NAME>Lung Tissue</LONG_NAME>
            <CON_ID>2679932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the recurrent disease pre</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the recurrent disease present in lung parenchyma?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lung, parenchymal</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lung, parenchymal</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>tc_base_tx_rlps_lung_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="436">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3120066</PUBLICID>
    <LONGNAME>Clinical Study Site Negation System Communication Mode java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>3119952v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A healthcare organization, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study._An operation in which a term denies or inverts the meaning of another term or construction.:A group of independent but interrelated elements comprising a unified whole.:The exchange of information between objects, people, or groups.:A particular functioning condition or arrangement._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3119952</PublicId>
      <PreferredName>2715172v1.0:3119850v1.0</PreferredName>
      <PreferredDefinition>A healthcare organization, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study._An operation in which a term denies or inverts the meaning of another term or construction.:A group of independent but interrelated elements comprising a unified whole.:The exchange of information between objects, people, or groups.:A particular functioning condition or arrangement.</PreferredDefinition>
      <LongName>Clinical Study Site Negation System Communication Mode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2715172</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70777</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70777</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Site</LONG_NAME>
            <CON_ID>2714955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3119850</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25700:C16452:C25571</PreferredName>
        <Version>1</Version>
        <LongName>Negation System Communication Mode</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16452</PREFERRED_NAME>
            <LONG_NAME>Communication</LONG_NAME>
            <CON_ID>2435936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25571</PREFERRED_NAME>
            <LONG_NAME>Mode</LONG_NAME>
            <CON_ID>2203852</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Study Site Negation System Communication Mode java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Study Site Negation System Communication Mode java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.StudySite.hostedMode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySite:hostedMode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="437">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3120381</PUBLICID>
    <LONGNAME>MicroRNA Probe Annotation Life Sciences Identifier Entity Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>3120369v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of single-stranded RNA which is typically 20-25 nucleotides in length and may regulate the expression of other genes. miRNAs are RNA genes which are transcribed from DNA, but are not translated into proteins.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3120369</PublicId>
      <PreferredName>3120359v1.0:2898546v1.0</PreferredName>
      <PreferredDefinition>A sequence of single-stranded RNA which is typically 20-25 nucleotides in length and may regulate the expression of other genes. miRNAs are RNA genes which are transcribed from DNA, but are not translated into proteins.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will (hybridize), a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:An explanatory or critical comment that has been added to a text._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>MicroRNA Probe Annotation Life Sciences Identifier Entity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3120359</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25966:C43523:C44272</PreferredName>
        <Version>1</Version>
        <LongName>MicroRNA Probe Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25966</PREFERRED_NAME>
            <LONG_NAME>MicroRNA</LONG_NAME>
            <CON_ID>2937841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43523</PREFERRED_NAME>
            <LONG_NAME>Probe</LONG_NAME>
            <CON_ID>2433326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898546</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C51070:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Entity Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element MicroRNA Probe Annotation Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element MicroRNA Probe Annotation Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.array.MiRNAProbeAnnotation.lsidObjectId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MiRNAProbeAnnotation:lsidObjectId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="438">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3121278</PUBLICID>
    <LONGNAME>Patient Personal Medical History Food or Food Substance Hypersensitivity Indicator</LONGNAME>
    <PREFERREDNAME>3121276v1.0:2182115v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No/Unknown indicator to identify patients/ participants who have a history of food allergy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3121276</PublicId>
      <PreferredName>2466333v1.0:3121274v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._an account of all medical events and problems a person has experienced._Processed or unprocessed substances obtained from animal, plant, microorganism and mining source that provide nutrients for living organisms to maintain biological processes or functions._A local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized.</PreferredDefinition>
      <LongName>Patient Personal Medical History Food or Food Substance Hypersensitivity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2466333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Patient Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3121274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1949:C3114</PreferredName>
        <Version>1</Version>
        <LongName>Food or Food Substance Hypersensitivity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1949</PREFERRED_NAME>
            <LONG_NAME>Food or Food Product</LONG_NAME>
            <CON_ID>2717948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3114</PREFERRED_NAME>
            <LONG_NAME>Hypersensitivity</LONG_NAME>
            <CON_ID>2203756</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>History of Food Allergy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>History of Food Allergy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history of allergy to pork products?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical lgg</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793251</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>food_allergy_history</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="439">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3121323</PUBLICID>
    <LONGNAME>Preoperative Corticosteroid Administered Indicator</LONGNAME>
    <PREFERREDNAME>3121321v1.0:2182115v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No/Unknown indicator to identify patients/ participants who have been administered pre-operative corticosteroids.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3121321</PublicId>
      <PreferredName>3121319v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Relating to or occurring during the period immediately before a surgical operation._Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)_The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Preoperative Corticosteroid Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3121319</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C2322</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Corticosteroid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2322</PREFERRED_NAME>
            <LONG_NAME>Corticosteroid</LONG_NAME>
            <CON_ID>2202884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pre-operative Corticosteroids</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pre-operative Corticosteroids Administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TCGA AML Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive steroids for this malignancy prior to procurement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical lgg</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793251</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>preoperative_corticosteroids</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="440">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3121404</PUBLICID>
    <LONGNAME>Patient Cow Milk Consumption Frequency</LONGNAME>
    <PREFERREDNAME>3121402v1.0:3120433v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary. A body substance containing proteins, fats, lactose, and various vitamins and minerals produced by the mammary glands of mature female bovines. The bodily process of taking in and using up something, especially the eating or drinking of something. The number of occurrences of something within a given time period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3121402</PublicId>
      <PreferredName>2233604v1.0:3121400v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary. A body substance containing proteins, fats, lactose, and various vitamins and minerals produced by the mammary glands of mature female bovines. The bodily process of taking in and using up something, especially the eating or drinking of something.</PreferredDefinition>
      <LongName>Patient Cow Milk Consumption</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3121400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66153:C66715</PreferredName>
        <Version>1</Version>
        <LongName>Cow Milk Consumption</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66153</PREFERRED_NAME>
            <LONG_NAME>Cow Milk</LONG_NAME>
            <CON_ID>3121399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66715</PREFERRED_NAME>
            <LONG_NAME>Consumption</LONG_NAME>
            <CON_ID>2635725</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3120433</PublicId>
      <PreferredName>3120433v1.0</PreferredName>
      <PreferredDefinition>The number of occurrences of something within a given time period. (NCI)</PreferredDefinition>
      <LongName>Beverage Consumption Frequency</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2443080</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25515</PreferredName>
        <Version>1</Version>
        <LongName>Temporal Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4+ per day</VALIDVALUE>
          <VALUEMEANING>4+ per day</VALUEMEANING>
          <MEANINGDESCRIPTION>4+ per day</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3110615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-3 per day</VALIDVALUE>
          <VALUEMEANING>2-3 per day</VALUEMEANING>
          <MEANINGDESCRIPTION>2-3 per day</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3110616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 per day</VALIDVALUE>
          <VALUEMEANING>1 per day</VALUEMEANING>
          <MEANINGDESCRIPTION>1 per day</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5-6 per week</VALIDVALUE>
          <VALUEMEANING>5-6 per week</VALUEMEANING>
          <MEANINGDESCRIPTION>5-6 per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-4 per week</VALIDVALUE>
          <VALUEMEANING>2-4 per week</VALUEMEANING>
          <MEANINGDESCRIPTION>2-4 per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 per week</VALIDVALUE>
          <VALUEMEANING>1 per week</VALUEMEANING>
          <MEANINGDESCRIPTION>1 per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never or less than 1 per week</VALIDVALUE>
          <VALUEMEANING>Never or less than 1 per week</VALUEMEANING>
          <MEANINGDESCRIPTION>Never or less than 1 per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3110617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6 or more times per day</VALIDVALUE>
          <VALUEMEANING>6 or more times per day</VALUEMEANING>
          <MEANINGDESCRIPTION>6 or more times per day</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4-5 times per day</VALIDVALUE>
          <VALUEMEANING>4-5 times per day</VALUEMEANING>
          <MEANINGDESCRIPTION>4-5 times per day</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3-4 times per week</VALIDVALUE>
          <VALUEMEANING>3-4 times per week</VALUEMEANING>
          <MEANINGDESCRIPTION>3-4 times per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 times per week</VALIDVALUE>
          <VALUEMEANING>2 times per week</VALUEMEANING>
          <MEANINGDESCRIPTION>2 times per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-3 times last month</VALIDVALUE>
          <VALUEMEANING>2-3 times last month</VALUEMEANING>
          <MEANINGDESCRIPTION>2-3 times last month</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 time last month</VALIDVALUE>
          <VALUEMEANING>1 time last month</VALUEMEANING>
          <MEANINGDESCRIPTION>1 time last month</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I don&#39;t drink fruit juice</VALIDVALUE>
          <VALUEMEANING>Negation Fruit Juice</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction._The liquid produced by squeezing or crushing fruit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71952, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than once per week</VALIDVALUE>
          <VALUEMEANING>Less than once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something occurs or occurred less than once a week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4804254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1-3 times per week</VALIDVALUE>
          <VALUEMEANING>One To Three Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object._Used as a function word to indicate direction, purpose, or movement._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069, C66834, C65107, C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>More than 3 times per week</VALIDVALUE>
          <VALUEMEANING>Greater Than Three Times Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._Three times per week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64528, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Unsweetened Milk (fat-free, 1</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Unsweetened Milk (fat-free, 1%, 2% or whole; exclude milk added to coffee drinks)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="441">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3134655</PUBLICID>
    <LONGNAME>Upper Right Third Molar Pain Pain Type</LONGNAME>
    <PREFERREDNAME>3134648v1.0:3134650v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Upper; higher in place or position; the topmost one of two._Right; being or located on or directed toward the side of the body to the east when facing north._Any one of the rearmost molars on each side of the upper and lower jaw in humans._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3134648</PublicId>
      <PreferredName>3134646v1.0:2177440v1.0</PreferredName>
      <PreferredDefinition>Upper; higher in place or position; the topmost one of two._Right; being or located on or directed toward the side of the body to the east when facing north._Any one of the rearmost molars on each side of the upper and lower jaw in humans._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.</PreferredDefinition>
      <LongName>Upper Right Third Molar Pain</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3134646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25355:C25228:C60732</PreferredName>
        <Version>1</Version>
        <LongName>Upper Right Third Molar</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25355</PREFERRED_NAME>
            <LONG_NAME>Upper</LONG_NAME>
            <CON_ID>2205320</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60732</PREFERRED_NAME>
            <LONG_NAME>Third Molar</LONG_NAME>
            <CON_ID>2481627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177440</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Pain</PreferredName>
        <Version>1</Version>
        <LongName>Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3134650</PublicId>
      <PreferredName>3134650v1.0</PreferredName>
      <PreferredDefinition>The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Tooth Location Pain Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3134649</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Pain Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain due to cavity</VALIDVALUE>
          <VALUEMEANING>Pain due to cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>Pain due to cavity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain on chewing</VALIDVALUE>
          <VALUEMEANING>Pain on chewing</VALUEMEANING>
          <MEANINGDESCRIPTION>Pain on chewing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infected gums</VALIDVALUE>
          <VALUEMEANING>Infected gums</VALUEMEANING>
          <MEANINGDESCRIPTION>Infected gums</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Swollen gums</VALIDVALUE>
          <VALUEMEANING>Swollen gums</VALUEMEANING>
          <MEANINGDESCRIPTION>Swollen gums</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Select all that apply for the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Select all that apply for the upper right wisdom tooth:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="442">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3143543</PUBLICID>
    <LONGNAME>Breast Erythema Present Longest Perpendicular Axis Value</LONGNAME>
    <PREFERREDNAME>3143285v1.0:3143410v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the greater length of two straight lines through a body or figure that is at a right angle to the longest dimension of erythema, redness of the skin produced by congestion of the capillaries of one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3143285</PublicId>
      <PreferredName>2411756v1.0:3143283v1.0</PreferredName>
      <PreferredDefinition>information related to the presence of redness of the skin produced by congestion of the capillaries of one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</PreferredDefinition>
      <LongName>Breast Erythema Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971</PreferredName>
        <Version>1</Version>
        <LongName>Breast</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3143283</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26901:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Erythema Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26901</PREFERRED_NAME>
            <LONG_NAME>Erythema</LONG_NAME>
            <CON_ID>2482163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3143410</PublicId>
      <PreferredName>3143410v1.0</PreferredName>
      <PreferredDefinition>the greater length of two straight lines through a body or figure that is at a right angle to the longest dimension.</PreferredDefinition>
      <LongName>Longest Perpendicular Axis Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat>99.9</DisplayFormat>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3143409</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C54649:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Longest Perpendicular Axis Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54649</PREFERRED_NAME>
            <LONG_NAME>Perpendicular Axis</LONG_NAME>
            <CON_ID>2479358</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Area of Erythema</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Area of Erythema</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="443">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3144919</PUBLICID>
    <LONGNAME>Speech Student Grammatical Impairment Assessment Score</LONGNAME>
    <PREFERREDNAME>3144918v1.0:3076086v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Speech; the exchange of spoken words._A person who is enrolled in an educational institution._A test that assesses a respondent&#39;s knowledge of grammar. It identifies respondents with specific language impairment (SLI) or other categories of language impairment._The final result of a determination of the value, significance, or extent of._A number or range of numeric values measuring performance, function, quality, or ability.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3144918</PublicId>
      <PreferredName>3139278v1.0:3144916v1.0</PreferredName>
      <PreferredDefinition>Speech; the exchange of spoken words._A person who is enrolled in an educational institution._A test that assesses a respondent&#39;s knowledge of grammar. It identifies respondents with specific language impairment (SLI) or other categories of language impairment.</PreferredDefinition>
      <LongName>Speech Student Grammatical Impairment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3139278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38025</PreferredName>
        <Version>1</Version>
        <LongName>Speech</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38025</PREFERRED_NAME>
            <LONG_NAME>Speech</LONG_NAME>
            <CON_ID>2202857</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3144916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75561:C92462</PreferredName>
        <Version>1</Version>
        <LongName>Student Grammatical Impairment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75561</PREFERRED_NAME>
            <LONG_NAME>Student</LONG_NAME>
            <CON_ID>2787652</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C92462</PREFERRED_NAME>
            <LONG_NAME>Grammatical Impairment</LONG_NAME>
            <CON_ID>3143354</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3076086</PublicId>
      <PreferredName>ASSES_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>This measure is a test that a</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>This measure is a test that assesses a student&#39;s knowledge of grammar.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Speech and Hearing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="444">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3148300</PUBLICID>
    <LONGNAME>Serum Aspartate Aminotransferase Measurement Hepatic Within Protocol Upper Limit of Normal Lab Ind-2</LONGNAME>
    <PREFERREDNAME>3148299v1.0:2181518v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for quantitative measurement of the amount of aspartate aminotransferase present in a sample of serum.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3148299</PublicId>
      <PreferredName>3148297v1.0:2603675v1.0</PreferredName>
      <PreferredDefinition>information related to the top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for quantitative measurement of the amount of aspartate aminotransferase present in a sample of serum.</PreferredDefinition>
      <LongName>Serum Aspartate Aminotransferase Measurement Hepatic Within Protocol Upper Limit of Normal Lab</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3148302</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61018:C13308</PreferredName>
        <Version>1</Version>
        <LongName>Serum Aspartate Aminotransferase Measurement Hepatic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61018</PREFERRED_NAME>
            <LONG_NAME>Serum Aspartate Aminotransferase Measurement</LONG_NAME>
            <CON_ID>3148301</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13308</PREFERRED_NAME>
            <LONG_NAME>Hepatic</LONG_NAME>
            <CON_ID>2202660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2603675</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25282:C25320:C25706:C37984</PreferredName>
        <Version>1</Version>
        <LongName>Within Protocol Upper Limit of Normal Laboratory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25282</PREFERRED_NAME>
            <LONG_NAME>Within</LONG_NAME>
            <CON_ID>2206273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25706</PREFERRED_NAME>
            <LONG_NAME>Upper Limit of Normal</LONG_NAME>
            <CON_ID>2203609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Aspartate transaminase (AST)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Aspartate transaminase (AST) &lt;=2.5 x ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>SGOT (AST) &lt;=2.5 x ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>SGOT (AST) &lt;=3 x ULN, unless evidence of direct liver involvement by lymphoma, then &lt;=5 x ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the AST less than or equal to 3 X ULN?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>SGOT (AST) &lt;=3 x ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) &lt;=2 x institutional upper limit of normal (ULN)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) &lt;=2.5 x institutional upper limit of normal (ULN)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) within institutional normal limits</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) within institutional limits</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) &lt;= 2.5 x institutional ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) &lt;=2.5 x institutional upper limit of normal</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AST (SGOT) &lt; 2.5 x institutional ULN (Values post biliary stenting are allowed for eligibility).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>SGOT (AST) less than or equal to 3.0 x upper limit of normal (ULN)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3253737</PublicId>
          <ContextName>CDC/PHIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CSTE Position Statements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acute Hepatitis B Infections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3262973</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3148299v1.0:2181518v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3148299v1.0:2181518v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3148299v1.0:2181518v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="445">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3151120</PUBLICID>
    <LONGNAME>Chemotherapy Negation Radiation Therapy Concurrent Not Administered Reason</LONGNAME>
    <PREFERREDNAME>3151119v1.0:3151821v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to capture the explanation for a chemotherapy not being given concurrent to radiation therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3151119</PublicId>
      <PreferredName>2404910v1.0:3151117v1.0</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An operation in which a term denies or inverts the meaning of another term or construction._use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively._Occurring or operating at the same time._Given.</PreferredDefinition>
      <LongName>Chemotherapy Negation Radiation Therapy Concurrent Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404910</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3151117</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C15313:C25456:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Negation Radiation Therapy Concurrent Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25456</PREFERRED_NAME>
            <LONG_NAME>Concurrent</LONG_NAME>
            <CON_ID>2206181</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3151821</PublicId>
      <PreferredName>3151821v1.0</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An operation in which a term denies or inverts the meaning of another term or construction._Given._An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Chemotherapy Negation Administered Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
      <Representation>
        <PublicId>3151820</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C25594:C25382:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Negation Administered Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done per treating physicians discretion</VALIDVALUE>
          <VALUEMEANING>Physician Decision</VALUEMEANING>
          <MEANINGDESCRIPTION>A position, opinion or judgment reached after consideration by a physician with reference to subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Participant refusal</VALIDVALUE>
          <VALUEMEANING>Patient refused to answer</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: To decline to do, accept, give, or allow something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49161, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2871569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scheduling problems</VALIDVALUE>
          <VALUEMEANING>Schedule Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A schedule is an ordered list of times at which things are planned to occur.: Problem; a state of difficulty that needs to be resolved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C25211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3121416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adverse event/ complications</VALIDVALUE>
          <VALUEMEANING>Adverse Event Complication</VALUEMEANING>
          <MEANINGDESCRIPTION>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.: Complication; any disease or disorder that occurs during the course of (or because of) another disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2959, C41331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2834563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Primary Reason Chemotherapy W</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Primary Reason Chemotherapy Was Not Given Concurrent to Radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CESC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical cesc shared</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787531</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>chemotherapy_negation_radiation_therapy_concurrent_not_administered_reason</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="446">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3152464</PUBLICID>
    <LONGNAME>Pathology Facility Identifier Fifth Report Specimen Source Facility Identifier Number</LONGNAME>
    <PREFERREDNAME>3151623v1.0:3151787v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Facility ID number of the facility where the specimen described in the fifth path report was removed/collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3151623</PublicId>
      <PreferredName>2437801v1.0:2614990v1.0</PreferredName>
      <PreferredDefinition>A specialty concerned with the nature and cause of disease as expressed by changes in cellular or tissue structure and function caused by the disease process. (MSH98)_Services and space and equipment provided for a particular purpose; a building or place that provides a particular service or is used for a particular industry._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Pathology Facility Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18189</PreferredName>
        <Version>1</Version>
        <LongName>Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2614990</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62574:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Facility Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62574</PREFERRED_NAME>
            <LONG_NAME>Facility</LONG_NAME>
            <CON_ID>2542035</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3151787</PublicId>
      <PreferredName>3151787v1.0</PreferredName>
      <PreferredDefinition>Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position._Report; a short account._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Source; where something is available._Services and space and equipment provided for a particular purpose; a building or place that provides a particular service or is used for a particular industry._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Fifth Report Specimen Source Facility Identifier Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3151786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3151786v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Fifth Report Specimen Source Facility Identifier Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54567</PREFERRED_NAME>
            <LONG_NAME>Fifth</LONG_NAME>
            <CON_ID>2554146</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62574</PREFERRED_NAME>
            <LONG_NAME>Facility</LONG_NAME>
            <CON_ID>2542035</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Path Ordering Fac 5 Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Use the National Provider Identifier (NPI) if possible. Otherwise, use a number defined by the American Hospital Association (AHA), or some other standard-setting organization such as the American College of Surgeons (ACoS) or Clinical Laboratory Improvement Amendments (CLIA). This item accommodates only one path report. Information in this data item should refer to the path report described in data items 7014, 7094, 7104, and 7484.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rationale</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>Describes the origin of the fifth pathology report contributing to this cancer abstract. The facility where the specimen described in the fifth path report was obtained is most likely the location of the medical record for the patient as well as any residual tissue.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fifth Sample Collection Facil</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Fifth Sample Collection Facility</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899841</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464314</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>7194</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ORC-21 Ordering Facility Name #01311 (HL7)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PATH ORDERING FAC NO 5</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Path Ordering Facility Number (AHA Number)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Path Ordering Fac No 5</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="447">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3158820</PUBLICID>
    <LONGNAME>Disease First-Line Therapy Progression Ind-3</LONGNAME>
    <PREFERREDNAME>3158819v1.0:2018751v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator whether there has been progression or relapse of the patient&#39;s disease following administration of the preferred standard treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3158819</PublicId>
      <PreferredName>2177151v1.0:3158817v1.0</PreferredName>
      <PreferredDefinition>the progression or relapse of the patient&#39;s disease following administration of the preferred standard treatment.</PreferredDefinition>
      <LongName>Disease First-Line Therapy Progression</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3158817</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45792:C25331</PreferredName>
        <Version>1</Version>
        <LongName>First-Line Therapy Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45792</PREFERRED_NAME>
            <LONG_NAME>First-Line Therapy</LONG_NAME>
            <CON_ID>2229260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25331</PREFERRED_NAME>
            <LONG_NAME>Progression</LONG_NAME>
            <CON_ID>2202788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has disease progressed follow</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has disease progressed following at least one line of standard therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TCGA Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Progression of Disease After Hormonal Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient experience first episode of recurrent disease following completion of aggressive multi-drug front line therapy?*</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AECC Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient&#39;s disease progressed after at least one line of endocrine therapy for metastatic disease (includes relapse while receiving endocrine therapy)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient progressed on first-line therapy for advanced Non-Small Lung Cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient progressed on front-line therapy for advanced non-small cell lung cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient progress while on standard therapies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have at least one episode of disease recurrence in the lungs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient failed standard therapy and at the time of study entry has recurrent, progressive or refractory disease with no known curative options?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient experience first episode of recurrent high-risk disease following completion of aggressive multi-drug frontline high-risk therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient progressed after first-line treatment for recurrent or persistent disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have progressive or refractory disease or experience relapse after at least one previous systemic treatment strategy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DZS_1ST_TX_PD</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DZS_FIRST_TX_PD</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="448">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3162636</PUBLICID>
    <LONGNAME>Tumor Burden Radiologic Finding Value</LONGNAME>
    <PREFERREDNAME>3162621v1.0:3162623v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Sum of the maximum diameter of the primary tumors as reported on the CT scan or MRI immediately preceding surgical resection. This should include both well-differentiaed and de-differentiaed components.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3162621</PublicId>
      <PreferredName>3162618v1.0:3162619v1.0</PreferredName>
      <PreferredDefinition>Refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body. Also called tumor load._Results that have been obtained through x-ray imaging.</PreferredDefinition>
      <LongName>Tumor Burden Radiologic Finding</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3162618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28384</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Burden</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28384</PREFERRED_NAME>
            <LONG_NAME>Tumor Burden</LONG_NAME>
            <CON_ID>2551884</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3162619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C35869</PreferredName>
        <Version>1</Version>
        <LongName>Radiologic Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35869</PREFERRED_NAME>
            <LONG_NAME>Radiologic Finding</LONG_NAME>
            <CON_ID>2551216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3162623</PublicId>
      <PreferredName>3162623v1.0</PreferredName>
      <PreferredDefinition>Refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body. Also called tumor load._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Tumor Burden Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
      <Representation>
        <PublicId>3162622</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28384:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Burden Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28384</PREFERRED_NAME>
            <LONG_NAME>Tumor Burden</LONG_NAME>
            <CON_ID>2551884</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radiologic Tumor Burden</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Radiologic Tumor Burden</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical sarc shared</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793091</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>radiologic_tumor_burden</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="449">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3170040</PUBLICID>
    <LONGNAME>Behavioral History Assessment Date</LONGNAME>
    <PREFERREDNAME>BEHAV_HIST_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which an observation was made on the aggregate of past human activity studied in terms of motivation, direction, result, emotion, perception, or etiology.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3170039</PublicId>
      <PreferredName>BEHAV_HIST_ASSMNT</PreferredName>
      <PreferredDefinition>The aggregate of past human activity studied in terms of motivation, direction, result, emotion, perception, or etiology.</PreferredDefinition>
      <LongName>Behavior History Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3170037</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16326:C54625</PreferredName>
        <Version>1</Version>
        <LongName>Behavior History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16326</PREFERRED_NAME>
            <LONG_NAME>Behavior</LONG_NAME>
            <CON_ID>2203709</CON_ID>
            <DEFINITION_SOURCE>CSP2000</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2465182</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217</PreferredName>
        <Version>1</Version>
        <LongName>Assessed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date behavioral history taken</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date behavioral history taken</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Participant/Subject History and Family History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Health History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Behavioral History at Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Behavioral History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3192771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Health History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000274</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Participant/Subject History and Family History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000583</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="450">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175701</PUBLICID>
    <LONGNAME>Evaluation Observation Outcome Relationship Probability Percent Unit ISO21090.REAL.v1.0</LONGNAME>
    <PREFERREDNAME>3174605v1.0:2803201v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A number representing the likelihood of the identified cause of an adverse event. EXAMPLE(S): 60% likelihood that an adverse event was caused by the evaluated result of diabetes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174605</PublicId>
      <PreferredName>3174127v1.0:3174256v1.0</PreferredName>
      <PreferredDefinition>Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:Watching something and taking note of what happens.:The result of an action.:A state of connectedness between people, objects, or events; to be associated or connected with something._A measure of the expectation of the occurrence of a particular event.:A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</PreferredDefinition>
      <LongName>Evaluation Observation Outcome Relationship Probability Percent Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174127</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25214:C25598:C20200:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation Observation Outcome Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174256</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54154:C48570</PreferredName>
        <Version>1</Version>
        <LongName>Probability Percent Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54154</PREFERRED_NAME>
            <LONG_NAME>Probability</LONG_NAME>
            <CON_ID>2525376</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48570</PREFERRED_NAME>
            <LONG_NAME>Percent Unit</LONG_NAME>
            <CON_ID>2475072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803201</PublicId>
      <PreferredName>2803201v1.0</PreferredName>
      <PreferredDefinition>Fractional numbers represented by decimals.</PreferredDefinition>
      <LongName>ISO21090.REAL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090REALv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Evaluation Observation Outcome Relationship Probability Percent Unit ISO21090.REAL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Evaluation Observation Outcome Relationship Probability Percent Unit ISO21090.REAL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.EvaluatedResultRelationship.probabilityPercent</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EvaluatedResultRelationship:probabilityPercent</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain.EvaluatedResultRelationship.probabilityPercent</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EvaluatedResultRelationship.probabilityPercent</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CausalAssessment.probability</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="451">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175763</PUBLICID>
    <LONGNAME>Package Lot Number Text ISO21090.ST.SIMPLE.v1.0</LONGNAME>
    <PREFERREDNAME>2868215v1.0:3165771v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An alphanumeric string used to identify a particular batch of package.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868215</PublicId>
      <PreferredName>2867664v1.0:2867752v1.0</PreferredName>
      <PreferredDefinition>A product container with any accompanying materials or components._A defined quantity of manufactured material or product produced in a single manufacturing process or series of process steps so that it reasonably is expected to be homogeneous.:A numeral or string of numerals expressing value, quantity, or identification.:The words of something written.</PreferredDefinition>
      <LongName>Package Lot Number Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867664</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C79887</PreferredName>
        <Version>1</Version>
        <LongName>Package</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79887</PREFERRED_NAME>
            <LONG_NAME>Package</LONG_NAME>
            <CON_ID>2839817</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867752</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41396:C25337:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Lot Number Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41396</PREFERRED_NAME>
            <LONG_NAME>Lot</LONG_NAME>
            <CON_ID>2493175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3165771</PublicId>
      <PreferredName>3165771v1.0</PreferredName>
      <PreferredDefinition>Constrains ST.NT so that it has no language.</PreferredDefinition>
      <LongName>ISO21090.ST.SIMPLE.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STSIMv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Package Lot Number Text ISO21090.ST.SIMPLE.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Package Lot Number Text ISO21090.ST.SIMPLE.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Package.lotNumberText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Package:lotNumberText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="452">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175971</PUBLICID>
    <LONGNAME>Access Extension Study Protocol Version Intervention or Procedure Description ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3174856v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of A character string that provides the key details of the intervention. EXAMPLE(S): Interventions involving drugs may include dosage form, dosage, frequency and duration. (50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174856</PublicId>
      <PreferredName>3174218v1.0:2992658v1.0</PreferredName>
      <PreferredDefinition>The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.:An addition to the length of something; the spreading of something into new regions.:The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.:A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Access Extension Study Protocol Version Intervention or Procedure Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174218</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25396:C25270:C70817:C25714</PreferredName>
        <Version>1</Version>
        <LongName>Access Extension Study Protocol Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25396</PREFERRED_NAME>
            <LONG_NAME>Access</LONG_NAME>
            <CON_ID>2203568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25270</PREFERRED_NAME>
            <LONG_NAME>Extend</LONG_NAME>
            <CON_ID>2203922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70817</PREFERRED_NAME>
            <LONG_NAME>Study Protocol</LONG_NAME>
            <CON_ID>2753699</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Intervention or Procedure Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Access Extension Study Protocol Version Intervention or Procedure Description ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Access Extension Study Protocol Version Intervention or Procedure Description ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ExpandedAccessStudyProtocolVersion.interventionDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExpandedAccessStudyProtocolVersion:interventionDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="453">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175988</PUBLICID>
    <LONGNAME>Submission Document Collection Group Status Date and Time ISO21090.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3174871v1.0:3148148v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date (and time) on which the status is assigned to the submission.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174871</PublicId>
      <PreferredName>2867699v1.0:2867759v1.0</PreferredName>
      <PreferredDefinition>Something submitted for the judgment or consideration of others.:An organized collection of records that describe a particular body of data.:The act of gathering things together; having been brought together in one place.:Any number of entities (members) considered as a unit._A condition or state at a particular time.:An expression of both date and time that an event has happened or will happen.</PreferredDefinition>
      <LongName>Submission Document Collection Group Status Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25694:C19498:C25453:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Submission Document Collection Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25694</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2202488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C37939</PreferredName>
        <Version>1</Version>
        <LongName>Status Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3148148</PublicId>
      <PreferredName>3148148v1.0</PreferredName>
      <PreferredDefinition>Constrains TS so that it&#39;s precision can not be more precise than seconds.</PreferredDefinition>
      <LongName>ISO21090.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSDTTIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Submission Document Collection Group Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Submission Document Collection Group Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Submission.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submission:statusDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain.Submission.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submission.statusDate</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="454">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176033</PUBLICID>
    <LONGNAME>Performed Observation Outcome Target Anatomic Site Laterality Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3174907v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the side of the body (or a paired organ) that is a target site for an observation result. EXAMPLE(S): bilateral, left, right.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174907</PublicId>
      <PreferredName>2867619v1.0:2867928v1.0</PreferredName>
      <PreferredDefinition>Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._An object fixed as a goal or point of examination; something to point at; a destination.:Named locations of or within the body.:Dominant use or manifestations of one side of the body versus the other; referring to a side of the body or of a structure.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Performed Observation Outcome Target Anatomic Site Laterality Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867928</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25702:C13717:C25185:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Target Anatomic Site Laterality Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25185</PREFERRED_NAME>
            <LONG_NAME>Laterality</LONG_NAME>
            <CON_ID>2203596</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Performed Observation Outcome Target Anatomic Site Laterality Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Performed Observation Outcome Target Anatomic Site Laterality Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedObservationResult.targetAnatomicSiteLateralityCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult:targetAnatomicSiteLateralityCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="455">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176097</PUBLICID>
    <LONGNAME>Study Site Research Personnel Role Postal Address ISO21090.AD.v1.0</LONGNAME>
    <PREFERREDNAME>3174946v1.0:2803162v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A contact point used to send physical forms of communication to the study site personnel.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174946</PublicId>
      <PreferredName>3174248v1.0:2715040v1.0</PreferredName>
      <PreferredDefinition>A facility in which study/protocol activities are conducted.:People engaged in research.:The usual or expected function of something; the part something plays in an action or event._A physical location used by a person or organization for the purpose of receiving postal mail deliveries.</PreferredDefinition>
      <LongName>Study Site Research Personnel Role Postal Address</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174248</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80403:C17089:C48835</PreferredName>
        <Version>1</Version>
        <LongName>Study Site Research Personnel Role</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80403</PREFERRED_NAME>
            <LONG_NAME>Study Site</LONG_NAME>
            <CON_ID>2866824</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17089</PREFERRED_NAME>
            <LONG_NAME>Research Personnel</LONG_NAME>
            <CON_ID>2202675</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48835</PREFERRED_NAME>
            <LONG_NAME>Role</LONG_NAME>
            <CON_ID>2519065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715040</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70946</PreferredName>
        <Version>1</Version>
        <LongName>Postal Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70946</PREFERRED_NAME>
            <LONG_NAME>Postal Address</LONG_NAME>
            <CON_ID>2714916</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803162</PublicId>
      <PreferredName>2803162v1.0</PreferredName>
      <PreferredDefinition>Parts for mailing and home or office addresses.</PreferredDefinition>
      <LongName>ISO21090.AD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090ADv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Site Research Personnel Role Postal Address ISO21090.AD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Site Research Personnel Role Postal Address ISO21090.AD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySitePersonnel:postalAddress</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudySitePersonnel.postalAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.StudySitePersonnel.postalAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address.city &gt; SiteResearchStaff</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySiteContact.postalAddress</AlternateName>
        <AlternateNameType>Map:CTRRr3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyParticipationContact.postalAddress</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address.state &gt; SiteResearchStaff</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address.street &gt; SiteResearchStaff</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySiteInvestigator.postalAddress</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySitePersonnel.postalAddress</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudySiteContact.postalAddress</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address.country &gt; SiteResearchStaff</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address.zip &gt; SiteResearchStaff</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="456">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176179</PUBLICID>
    <LONGNAME>Funding Research Resource Active Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3175022v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Fiscal support for research from industry, government, or non-commercial, non-governmental organizations. EXAMPLE(S): Funding from pharmaceutical, device or biotechnology companies, the US NIH or the Gates Foundation. Specifies whether the resource is active.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175022</PublicId>
      <PreferredName>3174232v1.0:2737789v1.0</PreferredName>
      <PreferredDefinition>A sum of money or other resources set aside for a specific purpose.:The funding, research facilities, and materials available for research_Exerting influence or producing an effect; taking part in an activity.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Funding Research Resource Active Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174232</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17769:C15321</PreferredName>
        <Version>1</Version>
        <LongName>Funding Research Resource</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17769</PREFERRED_NAME>
            <LONG_NAME>Funding</LONG_NAME>
            <CON_ID>2514003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15321</PREFERRED_NAME>
            <LONG_NAME>Research Resource</LONG_NAME>
            <CON_ID>2867549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2737789</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45329:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Active Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45329</PREFERRED_NAME>
            <LONG_NAME>Active</LONG_NAME>
            <CON_ID>2342187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Funding Research Resource Active Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Funding Research Resource Active Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Funding.activeIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Funding:activeIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.Funding.activeIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="457">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176312</PUBLICID>
    <LONGNAME>Notification Plan Study Activity Repeat Frequency Ratio ISO21090.RTO.INT.NONNEG,PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>3175154v1.0:3152483v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity that is intended to occur at some point in the course of a particular study that represents the communication of a message to a recipient. A ratio representing the number of occurrences of a planned activity within a given time period. EXAMPLE(S): Once per 12 hours, 2 times per day.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175154</PublicId>
      <PreferredName>3174178v1.0:3174538v1.0</PreferredName>
      <PreferredDefinition>Informing by words.:To devise, contrive, or formed in design.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._Make or do or perform again.:The number of occurrences of something within a given time period.:Quotient of quantities of the same kind for different components within the same system.</PreferredDefinition>
      <LongName>Notification Plan Study Activity Repeat Frequency Ratio</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174178</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25297:C25619:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Notification Plan Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174538</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47886:C25515:C44256</PreferredName>
        <Version>1</Version>
        <LongName>Repeat Frequency Ratio</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152483</PublicId>
      <PreferredName>3152483v1.0</PreferredName>
      <PreferredDefinition>Quantity quotient of a numerator of type INT.NONNEG divided by a denominator of type PQ.TIME.</PreferredDefinition>
      <LongName>ISO21090.RTO.INT.NONNEG,PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090RTOv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Notification Plan Study Activity Repeat Frequency Ratio ISO21090.RTO.INT.NONNEG,PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Notification Plan Study Activity Repeat Frequency Ratio ISO21090.RTO.INT.NONNEG,PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PlannedNotification.repeatFrequencyRatio</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PlannedNotification:repeatFrequencyRatio</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.PlannedNotification.repeatFrequencyRatio</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="458">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176331</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Observation Performed Study Activity Repetition Number ISO21090.INT.POS.v1.0</LONGNAME>
    <PREFERREDNAME>3175166v1.0:2848082v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>One of a set of conditions that a study subject must meet in order to participate in a study. An integer that identfies the particular occurrence of a repeating activity. The first repetition is defined as &#39;1&#39;. EXAMPLE(S): A PlannedActivity might have a repeatQuantity of 4 which would result in 4 ScheduledActivity and PerformedActivity with repetitionNumbers of 1, 2, 3, and 4 respectively.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175166</PublicId>
      <PreferredName>2867671v1.0:3174579v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._An integer that identifies the particular occurrence of a repeating activity or entity.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Observation Performed Study Activity Repetition Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867671v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93651</PreferredName>
        <Version>1</Version>
        <LongName>Repetition Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93651</PREFERRED_NAME>
            <LONG_NAME>Repetition Number</LONG_NAME>
            <CON_ID>3162373</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2848082</PublicId>
      <PreferredName>2848082v1.0</PreferredName>
      <PreferredDefinition>Constrains INT to a value of greater than 0.</PreferredDefinition>
      <LongName>ISO21090.INT.POS.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTPOSv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2433737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255</PreferredName>
        <Version>1</Version>
        <LongName>Integer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Eligibility Criteria Observation Performed Study Activity Repetition Number ISO21090.INT.POS.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Eligibility Criteria Observation Performed Study Activity Repetition Number ISO21090.INT.POS.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedEligibilityCriterion.repetitionNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedEligibilityCriterion:repetitionNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedEligibilityCriterion.repetitionNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="459">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176371</PUBLICID>
    <LONGNAME>Administration, Management Performed Study Activity Actual Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>2868708v1.0:3152480v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._Existing in fact; real.:An expression of both date and time that an event has happened or will happen.:The difference between the lowest and highest numerical values; the limits or scale of variation._Set of consecutive values of an ordered base datatype of the type TS.DATETIME.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868708</PublicId>
      <PreferredName>2867692v1.0:2867940v1.0</PreferredName>
      <PreferredDefinition>Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._Existing in fact; real.:An expression of both date and time that an event has happened or will happen.:The difference between the lowest and highest numerical values; the limits or scale of variation.</PreferredDefinition>
      <LongName>Administration, Management Performed Study Activity Actual Date and Time Range</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48905:C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Administration, Management Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867940</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C37939:C38013</PreferredName>
        <Version>1</Version>
        <LongName>Actual Date and Time Range</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152480</PublicId>
      <PreferredName>3152480v1.0</PreferredName>
      <PreferredDefinition>Set of consecutive values of an ordered base datatype of the type TS.DATETIME.</PreferredDefinition>
      <LongName>ISO21090.IVL.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IVLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Administration, Management Performed Study Activity Actual Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Administration, Management Performed Study Activity Actual Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedAdministrativeActivity.actualDateRange</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedAdministrativeActivity:actualDateRange</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="460">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176389</PUBLICID>
    <LONGNAME>Imaging Technique Observation Reuse Template Study Activity Body Position Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175217v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at the global library level whose intention is to obtain pictures of the interior or exterior of the body usually for diagnostic reasons. EXAMPLE(S): X-ray, MRI A coded value specifying the 3-dimensional spatial orientation of a subject during a particular observation. EXAMPLE(S): supine, trendelenburg, standing</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175217</PublicId>
      <PreferredName>3174173v1.0:2724647v1.0</PreferredName>
      <PreferredDefinition>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.:Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._The spatial property of a body; where it is or the way in which it is situated.:A symbol or combination of symbols which are given certain arbitrary meanings within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Imaging Technique Observation Reuse Template Study Activity Body Position Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174173</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174173v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technique Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17369</PREFERRED_NAME>
            <LONG_NAME>Imaging Procedure</LONG_NAME>
            <CON_ID>2713347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2724647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62164:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Body Position Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62164</PREFERRED_NAME>
            <LONG_NAME>Body Position</LONG_NAME>
            <CON_ID>2724644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Imaging Technique Observation Reuse Template Study Activity Body Position Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Imaging Technique Observation Reuse Template Study Activity Body Position Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedImaging.bodyPositionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedImaging:bodyPositionCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedImaging.bodyPositionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="461">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176882</PUBLICID>
    <LONGNAME>Negation Study Subject Administration, Management Performed Study Activity Actual Duration ISO21090.PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>2869357v1.0:2848092v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed study level administrative activity that is independent of a study subject. EXAMPLE(S): IRB Approval, site enrollment, FDA audit. The period of time over which the activity is performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2869357</PublicId>
      <PreferredName>2867640v1.0:2867941v1.0</PreferredName>
      <PreferredDefinition>An operation in which a term denies or inverts the meaning of another term or construction.:A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._Existing in fact; real.:The period of time during which something continues.</PreferredDefinition>
      <LongName>Negation Study Subject Administration, Management Performed Study Activity Actual Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867640</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867640v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Negation Study Subject Administration, Management Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41189</PREFERRED_NAME>
            <LONG_NAME>Study Subject</LONG_NAME>
            <CON_ID>2202706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C25330</PreferredName>
        <Version>1</Version>
        <LongName>Actual Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2848092</PublicId>
      <PreferredName>2848092v1.0</PreferredName>
      <PreferredDefinition>Constrains PQ to have units that describe a period of time.</PreferredDefinition>
      <LongName>ISO21090.PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090PQTIMEv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Negation Study Subject Administration, Management Performed Study Activity Actual Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Negation Study Subject Administration, Management Performed Study Activity Actual Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedStudyAdministrativeActivity.actualDuration</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedStudyAdministrativeActivity:actualDuration</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="462">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176930</PUBLICID>
    <LONGNAME>Adverse Event Outcome Performed Observation Outcome Organ System Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175427v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An assessment result of the final state in a person who experienced an adverse event, which takes place after the adverse event occurs. EXAMPLE(S): Recovered/Resolved, Recovering/Resolving, Not Recovered/Not Resolved, Recovered/Resolved with Sequelae, Fatal, Unknown A coded value specifying the anatomical structure that consists of organs and organ subclasses responsible for certain body functions. EXAMPLE(S): gastrointestinal system, urinary system, hematopoietic system</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175427</PublicId>
      <PreferredName>3174128v1.0:3174586v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.  Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).:The result of an action.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._An anatomical structure that consists of organs and organ subclasses responsible for certain body functions.  Representative examples are the gastrointestinal system, urinary system, and hematopoietic system.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Adverse Event Outcome Performed Observation Outcome Organ System Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174128</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174128v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Outcome Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174586</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12919:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Organ System Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12919</PREFERRED_NAME>
            <LONG_NAME>Organ System</LONG_NAME>
            <CON_ID>2589988</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Outcome Performed Observation Outcome Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Outcome Performed Observation Outcome Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventOutcomeResult.bodySystemCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEventOutcomeResult:bodySystemCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="463">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177053</PUBLICID>
    <LONGNAME>Protocol Agent Transfer Reuse Template Study Activity Description ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3175550v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An administrative activity defined at a global library level that is an action in which an authorized party at a designated study site dispenses or receives a study agent to/from a study subject, though as a defined activity, no actual study subject is identified. EXAMPLE(S): Dispensing a bottle of pills The textual representation of the activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175550</PublicId>
      <PreferredName>3174212v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A medical product, practice, or application that is tested in a clinical trial.:The act of conveying or transporting from one place to another.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A statement or an account describing something.</PreferredDefinition>
      <LongName>Protocol Agent Transfer Reuse Template Study Activity Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174212v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent Transfer Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41161</PREFERRED_NAME>
            <LONG_NAME>Protocol Agent</LONG_NAME>
            <CON_ID>2390873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48167</PREFERRED_NAME>
            <LONG_NAME>Transfer</LONG_NAME>
            <CON_ID>2422624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protocol Agent Transfer Reuse Template Study Activity Description ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protocol Agent Transfer Reuse Template Study Activity Description ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedStudyAgentTransfer.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedStudyAgentTransfer:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedStudyAgentTransfer.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="464">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177084</PUBLICID>
    <LONGNAME>Intervention Trial Study Protocol Version Trial Phase Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175578v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An action plan of a pre-clinical or clinical study in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Study subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. A coded value specifying the designation of approval phase for a study. EXAMPLE(S): I, I/II, II, III, N/A. NOTE(S): Studies are categorized into four or five phases. An investigational medicine or product may be evaluated in two or more phases simultaneously in different studies; some studies may overlap two different phases. Phase 1 - initial introduction of investigational new drug into humans; typically closely monitored; may be conducted in subjects or normal volunteer subjects. Phase 2 - controlled clinical studies conducted to evaluate effectiveness of drug for particular indication(s) in subjects with disease or condition under study and to determine common short-term side effects and risks. Phase 3 - expanded controlled and uncontrolled trials; performed after preliminary evidence suggests effectiveness of drug; intended to gather additional information about effectiveness and safety that is needed to evaluate overall benefit-risk relationship of drug and to provide adequate basis for physician labeling. Phase 3b - subcategory of phase 3 trials near time of approval to elicit additional findings. Phase 4 - concurrent with marketing approval, Food and Drug Administration (FDA) may seek agreement from sponsor to conduct certain post-marketing studies to delineate additional information about drug&#39;s risks, benefits, and optimal use. Phase 5 - Post-marketing surveillance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175578</PublicId>
      <PreferredName>3174201v1.0:2607562v1.0</PreferredName>
      <PreferredDefinition>A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.:A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Intervention Trial Study Protocol Version Trial Phase Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16140:C70817:C25714</PreferredName>
        <Version>1</Version>
        <LongName>Intervention Trial Study Protocol Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16140</PREFERRED_NAME>
            <LONG_NAME>Intervention Trial</LONG_NAME>
            <CON_ID>2867568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70817</PREFERRED_NAME>
            <LONG_NAME>Study Protocol</LONG_NAME>
            <CON_ID>2753699</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607562</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48281:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Trial Phase Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48281</PREFERRED_NAME>
            <LONG_NAME>Trial Phase</LONG_NAME>
            <CON_ID>2480712</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Intervention Trial Study Protocol Version Trial Phase Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Intervention Trial Study Protocol Version Trial Phase Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.InterventionalStudyProtocolVersion.phaseCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InterventionalStudyProtocolVersion:phaseCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.InterventionalStudyProtocolVersion.phaseCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="465">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177137</PUBLICID>
    <LONGNAME>Biologically-Derived Material Product Material Name Code Change Text ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3175633v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A substance made from living organisms or things they produce. EXAMPLE(S): virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, analogous product A character string that is a revision of the original text of the product to enable the coding of the text. EXAMPLE(S): If the original text is &quot;aspriin&quot;, the nameCodeModifiedText could be set to &quot;aspirin&quot;, so that the text can be successfully coded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175633</PublicId>
      <PreferredName>2867618v1.0:3174512v1.0</PreferredName>
      <PreferredDefinition>Natural substances derived from living organisms such as cells, tissues, proteins, and DNA.:The end result of a manufacturing process; anything that is produced.:The tangible substance that goes into the makeup of a physical object._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.:The act of alteration or modification; changed or altered in form or character.:The words of something written.</PreferredDefinition>
      <LongName>Biologically-Derived Material Product Material Name Code Change Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43376:C51980:C48187</PreferredName>
        <Version>1</Version>
        <LongName>Biologically-Derived Material Product Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43376</PREFERRED_NAME>
            <LONG_NAME>Biologically-Derived Material</LONG_NAME>
            <CON_ID>2236534</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174512</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614:C25162:C25446:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Name Code Change Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biologically-Derived Material Product Material Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biologically-Derived Material Product Material Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Biologic.nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Biologic:nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="466">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3180986</PUBLICID>
    <LONGNAME>Standard Operating Procedure Status Indicator</LONGNAME>
    <PREFERREDNAME>SOP_STAT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The response to a question that asks is the standard operating procedure (SOP) is part of the appendix.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772615</PublicId>
      <PreferredName>2772260v1.0:2320064v1.0</PreferredName>
      <PreferredDefinition>An established procedure to be followed in carrying out a given operation or in a given situation._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Standard Operating Procedure Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48443</PreferredName>
        <Version>1</Version>
        <LongName>Standard Operating Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48443</PREFERRED_NAME>
            <LONG_NAME>Standard Operating Procedure</LONG_NAME>
            <CON_ID>2612106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018691</PublicId>
      <PreferredName>YES_NO_U_IND</PreferredName>
      <PreferredDefinition>Text terms to determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the SOP attached as an App</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the SOP attached as an Appendix?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939361</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCTD</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Immunohistochemical Biomarker</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3165540</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="467">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3182768</PUBLICID>
    <LONGNAME>Person Serum Potassium Clinical Trial Eligibility Criteria Ind-2</LONGNAME>
    <PREFERREDNAME>3182760v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether a person has a lower serum potassium level, a metallic element that is important in body functions such as regulation of blood pressure and of water content in cells, transmission of nerve impulses, digestion, muscle contraction, and heartbeat, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3182760</PublicId>
      <PreferredName>2236731v1.0:3182758v1.0</PreferredName>
      <PreferredDefinition>information related to a person&#39;s serum potassium level, a metallic element that is important in body functions such as regulation of blood pressure and of water content in cells, transmission of nerve impulses, digestion, muscle contraction, and heartbeat.as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Person Serum Potassium Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3182758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13325:C765:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Serum Potassium Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13325</PREFERRED_NAME>
            <LONG_NAME>Serum</LONG_NAME>
            <CON_ID>2203797</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C765</PREFERRED_NAME>
            <LONG_NAME>Potassium</LONG_NAME>
            <CON_ID>2206347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a basel</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a baseline serum potassium less than 3.5 mmol/L?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the potassium greater than or equal to 4.0 mEq/L (or mmol/L)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the potassium within the normal reference range for the laboratory?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is pre-study serum potassium greater than 3.5 mmol/L (potassium supplementation may be given to restore the serum potassium above this level prior to study entry)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>WF-1801 v5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Baseline potassium level &lt; 5.0 mEq/L. High potassium values that are thought to be a result of sample hemolysis may be repeated to determine an accurate potassium level and to determine potential study eligibility. Likewise high potassium values thought to be a result of potassium supplementation  may  be  repeated  at  an  appropriate  time  (5  half-lives  after  supplement discontinuation) to determine potential study eligibility.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0227G</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104881</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000430</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6147165</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WFB Medical Center</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WFB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6147167</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3182760v1.0:2018257v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="468">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3183473</PUBLICID>
    <LONGNAME>Prior Cytotoxic Chemotherapy Uterine Endometrial Carcinoma Administered Ind-2</LONGNAME>
    <PREFERREDNAME>3183472v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether there was prior use of anticancer drugs that kill cells, especially cancer cells for management of a malignant tumor arising from the epithelium that lines the cavity of the uterine body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3183472</PublicId>
      <PreferredName>2951157v1.0:3183470v1.0</PreferredName>
      <PreferredDefinition>information related to prior use of anticancer drugs that kill cells, especially cancer cells for management of a malignant tumor arising from the epithelium that lines the cavity of the uterine body.</PreferredDefinition>
      <LongName>Prior Cytotoxic Chemotherapy Uterine Endometrial Carcinoma Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2951157</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15681</PreferredName>
        <Version>1</Version>
        <LongName>Prior Cytotoxic Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15681</PREFERRED_NAME>
            <LONG_NAME>Cytotoxic Chemotherapy</LONG_NAME>
            <CON_ID>2464253</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3183470</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7558:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Endometrial Carcinoma Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C7558</PREFERRED_NAME>
            <LONG_NAME>Endometrial Carcinoma</LONG_NAME>
            <CON_ID>2974466</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient received one</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient received one prior chemotherapeutic regimen for management of endometrial carcinoma?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have at least one prior chemotherapeutic regimen for management of endometrial carcinoma?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3183472v1.0:2018257v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="469">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3185350</PUBLICID>
    <LONGNAME>Thyroid Antimicrosomal Antibody Measurement Outcome Status</LONGNAME>
    <PREFERREDNAME>3185349v1.0:2180450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the result of a test to detect the presence of thyroid antimicrosomal antibodies in a sample.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3185349</PublicId>
      <PreferredName>3185347v1.0:2177438v1.0</PreferredName>
      <PreferredDefinition>information related to result from determination of the amount of thyroid antimicrosomal antibodies present in a sample.</PreferredDefinition>
      <LongName>Thyroid Antimicrosomal Antibody Measurement Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3185347</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81991</PreferredName>
        <Version>1</Version>
        <LongName>Thyroid Antimicrosomal Antibody Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81991</PREFERRED_NAME>
            <LONG_NAME>Thyroid Antimicrosomal Antibody Measurement</LONG_NAME>
            <CON_ID>3185346</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177438</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Outcome</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180450</PublicId>
      <PreferredName>AB_TST_STAT</PreferredName>
      <PreferredDefinition>the result of a test to detect the presence of an antibody in a patient.</PreferredDefinition>
      <LongName>Antibody Test Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Involving advantage or good.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3128156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2840098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5042698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Antimicrosomal antibody</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Antimicrosomal antibody</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="470">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3185835</PUBLICID>
    <LONGNAME>Melanoma Malignant Neoplasm Metastatic Distant Involvement Site</LONGNAME>
    <PREFERREDNAME>3185831v1.0:3185833v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>an anatomic location related to evidence of the distant spread of cancer from a tumor, composed of atypical neoplastic melanocytes and often located on the skin, to another part of the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3185831</PublicId>
      <PreferredName>2443356v1.0:3185829v1.0</PreferredName>
      <PreferredDefinition>information related to evidence of the distant spread of cancer from a tumor, composed of atypical neoplastic melanocytes and often located on the skin, to another part of the body.</PreferredDefinition>
      <LongName>Melanoma Malignant Neoplasm Metastatic Distant Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443356</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3224:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Melanoma Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3224</PREFERRED_NAME>
            <LONG_NAME>Melanoma</LONG_NAME>
            <CON_ID>2202743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3185829</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14174:C25321:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Distant Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25321</PREFERRED_NAME>
            <LONG_NAME>Distant</LONG_NAME>
            <CON_ID>2204917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3185833</PublicId>
      <PreferredName>3185833v1.0</PreferredName>
      <PreferredDefinition>an anatomic location where evidence is detected for distant spread of cancer from a tumor composed of atypical neoplastic melanocytes, and often located on the skin, to another part of the body.</PreferredDefinition>
      <LongName>Melanoma Malignant Neoplasm Metastatic Distant Involvement Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodal</VALIDVALUE>
          <VALUEMEANING>Nodal</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or pertaining to a node, any bulge or swelling of an anatomical structure or part.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3166341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cutaneous</VALIDVALUE>
          <VALUEMEANING>Cutaneous</VALUEMEANING>
          <MEANINGDESCRIPTION>(kyoo-TAY-nee-us) Having to do with the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Visceral Metastases</VALIDVALUE>
          <VALUEMEANING>Other Visceral Metastases</VALUEMEANING>
          <MEANINGDESCRIPTION>Other Visceral Metastases</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-11-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4582851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Distant metastases</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Distant metastases</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Distant metastasis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="471">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3186044</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3175472v1.0:3152480v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that identifies one of a set of conditions that a subject must meet in order to participate in a study, or that a study subject must meet into order to participate in a certain part of the study. The time period in which the observation result is held to be true, expressed either as a simple date range or as an evaluable expression that references a study-defined date or milestone. EXAMPLE(S): For a survey question, &quot;Have you traveled to Europe between 1990 and 1999?&quot;, the focalDateRange would be &quot;January 1, 1990 to December 31, 1999&quot;. For the question, &quot;Have you smoked in the last 2 months&quot;, the focalDateRange would be an expression referencing a variable that represents the PerformedObservation.actualDateRange (a value yet to be defined) and a formula for the date range between when the question is asked (PerformedObservation.actualDateRange.low) and 2 months prior (PerformedObservation.actualDateRange.low - 2 months).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175472</PublicId>
      <PreferredName>3174207v1.0:3174559v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._Area of greatest concentration, attention, or activity; a central point or locus, especially of an infection.:An expression of both date and time that an event has happened or will happen.:The difference between the lowest and highest numerical values; the limits or scale of variation.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Date and Time Range</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174207v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174559</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25511:C37939:C38013</PreferredName>
        <Version>1</Version>
        <LongName>Foci Date and Time Range</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25511</PREFERRED_NAME>
            <LONG_NAME>Focus</LONG_NAME>
            <CON_ID>2203817</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152480</PublicId>
      <PreferredName>3152480v1.0</PreferredName>
      <PreferredDefinition>Set of consecutive values of an ordered base datatype of the type TS.DATETIME.</PreferredDefinition>
      <LongName>ISO21090.IVL.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IVLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedEligibilityCriterion.focalDateRange</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedEligibilityCriterion:focalDateRange</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedEligibilityCriterion.focalDateRange</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="472">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3187606</PUBLICID>
    <LONGNAME>Cancer Diagnosis Hepatic Involvement Category</LONGNAME>
    <PREFERREDNAME>CA_DX_HEP_INV_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Classification to describe the amount of liver involvement with a diagnosis of carcinoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2928081</PublicId>
      <PreferredName>LIVER_LOBE_DD_INVLV</PreferredName>
      <PreferredDefinition>information related to disease involvment of lobe(s) of a triangular-shaped organ located under the diaphragm in the right hypochondrium.</PreferredDefinition>
      <LongName>Liver Lobe Disease or Disorder Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2928079</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C13393:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Liver Lobe Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13393</PREFERRED_NAME>
            <LONG_NAME>Lobe</LONG_NAME>
            <CON_ID>2202337</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192548</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25548</PreferredName>
        <Version>1</Version>
        <LongName>Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3187601</PublicId>
      <PreferredName>CA_DX_HEP_INV_CAT</PreferredName>
      <PreferredDefinition>General term for detecting and classifying cancer in patients. (from CSP94)_Refers to the liver._To have a connection by participation or association or use; sharing in an activity or process._Category; used informally to mean a class of things.</PreferredDefinition>
      <LongName>Cancer Diagnosis Hepatic Involvement Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3187600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16213:C13308:C25548:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Cancer Diagnosis Hepatic Involvement Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16213</PREFERRED_NAME>
            <LONG_NAME>Cancer Diagnosis</LONG_NAME>
            <CON_ID>2923267</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13308</PREFERRED_NAME>
            <LONG_NAME>Hepatic</LONG_NAME>
            <CON_ID>2202660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76-100%</VALIDVALUE>
          <VALUEMEANING>76 to 100 percent</VALUEMEANING>
          <MEANINGDESCRIPTION>76 to 100 percent of liver involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51-75%</VALIDVALUE>
          <VALUEMEANING>51 to 75 percent</VALUEMEANING>
          <MEANINGDESCRIPTION>51 to 75 percent liver involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26-50%</VALIDVALUE>
          <VALUEMEANING>26 to 50 percent</VALUEMEANING>
          <MEANINGDESCRIPTION>26 to 50 percent liver involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0-25%</VALIDVALUE>
          <VALUEMEANING>0 to 25 percent</VALUEMEANING>
          <MEANINGDESCRIPTION>0 to 25 percent liver involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Liver Involvement</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Liver Involvement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="473">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3189937</PUBLICID>
    <LONGNAME>Complete Bundle Branch Block Pattern Absent Present Indicator</LONGNAME>
    <PREFERREDNAME>CMP_BNDL_BRN_BLCK_AP</PREFERREDNAME>
    <PREFERREDDEFINITION>Absent or present indicator of complete block caused by damage of one of the bundle branches, resulting in the delay or obstruction of the conduction of electrical impulses. An electrocardiographic finding defined by prolongation of the QRS complex.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3189920</PublicId>
      <PreferredName>CMPLT_B_B_BLCK_PTRN</PreferredName>
      <PreferredDefinition>An electrocardiographic finding defined by prolongation of the QRS complex. It is caused by damage of one of the bundle branches, resulting in the delay or obstruction of the conduction of electrical impulses.</PreferredDefinition>
      <LongName>Complete Bundle Branch Block Pattern</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3189918</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250:C84603</PreferredName>
        <Version>1</Version>
        <LongName>Complete Bundle Branch Block</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84603</PREFERRED_NAME>
            <LONG_NAME>Bundle Branch Block by ECG Finding</LONG_NAME>
            <CON_ID>3189917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2548505</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25336</PreferredName>
        <Version>1</Version>
        <LongName>Pattern</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25336</PREFERRED_NAME>
            <LONG_NAME>Pattern</LONG_NAME>
            <CON_ID>2203946</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3189707</PublicId>
      <PreferredName>ABSNT_PRESNT_IND</PreferredName>
      <PreferredDefinition>Indicator of being absent or present.</PreferredDefinition>
      <LongName>Absent Present Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
      <Representation>
        <PublicId>3189706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48190:C25626:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Absent Present Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48190</PREFERRED_NAME>
            <LONG_NAME>Absent</LONG_NAME>
            <CON_ID>2425465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>patterns of complete bundle b</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>patterns of complete bundle branch block</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Electrocardiogram (ECG)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3151276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Non-Imaging Diagnostics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000068</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Assessments and Examinations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="474">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3190401</PUBLICID>
    <LONGNAME>Patient Web Site Smoking Cessation Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3190400v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to a patient&#39;s smoking cessation on a collection of web pages within a domain.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3190400</PublicId>
      <PreferredName>2177068v1.0:3190398v1.0</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s smoking cessation on a collection of web pages within a domain.</PreferredDefinition>
      <LongName>Patient Web Site Smoking Cessation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3190398</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67518:C0085134</PreferredName>
        <Version>1</Version>
        <LongName>Web Site Smoking Cessation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67518</PREFERRED_NAME>
            <LONG_NAME>Web Site</LONG_NAME>
            <CON_ID>2771000</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0085134</PREFERRED_NAME>
            <LONG_NAME>Smoking Cessation</LONG_NAME>
            <CON_ID>2203060</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DPBRN CRF:Dental Practice-Based Research Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you ever visited a smoki</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you ever visited a smoking cessation website</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="475">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3190411</PUBLICID>
    <LONGNAME>Malignant Breast Neoplasm Five-year Survival Rate Assessment Percent Number</LONGNAME>
    <PREFERREDNAME>3190343v1.0:2475074v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the percentage of people in a study or treatment group who are alive five years after they were diagnosed with or treated for a breast neoplasm with metastatic potential arising from the breast parenchyma or the nipple.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3190343</PublicId>
      <PreferredName>2233188v1.0:3190341v1.0</PreferredName>
      <PreferredDefinition>information related to the percentage of people in a study or treatment group who are alive five years after they were diagnosed with or treated for a breast neoplasm with metastatic potential arising from the breast parenchyma or the nipple.</PreferredDefinition>
      <LongName>Malignant Breast Neoplasm Five-year Survival Rate Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233188</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9335</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Breast Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9335</PREFERRED_NAME>
            <LONG_NAME>Malignant Breast Neoplasm</LONG_NAME>
            <CON_ID>2233187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3190341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94503:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Five-year Survival Rate Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94503</PREFERRED_NAME>
            <LONG_NAME>Five-year Survival Rate</LONG_NAME>
            <CON_ID>3190340</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2475074</PublicId>
      <PreferredName>PCT_NUM</PreferredName>
      <PreferredDefinition>Numeric value representing a percentage.</PreferredDefinition>
      <LongName>Percent Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2475073</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48570:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Percent Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48570</PREFERRED_NAME>
            <LONG_NAME>Percent Unit</LONG_NAME>
            <CON_ID>2475072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>5 year predicted breast cance</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>5 year predicted breast cancer risk</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="476">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3191976</PUBLICID>
    <LONGNAME>Patient Reported Outcome Problem Weight Gain Past Week Severity Score_11 Point Scale</LONGNAME>
    <PREFERREDNAME>3191947v1.0:3186243v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of how bad, if at all, weight gain has been a problem during the past week, including today, using an 11-point Likert scale where 0 is not a problem and 10 is as bad as possible.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCM:Patient Care Monitor</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3191947</PublicId>
      <PreferredName>3191919v1.0:3191926v1.0</PreferredName>
      <PreferredDefinition>Information collected directly from a patient that typically includes subjective feelings regarding symptons, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.:A difficulty, disorder, or condition needing resolution._An increase in overall body mass.:The most recent week, including today.:Severity; used of the degree of something undesirable e.g. pain or weather.:A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Patient Reported Outcome Problem Weight Gain Past Week Severity Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3191919</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95401:C28020</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcome Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95401</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcome</LONG_NAME>
            <CON_ID>3185129</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3191926</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62754:C95402:C25676:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Weight Gain Past Week Severity Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62754</PREFERRED_NAME>
            <LONG_NAME>Weight Gain</LONG_NAME>
            <CON_ID>2528492</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PCM:Patient Care Monitor</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3186243</PublicId>
      <PreferredName>3186243v1.0</PreferredName>
      <PreferredDefinition>The most recent week, including today._Severity; used of the degree of something undesirable e.g. pain or weather._A number or range of numeric values measuring performance, function, quality, or ability._A number with no fractional part.::11_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Past Week Severity Score_11 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ePRO:ePRO Data Dictionary</Origin>
      <Representation>
        <PublicId>3186242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3186242v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Severity Score Integer::11 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>A score of 10 on an 11 point scale meaning As Bad as Possible.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 10 on an 11 point scale meaning As Bad as Possible.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>A score of 9 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 9 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>A score of 8 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 8 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>A score of 7 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 7 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>A score of 6 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 6 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>A score of 5 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 5 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>A score of 4 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 4 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>A score of 3 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 3 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A score of 2 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 2 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A score of 1 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 1 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>A score of 0 on an 11 point scale meaning Not a Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 0 on an 11 point scale meaning Not a Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Instrument Creator</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>ACORN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Weight gain</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Weight gain</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Touch the red dot below that best describes how bad, if at all, weight gain has been a problem for you during the past week, including today.</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Touch the red dot below that best describes how bad, if at all, weight gain has been a problem for you during the past week, including today.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3185645</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BIGHealth ePRO Data Dictionary</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Care Monitor_PCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3185646</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCM90001</AlternateName>
        <AlternateNameType>ePRO Field Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="477">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3192209</PUBLICID>
    <LONGNAME>Umbilical Cord Blood Temperature Monitoring Indicator</LONGNAME>
    <PREFERREDNAME>3192207v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indictor that describes whether or not temperature monitoring was used for the umbilical cord blood.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192207</PublicId>
      <PreferredName>3192204v1.0:3192205v1.0</PreferredName>
      <PreferredDefinition>Blood from the umbilical cord of a newborn baby. This blood contains high concentrations of stem cells (cells from which all blood cells develop)._A measure of the average kinetic energy of a system of particles. Temperature may be quantified, in the context of thermodynamics, as the potential of one system to transfer thermal energy to another system until both systems reach a state of thermal equilibrium._The act of observing something (and sometimes keeping a record of it). [Manually curated]</PreferredDefinition>
      <LongName>Umbilical Cord Blood Temperature Monitoring</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3192204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13300:C25206</PreferredName>
        <Version>1</Version>
        <LongName>Umbilical Cord Blood Temperature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13300</PREFERRED_NAME>
            <LONG_NAME>Umbilical Cord Blood</LONG_NAME>
            <CON_ID>2527864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25206</PREFERRED_NAME>
            <LONG_NAME>Temperature</LONG_NAME>
            <CON_ID>2202772</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192205</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61256</PreferredName>
        <Version>1</Version>
        <LongName>Monitoring</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61256</PREFERRED_NAME>
            <LONG_NAME>Monitoring</LONG_NAME>
            <CON_ID>2691603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a method of temperature m</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a method of temperature monitoring used for the cord blood unit?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2007r1:Cord Blood Unit -SCTOD Data Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3191905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>temp_mon_cryoguard</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>temp_mon_elect</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>temp_mon_oth</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="478">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3192210</PUBLICID>
    <LONGNAME>Umbilical Cord Blood Temperature Monitoring Specify Text</LONGNAME>
    <PREFERREDNAME>3192207v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe another method of temperature monitoring used for the umbilical cord blood.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192207</PublicId>
      <PreferredName>3192204v1.0:3192205v1.0</PreferredName>
      <PreferredDefinition>Blood from the umbilical cord of a newborn baby. This blood contains high concentrations of stem cells (cells from which all blood cells develop)._A measure of the average kinetic energy of a system of particles. Temperature may be quantified, in the context of thermodynamics, as the potential of one system to transfer thermal energy to another system until both systems reach a state of thermal equilibrium._The act of observing something (and sometimes keeping a record of it). [Manually curated]</PreferredDefinition>
      <LongName>Umbilical Cord Blood Temperature Monitoring</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3192204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13300:C25206</PreferredName>
        <Version>1</Version>
        <LongName>Umbilical Cord Blood Temperature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13300</PREFERRED_NAME>
            <LONG_NAME>Umbilical Cord Blood</LONG_NAME>
            <CON_ID>2527864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25206</PREFERRED_NAME>
            <LONG_NAME>Temperature</LONG_NAME>
            <CON_ID>2202772</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192205</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61256</PreferredName>
        <Version>1</Version>
        <LongName>Monitoring</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61256</PREFERRED_NAME>
            <LONG_NAME>Monitoring</LONG_NAME>
            <CON_ID>2691603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other method of t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the other method of temperature monitoring used for the cord blood unit:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other temperature monitor used:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other temperature monitor used:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2007r1:Cord Blood Unit -SCTOD Data Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3191905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>temp_mon_oth_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="479">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3192300</PUBLICID>
    <LONGNAME>Umbilical Cord Blood Process Specify Text</LONGNAME>
    <PREFERREDNAME>3192117v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the device used to process the umbilical cord blood.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192117</PublicId>
      <PreferredName>2785788v1.0:2183791v1.0</PreferredName>
      <PreferredDefinition>Blood from the umbilical cord of a newborn baby. This blood contains high concentrations of stem cells (cells from which all blood cells develop)._A sequence of events which produces some outcome. [Manually curated]</PreferredDefinition>
      <LongName>Umbilical Cord Blood Process</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2785788</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13300</PreferredName>
        <Version>1</Version>
        <LongName>Umbilical Cord Blood</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13300</PREFERRED_NAME>
            <LONG_NAME>Umbilical Cord Blood</LONG_NAME>
            <CON_ID>2527864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2183791</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29862</PreferredName>
        <Version>1</Version>
        <LongName>Process</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29862</PREFERRED_NAME>
            <LONG_NAME>Process</LONG_NAME>
            <CON_ID>2202628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the device used to pr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the device used to process the cord blood unit:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other system:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other system:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2007r1:Cord Blood Unit -SCTOD Data Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3191905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cbu_proc_syst_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="480">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3192527</PUBLICID>
    <LONGNAME>Biospecimen Freeze And Thaw Cycle Number</LONGNAME>
    <PREFERREDNAME>BSPC_FRZ_THW_CYC_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Number of biospecimen freeze and thaw cycles.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192526</PublicId>
      <PreferredName>BSPC_FRZ_THW_CYCL</PreferredName>
      <PreferredDefinition>Freeze and thaw cycle of biospecimen</PreferredDefinition>
      <LongName>Biospecimen Freeze And Thaw Cycle</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192524</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48160:C37912:C48165:C25472</PreferredName>
        <Version>1</Version>
        <LongName>Freezing And Thaw Cycle</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48160</PREFERRED_NAME>
            <LONG_NAME>Freezing</LONG_NAME>
            <CON_ID>2513273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48165</PREFERRED_NAME>
            <LONG_NAME>Thaw</LONG_NAME>
            <CON_ID>2513278</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182118</PublicId>
      <PreferredName>NUMBER</PreferredName>
      <PreferredDefinition>A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of freeze-thaw cycles</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of freeze-thaw cycles</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>5542682</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Reused-CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>5543567</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Assessments and Examinations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3139477</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Test and Biospecimens/Biomarkers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3191792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Collection and Processing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3191793</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EDRN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Reused-CDEs.Biospecimen.SPECIMEN_FREEZE-THAW-VALUE_945</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Biospecimen:SPECIMEN_FREEZE-THAW-VALUE_945</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="481">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3194239</PUBLICID>
    <LONGNAME>Breast Tumor Regional Recurrence Date</LONGNAME>
    <PREFERREDNAME>2640531v1.0:2018550v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the date related to tumor recurrence in area limited to location of breast.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640531</PublicId>
      <PreferredName>BRST_TUM_RG_RECUR</PreferredName>
      <PreferredDefinition>information related to tumor recurrence in area limited to location of breast.</PreferredDefinition>
      <LongName>Breast Tumor Regional Recurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Breast Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2640529</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25643:C3352</PreferredName>
        <Version>1</Version>
        <LongName>Regional Recurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25643</PREFERRED_NAME>
            <LONG_NAME>Regional</LONG_NAME>
            <CON_ID>2205257</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3352</PREFERRED_NAME>
            <LONG_NAME>Recurrence</LONG_NAME>
            <CON_ID>2202848</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of regional recurrence</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of regional recurrence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2640531v1.0:2018550v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="482">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3197318</PUBLICID>
    <LONGNAME>Participant Personal Medical History Hypertension Indicator</LONGNAME>
    <PREFERREDNAME>MH_HYPERTNSN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown response related to the participant&#39;s medical history of hypertension.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3194130</PublicId>
      <PreferredName>MH_HYPERTNSN</PreferredName>
      <PreferredDefinition>Participant medical history - hypertension: pathological increase in blood pressure; a repeatedly elevated blood pressure exceeding 140 over 90 mmHg.</PreferredDefinition>
      <LongName>Participant Personal Medical History Hypertension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747584</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Participant Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2936242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3117</PreferredName>
        <Version>1</Version>
        <LongName>Hypertension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3117</PREFERRED_NAME>
            <LONG_NAME>Hypertension</LONG_NAME>
            <CON_ID>2202655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hypertension</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Hypertension</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history of hypertension?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Health History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000398</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Participant/Subject History and Family History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000583</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="483">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3203189</PUBLICID>
    <LONGNAME>Prostate Quality of Life Hematuria Problem Scale</LONGNAME>
    <PREFERREDNAME>PRS_QOL_HEMTR_PR_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>a set of values rating changes in bleeding with expelling urine due to interference from symptoms of prostate cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528103</PublicId>
      <PreferredName>PRS_QOL_HEMTR_PROB</PreferredName>
      <PreferredDefinition>related to changes in routine tasks of daily living due to interference from symptoms of bleeding with the excreting of urine from the bladder due to interference from symptoms of prostate cancer.</PreferredDefinition>
      <LongName>Prostate Quality of Life Hematuria Problem</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2527736</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12410:C17047</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3090:C28020</PreferredName>
        <Version>1</Version>
        <LongName>Hematuria Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3090</PREFERRED_NAME>
            <LONG_NAME>Hematuria</LONG_NAME>
            <CON_ID>2206233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3203147</PublicId>
      <PreferredName>PRS_QOL_SM_SCALE</PreferredName>
      <PreferredDefinition>a scaled set of values rating interference from prostate cancer symptoms.</PreferredDefinition>
      <LongName>Prostate Quality of Life Symptom Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184332</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Scale</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Five or more</VALIDVALUE>
          <VALUEMEANING>Five or more</VALUEMEANING>
          <MEANINGDESCRIPTION>Five or more</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Three to four</VALIDVALUE>
          <VALUEMEANING>Three to four</VALUEMEANING>
          <MEANINGDESCRIPTION>Three to four</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Two or less</VALIDVALUE>
          <VALUEMEANING>Two or less</VALUEMEANING>
          <MEANINGDESCRIPTION>Two or less</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Usually</VALIDVALUE>
          <VALUEMEANING>Usually</VALUEMEANING>
          <MEANINGDESCRIPTION>That which is considered customary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About half the time</VALIDVALUE>
          <VALUEMEANING>Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rarely</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About once a day</VALIDVALUE>
          <VALUEMEANING>ONCE A DAY</VALUEMEANING>
          <MEANINGDESCRIPTION>ONCE A DAY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About once a week</VALIDVALUE>
          <VALUEMEANING>ABOUT ONCE A WEEK</VALUEMEANING>
          <MEANINGDESCRIPTION>About once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily</VALIDVALUE>
          <VALUEMEANING>About once a day</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Several times a week</VALIDVALUE>
          <VALUEMEANING>Several times a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Several times a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than once a week</VALIDVALUE>
          <VALUEMEANING>Less than once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3120272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>More than once a day</VALIDVALUE>
          <VALUEMEANING>MORE THAN ONCE A DAY</VALUEMEANING>
          <MEANINGDESCRIPTION>MORE THAN ONCE A DAY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>More than once a week</VALIDVALUE>
          <VALUEMEANING>MORE THAN ONCE A WEEK</VALUEMEANING>
          <MEANINGDESCRIPTION>More than once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rarely or never</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Over the past 4 weeks, how of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Over the past 4 weeks, how often have you urinated blood</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>epic_24</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRS_QOL_HEMTR_PR_SC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="484">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3206658</PUBLICID>
    <LONGNAME>Cervix Uteri Malignant Neoplasm Pelvic Lymph Node Parametrium Positive Surgical Margin Present Ind-2</LONGNAME>
    <PREFERREDNAME>3206398v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether a malignant neoplasm of the cervix uteri, a tumor composed of atypical neoplastic cells originating from the lower, narrow end of the uterus that forms a canal between the uterus and vagina, has spread to any lymph node within the pelvic region or the subserous connective tissue of the pelvic floor of the supracervical portion of the uterus, or there are tumor cells at the edge of a surgically excised specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3206398</PublicId>
      <PreferredName>2888997v1.0:3206396v1.0</PreferredName>
      <PreferredDefinition>information related to a malignant neoplasm of the cervix uteri, a tumor composed of atypical neoplastic cells originating from the lower, narrow end of the uterus that forms a canal between the uterus and vagina, that has spread to any lymph node within the pelvic region or the subserous connective tissue of the pelvic floor of the supracervical portion of the uterus, or there are tumor cells at the edge of a surgically excised specimen.</PreferredDefinition>
      <LongName>Cervix Uteri Malignant Neoplasm Pelvic Lymph Node Parametrium Positive Surgical Margin Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2888997</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12311:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Cervix Uteri Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12311</PREFERRED_NAME>
            <LONG_NAME>Cervix Uteri</LONG_NAME>
            <CON_ID>2205926</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3206396</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12363:C12320:C48620:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Pelvic Lymph Node Parametrium Positive Surgical Margin Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12363</PREFERRED_NAME>
            <LONG_NAME>Pelvic Lymph Node</LONG_NAME>
            <CON_ID>2205344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12320</PREFERRED_NAME>
            <LONG_NAME>Parametrium</LONG_NAME>
            <CON_ID>2480906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48620</PREFERRED_NAME>
            <LONG_NAME>Positive Surgical Margin</LONG_NAME>
            <CON_ID>2431157</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have tumor i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3206398v1.0:2018257v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="485">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3210249</PUBLICID>
    <LONGNAME>NIH Stroke Scale Evaluation Dysarthria Score</LONGNAME>
    <PREFERREDNAME>NIHSS_DYSRTHRIA_SCR</PREFERREDNAME>
    <PREFERREDDEFINITION>NIH stroke scale (NIHSS) dysarthria score.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3199132</PublicId>
      <PreferredName>NIHSS_EVAL</PreferredName>
      <PreferredDefinition>NIH stroke scale (NIHSS) evaluation.</PreferredDefinition>
      <LongName>National Institutes of Health Cerebrovascular Accident Scale Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3199130</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16895:C3390:C25664</PreferredName>
        <Version>1</Version>
        <LongName>National Institutes of Health Cerebrovascular Accident Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16895</PREFERRED_NAME>
            <LONG_NAME>National Institutes of Health</LONG_NAME>
            <CON_ID>2202459</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3390</PREFERRED_NAME>
            <LONG_NAME>Stroke</LONG_NAME>
            <CON_ID>2444514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177570</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Evaluation</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3204401</PublicId>
      <PreferredName>DYSRTHRIA_SCL</PreferredName>
      <PreferredDefinition>Dysarthria scale.</PreferredDefinition>
      <LongName>Dysarthria Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
      <Representation>
        <PublicId>3204400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C79549:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Dysarthria Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79549</PREFERRED_NAME>
            <LONG_NAME>Dysarthria</LONG_NAME>
            <CON_ID>2946512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Mild-to-moderate dysarthria</VALUEMEANING>
          <MEANINGDESCRIPTION>Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood with some difficulty</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Severe dysarthria</VALUEMEANING>
          <MEANINGDESCRIPTION>Severe dysarthria; patient&#39;s speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UN</VALIDVALUE>
          <VALUEMEANING>Intubated</VALUEMEANING>
          <MEANINGDESCRIPTION>Intubated or other physical barrier</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dysarthria</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dysarthria</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sickle Cell Disease Collection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4809631</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sickle Cell Disease WG 2: Neurology, Quality of Life, and Health Services</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4925592</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neurological Impairment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3198911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIH Stroke Scale (NIHSS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3198915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Outcomes and End Points</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="486">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3212384</PUBLICID>
    <LONGNAME>Chimerism Negation Quantitative Laboratory Procedure Tissue Donor Cell Present Laboratory Finding Result</LONGNAME>
    <PREFERREDNAME>3212382v1.0:2676304v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the donor cells present determined by non-quantitative means.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3212382</PublicId>
      <PreferredName>3212356v1.0:3212380v1.0</PreferredName>
      <PreferredDefinition>The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual._An operation in which a term denies or inverts the meaning of another term or construction._Capable of being estimated or expressed with numeric values._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Someone who gives blood or tissue or an organ to be used in another person._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._Being or existing in a specified place or at the specified time</PreferredDefinition>
      <LongName>Chimerism Negation Quantitative Laboratory Procedure Tissue Donor Cell Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3212356</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62582:C25594:C70766:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Chimerism Negation Quantitative Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62582</PREFERRED_NAME>
            <LONG_NAME>Chimerism</LONG_NAME>
            <CON_ID>2521747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70766</PREFERRED_NAME>
            <LONG_NAME>Quantitative Concept</LONG_NAME>
            <CON_ID>2772180</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3212380</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25168:C12508:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Donor Cell Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25168</PREFERRED_NAME>
            <LONG_NAME>Tissue Donor</LONG_NAME>
            <CON_ID>2202520</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were donor cells present as d</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were donor cells present as determined by non-quantitative means?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:3212384</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value WHERE PerformedClinicalResult.value = &quot;present&quot; AND PerformedObservation.methodCode = &quot;non-quantitative&quot; AND PerformedObservation &gt; DefinedObservation.nameCode = &quot;Determine Tissue Donor Cell Present&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2451:Chimerism Studies</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3160396</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>chimrsm_sgl_nquant_dnr</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>chimrsm_mult_nquant_dnr</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="487">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3212385</PUBLICID>
    <LONGNAME>Center for Epidemiologic Studies Depression Scale Time</LONGNAME>
    <PREFERREDNAME>CES_D_EVL_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>Time of the day of self-reported center for epidemiologic studies depression scale evaluation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3212304</PublicId>
      <PreferredName>CES_D_EVL</PreferredName>
      <PreferredDefinition>Self-reported center for epidemiologic studies depression scale evaluation.</PreferredDefinition>
      <LongName>Center for Epidemiologic Studies Depression Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2802596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C77964</PreferredName>
        <Version>1</Version>
        <LongName>Center for Epidemiologic Studies Depression Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77964</PREFERRED_NAME>
            <LONG_NAME>Center for Epidemiologic Studies Depression Scale</LONG_NAME>
            <CON_ID>2802550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239847</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25214</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017049</PublicId>
      <PreferredName>TIME</PreferredName>
      <PreferredDefinition>The continuum of experience in which events pass from the future through the present to the past.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Center for Epidemiologic Studies Depression Scale Time does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Center for Epidemiologic Studies Depression Scale Time does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/default.aspx</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Emotional and Cognitive Status</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3198913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Center for Epidemiologic Studies-Depression Scale (CES-D)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3198919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Outcomes and End Points</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="488">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3212390</PUBLICID>
    <LONGNAME>Coordinating Group Identifier Text</LONGNAME>
    <PREFERREDNAME>2008946v2.31:3212387v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field relating to the name or idenifier of the coordinating Group.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CDUS:Clinical Data Update System</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2008946</PublicId>
      <PreferredName>COORD_GP_ID</PreferredName>
      <PreferredDefinition>information related to coordinating group name or identifier.</PreferredDefinition>
      <LongName>Coordinating Group Identifier</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206384</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25462:C17005</PreferredName>
        <Version>1</Version>
        <LongName>Coordinating Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25462</PREFERRED_NAME>
            <LONG_NAME>Coordination</LONG_NAME>
            <CON_ID>2206184</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17005</PREFERRED_NAME>
            <LONG_NAME>Population Group</LONG_NAME>
            <CON_ID>2202651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3212387</PublicId>
      <PreferredName>3212387v1.0</PreferredName>
      <PreferredDefinition>the free text field relating to the coordinating Group.</PreferredDefinition>
      <LongName>Coordinating Group Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Coordinating Group</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Coordinating Group</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="489">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3225707</PUBLICID>
    <LONGNAME>Ablation Performed Month Number</LONGNAME>
    <PREFERREDNAME>3225605v1.0:2895904v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the month the ablation was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3225605</PublicId>
      <PreferredName>3225603v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance._Performed; carried out.</PreferredDefinition>
      <LongName>Ablation Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3225603</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20985</PreferredName>
        <Version>1</Version>
        <LongName>Ablation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20985</PREFERRED_NAME>
            <LONG_NAME>Ablation Therapy</LONG_NAME>
            <CON_ID>2202276</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2895904</PublicId>
      <PreferredName>EVT_MON_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Event Month Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2895903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29846:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Month Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>One of ten equal parts; a quantity corresponding to one tenth of the whole.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C81010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::12: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::9: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::7: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the third position in an ordering or series; coming next after the third and just before the fifth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3rd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the second position in an ordering or series.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Coming next after the first in position in space or time or degree or magnitude.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1st month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Preceding all others in time or space or degree.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2896404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Month of Ablation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Month of Ablation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="490">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3228233</PUBLICID>
    <LONGNAME>Breast Tumor Post Neoadjuvant Therapy Response Status</LONGNAME>
    <PREFERREDNAME>3228225v1.0:3228226v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of response of a neoplasm of the breast to treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3228225</PublicId>
      <PreferredName>2206465v1.0:3228223v1.0</PreferredName>
      <PreferredDefinition>information related to the response of a neoplasm of the breast to treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.</PreferredDefinition>
      <LongName>Breast Tumor Post Neoadjuvant Therapy Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Breast Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3228223</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C15665:C50995</PreferredName>
        <Version>1</Version>
        <LongName>Post Neoadjuvant Therapy Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50995</PREFERRED_NAME>
            <LONG_NAME>Disease Response</LONG_NAME>
            <CON_ID>2459436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3228226</PublicId>
      <PreferredName>3228226v1.0</PreferredName>
      <PreferredDefinition>A condition or state of neoplasm following neoadjuvant therapy at a particular time.</PreferredDefinition>
      <LongName>Neoplasm Neoadjuvant Therapy Response Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>65</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progression [e.g., sum diameters &gt;= 20% increase]</VALIDVALUE>
          <VALUEMEANING>Progression</VALUEMEANING>
          <MEANINGDESCRIPTION>Sum of tumor diameters &gt;=20% increase</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial response [e.g., sum of diameters &gt;=30% reduction]</VALIDVALUE>
          <VALUEMEANING>Partial response</VALUEMEANING>
          <MEANINGDESCRIPTION>Sum of tumor diameters &gt;=30% reduction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinically complete response but no pathological information</VALIDVALUE>
          <VALUEMEANING>Clinically complete response but no pathological information</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinically complete response but no pathological information</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinically complete response with tumour cells remaining</VALIDVALUE>
          <VALUEMEANING>Clinically complete response with tumour cells remaining</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinically complete response with tumour cells remaining</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinically complete response (cCR) with negative pathology</VALIDVALUE>
          <VALUEMEANING>Clinically complete response (cCR) with negative pathology</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinically complete response (cCR) with negative pathology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoadjuvant not given</VALIDVALUE>
          <VALUEMEANING>No Administration Neoadjuvant Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Performing or possessing executive duties; acting as a supervisor or manager.: Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15665, C48905, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stable</VALIDVALUE>
          <VALUEMEANING>Stable</VALUEMEANING>
          <MEANINGDESCRIPTION>Stable; subject to little fluctuation; showing little if any change.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C30103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Other treatment cannot be appropriately assigned to specific data item (i.e. phlebotomy, transfusion, and aspirin or other disease modifying agent). Use for hematopoietic diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3089560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No evidence of pathological response</VALIDVALUE>
          <VALUEMEANING>No Evidence of Disease Pathologic Disease Response</VALUEMEANING>
          <MEANINGDESCRIPTION>Diagnostic tests fail to detect presence of disease.: Caused by or altered by or manifesting disease or pathology.: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50995, C25610, C40413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6004482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete response nodes</VALIDVALUE>
          <VALUEMEANING>Clinical Complete Response Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer based on physical exam, such as palpation.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C123574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6004483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete response breast</VALIDVALUE>
          <VALUEMEANING>Clinical Complete Response Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer based on physical exam, such as palpation.: One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12971, C123574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6004484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete response both breast and nodes</VALIDVALUE>
          <VALUEMEANING>Clinical Complete Response</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer based on physical exam, such as palpation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5838504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Breast tumour response after</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Breast tumour response after neoadjuvant therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Neoadjuvant response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="491">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3229530</PUBLICID>
    <LONGNAME>In Situ Hybridization DNA Probe Name</LONGNAME>
    <PREFERREDNAME>3229496v1.0:3229498v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The words that describe the kind of in situ hybridization DNA probe.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3229496</PublicId>
      <PreferredName>3229493v1.0:3229494v1.0</PreferredName>
      <PreferredDefinition>Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues_A piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.  Applications include Northern and Southern blots, in situ hybridization techniques, and diagnostic tests.  DNA probes can be highly specific or degenerate.</PreferredDefinition>
      <LongName>in situ Hybridization DNA Probe</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3229493</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17562</PreferredName>
        <Version>1</Version>
        <LongName>in situ Hybridization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17562</PREFERRED_NAME>
            <LONG_NAME>In Situ Hybridization</LONG_NAME>
            <CON_ID>2202909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3229494</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C451</PreferredName>
        <Version>1</Version>
        <LongName>DNA Probes</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C451</PREFERRED_NAME>
            <LONG_NAME>DNA Probes</LONG_NAME>
            <CON_ID>2203991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3229498</PublicId>
      <PreferredName>3229498v1.0</PreferredName>
      <PreferredDefinition>A piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.  Applications include Northern and Southern blots, in situ hybridization techniques, and diagnostic tests.  DNA probes can be highly specific or degenerate._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>DNA Probe Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3229497</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C451:C42614</PreferredName>
        <Version>1</Version>
        <LongName>DNA Probes Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C451</PREFERRED_NAME>
            <LONG_NAME>DNA Probes</LONG_NAME>
            <CON_ID>2203991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAC Clone</VALIDVALUE>
          <VALUEMEANING>Bacterial Artificial Chromosome</VALUEMEANING>
          <MEANINGDESCRIPTION>Based upon the natural F plasmid of E. coli.  Inserts up to 300 Kb can be cloned and stably maintained as circular molecules.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3229499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oligonucleotide</VALIDVALUE>
          <VALUEMEANING>Oligonucleotide</VALUEMEANING>
          <MEANINGDESCRIPTION>Polymers made up of a few (2-20) nucleotides.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3229500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of probe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of probe</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939361</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCTD</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>In Situ Hybridization Biomarker Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3232302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="492">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3233401</PUBLICID>
    <LONGNAME>Specimen Histology Tumor And Bone Marrow Agreement Level Description Type</LONGNAME>
    <PREFERREDNAME>3233314v1.0:3233398v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to define the histologic level of agreement between the tumor sample and the bone marrow sample.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3233314</PublicId>
      <PreferredName>3233311v1.0:3233392v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.__A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A position on a scale measuring intensity, quality, or amount.  (NCI)_Description; a statement that represents something in words.</PreferredDefinition>
      <LongName>Specimen Histology Neoplasm And Bone Marrow Agreement Level Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3233311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C16681</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Histology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16681</PREFERRED_NAME>
            <LONG_NAME>Histology</LONG_NAME>
            <CON_ID>2202345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3233392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3233392v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm And Bone Marrow Agreement Level Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3233398</PublicId>
      <PreferredName>3233398v1.0</PreferredName>
      <PreferredDefinition>The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A position on a scale measuring intensity, quality, or amount.  (NCI)_Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Histology Agreement Level Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3233397</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16681:C25369:C25554:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Histology Agreement Level Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16681</PREFERRED_NAME>
            <LONG_NAME>Histology</LONG_NAME>
            <CON_ID>2202345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Discordant Histology</VALIDVALUE>
          <VALUEMEANING>Histology Negation Agreement</VALUEMEANING>
          <MEANINGDESCRIPTION>The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.: An operation in which a term denies or inverts the meaning of another term or construction.: 1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25369, C25594, C16681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3233399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Concordant Histology</VALIDVALUE>
          <VALUEMEANING>Histology Agreement</VALUEMEANING>
          <MEANINGDESCRIPTION>The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.: 1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25369, C16681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3233400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histology of Bone Marrow Samp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Histology of Bone Marrow Sample</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3590028</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Enrollment Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3590030</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Enrollment Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000269</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="493">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3233629</PUBLICID>
    <LONGNAME>Prior Personal Medical History Immunologic Disease Other Specify Text</LONGNAME>
    <PREFERREDNAME>3233625v1.0:2857322v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text to describe a patient&#39;s other prior medical history as related to immunological diseases not already specified or mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3233625</PublicId>
      <PreferredName>3233622v1.0:3233623v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._an account of all medical events and problems a person has experienced._The study of the body&#39;s immune system._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Description; a statement that represents something in words.</PreferredDefinition>
      <LongName>Prior Personal Medical History Immunologic Disease or Disorder Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3233622</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Prior Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3233623</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18011:C2991:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Immunology Disease or Disorder Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18011</PREFERRED_NAME>
            <LONG_NAME>Immunology</LONG_NAME>
            <CON_ID>2624561</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Specified Patient Histo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Specified Patient History of Immunologic Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="494">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3235533</PUBLICID>
    <LONGNAME>Pneumococcal Polyvalent Vaccine Analysis Serotype Defense Level Count</LONGNAME>
    <PREFERREDNAME>3235523v1.0:3235529v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric value related to number of serotypes producing a defense level following the pneumococcal polyvalent vaccine.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3235523</PublicId>
      <PreferredName>3235521v1.0:2261838v1.0</PreferredName>
      <PreferredDefinition>An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years._Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.</PreferredDefinition>
      <LongName>Pneumococcal Polyvalent Vaccine Analysis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3235521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1643</PreferredName>
        <Version>1</Version>
        <LongName>Pneumococcal Polyvalent Vaccine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1643</PREFERRED_NAME>
            <LONG_NAME>Pneumococcal Polyvalent Vaccine</LONG_NAME>
            <CON_ID>3235516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2261838</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25391</PreferredName>
        <Version>1</Version>
        <LongName>Analysis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3235529</PublicId>
      <PreferredName>3235529v1.0</PreferredName>
      <PreferredDefinition>A characterization of a cell or microorganism based on the antigenic properties of the molecules on its surface._Protection from harm._A position on a scale measuring intensity, quality, or amount._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Serotype Defense Level Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3235528</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88894:C61556:C25554:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Serotype Defense Level Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88894</PREFERRED_NAME>
            <LONG_NAME>Serotype</LONG_NAME>
            <CON_ID>3081918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61556</PREFERRED_NAME>
            <LONG_NAME>Defense</LONG_NAME>
            <CON_ID>2965930</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the number of serotyp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the number of serotypes producing a protective level?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2131r2: Immune Deficiencies Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3234637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r2: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3638517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_abody_pneumoc_num</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_uncon_pneumoc_num</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_conju_pneumoc_num</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="495">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3238346</PUBLICID>
    <LONGNAME>Family Gastrointestinal History Category</LONGNAME>
    <PREFERREDNAME>FAM_GI_HX_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to indicate the type of  gastrointestinal problems the individual&#39;s family has had.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3238345</PublicId>
      <PreferredName>FAM_GI_HX</PreferredName>
      <PreferredDefinition>Family; a domestic group, or a number of domestic groups linked through descent (demonstrated or stipulated) from a common ancestor, marriage, or adoption._(GAS-tro-in-TES-tih-nul) GI.  Refers to the stomach and intestines._The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.</PreferredDefinition>
      <LongName>Family Gastrointestinal History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177165</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Family</PreferredName>
        <Version>1</Version>
        <LongName>Family</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25173</PREFERRED_NAME>
            <LONG_NAME>Family</LONG_NAME>
            <CON_ID>2202639</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3238337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13359:C54625</PreferredName>
        <Version>1</Version>
        <LongName>Gastrointestinal History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13359</PREFERRED_NAME>
            <LONG_NAME>Gastrointestinal</LONG_NAME>
            <CON_ID>2202578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3238341</PublicId>
      <PreferredName>GI_HX_CAT</PreferredName>
      <PreferredDefinition>The text term to indicate the type of  gastrointestinal problem.</PreferredDefinition>
      <LongName>Gastrointestinal History Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3238340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13359:C54625:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Gastrointestinal History Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13359</PREFERRED_NAME>
            <LONG_NAME>Gastrointestinal</LONG_NAME>
            <CON_ID>2202578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hereditary Nonpolyposis Colorectal Cancer (HNPCC)</VALIDVALUE>
          <VALUEMEANING>Hereditary Nonpolyposis Colorectal Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>Hereditary Nonpolyposis Colorectal Cancer (HNPCC)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3238342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Familial Adenomatous Polyposis (FAP)</VALIDVALUE>
          <VALUEMEANING>Adenomatous Polyposis Coli</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colitis</VALIDVALUE>
          <VALUEMEANING>Colitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammation of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2684803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crohn&#39;s Disease</VALIDVALUE>
          <VALUEMEANING>Crohn Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn&#39;s disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyps</VALIDVALUE>
          <VALUEMEANING>Polyp</VALUEMEANING>
          <MEANINGDESCRIPTION>A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2684804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imflammatory Bowel Disease (IBD)</VALIDVALUE>
          <VALUEMEANING>Inflammatory Bowel Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn&#39;s disease, ulcerative colitis, and colitis of indeterminate type. --2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3305590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gardner&#39;s Syndrome</VALIDVALUE>
          <VALUEMEANING>Gardner&#39;s Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant syndrome characterised by multiple colonic polyps predisposing to carcinoma of the colon, osteomas of the skull, epidermoid cysts, and fibromas.  It is associated with mutation of the APC gene. -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Family History of GI Problems</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Family History of GI Problems by Category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Caris Alternate Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Family History of GI Problems</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="496">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3240955</PUBLICID>
    <LONGNAME>Acute Graft Versus Host Disease Diagnosis Type</LONGNAME>
    <PREFERREDNAME>AGVHD_DX_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to further classify a diagnosis of acute Graft vs. Host Disease (AGVHD).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3240940</PublicId>
      <PreferredName>AGVHD_DX</PreferredName>
      <PreferredDefinition>information related to the investigation, analysis and recognition of the presence and nature of graft versus host disease, an incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.</PreferredDefinition>
      <LongName>Acute Graft Versus Host Disease Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512823</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4980</PreferredName>
        <Version>1</Version>
        <LongName>Acute Graft Versus Host Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4980</PREFERRED_NAME>
            <LONG_NAME>Acute Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202363</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3240942</PublicId>
      <PreferredName>AGVHD_TP</PreferredName>
      <PreferredDefinition>A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Acute Graft Versus Host Disease Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3240941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4980:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Acute Graft Versus Host Disease Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4980</PREFERRED_NAME>
            <LONG_NAME>Acute Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202363</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Classic</VALIDVALUE>
          <VALUEMEANING>Classic AGVHD</VALUEMEANING>
          <MEANINGDESCRIPTION>Classic Graft vs. Host Disease (AGVHD) onset &lt; or = 100 days post transplant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3240943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Late</VALIDVALUE>
          <VALUEMEANING>Late AGVHD</VALUEMEANING>
          <MEANINGDESCRIPTION>Acute Graft vs. Host Disease (AGVHD) onset &gt; 100 days post transplant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3240944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Acute GVHD Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Acute GVHD Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="497">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3243017</PUBLICID>
    <LONGNAME>Participant Registration Randomization Eligibility Determination Indicator</LONGNAME>
    <PREFERREDNAME>PT_REG_RAND_ELIG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indentifer that indicates whether the participant satisfies the registration/randomization eligibility criteria.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3243016</PublicId>
      <PreferredName>PT_REG_RAND_ELIG_DET</PreferredName>
      <PreferredDefinition>Someone who takes part in an activity._The act of listing or recording officially; officially qualified or enrolled._The allocation of individuals to groups by chance, especially in order to control the variables in an experiment._Criteria to determine eligibility of patients for medical care programs and services.</PreferredDefinition>
      <LongName>Participant Registration Randomization Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867</PreferredName>
        <Version>1</Version>
        <LongName>Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3243014</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25646:C25196:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Registration Randomization Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25196</PREFERRED_NAME>
            <LONG_NAME>Randomization</LONG_NAME>
            <CON_ID>2202624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018691</PublicId>
      <PreferredName>YES_NO_U_IND</PreferredName>
      <PreferredDefinition>Text terms to determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the participant satisfy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the participant satisfy all of the Registration/Randomization eligibility crtieria?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="498">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3243996</PUBLICID>
    <LONGNAME>Subject Oral Contraceptive Last 10 Year Received Indicator</LONGNAME>
    <PREFERREDNAME>SUB_OC_LT_TEN_YR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator whether subject has taken oral contraceptives within the last 10 years.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3243995</PublicId>
      <PreferredName>SUB_OC_L_TEN_YR_RCVD</PreferredName>
      <PreferredDefinition>Some matter, situation, or event that is thought about, written about, or discussed._Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both._Coming after all others in time or space or degree or being the only one remaining._A number with no fractional part.::10_The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._To take, accept, or got something offered.</PreferredDefinition>
      <LongName>Subject Oral Contraceptive Last 10 Year Received</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3243993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48910:C389</PreferredName>
        <Version>1</Version>
        <LongName>Subject Oral Contraceptive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48910</PREFERRED_NAME>
            <LONG_NAME>Subject</LONG_NAME>
            <CON_ID>2553605</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C389</PREFERRED_NAME>
            <LONG_NAME>Oral Contraceptive</LONG_NAME>
            <CON_ID>2436684</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3243997</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3243997v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Last Integer::10 Year Receive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::10</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018691</PublicId>
      <PreferredName>YES_NO_U_IND</PreferredName>
      <PreferredDefinition>Text terms to determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has subject taken oral contra</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has subject taken oral contraceptives within the last 10 years?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000006</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="499">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3245428</PUBLICID>
    <LONGNAME>Miniscrew Temporary Anchorage Device Use Name</LONGNAME>
    <PREFERREDNAME>3245402v1.0:3245403v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The words or language units by which a thing is known.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3245402</PublicId>
      <PreferredName>3244920v1.0:2234899v1.0</PreferredName>
      <PreferredDefinition>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Miniscrew Temporary Anchorage Device Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3244920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82082</PreferredName>
        <Version>1</Version>
        <LongName>Miniscrew Temporary Anchorage Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82082</PREFERRED_NAME>
            <LONG_NAME>Miniscrew Temporary Anchorage Device</LONG_NAME>
            <CON_ID>2904796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3245403</PublicId>
      <PreferredName>3245403v1.0</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Miniscrew Temporary Ancorage Device Use Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tomas (Dentaurum)</VALIDVALUE>
          <VALUEMEANING>Tomas (Dentaurum)</VALUEMEANING>
          <MEANINGDESCRIPTION>Tomas (Dentaurum)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AbsoAnchor, Dentos (Daegu City, Korea)</VALIDVALUE>
          <VALUEMEANING>AbsoAnchor, Dentos (Daegu City, Korea)</VALUEMEANING>
          <MEANINGDESCRIPTION>AbsoAnchor, Dentos (Daegu City, Korea)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteomed (Dallas, TX)</VALIDVALUE>
          <VALUEMEANING>Osteomed (Dallas, TX)</VALUEMEANING>
          <MEANINGDESCRIPTION>Osteomed (Dallas, TX)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Straumann</VALIDVALUE>
          <VALUEMEANING>Straumann</VALUEMEANING>
          <MEANINGDESCRIPTION>Straumann</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DualTop (RMO)</VALIDVALUE>
          <VALUEMEANING>DualTop (RMO)</VALUEMEANING>
          <MEANINGDESCRIPTION>DualTop (RMO)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gebruder, Martin (Tuttlingen, Ger)</VALIDVALUE>
          <VALUEMEANING>Gebruder, Martin (Tuttlingen, Ger)</VALUEMEANING>
          <MEANINGDESCRIPTION>Gebruder, Martin (Tuttlingen, Ger)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imtec</VALIDVALUE>
          <VALUEMEANING>Imtec</VALUEMEANING>
          <MEANINGDESCRIPTION>Imtec</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M.A.S. (Jazi Dental)</VALIDVALUE>
          <VALUEMEANING>M.A.S. (Jazi Dental)</VALUEMEANING>
          <MEANINGDESCRIPTION>M.A.S. (Jazi Dental)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ACR</VALIDVALUE>
          <VALUEMEANING>ACR</VALUEMEANING>
          <MEANINGDESCRIPTION>ACR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector TAS (Ormco)</VALIDVALUE>
          <VALUEMEANING>Vector TAS (Ormco)</VALUEMEANING>
          <MEANINGDESCRIPTION>Vector TAS (Ormco)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What miniscrew TAD system hav</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What miniscrew TAD system have you used? (Choose all that apply.)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="500">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3245708</PUBLICID>
    <LONGNAME>Patient Clinical Trial Safety Compliance Ind-2</LONGNAME>
    <PREFERREDNAME>3245707v1.0:2018257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related for the cooperation by the patient for evaluating the state of being certain that adverse effects will not be caused by some agent under defined conditions as required for a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3245707</PublicId>
      <PreferredName>2233604v1.0:3245705v1.0</PreferredName>
      <PreferredDefinition>information related for the cooperation by the patient for evaluating the state of being certain that adverse effects will not be caused by some agent under defined conditions as required for a clinical trial.</PreferredDefinition>
      <LongName>Patient Clinical Trial Safety Compliance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3245705</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71104:C60828:C25194</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Safety Compliance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71104</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial</LONG_NAME>
            <CON_ID>2735720</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60828</PREFERRED_NAME>
            <LONG_NAME>Safety</LONG_NAME>
            <CON_ID>2612105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25194</PREFERRED_NAME>
            <LONG_NAME>Compliance</LONG_NAME>
            <CON_ID>2202336</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is patient, in the opinion of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is patient, in the opinion of the investigator, able to comply with the safety monitoring requirements of the study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient, in the opinion of the investigator, able to comply with the safety monitoring requirements of the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In the opinion of the investigator is the patient unable or unlikely to comply with the dosing schedule and study evaluations?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In the opinion of the investigator, is patient unable to comply with the safety monitoring requirements of the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any significant issues listed below that would compromise patient safety or compliance with protocol therapy, or interfere with consent, study participation, follow up, or interpretation of study results?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have a significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with protocol therapy, or interfere with consent, study participation, follow up, or interpretation of study results?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any medical, psychiatric or social issues that would compromise patient safety or compliance with protocol therapy, or interfere with consent, study participation, follow up, or interpretation of study results?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient, in the opinion of the investigator, not able to comply with the study procedures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have the psychological ability and general health that permits completion of the study requirements and required follow up?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 100</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In the opinion of the investigator, is the patient unable to comply with the study procedures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In the opinion of the investigator, is this patient able to comply with the safety monitoring requirements of the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient in the investigators judgement unlikely to complete protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation, or in the investigator&#39;s judgment, is the patient likely to develop significant toxicity and morbidity from CAR-T cell expansion mediated inflammation based on location of tumor site?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In the opinion of the investigator, is the patient unable to comply with study procedures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>3245707v1.0:2018257v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3245707v1.0:2018257v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PtInvstgtrOpinionCompl</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Invstgropnptcomplystdy</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="501">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3247114</PUBLICID>
    <LONGNAME>Dental Alcohol Use Evaluation Status</LONGNAME>
    <PREFERREDNAME>3247102v1.0:3247094v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a condition or state at a particular time related to evaluation of alcohol use as it pertains to a tooth or teeth, or to odontology.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3247102</PublicId>
      <PreferredName>2921832v1.0:3247100v1.0</PreferredName>
      <PreferredDefinition>information related to evaluation of alcohol use as it pertains to a tooth or teeth, or to odontology.</PreferredDefinition>
      <LongName>Dental Alcohol Use Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2921832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136</PreferredName>
        <Version>1</Version>
        <LongName>Dental</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3247100</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2190:C25340:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Alcohol Use Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2190</PREFERRED_NAME>
            <LONG_NAME>Alcohol</LONG_NAME>
            <CON_ID>2202315</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3247094</PublicId>
      <PreferredName>3247094v1.0</PreferredName>
      <PreferredDefinition>a condition or state at a particular time for dental evaluation.</PreferredDefinition>
      <LongName>Dental Evaluation Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very unimportant</VALIDVALUE>
          <VALUEMEANING>Very unimportant</VALUEMEANING>
          <MEANINGDESCRIPTION>Very unimportant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat unimportant</VALIDVALUE>
          <VALUEMEANING>Somewhat unimportant</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat unimportant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not sure</VALIDVALUE>
          <VALUEMEANING>Not sure</VALUEMEANING>
          <MEANINGDESCRIPTION>Not certain</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2594711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat Important</VALIDVALUE>
          <VALUEMEANING>Somewhat Important</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat Important</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very Important</VALIDVALUE>
          <VALUEMEANING>very important</VALUEMEANING>
          <MEANINGDESCRIPTION>very important</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alcohol use</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Alcohol use</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="502">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3248454</PUBLICID>
    <LONGNAME>Miniscrew Temporary Anchorage Device Complication Date</LONGNAME>
    <PREFERREDNAME>3248453v1.0:3115557v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Complication; any disease or disorder that occurs during the course of (or because of) another disease._a particular day specified as the time something has, or will, happen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3248453</PublicId>
      <PreferredName>3244920v1.0:2430116v1.0</PreferredName>
      <PreferredDefinition>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Complication; any disease or disorder that occurs during the course of (or because of) another disease.</PreferredDefinition>
      <LongName>Miniscrew Temporary Anchorage Device Complication</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3244920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82082</PreferredName>
        <Version>1</Version>
        <LongName>Miniscrew Temporary Anchorage Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82082</PREFERRED_NAME>
            <LONG_NAME>Miniscrew Temporary Anchorage Device</LONG_NAME>
            <CON_ID>2904796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2430116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2959</PreferredName>
        <Version>1</Version>
        <LongName>Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2959</PREFERRED_NAME>
            <LONG_NAME>Complication</LONG_NAME>
            <CON_ID>2203884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of complication: (MM/DD/</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of complication: (MM/DD/YYYY)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="503">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3249338</PUBLICID>
    <LONGNAME>Miniscrew Temporary Anchorage Device Problem Encounter Specify Text</LONGNAME>
    <PREFERREDNAME>3249326v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Problem; a state of difficulty that needs to be resolved._Each individual, unique interaction between two subjects of interest._Be specific about something; define clearly._Text; the words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3249326</PublicId>
      <PreferredName>3244920v1.0:3249324v1.0</PreferredName>
      <PreferredDefinition>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Problem; a state of difficulty that needs to be resolved._Each individual, unique interaction between two subjects of interest.</PreferredDefinition>
      <LongName>Miniscrew Temporary Anchorage Device Problem Encounter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3244920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82082</PreferredName>
        <Version>1</Version>
        <LongName>Miniscrew Temporary Anchorage Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82082</PREFERRED_NAME>
            <LONG_NAME>Miniscrew Temporary Anchorage Device</LONG_NAME>
            <CON_ID>2904796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3249324</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28020:C62143</PreferredName>
        <Version>1</Version>
        <LongName>Problem Encounter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62143</PREFERRED_NAME>
            <LONG_NAME>Encounter</LONG_NAME>
            <CON_ID>2804841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="504">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3250124</PUBLICID>
    <LONGNAME>Pain Medication Recommendation Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3248364v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to pain medication recommendation.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3248364</PublicId>
      <PreferredName>2207030v1.0:2224050v1.0</PreferredName>
      <PreferredDefinition>The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products._Recommendation; advice telling someone what the best thing to do is.</PreferredDefinition>
      <LongName>Pain Medication Recommendation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2207030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C459</PreferredName>
        <Version>1</Version>
        <LongName>Pain Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224050</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25197</PreferredName>
        <Version>1</Version>
        <LongName>Recommendation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25197</PREFERRED_NAME>
            <LONG_NAME>Recommendation</LONG_NAME>
            <CON_ID>2203959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Would you recommend a medicat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Would you recommend a medication</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="505">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3250758</PUBLICID>
    <LONGNAME>Prior Dental Restoration Core Use Type</LONGNAME>
    <PREFERREDNAME>3250754v1.0:3250755v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Earlier in time or order._Replacement or reconstruction of a lost tooth structure._The center of an object; indispensable_Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3250754</PublicId>
      <PreferredName>3250724v1.0:3250752v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._Replacement or reconstruction of a lost tooth structure._The center of an object; indispensable_Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Prior Dental Restoration Core Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3250724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C60718</PreferredName>
        <Version>1</Version>
        <LongName>Prior Dental Restoration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60718</PREFERRED_NAME>
            <LONG_NAME>Dental Restoration</LONG_NAME>
            <CON_ID>2481613</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3250752</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25327:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Core Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25327</PREFERRED_NAME>
            <LONG_NAME>Core</LONG_NAME>
            <CON_ID>2206185</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3250755</PublicId>
      <PreferredName>3250755v1.0</PreferredName>
      <PreferredDefinition>Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Prior Dental Restoration Core Use Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conventional glass ionomer</VALIDVALUE>
          <VALUEMEANING>Conventional glass ionomer</VALUEMEANING>
          <MEANINGDESCRIPTION>Conventional glass ionomer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3250756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resin modified glass ionomer</VALIDVALUE>
          <VALUEMEANING>Resin modified glass ionomer</VALUEMEANING>
          <MEANINGDESCRIPTION>Resin modified glass ionomer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3250757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceramic</VALIDVALUE>
          <VALUEMEANING>Ceramic</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental restorative material made from fired porcelain.  This may include restorations that are both metal and ceramic such as porcelain bonded to metal crowns.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cast metal</VALIDVALUE>
          <VALUEMEANING>Cast Metal</VALUEMEANING>
          <MEANINGDESCRIPTION>Molten metal (of electropositive elements that usually have a shiny surface) poured into a mold</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2632155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite</VALIDVALUE>
          <VALUEMEANING>Composite</VALUEMEANING>
          <MEANINGDESCRIPTION>Consisting of separate interconnected parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amalgam</VALIDVALUE>
          <VALUEMEANING>Amalgam</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental restorative material consisting primarily of an analgamation of silver, tin and mercury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What type of core material?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What type of core material?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="506">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3263643</PUBLICID>
    <LONGNAME>Person Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinue Clinical Trial Eligibility Criteria Status</LONGNAME>
    <PREFERREDNAME>3192315v1.0:3263638v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a condition or state at a particular time related to the discontinuation of prior administration of platinum-based chemotherapy to treat the primary cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192315</PublicId>
      <PreferredName>2236731v1.0:3192313v1.0</PreferredName>
      <PreferredDefinition>information related to the discontinuation of prior administration of platinum-based chemotherapy to treat the primary cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Person Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinue Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3192313v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinued Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1450</PREFERRED_NAME>
            <LONG_NAME>Platinum Compound</LONG_NAME>
            <CON_ID>2716561</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C8509</PREFERRED_NAME>
            <LONG_NAME>Primary Neoplasm</LONG_NAME>
            <CON_ID>2240094</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25484</PREFERRED_NAME>
            <LONG_NAME>Discontinue</LONG_NAME>
            <CON_ID>2203906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3263638</PublicId>
      <PreferredName>3263638v1.0</PreferredName>
      <PreferredDefinition>A condition or state at a particular time for the clinical trial eligibility as it relates to prior platinum compound chemotherapy for primary neoplasm.</PreferredDefinition>
      <LongName>Prior Platinum Compound Chemotherapy Primary Neoplasm Clinical Trial Eligibility Criteria Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable-pt. received more than one cytotoxic regimen</VALIDVALUE>
          <VALUEMEANING>Not Applicable-pt. received more than one cytotoxic regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Not Applicable-pt. received more than one cytotoxic regimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Had persistent disease after platinum therapy</VALIDVALUE>
          <VALUEMEANING>Had persistent disease after platinum therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Had persistent disease after platinum therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressed during platinum therapy</VALIDVALUE>
          <VALUEMEANING>Progressed during platinum therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressed during platinum therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Had a platinum-free interval of less than 12 months</VALIDVALUE>
          <VALUEMEANING>Had a platinum-free interval of less than 12 months</VALUEMEANING>
          <MEANINGDESCRIPTION>Had a platinum-free interval of less than 12 months</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If the patient has received o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If the patient has received only one prior cytotoxic regimen (platinum-based regimen for management of primary disease), has the patient</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000501</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170Q</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3192315v1.0:3263638v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="507">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3278633</PUBLICID>
    <LONGNAME>Treatment First Course Other Therapy Intervention or Procedure Date Flag Health Level Seven Null Value Code</LONGNAME>
    <PREFERREDNAME>3278632v1.0:3151988v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Flag that explains why no appropriate value is in the field, RX Date--Other [1250].</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3278632</PublicId>
      <PreferredName>2691043v1.0:3278630v1.0</PreferredName>
      <PreferredDefinition>Explains why no appropriate value is in the field, RX Date--Other [1250].</PreferredDefinition>
      <LongName>Treatment First Course Other Therapy Intervention or Procedure Date Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2691043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25509:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure First Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3278630</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3278630v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Other Therapy Intervention or Procedure Date Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3151988</PublicId>
      <PreferredName>3151988v1.0</PreferredName>
      <PreferredDefinition>A Standards Developing Organization (SDO) operating in the healthcare arena with an emphasis on the domain of clinical and administrative data._A special value that may be stored in some database columns to represent an unknown, missing, not applicable, or undefined value. (from Free On-Line Dictionary of Computing)_The information contained in a data field._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Health Level Seven Null Value Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>3151987</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80485:C47840:C49100:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Health Level Seven Null Value Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80485</PREFERRED_NAME>
            <LONG_NAME>Health Level Seven</LONG_NAME>
            <CON_ID>2928160</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47840</PREFERRED_NAME>
            <LONG_NAME>Null</LONG_NAME>
            <CON_ID>2423499</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Hidden</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accessible to view.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2929841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Negative Infinity</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with a value that is less than any other negative number.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2929835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Positive Infinity</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with a value that is larger than any other positive number.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2929836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Temporary Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>Not permanent; not lasting; lacking continuity or regularity.:An operation in which a term denies or inverts the meaning of another term or construction.:The quality of being obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53288, C25594, C25429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2929839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Not asked</VALUEMEANING>
          <MEANINGDESCRIPTION>This information has not been sought (e.g., patient was not asked)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2839358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>No Information Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3151989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Other Flag</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Other Flag</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899849</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>1251</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX DATE--OTHER FLAG</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Date--Other Flag</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Date Other Flag</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="508">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3279221</PUBLICID>
    <LONGNAME>Future Cessation Cigarette Smoking Or Tobacco Use Category</LONGNAME>
    <PREFERREDNAME>3276546v1.0:3276561v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that describes whether or not a person is considering stopping smoking or use of tobacco products and the timeframe for taking action.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3276546</PublicId>
      <PreferredName>3276543v1.0:3276544v1.0</PreferredName>
      <PreferredDefinition>A time that is yet to come._A stopping._Inhaling smoke from tobacco in the form of a cigarette._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Use of tobacco in any form i.e. smoking, chewing or sniffing.</PreferredDefinition>
      <LongName>Future Cessation Cigarette Smoking Or Tobacco Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3276543</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67527:C61497</PreferredName>
        <Version>1</Version>
        <LongName>Future Cessation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67527</PREFERRED_NAME>
            <LONG_NAME>Future</LONG_NAME>
            <CON_ID>2653011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61497</PREFERRED_NAME>
            <LONG_NAME>Cessation</LONG_NAME>
            <CON_ID>2593553</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3276544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18270:C37998:C18059</PreferredName>
        <Version>1</Version>
        <LongName>Cigarette Smoking Or Tobacco Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18270</PREFERRED_NAME>
            <LONG_NAME>Cigarette Smoking</LONG_NAME>
            <CON_ID>2202494</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18059</PREFERRED_NAME>
            <LONG_NAME>Tobacco Use</LONG_NAME>
            <CON_ID>2202335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3276561</PublicId>
      <PreferredName>3276561v1.0</PreferredName>
      <PreferredDefinition>A stopping._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied._the continuum of experience in which events pass from the future through the present to the past._Category; used informally to mean a class of things.</PreferredDefinition>
      <LongName>Cessation Indicator Time Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3276560</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61497:C25180:C25207:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Cessation Indicator Time Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61497</PREFERRED_NAME>
            <LONG_NAME>Cessation</LONG_NAME>
            <CON_ID>2593553</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, I am not thinking of quitting</VALIDVALUE>
          <VALUEMEANING>No Future Smoking Cessation</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A time that is yet to come.: The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.: A stopping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61497, C17934, C67527, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, within the next 6 months</VALIDVALUE>
          <VALUEMEANING>Yes Within Integer::6 Month</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.: On the inside; contained in.: A number with no fractional part.::6: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25282, C49488, C29846, C45255::6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 3, 0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, within the next 30 days</VALIDVALUE>
          <VALUEMEANING>Yes Within Integer::30 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.: On the inside; contained in.: A number with no fractional part.::30: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::30, C25282, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you currently seriously t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you currently seriously thinking of quitting smoking or using other tobacco products?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Are you seriously thinking about quitting in the next month?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Are you seriously thinking about quitting smoking in the next 6 months?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Related Risks </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="509">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3279223</PUBLICID>
    <LONGNAME>Smoking Cessation Medication Use Type</LONGNAME>
    <PREFERREDNAME>3276640v1.0:3276672v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text to describe the kind of medication used to help stop smoking.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3276640</PublicId>
      <PreferredName>2435430v1.0:3276643v1.0</PreferredName>
      <PreferredDefinition>The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe._A stopping.__A drug or medicine that treats or prevents or alleviates the symptoms of disease._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Smoking Cessation Medication Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2435430</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17934</PreferredName>
        <Version>1</Version>
        <LongName>Smoking</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17934</PREFERRED_NAME>
            <LONG_NAME>Tobacco Smoking</LONG_NAME>
            <CON_ID>2202827</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3276643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61497:C459:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Cessation Medication Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61497</PREFERRED_NAME>
            <LONG_NAME>Cessation</LONG_NAME>
            <CON_ID>2593553</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3276672</PublicId>
      <PreferredName>3276672v1.0</PreferredName>
      <PreferredDefinition>The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe._A stopping._biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Smoking Cessation Medication Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3276671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17934:C61497:C459:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Smoking Cessation Medication Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17934</PREFERRED_NAME>
            <LONG_NAME>Tobacco Smoking</LONG_NAME>
            <CON_ID>2202827</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61497</PREFERRED_NAME>
            <LONG_NAME>Cessation</LONG_NAME>
            <CON_ID>2593553</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not sure</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chantix</VALIDVALUE>
          <VALUEMEANING>Varenicline Tartrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to help people stop smoking by acting the same way nicotine acts in the brain. It is a type of nicotine receptor partial agonist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zyban or buproprion</VALIDVALUE>
          <VALUEMEANING>Bupropion Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an aminoketone antidepressant. The molecular mechanism of the antidepressant effect of bupropion is unknown.  This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotine lozenge</VALIDVALUE>
          <VALUEMEANING>Nicotine Lozenge</VALUEMEANING>
          <MEANINGDESCRIPTION>A lozenge preparation containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the lozenge, nicotine is released and, although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotine nasal spray</VALIDVALUE>
          <VALUEMEANING>Nicotine Nasal Spray</VALUEMEANING>
          <MEANINGDESCRIPTION>A nasal spray composed of an aqueous solution containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the spray into the nostrils, nicotine is taken up from the nasal mucosa into the bloodstream. Although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotine inhaler</VALIDVALUE>
          <VALUEMEANING>Nicotine Inhaler</VALUEMEANING>
          <MEANINGDESCRIPTION>A device consisting of a mouthpiece and a thin, plastic cartridge that contains nicotine plug and delivers nicotine in a vapor that is absorbed in the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotine gum</VALIDVALUE>
          <VALUEMEANING>Nicotine Gum</VALUEMEANING>
          <MEANINGDESCRIPTION>A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3276683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotine skin patch</VALIDVALUE>
          <VALUEMEANING>Nicotine Patch</VALUEMEANING>
          <MEANINGDESCRIPTION>A transepidermal patch designed to deliver nicotine, the addictive substance contained in cigarettes, directly through the skin and into the blood stream. Used for cessation of smoking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17955</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Which stop-smoking medication</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Which stop-smoking medications have you used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Related Risks </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="510">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3284922</PUBLICID>
    <LONGNAME>Leukemia Treatment Type</LONGNAME>
    <PREFERREDNAME>3284242v1.0:3282849v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term that describes the kind of treatment that was given for the primary leukemia.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3284242</PublicId>
      <PreferredName>2456829v1.0:3284230v1.0</PreferredName>
      <PreferredDefinition>A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Leukemia Treatment Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2456829</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3161</PreferredName>
        <Version>1</Version>
        <LongName>Leukemia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3161</PREFERRED_NAME>
            <LONG_NAME>Leukemia</LONG_NAME>
            <CON_ID>2202669</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3284230</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3282849</PublicId>
      <PreferredName>3282849v1.1</PreferredName>
      <PreferredDefinition>Any intervention for management of a malignant neoplasm._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Cancer Treatment Type</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3282848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16212:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Cancer Treatment Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16212</PREFERRED_NAME>
            <LONG_NAME>Cancer Therapeutic Procedure</LONG_NAME>
            <CON_ID>2615819</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Treatment</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Treatment</VALIDVALUE>
          <VALUEMEANING>Other Therapeutic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery</VALIDVALUE>
          <VALUEMEANING>Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemotherapy</VALIDVALUE>
          <VALUEMEANING>Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation</VALIDVALUE>
          <VALUEMEANING>Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Concurrent Chemotherapy</VALIDVALUE>
          <VALUEMEANING>Concurrent Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or operating at the same time.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25456, C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cryoablation</VALIDVALUE>
          <VALUEMEANING>Cryosurgery</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a body part, pathway, or function by freezing the desired entity. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3648722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation and Chemotherapy</VALIDVALUE>
          <VALUEMEANING>Radiation Therapy And Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632, C37912, C15313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3703331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplant</VALIDVALUE>
          <VALUEMEANING>Hematopoietic Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4395931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What type of treatment did yo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What type of treatment did you receive for cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Personal History of Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259226</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="511">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3287336</PUBLICID>
    <LONGNAME>Immediate Family History Lymphoma Relative Count Type</LONGNAME>
    <PREFERREDNAME>3286937v1.0:3285523v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that describes which and how many of the patient&#39;s first degree relatives have been diagnosed with lymphoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3286937</PublicId>
      <PreferredName>3286580v1.0:2624568v1.0</PreferredName>
      <PreferredDefinition>A person related by descent rather than by marriage or law._Chronological record of health and disease events of family members and ancestors. (WEBS84)._A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Immediate Family History Lymphoma</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3286580</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71384:C17726</PreferredName>
        <Version>1</Version>
        <LongName>Biological Relative Family Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71384</PREFERRED_NAME>
            <LONG_NAME>Biological Relative</LONG_NAME>
            <CON_ID>2714720</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17726</PREFERRED_NAME>
            <LONG_NAME>Family Medical History</LONG_NAME>
            <CON_ID>2202638</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2624568</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3208:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3285523</PublicId>
      <PreferredName>3285523v1.0</PreferredName>
      <PreferredDefinition>Any relative who is one meiosis away from a particular individual in a family; a relative with whom one half of an individual&#39;s genes is shared (i.e., parent, sibling, offspring) (from Genetics Home Reference glossary)_To determine the number or amount of something; the result of this activity._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>First Degree Relative Count Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3285522</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21481:C25463:C25284</PreferredName>
        <Version>1</Version>
        <LongName>First Degree Relative Count Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21481</PREFERRED_NAME>
            <LONG_NAME>First Degree Relative</LONG_NAME>
            <CON_ID>2400271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 or more brothers and/or sons</VALIDVALUE>
          <VALUEMEANING>Integer::2 Or Greater Than Two Brother Or Son</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::2: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: Brother; a male sibling.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Son; a male human offspring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25205, C37998, C25289, C66833, C61584, C37998, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3285524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 brother or son</VALIDVALUE>
          <VALUEMEANING>One Brother Or Son</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.: Brother; a male sibling.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Son; a male human offspring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25205, C37998, C25289, C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3285525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 or more sisters and/or daughters</VALIDVALUE>
          <VALUEMEANING>Integer::2 Or Greater Than Two Sister Or Daughter</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::2: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: Sister; a female sibling.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Daughter; a female human offspring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61584, C37998, C45255::2, C25165, C37998, C25680, C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>4, 5, 6, 0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3285526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 sister or daughter</VALIDVALUE>
          <VALUEMEANING>One Sister Or Daughter</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.: Sister; a female sibling.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Daughter; a female human offspring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25165, C37998, C25680, C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3285527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Father</VALIDVALUE>
          <VALUEMEANING>Father</VALUEMEANING>
          <MEANINGDESCRIPTION>Father; a male parent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mother</VALIDVALUE>
          <VALUEMEANING>Mother</VALUEMEANING>
          <MEANINGDESCRIPTION>Mother; a female parent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has anyone in your immediate</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has anyone in your immediate family (mother, father, full sisters, full brothers, sons, or daughters) ever had any of the following types of cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Family History of Cancer </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259227</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="512">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3291303</PUBLICID>
    <LONGNAME>Breast Reconstruction Delay Day Count</LONGNAME>
    <PREFERREDNAME>3291284v1.0:2018594v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Number of days delay in a surgical procedure</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BOLD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BOLD:Breast Oncology Local Disease Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3291284</PublicId>
      <PreferredName>3291282v1.0:2718948v1.0</PreferredName>
      <PreferredDefinition>Surgery to rebuild a breast&#39;s shape after a mastectomy._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.</PreferredDefinition>
      <LongName>Breast Reconstruction Delay</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3291282</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15354</PreferredName>
        <Version>1</Version>
        <LongName>Breast Reconstruction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15354</PREFERRED_NAME>
            <LONG_NAME>Mammoplasty</LONG_NAME>
            <CON_ID>2716449</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2718948</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25476</PreferredName>
        <Version>1</Version>
        <LongName>Delay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25476</PREFERRED_NAME>
            <LONG_NAME>Delay</LONG_NAME>
            <CON_ID>2203898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018594</PublicId>
      <PreferredName>D_CT</PreferredName>
      <PreferredDefinition>the quantity of days.</PreferredDefinition>
      <LongName>Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Day Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Length of delay (days)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Length of delay (days)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Surgery Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886759</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Surgery Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902142</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="513">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3294410</PUBLICID>
    <LONGNAME>Limited Activity Due To Impairment Or Health Problem Indicator</LONGNAME>
    <PREFERREDNAME>3291786v1.0:3270332v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify whether or not a person is limited in any way due to an imparirment or health condition.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3291786</PublicId>
      <PreferredName>3291783v1.0:3291784v1.0</PreferredName>
      <PreferredDefinition>Anything that limits; a limitation._The state of being active; any specific activity._Expected or scheduled._Used as a function word to indicate direction, purpose, or movement._Loss or abnormality of psychological, physiological, or anatomic structure or function._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The state of the organism when it functions optimally without evidence of disease._Problem; a state of difficulty that needs to be resolved.</PreferredDefinition>
      <LongName>Limit Activity Due To Impairment Or Health Problem</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3291783</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53452:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Restriction Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53452</PREFERRED_NAME>
            <LONG_NAME>Restriction</LONG_NAME>
            <CON_ID>2726208</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3291784</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3291784v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Due To Impairment Or Health Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45263</PREFERRED_NAME>
            <LONG_NAME>Due</LONG_NAME>
            <CON_ID>2689734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21055</PREFERRED_NAME>
            <LONG_NAME>Impairment</LONG_NAME>
            <CON_ID>2470784</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25178</PREFERRED_NAME>
            <LONG_NAME>Health</LONG_NAME>
            <CON_ID>2202325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3270332</PublicId>
      <PreferredName>3270332v1.0</PreferredName>
      <PreferredDefinition>The affirmative response to a question or activity._The non-affirmative response to a question._The answer is not known by the person answering._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Yes No Does Not Know Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3270331</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C67142:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Does Not Know Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67142</PREFERRED_NAME>
            <LONG_NAME>Does Not Know</LONG_NAME>
            <CON_ID>2653836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you limited in any way in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you limited in any way in any activities because of any impairment or health problem?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Quality of Life</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259230</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="514">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3294764</PUBLICID>
    <LONGNAME>Person Osteoporosis Fracture Personal Medical History Ind-2</LONGNAME>
    <PREFERREDNAME>3294763v1.0:2179984v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator relating to a record of a patient&#39;s background regarding a fracture from disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3294763</PublicId>
      <PreferredName>2236731v1.0:3294761v1.0</PreferredName>
      <PreferredDefinition>information relating to a record of a patient&#39;s background regarding a fracture from disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition).</PreferredDefinition>
      <LongName>Person Osteoporosis Fracture Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3294761</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3298:C3046:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Osteoporosis Fracture Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3298</PREFERRED_NAME>
            <LONG_NAME>Osteoporosis</LONG_NAME>
            <CON_ID>2202545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3046</PREFERRED_NAME>
            <LONG_NAME>Fracture</LONG_NAME>
            <CON_ID>2203813</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Osteoporotic fracture</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Osteoporotic fracture</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3294763v1.0:2179984v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="515">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3302264</PUBLICID>
    <LONGNAME>Randomization To Event Calculation Day Month Duration Value</LONGNAME>
    <PREFERREDNAME>3302263v1.0:3302238v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Calculation of the time (in days/months) from an individual&#39;s randomization to a clinical trial to another protocol-related event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BOLD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BOLD:Breast Oncology Local Disease Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3302263</PublicId>
      <PreferredName>3302261v1.0:2825201v1.0</PreferredName>
      <PreferredDefinition>The allocation of individuals to groups by chance, especially in order to control the variables in an experiment._Used as a function word to indicate direction, purpose, or movement._Event; something that happens at a given place and time.information related to a protocol-defined event from the time or instance of registration or enrollment.</PreferredDefinition>
      <LongName>Randomization To Event Duration Calculation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3302261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25196:C65107:C25499:C25330</PreferredName>
        <Version>1</Version>
        <LongName>Randomization To Event Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25196</PREFERRED_NAME>
            <LONG_NAME>Randomization</LONG_NAME>
            <CON_ID>2202624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2825201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54125</PreferredName>
        <Version>1</Version>
        <LongName>Calculation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54125</PREFERRED_NAME>
            <LONG_NAME>Calculation</LONG_NAME>
            <CON_ID>2654477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3302238</PublicId>
      <PreferredName>DAY_MON_DUR_VAL</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._The period of time during which something continues._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Day Month Duration Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3302237</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C29846:C25330:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Day Month Duration Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Duration</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Duration</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461588</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886753</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>General Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902138</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>CALCULATED</DerivationType>
      <DerivationTypeDescription>CALCULATED</DerivationTypeDescription>
      <Methods/>
      <Rule>Based on event in #1, calculate duration of event (#2) and express as in derived data element.</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>2540016</PublicId>
          <LongName>Randomization Protocol Event Type</LongName>
          <PreferredName>RAND_PROT_EVENT_TP</PreferredName>
          <PreferredDefinition>the type of protocol-defined event from the time or instance of randomization, the allocation of individuals to groups by chance.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>CTEP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>3150982</PublicId>
          <LongName>Time Duration Number Value</LongName>
          <PreferredName>TM_DURN_VAL</PreferredName>
          <PreferredDefinition>Value that is paired with a unit of measure (hours, weeks, days) to express the length of time that an activity or event lasted.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>CCR</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="516">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2540016</PUBLICID>
    <LONGNAME>Randomization Protocol Event Type</LONGNAME>
    <PREFERREDNAME>RAND_PROT_EVENT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of protocol-defined event from the time or instance of randomization, the allocation of individuals to groups by chance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>Breast CDE Disease Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="517">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3150982</PUBLICID>
    <LONGNAME>Time Duration Number Value</LONGNAME>
    <PREFERREDNAME>TM_DURN_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Value that is paired with a unit of measure (hours, weeks, days) to express the length of time that an activity or event lasted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="518">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3316622</PUBLICID>
    <LONGNAME>Measurable Evaluable Disease Present Date</LONGNAME>
    <PREFERREDNAME>2644180v1.0:2532012v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The month, day, and year measurable evaluable disease was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2644180</PublicId>
      <PreferredName>MSRBL_EVAL_DZ_PRES</PreferredName>
      <PreferredDefinition>information relating to measurable or evaluable disease being present.</PreferredDefinition>
      <LongName>Measurable Evaluable Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2644178</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37894:C8503:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Measurable Evaluable Disease Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37894</PREFERRED_NAME>
            <LONG_NAME>Measurable</LONG_NAME>
            <CON_ID>2202455</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C8503</PREFERRED_NAME>
            <LONG_NAME>Evaluable Disease</LONG_NAME>
            <CON_ID>2206207</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2532012</PublicId>
      <PreferredName>DATE</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY-MM-DD</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the date of first evidence of disease activity:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the date of first evidence of disease activity:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the date measurable e</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the date measurable evaluable disease was present:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ms_post_dx_pres_crnt_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="519">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3320020</PUBLICID>
    <LONGNAME>Invasive Malignant Neoplasm Necrosis Status Indicator</LONGNAME>
    <PREFERREDNAME>3319914v1.0:3151609v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term that describes the state of necrosis in the invasive portion of the cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3319914</PublicId>
      <PreferredName>2206790v1.0:3319912v1.0</PreferredName>
      <PreferredDefinition>Marked by a tendency to spread especially into healthy tissue._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas, leukemias, melanomas, and sarcomas. -- 2004_Relating to or affected by necrosis._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Invasive Malignant Neoplasm Necrosis Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206790</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14159:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Invasive Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14159</PREFERRED_NAME>
            <LONG_NAME>Invasive</LONG_NAME>
            <CON_ID>2203841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3319912</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25286:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Necrotic Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25286</PREFERRED_NAME>
            <LONG_NAME>Necrotic</LONG_NAME>
            <CON_ID>2206318</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3151609</PublicId>
      <PreferredName>3151609v1.0</PreferredName>
      <PreferredDefinition>To have a connection by participation or association or use; sharing in an activity or process._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Involvement Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Transplant CDE Committee</Origin>
      <Representation>
        <PublicId>2593062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25548:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Involvement Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not identified</VALIDVALUE>
          <VALUEMEANING>Not Identified</VALUEMEANING>
          <MEANINGDESCRIPTION>The finding is not present, but a value of &#39;none&#39; cannot be unequivocally established absence in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate/Extensive</VALIDVALUE>
          <VALUEMEANING>Moderate And/Or Extensive</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: Used to indicate that either or both of two items or options may be valid.: Large in quantity, range, or spatial extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47863, C48928, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3319728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent/Minimal</VALIDVALUE>
          <VALUEMEANING>Absent And/Or Minimum</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.: Used to indicate that either or both of two items or options may be valid.: The smallest possible quantity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25570, C48928, C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3319729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cannot be determined</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, value not specified</VALIDVALUE>
          <VALUEMEANING>Yes Value Not Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: A numerical quantity measured or assigned or computed.: An operation in which a term denies or inverts the meaning of another term or construction.: Clearly and explicitly stated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38024, C25594, C25712, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6825356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, value available (specify)</VALIDVALUE>
          <VALUEMEANING>Yes Value Available</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: A numerical quantity measured or assigned or computed.: The quality of being obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25712, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6825357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Necrosis in invasive portion</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Necrosis in invasive portion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="520">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3320289</PUBLICID>
    <LONGNAME>Frozen Specimen Tissue Other Anatomic Site Text</LONGNAME>
    <PREFERREDNAME>3320138v1.0:2239890v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Name of the anatomic site of a frozen biospecimen that is different from those already specified of mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3320138</PublicId>
      <PreferredName>3081910v1.0:2207113v1.0</PreferredName>
      <PreferredDefinition>A specimen that has been subjected to and immobilized by severe cold. (NCI)_An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._Different than the one(s) previously specified or mentioned._Named locations of or within the body.</PreferredDefinition>
      <LongName>Frozen Specimen Tissue Other Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3081910</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70717:C12801</PreferredName>
        <Version>1</Version>
        <LongName>Frozen Specimen Tissue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70717</PREFERRED_NAME>
            <LONG_NAME>Frozen Specimen</LONG_NAME>
            <CON_ID>2960212</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207113</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Other Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2239890</PublicId>
      <PreferredName>ANAT_SITES_TXT</PreferredName>
      <PreferredDefinition>the text field to describe the position of an organ or structure within the body.</PreferredDefinition>
      <LongName>Anatomic Sites Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Anatomic Site of Frozen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Anatomic Site of Frozen Biospecimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BRCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CESC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>COAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787503</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KICH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787508</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787513</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PAAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>READ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SKCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787519</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>STAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787520</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>THCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCEC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical cqcf</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLGSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5655940</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>other_anatomic_site</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="521">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3348805</PUBLICID>
    <LONGNAME>X-Ray Diagnostic Imaging Chest Width Assessment Measurement</LONGNAME>
    <PREFERREDNAME>3348349v1.0:3348356v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the value associated with the measurement of the maximum width of the chest/thorax.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3348349</PublicId>
      <PreferredName>2603734v1.0:3348347v1.0</PreferredName>
      <PreferredDefinition>information relating to an assessment of the chest (the part of the human body between the neck and the diaphragm, or abdomen) width (the extent of something from side to side) and X-ray imaging (diagnostic imaging through means of roentgen rays, recording the image on a sensitized surface).</PreferredDefinition>
      <LongName>X-Ray Diagnostic Imaging Chest Width Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2603734</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17261:C16502</PreferredName>
        <Version>1</Version>
        <LongName>X-Ray Diagnostic Imaging</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17261</PREFERRED_NAME>
            <LONG_NAME>X-Ray</LONG_NAME>
            <CON_ID>2202559</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16502</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Imaging</LONG_NAME>
            <CON_ID>2321519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3348347</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25389:C25345:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Chest Width Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25389</PREFERRED_NAME>
            <LONG_NAME>Chest</LONG_NAME>
            <CON_ID>2202707</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25345</PREFERRED_NAME>
            <LONG_NAME>Width</LONG_NAME>
            <CON_ID>2203977</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3348356</PublicId>
      <PreferredName>3348356v1.0</PreferredName>
      <PreferredDefinition>the value associated with the measurement of the maximum width of the chest/thorax.</PreferredDefinition>
      <LongName>Chest Width Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the maximum width of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the maximum width of the thorax</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="522">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3351890</PUBLICID>
    <LONGNAME>Prostate Cancer Patient Computed Tomography Result Clinical TNM Finding Stage</LONGNAME>
    <PREFERREDNAME>3350703v1.0:3351747v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text statement to describe the results of a CT scan performed on a patient with prostate cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3350703</PublicId>
      <PreferredName>3350696v1.0:3350701v1.0</PreferredName>
      <PreferredDefinition>Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._The result of an action.</PreferredDefinition>
      <LongName>Prostate Carcinoma Patient Computed Tomography Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3350696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4863:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Carcinoma Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4863</PREFERRED_NAME>
            <LONG_NAME>Prostate Carcinoma</LONG_NAME>
            <CON_ID>2237042</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3350701</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17204:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Computed Tomography Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17204</PREFERRED_NAME>
            <LONG_NAME>Computed Tomography</LONG_NAME>
            <CON_ID>2202436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3351747</PublicId>
      <PreferredName>3351747v1.0</PreferredName>
      <PreferredDefinition>Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_TNM staging performed with access to clinical information only._The data or image obtained by gathering information with a sensing device._The result of an action._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Prostate Cancer Clinical TNM Finding Scan Result Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3351871</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3351871v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Carcinoma Clinical TNM Finding Scan Outcome Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4863</PREFERRED_NAME>
            <LONG_NAME>Prostate Carcinoma</LONG_NAME>
            <CON_ID>2237042</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48881</PREFERRED_NAME>
            <LONG_NAME>Clinical TNM Finding</LONG_NAME>
            <CON_ID>2434282</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17999</PREFERRED_NAME>
            <LONG_NAME>Scan</LONG_NAME>
            <CON_ID>2202631</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extraprostatic Extension, Regional Lymphadenopathy [e.g., cN1]</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer cN1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3351759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Distant Metastasis [e.g., cM1]</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer cM1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer with distant metastasis. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3351757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extraprostatic Extension, Localized (e.g., seminal vesicles)</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer pT3b TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer extending beyond the capsule of the prostate gland, with involvement of the seminal vesicles. (from AJCC 6th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2833389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Evidence of Extraprostatic Extension</VALIDVALUE>
          <VALUEMEANING>No Evidence of Extraprostatic Extension</VALUEMEANING>
          <MEANINGDESCRIPTION>Diagnostic tests fail to detect presence of metastatic lesions._Situated outside of the prostate._The spread or migration of cancer cells through the wall of an organ into surrounding organs and/or adjacent tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120271, C25505, C48558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3351760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CT Scan Results</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CT Scan Results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical prad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3788453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>diagnostic_ct_abd_pelvis_result</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="523">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3351916</PUBLICID>
    <LONGNAME>Prostate Cancer Second Recurrent Disease Biochemical Diagnosis Year Number</LONGNAME>
    <PREFERREDNAME>3351710v1.0:2896906v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the year of the second biochemical recurrence.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3351710</PublicId>
      <PreferredName>3351708v1.0:3351702v1.0</PreferredName>
      <PreferredDefinition>Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Coming next after the first in position in space or time or degree or magnitude._The return of a disease after a period of remission._Biochemical; of or relating to biochemistry; involving chemical processes in living organisms._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Prostate Carcinoma Second Recurrent Disease Biochemical Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3351708</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4863:C25666:C38155</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Carcinoma Second Recurrent Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4863</PREFERRED_NAME>
            <LONG_NAME>Prostate Carcinoma</LONG_NAME>
            <CON_ID>2237042</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3351702</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25434:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Biochemical Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25434</PREFERRED_NAME>
            <LONG_NAME>Biochemical</LONG_NAME>
            <CON_ID>2205255</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2896906</PublicId>
      <PreferredName>EVT_YR_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Event Year Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY </DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2896905</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29848:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Year Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year of Second Biochemical Re</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Year of Second Biochemical Recurrence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical prad followup  1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>year_of_second_biochemical_recurrence</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="524">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3357392</PUBLICID>
    <LONGNAME>Histologic Metastatic Nonmetastatic Choriocarcinoma Diagnosis Type</LONGNAME>
    <PREFERREDNAME>Hist_Meta_Nonm_Chor_Diag_Nonm_</PREFERREDNAME>
    <PREFERREDDEFINITION>Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3357388</PublicId>
      <PreferredName>Hist_Meta_Nonm_Chor_Diag</PreferredName>
      <PreferredDefinition>Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.</PreferredDefinition>
      <LongName>Histologic Metastatic Nonmetastatic Choriocarcinoma Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3379148</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C14174:C14148</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Metastatic Nonmetastatic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14148</PREFERRED_NAME>
            <LONG_NAME>Nonmetastatic</LONG_NAME>
            <CON_ID>3357384</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3357386</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2948:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Choriocarcinoma Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2948</PREFERRED_NAME>
            <LONG_NAME>Choriocarcinoma</LONG_NAME>
            <CON_ID>2204755</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3357390</PublicId>
      <PreferredName>Nonm_Meta_Chor_Diag_Type</PreferredName>
      <PreferredDefinition>Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Basis; the fundamental assumptions underlying an explanation or a relation that provides the foundation for something._Type; a subdivision of a particular kind of thing._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Nonmetastatic Choriocarcinoma Diagnosis Basis Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3357389</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3357389v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Nonmetastatic Choriocarcinoma Diagnosis Basis Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14148</PREFERRED_NAME>
            <LONG_NAME>Nonmetastatic</LONG_NAME>
            <CON_ID>3357384</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2948</PREFERRED_NAME>
            <LONG_NAME>Choriocarcinoma</LONG_NAME>
            <CON_ID>2204755</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25430</PREFERRED_NAME>
            <LONG_NAME>Basis</LONG_NAME>
            <CON_ID>2203857</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes-Metastatic choriocarcinoma</VALIDVALUE>
          <VALUEMEANING>Choriocarcinoma Metastatic Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004: A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3261, C2948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes-Non-metastatic choriocarcinoma</VALIDVALUE>
          <VALUEMEANING>Nonmetastatic Choriocarcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has not spread from the primary site (place where it started) to other places in the body.: An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2948, C14148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-metastatic choriocarcinoma</VALIDVALUE>
          <VALUEMEANING>Nonmetastatic Choriocarcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has not spread from the primary site (place where it started) to other places in the body.: An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2948, C14148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have histolo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have histologically proven non-metastatic or metastatic choriocarcinoma?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Hist_Meta_Nonm_Chor_Diag_Nonm_</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="525">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3357637</PUBLICID>
    <LONGNAME>Cutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T Stage</LONGNAME>
    <PREFERREDNAME>3357533v1.0:3357548v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the primary melanoma of the skin based on evidence obtained from clinical assessment parameters determined prior to treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</ORIGIN>
    <REGISTRATIONSTATUS>Preferred Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3357533</PublicId>
      <PreferredName>2431290v1.0:2207100v1.0</PreferredName>
      <PreferredDefinition>A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma._Having to do with the examination and treatment of patients._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).</PreferredDefinition>
      <LongName>Cutaneous Melanoma Clinical T Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431290</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3510</PreferredName>
        <Version>1</Version>
        <LongName>Cutaneous Melanoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3510</PREFERRED_NAME>
            <LONG_NAME>Cutaneous Melanoma</LONG_NAME>
            <CON_ID>2431169</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207100</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25728</PreferredName>
        <Version>1</Version>
        <LongName>Clinical T Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3357548</PublicId>
      <PreferredName>3357548v1.0</PreferredName>
      <PreferredDefinition>A finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v7 classification system.  The TNM clinical and pathologic regional lymph nodes tumor classifications of cutaneous melanoma are not the same. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Cutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 T Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>3357547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88378:C39315:C25728:C16899</PreferredName>
        <Version>1</Version>
        <LongName>Cutaneous Melanoma TNM Finding v7 American Joint Committee on Cancer T Stage Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88378</PREFERRED_NAME>
            <LONG_NAME>Cutaneous Melanoma TNM Finding v7</LONG_NAME>
            <CON_ID>3357546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT2 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 1.01 to 2 mm in thickness, with or without ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2a</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT2a TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 1.01 to 2 mm in thickness, with no ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48846</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2b</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT2b TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 1.01 to 2 mm thick, with ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T3</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT3 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 2.01 to 4 mm thick, with or without ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T3a</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT3a TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 2.01 to 4 mm in thickness, with no ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T3b</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT3b TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma 2.01 to 4 mm thick, with ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T4</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT4 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma greater than 4.0 mm in thickness, with or without ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T4a</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT4a TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma greater than 4.0 mm in thickness, without ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T4b</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT4b TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma greater than 4.0 mm in thickness, with ulceration. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tis</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pTis TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma in situ. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1b</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT1b TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, with ulceration or mitoses equal to or more than 1/mm2. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1a</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT1a TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, without ulceration and with mitosis less than 1/mm2. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T0</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pT0 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma with no evidence of primary tumor. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TX</VALIDVALUE>
          <VALUEMEANING>Cutaneous Melanoma pTX TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Cutaneous melanoma in which the primary tumor cannot be assessed (e.g., curettaged or severely regressed melanoma). (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Clinical T Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Clinical T Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>T</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>T</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TNM Staging: T Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cutaneous Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434439</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461150</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cutaneous Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000347</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AJCCT</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MELANM_TUMOR_C_T_STG</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="526">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3361878</PUBLICID>
    <LONGNAME>Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Upper Limit of Normal Outcome Human Chorionic Gonadotropin Beta Subunit Value</LONGNAME>
    <PREFERREDNAME>LP_BHCG_ULN_VALU</PREFERREDNAME>
    <PREFERREDDEFINITION>Value of upper limit of normal of beta-hCG.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3361875</PublicId>
      <PreferredName>Labo_Huma_Uppe_Outc</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Upper Limit of Normal Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3396646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17479:C25706:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Human Chorionic Gonadotropin Beta Subunit Upper Limit of Normal Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17479</PREFERRED_NAME>
            <LONG_NAME>Choriogonadotropin Subunit Beta 3</LONG_NAME>
            <CON_ID>2633457</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25706</PREFERRED_NAME>
            <LONG_NAME>Upper Limit of Normal</LONG_NAME>
            <CON_ID>2203609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3361882</PublicId>
      <PreferredName>Huma_Valu</PreferredName>
      <PreferredDefinition>The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Human Chorionic Gonadotropin Beta Subunit Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3361881</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17479:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Human Chorionic Gonadotropin Beta Subunit Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17479</PREFERRED_NAME>
            <LONG_NAME>Choriogonadotropin Subunit Beta 3</LONG_NAME>
            <CON_ID>2633457</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please provide the beta-hCG u</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please provide the beta-hCG upper limit of normal at the testing laboratory</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Institutional normal for serum hCGB (mIU/mL)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Institutional normal for CSF hCGB (mIU/mL)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Beta-HCG  (mIU/mL) ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LP_BHCG_ULN_VALU</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="527">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3364720</PUBLICID>
    <LONGNAME>Systemic Therapy And/Or Intrathecal Route of Administration Therapeutic Procedure Cycle Administered Count Missing Value Reason Indicator</LONGNAME>
    <PREFERREDNAME>2763973v1.0:3292826v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An explanation that describes why the number of systemic and/or intrathecal therapy cycles are missing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2763973</PublicId>
      <PreferredName>SYS_AO_IRA_TP_CYC_AD</PreferredName>
      <PreferredDefinition>(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._Used to indicate that either or both of two items or options may be valid._Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Systemic Therapy And/Or Intrathecal Route of Administration Therapeutic Procedure Cycle Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2769834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15698:C48928:C38267:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Therapy And/Or Intrathecal Route of Administration Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15698</PREFERRED_NAME>
            <LONG_NAME>Systemic Therapy</LONG_NAME>
            <CON_ID>2202843</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38267</PREFERRED_NAME>
            <LONG_NAME>Intrathecal Route of Administration</LONG_NAME>
            <CON_ID>2453306</CON_ID>
            <DEFINITION_SOURCE>FDA</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2763971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25472:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Cycle Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3292826</PublicId>
      <PreferredName>3292826v1.0</PreferredName>
      <PreferredDefinition>To determine the number or amount of something; the result of this activity._A specific reason explaining why a meaningful value is not available.  A meaningful value answers the question posed by a Data Element Concept.  In contrast, a Missing Value Reason answers the implicit question &quot;Why is there no &#39;meaningful&#39; value?&quot;, when there is none._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Count Missing Value Reason Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3293661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463:C48655:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Count Missing Value Reason Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48655</PREFERRED_NAME>
            <LONG_NAME>Missing Value Reason</LONG_NAME>
            <CON_ID>2431146</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-quantitative</VALIDVALUE>
          <VALUEMEANING>Negation Quantitative</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of being estimated or expressed with numeric values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70766, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2777712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not measurable</VALIDVALUE>
          <VALUEMEANING>Non-Measurable</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-Measurable; not possible to be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2678954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Negation Test</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47891, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown/not applicable</VALIDVALUE>
          <VALUEMEANING>Unknown Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.: Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660, C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the reason for the sy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the reason for the systemic therapy and/or intrathecal therapeutic procedure cycle administered count missing value?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the reason for the number of cycles missing value?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the reason for the number of cycles missing value?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:3364720</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedSubstanceAdministration.negationIndicator(BL).nullFlavor WHERE PerformedSubstanceAdministration &gt; DefinedSubstanceAdministration.nameCode = {Specified substance administration therapy} AND DefinedSubstanceAdministration.routeOfAdministrationCode = &quot;Intrathecal&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2010r1: Acute Myelogenous Leukemia Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2011r1: ALL Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964928</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>all_base_tx_num_cyc_unk</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_base_tx_num_cyc_unk</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedSubstanceAdministration:negationIndicator</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="528">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3366930</PUBLICID>
    <LONGNAME>Lymphoma Therapeutic Procedure Administered Other Specify Text</LONGNAME>
    <PREFERREDNAME>3366928v1.0:2857322v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term or abbreviation to represent another name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma that was not already mentioned or specified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3366928</PublicId>
      <PreferredName>2475110v1.0:3366926v1.0</PreferredName>
      <PreferredDefinition>A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._Different than the one(s) previously specified or mentioned._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Lymphoma Other Therapeutic Procedure Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475110</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3208</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3366926</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C49236:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Other Therapeutic Procedure Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If Other Pharmaceutical Regim</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If Other Pharmaceutical Regimen, Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="529">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3370090</PUBLICID>
    <LONGNAME>Computed Tomography Colonography Performed Date</LONGNAME>
    <PREFERREDNAME>CT_CLNGRPHY_PERF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Records the date of Virtual Colonoscopy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3364657</PublicId>
      <PreferredName>3364579v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>An imaging technique of the colon involving helical computed tomography and computer software to generate high-resolution 2-dimensional and 3-dimensional images of the inner surface of the colon. These images are then interpreted by a radiologist to determine the presence of several types of abnormalities of the colon._Performed; carried out.</PreferredDefinition>
      <LongName>Computed Tomography Colonography Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3364579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28395</PreferredName>
        <Version>1</Version>
        <LongName>Computed Tomography Colonography</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28395</PREFERRED_NAME>
            <LONG_NAME>Computed Tomography Colonography</LONG_NAME>
            <CON_ID>3364578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3364658</PublicId>
      <PreferredName>ALPHA_DVG_UNK_DT</PreferredName>
      <PreferredDefinition>Oracle&#39;s Discrete Value Group (DVG): Date used with a text Unknown indicator.</PreferredDefinition>
      <LongName>Alpha DVG for  Unknown or Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <Datatype>Date Alpha DVG</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Virtual Colonoscopy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Virtual Colonoscopy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="530">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3377210</PUBLICID>
    <LONGNAME>Liver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N Stage</LONGNAME>
    <PREFERREDNAME>2452427v1.0:3376981v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the regional lymph node involvement for the hepatocellular carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</ORIGIN>
    <REGISTRATIONSTATUS>Preferred Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2452427</PublicId>
      <PreferredName>LIVER_TUMOR_C_N_S</PreferredName>
      <PreferredDefinition>information related to clinical evaluated N stage of a large organ located in the upper abdomen that cleanses the blood and aids in digestion by secreting bile (the liver).</PreferredDefinition>
      <LongName>Liver Tumor Clinical N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2452420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Liver Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428496</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Clinical N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3376981</PublicId>
      <PreferredName>3376981v1.0</PreferredName>
      <PreferredDefinition>A finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system.  Intrahepatic bile duct cancers are no longer included in this classification.  The staging of liver cancer now includes only hepatocellular carcinoma. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. N refers to the extent of lymph node involvement._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Liver Cancer American Joint Committee on Cancer (AJCC) Edition 7 N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>3376980</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C90149:C39315:C25580:C16899</PreferredName>
        <Version>1</Version>
        <LongName>Liver Cancer TNM Finding v7 American Joint Committee on Cancer N Stage Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C90149</PREFERRED_NAME>
            <LONG_NAME>Liver Cancer TNM Finding v7</LONG_NAME>
            <CON_ID>3376977</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Liver Cancer pN1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Liver cancer with regional lymph node metastasis. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3179795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>Liver Cancer pN0 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Liver cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3179797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>Liver Cancer pNX TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Liver cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3179799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Clinical N Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Clinical N Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Liver</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434440</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461150</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Liver</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000291</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="531">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3412557</PUBLICID>
    <LONGNAME>Off Treatment Contribution Reason</LONGNAME>
    <PREFERREDNAME>OFF_TX_CBT_DES_RSN</PREFERREDNAME>
    <PREFERREDDEFINITION>The reason for the discontinuation of protocol therapy in an explanation of the contributing cause of Off-Treatment; the phase of a protocol during which a patient does not receive treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3397319</PublicId>
      <PreferredName>2184317v1.0:3397317v1.0</PreferredName>
      <PreferredDefinition>An explanation of the contributing cause of Off-Treatment; the phase of a protocol during which a patient does not receive treatment.</PreferredDefinition>
      <LongName>Off Treatment Contribution Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184317</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Off-Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Off-Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3384623</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61412:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Contribution Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61412</PREFERRED_NAME>
            <LONG_NAME>Contribution</LONG_NAME>
            <CON_ID>2512710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3389970</PublicId>
      <PreferredName>Disc_Reas</PreferredName>
      <PreferredDefinition>The reason for the discontinuation of protocol therapy.</PreferredDefinition>
      <LongName>Therapeutic Procedure Discontinued Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2322180</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25484:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Discontinued Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25484</PREFERRED_NAME>
            <LONG_NAME>Discontinue</LONG_NAME>
            <CON_ID>2203906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>176</VALIDVALUE>
          <VALUEMEANING>Patient experiences Grade 2 or greater SOS</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient experiences Grade 2 or greater SOS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6144268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Germinoma (Stratum 2) patients with PD and positive markers at the end of Induction chemotherapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Germinoma (Stratum 2) patients with PD and positive markers at the end of Induction chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma) after second look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma) after second look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Radiotherapy cannot be initiated within 6 weeks after completion of Induction chemotherapy or within 31 days after second look surgery. (See Sections 15.2.3 and 15.2.4).</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiotherapy cannot be initiated within 6 weeks after completion of Induction chemotherapy or within 31 days after second look surgery. (See Sections 15.2.3 and 15.2.4).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Progressive disease and/or increasing markers at the end of Induction chemotherapy, following second look surgery or during radiation therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease and/or increasing markers at the end of Induction chemotherapy, following second look surgery or during radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>NGGCT (Stratum 1) patients with &lt; PR after second look surgery or any viable tumor after second look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>NGGCT (Stratum 1) patients with &lt; PR after second look surgery or any viable tumor after second look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3421708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>NGGCT (Stratum 1) patients with positive markers at the end of Induction chemotherapy or who have &lt; PR after Induction chemotherapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>NGGCT (Stratum 1) patients with positive markers at the end of Induction chemotherapy or who have &lt; PR after Induction chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3421710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Withdrawal of consent for any further data submissions</VALUEMEANING>
          <MEANINGDESCRIPTION>Withdrawal of consent for any further data submissions</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG study with tumor therapeutic intent</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG study with tumor therapeutic intent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Patient is enrolled but rechecked labs are outside the limits of eligibility prior to starting therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is enrolled but rechecked labs are outside the limits of eligibility prior to starting therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Completion of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3030997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Progressive Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is increasing in scope or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Germinoma (Stratum 2) patients who are unable to undergo second look surgery due to safety concerns or &lt;PR without second look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Germinoma (Stratum 2) patients who are unable to undergo second look surgery due to safety concerns or &lt;PR without second look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3421711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Development of second malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)_Coming next after the first in position in space or time or degree or magnitude._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9305, C25666, C18732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Lost to follow-up</VALUEMEANING>
          <MEANINGDESCRIPTION>The loss or lack of continuation of subject participation after a study has officially closed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Physician determines it is in patient&#39;s best interest</VALUEMEANING>
          <MEANINGDESCRIPTION>Physician determines it is in patient&#39;s best interest</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Progressive disease with increasing markers during Induction chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease with increasing markers during Induction chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Refusal of further protocol therapy by patient/parent/guardian</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal of further protocol therapy by patient/parent/guardian</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>Patients who do not meet criteria to start next treatment cycle within 21 days after planned subsequent cycle start date (&gt;= 3 week delay in start of next cycle)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who do not meet criteria to start next treatment cycle within 21 days after planned subsequent cycle start date (&gt;= 3 week delay in start of next cycle)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3574983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>Completion of maximum allowable number of cycles of therapy (section 4.1)</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of maximum allowable number of cycles of therapy (section 4.1)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3574984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>Intolerance of study therapy as described in Section 5</VALUEMEANING>
          <MEANINGDESCRIPTION>Intolerance of study therapy as described in Section 5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3574985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies are outside the parameters required for eligibility (section  3.2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies are outside the parameters required for eligibility (section  3.2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3574986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>Initiation of other non-protocol anti-cancer therapy prior to completion of BuMel transplant and local radiation</VALUEMEANING>
          <MEANINGDESCRIPTION>Initiation of other non-protocol anti-cancer therapy prior to completion of BuMel transplant and local radiation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3649117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>Patient unable to meet criteria to begin consolidation therapy within 12 weeks from the start of cycle 5 induction therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient unable to meet criteria to begin consolidation therapy within 12 weeks from the start of cycle 5 induction therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3652351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>Grade 4 organ toxicity during Induction not related to underlying infection or metabolic derangement that fails to resolve to &lt; Grade 2 or cannot be controlled by treatment by 8 weeks from last cycle of Induction chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 4 organ toxicity during Induction not related to underlying infection or metabolic derangement that fails to resolve to &lt; Grade 2 or cannot be controlled by treatment by 8 weeks from last cycle of Induction chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>Patients unable to receive radiotherapy and will have completed Consolidation phase of treatment at the time of initiation of any subsequent therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients unable to receive radiotherapy and will have completed Consolidation phase of treatment at the time of initiation of any subsequent therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>Progressive disease at the end of cycle 4 or 5 of Induction therapy or any time after BuMel Consolidation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease at the end of cycle 4 or 5 of Induction therapy or any time after BuMel Consolidation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Criteria to proceed to HCT not met within 1 year of enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Criteria to proceed to HCT not met within 1 year of enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-05-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3755511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>RELAPSE</VALUEMEANING>
          <MEANINGDESCRIPTION>RELAPSE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>Completion of planned therapy and post-therapy sample collections</VALUEMEANING>
          <MEANINGDESCRIPTION>To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: Planned; devised, contrived, or formed in design.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Occurring after a procedure.
: Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.: The act of gathering things together; having been brought together in one place.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37912, C49236, C25619, C25250, C25453, C70699, C54735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>3, 4, 5, 6, 0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3762701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>33</VALIDVALUE>
          <VALUEMEANING>Study is terminated by Sponsor</VALUEMEANING>
          <MEANINGDESCRIPTION>Study is terminated by Sponsor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>43</VALIDVALUE>
          <VALUEMEANING>Pregnancy</VALUEMEANING>
          <MEANINGDESCRIPTION>The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>42</VALIDVALUE>
          <VALUEMEANING>Adverse Events requiring removal from protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Adverse Events requiring removal from protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>37</VALIDVALUE>
          <VALUEMEANING>Enrollment onto COG study ACCL0934</VALUEMEANING>
          <MEANINGDESCRIPTION>Enrollment onto another clinical protocol, Protocol # ACCL0934 sponsored by the Children&#39;s Oncology Group</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3904087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>36</VALIDVALUE>
          <VALUEMEANING>Emergent un-blinding</VALUEMEANING>
          <MEANINGDESCRIPTION>A protocol specific reason for being off-treatment due to emergent unblinding</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3903212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>35</VALIDVALUE>
          <VALUEMEANING>Patient received Sorafenib after study enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>A protocol-specific reason for patient to be off protocol therapy or off study due to administration of contraindicated medication (sorafenib) after time of patient enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3902411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>34</VALIDVALUE>
          <VALUEMEANING>A problem with skin integrity (generalized skin breakdown such as severe skin GVHD or other severe generalized skin disruption) judged by the attending physician to prevent administration of study treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>A protocol-specific reason for patient to be off protocol therapy or off study as determined by the physician that treatment cannot be administered due to severe skin disruption or breakdown</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3902412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>38</VALIDVALUE>
          <VALUEMEANING>Completion of planned study assessments</VALUEMEANING>
          <MEANINGDESCRIPTION>Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. : The final result of a determination of the value, significance, or extent of.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25250, C0679207, C15206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3905685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Any skin reaction thought to be caused by allergy to the cleansing product</VALUEMEANING>
          <MEANINGDESCRIPTION>Any skin reaction thought to be caused by allergy to the cleansing product.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3905728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>41</VALIDVALUE>
          <VALUEMEANING>Any non-allergic skin reaction &gt;= Grade 3 possibly, probably, or definitely related to the cleansing product</VALUEMEANING>
          <MEANINGDESCRIPTION>Any non-allergic skin reaction greater or equal to Grade 3 that is possibly, probably, or definitely related to the cleansing product.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3905727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>46</VALIDVALUE>
          <VALUEMEANING>Breastfeeding</VALUEMEANING>
          <MEANINGDESCRIPTION>Breastfeeding</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3983811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>45</VALIDVALUE>
          <VALUEMEANING>Non-compliance that in the opinion of the investigator does not allow for ongoing participation.</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-compliance that in the opinion of the investigator does not allow for ongoing participation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3983812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>44</VALIDVALUE>
          <VALUEMEANING>Patients received concurrent anticancer or investigational therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients received concurrent anticancer or investigational therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3983813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>Central artery occlusion after an injection which does not recanalize prior to the subsequent injection</VALUEMEANING>
          <MEANINGDESCRIPTION>Central artery occlusion after an injection which does not recanalize prior to the subsequent injection</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4142253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>Positive disease found in the contralateral eye after receiving protocol treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>Positive disease found in the contralateral eye after receiving protocol treatment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4142254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>Enucleation occurred prior to any Melphalan injection.</VALUEMEANING>
          <MEANINGDESCRIPTION>Enucleation occurred prior to any Melphalan injection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>50</VALIDVALUE>
          <VALUEMEANING>Massive/Profound intra-vitreal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>Massive/Profound intra-vitreal hemorrhage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>49</VALIDVALUE>
          <VALUEMEANING>Occurrence of metastases</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurrence of metastases</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>48</VALIDVALUE>
          <VALUEMEANING>Intraocular progression of disease is documented by the institutional assessment.</VALUEMEANING>
          <MEANINGDESCRIPTION>Intraocular progression of disease is documented by the institutional assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>47</VALIDVALUE>
          <VALUEMEANING>Any non-protocol chemotherapy or external beam radiation therapy is given.</VALUEMEANING>
          <MEANINGDESCRIPTION>Any non-protocol chemotherapy or external beam radiation therapy is given.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>VHR T-LLy with biopsy-proven persistent disease and/or morphologically positive bone marrow at end of 3 HR Intensification Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>VHR T-LLy with biopsy-proven persistent disease and/or morphologically positive bone marrow at end of 3 HR Intensification Blocks</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4436911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>Mandatory baseline specimens not submitted (patient declared ineligible)</VALUEMEANING>
          <MEANINGDESCRIPTION>The scientific study of living organisms.: A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.: Data from an original source is not present, accessible or ready for use or service.: Something that is a necessary condition; something that is obligatory.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25652, C67329, C63536, C16345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity due to protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity due to protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4264211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>39</VALIDVALUE>
          <VALUEMEANING>Entry onto another COG therapeutic protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>Entry onto another COG therapeutic protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity due to protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity due to protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4236871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>Metastatic disease progression at any time during treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>Metastatic disease progression at any time during treatment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4359387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>Patients who meet Group B clinical criteria but whose tumors are found to have unfavorable histology and/or unfavorable genomic features</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who meet Group B clinical criteria but whose tumors are found to have unfavorable histology and/or unfavorable genomic features</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4359388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>Group B patients who fail to achieve a PR or better after 8 cycles of First-Line ANBL1232 chemotherapy +/- surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Group B patients who fail to achieve a PR or better after 8 cycles of First-Line ANBL1232 chemotherapy +/- surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4359525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>Developed a new metastatic site at any time during treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>Developed a new metastatic site at any time during treatment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4359738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>Group A patients with disease progression or persistently elevated urine or serum catecholamines who go on to have surgical resection.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group A patients with disease progression or persistently elevated urine or serum catecholamines who go on to have surgical resection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4363991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>Progressive disease - Unable to control disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease - Unable to control disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4155114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>Patients found to have high-risk neuroblastoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients found to have high-risk neuroblastoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4351859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>Group B patients with unfavorable histology and/or unfavorable genomic features</VALUEMEANING>
          <MEANINGDESCRIPTION>Group B patients with unfavorable histology and/or unfavorable genomic features</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4351860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>Surgery or radiation performed on any site of measurable disease before the end of the 5th cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery or radiation performed on any site of measurable disease before the end of the 5th cycle</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4297021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>Biopsy positive viable tumor after completion of Metastatic Site Radiation</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy positive viable tumor after completion of Metastatic Site Radiation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4251211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>Biopsy positive residual bone marrow metastatic disease by routine morphology at the end-Consolidation</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy positive residual bone marrow metastatic disease by routine morphology at the end-Consolidation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4251212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>Failure to recover from surgery within 6 weeks</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to recover from surgery within 6 weeks</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4313180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>VHR T-ALL who have an M2/M3 marrow and/or detectable MRD at the end of the 3 HR Intensification Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>VHR T-ALL who have an M2/M3 marrow and/or detectable MRD at the end of the 3 HR Intensification Blocks</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4409051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>Group B patients who fail to achieve a PR or better after 8 cycles of first-line ANBL1232 chemotherapy +/- surgery or who experience metastatic disease progression at any time during treatment.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group B patients who fail to achieve a PR or better after 8 cycles of first-line ANBL1232 chemotherapy +/- surgery or who experience metastatic disease progression at any time during treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4377784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of First-Line ANBL1232 chemotherapy or who develop a new metastatic site at any time during treatment.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of First-Line ANBL1232 chemotherapy or who develop a new metastatic site at any time during treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4378100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>Relapse/Progression</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse/Progression</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4404349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>Inevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>No imaging/ measurement is done at all at a particular time point</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3859385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>Identified to have Ph+ T-LLy</VALUEMEANING>
          <MEANINGDESCRIPTION>Identified to have Ph+ T-LLy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4400358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>Identified to have Ph+ T-ALL</VALUEMEANING>
          <MEANINGDESCRIPTION>Identified to have Ph+ T-ALL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4400359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>Pre-Randomization (HR/IR or LR): Interval development of significant central nervous system pathology that would preclude treatment with blinatumomab (see Section 3.2.5.13 for definition)</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Randomization (HR/IR or LR): Interval development of significant central nervous system pathology that would preclude treatment with blinatumomab (see Section 3.2.5.13 for definition)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4515178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>Treatment failure but not eligible to receive blinatumomab salvage</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment failure but not eligible to receive blinatumomab salvage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4515179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>Found to be ineligible for HSCT  (see section 4.9.1)</VALUEMEANING>
          <MEANINGDESCRIPTION>Found to be ineligible for HSCT  (see section 4.9.1)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4518048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>Second relapse at any site</VALUEMEANING>
          <MEANINGDESCRIPTION>Second relapse at any site</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4522737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>90</VALIDVALUE>
          <VALUEMEANING>Group C patients who develop a new metastatic lesion at any time during treatment.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group C patients who develop a new metastatic lesion at any time during treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4671231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>89</VALIDVALUE>
          <VALUEMEANING>Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of first-line ANBL1232 chemotherapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group C patients who fail to achieve a PR or better and resolution of symptoms after 8 cycles of first-line ANBL1232 chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4671232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>87</VALIDVALUE>
          <VALUEMEANING>Group B patients who experience metastatic disease progression at any time during treatment.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group B patients who experience metastatic disease progression at any time during treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4671234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>86</VALIDVALUE>
          <VALUEMEANING>Group A patients who go on to have surgical resection and have completed a 60 day evaluation period following resection.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group A patients who go on to have surgical resection and have completed a 60 day evaluation period following resection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4671235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>85</VALIDVALUE>
          <VALUEMEANING>Group A patients who experience disease progression and do not go on to have surgical resection.</VALUEMEANING>
          <MEANINGDESCRIPTION>Group A patients who experience disease progression and do not go on to have surgical resection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4671236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>Treatment failure that receives Blinatumomab salvage but does not achieve CR</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment failure that receives Blinatumomab salvage but does not achieve CR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-11-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4570754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>83</VALIDVALUE>
          <VALUEMEANING>RQ-PCR determines patient to be PML-RARα negative at diagnosis or RQ-PCR inevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>RQ-PCR determines patient to be PML-RAR&amp;#945; negative at diagnosis or RQ-PCR inevaluable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4645860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>84</VALIDVALUE>
          <VALUEMEANING>RQ-PCR sample not collected prior to initiation of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>RQ-PCR sample not collected prior to initiation of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4645859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>96</VALIDVALUE>
          <VALUEMEANING>Progressive disease with positive or increasing markers at the end of Induction chemotherapy, following second-look surgery or during radiation therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease with positive or increasing markers at the end of Induction chemotherapy, following second-look surgery or during radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4720754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>103</VALIDVALUE>
          <VALUEMEANING>Patient did not receive protocol treatment after study enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient did not receive protocol treatment after study enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4865696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>102</VALIDVALUE>
          <VALUEMEANING>Fracture excluding pathological fracture at the site of osteosarcoma bone metastasis or fracture at the site of prior orthopedic surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Fracture excluding pathological fracture at the site of osteosarcoma bone metastasis or fracture at the site of prior orthopedic surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4835731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>101</VALIDVALUE>
          <VALUEMEANING>Osteonecrosis of the jaw</VALUEMEANING>
          <MEANINGDESCRIPTION>Osteonecrosis of the jaw</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4835732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>113</VALIDVALUE>
          <VALUEMEANING>Failure to obtain a result for the MRD test at the end of Induction I</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to obtain a result for the MRD test at the end of Induction I</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>111</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4854741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>110</VALIDVALUE>
          <VALUEMEANING>Grade 3 or  greater neurotoxicity, myelitis and nervous system disorder, and other, including cerebellar toxicity from HD Ara-C</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 or  greater neurotoxicity, myelitis and nervous system disorder, and other, including cerebellar toxicity from HD Ara-C</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>112</VALIDVALUE>
          <VALUEMEANING>Patient received concurrent anticancer or investigational therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient received concurrent anticancer or investigational therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4861212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>104</VALIDVALUE>
          <VALUEMEANING>Persistent CNS leukemia after 6 doses of IT Arac-C after Induction I</VALUEMEANING>
          <MEANINGDESCRIPTION>Persistent CNS leukemia after 6 doses of IT Arac-C after Induction I</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>105</VALIDVALUE>
          <VALUEMEANING>PR, RD, or relapse following Induction II</VALUEMEANING>
          <MEANINGDESCRIPTION>PR, RD, or relapse following Induction II</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>106</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>108</VALIDVALUE>
          <VALUEMEANING>Surgery or radiation performed in a patient who has not achieved a confirmed complete or partial response</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery or radiation performed in a patient who has not achieved a confirmed complete or partial response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4883091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>109</VALIDVALUE>
          <VALUEMEANING>Completion of planned therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of planned therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>98</VALIDVALUE>
          <VALUEMEANING>Germinoma (Stratum 2) patients who are unable to undergo second-look surgery due to safety concerns and they do not meet the criteria for at least PR with &lt;= 1.5 cm residual disease without second-look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Germinoma (Stratum 2) patients who are unable to undergo second-look surgery due to safety concerns and they do not meet the criteria for at least PR with &lt;= 1.5 cm residual disease without second-look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4740555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100</VALIDVALUE>
          <VALUEMEANING>Relapse during Consolidation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse during Consolidation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4770781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Failure to achieve molecular remission following the MRD Positive Consolidation cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to achieve molecular remission following the MRD Positive Consolidation cycle</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4770782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>91</VALIDVALUE>
          <VALUEMEANING>Failure to achieve hCR/hCRi by Day 70 of induction</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to achieve hCR/hCRi by Day 70 of induction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4770783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>92</VALIDVALUE>
          <VALUEMEANING>Refractory CNS leukemia following 6 doses of intrathecal therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Refractory CNS leukemia following 6 doses of intrathecal therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4770784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>95</VALIDVALUE>
          <VALUEMEANING>Radiotherapy cannot be initiated within 6 weeks after Day 1 of the last cycle of Induction chemotherapy or within 31 days after second-look surgery (Sections 15.2.3 and 15.2.4).</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiotherapy cannot be initiated within 6 weeks after Day 1 of the last cycle of Induction chemotherapy or within 31 days after second-look surgery (Sections 15.2.3 and 15.2.4).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>94</VALIDVALUE>
          <VALUEMEANING>Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma, fibrosis, scar or non-viable tumor) after second-look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Germinoma (Stratum 2) patients with any viable tumor (except mature teratoma, fibrosis, scar or non-viable tumor) after second-look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>93</VALIDVALUE>
          <VALUEMEANING>NGGCT (Stratum 1) patients with &lt; PR after second look surgery or any viable tumor (except mature teratoma) after second-look surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>NGGCT (Stratum 1) patients with &lt; PR after second look surgery or any viable tumor (except mature teratoma) after second-look surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>97</VALIDVALUE>
          <VALUEMEANING>NGGCT (Stratum 1) patients who are unable to undergo second-look surgery due to safety or other reasons and do not meet criteria for CR/PR (imaging and tumor markers).</VALUEMEANING>
          <MEANINGDESCRIPTION>NGGCT (Stratum 1) patients who are unable to undergo second-look surgery due to safety or other reasons and do not meet criteria for CR/PR (imaging and tumor markers).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4720751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>117</VALIDVALUE>
          <VALUEMEANING>Treatment failure</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment failure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5067151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>115</VALIDVALUE>
          <VALUEMEANING>The fifth anniversary of the date the patient was enrolled on this study.</VALUEMEANING>
          <MEANINGDESCRIPTION>The fifth anniversary of the date the patient was enrolled on this study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5098831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>116</VALIDVALUE>
          <VALUEMEANING>Relapsed disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapsed disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5067152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>114</VALIDVALUE>
          <VALUEMEANING>Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>121</VALIDVALUE>
          <VALUEMEANING>Progressive disease or relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease or relapse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5166202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>122</VALIDVALUE>
          <VALUEMEANING>FOXO1 fusion positive with Group IV/Stage 4 disease</VALUEMEANING>
          <MEANINGDESCRIPTION>FOXO1 fusion positive with Group IV/Stage 4 disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5166201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>123</VALIDVALUE>
          <VALUEMEANING>Refusal to transfer to Regimen C for patients meeting eligibility requirements for Regimen C</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal to transfer to Regimen C for patients meeting eligibility requirements for Regimen C</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5166200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>119</VALIDVALUE>
          <VALUEMEANING>FOXO1 fusion status not determined by the institution by Day 21</VALUEMEANING>
          <MEANINGDESCRIPTION>FOXO1 fusion status not determined by the institution by Day 21</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>124</VALIDVALUE>
          <VALUEMEANING>Relapse/Progressive disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse/Progressive disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>127</VALIDVALUE>
          <VALUEMEANING>Patient became pregnant</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient became pregnant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>126</VALIDVALUE>
          <VALUEMEANING>Patient could not begin treatment within 36 days after definitive surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient could not begin treatment within 36 days after definitive surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>125</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies are outside the parameters required for eligibility (Section 3.3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies are outside the parameters required for eligibility (Section 3.3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>128</VALIDVALUE>
          <VALUEMEANING>Maintenance cannot be initiated within 6 weeks after completion of radiation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Maintenance cannot be initiated within 6 weeks after completion of radiation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5252615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>135</VALIDVALUE>
          <VALUEMEANING>Assigned to Arm LMP-TC without an available matched LMP-specific T cell product</VALUEMEANING>
          <MEANINGDESCRIPTION>Assigned to Arm LMP-TC without an available matched LMP-specific T cell product</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5509530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>136</VALIDVALUE>
          <VALUEMEANING>Assigned to Arm LMP-TC without HLA typing available by the Callback</VALUEMEANING>
          <MEANINGDESCRIPTION>Assigned to Arm LMP-TC without HLA typing available by the Callback</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5509529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>137</VALIDVALUE>
          <VALUEMEANING>Progressive disease after or during Course RTX2, Course LMP-TC1, Course LMP-TC2</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease after or during Course RTX2, Course LMP-TC1, Course LMP-TC2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5509531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>138</VALIDVALUE>
          <VALUEMEANING>Evidence of Hepatitis B or C infection during any course of treatment with rituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>Evidence of Hepatitis B or C infection during any course of treatment with rituximab</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5508822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>134</VALIDVALUE>
          <VALUEMEANING>Adverse events/side effects/complications</VALUEMEANING>
          <MEANINGDESCRIPTION>Adverse events/side effects/complications</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3090987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>133</VALIDVALUE>
          <VALUEMEANING>Relapse at any site after achieving remission</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse at any site after achieving remission</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5505893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>132</VALIDVALUE>
          <VALUEMEANING>Failure to achieve M1 marrow status following completion of Consolidation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to achieve M1 marrow status following completion of Consolidation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5505894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>131</VALIDVALUE>
          <VALUEMEANING>Two or more dose limiting toxicities (DLTs) in an individual patient</VALUEMEANING>
          <MEANINGDESCRIPTION>Two or more dose limiting toxicities (DLTs) in an individual patient</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5505895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>130</VALIDVALUE>
          <VALUEMEANING>Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 50</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 50</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5505896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>129</VALIDVALUE>
          <VALUEMEANING>Patients without KMT2A (MLL) rearranged leukemia following Induction and prior to EPI Block #1</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients without KMT2A (MLL) rearranged leukemia following Induction and prior to EPI Block #1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5505897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>140</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG anti-cancer therapeutic study (e.g., at recurrence) (section 8.2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG anti-cancer therapeutic study (e.g., at recurrence) (section 8.2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5577149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>139</VALIDVALUE>
          <VALUEMEANING>Patient experiences Grade 2 or greater SOS/VOD</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient experiences Grade 2 or greater SOS/VOD</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5577150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>148</VALIDVALUE>
          <VALUEMEANING>Patients with KMT2A-R leukemia who meet criteria to start EPI Block #1, following the treatment of 6 patients with azacitidine, but prior to completion of interim toxicity analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with KMT2A-R leukemia who meet criteria to start EPI Block #1, following the treatment of 6 patients with azacitidine, but prior to completion of interim toxicity analysis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5615617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>147</VALIDVALUE>
          <VALUEMEANING>Treatment failure as defined in Section 3.5.10</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment failure as defined in Section 3.5.10</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5603984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>146</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity (DLT related) due to protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity (DLT related) due to protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>145</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity (non-DLT related) due to protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity (non-DLT related) due to protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>144</VALIDVALUE>
          <VALUEMEANING>Progressive disease during Cycle 1 or 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease during Cycle 1 or 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>143</VALIDVALUE>
          <VALUEMEANING>Patient fails to achieve CR or CRi at the end of Cycle 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient fails to achieve CR or CRi at the end of Cycle 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>142</VALIDVALUE>
          <VALUEMEANING>CNS3 patient has persistent CNS3 disease after Cycle 1</VALUEMEANING>
          <MEANINGDESCRIPTION>CNS3 patient has persistent CNS3 disease after Cycle 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>141</VALIDVALUE>
          <VALUEMEANING>Patient is CNS2 or CNS3 or has persistent testicular or other extramedullary disease at the end of Cycle 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is CNS2 or CNS3 or has persistent testicular or other extramedullary disease at the end of Cycle 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>155</VALIDVALUE>
          <VALUEMEANING>Complete End Point Follow-up</VALUEMEANING>
          <MEANINGDESCRIPTION>To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.: The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16033, C25212, C25250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5702589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>151</VALIDVALUE>
          <VALUEMEANING>Resistant disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Resistant disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5659944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>150</VALIDVALUE>
          <VALUEMEANING>HR patients who receive any other chemotherapy pre-HSCT other than treatment specified in the protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>HR patients who receive any other chemotherapy pre-HSCT other than treatment specified in the protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5659945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>152</VALIDVALUE>
          <VALUEMEANING>Development of LBP-associated bacteremia</VALUEMEANING>
          <MEANINGDESCRIPTION>Development of LBP-associated bacteremia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5684627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>153</VALIDVALUE>
          <VALUEMEANING>Subject Unblinding Event Record Emergency</VALUEMEANING>
          <MEANINGDESCRIPTION>A record detailing the act of breaking the blind for an individual subject, urgently if needed, or when interim or final unblinding occurs. Treatment unblinding may be controlled by interactive response technology (IRT) or manually. [Adapted from TMF-RM]: A sudden unforeseen crisis that requires immediate action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62648, C115572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5699587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>149</VALIDVALUE>
          <VALUEMEANING>Tenth anniversary of the date the patient was enrolled on this study</VALUEMEANING>
          <MEANINGDESCRIPTION>Tenth anniversary of the date the patient was enrolled on this study</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5632753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>154</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Subject Unblinding Event Record</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A record detailing the act of breaking the blind for an individual subject, urgently if needed, or when interim or final unblinding occurs. Treatment unblinding may be controlled by interactive response technology (IRT) or manually. [Adapted from TMF-RM]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115572, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5702588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>156</VALIDVALUE>
          <VALUEMEANING>Progressive disease for patients receiving chemotherapy according to SR1 and SR2 treatment plan</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease for patients receiving chemotherapy according to SR1 and SR2 treatment plan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5630549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>157</VALIDVALUE>
          <VALUEMEANING>SR patients who decline randomization</VALUEMEANING>
          <MEANINGDESCRIPTION>SR patients who decline randomization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5658009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>158</VALIDVALUE>
          <VALUEMEANING>Toxicity requiring removal as defined in Section 5</VALUEMEANING>
          <MEANINGDESCRIPTION>Toxicity requiring removal as defined in Section 5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5630550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>159</VALIDVALUE>
          <VALUEMEANING>Neoplasm ALK Gene Defect History Thromboembolism</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: This gene is involved in brain development and neuronal specificity.: A failing or deficiency.: The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.: Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28195, C54625, C43429, C38184, C3262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>160</VALIDVALUE>
          <VALUEMEANING>Delay Therapeutic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49236, C25476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>166</VALIDVALUE>
          <VALUEMEANING>Completion of 12 cycles of therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of 12 cycles of therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5776341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>163</VALIDVALUE>
          <VALUEMEANING>Any Time Begin Cycle Three Until End Therapeutic Procedure Progressive Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>One, some, every, or all without specification.: The continuum of experience in which events pass from the future through the present to the past.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: Up to the point of some specific time or event.: The point or place at which something terminates in time, space, or extent.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A disease process that is increasing in scope or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35571, C49236, C25496, C65136, C66834, C25472, C25431, C25207, C81168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>162</VALIDVALUE>
          <VALUEMEANING>Inadequate To Support Arm Assignment Or Negation Ability Harvest Procedure Stem Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Not meeting a quantitative or qualitative measure necessary for a requirement.: Used as a function word to indicate direction, purpose, or movement.: Moral, psychological, physical, or financial aid or assistance; approval.: The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.: An allotting or an appointment to a particular person or use, or for a particular time or object.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Remove from a culture or a living or dead body, as for the purposes of transplantation.: An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12662, C37963, C78209, C25594, C37998, C25426, C32141, C37902, C65107, C69177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8, 9</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>161</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Consent Assignment Arm Or Parent Patient Guardian Refuse</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Permission to do something.: An allotting or an appointment to a particular person or use, or for a particular time or object.: The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A mother or a father; an immediate progenitor.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.: To decline to do, accept, give, or allow something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49161, C51828, C16960, C42709, C37998, C32141, C25426, C25460, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>167</VALIDVALUE>
          <VALUEMEANING>Patients initially enrolled and randomized with a diagnosis of Ewing sarcoma or PNET for whom the initial enrolling diagnosis is changed to a diagnosis other than Ewing sarcoma or PNET</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients initially enrolled and randomized with a diagnosis of Ewing sarcoma or PNET for whom the initial enrolling diagnosis is changed to a diagnosis other than Ewing sarcoma or PNET</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5907539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>164</VALIDVALUE>
          <VALUEMEANING>No Receive Allogeneic Conditioning</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: To take, accept, or get something offered.: A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation and to provide immunosuppression to prevent the rejection of the donor&#39;s stem cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107095, C25639, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5801514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>165</VALIDVALUE>
          <VALUEMEANING>Never Receive Transplant</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: To take, accept, or get something offered.: Used with organs, tissues, or cells for transplantation from one site to another within the same subject, or from one subject to another of the same species or different species.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0040733, C25639, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5826018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>168</VALIDVALUE>
          <VALUEMEANING>Patient Begin Date Therapeutic Procedure Greater Than Forty Two Day From Date Collection Material Established Diagnosis Rhabdomyosarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: Begin Date; the calendar date on which an event began.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: The particular day, month and year an event has happened or will happen.: The act of gathering things together; having been brought together in one place.: The tangible substance that goes into the makeup of a physical object.: Shown to be valid beyond a reasonable doubt.: The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.: A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3359, C15220, C71155, C48187, C25453, C25164, C25516, C25301, C66833, C105795, C61584, C49236, C25383, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6001119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>169</VALIDVALUE>
          <VALUEMEANING>Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 64</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with KMT2A (MLL) rearranged leukemia who do not meet the criteria to start EPI Block #1 by Day 64</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-01-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6059535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>175</VALIDVALUE>
          <VALUEMEANING>For Group B and D patients, failure to complete treatment assignment Callback following completion of Cycle 2 (Group B) or induction Block 3 (Group D) but before initiation of the next cycle of protocol-specified chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>For Group B and D patients, failure to complete treatment assignment Callback following completion of Cycle 2 (Group B) or induction Block 3 (Group D) but before initiation of the next cycle of protocol-specified chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>173</VALIDVALUE>
          <VALUEMEANING>Rapid central pathologic review (if applicable) is not completed within 14 days of enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Rapid central pathologic review (if applicable) is not completed within 14 days of enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>172</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity as defined in Section 5.0.</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity as defined in Section 5.0.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>171</VALIDVALUE>
          <VALUEMEANING>Failure to resume post-resection chemotherapy within 42 days of primary tumor resection</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to resume post-resection chemotherapy within 42 days of primary tumor resection</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>170</VALIDVALUE>
          <VALUEMEANING>Failure to begin protocol therapy within 14 days of biopsy or within 42 days of upfront surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to begin protocol therapy within 14 days of biopsy or within 42 days of upfront surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>174</VALIDVALUE>
          <VALUEMEANING>Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected HB patients who are either ≥ 8 years of age or have an AFP &lt; 100 at diagnosis who are found to have HCC by central review)</VALUEMEANING>
          <MEANINGDESCRIPTION>Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected HB patients who are either ≥ 8 years of age or have an AFP &lt; 100 at diagnosis who are found to have HCC by central review)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6080702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>186</VALIDVALUE>
          <VALUEMEANING>Patient failed to discontinue TKI within 5 working days of enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient failed to discontinue TKI within 5 working days of enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6381261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>187</VALIDVALUE>
          <VALUEMEANING>For patients who lose their molecular remission, patient fails to restart TKI within 7 calendar days from the date the RQ-PCR result becomes available</VALUEMEANING>
          <MEANINGDESCRIPTION>For patients who lose their molecular remission, patient fails to restart TKI within 7 calendar days from the date the RQ-PCR result becomes available</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6381260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>177</VALIDVALUE>
          <VALUEMEANING>Patient Negation Ability Begin Radiation Therapy Within Thirty One Day Definitive Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: On the inside; contained in.: A natural number greater than thirty and less than thirty-two and the quantity that it denotes.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Supplying or being a final or conclusive settlement or result.: The branch of medical science that treats disease or injury by operative procedures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173, C62607, C25301, C126863, C25282, C15313, C25431, C78209, C25594, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8, 9</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6369278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>178</VALIDVALUE>
          <VALUEMEANING>Patient Negation Ability Begin Protocol Agent Within Thirty Four Day Definitive Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An operation in which a term denies or inverts the meaning of another term or construction.: The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.: Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: A medical product, practice, or application that is tested in a clinical trial.: On the inside; contained in.: A natural number greater than twenty-nine and less than thirty-one and the quantity that it denotes.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.: Supplying or being a final or conclusive settlement or result.: The branch of medical science that treats disease or injury by operative procedures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173, C62607, C25301, C66835, C105797, C25282, C41161, C25431, C78209, C25594, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6369279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>185</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>184</VALIDVALUE>
          <VALUEMEANING>Surgical resection of tumor lesions that are increasing in size while on therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical resection of tumor lesions that are increasing in size while on therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>183</VALIDVALUE>
          <VALUEMEANING>Tumor is surgically resected within the first 12 weeks of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor is surgically resected within the first 12 weeks of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>182</VALIDVALUE>
          <VALUEMEANING>Response followed by progression</VALUEMEANING>
          <MEANINGDESCRIPTION>Response followed by progression</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>181</VALIDVALUE>
          <VALUEMEANING>Progressive disease of &gt;= 20% increase from baseline in tumor size that occurs &gt; 12 weeks after start of protocol therapy except pseudoprogression</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease of &gt;= 20% increase from baseline in tumor size that occurs &gt; 12 weeks after start of protocol therapy, except if a patient met the criteria for pseudoprogression in the first 12 weeks and the tumor subsequently stabilizes or decreases in size</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>180</VALIDVALUE>
          <VALUEMEANING>Progressive disease of &gt;= 40% increase from baseline in tumor size at any time during protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease of &gt;= 40% increase from baseline in tumor size at any time during protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>179</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another research study with tumor therapeutic intent</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another research study with tumor therapeutic intent (eg, at recurrence)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>198</VALIDVALUE>
          <VALUEMEANING>Development Severe Persistent Anemia Need Blood Transfusion To Maintenance Greater Than Or Same As Ten Gram Per Deciliter Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI): Intensely bad or unpleasant in degree, quality or extent.: Retained; never-ceasing.: A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.: Anything that is necessary but lacking; the psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior.: The infusion of components of blood or whole blood into the bloodstream. The blood may be donated from another person, or it may have been taken from the person earlier and stored until needed.: Used as a function word to indicate direction, purpose, or movement.: The act of sustaining something in its current form or proper condition; upkeep.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Equal, or closely similar or comparable, in kind or quality or quantity or degree.: In the same amount or manner; to the same degree; in the role, function, or capacity of.: A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: The metric unit of mass equal to one thousandth of a kil</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C64697, C65039, C48155, C69122, C64938, C64637, C37998, C61584, C53297, C65107, C15192, C41204, C2869, C43623, C70667, C18732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6411305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>188</VALIDVALUE>
          <VALUEMEANING>Patient stops taking TKI medication after restarting</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient stops taking TKI medication after restarting</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>195</VALIDVALUE>
          <VALUEMEANING>Patient failed to discontinue TKI within 10 calendar days after enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient failed to discontinue TKI within 10 calendar days after enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6489428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>194</VALIDVALUE>
          <VALUEMEANING>Patient becomes pregnant while taking TKI or with the need to restart TKI</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient becomes pregnant while taking TKI or with the need to restart TKI</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6571043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>199</VALIDVALUE>
          <VALUEMEANING>Stable Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is neither decreasing nor increasing in extent or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2982985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback</VALIDVALUE>
          <VALUEMEANING>Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback</VALUEMEANING>
          <MEANINGDESCRIPTION>Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6617418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>192</VALIDVALUE>
          <VALUEMEANING>Delays in therapy that meet the criteria in Sections 4.6.6 and 4.9.1</VALUEMEANING>
          <MEANINGDESCRIPTION>Delays in therapy that meet the criteria in Sections 4.6.6 and 4.9.1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6569789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>191</VALIDVALUE>
          <VALUEMEANING>Progressive disease at any time from the end of Induction Cycle 4 until the end of protocol therapy. Patients with stable disease or better may remain on protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease at any time from the end of Induction Cycle 4 until the end of protocol therapy. Patients with stable disease or better may remain on protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6569790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>190</VALIDVALUE>
          <VALUEMEANING>Did not receive dinutuximab during Induction therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Did not receive dinutuximab during Induction therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6569791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>189</VALIDVALUE>
          <VALUEMEANING>Lack of sufficient stem cells to support tandem transplant or inability to harvest stem cells prior to Consolidation</VALUEMEANING>
          <MEANINGDESCRIPTION>Lack of sufficient stem cells to support tandem transplant or inability to harvest stem cells prior to Consolidation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6569792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>193</VALIDVALUE>
          <VALUEMEANING>For patients enrolled after the implementation of Amendment #4A: Patient is Standard Risk (MRD &lt; 0.05% in the bone marrow) after Induction I.</VALUEMEANING>
          <MEANINGDESCRIPTION>For patients enrolled after the implementation of Amendment #4A: Patient is Standard Risk (MRD &lt; 0.05% in the bone marrow) after Induction I.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6580683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>301</VALIDVALUE>
          <VALUEMEANING>Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback</VALUEMEANING>
          <MEANINGDESCRIPTION>Assigned to Arm LMP-TC without HLA typing available by the Day 22 post induction Callback</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6617418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>200</VALIDVALUE>
          <VALUEMEANING>Persistent CNS leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Persistent CNS leukemia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6660760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>196</VALIDVALUE>
          <VALUEMEANING>Patient found at any point after enrollment to be inevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient found at any point after enrollment to be inevaluable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>197</VALIDVALUE>
          <VALUEMEANING>Patient found to be ineligible after enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient found to be ineligible after enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient found at any point after enrollment to be inevaluable</VALIDVALUE>
          <VALUEMEANING>Patient found at any point after enrollment to be inevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient found at any point after enrollment to be inevaluable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>201</VALIDVALUE>
          <VALUEMEANING>Delay in selumetinib treatment of &gt; 42 days for any reason (for example, decrease in BSA below 0.5 m2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Delay in selumetinib treatment of &gt; 42 days for any reason (for example, decrease in BSA below 0.5 m2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6674819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>213</VALIDVALUE>
          <VALUEMEANING>Incomplete Induction data for risk stratification</VALUEMEANING>
          <MEANINGDESCRIPTION>Incomplete Induction data for risk stratification</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6720481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>212</VALIDVALUE>
          <VALUEMEANING>Incomplete Induction data for risk stratification</VALUEMEANING>
          <MEANINGDESCRIPTION>Incomplete Induction data for risk stratification</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6720481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>211</VALIDVALUE>
          <VALUEMEANING>Identified as Philadelphia Chromosome-positive (BCR-ABL1)</VALUEMEANING>
          <MEANINGDESCRIPTION>Identified as Philadelphia Chromosome-positive (BCR-ABL1)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6720482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>210</VALIDVALUE>
          <VALUEMEANING>Adverse Event requiring removal from protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Adverse Event requiring removal from protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>209</VALIDVALUE>
          <VALUEMEANING>Patient found at any point after enrollment to be inevaluable (e.g., major deviations from protocol therapy)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient found at any point after enrollment to be inevaluable (e.g., major deviations from protocol therapy)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>208</VALIDVALUE>
          <VALUEMEANING>Definitive relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitive relapse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>207</VALIDVALUE>
          <VALUEMEANING>Failure to achieve CR at the end of Consolidation</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to achieve CR at the end of Consolidation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>206</VALIDVALUE>
          <VALUEMEANING>Consolidation failure</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment that is given after initial therapy to kill any remaining cancer cells._A lack of occurrence or performance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25745, C15679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>205</VALIDVALUE>
          <VALUEMEANING>Progressive disease at the end of Induction</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease at the end of Induction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6705353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>250</VALIDVALUE>
          <VALUEMEANING>Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5 percent by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5 percent by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>251</VALIDVALUE>
          <VALUEMEANING>Incomplete cytogenetic testing for Ph+, done as part of APEC14B1</VALUEMEANING>
          <MEANINGDESCRIPTION>Incomplete cytogenetic testing for Ph+, done as part of APEC14B1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>264</VALIDVALUE>
          <VALUEMEANING>Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5% by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Induction Failure, with the exception of isolated biopsy-proven testicular disease at EOI (EOI MRD greater than or equal to 5% by central flow cytometry, IF-M3, IF- EM, or IF-MPAL as defined in Section 3.3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>263</VALIDVALUE>
          <VALUEMEANING>End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for MPAL patients</VALUEMEANING>
          <MEANINGDESCRIPTION>End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for MPAL patients</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>252</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>262</VALIDVALUE>
          <VALUEMEANING>Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for MPAL patients</VALUEMEANING>
          <MEANINGDESCRIPTION>Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for MPAL patients</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>261</VALIDVALUE>
          <VALUEMEANING>End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for NCI HR patients</VALUEMEANING>
          <MEANINGDESCRIPTION>End of Consolidation marrow with MRD greater than or equal to 0.01% to less than 1% by central flow cytometry for NCI HR patients</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>260</VALIDVALUE>
          <VALUEMEANING>Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for both NCI HR B-ALL and NCI SR B-ALL patients</VALUEMEANING>
          <MEANINGDESCRIPTION>Consolidation Failure (EOC MRD greater than or equal to 1% by central flow cytometry or extramedullary disease) for both NCI HR B-ALL and NCI SR B-ALL patients</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>265</VALIDVALUE>
          <VALUEMEANING>Patient did not start radiation therapy within 31 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient did not start radiation therapy within 31 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6930724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>220</VALIDVALUE>
          <VALUEMEANING>Randomization Inotuzumab Ozogamicin Closed</VALUEMEANING>
          <MEANINGDESCRIPTION>The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.: A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.: Not affording passage or access; blocked against entry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49070, C71542, C25196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6819952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>266</VALIDVALUE>
          <VALUEMEANING>Patient did not start Selinexor treatment within 38 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient did not start Selinexor treatment within 38 days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6930752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>258</VALIDVALUE>
          <VALUEMEANING>Relapse as defined in Section 3.3 (B-ALL and MPAL see Section 3.3, B-LLy requires biopsy)</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse as defined in Section 3.3 (B-ALL and MPAL see Section 3.3, B-LLy requires biopsy)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>257</VALIDVALUE>
          <VALUEMEANING>CD22-negative blasts on central review of diagnostic specimen (HR B-ALL only, off protocol therapy after Consolidation)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD22-negative blasts on central review of diagnostic specimen (HR B-ALL only, off protocol therapy after Consolidation)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>259</VALIDVALUE>
          <VALUEMEANING>InO randomization for HR B-ALL temporarily closed due to safety phase analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>InO randomization for HR B-ALL temporarily closed due to safety phase analysis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>214</VALIDVALUE>
          <VALUEMEANING>Progressive disease during protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease of ≥ 20% increase from baseline in tumor size at any time during protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6774227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>270</VALIDVALUE>
          <VALUEMEANING>Excluded constitutional condition or oncologic diagnoses identified after enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Excluded constitutional condition or oncologic diagnoses identified after enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>269</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5083512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>268</VALIDVALUE>
          <VALUEMEANING>Patient became pregnant</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient became pregnant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>271</VALIDVALUE>
          <VALUEMEANING>Patient became pregnant</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient became pregnant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5234436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>226</VALIDVALUE>
          <VALUEMEANING>A patient with FLT3 ITD AR greater than 0.1 and assigned to the High Risk group who has a suitable donor identified receives HSCT prior to receiving Intensification 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A patient with FLT3 ITD AR greater than 0.1 and assigned to the High Risk group who has a suitable donor identified receives HSCT prior to receiving Intensification 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>228</VALIDVALUE>
          <VALUEMEANING>Patient becomes pregnant during protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient becomes pregnant during protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>227</VALIDVALUE>
          <VALUEMEANING>Relapse of any site following remission</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse of any site following remission</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>225</VALIDVALUE>
          <VALUEMEANING>Grade 3 or greater neurotoxicity from HD cytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 or greater neurotoxicity from HD cytarabine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>224</VALIDVALUE>
          <VALUEMEANING>Failure to achieve CNS1 status by the end of Induction 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to achieve CNS1 status by the end of Induction 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>223</VALIDVALUE>
          <VALUEMEANING>Patient was newly diagnosed with CNS3a or CNS3b at the start of Induction 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient was newly diagnosed with CNS3a or CNS3b at the start of Induction 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>222</VALIDVALUE>
          <VALUEMEANING>Patient with CNS3a or CNS3b status at the end of Induction I</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient with CNS3a or CNS3b status at the end of Induction I</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>221</VALIDVALUE>
          <VALUEMEANING>Failure to attain CR at the end of Induction 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Failure to attain CR at the end of Induction 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7090348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>267</VALIDVALUE>
          <VALUEMEANING>Patient received concurrent non-protocol anticancer therapy, including chemotherapy,  immunotherapy, or biologic therapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient received concurrent non-protocol anticancer therapy, including chemotherapy, 
immunotherapy, or biologic therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7001814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>272</VALIDVALUE>
          <VALUEMEANING>Patient found to be HR/IR at the completion of Block 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient found to be HR/IR at the completion of Block 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7128545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>107</VALIDVALUE>
          <VALUEMEANING>Patient Finish Second Year Clinical Study Participation</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: Use up completely.: A suffix denoting the second person having the same complete name (first, middle, and family names).: A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.: The act of taking part in an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25608, C15206, C29848, C49463, C64943, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7213182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>229</VALIDVALUE>
          <VALUEMEANING>Inability to attain and maintain therapeutic immunosuppressive drug levels on the LMP TC arm</VALUEMEANING>
          <MEANINGDESCRIPTION>Inability to attain and maintain therapeutic immunosuppressive drug levels on the LMP TC arm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7217478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>215</VALIDVALUE>
          <VALUEMEANING>Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>992</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-06-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>300</VALIDVALUE>
          <VALUEMEANING>Radiation Therapy Receive</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: To take, accept, or get something offered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313, C25639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7359965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>991</VALIDVALUE>
          <VALUEMEANING>Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected relapsed FHWT patients who are found to have anaplasia by central review)</VALUEMEANING>
          <MEANINGDESCRIPTION>Rapid central pathologic review (if applicable) does not agree with institutional diagnosis (e.g., suspected relapsed FHWT patients who are found to have anaplasia by central review)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>275</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG anti-cancer therapeutic study (eg, at recurrence).</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG anti-cancer therapeutic study (eg, at recurrence).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7406432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>274</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7406433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>993</VALIDVALUE>
          <VALUEMEANING>Receives other concurrent investigational or desmoid directed therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Receives other concurrent investigational or desmoid directed therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>302</VALIDVALUE>
          <VALUEMEANING>Found not to have MPAL by central confirmation of diagnostic specimen or incomplete testing, done as part of APEC14B1</VALUEMEANING>
          <MEANINGDESCRIPTION>Found not to have MPAL by central confirmation of diagnostic specimen or incomplete testing, done as part of APEC14B1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7496251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>303</VALIDVALUE>
          <VALUEMEANING>Use of radiation therapy other than cranial and testicular radiation as defined in the protocol.</VALUEMEANING>
          <MEANINGDESCRIPTION>Use of radiation therapy other than cranial and testicular radiation as defined in the protocol.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7496252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>282</VALIDVALUE>
          <VALUEMEANING>Patient never received protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient never received protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7457499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>281</VALIDVALUE>
          <VALUEMEANING>An acute neurological event or condition with an observable change in clinical presentation that would compromise the validity of further cognitive testing</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute neurological event or condition with an observable change in clinical presentation that would compromise the validity of further cognitive testing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7457500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>280</VALIDVALUE>
          <VALUEMEANING>Patient requires emergency unblinding</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient requires emergency unblinding</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7457501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>307</VALIDVALUE>
          <VALUEMEANING>Withdrawal of consent by patient/family/guardian for any further required observation or data submission</VALUEMEANING>
          <MEANINGDESCRIPTION>Withdrawal of consent by patient/family/guardian for any further required observation or data submission</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>306</VALIDVALUE>
          <VALUEMEANING>The fifth anniversary of the most recent date of patient enrollment onto a PedAL or COG therapeutic protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>The fifth anniversary of the most recent date of patient enrollment onto a PedAL or COG therapeutic protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>305</VALIDVALUE>
          <VALUEMEANING>Three years from the date of patient enrollment onto APAL2020SC if enrolling site failed to obtain an evaluable sample associated with APAL2020SC enrollment with no plans to submit subsequent samples</VALUEMEANING>
          <MEANINGDESCRIPTION>Three years from the date of patient enrollment onto APAL2020SC if enrolling site failed to obtain an evaluable sample associated with APAL2020SC enrollment with no plans to submit subsequent samples</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>304</VALIDVALUE>
          <VALUEMEANING>Five years from the date of patient enrollment onto APAL2020SC if not enrolled onto a sub-protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>Five years from the date of patient enrollment onto APAL2020SC if not enrolled onto a sub-protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>202</VALIDVALUE>
          <VALUEMEANING>Less Than Complete Remission Or Partial Remission With Normal Tumor Marker</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: The disappearance of all signs of cancer in response to treatment.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.: Used to indicate the presence of something or someone.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17220, C14165, C62355, C18058, C37998, C4870, C61585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7589442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>308</VALIDVALUE>
          <VALUEMEANING>Three years from the date of patient enrollment onto APAL2020SC if the diagnosis of relapsed AML, ALL, or MPAL cannot be confirmed</VALUEMEANING>
          <MEANINGDESCRIPTION>Three years from the date of patient enrollment onto APAL2020SC if the diagnosis of relapsed AML, ALL, or MPAL cannot be confirmed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Initiation Timeline Unmet</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: The act of starting something; an act that sets in motion some course of events.: A chronological schedule of when activities or events occurred or will occur.: A need or request was not fulfilled.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99757, C54576, C47938, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7582191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>203</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Timing</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: The chronological relationship between temporal events.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80484, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7595546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>231</VALIDVALUE>
          <VALUEMEANING>Patient developed graft failure</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient developed graft failure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7652878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>Diagnosis Criterion Unmet</VALUEMEANING>
          <MEANINGDESCRIPTION>The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.: That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.: A need or request was not fulfilled.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99757, C25466, C15220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7582185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>118</VALIDVALUE>
          <VALUEMEANING>Treating Physician Disagreement With Central Reviewer</VALUEMEANING>
          <MEANINGDESCRIPTION>Providing treatment for.: A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.: Inconsistency or lack of agreement between data, facts, claims, or opinions.: Used to indicate the presence of something or someone.: A single person who critically evaluates and reports on laboratory test results, protocols, or other data.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51807, C62355, C54274, C25741, C25705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7577463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pregnancy</VALIDVALUE>
          <VALUEMEANING>Pregnancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Pregnancy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unacceptable toxicity due to protocol therapy (See Section 5.0)</VALIDVALUE>
          <VALUEMEANING>Unacceptable toxicity due to protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Unacceptable toxicity due to protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4264211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Completion of planned therapy</VALIDVALUE>
          <VALUEMEANING>Completion of planned therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of planned therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3397022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refusal of further protocol therapy by patient/parent/guardian.</VALIDVALUE>
          <VALUEMEANING>Refusal of further protocol therapy by patient/parent/guardian</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal of further protocol therapy by patient/parent/guardian</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7751533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)</VALIDVALUE>
          <VALUEMEANING>Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients whose institutional FOXO1 status cannot be confirmed within 4 weeks (28 days) of study entry (See Section 3.3.2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7743408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)</VALIDVALUE>
          <VALUEMEANING>Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients whose institutions are unable to comply with local fusion testing protocol requirements (See Section 3.3.1)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7743409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients who are FOXO1 fusion negative and &lt;10 years old (See Section 3.3.3)</VALIDVALUE>
          <VALUEMEANING>Patients who are FOXO1 fusion negative and &lt;10 years old (See Section 3.3.3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who are FOXO1 fusion negative and &lt;10 years old (See Section 3.3.3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7743410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Withdrawal of consent for any further data submissions</VALIDVALUE>
          <VALUEMEANING>Withdrawal of consent for any further data submissions</VALUEMEANING>
          <MEANINGDESCRIPTION>Withdrawal of consent for any further data submissions</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>995</VALIDVALUE>
          <VALUEMEANING>Lost To Follow-up</VALUEMEANING>
          <MEANINGDESCRIPTION>Parted with; no longer held or possessed; incapable of being recovered or regained._Used as a function word to indicate direction, purpose, or movement._The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16033, C65107, C25560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2683428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4854741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2956827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility (see Section 3.2).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4844451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Development of second malignancy</VALIDVALUE>
          <VALUEMEANING>Development of second malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)_Coming next after the first in position in space or time or degree or magnitude._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9305, C25666, C18732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physician determines it is in patient&#39;s best interest</VALIDVALUE>
          <VALUEMEANING>Physician determines it is in patient&#39;s best interest</VALUEMEANING>
          <MEANINGDESCRIPTION>Physician determines it is in patient&#39;s best interest</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refusal of further protocol therapy by patient/parent/guardian, including refusal of randomization</VALIDVALUE>
          <VALUEMEANING>Refusal of further protocol therapy by patient/parent/guardian</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal of further protocol therapy by patient/parent/guardian</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3389978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease</VALIDVALUE>
          <VALUEMEANING>Progressive disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5776731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG anti-cancer therapeutic study (e.g. at recurrence)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7751604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Development of a second malignancy.</VALIDVALUE>
          <VALUEMEANING>Development of a second malignancy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Development of a second malignancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7751605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physician determines it is in the patient&#39;s best interest.</VALIDVALUE>
          <VALUEMEANING>Physician determines it is in the patient&#39;s best interest.</VALUEMEANING>
          <MEANINGDESCRIPTION>Physician determines it is in the patient&#39;s best interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7751606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>994</VALIDVALUE>
          <VALUEMEANING>Development of a second malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Development of a second malignancy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5083510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>309</VALIDVALUE>
          <VALUEMEANING>Patient never received cranial or craniospinal radiation treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient never received cranial or craniospinal radiation treatment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-08-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7757343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>186</VALIDVALUE>
          <VALUEMEANING>Patient has received 26 cycles OR two years of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient has received 26 cycles OR two years of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7975292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient has received 26 cycles OR two years of protocol therapy</VALIDVALUE>
          <VALUEMEANING>Patient has received 26 cycles OR two years of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient has received 26 cycles OR two years of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7975292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy</VALIDVALUE>
          <VALUEMEANING>Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Appearance of one or more new lesions or unequivocal progression of non-target lesions (see Section 10.2.5.2) and refer to Section 10.2.1 for exceptions within the first 12 weeks of therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resection of any lesions that are increasing in size at any time while on protocol therapy</VALIDVALUE>
          <VALUEMEANING>Resection of any lesions that are increasing in size at any time while on protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Resection of any lesions that are increasing in size at any time while on protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7977974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resection of any malignant lesion within the first 12 weeks of protocol therapy</VALIDVALUE>
          <VALUEMEANING>Resection of any malignant lesion within the first 12 weeks of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Resection of any malignant lesion within the first 12 weeks of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7977975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Response followed by ≥ 20% increase in total tumor burden from the nadir at any time during protocol therapy</VALIDVALUE>
          <VALUEMEANING>Response followed by ≥ 20% increase in total tumor burden from the nadir at any time during protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Response followed by ≥ 20% increase in total tumor burden from the nadir at any time during protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7977976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease of ≥ 20% increase from baseline or nadir in total tumor burden at any time during protocol therapy</VALIDVALUE>
          <VALUEMEANING>Progressive disease of ≥ 20% increase from baseline or nadir in total tumor burden at any time during protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease of ≥ 20% increase from baseline or nadir in total tumor burden at any time during protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7977977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>277</VALIDVALUE>
          <VALUEMEANING>Patient never received initial vaccine dose by 3 months after enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient never received initial vaccine dose by 3 months after enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8028951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>276</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of vaccination are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of vaccination are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8028952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.</VALIDVALUE>
          <VALUEMEANING>Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of the final QOL assessment or the 3-month post-op Ct scan, whichever is later.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the second staged procedure.</VALIDVALUE>
          <VALUEMEANING>Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the second staged procedure.</VALUEMEANING>
          <MEANINGDESCRIPTION>Adverse experience after first thoracic intervention of a planned staged procedure that would limit the ability to complete the secoond staged procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.</VALIDVALUE>
          <VALUEMEANING>Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease at a site outside of the lung between 1st and 2nd procedure of a staged thoracic surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refusal to accept the assigned surgery post-randomization by physician.</VALIDVALUE>
          <VALUEMEANING>Refusal to accept the assigned surgery post-randomization by physician.</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal to accept the assigned surgery post-randomization by physician.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.</VALIDVALUE>
          <VALUEMEANING>Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal to accept the assigned surgery post-randomization by patient/parent/guardian.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rapid central imaging review indicates the patient is not eligible.</VALIDVALUE>
          <VALUEMEANING>Rapid central imaging review indicates the patient is not eligible.</VALUEMEANING>
          <MEANINGDESCRIPTION>Rapid central imaging review indicates the patient is not eligible.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tenth anniversary of the date the patient was enrolled on this study.</VALIDVALUE>
          <VALUEMEANING>Tenth anniversary of the date the patient was enrolled on this study.</VALUEMEANING>
          <MEANINGDESCRIPTION>Tent anniversary of the date the patient was enrolled on this study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7992200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E</VALIDVALUE>
          <VALUEMEANING>History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E</VALUEMEANING>
          <MEANINGDESCRIPTION>History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-01-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8019049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refusal of further participation by patient/parent/guardian</VALIDVALUE>
          <VALUEMEANING>Refusal of further participation by patient/parent/guardian</VALUEMEANING>
          <MEANINGDESCRIPTION>Refusal of further participation by patient/parent/guardian</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8040156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cohort 1 Treatment failure</VALIDVALUE>
          <VALUEMEANING>Cohort 1 Treatment failure</VALUEMEANING>
          <MEANINGDESCRIPTION>Cohort 1 Treatment failure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8119804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>310</VALIDVALUE>
          <VALUEMEANING>History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E</VALUEMEANING>
          <MEANINGDESCRIPTION>History of defined psychiatric co-morbidities in a patient whose tumor is found to have an ALK aberration that would otherwise render the patient eligible for assignment to Arm E</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8019049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients who are FOXO1 fusion positive.</VALIDVALUE>
          <VALUEMEANING>Patients who are FOXO1 fusion positive.</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who are FOXO1 fusion positive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8093293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility studies (if required) prior to the initiation of protocol therapy are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6823642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient enrollment onto another COG anti-cancer therapy study</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG anti-cancer therapy study</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG anti-cancer therapy study</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8148228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapse or imminent relapse</VALIDVALUE>
          <VALUEMEANING>Relapse or imminent relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse or imminent relapse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pregnancy before starting HCT conditioning</VALIDVALUE>
          <VALUEMEANING>Pregnancy before starting HCT conditioning</VALUEMEANING>
          <MEANINGDESCRIPTION>Pregnancy before starting HCT conditioning</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Does not meet criteria to receive HCT within week 12 post randomization</VALIDVALUE>
          <VALUEMEANING>Does not meet criteria to receive HCT within week 12 post randomization</VALUEMEANING>
          <MEANINGDESCRIPTION>Does not meet criteria to receive HCT within week 12 post randomization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient enrollment onto another COG anti-cancer therapeutic study post HCT</VALIDVALUE>
          <VALUEMEANING>Patient enrollment onto another COG anti-cancer therapeutic study post HCT</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient enrollment onto another COG anti-cancer therapeutic study post HCT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>283</VALIDVALUE>
          <VALUEMEANING>Relapse or imminent relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse or imminent relapse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>236</VALIDVALUE>
          <VALUEMEANING>Does not meet criteria to receive HCT within week 12 post randomization</VALUEMEANING>
          <MEANINGDESCRIPTION>Does not meet criteria to receive HCT within week 12 post randomization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-07-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10497261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>311</VALIDVALUE>
          <VALUEMEANING>For suspected relapsed FHWT patients, retrospective central pathology review materials were not submitted within 6 weeks of enrollment on AREN1921</VALUEMEANING>
          <MEANINGDESCRIPTION>For suspected relapsed FHWT patients, retrospective central pathology review materials were not submitted within 6 weeks of enrollment on AREN1921</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10939476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>402</VALIDVALUE>
          <VALUEMEANING>Receipt of non-protocol anti-cancer therapy (any therapy other than outlined in Section 4.0 and Section 13.0) to the study eye(s), including external beam radiation therapy to study eye or contralateral eye, or enucleation of study eye(s)</VALUEMEANING>
          <MEANINGDESCRIPTION>Receipt of non-protocol anti-cancer therapy (any therapy other than outlined in Section 4.0 and Section 13.0) to the study eye(s), including external beam radiation therapy to study eye or contralateral eye, or enucleation of study eye(s)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11160675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>400</VALIDVALUE>
          <VALUEMEANING>Progressive disease in the vitreous seeds (as defined in Section 10.2.2) confirmed by rapid central review.</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease in the vitreous seeds (as defined in Section 10.2.2) confirmed by rapid central review.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11167467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>401</VALIDVALUE>
          <VALUEMEANING>Progressive disease in subretinal seeds or retinal tumor (as defined in Section 10.2.2.2 and 10.2.2.3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Progressive disease in subretinal seeds or retinal tumor (as defined in Section 10.2.2.2 and 10.2.2.3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11167468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>590</VALIDVALUE>
          <VALUEMEANING>Female patient of childbearing potential has a positive pregnancy test while receiving CVE chemotherapy.</VALUEMEANING>
          <MEANINGDESCRIPTION>Female patient of childbearing potential has a positive pregnancy test while receiving CVE chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11167469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>216</VALIDVALUE>
          <VALUEMEANING>Change to ineligible chemotherapy regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Change to ineligible chemotherapy regimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12051857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>217</VALIDVALUE>
          <VALUEMEANING>Patient never received asparaginase chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient never received asparaginase chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12051859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility</VALIDVALUE>
          <VALUEMEANING>Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility</VALUEMEANING>
          <MEANINGDESCRIPTION>Repeat eligibility laboratory studies (if required) are outside the parameters required for eligibility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-03-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13110850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>New relapse on protocol therapy</VALIDVALUE>
          <VALUEMEANING>New relapse on protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>New relapse on protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13190982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)</VALIDVALUE>
          <VALUEMEANING>Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)</VALUEMEANING>
          <MEANINGDESCRIPTION>Regimen A patient does not complete post-Cycle 1 Callback per protocol (see Section 3.1.6)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13190983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Start of anti-CMV antiviral medication as pre-emptive therapy</VALIDVALUE>
          <VALUEMEANING>Start of anti-CMV antiviral medication as pre-emptive therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Start of anti-CMV antiviral medication as pre-emptive therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13341059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Administration of currently available formulations of the study medication is not feasible</VALIDVALUE>
          <VALUEMEANING>Administration of currently available formulations of the study medication is not feasible</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of currently available formulations of the study medication is not feasible</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13341060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive plasma CMV PCR</VALIDVALUE>
          <VALUEMEANING>Positive plasma CMV PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>Positive plasma CMV PCR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13341061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient developed severe renal impairment or severe hepatic impairment</VALIDVALUE>
          <VALUEMEANING>Patient developed severe renal impairment or severe hepatic impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient developed severe renal impairment or severe hepatic impairment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13341062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient did not receive transplant</VALIDVALUE>
          <VALUEMEANING>Patient did not receive transplant</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient did not receive transplant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13341063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Start of preparative regimen for subsequent transplant</VALIDVALUE>
          <VALUEMEANING>Begin Hematopoietic Cell Transplantation Preparative Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61155, C15431, C25431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13361717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>312</VALIDVALUE>
          <VALUEMEANING>Found not to have MPAL and not be eligible as B-ALL upon by central assessment of a diagnostic specimen, or to have incomplete confirmatory testing, done as part of APEC14B1</VALUEMEANING>
          <MEANINGDESCRIPTION>Found not to have MPAL and not be eligible as B-ALL upon by central assessment of a diagnostic specimen, or to have incomplete confirmatory testing, done as part of APEC14B1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14608597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>313</VALIDVALUE>
          <VALUEMEANING>HR B-ALL patients randomized to Arm C but unable to receive at least one dose of Inotuzumab Ozogamicin in InO Block 2 due to toxicity</VALUEMEANING>
          <MEANINGDESCRIPTION>HR B-ALL patients randomized to Arm C but unable to receive at least one dose of Inotuzumab Ozogamicin in InO Block 2 due to toxicity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14608598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Completion of the 3-month post-op CT scan</VALIDVALUE>
          <VALUEMEANING>Completion of the 3-month post-op CT scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Completion of the 3-month post-op CT scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14741329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>278</VALIDVALUE>
          <VALUEMEANING>Reached and completed the 2-Years Off Cancer Therapy study timepoint and did not provide optional consent for long-term follow-up</VALUEMEANING>
          <MEANINGDESCRIPTION>Reached and completed the 2-Years Off Cancer Therapy study timepoint and did not provide optional consent for long-term follow-up</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15097765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>218</VALIDVALUE>
          <VALUEMEANING>Relapse/progression prior to start of protocol therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse/progression prior to start of protocol therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15159435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>316</VALIDVALUE>
          <VALUEMEANING>Patients who do not receive a qualifying Interim or Final Stratum Assignment by the required timepoint</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who do not receive a qualifying Interim or Final Stratum Assignment by the required timepoint</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15172424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>315</VALIDVALUE>
          <VALUEMEANING>Stage II and III patients subsequently assigned to a doxorubicin-containing stratum who do not meet the adequate cardiac function criteria defined in Section 3.2.7.2</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II and III patients subsequently assigned to a doxorubicin-containing stratum who do not meet the adequate cardiac function criteria defined in Section 3.2.7.2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15172423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>314</VALIDVALUE>
          <VALUEMEANING>Modified Very Low Risk Patients that relapse and are found to have metachronous tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Modified Very Low Risk Patients that relapse and are found to have metachronous tumor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15172422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>321</VALIDVALUE>
          <VALUEMEANING>Never started initial systemic therapy or observation (as assigned via APEC14B1-REN).</VALUEMEANING>
          <MEANINGDESCRIPTION>Never started initial systemic therapy or observation (as assigned via APEC14B1-REN).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15172425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central review determines the enrolling diagnosis is Type I or Ir PPB and the patient has started protocol therapy for Type II/III PPB</VALIDVALUE>
          <VALUEMEANING>Central review determines the enrolling diagnosis is Type I or Ir PPB and the patient has started protocol therapy for Type II/III PPB</VALUEMEANING>
          <MEANINGDESCRIPTION>Central review determines the enrolling diagnosis is Type I or Ir PPB and the patient has started protocol therapy for Type II/III PPB</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15237720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central pathology review determines the enrolling diagnosis is not pleuropulmonary blastoma</VALIDVALUE>
          <VALUEMEANING>Central pathology review determines the enrolling diagnosis is not pleuropulmonary blastoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Central pathology review determines the enrolling diagnosis is not pleuropulmonary blastoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-10-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15238313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>317</VALIDVALUE>
          <VALUEMEANING>As of Amendment #6B- Not eligible for Arm AC or AD or eligible but decline enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>As of Amendment #6B- Not eligible for Arm AC or AD or eligible but decline enrollment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-11-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15329297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>998</VALIDVALUE>
          <VALUEMEANING>Patients who undergo a delayed nephrectomy before initiation of Cycle 2 of chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who undergo a delayed nephrectomy before initiation of Cycle 2 of chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15361408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>997</VALIDVALUE>
          <VALUEMEANING>Patients found to have anaplasia by central pathology review of delayed nephrectomy or pulmonary metastasectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients found to have anaplasia by central pathology review of delayed nephrectomy or pulmonary metastasectomy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15361407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>996</VALIDVALUE>
          <VALUEMEANING>Patients who do not have a lymph node sampled at upfront or delayed nephrectomy as confirmed by central pathology review</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients who do not have a lymph node sampled at upfront or delayed nephrectomy as confirmed by central pathology review</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15361406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>219</VALIDVALUE>
          <VALUEMEANING>Identified as seropositive for Hepatitis B or C or HIV</VALUEMEANING>
          <MEANINGDESCRIPTION>Identified as seropositive for Hepatitis B or C or HIV</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15427082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Contributing reason(s) patien</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Contributing reason(s) patient is off protocol therapy/off study:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="532">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3431317</PUBLICID>
    <LONGNAME>Current Assessment Total Diameter Measurement Value</LONGNAME>
    <PREFERREDNAME>CUR_TTL_DM_MSR_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the current aggregated sum of assessed lesion diameters.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3431303</PublicId>
      <PreferredName>CUR_ASM_TTL_DM_MSR</PreferredName>
      <PreferredDefinition>Occurring in or belonging to the present time._Having determined the value, significance, or extent of._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Diameter; the length of a straight line passing through the center of a circle and connecting two points on the circumference.__Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.</PreferredDefinition>
      <LongName>Current Assessment Total Diameter Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008546</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ORGAN_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Organ Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3431301</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25217:C25304:C25285</PreferredName>
        <Version>1</Version>
        <LongName>Current Assessment Total Diameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2188090</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3431293</PublicId>
      <PreferredName>LES_DIAM_MSRMT</PreferredName>
      <PreferredDefinition>A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Diameter; the length of a straight line passing through the center of a circle and connecting two points on the circumference._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.</PreferredDefinition>
      <LongName>Lesion Diameter Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3431292</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824:C25285:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Lesion Diameter Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Current Total Diameters</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Current Total Diameters</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="533">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3442308</PUBLICID>
    <LONGNAME>Study Specimen Identification Sample Name</LONGNAME>
    <PREFERREDNAME>3434452v1.0:3438619v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The unique identification name of a sample.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3434452</PublicId>
      <PreferredName>2619600v1.0:3434450v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it; the activities undertaken during a study._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The procedure of having an identity established.</PreferredDefinition>
      <LongName>Study Specimen Identification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2619600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536</PreferredName>
        <Version>1</Version>
        <LongName>Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3434450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C25737</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Identification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3438619</PublicId>
      <PreferredName>3438619v1.0</PreferredName>
      <PreferredDefinition>The unique identification name of a sample.</PreferredDefinition>
      <LongName>Sample Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</Origin>
      <Representation>
        <PublicId>3434384</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sample Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sample Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Study V1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Assay V1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Assay V1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286099</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Study V1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286101</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Sample Name</AlternateName>
        <AlternateNameType>ISA-TAB-Nano Col Nm</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="534">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3451587</PUBLICID>
    <LONGNAME>Protocol Agent Dose Modification Scale</LONGNAME>
    <PREFERREDNAME>2192837v1.0:3451583v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale related to the dose modification of a protocol agent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192837</PublicId>
      <PreferredName>PROT_AGT_DOSE_MOD</PreferredName>
      <PreferredDefinition>information related to the dose modification of a protocol agent.</PreferredDefinition>
      <LongName>Protocol Agent Dose Modification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660645</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488:C25572</PreferredName>
        <Version>1</Version>
        <LongName>Dose Modification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25572</PREFERRED_NAME>
            <LONG_NAME>Modification</LONG_NAME>
            <CON_ID>2203850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3451583</PublicId>
      <PreferredName>3451583v1.0</PreferredName>
      <PreferredDefinition>the scale related to the dose modification of a protocol agent.</PreferredDefinition>
      <LongName>Protocol Agent Dose Modification Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>-2</VALIDVALUE>
          <VALUEMEANING>Dose Level -2</VALUEMEANING>
          <MEANINGDESCRIPTION>Second Dose Level Reduction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3451584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>-1</VALIDVALUE>
          <VALUEMEANING>Dose Level -1</VALUEMEANING>
          <MEANINGDESCRIPTION>First Dose Level Reduction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3451585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Dose Level Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>Maximum starting dose</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3451586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose Level Received</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose Level Received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PROT_AGT_DOSE_MOD_SCL</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2192837v1.0:3451583v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="535">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3461337</PUBLICID>
    <LONGNAME>Colonoscopy Visit Colonoscopy Reason</LONGNAME>
    <PREFERREDNAME>CLNPSY_VISIT_RSN</PREFERREDNAME>
    <PREFERREDDEFINITION>Purpose for the colonoscopy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2185817</PublicId>
      <PreferredName>CLNPSY_VISIT</PreferredName>
      <PreferredDefinition>Purpose for the visit.</PreferredDefinition>
      <LongName>Colonoscopy Visit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008529</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RSCH_PROT</PreferredName>
        <Version>1</Version>
        <LongName>Research Protocols</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184779</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0009378</PreferredName>
        <Version>1</Version>
        <LongName>Colonoscopy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0009378</PREFERRED_NAME>
            <LONG_NAME>Colonoscopy</LONG_NAME>
            <CON_ID>2203084</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177326</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Visit</PreferredName>
        <Version>1</Version>
        <LongName>Visit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25716</PREFERRED_NAME>
            <LONG_NAME>Visit</LONG_NAME>
            <CON_ID>2202626</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3461332</PublicId>
      <PreferredName>3461332v1.0</PreferredName>
      <PreferredDefinition>Explanation for the colonoscopy.</PreferredDefinition>
      <LongName>Colonoscopy Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3370234</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16450:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Colonoscopy Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16450</PREFERRED_NAME>
            <LONG_NAME>Colonoscopy</LONG_NAME>
            <CON_ID>2528526</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Year 8 post-registration</VALIDVALUE>
          <VALUEMEANING>Year 8 post-registration</VALUEMEANING>
          <MEANINGDESCRIPTION>Year 8 post-registration</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, as clinically indicated</VALIDVALUE>
          <VALUEMEANING>Other, as clinically indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Other, as clinically indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Month 36</VALIDVALUE>
          <VALUEMEANING>Month 36</VALUEMEANING>
          <MEANINGDESCRIPTION>Month 36</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pre-registration</VALIDVALUE>
          <VALUEMEANING>Pre-Registration</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Registration</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2738388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M36</VALIDVALUE>
          <VALUEMEANING>Month 36</VALUEMEANING>
          <MEANINGDESCRIPTION>Month 36</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTH</VALIDVALUE>
          <VALUEMEANING>Other, as clinically indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Other, as clinically indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRE</VALIDVALUE>
          <VALUEMEANING>Pre-Registration</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Registration</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2738388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YR8</VALIDVALUE>
          <VALUEMEANING>Year 8 post-registration</VALUEMEANING>
          <MEANINGDESCRIPTION>Year 8 post-registration</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason for colonoscopy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason for colonoscopy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="536">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3461433</PUBLICID>
    <LONGNAME>Person Feces Specimen Future Clinical or Research Activity Consent Ind-3</LONGNAME>
    <PREFERREDNAME>3461426v1.0:2189909v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator related to consent from a patient/participant to use a portion of blood, tissue, or other substance from the body in future cancer research, specifically the material discharged from the bowel during defecation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3461426</PublicId>
      <PreferredName>2236731v1.0:3461424v1.0</PreferredName>
      <PreferredDefinition>Information related to the consent or permission from a person to use a portion of blood, tissue, or other substance from the body in future cancer research, the material discharged from the bowel during defecation.</PreferredDefinition>
      <LongName>Person Feces Specimen Future Clinical or Research Activity Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3461424</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3461424v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Feces Specimen Future Clinical or Research Activity Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13234</PREFERRED_NAME>
            <LONG_NAME>Feces</LONG_NAME>
            <CON_ID>2202536</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67527</PREFERRED_NAME>
            <LONG_NAME>Future</LONG_NAME>
            <CON_ID>2653011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16203</PREFERRED_NAME>
            <LONG_NAME>Clinical or Research Activity</LONG_NAME>
            <CON_ID>2222474</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient has given permission</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient has given permission to store and use his/her stool sample(s) for use in future research to learn about, prevent, or treat cancer.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="537">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3461678</PUBLICID>
    <LONGNAME>Flare Or Pseudoprogression Response Occurrence Date</LONGNAME>
    <PREFERREDNAME>FLARE_PSPRG_RESP_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Calendar date to represent when a patient experienced a flare or a false positive finding of progression and enhancement of a lesion.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3461659</PublicId>
      <PreferredName>FLARE_PSPRG_RESP</PreferredName>
      <PreferredDefinition>Flare; reddening of the skin spreading outward from a focus of infection or irritation; a sudden recurrence or worsening of symptoms._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Flare Or Pseudoprogression Response Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3461657</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37953:C37998:C98298:C50995</PreferredName>
        <Version>1</Version>
        <LongName>Flare Or Pseudoprogression Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37953</PREFERRED_NAME>
            <LONG_NAME>Flare</LONG_NAME>
            <CON_ID>2203730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C98298</PREFERRED_NAME>
            <LONG_NAME>Pseudoprogression</LONG_NAME>
            <CON_ID>3294140</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50995</PREFERRED_NAME>
            <LONG_NAME>Disease Response</LONG_NAME>
            <CON_ID>2459436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Flare/Pseudoprogression Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Flare/Pseudoprogression Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="538">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3462297</PUBLICID>
    <LONGNAME>Other Malignant Neoplasm Diagnosis Month Number</LONGNAME>
    <PREFERREDNAME>3462290v1.0:2895904v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the month of the initial diagnosis of any malignancy diagnosed prior to or at the same time as the submitted tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3462290</PublicId>
      <PreferredName>2660471v1.0:2239981v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas, leukemias, melanomas, and sarcomas. -- 2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Other Malignant Neoplasm Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Other Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2895904</PublicId>
      <PreferredName>EVT_MON_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Event Month Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2895903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29846:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Month Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>One of ten equal parts; a quantity corresponding to one tenth of the whole.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C81010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::12: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::9: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::7: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the third position in an ordering or series; coming next after the third and just before the fifth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3rd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the second position in an ordering or series.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Coming next after the first in position in space or time or degree or magnitude.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1st month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Preceding all others in time or space or degree.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2896404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Month of Initial Diagnosis of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Month of Initial Diagnosis of Other Malignancy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5589063</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDDP/CTSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDDP/CTSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5589068</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="539">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3474983</PUBLICID>
    <LONGNAME>Gynecologic Fallopian Tube Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 Stage</LONGNAME>
    <PREFERREDNAME>3474754v1.0:3474950v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Anatomic extent of the primary fallopian tube carcinoma based on surgical pathologic examination.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FIGO:International Federal of Gynecology and Obstetrics</ORIGIN>
    <REGISTRATIONSTATUS>Preferred Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3474754</PublicId>
      <PreferredName>2206690v1.0:3474752v1.0</PreferredName>
      <PreferredDefinition>Of or relating to or practicing gynecology; pertaining to the health issues of women._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Gynecologic Neoplasm Fallopian Tube Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206690</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28016:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Gynecologic Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28016</PREFERRED_NAME>
            <LONG_NAME>Gynecologic</LONG_NAME>
            <CON_ID>2202649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3474752</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12403:C16899</PreferredName>
        <Version>1</Version>
        <LongName>Fallopian Tube Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12403</PREFERRED_NAME>
            <LONG_NAME>Fallopian Tube</LONG_NAME>
            <CON_ID>2204784</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3474950</PublicId>
      <PreferredName>3474950v1.0</PreferredName>
      <PreferredDefinition>A carcinoma arising from the fallopian tube which is attached to the uterine corpus (uterine body). Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas._An international organization with a mission to promote the wellbeing of women and to raise the standards of practice in obstetrics and gynecology. They are the creator of staging criteria to describe the extent and spread of gynecologic malignancies._A number with no fractional part, including the negative and positive numbers as well as zero.::2009_The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Fallopian Tube Carcinoma Federation of Gynecology and Obstetrics (FIGO) 2009 Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>FIGO:International Federal of Gynecology and Obstetrics</Origin>
      <Representation>
        <PublicId>3474949</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3474949v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Fallopian Tube Carcinoma Federation of Gynecology and Obstetrics Integer::2009 Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3867</PREFERRED_NAME>
            <LONG_NAME>Fallopian Tube Carcinoma</LONG_NAME>
            <CON_ID>3204750</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89808</PREFERRED_NAME>
            <LONG_NAME>Federation of Gynecology and Obstetrics</LONG_NAME>
            <CON_ID>3108626</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IV</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pM1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with distant metastasis (excluding metastasis within the peritoneal cavity). (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer limited to fallopian tube(s). (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IA</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT1a TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with tumor limited to one tube, without penetrating the serosal surface; no ascites.  (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IB</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT1b TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with tumor limited to both tubes, without penetrating the serosal surface; no ascites. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IC</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT1c TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>II</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT2 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with tumor involving one or both fallopian tubes with pelvic extension. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIA</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT2a TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with extension and/or metastasis to the uterus and/or ovaries. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89675</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIB</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT2b TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with extension to other pelvic structures. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIC</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT2c TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with pelvic extension and malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>III</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT3 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with tumor involving one or both fallopian tubes, with peritoneal implants outside the pelvis. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIA</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT3a TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with microscopic peritoneal metastasis outside the pelvis. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIB</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT3b TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IIIC</VALIDVALUE>
          <VALUEMEANING>Fallopian Tube Cancer pT3c TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Fallopian tube cancer with peritoneal metastasis outside the pelvis and more than 2 cm in diameter. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3447147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FIGO Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>FIGO Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Fallopian Tube</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3444896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FIGO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FIGO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000585</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="540">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3475090</PUBLICID>
    <LONGNAME>Recurrent Disease Risk Stratification Stage</LONGNAME>
    <PREFERREDNAME>3475085v1.0:3475086v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The process of classifying patients into strata as part of the randomization process according to the risk of the return of a disease after a remission.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3475085</PublicId>
      <PreferredName>2678101v1.0:3475083v1.0</PreferredName>
      <PreferredDefinition>The process of classifying patients into strata as part of the randomization process according to the risk of the return of a disease after a remission.</PreferredDefinition>
      <LongName>Recurrent Disease Risk Stratification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2678101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38155</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3475083</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17102:C25689</PreferredName>
        <Version>1</Version>
        <LongName>Risk Stratification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17102</PREFERRED_NAME>
            <LONG_NAME>Risk</LONG_NAME>
            <CON_ID>2412275</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25689</PREFERRED_NAME>
            <LONG_NAME>Stratification</LONG_NAME>
            <CON_ID>2203803</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3475086</PublicId>
      <PreferredName>3475086v1.0</PreferredName>
      <PreferredDefinition>The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Recurrent Disease Risk Stratification Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Stage III</VALUEMEANING>
          <MEANINGDESCRIPTION>Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Stage II with no prior chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II with no prior chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3475088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Stage II with prior chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II with prior chemotherapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3475087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Stage 0 or I</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage 0 or I</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3475089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Stage II with prior chemotherapy or radiation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II with prior chemotherapy or radiation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4760031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Stage II with no prior chemotherapy or radiation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II with no prior chemotherapy or radiation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4760032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Risk of recurrence</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Risk of recurrence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="541">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3475269</PUBLICID>
    <LONGNAME>Laboratory Procedure Activated Partial Thromboplastin Time Assessment Value</LONGNAME>
    <PREFERREDNAME>aPTT</PREFERREDNAME>
    <PREFERREDDEFINITION>The value for the level of any procedure that involves testing or manipulating a sample of blood in a laboratory setting related to activated partial thromboplastin time measured to a tenth of a second, which is a measurement of the intrinsic pathway of coagulation.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3475268</PublicId>
      <PreferredName>2543047v1.0:3475266v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood in a laboratory setting related to activated partial thromboplastin time, which is a measurement of the intrinsic pathway of coagulation.</PreferredDefinition>
      <LongName>Laboratory Procedure Activated Partial Thromboplastin Time Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3475266</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64382:C38462:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Activation Partial Thromboplastin Time Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64382</PREFERRED_NAME>
            <LONG_NAME>Activation</LONG_NAME>
            <CON_ID>2612149</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38462</PREFERRED_NAME>
            <LONG_NAME>Activated Partial Thromboplastin Time</LONG_NAME>
            <CON_ID>2206355</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4793991</PublicId>
      <PreferredName>PTT1_VAL</PreferredName>
      <PreferredDefinition>Value for level of partial thromboplastin time measured in tenths of seconds.</PreferredDefinition>
      <LongName>Partial Thromboplastin Time Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>seconds</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>aPTT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>aPTT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Activated Partial Thromboplastin Time (APTT)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>aPTT:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Activated Partial Thromboplastin Time:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>aPTT (&lt;= 1.5 x ULN)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>aPTT institutional ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Activated Partial Thromboplastin Time (APTT):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>APTT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aPTT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="542">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3478322</PUBLICID>
    <LONGNAME>Metastatic Disease Present At Study Enrollment Ind-2</LONGNAME>
    <PREFERREDNAME>M_DZ_PRS_ENROL_IND-2</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to metastatic disease being present at the time of the study enrollment.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3478313</PublicId>
      <PreferredName>METC_DZ_PRES_S_ENROL</PreferredName>
      <PreferredDefinition>A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Being or existing in a specified place or at the specified time._Used to indicate position, location, or state._A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it; the activities undertaken during a study._Enrollment; to insert, register, or enter in a list, catalog, or roll. (Merriam-Webster Online)</PreferredDefinition>
      <LongName>Metastatic Disease Present At Study Enrollment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2230313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14174:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3478311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626:C25427:C63536:C37948</PreferredName>
        <Version>1</Version>
        <LongName>Present At Study Enrollment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25427</PREFERRED_NAME>
            <LONG_NAME>At</LONG_NAME>
            <CON_ID>2261927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37948</PREFERRED_NAME>
            <LONG_NAME>Enrollment</LONG_NAME>
            <CON_ID>2203918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was metastatic disease presen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was metastatic disease present at study enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient diagnosed with metastatic disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was this site of metastatic progression/relapse present at study entry?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="543">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3536327</PUBLICID>
    <LONGNAME>EBER ISH Result</LONGNAME>
    <PREFERREDNAME>3536324v1.0:3536326v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Result of EBER (Epstein-Barr Virus Small RNA) in situ hybridization (ISH) testing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HTMCP:HIV+ Tumor Molecular Characterization Project</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3536324</PublicId>
      <PreferredName>3536322v1.0:2238473v1.0</PreferredName>
      <PreferredDefinition>A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt&#39;s lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations._RNA Binding is the molecular interaction between an RNA molecule and a macromolecule (usually protein or nucleic acid) for transport, catalysis, localization, or modification of function._Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues that uses fluorescent tags to detect hybridization_A position on a scale measuring intensity, quality, or amount.  (NCI)</PreferredDefinition>
      <LongName>Epstein-Barr Virus Small RNA Fluorescence in situ Hybridization Level</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3536322</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14204:C20737:C17563</PreferredName>
        <Version>1</Version>
        <LongName>Epstein-Barr Virus RNA Binding Fluorescence in situ Hybridization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14204</PREFERRED_NAME>
            <LONG_NAME>Epstein-Barr Virus</LONG_NAME>
            <CON_ID>2205370</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20737</PREFERRED_NAME>
            <LONG_NAME>RNA Binding</LONG_NAME>
            <CON_ID>3297705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17563</PREFERRED_NAME>
            <LONG_NAME>Fluorescence In Situ Hybridization</LONG_NAME>
            <CON_ID>2221360</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2238473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25554</PreferredName>
        <Version>1</Version>
        <LongName>Level</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3536326</PublicId>
      <PreferredName>3536326v1.0</PreferredName>
      <PreferredDefinition>Result of Her-2 Testing for amplification, expressed as not amplified, indeterminate, or amplified._In Situ Hybridization staining is an immunohistochemistry staining procedure which allows the demonstration of specific nucleic acid sequences (genes) in their cellular environment. The DNA sequence in the host cell is detected by hybridization with a biotin-labeled cDNA probe. Used for detecting protein and gene expression, determining tissue specificity, and localizing genes and proteins within tissue samples._The result of an action.</PreferredDefinition>
      <LongName>ISH (in situ Hybridization) Staining Method Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3536325</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C23022:C20200</PreferredName>
        <Version>1</Version>
        <LongName>in situ Hybridization Staining Method Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C23022</PREFERRED_NAME>
            <LONG_NAME>In Situ Hybridization Staining Method</LONG_NAME>
            <CON_ID>3108220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amplified</VALIDVALUE>
          <VALUEMEANING>Gene Amplification Technique</VALUEMEANING>
          <MEANINGDESCRIPTION>This technique refers to selectively replicate DNA sequence of interest to multiple extra copies that meet the need of research or health care activity. Polymerase chain reaction (PCR), can be considered a type of man-made gene amplification process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3534096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Amplified</VALIDVALUE>
          <VALUEMEANING>NOT AMPLIFIED</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Addition of extra material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25418, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>No testing done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EBER ISH Result</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>EBER ISH Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335152</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HTMCP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HTMCP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3257277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655968</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HTMCP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HTMCP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000067</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EBER_ISH_RES</AlternateName>
        <AlternateNameType>Synonym</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="544">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3553502</PUBLICID>
    <LONGNAME>Patient Response in Target Lesion Radiation Therapy Receive Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_RPNS_TGT_LSN_RX_RCV_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator related to the eligibility of a person who receives medical attention takes a treatment by means of exposure of the target or the whole body to radiation as a quantitative measurement of the response of a target tumor to the therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3553501</PublicId>
      <PreferredName>PT_TGT_LSN_RPNS_RX_RCV</PreferredName>
      <PreferredDefinition>A person who receives medical attention takes a treatment by means of exposure of the target or the whole body to radiation as a quantitative measurement of the response of a target tumor to the therapy.</PreferredDefinition>
      <LongName>Patient Response in Target Lesion Radiation Therapy Receive</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3553878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94534:C15313:C25639</PreferredName>
        <Version>1</Version>
        <LongName>Response in Target Lesion Radiation Therapy Receive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94534</PREFERRED_NAME>
            <LONG_NAME>Response in Target Lesion</LONG_NAME>
            <CON_ID>3553498</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received radiatio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient received radiation to any lesion that will be identified as a target lesion to measure tumor response?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received radiation to any lesion that will be identified as a target lesion to measure tumor response within 4 weeks prior to study entry?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="545">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3564477</PUBLICID>
    <LONGNAME>Intervention Negative Therapeutic Effect Increased Motor Activity Intensity Code</LONGNAME>
    <PREFERREDNAME>3564393v1.0:3559839v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to represent the degree to which an individual experiences an increase in motor activity attributed to the study medication.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3564393</PublicId>
      <PreferredName>2233215v1.0:3564391v1.0</PreferredName>
      <PreferredDefinition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population.  This is a general term that encompasses the medical, social, behavioral, and environmnetal acts that can have preventive, therapeutic, or palliative effects._Negative; involving disadvantage or harm._Therapeutic Effect; a drug&#39;s intended effect or result._A process of becoming larger, more numerous, more important, or more likely._In medicine, having to do with the movement of body parts._An active process; excludes processes and mechanisms which fulfill biological functions. _The degree or magnitude of strength, energy, or feeling.</PreferredDefinition>
      <LongName>Intervention or Procedure Negative Therapeutic Effect Increased Motor Activity Intensity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218</PreferredName>
        <Version>1</Version>
        <LongName>Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3564391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3564391v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Negative Therapeutic Effect Increase Motor Activity Intensity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25247</PREFERRED_NAME>
            <LONG_NAME>Negative</LONG_NAME>
            <CON_ID>2204840</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38032</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Effect</LONG_NAME>
            <CON_ID>2203965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25533</PREFERRED_NAME>
            <LONG_NAME>Increase</LONG_NAME>
            <CON_ID>2203826</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28367</PREFERRED_NAME>
            <LONG_NAME>Motor</LONG_NAME>
            <CON_ID>2206368</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25539</PREFERRED_NAME>
            <LONG_NAME>Intensity</LONG_NAME>
            <CON_ID>2202454</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3559839</PublicId>
      <PreferredName>3559839v1.0</PreferredName>
      <PreferredDefinition>The degree or magnitude of strength, energy, or feeling._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Intensity Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3559838</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25539:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Intensity Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25539</PREFERRED_NAME>
            <LONG_NAME>Intensity</LONG_NAME>
            <CON_ID>2202454</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Symptom not present</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.: An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3559837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Mild Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.: An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3559836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Moderate Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3559835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Severe Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.: An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3559834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Intensity</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Intensity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="546">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3587176</PUBLICID>
    <LONGNAME>Person Health Insurance Status Type</LONGNAME>
    <PREFERREDNAME>2518942v1.0:3587172v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A condition of a person in reference to having coverage from a health insurance organization._A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss._Something distinguishable as an identifiable class based on common qualities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2518942</PublicId>
      <PreferredName>PRSN_HLTH_INSUR_STAT</PreferredName>
      <PreferredDefinition>A condition of a person in reference to having coverage from a health insurance organization.</PreferredDefinition>
      <LongName>Person Health Insurance Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2518940</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C25178:C16745</PreferredName>
        <Version>1</Version>
        <LongName>Person Health Insurance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25178</PREFERRED_NAME>
            <LONG_NAME>Health</LONG_NAME>
            <CON_ID>2202325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16745</PREFERRED_NAME>
            <LONG_NAME>Insurance</LONG_NAME>
            <CON_ID>2413105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3587172</PublicId>
      <PreferredName>3587172v1.0</PreferredName>
      <PreferredDefinition>Type of insurance</PreferredDefinition>
      <LongName>Insurance Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008540</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PYMT_METH</PreferredName>
        <Version>1</Version>
        <LongName>Payment Methods</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3587171</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16745:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Insurance Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16745</PREFERRED_NAME>
            <LONG_NAME>Insurance</LONG_NAME>
            <CON_ID>2413105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Private health insurance</VALIDVALUE>
          <VALUEMEANING>Private Health Insurance</VALUEMEANING>
          <MEANINGDESCRIPTION>Financial coverage provided through third party reimbursement, that is designed to minimize monetary loss associated with health care costs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3587173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Public health insurance</VALIDVALUE>
          <VALUEMEANING>Insurance, Health, Reimbursement Public</VALUEMEANING>
          <MEANINGDESCRIPTION>Payment by a third-party payer in a sum equal to the amount expended by a health care provider or facility for health services rendered to an insured or program beneficiary. (From Facts on File Dictionary of Health Care Management, 1988): Not private; open to or concerning the people as a whole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49060, C16746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3587174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No insurance</VALIDVALUE>
          <VALUEMEANING>Insurance No</VALUEMEANING>
          <MEANINGDESCRIPTION>A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.: The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487, C16745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3587175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spouse&#39;s insurance</VALIDVALUE>
          <VALUEMEANING>Spouse Insurance</VALUEMEANING>
          <MEANINGDESCRIPTION>A person&#39;s partner in marriage.: A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16745, C62649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Employer Sponsored</VALIDVALUE>
          <VALUEMEANING>Employer Insurance</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or entity which hires the services of another.: A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54144, C16745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medicaid</VALIDVALUE>
          <VALUEMEANING>Medicaid</VALUEMEANING>
          <MEANINGDESCRIPTION>A joint federal and state program that provides assistance with healthcare costs to people with low income and limited resources. Medicaid is run by state and local governments within federal guidelines. Healthcare bills are paid from federal, state and local tax funds. The eligibility for the program does not depend on a person&#39;s age. Participating beneficiaries usually pay no part of costs for covered healthcare expenses except a small co-payment required in some cases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2865123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medicare</VALIDVALUE>
          <VALUEMEANING>Medicare</VALUEMEANING>
          <MEANINGDESCRIPTION>A program under the U.S. Social Security Administration that reimburses hospitals and physicians for medical care provided to qualifying people over 65 years old.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Private insurance plus Medicaid CHIP</VALIDVALUE>
          <VALUEMEANING>Private Insurance With Medicaid Children&#39;s Health Insurance Program</VALUEMEANING>
          <MEANINGDESCRIPTION>Not public; kept secret or restricted.: A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.: Used to indicate the presence of something or someone.: A joint federal and state program that provides assistance with healthcare costs to people with low income and limited resources. Medicaid is run by state and local governments within federal guidelines. Healthcare bills are paid from federal, state and local tax funds. The eligibility for the program does not depend on a person&#39;s age. Participating beneficiaries usually pay no part of costs for covered healthcare expenses except a small co-payment required in some cases.: A state-run insurance program that provides low-cost health coverage to children in families that earn too much money to qualify for Medicaid but not enough to buy private insurance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157359, C68633, C62355, C16745, C54104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6730380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Both Provincial or Territorial and Private Insurance</VALIDVALUE>
          <VALUEMEANING>Both Provincial/Territorial and Private Insurance</VALUEMEANING>
          <MEANINGDESCRIPTION>Both Provincial/Territorial and Private Insurance</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6734085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Provincial or Territorial Health Care Coverage</VALIDVALUE>
          <VALUEMEANING>Provincial or Territorial Health Care Coverage</VALUEMEANING>
          <MEANINGDESCRIPTION>Provincial or Territorial Health Care Coverage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6734086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6424136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Insurance status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Insurance status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>coverage</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What type of health care insurance coverage do you have?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was your child&#39;s health insurance before his/her leukemia diagnosis:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is your child&#39;s current health insurance:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was your child&#39;s current health insurance:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was your child&#39;s health insurance before his/her cancer diagnosis:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRSN_HLTH_INSR_TYP</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CH_HLH_INS_PR_CAN_DX</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="547">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600243</PUBLICID>
    <LONGNAME>Annotation Entity Template Unique Identifier ISO21090.II.v1.0</LONGNAME>
    <PREFERREDNAME>3599720v1.0:2803193v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An explanatory or critical comment that has been added to a text.:That which is perceived or known or inferred to have its own distinct existence (living or nonliving)._Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data._Identifier that uniquely identifies a thing or object.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599720</PublicId>
      <PreferredName>2534205v1.0:3599620v1.0</PreferredName>
      <PreferredDefinition>An explanatory or critical comment that has been added to a text.:That which is perceived or known or inferred to have its own distinct existence (living or nonliving)._Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data.</PreferredDefinition>
      <LongName>Annotation Entity Template Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2534205</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44272:C51070</PreferredName>
        <Version>1</Version>
        <LongName>Annotation Entity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3599620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45677:C70663</PreferredName>
        <Version>1</Version>
        <LongName>Template Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70663</PREFERRED_NAME>
            <LONG_NAME>Unique Identifier</LONG_NAME>
            <CON_ID>2714899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803193</PublicId>
      <PreferredName>2803193v1.0</PreferredName>
      <PreferredDefinition>Identifier that uniquely identifies a thing or object.</PreferredDefinition>
      <LongName>ISO21090.II.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Annotation Entity Template Unique Identifier ISO21090.II.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Annotation Entity Template Unique Identifier ISO21090.II.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnnotationEntity:templateUid</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.AnnotationEntity.templateUid</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="548">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600262</PUBLICID>
    <LONGNAME>Internet Medical Image Reference Object Uniform Resource Identifier ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>2750231v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A worldwide, decentralized network of computer networks connecting individuals and organizations to information and electronic mail services.:Any record of a medical imaging event whether physical or electronic.:Something referred to; the object of a reference._A Uniform Resource Identifier is a character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL. (from http://www.computeruser.com)_Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750231</PublicId>
      <PreferredName>2750185v1.0:2236656v1.0</PreferredName>
      <PreferredDefinition>A worldwide, decentralized network of computer networks connecting individuals and organizations to information and electronic mail services.:Any record of a medical imaging event whether physical or electronic.:Something referred to; the object of a reference._A Uniform Resource Identifier is a character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL. (from http://www.computeruser.com)</PreferredDefinition>
      <LongName>Internet Medical Image Reference Object Uniform Resource Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20342:C19477:C48294</PreferredName>
        <Version>1</Version>
        <LongName>Internet Medical Image Reference Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20342</PREFERRED_NAME>
            <LONG_NAME>Internet</LONG_NAME>
            <CON_ID>2228361</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236656</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42778</PreferredName>
        <Version>1</Version>
        <LongName>Uniform Resource Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42778</PREFERRED_NAME>
            <LONG_NAME>Uniform Resource Identifier</LONG_NAME>
            <CON_ID>2236546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Internet Medical Image Reference Object Uniform Resource Identifier ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Internet Medical Image Reference Object Uniform Resource Identifier ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.UriImageReferenceEntity.uri</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UriImageReferenceEntity:uri</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="549">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600264</PUBLICID>
    <LONGNAME>Image Plane Row Image Orientation X-Coordinate ISO21090.REAL.v1.0</LONGNAME>
    <PREFERREDNAME>3599737v1.0:2803201v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The position and orientation of the image slice relative to the patient-based coordinate system._An arrangement of objects side by side in a line.:Any record of an imaging event whether physical or electronic.:Position or alignment relative to points of the compass or other specific directions.:A horizontal coordinate that is used together with a vertical coordinate to specify an exact point in space._Fractional numbers represented by decimals.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599737</PublicId>
      <PreferredName>3499317v1.0:3599633v1.0</PreferredName>
      <PreferredDefinition>The position and orientation of the image slice relative to the patient-based coordinate system._An arrangement of objects side by side in a line.:Any record of an imaging event whether physical or electronic.:Position or alignment relative to points of the compass or other specific directions.:A horizontal coordinate that is used together with a vertical coordinate to specify an exact point in space.</PreferredDefinition>
      <LongName>Image Plane Row Image Orientation X-Coordinate</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3499317</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102516</PreferredName>
        <Version>1</Version>
        <LongName>Image Plane</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102516</PREFERRED_NAME>
            <LONG_NAME>Image Plane</LONG_NAME>
            <CON_ID>3479213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3599633</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43378:C48179:C45788:C44477</PreferredName>
        <Version>1</Version>
        <LongName>Row Image Orientation X-Coordinate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43378</PREFERRED_NAME>
            <LONG_NAME>Row</LONG_NAME>
            <CON_ID>2236514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45788</PREFERRED_NAME>
            <LONG_NAME>Spatial Orientation</LONG_NAME>
            <CON_ID>2236529</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44477</PREFERRED_NAME>
            <LONG_NAME>X-Coordinate</LONG_NAME>
            <CON_ID>2236519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803201</PublicId>
      <PreferredName>2803201v1.0</PreferredName>
      <PreferredDefinition>Fractional numbers represented by decimals.</PreferredDefinition>
      <LongName>ISO21090.REAL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090REALv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Plane Row Image Orientation X-Coordinate ISO21090.REAL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Plane Row Image Orientation X-Coordinate ISO21090.REAL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagePlane:rowImageOrientationX</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ImagePlane.rowImageOrientationX</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="550">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600350</PUBLICID>
    <LONGNAME>2-Dimensional Point Line Opacity ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3599821v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The property of being measured and described using two orthogonal directions.:The precise location of something; a spatially limited location._A mark that is long relative to its width; a length (straight or curved) without breadth or thickness; the trace of a moving point.:The quality of being opaque to a degree; the degree to which something reduces the passage of light._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599821</PublicId>
      <PreferredName>3599547v1.0:2750162v1.0</PreferredName>
      <PreferredDefinition>The property of being measured and described using two orthogonal directions.:The precise location of something; a spatially limited location._A mark that is long relative to its width; a length (straight or curved) without breadth or thickness; the trace of a moving point.:The quality of being opaque to a degree; the degree to which something reduces the passage of light.</PreferredDefinition>
      <LongName>2-Dimensional Point Line Opacity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48282:C70656</PreferredName>
        <Version>1</Version>
        <LongName>2-Dimensional Point</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48282</PREFERRED_NAME>
            <LONG_NAME>2-Dimensional</LONG_NAME>
            <CON_ID>2422614</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750162</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71604:C71596</PreferredName>
        <Version>1</Version>
        <LongName>Line Opacity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71604</PREFERRED_NAME>
            <LONG_NAME>Line</LONG_NAME>
            <CON_ID>2750137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71596</PREFERRED_NAME>
            <LONG_NAME>Opacity</LONG_NAME>
            <CON_ID>2750136</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element 2-Dimensional Point Line Opacity ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element 2-Dimensional Point Line Opacity ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TwoDimensionPoint:lineOpacity</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.TwoDimensionPoint.lineOpacity</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="551">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600431</PUBLICID>
    <LONGNAME>Dimension Point Question Index ISO21090.INT.v1.0</LONGNAME>
    <PREFERREDNAME>3599893v1.0:2803195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial outline of an object as described by the configuration of straight or curved lines.:The precise location of something; a spatially limited location._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence._Number results from counting and enumerating.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599893</PublicId>
      <PreferredName>3599542v1.0:2899730v1.0</PreferredName>
      <PreferredDefinition>The spatial outline of an object as described by the configuration of straight or curved lines.:The precise location of something; a spatially limited location._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.</PreferredDefinition>
      <LongName>Dimension Point Question Index</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599542</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25483:C70656</PreferredName>
        <Version>1</Version>
        <LongName>Dimension Point</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899730</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C25390</PreferredName>
        <Version>1</Version>
        <LongName>Question Index</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25390</PREFERRED_NAME>
            <LONG_NAME>Index</LONG_NAME>
            <CON_ID>2203825</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803195</PublicId>
      <PreferredName>2803195v1.0</PreferredName>
      <PreferredDefinition>Number results from counting and enumerating.</PreferredDefinition>
      <LongName>ISO21090.INT.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Dimension Point Question Index ISO21090.INT.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Dimension Point Question Index ISO21090.INT.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ThreeDimensionPoint:questionIndex</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ThreeDimensionPoint.questionIndex</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="552">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600569</PUBLICID>
    <LONGNAME>2-Dimensional Circle Reference Object Frame Device Component Number ISO21090.INT.v1.0</LONGNAME>
    <PREFERREDNAME>3600028v1.0:2803195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The property of being measured and described using two orthogonal directions.:A ring-shaped structure with every point equidistant from the center._Something referred to; the object of a reference.:A structure designed to support or contain an object.:A numeral or string of numerals expressing value, quantity, or identification._Number results from counting and enumerating.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3600028</PublicId>
      <PreferredName>3599551v1.0:3599649v1.0</PreferredName>
      <PreferredDefinition>The property of being measured and described using two orthogonal directions.:A ring-shaped structure with every point equidistant from the center._Something referred to; the object of a reference.:A structure designed to support or contain an object.:A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>2-Dimensional Circle Reference Object Frame Device Component Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48282:C45789</PreferredName>
        <Version>1</Version>
        <LongName>2-Dimensional Circle</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48282</PREFERRED_NAME>
            <LONG_NAME>2-Dimensional</LONG_NAME>
            <CON_ID>2422614</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45789</PREFERRED_NAME>
            <LONG_NAME>Circle</LONG_NAME>
            <CON_ID>2236602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3599649</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48294:C49963:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Reference Object Frame Device Component Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49963</PREFERRED_NAME>
            <LONG_NAME>Frame Device</LONG_NAME>
            <CON_ID>3599511</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803195</PublicId>
      <PreferredName>2803195v1.0</PreferredName>
      <PreferredDefinition>Number results from counting and enumerating.</PreferredDefinition>
      <LongName>ISO21090.INT.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element 2-Dimensional Circle Reference Object Frame Device Component Number ISO21090.INT.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element 2-Dimensional Circle Reference Object Frame Device Component Number ISO21090.INT.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.TwoDimensionCircle.referencedFrameNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TwoDimensionCircle:referencedFrameNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="553">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3607996</PUBLICID>
    <LONGNAME>Dose Limiting Toxicity</LONGNAME>
    <PREFERREDNAME>2184272v1.0:3607993v1.0_360798</PREFERREDNAME>
    <PREFERREDDEFINITION>Toxicity type that makes it impossible to escalate the dosage of a therapy agent/measure._A position on a scale of intensity or amount or quality for dose limiting toxicity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012911</PublicId>
      <PreferredName>DOSE_LIMT_TOX</PreferredName>
      <PreferredDefinition>Toxicity type that makes it impossible to escalate the dosage of a therapy agent/measure.</PreferredDefinition>
      <LongName>Dose Limiting Toxicity</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206422</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488:CL110648</PreferredName>
        <Version>1</Version>
        <LongName>Dose Limited</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL110648</PREFERRED_NAME>
            <LONG_NAME>Limited</LONG_NAME>
            <CON_ID>2203515</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177313</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Toxicity</PreferredName>
        <Version>1</Version>
        <LongName>Toxicity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27990</PREFERRED_NAME>
            <LONG_NAME>Toxicity</LONG_NAME>
            <CON_ID>2202546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3607987</PublicId>
      <PreferredName>3607987v1.0</PreferredName>
      <PreferredDefinition>A position on a scale of intensity or amount or quality for dose limiting toxicity.</PreferredDefinition>
      <LongName>Adverse Event Worst Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2453188</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48309</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Greater than or equal to Grade 3 non-hematologic toxicity, not an expected toxicity of Cis-Etop regimen, specify</VALIDVALUE>
          <VALUEMEANING>Negation Hematologic Severe Adverse Event</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Pertaining to or related to the blood and blood-forming organs.: Severe adverse event is an experience that requires therapeutic intervention and interrupts busual daily activities. See NCI Common Terminology Criteria for Adverse Events.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41340, C62780, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 anemia</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2869, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 thrombocytopenia</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Thrombocytopenia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A condition in which there is an abnormally small number of platelets in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3408, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 neutropenia</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Neutrophil Count Decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A decrease in the number of neutrophils in the peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80520, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 neutropenia with persisent fever (febrile neutropenia) for more than 7 days</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Neutropenic Fever</VALUEMEANING>
          <MEANINGDESCRIPTION>Severe adverse event is an experience that requires therapeutic intervention and interrupts busual daily activities. See NCI Common Terminology Criteria for Adverse Events.: Neutropenia associated with fever, the latter indicating the presence of an infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35665, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 diarrhea lasting for more than 72 hours despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Diarrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Watery bowel movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2987, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 vomiting lasting for more than 72 hours despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Forceful ejection of the contents of the stomach through the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3442, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 nausea lasting for more than 72 hours despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Nausea</VALUEMEANING>
          <MEANINGDESCRIPTION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Upper abdominal discomfort associated with an urge to vomit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3258, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3+ non-hematological toxicity</VALIDVALUE>
          <VALUEMEANING>Grade 3+ non-hematological toxicity</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3+ non-hematological toxicity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 hypophosphatemia with life-threatening consequence</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Hypophosphatemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of phosphates in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37977, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 hyponatremia with life-threatening consequence</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Hyponatremia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of sodium in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37976, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 hypomagnesemia with life-threatening consequence</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Hypomagnesemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of magnesium in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37975, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 hypokalemia with life-threatening consequence</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Hypokalemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of potassium in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37974, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 hypophosphatemia lasting longer than 72 hours despite active replacement</VALIDVALUE>
          <VALUEMEANING>Hypophosphatemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Hypophosphatemia; lower than normal levels of phosphates in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2751402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 hyponatremia lasting longer than 72 hours despite active replacement</VALIDVALUE>
          <VALUEMEANING>Hyponatremia</VALUEMEANING>
          <MEANINGDESCRIPTION>Lower than normal levels of sodium in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4291753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 hypomagnesemia lasting longer than 72 hours despite active replacement</VALIDVALUE>
          <VALUEMEANING>Hypomagnesemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the  blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 hypokalemia lasting longer than 72 hours despite active replacement</VALIDVALUE>
          <VALUEMEANING>Hypokalemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of potassium in the  blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 hyperglycemia lasting longer than 24 hours despite active management or any duration with life-threatening consequences</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Hyperglycemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Abnormally high level of glucose in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26797, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 creatinine lasting longer than 72 hours despite hydration</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 creatinine</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 bilirubin increased</VALIDVALUE>
          <VALUEMEANING>Hyperbilirubinemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27088</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4395655</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 AST</VALIDVALUE>
          <VALUEMEANING>SGOT (AST)</VALUEMEANING>
          <MEANINGDESCRIPTION>A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 ALT</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 ALT</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 ALT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 GGT</VALIDVALUE>
          <VALUEMEANING>Gamma-Glutamyl Transpeptidase</VALUEMEANING>
          <MEANINGDESCRIPTION>GGT participates in the transfer of amino acids across the cellular membrane and in glutathione metabolism. High concentrations are found in the liver, bile ducts, and the kidney.  A test that measures the amount of GGT in the blood is used to detect diseases of the liver, bile ducts, and kidney; and to differentiate liver or bile duct (hepatobiliary) disorders from bone disease. (from http://health.allrefer.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3467391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 diarrhea</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Diarrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Watery bowel movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2987, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 vomiting</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Forceful ejection of the contents of the stomach through the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3442, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 nausea</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Nausea</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Upper abdominal discomfort associated with an urge to vomit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3258, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematologic toxicity resulting in treatment delay of more than 14 days</VALIDVALUE>
          <VALUEMEANING>Hematologic toxicity resulting in treatment delay of more than 14 days</VALUEMEANING>
          <MEANINGDESCRIPTION>Hematologic toxicity resulting in treatment delay of more than 14 days</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 thrombocytopenia in the presence of bleeding</VALIDVALUE>
          <VALUEMEANING>Severe Adverse Event Thrombocytopenia</VALUEMEANING>
          <MEANINGDESCRIPTION>An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: A condition in which there is an abnormally small number of platelets in the circulating blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3408, C41340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4420612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 anemia for more than 7 days</VALIDVALUE>
          <VALUEMEANING>Life Threatening or Disabling Adverse Event Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2869, C41337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3607989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 febrile neutropenia</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 Febrile Neutropenia</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 Febrile Neutropenia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2636912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 headache for more than 7 days despite maximum supportive care measures</VALIDVALUE>
          <VALUEMEANING>Grade 3 headache for more than 7 days despite maximum supportive care measures</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 headache for more than 7 days despite maximum supportive care measures</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Existing &gt; Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy</VALIDVALUE>
          <VALUEMEANING>Existing &gt; Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Existing &gt; Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Development of &gt; Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</VALIDVALUE>
          <VALUEMEANING>Development of &gt; Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</VALUEMEANING>
          <MEANINGDESCRIPTION>Development of &gt; Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 diarrhea occurring despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 diarrhea occurring despite optimal medical management</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 diarrhea occurring despite optimal medical management</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</VALIDVALUE>
          <VALUEMEANING>Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</VALUEMEANING>
          <MEANINGDESCRIPTION>Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 anorexia occurring despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 anorexia occurring despite optimal medical management</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 anorexia occurring despite optimal medical management</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 vomiting occurring despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 vomiting occurring despite optimal medical management</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 vomiting occurring despite optimal medical management</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 nausea occurring despite optimal medical management</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 nausea occurring despite optimal medical management</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 nausea occurring despite optimal medical management</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 4 neutropenia for more than 7 days</VALIDVALUE>
          <VALUEMEANING>Grade 4 neutropenia for more than 7 days</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 4 neutropenia for more than 7 days</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4649518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Myelosuppression</VALIDVALUE>
          <VALUEMEANING>Other Myelosuppression</VALUEMEANING>
          <MEANINGDESCRIPTION>Other Myelosuppression</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 AST elevation</VALIDVALUE>
          <VALUEMEANING>Grade 3 AST elevation</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 AST elevation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 ALT elevation</VALIDVALUE>
          <VALUEMEANING>Grade 3 ALT elevation</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 ALT elevation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 or greater bowel perforation</VALIDVALUE>
          <VALUEMEANING>Grade 3 or greater bowel perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 or greater bowel perforation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3 or greater colitis</VALIDVALUE>
          <VALUEMEANING>Grade 3 or greater colitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3 or greater colitis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 pneumonitis</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 pneumonitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 pneumonitis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 immune related adverse event</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 immune related adverse event</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 immune related adverse event</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 hypersensitivity reaction</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 hypersensitivity reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 hypersensitivity reaction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3-4 non-hematologic toxicity</VALIDVALUE>
          <VALUEMEANING>Grade 3-4 non-hematologic toxicity</VALUEMEANING>
          <MEANINGDESCRIPTION>Grade 3-4 non-hematologic toxicity</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Worst grade</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Worst grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose Limiting Toxicity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="554">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3607997</PUBLICID>
    <LONGNAME>New Malignant Neoplasm Present Indicator</LONGNAME>
    <PREFERREDNAME>2526463v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a new malignant neoplasm was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2526463</PublicId>
      <PreferredName>NEW_MALNEO_PRES</PreferredName>
      <PreferredDefinition>information related to a new tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues being found during specified time.</PreferredDefinition>
      <LongName>New Malignant Neoplasm Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206435</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25586:C9305</PreferredName>
        <Version>1</Version>
        <LongName>New Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>New Malignancy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>New Malignancy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="555">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3610083</PUBLICID>
    <LONGNAME>Retinopathy Disease Present Indicator</LONGNAME>
    <PREFERREDNAME>2527444v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not retinopathy was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527444</PublicId>
      <PreferredName>RET_DZ_PRES</PreferredName>
      <PreferredDefinition>information related to any abnormal condition of the retina, the light-sensitive membrane lining the posterior part of the inside of the eye, that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person being found.</PreferredDefinition>
      <LongName>Retinopathy Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2527442</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62601:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Retinopathy Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62601</PREFERRED_NAME>
            <LONG_NAME>Retinopathy</LONG_NAME>
            <CON_ID>2521763</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Retinopathy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Retinopathy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history of retinal vein occlusion (RVO)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history or current evidence/risk of retinal vein occlusion (RVO)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have ongoing retinopathy greater than Grade 2</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have ongoing retinopathy greater than Grade 2?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2527444v1.0:2784450v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_RETIN_PATH_IND</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="556">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3611047</PUBLICID>
    <LONGNAME>Growth Hormone Secretion Abnormality Disease Present Indicator</LONGNAME>
    <PREFERREDNAME>2550668v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a growth hormone secretion abnormality was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2550668</PublicId>
      <PreferredName>GRWTHHORSEC_DZ_PRES</PreferredName>
      <PreferredDefinition>information related to an abnormality of growth hormone production resulting in  below normal levels of circulating growth that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person being found.</PreferredDefinition>
      <LongName>Growth Hormone Secretion Abnormality Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2550666</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62800:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Growth Hormone Secretion Abnormality Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62800</PREFERRED_NAME>
            <LONG_NAME>Growth Hormone Secretion Abnormality</LONG_NAME>
            <CON_ID>2528504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Growth hormone secretion abno</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Growth hormone secretion abnormality</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="557">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3622221</PUBLICID>
    <LONGNAME>Oropharynx Primary Malignant Neoplasm Diagnosis Yes No Indicator</LONGNAME>
    <PREFERREDNAME>Orop_Prim_Mali_Diag_YES_NO_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the presence of the original site of a tumor composed of atypical neoplastic being in the part of the pharynx between the soft palate and the upper portion of the epiglottis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3622220</PublicId>
      <PreferredName>Orop_Prim_Mali_Diag</PreferredName>
      <PreferredDefinition>information related to presence of the original site of a tumor composed of atypical neoplastic being in the part of the pharynx between the soft palate and the upper portion of the epiglottis.</PreferredDefinition>
      <LongName>Oropharynx Primary Malignant Neoplasm Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3622218</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12762:C25251:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Oropharynx Primary Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12762</PREFERRED_NAME>
            <LONG_NAME>Oropharynx</LONG_NAME>
            <CON_ID>2202771</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have Orophar</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have Oropharynx primary</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ORO_P_MAL_DIAG_YN</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Orop_Prim_Mali_Diag_YES_NO_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="558">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3626299</PUBLICID>
    <LONGNAME>Epstein-Barr Virus Infection Occurrence Indicator</LONGNAME>
    <PREFERREDNAME>3626298v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not an Epstein-Barr virus infection occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3626298</PublicId>
      <PreferredName>3626296v1.0:2234856v1.0</PreferredName>
      <PreferredDefinition>A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt&#39;s lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations._A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Epstein-Barr Virus Infection Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3626296</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14204:C26726</PreferredName>
        <Version>1</Version>
        <LongName>Epstein-Barr Virus Infection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14204</PREFERRED_NAME>
            <LONG_NAME>Epstein-Barr Virus</LONG_NAME>
            <CON_ID>2205370</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26726</PREFERRED_NAME>
            <LONG_NAME>Infectious Disorder</LONG_NAME>
            <CON_ID>2203837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did an Epstein-Barr virus inf</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did an Epstein-Barr virus infection occur?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Epstein-Barr virus (EBV):</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Epstein-Barr virus (EBV):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2039r1: Hemophagocytic Lymphohistiocytosis Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3279244</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>felh_base_diag_ebv_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HLHpre_infect_prep_ebv_infect_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="559">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3639037</PUBLICID>
    <LONGNAME>Person Peak Systolic Blood Pressure Measurement Value</LONGNAME>
    <PREFERREDNAME>PEAK_SYS_BP_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The highest systolic blood pressure obtained during a period of activity or exercise.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3639019</PublicId>
      <PreferredName>PEAK_SYS_BP_RATE</PreferredName>
      <PreferredDefinition>The most extreme possible amount or value; the highest point._ (NCI)_The blood pressure during the contraction of the left ventricle of the heart._Measurement is the determination of the size or magnitude of something.  It is also used ro refer to the result of this act.</PreferredDefinition>
      <LongName>Person Peak Systolic Blood Pressure Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3639017</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C48054:C25298</PreferredName>
        <Version>1</Version>
        <LongName>Person Peak Systolic Blood Pressure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48054</PREFERRED_NAME>
            <LONG_NAME>Peak</LONG_NAME>
            <CON_ID>2483456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25298</PREFERRED_NAME>
            <LONG_NAME>Systolic Blood Pressure</LONG_NAME>
            <CON_ID>2206259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2697685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37990</PreferredName>
        <Version>1</Version>
        <LongName>Measurement - Retired</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37990</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2534954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182880</PublicId>
      <PreferredName>BLOOD_PRESSURE_SYSTOLIC</PreferredName>
      <PreferredDefinition>Indicating the maximum arterial pressure occurring during contraction of the left ventricle of the heart.</PreferredDefinition>
      <LongName>Blood Pressure, Systolic</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mmHg</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Exercise peak systolic blood</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Exercise peak systolic blood pressure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="560">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3647034</PUBLICID>
    <LONGNAME>Person Person Cerebrospinal Fluid Collection Other Disease or Disorder Research Activity Consent Yes No Indicator</LONGNAME>
    <PREFERREDNAME>Pers_Cere_Coll_Othe_Dise_Rese_</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the consent and collection of a cerebrospinal fluid specimen used in research.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647031</PublicId>
      <PreferredName>Pers_Cere_Coll_Othe_Dise_Rese_</PreferredName>
      <PreferredDefinition>information related to the consent and collection of a cerebrospinal fluid specimen used in research.</PreferredDefinition>
      <LongName>Person Cerebrospinal Fluid Collection Other Disease or Disorder Research Activity Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3647029v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Cerebrospinal Fluid Collection Other Disease or Disorder Research Activity Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12692</PREFERRED_NAME>
            <LONG_NAME>Cerebrospinal Fluid</LONG_NAME>
            <CON_ID>2202710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15429</PREFERRED_NAME>
            <LONG_NAME>Research Activity</LONG_NAME>
            <CON_ID>2528433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>My cerebrospinal fluid may be</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>My cerebrospinal fluid may be kept for use in research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer&#39;s disease, or heart disease).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1114</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Pers_Cere_Coll_Othe_Dise_Rese_</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="561">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3651255</PUBLICID>
    <LONGNAME>Surgical Procedure Lumpectomy Excisional Biopsy Performed Indicator</LONGNAME>
    <PREFERREDNAME>2011455v3.0:3270332v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No/Don&#39;t know indicator to signify whether an excisional biopsy or lumpectomy was performed</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2011455</PublicId>
      <PreferredName>SX_LUMP_BX_PERF</PreferredName>
      <PreferredDefinition>information related to lumpectomy, the removal of a cancer as well as some of the breast tissue around the tumor and the lining over the chest muscles below the tumor, or excisional biopsy, a surgical procedure in which an entire lump or suspicious area is removed for diagnosis, sed for operative procedures on organs, as the surgical procedure being performed.</PreferredDefinition>
      <LongName>Surgical Procedure Lumpectomy Excisional Biopsy Performed</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2728659</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15755:C15385:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Lumpectomy Excisional Biopsy Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15755</PREFERRED_NAME>
            <LONG_NAME>Lumpectomy</LONG_NAME>
            <CON_ID>2204902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15385</PREFERRED_NAME>
            <LONG_NAME>Excisional Biopsy</LONG_NAME>
            <CON_ID>2407152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3270332</PublicId>
      <PreferredName>3270332v1.0</PreferredName>
      <PreferredDefinition>The affirmative response to a question or activity._The non-affirmative response to a question._The answer is not known by the person answering._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Yes No Does Not Know Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3270331</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C67142:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Does Not Know Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67142</PREFERRED_NAME>
            <LONG_NAME>Does Not Know</LONG_NAME>
            <CON_ID>2653836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you ever had a surgical</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you ever had a surgical breast biopsy, which is the removal of breast tissue by surgery for the purpose of making a diagnosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>lumpectomy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you ever had a surgical procedure to have a breast lump or tumor removed (lumpectomy)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="562">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3653024</PUBLICID>
    <LONGNAME>Medication COX-2 Inhibitor Current Use Indicator</LONGNAME>
    <PREFERREDNAME>3379228v1.0:3624918v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A manner, or usual, or accepted practice of using a subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation._Occurring in or belonging to the present time._A drug or medicine that treats or prevents or alleviates the symptoms of disease._put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3379228</PublicId>
      <PreferredName>2411879v1.0:3379226v1.0</PreferredName>
      <PreferredDefinition>A manner, or usual, or accepted practice of using a subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.</PreferredDefinition>
      <LongName>Medication COX-2 Inhibitor Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411879</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C459</PreferredName>
        <Version>1</Version>
        <LongName>Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3379226</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80509:C25340</PreferredName>
        <Version>1</Version>
        <LongName>COX-2 Inhibitor Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80509</PREFERRED_NAME>
            <LONG_NAME>COX-2 Inhibitor</LONG_NAME>
            <CON_ID>3218961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3624918</PublicId>
      <PreferredName>3624918v1.0</PreferredName>
      <PreferredDefinition>Occurring in or belonging to the present time._A drug or medicine that treats or prevents or alleviates the symptoms of disease._put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Current Medication Use Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3624917</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C459:C0449865:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Current Medication Use Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0449865</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2204113</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>no</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you currently taking Cox-</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you currently taking Cox-2 inhibitor medications?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="563">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3653312</PUBLICID>
    <LONGNAME>Lowest Weight since Age 18 years Value</LONGNAME>
    <PREFERREDNAME>3651575v1.0:3187759v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Lowest weight since age 18_The numerical result of the determination of the vertical force exerted by the mass of an individual as a result of gravity using the following format:__lbs__oz.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3651575</PublicId>
      <PreferredName>3651573v1.0:3651557v1.0</PreferredName>
      <PreferredDefinition>Lowest weight since age 18</PreferredDefinition>
      <LongName>Lowest Weight since Age 18 years</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3651573</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43517:C25208</PreferredName>
        <Version>1</Version>
        <LongName>Lowest Weight</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43517</PREFERRED_NAME>
            <LONG_NAME>Lowest</LONG_NAME>
            <CON_ID>2202385</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3651557</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3651557v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Age Post Integer::18 Year</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::18</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3187759</PublicId>
      <PreferredName>WT_VAL</PreferredName>
      <PreferredDefinition>The numerical result of the determination of the vertical force exerted by the mass of an individual as a result of gravity using the following format:__lbs__oz.</PreferredDefinition>
      <LongName>Weight Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>lb</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
      <Representation>
        <PublicId>3187762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25208:C48531:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Weight Pound Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48531</PREFERRED_NAME>
            <LONG_NAME>Pound</LONG_NAME>
            <CON_ID>2480771</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Since age 18, what is the lea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Since age 18, what is the least you have ever weighed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="564">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3656077</PUBLICID>
    <LONGNAME>Radiation Therapy Motion Control Technique Yes No Indicator</LONGNAME>
    <PREFERREDNAME>Radi_Moti_Cont_Tech_Yes_No</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether managing movement in the treatment of a disease by means of exposure of the target or the whole body to radiation was used.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3567408</PublicId>
      <PreferredName>Radi_Moti_Cont_Tech</PreferredName>
      <PreferredDefinition>information related to the method of managing movement in the treatment of a disease by means of exposure of the target or the whole body to radiation.</PreferredDefinition>
      <LongName>Radiation Therapy Motion Control Technique</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3587324</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75602:C61299:C16847</PreferredName>
        <Version>1</Version>
        <LongName>Motion Control Technique</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75602</PREFERRED_NAME>
            <LONG_NAME>Motion</LONG_NAME>
            <CON_ID>2775974</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61299</PREFERRED_NAME>
            <LONG_NAME>Control</LONG_NAME>
            <CON_ID>2527789</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16847</PREFERRED_NAME>
            <LONG_NAME>Technique</LONG_NAME>
            <CON_ID>2203854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was chest wall motion control</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was chest wall motion control used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="565">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3679672</PUBLICID>
    <LONGNAME>Person Cytochrome P450 3A4 Induction Agent Eligibility Determination End Date</LONGNAME>
    <PREFERREDNAME>CYP3A4INDCRDT</PREFERREDNAME>
    <PREFERREDDEFINITION>the last date an agent was received that induces the human CYP3A4 gene.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3233732</PublicId>
      <PreferredName>2236731v1.0:3233730v1.0</PreferredName>
      <PreferredDefinition>information related to criteria to determine eligibility of patients for medical care programs and services based on having received an agent that induces human CYP3A4 Gene.</PreferredDefinition>
      <LongName>Person Cytochrome P450 3A4 Induction Agent Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3233730</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17573:C61367:C1708:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Cytochrome P450 3A4 Induction Agent Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17573</PREFERRED_NAME>
            <LONG_NAME>Cytochrome P450 3A4</LONG_NAME>
            <CON_ID>2944364</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61367</PREFERRED_NAME>
            <LONG_NAME>Induction</LONG_NAME>
            <CON_ID>2612143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188674</PublicId>
      <PreferredName>END_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event ended.</PreferredDefinition>
      <LongName>End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184285</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CYP3A4 inducer therapy end da</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CYP3A4 inducer therapy end date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of CYP3A4 inducer treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of CYP3A4 inducer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of strong CYP3A4 inducer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last CYP3A4 Inducer Treatment Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CYP3A4INDCRDT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CMSTDAT_CYPIND</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="566">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3704171</PUBLICID>
    <LONGNAME>Pain Medication Side Effect Descriptive Text</LONGNAME>
    <PREFERREDNAME>PN_MED_SD_EFF_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text to describe the side effects attributed to the use of pain medication.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3704163</PublicId>
      <PreferredName>2207030v1.0:2710574v1.0</PreferredName>
      <PreferredDefinition>The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._A drug or medicine that treats or prevents or alleviates the symptoms of disease._An unwanted side effect of treatment.</PreferredDefinition>
      <LongName>Pain Medication Side Effect</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2207030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C459</PreferredName>
        <Version>1</Version>
        <LongName>Pain Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710574</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2861</PreferredName>
        <Version>1</Version>
        <LongName>Side Effect</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2861</PREFERRED_NAME>
            <LONG_NAME>Side Effect</LONG_NAME>
            <CON_ID>2202904</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Which side effects?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Which side effects?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="567">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3722714</PUBLICID>
    <LONGNAME>Lymphedema and Breast Cancer Questionnaire Today Or Past Month Feel Weakness in Arm or Hand Experience Indicator</LONGNAME>
    <PREFERREDNAME>3722462v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of whether or not today or in the past month they feel or felt weakness in their arm or hand, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3722462</PublicId>
      <PreferredName>3718831v1.0:3722460v1.0</PreferredName>
      <PreferredDefinition>A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer._The day that includes the present moment, as distinct from yesterday or tomorrow._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Before the present time._One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks_A question about whether an individual has or had weakness in their arm or hand._The accumulation of knowledge or skill that results from direct participation in events or activities.</PreferredDefinition>
      <LongName>Lymphedema and Breast Cancer Questionnaire Today Or Past Month Feel Weakness in Arm or Hand Experience</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3718831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105763</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema and Breast Cancer Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105763</PREFERRED_NAME>
            <LONG_NAME>Lymphedema and Breast Cancer Questionnaire</LONG_NAME>
            <CON_ID>3715997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3722460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3722460v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Today Or Past Month Feel Weakness in Arm or Hand Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41134</PREFERRED_NAME>
            <LONG_NAME>Today</LONG_NAME>
            <CON_ID>2527867</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105768</PREFERRED_NAME>
            <LONG_NAME>Feel Weakness in Arm or Hand Question</LONG_NAME>
            <CON_ID>3715840</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does your arm or hand feel we</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does your arm or hand feel weak now?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does your arm or hand feel weak today?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3704455</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LBCQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LBCQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3704456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema and Breast Cancer Questionnaire (LBCQ)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="568">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3723619</PUBLICID>
    <LONGNAME>Lymphedema and Breast Cancer Questionnaire During Past Year Have Swelling with Pitting Experience Indicator</LONGNAME>
    <PREFERREDNAME>3722531v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of whether or not during the past year they have or had swelling with pitting in their arm, breast, or chest, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3722531</PublicId>
      <PreferredName>3718831v1.0:3722529v1.0</PreferredName>
      <PreferredDefinition>A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer._At some point in a given period of time._Past; before the present time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._A question about whether an individual has or had swelling or pitting; which occurs when you press firmly on your skin and the dent stays long enough to feel it when you slide the pad of your finger across it._The accumulation of knowledge or skill that results from direct participation in events or activities.</PreferredDefinition>
      <LongName>Lymphedema and Breast Cancer Questionnaire During Past Year Have Swelling with Pitting Experience</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3718831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105763</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema and Breast Cancer Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105763</PREFERRED_NAME>
            <LONG_NAME>Lymphedema and Breast Cancer Questionnaire</LONG_NAME>
            <CON_ID>3715997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3722529</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3722529v1.0</PreferredName>
        <Version>1</Version>
        <LongName>During Past Year Have Swelling with Pitting Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105771</PREFERRED_NAME>
            <LONG_NAME>Have Swelling with Pitting Question</LONG_NAME>
            <CON_ID>3715994</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you experienced swelling</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you experienced swelling with pitting during the past year?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Pitting is when you press firmly on your skin and the dent stays long enough to feel it when you slide the pad of your finger across it.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3704455</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LBCQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LBCQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3704456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema and Breast Cancer Questionnaire (LBCQ)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="569">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3724338</PUBLICID>
    <LONGNAME>Lymphedema and Breast Cancer Questionnaire During Past Year Have Blistering Experience Indicator</LONGNAME>
    <PREFERREDNAME>3722537v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of whether or not during the past year they have or had blistering in their arm, breast, or chest, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3722537</PublicId>
      <PreferredName>3718831v1.0:3722535v1.0</PreferredName>
      <PreferredDefinition>A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer._At some point in a given period of time._Past; before the present time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._A question about whether an individual has or had blistering._The accumulation of knowledge or skill that results from direct participation in events or activities.</PreferredDefinition>
      <LongName>Lymphedema and Breast Cancer Questionnaire During Past Year Have Blistering Experience</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3718831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105763</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema and Breast Cancer Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105763</PREFERRED_NAME>
            <LONG_NAME>Lymphedema and Breast Cancer Questionnaire</LONG_NAME>
            <CON_ID>3715997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3722535</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3722535v1.0</PreferredName>
        <Version>1</Version>
        <LongName>During Past Year Have Blistering Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105773</PREFERRED_NAME>
            <LONG_NAME>Have Blistering Question</LONG_NAME>
            <CON_ID>3715999</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you experienced blisteri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you experienced blistering during the past year?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3704455</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LBCQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LBCQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3704456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema and Breast Cancer Questionnaire (LBCQ)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="570">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3725939</PUBLICID>
    <LONGNAME>Lymphedema and Breast Cancer Questionnaire Have Other Symptoms Action Performed Descriptive Text</LONGNAME>
    <PREFERREDNAME>3722651v1.0:2181231v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s description of the action taken for other symptoms in their arm, breast, or chest, using a text field.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3722651</PublicId>
      <PreferredName>3718831v1.0:3722649v1.0</PreferredName>
      <PreferredDefinition>A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer._A question about whether an individual has or had other symptoms._A thing done._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Lymphedema and Breast Cancer Questionnaire Have Other Symptoms Action Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3718831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105763</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema and Breast Cancer Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105763</PREFERRED_NAME>
            <LONG_NAME>Lymphedema and Breast Cancer Questionnaire</LONG_NAME>
            <CON_ID>3715997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3722649</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105783:C25404:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Have Other Symptoms Action Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105783</PREFERRED_NAME>
            <LONG_NAME>Have Other Symptoms Question</LONG_NAME>
            <CON_ID>3715988</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25404</PREFERRED_NAME>
            <LONG_NAME>Action</LONG_NAME>
            <CON_ID>2203586</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What action you did for this</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What action you did for this symptom: Please describe.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3704455</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LBCQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LBCQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3704456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema and Breast Cancer Questionnaire (LBCQ)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="571">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3745012</PUBLICID>
    <LONGNAME>Lung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N Stage</LONGNAME>
    <PREFERREDNAME>2188855v1.0:3744935v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the regional lymph node involvement for the lung carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</ORIGIN>
    <REGISTRATIONSTATUS>Preferred Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188855</PublicId>
      <PreferredName>LUNG_TUMOR_C_N</PreferredName>
      <PreferredDefinition>Information related to clinical N stage of a lung tumor.</PreferredDefinition>
      <LongName>Lung Tumor Clinical N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206550</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Lung Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428496</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Clinical N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3744935</PublicId>
      <PreferredName>3744935v1.0</PreferredName>
      <PreferredDefinition>A finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system.  This classification is used for both non-small cell and small cell lung carcinomas and for carcinoid tumors of the lung.  Sarcomas and other rare tumors of the lung are not included. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. N refers to the extent of lymph node involvement._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Lung Cancer American Joint Committee on Cancer Edition 7 N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>3744934</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88865:C39315:C25580:C16899</PreferredName>
        <Version>1</Version>
        <LongName>Lung Cancer TNM Finding v7 American Joint Committee on Cancer N Stage Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88865</PREFERRED_NAME>
            <LONG_NAME>Lung Cancer TNM Finding v7</LONG_NAME>
            <CON_ID>3744911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N3</VALIDVALUE>
          <VALUEMEANING>Lung Cancer N3 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2924666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N2</VALIDVALUE>
          <VALUEMEANING>Lung Cancer N2 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2924668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Lung Cancer N1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3744937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>Lung Cancer N0 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer with no evidence of metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3744938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>Lung Cancer NX TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Lung cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3744939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Clinical N Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Clinical N Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>N</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>N</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL Path-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical TNM Class N</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical TNM Class N</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Lung-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Clinical TNM Class N</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA-Lung-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>American Joint Committee on Cancer clinical regional lymph node N stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Template Name</Name>
        <OrganizationName/>
        <DocumentType>Data Collection Template</DocumentType>
        <DocumentText>lung_v0_2021_08_25-metrics.xlsx</DocumentText>
        <URL>https://mcl.nci.nih.gov/resources/standards/mcl-cdes</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung (Non-Small Cell)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3744891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461150</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5271072</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung-Vanderbilt</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5152114</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506111</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung-Vanderbilt</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5506169</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506111</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5506172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506111</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7781146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506115</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vanderbilt Image Archive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5983666</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506116</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pathology</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung Pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5855641</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung-NSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5777523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6437797</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pre-Cancer Atlas (PCA) Pilot</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7001792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AJCCN</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ajcc_7_lung_clinical_n</AlternateName>
        <AlternateNameType>MCL Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="572">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3757180</PUBLICID>
    <LONGNAME>Nucleated Blood Cell Laboratory Procedure Yes No Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>NucClTtlIND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/not applicable indicator related to the testing of the cellular material of blood consisting of white blood cells and nucleated red blood cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760135</PublicId>
      <PreferredName>NUCL_CEL_LAB_PRO</PreferredName>
      <PreferredDefinition>The cellular material of blood consisting of white blood cells and nucleated red blood cells._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.</PreferredDefinition>
      <LongName>Nucleated Blood Cell Laboratory Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2760133</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73126</PreferredName>
        <Version>1</Version>
        <LongName>Nucleated Blood Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73126</PREFERRED_NAME>
            <LONG_NAME>Nucleated Blood Cell</LONG_NAME>
            <CON_ID>2735707</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2486250</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was total nucleated cell coun</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was total nucleated cell count (TNC) performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="573">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760747</PUBLICID>
    <LONGNAME>Generalized Statistics Factor Type Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3759973v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the kind of general statistical consideration. EXAMPLE(S): subgroup, analysis set, missing data algorithm, derivation algorithm, assessment window, multiple comparison strategy, center pooling.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3759973</PublicId>
      <PreferredName>3757163v1.0:2607570v1.0</PreferredName>
      <PreferredDefinition>Widespread, broadly dispersed, common.:A branch of applied mathematics concerned with the collection and interpretation of quantitative data and the use of probability theory to estimate population parameters.:Anything that contributes causally to a result._Something distinguishable as an identifiable class based on common qualities.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Generalized Statistics Factor Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757163</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63764:C17167:C25506</PreferredName>
        <Version>1</Version>
        <LongName>Generalized Statistics Factor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63764</PREFERRED_NAME>
            <LONG_NAME>Generalized</LONG_NAME>
            <CON_ID>2547905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17167</PREFERRED_NAME>
            <LONG_NAME>Statistics</LONG_NAME>
            <CON_ID>2542369</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25506</PREFERRED_NAME>
            <LONG_NAME>Factor</LONG_NAME>
            <CON_ID>2202640</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607570</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Type Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Generalized Statistics Factor Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Generalized Statistics Factor Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StatisticalAnalysisSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneralStatisticalConsideration:typeCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StatisticalAnalysisSubDomain.GeneralStatisticalConsideration.typeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneralStatisticalConsideration.typeCode</AlternateName>
        <AlternateNameType>Map:Statistics v1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="574">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760800</PUBLICID>
    <LONGNAME>Report Received By Receive Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3760024v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies whether the receiver received the report.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760024</PublicId>
      <PreferredName>3174163v1.0:3758153v1.0</PreferredName>
      <PreferredDefinition>A short textual account; having provided a short account.:Indicates the person or authoritative body who has received something._To take, accept, or get something offered.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Report Received By Receive Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174163</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25375:C45265</PreferredName>
        <Version>1</Version>
        <LongName>Report Received By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45265</PREFERRED_NAME>
            <LONG_NAME>Received By</LONG_NAME>
            <CON_ID>2612103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3758153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Receive Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Report Received By Receive Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Report Received By Receive Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.CommonSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReportReceiver:receivedIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.CommonSubDomain.ReportReceiver.receivedIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PrimaryInformationRecipient.negationInd (in IndividualCaseSafetyReport)</AlternateName>
        <AlternateNameType>Map:ICSRr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReportReceiver.receivedIndicator</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="575">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760808</PUBLICID>
    <LONGNAME>Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3760031v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A character string that is a revision of the original text of the procedure to enable the coding of the text. EXAMPLE(S): If the original text is &quot;message&quot;, the name code modified text could be set to &quot;massage&quot;, so that the text can be successfully coded. NOTE(S): In the context of BRIDG, text modification occurs a single time for a given instance of original text.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760031</PublicId>
      <PreferredName>3174171v1.0:3174512v1.0</PreferredName>
      <PreferredDefinition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.:The act of alteration or modification; changed or altered in form or character.:The words of something written.</PreferredDefinition>
      <LongName>Intervention or Procedure Reuse Template Study Activity Name Code Change Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174171</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174171v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Intervention or Procedure Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174512</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614:C25162:C25446:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Name Code Change Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedProcedure.nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedProcedure:nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Model Integrity</AlternateName>
        <AlternateNameType>Map:BRIDGSCC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="576">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760815</PUBLICID>
    <LONGNAME>Protocol Treatment Arm Randomization Proportion ISO21090.RTO.INT.NONNEG,INT.POS.v1.0</LONGNAME>
    <PREFERREDNAME>3174740v1.0:3631472v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The relative proportion of study subjects to be randomized to the arm. EXAMPLE(S): If 1/3 of study subjects are to be randomized to Arm A and 2/3 to Arm B, then the values of randomizationWeight for Arms A and B, respectively, could be expressed as 1 and 2 or as 1/3 and 2/3.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174740</PublicId>
      <PreferredName>2454523v1.0:3174549v1.0</PreferredName>
      <PreferredDefinition>A specific treatment protocol used in a clinical trial._The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.:A part, fraction, share, or number considered in relation to the whole amount or number.</PreferredDefinition>
      <LongName>Protocol Treatment Arm Randomization Proportion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2454523</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15538</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Treatment Arm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15538</PREFERRED_NAME>
            <LONG_NAME>Protocol Treatment Arm</LONG_NAME>
            <CON_ID>2206366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25196:C49159</PreferredName>
        <Version>1</Version>
        <LongName>Randomization Proportion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25196</PREFERRED_NAME>
            <LONG_NAME>Randomization</LONG_NAME>
            <CON_ID>2202624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49159</PREFERRED_NAME>
            <LONG_NAME>Proportion</LONG_NAME>
            <CON_ID>2829709</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3631472</PublicId>
      <PreferredName>3631472v1.0</PreferredName>
      <PreferredDefinition>Quantity quotient of a numerator of type INT.NONNEG divided by a denominator of type INT.POS.</PreferredDefinition>
      <LongName>ISO21090.RTO.INT.NONNEG,INT.POS.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090RTOv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protocol Treatment Arm Randomization Proportion ISO21090.RTO.INT.NONNEG,INT.POS.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protocol Treatment Arm Randomization Proportion ISO21090.RTO.INT.NONNEG,INT.POS.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Arm:randomizationWeight</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.Arm.randomizationWeight</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Arm.randomizationWeight</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyDesignArm.randomizationWeightForArm</AlternateName>
        <AlternateNameType>Map:TDM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="577">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760891</PUBLICID>
    <LONGNAME>Relevance Regulation Applicable Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3760108v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies whether this study must be registered as required by applicable laws. OTHER NAME(S): Section 801 Clinical Trial NOTE(S): Under US Public Law 110-85, Title VIII, Section 801, applicable drug trials include controlled clinical investigations, other than Phase I investigations, of a drug or biologic subject to US FDA regulation. Applicable device clinical trials are controlled trials with health outcomes of devices subject to FDA regulation, other than small feasibility studies, and pediatric postmarket surveillance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760108</PublicId>
      <PreferredName>3757291v1.0:2992619v1.0</PreferredName>
      <PreferredDefinition>The relation of something to the matter at hand.:A rule or order issued by an authority stating what may or may not be done or how something must be done._Having relevance; capable of being applied.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Relevance Regulation Applicable Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70664:C68821</PreferredName>
        <Version>1</Version>
        <LongName>Relevance Regulation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70664</PREFERRED_NAME>
            <LONG_NAME>Relevance</LONG_NAME>
            <CON_ID>2710254</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68821</PREFERRED_NAME>
            <LONG_NAME>Regulation</LONG_NAME>
            <CON_ID>2867554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44483:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Applicable Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44483</PREFERRED_NAME>
            <LONG_NAME>Applicable</LONG_NAME>
            <CON_ID>2734799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Relevance Regulation Applicable Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Relevance Regulation Applicable Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RelevantRegulation:applicableIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain.RelevantRegulation.applicableIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyProtocol.section801Indicator</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyProtocol.FDAregulatedIndicator</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Study.applicableClinicalTrialIndicator</AlternateName>
        <AlternateNameType>Map:CTRRr3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="578">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760963</PUBLICID>
    <LONGNAME>Study Execution Effective Date and Time Range ISO21090.IVL.TS.DATE.FULL.v1.0</LONGNAME>
    <PREFERREDNAME>3760186v1.0:3631471v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies the period of time over which the study was executed. NOTE(S): May specify the start and/or end or duration.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760186</PublicId>
      <PreferredName>3174254v1.0:2867942v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:The act of carrying out some order or instruction to accomplish an aim._Existing in fact and ready for service.:An expression of both date and time that an event has happened or will happen.:The difference between the lowest and highest numerical values; the limits or scale of variation.</PreferredDefinition>
      <LongName>Study Execution Effective Date and Time Range</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174254</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536:C48293</PreferredName>
        <Version>1</Version>
        <LongName>Study Execution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48293</PREFERRED_NAME>
            <LONG_NAME>Execution</LONG_NAME>
            <CON_ID>2388829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867942</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49287:C37939:C38013</PreferredName>
        <Version>1</Version>
        <LongName>Effective Date and Time Range</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49287</PREFERRED_NAME>
            <LONG_NAME>Effective</LONG_NAME>
            <CON_ID>2790040</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3631471</PublicId>
      <PreferredName>3631471v1.0</PreferredName>
      <PreferredDefinition>Set of consecutive values of an ordered base datatype of the type TS.DATE.FULL.</PreferredDefinition>
      <LongName>ISO21090.IVL.TS.DATE.FULL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IVLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Execution Effective Date and Time Range ISO21090.IVL.TS.DATE.FULL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Execution Effective Date and Time Range ISO21090.IVL.TS.DATE.FULL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyExecution:effectiveDateRange</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.StudyExecution.effectiveDateRange</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="579">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761113</PUBLICID>
    <LONGNAME>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Approach Anatomic Site Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760330v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that identifies a characteristic or requirement intended to be applied to a potential study subject to determine whether they may not participate in a study. EXAMPLE(S): Must be over the age of 18. A coded value specifying the anatomic location or access point for an observation. EXAMPLE(S): Anus for a colonoscopy observation NOTE(S): (1) Neither target anatomic site nor approach anatomic site is necessarily required or relevant for certain observations, however if either or both are present then the distinction between them is that the approach site is the access point for the measurement or observation and the target site is what is ultimately being evaluated. (2) Anatomic site and laterality both are included in this concept.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760330</PublicId>
      <PreferredName>3174215v1.0:2867756v1.0</PreferredName>
      <PreferredDefinition>Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A way of entering or leaving.:Named locations of or within the body.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Approach Anatomic Site Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174215v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25370</PREFERRED_NAME>
            <LONG_NAME>Exclusion Criteria</LONG_NAME>
            <CON_ID>2203927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25424:C13717:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Approach Anatomic Site Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25424</PREFERRED_NAME>
            <LONG_NAME>Approach</LONG_NAME>
            <CON_ID>2203577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Approach Anatomic Site Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Approach Anatomic Site Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedExclusionCriterion.approachAnatomicSiteCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedExclusionCriterion:approachAnatomicSiteCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="580">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761140</PUBLICID>
    <LONGNAME>Material Storage Administration Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3760355v1.0:3148148v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action of safekeeping harvested material in a depository. EXAMPLE(S): refrigeration, cryopreservation, dehydration, etc. NOTE(S): There is a difference between the act of changing the state of material, and the act of maintaining state of the material by storing it, which is represented here. The date (and time) on which the status is assigned to the activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760355</PublicId>
      <PreferredName>3757328v1.0:2867759v1.0</PreferredName>
      <PreferredDefinition>The tangible substance that goes into the makeup of a physical object.:The act of safekeeping goods in a depository.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._A condition or state at a particular time.:An expression of both date and time that an event has happened or will happen.</PreferredDefinition>
      <LongName>Material Storage Administration Performed Study Activity Status Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757328</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757328v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Material Storage Administration Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60824</PREFERRED_NAME>
            <LONG_NAME>Storage</LONG_NAME>
            <CON_ID>2547381</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C37939</PreferredName>
        <Version>1</Version>
        <LongName>Status Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3148148</PublicId>
      <PreferredName>3148148v1.0</PreferredName>
      <PreferredDefinition>Constrains TS so that it&#39;s precision can not be more precise than seconds.</PreferredDefinition>
      <LongName>ISO21090.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSDTTIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Material Storage Administration Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Material Storage Administration Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedMaterialStorage.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedMaterialStorage:statusDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="581">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761261</PUBLICID>
    <LONGNAME>Causality Assessment Observation Performed Study Activity Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3760466v1.0:3152480v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The judgment of relatedness between an adverse event and an activity or observation result. EXAMPLE(S): The observation result of &quot;diabetes&quot; is assessed to have caused the AE. The activity of administering a concomitant medication is assessed to have caused the AE. The activity of administering the study drug is assessed to have caused the AE. The date and time span when this activity began and ended. EXAMPLE(S): (1) Date and time when sample is taken from subject. (2) Chemotherapy dose given on June 12th starting 9am, finishing 12pm. NOTE(S): (1) Whether administrative or preparatory activities are included in this time frame is up to whoever is defining the activity - this time frame is all that matters when the activity occurred. (2) Date range is an interval data type, i.e. has a beginning (low) and end (high) values; is also TS.DATETIME data type, i.e. dates can have uncertain values (e.g., a range). So, if subject was diagnosed w/ leukemia sometime in 2009 and had transplant (substance administration) sometime in 2010, can surmise subject had preparative regimen between those times. I.e. preparative regimen would have beginning (low) date range of between 2009-01-01 and 2009-12-31; and ending (high) date range of between 2010-01-01 and 2010-12-31: IVL&lt;TS.DATETIME&gt;.low.uncertainRange.low = 2009-01-01, IVL&lt;TS.DATETIME&gt;.low.uncertainRange.high = 2009-12-31, IVL&lt;TS.DATETIME&gt;.high.uncertainRange.low = 2010-01-01, IVL&lt;TS.DATETIME&gt;.high.uncertainRange.high = 2010-12-31; [times left out to keep it simple.]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760466</PublicId>
      <PreferredName>3174131v1.0:2867768v1.0</PreferredName>
      <PreferredDefinition>The principle that a relationship exists between a primary entity A, or cause, and the occurrence of a secondary entity B, or effect.:The final result of a determination of the value, significance, or extent of.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._An expression of both date and time that an event has happened or will happen.:The difference between the lowest and highest numerical values; the limits or scale of variation.</PreferredDefinition>
      <LongName>Causality Assessment Observation Performed Study Activity Date and Time Range</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174131v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Causality Assessment Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82552</PREFERRED_NAME>
            <LONG_NAME>Causality</LONG_NAME>
            <CON_ID>3174117</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867768</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939:C38013</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time Range</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152480</PublicId>
      <PreferredName>3152480v1.0</PreferredName>
      <PreferredDefinition>Set of consecutive values of an ordered base datatype of the type TS.DATETIME.</PreferredDefinition>
      <LongName>ISO21090.IVL.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IVLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Causality Assessment Observation Performed Study Activity Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Causality Assessment Observation Performed Study Activity Date and Time Range ISO21090.IVL.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CausalAssessment:dateRange</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain.CausalAssessment.dateRange</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="582">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761271</PUBLICID>
    <LONGNAME>Material Process Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3760476v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that is an action of processing a material. EXAMPLE(S): freezing, thawing, spinning, embedding, dividing, aliquot, adding additives or growth factors OTHER NAME(S): product manipulation NOTE(S): Material process may be performed on any kind of material, such as a specimen, nanomaterial, or biologic. The result of the process may a similar or different kind of material, for instance a specimen may be the result of a specimen processing step (e.g., aliquot or division of a specimen), or alternatively a blood product has anticoagulants added to it to preserve the product. Other processing steps, such as adding growth factor to induce cell growth, may be performed on the blood product. A character string that is a revision of the original text of the procedure to enable the coding of the text. EXAMPLE(S): If the original text is &quot;message&quot;, the name code modified text could be set to &quot;massage&quot;, so that the text can be successfully coded. NOTE(S): In the context of BRIDG, text modification occurs a single time for a given instance of original text</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760476</PublicId>
      <PreferredName>3757183v1.0:3174512v1.0</PreferredName>
      <PreferredDefinition>The tangible substance that goes into the makeup of a physical object.:A sequence of events which produces some outcome.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.:The act of alteration or modification; changed or altered in form or character.:The words of something written.</PreferredDefinition>
      <LongName>Material Process Intervention or Procedure Reuse Template Study Activity Name Code Change Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757183</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757183v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Material Process Intervention or Procedure Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29862</PREFERRED_NAME>
            <LONG_NAME>Process</LONG_NAME>
            <CON_ID>2202628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174512</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614:C25162:C25446:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Name Code Change Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Material Process Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Material Process Intervention or Procedure Reuse Template Study Activity Name Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedMaterialProcessStep:nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedMaterialProcessStep.nameCodeModifiedText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="583">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761290</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Answer Reuse Template Observation Outcome Type Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760495v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A reusable, &quot;template&quot; description of an allowable response to an eligibility criterion question. A coded value specifying the kind of observation result. EXAMPLE(S): For blood pressure, the results might be 120 for systolic and 80 for diastolic, where systolic and diastolic are the type code distinguishing the two numbers.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760495</PublicId>
      <PreferredName>3757189v1.0:2607570v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:A statement (either spoken or written) that is made in reply to a question or request or criticism or accusation; a statement that solves a problem or explains how to solve the problem.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:Watching something and taking note of what happens.:The result of an action._Something distinguishable as an identifiable class based on common qualities.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Answer Reuse Template Observation Outcome Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757189</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757189v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria Answer Reuse Template Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49149</PREFERRED_NAME>
            <LONG_NAME>Answer</LONG_NAME>
            <CON_ID>2538654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607570</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Type Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Eligibility Criteria Answer Reuse Template Observation Outcome Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Eligibility Criteria Answer Reuse Template Observation Outcome Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedEligibilityCriterionAnswer:typeCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedEligibilityCriterionAnswer.typeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="584">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761361</PUBLICID>
    <LONGNAME>Product Transfer Performed Study Activity Negation Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3760561v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A completed action of transporting a product between a point of origin and a point of destination. EXAMPLE(S): Delivery of drugs from the manufacturer to a medical facility. Specifies whether an activity did not occur. EXAMPLE(S): If a subject did not take aspirin in the previous week, the negation indicator = &quot;true&quot;. NOTE(S): If it is important to capture the fact that a particular activity did not occur, then this attribute is used, often along with negation reason.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760561</PublicId>
      <PreferredName>3757294v1.0:2388852v1.0</PreferredName>
      <PreferredDefinition>The end result of a manufacturing process; anything that is produced.:The act of conveying or transporting from one place to another.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._Negation is an operation in which a term denies or inverts the meaning of another term or construction.:An indicator that can be set or unset in order to signal whether a particular condition is true. The indicator usually takes the form of a single binary digit, or bit (either 0 or 1). (from Dictionary of Computers)</PreferredDefinition>
      <LongName>Product Transfer Performed Study Activity Negation Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757294</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757294v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Product Transfer Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48167</PREFERRED_NAME>
            <LONG_NAME>Transfer</LONG_NAME>
            <CON_ID>2422624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388852</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Negation Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Product Transfer Performed Study Activity Negation Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Product Transfer Performed Study Activity Negation Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedProductTransport.negationIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProductTransport:negationIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="585">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761393</PUBLICID>
    <LONGNAME>Amendment Change Summary Document Version Date and Time ISO21090.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3760592v1.0:3148148v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A document, memo or brief that enumerates the differences between two versions of a study protocol document. OTHER NAME(S): Amendment NOTE(S): The term &quot;Amendment&quot; needs to be disambiguated since it sometimes refers to the amended version of the protocol (study protocol document version) and other times refers to the summary of changes (amendment change summary version) that are applied to a protocol to create a new version of the protocol. The date (and time) on which the document is versioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760592</PublicId>
      <PreferredName>3174200v1.0:2437776v1.0</PreferredName>
      <PreferredDefinition>A change in a document made by correction, adding, substituting or omitting a certain part. Amendments are the mechanism of changes introduction, further development and improvement of previously submitted or approved clinical study protocols and proposals.:The act of alteration or modification; changed or altered in form or character.:A shortened version of a speech or written text, containing only the main points.:An organized collection of records that describe a particular body of work.:A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._An expression of both date and time that an event has happened or will happened.</PreferredDefinition>
      <LongName>Amendment Change Summary Document Version Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174200</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174200v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Amendment Change Summary Document Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41200</PREFERRED_NAME>
            <LONG_NAME>Amendment</LONG_NAME>
            <CON_ID>2551428</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42581</PREFERRED_NAME>
            <LONG_NAME>Summary</LONG_NAME>
            <CON_ID>2203701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2437776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3148148</PublicId>
      <PreferredName>3148148v1.0</PreferredName>
      <PreferredDefinition>Constrains TS so that it&#39;s precision can not be more precise than seconds.</PreferredDefinition>
      <LongName>ISO21090.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSDTTIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Amendment Change Summary Document Version Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Amendment Change Summary Document Version Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AmendmentChangeSummaryVersion:date</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.AmendmentChangeSummaryVersion.date</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="586">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761496</PUBLICID>
    <LONGNAME>Material Storage Administration Reuse Template Study Activity Subcategory Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760692v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An administrative activity defined at a global library level that is an action of safekeeping harvested material in a repository or depository. EXAMPLE(S): refrigeration, cryopreservation, dehydration NOTE(S): There is a difference between the act of changing the state of material, which is represented here, and the act of maintaining state of the material by storing it. A coded value specifying a subdivision within a larger category of activities. EXAMPLE(S): (1) chemotherapy, radiotherapy, hormonal therapy, alternative therapy (2) In the case where category code = &quot;anti-cancer treatment&quot;, subcategory code may = &quot;radiotherapy&quot;, and name code may = &quot;external beam radiotherapy&quot;. (3) If category code = &quot;Intervention&quot;, subcategory code may = &quot;Drug&quot; (including placebo), &quot;Device&quot; (including sham), &quot;Biological/Vaccine&quot;, &quot;Procedure/Surgery&quot;, &quot;Radiation&quot;, &quot;Behavioral&quot; (e.g., Psychotherapy, Lifestyle Counseling), &quot;Genetic&quot; (including gene transfer, stem cell and recombinant DNA), Dietary Supplement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760692</PublicId>
      <PreferredName>3757185v1.0:2867795v1.0</PreferredName>
      <PreferredDefinition>The tangible substance that goes into the makeup of a physical object.:The act of safekeeping goods in a depository.:Performing or possessing executive duties; acting as a supervisor or manager.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._A subdivision that has common differentiating characteristics within a larger category.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Material Storage Administration Reuse Template Study Activity Subcategory Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757185v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Material Storage Administration Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60824</PREFERRED_NAME>
            <LONG_NAME>Storage</LONG_NAME>
            <CON_ID>2547381</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867795</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25692:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Subcategory Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25692</PREFERRED_NAME>
            <LONG_NAME>Subcategory</LONG_NAME>
            <CON_ID>2203589</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Material Storage Administration Reuse Template Study Activity Subcategory Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Material Storage Administration Reuse Template Study Activity Subcategory Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG 3.2 Release Note</Name>
        <OrganizationName/>
        <DocumentType>Associations</DocumentType>
        <DocumentText>Due to technical difficulties we are unable to correct a known error in the BRIDG model as loaded to caDSR. The association between DefinedMaterialStorage and Specimen is deprecated in BRIDG 3.2 and should not have been loaded to caDSR.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedMaterialStorage:subcategoryCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedMaterialStorage.subcategoryCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="587">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761540</PUBLICID>
    <LONGNAME>Inclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760734v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A characteristic or requirement that a subject must meet to participate in a study. EXAMPLE(S): Must be over the age of 18 A coded value specifying the anatomical structure that consists of organs and organ subclasses responsible for certain body functions. EXAMPLE(S): gastrointestinal system, urinary system, hematopoietic system.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760734</PublicId>
      <PreferredName>2867698v1.0:3174586v1.0</PreferredName>
      <PreferredDefinition>Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._An anatomical structure that consists of organs and organ subclasses responsible for certain body functions.  Representative examples are the gastrointestinal system, urinary system, and hematopoietic system.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Inclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Organ System Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867698</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867698v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Inclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25532</PREFERRED_NAME>
            <LONG_NAME>Inclusion Criteria</LONG_NAME>
            <CON_ID>2202445</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174586</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12919:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Organ System Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12919</PREFERRED_NAME>
            <LONG_NAME>Organ System</LONG_NAME>
            <CON_ID>2589988</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Inclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Inclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedInclusionCriterion:bodySystemCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedInclusionCriterion.bodySystemCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="588">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3763206</PUBLICID>
    <LONGNAME>Patient Somatic Mutation PTPN11 Gene Detected Indicator</LONGNAME>
    <PREFERREDNAME>PtSmtcMtnPTPN11DtcIND</PREFERREDNAME>
    <PREFERREDDEFINITION>the indicator related to the detection of a mutation that occurs in the somatic tissues of an organism for the PTPN11 gene.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3763205</PublicId>
      <PreferredName>PtSmtcMtnPTPN11Dtc</PreferredName>
      <PreferredDefinition>information related to the detection of a mutation that occurs in the somatic tissues of an organism for the PTPN11 gene, that plays a role in the regulation of cell signaling, cell migration, metabolic control, mitogenic activation and gene transcription.</PreferredDefinition>
      <LongName>Patient Somatic Mutation PTPN11 Gene Detected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3763203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18060:C26337:C25481</PreferredName>
        <Version>1</Version>
        <LongName>Somatic Mutation PTPN11 Gene Detected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18060</PREFERRED_NAME>
            <LONG_NAME>Somatic Variation</LONG_NAME>
            <CON_ID>2528557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26337</PREFERRED_NAME>
            <LONG_NAME>PTPN11 Gene</LONG_NAME>
            <CON_ID>3755839</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25481</PREFERRED_NAME>
            <LONG_NAME>Detected</LONG_NAME>
            <CON_ID>2203891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2646676</PublicId>
      <PreferredName>ASSESS_IND</PreferredName>
      <PreferredDefinition>the indicator relating to the results of an assessment.</PreferredDefinition>
      <LongName>Assessment Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None reported</VALIDVALUE>
          <VALUEMEANING>None Report</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3238310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3855538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Unavailable</VALUEMEANING>
          <MEANINGDESCRIPTION>The desired information is not available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5828000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient have somatic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient have somatic mutation in PTPN11 detected during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="589">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3763222</PUBLICID>
    <LONGNAME>Laboratory Procedure Chimerism Study Bone Marrow Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>LabPdrChmSdyBMIND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the laboratory procedure that involves testing the bone marrow for the occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3763221</PublicId>
      <PreferredName>LabPdrChmSdyBM</PreferredName>
      <PreferredDefinition>information related to the laboratory procedure that involves testing the bone marrow (tissue occupying the spaces of bone, consisting of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes) for the occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals.</PreferredDefinition>
      <LongName>Laboratory Procedure Chimerism Study Bone Marrow Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3763219</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62582:C63536:C12431:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Chimerism Study Bone Marrow Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62582</PREFERRED_NAME>
            <LONG_NAME>Chimerism</LONG_NAME>
            <CON_ID>2521747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a chimerism study done on</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a chimerism study done on the patient&#39;s unsorted bone marrow?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were other blood chimerism tests performed:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="590">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3766677</PUBLICID>
    <LONGNAME>Laboratory Procedure Copy Number Analysis Tool Loss of Heterozygosity NRAS Involved Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>LPCNALOHNRASInvIND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown/not applicable indicator related to the NRAS gene involving a software application that performs copy number and loss of heterozygosity (LOH) analysis on data from Affymetrix mapping genotyping microarrays.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3766676</PublicId>
      <PreferredName>LPCNALOHNRASInv</PreferredName>
      <PreferredDefinition>information related to the procedure using the NRAS gene (which plays a role in signal transduction and cell cycle regulation) in a software application that performs copy number and loss of heterozygosity (LOH) analysis on data from Affymetrix mapping genotyping microarrays.</PreferredDefinition>
      <LongName>Laboratory Procedure Copy Number Analysis Tool NRAS Loss of Heterozygosity NRAS Involved</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3768311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81017:C18016:C25786:C25547</PreferredName>
        <Version>1</Version>
        <LongName>Copy Number Analysis Tool Loss of Heterozygosity NRAS Gene Involved</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81017</PREFERRED_NAME>
            <LONG_NAME>Copy Number Analysis Tool</LONG_NAME>
            <CON_ID>2880141</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18016</PREFERRED_NAME>
            <LONG_NAME>Loss of Heterozygosity</LONG_NAME>
            <CON_ID>2203611</CON_ID>
            <DEFINITION_SOURCE>CSP2000</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25786</PREFERRED_NAME>
            <LONG_NAME>NRAS Gene</LONG_NAME>
            <CON_ID>3766673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25547</PREFERRED_NAME>
            <LONG_NAME>Involved</LONG_NAME>
            <CON_ID>2203840</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CNA or LOH involving 11p13.2</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CNA or LOH involving 11p13.2 (NRAS at 11p13.2)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="591">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3783584</PUBLICID>
    <LONGNAME>Witness Confirmation Patient Withdraw Quality of Life Consent Date</LONGNAME>
    <PREFERREDNAME>3783582v1.0:2018550v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Calendar date a witness confirms that a participant notified the treating site of the desire to withdraw consent from the Quality of Life portion of a study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCISTD: NCI CRF Harmonization and Standards Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3783582</PublicId>
      <PreferredName>3783579v1.0:3783580v1.0</PreferredName>
      <PreferredDefinition>Having been established or verified._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._Permission to do something.</PreferredDefinition>
      <LongName>Witness Confirmation Patient Withdraw Quality of Life Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3783579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25458:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Confirmed Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3783580</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38061:C17047:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Withdraw Quality of Life Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38061</PREFERRED_NAME>
            <LONG_NAME>Withdraw</LONG_NAME>
            <CON_ID>2434706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Witness confirmed study</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Witness confirmed study participant withdrew consent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consent Withdrawal QOL CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3914855</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consent Withdrawal QOL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635304</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>WN_CON_PT_WD_QOL_CNST_DT</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="592">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3788674</PUBLICID>
    <LONGNAME>Fatigue Severity Scale Past Week Exercise Brings on Fatigue Agreement Score 7 Point Scale</LONGNAME>
    <PREFERREDNAME>FSS_EXERC_BRNG_FATG_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of their agreement with a statement about exercise bringing on their fatigue in the past week, using a seven point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FSS:Fatigue Severity Scale, Lauren B. Krupp, 1989</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3788553</PublicId>
      <PreferredName>3788517v1.0:3788551v1.0</PreferredName>
      <PreferredDefinition>A numeric scale to assess the severity of an individual&#39;s fatigue over the past week while performing a variety of usual tasks._The most recent week, including today._A question about whether exercise brings or brought on an individual&#39;s fatigue._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Fatigue Severity Scale Past Week Exercise Brings on Fatigue Agreement Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3788517</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106621</PreferredName>
        <Version>1</Version>
        <LongName>Fatigue Severity Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106621</PREFERRED_NAME>
            <LONG_NAME>Fatigue Severity Scale</LONG_NAME>
            <CON_ID>3781300</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3788551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C106626:C25369:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Exercise Brings on Fatigue Agreement Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106626</PREFERRED_NAME>
            <LONG_NAME>Exercise Brings on Fatigue Question</LONG_NAME>
            <CON_ID>3781303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FSS:Fatigue Severity Scale, Lauren B. Krupp, 1989</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3788194</PublicId>
      <PreferredName>AGRMT_SVNPT_SCL</PreferredName>
      <PreferredDefinition>The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number with no fractional part, including the negative and positive numbers as well as zero.::7_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Agreement 7 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>FSS:Fatigue Severity Scale, Lauren B. Krupp, 1989</Origin>
      <Representation>
        <PublicId>3788193</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255::7:C70656:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Integer::7 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>To concur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A score of 2 on an seven-point scale from disagree to agree</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.: Used as a function word to indicate direction, purpose, or movement.: To concur.: A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The precise location of something; a spatially limited location.: The difference between the lowest and highest numerical values; the limits or scale of variation.: A subjective score of 2 on a Likert scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91291, C38013, C70656, C66838, C104478, C65107, C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>A score of 4 on an seven-point scale from disagree to agree.</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.: Used as a function word to indicate direction, purpose, or movement.: To concur.: A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The precise location of something; a spatially limited location.: The difference between the lowest and highest numerical values; the limits or scale of variation.: A subjective score of 4 on a Likert scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91293, C38013, C70656, C66838, C104478, C65107, C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>A score of 5 on an seven-point scale from disagree to agree.</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.: Used as a function word to indicate direction, purpose, or movement.: To concur.: A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The precise location of something; a spatially limited location.: The difference between the lowest and highest numerical values; the limits or scale of variation.: A subjective score of 5 on a Likert scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91294, C38013, C70656, C66838, C104478, C65107, C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>A score of 3 on an seven-point scale from disagree to agree.</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.: Used as a function word to indicate direction, purpose, or movement.: To concur.: A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The precise location of something; a spatially limited location.: The difference between the lowest and highest numerical values; the limits or scale of variation.: A subjective score of 3 on a Likert scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91292, C38013, C70656, C66838, C104478, C65107, C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>A score of 6 on an seven-point scale from disagree to agree.</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.: Used as a function word to indicate direction, purpose, or movement.: To concur.: A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The precise location of something; a spatially limited location.: The difference between the lowest and highest numerical values; the limits or scale of variation.: A subjective score of 6 on a Likert scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103507, C38013, C70656, C66838, C104478, C65107, C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Exercise brings on my fatigue.</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Exercise brings on my fatigue.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3788451</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FSS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FSS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3788452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Fatigue Severity Scale (FSS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="593">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3793399</PUBLICID>
    <LONGNAME>Patient Substance Abuse Eligibility Determination Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3793395v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response regarding whether a person enrolling in a clinical trial has developed a maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems meeting the criteria for enrollment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHC-NCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3793395</PublicId>
      <PreferredName>2233604v1.0:3793393v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems._Criteria to determine eligibility of patients for medical care programs and services.</PreferredDefinition>
      <LongName>Patient Substance Abuse Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHC-NCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3793393</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18272:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Substance Abuse Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18272</PREFERRED_NAME>
            <LONG_NAME>Substance Abuse</LONG_NAME>
            <CON_ID>2585790</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Active substance abuse disord</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Active substance abuse disorders that include illicit drugs and alcohol</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current alcohol or drug abuse</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>WF-1901</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has a known or suspected diagnosable substance use disorder or opioid overuse disorder (according to DSM-5 criteria), or is actively receiving treatment for a substance use disorder, as per patient report or documented in the medical record.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6147165</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WFB Medical Center</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WFB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6147167</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHC-NCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_SUB_ABU_ELIG_DET_IND</AlternateName>
        <AlternateNameType>OID, NHC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_SUB_ABU_ELIG_DET_IND</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUB_ABUS_IND</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3793395v1.0:3506068v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="594">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3808778</PUBLICID>
    <LONGNAME>NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool Past Week Distress over Physical Problem with Bathing or Dressing Indicator</LONGNAME>
    <PREFERREDNAME>NCCN_DSTMG_BTHDRS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how distressed they have been during the past week over physical problems with bathing or dressing, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCN 1.2011 Distress Management Guidelines, 10/12/2010</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3807940</PublicId>
      <PreferredName>3799951v1.0:3807938v1.0</PreferredName>
      <PreferredDefinition>A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient problems in five categories._The most recent week, including today._A question about an individual&#39;s distress related to their physical problems with bathing or dressing.</PreferredDefinition>
      <LongName>NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool Past Week Distress over Physical Problem with Bathing or Dressing</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3799951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107157</PreferredName>
        <Version>1</Version>
        <LongName>NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107157</PREFERRED_NAME>
            <LONG_NAME>NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011</LONG_NAME>
            <CON_ID>3794690</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3807938</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C107187</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Distress over Physical Problem with Bathing or Dressing</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107187</PREFERRED_NAME>
            <LONG_NAME>Distress over Physical Problem with Bathing or Dressing Question</LONG_NAME>
            <CON_ID>3794741</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCN 1.2011 Distress Management Guidelines, 10/12/2010</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bathing/dressing</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bathing/dressing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3793272</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCN Guidelines</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Distress Management v1.2011</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793273</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="595">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3812351</PUBLICID>
    <LONGNAME>Therapeutic Procedure Flavonoid Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>FLAVONOID</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the administration of flavonoids.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3812350</PublicId>
      <PreferredName>FLAVONOID</PreferredName>
      <PreferredDefinition>Information related to the administration of flavonoids, one of a number of chemical compounds found in certain fruits, vegetables and seeds with antioxidant properties and potential antineoplastic properties. As polyphenolic, soluble plant pigments, flavonoids are usually subdivided into 5 subgroups flavonols, flavones, flavonones, flavan-3-ols, anthocyanidins.  Although not considered essential nutrients, some flavonoids may be beneficial to health by strengthening and protecting blood vessels and connective tissue and acting as anti-inflammatory, antihistaminic, and antiviral agents.  As antioxidants, some flavonoids may protect lipids from oxidative damage or retard the formation of cataracts.</PreferredDefinition>
      <LongName>Therapeutic Procedure Flavonoid Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3812348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1745:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Flavonoid Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1745</PREFERRED_NAME>
            <LONG_NAME>Flavonoid</LONG_NAME>
            <CON_ID>3812347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Benzopyrones</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Benzopyrones</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="596">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3852552</PUBLICID>
    <LONGNAME>Nausea Vomiting Risk Factor History of Motion Sickness Yes No Indicator</LONGNAME>
    <PREFERREDNAME>NVRF_Q1A</PREFERREDNAME>
    <PREFERREDDEFINITION>The sensation that one is about to vomit._The reflex act of ejecting the contents of the stomach through the mouth._Anything that increases a person&#39;s chance of developing a disease. Some examples of risk factors for cancer include a family history of cancer, use of tobacco products, certain foods, exposure to radiation or cancer-causing agents, and certain genetic alterations._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._Disorder caused by motion, as sea sickness, train sickness, car sickness, air sickness, or SPACE MOTION SICKNESS. It may include nausea, vomiting and dizziness._The preferred Value Domain to indicate a question with permissible values of yes/no.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3852508</PublicId>
      <PreferredName>3852504v1.0:3852506v1.0</PreferredName>
      <PreferredDefinition>The sensation that one is about to vomit._The reflex act of ejecting the contents of the stomach through the mouth._Anything that increases a person&#39;s chance of developing a disease. Some examples of risk factors for cancer include a family history of cancer, use of tobacco products, certain foods, exposure to radiation or cancer-causing agents, and certain genetic alterations._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._Disorder caused by motion, as sea sickness, train sickness, car sickness, air sickness, or SPACE MOTION SICKNESS. It may include nausea, vomiting and dizziness.</PreferredDefinition>
      <LongName>Nausea Vomiting Risk Factor History of Motion Sickness</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3852504</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3258:C3442:C17103</PreferredName>
        <Version>1</Version>
        <LongName>Nausea Vomiting Risk Factor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3258</PREFERRED_NAME>
            <LONG_NAME>Nausea</LONG_NAME>
            <CON_ID>2202607</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3442</PREFERRED_NAME>
            <LONG_NAME>Vomiting</LONG_NAME>
            <CON_ID>2202859</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17103</PREFERRED_NAME>
            <LONG_NAME>Risk Factor</LONG_NAME>
            <CON_ID>2217585</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3852506</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772:C34824</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History Motion Sickness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C34824</PREFERRED_NAME>
            <LONG_NAME>Motion Sickness</LONG_NAME>
            <CON_ID>3852505</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>History of  motion sickness</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>History of  motion sickness</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="597">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3853368</PUBLICID>
    <LONGNAME>Six Minute Walk Run Test Recovery Oxygen Saturation Percentage Value</LONGNAME>
    <PREFERREDNAME>2199583v1.0:3853366v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Oxygen saturation percentage measured at recovery from a six minute walk run test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>LCC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2199583</PublicId>
      <PreferredName>SIX_MIN_WK_RUN_TST</PreferredName>
      <PreferredDefinition>Test of the effect of walking and running on a subject&#39;s pulse and blood pressure.</PreferredDefinition>
      <LongName>Six Minute Walk Run Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939338</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66837:C48154</PreferredName>
        <Version>1</Version>
        <LongName>Six Minute</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66837</PREFERRED_NAME>
            <LONG_NAME>Six</LONG_NAME>
            <CON_ID>2647606</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48154</PREFERRED_NAME>
            <LONG_NAME>Minute</LONG_NAME>
            <CON_ID>2513263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2939339</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73554:C47911:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Walking Run Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73554</PREFERRED_NAME>
            <LONG_NAME>Walking</LONG_NAME>
            <CON_ID>2743260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47911</PREFERRED_NAME>
            <LONG_NAME>Run</LONG_NAME>
            <CON_ID>2422617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3853366</PublicId>
      <PreferredName>3853366v1.0</PreferredName>
      <PreferredDefinition>A getting back or regaining._The determination of oxygen-hemoglobin saturation of blood either by withdrawing a sample and passing it through a classical photoelectric oximeter or by electrodes attached to some translucent part of the body like finger, earlobe, or skin fold. It includes non-invasive oxygen monitoring by pulse oximetry._Percentage; a fraction or ratio with 100 understood as the denominator._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Recovery Oxygen Saturation Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>LCC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3853365</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70827:C60832:C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Recovery Oxygen Saturation Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70827</PREFERRED_NAME>
            <LONG_NAME>Recovery</LONG_NAME>
            <CON_ID>2710284</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60832</PREFERRED_NAME>
            <LONG_NAME>Oxygen Saturation Measurement</LONG_NAME>
            <CON_ID>2482516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>LCC Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Recovery Oxygen Saturation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Recovery</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Recovery</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SMWR_OSAT_PER_VAL</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2199583v1.0:3853366v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SMWR_RCV_OSAT_VAL</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="598">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3863424</PUBLICID>
    <LONGNAME>CD3 Complex CD4 Antigen Laboratory Procedure Performed Cell Total Integer::2 Decimal Place Count</LONGNAME>
    <PREFERREDNAME>3863422v1.0:2794421v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The 2 decimal place total number of CD3+ CD4+ cells in a laboratory specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3863422</PublicId>
      <PreferredName>3955951v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Consisting of cell surface type I membrane Delta, Epsilon, Gamma, Zeta, and Eta protein subunits with ITAM domains and noncovalently associated with the disulfide bound heterodimeric alpha/beta and gamma/delta TCR, the CD3 complex couples receptor antigen recognition to signal transduction pathways during T-cell activation. During TCR engagement with MHC-associated antigen on host cell surfaces and synapse formation, CD3 activity leads to Tyr-phosphorylated CD3 subunits, Tyr phosphorylation of LAT colocalized in lipid rafts, and MAPK activation. CD3 signal transduction appears to involve LCK, ZAP70, Nck, SLA, SLA2, and DOCK2. CD3 subunits may also associate with the cytoskeleton. CD3 also mediates TCR signal transduction during the developmental transition through positive selection of immature thymocytes to mature CD4+ or CD8+ T cells. (NCI)_CD4 Antigen, encoded by the CD4 gene, is a T-cell surface glycoprotein. CD4 has a role in cell-cell interactions and may act in signal transduction. CD4 is a accessory protein for MHC class-II antigen/T-cell receptor interaction and functions to initiate or augment the early phase of T-cell activation. CD4 enhances T-cell sensitivity to antigen and binds to LCK, which phosphorylates CD3-zeta. CD4 Antigen also serves as an HIV receptor, binding directly to the envelope protein gp120 on HIV. (From LocusLink, OMIM and NCI)_Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>CD3 Complex CD4 Antigen Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3955951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38897:C16300:C25294</PreferredName>
        <Version>1</Version>
        <LongName>CD3 Complex CD4 Antigen Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38897</PREFERRED_NAME>
            <LONG_NAME>CD3 Complex</LONG_NAME>
            <CON_ID>2593496</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16300</PREFERRED_NAME>
            <LONG_NAME>T-Cell Surface Glycoprotein CD4</LONG_NAME>
            <CON_ID>2593503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2794421</PublicId>
      <PreferredName>CELL_TTL_2D_CT</PreferredName>
      <PreferredDefinition>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A number with no fractional part, including the negative and positive numbers as well as zero.::2_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Cell Total Integer::2 Decimal Place Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>9999.99</DisplayFormat>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2794420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12508:C25304:C45255::2:C42646</PreferredName>
        <Version>1</Version>
        <LongName>Cell Total Integer::2 Decimal Place Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total value of CD3+CD4+ cells:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total value of CD3+CD4+ cells:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total number of CD3+CD4+ cells:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total number of CD3+CD4+ cells:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total number of CD3+CD4+ cells:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Total number of CD3+CD4+ cells:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CD3+CD4+ Absolute count:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_cd3_cd4_cell_value</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="599">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3872068</PUBLICID>
    <LONGNAME>OARS Physical Health Comorbidity Scale Have Current Illness Impaired Circulation in Arm or Leg Indicator</LONGNAME>
    <PREFERREDNAME>OARS_PHC_CIRCUL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of whether or not they currently have circulation trouble in their arms or legs, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OAMFQ:Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire, Fillenbaum, G.G. &amp; Smyer, M., 1981</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3871911</PublicId>
      <PreferredName>3871831v1.0:3871909v1.0</PreferredName>
      <PreferredDefinition>A section of the Older Americans Resources and Services (OARS) physical health questionnaire that rates the type of comorbidity and the impact of that comorbidity on an individual&#39;s daily function._A question about whether an individual currently has a disease._The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._One of the two lower extremities in humans used for locomotion and support._The movement of blood to and from the heart and to the rest of the body&#39;s organs, tissues, and cells through the network of arteries, veins, and capillaries. (NCI)_Loss or abnormality of psychological, physiological, or anatomic structure or function.</PreferredDefinition>
      <LongName>OARS Physical Health Comorbidity Scale Have Current Illness Arm Or Leg Circulatory Impairment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3871831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110967</PreferredName>
        <Version>1</Version>
        <LongName>Older Americans Resources and Services Comorbidity Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110967</PREFERRED_NAME>
            <LONG_NAME>Older Americans Resources and Services Comorbidity Scale</LONG_NAME>
            <CON_ID>3871073</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3871909</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3871909v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Have Current Illness Arm Or Leg Blood Circulation Impairment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110955</PREFERRED_NAME>
            <LONG_NAME>Have Current Illness Question</LONG_NAME>
            <CON_ID>3863084</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32141</PREFERRED_NAME>
            <LONG_NAME>Arm</LONG_NAME>
            <CON_ID>2202427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32974</PREFERRED_NAME>
            <LONG_NAME>Leg</LONG_NAME>
            <CON_ID>2516717</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16353</PREFERRED_NAME>
            <LONG_NAME>Blood Circulation</LONG_NAME>
            <CON_ID>2547793</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21055</PREFERRED_NAME>
            <LONG_NAME>Impairment</LONG_NAME>
            <CON_ID>2470784</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>OAMFQ:Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire, Fillenbaum, G.G. &amp; Smyer, M., 1981</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Circulation trouble in arms o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Circulation trouble in arms or legs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863413</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OAMFQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Comorbidity Assessment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3867573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863413</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OAMFQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical Health</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000702</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4471913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE2</ClassificationSchemeItemType>
        <CsiPublicId>4514847</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OARS_PHC_CIRCUL_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OARS_PHC_CIRCUL_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="600">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3872139</PUBLICID>
    <LONGNAME>OARS Physical Health Comorbidity Scale Have Current Illness Speech Manifestations Symptoms Interfere with Life 3 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>OARS_PHCB_SPEECH_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of how much speech impediment or impairment interferes with their activities, using a 3 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OAMFQ:Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire, Fillenbaum, G.G. &amp; Smyer, M., 1981</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3872045</PublicId>
      <PreferredName>3871831v1.0:3872043v1.0</PreferredName>
      <PreferredDefinition>A section of the Older Americans Resources and Services (OARS) physical health questionnaire that rates the type of comorbidity and the impact of that comorbidity on an individual&#39;s daily function._A question about whether an individual currently has a disease._A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders._A question about an individual&#39;s feeling that symptoms are or were interfering with their life.</PreferredDefinition>
      <LongName>OARS Physical Health Comorbidity Scale Have Current Illness Speech Manifestations Symptoms Interfere with Life</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3871831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110967</PreferredName>
        <Version>1</Version>
        <LongName>Older Americans Resources and Services Comorbidity Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110967</PREFERRED_NAME>
            <LONG_NAME>Older Americans Resources and Services Comorbidity Scale</LONG_NAME>
            <CON_ID>3871073</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3872043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110955:C5041:C105546</PreferredName>
        <Version>1</Version>
        <LongName>Have Current Illness Speech Manifestations Symptoms Interfere with Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110955</PREFERRED_NAME>
            <LONG_NAME>Have Current Illness Question</LONG_NAME>
            <CON_ID>3863084</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C5041</PREFERRED_NAME>
            <LONG_NAME>Speech Disorder</LONG_NAME>
            <CON_ID>3205744</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105546</PREFERRED_NAME>
            <LONG_NAME>Symptoms Interfere with Life Question</LONG_NAME>
            <CON_ID>3698716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>OAMFQ:Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire, Fillenbaum, G.G. &amp; Smyer, M., 1981</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3872060</PublicId>
      <PreferredName>3872060v1.0</PreferredName>
      <PreferredDefinition>The act of hindering or obstructing or impeding._How much there is of something that you can measure; the total amount or number._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Interference Quantity 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>OAMFQ:Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire, Fillenbaum, G.G. &amp; Smyer, M., 1981</Origin>
      <Representation>
        <PublicId>3872059</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3872059v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Interference Quantity Three Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72886</PREFERRED_NAME>
            <LONG_NAME>Interference</LONG_NAME>
            <CON_ID>2734007</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66834</PREFERRED_NAME>
            <LONG_NAME>Three</LONG_NAME>
            <CON_ID>2635616</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A Great Deal</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A Little</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at All</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How much does it interfere wi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much does it interfere with your activities?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863413</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OAMFQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Comorbidity Assessment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3867573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863413</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OAMFQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical Health</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000702</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="601">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3901836</PUBLICID>
    <LONGNAME>Laboratory Procedure Post Orchiectomy Luteinizing Hormone Measurement Value</LONGNAME>
    <PREFERREDNAME>3896532v1.0:2180583v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numerical representation of the amount of lutenizing hormone in serum measured after orchiectomy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3896532</PublicId>
      <PreferredName>2543047v1.0:3896530v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The time period following a point or another period of time. (NCI)_Surgical removal of one or both testicles._The determination of the amount of luteinizing hormone present in a sample.</PreferredDefinition>
      <LongName>Laboratory Procedure Post Orchiectomy Luteinizing Hormone Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3896530</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C15288:C74790</PreferredName>
        <Version>1</Version>
        <LongName>Post Orchiectomy Luteinizing Hormone Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15288</PREFERRED_NAME>
            <LONG_NAME>Orchiectomy</LONG_NAME>
            <CON_ID>2202774</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74790</PREFERRED_NAME>
            <LONG_NAME>Luteinizing Hormone Measurement</LONG_NAME>
            <CON_ID>3293684</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180583</PublicId>
      <PreferredName>LH_SPEC_VAL</PreferredName>
      <PreferredDefinition>information related to the specified value for a patient&#39;s luteinizing hormone.</PreferredDefinition>
      <LongName>Luteinizing Hormone Specified Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>999.9</DisplayFormat>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184351</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Value</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Luteinizing Hormone (LH)  Aft</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Luteinizing Hormone (LH)  After Orchiectomy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="602">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3906051</PUBLICID>
    <LONGNAME>Laboratory Procedure B-Lymphocyte CD20 Antigen Outcome Result</LONGNAME>
    <PREFERREDNAME>LPBClCD20Rslt</PREFERREDNAME>
    <PREFERREDDEFINITION>the laboratory result of a medical procedure that involves testing a sample of blood for a CD20+ B-lymphocytes, a type of white blood cell that plays a role in both the activation and proliferation of B-cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3226319</PublicId>
      <PreferredName>2543047v1.0:3226340v1.0</PreferredName>
      <PreferredDefinition>information relating to the results of the medical procedure that involves testing a sample of blood for a CD20+ B-lymphocytes, a type of white blood cell that plays a role in both the activation and proliferation of B-cells.</PreferredDefinition>
      <LongName>Laboratory Procedure B-Lymphocyte CD20 Antigen Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3226340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12474:C38896:C20200</PreferredName>
        <Version>1</Version>
        <LongName>B-Lymphocyte CD20 Antigen Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12474</PREFERRED_NAME>
            <LONG_NAME>B-Lymphocyte</LONG_NAME>
            <CON_ID>2529669</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38896</PREFERRED_NAME>
            <LONG_NAME>B-Lymphocyte Antigen CD20</LONG_NAME>
            <CON_ID>2763229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>B-Cell-CD20</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>B-Cell-CD20</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>B-Cell CD20</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CD20</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD20</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>CD20</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>B-Cell CD20:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG OPEN CheckList</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>B-Cell-CD20 status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_IR_cd20_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNfup_lym_anly_cd20_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNbase_lym_anly_mult_cd20_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="603">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3906475</PUBLICID>
    <LONGNAME>Arms Plaque Weight Score</LONGNAME>
    <PREFERREDNAME>ARM_PLQ_WT_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value representing the sum of plaque characteristics occurring on the arms multiplied by a modifier value of 0.2 to yield a weighted plaque score.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3906399</PublicId>
      <PreferredName>3902155v1.0:3906395v1.0</PreferredName>
      <PreferredDefinition>The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb._Abnormal tissue that results from the progressive accumulation or deposit of certain substances in a body cavity, surface, or lumen._An adjustment in a value based on scientific observations within the data._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Arm Plaque Importance Weight Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3902155</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C32141:C95603</PreferredName>
        <Version>1</Version>
        <LongName>Arm Plaque</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32141</PREFERRED_NAME>
            <LONG_NAME>Arm</LONG_NAME>
            <CON_ID>2202427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95603</PREFERRED_NAME>
            <LONG_NAME>Plaque</LONG_NAME>
            <CON_ID>3902150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3906395</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48192:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Importance Weight Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48192</PREFERRED_NAME>
            <LONG_NAME>Importance Weight</LONG_NAME>
            <CON_ID>2422629</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3906437</PublicId>
      <PreferredName>PLAQ_WT_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Plaque Weighted Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>99.9</DisplayFormat>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>6.4</MaximumValue>
      <MinimumValue>0.0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Arms weighted plaque score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Arms weighted plaque score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="604">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3912480</PUBLICID>
    <LONGNAME>FACT-NP Questionnaire Past Seven Days Bothered by Worsening Eyesight How True Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FCTNP_PWK_WREYES_FVPT_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how true in the past 7 days they are bothered by worsening eyesight, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-NP:Functional Assessment of Cancer Therapy - Nasopharyngeal, David Cella, Ph.D., Version 4, April 14, 2010</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3912448</PublicId>
      <PreferredName>3912433v1.0:3912446v1.0</PreferredName>
      <PreferredDefinition>A subscale complement to the FACT-G developed specifically for evaluating the quality of life of nasopharyngeal cancer patients._The most recent week, including today._A survey question about a person&#39;s agreement with a statement._A question about whether an individual is or was bothered by worsening eyesight._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-NP Questionnaire Past Week How True Bothered by Worsening Eyesight Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3912433</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111635</PreferredName>
        <Version>1</Version>
        <LongName>FACT-NP Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111635</PREFERRED_NAME>
            <LONG_NAME>FACT-NP Questionnaire</LONG_NAME>
            <CON_ID>3907433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3912446</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C91781:C111638:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How True Bothered by Worsening Eyesight Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111638</PREFERRED_NAME>
            <LONG_NAME>Bothered by Worsening Eyesight Question</LONG_NAME>
            <CON_ID>3907448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACT-NP:Functional Assessment of Cancer Therapy - Nasopharyngeal, David Cella, Ph.D., Version 4, April 14, 2010</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3144287</PublicId>
      <PreferredName>3144287v1.1</PreferredName>
      <PreferredDefinition>Numeric representation of how true in the past 7 days a person experienced something about a their illness using a five-point Likert scale.</PreferredDefinition>
      <LongName>Past 7 Days How True Score_5 Point Scale</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Some-what</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am bothered by worsening ey</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am bothered by worsening eyesight</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4811884</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FACIT System Scales</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-NP (Functional Assessment of Cancer Therapy - Nasopharyngeal)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4918171</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FCTNP_PWK_WREYES_FVPT_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="605">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3913245</PUBLICID>
    <LONGNAME>Person Dose Body Weight Unit of Measure Name</LONGNAME>
    <PREFERREDNAME>2875646v1.0:3913241v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>The unit of measure that represents a person&#39;s body weight for dosing requirements.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2875646</PublicId>
      <PreferredName>2236731v1.0:3234302v1.0</PreferredName>
      <PreferredDefinition>A human being._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The weight of a subject.</PreferredDefinition>
      <LongName>Person Dose Body Weight</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3234302</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488:C81328</PreferredName>
        <Version>1</Version>
        <LongName>Dose Body Weight</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81328</PREFERRED_NAME>
            <LONG_NAME>Body Weight</LONG_NAME>
            <CON_ID>3234301</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3913241</PublicId>
      <PreferredName>3913241v1.1</PreferredName>
      <PreferredDefinition>The vertical force exerted by a mass as a result of gravity._A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Weight Unit of Measure Name</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3913240</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25208:C25709:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Weight Unit of Measure Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kilograms</VALIDVALUE>
          <VALUEMEANING>Kilograms</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is definied as the mass of an  international prototype in the form of a platinum-iridium cylinder kept at Sevres in france.   A kilogram is equal to 1,000 grams and 2.2046226 pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pounds</VALIDVALUE>
          <VALUEMEANING>Pound</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-01-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the dosing body weigh</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the dosing body weight unit of measure?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>base_PRD_dosing_body_wt_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="606">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3914393</PUBLICID>
    <LONGNAME>Dose Escalation Checkbox Indicator</LONGNAME>
    <PREFERREDNAME>DOSE_ESCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Checkbox indicator determining whether or not the administration of a dose of an agent or treatment regimen was escalated.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3914380</PublicId>
      <PreferredName>2411801v1.0:3914378v1.0</PreferredName>
      <PreferredDefinition>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._Held_The act of administration._A stepwise increase in the amount of a therapeutic or investigational agent given to an individual._A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.</PreferredDefinition>
      <LongName>Dose Escalation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3914378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107213</PreferredName>
        <Version>1</Version>
        <LongName>Dose Escalation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107213</PREFERRED_NAME>
            <LONG_NAME>Dose Escalation</LONG_NAME>
            <CON_ID>3808628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2185839</PublicId>
      <PreferredName>CHECKBOX_IND</PreferredName>
      <PreferredDefinition>Indicator determining determining whether or not certain stated circumstances exist._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Checkbox Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose escalated</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose escalated</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="607">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3914445</PUBLICID>
    <LONGNAME>Dose Reduced Checkbox Indicator</LONGNAME>
    <PREFERREDNAME>DOSE_REDUCE</PREFERREDNAME>
    <PREFERREDDEFINITION>Checkbox indicator determining whether or not the administration of a dose of an agent or treatment regimen was reduced.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3914442</PublicId>
      <PreferredName>2411801v1.0:3914440v1.0</PreferredName>
      <PreferredDefinition>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.</PreferredDefinition>
      <LongName>Dose Reduced</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3914440</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49505</PreferredName>
        <Version>1</Version>
        <LongName>Dose Reduced</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49505</PREFERRED_NAME>
            <LONG_NAME>Dose Reduced</LONG_NAME>
            <CON_ID>2452860</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2185839</PublicId>
      <PreferredName>CHECKBOX_IND</PreferredName>
      <PreferredDefinition>Indicator determining determining whether or not certain stated circumstances exist._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Checkbox Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose reduced</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose reduced</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="608">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3914684</PUBLICID>
    <LONGNAME>Study Site Personnel Availability Yes No Indicator</LONGNAME>
    <PREFERREDNAME>SSAVAIL</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for information related to the availability of study site personnel.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3914683</PublicId>
      <PreferredName>SITEAVAILABLE</PreferredName>
      <PreferredDefinition>Information related to the availability of study site personnel.</PreferredDefinition>
      <LongName>Study Site Personnel Availability</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3914681</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93442</PreferredName>
        <Version>1</Version>
        <LongName>Study Site Personnel</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93442</PREFERRED_NAME>
            <LONG_NAME>Study Site Personnel</LONG_NAME>
            <CON_ID>3350615</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2443317</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25429</PreferredName>
        <Version>1</Version>
        <LongName>Available</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25429</PREFERRED_NAME>
            <LONG_NAME>Availability</LONG_NAME>
            <CON_ID>2204038</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the reference radiologist</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the reference radiologist or local investigator available for bone imaging interpretation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SSAVAIL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="609">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3918174</PUBLICID>
    <LONGNAME>Diet Health Behavior Performance Status Assessment Indicator</LONGNAME>
    <PREFERREDNAME>3918173v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No indicator to assess if a person has been eating a healthy diet.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3918173</PublicId>
      <PreferredName>3918171v1.0:2233077v1.0</PreferredName>
      <PreferredDefinition>information related to the dietary performance status assessment._The final result of a determination of the value, significance, or extent of._A measure of how well a patient is able to perform ordinary tasks and carry out daily activities._Regular course of eating and drinking adopted by a person or animal. This does not include DIET THERAPY, a specific diet prescribed in the treatment of a disease._Behaviors expressed by individuals to protect, maintain or promote their health status. For example, proper diet, and appropriate exercise are activities perceived to influence health status. Life style is closely associated with health behavior and factors influencing life style are socioeconomic, educational, and cultural. (MSH2001)</PreferredDefinition>
      <LongName>Diet Health Behavior Performance Status Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3918171</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15222:C16663:C20641</PreferredName>
        <Version>1</Version>
        <LongName>Diet Health Behavior Performance Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15222</PREFERRED_NAME>
            <LONG_NAME>Diet</LONG_NAME>
            <CON_ID>2202294</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16663</PREFERRED_NAME>
            <LONG_NAME>Health Behavior</LONG_NAME>
            <CON_ID>3081761</CON_ID>
            <DEFINITION_SOURCE>MeSH-2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20641</PREFERRED_NAME>
            <LONG_NAME>Performance Status</LONG_NAME>
            <CON_ID>2202910</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you feel you are eating pr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you feel you are eating properly?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="610">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3919234</PUBLICID>
    <LONGNAME>Plerixafor Prior Preparative Regimen Administered Indicator</LONGNAME>
    <PREFERREDNAME>3919233v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not plerixafor was administered prior to the preparative regimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3919233</PublicId>
      <PreferredName>3837074v1.0:3919231v1.0</PreferredName>
      <PreferredDefinition>A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation._Earlier in time or order._The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Plerixafor Prior Preparative Regimen Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3837074</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1777</PreferredName>
        <Version>1</Version>
        <LongName>Plerixafor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1777</PREFERRED_NAME>
            <LONG_NAME>Plerixafor</LONG_NAME>
            <CON_ID>3631679</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3919231</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C61155:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Prior Preparative Regimen Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61155</PREFERRED_NAME>
            <LONG_NAME>Preparative Regimen</LONG_NAME>
            <CON_ID>2486806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was plerixafor administered p</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was plerixafor administered prior to the preparative regimen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was plerixafor (Mozobil) given at any time prior to the preparative regimen?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was plerixafor (Mozobil) given at any time prior to the preparative regimen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was plerixafor given at any time prior to the preparative regimen?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was plerixafor given at any time prior to the preparative regimen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_donor_multi_plerixafor_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="611">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3921643</PUBLICID>
    <LONGNAME>Specimen Hypodiploidy Cytogenetic Abnormality Present Yes No Indicator</LONGNAME>
    <PREFERREDNAME>HYPODIPLOID</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the presence of the cytogenetic abnormality, hypodiploidy (a chromosomal abnormality in which the chromosomal number is less than the normal diploid number).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3921564</PublicId>
      <PreferredName>HYPODIPLOID</PreferredName>
      <PreferredDefinition>Information related to the presence of the cytogenetic abnormality, hypodiploidy (a chromosomal abnormality in which the chromosomal number is less than the normal diploid number).</PreferredDefinition>
      <LongName>Specimen Hypodiploidy Cytogenetic Abnormality Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3921562</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80337:C2950:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Hypodiploidy Cytogenetic Abnormality Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80337</PREFERRED_NAME>
            <LONG_NAME>Hypodiploidy</LONG_NAME>
            <CON_ID>3028369</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2950</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Abnormality</LONG_NAME>
            <CON_ID>2459194</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hypodiploidy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Hypodiploidy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HYPODIPLOID</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="612">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3924016</PUBLICID>
    <LONGNAME>Right Plantar Region Plaque Body Surface Area Scale</LONGNAME>
    <PREFERREDNAME>RPTR_PLQ_BSA_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to represent the extent of body surface area on the sole of the right foot with plaque involvement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3923649</PublicId>
      <PreferredName>3923438v1.0:3906404v1.0</PreferredName>
      <PreferredDefinition>Being or located on or directed toward the side of the body to the east when facing north._The undersurface of the foot._Abnormal tissue that results from the progressive accumulation or deposit of certain substances in a body cavity, surface, or lumen._A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing.</PreferredDefinition>
      <LongName>Right Plantar Region Plaque Body Surface Area Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3923438</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25228:C33326:C95603</PreferredName>
        <Version>1</Version>
        <LongName>Right Plantar Region Plaque</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C33326</PREFERRED_NAME>
            <LONG_NAME>Plantar Region</LONG_NAME>
            <CON_ID>2774738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95603</PREFERRED_NAME>
            <LONG_NAME>Plaque</LONG_NAME>
            <CON_ID>3902150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3906404</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25157:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Body Surface Area Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25157</PREFERRED_NAME>
            <LONG_NAME>Body Surface Area</LONG_NAME>
            <CON_ID>2203871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3906439</PublicId>
      <PreferredName>BSA_SCL</PreferredName>
      <PreferredDefinition>A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing._an ordered reference standard.</PreferredDefinition>
      <LongName>Body Surface Area Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3906438</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25157:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Body Surface Area Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25157</PREFERRED_NAME>
            <LONG_NAME>Body Surface Area</LONG_NAME>
            <CON_ID>2203871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>90-100%</VALUEMEANING>
          <MEANINGDESCRIPTION>90-100%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>70-89%</VALUEMEANING>
          <MEANINGDESCRIPTION>70-89%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>50-69%</VALUEMEANING>
          <MEANINGDESCRIPTION>50-69%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>30-49%</VALUEMEANING>
          <MEANINGDESCRIPTION>30-49%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>10-29%</VALUEMEANING>
          <MEANINGDESCRIPTION>10-29%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1-9%</VALUEMEANING>
          <MEANINGDESCRIPTION>1-9%</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Right Sole area score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Right Sole area score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="613">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3960070</PUBLICID>
    <LONGNAME>Culture Procedure Bacteria Or Fungus Infectious Disorder Performed Laboratory Finding Result</LONGNAME>
    <PREFERREDNAME>3960068v1.0:2676304v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the assessment of a bacterial or fungal infection culture.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3960068</PublicId>
      <PreferredName>3192146v1.0:3960066v1.0</PreferredName>
      <PreferredDefinition>Any laboratory procedure for growing microorganisms._Unicellular, prokaryotic organisms that reproduce by cell division and usually have cell walls; can be shaped like spheres, rods or spirals and can be found in virtually any environment._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to those that grow as multicellular colonies (mushrooms and molds)._A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Culture Procedure Bacteria Or Fungus Infectious Disorder Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3192146</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25300</PreferredName>
        <Version>1</Version>
        <LongName>Culture Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25300</PREFERRED_NAME>
            <LONG_NAME>Microbial Culture Procedure</LONG_NAME>
            <CON_ID>2440590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3960066</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3960066v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Bacteria Or Fungi Infection Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14187</PREFERRED_NAME>
            <LONG_NAME>Bacteria</LONG_NAME>
            <CON_ID>2205367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14209</PREFERRED_NAME>
            <LONG_NAME>Fungus</LONG_NAME>
            <CON_ID>2204012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26726</PREFERRED_NAME>
            <LONG_NAME>Infectious Disorder</LONG_NAME>
            <CON_ID>2203837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify results:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify results:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What were the results for the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What were the results for the bacterial or fungal infection culture procedure assessment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify results</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify results</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRFT Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was diagnosis of invasive fungal infection determined through culture?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_cult_perform_bac_fung_result</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DxIFIDtmnCltr</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FungalCultPerf</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="614">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3983608</PUBLICID>
    <LONGNAME>Urinary Frequency Duration Day Count</LONGNAME>
    <PREFERREDNAME>3983366v1.0:3294157v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Urination at short intervals; it may result from increased urine formation, decreased bladder capacity, or lower urinary tract irritation._The period of time during which something continues._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3983366</PublicId>
      <PreferredName>2742641v1.0:2234809v1.0</PreferredName>
      <PreferredDefinition>Urination at short intervals; it may result from increased urine formation, decreased bladder capacity, or lower urinary tract irritation._The period of time during which something continues.</PreferredDefinition>
      <LongName>Urinary Frequency Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2742641</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26906</PreferredName>
        <Version>1</Version>
        <LongName>Urinary Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26906</PREFERRED_NAME>
            <LONG_NAME>Urinary Frequency</LONG_NAME>
            <CON_ID>2203691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234809</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25330</PreferredName>
        <Version>1</Version>
        <LongName>Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3294157</PublicId>
      <PreferredName>3294157v1.0</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>100</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2207941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Day Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Day -2</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::2: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Day 20</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::20: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::20</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>Day 21</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>Day 22</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::22: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::22</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>Day 23</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::23: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::23</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>Day 24</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::24: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::24</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>Day 25</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::25: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::25</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>Day 26</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::26: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::26</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>Day 27</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::27: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::27</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>Day 28</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::28: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::28</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>Day 29</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::29: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::29</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Day 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::3: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::3</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Day 30</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::30: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::30</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>Integer::31 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::31: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::31</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>Integer::32 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::32: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::32</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>33</VALIDVALUE>
          <VALUEMEANING>Integer::33 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::33: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::33</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>34</VALIDVALUE>
          <VALUEMEANING>Integer::34 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::34: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::34</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>35</VALIDVALUE>
          <VALUEMEANING>Integer::35 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::35: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::35</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>36</VALIDVALUE>
          <VALUEMEANING>Integer::36 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::36: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::36</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>37</VALIDVALUE>
          <VALUEMEANING>Integer::37 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::37: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::37</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>38</VALIDVALUE>
          <VALUEMEANING>Integer::38 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::38: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::38</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>39</VALIDVALUE>
          <VALUEMEANING>Integer::39 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::39: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::39</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Integer::4 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::4: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::4</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Integer::40 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::40: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::40</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>41</VALIDVALUE>
          <VALUEMEANING>Integer::41 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::41: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::41</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>42</VALIDVALUE>
          <VALUEMEANING>Integer::42 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::42: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::42</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>43</VALIDVALUE>
          <VALUEMEANING>Integer::43 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::43: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::43</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>44</VALIDVALUE>
          <VALUEMEANING>Integer::44 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::44: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::44</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>45</VALIDVALUE>
          <VALUEMEANING>Integer::45 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::45: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::45</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>46</VALIDVALUE>
          <VALUEMEANING>Integer::46 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::46: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::46</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>47</VALIDVALUE>
          <VALUEMEANING>Integer::47 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::47: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::47</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>48</VALIDVALUE>
          <VALUEMEANING>Integer::48 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::48: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::48</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>49</VALIDVALUE>
          <VALUEMEANING>Integer::49 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::49: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::49</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Day 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::5: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::5</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>50</VALIDVALUE>
          <VALUEMEANING>Integer::50 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::50: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::50</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>Integer::51 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::51: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::51</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>Integer::52 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::52: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::52</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>Integer::53 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::53: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::53</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>Integer::54 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::54: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::54</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>Integer::55 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::55: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::55</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>Integer::56 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::56: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::56</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>Integer::57 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::57: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::57</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>Integer::58 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::58: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::58</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>Integer::59 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::59: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::59</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Integer::6 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::6: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>Integer::60 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::60: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::60</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>Integer::61 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::61: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::61</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>Integer::62 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::62: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::62</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>Integer::63 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::63: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::63</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>Integer::64 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::64: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::64</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>Integer::65 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::65: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::65</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>Integer::66 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::66: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::66</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>Integer::67 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::67: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::67</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>Integer::68 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::68: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::68</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>Integer::69 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::69: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::69</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Integer::7 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::7: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>Integer::70 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::70: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::70</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>Integer::71 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::71: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::71</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>Integer::72 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::72: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::72</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>Integer::73 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::73: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::73</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>Integer::74 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::74: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::74</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>Integer::75 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::75: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::75</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>Integer::76 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::76: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::76</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>Integer::77 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::77: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::77</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>Integer::78 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::78: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::78</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>Integer::79 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::79: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::79</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Day 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>Integer::80 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::80: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::80</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>Integer::81 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::81: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::81</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>Integer::82 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::82: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::82</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>83</VALIDVALUE>
          <VALUEMEANING>Integer::83 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::83: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::83</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>84</VALIDVALUE>
          <VALUEMEANING>Integer::84 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::84: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::84</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>85</VALIDVALUE>
          <VALUEMEANING>Integer::85 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::85: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::85</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>86</VALIDVALUE>
          <VALUEMEANING>Integer::86 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::86: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::86</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>87</VALIDVALUE>
          <VALUEMEANING>Integer::87 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::87: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::87</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>Integer::88 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::88: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::88</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>89</VALIDVALUE>
          <VALUEMEANING>Integer::89 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::89: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::89</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Integer::9 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::9: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>90</VALIDVALUE>
          <VALUEMEANING>Integer::90 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::90: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::90</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>91</VALIDVALUE>
          <VALUEMEANING>Integer::91 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::91: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::91</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>92</VALIDVALUE>
          <VALUEMEANING>Integer::92 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::92: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::92</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>93</VALIDVALUE>
          <VALUEMEANING>Integer::93 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::93: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::93</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>94</VALIDVALUE>
          <VALUEMEANING>Integer::94 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::94: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::94</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>95</VALIDVALUE>
          <VALUEMEANING>Integer::95 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::95: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::95</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>96</VALIDVALUE>
          <VALUEMEANING>Integer::96 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::96: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::96</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>97</VALIDVALUE>
          <VALUEMEANING>Integer::97 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::97: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::97</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>98</VALIDVALUE>
          <VALUEMEANING>Integer::98 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::98: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::98</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Integer::99 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::99: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::99</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100</VALIDVALUE>
          <VALUEMEANING>Integer::100 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::100: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2787406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Integer::1 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::1: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::1</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Day 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::10: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::10</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Day 11</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::11: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Day 12</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::12: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Day 13</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::13: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::13</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>Day 14</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::14</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Day 15</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::15: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::15</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Day 16</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::16: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::16</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Day 17</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::17: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::17</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Day 18</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::18: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::18</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Day 19</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::19: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::19</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Urinary Frequency</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Urinary Frequency</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="615">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3987710</PUBLICID>
    <LONGNAME>Same Disease or Disorder Next Transplantation Recurrent Disease Or Disease Progression Reason Indicator</LONGNAME>
    <PREFERREDNAME>3987695v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the subsequent transplant was for relapse or progression of the same disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3987695</PublicId>
      <PreferredName>3987692v1.0:3987693v1.0</PreferredName>
      <PreferredDefinition>Equal, or closely similar or comparable, in kind or quality or quantity or degree._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Subsequent; immediately following in time or order._Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species._The return of a disease after a period of remission._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The worsening of a disease over time_An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Same Disease or Disorder Next Transplantation Recurrent Disease Or Disease Progression Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3987692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64637:C2991:C53286:C15342</PreferredName>
        <Version>1</Version>
        <LongName>Same Disease or Disorder Next Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64637</PREFERRED_NAME>
            <LONG_NAME>Same</LONG_NAME>
            <CON_ID>2673124</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53286</PREFERRED_NAME>
            <LONG_NAME>Next</LONG_NAME>
            <CON_ID>2443959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3987693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38155:C37998:C17747:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Disease Or Disease Progression Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17747</PREFERRED_NAME>
            <LONG_NAME>Disease Progression</LONG_NAME>
            <CON_ID>2202885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the subsequent transplant</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the subsequent transplant for relapse or progression of the same disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the second or subsequent transplant for relapse or progression of the same disease?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Is the second or subsequent transplant for relapse or progression of the same disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the second or subsequent transplant for relapse or progression of the same disease?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the second or subsequent transplant for relapse or progression of the same disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_sub_hct_rel_progress_same_dis_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_sub_hct_rel_progress_same_dis_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MACpre_sub_hct_rel_progress_same_dis_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="616">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3991403</PUBLICID>
    <LONGNAME>Ofatumumab Administered Indicator</LONGNAME>
    <PREFERREDNAME>3988219v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not ofatumumab was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3988219</PublicId>
      <PreferredName>3988217v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Ofatumumab Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3988217</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66952</PreferredName>
        <Version>1</Version>
        <LongName>Ofatumumab</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66952</PREFERRED_NAME>
            <LONG_NAME>Ofatumumab</LONG_NAME>
            <CON_ID>3243441</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was ofatumumab administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was ofatumumab administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ofatumumab</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Ofatumumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ofatumumab</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Ofatumumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CLLP_LTHM_ofatumumab_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_therapy_multi_ofatumumab_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CLLF_DRPI_ofatumumab_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="617">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4152066</PUBLICID>
    <LONGNAME>Person Malignant Neoplasm Detection Evaluation Method Clinical Trial Eligibility Criteria Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>2236731v1.0:3192271v1.0_YES_NO</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown/not applicable indicator regarding information related to the method or test used to determine the presence of a malignant neoplastic tumor as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192273</PublicId>
      <PreferredName>2236731v1.0:3192271v1.0</PreferredName>
      <PreferredDefinition>information related to the method or test used to determine the presence of a malignant neoplastic tumor as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Person Malignant Neoplasm Detection Evaluation Method Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3192271v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Detection Evaluation Method Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have detecta</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have detectable disease defined as symptomatic ascites or pleural effusions, solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions and/or biopsy proven recurrence?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have biopsy proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2236731v1.0:3192271v1.0_YES_NO</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="618">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4162687</PUBLICID>
    <LONGNAME>Surgical Treatment Timepoint and Assigned Dose Schedule Type</LONGNAME>
    <PREFERREDNAME>SURG_TMP_DOSE_SCH_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to describe the assigned dose schedule as related to the timing of surgical treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4162677</PublicId>
      <PreferredName>2322305v1.0:4162675v1.0</PreferredName>
      <PreferredDefinition>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A specific point in the time continuum, including those established relative to an event._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._An allotting or an appointment to a particular person or use, or for a particular time or object._An ordered list of times at which things are planned to occur.</PreferredDefinition>
      <LongName>Surgical Treatment Timepoint and Dose Assignment Schedule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4162675</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4162675v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Timepoint And Dose Assignment Schedule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68568</PREFERRED_NAME>
            <LONG_NAME>Timepoint</LONG_NAME>
            <CON_ID>2656619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25426</PREFERRED_NAME>
            <LONG_NAME>Assignment</LONG_NAME>
            <CON_ID>2204040</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4162682</PublicId>
      <PreferredName>SURG_TMP_DOSE_SCH_TP</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Surgery Timepoint and Dose Schedule Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post-Surgical: 5 Days/Week</VALIDVALUE>
          <VALUEMEANING>Post-Surgical: 5 Days/Week</VALUEMEANING>
          <MEANINGDESCRIPTION>Post-Surgical: 5 Days/Week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4179971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post-Surgical: Once Weekly</VALIDVALUE>
          <VALUEMEANING>Post-Surgical: Once Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>Post-Surgical: Once Weekly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4162683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post-Surgical: Daily x 28 Days</VALIDVALUE>
          <VALUEMEANING>Post-Surgical: Daily x 28 Days</VALUEMEANING>
          <MEANINGDESCRIPTION>Post-Surgical: Daily x 28 Days</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4162684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pre-Surgical: One 40 mg Dose on Day of Surgery</VALIDVALUE>
          <VALUEMEANING>Pre-Surgical: One 40 mg Dose on Day of Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Surgical: One 40 mg Dose on Day of Surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4162685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pre-Surgical: Daily 5 mg x 7 Days</VALIDVALUE>
          <VALUEMEANING>Pre-Surgical: Daily 5 mg x 7 Days</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Surgical: Daily 5 mg x 7 Days</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4162686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pre-Surgical: One 30 mg Dose on Day of Surgery</VALIDVALUE>
          <VALUEMEANING>Pre-Surgical: One 30 mg Dose on Day of Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-Surgical: One 30 mg Dose on Day of Surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5567192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Days 1-7</VALIDVALUE>
          <VALUEMEANING>Days 1-7</VALUEMEANING>
          <MEANINGDESCRIPTION>Days 1-7</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6117799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Days 1-5</VALIDVALUE>
          <VALUEMEANING>Days 1-5</VALUEMEANING>
          <MEANINGDESCRIPTION>Days 1-5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6117800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>New assigned dosing schedule</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>New assigned dosing schedule</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Assigned dose schedule</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Assigned dose schedule</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 1301</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4162688</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="619">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4163215</PUBLICID>
    <LONGNAME>Unrelated Umbilical Cord Blood Type</LONGNAME>
    <PREFERREDNAME>UNRLTD_CORD_BLOOD_SP</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of unrelated umbilical cord blood (Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of autologous lymphocytes for transplantation to a patient later diagnosed and treated for leukemia or lymphoma).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4163197</PublicId>
      <PreferredName>4163195v1.0:2223243v1.0</PreferredName>
      <PreferredDefinition>Not connected or associated e.g. by kinship._Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of autologous lymphocytes for transplantation to a patient later diagnosed and treated for leukemia or lymphoma._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Unrelated Umbilical Cord Blood Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4163195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25328:C13300</PreferredName>
        <Version>1</Version>
        <LongName>Unrelated Umbilical Cord Blood</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25328</PREFERRED_NAME>
            <LONG_NAME>Unrelated</LONG_NAME>
            <CON_ID>2204954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13300</PREFERRED_NAME>
            <LONG_NAME>Umbilical Cord Blood</LONG_NAME>
            <CON_ID>2527864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4163213</PublicId>
      <PreferredName>4163213v1.0</PreferredName>
      <PreferredDefinition>Type of unrelated umbilical cord blood.</PreferredDefinition>
      <LongName>Unrelated Umbilical Cord Blood Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>33</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>4163212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25328:C13300:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Unrelated Umbilical Cord Blood Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25328</PREFERRED_NAME>
            <LONG_NAME>Unrelated</LONG_NAME>
            <CON_ID>2204954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13300</PREFERRED_NAME>
            <LONG_NAME>Umbilical Cord Blood</LONG_NAME>
            <CON_ID>2527864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Double</VALIDVALUE>
          <VALUEMEANING>Double Umbilical Cord Blood</VALUEMEANING>
          <MEANINGDESCRIPTION>A 64-bit floating point primitive. When wrapped in an immutable Object, it is called a Double.: Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of autologous lymphocytes for transplantation to a patient later diagnosed and treated for leukemia or lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13300, C48870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4163214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Single</VALIDVALUE>
          <VALUEMEANING>Single Umbilical Cord Blood</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others; exclusive of anyone or anything else.: Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13300, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify Unrelated Cord Blood</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify Unrelated Cord Blood</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="620">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4163754</PUBLICID>
    <LONGNAME>Peripheral Blood Other Culture Method Metaphase Present Number</LONGNAME>
    <PREFERREDNAME>4163753v1.0:2017272v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the number of metaphases present in peripheral blood sample subjected to a culture other than those previously specified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4163753</PublicId>
      <PreferredName>4163751v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>information related to metaphases present in peripheral blood sample subjected to a culture other than those previously specified.</PreferredDefinition>
      <LongName>Peripheral Blood Other Culture Method Metaphase Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4163751</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4163751v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Peripheral Blood Other Culture Procedure Metaphase Process</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25233</PREFERRED_NAME>
            <LONG_NAME>Peripheral</LONG_NAME>
            <CON_ID>2206343</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25300</PREFERRED_NAME>
            <LONG_NAME>Microbial Culture Procedure</LONG_NAME>
            <CON_ID>2440590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16846</PREFERRED_NAME>
            <LONG_NAME>Metaphase Process</LONG_NAME>
            <CON_ID>2466367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017272</PublicId>
      <PreferredName>META_PRES_NUM</PreferredName>
      <PreferredDefinition>the number of metaphases present in sample.</PreferredDefinition>
      <LongName>Metaphase Present Number</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other culture method</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other culture method</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cytogenetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811952</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OTHCMPB</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="621">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4169522</PUBLICID>
    <LONGNAME>Visual Acuity Attempt Evaluation Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>VisAcuityAtmt</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no/unknown/not applicable indicator related to the intention of the evaluation with sharpness of vision, the ability to discern fine detail.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4169521</PublicId>
      <PreferredName>VisAcuityAtmt</PreferredName>
      <PreferredDefinition>information related to the intention of the evaluation with sharpness of vision, the ability to discern fine detail.</PreferredDefinition>
      <LongName>Visual Acuity Attempt Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4144251</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C87149</PreferredName>
        <Version>1</Version>
        <LongName>Visual Acuity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87149</PREFERRED_NAME>
            <LONG_NAME>Visual Acuity</LONG_NAME>
            <CON_ID>3009181</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4170331</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39769:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Attempt Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39769</PREFERRED_NAME>
            <LONG_NAME>Attempt</LONG_NAME>
            <CON_ID>2203722</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the visual acuity test at</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the visual acuity test attempted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="622">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4182555</PUBLICID>
    <LONGNAME>Person Occupation Assessment Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>JOBHELD</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator for information related to the assessment of the principal activity that a person does to earn money.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4182272</PublicId>
      <PreferredName>OCCUPATION</PreferredName>
      <PreferredDefinition>Information related to the assessment of the principal activity that a person does to earn money.</PreferredDefinition>
      <LongName>Person Occupation Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4182270</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25193:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Occupation Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25193</PREFERRED_NAME>
            <LONG_NAME>Occupation</LONG_NAME>
            <CON_ID>2202912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Job held</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Job held</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JOBHELD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="623">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4184821</PUBLICID>
    <LONGNAME>Bortezomib/Dexamethasone/Lenalidomide Regimen Administered Indicator</LONGNAME>
    <PREFERREDNAME>4184735v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not bortezomib, dexamethasone, lenalidomide (RVD/VRD) regimen was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4184735</PublicId>
      <PreferredName>4184733v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A treatment regimen consisting of a combination of bortezomib, dexamethasone and lenalidomide._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Bortezomib/Dexamethasone/Lenalidomide Regimen Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4184733</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113827</PreferredName>
        <Version>1</Version>
        <LongName>Bortezomib/Dexamethasone/Lenalidomide Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113827</PREFERRED_NAME>
            <LONG_NAME>RVD Regimen</LONG_NAME>
            <CON_ID>4183270</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the bortezomib, dexametha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the bortezomib, dexamethasone, lenalidomide regimen administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RVD / VRD</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RVD / VRD</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RVD / VRD (Bortezomib (Velcade), dexamethasone, Lenalidomide (Revlimid))</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>RVD / VRD (Bortezomib (Velcade), dexamethasone, Lenalidomide (Revlimid)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpre_therapy_multi_rvd_vrd_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="624">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4188622</PUBLICID>
    <LONGNAME>Patient Prior Immunosuppressive Therapy Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>4188620v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/no response to information relating to prior immunosuppressive therapy (therapy used to decrease the body&#39;s immune response, such as drugs given to prevent transplant rejection) received by the patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4188620</PublicId>
      <PreferredName>2233604v1.0:4188618v1.0</PreferredName>
      <PreferredDefinition>information relating to prior immunosuppressive therapy (therapy used to decrease the body&#39;s immune response, such as drugs given to prevent transplant rejection) received by the patient.</PreferredDefinition>
      <LongName>Patient Prior Immunosuppressive Therapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4188618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15261:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Prior Immunosuppressive Therapy Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15261</PREFERRED_NAME>
            <LONG_NAME>Immunosuppressive Therapy</LONG_NAME>
            <CON_ID>2202362</CON_ID>
            <DEFINITION_SOURCE>CSP2000</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received any immu</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient received any immunosuppressive medications (excluding intranasal/inhaled corticosteroids, or systemic corticosteroids &lt;= 10 mg/day)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received any immunosuppressive medications (excluding intranasal/inhaled corticosteroids, or systemic corticosteroids &lt;= 10 mg/day) since discontinuing MEDI4736?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received any immunosuppressive medications (excluding intranasal/inhaled corticosteroids, or systemic corticosteroids &lt;= 10 mg/day) since discontinuing MEDI4736?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current or prior use of immunosuppressive medication within 14 days before registration</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (with the exception of those allowed in section 3.3 of the protocol)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immunosuppressive medication?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text_3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current or prior use of immunosuppressive medication within 14 days before registration (with the exception of those allowed in section 3.2 of the protocol)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IMSP</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="625">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4188891</PUBLICID>
    <LONGNAME>Non-Steroidal Aromatase Inhibitor Resistance Process Patient Description</LONGNAME>
    <PREFERREDNAME>4188857v1.0:3775432v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Description of the setting in which the patient developed resistance to prior non-steroidal aromatase inhibitor (AI) treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4188857</PublicId>
      <PreferredName>4188855v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>Description of the setting in which the patient developed resistance to a non-steroidal aromatase inhibitor treatment.</PreferredDefinition>
      <LongName>Non-Steroidal Aromatase Inhibitor Resistance Process Patient Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4188855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2018:C41546:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Non-Steroidal Aromatase Inhibitor Resistance Process Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2018</PREFERRED_NAME>
            <LONG_NAME>Non-Steroidal Aromatase Inhibitor</LONG_NAME>
            <CON_ID>4188854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41546</PREFERRED_NAME>
            <LONG_NAME>Resistance Process</LONG_NAME>
            <CON_ID>3232841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3775432</PublicId>
      <PreferredName>TX_INT_TP</PreferredName>
      <PreferredDefinition>the description of a drug regimen or type of treatment given to a patient.</PreferredDefinition>
      <LongName>Treatment Intent Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AECC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adjuvant and Advanced</VALIDVALUE>
          <VALUEMEANING>Adjuvant And Advanced</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Far along in course.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25411, C37912, C2140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3775433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adjuvant</VALIDVALUE>
          <VALUEMEANING>Adjuvant</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3646981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Advanced</VALIDVALUE>
          <VALUEMEANING>ADVANCED</VALUEMEANING>
          <MEANINGDESCRIPTION>ADVANCED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoadjuvant</VALIDVALUE>
          <VALUEMEANING>Neoadjuvant Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Locally advanced unresectable disease</VALIDVALUE>
          <VALUEMEANING>Advanced Unresectable Localized Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Far along in course.: Unable to be removed with surgery.: A disease that is confined to a specific organ or tissue and has not spread to other anatomic sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36162, C14151, C25411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3860591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metastatic</VALIDVALUE>
          <VALUEMEANING>Metastatic</VALUEMEANING>
          <MEANINGDESCRIPTION>A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Locally advanced/metastatic</VALIDVALUE>
          <VALUEMEANING>Locally advanced or metastatic disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that has spread from where it started to nearby tissue or lymph nodes.: Having to do with metastasis, which is the spread of cancer from the primary site (place where it started) to other places in the body.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2991, C14174, C8524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4213257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Setting in which patient deve</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Setting in which patient developed resistance to prior non steroidal AI treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="626">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4219071</PUBLICID>
    <LONGNAME>Genotype Epidermal Growth Factor Receptor Promoter-216 Assessment Type</LONGNAME>
    <PREFERREDNAME>GntEGFRPmt216Tp</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of Epidermal growth factor receptor (EGFR) promotor-216, a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4219054</PublicId>
      <PreferredName>GntEGFRPmt216Ass</PreferredName>
      <PreferredDefinition>information related to the determination of Epidermal growth factor receptor (EGFR) promotor-216, a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma.</PreferredDefinition>
      <LongName>Genotype Epidermal Growth Factor Receptor Promoter-216 Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611788</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16631</PreferredName>
        <Version>1</Version>
        <LongName>Genotype</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16631</PREFERRED_NAME>
            <LONG_NAME>Genotype</LONG_NAME>
            <CON_ID>2221799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4219052</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4219052v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Epidermal Growth Factor Receptor Promoter Integer::-216 Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17068</PREFERRED_NAME>
            <LONG_NAME>Epidermal Growth Factor Receptor</LONG_NAME>
            <CON_ID>2202420</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13297</PREFERRED_NAME>
            <LONG_NAME>Promoter</LONG_NAME>
            <CON_ID>2223996</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::-216</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4219064</PublicId>
      <PreferredName>EGFRPmt216Tp</PreferredName>
      <PreferredDefinition>the type of Epidermal growth factor receptor (EGFR) promotor-216, a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma.</PreferredDefinition>
      <LongName>EGFR promoter-216 Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T/G</VALIDVALUE>
          <VALUEMEANING>T/G</VALUEMEANING>
          <MEANINGDESCRIPTION>T/G</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4219065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T/T</VALIDVALUE>
          <VALUEMEANING>T/T</VALUEMEANING>
          <MEANINGDESCRIPTION>T/T</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4219066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G/G</VALIDVALUE>
          <VALUEMEANING>G/G</VALUEMEANING>
          <MEANINGDESCRIPTION>G/G</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4219067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genotype at EGFR promoter-216:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Genotype at EGFR promoter-216:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="627">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4233309</PUBLICID>
    <LONGNAME>Mercaptopurine Administered Indicator</LONGNAME>
    <PREFERREDNAME>4233307v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not mercaptopurine was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4233307</PublicId>
      <PreferredName>4233305v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Mercaptopurine Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4233305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C195</PreferredName>
        <Version>1</Version>
        <LongName>Mercaptopurine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C195</PREFERRED_NAME>
            <LONG_NAME>Mercaptopurine</LONG_NAME>
            <CON_ID>2416389</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was mercaptopurine administer</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was mercaptopurine administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>6-Mercaptopurine</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>6-Mercaptopurine</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>6-Mercaptopurine</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>6-Mercaptopurine</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JMMLpre_therapy_mercaptopurine_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="628">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4242141</PUBLICID>
    <LONGNAME>Prior Therapy Paclitaxel Administered Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>PRIPACLITAXEL</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator related to the prior administration of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4242120</PublicId>
      <PreferredName>PRIPACLITAXEL</PreferredName>
      <PreferredDefinition>Information related to the prior administration of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).</PreferredDefinition>
      <LongName>Prior Therapy Paclitaxel Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3693401</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Prior Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647284</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1411:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Paclitaxel Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1411</PREFERRED_NAME>
            <LONG_NAME>Paclitaxel</LONG_NAME>
            <CON_ID>2204907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Paclitaxel</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Paclitaxel</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior paclitaxel</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIPACLITAXEL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="629">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4250695</PUBLICID>
    <LONGNAME>Radiation Therapy Credential Status Category</LONGNAME>
    <PREFERREDNAME>RTCrdntlStCat</PREFERREDNAME>
    <PREFERREDDEFINITION>Classification related to the status confirmation of the treatment of a disease by means of exposure of the target or the whole body to radiation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4250693</PublicId>
      <PreferredName>RTCredSt</PreferredName>
      <PreferredDefinition>Information related to the status confirmation of the treatment of a disease by means of exposure of the target or the whole body to radiation.</PreferredDefinition>
      <LongName>Radiation Therapy Credential Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2188542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Radiation Therapy</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4250691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73925:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Credential Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73925</PREFERRED_NAME>
            <LONG_NAME>Credential</LONG_NAME>
            <CON_ID>2768659</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4250694</PublicId>
      <PreferredName>CrdentlCat</PreferredName>
      <PreferredDefinition>This term is used informally to mean a class of things.</PreferredDefinition>
      <LongName>Credentialing Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete</VALIDVALUE>
          <VALUEMEANING>Complete</VALUEMEANING>
          <MEANINGDESCRIPTION>To possess every necessary or normal part or component or step; having come or been brought to a conclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2950479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Credentialing:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Credentialing:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="630">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4252014</PUBLICID>
    <LONGNAME>Fibrinogen Antigen Assay Performed Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>4252013v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the results for the fibrinogen antigen assay.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4252013</PublicId>
      <PreferredName>4252011v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>A fibrillar protein present in blood plasma; it converts to fibrin during the process of blood clot formation._Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens._A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological potency of a drug._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Fibrinogen Antigen Assay Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4252011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25736:C268:C60819</PreferredName>
        <Version>1</Version>
        <LongName>Fibrinogen Antigen Assay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25736</PREFERRED_NAME>
            <LONG_NAME>Fibrinogen</LONG_NAME>
            <CON_ID>2204944</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C268</PREFERRED_NAME>
            <LONG_NAME>Antigen</LONG_NAME>
            <CON_ID>2202300</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60819</PREFERRED_NAME>
            <LONG_NAME>Assay</LONG_NAME>
            <CON_ID>2528534</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the fib</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the fibrinogen antigen assay finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fibrinogen antigen assay</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Fibrinogen antigen assay</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fibrinogen antigen assay</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Fibrinogen antigen assay</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HLHpost_assess_fibrinogen_antigen_assay_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HLHpre_clin_feat_lab_diag_fibrinogen_anti_assay_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HLHpre_clin_feat_lab_prep_fibrinogen_anti_assay_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>XLPpost_lab_eval_fibrinogen_antigen_assay_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>XLPpre_dis_stat_prep_fibrinogen_antigen_assay_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="631">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4261292</PUBLICID>
    <LONGNAME>Further Treatment Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>2009199v3.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/no response to whether further treatment will be administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2009199</PublicId>
      <PreferredName>FURTHER_TX_ADM</PreferredName>
      <PreferredDefinition>information related to further treatment being administered.</PreferredDefinition>
      <LongName>Further Treatment Administered</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206799</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25519:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Further Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25519</PREFERRED_NAME>
            <LONG_NAME>Further</LONG_NAME>
            <CON_ID>2206222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Will patient receive further</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Will patient receive further treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol/Admin.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811961</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="632">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4274827</PUBLICID>
    <LONGNAME>Electroporation Therapy Array Perpendicular Insertion Indicator</LONGNAME>
    <PREFERREDNAME>ELPO_ARR_PER_INS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response regarding whether the electroporation therapy array was inserted into the skin/tissue at a right angle to the given plane.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4274803</PublicId>
      <PreferredName>4273674v1.0:4274801v1.0</PreferredName>
      <PreferredDefinition>Treatment that generates electrical pulses through an electrode placed in a tumor to enhance the ability of anticancer drugs to enter tumor cells._An orderly arrangement._The act of putting one thing into another._At a right angle to a given line or plane.</PreferredDefinition>
      <LongName>Electroporation Therapy Array Perpendicular Insertion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4273674</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15707:C26358</PreferredName>
        <Version>1</Version>
        <LongName>Electroporation Therapy Array</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15707</PREFERRED_NAME>
            <LONG_NAME>Electroporation</LONG_NAME>
            <CON_ID>4273673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26358</PREFERRED_NAME>
            <LONG_NAME>Array</LONG_NAME>
            <CON_ID>2236563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4274801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C96557:C48685</PreferredName>
        <Version>1</Version>
        <LongName>Perpendicular Insertion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C96557</PREFERRED_NAME>
            <LONG_NAME>Perpendicular</LONG_NAME>
            <CON_ID>4274800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48685</PREFERRED_NAME>
            <LONG_NAME>Insertion</LONG_NAME>
            <CON_ID>2437659</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was array inserted perpendicu</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was array inserted perpendicular to arm?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="633">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4319853</PUBLICID>
    <LONGNAME>FAACT Questionnaire Past Seven Days Seem to Get Full Quickly How True Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FAACT_GET_FULL_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how true in the past 7 days when they eat, they seem to get full quickly, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FAACT:Functional Assessment of Anorexia/Cachexia Treatment, David Cella, Ph.D., Version 4, Nov. 2007</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4319836</PublicId>
      <PreferredName>4042612v1.0:4319834v1.0</PreferredName>
      <PreferredDefinition>A questionnaire used to assess general aspects of quality of life related to anorexia and cachexia._The most recent week, including today._A survey question about a person&#39;s agreement with a statement._A question about whether an individual gets full quickly when they eat._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FAACT Questionnaire Past Week How True Seem to Get Full Quickly Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4042612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113301</PreferredName>
        <Version>1</Version>
        <LongName>FAACT Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113301</PREFERRED_NAME>
            <LONG_NAME>FAACT Questionnaire</LONG_NAME>
            <CON_ID>4040174</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4319834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C91781:C115347:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How True Seem to Get Full Quickly Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C115347</PREFERRED_NAME>
            <LONG_NAME>Seem to Get Full Quickly Question</LONG_NAME>
            <CON_ID>4311429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FAACT:Functional Assessment of Anorexia/Cachexia Treatment, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3144287</PublicId>
      <PreferredName>3144287v1.1</PreferredName>
      <PreferredDefinition>Numeric representation of how true in the past 7 days a person experienced something about a their illness using a five-point Likert scale.</PreferredDefinition>
      <LongName>Past 7 Days How True Score_5 Point Scale</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Some-what</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>When I eat, I seem to get ful</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>When I eat, I seem to get full quickly</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4811884</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FACIT System Scales</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FAACT (Functional Assessment of Anorexia/Cachexia Treatment) </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4813471</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="634">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4358299</PUBLICID>
    <LONGNAME>Patient Movement Protocol Treatment Yes No Coded Indicator</LONGNAME>
    <PREFERREDNAME>PT_MVT_TX_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify whether a protocol subject progressed to the treatment regimen or phase of a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2475222</PublicId>
      <PreferredName>PT_MVMT_PROT_TX</PreferredName>
      <PreferredDefinition>A protocol subject&#39;s progression to the treatment regimen or phase of the trial.</PreferredDefinition>
      <LongName>Patient Movement Protocol Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475219</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C37994</PreferredName>
        <Version>1</Version>
        <LongName>Patient Movement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37994</PREFERRED_NAME>
            <LONG_NAME>Movement</LONG_NAME>
            <CON_ID>2203634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2475220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25320:C15697</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15697</PREFERRED_NAME>
            <LONG_NAME>Treatment Regimen</LONG_NAME>
            <CON_ID>2203773</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183836</PublicId>
      <PreferredName>YES_NO_CD_IND</PreferredName>
      <PreferredDefinition>Yes or No response to a question coded as 1 (Yes) or 2 (No).</PreferredDefinition>
      <LongName>Yes No Coded Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the Patient proceed to Pr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the Patient proceed to Protocol Treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="635">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4386477</PUBLICID>
    <LONGNAME>Prior Whipple Procedure Performed Date</LONGNAME>
    <PREFERREDNAME>WHIPPLE_SURG_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date the patient had previous Whipple surgery as treatment for this cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4386474</PublicId>
      <PreferredName>WHIPPLE_SURG</PreferredName>
      <PreferredDefinition>Earlier in time or order._Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Prior Whipple Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4386472</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15356</PreferredName>
        <Version>1</Version>
        <LongName>Prior Whipple Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15356</PREFERRED_NAME>
            <LONG_NAME>Whipple Procedure</LONG_NAME>
            <CON_ID>2794446</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Whipple surgery date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior Whipple surgery date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="636">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4420721</PUBLICID>
    <LONGNAME>Laboratory Procedure KIT Biomarker Result</LONGNAME>
    <PREFERREDNAME>CD117MrkRslt</PREFERREDNAME>
    <PREFERREDDEFINITION>the outcome related to the evaluation of human KIT wild-type allele/CD117 response to a particular therapeutic intervention which is located within 4q11-q12 and is approximately 83 kb in length. This allele, which encodes mast/stem cell growth factor receptor protein, plays a role in the mediation of transmembrane-receptor interactions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4420720</PublicId>
      <PreferredName>CD117MrkEvl</PreferredName>
      <PreferredDefinition>information related to the evaluation of human KIT wild-type allele/CD117 response to a particular therapeutic intervention which is located within 4q11-q12 and is approximately 83 kb in length. This allele, which encodes mast/stem cell growth factor receptor protein, plays a role in the mediation of transmembrane-receptor interactions.</PreferredDefinition>
      <LongName>Laboratory Procedure KIT Biomarker Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4420718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C51741:C16342:C25214</PreferredName>
        <Version>1</Version>
        <LongName>KIT wt Allele Biomarker Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51741</PREFERRED_NAME>
            <LONG_NAME>KIT wt Allele</LONG_NAME>
            <CON_ID>4420717</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD117</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CD117</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>KIT (CD117) mutation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="637">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4512932</PUBLICID>
    <LONGNAME>Telapristone Pharmacokinetics Outcome Value</LONGNAME>
    <PREFERREDNAME>TEL_PK_OUT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric response regarding the quantity of Telapristone, an orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), as measured in ng/g utilizing pharmacokinetics.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4353955</PublicId>
      <PreferredName>4353952v1.0:4353953v1.0</PreferredName>
      <PreferredDefinition>An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities._The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements._The result of an action.</PreferredDefinition>
      <LongName>Telapristone Pharmacokinetics Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4353952</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C104057</PreferredName>
        <Version>1</Version>
        <LongName>Telapristone</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104057</PREFERRED_NAME>
            <LONG_NAME>Telapristone</LONG_NAME>
            <CON_ID>4353951</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4353953</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15299:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacokinetics Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15299</PREFERRED_NAME>
            <LONG_NAME>Pharmacokinetics</LONG_NAME>
            <CON_ID>2204958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4512915</PublicId>
      <PreferredName>4512915v1.0</PreferredName>
      <PreferredDefinition>The charachteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements._The result of an action._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Pharmacokinetics Outcome Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>4512914</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15299:C20200:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacokinetics Outcome Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15299</PREFERRED_NAME>
            <LONG_NAME>Pharmacokinetics</LONG_NAME>
            <CON_ID>2204958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Result (Telapristone measurem</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Result (Telapristone measurement)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="638">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4514233</PUBLICID>
    <LONGNAME>Tissue Specimen Collected Location Text</LONGNAME>
    <PREFERREDNAME>TIS_SPE_COL_LOC_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The response regarding the location or position of a tissue specimen collected for research purposes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2217549</PublicId>
      <PreferredName>TISS_SPEC_COLLECT</PreferredName>
      <PreferredDefinition>information related to a tissue specimen being collected.</PreferredDefinition>
      <LongName>Tissue Specimen Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206399</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12801:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177590</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Collected</PreferredName>
        <Version>1</Version>
        <LongName>Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2547415</PublicId>
      <PreferredName>LOC_TXT</PreferredName>
      <PreferredDefinition>A free text field used to describe a location of a position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Location Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2547414</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25341:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Location Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tissue Location</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tissue Location</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Tissue Location (cm from anal verge)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Parent specimen type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-08-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="639">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4529262</PUBLICID>
    <LONGNAME>Peripheral Blood Stem Cell CD34+ Cell Harvest Performed Day Count</LONGNAME>
    <PREFERREDNAME>CD34DAYCOUNT</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of days related to a peripheral blood stem CD34+ cell harvest performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014800</PublicId>
      <PreferredName>PBSCCD34_HARVST_PERF</PreferredName>
      <PreferredDefinition>information relating to a peripheral blood stem CD34+ cell harvest performed.</PreferredDefinition>
      <LongName>Peripheral Blood Stem Cell CD34+ Cell Harvest Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2464105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12946:C0882849:C37963</PreferredName>
        <Version>1</Version>
        <LongName>PBSC CD34+ cell Harvest</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12946</PREFERRED_NAME>
            <LONG_NAME>Peripheral Blood Stem Cell</LONG_NAME>
            <CON_ID>2202777</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0882849</PREFERRED_NAME>
            <LONG_NAME>CD34+ cell</LONG_NAME>
            <CON_ID>2464104</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37963</PREFERRED_NAME>
            <LONG_NAME>Harvest Procedure</LONG_NAME>
            <CON_ID>2202648</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4529260</PublicId>
      <PreferredName>DAYCOUNT</PreferredName>
      <PreferredDefinition>To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6 or more</VALIDVALUE>
          <VALUEMEANING>6 or more</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66837, C61583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4529261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>0</VALUEMEANING>
          <MEANINGDESCRIPTION>A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of days it took to col</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of days it took to collect above quantity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="640">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4529346</PUBLICID>
    <LONGNAME>Surgical Excision Residual Lesion Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>SURGRESIDLES</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for information related to the surgical resection of residual lesions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4529345</PublicId>
      <PreferredName>SURGRESIDLES</PreferredName>
      <PreferredDefinition>Information related to the surgical resection of residual lesions.</PreferredDefinition>
      <LongName>Surgical Excision Residual Lesion Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25698:C15232</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Resection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25698</PREFERRED_NAME>
            <LONG_NAME>Surgical</LONG_NAME>
            <CON_ID>2202592</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4529343</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37895:C3824:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Residual Lesion Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37895</PREFERRED_NAME>
            <LONG_NAME>Residual</LONG_NAME>
            <CON_ID>2206361</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did patient undergo surgical</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did patient undergo surgical resection of residual lesions?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="641">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4566275</PUBLICID>
    <LONGNAME>FACT-Br Questionnaire Version 4 Br18 How True Past Seven Days Able to Drive a Vehicle Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FACTBR_V4_BR18_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how true in the past 7 days they are able to drive a vehicle (car, truck, etc.), using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-Br:Functional Assessment of Cancer Therapy - Brain, David Cella, Ph.D., Version 4, Nov. 2007</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3876380</PublicId>
      <PreferredName>2555185v1.0:3876378v1.0</PreferredName>
      <PreferredDefinition>A 50-item instrument that assesses general physical, social, emotional and functional well-being, as well as brain tumor-specific concerns._The most recent week, including today._A survey question about a person&#39;s agreement with a statement.ability._A question about whether an individual is or was able to drive a vehicle._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-Br Questionnaire Past Seven Days Able to Drive a Vehicle How True Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2555185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63928</PreferredName>
        <Version>1</Version>
        <LongName>FACT-BR Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63928</PREFERRED_NAME>
            <LONG_NAME>FACT-BR Questionnaire</LONG_NAME>
            <CON_ID>2549644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3876378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C91781:C111061:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How True Able to Drive a Vehicle Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111061</PREFERRED_NAME>
            <LONG_NAME>Able to Drive a Vehicle Question</LONG_NAME>
            <CON_ID>3875919</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACT-Br:Functional Assessment of Cancer Therapy - Brain, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4552765</PublicId>
      <PreferredName>4552765v1.0</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Not at all) to 4 (Very Much) on a Likert scale used on FACT questionnaires.</PreferredDefinition>
      <LongName>FACT Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACT-G:Functional Assessment of Cancer Therapy - General, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Some-what</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am able to drive a vehicle</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am able to drive a vehicle (my car, truck, etc.)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-Br</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>I am able to drive a vehicle (my car, truck, etc.) (47)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Link to Scoring and Interpretation Materials</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the  measure.  The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Br </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4718290</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Br (Functional Assessment of Cancer Therapy - Brain) </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4551833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT/FACT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Br (Version 4)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918033</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCI Standards</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="642">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4609702</PUBLICID>
    <LONGNAME>FACT-Cog Questionnaire Version 3 CogF23 How Often Past Seven Days Have to Work Really Hard to Pay Attention or Would Make Mistake Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FACTCOG_V3_COGF23_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A persons&#39; stated observation of how often in the past 7 days they have had to work really hard to pay attention or they would make a mistake, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4609607</PublicId>
      <PreferredName>4609571v1.0:4621413v1.0</PreferredName>
      <PreferredDefinition>The FACT-Cognitive Function questionnaire is a 37 item measure developed by Dr. David Cella to evaluate knowledge and information processing._A question about the frequency of an event or behavior._The most recent week, including today._A question about whether an individual has or had to work really hard to pay attention or they would make a mistake._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-Cognitive Function How Often Past Week Have to Work Really Hard to Pay Attention or Would Make Mistake Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4609571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103850</PreferredName>
        <Version>1</Version>
        <LongName>FACT-Cognitive Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103850</PREFERRED_NAME>
            <LONG_NAME>FACT-Cognitive Function</LONG_NAME>
            <CON_ID>3640861</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4621413</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C118873:C95402:C118684:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Often Past Week Have to Work Really Hard to Pay Attention or Would Make Mistake Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118873</PREFERRED_NAME>
            <LONG_NAME>How Often Question</LONG_NAME>
            <CON_ID>4615091</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118684</PREFERRED_NAME>
            <LONG_NAME>Have to Work Really Hard to Pay Attention or Would Make Mistake Question</LONG_NAME>
            <CON_ID>4601419</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4614311</PublicId>
      <PreferredName>FACT_FREQ_5PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Never) to 4 (Several Times Daily) on a Likert scale used for FACT questionnaires.</PreferredDefinition>
      <LongName>FACT Day Week Frequency Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>About once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of approximately once per week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two to three times a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of two or three times per week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Nearly every day</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency bordering on daily.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Several times a day</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of several times per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have had to work really har</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have had to work really hard to pay attention or I would make a mistake</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-Cognitive Function</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>I have had to work really hard to pay attention or I would make a mistake (12)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Link to Scoring and Interpretation Materials</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cog </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4718476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cog (Functional Assessment of Cancer Therapy - Cognitive Function)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4551753</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT/FACT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cognitive Function (Version 3)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918034</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCI Standards</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="643">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4630125</PUBLICID>
    <LONGNAME>Current Melanoma Status Type</LONGNAME>
    <PREFERREDNAME>2528340v1.0:4630120v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the disease status of myeloma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528340</PublicId>
      <PreferredName>DZ_CUR_DESC</PreferredName>
      <PreferredDefinition>information related to the current description or status of any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PreferredDefinition>
      <LongName>Diseases and Disorders Current Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207323</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Current Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4630120</PublicId>
      <PreferredName>2939785v1.1</PreferredName>
      <PreferredDefinition>Type; a subdivision of a particular kind of thing.__A malignant neoplasm comprised of melanocytes typically arising in the skin._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Melanoma Status Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>4630119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3224:C25688:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Melanoma Status Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3224</PREFERRED_NAME>
            <LONG_NAME>Melanoma</LONG_NAME>
            <CON_ID>2202743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown primary melanoma</VALIDVALUE>
          <VALUEMEANING>Unknown primary melanoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Unknown primary melanoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4630121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously diagnosed primary cutaneous melanoma</VALIDVALUE>
          <VALUEMEANING>Previously diagnosed primary cutaneous melanoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Previously diagnosed primary cutaneous melanoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4630122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Newly diagnosed primary cutaneous melanoma</VALIDVALUE>
          <VALUEMEANING>Newly diagnosed primary cutaneous melanoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Newly diagnosed primary cutaneous melanoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4630123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Current Disease Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Current Disease Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="644">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4700312</PUBLICID>
    <LONGNAME>FACT-P Questionnaire Version 4 P3 How True Past Seven Days Pain Keeps Me From Doing Things I Want to Do Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FACTP_V4_P3_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how true in the past 7 days their pain keeps them from doing things they want to do, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-P:Functional Assessment of Cancer Therapy - Prostate, David Cella, Ph.D., Version 4, Nov. 2007</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647302</PublicId>
      <PreferredName>3645942v1.0:3647300v1.0</PreferredName>
      <PreferredDefinition>The FACT-P is a multidimensional, self-report quality of life instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms (from GEM website https://www.gem-beta.org/public/MeasureDetail.aspx?mid=1074&amp;cat=2)_Past; before the present time._A number with no fractional part, including the negative and positive numbers as well as zero.::7_The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._A survey question about a person experiencing pain that keeps them from doing things they want to do._A survey question about a person&#39;s agreement with a statement._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-P Questionnaire Past 7 Days Pain Keeps Me From Doing Things I Want to Do How True Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3645942</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103832</PreferredName>
        <Version>1</Version>
        <LongName>FACT-P Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103832</PREFERRED_NAME>
            <LONG_NAME>FACT-P Questionnaire</LONG_NAME>
            <CON_ID>3640488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647300</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3647300v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::7 Day Pain Keeps Me From Doing Things I Want to Do How True Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::7</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103967</PREFERRED_NAME>
            <LONG_NAME>Pain Keeps Me From Doing Things I Want to Do Question</LONG_NAME>
            <CON_ID>3647250</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4552765</PublicId>
      <PreferredName>4552765v1.0</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Not at all) to 4 (Very Much) on a Likert scale used on FACT questionnaires.</PreferredDefinition>
      <LongName>FACT Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACT-G:Functional Assessment of Cancer Therapy - General, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Some-what</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>My pain keeps me from doing t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>My pain keeps me from doing things I want to do</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-P</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>My pain keeps me from doing things I want to do (33)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Link to Scoring and Interpretation Materials</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCCN-FACT FPSI-17</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>My pain keeps me from doing things I want to do (8)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medidata ePRO CDE</Name>
        <OrganizationName/>
        <DocumentType>ePRO Compliant</DocumentType>
        <DocumentText>This CDE has been validated for use with the Medidata Rave ePRO module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-P </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4718485</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-P (Functional Assessment of Cancer Therapy-Prostate)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4700291</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NCCN-FACT FPSI-17 (National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Prostate Symptom Index 17)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4916709</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT/FACT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-P (Version 4)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918030</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6051063</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Electronic PROs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-P</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3638605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="645">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4709529</PUBLICID>
    <LONGNAME>Ipsilateral Breast Radiation Therapy Prescription Dose Percentage Value</LONGNAME>
    <PREFERREDNAME>IPL_BRST_DOS_PCT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the percentage of the ipsilateral breast receiving 100% of the prescription dose of radiation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4700414</PublicId>
      <PreferredName>4700411v1.0:4700412v1.0</PreferredName>
      <PreferredDefinition>Having to do with the same side of the body._One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A doctor&#39;s order for medicine or another intervention._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.</PreferredDefinition>
      <LongName>Ipsilateral Breast Radiation Therapy Prescription Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4700411</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25308:C12971:C15313:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Ipsilateral Breast Radiation Therapy Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25308</PREFERRED_NAME>
            <LONG_NAME>Ipsilateral</LONG_NAME>
            <CON_ID>2206283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4700412</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28180:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Prescription Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28180</PREFERRED_NAME>
            <LONG_NAME>Prescription</LONG_NAME>
            <CON_ID>2230250</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2903088</PublicId>
      <PreferredName>PER_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity measured or assigned or computed that is a fraction or ratio with 100 understood as the denominator.</PreferredDefinition>
      <LongName>Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>V30Gy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>V30Gy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="646">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4719204</PUBLICID>
    <LONGNAME>Tobacco Use Youth e-Cigarette Flavor Preference Questionnaire Assessment Text</LONGNAME>
    <PREFERREDNAME>Toba_Yout_Ciga_Extr_Pref_Ques_</PREFERREDNAME>
    <PREFERREDDEFINITION>Use of tobacco in any form i.e. smoking, chewing or sniffing._The time of life between childhood and maturity.  This period overlaps with adolescence._Finely cut tobacco encased in a wrapper of thin paper and rolled for smoking._A solution of essential constituents of a complex material; a substance removed from another substance._The act, fact, or principle of giving advantages to some particular person, object, or course of action over others; designated as more desirable._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4719203</PublicId>
      <PreferredName>Toba_Yout_Elec_Flav_Pref_Ques</PreferredName>
      <PreferredDefinition>Use of tobacco in any form i.e. smoking, chewing or sniffing._The time of life between childhood and maturity.  This period overlaps with adolescence._A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette._The distinctive taste of something as detected in the mouth and also by the nose._The act, fact, or principle of giving advantages to some particular person, object, or course of action over others; designated as more desirable._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.</PreferredDefinition>
      <LongName>Tobacco Use Youth Electronic Cigarette Extract Preference Questionnaire Flavor Preference</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3024963</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18059</PreferredName>
        <Version>1</Version>
        <LongName>Tobacco Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18059</PREFERRED_NAME>
            <LONG_NAME>Tobacco Use</LONG_NAME>
            <CON_ID>2202335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4797982</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4797982v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Youth Electronic Cigarette Flavor Preference Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17471</PREFERRED_NAME>
            <LONG_NAME>Youth</LONG_NAME>
            <CON_ID>2202284</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120482</PREFERRED_NAME>
            <LONG_NAME>Electronic Cigarette</LONG_NAME>
            <CON_ID>4732164</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121659</PREFERRED_NAME>
            <LONG_NAME>Flavor</LONG_NAME>
            <CON_ID>4796873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41187</PREFERRED_NAME>
            <LONG_NAME>Preference</LONG_NAME>
            <CON_ID>2435947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tobacco Use Youth e-Cigarette Flavor Preference Questionnaire Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tobacco Use Youth e-Cigarette Flavor Preference Questionnaire Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tobacco Regulatory Research Specialty Collections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Host: Social/Cognitive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Host: Biobehavioral</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="647">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4722511</PUBLICID>
    <LONGNAME>Laboratory Procedure Serum Glutamic Pyruvic Transaminase Performed Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>3157901v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory results for serum glutamic pyruvic transaminase.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3157901</PublicId>
      <PreferredName>2543047v1.0:3157899v1.0</PreferredName>
      <PreferredDefinition>information related to a medical procedure being performed that involves testing a sample of blood for serum glutamic pyruvic transaminase, pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis and mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate.</PreferredDefinition>
      <LongName>Laboratory Procedure Serum Glutamic Pyruvic Transaminase Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3157899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25293:C38000</PreferredName>
        <Version>1</Version>
        <LongName>SGPT (ALT) Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25293</PREFERRED_NAME>
            <LONG_NAME>Alanine Aminotransferase</LONG_NAME>
            <CON_ID>2206251</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the ALT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the ALT finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ALT (SGPT)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ALT (SGPT)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ALT (SGPT)</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>ALT (SGPT)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VOD_LABD_alt_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNfup_orgn_fnc_alt_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNbase_orgn_fnc_alt_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>base_organ_func_prep_alt_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="648">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4725000</PUBLICID>
    <LONGNAME>Laboratory Procedure B-Lymphocyte CD20 Antigen Outcome Lab Unit of Measure Name</LONGNAME>
    <PREFERREDNAME>3226319v1.0:2017137v3.2</PREFERREDNAME>
    <PREFERREDDEFINITION>The unit of measure that represents a determinate amount or quantity of CD20 antigen in a laboratory specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3226319</PublicId>
      <PreferredName>2543047v1.0:3226340v1.0</PreferredName>
      <PreferredDefinition>information relating to the results of the medical procedure that involves testing a sample of blood for a CD20+ B-lymphocytes, a type of white blood cell that plays a role in both the activation and proliferation of B-cells.</PreferredDefinition>
      <LongName>Laboratory Procedure B-Lymphocyte CD20 Antigen Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3226340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12474:C38896:C20200</PreferredName>
        <Version>1</Version>
        <LongName>B-Lymphocyte CD20 Antigen Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12474</PREFERRED_NAME>
            <LONG_NAME>B-Lymphocyte</LONG_NAME>
            <CON_ID>2529669</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38896</PREFERRED_NAME>
            <LONG_NAME>B-Lymphocyte Antigen CD20</LONG_NAME>
            <CON_ID>2763229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017137</PublicId>
      <PreferredName>LAB_UOM_NM</PreferredName>
      <PreferredDefinition>Unit of measure standard values to describe a lab test result.</PreferredDefinition>
      <LongName>Lab Unit of Measure Name</LongName>
      <Version>3.2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>LITER</VALUEMEANING>
          <MEANINGDESCRIPTION>LITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol</VALIDVALUE>
          <VALUEMEANING>MILLIMOLE</VALUEMEANING>
          <MEANINGDESCRIPTION>MILLIMOLE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/L</VALIDVALUE>
          <VALUEMEANING>millimole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>millimole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg</VALIDVALUE>
          <VALUEMEANING>milligram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Any division of quantity accepted as a standard of measurement or exchange.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL</VALIDVALUE>
          <VALUEMEANING>Nanograms per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Grams (g)</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one one thousandth of a kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/L</VALIDVALUE>
          <VALUEMEANING>International unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq</VALIDVALUE>
          <VALUEMEANING>Milliequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/24hr</VALIDVALUE>
          <VALUEMEANING>Milliequivalents per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/dL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/L</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL</VALIDVALUE>
          <VALUEMEANING>Milligram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million</VALIDVALUE>
          <VALUEMEANING>Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one-thousandth of an international unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/m2</VALIDVALUE>
          <VALUEMEANING>Milliinternational units per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one-thousandth (10E-3) of an arbitrary unit of biological activity (International Unit) of substance per square meter of body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg</VALIDVALUE>
          <VALUEMEANING>Picograms</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand</VALIDVALUE>
          <VALUEMEANING>Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg</VALIDVALUE>
          <VALUEMEANING>Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>Thousand per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E12 Cells per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell concentration expressed as a number of cells in trillions per unit volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E3 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E3 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mill PFU</VALIDVALUE>
          <VALUEMEANING>Million Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of viable infectious entities expressed in millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Srce</VALIDVALUE>
          <VALUEMEANING>No Source Data</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L</VALIDVALUE>
          <VALUEMEANING>Kilounit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>Cubic microns</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The property used in conjunction with a nutrient or food component, typically expressed in gram (g), milligram (mg), microgram (mcg), joule, or kilojoule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/dL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/mL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fL</VALIDVALUE>
          <VALUEMEANING>Femtoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI equal to one quadrillionth of a liter (10E-15 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/24hr</VALIDVALUE>
          <VALUEMEANING>Gram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/dL</VALIDVALUE>
          <VALUEMEANING>Gram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/L</VALIDVALUE>
          <VALUEMEANING>Gram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/microL</VALIDVALUE>
          <VALUEMEANING>Gram per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPF</VALIDVALUE>
          <VALUEMEANING>Per High Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per High Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iunit</VALIDVALUE>
          <VALUEMEANING>INTERNATIONAL UNIT</VALUEMEANING>
          <MEANINGDESCRIPTION>INTERNATIONAL UNIT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/m2</VALIDVALUE>
          <VALUEMEANING>International unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>International unit per meter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>International unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>IU/mL</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE>2019-04-30</PVENDDATE>
          <VMPUBLICID>2573880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LPF</VALIDVALUE>
          <VALUEMEANING>Per Low Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per Low Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/24hr</VALIDVALUE>
          <VALUEMEANING>Microgram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/dL</VALIDVALUE>
          <VALUEMEANING>Microgram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/L</VALIDVALUE>
          <VALUEMEANING>microgram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>microgram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/spec</VALIDVALUE>
          <VALUEMEANING>Microgram per specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per specimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/kg</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliequivalent per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/L</VALIDVALUE>
          <VALUEMEANING>Milligram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL/min</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microIU/mL</VALIDVALUE>
          <VALUEMEANING>Micro International Unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micro International Unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microL</VALIDVALUE>
          <VALUEMEANING>MICROLITER</VALUEMEANING>
          <MEANINGDESCRIPTION>MICROLITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/24hr</VALIDVALUE>
          <VALUEMEANING>Micromole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/dL</VALIDVALUE>
          <VALUEMEANING>Micromole per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/L</VALIDVALUE>
          <VALUEMEANING>Micromole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Million per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/mL</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliinternational unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Milliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/1.73/BSA</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute times 1.73 times BSA</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute times 1.73 times BSA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg</VALIDVALUE>
          <VALUEMEANING>Milliter per minute per millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter per minute per millimeters of Mercury</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm/hr</VALIDVALUE>
          <VALUEMEANING>Millimeter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter per hour</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm3</VALIDVALUE>
          <VALUEMEANING>Millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmHg</VALIDVALUE>
          <VALUEMEANING>Millimeter of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth&#39;s surface. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/24hr</VALIDVALUE>
          <VALUEMEANING>Millimole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosmol/kg</VALIDVALUE>
          <VALUEMEANING>Milliosmole per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliosmole per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MU/mL</VALIDVALUE>
          <VALUEMEANING>Million units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not applicable; no UOM required</VALUEMEANING>
          <MEANINGDESCRIPTION>Not applicable; no UOM required</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL/hr</VALIDVALUE>
          <VALUEMEANING>Nanogram per milliliter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to mass concentration of a substance expressed in nanograms per unit volume of one milliliter per time period of one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nMol/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL</VALIDVALUE>
          <VALUEMEANING>Nanomole per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/dL</VALIDVALUE>
          <VALUEMEANING>Picogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pgPGE2/mg protein</VALIDVALUE>
          <VALUEMEANING>pgPGE2/mg protein</VALUEMEANING>
          <MEANINGDESCRIPTION>pgPGE2/mg protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/L</VALIDVALUE>
          <VALUEMEANING>Picomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ratio</VALIDVALUE>
          <VALUEMEANING>ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>ratio</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>sec</VALIDVALUE>
          <VALUEMEANING>seconds</VALUEMEANING>
          <MEANINGDESCRIPTION>seconds</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0457385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/24hr</VALIDVALUE>
          <VALUEMEANING>Unit per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/L</VALIDVALUE>
          <VALUEMEANING>Unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mL</VALIDVALUE>
          <VALUEMEANING>Unit per millilliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millilliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mm3</VALIDVALUE>
          <VALUEMEANING>Unit per millimeters cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millimeters cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 Cells/kg</VALIDVALUE>
          <VALUEMEANING>10E7 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min</VALIDVALUE>
          <VALUEMEANING>Liters per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/24hr</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/m2</VALIDVALUE>
          <VALUEMEANING>Unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed as a number of arbitrary units of substance per one square meter of a body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%/100 WBC</VALIDVALUE>
          <VALUEMEANING>Percent Per 100 WBC</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for percentage measurement of fraction of any type of white blood cells in the total white blood cell count differential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mm3</VALIDVALUE>
          <VALUEMEANING>Per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells</VALIDVALUE>
          <VALUEMEANING>10E6 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per microLiter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per microLiter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/mm3</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 Cells</VALIDVALUE>
          <VALUEMEANING>10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E8 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells</VALIDVALUE>
          <VALUEMEANING>10E9 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/microL</VALIDVALUE>
          <VALUEMEANING>Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies</VALIDVALUE>
          <VALUEMEANING>Copies</VALUEMEANING>
          <MEANINGDESCRIPTION>Copies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/dL</VALIDVALUE>
          <VALUEMEANING>nanogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>nanogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mL</VALIDVALUE>
          <VALUEMEANING>Picrogram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picrogram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100 WBC</VALIDVALUE>
          <VALUEMEANING>Per 100 identifiable White blood cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit for measurement of portion of a particular type of blood cells (such as any type of white blood cells or nucleated red blood cells) in the total white blood cell count expressed per count of 100.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAE Unit</VALIDVALUE>
          <VALUEMEANING>Complement activity enzyme unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Complement activity enzyme unit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Titer</VALIDVALUE>
          <VALUEMEANING>Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>Titer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA copies/mL</VALIDVALUE>
          <VALUEMEANING>RNA copies per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>RNA copies per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>Million per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MIC</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic Microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICR</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICRON</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GPL</VALIDVALUE>
          <VALUEMEANING>IgG anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgG anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Index value</VALIDVALUE>
          <VALUEMEANING>Index value</VALUEMEANING>
          <MEANINGDESCRIPTION>Index value</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microU/mL</VALIDVALUE>
          <VALUEMEANING>Microunit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microunit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>MILL/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Mil/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>MILL/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>MILL/CMM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg/L</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute per millimeter Hg per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute per millimeter Hg per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/min/kPa/L</VALIDVALUE>
          <VALUEMEANING>Millimole per minute per thousand Pascal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per minute per thousand Pascal per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MPL</VALIDVALUE>
          <VALUEMEANING>IgM anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgM anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/UL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOUS/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>K/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>1000/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>THOU/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>1000/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>1000/mm3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thous/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/sec</VALIDVALUE>
          <VALUEMEANING>Liter per second</VALUEMEANING>
          <MEANINGDESCRIPTION>Liter per second</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>1000/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Threshold</VALIDVALUE>
          <VALUEMEANING>Threshold</VALUEMEANING>
          <MEANINGDESCRIPTION>The lowest limit at which something becomes detectable or relevant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6/L</VALIDVALUE>
          <VALUEMEANING>10E6 per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2755857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ukat/L</VALIDVALUE>
          <VALUEMEANING>Microkatal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Picomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Picomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trillion/L</VALIDVALUE>
          <VALUEMEANING>Trillion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Trillion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Billion/L</VALIDVALUE>
          <VALUEMEANING>Billion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Billion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g</VALIDVALUE>
          <VALUEMEANING>milligram per gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3170018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minutes</VALIDVALUE>
          <VALUEMEANING>Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit measure of time equal to 60 seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/24hr</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Integer::24 Hour Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: For each, generally denoting a ratio.: A number with no fractional part, including the negative and positive numbers as well as zero.::24: In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C25529, C45255::24, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mL</VALIDVALUE>
          <VALUEMEANING>Milliunit Per Milliliter Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to the one thousandth unit (10E-3 unit).: For each, generally denoting a ratio.: A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28254, C65039, C67315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hours</VALIDVALUE>
          <VALUEMEANING>Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/kg</VALIDVALUE>
          <VALUEMEANING>Cell Per Kilogram Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>Any small compartment.: For each, generally denoting a ratio.: A basic SI unit of mass. It is definied as the mass of an  international prototype in the form of a platinum-iridium cylinder kept at Sevres in france.   A kilogram is equal to 1,000 grams and 2.2046226 pounds.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28252, C65039, C48694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies/mL</VALIDVALUE>
          <VALUEMEANING>Copy per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration of RNA copies expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E6 Cells</VALIDVALUE>
          <VALUEMEANING>Integer::2 Multiplication Million Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::2: An arithmetic operation by which the product of two numbers is computed; the inverse of division.: A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508, C67238, C65000, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 10 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::10, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E2</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 2 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::2: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::2, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 3 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::3: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255::3, C95157, C25709, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 2, 0, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E5</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 5 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::5: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::5, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E4</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 4 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::4: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::4, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 7 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::7: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::7, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 6 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::6: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::6, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 9 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::9: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::9, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 8 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::8: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::8, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 12 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::12: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::12, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11</VALIDVALUE>
          <VALUEMEANING>Ten Exponent:11 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::11: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::11, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E14</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 14 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::14: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::14, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E13</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 13 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::13: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::13, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E16</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 16 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::16: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::16, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E15</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 15 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E18</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 18 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::18: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::18, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E17</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 17 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::17: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::17, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E20</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 20 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::20: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::20, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E19</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 19 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::19: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::19, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E8 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 8 (one hundred million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E7 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E7 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 7 (ten million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Minute </VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3652827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log</VALIDVALUE>
          <VALUEMEANING>Logarithm</VALUEMEANING>
          <MEANINGDESCRIPTION>For a specified base b, a function such that its argument results when b is raised to the power given by this function&#39;s value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3703164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol CO/min/kPa</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Millimoles per Minute per Kilopascal</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit of gas diffusion capacity equal to one millimole per minute per kilopascal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116242, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ml CO/min/mm Hg</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Milliliter per Minute per Millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit for measuring a pulmonary diffusing capacity expressed in units of gas flow rate (in milliliters per minute) per a unit of pressure (in torrs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67417, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm H2O</VALIDVALUE>
          <VALUEMEANING>Centimeters of water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5477037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>copies/L</VALIDVALUE>
          <VALUEMEANING>Copy Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A secondary representation, reproduction, or replica.: A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C67336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5637481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log10 IU/mL</VALIDVALUE>
          <VALUEMEANING>Log10 International Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5778792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL FEU</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter Fibrinogen Equivalent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.: A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96649, C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6479361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mmol</VALIDVALUE>
          <VALUEMEANING>Gram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E-15L (fL)</VALIDVALUE>
          <VALUEMEANING>Ten Exponential Function 15 Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A function of the form f(x) = ab^x, characterized by the fact that the growth rate of such a function is directly proportional to the value of the function.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8057682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Log10 Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arbitrary unit per milliliter</VALIDVALUE>
          <VALUEMEANING>Arbitrary Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C75765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10631416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15128242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/nL</VALIDVALUE>
          <VALUEMEANING>Per Nanoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one nanoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/pL</VALIDVALUE>
          <VALUEMEANING>Per Picoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one picoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the unit of measure f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the unit of measure for CD20 antigen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the unit of measure for CD20?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the unit of measure for CD20?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_IR_cd20_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNfup_lym_anly_cd20_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNbase_lym_anly_mul_cd20_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="649">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4731395</PUBLICID>
    <LONGNAME>Patient Prior Therapy Disease Progression Yes No Indicator</LONGNAME>
    <PREFERREDNAME>4731394v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator of whether a person has been previously treated for the same condition or with the same therapy and there has been a worsening of a disease over time.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4731394</PublicId>
      <PreferredName>2233604v1.0:4731392v1.0</PreferredName>
      <PreferredDefinition>An indicator that a person has been previously treated for the same condition or with the same therapy and there has been a worsening of a disease over time.</PreferredDefinition>
      <LongName>Patient Prior Therapy Disease Progression</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4731392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16124:C17747</PreferredName>
        <Version>1</Version>
        <LongName>Prior Therapy Disease Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16124</PREFERRED_NAME>
            <LONG_NAME>Prior Therapy</LONG_NAME>
            <CON_ID>2202433</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17747</PREFERRED_NAME>
            <LONG_NAME>Disease Progression</LONG_NAME>
            <CON_ID>2202885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient progressed on</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient progressed on prior therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient progressed on prior treatment for squamous cell lung cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have progressive disease following the most recent line of therapy?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have progressive disease following the most recent line of therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient had progressive disease or induction failure, requiring off-protocol therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have progressive disease while on therapy with vinblastine and/or MEK inhibitors?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PtPrTxDzProg</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PR_TYP_DSZ_PRG_IND</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="650">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4743131</PUBLICID>
    <LONGNAME>Breast Cancer Treatment Outcomes Scale Cosmetic Status Scar Tissue Difference Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>BCT_SCAR_TISS_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of scar tissue between the treated and untreated breast since being treated for breast cancer, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BCTOS Based:Based on Breast Cancer Treatment Outcomes Scale</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3628918</PublicId>
      <PreferredName>3628906v1.0:3628916v1.0</PreferredName>
      <PreferredDefinition>A measure of perceived aesthetics after breast-conserving surgical treatment and radiotherapy._A person&#39;s stated observation of the difference in breast shape between the treated and untreated breast since treatment for breast cancer._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Breast Cancer Treatment Outcomes Scale Cosmetic Status Breast Shape Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3628906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103331</PreferredName>
        <Version>1</Version>
        <LongName>Breast Cancer Treatment Outcomes Scale - Cosmetic Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103331</PREFERRED_NAME>
            <LONG_NAME>Breast Cancer Treatment Outcomes Scale-Cosmetic Status</LONG_NAME>
            <CON_ID>3626538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3628916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103335:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Breast Shape Difference Since Cancer Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103335</PREFERRED_NAME>
            <LONG_NAME>Breast Shape Different Since Cancer Treatment Question</LONG_NAME>
            <CON_ID>3626542</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3630258</PublicId>
      <PreferredName>3630258v1.0</PreferredName>
      <PreferredDefinition>The quality of being unlike or dissimilar._A number or range of numeric values measuring performance, function, quality, or ability._A number with no fractional part, including the negative and positive numbers as well as zero.::4_The precise location of something; a spatially limited location._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Difference Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>BCTOS:Breast Cancer Treatment Outcomes Scale Questionnaire. Stanton AL, Krishnan L, Collins CA: Cancer 91:2273-81, 2001.</Origin>
      <Representation>
        <PublicId>3630257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3630257v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Difference Score Integer::4 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C46003</PREFERRED_NAME>
            <LONG_NAME>Difference</LONG_NAME>
            <CON_ID>2342191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Slight</VALUEMEANING>
          <MEANINGDESCRIPTION>Small in amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Large</VALUEMEANING>
          <MEANINGDESCRIPTION>Of considerable or relatively great size, extent, or capacity.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2581016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scar tissue</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Scar tissue</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer Treatment Outcomes (BCT Outcomes)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14888136</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="651">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4744252</PUBLICID>
    <LONGNAME>Person Replication Competent Lentivirus Present Yes No Indicator</LONGNAME>
    <PREFERREDNAME>REP_COMP_LENTIVR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify whether a patient has been diagnosed with Replication Competent Lentivirus (RCL).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4744234</PublicId>
      <PreferredName>4736054v1.0:4744232v1.0</PreferredName>
      <PreferredDefinition>A human being._A genus of the family Retroviridae consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3&#39; env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Person Replication Competent Lentivirus Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4736054</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C112045</PreferredName>
        <Version>1</Version>
        <LongName>Person Replication Competent Retrovirus</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C112045</PREFERRED_NAME>
            <LONG_NAME>Replication Competent Retrovirus</LONG_NAME>
            <CON_ID>3961392</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4744232</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14290:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Lentivirus Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14290</PREFERRED_NAME>
            <LONG_NAME>Lentivirus</LONG_NAME>
            <CON_ID>4744231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have Replica</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have Replication Competent Lentivirus?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="652">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4750936</PUBLICID>
    <LONGNAME>Adaptive Behavior Assessment System Parent Rating Form Social Skills Scaled Score Value</LONGNAME>
    <PREFERREDNAME>ABAS_PR_SOCL_SSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the scaled score for Social Skills in the Adaptive Behavior Assessment System Parent Form.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ABAS Parent Form:Adaptive Behavior Assessment System, Parent Form. Harrison, P.L., &amp; Oakland, T. The Psychological Corporation, San Antonio, TX, 2003.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4750779</PublicId>
      <PreferredName>5243773v1.0:5243434v1.0</PreferredName>
      <PreferredDefinition>A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. This form is completed by parents or others responsible for the child&#39;s primary care._An assessment of the Adaptive Behavior Assessment System where social skills needed to interact socially, get along with others, have friends, show and recognize emotions, and using manners are evaluated._Conversion of a raw score on a test to a common scale that allows for a numerical comparison.</PreferredDefinition>
      <LongName>Adaptive Behavior Assessment System, Parent Rating Form Social Skills Scaled Score</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5243773</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121188:C121201</PreferredName>
        <Version>1</Version>
        <LongName>Adaptive Behavior Assessment System, Parent Rating Form Social Skills</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121188</PREFERRED_NAME>
            <LONG_NAME>Adaptive Behavior Assessment System, Parent Rating Form</LONG_NAME>
            <CON_ID>4747481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121201</PREFERRED_NAME>
            <LONG_NAME>Social Skills</LONG_NAME>
            <CON_ID>4747491</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5243434</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120341</PreferredName>
        <Version>1</Version>
        <LongName>Scaled Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120341</PREFERRED_NAME>
            <LONG_NAME>Scaled Score</LONG_NAME>
            <CON_ID>4723451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4744131</PublicId>
      <PreferredName>ABAS_SCL_SCR_VL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of a raw score to a common scale from the  Adaptive Behavior Assessment System.</PreferredDefinition>
      <LongName>ABAS Scaled Score Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ABAS Adult Form:Adaptive Behavior Assessment System, Adult Form. Harrison, P.L., &amp; Oakland, T. The Psychological Corporation, San Antonio, TX, 2003.</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Adaptive Behavior Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Social scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABAS-II</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Second Edition (ABAS-II) - Social scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABAS-III</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Third Edition (ABAS-III) - Social scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5236432</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ABAS and BASC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5236433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="653">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4750941</PUBLICID>
    <LONGNAME>Adaptive Behavior Assessment System Parent Rating Form Work Skills Scaled Score Value</LONGNAME>
    <PREFERREDNAME>ABAS_PR_WORK_SSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the scaled score for Work Skills in the Adaptive Behavior Assessment System Parent Form.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ABAS Parent Form:Adaptive Behavior Assessment System, Parent Form. Harrison, P.L., &amp; Oakland, T. The Psychological Corporation, San Antonio, TX, 2003.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4750783</PublicId>
      <PreferredName>5243780v1.0:5243434v1.0</PreferredName>
      <PreferredDefinition>A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. This form is completed by parents or others responsible for the child&#39;s primary care._An assessment of the Adaptive Behavior Assessment System where skills needed for successful functioning and holding a job in a work setting are evaluated._Conversion of a raw score on a test to a common scale that allows for a numerical comparison.</PreferredDefinition>
      <LongName>Adaptive Behavior Assessment System, Parent Rating Form Work Skills Scaled Score</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5243780</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121188:C121203</PreferredName>
        <Version>1</Version>
        <LongName>Adaptive Behavior Assessment System, Parent Rating Form Work Skills</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121188</PREFERRED_NAME>
            <LONG_NAME>Adaptive Behavior Assessment System, Parent Rating Form</LONG_NAME>
            <CON_ID>4747481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121203</PREFERRED_NAME>
            <LONG_NAME>Work Skills</LONG_NAME>
            <CON_ID>4747493</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5243434</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120341</PreferredName>
        <Version>1</Version>
        <LongName>Scaled Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120341</PREFERRED_NAME>
            <LONG_NAME>Scaled Score</LONG_NAME>
            <CON_ID>4723451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4744131</PublicId>
      <PreferredName>ABAS_SCL_SCR_VL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of a raw score to a common scale from the  Adaptive Behavior Assessment System.</PreferredDefinition>
      <LongName>ABAS Scaled Score Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ABAS Adult Form:Adaptive Behavior Assessment System, Adult Form. Harrison, P.L., &amp; Oakland, T. The Psychological Corporation, San Antonio, TX, 2003.</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Adaptive Behavior Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Work scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABAS-II</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Second Edition (ABAS-II) - Work scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABAS-III</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adaptive Behavior Assessment System - Third Edition (ABAS-III) - Work scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5236432</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ABAS and BASC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5236433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="654">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4753816</PUBLICID>
    <LONGNAME>Outcome Satisfaction Questionnaire Current Appearance of Arm or Leg After Treatment Score 5 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>CS_ARMLEG_APPEAR_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of their satisfaction now with the appearance of their arm or leg after treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCI CRF:  Duke Cancer Institute Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4753662</PublicId>
      <PreferredName>4751032v1.0:4753660v1.0</PreferredName>
      <PreferredDefinition>A set of questions and responses designed to evaluate an individual&#39;s self-reported satisfaction with the outcome of treatment._Occurring in or belonging to the present time._A question about the appearance of an individual&#39;s arm or leg since treatment._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Outcome Satisfaction Questionnaire Current Appearance of Arm or Leg After Treatment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4751032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120952</PreferredName>
        <Version>1</Version>
        <LongName>Outcome Satisfaction Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120952</PREFERRED_NAME>
            <LONG_NAME>Outcome Satisfaction Questionnaire</LONG_NAME>
            <CON_ID>4743065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4753660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C120965:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Current Appearance of Arm or Leg After Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120965</PREFERRED_NAME>
            <LONG_NAME>Appearance of Arm or Leg After Treatment Question</LONG_NAME>
            <CON_ID>4743076</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4753671</PublicId>
      <PreferredName>OS_SATISF_5_LIK_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Extremely satisfied) to 5 (Extremely dissatisfied) on a Likert scale used on Outcome Satisfaction Questionnaire.</PreferredDefinition>
      <LongName>Outcome Satisfaction Questionnaire How Satisfied Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Extremely dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is extremely dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Somewhat Dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is somewhat dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Neutral, Neither Satisfied Nor Dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indication that an individual is neither satisfied nor dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Somewhat Satisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is somewhat satisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Extremely satisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is extremely satisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How satisfied are you with th</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How satisfied are you with the appearance of your arm/leg?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4748831</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prospective Sarcoma PRO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4748832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="655">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4757111</PUBLICID>
    <LONGNAME>Behavior Assessment System for Children Parent Rating Scales Hyperactivity T-Score Value</LONGNAME>
    <PREFERREDNAME>BASC_PRS_HYPR_TSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the T-score for the Hyperactivity Scale in the Behavior Assessment System for Children Parent Rating Form.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BASC PRS:Behavior Assessment System for Children, Parent Rating Form. Reynolds, C.R., &amp; Kamphaus, R.W., AGS Publishing, Circle Pines, MN, 2004.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4753921</PublicId>
      <PreferredName>5236660v1.0:5236691v1.0</PreferredName>
      <PreferredDefinition>The Parent Rating Scales is used to measure both adaptive behavior and problem behavior in the community and home setting in individuals aged 2-21._A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual&#39;s thoughts and feelings._A rating scale included in the Behavior Assessment System for Children that measures the tendency to be overly active, rush through work or activities, and act without thinking._A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.</PreferredDefinition>
      <LongName>Behavior Assessment System for Children Parent Rating Scales Hyperactivity Scale T-Score</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5236660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121269:C121272</PreferredName>
        <Version>1</Version>
        <LongName>Behavior Assessment System for Children Parent Rating Scales</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121269</PREFERRED_NAME>
            <LONG_NAME>Behavior Assessment System for Children, Second Edition</LONG_NAME>
            <CON_ID>4748791</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121272</PREFERRED_NAME>
            <LONG_NAME>Parent Rating Scales</LONG_NAME>
            <CON_ID>4748816</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5236691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121282:C120401</PreferredName>
        <Version>1</Version>
        <LongName>Hyperactivity Scale T-Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121282</PREFERRED_NAME>
            <LONG_NAME>Hyperactivity Scale</LONG_NAME>
            <CON_ID>4748805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120401</PREFERRED_NAME>
            <LONG_NAME>T-Score</LONG_NAME>
            <CON_ID>4733378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4753677</PublicId>
      <PreferredName>BASC_TSCORE_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of an individual score into a standard form made without knowledge of the population standard deviation and mean.</PreferredDefinition>
      <LongName>BASC T Score Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>BASC PRS:Behavior Assessment System for Children, Parent Rating Form. Reynolds, C.R., &amp; Kamphaus, R.W., AGS Publishing, Circle Pines, MN, 2004.</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BASC-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children, Second Edition (BASC-2) - Hyperactivity T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BASC-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children, Third Edition (BASC-3) - Hyperactivity T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Behavior Assessment System fo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children - Hyperactivity T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5236432</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ABAS and BASC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BASC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5236434</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="656">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4757245</PUBLICID>
    <LONGNAME>Behavior Assessment System for Children Self-Report of Personality Self-Esteem Scale T-Score Value</LONGNAME>
    <PREFERREDNAME>BASC_SRP_SEST_TSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the T-score for the Self-Esteem Scale in the Behavior Assessment System for Children Self-Report of Personality Form.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BASC SRP:Behavior Assessment System for Children, Self-Report of Personality. Reynolds, C.R., &amp; Kamphaus, R.W., AGS Publishing, Circle Pines, MN, 2004.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4755181</PublicId>
      <PreferredName>5236714v1.0:5241868v1.0</PreferredName>
      <PreferredDefinition>A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual&#39;s thoughts and feelings._A clinical assessment tool that uses targeted forms for monitoring changes in behavior or emotional status. It provides insight into a child&#39;s or adult&#39;s thoughts and feelings._A rating scale included in the Behavior Assessment System for Children that measures a subject&#39;s feelings about self, respect, and self-acceptance._A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.</PreferredDefinition>
      <LongName>Behavior Assessment System for Children Self-Report of Personality Self-Esteem Scale T-Score</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5236714</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121269:C121270</PreferredName>
        <Version>1</Version>
        <LongName>Behavior Assessment System for Children Self-Report of Personality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121269</PREFERRED_NAME>
            <LONG_NAME>Behavior Assessment System for Children, Second Edition</LONG_NAME>
            <CON_ID>4748791</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121270</PREFERRED_NAME>
            <LONG_NAME>Self-Report of Personality</LONG_NAME>
            <CON_ID>4748793</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5241868</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121289:C120401</PreferredName>
        <Version>1</Version>
        <LongName>Self-Esteem Scale T-Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121289</PREFERRED_NAME>
            <LONG_NAME>Self-Esteem Scale</LONG_NAME>
            <CON_ID>4748813</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120401</PREFERRED_NAME>
            <LONG_NAME>T-Score</LONG_NAME>
            <CON_ID>4733378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4753677</PublicId>
      <PreferredName>BASC_TSCORE_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of an individual score into a standard form made without knowledge of the population standard deviation and mean.</PreferredDefinition>
      <LongName>BASC T Score Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>BASC PRS:Behavior Assessment System for Children, Parent Rating Form. Reynolds, C.R., &amp; Kamphaus, R.W., AGS Publishing, Circle Pines, MN, 2004.</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Behavior Assessment System fo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children - Self-Esteem T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BASC-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children, Second Edition (BASC-2) - Self-Esteem T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BASC-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Assessment System for Children, Third Edition (BASC-3) - Self-Esteem T-score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5236432</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ABAS and BASC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BASC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5236434</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="657">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4763614</PUBLICID>
    <LONGNAME>Toronto Extremity Salvage Score, Lower Extremity Past Week Difficulty Ability to Prepare and Serve Meals Score 5 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>TESSLE_SERVEMEAL_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of the difficulty in the past week preparing and serving meals, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Toronto Extremity Salvage Score (TESS); 1996</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4761440</PublicId>
      <PreferredName>4761151v1.0:4762413v1.0</PreferredName>
      <PreferredDefinition>A self-administered questionnaire designed to assess physical disability for patients undergoing lower limb salvage sugery for musculoskeletal tumors._The most recent week, including today._Something not easily done, accomplished, comprehended, or solved._A question about an individual&#39;s ability to prepare and serve meals._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Toronto Extremity Salvage Score, Lower Extremity Past Week Difficulty Ability to Prepare and Serve Meals Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4761151</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121218</PreferredName>
        <Version>1</Version>
        <LongName>Toronto Extremity Salvage Score, Lower Extremity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121218</PREFERRED_NAME>
            <LONG_NAME>Toronto Extremity Salvage Score, Lower Extremity</LONG_NAME>
            <CON_ID>4747333</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4762413</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C62189:C121251:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Difficulty Ability to Prepare and Serve Meals Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62189</PREFERRED_NAME>
            <LONG_NAME>Difficulty</LONG_NAME>
            <CON_ID>2503546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121251</PREFERRED_NAME>
            <LONG_NAME>Ability to Prepare and Serve Meals Question</LONG_NAME>
            <CON_ID>4747441</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Toronto Extremity Salvage Score (TESS); 1996</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4744189</PublicId>
      <PreferredName>TESS_DIFFICULTY_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Impossible to do) to 5 (Not at all difficult) on a Likert scale used on the Toronto Extremity Salvage Score questionnaires.</PreferredDefinition>
      <LongName>Toronto Extremity Salvage Score Difficulty 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>888</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>Toronto Extremity Salvage Score (TESS); 1996</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>888</VALIDVALUE>
          <VALUEMEANING>This task is not applicable to me</VALUEMEANING>
          <MEANINGDESCRIPTION>An assigned piece of work, usually with a time allotment.: Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660, C101129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3811316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>A little bit Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderately Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Extremely Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3811313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Impossible to do</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of happening or occurring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82490, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4744212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Preparing and serving meals i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Preparing and serving meals is:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4748831</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prospective Sarcoma PRO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4748832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="658">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4770677</PUBLICID>
    <LONGNAME>Behavior Rating Inventory of Executive Function-Parent Form Organization of Materials Scale T-Score Value</LONGNAME>
    <PREFERREDNAME>BRIEF_ORG_MAT_TSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the T-score for the Organization of Materials Scale in the Behavior Rating Inventory of Executive Function-Parent Form.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BRIEF-Parent Version:Behavior Rating Inventory of Executive Function-Parent Version. Gerard A. Gioia, PhD, Peter K. Isquith, PhD, Steven C. Guy, PhD, and Lauren Kenworthy, PhD, Psychological Assessment Resources, Lutz, FL, 2000</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4770466</PublicId>
      <PreferredName>4770283v1.0:4770464v1.0</PreferredName>
      <PreferredDefinition>A standardized rating scale designed to assess the executive function behaviors in the school and home environments for children and adolescents as observed by a parent or teacher._A questionnaire included in the Behavior Rating Inventory of Executive Function. The parent form is completed by one or both parents who must have recent and extensive contact with the child over the past 6 months._A rating scale included in the Behavior Rating Inventory of Executive Function that measures orderliness of living, work, play, and storage spaces (e.g., rooms, desks, lockers, backpacks, and bedrooms)._A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.</PreferredDefinition>
      <LongName>Behavior Rating Inventory of Executive Function BRIEF Parent Form Questionnaire Organization of Materials Scale T-Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4770283</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121459</PreferredName>
        <Version>1</Version>
        <LongName>Behavior Rating Inventory of Executive Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121459</PREFERRED_NAME>
            <LONG_NAME>Behavior Rating Inventory of Executive Function</LONG_NAME>
            <CON_ID>4769210</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4770464</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121461:C121471:C120401</PreferredName>
        <Version>1</Version>
        <LongName>BRIEF Parent Form Questionnaire Organization of Materials Scale T-Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121461</PREFERRED_NAME>
            <LONG_NAME>BRIEF Parent Form Questionnaire</LONG_NAME>
            <CON_ID>4769211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121471</PREFERRED_NAME>
            <LONG_NAME>Organization of Materials Scale</LONG_NAME>
            <CON_ID>4769237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120401</PREFERRED_NAME>
            <LONG_NAME>T-Score</LONG_NAME>
            <CON_ID>4733378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BRIEF-Parent Version:Behavior Rating Inventory of Executive Function-Parent Version. Gerard A. Gioia, PhD, Peter K. Isquith, PhD, Steven C. Guy, PhD, and Lauren Kenworthy, PhD, Psychological Assessment Resources, Lutz, FL, 2000</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4757289</PublicId>
      <PreferredName>BRIEF_TSCORE_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of an individual score into a standard form made without knowledge of the population standard deviation and mean for the Behavior Rating Inventory of Executive Function.</PreferredDefinition>
      <LongName>BRIEF T Score Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>BRIEF-SR: Behavior Rating Inventory of Executive Function-Self-Report Version. Steven C. Guy, PhD, Peter K. Isquith, PhD, Gerard A. Gioia, PhD, Psychological Assessment Resources, 2004</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Behavior Rating Inventory of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Behavior Rating Inventory of Executive Function (BRIEF) - Organization of Materials T-Score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Rating Inventory of Executive Function (BRIEF-2) - Organization of Materials T-Score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Behavior Rating Inventory of Executive Function Second Edition (BRIEF-2) - Organization of Materials T-Score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PhenX</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhenX</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="659">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4805211</PUBLICID>
    <LONGNAME>Laboratory Procedure Thyroid Stimulating Hormone Thyrotropin Measurement Date</LONGNAME>
    <PREFERREDNAME>TSHDT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date relating to the result of the medical procedure that involves testing a sample of blood for thyroid stimulating hormone (TSH), a hormone produced by the pituitary gland that stimulates the release of thyroid hormone from thyroglobulin.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2847507</PublicId>
      <PreferredName>LAB_TSH_THYROMSRMT</PreferredName>
      <PreferredDefinition>information relating to the result of the medical procedure that involves testing a sample of blood for thyroid stimulating hormone (TSH), a hormone produced by the pituitary gland that stimulates the release of thyroid hormone from thyroglobulin.</PreferredDefinition>
      <LongName>Laboratory Procedure Thyroid Stimulating Hormone Thyrotropin Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2847505</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2280:C64813</PreferredName>
        <Version>1</Version>
        <LongName>Thyroid Stimulating Hormone Thyrotropin Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2280</PREFERRED_NAME>
            <LONG_NAME>Thyroid-Stimulating Hormone</LONG_NAME>
            <CON_ID>2833117</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64813</PREFERRED_NAME>
            <LONG_NAME>Thyrotropin Measurement</LONG_NAME>
            <CON_ID>2833118</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TSH date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Thyroid Stimulating Hormone (TSH) Test Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="660">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4828451</PUBLICID>
    <LONGNAME>Person Diagnosis Age Category</LONGNAME>
    <PREFERREDNAME>PER_DX_AGE_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The response indicating the category of the person&#39;s age when they were diagnosed with a specific disease or disorder.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>iCaRe2</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>iCaRe2: Case Report Forms</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3070767</PublicId>
      <PreferredName>2236731v1.0:2554159v1.0</PreferredName>
      <PreferredDefinition>Person; a human being._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A period or stage in life, usually stated in years since birth.</PreferredDefinition>
      <LongName>Person Diagnosis Age</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2554159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220:C25150</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis Age</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4828331</PublicId>
      <PreferredName>PRSN_AGE_CAT</PreferredName>
      <PreferredDefinition>A human being._How long something has existed; elapsed time since birth._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Person Age Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>iCaRe2</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>iCaRe2: Case Report Forms</Origin>
      <Representation>
        <PublicId>2684728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C25150:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Person Age Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>86-90 years old</VALIDVALUE>
          <VALUEMEANING>Integer::86 To Integer::90 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::86: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::90: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::90, C65107, C45255::86</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Greater than 90 years old</VALIDVALUE>
          <VALUEMEANING>Greater Than Integer::90 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::90: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::90, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81-85 years old</VALIDVALUE>
          <VALUEMEANING>Integer::81 To Integer::85 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::81: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::85: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::85, C65107, C45255::81</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76-80 years old</VALIDVALUE>
          <VALUEMEANING>Integer::76 To Integer::80 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::76: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::80: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::80, C65107, C45255::76</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71-75 years old</VALIDVALUE>
          <VALUEMEANING>Integer::71 To Integer::71 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::71: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::71: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::71, C65107, C45255::71</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66-70 years old</VALIDVALUE>
          <VALUEMEANING>Integer::66 To Integer::70 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::66: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::70: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::70, C65107, C45255::66</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61-65 years old</VALIDVALUE>
          <VALUEMEANING>Integer::61 To Integer::65 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::61: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::65: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::65, C65107, C45255::61</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51-55 years old</VALIDVALUE>
          <VALUEMEANING>Integer::51 To Integer::55 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::51: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::55: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::55, C65107, C45255::51</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56-60 years old</VALIDVALUE>
          <VALUEMEANING>Integer::56 To Integer::60 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::56: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::60: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::60, C65107, C45255::56</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>46-50 years old</VALIDVALUE>
          <VALUEMEANING>Integer::46 To Integer::50 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::46: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::50: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::50, C65107, C45255::46</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>41-45 years old</VALIDVALUE>
          <VALUEMEANING>Integer::41 To Integer::45 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::41: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::45: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::45, C65107, C45255::41</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>36-40 years old</VALIDVALUE>
          <VALUEMEANING>Integer::36 To Integer::40 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::36: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::40: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::40, C65107, C45255::36</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31-35 years old</VALIDVALUE>
          <VALUEMEANING>Integer::31 To Integer::35 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::31: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::35: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::35, C65107, C45255::31</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26-30 years old</VALIDVALUE>
          <VALUEMEANING>Integer::26 To Integer::30 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::26: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::30: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::30, C65107, C45255::26</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21-25 years old</VALIDVALUE>
          <VALUEMEANING>Integer::21 To Integer::25 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::25: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::25, C65107, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16-20 years old</VALIDVALUE>
          <VALUEMEANING>Integer::16 To Integer::20 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::16: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::20: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::20, C65107, C45255::16</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11-15 years old</VALIDVALUE>
          <VALUEMEANING>Integer::11 To Integer::15 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::15, C65107, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6-10 years old</VALIDVALUE>
          <VALUEMEANING>Integer::6 To Integer::10 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::6: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::10, C65107, C45255::6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0-5 years old</VALIDVALUE>
          <VALUEMEANING>Integer::0 To Integer::5 Age-Years</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::0: Used as a function word to indicate direction, purpose, or movement.: A number with no fractional part, including the negative and positive numbers as well as zero.::5: The length of a person&#39;s life, stated in years since birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37908, C45255::5, C65107, C45255::0</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Age Diagnosed</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Age Diagnosed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4826811</PublicId>
          <ContextName>iCaRe2</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4826814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="661">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4828515</PUBLICID>
    <LONGNAME>Hepatic Disease Diagnosis Type</LONGNAME>
    <PREFERREDNAME>HEPATIC_DZ_DIAG_TYP</PREFERREDNAME>
    <PREFERREDDEFINITION>The text response that describes the type of liver disease that is currently present or is part of the person&#39;s medical history.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>iCaRe2</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>iCaRe2: Case Report Forms</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760844</PublicId>
      <PreferredName>2970299v1.0:2239981v1.0</PreferredName>
      <PreferredDefinition>Any disease or dysfunction of the liver and the intrahepatic bile ducts._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Hepatic Disorder Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2970299</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3196</PreferredName>
        <Version>1</Version>
        <LongName>Hepatic Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3196</PREFERRED_NAME>
            <LONG_NAME>Liver and Intrahepatic Bile Duct Disorder</LONG_NAME>
            <CON_ID>2516836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4828504</PublicId>
      <PreferredName>LIVER_DZ_TYPE</PreferredName>
      <PreferredDefinition>A triangular-shaped organ located under the diaphragm in the right hypochondrium.  It is the largest internal organ of the body, weighting up to 2 kg.  Metabolism and bile secretion are its main functions.  It is composed of cells which have the ability to regenerate._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Liver Disease or Disorder Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>iCaRe2</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>iCaRe2: Case Report Forms</Origin>
      <Representation>
        <PublicId>4828503</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C2991:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Liver Disease or Disorder Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cirrhosis or serious liver disease</VALIDVALUE>
          <VALUEMEANING>Cirrhosis Or Serious Liver Disease or Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Causing fear or anxiety by threatening great harm; of great consequence.: A triangular-shaped organ located under the diaphragm in the right hypochondrium.  It is the largest internal organ of the body, weighting up to 2 kg.  Metabolism and bile secretion are its main functions.  It is composed of cells which have the ability to regenerate.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2991, C12392, C54035, C37998, C2951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis</VALIDVALUE>
          <VALUEMEANING>Hepatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3257061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver damage/jaundice</VALIDVALUE>
          <VALUEMEANING>Liver Damage Or Jaundice</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium.  It is the largest internal organ of the body, weighting up to 2 kg.  Metabolism and bile secretion are its main functions.  It is composed of cells which have the ability to regenerate.: Physical harm reducing the value, operation, or usefulness of something.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A condition in which the skin and the whites of the eyes become yellow, urine darkens, and the color of stool becomes lighter than normal. Jaundice occurs when the liver is not working properly or when a bile duct is blocked.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3143, C37998, C61555, C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Liver disease type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Liver disease type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4826811</PublicId>
          <ContextName>iCaRe2</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4826814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="662">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4828594</PUBLICID>
    <LONGNAME>Malignant Neoplasm Greater Than or Equal To Integer::5 Year Remission Checkbox Indicator</LONGNAME>
    <PREFERREDNAME>MALIG_GTE_5Y_REM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The response indicating whether a patient&#39;s cancer has been in remission for five or more years.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>iCaRe2</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>iCaRe2: Case Report Forms</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4828588</PublicId>
      <PreferredName>MALIGN_GTE_5YR_REM</PreferredName>
      <PreferredDefinition>A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::5_A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period._An abatement in intensity or degree (as in the manifestations of a disease).</PreferredDefinition>
      <LongName>Malignant Neoplasm Greater Than or Equal To Integer::5 Year Remission</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>iCaRe2</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177129</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Cancer</PreferredName>
        <Version>1</Version>
        <LongName>Cancer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4828586</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61583:C45255::5:C29848:C18246</PreferredName>
        <Version>1</Version>
        <LongName>Greater Than or Equal To Integer::5 Year Remission</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61583</PREFERRED_NAME>
            <LONG_NAME>Greater Than or Equal To</LONG_NAME>
            <CON_ID>2673224</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::5</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18246</PREFERRED_NAME>
            <LONG_NAME>Remission</LONG_NAME>
            <CON_ID>2203779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>iCaRe2: Case Report Forms</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2185839</PublicId>
      <PreferredName>CHECKBOX_IND</PreferredName>
      <PreferredDefinition>Indicator determining determining whether or not certain stated circumstances exist._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Checkbox Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cancer-free for five years or</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cancer-free for five years or more?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4826811</PublicId>
          <ContextName>iCaRe2</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4826814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="663">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4841732</PUBLICID>
    <LONGNAME>FACIT-TS-G Version 1 TS4 Feel Treatment was Right Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>FACIT_TSG_TS4_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of whether or not they feel their treatment was right for them and to what extent, using a 4 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACIT-TS-G:Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General, David Cella, Ph.D., Version 1, February 24, 2006</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4841583</PublicId>
      <PreferredName>4841571v1.0:4841581v1.0</PreferredName>
      <PreferredDefinition>A patient-reported outcome measure designed specifically to evaluate general satisfaction with treatment._A question about whether an individual feels or felt that the treatment they received was right for them._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACIT-TS-G Feel Treatment was Right Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4841571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121902</PreferredName>
        <Version>1</Version>
        <LongName>Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121902</PREFERRED_NAME>
            <LONG_NAME>Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General</LONG_NAME>
            <CON_ID>4827211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4841581</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121906:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Feel Treatment was Right Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121906</PREFERRED_NAME>
            <LONG_NAME>Feel Treatment was Right Question</LONG_NAME>
            <CON_ID>4827351</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACIT-TS-G:Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General, David Cella, Ph.D., Version 1, February 24, 2006</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4840971</PublicId>
      <PreferredName>4840971v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard with values ranging from 0 (No, not at all) to 3 (Yes, completely) used in FACIT questionnaires.</PreferredDefinition>
      <LongName>FACIT Indicator Extent Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>3</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACIT-TS-G:Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General, David Cella, Ph.D., Version 1, February 24, 2006</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Yes, completely</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25250, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4840972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Yes, for the most part</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: An indication that something has been mostly accomplished or has been mostly satisfying.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121916, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4840973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes, to some extent</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: An indication that something has been accomplished to some degree or has resulted in some amount of satisfaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121915, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4840974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No, not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4840975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you feel you received the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you feel you received the treatment that was right for you?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACIT-TS-G Version 1</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #4 of 8</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Materials Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4811884</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FACIT System Scales</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT-TS-G Version 1 (Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4840991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="664">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4883518</PUBLICID>
    <LONGNAME>Tobacco Use House Rule Assessment Text</LONGNAME>
    <PREFERREDNAME>4883517v1.0:2018321v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Use of tobacco in any form i.e. smoking, chewing or sniffing._A dwelling that serves as living quarters for one or more families._A prescribed guide for conduct or action._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4883517</PublicId>
      <PreferredName>Toba_Hous_Rule</PreferredName>
      <PreferredDefinition>Use of tobacco in any form i.e. smoking, chewing or sniffing._A dwelling that serves as living quarters for one or more families._A prescribed guide for conduct or action.</PreferredDefinition>
      <LongName>Tobacco Use House Rule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3024963</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18059</PreferredName>
        <Version>1</Version>
        <LongName>Tobacco Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18059</PREFERRED_NAME>
            <LONG_NAME>Tobacco Use</LONG_NAME>
            <CON_ID>2202335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4883515</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80508:C78269</PreferredName>
        <Version>1</Version>
        <LongName>House Rule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80508</PREFERRED_NAME>
            <LONG_NAME>House</LONG_NAME>
            <CON_ID>2928179</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78269</PREFERRED_NAME>
            <LONG_NAME>Rule</LONG_NAME>
            <CON_ID>2867555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tobacco Use House Rule Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tobacco Use House Rule Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tobacco Regulatory Research Specialty Collections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Agent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="665">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4887041</PUBLICID>
    <LONGNAME>Metastatic Tumor Other Radiation Therapy Type</LONGNAME>
    <PREFERREDNAME>4887033v1.0:2184485v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text field to describe the other type of radiation administered for the metastatic tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4887033</PublicId>
      <PreferredName>2403872v1.0:4887031v1.0</PreferredName>
      <PreferredDefinition>Information related to treatment of another therapeutic radiation not previously specified given to an individual for disease that has spread from its original site of growth to another site.</PreferredDefinition>
      <LongName>Radiation Therapy Metastatic Neoplasm Other Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4887031</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3261:C17649:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Neoplasm Other Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3261</PREFERRED_NAME>
            <LONG_NAME>Metastatic Neoplasm</LONG_NAME>
            <CON_ID>2443854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2184485</PublicId>
      <PreferredName>RT_TP_TXT</PreferredName>
      <PreferredDefinition>a text field to describe of a method of radiation treatment administered to a patient.</PreferredDefinition>
      <LongName>RT Type Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Radiation Type for Meta</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Radiation Type for Metastatic Tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="666">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4896471</PUBLICID>
    <LONGNAME>Injection Site Tenderness Occurrence Yes None Indicator</LONGNAME>
    <PREFERREDNAME>INJ_SIT_TEND_YES_NONE_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/none response to signify whether tenderness (pain with touch) occurred at the site of an injection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4896453</PublicId>
      <PreferredName>INJ_SIT_TEND_TYP</PreferredName>
      <PreferredDefinition>The anatomic site at which a medication or a vaccine is injected._Discomfort elicited through touch or pressure._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Injection Site Tenderness Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4896451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C77680:C75540</PreferredName>
        <Version>1</Version>
        <LongName>Injection Site Tenderness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77680</PREFERRED_NAME>
            <LONG_NAME>Injection Site</LONG_NAME>
            <CON_ID>3377282</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75540</PREFERRED_NAME>
            <LONG_NAME>Tenderness</LONG_NAME>
            <CON_ID>2787642</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4684012</PublicId>
      <PreferredName>4684012v1.0</PreferredName>
      <PreferredDefinition>The affirmative response to a question._No person or thing, nobody, not any._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Yes None Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>4684011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C41132:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Yes None Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41132</PREFERRED_NAME>
            <LONG_NAME>None</LONG_NAME>
            <CON_ID>2433421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tenderness (pain at the injec</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tenderness (pain at the injection site with touch)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="667">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4902226</PUBLICID>
    <LONGNAME>Patient Vascular Or Peripheral Vascular Disorder Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>VASC_PER_VASC_DIS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response indicating that a patient has peripheral vascular disease or vascular disease that meets the eligibility criteria for participation in a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4901121</PublicId>
      <PreferredName>2233604v1.0:4901119v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Relating to or containing blood vessels._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Any disorder affecting blood flow through the veins or arteries outside of the heart._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Vascular Or Peripheral Vascular Disorder Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4901119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13311:C37998:C35136:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Vascular Or Peripheral Vascular Disorder Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13311</PREFERRED_NAME>
            <LONG_NAME>Vascular</LONG_NAME>
            <CON_ID>2202503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35136</PREFERRED_NAME>
            <LONG_NAME>Peripheral Vascular Disorder</LONG_NAME>
            <CON_ID>3158625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have clinically</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant peripheral vascular disease or vascular disease (abdominal aortic aneurysm (greater than 5 cm) or aortic dissection)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant peripheral vascular disease or known abdominal aortic aneurysm (greater than 5 cm in diameter) or history of aortic dissection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant peripheral vascular disease  or abdominal aortic aneurysm (greater than 5 cm) or aortic dissection ?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant peripheral vascular disease or  ( abdominal aortic aneurysm (greater than 5 cm) or aortic dissection  ) ?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient at risk of brain perfusion problems, e.g., medical history of carotid stenosis or pre-syncopal or syncopal episodes, history of TIAs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical &amp; Concomitant Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000083</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="668">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4922418</PUBLICID>
    <LONGNAME>Primary Tumor Resection Percentage Necrosis Type</LONGNAME>
    <PREFERREDNAME>PriTmrRstNcrPctTp</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of cell death fraction of a primary tumor at the surgical removal process.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4922413</PublicId>
      <PreferredName>2721570v1.0:4925376v1.0</PreferredName>
      <PreferredDefinition>information related to the fraction of cell death of a primary tumor at the surgical removal process.</PreferredDefinition>
      <LongName>Primary Tumor Resection Percentage Necrosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2721570</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C8509</PreferredName>
        <Version>1</Version>
        <LongName>Primary Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C8509</PREFERRED_NAME>
            <LONG_NAME>Primary Neoplasm</LONG_NAME>
            <CON_ID>2240094</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4925376</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15232:C25613:C16897</PreferredName>
        <Version>1</Version>
        <LongName>Excision Percentage Necrotic Process</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16897</PREFERRED_NAME>
            <LONG_NAME>Necrotic Process</LONG_NAME>
            <CON_ID>2202853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4922415</PublicId>
      <PreferredName>4922415v1.0</PreferredName>
      <PreferredDefinition>the type of cell death fraction of a primary tumor at the surgical removal process.</PreferredDefinition>
      <LongName>Primary Tumor Resection Percentage Necrosis Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>4925378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4925378v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Primary Neoplasm Excision Percentage Necrotic Process Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C8509</PREFERRED_NAME>
            <LONG_NAME>Primary Neoplasm</LONG_NAME>
            <CON_ID>2240094</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16897</PREFERRED_NAME>
            <LONG_NAME>Necrotic Process</LONG_NAME>
            <CON_ID>2202853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Good</VALIDVALUE>
          <VALUEMEANING>Good(0-10% viable)</VALUEMEANING>
          <MEANINGDESCRIPTION>Good(0-10% viable)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4922417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poor</VALIDVALUE>
          <VALUEMEANING>Poor(&gt;10% viable)</VALUEMEANING>
          <MEANINGDESCRIPTION>Poor(&gt;10% viable)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4922416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Percent necrosis in primary t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Percent necrosis in primary tumor at the time of initial resection:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="669">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4931475</PUBLICID>
    <LONGNAME>Transient Myeloproliferative Disorder First Remission Confirmation Date</LONGNAME>
    <PREFERREDNAME>TMDFstRmCfmDt</PREFERREDNAME>
    <PREFERREDDEFINITION>The date of the first remission of Transient Myeloproliferative Disorder, a myeloid proliferation occurring in newborns with Down syndrome.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4931473</PublicId>
      <PreferredName>4867822v1.0:4931471v1.0</PreferredName>
      <PreferredDefinition>Information related to the confirmation of the first remission of  Transient Myeloproliferative Disorder, a myeloid proliferation occurring in newborns with Down syndrome.</PreferredDefinition>
      <LongName>Transient Myeloproliferative Disorder First Remission Confirmation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4867822</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82339</PreferredName>
        <Version>1</Version>
        <LongName>Transient Abnormal Myelopoiesis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82339</PREFERRED_NAME>
            <LONG_NAME>Transient Abnormal Myelopoiesis Associated with Down Syndrome</LONG_NAME>
            <CON_ID>4858054</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4931471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C18246:C25458</PreferredName>
        <Version>1</Version>
        <LongName>First Remission Confirmation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18246</PREFERRED_NAME>
            <LONG_NAME>Remission</LONG_NAME>
            <CON_ID>2203779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Remission date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Remission date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="670">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4982455</PUBLICID>
    <LONGNAME>Rosenberg Self-Esteem Scale RSE5 Rate Agreement Do Not Have Much to be Proud of Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>ROSENBERG_SE_RSE5_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of rated agreement do not have much to be proud of using a 4 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4982377</PublicId>
      <PreferredName>4982234v1.0:4982375v1.0</PreferredName>
      <PreferredDefinition>A 10-item scale for the subjective scoring of a person&#39;s self esteem, developed by Dr. Morris Rosenberg, that ranges from strongly agree to strongly disagree. Five of the items have positively worded statements and five have negatively worded statements._A measurement of degree, speed, or frequency relative to time._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._ question about whether an individual feels they do not have much to be proud feeling._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Rosenberg Self-Esteem Scale Rate Agreement Do Not Have Much to be Proud of Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4982234</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123318</PreferredName>
        <Version>1</Version>
        <LongName>Rosenberg Self-Esteem Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123318</PREFERRED_NAME>
            <LONG_NAME>Rosenberg Self-Esteem Scale</LONG_NAME>
            <CON_ID>4980743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4982375</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25636:C25369:C123323:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Rate Agreement Do Not Have Much to be Proud of Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25636</PREFERRED_NAME>
            <LONG_NAME>Rate</LONG_NAME>
            <CON_ID>2203725</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123323</PREFERRED_NAME>
            <LONG_NAME>Do Not Have Much to be Proud of Question</LONG_NAME>
            <CON_ID>4980748</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4982444</PublicId>
      <PreferredName>SELF_ESTEEM_NEG_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Strongly agree) to 3 (Strongly disagree) on a Likert scale used on the Rosenberg Self Esteem Scale questionnaire.</PreferredDefinition>
      <LongName>Rosenberg Self Esteem Scale Negative Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>To concur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Strongly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Strongly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intense concurrence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I feel I do not have much to</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I feel I do not have much to be proud of</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="671">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4987338</PUBLICID>
    <LONGNAME>Adult Hope Scale How True Usually Find Myself Worrying About Something Score 8 Point Scale</LONGNAME>
    <PREFERREDNAME>AHS_FIND_WORRY_SCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how true or false a statement is about usually finding themselves worrying about something, using an 8 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AHS:Adult Hope Scale. Snyder, C. R., Harris, C., Anderson, J. R., Holleran, S. A., Irving, L. M., Sigmon, S. T., et al.(1991).</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4987179</PublicId>
      <PreferredName>4987011v1.0:4987177v1.0</PreferredName>
      <PreferredDefinition>12-item measure of a respondent&#39;s level of hope. Each item is answered using an 8-point Likert-type scale ranging from Definitely False to Definitely True._A question about an individual&#39;s agreement with a statement._A question about whether an individual usually finds themself worrying about something._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Adult Hope Scale How True Usually Find Myself Worrying About Something Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4987011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123340</PreferredName>
        <Version>1</Version>
        <LongName>Adult Hope Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123340</PREFERRED_NAME>
            <LONG_NAME>Adult Hope Scale</LONG_NAME>
            <CON_ID>4986832</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4987177</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C91781:C123350:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How True Usually Find Myself Worrying About Something Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123350</PREFERRED_NAME>
            <LONG_NAME>Usually Find Myself Worrying About Something Question</LONG_NAME>
            <CON_ID>4986842</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AHS:Adult Hope Scale. Snyder, C. R., Harris, C., Anderson, J. R., Holleran, S. A., Irving, L. M., Sigmon, S. T., et al.(1991).</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4986942</PublicId>
      <PreferredName>ADULT_HOPE_SCALE</PreferredName>
      <PreferredDefinition>An ordered reference standard used with the Adult Hope Scale with values ranging from 1:Definitely False to 8:Definitely True.</PreferredDefinition>
      <LongName>Adult Hope Scale Score 8 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>8</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>AHS:Adult Hope Scale. Snyder, C. R., Harris, C., Anderson, J. R., Holleran, S. A., Irving, L. M., Sigmon, S. T., et al.(1991).</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Definitely True</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is definitely true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Mostly True</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is mostly true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Somewhat True</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is somewhat true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Slightly True</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is slightly true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Slightly False</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is slightly false.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Somewhat False</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is somewhat false.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mostly False</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is mostly false.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Definitely False</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is definitely false.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4986943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I usually find myself worryin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I usually find myself worrying about something.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4986872</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AHS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4986914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult Hope Scale (AHS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14883066</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="672">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5021495</PUBLICID>
    <LONGNAME>Pulmonary Function Test Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide Measurement Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>5021494v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the pulmonary function test results for the carbon monoxide diffusion capacity corrected for hemoglobin measurement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5021494</PublicId>
      <PreferredName>5021511v1.0:2188090v1.0</PreferredName>
      <PreferredDefinition>A broad range of tests that are performed to assess how well lungs inhale and exhale air and how efficiently they transfer oxygen into the blood._An assessment of the diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.</PreferredDefinition>
      <LongName>Pulmonary Function Test Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5021511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38081:C120825</PreferredName>
        <Version>1</Version>
        <LongName>Pulmonary Function Test Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38081</PREFERRED_NAME>
            <LONG_NAME>Pulmonary Function Test</LONG_NAME>
            <CON_ID>2737312</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120825</PREFERRED_NAME>
            <LONG_NAME>Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide</LONG_NAME>
            <CON_ID>5021491</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2188090</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the car</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the carbon monoxide diffusion capacity corrected for hemoglobin measurement finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DLCO (corrected)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>DLCO (corrected)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DLCO (corrected)</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>DLCO (corrected)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>base_DLCO_corrected_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="673">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5025027</PUBLICID>
    <LONGNAME>Preventive Intervention Pharmacotherapy Administered Specify Text</LONGNAME>
    <PREFERREDNAME>3235616v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the preventive intervention pharmacotherapy that was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3235616</PublicId>
      <PreferredName>3235614v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Treatment of disease through the use of drugs._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Preventive Intervention Pharmacotherapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3235614</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15843:C15986</PreferredName>
        <Version>1</Version>
        <LongName>Preventive Intervention Pharmacotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15843</PREFERRED_NAME>
            <LONG_NAME>Preventive Intervention</LONG_NAME>
            <CON_ID>2488996</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15986</PREFERRED_NAME>
            <LONG_NAME>Pharmacotherapy</LONG_NAME>
            <CON_ID>2673143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What pharmacotherapy preventi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What pharmacotherapy preventive intervention was administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other prophylaxis agent:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other prophylaxis agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="674">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5046518</PUBLICID>
    <LONGNAME>Axillary Lymph Node Dissection Sentinel Lymph Node Biopsy Yes No Indicator</LONGNAME>
    <PREFERREDNAME>5046471v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to eligibility for patients who have sentinel lymph node biopsy followed by axillary node dissection</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5046471</PublicId>
      <PreferredName>5046469v1.0:5046466v1.0</PreferredName>
      <PreferredDefinition>Information pertaining to patients who have had sentinel lymph node biopsy followed by additional axillary surgery</PreferredDefinition>
      <LongName>Axillary Lymph Node Dissection Sentinel Lymph Node Biopsy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5046469</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15677</PreferredName>
        <Version>1</Version>
        <LongName>Axillary Lymph Node Dissection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15677</PREFERRED_NAME>
            <LONG_NAME>Axillary Lymph Node Dissection</LONG_NAME>
            <CON_ID>2434222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5046466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15667</PreferredName>
        <Version>1</Version>
        <LongName>Sentinel Lymph Node Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15667</PREFERRED_NAME>
            <LONG_NAME>Sentinel Lymph Node Biopsy</LONG_NAME>
            <CON_ID>2204871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient have sentinel</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient have sentinel lymph node biopsy performed after neoadjuvant chemotherapy: sentinel lymph node biopsy alone if negative or positive sentinel lymph node biopsy (micrometastases are regarded as positive) followed by additional axillary surgery?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="675">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5047371</PUBLICID>
    <LONGNAME>Disease Detection Method Assessment Type</LONGNAME>
    <PREFERREDNAME>3629969v1.0:2015230v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the assessment method used to detect disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3629969</PublicId>
      <PreferredName>2770347v1.0:2730351v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The activity of perceiving, discerning, discovering or identifying._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Disease Detection Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2770347</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C16210</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Detection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2730351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460</PreferredName>
        <Version>1</Version>
        <LongName>Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015230</PublicId>
      <PreferredName>ASSESS_METH_TP</PreferredName>
      <PreferredDefinition>the enumerated list of methods of conducting diagnostic evaluation.</PreferredDefinition>
      <LongName>Assessment Method Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone scan</VALIDVALUE>
          <VALUEMEANING>Bone Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclear imaging method used to evaluate pathological bone metabolism. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT scan</VALIDVALUE>
          <VALUEMEANING>CT Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest x-ray</VALIDVALUE>
          <VALUEMEANING>Chest X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>Chest X-Ray</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical examination</VALIDVALUE>
          <VALUEMEANING>CLINICAL EXAMINATION (PE)</VALUEMEANING>
          <MEANINGDESCRIPTION>CLINICAL EXAMINATION (PE)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytology</VALIDVALUE>
          <VALUEMEANING>Cytology</VALUEMEANING>
          <MEANINGDESCRIPTION>Cytology; the branch of biology that studies the structure and function of cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine needle aspiration biopsy</VALIDVALUE>
          <VALUEMEANING>FINE NEEDLE ASPIRATION BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy by a fine needle aspiration technique</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2005-04-13</PVENDDATE>
          <VMPUBLICID>2574518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine needle aspiration biopsy, with wire localization</VALIDVALUE>
          <VALUEMEANING>FINE NEEDLE ASPIRATION BIOPSY WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy by a fine needle aspiration technique using wire localization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2005-04-13</PVENDDATE>
          <VMPUBLICID>2574519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histology</VALIDVALUE>
          <VALUEMEANING>HISTOLOGY</VALUEMEANING>
          <MEANINGDESCRIPTION>HISTOLOGY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incisional biopsy</VALIDVALUE>
          <VALUEMEANING>INCISIONAL BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which part of a lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incisional biopsy, with wire localization</VALIDVALUE>
          <VALUEMEANING>INCISIONAL BIOPSY, WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>INCISIONAL BIOPSY, WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI (NMR)</VALIDVALUE>
          <VALUEMEANING>MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2015-10-29</PVENDDATE>
          <VMPUBLICID>2559279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mastectomy</VALIDVALUE>
          <VALUEMEANING>Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Needle biopsy (tru-cut or core)</VALIDVALUE>
          <VALUEMEANING>NEEDLE BIOPSY (TRU-CUT OR CORE)</VALUEMEANING>
          <MEANINGDESCRIPTION>NEEDLE BIOPSY (TRU-CUT OR CORE)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Needle biopsy (tru-cut or core), with wire localization)</VALIDVALUE>
          <VALUEMEANING>NEEDLE BIOPSY (TRU-CUT OR CORE), WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>NEEDLE BIOPSY (TRU-CUT OR CORE), WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resection/re-excision of lumpectomy margins</VALIDVALUE>
          <VALUEMEANING>RESECTION/RE-EXCISION OF LUMPECTOMY MARGINS</VALUEMEANING>
          <MEANINGDESCRIPTION>RESECTION/RE-EXCISION OF LUMPECTOMY MARGINS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiral CT scan</VALIDVALUE>
          <VALUEMEANING>SPIRAL CT SCAN</VALUEMEANING>
          <MEANINGDESCRIPTION>SPIRAL CT SCAN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor markers</VALIDVALUE>
          <VALUEMEANING>Tumor Markers</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor Markers</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>Very high frequency sound. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autopsy</VALIDVALUE>
          <VALUEMEANING>Autopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Autopsy; an examination and dissection of a dead body to determine cause of death or the changes produced by disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axillary dissection</VALIDVALUE>
          <VALUEMEANING>AXILLARY DISSECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to the armpit area, including the lymph nodes that are located there.: The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15227, C13351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ductal lavage</VALIDVALUE>
          <VALUEMEANING>DUCTAL LAVAGE</VALUEMEANING>
          <MEANINGDESCRIPTION>DUCTAL LAVAGE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL054589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ductoscopic biopsy</VALIDVALUE>
          <VALUEMEANING>DUCTOSCOPIC BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>DUCTOSCOPIC BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy or lumpectomy</VALIDVALUE>
          <VALUEMEANING>EXCISIONAL BIOPSY OR LUMPECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>EXCISIONAL BIOPSY OR LUMPECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy or lumpectomy, with wire localization</VALIDVALUE>
          <VALUEMEANING>LUMPECTOMY, WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>LUMPECTOMY, WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, ascites</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, ASCITES</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, ASCITES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, cerebrospinal fluid</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, CEREBROSPINAL FLUID</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, CEREBROSPINAL FLUID</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, pleural</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, PLEURAL</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, PLEURAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nipple fluid</VALIDVALUE>
          <VALUEMEANING>NIPPLE FLUID</VALUEMEANING>
          <MEANINGDESCRIPTION>NIPPLE FLUID</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prophalactic mastectomy</VALIDVALUE>
          <VALUEMEANING>Prophylactic Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to reduce the risk of developing breast cancer by removing one or both breasts before disease develops.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sentinel node biopsy</VALIDVALUE>
          <VALUEMEANING>SENTINEL NODE BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>SENTINEL NODE BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparotomy</VALIDVALUE>
          <VALUEMEANING>LAPAROTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>LAPAROTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparoscopy</VALIDVALUE>
          <VALUEMEANING>Laparoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(lap-a-RAHS-ko-pee) The insertion of a thin, lighted tube (called a laparoscope) through the abdominal wall to inspect the inside of the abdomen and remove tissue samples.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy other</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE>2012-07-10</PVENDDATE>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preoperative CT scan</VALIDVALUE>
          <VALUEMEANING>CT Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE>2018-06-06</PVENDDATE>
          <VMPUBLICID>2570151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EKG</VALIDVALUE>
          <VALUEMEANING>EKG</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure to assess heart function using an electrocardiogram (EKG) device</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-08-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathologic</VALIDVALUE>
          <VALUEMEANING>Pathologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or altered by or manifesting disease or pathology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical exam</VALIDVALUE>
          <VALUEMEANING>PHYSICAL EXAM</VALUEMEANING>
          <MEANINGDESCRIPTION>PHYSICAL EXAM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiograph</VALIDVALUE>
          <VALUEMEANING>RADIOGRAPH</VALUEMEANING>
          <MEANINGDESCRIPTION>RADIOGRAPH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bilateral mammogram</VALIDVALUE>
          <VALUEMEANING>Bilateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Affecting both sides of the body or a matched pair of organs.: A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13332, C20178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bimanual examination</VALIDVALUE>
          <VALUEMEANING>BIMANUAL EXAMINATION</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to, or performed by, both hands.: A formal or careful inspection of an object or subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131902, C25433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection</VALIDVALUE>
          <VALUEMEANING>DIRECT INSPECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>DIRECT INSPECTION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative ultrasound</VALIDVALUE>
          <VALUEMEANING>INTRAOPERATIVE ULTRASOUND</VALUEMEANING>
          <MEANINGDESCRIPTION>INTRAOPERATIVE ULTRASOUND</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery</VALIDVALUE>
          <VALUEMEANING>Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary surgery</VALIDVALUE>
          <VALUEMEANING>PRIMARY SURGERY</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery of curative intent to remove tumor or malignant tissue</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X-ray</VALIDVALUE>
          <VALUEMEANING>X-RAY </VALUEMEANING>
          <MEANINGDESCRIPTION>X-RAY </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET scan</VALIDVALUE>
          <VALUEMEANING>PET Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Positron Emission Tomography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallium scan</VALIDVALUE>
          <VALUEMEANING>Gallium Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Gallium Scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Differential</VALIDVALUE>
          <VALUEMEANING>DIFFERENTIAL</VALUEMEANING>
          <MEANINGDESCRIPTION>evaluation by differential</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visual assessment</VALIDVALUE>
          <VALUEMEANING>VISUAL ASSESSMENT</VALUEMEANING>
          <MEANINGDESCRIPTION>evaluation by visual assessment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical</VALIDVALUE>
          <VALUEMEANING>Clinical</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the examination and treatment of patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytologic confirmation</VALIDVALUE>
          <VALUEMEANING>Cytologic confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Cytologic confirmation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytoscopy</VALIDVALUE>
          <VALUEMEANING>Cytoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination of the bladder and urethra using a cystoscope, inserted into the urethra. A cystoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cystoscopy</VALIDVALUE>
          <VALUEMEANING>Cystoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the urinary bladder or urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palpation</VALIDVALUE>
          <VALUEMEANING>Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient&#39;s body to examine the size, consistency, texture, location and tenderness of an organ or body part.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visualization</VALIDVALUE>
          <VALUEMEANING>Visualization</VALUEMEANING>
          <MEANINGDESCRIPTION>Visualization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colposcopy</VALIDVALUE>
          <VALUEMEANING>Colposcopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Colposcopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy</VALIDVALUE>
          <VALUEMEANING>Endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(en-DAHS-ko-pee) The use of a thin, lighted tube (called an endoscope) to examine the inside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI scan</VALIDVALUE>
          <VALUEMEANING>MRI scan</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain film/X-ray without contrast</VALIDVALUE>
          <VALUEMEANING>Plain film/X-ray without contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Plain film/X-ray without contrast</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain film/X-ray with contrast</VALIDVALUE>
          <VALUEMEANING>Plain film/X-ray with contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Plain film/X-ray with contrast</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radioisotope scan</VALIDVALUE>
          <VALUEMEANING>Radioisotope scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Radioisotope scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histologic confirmation</VALIDVALUE>
          <VALUEMEANING>Histologic confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Histologic confirmation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histologic</VALIDVALUE>
          <VALUEMEANING>histologic</VALUEMEANING>
          <MEANINGDESCRIPTION>histologic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic</VALIDVALUE>
          <VALUEMEANING>Radiographic</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of Radiographic methodology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor Marker</VALIDVALUE>
          <VALUEMEANING>Tumor Marker</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor Marker</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mammogram</VALIDVALUE>
          <VALUEMEANING>Mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Echocardiogram</VALIDVALUE>
          <VALUEMEANING>Echocardiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An image of the heart produced by ultrasonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUGA scan</VALIDVALUE>
          <VALUEMEANING>MUGA Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-gated acquisition (MUGA) scan and a form of radionuclide imaging that provides a comprehensive look at blood flow and the function of the lower chambers of the heart ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contrast enhanced CT scan/CT perfusion exam</VALIDVALUE>
          <VALUEMEANING>CONTRAST ENHANCED CT SCAN</VALUEMEANING>
          <MEANINGDESCRIPTION>Contrast enhanced computed tomography scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MSK Nomogram</VALIDVALUE>
          <VALUEMEANING>Nomograms</VALUEMEANING>
          <MEANINGDESCRIPTION>Graphical representation of a statistical model containing scales for calculating the prognostic weight of a value for each individual variable. Nomograms are instruments that can be used to predict outcomes using specific clinical parameters. They use ALGORITHMS that incorporate several variables to calculate the predicted probability that a patient will achieve a particular clinical endpoint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1450294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/CT scan</VALIDVALUE>
          <VALUEMEANING>Positron Emission Tomography and Computed Tomography Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSA Assessment</VALIDVALUE>
          <VALUEMEANING>Prostate-Specific Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Digital rectal exam</VALIDVALUE>
          <VALUEMEANING>Digital Rectal Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>Digital rectal examination.  An examination in which a doctor inserts a lubricated, gloved finger into the rectum to feel for abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral Axilla Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ipsilateral Axilla Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>Ipsilateral Axilla Ultrasound</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT/MRI scan</VALIDVALUE>
          <VALUEMEANING>CT/MRI scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Computed tomographic and magnetic image resonance scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2604641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy with biopsy</VALIDVALUE>
          <VALUEMEANING>Endoscopy with biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopy with biopsy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2604642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiological</VALIDVALUE>
          <VALUEMEANING>Radiologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.: The use of radiation (such as x-rays) or other imaging technologies (such as ultrasound and magnetic resonance imaging) to diagnose or treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17059, C118849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2640362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchoscopy</VALIDVALUE>
          <VALUEMEANING>Bronchoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which a thin, lighted tube is inserted through the nose or mouth. NCI Concept Code C16366</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper endoscopy</VALIDVALUE>
          <VALUEMEANING>Upper Endoscopy Esophagogastroduodenoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Upper Endoscopy Esophagogastroduodenoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonoscopy</VALIDVALUE>
          <VALUEMEANING>Colonoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the luminal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Sigmoidoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proctoscopy/sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Proctoscopy/sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination of the anus or sigmoid colon using a flexible tube enclosing a light and camera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal MRI</VALIDVALUE>
          <VALUEMEANING>Abdominal MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or related to, the abdomen.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C25342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2673036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transrectal ultrasound</VALIDVALUE>
          <VALUEMEANING>Transrectal Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure that uses sound waves to create a video image of the prostate gland. A small, lubricated probe placed into the rectum releases sound waves, which create echoes as they enter the prostate. Prostate tumors sometimes create echoes that are different from normal prostate tissue. The echoes that bounce back are sent to a computer that translates the pattern of echoes into a picture of the prostate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest CT</VALIDVALUE>
          <VALUEMEANING>Chest Radiography</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray examination of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal CT</VALIDVALUE>
          <VALUEMEANING>Abdominal CT-scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or related to, the abdomen.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25342, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2667062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic CT</VALIDVALUE>
          <VALUEMEANING>Pelvic CT</VALUEMEANING>
          <MEANINGDESCRIPTION>Pelvic computed tomography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2671035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Evaluated but no disease found</VALIDVALUE>
          <VALUEMEANING>Evaluated but no disease found</VALUEMEANING>
          <MEANINGDESCRIPTION>Evaluated but no disease found</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2738850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Core biopsy</VALIDVALUE>
          <VALUEMEANING>Core Needle Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy with frozen section</VALIDVALUE>
          <VALUEMEANING>Excisional biopsy with frozen section</VALUEMEANING>
          <MEANINGDESCRIPTION>Excisional biopsy with frozen section</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2722512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin biopsy</VALIDVALUE>
          <VALUEMEANING>Skin biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>the removal of a piece of skin to diagnose or rule out an illness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2722511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contralateral mammogram</VALIDVALUE>
          <VALUEMEANING>Contralateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray picture of the breast not involved with the primary tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2697040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral mammogram</VALIDVALUE>
          <VALUEMEANING>Ipsilateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray picture of the breast with the primary tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2697041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEA</VALIDVALUE>
          <VALUEMEANING>Carcinoembryonic Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Carcinoembryonic antigen. A substance that is sometimes found in an increased amount in the blood of people with certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2633456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic MRI</VALIDVALUE>
          <VALUEMEANING>Pelvic Magnetic Resonance imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which a magnet linked to a computer is used to create detailed pictures of areas inside the pelivs. Also called nuclear magnetic resonance </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonscopy/proctoscopy</VALIDVALUE>
          <VALUEMEANING>Colonscopy/proctoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>An examination of the rectum using a thin, lighted tube called a proctoscope or An examination of the inside of the colon using a thin, lighted tube (called a colonoscope).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>CT of Abdomen/Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>CT of Abdomen/Pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2765399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>MRI of Abdomen/Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Abdomen/Pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2765400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diagnostic Imaging</VALIDVALUE>
          <VALUEMEANING>Diagnostic Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation..</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow cytometry, cerebrospinal fluid</VALIDVALUE>
          <VALUEMEANING>Flow cytometry, cerebrospinal fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Flow cytometry, cerebrospinal fluid</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2824966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVP</VALIDVALUE>
          <VALUEMEANING>Intravenous Pyelogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Intravenous Pyelogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphangiogram</VALIDVALUE>
          <VALUEMEANING>Lymphangiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray image of the lymphatic system using a radiopaque imaging agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiologic</VALIDVALUE>
          <VALUEMEANING>Radiologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.: The use of radiation (such as x-rays) or other imaging technologies (such as ultrasound and magnetic resonance imaging) to diagnose or treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17059, C118849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-10-07</PVBEGINDATE>
          <PVENDDATE>2016-01-05</PVENDDATE>
          <VMPUBLICID>2640362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-D Echocardiogram</VALIDVALUE>
          <VALUEMEANING>2-D Echocardiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>The property of being measured and described using two orthogonal directions.: An image of the heart produced by ultrasonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37945, C48282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2847201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serological</VALIDVALUE>
          <VALUEMEANING>Serology</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT w/contrast</VALIDVALUE>
          <VALUEMEANING>CT w/contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Computed tomography that uses a contrast agent to visualize anatomic structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2876591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ECHO</VALIDVALUE>
          <VALUEMEANING>ECHO</VALUEMEANING>
          <MEANINGDESCRIPTION>Echocardiogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2951058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET</VALIDVALUE>
          <VALUEMEANING>Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2919109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Biopsy</VALIDVALUE>
          <VALUEMEANING>BONE MARROW BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>BONE MARROW BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Aspirate</VALIDVALUE>
          <VALUEMEANING>Aspirate, Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>(as-per-AY-shun) The removal of a small sample of bone marrow (usually from the hip) through a needle for examination under a microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral Blood Counts</VALIDVALUE>
          <VALUEMEANING>Peripheral Blood Counts</VALUEMEANING>
          <MEANINGDESCRIPTION>Peripheral Blood Counts</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2978652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiral CT</VALIDVALUE>
          <VALUEMEANING>Spiral CT</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain X-Ray</VALIDVALUE>
          <VALUEMEANING>X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-energy radiation.  In low doses, x-rays are used to diagnose diseases by making pictures of the inside of the body.  In high doses, x-rays are used to treat cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunophenotyping (4 Color flow cytometry)</VALIDVALUE>
          <VALUEMEANING>Four Color Flow Cytometry Immunophenotype</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation.: A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.: Immunophenotype is the characterization of a set of cells according to the antigens expressed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20072, C16585, C37927, C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3027791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heavy chain gene rearrangement</VALIDVALUE>
          <VALUEMEANING>Immunoglobulin Heavy Chain Gene Rearrangement</VALUEMEANING>
          <MEANINGDESCRIPTION>A protein complex that consists of two heavy chains (gamma, alpha, delta, epsilon or mu). The larger of the two immunoglobulin chain types determines the immunoglobulin class (G, A, D, E or M, respectively). The heavy chain molecules exhibit the same structure and composition, which consists of constant, variable, and hypervariable regions._Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16611, C16717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3027713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytogenetic analysis by FISH</VALIDVALUE>
          <VALUEMEANING>Cytogenetic Analysis Fluorescence in situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563, C18280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical and/or hematologic analysis</VALIDVALUE>
          <VALUEMEANING>Clinical And/Or Hematologic Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the examination and treatment of patients.: Used to indicate that either or both of two items or options: Pertaining to or related to the blood and blood-forming organs.: Analysis; examination and interpretation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25391, C62780, C48928, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytogenetic Analysis</VALIDVALUE>
          <VALUEMEANING>Cytogenetic Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2861225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular Analysis</VALIDVALUE>
          <VALUEMEANING>Molecular Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2861224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEXA scan</VALIDVALUE>
          <VALUEMEANING>Scan, Dual-Energy X-ray Absorpitometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for scanning bone and measuring bone mineral density (BMD). A DXA scanner produces 2 X-ray beams, each with different energy levels. One beam is high energy while the other is low energy. The amount of x-rays that pass through the bone is measured for each beam. This will vary depending on the thickness of the bone. Based on the difference between the 2 beams, the bone density can be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caliper measurement by clinical exam</VALIDVALUE>
          <VALUEMEANING>Vernier Caliper Measurement Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A medical device that is a combination of ruler and caliper that can measure the distance between two points. The configuration of this device permits the measurement of internal dimensions.: Measurement; the size or magnitude of something.: A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989, C25209, C81184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Culture</VALIDVALUE>
          <VALUEMEANING>Culture Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Any laboratory procedure for growing microorganisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspergillus galactomannan assay</VALIDVALUE>
          <VALUEMEANING>ELISA</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attatched, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3173905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KOH / calcofluor stain</VALIDVALUE>
          <VALUEMEANING>Calcofluor White Stain</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorescent stain that binds to the cell wall.  It is used for the detection of fungi, parasites, and yeasts, using fluorescent microscopy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3181377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/Conventional CT</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. : A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/Spiral CT</VALIDVALUE>
          <VALUEMEANING>Spiral CT Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44): A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C20645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Spine</VALIDVALUE>
          <VALUEMEANING>MRI of Spine</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Spine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Brain</VALIDVALUE>
          <VALUEMEANING>MRI of Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Brain</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine catecholamines</VALIDVALUE>
          <VALUEMEANING>Urine catecholamines</VALUEMEANING>
          <MEANINGDESCRIPTION>Urine catecholamines</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3566835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow morphology</VALIDVALUE>
          <VALUEMEANING>Bone marrow morphology</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow morphology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIBG scintiscan</VALIDVALUE>
          <VALUEMEANING>MIBG scintiscan</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging test that uses a radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine) tracer and a special scanner to find or confirm the presence of pheochromocytoma and neuroblastoma, which are tumors of specific types of nervous tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3458598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CA-125 assay</VALIDVALUE>
          <VALUEMEANING>CA-125 assay</VALUEMEANING>
          <MEANINGDESCRIPTION>CA-125 assay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3485237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic Imaging</VALIDVALUE>
          <VALUEMEANING>Radiograph Imaging Technique</VALUEMEANING>
          <MEANINGDESCRIPTION>An image produced on a radiosensitive surface by x-ray radiation that has penetrated and passed through a structure.: Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17369, C60727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3626193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymerase Chain Reaction</VALIDVALUE>
          <VALUEMEANING>Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3234683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>in situ hybridization</VALIDVALUE>
          <VALUEMEANING>in situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow Cytometry</VALIDVALUE>
          <VALUEMEANING>Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2974014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical examination with imaging</VALIDVALUE>
          <VALUEMEANING>Imaging With Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.: Used to indicate the presence of something or someone.: A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989, C62355, CL024911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microscopic evaluation</VALIDVALUE>
          <VALUEMEANING>Microscopic evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>Microscopic evaluation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macroscopic evaluation</VALIDVALUE>
          <VALUEMEANING>Macroscopic evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>Macroscopic evaluation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antigen</VALIDVALUE>
          <VALUEMEANING>Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Any substance that appears foreign or potentially adverse to the body and elicits immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3167779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI + DWI</VALIDVALUE>
          <VALUEMEANING>MRI DWI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.: A diffusion MRI technique in which diffusion-sensitizing gradients are applied to the imaging sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111116, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4253231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shell Vial Culture</VALIDVALUE>
          <VALUEMEANING>Shell Vial Culture</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for virus culture and detection in which a virus sample is mixed with a susceptible cell type and then centrifuged into a single layer of cells. Following a short incubation, viral growth is determined using immunological detection techniques.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4262871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T2</VALIDVALUE>
          <VALUEMEANING>MRI T2</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the transverse relaxation of a tissue&#39;s net magnetization vector; it measures the time taken for spinning protons to lose phase coherence among the nuclei spinning perpendicular to the main field. This MRI sequence is produced by using a longer time to echo (TE) and repetition time (TR) than a T1-weighted sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4231311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T1gad</VALIDVALUE>
          <VALUEMEANING>MRI T1gad</VALUEMEANING>
          <MEANINGDESCRIPTION>Magnetic resonance imaging (MRI) of the T1gad signal intensity ratio (SIR)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4231312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T1gad and MRI T2</VALIDVALUE>
          <VALUEMEANING>MRI T1gad and MRI T2</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI T1gad and MRI T2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4377743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Neck</VALIDVALUE>
          <VALUEMEANING>CT of Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>CT of Neck</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4512871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combination of these methods</VALIDVALUE>
          <VALUEMEANING>Combination of these methods</VALUEMEANING>
          <MEANINGDESCRIPTION>Combination of these methods</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection / endoscopy under anesthesia</VALIDVALUE>
          <VALUEMEANING>Direct inspection / endoscopy under anesthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>Direct inspection / endoscopy under anesthesia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection / in office endoscopy</VALIDVALUE>
          <VALUEMEANING>Direct inspection / in office endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Direct inspection / in office endoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fiberoptic nasopharyngolaryngoscopy</VALIDVALUE>
          <VALUEMEANING>Fiberoptic nasopharyngolaryngoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Fiberoptic nasopharyngolaryngoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4726691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngoscopy</VALIDVALUE>
          <VALUEMEANING>Laryngoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2832055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WBC differential</VALIDVALUE>
          <VALUEMEANING>WBC differential</VALUEMEANING>
          <MEANINGDESCRIPTION>A hematologic procedure for the evaluation of the qualitative and quantitative characteristics of the white cells in peripheral blood smears and bone marrow aspirates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4845352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral smear</VALIDVALUE>
          <VALUEMEANING>Peripheral smear</VALUEMEANING>
          <MEANINGDESCRIPTION>A sample of blood applied in a thin film to a microscope slide for study under a microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4845353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelin-Associated Glycoprotein</VALIDVALUE>
          <VALUEMEANING>Myelin-Associated Glycoprotein</VALUEMEANING>
          <MEANINGDESCRIPTION>An autoantibody directed against myelin-associated glycoprotein (MAG). It is associated with active demyelination in peripheral neuropathy and is detected in about 50% of patients with IgM&amp;#8200;paraproteinemia and may occur in some patients with multiple sclerosis, Guillain-Barre syndrome, chronic polyneuropathy, or myasthenia gravis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4811579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIBG</VALIDVALUE>
          <VALUEMEANING>MIBG</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRV</VALIDVALUE>
          <VALUEMEANING>MRV</VALUEMEANING>
          <MEANINGDESCRIPTION>Magnetic resonance venography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRA</VALIDVALUE>
          <VALUEMEANING>MRI-Based Angiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An image of blood vessels constructed using magnetic resonance imaging.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None of the above</VALUEMEANING>
          <MEANINGDESCRIPTION>None of the choices above are suitable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary cytology with mass visualized during upper tract endoscopy</VALIDVALUE>
          <VALUEMEANING>Urinary cytology with mass visualized during upper tract endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Urinary cytology with mass visualized during upper tract endoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</VALIDVALUE>
          <VALUEMEANING>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Image-guided Biopsy</VALIDVALUE>
          <VALUEMEANING>Image-guided Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis, using imaging technology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electromyography</VALIDVALUE>
          <VALUEMEANING>Electromyography</VALUEMEANING>
          <MEANINGDESCRIPTION>An assessment of skeletal muscle function and nerve control, obtained by recording and studying the intrinsic electrical properties of the muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4821875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SQUID</VALIDVALUE>
          <VALUEMEANING>Superconducting Quantum Interference Device</VALUEMEANING>
          <MEANINGDESCRIPTION>A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5039992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver Biopsy</VALIDVALUE>
          <VALUEMEANING>Liver Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue from the liver for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2831213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI</VALIDVALUE>
          <VALUEMEANING>Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5039993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disease specific molecular marker</VALIDVALUE>
          <VALUEMEANING>Disease specific molecular marker</VALUEMEANING>
          <MEANINGDESCRIPTION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.::2: Clearly and explicitly stated.::2: A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16342, C38024, C2991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5084231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chimerism testing</VALIDVALUE>
          <VALUEMEANING>Chimerism testing</VALUEMEANING>
          <MEANINGDESCRIPTION>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62582, C25294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET + MRI</VALIDVALUE>
          <VALUEMEANING>FDG-PET + MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>FDG-PET + MRI</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5170915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET + CT</VALIDVALUE>
          <VALUEMEANING>FDG-PET + CT</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging procedure that combines FDG PET with a CT scan to overlay activity data onto detailed anatomic images.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5170916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical Palpation</VALIDVALUE>
          <VALUEMEANING>Clinical Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.: A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient&#39;s body to examine the size, consistency, texture, location and tenderness of an organ or body part.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5283971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging</VALIDVALUE>
          <VALUEMEANING>Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5283972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sokal</VALIDVALUE>
          <VALUEMEANING>Sokal Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. The numerical value is calculated at diagnosis from the percentage of blast cells in peripheral blood, the platelet count, the spleen size, and the age of the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hasford</VALIDVALUE>
          <VALUEMEANING>Hasford Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high, medium, or low risk on the basis of age, spleen size, and eosinophil, basophil, and platelet counts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EUTOS</VALIDVALUE>
          <VALUEMEANING>European Treatment Outcome Study Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high or low risk on the basis of the percentage of basophils in the peripheral blood and spleen size at diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IgH/TCR PCR</VALIDVALUE>
          <VALUEMEANING>Immunoglobulin Heavy Locus T-Cell Receptor Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink): Heterodimeric antigen receptors present on the surface of T-cells.  Two T-cell antigen receptors have been identified, consisting of heterodimeric 40-55 kD Ig-like alpha/beta or gamma/delta integral membrane glycoproteins.  Genes for TCR alpha, beta, gamma, and delta subunits are assembled during T-cell development by somatic rearrangement of germline gene segments, resembling B-cell Ig genes in their mechanisms of diversity generation and activation of expression.  Alpha/beta heterodimers are found on helper and cytotoxic T-cells and are specific for antigenic peptides presented by MHC gene products.  T-cells expressing gamma/delta heterodimers directly recognize proteins and non-proteinacious phospho-ligands.  T-cell receptors are non-covalently associated with CD3, forming the TCR-CD3 complex.  TCRs activate MAPKs and JNK1 through the CD3 antigens, the adaptor protein LAT, and tyrosine kinases LCK and ZAP70.  (from OMIM and NCI): A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly s</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003, C17065, C26422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5664683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCR-ABL1/FISH</VALIDVALUE>
          <VALUEMEANING>BCR Protein Fluorescence in Situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>The 160 kD BCR phosphoprotein exhibits a unique serine/threonine kinase activity, at least two SH2 binding sites, and a C-terminal GTPase activating domain for p21(rac).  The Philadelphia translocation produces a BCR-ABL1 chimeric product required for induction and maintenance of leukemia.  (from OMIM 151410 and NCI): A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563, C17477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5664705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morphology</VALIDVALUE>
          <VALUEMEANING>Morphology</VALUEMEANING>
          <MEANINGDESCRIPTION>The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4661331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunohistochemistry</VALIDVALUE>
          <VALUEMEANING>Immunohistochemistry Staining Method</VALUEMEANING>
          <MEANINGDESCRIPTION>Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C23020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic confirmation only</VALIDVALUE>
          <VALUEMEANING>Radiographic Examination Confirmation Only</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiographic procedure using the emission of penetrating energy waves to form an image of the structure penetrated by the radiation._Having been established or verified._Not accompanied by another or others; exclusive of anyone or anything else.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48440, C25458, C128940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5977653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathologic confirmation</VALIDVALUE>
          <VALUEMEANING>Pathologic Confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or altered by or manifesting disease or pathology.: Having been established or verified.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25458, C25610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5633738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gene expression profile</VALIDVALUE>
          <VALUEMEANING>Microarray Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3600806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Brain</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.: An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6058859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLAIR</VALIDVALUE>
          <VALUEMEANING>Fluid Attenuated Inversion Recovery</VALUEMEANING>
          <MEANINGDESCRIPTION>A magnetic resonance imaging (MRI) pulse sequence that uses an inversion recovery technique to null fluids present in the imaging area, improving clarity of the object of interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6147291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Both</VALIDVALUE>
          <VALUEMEANING>Both</VALUEMEANING>
          <MEANINGDESCRIPTION>One and the other; relating to or being two in conjunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axumin PET Scan</VALIDVALUE>
          <VALUEMEANING>Fluciclovine F18 Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C74002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6399698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSMA PET Scan</VALIDVALUE>
          <VALUEMEANING>Glutamate Carboxypeptidase 2 Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Glutamate carboxypeptidase 2 (750 aa, ~84 kDa) is encoded by the human FOLH1 gene. This protein plays a role in the mediation of folate metabolism.: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C17796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6399696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preoperative CT Scan</VALIDVALUE>
          <VALUEMEANING>Preoperative Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or occurring during the period immediately before a surgical operation.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C54732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6332631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS)</VALIDVALUE>
          <VALUEMEANING>Next Generation Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4448577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver MRI</VALIDVALUE>
          <VALUEMEANING>Liver Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capillary electrophoresis</VALIDVALUE>
          <VALUEMEANING>Capillary Electrophoresis</VALUEMEANING>
          <MEANINGDESCRIPTION>An electrophoresis procedure, in which a sample is introduced into a capillary tube and the components are separated by the application of high voltage. Due to the large surface to volume ratio, cooling is more efficient, allowing use of higher voltages.  As a result, separation occurs more quickly and sensitivity is increased. The technique allows for separation of proteins, nucleic acids, and carbohydrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2915741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SQUID MRI</VALIDVALUE>
          <VALUEMEANING>Superconducting Quantum Interference Device Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C124066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2 MRI</VALIDVALUE>
          <VALUEMEANING>T2 (Observed)-Weighted Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI imaging based on the observed T2 relaxation time of tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FerriScan</VALIDVALUE>
          <VALUEMEANING>FerriScan</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary method to determine liver iron concentration through an MRI-based imaging technology that uses R2-MRI relaxometry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153820 </MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymerase Chain Reaction (PCR)</VALIDVALUE>
          <VALUEMEANING>Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE>2019-07-15</PVENDDATE>
          <VMPUBLICID>3234683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FISH</VALIDVALUE>
          <VALUEMEANING>Fluorescence in Situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5622317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Karyotype</VALIDVALUE>
          <VALUEMEANING>Karyotype</VALUEMEANING>
          <MEANINGDESCRIPTION>The assessment of the chromosomal morphology and number in somatic cells of an individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of the Brain with orbital cuts</VALIDVALUE>
          <VALUEMEANING>MRI of the Brain with orbital cuts</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of the Brain with orbital cuts</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6649483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunofluorescence</VALIDVALUE>
          <VALUEMEANING>Fluorescent Antibody Technique</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunological technique in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2978232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mass spectrometry</VALIDVALUE>
          <VALUEMEANING>Mass Spectrometry</VALUEMEANING>
          <MEANINGDESCRIPTION>An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3339145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ICE</VALIDVALUE>
          <VALUEMEANING>Immune Effector Encephalopathy - ICE Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>A grading system for Immune Effector Cell Associated Neurotoxicity Syndrome that includes: orientation to year, month, city, hospital; ability to name objects; ability to follow simple commands; ability to write a standard sentence; and ability to count backwards from 100 by 10. Grading ranges from 10: no impairment to 0: patient unarousable and unable to perform ICE assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6927187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CARTOX</VALIDVALUE>
          <VALUEMEANING>CARTOX 10 Point Neurological Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>A test to monitor for neurotoxicity related to CAR T therapy: orientation to year, month, city, hospital, and President; ability to name 3 specified objects; ability to write a standard sentence; ability to count backwards from 100 by 10.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6927188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum ferritin</VALIDVALUE>
          <VALUEMEANING>Serum Ferritin Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.: The determination of the amount of ferritin present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74737, C13325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multicolor flow cytometry</VALIDVALUE>
          <VALUEMEANING>Multiple Color Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold.: The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation.: A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585, C37927, C17648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7246031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular assay</VALIDVALUE>
          <VALUEMEANING>Molecular Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or produced by or consisting of molecules.: A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60819, C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7246030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right Heart Catheterization</VALIDVALUE>
          <VALUEMEANING>Right Heart Catheterization</VALUEMEANING>
          <MEANINGDESCRIPTION>A diagnostic procedure in which a catheter is guided into the right heart, where pressures may be measured and radiocontrast material may be injected to visualize blood flow in and around the right heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7244953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical exam</VALIDVALUE>
          <VALUEMEANING>Clinical exam</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinical exam</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7340571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete red blood cell count</VALIDVALUE>
          <VALUEMEANING>Complete Erythrocyte Count</VALUEMEANING>
          <MEANINGDESCRIPTION>To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: The determination of the number of erythrocytes in a blood sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51946, C25250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7320617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pitted Erythrocyte Count</VALIDVALUE>
          <VALUEMEANING>Pitted Erythrocyte Count</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of pitted erythrocytes in a blood sample, expressed as a percentage. It is used as an indicator of splenic function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7320618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS) by Guardant360</VALIDVALUE>
          <VALUEMEANING>Guardant360 Genomic Profiling</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary genomic profiling system that utilizes a proprietary next generation Digital Sequencing technology on samples obtain from blood. It is designed to detect alterations in over 70 genes relevant to multiple solid tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7334407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS) by FoundationOne</VALIDVALUE>
          <VALUEMEANING>FoundationOne Genomic Profiling</VALUEMEANING>
          <MEANINGDESCRIPTION>A set of proprietary genomic profiling techniques that utilize next generation sequencing. FoundationOne CDX is optimized for PPFE samples from solid tumors; FoundationOne Liquid is optimized for peripheral whole blood, targeting solid tumors; FoundationOne Heme is optimized for leukemias, lymphomas, sarcomas, and solid tumors using RNA sequencing on samples obtained from FFPE, peripheral whole blood, or bone marrow aspirate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7334408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic Scan</VALIDVALUE>
          <VALUEMEANING>Splenic Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radionuclide imaging technique that is used to evaluate the size and shape of the spleen, and to detect and evaluate lesions, rupture, and hematomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Research Flexible Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Research Activity Flexible Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.: Able to be adjusted readily to different conditions.: Endoscopic examination of the luminal surface of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17131, C80495, C15429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7536999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flexible Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Flexible Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Able to be adjusted readily to different conditions.: Endoscopic examination of the luminal surface of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17131, C80495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7537000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Open / thorascopic (VATS) lung biopsy</VALIDVALUE>
          <VALUEMEANING>Open Lung Biopsy Or Video-assisted Thoracic Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue from the lung, for microscopic examination, obtained during an open surgical procedure.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Thoracic surgery that is aided by the use of a video camera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63704, C37998, C51923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7715759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchoalveolar Lavage</VALIDVALUE>
          <VALUEMEANING>Bronchoalveolar Lavage</VALUEMEANING>
          <MEANINGDESCRIPTION>Washing out the bronchi and alveoli by flushing with a fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transbronchial Biopsy</VALIDVALUE>
          <VALUEMEANING>Transbronchial Lung Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue through the bronchial wall, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multiplex ligation-dependent probe amplification (MLPA)</VALIDVALUE>
          <VALUEMEANING>Multiplex Ligation-dependent Probe Amplification</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-throughput, multiplex PCR method used to determine abnormal DNA copy number changes of up to 50 genomic DNA or RNA sequences with a single pair of PCR primers. It is frequently used in the detection of genetic aberrations in tumors, and can distinguish sequences differing in only a single nucleotide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6413914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Loss of heterozygosity (LOH)</VALIDVALUE>
          <VALUEMEANING>Loss of Heterozygosity</VALUEMEANING>
          <MEANINGDESCRIPTION>genetic phenomenon due to deletion or mutation in one allele of a polymorphic gene, as detected by expression after cell fusion; used as a test for tumor-promoting mutations; do not confuse with &quot;loss of heterogeneity&quot; which applies to diverse cell populations within a tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18016</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3082343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT-PCR amplification (e.g., MethyLight)</VALIDVALUE>
          <VALUEMEANING>RT-PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>RT-PCR is short for reverse transcriptase-polymerase chain reaction. It is a technique in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase. (from Wikipedia)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18136</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3121570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sequencing (e.g., bisulfite sequencing)</VALIDVALUE>
          <VALUEMEANING>Bisulfite Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7736012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quantitative CT</VALIDVALUE>
          <VALUEMEANING>Quantitative Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of computed tomography in which a calibration standard correlates radiodensity values to quantitative tissue density values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF examination</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.: A formal or careful inspection of an object or subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131902, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8078596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Not Assessed</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that an assessment was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5189423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Karyotyping</VALIDVALUE>
          <VALUEMEANING>Karyotyping</VALUEMEANING>
          <MEANINGDESCRIPTION>The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5095203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clonality Analysis</VALIDVALUE>
          <VALUEMEANING>Clonality Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10382636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mutation Abnormality</VALIDVALUE>
          <VALUEMEANING>Mutation Abnormality</VALUEMEANING>
          <MEANINGDESCRIPTION>A general term referring to single or multiple alterations in the genetic material of an organism that ranges from a single base change in a gene to the loss or addition of complete chromosomes. A mutation abnormality may be heritable or occur somatically.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3219495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical biopsy</VALIDVALUE>
          <VALUEMEANING>Excisional Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which an entire lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular testing / NextGen sequencing</VALIDVALUE>
          <VALUEMEANING>Molecular Analysis And/Or Next Generation Sequencing Method</VALUEMEANING>
          <MEANINGDESCRIPTION>A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._Used to indicate that either or both of two items or options may be valid._Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71460, C101293, C48928, C19770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12134398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allelic editing frequency</VALIDVALUE>
          <VALUEMEANING>Allelic Editing Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of allele editing detected after a subject is exposed to gene editing agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clonal expansion</VALIDVALUE>
          <VALUEMEANING>Clonal Expansion</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiplication or reproduction by cell division of a population of identical cells descended from a single progenitor. In immunology, may refer to the clonal proliferation of cells responsive to a specific antigen as part of an immune response. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Homology directed DNA repair (HDR) frequency</VALIDVALUE>
          <VALUEMEANING>Homology-Directed DNA Repair Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of directed gene modification or DNA repair occurring after a subject is exposed to homology-directed DNA repair promoting agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indel mutations frequency</VALIDVALUE>
          <VALUEMEANING>Indel Mutation Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of indel mutations in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transgene expression</VALIDVALUE>
          <VALUEMEANING>Transgene Expression Level Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the level of expression of a transgene in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector copy number</VALIDVALUE>
          <VALUEMEANING>Vector Copy Number</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of vector molecules present in a cell or sub-cellular location, sometimes stated as copies per diploid genome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gene therapy globin expression</VALIDVALUE>
          <VALUEMEANING>Therapeutic Globin Gene Level Expression Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the level of expression of a therapeutic globin gene in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ddPCR</VALIDVALUE>
          <VALUEMEANING>Droplet Digital PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of digital polymerase chain reaction technique in which the sample is fractionated into thousands of tiny droplets using a water-oil emulsion droplet technology, within which individual PCR reactions occur in each droplet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7167105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MicroRNA Sequencing</VALIDVALUE>
          <VALUEMEANING>MicroRNA Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13331403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>qPCR</VALIDVALUE>
          <VALUEMEANING>Real Time PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>A modified polymerase chain reaction (PCR) technique in which DNA amplification is detected and quantified as the PCR reaction progresses, through the use of fluorescent DNA probes in the reaction mixture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3727155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ClonoSEQ</VALIDVALUE>
          <VALUEMEANING>clonoSEQ Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>A next generation sequencing-based proprietary immunogenetic assay that identifies and quantitates the expression of the B-cell receptor (BCR) and T-cell receptor (TCR) variable, diversity and joining segments in a peripheral blood sample from subject. This assay can establish a genetic barcode for clonal lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (B-ALL), and can be leveraged to monitor clonal recurrence and/or measurable residual disease during and after treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11509111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the disease detectio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the disease detection assessment method?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the method(s) of disease detection for which intervention was given</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the method(s) of disease detection for which intervention was given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the method(s) of detection for which intervention was given</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the method(s) of detection for which intervention was given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the method(s) of detection for which intervention was given</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify the method(s) of detection for which intervention was given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How was this disease detected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Method utilized for CD79b detection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_RP_disease_detect_meth</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DS_DCT_MTH_TP</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DLBL0116</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="676">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5073411</PUBLICID>
    <LONGNAME>Person Breast Feeding Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>4722437v1.0:2017177v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to patient eligibility based on current breast feeding status</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4722437</PublicId>
      <PreferredName>2236731v1.0:4722435v1.0</PreferredName>
      <PreferredDefinition>information related to a person breast feeding, the nursing of an infant at the mother&#39;s breast, as the medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person Breast Feeding Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4722435</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25596:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Breast Feeding Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25596</PREFERRED_NAME>
            <LONG_NAME>Breast Feeding</LONG_NAME>
            <CON_ID>2419414</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017177</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2179965</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If the patient is actively br</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If the patient is actively breastfeeding, does she agree to discontinue breastfeeding before the initiation of protocol therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="677">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5090565</PUBLICID>
    <LONGNAME>Treatment Cohort Study CITN12 Code</LONGNAME>
    <PREFERREDNAME>TX_COH_SDY_CITN12_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study CITN-12.</PREFERREDDEFINITION>
    <VERSION>2.1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2497526</PublicId>
      <PreferredName>TX_COHORT_STDY</PreferredName>
      <PreferredDefinition>Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.</PreferredDefinition>
      <LongName>Treatment Cohort Study</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2497524</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15208</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15208</PREFERRED_NAME>
            <LONG_NAME>Cohort Study</LONG_NAME>
            <CON_ID>2497523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5090561</PublicId>
      <PreferredName>5090561v1.0</PreferredName>
      <PreferredDefinition>A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>CITN12 Cohort Code</LongName>
      <Version>2.1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>4386398</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61512:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61512</PREFERRED_NAME>
            <LONG_NAME>Cohort</LONG_NAME>
            <CON_ID>2555083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG03</VALIDVALUE>
          <VALUEMEANING>Cohort 3: &gt;350 CD4+ T cells/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Cohort 3: &gt;350 CD4+ T cells/mcL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5090562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG02</VALIDVALUE>
          <VALUEMEANING>Cohort 2: 200-350 CD4+ T cells/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Cohort 2: 200-350 CD4+ T cells/mcL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5090563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG01</VALIDVALUE>
          <VALUEMEANING>Cohort 1: 100-199 CD4+ T cells/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Cohort 1: 100-199 CD4+ T cells/mcL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5090564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG04</VALIDVALUE>
          <VALUEMEANING>Cohort 4: Kaposi sarcoma, &gt;=100 CD4+ T cells/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Cohort 4: Kaposi sarcoma, &gt;=100 CD4+ T cells/mcL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7263232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cohort</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Subgroup</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Subgroup</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876594</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Theradex</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Theradex - CTMS 3.14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3876603</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="678">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5092508</PUBLICID>
    <LONGNAME>Knowledge Understanding and Judgement Scale Without Treatment One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Indicator</LONGNAME>
    <PREFERREDNAME>KUJ_DIE_WO_TRMT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated understanding of the statement, without treatment, one out of three patients will die within 10 years due to prostate cancer, using a true or false indictor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>KUJ:Knowledge, Understanding and Judgement Scale</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5092468</PublicId>
      <PreferredName>5092397v1.0:5092466v1.0</PreferredName>
      <PreferredDefinition>A questionnaire developed to assess a patient&#39;s knowledge of prostate cancer, understanding of treatment choices, and judgment of survival with and without treatment._A question about whether an individual thinks that, without treatment, one out of three patients will die within ten years due to prostate cancer.</PreferredDefinition>
      <LongName>Knowledge, Understanding and Judgment Scale One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5092397</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C124803</PreferredName>
        <Version>1</Version>
        <LongName>Knowledge, Understanding and Judgment Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C124803</PREFERRED_NAME>
            <LONG_NAME>Knowledge, Understanding and Judgment Scale</LONG_NAME>
            <CON_ID>5085191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5092466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C124817</PreferredName>
        <Version>1</Version>
        <LongName>One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C124817</PREFERRED_NAME>
            <LONG_NAME>One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment Question</LONG_NAME>
            <CON_ID>5085295</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>KUJ:Knowledge, Understanding and Judgement Scale</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5092391</PublicId>
      <PreferredName>KUJ_TRUE_FALSE_IND</PreferredName>
      <PreferredDefinition>A response of true or false related to statements associated with the Knowledge, Understanding and Judgement Scale (KUJ).</PreferredDefinition>
      <LongName>KUJ True False Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>KUJ:Knowledge, Understanding and Judgement Scale</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>False</VALIDVALUE>
          <VALUEMEANING>False</VALUEMEANING>
          <MEANINGDESCRIPTION>Not in accordance with the fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>True</VALIDVALUE>
          <VALUEMEANING>True</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Without treatment, one out of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Without treatment, one out of three patients will die within 10 years due to prostate cancer.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5090547</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>KUJ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KUJ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5090548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="679">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5095223</PUBLICID>
    <LONGNAME>Pembrolizumab Administered Indicator</LONGNAME>
    <PREFERREDNAME>5095222v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not pembrolizumab was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5095222</PublicId>
      <PreferredName>5095220v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Pembrolizumab Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5095220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106432</PreferredName>
        <Version>1</Version>
        <LongName>Pembrolizumab</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106432</PREFERRED_NAME>
            <LONG_NAME>Pembrolizumab</LONG_NAME>
            <CON_ID>3911936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was pembrolizumab administere</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was pembrolizumab administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pembrolizumab</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pembrolizumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pembrolizumab</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Pembrolizumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If Neoadjuvant, Has the patient received 3 doses of pre-operative pembrolizumab?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Neoadjuvant, Has the patient received 3 doses of pre-operative pembrolizumab?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient ever take MK-3475 (Pembrolizumab)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient received prior non-induction pembrolizumab?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_PHCT_pembrolizumab_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_RP_pembrolizumab_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_PEMBRO</AlternateName>
        <AlternateNameType>OID, RTOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="680">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5097014</PUBLICID>
    <LONGNAME>Laboratory Procedure HLA-A2 Outcome Category</LONGNAME>
    <PREFERREDNAME>LAB_PROC_HLA_A2_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The positive/negative indicator that asks the status of the procedure that involves testing the HLA class I histocompatibility antigen, A-2 alpha chain (365 aa, ~41 kDa).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5097013</PublicId>
      <PreferredName>2543047v1.0:5097011v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._HLA class I histocompatibility antigen, A-2 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in antigen presentation._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure HLA-A2 Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5097011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16691:C20200</PreferredName>
        <Version>1</Version>
        <LongName>HLA Class I Histocompatibility Antigen, A-2 Alpha Chain Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16691</PREFERRED_NAME>
            <LONG_NAME>HLA Class I Histocompatibility Antigen, A-2 Alpha Chain</LONG_NAME>
            <CON_ID>2821325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3911843</PublicId>
      <PreferredName>POS_NEG_ND_CAT</PreferredName>
      <PreferredDefinition>Involving advantage or good._Negative; not indicating the presence of microorganisms or disease or a specific condition._Category; used informally to mean a class of things.</PreferredDefinition>
      <LongName>Positive Negative Not Done Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3911842</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25246:C38757:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Positive Negative Finding Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25246</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2202905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38757</PREFERRED_NAME>
            <LONG_NAME>Negative Finding</LONG_NAME>
            <CON_ID>2203934</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>An observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2840097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HLA-A2 Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>HLA-A2 Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>HLA-A2 Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="681">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5103261</PUBLICID>
    <LONGNAME>TAPS Tool - Interviewer Version 1.0 Past 3 Months Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week or More Often Indicator</LONGNAME>
    <PREFERREDNAME>5103201v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of whether or not they had a strong desire or urge to use such a medication at least once a week or more often in the past three months.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDA</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TAPS Tool:TAPS Tool - Interviewer Version 1.0. Robert P. Schwartz, Li-Tzy Wu, Jennifer McNeely. 2016</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5103201</PublicId>
      <PreferredName>5103131v1.0:5103199v1.0</PreferredName>
      <PreferredDefinition>An instrument designed to screen and assess adult primary care patients for tobacco, alcohol, prescription drug, and drug use and problems related to their use._A period of time consisting of the 3 months before the present._A question about whether an individual has or had a strong desire or urge to use a sedative or sleeping medication at least once a week or more often.</PreferredDefinition>
      <LongName>TAPS Tool - Interviewer Version Past 3 Months Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDA</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5103131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125105</PreferredName>
        <Version>1</Version>
        <LongName>TAPS Tool - Interviewer Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125105</PREFERRED_NAME>
            <LONG_NAME>TAPS Tool - Interviewer Version</LONG_NAME>
            <CON_ID>5103091</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5103199</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125104:C125134</PreferredName>
        <Version>1</Version>
        <LongName>Past 3 Months Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125104</PREFERRED_NAME>
            <LONG_NAME>Past 3 Months</LONG_NAME>
            <CON_ID>5103092</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125134</PREFERRED_NAME>
            <LONG_NAME>Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week Question</LONG_NAME>
            <CON_ID>5103111</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TAPS Tool:TAPS Tool - Interviewer Version 1.0. Robert P. Schwartz, Li-Tzy Wu, Jennifer McNeely. 2016</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you had a strong desire</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you had a strong desire or urge to use medications for anxiety or sleep at least once a week or more often?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3696642</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Instrument</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TAPS Tool</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5105915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Research</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952294</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="682">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5105732</PUBLICID>
    <LONGNAME>Patient Sustained Symptomatic Ventricular Arrhythmia Uncontrolled Pharmacotherapy Medical Device Eligibility Determination Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>SustndSxDysrhythUncontrll</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no/unknown/not applicable indicator related to eligibility of a patient who receives medical attention, care, or treatment, exhibiting the sustained or symptomatic disease, relating to any variation from the normal rate or rhythm in the heart, which is not controlled, regulated, or constrained through the use of drugs or treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5105595</PublicId>
      <PreferredName>2233604v1.0:5105593v1.0</PreferredName>
      <PreferredDefinition>Information related to Eligibility of a patient who receives medical attention, care, or treatment, exhibiting the sustained or symptomatic disease, relating to any variation from the normal rate or rhythm in the heart, which is not controlled, regulated, or constrained through the use of drugs or treatment</PreferredDefinition>
      <LongName>Patient Sustained Symptomatic Ventricular Arrhythmia Uncontrolled Pharmacotherapy Medical Device Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5105593</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5105593v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Sustained Symptomatic Ventricular Arrhythmia Uncontrolled Pharmacotherapy Medical Device Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL212580</PREFERRED_NAME>
            <LONG_NAME>Sustained</LONG_NAME>
            <CON_ID>2234862</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25269</PREFERRED_NAME>
            <LONG_NAME>Symptomatic</LONG_NAME>
            <CON_ID>2203607</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38055</PREFERRED_NAME>
            <LONG_NAME>Ventricular</LONG_NAME>
            <CON_ID>2615984</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2881</PREFERRED_NAME>
            <LONG_NAME>Arrhythmia</LONG_NAME>
            <CON_ID>2202296</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48932</PREFERRED_NAME>
            <LONG_NAME>Uncontrolled</LONG_NAME>
            <CON_ID>2437662</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15986</PREFERRED_NAME>
            <LONG_NAME>Pharmacotherapy</LONG_NAME>
            <CON_ID>2673143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16830</PREFERRED_NAME>
            <LONG_NAME>Medical Device</LONG_NAME>
            <CON_ID>2240760</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have sustained o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have sustained or symptomatic ventricular dysrhythmias uncontrolled with drug therapy or implantable device?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="683">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5109101</PUBLICID>
    <LONGNAME>Cellular Therapy Product Manufacture Location Type</LONGNAME>
    <PREFERREDNAME>5109093v1.0:5109095v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of where the cellular therapy product was manufactured or processed.  Includes donor lymphocyte infusions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5109093</PublicId>
      <PreferredName>5109091v1.0:2240715v1.0</PreferredName>
      <PreferredDefinition>Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._A thing produced by or resulting from a process. EXAMPLE(S): drug, device. The FDA list of regulated products: animal and human drugs; therapeutic biologics; allergenics; cell, tissue and gene therapy products; blood components; blood derivative products; devices; and animal (pets and livestock) and human food/feed (medicated and un-medicated); cosmetics; pet treats; and dietary supplements._The act of making something (a product) from raw materials._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Cellular Therapy Product Manufacture Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5109091</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70601:C51980:C43360</PreferredName>
        <Version>1</Version>
        <LongName>Cellular Therapy Product Manufacture</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70601</PREFERRED_NAME>
            <LONG_NAME>Cellular Therapy</LONG_NAME>
            <CON_ID>2688746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43360</PREFERRED_NAME>
            <LONG_NAME>Manufacture</LONG_NAME>
            <CON_ID>2236530</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25341</PreferredName>
        <Version>1</Version>
        <LongName>Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5109095</PublicId>
      <PreferredName>5109095v1.0</PreferredName>
      <PreferredDefinition>The act of making something (a product) from raw materials._A position, site, or point in space where something can be found._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Manufacture Location Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>5109094</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43360:C25341:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Manufacture Location Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43360</PREFERRED_NAME>
            <LONG_NAME>Manufacture</LONG_NAME>
            <CON_ID>2236530</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell processing laboratory off site</VALIDVALUE>
          <VALUEMEANING>Cellular Therapy Processing Laboratory Off-Site</VALUEMEANING>
          <MEANINGDESCRIPTION>Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.: The act of preparing or putting through a prescribed procedure.: A facility equipped and competent to conduct scientific experiments, observations, tests, investigations, and/or to manufacture chemicals or medical products.: Taking place or located away from the study site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113778, C37984, C48177, C70601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other site</VALIDVALUE>
          <VALUEMEANING>Other Location</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: A position, site, or point in space where something can be found.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell processing laboratory at the same center as the product is being infused</VALIDVALUE>
          <VALUEMEANING>Cellular Therapy Processing Laboratory Same Institution Product Infusion Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.: The act of preparing or putting through a prescribed procedure.: A facility equipped and competent to conduct scientific experiments, observations, tests, investigations, and/or to manufacture chemicals or medical products.: Equal, or closely similar or comparable, in kind or quality or quantity or degree.: An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization.: The end result of a manufacturing process; anything that is produced.: A method of putting fluids, including drugs, into the bloodstream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15388, C51980, C41206, C64637, C37984, C48177, C70601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharmaceutical / biotech company</VALIDVALUE>
          <VALUEMEANING>Drug Company And/Or Biotechnology Company</VALUEMEANING>
          <MEANINGDESCRIPTION>A company licensed to discover, develop, market and distribute drugs.: Used to indicate that either or both of two items or options may be valid.: body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful; alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus.: Any formal business entity for profit, which may be a corporation, a partnership, association or individual proprietorship.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54131, C16351, C48928, C54149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where the cellular therapy pr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Where the cellular therapy product was manufactured?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was the cellular therapy product manufactured?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Where was the cellular therapy product manufactured?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was the cellular therapy product manufactured?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Where was the cellular therapy product manufactured?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was the cellular therapy product manufactured / processed?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Where was the cellular therapy product manufactured / processed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was the gene therapy product manufactured / processed?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Where was the gene therapy product manufactured / processed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2552643</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Training Class Examples</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3637837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CTPI_ct_prd_mfr_location</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_DIM_ct_prd_mfr_location</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:postalAddress</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTP_CPS_ct_prd_mfr_location</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="684">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5116163</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale 34 Past Week Other Symptom 2 Indicator</LONGNAME>
    <PREFERREDNAME>MSAS_OTHER2_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of whether or not they were experiencing the second of other symptoms, within the past week, using a yes or no response.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS:Memorial Symptom Assessment Scale. Portenoy, RK, et.al. Eur J Cancer. 1994;30A(9):1326-36.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5116126</PublicId>
      <PreferredName>5114473v1.0:5116124v1.0</PreferredName>
      <PreferredDefinition>A patient-rated instrument developed to provide multidimensional information about a diverse group of common symptoms. This 32-question, self-rated questionnaire evaluates the prevalence, characteristics, and distress associated with each of the symptoms._The most recent week, including today._A question about an individual&#39;s distress from the second of their other symptoms.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale Past Week Other Symptom 2</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5114473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125238</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125238</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale</LONG_NAME>
            <CON_ID>5109052</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5116124</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C125402</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Much Distress Other Symptom 2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125402</PREFERRED_NAME>
            <LONG_NAME>How Much Distress Other Symptom 2 Question</LONG_NAME>
            <CON_ID>5115642</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS:Memorial Symptom Assessment Scale. Portenoy, RK, et.al. Eur J Cancer. 1994;30A(9):1326-36.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you have other symptoms?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you have other symptoms?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure.  The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents.  Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS (Memorial Symptom Assessment Scale)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5115651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="685">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5116166</PUBLICID>
    <LONGNAME>Crofelemer Afternoon Taken Time</LONGNAME>
    <PREFERREDNAME>CROFELEMER_PM_TIME</PREFERREDNAME>
    <PREFERREDDEFINITION>The time crofelemer was taken after noon.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>LCC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5116139</PublicId>
      <PreferredName>5116131v1.0:5116137v1.0</PreferredName>
      <PreferredDefinition>An oligomeric proanthocyanidin extracted from the latex produced by the tree Croton lechleri (Euphorbiaceae), with antidiarrheal, and potential antiviral and antimicrobial activities. Upon oral administration, crofelemer acts locally within the gastrointestinal (GI) tract by inhibiting both the cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl-) channel and the calcium-activated Cl- channel (CaCC) expressed on the luminal surface of enterocytes. This inhibits the secretion of chloride ions into the intestinal lumen and prevents high volume water loss. By normalizing Cl- and water balance in the intestines, crofelemer relieves secretory diarrhea._The time period between noon and sunset._Having been accepted for some purpose; ingested as a medication.</PreferredDefinition>
      <LongName>Crofelemer Afternoon Taken</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>LCC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5116131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125392</PreferredName>
        <Version>1</Version>
        <LongName>Crofelemer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125392</PREFERRED_NAME>
            <LONG_NAME>Crofelemer</LONG_NAME>
            <CON_ID>5115491</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5116137</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64935:C25701</PreferredName>
        <Version>1</Version>
        <LongName>Afternoon Taken</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64935</PREFERRED_NAME>
            <LONG_NAME>Afternoon</LONG_NAME>
            <CON_ID>3640876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017049</PublicId>
      <PreferredName>TIME</PreferredName>
      <PreferredDefinition>The continuum of experience in which events pass from the future through the present to the past.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time (write the time you took</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Time (write the time you took crofelemer in hh:mm format) PM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="686">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5118223</PUBLICID>
    <LONGNAME>Disease or Disorder Physiologic Resolution Indicator</LONGNAME>
    <PREFERREDNAME>5083672v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the disease or disorder resolved.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5083672</PublicId>
      <PreferredName>2404658v1.0:2503262v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</PreferredDefinition>
      <LongName>Disease or Disorder Physiologic Resolution</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2503262</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25655</PreferredName>
        <Version>1</Version>
        <LongName>Resolution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25655</PREFERRED_NAME>
            <LONG_NAME>Physiologic Resolution</LONG_NAME>
            <CON_ID>2202897</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the disease or disorder r</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the disease or disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did cytokine release syndrome resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did cytokine release syndrome resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did neurotoxicity resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did neurotoxicity resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the disease or disorder resolve?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Did the disease or disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did hypogammaglobulinema resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did hypogammaglobulinema resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did tumor lysis syndrome resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did tumor lysis syndrome resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did other toxicity resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did other toxicity resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the other toxicity resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the other toxicity resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did neurotoxicity (ICANS) resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did neurotoxicity (ICANS) resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the personality change(s) resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the personality change(s) resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did cerebral edema resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did cerebral edema resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the motor neuron disorder resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the motor neuron disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the depressed level of consciousness resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the depressed level of consciousness resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the movement disorder resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the movement disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH) resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH) resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the cognitive impairment resolve?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the cognitive impairment resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH)-like toxicities resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did IPn or ARDS / IPS resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did non-infectious pulmonary abnormality resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did non-infectious liver toxicity resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the renal impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the cardiac impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the vascular impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the neurological impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the endocrine impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the genitourinary impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the musculoskeletal impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the psychiatric impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the other impairment / disorder resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the hemorrhagic cystitis / hematuria requiring medical intervention resolve?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_CRS_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_NEU_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_crs_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_neu_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_tum_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_OTOX_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_ced_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mov_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mot_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_con_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mas_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_cog_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_per_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_OF_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_REN_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_CAR_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_GU_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_NEU_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_ENDO_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_VASC_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_ONPA_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_NILT_dis_resolve_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="687">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5118235</PUBLICID>
    <LONGNAME>Disease or Disorder Timepoint  Assessment</LONGNAME>
    <PREFERREDNAME>Dise_Time_Asse_5118231v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The detrmination of the value, significance, or extent of any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person occurring at a specific point in the time continuum, including those established relative to an event._Evaluation of abnormal condition of the body. The final result of a determination of the value, significance, or extent of._A specific point in the time continuum, including those established relative to an event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3385928</PublicId>
      <PreferredName>2404658v1.00:3783694v1.00</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A specific point in the time continuum, including those established relative to an event._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Disease or Disorder Timepoint Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3783694</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68568:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Timepoint Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68568</PREFERRED_NAME>
            <LONG_NAME>Timepoint</LONG_NAME>
            <CON_ID>2656619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5118231</PublicId>
      <PreferredName>5118231v1.0</PreferredName>
      <PreferredDefinition>Evaluation of abnormal condition of the body. The final result of a determination of the value, significance, or extent of._A specific point in the time continuum, including those established relative to an event.</PreferredDefinition>
      <LongName>Disease or Disorder Assessment Timepoint</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>5118230</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C25217:C68568</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Assessment Timepoint</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68568</PREFERRED_NAME>
            <LONG_NAME>Timepoint</LONG_NAME>
            <CON_ID>2656619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>First on study progression diagnosed at this visit</VALIDVALUE>
          <VALUEMEANING>First on study progression diagnosed at this visit</VALUEMEANING>
          <MEANINGDESCRIPTION>The first progression on study has been diagnosed at this time point assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5118232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>After first progression on study</VALIDVALUE>
          <VALUEMEANING>After first progression on study</VALUEMEANING>
          <MEANINGDESCRIPTION>The unscheduled tumor assessment time point is after the first progression on study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5118233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Before first progression on study</VALIDVALUE>
          <VALUEMEANING>Before first progression on study</VALUEMEANING>
          <MEANINGDESCRIPTION>The unscheduled tumor assessment time point is before the first progression on study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5118234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient is N1 at time of surgery</VALIDVALUE>
          <VALUEMEANING>Patient is N1 at time of surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate position, location, or state._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48706, C15329, C25427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14810443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient is N1 on imaging at time of recurrence</VALIDVALUE>
          <VALUEMEANING>At Recurrence Upon Imaging Technique N1 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate position, location, or state._Happening again (especially at regular intervals)._Used to indicate that an event is to immediately follow another event._Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48706, C17369, C65137, C3352, C25427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14812125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient is N1 both at surgery and on imaging at time of recurrence</VALIDVALUE>
          <VALUEMEANING>Surgical Procedure And Recurrence Imaging Technique N1 TNM Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Happening again (especially at regular intervals)._Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48706, C17369, C3352, C37912, C15329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14812126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Disease Assessment Timepoint</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Disease Assessment Timepoint</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Nodal disease status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="688">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5118973</PUBLICID>
    <LONGNAME>Patient Satisfaction Questionnaire Short Form Have to Pay More of My Medical Care Than I Can Afford Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PSQ18_PAY_MORE_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of how they have to pay for more of their medical care than they can afford, using a 5-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PSQ-18: Patient Satisfaction Questionnaire Short Form.  Marshall GN, Hays RD. Santa Monica, CA: RAND Corporation; 1994.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5118933</PublicId>
      <PreferredName>5118911v1.0:5118931v1.0</PreferredName>
      <PreferredDefinition>A short-form version of the 50-item Patient Satisfaction Questionnaire III designed to evaluate patient satisfaction with seven aspects of medical care._A question about whether an individual feels they have to pay for more of their medical care than they can afford._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Patient Satisfaction Questionnaire Short Form Have to Pay More of My Medical Care Than I Can Afford Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5118911</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125501</PreferredName>
        <Version>1</Version>
        <LongName>Patient Satisfaction Questionnaire Short Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125501</PREFERRED_NAME>
            <LONG_NAME>Patient Satisfaction Questionnaire Short Form</LONG_NAME>
            <CON_ID>5118591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5118931</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125511:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Have to Pay More of My Medical Care Than I Can Afford Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125511</PREFERRED_NAME>
            <LONG_NAME>Have to Pay More of My Medical Care Than I Can Afford Question</LONG_NAME>
            <CON_ID>5118659</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PSQ-18: Patient Satisfaction Questionnaire Short Form.  Marshall GN, Hays RD. Santa Monica, CA: RAND Corporation; 1994.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5118909</PublicId>
      <PreferredName>PSQ18_5PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Strongly Agree) to 5 (Strongly Disagree) on a Likert scale used on the Patient Satisfaction Questionnaire Short Form.</PreferredDefinition>
      <LongName>Patient Satisfaction Questionnaire Short Form Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>PSQ-18: Patient Satisfaction Questionnaire Short Form.  Marshall GN, Hays RD. Santa Monica, CA: RAND Corporation; 1994.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have to pay for more of my</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have to pay for more of my medical care than I can afford</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient Satisfaction Questionnaire (PSQ-18) Short Form</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 7 of 18</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5115671</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PSQ-18</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PSQ-18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5115672</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Satisfaction Questionnaire Short Form (PSQ-18)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900343</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="689">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5119419</PUBLICID>
    <LONGNAME>Cellular Therapy Product Manufacture Location Country Text Name</LONGNAME>
    <PREFERREDNAME>5109093v1.0:2542174v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Name of the country where the cellular product was manufactured.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5109093</PublicId>
      <PreferredName>5109091v1.0:2240715v1.0</PreferredName>
      <PreferredDefinition>Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._A thing produced by or resulting from a process. EXAMPLE(S): drug, device. The FDA list of regulated products: animal and human drugs; therapeutic biologics; allergenics; cell, tissue and gene therapy products; blood components; blood derivative products; devices; and animal (pets and livestock) and human food/feed (medicated and un-medicated); cosmetics; pet treats; and dietary supplements._The act of making something (a product) from raw materials._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Cellular Therapy Product Manufacture Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5109091</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70601:C51980:C43360</PreferredName>
        <Version>1</Version>
        <LongName>Cellular Therapy Product Manufacture</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70601</PREFERRED_NAME>
            <LONG_NAME>Cellular Therapy</LONG_NAME>
            <CON_ID>2688746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43360</PREFERRED_NAME>
            <LONG_NAME>Manufacture</LONG_NAME>
            <CON_ID>2236530</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25341</PreferredName>
        <Version>1</Version>
        <LongName>Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2542174</PublicId>
      <PreferredName>C25464:2542174v1.0</PreferredName>
      <PreferredDefinition>The collective generic term &quot;Country&quot; refers to a wide variety of dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. (from CIA World Factbook 2002: http://www.cia.gov/cia/publications/factbook/docs/notesanddefs.html)_The words of something written._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Country Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI Thesaurus</Origin>
      <Representation>
        <PublicId>2261898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Text Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the name of the count</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the name of the country where the cellular product was manufactured?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Country:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Country:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Country:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Country:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CTPI_ct_prd_mfr_loc_cntry</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_PI_ct_prd_mfr_loc_cntry</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:postalAddress.countryCode</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTP_CPS_ct_prd_mfr_loc_cntry</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="690">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5121420</PUBLICID>
    <LONGNAME>Decisional Conflict Scale 11QF Agreement Sure About What to Choose Indicator Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>DCSQF_SURE_CHOICE_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated indication of agreement that they feel sure about what to choose, using a 5-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCS:Decisional Conflict Scale</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5113031</PublicId>
      <PreferredName>5112971v1.0:5113029v1.0</PreferredName>
      <PreferredDefinition>A questionnaire that measures health-care consumers&#39; uncertainty in making a health-related decisions, the modifiable factors contributing to the uncertainty, and health-care consumers&#39; perceived effective decision making._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A question about an individual&#39;s assessment of whether they are or were sure about what to choose._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Decisional Conflict Scale Agreement Sure About What to Choose Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5112971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125082</PreferredName>
        <Version>1</Version>
        <LongName>Decisional Conflict Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125082</PREFERRED_NAME>
            <LONG_NAME>Decisional Conflict Scale</LONG_NAME>
            <CON_ID>5100492</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5113029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25369:C125093:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Agreement Sure About What to Choose Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125093</PREFERRED_NAME>
            <LONG_NAME>Sure About What to Choose Question</LONG_NAME>
            <CON_ID>5100503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCS:Decisional Conflict Scale</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5120271</PublicId>
      <PreferredName>DCS_IND_5PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Yes) to 4 (No) on a Likert scale used on the Decisional Conflict Scale.</PreferredDefinition>
      <LongName>Decisional Conflict Scale Indicator Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>LCC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>DCS:Decisional Conflict Scale</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3006497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Probably no</VALUEMEANING>
          <MEANINGDESCRIPTION>Having a good chance of being the case or of coming about.: The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487, C85550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Probably yes</VALUEMEANING>
          <MEANINGDESCRIPTION>Having a good chance of being the case or of coming about.: The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488, C85550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you feel sure about what t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you feel sure about what to choose?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Decisional Conflict Scale (DCS) QF</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 11 of 16</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5090651</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DCS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5090652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Decisional Conflict Scale (DCS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14888280</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="691">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5123201</PUBLICID>
    <LONGNAME>Kidney Biopsy Performed Laboratory Finding Result</LONGNAME>
    <PREFERREDNAME>3029688v1.0:2676304v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the assessment of the kidney biopsy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3029688</PublicId>
      <PreferredName>3029685v1.0:2828214v1.0</PreferredName>
      <PreferredDefinition>Removal of tissue from the kidney, for microscopic examination._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Kidney Biopsy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3029685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C51699</PreferredName>
        <Version>1</Version>
        <LongName>Kidney Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51699</PREFERRED_NAME>
            <LONG_NAME>Kidney Biopsy</LONG_NAME>
            <CON_ID>2831200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the kidney biopsy re</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the kidney biopsy result?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Kidney</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Kidney</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Kidney</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Kidney</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_OF_kidney_bx_result</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="692">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5126415</PUBLICID>
    <LONGNAME>Negation Corticosteroid Immunosuppressive Therapy Administered Indicator</LONGNAME>
    <PREFERREDNAME>5126414v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a non-steroid immunosuppressive therapy was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5126414</PublicId>
      <PreferredName>5126412v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>An operation in which a term denies or inverts the meaning of another term or construction._Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation)._Therapy used to decrease the body&#39;s immune response, such as drugs given to prevent transplant rejection._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Negation Corticosteroid Immunosuppressive Therapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5126412</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C2322:C15261</PreferredName>
        <Version>1</Version>
        <LongName>Negation Corticosteroid Immunosuppressive Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2322</PREFERRED_NAME>
            <LONG_NAME>Corticosteroid</LONG_NAME>
            <CON_ID>2202884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15261</PREFERRED_NAME>
            <LONG_NAME>Immunosuppressive Therapy</LONG_NAME>
            <CON_ID>2202362</CON_ID>
            <DEFINITION_SOURCE>CSP2000</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a non-steroid immunosuppr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a non-steroid immunosuppressive therapy administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="693">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5145123</PUBLICID>
    <LONGNAME>Patient Ineligibility Timeline Bound Clinical Trial Participation Data Unknown Text</LONGNAME>
    <PREFERREDNAME>INELIGTIMELIMIT</PREFERREDNAME>
    <PREFERREDDEFINITION>A checkbox for information related to a patient&#39;s ineligibility to participate in a clinical trial due to timelines being exceeded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5145099</PublicId>
      <PreferredName>INELIGTIMELIMIT</PreferredName>
      <PreferredDefinition>Information related to a patient&#39;s ineligibility to participate in a clinical trial due to timelines being exceeded.</PreferredDefinition>
      <LongName>Patient Ineligibility Timeline Bound Clinical Trial Participation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5145097</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5145097v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Ineligibility Timeline Bound Clinical Trial Participation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40412</PREFERRED_NAME>
            <LONG_NAME>Ineligibility</LONG_NAME>
            <CON_ID>2204007</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54576</PREFERRED_NAME>
            <LONG_NAME>Timeline</LONG_NAME>
            <CON_ID>2523390</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70987</PREFERRED_NAME>
            <LONG_NAME>Bound</LONG_NAME>
            <CON_ID>2707893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71104</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial</LONG_NAME>
            <CON_ID>2735720</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25608</PREFERRED_NAME>
            <LONG_NAME>Participation</LONG_NAME>
            <CON_ID>2206339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200608</PublicId>
      <PreferredName>DATA_UNKNOWN_TEXT</PreferredName>
      <PreferredDefinition>a single character text field to record data.</PreferredDefinition>
      <LongName>Data Unknown Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ineligible, outside of enroll</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ineligible, outside of enrollment window</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="694">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5151978</PUBLICID>
    <LONGNAME>Viral Transfection Performed Indicator</LONGNAME>
    <PREFERREDNAME>5151977v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not viral transfection was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5151977</PublicId>
      <PreferredName>5232779v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Having to do with a virus._The process of introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cell&#39;s chromosomal DNA, so that the cells or progeny may express the integrated donor gene._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Viral Transfection Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5232779</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C27985:C17209</PreferredName>
        <Version>1</Version>
        <LongName>Viral Transfection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27985</PREFERRED_NAME>
            <LONG_NAME>Viral</LONG_NAME>
            <CON_ID>2205414</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17209</PREFERRED_NAME>
            <LONG_NAME>Transfection</LONG_NAME>
            <CON_ID>2673222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was viral transfection perfor</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was viral transfection performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Viral transfection</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Viral transfection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Viral transfection</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Viral transfection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CPM_viral_tranfection_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="695">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5152074</PUBLICID>
    <LONGNAME>Genetic Modification Performed Indicator</LONGNAME>
    <PREFERREDNAME>5152073v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not genetic modification was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5152073</PublicId>
      <PreferredName>5152071v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Techniques used for deliberately altering the genetic material of an organism in order to make them capable of making new substances or performing new or different functions._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Genetic Modification Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5152071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C22489</PreferredName>
        <Version>1</Version>
        <LongName>Organism Modification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C22489</PREFERRED_NAME>
            <LONG_NAME>Organism Modification</LONG_NAME>
            <CON_ID>2673209</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was genetic modification perf</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was genetic modification performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genetic manipulation</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Genetic manipulation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genetic manipulation</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Genetic manipulation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the product genetically modified?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the product genetically modified?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CPM_mth_genetic_manip_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="696">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5159874</PUBLICID>
    <LONGNAME>Other Adverse Event Occurrence Specify Text</LONGNAME>
    <PREFERREDNAME>5159872v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field that describes another adverse event that occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5159872</PublicId>
      <PreferredName>2733213v1.0:2234856v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Other Adverse Event Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2733213</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C41331</PreferredName>
        <Version>1</Version>
        <LongName>Other Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was another adverse even</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was another adverse event that occurred?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other side effect:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other side effect:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other side effect:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other side effect:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VOD_THPY_oth_side_eff_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="697">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5189676</PUBLICID>
    <LONGNAME>Human Activity Profile 41 Shopping by Yourself 3 Point Scale</LONGNAME>
    <PREFERREDNAME>HAP_Q41_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of their ability to shop by themselves, using a three point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5188944</PublicId>
      <PreferredName>5188571v1.0:5188942v1.0</PreferredName>
      <PreferredDefinition>A self-administered instrument designed to measure energy expenditure or physical fitness. It was originally developed to measure quality of life achieved by patients in rehabilitation programs for chronic obstructive pulmonary disease, but has also been used as a measure of physical activity in both healthy and impaired populations. The profile consists of 94 common daily activities listed in ascending order according to the energy required to perform them. Activities including self-care tasks, personal/household work, entertainment/social activities, and independent exercise pursuits and respondents are requested to indicate if they are currently able to perform the activity (unassisted), they have stopped performing the activity, or they have never performed the activity._A question about an individual&#39;s ability to shop alone.</PreferredDefinition>
      <LongName>Human Activity Profile Shopping by Yourself</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5188571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48948</PreferredName>
        <Version>1</Version>
        <LongName>Human Activity Profile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48948</PREFERRED_NAME>
            <LONG_NAME>Human Activity Profile</LONG_NAME>
            <CON_ID>5168044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5188942</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126177</PreferredName>
        <Version>1</Version>
        <LongName>Shopping by Yourself</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126177</PREFERRED_NAME>
            <LONG_NAME>Shopping by Yourself Question</LONG_NAME>
            <CON_ID>5168142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5188567</PublicId>
      <PreferredName>HAP_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>HAP Activity 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>32</MaximumLength>
      <MinimumLength>23</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never Did This Activity</VALIDVALUE>
          <VALUEMEANING>Never Did This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is never did an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Have Stopped Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Have Stopped Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has stopped doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Still Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Still Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is still doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Shopping (by yourself)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Shopping (by yourself)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Human Activity Profile (HAP)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 41 of 94</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5187973</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HAP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HAP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5187974</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Human Activity Profile (HAP)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900309</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="698">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5189798</PUBLICID>
    <LONGNAME>Human Activity Profile 63 Walking 1 Mile 3 Point Scale</LONGNAME>
    <PREFERREDNAME>HAP_Q63_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of their ability to walk 1 mile, using a three point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5189147</PublicId>
      <PreferredName>5188571v1.0:5189145v1.0</PreferredName>
      <PreferredDefinition>A self-administered instrument designed to measure energy expenditure or physical fitness. It was originally developed to measure quality of life achieved by patients in rehabilitation programs for chronic obstructive pulmonary disease, but has also been used as a measure of physical activity in both healthy and impaired populations. The profile consists of 94 common daily activities listed in ascending order according to the energy required to perform them. Activities including self-care tasks, personal/household work, entertainment/social activities, and independent exercise pursuits and respondents are requested to indicate if they are currently able to perform the activity (unassisted), they have stopped performing the activity, or they have never performed the activity._A question about an individual&#39;s ability to walk 1 mile.</PreferredDefinition>
      <LongName>Human Activity Profile Walking 1 Mile</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5188571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48948</PreferredName>
        <Version>1</Version>
        <LongName>Human Activity Profile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48948</PREFERRED_NAME>
            <LONG_NAME>Human Activity Profile</LONG_NAME>
            <CON_ID>5168044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5189145</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126199</PreferredName>
        <Version>1</Version>
        <LongName>Walking 1 Mile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126199</PREFERRED_NAME>
            <LONG_NAME>Walking 1 Mile Question</LONG_NAME>
            <CON_ID>5168254</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5188567</PublicId>
      <PreferredName>HAP_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>HAP Activity 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>32</MaximumLength>
      <MinimumLength>23</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never Did This Activity</VALIDVALUE>
          <VALUEMEANING>Never Did This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is never did an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Have Stopped Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Have Stopped Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has stopped doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Still Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Still Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is still doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Walking 1 mile</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Walking 1 mile</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Human Activity Profile (HAP)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 63 of 94</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5187973</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HAP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HAP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5187974</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Human Activity Profile (HAP)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900309</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="699">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5205574</PUBLICID>
    <LONGNAME>Person Imaging Procedure Contraindicated Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>IMG_CNTRD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response as to whether any method of imaging is considered unsuitable or inadvisable as outlined in the study protocol, to allow a patient to participate in the clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5205593</PublicId>
      <PreferredName>2236731v1.0:5205591v1.0</PreferredName>
      <PreferredDefinition>A human being._Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person Imaging Technique Contraindicated Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5205591</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17369:C37933:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technique Contraindicated Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17369</PREFERRED_NAME>
            <LONG_NAME>Imaging Procedure</LONG_NAME>
            <CON_ID>2713347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37933</PREFERRED_NAME>
            <LONG_NAME>Contraindicated</LONG_NAME>
            <CON_ID>2203882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is patient unable to undergo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is patient unable to undergo an MRI or is otherwise contraindicated (e.g. presence of errant metal, cardiac pacemakers, pain pumps or other MRI incompatible devices; or history of claustrophobia or anxiety related to undergoing MRI)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is there any contraindication to MRI (i.e. patients with pacemakers or other metal implanted medical devices)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient unable to get MRIs due to any reason including pacemakers or AICD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a contraindication to MR imaging such as implanted metal devices or foreign bodies, or contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient unable to undergo MRI and/or contraindication for MRI examinations following the MRI protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Data (including serologic/viral status)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="700">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5211070</PUBLICID>
    <LONGNAME>Lung Tumor Histologic Classification Other Specify</LONGNAME>
    <PREFERREDNAME>LNG_HX_CLASS_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of tumor submitted/identified upon slide review that has not been previously listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2189077</PublicId>
      <PreferredName>LUNG_TUMO_HIST_CLASS</PreferredName>
      <PreferredDefinition>information related to the lung tumor histologic classification or category.</PreferredDefinition>
      <LongName>Lung Tumor Histologic Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206550</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Lung Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histologic Type - other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Histologic Type - other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung Local Path Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="701">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5214777</PUBLICID>
    <LONGNAME>Sedative and Hypnotic Agent Preoperative Intravenous Administration Other Specify</LONGNAME>
    <PREFERREDNAME>SEDAGT_PREOP_IV_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the sedation drug(s) or medicine(s) administered intravenously prior to surgery in order to induce total or partial loss of sensation especially tactile sensation and pain that has not been previously listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5211094</PublicId>
      <PreferredName>5211095v1.0:5211092v1.0</PreferredName>
      <PreferredDefinition>Any agent that depresses the central nervous system (CNS) and is used to induce calm and sleep._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Relating to or occurring during the period immediately before a surgical operation._Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</PreferredDefinition>
      <LongName>Sedative and Hypnotic Agent Preoperative Intravenous Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5211095</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29756:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Sedative and Hypnotic Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29756</PREFERRED_NAME>
            <LONG_NAME>Sedative and Hypnotic</LONG_NAME>
            <CON_ID>3269838</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5211092</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C13346:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Intravenous Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13346</PREFERRED_NAME>
            <LONG_NAME>Intravenous</LONG_NAME>
            <CON_ID>2450528</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pre-operative IV Sedation adm</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pre-operative IV Sedation administered - other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colon Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736432</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Kidney Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736434</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovary Sugery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736435</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="702">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5216293</PUBLICID>
    <LONGNAME>Patient Informed Consent Witness Date</LONGNAME>
    <PREFERREDNAME>INF_CONS_WITNESS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which the candidate&#39;s consent was witnessed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5215979</PublicId>
      <PreferredName>2177068v1.0:5215977v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved._To attest to the genuineness of a document or signature.</PreferredDefinition>
      <LongName>Patient Informed Consent Witness</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5215977</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16735:C126368</PreferredName>
        <Version>1</Version>
        <LongName>Informed Consent Witness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16735</PREFERRED_NAME>
            <LONG_NAME>Informed Consent</LONG_NAME>
            <CON_ID>2202451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126368</PREFERRED_NAME>
            <LONG_NAME>Witness</LONG_NAME>
            <CON_ID>5209162</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Witness of Consent</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Witness of Consent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CPTAC-Consent-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Witness of Consent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate Consent and Enrollment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736416</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>All Generic CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6776734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000181</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCCPR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCCPR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="703">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5227602</PUBLICID>
    <LONGNAME>Block Section Thickness Other Specify</LONGNAME>
    <PREFERREDNAME>BLOCK_SEC_THICK_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The thickness of the section measured in micrometers that has not been previously listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5219698</PublicId>
      <PreferredName>5219691v1.0:3021162v1.0</PreferredName>
      <PreferredDefinition>Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining._A very thin slice (of tissue or mineral or other substance) for examination under a microscope._The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.</PreferredDefinition>
      <LongName>Block Section Thickness</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5219691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25436</PreferredName>
        <Version>1</Version>
        <LongName>Block</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25436</PREFERRED_NAME>
            <LONG_NAME>Fixed Block</LONG_NAME>
            <CON_ID>2203894</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3021162</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25668:C41145</PreferredName>
        <Version>1</Version>
        <LongName>Section Thickness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25668</PREFERRED_NAME>
            <LONG_NAME>Section</LONG_NAME>
            <CON_ID>2202808</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41145</PREFERRED_NAME>
            <LONG_NAME>Thickness</LONG_NAME>
            <CON_ID>2413316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify Other section thickne</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify Other section thickness</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FFPE Section-Stain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="704">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5227843</PUBLICID>
    <LONGNAME>Biospecimen Collection PAXgene Blood DNA Tube Barcode Identifier</LONGNAME>
    <PREFERREDNAME>PAX_BLOD_DNA_BCD_ID</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of characters that specifically identifies a particular DNA PAXgene tube.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5226457</PublicId>
      <PreferredName>2715159v1.0:5226455v1.0</PreferredName>
      <PreferredDefinition>The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes._A blood collection tube that uses proprietary reagents for whole blood collection and stabilization prior to genomic DNA isolation._A machine-readable representation of information in a visual format on a surface._A machine-readable representation of information in a visual format on a surface.</PreferredDefinition>
      <LongName>Biospecimen Collection PAXgene Blood DNA Tube Barcode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2715159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70945</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70945</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Collection</LONG_NAME>
            <CON_ID>2714902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5226455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126393:C43361</PreferredName>
        <Version>1</Version>
        <LongName>PAXgene Blood DNA Tube Barcode</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126393</PREFERRED_NAME>
            <LONG_NAME>PAXgene Blood DNA Tube</LONG_NAME>
            <CON_ID>5209223</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43361</PREFERRED_NAME>
            <LONG_NAME>Barcode</LONG_NAME>
            <CON_ID>2236527</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018694</PublicId>
      <PreferredName>ID</PreferredName>
      <PreferredDefinition>One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177869</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Identifier</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DNA PAXgene tube Specimen Bar</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>DNA PAXgene tube Specimen Barcode ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Blood Collection and Processing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="705">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5230156</PUBLICID>
    <LONGNAME>Biospecimen Tissue Collection And Processing Standard Operating Procedure Additional Tissue Variation Text</LONGNAME>
    <PREFERREDNAME>COL_PROC_SOP_ADT_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The description of deviations that occurred in processing additional tissue specimens from the BPV biospecimen tissue collection and processing standard operating procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5228939</PublicId>
      <PreferredName>2859635v1.0:5228937v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The act of gathering things together; having been brought together in one place._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The act of preparing or putting through a prescribed procedure._An established procedure to be followed in carrying out a given operation or in a given situation._Added; extra; further._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._An alteration or difference from a norm or standard.</PreferredDefinition>
      <LongName>Biospecimen Tissue Collection And Processing Standard Operating Procedure Additional Tissue Variation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5228937</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5228937v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Collection And Processing Standard Operating Procedure Additional Tissue Variation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48177</PREFERRED_NAME>
            <LONG_NAME>Processing</LONG_NAME>
            <CON_ID>2422623</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48443</PREFERRED_NAME>
            <LONG_NAME>Standard Operating Procedure</LONG_NAME>
            <CON_ID>2612106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015802</PublicId>
      <PreferredName>COM_TXT</PreferredName>
      <PreferredDefinition>The free text field for general notes.</PreferredDefinition>
      <LongName>Comments Text</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>800</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comments/issues with tissue r</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Comments/issues with tissue receipt or deviations from SOP</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Processing Wksht</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="706">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5235926</PUBLICID>
    <LONGNAME>Tissue Donor State Run Group Therapy Home Resident Indicator</LONGNAME>
    <PREFERREDNAME>DON_ST_GRPTX_HOM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication of whether the donor was a resident of a state run group home at time of death as provided by the primary history source.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5234613</PublicId>
      <PreferredName>2512816v1.0:5234611v1.0</PreferredName>
      <PreferredDefinition>Someone who gives blood or tissue or an organ to be used in another person._A constituent administrative district of a nation._The act of testing or performing something._A form of psychiatric treatment in which six to eight patients meet a specific number of times with a therapist.  The value of this type of therapy is the opportunity for gaining insight from others into one&#39;s life experience. (Taber&#39;s)_A person&#39;s permanent place of residence._Someone who lives at a particular place for a prolonged period or who was born there.</PreferredDefinition>
      <LongName>Tissue Donor State Run Group Therapy Home Resident</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512816</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25168</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Donor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25168</PREFERRED_NAME>
            <LONG_NAME>Tissue Donor</LONG_NAME>
            <CON_ID>2202520</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5234611</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5234611v1.0</PreferredName>
        <Version>1</Version>
        <LongName>State Run Group Therapy Home Resident</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87194</PREFERRED_NAME>
            <LONG_NAME>State</LONG_NAME>
            <CON_ID>3012612</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47911</PREFERRED_NAME>
            <LONG_NAME>Run</LONG_NAME>
            <CON_ID>2422617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21042</PREFERRED_NAME>
            <LONG_NAME>Group Therapy</LONG_NAME>
            <CON_ID>2922987</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18002</PREFERRED_NAME>
            <LONG_NAME>Home</LONG_NAME>
            <CON_ID>2205248</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71416</PREFERRED_NAME>
            <LONG_NAME>Resident</LONG_NAME>
            <CON_ID>5234610</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>A resident of a state run gro</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>A resident of a state run group home at time of death</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GTEx - Postmortem Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Donor Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="707">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5236199</PUBLICID>
    <LONGNAME>Tissue Donor Multiple Sclerosis Personal Medical History Indicator</LONGNAME>
    <PREFERREDNAME>TDON_MULT_SCLERO_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication of whether the donor has a history of  multiple sclerosis as provided by the primary history source.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5234637</PublicId>
      <PreferredName>2512816v1.0:5234635v1.0</PreferredName>
      <PreferredDefinition>Someone who gives blood or tissue or an organ to be used in another person._A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.</PreferredDefinition>
      <LongName>Tissue Donor Multiple Sclerosis Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512816</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25168</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Donor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25168</PREFERRED_NAME>
            <LONG_NAME>Tissue Donor</LONG_NAME>
            <CON_ID>2202520</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5234635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3243:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Multiple Sclerosis Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3243</PREFERRED_NAME>
            <LONG_NAME>Multiple Sclerosis</LONG_NAME>
            <CON_ID>2534890</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>History of MS (multiple scler</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>History of MS (multiple sclerosis)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GTEx - Postmortem Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Donor Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="708">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5243282</PUBLICID>
    <LONGNAME>Biospecimen Brain Aliquot Preparation End Time</LONGNAME>
    <PREFERREDNAME>BIO_BRN_PREP_ENDTIM</PREFERREDNAME>
    <PREFERREDDEFINITION>The time at which brain aliquot preparation ended.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5396559</PublicId>
      <PreferredName>2859635v1.0:5396557v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium._Pertaining to a portion of the whole; any one of two or more samples of something, of the same volume or weight._The act or process of making something ready.</PreferredDefinition>
      <LongName>Biospecimen Brain Aliquot Preparation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5396557</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12439:C25414:C25625</PreferredName>
        <Version>1</Version>
        <LongName>Brain Aliquot Preparation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12439</PREFERRED_NAME>
            <LONG_NAME>Brain</LONG_NAME>
            <CON_ID>2202698</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25414</PREFERRED_NAME>
            <LONG_NAME>Aliquot</LONG_NAME>
            <CON_ID>2202438</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25625</PREFERRED_NAME>
            <LONG_NAME>Preparation</LONG_NAME>
            <CON_ID>2202599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201278</PublicId>
      <PreferredName>END_TM</PreferredName>
      <PreferredDefinition>the time a procedure or assessment ended.</PreferredDefinition>
      <LongName>End Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>End Brain Aliquot Prep</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>End Brain Aliquot Prep</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GTEx - Postmortem Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188871</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GTEx - Postmortem Biospecimen </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Recovery Case Report</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736405</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="709">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5270400</PUBLICID>
    <LONGNAME>Reduced Skin Flap Survival Yes No Indicator</LONGNAME>
    <PREFERREDNAME>5270399v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for a continuance of life or existence especially under adverse conditions of a type of reconstruction, in which a flap of tissue is surgically moved from another area of the body, is less in size or amount.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5270399</PublicId>
      <PreferredName>5270396v1.0:5270397v1.0</PreferredName>
      <PreferredDefinition>A continuance of life or existence especially under adverse conditions of a type of reconstruction, in which a flap of tissue is surgically moved from another area of the body, is less in size or amount.</PreferredDefinition>
      <LongName>Reduced Skin Flap Survival</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008573</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5270396</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25640</PreferredName>
        <Version>1</Version>
        <LongName>Reduced</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5270397</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12470:C93317:C17177</PreferredName>
        <Version>1</Version>
        <LongName>Skin Tissue Flap Reconstruction Survival</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93317</PREFERRED_NAME>
            <LONG_NAME>Tissue Flap Breast Reconstruction</LONG_NAME>
            <CON_ID>3645730</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17177</PREFERRED_NAME>
            <LONG_NAME>Survival</LONG_NAME>
            <CON_ID>2202477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reduced skin flap survival</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reduced skin flap survival</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="710">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5273381</PUBLICID>
    <LONGNAME>CRQ-SAS 16 Last 2 Weeks How Often Feel Discouraged or Down in Dumps Score 7 Point Scale</LONGNAME>
    <PREFERREDNAME>CRQSAS_Q16_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation in the last 2 weeks of how often they felt discouraged or down in the dumps, using an 7 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CRQ-SAS:Chronic Respiratory Questionnaire Self-Administered Standardized Format, Peggy Austin, Dr. Holger J. Schünemann, Dr. Gordon H. Guyatt, Department of Clinical Epidemiology and Biostatistics, February 2006.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5273335</PublicId>
      <PreferredName>5273271v1.0:5273333v1.0</PreferredName>
      <PreferredDefinition>A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation._A period of time consisting of the 14 days before the present._A question about the frequency of an event or behavior._A question about an individual feeling discouraged or down in the dumps._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Chronic Respiratory Questionnaire Self-Administered Standardized Format Past 2 Weeks How Often Feel Discouraged or Down in Dumps Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5273271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126891</PreferredName>
        <Version>1</Version>
        <LongName>Chronic Respiratory Questionnaire Self-Administered Standardized Format</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126891</PREFERRED_NAME>
            <LONG_NAME>Chronic Respiratory Questionnaire Self-Administered Standardized Format</LONG_NAME>
            <CON_ID>5271352</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5273333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126890:C118873:C126921:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past 2 Weeks How Often Feel Discouraged or Down in Dumps Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126890</PREFERRED_NAME>
            <LONG_NAME>Past 2 Weeks</LONG_NAME>
            <CON_ID>5271604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118873</PREFERRED_NAME>
            <LONG_NAME>How Often Question</LONG_NAME>
            <CON_ID>4615091</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126921</PREFERRED_NAME>
            <LONG_NAME>Feel Discouraged or Down in Dumps Question</LONG_NAME>
            <CON_ID>5271446</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5273211</PublicId>
      <PreferredName>TIME_7PT_SCL</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>How Much Time Score 7 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>7</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Hardly at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something occurs rarely or with very little intensity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4267061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3875586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Most of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3875587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>A Good Bit of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened a good bit of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Some of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened some of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3875588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>A Little of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened a little of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3875589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>None of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened none of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3875590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In general, how often during</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In general, how often during the LAST 2 WEEKS have you felt discouraged or down in the dumps?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5273171</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRQ-SAS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CRQ-SAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5273172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Chronic Respiratory Questionnaire Self-Administered Standardized (CRQ-SAS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14888198</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="711">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5285102</PUBLICID>
    <LONGNAME>Laboratory Procedure Serum Cortisol Result Value</LONGNAME>
    <PREFERREDNAME>LAB_CORT_OC_UNS_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of serum cortisol laboratory measurement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5285096</PublicId>
      <PreferredName>2543047v1.0:5285094v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins._The determination of the amount of cortisol present in a sample._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure Serum Cortisol Measurement Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5285094</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13325:C74781:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Serum Cortisol Measurement Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13325</PREFERRED_NAME>
            <LONG_NAME>Serum</LONG_NAME>
            <CON_ID>2203797</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74781</PREFERRED_NAME>
            <LONG_NAME>Cortisol Measurement</LONG_NAME>
            <CON_ID>5285093</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5285222</PublicId>
      <PreferredName>5285222v1.0</PreferredName>
      <PreferredDefinition>Not stated explicitly or in detail._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>3, 1 Unspecified Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2586710</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cortisol, serum</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cortisol, serum</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lab Value</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="712">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5285751</PUBLICID>
    <LONGNAME>Cancer Patient Tobacco Use Questionnaire 1 Smoked at Least 100 Cigarettes in Entire Life Indicator</LONGNAME>
    <PREFERREDNAME>CTUQ_Q1_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of whether or not they have smoked at least 100 cigarettes in their entire life, where 5 packs is equal to 100 cigarettes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C-TUQ:Cancer Patient Tobacco Use Questionnaire. NCI-AACR Cancer Patient Tobacco Use Assessment Task Force, 6/19/2015</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5285226</PublicId>
      <PreferredName>5285223v1.0:5285224v1.0</PreferredName>
      <PreferredDefinition>A questionnaire developed for the baseline and longitudinal assessment of tobacco use in the cancer setting. Domains include cigarette smoking history and current use, use relative to cancer diagnosis and treatment, other tobacco product use, cessation, and second-hand exposure._A question about whether an individual has smoked at least 100 cigarettes in their entire lifetime.</PreferredDefinition>
      <LongName>Cancer Patient Tobacco Use Questionnaire Smoked at Least 100 Cigarettes in Entire Life</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5285223</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C127024</PreferredName>
        <Version>1</Version>
        <LongName>Cancer Patient Tobacco Use Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C127024</PREFERRED_NAME>
            <LONG_NAME>Cancer Patient Tobacco Use Questionnaire</LONG_NAME>
            <CON_ID>5279991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5285224</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C127059</PreferredName>
        <Version>1</Version>
        <LongName>Smoked at Least 100 Cigarettes in Entire Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C127059</PREFERRED_NAME>
            <LONG_NAME>Smoked at Least 100 Cigarettes in Entire Life Question</LONG_NAME>
            <CON_ID>5279992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>C-TUQ:Cancer Patient Tobacco Use Questionnaire. NCI-AACR Cancer Patient Tobacco Use Assessment Task Force, 6/19/2015</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194710</PublicId>
      <PreferredName>SMOK_IND</PreferredName>
      <PreferredDefinition>An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Smoking Indicator</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2194906</PublicId>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Ind-4</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable; I have not smoked cigarettes since my diagnosis.</VALIDVALUE>
          <VALUEMEANING>Not Applicable Have Not Smoked Since Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.: A response indicating that an individual has not smoked since they have been diagnosed with cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127036, C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5285931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refused</VALIDVALUE>
          <VALUEMEANING>Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>To decline to do, accept, give, or allow something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t Know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t know/Not sure</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know or Not Sure When Smoked a Cigarette</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual doesn&#39;t know or is not sure whether they smoked a cigarette.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5285166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>C-TUQ Question Sequence</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>1 of 47</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value sets in order to retain the validity and reliability associated with the measure. Changes may not be made to these CDEs.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you smoked at least 100</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you smoked at least 100 cigarettes (5 packs=100 cigarettes) in your entire life?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C-TUQ (Cancer Patient Tobacco Use Questionnaire)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5285152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="713">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5292951</PUBLICID>
    <LONGNAME>Past Menstrual Cycle Regular Duration</LONGNAME>
    <PREFERREDNAME>PAST_MENS_CYCLE_REG_DURA</PREFERREDNAME>
    <PREFERREDDEFINITION>Pattern of the recurring menstrual cycle. A description of the reproductive status of a woman as indicated by start of menopause.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183228</PublicId>
      <PreferredName>MENS_CYCLE_REG</PreferredName>
      <PreferredDefinition>Pattern of the recurring menstrual cycle.</PreferredDefinition>
      <LongName>Menstrual Cycle Regularity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2183225</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Menstrual Cycle</PreferredName>
        <Version>1</Version>
        <LongName>Menstrual Cycle</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0025329</PREFERRED_NAME>
            <LONG_NAME>Menstrual Cycle</LONG_NAME>
            <CON_ID>2202943</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2183226</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Regular</PreferredName>
        <Version>1</Version>
        <LongName>Regular</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0814444</PREFERRED_NAME>
            <LONG_NAME>Regular</LONG_NAME>
            <CON_ID>2204114</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5291212</PublicId>
      <PreferredName>PAST_MENS_DURA</PreferredName>
      <PreferredDefinition>A description of the reproductive status of a woman as indicated by start of menopause.A condition or state at a particular time.</PreferredDefinition>
      <LongName>Past Menstrual Cycle Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>155</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>5292971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25609:C16838:C25330</PreferredName>
        <Version>1</Version>
        <LongName>Past Menstrual Cycle Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16838</PREFERRED_NAME>
            <LONG_NAME>Menstrual Cycle</LONG_NAME>
            <CON_ID>2202740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less often than once every 12 months</VALIDVALUE>
          <VALUEMEANING>Less Than Once Every Twelve Month</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: One time.: Including all possibilities or occurring at regular intervals.: A natural number greater than 11 and less than 13 and the quantity that it denotes.: One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C113426, C64651, C64576, C61585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Once every 6-12 months</VALIDVALUE>
          <VALUEMEANING>Once Every Six To Twelve Month</VALUEMEANING>
          <MEANINGDESCRIPTION>One time.: Including all possibilities or occurring at regular intervals.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 11 and less than 13 and the quantity that it denotes.: One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C113426, C65107, C66837, C64651, C64576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>At least once every month</VALIDVALUE>
          <VALUEMEANING>Once monthly</VALUEMEANING>
          <MEANINGDESCRIPTION>One time._Every month.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64498, C64576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Once every 2 months</VALIDVALUE>
          <VALUEMEANING>Once Every Two Months</VALUEMEANING>
          <MEANINGDESCRIPTION>One time.: Every two months.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64536, C64576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Once every 2-6 months</VALIDVALUE>
          <VALUEMEANING>Once Every Two To Six Month</VALUEMEANING>
          <MEANINGDESCRIPTION>One time.: Including all possibilities or occurring at regular intervals.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C66837, C65107, C66833, C64651, C64576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>On average in the past 6 mont</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>On average in the past 6 months, how often did you have your menstrual period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="714">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5296513</PUBLICID>
    <LONGNAME>Head and Neck Surgery Specific Complication Postoperative Fistula Other Specify Text</LONGNAME>
    <PREFERREDNAME>HNSS_OTHR_FISTL_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that describes another postoperative fistula complication specific to head and neck surgery not previously mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5294544</PublicId>
      <PreferredName>5294247v1.0:5294542v1.0</PreferredName>
      <PreferredDefinition>Any surgery involving a structure in the head and neck region._Clearly and explicitly stated._Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure._Different than the one(s) previously specified or mentioned._Relating to or occurring during the period immediately following a surgical operation._Abnormal epithelial-lined communication between two anatomical structures.</PreferredDefinition>
      <LongName>Head and Neck Surgery Specified Complication Other Postoperative Fistula</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5294247</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15454:C38024:C2959</PreferredName>
        <Version>1</Version>
        <LongName>Head and Neck Surgery Specified Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15454</PREFERRED_NAME>
            <LONG_NAME>Head and Neck Surgery</LONG_NAME>
            <CON_ID>5294113</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38024</PREFERRED_NAME>
            <LONG_NAME>Specified</LONG_NAME>
            <CON_ID>2211671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2959</PREFERRED_NAME>
            <LONG_NAME>Complication</LONG_NAME>
            <CON_ID>2203884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5294542</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C28006:C3045</PreferredName>
        <Version>1</Version>
        <LongName>Other Postoperative Fistula</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28006</PREFERRED_NAME>
            <LONG_NAME>Postoperative</LONG_NAME>
            <CON_ID>2211921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3045</PREFERRED_NAME>
            <LONG_NAME>Fistula</LONG_NAME>
            <CON_ID>2203643</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other (specify:)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other (specify:)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5294254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HNCTT</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNCTT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5294255</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="715">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5334268</PUBLICID>
    <LONGNAME>Date form completed</LONGNAME>
    <PREFERREDNAME>2013942v1.0:5332931v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Determination of the date of the Summary of Initial Report (SIR) form.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AHRQ</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AHRQ:AHRQ Common Formats</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013942</PublicId>
      <PreferredName>FORM_COMP</PreferredName>
      <PreferredDefinition>the completion of data collection for the CRF.</PreferredDefinition>
      <LongName>Case Report Form Complete</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2542290</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40988</PreferredName>
        <Version>1</Version>
        <LongName>Case Report Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40988</PREFERRED_NAME>
            <LONG_NAME>Case Report Form</LONG_NAME>
            <CON_ID>2202500</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2405014</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250</PreferredName>
        <Version>1</Version>
        <LongName>Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5332931</PublicId>
      <PreferredName>5332931v1.0</PreferredName>
      <PreferredDefinition>A data type comprised of a date and time value that corresponds with a specific point in the time continuum._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Point in Time Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>HL7TSv3</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AHRQ:AHRQ Common Formats</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the date of the summa</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the date of the summary of the initial report?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HERF|74495-3</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Healthcare Event Reporting Form|Patient safety event report - hospital: healthcare event reporting form (HERF) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;93&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PIF|74502-6</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Healthcare Event Reporting Form|Patient safety event report - hospital: patient information form (PIF) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;94&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SIR|74501-8</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Healthcare Event Reporting Form|Patient safety event report - hospital: summary of initial report (SIR) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;95&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DEVICE|74725-3</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Healthcare Event Reporting Form|Patient safety event report - hospital: device or medical AndOr surgical supply, including health information technology (HIT) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;97&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MEDICATION|74080-3</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Healthcare Event Reporting Form|Patient safety event report - hospital: medication or other substance - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;100&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Initial Report Date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Initial Report Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Report Date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AHRQ Alternate question text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the date of the summary of the initial report?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the date of the summary of the initial report?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PIF 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HERF 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SIR 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MEDICATION 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406431</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DEVICE 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406432</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DE75</AlternateName>
        <AlternateNameType>AHRQ Identifier</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DE30</AlternateName>
        <AlternateNameType>AHRQ Identifier</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="716">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5334793</PUBLICID>
    <LONGNAME>Anticipated duration of harm to the patient</LONGNAME>
    <PREFERREDNAME>5326430v1.0:5333791v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Determination of the anticipated duration of the harm to the patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AHRQ</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AHRQ:AHRQ Common Formats</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5326430</PublicId>
      <PreferredName>5326428v1.0</PreferredName>
      <PreferredDefinition>No Value Exists</PreferredDefinition>
      <LongName>Anticipated duration of harm to the patient</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5326428</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>74559-6</PreferredName>
        <Version>1</Version>
        <LongName>Anticipated duration of harm to the patient:Find:Pt:^Patient:Ord:AHRQ</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>74559-6</PREFERRED_NAME>
            <LONG_NAME>Anticipated duration of harm to the patient:Find:Pt:^Patient:Ord:AHRQ</LONG_NAME>
            <CON_ID>5326427</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>LOINC_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7318108</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C42605</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Property</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42605</PREFERRED_NAME>
            <LONG_NAME>Property</LONG_NAME>
            <CON_ID>2231569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AHRQ:AHRQ Common Formats</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5333791</PublicId>
      <PreferredName>5333791v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Anticipated duration of harm Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>HL7CDv3</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AHRQ:AHRQ Common Formats</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A192</VALIDVALUE>
          <VALUEMEANING>Permanent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not expected to revert to approximately normal (i.e., patient&#39;s baseline)(AHRQ)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>LA20750-8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>LOINC</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5333794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A194</VALIDVALUE>
          <VALUEMEANING>Temporary</VALUEMEANING>
          <MEANINGDESCRIPTION>No Value Exists</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>LA20751-6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5333793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNK</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the anticipated durat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the anticipated duration of the harm to the patient?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PIF|74502-6</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>AHRQ Patient Information Form|Patient safety event report - hospital: patient information form (PIF) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;94&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PIF 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DE59</AlternateName>
        <AlternateNameType>AHRQ Identifier</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="717">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5334892</PUBLICID>
    <LONGNAME>Medication or other substance was involved</LONGNAME>
    <PREFERREDNAME>5330222v1.0:5333451v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Determination if the event or unsafe condition involved a medication or other substance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AHRQ</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AHRQ:AHRQ Common Formats</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5330222</PublicId>
      <PreferredName>5330220v1.0</PreferredName>
      <PreferredDefinition>No Value Exists</PreferredDefinition>
      <LongName>Medication or other substance was involved</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5330220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>74707-1</PreferredName>
        <Version>1</Version>
        <LongName>Medication or other substance was involved:Find:Pt:^Event:Ord:AHRQ</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>74707-1</PREFERRED_NAME>
            <LONG_NAME>Medication or other substance was involved:Find:Pt:^Event:Ord:AHRQ</LONG_NAME>
            <CON_ID>5330219</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>LOINC_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7318108</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C42605</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Property</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42605</PREFERRED_NAME>
            <LONG_NAME>Property</LONG_NAME>
            <CON_ID>2231569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AHRQ:AHRQ Common Formats</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5333451</PublicId>
      <PreferredName>5333451v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Yes No Unknown Response Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>HL7CDv3</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AHRQ:AHRQ Common Formats</Origin>
      <Representation>
        <PublicId>5333131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A15</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3006497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A18</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5349775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNK</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the event or unsafe condi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the event or unsafe condition involve a medication or other substance?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DEVICE|74725-3</Name>
        <OrganizationName/>
        <DocumentType>AHRQ Form</DocumentType>
        <DocumentText>Device or Medical/Surgical Supply, including Heath Information Technology (HIT)|Patient safety event report - hospital: device or medical AndOr surgical supply, including health information technology (HIT) - version 1.2 [AHRQ]</DocumentText>
        <URL>https://www.psoppc.org/psoppc_web/DLMS/downloadDocument?groupId&amp;#61;97&amp;amp;pageName&amp;#61;common%20formats%20version%201.2%20technical%20specifications</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4382693</PublicId>
          <ContextName>AHRQ</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AHRQ Common Formats</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DEVICE 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5406432</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DE531</AlternateName>
        <AlternateNameType>AHRQ Identifier</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="718">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5365404</PUBLICID>
    <LONGNAME>Hopkins Verbal Learning Test Revised Trial 1 Raw Score</LONGNAME>
    <PREFERREDNAME>HVLTR_TL1_RAW_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Number of responses during first trial of the Hopkins Verbal Learning Test-Revised or HVLT-R.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HVLT-R:Hopkins Verbal Learning Test-Revised, Jason Brandt, PhD, 1991</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5356413</PublicId>
      <PreferredName>3566815v1.0:5356411v1.0</PreferredName>
      <PreferredDefinition>An assessment tool to ascertain verbal learning and memory skills that is well tolerated by those with moderate to severe dementia._An activity intended to do or accomplish something.  Routinely used as in &quot;number of tries to complete a procedure&quot;._A number with no fractional part, including the negative and positive numbers as well as zero.::1_The result of an action.</PreferredDefinition>
      <LongName>Hopkins Verbal Learning Test Revised Trial 1 Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3566815</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102866</PreferredName>
        <Version>1</Version>
        <LongName>Hopkins Verbal Learning Test Revised</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102866</PREFERRED_NAME>
            <LONG_NAME>Hopkins Verbal Learning Test Revised</LONG_NAME>
            <CON_ID>3565546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5356411</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39769:C45255::1:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Attempt Integer::1 Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39769</PREFERRED_NAME>
            <LONG_NAME>Attempt</LONG_NAME>
            <CON_ID>2203722</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::1</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HVLT-R:Hopkins Verbal Learning Test-Revised, Jason Brandt, PhD, 1991</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5361824</PublicId>
      <PreferredName>HVLTR_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Hopkins Verbal Learning Revised Trial Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>12</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>HVLT-R:Hopkins Verbal Learning Test-Revised, Jason Brandt, PhD, 1991</Origin>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 11 and less than 13 and the quantity that it denotes.: A specific point in the time continuum, including those established relative to an event.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68568, C113426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 10 and less than 12 and the quantity that it denotes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>0</VALUEMEANING>
          <MEANINGDESCRIPTION>A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Trial 1 Raw Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Trial 1 Raw Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="719">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5408674</PUBLICID>
    <LONGNAME>Biospecimen Tissue Receive And Dissection Biospecimen Pre-analytical Variables Program Standard Operating Procedure Variation Comments Text</LONGNAME>
    <PREFERREDNAME>BIO_RCV_DIS_SOP_TEXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The text description of comments/issues regarding tissue receipt or deviations from the SOP.  </PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5408673</PublicId>
      <PreferredName>2859635v1.0:5408671v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._To take, accept, or get something offered._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure._A program designed to systematically investigate the effects of individual pre-analytical factors on the molecular profiles of biospecimens. The results of this study will be used to develop evidence-based protocols and best practices for optimal collection, processing, and storage of biospecimens._An established procedure to be followed in carrying out a given operation or in a given situation._An alteration or difference from a norm or standard.</PreferredDefinition>
      <LongName>Biospecimen Tissue Receive And Dissection Biospecimen Pre-analytical Variables Program Standard Operating Procedure Variation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5408671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5408671v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Receive And Dissection Biospecimen Pre-analytical Variables Program Standard Operating Procedure Variation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15227</PREFERRED_NAME>
            <LONG_NAME>Dissection</LONG_NAME>
            <CON_ID>2203903</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126489</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Pre-analytical Variables Program</LONG_NAME>
            <CON_ID>5215518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48443</PREFERRED_NAME>
            <LONG_NAME>Standard Operating Procedure</LONG_NAME>
            <CON_ID>2612106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015802</PublicId>
      <PreferredName>COM_TXT</PreferredName>
      <PreferredDefinition>The free text field for general notes.</PreferredDefinition>
      <LongName>Comments Text</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>800</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comments/issues with tissue r</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Comments/issues with tissue receipt or deviations from SOP</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Receipt - Dissection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736431</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="720">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5509053</PUBLICID>
    <LONGNAME>Biospecimen Collection Safety Monitoring And Biomarker Analysis Consent Indicator</LONGNAME>
    <PREFERREDNAME>SAF_BMARK_CONS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The response that indicates whether a patient is willing to provide blood and tissue samples for toxicity monitoring and biomarker analysis in order to determine eligibility for participation in a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5509052</PublicId>
      <PreferredName>2715159v1.0:5509050v1.0</PreferredName>
      <PreferredDefinition>The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes._The state of being certain that adverse effects will not be caused by some agent under defined conditions._The act of observing something (and sometimes keeping a record of it)._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A method of biological assay that looks for the presence of unique molecules or sequences considered indicative for a condition or state._Permission to do something.</PreferredDefinition>
      <LongName>Biospecimen Collection Safety Monitoring And Biomarker Analysis Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2715159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70945</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70945</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Collection</LONG_NAME>
            <CON_ID>2714902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5509050</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5509050v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Safety Monitoring And Biomarker Analysis Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60828</PREFERRED_NAME>
            <LONG_NAME>Safety</LONG_NAME>
            <CON_ID>2612105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61256</PREFERRED_NAME>
            <LONG_NAME>Monitoring</LONG_NAME>
            <CON_ID>2691603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63333</PREFERRED_NAME>
            <LONG_NAME>Biomarker Analysis</LONG_NAME>
            <CON_ID>2926772</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Willingness to provide blood</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Willingness to provide blood and tissue samples for safety/toxicity monitoring and biomarker analyses</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="721">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5527597</PUBLICID>
    <LONGNAME>Immune Dysregulation Type</LONGNAME>
    <PREFERREDNAME>IMMUN_DYSREG_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name to identify a category of immune dysregulation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5527587</PublicId>
      <PreferredName>2716886v1.0:2322316v1.0</PreferredName>
      <PreferredDefinition>A disorder resulting from an abnormality in the immune system._The procedure of having an identity established.</PreferredDefinition>
      <LongName>Immune Dysregulation Identification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2716886</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3507</PreferredName>
        <Version>1</Version>
        <LongName>Immune System Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3507</PREFERRED_NAME>
            <LONG_NAME>Immune System Disorder</LONG_NAME>
            <CON_ID>2469349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2322316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25737</PreferredName>
        <Version>1</Version>
        <LongName>Identified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5527594</PublicId>
      <PreferredName>IMM_DYSREG_TP</PreferredName>
      <PreferredDefinition>Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Immune Dysregulation Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435021</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20047</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic or Prognostic Factor</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Granuloma formation</VALIDVALUE>
          <VALUEMEANING>Granuloma Formation</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of forming something or the structure formed.: An inflammatory reaction usually caused by infectious organisms, foreign bodies, or cholesterol deposits. It is characterized by the presence of epithelioid histiocytes and chronic inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3064, C25513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5527595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenomegaly</VALIDVALUE>
          <VALUEMEANING>Splenomegaly</VALUEMEANING>
          <MEANINGDESCRIPTION>Splenomegaly is greater than 3 cm below left costal margin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3626238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HLH</VALIDVALUE>
          <VALUEMEANING>Hemophagocytic Lymphohistiocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5527596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atopy</VALIDVALUE>
          <VALUEMEANING>Atopy</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic predisposition to form IgE antibodies in response to exposure to allergens and therefore, for the development of immediate (type I) hypersensitivity and atopic conditions, such as allergic rhinitis; bronchial asthma, atopic dermatitis, and food allergy. Mutations of specific alleles on the long arm of chromosome 5 have been associated with higher levels of IL-4 and IgE and are known as IL-4 promoter polymorphisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5487973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Immune dysregulation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Immune dysregulation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="722">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5527850</PUBLICID>
    <LONGNAME>Serological Hematology Hepatitis C Antibody Test Collection Status-Ind</LONGNAME>
    <PREFERREDNAME>SER_HEM_HCAB_TST_COL_ST_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the collection of a serological hematology test, the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens, for hepatitis C, an RNA virus, causes non-A and non-B Hepatitis and liver cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5527694</PublicId>
      <PreferredName>SER_HEM_HCAB_TST_COL_ST</PreferredName>
      <PreferredDefinition>information related to the serological hematology test, the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens, for hepatitis C, an RNA virus, causes non-A and non-B Hepatitis and liver cancer_(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen)._The act of gathering things together; having been brought together in one place._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Serological Hematology Hepatitis C Antibody Test Collection Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2634499</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41264:C16673</PreferredName>
        <Version>1</Version>
        <LongName>Serological Hematology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41264</PREFERRED_NAME>
            <LONG_NAME>Serological</LONG_NAME>
            <CON_ID>2634498</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16673</PREFERRED_NAME>
            <LONG_NAME>Hematology</LONG_NAME>
            <CON_ID>2202645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5527692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5527692v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Hepatitis C Infection Antibody Collection Status Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3098</PREFERRED_NAME>
            <LONG_NAME>Hepatitis C Infection</LONG_NAME>
            <CON_ID>2205375</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was Hepatitis C antibody coll</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was Hepatitis C antibody collected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="723">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5543113</PUBLICID>
    <LONGNAME>Breast Carcinoma Detection Method Type</LONGNAME>
    <PREFERREDNAME>5528657v1.0:5542789v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit:The activity of perceiving, discerning, discovering or identifying_A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Records the mode of detection for the breast cancer under consideration.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>EDRN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5528657</PublicId>
      <PreferredName>5528237v1.0:2730351v1.0</PreferredName>
      <PreferredDefinition>A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit:The activity of perceiving, discerning, discovering or identifying_A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Breast Carcinoma Detection Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5528237</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4872:C16210</PreferredName>
        <Version>1</Version>
        <LongName>Breast Carcinoma Detection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4872</PREFERRED_NAME>
            <LONG_NAME>Breast Carcinoma</LONG_NAME>
            <CON_ID>2475940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2730351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460</PreferredName>
        <Version>1</Version>
        <LongName>Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5542789</PublicId>
      <PreferredName>5542789v1.0</PreferredName>
      <PreferredDefinition>Records the mode of detection for the breast cancer under consideration.</PreferredDefinition>
      <LongName>Neoplasm Detection Method Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>EDRN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2748899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262:C16210:C71460:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm Detection Method Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mammography</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging examination of the breast by means of x-rays.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2582138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination by pressing on the surface of the body to feel the organs or tissues underneath.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2832987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the mode of breast c</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the mode of breast cancer detection? (check all that apply)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>5542682</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EDRN-CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000601</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EDRN-CDEs.Breast_Carcinoma_Detection.PROC_BREAST_MODEDETECT_CODE_1636</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Breast_Carcinoma_Detection:PROC_BREAST_MODEDETECT_CODE_1636</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="724">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5573441</PUBLICID>
    <LONGNAME>Disease or Disorder Status Assessment Molecular Analysis Method Indicator</LONGNAME>
    <PREFERREDNAME>5573440v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the disease status was assessed via molecular analysis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5573440</PublicId>
      <PreferredName>5434411v1.0:2770348v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time._The final result of a determination of the value, significance, or extent of._A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Disease or Disorder Status Assessment Molecular Analysis Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5434411</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C25688:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2770348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19770:C71460</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Analysis Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19770</PREFERRED_NAME>
            <LONG_NAME>Molecular Analysis</LONG_NAME>
            <CON_ID>2528322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the disease status assess</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the disease status assessed via molecular analysis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the disease status assessed by molecular testing (e.g. PCR)?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the disease status assessed by molecular testing (e.g. PCR)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the disease status assessed by molecular testing?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was the disease status assessed by molecular testing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="725">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5596095</PUBLICID>
    <LONGNAME>Health Assessment Questionnaire Disability Index Past Week Difficulty Ability to Lift Full Cup or Glass to Mouth 4 Point Scale</LONGNAME>
    <PREFERREDNAME>HAQDI_PWD_LIFT_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of the difficulty they had lifting a full cup or glass to their mouth over the past week, using a 4 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5592202</PublicId>
      <PreferredName>5590830v1.0:5592200v1.0</PreferredName>
      <PreferredDefinition>A standardized questionnaire developed by James F. Fries in 1983, which is originally used to measure outcome in patients with Rheumatoid Arthritis. It has also been applied to patients with HIV/AIDS and in studies of normal aging. The HAQ-DI is a generic instrument which focuses on self-reported, patient-oriented outcome measures. The questionnaire contains 8 categories of 46 items; dressing and grooming, arising, eating, walking, hygiene, reaching, grip, and activities. A 0-3 grade scale is used, where grade 0 represents category performed without any difficulty and grade 3 represents category performed with the greatest difficulty (unable to do)._The most recent week, including today._Something not easily done, accomplished, comprehended, or solved._A question about the ability of an individual to lift a full cup or glass to their mouth.</PreferredDefinition>
      <LongName>Health Assessment Questionnaire Disability Index Questionnaire Past Week Difficulty Ability to Lift a Full Cup or Glass to Mouth</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5590830</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106699</PreferredName>
        <Version>1</Version>
        <LongName>Health Assessment Questionnaire Disability Index Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106699</PREFERRED_NAME>
            <LONG_NAME>Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire</LONG_NAME>
            <CON_ID>5590829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5592200</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C62189:C129997</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Difficulty Ability to Lift a Full Cup or Glass to Mouth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62189</PREFERRED_NAME>
            <LONG_NAME>Difficulty</LONG_NAME>
            <CON_ID>2503546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129997</PREFERRED_NAME>
            <LONG_NAME>Ability to Lift a Full Cup or Glass to Mouth Question</LONG_NAME>
            <CON_ID>5586809</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5589436</PublicId>
      <PreferredName>ACT_DIFF_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Activity Difficulty 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>22</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNABLE TO DO</VALIDVALUE>
          <VALUEMEANING>Unable to Do</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is unable to do something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITH MUCH DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>With Much Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with much difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITH SOME DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>With Some Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with some difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITHOUT ANY DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>Without Any Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something without any difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you able to lift a full c</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you able to lift a full cup or glass to your mouth?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="726">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5627045</PUBLICID>
    <LONGNAME>Invasive Lesion Core Biopsy Specimen Number</LONGNAME>
    <PREFERREDNAME>5627041v1.0:2182118v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of cores containing invasive tumor</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5627041</PublicId>
      <PreferredName>5627039v1.0</PreferredName>
      <PreferredDefinition>A malignant cellular population that has increased in size and infiltrates the surrounding tissues._The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</PreferredDefinition>
      <LongName>Invasive Lesion Core Biopsy Specimen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5627039</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36117:C15680:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Invasive Lesion Core Biopsy Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36117</PREFERRED_NAME>
            <LONG_NAME>Invasive Lesion</LONG_NAME>
            <CON_ID>2528552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15680</PREFERRED_NAME>
            <LONG_NAME>Core Biopsy</LONG_NAME>
            <CON_ID>2202468</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7318108</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C42605</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Property</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42605</PREFERRED_NAME>
            <LONG_NAME>Property</LONG_NAME>
            <CON_ID>2231569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182118</PublicId>
      <PreferredName>NUMBER</PreferredName>
      <PreferredDefinition>A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of cores containing in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of cores containing invasive tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="727">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5627213</PUBLICID>
    <LONGNAME>Rotterdam Symptom Checklist 10 Past Week How Much Bothered by Nausea 4 Point Scale</LONGNAME>
    <PREFERREDNAME>RSC_SYMPT10_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how much they have been bothered by nausea during the past week, using a four-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RSCL:Rotterdam Symptom Checklist, de Haes, J.C., Olschewski, M., Fayers, P., Visser, M.R.M., Cull, A., Hopwood, P., Sanderman, R., 1982</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5627073</PublicId>
      <PreferredName>5627024v1.0:5627071v1.0</PreferredName>
      <PreferredDefinition>A questionnaire designed to measure both physical and psychological aspects of quality of life as an outcome measure of symptom control._The most recent week, including today._How much there is of something that you can measure; the total amount or number._A question about whether an individual is or was bothered by nausea.</PreferredDefinition>
      <LongName>Rotterdam Symptom Checklist Past Week Quantity Bothered by Nausea</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5627024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131387</PreferredName>
        <Version>1</Version>
        <LongName>Rotterdam Symptom Checklist</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131387</PREFERRED_NAME>
            <LONG_NAME>Rotterdam Symptom Checklist</LONG_NAME>
            <CON_ID>5622495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5627071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C25256:C125646</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Quantity Bothered by Nausea</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125646</PREFERRED_NAME>
            <LONG_NAME>Bothered by Nausea Question</LONG_NAME>
            <CON_ID>5127653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RSCL:Rotterdam Symptom Checklist, de Haes, J.C., Olschewski, M., Fayers, P., Visser, M.R.M., Cull, A., Hopwood, P., Sanderman, R., 1982</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5626980</PublicId>
      <PreferredName>5626980v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>How Much 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>11</MaximumLength>
      <MinimumLength>8</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RSCL:Rotterdam Symptom Checklist, de Haes, J.C., Olschewski, M., Fayers, P., Visser, M.R.M., Cull, A., Hopwood, P., Sanderman, R., 1982</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>a little</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you, during the past wee</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you, during the past week, been bothered by nausea</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5626752</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>RSCL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RSCL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5626753</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rotterdam Symptom Checklist (RSCL)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900350</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="728">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5628501</PUBLICID>
    <LONGNAME>FLT3 Internal Tandem Duplication Allele Ratio Laboratory Procedure Performed Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>5628500v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory results for FLT3-Internal Tandem Duplication allelic ratio.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5628500</PublicId>
      <PreferredName>5629181v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis._Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in nucleotide sequence and governing the same biochemical and developmental process._Quotient of quantities of the same kind for different components within the same system._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>FLT3 Internal Tandem Duplication Allele Ratio Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5629181</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67494:C16277:C44256:C25294</PreferredName>
        <Version>1</Version>
        <LongName>FLT3 Internal Tandem Duplication Allele Ratio Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67494</PREFERRED_NAME>
            <LONG_NAME>FLT3 Internal Tandem Duplication</LONG_NAME>
            <CON_ID>2722904</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16277</PREFERRED_NAME>
            <LONG_NAME>Allele</LONG_NAME>
            <CON_ID>2223183</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the FLT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the FLT3-Internal Tandem Duplication allelic ratio?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FLT3 - ITD allelic ratio</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>FLT3 - ITD allelic ratio</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FLT3 - ITD allelic ratio</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FLT3 - ITD allelic ratio</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_AML_dx_flt3_itd_ratio_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_AML_bet_flt3_itd_ratio_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_AML_le_flt3_itd_ratio_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="729">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5628936</PUBLICID>
    <LONGNAME>Pediatric Quality of Life Inventory Version 4 Past One Month Quantity Worry About What Will Happen Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PQL_INV_V4_EF5_5P_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how much of a problem it has been in the past one month with worrying about what will happen, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5613822</PublicId>
      <PreferredName>3202917v1.0:5628200v1.0</PreferredName>
      <PreferredDefinition>A parent report or patient self report for measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model uses a modular approach that integrates both generic core scales and disease-specific modules into one measurement system. (Copyright 1998-2008 James W. Varni, Ph.D.)_A period of time consisting of the 30 days before the present._How much there is of something that you can measure; the total amount or number._A question about whether an individual worries or worried about what will happen._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Pediatric Quality of Life Inventory Past 30 Days Quantity Worry About What Will Happen Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3202917</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78652</PreferredName>
        <Version>1</Version>
        <LongName>Pediatric Quality of Life Inventory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78652</PREFERRED_NAME>
            <LONG_NAME>Pediatric Quality of Life Inventory</LONG_NAME>
            <CON_ID>2808023</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5628200</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131330:C25256:C131236:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past 30 Days Quantity Worry About What Will Happen Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131330</PREFERRED_NAME>
            <LONG_NAME>Past 30 days</LONG_NAME>
            <CON_ID>5615928</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131236</PREFERRED_NAME>
            <LONG_NAME>Worry About What Will Happen Question</LONG_NAME>
            <CON_ID>5612566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5627410</PublicId>
      <PreferredName>PEDSQL_5_POINT_SCALE</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Pediatric Quality of Life Inventory Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Almost All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5273232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Often</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something occurs frequently.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5628246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Almost Never</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something rarely happens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I worry about what will happe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I worry about what will happen to me</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pediatric QoL Inventory Parent (5-7)(8-12)(13-18)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Worrying about what will happen to him or her</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PedsQL Pediatric Quality of Life Inventory Report (8-12)(13-18)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #5 of 5 (About My Feelings)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pediatric QoL Inventory (8-12)(13-18)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I worry about what will happen to me</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pediatric QoL Inventory Parent (2-4)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Worrying</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PedsQL Pediatric Quality of Life Inventory Parent Report (2-4)(5-7)(8-12)(13-18)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #5 of 5 (Emotional Functioning)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure</DocumentText>
        <URL>http://www.pedsql.org/score.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_WRRDHPPN</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="730">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5629893</PUBLICID>
    <LONGNAME>Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Therapy End Date</LONGNAME>
    <PREFERREDNAME>3647270v1.0:2179471v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Last day of FAC</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647270</PublicId>
      <PreferredName>2206713v1.0:3647268v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of a neoadjuvant chemotherapy regimen consisting of FAC: 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide.</PreferredDefinition>
      <LongName>Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647268</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C505:C1326:C405:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C505</PREFERRED_NAME>
            <LONG_NAME>Fluorouracil</LONG_NAME>
            <CON_ID>2204927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1326</PREFERRED_NAME>
            <LONG_NAME>Doxorubicin Hydrochloride</LONG_NAME>
            <CON_ID>2751680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C405</PREFERRED_NAME>
            <LONG_NAME>Cyclophosphamide</LONG_NAME>
            <CON_ID>2204906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179471</PublicId>
      <PreferredName>THERAPY_ENDDT</PreferredName>
      <PreferredDefinition>The date a therapy ended.  (The date the last dose of agent was taken.)</PreferredDefinition>
      <LongName>Therapy End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008565</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TEMPORAL_CONCEPTS</PreferredName>
        <Version>1</Version>
        <LongName>Temporal concepts</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>10</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Last Dose</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Last Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="731">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5633881</PUBLICID>
    <LONGNAME>Pediatric Quality of Life Inventory-Multidimensional Fatigue SRF6 Past One Month Quantity Problem Spend a Lot of Time in Bed Score 3 Point Scale</LONGNAME>
    <PREFERREDNAME>PQOL_F_SRF6_3PT_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how much of a problem it has been in the past one month with spending a lot of time in bed, using a 3 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5630519</PublicId>
      <PreferredName>5633962v1.0:5630517v1.0</PreferredName>
      <PreferredDefinition>An 18 item component of the Pediatric Quality of Life Inventory is a generic symptom-specific instrument to measure fatigue in pediatric patients ages 2?18 comprised of General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue domains._A period of time consisting of the 30 days before the present._How much there is of something that you can measure; the total amount or number._A difficulty, disorder, or condition needing resolution._A question about whether an individual spends or spent a lot of time in bed._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale Past 30 Days Quantity Problem Spend a Lot of Time in Bed Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5633962</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131369</PreferredName>
        <Version>1</Version>
        <LongName>Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131369</PREFERRED_NAME>
            <LONG_NAME>Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale</LONG_NAME>
            <CON_ID>5633959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5630517</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5630517v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past 30 Days Quantity Problem Spend a Lot of Time in Bed Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131330</PREFERRED_NAME>
            <LONG_NAME>Past 30 days</LONG_NAME>
            <CON_ID>5615928</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131379</PREFERRED_NAME>
            <LONG_NAME>Spend a Lot of Time in Bed Question</LONG_NAME>
            <CON_ID>5621349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5629185</PublicId>
      <PreferredName>PEDSQL_3_POINT_SCALE</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Pediatric Quality of Life Inventory Score 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>PedsQL: Pediatric Quality of Life, James W. Varni, Ph.D., 1998</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you spend a lot of time in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you spend a lot of time in bed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure.</DocumentText>
        <URL>http://www.pedsql.org/score.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PedsQL (5-7) Fatigue</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you spend a lot of time in bed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PedsQL (5-7) Fatigue</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #6 of 6 (Sleep/Rest Fatigue)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="732">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5633901</PUBLICID>
    <LONGNAME>Patient With Friend Or Relative Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_WITH_FRND_OR_REL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to a patient who is with a friend or relative.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5633733</PublicId>
      <PreferredName>PT_WITH_FRND_OR_REL</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A person related by blood or marriage._Used to indicate the presence of something or someone._A person whom an individual knows, likes, and trusts._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.</PreferredDefinition>
      <LongName>Patient With Friend Or Relative</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5633731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62355:C72884:C37998:C21480</PreferredName>
        <Version>1</Version>
        <LongName>With Friend Or Relative</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62355</PREFERRED_NAME>
            <LONG_NAME>With</LONG_NAME>
            <CON_ID>2532083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72884</PREFERRED_NAME>
            <LONG_NAME>Friend</LONG_NAME>
            <CON_ID>2734005</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21480</PREFERRED_NAME>
            <LONG_NAME>Relative</LONG_NAME>
            <CON_ID>2202798</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the patient accompanied b</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the patient accompanied by a friend or relative?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="733">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5633932</PUBLICID>
    <LONGNAME>Pregnancy Edinburgh Postnatal Depression Scale Assessment Score</LONGNAME>
    <PREFERREDNAME>Preg_Edin_ASSES_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth._A 10-item, self-rating questionnaire designed to screen postpartum women for indications of depression._A number or range of numeric values measuring performance, function, quality, or ability.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5633931</PublicId>
      <PreferredName>Preg_Edin</PreferredName>
      <PreferredDefinition>The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth._A 10-item, self-rating questionnaire designed to screen postpartum women for indications of depression.</PreferredDefinition>
      <LongName>Pregnancy Edinburgh Postnatal Depression Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2555192</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25742</PreferredName>
        <Version>1</Version>
        <LongName>Pregnancy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5646665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131844</PreferredName>
        <Version>1</Version>
        <LongName>Edinburgh Postnatal Depression Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131844</PREFERRED_NAME>
            <LONG_NAME>Edinburgh Postnatal Depression Scale</LONG_NAME>
            <CON_ID>5644687</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3076086</PublicId>
      <PreferredName>ASSES_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>The Edinburgh Postnatal Depre</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>The Edinburgh Postnatal Depression Scale© (EPDS) was developed to screen prenatal and postpartum women for the indication of depression. This 10-question self-report instrument is designed to screen for depression in the previous 7 days.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pregnancy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5622163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="734">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5682563</PUBLICID>
    <LONGNAME>Toxoplasmosis IgM Laboratory Procedure Performed Laboratory Finding Result</LONGNAME>
    <PREFERREDNAME>5682562v1.0:2676304v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the assessment of toxoplasmosis IgM.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5682562</PublicId>
      <PreferredName>5682560v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>A parasitic disease contracted by the ingestion or fetal transmission of toxoplasma gondii._The major immunoglobulin secreted during a primary immune response.  IgM binds with low affinity but high avidity (multiple binding sites) because it not only occurs as monomers but also as pentamers and hexamers._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Toxoplasmosis IgM Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5682560</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3418:C569:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Toxoplasmosis IgM Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3418</PREFERRED_NAME>
            <LONG_NAME>Toxoplasmosis</LONG_NAME>
            <CON_ID>3809562</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C569</PREFERRED_NAME>
            <LONG_NAME>IgM</LONG_NAME>
            <CON_ID>2206240</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2676304</PublicId>
      <PreferredName>LAB_RSLT</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Laboratory Finding Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>41</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2876957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elevated</VALIDVALUE>
          <VALUEMEANING>Elevated</VALUEMEANING>
          <MEANINGDESCRIPTION>Elevated; raised or increased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-05</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes: C49488</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never below</VALIDVALUE>
          <VALUEMEANING>Never Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61585, C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2682054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactive</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported reactive, not tested</VALIDVALUE>
          <VALUEMEANING>Previous Report Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Report</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not performed; HIV NAT testing performed</VALIDVALUE>
          <VALUEMEANING>Human Immunodeficiency Virus Nucleic Acid Amplification Test Performed</VALUEMEANING>
          <MEANINGDESCRIPTION>Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.: Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.: Performed; carried out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38000, C20055, C14219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2727600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-reactive</VALIDVALUE>
          <VALUEMEANING>Not Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Laboratory Finding Received</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition.: Received; taken, gotten, or acquired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25639, C38470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2729916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-09</PVBEGINDATE>
          <PVENDDATE>2013-12-17</PVENDDATE>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Borderline</VALIDVALUE>
          <VALUEMEANING>Borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Straddling the dividing line between two categories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced; decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE>2012-06-29</PVENDDATE>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3079341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Invalid neutralization</VALIDVALUE>
          <VALUEMEANING>Unacceptable Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to satisfy an established set of qualifying measures.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C63354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutralized</VALIDVALUE>
          <VALUEMEANING>Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not neutralizable</VALIDVALUE>
          <VALUEMEANING>Negation Neutralization</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The act of rendering something ineffective or inactive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95533, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3204286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Increased</VALIDVALUE>
          <VALUEMEANING>Increase</VALUEMEANING>
          <MEANINGDESCRIPTION>Increase; a process of becoming larger or more numerous or more important.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decreased</VALIDVALUE>
          <VALUEMEANING>Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3135563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Severe</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Not severe or strong; far from extreme; not serious enough to endanger life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Assessable/Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carrier of the trait</VALIDVALUE>
          <VALUEMEANING>Genetic Carrier Trait</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who carries an inheritable genetic mutation without manifestation of the associated condition.: Any genetically determined characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85496, C111031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3872849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate/equivocal</VALIDVALUE>
          <VALUEMEANING>Indeterminate Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C37998, C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4012172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resolved</VALIDVALUE>
          <VALUEMEANING>Resolved</VALUEMEANING>
          <MEANINGDESCRIPTION>Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved</VALIDVALUE>
          <VALUEMEANING>Better</VALUEMEANING>
          <MEANINGDESCRIPTION>In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Worse</VALIDVALUE>
          <VALUEMEANING>Worse</VALUEMEANING>
          <MEANINGDESCRIPTION>In an declined condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unchanged</VALIDVALUE>
          <VALUEMEANING>About the same</VALUEMEANING>
          <MEANINGDESCRIPTION>In an unchanged or similar condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Involved</VALIDVALUE>
          <VALUEMEANING>Involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>To have a connection by participation or association or use; sharing in an activity or process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4244451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Negation Availability</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25429, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-secretory</VALIDVALUE>
          <VALUEMEANING>Non-Secretory Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive/Suggestive</VALIDVALUE>
          <VALUEMEANING>Positive Finding And/Or Characteristic</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.: Used to indicate that either or both of two items or options may be valid.: The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25447, C48928, C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5036957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inconclusive / equivocal</VALIDVALUE>
          <VALUEMEANING>Uncertain And/Or Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.: Used to indicate that either or both of two items or options may be valid.: Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071, C48928, C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suggestive</VALIDVALUE>
          <VALUEMEANING>Suggestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A proposal offered for acceptance or rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5070731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Negation Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C25217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4982117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confirmed positive</VALIDVALUE>
          <VALUEMEANING>Confirmation Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been established or verified.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C25458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5677531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No growth</VALIDVALUE>
          <VALUEMEANING>Negation Growth</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A process of becoming larger or longer or more numerous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64379, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5653622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsatisfactory</VALIDVALUE>
          <VALUEMEANING>Unsatisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Failing to meet the quantitative or qualitative measures for the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No result</VALIDVALUE>
          <VALUEMEANING>Negation Laboratory Test Result</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The outcome of a laboratory test.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36292, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7096109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contraindicated</VALIDVALUE>
          <VALUEMEANING>Contraindicated</VALUEMEANING>
          <MEANINGDESCRIPTION>State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14665139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What were the results for the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What were the results for the toxoplasmosis IgM assessment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Toxoplasmosis IgM</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Toxoplasmosis IgM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Toxoplasmosis IgM</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Toxoplasmosis IgM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="735">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5700802</PUBLICID>
    <LONGNAME>Race</LONGNAME>
    <PREFERREDNAME>2388875v1.0:5021391v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The race of a person.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ONC SDC Project</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>2015 Edition Common Clinical Data Set - 45 CFR 170.102</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2388875</PublicId>
      <PreferredName>2233604v1.0:2388842v1.0</PreferredName>
      <PreferredDefinition>A person who requires medical care._An arbitrary classification of taxonomic group that is a division of a species; usually arise as a consequence of geographical isolation within a species and characterised by shared heredity, physical attributes and behavior, and in case of humans, by common history, nationality, or geographic distribution.</PreferredDefinition>
      <LongName>Patient Race</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388842</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17049</PreferredName>
        <Version>1</Version>
        <LongName>Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5021391</PublicId>
      <PreferredName>5021391v1.0</PreferredName>
      <PreferredDefinition>Major living subspecies of man differentiated by genetic and physical characteristics. There are four racial groups: Australoid, Caucasoid, Mongoloid, and Negroid._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Race Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ONC SDC Project</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>2015 Edition Common Clinical Data Set - 45 CFR 170.102</Origin>
      <Representation>
        <PublicId>2486830</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17049:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Race Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>American Indian or Alaska Native</VALIDVALUE>
          <VALUEMEANING>American Indian or Alaska Native</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asian</VALIDVALUE>
          <VALUEMEANING>Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>White</VALIDVALUE>
          <VALUEMEANING>White</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Native Hawaiian or Other Pacific Islander</VALIDVALUE>
          <VALUEMEANING>Native Hawaiian or Other Pacific Islander</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Black or African American</VALIDVALUE>
          <VALUEMEANING>Black or African American</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the Black racial groups of Africa. Terms such as &quot;Haitian&quot; or &quot;Negro&quot; can be used in addition to &quot;Black or African American&quot;. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Race</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Race</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>2015 Edition Common Clinical Data Set</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>CFR_Part_45_170.315</DocumentText>
        <URL>http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;amp;SID=100cd9d5ee5778b04fdc629f70dc02a1&amp;amp;mc=true&amp;amp;r=SECTION&amp;amp;n=se45.1.170_1315</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Standard Referenced 1</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>§ 170.207(f)(1) The Office of Management and Budget Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity, Statistical Policy Directive No. 15, as revised, October 30, 1997</DocumentText>
        <URL>http://www.whitehouse.gov/omb/fedreg_1997standards</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Standard Referenced 2</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>§ 170.207(f)(2) CDC Race and Ethnicity Code Set Version 1.0 (March 2000) - Navigate to the CDCREC Roll-up codes tab</DocumentText>
        <URL>http://vsac.nlm/nih.gov/#download-tab</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4970851</PublicId>
          <ContextName>ONC SDC Project</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MU Clinical Data Set</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Meaningful Use 2015 Edition Common Clinical Data Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5700858</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="736">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5702212</PUBLICID>
    <LONGNAME>Fluorescence In Situ Hybridization Plasma Cell Enrichment Type</LONGNAME>
    <PREFERREDNAME>5702211v1.0:5697806v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to represent whether the plasma cells used for analysis were enriched.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5702211</PublicId>
      <PreferredName>2743078v1.0:5702209v1.0</PreferredName>
      <PreferredDefinition>A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping._Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.</PreferredDefinition>
      <LongName>Fluorescence In Situ Hybridization Plasma Cell Enrichment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2743078</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17563</PreferredName>
        <Version>1</Version>
        <LongName>Fluorescence in situ Hybridization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17563</PREFERRED_NAME>
            <LONG_NAME>Fluorescence In Situ Hybridization</LONG_NAME>
            <CON_ID>2221360</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5702209</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C132297</PreferredName>
        <Version>1</Version>
        <LongName>Plasma Cell Enrichment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C132297</PREFERRED_NAME>
            <LONG_NAME>Plasma Cell Enrichment</LONG_NAME>
            <CON_ID>5699580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5697806</PublicId>
      <PreferredName>5697806v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>FISH Cell Enrichment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-enriched plasma cells</VALIDVALUE>
          <VALUEMEANING>Non-enriched Plasma Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132297, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enriched plasma cells</VALIDVALUE>
          <VALUEMEANING>Enriched Plasma Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were cells enriched for FISH</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were cells enriched for FISH analysis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="737">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5702335</PUBLICID>
    <LONGNAME>Person Mother Pregnancy Diethylstilbestrol Receive Indicator</LONGNAME>
    <PREFERREDNAME>MTHR_PGNY_DES_RCV</PREFERREDNAME>
    <PREFERREDDEFINITION>A human being._A female parent._The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth._A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration._To take, accept, or get something offered._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACRIN:American College of Radiology Imaging Network</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5702334</PublicId>
      <PreferredName>5702331v1.0:5702332v1.0</PreferredName>
      <PreferredDefinition>A human being._A female parent._The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth._A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration._To take, accept, or get something offered.</PreferredDefinition>
      <LongName>Person Mother Pregnancy Diethylstilbestrol Receive</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5702331</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C25189</PreferredName>
        <Version>1</Version>
        <LongName>Person Mother</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25189</PREFERRED_NAME>
            <LONG_NAME>Mother</LONG_NAME>
            <CON_ID>2202747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5702332</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25742:C433:C25639</PreferredName>
        <Version>1</Version>
        <LongName>Pregnancy Diethylstilbestrol Receive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C433</PREFERRED_NAME>
            <LONG_NAME>Diethylstilbestrol</LONG_NAME>
            <CON_ID>2451833</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient&#39;s mother take</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient&#39;s mother take DES while pregnant?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314482</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="738">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5711133</PUBLICID>
    <LONGNAME>Symptom Onset Date</LONGNAME>
    <PREFERREDNAME>2179569v2.0:2532012v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The month, day, and year of the symptom onset.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2179569</PublicId>
      <PreferredName>SYMPTOM_ONSET</PreferredName>
      <PreferredDefinition>The start, beginning, or early stages of a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</PreferredDefinition>
      <LongName>Symptom Onset</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2181698</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Symptom</PreferredName>
        <Version>1</Version>
        <LongName>Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177433</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Onset</PreferredName>
        <Version>1</Version>
        <LongName>Onset</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25279</PREFERRED_NAME>
            <LONG_NAME>Onset</LONG_NAME>
            <CON_ID>2202391</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2532012</PublicId>
      <PreferredName>DATE</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY-MM-DD</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the date of the symp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the date of the symptom onset?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of onset:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Date of onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of neurotoxicity (ICANS) onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of neurotoxicity (ICANS) onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of cerebral vascular accident onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cerebral vascular accident onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of cerebrovascular accident onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cerebrovascular accident onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of fever onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of fever onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of hypotension onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of hypotension onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of hypoxia onset for minimal supplemental oxygen (FiO2 &lt; 40%):</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of hypoxia onset for minimal supplemental oxygen (FiO2 &lt; 40%):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of hypoxia onset for more than minimal supplemental oxygen (FiO2 &gt; 40%):</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of hypoxia onset for more than minimal supplemental oxygen (FiO2 &gt; 40%):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of MAS / HLH onset:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of MAS / HLH onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of other manifestation onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cerebral edema onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cognitive impairment onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of depressed level of consciousness onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of motor neuron disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of movement disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of personality change onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of seizure onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of speech impairment onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of IPn or ARDS / IPS onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of non-infectious pulmonary abnormality onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of non-infectious liver toxicity onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of TMA or similar syndrome onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of renal impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 15</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cardiac impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 16</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of vascular impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 17</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of neurological impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 18</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of endocrine impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 19</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of renal impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 20</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of renal impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 21</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of psychiatric impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 22</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of other impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 23</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of genitourinary impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 24</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of musculoskeletal impairment / disorder onset:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_ano_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_fev_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_gl_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_heart_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_hypo_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_kidney_symp_onset_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_liver_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_lung_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mal_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_min_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mor_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_msk_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mya_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_nau_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_neuro_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_ocon_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_othorg_symp_onset_dte</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_rig_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_neu_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_otox_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_str_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_tum_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_cva_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_gi3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_hrt3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_kid3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_liv3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_lun3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_msk3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_neu3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_oth3_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_OTOX_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_GRFT_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_GRTT_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_pe_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_sz_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_sp_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mo_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_cn_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_mv_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_ed_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_cg_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_ONPA_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_NILT_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_OTH_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_NEU_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_GU_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_MUSC_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_PSYC_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_ENDO_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_VASC_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_REN_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_CAR_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_OF_ipn_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_OF_tma_symp_onset_date</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="739">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5717704</PUBLICID>
    <LONGNAME>Patient Hypersensitivity Status Yes No Indicator</LONGNAME>
    <PREFERREDNAME>5717703v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to a patient&#39;s hypersensitivity status</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5717703</PublicId>
      <PreferredName>5717701v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Patient Hypersensitivity Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5717701</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C3114:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Patient Hypersensitivity Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3114</PREFERRED_NAME>
            <LONG_NAME>Hypersensitivity</LONG_NAME>
            <CON_ID>2203756</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7318108</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C42605</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Property</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42605</PREFERRED_NAME>
            <LONG_NAME>Property</LONG_NAME>
            <CON_ID>2231569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a known</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose the patient have known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant antibodies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have a history of anaphalactic reactions attributed to anti-GD2 antibodies or to compounds of similar chemical or biologic composition to GD2CART, cyclophosphamide, fludarabine, or other agents used in this study or a history of hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any of the components of Pulmozyme?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HYPER_STAT_IND</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="740">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5718115</PUBLICID>
    <LONGNAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Family Problem with Ability to Have Children Indicator</LONGNAME>
    <PREFERREDNAME>NCCN_DTPL_HVCHLD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how distressed they have been during the past week over practical problems with their ability to have children, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5717491</PublicId>
      <PreferredName>5717471v1.0:3799977v1.0</PreferredName>
      <PreferredDefinition>A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source and patient problems in five categories._The most recent week, including today._A question about an individual&#39;s distress related to their family problems with the ability to have children.</PreferredDefinition>
      <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Family Problem with Ability to Have Children</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5717471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C132492</PreferredName>
        <Version>1</Version>
        <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C132492</PREFERRED_NAME>
            <LONG_NAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LONG_NAME>
            <CON_ID>5709921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3799977</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C107177</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Distress over Family Problem with Ability to Have Children</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107177</PREFERRED_NAME>
            <LONG_NAME>Distress over Family Problem with Ability to Have Children Question</LONG_NAME>
            <CON_ID>3794729</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ability to have children</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ability to have children</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Family Problems - Ability to have Children</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3793272</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCN Guidelines</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Distress Thermometer and Problem List for Patients Version 2.2016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5717470</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="741">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5718295</PUBLICID>
    <LONGNAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Physical Problem with Feeling Swollen Indicator</LONGNAME>
    <PREFERREDNAME>NCCN_DTPL_FLSWLN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how distressed they have been during the past week over physical problems with feeling swollen, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5717525</PublicId>
      <PreferredName>5717471v1.0:3807959v1.0</PreferredName>
      <PreferredDefinition>A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source and patient problems in five categories._The most recent week, including today._A question about an individual&#39;s distress related to their physical problems with feeling swollen.</PreferredDefinition>
      <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Physical Problem with Feeling Swollen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5717471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C132492</PreferredName>
        <Version>1</Version>
        <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C132492</PREFERRED_NAME>
            <LONG_NAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LONG_NAME>
            <CON_ID>5709921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3807959</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C107197</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Distress over Physical Problem with Feeling Swollen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107197</PREFERRED_NAME>
            <LONG_NAME>Distress over Physical Problem with Feeling Swollen Question</LONG_NAME>
            <CON_ID>3794756</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Feeling Swollen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Feeling Swollen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Physical Problems - Feeling Swollen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3793272</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCN Guidelines</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Distress Thermometer and Problem List for Patients Version 2.2016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5717470</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="742">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5727231</PUBLICID>
    <LONGNAME>Patient Period Post Last Dose Biological Agent Eligibility Determination Indicator</LONGNAME>
    <PREFERREDNAME>PRD_LSDS_BIO_TX_ELIG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The response indicating the patient meets the eligibility requirements for participation in a clinical trial with regards to time elapsed since the last dose of biological agent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5722148</PublicId>
      <PreferredName>2183985v1.0:5722146v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:An interval of time._Happening at a time subsequent to a reference time; later in time or order._Coming after all others in time or space or degree or being the only one remaining._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.</PreferredDefinition>
      <LongName>Patient Period Post Last Dose Biological Agent Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5722146</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5722146v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Period Post Last Dose Biological Agent Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25616</PREFERRED_NAME>
            <LONG_NAME>Period</LONG_NAME>
            <CON_ID>2202575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C307</PREFERRED_NAME>
            <LONG_NAME>Biological Agent</LONG_NAME>
            <CON_ID>2918783</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has time elapsed since last dose of a biological agent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has it been at least 7 days since completion of therapy with a biologic agent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have at least 7 days elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor, or metronomic non-myelosuppressive regimen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="743">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5779975</PUBLICID>
    <LONGNAME>Patient Induction Therapy Delay From Initiation Chemotherapy Yes No Indicator</LONGNAME>
    <PREFERREDNAME>CHX_CPLT_GT_WK_PST_INI_DLY_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator of whether or not the patient had delays in induction therapy that resulted in completion of induction greater than or equal to 28 weeks from initiation.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5779974</PublicId>
      <PreferredName>2233604v1.0:7997433v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The first choice of treatment for a particular type of cancer._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later._Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument._The act of starting something; an act that sets in motion some course of events._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.</PreferredDefinition>
      <LongName>Patient Induction Therapy Delay From Initiation Chemotherapy</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7997433</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7997433v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Induction Therapy Delay From Initiation Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C158876</PREFERRED_NAME>
            <LONG_NAME>Induction Therapy</LONG_NAME>
            <CON_ID>6859324</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25476</PREFERRED_NAME>
            <LONG_NAME>Delay</LONG_NAME>
            <CON_ID>2203898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25516</PREFERRED_NAME>
            <LONG_NAME>From</LONG_NAME>
            <CON_ID>2206220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47938</PREFERRED_NAME>
            <LONG_NAME>Initiation</LONG_NAME>
            <CON_ID>2443907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did patient have delays in in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did patient have delays in induction therapy that result in completion of induction in ≥ 28 weeks from initiation of chemotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient have delays in induction therapy that result in completion of induction in &gt;= 28 weeks from initiation of chemotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="744">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5782160</PUBLICID>
    <LONGNAME>Chemotherapy Mercaptopurine Methotrexate Agent Not Taken As Prescribed Outcome Chemotherapy Agent Not Taken As Prescribed Outcome</LONGNAME>
    <PREFERREDNAME>5782159v1.0:5782151v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the outcome of not taking chemotherapy agents, Mercaptopurine or Methotrexate, as prescribed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5782159</PublicId>
      <PreferredName>5782078v1.0:5782157v1.0</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An operation in which a term denies or inverts the meaning of another term or construction._Having been accepted for some purpose; ingested as a medication._The result of an action._In the same amount or manner; to the same degree; in the role, function, or capacity of._Directions written for the preparation and adminstration of a drug.</PreferredDefinition>
      <LongName>Chemotherapy Mercaptopurine Methotrexate Agent Not Taken As Prescribed Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5782078</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C195:C642:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Mercaptopurine Methotrexate Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C195</PREFERRED_NAME>
            <LONG_NAME>Mercaptopurine</LONG_NAME>
            <CON_ID>2416389</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C642</PREFERRED_NAME>
            <LONG_NAME>Methotrexate</LONG_NAME>
            <CON_ID>2204926</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5782157</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5782157v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Negation Taken As Drug Prescribing Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64938</PREFERRED_NAME>
            <LONG_NAME>As</LONG_NAME>
            <CON_ID>2718939</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0033081</PREFERRED_NAME>
            <LONG_NAME>Drug Prescribing</LONG_NAME>
            <CON_ID>2204323</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5782151</PublicId>
      <PreferredName>5782151v1.0</PreferredName>
      <PreferredDefinition>The result of an action._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An operation in which a term denies or inverts the meaning of another term or construction._Having been accepted for some purpose; ingested as a medication._In the same amount or manner; to the same degree; in the role, function, or capacity of._Directions written for the preparation and adminstration of a drug.</PreferredDefinition>
      <LongName>Chemotherapy Agent Not Taken As Prescribed Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>5782150</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5782150v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Agent Negation Taken As Drug Prescribing Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64938</PREFERRED_NAME>
            <LONG_NAME>As</LONG_NAME>
            <CON_ID>2718939</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0033081</PREFERRED_NAME>
            <LONG_NAME>Drug Prescribing</LONG_NAME>
            <CON_ID>2204323</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I would get an infection</VALIDVALUE>
          <VALUEMEANING>Acquisition Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>The process by which something is acquired or obtained.: The invasion of an organism&#39;s body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128320, C43384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>My doctor would not be happy with me</VALIDVALUE>
          <VALUEMEANING>Doctor Feelings Sadness</VALUEMEANING>
          <MEANINGDESCRIPTION>A courtesy title for a person who has received a doctorate degree or who practices medicine.: Emotional sensations.: Feelings of grief or unhappiness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74534, C77965, C69164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>My spouse/parent/significant other would be disappointed with me</VALIDVALUE>
          <VALUEMEANING>Spouse Parent Significant Other Frustration</VALUEMEANING>
          <MEANINGDESCRIPTION>A person&#39;s partner in marriage.: A mother or a father; an immediate progenitor.: A gender-neutral term for a person&#39;s partner in an intimate or romantic relationship without disclosing or presuming marital status or sexual orientation.: The motivational and/or affective state of annoyance resulting from being blocked, thwarted, disappointed or defeated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61483, C119265, C42709, C62649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I would feel better</VALIDVALUE>
          <VALUEMEANING>Feelings Better</VALUEMEANING>
          <MEANINGDESCRIPTION>Emotional sensations.: In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685, C77965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I might have a relapse/leukemia might come back</VALIDVALUE>
          <VALUEMEANING>Potential Relapse Leukemia Potential Recurrence</VALUEMEANING>
          <MEANINGDESCRIPTION>The likelihood or possibility that a specific state or condition will exist or that an action will occur.: The return of signs and symptoms of cancer after a period of improvement.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: The likelihood or possibility that a specific state or condition will exist or that an action will occur.: To come back or to return.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3352, C62230, C3161, C0699753, C62230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I don&#39;t really know</VALIDVALUE>
          <VALUEMEANING>Does Not Know</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None Above</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.: In a place or position that is higher.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75329, C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5293617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What do you think would happe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What do you think would happen if you don&#39;t take your 6MP or Methotrexate as prescribed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="745">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5794569</PUBLICID>
    <LONGNAME>Chemotherapy Agent Have Many Side Effects Severity Problem QOL Experience Type</LONGNAME>
    <PREFERREDNAME>5794568v1.0:2016885v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A list of values that describe the extent to which a patient has experienced a chemotherapy agent problem of having many side effects.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5794568</PublicId>
      <PreferredName>5413011v1.0:5794566v1.0</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Used to describe the possession, relationships, or the state of something or someone._An indefinite large quantity that is considered to be greater than several._The term was used in various ways in the past, to describe unintended effects of medical intervention, usually negative (unfavourable), but also positive (favourable) ones. It is recommended that this term no longer be used and particularly should not be regarded as synonymous with adverse event or adverse reaction._Severity; used of the degree of something undesirable e.g. pain or weather._A difficulty, disorder, or condition needing resolution.</PreferredDefinition>
      <LongName>Chemotherapy Agent Have Many Side Effects Severity Problem</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5413011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5794566</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5794566v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Have Many Side Effect Problem Severity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C101282</PREFERRED_NAME>
            <LONG_NAME>Have</LONG_NAME>
            <CON_ID>3437377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78728</PREFERRED_NAME>
            <LONG_NAME>Many</LONG_NAME>
            <CON_ID>3111307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2861</PREFERRED_NAME>
            <LONG_NAME>Side Effect</LONG_NAME>
            <CON_ID>2202904</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016885</PublicId>
      <PreferredName>QOL_EXP_TP</PreferredName>
      <PreferredDefinition>list of values that describe the extent to which a patient has experienced an illness or symptom.</PreferredDefinition>
      <LongName>QOL Experience Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A great deal</VALIDVALUE>
          <VALUEMEANING>A GREAT DEAL</VALUEMEANING>
          <MEANINGDESCRIPTION>A GREAT DEAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Big problem</VALIDVALUE>
          <VALUEMEANING>Big problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Big problem</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate problem</VALIDVALUE>
          <VALUEMEANING>MODERATE PROBLEM</VALUEMEANING>
          <MEANINGDESCRIPTION>MODERATE PROBLEM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small problem</VALIDVALUE>
          <VALUEMEANING>Small problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Small problem</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very small problem</VALIDVALUE>
          <VALUEMEANING>Very small problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Very small problem</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No problem</VALIDVALUE>
          <VALUEMEANING>No Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A Medium Problem</VALIDVALUE>
          <VALUEMEANING>Medium Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Mid-way between small and large in number, quantity, magnitude or extent.: A difficulty, disorder, or condition needing resolution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5784016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has a lot of side effects</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has a lot of side effects</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="746">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5828038</PUBLICID>
    <LONGNAME>Informed Consent Disease Screening Signature Indicator</LONGNAME>
    <PREFERREDNAME>IC_Screening_ Sign_Ind</PREFERREDNAME>
    <PREFERREDDEFINITION>The response which indicates whether a person has signed the screening consent</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PBTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2874155</PublicId>
      <PreferredName>2874149v1.0:2874153v1.0</PreferredName>
      <PreferredDefinition>information related to the signature of a patient to consent to participation in disease screening, checking for disease when there may be no symptoms the individual being screened is aware, after achieving an understanding of the relevant medical facts and the risks involved.</PreferredDefinition>
      <LongName>Informed Consent Disease Screening Signature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2874149</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16735</PreferredName>
        <Version>1</Version>
        <LongName>Informed Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16735</PREFERRED_NAME>
            <LONG_NAME>Informed Consent</LONG_NAME>
            <CON_ID>2202451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2874153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15419:C25678</PreferredName>
        <Version>1</Version>
        <LongName>Disease Screening Signature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15419</PREFERRED_NAME>
            <LONG_NAME>Disease Screening</LONG_NAME>
            <CON_ID>2321289</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient signed the sc</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient signed the screening consent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient signed the release of medical information to allow upload of images for central review?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="747">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5833882</PUBLICID>
    <LONGNAME>Viable Cell Laboratory Procedure Performed Indicator</LONGNAME>
    <PREFERREDNAME>5870682v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not viability of cells was done.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5870682</PublicId>
      <PreferredName>5870680v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Capable of life or normal growth and development._The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Viable Cell Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5870680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25324:C12508:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Viable Cell Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25324</PREFERRED_NAME>
            <LONG_NAME>Viable</LONG_NAME>
            <CON_ID>2206271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was viability of cells done?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was viability of cells done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was viability of cells done?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was viability of cells done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CPA_cell_viab_perf_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTP_CPA_cell_viab_perf_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>performedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="748">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5840761</PUBLICID>
    <LONGNAME>Indirect Fundoscopy Examination Indicator</LONGNAME>
    <PREFERREDNAME>IND_FUNDSC_EXM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not fundoscopic examination was indirect.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Princess Margaret Cancer Centre, Toronto, ON</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5840718</PublicId>
      <PreferredName>4888342v1.0:5840716v1.0</PreferredName>
      <PreferredDefinition>An exam of the inside of the back of the eye using a beam of light and a hand-held lens. Indirect ophthalmoscopy gives a wider view inside the eye than an exam using an ophthalmoscope does._A formal or careful inspection of an object or subject.</PreferredDefinition>
      <LongName>Indirect Ophthalmoscopy Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4888342</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94199</PreferredName>
        <Version>1</Version>
        <LongName>Indirect Ophthalmoscopy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94199</PREFERRED_NAME>
            <LONG_NAME>Indirect Ophthalmoscopy</LONG_NAME>
            <CON_ID>4888341</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5840716</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131902</PreferredName>
        <Version>1</Version>
        <LongName>Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131902</PREFERRED_NAME>
            <LONG_NAME>Examination</LONG_NAME>
            <CON_ID>5655629</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Princess Margaret Cancer Centre, Toronto, ON</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of examination indirect?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of examination indirect?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="749">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5854632</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week Usual Severity Feeling of I Don&#39;t Look Myself Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MSAS10_18_S_APPEA_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation in the past week of the usual severity of their feelings that they don&#39;t look like themselves, using a four-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5845103</PublicId>
      <PreferredName>5840805v1.0:5114841v1.0</PreferredName>
      <PreferredDefinition>A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to children with cancer aged 10-18. This 30-question instrument was adapted from a previously-validated adult version._The most recent week, including today._A question about the usual severity of an individual&#39;s feeling of not looking like themselves._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week Usual Severity Feeling of I Don&#39;t Look Like Myself Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5840805</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C134965</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C134965</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale (MSAS) 10-18</LONG_NAME>
            <CON_ID>5840197</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5114841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C125328:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Usual Severity Feeling of I Don&#39;t Look Like Myself Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125328</PREFERRED_NAME>
            <LONG_NAME>Usual Severity Feeling of I Don&#39;t Look Like Myself Question</LONG_NAME>
            <CON_ID>5109166</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5114471</PublicId>
      <PreferredName>MSAS_SEVERE_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Slight) to 4 (Very Severe) on a Likert scale used on the Memorial Symptom Assessment Scale questionnaire.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale Severity Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>MSAS-SF:Memorial Symptom Assessment Scale Short Form.Chang VT, et.al., Cancer. 2000 Sep 1;89(5):1162-71.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Exceedingly intense or unpleasant in degree, quality or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely bad or unpleasant in degree, quality or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4633034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Slight</VALUEMEANING>
          <MEANINGDESCRIPTION>Small or little in size, quantity, or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How severe was the feeling th</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How severe was the feeling that &quot;I don&#39;t look like myself&quot; usually?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MSAS 10-18</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #108 of 112</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840828</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS 10-18 (Memorial Symptom Assessment Scale 10-18)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840838</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_SVR_DNTLLKMYSLF</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="750">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5873909</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale (MSAS) 7-12 Yesterday or Today How Much Time Itchy Score 3 Point Scale</LONGNAME>
    <PREFERREDNAME>MSAS7_12_A_ITCH_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of how much of the time they were itchy yesterday or today, using a three-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS 7-10: Memorial Symptom Assessment Scale (7-10). J. Collins, et al. Journal of Pain and Symptom Management. 2002 Jan; 23(1): 10-16</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5873784</PublicId>
      <PreferredName>5873754v1.0:5873782v1.0</PreferredName>
      <PreferredDefinition>A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to young children with cancer aged 7-12. This 8-question instrument was adapted from a previously-validated adult version._The time period consisting of the current day and the preceding day._A question about how much of the time an individual was itchy._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (MSAS) 7-12 Yesterday or Today How Much Time Itchy Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5873754</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C136319</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale (MSAS) 7-12</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136319</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale (MSAS) 7-12</LONG_NAME>
            <CON_ID>5872235</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5873782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C136321:C136355:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Yesterday or Today How Much Time Itchy Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136321</PREFERRED_NAME>
            <LONG_NAME>Yesterday or Today</LONG_NAME>
            <CON_ID>5872236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136355</PREFERRED_NAME>
            <LONG_NAME>How Much Time Itchy Question</LONG_NAME>
            <CON_ID>5872259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS 7-10: Memorial Symptom Assessment Scale (7-10). J. Collins, et al. Journal of Pain and Symptom Management. 2002 Jan; 23(1): 10-16</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5873751</PublicId>
      <PreferredName>MSAS7_10_TIME_SC</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (A very short time) to 3 (Almost all the time) on a Likert scale used on the Memorial Symptom Assessment Scale (Pediatrics 7-12) questionnaire.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (Pediatrics 7-10)  How Much of the Time 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>3</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>MSAS 7-10: Memorial Symptom Assessment Scale (7-10). J. Collins, et al. Journal of Pain and Symptom Management. 2002 Jan; 23(1): 10-16</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A Very Short Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened for a very short time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5873745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Medium Amount of Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened for a medium amount of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5873744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Almost All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5273232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MSAS 7-12</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #10 of 30</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How much of the time were you</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much of the time were you itchy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840828</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS 7-12 (Memorial Symptom Assessment Scale 7-12)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840839</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="751">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5935642</PUBLICID>
    <LONGNAME>Sputum Cytology Induction With Hypertonic Saline Performed Indicator</LONGNAME>
    <PREFERREDNAME>5935640v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A diagnostic technique for lung cancer detection using a solution of water with a concentration of NaCl higher than that found in physiological saline (0.9% w/v).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5935640</PublicId>
      <PreferredName>5935636v1.0:5935638v1.0</PreferredName>
      <PreferredDefinition>A diagnostic technique for lung cancer detection.  Looks for abnormal cell cytology in sputum._The act of bringing about something._Used to indicate the presence of something or someone._Any solution of sodium chloride (NaCl) in water with a concentration of NaCl higher than that found in physiological saline (0.9% w/v). When administered in vivo, hypertonic saline (HTS) exhibits several physiological effects beneficial to cerebral injury including: 1) osmotic and vasoregulatory - by promoting the flow of excess water from cerebral tissue to the blood via osmosis and decreasing edema in the vascular endothelium of injured tissues, thus lowering vascular resistance and allowing more blood flow; 2) hemodynamic - by effectively expanding plasma volume; 3) immunomodulatory - by preventing leukocytes from becoming activated and adhering to injured neurons and; 4) neurochemical - by counteracting detrimental excitatory amino acids through the normalization of neuronal cell membranes and by restoration of normal electrolyte and neurotransmitter levels in brain cells, and normal cell volumes._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Sputum Cytology Induction With Hypertonic Saline Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435020</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19238</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic, Therapeutic, and Research Equipment</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5935636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16192</PreferredName>
        <Version>1</Version>
        <LongName>Sputum Cytology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16192</PREFERRED_NAME>
            <LONG_NAME>Sputum Cytology</LONG_NAME>
            <CON_ID>5935635</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5935638</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61367:C62355:C60814:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Induction With Hypertonic Saline Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61367</PREFERRED_NAME>
            <LONG_NAME>Induction</LONG_NAME>
            <CON_ID>2612143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62355</PREFERRED_NAME>
            <LONG_NAME>With</LONG_NAME>
            <CON_ID>2532083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60814</PREFERRED_NAME>
            <LONG_NAME>Hypertonic Saline</LONG_NAME>
            <CON_ID>5935637</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was sputum induction with hyp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was sputum induction with hypertonic saline performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="752">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5944587</PUBLICID>
    <LONGNAME>Sexual Health Inventory for Men 1 Past 6 Months Can Get and Keep Erection Confidence Rating Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>SHIM_Q1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how they would rate their confidence that they could get and keep an erection, using a 5 point scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>SHIM:Sexual Health Inventory for Men, Rosen, RC, et.al., Dec. 1999</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5944076</PublicId>
      <PreferredName>5944073v1.0:5944074v1.0</PreferredName>
      <PreferredDefinition>A 5-item questionnaire for screening and diagnosis of erectile dysfunction (ED) and severity of ED in clinical practice and research._A period of time consisting of the 6 months before the present._A question to rate the confidence of an individual with regard to getting and keeping an erection._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Sexual Health Inventory for Men Past 6 Months Confidence Can Get and Keep Erection Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5944073</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C138113</PreferredName>
        <Version>1</Version>
        <LongName>Sexual Health Inventory for Men</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C138113</PREFERRED_NAME>
            <LONG_NAME>Sexual Health Inventory for Men</LONG_NAME>
            <CON_ID>5941888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5944074</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110987:C138114:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past 6 Months Confidence Can Get and Keep Erection Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110987</PREFERRED_NAME>
            <LONG_NAME>Past 6 Months</LONG_NAME>
            <CON_ID>3871097</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C138114</PREFERRED_NAME>
            <LONG_NAME>Confidence Can Get and Keep Erection Question</LONG_NAME>
            <CON_ID>5941889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SHIM:Sexual Health Inventory for Men, Rosen, RC, et.al., Dec. 1999</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5944099</PublicId>
      <PreferredName>SHIM_CONF_SCL</PreferredName>
      <PreferredDefinition>A 5-item questionnaire for screening and diagnosis of erectile dysfunction (ED) and severity of ED in clinical practice and research._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>SHIM Confidence Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>SHIM:Sexual Health Inventory for Men, Rosen, RC, et.al., Dec. 1999</Origin>
      <Representation>
        <PublicId>5944098</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C138113:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Sexual Health Inventory for Men Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C138113</PREFERRED_NAME>
            <LONG_NAME>Sexual Health Inventory for Men</LONG_NAME>
            <CON_ID>5941888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Low or No Confidence</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating a very low level of confidence or an absence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5698108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Low confidence</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating a low level of confidence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5698109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate confidence</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating a moderate level of confidence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5698111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>High confidence</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating a high level of confidence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5698113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very high confidence</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating a very high level of confidence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5698115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How do you rate your confiden</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How do you rate your confidence that you could get and keep an erection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SHIM (Sexual Health Inventory for Men)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5944072</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="753">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5946070</PUBLICID>
    <LONGNAME>Fluorescence in Situ Hybridization Cytogenetic or Molecular Genetic Abnormality Present Indicator</LONGNAME>
    <PREFERREDNAME>5946067v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a fluorescence in situ hybridization cytogenetic or molecular genetic abnormality was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5946067</PublicId>
      <PreferredName>5946065v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping._A molecular or cytogenic abnormality which occurs in either human disease states or disease models._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Fluorescence in Situ Hybridization Cytogenetic or Molecular Genetic Abnormality Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5946065</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17563:C3910</PreferredName>
        <Version>1</Version>
        <LongName>Fluorescence in Situ Hybridization Molecular Abnormality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17563</PREFERRED_NAME>
            <LONG_NAME>Fluorescence In Situ Hybridization</LONG_NAME>
            <CON_ID>2221360</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3910</PREFERRED_NAME>
            <LONG_NAME>Molecular Abnormality</LONG_NAME>
            <CON_ID>2582540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(2;5)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(2;5)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(2;8)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(2;8)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(8;14)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(8;14)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(8;22)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(8;22)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(11;14)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(11;14)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(11;18)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(11;18)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(14;18)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(14;18)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>i(7q)(q10)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>i(7q)(q10)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BCL-2 rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>BCL-2 rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BCL-2 amplification</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>BCL-2 amplification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BCL-6 rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>BCL-6 rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BCL-6 amplification</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>BCL-6 amplification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>C-MYC rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>C-MYC rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>C-MYC amplification</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>C-MYC amplification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DUSP22-rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>DUSP22-rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Immunoglobulin heavy (IgH) chain rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunoglobulin heavy (IgH) chain rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TP63-rearrangement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TP63-rearrangement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other abnormality</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other abnormality</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>t(1;14)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>t(1;14)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a fluorescence in situ hy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a fluorescence in situ hybridization cytogenetic or molecular genetic abnormality present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the cytogenetic abnormality or gene rearrangement present using FISH?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the cytogenetic abnormality or gene rearrangement present using FISH?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>P53 deletion</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>P53 deletion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>del(17p) / 17p-</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>del(17p) / 17p-</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex -1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have double-hit DLBCL defined by FISH?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_BCL2_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_BCL2_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_BCL6_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_BCL6_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_CMYC_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_CMYC_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_del17p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_del53p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_DUSP22_rearng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_i7q_q10_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_IgH_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_oth_abnorm_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t11_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t11_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t14_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t1_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t2_5_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t2_8_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t8_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_t8_22_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_ASDG_TP63_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_BCL2_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_BCL2_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_BCL6_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_BCL6_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_CMYC_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_CMYC_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_del17p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_del53p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_DUSP22_rearg_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_i7q_q10_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_IgH_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_oth_abnorm_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t11_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t11_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t14_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t1_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t2_5_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t2_8_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t8_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_t8_22_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_astrn_TP63_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_BCL2_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_BCL2_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_BCL6_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_BCL6_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_CMYC_amp_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_CMYC_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_del17p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_del53p_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_DUSP22_rearrng_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_i7q_q10_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_IgH_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_oth_abnorm_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t11_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t11_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t14_18_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t1_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t2_5_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t2_8_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t8_14_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_t8_22_ab_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_dsp_TP63_rearrang_ynnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DLBL0105</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="754">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5981320</PUBLICID>
    <LONGNAME>Invasive Breast Carcinoma Glandular Acinar Tubular Differentiation Nottingham Histologic Score Outcome</LONGNAME>
    <PREFERREDNAME>IBC_GATD_NOTSC_OUTCM</PREFERREDNAME>
    <PREFERREDDEFINITION>Results of the Nottingham histologic score for the percentage of glandular/tubular structures in a breast specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5981239</PublicId>
      <PreferredName>2431278v1.0:5981237v1.0</PreferredName>
      <PreferredDefinition>A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women._A morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm.</PreferredDefinition>
      <LongName>Invasive Breast Carcinoma Glandular Acinar Tubular Differentiation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9245</PreferredName>
        <Version>1</Version>
        <LongName>Invasive Breast Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9245</PREFERRED_NAME>
            <LONG_NAME>Invasive Breast Carcinoma</LONG_NAME>
            <CON_ID>2431159</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5981237</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C139289</PreferredName>
        <Version>1</Version>
        <LongName>Glandular (Acinar)/Tubular Differentiation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C139289</PREFERRED_NAME>
            <LONG_NAME>Glandular (Acinar)/Tubular Differentiation</LONG_NAME>
            <CON_ID>5981065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5979388</PublicId>
      <PreferredName>5979388v1.0</PreferredName>
      <PreferredDefinition>A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index._A morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm._The result of an action.</PreferredDefinition>
      <LongName>Nottingham Histologic Score Glandular Acinar Tubular Differentiation Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>7</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>5981236</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25595:C139289:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Nottingham Score Glandular (Acinar)/Tubular Differentiation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25595</PREFERRED_NAME>
            <LONG_NAME>Nottingham Score</LONG_NAME>
            <CON_ID>2202763</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C139289</PREFERRED_NAME>
            <LONG_NAME>Glandular (Acinar)/Tubular Differentiation</LONG_NAME>
            <CON_ID>5981065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Score cannot be determined</VALIDVALUE>
          <VALUEMEANING>Score Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>A number or range of numeric values measuring performance, function, quality, or ability.: Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658, C25338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Only microinvasion present not graded</VALIDVALUE>
          <VALUEMEANING>Microinvasive Breast Carcinoma Present Negation Histologic Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>Ductal carcinoma in situ of the breast with minimal stromal invasion.  Lymph node involvement is uncommon and the prognosis is generally good.: Being or existing in a specified place or at the specified time.: An operation in which a term denies or inverts the meaning of another term or construction.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C25594, C25626, C40374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No residual invasive carcinoma</VALIDVALUE>
          <VALUEMEANING>Negation Residual Invasive Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Remaining or left behind.: A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9480, C37895, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Score 3</VALIDVALUE>
          <VALUEMEANING>Glandular (Acinar)/Tubular Differentiation Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than 10% of tumor area shows glandular/tubular structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Score 2</VALIDVALUE>
          <VALUEMEANING>Glandular (Acinar)/Tubular Differentiation Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>10% to 75% of tumor area shows glandular/tubular structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Score 1</VALIDVALUE>
          <VALUEMEANING>Glandular (Acinar)/Tubular Differentiation Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than 75% of tumor area shows glandular/tubular structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5979391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Glandular tubular differentia</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Glandular tubular differentiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Round 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Glandular (acinar)/tubular differentiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>College of American Pathologists Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Version: Invasive Breast 4.0.0.0; Protocol Posting Date: June 2017</DocumentText>
        <URL>http://www.cap.org/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA -1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Glandular (acinar)/tubular differentiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the Nottingham tubule formation score?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Nottingham tubule formation score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506112</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Breast</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Initial Diagnosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6643181</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506116</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pathology</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5855640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Microscopic Pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5915898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7434158</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CTEP CDISC Harmonization</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Diagnosis Microscopic Pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>11422194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>MI_MIORRES_TBLFRM</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="755">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5983959</PUBLICID>
    <LONGNAME>Bronchodilator Usage Since Last Dose Time</LONGNAME>
    <PREFERREDNAME>BRNC_LAST_USE_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>The length of time since last usage of bronchodilator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5338975</PublicId>
      <PreferredName>5338973v1.0:2816272v1.0</PreferredName>
      <PreferredDefinition>Agents that cause an increase in the expansion of a bronchus or bronchial tubes._A manner, or usual, or accepted practice of using something.</PreferredDefinition>
      <LongName>Bronchodilator Usage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5338973</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C319</PreferredName>
        <Version>1</Version>
        <LongName>Bronchodilator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C319</PREFERRED_NAME>
            <LONG_NAME>Bronchodilator</LONG_NAME>
            <CON_ID>2970275</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2816272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71477</PreferredName>
        <Version>1</Version>
        <LongName>Usage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71477</PREFERRED_NAME>
            <LONG_NAME>Usage</LONG_NAME>
            <CON_ID>2790010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5983958</PublicId>
      <PreferredName>5983958v1.0</PreferredName>
      <PreferredDefinition>Subsequent to; after._Coming after all others in time or space or degree or being the only one remaining._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The continuum of experience in which events pass from the future through the present to the past.</PreferredDefinition>
      <LongName>Since Last Dose Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008539</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>hh:mm</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>5983957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45325:C25551:C25488:C25207</PreferredName>
        <Version>1</Version>
        <LongName>Since Last Dose Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45325</PREFERRED_NAME>
            <LONG_NAME>Since</LONG_NAME>
            <CON_ID>2240692</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bronchodilator: Time since la</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bronchodilator: Time since last dose (HH:MM)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="756">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5984754</PUBLICID>
    <LONGNAME>Preoperative Assessment Indicator</LONGNAME>
    <PREFERREDNAME>PRE_OP_ASSESS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator for whether or not a pre-operative assessment was done.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Princess Margaret Cancer Centre, Toronto, ON</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5984753</PublicId>
      <PreferredName>4649596v1.0:2465182v1.0</PreferredName>
      <PreferredDefinition>Relating to or occurring during the period immediately before a surgical operation._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Preoperative Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4649596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2465182</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217</PreferredName>
        <Version>1</Version>
        <LongName>Assessed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Princess Margaret Cancer Centre, Toronto, ON</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a pre-operative assessmen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a pre-operative assessment done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was preoperative AE Assessment previously reported in weeks 16-18 folder?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="757">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5985748</PUBLICID>
    <LONGNAME>Fibrosis-4 Score</LONGNAME>
    <PREFERREDNAME>FIB_SCOR</PREFERREDNAME>
    <PREFERREDDEFINITION>The score of a noninvasive test to assess hepatic fibrosis that utilizes common laboratory findings according to the formula: age (years) x aspartate aminotransferase (AST) [U/L]/(platelets [10^9/L] x alanine aminotransferase (ALT) [U/L])^1/2).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5985743</PublicId>
      <PreferredName>5985741v1.0:2177731v1.0</PreferredName>
      <PreferredDefinition>A noninvasive test to assess hepatic fibrosis that utilizes common laboratory findings according to the formula: age (years) x aspartate aminotransferase (AST) [U/L]/(platelets [10^9/L] x alanine aminotransferase (ALT) [U/L])^1/2)._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Fibrosis-4 Score Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5985741</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C138330</PreferredName>
        <Version>1</Version>
        <LongName>Fibrosis-4 Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C138330</PREFERRED_NAME>
            <LONG_NAME>Fibrosis-4 Score</LONG_NAME>
            <CON_ID>5978106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177731</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5985747</PublicId>
      <PreferredName>5985747v1.0</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FIB-4 Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FIB-4 Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>FIB-4 Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="758">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5990052</PUBLICID>
    <LONGNAME>Prostate Cancer AJCC Edition 8 Pathologic Regional Lymph Node N Category</LONGNAME>
    <PREFERREDNAME>PROS_AJC8_PTH_N_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the regional lymph node involvement for prostate carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188819</PublicId>
      <PreferredName>PRS_TUMOR_P_N</PreferredName>
      <PreferredDefinition>Information related to pathologic N stage for prostate tumor.</PreferredDefinition>
      <LongName>Prostate Tumor Pathologic N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206573</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12410:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6038866</PublicId>
      <PreferredName>6038866v1.0</PreferredName>
      <PreferredDefinition>A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  N refers to the extent of lymph node involvement._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Prostate Carcinoma American Joint Committee on Cancer Edition 8 Pathologic N Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>6059344</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C140157:C39315:C25580:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v8 American Joint Committee on Cancer N Category Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C140157</PREFERRED_NAME>
            <LONG_NAME>Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v8</LONG_NAME>
            <CON_ID>6032135</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer pN0 TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer with no positive regional nodes. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6032875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer pN1 TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer with metastases in regional node(s). (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140160</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6032873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer pNX TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Prostate cancer in which the regional nodes were not assessed. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6032877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic N category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic N category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CPTAC-BSLN-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathologic Regional Lymph Node Status (pN)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA-prostate-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>American Joint Committee on Cancer lymph node stage  code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Template Name</Name>
        <OrganizationName/>
        <DocumentType>Data Collection Template</DocumentType>
        <DocumentText>prostate_v0_13aug2020.xlsx</DocumentText>
        <URL>https://mcl.nci.nih.gov/resources/standards/mcl-cdes</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506113</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prostate</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7781145</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 8</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6005920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6437797</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pre-Cancer Atlas (PCA) Pilot</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7001794</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635376</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6779561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCCPR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCCPR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ajcc_8_prostate_pathologic_n</AlternateName>
        <AlternateNameType>MCL Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="759">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6002205</PUBLICID>
    <LONGNAME>Histone H3 Gene Mutation Identification Type</LONGNAME>
    <PREFERREDNAME>6002156v1.0:6002157v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The mutated histone H3 gene. Mutations in histone H3 are commonly seen in pediatric brain tumors.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6002156</PublicId>
      <PreferredName>6002154v1.0:2322316v1.0</PreferredName>
      <PreferredDefinition>Histone H3 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)_change occurring in one gene._The procedure of having an identity established.</PreferredDefinition>
      <LongName>Histone H3 Gene Mutation Identification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3910</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Abnormality</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6002154</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16685:C18093</PreferredName>
        <Version>1</Version>
        <LongName>Histone H3 Gene Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16685</PREFERRED_NAME>
            <LONG_NAME>Histone H3</LONG_NAME>
            <CON_ID>3416099</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18093</PREFERRED_NAME>
            <LONG_NAME>Gene Mutation</LONG_NAME>
            <CON_ID>3086322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2322316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25737</PreferredName>
        <Version>1</Version>
        <LongName>Identified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6002157</PublicId>
      <PreferredName>6002157v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Histone H3 Mutation Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3910</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Abnormality</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other </VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None </VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H3.3</VALIDVALUE>
          <VALUEMEANING>Histone H3.3</VALUEMEANING>
          <MEANINGDESCRIPTION>Histone H3.3 (136 aa, ~15 kDa) is encoded by both the human H3F3A and H3F3B genes. This protein plays a role in chromosomal structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6002159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H3.1</VALIDVALUE>
          <VALUEMEANING>Histone H3.1</VALUEMEANING>
          <MEANINGDESCRIPTION>Histone H3.1 (136 aa, ~15 kDa) is encoded by the human HIST1H3B gene. This protein plays a role in the formation of chromatin structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6002161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>H3 mutation identified</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>H3 mutation identified</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIPG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7589450</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>H3_mutationmi</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="760">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6005095</PUBLICID>
    <LONGNAME>Derived Cancer Model Osteosarcoma Tissue Anatomic Site Name</LONGNAME>
    <PREFERREDNAME>6005094v1.0:4742892v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term that represents the anatomic site of the osteosarcoma from which the model was derived.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6005094</PublicId>
      <PreferredName>6005097v1.0:2553144v1.0</PreferredName>
      <PreferredDefinition>The source from which something comes or issues; to take, obtain, or receive from a source._Any model that can be used to study issues important in cancer such as cancer development or prediction._A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._Named locations of or within the body.</PreferredDefinition>
      <LongName>Derivation Cancer Model Osteosarcoma Tissue Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6005097</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42885:C19691:C9145</PreferredName>
        <Version>1</Version>
        <LongName>Derivation Cancer Model Osteosarcoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42885</PREFERRED_NAME>
            <LONG_NAME>Derivation</LONG_NAME>
            <CON_ID>2231196</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19691</PREFERRED_NAME>
            <LONG_NAME>Cancer Model</LONG_NAME>
            <CON_ID>2224027</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9145</PREFERRED_NAME>
            <LONG_NAME>Osteosarcoma</LONG_NAME>
            <CON_ID>3158555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553144</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12801:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4742892</PublicId>
      <PreferredName>4742892v1.0</PreferredName>
      <PreferredDefinition>The name of the anatomic site and/or location of the submitted tumor sample.</PreferredDefinition>
      <LongName>Submitted Tumor Sample Anatomic Site Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>120</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buccal Mucosa</VALIDVALUE>
          <VALUEMEANING>Buccal Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The mucosal membranes located on the inside of the cheek, in the buccal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3522966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cecum</VALIDVALUE>
          <VALUEMEANING>Cecum</VALUEMEANING>
          <MEANINGDESCRIPTION>A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Choroid</VALIDVALUE>
          <VALUEMEANING>Choroid</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood vessel-containing membrane of the eye that lies between the retina and the sclera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ciliary Body</VALIDVALUE>
          <VALUEMEANING>Ciliary Body</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Descending Colon</VALIDVALUE>
          <VALUEMEANING>Descending Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endometrium</VALIDVALUE>
          <VALUEMEANING>Endometrium</VALUEMEANING>
          <MEANINGDESCRIPTION>The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fundus of the Stomach</VALIDVALUE>
          <VALUEMEANING>Fundus of the Stomach</VALUEMEANING>
          <MEANINGDESCRIPTION>The superior portion of the body of the stomach above the level of the cardiac notch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fundus Uteri</VALIDVALUE>
          <VALUEMEANING>Fundus Uteri</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper, rounded portion of the uterus which is opposite from the cervix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3684592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastroesophageal Junction</VALIDVALUE>
          <VALUEMEANING>Gastroesophageal Junction</VALUEMEANING>
          <MEANINGDESCRIPTION>The anatomical location where the esophagus joins to the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic Flexure</VALIDVALUE>
          <VALUEMEANING>Hepatic Flexure</VALUEMEANING>
          <MEANINGDESCRIPTION>Hepatic Flexure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypopharynx</VALIDVALUE>
          <VALUEMEANING>Hypopharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the pharynx that connects to the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3595986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iris</VALIDVALUE>
          <VALUEMEANING>Iris</VALUEMEANING>
          <MEANINGDESCRIPTION>The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4503817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isthmus</VALIDVALUE>
          <VALUEMEANING>Isthmus</VALUEMEANING>
          <MEANINGDESCRIPTION>A narrow part inside the body that connects two larger structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isthmus Uteri</VALIDVALUE>
          <VALUEMEANING>Isthmus Uteri</VALUEMEANING>
          <MEANINGDESCRIPTION>An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3691230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lip</VALIDVALUE>
          <VALUEMEANING>Lip</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two fleshy, full-blooded margins of the mouth. (MeSH)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower</VALIDVALUE>
          <VALUEMEANING>Lower</VALUEMEANING>
          <MEANINGDESCRIPTION>Lower; the bottom one of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Middle</VALIDVALUE>
          <VALUEMEANING>Middle</VALUEMEANING>
          <MEANINGDESCRIPTION>An intermediate part or section; an area that is approximately central within some larger region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myometrium</VALIDVALUE>
          <VALUEMEANING>Myometrium</VALUEMEANING>
          <MEANINGDESCRIPTION>The smooth muscle lining the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oropharynx</VALIDVALUE>
          <VALUEMEANING>Oropharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>(or-o-FAIR-inks) The middle part of the throat that includes the soft palate, the base of the tongue, and the tonsils.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3126125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic Body</VALIDVALUE>
          <VALUEMEANING>Body of the Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic Head</VALIDVALUE>
          <VALUEMEANING>Head of the Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>That portion of the pancreas lying in the concavity of the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic Tail</VALIDVALUE>
          <VALUEMEANING>Tail of the Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>The left extremity of the pancreas within the lienorenal ligament.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proximal</VALIDVALUE>
          <VALUEMEANING>Proximal</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated nearest to a point of attachment or origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectosigmoid Junction</VALIDVALUE>
          <VALUEMEANING>Rectosigmoid Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The area where the sigmoid colon joins the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sigmoid Colon</VALIDVALUE>
          <VALUEMEANING>Sigmoid Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>Sigmoid Colon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic Flexure</VALIDVALUE>
          <VALUEMEANING>Splenic Flexure</VALUEMEANING>
          <MEANINGDESCRIPTION>The bend at the junction of the transverse and descending colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supratentorial</VALIDVALUE>
          <VALUEMEANING>Supratentorial</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the upper part of the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4289607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tonsil</VALIDVALUE>
          <VALUEMEANING>Tonsil</VALUEMEANING>
          <MEANINGDESCRIPTION>The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transverse Colon</VALIDVALUE>
          <VALUEMEANING>Transverse Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper</VALIDVALUE>
          <VALUEMEANING>Upper</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ureteric Orifice</VALIDVALUE>
          <VALUEMEANING>Ureteric Orifice</VALUEMEANING>
          <MEANINGDESCRIPTION>The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3684632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Distal</VALIDVALUE>
          <VALUEMEANING>Distal</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wall Posterior</VALIDVALUE>
          <VALUEMEANING>Posterior Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.: A layer of material that encloses space or that encloses a structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64373, C25622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wall NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: A layer of material that encloses space or that encloses a structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64373, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wall Lateral</VALIDVALUE>
          <VALUEMEANING>Lateral Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated at or extending to the side.: A layer of material that encloses space or that encloses a structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64373, C25230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wall Anterior</VALIDVALUE>
          <VALUEMEANING>Anterior Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the front surface of the body; often used to indicate the position of one structure relative to another.: A layer of material that encloses space or that encloses a structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64373, C25231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trigone</VALIDVALUE>
          <VALUEMEANING>Bladder Trigone</VALUEMEANING>
          <MEANINGDESCRIPTION>The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3130369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tongue, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Tongue</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12422, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Posterior Fossa</VALIDVALUE>
          <VALUEMEANING>Posterior Fossa</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.: A concavity in a surface, especially an anatomical depression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34007, C25622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palate, Hard</VALIDVALUE>
          <VALUEMEANING>Hard Palate</VALUEMEANING>
          <MEANINGDESCRIPTION>The bony anterior part of the roof of the mouth separating the nose from the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3522964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Overlapping Regions</VALIDVALUE>
          <VALUEMEANING>Overlap Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The phenomenon of coinciding partially or wholly; extending over and covering a part of.: An area or portion of something with more or less definite boundaries designed or specified according to some established biological, administrative, economic, demographic, etc. criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41129, C54669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Tongue</VALIDVALUE>
          <VALUEMEANING>Oral Tongue</VALUEMEANING>
          <MEANINGDESCRIPTION>Oral; of, or relating to, or affecting, or for use in the mouth.: The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12422, C25311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3684608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower uterine segment/ Isthmus uteri</VALIDVALUE>
          <VALUEMEANING>Lower Uterus Segment Isthmus Uteri</VALUEMEANING>
          <MEANINGDESCRIPTION>The bottom one of two.: A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.: One of the parts into which something naturally divides.: An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12312, C45312, C12405, C25309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3684607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Cavity, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Oral Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12421, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: The region that connects the head to the rest of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13063, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larynx, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Larynx</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12420, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardia; Proximal</VALIDVALUE>
          <VALUEMEANING>Proximal Gastric Cardia</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated nearest to a point of attachment or origin.: The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12256, C25236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4134138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Floor of Mouth</VALIDVALUE>
          <VALUEMEANING>Floor of Mouth</VALUEMEANING>
          <MEANINGDESCRIPTION>The area of the mouth under the ventral surface of the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dome</VALIDVALUE>
          <VALUEMEANING>Dome of the Bladder</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper, convex surface of the bladder.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endometrium, Lower Segment/Isthmus</VALIDVALUE>
          <VALUEMEANING>Lower Segment Isthmus Endometrium</VALUEMEANING>
          <MEANINGDESCRIPTION>The bottom one of two.: One of the parts into which something naturally divides.: A narrow part inside the body that connects two larger structures.: The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12313, C93172, C45312, C25309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4742913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endometrium, Adenomyosis</VALIDVALUE>
          <VALUEMEANING>Uterine Adenomyosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The growth of endometrial tissue inside the muscular wall of the uterus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alveolar</VALIDVALUE>
          <VALUEMEANING>Alveolar</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or relating to the alveoli.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4214606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anterior</VALIDVALUE>
          <VALUEMEANING>Anterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the front surface of the body; often used to indicate the position of one structure relative to another.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antrum</VALIDVALUE>
          <VALUEMEANING>Antrum</VALUEMEANING>
          <MEANINGDESCRIPTION>A chamber formation in an organ.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascending Colon</VALIDVALUE>
          <VALUEMEANING>Ascending Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>Ascending Colon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Base of the Tongue</VALIDVALUE>
          <VALUEMEANING>Base of the Tongue</VALUEMEANING>
          <MEANINGDESCRIPTION>The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx responsible for swallowing and modification of the voice in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lingula (left only)</VALIDVALUE>
          <VALUEMEANING>Lingula of the Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>A small tongue-like projection from the lower portion of the upper lobe of the left lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C40373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3773789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower Outer Quadrant</VALIDVALUE>
          <VALUEMEANING>Lower Outer Quadrant</VALUEMEANING>
          <MEANINGDESCRIPTION>To become lower, grow less, or diminish, as in amount, intensity, degree, or value.: Being on or toward the outside of the body or object.: One quarter of a circle. In anatomy, one part of an area divided into quarters for descriptive purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61106, C38166, C86568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower Inner Quadrant</VALIDVALUE>
          <VALUEMEANING>Lower Inner Quadrant</VALUEMEANING>
          <MEANINGDESCRIPTION>To become lower, grow less, or diminish, as in amount, intensity, degree, or value.: Inside or closer to the inside of the body or object.: One quarter of a circle. In anatomy, one part of an area divided into quarters for descriptive purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61106, C37980, C86568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper Outer Quadrant</VALIDVALUE>
          <VALUEMEANING>Upper Outer Quadrant</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: Being on or toward the outside of the body or object.: One quarter of a circle. In anatomy, one part of an area divided into quarters for descriptive purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61106, C38166, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper Inner Quadrant</VALIDVALUE>
          <VALUEMEANING>Upper Inner Quadrant</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: Inside or closer to the inside of the body or object.: One quarter of a circle. In anatomy, one part of an area divided into quarters for descriptive purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61106, C37980, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5724614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Nodes</VALIDVALUE>
          <VALUEMEANING>Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3387894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneum</VALIDVALUE>
          <VALUEMEANING>Peritoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue that lines the wall of the abdominal cavity, intestine, and mesentery. It consists of the parietal peritoneum that covers the inside of the abdominal wall and the visceral peritoneum that covers the surface of the intestine and mesentery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3625362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4363636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvis</VALIDVALUE>
          <VALUEMEANING>Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spine</VALIDVALUE>
          <VALUEMEANING>Vertebral Column</VALUEMEANING>
          <MEANINGDESCRIPTION>A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4550853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower extremity</VALIDVALUE>
          <VALUEMEANING>Lower Extremity</VALUEMEANING>
          <MEANINGDESCRIPTION>The bottom one of two.: A body region referring to an upper or lower extremity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12429, C25309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper extremity</VALIDVALUE>
          <VALUEMEANING>Upper Extremity</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: A body region referring to an upper or lower extremity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12429, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinum</VALIDVALUE>
          <VALUEMEANING>Mediastinum</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleura</VALIDVALUE>
          <VALUEMEANING>Pleura</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue that lines the wall of the thoracic cavity and the surface of the lungs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3639609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5446318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anatomic site of osteosarcoma</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Anatomic site of osteosarcoma from which model was derived</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pediatric Osteosarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5806869</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>osteosarcoma_specimen_derived_site</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="761">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6021656</PUBLICID>
    <LONGNAME>Surgical Procedure Perioperative Complication Indicator</LONGNAME>
    <PREFERREDNAME>SURG_PROC_POPCMP_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not perioperative complications occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Princess Margaret Cancer Centre, Toronto, ON</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6021655</PublicId>
      <PreferredName>2322305v1.0:6021653v1.0</PreferredName>
      <PreferredDefinition>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._Around the time of surgery. This usually lasts from the time the patient goes into the hospital or doctor&#39;s office for surgery until the time the patient goes home._Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.</PreferredDefinition>
      <LongName>Surgical Procedure Perioperative Complication</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6021653</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28374:C2959</PreferredName>
        <Version>1</Version>
        <LongName>Perioperative Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28374</PREFERRED_NAME>
            <LONG_NAME>Perioperative</LONG_NAME>
            <CON_ID>2685271</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2959</PREFERRED_NAME>
            <LONG_NAME>Complication</LONG_NAME>
            <CON_ID>2203884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Princess Margaret Cancer Centre, Toronto, ON</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Peri  operative complications</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Peri  operative complications</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="762">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6025027</PUBLICID>
    <LONGNAME>Systemic Therapy And/Or Chemotherapy Regimen Therapeutic Procedure Administered Type</LONGNAME>
    <PREFERREDNAME>6025026v1.0:6025015v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the systemic therapy and or chemotherapy regimen that was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6025026</PublicId>
      <PreferredName>6025024v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._Used to indicate that either or both of two items or options may be valid._Any regimen that can be used for the treatment of cancer._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Systemic Therapy And/Or Chemotherapy Regimen Therapeutic Procedure Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6025024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15698:C48928:C62634:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Therapy And/Or Chemotherapy Regimen Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15698</PREFERRED_NAME>
            <LONG_NAME>Systemic Therapy</LONG_NAME>
            <CON_ID>2202843</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62634</PREFERRED_NAME>
            <LONG_NAME>Chemo/immuno/hormone Therapy Regimen</LONG_NAME>
            <CON_ID>3595834</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6025015</PublicId>
      <PreferredName>6025015v1.0</PreferredName>
      <PreferredDefinition>Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._Used to indicate that either or both of two items or options may be valid._Any regimen that can be used for the treatment of cancer._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Systemic Therapy And/Or Chemotherapy Regimen Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>6025023</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15698:C48928:C62634:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Therapy And/Or Chemotherapy Regimen Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15698</PREFERRED_NAME>
            <LONG_NAME>Systemic Therapy</LONG_NAME>
            <CON_ID>2202843</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62634</PREFERRED_NAME>
            <LONG_NAME>Chemo/immuno/hormone Therapy Regimen</LONG_NAME>
            <CON_ID>3595834</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corticosteroids</VALIDVALUE>
          <VALUEMEANING>Systemic Corticosteroid Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bortezomib</VALIDVALUE>
          <VALUEMEANING>Bortezomib</VALUEMEANING>
          <MEANINGDESCRIPTION>A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmustine</VALIDVALUE>
          <VALUEMEANING>Carmustine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cisplatin</VALIDVALUE>
          <VALUEMEANING>Cisplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5544728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclophosphamide</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytarabine</VALIDVALUE>
          <VALUEMEANING>Cytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that belongs to the family of drugs called antimetabolites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3270479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin</VALIDVALUE>
          <VALUEMEANING>Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin liposomal</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Hydrochloride Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoposide</VALIDVALUE>
          <VALUEMEANING>Etoposide</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idarubicin</VALIDVALUE>
          <VALUEMEANING>Idarubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2744955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenalidomide</VALIDVALUE>
          <VALUEMEANING>Lenalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melphalan</VALIDVALUE>
          <VALUEMEANING>Melphalan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other systemic therapy</VALIDVALUE>
          <VALUEMEANING>Other Systemic Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15698, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vorinostat</VALIDVALUE>
          <VALUEMEANING>Vorinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thalidomide</VALIDVALUE>
          <VALUEMEANING>Thalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pomalidomide</VALIDVALUE>
          <VALUEMEANING>Pomalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3944871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon alpha</VALIDVALUE>
          <VALUEMEANING>Interferon Alpha</VALUEMEANING>
          <MEANINGDESCRIPTION>A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elotuzumab</VALIDVALUE>
          <VALUEMEANING>Elotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clarithromycin</VALIDVALUE>
          <VALUEMEANING>Clarithromycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carfilzomib</VALIDVALUE>
          <VALUEMEANING>Carfilzomib</VALUEMEANING>
          <MEANINGDESCRIPTION>An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bendamustine</VALIDVALUE>
          <VALUEMEANING>Bendamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4862971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RD</VALIDVALUE>
          <VALUEMEANING>Lenalidomide-Dexamethasone Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of lenalidomide and dexamethasone used to treat relapsed or refractory multiple myeloma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DVD / VDD</VALIDVALUE>
          <VALUEMEANING>Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment regimen consisting of a combination of bortezomib, dexamethasone and pegylated liposomal doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RVD / VRD</VALIDVALUE>
          <VALUEMEANING>Bortezomib/Dexamethasone/Lenalidomide Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment regimen consisting of a combination of bortezomib, dexamethasone and lenalidomide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VCD</VALIDVALUE>
          <VALUEMEANING>Bortezomib/Cyclophosphamide/Dexamethasone Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment regimen consisting of a combination of bortezomib, cyclophosphamide and dexamethasone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MLN 9708</VALIDVALUE>
          <VALUEMEANING>Ixazomib Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nivolumab and Ipilimumab</VALIDVALUE>
          <VALUEMEANING>Ipilimumab and Nivolumab Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6409150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nivolumab</VALIDVALUE>
          <VALUEMEANING>Nivolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the systemic therapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the systemic therapy and or chemotherapy regimen that was administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Systemic drugs</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Systemic drugs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Systemic drugs</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Systemic drugs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What treatment will patient receive in the next cycle?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SYSTX_CT_RGM_ADM_TP</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="763">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6028518</PUBLICID>
    <LONGNAME>Mammogram Machine Type Text</LONGNAME>
    <PREFERREDNAME>6028471v1.0:2181231v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The text to capture the type of mammogram machine.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6028471</PublicId>
      <PreferredName>2495101v1.0:6028469v1.0</PreferredName>
      <PreferredDefinition>A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts._No Value Exists_Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Mammogram Machine Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2495101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20178</PreferredName>
        <Version>1</Version>
        <LongName>Mammogram</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20178</PREFERRED_NAME>
            <LONG_NAME>Mammogram</LONG_NAME>
            <CON_ID>2202867</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6028469</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL161587:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Machine Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL161587</PREFERRED_NAME>
            <LONG_NAME>Machine</LONG_NAME>
            <CON_ID>2503522</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mammography machine type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mammography machine type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="764">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6029933</PUBLICID>
    <LONGNAME>Image Collected Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6029916v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to if an image was collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6029916</PublicId>
      <PreferredName>2423453v1.0:2402572v1.0</PreferredName>
      <PreferredDefinition>Any record of an imaging event whether physical or electronic._Collected refers to objects having been brought together in one place.</PreferredDefinition>
      <LongName>Image Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2423453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179</PreferredName>
        <Version>1</Version>
        <LongName>Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2402572</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25452</PreferredName>
        <Version>1</Version>
        <LongName>Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was image collected?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was image collected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="765">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6045207</PUBLICID>
    <LONGNAME>Biospecimen Collection Biospecimen Type</LONGNAME>
    <PREFERREDNAME>BIOSPEC_COLL_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Collection of any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._Something distinguishable as an identifiable class based on common qualities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192115</PublicId>
      <PreferredName>BSPC_CLLCT</PreferredName>
      <PreferredDefinition>Collection of any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.</PreferredDefinition>
      <LongName>Biospecimen Collection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2413010</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25453</PreferredName>
        <Version>1</Version>
        <LongName>Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6045205</PublicId>
      <PreferredName>6045205v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Biospecimen Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17828 </PreferredName>
        <Version>1</Version>
        <LongName>Biological Process</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>3153680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood for research samples</VALIDVALUE>
          <VALUEMEANING>Blood for research samples</VALUEMEANING>
          <MEANINGDESCRIPTION>Blood for research samples</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical Brushing</VALIDVALUE>
          <VALUEMEANING>Cervical Brushing</VALUEMEANING>
          <MEANINGDESCRIPTION>Cervical Brushing</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Swab of the vagina</VALIDVALUE>
          <VALUEMEANING>Swab of the vagina</VALUEMEANING>
          <MEANINGDESCRIPTION>Swab of the vagina</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Swab of the cervix</VALIDVALUE>
          <VALUEMEANING>Swab of the cervix</VALUEMEANING>
          <MEANINGDESCRIPTION>Swab of the cervix</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervicovaginal Lavage</VALIDVALUE>
          <VALUEMEANING>Cervicovaginal Lavage</VALUEMEANING>
          <MEANINGDESCRIPTION>Cervicovaginal Lavage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical Cells for Pap Smear</VALIDVALUE>
          <VALUEMEANING>Cervical Cells for Pap Smear</VALUEMEANING>
          <MEANINGDESCRIPTION>Cervical Cells for Pap Smear</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine for research samples</VALIDVALUE>
          <VALUEMEANING>Urine for research samples</VALUEMEANING>
          <MEANINGDESCRIPTION>Urine for research samples</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-12-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6045213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Research Specimen Collection</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Research Specimen Collection Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6046252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="766">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6058832</PUBLICID>
    <LONGNAME>Atezolizumab Administered Indicator</LONGNAME>
    <PREFERREDNAME>6058831v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not atezolizumab was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6058831</PublicId>
      <PreferredName>6058829v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Atezolizumab Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6058829</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106250</PreferredName>
        <Version>1</Version>
        <LongName>Atezolizumab</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106250</PREFERRED_NAME>
            <LONG_NAME>Atezolizumab</LONG_NAME>
            <CON_ID>5242661</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Atezolizumab</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Atezolizumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Atezolizumab</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Atezolizumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was atezolizumab administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was atezolizumab administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive Atezolizumab in combination with etoposide/platinum?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="767">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6059342</PUBLICID>
    <LONGNAME>Immune Checkpoint Inhibitor Administered Specify Text</LONGNAME>
    <PREFERREDNAME>6059281v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the immune checkpoint inhibitor that was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6059281</PublicId>
      <PreferredName>6059279v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>An agent that inhibits any of the immune checkpoint inhibitory proteins._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Immune Checkpoint Inhibitor Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6059279</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C143250</PreferredName>
        <Version>1</Version>
        <LongName>Immune Checkpoint Inhibitor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C143250</PREFERRED_NAME>
            <LONG_NAME>Immune Checkpoint Inhibitor</LONG_NAME>
            <CON_ID>6059263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify immune check point in</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify immune check point inhibitor:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="768">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6113696</PUBLICID>
    <LONGNAME>Breast Carcinoma Lymph Node Largest Metastasis Diameter Measurement</LONGNAME>
    <PREFERREDNAME>BRCA_LN_LRG_METS_DIAM_MSRMT</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric annotation to indicate the largest diameter of lymph node metastases measured in mm.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3293778</PublicId>
      <PreferredName>3293776v1.0:2492778v1.0</PreferredName>
      <PreferredDefinition>related to the length of a straight line passing through the center of the largest rounded mass of lymphatic tissue to which cancer has first spread from a primary tumor of the mammary organs._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter&#39;s syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._Greatest in size of those under consideration._The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.</PreferredDefinition>
      <LongName>Breast Carcinoma Lymph Node largest Metastasis Diameter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3293776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4872:C12745</PreferredName>
        <Version>1</Version>
        <LongName>Breast Carcinoma Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4872</PREFERRED_NAME>
            <LONG_NAME>Breast Carcinoma</LONG_NAME>
            <CON_ID>2475940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3793746</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25550:C19151:C25285</PreferredName>
        <Version>1</Version>
        <LongName>Largest Metastasis Diameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25550</PREFERRED_NAME>
            <LONG_NAME>Largest</LONG_NAME>
            <CON_ID>2206285</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19151</PREFERRED_NAME>
            <LONG_NAME>Metastasis</LONG_NAME>
            <CON_ID>2202751</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6113695</PublicId>
      <PreferredName>6113695v1.0</PreferredName>
      <PreferredDefinition>Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.</PreferredDefinition>
      <LongName>Millimeter Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat>99.9</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
      <Representation>
        <PublicId>2184312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Measurement of largest metast</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Measurement of largest metastases</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BRCA_LN_LRG_METS_DIAM_MSRMT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="769">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6133609</PUBLICID>
    <LONGNAME>Genetic Disorder Diagnosis Type</LONGNAME>
    <PREFERREDNAME>genetic_syndrome_diagnosis</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term used to describe clinically diagnosed  genetic diseases or disorders.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>GDC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GDC:NCI Genomic Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6133601</PublicId>
      <PreferredName>3133968v1.0:2239981v1.0</PreferredName>
      <PreferredDefinition>Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Genetic Disorder Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>GDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3133968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3101</PreferredName>
        <Version>1</Version>
        <LongName>Genetic Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3101</PREFERRED_NAME>
            <LONG_NAME>Genetic Disorder</LONG_NAME>
            <CON_ID>2958272</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GDC:NCI Genomic Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6001793</PublicId>
      <PreferredName>6001793v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Genetic Disorder Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lynch syndrome</VALIDVALUE>
          <VALUEMEANING>Hereditary Non-Polyposis Colon Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma.  Patients often develop colorectal carcinomas at an early age (mean, 45 years).  In the majority of the cases the lesions arise from the proximal colon.  At the molecular level, high-frequency microsatellite instability is present.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2716424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Li-Fraumeni syndrome</VALIDVALUE>
          <VALUEMEANING>Li-Fraumeni Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fanconi anemia</VALIDVALUE>
          <VALUEMEANING>Fanconi Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare inherited disorder in which the bone marrow does not make blood cells. It is usually diagnosed in children between 2 and 15 years old. Symptoms include frequent infections, easy bleeding, and extreme tiredness. People with Fanconi anemia may have a small skeleton and brown spots on the skin. They also have an increased risk of developing certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5651022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gorlin syndrome</VALIDVALUE>
          <VALUEMEANING>Nevoid Basal Cell Carcinoma Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant genetic syndrome caused by abnormalities in the PTCH gene.  It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida).  Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rubinstein-Taybi syndrome</VALIDVALUE>
          <VALUEMEANING>Rubinstein-Taybi Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene.  It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes.  Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable </VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown </VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Turcot syndrome</VALIDVALUE>
          <VALUEMEANING>Turcot Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6002212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cirrhosis unknown etiology</VALIDVALUE>
          <VALUEMEANING>Cirrhosis Unknown Etiology</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.: Not known, not observed, not recorded, or refused.: The cause of a disease or abnormal condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16390, C17998, C2951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6133539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha-1 antitrypsin</VALIDVALUE>
          <VALUEMEANING>Alpha-1 Antitrypsin Deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beckwith-Wiedemann</VALIDVALUE>
          <VALUEMEANING>Beckwith-Wiedemann Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic syndrome caused by abnormalities in chromosome 11.  It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia.  Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, Rhabdomyosarcoma) and adrenal cortex carcinomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2967368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biliary disorder</VALIDVALUE>
          <VALUEMEANING>Biliary Tract Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-neoplastic or neoplastic disorder affecting the intrahepatic or extrahepatic biliary tract. Examples of non-neoplastic disorders include infection and atresia. Examples of neoplastic disorders include adenoma and carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glycogen Storage Disease</VALIDVALUE>
          <VALUEMEANING>Glycogen Storage Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosinemia</VALIDVALUE>
          <VALUEMEANING>Tyrosinemia</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6013366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hereditary renal oncocytoma</VALIDVALUE>
          <VALUEMEANING>Hereditary Kidney Oncocytoma</VALUEMEANING>
          <MEANINGDESCRIPTION>An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tuberous sclerosis</VALIDVALUE>
          <VALUEMEANING>Tuberous Sclerosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2962075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Familial renal cancer</VALIDVALUE>
          <VALUEMEANING>Hereditary Renal Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Birt-Hogg-Dube syndrome</VALIDVALUE>
          <VALUEMEANING>Birt-Hogg-Dube Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28244</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hereditary leiomyoma-renal cell carcinoma</VALIDVALUE>
          <VALUEMEANING>Hereditary Leiomyomatosis and Renal Cell Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to leiomyomas of the skin and uterus, renal cell carcinoma, and leiomyosarcoma of the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51302</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hereditary papillary renal cell carcinoma</VALIDVALUE>
          <VALUEMEANING>Hereditary Papillary Renal Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A familiar carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SDH associated renal cancer</VALIDVALUE>
          <VALUEMEANING>Associated SDH Complex Gene Mutation Kidney Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Joined in some kind of relationship.: A change in the nucleotide sequence of any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.: A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9384, C48301, C25281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PTEN hamartoma syndrome (Cowden syndrome)</VALIDVALUE>
          <VALUEMEANING>Cowden Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAP1 mutant disease</VALIDVALUE>
          <VALUEMEANING>BAP1 Gene Mutation Disease or Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the nucleotide sequence of the BAP1 gene.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2991, C128813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6789683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>von Hippel-Lindau Syndrome</VALIDVALUE>
          <VALUEMEANING>Von Hippel-Lindau Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2962084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genetic syndrome diagnoses</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Genetic syndrome diagnoses</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5428034</PublicId>
          <ContextName>GDC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Followup</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6059563</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="770">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6133615</PUBLICID>
    <LONGNAME>Patient Central Nervous System Disease or Disorder Eligibility Determination Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>2974446v1.0:3506035v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The information (yes/no/unknown/not applicable) related to eligibility criteria for person who receives medical attention, care, or treatment having disease related to the brain and spinal cord.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PBTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2974446</PublicId>
      <PreferredName>2233604v1.0:2974444v1.0</PreferredName>
      <PreferredDefinition>information related to eligibility criteria for person who receives medical attention, care, or treatment having disease related to the brain and spinal cord.</PreferredDefinition>
      <LongName>Patient Central Nervous System Disease or Disorder Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2974478</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12438:C2991:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Central Nervous System Disease or Disorder Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12438</PREFERRED_NAME>
            <LONG_NAME>Central Nervous System</LONG_NAME>
            <CON_ID>2202492</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a recur</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a recurrent, progressive or refractory primary CNS tumor with evidence of genetic activation of the MET pathway, regardless of histology?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have evidence of genetic activation of the MET pathway, confirmed using FDA approved panel such as MSK-IMPACT, FoundationOne, Oncomine?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If the patient has brain metastasis, have the criteria in 3.3.7 been met?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have radiographic diagnosis of leptomeningeal metastasis with linear and/or nodular disease and documentation of typical clinical signs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_RG_DX_LM_M</AlternateName>
        <AlternateNameType>OID, NRG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="771">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6141596</PUBLICID>
    <LONGNAME>Breast Feeding Last Birth Duration Number</LONGNAME>
    <PREFERREDNAME>BRSTFED_LST_BTH_DURT_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The length of breast feeding for last child birth.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6141583</PublicId>
      <PreferredName>3355097v1.0:6141581v1.0</PreferredName>
      <PreferredDefinition>The nursing of an infant at the mother&#39;s breast._Coming after all others in time or space or degree or being the only one remaining._The event of being born._The period of time during which something continues.</PreferredDefinition>
      <LongName>Breast Feeding Last Birth Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3355097</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25596</PreferredName>
        <Version>1</Version>
        <LongName>Breast Feeding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25596</PREFERRED_NAME>
            <LONG_NAME>Breast Feeding</LONG_NAME>
            <CON_ID>2419414</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6141581</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25551:C25155:C25330</PreferredName>
        <Version>1</Version>
        <LongName>Last Birth Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6013152</PublicId>
      <PreferredName>6013152v1.0</PreferredName>
      <PreferredDefinition>A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>19</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>4</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Duration of breastfeeding for</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Duration of breastfeeding for last birth</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="772">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6161339</PUBLICID>
    <LONGNAME>Arm and Breast Symptom Questionnaire 19 Past 7 Days How Much Bothered by Tingling in Affected Breast or Chest Area Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>ARM_BRST_19_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how much they have been bothered in the past 7 days by tingling sensation (&quot;pins &amp; needles&quot;) in their affected breast or chest area, using a 5-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6161266</PublicId>
      <PreferredName>6161207v1.0:6161319v1.0</PreferredName>
      <PreferredDefinition>The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._Subjective evidence of disease perceived by the patient._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._The most recent week, including today._A question about how bothered an individual is by tingling sensation in their breast or chest area._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Arm and Breast Symptom Questionnaire Past Week How Much Bothered by Tingling in Affected Breast or Chest Area Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6161207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6161207v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Arm And Breast Symptom Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32141</PREFERRED_NAME>
            <LONG_NAME>Arm</LONG_NAME>
            <CON_ID>2202427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6161319</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C148220:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Much Bothered by Tingling in Affected Breast or Chest Area Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C148220</PREFERRED_NAME>
            <LONG_NAME>How Much Bothered by Tingling in Affected Breast or Chest Area Question</LONG_NAME>
            <CON_ID>6161134</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6161291</PublicId>
      <PreferredName>ARM_BRST_BTHRD_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (not at all difficult) to 5 (Unable to do) on a 5-point Likert scale.</PreferredDefinition>
      <LongName>Arm and Breast Symptom Questionnaire Bothered 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tingling sensation (&quot;pins &amp; needles&quot;) in the breast or chest area?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6009267</PublicId>
          <ContextName>CCTG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCTG </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Registration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000709</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ARM_BRST_19_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="773">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6180808</PUBLICID>
    <LONGNAME>Person Prior Combination Drug Therapy Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>PER_COMB_ DRG_THPY_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior drug combination therapy as outlined in the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6180782</PublicId>
      <PreferredName>2236731v1.0:6180847v1.0</PreferredName>
      <PreferredDefinition>A human being._Earlier in time or order._Drug therapy with two or more drugs given separately or together for a combined effect._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person Prior Combination Drug Therapy Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6180847</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C16144:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Prior Combination Drug Therapy Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16144</PREFERRED_NAME>
            <LONG_NAME>Combination Drug Therapy</LONG_NAME>
            <CON_ID>3794711</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If patient is in the Doublet</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If patient is in the Doublet cohort and Triplet safety run-in phase, has patient received prior treatment with a combination of a P13K inhibitor and a PD-1 inhibitor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior treatment with a PI3K/mTOR/AKT pathway inhibitor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If enrolled in the Phase-1B, is patient a considered candidate for trastuzumab and pertuzumab combination or on maintenance trastuzumab and pertuzumab (with or without prior chemotherapy) as long as DLT can be determined?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatments</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876424</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="774">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6270379</PUBLICID>
    <LONGNAME>Infusion Catheter Placement Location Other Specify</LONGNAME>
    <PREFERREDNAME>INF_CATH_OTH_PLCM_SP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of another vessel location, not previously specified, in which an infusion catheter tip is placed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3234566</PublicId>
      <PreferredName>INFUS_CATH_PLCM_TP</PreferredName>
      <PreferredDefinition>(KATH-i-ter) A flexible tube used to deliver fluids into or withdraw fluids from the body._A flexible tube designed to transfer fluids into or out of the body._A position, site, or point in space where something can be found._Position or arrangement, as of the teeth; the state of being placed or arranged, as the assignment of a person to a appropriate clinical study._</PreferredDefinition>
      <LongName>Infusion Catheter Placement Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3234564</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15388:C50344:C41148</PreferredName>
        <Version>1</Version>
        <LongName>Infusion Procedure Catheter Placement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15388</PREFERRED_NAME>
            <LONG_NAME>Infusion Procedure</LONG_NAME>
            <CON_ID>2203835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50344</PREFERRED_NAME>
            <LONG_NAME>Catheter Device</LONG_NAME>
            <CON_ID>3212279</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41148</PREFERRED_NAME>
            <LONG_NAME>Placement</LONG_NAME>
            <CON_ID>2422733</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25341</PreferredName>
        <Version>1</Version>
        <LongName>Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Catheter placement site, othe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Catheter placement site, other specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="775">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6273332</PUBLICID>
    <LONGNAME>Pathology Tissue Specimen Source Type</LONGNAME>
    <PREFERREDNAME>PATH_TISS_SPEC_TYP</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of tissue that was submitted for assessment of disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010772</PublicId>
      <PreferredName>PATH_TISS_SPEC_DESC</PreferredName>
      <PreferredDefinition>related to the description for the sample of cells with similar specialized characteristics used for assessment of disease by a specialist in cellular and tissue function and changes.</PreferredDefinition>
      <LongName>Pathology Tissue Specimen Description</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2488643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18189:C12801:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Pathology Tissue Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6273326</PublicId>
      <PreferredName>6273326v1.0</PreferredName>
      <PreferredDefinition>a description for the origin (type or location within the body) of a sample of tissue used for assessment of disease by a specialist in cellular and tissue function and changes.</PreferredDefinition>
      <LongName>Pathology Tissue Specimen Source Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>18</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O</VALIDVALUE>
          <VALUEMEANING>OTHER SPECIFY</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M</VALIDVALUE>
          <VALUEMEANING>Metastatic</VALUEMEANING>
          <MEANINGDESCRIPTION>Metastatic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>Normal Histology</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16681, C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P</VALIDVALUE>
          <VALUEMEANING>PRIMARY</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring first in time or sequence; original; of greatest rank or importance or value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What type of tissue was submi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What type of tissue was submitted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Please specify tissue source:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="776">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6289478</PUBLICID>
    <LONGNAME>Patient Authorization Inherited Mutation Result Consent Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_AUTH_INHER_MUT_RES_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The Yes No inidcator that indicates whether the patient chooses to have their study doctor to receive information about inherited mutations uncovered in this study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6289471</PublicId>
      <PreferredName>2233604v1.0:6289469v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Decision of the competent authorities in form of a letter, document, or verbal or electronic form, that confirms that somebody has permission to do something or be somewhere, e.g. to realize a given project._Transmitted through genes from parents to offspring. (genome.gov)_Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._The result of an action._Permission to do something.</PreferredDefinition>
      <LongName>Patient Authorization Inherited Mutation Result Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6289469</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6289469v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Authorization Inherited Mutation Abnormality Outcome Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41192</PREFERRED_NAME>
            <LONG_NAME>Authorization</LONG_NAME>
            <CON_ID>2204028</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28018</PREFERRED_NAME>
            <LONG_NAME>Inherited</LONG_NAME>
            <CON_ID>2437674</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45576</PREFERRED_NAME>
            <LONG_NAME>Mutation Abnormality</LONG_NAME>
            <CON_ID>2532673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If you choose NO, indicating</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If you choose NO, indicating that you do not want to be told about inherited mutations, do you want your study doctor to receive information about inherited mutations uncovered in this study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="777">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6290028</PUBLICID>
    <LONGNAME>Liquid Enzalutamide Formulation Overall Taste Rating Scale</LONGNAME>
    <PREFERREDNAME>EZLTMD_LQ_OVR_TST_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>The patient&#39;s overall rating of the taste of the liquid enzalutamide formulation, using a 4 point scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6289605</PublicId>
      <PreferredName>6289595v1.0:6289603v1.0</PreferredName>
      <PreferredDefinition>A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.)_An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance._Including everything._The faculty of taste, distinguishing substances by means of the taste buds._The act of ascertaining or fixing the value or worth of something.</PreferredDefinition>
      <LongName>Liquid Dosage Form Enzalutamide Overall Gustation Rating</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6289595</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42953:C71744</PreferredName>
        <Version>1</Version>
        <LongName>Liquid Dosage Form Enzalutamide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42953</PREFERRED_NAME>
            <LONG_NAME>Liquid Dosage Form</LONG_NAME>
            <CON_ID>2480295</CON_ID>
            <DEFINITION_SOURCE>FDA</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71744</PREFERRED_NAME>
            <LONG_NAME>Enzalutamide</LONG_NAME>
            <CON_ID>3441944</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6289603</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25605:C20620:C77538</PreferredName>
        <Version>1</Version>
        <LongName>Overall Gustation Rating</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25605</PREFERRED_NAME>
            <LONG_NAME>Overall</LONG_NAME>
            <CON_ID>2203597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20620</PREFERRED_NAME>
            <LONG_NAME>Gustation</LONG_NAME>
            <CON_ID>2500851</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77538</PREFERRED_NAME>
            <LONG_NAME>Rating</LONG_NAME>
            <CON_ID>2793832</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCR:Center for Cancer Research</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6289668</PublicId>
      <PreferredName>TASTE_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Taste Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>good</VALIDVALUE>
          <VALUEMEANING>Good</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>acceptable</VALIDVALUE>
          <VALUEMEANING>Acceptable</VALUEMEANING>
          <MEANINGDESCRIPTION>Satisfying an established set of qualifying measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>almost acceptable</VALIDVALUE>
          <VALUEMEANING>Nearly Acceptable</VALUEMEANING>
          <MEANINGDESCRIPTION>Not quite or just short of.: Satisfying an established set of qualifying measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63350, C107222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6289669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bad</VALIDVALUE>
          <VALUEMEANING>Bad</VALUEMEANING>
          <MEANINGDESCRIPTION>Having undesirable or negative qualities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6289670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please rate the overall taste</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please rate the overall taste of the liquid enzalutamide formulation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="778">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6298145</PUBLICID>
    <LONGNAME>Deep Inguinal Lymph Node Dissection Positive Finding Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>6298144v1.0:3506034v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator that asks whether lymph nodes located in the deep inguinal region were removed according to a surgical dissection technique had a positive finding.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6298144</PublicId>
      <PreferredName>6298142v1.0:6299841v1.0</PreferredName>
      <PreferredDefinition>Extending relatively far inward._A superficial or deep lymph node located in the inguinal area._The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</PreferredDefinition>
      <LongName>Deep Inguinal Lymph Node Dissection Positive Finding</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6298142</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25240:C32801</PreferredName>
        <Version>1</Version>
        <LongName>Deep Inguinal Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25240</PREFERRED_NAME>
            <LONG_NAME>Deep</LONG_NAME>
            <CON_ID>2206195</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32801</PREFERRED_NAME>
            <LONG_NAME>Inguinal Lymph Node</LONG_NAME>
            <CON_ID>2205343</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6299841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15227:C38758</PreferredName>
        <Version>1</Version>
        <LongName>Dissection Positive Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15227</PREFERRED_NAME>
            <LONG_NAME>Dissection</LONG_NAME>
            <CON_ID>2203903</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38758</PREFERRED_NAME>
            <LONG_NAME>Positive Finding</LONG_NAME>
            <CON_ID>2516404</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lymph node of cloquet</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lymph node of cloquet</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="779">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6298260</PUBLICID>
    <LONGNAME>Baseline Abnormality Common Terminology Criteria for Adverse Events Version 5.0 Term Name</LONGNAME>
    <PREFERREDNAME>BABN_CTCAE5_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that represents the Common Terminology Criteria for Adverse Events low level term name for an adverse event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ABTC: Adult Brain Tumor Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195084</PublicId>
      <PreferredName>PT_BSL_ABN</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s baseline abnormality.</PreferredDefinition>
      <LongName>Patient Baseline Abnormality</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207520</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25213:C9440</PreferredName>
        <Version>1</Version>
        <LongName>Baseline Abnormality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25213</PREFERRED_NAME>
            <LONG_NAME>Baseline</LONG_NAME>
            <CON_ID>2202304</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9440</PREFERRED_NAME>
            <LONG_NAME>Abnormality</LONG_NAME>
            <CON_ID>2203567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6060119</PublicId>
      <PreferredName>CTCAE5_LLT_NM</PreferredName>
      <PreferredDefinition>A standard terminology of low level terms developed to report adverse events occurring in cancer clinical trials.</PreferredDefinition>
      <LongName>Common Terminology Criteria for Adverse Events Version 5 Term Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAEv5.0:Common Terminology Criteria for Adverse Events v5.0</Origin>
      <Representation>
        <PublicId>6044851</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6044851v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events Version Integer::5 Term Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death NOS</VALIDVALUE>
          <VALUEMEANING>Death NOS</VALUEMEANING>
          <MEANINGDESCRIPTION>Death that cannot be attributed to a CTCAE term associated with Grade 5.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Death neonatal</VALIDVALUE>
          <VALUEMEANING>Death neonatal</VALUEMEANING>
          <MEANINGDESCRIPTION>Newborn death occurring during the first 28 days after birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chills</VALIDVALUE>
          <VALUEMEANING>Chills</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vomiting</VALIDVALUE>
          <VALUEMEANING>Vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visceral arterial ischemia</VALIDVALUE>
          <VALUEMEANING>Visceral arterial ischemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper gastrointestinal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Upper gastrointestinal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Typhlitis</VALIDVALUE>
          <VALUEMEANING>Typhlitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by necrotizing enterocolitis in neutropenic patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tooth discoloration</VALIDVALUE>
          <VALUEMEANING>Tooth discoloration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in tooth hue or tint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tooth development disorder</VALIDVALUE>
          <VALUEMEANING>Tooth development disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a pathological process of the teeth occurring during tooth development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stomach pain</VALIDVALUE>
          <VALUEMEANING>Stomach pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestine ulcer</VALIDVALUE>
          <VALUEMEANING>Small intestine ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143846</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestinal stenosis</VALIDVALUE>
          <VALUEMEANING>Small intestinal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestinal perforation</VALIDVALUE>
          <VALUEMEANING>Small intestinal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the small intestine wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestinal obstruction</VALIDVALUE>
          <VALUEMEANING>Small intestinal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestinal mucositis</VALIDVALUE>
          <VALUEMEANING>Small intestinal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143842</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salivary gland fistula</VALIDVALUE>
          <VALUEMEANING>Salivary gland fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salivary duct inflammation</VALIDVALUE>
          <VALUEMEANING>Salivary duct inflammation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the salivary duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retroperitoneal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Retroperitoneal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the retroperitoneal area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal ulcer</VALIDVALUE>
          <VALUEMEANING>Rectal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal stenosis</VALIDVALUE>
          <VALUEMEANING>Rectal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal perforation</VALIDVALUE>
          <VALUEMEANING>Rectal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the rectal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal pain</VALIDVALUE>
          <VALUEMEANING>Rectal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the rectal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal obstruction</VALIDVALUE>
          <VALUEMEANING>Rectal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal necrosis</VALIDVALUE>
          <VALUEMEANING>Rectal necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the rectal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal mucositis</VALIDVALUE>
          <VALUEMEANING>Rectal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Rectal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the rectal wall and discharged from the anus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal fistula</VALIDVALUE>
          <VALUEMEANING>Rectal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57859</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proctitis</VALIDVALUE>
          <VALUEMEANING>Proctitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneal necrosis</VALIDVALUE>
          <VALUEMEANING>Peritoneal necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Periodontal disease</VALIDVALUE>
          <VALUEMEANING>Periodontal disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder in the gingival tissue around the teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatitis</VALIDVALUE>
          <VALUEMEANING>Pancreatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the pancreas with no documented pancreas infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic necrosis</VALIDVALUE>
          <VALUEMEANING>Pancreatic necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic hemorrhage</VALIDVALUE>
          <VALUEMEANING>Pancreatic hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic fistula</VALIDVALUE>
          <VALUEMEANING>Pancreatic fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic duct stenosis</VALIDVALUE>
          <VALUEMEANING>Pancreatic duct stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the pancreatic duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral pain</VALIDVALUE>
          <VALUEMEANING>Oral pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral hemorrhage</VALIDVALUE>
          <VALUEMEANING>Oral hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cataract</VALIDVALUE>
          <VALUEMEANING>Cataract</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Virilization</VALIDVALUE>
          <VALUEMEANING>Virilization</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Precocious puberty</VALIDVALUE>
          <VALUEMEANING>Precocious puberty</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypothyroidism</VALIDVALUE>
          <VALUEMEANING>Hypothyroidism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoparathyroidism</VALIDVALUE>
          <VALUEMEANING>Hypoparathyroidism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperthyroidism</VALIDVALUE>
          <VALUEMEANING>Hyperthyroidism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperparathyroidism</VALIDVALUE>
          <VALUEMEANING>Hyperparathyroidism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Growth accelerated</VALIDVALUE>
          <VALUEMEANING>Growth accelerated</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by greater growth than expected for age.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endocrine disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Endocrine disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Endocrine disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delayed puberty</VALIDVALUE>
          <VALUEMEANING>Delayed puberty</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by unusually late sexual maturity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cushingoid</VALIDVALUE>
          <VALUEMEANING>Cushingoid</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by signs and symptoms that resemble Cushing&#39;s disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adrenal insufficiency</VALIDVALUE>
          <VALUEMEANING>Adrenal insufficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison&#39;s disease or primary adrenal insufficiency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vestibular disorder</VALIDVALUE>
          <VALUEMEANING>Vestibular disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dizziness, imbalance, nausea, and vision problems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertigo</VALIDVALUE>
          <VALUEMEANING>Vertigo</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tinnitus</VALIDVALUE>
          <VALUEMEANING>Tinnitus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Middle ear inflammation</VALIDVALUE>
          <VALUEMEANING>Middle ear inflammation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>External ear pain</VALIDVALUE>
          <VALUEMEANING>External ear pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the external ear region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ear pain</VALIDVALUE>
          <VALUEMEANING>Ear pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ear and labyrinth disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Ear and labyrinth disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Ear and labyrinth disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Congenital, familial and genetic disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Congenital, familial and genetic disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Congenital, familial and genetic disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ventricular tachycardia</VALIDVALUE>
          <VALUEMEANING>Ventricular tachycardia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ventricular fibrillation</VALIDVALUE>
          <VALUEMEANING>Ventricular fibrillation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ventricular arrhythmia</VALIDVALUE>
          <VALUEMEANING>Ventricular arrhythmia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia that originates in the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tricuspid valve disease</VALIDVALUE>
          <VALUEMEANING>Tricuspid valve disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a defect in tricuspid valve function or structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supraventricular tachycardia</VALIDVALUE>
          <VALUEMEANING>Supraventricular tachycardia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus tachycardia</VALIDVALUE>
          <VALUEMEANING>Sinus tachycardia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus bradycardia</VALIDVALUE>
          <VALUEMEANING>Sinus bradycardia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sick sinus syndrome</VALIDVALUE>
          <VALUEMEANING>Sick sinus syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right ventricular dysfunction</VALIDVALUE>
          <VALUEMEANING>Right ventricular dysfunction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Restrictive cardiomyopathy</VALIDVALUE>
          <VALUEMEANING>Restrictive cardiomyopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary valve disease</VALIDVALUE>
          <VALUEMEANING>Pulmonary valve disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a defect in pulmonary valve function or structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericarditis</VALIDVALUE>
          <VALUEMEANING>Pericarditis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericardial tamponade</VALIDVALUE>
          <VALUEMEANING>Pericardial tamponade</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericardial effusion</VALIDVALUE>
          <VALUEMEANING>Pericardial effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paroxysmal atrial tachycardia</VALIDVALUE>
          <VALUEMEANING>Paroxysmal atrial tachycardia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palpitations</VALIDVALUE>
          <VALUEMEANING>Palpitations</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myocarditis</VALIDVALUE>
          <VALUEMEANING>Myocarditis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the muscle tissue of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myocardial infarction</VALIDVALUE>
          <VALUEMEANING>Myocardial infarction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mobitz type I</VALIDVALUE>
          <VALUEMEANING>Mobitz type I</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mobitz (type) II atrioventricular block</VALIDVALUE>
          <VALUEMEANING>Mobitz (type) II atrioventricular block</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitral valve disease</VALIDVALUE>
          <VALUEMEANING>Mitral valve disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a defect in mitral valve function or structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left ventricular systolic dysfunction</VALIDVALUE>
          <VALUEMEANING>Left ventricular systolic dysfunction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by failure of the left ventricle to produce adequate output.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heart failure</VALIDVALUE>
          <VALUEMEANING>Heart failure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conduction disorder</VALIDVALUE>
          <VALUEMEANING>Conduction disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by pathological irregularities in the cardiac conduction system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest pain - cardiac</VALIDVALUE>
          <VALUEMEANING>Chest pain - cardiac</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Cardiac disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Cardiac disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac arrest</VALIDVALUE>
          <VALUEMEANING>Cardiac arrest</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by cessation of the pumping function of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atrioventricular block first degree</VALIDVALUE>
          <VALUEMEANING>Atrioventricular block first degree</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atrioventricular block complete</VALIDVALUE>
          <VALUEMEANING>Atrioventricular block complete</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atrial flutter</VALIDVALUE>
          <VALUEMEANING>Atrial flutter</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atrial fibrillation</VALIDVALUE>
          <VALUEMEANING>Atrial fibrillation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asystole</VALIDVALUE>
          <VALUEMEANING>Asystole</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aortic valve disease</VALIDVALUE>
          <VALUEMEANING>Aortic valve disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a defect in aortic valve function or structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thrombotic thrombocytopenic purpura</VALIDVALUE>
          <VALUEMEANING>Thrombotic thrombocytopenic purpura</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methemoglobinemia</VALIDVALUE>
          <VALUEMEANING>Methemoglobinemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate increased methemoglobin in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143191</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node pain</VALIDVALUE>
          <VALUEMEANING>Lymph node pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in a lymph node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leukocytosis</VALIDVALUE>
          <VALUEMEANING>Leukocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemolytic uremic syndrome</VALIDVALUE>
          <VALUEMEANING>Hemolytic uremic syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemolysis</VALIDVALUE>
          <VALUEMEANING>Hemolysis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eosinophilia</VALIDVALUE>
          <VALUEMEANING>Eosinophilia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an increased number of eosinophils in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disseminated intravascular coagulation</VALIDVALUE>
          <VALUEMEANING>Disseminated intravascular coagulation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow hypocellular</VALIDVALUE>
          <VALUEMEANING>Bone marrow hypocellular</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood and lymphatic system disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Blood and lymphatic system disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Blood and lymphatic system disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anemia</VALIDVALUE>
          <VALUEMEANING>Anemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral dysesthesia</VALIDVALUE>
          <VALUEMEANING>Oral dysesthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral cavity fistula</VALIDVALUE>
          <VALUEMEANING>Oral cavity fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obstruction gastric</VALIDVALUE>
          <VALUEMEANING>Obstruction gastric</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents in the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nausea</VALIDVALUE>
          <VALUEMEANING>Nausea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a queasy sensation and/or the urge to vomit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mucositis oral</VALIDVALUE>
          <VALUEMEANING>Mucositis oral</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation of the oral mucosal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder perforation</VALIDVALUE>
          <VALUEMEANING>Gallbladder perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the gallbladder wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder pain</VALIDVALUE>
          <VALUEMEANING>Gallbladder pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the gallbladder region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder obstruction</VALIDVALUE>
          <VALUEMEANING>Gallbladder obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents of the gallbladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder necrosis</VALIDVALUE>
          <VALUEMEANING>Gallbladder necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the gallbladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder fistula</VALIDVALUE>
          <VALUEMEANING>Gallbladder fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cholecystitis</VALIDVALUE>
          <VALUEMEANING>Cholecystitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biliary fistula</VALIDVALUE>
          <VALUEMEANING>Biliary fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bile duct stenosis</VALIDVALUE>
          <VALUEMEANING>Bile duct stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the bile duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sudden death NOS</VALIDVALUE>
          <VALUEMEANING>Sudden death NOS</VALUEMEANING>
          <MEANINGDESCRIPTION>An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain</VALIDVALUE>
          <VALUEMEANING>Pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the sensation of marked discomfort, distress or agony.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-cardiac chest pain</VALIDVALUE>
          <VALUEMEANING>Non-cardiac chest pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck edema</VALIDVALUE>
          <VALUEMEANING>Neck edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-organ failure</VALIDVALUE>
          <VALUEMEANING>Multi-organ failure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Malaise</VALIDVALUE>
          <VALUEMEANING>Malaise</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Localized edema</VALIDVALUE>
          <VALUEMEANING>Localized edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injection site reaction</VALIDVALUE>
          <VALUEMEANING>Injection site reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infusion site extravasation</VALIDVALUE>
          <VALUEMEANING>Infusion site extravasation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypothermia</VALIDVALUE>
          <VALUEMEANING>Hypothermia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>General disorders and administration site conditions - Other, specify</VALIDVALUE>
          <VALUEMEANING>General disorders and administration site conditions - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>General disorders and administration site conditions - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gait disturbance</VALIDVALUE>
          <VALUEMEANING>Gait disturbance</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by walking difficulties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flu like symptoms</VALIDVALUE>
          <VALUEMEANING>Flu like symptoms</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fever</VALIDVALUE>
          <VALUEMEANING>Fever</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by elevation of the body&#39;s temperature above the upper limit of normal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fatigue</VALIDVALUE>
          <VALUEMEANING>Fatigue</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146753</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Facial pain</VALIDVALUE>
          <VALUEMEANING>Facial pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the face.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edema trunk</VALIDVALUE>
          <VALUEMEANING>Edema trunk</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edema limbs</VALIDVALUE>
          <VALUEMEANING>Edema limbs</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edema face</VALIDVALUE>
          <VALUEMEANING>Edema face</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower gastrointestinal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Lower gastrointestinal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lip pain</VALIDVALUE>
          <VALUEMEANING>Lip pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort of the lip.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal ulcer</VALIDVALUE>
          <VALUEMEANING>Jejunal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal stenosis</VALIDVALUE>
          <VALUEMEANING>Jejunal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the jejunum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal perforation</VALIDVALUE>
          <VALUEMEANING>Jejunal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the jejunal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal obstruction</VALIDVALUE>
          <VALUEMEANING>Jejunal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal fistula</VALIDVALUE>
          <VALUEMEANING>Jejunal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Jejunal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the jejunal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intra-abdominal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Intra-abdominal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding in the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileus</VALIDVALUE>
          <VALUEMEANING>Ileus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by failure of the ileum to transport intestinal contents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal ulcer</VALIDVALUE>
          <VALUEMEANING>Ileal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal stenosis</VALIDVALUE>
          <VALUEMEANING>Ileal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the ileum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal perforation</VALIDVALUE>
          <VALUEMEANING>Ileal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the ileal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal obstruction</VALIDVALUE>
          <VALUEMEANING>Ileal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Ileal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the ileal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileal fistula</VALIDVALUE>
          <VALUEMEANING>Ileal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemorrhoidal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Hemorrhoidal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the hemorrhoids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gingival pain</VALIDVALUE>
          <VALUEMEANING>Gingival pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the gingival region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastroparesis</VALIDVALUE>
          <VALUEMEANING>Gastroparesis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal pain</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal fistula</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Gastrointestinal disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastroesophageal reflux disease</VALIDVALUE>
          <VALUEMEANING>Gastroesophageal reflux disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastritis</VALIDVALUE>
          <VALUEMEANING>Gastritis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric ulcer</VALIDVALUE>
          <VALUEMEANING>Gastric ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal infection</VALIDVALUE>
          <VALUEMEANING>Vaginal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine infection</VALIDVALUE>
          <VALUEMEANING>Uterine infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary tract infection</VALIDVALUE>
          <VALUEMEANING>Urinary tract infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urethral infection</VALIDVALUE>
          <VALUEMEANING>Urethral infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper respiratory infection</VALIDVALUE>
          <VALUEMEANING>Upper respiratory infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheitis</VALIDVALUE>
          <VALUEMEANING>Tracheitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the trachea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tooth infection</VALIDVALUE>
          <VALUEMEANING>Tooth infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving a tooth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stoma site infection</VALIDVALUE>
          <VALUEMEANING>Stoma site infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic infection</VALIDVALUE>
          <VALUEMEANING>Splenic infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the spleen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft tissue infection</VALIDVALUE>
          <VALUEMEANING>Soft tissue infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving soft tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestine infection</VALIDVALUE>
          <VALUEMEANING>Small intestine infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin infection</VALIDVALUE>
          <VALUEMEANING>Skin infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the skin such as cellulitis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinusitis</VALIDVALUE>
          <VALUEMEANING>Sinusitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scrotal infection</VALIDVALUE>
          <VALUEMEANING>Scrotal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the scrotum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salivary gland infection</VALIDVALUE>
          <VALUEMEANING>Salivary gland infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the salivary gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143822</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhinitis infective</VALIDVALUE>
          <VALUEMEANING>Rhinitis infective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the nasal mucosal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rash pustular</VALIDVALUE>
          <VALUEMEANING>Rash pustular</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed and elevated skin lesion filled with pus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostate infection</VALIDVALUE>
          <VALUEMEANING>Prostate infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the prostate gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural infection</VALIDVALUE>
          <VALUEMEANING>Pleural infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the pleura.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phlebitis infective</VALIDVALUE>
          <VALUEMEANING>Phlebitis infective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngitis</VALIDVALUE>
          <VALUEMEANING>Pharyngitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the throat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneal infection</VALIDVALUE>
          <VALUEMEANING>Peritoneal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143753</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral nerve infection</VALIDVALUE>
          <VALUEMEANING>Peripheral nerve infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the peripheral nerves.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Periorbital infection</VALIDVALUE>
          <VALUEMEANING>Periorbital infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the orbit of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penile infection</VALIDVALUE>
          <VALUEMEANING>Penile infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the penis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic infection</VALIDVALUE>
          <VALUEMEANING>Pelvic infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the pelvic cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paronychia</VALIDVALUE>
          <VALUEMEANING>Paronychia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the soft tissues around the nail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Papulopustular rash</VALIDVALUE>
          <VALUEMEANING>Papulopustular rash</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreas infection</VALIDVALUE>
          <VALUEMEANING>Pancreas infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the pancreas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovarian infection</VALIDVALUE>
          <VALUEMEANING>Ovarian infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the ovary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Otitis media</VALIDVALUE>
          <VALUEMEANING>Otitis media</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the middle ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Otitis externa</VALIDVALUE>
          <VALUEMEANING>Otitis externa</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer&#39;s ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nail infection</VALIDVALUE>
          <VALUEMEANING>Nail infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the nail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelitis</VALIDVALUE>
          <VALUEMEANING>Myelitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mucosal infection</VALIDVALUE>
          <VALUEMEANING>Mucosal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving a mucosal surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinal infection</VALIDVALUE>
          <VALUEMEANING>Mediastinal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the mediastinum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph gland infection</VALIDVALUE>
          <VALUEMEANING>Lymph gland infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung infection</VALIDVALUE>
          <VALUEMEANING>Lung infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the lungs, including pneumonia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lip infection</VALIDVALUE>
          <VALUEMEANING>Lip infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the lips.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngitis</VALIDVALUE>
          <VALUEMEANING>Laryngitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inflammatory process involving the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143641</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney infection</VALIDVALUE>
          <VALUEMEANING>Kidney infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joint infection</VALIDVALUE>
          <VALUEMEANING>Joint infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving a joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infective myositis</VALIDVALUE>
          <VALUEMEANING>Infective myositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the skeletal muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infections and infestations - Other, specify</VALIDVALUE>
          <VALUEMEANING>Infections and infestations - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Infections and infestations - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiculitis</VALIDVALUE>
          <VALUEMEANING>Radiculitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reversible posterior leukoencephalopathy syndrome</VALIDVALUE>
          <VALUEMEANING>Reversible posterior leukoencephalopathy syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recurrent laryngeal nerve palsy</VALIDVALUE>
          <VALUEMEANING>Recurrent laryngeal nerve palsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by paralysis of the recurrent laryngeal nerve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyramidal tract syndrome</VALIDVALUE>
          <VALUEMEANING>Pyramidal tract syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Presyncope</VALIDVALUE>
          <VALUEMEANING>Presyncope</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phantom pain</VALIDVALUE>
          <VALUEMEANING>Phantom pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral sensory neuropathy</VALIDVALUE>
          <VALUEMEANING>Peripheral sensory neuropathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by damage or dysfunction of the peripheral sensory nerves.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral motor neuropathy</VALIDVALUE>
          <VALUEMEANING>Peripheral motor neuropathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by damage or dysfunction of the peripheral motor nerves.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olfactory nerve disorder</VALIDVALUE>
          <VALUEMEANING>Olfactory nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oculomotor nerve disorder</VALIDVALUE>
          <VALUEMEANING>Oculomotor nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nystagmus</VALIDVALUE>
          <VALUEMEANING>Nystagmus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by involuntary movements of the eyeballs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neuralgia</VALIDVALUE>
          <VALUEMEANING>Neuralgia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by intense painful sensation along a nerve or group of nerves.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143703</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nervous system disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Nervous system disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Nervous system disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle weakness right-sided</VALIDVALUE>
          <VALUEMEANING>Muscle weakness right-sided</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the muscles on the right side of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle weakness left-sided</VALIDVALUE>
          <VALUEMEANING>Muscle weakness left-sided</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the muscles on the left side of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Movements involuntary</VALIDVALUE>
          <VALUEMEANING>Movements involuntary</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by uncontrolled and purposeless movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Meningismus</VALIDVALUE>
          <VALUEMEANING>Meningismus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Memory impairment</VALIDVALUE>
          <VALUEMEANING>Memory impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a deterioration in memory function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leukoencephalopathy</VALIDVALUE>
          <VALUEMEANING>Leukoencephalopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lethargy</VALIDVALUE>
          <VALUEMEANING>Lethargy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ischemia cerebrovascular</VALIDVALUE>
          <VALUEMEANING>Ischemia cerebrovascular</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intracranial hemorrhage</VALIDVALUE>
          <VALUEMEANING>Intracranial hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143596</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoglossal nerve disorder</VALIDVALUE>
          <VALUEMEANING>Hypoglossal nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypersomnia</VALIDVALUE>
          <VALUEMEANING>Hypersomnia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by characterized by excessive sleepiness during the daytime.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydrocephalus</VALIDVALUE>
          <VALUEMEANING>Hydrocephalus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Headache</VALIDVALUE>
          <VALUEMEANING>Headache</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glossopharyngeal nerve disorder</VALIDVALUE>
          <VALUEMEANING>Glossopharyngeal nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Facial nerve disorder</VALIDVALUE>
          <VALUEMEANING>Facial nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Facial muscle weakness</VALIDVALUE>
          <VALUEMEANING>Facial muscle weakness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the facial muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extrapyramidal disorder</VALIDVALUE>
          <VALUEMEANING>Extrapyramidal disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encephalopathy</VALIDVALUE>
          <VALUEMEANING>Encephalopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a pathologic process involving the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edema cerebral</VALIDVALUE>
          <VALUEMEANING>Edema cerebral</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysphasia</VALIDVALUE>
          <VALUEMEANING>Dysphasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysgeusia</VALIDVALUE>
          <VALUEMEANING>Dysgeusia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysesthesia</VALIDVALUE>
          <VALUEMEANING>Dysesthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysarthria</VALIDVALUE>
          <VALUEMEANING>Dysarthria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dizziness</VALIDVALUE>
          <VALUEMEANING>Dizziness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Depressed level of consciousness</VALIDVALUE>
          <VALUEMEANING>Depressed level of consciousness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in ability to perceive and respond.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Concentration impairment</VALIDVALUE>
          <VALUEMEANING>Concentration impairment</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a deterioration in the ability to concentrate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cognitive disturbance</VALIDVALUE>
          <VALUEMEANING>Cognitive disturbance</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a conspicuous change in cognitive function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrospinal fluid leakage</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal fluid leakage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central nervous system necrosis</VALIDVALUE>
          <VALUEMEANING>Central nervous system necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brachial plexopathy</VALIDVALUE>
          <VALUEMEANING>Brachial plexopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ataxia</VALIDVALUE>
          <VALUEMEANING>Ataxia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arachnoiditis</VALIDVALUE>
          <VALUEMEANING>Arachnoiditis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aphonia</VALIDVALUE>
          <VALUEMEANING>Aphonia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amnesia</VALIDVALUE>
          <VALUEMEANING>Amnesia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by systematic and extensive loss of memory.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Akathisia</VALIDVALUE>
          <VALUEMEANING>Akathisia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acoustic nerve disorder NOS</VALIDVALUE>
          <VALUEMEANING>Acoustic nerve disorder NOS</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Accessory nerve disorder</VALIDVALUE>
          <VALUEMEANING>Accessory nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abducens nerve disorder</VALIDVALUE>
          <VALUEMEANING>Abducens nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor pain</VALIDVALUE>
          <VALUEMEANING>Tumor pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146782</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treatment related secondary malignancy</VALIDVALUE>
          <VALUEMEANING>Treatment related secondary malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</VALIDVALUE>
          <VALUEMEANING>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelodysplastic syndrome</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leukemia secondary to oncology chemotherapy</VALIDVALUE>
          <VALUEMEANING>Leukemia secondary to oncology chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unequal limb length</VALIDVALUE>
          <VALUEMEANING>Unequal limb length</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trismus</VALIDVALUE>
          <VALUEMEANING>Trismus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superficial soft tissue fibrosis</VALIDVALUE>
          <VALUEMEANING>Superficial soft tissue fibrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fibrotic degeneration of the superficial soft tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft tissue necrosis upper limb</VALIDVALUE>
          <VALUEMEANING>Soft tissue necrosis upper limb</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft tissue necrosis lower limb</VALIDVALUE>
          <VALUEMEANING>Soft tissue necrosis lower limb</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic soft tissue necrosis</VALIDVALUE>
          <VALUEMEANING>Pelvic soft tissue necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain in extremity</VALIDVALUE>
          <VALUEMEANING>Pain in extremity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteoporosis</VALIDVALUE>
          <VALUEMEANING>Osteoporosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteonecrosis of jaw</VALIDVALUE>
          <VALUEMEANING>Osteonecrosis of jaw</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the bone of the mandible.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spermatic cord obstruction</VALIDVALUE>
          <VALUEMEANING>Spermatic cord obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spermatic cord hemorrhage</VALIDVALUE>
          <VALUEMEANING>Spermatic cord hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the spermatic cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scrotal pain</VALIDVALUE>
          <VALUEMEANING>Scrotal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the scrotal area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reproductive system and breast disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Reproductive system and breast disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Reproductive system and breast disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostatic pain</VALIDVALUE>
          <VALUEMEANING>Prostatic pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the prostate gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostatic obstruction</VALIDVALUE>
          <VALUEMEANING>Prostatic obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostatic hemorrhage</VALIDVALUE>
          <VALUEMEANING>Prostatic hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the prostate gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Premature menopause</VALIDVALUE>
          <VALUEMEANING>Premature menopause</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perineal pain</VALIDVALUE>
          <VALUEMEANING>Perineal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penile pain</VALIDVALUE>
          <VALUEMEANING>Penile pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the penis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic pain</VALIDVALUE>
          <VALUEMEANING>Pelvic pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic floor muscle weakness</VALIDVALUE>
          <VALUEMEANING>Pelvic floor muscle weakness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovulation pain</VALIDVALUE>
          <VALUEMEANING>Ovulation pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovarian rupture</VALIDVALUE>
          <VALUEMEANING>Ovarian rupture</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by tearing or disruption of the ovarian tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovarian hemorrhage</VALIDVALUE>
          <VALUEMEANING>Ovarian hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the ovary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oligospermia</VALIDVALUE>
          <VALUEMEANING>Oligospermia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in the number of spermatozoa in the semen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nipple deformity</VALIDVALUE>
          <VALUEMEANING>Nipple deformity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a malformation of the nipple.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Menorrhagia</VALIDVALUE>
          <VALUEMEANING>Menorrhagia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormally heavy vaginal bleeding during menses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lactation disorder</VALIDVALUE>
          <VALUEMEANING>Lactation disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irregular menstruation</VALIDVALUE>
          <VALUEMEANING>Irregular menstruation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in cycle or duration of menses from baseline.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematosalpinx</VALIDVALUE>
          <VALUEMEANING>Hematosalpinx</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of blood in a fallopian tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genital edema</VALIDVALUE>
          <VALUEMEANING>Genital edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Feminization acquired</VALIDVALUE>
          <VALUEMEANING>Feminization acquired</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143483</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fallopian tube obstruction</VALIDVALUE>
          <VALUEMEANING>Fallopian tube obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erectile dysfunction</VALIDVALUE>
          <VALUEMEANING>Erectile dysfunction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ejaculation disorder</VALIDVALUE>
          <VALUEMEANING>Ejaculation disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dyspareunia</VALIDVALUE>
          <VALUEMEANING>Dyspareunia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by painful or difficult coitus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysmenorrhea</VALIDVALUE>
          <VALUEMEANING>Dysmenorrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormally painful abdominal cramps during menses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast pain</VALIDVALUE>
          <VALUEMEANING>Breast pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the breast region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast atrophy</VALIDVALUE>
          <VALUEMEANING>Breast atrophy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by underdevelopment of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azoospermia</VALIDVALUE>
          <VALUEMEANING>Azoospermia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anorgasmia</VALIDVALUE>
          <VALUEMEANING>Anorgasmia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inability to achieve orgasm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal ulcer</VALIDVALUE>
          <VALUEMEANING>Anal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal stenosis</VALIDVALUE>
          <VALUEMEANING>Anal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the anal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal pain</VALIDVALUE>
          <VALUEMEANING>Anal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the anal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal necrosis</VALIDVALUE>
          <VALUEMEANING>Anal necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the anal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal mucositis</VALIDVALUE>
          <VALUEMEANING>Anal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Anal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the anal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal fistula</VALIDVALUE>
          <VALUEMEANING>Anal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle cramp</VALIDVALUE>
          <VALUEMEANING>Muscle cramp</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by marked cramping sensation originating from a muscle or group of muscles.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal distension</VALIDVALUE>
          <VALUEMEANING>Abdominal distension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling of the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Watering eyes</VALIDVALUE>
          <VALUEMEANING>Watering eyes</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uveitis</VALIDVALUE>
          <VALUEMEANING>Uveitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation to the uvea of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scleral disorder</VALIDVALUE>
          <VALUEMEANING>Scleral disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by involvement of the sclera of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinal vascular disorder</VALIDVALUE>
          <VALUEMEANING>Retinal vascular disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by pathological retinal blood vessels that adversely affects vision.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143815</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinal tear</VALIDVALUE>
          <VALUEMEANING>Retinal tear</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinal detachment</VALIDVALUE>
          <VALUEMEANING>Retinal detachment</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Photophobia</VALIDVALUE>
          <VALUEMEANING>Photophobia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fear and avoidance of light.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Periorbital edema</VALIDVALUE>
          <VALUEMEANING>Periorbital edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Optic nerve disorder</VALIDVALUE>
          <VALUEMEANING>Optic nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by involvement of the optic nerve (second cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Night blindness</VALIDVALUE>
          <VALUEMEANING>Night blindness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inability to see clearly in dim light.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Keratitis</VALIDVALUE>
          <VALUEMEANING>Keratitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation to the cornea of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glaucoma</VALIDVALUE>
          <VALUEMEANING>Glaucoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55842</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Floaters</VALIDVALUE>
          <VALUEMEANING>Floaters</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flashing lights</VALIDVALUE>
          <VALUEMEANING>Flashing lights</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden or brief burst of light.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eyelid function disorder</VALIDVALUE>
          <VALUEMEANING>Eyelid function disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by impaired eyelid function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye pain</VALIDVALUE>
          <VALUEMEANING>Eye pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Eye disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Eye disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extraocular muscle paresis</VALIDVALUE>
          <VALUEMEANING>Extraocular muscle paresis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by incomplete paralysis of an extraocular muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dry eye</VALIDVALUE>
          <VALUEMEANING>Dry eye</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dryness of the cornea and conjunctiva.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corneal ulcer</VALIDVALUE>
          <VALUEMEANING>Corneal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adult respiratory distress syndrome</VALIDVALUE>
          <VALUEMEANING>Adult respiratory distress syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal stricture</VALIDVALUE>
          <VALUEMEANING>Vaginal stricture</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the vaginal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143926</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal perforation</VALIDVALUE>
          <VALUEMEANING>Vaginal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the vaginal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal pain</VALIDVALUE>
          <VALUEMEANING>Vaginal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal obstruction</VALIDVALUE>
          <VALUEMEANING>Vaginal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of vaginal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal inflammation</VALIDVALUE>
          <VALUEMEANING>Vaginal inflammation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Vaginal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal fistula</VALIDVALUE>
          <VALUEMEANING>Vaginal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal dryness</VALIDVALUE>
          <VALUEMEANING>Vaginal dryness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal discharge</VALIDVALUE>
          <VALUEMEANING>Vaginal discharge</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143922</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine pain</VALIDVALUE>
          <VALUEMEANING>Uterine pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine obstruction</VALIDVALUE>
          <VALUEMEANING>Uterine obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the uterine outlet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine hemorrhage</VALIDVALUE>
          <VALUEMEANING>Uterine hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine fistula</VALIDVALUE>
          <VALUEMEANING>Uterine fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testicular pain</VALIDVALUE>
          <VALUEMEANING>Testicular pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the testis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testicular hemorrhage</VALIDVALUE>
          <VALUEMEANING>Testicular hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the testis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testicular disorder</VALIDVALUE>
          <VALUEMEANING>Testicular disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormal function or appearance of the testis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary edema</VALIDVALUE>
          <VALUEMEANING>Pulmonary edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Productive cough</VALIDVALUE>
          <VALUEMEANING>Productive cough</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by expectorated secretions upon coughing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Postnasal drip</VALIDVALUE>
          <VALUEMEANING>Postnasal drip</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pneumothorax</VALIDVALUE>
          <VALUEMEANING>Pneumothorax</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58201</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleuritic pain</VALIDVALUE>
          <VALUEMEANING>Pleuritic pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the pleura.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural hemorrhage</VALIDVALUE>
          <VALUEMEANING>Pleural hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the pleural cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural effusion</VALIDVALUE>
          <VALUEMEANING>Pleural effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasal congestion</VALIDVALUE>
          <VALUEMEANING>Nasal congestion</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by obstruction of the nasal passage due to mucosal edema.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Mediastinal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the mediastinum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngospasm</VALIDVALUE>
          <VALUEMEANING>Laryngospasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngopharyngeal dysesthesia</VALIDVALUE>
          <VALUEMEANING>Laryngopharyngeal dysesthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal stenosis</VALIDVALUE>
          <VALUEMEANING>Laryngeal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the laryngeal airway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal obstruction</VALIDVALUE>
          <VALUEMEANING>Laryngeal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the laryngeal airway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal mucositis</VALIDVALUE>
          <VALUEMEANING>Laryngeal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal inflammation</VALIDVALUE>
          <VALUEMEANING>Laryngeal inflammation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inflammation involving the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Laryngeal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal fistula</VALIDVALUE>
          <VALUEMEANING>Laryngeal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngeal edema</VALIDVALUE>
          <VALUEMEANING>Laryngeal edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoxia</VALIDVALUE>
          <VALUEMEANING>Hypoxia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in the level of oxygen in the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hiccups</VALIDVALUE>
          <VALUEMEANING>Hiccups</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epistaxis</VALIDVALUE>
          <VALUEMEANING>Epistaxis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the nose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dyspnea</VALIDVALUE>
          <VALUEMEANING>Dyspnea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable sensation of difficulty breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cough</VALIDVALUE>
          <VALUEMEANING>Cough</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58028</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chylothorax</VALIDVALUE>
          <VALUEMEANING>Chylothorax</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58027</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchospasm</VALIDVALUE>
          <VALUEMEANING>Bronchospasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchopulmonary hemorrhage</VALIDVALUE>
          <VALUEMEANING>Bronchopulmonary hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchial stricture</VALIDVALUE>
          <VALUEMEANING>Bronchial stricture</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the bronchial tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchial obstruction</VALIDVALUE>
          <VALUEMEANING>Bronchial obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchial fistula</VALIDVALUE>
          <VALUEMEANING>Bronchial fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atelectasis</VALIDVALUE>
          <VALUEMEANING>Atelectasis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the collapse of part or the entire lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58022</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspiration</VALIDVALUE>
          <VALUEMEANING>Aspiration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inhalation of solids or liquids into the lungs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apnea</VALIDVALUE>
          <VALUEMEANING>Apnea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by cessation of breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allergic rhinitis</VALIDVALUE>
          <VALUEMEANING>Allergic rhinitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine discoloration</VALIDVALUE>
          <VALUEMEANING>Urine discoloration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the color of the urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary tract pain</VALIDVALUE>
          <VALUEMEANING>Urinary tract pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the urinary tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary tract obstruction</VALIDVALUE>
          <VALUEMEANING>Urinary tract obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of contents of the urinary tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061820</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary retention</VALIDVALUE>
          <VALUEMEANING>Urinary retention</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary incontinence</VALIDVALUE>
          <VALUEMEANING>Urinary incontinence</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inability to control the flow of urine from the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146786</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary frequency</VALIDVALUE>
          <VALUEMEANING>Urinary frequency</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by urination at short intervals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary fistula</VALIDVALUE>
          <VALUEMEANING>Urinary fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Renal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061825</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal colic</VALIDVALUE>
          <VALUEMEANING>Renal colic</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal calculi</VALIDVALUE>
          <VALUEMEANING>Renal calculi</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal and urinary disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Renal and urinary disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Renal and urinary disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proteinuria</VALIDVALUE>
          <VALUEMEANING>Proteinuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemoglobinuria</VALIDVALUE>
          <VALUEMEANING>Hemoglobinuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematuria</VALIDVALUE>
          <VALUEMEANING>Hematuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate blood in the urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cystitis noninfective</VALIDVALUE>
          <VALUEMEANING>Cystitis noninfective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic kidney disease</VALIDVALUE>
          <VALUEMEANING>Chronic kidney disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder spasm</VALIDVALUE>
          <VALUEMEANING>Bladder spasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden and involuntary contraction of the bladder wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder perforation</VALIDVALUE>
          <VALUEMEANING>Bladder perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the bladder wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute kidney injury</VALIDVALUE>
          <VALUEMEANING>Acute kidney injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suicide attempt</VALIDVALUE>
          <VALUEMEANING>Suicide attempt</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by self-inflicted harm in an attempt to end one&#39;s own life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suicidal ideation</VALIDVALUE>
          <VALUEMEANING>Suicidal ideation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by thoughts of taking one&#39;s own life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Restlessness</VALIDVALUE>
          <VALUEMEANING>Restlessness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inability to rest, relax or be still.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Psychiatric disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Psychiatric disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Psychiatric disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personality change</VALIDVALUE>
          <VALUEMEANING>Personality change</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a conspicuous change in a person&#39;s behavior and thinking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mania</VALIDVALUE>
          <VALUEMEANING>Mania</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Libido increased</VALIDVALUE>
          <VALUEMEANING>Libido increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in sexual desire.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Libido decreased</VALIDVALUE>
          <VALUEMEANING>Libido decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in sexual desire.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irritability</VALIDVALUE>
          <VALUEMEANING>Irritability</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Insomnia</VALIDVALUE>
          <VALUEMEANING>Insomnia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by difficulty in falling asleep and/or remaining asleep.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hallucinations</VALIDVALUE>
          <VALUEMEANING>Hallucinations</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a false sensory perception in the absence of an external stimulus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Euphoria</VALIDVALUE>
          <VALUEMEANING>Euphoria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Depression</VALIDVALUE>
          <VALUEMEANING>Depression</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by melancholic feelings of grief or unhappiness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delusions</VALIDVALUE>
          <VALUEMEANING>Delusions</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delirium</VALIDVALUE>
          <VALUEMEANING>Delirium</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delayed orgasm</VALIDVALUE>
          <VALUEMEANING>Delayed orgasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by sexual dysfunction characterized by a delay in climax.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Confusion</VALIDVALUE>
          <VALUEMEANING>Confusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a lack of clear and orderly thought and behavior.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anxiety</VALIDVALUE>
          <VALUEMEANING>Anxiety</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agitation</VALIDVALUE>
          <VALUEMEANING>Agitation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Premature delivery</VALIDVALUE>
          <VALUEMEANING>Premature delivery</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pregnancy, puerperium and perinatal conditions - Other, specify</VALIDVALUE>
          <VALUEMEANING>Pregnancy, puerperium and perinatal conditions - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Pregnancy, puerperium and perinatal conditions - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fetal growth retardation</VALIDVALUE>
          <VALUEMEANING>Fetal growth retardation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vasovagal reaction</VALIDVALUE>
          <VALUEMEANING>Vasovagal reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143932</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vagus nerve disorder</VALIDVALUE>
          <VALUEMEANING>Vagus nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trigeminal nerve disorder</VALIDVALUE>
          <VALUEMEANING>Trigeminal nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tremor</VALIDVALUE>
          <VALUEMEANING>Tremor</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transient ischemic attacks</VALIDVALUE>
          <VALUEMEANING>Transient ischemic attacks</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syncope</VALIDVALUE>
          <VALUEMEANING>Syncope</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spasticity</VALIDVALUE>
          <VALUEMEANING>Spasticity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somnolence</VALIDVALUE>
          <VALUEMEANING>Somnolence</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by characterized by excessive sleepiness and drowsiness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seizure</VALIDVALUE>
          <VALUEMEANING>Seizure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sore throat</VALIDVALUE>
          <VALUEMEANING>Sore throat</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by marked discomfort in the throat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Febrile neutropenia</VALIDVALUE>
          <VALUEMEANING>Febrile neutropenia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an ANC &lt;1000/mm3 and a single temperature of &gt;38.3 degrees C (101 degrees F) or a sustained temperature of &gt;=38 degrees C (100.4 degrees F) for more than one hour</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eczema</VALIDVALUE>
          <VALUEMEANING>Eczema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by skin which becomes itchy, red, inflamed, crusty, thick, scaly, and/or forms blisters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal soft tissue necrosis</VALIDVALUE>
          <VALUEMEANING>Abdominal soft tissue necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electrocardiogram T wave abnormal</VALIDVALUE>
          <VALUEMEANING>Electrocardiogram T wave abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by Electrocardiogram T wave amplitude changes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal fissure</VALIDVALUE>
          <VALUEMEANING>Anal fissure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a tear in the lining of the anus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epstein-Barr virus infection reactivation</VALIDVALUE>
          <VALUEMEANING>Epstein-Barr virus infection reactivation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reactivation of Epstein-Barr virus (EBV).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folliculitis</VALIDVALUE>
          <VALUEMEANING>Folliculitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation or infection of the hair follicles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fungemia</VALIDVALUE>
          <VALUEMEANING>Fungemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of fungus in the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Generalized edema</VALIDVALUE>
          <VALUEMEANING>Generalized edema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fluid accumulation in the tissues of the body including the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glucosuria</VALIDVALUE>
          <VALUEMEANING>Glucosuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate glucose in the urine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Guillain-Barre syndrome</VALIDVALUE>
          <VALUEMEANING>Guillain-Barre syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the body&#39;s immune system attacking the peripheral nervous system causing ascending paralysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hair color changes</VALIDVALUE>
          <VALUEMEANING>Hair color changes</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by change in hair color or loss of normal pigmentation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143244</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hair texture abnormal</VALIDVALUE>
          <VALUEMEANING>Hair texture abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the way the hair feels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis B reactivation</VALIDVALUE>
          <VALUEMEANING>Hepatitis B reactivation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reactivation of hepatitis B virus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Herpes simplex reactivation</VALIDVALUE>
          <VALUEMEANING>Herpes simplex reactivation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reactivation of Herpes simplex virus</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperkeratosis</VALIDVALUE>
          <VALUEMEANING>Hyperkeratosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a thickening of the outer layer of the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperlipidemia</VALIDVALUE>
          <VALUEMEANING>Hyperlipidemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of lipids in blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143221</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperphosphatemia</VALIDVALUE>
          <VALUEMEANING>Hyperphosphatemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of phosphate in a blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypophysitis</VALIDVALUE>
          <VALUEMEANING>Hypophysitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation and cellular infiltration of the pituitary gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypopituitarism</VALIDVALUE>
          <VALUEMEANING>Hypopituitarism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in production of hormones from the pituitary gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myasthenia gravis</VALIDVALUE>
          <VALUEMEANING>Myasthenia gravis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by weakness and rapid fatigue of any of the skeletal muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nail changes</VALIDVALUE>
          <VALUEMEANING>Nail changes</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the nails.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nephrotic syndrome</VALIDVALUE>
          <VALUEMEANING>Nephrotic syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061830</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oropharyngeal pain</VALIDVALUE>
          <VALUEMEANING>Oropharyngeal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the oropharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143241</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteonecrosis</VALIDVALUE>
          <VALUEMEANING>Osteonecrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pregnancy loss</VALIDVALUE>
          <VALUEMEANING>Pregnancy loss</VALUEMEANING>
          <MEANINGDESCRIPTION>Death in utero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal fissure</VALIDVALUE>
          <VALUEMEANING>Rectal fissure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a tear in the lining of the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhabdomyolysis</VALIDVALUE>
          <VALUEMEANING>Rhabdomyolysis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the breakdown of muscle tissue resulting in the release of muscle fiber contents into the bloodstream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhinorrhea</VALIDVALUE>
          <VALUEMEANING>Rhinorrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive mucous secretions draining from the nose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rotator cuff injury</VALIDVALUE>
          <VALUEMEANING>Rotator cuff injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an injury of the rotator cuff.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shingles</VALIDVALUE>
          <VALUEMEANING>Shingles</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reactivation of herpes zoster virus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinusoidal obstruction syndrome</VALIDVALUE>
          <VALUEMEANING>Sinusoidal obstruction syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by severe hepatic injury as a result of the blood vessels of the liver becoming inflamed and/or blocked.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin papilloma</VALIDVALUE>
          <VALUEMEANING>Skin papilloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of one or more warts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spinal cord compression</VALIDVALUE>
          <VALUEMEANING>Spinal cord compression</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by pressure on the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subcutaneous emphysema</VALIDVALUE>
          <VALUEMEANING>Subcutaneous emphysema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by air in the subcutaneous tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tendon reflex decreased</VALIDVALUE>
          <VALUEMEANING>Tendon reflex decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by less than normal deep tendon reflexes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testosterone deficiency</VALIDVALUE>
          <VALUEMEANING>Testosterone deficiency</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by low testosterone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thrush</VALIDVALUE>
          <VALUEMEANING>Thrush</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a suspected candidal infection involving an oral mucosal surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroid stimulating hormone increased</VALIDVALUE>
          <VALUEMEANING>Thyroid stimulating hormone increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in thyroid stimulating hormone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trochlear nerve disorder</VALIDVALUE>
          <VALUEMEANING>Trochlear nerve disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor hemorrhage</VALIDVALUE>
          <VALUEMEANING>Tumor hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding in a tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaccination complication</VALIDVALUE>
          <VALUEMEANING>Vaccination complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder that occurs after the injection of a substance with antigenic properties, administered to activate the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaccination site lymphadenopathy</VALIDVALUE>
          <VALUEMEANING>Vaccination site lymphadenopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by lymph node enlargement after vaccination</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Viremia</VALIDVALUE>
          <VALUEMEANING>Viremia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of a virus in the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vision decreased</VALIDVALUE>
          <VALUEMEANING>Vision decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in visual acuity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck soft tissue necrosis</VALIDVALUE>
          <VALUEMEANING>Neck soft tissue necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the neck.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck pain</VALIDVALUE>
          <VALUEMEANING>Neck pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the neck area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myositis</VALIDVALUE>
          <VALUEMEANING>Myositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving the skeletal muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myalgia</VALIDVALUE>
          <VALUEMEANING>Myalgia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Musculoskeletal deformity</VALIDVALUE>
          <VALUEMEANING>Musculoskeletal deformity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a malformation of the musculoskeletal system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Musculoskeletal and connective tissue disorder - Other, specify</VALIDVALUE>
          <VALUEMEANING>Musculoskeletal and connective tissue disorder - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Musculoskeletal and connective tissue disorder - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle weakness upper limb</VALIDVALUE>
          <VALUEMEANING>Muscle weakness upper limb</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the upper limb muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle weakness trunk</VALIDVALUE>
          <VALUEMEANING>Muscle weakness trunk</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the trunk muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle weakness lower limb</VALIDVALUE>
          <VALUEMEANING>Muscle weakness lower limb</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of the lower limb muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lordosis</VALIDVALUE>
          <VALUEMEANING>Lordosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kyphosis</VALIDVALUE>
          <VALUEMEANING>Kyphosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joint range of motion decreased lumbar spine</VALIDVALUE>
          <VALUEMEANING>Joint range of motion decreased lumbar spine</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in flexibility of a lumbar spine joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143628</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joint range of motion decreased cervical spine</VALIDVALUE>
          <VALUEMEANING>Joint range of motion decreased cervical spine</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in flexibility of a cervical spine joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joint range of motion decreased</VALIDVALUE>
          <VALUEMEANING>Joint range of motion decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in joint flexibility of any joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joint effusion</VALIDVALUE>
          <VALUEMEANING>Joint effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Head soft tissue necrosis</VALIDVALUE>
          <VALUEMEANING>Head soft tissue necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the head.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Growth suppression</VALIDVALUE>
          <VALUEMEANING>Growth suppression</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by stature that is smaller than normal as expected for age.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Generalized muscle weakness</VALIDVALUE>
          <VALUEMEANING>Generalized muscle weakness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flank pain</VALIDVALUE>
          <VALUEMEANING>Flank pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibrosis deep connective tissue</VALIDVALUE>
          <VALUEMEANING>Fibrosis deep connective tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fibrotic degeneration of the deep connective tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exostosis</VALIDVALUE>
          <VALUEMEANING>Exostosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by non-neoplastic overgrowth of bone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest wall pain</VALIDVALUE>
          <VALUEMEANING>Chest wall pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the chest wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buttock pain</VALIDVALUE>
          <VALUEMEANING>Buttock pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the buttocks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone pain</VALIDVALUE>
          <VALUEMEANING>Bone pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the bones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Back pain</VALIDVALUE>
          <VALUEMEANING>Back pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the back region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avascular necrosis</VALIDVALUE>
          <VALUEMEANING>Avascular necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arthritis</VALIDVALUE>
          <VALUEMEANING>Arthritis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving a joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143299</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arthralgia</VALIDVALUE>
          <VALUEMEANING>Arthralgia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in a joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor lysis syndrome</VALIDVALUE>
          <VALUEMEANING>Tumor lysis syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obesity</VALIDVALUE>
          <VALUEMEANING>Obesity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by having a high amount of body fat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metabolism and nutrition disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Metabolism and nutrition disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Metabolism and nutrition disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest wall necrosis</VALIDVALUE>
          <VALUEMEANING>Chest wall necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the soft tissues of the chest wall including breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypophosphatemia</VALIDVALUE>
          <VALUEMEANING>Hypophosphatemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyponatremia</VALIDVALUE>
          <VALUEMEANING>Hyponatremia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypomagnesemia</VALIDVALUE>
          <VALUEMEANING>Hypomagnesemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypokalemia</VALIDVALUE>
          <VALUEMEANING>Hypokalemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chylous ascites</VALIDVALUE>
          <VALUEMEANING>Chylous ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by accumulation of milky fluid in the peritoneal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypocalcemia</VALIDVALUE>
          <VALUEMEANING>Hypocalcemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoalbuminemia</VALIDVALUE>
          <VALUEMEANING>Hypoalbuminemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperuricemia</VALIDVALUE>
          <VALUEMEANING>Hyperuricemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061655</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyanosis</VALIDVALUE>
          <VALUEMEANING>Cyanosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a bluish discoloration of the skin and/or mucous membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytomegalovirus infection reactivation</VALIDVALUE>
          <VALUEMEANING>Cytomegalovirus infection reactivation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reactivation of cytomegalovirus (CMV).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypernatremia</VALIDVALUE>
          <VALUEMEANING>Hypernatremia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypermagnesemia</VALIDVALUE>
          <VALUEMEANING>Hypermagnesemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disease progression</VALIDVALUE>
          <VALUEMEANING>Disease progression</VALUEMEANING>
          <MEANINGDESCRIPTION>Death due to disease progression that cannot be attributed to a CTCAE term associated with Grade 5.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143201</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperkalemia</VALIDVALUE>
          <VALUEMEANING>Hyperkalemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperglycemia</VALIDVALUE>
          <VALUEMEANING>Hyperglycemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypercalcemia</VALIDVALUE>
          <VALUEMEANING>Hypercalcemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glucose intolerance</VALIDVALUE>
          <VALUEMEANING>Glucose intolerance</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inability to properly metabolize glucose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dehydration</VALIDVALUE>
          <VALUEMEANING>Dehydration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anorexia</VALIDVALUE>
          <VALUEMEANING>Anorexia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a loss of appetite.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alkalosis</VALIDVALUE>
          <VALUEMEANING>Alkalosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alcohol intolerance</VALIDVALUE>
          <VALUEMEANING>Alcohol intolerance</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acidosis</VALIDVALUE>
          <VALUEMEANING>Acidosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>White blood cell decreased</VALIDVALUE>
          <VALUEMEANING>White blood cell decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysuria</VALIDVALUE>
          <VALUEMEANING>Dysuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by painful urination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine perforation</VALIDVALUE>
          <VALUEMEANING>Uterine perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the uterine wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterine anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Uterine anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urostomy stenosis</VALIDVALUE>
          <VALUEMEANING>Urostomy stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of narrowing of the opening of a urostomy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urostomy site bleeding</VALIDVALUE>
          <VALUEMEANING>Urostomy site bleeding</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the urostomy site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urostomy obstruction</VALIDVALUE>
          <VALUEMEANING>Urostomy obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the urostomy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urostomy leak</VALIDVALUE>
          <VALUEMEANING>Urostomy leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage of contents from a urostomy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143910</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urethral anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Urethral anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ureteric anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Ureteric anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheostomy site bleeding</VALIDVALUE>
          <VALUEMEANING>Tracheostomy site bleeding</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the tracheostomy site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheal obstruction</VALIDVALUE>
          <VALUEMEANING>Tracheal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the lumen of the trachea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Tracheal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the trachea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stomal ulcer</VALIDVALUE>
          <VALUEMEANING>Stomal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stenosis of gastrointestinal stoma</VALIDVALUE>
          <VALUEMEANING>Stenosis of gastrointestinal stoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spinal fracture</VALIDVALUE>
          <VALUEMEANING>Spinal fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spermatic cord anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Spermatic cord anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestinal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Small intestinal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seroma</VALIDVALUE>
          <VALUEMEANING>Seroma</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of tumor-like collection of serum in the tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Rectal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation recall reaction (dermatologic)</VALIDVALUE>
          <VALUEMEANING>Radiation recall reaction (dermatologic)</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prolapse of urostomy</VALIDVALUE>
          <VALUEMEANING>Prolapse of urostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of displacement of the urostomy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143782</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prolapse of intestinal stoma</VALIDVALUE>
          <VALUEMEANING>Prolapse of intestinal stoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Postoperative thoracic procedure complication</VALIDVALUE>
          <VALUEMEANING>Postoperative thoracic procedure complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of a previously undocumented problem that occurs after a thoracic procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Postoperative hemorrhage</VALIDVALUE>
          <VALUEMEANING>Postoperative hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding occurring after a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Pharyngeal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Pancreatic anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Large intestinal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Large intestinal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Kidney anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative venous injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative venous injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to a vein during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative urinary injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative urinary injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the urinary system during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative splenic injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative splenic injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the spleen during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative respiratory injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative respiratory injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the respiratory system during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143611</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative reproductive tract injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative reproductive tract injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the reproductive organs during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative renal injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative renal injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the kidney during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143609</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative ocular injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative ocular injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the eye during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative neurological injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative neurological injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the nervous system during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative musculoskeletal injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative musculoskeletal injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the musculoskeletal system during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative hepatobiliary injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative hepatobiliary injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative hemorrhage</VALIDVALUE>
          <VALUEMEANING>Intraoperative hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of uncontrolled bleeding during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143604</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative head and neck injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative head and neck injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the head and neck during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative gastrointestinal injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative gastrointestinal injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the gastrointestinal system during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143602</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061582</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative endocrine injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative endocrine injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the endocrine gland during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative ear injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative ear injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the ear during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative cardiac injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative cardiac injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the heart during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative breast injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative breast injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the breast parenchyma during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative arterial injury</VALIDVALUE>
          <VALUEMEANING>Intraoperative arterial injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to an artery during a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intestinal stoma site bleeding</VALIDVALUE>
          <VALUEMEANING>Intestinal stoma site bleeding</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the intestinal stoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intestinal stoma obstruction</VALIDVALUE>
          <VALUEMEANING>Intestinal stoma obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143593</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intestinal stoma leak</VALIDVALUE>
          <VALUEMEANING>Intestinal stoma leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injury, poisoning and procedural complications - Other, specify</VALIDVALUE>
          <VALUEMEANING>Injury, poisoning and procedural complications - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Injury, poisoning and procedural complications - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injury to superior vena cava</VALIDVALUE>
          <VALUEMEANING>Injury to superior vena cava</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the superior vena cava.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injury to jugular vein</VALIDVALUE>
          <VALUEMEANING>Injury to jugular vein</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the jugular vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injury to inferior vena cava</VALIDVALUE>
          <VALUEMEANING>Injury to inferior vena cava</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the inferior vena cava.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injury to carotid artery</VALIDVALUE>
          <VALUEMEANING>Injury to carotid artery</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the carotid artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infusion related reaction</VALIDVALUE>
          <VALUEMEANING>Infusion related reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hip fracture</VALIDVALUE>
          <VALUEMEANING>Hip fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal stoma necrosis</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal stoma necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Gastric anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fracture</VALIDVALUE>
          <VALUEMEANING>Fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of traumatic injury to the bone in which the continuity of the bone is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fallopian tube perforation</VALIDVALUE>
          <VALUEMEANING>Fallopian tube perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture of the fallopian tube wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fallopian tube anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Fallopian tube anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Esophageal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143451</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dermatitis radiation</VALIDVALUE>
          <VALUEMEANING>Dermatitis radiation</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burn</VALIDVALUE>
          <VALUEMEANING>Burn</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruising</VALIDVALUE>
          <VALUEMEANING>Bruising</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Bladder anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biliary anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Biliary anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arterial injury</VALIDVALUE>
          <VALUEMEANING>Arterial injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to an artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143296</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aortic injury</VALIDVALUE>
          <VALUEMEANING>Aortic injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the aorta.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ankle fracture</VALIDVALUE>
          <VALUEMEANING>Ankle fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vulval infection</VALIDVALUE>
          <VALUEMEANING>Vulval infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the vulva.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Weight gain</VALIDVALUE>
          <VALUEMEANING>Weight gain</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vital capacity abnormal</VALIDVALUE>
          <VALUEMEANING>Vital capacity abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatitis viral</VALIDVALUE>
          <VALUEMEANING>Hepatitis viral</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a viral pathologic process involving the liver parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic infection</VALIDVALUE>
          <VALUEMEANING>Hepatic infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gum infection</VALIDVALUE>
          <VALUEMEANING>Gum infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the gums.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder infection</VALIDVALUE>
          <VALUEMEANING>Gallbladder infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the gallbladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye infection</VALIDVALUE>
          <VALUEMEANING>Eye infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal infection</VALIDVALUE>
          <VALUEMEANING>Esophageal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enterocolitis infectious</VALIDVALUE>
          <VALUEMEANING>Enterocolitis infectious</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the small and large intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endophthalmitis</VALIDVALUE>
          <VALUEMEANING>Endophthalmitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the internal structures of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endocarditis infective</VALIDVALUE>
          <VALUEMEANING>Endocarditis infective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the endocardial layer of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encephalomyelitis infection</VALIDVALUE>
          <VALUEMEANING>Encephalomyelitis infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the brain and spinal cord tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encephalitis infection</VALIDVALUE>
          <VALUEMEANING>Encephalitis infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the brain tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal infection</VALIDVALUE>
          <VALUEMEANING>Duodenal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Device related infection</VALIDVALUE>
          <VALUEMEANING>Device related infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the use of a medical device.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cranial nerve infection</VALIDVALUE>
          <VALUEMEANING>Cranial nerve infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving a cranial nerve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corneal infection</VALIDVALUE>
          <VALUEMEANING>Corneal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the cornea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conjunctivitis infective</VALIDVALUE>
          <VALUEMEANING>Conjunctivitis infective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conjunctivitis</VALIDVALUE>
          <VALUEMEANING>Conjunctivitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervicitis infection</VALIDVALUE>
          <VALUEMEANING>Cervicitis infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the uterine cervix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cecal infection</VALIDVALUE>
          <VALUEMEANING>Cecal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the cecum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Catheter related infection</VALIDVALUE>
          <VALUEMEANING>Catheter related infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process that arises secondary to catheter use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchial infection</VALIDVALUE>
          <VALUEMEANING>Bronchial infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the bronchi.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast infection</VALIDVALUE>
          <VALUEMEANING>Breast infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone infection</VALIDVALUE>
          <VALUEMEANING>Bone infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the bones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder infection</VALIDVALUE>
          <VALUEMEANING>Bladder infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biliary tract infection</VALIDVALUE>
          <VALUEMEANING>Biliary tract infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the biliary tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arteritis infective</VALIDVALUE>
          <VALUEMEANING>Arteritis infective</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving an artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appendicitis perforated</VALIDVALUE>
          <VALUEMEANING>Appendicitis perforated</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appendicitis</VALIDVALUE>
          <VALUEMEANING>Appendicitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anorectal infection</VALIDVALUE>
          <VALUEMEANING>Anorectal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the anal area and the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal infection</VALIDVALUE>
          <VALUEMEANING>Abdominal infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum sickness</VALIDVALUE>
          <VALUEMEANING>Serum sickness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immune system disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Immune system disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Immune system disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine output decreased</VALIDVALUE>
          <VALUEMEANING>Urine output decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on test results that indicate urine production is less relative to previous output.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum amylase increased</VALIDVALUE>
          <VALUEMEANING>Serum amylase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platelet count decreased</VALIDVALUE>
          <VALUEMEANING>Platelet count decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic enzymes decreased</VALIDVALUE>
          <VALUEMEANING>Pancreatic enzymes decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutrophil count decreased</VALIDVALUE>
          <VALUEMEANING>Neutrophil count decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocyte count increased</VALIDVALUE>
          <VALUEMEANING>Lymphocyte count increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocyte count decreased</VALIDVALUE>
          <VALUEMEANING>Lymphocyte count decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipase increased</VALIDVALUE>
          <VALUEMEANING>Lipase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Investigations - Other, specify</VALIDVALUE>
          <VALUEMEANING>Investigations - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Investigations - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INR increased</VALIDVALUE>
          <VALUEMEANING>INR increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the ratio of the patient&#39;s prothrombin time to a control sample in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemoglobin increased</VALIDVALUE>
          <VALUEMEANING>Hemoglobin increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Haptoglobin decreased</VALIDVALUE>
          <VALUEMEANING>Haptoglobin decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Growth hormone abnormal</VALIDVALUE>
          <VALUEMEANING>Growth hormone abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GGT increased</VALIDVALUE>
          <VALUEMEANING>GGT increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Forced expiratory volume decreased</VALIDVALUE>
          <VALUEMEANING>Forced expiratory volume decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibrinogen decreased</VALIDVALUE>
          <VALUEMEANING>Fibrinogen decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electrocardiogram QT corrected interval prolonged</VALIDVALUE>
          <VALUEMEANING>Electrocardiogram QT corrected interval prolonged</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ejection fraction decreased</VALIDVALUE>
          <VALUEMEANING>Ejection fraction decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Creatinine increased</VALIDVALUE>
          <VALUEMEANING>Creatinine increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CPK increased</VALIDVALUE>
          <VALUEMEANING>CPK increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cholesterol high</VALIDVALUE>
          <VALUEMEANING>Cholesterol high</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD4 lymphocytes decreased</VALIDVALUE>
          <VALUEMEANING>CD4 lymphocytes decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac troponin T increased</VALIDVALUE>
          <VALUEMEANING>Cardiac troponin T increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiac troponin I increased</VALIDVALUE>
          <VALUEMEANING>Cardiac troponin I increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carbon monoxide diffusing capacity decreased</VALIDVALUE>
          <VALUEMEANING>Carbon monoxide diffusing capacity decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood prolactin abnormal</VALIDVALUE>
          <VALUEMEANING>Blood prolactin abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061699</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood gonadotrophin abnormal</VALIDVALUE>
          <VALUEMEANING>Blood gonadotrophin abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood corticotrophin decreased</VALIDVALUE>
          <VALUEMEANING>Blood corticotrophin decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood bilirubin increased</VALIDVALUE>
          <VALUEMEANING>Blood bilirubin increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood antidiuretic hormone abnormal</VALIDVALUE>
          <VALUEMEANING>Blood antidiuretic hormone abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspartate aminotransferase increased</VALIDVALUE>
          <VALUEMEANING>Aspartate aminotransferase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alkaline phosphatase increased</VALIDVALUE>
          <VALUEMEANING>Alkaline phosphatase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alanine aminotransferase increased</VALIDVALUE>
          <VALUEMEANING>Alanine aminotransferase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Activated partial thromboplastin time prolonged</VALIDVALUE>
          <VALUEMEANING>Activated partial thromboplastin time prolonged</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wrist fracture</VALIDVALUE>
          <VALUEMEANING>Wrist fracture</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autoimmune disorder</VALIDVALUE>
          <VALUEMEANING>Autoimmune disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytokine release syndrome</VALIDVALUE>
          <VALUEMEANING>Cytokine release syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anaphylaxis</VALIDVALUE>
          <VALUEMEANING>Anaphylaxis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allergic reaction</VALIDVALUE>
          <VALUEMEANING>Allergic reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an adverse local or general response from exposure to an allergen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Portal vein thrombosis</VALIDVALUE>
          <VALUEMEANING>Portal vein thrombosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Portal hypertension</VALIDVALUE>
          <VALUEMEANING>Portal hypertension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in blood pressure in the portal venous system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perforation bile duct</VALIDVALUE>
          <VALUEMEANING>Perforation bile duct</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatobiliary disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Hepatobiliary disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Hepatobiliary disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic pain</VALIDVALUE>
          <VALUEMEANING>Hepatic pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the liver region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic necrosis</VALIDVALUE>
          <VALUEMEANING>Hepatic necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the hepatic parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic hemorrhage</VALIDVALUE>
          <VALUEMEANING>Hepatic hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic failure</VALIDVALUE>
          <VALUEMEANING>Hepatic failure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy&#39;s Law.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vasculitis</VALIDVALUE>
          <VALUEMEANING>Vasculitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation involving the wall of a vessel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Vascular disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Vascular disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superior vena cava syndrome</VALIDVALUE>
          <VALUEMEANING>Superior vena cava syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superficial thrombophlebitis</VALIDVALUE>
          <VALUEMEANING>Superficial thrombophlebitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phlebitis</VALIDVALUE>
          <VALUEMEANING>Phlebitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the wall of a vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral ischemia</VALIDVALUE>
          <VALUEMEANING>Peripheral ischemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by impaired circulation to an extremity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocele</VALIDVALUE>
          <VALUEMEANING>Lymphocele</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a cystic lesion containing lymph.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphedema</VALIDVALUE>
          <VALUEMEANING>Lymphedema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive fluid collection in tissues that causes swelling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph leakage</VALIDVALUE>
          <VALUEMEANING>Lymph leakage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypotension</VALIDVALUE>
          <VALUEMEANING>Hypotension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypertension</VALIDVALUE>
          <VALUEMEANING>Hypertension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a pathological increase in blood pressure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hot flashes</VALIDVALUE>
          <VALUEMEANING>Hot flashes</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematoma</VALIDVALUE>
          <VALUEMEANING>Hematoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flushing</VALIDVALUE>
          <VALUEMEANING>Flushing</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capillary leak syndrome</VALIDVALUE>
          <VALUEMEANING>Capillary leak syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical and medical procedures - Other, specify</VALIDVALUE>
          <VALUEMEANING>Surgical and medical procedures - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical and medical procedures - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143869</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Social circumstances - Other, specify</VALIDVALUE>
          <VALUEMEANING>Social circumstances - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Social circumstances - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urticaria</VALIDVALUE>
          <VALUEMEANING>Urticaria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58019</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toxic epidermal necrolysis</VALIDVALUE>
          <VALUEMEANING>Toxic epidermal necrolysis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telangiectasia</VALIDVALUE>
          <VALUEMEANING>Telangiectasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stevens-Johnson syndrome</VALIDVALUE>
          <VALUEMEANING>Stevens-Johnson syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143859</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin ulceration</VALIDVALUE>
          <VALUEMEANING>Skin ulceration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin induration</VALIDVALUE>
          <VALUEMEANING>Skin induration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an area of hardness in the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin hypopigmentation</VALIDVALUE>
          <VALUEMEANING>Skin hypopigmentation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by loss of skin pigment (e.g., vitiligo).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin hyperpigmentation</VALIDVALUE>
          <VALUEMEANING>Skin hyperpigmentation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by darkening of the skin due to excessive melanin deposition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin atrophy</VALIDVALUE>
          <VALUEMEANING>Skin atrophy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the degeneration and thinning of the epidermis and dermis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin and subcutaneous tissue disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Skin and subcutaneous tissue disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Skin and subcutaneous tissue disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scalp pain</VALIDVALUE>
          <VALUEMEANING>Scalp pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rash maculo-papular</VALIDVALUE>
          <VALUEMEANING>Rash maculo-papular</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rash acneiform</VALIDVALUE>
          <VALUEMEANING>Rash acneiform</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Purpura</VALIDVALUE>
          <VALUEMEANING>Purpura</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pruritus</VALIDVALUE>
          <VALUEMEANING>Pruritus</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an intense itching sensation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Photosensitivity</VALIDVALUE>
          <VALUEMEANING>Photosensitivity</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in sensitivity of the skin to light.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palmar-plantar erythrodysesthesia syndrome</VALIDVALUE>
          <VALUEMEANING>Palmar-plantar erythrodysesthesia syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound dehiscence</VALIDVALUE>
          <VALUEMEANING>Wound dehiscence</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of separation of the approximated margins of a surgical wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound complication</VALIDVALUE>
          <VALUEMEANING>Wound complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of development of a new problem at the site of an existing wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Venous injury</VALIDVALUE>
          <VALUEMEANING>Venous injury</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of damage to a vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular access complication</VALIDVALUE>
          <VALUEMEANING>Vascular access complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of a previously undocumented problem related to the vascular access site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vas deferens anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Vas deferens anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Vaginal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngolaryngeal pain</VALIDVALUE>
          <VALUEMEANING>Pharyngolaryngeal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal stenosis</VALIDVALUE>
          <VALUEMEANING>Pharyngeal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the pharyngeal airway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal necrosis</VALIDVALUE>
          <VALUEMEANING>Pharyngeal necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal mucositis</VALIDVALUE>
          <VALUEMEANING>Pharyngeal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Pharyngeal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharyngeal fistula</VALIDVALUE>
          <VALUEMEANING>Pharyngeal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound infection</VALIDVALUE>
          <VALUEMEANING>Wound infection</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an infectious process involving the wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Weight loss</VALIDVALUE>
          <VALUEMEANING>Weight loss</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vitreous hemorrhage</VALIDVALUE>
          <VALUEMEANING>Vitreous hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding into the vitreous humor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary urgency</VALIDVALUE>
          <VALUEMEANING>Urinary urgency</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sudden compelling urge to urinate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toothache</VALIDVALUE>
          <VALUEMEANING>Toothache</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the tooth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thromboembolic event</VALIDVALUE>
          <VALUEMEANING>Thromboembolic event</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stroke</VALIDVALUE>
          <VALUEMEANING>Stroke</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sepsis</VALIDVALUE>
          <VALUEMEANING>Sepsis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scoliosis</VALIDVALUE>
          <VALUEMEANING>Scoliosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a malformed, lateral curvature of the spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinopathy</VALIDVALUE>
          <VALUEMEANING>Retinopathy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder involving the retina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Psychosis</VALIDVALUE>
          <VALUEMEANING>Psychosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pneumonitis</VALIDVALUE>
          <VALUEMEANING>Pneumonitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric stenosis</VALIDVALUE>
          <VALUEMEANING>Gastric stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric perforation</VALIDVALUE>
          <VALUEMEANING>Gastric perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the stomach wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric necrosis</VALIDVALUE>
          <VALUEMEANING>Gastric necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the gastric wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric hemorrhage</VALIDVALUE>
          <VALUEMEANING>Gastric hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the gastric wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric fistula</VALIDVALUE>
          <VALUEMEANING>Gastric fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flatulence</VALIDVALUE>
          <VALUEMEANING>Flatulence</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a discharge of excessive gas from the lower GI tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fecal incontinence</VALIDVALUE>
          <VALUEMEANING>Fecal incontinence</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inability to control the escape of stool from the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophagitis</VALIDVALUE>
          <VALUEMEANING>Esophagitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the esophageal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal varices hemorrhage</VALIDVALUE>
          <VALUEMEANING>Esophageal varices hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from esophageal varices.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal ulcer</VALIDVALUE>
          <VALUEMEANING>Esophageal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal stenosis</VALIDVALUE>
          <VALUEMEANING>Esophageal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal perforation</VALIDVALUE>
          <VALUEMEANING>Esophageal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the wall of the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal pain</VALIDVALUE>
          <VALUEMEANING>Esophageal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the esophageal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal obstruction</VALIDVALUE>
          <VALUEMEANING>Esophageal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the contents in the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain of skin</VALIDVALUE>
          <VALUEMEANING>Pain of skin</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nail ridging</VALIDVALUE>
          <VALUEMEANING>Nail ridging</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by vertical or horizontal ridges on the nails.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nail loss</VALIDVALUE>
          <VALUEMEANING>Nail loss</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by loss of all or a portion of the nail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nail discoloration</VALIDVALUE>
          <VALUEMEANING>Nail discoloration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the color of the nail plate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anosmia</VALIDVALUE>
          <VALUEMEANING>Anosmia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the sense of smell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipohypertrophy</VALIDVALUE>
          <VALUEMEANING>Lipohypertrophy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypohidrosis</VALIDVALUE>
          <VALUEMEANING>Hypohidrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by reduced sweating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypertrichosis</VALIDVALUE>
          <VALUEMEANING>Hypertrichosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143561</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amenorrhea</VALIDVALUE>
          <VALUEMEANING>Amenorrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the abnormal absence of menses for at least three consecutive menstrual cycles</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperhidrosis</VALIDVALUE>
          <VALUEMEANING>Hyperhidrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive sweating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hirsutism</VALIDVALUE>
          <VALUEMEANING>Hirsutism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arterial thromboembolism</VALIDVALUE>
          <VALUEMEANING>Arterial thromboembolism</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by occlusion of an arterial vessel by a blood clot that develops in an artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bacteremia</VALIDVALUE>
          <VALUEMEANING>Bacteremia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of bacteria in the blood stream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fat atrophy</VALIDVALUE>
          <VALUEMEANING>Fat atrophy</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by shrinking of adipose tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belching</VALIDVALUE>
          <VALUEMEANING>Belching</VALUEMEANING>
          <MEANINGDESCRIPTION>To expel gas noisily from the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erythema multiforme</VALIDVALUE>
          <VALUEMEANING>Erythema multiforme</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by target lesions (a pink-red ring around a pale center).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood bicarbonate decreased</VALIDVALUE>
          <VALUEMEANING>Blood bicarbonate decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in levels of bicarbonate in a venous blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dry skin</VALIDVALUE>
          <VALUEMEANING>Dry skin</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bullous dermatitis</VALIDVALUE>
          <VALUEMEANING>Bullous dermatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Body odor</VALIDVALUE>
          <VALUEMEANING>Body odor</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alopecia</VALIDVALUE>
          <VALUEMEANING>Alopecia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wheezing</VALIDVALUE>
          <VALUEMEANING>Wheezing</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Voice alteration</VALIDVALUE>
          <VALUEMEANING>Voice alteration</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a change in the sound and/or speed of the voice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143941</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheal stenosis</VALIDVALUE>
          <VALUEMEANING>Tracheal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the trachea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheal mucositis</VALIDVALUE>
          <VALUEMEANING>Tracheal mucositis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tracheal fistula</VALIDVALUE>
          <VALUEMEANING>Tracheal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C58205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stridor</VALIDVALUE>
          <VALUEMEANING>Stridor</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood lactate dehydrogenase increased</VALIDVALUE>
          <VALUEMEANING>Blood lactate dehydrogenase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate increased levels of lactate dehydrogenase in the blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sneezing</VALIDVALUE>
          <VALUEMEANING>Sneezing</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the involuntary expulsion of air from the nose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sleep apnea</VALIDVALUE>
          <VALUEMEANING>Sleep apnea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by cessation of breathing for short periods during sleep.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus pain</VALIDVALUE>
          <VALUEMEANING>Sinus pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus disorder</VALIDVALUE>
          <VALUEMEANING>Sinus disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by involvement of the paranasal sinuses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Budd-Chiari syndrome</VALIDVALUE>
          <VALUEMEANING>Budd-Chiari syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by occlusion of the hepatic veins and typically presents with abdominal pain, ascites and hepatomegaly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6061397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinoic acid syndrome</VALIDVALUE>
          <VALUEMEANING>Retinoic acid syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C56635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Respiratory, thoracic and mediastinal disorders - Other, specify</VALIDVALUE>
          <VALUEMEANING>Respiratory, thoracic and mediastinal disorders - Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Respiratory, thoracic and mediastinal disorders - Other, specify</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Respiratory failure</VALIDVALUE>
          <VALUEMEANING>Respiratory failure</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary hypertension</VALIDVALUE>
          <VALUEMEANING>Pulmonary hypertension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary fistula</VALIDVALUE>
          <VALUEMEANING>Pulmonary fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary fibrosis</VALIDVALUE>
          <VALUEMEANING>Pulmonary fibrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6062490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paresthesia</VALIDVALUE>
          <VALUEMEANING>Paresthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Papilledema</VALIDVALUE>
          <VALUEMEANING>Papilledema</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by swelling around the optic disc.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Meningitis</VALIDVALUE>
          <VALUEMEANING>Meningitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Malabsorption</VALIDVALUE>
          <VALUEMEANING>Malabsorption</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iron overload</VALIDVALUE>
          <VALUEMEANING>Iron overload</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by accumulation of iron in the tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoglycemia</VALIDVALUE>
          <VALUEMEANING>Hypoglycemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypertriglyceridemia</VALIDVALUE>
          <VALUEMEANING>Hypertriglyceridemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hoarseness</VALIDVALUE>
          <VALUEMEANING>Hoarseness</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemorrhoids</VALIDVALUE>
          <VALUEMEANING>Hemorrhoids</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the presence of dilated veins in the rectum and surrounding area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hearing impaired</VALIDVALUE>
          <VALUEMEANING>Hearing impaired</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gynecomastia</VALIDVALUE>
          <VALUEMEANING>Gynecomastia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by excessive development of the breasts in males.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fall</VALIDVALUE>
          <VALUEMEANING>Fall</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of sudden movement downward, usually resulting in injury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erythroderma</VALIDVALUE>
          <VALUEMEANING>Erythroderma</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves &gt; 90% of the body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diarrhea</VALIDVALUE>
          <VALUEMEANING>Diarrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an increase in frequency and/or loose or watery bowel movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cheilitis</VALIDVALUE>
          <VALUEMEANING>Cheilitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the lip.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchopleural fistula</VALIDVALUE>
          <VALUEMEANING>Bronchopleural fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blurred vision</VALIDVALUE>
          <VALUEMEANING>Blurred vision</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by visual perception of unclear or fuzzy images.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C55906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal pain</VALIDVALUE>
          <VALUEMEANING>Abdominal pain</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a sensation of marked discomfort in the abdominal region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6063484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal necrosis</VALIDVALUE>
          <VALUEMEANING>Esophageal necrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a necrotic process occurring in the esophageal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Esophageal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the esophagus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal fistula</VALIDVALUE>
          <VALUEMEANING>Esophageal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enterovesical fistula</VALIDVALUE>
          <VALUEMEANING>Enterovesical fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the urinary bladder and the intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enterocolitis</VALIDVALUE>
          <VALUEMEANING>Enterocolitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the small and large intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dysphagia</VALIDVALUE>
          <VALUEMEANING>Dysphagia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by difficulty in swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dyspepsia</VALIDVALUE>
          <VALUEMEANING>Dyspepsia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal ulcer</VALIDVALUE>
          <VALUEMEANING>Duodenal ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal stenosis</VALIDVALUE>
          <VALUEMEANING>Duodenal stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal perforation</VALIDVALUE>
          <VALUEMEANING>Duodenal perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the duodenal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal obstruction</VALIDVALUE>
          <VALUEMEANING>Duodenal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Duodenal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenal fistula</VALIDVALUE>
          <VALUEMEANING>Duodenal fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dry mouth</VALIDVALUE>
          <VALUEMEANING>Dry mouth</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by reduced salivary flow in the oral cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dental caries</VALIDVALUE>
          <VALUEMEANING>Dental caries</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Constipation</VALIDVALUE>
          <VALUEMEANING>Constipation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic ulcer</VALIDVALUE>
          <VALUEMEANING>Colonic ulcer</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic stenosis</VALIDVALUE>
          <VALUEMEANING>Colonic stenosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a narrowing of the lumen of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic perforation</VALIDVALUE>
          <VALUEMEANING>Colonic perforation</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a rupture in the colonic wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic obstruction</VALIDVALUE>
          <VALUEMEANING>Colonic obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic hemorrhage</VALIDVALUE>
          <VALUEMEANING>Colonic hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonic fistula</VALIDVALUE>
          <VALUEMEANING>Colonic fistula</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colitis</VALIDVALUE>
          <VALUEMEANING>Colitis</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C57134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cecal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Cecal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the cecum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bloating</VALIDVALUE>
          <VALUEMEANING>Bloating</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Baseline Abnormality</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Baseline Abnormality</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4280691</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Abnormalities</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4280695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="780">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6304258</PUBLICID>
    <LONGNAME>Clinical Trial Defined Administrative Activity Specify</LONGNAME>
    <PREFERREDNAME>6304257v1.0:5566342v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field to define the response for administrative.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6304257</PublicId>
      <PreferredName>2813546v1.0:6304255v1.0</PreferredName>
      <PreferredDefinition>A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes._An activity defined at a global library level that is not directly related to hypothesis evaluation or testing, but is typically essential to the efficient and/or effective coordination and execution of a study.</PreferredDefinition>
      <LongName>Clinical Trial Defined Administrative Activity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2813546</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71104</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71104</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial</LONG_NAME>
            <CON_ID>2735720</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6304255</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93353</PreferredName>
        <Version>1</Version>
        <LongName>Defined Administrative Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93353</PREFERRED_NAME>
            <LONG_NAME>Defined Administrative Activity</LONG_NAME>
            <CON_ID>6304254</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5566342</PublicId>
      <PreferredName>5566342v1.0</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2390957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Administrative, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Administrative, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>6304257v1.0:5566342v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BE_BEREASND_ADMIN_OTH</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="781">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6304262</PUBLICID>
    <LONGNAME>Investigator Decision Specify</LONGNAME>
    <PREFERREDNAME>6304261v1.0:5566342v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field to define the response for investigator decision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6304261</PublicId>
      <PreferredName>2528490v1.0:2678062v1.0</PreferredName>
      <PreferredDefinition>An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements._A position, opinion, or judgment reached on an issue under consideration.</PreferredDefinition>
      <LongName>Investigator Decision</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528490</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25936</PreferredName>
        <Version>1</Version>
        <LongName>Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25936</PREFERRED_NAME>
            <LONG_NAME>Investigator</LONG_NAME>
            <CON_ID>2202869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2678062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53285</PreferredName>
        <Version>1</Version>
        <LongName>Decision</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53285</PREFERRED_NAME>
            <LONG_NAME>Decision</LONG_NAME>
            <CON_ID>2443958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5566342</PublicId>
      <PreferredName>5566342v1.0</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2390957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Investigator decision, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Investigator decision, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Investigator discretion, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>6304261v1.0:5566342v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BE_BEREASND_INVEST_OTH</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="782">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6306968</PUBLICID>
    <LONGNAME>Inotuzumab Ozogamicin Per Cycle Combination Dose Administered 1 Decimal Place Milligram per Square Meter Value</LONGNAME>
    <PREFERREDNAME>6306960v1.0:6306967v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The 1 decimal place milligram per square meter numeric combined dose per cycle value measured, assigned or computed related to the inotuzumab ozogamicin administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6306960</PublicId>
      <PreferredName>6324340v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._For each, generally denoting a ratio._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._A collection of things that have been assembled together to form a new whole._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Inotuzumab Ozogamicin Per Cycle Combination Dose Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6324340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6324340v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Inotuzumab Ozogamicin Per Cycle Combination Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71542</PREFERRED_NAME>
            <LONG_NAME>Inotuzumab Ozogamicin</LONG_NAME>
            <CON_ID>5576812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61517</PREFERRED_NAME>
            <LONG_NAME>Combination</LONG_NAME>
            <CON_ID>2673231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6306967</PublicId>
      <PreferredName>6306967v1.0</PreferredName>
      <PreferredDefinition>A number with no fractional part, including the negative and positive numbers as well as zero.::1_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>1 Decimal Place Milligram per Square Meter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/m2</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>6306966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255::1:C42646:C67402:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Integer::1 Decimal Place Milligram per Square Meter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67402</PREFERRED_NAME>
            <LONG_NAME>Milligram per Square Meter</LONG_NAME>
            <CON_ID>2725140</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the inotuzumab ozoga</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the inotuzumab ozogamicin administered combined dose per cycle value?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Dose:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>INOT_CYC_ino_com_ds_pr_cy_val</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="783">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6326084</PUBLICID>
    <LONGNAME>Ampulla of Vater Cancer Targeted Therapy Type</LONGNAME>
    <PREFERREDNAME>AVC_targeted_therapy</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to identify a targeted molecular therapy agent administered to an individual with Ampulla of Vater cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6324364</PublicId>
      <PreferredName>6324351v1.0:5981618v1.0</PreferredName>
      <PreferredDefinition>A carcinoma arising from the ampulla of Vater.  The vast majority of cases are adenocarcinomas.  Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss._Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.</PreferredDefinition>
      <LongName>Ampulla of Vater Carcinoma Targeted Molecular Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6324351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3908</PreferredName>
        <Version>1</Version>
        <LongName>Ampulla of Vater Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3908</PREFERRED_NAME>
            <LONG_NAME>Ampulla of Vater Carcinoma</LONG_NAME>
            <CON_ID>6324350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5981618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C76243</PreferredName>
        <Version>1</Version>
        <LongName>Targeted Molecular Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C76243</PREFERRED_NAME>
            <LONG_NAME>Targeted Molecular Therapy</LONG_NAME>
            <CON_ID>2786908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5880214</PublicId>
      <PreferredName>5880214v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Targeted Therapy Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribociclib</VALIDVALUE>
          <VALUEMEANING>Ribociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6072178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Everolimus</VALIDVALUE>
          <VALUEMEANING>Everolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palbociclib</VALIDVALUE>
          <VALUEMEANING>PD-0332991</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lapatinib</VALIDVALUE>
          <VALUEMEANING>Lapatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4916291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ado-trastuzumab emtansine</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Emtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4255113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pertuzumab</VALIDVALUE>
          <VALUEMEANING>Pertuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other (specify)</VALIDVALUE>
          <VALUEMEANING>Specify Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4888051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ramucirumab (Cyramza)</VALIDVALUE>
          <VALUEMEANING>Ramucirumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3553252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab (Herceptin)</VALIDVALUE>
          <VALUEMEANING>Trastuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sorafenib</VALIDVALUE>
          <VALUEMEANING>Sorafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temsirolimus</VALIDVALUE>
          <VALUEMEANING>Temsirolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IGF-1R Inhibitor</VALIDVALUE>
          <VALUEMEANING>Linsitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3444804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor</VALIDVALUE>
          <VALUEMEANING>ALK Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141136</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6010235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIBG</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Metaiodobenzylguanidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Meta-iodobenzylguanidine localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3585878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erlotinib</VALIDVALUE>
          <VALUEMEANING>Erlotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avitinib</VALIDVALUE>
          <VALUEMEANING>Avitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147125</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nazartinib</VALIDVALUE>
          <VALUEMEANING>Nazartinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115109</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olmutinib</VALIDVALUE>
          <VALUEMEANING>Olmutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor HM61713 binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ASP8273</VALIDVALUE>
          <VALUEMEANING>EGFR Inhibitor ASP8273</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PF-06747775</VALIDVALUE>
          <VALUEMEANING>Mavelertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Afatinib</VALIDVALUE>
          <VALUEMEANING>Afatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4713538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gefitinib</VALIDVALUE>
          <VALUEMEANING>Gefitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Necitumumab</VALIDVALUE>
          <VALUEMEANING>Necitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crizotinib</VALIDVALUE>
          <VALUEMEANING>Crizotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceritinib</VALIDVALUE>
          <VALUEMEANING>Ceritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4369572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alectinib</VALIDVALUE>
          <VALUEMEANING>Alectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nivolumab</VALIDVALUE>
          <VALUEMEANING>Nivolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osimertinib</VALIDVALUE>
          <VALUEMEANING>Osimertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5305951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rociletinib</VALIDVALUE>
          <VALUEMEANING>Rociletinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-1 inhibitor</VALIDVALUE>
          <VALUEMEANING>PD1 Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6059143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regorafenib</VALIDVALUE>
          <VALUEMEANING>Regorafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3729312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Panitumumab</VALIDVALUE>
          <VALUEMEANING>Panitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab</VALIDVALUE>
          <VALUEMEANING>Cetuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ziv-aflibercept</VALIDVALUE>
          <VALUEMEANING>Aflibercept</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3880514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bevacizumab</VALIDVALUE>
          <VALUEMEANING>Bevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4916311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linifanib</VALIDVALUE>
          <VALUEMEANING>Linifanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6423718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PTK787</VALIDVALUE>
          <VALUEMEANING>Vatalanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brivanib</VALIDVALUE>
          <VALUEMEANING>Brivanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6423720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vemurafenib</VALIDVALUE>
          <VALUEMEANING>Vemurafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trametinib</VALIDVALUE>
          <VALUEMEANING>Trametinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3523220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nilotinib</VALIDVALUE>
          <VALUEMEANING>Nilotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imatinib</VALIDVALUE>
          <VALUEMEANING>Imatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dabrafenib</VALIDVALUE>
          <VALUEMEANING>Dabrafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4539014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cobimetinib</VALIDVALUE>
          <VALUEMEANING>MEK inhibitor GDC-0973</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rucaparib</VALIDVALUE>
          <VALUEMEANING>Rucaparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olaparib</VALIDVALUE>
          <VALUEMEANING>Olaparib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Niraparib</VALIDVALUE>
          <VALUEMEANING>Niraparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MK2206</VALIDVALUE>
          <VALUEMEANING>Akt Inhibitor MK2206</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3374409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AZD5363</VALIDVALUE>
          <VALUEMEANING>Capivasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6819518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenvatinib</VALIDVALUE>
          <VALUEMEANING>Lenvatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6682739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab, Carboplatin (Cisplatin), Fluorouracil</VALIDVALUE>
          <VALUEMEANING>Carboplatin/Fluorouracil/Cetuximab Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemoimmunotherapy regimen consisting of carboplatin, fluorouracil (5-FU) and cetuximab that can be used for the treatment of head and neck cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6776302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab, Carboplatin, and Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Cetuximab Carboplatin Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1411, C1282, C1723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6776300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axitinib</VALIDVALUE>
          <VALUEMEANING>Axitinib Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of axitinib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, and kidney cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6815963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cabozantinib</VALIDVALUE>
          <VALUEMEANING>Cabozantinib Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of cabozantinib that may be used in the treatment of follicular, medullary, papillary and Hurthle cell thyroid carcinomas; hepatobiliary and kidney cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6815965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenvatinib and Everolimus</VALIDVALUE>
          <VALUEMEANING>Lenvatinib/Everolimus Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of bevacizumab and everolimus that can be used for the treatment of kidney cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6682741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pazopanib</VALIDVALUE>
          <VALUEMEANING>Pazopanib Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of pazopanib that may be used in the treatment of soft tissue and uterine sarcomas; follicular, medullary, papillary, and Hurthle cell thyroid carcinomas; gastrointestinal stromal tumors (GISTs); and kidney cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6815967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sunitinib</VALIDVALUE>
          <VALUEMEANING>Sunitinib Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of sunitinib that may be used in the treatment of soft tissue sarcomas (including alveolar soft part sarcomas); follicular, medullary, papillary, Hurthle cell thyroid carcinomas; thymic carcinomas and thymomas; gastrointestinal stromal tumors (GISTs); kidney and bone cancers; solitary fibrous tumor/hemangiopericytoma; and pancreatic neuroendocrine tumors (NETs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160119</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6815969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ridaforolimus</VALIDVALUE>
          <VALUEMEANING>Ridaforolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-10-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Catequentinib</VALIDVALUE>
          <VALUEMEANING>Catequentinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15180257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel</VALIDVALUE>
          <VALUEMEANING>Docetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eribulin</VALIDVALUE>
          <VALUEMEANING>Eribulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4311896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine</VALIDVALUE>
          <VALUEMEANING>Gemcitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that belongs to the family of drugs called antimetabolites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3145831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olaratumab</VALIDVALUE>
          <VALUEMEANING>Anti-PDGFR alpha Monoclonal Antibody IMC-3G3</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trabectedin</VALIDVALUE>
          <VALUEMEANING>Trabectedin</VALUEMEANING>
          <MEANINGDESCRIPTION>A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Targeted therapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Targeted therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AVC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7589445</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="784">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6335623</PUBLICID>
    <LONGNAME>Peritoneal Disease Not Omentum Location Anatomic Site</LONGNAME>
    <PREFERREDNAME>6335580v1.0:6334878v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The location of non-neoplastic or neoplastic disease that affects the peritoneal cavity not located in the fold of peritoneum originating at the stomach and supporting the viscera.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6335580</PublicId>
      <PreferredName>6315975v1.0:6335578v1.0</PreferredName>
      <PreferredDefinition>A non-neoplastic or neoplastic disorder that affects the peritoneal cavity.  Representative examples of non-neoplastic disorders include peritonitis and panniculitis.  Representative examples of neoplastic disorders include adenomatoid tumor, primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma._An operation in which a term denies or inverts the meaning of another term or construction._A fold of peritoneum originating at the stomach and supporting the viscera._Named locations of or within the body.</PreferredDefinition>
      <LongName>Peritoneal Disease Not Omentum Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12219</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Structure, System, or Substance</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6315975</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26848</PreferredName>
        <Version>1</Version>
        <LongName>Peritoneal Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26848</PREFERRED_NAME>
            <LONG_NAME>Peritoneal Disorder</LONG_NAME>
            <CON_ID>6315974</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6335578</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C33209:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Negation Omentum Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C33209</PREFERRED_NAME>
            <LONG_NAME>Omentum</LONG_NAME>
            <CON_ID>2204846</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6334878</PublicId>
      <PreferredName>6334878v1.0</PreferredName>
      <PreferredDefinition>A non-neoplastic or neoplastic disorder that affects the peritoneal cavity.  Representative examples of non-neoplastic disorders include peritonitis and panniculitis.  Representative examples of neoplastic disorders include adenomatoid tumor, primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma._Named locations of or within the body.</PreferredDefinition>
      <LongName>Peritoneal Disease Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12219</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Structure, System, or Substance</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>6334877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26848:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Peritoneal Disorder Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26848</PREFERRED_NAME>
            <LONG_NAME>Peritoneal Disorder</LONG_NAME>
            <CON_ID>6315974</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Define-able mesenteric implant</VALIDVALUE>
          <VALUEMEANING>Definable Mesentery Tumor Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>Able to concisely explain of the meaning of a word or phrase or symbol.: A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.: A nodule of a malignant tumor that develops at a site in a body cavity at a distance from the initial site of cancer. This is a finding typical of ovarian cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151403, C33103, C151401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6343308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver, right upper quadrant</VALIDVALUE>
          <VALUEMEANING>Liver Right Upper Quadrant of Abdomen</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: The region of the abdomen that extends from the median plane to the right of the patient, and from the umbilical plane to the right ribcage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151398, C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6343309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lesser sac</VALIDVALUE>
          <VALUEMEANING>Hepatogastric Ligament</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the lesser omentum between the liver and the lesser curvature of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6343311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrosplenic, gastrocolic, spleen, left upper quadrant</VALIDVALUE>
          <VALUEMEANING>Gastrosplenic Ligament Gastrocolic Ligament Spleen Left Upper Quadrant of Abdomen</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the greater omentum between the greater curvature of the stomach and the hilum of the spleen.: A major portion of the greater omentum between the stomach and the transverse colon.: An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.: The region of the abdomen that extends from the median plane to the left of the patient, and from the umbilical plane to the left ribcage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151397, C12432, C32667, C32671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6343314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pouch of Douglas</VALIDVALUE>
          <VALUEMEANING>Recto-Vaginal Pouch</VALUEMEANING>
          <MEANINGDESCRIPTION>The peritoneal reflection of the superior part of the posterior wall of the vagina, anterior to the rectum, which is the deepest point of the peritoneal cavity in females.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6343316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paracolic gutters (left, right)</VALIDVALUE>
          <VALUEMEANING>Paracolic Gutter</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two naturally ocurring spaces between the colon and the abdominal wall, lateral to the ascending and descending colons.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5630081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesentery (including infiltration/tethering of the mesenteric root)</VALIDVALUE>
          <VALUEMEANING>Mesentery</VALUEMEANING>
          <MEANINGDESCRIPTION>A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Locations of peritoneal disea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Locations of peritoneal disease (other than omentum)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CIP-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Locations of peritoneal disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180933</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>LIDC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovarian Features</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6343663</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="785">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6335749</PUBLICID>
    <LONGNAME>Distant Metastasis Location Anatomic Site</LONGNAME>
    <PREFERREDNAME>DIST_MET_STATION</PREFERREDNAME>
    <PREFERREDDEFINITION>The location of relocated ovarian malignant cells to a distal locus within the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6335597</PublicId>
      <PreferredName>2782798v1.0:2186622v1.0</PreferredName>
      <PreferredDefinition>A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors._Named locations of or within the body.</PreferredDefinition>
      <LongName>Distant Metastasis Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12219</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Structure, System, or Substance</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782798</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18206</PreferredName>
        <Version>1</Version>
        <LongName>Distant Metastasis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18206</PREFERRED_NAME>
            <LONG_NAME>Distant Metastasis</LONG_NAME>
            <CON_ID>2204770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2186622</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6333866</PublicId>
      <PreferredName>6333866v1.0</PreferredName>
      <PreferredDefinition>A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors._Named locations of or within the body.</PreferredDefinition>
      <LongName>Distant Metastasis Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>6335750</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18206:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Distant Metastasis Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18206</PREFERRED_NAME>
            <LONG_NAME>Distant Metastasis</LONG_NAME>
            <CON_ID>2204770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleura</VALIDVALUE>
          <VALUEMEANING>Pleura</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue that lines the wall of the thoracic cavity and the surface of the lungs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3639609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5400972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spleen</VALIDVALUE>
          <VALUEMEANING>Spleen</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Locations</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Locations</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CIP-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Distant Metastases Location</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CIP-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Distant Metastases Locations</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180933</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>LIDC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovarian Features</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6343663</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="786">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6341381</PUBLICID>
    <LONGNAME>Patient Hospitalization Reason</LONGNAME>
    <PREFERREDNAME>HOSP_REAS</PREFERREDNAME>
    <PREFERREDDEFINITION>An explanation for the condition of being treated as a patient in a hospital.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014066</PublicId>
      <PreferredName>PT_HOSP</PreferredName>
      <PreferredDefinition>the in-patient hospitalization of an individual. </PreferredDefinition>
      <LongName>Patient Hospitalization</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Hospitalization</PreferredName>
        <Version>1</Version>
        <LongName>Hospitalization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25179</PREFERRED_NAME>
            <LONG_NAME>Hospitalization</LONG_NAME>
            <CON_ID>2202493</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338193</PublicId>
      <PreferredName>6338193v1.0</PreferredName>
      <PreferredDefinition>An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Hospitalization Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCTG: Canadian Cancer Trials Group</Origin>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PK or PD sampling</VALIDVALUE>
          <VALUEMEANING>Pharmacokinetics Or Pharmacodynamics Sampling</VALUEMEANING>
          <MEANINGDESCRIPTION>The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.: The selection and obtaining of small representative quantities of biological material for the purpose of analysis; also, in biomedical statistics, sampling is the selection and implementation of statistical observations in order to estimate properties of an underlying population; also, in environmental science, the collection of representative specimens analyzed to characterize site conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25662, C15720, C37998, C15299</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elective surgery or procedure</VALIDVALUE>
          <VALUEMEANING>Elective Surgical Procedure Or Intervention or Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery that may be scheduled or undertaken by choice.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25218, C37998, C51996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transfusion support</VALIDVALUE>
          <VALUEMEANING>Blood Transfusion Support</VALUEMEANING>
          <MEANINGDESCRIPTION>The infusion of components of blood or whole blood into the bloodstream. The blood may be donated from another person, or it may have been taken from the person earlier and stored until needed.: Moral, psychological, physical, or financial aid or assistance; approval.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37902, C15192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serious adverse event (SAE)</VALIDVALUE>
          <VALUEMEANING>Serious Adverse Event</VALUEMEANING>
          <MEANINGDESCRIPTION>Any expected or unexpected adverse event, related or unrelated to the intervention, occurring at any agent dose, any phase of product o procedure testing, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect. Important medical events that may not result in the listed outcomes may be considered as serious when, based upon appropriate medical judgment, they represent significant hazards or potentially serious harm to the research subject or others and may require medical intervention to prevent one of the outcomes listed in this definition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palliative or terminal care</VALIDVALUE>
          <VALUEMEANING>Palliative Or Terminal Disease Patient Care</VALUEMEANING>
          <MEANINGDESCRIPTION>Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An illness that has a prognosis of death.: Any of the services rendered for the benefit of a patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15239, C9228, C37998, C101516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Study drug administration</VALIDVALUE>
          <VALUEMEANING>Protocol Agent Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>A medical product, practice, or application that is tested in a clinical trial.: The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25409, C41161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason for hospitalization</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason for hospitalization</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HOSP_REAS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HO_HOREAS</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPHO_QVAL_HOREAS</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="787">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6341850</PUBLICID>
    <LONGNAME>Patient Blood Pressure Measurement Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_BP_MEASUREMENT_YES_NO</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no criteria stating whether a patient is willing and able to record daily blood pressure measurements</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5335693</PublicId>
      <PreferredName>2233604v1.0:5335691v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The pressure of the circulating blood against the walls of the blood vessels._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Blood Pressure Measurement Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5335691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54706:C25209:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Blood Pressure Measurement Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54706</PREFERRED_NAME>
            <LONG_NAME>Blood Pressure</LONG_NAME>
            <CON_ID>2552352</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the patient willing and ab</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the patient willing and able to check and record daily blood pressure readings?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="788">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6345598</PUBLICID>
    <LONGNAME>Plasma Preparation Tube Blood Collection Count</LONGNAME>
    <PREFERREDNAME>PPT_BLOOD_COLLECT_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of PPT (Plasma Preparation Tube) Blood Draw Tubes collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ABTC: Adult Brain Tumor Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6345591</PublicId>
      <PreferredName>6345405v1.0:6345406v1.0</PreferredName>
      <PreferredDefinition>An evacuated blood collection tube that contains an inert gel and spray-dried K2EDTA anticoagulant, intended for the collection of whole blood and the separation of plasma._A test tube, capillary tube, or other tube designed for the collection of blood._The act of gathering things together; having been brought together in one place.</PreferredDefinition>
      <LongName>Plasma Preparation Tube Blood Collection Tube Collection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6345589</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C153167</PreferredName>
        <Version>1</Version>
        <LongName>Plasma Preparation Tube</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C153167</PREFERRED_NAME>
            <LONG_NAME>Plasma Preparation Tube</LONG_NAME>
            <CON_ID>6345385</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6345406</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113122:C25453</PreferredName>
        <Version>1</Version>
        <LongName>Blood Collection Tube Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113122</PREFERRED_NAME>
            <LONG_NAME>Blood Collection Tube</LONG_NAME>
            <CON_ID>4761273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ABTC: Adult Brain Tumor Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018392</PublicId>
      <PreferredName>CT</PreferredName>
      <PreferredDefinition>The quantity of the specified item.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of PPT Blood Draw Tube</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of PPT Blood Draw Tubes Collected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4280691</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>On-Study Surgical Specimen Collection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4280708</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="789">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6352122</PUBLICID>
    <LONGNAME>Patient Stage I Malignant Testicular Germ Cell Tumor Procedure Retrospective Retroperitoneal Lymph Node Dissection Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_TTC_CA_PDR_RPLND_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator to determine if patient having Stage 1 testicular cancer has undergone primary retroperitoneal lymph node dissection (RPLND) as eligibility criteria.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6352118</PublicId>
      <PreferredName>2233604v1.0:6352116v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Invasive cancer confined to the original anatomic site of growth without lymph node involvement._A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor._Any stepwise set of actions._Looking back at events that have already taken place._The surgical removal of retroperitoneal lymph nodes from the abdominal cavity. The surgery is a therapeutic treatment for testicular cancer, performed after (orchiectomy) or testicular removal. The surgery is recommended for men who are at an increased risk of metastasis, or who decline other treatment options such as radiation or chemotherapy._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Stage I Malignant Testicular Germ Cell Tumor Procedure Retrospective Retroperitoneal Lymph Node Dissection Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6464685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6464685v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Stage I Malignant Testicular Germ Cell Tumor Procedure Retrospective Retroperitoneal Lymph Node Dissection Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27966</PREFERRED_NAME>
            <LONG_NAME>Stage I</LONG_NAME>
            <CON_ID>2205259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9063</PREFERRED_NAME>
            <LONG_NAME>Malignant Testicular Germ Cell Tumor</LONG_NAME>
            <CON_ID>2672903</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79751</PREFERRED_NAME>
            <LONG_NAME>Procedure</LONG_NAME>
            <CON_ID>2833027</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28010</PREFERRED_NAME>
            <LONG_NAME>Retrospective</LONG_NAME>
            <CON_ID>2205043</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48184</PREFERRED_NAME>
            <LONG_NAME>Retroperitoneal Lymph Node Dissection</LONG_NAME>
            <CON_ID>6352115</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have Stage I tes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have Stage I testicular cancer who has undergone primary RPLND (retroperitoneal lymph node dissection)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="790">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6379857</PUBLICID>
    <LONGNAME>Biospecimen Anatomic Site Name Name</LONGNAME>
    <PREFERREDNAME>SPC_SITE</PREFERREDNAME>
    <PREFERREDDEFINITION>The anatomic site name.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3253891</PublicId>
      <PreferredName>3253885v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._Named locations of, or within, the body._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Biospecimen Anatomic Site Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12219</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Structure, System, or Substance</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3253885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CHTN:Cooperative Human Tissue Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6379856</PublicId>
      <PreferredName>6379856v1.0</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>500</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right Kidney</VALIDVALUE>
          <VALUEMEANING>Right Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped retroperitoneal organ situated below the diaphragm and posterior to the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left Kidney</VALIDVALUE>
          <VALUEMEANING>Left Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped retroperitoneal organ situated below the diaphragm and posterior to the spleen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-regional lymph node</VALIDVALUE>
          <VALUEMEANING>Regional Lymph Node Negation</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node that drains lymph from a region of interest.: An operation in which a term denies or inverts the meaning of another term or construction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C49018</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6369467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regional Lymph Node</VALIDVALUE>
          <VALUEMEANING>Regional Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node that drains lymph from a region of interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49018</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneum</VALIDVALUE>
          <VALUEMEANING>Peritoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue that lines the wall of the abdominal cavity, intestine, and mesentery. It consists of the parietal peritoneum that covers the inside of the abdominal wall and the visceral peritoneum that covers the surface of the intestine and mesentery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3625362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retroperitoneum</VALIDVALUE>
          <VALUEMEANING>Retroperitoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>The back of the abdomen where the kidneys lie and the great blood vessels run.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney</VALIDVALUE>
          <VALUEMEANING>Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5400972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brain</VALIDVALUE>
          <VALUEMEANING>Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specimen anatomic site name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specimen anatomic site name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="791">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6381601</PUBLICID>
    <LONGNAME>Substance Administration Intervention or Procedure Performed Study Activity Dose Change Reason OMOP CDM Drug Stop Reason</LONGNAME>
    <PREFERREDNAME>3174957v1.0:6381564v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A material with particular features.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of alteration or modification; changed or altered in form or character.:An explanation of the cause of some phenomenon or action._The reason the Drug was stopped. Reasons include regimen completed, changed, removed, etc.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174957</PublicId>
      <PreferredName>3174249v1.0:2867914v1.0</PreferredName>
      <PreferredDefinition>A material with particular features.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of alteration or modification; changed or altered in form or character.:An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Substance Administration Intervention or Procedure Performed Study Activity Dose Change Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174249v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Substance Administration Intervention or Procedure Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45306</PREFERRED_NAME>
            <LONG_NAME>Substance</LONG_NAME>
            <CON_ID>2523396</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867914</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488:C25446:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Dose Change Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6381564</PublicId>
      <PreferredName>6381564v1.0</PreferredName>
      <PreferredDefinition>The reason the Drug was stopped. Reasons include regimen completed, changed, removed, etc.</PreferredDefinition>
      <LongName>OMOP CDM Drug Stop Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <Datatype>varchar</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</Origin>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason Drug Stopped</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason Drug Stopped</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5279492</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.2</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug Exposure</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6093497</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5279492</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.31</PreferredName>
          <Version>5.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug Exposure</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>8003198</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>stop_reason</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DRUG_EXPOSURE</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="792">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6381611</PUBLICID>
    <LONGNAME>Clinical Performed Observation Outcome Data OMOP CDM Mathematical Operator Concept Identifier</LONGNAME>
    <PREFERREDNAME>operator_concept_id</PREFERREDNAME>
    <PREFERREDDEFINITION>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._A foreign key identifier to the predefined Concept in the Standardized Vocabularies reflecting the mathematical operator that is applied to the value_as_number. Operators are &lt;, &lt;=, =, &gt;=, &gt;.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175329</PublicId>
      <PreferredName>2867629v1.0:2423441v1.0</PreferredName>
      <PreferredDefinition>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.</PreferredDefinition>
      <LongName>Clinical Performed Observation Outcome Data</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C38000:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423441</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474</PreferredName>
        <Version>1</Version>
        <LongName>Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6381304</PublicId>
      <PreferredName>6381304v1.0</PreferredName>
      <PreferredDefinition>A foreign key identifier to the predefined Concept in the Standardized Vocabularies reflecting the mathematical operator that is applied to the value_as_number. Operators are &lt;, &lt;=, =, &gt;=, &gt;.</PreferredDefinition>
      <LongName>OMOP CDM Mathematical Operator Concept Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mathematical Operator Concept</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mathematical Operator Concept ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5279492</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.2</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Measurement</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6093500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5279492</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.31</PreferredName>
          <Version>5.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Measurement</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>8003199</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>operator_concept_id</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MEASUREMENT</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="793">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6385043</PUBLICID>
    <LONGNAME>Serum Iron Measurement Laboratory Procedure Performed Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>6385042v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory results for serum iron measurement.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6385042</PublicId>
      <PreferredName>6385040v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed._A measurement of the iron in a biological specimen._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Serum Iron Measurement Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6385040</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13325:C74679:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Serum Iron Measurement Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13325</PREFERRED_NAME>
            <LONG_NAME>Serum</LONG_NAME>
            <CON_ID>2203797</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74679</PREFERRED_NAME>
            <LONG_NAME>Iron Measurement</LONG_NAME>
            <CON_ID>3654515</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the ser</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the serum iron measurement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serum iron</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Serum iron</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serum iron</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Serum iron</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_IAED_serum_iron_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_HMGL_serum_iron_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="794">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6395382</PUBLICID>
    <LONGNAME>Prior Inotuzumab Ozogamicin Other CD22 Gene Direct Therapeutic Procedure Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6395363v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to prior administration of inotuzumab ozogamicin or other CD22 gene direct therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6395363</PublicId>
      <PreferredName>6395361v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._Different than the one(s) previously specified or mentioned._This gene is involved in mediating the adhesion between B cells and is a molecular marker for B-cell precursor acute lymphocytic leukemia._As an immediate result; having nothing intervening; without deviation or interruption._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Prior Inotuzumab Ozogamicin Other CD22 Gene Direct Therapeutic Procedure Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6395361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6395361v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Prior Inotuzumab Ozogamicin Other CD22 Gene Direct Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71542</PREFERRED_NAME>
            <LONG_NAME>Inotuzumab Ozogamicin</LONG_NAME>
            <CON_ID>5576812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20990</PREFERRED_NAME>
            <LONG_NAME>CD22 Gene</LONG_NAME>
            <CON_ID>3649405</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62254</PREFERRED_NAME>
            <LONG_NAME>Direct</LONG_NAME>
            <CON_ID>2660101</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior treatment with inotuzum</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior treatment with inotuzumab ozogamicin or other CD22-directed therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PR_TRT_CD22_ADM_IND</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="795">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6400715</PUBLICID>
    <LONGNAME>Observation Reuse Template Study Activity Name Code ACT I2B2 CDM Laboratory Test Classification System Version Text</LONGNAME>
    <PREFERREDNAME>3174974v1.0:6399648v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._Laboratory test classification system version.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACT CDM:The Accrual to Clinical Trials Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174974</PublicId>
      <PreferredName>3174191v1.0:2867793v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Observation Reuse Template Study Activity Name Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174191v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867793</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Name Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6399648</PublicId>
      <PreferredName>6399648v1.0</PreferredName>
      <PreferredDefinition>Laboratory test classification system version.</PreferredDefinition>
      <LongName>ACT I2B2 CDM Laboratory Test Classification System Version Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACT CDM:The Accrual to Clinical Trials Network Common Data Model</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Laboratory Test Classificatio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Laboratory Test Classification System Version</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6093471</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>i2b2 ACT Network CDM 1.4</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Test</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6093475</CsiPublicId>
        <CsiVersion>1.4</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_CLASSIFICATION_SYSTEM_VERSION</AlternateName>
        <AlternateNameType>ACT Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LABORATORY_TEST</AlternateName>
        <AlternateNameType>ACT Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="796">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6408612</PUBLICID>
    <LONGNAME>Any Study Treatment Taken</LONGNAME>
    <PREFERREDNAME>ECYN</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication whether or not the subject took study medication/ treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6408518</PublicId>
      <PreferredName>6407207v1.0:6421711v1.0</PreferredName>
      <PreferredDefinition>This interventions domain model reflects protocol-specified study treatment administrations, as collected._A medical product, practice, or application that is tested in a clinical trial._Having been accepted for some purpose; ingested as a medication.</PreferredDefinition>
      <LongName>Exposure as Collected Domain Protocol Agent Taken</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117466</PreferredName>
        <Version>1</Version>
        <LongName>Exposure as Collected Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117466</PREFERRED_NAME>
            <LONG_NAME>Exposure as Collected Domain</LONG_NAME>
            <CON_ID>6407206</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6421711</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41161:C25701</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent Taken</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41161</PREFERRED_NAME>
            <LONG_NAME>Protocol Agent</LONG_NAME>
            <CON_ID>2390873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were any study treatments tak</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were any study treatments taken?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Any Study Treatments</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.</DocumentText>
        <URL>https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C66742</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form  Completion Instructions</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Indicate if the subject took any medications. If Yes, include the appropriate details where indicated.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>N/A</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Does not map to an SDTMIG variable. The SDTM Annotated CRF is annotated to indicate that this field is NOT SUBMITTED.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>The intent/purpose of collecting this field is to help with data cleaning and monitoring. It provides verification that all other fields on the CRF were deliberately left blank. The ECYN is meant to indicate that the exposure as collected form should be completed or inserted into the case book. ECOCCUR would be used when the actual drug name is preprinted on the CRF. While these might be equivalent in a single drug study, there are differences in how they would be used in most trials. Therefore, it does not map into the SDTM variable ECOCCUR, since ECOCCUR indicates whether the subject was actually administered treatment/medication. If actual treatment data is available (ECYN = &quot;Y&quot;), ECOCCUR may be populated based on whether subject was actually administered treatment/medication.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the subject had any Pre-immunotherapy after enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the subject had any VXLD Reinduction therapy after enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient had any Immunotherapy treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient had any Post-VXLD treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start protocol therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start protocol treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive Nivolumab during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient start protocol treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive DAY101 during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start protocol procedures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start post-Induction treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was glucarpidase administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient start randomized protocol treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was at least one agent prescribed by the protocol administered during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start assigned treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 15</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive the treatment with irinotecan, temozolomide and dinutuximab as their first treatment after being removed from protocol therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 16</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start Induction treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 17</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient start maintenance treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were any study treatments taken?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 18</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient&#39;s maintenance therapy begun?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exposure as Collected (EC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Exposure as Collected (EC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943380</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_PRETX</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_VXLD</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_IMMTX_G1</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_IMMTX_DS</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_POSTVXLD</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_NIVO</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_GCPSE</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_CALLBACK</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_PRSCRB</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_POSTCALLBRANDOM</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_POSTCALLBEOI</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_OFF_EOT_F_TX</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_POST_CALLB</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECYN_POST_CALLB3</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>EC_ECYN</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="797">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6408629</PUBLICID>
    <LONGNAME>Ongoing Clinical Event</LONGNAME>
    <PREFERREDNAME>CEONGO</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication the clinical event is ongoing when no end date is provided.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6408552</PublicId>
      <PreferredName>6407330v1.0:6408550v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to clinical events._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._Something that happens at a given place and time._Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.</PreferredDefinition>
      <LongName>Clinical Events Domain Clinical Event Continue</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407330</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85441</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Events Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85441</PREFERRED_NAME>
            <LONG_NAME>Clinical Events Domain</LONG_NAME>
            <CON_ID>6407329</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6408550</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25499:C53279</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Event Continue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53279</PREFERRED_NAME>
            <LONG_NAME>Continue</LONG_NAME>
            <CON_ID>2443956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the [clinical event] ongo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the [clinical event] ongoing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.</DocumentText>
        <URL>https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C66742</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form  Completion Instructions</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Check the box if the clinical event has not resolved at the time of data collection; leave the End Date blank.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CEENRTPT; CEENRF</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>This does not map directly to an SDTMIG variable. May be used to populate a value into an SDTMIG relative timing variable such as CEENRF or CEENRTPT. When populating CEENRF, if the value of CEONGO is &quot;Y&quot;, the value of &quot;DURING&quot;, &quot;AFTER&quot; or &quot;DURING/AFTER&quot; may be used. When populating CEENRTPT, if the value of CEONGO is &quot;Y&quot;, the value of &quot;ONGOING&quot; may be used. When CEONGO refers to the Study Reference Period (defined in DM.RFSTDTC to DM.RFENDTC) the SDTMIG variable CEENRF should be populated. When CEONGO is compared to any other time point, the SDTMIG variables CEENRTPT and CEENTPT should be used. Note: CEENRTPT must refer to a time point anchor described in CEENTPT.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>Completed to indicate that the CE has not resolved at the time of data collection, when no End Date is collected. In some cases the ongoing status may be determined from CE Outcome. The purpose of collecting this field is to help with data cleaning and monitoring, since this field provides further confirmation that the End Date was deliberately left blank. Often used as a tick/checkbox.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible;Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible;Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Ongoing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the [clinical event] ongoing?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the [clinical event] ongoing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Event (CE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329787</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Clinical Event (CE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943371</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CE_CEONGO</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="798">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6408669</PUBLICID>
    <LONGNAME>Clinical Significance</LONGNAME>
    <PREFERREDNAME>FACLSIG</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication whether the test results were clinically significant</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6408605</PublicId>
      <PreferredName>6407857v1.0:6408603v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to findings about events or interventions._Clinical, laboratory or molecular evidence, or absence of evidence of disease._A finding that has treatment or management implications for a patient&#39;s condition.</PreferredDefinition>
      <LongName>Findings About Events or Interventions Domain Finding Clinical Significance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407857</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85442</PreferredName>
        <Version>1</Version>
        <LongName>Findings About Events or Interventions Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85442</PREFERRED_NAME>
            <LONG_NAME>Findings About Events or Interventions Domain</LONG_NAME>
            <CON_ID>6407856</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6408603</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3367:C82562</PreferredName>
        <Version>1</Version>
        <LongName>Finding Clinical Significance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82562</PREFERRED_NAME>
            <LONG_NAME>Clinical Significance</LONG_NAME>
            <CON_ID>3179443</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>[Is/Was] the ([measurement/te</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>[Is/Was] the ([measurement/test/examination]) result clinically significant?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>([Measurement/Test/Examination/])/Clinically Significant</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.</DocumentText>
        <URL>https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C66742</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form  Completion Instructions</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Record whether [FATEST] result was clinically significant.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SUPPFA.QVAL</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>This does not map directly to an SDTMIG variable. This information could be submitted in a SUPPFA dataset as the value of SUPPFA.QVAL when SUPPFA.QNAM = &quot;CLSIG&quot; and SUPPFA.QLABEL = &quot;Clinical Significance&quot;. Refer to the current SDTM and SDTMIG for instructions on placement of non-standard variables in SDTM domains.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>[Is/Was] the ([measurement/test/examination]) result clinically significant?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Findings About (FA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329798</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Findings About (FA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943384</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>FA_FACLSIG</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="799">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6409604</PUBLICID>
    <LONGNAME>Date of Subject Characteristics Collection</LONGNAME>
    <PREFERREDNAME>SCDAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date of collection represented in an unambiguous date format (e.g., DD-MON-YYYY).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6409284</PublicId>
      <PreferredName>6408455v1.0:2958350v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics._The date on which the sample or data was collected.</PreferredDefinition>
      <LongName>Subject Characteristics Domain Collection Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6408455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49610</PreferredName>
        <Version>1</Version>
        <LongName>Subject Characteristics Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49610</PREFERRED_NAME>
            <LONG_NAME>Subject Characteristics Domain</LONG_NAME>
            <CON_ID>2469075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2958350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81286</PreferredName>
        <Version>1</Version>
        <LongName>Collection Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81286</PREFERRED_NAME>
            <LONG_NAME>Collection Date</LONG_NAME>
            <CON_ID>2958277</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338240</PublicId>
      <PreferredName>CDISCDAT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>11</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396655</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25164</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the date the subject</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the date the subject characteristic(s) was collected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Record date the subject characteristic(s) was collected using the format (DD-MON-YYYY).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SCDTC</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>This does not map directly to an SDTMIG variable. For the SDTM submission dataset, concatenate all collected CDASH DATE and TIME components and populate the SDTMIG variable SCDTC in ISO 8601 format.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>The date of collection can be determined from a collected date of the visit (VISDAT) and in such cases a date field is not required.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recommended/Conditional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject Characteristics (SC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="800">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6411550</PUBLICID>
    <LONGNAME>Modified Procedure Name</LONGNAME>
    <PREFERREDNAME>PRMODIFY</PREFERREDNAME>
    <PREFERREDDEFINITION>If the value for PRTERM is modified for coding purposes, then the modified text is placed here.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6411458</PublicId>
      <PreferredName>6407261v1.0:6411456v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._A character string that is a revision of the original text to enable the coding of the text.</PreferredDefinition>
      <LongName>Procedure Domain Name Code Modified Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102700</PreferredName>
        <Version>1</Version>
        <LongName>Procedure Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102700</PREFERRED_NAME>
            <LONG_NAME>Procedure Domain</LONG_NAME>
            <CON_ID>6407260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6411456</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93601</PreferredName>
        <Version>1</Version>
        <LongName>Name Code Modified Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93601</PREFERRED_NAME>
            <LONG_NAME>Name Code Modified Text</LONG_NAME>
            <CON_ID>6411455</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353425</PublicId>
      <PreferredName>CDISCNAM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C42614</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Modified Procedure Name does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Modified Procedure Name does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PRMODIFY</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Maps directly to the SDTMIG variable.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>This is not a data collection field that will appear on the CRF. If the sponsor chooses to code the procedure, the sponsor will populate this through the coding process.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Procedures (PR) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329808</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="801">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6413063</PUBLICID>
    <LONGNAME>Subcategory for Subject Characteristic</LONGNAME>
    <PREFERREDNAME>SCSCAT</PREFERREDNAME>
    <PREFERREDDEFINITION>A sub-division of the SCCAT values based on user defined characteristics.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6412926</PublicId>
      <PreferredName>6408455v1.0:6412924v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics._A subdivision of subject characteristics data.</PreferredDefinition>
      <LongName>Subject Characteristics Domain Subject Characteristics Subcategory</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6408455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49610</PreferredName>
        <Version>1</Version>
        <LongName>Subject Characteristics Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49610</PREFERRED_NAME>
            <LONG_NAME>Subject Characteristics Domain</LONG_NAME>
            <CON_ID>2469075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6412924</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83402</PreferredName>
        <Version>1</Version>
        <LongName>Subject Characteristics Subcategory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83402</PREFERRED_NAME>
            <LONG_NAME>Subject Characteristics Subcategory</LONG_NAME>
            <CON_ID>6412920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the subcategory of t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the subcategory of the subject characteristics?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>[Subject Characteristics Subcategory ]; NULL</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Record the subject characteristics subcategory, if not pre-printed on the CRF.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SCSCAT</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Maps directly to the SDTMIG variable.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>Sponsor-defined Controlled Terminology. This would most commonly be either a heading, or a pre-printed category value on the CRF and not a question to which the site would provide an answer. If a question is asked, the response would typically be a sponsor-defined codelist. If the form is laid out as a grid, then words such as &quot;Subcategory&quot; can be included as the column header. SCSCAT can only be used if there is an SCCAT and it must be a subcategorization of SCCAT.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject Characteristics (SC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Semantically Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685479</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="802">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6414103</PUBLICID>
    <LONGNAME>Clinical Event Dictionary-Derived/Standardized Term</LONGNAME>
    <PREFERREDNAME>CEDECOD</PREFERREDNAME>
    <PREFERREDDEFINITION>The dictionary or sponsor defined standardized text description of CETERM or the modified topic variable (CEMODIFY), if applicable.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6413369</PublicId>
      <PreferredName>6407330v1.0:6413367v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to clinical events._The name of a clinical event as described in a dictionary.</PreferredDefinition>
      <LongName>Clinical Events Domain Clinical Events Dictionary Derived Term</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407330</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85441</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Events Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85441</PREFERRED_NAME>
            <LONG_NAME>Clinical Events Domain</LONG_NAME>
            <CON_ID>6407329</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6413367</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C87846</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Events Dictionary Derived Term</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87846</PREFERRED_NAME>
            <LONG_NAME>Clinical Events Dictionary Derived Term</LONG_NAME>
            <CON_ID>6413366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Event Dictionary-Derived/Standardized Term does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Event Dictionary-Derived/Standardized Term does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CEDECOD</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Maps directly to the SDTMIG variable. The sponsor is expected to provide the dictionary name and version used to map the terms utilizing the Define-XML external codelist attributes. Sponsors should include an Origin in the define metadata document to indicate that the data was &quot;ASSIGNED&quot;.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>This is typically not a data collection field that will appear on the CRF. Sponsors will populate this through the coding process. Equivalent to the Preferred Term (PT in MedDRA).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Describe infection:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Describe the inflammatory process:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>(Standardized) [Event/Event Topic]</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>(Standardized) [Event/Event Topic]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Event (CE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329787</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Clinical Event (CE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943371</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CE_CEDECOD_INFX</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CE_CEDECOD_INFLM</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CE_CEDECOD</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="803">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6421487</PUBLICID>
    <LONGNAME>Medical History Event Date Type</LONGNAME>
    <PREFERREDNAME>MHEVDTYP</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies the aspect of the medical condition or event by which MHSTDTC and/or the MHENDTC is defined.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6421019</PublicId>
      <PreferredName>6401571v1.0:6421017v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject medical history._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._Something that happens at a given place and time.</PreferredDefinition>
      <LongName>Medical History Domain Personal Medical History Event</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6401571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49603</PreferredName>
        <Version>1</Version>
        <LongName>Medical History Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49603</PREFERRED_NAME>
            <LONG_NAME>Medical History Domain</LONG_NAME>
            <CON_ID>2469069</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6421017</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772:C25499</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6677944</PublicId>
      <PreferredName>MHEDTTYP</PreferredName>
      <PreferredDefinition>Terminology associated with the medical history event date type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>CDISC SDTM Medical History Event Date Type Terminology Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6677943</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C124301:C25284</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Medical History Event Date Type Terminology Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C124301</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Medical History Event Date Type Terminology</LONG_NAME>
            <CON_ID>6677942</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SYMPTOM ONSET</VALIDVALUE>
          <VALUEMEANING>Symptom Onset</VALUEMEANING>
          <MEANINGDESCRIPTION>The point at which the symptoms began or were first noted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EXACERBATION</VALIDVALUE>
          <VALUEMEANING>Exacerbation</VALUEMEANING>
          <MEANINGDESCRIPTION>A worsening of a problem, condition, or disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EPISODE</VALIDVALUE>
          <VALUEMEANING>Episode</VALUEMEANING>
          <MEANINGDESCRIPTION>A noteworthy happening that is distinctive in a series of related events.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DIAGNOSIS</VALIDVALUE>
          <VALUEMEANING>Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4434771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLARE</VALIDVALUE>
          <VALUEMEANING>Flare-up</VALUEMEANING>
          <MEANINGDESCRIPTION>A sudden worsening of a condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7240262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DISEASE RELAPSE</VALIDVALUE>
          <VALUEMEANING>Recurrent Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The return of a disease after a period of remission.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3828963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATHOLOGICAL DIAGNOSIS</VALIDVALUE>
          <VALUEMEANING>Pathological Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Diagnosis based on a pathological assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOST RECENT DIAGNOSIS</VALIDVALUE>
          <VALUEMEANING>Most Recent Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The latest diagnosis of the disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PROGRESSION</VALIDVALUE>
          <VALUEMEANING>Disease Progression</VALUEMEANING>
          <MEANINGDESCRIPTION>The worsening of a disease over time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INITIAL DIAGNOSIS</VALIDVALUE>
          <VALUEMEANING>Initial Diagnosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The first diagnosis of the individual&#39;s condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAGING</VALIDVALUE>
          <VALUEMEANING>STAGING</VALUEMEANING>
          <MEANINGDESCRIPTION>STAGING</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RESTAGING</VALIDVALUE>
          <VALUEMEANING>Restaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Staging that is performed to determine the extent of cancer that has reoccurred following treatment or how the cancer responded to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132008</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INITIAL DISEASE RELAPSE</VALIDVALUE>
          <VALUEMEANING>First Relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following a single documented period of remission.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6333656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DISEASE TRANSFORMATION</VALIDVALUE>
          <VALUEMEANING>Disease Transformation</VALUEMEANING>
          <MEANINGDESCRIPTION>A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6674539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOST RECENT EPISODE</VALIDVALUE>
          <VALUEMEANING>Most Recent Episode</VALUEMEANING>
          <MEANINGDESCRIPTION>The latest occurrence of an episode.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12920218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOST RECENT DISEASE RELAPSE</VALIDVALUE>
          <VALUEMEANING>Most Recent Disease Relapse</VALUEMEANING>
          <MEANINGDESCRIPTION>The latest relapse of the disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C204662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14920905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DISEASE BECAME METASTATIC</VALIDVALUE>
          <VALUEMEANING>Metastatic Lesion</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor arising at a location distant to the primary lesion.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C40557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3860639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the medical history</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the medical history event date type?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Medical History Event Date Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>The instructions depend upon the format of the CRF. Sponsors may pre-print these values on the CRF or use them as defaulted or hidden text.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SUPPMH.QVAL</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>This field does not map directly to an SDTM variable. This information could be submitted in a SUPPMH dataset as the value of SUPPMH.QVAL when SUPPMH.QNAM = &quot;MHEVDTYP&quot; and SUPPMH.QLABEL= &quot;Medical History Event Date Type&quot;. Refer to the current SDTM and SDTMIG for instructions on placement of non-standard variables in SDTM domains.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>The type of start/ and or end date (e.g., DIAGNOSIS, SYMPTOMS, RELAPSE, INFECTION). It is not related to the trial&#39;s condition. This date type cannot be a PRIMARY DIAGNOSIS, SECONDARY DIAGNOSIS since these terms do not define the date type.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC SDTM Medical History Event Date Type Terminology</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Terminology associated with the medical history event date type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).</DocumentText>
        <URL>https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C124301</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History (MH) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329803</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Optional Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329805</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History (MH) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000443</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MH</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MHEVDTYP</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="804">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6454609</PUBLICID>
    <LONGNAME>Adult Trail Making Test Assessment Text</LONGNAME>
    <PREFERREDNAME>Adul_Trai_ASSESS_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>A human who has reached reproductive age._A neuropsychological test of visual attention and task switching that requires a subject to connect a sequence of 25 consecutive targets. It provides an easy to administer and reliable assessment of attention, sequencing, cognition, visual search, and motor function._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6454608</PublicId>
      <PreferredName>Adul_Trai</PreferredName>
      <PreferredDefinition>A human who has reached reproductive age._A neuropsychological test of visual attention and task switching that requires a subject to connect a sequence of 25 consecutive targets. It provides an easy to administer and reliable assessment of attention, sequencing, cognition, visual search, and motor function.</PreferredDefinition>
      <LongName>Adult Trail Making Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2944354</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17600</PreferredName>
        <Version>1</Version>
        <LongName>Adult</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17600</PREFERRED_NAME>
            <LONG_NAME>Adult</LONG_NAME>
            <CON_ID>2204022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3151325</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C92205</PreferredName>
        <Version>1</Version>
        <LongName>Trail Making Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C92205</PREFERRED_NAME>
            <LONG_NAME>Trail Making Test</LONG_NAME>
            <CON_ID>3139607</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adult Trail Making Test Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adult Trail Making Test Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neurology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009616</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="805">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6468758</PUBLICID>
    <LONGNAME>Accelerated Phase Chronic Myelogenous Leukemia Cytogenetic Response Indicator</LONGNAME>
    <PREFERREDNAME>ACCEL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>confirmation of CML accelerated phase evaluation with permissible values of yes/no/unknown/not applicable.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3854990</PublicId>
      <PreferredName>3854988v1.0:3853590v1.0</PreferredName>
      <PreferredDefinition>A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)_The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</PreferredDefinition>
      <LongName>Accelerated Phase Chronic Myelogenous Leukemia Cytogenetic Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3854988</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3173:C50995</PreferredName>
        <Version>1</Version>
        <LongName>Accelerated Phase Chronic Myelogenous Leukemia Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3173</PREFERRED_NAME>
            <LONG_NAME>Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive</LONG_NAME>
            <CON_ID>2675143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50995</PREFERRED_NAME>
            <LONG_NAME>Disease Response</LONG_NAME>
            <CON_ID>2459436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3853590</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18280:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetic Analysis Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18280</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Analysis</LONG_NAME>
            <CON_ID>2528326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCISTD: NCI CRF Harmonization and Standards Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did patient experience any accelerated phase during this observation period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient experience any accelerated phase criteria during this observation period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="806">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6474185</PUBLICID>
    <LONGNAME>Molecular Sequence Analysis Pathogen Gene Mutation Status</LONGNAME>
    <PREFERREDNAME>6472278v1.0:2876255v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the mutation status of permanent changes in genetic material identified by computational analysis of DNA molecules that indicate disease risk due to changed elements in pathogenic gene expression regulation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6472278</PublicId>
      <PreferredName>2497248v1.0:6472276v1.0</PreferredName>
      <PreferredDefinition>Relating to or produced by or consisting of molecules._The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA._An agent of disease; a disease producer._The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.</PreferredDefinition>
      <LongName>Molecular Sequence Analysis Pathogen Gene Mutation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2497248</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25574:C17565</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Sequence Analysis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25574</PREFERRED_NAME>
            <LONG_NAME>Molecular</LONG_NAME>
            <CON_ID>2202608</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17565</PREFERRED_NAME>
            <LONG_NAME>Sequence Analysis</LONG_NAME>
            <CON_ID>2202818</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6472276</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80324:C18093</PreferredName>
        <Version>1</Version>
        <LongName>Pathogen Gene Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80324</PREFERRED_NAME>
            <LONG_NAME>Pathogen</LONG_NAME>
            <CON_ID>6472275</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18093</PREFERRED_NAME>
            <LONG_NAME>Gene Mutation</LONG_NAME>
            <CON_ID>3086322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2876255</PublicId>
      <PreferredName>2876255v1.0</PreferredName>
      <PreferredDefinition>A condition or state of a mutation at a particular time.</PreferredDefinition>
      <LongName>Mutation Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MSI-Negative</VALIDVALUE>
          <VALUEMEANING>Microsatellite Instability Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Genomic instability associated with the presence of hypermutability in specific genetic marker regions resulting from defective DNA mismatch repair._A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757, C36318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2876256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MSI-Positive</VALIDVALUE>
          <VALUEMEANING>Microsatellite Instability</VALUEMEANING>
          <MEANINGDESCRIPTION>Genomic instability associated with the presence of hypermutability in specific genetic marker regions resulting from defective DNA mismatch repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C36318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2876257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ND</VALIDVALUE>
          <VALUEMEANING>Not Determined</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2876209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No mutation detected</VALIDVALUE>
          <VALUEMEANING>No mutation detected</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45576, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Specific variant/mutation not identified</VALIDVALUE>
          <VALUEMEANING>Specific variant/mutation not identified</VALUEMEANING>
          <MEANINGDESCRIPTION>Specific variant/mutation not identified</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genetic variant of uncertain significance</VALIDVALUE>
          <VALUEMEANING>Genetic variant of uncertain significance</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.: A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent.: Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17248, C41130, C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genetic variant, favor polymorphism</VALIDVALUE>
          <VALUEMEANING>Genetic variant, favor polymorphism</VALUEMEANING>
          <MEANINGDESCRIPTION>Genetic variant, favor polymorphism</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genetic variant, suspected deleterious</VALIDVALUE>
          <VALUEMEANING>Genetic variant, suspected deleterious</VALUEMEANING>
          <MEANINGDESCRIPTION>Genetic variant, suspected deleterious</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deleterious mutation</VALIDVALUE>
          <VALUEMEANING>Deleterious mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>Deleterious mutation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4060307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No/variant of undetermined significance</VALIDVALUE>
          <VALUEMEANING>No Variation Undetermined Significant</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: An alteration or difference from a norm or standard.: A term referring to the lack of definitive criteria for classification of a finding.: A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25713, C49487, C41130, C124294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 3, 0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6472356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Likely benign/benign</VALIDVALUE>
          <VALUEMEANING>Benign</VALUEMEANING>
          <MEANINGDESCRIPTION>Not cancerous. Benign tumors may grow larger but do not spread to other parts of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4824471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uncertain significance</VALIDVALUE>
          <VALUEMEANING>Uncertain significance</VALUEMEANING>
          <MEANINGDESCRIPTION>Uncertain significance</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathogenic/likely pathogenic</VALIDVALUE>
          <VALUEMEANING>Pathogen</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent of disease; a disease producer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate or Low</VALIDVALUE>
          <VALUEMEANING>Moderate Or Low</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A minimum level or position or degree; less than normal in degree, intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722, C37998, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-08-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14367329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is this a known or suspected</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is this a known or suspected pathogenic mutation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>is this a known or suspected pathogenic mutation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="807">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6492202</PUBLICID>
    <LONGNAME>Molecular Analysis Complete Remission Confirmed Assessment Indicator</LONGNAME>
    <PREFERREDNAME>2740537v1.0:2646676v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The assessment indicator related to whether molecular complete remission was confirmed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2740537</PublicId>
      <PreferredName>MOL_ANA_CR_CNFM</PreferredName>
      <PreferredDefinition>Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA)._The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured._Confirmed; having been established or verified.</PreferredDefinition>
      <LongName>Molecular Analysis Complete Remission Confirmed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2740387</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19770:C4870</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Analysis CR</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19770</PREFERRED_NAME>
            <LONG_NAME>Molecular Analysis</LONG_NAME>
            <CON_ID>2528322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4870</PREFERRED_NAME>
            <LONG_NAME>Complete Remission</LONG_NAME>
            <CON_ID>2202721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240805</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25458</PreferredName>
        <Version>1</Version>
        <LongName>Confirmed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2646676</PublicId>
      <PreferredName>ASSESS_IND</PreferredName>
      <PreferredDefinition>the indicator relating to the results of an assessment.</PreferredDefinition>
      <LongName>Assessment Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None reported</VALIDVALUE>
          <VALUEMEANING>None Report</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3238310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3855538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not available</VALIDVALUE>
          <VALUEMEANING>Unavailable</VALUEMEANING>
          <MEANINGDESCRIPTION>The desired information is not available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5828000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient also achieve</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient also achieve a molecular complete remission</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="808">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6517178</PUBLICID>
    <LONGNAME>Patient NGS Report Availability TP53 Gene Mutation Confirmation CLIA Certification Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>NGS_REP_TP53_CONF_CLIA_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded indicator to determine study eligibility that addresses the availability of the Next Generation Sequencing report confirming TP53 mutation by a CLIA-certified lab as outlined in the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6514638</PublicId>
      <PreferredName>2233604v1.0:6514636v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA._A short textual account; having provided a short account._The quality of being obtainable or accessible and ready for use or service._A change in the nucleotide sequence of the TP53 gene._Having been established or verified._A Federal law establishing quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed and also to determine if laboratories are achieving those standards._The process by which a person demonstrates specific knowledge, skills, or abilities in the view of a certifying body.  Similarly, the process by which a product or process can achieve certification indicating its suitability for a specific purpose._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Next Generation Sequencing Report Availability TP53 Gene Mutation Confirmation Clinical Laboratory Improvement Act Certification Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6514636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6514636v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Next Generation Sequencing Report Availability TP53 Gene Mutation Confirmation Clinical Laboratory Improvement Act Certification Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C101293</PREFERRED_NAME>
            <LONG_NAME>Next Generation Sequencing</LONG_NAME>
            <CON_ID>4448576</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25429</PREFERRED_NAME>
            <LONG_NAME>Availability</LONG_NAME>
            <CON_ID>2204038</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118396</PREFERRED_NAME>
            <LONG_NAME>TP53 Gene Mutation</LONG_NAME>
            <CON_ID>4529340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83475</PREFERRED_NAME>
            <LONG_NAME>Clinical Laboratory Improvement Act</LONG_NAME>
            <CON_ID>2939416</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43610</PREFERRED_NAME>
            <LONG_NAME>Certification</LONG_NAME>
            <CON_ID>2536953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Will the NGS report be availa</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Will the NGS report be available for review in Rave by the study team for confirmation of TP53 mutation (only those known hot-spot mutations that fall within exon 2 or exons 4-11) as determined from available archived tumor tissue that has been subjected to NGS through FoundationOne/FoundationOneCDx or a similar assay performed in a CLIA-certified laboratory?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="809">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6548431</PUBLICID>
    <LONGNAME>Tricuspid Valve Regurgitation Velocity Echocardiography Performed 0 Decimal Place Meter per Second Value</LONGNAME>
    <PREFERREDNAME>6547902v1.0:6547946v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The 0 decimal place numeric value measured, assigned or computed related to the echocardiography assessment of the tricuspid valve regurgitation velocity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6547902</PublicId>
      <PreferredName>5914910v1.0:6796616v1.0</PreferredName>
      <PreferredDefinition>A measurement of the backward flow of blood through the tricuspid valve during right ventricle contraction. It correlates with pulmonary artery systolic pressure at rest and with exercise. A tricuspid regurgitation velocity greater than or equal to 2.5 m/sec on echocardiography is a surrogate marker for pulmonary hypertension in adults with sickle cell disease._A test that uses high-frequency sound waves (ultrasound) to create an image of the heart._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Tricuspid Valve Regurgitation Velocity Echocardiography Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5914910</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C136979</PreferredName>
        <Version>1</Version>
        <LongName>Tricuspid Valve Regurgitation Velocity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136979</PREFERRED_NAME>
            <LONG_NAME>Tricuspid Valve Regurgitation Velocity</LONG_NAME>
            <CON_ID>5914907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6796616</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16525:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Echocardiography Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16525</PREFERRED_NAME>
            <LONG_NAME>Echocardiography</LONG_NAME>
            <CON_ID>2205316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6547946</PublicId>
      <PreferredName>6547946v1.0</PreferredName>
      <PreferredDefinition>A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A SI derived unit of both speed (scalar) and velocity (vector), defined as the distance of one meter travelled per unit time equal to one second._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>0 Decimal Place Meter per Second Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>m/sec</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>6547945</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255::0:C42646:C42571:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Integer::0 Decimal Place Meter per Second Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42571</PREFERRED_NAME>
            <LONG_NAME>Meter per Second</LONG_NAME>
            <CON_ID>6406349</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the value of the tric</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the value of the tricuspid valve regurgitation velocity?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TRJV measurement:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TRJV measurement:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TRJV measurement:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>TRJV measurement:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TRJV:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TRJV:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_IAED_trjv_echo_meas_val</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="810">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6551923</PUBLICID>
    <LONGNAME>Protocol Deviation Occurrence Participant Action Reason</LONGNAME>
    <PREFERREDNAME>2434996v1.0:6551920v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to a protocol deviation as to why a participant may not continue on the study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CITN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CITN CRF: Cancer Immunotherapy Trials Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2434996</PublicId>
      <PreferredName>PROT_DEV_OCURS</PreferredName>
      <PreferredDefinition>Information related to the occurrence of a protocol deviation.</PreferredDefinition>
      <LongName>Protocol Deviation Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2434994</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C50996</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Deviation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50996</PREFERRED_NAME>
            <LONG_NAME>Protocol Deviation</LONG_NAME>
            <CON_ID>2434968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6551920</PublicId>
      <PreferredName>6551920v1.0</PreferredName>
      <PreferredDefinition>Someone who takes part in an activity._A thing done._An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Participant Action Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CITN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CITN CRF: Cancer Immunotherapy Trials Network Case Report Form</Origin>
      <Representation>
        <PublicId>6551919</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867:C25404:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Participant Action Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25404</PREFERRED_NAME>
            <LONG_NAME>Action</LONG_NAME>
            <CON_ID>2203586</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unanticipated Problem Increasing Risk</VALIDVALUE>
          <VALUEMEANING>Unexpected Problem Increase Risk</VALUEMEANING>
          <MEANINGDESCRIPTION>Something that is not planned or anticipated.: A difficulty, disorder, or condition needing resolution.: A process of becoming larger, more numerous, more important, or more likely.: The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17102, C25533, C28020, C127832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6551921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serious/Continuing Noncompliance</VALIDVALUE>
          <VALUEMEANING>Continue Serious Non-Compliance With Study Device</VALUEMEANING>
          <MEANINGDESCRIPTION>Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.: Causing fear or anxiety by threatening great harm; of great consequence.: An indication that a subject has not agreed with, or followed the instructions related to, the study device.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139241, C54035, C53279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6551922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serious/Continuing Noncomplia</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Serious/Continuing Noncompliance OR Unanticipated Problem Increasing Risk?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="811">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6560497</PUBLICID>
    <LONGNAME>Symptom Screening in Pediatrics 16 How Much Does It Bother You Yesterday or Today Muscle Pain Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>SSPEDI_16_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how bothered they were yesterday or today by muscle pain, using a 5-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6560493</PublicId>
      <PreferredName>6539435v1.0:6560491v1.0</PreferredName>
      <PreferredDefinition>A self-report screening tool, originally developed by Tomlinson et al. in 2013, that is used for symptom assessment in children with cancer and pediatric hematopoietic stem cell transplantation recipients._A question about how much something bothers an individual._The time period consisting of the current day and the preceding day._Painful sensation originating from a muscle or group of muscles._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Symptom Screening in Pediatrics How Much Does It Bother You Yesterday or Today Myalgia Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6539435</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156105</PreferredName>
        <Version>1</Version>
        <LongName>Symptom Screening in Pediatrics</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156105</PREFERRED_NAME>
            <LONG_NAME>Symptom Screening in Pediatrics</LONG_NAME>
            <CON_ID>6535682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6560491</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105747:C136321:C27009:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Much Does It Bother You Yesterday or Today Myalgia Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105747</PREFERRED_NAME>
            <LONG_NAME>How Much Does It Bother You Question</LONG_NAME>
            <CON_ID>3714556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136321</PREFERRED_NAME>
            <LONG_NAME>Yesterday or Today</LONG_NAME>
            <CON_ID>5872236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27009</PREFERRED_NAME>
            <LONG_NAME>Myalgia</LONG_NAME>
            <CON_ID>2204990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6544065</PublicId>
      <PreferredName>SSPEDI_5PT_SCALE</PreferredName>
      <PreferredDefinition>5 point Likert scale.</PreferredDefinition>
      <LongName>SSPedi 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>19</MaximumLength>
      <MinimumLength>5</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely bothered</VALIDVALUE>
          <VALUEMEANING>Extremely Bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was extremely bothered, to the point where they could not take care of things.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6544074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A lot</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medium</VALIDVALUE>
          <VALUEMEANING>Moderately Bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was moderately bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6544075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Muscle pain</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Muscle pain</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SSPedi (Symptom Screening in Pediatrics)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6540049</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="812">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6563015</PUBLICID>
    <LONGNAME>Patient Sufficient Hematologic And Target Organ Function Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>HEM_ENDORG_FCTN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether the patient meets the eligibility requirements for participation in a clinical trial with regarding having adequate hematologic and end organ function.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CITN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6563008</PublicId>
      <PreferredName>2233604v1.0:6563006v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation._Pertaining to or related to the blood and blood-forming organs._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An object fixed as a goal or point of examination; something to point at; a destination._A unique macroscopic (gross) anatomic structure that performs specific functions. It is composed of various tissues.  An organ is part of an anatomic system or a body region. Representative examples include the heart, lung, liver, spleen, and uterus._The normal action performed by a structure or device._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Sufficient Hematologic And Target Organ Function Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CITN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6563006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6563006v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Sufficient Hematologic And Target Organ Function Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63351</PREFERRED_NAME>
            <LONG_NAME>Sufficient</LONG_NAME>
            <CON_ID>2538604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62780</PREFERRED_NAME>
            <LONG_NAME>Hematologic</LONG_NAME>
            <CON_ID>2528497</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13018</PREFERRED_NAME>
            <LONG_NAME>Organ</LONG_NAME>
            <CON_ID>2202464</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient has adequate hematolo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient has adequate hematologic and end organ function</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="813">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6576370</PUBLICID>
    <LONGNAME>Dynamic Positron Emission Tomography and Computed Tomography Scan End Time</LONGNAME>
    <PREFERREDNAME>DNY_PETCT_END_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>The end time of the dynamic PET CT imaging scan.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Princess Margaret Cancer Centre, Toronto, ON</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6576369</PublicId>
      <PreferredName>6576364v1.0:2236677v1.0</PreferredName>
      <PreferredDefinition>Scan having a number of sequential frames._An imaging technique that utilizes positron emission tomography and computed tomography in a single machine._The point or place at which something terminates in time, space, or extent.</PreferredDefinition>
      <LongName>Dynamic Scan Positron Emission Tomography and Computed Tomography Scan End</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6576364</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94890:C103512</PreferredName>
        <Version>1</Version>
        <LongName>Dynamic Scan Positron Emission Tomography and Computed Tomography Scan</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94890</PREFERRED_NAME>
            <LONG_NAME>Dynamic Scan</LONG_NAME>
            <CON_ID>6576363</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103512</PREFERRED_NAME>
            <LONG_NAME>Positron Emission Tomography and Computed Tomography Scan</LONG_NAME>
            <CON_ID>4136311</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496</PreferredName>
        <Version>1</Version>
        <LongName>End</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Princess Margaret Cancer Centre, Toronto, ON</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3379100</PublicId>
      <PreferredName>3379100v1.0</PreferredName>
      <PreferredDefinition>An ISO 8061 time recorded as hh:mm:ss based on a 24 hour clock.   Precision can be truncated by omitting the seconds or both the seconds and minutes (23:59 or 23).</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>hh:mm:ss</DisplayFormat>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
      <Representation>
        <PublicId>2193249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dynamic PET CT Imaging Stop T</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dynamic PET CT Imaging Stop Time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="814">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6606194</PUBLICID>
    <LONGNAME>Weight Unit</LONGNAME>
    <PREFERREDNAME>WEIGHT_VSORRESU</PREFERREDNAME>
    <PREFERREDDEFINITION>The unit of the result as originally received or collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6605956</PublicId>
      <PreferredName>6354444v1.0:6605954v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to vital sign._The vertical force exerted by a mass as a result of gravity._The unit of measure for the original vital signs test result.</PreferredDefinition>
      <LongName>Vital Signs Domain Weight Vital Signs Original Result Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6354444</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49622</PreferredName>
        <Version>1</Version>
        <LongName>Vital Signs Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49622</PREFERRED_NAME>
            <LONG_NAME>Vital Signs Domain</LONG_NAME>
            <CON_ID>2469086</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6605954</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25208:C83161</PreferredName>
        <Version>1</Version>
        <LongName>Weight Vital Signs Original Result Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25208</PREFERRED_NAME>
            <LONG_NAME>Weight</LONG_NAME>
            <CON_ID>2202868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83161</PREFERRED_NAME>
            <LONG_NAME>Vital Signs Original Result Unit</LONG_NAME>
            <CON_ID>6409804</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6352121</PublicId>
      <PreferredName>VSRESU</PreferredName>
      <PreferredDefinition>Terminology codelist used with Unit for Vital Sign Result within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>CDISC SDTM Unit for Vital Sign Result Terminology Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6352120</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66770:C25162</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Unit for Vital Sign Result Terminology Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66770</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Unit for Vital Sign Result Terminology</LONG_NAME>
            <CON_ID>6352119</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmHg</VALIDVALUE>
          <VALUEMEANING>Millimeter of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth&#39;s surface. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>Degree Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42559</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm</VALIDVALUE>
          <VALUEMEANING>Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hz</VALIDVALUE>
          <VALUEMEANING>Hertz</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of frequency; equal to one oscillation per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm</VALIDVALUE>
          <VALUEMEANING>Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg</VALIDVALUE>
          <VALUEMEANING>Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>in</VALIDVALUE>
          <VALUEMEANING>Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length equal to 1/12 of a foot or 2.54 centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LB</VALIDVALUE>
          <VALUEMEANING>Pound</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5035620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/day</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy equal to one kilocalorie per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cmHg</VALIDVALUE>
          <VALUEMEANING>Centimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one centimeter rise of mercury in a barometer at the Earth&#39;s surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET</VALIDVALUE>
          <VALUEMEANING>Metabolic Equivalent of Task Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy expenditure equal to the ratio of the metabolic rate during physical activity in comparison to a reference metabolic rate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percentage</VALUEMEANING>
          <MEANINGDESCRIPTION>Percentage; a fraction or ratio with 100 understood as the denominator.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Watt</VALIDVALUE>
          <VALUEMEANING>Watt</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of power equal to the power which in one second produces or transfers the energy of one joule. The unit is used in measurements of power emitted, transferred or received as radiation, sound waves, heat flow rate, and rate of energy transfer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RATIO</VALIDVALUE>
          <VALUEMEANING>Ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>Quotient of quantities of the same kind for different components within the same system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>Fahrenheit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of temperature of the temperature scale designed so that the freezing point of water is 32 degrees and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. One degree Fahrenheit is 5/9ths of a kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5387072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>breaths/min</VALIDVALUE>
          <VALUEMEANING>Breaths per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of breaths (inhalation and exhalation) taken per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>beats/min</VALIDVALUE>
          <VALUEMEANING>Beats per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of heartbeats measured per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2659976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pa</VALIDVALUE>
          <VALUEMEANING>Pascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to one newton per square meter or 10 bars or to 1.45x10E-4 pounds per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/m2</VALIDVALUE>
          <VALUEMEANING>Kilogram Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of spread rate of a substance by mass, used also as a measure of area density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m2</VALIDVALUE>
          <VALUEMEANING>Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>Square meter is the SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 ares; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K</VALIDVALUE>
          <VALUEMEANING>Kelvin</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic unit of thermodynamic temperature, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is 1/273.16th of the thermodynamic temperature of the triple point of water, This sets the size of the kelvin unit for temperature differences and defines the thermodynamic temperature of an equilibrium mixture of waters ice-liquid-vapor as 273.16 K, where 0 K is the lowest possible temperature (&quot;absolute zero&quot;).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m</VALIDVALUE>
          <VALUEMEANING>Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of linear measure in the metric system, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). Meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ms</VALIDVALUE>
          <VALUEMEANING>Millisecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one thousandth of a second (10E-3 second).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>s</VALIDVALUE>
          <VALUEMEANING>Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5656836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>oz</VALIDVALUE>
          <VALUEMEANING>Ounce</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. The avoirdupois ounce is equal to 1/16 pound, or 28.3495 grams, or 0.911 457 troy ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL</VALIDVALUE>
          <VALUEMEANING>Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ft</VALIDVALUE>
          <VALUEMEANING>International Foot</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the unit of the weig</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the unit of the weight measurement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Weight Unit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Units for weight:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Weight units:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 001</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Units:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Weight unit of measure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Model Permissible</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6592748</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VS_VSORRESU_WEIGHT</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="815">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6608428</PUBLICID>
    <LONGNAME>Prostate Gland Cryosurgery Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PROS_GL_CRYO_PERFORMED</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to prior treatment performed with an instrument that freezes and destroys tumor for the prostate.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6608309</PublicId>
      <PreferredName>2320019v1.0:6608759v1.0</PreferredName>
      <PreferredDefinition>The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions._Executed and carried through to completion._The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.</PreferredDefinition>
      <LongName>Prostate Gland Cryosurgery Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2320019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12410</PreferredName>
        <Version>1</Version>
        <LongName>Prostate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6608759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15215:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Cryosurgery Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15215</PREFERRED_NAME>
            <LONG_NAME>Cryosurgery</LONG_NAME>
            <CON_ID>2322465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior cryosurgery for prostat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior cryosurgery for prostate cancer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="816">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6608757</PUBLICID>
    <LONGNAME>Proteasome Sensitive Recurrent/Refractory Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>PRT_SENS_REC_REL_THPY_PROC_CD_</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response to questions which are necessary to allow a person to participate in a clinical study that are related proteasome sensitivity and recurrent, refractory disease and one line of therapy as outlined in the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6608756</PublicId>
      <PreferredName>6608753v1.0:6608754v1.0</PreferredName>
      <PreferredDefinition>Proteolytic complexes, proteolytic core of the proteasome system, that degrade cytosolic and nuclear proteins are implicated in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cells. The 20S proteasome (700 kD), essential in ATP ubiquitin degradation pathway, has 13-15 subunits each of which has three or four different peptidase activities. The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the degradation of ubiquitinated cellular proteins and certain non-ubiquitinated proteins. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD)._The ability to respond to physical stimuli or to register small physical amounts or differences._The return of a disease after a period of remission._A disease that resists treatment._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Proteasome Sensitivity Recurrent Disease Refractory Disease Therapeutic Procedure Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6608753</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13314:C25201:C38155</PreferredName>
        <Version>1</Version>
        <LongName>Proteasome Sensitivity Recurrent Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13314</PREFERRED_NAME>
            <LONG_NAME>Proteasome</LONG_NAME>
            <CON_ID>3351687</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25201</PREFERRED_NAME>
            <LONG_NAME>Sensitivity</LONG_NAME>
            <CON_ID>2203788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6608754</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39752:C49236:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Refractory Disease Therapeutic Procedure Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39752</PREFERRED_NAME>
            <LONG_NAME>Refractory Disease</LONG_NAME>
            <CON_ID>2789862</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If patient is in the proteaso</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If patient is in the proteasome-sensitive expansion cohort, does patient have multiple myeloma that has relapsed or is refractory to at least one line of prior therapy that did not include a PI?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatments</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000494</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="817">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6610549</PUBLICID>
    <LONGNAME>Patient Discharge New Mobility Assistance Use Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6607801v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the use of new mobility assistance at patient discharge.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6607801</PublicId>
      <PreferredName>5257169v1.0:6607799v1.0</PreferredName>
      <PreferredDefinition>The release of a patient from a course of care._Having no previous example or precedent or parallel; of a kind not seen before._The ability to move with ease and without restriction._The act of contributing to the fulfillment of a need or furtherance of an effort._To put into action or service.</PreferredDefinition>
      <LongName>Patient Discharge New Mobility Assistance Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5257169</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25166</PreferredName>
        <Version>1</Version>
        <LongName>Patient Discharge</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25166</PREFERRED_NAME>
            <LONG_NAME>Patient Discharge</LONG_NAME>
            <CON_ID>2203907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6610547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25586:C77919:C89271:C95018</PreferredName>
        <Version>1</Version>
        <LongName>New Mobility Assistance Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77919</PREFERRED_NAME>
            <LONG_NAME>Mobility</LONG_NAME>
            <CON_ID>2798954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89271</PREFERRED_NAME>
            <LONG_NAME>Assistance</LONG_NAME>
            <CON_ID>3111305</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95018</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>3248409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>New use of mobility aid at ti</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>New use of mobility aid at time of discharge</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="818">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6617404</PUBLICID>
    <LONGNAME>Iron Chelation Therapeutic Procedure Year Begin Known Unknown Indicator</LONGNAME>
    <PREFERREDNAME>6617403v1.0:2935542v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes if the year iron chelation therapy began was known or unknown.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6617403</PublicId>
      <PreferredName>6617400v1.0:6617401v1.0</PreferredName>
      <PreferredDefinition>Iron Chelation involves non-covalent coordination bonding between iron and an organic chemical, often as part of an enzyme or protein complex, as in the iron-binding porphyrin group of hemoglobin._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.</PreferredDefinition>
      <LongName>Iron Chelation Therapeutic Procedure Year Begin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6617400</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40516:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Iron Chelation Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40516</PREFERRED_NAME>
            <LONG_NAME>Iron Chelation</LONG_NAME>
            <CON_ID>2873820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6617401</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29848:C25431</PreferredName>
        <Version>1</Version>
        <LongName>Year Begin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2935542</PublicId>
      <PreferredName>2935542v1.0</PreferredName>
      <PreferredDefinition>Recognized, familiar, or within the scope of knowledge._Not known, not observed, not recorded, or refused._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Known Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2935541</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80137:C17998:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Known Unknown Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80137</PREFERRED_NAME>
            <LONG_NAME>Known</LONG_NAME>
            <CON_ID>2858228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the year iron chelation t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the year iron chelation therapy began known or unknown?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year iron chelation therapy started</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Year iron chelation therapy started</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year iron chelation therapy started</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Year iron chelation therapy started</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_IAED_iron_ch_start_yr_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_HMGL_iron_ch_start_yr_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="819">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6618539</PUBLICID>
    <LONGNAME>Patient Preoperative Education Information Receive Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6618534v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to a patient receiving preoperative education information.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6618534</PublicId>
      <PreferredName>2233604v1.0:6618532v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Relating to or occurring during the period immediately before a surgical operation._The activities of educating or instructing or teaching; activities that impart knowledge or skill._Knowledge derived from study, experience, or instruction that has been gathered or received by communication._To take, accept, or get something offered.</PreferredDefinition>
      <LongName>Patient Preoperative Education Information Receive</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6618532</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C16529:C48191:C25639</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Education Information Receive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16529</PREFERRED_NAME>
            <LONG_NAME>Education</LONG_NAME>
            <CON_ID>2202507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient receive the O</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient receive the OPTI-Surg pre-surgery educational materials?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="820">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6620817</PUBLICID>
    <LONGNAME>Evaluator</LONGNAME>
    <PREFERREDNAME>MOEVAL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who determines the significance of a morphology assessment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6608771</PublicId>
      <PreferredName>6607847v1.0:6608769v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to morphology findings._A person who determines the significance of a morphology assessment.</PreferredDefinition>
      <LongName>Morphology Findings Domain Morphology Evaluator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607847</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102671</PreferredName>
        <Version>1</Version>
        <LongName>Morphology Findings Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102671</PREFERRED_NAME>
            <LONG_NAME>Morphology Findings Domain</LONG_NAME>
            <CON_ID>6607846</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6608769</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117628</PreferredName>
        <Version>1</Version>
        <LongName>Morphology Evaluator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117628</PREFERRED_NAME>
            <LONG_NAME>Morphology Evaluator</LONG_NAME>
            <CON_ID>6608768</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6406916</PublicId>
      <PreferredName>EVAL</PreferredName>
      <PreferredDefinition>Terminology associated with the evaluator codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>CDISC SDTM Evaluator Terminology Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6406915</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78735:C25284</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Evaluator Terminology Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78735</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Evaluator Terminology</LONG_NAME>
            <CON_ID>6406914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL STUDY SPONSOR</VALIDVALUE>
          <VALUEMEANING>Clinical Study Sponsor</VALUEMEANING>
          <MEANINGDESCRIPTION>An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6260462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INVESTIGATOR</VALIDVALUE>
          <VALUEMEANING>Investigator</VALUEMEANING>
          <MEANINGDESCRIPTION>a researcher in a clinical trial or clinical study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL RESEARCH ASSOCIATE</VALIDVALUE>
          <VALUEMEANING>Clinical research associate</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who is employed by a study sponsor or by a contract research organization (CRO), operates independently from the clinical study site and functions as a monitor, and/or auditor, and/or a project director within a particular trial or institution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL RESEARCH COORDINATOR</VALIDVALUE>
          <VALUEMEANING>Clinical Coordinator</VALUEMEANING>
          <MEANINGDESCRIPTION>A person to whom a clinical investigator delegates a few of the routine administrative requirements of a protocol. The duties and responsibilities of a clinical research coordinator may vary across different infrastructures. Generally, the coordinator manages the subject&#39;s clinical trial participation and provides a vital linkage between the subject, the investigator, and the sponsor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STUDY SUBJECT</VALIDVALUE>
          <VALUEMEANING>Study Subject</VALUEMEANING>
          <MEANINGDESCRIPTION>A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5042327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAREGIVER</VALIDVALUE>
          <VALUEMEANING>Caregiver</VALUEMEANING>
          <MEANINGDESCRIPTION>The primary person in charge of the care of a patient, usually a family member or a designated health care professional.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2959588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIBLING</VALIDVALUE>
          <VALUEMEANING>Sibling</VALUEMEANING>
          <MEANINGDESCRIPTION>Sibling; a person&#39;s brother or sister.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DOMESTIC PARTNER</VALIDVALUE>
          <VALUEMEANING>Domestic Partner</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a person who is a member of an unmarried couple, including same sex couples, living together in longstanding relationships, that are registered or unregistered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARENT</VALIDVALUE>
          <VALUEMEANING>Parent</VALUEMEANING>
          <MEANINGDESCRIPTION>A mother or a father; the immediate progenitor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2716524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GUARDIAN</VALIDVALUE>
          <VALUEMEANING>Guardian</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HEALTH CARE PROFESSIONAL</VALIDVALUE>
          <VALUEMEANING>Health Care Professional</VALUEMEANING>
          <MEANINGDESCRIPTION>A person qualified to be engaged in activity directed at preservation of mental and physical health by diseases prevention and treatment as a source of livelihood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2997903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SPOUSE</VALIDVALUE>
          <VALUEMEANING>Spouse</VALUEMEANING>
          <MEANINGDESCRIPTION>A person&#39;s partner in marriage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAMILY MEMBER</VALIDVALUE>
          <VALUEMEANING>Family Member</VALUEMEANING>
          <MEANINGDESCRIPTION>A member of the fundamental unit of society designed primarily to regulate sexual behavior and reproduce, nurture, protect, and socialize the youngs, traditionally organized around kinship ties, descend from the common progenitor or related by marriage or by a feeling of closeness; or of any of various social units differing from but regarded as equivalent to the traditional family.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2635293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VENDOR</VALIDVALUE>
          <VALUEMEANING>Vendor</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or agency that promotes or exchanges goods or services for money; a seller.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INDEPENDENT ASSESSOR</VALIDVALUE>
          <VALUEMEANING>Independent Rater</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual qualified to perform an evaluation who is masked from a subject&#39;s data in order to minimize bias or maximize consistency and quality.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTERVIEWER</VALIDVALUE>
          <VALUEMEANING>Interviewer</VALUEMEANING>
          <MEANINGDESCRIPTION>The person who manages an interview and asks the questions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADJUDICATION COMMITTEE</VALIDVALUE>
          <VALUEMEANING>Adjudication Committee</VALUEMEANING>
          <MEANINGDESCRIPTION>An external committee whose purpose is to evaluate study data and decide whether a study endpoint or other criterion has been met.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3828961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FRIEND</VALIDVALUE>
          <VALUEMEANING>Friend</VALUEMEANING>
          <MEANINGDESCRIPTION>A person whom an individual knows, likes, and trusts. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3009807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADJUDICATOR</VALIDVALUE>
          <VALUEMEANING>Adjudicator</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual that presides over and arbitrates disputes between individuals or organizations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96561</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3362048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHILD</VALIDVALUE>
          <VALUEMEANING>Child Relation</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual&#39;s biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PROXY</VALIDVALUE>
          <VALUEMEANING>Proxy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of advance directive that gives a person the authority to make decisions for another individual. It becomes active when that person loses the ability to make decisions for him- or herself.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIGNIFICANT OTHER</VALIDVALUE>
          <VALUEMEANING>Significant Other</VALUEMEANING>
          <MEANINGDESCRIPTION>A gender-neutral term for a person&#39;s partner in an intimate or romantic relationship without disclosing or presuming marital status or sexual orientation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5741862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NON-HEALTH CARE PROFESSIONAL</VALIDVALUE>
          <VALUEMEANING>Non-Healthcare Professional</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual qualified in a profession outside the healthcare field.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7448882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUBINVESTIGATOR</VALIDVALUE>
          <VALUEMEANING>Subinvestigator</VALUEMEANING>
          <MEANINGDESCRIPTION>Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions (e.g., associates, residents, research fellows).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7637919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRINCIPAL INVESTIGATOR</VALIDVALUE>
          <VALUEMEANING>Principal Investigator</VALUEMEANING>
          <MEANINGDESCRIPTION>An investigator who is responsible for all aspects of the conduct of a study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CARDIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Cardiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A physician who specializes in the diagnosis and treatment of heart disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MICROSCOPIST</VALIDVALUE>
          <VALUEMEANING>Microscopist</VALUEMEANING>
          <MEANINGDESCRIPTION>A health care professional trained in the visualization of structures too small to be seen by the naked eye, using various microscopic techniques.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RATER</VALIDVALUE>
          <VALUEMEANING>Rater</VALUEMEANING>
          <MEANINGDESCRIPTION>Any individual qualified to perform an evaluation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPTOMETRIST</VALIDVALUE>
          <VALUEMEANING>Optometrist</VALUEMEANING>
          <MEANINGDESCRIPTION>A physician with a Doctor of Optometry degree (or analogous) that specializes in the diagnosis and treatment of eye disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL PATHOLOGIST</VALIDVALUE>
          <VALUEMEANING>Clinical Pathologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A physician specializing in medical diagnosis based on both the macroscopic and the microscopic changes to tissues and organs caused by a disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FORENSIC PATHOLOGIST</VALIDVALUE>
          <VALUEMEANING>Forensic Pathologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A physician specializing in the diagnosis of both the cause of death and the manner of death of another human being.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN</VALIDVALUE>
          <VALUEMEANING>Developmental Behavioral Pediatrician</VALUEMEANING>
          <MEANINGDESCRIPTION>A pediatrician who specializes in diagnosing and treating developmental and behavioral disorders in children.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL PSYCHOLOGIST</VALIDVALUE>
          <VALUEMEANING>Developmental Psychologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A psychologist who specializes in diagnosing and treating emotional and behavioral problems associated with developmental delay or disability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEDIATRIC NEUROLOGIST</VALIDVALUE>
          <VALUEMEANING>Pediatric Neurologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A neurologist that specializes in diagnosing and treating children.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEUROLOGIST</VALIDVALUE>
          <VALUEMEANING>Neurologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diagnosing and treating diseases and disorders of the nervous system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATHOLOGIST</VALIDVALUE>
          <VALUEMEANING>Pathologist</VALUEMEANING>
          <MEANINGDESCRIPTION>Pathologist is a doctor specialized in medical diagnosis based on the macroscopic and microscopic study of structural changes of tissues and organs caused by the disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DERMATOLOGIST</VALIDVALUE>
          <VALUEMEANING>Dermatologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor concerned with the diagnosis and treatment of skin conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ENDOCRINOLOGIST</VALIDVALUE>
          <VALUEMEANING>Endocrinologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diagnosing and treating conditions affecting the endocrine system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7236103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ONCOLOGIST</VALIDVALUE>
          <VALUEMEANING>Oncologist</VALUEMEANING>
          <MEANINGDESCRIPTION>(on-KOL-o-jist) A doctor who specializes in treating cancer.  Some oncologists specialize in a particular type of cancer treatment.  For example, a radiation oncologist specializes in treating cancer with radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3534009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPHTHALMOLOGIST</VALIDVALUE>
          <VALUEMEANING>Ophthalmologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diagnosing and treating eye problems, including injury and disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17822</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTOLARYNGOLOGIST</VALIDVALUE>
          <VALUEMEANING>Otolaryngologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in treating diseases of the ear, nose, and throat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7544424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RADIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Radiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>(RAY-dee-OL-o-jist) A doctor who specializes in creating and interpreting pictures of areas inside the body. The pictures are produced with x-rays, sound waves, or other types of energy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UROLOGIST</VALIDVALUE>
          <VALUEMEANING>Urologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diseases of the urinary organs in females and the urinary and sex organs in males.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4537146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HEMATOLOGIST</VALIDVALUE>
          <VALUEMEANING>Hematologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diagnosing and treating diseases and disorders of the blood and blood-forming organs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3534011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTERNIST</VALIDVALUE>
          <VALUEMEANING>Internist</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialist in internal medicine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7236101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>READER</VALIDVALUE>
          <VALUEMEANING>Reader</VALUEMEANING>
          <MEANINGDESCRIPTION>The specific medical individual, usually a radiologist, who looks at and interprets a medical image.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PHYSIOTHERAPIST</VALIDVALUE>
          <VALUEMEANING>Physical Therapist</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual trained and certified to apply knowledge of the concepts, principles, and practices of physical therapy for the treatment or prevention of physical disability or disease. Physical therapist plans and carries out treatment utilizing therapeutic exercise, massage, and physical agents such as air, water, electricity, sound, and radiant energy; performs tests and measurements involving manual or electrical means; and interpret results. Therapist also devises adaptations of equipment to meet the specific needs of patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4385307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEURORADIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Neuroradiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor trained in radiology who specializes in creating and interpreting pictures of the nervous system. The pictures are produced using forms of radiation, such as x-rays, sound waves, or other types of energy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CERTIFIED ASSESSOR</VALIDVALUE>
          <VALUEMEANING>Certified Assessor</VALUEMEANING>
          <MEANINGDESCRIPTION>A person authorized through certification to perform an evaluation or assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NUCLEAR MEDICINE PHYSICIAN</VALIDVALUE>
          <VALUEMEANING>Nuclear Medicine Physician</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiologist who specializes in procedures using radioactive materials to diagnose and/or treat patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PHARMACOKINETICIST</VALIDVALUE>
          <VALUEMEANING>Pharmacokineticist</VALUEMEANING>
          <MEANINGDESCRIPTION>A scientist who studies and/or works in the field of pharmacokinetics.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEUROONCOLOGIST</VALIDVALUE>
          <VALUEMEANING>Neuro-oncologist</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GYNECOLOGIST</VALIDVALUE>
          <VALUEMEANING>Gynecologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A doctor who specializes in diagnosing and treating diseases and disorders of the female reproductive organs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12539158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIDWIFE</VALIDVALUE>
          <VALUEMEANING>Midwife</VALUEMEANING>
          <MEANINGDESCRIPTION>A health professional educated in the discipline of midwifery, including care of women during pregnancy, child birth, and post-partum care.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12918083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OBSTETRICIAN</VALIDVALUE>
          <VALUEMEANING>Obstetrician</VALUEMEANING>
          <MEANINGDESCRIPTION>A physician that specializes in the treatment of women as it relates to pregnancy, child birth, and post-partum care.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12918084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEDIATRIC CARDIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Pediatric Cardiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A cardiologist who specializes in the treatment of children.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12918085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SONOGRAPHER</VALIDVALUE>
          <VALUEMEANING>Sonographer</VALUEMEANING>
          <MEANINGDESCRIPTION>A health professional educated in the discipline of sonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12918086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AUDIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Audiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A trained non-medical health professional who specializes in the identification, testing, habilitation and rehabilitation of hearing loss and other auditory and balance disorders. Particularly, an audiologist may be involved in diagnostic and screening procedures to determine hearing deficits, as well as in assessment of amplification devices and instruction in their care, training in speechreading, and may serve as consultant to government and industry on issues concerning environmental, noise-induced hearing loss. Certification requirements for clinical audiology professional are currently defined at a single level - Certificate of Clinical Competency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STATISTICIAN</VALIDVALUE>
          <VALUEMEANING>Statistician</VALUEMEANING>
          <MEANINGDESCRIPTION>A person responsible for the compilation, organization, and analysis of mathematical data.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EPIDEMIOLOGIST</VALIDVALUE>
          <VALUEMEANING>Epidemiologist</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who works in epidemiology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14919774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Evaluator</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Evaluator</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC SDTM Evaluator Terminology</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Terminology associated with the evaluator codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).</DocumentText>
        <URL>https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C78735</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Morphology (MO) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MO.MOEVAL</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MO</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MOEVAL</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="821">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6631729</PUBLICID>
    <LONGNAME>End Reference Time Point</LONGNAME>
    <PREFERREDNAME>HOENTPT</PREFERREDNAME>
    <PREFERREDDEFINITION>A point in time that indicates the conclusion of a healthcare encounter.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6631682</PublicId>
      <PreferredName>6408410v1.0:6631680v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a subject&#39;s healthcare encounter._A point in time that indicates the conclusion of a healthcare encounter.</PreferredDefinition>
      <LongName>Healthcare Encounters Domain Healthcare Encounters Reference End Time Point End</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6408410</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117757</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounters Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117757</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounters Domain</LONG_NAME>
            <CON_ID>6408409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6631680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123966</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounters Reference End Time Point End</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123966</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounters Reference End Time Point End</LONG_NAME>
            <CON_ID>6631679</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>End Reference Time Point</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>End Reference Time Point</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Healthcare Encounters (HO) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HO.HOENTPT</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HO</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HOENTPT</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="822">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6632203</PUBLICID>
    <LONGNAME>Past Week Hours Missing From Work Due To Problems Associated With Breast Carcinoma Number</LONGNAME>
    <PREFERREDNAME>6632186v1.0:2731654v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A persons&#39; stated observation of how many hours they have missed from work in the past seven days because of their breast carcinoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6632186</PublicId>
      <PreferredName>6632183v1.0:6632184v1.0</PreferredName>
      <PreferredDefinition>The most recent week. May include the present day._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day._Not existing; not able to be found._Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument._Exertion or effort directed to produce or accomplish something._Caused by or resulting from._A difficulty, disorder, or condition needing resolution._Joined in some kind of relationship._Used to indicate the presence of something or someone._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.</PreferredDefinition>
      <LongName>Past Week Hour Missing From Work Due To Problem Associated With Breast Carcinoma</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6632183</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402</PreferredName>
        <Version>1</Version>
        <LongName>Past Week</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6632184</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6632184v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Hour Missing From Work Due To Problem Associated With Breast Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25529</PREFERRED_NAME>
            <LONG_NAME>Hour</LONG_NAME>
            <CON_ID>2203682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>8</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54031</PREFERRED_NAME>
            <LONG_NAME>Missing</LONG_NAME>
            <CON_ID>2493164</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25516</PREFERRED_NAME>
            <LONG_NAME>From</LONG_NAME>
            <CON_ID>2206220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74299</PREFERRED_NAME>
            <LONG_NAME>Work</LONG_NAME>
            <CON_ID>2758919</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89272</PREFERRED_NAME>
            <LONG_NAME>Due To</LONG_NAME>
            <CON_ID>3111313</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25281</PREFERRED_NAME>
            <LONG_NAME>Associated</LONG_NAME>
            <CON_ID>2202442</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62355</PREFERRED_NAME>
            <LONG_NAME>With</LONG_NAME>
            <CON_ID>2532083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4872</PREFERRED_NAME>
            <LONG_NAME>Breast Carcinoma</LONG_NAME>
            <CON_ID>2475940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2731654</PublicId>
      <PreferredName>HR_NUM</PreferredName>
      <PreferredDefinition>the number to represent a unit measure of time equal to 3,600 seconds or 60 minutes.</PreferredDefinition>
      <LongName>Hour Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2731653</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25529:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Hour Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25529</PREFERRED_NAME>
            <LONG_NAME>Hour</LONG_NAME>
            <CON_ID>2203682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>During the past seven days, h</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>During the past seven days, how many hours did you miss from work because of problems associated with your breast cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="823">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6635863</PUBLICID>
    <LONGNAME>Sponsor-Defined Identifier</LONGNAME>
    <PREFERREDNAME>DSSPID</PREFERREDNAME>
    <PREFERREDDEFINITION>One or more sponsor defined characters used to name a disposition event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6635792</PublicId>
      <PreferredName>2859364v1.0:6635790v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition._One or more sponsor defined characters used to name a disposition event.</PreferredDefinition>
      <LongName>Disposition Domain Disposition Sponsor Defined Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859364</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49576</PreferredName>
        <Version>1</Version>
        <LongName>Disposition Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49576</PREFERRED_NAME>
            <LONG_NAME>Disposition Domain</LONG_NAME>
            <CON_ID>2469056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6635790</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83250</PreferredName>
        <Version>1</Version>
        <LongName>Disposition Sponsor Defined Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83250</PREFERRED_NAME>
            <LONG_NAME>Disposition Sponsor Defined Identifier</LONG_NAME>
            <CON_ID>6635789</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353492</PublicId>
      <PreferredName>CDISCID</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25364</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sponsor-Defined Identifier</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sponsor-Defined Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Alternate Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Step No</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>[Line Number/DS Number]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disposition (DS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000603</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Disposition (DS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943378</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DS_DSSPID</AlternateName>
        <AlternateNameType>OID, NRDS Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DSSPID</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>DS_DSSPID</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="824">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6636046</PUBLICID>
    <LONGNAME>Reference ID</LONGNAME>
    <PREFERREDNAME>RSREFID</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of characters used to identify, name, or characterize the disease response reference.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6636023</PublicId>
      <PreferredName>6608777v1.0:6636021v1.0</PreferredName>
      <PreferredDefinition>A domain for disease response evaluations._A sequence of characters used to identify, name, or characterize the disease response reference.</PreferredDefinition>
      <LongName>Disease Response Domain Disease Response Reference Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6608777</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107097</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107097</PREFERRED_NAME>
            <LONG_NAME>Disease Response Domain</LONG_NAME>
            <CON_ID>6608776</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6636021</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117399</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response Reference Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117399</PREFERRED_NAME>
            <LONG_NAME>Disease Response Reference Identifier</LONG_NAME>
            <CON_ID>6636020</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353492</PublicId>
      <PreferredName>CDISCID</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25364</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reference ID</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reference ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Response (RS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331361</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="825">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6639690</PUBLICID>
    <LONGNAME>Study Day of Visit/Collection/Exam</LONGNAME>
    <PREFERREDNAME>MBDY</PREFERREDNAME>
    <PREFERREDDEFINITION>The day that a microbiology specimen is collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6639253</PublicId>
      <PreferredName>6607833v1.0:6639251v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microbiology specimen._The day that a microbiology specimen is collected.</PreferredDefinition>
      <LongName>Microbiology Specimen Domain Study Day of Microbiology Specimen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607833</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49602</PreferredName>
        <Version>1</Version>
        <LongName>Microbiology Specimen Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49602</PREFERRED_NAME>
            <LONG_NAME>Microbiology Specimen Domain</LONG_NAME>
            <CON_ID>2469068</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6639251</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C87903</PreferredName>
        <Version>1</Version>
        <LongName>Study Day of Microbiology Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87903</PREFERRED_NAME>
            <LONG_NAME>Study Day of Microbiology Specimen</LONG_NAME>
            <CON_ID>6639250</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6623992</PublicId>
      <PreferredName>CDISCNUM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6623991</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25337</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Study Day of Visit/Collection</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Study Day of Visit/Collection/Exam</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Microbiology Specimen (MB) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB.MBDY</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB.MBDY</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB.MBDY</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MBDY</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="826">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6642009</PUBLICID>
    <LONGNAME>Reason Not Done</LONGNAME>
    <PREFERREDNAME>DAREASND</PREFERREDNAME>
    <PREFERREDDEFINITION>The explanation given as to why drug accountability was not assessed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6640776</PublicId>
      <PreferredName>6407461v1.0:6640774v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to drug accountability._The explanation given as to why drug accountability was not assessed.</PreferredDefinition>
      <LongName>Drug Accountability Domain Drug Accountability Assessment Reason Not Done</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407461</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49578</PreferredName>
        <Version>1</Version>
        <LongName>Drug Accountability Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49578</PREFERRED_NAME>
            <LONG_NAME>Product Accountability Domain</LONG_NAME>
            <CON_ID>2469057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6640774</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C87867</PreferredName>
        <Version>1</Version>
        <LongName>Drug Accountability Assessment Reason Not Done</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87867</PREFERRED_NAME>
            <LONG_NAME>Drug Accountability Assessment Reason Not Done</LONG_NAME>
            <CON_ID>6640773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason Not Done</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason Not Done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the [is/was] the reason that the [Findings topic/data/information/sponsor-defined phrase] was not [collected/answered/done/assessed/evaluated]?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug Accountability (DA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331373</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Drug Accountability (DA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943375</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA.DAREASND</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA.DAREASND</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA.DAREASND</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA.DAREASND</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DAREASND</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>DA_DAREASND</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="827">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6642267</PUBLICID>
    <LONGNAME>Character Result/Finding in Std Format</LONGNAME>
    <PREFERREDNAME>QSSTRESC</PREFERREDNAME>
    <PREFERREDDEFINITION>The standard character or string for representation and reporting of questionnaire data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6641709</PublicId>
      <PreferredName>6607890v1.0:6641707v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to questionnaire._The standard character or string for representation and reporting of questionnaire data.</PreferredDefinition>
      <LongName>Questionnaire Domain Questionnaire Character Result in Standard Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607890</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49609</PreferredName>
        <Version>1</Version>
        <LongName>Questionnaire Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49609</PREFERRED_NAME>
            <LONG_NAME>Questionnaire Domain</LONG_NAME>
            <CON_ID>2469074</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6641707</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83382</PreferredName>
        <Version>1</Version>
        <LongName>Questionnaire Character Result in Standard Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83382</PREFERRED_NAME>
            <LONG_NAME>Questionnaire Character Result in Standard Unit</LONG_NAME>
            <CON_ID>6641706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Expected</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Expected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Character Result/Finding in S</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Character Result/Finding in Std Format</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Questionnaires (QS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS.QSSTRESC</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS.QSSTRESC</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS.QSSTRESC</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS.QSSTRESC</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QSSTRESC</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="828">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6650488</PUBLICID>
    <LONGNAME>Neurocognitive Assessment Quality of Life Assessment Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>NEURCOG_QOL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator that asks whether the neurocognitive function and quality of life assesments were performed</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6650487</PublicId>
      <PreferredName>6650485v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Tests to assess aspects of cognition, including attention, memory, language, reaction time, and perception._The subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._The final result of a determination of the value, significance, or extent of._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Neurocognitive Assessment Quality of Life Assessment Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6650485</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156775:C17047:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Neurocognitive Assessment Quality of Life Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156775</PREFERRED_NAME>
            <LONG_NAME>Neurocognitive Assessment</LONG_NAME>
            <CON_ID>6650484</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were neurocognitive function</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 02</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed within 4 weeks prior to the start of protocol therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 03</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed during this follow-up period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 04</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed within 2 weeks prior to or after enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 001</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were neurocognitive function and quality of life assessments performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="829">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6661729</PUBLICID>
    <LONGNAME>Planned Order of Element within Arm</LONGNAME>
    <PREFERREDNAME>TAETORD</PREFERREDNAME>
    <PREFERREDDEFINITION>The order in which elements are organized within the trial arm of a study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6661722</PublicId>
      <PreferredName>6409461v1.0:6661720v1.0</PreferredName>
      <PreferredDefinition>A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS)._The order in which elements are organized within the trial arm of a study.</PreferredDefinition>
      <LongName>CDISC Domain Trial Arm Order</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6409461</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103182</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103182</PREFERRED_NAME>
            <LONG_NAME>CDISC Domain</LONG_NAME>
            <CON_ID>6409460</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6661720</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83438</PreferredName>
        <Version>1</Version>
        <LongName>Trial Arm Order</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83438</PREFERRED_NAME>
            <LONG_NAME>Trial Arm Order</LONG_NAME>
            <CON_ID>6661719</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6623992</PublicId>
      <PreferredName>CDISCNUM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6623991</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25337</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Permissible</Name>
        <OrganizationName/>
        <DocumentType>SDTM Core</DocumentType>
        <DocumentText>Permissible</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Planned Order of Element with</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Planned Order of Element within Arm</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events (AE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329786</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Substance Use (SU) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7329813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject Elements (SE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Respiratory System Findings (RE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Procedure Agents (AG) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330203</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ophthalmic Examinations (OE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330204</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Musculoskeletal System Findings (MK) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330207</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Nervous System Findings (NV) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330208</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cardiovascular System Findings (CV) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330209</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Meal Data (ML) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tumor Identification (TU) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject Status (SS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331360</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Response (RS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331361</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK Parameters (PP) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tumor Results (TR) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331363</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Questionnaires (QS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Urinary System Findings (UR) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331365</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Microbiology Susceptibility Test (MS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Morphology (MO) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Immunogenicity Specimen Assessments (IS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331368</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Microbiology Specimen (MB) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Reproductive System Findings (RP) domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inclusion/Exclusion Criteria Not Met (IE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331371</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Concomitant Medications (CM) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug Accountability (DA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331373</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Funtional Tests (FT) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331374</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Event (CE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ECG Test Results (EG) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000096</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Findings About (FA) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Microscopic Findings (MI) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000098</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exposure (EX) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000099</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory (LB) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol Deviations (DV) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exposure as Collected (EC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000186</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject Characteristics (SC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vital Signs (VS) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000359</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History (MH) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000443</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Procedures (PR) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000444</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Skin Response (SR) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Healthcare Encounters (HO) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pharmacokinetics Concentrations (PC) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000717</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical Examination (PE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000718</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SE.TAETORD</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EX.TAETORD</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TA.TAETORD</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TA.TAETORD</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.1.3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SE.TAETORD</AlternateName>
        <AlternateNameType>Map:SDTM IGv3.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TAETORD</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CV</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CM</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DA</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EG</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EX</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FA</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FT</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HO</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LB</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ML</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MB</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MH</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MI</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MK</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MO</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NV</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PC</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AG</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PP</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PR</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DV</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RP</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SC</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SR</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SU</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TU</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TR</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UR</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VS</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="830">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6663247</PUBLICID>
    <LONGNAME>Meal Collected Duration</LONGNAME>
    <PREFERREDNAME>MLCDUR</PREFERREDNAME>
    <PREFERREDDEFINITION>The collected duration of meal.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Incomplete</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6663246</PublicId>
      <PreferredName>6663242v1.0:6662810v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to meal data._The act of gathering things together; having been brought together in one place._The amount of time that a thing is consumed or employed.</PreferredDefinition>
      <LongName>Meal Data Domain Collection Duration of Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6663242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49604</PreferredName>
        <Version>1</Version>
        <LongName>Meal Data Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49604</PREFERRED_NAME>
            <LONG_NAME>Meal Data Domain</LONG_NAME>
            <CON_ID>2469067</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6662810</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25453:C83168</PreferredName>
        <Version>1</Version>
        <LongName>Collection Duration of Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83168</PREFERRED_NAME>
            <LONG_NAME>Duration of Use</LONG_NAME>
            <CON_ID>6420466</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6414050</PublicId>
      <PreferredName>CDISCDUR</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The period of time during which something continues.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6399749</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25330</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Meal Collected Duration</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Meal Collected Duration</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDASH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6338163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Meal Data (ML) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ML</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MLCDUR</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="831">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6674994</PUBLICID>
    <LONGNAME>Malignant Neoplasm Metastatic Abdominal Wall Involvement Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6674993v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator to ask if evidence is detected for spread of cancer from a tumor composed of atypical neoplastic cells to the abdominal wall.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6674993</PublicId>
      <PreferredName>2186369v1.0:6674991v1.0</PreferredName>
      <PreferredDefinition>A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles._To have a connection by participation or association or use; sharing in an activity or process.</PreferredDefinition>
      <LongName>Malignant Neoplasm Metastatic Abdominal Wall Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2186369</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6674991</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14174:C77608:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Abdominal Wall Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77608</PREFERRED_NAME>
            <LONG_NAME>Abdominal Wall</LONG_NAME>
            <CON_ID>2856475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Abdominal wall</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Abdominal wall</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="832">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6679317</PUBLICID>
    <LONGNAME>Other Exam And Finding Symptom Review Text</LONGNAME>
    <PREFERREDNAME>OTHR_EX_FIND_SYMPT_TX</PREFERREDNAME>
    <PREFERREDDEFINITION>A descriptive text of other medical exams and finding on the evaluation of symptoms.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6679316</PublicId>
      <PreferredName>6679313v1.0:6679965v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._An appraisal or evaluation of a patient&#39;s condition by a clinician that is based on a physical exam, medical history, and the patient&#39;s account of symptoms._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Clinical, laboratory or molecular evidence, or absence of evidence of disease._An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain._The act of appraisal, evaluation, or analysis.</PreferredDefinition>
      <LongName>Other Medical Examination And Finding Symptom Review</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6679313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25305</PreferredName>
        <Version>1</Version>
        <LongName>Other Medical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6679965</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37912:C3367:C4876:C42729</PreferredName>
        <Version>1</Version>
        <LongName>And Finding Symptom Review</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42729</PREFERRED_NAME>
            <LONG_NAME>Review</LONG_NAME>
            <CON_ID>2202331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Exams and Findings as C</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Exams and Findings as Clinically Indicated based on Symptomatology</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="833">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6680271</PUBLICID>
    <LONGNAME>Total CFU-GEMM Laboratory Procedure Assessment Performed Status</LONGNAME>
    <PREFERREDNAME>6680268v1.0:2528343v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the assessment of total CFU-GEMM.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6680268</PublicId>
      <PreferredName>6680266v1.0:2486250v1.0</PreferredName>
      <PreferredDefinition>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A stem cell derived from the hematopoietic stem cell that generates myeloid cells (granulocyte, erythrocyte, monocyte, megakaryocyte)._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.</PreferredDefinition>
      <LongName>Total CFU-GEMM Laboratory Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6680266</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C158542</PreferredName>
        <Version>1</Version>
        <LongName>Total Myeloid Stem Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C158542</PREFERRED_NAME>
            <LONG_NAME>Myeloid Stem Cell</LONG_NAME>
            <CON_ID>6680229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2486250</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2528343</PublicId>
      <PreferredName>ASSESS_PERFM_STAT</PreferredName>
      <PreferredDefinition>The condition or state of an evaluation being performed at a particular time.</PreferredDefinition>
      <LongName>Assessment Performed Status</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3863379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217:C38000:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Performed Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Done</VALIDVALUE>
          <VALUEMEANING>Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has been performed and completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3954417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the total CFU-GEMM a</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the total CFU-GEMM assessment status?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total CFU-GEMM</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total CFU-GEMM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total CFU-GEMM</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Total CFU-GEMM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_cfu_gemm_dnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="834">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6681602</PUBLICID>
    <LONGNAME>Anogenital Neoplasm Anatomic Site</LONGNAME>
    <PREFERREDNAME>6681601v1.0:6681533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The location of a anogenital neoplasm.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6681601</PublicId>
      <PreferredName>6681599v1.0:2186622v1.0</PreferredName>
      <PreferredDefinition>Having to do with the anus, which is the posterior opening of the large bowel._The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Named locations of or within the body.</PreferredDefinition>
      <LongName>Anal Genital Neoplasm Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6681599</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28048:C13348:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Anal Genital Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28048</PREFERRED_NAME>
            <LONG_NAME>Anal</LONG_NAME>
            <CON_ID>2615799</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13348</PREFERRED_NAME>
            <LONG_NAME>Genital</LONG_NAME>
            <CON_ID>2203629</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2186622</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6681533</PublicId>
      <PreferredName>6681533v1.0</PreferredName>
      <PreferredDefinition>The location of a anogenital neoplasm.</PreferredDefinition>
      <LongName>Anogenital Neoplasm Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal</VALIDVALUE>
          <VALUEMEANING>Anal</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the anus, which is the posterior opening of the large bowel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28048</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genital</VALIDVALUE>
          <VALUEMEANING>Genital</VALUEMEANING>
          <MEANINGDESCRIPTION>The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2873892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>anogenital</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>anogenital</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="835">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6689964</PUBLICID>
    <LONGNAME>Adapted WLQ Past 4 Weeks How Much of the Time Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working Difficulty 6 Point Scale</LONGNAME>
    <PREFERREDNAME>DIFF_SPEAK_6PT_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how much of the time their caregiving responsibilities made it difficult for them to speak with people in-person, in meetings or on the phone when working, using a 6 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6689712</PublicId>
      <PreferredName>6689338v1.0:6689710v1.0</PreferredName>
      <PreferredDefinition>The act of alteration or modification; changed or altered in form or character._A standardized rating scale originally developed by Lerner et al in 1998. This instrument is used to measure the degree to which health problems interfere with specific aspects of job performance and health-related productivity loss in employed individuals._A period of time consisting of the 28 days before the present._A question about how much of the time something is occurring or has occurred._A question about if an individual&#39;s caregiving responsibilities made it difficult to speak with people in-person, in meetings or on the phone when working.</PreferredDefinition>
      <LongName>Change WLQ Past 4 Weeks How Much of the Time Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6689338</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C119096</PreferredName>
        <Version>1</Version>
        <LongName>Change Work Limitations Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C119096</PREFERRED_NAME>
            <LONG_NAME>Work Limitations Questionnaire</LONG_NAME>
            <CON_ID>6643422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6689710</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110986:C111702:C159149</PreferredName>
        <Version>1</Version>
        <LongName>Past 4 Weeks How Much of the Time Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110986</PREFERRED_NAME>
            <LONG_NAME>Past 4 Weeks</LONG_NAME>
            <CON_ID>3871096</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111702</PREFERRED_NAME>
            <LONG_NAME>How Much of the Time Question</LONG_NAME>
            <CON_ID>3930498</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159149</PREFERRED_NAME>
            <LONG_NAME>Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working Question</LONG_NAME>
            <CON_ID>6689440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6689792</PublicId>
      <PreferredName>6689792v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Difficulty 6 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Does not apply to my job</VALIDVALUE>
          <VALUEMEANING>Does Not Apply to My Job</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something does not apply to an individual&#39;s job.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Difficult none of the time (0%)</VALIDVALUE>
          <VALUEMEANING>Difficult None of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is or was difficult none of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Difficult a slight bit of the time</VALIDVALUE>
          <VALUEMEANING>Difficult a Slight Bit of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is or was difficult a slight bit of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159186</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Difficult some of the time</VALIDVALUE>
          <VALUEMEANING>Difficult Some of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is or was difficult some of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Difficult most of the time</VALIDVALUE>
          <VALUEMEANING>Difficult Most of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is or was difficult most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Difficult all of the time</VALIDVALUE>
          <VALUEMEANING>Difficult All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something is or was difficult all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6689798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How much of the time did your</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much of the time did your caregiving responsibilities make it difficult for you to speak with people in-person, in meetings or on the phone when working?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="836">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6691074</PUBLICID>
    <LONGNAME>Patient Have Interstitial Lung Disorder Or Pneumonitis Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>INST_LG_DSZ_PNEU_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication as to whether the patient has interstitial lung disease or pneumonitis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6689715</PublicId>
      <PreferredName>2233604v1.0:6689713v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Used to describe the possession, relationships, or the state of something or someone._A disease occurring chiefly in the connective-tissue framework of an organ._A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inflammatory process affecting the lung parenchyma. It is a milder form of lung inflammation compared to pneumonia._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Have Interstitial Disease Lung Disorder Or Pneumonitis Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6689713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6689713v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Have Interstitial Disease Lung Disorder Or Pneumonitis Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C101282</PREFERRED_NAME>
            <LONG_NAME>Have</LONG_NAME>
            <CON_ID>3437377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62410</PREFERRED_NAME>
            <LONG_NAME>Interstitial Disease</LONG_NAME>
            <CON_ID>2534125</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3198</PREFERRED_NAME>
            <LONG_NAME>Lung Disorder</LONG_NAME>
            <CON_ID>2689692</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113159</PREFERRED_NAME>
            <LONG_NAME>Pneumonitis</LONG_NAME>
            <CON_ID>4722717</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have interst</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have interstitial lung disease or pneumonitis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="837">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6703723</PUBLICID>
    <LONGNAME>Classroom Prior Diagnosis Type</LONGNAME>
    <PREFERREDNAME>PRIOR_DX_CLSSRM_TYPE</PREFERREDNAME>
    <PREFERREDDEFINITION>Type of classroom attended prior to diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6701073</PublicId>
      <PreferredName>6701068v1.0:6701071v1.0</PreferredName>
      <PreferredDefinition>A room or space, especially in a school, where classes are held._Earlier in time or order._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Classroom Prior Diagnosis Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6701068</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159271</PreferredName>
        <Version>1</Version>
        <LongName>Classroom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159271</PREFERRED_NAME>
            <LONG_NAME>Classroom</LONG_NAME>
            <CON_ID>6689871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6701071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15220:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Prior Diagnosis Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6702705</PublicId>
      <PreferredName>6702705v1.0</PreferredName>
      <PreferredDefinition>A room or space, especially in a school, where classes are held._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Classroom Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>6702704</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159271:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Classroom Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159271</PREFERRED_NAME>
            <LONG_NAME>Classroom</LONG_NAME>
            <CON_ID>6689871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hospital</VALIDVALUE>
          <VALUEMEANING>Hospital</VALUEMEANING>
          <MEANINGDESCRIPTION>An institution that provides medical, surgical, or psychiatric care and treatment for the sick or the injured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Special Education</VALIDVALUE>
          <VALUEMEANING>Special Education</VALUEMEANING>
          <MEANINGDESCRIPTION>The practice of educating students with identified disabilities through specialized instruction that addresses their individual differences and needs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6702708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Homebound</VALIDVALUE>
          <VALUEMEANING>Homebound Instruction</VALUEMEANING>
          <MEANINGDESCRIPTION>Instruction to children unable to attend school because of physical disabilities, special health problems, or temporary injuries or illness. This instruction is usually provided by the local school district, usually with a teacher visiting the child in their home, but would include alternative methods, such as online teaching.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6704131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Traditional/Inclusion</VALIDVALUE>
          <VALUEMEANING>Traditional Education</VALUEMEANING>
          <MEANINGDESCRIPTION>Education that takes place in a public school, divided into grades, and governed by a school district.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6704133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Home Schooled</VALIDVALUE>
          <VALUEMEANING>Home School</VALUEMEANING>
          <MEANINGDESCRIPTION>Education that takes place outside of a traditional school, in a home or other facility, with the teaching being conducted by a parent, tutor, or online instructor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6704132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of classroom before diagnosis (check all that apply):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of classroom before diag</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of classroom before diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="838">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6719738</PUBLICID>
    <LONGNAME>Person Exercise Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>6691713v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator related to Exercise for clinical trial eligibility</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6691713</PublicId>
      <PreferredName>2236731v1.0:6691711v1.0</PreferredName>
      <PreferredDefinition>A human being._Activity that requires physical or mental exertion, especially when performed to develop or maintain fitness._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person Exercise Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6691711</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16567:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Exercise Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16567</PREFERRED_NAME>
            <LONG_NAME>Exercise</LONG_NAME>
            <CON_ID>2606079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Able to exercise on a treadmi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Able to exercise on a treadmill or stationary cycle</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6147165</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WFB Medical Center</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WFB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6147167</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="839">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6730508</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week How Often Lack of Appetite Score Memorial Symptom Assessment Scale (10-18) Frequency Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MSAS10_18_F_APPET_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>A question about how often an individual has lack of appetite or does not want to eat. The question uses &#39;almost never, sometimes, a lot, and almost always&#39; indicators to determine the level of experience.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5844937</PublicId>
      <PreferredName>5840805v1.0:5114533v1.0</PreferredName>
      <PreferredDefinition>A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to children with cancer aged 10-18. This 30-question instrument was adapted from a previously-validated adult version._The most recent week, including today._A question about how often an individual has or had a lack of appetite._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week How Often Lack of Appetite Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5840805</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C134965</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C134965</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale (MSAS) 10-18</LONG_NAME>
            <CON_ID>5840197</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5114533</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C125286:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Often Lack of Appetite Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125286</PREFERRED_NAME>
            <LONG_NAME>How Often Lack of Appetite Question</LONG_NAME>
            <CON_ID>5109075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6729553</PublicId>
      <PreferredName>6729553v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (10-18) Frequency Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Almost always</VALIDVALUE>
          <VALUEMEANING>Almost Always</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4633044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A lot</VALIDVALUE>
          <VALUEMEANING>A lot</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3679493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2889147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Almost never</VALIDVALUE>
          <VALUEMEANING>Almost never</VALUEMEANING>
          <MEANINGDESCRIPTION>Almost never</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often did you have the la</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often did you have the lack of appetite or not wanting to eat?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_OFTN_LACKAPPT</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="840">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6753721</PUBLICID>
    <LONGNAME>Lymphedema Symptom Intensity and Distress Survey-Arm V 2.0 During Past Week Have Inability to Complete Hobbies or Leisure Activities Indicator</LONGNAME>
    <PREFERREDNAME>LSIDSA_27_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of whether or not they had inability to complete hobbies or leisure activities during the past week, using a yes or no response.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LSIDS-A:Lymphedema Symptom and Intensity Survey-Arm; SH Ridner et al., Support Care Cancer (2015)</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6751719</PublicId>
      <PreferredName>6752947v1.0:6753514v1.0</PreferredName>
      <PreferredDefinition>A self-report tool designed to evaluate arm lymphedema and associated symptoms in breast cancer survivors._At some point in a given period of time._The most recent week. May include the present day._A question about whether an individual has or had an inability to complete hobbies or leisure activities they used to do.</PreferredDefinition>
      <LongName>Lymphedema Symptom Intensity and Distress Survey-Arm During Past Week Have Inability to Complete Hobbies or Leisure Activities</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6752947</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159908</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema Symptom Intensity and Distress Survey-Arm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159908</PREFERRED_NAME>
            <LONG_NAME>Lymphedema Symptom Intensity and Distress Survey - Arm</LONG_NAME>
            <CON_ID>6751805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6753514</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25490:C95402:C159931</PreferredName>
        <Version>1</Version>
        <LongName>During Past Week Have Inability to Complete Hobbies or Leisure Activities</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159931</PREFERRED_NAME>
            <LONG_NAME>Have Inability to Complete Hobbies or Leisure Activities Question</LONG_NAME>
            <CON_ID>6751829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LSIDS-A:Lymphedema Symptom and Intensity Survey-Arm; SH Ridner et al., Support Care Cancer (2015)</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lymphedema Symptom Intensity and Distress Survey-Arm Version 2.0</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #79 of 90</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Inability to complete hobbies</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Inability to complete hobbies or leisure activities you used to do</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900320</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6736342</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LSIDS-A</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LSIDS-A</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6736343</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="841">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6784205</PUBLICID>
    <LONGNAME>Patient GFAP Gene Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria Yes No Unknown</LONGNAME>
    <PREFERREDNAME>GFAP_MTD_SPC_SBN_YN_UNK</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication as to whether a GFAP stained slide was submitted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6346556</PublicId>
      <PreferredName>2233604v1.0:6346554v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._This gene may be involved in the regulation of astrocyte morphology and function._Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination._Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The act of referring for judgment or consideration by others; the act of handing over something._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient GFAP Gene Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6346554</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6346554v1.0</PreferredName>
        <Version>1</Version>
        <LongName>GFAP Gene Staining Method Biospecimen Submission Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68802</PREFERRED_NAME>
            <LONG_NAME>GFAP Gene</LONG_NAME>
            <CON_ID>3685446</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C23010</PREFERRED_NAME>
            <LONG_NAME>Staining Method</LONG_NAME>
            <CON_ID>2224007</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25695</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2203811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a GFAP stained slide subm</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a GFAP stained slide submitted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a GFAP stained slide submitted or projected to be submitted through APEC14B1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a GFAP stained slide submitted, or projected to be submitted, through APEC14B1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPBE_QVAL_SUBMITSL_GFAP</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="842">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6787381</PUBLICID>
    <LONGNAME>Individual Cancer History of Any Treatments Type</LONGNAME>
    <PREFERREDNAME>6788213v1.0:5102331v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The history of any known treatments for an individual.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6788213</PublicId>
      <PreferredName>6788187v1.0:6852707v1.0</PreferredName>
      <PreferredDefinition>A record of a patient&#39;s medical background regarding the occurrence of cancer and cancer-related problems._The history of known treatments for an individual.</PreferredDefinition>
      <LongName>Individual Cancer History History of any Treatments</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6788187</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18849</PreferredName>
        <Version>1</Version>
        <LongName>Individual Cancer History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18849</PREFERRED_NAME>
            <LONG_NAME>Individual Cancer History</LONG_NAME>
            <CON_ID>2204001</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6852707</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159571</PreferredName>
        <Version>1</Version>
        <LongName>Is there a History of any Treatments</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159571</PREFERRED_NAME>
            <LONG_NAME>History of any Treatments</LONG_NAME>
            <CON_ID>6852706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5102331</PublicId>
      <PreferredName>5102331v1.0</PreferredName>
      <PreferredDefinition>Therapeutic procedures distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Treatment Method Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Treatment Type</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Other</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: Not otherwise specified.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2761986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation Therapy</VALIDVALUE>
          <VALUEMEANING>Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2567129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharmaceutical Therapy</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Pharmacologic Substance</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1909, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5102351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery</VALIDVALUE>
          <VALUEMEANING>Surgical Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3440172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Targeted Molecular Therapy</VALIDVALUE>
          <VALUEMEANING>Targeted Molecular Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotherapy</VALIDVALUE>
          <VALUEMEANING>Immunotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Therapy designed to induce changes in a patient&#39;s immune status in order to treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5102332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hormone Therapy</VALIDVALUE>
          <VALUEMEANING>Endocrine Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4340414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemotherapy</VALIDVALUE>
          <VALUEMEANING>Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5102333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Systemic Radiation</VALIDVALUE>
          <VALUEMEANING>Systemic Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiation therapy in which a radioactive substance, such radioactive iodine or a radioactively labeled monoclonal antibody, is swallowed or injected into the body and travels through the blood, locating and killing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3428270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Internal Radiation</VALIDVALUE>
          <VALUEMEANING>Internal Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5102334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>External Radiation</VALIDVALUE>
          <VALUEMEANING>External Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4947832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery Only</VALIDVALUE>
          <VALUEMEANING>Single Surgical Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others; exclusive of anyone or anything else.: A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15329, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-13</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5102335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Treatment</VALIDVALUE>
          <VALUEMEANING>Negation Therapeutic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49236, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-29</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3308097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplant</VALIDVALUE>
          <VALUEMEANING>Peripheral Stem Cell Transplant</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of hematopoietic reconstitution, Peripheral Stem Cell Transplants utilize (transfuse) hematopoietic stem cells harvested from circulating blood of an autologous, syngeneic, or allogeneic donor to reconstitute the bone marrow of the transplant recipient. Peripheral stem cell transplants are performed following partial or complete bone marrow ablation of a patient, done as therapy for certain blood diseases or following high dose chemotherapy or radiation treatment for cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-29</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5438252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation (NOS)</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4630312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytotoxic chemotherapy</VALIDVALUE>
          <VALUEMEANING>Cytotoxic Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Anticancer drugs that kill cells, especially cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>4780585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, whole brain radiation therapy</VALIDVALUE>
          <VALUEMEANING>Whole Brain Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors. This is a standard treatment for multiple brain metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2578538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stereotactic radiosurgery</VALIDVALUE>
          <VALUEMEANING>Stereotactic Radiosurgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, stereotactic body</VALIDVALUE>
          <VALUEMEANING>Stereotactic Body Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3193538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, proton beam</VALIDVALUE>
          <VALUEMEANING>Proton Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation therapy, NOS</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313, C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4630312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, intensity-modulated radiotherapy</VALIDVALUE>
          <VALUEMEANING>IMRT</VALUEMEANING>
          <MEANINGDESCRIPTION>An advanced form of 3-Dimensional Conformal Radiation Therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3991473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brachytherapy, Low Dose</VALIDVALUE>
          <VALUEMEANING>Low-Dose Rate Brachytherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Internal radiation treatment that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brachytherapy, High Dose</VALIDVALUE>
          <VALUEMEANING>High-Dose Rate Brachytherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Internal radiation treatment that targets a cancerous tissue with accurate, high doses of radiation through the use of inserted temporary implants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2584511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, 3D conformal</VALIDVALUE>
          <VALUEMEANING>3-Dimensional Conformal Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palliative Care</VALIDVALUE>
          <VALUEMEANING>Palliative</VALUEMEANING>
          <MEANINGDESCRIPTION>Palliative care is the patient-and family-centered active holistic care of patients with advanced, progressive disease. Traditional models reflect abandonment of proactive treatment and a simultaneous increase in symptom control and comfort-related services, as a disease progressed in linear fashion through its course. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-05-21</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2971623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ablation, NOS</VALIDVALUE>
          <VALUEMEANING>Ablation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5633958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ablation, Microwave</VALIDVALUE>
          <VALUEMEANING>Microwave Ablation</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment modality that uses directed electromagnetic waves within the microwave spectrum to heat the targeted tissue for the purpose of causing tissue necrosis within solid tissue tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ablation, Radiofrequency</VALIDVALUE>
          <VALUEMEANING>Radiofrequency Ablation</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic procedure to eradicate or reduce small tumors using radiowaves to generate heat. The procedure is performed by the insertion of a thin needle through the skin and into a tumor, which is guided by computed tomography (CT) or ultrasound. Electrical energy delivered through this needle (electrode) heats and destroys the tumor. This therapeutic option is widely utilized by patients that have inoperable cancers, or are unsuitable chemotherapy candidates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3029158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ablation, Radiosurgical</VALIDVALUE>
          <VALUEMEANING>Radiosurgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>4287124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ancillary Treatment</VALIDVALUE>
          <VALUEMEANING>Ancillary Treatment</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment used in addition to the primary therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antiseizure Treatment</VALIDVALUE>
          <VALUEMEANING>Anticonvulsant Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug treatment to prevent, stop, or reduce the severity of seizures or convulsions, commonly used in cases of epilepsy or other seizure disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisphosphonate Therapy</VALIDVALUE>
          <VALUEMEANING>Bisphosphonate Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of biphosphonate compounds to treat low bone density or fragile bone conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blinded Study, Treatment Unknown</VALIDVALUE>
          <VALUEMEANING>Blinded Clinical Study</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2789519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemoembolization</VALIDVALUE>
          <VALUEMEANING>Chemoembolization</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This permits a higher concentration of drug to be in contact with the tumor for a longer period of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3225721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemoprotectant</VALIDVALUE>
          <VALUEMEANING>Chemoprotective Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>Chemicals which protect normal cells from the effects of chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Concurrent Chemoradiation</VALIDVALUE>
          <VALUEMEANING>Concurrent Chemoradiation</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment in which radiation therapy is administered at the same time as chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13328537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Embolization</VALIDVALUE>
          <VALUEMEANING>Embolization Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3630019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I-131 Radiation Therapy</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation Therapy that uses iodine I-131. It is typically used to treat thyroid conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isolated Limb Perfusion (ILP)</VALIDVALUE>
          <VALUEMEANING>Isolated Limb Perfusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure used to deliver anticancer drugs directly to an arm or leg but not to the rest of the body. The flow of blood to and from the limb is temporarily stopped with a tourniquet (a tight band around the limb). Catheters (small, flexible tubes) attached to a pump are put into an artery and a vein in the limb so that blood can be circulated through the pump into the limb. Anticancer drugs are injected into the catheters. Wrapping the limb in a heated blanket or warming the drugs or blood may help the drugs work better.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>4320573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Organ Transplantation</VALIDVALUE>
          <VALUEMEANING>Organ Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient&#39;s damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5621713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharmaceutical Therapy, NOS</VALIDVALUE>
          <VALUEMEANING>Pharmacotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of disease through the use of drugs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6118797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleurodesis</VALIDVALUE>
          <VALUEMEANING>Pleurodesis</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>6227530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleurodesis, Talc</VALIDVALUE>
          <VALUEMEANING>Talc Poudrage</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which talc is insufflated into the pleural space during thoracoscopy to promote the adhesion of the visceral and parietal layers of the pleura as a treatment for recurring pleural effusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, 2D Conventional</VALIDVALUE>
          <VALUEMEANING>Conventional Radiotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A course of radiotherapy where minimal imaging support (i.e. X-rays films) is used to determine the positioning of radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7735393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Combination</VALIDVALUE>
          <VALUEMEANING>Combination Radiotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Simultaneous or consecutive use of radiotherapy and one or more non-radiation based treatment modalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Cyberknife</VALIDVALUE>
          <VALUEMEANING>CyberKnife</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, robotic radiosurgery system designed to deliver precise beams of high does radiation to tumors with extreme accuracy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3443469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, External Beam</VALIDVALUE>
          <VALUEMEANING>External Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5270692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Hypofractionated</VALIDVALUE>
          <VALUEMEANING>Hypofractionated Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3191485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Implants</VALIDVALUE>
          <VALUEMEANING>Interstitial Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue. (Cancer.gov)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>2578466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Mixed Photon Beam</VALIDVALUE>
          <VALUEMEANING>Direct Mixed Photon and Electron Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiation therapy technique where external photon and electron beams are used to deliver treatment of superficial and deep-seated malignancies, respectively, while sparing underlying organs at risk.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Photon Beam</VALIDVALUE>
          <VALUEMEANING>Photon Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation therapy using photon beam.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3763332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Radioisotope</VALIDVALUE>
          <VALUEMEANING>Isotope Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment of a disease by means of exposure of the target to radioisotopes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiation, Systemic</VALIDVALUE>
          <VALUEMEANING>Systemic Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiation therapy in which a radioactive substance, such radioactive iodine or a radioactively labeled monoclonal antibody, is swallowed or injected into the body and travels through the blood, locating and killing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3428270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radioactive Iodine Therapy</VALIDVALUE>
          <VALUEMEANING>Radioactive Iodine Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of radioactive iodine to treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radioembolization</VALIDVALUE>
          <VALUEMEANING>Radioembolization</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of radiation therapy used to treat liver cancer that is advanced or has come back. Tiny beads that hold the radioisotope yttrium Y 90 are injected into the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the yttrium Y 90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the cancer cells. Radioembolization is a type of selective internal radiation therapy (SIRT).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3225720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiosensitizing Agent</VALIDVALUE>
          <VALUEMEANING>Radiosensitizing Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>5027911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Allogeneic</VALIDVALUE>
          <VALUEMEANING>Allogeneic Hematopoietic Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical treatment in which HSC capable of reconstituting the immune system and blood production (hematopoiesis) are transferred from one genetically dissimilar individual to another. The donor and recipient may or may not be related. 2005</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C46089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Autologous</VALIDVALUE>
          <VALUEMEANING>Autologous Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>The transference of stem cells within the same individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Double Autologous</VALIDVALUE>
          <VALUEMEANING>Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Haploidentical</VALIDVALUE>
          <VALUEMEANING>Haploidentical Hematopoietic Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical treatment in which hematopoietic stem cells are transferred from a HLA half-matched donor to a recipient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Non-Myeloablative</VALIDVALUE>
          <VALUEMEANING>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, NOS</VALIDVALUE>
          <VALUEMEANING>Hematopoietic Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>4395931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Transplantation, Syngenic</VALIDVALUE>
          <VALUEMEANING>Syngeneic Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13328604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cell Treatment</VALIDVALUE>
          <VALUEMEANING>Stem Cell Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment modality that leverages stem cells to prevent or treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>7353108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Steroid Therapy</VALIDVALUE>
          <VALUEMEANING>Steroid Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>7433982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cryoablation</VALIDVALUE>
          <VALUEMEANING>Cryosurgery</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-06</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>4129688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethanol Injection Ablation</VALIDVALUE>
          <VALUEMEANING>Ethanol Ablation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>An injection of ethanol (alcohol) through the skin directly into a tumor to kill cancer cells. Ultrasound or a CT scan is used to guide the needle into the tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>3225700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotherapy (Including Vaccines)</VALIDVALUE>
          <VALUEMEANING>Immunotherapy (Including Vaccines)</VALUEMEANING>
          <MEANINGDESCRIPTION>Therapy designed to induce changes in a patient&#39;s immune status in order to treat disease._Including the stated limits._Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C923, C166400, C15262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-08</PVBEGINDATE>
          <PVENDDATE>2023-10-17</PVENDDATE>
          <VMPUBLICID>13535057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>History of any Treatments</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>History of any Treatments</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CPTAC-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>History of any Treatments (Surgery, Radiation Therapy, Chemotherapy, Molecular Targeted Therapy, Immunotherapy, Other, None, Unknown)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>All Generic CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6776734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medical History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000400</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="843">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6790119</PUBLICID>
    <LONGNAME>Rhabdoid Tumor Characteristic Present Percentage Value</LONGNAME>
    <PREFERREDNAME>RHAB_PRES_PCT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the percentage of the rhabdoid features present in the patient&#39;s cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6789104</PublicId>
      <PreferredName>6789102v1.0:2712690v1.0</PreferredName>
      <PreferredDefinition>An aggressive malignant embryonal neoplasm usually occurring during childhood.  It is characterized by the presence of large cells with abundant cytoplasm, large eccentric nucleus, and a prominent nucleolus and it is associated with abnormalities of chromosome 22.  It can arise from the central nervous system, kidney, and the soft tissues.  The prognosis is poor._The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Rhabdoid Tumor Characteristic Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6789102</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3808</PreferredName>
        <Version>1</Version>
        <LongName>Rhabdoid Tumor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3808</PREFERRED_NAME>
            <LONG_NAME>Rhabdoid Tumor</LONG_NAME>
            <CON_ID>2962177</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2712690</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25447:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Characteristics Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2903088</PublicId>
      <PreferredName>PER_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity measured or assigned or computed that is a fraction or ratio with 100 understood as the denominator.</PreferredDefinition>
      <LongName>Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If rhabdoid features are pres</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If rhabdoid features are present, indicate the percentage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Renal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6788377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="844">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6790145</PUBLICID>
    <LONGNAME>SDH Complex Gene Mutation Abnormality Molecular Analysis Performed Indicator</LONGNAME>
    <PREFERREDNAME>SDHCOM_gene_analysis</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not an analysis for mutation in the SDH gene complex was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6789175</PublicId>
      <PreferredName>6789173v1.0:6060290v1.0</PreferredName>
      <PreferredDefinition>A change in the nucleotide sequence of any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex._Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._Executed and carried through to completion.</PreferredDefinition>
      <LongName>SDH Complex Gene Mutation Abnormality Molecular Analysis Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6789173</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48301</PreferredName>
        <Version>1</Version>
        <LongName>SDH Complex Gene Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48301</PREFERRED_NAME>
            <LONG_NAME>SDH Complex Gene Mutation</LONG_NAME>
            <CON_ID>5892063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6060290</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45576:C19770:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Mutation Abnormality Molecular Analysis Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45576</PREFERRED_NAME>
            <LONG_NAME>Mutation Abnormality</LONG_NAME>
            <CON_ID>2532673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19770</PREFERRED_NAME>
            <LONG_NAME>Molecular Analysis</LONG_NAME>
            <CON_ID>2528322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was SDHB/C/D mutation analysi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was SDHB/C/D mutation analysis performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Renal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6788377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="845">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6790772</PUBLICID>
    <LONGNAME>Reference ID</LONGNAME>
    <PREFERREDNAME>FTREFID</PREFERREDNAME>
    <PREFERREDDEFINITION>A character or string that represents a functional test assessment event reference.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6790753</PublicId>
      <PreferredName>6787609v1.0:6790751v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a functional test._A character or string that represents a functional test assessment event reference.</PreferredDefinition>
      <LongName>Functional Tests Domain Functional Tests Reference Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6787609</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117756</PreferredName>
        <Version>1</Version>
        <LongName>Functional Tests Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117756</PREFERRED_NAME>
            <LONG_NAME>Functional Tests Domain</LONG_NAME>
            <CON_ID>6787608</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6790751</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C162131</PreferredName>
        <Version>1</Version>
        <LongName>Functional Tests Reference Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C162131</PREFERRED_NAME>
            <LONG_NAME>Functional Tests Reference Identifier</LONG_NAME>
            <CON_ID>6790470</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353492</PublicId>
      <PreferredName>CDISCID</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25364</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reference ID</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reference ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTEP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What [is/was] the [test/procedure/domain/observation/specimen/sample] [reference identifier/accession number/identifier]?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Funtional Tests (FT) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7331374</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Functional Tests (FT) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943385</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FT</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FTREFID</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>FT_FTREFID</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="846">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6813530</PUBLICID>
    <LONGNAME>Name of Ophthalmic Test or Exam</LONGNAME>
    <PREFERREDNAME>OETEST</PREFERREDNAME>
    <PREFERREDDEFINITION>The literal identifier of a test related to ophthalmic examinations.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6813521</PublicId>
      <PreferredName>6789652v1.0:6813511v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to ophthalmic examinations._The literal identifier of an examination.</PreferredDefinition>
      <LongName>Ophthalmic Examinations Domain Test Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6789652</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C147180</PreferredName>
        <Version>1</Version>
        <LongName>Ophthalmic Examinations Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C147180</PREFERRED_NAME>
            <LONG_NAME>Ophthalmic Examinations Domain</LONG_NAME>
            <CON_ID>6789651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6813511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82541</PreferredName>
        <Version>1</Version>
        <LongName>Test Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82541</PREFERRED_NAME>
            <LONG_NAME>Test Name</LONG_NAME>
            <CON_ID>6141102</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6677720</PublicId>
      <PreferredName>OETEST</PreferredName>
      <PreferredDefinition>Terminology associated with the ophthalmic exam test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>CDISC SDTM Ophthalmic Exam Test Name Terminology Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6677719</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117742:C42614</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Ophthalmic Exam Test Name Terminology Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Ophthalmic Exam Test Name Terminology</LONG_NAME>
            <CON_ID>6677718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subject to Eye Chart Actual Distance</VALIDVALUE>
          <VALUEMEANING>Actual Subject to Eye Chart Distance</VALUEMEANING>
          <MEANINGDESCRIPTION>The actual distance between the subject and the eye chart during an eye assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spherical Refractive Error</VALIDVALUE>
          <VALUEMEANING>Spherical Refractive Error</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the extent of defect in vision caused by a mismatch of optimal power between the cornea and/or lens and the length of the eyeball, resulting in sub-optimal reflection of light onto the retina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shape</VALIDVALUE>
          <VALUEMEANING>Shape</VALUEMEANING>
          <MEANINGDESCRIPTION>The spatial arrangement of something as distinct from its substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reactivity</VALIDVALUE>
          <VALUEMEANING>Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>Reaction; a bodily process occurring due to the effect of some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2707888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Number of Lines Unread</VALIDVALUE>
          <VALUEMEANING>Number of Lines Unread</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of lines not able to be read by the subject during an eye chart assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Number of Lines Read</VALIDVALUE>
          <VALUEMEANING>Number of Eye Chart Lines Read</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of lines read by the subject during an eye chart assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Number of Letters Correct</VALIDVALUE>
          <VALUEMEANING>Number of Correct Eye Chart Letters</VALUEMEANING>
          <MEANINGDESCRIPTION>The integer that describes the number of letters correctly identified by the subject during an eye chart assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Number of Characters Unread</VALIDVALUE>
          <VALUEMEANING>Number of Characters Unread</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of letters not able to be read by the subject during an eye chart assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Number of Characters Read</VALIDVALUE>
          <VALUEMEANING>Number of Characters Read</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of letters read by the subject during an eye chart assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Near-Point Accommodation</VALIDVALUE>
          <VALUEMEANING>Near-Point Accommodation</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum distance from the retina that an object remains in clear focus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minimum Angle of Resolution, Log10</VALIDVALUE>
          <VALUEMEANING>Log10 Minimum Angle of Resolution</VALUEMEANING>
          <MEANINGDESCRIPTION>The base-10 logarithm of the minimum angle of resolution achieved by an individual during testing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minimum Angle of Resolution</VALIDVALUE>
          <VALUEMEANING>Minimum Angle of Resolution</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest angle of separation that allows an image-forming device to distinguish two objects as distinct entities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log Score</VALIDVALUE>
          <VALUEMEANING>Log Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A number or range of numeric values on the log scale that measures performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Longest Diameter</VALIDVALUE>
          <VALUEMEANING>Longest Diameter</VALUEMEANING>
          <MEANINGDESCRIPTION>The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6658374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lens Status</VALIDVALUE>
          <VALUEMEANING>Lens Status</VALUEMEANING>
          <MEANINGDESCRIPTION>The condition or state of the lens of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraocular Pressure</VALIDVALUE>
          <VALUEMEANING>Intraocular Pressure</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid pressure within the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperemia Grade</VALIDVALUE>
          <VALUEMEANING>Hyperemia Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>An evaluation of the presence and extent of hyperemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye Drop Comfort Grade</VALIDVALUE>
          <VALUEMEANING>Eye Drop Comfort Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>The position on a scale of intensity, amount or quality of eye drop comfort.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diameter, Standard Deviation</VALIDVALUE>
          <VALUEMEANING>Standard Deviation of Diameter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the range of values in a set of values that describe the diameter of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diameter, Minimum</VALIDVALUE>
          <VALUEMEANING>Minimum Diameter</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum value in a range of values that describe the diameter of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diameter, Mean</VALIDVALUE>
          <VALUEMEANING>Mean Diameter</VALUEMEANING>
          <MEANINGDESCRIPTION>The arithmetic mean of a range of values that describe the diameter of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diameter</VALIDVALUE>
          <VALUEMEANING>Diameter</VALUEMEANING>
          <MEANINGDESCRIPTION>The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2753170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cylindrical Refraction Error</VALIDVALUE>
          <VALUEMEANING>Cylindrical Refractive Error</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the extent of defect in vision caused by a mismatch of optical power between the cylindrical and horizontal meridians, resulting in sub-optimal reflection of light onto the retina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cup to Disc Ratio</VALIDVALUE>
          <VALUEMEANING>Optic Cup to Disc Ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>The ratio of the diameter of the optic cup compared to the diameter of the optic disc.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Color</VALIDVALUE>
          <VALUEMEANING>Color</VALUEMEANING>
          <MEANINGDESCRIPTION>The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Density, Standard Deviation</VALIDVALUE>
          <VALUEMEANING>Standard Deviation of Cell Density</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the range of values in a set of values that describe the cell density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Density, Mean</VALIDVALUE>
          <VALUEMEANING>Mean Cell Density</VALUEMEANING>
          <MEANINGDESCRIPTION>The arithmetic mean of a range of values that describe the cell density of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Density, Maximum</VALIDVALUE>
          <VALUEMEANING>Maximum Cell Density</VALUEMEANING>
          <MEANINGDESCRIPTION>The maximum value in a range of values that describe cell density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Density</VALIDVALUE>
          <VALUEMEANING>Cell Density</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the number of cells per unit volume or area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Density, Minimum</VALIDVALUE>
          <VALUEMEANING>Minimum Cell Density</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum value in a range of values that describe cell density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visual Acuity Card Grating Frequency</VALIDVALUE>
          <VALUEMEANING>Acuity Card Grating Frequency</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the number of horizontal or vertical lines within a pre-determined unit of length on a visual acuity card.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thickness, Standard Deviation</VALIDVALUE>
          <VALUEMEANING>Standard Deviation of Thickness</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the range of values in a set of values that describe the thickness of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thickness, Minimum</VALIDVALUE>
          <VALUEMEANING>Minimum Thickness</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum value in a range of values that describe the thickness of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thickness, Mean</VALIDVALUE>
          <VALUEMEANING>Mean Thickness</VALUEMEANING>
          <MEANINGDESCRIPTION>The arithmetic mean of a range of values that describe the thickness of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thickness, Maximum</VALIDVALUE>
          <VALUEMEANING>Maximum Thickness</VALUEMEANING>
          <MEANINGDESCRIPTION>The maximum value in a range of values that describe the thickness of an entity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thickness</VALIDVALUE>
          <VALUEMEANING>Thickness</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41145</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4493983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subject to Eye Chart Planned Distance</VALIDVALUE>
          <VALUEMEANING>Planned Subject to Eye Chart Distance</VALUEMEANING>
          <MEANINGDESCRIPTION>The planned distance between the subject and the eye chart during an eye assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Astigmatism Axis</VALIDVALUE>
          <VALUEMEANING>Astigmatism Axis</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the location, in degrees, of the flatter principal meridian on a 180-degree scale, where 90 degrees designates the vertical meridian and 180 degrees designates the horizontal meridian.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6677722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interpretation</VALIDVALUE>
          <VALUEMEANING>Interpretation</VALUEMEANING>
          <MEANINGDESCRIPTION>An act or process of elucidation, explication, or explanation of the meaning of an event or thing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6407004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ophthalmic Examination</VALIDVALUE>
          <VALUEMEANING>Eye Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A test performed by an ophthalmologist or optometrist assessing vision and ability to focus on and discern objects, as well as other tests and examinations pertaining to the eyes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2831578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tear Secretion Rate</VALIDVALUE>
          <VALUEMEANING>Tear Secretion Rate</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the amount of tears being secreted over a defined amount of time (e.g. 5 minutes).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172575</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7351266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tear Secretion</VALIDVALUE>
          <VALUEMEANING>Tear Secretion Amount</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the amount of tears produced by the subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7351268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edema</VALIDVALUE>
          <VALUEMEANING>Edema Evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>An evaluation of edema in a biological specimen or location.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyperemia</VALIDVALUE>
          <VALUEMEANING>Hyperemia Evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>An evaluation of hyperemia in a biological specimen or location.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178048</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corrective Lens Type for Distance</VALIDVALUE>
          <VALUEMEANING>Corrective Lens Type for Distance</VALUEMEANING>
          <MEANINGDESCRIPTION>A description of the type of eye lens(es) worn by the subject to correct for distance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C181512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7797832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corrective Lens for Distance Indicator</VALIDVALUE>
          <VALUEMEANING>Corrective Lens for Distance Indicator</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication as to whether an eye lens(es) is worn by the subject to correct for distance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C181511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7797835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diabetic Macular Edema Grade</VALIDVALUE>
          <VALUEMEANING>Diabetic Macular Edema Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>The position on a scale to assess diabetic macular edema.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11010727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diabetic Retinopathy Grade</VALIDVALUE>
          <VALUEMEANING>Diabetic Retinopathy Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>The position on a scale to assess diabetic retinopathy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11010728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Opacity</VALIDVALUE>
          <VALUEMEANING>Opacity Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>An assessment of the degree of opaqueness or the lack of transparency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Margin Reflex Distance 1</VALIDVALUE>
          <VALUEMEANING>Margin Reflex Distance 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the distance between the corneal light reflection to the central upper-eyelid margin, with the patient&#39;s gaze in the primary position (i.e., straight ahead).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189624</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Margin Reflex Distance 2</VALIDVALUE>
          <VALUEMEANING>Margin Reflex Distance 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the distance between the corneal light reflection to central lower-eyelid margin, with the patient&#39;s gaze in the primary position (i.e., straight ahead).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Margin Limbal Distance</VALIDVALUE>
          <VALUEMEANING>Margin Limbal Distance</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the distance from the inferior limbus to the central upper-eyelid margin, with the patient&#39;s gaze pointed upward.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Score</VALIDVALUE>
          <VALUEMEANING>Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3566833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Name of Ophthalmic Test or Ex</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Name of Ophthalmic Test or Exam</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC Publication Package</Name>
        <OrganizationName/>
        <DocumentType>CDISC EVS Controlled Terminology Update</DocumentType>
        <DocumentText>CDISC value sets have been updated to the P41 publication version (2020-03-27).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ophthalmic Examinations (OE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330204</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OETEST</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="847">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6819588</PUBLICID>
    <LONGNAME>Primary Tumor Diagnostic Imaging Performed Type</LONGNAME>
    <PREFERREDNAME>6819327v1.0:3178305v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term that represents the kind of imaging used to diagnose the primary tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6819327</PublicId>
      <PreferredName>5731699v1.0:6819325v1.0</PreferredName>
      <PreferredDefinition>A malignant tumor at the original site of growth._Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Primary Malignant Neoplasm Diagnostic Imaging Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5731699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C84509</PreferredName>
        <Version>1</Version>
        <LongName>Primary Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84509</PREFERRED_NAME>
            <LONG_NAME>Primary Malignant Neoplasm</LONG_NAME>
            <CON_ID>3205843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6819325</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16502:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Imaging Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16502</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Imaging</LONG_NAME>
            <CON_ID>2321519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3178305</PublicId>
      <PreferredName>3178305v1.0</PreferredName>
      <PreferredDefinition>Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._A method of examination, as to determine the presence or absence of a definite disease or of some substance in any of the fluids, tissues, or excretions of the body, or to determine the presence or degree of a psychological or behavioral trait. (from STED26)_Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Diagnostic Imaging Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>3134777</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16502:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Imaging Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16502</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Imaging</LONG_NAME>
            <CON_ID>2321519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ultrasound Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2926813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI with contrast</VALIDVALUE>
          <VALUEMEANING>With Contrast Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate the presence of something or someone.: The degree of difference between the lightest and darkest areas of an image or object.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C70754, C62355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT with contrast</VALIDVALUE>
          <VALUEMEANING>With Contrast Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate the presence of something or someone.: The degree of difference between the lightest and darkest areas of an image or object.: A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C70754, C62355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT without contrast</VALIDVALUE>
          <VALUEMEANING>Without Contrast Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): The degree of difference between the lightest and darkest areas of an image or object.: A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C70754, C25718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI without contrast</VALIDVALUE>
          <VALUEMEANING>Without Contrast Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): The degree of difference between the lightest and darkest areas of an image or object.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C70754, C25718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>ULTRASOUND</VALUEMEANING>
          <MEANINGDESCRIPTION>High frequency sound, generally with a frequency greater than 20,000 Hz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-29</PVBEGINDATE>
          <PVENDDATE>2019-07-17</PVENDDATE>
          <VMPUBLICID>2560382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99mTc bone scintiscanning</VALIDVALUE>
          <VALUEMEANING>Technetium Tc-99m Bone Radionuclide Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Technetium Tc-99m Bone Radionuclide Imaging</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6819601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT scan</VALIDVALUE>
          <VALUEMEANING>Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI</VALIDVALUE>
          <VALUEMEANING>Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET (specify)</VALIDVALUE>
          <VALUEMEANING>Specify Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6819577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other (specify)</VALIDVALUE>
          <VALUEMEANING>Specify Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6060199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DCE</VALIDVALUE>
          <VALUEMEANING>Dynamic Contrast-enhanced Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A modification of contrast-enhanced MRI that allows observation of functional properties in addition to structural properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6401748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DTI</VALIDVALUE>
          <VALUEMEANING>Diffusion Tensor Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of diffusion-weighted magnetic resonance imaging (DW-MRI) that maps the diffusion of water in three dimensions, the principal purpose of which is to image the white matter of the brain, specifically measuring the anisotropy, location, and orientation of the neural tracts, which can demonstrate microstructural changes or differences with neuropathology and treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6427012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4001711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLAIR MRI</VALIDVALUE>
          <VALUEMEANING>Fluid Attenuated Inversion Recovery</VALUEMEANING>
          <MEANINGDESCRIPTION>A magnetic resonance imaging (MRI) pulse sequence that uses an inversion recovery technique to null fluids present in the imaging area, improving clarity of the object of interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6147291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2W MRI</VALIDVALUE>
          <VALUEMEANING>T2-Weighted Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the transverse relaxation of a tissue&#39;s net magnetization vector; it measures the time taken for spinning protons to lose phase coherence among the nuclei spinning perpendicular to the main field. This MRI sequence is produced by using a longer time to echo (TE) and repetition time (TR) than a T1-weighted sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7736636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1W MRI with contrast</VALIDVALUE>
          <VALUEMEANING>T1-Weighted Magnetic Resonance Imaging with Contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>T1 weighted magnetic resonance imaging done with the addition of a contrast agent to enhance tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7736637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1W MRI</VALIDVALUE>
          <VALUEMEANING>T1-Weighted Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the longitudinal relaxation of a tissue&#39;s net magnetization vector; it measures the time taken for spinning protons to realign with the external magnetic field. This MRI sequence is produced by using short  time to echo (TE) and repetition times (TR).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7736638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kv/Mv</VALIDVALUE>
          <VALUEMEANING>Kv/Mv Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Any imaging method that makes use of high-energy radiation in the Kv or Mv range.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12951609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CBCT</VALIDVALUE>
          <VALUEMEANING>Cone-Beam Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography that utilizes a cone shaped X- ray beam that captures a full volume of image as the X-ray source and detector simultaneously move in a single rotation around a stabilized target.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12951610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Indicate the imaging method(s</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Indicate the imaging method(s) used in diagnosis of the primary tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000016</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="848">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6824903</PUBLICID>
    <LONGNAME>Evaluator Identifier</LONGNAME>
    <PREFERREDNAME>REEVALID</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of characters used to distinguish multiple evaluators with the same role who provided the evaluation related to respiratory system findings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6823773</PublicId>
      <PreferredName>6783895v1.0:6421660v1.0</PreferredName>
      <PreferredDefinition>A findings domain that contains physiological and morphological findings related to the respiratory system, including the organs that are involved in breathing such as the nose, throat, larynx, trachea, bronchi and lungs._A sequence of characters used to identify, name, or characterize the evaluator.</PreferredDefinition>
      <LongName>Respiratory Domain Evaluator Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6783895</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95098</PreferredName>
        <Version>1</Version>
        <LongName>Respiratory Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95098</PREFERRED_NAME>
            <LONG_NAME>Respiratory Domain</LONG_NAME>
            <CON_ID>6783894</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6421660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117043</PreferredName>
        <Version>1</Version>
        <LongName>Evaluator Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117043</PREFERRED_NAME>
            <LONG_NAME>Evaluator Identifier</LONG_NAME>
            <CON_ID>6421656</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6421601</PublicId>
      <PreferredName>MEDEVAL</PreferredName>
      <PreferredDefinition>Terminology associated with the medical evaluator codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>CDISC SDTM Medical Evaluator Terminology Identifier</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6421600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C96777:C25364</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Medical Evaluator Terminology Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C96777</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Medical Evaluator Identifier Terminology</LONG_NAME>
            <CON_ID>6421599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADJUDICATOR 1</VALIDVALUE>
          <VALUEMEANING>Adjudicator 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An adjudicator performing the assessment that is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RATER 1</VALIDVALUE>
          <VALUEMEANING>Rater 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of raters that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ONCOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Oncologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of oncologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ONCOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Oncologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of oncologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96611</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEUROLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Neurologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of neurologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEUROLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Neurologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of neurologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RATER 2</VALIDVALUE>
          <VALUEMEANING>Rater 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of raters that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RADIOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Radiologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of radiologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RADIOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Radiologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of radiologists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MICROSCOPIST 3</VALIDVALUE>
          <VALUEMEANING>Microscopist 3</VALUEMEANING>
          <MEANINGDESCRIPTION>The third in a series of microscopists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MICROSCOPIST 2</VALIDVALUE>
          <VALUEMEANING>Microscopist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of microscopists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MICROSCOPIST 1</VALIDVALUE>
          <VALUEMEANING>Microscopist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of microscopists that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADJUDICATOR 3</VALIDVALUE>
          <VALUEMEANING>Adjudicator 3</VALUEMEANING>
          <MEANINGDESCRIPTION>An adjudicator performing the assessment that is given the designation of three.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150869</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADJUDICATOR 2</VALIDVALUE>
          <VALUEMEANING>Adjudicator 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An adjudicator performing the assessment that is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421655</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>READER 3</VALIDVALUE>
          <VALUEMEANING>Reader 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A reader performing the assessment that is given the designation of three.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6421605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>READER 2</VALIDVALUE>
          <VALUEMEANING>Reader 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The second in a series of readers that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3362052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>READER 1</VALIDVALUE>
          <VALUEMEANING>Reader 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The first in a series of readers that are performing an assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3362050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATHOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Pathologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A pathologist performing the assessment that is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6636229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATHOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Pathologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A pathologist performing the assessment that is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6636231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEURORADIOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Neuroradiologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A neuroradiologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEURORADIOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Neuroradiologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A neuroradiologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ENDOCRINOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Endocrinologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An endocrinologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FORENSIC PATHOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Forensic Pathologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A forensic pathologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTERNIST 1</VALIDVALUE>
          <VALUEMEANING>Internist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An internist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPHTHALMOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Ophthalmologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An ophthalmologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPTOMETRIST 1</VALIDVALUE>
          <VALUEMEANING>Optometrist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An optometrist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HEMATOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Hematologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A hematologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTOLARYNGOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Otolaryngologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A otolaryngologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEDIATRIC NEUROLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Pediatric Neurologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A pediatric neurologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PHYSIOTHERAPIST 1</VALIDVALUE>
          <VALUEMEANING>Physiotherapist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A physiotherapist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RADIOLOGIST 3</VALIDVALUE>
          <VALUEMEANING>Radiologist 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiologist performing the assessment who is given the designation of three.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UROLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Urologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An urologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CARDIOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Cardiologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A cardiologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL PATHOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Clinical Pathologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical pathologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DERMATOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Dermatologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A dermatologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN 1</VALIDVALUE>
          <VALUEMEANING>Developmental Behavioral Pediatrician 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A developmental behavioral pediatrician performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL PSYCHOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Developmental Psychologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A developmental psychologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C187880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11009138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEUROONCOLOGIST 1</VALIDVALUE>
          <VALUEMEANING>Neuro-oncologist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A neurooncologist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NUCLEAR MEDICINE PHYSICIAN 1</VALIDVALUE>
          <VALUEMEANING>Nuclear Medicine Physician 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclear medicine physician performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PHARMACOKINETICIST 1</VALIDVALUE>
          <VALUEMEANING>Pharmacokineticist 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A pharmacokineticist performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CERTIFIED ASSESSOR 1</VALIDVALUE>
          <VALUEMEANING>Certified Assessor 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A certified assessor performing the assessment who is given the designation of one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLINICAL PATHOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Clinical Pathologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical pathologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DERMATOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Dermatologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A dermatologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN 2</VALIDVALUE>
          <VALUEMEANING>Developmental Behavioral Pediatrician 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A developmental behavioral pediatrician performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEVELOPMENTAL PSYCHOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Developmental Psychologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A developmental psychologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ENDOCRINOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Endocrinologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An endocrinologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189593</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CARDIOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Cardiologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A cardiologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FORENSIC PATHOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Forensic Pathologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A forensic pathologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HEMATOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Hematologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A hematologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTERNIST 2</VALIDVALUE>
          <VALUEMEANING>Internist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An internist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189596</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPTOMETRIST 2</VALIDVALUE>
          <VALUEMEANING>Optometrist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An optometrist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTOLARYNGOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Otolaryngologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An otolaryngologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEDIATRIC NEUROLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Pediatric Neurologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A pediatric neurologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PHYSIOTHERAPIST 2</VALIDVALUE>
          <VALUEMEANING>Physiotherapist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A physiotherapist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UROLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Urologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A urologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189602</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPHTHALMOLOGIST 2</VALIDVALUE>
          <VALUEMEANING>Ophthalmologist 2</VALUEMEANING>
          <MEANINGDESCRIPTION>An ophthalmologist performing the assessment who is given the designation of two.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11501780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Evaluator Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SDTM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218795</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6338162</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Respiratory System Findings (RE) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7330202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RE</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>REEVALID</AlternateName>
        <AlternateNameType>CDISC SDTM Variable</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="849">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6825621</PUBLICID>
    <LONGNAME>Patient Left Ventricular Ejection Fraction Outcome Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>4901086v1.0:3506036v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes, No, N/A indicator for clinical trial eligibility related to the fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4901086</PublicId>
      <PreferredName>2233604v1.0:4901084v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume._The result of an action._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Left Ventricular Ejection Fraction Outcome Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4901084</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C99524:C20200:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Left Ventricular Ejection Fraction Outcome Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C99524</PREFERRED_NAME>
            <LONG_NAME>Left Ventricular Ejection Fraction</LONG_NAME>
            <CON_ID>4363958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If previously measured, known</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If previously measured, known LVEF &lt; 50%</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6147165</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WFB Medical Center</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WFB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6147167</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="850">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6841706</PUBLICID>
    <LONGNAME>Laboratory Procedure Urine Protein to Creatinine Ratio Measurement Outcome Lab Unit of Measure Name</LONGNAME>
    <PREFERREDNAME>6118035v1.0:2017137v3.2</PREFERREDNAME>
    <PREFERREDDEFINITION>The unit of measure that represents a determinate amount or quantity of urine protein to creatinine ratio measurement in a laboratory specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6118035</PublicId>
      <PreferredName>2543047v1.0:6118033v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra._The determination of the ratio of total protein compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure Urine Protein to Creatinine Ratio Measurement Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6118033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13283:C79463:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Urine Protein to Creatinine Ratio Measurement Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13283</PREFERRED_NAME>
            <LONG_NAME>Urine</LONG_NAME>
            <CON_ID>2202425</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79463</PREFERRED_NAME>
            <LONG_NAME>Protein to Creatinine Ratio Measurement</LONG_NAME>
            <CON_ID>6117919</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017137</PublicId>
      <PreferredName>LAB_UOM_NM</PreferredName>
      <PreferredDefinition>Unit of measure standard values to describe a lab test result.</PreferredDefinition>
      <LongName>Lab Unit of Measure Name</LongName>
      <Version>3.2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>LITER</VALUEMEANING>
          <MEANINGDESCRIPTION>LITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol</VALIDVALUE>
          <VALUEMEANING>MILLIMOLE</VALUEMEANING>
          <MEANINGDESCRIPTION>MILLIMOLE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/L</VALIDVALUE>
          <VALUEMEANING>millimole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>millimole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg</VALIDVALUE>
          <VALUEMEANING>milligram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Any division of quantity accepted as a standard of measurement or exchange.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL</VALIDVALUE>
          <VALUEMEANING>Nanograms per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Grams (g)</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one one thousandth of a kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/L</VALIDVALUE>
          <VALUEMEANING>International unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq</VALIDVALUE>
          <VALUEMEANING>Milliequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/24hr</VALIDVALUE>
          <VALUEMEANING>Milliequivalents per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/dL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/L</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL</VALIDVALUE>
          <VALUEMEANING>Milligram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million</VALIDVALUE>
          <VALUEMEANING>Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one-thousandth of an international unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/m2</VALIDVALUE>
          <VALUEMEANING>Milliinternational units per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one-thousandth (10E-3) of an arbitrary unit of biological activity (International Unit) of substance per square meter of body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg</VALIDVALUE>
          <VALUEMEANING>Picograms</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand</VALIDVALUE>
          <VALUEMEANING>Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg</VALIDVALUE>
          <VALUEMEANING>Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>Thousand per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E12 Cells per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell concentration expressed as a number of cells in trillions per unit volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E3 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E3 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mill PFU</VALIDVALUE>
          <VALUEMEANING>Million Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of viable infectious entities expressed in millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Srce</VALIDVALUE>
          <VALUEMEANING>No Source Data</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L</VALIDVALUE>
          <VALUEMEANING>Kilounit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>Cubic microns</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The property used in conjunction with a nutrient or food component, typically expressed in gram (g), milligram (mg), microgram (mcg), joule, or kilojoule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/dL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/mL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fL</VALIDVALUE>
          <VALUEMEANING>Femtoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI equal to one quadrillionth of a liter (10E-15 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/24hr</VALIDVALUE>
          <VALUEMEANING>Gram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/dL</VALIDVALUE>
          <VALUEMEANING>Gram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/L</VALIDVALUE>
          <VALUEMEANING>Gram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/microL</VALIDVALUE>
          <VALUEMEANING>Gram per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPF</VALIDVALUE>
          <VALUEMEANING>Per High Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per High Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iunit</VALIDVALUE>
          <VALUEMEANING>INTERNATIONAL UNIT</VALUEMEANING>
          <MEANINGDESCRIPTION>INTERNATIONAL UNIT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/m2</VALIDVALUE>
          <VALUEMEANING>International unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>International unit per meter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>International unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>IU/mL</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE>2019-04-30</PVENDDATE>
          <VMPUBLICID>2573880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LPF</VALIDVALUE>
          <VALUEMEANING>Per Low Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per Low Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/24hr</VALIDVALUE>
          <VALUEMEANING>Microgram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/dL</VALIDVALUE>
          <VALUEMEANING>Microgram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/L</VALIDVALUE>
          <VALUEMEANING>microgram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>microgram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/spec</VALIDVALUE>
          <VALUEMEANING>Microgram per specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per specimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/kg</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliequivalent per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/L</VALIDVALUE>
          <VALUEMEANING>Milligram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL/min</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microIU/mL</VALIDVALUE>
          <VALUEMEANING>Micro International Unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micro International Unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microL</VALIDVALUE>
          <VALUEMEANING>MICROLITER</VALUEMEANING>
          <MEANINGDESCRIPTION>MICROLITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/24hr</VALIDVALUE>
          <VALUEMEANING>Micromole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/dL</VALIDVALUE>
          <VALUEMEANING>Micromole per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/L</VALIDVALUE>
          <VALUEMEANING>Micromole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Million per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/mL</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliinternational unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Milliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/1.73/BSA</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute times 1.73 times BSA</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute times 1.73 times BSA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg</VALIDVALUE>
          <VALUEMEANING>Milliter per minute per millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter per minute per millimeters of Mercury</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm/hr</VALIDVALUE>
          <VALUEMEANING>Millimeter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter per hour</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm3</VALIDVALUE>
          <VALUEMEANING>Millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmHg</VALIDVALUE>
          <VALUEMEANING>Millimeter of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth&#39;s surface. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/24hr</VALIDVALUE>
          <VALUEMEANING>Millimole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosmol/kg</VALIDVALUE>
          <VALUEMEANING>Milliosmole per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliosmole per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MU/mL</VALIDVALUE>
          <VALUEMEANING>Million units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not applicable; no UOM required</VALUEMEANING>
          <MEANINGDESCRIPTION>Not applicable; no UOM required</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL/hr</VALIDVALUE>
          <VALUEMEANING>Nanogram per milliliter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to mass concentration of a substance expressed in nanograms per unit volume of one milliliter per time period of one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nMol/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL</VALIDVALUE>
          <VALUEMEANING>Nanomole per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/dL</VALIDVALUE>
          <VALUEMEANING>Picogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pgPGE2/mg protein</VALIDVALUE>
          <VALUEMEANING>pgPGE2/mg protein</VALUEMEANING>
          <MEANINGDESCRIPTION>pgPGE2/mg protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/L</VALIDVALUE>
          <VALUEMEANING>Picomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ratio</VALIDVALUE>
          <VALUEMEANING>ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>ratio</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>sec</VALIDVALUE>
          <VALUEMEANING>seconds</VALUEMEANING>
          <MEANINGDESCRIPTION>seconds</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0457385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/24hr</VALIDVALUE>
          <VALUEMEANING>Unit per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/L</VALIDVALUE>
          <VALUEMEANING>Unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mL</VALIDVALUE>
          <VALUEMEANING>Unit per millilliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millilliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mm3</VALIDVALUE>
          <VALUEMEANING>Unit per millimeters cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millimeters cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 Cells/kg</VALIDVALUE>
          <VALUEMEANING>10E7 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min</VALIDVALUE>
          <VALUEMEANING>Liters per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/24hr</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/m2</VALIDVALUE>
          <VALUEMEANING>Unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed as a number of arbitrary units of substance per one square meter of a body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%/100 WBC</VALIDVALUE>
          <VALUEMEANING>Percent Per 100 WBC</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for percentage measurement of fraction of any type of white blood cells in the total white blood cell count differential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mm3</VALIDVALUE>
          <VALUEMEANING>Per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells</VALIDVALUE>
          <VALUEMEANING>10E6 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per microLiter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per microLiter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/mm3</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 Cells</VALIDVALUE>
          <VALUEMEANING>10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E8 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells</VALIDVALUE>
          <VALUEMEANING>10E9 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/microL</VALIDVALUE>
          <VALUEMEANING>Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies</VALIDVALUE>
          <VALUEMEANING>Copies</VALUEMEANING>
          <MEANINGDESCRIPTION>Copies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/dL</VALIDVALUE>
          <VALUEMEANING>nanogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>nanogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mL</VALIDVALUE>
          <VALUEMEANING>Picrogram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picrogram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100 WBC</VALIDVALUE>
          <VALUEMEANING>Per 100 identifiable White blood cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit for measurement of portion of a particular type of blood cells (such as any type of white blood cells or nucleated red blood cells) in the total white blood cell count expressed per count of 100.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAE Unit</VALIDVALUE>
          <VALUEMEANING>Complement activity enzyme unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Complement activity enzyme unit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Titer</VALIDVALUE>
          <VALUEMEANING>Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>Titer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA copies/mL</VALIDVALUE>
          <VALUEMEANING>RNA copies per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>RNA copies per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>Million per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MIC</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic Microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICR</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICRON</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GPL</VALIDVALUE>
          <VALUEMEANING>IgG anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgG anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Index value</VALIDVALUE>
          <VALUEMEANING>Index value</VALUEMEANING>
          <MEANINGDESCRIPTION>Index value</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microU/mL</VALIDVALUE>
          <VALUEMEANING>Microunit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microunit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>MILL/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Mil/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>MILL/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>MILL/CMM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg/L</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute per millimeter Hg per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute per millimeter Hg per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/min/kPa/L</VALIDVALUE>
          <VALUEMEANING>Millimole per minute per thousand Pascal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per minute per thousand Pascal per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MPL</VALIDVALUE>
          <VALUEMEANING>IgM anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgM anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/UL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOUS/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>K/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>1000/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>THOU/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>1000/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>1000/mm3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thous/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/sec</VALIDVALUE>
          <VALUEMEANING>Liter per second</VALUEMEANING>
          <MEANINGDESCRIPTION>Liter per second</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>1000/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Threshold</VALIDVALUE>
          <VALUEMEANING>Threshold</VALUEMEANING>
          <MEANINGDESCRIPTION>The lowest limit at which something becomes detectable or relevant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6/L</VALIDVALUE>
          <VALUEMEANING>10E6 per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2755857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ukat/L</VALIDVALUE>
          <VALUEMEANING>Microkatal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Picomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Picomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trillion/L</VALIDVALUE>
          <VALUEMEANING>Trillion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Trillion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Billion/L</VALIDVALUE>
          <VALUEMEANING>Billion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Billion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g</VALIDVALUE>
          <VALUEMEANING>milligram per gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3170018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minutes</VALIDVALUE>
          <VALUEMEANING>Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit measure of time equal to 60 seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/24hr</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Integer::24 Hour Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: For each, generally denoting a ratio.: A number with no fractional part, including the negative and positive numbers as well as zero.::24: In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C25529, C45255::24, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mL</VALIDVALUE>
          <VALUEMEANING>Milliunit Per Milliliter Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to the one thousandth unit (10E-3 unit).: For each, generally denoting a ratio.: A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28254, C65039, C67315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hours</VALIDVALUE>
          <VALUEMEANING>Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/kg</VALIDVALUE>
          <VALUEMEANING>Cell Per Kilogram Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>Any small compartment.: For each, generally denoting a ratio.: A basic SI unit of mass. It is definied as the mass of an  international prototype in the form of a platinum-iridium cylinder kept at Sevres in france.   A kilogram is equal to 1,000 grams and 2.2046226 pounds.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28252, C65039, C48694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies/mL</VALIDVALUE>
          <VALUEMEANING>Copy per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration of RNA copies expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E6 Cells</VALIDVALUE>
          <VALUEMEANING>Integer::2 Multiplication Million Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::2: An arithmetic operation by which the product of two numbers is computed; the inverse of division.: A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508, C67238, C65000, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 10 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::10, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E2</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 2 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::2: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::2, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 3 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::3: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255::3, C95157, C25709, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 2, 0, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E5</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 5 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::5: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::5, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E4</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 4 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::4: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::4, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 7 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::7: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::7, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 6 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::6: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::6, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 9 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::9: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::9, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 8 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::8: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::8, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 12 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::12: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::12, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11</VALIDVALUE>
          <VALUEMEANING>Ten Exponent:11 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::11: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::11, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E14</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 14 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::14: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::14, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E13</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 13 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::13: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::13, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E16</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 16 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::16: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::16, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E15</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 15 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E18</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 18 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::18: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::18, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E17</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 17 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::17: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::17, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E20</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 20 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::20: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::20, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E19</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 19 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::19: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::19, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E8 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 8 (one hundred million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E7 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E7 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 7 (ten million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Minute </VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3652827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log</VALIDVALUE>
          <VALUEMEANING>Logarithm</VALUEMEANING>
          <MEANINGDESCRIPTION>For a specified base b, a function such that its argument results when b is raised to the power given by this function&#39;s value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3703164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol CO/min/kPa</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Millimoles per Minute per Kilopascal</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit of gas diffusion capacity equal to one millimole per minute per kilopascal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116242, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ml CO/min/mm Hg</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Milliliter per Minute per Millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit for measuring a pulmonary diffusing capacity expressed in units of gas flow rate (in milliliters per minute) per a unit of pressure (in torrs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67417, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm H2O</VALIDVALUE>
          <VALUEMEANING>Centimeters of water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5477037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>copies/L</VALIDVALUE>
          <VALUEMEANING>Copy Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A secondary representation, reproduction, or replica.: A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C67336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5637481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log10 IU/mL</VALIDVALUE>
          <VALUEMEANING>Log10 International Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5778792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL FEU</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter Fibrinogen Equivalent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.: A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96649, C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6479361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mmol</VALIDVALUE>
          <VALUEMEANING>Gram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E-15L (fL)</VALIDVALUE>
          <VALUEMEANING>Ten Exponential Function 15 Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A function of the form f(x) = ab^x, characterized by the fact that the growth rate of such a function is directly proportional to the value of the function.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8057682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Log10 Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arbitrary unit per milliliter</VALIDVALUE>
          <VALUEMEANING>Arbitrary Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C75765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10631416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15128242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/nL</VALIDVALUE>
          <VALUEMEANING>Per Nanoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one nanoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/pL</VALIDVALUE>
          <VALUEMEANING>Per Picoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one picoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the unit of measure f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the unit of measure for the urine protein to creatinine ratio measurement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="851">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6857210</PUBLICID>
    <LONGNAME>Specimen Adequate Assessment Other Specify Text</LONGNAME>
    <PREFERREDNAME>SPEC_ADQ_ASSMT_OTHR_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field that describes other requirement for specimen assessment which are different from the ones previously specified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6601784</PublicId>
      <PreferredName>2241613v1.0:3589764v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Specimen Adequate Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3589764</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63351:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Sufficient Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63351</PREFERRED_NAME>
            <LONG_NAME>Sufficient</LONG_NAME>
            <CON_ID>2538604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6857307</PublicId>
      <PreferredName>6857307v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly. The text that provides a description of a topic</PreferredDefinition>
      <LongName>Other Specify 1999 Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1999</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If Other is chosen above, ple</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If Other is chosen above, please provide details here</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="852">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6857381</PUBLICID>
    <LONGNAME>Patient Breast Surgical Procedure And Chemotherapy Complete Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>BRST_SX_CHEM_COMP_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded indicator to determine clinical trial participation as to whether the patient has completed breast surgery and chemotherapy as outlined in the study protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6857380</PublicId>
      <PreferredName>2233604v1.0:7497102v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Breast Surgical Procedure And Chemotherapy Complete Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7497102</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7497102v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Breast Surgical Procedure And Chemotherapy Complete Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient completed their f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient completed their final breast surgery including re-excision of margins for invasive cancer and DCIS, within 90 but not fewer than 21 days prior to registration unless patient received postoperative chemotherapy in which case patients must have completed their adjuvant chemotherapy within 90 days but not fewer than 28 days prior to registration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatments</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000494</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="853">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6922131</PUBLICID>
    <LONGNAME>Transplant Conditioning Without HPV-16 E7 TCR Expressing T-cells Begin Yes No Indicator</LONGNAME>
    <PREFERREDNAME>CND_WO_TCELL_BGN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication whether the patient began the conditioning chemotherapy regimen without receiving HPV-16 E7 TCR expressing t-cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6922128</PublicId>
      <PreferredName>2594982v1.0:6922126v1.0</PreferredName>
      <PreferredDefinition>Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient&#39;s abnormal blood cells or cancer, as well as slows the patient&#39;s immune response against the donor bone marrow (graft rejection)._Used to indicate the absence or lack of something or someone._A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.</PreferredDefinition>
      <LongName>Transplant Conditioning Without HPV-16 E7 TCR Expressing T-cells Begin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2594982</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64468</PreferredName>
        <Version>1</Version>
        <LongName>Transplant Conditioning</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64468</PREFERRED_NAME>
            <LONG_NAME>Transplant Conditioning</LONG_NAME>
            <CON_ID>2590852</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6922126</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25718:C128485:C25431</PreferredName>
        <Version>1</Version>
        <LongName>Without HPV-16 E7 TCR Expressing T-cells Begin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25718</PREFERRED_NAME>
            <LONG_NAME>Without</LONG_NAME>
            <CON_ID>2206274</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128485</PREFERRED_NAME>
            <LONG_NAME>HPV-16 E7 TCR Expressing T-cells</LONG_NAME>
            <CON_ID>6867749</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCR:Center for Cancer Research</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient starts the conditioni</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient starts the conditioning regimen chemotherapy but does not receive the E7 TCR T Cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="854">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6941748</PUBLICID>
    <LONGNAME>IIRS 1 How Much Does Illness and/or Treatment Interfere with Health Score 7 Point Scale</LONGNAME>
    <PREFERREDNAME>IIRS_1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation about how much their illness and/or its treatment interferes with their health, using a 7 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>IIRS: Illness Intrusiveness Ratings Scale; GM Devins, Journal of Psychosomatic Research (2010)</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6941663</PublicId>
      <PreferredName>6941660v1.0:6941661v1.0</PreferredName>
      <PreferredDefinition>A questionnaire and scale designed to assess the extent that a person&#39;s illness, and/or its treatment, interferes with aspects of their life. Responses range from 1: Not Very Much to 7: Very Much._A question about how much an individual&#39;s illness and/or treatment interferes with their health._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Illness Intrusiveness Ratings Scale How Much Does Illness and/or Treatment Interfere with Health Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6941660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C163766</PreferredName>
        <Version>1</Version>
        <LongName>Illness Intrusiveness Ratings Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C163766</PREFERRED_NAME>
            <LONG_NAME>Illness Intrusiveness Ratings Scale</LONG_NAME>
            <CON_ID>6868914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6941661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C163775:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Much Does Illness and/or Treatment Interfere with Health Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C163775</PREFERRED_NAME>
            <LONG_NAME>How Much Does Illness and/or Treatment Interfere with Health Question</LONG_NAME>
            <CON_ID>6868922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>IIRS: Illness Intrusiveness Ratings Scale; GM Devins, Journal of Psychosomatic Research (2010)</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6923795</PublicId>
      <PreferredName>6923795v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes; ranges from 1: Not very much to 7: Very much</PreferredDefinition>
      <LongName>IIRS 7 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>7</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>IIRS: Illness Intrusiveness Ratings Scale; GM Devins, Journal of Psychosomatic Research (2010)</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 7 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 6</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 6 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 5 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 4 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 3 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 2 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Illness Intrusiveness Rating 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A response of 1 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6923802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How much does your illness an</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much does your illness and/or its treatment interfere with your: HEALTH</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Illness Intrusiveness Ratings Scale (IIRS)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 1 of 13</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Illness Intrusiveness Ratings Scale (IIRS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900315</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921238</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>IIRS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>IIRS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6921239</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="855">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6943252</PUBLICID>
    <LONGNAME>Disease Status Evaluation Guideline Used Type</LONGNAME>
    <PREFERREDNAME>6943229v1.0:6943244v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of guideline used for disease status evaluation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6943229</PublicId>
      <PreferredName>2847331v1.0:6943227v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels._To put into action or service.</PreferredDefinition>
      <LongName>Disease or Disorder Status Evaluation Guideline Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2847331</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C25688:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Status Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6943227</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17564:C95018</PreferredName>
        <Version>1</Version>
        <LongName>Guideline Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17564</PREFERRED_NAME>
            <LONG_NAME>Guideline</LONG_NAME>
            <CON_ID>2443697</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95018</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>3248409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6943244</PublicId>
      <PreferredName>6943244v1.0</PreferredName>
      <PreferredDefinition>The type of guideline used to determine disease status.</PreferredDefinition>
      <LongName>Disease Status Guideline Used Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6424136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RECIST</VALIDVALUE>
          <VALUEMEANING>Response Evaluation Criteria in Solid Tumors</VALUEMEANING>
          <MEANINGDESCRIPTION>Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (&quot;respond&quot;), stay the same (&quot;stable&quot;), or worsen (&quot;progression&quot;) during treatments. (from www.recist.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2627734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Guideline used</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Guideline used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="856">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6964545</PUBLICID>
    <LONGNAME>Lab End Date</LONGNAME>
    <PREFERREDNAME>LBENDAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The end date related to laboratory data represented in an unambiguous date format (e.g., DD-MON-YYYY).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6962765</PublicId>
      <PreferredName>6401816v1.0:2715153v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to laboratory data._The calendar date on which something is to terminate or did terminate.</PreferredDefinition>
      <LongName>Laboratory Data Domain End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6401816</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49592</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Data Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49592</PREFERRED_NAME>
            <LONG_NAME>Laboratory Data Domain</LONG_NAME>
            <CON_ID>2469066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68617</PreferredName>
        <Version>1</Version>
        <LongName>End Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68617</PREFERRED_NAME>
            <LONG_NAME>End Date</LONG_NAME>
            <CON_ID>2714918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338240</PublicId>
      <PreferredName>CDISCDAT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>11</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396655</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25164</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lab End Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lab End Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>End Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="857">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>6996527</PUBLICID>
    <LONGNAME>Patient Mixed Phenotype Acute Leukemia Diagnosis With BCR/ABL1 Fusion Gene Evidence Karyotype Fluorescence in Situ Hybridization Reverse Transcriptase-Polymerase Chain Reaction Eligibility Determination Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>PT_MPAL_DX_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response to a question asking whether a patient has been newly diagnosed with mixed phenotype acute leukemia (MPAL meeting 2016 WHO definition) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6996522</PublicId>
      <PreferredName>2233604v1.0:6996534v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Used to indicate the presence of something or someone._A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5&#39; part of the BCR gene to the 5&#39; side of exon 2 of the ABL1 gene. There are 3 potential products that are formed depending on which BCR exon has the breakpoint. All of the protein products have constitutively active tyrosine kinase activity. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia._Knowledge on which to base belief._The assessment of the chromosomal morphology and number in somatic cells of an individual._A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping._A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.</PreferredDefinition>
      <LongName>Patient Mixed Phenotype Acute Leukemia Diagnosis With BCR/ABL1 Fusion Gene Evidence Karyotype Fluorescence in Situ Hybridization Reverse Transcriptase-Polymerase Chain Reaction Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6996534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>6996534v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Mixed Phenotype Acute Leukemia Diagnosis With BCR/ABL1 Fusion Gene Evidence Karyotype Fluorescence in Situ Hybridization Reverse Transcriptase-Polymerase Chain Reaction Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82179</PREFERRED_NAME>
            <LONG_NAME>Mixed Phenotype Acute Leukemia</LONG_NAME>
            <CON_ID>6764287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>8</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62355</PREFERRED_NAME>
            <LONG_NAME>With</LONG_NAME>
            <CON_ID>2532083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94600</PREFERRED_NAME>
            <LONG_NAME>BCR/ABL1 Fusion Gene</LONG_NAME>
            <CON_ID>3613651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43583</PREFERRED_NAME>
            <LONG_NAME>Evidence</LONG_NAME>
            <CON_ID>2228358</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25215</PREFERRED_NAME>
            <LONG_NAME>Karyotype</LONG_NAME>
            <CON_ID>2202673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17563</PREFERRED_NAME>
            <LONG_NAME>Fluorescence In Situ Hybridization</LONG_NAME>
            <CON_ID>2221360</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18136</PREFERRED_NAME>
            <LONG_NAME>Reverse Transcriptase-Polymerase Chain Reaction</LONG_NAME>
            <CON_ID>2202804</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have newly diagn</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have newly diagnosed mixed phenotype acute leukemia (MPAL meeting 2016 WHO definition) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have newly diagnosed mixed phenotype acute leukemia (MPAL meeting 2016 WHO definition) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or molecular methodologies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="858">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7001243</PUBLICID>
    <LONGNAME>Tracking Number</LONGNAME>
    <PREFERREDNAME>TRKNUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field for the sample tracking number.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6982637</PublicId>
      <PreferredName>6982657v1.0:6982658v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The act or process of following a person, animal, or object through space or time._The act or process of following a person, animal, or object through space or time._A numeral or string of numerals expressing value, quantity, or identification</PreferredDefinition>
      <LongName>Biospecimen Tracking Tracking Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6982657</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699:C45275</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Tracking</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45275</PREFERRED_NAME>
            <LONG_NAME>Tracking</LONG_NAME>
            <CON_ID>2598128</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6982658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45275:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Tracking Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45275</PREFERRED_NAME>
            <LONG_NAME>Tracking</LONG_NAME>
            <CON_ID>2598128</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666625</PublicId>
      <PreferredName>2666625v1.0</PreferredName>
      <PreferredDefinition>A number with no fractional part.::40_An expression consisting of a linear sequence of symbols (characters or words or phrases)._An expression consisting of a linear sequence of symbols (characters or words or phrases).</PreferredDefinition>
      <LongName>40 Character Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
      <Representation>
        <PublicId>2666624</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255::40:C45253:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Integer::40 String Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45253</PREFERRED_NAME>
            <LONG_NAME>String</LONG_NAME>
            <CON_ID>2539471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tracking Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tracking Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="859">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7002944</PUBLICID>
    <LONGNAME>Residual Clone Cell Count Less Than 1 Per Million Detection Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>RES_CN_CL_DTC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response to a question asking whether the number of residual clonal cells per million in a residual sequence is less than 1.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7002937</PublicId>
      <PreferredName>6707430v1.0:7002935v1.0</PreferredName>
      <PreferredDefinition>Remaining or left behind._A group of genetically identical cells, organisms, or DNA molecules._A procedure to determine the number of cells in a sample. Also used to mean the result of such a procedure._A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._A number with no fractional part, including the negative and positive numbers as well as zero.::1_For each, generally denoting a ratio._A natural number following 999999 and preceding 1000001 and the quantity that it denotes: one thousand thousands._The activity of perceiving, discerning, discovering or identifying.</PreferredDefinition>
      <LongName>Residual Clone Cell Count Less Than 1 Per Million Detection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7002947</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37895:C37925:C48938</PreferredName>
        <Version>1</Version>
        <LongName>Residual Clone Cell Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37895</PREFERRED_NAME>
            <LONG_NAME>Residual</LONG_NAME>
            <CON_ID>2206361</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37925</PREFERRED_NAME>
            <LONG_NAME>Clone</LONG_NAME>
            <CON_ID>2223235</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48938</PREFERRED_NAME>
            <LONG_NAME>Cell Count</LONG_NAME>
            <CON_ID>2488847</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7002948</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7002948v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Less Than Integer::1 Per Million Detection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61585</PREFERRED_NAME>
            <LONG_NAME>Less Than</LONG_NAME>
            <CON_ID>2620099</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::1</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67238</PREFERRED_NAME>
            <LONG_NAME>Million</LONG_NAME>
            <CON_ID>2719291</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If residual sequence detected</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If residual sequence detected, were the number of residual clonal cells per million less than 1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="860">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7027278</PUBLICID>
    <LONGNAME>Laboratory Procedure Troponin T Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>LAB_TNNT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response as to whether the patient&#39;s lab test for troponin T meets the eligibility criteria outlined in the study protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7027226</PublicId>
      <PreferredName>2543047v1.0:7027224v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Troponin I, troponin T, and troponin C are the three closely associated subunits of the troponin complex of thin filaments in muscle. The complex serves as a calcium-sensitive switch that regulates muscle contraction. Troponin T binds tropomyosin to the troponin complex and inhibits F-actin-myosin interactions. The troponin T gene family comprises three isoforms: slow skeletal (TNNT1), cardiac (TNNT2) and fast skeletal (TNNT3). Because it is not normally found in blood, cardiac troponin-T in serum is a sensitive indicator of myocardial cell injury._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Laboratory Procedure Troponin T Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7027224</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38041:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Troponin T Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38041</PREFERRED_NAME>
            <LONG_NAME>Troponin T</LONG_NAME>
            <CON_ID>2978372</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is pre-study troponin T less</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is pre-study troponin T less than or equal to upper limit of normal?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is pre-study troponin within normal limits?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is pre-study troponin less than or equal to the upper limit of normal?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Data (including serologic/viral status)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="861">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7028292</PUBLICID>
    <LONGNAME>Para-Aortic Lymph Node Micrometastases Present Count</LONGNAME>
    <PREFERREDNAME>PRATC_LN_MICMTS_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric response that indicates the number of paraaortic lymph nodes that have micrometastases present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HCMI:Human Cancer Models Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7027506</PublicId>
      <PreferredName>7027431v1.0:2488532v1.0</PreferredName>
      <PreferredDefinition>A lymph node located adjacent to the lumbar region of the spine._Metastasis in the form of small clusters of malignant cells identifiable only under the microscope._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Paraaortic Lymph Node Micrometastasis Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7027431</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C77643</PreferredName>
        <Version>1</Version>
        <LongName>Paraaortic Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77643</PREFERRED_NAME>
            <LONG_NAME>Paraaortic Lymph Node</LONG_NAME>
            <CON_ID>3137526</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2488532</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38486:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Micromets Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38486</PREFERRED_NAME>
            <LONG_NAME>Micrometastasis</LONG_NAME>
            <CON_ID>2202750</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HCMI:Human Cancer Models Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018392</PublicId>
      <PreferredName>CT</PreferredName>
      <PreferredDefinition>The quantity of the specified item.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of para-aortic nodes w</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of para-aortic nodes with micrometastases</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7026248</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="862">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7032121</PUBLICID>
    <LONGNAME>Treatment Cohort Study EC10221 Code</LONGNAME>
    <PREFERREDNAME>TX_COH_SDY_EC10221_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The code that represents the information pertaining to protocol 10221 in which subsets of a defined population are identified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2497526</PublicId>
      <PreferredName>TX_COHORT_STDY</PreferredName>
      <PreferredDefinition>Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.</PreferredDefinition>
      <LongName>Treatment Cohort Study</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2497524</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15208</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15208</PREFERRED_NAME>
            <LONG_NAME>Cohort Study</LONG_NAME>
            <CON_ID>2497523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7032116</PublicId>
      <PreferredName>7032116v1.0</PreferredName>
      <PreferredDefinition>A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>10221 Cohort Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>250</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>4386398</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61512:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61512</PREFERRED_NAME>
            <LONG_NAME>Cohort</LONG_NAME>
            <CON_ID>2555083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG3</VALIDVALUE>
          <VALUEMEANING>PIK3CA and PTEN Wild Type</VALUEMEANING>
          <MEANINGDESCRIPTION>PIK3CA and PTEN Wild Type</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7031979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG2</VALIDVALUE>
          <VALUEMEANING>PTEN Mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>PTEN Mutation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7031980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG4</VALIDVALUE>
          <VALUEMEANING>Dose Escalation</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose Escalation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6635852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG1</VALIDVALUE>
          <VALUEMEANING>PIK3CA Mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>A molecular genetic abnormality indicating the presence of a mutation in the PI3KCA (phosphatidyl inositol 3-kinase) gene on chromosome 3q26.32.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4411273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please select the subgroup</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please select the subgroup</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="863">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7032757</PUBLICID>
    <LONGNAME>Patient Central Nervous System Metastases And Or Meningeal Carcinomatosis Diagnosis Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>CNSMETS_CM_DX_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded indicator to determine patient eligibility for questions related to the diagnosis of central nervous system (CNS) metastases and/or carcinomatous meningitis as outlined in the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7032607</PublicId>
      <PreferredName>2233604v1.0:7032605v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A malignant neoplasm that has spread to the central nervous system from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas)._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Diffuse spread of cancer to the meninges._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Metastatic Malignant Neoplasm in the Central Nervous System And Or Meningeal Carcinomatosis Diagnosis Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7032605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7032605v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Malignant Neoplasm in the Central Nervous System And Or Meningeal Carcinomatosis Diagnosis Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4015</PREFERRED_NAME>
            <LONG_NAME>Metastatic Malignant Neoplasm in the Central Nervous System</LONG_NAME>
            <CON_ID>6835446</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27383</PREFERRED_NAME>
            <LONG_NAME>Meningeal Carcinomatosis</LONG_NAME>
            <CON_ID>7032604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have known activ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have known active CNS disease and/or carcinomatous meningitis before study enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have known active CNS disease and/or carcinomatous meningitis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have carcinomatous meningitis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have known active central nervous system (CNS) metastases and/or carcinomatous meningitis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except as noted in protocol section 3.2.3?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have active central nervous system (CNS) metastases, including lymphomatous meningitis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have known brain metastases or carcinomatous meningitis, unless brain metastatic disease status has remained stable for greater than or equal to 1 month after treatment of the brain metastases?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have current active CNS metastasis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000703</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="864">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7038758</PUBLICID>
    <LONGNAME>Biospecimen Collection Method Name</LONGNAME>
    <PREFERREDNAME>MICOLLNM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the biospecimen collection method.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7038627</PublicId>
      <PreferredName>6407670v1.0:7038625v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microscopic findings._The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Microscopic Findings Domain Biospecimen Collection Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407670</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95095</PreferredName>
        <Version>1</Version>
        <LongName>Microscopic Findings Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95095</PREFERRED_NAME>
            <LONG_NAME>Microscopic Findings Domain</LONG_NAME>
            <CON_ID>6407669</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7038625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70945:C71460</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Collection Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70945</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Collection</LONG_NAME>
            <CON_ID>2714902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3131217</PublicId>
      <PreferredName>SPEC_COLL_METH_NM</PreferredName>
      <PreferredDefinition>The way a specimen or sample is collected._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Specimen Collection Method Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colostomy Descending</VALIDVALUE>
          <VALUEMEANING>Descending Colon Colostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.: (ko-LAHS-toe-mee) An opening into the colon from the outside of the body. A colostomy provides a new path for waste material to leave the body after part of the colon has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15211, C12268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonoscopy</VALIDVALUE>
          <VALUEMEANING>Colonoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the luminal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colostomy Ascending</VALIDVALUE>
          <VALUEMEANING>Ascending Colon Colostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.: (ko-LAHS-toe-mee) An opening into the colon from the outside of the body. A colostomy provides a new path for waste material to leave the body after part of the colon has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15211, C12265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertical Hemilaryntectomy, Right</VALIDVALUE>
          <VALUEMEANING>Vertical Hemilaryntectomy, Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the east when facing north.::1: Upright in position or posture.::2: Surgery to remove one half of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51906, C25243, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE>2015-02-24</PVENDDATE>
          <VMPUBLICID>3131288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertical Hemilaryntectomy, Left</VALIDVALUE>
          <VALUEMEANING>Vertical Hemilaryntectomy, Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the west when facing north.::1: Upright in position or posture.::2: Surgery to remove one half of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51906, C25243, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE>2015-02-24</PVENDDATE>
          <VMPUBLICID>3131289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roux-en-Y Gastric Bypass</VALIDVALUE>
          <VALUEMEANING>Roux-en-Y Anastomosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Gastric bypass procedure in which part of the stomach is closed off with staples, and part of the small intestine is bypassed.  This procedure is performed in severely obese patients, for permanent weight loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secterectomy, Right Posterior</VALIDVALUE>
          <VALUEMEANING>Secterectomy, Right Posterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.::1: Surgical removal of the right part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51623, C25622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secterectomy, Right Anterior</VALIDVALUE>
          <VALUEMEANING>Secterectomy, Right Anterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the front surface of the body; often used to indicate the position of one structure relative to another.::1: Surgical removal of the right part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51623, C25231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUGA Scan</VALIDVALUE>
          <VALUEMEANING>MUGA Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-gated acquisition (MUGA) scan and a form of radionuclide imaging that provides a comprehensive look at blood flow and the function of the lower chambers of the heart ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secterectomy, Left Medial</VALIDVALUE>
          <VALUEMEANING>Secterectomy, Left Medial</VALUEMEANING>
          <MEANINGDESCRIPTION>Toward the middle or inside (as opposed to lateral).::1: Surgical removal of the left part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51624, C25232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Secterectomy, Left Lateral</VALIDVALUE>
          <VALUEMEANING>Secterectomy, Left Lateral</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated at or extending to the side.::1: Surgical removal of the left part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51624, C25230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiofrequency Ablation</VALIDVALUE>
          <VALUEMEANING>Radiofrequency Ablation</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic procedure to eradicate or reduce small tumors using radiowaves to generate heat. The procedure is performed by the insertion of a thin needle through the skin and into a tumor, which is guided by computed tomography (CT) or ultrasound. Electrical energy delivered through this needle (electrode) heats and destroys the tumor. This therapeutic option is widely utilized by patients that have inoperable cancers, or are unsuitable chemotherapy candidates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3029158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radical Mastectomy</VALIDVALUE>
          <VALUEMEANING>Radical Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of the breast, pectoral muscles, axillary lymph nodes, and associated skin and subcutaneous tissue (from MeSH).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2839762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Re-excision</VALIDVALUE>
          <VALUEMEANING>Re-excision</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure to remove the remaining abnormal tissues from the body, not completely removed in an earlier attempt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cholecystectomy</VALIDVALUE>
          <VALUEMEANING>Cholecystectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the gallbladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAT Scan</VALIDVALUE>
          <VALUEMEANING>Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2979517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appendectomy and right colectomy</VALIDVALUE>
          <VALUEMEANING>Appendectomy And Right Colectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the vermiform appendix.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Surgical removal of the right part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51623, C37912, C51687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood Draw</VALIDVALUE>
          <VALUEMEANING>Blood Collection</VALUEMEANING>
          <MEANINGDESCRIPTION>Blood circulating throughout the body.: The act of gathering something together.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25453, C12434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Scan</VALIDVALUE>
          <VALUEMEANING>Bone Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclear imaging method used to evaluate pathological bone metabolism. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3057576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a small sample of bone marrow (usually from the hip) through a needle for examination under a microscope to see whether cancer cells are present.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proximal  Gastrectomy</VALIDVALUE>
          <VALUEMEANING>Proximal Gastrectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Proximal; situated nearest to a point of attachment or origin.: Surgical removal of part or all of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15236, C25236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polypectomy</VALIDVALUE>
          <VALUEMEANING>Polypectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Polypectomy; surgical removal of a polyp.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2794442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pneumonectomy</VALIDVALUE>
          <VALUEMEANING>Pneumonectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>(noo-mo-NEK-toe-mee) An operation to remove an entire lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penumonectomy, Right</VALIDVALUE>
          <VALUEMEANING>Right Pneumonectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: (noo-mo-NEK-toe-mee) An operation to remove an entire lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15305, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pneumonectomy, Left</VALIDVALUE>
          <VALUEMEANING>Left Pneumonectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: (noo-mo-NEK-toe-mee) An operation to remove an entire lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15305, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical Examination</VALIDVALUE>
          <VALUEMEANING>Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET</VALIDVALUE>
          <VALUEMEANING>PET scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneoscopy</VALIDVALUE>
          <VALUEMEANING>Peritoneoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2833000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Percutaneous Hepatic Perfusion</VALIDVALUE>
          <VALUEMEANING>Percutaneous Route of Administration Hepatic Perfusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration through the skin.: Refers to the liver.: Bathing an organ or tissue with a fluid. In regional perfusion, a specific area of the body (usually an arm or a leg) receives high doses of anticancer drugs through a blood vessel. Such a procedure is performed to treat cancer that has not spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15295, C13308, C38676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial  Pharyngectomy</VALIDVALUE>
          <VALUEMEANING>Partial Pharyngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial; being or affecting only a part; not total: Surgery involving the complete or partial excision of the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51608, C25378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial  Mastectomy</VALIDVALUE>
          <VALUEMEANING>Partial Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial; being or affecting only a part; not total: Surgical removal of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15277, C25378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial Laryngectomy</VALIDVALUE>
          <VALUEMEANING>Partial Laryngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial; being or affecting only a part; not total: Surgery to remove part or all of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15267, C25378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Laryngectomy</VALIDVALUE>
          <VALUEMEANING>Total Laryngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to completely remove the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreaticoduodenectomy (Whipple Resection)</VALIDVALUE>
          <VALUEMEANING>Whipple Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3029187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatectomy, Total</VALIDVALUE>
          <VALUEMEANING>Total Pancreatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.: Surgical removal of the pancreas. (Dorland, 28th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15294, C25304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatectomy, Tail</VALIDVALUE>
          <VALUEMEANING>Tail of the Pancreas Pancreatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The left extremity of the pancreas within the lienorenal ligament.: Surgical removal of the pancreas. (Dorland, 28th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15294, C12271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatectomy, Head</VALIDVALUE>
          <VALUEMEANING>Head of the Pancreas Pancreatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>That portion of the pancreas lying in the concavity of the duodenum.: Surgical removal of the pancreas. (Dorland, 28th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15294, C12269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatectomy, Body</VALIDVALUE>
          <VALUEMEANING>Body of the Pancreas Pancreatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.: Surgical removal of the pancreas. (Dorland, 28th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15294, C12270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other (specify)</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omentectomy</VALIDVALUE>
          <VALUEMEANING>Omentectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial or complete resection of the omentum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Specified</VALIDVALUE>
          <VALUEMEANING>Not Stated Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.: Specified; clearly and explicitly stated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38024, C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck Lymph Node Dissection</VALIDVALUE>
          <VALUEMEANING>Neck Lymph Node Dissection</VALUEMEANING>
          <MEANINGDESCRIPTION>The region that connects the head to the rest of the body.: A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph glands filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels. Also called a lymph node.: The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure. (MedicineNet.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15227, C12745, C13063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modified Radical Mastectomy</VALIDVALUE>
          <VALUEMEANING>Modified Radical Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery for breast cancer in which the breast, most or all of the lymph nodes under the arm, and the lining over the chest muscles are removed. Sometimes the surgeon also removes part of the chest wall muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microwave Ablation</VALIDVALUE>
          <VALUEMEANING>Microwave Radiation Ablation</VALUEMEANING>
          <MEANINGDESCRIPTION>Electromagnetic radiation between the ultrahigh frequency radio and infrared (in the 10e-3 (micro) to about 0.5 X 10e-1 meter) region of the spectrum.: Removal of a part, pathway, or function by surgery, chemical destruction, electrocautery, or radiofrequency. (Taber&#39;s)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20985, C16862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mastectomy</VALIDVALUE>
          <VALUEMEANING>Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2845306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Wedge Resection, Right</VALIDVALUE>
          <VALUEMEANING>Right Wedge Resection of Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Surgical removal of a wedge-shaped section of lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51625, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Wedge Resection, Multiple</VALIDVALUE>
          <VALUEMEANING>Multiple Wedge Resection of Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>many copies of or many forms: Surgical removal of a wedge-shaped section of lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51625, C17648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Wedge Resection, Left</VALIDVALUE>
          <VALUEMEANING>Left Wedge Resection of Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Surgical removal of a wedge-shaped section of lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51625, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Wedge Resection, Bilateral</VALIDVALUE>
          <VALUEMEANING>Bilateral Wedge Resection of Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>Affecting both sides of the body, or a matched pair of organs.: Surgical removal of a wedge-shaped section of lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51625, C13332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumpectomy</VALIDVALUE>
          <VALUEMEANING>Lumpectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The surgical removal of a discrete mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lobectomy, Right</VALIDVALUE>
          <VALUEMEANING>Right Lobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: (lo-BEK-toe-mee) The removal of a lobe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15272, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lobectomy, Left</VALIDVALUE>
          <VALUEMEANING>Left Lobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: (lo-BEK-toe-mee) The removal of a lobe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15272, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lobectomy, Bilateral</VALIDVALUE>
          <VALUEMEANING>Bilateral Lobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Affecting both sides of the body, or a matched pair of organs.: (lo-BEK-toe-mee) The removal of a lobe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15272, C13332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lobectomy</VALIDVALUE>
          <VALUEMEANING>Lobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>(lo-BEK-toe-mee) The removal of a lobe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver Wedge Resection</VALIDVALUE>
          <VALUEMEANING>Wedge Biopsy of Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of a wedge-shaped portion of theliver, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2833159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver Resection</VALIDVALUE>
          <VALUEMEANING>Liver Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.: Resected; having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemicolectomy, Left</VALIDVALUE>
          <VALUEMEANING>Left Hemicolectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Surgical removal of approximately half of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86074, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3107659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatectomy, Left</VALIDVALUE>
          <VALUEMEANING>Left Hepatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Surgery to remove all or part of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15249, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatectomy, Left Partial</VALIDVALUE>
          <VALUEMEANING>Left Partial Hepatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Partial; being or affecting only a part; not total: Surgery to remove all or part of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15249, C25378, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparotomy</VALIDVALUE>
          <VALUEMEANING>Laparotomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Creation of a surgical opening into the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparoscopy</VALIDVALUE>
          <VALUEMEANING>Laparoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(lap-a-RAHS-ko-pee) The insertion of a thin, lighted tube (called a laparoscope) through the abdominal wall to inspect the inside of the abdomen and remove tissue samples.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2832056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incisional Biopsy</VALIDVALUE>
          <VALUEMEANING>Incisional Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which part of a lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2757939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileostomy</VALIDVALUE>
          <VALUEMEANING>Ileostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>(il-ee-AHS-toe-mee) An opening into the ileum, part of the small intestine, from the outside of the body. An ileostomy provides a new path for waste material to leave the body after part of the intestine has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow Cytometry</VALIDVALUE>
          <VALUEMEANING>Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2974014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional Biopsy</VALIDVALUE>
          <VALUEMEANING>Excisional Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which an entire lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERCP</VALIDVALUE>
          <VALUEMEANING>Endoscopic Retrograde Cholangiopancreatography</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic retrograde cholangiopancreatography (en-do-SKAH-pik RET-ro-grade ko-LAN-jee-o-PAN-kree-a-TAW-gra-fee). A procedure to x-ray the pancreatic duct, hepatic duct, common bile duct, duodenal papilla, and gallbladder. In this procedure, a thin, lighted tube (endoscope) is passed through the mouth and down into the first part of the small intestine (duodenum). A smaller tube (catheter) is then inserted through the endoscope into the bile and pancreatic ducts. A dye is injected through the catheter into the ducts, and an x-ray is taken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2926786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy</VALIDVALUE>
          <VALUEMEANING>Endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(en-DAHS-ko-pee) The use of a thin, lighted tube (called an endoscope) to examine the inside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2926784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LN Dissection</VALIDVALUE>
          <VALUEMEANING>Lymph Node Dissection</VALUEMEANING>
          <MEANINGDESCRIPTION>A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph glands filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels. Also called a lymph node.: The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure. (MedicineNet.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15227, C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cystectomy</VALIDVALUE>
          <VALUEMEANING>Cystectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>(sis-TEK-toe-mee) Surgery to remove all or part of the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2847403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colostomy Transverse</VALIDVALUE>
          <VALUEMEANING>Transverse Colon Colostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.: (ko-LAHS-toe-mee) An opening into the colon from the outside of the body. A colostomy provides a new path for waste material to leave the body after part of the colon has been removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15211, C12385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Left</VALIDVALUE>
          <VALUEMEANING>Left Colon Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the large intestine that includes the descending and sigmoid colon._Having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C33929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Right</VALIDVALUE>
          <VALUEMEANING>Right Colon Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The proximal segment of the large intestine that is located in the right side of the abdominal cavity. It includes the cecum (with the attached appendix) and the ascending colon._Having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Sigmoid</VALIDVALUE>
          <VALUEMEANING>Sigmoid Colon Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the colon that connects to the descending colon above and the rectum below.: Resected; having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Sigmoid Extended</VALIDVALUE>
          <VALUEMEANING>Colon Resection - Sigmoid Extended</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure involving the partial or complete resection of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Transverse</VALIDVALUE>
          <VALUEMEANING>Transverse Colon Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.: Resected; having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Transverse Extended</VALIDVALUE>
          <VALUEMEANING>Colon Resection - Transverse Extended</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the transverse colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X-Ray</VALIDVALUE>
          <VALUEMEANING>X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-energy radiation.  In low doses, x-rays are used to diagnose diseases by making pictures of the inside of the body.  In high doses, x-rays are used to treat cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wedge Resection, Single</VALIDVALUE>
          <VALUEMEANING>Single Wedge Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others.: Removal of a wedge-shaped portion of tissue, for microscopic examinaton.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51916, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wedge Resection, Multiple</VALIDVALUE>
          <VALUEMEANING>Multiple Wedge Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>many copies of or many forms: Removal of a wedge-shaped portion of tissue, for microscopic examinaton.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51916, C17648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Virtual Colonoscopy</VALIDVALUE>
          <VALUEMEANING>Virtual Endoscopy Colonoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of 3D CT or MRI scans to construct a simulated visualization of patient specific organs similar or equivalent to those produced by standard endoscopic procedures.  Virtual endoscopic visualization avoids the risks associated with real endoscopy.  Additionally, there are many body regions not accessible to or compatible with real endoscopy that can be explored with virtual endoscopy. (from R. Robb presentation at Visible Human Project Conference): Endoscopic examination of the luminal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16450, C20097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VATS, Left</VALIDVALUE>
          <VALUEMEANING>Left Video-assisted Thoracic Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Endoscopic surgery of the pleural cavity performed with visualization via video transmission.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63704, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VATS, Right</VALIDVALUE>
          <VALUEMEANING>Right Video-assisted Thoracic Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Endoscopic surgery of the pleural cavity performed with visualization via video transmission.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63704, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper Endoscopy</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Any endoscopic procedure that visualizes a part of the gastrointestinal tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2926780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>High frequency sound, generally with a frequency greater than 20,000 Hz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3109382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colectomy, Transverse</VALIDVALUE>
          <VALUEMEANING>Transverse Colon Colectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.: Surgical removal of part or all of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15209, C12385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound, Transrectal</VALIDVALUE>
          <VALUEMEANING>Transrectal Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure that uses sound waves to create a video image of the prostate gland. A small, lubricated probe placed into the rectum releases sound waves, which create echoes as they enter the prostate. Prostate tumors sometimes create echoes that are different from normal prostate tissue. The echoes that bounce back are sent to a computer that translates the pattern of echoes into a picture of the prostate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Thyroidectomy</VALIDVALUE>
          <VALUEMEANING>Total Thyroidectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery involving the complete excision of the thyroid gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total  Pharyngectomy</VALIDVALUE>
          <VALUEMEANING>Total Pharyngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.: Surgery involving the complete or partial excision of the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51608, C25304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total  Glossectomy</VALIDVALUE>
          <VALUEMEANING>Total Glossectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.: Surgery involving partial or complete excision of the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51604, C25304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total  Gastrectomy</VALIDVALUE>
          <VALUEMEANING>Total Gastrectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.: Surgical removal of part or all of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15236, C25304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Abdominal Hysterectomy</VALIDVALUE>
          <VALUEMEANING>Total Abdominal Hysterectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of all of the uterus, via an abdominal approach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Abdominal Colectomy</VALIDVALUE>
          <VALUEMEANING>Total Colectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the entire colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenectomy</VALIDVALUE>
          <VALUEMEANING>Splenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation to remove the spleen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Segmentectomy, Single</VALIDVALUE>
          <VALUEMEANING>Single Segmentectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others.: Resection of a segment of an organ or partial resection of a gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91061, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Segmentectomy, Multiple</VALIDVALUE>
          <VALUEMEANING>Multiple Segmentectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>many copies of or many forms: Resection of a segment of an organ or partial resection of a gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91061, C17648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Segmentectomy</VALIDVALUE>
          <VALUEMEANING>Segmentectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Resection of a segment of an organ or partial resection of a gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3124185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salpingoophorectomy, Right</VALIDVALUE>
          <VALUEMEANING>Right Salpingo-Oophorectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Surgical removal of the fallopian tube(s) and ovary(ies).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15323, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salpingoophorectomy, Left</VALIDVALUE>
          <VALUEMEANING>Left Salpingo-Oophorectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Left; being or located on or directed toward the side of the body to the west when facing north.: Surgical removal of the fallopian tube(s) and ovary(ies).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15323, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salpingoophorectomy, Bilateral</VALIDVALUE>
          <VALUEMEANING>Bilateral Salpingo-Oophorectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Affecting both sides of the body, or a matched pair of organs.: Surgical removal of the fallopian tube(s) and ovary(ies).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15323, C13332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatectomy, Right</VALIDVALUE>
          <VALUEMEANING>Right Hepatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Surgery to remove all or part of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15249, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemicolectomy, Right</VALIDVALUE>
          <VALUEMEANING>Right Hemicolectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Surgical removal of approximately half of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86074, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3107658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatectomy, Right Partial</VALIDVALUE>
          <VALUEMEANING>Right Partial Hepatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Right; being or located on or directed toward the side of the body to the east when facing north.: Partial; being or affecting only a part; not total: Surgery to remove all or part of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15249, C25378, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sectorectomy, Left Lateral</VALIDVALUE>
          <VALUEMEANING>Sectorectomy, Left Lateral</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the west when facing north._Situated at or extending to the side._Surgical excision of a sector of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200356, C25230, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sectorectomy, Left Medial</VALIDVALUE>
          <VALUEMEANING>Sectorectomy, Left Medial</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the west when facing north._Toward the middle or inside (as opposed to lateral)._Surgical excision of a sector of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200356, C25232, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sectorectomy, Right Anterior</VALIDVALUE>
          <VALUEMEANING>Sectorectomy, Right Anterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the east when facing north._Denoting the front surface of the body; often used to indicate the position of one structure relative to another._Surgical excision of a sector of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200356, C25231, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sectorectomy, Right Posterior</VALIDVALUE>
          <VALUEMEANING>Sectorectomy, Right Posterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the east when facing north._Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates._Surgical excision of a sector of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200356, C25622, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertical Hemilaryngectomy, Left</VALIDVALUE>
          <VALUEMEANING>Vertical Hemilaryngectomy, Left</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the west when facing north.::1: Surgery to remove one half of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51906, C25229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertical Hemilaryngectomy, Right</VALIDVALUE>
          <VALUEMEANING>Vertical Hemilaryngectomy, Right</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or located on or directed toward the side of the body to the east when facing north.::1: Surgery to remove one half of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51906, C25228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon Resection, Right Extended</VALIDVALUE>
          <VALUEMEANING>Right Colon Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The proximal segment of the large intestine that is located in the right side of the abdominal cavity. It includes the cecum (with the attached appendix) and the ascending colon._Having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Completion Pneumonectomy</VALIDVALUE>
          <VALUEMEANING>Completion Pneumonectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure involving the removal of the entire remaining lung tissue following partial lung resection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conon Resection - Left Extended</VALIDVALUE>
          <VALUEMEANING>Colon Resection - Left Extended</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the left part of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51624</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excision with wire-guided localization</VALIDVALUE>
          <VALUEMEANING>Wire-guided Localization Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure involving the removal of the entire remaining lung tissue following partial lung resection.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C91832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excision without wire-guided localization</VALIDVALUE>
          <VALUEMEANING>No Wire-guided Localization Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A surgical procedure involving the removal of the entire remaining lung tissue following partial lung resection.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C91832, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Feeding Tube, Gastric</VALIDVALUE>
          <VALUEMEANING>Gastric Feeding Tube</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the stomach.: A tube used to provide nutrients to patients who can not swallow. It may be inserted through the nose or placed into the stomach through the abdominal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91833, C13307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Feeding Tube, Jejunum</VALIDVALUE>
          <VALUEMEANING>Jejunum Feeding Tube</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the small intestine that extends from the duodenum to the ileum.: A tube used to provide nutrients to patients who can not swallow. It may be inserted through the nose or placed into the stomach through the abdominal wall.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91833, C12388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal bariatrics</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Bariatric Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>(GAS-tro-in-TES-tih-nul) GI.  Refers to the stomach and intestines.: Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84399, C13359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal fundoplication</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Fundoplication</VALUEMEANING>
          <MEANINGDESCRIPTION>(GAS-tro-in-TES-tih-nul) GI.  Refers to the stomach and intestines.: A therapeutic surgical procedure to treat gastroesophageal reflux disease and hiatus hernia. It involves the wrapping of the fundus of the stomach around the lower esophagus to strengthen the lower esophageal sphincter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91834, C13359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIPEC</VALIDVALUE>
          <VALUEMEANING>Hyperthermic Intraperitoneal Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low Anterior Resection</VALIDVALUE>
          <VALUEMEANING>Low Anterior Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.: Denoting the front surface of the body; often used to indicate the position of one structure relative to another.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C25231, C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Major Airway Resection</VALIDVALUE>
          <VALUEMEANING>Major Airway Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater or bigger in amount, extent, or size.: The part of the respiratory system between the nose or mouth and the lungs.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C89842, C45368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI Scan</VALIDVALUE>
          <VALUEMEANING>MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasogastric Tube</VALIDVALUE>
          <VALUEMEANING>Nasogastric Intubation</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure involving the insertion of a plastic tube into the stomach through the nose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic Exenteration</VALIDVALUE>
          <VALUEMEANING>Pelvic Exenteration</VALUEMEANING>
          <MEANINGDESCRIPTION>A major surgical procedure involving the removal of all the contents of the pelvic cavity, including reproductive organs, bladder, rectum, and anus. It is performed for cancers of the pelvic cavity organs that have not responded to other treatment options.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal/Rectosigmoid colon (Low anterior resection)</VALIDVALUE>
          <VALUEMEANING>Rectal Colon Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>Rectal; of, or pertaining to, the rectum.: The part of the large intestine between the cecum and the rectum; it extracts moisture from food residues before they are excreted.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C12382, C25224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resection</VALIDVALUE>
          <VALUEMEANING>Resection</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of cutting out; the surgical removal of part or all of a structure or organ.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sigmoidectomy</VALIDVALUE>
          <VALUEMEANING>Sigmoidectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure involving the partial or complete resection of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simple Mastectomy</VALIDVALUE>
          <VALUEMEANING>Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2845306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin/Nipple Sparing (Subcutaneous) Mastectomy</VALIDVALUE>
          <VALUEMEANING>Subcutaneous Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure that removes the breast tissue while leaving the skin, nipple, and areola intact.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small Bowel Resection</VALIDVALUE>
          <VALUEMEANING>Small Bowel Resected</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the digestive tube between the stomach and the cecum or beginning of the large intestine; it consists of three portions: duodenum, jejunum, and ileum. SYN intestinum tenue.: Resected; having been removed by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25654, C12386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supracricoid Laryngectomy</VALIDVALUE>
          <VALUEMEANING>Supracricoid Laryngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A conservation laryngeal surgery involving the resection of the true and false vocal cords, both paraglottic spaces, and the thyroid cartilage. In some cases the preepiglottic space and the epiglottis are also removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supraglottic Laryngectomy</VALIDVALUE>
          <VALUEMEANING>Supraglottic Laryngectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the portion of the larynx superior to the true vocal cords.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transanal Local Excision</VALIDVALUE>
          <VALUEMEANING>Anal Canal Local Excision</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.: Of or belonging to a restricted area or locality.: Removal or excision by surgical measures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15232, C67263, C12375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transoral Laser Excision (Glottis)</VALIDVALUE>
          <VALUEMEANING>Transoral Laser Surgery (Glottis)</VALUEMEANING>
          <MEANINGDESCRIPTION>An endoscopic laser microsurgical laryngeal procedure for patients with early glottis tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary Diversion</VALIDVALUE>
          <VALUEMEANING>Urinary Diversion</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical diversion of the urine flow following cystectomy or in patients with a non-functioning bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominoperineal Resection</VALIDVALUE>
          <VALUEMEANING>Abdominoperineal Resection</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic surgical procedure in which the anus, rectum, part of the sigmoid colon, and the regional lymph nodes are removed through abdominal and perineal incisions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adrenalectomy</VALIDVALUE>
          <VALUEMEANING>Adrenalectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Excision of one or both adrenal glands. (From Dorland, 28th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ampullectomy</VALIDVALUE>
          <VALUEMEANING>Ampullectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic endoscopic procedure performed to remove adenomas from the ampulla of Vater. It involves the excision of the ampulla of Vater and the implantation of the common bile duct and pancreatic main duct into the wall of duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appendectomy</VALIDVALUE>
          <VALUEMEANING>Appendectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the vermiform appendix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bilobectomy</VALIDVALUE>
          <VALUEMEANING>Bilobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic surgical procedure involving the removal of two lobes of the right lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bland Embolization</VALIDVALUE>
          <VALUEMEANING>Bland Embolization</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-chemotherapeutic embolization involving the injection of small particles through a catheter in the hepatic artery. It is performed to block the blood supply to liver cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central Liver Resection</VALIDVALUE>
          <VALUEMEANING>Central Hepatectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic surgical procedure to remove liver cancers located at the central segment of the liver. It involves the resection of the central hepatic segment with the left and right segments remaining intact.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91830</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Hepatectomy with Transplant</VALIDVALUE>
          <VALUEMEANING>Total Hepatectomy With Liver Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the entire liver.: Used to indicate the presence of something or someone.: The transference of a part of or an entire liver from one human or animal to another.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15271, C62355, C51781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extended Lobectomy</VALIDVALUE>
          <VALUEMEANING>Extended Lobectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Extension; an addition to the length of something.: (lo-BEK-toe-mee) The removal of a lobe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15272, C25270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extraperitoneal Lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>Extraperitoneal Lymphadenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>The space of the abdominal and pelvic cavities outside the peritoneum.: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15275, C92208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paraaortic Lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>Paraaortic Lymphadenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Regions near to the aorta.: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15275, C25316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic Lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>Pelvic Lymphadenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of one or more pelvic lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D&amp;C</VALIDVALUE>
          <VALUEMEANING>Dilation and Curettage</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical scraping and removal of the inner lining of the uterus through direct dilation of the uterine cervix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3528551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paracentesis</VALIDVALUE>
          <VALUEMEANING>Paracentesis</VALUEMEANING>
          <MEANINGDESCRIPTION>Insertion of a thin needle or tube into the abdomen to remove fluid from the peritoneal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracentesis</VALIDVALUE>
          <VALUEMEANING>Thoracentesis</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of excess fluid via needle puncture from the thoracic cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine Needle Aspirate</VALIDVALUE>
          <VALUEMEANING>Fine-Needle Aspiration</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of tissue or fluid with a thin needle for examination under a microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3226038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pap Smear</VALIDVALUE>
          <VALUEMEANING>Papanicolaou Smear Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2926792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radical Vulvectomy</VALIDVALUE>
          <VALUEMEANING>Radical Vulvectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to remove the entire vulva (the external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina) and nearby lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3774098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial Vulvectomy</VALIDVALUE>
          <VALUEMEANING>Partial Vulvectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to remove an affected area of the vulva (the external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina) along with a small amount of surrounding normal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3774096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stereotactic Biopsy</VALIDVALUE>
          <VALUEMEANING>Stereotactic Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>An X-ray procedure using multiple coordinates to precisely determine the location of a tumor or nodule so as to obtain a tissue sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3774109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Core Needle Biopsy</VALIDVALUE>
          <VALUEMEANING>Core Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3346664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal Hysterectomy</VALIDVALUE>
          <VALUEMEANING>Vaginal Hysterectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure to remove the uterine body and cervix, via the vaginal approach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apheresis</VALIDVALUE>
          <VALUEMEANING>Pheresis</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure that collects a component of the peripheral blood while returning the rest to the donor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15191</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumbar Puncture</VALIDVALUE>
          <VALUEMEANING>Lumbar Puncture</VALUEMEANING>
          <MEANINGDESCRIPTION>An invasive procedure in which a hollow needle is introduced through an intervertebral space in the lower back to access the subarachnoid space in order to sample cerebrospinal fluid or to administer medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspiration</VALIDVALUE>
          <VALUEMEANING>Aspiration</VALUEMEANING>
          <MEANINGDESCRIPTION>Procedure using suction, usually with a thin needle and syringe, to removal bodily fluid or tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3953965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bile Duct Resection with Anastomosis</VALIDVALUE>
          <VALUEMEANING>Hepaticojejunostomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A reconstructive surgical procedure involving the anastomosis of the hepatic duct to the jejunum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4645551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ommaya reservoir</VALIDVALUE>
          <VALUEMEANING>Ommaya Reservoir</VALUEMEANING>
          <MEANINGDESCRIPTION>A plastic, dome-shaped device, with a catheter attached to the underside used to deliver chemotherapy to the central nervous system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC Aligned NCI Standard Equivalent CDE</Name>
        <OrganizationName/>
        <DocumentType>CDISC Note</DocumentType>
        <DocumentText>This data element is to be used for CDISC aligned data collection in place of CDE 3131309 from the original NCI Standard CRF Template.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Procedure</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Procedure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnosis - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318328</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnosis Intervention - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318330</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="865">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7044582</PUBLICID>
    <LONGNAME>Vendor Name</LONGNAME>
    <PREFERREDNAME>BSNAM</PREFERREDNAME>
    <PREFERREDDEFINITION>The literal identifier of the vendor or laboratory that performs a biospecimen assessment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7044581</PublicId>
      <PreferredName>7044577v1.0:7044579v1.0</PreferredName>
      <PreferredDefinition>A findings domain that documents biospecimen handling information._The literal identifier of the vendor that performs an assessment or examination.</PreferredDefinition>
      <LongName>Biospecimen Domain Vendor Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7044577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111137</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111137</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Domain</LONG_NAME>
            <CON_ID>7044576</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7044579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117200</PreferredName>
        <Version>1</Version>
        <LongName>Vendor Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117200</PREFERRED_NAME>
            <LONG_NAME>Vendor Name</LONG_NAME>
            <CON_ID>7044578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353425</PublicId>
      <PreferredName>CDISCNAM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C42614</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Processing Laboratory Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Processing Laboratory Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Destination Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="866">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7051587</PUBLICID>
    <LONGNAME>Pediatric Child Household Composition Questionnaire Assessment Text</LONGNAME>
    <PREFERREDNAME>Pedi_Chil_Hous_Comp_Ques_ASSES</PREFERREDNAME>
    <PREFERREDDEFINITION>Having to do with children._An age group comprised of individuals who are not yet an adult. The specific cut-off age will vary by purpose._A social unit comprised of one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes._The way in which something is made, especially in terms of its different parts; its constituents._A predetermined set of questions._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7051586</PublicId>
      <PreferredName>Pedi_Chil_Hous_Comp_Ques</PreferredName>
      <PreferredDefinition>Having to do with children._An age group comprised of individuals who are not yet an adult. The specific cut-off age will vary by purpose._A social unit comprised of one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes._The way in which something is made, especially in terms of its different parts; its constituents._A predetermined set of questions.</PreferredDefinition>
      <LongName>Pediatric Child Household Composition Questionnaire</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4798257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39299</PreferredName>
        <Version>1</Version>
        <LongName>Pediatric</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39299</PREFERRED_NAME>
            <LONG_NAME>Pediatric</LONG_NAME>
            <CON_ID>2206340</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7051584</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16423:C41194:C53414:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Child Household Composition Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16423</PREFERRED_NAME>
            <LONG_NAME>Child</LONG_NAME>
            <CON_ID>2205406</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41194</PREFERRED_NAME>
            <LONG_NAME>Household</LONG_NAME>
            <CON_ID>2493178</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53414</PREFERRED_NAME>
            <LONG_NAME>Composition</LONG_NAME>
            <CON_ID>2512717</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Pediatric Child Household Composition Questionnaire Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Pediatric Child Household Composition Questionnaire Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pediatric Development</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6641383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="867">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7069470</PUBLICID>
    <LONGNAME>Patient Suicidal Ideation Personal Medical History Yes No Indicator</LONGNAME>
    <PREFERREDNAME>7069469v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator that asks if a person who receives medical care has a medical history of thoughts of taking one&#39;s own life.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7069469</PublicId>
      <PreferredName>2233604v1.0:7069467v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Thoughts of taking one&#39;s own life._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.</PreferredDefinition>
      <LongName>Patient Suicidal Ideation Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7069467</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80102:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Suicidal Ideation Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80102</PREFERRED_NAME>
            <LONG_NAME>Suicidal Ideation</LONG_NAME>
            <CON_ID>2944587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a histo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a history of suicidal thoughts?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="868">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7072119</PUBLICID>
    <LONGNAME>Scanner Patient Bed Position Number</LONGNAME>
    <PREFERREDNAME>SCNBEDNM</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of bed positions scanned using an emission scanner.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7071794</PublicId>
      <PreferredName>6407261v1.0:7071792v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._A scanner&#39;s narrow horizontal platform on which the subject lies to be moved axially within the gantry in order to position appropriate subject sections within the scanner&#39;s field of view._A reference to the alignment of an object, a particular situation or view of a situation, or the location of an object.</PreferredDefinition>
      <LongName>Procedure Domain Scanner Patient Bed Position</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102700</PreferredName>
        <Version>1</Version>
        <LongName>Procedure Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102700</PREFERRED_NAME>
            <LONG_NAME>Procedure Domain</LONG_NAME>
            <CON_ID>6407260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7071792</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95011:C104788</PreferredName>
        <Version>1</Version>
        <LongName>Scanner Patient Bed Position</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95011</PREFERRED_NAME>
            <LONG_NAME>Scanner Patient Bed</LONG_NAME>
            <CON_ID>7071791</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104788</PREFERRED_NAME>
            <LONG_NAME>Position</LONG_NAME>
            <CON_ID>5049971</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6623992</PublicId>
      <PreferredName>CDISCNUM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6623991</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25337</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of bed positions scann</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of bed positions scanned</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDISC Aligned NCI Standard Equivalent CDE</Name>
        <OrganizationName/>
        <DocumentType>CDISC Note</DocumentType>
        <DocumentText>This data element is to be used for CDISC aligned data collection in place of CDE 2717721 from the original NCI Standard CRF Template.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Emissions Scan - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318350</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="869">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7093927</PUBLICID>
    <LONGNAME>Breast Cancer AJCC Edition 8 Pathologic Distant Metastasis M Category</LONGNAME>
    <PREFERREDNAME>AJBR203P</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the distant metastasis for breast carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7093791</PublicId>
      <PreferredName>6607890v1.0:7093789v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to questionnaire._One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Caused by or altered by or manifesting disease or pathology._One criteria of the TNM staging system. M refers to the presence of metastasis.</PreferredDefinition>
      <LongName>Questionnaire Domain Breast Neoplasm Pathologic M Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607890</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49609</PreferredName>
        <Version>1</Version>
        <LongName>Questionnaire Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49609</PREFERRED_NAME>
            <LONG_NAME>Questionnaire Domain</LONG_NAME>
            <CON_ID>2469074</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7093789</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C3262:C25610:C25727</PreferredName>
        <Version>1</Version>
        <LongName>Breast Neoplasm Pathologic M Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25727</PREFERRED_NAME>
            <LONG_NAME>M Category</LONG_NAME>
            <CON_ID>2204010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6005691</PublicId>
      <PreferredName>6005691v1.0</PreferredName>
      <PreferredDefinition>A finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Breast Carcinoma American Joint Committee on Cancer Edition 8 M Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>6356799</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C139390:C39315:C25727:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Breast Cancer TNM Finding v8 American Joint Committee on Cancer M Category Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C139390</PREFERRED_NAME>
            <LONG_NAME>Breast Cancer TNM Finding v8</LONG_NAME>
            <CON_ID>6005562</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25727</PREFERRED_NAME>
            <LONG_NAME>M Category</LONG_NAME>
            <CON_ID>2204010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cM1</VALIDVALUE>
          <VALUEMEANING>Breast Cancer cM1 TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pM1</VALIDVALUE>
          <VALUEMEANING>Breast Cancer pM1 TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cM0</VALIDVALUE>
          <VALUEMEANING>Breast Cancer cM0 TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer without clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the cM0 category. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cM0(i+)</VALIDVALUE>
          <VALUEMEANING>Breast Cancer cM0(i+) TNM Finding v8</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer in which there is no clinical or radiographic evidence of distant metastases in the presence of tumor cells or deposits no larger than 0.2 mm detected microscopically or by molecular techniques in circulating blood, bone marrow, or other nonregional nodal tissue in a patient without symptoms or signs of metastases. (from AJCC 8th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6005695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic M category</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic M category</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318368</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC ED.8, Breast - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="870">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7118704</PUBLICID>
    <LONGNAME>Ancillary Study HBV Genotype Assay Text</LONGNAME>
    <PREFERREDNAME>7117850v1.00:6784451v2.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A textual description of an assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>DRAFT MOD</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7117850</PublicId>
      <PreferredName>7052721v1.0:7117848v1.0</PreferredName>
      <PreferredDefinition>A study that is secondary to another study._An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.</PreferredDefinition>
      <LongName>Ancillary Study HBV Genotype Assay</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3910</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Abnormality</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7052721</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16041</PreferredName>
        <Version>1</Version>
        <LongName>Ancillary Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16041</PREFERRED_NAME>
            <LONG_NAME>Ancillary Study</LONG_NAME>
            <CON_ID>2762310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7117848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117108</PreferredName>
        <Version>1</Version>
        <LongName>HBV Genotype Assay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117108</PREFERRED_NAME>
            <LONG_NAME>HBV Genotype Assay</LONG_NAME>
            <CON_ID>4458593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6784451</PublicId>
      <PreferredName>6784451v2.00</PreferredName>
      <PreferredDefinition>The words of something written.</PreferredDefinition>
      <LongName>Text</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>255</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>HBV Genotype</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bile duct and Liver</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6776762</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6779541</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="871">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7135903</PUBLICID>
    <LONGNAME>QuickDASH Outcome Measure 4 Last Week Ability to Wash Your Back Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>QDASH_4_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation in the last 4 weeks of their ability to wash their back, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7128438</PublicId>
      <PreferredName>7128426v1.0:7128436v1.0</PreferredName>
      <PreferredDefinition>An 11-item questionnaire designed to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb._The most recent week. May include the present day._A question about an individual&#39;s ability to wash their back._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>QuickDASH Outcome Measure Past Week Ability to Wash Your Back Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7128426</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C167293</PreferredName>
        <Version>1</Version>
        <LongName>QuickDASH Outcome Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C167293</PREFERRED_NAME>
            <LONG_NAME>QuickDASH Outcome Measure</LONG_NAME>
            <CON_ID>7122472</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7128436</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C167297:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Ability to Wash Your Back Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C167297</PREFERRED_NAME>
            <LONG_NAME>Ability to Wash Your Back Question</LONG_NAME>
            <CON_ID>7122476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7128547</PublicId>
      <PreferredName>7128547v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes with range from 1 &#39;No Difficulty&#39; to 5 &#39;Unable&#39;.</PreferredDefinition>
      <LongName>Difficulty 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Unable to Do</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is unable to do something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Severe Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had severe difficulty doing something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7128548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had moderate difficulty doing something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7128549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mild Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had mild difficulty doing something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7128550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>No Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has or had no difficulty doing something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7128551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Wash your back.</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Wash your back.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>QuickDASH Outcome Measure</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #4 of 11</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Quick Disabilities of the Arm and Shoulder and Hand (QuickDash)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900346</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7135883</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>QuickDASH Outcome Measure</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>QuickDASH Outcome Measure</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7135885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="872">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7147706</PUBLICID>
    <LONGNAME>Disease or Disorder Detection Days From Anchor Date Count</LONGNAME>
    <PREFERREDNAME>7147305v1.00:7069460v2.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of days between the date used for anchor/index and the date the lesion or tumor was detected.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>DRAFT MOD</WORKFLOWSTATUS>
    <CONTEXTNAME>MCL</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MCL:Molecular and Cellular Characterization of Screened Lesions</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7147305</PublicId>
      <PreferredName>2770347v1.0:7072102v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The activity of perceiving, discerning, discovering or identifying._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument._The base date from which all other dates within a cohort or data set are derived.</PreferredDefinition>
      <LongName>Disease or Disorder Detection Days From Anchor Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2770347</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C16210</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Detection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7072102</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25516:C160815</PreferredName>
        <Version>1</Version>
        <LongName>Day From Anchor Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25516</PREFERRED_NAME>
            <LONG_NAME>From</LONG_NAME>
            <CON_ID>2206220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C160815</PREFERRED_NAME>
            <LONG_NAME>Anchor Date</LONG_NAME>
            <CON_ID>6765617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7069460</PublicId>
      <PreferredName>7069460v2.00</PreferredName>
      <PreferredDefinition>To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>day</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Detection date number of days from anchor date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Template Name</Name>
        <OrganizationName/>
        <DocumentType>Data Collection Template</DocumentType>
        <DocumentText>clinicalcore_v0-1_template-1</DocumentText>
        <URL>https://mcl.nci.nih.gov/resources/standards/mcl-cdes</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA-Breast-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Days to detection date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Template Name 2</Name>
        <OrganizationName/>
        <DocumentType>Data Collection Template</DocumentType>
        <DocumentText>breast_v1-2_08sep2020.xlsx</DocumentText>
        <URL>https://mcl.nci.nih.gov/resources/standards/mcl-cdes</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5271073</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MCL Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6357645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5271073</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MCL Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7537143</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506112</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Breast</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7035094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6437797</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pre-Cancer Atlas (PCA) Pilot</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast PCA Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7001791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>days_to_detection_date</AlternateName>
        <AlternateNameType>MCL Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="873">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7153937</PUBLICID>
    <LONGNAME>IWG-MRT Myelofibrosis Symptom Response Accomplishment Indicator</LONGNAME>
    <PREFERREDNAME>7153936v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a IWG-MRT myelofibrosis symptom response was accomplished.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7153936</PublicId>
      <PreferredName>7158677v1.0:5152292v1.0</PreferredName>
      <PreferredDefinition>A greater than or equal to 50 percent reduction in the myeloproliferative neoplasm symptom assessment form total symptom score (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)_Something that has been achieved or completed successfully.</PreferredDefinition>
      <LongName>IWG-MRT Myelofibrosis Symptom Response Accomplishment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7158677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C168643</PreferredName>
        <Version>1</Version>
        <LongName>IWG-MRT Myelofibrosis Symptom Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C168643</PREFERRED_NAME>
            <LONG_NAME>IWG-MRT Myelofibrosis Symptom Response</LONG_NAME>
            <CON_ID>7158617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5152292</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C86038</PreferredName>
        <Version>1</Version>
        <LongName>Accomplishment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86038</PREFERRED_NAME>
            <LONG_NAME>Accomplishment</LONG_NAME>
            <CON_ID>3124083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a IWG-MRT myelofibrosis s</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a IWG-MRT myelofibrosis symptom response accomplished?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a symptom response achieved?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a symptom response achieved?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a symptom response achieved?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Was a symptom response achieved?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TDIS_MPN_symptom_response_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="874">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7155070</PUBLICID>
    <LONGNAME>Ancillary Study Prothrombin Time 3 Decimal Float</LONGNAME>
    <PREFERREDNAME>7118661v1.0:6841619v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A study that is secondary to another study._A finding that indicates the international normalized ratio of prothrombin time level in a sample._A number that can have its decimal point in any position.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7118661</PublicId>
      <PreferredName>7052721v1.0:7118659v1.0</PreferredName>
      <PreferredDefinition>A study that is secondary to another study._A finding that indicates the international normalized ratio of prothrombin time level in a sample.</PreferredDefinition>
      <LongName>Ancillary Study Prothrombin Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7052721</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16041</PreferredName>
        <Version>1</Version>
        <LongName>Ancillary Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16041</PREFERRED_NAME>
            <LONG_NAME>Ancillary Study</LONG_NAME>
            <CON_ID>2762310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7118659</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C157421</PreferredName>
        <Version>1</Version>
        <LongName>International Normalized Ratio of Prothrombin Time Level Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C157421</PREFERRED_NAME>
            <LONG_NAME>International Normalized Ratio of Prothrombin Time Level Finding</LONG_NAME>
            <CON_ID>7118658</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6841619</PublicId>
      <PreferredName>6841619v1.0</PreferredName>
      <PreferredDefinition>A number that can have its decimal point in any position.</PreferredDefinition>
      <LongName>3 Decimal Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>9999.999</DisplayFormat>
      <MaximumLength/>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>3</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue>.001</MinimumValue>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>2433735</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48150</PreferredName>
        <Version>1</Version>
        <LongName>Float</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48150</PREFERRED_NAME>
            <LONG_NAME>Float</LONG_NAME>
            <CON_ID>2433734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prothrombin Time</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prothrombin Time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bile duct and Liver</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6776762</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CHOL Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6779538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6779541</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="875">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7165836</PUBLICID>
    <LONGNAME>Other Reason for Tumor Score</LONGNAME>
    <PREFERREDNAME>TRREAS_OTH</PREFERREDNAME>
    <PREFERREDDEFINITION>A free text field that describes the other reason for a low pre-biopsy score.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7165835</PublicId>
      <PreferredName>6607916v1.0:7165833v1.0</PreferredName>
      <PreferredDefinition>A findings domain that represents quantitative measurements and/or qualitative assessments of the tumors identified in the TU domain._A minimum level or position or degree; less than normal in degree, intensity or amount._Earlier in time or order._The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis._A number or range of numeric values measuring performance, function, quality, or ability._An explanation of the cause of some phenomenon or action._Different than the one(s) previously specified or mentioned.</PreferredDefinition>
      <LongName>Tumor Results Domain Low Pre Biopsy Score Other Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106578</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Results Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106578</PREFERRED_NAME>
            <LONG_NAME>Tumor Results Domain</LONG_NAME>
            <CON_ID>6607915</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7165833</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7165833v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Low Prior Biopsy Score Other Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54722</PREFERRED_NAME>
            <LONG_NAME>Low</LONG_NAME>
            <CON_ID>2509528</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Reason for pre-biopsy s</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Reason for pre-biopsy score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="876">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7187799</PUBLICID>
    <LONGNAME>Subcategory for Substance Use</LONGNAME>
    <PREFERREDNAME>SU_SUSCAT_SPD</PREFERREDNAME>
    <PREFERREDDEFINITION>A sub-division of the SUCAT values based on sponsor defined characteristics.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRDS</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6412868</PublicId>
      <PreferredName>6408543v1.0:6412866v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to substance use._Classification of substance use data.</PreferredDefinition>
      <LongName>Substance Use Domain Substance Use Subcategory</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6408543</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49615</PreferredName>
        <Version>1</Version>
        <LongName>Substance Use Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49615</PREFERRED_NAME>
            <LONG_NAME>Substance Use Domain</LONG_NAME>
            <CON_ID>2469081</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6412866</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83427</PreferredName>
        <Version>1</Version>
        <LongName>Substance Use Subcategory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83427</PREFERRED_NAME>
            <LONG_NAME>Substance Use Subcategory</LONG_NAME>
            <CON_ID>6412865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7185228</PublicId>
      <PreferredName>SUSCAT_SPD</PreferredName>
      <PreferredDefinition>Classification of substance use data._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Substance Use Subcategory Clinical Study Sponsor Defined Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRDS</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>7185227</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83427:C70793:C165683:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Substance Use Subcategory Clinical Study Sponsor Defined Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83427</PREFERRED_NAME>
            <LONG_NAME>Substance Use Subcategory</LONG_NAME>
            <CON_ID>6412865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70793</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Sponsor</LONG_NAME>
            <CON_ID>2715021</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C165683</PREFERRED_NAME>
            <LONG_NAME>Defined</LONG_NAME>
            <CON_ID>7050024</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARTICIPANT&#39;S CURRENT HOUSEHOLD</VALIDVALUE>
          <VALUEMEANING>Secondhand Smoke Exposure in Current Household</VALUEMEANING>
          <MEANINGDESCRIPTION>Secondhand smoke exposure is present in the current household.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6788106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARTICIPANT&#39;S CHILDHOOD HOUSEHOLD</VALIDVALUE>
          <VALUEMEANING>Secondhand Smoke Exposure in Household during Childhood</VALUEMEANING>
          <MEANINGDESCRIPTION>Secondhand smoke exposure was present in the household during childhood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6788108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTHER</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the subcategory of t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the subcategory of the substance (used)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>[Substance (Used) Subcategory]; NULL</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>Sponsor-defined Controlled Terminology. The value for subcategory may be pre-printed on the CRF or hidden. SUSCAT can only be used if there is a SUCAT and it must be a subcategorization of SUCAT.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SUSCAT</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Maps directly to the SDTMIG variable.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form Completion Instructions</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>Record the Substance Use subcategory, if not pre-printed on the CRF.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If participant was exposed to second hand smoke, select exposure type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858962</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDISC (NRDS Implementation)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7066596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858962</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sponsor Defined</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7067375</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="877">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7197083</PUBLICID>
    <LONGNAME>Category for Healthcare Encounters</LONGNAME>
    <PREFERREDNAME>HO_HOCAT_SPD</PREFERREDNAME>
    <PREFERREDDEFINITION>A grouping of topic-variable values based on sponsor defined characteristics.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRDS</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6412966</PublicId>
      <PreferredName>6408410v1.0:6412964v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a subject&#39;s healthcare encounter._A classification of healthcare encounters data.</PreferredDefinition>
      <LongName>Healthcare Encounters Domain Healthcare Encounters Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6408410</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117757</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounters Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117757</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounters Domain</LONG_NAME>
            <CON_ID>6408409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6412964</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123940</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounters Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123940</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounters Category</LONG_NAME>
            <CON_ID>6412963</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7185263</PublicId>
      <PreferredName>HOCAT_SPD</PreferredName>
      <PreferredDefinition>A classification of healthcare encounters data._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Healthcare Encounters Category Clinical Study Sponsor Defined Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRDS</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>7185262</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123940:C70793:C165683:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounters Category Clinical Study Sponsor Defined Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123940</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounters Category</LONG_NAME>
            <CON_ID>6412963</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70793</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Sponsor</LONG_NAME>
            <CON_ID>2715021</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C165683</PREFERRED_NAME>
            <LONG_NAME>Defined</LONG_NAME>
            <CON_ID>7050024</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTHER</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the category of the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the category of the healthcare encounter?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH PROMPT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>[Healthcare Encounter Category]; NULL</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDASH Implementation Notes</Name>
        <OrganizationName/>
        <DocumentType>CDASH Implementation Note</DocumentType>
        <DocumentText>Sponsor-defined Controlled Terminology. This would most commonly be either a heading, or a pre-printed category value on the CRF and not a question to which the site would provide an answer. If a question is asked, the response would typically be a sponsor-defined codelist. If the form is laid out as a grid, then words such as &quot;Category&quot; can be included as the column header. Examples include HOSPITALIZATION and OUTPATIENT.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HOCAT</Name>
        <OrganizationName/>
        <DocumentType>CDASH to SDTM Mapping</DocumentType>
        <DocumentText>Maps directly to the SDTMIG variable.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Case Report Form Completion Instructions</Name>
        <OrganizationName/>
        <DocumentType>CDISC CRF Instruction</DocumentType>
        <DocumentText>If collected on the CRF, the sponsor provides instructions to ensure the data is entered as intended.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858962</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDISC (NRDS Implementation)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7066596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858962</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sponsor Defined</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7067375</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14943368</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>14943368v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Healthcare Encounters (HO) Domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14943386</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="878">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7283674</PUBLICID>
    <LONGNAME>Primary Disease Site Histologic Type Name</LONGNAME>
    <PREFERREDNAME>DZSITE_TYPE</PREFERREDNAME>
    <PREFERREDDEFINITION>Descriptive name of the primary disease site which may include histotype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7283667</PublicId>
      <PreferredName>7283665v1.0:2673286v1.0</PreferredName>
      <PreferredDefinition>The primary site of a disease of interest._Refers to the type of tissue in which a tumor originated.</PreferredDefinition>
      <LongName>Primary Site of Disease Histologic Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7283665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C158874</PreferredName>
        <Version>1</Version>
        <LongName>Primary Site of Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C158874</PREFERRED_NAME>
            <LONG_NAME>Primary Site of Disease</LONG_NAME>
            <CON_ID>7028337</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2673286</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61478</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61478</PREFERRED_NAME>
            <LONG_NAME>Histologic Type</LONG_NAME>
            <CON_ID>2553955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7283669</PublicId>
      <PreferredName>DZSITE_TYP_NM</PreferredName>
      <PreferredDefinition>The primary site of a disease of interest._Refers to the type of tissue in which a tumor originated._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Primary Site of Disease Histologic Type Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>150</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>7283668</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C158874:C61478:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Primary Site of Disease Histologic Type Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C158874</PREFERRED_NAME>
            <LONG_NAME>Primary Site of Disease</LONG_NAME>
            <CON_ID>7028337</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61478</PREFERRED_NAME>
            <LONG_NAME>Histologic Type</LONG_NAME>
            <CON_ID>2553955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LEUKEMIA: CHRONIC LYMPHOCYTIC</VALIDVALUE>
          <VALUEMEANING>Chronic Lymphocytic Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4264837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MERKEL CELL</VALIDVALUE>
          <VALUEMEANING>Merkel Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare malignant cutaneous tumor seen in elderly patients.  Its usual location is on the head, neck and extremities.  The tumor is composed of small round cells with scanty cytoplasm arranged in a trabecular pattern, or in ill-defined nodules or in a diffuse pattern.  The tumor cells contain cytoplasmic membrane-bound dense core granules resembling neurosecretory granules.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MELANOMA</VALIDVALUE>
          <VALUEMEANING>Melanoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5581342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BREAST: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Breast Carcinoma Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C4872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3590101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SKIN: SQUAMOUS CELL</VALIDVALUE>
          <VALUEMEANING>Skin Squamous Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4722553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BLADDER</VALIDVALUE>
          <VALUEMEANING>Bladder Urothelial Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>The most common morphologic subtype of urinary bladder carcinoma (over 90% of cases).  It arises from the transitional epithelium.  It most often affects males in their sixth and seventh decades of life.  Hematuria is the most common symptom at presentation.  Pathologic stage is the strongest predictor of survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ANUS</VALIDVALUE>
          <VALUEMEANING>Anus</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3625363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BREAST: DUCTAL</VALIDVALUE>
          <VALUEMEANING>Ductal Breast Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast.  Ductal carcinomas account for about two thirds of all breast cancers.  Two types of ductal carcinomas have been described: Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma, not otherwise specified.  The latter often spreads to the axillary lymph nodes and other anatomic sites.  The two forms of ductal carcinoma often coexist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4017</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LYMPHOMA: HODGKIN</VALIDVALUE>
          <VALUEMEANING>Hodgkin Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymphoma, previously known as Hodgkin&#39;s disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4981811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LYMPHOMA: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Lymphoma Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C3208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MULTIPLE MYELOMA</VALIDVALUE>
          <VALUEMEANING>Plasma Cell Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5581351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ESOPHAGUS: ADENOCARCINOMA</VALIDVALUE>
          <VALUEMEANING>Esophageal Adenocarcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4722733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>COLORECTAL</VALIDVALUE>
          <VALUEMEANING>Colorectal</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the colon and rectum, or to the entire large bowel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CERVIX</VALIDVALUE>
          <VALUEMEANING>Cervix Uteri</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LEUKEMIA: ACUTE LYMPHOBLASTIC/LYMPHOCYTIC</VALIDVALUE>
          <VALUEMEANING>Acute Lymphoblastic Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3322383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KIDNEY</VALIDVALUE>
          <VALUEMEANING>Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HEAD AND NECK</VALIDVALUE>
          <VALUEMEANING>Head and Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4320227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BREAST: LOBULAR</VALIDVALUE>
          <VALUEMEANING>Lobular Breast Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAIN</VALIDVALUE>
          <VALUEMEANING>Brain Central Nervous System</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.: The part of the nervous system that consists of the brain, spinal cord, and meninges.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12438, C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6763896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LEUKEMIA: CHRONIC MYELOID</VALIDVALUE>
          <VALUEMEANING>Chronic Myeloid Leukemia Pathway</VALUEMEANING>
          <MEANINGDESCRIPTION>Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LEUKEMIA: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Leukemia Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C3161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3323200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LYMPHOMA: FOLLICULAR</VALIDVALUE>
          <VALUEMEANING>Follicular Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LUNG: SMALL CELL</VALIDVALUE>
          <VALUEMEANING>Small Cell Lung Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3297699</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LUNG: SQUAMOUS CELL</VALIDVALUE>
          <VALUEMEANING>Squamous Cell Lung Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2956083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LUNG: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Lung Carcinoma Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C4878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3323202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SKIN: BASAL CELL</VALIDVALUE>
          <VALUEMEANING>Skin Basal Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2961462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SARCOMA</VALIDVALUE>
          <VALUEMEANING>Sarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant mesenchymal tumor for which a distinct line of differentiation cannot be determined. This term may be used for small biopsy specimens for which adequate tissue is not present for definitive classification.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SKIN: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Skin Carcinoma Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Skin cancer that arises in basal cells or squamous cells but not in melanocytes (pigment-producing cells of the skin).: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C4914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STOMACH</VALIDVALUE>
          <VALUEMEANING>Stomach</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine. The stomach is the primary organ of food digestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OTHER</VALIDVALUE>
          <VALUEMEANING>Specify Other</VALUEMEANING>
          <MEANINGDESCRIPTION>A directive to indicate a response not listed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157106</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6782229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UTERUS</VALIDVALUE>
          <VALUEMEANING>Uterus</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>THYROID</VALIDVALUE>
          <VALUEMEANING>Thyroid Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ESOPHAGUS: SQUAMOUS CELL</VALIDVALUE>
          <VALUEMEANING>Esophageal Squamous Cell Carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A squamous cell carcinoma arising from the esophagus.  It is associated with a long history of tobacco and alcohol abuse and is exceedingly rare before the age of 30.  The median age is around 65 in both males and females.  It is located mostly in the middle and lower third of the esophagus.  Grossly, polypoid, ulcerated, plaque-like and occult lesions have been described.  The microscopic features are the same as in other squamous cell carcinomas.  Any degree of differentiation may occur, and variation within a single tumor is common.  The prognosis is poor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4024</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4722729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LEUKEMIA: ACUTE MYELOID</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3171</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4263972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ESOPHAGUS: NOT OTHERWISE SPECIFIED</VALIDVALUE>
          <VALUEMEANING>Esophageal Carcinoma Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.: Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C3513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LYMPHOMA: DIFFUSE LARGE B CELL</VALIDVALUE>
          <VALUEMEANING>Diffuse Large B-Cell Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LUNG: ADENOCARCINOMA</VALIDVALUE>
          <VALUEMEANING>Lung Adenocarcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3106713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LIVER</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PROSTATE</VALIDVALUE>
          <VALUEMEANING>Prostate Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PANCREAS</VALIDVALUE>
          <VALUEMEANING>Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3297613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Primary disease site/histolog</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Primary disease site/histologic type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="879">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7290183</PUBLICID>
    <LONGNAME>Treatment Cohort Study EC10367 Code</LONGNAME>
    <PREFERREDNAME>TX_COH_STDY_10367_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The code that represents the information pertaining to protocol 10367 in which subsets of a defined population are identified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2497526</PublicId>
      <PreferredName>TX_COHORT_STDY</PreferredName>
      <PreferredDefinition>Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.</PreferredDefinition>
      <LongName>Treatment Cohort Study</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2497524</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15208</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15208</PREFERRED_NAME>
            <LONG_NAME>Cohort Study</LONG_NAME>
            <CON_ID>2497523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7290182</PublicId>
      <PreferredName>7290182v1.0</PreferredName>
      <PreferredDefinition>A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>EC10367 Cohort Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>250</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>4386398</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61512:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61512</PREFERRED_NAME>
            <LONG_NAME>Cohort</LONG_NAME>
            <CON_ID>2555083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG2</VALIDVALUE>
          <VALUEMEANING>SG2: Dose Expansion</VALUEMEANING>
          <MEANINGDESCRIPTION>SG2: Dose Expansion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7231944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG1</VALIDVALUE>
          <VALUEMEANING>SG1: Dose Escalation</VALUEMEANING>
          <MEANINGDESCRIPTION>SG1: Dose Escalation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6871986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Subgroup</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Subgroup</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="880">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7308907</PUBLICID>
    <LONGNAME>MUSE 1 Agreement Taking Medicine on Time was Easy Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MUSE_1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how easy it was to take medications on time, using a 4 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MUSE: Medication Understanding and Use Self-Efficacy Scale, Kenzie A. et al., Patient Education and Counseling 80, 2010; 372-376</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7308902</PublicId>
      <PreferredName>7308899v1.0:7308900v1.0</PreferredName>
      <PreferredDefinition>A tool designed to measure an individual&#39;s belief in their ability to understand instructions, use prescription medications, and adhere to medication regimens._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A response indicating that an individual feels or felt that taking their medicine on time was easy._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Medication Understanding and Use Self-Efficacy Scale Agreement Taking Medicine on Time was Easy Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7308899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C172283</PreferredName>
        <Version>1</Version>
        <LongName>Medication Understanding and Use Self-Efficacy Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C172283</PREFERRED_NAME>
            <LONG_NAME>Medication Understanding and Use Self-Efficacy Scale</LONG_NAME>
            <CON_ID>7297583</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7308900</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25369:C172284:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Agreement Taking Medicine on Time was Easy Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C172284</PREFERRED_NAME>
            <LONG_NAME>Taking Medicine on Time was Easy</LONG_NAME>
            <CON_ID>7297584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MUSE: Medication Understanding and Use Self-Efficacy Scale, Kenzie A. et al., Patient Education and Counseling 80, 2010; 372-376</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7308226</PublicId>
      <PreferredName>7308226v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes with ranges from 1 (Strongly Disagree) to 4 (Strongly Agree) on a 4-point Likert scale.</PreferredDefinition>
      <LongName>How Easy Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>MUSE: Medication Understanding and Use Self-Efficacy Scale, Kenzie A. et al., Patient Education and Counseling 80, 2010; 372-376</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Strongly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intense concurrence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Slightly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in slight agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5119337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Slightly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in slight disagreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5119338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Strongly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure.</DocumentText>
        <URL>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184839/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medication Understanding and Use Self-Efficacy Scale</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #1 of 8</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>It is easy for me to take my</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>It is easy for me to take my medicine on time.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7308267</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MUSE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MUSE</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7308364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="881">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7312805</PUBLICID>
    <LONGNAME>Patient Analgesic Agent Use Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>AGSC_AGT_USE_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indication of whether a patient is using analgesic agents that meets the criteria for participation in a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7312753</PublicId>
      <PreferredName>2233604v1.0:7312751v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary_Compounds that alleviate pain without loss of consciousness.  Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation.  Choice of analgesic may be determined by the type of pain.  These compounds include opioid, non-opioid and adjuvant analgesic agents._To put into action or service._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Analgesic Agent Use Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7312751</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C241:C95018:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Analgesic Agent Use Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C241</PREFERRED_NAME>
            <LONG_NAME>Analgesic Agent</LONG_NAME>
            <CON_ID>2202311</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95018</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>3248409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Be willing and able not to st</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Be willing and able not to start any new analgesic medications or change the dosages of any current analgesic medications (except acetaminophen (Tylenol) or NSAIDs (i.e., ibuprofen (Advil, Motrin), Naproxen (Aleve)) for the duration of the study.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6162769</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>URMC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>URCC Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6337044</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="882">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7339784</PUBLICID>
    <LONGNAME>Disease or Disorder Sickle Cell Disease Status Type</LONGNAME>
    <PREFERREDNAME>2512861v1.0:7339755v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the disease status of sickle cell disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2512861</PublicId>
      <PreferredName>2404658v1.0:2320064v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Disease or Disorder Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7339755</PublicId>
      <PreferredName>7339755v1.0</PreferredName>
      <PreferredDefinition>A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Sickle Cell Disease Status Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3285186</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C34383:C25688:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Sickle Cell Disease Status Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C34383</PREFERRED_NAME>
            <LONG_NAME>Sickle Cell Disease</LONG_NAME>
            <CON_ID>2593291</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recipient is receiving disease modifying therapy</VALIDVALUE>
          <VALUEMEANING>Recipient Receive Disease Change Therapeutic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who gets something._To take, accept, or get something offered._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The act of alteration or modification; changed or altered in form or character._Medical care intended to treat or cure a condition or lessen its symptoms. This includes the administration of drugs, surgical procedures, physical or psychotherapy, or the use of therapeutic devices.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25446, C2991, C25639, C53268, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 2, 3, 4, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7339757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hb electrophoresis (Hb S) &gt; 50% and clinical symptoms described are present</VALIDVALUE>
          <VALUEMEANING>Hemoglobin Electrophoresis Greater Than 50 Percentage And Sign or Symptom Present</VALUEMEANING>
          <MEANINGDESCRIPTION>The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb._The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode._A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A number with no fractional part, including the negative and positive numbers as well as zero.::50_A fraction or ratio with 100 understood as the denominator._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Objective evidence of disease perceptible to the examining practitioner (sign) and subjective evidence of disease perceived by the patient (symptom)._Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626, C100104, C37912, C25613, C45255::50, C61584, C16536, C16676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7339758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hb electrophoresis (Hb S) &gt; 50% and clinical symptoms described are absent</VALIDVALUE>
          <VALUEMEANING>Hemoglobin Electrophoresis Greater Than 50 Percentage And Absence of Signs or Symptoms</VALUEMEANING>
          <MEANINGDESCRIPTION>The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb._The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode._A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A number with no fractional part, including the negative and positive numbers as well as zero.::50_A fraction or ratio with 100 understood as the denominator._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Absence of detectable signs or symptoms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106101, C37912, C25613, C45255::50, C61584, C16536, C16676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7339759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hb electrophoresis (Hb S) ≤ 50% and clinical symptoms described are absent</VALIDVALUE>
          <VALUEMEANING>Hemoglobin Electrophoresis Less Than or Equal To 50 Percentage And Absence of Signs or Symptoms</VALUEMEANING>
          <MEANINGDESCRIPTION>The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb._The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::50_A fraction or ratio with 100 understood as the denominator._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Absence of detectable signs or symptoms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106101, C37912, C25613, C45255::50, C61586, C16536, C16676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7339760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hb electrophoresis (Hb S) ≤ 50% and clinical symptoms described are present</VALIDVALUE>
          <VALUEMEANING>Hemoglobin Electrophoresis Less Than or Equal To 50 Percentage And Sign or Symptom Present</VALUEMEANING>
          <MEANINGDESCRIPTION>The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb._The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::50_A fraction or ratio with 100 understood as the denominator._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Objective evidence of disease perceptible to the examining practitioner (sign) and subjective evidence of disease perceived by the patient (symptom)._Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626, C100104, C37912, C25613, C45255::50, C61586, C16536, C16676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15039494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the disease status of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the disease status of sickle cell disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of sickle cell disease?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>What is the status of sickle cell disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of sickle cell disease at the time of this report, or at the time of death?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the status of sickle cell disease at the time of this report, or at the time of death?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="883">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7342475</PUBLICID>
    <LONGNAME>Patient Prior Audiogram Improvement Yes No Not Evaluable Indicator</LONGNAME>
    <PREFERREDNAME>PT_HR_PR_ADGM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/not evalable response to whether patient experienced hearing improvement from prior audiogram.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7342472</PublicId>
      <PreferredName>2233604v1.0:7342470v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Earlier in time or order._A graphic record of the softest sounds that a person can hear at various frequencies, used to measure hearing loss._A condition superior to an earlier condition.</PreferredDefinition>
      <LongName>Patient Prior Audiogram Improvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7342470</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C92448:C94226</PreferredName>
        <Version>1</Version>
        <LongName>Prior Audiogram Improvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C92448</PREFERRED_NAME>
            <LONG_NAME>Audiogram</LONG_NAME>
            <CON_ID>3143341</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94226</PREFERRED_NAME>
            <LONG_NAME>Improvement</LONG_NAME>
            <CON_ID>3197285</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3682480</PublicId>
      <PreferredName>YES_NO_NE_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not evaluable.</PreferredDefinition>
      <LongName>Yes No Not Evaluable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>13</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is there an improvement in he</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is there an improvement in hearing compared to prior audiogram?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="884">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7351249</PUBLICID>
    <LONGNAME>CDISC Domain Clinical Report Type</LONGNAME>
    <PREFERREDNAME>QVAL_RPTTYP</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication of the type of report that was submitted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7351241</PublicId>
      <PreferredName>6409461v1.0:7385432v1.0</PreferredName>
      <PreferredDefinition>A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS)._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._A short textual account; having provided a short account.</PreferredDefinition>
      <LongName>CDISC Domain Clinical Report</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008555</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MED_RCD_AND_FORMS</PreferredName>
        <Version>1</Version>
        <LongName>Medical Records and Forms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6409461</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103182</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103182</PREFERRED_NAME>
            <LONG_NAME>CDISC Domain</LONG_NAME>
            <CON_ID>6409460</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7385432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7348666</PublicId>
      <PreferredName>7348666v1.0</PreferredName>
      <PreferredDefinition>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._A short textual account; having provided a short account._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Clinical Report Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008555</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MED_RCD_AND_FORMS</PreferredName>
        <Version>1</Version>
        <LongName>Medical Records and Forms</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>7385439</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C25375:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Report Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy of Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue from the breast for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2831195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast biopsy pathology report</VALIDVALUE>
          <VALUEMEANING>Breast Biopsy Pathology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.: A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28277, C15189, C12971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3794604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast MRI</VALIDVALUE>
          <VALUEMEANING>Breast Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12971, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3794603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast ultrasound</VALIDVALUE>
          <VALUEMEANING>Breast Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.: High frequency sound, generally with a frequency greater than 20,000 Hz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384, C12971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3794602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CBC with Differential</VALIDVALUE>
          <VALUEMEANING>Blood Cell Count with Differential</VALUEMEANING>
          <MEANINGDESCRIPTION>A hematologic procedure to determine the number of red blood cells, white blood cells, and platelets, including the white cell differential count and red cell morphology, in a blood sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6471396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central pathology review form</VALIDVALUE>
          <VALUEMEANING>Central Pathology Review Form</VALUEMEANING>
          <MEANINGDESCRIPTION>The process by which specimens are sent to a central lab for confirmatory analysis using standardized methods and result criteria in order to minimize inter-reviewer differences thereby improving the accuracy of pathology data.: A printed or electronic document with spaces to be filled out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19464, C71684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6763812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinic Note</VALIDVALUE>
          <VALUEMEANING>Clinical Note</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity.: A brief written record.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42619, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3523203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinic note documenting BCG therapy</VALIDVALUE>
          <VALUEMEANING>Clinical Note Documented BCG Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.: A brief written record.: Furnished with or supported by documents and documentation.: An immunotherapy regimen consisting of Bacillus Calmette-Guerin (BCG) that may be used in the treatment of bladder cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159996, C25356, C42619, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonoscopy</VALIDVALUE>
          <VALUEMEANING>Colonoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the luminal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT imaging report</VALIDVALUE>
          <VALUEMEANING>Medical Imaging Regulatory Report Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>In medicine, any technology which helps in visualization of any biological process, cell, tissue or organ for the screening, diagnosis, surgical procedure or therapy.: A type of report required by a regulatory agency.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C97107, C16831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6029622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CTEP-AERS report</VALIDVALUE>
          <VALUEMEANING>Cancer Therapy Evaluation Program Adverse Event Reporting System Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The program within the Division of Cancer Treatment and Diagnosis (DCTD) of the NCI which plans, assesses, and coordinates all aspects of clinical trials including extramural clinical research programs, internal resources, treatment methods and effectiveness, and compilation and exchange of data as it pertains to the development and evaluation of anticancer agents.: Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).: The act of providing a short account.: a group of independent but interrelated elements comprising a unified whole.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25651, C41331, C15794, C25375, C25700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 3, 4, 0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5874297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cystoscopy report</VALIDVALUE>
          <VALUEMEANING>Cystoscopy Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the urinary bladder or urethra.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16482, C25375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytogenetics/FISH</VALIDVALUE>
          <VALUEMEANING>Cytogenetics Fluorescence in Situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>The branch of biology that studies the cellular aspects of heredity, especially the chromosomes. Includes the study of disease states caused by numerical and structural chromosome abnormalities.: A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16487, C17563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6774815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily Pain Diary</VALIDVALUE>
          <VALUEMEANING>Daily Pain Diary</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.: The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.: A written record of an inividual&#39;s experiences and observations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159580, C3303, C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6825378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dMMR testing results</VALIDVALUE>
          <VALUEMEANING>DNA Mismatch Repair Deficiency Testing Outcome</VALUEMEANING>
          <MEANINGDESCRIPTION>A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.: The mismatch repair (MMR) system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops and heterologies generated during DNA replication and recombination. This function is critically dependent on the assembly of multimeric complexes involved in mismatch recognition and signal transduction to downstream repair events.: In medicine, a shortage of a substance (such as a vitamin or mineral) needed by the body.: A procedure for critical evaluation.: The result of an action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20200, C15336, C94372, C20639, C449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5873877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Echocardiogram</VALIDVALUE>
          <VALUEMEANING>Echocardiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An image of the heart produced by ultrasonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy report</VALIDVALUE>
          <VALUEMEANING>Endoscopic Procedure Report</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure that uses an endoscope to examine the inside of the body. An endoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4861271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye Exam</VALIDVALUE>
          <VALUEMEANING>Eye Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A test performed by an ophthalmologist or optometrist assessing vision and ability to focus on and discern objects, as well as other tests and examinations pertaining to the eyes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2831578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Form</VALIDVALUE>
          <VALUEMEANING>Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A printed or electronic document with spaces to be filled out.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3799943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging Report</VALIDVALUE>
          <VALUEMEANING>Imaging Technique Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3523202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging report PET/CT</VALIDVALUE>
          <VALUEMEANING>Medical Imaging Report Positron Emission Tomography Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>In medicine, any technology which helps in visualization of any biological process, cell, tissue or organ for the screening, diagnosis, surgical procedure or therapy.: A short textual account; having provided a short account.: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C17007, C25375, C16831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6774816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunophenotype reports</VALIDVALUE>
          <VALUEMEANING>Immunophenotype Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The characterization of a set of cells according to the antigens expressed.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C20072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Informed consent</VALIDVALUE>
          <VALUEMEANING>Informed Consent</VALUEMEANING>
          <MEANINGDESCRIPTION>Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2857225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node biopsy report</VALIDVALUE>
          <VALUEMEANING>Lymph Node Biopsy Report</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C15189, C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3611161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mammography</VALIDVALUE>
          <VALUEMEANING>Mammography</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging examination of the breast by means of x-rays.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular genetic testing</VALIDVALUE>
          <VALUEMEANING>Molecular Genetic Testing</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or produced by or consisting of molecules.: Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a specific disease or disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15709, C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6471394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular report</VALIDVALUE>
          <VALUEMEANING>Molecular Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or produced by or consisting of molecules.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5637294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular testing reports</VALIDVALUE>
          <VALUEMEANING>Molecular Testing Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or produced by or consisting of molecules.: A procedure for critical evaluation.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C15336, C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6338043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Spine</VALIDVALUE>
          <VALUEMEANING>MRI, Spine</VALUEMEANING>
          <MEANINGDESCRIPTION>A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Spine (Post-op)</VALIDVALUE>
          <VALUEMEANING>MRI, Spine (Post-op)</VALUEMEANING>
          <MEANINGDESCRIPTION>A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.: After surgery.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C28006, C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Spine (Pre-op)</VALIDVALUE>
          <VALUEMEANING>MRI, Spine (Pre-op)</VALUEMEANING>
          <MEANINGDESCRIPTION>A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.: Relating to or occurring during the period immediately before a surgical operation.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C54732, C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Whole brain</VALIDVALUE>
          <VALUEMEANING>MRI, Whole brain</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Whole brain (Post-op)</VALIDVALUE>
          <VALUEMEANING>MRI, Whole brain (Post-op)</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.: After surgery.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C28006, C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI, Whole brain (Pre-op)</VALIDVALUE>
          <VALUEMEANING>MRI, Whole brain (Pre-op)</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.: Relating to or occurring during the period immediately before a surgical operation.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C54732, C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5254834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Operative</VALIDVALUE>
          <VALUEMEANING>Operative</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring during or associated with a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Operative Note</VALIDVALUE>
          <VALUEMEANING>Operative Note</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring during or associated with a surgical procedure.: A brief written record.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42619, C54733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Operative pathology report</VALIDVALUE>
          <VALUEMEANING>Operative Pathology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring during or associated with a surgical procedure.: A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28277, C54733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology</VALIDVALUE>
          <VALUEMEANING>Pathology</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty concerned with the nature and cause of disease as expressed by changes in cellular or tissue structure and function caused by the disease process. (MSH98)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology Report</VALIDVALUE>
          <VALUEMEANING>Pathology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The description of cells and tissues made by a pathologist based on microscopic evidence, and sometimes used to make a diagnosis of a disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology Report from diagnostic procedures</VALIDVALUE>
          <VALUEMEANING>Pathology Report From Diagnostic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: Any procedure or test to diagnose a disease or disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18020, C25516, C28277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6659337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology Report from operative procedure</VALIDVALUE>
          <VALUEMEANING>Pathology Report From Operative Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: Occurring during or associated with a surgical procedure.: Any stepwise set of actions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79751, C54733, C25516, C28277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6659641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology Report of any documented axillary recurrence</VALIDVALUE>
          <VALUEMEANING>Pathology Report Any Documented Axillary Recurrence</VALUEMEANING>
          <MEANINGDESCRIPTION>A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.: One, some, every, or all without specification.: Furnished with or supported by documents and documentation.: Pertaining to the armpit area, including the lymph nodes that are located there.: To come back or to return.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3352, C13351, C25356, C81168, C28277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6659642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral blood flow report</VALIDVALUE>
          <VALUEMEANING>Peripheral Blood Circulation Report</VALUEMEANING>
          <MEANINGDESCRIPTION>On or near an edge or constituting an outer boundary; the outer area.: The movement of blood to and from the heart and to the rest of the body&#39;s organs, tissues, and cells through the network of arteries, veins, and capillaries. (NCI): A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16353, C25233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6347775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pre-operative imaging report</VALIDVALUE>
          <VALUEMEANING>Preoperative Medical Imaging Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or occurring during the period immediately before a surgical operation.: In medicine, any technology which helps in visualization of any biological process, cell, tissue or organ for the screening, diagnosis, surgical procedure or therapy.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16831, C54732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6588949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preparatory Interview Transcript</VALIDVALUE>
          <VALUEMEANING>Preparation Interview Transcript</VALUEMEANING>
          <MEANINGDESCRIPTION>The act or process of making something ready.: A conversation with an individual regarding his or her background and other personal and professional details, opinions on specific subjects posed by the interviewer, etc.: The initial RNA molecule produced by transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1936, C16751, C25625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6422926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiology report, other</VALIDVALUE>
          <VALUEMEANING>Radiology Report Other</VALUEMEANING>
          <MEANINGDESCRIPTION>The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.: A short textual account; having provided a short account.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25375, C17059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6622484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sentinel lymph node biopsy</VALIDVALUE>
          <VALUEMEANING>Sentinel Lymph Node Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spirometry, graphic record</VALIDVALUE>
          <VALUEMEANING>Graph Record Spirometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A drawing illustrating the relations between certain quantities plotted with reference to a set of axes.: Anything (e.g., a document) providing permanent evidence of or information about past events.: Measurement of the breathing capacity of the lung by means of a spirometer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85397, C25198, C37960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6046245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical Consult Transcript</VALIDVALUE>
          <VALUEMEANING>Surgical Consultation Transcript</VALUEMEANING>
          <MEANINGDESCRIPTION>of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.: A conference between two or more people to consider a particular question; the act of deliberating together; confering with another researcher, physician, or expert about an issue or a case.: The initial RNA molecule produced by transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1936, C41188, C25698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6422773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tissue block</VALIDVALUE>
          <VALUEMEANING>Tissue Block</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.: Blocks; refers to preserved specimens embedded in support material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C25436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transcript</VALIDVALUE>
          <VALUEMEANING>Transcript</VALUEMEANING>
          <MEANINGDESCRIPTION>The initial RNA molecule produced by transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6422774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor somatic variant testing result report</VALIDVALUE>
          <VALUEMEANING>Neoplasm Somatic Mutation Testing Outcome Report</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: Any mutation with an origin in cells that are not destined to become gametes. As a consequence, such mutations are not transmitted to progeny, though they will be transmitted during any mitosis within the individual. Somatic mutations may contribute to a broad variety of pathologies including cancer.: A procedure for critical evaluation.: The result of an action.: A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C20200, C15336, C18060, C3262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6535643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>High frequency sound, generally with a frequency greater than 20,000 Hz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3109382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Accessibility Interview Transcript</VALIDVALUE>
          <VALUEMEANING>Access Interview Transcript</VALUEMEANING>
          <MEANINGDESCRIPTION>The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.: A conversation with an individual regarding his or her background and other personal and professional details, opinions on specific subjects posed by the interviewer, etc.: The initial RNA molecule produced by transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1936, C16751, C25396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6422772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Audiometry Report</VALIDVALUE>
          <VALUEMEANING>Audiometric Test</VALUEMEANING>
          <MEANINGDESCRIPTION>Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5806321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axilla ultrasound</VALIDVALUE>
          <VALUEMEANING>Axilla Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>The underside concavity where the arm and the shoulder are joined.: High frequency sound, generally with a frequency greater than 20,000 Hz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384, C12674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3794601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axillary lymph node biopsy pathology report</VALIDVALUE>
          <VALUEMEANING>Axillary Lymph Node Biopsy Pathology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle. : Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.: A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28277, C15189, C12904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3794605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Baseline image summary</VALIDVALUE>
          <VALUEMEANING>Baseline Image Summary</VALUEMEANING>
          <MEANINGDESCRIPTION>A starting point to which things may be compared.: Any record of an imaging event whether physical or electronic.: A shortened version of a speech or written text, containing only the main points.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42581, C48179, C25213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6260074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow aspirate/biopsy and peripheral blood pathology reports</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Aspiration and Biopsy And Peripheral Blood Cell Pathology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which a small sample of bone marrow (soft, sponge-like tissue in the center of most bones) and bone is removed. A small area of skin and the surface of the bone underneath are numbed with an anesthetic. Then a special wide needle is pushed into the bone. A sample of liquid bone marrow is removed with a syringe attached to the needle. The syringe is then removed and the needle is rotated to remove a sample of the bone and the bone marrow. Both the bone marrow and bone samples are sent to a laboratory to be looked at under a microscope.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A general term describing the three cellular components of blood (white blood cells, red blood cells, and platelets), all which are made in the bone marrow. (Lymphoma Information Network Glossary): A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28277, C12519, C37912, C92958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6337037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Pathology</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Pathology</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18189, C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6471395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunohistochemistry Report</VALIDVALUE>
          <VALUEMEANING>Immunohistochemistry Assay Report</VALUEMEANING>
          <MEANINGDESCRIPTION>A short document that describes the data related to an immunohistochemical assay performed on a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10672192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fusion Report</VALIDVALUE>
          <VALUEMEANING>Gene Fusion Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Any hybrid gene formed from two previously separate genes. Such fusions occur as a result of translocation, intersititial deletion or chromosomal inversion, and often result in gene products with functions different from the two fusion partners. Gene fusions are associated frequently with hematological cancers, sarcomas and prostate cancer._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C20195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13168480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylation Report</VALIDVALUE>
          <VALUEMEANING>Methylation Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The covalent chemical or biochemical addition of a methyl group(s) to a compound. (NCI)_A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13168481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sequencing Report</VALIDVALUE>
          <VALUEMEANING>Sequence Analysis Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C17565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-03-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13168482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Audiogram</VALIDVALUE>
          <VALUEMEANING>Audiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A graphic record of the softest sounds that a person can hear at various frequencies, used to measure hearing loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAER</VALIDVALUE>
          <VALUEMEANING>Auditory Brainstem Response</VALUEMEANING>
          <MEANINGDESCRIPTION>A neurologic test of auditory brainstem function in response to auditory stimuli, used to diagnose suspected neurologic abnormalities of the 8th cranial nerve as well as the associated auditory pathways. It is an objective measurement of auditory pathway function from the auditory nerve to the mesencephalon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7994092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF AFP report</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid Alpha-Fetoprotein Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord._Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16278, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14737388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF hCGB report</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid Choriogonadotropin Subunit Beta 3 Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord._Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C17479, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14737389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum AFP report</VALIDVALUE>
          <VALUEMEANING>Serum Alpha-Fetoprotein Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins._Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16278, C13325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14737390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum hCGB report</VALIDVALUE>
          <VALUEMEANING>Serum Choriogonadotropin Subunit Beta 3 Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins._Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C17479, C13325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14737391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Audiometry report + audiogram</VALIDVALUE>
          <VALUEMEANING>Audiometric Test And Audiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A graphic record of the softest sounds that a person can hear at various frequencies, used to measure hearing loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92448, C37912, C38036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14822139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next Generation Sequencing</VALIDVALUE>
          <VALUEMEANING>Next Generation Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4448577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow Cytometry</VALIDVALUE>
          <VALUEMEANING>Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2974014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF Cytology</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid Cytology Report</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord._The light microscopic study of normal and abnormal cells in fine needle aspirates (FNAs), body cavity fluids, and smears._A short textual account; having provided a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C16491, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14968381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest X-ray</VALIDVALUE>
          <VALUEMEANING>Chest Radiography</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray examination of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT/MRI of metastatic sites</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Or Magnetic Resonance Imaging Metastatic Anatomic Site</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._Named locations of or within the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C14174, C16809, C37998, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15267629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT/MRI of Abdomen and Pelvis</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Or Magnetic Resonance Imaging Abdomen And Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12767, C37912, C12664, C16809, C37998, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15267628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT chest</VALIDVALUE>
          <VALUEMEANING>Chest Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Computed tomography of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15267627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone/PET scan</VALIDVALUE>
          <VALUEMEANING>Bone Scan Or Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclear imaging method used to evaluate pathological bone metabolism._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C37998, C17646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15267626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal ultrasound</VALIDVALUE>
          <VALUEMEANING>Transabdominal Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of ultrasound imaging in which the ultrasound probe is pressed against the skin of the abdomen in order to create an image of the abdominal organs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7742932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Report type:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Report type:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Tumor Profile Report Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Report type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of tumor marker report</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Type of imaging report</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Biomarker Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="885">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7351611</PUBLICID>
    <LONGNAME>Tumor Identifier Domain Magnetic Resonance Imaging With Additional Specified Image Yes No Unknown or Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>TU_TUMETHOD_MRISCATYN</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication as to whether or not the magnetic resonance imaging included certain specified images.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7351610</PublicId>
      <PreferredName>6607938v1.0:7351608v1.0</PreferredName>
      <PreferredDefinition>A domain that represents the data that uniquely identifies tumors._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._Used to indicate the presence of something or someone._Added; extra; further._Clearly and explicitly stated._Any record of an imaging event whether physical or electronic.</PreferredDefinition>
      <LongName>Tumor Identifier Domain Magnetic Resonance Imaging With Additional Specified Image</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607938</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106577</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Identifier Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106577</PREFERRED_NAME>
            <LONG_NAME>Tumor Identifier Domain</LONG_NAME>
            <CON_ID>6607937</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7351608</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7351608v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Magnetic Resonance Imaging With Additional Specified Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16809</PREFERRED_NAME>
            <LONG_NAME>Magnetic Resonance Imaging</LONG_NAME>
            <CON_ID>2202506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62355</PREFERRED_NAME>
            <LONG_NAME>With</LONG_NAME>
            <CON_ID>2532083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38024</PREFERRED_NAME>
            <LONG_NAME>Specified</LONG_NAME>
            <CON_ID>2211671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the MRI include additiona</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the MRI include additional specified images?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If an MRI of the brain was performed, did the MRI include orbital cuts?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="886">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7352172</PUBLICID>
    <LONGNAME>Doravirine Administration Indicator</LONGNAME>
    <PREFERREDNAME>PIFELTRO_CMOCCUR</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not the participant is receiving doravirine.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7351943</PublicId>
      <PreferredName>7351941v1.00:2320521v1.00</PreferredName>
      <PreferredDefinition>A pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), that is used to treat HIV infection. Upon oral administration, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</PreferredDefinition>
      <LongName>Doravirine Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7351941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C171848</PreferredName>
        <Version>1</Version>
        <LongName>Doravirine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C171848</PREFERRED_NAME>
            <LONG_NAME>Doravirine</LONG_NAME>
            <CON_ID>7351940</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25409</PreferredName>
        <Version>1</Version>
        <LongName>Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Currently receiving Pifeltro?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Currently receiving Pifeltro?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Evaluations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="887">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7352771</PUBLICID>
    <LONGNAME>Adverse Event Domain Regimen-Limiting Toxicity Wrong Classification Yes No Unknown or Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>SUPPAE_QVAL_AEDLT_NRPT</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication as to whether or not an institution failed to correctly identify any Regimen-Limiting Toxicities/Dose-Limiting Toxicities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7351706</PublicId>
      <PreferredName>2514626v1.0:7351704v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to an adverse event._A side effect of a drug or other treatment that is serious enough to necessitate a dose modification._Not accurate, correct, or appropriate._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Adverse Event Domain Regimen-Limiting Toxicity Wrong Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2514626</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49562</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Submission Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49562</PREFERRED_NAME>
            <LONG_NAME>Adverse Event Domain</LONG_NAME>
            <CON_ID>2469047</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7351704</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123282:C113666:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Regimen-Limiting Toxicity Wrong Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123282</PREFERRED_NAME>
            <LONG_NAME>Regimen-Limiting Toxicity</LONG_NAME>
            <CON_ID>4974874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113666</PREFERRED_NAME>
            <LONG_NAME>Wrong</LONG_NAME>
            <CON_ID>4144211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the site fail to correctl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the site fail to correctly identify any DLT&#39;s?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 100</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If the patient experienced adverse events during this reporting period, were there any AEs that the site failed to classify as DLTs that, according to the protocol, should have been classified as DLTs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If patient experienced adverse events, are there any adverse events that are DLTs according to protocol specification that were not identified as such by the institution?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="888">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7374304</PUBLICID>
    <LONGNAME>Patient Photograph Malignant Neoplasm Assessment Indicator</LONGNAME>
    <PREFERREDNAME>PHOTO_TUYN1</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not photos were taken of the malignant neoplasm.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640357</PublicId>
      <PreferredName>PT_PHOTO_MN_ASSESS</PreferredName>
      <PreferredDefinition>information relating to a patient assessment of a malignant neoplasm through use of photography (an image recorded by a camera).</PreferredDefinition>
      <LongName>Patient Photograph Malignant Neoplasm Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3202659</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C86035:C9305:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Photograph Malignant Neoplasm Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86035</PREFERRED_NAME>
            <LONG_NAME>Photograph</LONG_NAME>
            <CON_ID>3128143</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were Photos Taken?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were Photos Taken?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7312662</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PHOTO_TUYN2</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PHOTO_TUYN3</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PHOTO_TUYN4</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PHOTO_TUYN5</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="889">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7374430</PUBLICID>
    <LONGNAME>Patient Microsatellite Stability Assessment Hypermutation Carcinoma Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>MICSASSES_HYPER_CARC_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response to determine patient eligibility for clinical trial participation related to microsatellite stability assessment and other types of hypermutation carcinomas as outlined in the study protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7374429</PublicId>
      <PreferredName>2233604v1.0:7374438v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An assessment of the variability in length of an individual&#39;s microsatellite sequences; microsatellite length instability may be due to mismatch repair protein mutation._The presence of a hypermutation phenotype in non-germline cells._A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Microsatellite Stability Assessment Somatic Hypermutation Carcinoma Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7374438</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C139286:C162516:C2916:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Microsatellite Stability Assessment Somatic Hypermutation Carcinoma Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C139286</PREFERRED_NAME>
            <LONG_NAME>Microsatellite Stability Assessment</LONG_NAME>
            <CON_ID>6033166</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C162516</PREFERRED_NAME>
            <LONG_NAME>Somatic Hypermutation</LONG_NAME>
            <CON_ID>6819478</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2916</PREFERRED_NAME>
            <LONG_NAME>Carcinoma</LONG_NAME>
            <CON_ID>2202711</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have evidence of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have evidence of one or more of the following in current or previous tumor: Microsatellite instability (MSI-H); Mutation causing functional loss of mismatch repair gene expression (MLH1, MSH2, MSH6, PMS2, EPCAM or MSH3); Hypermutation in any tumor (including primary malignancy for patients with relapse or previous cancer diagnoses); Functional mutation of POLE or POLD1 genes; a syndrome linked to hypermutant cancer predisposition such as congenital mismatch repair deficiency (CMMRD), Lynch syndrome, or xeroderma pigmentosum (XP)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="890">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7374760</PUBLICID>
    <LONGNAME>Kaposi Sarcoma Lesion Additional Information Specify</LONGNAME>
    <PREFERREDNAME>TUCHANGE_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of additional information related to the Kaposi sarcoma lesion.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7374757</PublicId>
      <PreferredName>7372488v1.0:7374755v1.0</PreferredName>
      <PreferredDefinition>A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Added; extra; further._Knowledge derived from study, experience, or instruction that has been gathered or received by communication.</PreferredDefinition>
      <LongName>Kaposi Sarcoma Lesion Additional Information</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7372488</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9087:C3824</PreferredName>
        <Version>1</Version>
        <LongName>Kaposi Sarcoma Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9087</PREFERRED_NAME>
            <LONG_NAME>Kaposi Sarcoma</LONG_NAME>
            <CON_ID>2637488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7374755</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C48191</PreferredName>
        <Version>1</Version>
        <LongName>Additional Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7374759</PublicId>
      <PreferredName>7374759v1.0</PreferredName>
      <PreferredDefinition>Added; extra; further._Knowledge derived from study, experience, or instruction that has been gathered or received by communication._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Additional Information Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>255</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
      <Representation>
        <PublicId>7374758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C48191:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Additional Information Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please provide any additional</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please provide any additional information on lesions that fused, broke apart, or central clearing</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7312662</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="891">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7375422</PUBLICID>
    <LONGNAME>Upper Arm Curie mIBG Score</LONGNAME>
    <PREFERREDNAME>TRORRES_SPD_CSR6</PREFERREDNAME>
    <PREFERREDDEFINITION>The Curie mIBG score assigned to the upper arms segment to indicate the quantity of metastases, as defined by the sponsor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7375382</PublicId>
      <PreferredName>6607916v1.0:7375380v1.0</PreferredName>
      <PreferredDefinition>A findings domain that represents quantitative measurements and/or qualitative assessments of the tumors identified in the TU domain._The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb._A score assigned to a Curie body segment to indicate the quantity of metastases._The outcome of the tumor results assessment as originally received or collected.</PreferredDefinition>
      <LongName>Tumor Results Domain Arm Curie Extension Score Tumor Results Original Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106578</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Results Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106578</PREFERRED_NAME>
            <LONG_NAME>Tumor Results Domain</LONG_NAME>
            <CON_ID>6607915</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7375380</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C32141:C133467:C117416</PreferredName>
        <Version>1</Version>
        <LongName>Arm Curie Extension Score Tumor Results Original Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32141</PREFERRED_NAME>
            <LONG_NAME>Arm</LONG_NAME>
            <CON_ID>2202427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C133467</PREFERRED_NAME>
            <LONG_NAME>Curie Extension Score</LONG_NAME>
            <CON_ID>5768600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117416</PREFERRED_NAME>
            <LONG_NAME>Tumor Results Original Result</LONG_NAME>
            <CON_ID>6641911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7375364</PublicId>
      <PreferredName>TRORRES_SCOR_SPD</PreferredName>
      <PreferredDefinition>The outcome of the tumor results assessment as originally received or collected._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Tumor Results Original Result Clinical Study Sponsor Defined Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>7377996</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117416:C70793:C165683:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Results Original Result Clinical Study Sponsor Defined Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117416</PREFERRED_NAME>
            <LONG_NAME>Tumor Results Original Result</LONG_NAME>
            <CON_ID>6641911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70793</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Sponsor</LONG_NAME>
            <CON_ID>2715021</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C165683</PREFERRED_NAME>
            <LONG_NAME>Defined</LONG_NAME>
            <CON_ID>7050024</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Curie Extension Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>Diffuse involvement within a segment (&gt;50% of the segment).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5796792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Curie Extension Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>More than one metastatic site within a segment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5796793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Curie Extension Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>One metastatic site within a segment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5796794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Curie Extension Score 0</VALUEMEANING>
          <MEANINGDESCRIPTION>No metastatic sites within a segment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5796795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Upper arms</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Upper arms</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="892">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7381115</PUBLICID>
    <LONGNAME>Patient Experience 4000 Character Text</LONGNAME>
    <PREFERREDNAME>7381114v1.0:6847557v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the patient&#39;s experience.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7381114</PublicId>
      <PreferredName>2233604v1.0:3105451v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The accumulation of knowledge or skill that results from direct participation in events or activities.</PreferredDefinition>
      <LongName>Patient Experience</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3105451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54627</PreferredName>
        <Version>1</Version>
        <LongName>Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6847557</PublicId>
      <PreferredName>6847557v1.0</PreferredName>
      <PreferredDefinition>The words of something written.</PreferredDefinition>
      <LongName>4000 Character Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4000</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the patient&#39;s experi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the patient&#39;s experience?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is there anything else you would like to share with researchers about your experience?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Is there anything else you would like to share with researchers about your experience?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is there anything else you would like to share with researchers about your experience?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is there anything else you would like to share with researchers about your experience?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="893">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7391785</PUBLICID>
    <LONGNAME>Cohort</LONGNAME>
    <PREFERREDNAME>COHORT</PREFERREDNAME>
    <PREFERREDDEFINITION>One or more characters used to identify, name, or define the cohort.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7391776</PublicId>
      <PreferredName>6409089v1.0:7391774v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics._A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke)._The description of the characteristics that define a cohort.</PreferredDefinition>
      <LongName>Demographics Domain Cohort Study Cohort Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008529</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RSCH_PROT</PreferredName>
        <Version>1</Version>
        <LongName>Research Protocols</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6409089</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49572</PreferredName>
        <Version>1</Version>
        <LongName>Demographics Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49572</PREFERRED_NAME>
            <LONG_NAME>Demographics Domain</LONG_NAME>
            <CON_ID>2469053</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7391774</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15208:C166209</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Study Cohort Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15208</PREFERRED_NAME>
            <LONG_NAME>Cohort Study</LONG_NAME>
            <CON_ID>2497523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C166209</PREFERRED_NAME>
            <LONG_NAME>Cohort Description</LONG_NAME>
            <CON_ID>7391773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7391780</PublicId>
      <PreferredName>COHORTID</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics._A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke)._The description of the characteristics that define a cohort._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Demographics Domain Cohort Study Description Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008529</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RSCH_PROT</PreferredName>
        <Version>1</Version>
        <LongName>Research Protocols</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>7391779</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49572:C15208:C166209:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Demographics Domain Cohort Study Cohort Description Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49572</PREFERRED_NAME>
            <LONG_NAME>Demographics Domain</LONG_NAME>
            <CON_ID>2469053</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15208</PREFERRED_NAME>
            <LONG_NAME>Cohort Study</LONG_NAME>
            <CON_ID>2497523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C166209</PREFERRED_NAME>
            <LONG_NAME>Cohort Description</LONG_NAME>
            <CON_ID>7391773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>COHORT 2</VALIDVALUE>
          <VALUEMEANING>Cohort Description 2</VALUEMEANING>
          <MEANINGDESCRIPTION>The description of the characteristics that define a cohort.: A number with no fractional part, including the negative and positive numbers as well as zero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255, C166209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7391791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B - DL-2</VALIDVALUE>
          <VALUEMEANING>10130 Treatment Assignment Code Four</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::10130: An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835, C165236, C45255::10130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B - DL-1</VALIDVALUE>
          <VALUEMEANING>10130 Treatment Assignment Code Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::10130: An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834, C165236, C45255::10130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B - DL1</VALIDVALUE>
          <VALUEMEANING>10130 Treatment Assignment Code Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::10130: An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833, C165236, C45255::10130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A - DL1</VALIDVALUE>
          <VALUEMEANING>10130 Treatment Assignment Code One</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::10130: An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832, C165236, C45255::10130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DL6</VALIDVALUE>
          <VALUEMEANING>Cohort Study 9681 Treatment Assignment Description Six</VALUEMEANING>
          <MEANINGDESCRIPTION>A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).: A number with no fractional part, including the negative and positive numbers as well as zero.::9681: A complete description of each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66837, C165237, C45255::9681, C15208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DL2</VALIDVALUE>
          <VALUEMEANING>Cohort Study 9681 Treatment Assignment Description Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).: A number with no fractional part, including the negative and positive numbers as well as zero.::9681: A complete description of each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833, C165237, C45255::9681, C15208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7392319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>COHORT 1</VALIDVALUE>
          <VALUEMEANING>Cohort Description 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The description of the characteristics that define a cohort.: A number with no fractional part, including the negative and positive numbers as well as zero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255, C166209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7391786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG1</VALIDVALUE>
          <VALUEMEANING>Clinical Study Population Subgroup 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Relatively uniform groups (e.g. etiologically and pathogenetically more homogeneous, racial, ethnic, or gender-specific, or the disease- or condition-specific) of study subjects formed within a clinical study population for a separate analysis. The selection of the subgroups, methods of subgroup analysis, and anticipated difference in observation outcome(s) have to be defined and justified in the study protocol and based on known biological mechanisms, and/or findings in previous studies.: A number with no fractional part, including the negative and positive numbers as well as zero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255, C70730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7391781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TAC1</VALIDVALUE>
          <VALUEMEANING>Treatment Assignment Code 1</VALUEMEANING>
          <MEANINGDESCRIPTION>An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.: A number with no fractional part, including the negative and positive numbers as well as zero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255, C165236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7391802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cohort</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cohort</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="894">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7402836</PUBLICID>
    <LONGNAME>Recovered or Resolved From Therapeutic Procedure Date</LONGNAME>
    <PREFERREDNAME>7402835v1.0:2018550v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which the patient has recovered from treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7402835</PublicId>
      <PreferredName>7402832v1.0:7402833v1.0</PreferredName>
      <PreferredDefinition>One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated._Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument._Treatment.</PreferredDefinition>
      <LongName>Recovered or Resolved From Therapeutic Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7402832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49498</PreferredName>
        <Version>1</Version>
        <LongName>Recovered or Resolved</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49498</PREFERRED_NAME>
            <LONG_NAME>Recovered from Adverse Event</LONG_NAME>
            <CON_ID>2452936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7402833</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25516:C49236</PreferredName>
        <Version>1</Version>
        <LongName>From Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25516</PREFERRED_NAME>
            <LONG_NAME>From</LONG_NAME>
            <CON_ID>2206220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Recovered from Intervent</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Recovered from Intervention</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QVAL_RCVYDAT</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="895">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7409069</PUBLICID>
    <LONGNAME>Genomic Medicine Implementation Genomics Outcome Scale Assessment Scale</LONGNAME>
    <PREFERREDNAME>7406128v1.0:2016428v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A medical discipline that uses genomic information about an individual as part of their clinical care (e.g. for diagnostic or therapeutic decision-making) and for the health outcomes and policy implications of that clinical use. (NIH/NHGRI)_The act of carrying into effect._A 6-item patient-reported outcome used to evaluate patient empowerment after they have received genetic counseling and testing services._the scale to determine the patient&#39;s assessment of general health.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7406128</PublicId>
      <PreferredName>7406464v1.0:7409068v1.0</PreferredName>
      <PreferredDefinition>A medical discipline that uses genomic information about an individual as part of their clinical care (e.g. for diagnostic or therapeutic decision-making) and for the health outcomes and policy implications of that clinical use. (NIH/NHGRI)_The act of carrying into effect._A 6-item patient-reported outcome used to evaluate patient empowerment after they have received genetic counseling and testing services.</PreferredDefinition>
      <LongName>Genomic Medicine Implementation Genomics Outcome Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7406464</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C174131:C47899</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Medicine Implementation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C174131</PREFERRED_NAME>
            <LONG_NAME>Genomic Medicine</LONG_NAME>
            <CON_ID>7406463</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47899</PREFERRED_NAME>
            <LONG_NAME>Implementation</LONG_NAME>
            <CON_ID>2427515</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7409068</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C174135</PreferredName>
        <Version>1</Version>
        <LongName>Genomics Outcome Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C174135</PREFERRED_NAME>
            <LONG_NAME>Genomics Outcome Scale</LONG_NAME>
            <CON_ID>7408866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016428</PublicId>
      <PreferredName>ASSESS_SCALE</PreferredName>
      <PreferredDefinition>the scale to determine the patient&#39;s assessment of general health.</PreferredDefinition>
      <LongName>Assessment Scale</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>All of the time</VALIDVALUE>
          <VALUEMEANING>All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Most of the time</VALIDVALUE>
          <VALUEMEANING>Most of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A good bit of the time</VALIDVALUE>
          <VALUEMEANING>A Good Bit of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened a good bit of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Some of the time</VALIDVALUE>
          <VALUEMEANING>Some of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened some of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little of the time</VALIDVALUE>
          <VALUEMEANING>A Little of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened a little of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the time</VALIDVALUE>
          <VALUEMEANING>None of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened none of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted totally</VALIDVALUE>
          <VALUEMEANING>Disrupted totally</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was totally disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted quite a bit</VALIDVALUE>
          <VALUEMEANING>Disrupted quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted somewhat</VALIDVALUE>
          <VALUEMEANING>Disrupted somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disrupted a little</VALIDVALUE>
          <VALUEMEANING>Disrupted a little</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was a little disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not disrupted at all</VALIDVALUE>
          <VALUEMEANING>Not disrupted at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not at all disrupted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable/have not received instructions about taking 6MP</VALIDVALUE>
          <VALUEMEANING>Not Applicable Have Negation Receive Instruction Approximate Take Six Mercaptopurine</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.: Used to describe the possession, relationships, or the state of something or someone.: An operation in which a term denies or inverts the meaning of another term or construction.: To take, accept, or get something offered.: A message describing how something is to be done.: Not quite exact or correct; almost exact or correct.: As pertains to a medication: ingest, inhale, instill, or inject.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C195, C66837, C65105, C45828, C42688, C25639, C25594, C101282, C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7, 8</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About half of the time</VALIDVALUE>
          <VALUEMEANING>Approximate Half Time</VALUEMEANING>
          <MEANINGDESCRIPTION>Not quite exact or correct; almost exact or correct.: One of two equal parts; a quantity corresponding to one half of the whole.: The continuum of experience in which events pass from the future through the present to the past.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25207, C81009, C45828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5782772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>All or almost all the time</VALIDVALUE>
          <VALUEMEANING>All of the Time Or Almost All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened all of the time.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986, C37998, C110990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6630428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None or almost none of the time</VALIDVALUE>
          <VALUEMEANING>None of the Time Or Nearly None of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened none of the time.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Not quite or just short of.: A response indicating that something happens or happened none of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110994, C107222, C37998, C110994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6630427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>The Genomics Outcome Scale (G</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>The Genomics Outcome Scale (GOS) is a 6-item version of the 24-item Genetic Counselling Outcome Scale (GCOS-24). The survey focuses on empowerment.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Genomic Medicine Implementation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7407613</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="896">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7412450</PUBLICID>
    <LONGNAME>Bone Marrow Aspirate Volume Measurement  Milliliter Value</LONGNAME>
    <PREFERREDNAME>7412449v1.0:2823505v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric milliliter volume of the bone marrow aspirate.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7412449</PublicId>
      <PreferredName>6692755v1.0:7412447v1.0</PreferredName>
      <PreferredDefinition>Aspirate from bone marrow._The determination of the volume of a sample.</PreferredDefinition>
      <LongName>Bone Marrow Aspirate Volume Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6692755</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C133261</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Aspirate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C133261</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow Aspirate</LONG_NAME>
            <CON_ID>6692735</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7412447</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74720</PreferredName>
        <Version>1</Version>
        <LongName>Volume Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74720</PREFERRED_NAME>
            <LONG_NAME>Volume Measurement</LONG_NAME>
            <CON_ID>2896077</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2823505</PublicId>
      <PreferredName>VOL_ML_VAL</PreferredName>
      <PreferredDefinition>The amount of three dimensional space occupied by an object or the capacity of a space or container._A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Volume Milliliter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>ml</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2823504</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25335:C28254:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Volume Milliliter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28254</PREFERRED_NAME>
            <LONG_NAME>Milliliter</LONG_NAME>
            <CON_ID>2204829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Volume of Bone Marrow Collect</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Volume of Bone Marrow Collected:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>All Procurement CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409066</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="897">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7415495</PUBLICID>
    <LONGNAME>How Often Bothered by Problems Mouth Sore Occurrence Lee cGVHD Symptom Scale</LONGNAME>
    <PREFERREDNAME>7415494v1.0:7414600v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The measurement of how often bothered by a mouth sore occurrence based on the Lee cGVHD symptom scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7415494</PublicId>
      <PreferredName>7415492v1.0:2234856v1.0</PreferredName>
      <PreferredDefinition>A question about how often an individual is or was bothered by problems._An inflammatory lesion on the mucosal surface of the oral cavity._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>How Often Bothered by Problems Mouth Sore Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7415492</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107246:C27157</PreferredName>
        <Version>1</Version>
        <LongName>How Often Bothered by Problems Mouth Sore</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107246</PREFERRED_NAME>
            <LONG_NAME>How Often Bothered by Problems Question</LONG_NAME>
            <CON_ID>3812636</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27157</PREFERRED_NAME>
            <LONG_NAME>Mouth Sore</LONG_NAME>
            <CON_ID>2871865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7414600</PublicId>
      <PreferredName>7414600v1.0</PreferredName>
      <PreferredDefinition>A self-report questionnaire containing 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological), developed to measure symptoms of chronic graft-versus-host disease. Patients report their level of symptom bother on a 5-point Likert scale.</PreferredDefinition>
      <LongName>Lee cGVHD Symptom Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>7414599</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C174431</PreferredName>
        <Version>1</Version>
        <LongName>Lee Chronic Graft-versus-Host Disease Symptom Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C174431</PREFERRED_NAME>
            <LONG_NAME>Lee Chronic Graft-versus-Host Disease Symptom Scale</LONG_NAME>
            <CON_ID>7414564</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>Extreme</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5576772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3014718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often bothered are you bo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often bothered are you bothered by mouth sores?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you been bothered by ulcers in mouth?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Have you been bothered by ulcers in mouth?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you been bothered by ulcers in mouth?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you been bothered by ulcers in mouth?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you been bothered by ulcers in mouth in the past 7 days?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you been bothered by ulcers in mouth in the past 7 days?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="898">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7421807</PUBLICID>
    <LONGNAME>Cytomegalovirus Reactivation Second Event Treatment Start Date</LONGNAME>
    <PREFERREDNAME>CMVRCT_SCEV_TX_ST_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Start date of treatment related to the second CMV reactivation event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7421742</PublicId>
      <PreferredName>7421665v1.0:7421740v1.0</PreferredName>
      <PreferredDefinition>A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection._Coming next after the first in position in space or time or degree or magnitude._Something that happens at a given place and time._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.</PreferredDefinition>
      <LongName>Cytomegalovirus Reactivation Finding Second Event Therapeutic Procedure Begin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7421665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C148545</PreferredName>
        <Version>1</Version>
        <LongName>Cytomegalovirus Reactivation Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C148545</PREFERRED_NAME>
            <LONG_NAME>Cytomegalovirus Reactivation Finding</LONG_NAME>
            <CON_ID>6272244</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7421740</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C25499:C49236:C25431</PreferredName>
        <Version>1</Version>
        <LongName>Second Event Therapeutic Procedure Begin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCR:Center for Cancer Research</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Second CMV reactivation treat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Second CMV reactivation treatment start date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="899">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7434352</PUBLICID>
    <LONGNAME>Tumor Measurable Indicator</LONGNAME>
    <PREFERREDNAME>TU_TUORRES_MEASIND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication as to whether a measurable tumor is present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDISC Harmonization</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7434266</PublicId>
      <PreferredName>6607938v1.0:7434264v1.0</PreferredName>
      <PreferredDefinition>A domain that represents the data that uniquely identifies tumors._An indication as to whether a measurable tumor is present.</PreferredDefinition>
      <LongName>Tumor Identifier Domain Measurable Tumor Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607938</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106577</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Identifier Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106577</PREFERRED_NAME>
            <LONG_NAME>Tumor Identifier Domain</LONG_NAME>
            <CON_ID>6607937</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7434264</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C161482</PreferredName>
        <Version>1</Version>
        <LongName>Measurable Tumor Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C161482</PREFERRED_NAME>
            <LONG_NAME>Measurable Tumor Indicator</LONG_NAME>
            <CON_ID>6859322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CTEP CDISC Harmonization</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the tumor measurable?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the tumor measurable?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Measurable</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Measurable</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7434158</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CTEP CDISC Harmonization</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC RECIST v1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7473993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="900">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7446913</PUBLICID>
    <LONGNAME>Laboratory Data Domain Laboratory Test Not Done Specify</LONGNAME>
    <PREFERREDNAME>SUPPLB_QVAL_LBEVL_MIS_OTHS</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of a test or evaluation that was not performed.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7446912</PublicId>
      <PreferredName>6401816v1.0:7446910v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to laboratory data._A character or string that represents the full name of the laboratory assessment._Indicates a task, process or examination that has either not been initiated or not been completed._A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Laboratory Data Domain Laboratory Test Not Done Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6401816</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49592</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Data Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49592</PREFERRED_NAME>
            <LONG_NAME>Laboratory Data Domain</LONG_NAME>
            <CON_ID>2469066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7446910</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C117142:C49484:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Not Done Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117142</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Name</LONG_NAME>
            <CON_ID>5581796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Describe the test that was no</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Describe the test that was not performed:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Describe the tests that were not performed:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>List the clinical and laboratory evaluations that were missed:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Which tests from Table 4.4.2 were missed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Other, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="901">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7482920</PUBLICID>
    <LONGNAME>Hypotension Therapeutic Procedure Administered Specify Text</LONGNAME>
    <PREFERREDNAME>7482915v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the hypotension therapeutic procedure administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7482915</PublicId>
      <PreferredName>7482913v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Blood pressure that is abnormally low._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Hypotension Therapeutic Procedure Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7482913</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3128:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Hypotension Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3128</PREFERRED_NAME>
            <LONG_NAME>Hypotension</LONG_NAME>
            <CON_ID>2203673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the hypotension thera</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the hypotension therapeutic procedure administered:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other therapy:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other therapy:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other therapy:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other therapy:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_hypoten_thrpy_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="902">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7482970</PUBLICID>
    <LONGNAME>COVID-19 Healthcare Worker Personal Protective Equipment Use Questionnaire Assessment Text</LONGNAME>
    <PREFERREDNAME>7482969v1.0:2018321v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction._A person, including a healthcare professional or aide, technician, or other skilled or unskilled worker, who delivers health-related care or services._Masks, shields, gloves, gowns, boots, or other equipment used to provide coverage against infectious agents or environmental hazards._A manner, or usual, or accepted practice of using something._A predetermined set of questions._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7482969</PublicId>
      <PreferredName>7482945v1.0:7482967v1.0</PreferredName>
      <PreferredDefinition>An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction._A person, including a healthcare professional or aide, technician, or other skilled or unskilled worker, who delivers health-related care or services._Masks, shields, gloves, gowns, boots, or other equipment used to provide coverage against infectious agents or environmental hazards._A manner, or usual, or accepted practice of using something._A predetermined set of questions.</PreferredDefinition>
      <LongName>COVID-19 Healthcare Worker Personal Protective Equipment Use Questionnaire</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7482945</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C171133</PreferredName>
        <Version>1</Version>
        <LongName>SARS Coronavirus 2 Infection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C171133</PREFERRED_NAME>
            <LONG_NAME>COVID-19 Infection</LONG_NAME>
            <CON_ID>7252794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7482967</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C173826:C173748:C25340:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Worker Personal Protective Equipment Use Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C173826</PREFERRED_NAME>
            <LONG_NAME>Healthcare Worker</LONG_NAME>
            <CON_ID>7374388</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C173748</PREFERRED_NAME>
            <LONG_NAME>Personal Protective Equipment</LONG_NAME>
            <CON_ID>7482966</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element COVID-19 Healthcare Worker Personal Protective Equipment Use Questionnaire Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element COVID-19 Healthcare Worker Personal Protective Equipment Use Questionnaire Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Behaviors and Risks</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7482984</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>COVID-19 </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7482990</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="903">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7515724</PUBLICID>
    <LONGNAME>BCSES 8 Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer Agreement Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>BCSES_8_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how confident they are able to successfully work toward their personal goals since having breast cancer, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BCSES: Breast Cancer Self-Efficacy Scale; V. Champion et al., Oncol Nurs Forum, 2013 Nov</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7515695</PublicId>
      <PreferredName>7515651v1.0:7515693v1.0</PreferredName>
      <PreferredDefinition>A questionnaire designed to measure an individual&#39;s perceived ability to manage symptoms and quality-of-life problems resulting from the diagnosis and treatment of breast cancer._A question about whether an individual feels confident that they can successfully work toward their personal goals since they had breast cancer._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Breast Cancer Self Efficacy Scale Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer Agreement Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7515651</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C175992</PreferredName>
        <Version>1</Version>
        <LongName>Breast Cancer Self Efficacy Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C175992</PREFERRED_NAME>
            <LONG_NAME>Breast Cancer Self Efficacy Scale</LONG_NAME>
            <CON_ID>7509971</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7515693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C176000:C25369:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer Agreement Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C176000</PREFERRED_NAME>
            <LONG_NAME>Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer Question</LONG_NAME>
            <CON_ID>7510016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BCSES: Breast Cancer Self-Efficacy Scale; V. Champion et al., Oncol Nurs Forum, 2013 Nov</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6425431</PublicId>
      <PreferredName>ASK12_5_PT_SCL</PreferredName>
      <PreferredDefinition>5 point scale.</PreferredDefinition>
      <LongName>ASK-12 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>18</MaximumLength>
      <MinimumLength>5</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ASK-12:Adherence Starts With Knowledge 12 Questionnaire; Matza LS, et al. Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother. 2009;43:1621-1630</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Disagree</VALIDVALUE>
          <VALUEMEANING>Strongly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disagree</VALIDVALUE>
          <VALUEMEANING>Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutral</VALIDVALUE>
          <VALUEMEANING>Neutral</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person has a neutral opinion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6425435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agree</VALIDVALUE>
          <VALUEMEANING>Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>To concur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Agree</VALIDVALUE>
          <VALUEMEANING>Strongly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intense concurrence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am able to successfully wor</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am able to successfully work toward my personal goals since I had breast cancer.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Breast Cancer Self Efficacy Scale</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #8 of 11</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer Self-Efficacy Scale (BCSES)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14887995</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7516450</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BCSES</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BCSES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7516451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="904">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7518877</PUBLICID>
    <LONGNAME>Patient Proteinuria Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>6032321v1.0:3506036v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The presence of abnormal amounts of protein in the urine._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6032321</PublicId>
      <PreferredName>2233604v1.0:6032319v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The presence of abnormal amounts of protein in the urine._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Proteinuria Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6032319</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38012:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Proteinuria Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38012</PREFERRED_NAME>
            <LONG_NAME>Proteinuria</LONG_NAME>
            <CON_ID>2203669</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If the patient had 2+ protein</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If the patient had 2+ proteinuria on dipstick, did the patient have a 24-hour urine collection demonstrating protein of less than or equal to 500mg over 24 hours?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="905">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7525215</PUBLICID>
    <LONGNAME>Cervical Adenocarcinoma Present Finding Grade</LONGNAME>
    <PREFERREDNAME>CERV_ADENO_FDN_GRD</PREFERREDNAME>
    <PREFERREDDEFINITION>Grade to signify the cervical adenocarcinoma finding.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7525213</PublicId>
      <PreferredName>7525211v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Cervical Adenocarcinoma Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7525211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4029</PreferredName>
        <Version>1</Version>
        <LongName>Cervical Adenocarcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4029</PREFERRED_NAME>
            <LONG_NAME>Cervical Adenocarcinoma</LONG_NAME>
            <CON_ID>4722590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCR:Center for Cancer Research</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7523250</PublicId>
      <PreferredName>FND_GRD</PreferredName>
      <PreferredDefinition>Clinical, laboratory or molecular evidence, or absence of evidence of disease._A position on a scale of intensity or amount or quality.</PreferredDefinition>
      <LongName>Finding Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>7525360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3367:C48309</PreferredName>
        <Version>1</Version>
        <LongName>Finding Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LSIL CIN 1</VALIDVALUE>
          <VALUEMEANING>Low Grade Squamous Intraepithelial Neoplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition in which the cells of the uterine cervix are slightly abnormal. Low-grade squamous intraepithelial lesion is not cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3587191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HSIL CIN 2- 3</VALIDVALUE>
          <VALUEMEANING>High Grade Squamous Intraepithelial Neoplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3249985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ASCUS</VALIDVALUE>
          <VALUEMEANING>Atypical Squamous Cell of Undetermined Significance</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal cells from the outer walls of the cervix (the lower, narrow end of the uterus). Abnormal squamous cells (thin, flat cells that look like fish scales) are found in a low number of Pap smears (a procedure used to detect cervical cancer) and may indicate infection with the human papillomavirus (HPV) or another infectious agent. The risk of developing cervical cancer is very low for patients with ASCUS without HPV infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3587183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Grade</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="906">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7532236</PUBLICID>
    <LONGNAME>Normal Tissue Ischemia Time</LONGNAME>
    <PREFERREDNAME>7527825v1.0:7332471v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The period of time from blood supply separation or reduction to further processing, preservation, or blood supply reconnection of normal tissue from a non-diseased patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7527825</PublicId>
      <PreferredName>3364835v1.0:7433924v1.0</PreferredName>
      <PreferredDefinition>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The time interval from blood supply separation or reduction to further processing, preservation, or blood supply reconnection for a tissue, organ, or body part.</PreferredDefinition>
      <LongName>Normal Tissue Ischemia Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3364835</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14165:C12801</PreferredName>
        <Version>1</Version>
        <LongName>Normal Tissue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7433924</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C174013</PreferredName>
        <Version>1</Version>
        <LongName>Ischemia Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C174013</PREFERRED_NAME>
            <LONG_NAME>Ischemia Time</LONG_NAME>
            <CON_ID>7391751</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7332471</PublicId>
      <PreferredName>7332471v1.0</PreferredName>
      <PreferredDefinition>A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day._A unit measure of time equal to 60 seconds._The continuum of experience in which events pass from the future through the present to the past.</PreferredDefinition>
      <LongName>Hour Minute Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>2635753</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25529:C48154:C25207</PreferredName>
        <Version>1</Version>
        <LongName>Hour Minute Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25529</PREFERRED_NAME>
            <LONG_NAME>Hour</LONG_NAME>
            <CON_ID>2203682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48154</PREFERRED_NAME>
            <LONG_NAME>Minute</LONG_NAME>
            <CON_ID>2513263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ischemic time (Uterine≤35M |</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ischemic time (Uterine≤35M | Pancreatic≤55M)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>All Procurement CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Normal Tissue</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409067</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="907">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7544425</PUBLICID>
    <LONGNAME>Patient Radiation Therapy Prior Therapeutic Procedure Complete Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>RX_SCHED_TX_CMPT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indication of whether or not a patient meets the criteria for participation in a clinical trial regarding scheduled radiation therapy prior to the completion of therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7544396</PublicId>
      <PreferredName>2233604v1.0:7544426v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._To order a planned list of activities or events._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Radiation Therapy Scheduled Prior Therapeutic Procedure Complete Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7544426</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7544426v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy Scheduled Prior Therapeutic Procedure Complete Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125937</PREFERRED_NAME>
            <LONG_NAME>Scheduled</LONG_NAME>
            <CON_ID>5302898</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Be scheduled to receive activ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Be scheduled to receive active radiation prior to the completion of BBT-CI/HEAL interventions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6162769</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>URMC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>URCC Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6337044</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="908">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7554803</PUBLICID>
    <LONGNAME>Neoadjuvant Platinum-Based Chemotherapy Administered Ind.</LONGNAME>
    <PREFERREDNAME>7554802v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A response used to determine whether or not synthetic or naturally-occurring chemicals derived from or containing platinum were administered for treatment of a disease prior to the primary treatment for the purpose of making the primary treatment more effective.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7554802</PublicId>
      <PreferredName>2718486v1.0:7554800v1.0</PreferredName>
      <PreferredDefinition>The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._Derived from or containing platinum._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Neoadjuvant Therapy Platinum-Based Chemotherapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2718486</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7554800</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25620:C15632:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Platinum-Based Chemotherapy Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25620</PREFERRED_NAME>
            <LONG_NAME>Platinum-Based</LONG_NAME>
            <CON_ID>2206345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the platinum-based chemot</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the platinum-based chemotherapy administered in the neoadjuvant setting?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3852751</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapeutic</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3314497</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3852751</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapeutic</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000584</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="909">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7572702</PUBLICID>
    <LONGNAME>I-PSS 1 Past Week How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating Score 6 Point Scale</LONGNAME>
    <PREFERREDNAME>IPSS_1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation over the past week, of how often they had a sensation of not emptying their bladder completely after they finished urinating, using a 6 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>I-PSS:International Prostate Symptom Score</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7572681</PublicId>
      <PreferredName>5842417v1.0:7572679v1.0</PreferredName>
      <PreferredDefinition>A screening tool used to screen for, diagnose, track, and manage the symptoms of benign prostatic hyperplasia._The most recent week. May include the present day._A question about how often an individual has or had a sensation of not emptying their bladder completely after they finished urinating._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>International Prostate Symptom Score Past Week How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5842417</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113446</PreferredName>
        <Version>1</Version>
        <LongName>International Prostate Symptom Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113446</PREFERRED_NAME>
            <LONG_NAME>International Prostate Symptom Score</LONG_NAME>
            <CON_ID>5842416</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7572679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C138000:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C138000</PREFERRED_NAME>
            <LONG_NAME>How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating Question</LONG_NAME>
            <CON_ID>5937288</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>I-PSS:International Prostate Symptom Score</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5937456</PublicId>
      <PreferredName>AUASI_FREQ_SCL</PreferredName>
      <PreferredDefinition>A questionnaire designed to help men determine how bothersome their benign prostatic hyperplasia urinary symptoms are and to determine how effective their treatment is._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>AUASI Frequency 6 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>AUASI:American Urological Association Symptom Index for Benign Prostatic Hyperplasia, Barry, M.J., et.al., The Journal of Urology, Vol. 148, 1549-1557, Nov. 1992</Origin>
      <Representation>
        <PublicId>5937455</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113436:C25664</PreferredName>
        <Version>1</Version>
        <LongName>American Urological Association Symptom Score Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113436</PREFERRED_NAME>
            <LONG_NAME>American Urological Association Symptom Score</LONG_NAME>
            <CON_ID>5118762</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Five</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Four</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Less than 1 time in 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened less than one in five times.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138008</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5937457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Over the past week, how often</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Over the past week, how often have you had a sensation of not emptying your bladder completely after you finished urinating?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>International Prostate Symptom Score (I-PSS)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #1 of 8</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="910">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7587068</PUBLICID>
    <LONGNAME>New Metastatic Neoplasm Present First Relapse Indicator</LONGNAME>
    <PREFERREDNAME>NW_MET_NEOPLSM_PZT_FST_RP</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator of whether new sites of metastatic disease were present at first relapse.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7587067</PublicId>
      <PreferredName>7587064v1.0:7587065v1.0</PreferredName>
      <PreferredDefinition>Having no previous example or precedent or parallel; of a kind not seen before._A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology._The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following a single documented period of remission.</PreferredDefinition>
      <LongName>New Metastatic Neoplasm First Relapse</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7587064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25586:C3261</PreferredName>
        <Version>1</Version>
        <LongName>New Metastatic Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3261</PREFERRED_NAME>
            <LONG_NAME>Metastatic Neoplasm</LONG_NAME>
            <CON_ID>2443854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7587065</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123399</PreferredName>
        <Version>1</Version>
        <LongName>First Relapse</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123399</PREFERRED_NAME>
            <LONG_NAME>First Relapse</LONG_NAME>
            <CON_ID>6333655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was there one or more new sit</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was there one or more new sites of metastatic disease present at first relapse/progression?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="911">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7588600</PUBLICID>
    <LONGNAME>Minimal Residual Disease Positive Status Indicator Yes No Not Applicable</LONGNAME>
    <PREFERREDNAME>MRDPOS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Question to indicate whether patient had detectable MRD (positive status).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7588599</PublicId>
      <PreferredName>7588597v1.0:2415348v1.0</PreferredName>
      <PreferredDefinition>Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques._Confirmation of something, such as a positive lab test. In medicine, a positive lab test indicates the presence of a disease, condition, or microorganism. (NCI)_A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Minimal Residual Disease Positive Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7588597</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3896:C0205159:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Minimal Residual Disease Positive Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3896</PREFERRED_NAME>
            <LONG_NAME>Measurable Residual Disease</LONG_NAME>
            <CON_ID>2452231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0205159</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2222324</CON_ID>
            <DEFINITION_SOURCE>NCI04</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2415348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient develop detec</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient develop detectable MRD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient relapse or develop detectable MRD after initial MRD negative response post CAR T-cell infusion?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPRS_QVAL_MRDPOSTCART</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="912">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7588943</PUBLICID>
    <LONGNAME>Disease or Disorder Experience Want Someone to Talk to My Family or Friends about My Illness Agreement 5 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>7588942v1.0:3682709v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s agreement related to their disease or disorder experience with the statement, I want someone to talk to my family or friends about my illness using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7588942</PublicId>
      <PreferredName>7588552v1.0:7588940v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The accumulation of knowledge or skill that results from direct participation in events or activities._A question about how strongly an individual agrees that they want someone to talk to their family or friends about their illness._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Disease or Disorder Experience Want Someone to Talk to My Family or Friends about My Illness Agreement Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7588552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991:C54627</PreferredName>
        <Version>1</Version>
        <LongName>Disease or Disorder Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7588940</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C177267:C25369:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Want Someone to Talk to My Family or Friends about My Illness Agreement Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C177267</PREFERRED_NAME>
            <LONG_NAME>Want Someone to Talk to My Family or Friends about My Illness Question</LONG_NAME>
            <CON_ID>7572721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3682709</PublicId>
      <PreferredName>AGMT_5PT_SCL</PreferredName>
      <PreferredDefinition>A number with no fractional part, including the negative and positive numbers as well as zero.::5_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Agreement 5 Point Likert Scale</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MDADI:M.D.Anderson Dysphagia Inventory, Amy Y.Chen, 2000</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Disagree</VALIDVALUE>
          <VALUEMEANING>Strongly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disagree</VALIDVALUE>
          <VALUEMEANING>Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>To be at odds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Opinion</VALIDVALUE>
          <VALUEMEANING>Neither Agree or Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Without concurrence or opposition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agree</VALIDVALUE>
          <VALUEMEANING>Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>To concur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Agree</VALIDVALUE>
          <VALUEMEANING>Strongly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Intense concurrence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3682714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you agree with the stateme</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you agree with the statement, I want someone to talk to my family or friends about my illness?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I want someone to talk to my family or friends about my illness</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>I want someone to talk to my family or friends about my illness</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I want someone to talk to my family or friends about my illness</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I want someone to talk to my family or friends about my illness</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="913">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7590023</PUBLICID>
    <LONGNAME>Patient Hot Flashes Stratification Factors Daily Count</LONGNAME>
    <PREFERREDNAME>7589995v1.0:7590020v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of daily hot flashes the patient has as a stratification factor for participation on a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7589995</PublicId>
      <PreferredName>2233604v1.0:7589993v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A temporary feeling of intense body warmth, flushing, sometimes accompanied by sweating. A common, symptom of menopause; other conditions that can produce hot flushes include antidepressants and drugs blocking the effect of estrogens, carcinoid tumors and a sensitivity to sulfites or other food additives._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.</PreferredDefinition>
      <LongName>Patient Hot Flashes Stratification Factors</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7589993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3109:C16153</PreferredName>
        <Version>1</Version>
        <LongName>Hot Flashes Stratification Factors</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3109</PREFERRED_NAME>
            <LONG_NAME>Hot Flashes</LONG_NAME>
            <CON_ID>2526149</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16153</PREFERRED_NAME>
            <LONG_NAME>Stratification Factors</LONG_NAME>
            <CON_ID>2203599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7590020</PublicId>
      <PreferredName>7590020v1.0</PreferredName>
      <PreferredDefinition>The number of daily hot flashes.</PreferredDefinition>
      <LongName>Hot Flashes Stratification Factors Daily Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10 or more hot flashes per day</VALIDVALUE>
          <VALUEMEANING>Greater Than or Equal To Ten Hot Flashes Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A sudden, temporary onset of body warmth, flushing, and sweating (often associated with menopause).: A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C3109, C69122, C61583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7590021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4 to 9 hot flashes per day</VALIDVALUE>
          <VALUEMEANING>Four To Nine Hot Flashes Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one.: A sudden, temporary onset of body warmth, flushing, and sweating (often associated with menopause).: A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C3109, C66840, C65107, C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7590022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Daily hot flash frequency at</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Daily hot flash frequency at baseline</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="914">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7619729</PUBLICID>
    <LONGNAME>Lymphoma Lymph Node Large Diameter Lymph Node Diameter Large Indicator</LONGNAME>
    <PREFERREDNAME>BULKDIS_OCCUR_FAORRES</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the lymphoma lymph nodes having bulky diameter._A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference._Of considerable or relatively great size, extent, or capacity._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195419</PublicId>
      <PreferredName>LYMPH_LN_LG_DIAM</PreferredName>
      <PreferredDefinition>information related to the lymphoma lymph nodes having bulky diameter.</PreferredDefinition>
      <LongName>Lymphoma Lymph Node Large Diameter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206875</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3208:C12745</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660740</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49508:C25285</PreferredName>
        <Version>1</Version>
        <LongName>Large Diameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49508</PREFERRED_NAME>
            <LONG_NAME>Large</LONG_NAME>
            <CON_ID>2470752</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7626862</PublicId>
      <PreferredName>7626862v1.0</PreferredName>
      <PreferredDefinition>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference._Of considerable or relatively great size, extent, or capacity._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Lymph Node Diameter Large Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>7626861</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12745:C25285:C49508:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Lymph Node Diameter Large Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49508</PREFERRED_NAME>
            <LONG_NAME>Large</LONG_NAME>
            <CON_ID>2470752</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5697866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bulky Disease</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bulky Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Evaluations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="915">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7626542</PUBLICID>
    <LONGNAME>COVID-19 Positive Laboratory Test Result Present Yes No Prefer Not to Answer Indicator</LONGNAME>
    <PREFERREDNAME>COV19_POS_TST_RES_Y_N_PNTA_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A response of yes/no/prefer not to answer to indicate if a person received a positive COVID-19 test result.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7238864</PublicId>
      <PreferredName>7238862v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak._A laboratory test result that indicates that a specific disease, condition, or attribute being assessed is present._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>COVID-19 Positive Laboratory Test Result Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7238862</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C169076:C35682</PreferredName>
        <Version>1</Version>
        <LongName>SARS Coronavirus 2 Positive Laboratory Test Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C169076</PREFERRED_NAME>
            <LONG_NAME>SARS Coronavirus 2</LONG_NAME>
            <CON_ID>7215670</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35682</PREFERRED_NAME>
            <LONG_NAME>Positive Laboratory Test Result</LONG_NAME>
            <CON_ID>2431156</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7626538</PublicId>
      <PreferredName>7626538v1.0</PreferredName>
      <PreferredDefinition>The preferred value domain to indicate a question with permissible values of Yes, No, or Prefer not to answer.</PreferredDefinition>
      <LongName>Yes No Prefer Not to Answer Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>7626537</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C132222:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Prefer Not to Answer Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C132222</PREFERRED_NAME>
            <LONG_NAME>Prefer Not to Answer</LONG_NAME>
            <CON_ID>5684577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prefer not to answer</VALIDVALUE>
          <VALUEMEANING>Prefer Not to Answer</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual prefers or preferred not to answer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5684650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, have you ever received a positive test result?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you received a positive</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you received a positive COVID-19 test result?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, did you receive a positive test result?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Since your initial study visit, have you had a positive COVID-19 test?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you ever had a positive COVID-19 test in the last 3 months?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you had a positive COVID-19 test in the last 3 months?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="916">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7631794</PUBLICID>
    <LONGNAME>Follow-Up First Course Treatment Completion Measure of Success of Outcome Status</LONGNAME>
    <PREFERREDNAME>7631793v1.0:7074666v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The state or condition of an individual&#39;s success outcome when initial first course treatment concluded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7631793</PublicId>
      <PreferredName>6848724v1.0:7631791v1.0</PreferredName>
      <PreferredDefinition>Information regarding the follow-up period._A question regarding the success outcome after initial first course treatment.</PreferredDefinition>
      <LongName>Follow-Up First Course Treatment Completion Measure of Success of Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6848724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156846</PreferredName>
        <Version>1</Version>
        <LongName>Follow-Up Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156846</PREFERRED_NAME>
            <LONG_NAME>Follow-Up Information</LONG_NAME>
            <CON_ID>6848723</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7631791</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C158631</PreferredName>
        <Version>1</Version>
        <LongName>What is the First Course Treatment Completion Measure of Success of Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C158631</PREFERRED_NAME>
            <LONG_NAME>What is the First Course Treatment Completion Measure of Success of Outcome Question</LONG_NAME>
            <CON_ID>7631790</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7074666</PublicId>
      <PreferredName>7074666v1.0</PreferredName>
      <PreferredDefinition>Information regarding the follow-up period._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Follow-Up Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>7074665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156846:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Follow-Up Information Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156846</PREFERRED_NAME>
            <LONG_NAME>Follow-Up Information</LONG_NAME>
            <CON_ID>6848723</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable Outcome</VALUEMEANING>
          <MEANINGDESCRIPTION>The outcome is not applicable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7074668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown: Could not be determined or unsure.</VALIDVALUE>
          <VALUEMEANING>Unknown Outcome</VALUEMEANING>
          <MEANINGDESCRIPTION>The outcome is unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7074642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient Deceased</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>New Disease</VALIDVALUE>
          <VALUEMEANING>New Disease or Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no previous example or precedent or parallel; of a kind not seen before.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2991, C25586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7074669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Persistent Disease</VALIDVALUE>
          <VALUEMEANING>Persistent disease (Hematologic persistence)</VALUEMEANING>
          <MEANINGDESCRIPTION>A disease that does not go to remission despite treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease (PD)</VALIDVALUE>
          <VALUEMEANING>Progressive Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial response (PR)</VALIDVALUE>
          <VALUEMEANING>Partial Remission</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3951935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stable disease (SD)</VALIDVALUE>
          <VALUEMEANING>Stable Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is neither decreasing nor increasing in extent or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete Remission (CR)</VALIDVALUE>
          <VALUEMEANING>Complete Remission</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer in response to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3854972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Measure of success of outcome</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Measure of success of outcome at the completion of initial first course treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreas</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218863</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Uterus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218865</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218867</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Soft Tissue</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218984</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Marrow</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218985</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSCC Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CM Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634325</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAR Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634336</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634441</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCRCC Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634443</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LSCC LUAD Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634444</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PDA Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCEC Follow Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Kidney</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000348</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000599</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="917">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7652620</PUBLICID>
    <LONGNAME>Head and Neck Squamous Cell Carcinoma Lymph Node Dissection Performed CPTAC Indicator</LONGNAME>
    <PREFERREDNAME>7652619v1.0:6841630v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A response to indicate whether or not a lymph node dissection of the neck was performed during the study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OCCPR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CPTAC: Clinical Proteomic Tumor Analysis Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7652619</PublicId>
      <PreferredName>7651559v1.0:7652617v1.0</PreferredName>
      <PreferredDefinition>A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands._A question asking if lymph node dissection was performed during the study.</PreferredDefinition>
      <LongName>Head and Neck Squamous Cell Carcinoma Lymph Node Dissection Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7651559</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C34447</PreferredName>
        <Version>1</Version>
        <LongName>Head and Neck Squamous Cell Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C34447</PREFERRED_NAME>
            <LONG_NAME>Head and Neck Squamous Cell Carcinoma</LONG_NAME>
            <CON_ID>3088072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7652617</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159643</PreferredName>
        <Version>1</Version>
        <LongName>Was Lymph Node Dissection Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159643</PREFERRED_NAME>
            <LONG_NAME>Was Lymph Node Dissection Performed Question</LONG_NAME>
            <CON_ID>7652616</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6841630</PublicId>
      <PreferredName>6841630v1.0</PreferredName>
      <PreferredDefinition>A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CPTAC Yes No Unk Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OCCPR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CPTAC: Clinical Proteomic Tumor Analysis Consortium</Origin>
      <Representation>
        <PublicId>6841629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C157175:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Proteomic Tumor Analysis Consortium Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C157175</PREFERRED_NAME>
            <LONG_NAME>Clinical Proteomic Tumor Analysis Consortium</LONG_NAME>
            <CON_ID>6607697</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown: Could not be determined or unsure</VALIDVALUE>
          <VALUEMEANING>Indeterminate or Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something is indeterminate or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6841632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lymph Node Neck Dissection pe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lymph Node Neck Dissection performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have a salvage neck dissection &gt;20 weeks from the end of RT, with tumour present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_02</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have a salvage neck dissection in the neck not treated with RT at any time after registration with tumour present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7218867</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6601273</PublicId>
          <ContextName>OCCPR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CPTAC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSCC Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7634285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPRS_QVAL_WTARV</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPRS_QVAL_OTARV</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="918">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7717924</PUBLICID>
    <LONGNAME>Patient Activating FGFR Gene Mutation Detection Method Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>FGFR_DET_ELIG</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the means of identifying changes in the nucleotide sequence of an FGFR family gene.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7717911</PublicId>
      <PreferredName>2233604v1.0:7717909v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A change in the nucleotide sequence of an FGFR family gene that that results in constitutive activation the encoded fibroblast growth factor receptor protein and its downstream signaling pathways._The activity of perceiving, discerning, discovering or identifying._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Activating FGFR Gene Mutation Detection Method Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7717909</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C153103:C16210:C71460:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Activating FGFR Gene Mutation Detection Method Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C153103</PREFERRED_NAME>
            <LONG_NAME>Activating FGFR Gene Mutation</LONG_NAME>
            <CON_ID>6380835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have FGFR2/3 act</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have FGFR2/3 activating alterations identified by tumor tissue or plasma ctDNA profiling using a CLIA certified CAP accredited platform?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="919">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736705</PUBLICID>
    <LONGNAME>Derived Therapeutic Procedure Post Second Sample Collection Date Begin Day Calculation Value</LONGNAME>
    <PREFERREDNAME>days_initial_dx_to_tx_start_af</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric value to represent the date the therapy started after the second sample collection represented as a calculated number of days.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7736701</PublicId>
      <PreferredName>2512834v1.0:7736699v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Happening at a time subsequent to a reference time; later in time or order._A unit of time, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The act of gathering things together; having been brought together in one place._The particular day, month and year an event has happened or will happen._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.</PreferredDefinition>
      <LongName>Therapeutic Procedure Post Second Sample Collection Date Begin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7736699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7736699v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Post Second Specimen Collection Begin Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42535</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2534958</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCG:Center for Cancer Genomics</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3008213</PublicId>
      <PreferredName>DAY_CALC_VAL</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours._The procedure or activity of determining something by mathematical or logical methods._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Day Calculation Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
      <Representation>
        <PublicId>3008212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C54125:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Day Calculation Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54125</PREFERRED_NAME>
            <LONG_NAME>Calculation</LONG_NAME>
            <CON_ID>2654477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the date the therapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the date the therapy started after the second sample collection represented as a calculated number of days?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6705584</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCG_PTCL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HOPE-CARE</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7715738</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>days_initial_dx_to_tx_start_after_second_sample</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>CALCULATED</DerivationType>
      <DerivationTypeDescription>CALCULATED</DerivationTypeDescription>
      <Methods>Date 1 is the concatenation of the component CDE1 to CDE2 to CDE3 to form a date in the format of DDMMYYYY. Date 2 is the concatenation of the component CDE4 to CDE5 to CDE6 to form a date in the format of DDMMYYYY.</Methods>
      <Rule>Calculation is a as follows: 1. CDEs 1, 2, and 3 are concatenated to create one calendar date for the event referenced (Date1). 2. CDEs 4, 5, and 6 are concatenated to create one calendar date for the event referenced (Date2). 3. Values of both dates are converted to milliseconds since the epoch. 4. The values of Date 2 are subtracted from the value of Date 1. 5. The remainder of the subtraction will be divided by the number of milliseconds in a day (86,400,000).</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>7736702</PublicId>
          <LongName>Therapeutic Procedure Post Second Sample Collection Date Begin Day Number</LongName>
          <PreferredName>THRP_POST_SCND_SAMP_BGN_DAY</PreferredName>
          <PreferredDefinition>Numeric value that represents the day therapy started after the second sample collection.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>7736703</PublicId>
          <LongName>Therapeutic Procedure Post Second Sample Collection Date Begin Month Number</LongName>
          <PreferredName>THRP_POST_SCND_SAMP_BGN_MTH</PreferredName>
          <PreferredDefinition>Numeric value that represents the month therapy started after the second sample collection.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>7736704</PublicId>
          <LongName>Therapeutic Procedure Post Second Sample Collection Date Begin Year Number</LongName>
          <PreferredName>THRP_POST_SCND_SAMP_BGN_YR</PreferredName>
          <PreferredDefinition>Numeric value that represents the year therapy started after the second sample collection.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>3</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>7736613</PublicId>
          <LongName>Diagnosis Date Day Number</LongName>
          <PreferredName>DX_DAY</PreferredName>
          <PreferredDefinition>Numeric value that represents the day of the diagnosis.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>4</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>7736614</PublicId>
          <LongName>Diagnosis Date Month Number</LongName>
          <PreferredName>DX_MTH</PreferredName>
          <PreferredDefinition>Numeric value that represents the month of the diagnosis.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>5</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>7736615</PublicId>
          <LongName>Diagnosis Date Year Number</LongName>
          <PreferredName>DX_YEAR</PreferredName>
          <PreferredDefinition>Numeric value that represents the year of the diagnosis.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>6</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="920">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736702</PUBLICID>
    <LONGNAME>Therapeutic Procedure Post Second Sample Collection Date Begin Day Number</LONGNAME>
    <PREFERREDNAME>THRP_POST_SCND_SAMP_BGN_DAY</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the day therapy started after the second sample collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="921">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736703</PUBLICID>
    <LONGNAME>Therapeutic Procedure Post Second Sample Collection Date Begin Month Number</LONGNAME>
    <PREFERREDNAME>THRP_POST_SCND_SAMP_BGN_MTH</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the month therapy started after the second sample collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="922">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736704</PUBLICID>
    <LONGNAME>Therapeutic Procedure Post Second Sample Collection Date Begin Year Number</LONGNAME>
    <PREFERREDNAME>THRP_POST_SCND_SAMP_BGN_YR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the year therapy started after the second sample collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="923">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736613</PUBLICID>
    <LONGNAME>Diagnosis Date Day Number</LONGNAME>
    <PREFERREDNAME>DX_DAY</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the day of the diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="924">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736614</PUBLICID>
    <LONGNAME>Diagnosis Date Month Number</LONGNAME>
    <PREFERREDNAME>DX_MTH</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the month of the diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="925">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7736615</PUBLICID>
    <LONGNAME>Diagnosis Date Year Number</LONGNAME>
    <PREFERREDNAME>DX_YEAR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the year of the diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCG:Center for Cancer Genomics</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="926">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7764925</PUBLICID>
    <LONGNAME>Procedure Radiation Therapy Total Dose</LONGNAME>
    <PREFERREDNAME>PRDSTXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The total dose of radiation therapy administered measured in Gy (gray) unit of measure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6421233</PublicId>
      <PreferredName>6407261v1.0:2715130v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._A textual description of the agent dose level(s) or range(s) assigned to a subject according to the study protocol.</PreferredDefinition>
      <LongName>Procedure Domain Dose Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102700</PreferredName>
        <Version>1</Version>
        <LongName>Procedure Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102700</PREFERRED_NAME>
            <LONG_NAME>Procedure Domain</LONG_NAME>
            <CON_ID>6407260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715130</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70961</PreferredName>
        <Version>1</Version>
        <LongName>Dose Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70961</PREFERRED_NAME>
            <LONG_NAME>Dose Description</LONG_NAME>
            <CON_ID>2715001</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3287101</PublicId>
      <PreferredName>RT_TTL_GY_DOSE</PreferredName>
      <PreferredDefinition>the total dose of radiation therapy administered measured in Gy (gray) unit of measure.</PreferredDefinition>
      <LongName>Radiation Therapy Total Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>Gray</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</Origin>
      <Representation>
        <PublicId>2207921</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Total Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Dose Given</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Dose Given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline Evaluations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7283433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="927">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7781984</PUBLICID>
    <LONGNAME>Montreal Cognitive Assessment Version 7.1 Naming Test Score</LONGNAME>
    <PREFERREDNAME>MOCA_NAMING_V7_1_SCR</PREFERREDNAME>
    <PREFERREDDEFINITION>The score of the Naming test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MoCA:Montreal Cognitive Assessment; Z.S.Nasreddine et al., J AM Geriatric Society (2005)</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6848582</PublicId>
      <PreferredName>6848575v1.0:6848580v1.0</PreferredName>
      <PreferredDefinition>A standardized rating scale developed by Ziad Nasreddine in 1996 to screen for mild cognitive dysfunction and impairment. This instrument assesses the following cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation._In this test three pictures of animals are shown and the individual is asked to name each one.</PreferredDefinition>
      <LongName>Montreal Cognitive Assessment Functional Test Montreal Cognitive Assessment Naming Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6848575</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123667</PreferredName>
        <Version>1</Version>
        <LongName>Montreal Cognitive Assessment Functional Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123667</PREFERRED_NAME>
            <LONG_NAME>Montreal Cognitive Assessment Functional Test</LONG_NAME>
            <CON_ID>6681573</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6848580</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C162710</PreferredName>
        <Version>1</Version>
        <LongName>Montreal Cognitive Assessment Naming Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C162710</PREFERRED_NAME>
            <LONG_NAME>Montreal Cognitive Assessment Naming Test</LONG_NAME>
            <CON_ID>6841883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3297238</PublicId>
      <PreferredName>QUEST_TTL_SC</PreferredName>
      <PreferredDefinition>Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Questionnaire Total Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>30</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>3297237</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17048:C25304:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Questionnaire Total Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Naming</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Naming</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="928">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7788575</PUBLICID>
    <LONGNAME>OME TIFF Big Endian Byte Order True False Indicator</LONGNAME>
    <PREFERREDNAME>7784583v1.0:7788576v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A response of true or false to indicate if the Open Microscopy Environment (OME) tagged image file format (TIFF) image file consisted of multiple bytes in which the most significant bit is encoded first with the remaining bytes encoded in decreasing order of significance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>HTAN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HTAN:Human Tumor Atlas Network</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7784583</PublicId>
      <PreferredName>7781147v1.0:7788574v1.0</PreferredName>
      <PreferredDefinition>A tagged image file format (TIFF) image file format that contains an Open Microscopy Environment (OME) XML metadata block in the file header for storing microscopy information (pixels and metadata) using the OME Data Model._A binary number consisting of multiple bytes in which the most significant bit is encoded first with the remaining bytes encoded in decreasing order of significance.</PreferredDefinition>
      <LongName>OME Tagged Image File Format Big Endian Byte Order</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>HTAN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7781147</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C181618</PreferredName>
        <Version>1</Version>
        <LongName>Open Microscopy Environment Tagged Image File Format</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C181618</PREFERRED_NAME>
            <LONG_NAME>Open Microscopy Environment Tagged Image File Format</LONG_NAME>
            <CON_ID>7776161</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7788574</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C181703</PreferredName>
        <Version>1</Version>
        <LongName>Big Endian Byte Order</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C181703</PREFERRED_NAME>
            <LONG_NAME>Big Endian Byte Order</LONG_NAME>
            <CON_ID>7781315</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HTAN:Human Tumor Atlas Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7788576</PublicId>
      <PreferredName>7788576v1.0</PreferredName>
      <PreferredDefinition>A response of true or false._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>True False Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>HTAN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HTAN:Human Tumor Atlas Network</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>False</VALIDVALUE>
          <VALUEMEANING>False</VALUEMEANING>
          <MEANINGDESCRIPTION>Not in accordance with the fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>True</VALIDVALUE>
          <VALUEMEANING>True</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pixels Big Endian</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pixels Big Endian</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7576399</PublicId>
          <ContextName>HTAN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Biospecimen CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tier 2 Assay-specific</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7577840</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7639423</PublicId>
          <ContextName>HTAN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SRRS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SRRS Imaging</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7639428</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>HTAN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PixelsBigEndian</AlternateName>
        <AlternateNameType>HTAN Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="929">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7801600</PUBLICID>
    <LONGNAME>Patient Personal Medical History Invasive Cutaneous Melanoma Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>MELINV</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response as to whether the patient&#39;s medical history of invasive melanoma meets the eligibility criteria for participating in a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7802371</PublicId>
      <PreferredName>2233604v1.0:7802369v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._A melanoma of the skin that is not confined to the dermal-epidermal junction, and has infiltrated the dermis._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Personal Medical History Invasive Cutaneous Melanoma Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7802369</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772:C48607:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History Invasive Cutaneous Melanoma Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48607</PREFERRED_NAME>
            <LONG_NAME>Invasive Cutaneous Melanoma</LONG_NAME>
            <CON_ID>2434266</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7801087</PublicId>
      <PreferredName>7801087v1.0</PreferredName>
      <PreferredDefinition>A symbol or combination of symbols which is assigned to the members of a collection._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2208003</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>N/A</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6594241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>History of previous or concur</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>History of previous or concurrent (i.e. second primary) invasive melanoma</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="930">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7847764</PUBLICID>
    <LONGNAME>Parent Employed Status</LONGNAME>
    <PREFERREDNAME>PARENT_EMPL_STATUS</PREFERREDNAME>
    <PREFERREDDEFINITION>A textual description of the parent&#39;s employment status.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7847763</PublicId>
      <PreferredName>3111322v1.0:2512759v1.0</PreferredName>
      <PreferredDefinition>A mother or a father; an immediate progenitor._The state of being engaged in an activity or service for wages or salary.</PreferredDefinition>
      <LongName>Parent Employed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3111322</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42709</PreferredName>
        <Version>1</Version>
        <LongName>Parent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42709</PREFERRED_NAME>
            <LONG_NAME>Parent</LONG_NAME>
            <CON_ID>2222173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2512759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25172</PreferredName>
        <Version>1</Version>
        <LongName>Employment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25172</PREFERRED_NAME>
            <LONG_NAME>Employed</LONG_NAME>
            <CON_ID>2202381</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7847761</PublicId>
      <PreferredName>PRNT_EMPLYMNT_STAT</PreferredName>
      <PreferredDefinition>A mother or a father; an immediate progenitor._The state of being engaged in an activity or service for wages or salary._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Parent Employed Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008545</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>JOBS</PreferredName>
        <Version>1</Version>
        <LongName>Jobs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>7847760</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42709:C25172:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Parent Employed Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42709</PREFERRED_NAME>
            <LONG_NAME>Parent</LONG_NAME>
            <CON_ID>2222173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25172</PREFERRED_NAME>
            <LONG_NAME>Employed</LONG_NAME>
            <CON_ID>2202381</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disabled, Permanent or Temporarily</VALIDVALUE>
          <VALUEMEANING>Disabled Population</VALUEMEANING>
          <MEANINGDESCRIPTION>Groups with similar restrictions or lack or ability to perform physical or mental activities in a manner or within the range considered normal for a human being.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7557012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Employed full-time</VALIDVALUE>
          <VALUEMEANING>Full Time Employment</VALUEMEANING>
          <MEANINGDESCRIPTION>Employed for a standard number of hours of working time, at least 50% or 20 hours per week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2798166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Employed part-time</VALIDVALUE>
          <VALUEMEANING>Part Time Employment</VALUEMEANING>
          <MEANINGDESCRIPTION>Employment involving less than the standard or customary working time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2798164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Looking for Work, Unemployed</VALIDVALUE>
          <VALUEMEANING>Looking for Work Or Unemployment</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that an individual is seeking work.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The state of not having a job.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75563, C37998, C165487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7557013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not employed and not looking for work</VALIDVALUE>
          <VALUEMEANING>Unemployment Negation Looking for Work</VALUEMEANING>
          <MEANINGDESCRIPTION>The state of not having a job.: An operation in which a term denies or inverts the meaning of another term or construction.: An indication that an individual is seeking work.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165487, C25594, C75563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7847758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Only Temporarily Laid Off, Sick Leave or Maternity Leave</VALIDVALUE>
          <VALUEMEANING>Temporary Leave Sick Leave Or Maternity Leave</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that an individual is not working due to being laid off, but that it is only temporary.: A leave of absence granted because of illness.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The time that a woman takes off from work following the birth or adoption of a child.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172445, C37998, C148251, C177653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7557014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other/Specify</VALIDVALUE>
          <VALUEMEANING>If Other, Specify</VALUEMEANING>
          <MEANINGDESCRIPTION>A directive to specify when the listed responses are not sufficient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7557010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Raising Children Full-time or Keeping House</VALIDVALUE>
          <VALUEMEANING>Raising Children Full-time or Keeping House</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that an individual is employed in their home, either raising children full-time or keeping house.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7036351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retired</VALIDVALUE>
          <VALUEMEANING>Retirement</VALUEMEANING>
          <MEANINGDESCRIPTION>To stop working at one&#39;s occupation; the state of being retired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3009455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Student</VALIDVALUE>
          <VALUEMEANING>Student</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who is enrolled in an educational institution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75561</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2964673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Working without pay</VALIDVALUE>
          <VALUEMEANING>Work Without Pay</VALUEMEANING>
          <MEANINGDESCRIPTION>Exertion or effort directed to produce or accomplish something.: Used to indicate the absence or lack of something or someone.: Money or other benefits received in exchange for work.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180612, C25718, C74299</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7847759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Working Now</VALIDVALUE>
          <VALUEMEANING>Currently Employed</VALUEMEANING>
          <MEANINGDESCRIPTION>A question about whether an individual is currently employed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7557015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>We would like to know about w</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>We would like to know about what parent does - is parent working now, looking for work, retired, keeping house, a student, or what?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7244861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COVID-19</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>8038915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7244861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COVID-19</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Project 5 CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>8038916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7977821</PublicId>
          <ContextName>NIH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Project 5 COVID</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tier 1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7977823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Parent&#39;s Employment Status</AlternateName>
        <AlternateNameType>NIH COVID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="931">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7848332</PUBLICID>
    <LONGNAME>Pathogenic Variant ATRX Gene Present Percentage Value</LONGNAME>
    <PREFERREDNAME>LAB_SPC_ATRX_PCT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric percentage value of the pathogenic variant ATRX gene.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7848329</PublicId>
      <PreferredName>7848326v1.0:7848327v1.0</PreferredName>
      <PreferredDefinition>A genetic variant that is known to directly contribute to the development of disease._This gene plays a role in the regulation of both chromatin remodeling and transcription._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Pathogenic Variant ATRX Gene Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7848326</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C168799</PreferredName>
        <Version>1</Version>
        <LongName>Pathogenic Variant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C168799</PREFERRED_NAME>
            <LONG_NAME>Pathogenic Variant</LONG_NAME>
            <CON_ID>7164480</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>8026182</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74976:C25626</PreferredName>
        <Version>1</Version>
        <LongName>ATRX Gene Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74976</PREFERRED_NAME>
            <LONG_NAME>ATRX Gene</LONG_NAME>
            <CON_ID>3772155</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2199529</PublicId>
      <PreferredName>PTG_VAL</PreferredName>
      <PreferredDefinition>A fraction or ratio with 100 understood as the denominator._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Percentage Value</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the percentage value</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the percentage value of the pathogenic variant ATRX gene?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes or variant of unknown significance, what was the variant allele frequency?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="932">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7848485</PUBLICID>
    <LONGNAME>Liposome-encapsulated Daunorubicin-Cytarabine Administered Dose Unit of Measure Name</LONGNAME>
    <PREFERREDNAME>U_MSR_CPX351</PREFERREDNAME>
    <PREFERREDDEFINITION>A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids._The act of having given something (e.g., a medication or test)._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._The words or language units by which a thing is known.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7848484</PublicId>
      <PreferredName>7848482v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Liposome-encapsulated Daunorubicin-Cytarabine Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7848482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67504</PreferredName>
        <Version>1</Version>
        <LongName>Liposome-encapsulated Daunorubicin-Cytarabine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67504</PREFERRED_NAME>
            <LONG_NAME>Liposome-encapsulated Daunorubicin-Cytarabine</LONG_NAME>
            <CON_ID>7154913</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183860</PublicId>
      <PreferredName>DOSE_UOM_NM</PreferredName>
      <PreferredDefinition>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Dose Unit of Measure Name</LongName>
      <Version>3.3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3232737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25488:C25709:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Dose Unit of Measure Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YU</VALIDVALUE>
          <VALUEMEANING>Yeast Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.: Various single-celled members of the fungal families, ascomycetes, basidiomycetes and imperfect fungi that tend to be unicellular for the greater part of their life cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14286, C67238, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2874130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E7 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/g</VALIDVALUE>
          <VALUEMEANING>Unit per gram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in unit(s) per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/m2</VALIDVALUE>
          <VALUEMEANING>Microgram per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Course</VALIDVALUE>
          <VALUEMEANING>Cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Any division of quantity accepted as a standard of measurement or exchange.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL</VALIDVALUE>
          <VALUEMEANING>Nanograms per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caplet</VALIDVALUE>
          <VALUEMEANING>Caplet</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosing unit that contains medicinal substances in the form similar to a tablet enclosed within a tamper-resistant soluble container usually made from a suitable form of gelatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capsule</VALIDVALUE>
          <VALUEMEANING>Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid contained within either a hard or soft soluble shell, usually prepared from gelatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Applcatn</VALIDVALUE>
          <VALUEMEANING>Application</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosing measurement based on the application unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>au</VALIDVALUE>
          <VALUEMEANING>Atomic Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Atomic Unit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bill PFU</VALIDVALUE>
          <VALUEMEANING>Billion PFU</VALUEMEANING>
          <MEANINGDESCRIPTION>Billion Plaque Forming Units</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells</VALIDVALUE>
          <VALUEMEANING>Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cGy</VALIDVALUE>
          <VALUEMEANING>Centigray</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ci</VALIDVALUE>
          <VALUEMEANING>Curie</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radioactivity in the CGS system, defined as 3.7 E10 atomic disintegrations or other nuclear transformations per second. One curie is equal to 37 gigabecquerels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Course</VALIDVALUE>
          <VALUEMEANING>Course</VALUEMEANING>
          <MEANINGDESCRIPTION>A period of protocol-prescribed activity or intervention.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL</VALIDVALUE>
          <VALUEMEANING>Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose</VALIDVALUE>
          <VALUEMEANING>Dose</VALUEMEANING>
          <MEANINGDESCRIPTION>The amount of medicine taken, or radiation given, at one time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eq</VALIDVALUE>
          <VALUEMEANING>Equivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or thing equal to another in value or measure or force or effect or significance etc; being essentially equal to something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Grams (g)</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one one thousandth of a kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/m2</VALIDVALUE>
          <VALUEMEANING>Gram per m2</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>gtts</VALIDVALUE>
          <VALUEMEANING>Drops</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to approximately 0.08333 milliliter (1 mL = 12 medical drops).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gy</VALIDVALUE>
          <VALUEMEANING>Gray</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter; one gray equals 100 rads. The unit is named for the British physician L. Harold Gray, an authority on the use of radiation in the treatment of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hz</VALIDVALUE>
          <VALUEMEANING>Hertz</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of frequency; equal to one oscillation per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inhalatn</VALIDVALUE>
          <VALUEMEANING>Inhalation</VALUEMEANING>
          <MEANINGDESCRIPTION>Access within the respiratory tract by inhaling orally or nasally for a systemic or local effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit</VALIDVALUE>
          <VALUEMEANING>International unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/kg</VALIDVALUE>
          <VALUEMEANING>International unit per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in international units of biological activity per one kilogram of mass of the system. It is also used as a dose calculation unit expressed in international units of biological activity per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/L</VALIDVALUE>
          <VALUEMEANING>International unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jcm2</VALIDVALUE>
          <VALUEMEANING>Joules per centimeter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radiant exposure equal to radiant energy of one joule arriving upon a surface area of one square centimeter. The unit is also used for measurement of output of the energy-emitting source.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KeV</VALIDVALUE>
          <VALUEMEANING>Kib-electron volt</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy equal to 1000 electronvolts, or (approximately) 1,602 177 x 10-16 joule. The unit is accepted for use with SI units.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg</VALIDVALUE>
          <VALUEMEANING>Kilograms</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is definied as the mass of an  international prototype in the form of a platinum-iridium cylinder kept at Sevres in france.   A kilogram is equal to 1,000 grams and 2.2046226 pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kHz</VALIDVALUE>
          <VALUEMEANING>Kilohertz</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure denoting the frequency equal to 1000 cycles per second meaning e.g. that the cylical waveform changes from one state to the other (from one polarity to the other) 1000 times per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kPa</VALIDVALUE>
          <VALUEMEANING>Kilopascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to 1000 newtons per square meter or 10000 bars or to 0.145 pound per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU</VALIDVALUE>
          <VALUEMEANING>Kilounit</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to one thousand units (10E3 units).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A common metric unit of volume equal to one cubic decimeter, 1000 cubic centimeters, or 0.001 cubic meter, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg</VALIDVALUE>
          <VALUEMEANING>Microgram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/cm2</VALIDVALUE>
          <VALUEMEANING>Microgram per centimeter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/kg</VALIDVALUE>
          <VALUEMEANING>Microgram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mCi</VALIDVALUE>
          <VALUEMEANING>Millicurie</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Measure</VALIDVALUE>
          <VALUEMEANING>Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>To determine the magnitude or quantity of a substance by comparing it to some accepted standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq</VALIDVALUE>
          <VALUEMEANING>Milliequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/24hr</VALIDVALUE>
          <VALUEMEANING>Milliequivalents per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/dL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/L</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MeV</VALIDVALUE>
          <VALUEMEANING>Million electron volt</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.: A unit of energy defined as the kinetic energy acquired by an electron in passing through a potential difference of one volt in a vacuum. Its value is experimentally determined as 1,602 177 x 10E-19 joule (approximately). The unit is accepted for use with SI units.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67278, C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL</VALIDVALUE>
          <VALUEMEANING>Milligram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg</VALIDVALUE>
          <VALUEMEANING>Milligram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/m2</VALIDVALUE>
          <VALUEMEANING>Milligram per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MHz</VALIDVALUE>
          <VALUEMEANING>Megahertz</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of frequency; equal to one million oscillations per second or to 10E6 hertz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microL</VALIDVALUE>
          <VALUEMEANING>Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volume equal to one millionth of a liter or one one thousandth of a milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol</VALIDVALUE>
          <VALUEMEANING>Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million</VALIDVALUE>
          <VALUEMEANING>Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one milliliter of preparation per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol</VALIDVALUE>
          <VALUEMEANING>Millimole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mole</VALIDVALUE>
          <VALUEMEANING>Mole </VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is the amount of substance that contains as many elementary units as there are atoms in 0.012 kg of carbon-12. When the mole is used, the elementary entities must be specified and may be atoms, molecules, ions, electrons, other particles, or specified groups of such particles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosmol</VALIDVALUE>
          <VALUEMEANING>Milliosmole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic pressure equal to one thousandth of osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mrad</VALIDVALUE>
          <VALUEMEANING>Megarad</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of absorbed radiation dose equal to one million rad (10E6 rad), or 10000 Gy (10E4 Gy).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one-thousandth of an international unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/m2</VALIDVALUE>
          <VALUEMEANING>Milliinternational units per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one-thousandth (10E-3) of an arbitrary unit of biological activity (International Unit) of substance per square meter of body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mV</VALIDVALUE>
          <VALUEMEANING>Millivolt</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of an electric potential and electromotive force equal to one thousandth of a volt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MVP</VALIDVALUE>
          <VALUEMEANING>Million Viral Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for virus amount measurement that represents a number of viral particles (live and dead combined) expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nCi</VALIDVALUE>
          <VALUEMEANING>Nanocurie</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radioactivity equal to one billionth of a curie or 37 becquerels, and corresponding to radioactivity of 37 atomic disintegrations per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng</VALIDVALUE>
          <VALUEMEANING>Nanogram </VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/kg</VALIDVALUE>
          <VALUEMEANING>Nanogram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass fraction expressed as a number of nanograms of a substance per kilogram of the mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/L</VALIDVALUE>
          <VALUEMEANING>Nanogram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance per unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one nanogram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nm light</VALIDVALUE>
          <VALUEMEANING>Nanometer of Light</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanometer of Light</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol</VALIDVALUE>
          <VALUEMEANING>Nanomole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>osmol</VALIDVALUE>
          <VALUEMEANING>Osmolality</VALUEMEANING>
          <MEANINGDESCRIPTION>The concentration of osmoles of solute per kilogram of solvent present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>oz</VALIDVALUE>
          <VALUEMEANING>Ounce</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. The avoirdupois ounce is equal to 1/16 pound, or 28.3495 grams, or 0.911 457 troy ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pa</VALIDVALUE>
          <VALUEMEANING>Pascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to one newton per square meter or 10 bars or to 1.45x10E-4 pounds per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>packet</VALIDVALUE>
          <VALUEMEANING>Packet</VALUEMEANING>
          <MEANINGDESCRIPTION>Packet</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PFU</VALIDVALUE>
          <VALUEMEANING>Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of viable infectious entities (e.g. viral particles or group of particles) in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope and/or to the naked eye as a plaque. A number of plaque forming units (PFU) per unit volume is a conventional way to refer the titer of an infective entity in a specimen or preparation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg</VALIDVALUE>
          <VALUEMEANING>Picograms</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>psi</VALIDVALUE>
          <VALUEMEANING>Pounds per square inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of pressure equivalent to 6.894757 kilopascals, or 703.0696 kilograms per square meter, or 51.71507 millimeters of mercury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>puff</VALIDVALUE>
          <VALUEMEANING>Puff</VALUEMEANING>
          <MEANINGDESCRIPTION>Puff</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spray</VALIDVALUE>
          <VALUEMEANING>Spray</VALUEMEANING>
          <MEANINGDESCRIPTION>a substance propelled by gas(es)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suppstry</VALIDVALUE>
          <VALUEMEANING>Suppository</VALUEMEANING>
          <MEANINGDESCRIPTION>Suppository</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TCID</VALIDVALUE>
          <VALUEMEANING>Tissue Culture Infection Dose</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue Culture Infection Dose</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand</VALIDVALUE>
          <VALUEMEANING>Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Troche</VALIDVALUE>
          <VALUEMEANING>Troche</VALUEMEANING>
          <MEANINGDESCRIPTION>Troche</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>tsp</VALIDVALUE>
          <VALUEMEANING>Teaspoon</VALUEMEANING>
          <MEANINGDESCRIPTION>Teaspoon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/kg</VALIDVALUE>
          <VALUEMEANING>Unit per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in units of biological activity per unit of mass equal to one kilogram. Unit per kilogram is also used as a dose calculation unit expressed in arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microCi</VALIDVALUE>
          <VALUEMEANING>MicroCurie</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VP</VALIDVALUE>
          <VALUEMEANING>Viral Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for virus amount measurement that represents the total number of viral particles (live and dead combined).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RE</VALIDVALUE>
          <VALUEMEANING>Retinol Equivalents</VALUEMEANING>
          <MEANINGDESCRIPTION>Retinol Equivalents</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RAE</VALIDVALUE>
          <VALUEMEANING>Vitamin A Retinol</VALUEMEANING>
          <MEANINGDESCRIPTION>Retinol Equivalents of Vitamin A</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IU Vit A</VALIDVALUE>
          <VALUEMEANING>IU Vitamin A</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of measurement of the specific biological activity of vitamin A, defined by the International Conference for Unification of Formula as equal approximately to 0.30 micrograms of all-trans retinol or to 0.60 micrograms of the provitamin A, all-trans-beta-carotene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg</VALIDVALUE>
          <VALUEMEANING>Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IU/mg A-TE</VALIDVALUE>
          <VALUEMEANING>International Units OR milligram alpha Tocopherol</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit of alpha-Tocopherol per one milligram of preparation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MU</VALIDVALUE>
          <VALUEMEANING>Million units</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to one million units (10E6 units).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mill PFU</VALIDVALUE>
          <VALUEMEANING>Million Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of viable infectious entities expressed in millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>millunit</VALIDVALUE>
          <VALUEMEANING>Milliunit</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to the one thousandth unit (10E-3 unit).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Srce</VALIDVALUE>
          <VALUEMEANING>No Source Data</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallon</VALIDVALUE>
          <VALUEMEANING>Gallon</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of volume used for measuring liquids and dry matter. Gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since Roman times.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/wk</VALIDVALUE>
          <VALUEMEANING>Milligram per week</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/kg</VALIDVALUE>
          <VALUEMEANING>Kilounit per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/hr</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/hr</VALIDVALUE>
          <VALUEMEANING>Milligram per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/hr</VALIDVALUE>
          <VALUEMEANING>Microgram per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/hr</VALIDVALUE>
          <VALUEMEANING>Milliliter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rad</VALIDVALUE>
          <VALUEMEANING>Radiation absorbed dose </VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radiation absorbed dose equal to the amount of energy from any type of ionizing radiation (e.g., alpha, beta, gamma, neutrons, etc.) deposited in any medium (e.g., water, tissue, air). A dose of one rad means the absorption of 100 ergs per gram of absorbing tissue (100 rad = 1 gray). (The U.S. Nuclear Regulatory Commission, NRC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tablet</VALIDVALUE>
          <VALUEMEANING>Tablets</VALUEMEANING>
          <MEANINGDESCRIPTION>a solid, compressed dosage form</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tbsp</VALIDVALUE>
          <VALUEMEANING>Tablespoon</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume informally used in pharmacy. Under the metric system the tablespoon has been standardized at 15 milliliters in the US, Britain, Canada, and New Zealand, and at 20 milliliters in Australia and some European countries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L</VALIDVALUE>
          <VALUEMEANING>Kilounit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 PFU</VALIDVALUE>
          <VALUEMEANING>10E9 Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Plaque Forming Units</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patch</VALIDVALUE>
          <VALUEMEANING>Patch</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system that contains an adhesive backing and that permits its ingredients to diffuse from some portion of it (e.g., the backing itself, a reservoir, the adhesive, or some other component) into the body from the external site where it is applied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seed</VALIDVALUE>
          <VALUEMEANING>Seed</VALUEMEANING>
          <MEANINGDESCRIPTION>Seed (Radioactive)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Session</VALIDVALUE>
          <VALUEMEANING>Session</VALUEMEANING>
          <MEANINGDESCRIPTION>Time, period, or term devoted to some activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 PFU</VALIDVALUE>
          <VALUEMEANING>10E7 Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Plaque Forming Units</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 PFU</VALIDVALUE>
          <VALUEMEANING>10E8 Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>10E8 Plaque Forming Units</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AUC</VALIDVALUE>
          <VALUEMEANING>Area under the curve</VALUEMEANING>
          <MEANINGDESCRIPTION>The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bottle</VALIDVALUE>
          <VALUEMEANING>Bottle</VALUEMEANING>
          <MEANINGDESCRIPTION>A vessel with a narrow neck designed to accept a specific closure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IV Bag</VALIDVALUE>
          <VALUEMEANING>Intravenous bag</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosing unit equal to the amount of medicinal substance(s) contained in a portable container for packaging pharmaceutical dosage forms intended for administration through an intravenous delivery system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min</VALIDVALUE>
          <VALUEMEANING>Liters per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/24hr</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/inh</VALIDVALUE>
          <VALUEMEANING>Milligram per Inhalation</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhalation dosing unit equal to the quantity of medicinal substance(s) expressed in milligrams delivered per a single act of taking in breath.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Cubic centimeter (cc)</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic centimeter (cc)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/m2</VALIDVALUE>
          <VALUEMEANING>Unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed as a number of arbitrary units of substance per one square meter of a body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E4 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E4 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E4 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E5 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E5 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E5 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IU/mg</VALIDVALUE>
          <VALUEMEANING>International unit per milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milligram of substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mM/L</VALIDVALUE>
          <VALUEMEANING>Millimoles per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2990392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10 Cells</VALIDVALUE>
          <VALUEMEANING>10E10 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E10 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 Cells</VALIDVALUE>
          <VALUEMEANING>10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E8 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 Cells</VALIDVALUE>
          <VALUEMEANING>10E7 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells</VALIDVALUE>
          <VALUEMEANING>10E6 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E5 Cells</VALIDVALUE>
          <VALUEMEANING>10E5 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E5 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E4 Cells</VALIDVALUE>
          <VALUEMEANING>10E4 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E4 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cells</VALIDVALUE>
          <VALUEMEANING>10E3 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E3 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVRP</VALIDVALUE>
          <VALUEMEANING>Infectious Viral Replicon Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for virus amount measurement that represents the total number of viral particles (live and dead combined).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2684842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells</VALIDVALUE>
          <VALUEMEANING>10E9 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mBq</VALIDVALUE>
          <VALUEMEANING>Millibecquerel</VALUEMEANING>
          <MEANINGDESCRIPTION>Millibecquerel</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2761970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inch</VALIDVALUE>
          <VALUEMEANING>Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length equal to 2.54 centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mL</VALIDVALUE>
          <VALUEMEANING>Unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in unit(s) per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capful</VALIDVALUE>
          <VALUEMEANING>Capful</VALUEMEANING>
          <MEANINGDESCRIPTION>A top (as for a bottle).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2789561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BPM</VALIDVALUE>
          <VALUEMEANING>Breaths per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of breaths (inhalation and exhalation) taken per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ampule</VALIDVALUE>
          <VALUEMEANING>Ampule</VALUEMEANING>
          <MEANINGDESCRIPTION>A container capable of being hermetically sealed, intended to hold sterile materials.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2789562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MBq</VALIDVALUE>
          <VALUEMEANING>Megabecquerel</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of radioactivity equal to 10E6 nuclear disintegrations or other nuclear transformations per second, or to 10E6 becquerels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3014637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/kg</VALIDVALUE>
          <VALUEMEANING>Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell concentration expressed as a number of cells per mass unit equal to one kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3005028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg/day</VALIDVALUE>
          <VALUEMEANING>Milligram per kilogram per day</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3082337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 IU/kg</VALIDVALUE>
          <VALUEMEANING>10E3 International Unit per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E3 International Unit per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+11 Cells</VALIDVALUE>
          <VALUEMEANING>E+11 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+11 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+10 Cells</VALIDVALUE>
          <VALUEMEANING>E+10 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+10 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+9 Cells</VALIDVALUE>
          <VALUEMEANING>E+9 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+9 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+8 Cells</VALIDVALUE>
          <VALUEMEANING>E+8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+8 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+7 Cells</VALIDVALUE>
          <VALUEMEANING>E+7 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+7 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+6 Cells</VALIDVALUE>
          <VALUEMEANING>E+6 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+6 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+5 Cells</VALIDVALUE>
          <VALUEMEANING>E+5 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+5 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+4 Cells</VALIDVALUE>
          <VALUEMEANING>E+4 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+4 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E+3 Cells</VALIDVALUE>
          <VALUEMEANING>E+3 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>E+3 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3717819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sv</VALIDVALUE>
          <VALUEMEANING>Sievert</VALUEMEANING>
          <MEANINGDESCRIPTION>The international system (SI) unit for radiation dose equivalent equal to 1 Joule/kilogram. 1 sievert = 100 rem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E10 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::1000000000: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.: A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C28252, C12508, C45255::1000000000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5271411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in billions.: A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.: A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C28252, C67247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5271412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E8 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in hundreds of millions.: A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.: A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C28252, C67248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5271413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cell/kg</VALIDVALUE>
          <VALUEMEANING>10E4 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.: A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C28252, C12508, C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5271414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11 Cells/kg</VALIDVALUE>
          <VALUEMEANING>10E11 Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E11 Cells per Kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5637599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11 Viral Particles</VALIDVALUE>
          <VALUEMEANING>10E11 Viral Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>10E11 Viral Particles</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5699512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11 Cells</VALIDVALUE>
          <VALUEMEANING>10E11 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E11 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5671590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 PFU</VALIDVALUE>
          <VALUEMEANING>One Million Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 1000001 and the quantity that it denotes: one thousand thousands.: A measure of viable infectious entities (e.g. viral particles or group of particles) in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope and/or to the naked eye as a plaque. A number of plaque forming units (PFU) per unit volume is a conventional way to refer the titer of an infective entity in a specimen or preparation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67264, C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-07-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5914864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10 Viral Particles</VALIDVALUE>
          <VALUEMEANING>10E10 Viral Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>Ten billion viral particle units.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6321062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 IU/mL</VALIDVALUE>
          <VALUEMEANING>Billion International Units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Billion International Units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6771069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/L/min</VALIDVALUE>
          <VALUEMEANING>Micromole per Liter per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/h/mg</VALIDVALUE>
          <VALUEMEANING>Liter per Milligram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Liters per milligram per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6630525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cells/kg</VALIDVALUE>
          <VALUEMEANING>Thousand Cells per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number of cells in thousands per unit of mass equal to one kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6805526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uCi/kg</VALIDVALUE>
          <VALUEMEANING>Microcurie per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of specific radioactivity (massic activity) equal to activity of one microcurie of the sample with total mass of one kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3930156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E13 Viral Particles</VALIDVALUE>
          <VALUEMEANING>10E13 Viral Particles</VALUEMEANING>
          <MEANINGDESCRIPTION>Ten trillion viral particles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7391763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10^9 IFU/mL</VALIDVALUE>
          <VALUEMEANING>Billion Infectious Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of measure of viral infectious potency expressed as one billion infectious units per one milliliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C185175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10^8 IFU/mL</VALIDVALUE>
          <VALUEMEANING>Hundred Million Infectious Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of measure of viral infectious potency expressed as one hundred million infectious units per one milliliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C185174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3126125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Degree Celsius</VALIDVALUE>
          <VALUEMEANING>Degree Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42559</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/unit</VALIDVALUE>
          <VALUEMEANING>Milligram per unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per unit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15039522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/min</VALIDVALUE>
          <VALUEMEANING>Microgram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one minute. Microgram per minute is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6400548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mcg</VALIDVALUE>
          <VALUEMEANING>Unit per microgram</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per microgram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Units of measure:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Units of measure:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="933">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7852044</PUBLICID>
    <LONGNAME>Gynecological Examination Vaginal Moisture Score 3 Point Scale</LONGNAME>
    <PREFERREDNAME>GYNEX_MOIST_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>The level of vaginal moisture from a gynecological examination, using a 3-point scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7849152</PublicId>
      <PreferredName>8031118v1.0:8032153v1.0</PreferredName>
      <PreferredDefinition>Physical examination pertaining to the female reproductive system._A question about an individual&#39;s vaginal moisture._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Gynecological Examination Vaginal Moisture Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>8031118</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C137854</PreferredName>
        <Version>1</Version>
        <LongName>Gynecological Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C137854</PREFERRED_NAME>
            <LONG_NAME>Gynecological Examination</LONG_NAME>
            <CON_ID>7988466</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>8032153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C185357:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Vaginal Moisture Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C185357</PREFERRED_NAME>
            <LONG_NAME>Vaginal Moisture Question</LONG_NAME>
            <CON_ID>8028609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7852093</PublicId>
      <PreferredName>7852093v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Vaginal Moisture Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>99</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>NOT ASSESSED</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that an assessment was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4001711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Minimum</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest possible quantity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2753155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4494160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Moisture</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Moisture</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="934">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7855191</PUBLICID>
    <LONGNAME>Procedure Domain Preoperative Scan Date</LONGNAME>
    <PREFERREDNAME>SUPPPR_QVAL_PRIMGPRIORSURGDT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date of a scan, or scans, performed prior to surgery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7855137</PublicId>
      <PreferredName>6407261v1.0:7855135v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._Relating to or occurring during the period immediately before a surgical operation._The data or image obtained by gathering information with a sensing device._The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Procedure Domain Preoperative Scan Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6407261</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102700</PreferredName>
        <Version>1</Version>
        <LongName>Procedure Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102700</PREFERRED_NAME>
            <LONG_NAME>Procedure Domain</LONG_NAME>
            <CON_ID>6407260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7855135</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C17999:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Scan Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17999</PREFERRED_NAME>
            <LONG_NAME>Scan</LONG_NAME>
            <CON_ID>2202631</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338240</PublicId>
      <PreferredName>CDISCDAT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>11</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396655</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25164</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Pre-Operative scan(s):</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Pre-Operative scan(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 001</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of pre-operative scan(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of pre-operative spine scan(s) (if obtained):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of pre-operative brain scan(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="935">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7994121</PUBLICID>
    <LONGNAME>Tympanometry Audiometric Test Left Ear Outcome Normal Abnormal Comprehensive Indicator</LONGNAME>
    <PREFERREDNAME>TYMP_RSLT_LT_EAR</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication of the results of Tympanometry testing of the left ear.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7994039</PublicId>
      <PreferredName>7994035v1.0:2958391v1.0</PreferredName>
      <PreferredDefinition>The study of the mobility of the tympanic membrane and conduction bones through air pressure changes. It is used to detect middle ear abnormalities._Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss._The organ of hearing located on the left side of the head._The result of an action.</PreferredDefinition>
      <LongName>Tympanometry Audiometric Test Left Ear Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7994035</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88505:C38036</PreferredName>
        <Version>1</Version>
        <LongName>Tympanometry Audiometric Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88505</PREFERRED_NAME>
            <LONG_NAME>Tympanometry</LONG_NAME>
            <CON_ID>3079042</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38036</PREFERRED_NAME>
            <LONG_NAME>Audiometric Test</LONG_NAME>
            <CON_ID>2660092</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2958391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81259:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Left Ear Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81259</PREFERRED_NAME>
            <LONG_NAME>Left Ear</LONG_NAME>
            <CON_ID>2958310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7994094</PublicId>
      <PreferredName>7994094v1.0</PreferredName>
      <PreferredDefinition>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm._Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm._Broad in scope; including all or everything._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Normal Abnormal Comprehensive Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength>250</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>7994093</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14165:C25401:C61528:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Normal Abnormal Comprehensive Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25401</PREFERRED_NAME>
            <LONG_NAME>Abnormal</LONG_NAME>
            <CON_ID>2202623</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61528</PREFERRED_NAME>
            <LONG_NAME>Comprehensive</LONG_NAME>
            <CON_ID>3332482</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4494160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Within normal limits</VALIDVALUE>
          <VALUEMEANING>Within Normal Value</VALUEMEANING>
          <MEANINGDESCRIPTION>On the inside; contained in.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C14165, C25282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7994095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to determine</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Results not available</VALIDVALUE>
          <VALUEMEANING>Outcome Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>The result of an action.: The desired information is not available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126101, C20200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7994096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tympanometry results for the</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tympanometry results for the left ear:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="936">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7998314</PUBLICID>
    <LONGNAME>Systemic Indocyanine Green Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>SYS_ICG_ADMN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to whether or not systemic indocyanine green was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7998313</PublicId>
      <PreferredName>7998311v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Affecting an entire system._A nontoxic, fluorescent, tricarbocyanine dye with a peak spectral absorption at 790 nm, with application in determining cardiac output, hepatic function, liver blood flow, as well as ophthalmic angiography. Upon administration, indocyanine green (ICG) rapidly binds to its principle carrier, plasma protein, and is thereby confined to the vascular space. This agent, with a half-life of 150 to 180 seconds, is removed exclusively by the liver from circulation to bile juice. Furthermore, due to poor uptake, ICG is not suitable for angiography or functional output analysis of kidney, lung, cerebro-spinal, or peripheral tissues._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Systemic Indocyanine Green Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7998311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13310:C65913</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Indocyanine Green</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13310</PREFERRED_NAME>
            <LONG_NAME>Systemic</LONG_NAME>
            <CON_ID>2204930</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65913</PREFERRED_NAME>
            <LONG_NAME>Indocyanine Green</LONG_NAME>
            <CON_ID>7998310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was systemic indocyanine gree</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was systemic indocyanine green administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient receive systemic indocyanine green (ICG) in an attempt to visualize nodule(s)?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive systemic indocyanine green (ICG) in an attempt to visualize nodule(s)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="937">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>7998344</PUBLICID>
    <LONGNAME>Complication During Localization Technique Occurrence Yes No Indicator</LONGNAME>
    <PREFERREDNAME>COMP_LCL_TECH_OCC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to whether or not complications occurred during the localization technique.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7998335</PublicId>
      <PreferredName>3250183v1.0:7998333v1.0</PreferredName>
      <PreferredDefinition>Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure._At some point in a given period of time._The process of determining or marking the location or site of a lesion or disease. May also refer to the process of keeping a lesion or disease in a specific location or site._A practiced and regimented skill or series of actions._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Complication During Localization Technique Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3250183</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2959</PreferredName>
        <Version>1</Version>
        <LongName>Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2959</PREFERRED_NAME>
            <LONG_NAME>Complication</LONG_NAME>
            <CON_ID>2203884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7998333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25490:C28264:C16847:C25275</PreferredName>
        <Version>1</Version>
        <LongName>During Localization Technique Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28264</PREFERRED_NAME>
            <LONG_NAME>Localization</LONG_NAME>
            <CON_ID>2433276</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16847</PREFERRED_NAME>
            <LONG_NAME>Technique</LONG_NAME>
            <CON_ID>2203854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were there complications duri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were there complications during the localization technique?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="938">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8031119</PUBLICID>
    <LONGNAME>Hematology Erythrocyte Mean Corpuscular Volume Laboratory Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>2630228v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory finding for erythrocyte mean corpuscular volume.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2630228</PublicId>
      <PreferredName>HEM_E_MCV_LAB</PreferredName>
      <PreferredDefinition>information related laboratory for the blood and blood-forming organs and the diseases thereof regarding a quantitative measurement of the mean volume of erythrocytes in a biological specimen.</PreferredDefinition>
      <LongName>Hematology Erythrocyte Mean Corpuscular Volume Laboratory</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2425597</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16673</PreferredName>
        <Version>1</Version>
        <LongName>Hematology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16673</PREFERRED_NAME>
            <LONG_NAME>Hematology</LONG_NAME>
            <CON_ID>2202645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2630226</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64799:C37984</PreferredName>
        <Version>1</Version>
        <LongName>Erythrocyte Mean Corpuscular Volume Laboratory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64799</PREFERRED_NAME>
            <LONG_NAME>Erythrocyte Mean Corpuscular Volume</LONG_NAME>
            <CON_ID>2630225</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the ery</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the erythrocyte mean corpuscular volume finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mean corpuscular volume (MCV)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mean corpuscular volume (MCV)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mean corpuscular volume (MCV)</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Mean corpuscular volume (MCV)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="939">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8035922</PUBLICID>
    <LONGNAME>Biospecimen Index Date To Specimen Processing Day Count</LONGNAME>
    <PREFERREDNAME>8035907v1.0:7069460v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of days from the participant&#39;s index date to the date on which the biospecimen was prepared for storage, preservation, or further analysis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>HTAN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HTAN:Human Tumor Atlas Network</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>8035907</PublicId>
      <PreferredName>2859635v1.0:8035905v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A date used as a reference point for ensuing events, often a diagnosis date, or a first visit date, or the date a patient enrolled in a study._Used as a function word to indicate direction, purpose, or movement._The process of preparing a sample or portion of a sample for storage, preservation, or further analysis.</PreferredDefinition>
      <LongName>Biospecimen Index Date To Specimen Processing</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>HTAN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>8035905</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C146721:C65107:C41604</PreferredName>
        <Version>1</Version>
        <LongName>Index Date To Specimen Processing</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C146721</PREFERRED_NAME>
            <LONG_NAME>Index Date</LONG_NAME>
            <CON_ID>6059885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41604</PREFERRED_NAME>
            <LONG_NAME>Specimen Processing</LONG_NAME>
            <CON_ID>2202426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HTAN:Human Tumor Atlas Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7069460</PublicId>
      <PreferredName>7069460v1.0</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>day</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>2207941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Day Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Processing days from Index</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Processing days from Index</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HTAN Term</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Processing days from Index</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7576399</PublicId>
          <ContextName>HTAN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Biospecimen CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tier 2 Assay-specific</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7577840</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7639423</PublicId>
          <ContextName>HTAN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SRRS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SRRS Biospecimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7639046</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>HTAN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PROCESSING_DAYS_FROM_INDEX</AlternateName>
        <AlternateNameType>HTAN Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="940">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8064151</PUBLICID>
    <LONGNAME>Early Intervention Location Other Specify</LONGNAME>
    <PREFERREDNAME>EARLY_INTN_LOC_O_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test)._A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions._A position, site, or point in space where something can be found._a text field to describe of a method of early intervention treatment administered to a patient._A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>8064139</PublicId>
      <PreferredName>8064128v1.0:2177480v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test)._A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Early Intervention Therapeutic Procedure Administered Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>8064128</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159524:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Early Intervention Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159524</PREFERRED_NAME>
            <LONG_NAME>Early Intervention</LONG_NAME>
            <CON_ID>6716012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177480</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Location</PreferredName>
        <Version>1</Version>
        <LongName>Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>8064134</PublicId>
      <PreferredName>8064134v1.0</PreferredName>
      <PreferredDefinition>a text field to describe of a method of early intervention treatment administered to a patient._A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions.</PreferredDefinition>
      <LongName>Early Intervention Type Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>8064133</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C159524:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Early Intervention Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C159524</PREFERRED_NAME>
            <LONG_NAME>Early Intervention</LONG_NAME>
            <CON_ID>6716012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="941">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8093847</PUBLICID>
    <LONGNAME>Patient Questionnaire Language Type</LONGNAME>
    <PREFERREDNAME>QS_LANG_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of language used for patient questionnaires.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6813203</PublicId>
      <PreferredName>2516212v1.0:2231625v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A predetermined set of questions._A systematic means of communicating by the use of sounds, symbols, or gestures.</PreferredDefinition>
      <LongName>Patient Questionnaire Language</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2516212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Patient Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16779</PreferredName>
        <Version>1</Version>
        <LongName>Language</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16779</PREFERRED_NAME>
            <LONG_NAME>Language</LONG_NAME>
            <CON_ID>2203839</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>8093845</PublicId>
      <PreferredName>LANGUAGE_TP</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Language Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA (Patient does not speak or read English, Spanish, or French, or site is not located in United States or Canada)</VALIDVALUE>
          <VALUEMEANING>NA (Patient does not speak or read English, Spanish, or French, or site is not located in United States or Canada)</VALUEMEANING>
          <MEANINGDESCRIPTION>NA (Patient does not speak or read English, Spanish, or French, or site is not located in United States or Canada)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8093147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spanish</VALIDVALUE>
          <VALUEMEANING>Spanish</VALUEMEANING>
          <MEANINGDESCRIPTION>An Indo-European Romance language that originated in Spain. It is the primary language of 20 countries worldwide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6077873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>French</VALIDVALUE>
          <VALUEMEANING>French</VALUEMEANING>
          <MEANINGDESCRIPTION>A romance language spoken as the official language in France and 28 other countries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8093846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>English</VALIDVALUE>
          <VALUEMEANING>English</VALUEMEANING>
          <MEANINGDESCRIPTION>An Indo-European language belonging to the West Germanic branch; the official language of Britain and the United States, and most of the Commonwealth countries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6077874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA (Participant does not speak or read any of the above languages)</VALIDVALUE>
          <VALUEMEANING>Not Applicable (Participant does not speak or read any of the above languages)</VALUEMEANING>
          <MEANINGDESCRIPTION>Not Applicable (Participant does not speak or read any of the above languages)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-02-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7181392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA (The patient is unable to complete a questionnaire in English or Spanish or French)</VALIDVALUE>
          <VALUEMEANING>NA (The patient is unable to complete a questionnaire in English or Spanish or French.)</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5026035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Language for patient complete</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Language for patient completed questionnaires</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG-ACRIN - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In which language does the participant wish to complete surveys?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In what language were the assessments completed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_LNGGCMPL</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_LNGCOMP</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="942">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8155854</PUBLICID>
    <LONGNAME>Medical History Human Papillomavirus-11 Indicator</LONGNAME>
    <PREFERREDNAME>HPV11_IDENT_CODE_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Coded Indicator of whether HPV-11 was detected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>8155797</PublicId>
      <PreferredName>2431097v1.0:8155795v1.0</PreferredName>
      <PreferredDefinition>A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._A human papillomavirus that is a common causative agent of genital warts. Human papillomavirus-11 is considered low-risk for causing malignancies.</PreferredDefinition>
      <LongName>Personal Medical History Human Papillomavirus-11</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431097</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>8155795</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C99178</PreferredName>
        <Version>1</Version>
        <LongName>Human Papillomavirus-11</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C99178</PREFERRED_NAME>
            <LONG_NAME>Human Papillomavirus-11</LONG_NAME>
            <CON_ID>3331747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was HPV-11 detected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>11</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000686</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPV11_IDENT_MBORRES</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="943">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>8177627</PUBLICID>
    <LONGNAME>Tumor Extranodal Extension Evidence of Disease type</LONGNAME>
    <PREFERREDNAME>SUPPMH_QVAL_XNODEXTN</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to extranodal tumor extension._Situated outside of a node._Knowledge on which to base belief._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCTG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCTG: Canadian Cancer Trials Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192192</PublicId>
      <PreferredName>TUMOR_EXTND_EX</PreferredName>
      <PreferredDefinition>information related to extranodal tumor extension.</PreferredDefinition>
      <LongName>Tumor Extranodal Extension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176931</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Tumor</PreferredName>
        <Version>1</Version>
        <LongName>Tumor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207739</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25504:C25270</PreferredName>
        <Version>1</Version>
        <LongName>Extranodal Extension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25504</PREFERRED_NAME>
            <LONG_NAME>Extranodal</LONG_NAME>
            <CON_ID>2206211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25270</PREFERRED_NAME>
            <LONG_NAME>Extend</LONG_NAME>
            <CON_ID>2203922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>8177622</PublicId>
      <PreferredName>XNODEXTN_D</PreferredName>
      <PreferredDefinition>Situated outside of a node._Knowledge on which to base belief._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.</PreferredDefinition>
      <LongName>Evidence of Extranodal Disease type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCTG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>8177621</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25504:C43583:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Extranodal Evidence Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25504</PREFERRED_NAME>
            <LONG_NAME>Extranodal</LONG_NAME>
            <CON_ID>2206211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43583</PREFERRED_NAME>
            <LONG_NAME>Evidence</LONG_NAME>
            <CON_ID>2228358</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiologic evidence only</VALIDVALUE>
          <VALUEMEANING>Evidence Radiology</VALUEMEANING>
          <MEANINGDESCRIPTION>Knowledge on which to base belief.: The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17059, C43583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8177625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Both clinical and radiologic evidence</VALIDVALUE>
          <VALUEMEANING>Radiology Evidence Clinical</VALUEMEANING>
          <MEANINGDESCRIPTION>The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.: Knowledge on which to base belief.: Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25398, C43583, C17059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8177623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical evidence only</VALIDVALUE>
          <VALUEMEANING>Evidence Clinical</VALUEMEANING>
          <MEANINGDESCRIPTION>Knowledge on which to base belief.: Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25398, C43583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8177624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4001711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Evidence of extranodal extens</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Evidence of extranodal extension:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="944">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>10542993</PUBLICID>
    <LONGNAME>DSQ Past 30 Days Milk Usually Drink Type</LONGNAME>
    <PREFERREDNAME>DSQ_MILK_TYP</PREFERREDNAME>
    <PREFERREDDEFINITION>A participant&#39;s response about the type of milk they usually drank during the past month.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>10540223</PublicId>
      <PreferredName>10540215v1.00:10540222v1.00</PreferredName>
      <PreferredDefinition>_A 26-item questionnaire, developed by the Risk Factor Assessment Branch of the National Cancer Institute&#39;s Epidemiology and Genomics Research Program, that assesses the frequency of consumption in the past month of fruits and vegetables, added sugar, dairy, whole grains, calcium, fiber, red meat, and processed meat:A period of time consisting of the 30 days before the present._A question about the type of milk that an individual usually has or had.</PreferredDefinition>
      <LongName>Dietary Screener Questionnaire Past 30 Days Type of Milk Usually Drink</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>10540215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C188186</PreferredName>
        <Version>1</Version>
        <LongName>Dietary Screener Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C188186</PREFERRED_NAME>
            <LONG_NAME>Dietary Screener Questionnaire</LONG_NAME>
            <CON_ID>10538158</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>10540222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131330:C188087</PreferredName>
        <Version>1</Version>
        <LongName>Past 30 Days Type of Milk Usually Drink</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131330</PREFERRED_NAME>
            <LONG_NAME>Past 30 days</LONG_NAME>
            <CON_ID>5615928</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C188087</PREFERRED_NAME>
            <LONG_NAME>Type of Milk Usually Drink Question</LONG_NAME>
            <CON_ID>10471879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>10542642</PublicId>
      <PreferredName>10542642v1.00</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Milk Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Whole or regular milk</VALIDVALUE>
          <VALUEMEANING>Whole Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>Dairy milk that has not been altered nutritionally. It contains about 3.5% fat by total weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188111</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10542643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2% fat or reduced-­fat milk</VALIDVALUE>
          <VALUEMEANING>Reduced-fat Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>Dairy milk where milkfat is 2 percent of the total weight of the milk.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10542644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1%, ½%, or low-­fat milk</VALIDVALUE>
          <VALUEMEANING>Low-fat Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>Dairy milk where milkfat is 1 percent of the total weight of the milk.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178186</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10542645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fat­-free, skim or nonfat milk</VALIDVALUE>
          <VALUEMEANING>Fat-free Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>Dairy milk that does not contain milkfat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10542646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soy milk</VALIDVALUE>
          <VALUEMEANING>Soy Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>A plant-based drink produced by soaking and grinding soybeans, boiling the mixture, and filtering out the particulates. It is a stable emulsion of oil, water, and protein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C178188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7639588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other kind of milk</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6424136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>During the past month, what kind of milk did you usually drink? Mark one</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>During the past month, what kind of milk did you usually drink? Mark one</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="945">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>10570418</PUBLICID>
    <LONGNAME>Biospecimen Domain Test Name CDISC Variable Terminology Outcome</LONGNAME>
    <PREFERREDNAME>BS_BSORRES_CSFE</PREFERREDNAME>
    <PREFERREDDEFINITION>Result of the measurement or finding as finally received or collected</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>7044690</PublicId>
      <PreferredName>7044577v1.0:6813511v1.0</PreferredName>
      <PreferredDefinition>A findings domain that documents biospecimen handling information._The literal identifier of an examination.</PreferredDefinition>
      <LongName>Biospecimen Domain Test Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7044577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111137</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111137</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Domain</LONG_NAME>
            <CON_ID>7044576</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6813511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82541</PreferredName>
        <Version>1</Version>
        <LongName>Test Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82541</PREFERRED_NAME>
            <LONG_NAME>Test Name</LONG_NAME>
            <CON_ID>6141102</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6400810</PublicId>
      <PreferredName>CDISCRES</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The result of an action.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6400811</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C20200</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the result of the test?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the result of the cerebrospinal fluid  examination?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="946">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>10874285</PUBLICID>
    <LONGNAME>Myeloma Frailty Index Status</LONGNAME>
    <PREFERREDNAME>MYL_FRA_IDX_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The response of an individual&#39;s frailty as assessed by the Myeloma Frailty Index.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>10874280</PublicId>
      <PreferredName>10874279v1.00:2320064v1.00</PreferredName>
      <PreferredDefinition>A score based on age, comorbidities, cognitive, and physical conditions of myeloma patients designed to predict mortality and the risk of toxicity in elderly myeloma patients.:A condition or state at a particular time.</PreferredDefinition>
      <LongName>Myeloma Frailty Index Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>10874279</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C188471</PreferredName>
        <Version>1</Version>
        <LongName>Myeloma Frailty Index</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C188471</PREFERRED_NAME>
            <LONG_NAME>Myeloma Frailty Index</LONG_NAME>
            <CON_ID>10869949</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>10874281</PublicId>
      <PreferredName>MYL_FRA_IDX_STAT</PreferredName>
      <PreferredDefinition>A condition or state at a particular time.</PreferredDefinition>
      <LongName>Myeloma Frailty Index Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Fit by Myeloma Frailty Index</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 0 on the Myeloma Frailty Index.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10874282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Intermediate Fitness by Myeloma Frailty Index</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 1 on the Myeloma Frailty Index.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10874283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Frail by Myeloma Frailty Index</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of greater than or equal to 2 on the Myeloma Frailty Index.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-08-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10874284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Status as classified by the Myeloma Frailty Index</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="947">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>10939338</PUBLICID>
    <LONGNAME>Laboratory Procedure Lymphocyte Outcome Percentage 2 Decimal Place Value</LONGNAME>
    <PREFERREDNAME>2188765v1.00:7278997v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The 2 decimal place numeric laboratory value measured, assigned or computed related to the assessment of the percentage of lymphocytes in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188765</PublicId>
      <PreferredName>LAB_LYMPH_OC</PreferredName>
      <PreferredDefinition>information related the results of the medical procedure that involves testing a sample of blood for lymphocyte, a type of white blood cell that has a number of roles in the immune system, including the production of antibodies and other substances that fight infection and diseases.</PreferredDefinition>
      <LongName>Laboratory Procedure Lymphocyte Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2779791</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12535:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Lymphocyte Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12535</PREFERRED_NAME>
            <LONG_NAME>Lymphocyte</LONG_NAME>
            <CON_ID>2211956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7278997</PublicId>
      <PreferredName>7278997v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The result of an action._A fraction or ratio with 100 understood as the denominator._A number with no fractional part, including the negative and positive numbers as well as zero.::2_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Laboratory Procedure Outcome Percentage 2 Decimal Place Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>7278996</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7278996v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Outcome Percentage Integer::2 Decimal Place Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the value of lymphocytes?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Lymphocytes:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_DIFF_lymphocyte_2dec_pct</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="948">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>11287825</PUBLICID>
    <LONGNAME>Biopsy Performed Anatomic Site</LONGNAME>
    <PREFERREDNAME>BIOP_PRFM_STE</PREFERREDNAME>
    <PREFERREDDEFINITION>The description of location or site within the body Biopsy was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Transplant CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2638260</PublicId>
      <PreferredName>BX_ANASITE_PERF</PreferredName>
      <PreferredDefinition>information related to the named location of or within the body of a biopsy, removal and pathologic examination of specimens in the form of small pieces of tissue from the living body, executed and carried through to completion.</PreferredDefinition>
      <LongName>Biopsy Anatomic Site Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187705</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15189</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2638258</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>11287515</PublicId>
      <PreferredName>11287515v1.00</PreferredName>
      <PreferredDefinition>Named locations of or within the body.</PreferredDefinition>
      <LongName>Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>120</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectum/Sigmoid Colon</VALIDVALUE>
          <VALUEMEANING>Rectosigmoid Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>A portion of the large intestine that includes the descending colon, sigmoid colon and rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6403756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colorectal Neoplasm - Mass</VALIDVALUE>
          <VALUEMEANING>Colorectal Neoplasm Mass</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant neoplasm that affects the colon or rectum.  Representative examples of benign neoplasms include lipoma and leiomyoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.  Colorectal adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms._A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34808, C2956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11287823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colorectal Neoplasm - Polyp &gt; 5 mm</VALIDVALUE>
          <VALUEMEANING>Colorectal Neoplasm Polyp Greater Than Five Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign or malignant neoplasm that affects the colon or rectum.  Representative examples of benign neoplasms include lipoma and leiomyoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.  Colorectal adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms._A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations._A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one._A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28251, C66836, C61584, C3340, C2956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11287824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Biopsy Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="949">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>11449439</PUBLICID>
    <LONGNAME>Neuro-QOL Item Bank v2.0 Adult Mental Health Cognitive Function NQCOG67r1 Past 7 Days How Often Had Trouble Remembering Whether I Did Things I was Supposed to Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>NQCOG67R1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how often during the past 7 days they had trouble remembering whether they did things they were supposed to do, like taking a medicine or buying something they needed, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Neuro-QoL Item Bank v2.0  - Cognitive Function, David Cella and PROMIS Health Organization on behalf of NINDS. Sept. 8, 2014.</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>11449410</PublicId>
      <PreferredName>11449388v1.00:11449409v1.00</PreferredName>
      <PreferredDefinition>A domain of the Quality of Life in Neurological Disorders that assesses the status of an adult individual&#39;s mental health._The collection of Neuro-QoL item scales that assess perceived difficulties in cognitive abilities related to both executive function and general concerns.:_The most recent week. May include the present day._A question about how often an individual has or had trouble remembering they did things they were supposed to do._A number or range of numeric values measuring performance, function, quality, or ability</PreferredDefinition>
      <LongName>Neuro-QoL Adult Self-Reported Mental Health Domain Neuro QoL Cognitive Function Subdomain Past Week How Often Had Trouble Remembering Whether I Did Things I was Supposed to Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5920628</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C137841:C137842</PreferredName>
        <Version>1</Version>
        <LongName>Neuro-QoL Adult Self-Reported Mental Health Domain Neuro QoL Cognitive Function Subdomain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C137841</PREFERRED_NAME>
            <LONG_NAME>Neuro-QoL Adult Self-Reported Mental Health Domain</LONG_NAME>
            <CON_ID>5919203</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C137842</PREFERRED_NAME>
            <LONG_NAME>Neuro QoL Cognitive Function Subdomain</LONG_NAME>
            <CON_ID>5919204</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>11449409</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C190228:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Often Had Trouble Remembering Whether I Did Things I was Supposed to Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C190228</PREFERRED_NAME>
            <LONG_NAME>How Often Had Trouble Remembering Whether I Did Things I was Supposed to Question</LONG_NAME>
            <CON_ID>11421507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5920652</PublicId>
      <PreferredName>NEUROQOL_RVFREQ_SCL</PreferredName>
      <PreferredDefinition>A set of self-reported and proxy-reported measures of physical, mental, and social health for adults and children living with a neurological condition._An ordered reference standard used with the Neuro-QoL item bank that describes a reverse range of subjective scores for representing how often an individual experiences something from 5: Never, to 1: Very often.</PreferredDefinition>
      <LongName>Neuro-QoL Reverse Frequency 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Neuro-QoL Item Bank v2.0  - Cognitive Function, David Cella and PROMIS Health Organization on behalf of NINDS. Sept. 8, 2014.</Origin>
      <Representation>
        <PublicId>5920651</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C137840:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life in Neurological Disorders Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C137840</PREFERRED_NAME>
            <LONG_NAME>Quality of Life in Neurological Disorders</LONG_NAME>
            <CON_ID>5919202</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Rarely (Once)</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4869035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Sometimes (Two or three times)</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4869034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Often (About once a day)</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something occurs frequently.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4869033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Often (Several times a day)</VALUEMEANING>
          <MEANINGDESCRIPTION>On most occasions, or in most situations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4869032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I had trouble remembering whether I did things I was supposed to do, like taking a medicine or buying something I needed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Neuro-QOL Item Bank v2.0 - Cognitive Function</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #16 of 28</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="950">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>11482947</PUBLICID>
    <LONGNAME>Regional Lymph Node Short Axis Size Measurement</LONGNAME>
    <PREFERREDNAME>11482946v1.00:7349334v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>An annotation to indicate the size or magnitude of the regional lymph node short axis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>11482946</PublicId>
      <PreferredName>11482945v1.00:2224066v1.00</PreferredName>
      <PreferredDefinition>A lymph node that drains lymph from a region of interest._Line through and perpendicular to an object&#39;s long axis. This line may intersect the long axis anywhere within the object.:The physical magnitude of something.</PreferredDefinition>
      <LongName>Regional Lymph Node Short Axis Size</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>11482945</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49018:C94982</PreferredName>
        <Version>1</Version>
        <LongName>Regional Lymph Node Short Axis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49018</PREFERRED_NAME>
            <LONG_NAME>Regional Lymph Node</LONG_NAME>
            <CON_ID>2486807</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94982</PREFERRED_NAME>
            <LONG_NAME>Short Axis</LONG_NAME>
            <CON_ID>4748957</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224066</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25681</PreferredName>
        <Version>1</Version>
        <LongName>Size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25681</PREFERRED_NAME>
            <LONG_NAME>Size</LONG_NAME>
            <CON_ID>2203799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7349334</PublicId>
      <PreferredName>7349334v1.0</PreferredName>
      <PreferredDefinition>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._The physical magnitude of something._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.</PreferredDefinition>
      <LongName>Lymph Node Size Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008546</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ORGAN_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Organ Measurements</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Princess Margaret Cancer Centre, Toronto, ON</Origin>
      <Representation>
        <PublicId>7349333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12745:C25681:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Lymph Node Size Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25681</PREFERRED_NAME>
            <LONG_NAME>Size</LONG_NAME>
            <CON_ID>2203799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ITC &lt;0,2mm</VALIDVALUE>
          <VALUEMEANING>Isolated Tumor Cells Less than 0.2 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>A cluster of metastatic malignant cells measuring less than 0.2 mm along the greatest dimension.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7352986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macrometastases &gt;2,0 mm</VALIDVALUE>
          <VALUEMEANING>Macrometastasis Greater than 2.0 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of a macrometastasis measuring more than 2 mm along the greatest dimension.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7352987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Micrometastases 0.2 &lt;2.0 mm</VALIDVALUE>
          <VALUEMEANING>Micrometastasis 0.2 mm to 2.0 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of a micrometastasis measuring from 0. 2mm to 2 mm along the greatest dimension.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7352988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than 1.0 cm</VALIDVALUE>
          <VALUEMEANING>Less than 1.0 cm</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than 1.0 cm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11482948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Greater than or equal to 1.0 cm but less than 1.5 cm</VALIDVALUE>
          <VALUEMEANING>Greater than or equal to 1.0 cm but less than 1.5 cm</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than or equal to 1.0 cm but less than 1.5 cm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11482949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Regional Lymph Node Short Axis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="951">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>11532093</PUBLICID>
    <LONGNAME>Second-Line Therapy Post Failure After First Systemic Corticosteroid Therapy Start Date</LONGNAME>
    <PREFERREDNAME>SCDLN_TX_ ST_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The month, day, and year of the start of second-line therapy after failure of systemic corticosteroid first-line therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>11532091</PublicId>
      <PreferredName>11532090v1.00:2712679v1.00</PreferredName>
      <PreferredDefinition>The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs._Happening at a time subsequent to a reference time; later in time or order._Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).:The calendar date on which something is to start or did start.</PreferredDefinition>
      <LongName>Second-Line Therapy Post Systemic Corticosteroid Therapy Start Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>11532090</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54350:C38008:C122080</PreferredName>
        <Version>1</Version>
        <LongName>Second-Line Therapy Post Systemic Corticosteroid Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54350</PREFERRED_NAME>
            <LONG_NAME>Second-Line Therapy</LONG_NAME>
            <CON_ID>2971671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122080</PREFERRED_NAME>
            <LONG_NAME>Systemic Corticosteroid Therapy</LONG_NAME>
            <CON_ID>5127371</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2712679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68616</PreferredName>
        <Version>1</Version>
        <LongName>Start Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68616</PREFERRED_NAME>
            <LONG_NAME>Start Date</LONG_NAME>
            <CON_ID>2712678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2532012</PublicId>
      <PreferredName>DATE</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY-MM-DD</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date starting second line systemic therapy for steroid failure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="952">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12216533</PUBLICID>
    <LONGNAME>Participant Study Enrollment Status</LONGNAME>
    <PREFERREDNAME>BASELIGAMCSTAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Response indicating the enrollment status of the study participant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12216525</PublicId>
      <PreferredName>12216524v1.00:11284399v1.00</PreferredName>
      <PreferredDefinition>Any individiual that has a role in a study, including study personnel and study subjects.:The status of a study with regard to enrollment.</PreferredDefinition>
      <LongName>Study Participant Study Enrollment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>7218854</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C142710</PreferredName>
        <Version>1</Version>
        <LongName>Study Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C142710</PREFERRED_NAME>
            <LONG_NAME>Study Participant</LONG_NAME>
            <CON_ID>6943098</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12216526</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C171160</PreferredName>
        <Version>1</Version>
        <LongName>Study Enrollment Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C171160</PREFERRED_NAME>
            <LONG_NAME>Study Enrollment Status</LONG_NAME>
            <CON_ID>10044202</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>12216530</PublicId>
      <PreferredName>12216530v1.00</PreferredName>
      <PreferredDefinition>A condition or state at a particular time.</PreferredDefinition>
      <LongName>Enrollment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184340</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Status</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Considering enrollment</VALIDVALUE>
          <VALUEMEANING>Enrollment Consideration</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled._Careful thought or deliberation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113416, C37948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12216531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not planning to enroll</VALIDVALUE>
          <VALUEMEANING>No Enrollment Plan</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question._The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled._To devise, contrive, or form in design.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25619, C37948, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12216532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enrolled</VALIDVALUE>
          <VALUEMEANING>Study Subject Enrolled</VALUEMEANING>
          <MEANINGDESCRIPTION>Status in a clinical study when a participant agrees to participate following completion of the informed consent process. NOTE: In some cases, when the prospective participant is unable to legally consent, permission to participate may be obtained from their legally-authorized representative. In some cases, enrollment requires verification of eligibility and inclusion in the analysis database. [after Clinicaltrials.gov]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-01-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6059223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If “Yes”, indicate current status for enrollment in eligible AMC trials</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PART_STDY_ENRLL_STAT</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="953">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12232318</PUBLICID>
    <LONGNAME>Health Care Provider Myocardial Infarction Notification Indicator</LONGNAME>
    <PREFERREDNAME>HCP_MI_NTC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator of whether you have been notified of a myocardial infarction by a healthcare provider.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12232317</PublicId>
      <PreferredName>2675185v1.00:12232316v1.00</PreferredName>
      <PreferredDefinition>Persons who provides health care as part of their job responsibilities: or a person or organization who is licensed to supply health care.:Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis._Informing by words.</PreferredDefinition>
      <LongName>Health Care Provider Myocardial Infarction Notification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2675185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16666</PreferredName>
        <Version>1</Version>
        <LongName>Health Care Provider</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16666</PREFERRED_NAME>
            <LONG_NAME>Health Care Provider</LONG_NAME>
            <CON_ID>2479788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12264811</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C27996:C25297</PreferredName>
        <Version>1</Version>
        <LongName>Myocardial Infarction Notification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27996</PREFERRED_NAME>
            <LONG_NAME>Myocardial Infarction</LONG_NAME>
            <CON_ID>2202873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>12217215</PublicId>
      <PreferredName>12217215v1.00</PreferredName>
      <PreferredDefinition>A state of being, such as a state of health._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Condition Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>12217279</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>12217279v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Condition Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes, and the condition is still present</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, and the condition is still present</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-12-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12217216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Yes, but the condition is no longer present</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, but the condition is no longer present</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-12-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12217217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Not sure</VALUEMEANING>
          <MEANINGDESCRIPTION>Not certain</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-12-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2594711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you been notified of a myocardial infarction by a healthcare provider?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you ever been told by a doctor or other health care professional that you have, or have had a myocardial infarction (heart attack)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>A myocardial infarction (heart attack)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SJL_CV_F2_IND</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="954">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12309174</PUBLICID>
    <LONGNAME>Confirmation Pathologic Disease or Disorder Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>12309173v1.00:3506035v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response for questions to determine eligibility for clinical trial participation, as outlined in the protocol, to address pathological confirmation of any disease or disorder.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12309173</PublicId>
      <PreferredName>5654757v1.00:5633294v1.00</PreferredName>
      <PreferredDefinition>Having been established or verified._Caused by or altered by or manifesting disease or pathology._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Confirmation Pathologic Disease or Disorder Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5654757</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25458:C25610:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Confirmation Pathologic Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2494487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16112</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologically confirmed melanoma, renal cell carcinoma, non-small cell lung cancer, small-cell lung cancer, or breast cancer.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have pathologically (histologically or cytologically) proven diagnosis of Epithelial ovarian cancer, Fallopian tube cancer, or Primary peritoneal cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF TEXT 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathologically proven diagnosis of pancreatic ductal adenocarcinoma?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6147165</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WFB Medical Center</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WFB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6147167</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Walking Speed</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3198920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="955">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12326607</PUBLICID>
    <LONGNAME>Subject Age in Days at Adverse Event Resolution Count</LONGNAME>
    <PREFERREDNAME>12326606v1.00:7069460v2.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The age in days of the subject at adverse event resolution.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Pediatric Cancer</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCDC:Pediatric Cancer Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12326606</PublicId>
      <PreferredName>2523466v1.00:12326605v1.00</PreferredName>
      <PreferredDefinition>A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.:Age of subject (in days) at adverse event resolution.</PreferredDefinition>
      <LongName>Subject Age in Days at Adverse Event Resolution</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Pediatric Cancer</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2523466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41189</PreferredName>
        <Version>1</Version>
        <LongName>Study Subject</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41189</PREFERRED_NAME>
            <LONG_NAME>Study Subject</LONG_NAME>
            <CON_ID>2202706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12326605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C175043</PreferredName>
        <Version>1</Version>
        <LongName>Age in Days at Adverse Event Resolution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C175043</PREFERRED_NAME>
            <LONG_NAME>Age in Days at Adverse Event Resolution</LONG_NAME>
            <CON_ID>10046701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PCDC:Pediatric Cancer Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7069460</PublicId>
      <PreferredName>7069460v2.00</PreferredName>
      <PreferredDefinition>To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>day</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Age at AE Resolved</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ped Core Tier</Name>
        <OrganizationName/>
        <DocumentType>Tier</DocumentType>
        <DocumentText>Conditional</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173181</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173218</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13954630</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>All Pediatric Core CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Observation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14599256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AGE_AT_AE_RESOLVED</AlternateName>
        <AlternateNameType>PCDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Age at AE Resolved</AlternateName>
        <AlternateNameType>Ped Cancer Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="956">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12357523</PUBLICID>
    <LONGNAME>Person Driver&#39;s License Indicator</LONGNAME>
    <PREFERREDNAME>PRSN_DL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator of whether you have a driver&#39;s license.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12357510</PublicId>
      <PreferredName>2236731v1.00:12357509v1.00</PreferredName>
      <PreferredDefinition>A human being.:A document that authorizes a person to operate a motor vehicle on public roads.</PreferredDefinition>
      <LongName>Person Driver&#39;s License</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12357509</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C122899</PreferredName>
        <Version>1</Version>
        <LongName>Driver&#39;s License</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122899</PREFERRED_NAME>
            <LONG_NAME>Driver&#39;s License</LONG_NAME>
            <CON_ID>5379711</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7801087</PublicId>
      <PreferredName>7801087v1.0</PreferredName>
      <PreferredDefinition>A symbol or combination of symbols which is assigned to the members of a collection._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2208003</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>N/A</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6594241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Do you have a driver&#39;s license?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you have a driver&#39;s license?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Do you currently have a driver&#39;s license?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SJL_HLH_O19_IND</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="957">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12460865</PUBLICID>
    <LONGNAME>Immediate Treatment Not Required Determined Indicator</LONGNAME>
    <PREFERREDNAME>IMM_TX_NOTREQ_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Response indicating whether physician determined that no immediate treatment is required.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12459929</PublicId>
      <PreferredName>12459928v1.00:6002197v1.00</PreferredName>
      <PreferredDefinition>Without delay._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._An operation in which a term denies or inverts the meaning of another term or construction.:The establishment of a state or result.</PreferredDefinition>
      <LongName>Immediately Therapeutic Procedure Negation Determine</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>12459928</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64597:C49236:C25594</PreferredName>
        <Version>1</Version>
        <LongName>Immediately Therapeutic Procedure Negation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64597</PREFERRED_NAME>
            <LONG_NAME>Immediately</LONG_NAME>
            <CON_ID>2797587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6002197</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C136827</PreferredName>
        <Version>1</Version>
        <LongName>Determine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C136827</PREFERRED_NAME>
            <LONG_NAME>Determine</LONG_NAME>
            <CON_ID>6002196</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the treating physician determine that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="958">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12914462</PUBLICID>
    <LONGNAME>Disease Involvement Cohort Location</LONGNAME>
    <PREFERREDNAME>DZ_INV_COHORT_SITE</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the cohort disease involvement location.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014865</PublicId>
      <PreferredName>DZ_INVLT</PreferredName>
      <PreferredDefinition>involvement by the patient&#39;s disease.</PreferredDefinition>
      <LongName>Disease Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177473</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Involvement</PreferredName>
        <Version>1</Version>
        <LongName>Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>12914456</PublicId>
      <PreferredName>12914456v1.00</PreferredName>
      <PreferredDefinition>A group of individuals, identified by a common characteristic._The anatomic site of the disease._Named locations of or within the body.</PreferredDefinition>
      <LongName>Cohort Disease Involvement Site Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>12914458</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>12914458v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Cohort Disease Involvement Site Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61512</PREFERRED_NAME>
            <LONG_NAME>Cohort</LONG_NAME>
            <CON_ID>2555083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C173263</PREFERRED_NAME>
            <LONG_NAME>Disease Involvement Site</LONG_NAME>
            <CON_ID>7449164</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C1: Intrahepatic</VALIDVALUE>
          <VALUEMEANING>Intrahepatic</VALUEMEANING>
          <MEANINGDESCRIPTION>(in-tra-hep-AT-ik) Within the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3177658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C2: Extrahepatic</VALIDVALUE>
          <VALUEMEANING>Extrahepatic</VALUEMEANING>
          <MEANINGDESCRIPTION>(extra-heh-PAT-ik) Located or occurring outside the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3177657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C3: Gall bladder</VALIDVALUE>
          <VALUEMEANING>Gallbladder</VALUEMEANING>
          <MEANINGDESCRIPTION>A pear-shaped organ just below the liver that stores the bile secreted by the liver, delivering the bile through the bile ducts into the intestines to help with digestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3124021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cohort disease involvement location</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease Location</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="959">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>12982712</PUBLICID>
    <LONGNAME>Tumor Identifier Domain Planned Timepoint CDISC Variable Name</LONGNAME>
    <PREFERREDNAME>TUTPT</PREFERREDNAME>
    <PREFERREDDEFINITION>The planned timepoint of the tumor identification findings recorded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>12982711</PublicId>
      <PreferredName>6607938v1.00:12978758v1.00</PreferredName>
      <PreferredDefinition>A domain that represents the data that uniquely identifies tumors.:To devise, contrive, or form in design._A specific point in the time continuum, including those established relative to an event.</PreferredDefinition>
      <LongName>Tumor Identifier Domain Planned Timepoint</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6607938</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106577</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Identifier Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106577</PREFERRED_NAME>
            <LONG_NAME>Tumor Identifier Domain</LONG_NAME>
            <CON_ID>6607937</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12978758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25619:C68568</PreferredName>
        <Version>1</Version>
        <LongName>Plan Timepoint</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68568</PREFERRED_NAME>
            <LONG_NAME>Timepoint</LONG_NAME>
            <CON_ID>2656619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6353425</PublicId>
      <PreferredName>CDISCNAM</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C42614</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the planned time point?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="960">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13207341</PUBLICID>
    <LONGNAME>Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0 Past Week Hours Missed from Work Because of Health Problems Number</LONGNAME>
    <PREFERREDNAME>WPAISHP_MISWORK_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how many hours they missed from work because of their health problem.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>WPAI-GH:Work Productivity and Activity Impairment Questionnaire-General Health V2.0. Reilly MC, Zbrozek AS, Dukes EM., 1993.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13206822</PublicId>
      <PreferredName>13206821v1.00:4987855v1.00</PreferredName>
      <PreferredDefinition>A questionnaire designed to measure the effect of a limited or local physical or emotional problem or symptom on an individual’s ability to work and perform regular activities. It measures absenteeism, presenteeism, as well as impairments in unpaid activity because of a health problem.:The most recent week. May include the present day._A question about how many hours an individual missed from work because of their health problems.</PreferredDefinition>
      <LongName>Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Past Week Hours Missed from Work Because of Health Problems</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>13206821</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C198209</PreferredName>
        <Version>1</Version>
        <LongName>Work Productivity and Activity Impairment Questionnaire: Specific Health Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C198209</PREFERRED_NAME>
            <LONG_NAME>Work Productivity and Activity Impairment Questionnaire: Specific Health Problem</LONG_NAME>
            <CON_ID>13203415</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4987855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C123287</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Hours Missed from Work Because of Health Problems</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123287</PREFERRED_NAME>
            <LONG_NAME>Hours Missed from Work Because of Health Problems Question</LONG_NAME>
            <CON_ID>4980687</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>WPAI-GH:Work Productivity and Activity Impairment Questionnaire-General Health V2.0. Reilly MC, Zbrozek AS, Dukes EM., 1993.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2731654</PublicId>
      <PreferredName>HR_NUM</PreferredName>
      <PreferredDefinition>the number to represent a unit measure of time equal to 3,600 seconds or 60 minutes.</PreferredDefinition>
      <LongName>Hour Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2731653</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25529:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Hour Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25529</PREFERRED_NAME>
            <LONG_NAME>Hour</LONG_NAME>
            <CON_ID>2203682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>During the past seven days, how many hours did you miss from work because of problems related to your PROBLEM?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>During the past seven days, how many hours did you miss from work because of problems associated with your breast cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Work Productivity and Activity Impairment Questionnaire: General Health v2.0 (WPAI:GH)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900361</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="961">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13298781</PUBLICID>
    <LONGNAME>Oropharynx Carcinoma CDKN2A-p16 Positive Present Indicator</LONGNAME>
    <PREFERREDNAME>13298369v1.00:3506036v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator of whether CDKN2A-p16 positive oropharynx cancer was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13298369</PublicId>
      <PreferredName>13298367v1.00:13298368v1.00</PreferredName>
      <PreferredDefinition>Carcinoma, predominantly squamous cell, arising from the epithelial cells of the oropharynx._Indicates that CDKN2A-p16 expression has been detected in a sample.:Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Oropharynx Carcinoma CDKN2A-p16 Positive Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>13300467</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9105:C129258</PreferredName>
        <Version>1</Version>
        <LongName>Oropharyngeal Carcinoma CDKN2A-p16 Positive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9105</PREFERRED_NAME>
            <LONG_NAME>Oropharyngeal Carcinoma</LONG_NAME>
            <CON_ID>2594573</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129258</PREFERRED_NAME>
            <LONG_NAME>CDKN2A-p16 Positive</LONG_NAME>
            <CON_ID>5476718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was CDKN2A-p16 positive oropharynx cancer present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG-ACRIN - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>P16+ oropharynx cancer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="962">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13347079</PUBLICID>
    <LONGNAME>Gene Mutation ACMG Clinical Significance Category</LONGNAME>
    <PREFERREDNAME>13347073v1.00:13347078v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The treatment or management implications for a patient&#39;s condition caused by a gain, loss or alteration of the sequences comprising a gene, as defined by the American College of Medical Genetics and Genomics (ACMG) .</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>Pediatric Cancer</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCDC:Pediatric Cancer Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13347073</PublicId>
      <PreferredName>3226153v1.00:13347072v1.00</PreferredName>
      <PreferredDefinition>The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.:A nationally recognized interdisciplinary professional membership organization that represents the interests of the entire medical genetics field including clinical geneticists, clinical laboratory geneticists, and genetic counselors. The ACMG and its members engage in coordinated efforts to improve patient care, ensure optimal reimbursement for genetic service providers, establish standards of care and laboratory policy, and educate members about advances important to their practices. (https://www.acmg.net/)_A finding that has treatment or management implications for a patient&#39;s condition.</PreferredDefinition>
      <LongName>Gene Mutation ACMG Clinical Significance</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>Pediatric Cancer</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3226153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18093</PreferredName>
        <Version>1</Version>
        <LongName>Gene Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18093</PREFERRED_NAME>
            <LONG_NAME>Gene Mutation</LONG_NAME>
            <CON_ID>3086322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>13347072</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C198169:C82562</PreferredName>
        <Version>1</Version>
        <LongName>American College of Medical Genetics and Genomics Clinical Significance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C198169</PREFERRED_NAME>
            <LONG_NAME>American College of Medical Genetics and Genomics</LONG_NAME>
            <CON_ID>13196058</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82562</PREFERRED_NAME>
            <LONG_NAME>Clinical Significance</LONG_NAME>
            <CON_ID>3179443</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PCDC:Pediatric Cancer Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>13347078</PublicId>
      <PreferredName>13347078v1.00</PreferredName>
      <PreferredDefinition>A finding that has treatment or management implications for a patient&#39;s condition._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Clinical Significance Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>Pediatric Cancer</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PCDC:Pediatric Cancer Data Commons</Origin>
      <Representation>
        <PublicId>13347077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>13347077v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Significance Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82562</PREFERRED_NAME>
            <LONG_NAME>Clinical Significance</LONG_NAME>
            <CON_ID>3179443</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Variant Likely Benign</VALIDVALUE>
          <VALUEMEANING>Variant Likely Benign</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic variant that is not expected to contribute to the development of a disease, but the scientific evidence may be insufficient to prove this conclusively.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Variant Benign</VALIDVALUE>
          <VALUEMEANING>Variant Benign</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic variant that is known to not contribute to the development of a disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathogenic Variant</VALIDVALUE>
          <VALUEMEANING>Pathogenic Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic variant that is known to directly contribute to the development of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Likely Pathogenic Variant</VALIDVALUE>
          <VALUEMEANING>Likely Pathogenic Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetic variant that is known to have a high likelihood (greater than 90% certainty) to contribute to the development of a disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Variant of Unknown Significance</VALIDVALUE>
          <VALUEMEANING>Variant of Unknown Significance</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that there is not enough information to support a more definitive classification of the pathogenicity of a genetic variant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7165620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reported Significance</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PCDC Description</Name>
        <OrganizationName/>
        <DocumentType>DESCRIPTION</DocumentType>
        <DocumentText>The reported ACMG clinical significance of this genetic variation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Genetic Analysis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173196</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13954629</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCR</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Molecular</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14737353</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>REPORTED_SIGNIFICANCE</AlternateName>
        <AlternateNameType>PCDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Reported Significance</AlternateName>
        <AlternateNameType>NCCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="963">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13362250</PUBLICID>
    <LONGNAME>Laboratory Test Result Less Than Measurable Yes No Indicator</LONGNAME>
    <PREFERREDNAME>LAB_RSLT_LT_MSRMT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indication of whether or not the laboratory test result value was less than the quantifiable limit.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13361755</PublicId>
      <PreferredName>2555440v1.00:13361754v1.00</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test.:A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._Capable of being measured.</PreferredDefinition>
      <LongName>Laboratory Test Result Less Than Measurable</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2555440</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292</PreferredName>
        <Version>1</Version>
        <LongName>Test Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>13362253</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61585:C37894</PreferredName>
        <Version>1</Version>
        <LongName>Less Than Measurable</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61585</PREFERRED_NAME>
            <LONG_NAME>Less Than</LONG_NAME>
            <CON_ID>2620099</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37894</PREFERRED_NAME>
            <LONG_NAME>Measurable</LONG_NAME>
            <CON_ID>2202455</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was value detected below the quantifiable limit?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_RLT_LT_MS_IND</AlternateName>
        <AlternateNameType>OID, COG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="964">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13368777</PUBLICID>
    <LONGNAME>Study Patient Reported Outcome Measures Other Specify</LONGNAME>
    <PREFERREDNAME>13362450v1.00:2666713v2.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A reason different than the one(s) previously specified describing the survey measures that are completed by the patient which help assess patient status with regards to pain, mobility, quality of life, ability to perform daily tasks or notable events in a clinical study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>Pediatric Cancer</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCDC:Pediatric Cancer Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13362450</PublicId>
      <PreferredName>2619600v1.00:13362449v1.00</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:Survey measures that are completed by the patient which help assess patient status with regards to pain, mobility, quality of life, ability to perform daily tasks or notable events in a clinical study.</PreferredDefinition>
      <LongName>Study Patient Reported Outcome Measures</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>Pediatric Cancer</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2619600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536</PreferredName>
        <Version>1</Version>
        <LongName>Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>13362449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C177377</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcome Measures</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C177377</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcome Measures</LONG_NAME>
            <CON_ID>10049650</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PCDC:Pediatric Cancer Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pro Measures Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173181</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Reported Outcomes Metadata</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173255</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRO_MEASURES_OTHER</AlternateName>
        <AlternateNameType>PCDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="965">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13469107</PUBLICID>
    <LONGNAME>MICRA 11 Past Week Uncertain About What Genetic Test Result Means for Cancer Risk of Children and/or Family Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MICRA_11_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated response, in the past week, of being uncertain about what their test result means about their children&#39;s and/or family&#39;s cancer risk, using a 4 point frequency scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MICRA: Multidimensional Impact of Cancer Risk Assessment - D. Cella et al., Health Psychology, Dec 2002</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13443949</PublicId>
      <PreferredName>13443885v1.00:13443948v1.00</PreferredName>
      <PreferredDefinition>A questionnaire designed as a brief, practical, and targeted assessment of concerns and psychosocial issues associated with the disclosure of results following genetic testing.:The most recent week. May include the present day._A question about whether an individual is uncertain about what their genetic test result means about the cancer risk for their child(ren) and/or family._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Multidimensional Impact of Cancer Risk Past Week Uncertain About What Genetic Test Result Means for Cancer Risk of Children and/or Family Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>13443885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C198892</PreferredName>
        <Version>1</Version>
        <LongName>Multidimensional Impact of Cancer Risk Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C198892</PREFERRED_NAME>
            <LONG_NAME>Multidimensional Impact of Cancer Risk Assessment</LONG_NAME>
            <CON_ID>13434379</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>13443948</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C198915:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Uncertain About What Genetic Test Result Means for Cancer Risk of Children and/or Family Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C198915</PREFERRED_NAME>
            <LONG_NAME>Uncertain About What Genetic Test Result Means for Cancer Risk of Children and/or Family Question</LONG_NAME>
            <CON_ID>13434390</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>13460465</PublicId>
      <PreferredName>13460465v1.00</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes; 0-Never, 1-Rarely, 3-Sometimes, 5-Often</PreferredDefinition>
      <LongName>Frequency 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Often</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something occurs frequently.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4271632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Being uncertain about what my test result means for my child(ren) and/or family’s cancer risk.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Multidimensional Impact of Cancer Risk Assessment (MICRA)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #11 of 25</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="966">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13579886</PUBLICID>
    <LONGNAME>Therapeutic Procedure Agent Name</LONGNAME>
    <PREFERREDNAME>13579884v1.00:13579885v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the individual therapeutic agent(s) used as part of a treatment regimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CRDC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDS:Cancer Data Service</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13579884</PublicId>
      <PreferredName>2512834v1.00:2514627v1.00</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.</PreferredDefinition>
      <LongName>Therapeutic Procedure Agent</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2837878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1909</PreferredName>
        <Version>1</Version>
        <LongName>Pharmacologic Substance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDS:Cancer Data Service</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>13579885</PublicId>
      <PreferredName>13579885v1.00</PreferredName>
      <PreferredDefinition>A substance that inhibits the maturation, growth or spread of tumor cells.._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Antineoplastic Agent Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDS:Cancer Data Service</Origin>
      <Representation>
        <PublicId>14595024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14595024v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Antineoplastic Agent Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C274</PREFERRED_NAME>
            <LONG_NAME>Antineoplastic Agent</LONG_NAME>
            <CON_ID>2751673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10-Deacetyltaxol</VALIDVALUE>
          <VALUEMEANING>10-Deacetyltaxol</VALUEMEANING>
          <MEANINGDESCRIPTION>An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C957</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11C Topotecan</VALIDVALUE>
          <VALUEMEANING>11C Topotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata radiolabeled with carbon 11 (11C) with antineoplastic and radiotracer properties. During the S phase of the cell cycle, topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Quantitation of 11C topotecan accumulated in tumor tissues by positron emission tomography (PET) may help predict responses to topotecan therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11D10 AluGel Anti-Idiotype Monoclonal Antibody</VALIDVALUE>
          <VALUEMEANING>11D10 AluGel Anti-Idiotype Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal anti-idiotype antibody adsorbed to aluminum hydroxide gel (AluGel) with potential antineoplastic activity.  11D10 AluGel anti-idiotype monoclonal antibody mimics the human milk fat globule (HMFG) antigen found in breast and other cancers.  Vaccination with 11D10 AluGel anti-idiotype monoclonal antibody may induce a host antibody response against tumor cells positive for the HMFG antigen. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12-Allyldeoxoartemisinin</VALIDVALUE>
          <VALUEMEANING>12-Allyldeoxoartemisinin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic analogue of Artemisinin - a sesquiterpene lactone extracted from the dry leaves of Artemisia Annua (sweet wormwood) used as anti-malaria agent. Limited data is available on Artemisinin antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13-Deoxydoxorubicin</VALIDVALUE>
          <VALUEMEANING>13-Deoxydoxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  13-Deoxydoxorubicin intercalates DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent was designed to be a non-cardiotoxic anthracycline antibiotic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14C BMS-275183</VALIDVALUE>
          <VALUEMEANING>14C BMS-275183</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521</VALIDVALUE>
          <VALUEMEANING>17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2,6-Diaminopurine</VALIDVALUE>
          <VALUEMEANING>2,6-Diaminopurine</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a number of organic compounds that share a similar purine structure and possess antiviral and antitumor properties. 2,6-Diaminopurine nucleosides are versatile synthetic precursors for specific N-6 modifications of antiviral and antitumor agents. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2,6-Dimethoxyquinone</VALIDVALUE>
          <VALUEMEANING>2,6-Dimethoxyquinone</VALUEMEANING>
          <MEANINGDESCRIPTION>A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5271793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Deoxy-D-glucose</VALIDVALUE>
          <VALUEMEANING>2-Deoxyglucose (2DG)</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3431163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Ethylhydrazide</VALIDVALUE>
          <VALUEMEANING>2-Ethylhydrazide</VALUEMEANING>
          <MEANINGDESCRIPTION>A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2&#39;-F-ara-deoxyuridine</VALIDVALUE>
          <VALUEMEANING>2&#39;-F-ara-deoxyuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A deoxyuridine prodrug with potential antineoplastic activity. Upon cellular uptake, 2&#39;-F-ara-deoxyuridine (FAU) is phosphorylated by thymidine kinase to FAU monophosphate and subsequently methylated in the 5&#39;-position by thymidylate synthase (TS) to its activated form, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FMAUMP is incorporated into DNA leading to an inhibition of DNA synthesis and so cell growth. The catalytic activity of TS is critical to activation of FAU and subsequent incorporation into DNA. FAU may be beneficial in the case of tumors with high TS activity that are resistant to TS inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Fluoroadenine</VALIDVALUE>
          <VALUEMEANING>2-Fluoroadenine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Hydroxyestradiol</VALIDVALUE>
          <VALUEMEANING>2-Hydroxyestradiol</VALUEMEANING>
          <MEANINGDESCRIPTION>A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4810379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Hydroxyestrone</VALIDVALUE>
          <VALUEMEANING>2-Hydroxyestrone</VALUEMEANING>
          <MEANINGDESCRIPTION>No Value Exists</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3270706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Hydroxyflutamide Depot</VALIDVALUE>
          <VALUEMEANING>2-Hydroxyflutamide Depot</VALUEMEANING>
          <MEANINGDESCRIPTION>A depot formulation containing a bioresorbable, controlled-release, calcium sulphate-based paste of the nonsteroidal antiandrogen 2-hydroxyflutamide (2-HOF) with potential antineoplastic activity. Upon injection into the tumor site in the prostate, 2-hydroxyflutamide depot slowly releases 2-HOF, which competitively binds to androgen receptors (ARs), blocking the binding of dihydrotestosterone (DHT). This may inhibit androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest and decreased cellular proliferation. In addition, 2-HOF inhibits nuclear uptake of androgen in androgen-responsive tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Methoxyestradiol</VALIDVALUE>
          <VALUEMEANING>2-Methoxyestradiol</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Methoxyestradiol Nanocrystal Colloidal Dispersion</VALIDVALUE>
          <VALUEMEANING>2-Methoxyestradiol Nanocrystal Colloidal Dispersion</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable liquid formulation containing the small molecule 2-methoxyestradiol with potential antineoplastic activity. 2-Methoxyestradiol, a naturally occurring estradiol metabolite, exerts its antitumor effect by inhibiting endothelial cells as well as tumor cells through multiple mechanisms. This agent binds to tubulin and disrupts microtubule formation, thereby preventing mitosis and subsequent cellular proliferation. In addition, 2-methoxyestradiol induces caspase activation, resulting in cell cycle arrest in G2 phase and apoptosis in due course. This agent also down-regulates hypoxia inducible factor-one alpha (HIF-1a). The nanocrystal colloidal dispersion increases the absorption of 2-methoxyestradiol, thereby improving its bioavailability, which results in enhanced drug plasma levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Methoxyestrone</VALIDVALUE>
          <VALUEMEANING>2-Methoxyestrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3&#39;-C-ethynylcytidine</VALIDVALUE>
          <VALUEMEANING>3&#39;-C-ethynylcytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3&#39;-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3&#39;-dA Phosphoramidate NUC-7738</VALIDVALUE>
          <VALUEMEANING>3&#39;-dA Phosphoramidate NUC-7738</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphoramidate derivative of the monophosphate form of cordycepin (3&#39;-deoxyadenosine; 3&#39;-dA), an adenosine derivative first isolated from Cordyceps sinensis, with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon administration and cellular uptake of NUC-7738 by passive diffusion, cordycepin monophosphate (3&#39;-dAMP) is converted into its active anti-cancer metabolite 3&#39;-deoxyadenosine triphosphate (3&#39;-dATP). 3&#39;-dATP functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis. Also, 3&#39;-dAMP activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling. This prevents the hyperphosphorylation of the translation repressor protein 4E-BP1. This results in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers. Compared to cordycepin alone, the addition of the phosphoramidate moiety may overcome cancer resistance and allow for greater cytotoxicity as NUC-7738 does not require a nucleoside transporter for cellular uptake, is independent of  enzymatic activation by adenosine kinase (AK) and is not susceptible to enzymatic degradation by adenosine deaminase (ADA). Altogether, this may help overcome cancer resistance to cordycepin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4&#39;-Iodo-4&#39;-Deoxydoxorubicin</VALIDVALUE>
          <VALUEMEANING>4&#39;-Iodo-4&#39;-Deoxydoxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An iodinated doxorubicin analogue with antiamyloid activity. 4&#39;-Iodo-4&#39;-deoxydoxorubicin (IDOX) binds with high affinity to five types of natural amyloid fibrils including immunoglobulin light chains, amyloid A, transthyretin (methionine-30 variant), beta-protein (Alzheimer), and beta2-microglobulin. This agent may inhibit fibril growth, increasing the solubility of amyloid tissue deposits and facilitating their clearance. IDOX has also been shown to insulin amyloid fibrillogenesis in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4-Nitroestrone 3-Methyl Ether</VALIDVALUE>
          <VALUEMEANING>4-Nitroestrone 3-Methyl Ether</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels.  This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4-Thio-2-deoxycytidine</VALIDVALUE>
          <VALUEMEANING>4-Thio-2-deoxycytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5-Aza-4&#39;-thio-2&#39;-deoxycytidine</VALIDVALUE>
          <VALUEMEANING>5-Aza-4&#39;-thio-2&#39;-deoxycytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4&#39;-thio-2&#39;-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5-Fluoro-2-Deoxycytidine</VALIDVALUE>
          <VALUEMEANING>5-Fluoro-2-Deoxycytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158</VALIDVALUE>
          <VALUEMEANING>6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7-Cyanoquinocarcinol</VALIDVALUE>
          <VALUEMEANING>7-Cyanoquinocarcinol</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic analogue of the Streptomyces melanovinaceus-derived tetracyclic antitumor antibiotic quinocarmycin with potential antineoplastic activity. Quinocarmycin belongs to the naphthyridinomycin/saframycin class of antitumor antibiotics. These antibiotics appear to act through DNA alkylation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1611</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7-Hydroxystaurosporine</VALIDVALUE>
          <VALUEMEANING>7-Hydroxystaurosporine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8-Azaguanine</VALIDVALUE>
          <VALUEMEANING>8-Azaguanine</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine analogue with potential antineoplastic activity.  8-Azaguanine interferes with the modification of transfer ribonucleic acid (tRNA) by competing with guanine for incorporation into tRNA catalyzed by the enzyme tRNA-guanine ribosyltransferase (tRNA-guanine transglycosylase).  Altered guanine modification of tRNA has been implicated in cellular differentiation and neoplastic transformation.  8-Azaguanine also inhibits the formation of 43S and 80S initiation complexes, thereby interfering with initiation of translation and inhibiting protein synthesis.  This agent inhibits tumor cell growth and stimulates cell differentiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9-Ethyl 6-Mercaptopurine</VALIDVALUE>
          <VALUEMEANING>9-Ethyl 6-Mercaptopurine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alkyl derivative prodrug of the antineoplastic agent 6-mercaptopurine (6-MP).  In vivo, 9-ethyl 6-mercaptopurine appears to be converted to 6-MP, which substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9H-Purine-6Thio-98D</VALIDVALUE>
          <VALUEMEANING>9H-Purine-6Thio-98D</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite analogue of purine with antineoplastic and immuno-suppressant properties.  9H-Purine-6Thio-98D substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. In vivo, this agent, also known as 6MP-arabinoside, may occur as a metabolite of the antineoplastic agent mercaptopurine. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7-Ethyl-10-Hydroxycamptothecin</VALIDVALUE>
          <VALUEMEANING>7-Ethyl-10-Hydroxycamptothecin</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abagovomab</VALIDVALUE>
          <VALUEMEANING>Abagovomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abarelix</VALIDVALUE>
          <VALUEMEANING>Abarelix</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide antagonist of gonadotropin-releasing hormone. Abarelix binds to the luteinizing hormone-releasing hormone receptor, thereby inhibiting the secretion of gonadotropin releasing hormone and ultimately reducing testosterone production. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abemaciclib</VALIDVALUE>
          <VALUEMEANING>Abemaciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abemaciclib Mesylate</VALIDVALUE>
          <VALUEMEANING>Abemaciclib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abexinostat</VALIDVALUE>
          <VALUEMEANING>Abexinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68920</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abexinostat Tosylate</VALIDVALUE>
          <VALUEMEANING>Abexinostat Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abiraterone</VALIDVALUE>
          <VALUEMEANING>Abiraterone (Zytiga)</VALUEMEANING>
          <MEANINGDESCRIPTION>A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abiraterone Acetate</VALIDVALUE>
          <VALUEMEANING>Abiraterone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5425971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abituzumab</VALIDVALUE>
          <VALUEMEANING>Abituzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities. Abituzumab, a chimeric antibody which includes the antigen binding sites of the anti-integrin mouse antibody 17E6, binds to and inhibits the activity of alphaVbeta3 integrin (vitronectin receptor); this may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alphavbeta3-expressing tumor cells. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is expressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acai Berry Juice</VALIDVALUE>
          <VALUEMEANING>Acai Berry Juice</VALUEMEANING>
          <MEANINGDESCRIPTION>A juice product obtained from the fruit of the acai palm tree (Euterpe oleracea) with anti-inflammatory, antioxidant and potential chemopreventive activities. Besides high amounts of vitamins, minerals and fatty acids, acai berry is rich in phytonutrients such as anthocyanins and flavones which are potent scavengers of reactive oxygen species. The fruit also contains high amounts of the flavone velutin which exhibits potent anti-inflammatory properties. Velutin is able to inhibit the degradation of the inhibitor of nuclear factor kappa-B (NF-kB), thereby blocking the activation of NF-kB, as well as inhibiting phosphorylation of mitogen-activated protein kinase p38 and JNK. Inhibition of these processes results in suppression of the production of proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin 6.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acalabrutinib</VALIDVALUE>
          <VALUEMEANING>Acalabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of Bruton&#39;s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6028593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acalisib</VALIDVALUE>
          <VALUEMEANING>Acalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aceglatone</VALIDVALUE>
          <VALUEMEANING>Aceglatone</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of D-glucaro-1, 4-lactone with chemopreventive and anti-tumor activities. One of the key processes in which human body eliminates toxic chemicals as well as hormones (such as estrogen) is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Thereby, aceglatone may suppress the developments of hormone-dependent cancers mediated through beta-glucuronidase inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acetylcysteine</VALIDVALUE>
          <VALUEMEANING>Acetylcysteine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, a precursor of the antioxidant enzyme glutathione.  Acetylcysteine regenerates liver stores of glutathione. This agent also reduces disulfide bonds in mucoproteins, resulting in liquification of mucus.  Some evidence suggests that acetylcysteine may exert an anti-apoptotic effect due to its antioxidant activity, possibly preventing cancer cell development or growth.  In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3128727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acitretin</VALIDVALUE>
          <VALUEMEANING>Acitretin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acivicin</VALIDVALUE>
          <VALUEMEANING>Acivicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aclacinomycin B</VALIDVALUE>
          <VALUEMEANING>Aclacinomycin B</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic oligosaccharide anthracycline antibiotic isolated from the bacterium Streptomyces galilaeus.  Aclacinomycin B intercalates into DNA and inhibits both the topoisomerase I and II enzymes, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aclarubicin</VALIDVALUE>
          <VALUEMEANING>Affected by gastric pH</VALUEMEANING>
          <MEANINGDESCRIPTION>An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acodazole</VALIDVALUE>
          <VALUEMEANING>Acodazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C988</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acodazole Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Acodazole Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of acodazole, a synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acolbifene Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Acolbifene Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of acolbifene, a fourth-generation estrogen receptor modulator (SERM) with potential lipid lowering and antineoplastic activity. Acolbifene specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. Acolbifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the effects of estrogen in these tissues. This may inhibit tumor cell proliferation in ER-positive tumor cells. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acridine</VALIDVALUE>
          <VALUEMEANING>Acridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A polycyclic aromatic dye with antineoplastic, antimicrobial and imaging activities. Acridine and its derivatives intercalate within DNA and RNA by forming hydrogen-bonds and stacking between base pairs resulting in DNA crosslinks and strand breaks. In addition, acridine and its derivatives are a potent inhibitor of topoisomerase II enzyme. This results in the inhibition of DNA and RNA synthesis, predominantly occurring during S phase of the cell cycle and ultimately leads to cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acridine Carboxamide</VALIDVALUE>
          <VALUEMEANING>Acridine Carboxamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acronine</VALIDVALUE>
          <VALUEMEANING>Acronine</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural alkaloid with an acridine structure isolated from the bark of the plant Acronychia baueri (Australian scrub ash) with antineoplastic properties.  Acronycine appears to alkylate DNA and interfere with DNA replication. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinium Ac 225 Lintuzumab</VALIDVALUE>
          <VALUEMEANING>Actinium Ac 225 Lintuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinium Ac 225-FPI-1434</VALIDVALUE>
          <VALUEMEANING>Actinium Ac 225-FPI-1434</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158815</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591</VALIDVALUE>
          <VALUEMEANING>Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac-225 anti-PSMA monoclonal antibody J591 binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinomycin C2</VALIDVALUE>
          <VALUEMEANING>Actinomycin C2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C2 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms including, intercalating into the minor groove of DNA and interfering with the function of topoisomerase II. In addition, actinomycin C2 appears to block the interaction between the SH2 domain of growth factor receptor-bound protein-2 (GRB2) and the Src homology 2 domain containing transforming protein 1 adaptor protein SHC, which plays a key role in the Ras signaling pathway thereby halting cellular differentiation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinomycin C3</VALIDVALUE>
          <VALUEMEANING>Actinomycin C3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C3 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms such as intercalating into the minor groove of DNA and interfering with the function of topoisomerase II.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Actinomycin F1</VALIDVALUE>
          <VALUEMEANING>Actinomycin F1</VALUEMEANING>
          <MEANINGDESCRIPTION>A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Actinomycin F1 intercalates into the minor groove of DNA and binds to topoisomerase II, leading to the inhibition of DNA replication and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Activin Type 2B Receptor Fc Fusion Protein STM 434</VALIDVALUE>
          <VALUEMEANING>Activin Type 2B Receptor Fc Fusion Protein STM 434</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acyclic Nucleoside Phosphonate Prodrug ABI-1968</VALIDVALUE>
          <VALUEMEANING>Acyclic Nucleoside Phosphonate Prodrug ABI-1968</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151941</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adagloxad Simolenin</VALIDVALUE>
          <VALUEMEANING>Adagloxad Simolenin</VALUEMEANING>
          <MEANINGDESCRIPTION>A carbohydrate-based immunostimulant comprised of the Globo H hexasaccharide 1 (Globo H) epitope linked to the immunostimulant carrier protein keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration of adagloxad simolenin, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. Globo H is a tumor associated antigen (TAA) commonly found on a variety of tumor cells including breast cancer cells. KLH improves antigenic immune recognition and T-cell responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adavosertib</VALIDVALUE>
          <VALUEMEANING>Adavosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adecatumumab</VALIDVALUE>
          <VALUEMEANING>Adecatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human IgG1 monoclonal antibody (MoAb) directed against the tumor associated antigen (TAA) epithelial cell adhesion molecule (EpCAM) with potential antitumor activity. Adecatumumab binds to EpCAM, which may result in antibody-dependent cellular cytotoxicity (ADCC) directed against EpCAM-expressing tumor cells. EpCAM (CD326), a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells; for some cancers, overexpression has been correlated with decreased survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2A Receptor Antagonist NIR178</VALIDVALUE>
          <VALUEMEANING>Adenosine A2A Receptor Antagonist NIR178</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999</VALIDVALUE>
          <VALUEMEANING>Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2B Receptor Antagonist PBF-1129</VALIDVALUE>
          <VALUEMEANING>Adenosine A2B Receptor Antagonist PBF-1129</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, A2BR antagonist PBF-1129 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2A Receptor Antagonist CS3005</VALIDVALUE>
          <VALUEMEANING>Adenosine A2A Receptor Antagonist CS3005</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist CS3005 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201</VALIDVALUE>
          <VALUEMEANING>Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral Brachyury Vaccine ETBX-051</VALIDVALUE>
          <VALUEMEANING>Adenoviral Brachyury Vaccine ETBX-051</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143034</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6856470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral Cancer Vaccine PF-06936308</VALIDVALUE>
          <VALUEMEANING>Adenoviral Cancer Vaccine PF-06936308</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral MUC1 Vaccine ETBX-061</VALIDVALUE>
          <VALUEMEANING>Adenoviral MUC1 Vaccine ETBX-061</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6856472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001</VALIDVALUE>
          <VALUEMEANING>Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP</VALIDVALUE>
          <VALUEMEANING>Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10457691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901</VALIDVALUE>
          <VALUEMEANING>Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901</VALUEMEANING>
          <MEANINGDESCRIPTION>A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient&#39;s tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral-TSNA priming vaccine GRT-C901, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE</VALIDVALUE>
          <VALUEMEANING>Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant adenoviral serotype 5 (Ad5) in which the Ad5-based vector fiber is replaced by the fiber from the human B adenovirus serotype 35 (F35), encoding for the human guanylyl cyclase C (hGCC), and fused to the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the Ad5/F35-hGCC-PADRE, the Ad5/F35 targets CD46, which is expressed widely on most tumor cells, and the virus is taken up by cells. Once inside the cells, the virus expresses hGCC. The expressed hGCC induces both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated killing of tumor cells. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. The inclusion of the chimeric Ad5/F35 fiber increases viral uptake in cells through CD46.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918</VALIDVALUE>
          <VALUEMEANING>Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918</VALUEMEANING>
          <MEANINGDESCRIPTION>A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931</VALIDVALUE>
          <VALUEMEANING>Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931</VALUEMEANING>
          <MEANINGDESCRIPTION>A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001</VALIDVALUE>
          <VALUEMEANING>Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication incompetent adenovirus encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-2001) in combination with the proprietary activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer. Upon intratumoral administration of INXN-2001 and oral administration of INXN-1001, INXN-1001 is able to induce expression of IL-12 from INXN-2001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aderbasib</VALIDVALUE>
          <VALUEMEANING>Aderbasib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase &#39;sheddase&#39; activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or &quot;&quot;shedding&quot;&quot; soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). ADAM10 processes particular epithelial growth factor receptor (EGFR) ligands and appears to regulate Notch signaling through the cleavage of Notch and its related ligand delta-like ligand-1 (Dll-1). ADAM17 (also known as Tumor necrosis factor-Converting Enzyme or TACE) is involved in processing tumor necrosis factor (TNF) from its membrane bound precursor to its soluble circulating form and in processing ligands for the epidermal growth factor receptor (EGFR) family.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76115</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADH-1</VALIDVALUE>
          <VALUEMEANING>ADH-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ad-RTS-hIL-12</VALIDVALUE>
          <VALUEMEANING>Ad-RTS-hIL-12</VALUEMEANING>
          <MEANINGDESCRIPTION>An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</VALIDVALUE>
          <VALUEMEANING>Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AE37 Peptide/GM-CSF Vaccine</VALIDVALUE>
          <VALUEMEANING>AE37 Peptide/GM-CSF Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aerosol Gemcitabine</VALIDVALUE>
          <VALUEMEANING>Aerosol Gemcitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153133</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aerosolized Aldesleukin</VALIDVALUE>
          <VALUEMEANING>Aerosolized Aldesleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aerosolized Liposomal Rubitecan</VALIDVALUE>
          <VALUEMEANING>Aerosolized Liposomal Rubitecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An aerosolized liposomal preparation of rubitecan, a water-insoluble derivative of camptothecin with potential antineoplastic activity. Rubitecan (or 9-nitro-20 (S)-camptothecin) and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Afatinib Dimaleate</VALIDVALUE>
          <VALUEMEANING>Afatinib Dimaleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Afimoxifene</VALIDVALUE>
          <VALUEMEANING>Afimoxifene</VALUEMEANING>
          <MEANINGDESCRIPTION>A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Afuresertib</VALIDVALUE>
          <VALUEMEANING>Afuresertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agatolimod Sodium</VALIDVALUE>
          <VALUEMEANING>Agatolimod Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agerafenib</VALIDVALUE>
          <VALUEMEANING>Agerafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Afatinib</VALIDVALUE>
          <VALUEMEANING>Afatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4713538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aglatimagene Besadenovec</VALIDVALUE>
          <VALUEMEANING>Aglatimagene Besadenovec</VALUEMEANING>
          <MEANINGDESCRIPTION>An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949</VALIDVALUE>
          <VALUEMEANING>Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agonistic Anti-OX40 Monoclonal Antibody MEDI6469</VALIDVALUE>
          <VALUEMEANING>Agonistic Anti-OX40 Monoclonal Antibody MEDI6469</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AKR1C3-activated Prodrug OBI-3424</VALIDVALUE>
          <VALUEMEANING>AKR1C3-activated Prodrug OBI-3424</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N&#39;-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, AKR1C3-activated prodrug OBI-3424 is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, OBI-3424 is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AKT 1/2 Inhibitor BAY1125976</VALIDVALUE>
          <VALUEMEANING>AKT 1/2 Inhibitor BAY1125976</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111575</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Akt Inhibitor LY2780301</VALIDVALUE>
          <VALUEMEANING>Akt Inhibitor LY2780301</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Akt Inhibitor SR13668</VALIDVALUE>
          <VALUEMEANING>Akt Inhibitor SR13668</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities. Akt inhibitor SR13668 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation, and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alacizumab Pegol</VALIDVALUE>
          <VALUEMEANING>Alacizumab Pegol</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated, cross-linked, humanized divalent-Fab&#39; antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab&#39; antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alanosine</VALIDVALUE>
          <VALUEMEANING>Alanosine</VALUEMEANING>
          <MEANINGDESCRIPTION>An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Albumin-binding Cisplatin Prodrug BTP-114</VALIDVALUE>
          <VALUEMEANING>Albumin-binding Cisplatin Prodrug BTP-114</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Akt Inhibitor MK2206</VALIDVALUE>
          <VALUEMEANING>Akt Inhibitor MK2206</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3374409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aldesleukin</VALIDVALUE>
          <VALUEMEANING>Aldesleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aldoxorubicin</VALIDVALUE>
          <VALUEMEANING>Aldoxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alectinib</VALIDVALUE>
          <VALUEMEANING>Alectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alefacept</VALIDVALUE>
          <VALUEMEANING>Alefacept</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alestramustine</VALIDVALUE>
          <VALUEMEANING>Alestramustine</VALUEMEANING>
          <MEANINGDESCRIPTION>The l-alanine ester form of estramustine, a combination of the nitrogen mustard normustine coupled via a carbamate to estradiol, with antineoplastic activity. Upon conversion of alestramustine to estramustine, estramustine binds to microtubule-associated proteins (MAPs) and beta tubulin, thereby interfering with microtubule dynamics and leading to microtubule disassembly and cell cycle arrest. Due to the estrogen moiety, this agent is able to selectively bind to and be taken up by estrogen receptor-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alflutinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Alflutinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Algenpantucel-L</VALIDVALUE>
          <VALUEMEANING>Algenpantucel-L</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alisertib</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase Inhibitor MLN8237</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3205718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alitretinoin</VALIDVALUE>
          <VALUEMEANING>Alitretinoin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alemtuzumab</VALIDVALUE>
          <VALUEMEANING>Anti-CD52 (Alemtuzumab, Campath)</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5678503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor ASP3026</VALIDVALUE>
          <VALUEMEANING>ALK Inhibitor ASP3026</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor PLB 1003</VALIDVALUE>
          <VALUEMEANING>ALK Inhibitor PLB 1003</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor TAE684</VALIDVALUE>
          <VALUEMEANING>ALK Inhibitor TAE684</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the receptor tyrosine kinases (RTKs) anaplastic lymphoma kinase (ALK) and nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with potential antineoplastic activity. Upon administration, TAE684 binds to and inhibits ALK and NPM-ALK tyrosine kinases, which leads to a disruption of ALK- and NPM-ALK mediated signaling and eventually inhibits tumor cell growth in ALK- and NPM-ALK overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. NPM-ALK is an oncogenic fusion protein associated with ALK-positive anaplastic large cell lymphoma. ALK mutations are also associated with acquired resistance to small molecule tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK/FAK/Pyk2 Inhibitor CT-707</VALIDVALUE>
          <VALUEMEANING>ALK/FAK/Pyk2 Inhibitor CT-707</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK-FAK Inhibitor CEP-37440</VALIDVALUE>
          <VALUEMEANING>ALK-FAK Inhibitor CEP-37440</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alkotinib</VALIDVALUE>
          <VALUEMEANING>Alkotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, alkotinib binds to and inhibits the wild-type, point mutations and fusion proteins of ALK and ROS1. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of proliferation in tumor cells which these kinases are overexpressed, rearranged or mutated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allodepleted T Cell Immunotherapeutic ATIR101</VALIDVALUE>
          <VALUEMEANING>Allodepleted T Cell Immunotherapeutic ATIR101</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK/TRK Inhibitor TSR-011</VALIDVALUE>
          <VALUEMEANING>ALK/TRK Inhibitor TSR-011</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, &#39;off-the-shelf&#39; (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, the allogeneic anti-BCMA CAR-transduced T-cells ALLO-715 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient&#39;s own cells and are produced on an individual basis. In addition, if the ALLO-715 cells cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting both the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-BCMA/CS1 bispecific CAR-T cells target and bind to tumor cells expressing BCMA and/or CS1 and induce selective cytotoxicity in those cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells. Targeting the two different TAAs highly expressed on malignant plasma cells may improve coverage and protect against antigen escape and resistance as tumor cells would need to lose both antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-CD19 CAR T-cells ALLO-501A</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-CD19 CAR T-cells ALLO-501A</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, frozen, &#39;off-the-shelf&#39;, universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, allogeneic anti-CD19 CAR T-cells ALLO-501A specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. ALLO-501A lacks the rituximab recognition domains of ALLO-501.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-CD19 Universal CAR-T Cells CTA101</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-CD19 Universal CAR-T Cells CTA101</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 universal CAR-T cells CTA101 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CTA101 is genetically engineered to prevent graft-versus-host disease (GvHD) by the donor T-cells. OTS CAR-T cells require reduced production times when compared to autologous CAR-T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-CD20 CAR T-cells LUCAR-20S</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-CD20 CAR T-cells LUCAR-20S</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of donor-derived T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T-cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-CD20-CAR T-cells PBCAR20A</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-CD20-CAR T-cells PBCAR20A</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes, derived from healthy donors, that have been genetically modified using a proprietary synthetic endonuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20-CAR T-cells PBCAR20A specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-BCMA-CAR T-cells PBCAR269A</VALIDVALUE>
          <VALUEMEANING>Allogeneic Anti-BCMA-CAR T-cells PBCAR269A</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-BCMA-CAR T-cells PBCAR269A specifically recognize and kill BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22</VALIDVALUE>
          <VALUEMEANING>Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T-lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100</VALIDVALUE>
          <VALUEMEANING>Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Cellular Vaccine 1650-G</VALIDVALUE>
          <VALUEMEANING>Allogeneic Cellular Vaccine 1650-G</VALUEMEANING>
          <MEANINGDESCRIPTION>A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130</VALIDVALUE>
          <VALUEMEANING>Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A</VALIDVALUE>
          <VALUEMEANING>Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T-lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM</VALIDVALUE>
          <VALUEMEANING>Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001</VALIDVALUE>
          <VALUEMEANING>Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine</VALIDVALUE>
          <VALUEMEANING>Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic whole cell vaccine expressing human granulocyte macrophage-colony stimulating factor (GM-CSF) with potential antineoplastic activity. Tumor cells from prostate cancer patients are harvested and then genetically modified to secrete GM-CSF, an immune stimulatory growth factor that plays a key role in stimulating the body&#39;s immune responses against tumor cells. Because the vaccine is derived from allogenic cells, it has demonstrated a favorable side effect profile than other approaches of delivering long-lasting GM-CSF.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine</VALIDVALUE>
          <VALUEMEANING>Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic cancer vaccine composed of lethally irradiated whole melanoma cancer cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body&#39;s immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo</VALIDVALUE>
          <VALUEMEANING>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2</VALIDVALUE>
          <VALUEMEANING>Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of glucocorticoid receptor (GR) negative, allogeneic cytotoxic T-lymphocytes (CTLs) expressing a membrane-tethered interleukin 13 (IL13) cytokine chimeric T-cell antigen receptor (zetakine), with potential antineoplastic activity. Upon transfection of donor T-lymphocytes with a plasmid encoding a fusion protein of the IL13-zetakine and the selection-suicide expression enzyme HyTK, these modified CTLs are expanded and introduced into a patient with glioblastoma multiforme (GBM). This agent specifically targets IL13 receptor alpha2, a glioma-restricted cell-surface epitope; the CTLs exert their cytolytic effect thereby killing IL13Ra2-expressing glioma cells. In addition, IL13-zetakine redirected CTLs induce production of certain cytokines. Furthermore, due to the fact that these CTLs are GR negative, they can be used concomitantly with glucocorticoid therapy. The IL13-zetakine consists of an extracellular IL-13 E13Y mutein-human IgG4 hinge-Fc chimera fused to human cytoplasmic CD3-zeta via the transmembrane domain of human CD4.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90577</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Irradiated Melanoma Cell Vaccine CSF470</VALIDVALUE>
          <VALUEMEANING>Allogeneic Irradiated Melanoma Cell Vaccine CSF470</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body&#39;s immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307</VALIDVALUE>
          <VALUEMEANING>Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Melanoma Vaccine AGI-101H</VALIDVALUE>
          <VALUEMEANING>Allogeneic Melanoma Vaccine AGI-101H</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo</VALIDVALUE>
          <VALUEMEANING>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Natural Killer Cell Line MG4101</VALIDVALUE>
          <VALUEMEANING>Allogeneic Natural Killer Cell Line MG4101</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of allogeneic, cytotoxic natural killer (NK) cells with potential antitumor activity. Allogeneic natural killer cell line MG4101 is derived from cells of a normal, healthy donor upon leukapheresis and activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Natural Killer Cell Line NK-92</VALIDVALUE>
          <VALUEMEANING>Allogeneic Natural Killer Cell Line NK-92</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin&#39;s lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01</VALIDVALUE>
          <VALUEMEANING>Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T-cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19</VALIDVALUE>
          <VALUEMEANING>Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, third-party, CD4+ T-lymphocytes that specifically recognizes the human leukocyte antigen (HLA)-DPB1*0401 and transduced with a suicide gene, with potential antineoplastic activity. Upon administration, allogeneic third-party suicide gene-transduced anti-HLA-DPB1*0401 CD4+ T-cells CTL 19 specifically target and kill HLA-DPB1*0401-positive leukemic cells. The suicide gene causes the destruction of the T-cell clone upon the administration and presence of ganciclovir, which enhances the safety of the agent. HLA-DP is expressed by many leukemic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allovectin-7</VALIDVALUE>
          <VALUEMEANING>Allovectin-7</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Almurtide</VALIDVALUE>
          <VALUEMEANING>Almurtide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alobresib</VALIDVALUE>
          <VALUEMEANING>Alobresib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Renal Cell Carcinoma Vaccine MGN1601</VALIDVALUE>
          <VALUEMEANING>Allogeneic Renal Cell Carcinoma Vaccine MGN1601</VALUEMEANING>
          <MEANINGDESCRIPTION>A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alofanib</VALIDVALUE>
          <VALUEMEANING>Alofanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the fibroblast growth factor receptor (FGFR) type 2 (FGFR2), with potential antineoplastic and anti-angiogenic activities. Upon administration, alofanib targets, allosterically binds to the extracellular domain of FGFR2 and inhibits the activity of FGFR2, which may result in the inhibition of basic FGF (bFGF)/FGFR2-related signal transduction pathways. This inhibits FGF-induced endothelial cell proliferation and migration, and inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpelisib</VALIDVALUE>
          <VALUEMEANING>Alpelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha Galactosylceramide</VALIDVALUE>
          <VALUEMEANING>Alpha Galactosylceramide</VALUEMEANING>
          <MEANINGDESCRIPTION>A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha V Beta 1 Inhibitor ATN-161</VALIDVALUE>
          <VALUEMEANING>Alpha V Beta 1 Inhibitor ATN-161</VALUEMEANING>
          <MEANINGDESCRIPTION>A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha V Beta 8 Antagonist PF-06940434</VALIDVALUE>
          <VALUEMEANING>Alpha V Beta 8 Antagonist PF-06940434</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in the tumor microenvironment (TME) and blocks the activation of the cytokine transforming growth factor-beta 1 (TGF-b1), preventing TGF-b1-mediated signal transduction. This abrogates TGF-b1-mediated immunosuppression, enhances anti-tumor immunity in the TME and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGF-b1-dependent proliferation of cancer cells. Alpha v beta 8 integrin plays a key role in tumor initiation, growth, and progression through TGF-b1 activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha-Gal AGI-134</VALIDVALUE>
          <VALUEMEANING>Alpha-Gal AGI-134</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell membranes and triggers an anti-aGal antibody-mediated immune response leading to an initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC). This cytotoxicity causes release from tumor cells and subsequent uptake of released tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate a systemic immune response against the TAAs and may eradicate cancer cells. aGal is a cell-surface carbohydrate antigen not expressed by humans while being expressed by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly produced by humans due to exposure to aGal present on intestinal bacteria in the digestive system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H</VALIDVALUE>
          <VALUEMEANING>Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic proteolipid complex comprised of the alpha-1 domain of alpha-lactalbumin (lactose synthase B protein) and oleic acid, with potential antineoplastic activity. Upon intravesical instillation, alpha1H selectively accumulates in the nuclei of tumor cells and binds to histones H3, H4, and H2B. By binding to histones, alpha1H disrupts chromatin assembly and interferes with intact chromatin, thereby preventing tumor cell transcription and replication. Additionally, alpha1H inhibits the phosphorylation of multiple kinases involved in cancer-associated pathways including the Ras/Raf/ERK, PI3K/AKT, p38 MAPK and JNK signaling pathways. This may inhibit tumor cell proliferation and induce apoptosis in tumor cells that are driven by the dysregulation of certain kinases and oncogenic GTPases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha-tocopheryloxyacetic Acid</VALIDVALUE>
          <VALUEMEANING>Alpha-tocopheryloxyacetic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alsevalimab</VALIDVALUE>
          <VALUEMEANING>Alsevalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Altiratinib</VALIDVALUE>
          <VALUEMEANING>Altiratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Altretamine</VALIDVALUE>
          <VALUEMEANING>Hexamethylmelamine (Altretamine)</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alvespimycin</VALIDVALUE>
          <VALUEMEANING>17-Dimethylaminoethylamino-17-Demethoxygeldanamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the benzoquinone antineoplastic antibiotic geldanamycin.  17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins.  Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha-Thioguanine Deoxyriboside</VALIDVALUE>
          <VALUEMEANING>Alpha-Thioguanine Deoxyriboside</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine analog with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alvespimycin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Alvespimycin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alvocidib</VALIDVALUE>
          <VALUEMEANING>Alvocidib</VALUEMEANING>
          <MEANINGDESCRIPTION>The free base form of a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alvocidib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Flavopiridol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.  This agent is also a competitive inhibitor of adenosine triphosphate activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alvocidib Prodrug TP-1287</VALIDVALUE>
          <VALUEMEANING>Alvocidib Prodrug TP-1287</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ambamustine</VALIDVALUE>
          <VALUEMEANING>Ambamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ambazone</VALIDVALUE>
          <VALUEMEANING>Ambazone</VALUEMEANING>
          <MEANINGDESCRIPTION>An antiseptic agent with potential antibacterial and antileukemic activity. Although the exact mechanism of action remains to be fully elucidated, ambazone appears to interfere with the membrane-bound nucleotide system by increasing the intracellular concentration of cAMP in leukemia cells and macrophages, which potentially contributes to this agent&#39;s antineoplastic activity. Furthermore, this agent&#39;s affinity for various cellular targets, i.e. membranes, nucleic acids and proteins, may contribute to the overall antibacterial effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amblyomin-X</VALIDVALUE>
          <VALUEMEANING>Amblyomin-X</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amcasertib</VALIDVALUE>
          <VALUEMEANING>Cancer Stemness Kinase Inhibitor BBI503</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, BBI503 targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ametantrone</VALIDVALUE>
          <VALUEMEANING>Ametantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amatuximab</VALIDVALUE>
          <VALUEMEANING>Amatuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62483</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amifostine</VALIDVALUE>
          <VALUEMEANING>Amifostine</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphorylated aminosulfhydryl compound. After dephosphorylation by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, amifostine binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aminocamptothecin</VALIDVALUE>
          <VALUEMEANING>Aminocamptothecin</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent&#39;s antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aminocamptothecin Colloidal Dispersion</VALIDVALUE>
          <VALUEMEANING>Aminocamptothecin Colloidal Dispersion</VALUEMEANING>
          <MEANINGDESCRIPTION>A colloidal dispersion formulation of 9-Aminocamptothecin, a water-insoluble camptothecin derivative. Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages. Because the terminal lactone ring of aminocamptothecin required for the agent&#39;s antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aminoflavone Prodrug AFP464</VALIDVALUE>
          <VALUEMEANING>Aminoflavone Prodrug AFP464</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic lysyl prodrug of the amino-substituted flavone derivate aminoflavone with antiproliferative and antineoplastic activities. AFP464 is rapidly converted to aminoflavone in plasma. Aminoflavone activates the aryl hydrocarbon receptor (AhR) signaling pathway leading to an increase in cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1A2 (CYP1A2) expression and, to a lesser extent, an increase in cytochrome P450 1B1 (CYP1B1) expression. Subsequently, aminoflavone is metabolized to toxic metabolites by the cytochromome P450 enzymes that it induces; these toxic metabolites covalently bind to DNA, resulting in the phosphorylation of p53, the induction of the p53 downstream target p21Waf1/Cip1, and apoptosis. Pulmonary toxicity may be dose-limiting.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aminopterin Sodium</VALIDVALUE>
          <VALUEMEANING>Aminopterin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of a pterin derivative with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amivantamab</VALIDVALUE>
          <VALUEMEANING>Amivantamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amolimogene Bepiplasmid</VALIDVALUE>
          <VALUEMEANING>Amolimogene Bepiplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amonafide L-Malate</VALIDVALUE>
          <VALUEMEANING>Amonafide L-Malate</VALUEMEANING>
          <MEANINGDESCRIPTION>The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amrubicin</VALIDVALUE>
          <VALUEMEANING>Amrubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4076475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aminopterin</VALIDVALUE>
          <VALUEMEANING>Aminopterin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of pterins with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amrubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Amrubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3238483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amsacrine</VALIDVALUE>
          <VALUEMEANING>Amsacrine</VALUEMEANING>
          <MEANINGDESCRIPTION>An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent&#39;s cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amsacrine Lactate</VALIDVALUE>
          <VALUEMEANING>Amsacrine Lactate</VALUEMEANING>
          <MEANINGDESCRIPTION>The lactate form of amsacrine, an aminoacridine analog and topoisomerase II inhibitor, with antineoplastic activity. Although the exact relationship between DNA binding and its activity has yet to be fully elucidated, amsacrine intercalates DNA through its acridine moiety, and its nonintercalative headgroup impedes topoisomerase II activity, augmenting enzyme-mediated DNA cleavage and resulting in DNA double-strand breaks. This ultimately induces programmed cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amsilarotene</VALIDVALUE>
          <VALUEMEANING>Amsilarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A retinobenzoic acid with potential antineoplastic activity. Amsilarotene inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest.  This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amustaline Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Amustaline Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of amustaline, a quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amuvatinib</VALIDVALUE>
          <VALUEMEANING>Amuvatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amuvatinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Amuvatinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anakinra</VALIDVALUE>
          <VALUEMEANING>Anakinra</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7092700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anastrozole</VALIDVALUE>
          <VALUEMEANING>Anastrozole</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3145842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amustaline</VALIDVALUE>
          <VALUEMEANING>Amustaline</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75926</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anaxirone</VALIDVALUE>
          <VALUEMEANING>Anaxirone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ancitabine</VALIDVALUE>
          <VALUEMEANING>Ancitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine, which is converted to the active triphosphate form and competes with deoxycytidine triphosphate for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA and RNA polymerases, resulting in a decrease in cell growth. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ancitabine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Ancitabine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Andecaliximab</VALIDVALUE>
          <VALUEMEANING>Andecaliximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Antagonist APC-100</VALIDVALUE>
          <VALUEMEANING>Androgen Antagonist APC-100</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, vitamin E derivative and androgen receptor (AR) antagonist with potential anti-oxidant, chemopreventative and antineoplastic activity. APC-100 binds to ARs in target tissues thereby inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. By inhibiting the formation of the complex between androgen activated AR- and the AP1 transcription factor JunD, the expression of androgen-responsive genes are blocked. One of such gene is spermidine/spermine N1-acetyl transferase gene (SSAT) that is responsible for the breakdown of polyamines, which are produced in high levels by prostatic epithelial cells, into reactive oxygen species (ROS) that cause cellular damage. APC-100 may ultimately lead to an inhibition of growth in both AR-dependent and AR-independent prostate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antagonist TAS3681</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Antagonist TAS3681</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antagonist TRC253</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Antagonist TRC253</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antisense Oligonucleotide AZD5312</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Antisense Oligonucleotide AZD5312</VALUEMEANING>
          <MEANINGDESCRIPTION>An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antisense Oligonucleotide EZN-4176</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Antisense Oligonucleotide EZN-4176</VALUEMEANING>
          <MEANINGDESCRIPTION>A locked nucleic acid (LNA)-based antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon administration, EZN-4176 is hybridized and releases the complementary sequences of AR mRNA, thereby blocking translation of the AR protein and inhibiting AR-induced tumor cell growth and promoting tumor cell apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival. LNAs contain a methylene bridge linking 2&#39;-oxygen and 4&#39;-carbon of ribose sugar rings, thereby increasing their thermal stability and decreasing degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Degrader CC-94676</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Degrader CC-94676</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antagonist BAY 1161116</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Antagonist BAY 1161116</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Downregulator AZD3514</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Downregulator AZD3514</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Inhibitor EPI-7386</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Inhibitor EPI-7386</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor EPI-7386 specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. EPI-7386 may be more active and metabolically stable than first-generation AR NTD inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Andrographolide</VALIDVALUE>
          <VALUEMEANING>Andrographolide</VALUEMEANING>
          <MEANINGDESCRIPTION>A labdane diterpenoid that is produced by the Andrographis paniculata plant, which has a broad range of therapeutic applications including anti-inflammatory and anti-platelet aggregation activities and potential antineoplastic properties. Since andrographolide has multiple therapeutic activities there are several proposed mechanisms of action for this agent. The anti-inflammatory effects of this agent appear to be related to the inhibition of nitric oxide (NO) production by macrophages. This agent may activate the NO/cyclic GMP pathway and inhibit both the phospholipase C gamma 2 (PLC gamma2)/protein kinase C (PKC) and PI3K/AKT-MAPK signaling pathways in activated platelets to inhibit platelet aggregation. In activated platelets, these three signaling pathways are downstream of integrin activation mediated by collagen binding and influence the association of fibrinogen with its receptors. Additionally, andrographolide may exert its anti-cancer activity through the induction of cell cycle arrest at G0/G1 phase and the stimulation of lymphocyte proliferation and activation. These processes could result in decreased proliferation of and increased immunocytotoxicity against tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androstane Steroid HE3235</VALIDVALUE>
          <VALUEMEANING>Androstane Steroid HE3235</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable adrenal steroid analogue with potential antineoplastic activity. Androstane steroid HE3235 appears to bind the androgen receptor (AR), down-regulating anti-apoptotic genes, such as Bcl-2, while increasing the expression of pro-apoptotic genes, such as caspases. In vitro and in vivo studies indicate that this agent inhibits androstenediol-dependent LNCaP cell tumor growth. In addition, HE3235 may potentiate chemotherapeutic agents by down-regulating ABCG2, the gene encoding the multi-drug resistant (MDR) protein MDR2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anetumab Ravtansine</VALIDVALUE>
          <VALUEMEANING>Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin antibody-drug conjugate BAY 94-9343 targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3595596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241</VALIDVALUE>
          <VALUEMEANING>Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein containing angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) derived peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic aldolase monoclonal antibody, with potential antiangiogenic and antineoplastic activities. The Ang2/VEGF peptide moieties of Ang2/VEGF-binding peptides-antibody fusion protein CVX-241 bind to Ang2 and VEGF receptors, which may inhibit tumor angiogenesis and tumor cell proliferation. The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. This agent possesses an enhanced half-life compared to the naked peptides.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Angiogenesis Inhibitor JI-101</VALIDVALUE>
          <VALUEMEANING>Angiogenesis Inhibitor JI-101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Angiopoietin-2-specific Fusion Protein PF-04856884</VALIDVALUE>
          <VALUEMEANING>Angiopoietin-2-specific Fusion Protein PF-04856884</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10</VALIDVALUE>
          <VALUEMEANING>Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable steroidal cortexolone derivative and antagonist of the androgen receptor (AR) and glucocorticoid receptor (GR), with potential antineoplastic activity. Upon oral administration, AR/GR antagonist CB-03-10 specifically binds to AR and GR, inhibits AR and GR activation, and prevents AR- and GR-mediated signaling. This leads to an induction of both extrinsic and intrinsic apoptotic pathways and inhibits cell growth in AR- and GR-overexpressing tumor cells. AR and GR are overexpressed in certain types of cancer cells and are involved in proliferation, survival and chemoresistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anhydrous Enol-oxaloacetate</VALIDVALUE>
          <VALUEMEANING>Anhydrous Enol-oxaloacetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of enol-oxaloacetate, a small molecule blood glutamate scavenger, that can be used to lower glutamate plasma levels, and has potential neuroprotective activity. Upon administration, enol-oxaloacetate targets and binds to glutamate in the bloodstream. This lowers glutamate plasma levels and lowers the free glutamate available to be picked up by cells, such as tumor brain cells, thereby preventing glutamate metabolism and glutamate-mediated signaling. This prevents the proliferation of rapidly growing cells, such as brain tumor cells. And by lowering glutamate plasma levels, a molecular imbalance is formed and glutamate is excreted across the blood-brain barrier, resulting in lower free brain glutamate.  This may help protect the brain from excitotoxicity in conditions where there is a surge of glutamate production, such as traumatic brain injury, thereby protecting neuronal cells. Glutamate, a non-essential amino acid and the major excitatory neurotransmitter in the central nervous system (CNS), provides energy and generates building blocks for the production of macromolecules, which are needed for cellular growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anhydrovinblastine</VALIDVALUE>
          <VALUEMEANING>Anhydrovinblastine</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of the vinca alkaloid vinblastine, with potential antineoplastic activity. Like vinblastine, anhydrovinblastine targets and binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and causing tumor cell cycle arrest in the M phase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aniline Mustard</VALIDVALUE>
          <VALUEMEANING>Aniline Mustard</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Annamycin</VALIDVALUE>
          <VALUEMEANING>Annamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis.  This agent appears to not be a substrate for the p-glycoprotein associated multidrug-resistance (MDR) transporter; therefore, overcoming the resistance pattern seen with other anthracycline compounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Annonaceous Acetogenins</VALIDVALUE>
          <VALUEMEANING>Annonaceous Acetogenins</VALUEMEANING>
          <MEANINGDESCRIPTION>A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ansamitomicin P-3</VALIDVALUE>
          <VALUEMEANING>Ansamitomicin P-3</VALUEMEANING>
          <MEANINGDESCRIPTION>An ansamacrolide and maytansine analogue originally isolated from the Ethiopian shrub Maytenus serrata with antineoplastic activity. Ansamitomicin P-3 binds to tubulin at the maytansine-binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anthramycin</VALIDVALUE>
          <VALUEMEANING>Anthramycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolo(1,4)benzodiazepine antineoplastic antibiotic isolated from the bacterium Streptomyces refuineus var. thermotolerans.  Anthramycin binds covalently to guanine in the minor groove of DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anthrapyrazole</VALIDVALUE>
          <VALUEMEANING>Anthrapyrazole</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic antibiotic that intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Anthrapyrazoles may also block cell cycle division.  In the presence of electron donors, some anthrapyrazole antibiotics cause single-strand breaks in DNA via photosensitization by visible light.  These agents are less cardiotoxic than doxorubicin. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti c-KIT Antibody-drug Conjugate LOP628</VALIDVALUE>
          <VALUEMEANING>Anti c-KIT Antibody-drug Conjugate LOP628</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Annamycin Liposomal</VALIDVALUE>
          <VALUEMEANING>Annamycin Liposomal</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. Annamycin intercalates into DNA and inhibits topoisomerase II, resulting in the inhibition of DNA replication and repair and RNA and protein synthesis. This agent circumvents multidrug-resistance (MDR) transporters, including P-glycoprotein (P-gp). Liposomal annamycin is less toxic and shows improved antitumor activity compared to annamycin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-5T4 Antibody-drug Conjugate ASN004</VALIDVALUE>
          <VALUEMEANING>Anti-5T4 Antibody-drug Conjugate ASN004</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody directed against 5T4 and conjugated, via a non-cleavable linker, to a proprietary polymer carrying multiple auristatin analog molecules via a cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of ASN004 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell cytosol, free auristatin analog molecules binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-5T4 Antibody-Drug Conjugate PF-06263507</VALIDVALUE>
          <VALUEMEANING>Anti-5T4 Antibody-Drug Conjugate PF-06263507</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-5T4 Antibody-drug Conjugate SYD1875</VALIDVALUE>
          <VALUEMEANING>Anti-5T4 Antibody-drug Conjugate SYD1875</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the oncofetal antigen 5T4 and site-specifically conjugated to a duocarmycin-based linker-drug valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA), with potential antineoplastic activity. Upon administration, the antibody moiety of SYD1875 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell by proteases, the free and activated duocarmycin payload binds to the minor groove of DNA and alkylates adenine at the N3 position, which eventually leads to tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-A33 Monoclonal Antibody KRN330</VALIDVALUE>
          <VALUEMEANING>Anti-A33 Monoclonal Antibody KRN330</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fully human monoclonal antibody directed against the human A33 antigen, with potential immunomodulatory and antineoplastic activity. Anti-A33 monoclonal antibody KRN330 recognizes and binds to the human A33 antigen, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against A33-positive colorectal cancers. A33 antigen, a 43 kDa transmembrane glycoprotein of the immunoglobulin superfamily, is highly and homogenously expressed in 95% of colorectal cancer cancers with only restricted expression in normal colonic mucosa and small bowel epithelia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087</VALIDVALUE>
          <VALUEMEANING>Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AG7 Antibody Drug Conjugate AbGn-107</VALIDVALUE>
          <VALUEMEANING>Anti-AG7 Antibody Drug Conjugate AbGn-107</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AGS-16 Monoclonal Antibody AGS-16M18</VALIDVALUE>
          <VALUEMEANING>Anti-AGS-16 Monoclonal Antibody AGS-16M18</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-16 with potential antineoplastic activity. Anti-AGS-16 monoclonal antibody AGS-16M18 selectively binds to AGS-16, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells expressing AGS-16. While normally expressed at low levels in the proximal tubules of the kidney, AGS-16 has been found to be overexpressed in more than 95% of kidney and 40% of liver neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME</VALIDVALUE>
          <VALUEMEANING>Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) containing the fully human IgG2k monoclonal antibody targeting an epitope of SLC44A4 (AGS-5) linked, via a valine-citrulline (vc) maleimidocaproyl (mc) linker, to the antimicrotubulin drug monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of ASG-5ME selectively binds to AGS-5. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. SLC44A4, potentially a sodium-dependent transmembrane transport protein, is overexpressed on more than 80 percent of samples derived from patients with pancreatic, prostate and gastric cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AGS-8 Monoclonal Antibody AGS-8M4</VALIDVALUE>
          <VALUEMEANING>Anti-AGS-8 Monoclonal Antibody AGS-8M4</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-8 with potential antineoplastic activity. Anti-AGS-8 monoclonal antibody AGS-8M4 selectively binds to AGS-8, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing AGS-8. While normally expressed at low levels in the heart in response to ischemia, AGS-8 has been found to be expressed in more than 70% of ovarian neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-A5B1 Integrin Monoclonal Antibody PF-04605412</VALIDVALUE>
          <VALUEMEANING>Anti-A5B1 Integrin Monoclonal Antibody PF-04605412</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human alpha5beta1 integrin with potential antiangiogenic and antineoplastic activities. Anti-alpha5beta1 integrin monoclonal antibody PF-04605412 selectively binds to alpha5beta1 integrin, preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alpha5beta1-expressing tumor cells. Alpha5beta1 integrin, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-alpha5beta1 Integrin Antibody MINT1526A</VALIDVALUE>
          <VALUEMEANING>Anti-alpha5beta1 Integrin Antibody MINT1526A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ANG2 Monoclonal Antibody MEDI-3617</VALIDVALUE>
          <VALUEMEANING>Anti-ANG2 Monoclonal Antibody MEDI-3617</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody against angiopoietin 2 (ANG2), with potential antiangiogenic activity. Anti-ANG2 monoclonal antibody MEDI-3617 binds to Ang2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), thereby resulting in the disruption of vascular remodeling. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antiangiogenic Drug Combination TL-118</VALIDVALUE>
          <VALUEMEANING>Antiangiogenic Drug Combination TL-118</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-angiopoietin Monoclonal Antibody AMG 780</VALIDVALUE>
          <VALUEMEANING>Anti-angiopoietin Monoclonal Antibody AMG 780</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA Antibody SEA-BCMA</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA Antibody SEA-BCMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA Antibody-drug Conjugate AMG 224</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA Antibody-drug Conjugate AMG 224</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic combination agent composed of antigen receptor complex T cells (ARC-T cells) which contain a proprietary binding domain specific for a universal TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities. Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell- sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA, a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells, CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity is dependent on the sparX dose administered, the rate of tumor cell killing, and related toxicities are also dependent on the sparX dose administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459</VALUEMEANING>
          <MEANINGDESCRIPTION>A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody REGN5459 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA/PBD ADC MEDI2228</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA/PBD ADC MEDI2228</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150127</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-B7-H3 Antibody DS-5573a</VALIDVALUE>
          <VALUEMEANING>Anti-B7-H3 Antibody DS-5573a</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate ABBV-011</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate ABBV-011</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against an as of yet undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-011 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills tumor cells expressing this particular TAA through an as of yet undisclosed mechanism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-Drug Conjugate DFRF4539A</VALIDVALUE>
          <VALUEMEANING>Antibody-Drug Conjugate DFRF4539A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against a specific myeloma antigen and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DFRF4539A selectively binds to a specific protein expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate MEDI7247</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate MEDI7247</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate PF-06664178</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate PF-06664178</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate SC-002</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate SC-002</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an as of yet publicly unknown monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-002 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596582</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate SC-004</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate SC-004</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-004 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate SC-005</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate SC-005</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate SC-006</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate SC-006</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-006 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate PF-06647263</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate PF-06647263</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate SC-007</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate SC-007</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147029</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BTN3A Agonistic Monoclonal Antibody ICT01</VALIDVALUE>
          <VALUEMEANING>Anti-BTN3A Agonistic Monoclonal Antibody ICT01</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CA19-9 Monoclonal Antibody 5B1</VALIDVALUE>
          <VALUEMEANING>Anti-CA19-9 Monoclonal Antibody 5B1</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, monoclonal antibody 5B1 binds to CA19-9 and kills CA19-9-expressing tumor cells, possibly through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CA6-DM4 Immunoconjugate SAR566658</VALIDVALUE>
          <VALUEMEANING>Anti-CA6-DM4 Immunoconjugate SAR566658</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a humanized monoclonal antibody against the tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-CA6 monoclonal antibody moiety of SAR566658 targets and binds to the cell surface antigen CA6. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CA6-expressing tumor cells. The CA6 epitope is found on a variety of solid tumors, including breast, ovarian, cervical, lung and pancreatic tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1</VALIDVALUE>
          <VALUEMEANING>Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123 Monoclonal Antibody CSL360</VALIDVALUE>
          <VALUEMEANING>Anti-CD123 Monoclonal Antibody CSL360</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain) with potential antineoplastic activity. Derived from mouse monoclonal antibody 7G3, anti-CD123 monoclonal antibody CSL360 binds to and neutralizes CD123 which is upregulated on leukemic stem cells (LSC) in acute myeloid leukemia (AML). This may inhibit IL-3-dependent signalling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91093</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123 Monoclonal Antibody KHK2823</VALIDVALUE>
          <VALUEMEANING>Anti-CD123 Monoclonal Antibody KHK2823</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123/CD3 Bispecific Antibody APVO436</VALIDVALUE>
          <VALUEMEANING>Anti-CD123/CD3 Bispecific Antibody APVO436</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/CD3 monoclonal antibody APVO436 simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, APVO436 causes less cytokine release upon T-cell stimulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123/CD3 Bispecific Antibody JNJ-63709178</VALIDVALUE>
          <VALUEMEANING>Anti-CD123/CD3 Bispecific Antibody JNJ-63709178</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CCR7 Antibody-drug Conjugate JBH492</VALIDVALUE>
          <VALUEMEANING>Anti-CCR7 Antibody-drug Conjugate JBH492</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody targeting CC chemokine receptor 7 (CCR7) and conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-CCR7 ADC JBH492, the antibody moiety targets and binds to CCR7 on tumor cells. Upon antibody/antigen binding and internalization, the ADC releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics. This results in the inhibition of cell division and cell growth of CCR7-expressing tumor cells. CCR7, a G-protein coupled receptor, is normally expressed by subsets of immune cells and overexpressed by various types of cancer cells. Its overexpression has been associated with lymph node metastasis and poor survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123/CD3 BiTE Antibody SAR440234</VALIDVALUE>
          <VALUEMEANING>Anti-CD123/CD3 BiTE Antibody SAR440234</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A</VALIDVALUE>
          <VALUEMEANING>Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD137 Agonistic Monoclonal Antibody ADG106</VALIDVALUE>
          <VALUEMEANING>Anti-CD137 Agonistic Monoclonal Antibody ADG106</VALUEMEANING>
          <MEANINGDESCRIPTION>A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD137 Agonistic Monoclonal Antibody AGEN2373</VALIDVALUE>
          <VALUEMEANING>Anti-CD137 Agonistic Monoclonal Antibody AGEN2373</VALUEMEANING>
          <MEANINGDESCRIPTION>A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373 targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. In addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have a decreased toxicity profile and improved tolerability compared to other agents that activate CD137 signaling beyond the tumor site in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD157 Monoclonal Antibody MEN1112</VALIDVALUE>
          <VALUEMEANING>Anti-CD157 Monoclonal Antibody MEN1112</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19 Antibody-drug Conjugate SGN-CD19B</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 Antibody-drug Conjugate SGN-CD19B</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of T-lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T-cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19 iCAR NK Cells</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 iCAR NK Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19 Monoclonal Antibody DI-B4</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 Monoclonal Antibody DI-B4</VALUEMEANING>
          <MEANINGDESCRIPTION>A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD137 Agonistic Monoclonal Antibody CTX-471</VALIDVALUE>
          <VALUEMEANING>Anti-CD137 Agonistic Monoclonal Antibody CTX-471</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody CTX-471 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19 Monoclonal Antibody MDX-1342</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 Monoclonal Antibody MDX-1342</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL</VALIDVALUE>
          <VALUEMEANING>Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotoxin consisting of two scFv ligands recognizing human CD19 and CD22 linked to the first 389 amino acids of diphtheria toxin (DT), DT 390, with potential antineoplastic activity. The VH and VL regions of anti-CD22 (sFv) and anti-CD19 are reversed and linked by an aggregration stabilizing linker (ARL) consisting of a 20 amino acid segment of human muscle aldolase (hma) and an Xho1-compatible restriction site; the CDR3 region of the VH of anti-CD22 sFv is mutated to enhance its affinity. The anti-CD19 and anti CD-22 portions of the immunotoxin specifically bind to CD19 and CD22 receptors on tumor B cells. Upon internalization, DT catalyzes ADP ribosylation of elongation factor 2 (EF-2) which may result in the irreversible inhibition of protein synthesis and cell death in CD19- and CD22-expressing tumor cells. CD19 and CD22 are transmembrane proteins upregulated on malignant B cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19/CD22 CAR NK Cells</VALIDVALUE>
          <VALUEMEANING>Anti-CD19/CD22 CAR NK Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD22 CAR-NK cells target and bind to CD19 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19/CD3 BiTE Antibody AMG 562</VALIDVALUE>
          <VALUEMEANING>Anti-CD19/CD3 BiTE Antibody AMG 562</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody B001</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 Monoclonal Antibody B001</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody BAT4306F</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 Monoclonal Antibody BAT4306F</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173955</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody MIL62</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 Monoclonal Antibody MIL62</VALUEMEANING>
          <MEANINGDESCRIPTION>A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody MIL62, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, MIL62 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody PRO131921</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 Monoclonal Antibody PRO131921</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation, humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody PRO131921 specifically binds to the B cell-specific cell surface antigen CD20. This may result in the induction of a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B cell development and which is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody TL011</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 Monoclonal Antibody TL011</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody TL011 specifically binds to the B cell-specific cell surface antigen CD20 antigen (MS4A1; membrane-spanning 4-domains, subfamily A, member 1), thereby potentially triggering an immune response against CD20-positive B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19/CD3 Tetravalent Antibody AFM11</VALIDVALUE>
          <VALUEMEANING>Anti-CD19/CD3 Tetravalent Antibody AFM11</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD205 Antibody-drug Conjugate OBT076</VALIDVALUE>
          <VALUEMEANING>Anti-CD205 Antibody-drug Conjugate OBT076</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, anti-CD205 ADC OBT076 specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, OBT076 releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20-engineered Toxin Body MT-3724</VALIDVALUE>
          <VALUEMEANING>Anti-CD20-engineered Toxin Body MT-3724</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified form of the ribosome-inactivating alpha subunit of Shiga-like toxin 1 (Shiga-like Toxin-1 A or SLT-1A), with antineoplastic activity. Upon administration, the ScFv moiety of anti-CD20-engineered toxin body MT-3724 targets and binds to the CD20 antigen expressed on tumor cells. Upon internalization, the SLT-1A moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and eventually leads to apoptosis of CD20-expressing tumor cells. CD20, a B-cell specific transmembrane protein and tumor-associated antigen (TAA), is expressed during most stages of B-cell development and is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD22 ADC TRPH-222</VALIDVALUE>
          <VALUEMEANING>Anti-CD22 ADC TRPH-222</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A</VALIDVALUE>
          <VALUEMEANING>Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD26 Monoclonal Antibody YS110</VALIDVALUE>
          <VALUEMEANING>Anti-CD26 Monoclonal Antibody YS110</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD27L Antibody-Drug Conjugate AMG 172</VALIDVALUE>
          <VALUEMEANING>Anti-CD27L Antibody-Drug Conjugate AMG 172</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)</VALIDVALUE>
          <VALUEMEANING>Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)</VALUEMEANING>
          <MEANINGDESCRIPTION>A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) consists of 1-390 amino acid residues of chain A diphtheria toxin (DT) joined via a spacer to the Fv fragment of UCHT1, which is connected to a second UCHT1 Fv fragment via a disulfide bond (hence the &quot;bisFv&quot; designation); the addition of the second Fv fragment overcomes the steric hindrance of immunotoxin binding due to the large N-terminal DT domain. Once inside target T cells, the DT moiety catalyzes the transfer of the ADP-ribose moiety of NAD to diphthamide, a posttranslationally modified histidine residue found in elongation factor 2 (EF-2); inactivation of EF-2, disruption of polypeptide chain elongation, and cell death ensue. CD3 is a complex of five cell-surface polypeptides associated with the T cell receptor (TCR) complex.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044</VALIDVALUE>
          <VALUEMEANING>Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05</VALIDVALUE>
          <VALUEMEANING>Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05</VALUEMEANING>
          <MEANINGDESCRIPTION>A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. FBTA05 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human CD20, a tumor-associated antigen that is exclusively expressed on B cells during most stages of B cell development and often overexpressed in B-cell malignancies. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). FBTA05 brings T cells, CD20-expressing tumor B-cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells. Fc-mediated binding of APCs in the tricellular complex potentiates CD20 antigen presentation to T cells and the activation of anti-tumor cytotoxic T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD25 Monoclonal Antibody RO7296682</VALIDVALUE>
          <VALUEMEANING>Anti-CD25 Monoclonal Antibody RO7296682</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, the anti-CD25 monoclonal antibody RO7296682 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119</VALIDVALUE>
          <VALUEMEANING>Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T-cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424</VALIDVALUE>
          <VALUEMEANING>Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153147</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/CD7-Ricin Toxin A Immunotoxin</VALIDVALUE>
          <VALUEMEANING>Anti-CD3/CD7-Ricin Toxin A Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotoxin (IT) combination composed of two antibody-drug conjugates (ADCs), one containing a monoclonal antibody against CD3 and one against the CD7 antigen on activated T-cells and natural killer (NK) cells, and both conjugated to ricin toxin A (RTA), the A-chain form of the potent plant toxin ricin, that can potentially be used to destroy activated T- and NK cells. Upon administration of the anti-CD3/CD7-RTA immunotoxin, the anti-CD3 antibody moiety targets and binds to activated T-cells; the anti-CD7 antibody moiety targets and binds to CD7 on activated T-cells and NK cells. Upon internalization and cleavage, the RTA moiety irreversibly inhibits protein synthesis and induces apoptosis in the activated T-cells. This may eliminate activated T-cells and may improve conditions such as graft-versus-host-disease (GvHD). In addition, the binding and blocking of the anti-CD3 antibody to the T-cell receptor/CD3 complex (TCR/CD3) results in activation-induced cell death (AICD) and immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD30 Monoclonal Antibody MDX-1401</VALIDVALUE>
          <VALUEMEANING>Anti-CD30 Monoclonal Antibody MDX-1401</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, second-generation, nonfucosylated monoclonal antibody directed against the cell surface receptor CD30 with potential immunomodulating and antineoplastic activities. Anti-CD30 monoclonal antibody MDX-1401 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin&#39;s disease and some T-cell non-Hodgkin&#39;s lymphomas. Compared to conventional antibodies, deletion of fucose molecules on the antibody backbone, as is done in MDX-1401, may result in an increased affinity for Fc receptors and an enhanced antibody-dependent cellular cytotoxicity (ADCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD30/CD16A Monoclonal Antibody AFM13</VALIDVALUE>
          <VALUEMEANING>Anti-CD30/CD16A Monoclonal Antibody AFM13</VALUEMEANING>
          <MEANINGDESCRIPTION>A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Anti-CD30/CD16A monoclonal antibody AFM13 binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD30/DM1 Antibody-drug Conjugate F0002</VALIDVALUE>
          <VALUEMEANING>Anti-CD30/DM1 Antibody-drug Conjugate F0002</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) consisting of a monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of F0002 targets and binds to CD30-expressing tumor cells. Upon cellular uptake and internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits both cell division and the proliferation of tumor cells that express CD30. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8) may be constitutively expressed in some hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD32B Monoclonal Antibody BI-1206</VALIDVALUE>
          <VALUEMEANING>Anti-CD32B Monoclonal Antibody BI-1206</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33 Antibody-drug Conjugate IMGN779</VALIDVALUE>
          <VALUEMEANING>Anti-CD33 Antibody-drug Conjugate IMGN779</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33 Monoclonal Antibody BI 836858</VALIDVALUE>
          <VALUEMEANING>Anti-CD33 Monoclonal Antibody BI 836858</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD30 Monoclonal Antibody XmAb2513</VALIDVALUE>
          <VALUEMEANING>Anti-CD30 Monoclonal Antibody XmAb2513</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin&#39;s disease and some T-cell non-Hodgkin&#39;s lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633</VALIDVALUE>
          <VALUEMEANING>Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of the humanized monoclonal antibody huMy9-6 conjugated to the cytotoxic maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DM4 conjugate AVE9633 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DM4 moiety is released, binds tubulin, and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of cell division and cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33/CD3 Bispecific Antibody GEM 333</VALIDVALUE>
          <VALUEMEANING>Anti-CD33/CD3 Bispecific Antibody GEM 333</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33/CD3 Bispecific Antibody JNJ-67571244</VALIDVALUE>
          <VALUEMEANING>Anti-CD33/CD3 Bispecific Antibody JNJ-67571244</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162296</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD352 Antibody-drug Conjugate SGN-CD352A</VALIDVALUE>
          <VALUEMEANING>Anti-CD352 Antibody-drug Conjugate SGN-CD352A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD37 Monoclonal Antibody BI 836826</VALIDVALUE>
          <VALUEMEANING>Anti-CD37 Monoclonal Antibody BI 836826</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38 Antibody-drug Conjugate STI-6129</VALIDVALUE>
          <VALUEMEANING>Anti-CD38 Antibody-drug Conjugate STI-6129</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of STI-5171, a fully human monoclonal antibody targeting human cell surface glycoprotein and tumor-associated antigen (TAA) CD38, site-specifically conjugated, via a non-polyethylene glycol linker, to a monomethyl auristatin F (MMAF)-derived cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-CD38 ADC STI-6129, the antibody moiety targets and binds to CD38 on tumor cells. Upon antibody/antigen binding and internalization, the MMAF derivative binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38 Monoclonal Antibody SAR442085</VALIDVALUE>
          <VALUEMEANING>Anti-CD38 Monoclonal Antibody SAR442085</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257</VALIDVALUE>
          <VALUEMEANING>Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257</VALUEMEANING>
          <MEANINGDESCRIPTION>A tri-specific T-cell engager and monoclonal antibody targeting CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential antineoplastic activity. Upon intravenous administration, anti-CD38/CD3/CD28 tri-specific monoclonal antibody SAR442257 targets and binds to CD3 and CD28 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. In addition, SAR442257 can also directly target CD28 expressed on tumor cells, such as multiple myeloma cells, thereby enhancing the anti-tumor activity of this agent and allowing it to bind to tumor cells when CD38 is occupied by other antibodies. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342</VALIDVALUE>
          <VALUEMEANING>Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD37 MMAE Antibody-drug Conjugate AGS67E</VALIDVALUE>
          <VALUEMEANING>Anti-CD37 MMAE Antibody-drug Conjugate AGS67E</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD39 Monoclonal Antibody TTX-030</VALIDVALUE>
          <VALUEMEANING>Anti-CD39 Monoclonal Antibody TTX-030</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody TTX-030 specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40 Agonist Monoclonal Antibody CDX-1140</VALIDVALUE>
          <VALUEMEANING>Anti-CD40 Agonist Monoclonal Antibody CDX-1140</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40 Monoclonal Antibody Chi Lob 7/4</VALIDVALUE>
          <VALUEMEANING>Anti-CD40 Monoclonal Antibody Chi Lob 7/4</VALUEMEANING>
          <MEANINGDESCRIPTION>An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD44 Monoclonal Antibody RO5429083</VALIDVALUE>
          <VALUEMEANING>Anti-CD44 Monoclonal Antibody RO5429083</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD45 Monoclonal Antibody AHN-12</VALIDVALUE>
          <VALUEMEANING>Anti-CD45 Monoclonal Antibody AHN-12</VALUEMEANING>
          <MEANINGDESCRIPTION>A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD46 Antibody-drug Conjugate FOR46</VALIDVALUE>
          <VALUEMEANING>Anti-CD46 Antibody-drug Conjugate FOR46</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 ADC SGN-CD47M</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 ADC SGN-CD47M</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against human cell surface antigen CD47 conjugated to an as of yet not fully elucidated toxin, with potential antineoplastic activity. Upon administration of SGN-CD47M, the anti-CD47 monoclonal antibody moiety targets and binds to CD47 on tumor cell surfaces; upon internalization, the toxin moiety kills tumor cells through a mechanism of action that has not been elucidated. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody AO-176</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody AO-176</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G2 (IgG2) monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody AO-176 preferentially binds to CD47 on tumor cells because it exhibits enhanced binding at the acidic pH found in the tumor microenvironment (TME). This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. In addition, AO-176 induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs) from tumor cells, thereby further stimulating immune responses. AO-176 is also able to induce direct cytotoxic cell death by a cell autonomous mechanism. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody CC-90002</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody CC-90002</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428</VALIDVALUE>
          <VALUEMEANING>Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody composed of a binding domain for an epitope found on the cell-surface receptor CD40 linked to a binding domain directed to an as of yet undisclosed tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CD40/anti-TAA bispecific monoclonal antibody ABBV-428, the anti-TAA moiety targets and binds to the TAA expressed on the tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells. This leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells, which kills and inhibits the proliferation of the TAA-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody IMC-002</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody IMC-002</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody SHR-1603</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody SHR-1603</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A</VALIDVALUE>
          <VALUEMEANING>Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD52 Monoclonal Antibody ALLO-647</VALIDVALUE>
          <VALUEMEANING>Anti-CD52 Monoclonal Antibody ALLO-647</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby triggering a host immune response that results in the lysis of CD52-positive lymphocytes. This leads to immunodepletion and may prevent graft-versus-host disease (GvHD). CD52 is a glycoprotein expressed on the surface of many immune cells, including essentially all B- and T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD70 Antibody-drug Conjugate SGN-CD70A</VALIDVALUE>
          <VALUEMEANING>Anti-CD70 Antibody-drug Conjugate SGN-CD70A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD70 CAR-expressing T Lymphocytes</VALIDVALUE>
          <VALUEMEANING>Anti-CD70 CAR-expressing T Lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD70 Monoclonal Antibody MDX-1411</VALIDVALUE>
          <VALUEMEANING>Anti-CD70 Monoclonal Antibody MDX-1411</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered, fully human IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Anti-CD70 fully human monoclonal antibody MDX-1411 selectivity binds to the extracellular domain of CD70, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on renal cell carcinoma (RCC) cells among other cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029</VALIDVALUE>
          <VALUEMEANING>Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029</VALUEMEANING>
          <MEANINGDESCRIPTION>A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD73 Monoclonal Antibody BMS-986179</VALIDVALUE>
          <VALUEMEANING>Anti-CD73 Monoclonal Antibody BMS-986179</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the ectoenzyme 5&#39;-ecto-nucleotidase (cluster of differentiation 73; CD73; 5&#39;-NT; ecto-5&#39;-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD70 Antibody-Drug Conjugate MDX-1203</VALIDVALUE>
          <VALUEMEANING>Anti-CD70 Antibody-Drug Conjugate MDX-1203</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to a prodrug of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate MDX-1203 selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the prodrug moiety is released and activated and binds to double-stranded B-DNA within the minor groove, thereby alkylating the -3 position of adenine, which may result in the inhibition of cellular proliferation of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The antitumor antibiotic CC-1065, a DNA minor-groove-binding alkylating agent, was originally isolated from the bacterium Streptomyces zelensis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD73 Monoclonal Antibody NZV930</VALIDVALUE>
          <VALUEMEANING>Anti-CD73 Monoclonal Antibody NZV930</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody targeting the ectoenzyme 5&#39;-ecto-nucleotidase (cluster of differentiation 73; CD73; 5&#39;-NT; ecto-5&#39;-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD74 Antibody-drug Conjugate STRO-001</VALIDVALUE>
          <VALUEMEANING>Anti-CD74 Antibody-drug Conjugate STRO-001</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CDH6 Antibody-drug Conjugate HKT288</VALIDVALUE>
          <VALUEMEANING>Anti-CDH6 Antibody-drug Conjugate HKT288</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEA BiTE Monoclonal Antibody AMG211</VALIDVALUE>
          <VALUEMEANING>Anti-CEA BiTE Monoclonal Antibody AMG211</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody</VALIDVALUE>
          <VALUEMEANING>Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody (BsMAb) consisting of the Fab fragment of an anti-CEA monoclonal antibody (F6) coupled to the Fab fragment of an anti-DTPA-In monoclonal antibody (734) with potential radioimmunotherapeutic activity. In a two-step pretargeted radioimmunotherapeutic approach, this BsMAb, localizing to CEA-expressing tumor cells via the F6 Fab fragment, is introduced into patient first, followed by injection of indium 131-radiolabeled DTPA, which is recognized by the 734 Fab fragment of the BsMAb. Accordingly, a potentially lethal dose of indium 131 is delivered specifically to CEA-expressing tumor cells while minimizing radiotoxicity to normal tissues. CEA (carcinoembryonic antigen) is a tumor antigen overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. DTPA (diethylenetriaminepentaacetic acid) is a bivalent hapten.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596810</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2</VALIDVALUE>
          <VALUEMEANING>Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2</VALUEMEANING>
          <MEANINGDESCRIPTION>A tri-Fab bispecific monoclonal antibody (BiMoAb) divalent for the carcinoembryonic antigen (CEA) and monovalent for histamine-succinyl-glycine (HSG) peptide-hapten. Anti-CEA/anti-HSG bispecific monoclonal antibody TF2 binds to the tumor associated antigen (TAA) CEA on CEA-expressing tumor cells. Subsequently, an HSG peptide-hapten carrying a radionuclide is administered, binding to the anti-HSG binding fragment on the BiMoAb. Depending on the characteristics of the radionuclide used, CEA-expressing tumor cells may then be radioimaged and/or treated radioimmunotherapeutically.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEACAM1 Monoclonal Antibody CM-24</VALIDVALUE>
          <VALUEMEANING>Anti-CEACAM1 Monoclonal Antibody CM-24</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD98 Monoclonal Antibody IGN523</VALIDVALUE>
          <VALUEMEANING>Anti-CD98 Monoclonal Antibody IGN523</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47</VALIDVALUE>
          <VALUEMEANING>Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47</VALUEMEANING>
          <MEANINGDESCRIPTION>A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-fms Monoclonal Antibody AMG 820</VALIDVALUE>
          <VALUEMEANING>Anti-c-fms Monoclonal Antibody AMG 820</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (or CSFR1), with potential antineoplastic activity. Upon administration, anti-c-fms monoclonal antibody AMG 820 binds to and blocks c-fms, thereby blocking CSF-1 binding to its receptor and suppressing CSF-1-induced c-fms signaling. This results in the suppression of recruitment and activation of tumor associated macrophages (TAM) within the tumor microenvironment. This eventually leads to a decrease in tumor growth. c-fms, a transmembrane protein belonging to the tyrosine kinase family, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation. The presence of TAM is correlated with tumor proliferation, invasion and a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-KIT Monoclonal Antibody CDX 0158</VALIDVALUE>
          <VALUEMEANING>Anti-c-KIT Monoclonal Antibody CDX 0158</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-claudin18.2 Monoclonal Antibody AB011</VALIDVALUE>
          <VALUEMEANING>Anti-claudin18.2 Monoclonal Antibody AB011</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody AB011 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-Met Antibody-drug Conjugate HTI-1066</VALIDVALUE>
          <VALUEMEANING>Anti-c-Met Antibody-drug Conjugate HTI-1066</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-Met Antibody-drug Conjugate TR1801</VALIDVALUE>
          <VALUEMEANING>Anti-c-Met Antibody-drug Conjugate TR1801</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-Met Monoclonal Antibody ARGX-111</VALIDVALUE>
          <VALUEMEANING>Anti-c-Met Monoclonal Antibody ARGX-111</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596820</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-Met Monoclonal Antibody HLX55</VALIDVALUE>
          <VALUEMEANING>Anti-c-Met Monoclonal Antibody HLX55</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G2 monoclonal antibody directed against the human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-c-Met monoclonal antibody HLX55 specifically binds to the semaphorin (Sema)/Plexins-Semaphorins-Integrins (PSI) domain of c-Met, which prevents the binding of c-Met to its ligand HGF and the subsequent activation of the HGF/c-Met signaling pathway. In addition, HLX55 promotes c-Met degradation, which further inhibits c-Met-mediated signaling. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-C-met Monoclonal Antibody SAIT301</VALIDVALUE>
          <VALUEMEANING>Anti-C-met Monoclonal Antibody SAIT301</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CLDN6 Monoclonal Antibody ASP1650</VALIDVALUE>
          <VALUEMEANING>Anti-CLDN6 Monoclonal Antibody ASP1650</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CSF1 Monoclonal Antibody PD-0360324</VALIDVALUE>
          <VALUEMEANING>Anti-CSF1 Monoclonal Antibody PD-0360324</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CSF1R Monoclonal Antibody IMC-CS4</VALIDVALUE>
          <VALUEMEANING>Anti-CSF1R Monoclonal Antibody IMC-CS4</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. CSF1R monoclonal antibody IMC-CS4 binds to CSF1R which may trigger antitumoral antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells overexpressing CSF1R. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (Cluster of Differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1); this receptor is overexpressed or mutated in certain tumor cell types and plays major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA4 Antibody Fc Fusion Protein KN044</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA4 Antibody Fc Fusion Protein KN044</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596825</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody ADG116</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4 Monoclonal Antibody ADG116</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADG116 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA4 Monoclonal Antibody BMS-986218</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA4 Monoclonal Antibody BMS-986218</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody&#39;s Fc region, enhances its activity and decreases the toxicity of BMS-986218.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody ONC-392</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4 Monoclonal Antibody ONC-392</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody ONC-392 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As ONC-392 is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody REGN4659</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4 Monoclonal Antibody REGN4659</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596830</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Probody BMS-986288</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4 Probody BMS-986288</VALUEMEANING>
          <MEANINGDESCRIPTION>A probody composed of a modified version of ipilimumab, a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 probody BMS-986288, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986288 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217</VALUEMEANING>
          <MEANINGDESCRIPTION>A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody ADU-1604</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4 Monoclonal Antibody ADU-1604</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015</VALIDVALUE>
          <VALUEMEANING>Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CXCR4 Monoclonal Antibody PF-06747143</VALIDVALUE>
          <VALUEMEANING>Anti-CXCR4 Monoclonal Antibody PF-06747143</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Denatured Collagen Monoclonal Antibody TRC093</VALIDVALUE>
          <VALUEMEANING>Anti-Denatured Collagen Monoclonal Antibody TRC093</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, affinity-matured IgG1k antibody directed against denatured collagens (I-IV) with potential antiangiogenic and antineoplastic activities. Anti-denatured collagen recombinant monoclonal antibody TRC093 binds to multiple epitopes on denatured collagens, inhibiting proteolytic collagen-mediated signaling in the extracellular matrix (ECM) that is important to tumor angiogenesis, tumor growth, and metastasis. The epitopes on denatured collagen bound by this antibody are considered cryptic because, in vivo, they are accessible only on the subendothelial basement membrane of tumors or in normal tissues undergoing neovascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DKK1 Monoclonal Antibody BHQ880</VALIDVALUE>
          <VALUEMEANING>Anti-DKK1 Monoclonal Antibody BHQ880</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against Wnt antagonist Dickkopf-1 (DKK1) with potential anti-osteolytic activity. Anti-DKK1 monoclonal antibody BHQ880 binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1 is a potent Wnt signaling pathway antagonist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DR5 Agonist Monoclonal Antibody TRA-8</VALIDVALUE>
          <VALUEMEANING>Anti-DR5 Agonist Monoclonal Antibody TRA-8</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist mouse monoclonal antibody directed against TRAIL death receptor type 5 (DR5) with potential antineoplastic activity. Anti-DR5 agonist monoclonal antibody TRA-8 binds DR5, which may induce apoptosis in DR5-expressing tumor cells. DR5 is a tumor cell surface ligand that crosslinks with death receptor type 4 (DR4) when bound by TRAIL [Tumor necrosis (TNF)-related apoptosis-inducing ligand], triggering apoptosis via a death receptor signaling pathway. The apoptotic activity of this antibody may not require DR4/DR5 crosslinking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DR5 Agonistic Antibody DS-8273a</VALIDVALUE>
          <VALUEMEANING>Anti-DR5 Agonistic Antibody DS-8273a</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DR5 Agonistic Monoclonal Antibody INBRX-109</VALIDVALUE>
          <VALUEMEANING>Anti-DR5 Agonistic Monoclonal Antibody INBRX-109</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, INBRX-109 specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody CPGJ 602</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody CPGJ 602</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody EMD 55900</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody EMD 55900</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR) exhibiting anti-tumor activity. EMD 55900 antibody binds to the extracellular domain of EGFR close to the EGF binding domain and does not induce any tyrosine kinase activity on its own. As a result, EMD 55900 binding inhibits receptor activation by natural ligands thereby interrupting activation of downstream signaling cascade, required for tumor cell growth and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DLL4 Monoclonal Antibody MEDI0639</VALIDVALUE>
          <VALUEMEANING>Anti-DLL4 Monoclonal Antibody MEDI0639</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody GC1118</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody GC1118</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered form of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Anti-EGFR monoclonal antibody GT-MAB 5.2-GEX specifically binds to the extracellular domain of EGFR, thereby potentially inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells, eventually leading to tumor cell apoptosis and an inhibition of tumor cell growth. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, is overexpressed on the cell surfaces of various solid tumors. This antibody has a specific glycosylation profile that may enhance its ADCC response against EGFR-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94221</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody Mixture MM-151</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody Mixture MM-151</VALUEMEANING>
          <MEANINGDESCRIPTION>An oligoclonal therapeutic composed of three fully human monoclonal antibodies targeting epidermal growth factor receptor (EGFR or ErbB1), with potential antineoplastic activity. Upon administration of MM-151, the three antibodies bind to distinct, non-overlapping epitopes of EGFR, thereby preventing the binding of a full range of both high and low affinity EGFR ligands and inhibiting EGFR-ERK-mediated signaling. This eventually inhibits tumor cell proliferation in EGFR-overexpressing tumor cells. Furthermore, multi antibody-antigen bindings cause crosslinking of EGFR and downregulate receptor signalings that are mediated via heterodimerization of EGFR with other members of the EGFR family. EGFR, a receptor tyrosine kinase overexpressed in a variety of cancer cell types, is a key regulator of cancer cell proliferation, apoptosis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody SYN004</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody SYN004</VALUEMEANING>
          <MEANINGDESCRIPTION>A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR/CD16A Bispecific Antibody AFM24</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR/CD16A Bispecific Antibody AFM24</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EGFR/CD16A bispecific antibody AFM24 simultaneously targets and binds to the CD16A expressed on natural killer (NK) cells and macrophages, and to EGFR on EGFR-expressing tumor cells, thereby selectively cross-linking EGFR-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and eventually tumor cell lysis. EGFR, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. CD16A is specifically expressed on the surface of NK cells and macrophages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR/DM1 Antibody-drug Conjugate AVID100</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR/DM1 Antibody-drug Conjugate AVID100</VALUEMEANING>
          <MEANINGDESCRIPTION>A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFRvIII Antibody Drug Conjugate AMG 595</VALIDVALUE>
          <VALUEMEANING>Anti-EGFRvIII Antibody Drug Conjugate AMG 595</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a human monoclonal antibody directed against the deletion-mutant of epidermal growth factor receptor, EGFRvIII, conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to EGFRvIII on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that express the EGFRvIII mutant. EGFRvIII, a deletion mutation of exons 2-7 in the epidermal growth factor receptor gene, is overexpressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFRvIII Immunotoxin MR1-1</VALIDVALUE>
          <VALUEMEANING>Anti-EGFRvIII Immunotoxin MR1-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody SCT200</VALIDVALUE>
          <VALUEMEANING>Anti-EGFR Monoclonal Antibody SCT200</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGP-2 Immunotoxin MOC31-PE</VALIDVALUE>
          <VALUEMEANING>Anti-EGP-2 Immunotoxin MOC31-PE</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotoxin consisting of a monoclonal antibody directed against epithelial glycoprotein-2 (EP-2, or epithelial cell adhesion molecule (EpCAM)) conjugated to the bacterial toxin Pseudomonas exotoxin A (PE) with potential antineoplastic activity. Upon administration of anti-EGP-2 immunotoxin MOC31-PE, the monoclonal antibody moiety targets and binds to EP-2. Upon internalization, the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in EP-2-expressing cells. EP-2, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F</VALIDVALUE>
          <VALUEMEANING>Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F</VALIDVALUE>
          <VALUEMEANING>Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</VALIDVALUE>
          <VALUEMEANING>Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel&#39;s half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel&#39;s efficacy while lowering its systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EphA2 Monoclonal Antibody DS-8895a</VALIDVALUE>
          <VALUEMEANING>Anti-EphA2 Monoclonal Antibody DS-8895a</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547</VALIDVALUE>
          <VALUEMEANING>Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547</VALUEMEANING>
          <MEANINGDESCRIPTION>An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111</VALIDVALUE>
          <VALUEMEANING>Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody directed against the human epidermal growth factor receptors ErbB2 (Her2) and ErbB3 (Her3) with potential antineoplastic activity. The anti-ErB2 targeting arm of anti-ErbB2/anti-ErbB3 bispecific monoclonal antibody MM-111 binds to ErbB2 on tumor cells with high affinity while the anti-Erb3 therapeutic arm binds to ErbB3, which may result in the inhibition of cellular proliferation and differentiation in ErbB2-overexpressing tumor cells via inhibition of ErbB3-dependent signal transduction pathways. ErbB2 and ErB3 are members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and are frequently overexpressed in solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ErbB3 Monoclonal Antibody AV-203</VALIDVALUE>
          <VALUEMEANING>Anti-ErbB3 Monoclonal Antibody AV-203</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ErbB3 Monoclonal Antibody CDX-3379</VALIDVALUE>
          <VALUEMEANING>Anti-ErbB3 Monoclonal Antibody CDX-3379</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Ep-CAM Monoclonal Antibody ING-1</VALIDVALUE>
          <VALUEMEANING>Anti-Ep-CAM Monoclonal Antibody ING-1</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133022</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ErbB3 Monoclonal Antibody REGN1400</VALIDVALUE>
          <VALUEMEANING>Anti-ErbB3 Monoclonal Antibody REGN1400</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103859</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A</VALIDVALUE>
          <VALUEMEANING>Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FGFR3 Antibody-drug Conjugate LY3076226</VALIDVALUE>
          <VALUEMEANING>Anti-FGFR3 Antibody-drug Conjugate LY3076226</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FGFR4 Monoclonal Antibody U3-1784</VALIDVALUE>
          <VALUEMEANING>Anti-FGFR4 Monoclonal Antibody U3-1784</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FLT3 Monoclonal Antibody 4G8-SDIEM</VALIDVALUE>
          <VALUEMEANING>Anti-FLT3 Monoclonal Antibody 4G8-SDIEM</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FLT3 Monoclonal Antibody IMC-EB10</VALIDVALUE>
          <VALUEMEANING>Anti-FLT3 Monoclonal Antibody IMC-EB10</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, IgG1 monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody IMC-EB10 blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may result in the inhibition of cellular proliferation and survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012</VALIDVALUE>
          <VALUEMEANING>Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, anti-fucosyl-GM1 monoclonal antibody BMS-986012 binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962</VALIDVALUE>
          <VALUEMEANING>Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized anti-ganglioside GM2 (GM2) monoclonal antibody with potential antineoplastic and immunomodulating activities. Upon administration, anti-ganglioside GM2 monoclonal antibody BIW-8962 may activate an antibody dependent cellular cytotoxicity (ADCC) against GM2-expressing tumor cells. GM2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells, such as multiple myeloma (MM) cells and neuroblastoma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GCC Antibody-Drug Conjugate TAK-164</VALIDVALUE>
          <VALUEMEANING>Anti-GCC Antibody-Drug Conjugate TAK-164</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FLT3 Antibody-drug Conjugate AGS62P1</VALIDVALUE>
          <VALUEMEANING>Anti-FLT3 Antibody-drug Conjugate AGS62P1</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GD2 Monoclonal Antibody hu14.18K322A</VALIDVALUE>
          <VALUEMEANING>Anti-GD2 Monoclonal Antibody hu14.18K322A</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6608083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GD2 Monoclonal Antibody MORAb-028</VALIDVALUE>
          <VALUEMEANING>Anti-GD2 Monoclonal Antibody MORAb-028</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgM monoclonal antibody directed against disialoganglioside GD2 with potential immunomodulating activity. Upon administration, anti-GD2 monoclonal antibody MORAb-028 may stimulate the immune system to exert a complement-mediated cytotoxic response against GD2-expressing tumor cells. The glycosphingolipid GD2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GD3 Antibody-drug Conjugate PF-06688992</VALIDVALUE>
          <VALUEMEANING>Anti-GD3 Antibody-drug Conjugate PF-06688992</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV</VALIDVALUE>
          <VALUEMEANING>Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of antigen presenting cells (APCs) specific for human papillomavirus (HPV) type 16 E6 and E7 proteins, with potential immunomodulating and antineoplastic activities. Autologous peripheral blood mononuclear cells (PBMCs) were ex vivo manipulated, using a technique involving membrane disruption to get the HPV16 E6 and E7 proteins into the cells; the resulting APCs present the antigens in a major histocompatibility type I (MHC-I) manner.  Upon administration of the APCs-expressing HPV16 E6/E7 SQZ-PBMC-HPV, these cells activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HPV16 E6 and E7.  HPV16 E6 and E7 play an important role in the development of certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GITR Agonistic Monoclonal Antibody BMS-986156</VALIDVALUE>
          <VALUEMEANING>Anti-GITR Agonistic Monoclonal Antibody BMS-986156</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GITR Monoclonal Antibody GWN 323</VALIDVALUE>
          <VALUEMEANING>Anti-GITR Monoclonal Antibody GWN 323</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128028</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GITR Monoclonal Antibody MK-4166</VALIDVALUE>
          <VALUEMEANING>Anti-GITR Monoclonal Antibody MK-4166</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116065</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Globo H Monoclonal Antibody OBI-888</VALIDVALUE>
          <VALUEMEANING>Anti-Globo H Monoclonal Antibody OBI-888</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999</VALIDVALUE>
          <VALUEMEANING>Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of OBI-888 (OBI 888), a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) globohexaosylceramide (globo H), covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-globo H/MMAE ADC OBI 999, the antibody moiety of OBI 999, OBI 888, targets and binds to globo H on tumor cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE targets and binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in globo H-expressing tumor cells. Globo H, a hexasaccharide glycosphingolipid, is (over)expressed on the surface of many types of tumor cells. Globo H is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GITR Agonistic Monoclonal Antibody ASP1951</VALIDVALUE>
          <VALUEMEANING>Anti-GITR Agonistic Monoclonal Antibody ASP1951</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, high-affinity, tetravalent monospecific agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating activity. Upon administration, anti-GITR agonistic monoclonal antibody ASP1951 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Glypican 3/CD3 Bispecific Antibody ERY974</VALIDVALUE>
          <VALUEMEANING>Anti-Glypican 3/CD3 Bispecific Antibody ERY974</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GnRH Vaccine PEP223</VALIDVALUE>
          <VALUEMEANING>Anti-GnRH Vaccine PEP223</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-gpA33/CD3 Monoclonal Antibody MGD007</VALIDVALUE>
          <VALUEMEANING>Anti-gpA33/CD3 Monoclonal Antibody MGD007</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a</VALIDVALUE>
          <VALUEMEANING>Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) conjugated to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-GPR20/DXd ADC DS-6157a, the anti-GPR20 antibody targets and binds to GPR20-expressing tumor cells. Upon cellular uptake, the DXd moiety targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of GPR20-expressing tumor cells. GPR20 is overexpressed on certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HA Epitope Monoclonal Antibody MEDI8852</VALIDVALUE>
          <VALUEMEANING>Anti-HA Epitope Monoclonal Antibody MEDI8852</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HB-EGF Monoclonal Antibody KHK2866</VALIDVALUE>
          <VALUEMEANING>Anti-HB-EGF Monoclonal Antibody KHK2866</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary fucose-free monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HB-EGF Monoclonal Antibody KHK2866 binds to HBEGF, thereby blocking its binding to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation. The fucose-free monoclonal antibodies enhance antigen dependent cellular cytotoxicity (ADCC), and increase binding affinity to the Fc Receptor to overcome genetic polymorphism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HBEGF Monoclonal Antibody U3-1565</VALIDVALUE>
          <VALUEMEANING>Anti-HBEGF Monoclonal Antibody U3-1565</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HBEGF monoclonal antibody U3-1565 binds to HBEGF and blocks the binding of HBEGF to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-hepcidin Monoclonal Antibody LY2787106</VALIDVALUE>
          <VALUEMEANING>Anti-hepcidin Monoclonal Antibody LY2787106</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GRP78 Monoclonal Antibody PAT-SM6</VALIDVALUE>
          <VALUEMEANING>Anti-GRP78 Monoclonal Antibody PAT-SM6</VALUEMEANING>
          <MEANINGDESCRIPTION>A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate A166</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Antibody-drug Conjugate A166</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC A166, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate BAT8001</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Antibody-drug Conjugate BAT8001</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC BAT8001, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation and induces apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173966</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate DP303c</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Antibody-drug Conjugate DP303c</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DP303c, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate MEDI4276</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Antibody-drug Conjugate MEDI4276</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Immune Stimulator-antibody Conjugate NJH395</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Immune Stimulator-antibody Conjugate NJH395</VALUEMEANING>
          <MEANINGDESCRIPTION>An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Monoclonal Antibody B002</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Monoclonal Antibody B002</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody B002 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to antitumor activity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174121</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Monoclonal Antibody HLX22</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Monoclonal Antibody HLX22</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody HLX22 targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302</VALIDVALUE>
          <VALUEMEANING>Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Bispecific Antibody-drug Conjugate ZW49</VALIDVALUE>
          <VALUEMEANING>Anti-HER2 Bispecific Antibody-drug Conjugate ZW49</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162115</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522</VALIDVALUE>
          <VALUEMEANING>Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/MMAE Antibody-drug Conjugate MRG002</VALIDVALUE>
          <VALUEMEANING>Anti-HER2/MMAE Antibody-drug Conjugate MRG002</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-HER2/MMAE ADC MRG002 targets and binds to HER2 on the surface of tumor cells. Following internalization of MRG002, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A</VALIDVALUE>
          <VALUEMEANING>Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2-DM1 Antibody-drug Conjugate GQ1001</VALIDVALUE>
          <VALUEMEANING>Anti-HER2-DM1 Antibody-drug Conjugate GQ1001</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated, via a site-specific linker, to the cytotoxic maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration of anti-HER2-DM1 ADC GQ1001, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, DM1 binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits cell division and the proliferation of tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2-vc0101 ADC PF-06804103</VALIDVALUE>
          <VALUEMEANING>Anti-HER2-vc0101 ADC PF-06804103</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER3 Monoclonal Antibody GSK2849330</VALIDVALUE>
          <VALUEMEANING>Anti-HER3 Monoclonal Antibody GSK2849330</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HGF Monoclonal Antibody TAK-701</VALIDVALUE>
          <VALUEMEANING>Anti-HGF Monoclonal Antibody TAK-701</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody TAK-701 binds to the soluble ligand HGF, preventing HGF binding to and activation of the HGF receptor c-Met and so the activation of the c-Met signaling pathway; this may result in the induction of cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968</VALIDVALUE>
          <VALUEMEANING>Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1</VALIDVALUE>
          <VALUEMEANING>Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A gene transfer construct composed of a self-inactivating (SIN) lentiviral vector (LV) expressing a short hairpin RNA (shRNA) that targets the human C-C chemokine receptor type 5 (CCR5) mRNA (sh5) and expressing the HIV entry inhibitor C46, with potential anti-human immunodeficiency virus (HIV) type 1 (HIV-1) activity. Upon transduction of the anti-HIV-1 LVsh5/C46 Cal-1 in specified blood cell populations, such as peripheral blood mononuclear cells (PBMCs), hematopoietic stem/progenitor cells (HSPCs) and CD4+ T-lymphocytes, the cells express shCCR5 and C46. shCCR5 targets and binds to CCR5 mRNA, which inhibits the expression of CCR5 and prevents binding of the virus to the cellular CCR5 co-receptor. The cell surface expression of the cell membrane-anchored C46  peptide blocks HIV-1 fusion to the cellular membrane. The removal of CCR5 from and the production of C46 in the bone marrow and white blood cells, make the transduced cells resistant to and protect them from HIV-1 entry, infection and replication. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. C46 is a membrane-anchored 46-amino acid sequence found in HIV-1 gp41. CCR5 is a HIV-1 co-receptor that mediates HIV attachment and cell entry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2-DM1 ADC B003</VALIDVALUE>
          <VALUEMEANING>Anti-HER2-DM1 ADC B003</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HLA-DR Monoclonal Antibody IMMU-114</VALIDVALUE>
          <VALUEMEANING>Anti-HLA-DR Monoclonal Antibody IMMU-114</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HLA-G Antibody TTX-080</VALIDVALUE>
          <VALUEMEANING>Anti-HLA-G Antibody TTX-080</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-human GITR Monoclonal Antibody AMG 228</VALIDVALUE>
          <VALUEMEANING>Anti-human GITR Monoclonal Antibody AMG 228</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-human GITR Monoclonal Antibody TRX518</VALIDVALUE>
          <VALUEMEANING>Anti-human GITR Monoclonal Antibody TRX518</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95023</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3944882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ICOS Monoclonal Antibody MEDI-570</VALIDVALUE>
          <VALUEMEANING>Anti-ICOS Monoclonal Antibody MEDI-570</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IGF-1R Monoclonal Antibody AVE1642</VALIDVALUE>
          <VALUEMEANING>Anti-IGF-1R Monoclonal Antibody AVE1642</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. Anti-IGF-1R monoclonal antibody AVE1642 specifically binds to and blocks membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signal transduction, which may result in the induction of apoptosis and a decrease in cellular proliferation. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022</VALIDVALUE>
          <VALUEMEANING>Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IL-8 Monoclonal Antibody BMS-986253</VALIDVALUE>
          <VALUEMEANING>Anti-IL-8 Monoclonal Antibody HuMax-IL8</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, HuMax-IL8 directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, HuMax-IL8 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7070281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ILT4 Monoclonal Antibody MK-4830</VALIDVALUE>
          <VALUEMEANING>Anti-ILT4 Monoclonal Antibody MK-4830</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ICOS Agonist Monoclonal Antibody BMS-986226</VALIDVALUE>
          <VALUEMEANING>Anti-ICOS Agonist Monoclonal Antibody BMS-986226</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A</VALIDVALUE>
          <VALUEMEANING>Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388</VALIDVALUE>
          <VALUEMEANING>Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of an anti-integrin monoclonal antibody covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Integrin-targeted immunoconjugate IMGN388 binds to tumor cell surface integrins; upon internalization, the DM4 moiety is released from the immunoconjugate, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in inhibition of cell division and cell growth of integrin-expressing tumor cells. Integrins, a class of transmembrane cell surface receptors, link the extracellular matrix (ECM) to intracellular signaling pathways that control cell proliferation and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-KIR Monoclonal Antibody IPH 2101</VALIDVALUE>
          <VALUEMEANING>Anti-KIR Monoclonal Antibody IPH 2101</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3640461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</VALIDVALUE>
          <VALUEMEANING>Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG-3/PD-L1 Bispecific Antibody FS118</VALIDVALUE>
          <VALUEMEANING>Anti-LAG-3/PD-L1 Bispecific Antibody FS118</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAMP1 Antibody-drug Conjugate SAR428926</VALIDVALUE>
          <VALUEMEANING>Anti-LAMP1 Antibody-drug Conjugate SAR428926</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102</VALIDVALUE>
          <VALUEMEANING>Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human tumor-associated carbohydrate antigens (TACAs) Lewis B (LeB) and Lewis Y (LeY), with potential antineoplastic activity. Upon administration, anti-LeB/LeY monoclonal antibody GNX102 binds to branched LeB and LeY glycans, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against LeB- and LeY-expressing tumor cells. LeB and LeY antigens, tetrasaccharides with low to moderate expression in monomeric form in normal adult tissues, is overexpressed in branched form in multiple forms of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LGR5 Monoclonal Antibody BNC101</VALIDVALUE>
          <VALUEMEANING>Anti-LGR5 Monoclonal Antibody BNC101</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LILRB4 Monoclonal Antibody IO-202</VALIDVALUE>
          <VALUEMEANING>Anti-LILRB4 Monoclonal Antibody IO-202</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the immune inhibitory receptor leukocyte immunoglobulin-like receptor B4 (LILRB4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody IO-202 targets, binds to and inhibits LILRB4 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells, and inhibit tumor infiltration. LILRB4, an immune inhibitory receptor normally expressed on monocytic cells and highly expressed on monocytic acute myeloid leukemia (AML) cells, functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration in leukemias through multiple signaling pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG-3 Monoclonal Antibody IBI-110</VALIDVALUE>
          <VALUEMEANING>Anti-LAG-3 Monoclonal Antibody IBI-110</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody IBI110 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Ly6E Antibody-Drug Conjugate RG 7841</VALIDVALUE>
          <VALUEMEANING>Anti-Ly6E Antibody-Drug Conjugate RG 7841</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C</VALIDVALUE>
          <VALUEMEANING>Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Melanin Monoclonal Antibody PTI-6D2</VALIDVALUE>
          <VALUEMEANING>Anti-Melanin Monoclonal Antibody PTI-6D2</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody (MoAb) against extracellular melanin with tumor targeting activity. Anti-melanin monoclonal antibody PTI-6D2 binds to extracellular melanin, a melanocyte pigment which is released during tumor cell turnover from dead melanoma tumor cells, while avoiding the binding of melanin in normal, healthy tissue because of melanin&#39;s normal intracellular location. Upon labeling with the beta-emitting radioisotope rhenium Re 188 (PTI-188), this MoAb may target multiple melanoma (MM) cells, thereby delivering a cytotoxic dose of radiation specifically to the targeted tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-mesothelin Antibody-drug Conjugate BMS-986148</VALIDVALUE>
          <VALUEMEANING>Anti-mesothelin Antibody-drug Conjugate BMS-986148</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to an as of yet undisclosed cytotoxic drug, with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin ADC BMS-986148 targets and binds to the tumor associated antigen mesothelin. Upon internalization, the cytotoxic agent kills or prevents cellular proliferation of mesothelin-expressing tumor cells through an as of yet undescribed mechanism of action. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-mesothelin/MMAE Antibody-drug Conjugate RC88</VALIDVALUE>
          <VALUEMEANING>Anti-mesothelin/MMAE Antibody-drug Conjugate RC88</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-mesothelin/MMAE ADC RC88 targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100</VALIDVALUE>
          <VALUEMEANING>Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Met Monoclonal Antibody Mixture Sym015</VALIDVALUE>
          <VALUEMEANING>Anti-Met Monoclonal Antibody Mixture Sym015</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Met/EGFR Monoclonal Antibody LY3164530</VALIDVALUE>
          <VALUEMEANING>Anti-Met/EGFR Monoclonal Antibody LY3164530</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antimetabolite FF-10502</VALIDVALUE>
          <VALUEMEANING>Antimetabolite FF-10502</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A</VALIDVALUE>
          <VALUEMEANING>Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-MUC1 Monoclonal Antibody BTH1704</VALIDVALUE>
          <VALUEMEANING>Anti-MUC1 Monoclonal Antibody BTH1704</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A</VALIDVALUE>
          <VALUEMEANING>Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-NaPi2b Antibody-drug Conjugate XMT-1592</VALIDVALUE>
          <VALUEMEANING>Anti-NaPi2b Antibody-drug Conjugate XMT-1592</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of XMT-1535, a humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), that is site-specifically bioconjugated to the cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upon administration of anti-NaPi2b ADC XMT-1592, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Following internalization of XMT-1592 and release of AF-HPA, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antineoplastic Vaccine GV-1301</VALIDVALUE>
          <VALUEMEANING>Antineoplastic Vaccine GV-1301</VALUEMEANING>
          <MEANINGDESCRIPTION>Antineoplastic vaccine being developed against liver cancer. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antineoplaston AS2-1</VALIDVALUE>
          <VALUEMEANING>Antineoplaston AS2-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10.  Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis.  This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-nf-P2X7 Antibody Ointment BIL-010t</VALIDVALUE>
          <VALUEMEANING>Anti-nf-P2X7 Antibody Ointment BIL-010t</VALUEMEANING>
          <MEANINGDESCRIPTION>An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-NRP1 Antibody ASP1948</VALIDVALUE>
          <VALUEMEANING>Anti-NRP1 Antibody ASP1948</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Nucleolin Aptamer AS1411</VALIDVALUE>
          <VALUEMEANING>Anti-Nucleolin Aptamer AS1411</VALUEMEANING>
          <MEANINGDESCRIPTION>A 26-base guanine-rich oligodeoxynucleotide aptamer with potential apoptotic induction activity. Upon administration, anti-nucleolin aptamer AS1411 targets and binds to nucleolin, a nucleolar phosphoprotein which is overexpressed on the surface of certain cancer cells. Via binding to cell surface nucleolin, AS1411 is internalized and may prevent nucleolin from binding to and stabilizing mRNA of the anti-apoptotic BCL2, thereby destabilizing BCL2 mRNA, leading to a reduction in BCL2 protein synthesis. This may lead to the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A</VALIDVALUE>
          <VALUEMEANING>Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antineoplaston A10</VALIDVALUE>
          <VALUEMEANING>Antineoplaston A10</VALUEMEANING>
          <MEANINGDESCRIPTION>A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso</VALIDVALUE>
          <VALUEMEANING>Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OFA Immunotherapeutic BB-MPI-03</VALIDVALUE>
          <VALUEMEANING>Anti-OFA Immunotherapeutic BB-MPI-03</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Agonist Monoclonal Antibody BGB-A445</VALIDVALUE>
          <VALUEMEANING>Anti-OX40 Agonist Monoclonal Antibody BGB-A445</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 agonist monoclonal antibody BGB-A445 selectively binds to OX40, thereby activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Antibody BMS 986178</VALIDVALUE>
          <VALUEMEANING>Anti-OX40 Antibody BMS 986178</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128026</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Monoclonal Antibody GSK3174998</VALIDVALUE>
          <VALUEMEANING>Anti-OX40 Monoclonal Antibody GSK3174998</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Fusion Protein AMP-224</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1 Fusion Protein AMP-224</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody 609A</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1 Monoclonal Antibody 609A</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody 609A targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody BAT1306</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1 Monoclonal Antibody BAT1306</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody MEDI0680</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1 Monoclonal Antibody MEDI0680</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Hexavalent Agonist Antibody INBRX-106</VALIDVALUE>
          <VALUEMEANING>Anti-OX40 Hexavalent Agonist Antibody INBRX-106</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 hexavalent agonist antibody INBRX-106 selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody Sym021</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1 Monoclonal Antibody Sym021</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/CD47 Infusion Protein HX009</VALIDVALUE>
          <VALUEMEANING>Anti-PD-1/CD47 Infusion Protein HX009</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 infusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody CBT-502</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1 Monoclonal Antibody CBT-502</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody CBT-502 specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody FAZ053</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1 Monoclonal Antibody FAZ053</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody GR1405</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1 Monoclonal Antibody GR1405</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody MDX-1105</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1 Monoclonal Antibody MDX-1105</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the protein ligand PD-L1 (Programmed Death-1 Ligand 1) with immunomodulating and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor, PD-1 (Programmed Death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation in chronic infectious disease.  PD-L1 is expressed broadly on hematopoietic and parenchymal tissues; PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3773962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody RC98</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1 Monoclonal Antibody RC98</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody RC98 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB bispecific antibody INBRX-105 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, INBRX-105 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, INBRX-105 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1/CD137 Bispecific Antibody MCLA-145</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1/CD137 Bispecific Antibody MCLA-145</VALUEMEANING>
          <MEANINGDESCRIPTION>A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1/IL-15 Fusion Protein KD033</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1/IL-15 Fusion Protein KD033</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to the immunostimulatory cytokine interleukin-15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration of the anti-PD-L1/IL-15 fusion protein KD033, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, IL-15 stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the TME, which induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244</VALIDVALUE>
          <VALUEMEANING>Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PKN3 siRNA Atu027</VALIDVALUE>
          <VALUEMEANING>Anti-PKN3 siRNA Atu027</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and fusiogenic lipids with potential antineoplastic activity. Upon administration, catiogenic and fusiogenic lipids promote anti-PKN3 siRNA Atu02 uptake by tumor cells; the siRNAs moieties are subsequently released once inside the cell. The siRNAs bind to PKN3 mRNAs, which may result in the inhibition of translation and expression of the PKN3 protein and, so, growth inhibition of tumor cells that overexpress PKN3. The protein kinase C-related molecule PKN3, downstream in the phosphoinositide-3-kinase (PI3K) signaling pathway, is upregulated in many tumor cells and plays an important role in invasive cell growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4</VALIDVALUE>
          <VALUEMEANING>Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell receptor (TCR)-like monoclonal antibody against PR1, a 9 amino-acid (VLQELNVTV) human leukocyte antigen (HLA)-A2-restricted leukemia-associated antigen (LAA) derived from the myeloid leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PR1/HLA-A2 monoclonal antibody Hu8F4 selectively binds to a combined epitope of the PR1/HLA-A2 complex expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSC), and prevents PR1/HLA-A2-mediated signaling. This induces complement-dependent cytotoxicity (CDC), to a lesser extent, antibody-dependent cell-mediated cytotoxicity (ADCC), and CDC/ADCC-independent cytolysis of myeloid leukemia cells. This results in a reduction of cellular proliferation in PR1/HLA-A2-overexpressing leukemic cells. PR1 in combination with the HLA-A2 molecule is highly expressed on AML blasts and LSCs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PRAME Immunotherapeutic GSK2302032A</VALIDVALUE>
          <VALUEMEANING>Anti-PRAME Immunotherapeutic GSK2302032A</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C</VALIDVALUE>
          <VALUEMEANING>Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon administration of IMC-F106C, the TCR moiety of this agent targets and binds to PRAME on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PRL-3 Monoclonal Antibody PRL3-zumab</VALIDVALUE>
          <VALUEMEANING>Anti-PRL-3 Monoclonal Antibody PRL3-zumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against  phosphatase of regenerating liver 3 (PRL-3; PTP4A3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-PRL-3 monoclonal antibody PRL3-zumab targets, binds to and blocks PRL-3 expressed on tumor cells. Although the exact mechanism of action through which this antibody kills tumor cells has yet to be fully elucidated, PRL3-zumab binds to PRL-3. This prevents PRL-3-mediated signaling in, inhibits the proliferation of and induces apoptosis in PRL-3-expressing tumor cells. PRL-3, a member of the PRL family of protein tyrosine kinases, is upregulated in a variety of tumor cells. Its expression is associated with increased invasiveness, higher metastatic potential, increased tumor cell survival and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-prolactin Receptor Antibody LFA102</VALIDVALUE>
          <VALUEMEANING>Anti-prolactin Receptor Antibody LFA102</VALUEMEANING>
          <MEANINGDESCRIPTION>A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor antibody LFA102 binds to PRLR and prevents the binding of the peptide hormone prolactin (PRL) to its receptor. This binding induces an antibody-dependent cellular cytotoxicity (ADCC) and may eventually prevent tumor cell proliferation in PRLR-positive cancer cells. PRLR/PRL signaling pathway is frequently overexpressed in breast and prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PLGF Monoclonal Antibody TB-403</VALIDVALUE>
          <VALUEMEANING>Anti-PLGF Monoclonal Antibody TB-403</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody TB-403 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSCA Monoclonal Antibody AGS-1C4D4</VALIDVALUE>
          <VALUEMEANING>Anti-PSCA Monoclonal Antibody AGS-1C4D4</VALUEMEANING>
          <MEANINGDESCRIPTION>An IgG1k fully human monoclonal antibody directed against the human prostate stem cell antigen (PSCA) with potential antineoplastic activity. Anti-PSCA fully human monoclonal antibody MK4721 selectively targets and binds to PSCA, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing PSCA. PSCA is a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen found in cancers of the bladder, pancreas, and prostate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA Monoclonal Antibody MDX1201-A488</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA Monoclonal Antibody MDX1201-A488</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with a fluorescent dye A488, with potential imaging activity. Upon intravenous administration, the MDX1201 moiety of anti-PSMA monoclonal antibody MDX1201-A488 targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. A488 is a photostable fluorescent dye with a high quantum yield. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA Monoclonal Antibody-MMAE Conjugate</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA Monoclonal Antibody-MMAE Conjugate</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody directed against prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  The monoclonal antibody moiety of this conjugate selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA/CD3 Bispecific Antibody CCW702</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA/CD3 Bispecific Antibody CCW702</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169053</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-prostate specific membrane antigen (PSMA)/anti-CD3 bispecific humanized monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Anti-PSMA/CD3 monoclonal antibody MOR209/ES414 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for PSMA, a tumor-associated antigen (TAA) overexpressed on the surface of prostate tumor cells. Upon intravenous administration of MOR209/ES414, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and PSMA-expressing cancer cells, thereby crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in CTL-mediated cancer cell lysis of prostate cancer cells expressing PSMA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA/PBD ADC MEDI3726</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA/PBD ADC MEDI3726</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an engineered version of anti-human prostate-specific membrane antigen (PSMA) monoclonal antibody J591 conjugated, via a valine-alanine dipeptide linker, to tesirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-PSMA/PBD ADC MEDI3726, the antibody moiety targets the cell surface antigen PSMA, which is found on prostate cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage of the dipeptide linker, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of PSMA-overexpressing tumor cells. PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PVRIG Monoclonal Antibody COM701</VALIDVALUE>
          <VALUEMEANING>Anti-PVRIG Monoclonal Antibody COM701</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-RANKL Monoclonal Antibody GB-223</VALIDVALUE>
          <VALUEMEANING>Anti-RANKL Monoclonal Antibody GB-223</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in the inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. By blocking the activation of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated bone destruction and may result in tumor regression in bone tumors with high RANK and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA/CD28 Bispecific Antibody REGN5678</VALIDVALUE>
          <VALUEMEANING>Anti-PSMA/CD28 Bispecific Antibody REGN5678</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-PSMA/CD28 bispecific antibody REGN5678, this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Ribonucleoprotein Antibody ATRC-101</VALIDVALUE>
          <VALUEMEANING>Anti-Ribonucleoprotein Antibody ATRC-101</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered, human immunoglobulin (Ig) G1 monoclonal antibody directed against a ribonucleoprotein (RNP) complex, with potential immunostimulating and antineoplastic activities. Upon administration, anti-RNP antibody ATRC-101 targets and binds to its RNP complex antigen on tumor cells. This may activate the innate immune system, change the local tumor microenvironment (TME) and promote T cell-mediated killing of tumor cells. The tumor-restricted RNP complex is expressed in a variety of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002</VALIDVALUE>
          <VALUEMEANING>Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of NBE-002 targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the anthracycline-based toxin intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. This kills the ROR1-expressing cancer cells. In addition, the PNU-159682 derivate may promote immunogenic cell death (ICD) and activate a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response, thereby further killing the ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-S15 Monoclonal Antibody NC318</VALIDVALUE>
          <VALUEMEANING>Anti-S15 Monoclonal Antibody NC318</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting sialic acid binding Ig-like lectin 15 (Siglec-15; SIGLEC15; S15), a member of the sialic acid-binding immunoglobulin type lectins, with potential antineoplastic and immunomodulatory activities. Upon administration, anti-S15 monoclonal antibody NC318 targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells, inhibition of T-cell responses, and stimulation of tumor angiogenesis and disease progression. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, may play a role in the survival and differentiation of TAMs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TAG-72 Monoclonal Antibody scFV CC-49/218</VALIDVALUE>
          <VALUEMEANING>Anti-TAG-72 Monoclonal Antibody scFV CC-49/218</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin derived from the single-chain antigen-binding domain (sFv) of the monoclonal antibody CC-49 with potential antineoplastic activity.  The parent monoclonal antibody CC-49 binds to the tumor-associated glycoprotein TAG-72 with high affinity, recognizing many tumor cell types that express TAG-72. Because of its single-chain structure, CC-49/218 sFv may exhibit a longer half-life than the parent monoclonal antibody CC-49; 218 represents the linker sequence that helps reduce aggregation and proteolysis of this agent.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TF Monoclonal Antibody ALT-836</VALIDVALUE>
          <VALUEMEANING>Anti-TF Monoclonal Antibody ALT-836</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human-mouse chimeric monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody ALT-836 binds to TF or the TF-Factor VIIa (FVIIa) complex preventing binding and activation of Factor X (FX) and Factor IX (FIX). This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and procoagulant, is overexpressed in many tumor cell types, and is correlated with metastasis, angiogenesis, tumor growth and tumor-associated thrombosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TGF-beta Monoclonal Antibody SAR-439459</VALIDVALUE>
          <VALUEMEANING>Anti-TGF-beta Monoclonal Antibody SAR-439459</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody (mAb) directed against human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-TGF-beta monoclonal antibody SAR-439459 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGF-beta is overactivated. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a variety of cancer cell types, is involved in cancer cell proliferation and migration, and in tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TGF-beta RII Monoclonal Antibody IMC-TR1</VALIDVALUE>
          <VALUEMEANING>Anti-TGF-beta RII Monoclonal Antibody IMC-TR1</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIGIT Monoclonal Antibody BMS-986207</VALIDVALUE>
          <VALUEMEANING>Anti-TIGIT Monoclonal Antibody BMS-986207</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody BMS-986207 binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antisense Oligonucleotide GTI-2040</VALIDVALUE>
          <VALUEMEANING>Antisense Oligonucleotide GTI-2040</VALUEMEANING>
          <MEANINGDESCRIPTION>A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase.  GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIGIT Monoclonal Antibody COM902</VALIDVALUE>
          <VALUEMEANING>Anti-TIGIT Monoclonal Antibody COM902</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody COM902 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIGIT Monoclonal Antibody SGN-TGT</VALIDVALUE>
          <VALUEMEANING>Anti-TIGIT Monoclonal Antibody SGN-TGT</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonfucosylated human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody SGN-TGT targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs). This prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), and enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This enhances depletion of TIGIT-positive regulatory T-cells (Tregs) and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM-3 Antibody BMS-986258</VALIDVALUE>
          <VALUEMEANING>Anti-TIM-3 Antibody BMS-986258</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM-3 Monoclonal Antibody INCAGN02390</VALIDVALUE>
          <VALUEMEANING>Anti-TIM-3 Monoclonal Antibody INCAGN02390</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, INCAGN02390 forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM3 Monoclonal Antibody SHR-1702</VALIDVALUE>
          <VALUEMEANING>Anti-TIM3 Monoclonal Antibody SHR-1702</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIM3 monoclonal antibody SHR-1702 targets and binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM-3 Monoclonal Antibody Sym023</VALIDVALUE>
          <VALUEMEANING>Anti-TIM-3 Monoclonal Antibody Sym023</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody Sym023 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Tissue Factor Monoclonal Antibody MORAb-066</VALIDVALUE>
          <VALUEMEANING>Anti-Tissue Factor Monoclonal Antibody MORAb-066</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody MORAb-066 binds to TF and prevents Factor VIIa (FVIIa) from binding, thereby interfering with the activation of Factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor endothelial cells; its expression is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711</VALIDVALUE>
          <VALUEMEANING>Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711</VALUEMEANING>
          <MEANINGDESCRIPTION>A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2; death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis. CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity. CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted in normal liver tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TROP2 Antibody-drug Conjugate BAT8003</VALIDVALUE>
          <VALUEMEANING>Anti-TROP2 Antibody-drug Conjugate BAT8003</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC BAT8003, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM3 Monoclonal Antibody LY3321367</VALIDVALUE>
          <VALUEMEANING>Anti-TIM3 Monoclonal Antibody LY3321367</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TROP2 Antibody-drug Conjugate SKB264</VALIDVALUE>
          <VALUEMEANING>Anti-TROP2 Antibody-drug Conjugate SKB264</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC SKB264, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antitumor B Key Active Component-alpha</VALIDVALUE>
          <VALUEMEANING>Antitumor B Key Active Component-alpha</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available concentrated preparation of antitumor B (ATB, Zeng Sheng Ping), a Chinese herbal formula comprised of Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera, with potential antineoplastic activity. Upon administration, antitumor B key active component-alpha (ATB-KAC-alpha) may, through a not yet fully elucidated mechanism, inhibit tumorigenesis and prevent the development of certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TWEAK Monoclonal Antibody RG7212</VALIDVALUE>
          <VALUEMEANING>Anti-TWEAK Monoclonal Antibody RG7212</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. Anti-TWEAK monoclonal antibody RG7212 binds to TWEAK and prevents the binding of TWEAK to its receptor, FGF-inducible molecule 14 (Fn14), thereby blocking the TWEAK/Fn14 signaling. This may prevent tumor cell proliferation, invasion, migration and angiogenesis. TWEAK has pleiotropic effects, mediating proinflammatory and pro-angiogenic activity as well as stimulation of invasion, migration, and survival mediated via its receptor Fn14; Fn14 is expressed at relatively low levels in normal tissues, but is elevated in tumor cells and locally in injured and diseased tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGF Anticalin PRS-050-PEG40</VALIDVALUE>
          <VALUEMEANING>Anti-VEGF Anticalin PRS-050-PEG40</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated, proprietary lipocalin that targets human vascular endothelial growth factor (VEGF), with potential antineoplastic activity. Pegylated anti-VEGF anticalin PRS-050 specifically targets and binds to VEGF receptor 2 (VEGFR2 or KDR), thereby preventing its activity. This may inhibit angiogenesis and eventually reduce tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGF/ANG2 Nanobody BI 836880</VALIDVALUE>
          <VALUEMEANING>Anti-VEGF/ANG2 Nanobody BI 836880</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T</VALIDVALUE>
          <VALUEMEANING>Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, human immunoglobulin Fc fusion protein targeting both the transforming growth factor (TGF) beta 1 (TGF-beta 1; TGFb1) and the vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration of anti-VEGF/TGF-beta 1 fusion protein HB-002T, the fusion protein specifically and selectively targets, binds to and neutralizes both TGF-beta 1 and VEGF. This prevents TGFb1- and VEGF-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGFb1-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGFb1-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGFC Monoclonal Antibody VGX-100</VALIDVALUE>
          <VALUEMEANING>Anti-VEGFC Monoclonal Antibody VGX-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity. Anti-VEGFC monoclonal antibody VGX-100 specifically binds to and inhibits VEGFC protein, thereby preventing its binding to VEGFR3 (FLT4) or VEGFR2 (KDR or FLK1). This may prevent VEGFC-mediated signaling and may lead to the inhibition of vascular and lymphatic endothelial cell proliferation. The inhibition of tumor angiogenesis and lymphangiogenesis may eventually decrease tumor cell proliferation and prevent metastasis. VEGFC is overexpressed in a variety of cancer cells, and is associated with increased invasiveness and decreased survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGFR2 Monoclonal Antibody MSB0254</VALIDVALUE>
          <VALUEMEANING>Anti-VEGFR2 Monoclonal Antibody MSB0254</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, anti-VEGFR2 monoclonal antibody MSB0254 specifically binds to and inhibits VEGFR2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGFR3 Monoclonal Antibody IMC-3C5</VALIDVALUE>
          <VALUEMEANING>Anti-VEGFR3 Monoclonal Antibody IMC-3C5</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully-human monoclonal antibody directed against human vascular endothelial growth factor receptor 3 (VEGFR-3; Flt-4) with antiangiogenic activity. Anti-VEGFR-3 monoclonal antibody IMC-3C5 specifically binds to and inhibits VEGFR-3, which may result in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-3 plays a critical role in the embryonic vascular system development but is restricted postnatally to endothelial cells of lymphatic vessels and found to be expressed in many solid and hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGF Monoclonal Antibody hPV19</VALIDVALUE>
          <VALUEMEANING>Anti-VEGF Monoclonal Antibody hPV19</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antrodia cinnamomea Supplement</VALIDVALUE>
          <VALUEMEANING>Antrodia cinnamomea Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement containing extract from the medicinal fungus Antrodia cinnamomea with potential antiangiogenic, hepatoprotective and antioxidant activities. The components in Antrodia cinnamomea supplement are rather complex, however, rich in triterpenoids, polysaccharides, nucleosides (adenosine) nucleic acids, superoxide dismutase, other small molecular weight proteins and steroid like compounds. Neutral sugars in this supplement show inhibitory activity on endothelial tube formation, while maleimide and maleic anhydride derivative components in the extract, such as antrodin B and antrodin C and their metabolites, exhibit significant cytotoxic effects on tumor cells and hepatitis C virus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antroquinonol Capsule</VALIDVALUE>
          <VALUEMEANING>Antroquinonol Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available capsule containing antroquinonol, a farnesylated quinone derivative isolated from the mycelium of Antrodia camphorata, with potential antineoplastic activity. Upon oral administration, antroquinonol binds to and inhibits protein prenylation mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase 1 (GGTase-1). This prevents both post-translational prenylation and signaling activity of a number of Ras superfamily proteins, such as Ras and Rho. This results in the inhibition of downstream signaling, such as the PI3K/mTOR signaling pathway, and induces apoptosis in susceptible tumor cells. Ras superfamily proteins are overexpressed in numerous cancer cell types, and play a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apalutamide</VALIDVALUE>
          <VALUEMEANING>Apalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5811375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apatorsen</VALIDVALUE>
          <VALUEMEANING>Apatorsen</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>APC8015F</VALIDVALUE>
          <VALUEMEANING>APC8015F</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>APE1/Ref-1 Redox Inhibitor APX3330</VALIDVALUE>
          <VALUEMEANING>APE1/Ref-1 Redox Inhibitor APX3330</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, the APE1/Ref-1 Inhibitor APX3330 selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival.  APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. APX3330 specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aphidicoline Glycinate</VALIDVALUE>
          <VALUEMEANING>Aphidicoline Glycinate</VALUEMEANING>
          <MEANINGDESCRIPTION>A tetracyclic diterpene antibiotic isolated from the fungus Cephalosporium aphidicola and other fungal species with potential antineoplastic activity.  Aphidicoline glycinate blocks the cell cycle at early S-phase by specifically inhibiting DNA polymerases in eukaryotic cells, induces apoptosis, and stops the growth of eukaryotic cells and certain viruses by selectively inhibiting DNA polymerase II or viral-induced DNA polymerases. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apilimod Dimesylate Capsule</VALIDVALUE>
          <VALUEMEANING>Apilimod Dimesylate Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule containing the dimesylate salt form of apilimod, an inhibitor of the class III PI kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with potential antineoplastic and immunomodulatory activities. Upon oral administration of apilimod dimesylate capsule, apilimod selectively binds to and inhibits PIKfyve. The inhibition leads to disruption of PIKfyve-mediated signal transduction pathways and eventually inhibits tumor cell growth in PIKfyve-overexpressing tumor cells. Also, PIKfyve inhibition by apilimod inhibits the toll-like receptor (TLR)-induced production of various cytokines, including interleukin-12 (IL-12) and IL-23, thereby preventing IL-12/IL-23-mediated immune responses. PIKfyve, a lipid kinase dysregulated in various tumor types, plays a key role in TLR signaling and tumor cell migration, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apitolisib</VALIDVALUE>
          <VALUEMEANING>Dual PI3 Kinase/mTOR Inhibitor GDC-0980</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor GDC-0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apaziquone</VALIDVALUE>
          <VALUEMEANING>Apaziquone</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apolizumab</VALIDVALUE>
          <VALUEMEANING>Apolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apomab</VALIDVALUE>
          <VALUEMEANING>Apomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against human death receptor 5 (DR5; TRAIL-R2; TNFRSF10B) with potential pro-apoptotic and antineoplastic activities. Mimicking the natural ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), apomab binds to DR5, which may directly activate the extrinsic apoptosis pathway and indirectly induce the intrinsic apoptosis pathway in tumor cells. DR5 is a cell surface receptor of the TNF-receptor superfamily and is expressed in a broad range of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apomine</VALIDVALUE>
          <VALUEMEANING>Apomine</VALUEMEANING>
          <MEANINGDESCRIPTION>A 1,1-bisphosphonate ester with potential antineoplastic and hypocholesterolemic activities. SR-45023A binds to hydroxyapatite crystals in the bone matrix where it inhibits enzymatic activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for the formation of mevalonate, the precursor of cholesterol. Consequently, shortage of mevalonate impedes the synthesis of downstream isoprenoids that are essential for protein prenylation. This leads to the loss of activity of proteins involved in osteoclast function and cellular proliferation, such as Ras and Rho, leading to an inhibition of cellular proliferation, and induction of osteoclasts apoptosis. In addition, SR-45023A activates the farnesoid X activated receptor (FXR), a member of the nuclear hormone superfamily implicated in cholesterol metabolism and bile acid transport and may play a role in this agent&#39;s antineoplastic effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apoptosis Inducer BZL101</VALIDVALUE>
          <VALUEMEANING>Apoptosis Inducer BZL101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active aqueous extract derived from the plant Scutellaria barbata with potential antineoplastic activity. Sparing normal cells, apoptosis inducer BZL101 specifically facilitates translocation of the protein apoptosis-inducing factor (AIF) from the mitochondrial membrane into the nucleus in tumor cells, thereby causing tumor cell-specific chromatin condensation and DNA degradation followed by the induction of caspase-independent apoptosis. AIF is both a mitochondrial intermembrane flavoprotein with oxidoreductase activity and a caspase-independent death effector that, similar to cytochrome c, is released from mitochondria early in the apoptotic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apoptosis Inducer MPC-2130</VALIDVALUE>
          <VALUEMEANING>Apoptosis Inducer MPC-2130</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad-acting, apoptosis-inducing, small molecule with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, apoptosis inducer MPC-2130 exhibits proapoptotic activities in tumor cells, including membrane phosphatidylserine externalization, release of cytochrome C from mitochondria, caspase activation, cell condensation, and DNA fragmentation. In addition, because this agent is not a substrate for several types of multidrug resistance (MDR) ABC superfamily transporters, such as P-glycoprotein 1 (MDR-1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1/ABCG2), it may be useful in treating MDR tumors that express these particular MDR efflux pumps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apricoxib</VALIDVALUE>
          <VALUEMEANING>Apricoxib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74021</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aprinocarsen</VALIDVALUE>
          <VALUEMEANING>ISIS 3521</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, ISIS 3521 hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aprutumab</VALIDVALUE>
          <VALUEMEANING>Aprutumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, aprutumab binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aprutumab Ixadotin</VALIDVALUE>
          <VALUEMEANING>Aprutumab Ixadotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, the toxin selectively induces cell death, through an as of yet undisclosed mechanism of action, in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Apoptosis Inducer GCS-100</VALIDVALUE>
          <VALUEMEANING>Apoptosis Inducer GCS-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A galectin-binding polysaccharide derived from citrus pectin with potential antineoplastic activity. Apoptosis inducer GCS-100 binds to the carbohydrate-binding domain of the lectin galectin-3, which may result in apoptosis mediated through mitochondria/caspase activation cascades; this agent may overcome tumor growth mediated through anti-apoptotic protein Bcl-2, heat-shock protein 27 (Hsp27), and nuclear factor-kappa B (NF-kB). Galectin-3, a chimeric molecule consisting of both carbohydrate recognition and collagen-like domains, interacts with a variety of carbohydrate and protein ligands to form pentamers with unique crosslinking abilities; this lectin also exhibits anti-apoptotic properties, perhaps, in part, through the regulation of intracellular signaling pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AR Antagonist BMS-641988</VALIDVALUE>
          <VALUEMEANING>AR Antagonist BMS-641988</VALUEMEANING>
          <MEANINGDESCRIPTION>An androgen receptor (AR) antagonist with potential antineoplastic and anti-androgenic activities. BMS-641988 binds to the androgen receptor in target tissues, thereby preventing androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This may inhibit androgen-dependent gene expression, subsequently leading to an inhibition of cell growth and apoptosis in AR-expressing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arabinoxylan Compound MGN3</VALIDVALUE>
          <VALUEMEANING>Arabinoxylan Compound MGN3</VALUEMEANING>
          <MEANINGDESCRIPTION>An arabinoxylane polysaccharide composed of the hemicellulose-Beta extract of rice bran, treated with enzymes from Shiitake mushrooms, that exerts antitumor and antiviral activity by increasing the level of natural killer cells activation. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aranose</VALIDVALUE>
          <VALUEMEANING>Aranose</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitrosourea derivative with potential antineoplastic activity. Upon administration, aranose alkylates and crosslinks DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Archexin</VALIDVALUE>
          <VALUEMEANING>Archexin</VALUEMEANING>
          <MEANINGDESCRIPTION>A 20-mer antisense oligodeoxynucleotide (ODN) against the proto-oncogene Akt with potential antineoplastic activity. Akt-1 antisense oligonucleotide RX-0201 binds to Akt-1 mRNA, inhibiting translation of the transcript; suppression of Akt-1 expression may result in the inhibition of cellular proliferation and the induction of apoptosis in tumor cells that overexpress Akt-1. Akt-1 is a serine-threonine protein kinase that stimulates proliferation and inhibits apoptosis of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arcitumomab</VALIDVALUE>
          <VALUEMEANING>Arcitumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG monoclonal Fab&#39; fragment antibody directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, technetium-99m labeled arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arfolitixorin</VALIDVALUE>
          <VALUEMEANING>Arfolitixorin</VALUEMEANING>
          <MEANINGDESCRIPTION>The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2&#39;-deoxyuridine-5&#39;-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arginine Butyrate</VALIDVALUE>
          <VALUEMEANING>Arginine Butyrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound composed of the short chain fatty acid (SCFA) butyrate combined with the amino acid arginine, with potential Epstein-Barr virus thymidine kinase gene (EBV-TK)-inducing activity. Upon administration, arginine butyrate induces the expression of thymidine kinase (TK). This activates a co-administered antiviral, such as ganciclovir, and results in the destruction of EBV-infected cancer cells. In addition, butyrate inhibits histone deacetylase (HDAC), which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arnebia Indigo Jade Pearl Topical Cream</VALIDVALUE>
          <VALUEMEANING>Arnebia Indigo Jade Pearl Topical Cream</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary multiherbal topical cream based on Chinese herbal medicine with potential antineoplastic, antiviral, antibacterial and immunostimulatory activities. Arnebia Indigo Jade Pearl topical cream contains 12 ingredients including 9 herbs infused in sesame oil, with an additional three powdered ingredients and beeswax added to the infused oil to create the salve. The purported mechanism(s) of action is unclear due to the complexity of the herbal mixture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74013</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arsenic Trioxide</VALIDVALUE>
          <VALUEMEANING>Arsenic Trioxide</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ARC Fusion Protein SL-279252</VALIDVALUE>
          <VALUEMEANING>ARC Fusion Protein SL-279252</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist redirected checkpoint (ARC) fusion protein consisting of the extracellular domains of human programmed cell death 1 (PD-1; PDCD1; CD279) and tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 ligand; OX40L; CD252), linked by a central Fc domain (PD1-Fc-OX40L), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, ARC fusion protein SL-279252 simultaneously binds to both tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40) and PD-1 expressed on T-lymphocytes. Stimulation of OX40 may promote cytokine production and induce proliferation of memory and effector T-lymphocytes against tumor cells, while PD-1 binding disrupts PD-1 signaling and may restore immune function through the activation of T-cells. This may enhance the immune-mediated elimination of tumor cells more effectively than PD-1 blockade or OX40-agonism alone. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arsenic Trioxide Capsule Formulation ORH 2014</VALIDVALUE>
          <VALUEMEANING>Arsenic Trioxide Capsule Formulation ORH 2014</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells, including tumor cells. In addition, As2O3 causes damage to and induces degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein, and inhibits the activity of the enzyme thioredoxin reductase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Artemether Sublingual Spray</VALIDVALUE>
          <VALUEMEANING>Artemether Sublingual Spray</VALUEMEANING>
          <MEANINGDESCRIPTION>A sublingual spray containing artemether, a semisynthetic derivative of artemisinin, an endoperoxide extracted from the Chinese herb qinghaosu (Artemisia annua or annual wormwood), with antiparasitic and potential antineoplastic activity. Upon sublingual application of the spray, artemether exerts its antineoplastic activity through as of yet not fully elucidated mechanism(s) of action. This agent binds to heme molecules inside cells, thereby inducing reactive oxygen species (ROS)-mediated damage which selectively kills cancer cells. In addition, artemether appears to target and modulate the expression of various proteins involved in cancer cell proliferation, angiogenesis, invasion and metastasis. Also, this agent depletes T regulatory cells, and modulates the production of inflammatory cytokines, such as interleukin-4 and interferon-gamma. Altogether, this inhibits tumor cell proliferation. The sublingual spray allows faster absorption of a higher percentage of the artemether dose, when compared to the oral form, as it avoids first pass metabolism; this results in an increased efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Artemisinin Dimer</VALIDVALUE>
          <VALUEMEANING>Artemisinin Dimer</VALUEMEANING>
          <MEANINGDESCRIPTION>A sesquiterpene lactone peroxide and dimerized plant product derived from Artemisia annua L with anti-malarial, anti-proliferative and anti-angiogenic effects. Artemisinin contains an endoperoxide moiety which forms free radicals when it reacts with iron. The resultant carbon-based radical can lead to cellular damage and cell death by reacting with cellular macromolecules such as proteins and membrane lipids. Malaria parasites contain large amounts of heme-iron, a product from the digestion of hemoglobin. However, recently it has been suggested that activation of artemisinin inside the parasite is by ferrous iron. Furthermore, due to their rapid rate of division, cancer cells require and uptake a large amount of iron to proliferate, therefore they are more susceptible to the cytotoxic effect of artemisinin than non-cancerous cells. The dimer configuration has been shown to increase compound stability and reduce general toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arugula Seed Powder</VALIDVALUE>
          <VALUEMEANING>Arugula Seed Powder</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement containing an extract powder derived from the seeds of the cruciferous vegetable arugula (Eruca sativa), with potential chemopreventive and antioxidant activities. Arugula seed powder contains numerous vitamins and minerals, and is rich in phytonutrients, such as sulforaphane and indole-3-carbinol. Although the exact mechanism of action through which arugula seed powder may exert its anti-tumor effect has yet to be fully elucidated, the effects of this powder on cancer cells may be attributable to the antioxidant and pro-apoptotic activities of the phytonutrients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aryl Hydrocarbon Receptor Antagonist BAY2416964</VALIDVALUE>
          <VALUEMEANING>Aryl Hydrocarbon Receptor Antagonist BAY2416964</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR antagonist BAY2416964 specifically binds to AhR, inhibits AhR activation, and prevents AhR-mediated signaling. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, has important roles in regulating immunity and cellular differentiation. AhR can exhibit both pro-oncogenic and tumor suppressor-like functions depending on the tumor type; therefore, its expression may serve as a negative or positive prognostic factor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aryl Hydrocarbon Receptor Inhibitor IK-175</VALIDVALUE>
          <VALUEMEANING>Aryl Hydrocarbon Receptor Inhibitor IK-175</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76), with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR inhibitor IK-175 specifically targets and binds to AhR, inhibits AhR activation, prevents AhR-mediated signaling, and AhR-dependent tumor cell proliferation. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs), regulatory T-cells (Tregs) and decreases suppressive cytokines in the tumor microenvironment (TME). It stimulates cytotoxic T-cell activation and expansion. This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, plays key roles in regulating immunity and cellular differentiation. It mediates the expression of multiple immune related and tumor cell signal transduction and proliferation genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13314839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asaley</VALIDVALUE>
          <VALUEMEANING>Asaley</VALUEMEANING>
          <MEANINGDESCRIPTION>An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asciminib</VALIDVALUE>
          <VALUEMEANING>Asciminib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascrinvacumab</VALIDVALUE>
          <VALUEMEANING>Ascrinvacumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, IgG2 monoclonal antibody directed against activin-like receptor kinase 1 (ALK-1) with potential antineoplastic activity. Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis, eventually leading to an inhibition of tumor cell proliferation. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Artesunate</VALIDVALUE>
          <VALUEMEANING>Artesunate</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, semi-synthetic derivative of the sesquiterpine lactone artemisinin with anti-malarial, anti-schistosomiasis, antiviral, and potential anti-neoplastic activities. Upon hydrolysis of artesunate&#39;s active endoperoxide bridge moiety by liberated heme in parasite-infected red blood cells, reactive oxygen species and carbon-centered radicals form, which have been shown to damage and kill parasitic organisms. Additionally, in vitro studies demonstrate that this agent induces DNA breakage in a dose-dependent manner. Artesunate has also been shown to stimulate cell differentiation, arrest the cell cycle in the G1 and G2/M phases, inhibit cell proliferation, and induce apoptosis through mitochondrial and caspase signaling pathways. Artemisinin is isolated from the plant Artemisia annua.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ashwagandha Root Powder Extract</VALIDVALUE>
          <VALUEMEANING>Ashwagandha Root Powder Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement containing an extract powder derived from the root of the ashwagandha shrub with potential antineoplastic, antioxidant, immunostimulating and anti-angiogenic activities. Ashwagandha root powder extract contains numerous alkaloids, including withanine as the primary alkaloid, and steroidal lactone withanolides. The withanolides in this agent may suppress nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene expression, potentiating apoptosis and inhibiting tumor cell invasion. Cultivated in India and North America, ashwagandha (Withania somnifera Dunal or Indian ginseng) belongs to the Solanaceae (nightshade) family.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ASP4132</VALIDVALUE>
          <VALUEMEANING>ASP4132</VALUEMEANING>
          <MEANINGDESCRIPTION>A molecule with potential antineoplastic activity. Upon oral administration, ASP4132 affects oxidative phosphorylation in mitochondria of metabolically-active tumor cells, which reduces both energy production and tumor cell proliferation. Mitochondrial oxidative phosphorylation is hyperactivated in tumor cells and plays a key role in the promotion of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspacytarabine</VALIDVALUE>
          <VALUEMEANING>Aspacytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asparaginase</VALIDVALUE>
          <VALUEMEANING>Asparaginase Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3606704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10</VALIDVALUE>
          <VALUEMEANING>Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate composed of the anti-CD38 monoclonal antibody (MoAb) OKT10-B10 labeled with the alpha-emitting radionuclide astatine (At) 211 (211At), with potential antineoplastic activity. Upon administration of astatine At 211 anti-CD38 MoAb OKT10-B10, the MoAb moiety targets and binds to CD38-expressing tumor cells, thereby delivering a cytotoxic dose of alpha radiation directly to the CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein and tumor-associated antigen (TAA), is present on various immune cells and in hematologic malignancies; its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10</VALIDVALUE>
          <VALUEMEANING>Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MAb) BC8 where the lysine side groups have been conjugated with decaborate (closo-decaborate; B10) and labeled with astatine (At) 211, with potential immunotherapeutic activity. Astatine At 211 anti-CD45 monoclonal antibody BC8-B10 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of alpha radiation. Additionally, the radiolabel can be leveraged to assay the biodistribution and/or pharmacokinetics (absorption, distribution, metabolism and excretion) for this agent. The use of B10 rather than other labeling methods increases the therapeutic efficacy while decreasing the toxicity of the radioconjugate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Astuprotimut-R</VALIDVALUE>
          <VALUEMEANING>Astuprotimut-R</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asulacrine</VALIDVALUE>
          <VALUEMEANING>Asulacrine</VALUEMEANING>
          <MEANINGDESCRIPTION>An amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asulacrine Isethionate</VALIDVALUE>
          <VALUEMEANING>Asulacrine Isethionate</VALUEMEANING>
          <MEANINGDESCRIPTION>The isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asparaginase Erwinia chrysanthemi</VALIDVALUE>
          <VALUEMEANING>Asparaginase Erwinia chrysanthemi</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora). Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting leukemic cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  This agent also induces apoptosis in tumor cells. The Erwinia-derived product is often used for those patients who have experienced a hypersensitivity reaction to the E. Coli formulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asunercept</VALIDVALUE>
          <VALUEMEANING>Asunercept</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, soluble fusion protein consisting of the extracellular domain of the CD95 receptor fused to the Fc-domain of the human IgG antibody, with potential antineoplastic activity. Upon administration, asunercept binds to the CD95 ligand (CD95L) and blocks the binding of CD95L to the CD95 receptor. In tumor cells, blockage of CD95L-mediated signaling pathways may prevent cell migration and invasive cell growth; in healthy cells, blockage of CD95L-mediated signaling pathways may prevent apoptosis and may protect cell damage. Activation of the CD95 receptor plays an important role in the initiation of apoptosis in healthy cells or the invasive growth of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>At 211 Monoclonal Antibody 81C6</VALIDVALUE>
          <VALUEMEANING>At 211 Monoclonal Antibody 81C6</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atamestane</VALIDVALUE>
          <VALUEMEANING>Atamestane</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic steroidal substance with antineoplastic activity.  Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atezolizumab</VALIDVALUE>
          <VALUEMEANING>Atezolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5242662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atiprimod Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Atiprimod Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The dihydrochloride salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and anti-angiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6, vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atiprimod Dimaleate</VALIDVALUE>
          <VALUEMEANING>Atiprimod Dimaleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimaleate salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATM Inhibitor M 3541</VALIDVALUE>
          <VALUEMEANING>ATM Inhibitor M 3541</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of ataxia telangiectasia mutated kinase (ATM), with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, M 3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATM Kinase Inhibitor AZD0156</VALIDVALUE>
          <VALUEMEANING>ATM Kinase Inhibitor AZD0156</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, AZD0156 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, AZD0156 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATM Kinase Inhibitor AZD1390</VALIDVALUE>
          <VALUEMEANING>ATM Kinase Inhibitor AZD1390</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atiprimod</VALIDVALUE>
          <VALUEMEANING>Atiprimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atorvastatin Calcium</VALIDVALUE>
          <VALUEMEANING>atorvastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic lipid-lowering agent.  Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles.  This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atorvastatin Sodium</VALIDVALUE>
          <VALUEMEANING>Atorvastatin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atrasentan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Atrasentan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity.  As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Attenuated Measles Virus Encoding SCD Transgene TMV-018</VALIDVALUE>
          <VALUEMEANING>Attenuated Measles Virus Encoding SCD Transgene TMV-018</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, attenuated oncolytic measles virus (MV) encoding the prodrug converting enzyme super cytosine deaminase (SCD), that can potentially be used as an antineoplastic adjuvant and with potential antineoplastic activity. Upon intra-tumoral injection, TMV-018 preferentially enters and transfects tumor cells, and expresses SCD, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-fluorocytosine; 5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU by SCD. In addition, the oncolytic MV may infect and lyse tumor cells. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. This may further eradicate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Audencel</VALIDVALUE>
          <VALUEMEANING>Audencel</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of audencel, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Auranofin</VALIDVALUE>
          <VALUEMEANING>Auranofin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora A Kinase Inhibitor LY3295668</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase Inhibitor LY3295668</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora A Kinase Inhibitor LY3295668 Erbumine</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase Inhibitor LY3295668 Erbumine</VALUEMEANING>
          <MEANINGDESCRIPTION>The tert-butylamine salt form of LY3295668, an orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora A Kinase Inhibitor MK5108</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase Inhibitor MK5108</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A, with potential antimitotic and antineoplastic activity. Aurora A kinase inhibitor MK5108 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and eventually inhibition of cell division, proliferation and an induction of apoptosis in cells overexpressing Aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aurora kinases are overexpressed in a wide variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Atuveciclib</VALIDVALUE>
          <VALUEMEANING>Atuveciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T (CycT), with potential antineoplastic activity. Upon administration, atuveciclib binds to and inhibits the activity of P-TEFb, thereby preventing the phosphorylation of its downstream target, the carboxyl terminal domain (CTD) of RNA polymerase II (RNA Pol II), and inhibiting the activation of transcriptional elongation by RNA Pol II. This prevents the transcription of tumor promoting genes, induces tumor cell apoptosis, and inhibits tumor cell proliferation. P-TEFb plays an important role in the regulation of gene transcription; over-activation in cancer cells leads to both the transcription of key tumor-promoting genes and cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic small molecule with potential antiangiogenic and antineoplastic activities. Aurora A kinase/tyrosine kinase inhibitor ENMD-2076 selectively binds to and inhibits non-specified tyrosine kinases and Aurora kinases (AKs). The inhibition of AKs may result in the inhibition of cell division and proliferation and may induce apoptosis in tumor cells that overexpress AKs; antiangiogenic activity is related to the inhibition of angiogenic tyrosine kinases. AKs are serine-threonine kinases that play an essential role in mitotic checkpoint control during mitosis and are important regulators of cell division and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora B Serine/Threonine Kinase Inhibitor TAK-901</VALIDVALUE>
          <VALUEMEANING>Aurora B Serine/Threonine Kinase Inhibitor TAK-901</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B kinase inhibitor TAK-901 binds to and inhibits the activity of Aurora B, which may result in a decrease in the proliferation of tumor cells that overexpress Aurora B. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere; the segregation of sister chromatids to each daughter cell; and the separation of daughter cells during cytokinesis. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora B/C Kinase Inhibitor GSK1070916A</VALIDVALUE>
          <VALUEMEANING>Aurora B/C Kinase Inhibitor GSK1070916A</VALUEMEANING>
          <MEANINGDESCRIPTION>An ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C. Aurora kinases play essential roles in mitotic checkpoint control during mitosis, and are overexpressed by a wide variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91081</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor AMG 900</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor AMG 900</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of Aurora kinases A, B and C with potential antineoplastic activity. Aurora kinase inhibitor AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis and are overexpressed by a wide variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor MLN8054</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor MLN8054</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Auora kinase inhibitor MLN8054 binds to and inhibits Aurora kinase A, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A localizes in mitosis to the spindle poles and to spindle microtubules and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor PF-03814735</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor PF-03814735</VALUEMEANING>
          <MEANINGDESCRIPTION>An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of aurora kinases may result in an inhibition of cellular division and proliferation in tumor cells that overexpress aurora kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor SNS-314</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor SNS-314</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor TTP607</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor TTP607</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule pan-Aurora kinase inhibitor with potential antineoplastic activity. Aurora kinase inhibitor TTP607 selectively binds to and inhibits Aurora kinases A, B and C, which may result in the disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cellular division and proliferation in Aurora kinase-overexpressing tumor cells. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84846</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase/VEGFR2 Inhibitor CYC116</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase/VEGFR2 Inhibitor CYC116</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule multi-kinase inhibitor with antineoplastic activity. Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis. Aurora kinases are serine/threonine protein kinases that are only expressed in actively dividing cells and are critical in division or mitosis. VEGFR2 is a receptor tyrosine kinase that appears to account for most of the mitogenic and chemotactic effects of vascular endothelial growth factor (VEGF) on adult endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora Kinase Inhibitor BI 811283</VALIDVALUE>
          <VALUEMEANING>Aurora Kinase Inhibitor BI 811283</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the serine/threonine protein kinase Aurora kinase with potential antineoplastic activity. Aurora kinase inhibitor BI 811283 binds to and inhibits Aurora kinases, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74014</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707</VALIDVALUE>
          <VALUEMEANING>Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified, using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric protein containing, at least, the extracellular Fc receptor domain of CD16, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory signaling domain of CD28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products do not target a specific TAA and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055</VALIDVALUE>
          <VALUEMEANING>Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of human autologous T-lymphocytes transduced with a lentiviral vector encoding for a T-cell receptor (TCR) recognizing the human leukocyte antigen (HLA)-A*02:01 restricted human alpha-fetoprotein (AFP) 158-166 peptide (FMNKFIYEI), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the AFP specific TCR transduced T cells recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers while its expression is restricted in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA CAR T-cells PHE885</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA CAR T-cells PHE885</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells PHE885 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA CAR-transduced T-cells KITE-585</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA CAR-transduced T-cells KITE-585</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain optimizes T-cell expansion and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation consisting of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac) containing an undisclosed selection gene and encoding both an unidentified human-derived safety switch and a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing Tscm P-BCMA-101 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than agents based on antibody-derived single chain variable fragments (scFv), and this agent may exhibit increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can induce the rapid attenuation or elimination of P-BCMA-101. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous memory T-lymphocytes transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-B-cell maturation antigen (BCMA) single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137) and a CD3-zeta T-cell activation domain, with potential immunostimulating and antineoplastic activities. Upon intravenous administration back into the patient, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing memory T-lymphocytes bb21217 are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival. BCMA is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the epitome cluster E3 in the extracellular domain (ECD) of the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of ex vivo expanded autologous CD8+ and CD4+ T-cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD123 CAR-T Cells</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD123 CAR-T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD123 CAR-T cells target and bind to CD123 expressed on the surface of tumor cells. This induces selective toxicity in CD123-expressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. It is overexpressed on a variety of cancers, including myeloid leukemia, and the increased expression of CD123 on leukemic stem cells (LSCs) is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA CD8+ CAR T-cells Descartes-11 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR T-cells 19(T2)28z1xx specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells. The 19(T2)28z1xx CAR T-cells include a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR T-cells IM19</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR T-cells IM19</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells IM19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized single chain variable fragment (scFv) of anti-CD19 coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta) and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon re-introduction into the patient, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 (cluster of differentiation 19) is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the co-stimulatory signaling domains increases human T-cell function, expansion, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 target, bind to, and induce selective toxicity in CD19-expressing B cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158604</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 TAC-T cells TAC01-CD19</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 TAC-T cells TAC01-CD19</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes genetically engineered with a T cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) cluster of differentiation 19 (CD 19) and another domain that binds to the endogenous T cell receptor (TCR), anchored in the membrane via the CD4 co-receptor domain, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 TAC-T cells TAC01-CD19 targets and binds to CD19-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T cell-mediated killing of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 T-cell Receptor T cells ET190L1</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 T-cell Receptor T cells ET190L1</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous human peripheral blood T-lymphocytes transduced with a lentivirus encoding a proprietary expression construct composed of a T-cell receptor (TCR)-like human antibody, which is synthesized by a proprietary phage display platform, targeting peptides derived from the tumor-associated antigen (TAA) CD19 that are presented in the context of major histocompatibility complex (MHC) molecules, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the autologous anti-CD19 TCR T-cells ET190L1 target and bind to tumor cells expressing CD19 peptide/MHC complexes. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. CD19, cluster of differentiation antigen 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. ET190L1 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells; however, ET190L1 is less likely to stimulate cytokine release syndrome (CRS) and does not cause CAR T-cell-triggered neurotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148030</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 CAR-CD28 T-cells ET019002</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19 CAR-CD28 T-cells ET019002</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD28 T-cells ET019002 target, bind to, and induce selective toxicity in CD19-expressing B-cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that is nanobody-based and specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19/CD20 bispecific nanobody-based CAR-T cells target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19/CD22 CAR T-cells AUTO3</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19/CD22 CAR T-cells AUTO3</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen receptor (CAR) fused to OX40 co-stimulatory domain and an anti-CD22 CAR linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), optimized with a novel pentameric spacer derived from the collagen oligomeric matrix protein (COMP), with potential antineoplastic activity. Upon administration, the autologous anti-CD19/CD22 CAR T-cells AUTO3 bind to and induce selective toxicity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014</VALUEMEANING>
          <MEANINGDESCRIPTION>A defined preparation of CD4+ and CD8+ central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous human T-lymphocytes engineered to express dual chimeric antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains, fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous, C-X-C chemokine receptor type 5 (CXCR 5)-modified T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes target and bind to EGFR-expressing tumor cells, thereby inducing selective toxicity in EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. CXCR5, and its ligand C-X-C motif chemokine 13 (CXCL13), are associated with a variety of tumors. CXCR5-CXCL13 interactions may be involved in the regulation of lymphocyte infiltration within the tumor microenvironment (TME).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-FLT3 CAR T Cells AMG 553</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-FLT3 CAR T Cells AMG 553</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes genetically engineered with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-FLT3 CAR T cells AMG 553 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) antibody synthesized by a proprietary phage display platform, targeting the immunogenetic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02/AFP), with potential antineoplastic and immunomodulatory activities. Upon administration, the autologous anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202 specifically recognize and selectively bind to AFP peptides presented by HLA-A*02. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of AFP-expressing tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for an immunogenic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) epitope, AFP158-166, complexed with human leukocyte antigen (HLA)-A*02:01 (HLA-A*0201/AFP), fused to the co-stimulatory domains of CD28 and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-HLA-A*0201/AFP CAR T-cells ET1402L1 specifically recognize and selectively bind to the AFP158-166 peptide presented by HLA-A*0201. Upon binding to the AFP-MHC complex, the T-cells release cytokines and induce selective toxicity in HLA-A*0201/AFP-positive tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) containing the Inserted (I) domain variant of lymphocyte function-associated antigen-1 (LFA-1) which targets intercellular adhesion molecule-1 (ICAM-1 or CD54), and the co-stimulatory signaling domains of CD28, 4-1BB (CD137) and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100 recognize and kill ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers. CAR T-cells AIC100 are also engineered to express somatostatin receptor subtype 2 (SSTR2), allowing the imaging of the CAR T-cells in patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes (ATL) that have been genetically modified to express a chimeric antigen receptor (CAR) directed against the kappa light chain of immunoglobulin (Ig) and linked to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-kappa light chain CAR-CD28-expressing T-lymphocytes target and bind to the kappa light chain of Ig expressed on tumor cells, resulting in T-cell-mediated tumor cell lysis. In some B-cell malignancies, the expression of the Ig light chain kappa may be increased compared to the expression of Ig light chain lambda.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous tumor infiltrating lymphocytes (TILs) activated by an anti-programmed cell death protein 1 (PD1) antibody, with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and ex-vivo activated in the presence of anti-PD-1 antibody. Upon infusion of the autologous anti-PD1 antibody-activated TILs back into the patient, the cells specifically target and kill the patient&#39;s tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172191</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-PSMA CAR-T Cells P-PSMA-101</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-PSMA CAR-T Cells P-PSMA-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac), encoding both a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA), and a human-derived safety switch that can be activated by rimiducid, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-PSMA CAR-T cells P-PSMA-101 specifically recognize and induce selective toxicity in PSMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than CAR T-cells based on antibody-derived single chain variable fragments (scFv), and may allow for increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can be activated by the administration of rimiducid, which results in the rapid attenuation or elimination of P-PSMA-101. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B</VALIDVALUE>
          <VALUEMEANING>Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B</VALUEMEANING>
          <MEANINGDESCRIPTION>An autologous vaccine composed of the antigen presenting cells (APCs) B-lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous BCMA-targeted CAR T Cells CC-98633</VALIDVALUE>
          <VALUEMEANING>Autologous BCMA-targeted CAR T Cells CC-98633</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T cells CC-98633 specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous BCMA-targeted CAR T Cells LCAR-B4822M</VALIDVALUE>
          <VALUEMEANING>Autologous BCMA-targeted CAR T Cells LCAR-B4822M</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T-cells LCAR-B4822M specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F</VALIDVALUE>
          <VALUEMEANING>Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific BCMA/CD19-targeted CAR-T cells GC012F specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The processing platform used, FasT CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022</VALIDVALUE>
          <VALUEMEANING>Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous human T-lymphocytes engineered to express chimeric T-cell receptors (chimeric antigen receptors or CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific CD19/CD22-targeted CAR-T cells GC022 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171093</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous AXL-targeted CAR T-cells CCT301-38</VALIDVALUE>
          <VALUEMEANING>Autologous AXL-targeted CAR T-cells CCT301-38</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001</VALIDVALUE>
          <VALUEMEANING>Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with potential antiapoptotic and proangiogenic activities. Upon intracoronary infusion after a myocardial infarction (MI), autologous bone marrow-derived CD34/CXCR4-positive stem cells may preserve cardiac muscle cells and prevent apoptosis; thus improving myocardial perfusion. CD34/CXCR4-positive stem cells are naturally mobilized upon cell injury through signaling by hypoxia inducing factor (HIF), which is secreted in response to hypoxia. In turn, HIF induces the synthesis of stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) which mobilize CD34/CXCR4 positive stem cells; CXCR4 is the receptor for stromal-derived factor 1 (SDF-1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005</VALIDVALUE>
          <VALUEMEANING>Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting an undisclosed tumor-associated antigen (TAA), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous PRGN-3005 into the patient, the T-cells target and bind to the TAA-expressing tumor cells, thereby inducing selective toxicity in the TAA-expressing tumor cells. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006</VALIDVALUE>
          <VALUEMEANING>Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system, including a chimeric antigen receptor (CAR) targeting an undisclosed tumor-associated antigen (TAA), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous PRGN-3006 T-cells into the patient, these T-cells target, bind to and induce selective toxicity in cells expressing this particular TAA. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells. Use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD123-4SCAR-expressing T-cells 4SCAR123</VALIDVALUE>
          <VALUEMEANING>Autologous CD123-4SCAR-expressing T-cells 4SCAR123</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD123 (interleukin-3 receptor alpha chain or IL3RA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD123-4SCAR-expressing T-cells 4SCAR123 are directed to and induce selective toxicity in CD123-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD19/PD-1 Bispecific CAR-T Cells</VALIDVALUE>
          <VALUEMEANING>Autologous CD19/PD-1 Bispecific CAR-T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) and a programmed cell death protein 1 (PD1)/CD28 chimera, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD19/PD-1 bispecific CAR-T cells target and bind to CD19 and the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), expressed on tumor cells. The binding to CD19 leads to a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and cell lysis of these cells. The binding of the PD1/CD28 chimera to PD-L1 prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This enhances T-lymphocyte proliferation and anti-tumor activity. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity. It plays a key role in immune evasion and prevents tumor cell lysis. The construct of the PD1/CD28 chimera converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28 is a costimulatory molecule expressed by T-cells that enhances T-lymphocyte proliferation and activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD19-targeted CAR T Cells CC-97540</VALIDVALUE>
          <VALUEMEANING>Autologous CD19-targeted CAR T Cells CC-97540</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD19-targeted CAR T cells CC-97540 specifically target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD19-targeted CAR-T Cells GC007F</VALIDVALUE>
          <VALUEMEANING>Autologous CD19-targeted CAR-T Cells GC007F</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to as of yet not fully elucidated co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous CD19-targeted CAR-T cells GC007F target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasT (F) CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD20-4SCAR-expressing T-cells 4SCAR20</VALIDVALUE>
          <VALUEMEANING>Autologous CD20-4SCAR-expressing T-cells 4SCAR20</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T-cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD22-4SCAR-expressing T-cells 4SCAR22</VALIDVALUE>
          <VALUEMEANING>Autologous CD22-4SCAR-expressing T-cells 4SCAR22</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD22 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD22-4SCAR-expressing T-cells 4SCAR22 are directed to and induce selective toxicity in CD22-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1</VALIDVALUE>
          <VALUEMEANING>Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD38-4SCAR-expressing T-cells 4SCAR38</VALIDVALUE>
          <VALUEMEANING>Autologous CD38-4SCAR-expressing T-cells 4SCAR38</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD38 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD38-4SCAR-expressing T-cells 4SCAR38 are directed to and induce selective toxicity in CD38-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Clonal Neoantigen T Cells ATL001</VALIDVALUE>
          <VALUEMEANING>Autologous Clonal Neoantigen T Cells ATL001</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of personalized tumor-derived T-lymphocytes composed of tumor infiltrating lymphocytes (TILs) that are reactive to clonal cancer neoantigens, with potential immunostimulating and antineoplastic activities. The TILs are removed from the suppressive tumor microenvironment (TME) and re-activated. Upon reintroduction into the patient, the clonal neoantigen T (cNeT) cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient&#39;s tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19</VALIDVALUE>
          <VALUEMEANING>Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA to disrupt expression of endogenous hematopoietic progenitor kinase 1 (HPK1), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the autologous CRISPR-edited anti-CD19 CAR T-cells XYF19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Disrupting the expression of HPK1 may enhance immune response and autoimmunity. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. HPK1 is a Ste20-like serine/threonine kinase that suppresses immune responses and autoimmunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Deep IL-15 Primed T-cells TRQ15-01</VALIDVALUE>
          <VALUEMEANING>Autologous Deep IL-15 Primed T-cells TRQ15-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified, multi-antigen-directed autologous T-lymphocytes, that have particles, consisting of multiple chemically crosslinked human cytokine interleukin-15 (IL-15)/IL-15 receptor alpha (IL-15Ra)/Fc heterodimers, attached to their surface, with potential immunostimulating and antineoplastic activities. TRQ15-01 is made from monocyte-derived dendritic cells (moDCs) that are pulsed with peptides from multiple tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-15 particles. Upon administration of the autologous deep IL-15 primed T-cells, the IL-15/IL-15Ra fusion proteins are slowly released in vivo from the T-cells in a controlled manner and induce autocrine cytokine stimulation of the administered T-cells, thereby increasing T-cell division of the administered T-cells. The expanded T-cells target, bind to and kill tumor cells. This increases tumor cell growth inhibition by T-cells. IL-15 is a pro-survival, inflammatory cytokine and causes sustained T-cell expansion and enhanced anti-tumor activity. Compared to systemically delivered IL-15, IL-15 attached to the T-cells greatly increases target CD8 T-cell concentrations in the tumor, without significant systemic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158091</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa</VALIDVALUE>
          <VALUEMEANING>Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-folate receptor alpha (FRa; folate receptor 1; FOLR1) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa are directed to and induce selective toxicity in FRa-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. FRa is overexpressed in various tumor cell types, and is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells</VALIDVALUE>
          <VALUEMEANING>Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous genetically-modified MAGE-A4 C1032 CD8alpha T-cells bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858</VALIDVALUE>
          <VALUEMEANING>Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.  HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439</VALIDVALUE>
          <VALUEMEANING>Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted human papillomavirus type 16 isoform E7 protein (HPV16 E7) with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous HPV16 E7-specific HLA-A*02:01-restricted T-lymphocytes KITE-439 target and bind HPV16 E7-expressing tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 E7 antigen. HPV16 E7, a cell surface glycoprotein and tumor-associated antigen (TAA), is overexpressed in various HPV-mediated cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001</VALIDVALUE>
          <VALUEMEANING>Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Dendritic Cell Vaccine ACT2001</VALIDVALUE>
          <VALUEMEANING>Autologous Dendritic Cell Vaccine ACT2001</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718</VALIDVALUE>
          <VALUEMEANING>Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718</VALUEMEANING>
          <MEANINGDESCRIPTION>Human autologous T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135534</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR</VALIDVALUE>
          <VALUEMEANING>Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous CD4+ and CD62L-expressing CD8+ T-cells transduced with a third generation lentiviral vector (LV) to express the high affinity T-cell receptor (TCR) A2 -MCC1, specific for the human leukocyte antigen (HLA)-A02-restricted Merkel cell polyomavirus (MCPyV; MCV) viral oncoprotein, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD8+ and CD4+ T-cells FH-MCVA2TCR selectively bind to the KLLEIAPNC epitope (KLL epitope) within the MCPyV viral oncoprotein. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the MCPyV viral oncoprotein. Additionally, tumor-specific HLA-A02-restricted CD4+ cells promote class I-restricted CD8+ proliferation, survival and effector functions by producing interleukin (IL)-2 and facilitating the activation of dendritic cells (DCs). MCPyV viral oncoprotein is highly expressed in Merkel cell carcinoma (MCC) caused by MCPyV.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Mesenchymal Stem Cells Apceth_101</VALIDVALUE>
          <VALUEMEANING>Autologous Mesenchymal Stem Cells Apceth_101</VALUEMEANING>
          <MEANINGDESCRIPTION>Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of a patient and genetically modified with a self-inactivating retroviral vector expressing the suicide gene herpes simplex virus thymidine kinase (HSV-TK), that can be used to activate synthetic acyclic guanosine analogues when co-administered. Upon intravenous administration of autologous mesenchymal stem cells apceth_101, the cells are actively recruited to the tumor stroma, differentiate into more mature mesenchymal cells, and become part of the tumor microenvironment. When a synthetic acyclic guanosine analogue, such as ganciclovir, is co-administered, the HSV-TK within the HSV-TK-transduced MSCs will monophosphorylate this prodrug. Subsequently the monophosphate form is further converted to the diphosphate form and then to its active triphosphate form by cellular kinases. The active form of ganciclovir kills the HSV-TK-transduced MSCs and leads to a bystander effect, which eliminates neighboring cancer cells. Therefore, synthetic acyclic guanosine analogues are activated only at the tumor site, which increases their local efficacy and reduces systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11</VALIDVALUE>
          <VALUEMEANING>Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Multi-lineage Potential Cells</VALIDVALUE>
          <VALUEMEANING>Autologous Multi-lineage Potential Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous multi-lineage potential cells (AMPC) which were induced to de-differentiate from somatic leukocytes from peripheral blood, with potential immunomodulating and antineoplastic activities. Upon introduction into the patient, the AMPC may help replace the abnormal cells in the body to create healthy bone marrow in the treatment of acute myeloid leukemia (AML).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Nectin-4/FAP-targeted CAR-T Cells</VALIDVALUE>
          <VALUEMEANING>Autologous Nectin-4/FAP-targeted CAR-T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) nectin-4 and cell surface protein fibroblast activation protein (FAP), and additionally an inducible expression cassette encoding transgenic interleukin (IL) 7 (IL-7) or 12 (IL-12), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the autologous nectin-4/FAP-targeted CAR-T cells target and bind to nectin-4-expressing tumor cells and FAP-expressing cancer associated fibroblasts (CAFs). This results in a cytotoxic T-lymphocyte (CTL) response against nectin-4-expressing tumor cells and FAP-expressing CAFs, leading to cell lysis of these cells. Upon the binding to nectin-4 and FAP and the activation of the CAR-T cells, cytokine IL-7 or IL-12 is also released. This further augments the immune responses against the tumor cells, which may include the attack of nectin-4-negative tumor cells by tumor necrosis factor alpha (TNFa). Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. FAP, a cell surface glycoprotein, is overexpressed on CAFs but minimally expressed on normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous NKG2D CAR T-cells CYAD-02</VALIDVALUE>
          <VALUEMEANING>Autologous NKG2D CAR T-cells CYAD-02</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a retroviral vector to co-express a chimeric antigen receptor (CAR) encoding human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) with a short hairpin RNA (shRNA) targeting MHC class I chain-related protein A (MICA) and MICB, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR T-cells CYAD-02 specifically recognize and bind to tumor cells expressing NKG2D ligands, resulting in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-02 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MICA, MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The shRNA downregulates the expression of MICA and MICB on the CAR-T cells, which increases in-vitro cell expansion. This may enhance their persistence and increase anti-tumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01</VALIDVALUE>
          <VALUEMEANING>Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine</VALIDVALUE>
          <VALUEMEANING>Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate and mRNA containing and encoding tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration by perinodal injection using ultrasound guidance, the autologous pancreatic adenocarcinoma lysate and mRNA-loaded DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient&#39;s tumor cell-specific TAAs, which may result in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC</VALIDVALUE>
          <VALUEMEANING>Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous, monocyte-derived dendritic cells (mDCs) pulsed with tumor cell lysate containing tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration,the autologous tumor cell lysate-pulsed mDCs vaccine PV-001-DC may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient&#39;s tumor cell-specific TAAs, which may result in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001</VALIDVALUE>
          <VALUEMEANING>Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous peripheral blood lymphocytes (PBLs) harvested from chronic lymphocytic leukemia (CLL) patients previously treated with the Brutons&#39; tyrosine kinase (BTK) inhibitor ibrutinib with potential immunostimulating and antineoplastic activities. Upon intravenous administration, IOV-2001 generates an enhanced cytotoxic T-cell response against autologous leukemic B-cells in patients who have relapsed during treatment with ibrutinib. IOV-2001 is mostly comprised of T-cells of which the majority are of the effector memory phenotype which augments the specificity of the immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101</VALIDVALUE>
          <VALUEMEANING>Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA.  This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601</VALIDVALUE>
          <VALUEMEANING>Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) consisting of an anti-human prostate stem cell antigen (PSCA) scFv (single chain variable fragment) coupled to the zeta chain of the T-cell receptor (TCRzeta) and a drug-induced co-stimulatory molecule, composed of an inducible, chimeric MyD88/CD40 (inducible MC; iMC) co-stimulatory domain, in which both the MyD88 and CD40 lack their extracellular domains, with potential antineoplastic activity. Upon administration of BPX-601, the T-cells target and bind to PSCA-expressing cancer cells. Upon subsequent administration of the chemical inducer of dimerization (CID) agent rimiducid, this agent targets and binds to the drug binding domain, which leads to iMC expression, activation of both CD40- and MyD88-mediated signal transduction pathways, and an induction of selective cytotoxicity in, and eradication of PSCA-expressing cancer cells. iMC activation by rimiducid increases T-cell survival and anti-tumor activity of the administered T-cells, compared to T-cells without the drug iMC activation-switch. As these T-cells are engineered to only be fully activated by binding to both antigen and rimiducid, T-cell proliferation, activity and toxicity can be controlled by adjusting the dose of rimiducid, thereby preventing uncontrolled T-cell activation which increases the safety of the administered T-cells. PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell surface antigen overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201</VALIDVALUE>
          <VALUEMEANING>Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous rapamycin-resistant Th1/Tc1 cells, with potential immunomodulating activity. Upon administration, autologous rapamycin-resistant Th1/Tc1 cells RAPA-201 may recognize and kill tumor cells. Ex-vivo induction of rapamycin-resistance may increase the persistence of T-cells after adoptive transfer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous ROR2-targeted CAR T-cells CCT301-59</VALIDVALUE>
          <VALUEMEANING>Autologous ROR2-targeted CAR T-cells CCT301-59</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1</VALIDVALUE>
          <VALUEMEANING>Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous TCR-engineered T-cells IMA201</VALIDVALUE>
          <VALUEMEANING>Autologous TCR-engineered T-cells IMA201</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous TCR-engineered T-cells IMA202</VALIDVALUE>
          <VALUEMEANING>Autologous TCR-engineered T-cells IMA202</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) targeting patient-specific tumor associated antigens (TAAs), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA202 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous TCRm-expressing T-cells ET140203</VALIDVALUE>
          <VALUEMEANING>Autologous TCRm-expressing T-cells ET140203</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) construct targeting as of yet undisclosed tumor associated antigen(s) (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration, the autologous TCRm-expressing T-cells ET140203 specifically recognize and selectively bind to the as of yet undisclosed TAA(s). This results in cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing the TAA(s).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Tumor Infiltrating Lymphocytes LN-145</VALIDVALUE>
          <VALUEMEANING>Autologous Tumor Infiltrating Lymphocytes LN-145</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient&#39;s tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Tumor Infiltrating Lymphocytes LN-145-S1</VALIDVALUE>
          <VALUEMEANING>Autologous Tumor Infiltrating Lymphocytes LN-145-S1</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient&#39;s tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Tumor Infiltrating Lymphocytes MDA-TIL</VALIDVALUE>
          <VALUEMEANING>Autologous Tumor Infiltrating Lymphocytes MDA-TIL</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous tumor infiltrating lymphocytes (TILs) with potential antineoplastic activity. TILs are isolated from a patient&#39;s tumor tissue, then cultured and expanded in vitro in the presence of interleukin-2 (IL-2) and an agonistic anti-4-1BB (CD137) antibody. Upon infusion of the autologous expanded TILs back into the patient, the cells specifically recognize, target, and kill the patient&#39;s tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T</VALIDVALUE>
          <VALUEMEANING>Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that has been genetically engineered to express a fully humanized, universal, second generation chimeric antigen receptor (CAR) with a CD28/CD3zeta co-stimulatory domain, and a binding domain that can recognize a peptide motive of an antigen-specific targeting module (TM), with potential immunomodulating and antineoplastic activities. Upon administration, autologous universal CAR-expressing T-lymphocytes UniCAR02-T remain inactivated. Upon administration of an antigen-specific TM, the binding domain of UniCAR02-T binds to the nuclear antigen motif of the TM, and UniCAR02-T is activated when the antigen-binding moiety of the TM binds to the specific antigen expressed on tumor cells. This induces selective toxicity in and causes lysis of tumor cells expressing the specific antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avadomide</VALIDVALUE>
          <VALUEMEANING>Avadomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel, small molecule cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160786</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG</VALIDVALUE>
          <VALUEMEANING>Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avadomide Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Avadomide Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of avadomide, a novel, small molecule, cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avapritinib</VALIDVALUE>
          <VALUEMEANING>Avapritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7685535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avdoralimab</VALIDVALUE>
          <VALUEMEANING>Avdoralimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the C5a receptor (C5aR), with potential immunomodulating activity.  Upon administration, avdoralimab specifically targets, binds to and blocks C5aR expressed on subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. This prevents the binding of its ligand C5a to C5aR and prevents the C5aR-mediated activation and accumulation of these cells in the tumor microenvironment (TME), and abrogates the secretion of inflammatory and angiogenic factors by these cells. This results in the activation of T- and natural killer (NK) cells, the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avelumab</VALIDVALUE>
          <VALUEMEANING>Avelumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5799363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Avitinib Maleate</VALIDVALUE>
          <VALUEMEANING>Avitinib Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt form of avitinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axalimogene Filolisbac</VALIDVALUE>
          <VALUEMEANING>Axalimogene Filolisbac</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axatilimab</VALIDVALUE>
          <VALUEMEANING>Axatilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R), with potential antineoplastic activity. Upon intravenous administration, axatilimab binds to the ligand binding domain of CSF-1R, preventing binding and consequent activation by its natural ligands, IL-34 and colony-stimulating factor 1 (CSF-1). Inhibition of CSF-1R activation may disrupt the activity of tumor-associated macrophages (TAMs), which promote initiation and metastasis of tumor cells, inhibit T-cell responses, and stimulate tumor angiogenesis and disease progression. CSF-1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and cluster of differentiation 115 (CD115), is a tyrosine-protein kinase that plays an essential role in the regulation, proliferation, survival and differentiation of tissue macrophages as well as TAMs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axicabtagene Ciloleucel</VALIDVALUE>
          <VALUEMEANING>Axicabtagene Ciloleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6028573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axitinib</VALIDVALUE>
          <VALUEMEANING>Axitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aviscumine</VALIDVALUE>
          <VALUEMEANING>Aviscumine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein that inactivates the ribosome with potential antineoplastic and immunomodulating activities. Aviscumine binds to the cell surface sialyltransferase CD75 and is internalized; intracellularly, aviscumine cleaves an adenine-specific N-glycosidic bond on the 28S ribosomal subunit, which may result in tumor cell apoptosis. This agent has also been shown to activate natural killer (NK) cells, induce cytokine receptor expression, and stimulate the release of cytokines. CD75 is expressed on mature B-cells and subsets of T-cells and erythrocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AXL Inhibitor DS-1205c</VALIDVALUE>
          <VALUEMEANING>AXL Inhibitor DS-1205c</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, DS-1205c targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways and inhibits tumor cell proliferation and migration. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types. It plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AXL Inhibitor SLC-391</VALIDVALUE>
          <VALUEMEANING>AXL Inhibitor SLC-391</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential immunostimulating and antineoplastic activities. Upon oral administration, SLC-391 targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways, and inhibits both AXL-mediated tumor cell growth, proliferation and migration and AXL-mediated immunosuppression. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M</VALIDVALUE>
          <VALUEMEANING>AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axl/Mer Inhibitor INCB081776</VALIDVALUE>
          <VALUEMEANING>Axl/Mer Inhibitor INCB081776</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, INCB081776 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axl/Mer Inhibitor PF-07265807</VALIDVALUE>
          <VALUEMEANING>Axl/Mer Inhibitor PF-07265807</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, Axl/Mer inhibitor PF-07265807 specifically targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azacitidine</VALIDVALUE>
          <VALUEMEANING>Azacitidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3013054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azapicyl</VALIDVALUE>
          <VALUEMEANING>Azapicyl</VALUEMEANING>
          <MEANINGDESCRIPTION>A hydrazine compound that has been investigated for antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azaribine</VALIDVALUE>
          <VALUEMEANING>Azaribine</VALUEMEANING>
          <MEANINGDESCRIPTION>The triacetate salt of azauridine, a synthetic triazine nucleoside derivative possessing antineoplastic and anti-psoriatic activity. After metabolism to 6-azauridine-5-prime monophosphate, 6-Azauridine inhibits de novo pyrimidine biosynthesis and its 5-prime triphosphate metabolite gets incorporated into RNA, thereby preventing RNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1008</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azaserine</VALIDVALUE>
          <VALUEMEANING>Azaserine</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring serine derivative diazo compound with antineoplastic properties, Azaserine functions as a purine antagonist and glutamine analogue (glutamine amidotransferase inhibitor) that competitively inhibits pathways in which glutamine is metabolized. An antibiotic and antitumor agent, Azaserine is used in clinical studies as a potential antineoplastic agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AXL/ FLT3/VEGFR2 Inhibitor KC1036</VALIDVALUE>
          <VALUEMEANING>AXL/ FLT3/VEGFR2 Inhibitor KC1036</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of three receptor tyrosine kinases: AXL (UFO), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2), and the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, KC1036 targets, binds to and prevents the activation of AXL, FLT3 and VEGFR2. This blocks AXL, FLT3 and VEGFR2-mediated signal transduction pathways, and inhibits both AXL-, FLT3- and VEGFR2-mediated proliferation of tumor cells and the VEGFR2-mediated proliferation, survival and migration of endothelial cells. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias. VEGFR2 is frequently overexpressed by a variety of tumor types and tumor-associated endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azimexon</VALIDVALUE>
          <VALUEMEANING>Azimexon</VALUEMEANING>
          <MEANINGDESCRIPTION>Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azintuxizumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Azintuxizumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody targeting CS1 (SLAMF7/CD319) that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a cathepsin-cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of azintuxizumab vedotin binds to CS1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CS1-expressing tumor cells.  CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is expressed with high levels and prevalence on multiple myeloma (MM) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aziridinylbenzoquinone RH1</VALIDVALUE>
          <VALUEMEANING>Aziridinylbenzoquinone RH1</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5&#39;-GNC-3&#39; sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azurin:50-77 Cell Penetrating Peptide p28</VALIDVALUE>
          <VALUEMEANING>Azurin:50-77 Cell Penetrating Peptide p28</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, amphipathic, 28 amino acid (amino acids 50-77), 2.9 kD fragment peptide (p28) derived from the protein azurin with potential antineoplastic and antiangiogenic activities. Although the mechanism has yet to be fully elucidated, the preferential cellular uptake of azurin-derived cell-penetrating peptide p28 by tumor cells and endothelial cells is likely via caveolae-mediated endocytosis; the C-terminal 18 amino acid residues (50-67) appear to be responsible for this preferential uptake. After cell entry, the first 12 amino acid residues interact with tumor suppressor p53 and form a p28:p53 complex, which may result in a reduction of proteasomal degradation of p53, increased p53 levels, and p53-mediated cell cycle inhibition and apoptosis. Azurin is a cupredoxin secreted by the bacterium Pseudomonas aeruginosa. Cell penetrating peptides (CPPs) are cationic and/or amphipathic peptides, typically less than 30 amino acids in length, that can penetrate cell membranes easily and may transport molecular cargo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Babaodan Capsule</VALIDVALUE>
          <VALUEMEANING>Babaodan Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available mixed powder of traditional Chinese medicine containing eight constituents including natural calculus bovis, snake gall, antelope horn, pearl, musk, radix notoginseng, and other as of yet not disclosed ingredients, with potential antifibrotic, immunomodulatory, and antineoplastic activities. Upon oral administration, babaodan may ameliorate substance-induced liver injury and fibrosis, and inhibit lipopolysaccharide (LPS)-induced hepatic stellate cell (HSC) activation and proliferation through toll-like receptor 4 (TLR4)/nuclear factor-kappa B and TLR4/extracellular-signal-regulated kinase (ERK) pathways. Babaodan may, through an as of yet not elucidated mechanism, enhance the efficacy of chemotherapeutic drugs and may inhibit the occurrence and development of certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bactobolin</VALIDVALUE>
          <VALUEMEANING>Bactobolin</VALUEMEANING>
          <MEANINGDESCRIPTION>A 3-dichloromethylactinobolin antineoplastic antibiotic isolated from various Pseudomonas bacterial species.  BN-183 induces apoptosis via a caspase-dependent pathway.  This agent also has immunomodulatory properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bafetinib</VALIDVALUE>
          <VALUEMEANING>Bafetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active 2-phenylaminopyrimidine derivative with potential antineoplastic activity. INNO-406 specifically binds to and inhibits the Bcr/Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). Furthermore, this agent also inhibits the Src-family member Lyn tyrosine kinase, upregulated in imatinib-resistant CML cells and in a variety of solid cancer cell types. The inhibitory effect of INNO-406 on these specific tyrosine kinases decreases cellular proliferation and induces apoptosis. A high percentage of CML patients are refractory to imatinib, which sometimes results from point mutations occurring in the kinase domain of the Bcr/Abl fusion product. Due to its dual inhibitory activity, INNO-406 has been shown to overcome this particular drug resistance and to be a potent and effective agent in the treatment of imatinib-resistant CML.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Balixafortide</VALIDVALUE>
          <VALUEMEANING>CXCR4 Inhibitor POL6326</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor POL6326 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91094</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Balstilimab</VALIDVALUE>
          <VALUEMEANING>Balstilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azotomycin</VALIDVALUE>
          <VALUEMEANING>Azotomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic-antibiotic diazo analog of L-glutamine isolated from the bacterium Streptomyces ambofaciens.  Azotomycin inhibits glutamine-dependent enzymes involved in purine and pyrimidine biosynthesis, resulting in inhibition of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Baltaleucel-T</VALIDVALUE>
          <VALUEMEANING>Baltaleucel-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Banoxantrone</VALIDVALUE>
          <VALUEMEANING>Banoxantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Barasertib</VALIDVALUE>
          <VALUEMEANING>Barasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. Upon administration and rapid conversion from the prodrug form in plasma, AZD1152-HQPA specifically binds to and inhibits Aurora kinase B, which results in the disruption of spindle checkpoint functions and chromosome alignment and, so, the disruption of chromosome segregation and cytokinesis. Consequently, cell division and cell proliferation are inhibited and apoptosis is induced in Aurora kinase B-overexpressing tumor cells. Aurora kinase B, a serine/threonine protein kinase that functions in the attachment of the mitotic spindle to the centromere, is overexpressed in a wide variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bardoxolone</VALIDVALUE>
          <VALUEMEANING>Bardoxolone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Baricitinib</VALIDVALUE>
          <VALUEMEANING>Baricitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Batabulin</VALIDVALUE>
          <VALUEMEANING>Batabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to beta tubulin, resulting in a disruption of microtubule polymerization, collapse of the cytoskeleton, cell cycle arrest, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Batabulin Sodium</VALIDVALUE>
          <VALUEMEANING>Batabulin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Batimastat</VALIDVALUE>
          <VALUEMEANING>Batimastat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic hydroxamate with potential antineoplastic activity.  Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bavituximab</VALIDVALUE>
          <VALUEMEANING>Bavituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49088</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bardoxolone Methyl</VALIDVALUE>
          <VALUEMEANING>Bardoxolone Methyl</VALUEMEANING>
          <MEANINGDESCRIPTION>The methyl ester form of bardoxolone, a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bazedoxifene</VALIDVALUE>
          <VALUEMEANING>Bazedoxifene</VALUEMEANING>
          <MEANINGDESCRIPTION>An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. Bazedoxifene functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bazlitoran</VALIDVALUE>
          <VALUEMEANING>Bazlitoran</VALUEMEANING>
          <MEANINGDESCRIPTION>An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Bazlitoran binds to and inhibits the translation of mutated MYD88 L265P mRNA. This prevents overactivation of signaling pathways mediated by toll-like receptors (TLRs) 7, 8, and 9, nuclear factor-kappa B (NF-kB) activity, Janus-associated kinases-signal transducer and activator of transcription (JAK-STAT) signaling and the production of various cytokines. Together, this leads to an induction of apoptosis and an inhibition of tumor cell proliferation in MYD88 L265P-expressing tumor cells. MYD88, a key adaptor protein in the TLR signaling pathway, is mutated in a variety of B-cell lymphomas, including Waldenstrom&#39;s macroglobulinemia (WM) and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BC-819 Plasmid/Polyethylenimine Complex</VALIDVALUE>
          <VALUEMEANING>BC-819 Plasmid/Polyethylenimine Complex</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA encoding for the A fragment of Diphtheria Toxin (DTA) under the control of the H19 gene promoter (BC-819 or DTA-H19) and mixed with the transfectant polyethylenimine (PEI), with potential antineoplastic activity. Upon administration, the PEI moiety enhances the entry of the agent into rapidly dividing cells. Upon cell entry, activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. H19, an oncofetal, regulatory RNA, is overexpressed in certain cancer cells while its expression in normal cells is minimal or absent; it plays a key role in cancer progression, angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCG Solution</VALIDVALUE>
          <VALUEMEANING>BCG Solution</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3436270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCG Vaccine</VALIDVALUE>
          <VALUEMEANING>BCG Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5654664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-2 Inhibitor BCL201</VALIDVALUE>
          <VALUEMEANING>Bcl-2 Inhibitor BCL201</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-2 Inhibitor BGB-11417</VALIDVALUE>
          <VALUEMEANING>Bcl-2 Inhibitor BGB-11417</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor BGB-11417 specifically binds to and inhibits the activity of the pro-survival protein Bcl-2. This restores apoptotic processes and inhibits cell proliferation in Bcl-2-overexpressing tumor cells. Bcl-2, a protein that belongs to the Bcl-2 family, is overexpressed in various tumor cell types and plays an important role in the negative regulation of apoptosis. Its tumor expression is associated with increased drug resistance and cancer cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-2 Inhibitor LP-108</VALIDVALUE>
          <VALUEMEANING>Bcl-2 Inhibitor LP-108</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor LP-108 targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-Xs Adenovirus Vaccine</VALIDVALUE>
          <VALUEMEANING>Bcl-Xs Adenovirus Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity.  Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected.  Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCG Tokyo-172 Strain Solution</VALIDVALUE>
          <VALUEMEANING>BCG Tokyo-172 Strain Solution</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution containing an attenuated, live culture preparation of the bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with potential immunostimulating and antineoplastic activities. Although the precise mechanism of action is unknown, upon intravesical instillation through a catheter, the attenuated, live BCG bacteria in the BCG Tokyo-172 strain solution come into direct contact with the bladder wall and elicits a local, multifaceted immune response against the BCG antigens, which kills the bladder cancer cells. Previous vaccination with a systemic BCG vaccine may enhance the immune system&#39;s response against the BCG antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13606227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCMA x CD3 T-cell Engaging Antibody CC-93269</VALIDVALUE>
          <VALUEMEANING>BCMA x CD3 T-cell Engaging Antibody CC-93269</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-BCMA/CD3 T-cell engaging antibody CC-93269, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156052</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCMA/CD3e Tri-specific T-cell Activating Construct HPN217</VALIDVALUE>
          <VALUEMEANING>BCMA/CD3e Tri-specific T-cell Activating Construct HPN217</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes, and albumin, with potential immunostimulating and antineoplastic activities. Upon administration, BCMA/CD3e TriTAC HPN217 targets and binds to BCMA on tumor cells and CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN217. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is overexpressed on malignant plasma cells and plays a key role in plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCMA-CD19 Compound CAR T Cells</VALIDVALUE>
          <VALUEMEANING>BCMA-CD19 Compound CAR T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the BCMA-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beauvericin</VALIDVALUE>
          <VALUEMEANING>Beauvericin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclic hexadepsipeptide antibiotic and mycotoxin isolated from the fungus Beauveria bassiana and various Fusarium fungal species.  As a potassium-specific ionophore, beauvericin A increases intracellular calcium concentrations and triggers DNA fragmentation and apoptosis through a calcium dependent caspase 3-sensitive pathway.  This agent has been studied as a potential antineoplastic agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1011</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Becatecarin</VALIDVALUE>
          <VALUEMEANING>Becatecarin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin.  Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belagenpumatucel-L</VALIDVALUE>
          <VALUEMEANING>Belagenpumatucel-L (Lucanix)</VALUEMEANING>
          <MEANINGDESCRIPTION>A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3140555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belantamab Mafodotin</VALIDVALUE>
          <VALUEMEANING>Belantamab Mafodotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114299</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7554856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belapectin</VALIDVALUE>
          <VALUEMEANING>Belapectin</VALUEMEANING>
          <MEANINGDESCRIPTION>A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Belapectin binds to the carbohydrate-binding domain of galectins, especially galectin-3, and may result in an induction of apoptosis mediated through activation of both mitochondria and caspases. This may reduce tumor growth in galectin-overexpressing tumor cells. Galectins, often overexpressed on tumor cells, play a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115111</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belimumab</VALIDVALUE>
          <VALUEMEANING>Belimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belinostat</VALIDVALUE>
          <VALUEMEANING>Belinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belotecan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Belotecan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the semi-synthetic camptothecin analogue belotecan with potential antitumor activity. Belotecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belvarafenib</VALIDVALUE>
          <VALUEMEANING>Belvarafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Belzutifan</VALIDVALUE>
          <VALUEMEANING>Belzutifan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bemcentinib</VALIDVALUE>
          <VALUEMEANING>Bemcentinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration, bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bempegaldesleukin</VALIDVALUE>
          <VALUEMEANING>Bempegaldesleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the endogenous cytokine interleukin-2 (IL-2) conjugated to six releasable polyethylene glycol (PEG) chains, with potential immunostimulating activity. Upon administration of bempegaldesleukin, the IL-2 moiety binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells primarily causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells. PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (IL2Ra) because signaling through IL2Ra activates CD4-positive regulatory, immunosuppressive T-cells (Tregs), which would suppress tumor cell killing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131019</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Benaxibine</VALIDVALUE>
          <VALUEMEANING>Benaxibine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclophosphamide synergizer with antineoplastic, antidiabetic, antihypertensive and immunopotentiating activity. Benaxibine is active against integrin alph-4 precursor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bendamustine</VALIDVALUE>
          <VALUEMEANING>Bendamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4862971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bemarituzumab</VALIDVALUE>
          <VALUEMEANING>Bemarituzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bendamustine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Bendamustine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bendamustine-containing Nanoparticle-based Formulation RXDX-107</VALIDVALUE>
          <VALUEMEANING>Bendamustine-containing Nanoparticle-based Formulation RXDX-107</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124053</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Benzaldehyde Dimethane Sulfonate</VALIDVALUE>
          <VALUEMEANING>Benzaldehyde Dimethane Sulfonate</VALUEMEANING>
          <MEANINGDESCRIPTION>A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Berberine Chloride</VALIDVALUE>
          <VALUEMEANING>Berberine Chloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable, hydrochloride salt form of berberine, a quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation.  In addition, berberine modulates lipid and glucose metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bermekimab</VALIDVALUE>
          <VALUEMEANING>Bermekimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B-lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bersanlimab</VALIDVALUE>
          <VALUEMEANING>Bersanlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Benzoylphenylurea</VALIDVALUE>
          <VALUEMEANING>Benzoylphenylurea</VALUEMEANING>
          <MEANINGDESCRIPTION>A low molecular weight agent with antineoplastic activity. Benzoylphenylurea binds to the colchicine binding site on tubulin, thereby blocking tubulin polymerization and disrupting mitotic function.  This agent also inhibits DNA polymerase, and has been shown to arrest leukemia cells in the G1-S transition phase of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Berubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Berubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. Unlike other anthracycline derivatives, this agent crosses the blood-brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Berzosertib</VALIDVALUE>
          <VALUEMEANING>ATR Kinase Inhibitor VX-970</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5260852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Bromodomain Inhibitor ZEN-3694</VALIDVALUE>
          <VALUEMEANING>BET Bromodomain Inhibitor ZEN-3694</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ZEN-3694 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor ABBV-744</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor ABBV-744</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor BMS-986158</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor BMS-986158</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BMS-986158 binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor FT-1101</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor FT-1101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor GSK2820151</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor GSK2820151</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor GSK2820151 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor INCB054329</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor INCB054329</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the Bromodomain and Extra-Terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor BAY1238097</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor BAY1238097</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor INCB057643</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor INCB057643</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the Bromodomain (BRD) and Extra-Terminal (BET) family of BRD-containing proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. BET proteins are transcriptional regulators that are overexpressed in certain tumor cells and play an important role in cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor RO6870810</VALIDVALUE>
          <VALUEMEANING>BET Inhibitor RO6870810</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor RO6870810 binds to the acetylated lysine recognition motifs found in the bromodomain of BET proteins, which prevents the interaction between BET proteins and acetylated histones. This interaction disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta Alethine</VALIDVALUE>
          <VALUEMEANING>Beta Alethine</VALUEMEANING>
          <MEANINGDESCRIPTION>A disulfide agent that stimulates T and B-cell functions and exhibits anti-tumor and immunostimulant activity. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-elemene</VALIDVALUE>
          <VALUEMEANING>Beta-elemene</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the isomers of elemene, a lipid soluble sesquiterpene and the active component isolated from the Chinese medicinal herb Rhizoma zedoariae with potential antineoplastic and chemopreventive activities. Although the exact mechanism of action through which beta-elemene exerts its effect has yet to be fully elucidated, this agent appears to induce apoptosis through different mechanisms of action and induces cell cycle arrest at different stages based on the tumor cell type involved. Beta-elemene may sensitize cancer cells to other chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-Glucan</VALIDVALUE>
          <VALUEMEANING>Beta-Glucan</VALUEMEANING>
          <MEANINGDESCRIPTION>A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3431170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-Glucan MM-10-001</VALIDVALUE>
          <VALUEMEANING>Beta-Glucan MM-10-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A powder formulation containing a triple helix beta-glucan, isolated from the cell walls of the shiitake mushroom (Lentinula edodes), with potential immunostimulating activity. The beta-glucan in beta-glucan MM-10-001 binds to a lectin site within the complement receptor 3 (CR3 or iC3b receptor) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to iC3b-opsonized tumor cells. iC3b is the proteolyticly inactive product of the complement cleavage fragment C3b.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Betaglucin Gel</VALIDVALUE>
          <VALUEMEANING>Betaglucin Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble gel containing the beta-glucan betaglucin, with potential immunostimulating activity. Upon topical administration of the betaglucin gel, betaglucin is able to increase the number of macrophages and natural killer (NK) cells. NK cells and macrophages may kill a variety of tumor cells, and virally infected cells. This may treat human papillomavirus (HPV)-related anogenital warts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-lapachone Prodrug ARQ 761</VALIDVALUE>
          <VALUEMEANING>Beta-lapachone Prodrug ARQ 761</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, soluble prodrug of beta-lapachone, a poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. ARQ 761 is converted to beta-lapachone (b-lap) in vivo. When b-lap is activated by NAD(P)H:quinone oxidoreductase-1 (NQO1) this agent creates a futile oxidoreduction, generating highly reactive oxygen species (ROS) that results in DNA damage. The activation of b-lap also causes hyperactivation of poly (ADP-ribose) polymerase-1 (PARP-1), an enzyme that facilitates DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and endoplasmic reticulum (ER) stress-induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. In addition, b-lap induces expression of the checkpoints activator E2F transcription factor 1 (E2F1) and thereby activates the E2F1-mediated checkpoint pathway that directly triggers apoptosis. As ARQ 761 is soluble and requires less solvent, this formulation may cause less hemolytic anemia associated with administration of the synthetic b-lap ARQ 501.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99146</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-Thioguanine Deoxyriboside</VALIDVALUE>
          <VALUEMEANING>Beta-Thioguanine Deoxyriboside</VALUEMEANING>
          <MEANINGDESCRIPTION>A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Beta-Carotene</VALIDVALUE>
          <VALUEMEANING>Beta Carotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A vitamin A precursor. Beta carotene belongs to the family of fat-soluble vitamins called carotenoids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1016</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET-bromodomain Inhibitor ODM-207</VALIDVALUE>
          <VALUEMEANING>BET-bromodomain Inhibitor ODM-207</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ODM-207 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression of oncogenic drivers that are important for cell proliferation and survival. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that bind to acetylated lysine residues in histones and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Betulinic Acid</VALIDVALUE>
          <VALUEMEANING>Betulinic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38126</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bevacizumab</VALIDVALUE>
          <VALUEMEANING>Bevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4916311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bexarotene</VALIDVALUE>
          <VALUEMEANING>Bexarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BF-200 Gel Formulation</VALIDVALUE>
          <VALUEMEANING>BF-200 Gel Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BH3 Mimetic ABT-737</VALIDVALUE>
          <VALUEMEANING>BH3 Mimetic ABT-737</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bicalutamide</VALIDVALUE>
          <VALUEMEANING>Bicalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bimiralisib</VALIDVALUE>
          <VALUEMEANING>Bimiralisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Bimiralisib inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. As mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase. By inhibiting mTOR to a lesser extent than PI3K, PQR309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Binetrakin</VALIDVALUE>
          <VALUEMEANING>Binetrakin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant agent chemically identical to or similar to the endogenous cytokine interleukin-4 (IL-4). Produced primarily by activated T-cells, IL-4 binds to and activates its cell-surface receptor, stimulating the proliferation and differentiation of activated B-cells and enhancing their ability to present antigens to T-cells. As a potential immunotherapeutic agent, binetrakin also augments the effects of other cytokines on dendritic cells (DC), cytotoxic T lymphocytes (CTL), and tumor-infiltrating lymphocytes (TIL).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bexmarilimab</VALIDVALUE>
          <VALUEMEANING>Bexmarilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Binimetinib</VALIDVALUE>
          <VALUEMEANING>Binimetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bintrafusp Alfa</VALIDVALUE>
          <VALUEMEANING>Bintrafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional fusion protein composed of avelumab, an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the TGFbetaRII moiety of bintrafusp alfa binds to and neutralizes TGFbeta while the avelumab moiety simultaneously binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7405919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Birabresib</VALIDVALUE>
          <VALUEMEANING>Birabresib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. Upon administration, birabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, including c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, the BET proteins BRD2, BRD3, BRD4 are transcriptional regulators that play an important role in cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Birinapant</VALIDVALUE>
          <VALUEMEANING>Birinapant</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule that is both a peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. As a SMAC mimetic and IAP antagonist, birinapant selectively binds to and inhibits the activity of IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 (cIAP1) and 2 (cIAP2), with a greater effect on cIAP1 than cIAP2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells and inactivate the nuclear factor-kappa B (NF-kB)-mediated survival pathway. IAPs are overexpressed by many cancer cell types. They are able to suppress apoptosis by binding to, via their baculoviral lAP repeat (BIR) domains, and inhibiting active caspases-3, -7 and -9. IAP overexpression promotes both cancer cell survival and chemotherapy resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisantrene Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Bisantrene Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the helical structure of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614582</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisnafide</VALIDVALUE>
          <VALUEMEANING>Bisnafide</VALUEMEANING>
          <MEANINGDESCRIPTION>A bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73611</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisnafide Dimesylate</VALIDVALUE>
          <VALUEMEANING>Bisnafide Dimesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimesylate salt form of bisnafide, a bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody 2B1</VALIDVALUE>
          <VALUEMEANING>Bispecific Antibody 2B1</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody with potential antineoplastic activity.  Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific antibody 2B1 may enhance cellular immune responses against c-erbB-2-positive cells, resulting in increased tumor cell lysis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody AGEN1223</VALIDVALUE>
          <VALUEMEANING>Bispecific Antibody AGEN1223</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T-cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T-cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T-cells, resulting in tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisantrene</VALIDVALUE>
          <VALUEMEANING>Bisantrene</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication.  This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1019</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody AMG 509</VALIDVALUE>
          <VALUEMEANING>Bispecific Antibody AMG 509</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, AMG 509 targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody MDX447</VALIDVALUE>
          <VALUEMEANING>Bispecific Antibody MDX447</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody with potential antineoplastic activity. Specific for both the high-affinity immunoglobulin G (IgG) receptor CD64 and epidermal growth factor receptor (EGFR), bispecific antibody MDX447 may enhance cellular immune responses against EGFR positive cells, resulting in increased tumor cell lysis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody MDX-H210</VALIDVALUE>
          <VALUEMEANING>Bispecific Antibody MDX-H210</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab&#39; fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab&#39; fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bisthianostat</VALIDVALUE>
          <VALUEMEANING>Bisthianostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan-inhibitor of human histone deacetylase (HDAC), with potential antineoplastic activity. Upon administration, bisthianostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes. This prevents cell division, induces cell cycle arrest and apoptosis. This may inhibit the proliferation of susceptible tumor cells. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bizalimogene Ralaplasmid</VALIDVALUE>
          <VALUEMEANING>Bizalimogene Ralaplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, bizalimogene ralaplasmid expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bizelesin</VALIDVALUE>
          <VALUEMEANING>Bizelesin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cyclopropylpyrroloindole antineoplastic antibiotic.  Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis.  Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BL22 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>BL22 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1842</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Black Cohosh</VALIDVALUE>
          <VALUEMEANING>Black Cohosh</VALUEMEANING>
          <MEANINGDESCRIPTION>A triterpene-containing herb isolated from the roots and rhizomes of the plant Cimicifuga racemosa (also known as Actaea racemosa). While the mechanism of action of black cohosh is not completely understood, it appears to act as a selective estrogen receptor modulator.  In vitro, this preparation has been shown to induce cell cycle arrest and caspase-dependent apoptosis of estrogen-sensitive breast cancer cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Black Raspberry Nectar</VALIDVALUE>
          <VALUEMEANING>Black Raspberry Nectar</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentrated fruit juice containing black raspberries, with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, anthocyanidins, and flavonoids. Upon oral administration, the phytochemicals in the black raspberry nectar inhibit the activation of several signal transduction pathways involved in carcinogenesis and the expression of downstream target genes that are upregulated in a variety of cancer cell types. In addition, the phytochemicals in black raspberry may protect the oral microbiome and may enhance the bacterial defense against pathogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bivalent BRD4 Inhibitor AZD5153</VALIDVALUE>
          <VALUEMEANING>Bivalent BRD4 Inhibitor AZD5153</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable bivalent inhibitor of  bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bleomycin</VALIDVALUE>
          <VALUEMEANING>Bleomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bleomycin A2</VALIDVALUE>
          <VALUEMEANING>Bleomycin A2</VALUEMEANING>
          <MEANINGDESCRIPTION>The primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Bleomycin A2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bleomycin B2</VALIDVALUE>
          <VALUEMEANING>Bleomycin B2</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of glycopeptide bleomycin A2 and B2 isolated from Streptomyces verticillus with potential antineoplastic activity. Bleomycin B2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bleomycin Sulfate</VALIDVALUE>
          <VALUEMEANING>Bleomycin Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blueberry Powder Supplement</VALIDVALUE>
          <VALUEMEANING>Blueberry Powder Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, dietary supplement consisting of lyophilized blueberry powder, with antioxidant and potential chemopreventive and chemosensitizing activity. In addition to vitamins and minerals, blueberries are rich in phytonutrients, such as proanthocyanidins, anthocyanins (e.g. malvidin, delphinidin, pelargonidin, cyanidin, petunidin, and peonidin), hydroxycinnamic acids, hydroxybenzoic acids, pterostilbene, resveratrol, and flavonols (e.g. kaempferol, quercetin and myricetin). Although the exact mechanism of action through which blueberries may exert their anti-tumor effect has yet to be fully elucidated, the effects of blueberry powder on cancer cells may be attributable to the phytonutrient&#39;s antioxidant and pro-apoptotic activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BMS-184476</VALIDVALUE>
          <VALUEMEANING>BMS-184476</VALUEMEANING>
          <MEANINGDESCRIPTION>A 7-methylthiomethyl ether derivative of paclitaxel with antineoplastic activity.  BMS-184476 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BMS-188797</VALIDVALUE>
          <VALUEMEANING>BMS-188797</VALUEMEANING>
          <MEANINGDESCRIPTION>An analog of paclitaxel with antineoplastic activity.  BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1859</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BMS-214662</VALIDVALUE>
          <VALUEMEANING>BMS-214662</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsedating benzodiazepine derivative with potential antineoplastic activity. Farnesyltransferase inhibitor BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BMS-275183</VALIDVALUE>
          <VALUEMEANING>BMS-275183</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blinatumomab</VALIDVALUE>
          <VALUEMEANING>Blinatumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3690103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Boanmycin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Boanmycin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of boanmycin (aka bleomycin A6), a component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bomedemstat</VALIDVALUE>
          <VALUEMEANING>Bomedemstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Boronophenylalanine-Fructose Complex</VALIDVALUE>
          <VALUEMEANING>Boronophenylalanine-Fructose Complex</VALUEMEANING>
          <MEANINGDESCRIPTION>A boronated phenylalanine complexed with fructose to increase its solubility. When exposed to neutron irradiation, boronophenylalanine absorbs neutrons and self-destructs releasing short-range alpha radiation and &#39;recoil&#39; lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bortezomib</VALIDVALUE>
          <VALUEMEANING>Bortezomib</VALUEMEANING>
          <MEANINGDESCRIPTION>A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bosutinib Monohydrate</VALIDVALUE>
          <VALUEMEANING>Bosutinib (BOSULIF)</VALUEMEANING>
          <MEANINGDESCRIPTION>The monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Botanical Agent BEL-X-HG</VALIDVALUE>
          <VALUEMEANING>Botanical Agent BEL-X-HG</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available botanically-based agent with potential antineoplastic activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects against cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Botanical Agent LEAC-102</VALIDVALUE>
          <VALUEMEANING>Botanical Agent LEAC-102</VALUEMEANING>
          <MEANINGDESCRIPTION>A botanical-based formulation derived from the Taiwanese mushroom Antrodia cinnamomea, with potential antineoplastic activity, Upon administration, the components in LEAC-102 may exert cytotoxic effects against cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bovine Cartilage</VALIDVALUE>
          <VALUEMEANING>Bovine Cartilage</VALUEMEANING>
          <MEANINGDESCRIPTION>Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BP-Cx1-Platinum Complex BP-C1</VALIDVALUE>
          <VALUEMEANING>BP-Cx1-Platinum Complex BP-C1</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bosutinib</VALIDVALUE>
          <VALUEMEANING>Bosutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BR96-Doxorubicin Immunoconjugate</VALIDVALUE>
          <VALUEMEANING>BR96-Doxorubicin Immunoconjugate</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin.  The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types.  Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brachyury-expressing Yeast Vaccine GI-6301</VALIDVALUE>
          <VALUEMEANING>Brachyury-expressing Yeast Vaccine GI-6301</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF Inhibitor ARQ 736</VALIDVALUE>
          <VALUEMEANING>BRAF Inhibitor ARQ 736</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly soluble phosphate prodrug of B-raf (BRAF) protein kinase with potential antineoplastic activity. BRAF inhibitor ARQ 736 is converted into its active form ARQ 680 in the presence of phosphatases. In turn, ARQ 680 selectively binds to and inhibits the activity of oncogenic B-raf, which may inhibit the proliferation of tumor cells expressing mutated B-raf gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. The valine to glutamic acid substitution at residue 600 (V600E) accounts for about 90% of BRAF gene mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF Inhibitor BGB-3245</VALIDVALUE>
          <VALUEMEANING>BRAF Inhibitor BGB-3245</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of both monomer and dimer forms of activating mutations of the serine/threonine-protein kinase BRAF (B-raf) protein, including V600 BRAF mutations, non-V600 BRAF mutations, and RAF fusions, with potential antineoplastic activity. Upon administration, BRAF inhibitor BGB-3245 targets and binds to both monomeric and dimeric forms of activating BRAF mutations and fusions. This may result in the inhibition of BRAF-mediated signaling and inhibit proliferation in tumor cells expressing BRAF mutations and fusions. BRAF belongs to the RAF family of serine/threonine protein kinases and plays a role in regulating the mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. BRAF mutations and fusions have been identified in a number of solid tumors and are drivers of cancer growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF(V600E) Kinase Inhibitor RO5212054</VALIDVALUE>
          <VALUEMEANING>BRAF(V600E) Kinase Inhibitor RO5212054</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small-molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. BRAF(V600E) kinase inhibitor RO5212054 selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations; the oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B-Raf/VEGFR-2 Inhibitor RAF265</VALIDVALUE>
          <VALUEMEANING>B-Raf/VEGFR-2 Inhibitor RAF265</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAFV600/PI3K Inhibitor ASN003</VALIDVALUE>
          <VALUEMEANING>BRAFV600/PI3K Inhibitor ASN003</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective inhibitor of mutated forms of B-RAF kinase at amino acid position 600 (BRAFV600), including BRAFV600E, the alpha, delta and, to a lesser extent, beta isoforms of phosphatidylinositide 3-kinase (PI3K), including mutated forms of PI3KCA, which encodes the p110-alpha catalytic subunit of the class I PI3K, and the phosphatase and tensin homologs (PTEN) with loss-of-function mutation, with potential antineoplastic activity. Upon administration of ASN003, this agent selectively targets, binds to and inhibits the activity of BRAFV600 mutants as well as mutated isoforms of PI3K. This inhibits signaling through B-RAF- and PI3K/mechanistic target of rapamycin (mTOR)-mediated pathways and inhibits cellular proliferation in tumor cells with BRAFV600 mutations, those expressing PI3K and/or those driven by PTEN. Dysregulation of the B-RAF- and PI3K-mediated pathways is frequently seen in a variety of tumors and results in increased tumor cell growth and survival. Dual targeting of both pathways may increase efficacy and anti-tumor potential compared to the targeting of just one pathway by a selective B-RAF inhibitor or selective PI3K pathway inhibitor alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRD4 Inhibitor PLX2853</VALIDVALUE>
          <VALUEMEANING>BRD4 Inhibitor PLX2853</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRD4 Inhibitor PLX51107</VALIDVALUE>
          <VALUEMEANING>BRD4 Inhibitor PLX51107</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon administration, the BRD4 inhibitor PLX51107 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF(V600E) Kinase Inhibitor ABM-1310</VALIDVALUE>
          <VALUEMEANING>BRAF(V600E) Kinase Inhibitor ABM-1310</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. Upon oral administration, BRAF(V600E) kinase inhibitor ABM-1310 selectively binds to and inhibits the activity of BRAF(V600E) kinase, which may result in the inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. BRAF belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations. The oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in about 8% of all tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breflate</VALIDVALUE>
          <VALUEMEANING>Breflate</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble analogue of the antineoplastic agent brefeldin A (BFA). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brentuximab</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody SGN-30</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brentuximab Vedotin</VALIDVALUE>
          <VALUEMEANING>Brentuximab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brequinar Sodium</VALIDVALUE>
          <VALUEMEANING>Brequinar Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of Brequinar.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Briciclib Sodium</VALIDVALUE>
          <VALUEMEANING>Briciclib Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, briciclib is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brigatinib</VALIDVALUE>
          <VALUEMEANING>Brigatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6117828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brilanestrant</VALIDVALUE>
          <VALUEMEANING>Brilanestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brivanib</VALIDVALUE>
          <VALUEMEANING>Brivanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6423720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brivanib Alaninate</VALIDVALUE>
          <VALUEMEANING>Brivanib Alaninate</VALUEMEANING>
          <MEANINGDESCRIPTION>The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brequinar</VALIDVALUE>
          <VALUEMEANING>Brequinar</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic quinolinecarboxylic acid analogue with antineoplastic properties.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brivudine</VALIDVALUE>
          <VALUEMEANING>Brivudine</VALUEMEANING>
          <MEANINGDESCRIPTION>A uridine derivative and nucleoside analog with pro-apoptotic and chemosensitizing properties. In vitro, bromovinyl-deoxyuridine (BVDU) has been shown to downregulate the multifunctional DNA repair enzyme APEX nuclease 1, resulting in the inhibition of DNA repair and the induction of apoptosis. In addition, this agent may inhibit the expression of STAT3 (signal transducer and activator of transcription 3), which may result in the downregulation of vascular endothelial growth factor (VEGF). BVDU has also been found to inhibit the upregulation of chemoresistance genes (Mdr1 and DHFR) during chemotherapy. Overall, the gene expression changes associated with BVDU treatment result in the decrease or prevention of chemoresistance. In addition, this agent has been shown to enhance the cytolytic activity of NK-92 natural killer cells towards a pancreatic cancer cell line in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67088</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brivudine Phosphoramidate</VALIDVALUE>
          <VALUEMEANING>Brivudine Phosphoramidate</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2&#39;-deoxyuridine (BVdU) with potential antineoplastic activity. Selectively active against tumor cells expressing high levels of thymidylate synthase (TS), brivudine is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites. As key enzyme in the de novo synthesis of dTMP, TS is an enzyme critical to DNA biosynthesis and is overexpressed in many solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Broad-Spectrum Human Papillomavirus Vaccine V505</VALIDVALUE>
          <VALUEMEANING>Broad-Spectrum Human Papillomavirus Vaccine V505</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-infectious recombinant cancer vaccine prepared from the human papillomavirus (HPV) with potential immunoprophylactic activity. Vaccination with broad-spectrum human papillomavirus vaccine V505 may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte (CTL) responses against HPV-infected cells. HPV infection, the cause of genital warts, is a risk factor for the development of cancers of the cervix, vagina, vulva, anus, and penis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bromacrylide</VALIDVALUE>
          <VALUEMEANING>Bromacrylide</VALUEMEANING>
          <MEANINGDESCRIPTION>A propenamide-based agent with antineoplastic activity. Bromacrylide has been shown to decrease tumor growth in animal models, but is accompanied with severe toxicity, including severe bone marrow suppression and weight loss.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bromebric Acid</VALIDVALUE>
          <VALUEMEANING>Bromebric Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of bromoacrylic acid with cytostatic and antineoplastic activity. Bromebric acid appears to inhibit purine synthesis, oxidative phosphorylation and DNA synthesis. This agent inhibits tumor cell growth and causes cell cycle arrest. This agent may also have some use in the phrophylaxis of migraine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bromocriptine Mesylate</VALIDVALUE>
          <VALUEMEANING>Bromocriptine</VALUEMEANING>
          <MEANINGDESCRIPTION>Bromocriptine belongs to the group of medicines known as ergot alkaloids. It acts as a dopamine agonist primarily activating the dopamine D2 receptors. It blocks release of prolactin from the pituitary gland, and is used in the therapy of amenorrhea, infertility in women, abnormal breast milk discharge, hypogonadism, Parkinsons disease, and acromegaly. It is also used in the treatment of pituitary prolactinoma, neuroleptic malignant syndrome, cocaine addiction, and painful breast condition. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brontictuzumab</VALIDVALUE>
          <VALUEMEANING>Brontictuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brostacillin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Brostacillin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of brostacillin, a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brostallicin</VALIDVALUE>
          <VALUEMEANING>Brostallicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Broccoli Sprout/Broccoli Seed Extract Supplement</VALIDVALUE>
          <VALUEMEANING>Broccoli Sprout/Broccoli Seed Extract Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5&#39; flanking region of many phase II detoxification enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Broxuridine</VALIDVALUE>
          <VALUEMEANING>Broxuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5002167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol A</VALIDVALUE>
          <VALUEMEANING>Bruceanol A</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol B</VALIDVALUE>
          <VALUEMEANING>Bruceanol B</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol C</VALIDVALUE>
          <VALUEMEANING>Bruceanol C</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol E</VALIDVALUE>
          <VALUEMEANING>Bruceanol E</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol F</VALIDVALUE>
          <VALUEMEANING>Bruceanol F</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol G</VALIDVALUE>
          <VALUEMEANING>Bruceanol G</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural quassinoid agent extracted from Brucea antidysenterica with potential antineoplastic activity that is cytotoxic to certain cancer cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol H</VALIDVALUE>
          <VALUEMEANING>Bruceanol H</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceantin</VALIDVALUE>
          <VALUEMEANING>Bruceantin</VALUEMEANING>
          <MEANINGDESCRIPTION>A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica.  Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.  Bruceantin also has antiamoebic and antimalarial activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bruceanol D</VALIDVALUE>
          <VALUEMEANING>Bruceanol D</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated form the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bryostatin 1</VALIDVALUE>
          <VALUEMEANING>Bryostatin 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1026</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor CT-1530</VALIDVALUE>
          <VALUEMEANING>BTK Inhibitor CT-1530</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, CT-1530 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor DTRMWXHS-12</VALIDVALUE>
          <VALUEMEANING>BTK Inhibitor DTRMWXHS-12</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor M7583</VALIDVALUE>
          <VALUEMEANING>BTK Inhibitor M7583</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of Bruton&#39;s tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, M7583 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Budigalimab</VALIDVALUE>
          <VALUEMEANING>Budigalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Budotitane</VALIDVALUE>
          <VALUEMEANING>Budotitane</VALUEMEANING>
          <MEANINGDESCRIPTION>A titanium metal complex, coordinated with asymmetric beta-diketonate ligands, with antineoplastic activity. Although the exact mechanism of action remains to be elucidated, budotitane potentially binds either to macromolecules via coordinative covalent bonds, or via intercalation between nucleic acids strands by the aromatic ring of the beta-diketonate. In addition, this agent appears to cause cardiac arrhythmias and is toxic to the liver and kidneys at higher doses. The development of budotitane was halted due to the rapid loss of its labile groups under physiological conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bufalin</VALIDVALUE>
          <VALUEMEANING>Bufalin</VALUEMEANING>
          <MEANINGDESCRIPTION>An active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3855748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buparlisib</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor BKM120</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burixafor</VALIDVALUE>
          <VALUEMEANING>Burixafor</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation; this may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor HZ-A-018</VALIDVALUE>
          <VALUEMEANING>BTK Inhibitor HZ-A-018</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Bruton&#39;s tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, BTK inhibitor HZ-A-018 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burixafor Hydrobromide</VALIDVALUE>
          <VALUEMEANING>Burixafor Hydrobromide</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrobromide salt form of burixafor, an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with hematopoietic stem cell (HSC)-mobilization and chemosensitizing activities. Upon administration, burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into the peripheral circulation. Additionally, burixafor-mediated mobilization of disseminated tumor cells (DTCs) from the bone marrow into the blood may make these metastatic tumor cells more susceptible to the actions of chemotherapeutic agents. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burosumab</VALIDVALUE>
          <VALUEMEANING>Burosumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buserelin</VALIDVALUE>
          <VALUEMEANING>Buserelin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bushen Culuan Decoction</VALIDVALUE>
          <VALUEMEANING>Bushen Culuan Decoction</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) decoction containing a mixture of ten Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong, with potential to induce ovulation. Upon oral administration, Bushen Culuan decoction may, through a not yet fully elucidated mechanism, depress follicle-stimulating hormone (FSH) levels, elevate anti-Mullerian hormone (AMH) levels, and increase the number of antral follicle counts (AFCs), thereby promoting ovulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bushen-Jianpi Decoction</VALIDVALUE>
          <VALUEMEANING>Bushen-Jianpi Decoction</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) that is used for Yin deficiency of the liver, kidney and spleen, with potential immunomodulating and antineoplastic activities. Bushen-Jianpi decoction (BSJPD; BJD) consists of various herbs, including, but not limited to, Radix Codonopsis (Dang Shen), Fructus Lycii (the fruit of Chinese wolfberry), Rhizoma Atractylodis Macrocephalae (Baishu; Bai Zhu), Fructus Ligustri Lucidi, Cuscuta chinensis (Chinese dodder) seed, and Psoralea corylifolia Linn. As a TCM, Bushen-Jianpi is used as an antineoplastic agent as it is thought to invigorate the spleen and tonify the kidney, which presumably prevents or treats a variety of cancers. Upon administration of Bushen-Jianpi decoction, the ingredients in the decoction may affect signaling pathways involved in carcinogenesis and enhance the immune system by increasing the levels of numerous cytokines and a variety of immune cells, such as cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs) and macrophages. It may also reduce the expression of various proteins involved in tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Busulfan</VALIDVALUE>
          <VALUEMEANING>Busulfan</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C321</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buthionine Sulfoximine</VALIDVALUE>
          <VALUEMEANING>Buthionine Sulfoximine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1029</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BXQ-350 Nanovesicle Formulation</VALIDVALUE>
          <VALUEMEANING>BXQ-350 Nanovesicle Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7071769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C/EBP Beta Antagonist ST101</VALIDVALUE>
          <VALUEMEANING>C/EBP Beta Antagonist ST101</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide antagonist of the transcription factor CCAAT/enhancer-binding protein beta (C/EBP beta), with potential antineoplastic activity. Upon administration, C/EBP beta antagonist ST101 targets and inhibits the activity of C/EBP beta. This prevents the expression of C/EBP beta target genes and proteins, including the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), cyclins and inhibitor of differentiation (ID) family of proteins, which are involved in cell proliferation, differentiation, and cell cycle regulation. This may lead to apoptosis in tumor cells. C/EBP beta is overexpressed in many cancers and plays an important role in the regulation of cell differentiation; its expression is associated with tumor cell survival and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cabiralizumab</VALIDVALUE>
          <VALUEMEANING>Cabiralizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7431039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cabozantinib</VALIDVALUE>
          <VALUEMEANING>Cabozantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6824783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cabozantinib S-malate</VALIDVALUE>
          <VALUEMEANING>XL184 (Cabozantinib-S-malate)</VALUEMEANING>
          <MEANINGDESCRIPTION>The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cactinomycin</VALIDVALUE>
          <VALUEMEANING>Cactinomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Cactinomycin binds to DNA by intercalating between guanine and cytosine, forming stable antibiotic-DNA complexes that inhibit RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1032</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caffeic Acid Phenethyl Ester</VALIDVALUE>
          <VALUEMEANING>Caffeic Acid Phenethyl Ester</VALUEMEANING>
          <MEANINGDESCRIPTION>The phenethyl alcohol ester of caffeic acid and a bioactive component of honeybee hive propolis, with antineoplastic, cytoprotective and immunomodulating activities. Upon administration, caffeic acid phenethyl ester (CAPE) inhibits the activation of nuclear transcription factor NF-kappa B and may suppress p70S6K and Akt-driven signaling pathways. In addition, CAPE inhibits PDGF-induced proliferation of vascular smooth muscle cells through the activation of p38 mitogen-activated protein kinase (MAPK) and hypoxia-inducible factor (HIF)-1alpha and subsequent induction of heme oxygenase-1 (HO-1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cabazitaxel</VALIDVALUE>
          <VALUEMEANING>Cabazitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAIX Inhibitor DTP348</VALIDVALUE>
          <VALUEMEANING>CAIX Inhibitor DTP348</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, nitroimidazole-based sulfamide, carbonic anhydrase IX (CAIX) inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor DTP348 inhibits tumor-associated CAIX, a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents the acidification of the tumor&#39;s extracellular microenvironment and decreases the intracellular pH. This results in increased cell death in CAIX-expressing, hypoxic tumors. In addition, DTP348, through its nitroimidazole moiety, is able to sensitize hypoxic tumor cells to irradiation. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAIX Inhibitor SLC-0111</VALIDVALUE>
          <VALUEMEANING>CAIX Inhibitor SLC-0111</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfonamide carbonic anhydrase inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor SLC-0111 inhibits tumor-associated carbonic anhydrase IX (CAIX), an hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents both the acidification of the tumor&#39;s extracellular microenvironment and cytoplasmic alkalization. This increases cell death in CAIX-expressing, hypoxic tumors. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion; it is also involved in resistance to both chemo- and radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calcitriol</VALIDVALUE>
          <VALUEMEANING>Calcitriol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calcium Release-activated Channels Inhibitor RP4010</VALIDVALUE>
          <VALUEMEANING>Calcium Release-activated Channels Inhibitor RP4010</VALUEMEANING>
          <MEANINGDESCRIPTION>A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential antineoplastic activity. Upon administration, RP4010 binds to and inhibits CRACs, thereby preventing the transport of extracellular Ca2+ into the cell and inhibiting the subsequent activation of Ca2+-mediated signaling and transcription of target genes. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), play key roles in calcium homeostasis and are over-activated in a number of cancer cell types. Aberrant activation of CRACs leads to increased cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calculus bovis/Moschus/Olibanum/Myrrha Capsule</VALIDVALUE>
          <VALUEMEANING>Calculus bovis/Moschus/Olibanum/Myrrha Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available traditional Chinese medicine (TCM)-based capsule formulation containing Calculus bovis, the dried gallstones of cattle, Moschus, also referred to as deer musk, the resin Olibanum and the resin Myrrha, with potential antineoplastic and chemopreventive activities. Although the exact mechanisms of action through which the active ingredients in the Calculus bovis/Moschus/Olibanum/Myrrha capsule elicit their effects have yet to be fully elucidated, they may, upon intake, exert their antineoplastic activity through modulation of the immune system, inhibition of tumor cell proliferation and induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calicheamicin Gamma 1I</VALIDVALUE>
          <VALUEMEANING>Calicheamicin Gamma 1I</VALUEMEANING>
          <MEANINGDESCRIPTION>An oligosaccharide enediyne antitumor antibiotic isolated from Micromonospora echinospora ssp. Calichensis.  Calicheamicin Gamma 1I binds to the minor groove of DNA, resulting in site-specific double-strand breaks and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camidanlumab Tesirine</VALIDVALUE>
          <VALUEMEANING>Camidanlumab Tesirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25) and conjugated, via a cleavable linker, to a synthetic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer that targets DNA minor grooves, with potential antineoplastic activity. The monoclonal antibody portion of the anti-CD25 antibody-drug conjugate (ADC) ADCT-301 specifically binds to the cell surface antigen CD25. This causes the internalization of ADCT-301 and the subsequent release of the cytotoxic PBD moiety. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD25-overexpressing tumor cells. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camptothecin</VALIDVALUE>
          <VALUEMEANING>Camptothecin</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camptothecin Analogue TLC388</VALIDVALUE>
          <VALUEMEANING>Camptothecin Analogue TLC388</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analogue of camptothecin with potential antineoplastic and radio-sensitizing activities. Camptothecin analogue TLC388 selectively stabilizes topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Topoisomerase I relaxes negative super-coiled DNA during replication and transcription. This agent has been chemically modified to enhance the potency and stability of camptothecin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80047</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calcium Saccharate</VALIDVALUE>
          <VALUEMEANING>Calcium D-Glucarate</VALUEMEANING>
          <MEANINGDESCRIPTION>The calcium salt form of glucaric acid, a natural substance found in many fruits and vegetables, with potential anti-cancer property. One of the key processes in which the human body eliminates toxic chemicals as well as hormones (such as estrogen) is by attaching glucuronic acid to them in the liver and then excreting the complex in the bile. When beta-glucuronidase breaks the bond, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Therefore, supplementing calcium glucarate may suppress the developments of hormone-dependent cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camptothecin Sodium</VALIDVALUE>
          <VALUEMEANING>Camptothecin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The sodium salt of camptothecin is more water-soluble than the parent molecule. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camptothecin-20(S)-O-Propionate Hydrate</VALIDVALUE>
          <VALUEMEANING>Camptothecin-20(S)-O-Propionate Hydrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrated, crystalline propionate ester (attached in position C-20) prodrug of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with potential antineoplastic activity. Upon entry into cells, camptothecin-20(S)-O-propionate is hydrolyzed by esterases into the active form camptothecin. Camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery, thus inhibiting DNA replication and triggering apoptotic cell death. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active, S-configured lactone structure to an inactive carboxylate form. The ester chain in the vicinity of the S-configured lactone moiety, a key determinant for the chemotherapeutic efficacy of the camptothecins, inhibits protein binding, rendering this agent resistant to hydrolysis and prolonging its half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camrelizumab</VALIDVALUE>
          <VALUEMEANING>Camrelizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camsirubicin</VALIDVALUE>
          <VALUEMEANING>Camsirubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Camsirubicin intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cancer Peptide Vaccine S-588410</VALIDVALUE>
          <VALUEMEANING>Cancer Peptide Vaccine S-588410</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer peptide vaccine containing five human leukocyte antigen (HLA)-A*2402-restricted epitope peptides derived from as of yet not disclosed oncoantigens, with potential immunostimulating and antineoplastic activities. Upon administration of the cancer peptide vaccine S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Canerpaturev</VALIDVALUE>
          <VALUEMEANING>Canerpaturev</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-engineered, naturally oncolytic, replication-competent spontaneous herpes simplex virus (HSV) type I mutant variant. Upon intratumoral injection, canerpaturev transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. In addition, this agent may increase host immune responses that may kill non-infected tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Canertinib Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Canertinib Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Canfosfamide</VALIDVALUE>
          <VALUEMEANING>Canfosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor cell proliferation. Glutathione S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Canfosfamide Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Canfosfamide Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a modified glutathione analogue with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor proliferation. S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2641</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cancell</VALIDVALUE>
          <VALUEMEANING>Cancell</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancell (Entelev or Cantron), is a liquid that has been produced in various forms, principally by two manufacturers, since the late 1930s.  The exact composition of Cancell/Entelev is unknown, but the U.S. Food and Drug Administration (FDA) has listed the components as inositol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol.  NCI studies determined that the mixture lacked substantial antitumor activity. (from CancerNet)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cannabidiol</VALIDVALUE>
          <VALUEMEANING>Cannabidiol</VALUEMEANING>
          <MEANINGDESCRIPTION>A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6846828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cantrixil</VALIDVALUE>
          <VALUEMEANING>Cantrixil</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclodextrin-encapsulated, third generation super-benzopyran (SBP) compound with potential antineoplastic activity. Upon intraperitoneal (IP) administration, cantrixil enhances the activation and expression of c-Jun, downregulates phosphorylated extracellular signal-regulated kinase (p-ERK) and induces activation of caspase-3, -7 and -9, thereby inducing tumor cell apoptosis. c-Jun, an activator protein-1 (AP-1) transcription factor component, is involved in a wide range of cellular processes including cell cycle progression, differentiation, cell transformation and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cantuzumab Ravtansine</VALIDVALUE>
          <VALUEMEANING>Cantuzumab Ravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated to a derivative of the cytotoxic agent maytansine, DM4, with potential antitumor activity. Cantuzumab ravtansine is generated from MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capecitabine</VALIDVALUE>
          <VALUEMEANING>Capecitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capivasertib</VALIDVALUE>
          <VALUEMEANING>Capivasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6819518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capmatinib</VALIDVALUE>
          <VALUEMEANING>Capmatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Captopril</VALIDVALUE>
          <VALUEMEANING>Captopril</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAR T-Cells AMG 119</VALIDVALUE>
          <VALUEMEANING>CAR T-Cells AMG 119</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caracemide</VALIDVALUE>
          <VALUEMEANING>Caracemide</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent derived from acetohydroxamic acid with potential antineoplastic activity.  Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase.  In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent&#39;s acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capecitabine Rapidly Disintegrating Tablet</VALIDVALUE>
          <VALUEMEANING>Capecitabine Rapidly Disintegrating Tablet</VALUEMEANING>
          <MEANINGDESCRIPTION>A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5&#39;-deoxy-5-fluorocytidine (5&#39;-DFCR) by hepatic carboxylesterase and then to 5&#39;-deoxy-5-fluorouridine (5&#39;-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carbendazim</VALIDVALUE>
          <VALUEMEANING>Carbendazim</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614699</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carbetimer</VALIDVALUE>
          <VALUEMEANING>Carbetimer</VALUEMEANING>
          <MEANINGDESCRIPTION>Carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride.  It has demonstrated antitumor activity against several animal models.  It has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carbogen</VALIDVALUE>
          <VALUEMEANING>Carbogen</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties.  Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carbon C 14-pamiparib</VALIDVALUE>
          <VALUEMEANING>Carbon C 14-pamiparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(ADP-ribose) polymerase (PARP) inhibitor, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon C 14 allows for the evaluation of pamiparib&#39;s pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboplatin</VALIDVALUE>
          <VALUEMEANING>Carboplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboquone</VALIDVALUE>
          <VALUEMEANING>Carboquone</VALUEMEANING>
          <MEANINGDESCRIPTION>An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in carboquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent&#39;s cytotoxic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboxyamidotriazole</VALIDVALUE>
          <VALUEMEANING>Carboxyamidotriazole</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboxyamidotriazole Orotate</VALIDVALUE>
          <VALUEMEANING>Carboxyamidotriazole Orotate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91090</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboxyphenyl Retinamide</VALIDVALUE>
          <VALUEMEANING>Carboxyphenyl Retinamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis.  This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caricotamide/Tretazicar</VALIDVALUE>
          <VALUEMEANING>Caricotamide/Tretazicar</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80048</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carlumab</VALIDVALUE>
          <VALUEMEANING>Carlumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgG1 kappa monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Carlumab binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmofur</VALIDVALUE>
          <VALUEMEANING>Carmofur</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C955</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmustine</VALIDVALUE>
          <VALUEMEANING>Carmustine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmustine Implant</VALIDVALUE>
          <VALUEMEANING>Polifeprosan 20 with Carmustine Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carfilzomib</VALIDVALUE>
          <VALUEMEANING>Carfilzomib</VALUEMEANING>
          <MEANINGDESCRIPTION>An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmustine in Ethanol</VALIDVALUE>
          <VALUEMEANING>Carmustine in Ethanol</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing carmustine dissolved in ethanol for intra-tumoral administration that allows carmustine to enter both aqueous and lipid compartments of the target tissue. As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2602</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carmustine Sustained-Release Implant Wafer</VALIDVALUE>
          <VALUEMEANING>Carmustine Sustained-Release Implant Wafer</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carotuximab</VALIDVALUE>
          <VALUEMEANING>Anti-Endoglin Chimeric Monoclonal Antibody TRC105</VALUEMEANING>
          <MEANINGDESCRIPTION>A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Anti-endoglin monoclonal antibody TRC105 binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3690105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carubicin</VALIDVALUE>
          <VALUEMEANING>Carubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carzelesin</VALIDVALUE>
          <VALUEMEANING>Carzelesin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclopropylpyrroloindole prodrug analogue and DNA minor groove binding agent, with antineoplastic activity.  After hydrolysis, the cyclopropyl group of carzelesin alkylates N3-adenine in a sequence-selective fashion. This results in tumor growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carzinophilin</VALIDVALUE>
          <VALUEMEANING>Carzinophilin</VALUEMEANING>
          <MEANINGDESCRIPTION>An ethylenimine antineoplastic antibiotic isolated from the bacterium Streptomyces sahachiroi.  Carzinophilin forms interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cationic Liposome-Encapsulated Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Cationic Liposome-Encapsulated Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A cationic liposome preparation of paclitaxel with antineoplastic activity. Paclitaxel, the active ingredient in cationic liposome-encapsulated paclitaxel, binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis and cellular proliferation, and apoptosis. Cationic liposome encapsulation of paclitaxel allows the delivery of high doses of paclitaxel to target tissues while minimizing systemic toxicity. Tumor endothelial cells may preferentially bind and internalize cationic liposomes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cationic Peptide Cream Cypep-1</VALIDVALUE>
          <VALUEMEANING>Cationic Peptide Cream Cypep-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical cream containing Cypep-1, a cationic lytic peptide of 27 amino acids, with potential antineoplastic activity. Upon topical administration, Cypep-1 selectively targets tumor cells with negatively charged cell membranes and ruptures the cell membranes. This leads to tumor cell lysis and the release of neoantigens into the tumor microenvironment (TME) and circulation. This elicits a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Warts are benign skin tumors caused by human papilloma virus (HPV).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Catumaxomab</VALIDVALUE>
          <VALUEMEANING>Catumaxomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Carubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the anthracycline antineoplastic antibiotic carubicin.  Carubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CBP/beta-catenin Modulator E7386</VALIDVALUE>
          <VALUEMEANING>CBP/beta-catenin Modulator E7386</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CCR2 Antagonist CCX872-B</VALIDVALUE>
          <VALUEMEANING>CCR2 Antagonist CCX872-B</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120302</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CCR2 Antagonist PF-04136309</VALIDVALUE>
          <VALUEMEANING>CCR2 Antagonist PF-04136309</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CCR2/CCR5 Antagonist BMS-813160</VALIDVALUE>
          <VALUEMEANING>CCR2/CCR5 Antagonist BMS-813160</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD11b Agonist GB1275</VALIDVALUE>
          <VALUEMEANING>CD11b Agonist GB1275</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule agonist of CD11b (integrin alpha-M; ITGAM; integrin alpha M chain), with potential immunomodulating activity. Upon administration, CD11b agonist GB1275 targets and binds to CD11b, thereby activating CD11b. This leads to CD11b-mediated signaling and promotes pro-inflammatory macrophage polarization while suppressing immunosuppressive macrophage polarization. This reduces influx of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), promotes anti-tumor immune responses, induces cytotoxic T-lymphocytes (CTLs) and suppresses tumor growth. CD11b, a member of the integrin family of cell adhesion receptors highly expressed on immune system cells, is a negative regulator of immune suppression and activates anti-tumor innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD123-CD33 Compound CAR T Cells</VALIDVALUE>
          <VALUEMEANING>CD123-CD33 Compound CAR T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the CD123 (interleukin-3 receptor alpha chain or IL3RA) antigen and one specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, the CD123-CD33 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD123 and/or CD33. This induces selective toxicity in tumor cells that express the CD123 antigen and/or the CD33 antigen. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. Additionally, the CD123-CD33 cCAR T cells express CD52 on the cell surface. This allows the depletion of the CD123-CD33 cCAR T cells with the administration of the anti-CD52 monoclonal antibody alemtuzumab, in case of unacceptable side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD123-specific Targeting Module TM123</VALIDVALUE>
          <VALUEMEANING>CD123-specific Targeting Module TM123</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of soluble adapter molecules consisting of an antigen-binding moiety targeting CD123 linked to a peptide motif recognizable by UniCAR02-T, that may be used to activate UniCAR02-T.  Upon administration of CD123-specific targeting module (TM) TM123, and upon co-administration of UniCAR02-T, the antigen-binding moiety of TM123 targets and binds to cancer cells expressing CD123, and the binding domain of UniCAR02-T binds to the nuclear antigen motif of TM123. This activates UniCAR02-T, and induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD20-CD19 Compound CAR T Cells</VALIDVALUE>
          <VALUEMEANING>CD20-CD19 Compound CAR T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the CD20-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD20 and/or CD19. This induces selective toxicity in tumor cells that express CD20 and/or CD19. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD44 Targeted Agent SPL-108</VALIDVALUE>
          <VALUEMEANING>CD44 Targeted Agent SPL-108</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary agent that targets the cancer stem cell (CSC) antigen CD44, with potential antineoplastic activity. Although the mechanism of action has not been elucidated, following subcutaneous administration, CD44 targeted agent SPL-108 binds to CD44 and prevents the activation of various CD44-mediated signal transduction pathways, which may lead to reduced proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in the proliferation, migration and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CCR4 Inhibitor FLX475</VALIDVALUE>
          <VALUEMEANING>CCR4 Inhibitor FLX475</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, FLX475 inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T-cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T-cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD44v6-specific CAR T-cells</VALIDVALUE>
          <VALUEMEANING>CD44v6-specific CAR T-cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a fourth-generation specific chimeric antigen receptor (4SCAR) specific for CD44 variant domain 6 (CD44v6), with potential immunomodulating and antineoplastic activities. Upon administration, CD44v6-specific CAR T-cells specifically recognize and kill CD44v6-expressing tumor cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types. CD44v6, the isoform containing the variant domain 6 of CD44 gene, plays a key role in tumor cell invasion, proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD4-specific Telomerase Peptide Vaccine UCPVax</VALIDVALUE>
          <VALUEMEANING>CD4-specific Telomerase Peptide Vaccine UCPVax</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129596</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD73 Inhibitor LY3475070</VALIDVALUE>
          <VALUEMEANING>CD73 Inhibitor LY3475070</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5&#39;-ecto-nucleotidase; 5&#39;-NT; ecto-5&#39;-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon oral administration, CD73 inhibitor LY3475070 targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against tumor cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine. It is upregulated in a number of cancer cell types and plays a key role in adenosine-mediated immunosuppression within the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD80-Fc Fusion Protein FPT155</VALIDVALUE>
          <VALUEMEANING>CD80-Fc Fusion Protein FPT155</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDC7 Kinase Inhibitor BMS-863233</VALIDVALUE>
          <VALUEMEANING>CDC7 Kinase Inhibitor BMS-863233</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDC7 Kinase Inhibitor LY3143921 Hydrate</VALIDVALUE>
          <VALUEMEANING>CDC7 Kinase Inhibitor LY3143921 Hydrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrated form of an orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon administration of CDC7 kinase inhibitor LY3143921 hydrate, LY3143921 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 plays a key role in DNA replication by binding to and  phosphorylating serine (Ser)-40 and 53 of MCM2 (minichromosome maintenance complex component 2), which is required for the initiation of DNA replication. Although expressed at low levels in healthy, normal cells, CDC7 is expressed at much higher levels in cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDC7 Kinase Inhibitor NMS-1116354</VALIDVALUE>
          <VALUEMEANING>CDC7 Kinase Inhibitor NMS-1116354</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor NMS-1116354 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 initiates DNA replication by phosphorylating MCM2 (minichromosome maintenance complex component 2) at Ser40 and Ser53.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK Inhibitor R547</VALIDVALUE>
          <VALUEMEANING>CDK Inhibitor R547</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable diaminopyrimidine compound and a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and are frequently overexpressed in cancerous cells. R547 selectively binds to and inhibits CDKs, especially CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. The inhibition of CDKs results in cell cycle arrest, inhibition of tumor cell proliferation, and induction of apoptosis. By inhibiting CDK activity, R547 also reduces phosphorylation of the retinoblastoma (Rb) protein, thereby preventing activation of transcription factor E2F and leading to further suppression of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK Inhibitor SNS-032</VALIDVALUE>
          <VALUEMEANING>CDK Inhibitor SNS-032</VALUEMEANING>
          <MEANINGDESCRIPTION>A small aminothiazole molecule and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. SNS-032 binds to and prevents the phosphorylation of cyclin-dependent kinases, especially CDK2, 7, and 9 that regulate cell cycle progression. Inhibition of CDKs leads to cell cycle arrest and induces apoptosis. As a result, this agent causes cytotoxicity and prevents further tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK1/2/4 Inhibitor AG-024322</VALIDVALUE>
          <VALUEMEANING>CDK1/2/4 Inhibitor AG-024322</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK2 Inhibitor PF-07104091</VALIDVALUE>
          <VALUEMEANING>CDK2 Inhibitor PF-07104091</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, CDK2 inhibitor PF-07104091 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK2/4/6/FLT3 Inhibitor FN-1501</VALIDVALUE>
          <VALUEMEANING>CDK2/4/6/FLT3 Inhibitor FN-1501</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule multi-kinase inhibitor of cyclin-dependent kinase (CDK) subtypes 2 (CDK2), 4 (CDK4), and 6 (CDK6) and FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon intravenous administration, CDK2/4/6/FLT3 inhibitor FN-1501 binds to and inhibits CDK2, CDK4, and CDK6, as well as FLT3. This may induce apoptosis and inhibit tumor cell proliferation in cancer cells that overexpress these kinases. CDKs are serine/threonine kinases that assist in cell cycle regulation and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in many cancer types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK Inhibitor AT7519</VALIDVALUE>
          <VALUEMEANING>CDKI AT7519</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4 Inhibitor P1446A-05</VALIDVALUE>
          <VALUEMEANING>CDK4 Inhibitor P1446A-05</VALUEMEANING>
          <MEANINGDESCRIPTION>A protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. CDK4 inhibitor P1446A-05 specifically inhibits CDK4-mediated G1-S phase transition, arresting cell cycling and inhibiting cancer cell growth. The serine/threonine kinase CDK4 is found in a complex with D-type G1 cyclins and is the first kinase to become activated upon mitogenic stimulation, releasing cells from a quiescent stage into the G1/S growth cycling stage; CDK-cyclin complexes have been shown to phosphorylate the retinoblastoma (Rb) transcription factor in early G1, displacing histone deacetylase (HDAC) and blocking transcriptional repression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor BPI-16350</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor BPI-16350</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor CS3002</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor CS3002</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor CS3002 selectively targets and inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor HS-10342</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor HS-10342</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecular, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor HS-10342 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor TQB3616</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor TQB3616</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor TQB3616 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK7 Inhibitor SY-5609</VALIDVALUE>
          <VALUEMEANING>CDK7 Inhibitor SY-5609</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon oral administration, SY-5609 selectively targets, binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated signaling. Specifically, inhibition of CDK7 prevents phosphorylation of the carboxy-terminal domain (CTD) of RNA Polymerase II, thereby preventing transcription of important cancer-promoting genes. In addition, it prevents phosphorylation of the cell cycle kinases CDK1, 2, 4, and 6, thereby disrupting uncontrolled cell cycle progression. Altogether, this may induce apoptosis, cause cell cycle arrest, inhibit DNA damage repair and inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc and beta-catenin, through the phosphorylation of RNA polymerase II.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK8/19 Inhibitor SEL 120</VALIDVALUE>
          <VALUEMEANING>CDK8/19 Inhibitor SEL 120</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor SEL 120 targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK9 Inhibitor AZD4573</VALIDVALUE>
          <VALUEMEANING>CDK9 Inhibitor AZD4573</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEA-MUC-1-TRICOM Vaccine CV301</VALIDVALUE>
          <VALUEMEANING>CEA-MUC-1-TRICOM Vaccine CV301</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7405921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor FCN-437</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor FCN-437</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor FCN-437 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1/S transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play key roles in the regulation of both cell cycle progression from the G1-phase into the S-phase and cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEA-targeting Agent RG6123</VALIDVALUE>
          <VALUEMEANING>CEA-targeting Agent RG6123</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent targeting the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, CEA-targeting agent RG6123 targets and binds to human CEA that is specifically expressed on certain tumor cells. This may, through an as of yet not elucidated mechanism of action, kill CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEBPA-targeting saRNA MTL-CEBPA Liposome</VALIDVALUE>
          <VALUEMEANING>CEBPA-targeting saRNA MTL-CEBPA Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cedazuridine</VALIDVALUE>
          <VALUEMEANING>Cedazuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164146</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cedazuridine/Azacitidine Combination Agent ASTX030</VALIDVALUE>
          <VALUEMEANING>Cedazuridine/Azacitidine Combination Agent ASTX030</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite azacitidine, with potential antineoplastic activity. Upon oral administration of the cedazuridine/azacitidine combination agent ASTX030, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of azacitidine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of azacitidine. Azacitidine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase (DNMT), thereby blocking DNA methylation and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cedefingol</VALIDVALUE>
          <VALUEMEANING>Cedefingol</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of sphingosine, with potential antineoplastic activity. As a sphingosine derivative, cedefingol appears to inhibit protein kinase C (PKC), a kinase that plays an important role in tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78081</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cediranib</VALIDVALUE>
          <VALUEMEANING>Cediranib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cediranib Maleate</VALIDVALUE>
          <VALUEMEANING>Cediranib Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Celecoxib</VALIDVALUE>
          <VALUEMEANING>Celecoxib</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Cycle Checkpoint/DNA Repair Antagonist IC83</VALIDVALUE>
          <VALUEMEANING>Cell Cycle Checkpoint/DNA Repair Antagonist IC83</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary agent with potential antineoplastic activity. IC83 appears to target cell cycle checkpoint/DNA repair enzymes, which are involved in the recognition and repair of damaged DNA and are overexpressed in many types of cancer cells. Inhibition of cell cycle checkpoint/DNA repair enzymes may enhance the cytotoxicity of DNA damaging agents and dissipate tumor cell resistance to chemotherapy and radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cemadotin</VALIDVALUE>
          <VALUEMEANING>Cemadotin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cemadotin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Cemadotin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of cemadotin, a synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cemiplimab</VALIDVALUE>
          <VALUEMEANING>Cemiplimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6687982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cenersen</VALIDVALUE>
          <VALUEMEANING>Cenersen</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cenisertib</VALIDVALUE>
          <VALUEMEANING>Cenisertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, synthetic small molecule with potential antineoplastic activity. Cenisertib selectively binds to and inhibits aurora kinases (AKs), a family of serine-threonine kinases which are important regulators of cell division and proliferation, and which are overexpressed in certain types of cancer. Inhibition of aurora kinases inhibits cell division and proliferation and induces apoptosis in tumor cells overexpressing AKs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceramide Nanoliposome</VALIDVALUE>
          <VALUEMEANING>Ceramide Nanoliposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerdulatinib</VALIDVALUE>
          <VALUEMEANING>Cerdulatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin&#39;s lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cergutuzumab Amunaleukin</VALIDVALUE>
          <VALUEMEANING>Cergutuzumab Amunaleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha (CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however, IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceritinib</VALIDVALUE>
          <VALUEMEANING>Ceritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4369572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cesalin</VALIDVALUE>
          <VALUEMEANING>Cesalin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic protein isolated from the seeds of the plant Caesalpinia gilliesii with antineoplastic activity.  Cesalin intercalates into and crosslinks DNA and inhibits the incorporation of the nucleotides uridine and thymidine into DNA, thereby inhibiting DNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceralasertib</VALIDVALUE>
          <VALUEMEANING>Ceralasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cEt KRAS Antisense Oligonucleotide AZD4785</VALIDVALUE>
          <VALUEMEANING>cEt KRAS Antisense Oligonucleotide AZD4785</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2&#39;-4&#39; constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetrelimab</VALIDVALUE>
          <VALUEMEANING>Cetrelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab</VALIDVALUE>
          <VALUEMEANING>Cetuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)</VALIDVALUE>
          <VALUEMEANING>Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cevipabulin Fumarate</VALIDVALUE>
          <VALUEMEANING>Cevipabulin Fumarate</VALUEMEANING>
          <MEANINGDESCRIPTION>The fumarate salt of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth., a small, water soluble, synthetic tubulin-binding agent with potential antineoplastic activity.  Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and may reduce cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73815</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cevipabulin Succinate</VALIDVALUE>
          <VALUEMEANING>Cevipabulin Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The succinate salt form of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin binds at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. This stabilizes tubulin and prevents microtubule disassembly. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cevostamab</VALIDVALUE>
          <VALUEMEANING>Cevostamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cFMS Tyrosine Kinase Inhibitor ARRY-382</VALIDVALUE>
          <VALUEMEANING>cFMS Tyrosine Kinase Inhibitor ARRY-382</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; cFMS) with potential antineoplastic activity. cFMS tyrosine kinase inhibitor ARRY-382 binds to and inhibits the activity of cFMS. By preventing colony-stimulating factor-1 (CSF-1)-cFMS signaling, this agent may inhibit tumor cell proliferation in cFMS-overexpressing tumor cells. cFMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chaparrin</VALIDVALUE>
          <VALUEMEANING>Chaparrin</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from Simaba cedron and other plant species with potential antineoplastic activity.  Chaparrin is a mixture of compounds that includes flavonoids, antioxidants, and nordihydroguaiaretic acid (NDGA).  NDGA is an antioxidant and lipoxygenase inhibitor that promotes cell differentiation, induces G1 phase cell-cycle arrest, and causes apoptosis in certain cancer cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cevipabulin</VALIDVALUE>
          <VALUEMEANING>Cevipabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chaparrinone</VALIDVALUE>
          <VALUEMEANING>Chaparrinone</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from Ailanthus integrifolia sp. calycina and other plant species with potential antineoplastic activity.  Chaparrinone inhibits protein synthesis, has antimalarial properties, and is cytotoxic to some tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Checkpoint Kinase Inhibitor AZD7762</VALIDVALUE>
          <VALUEMEANING>Checkpoint Kinase Inhibitor AZD7762</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Checkpoint Kinase Inhibitor XL844</VALIDVALUE>
          <VALUEMEANING>Checkpoint Kinase Inhibitor XL844</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chk1 Inhibitor GDC-0425</VALIDVALUE>
          <VALUEMEANING>Chk1 Inhibitor GDC-0425</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor GDC-0425 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. GDC-0425 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chk1 Inhibitor GDC-0575</VALIDVALUE>
          <VALUEMEANING>Chk1 Inhibitor GDC-0575</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. Chk1 inhibitor GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis. Therefore, Chk1 inhibition may sensitize tumor cells to the DNA-damaging effects of certain chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that phosphorylates cdc25 phosphatases in response to DNA damage. This results in both inhibitory tyrosine phosphorylation of cyclin-dependent kinase (CDK)-cyclin complexes and cell cycle arrest, which facilitates DNA damage repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHK1 Inhibitor MK-8776</VALIDVALUE>
          <VALUEMEANING>CHK1 Inhibitor MK-8776</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. Chk1 inhibitor MK-8776 specifically binds to and inhibits Chk1, which may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases to undergo DNA repair prior to entry into mitosis; tumor cells may thus be sensitized to the DNA-damaging effects of ionizing radiation and alkylating chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that in response to DNA damage phosphorylates cdc25 phosphatases, resulting in inhibitory tyrosine phosphorylation of CDK-cyclin complexes and cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHK1 Inhibitor PF-477736</VALIDVALUE>
          <VALUEMEANING>CHK1 Inhibitor PF-477736</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3143932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chlorambucil</VALIDVALUE>
          <VALUEMEANING>Chlorambucil</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chlorodihydropyrimidine</VALIDVALUE>
          <VALUEMEANING>Chlorodihydropyrimidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrimidine derivative with antitumor activity. Chlorodihydropyrimidine competitively and reversibly inhibits dihydropyrimidine dehydrogenase, a rate-limiting enzyme in the catabolism of fluoropyrimidines thereby blocking the degradation of the fluoropyrimidines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2085</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ChiNing Decoction</VALIDVALUE>
          <VALUEMEANING>ChiNing Decoction</VALUEMEANING>
          <MEANINGDESCRIPTION>A decoction of Liang Ge San, a traditional Chinese herbal medicine, with potential anti-inflammatory and anti-stomatitis activities. Although the complete mechanism of action through which the ChiNing decoction works has yet to be fully elucidated, upon oral administration, the active ingredients may inhibit the inflammatory response, possibly by reducing the levels of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNFa), in the saliva. This may protect the oral mucosa against these inflammatory mediators, and may reduce and relieve radiation-induced stomatitis and the associated pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chloroquine</VALIDVALUE>
          <VALUEMEANING>Chloroquine</VALUEMEANING>
          <MEANINGDESCRIPTION>A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine&#39;s potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7850300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chloroquinoxaline Sulfonamide</VALIDVALUE>
          <VALUEMEANING>Chloroquinoxaline Sulfonamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A chlorinated heterocyclic sulfanilamide with potential antineoplastic activity and potential immunosuppressive activity.  Chloroquinoxaline sulfonamide poisons topoisomerase II alpha and topoisomerase II beta, thereby causing double-stranded breaks in DNA, accumulation of unrepaired DNA, and apoptosis.  This agent also exhibits lymphotoxicity by inhibiting lymphocyte activation in a cell cycle-specific manner. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chlorotoxin</VALIDVALUE>
          <VALUEMEANING>Chlorotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A neurotoxin with potential anticancer property. Chlorotoxin (CTX) is a 36-amino acid peptide found in the venom of the deathstalker scorpion, and a chloride channel blocker. This toxin binds preferentially to glioma cells via the transmembrane endopeptidase matrix metalloproteinase-2 (MMP-2), and thereby prevents the spread of tumor cells. MMP-2 is specifically up-regulated in gliomas and related cancers, but is not normally expressed in brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes</VALIDVALUE>
          <VALUEMEANING>Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of a CD28 co-stimulatory signaling domain fused to the zeta chain of the TCR/CD3 complex (CD3zeta), a truncated form of CD19 (CD19t), an immunoglobulin (Ig) G4-Fc (EQ) spacer, and a peptide derived from chlorotoxin (CLTX), with potential imaging and antineoplastic activities. Upon administration, chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes are re-directed to specific tumor cells in the brain inducing selective toxicity in these tumor cells. CLTX, a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) and a chloride channel blocker, preferentially binds to glioma (and other neuroectodermal origin) cells via membrane bound forms of the endopeptidase matrix metalloproteinase-2 (MMP-2). This may direct the T-lymphocytes to and induce selective toxicity in MMP-2-expressing tumor cells. Additionally, binding to MMP-2 on glioma cells may both interfere with transmembrane chloride exchange and inhibit proteolytic extracellular matrix remodeling by MMP-2, which may further limit the spread of these tumor cells. MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in brain. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling; its inclusion may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3 zeta chain alone. IgG4-Fc (EQ) contains two point mutations in its spacer region which prevents recognition of the CAR by Fc receptors (FcRs) without altering the ability of the CAR to mediate antigen-specific lysis. CD19t, which lacks the cytoplasmic signaling tail, provides a non-immunogenic surface marker that allows for accurate measurement, efficient cell tracking and/or imaging of the therapeutic T-cells in vivo following adoptive transfer. Additionally, co-expression of CD19t functions as a &quot;suicide&quot; switch via clinically available antibodies or immunotoxins which can be used to selectively eliminate the genetically modified cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chlorozotocin</VALIDVALUE>
          <VALUEMEANING>Chlorozotocin</VALUEMEANING>
          <MEANINGDESCRIPTION>A glucose-linked chloroethylnitrosourea with potential antineoplastic activity.  Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death.  This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models.  Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Choline Kinase Alpha Inhibitor TCD-717</VALIDVALUE>
          <VALUEMEANING>Choline Kinase Alpha Inhibitor TCD-717</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHP-NY-ESO-1 Peptide Vaccine IMF-001</VALIDVALUE>
          <VALUEMEANING>CHP-NY-ESO-1 Peptide Vaccine IMF-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein, with potential immunostimulating and antineoplastic activities.  Upon administration, CHP-NY-ESO-1 peptide vaccine IMF-001 may stimulate the host immune system to mount a humoral and cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. NY-ESO-1, an antigen found in normal testis, is upregulated in various cancers, including bladder, breast, hepatocellular, melanoma, and prostate cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chromomycin A3</VALIDVALUE>
          <VALUEMEANING>Chromomycin A3</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycosidic antineoplastic antibiotic isolated from the bacterium Streptomyces griseus.  Chromomycin A3 reversibly binds to guanine-cytosine (G-C) base pairs in the minor groove of DNA, thereby inhibiting RNA synthesis.  This agent is used as a fluorescent chromosome dye. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement</VALIDVALUE>
          <VALUEMEANING>PC-SPES</VALUEMEANING>
          <MEANINGDESCRIPTION>An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cidan Herbal Capsule</VALIDVALUE>
          <VALUEMEANING>Cidan Herbal Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule-based formulation containing artificial bezoar, Strychni pulveratum (strychnos powder), camphol alcohol (borneol or borneo camphor) and extracts from Zedoary rhizome (Rhizoma curcumae), Pseudobulbus cremastrae seu pleiones (dried pseudobulb of Cremastra appendiculata), Yatantzu (seed of Brucca javanica), beehive, Bombyx mori (Bombyx batryticatus or silkworm), Danshen (dried root of Salvia miltiorrhiza or red sage root), Radix astragali, and Angelica, with potential antineoplastic activity. Upon oral administration of the cidan herbal capsule, the active ingredients in the plant extracts may induce tumor cell apoptosis and reduce tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118451</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ciforadenant</VALIDVALUE>
          <VALUEMEANING>Ciforadenant</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cilengitide</VALIDVALUE>
          <VALUEMEANING>Cilengitide</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ciltacabtagene Autoleucel</VALIDVALUE>
          <VALUEMEANING>Ciltacabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7476588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cimetidine</VALIDVALUE>
          <VALUEMEANING>Cimetidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine&#39;s ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine&#39;s growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cibisatamab</VALIDVALUE>
          <VALUEMEANING>Cibisatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6847013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cinacalcet Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Cinacalcet Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cinobufagin</VALIDVALUE>
          <VALUEMEANING>Cinobufagin</VALUEMEANING>
          <MEANINGDESCRIPTION>A bufadienolide compound extracted from the dried venom secreted by the parotid glands of toads and one of the glycosides in the traditional Chinese medicine ChanSu, with potential antineoplastic activity. Although the mechanism of action of cinobufagin is still under investigation, it has been found to suppress cancer cell proliferation and cause apoptosis in cancer cells via a sequence of apoptotic modulators that include mitochondrial Bax and cytosolic chromosome c, and caspases 3, 8, and 9. Possible upstream mediators of cinobufagin-induced apoptosis include Fas and p53.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95021</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3855747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cinobufotalin</VALIDVALUE>
          <VALUEMEANING>Cinobufotalin</VALUEMEANING>
          <MEANINGDESCRIPTION>A bufadienolide isolated from toad venom and utilized in traditional Chinese medicine (TCM) for its cardiotonic, diuretic and hemostatic effects, with potential cytotoxic and antineoplastic activities. Upon administration and although the exact mechanism of action(s) (MoAs) through which this agent exerts its effects have yet to be fully discovered, cinobufotalin causes DNA fragmentation, decreases mitochondrial membrane potential (MMP), increases intracellular calcium (Ca2+) ion concentrations and reactive oxygen species (ROS) production, upregulates Fas protein and activates cytochrome C, various caspases, Bid and Bax. This causes cell cycle arrest, induces apoptosis and inhibits tumor cell growth and survival. In addition, cinobufotalin inhibits the activity of sphingosine kinase 1 (SphK1) and induces pro-apoptotic ceramide production, which further promotes tumor cell apoptosis. Cinobufotalin also induces mitochondrial protein cyclophilin D (Cyp-D)-dependent opening of the mitochondrial permeability transition pore (mPTP), which may contribute to cinobufotalin-induced non-apoptotic death of certain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cinrebafusp Alfa</VALIDVALUE>
          <VALUEMEANING>Cinrebafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cintredekin Besudotox</VALIDVALUE>
          <VALUEMEANING>Cintredekin Besudotox</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cisplatin</VALIDVALUE>
          <VALUEMEANING>Cisplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5544728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cisplatin Liposomal</VALIDVALUE>
          <VALUEMEANING>Cisplatin Liposomal</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids.  Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin&#39;s tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly.  Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6</VALIDVALUE>
          <VALUEMEANING>Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cisplatin-E Therapeutic Implant</VALIDVALUE>
          <VALUEMEANING>Cisplatin-E Therapeutic Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cintirorgon</VALIDVALUE>
          <VALUEMEANING>Cintirorgon</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). This may increase the expression of co-stimulatory molecules and decrease the expression of co-inhibitory molecules on T-cells leading to increased production of cytokines and chemokines by T-cells, decreased proliferation of regulatory T-cells (Tregs), and abrogation of tumor-induced immunosuppression. This ultimately induces a T-cell-mediated immune response against cancer cells and leads to a reduction in tumor cell growth. RORg, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cis-Urocanic Acid</VALIDVALUE>
          <VALUEMEANING>cis-Urocanic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the amino acid histidine, formed in the mammalian skin from trans-urocanic acid upon ultraviolet radiation, and protodynamic agent, with potential anti-inflammatory and antiproliferative activity. Upon intravesical instillation of cis-urocanic acid (cis-UCA), this agent is protonated at the imidazolyl moiety in the mildly acidic extracellular tumor environment and penetrates into the cancer cell. Once inside the cell and due to the slightly alkaline pH inside the tumor cell, cis-UCA is deprotonated, i.e. the imidazolyl proton is released into the cytosol which eventually raises the intracellular acidity. This acidification impairs many cellular processes, such as metabolic activity, and may lead to cell cycle arrest, an induction of cellular apoptosis and necrotic cell death. In addition, cis-UCA enhances ERK and JNK signaling pathways by inhibiting the activity of serine/threonine and tyrosine phosphatases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99125</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Citarinostat</VALIDVALUE>
          <VALUEMEANING>Citarinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, citarinostat inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121641</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Citatuzumab Bogatox</VALIDVALUE>
          <VALUEMEANING>Citatuzumab Bogatox</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a modified bouganin cytotoxin with potential antineoplastic activity. Citatuzumab bogatox binds to EpCAM, delivering modified bouganin cytotoxin directly to EpCam-positive tumor cells, which may result in the inhibition of tumor cell protein synthesis and tumor cell death. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Bouganin is a plant-derived ribosome-inactivating protein (RIP), a toxic plant N-glycosidase that depurinates the universally conserved alpha-sarcin loop of ribosomal rRNA, inactivating the ribosome and preventing protein synthesis. Compared to unmodified bouganins, modified bouganins may have a reduced propensity to activate human T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CK1alpha/CDK7/CDK9 Inhibitor BTX-A51</VALIDVALUE>
          <VALUEMEANING>CK1alpha/CDK7/CDK9 Inhibitor BTX-A51</VALUEMEANING>
          <MEANINGDESCRIPTION>The ditosylated salt of A51, an orally bioavailable inhibitor of casein kinase 1alpha (CK1alpha) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), with potential antineoplastic activity. Upon administration, BTX-A51 binds to and inhibits the activity of CK1alpha, CDK7, and CDK9. Blocking the phosphorylation and kinase activity of CK1alpha prevents the enhanced binding of murine double minute X (MDMX) to p53, the formation of CK1alpha and MDM2 complex, and the resulting inhibition of p53. This induces p53-mediated cell cycle arrest, slowing tumor cell proliferation. Blocking the phosphorylation and kinase activity of CDK7 and CDK9 prevents the positive transcription elongation factor b (PTEFb)-mediated activation of RNA polymerase II (RNA Pol II) and leads to the inhibition of gene transcription of various anti-apoptotic proteins. This also induces cell cycle arrest and apoptosis, slowing tumor cell proliferation. CK1alpha, a serine/threonine kinase and a leukemic stem cell target, acts as a tumor suppressor in several cancers through the negative regulation of Wnt/beta-catenin signaling and p53. It negatively regulates p53 by phosphorylating MDMX, thus enhancing binding of MDMX to p53, as well as by forming a complex with MDM2. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA Pol II. CDK9, also a serine/threonine kinase, regulates elongation of transcription through phosphorylation of RNA Pol II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of RNA Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169027</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CK2-targeting Synthetic Peptide CIGB-300</VALIDVALUE>
          <VALUEMEANING>CK2-targeting Synthetic Peptide CIGB-300</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2 substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CL 246738</VALIDVALUE>
          <VALUEMEANING>CL 246738</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunomodulator, 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride, used in a phase I study for possible immunostimulatory effects in colorectal cancer. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1052</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cladribine</VALIDVALUE>
          <VALUEMEANING>Cladribine</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2829877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clanfenur</VALIDVALUE>
          <VALUEMEANING>Clanfenur</VALUEMEANING>
          <MEANINGDESCRIPTION>A substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity. Upon administration, clanfenur binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clarithromycin</VALIDVALUE>
          <VALUEMEANING>Clarithromycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cixutumumab</VALIDVALUE>
          <VALUEMEANING>Cixutumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class 1/4 Histone Deacetylase Inhibitor OKI-179</VALIDVALUE>
          <VALUEMEANING>Class 1/4 Histone Deacetylase Inhibitor OKI-179</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the histone deacetylase (HDAC) subtypes 1 and 4, with potential antineoplastic activity. Upon administration, class 1/4 HDAC inhibitor OKI-179 targets, binds to and inhibits the activity of HDAC1/4. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This consequently results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC1/4. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins and plays a key role in transcriptional regulation and cell cycle progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clioquinol</VALIDVALUE>
          <VALUEMEANING>Clioquinol</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clivatuzumab</VALIDVALUE>
          <VALUEMEANING>Clivatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1, with potential antineoplastic activity. Clivatuzumab binds to tumor cells expressing the MUC1 antigen and prevents MUC1-mediated signaling. MUC1, a mucin antigen, is overexpressed in pancreatic cancer but not in normal, healthy pancreatic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clofarabine</VALIDVALUE>
          <VALUEMEANING>Clofarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5&#39;-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clomiphene</VALIDVALUE>
          <VALUEMEANING>Clomiphene</VALUEMEANING>
          <MEANINGDESCRIPTION>A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clomiphene Citrate</VALIDVALUE>
          <VALUEMEANING>Clomid</VALUEMEANING>
          <MEANINGDESCRIPTION>A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clostridium Novyi-NT Spores</VALIDVALUE>
          <VALUEMEANING>Clostridium Novyi-NT Spores</VALUEMEANING>
          <MEANINGDESCRIPTION>Spores of the bacterial strain Clostridium novyi-NT, the attenuated obligate anaerobic C. novyi, with potential immunostimulating, bacteriolytic, and antineoplastic activities. Upon intravenous administration, Clostridium novyi-NT spores germinate exclusively in hypoxic tissue, such as avascular regions of tumors. Germination results in lysis and destruction of surrounding viable tumor cells. Due to their anaerobic nature, C. novyi-NT spores do not proliferate in oxygenated tumor regions. However, this agent may stimulate the immune system to exert a cellular immune response, resulting in additional killing of tumor cells not lysed by the bacteria, including those in the well-oxygenated tumor area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor ABN401</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor ABN401</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, ABN401 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor AL2846</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor AL2846</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration AL2846 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clomesone</VALIDVALUE>
          <VALUEMEANING>Clomesone</VALUEMEANING>
          <MEANINGDESCRIPTION>The 2-chloroethyl ester of (methylsulfonyl) methanesulfonic acid with potential antineoplastic effects.  Acting as a chloroethylating agent, clomesone induces the formation of DNA interstrand crosslinks in some cell lines, and exhibits antitumor activity in some animal models.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor AMG 208</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor AMG 208</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor AMG 337</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor AMG 337</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor GST-HG161</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor GST-HG161</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor GST-HG161 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor JNJ-38877605</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor JNJ-38877605</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor MK2461</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor MK2461</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor MK2461 preferentially inhibits activated c-Met in an ATP-competitive manner, thereby inhibiting its tyrosine kinase activity, which may inhibit c-Met signaling and result in cell growth inhibition in tumors that overexpress c-Met. c-Met, encoding the hepatocyte growth factor receptor (HGFR) tyrosine kinase, plays an important role in tumor cell proliferation and has been shown to be overexpressed or mutated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor MK8033</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor MK8033</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits the autophosphorylation of the c-Met protein, which disrupts c-Met signal transduction pathways and may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. In addition, MK8033 inhibits Ron (receptor originated from nantes, MST1R). c-Met protein, which is encoded by the proto-oncogene MET, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Ron, a member of the Met family of cell surface receptor tyrosine kinases, is also overexpressed on certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C-myb Antisense Oligonucleotide G4460</VALIDVALUE>
          <VALUEMEANING>C-myb Antisense Oligonucleotide G4460</VALUEMEANING>
          <MEANINGDESCRIPTION>A 24-base phosphorothiolate antisense oligodeoxynucleotide (ODN) for the proto-oncogene c-myb with potential antineoplastic activity. C-myb antisense oligonucleotide G4460 binds to codon sequences 2 to 9 of c-myb mRNA, inhibiting translation of the transcript. Suppression of c-myb expression with this agent may result in the restoration of normal differentiation pathways, increased antiproliferative effects, and the induction of apoptosis in early progenitor hematopoietic cells and in tumor cells that overexpress c-myb. Tumor-cell overexpression of c-myb blocks differentiation, promotes proliferation, and inhibits apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cobimetinib</VALIDVALUE>
          <VALUEMEANING>MEK inhibitor GDC-0973</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cobolimab</VALIDVALUE>
          <VALUEMEANING>Cobolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor HS-10241</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor HS-10241</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cobomarsen</VALIDVALUE>
          <VALUEMEANING>Cobomarsen</VALUEMEANING>
          <MEANINGDESCRIPTION>A locked nucleic acid (LNA)-based oligonucleotide inhibitor of microRNA (miRNA) 155 (miR-155), with potential antineoplastic activity. Upon administration, cobomarsen targets, binds to and inhibits miR-155. This silences miR-155 and prevents the translation of certain tumor promoting genes, which leads to the induction of cancer cell apoptosis and the inhibition of tumor cell growth. miR-155, an oncogenic single-stranded, non-coding RNA that is critical to the regulation of gene expression, is overexpressed in certain tumor cell types. Up-regulation of miR-155 plays a key role in increased tumor cell proliferation and survival. The LNA is an RNA analog in which the ribose ring is locked in a particular confirmation that increases stability. Compared to the unmodified oligonucleotide, the LNA-modified oligonucleotide shows increased affinity for its target miR-155.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Codrituzumab</VALIDVALUE>
          <VALUEMEANING>Codrituzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80043</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coenzyme Q10</VALIDVALUE>
          <VALUEMEANING>Coenzyme-Q</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme-Q functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme-Q may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577820</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cofetuzumab Pelidotin</VALIDVALUE>
          <VALUEMEANING>Antibody-drug Conjugate PF-06647020</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of PF-06647020 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6199777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cold Contaminant-free Iobenguane I-131</VALIDVALUE>
          <VALUEMEANING>Cold Contaminant-free Iobenguane I-131</VALUEMEANING>
          <MEANINGDESCRIPTION>An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine, manufactured with a proprietary process, with radioisotopic and potential antineoplastic activities. Cold contaminant-free iobenguane I 131 (MIBG) localizes to adrenergic tissue and may be used to image or eradicate tumor cells that accumulate and metabolize norepinephrine. This agent is manufactured using a technology that avoids the production of unwanted &quot;cold contaminants&quot; (i.e., carrier molecules), which may cause undesirable side effects and compete with MIBG for binding on target receptor sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colloidal Gold-Bound Tumor Necrosis Factor</VALIDVALUE>
          <VALUEMEANING>Colloidal Gold-Bound Tumor Necrosis Factor</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colorectal Cancer Peptide Vaccine PolyPEPI1018</VALIDVALUE>
          <VALUEMEANING>Colorectal Cancer Peptide Vaccine PolyPEPI1018</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colorectal Tumor-Associated Peptides Vaccine IMA910</VALIDVALUE>
          <VALUEMEANING>Colorectal Tumor-Associated Peptides Vaccine IMA910</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tumor-associated peptide (TUMAP)-based cancer vaccine directed against colorectal cancer with potential immunostimulatory and antineoplastic activities. Synthetic colorectal tumor-associated peptides vaccine IMA910 contains 13 different synthetic TUMAPs, each of which represents a tumor associated antigen (TAA) specific for colorectal cancer. Upon administration, this agent may elicit a cytotoxic T-lymphocyte (CTL) response against colorectal tumors expressing these TAAs, which may result in a reduction in colorectal tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coltuximab Ravtansine</VALIDVALUE>
          <VALUEMEANING>Coltuximab Ravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Coltuximab ravtansine targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colchicine-Site Binding Agent ABT-751</VALIDVALUE>
          <VALUEMEANING>Colchicine-Site Binding Agent ABT-751</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antimitotic sulfonamide. ABT- 751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combretastatin</VALIDVALUE>
          <VALUEMEANING>Combretastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A stilbenoid phenol, originally isolated from the bark of the African bush willow tree Combretum caffrum, with vascular disrupting and antineoplastic activities. Combretastatin targets and binds to the colchicine-binding site of tubulin, thereby impairs the polymerization of tubulin dimers and prevents the formation of microtubules in the endothelial cells of tumor. As a result, this may eventually lead to a destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80014</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combretastatin A-1</VALIDVALUE>
          <VALUEMEANING>Combretastatin A-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A stilbenoid originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 (CA1) promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis; destruction of the tumor vasculature; disruption of tumor blood flow; and tumor cell necrosis. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combretastatin A1 Diphosphate</VALIDVALUE>
          <VALUEMEANING>Combretastatin A1 Diphosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 diphosphate (CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1), which promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production. CA1 binds to tubulin at the same site as colchicine but with higher affinity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Compound Kushen Injection</VALIDVALUE>
          <VALUEMEANING>Compound Kushen Injection</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) formulation composed of compound Kushen injection (CKI) containing aqueous extracts from the roots of Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma smilacis Glabrae), with potential antineoplastic and immunomodulating activities. CKI contains numerous chemicals including alkaloids, such as matrine and oxymatrine, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Although the exact mechanism(s) of action through which CKI exerts its effects has yet to be fully elucidated, CKI is able to interfere with the activation of various signal transduction pathways, such as the Wnt/beta-catenin signaling pathway, inhibit nuclear factor-kappa B (NF-KB) activation, and block the activity of multiple receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). CKI induces apoptosis in and inhibits proliferation, migration, invasion and adhesion of tumor cells. CKI also modulates the production of inflammatory mediators.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conatumumab</VALIDVALUE>
          <VALUEMEANING>Conatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conbercept</VALIDVALUE>
          <VALUEMEANING>Conbercept</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, soluble, vascular endothelial growth factor receptor (VEGFR) protein composed of the second immunoglobulin (Ig) domain of VEGFR-1, the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of human immunoglobulin G1 (IgG1) with potential anti-angiogenic activities. Upon intravitreal injection, conbercept, functioning as a soluble decoy receptor, binds with high affinity to all VEGF-A isoforms, VEGF-B, as well as placenta growth factor (PlGF)-1 and PlGF-2. This prevents the binding of these growth factors to their endogenous receptors, potentially inhibiting angiogenesis and tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Concentrated Lingzhi Mushroom Extract</VALIDVALUE>
          <VALUEMEANING>Concentrated Lingzhi Mushroom Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement and traditional Chinese medicine (TCM) composed of a highly concentrated extract of the fruiting body of the red reishi mushroom Ganoderma lucidum  (G. lucidum; lingzhi), with potential immunomodulating activities. Upon administration, the concentrated lingzhi mushroom extract may support the body&#39;s immune function and may support the immune system to eliminate tumor cells. The lingzhi mushroom extract contains high amounts of G. lucidum polysaccharides and G. lucidum triterpenoids (GLTs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copanlisib</VALIDVALUE>
          <VALUEMEANING>Copanlisib</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5982159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copper Cu 64-ATSM</VALIDVALUE>
          <VALUEMEANING>Copper Cu 64-ATSM</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of a lipophilic copper(II)bis(thiosemicarbazone) labeled with the positron- and beta-emitting isotope (64)Cu with hypoxia-selective and antineoplastic activities. With a high membrane permeability and redox potential, copper Cu 64-ATSM is preferentially taken up by hypoxic cells compared to normoxic cells; the extent of retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia by positron emission tomography (PET). In addition, the radioactive copper moiety of this agent may deliver a selective cytotoxic dose of beta radiation to hypoxic tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Commensal Bacterial Strain Formulation VE800</VALIDVALUE>
          <VALUEMEANING>Commensal Bacterial Strain Formulation VE800</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable formulation composed of eleven alive, distinct nonpathogenic, nontoxigenic, human commensal bacterial strains, isolated from healthy human donor feces, with potential immunostimulating and antineoplastic activities. Upon administration of the commensal bacterial strain formulation VE800, the bacterial strains induce an interferon-gamma (IFN-g)-producing CD8-positive T-cell-mediated immune response in the intestines. This may activate an IFN-g-expressing CD8+ T-cell -mediated anti-cancer immune response and may eradicate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copper Cu 67 Tyr3-octreotate</VALIDVALUE>
          <VALUEMEANING>Copper Cu 67 Tyr3-octreotate</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and radiolabeled with the beta-emitting radioisotope copper Cu 67, with potential antineoplastic activity. Upon administration, copper Cu 67 Tyr3-octreotate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copper Gluconate</VALIDVALUE>
          <VALUEMEANING>Copper Gluconate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable copper salt of D-gluconic acid. In addition to its roles as an enzyme cofactor for cytochrome C oxidase and superoxide dismutase, copper forms complexes with the thiocarbamate disulfiram (DSF) forming DSF-copper complexes, which enhances the DSF-mediated inhibition of the 26S proteasome; proteasome inhibition may result in inhibition of cellular protein degradation, cessation of cell cycle progression, inhibition of cellular proliferation, and the induction of apoptosis in susceptible tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cord Blood Derived CAR T-Cells</VALIDVALUE>
          <VALUEMEANING>Cord Blood Derived CAR T-Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of umbilical cord blood (CB)-derived T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the cord blood derived CAR T-cells, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cordycepin</VALIDVALUE>
          <VALUEMEANING>Cordycepin</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cordycepin Triphosphate</VALIDVALUE>
          <VALUEMEANING>Cordycepin Triphosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The triphosphate salt of cordycepin, a purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK), and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coriolus Versicolor Extract</VALIDVALUE>
          <VALUEMEANING>Coriolus Versicolor Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corticorelin Acetate</VALIDVALUE>
          <VALUEMEANING>Corticorelin Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt form of coticorelin, a synthetic peptide of neurohormone corticotropin-releasing factor (CRF), with potential antitumor and antiangiogenesis activities. Upon administration, corticorelin stimulates adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary gland. In turn, ACTH stimulates cortisol production from the adrenal cortex and is regulated by a negative feedback mechanism. Corticorelin appears to inhibit swelling around brain tumors through reduction in vascular leakage and maintenance of endothelial cell integrity. This agent potentially suppresses vascularization and tumor cell growth through reduction of vascular endothelial growth factor (VEGF) that appears to be via activation of corticotrophin-releasing factor receptor 2 (CRFR2), a G protein-coupled receptor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cortisone Acetate</VALIDVALUE>
          <VALUEMEANING>Cortisone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of Cortisone. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cosibelimab</VALIDVALUE>
          <VALUEMEANING>Cosibelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cord Blood-derived Expanded Natural Killer Cells PNK-007</VALIDVALUE>
          <VALUEMEANING>Cord Blood-derived Expanded Natural Killer Cells PNK-007</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of allogeneic lytic natural killer (NK) cells derived from human umbilical cord blood (UCB), with potential cytotoxic activity. Hematopoietic stem cells (HSC) are isolated from human UCB; this is followed by ex vivo differentiation into mature, highly lytic, NK cells, and expansion. Upon administration, the CB-derived expanded NK cells PNK-007 may lyse cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cositecan</VALIDVALUE>
          <VALUEMEANING>Cositecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug being studied in the treatment of cancer.  It belongs to a family of drugs called topoisomerase inhibitors. It is related to the anticancer drug camptothecin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CpG Oligodeoxynucleotide GNKG168</VALIDVALUE>
          <VALUEMEANING>CpG Oligodeoxynucleotide GNKG168</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-raf Antisense Oligonucleotide ISIS 5132</VALIDVALUE>
          <VALUEMEANING>ISIS 5132</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crenolanib</VALIDVALUE>
          <VALUEMEANING>Crenolanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. PDGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crenolanib Besylate</VALIDVALUE>
          <VALUEMEANING>Crenolanib Besylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crolibulin</VALIDVALUE>
          <VALUEMEANING>Crolibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Microtubulin inhibitor EPC2407 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of tubulin into microtubules, which may result in cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. As a vascular disruption agent (VDA), this agent also disrupts tumor neovascularization, which may result in a reduction in tumor blood flow and tumor hypoxia and ischemic necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cryptophycin</VALIDVALUE>
          <VALUEMEANING>Cryptophycin</VALUEMEANING>
          <MEANINGDESCRIPTION>The cryptophycins are a family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and induction of bcl-2 phosphorylation leading to apoptosis. Cryptophycins demonstrated activity against the wide spectrum of solid tumors including those that overexpress the multidrug resistance efflux pump P-glycoprotein. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cryptophycin 52</VALIDVALUE>
          <VALUEMEANING>Cryptophycin 52</VALUEMEANING>
          <MEANINGDESCRIPTION>A member of the cryptophycin family of antitumor agents that binds to microtubules, inducing growth arrest and apoptosis in solid tumors. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crystalline Genistein Formulation AXP107-11</VALIDVALUE>
          <VALUEMEANING>Crystalline Genistein Formulation AXP107-11</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available crystalline formulation of genistein, a soy-derived isoflavone and phytoestrogen with potential antineoplastic, chemosensitizing, and antioxidant activities. Similar to genistein, crystalline genistein formulation AXP107-11 increases expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. This agent also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits NF-kB activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, this crystalline formulation shows improved solubility and bioavailability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Crizotinib</VALIDVALUE>
          <VALUEMEANING>Crizotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF1R Inhibitor ABSK021</VALIDVALUE>
          <VALUEMEANING>CSF1R Inhibitor ABSK021</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, CSF1R inhibitor ABSK021 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF1R Inhibitor PLX73086</VALIDVALUE>
          <VALUEMEANING>CSF1R Inhibitor PLX73086</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antineoplastic activity. Upon administration, CSF1R inhibitor PLX73086 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activity of tumor-associated macrophages (TAMs) in the tumor tissue and prevents TAM-related tumor cell growth. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT2584 HMS</VALIDVALUE>
          <VALUEMEANING>CT2584 HMS</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid metabolism modulator which may inhibit angiogenesis, thereby possibly having antitumor activity. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CTLA-4-directed Probody BMS-986249</VALIDVALUE>
          <VALUEMEANING>CTLA-4-directed Probody BMS-986249</VALUEMEANING>
          <MEANINGDESCRIPTION>A probody composed of ipilimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of CTLA-4-directed probody BMS-986249, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986249 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110</VALIDVALUE>
          <VALUEMEANING>Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cusatuzumab</VALIDVALUE>
          <VALUEMEANING>Cusatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Custirsen Sodium</VALIDVALUE>
          <VALUEMEANING>Custirsen Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C-VISA BikDD:Liposome</VALIDVALUE>
          <VALUEMEANING>C-VISA BikDD:Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of DOTAP:cholesterol liposome nanoparticles complexed with the plasmid C-VISA BiKDD, with potential antineoplastic activity. C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16-GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR (cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene BikDD, a mutant form of the potent proapoptotic gene Bik (Bcl-2 interacting killer). Upon administration and transduction into pancreatic tumor cells, expression of BikDD by C-VISA BikDD:liposome may induce pancreatic tumor cell apoptosis and suppress pancreatic tumor cell proliferation. BikDD binds with greater affinity to anti-apoptotic proteins bcl-2, bcl-xl, bcl-w and Mcl-1 and is more potent than wild-type Bik. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at molar ratio of 1:1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXC Chemokine Receptor 2 Antagonist AZD5069</VALIDVALUE>
          <VALUEMEANING>CXC Chemokine Receptor 2 Antagonist AZD5069</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Curcumin</VALIDVALUE>
          <VALUEMEANING>Curcumin (Curcuma Longa, Turmeric Root, Wild Curcuma)</VALUEMEANING>
          <MEANINGDESCRIPTION>A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent&#39;s observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7675413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR1/2 Inhibitor SX-682</VALIDVALUE>
          <VALUEMEANING>CXCR1/2 Inhibitor SX-682</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8049068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR2 Antagonist QBM076</VALIDVALUE>
          <VALUEMEANING>CXCR2 Antagonist QBM076</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule antagonist of the G protein-coupled receptor, C-X-C motif chemokine receptor 2 (CXCR2), with potential immunomodulating and antineoplastic activities. Upon administration, QBM076 binds to and inhibits the activation of CXCR2, resulting in reduced neutrophil recruitment, myeloid-derived suppressor cell (MDSC) accumulation, and may potentially slow tumorigenesis and metastatic processes. CXCR2 is upregulated in a variety of cancer types, predominately in neutrophils/MDSCs rather than tumor cells, and is thought to contribute to tumor cell proliferation, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR4 Antagonist USL311</VALIDVALUE>
          <VALUEMEANING>CXCR4 Antagonist USL311</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, USL311 binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131534</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR4 Inhibitor Q-122</VALIDVALUE>
          <VALUEMEANING>CXCR4 Inhibitor Q-122</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74022</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR4/E-selectin Antagonist GMI-1359</VALIDVALUE>
          <VALUEMEANING>CXCR4/E-selectin Antagonist GMI-1359</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of both the C-X-C chemokine receptor type 4 (CXCR4) and E-selectin (CD62E), with potential antineoplastic activity. Upon administration, CXCR4/E-selectin antagonist GMI-1359 binds to both CXCR4 and E-selectin expressed on endothelial cells. The binding to CXCR4 prevents the binding of stromal-cell derived factor-1 (SDF-1; CXCL12) to CXCR4 and inhibits CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. The binding to E-selectin expressed on endothelial cells prevents their interaction with E-selectin ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis. Its overexpression has been associated with tumor angiogenesis and metastasis in several cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclin-dependent Kinase 8/19 Inhibitor BCD 115</VALIDVALUE>
          <VALUEMEANING>Cyclin-dependent Kinase 8/19 Inhibitor BCD 115</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor BCD 115 binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of certain tumor promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. CDK8 plays a key role in transcription regulation and is an important oncogenic driver in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclodisone</VALIDVALUE>
          <VALUEMEANING>Cyclodisone</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclic sulfonate ester with potential antineoplastic activity.  As an alkylating agent, clyclodisone induces the formation of DNA interstrand crosslinks, DNA strand breaks, and alkali-labile lesions in the DNA of some tumor cell lines.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cycloleucine</VALIDVALUE>
          <VALUEMEANING>Cycloleucine</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-metabolizable synthetic amino acid, formed through the cyclization of the amino acid leucine, with immunosuppressive, antineoplastic, and cytostatic activities. Cycloleucine competitively inhibits the enzyme methionine adenosyltransferase, resulting in the inhibition of S-adenosylmethionine (SAM) synthesis from methionine and ATP, and subsequent nucleic acid methylation and polyamine production; RNA, and perhaps to a lesser extent, DNA biosyntheses and cell cycle progression are finally disrupted. This agent is also a competitive inhibitor at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclopentenyl Cytosine</VALIDVALUE>
          <VALUEMEANING>Cyclopentenyl Cytosine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5&#39;-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CXCR4 Peptide Antagonist LY2510924</VALIDVALUE>
          <VALUEMEANING>CXCR4 Peptide Antagonist LY2510924</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclophosphamide</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclophosphamide Anhydrous</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of cyclophosphamide, a synthetic nitrogen mustard alkylating agent, with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to active metabolites including phosphoramide mustard, which binds to and crosslinks DNA and RNA, thereby inhibiting DNA replication and protein synthesis. This agent, at low doses, is also a potent immunosuppressant primarily by depleting T-regulatory cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYL-02 Plasmid DNA</VALIDVALUE>
          <VALUEMEANING>CYL-02 Plasmid DNA</VALUEMEANING>
          <MEANINGDESCRIPTION>A gene transfer preparation of a plasmid DNA encoding mouse somatostatin receptor subtype 2 (sst2) and a fusion protein of human deoxycytidine kinase (DCK) and uridine monophosphate kinase (UMK), complexed to a synthetic polycationic carrier, polyethylenimine, with antineoplastic adjuvant application. Upon administration, CYL-02 plasmid DNA expresses DCK::UMK fusion protein that converts gemcitabine into its toxic phosphorylated metabolite. Expression of sst2 protein by this agent could induce both antioncogenic and local antitumor bystander effects. A loss of sst2 gene expression often is found in pancreatic and colorectal cancers, and is the receptor for somatostatin which negatively regulates a number of processes such as epithelial cell proliferation. Combination effects of these gene products allows for less chemotherapy to cause tumor cell lysis in not only the original tumor, but in distant tumors as well.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYP11A1 Inhibitor ODM-209</VALIDVALUE>
          <VALUEMEANING>CYP11A1 Inhibitor ODM-209</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc)(CYP11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor ODM-209 targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit the proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-limiting step in steroid hormone biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172052</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYP17 Lyase Inhibitor ASN001</VALIDVALUE>
          <VALUEMEANING>CYP17 Lyase Inhibitor ASN001</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, CYP17 lyase inhibitor ASN001 selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands, resulting in a significant reduction in androgen production to castrate-range levels. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The selective inhibition of CYP17A1 lyase activity by ASN001 prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYP17/Androgen Receptor Inhibitor ODM 204</VALIDVALUE>
          <VALUEMEANING>CYP17/Androgen Receptor Inhibitor ODM 204</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of both the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17) and androgen receptor (AR), with potential anti-androgen and antineoplastic activities. Upon oral administration, CYP17/AR inhibitor ODM 204 selectively inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. In addition, ODM 204 binds to ARs in target tissues and inhibits androgen-induced receptor activation and AR nuclear translocation, which prevents the binding to and transcription of AR-responsive genes. This leads to an inhibition of growth in AR-expressing prostate cancer cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYP17/CYP11B2 Inhibitor LAE001</VALIDVALUE>
          <VALUEMEANING>CYP17 Inhibitor CFG920</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyproterone</VALIDVALUE>
          <VALUEMEANING>Cyproterone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic steroidal anti-androgen with antineoplastic activity. Cyproterone, in its acetate form, binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation and inhibiting the growth of testosterone-sensitive tumor cells.  This agent also exerts progesterogenic activity, resulting in a reduction in testicular androgen secretion and total androgen blockade. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyproterone Acetate</VALIDVALUE>
          <VALUEMEANING>Cyproterone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CYP11A1 inhibitor ODM-208</VALIDVALUE>
          <VALUEMEANING>CYP11A1 inhibitor ODM-208</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor ODM-208 targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytarabine</VALIDVALUE>
          <VALUEMEANING>Cytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that belongs to the family of drugs called antimetabolites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3270479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytarabine Monophosphate Prodrug MB07133</VALIDVALUE>
          <VALUEMEANING>Cytarabine Monophosphate Prodrug MB07133</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytochlor</VALIDVALUE>
          <VALUEMEANING>Cytochlor</VALUEMEANING>
          <MEANINGDESCRIPTION>A radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity.  Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase; deoxycytidine kinase and dCMP deaminase have been found in abnormally high concentrations in most cancers. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytokine-based Biologic Agent IRX-2</VALIDVALUE>
          <VALUEMEANING>Cytokine-based Biologic Agent IRX-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-free mixture comprised of a variety of naturally-derived cytokines obtained from normal, unrelated donor lymphocytes with potential immunostimulatory activity. The cytokines in IRX-2, including interleukin (IL)-1, -2, -6, -8, -10, -12, tumor necrosis factor alpha (TNF-a), interferon-gamma (IFN-g) and colony stimulating factors (CSFs), play vital roles in regulating cellular immunity and may synergistically stimulate a cellular immune response against tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DAB389 Epidermal Growth Factor</VALIDVALUE>
          <VALUEMEANING>DAB389 Epidermal Growth Factor</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein composed of the diphtheria toxin with the receptor-binding domain replaced by human epidermal growth factor (EGF).  When administered, EGF binds to the endothelial cell growth factor receptor, EGFR, which is upregulated in many solid tumors.  After binding to the EGF receptor, the agent is internalized by the cell, where the diphtheria toxin moiety exerts its cytotoxic effect, inhibiting protein synthesis through ADP-ribosylation of elongation factor 2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dabrafenib</VALIDVALUE>
          <VALUEMEANING>Dabrafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4539014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dabrafenib Mesylate</VALIDVALUE>
          <VALUEMEANING>Dabrafenib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dacarbazine</VALIDVALUE>
          <VALUEMEANING>Dacarbazine</VALUEMEANING>
          <MEANINGDESCRIPTION>A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dacetuzumab</VALIDVALUE>
          <VALUEMEANING>Dacetuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin&#39;s lymphoma, chronic lymphocytic leukemia, Hodgkin&#39;s disease and acute lymphoblastic leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62179</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3950197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DACH-Platin Micelle NC-4016</VALIDVALUE>
          <VALUEMEANING>DACH-Platin Micelle NC-4016</VALUEMEANING>
          <MEANINGDESCRIPTION>Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daclizumab</VALIDVALUE>
          <VALUEMEANING>Anti-CD25 (Zenapax, Daclizumab)</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5678504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dacomitinib</VALIDVALUE>
          <VALUEMEANING>Dacomitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dactinomycin</VALIDVALUE>
          <VALUEMEANING>Dactinomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dactolisib</VALIDVALUE>
          <VALUEMEANING>Dactolisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DACH Polymer Platinate AP5346</VALIDVALUE>
          <VALUEMEANING>DACH Polymer Platinate AP5346</VALUEMEANING>
          <MEANINGDESCRIPTION>A low molecular weight polymer-conjugated platinum complex with potential antineoplastic activity. This polymer drug delivery system consists of cytotoxic diaminocyclohexane (DACH)-platinum (Pt) coupled to a water-soluble biocompatible hydroxypropylmethacrylamide (HPMA) copolymer via a pH sensitive linker. Due to decreased pH at the tumor site, the linker is cleaved and the chelated active moiety DACH-Pt is released in tumor cells. DACH-Pt alkylates macromolecules and causes both inter- and intra-strand platinum-DNA crosslinks, which impede DNA replication and transcription, thereby resulting in cell-cycle independent cytotoxicity. The HPMA-based drug delivery system enhances the concentration of DACH-Pt at the tumor site and prolongs the half life of the agent, thereby increasing exposure and efficacy at the target tumor sites while minimizing side effects in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dactolisib Tosylate</VALIDVALUE>
          <VALUEMEANING>Dactolisib Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt form of dactolisib, an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Upon administration, dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dalantercept</VALIDVALUE>
          <VALUEMEANING>Dalantercept</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble fusion protein containing the extracellular domain of activin receptor-like kinase-1 (ALK1) fused to a human Fc domain (ALK1-Fc fusion protein), with potential antiangiogenic and antineoplastic activities. Upon administration, dalantercept binds to various ALK1 ligands, preventing activation of tumor cell ALK1 receptors and so inhibiting the ALK1 signaling pathway; growth factor-induced angiogenesis is thus inhibited, which may result in the inhibition of tumor cell proliferation and tumor cell death. ALK1 is a type I cell surface receptor with serine/threonine kinase activity that mediates signaling by members of the transforming growth factor-beta (TGFbeta) superfamily and plays a key role in angiogenesis; ligands for this receptor include TGFbeta1 and TGFbeta2. The Fc moiety of this fusion protein mediates clearance of ligand-fusion protein complexes by the reticuloendothelial system (RES).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88296</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dalotuzumab</VALIDVALUE>
          <VALUEMEANING>Dalotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF1R signaling has been highly implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74011</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daniquidone</VALIDVALUE>
          <VALUEMEANING>Daniquidone</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Danvatirsen</VALIDVALUE>
          <VALUEMEANING>Danvatirsen</VALUEMEANING>
          <MEANINGDESCRIPTION>An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daporinad</VALIDVALUE>
          <VALUEMEANING>Daporinad</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule with potential antineoplastic and antiangiogenic activities. Daporinad binds to and inhibits nicotinamide phosphoribosyltransferase (NMPRTase), inhibiting the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from niacinamide (vitamin B3), which may deplete energy reserves in metabolically active tumor cells and induce tumor cell apoptosis. In addition, this agent may inhibit tumor cell production of vascular endothelial growth factor (VEGF), resulting in the inhibition of tumor angiogenesis. The coenzyme NAD+ plays an essential role in cellular redox reactions, including the redox reaction linking the citric acid cycle and oxidative phosphorylation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67043</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daratumumab</VALIDVALUE>
          <VALUEMEANING>Daratumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daratumumab and Hyaluronidase-fihj</VALIDVALUE>
          <VALUEMEANING>Daratumumab and Hyaluronidase-fihj</VALUEMEANING>
          <MEANINGDESCRIPTION>A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Darinaparsin</VALIDVALUE>
          <VALUEMEANING>Darinaparsin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Danusertib</VALIDVALUE>
          <VALUEMEANING>Danusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. This agent may preferentially bind to and inhibit Aurora B kinase. Aurora kinases, a family of serine-threonine kinases, are important regulators of cellular proliferation and division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Darleukin</VALIDVALUE>
          <VALUEMEANING>Darleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of L19-IL2 monoclonal antibody-cytokine fusion protein binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 moiety may locally activate natural killer (NK) cells and macrophages, and may induce T cell cytotoxic immune responses against ED-B fibronectin-expressing tumor cells. This may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Darolutamide</VALIDVALUE>
          <VALUEMEANING>Darolutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daromun</VALIDVALUE>
          <VALUEMEANING>Daromun</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dasatinib</VALIDVALUE>
          <VALUEMEANING>Dasatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2737464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daunorubicin Citrate</VALIDVALUE>
          <VALUEMEANING>Daunorubicin Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic anthracycline glycoside antibiotic obtained from Streptomyces with antineoplastic activity. Daunorubicin citrate intercalates DNA, which leads to inhibition of DNA and RNA synthesis, and consequently blocks cell division and results in apoptosis. This anti-tumor antibiotic is most active in the S phase of cell division. Daunorubicin is indicated in the treatment of a wide variety of cancers including acute non-lymphocytic leukemia, non-Hodgkin lymphomas, Ewing&#39;s sarcoma, Wilms&#39; tumor, and chronic myelocytic leukemia. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daunorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Daunorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decitabine</VALIDVALUE>
          <VALUEMEANING>Decitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decitabine and Cedazuridine</VALIDVALUE>
          <VALUEMEANING>Decitabine and Cedazuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Defactinib</VALIDVALUE>
          <VALUEMEANING>Defactinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daunorubicin</VALIDVALUE>
          <VALUEMEANING>Daunorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62091</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Defactinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Defactinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of defactinib, an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deferoxamine</VALIDVALUE>
          <VALUEMEANING>Deferoxamine</VALUEMEANING>
          <MEANINGDESCRIPTION>An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7135786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deferoxamine Mesylate</VALIDVALUE>
          <VALUEMEANING>Deferoxamine Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Degarelix</VALIDVALUE>
          <VALUEMEANING>Degarelix</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3240855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Degarelix Acetate</VALIDVALUE>
          <VALUEMEANING>Degarelix Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5424692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delolimogene Mupadenorepvec</VALIDVALUE>
          <VALUEMEANING>Delolimogene Mupadenorepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Demcizumab</VALIDVALUE>
          <VALUEMEANING>Demcizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Demecolcine</VALIDVALUE>
          <VALUEMEANING>Demecolcine</VALUEMEANING>
          <MEANINGDESCRIPTION>A colchicine analog with potential antimitotic and antineoplastic activities. Demecolcine acid binds to the colchicine-binding site of tubulin, inhibiting its polymerization into microtubules, causing cell cycle arrest at metaphase and preventing cell division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Demplatin Pegraglumer</VALIDVALUE>
          <VALUEMEANING>Demplatin Pegraglumer</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity. In demplatin pegraglumer, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polyamino acids. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Delanzomib</VALIDVALUE>
          <VALUEMEANING>Delanzomib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466</VALIDVALUE>
          <VALUEMEANING>Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug-dendrimer conjugate composed of a B-cell lymphoma 2 (Bcl-2)/Bcl-XL inhibitor AZD4320 that is chemically conjugated to a proprietary 5-generation pegylated poly-lysine dendrimer via a hydrolytically labile linker, with potential pro-apoptotic and antineoplastic activities. Upon administration of AZD0466, AZD4320 is released through hydrolytic cleavage of the linker. AZD4320 is a Bcl2-homology domain 3 (BH3) mimetic that specifically binds to and inhibits the activity of the anti-apoptotic proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells. Bcl-2 and Bcl-XL, proteins belonging to the Bcl-2 family that are overexpressed in many cancers, play an important role in the negative regulation of apoptosis. Their expression in tumors is associated with increased drug resistance and cancer cell survival. The conjugation of AZD 4320 to the dendrimer construct may allow extended release of the agent, which may improve efficacy and lower toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dendritic Cell-Autologous Lung Tumor Vaccine</VALIDVALUE>
          <VALUEMEANING>Dendritic Cell-Autologous Lung Tumor Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells.  The dendritic cells are transduced with the gene encoding an antigen specific to the patient&#39;s cancer and then returned to the patient.  In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen.  Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dendritic Cell-targeting Lentiviral Vector ID-LV305</VALIDVALUE>
          <VALUEMEANING>Dendritic Cell-targeting Lentiviral Vector ID-LV305</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dengue Virus Adjuvant PV-001-DV</VALIDVALUE>
          <VALUEMEANING>Dengue Virus Adjuvant PV-001-DV</VALUEMEANING>
          <MEANINGDESCRIPTION>An attenuated strain of dengue virus that was originally developed as a potential preventative vaccine for dengue fever by the US Army as Dengue Virus-1 #45AZ5, with potential immunostimulating activity. Upon administration of dengue virus adjuvant PV-001-DV, the virus may activate both the innate and adaptive immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denibulin</VALIDVALUE>
          <VALUEMEANING>Denibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecular vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77065</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denibulin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Denibulin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of denibulin, a small molecular vascular disrupting agent, with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation., a small molecule vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activity. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells (EC), ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denileukin Diftitox</VALIDVALUE>
          <VALUEMEANING>Denileukin Diftitox</VALUEMEANING>
          <MEANINGDESCRIPTION>A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denintuzumab Mafodotin</VALIDVALUE>
          <VALUEMEANING>Denintuzumab Mafodotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases MMAF, which binds to tubulin and inhibits its polymerization. Inhibition of tubulin polymerization may result in G2/M phase arrest and tumor cell apoptosis. This causes inhibition of cell growth of CD19-expressing tumor cells. CD19, a B-cell antigen, is overexpressed by a variety of different cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105150</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denosumab</VALIDVALUE>
          <VALUEMEANING>Denosumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4882994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Denenicokin</VALIDVALUE>
          <VALUEMEANING>Wildtype</VALUEMEANING>
          <MEANINGDESCRIPTION>The naturally-occuring, normal, non-mutated version of a gene or genome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Depatuxizumab</VALIDVALUE>
          <VALUEMEANING>Depatuxizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. Depatuxizumab targets the EGFR deletion variant, de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization result in an inhibition in signal transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Depatuxizumab Mafodotin</VALIDVALUE>
          <VALUEMEANING>Depatuxizumab Mafodotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Derazantinib</VALIDVALUE>
          <VALUEMEANING>Derazantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deslorelin</VALIDVALUE>
          <VALUEMEANING>Deslorelin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3439554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Detirelix</VALIDVALUE>
          <VALUEMEANING>Detirelix</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Detorubicin</VALIDVALUE>
          <VALUEMEANING>Detorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Devimistat</VALIDVALUE>
          <VALUEMEANING>Devimistat</VALUEMEANING>
          <MEANINGDESCRIPTION>A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexamethasone</VALIDVALUE>
          <VALUEMEANING>Dexamethasone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexanabinol</VALIDVALUE>
          <VALUEMEANING>Dexanabinol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, terpene-based cannabinoid derivative devoid of cannabinoid receptors 1 and 2 agonist activity and with potential neuroprotective, antiinflammatory and antineoplastic activities. Functioning as an N-Methyl-D-aspartate (NMDA) receptor antagonist, dexanabinol protects neuronal cells against NMDA and glutamate neurotoxicity. This agent also scavenges peroxy radicals and protects neurons from the damages of reactive oxygen species. Furthermore, dexanabinol inhibits the activity of nuclear factor kappa B (NF-kB), thereby preventing the expression of NF-kB target genes, such as tumor necrosis factor alpha, cytokines and inducible nitric oxide synthase. As a result, this agent may restore apoptotic processes in cancerous cells. NF-kB is activated in a variety of cancer cells and plays a key role in the regulation of apoptosis and cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deslorelin Acetate</VALIDVALUE>
          <VALUEMEANING>Deslorelin Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexrazoxane</VALIDVALUE>
          <VALUEMEANING>Dexrazoxane</VALUEMEANING>
          <MEANINGDESCRIPTION>A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexrazoxane Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Dexrazoxane Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues.  This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dezaguanine</VALIDVALUE>
          <VALUEMEANING>Dezaguanine</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine nucleoside analogue with antineoplastic and antiviral activities.  By replacing guanine, dezaguanine incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dezaguanine Mesylate</VALIDVALUE>
          <VALUEMEANING>Dezaguanine Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of dezaguanine, a purine nucleoside analogue with antineoplastic and antiviral activities.  By competing with guanine, dezaguanine gets incorporated into DNA and inhibits DNA synthesis, thereby inducing cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DHA-Paclitaxel</VALIDVALUE>
          <VALUEMEANING>DHA-Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel.  Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).  DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DHEA Mustard</VALIDVALUE>
          <VALUEMEANING>DHEA Mustard</VALUEMEANING>
          <MEANINGDESCRIPTION>A steroidal alkylating agent with potential antineoplastic activity.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3270590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dianhydrogalactitol</VALIDVALUE>
          <VALUEMEANING>Dianhydrogalactitol</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diarylsulfonylurea Compound ILX-295501</VALIDVALUE>
          <VALUEMEANING>Diarylsulfonylurea Compound ILX-295501</VALUEMEANING>
          <MEANINGDESCRIPTION>ILX-295501 is a novel sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diazepinomicin</VALIDVALUE>
          <VALUEMEANING>Diazepinomicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A potent inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity. Diazepinomicin binds to and inhibits Ras kinase, thereby preventing the phosphorylation and activation of proteins downstream of the Ras signal transduction pathway, including serine/threonine kinase RAF (BRAF) and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK-2), that play a crucial role in regulating cell growth and survival. Diazepinomicin also selectively binds to the peripheral benzodiazepine receptor (BZRP), a receptor highly expressed in certain cancer cells, thus inducing cell cycle arrest and apoptosis in BZRP-expressing cells. In addition, diazepinomicin is able to cross the blood-brain barrier, thereby reaching therapeutic concentrations in the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dezapelisib</VALIDVALUE>
          <VALUEMEANING>Dezapelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diaziquone</VALIDVALUE>
          <VALUEMEANING>Diaziquone</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5&#39;-GNC-3&#39; sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diazooxonorleucine</VALIDVALUE>
          <VALUEMEANING>Diazooxonorleucine</VALUEMEANING>
          <MEANINGDESCRIPTION>An L-glutamine diazo analogue amino acid antibiotic isolated from a species of the bacterial genus Streptomyces with potential antineoplastic activity. Diazooxonorleucine inhibits several glutamine-dependent biosynthetic pathways involved in the syntheses of D-glucosamine phosphate, purines and pyrimidines. This agent inhibits phosphate-activated glutaminase, a key enzyme for the synthesis of releasable glutamine, depleting cells of this essential amino acid and reducing their capacity to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dibrospidium Chloride</VALIDVALUE>
          <VALUEMEANING>Dibrospidium Chloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A dispirotripiperazine derivative and alkylating agent with potential antineoplastic and anti-inflammatory activities. Dibrospidium chloride has been examined for the treatment of bone cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dichloroallyl Lawsone</VALIDVALUE>
          <VALUEMEANING>Dichloroallyl Lawsone</VALUEMEANING>
          <MEANINGDESCRIPTION>A triazine derivative with antineoplastic activity.  Dichloroallyl lawsone inhibits mitochondrial dihydroorotate dehydrogenase (DHOD), an enzyme that catalyzes the only redox step in de novo pyrimidine biosynthesis, and nucleotide (RNA and DNA) biosynthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dienogest</VALIDVALUE>
          <VALUEMEANING>Dienogest</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diethylnorspermine</VALIDVALUE>
          <VALUEMEANING>Diethylnorspermine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic bis-ethyl analogue of spermine with potential antineoplastic activity. N(1),N(11)-bis(ethyl)norspermine (DENSPM), a N-terminally alkylated tetraamine and polyamine mimetics, disrupts polyamine pool homeostasis by modulating the activities of the biosynthetic enzymes, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC). This agent also reduces polyamine concentrations through the induction of the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT). Polyamines, an integral part of the DNA helix structure, play a critical role in cell division, differentiation and membrane function. Disruption of normal polyamine concentrations by DENSPM may lead to cell growth inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Digitoxin</VALIDVALUE>
          <VALUEMEANING>Digitoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid soluble cardiac glycoside that inhibits the plasma membrane sodium potassium ATPase, leading to increased intracellular sodium and calcium levels and decreased intracellular potassium levels.  In studies increased intracellular calcium precedes cell death and decreased intracellular potassium increase caspase activation and DNA fragmentation, causing apoptosis and inhibition of cancer cell growth. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Digoxin</VALIDVALUE>
          <VALUEMEANING>Digoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dihydro-5-Azacytidine</VALIDVALUE>
          <VALUEMEANING>Dihydro-5-Azacytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dicycloplatin</VALIDVALUE>
          <VALUEMEANING>Dicycloplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dihydrolenperone</VALIDVALUE>
          <VALUEMEANING>Dihydrolenperone</VALUEMEANING>
          <MEANINGDESCRIPTION>A butyrophenone that has been investigated for antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diindolylmethane</VALIDVALUE>
          <VALUEMEANING>Diindolylmethane</VALUEMEANING>
          <MEANINGDESCRIPTION>A phytonutrient and plant indole found in cruciferous vegetables including broccoli, Brussels sprouts, cabbage, cauliflower and kale, with potential anti-androgenic and antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) promotes beneficial estrogen metabolism in both sexes by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of 2-hydroxy estrogen metabolites, resulting in increased antioxidant activity. Although this agent induces apoptosis in tumor cells in vitro, the exact mechanism by which DIM exhibits its antineoplastic activity in vivo is unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DI-Leu16-IL2 Immunocytokine</VALIDVALUE>
          <VALUEMEANING>DI-Leu16-IL2 Immunocytokine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein consisting of de-immunized and humanized anti-CD20 monoclonal antibody Leu16 fused to human cytokine interleukin-2 (IL2) with potential antineoplastic activity. The antibody moiety of DI-Leu16-IL2 immunocytokine binds to tumor cells expressing the CD20 antigen, which may result in an antibody-dependent cell-mediated cytotoxicity (ADCC) towards CD20-expressing tumor cells; the localized IL2 moiety of this fusion protein may stimulate natural killer (NK) and T-lymphocyte mediated immune responses, enhancing the ADCC response. De-immunization involves the modification of potential helper T cell epitopes that bind to MHC class II molecules; humanization involves combining recombinant murine variable (V) regions with human immunoglobulin light and heavy chain constant regions. CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes, is overexpressed by various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78451</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dimethylmyleran</VALIDVALUE>
          <VALUEMEANING>Dimethylmyleran</VALUEMEANING>
          <MEANINGDESCRIPTION>An aliphatic analogue of busulfan with potential antineoplastic activity.  As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dinaciclib</VALIDVALUE>
          <VALUEMEANING>Dinaciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dinutuximab</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody Ch14.18</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3597790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dioscorea nipponica Makino Extract DNE3</VALIDVALUE>
          <VALUEMEANING>Dioscorea nipponica Makino Extract DNE3</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract of the plant Dioscorea nipponica Makino and inhibitor of both the serine/threonine protein kinase Akt (protein kinase B) and members of the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, with potential antineoplastic and anti-metastatic activities. Dioscorea nipponica Makino extracted with ethyl acetate (DNE3) binds to and inhibits PI3K and Akt. This inhibits PI3K/Akt-mediated signaling and prevents both growth and survival of PI3K/Akt-overexpressing tumor cells. In addition, DNE3 increases the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), inhibits the secretion of matrix metalloproteinases (MMPs), primarily MMP-2 and MMP-9, and inhibits the serine protease urokinase (urokinase-type plasminogen activator; u-PA). This inhibits tumor cell invasion, migration, motility, and adhesion. This agent also inhibits the activation of both cAMP response element-binding (CREB) and activating protein-1 (AP-1), and increases the expression of IkappaB (IkB), which inhibits the activation of nuclear factor-kappa B (NF-kB). These processes further contribute to this agent&#39;s anti-tumor potential in susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ditiocarb</VALIDVALUE>
          <VALUEMEANING>Ditiocarb</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015</VALIDVALUE>
          <VALUEMEANING>DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody directed against the cell surface-associated protein Cripto and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of DM4-conjugated anti-Cripto monoclonal antibody BIIB015 binds to the tumor associated antigen (TAA) Cripto; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of Cripto-expressing tumor cells. Constitutively expressed during embryogenesis, Cripto belongs to the EGF-CFC family of growth factor-like molecules and plays a key role in signaling pathways of certain transforming growth factor-beta superfamily members; as a TAA, Cripto is overexpressed in carcinomas such as those of the breast, ovary, stomach, lung, and pancreas while its expression is absent in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dilpacimab</VALIDVALUE>
          <VALUEMEANING>Dilpacimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A dual-specific, tetravalent immunoglobulin (Ig) G-like molecule targeting two as of yet not publicly known targets, with potential antineoplastic activity. The target-binding variable domains of two monoclonal antibodies, which are not publicly known, are combined, via linkers, to create the tetravalent, dual-targeting single agent ABT-165. Upon administration of dual variable domain immunoglobulin (DVD-Ig) ABT-165, the target-binding variable domains specifically recognize and simultaneously bind to their two antigens expressed on tumor cells. This may both prevent antigen-mediated signaling and lead to an inhibition of cellular proliferation in susceptible tumor cells. The antigen targets are overexpressed on certain tumor cell types. The DVD-Ig may have enhanced physicochemical and pharmacokinetic properties as compared to their antibody counterparts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D-methionine Formulation MRX-1024</VALIDVALUE>
          <VALUEMEANING>D-methionine Formulation MRX-1024</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary oral formulation of D-methionine with antioxidant and antimucositis activities. D-methionine formulation MRX-1024 may selectively protect the oral mucosa from the toxic effects of chemotherapy and radiation therapy without compromising antitumor activity. D-methionine may be converted into the L- isomer in vivo, particularly in instances of L-methionine deprivation; both isomers have antioxidant activity which may be due, in part, to their sulfur moieties and chelating properties. L-methionine, an essential amino acid, also may help to maintain the ratio of reduced glutathione to oxidized glutathione in cells undergoing oxidative stress and may provide a source of L-cysteine for glutathione synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Interference Oligonucleotide PNT2258</VALIDVALUE>
          <VALUEMEANING>DNA Interference Oligonucleotide PNT2258</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to untranscribed DNA sequence upstream of BCL2 promoters, thereby interfering with DNA replication and transcription of the BCL2 gene. This may promote and restore the apoptotic pathway in BCL2-overexpressing tumor cells. BCL2, an anti-apoptotic protein, is overexpressed in a wide variety of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Minor Groove Binding Agent SG2000</VALIDVALUE>
          <VALUEMEANING>DNA Minor Groove Binding Agent SG2000</VALUEMEANING>
          <MEANINGDESCRIPTION>A sequence-selective pyrrolobenzodiazepine (PBD) dimer with potential antineoplastic activity. Following intravenous administration, DNA minor groove binding agent SG2000 preferentially and covalently binds to purine-GATC-pyrimidine sequences, with the imine/carbinolamine moieties of SG2000 binding to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links and inhibits both DNA replication and gene transcription, which lead to the inhibition of cell growth. With a preference for binding to purine-GATC-pyrimidine sequences, SG2000 adducts do not appear to be susceptible to p53-mediated DNA excision repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151</VALIDVALUE>
          <VALUEMEANING>DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA-based combined formulation composed of INO-5150, DNA plasmids encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), and INO-9012, a plasmid DNA vaccine encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery of INO-5151 and electroporation of the PSA/PSMA DNA plasmid INO-5150, PSA and PSMA are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing PSA and PSMA, resulting in tumor cell lysis. Upon electroporation of the DNA plasmid encoding IL-12 INO-9012, IL-12 is translated in cells and the expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of INO-5150 alone. PSA and PSMA are overexpressed on a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Vaccine VB10.16</VALIDVALUE>
          <VALUEMEANING>DNA Vaccine VB10.16</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA-dependent Protein Kinase Inhibitor VX-984</VALIDVALUE>
          <VALUEMEANING>DNA-dependent Protein Kinase Inhibitor VX-984</VALUEMEANING>
          <MEANINGDESCRIPTION>An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, DNA-PK inhibitor VX-984 binds to and inhibits the catalytic subunit of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA-PK inhibitor AZD7648</VALIDVALUE>
          <VALUEMEANING>DNA-PK inhibitor AZD7648</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), with potential chemo/radiosensitizing and antineoplastic activites. Upon oral administration, DNA-PK inhibitor AZD7648 selectively targets, binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity leading to enhanced tumor cell death. AZD7648 may also increase the effect of poly(ADP-ribose) polymerase (PARP) inhibitors and may work as a monotherapy in tumors with high endogenous levels of DNA damage resulting from defects in other DNA repair pathways. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. DNA-PK plays a key role in the NHEJ pathway and DSB repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA-PK/PI3K-delta Inhibitor BR101801</VALIDVALUE>
          <VALUEMEANING>DNA-PK/PI3K-delta Inhibitor BR101801</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and immunomodulating activities. Upon oral administration, the DNA-PK/PI3K-delta inhibitor BR101801 inhibits the activity of both PI3K-delta and DNA-PK. This prevents PI3K-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K-overexpressing tumor cells. Specifically, since PI3K regulates c-myc expression, inhibition of PI3K signaling may lead to a decrease in proliferation of c-myc-expressing tumor cells. Also, by inhibiting the activity of DNA-PK, this agent interferes with the non-homologous end joining (NHEJ) process and prevents the repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity by inhibiting the ability of tumor cells to repair damaged DNA. The PI3K pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. In addition, BR101801 is able to decrease Tregs and increase CD8 lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172111</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA-PK/TOR Kinase Inhibitor CC-115</VALIDVALUE>
          <VALUEMEANING>DNA-PK/TOR Kinase Inhibitor CC-115</VALUEMEANING>
          <MEANINGDESCRIPTION>A dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. CC-115 binds to and inhibits the activity of DNA-PK and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR. DNA-PK, a serine/threonine kinase and a member of the PI3K-related kinase subfamily of protein kinases, is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway; mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457</VALIDVALUE>
          <VALUEMEANING>DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA-based combination immunotherapeutic, MEDI0457, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNMT1 Inhibitor NTX-301</VALIDVALUE>
          <VALUEMEANING>DNMT1 Inhibitor NTX-301</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human DNA methyltransferase 1 (DNMT1), with potential antineoplastic activity. Upon oral administration, DNMT1 inhibitor NTX-301 targets ad binds to DNMT1, thereby inhibiting the activity of DNMT1. This may prevent DNA methylation, induce DNA hypomethylation, and activate tumor suppressor genes silenced by hypermethylation. This may inhibit tumor cell proliferation. DNMT1, a member of the DNA methyltransferase (DNMT) family, plays an important role in maintaining the DNA methylation pattern. Dysregulation of DNMT1 has been associated with a number of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98</VALIDVALUE>
          <VALUEMEANING>MG 98</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3&#39; un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel</VALIDVALUE>
          <VALUEMEANING>Docetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Anhydrous</VALIDVALUE>
          <VALUEMEANING>Docetaxel Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of docetaxel, a semisynthetic side-chain analogue of paclitaxel with antineoplastic property. Docetaxel binds specifically to the beta-tubulin subunit of microtubules and thereby antagonizes the disassembly of the microtubule proteins. This results in the persistence of aberrant microtubule structures and results in cell-cycle arrest and subsequent cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Formulation CKD-810</VALIDVALUE>
          <VALUEMEANING>Docetaxel Formulation CKD-810</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Lipid Microspheres</VALIDVALUE>
          <VALUEMEANING>Docetaxel Lipid Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid microsphere (LM)-based formulation containing the poorly water soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which causes cell cycle arrest at the G2/M phase and leads to cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the LM formulation may enhance stability, improve efficacy and may reduce toxicity; this formulation does not contain toxic detergents needed to solubilize docetaxel which further improves its side effect profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Nanoparticle CPC634</VALIDVALUE>
          <VALUEMEANING>Docetaxel Nanoparticle CPC634</VALUEMEANING>
          <MEANINGDESCRIPTION>A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&#39;s vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel&#39;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Polymeric Micelles</VALIDVALUE>
          <VALUEMEANING>Docetaxel Polymeric Micelles</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&#39;s vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel&#39;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel/Ritonavir</VALIDVALUE>
          <VALUEMEANING>Docetaxel/Ritonavir</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable combination agent containing docetaxel, a second generation taxane, and ritonavir, a cytochrome P450 (CYP) 3A4 inhibitor, with potential enhanced antineoplastic activity. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  Docetaxel is metabolized by CYP3A4  enzymes which is inhibited by the presence of ritonavir. This increases the plasma concentration of docetaxel and may increase docetaxel&#39;s efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel Emulsion ANX-514</VALIDVALUE>
          <VALUEMEANING>Docetaxel Emulsion ANX-514</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable emulsion formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Docetaxel emulsion ANX-514 is formulated without polysorbate 80 or other detergents in order to reduce the incidence and severity of hypersensitivity reactions. In addition, the exclusion of polysorbate 80 in this formulation precludes foaming during the preparation process, thus facilitating preparation and administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78196</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel-loaded Nanopharmaceutical CRLX301</VALIDVALUE>
          <VALUEMEANING>Docetaxel-loaded Nanopharmaceutical CRLX301</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&#39;s vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel&#39;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Docetaxel-PNP</VALIDVALUE>
          <VALUEMEANING>Docetaxel-PNP</VALUEMEANING>
          <MEANINGDESCRIPTION>A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dociparstat sodium</VALIDVALUE>
          <VALUEMEANING>Dociparstat sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A heparin derivative in which the 2-O and 3-O sulfate groups of heparin are removed and that lacks anticoagulant activity, with potential anti-inflammatory, immodulatory and antineoplastic activities. Upon administration, dociparstat sodium binds to both chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) and CXC chemokine receptor 4 (CXCR4). This prevents the interaction of CXCL12 with CXCR4, blocks CXCR4 activation, and may result in decreased proliferation and migration in CXCR4-overexpressing tumor cells. In addition, inhibition of CXCL12/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into the blood.  In addition, dociparstat sodium prevents the interaction of the receptor for advanced glycation end-products (RAGE) with its ligands, including advanced glycation end-products (AGEs), Mac-1(CD11b/CD18), the nuclear pro-inflammatory protein high mobility group box protein-1 (HMGB-1), carboxymethyl lysine-bovine serum albumin (CML-BSA) and members of the S100 calgranulin family. In addition, this agent inhibits the enzymes heparanase, cathepsin G, and human leukocyte elastase, which are involved in inflammation and metastasis. Altogether, this may inhibit tumor cell invasiveness and metastasis. Dociparstat sodium also binds to platelet factor 4 (PF4 or CXCL4) and may prevent PF4&#39;s inhibitory effect on platelet production. This may increase platelet production. Unlike heparin, this agent does not induce heparin-induced thrombocytopenia (HIT). RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. CXCR4 is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family that plays an important role in chemotaxis, chemoresistance and angiogenesis, and is upregulated in several tumor cell types. The interaction between CXCL12/CXCR4 induces retention of hematopoietic cells in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dolastatin 15</VALIDVALUE>
          <VALUEMEANING>Dolastatin 15</VALUEMEANING>
          <MEANINGDESCRIPTION>A depsipeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Less potent than the structurally-related compound dolastatin 10, dolastatin 15 binds weakly to tubulin and blocks microtubule assembly, thereby inhibiting mitosis.  Dolastatin 15 also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Domatinostat</VALIDVALUE>
          <VALUEMEANING>Domatinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity. Domatinostat selectively binds to and inhibits class I HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the selective transcription of tumor suppressor genes, and the tumor suppressor protein-mediated inhibition of tumor cell division and eventually the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Donafenib</VALIDVALUE>
          <VALUEMEANING>Donafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, this agent may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Raf, a serine/threonine protein kinase, plays a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway. Deregulation of this pathway often results in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dostarlimab</VALIDVALUE>
          <VALUEMEANING>Dostarlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dovitinib</VALIDVALUE>
          <VALUEMEANING>Dovitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzimidazole-quinolinone compound and receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dovitinib Lactate</VALIDVALUE>
          <VALUEMEANING>Dovitinib Lactate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dolastatin 10</VALIDVALUE>
          <VALUEMEANING>Dolastatin 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis.  This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxazosin</VALIDVALUE>
          <VALUEMEANING>Doxazosin</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2830038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxercalciferol</VALIDVALUE>
          <VALUEMEANING>Doxercalciferol</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that is being studied in the prevention of recurrent prostate cancer. It belongs to the family of drugs called vitamin D analogs. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxifluridine</VALIDVALUE>
          <VALUEMEANING>Doxifluridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin</VALIDVALUE>
          <VALUEMEANING>Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2744954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5567088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation consisting of SQL70, a prodrug-activating biomaterial, and SQP33, a prodrug of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of SQ3370, which consists of the injection of SQL70 at the tumor site followed by the intravenous administration of SQ3370, the prodrug SQP33 binds to, through an as of yet not identifiable mechanism, to SQL70 at the tumor site. After binding, doxorubicin is released over a period of days, intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. Compared to the systemic administration of doxorubicin alone, SQ3370 may allow for higher and sustained delivery of active doxorubicin directly to the tumor, which may increase its efficacy and limit its off-site, systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167221</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin-Eluting Beads</VALIDVALUE>
          <VALUEMEANING>Doxorubicin-Eluting Beads</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin-HPMA Conjugate</VALIDVALUE>
          <VALUEMEANING>Doxorubicin-HPMA Conjugate</VALUEMEANING>
          <MEANINGDESCRIPTION>A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin-loaded EGFR-targeting Nanocells</VALIDVALUE>
          <VALUEMEANING>Doxorubicin-loaded EGFR-targeting Nanocells</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of doxorubicin-loaded EGFR-targeting nanocells, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of doxorubicin to tumor cells overexpressing EGFR. Upon endocytosis by the tumor cells, the nanocell is broken down and releases doxorubicin, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted delivery of doxorubicin improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell is a bacterially derived nanosphere; the bacterial components are unlikely to induce an immune response in the immunosuppressed tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin Prodrug L-377,202</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Prodrug L-377,202</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin.  This complex is hydrolyzed by the enzyme prostate-specific antigen (PSA), resulting in the formation of doxorubicin and leucine-doxorubicin.  Selective targeting of these drugs to prostate tumor cells occurs because the hydrolyzing PSA enzyme is localized to the prostate gland.  Doxorubicin and leucine-doxorubicin intercalate into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  These agents also produce toxic free-radical intermediates and interact with cell membrane lipids causing lipid peroxidation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Doxorubicin-Magnetic Targeted Carrier Complex</VALIDVALUE>
          <VALUEMEANING>Doxorubicin-Magnetic Targeted Carrier Complex</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the anthracycline antibiotic doxorubicin in which doxorubicin is bound to microscopic beads of activated carbon and iron as a magnetic-targeted carrier (MTC). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipids. Guided by the placement of a magnet on the body surface overlying a tumor site, the doxorubicin-MTC complex delivers doxorubicin directly to the tumor site, thereby targeting and prolonging the duration of doxorubicin-mediated cytotoxicity to the tumor bed while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DPT/BCG/Measles/Serratia/Pneumococcus Vaccine</VALIDVALUE>
          <VALUEMEANING>DPT/BCG/Measles/Serratia/Pneumococcus Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine</VALIDVALUE>
          <VALUEMEANING>DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), typhoid, Staphylococcus aureus, paratyphoid A and paratyphoid B, with potential immunostimulating activity. Subcutaneous administration of the DPT/typhoid/Staphylococcus aureus/paratyphoid A/paratyphoid B vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR5-targeting Tetrameric Nanobody Agonist TAS266</VALIDVALUE>
          <VALUEMEANING>DR5-targeting Tetrameric Nanobody Agonist TAS266</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dromostanolone Propionate</VALIDVALUE>
          <VALUEMEANING>Dromostanolone Propionate</VALUEMEANING>
          <MEANINGDESCRIPTION>The propionate salt form of dromostanolone, a synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects.  Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drozitumab</VALIDVALUE>
          <VALUEMEANING>Drozitumab</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555</VALIDVALUE>
          <VALUEMEANING>DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable combination of DTRMWXHS-12, a Bruton&#39;s tyrosine kinase (BTK) inhibitor, everolimus, a mammalian Target of Rapamycin (mTOR) inhibitor, and pomalidomide, an immunomodulatory drug (IMiD), that may be used for the treatment of B-cell malignancies. Upon oral administration of DTRM-555, the DTRMWXHS-12 component inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, and leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes. The everolimus component binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of mTOR, a key regulatory kinase. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway. The pomalidomide component may inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoiesis. The combination of a BTK inhibitor, an mTOR inhibitor and an IMiD may work synergistically to kill malignant B-cells and prevent drug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173999</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dual IGF-1R/InsR Inhibitor BMS-754807</VALIDVALUE>
          <VALUEMEANING>Dual IGF-1R/InsR Inhibitor BMS-754807</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases with potential antineoplastic activity. Dual IGF-IR/InsR inhibitor BMS-754807 binds reversibly to and inhibits the activities of IGF-1R and InsR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R and InsR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in mitogenesis, angiogenesis, and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74043</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dubermatinib</VALIDVALUE>
          <VALUEMEANING>Dubermatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7656772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DPX-E7 HPV Vaccine</VALIDVALUE>
          <VALUEMEANING>DPX-E7 HPV Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duborimycin</VALIDVALUE>
          <VALUEMEANING>Duborimycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Duborimycin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dulanermin</VALIDVALUE>
          <VALUEMEANING>Dulanermin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human soluble protein corresponding to amino acids 114-281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (RhApo2L/TRAIL) with potential antineoplastic activity. Dulanermin binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, also known as DR4 (death receptor 4) and DR5 (death receptor 5), are members of the TNF receptor family and are overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duligotuzumab</VALIDVALUE>
          <VALUEMEANING>Duligotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116628</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dupilumab</VALIDVALUE>
          <VALUEMEANING>Dupilumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dusigitumab</VALIDVALUE>
          <VALUEMEANING>Dusigitumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against insulin-like growth factors 1 and 2 (IGF-1/2) with potential antineoplastic activity. Dusigitumab inhibits IGF1- and IGF2-stimulated activation of membrane-bound IGF receptors and the subsequent triggering of proliferation and survival signaling pathways. This may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF1/2 ligands stimulate cell proliferation, enable oncogenic transformation, and suppress apoptosis; IGF1/2 signaling has been highly implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dUTPase/DPD Inhibitor TAS-114</VALIDVALUE>
          <VALUEMEANING>dUTPase/DPD Inhibitor TAS-114</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duvelisib</VALIDVALUE>
          <VALUEMEANING>Duvelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7464061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duvortuxizumab</VALIDVALUE>
          <VALUEMEANING>Duvortuxizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dynemicin</VALIDVALUE>
          <VALUEMEANING>Dynemicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antitumor antibiotic of the enediyne class. It has demonstrated high DNA cleavage activity in the presence of NADPH, antimicrobial and tumor growth-inhibiting properties. Dynemicin recognizes and cleaves conformationally flexible regions of DNA. It attacks bases at 3&#39;-side of purine residues such as 5&#39;-AG, 5&#39;-AT, and 5&#39;-GC sequences. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Durvalumab</VALIDVALUE>
          <VALUEMEANING>Durvalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5755432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dynemicin A</VALIDVALUE>
          <VALUEMEANING>Dynemicin A</VALUEMEANING>
          <MEANINGDESCRIPTION>An enediyne antineoplastic antibiotic hybrid containing an anthraquinone moiety isolated from the bacterium Micromonospora chersina.  The anthraquinone moiety intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in double-strand breaks in DNA, inhibition of DNA replication and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E2F1 Pathway Activator ARQ 171</VALIDVALUE>
          <VALUEMEANING>E2F1 Pathway Activator ARQ 171</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation E2F1 pathway activator with potential antineoplastic activity. ARQ 171 induces the expression of E2F transcription factor 1, thereby activating the E2F1-mediated checkpoint process. E2F1, down-regulated in cancer cells, regulates expression of genes involved in the cell cycle progression from G1 into S phase. The G1/S checkpoint process selectively induces cell cycle arrest in cancer cells with irreparable DNA damages and triggers subsequent apoptosis, while allowing cell division to proceed in cells without or with minor reparable DNA damage. As a result, this agent exerts anti-tumor activity through checkpoint activation independent of p53 mediated tumor suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EBNA-1 inhibitor VK-2019</VALIDVALUE>
          <VALUEMEANING>EBNA-1 inhibitor VK-2019</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) with potential antineoplastic activity. Upon administration, EBNA-1 inhibitor VK-2019 binds to EBNA-1 and inhibits EBNA-1 DNA binding activity. This disrupts the replication, maintenance and segregation of the Epstein-Barr virus (EBV) genome, which may lead to tumor cell death in EBV-associated malignancies. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ecromeximab</VALIDVALUE>
          <VALUEMEANING>Ecromeximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A low-fucose, human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity targeting at the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. Monoclonal antibody KW-2871 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. This agent is prepared by fusing murine immunoglobulin (Ig) light and heavy variable regions derived from the murine IgG3 antibody KM-641 to a human constant (Fc) region. The low fucose content of the oligosaccharide side chains of this antibody may enhance binding of the antibody Fc region to lymphocyte Fc receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edatrexate</VALIDVALUE>
          <VALUEMEANING>Edatrexate</VALUEMEANING>
          <MEANINGDESCRIPTION>A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edelfosine</VALIDVALUE>
          <VALUEMEANING>Edelfosine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analog of lysophosphatidylcholine, an ether lipid, possessing anti-leishmanial and antineoplastic activity.  The mechanism of action for edelfosine has not been fully elucidated.  Targeting cellular membranes, edelfosine modulates membrane permeability, membrane lipid composition, and phospholipid metabolism.  Edelfosine also inhibits the phosphatidylinositol 3 kinase (PI3K)-AKT/PKB survival pathway, possibly activating the pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  In addition, this agent inhibits protein kinase C, intracellular activation of the Fas/CD95 receptor, and intracellular acidification.  Anti-leishmanial activity may be due to inhibition of a glycosomal alkyl-specific-acylCoA acyltransferase. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edicotinib</VALIDVALUE>
          <VALUEMEANING>Edicotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edodekin alfa</VALIDVALUE>
          <VALUEMEANING>Edodekin alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity.  Edodekin alfa binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edotecarin</VALIDVALUE>
          <VALUEMEANING>Edotecarin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic indolocarbazole with antineoplastic activity. Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Echinomycin</VALIDVALUE>
          <VALUEMEANING>Echinomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A polypeptide quinoxaline antineoplastic antibiotic isolated from the bacterium Streptomyces echinatus.  Echinomycin intercalates into DNA at two locations simultaneously in a sequence-specific fashion, thereby inhibiting DNA replication and RNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Edrecolomab</VALIDVALUE>
          <VALUEMEANING>Edrecolomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body&#39;s immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6153886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EED Inhibitor MAK683</VALIDVALUE>
          <VALUEMEANING>EED Inhibitor MAK683</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon administration, MAK683 selectively binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). Disruption of the EED-EZH2 protein-protein interaction (PPI) results in a loss of H3K27me3-stimulated PRC2 activity and prevents H3K27 trimethylation. This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2-mutated and PRC2-dependent cancer cells. PRC2, a histone H3 lysine 27 methyltransferase and multi-protein complex comprised of EZH2, EED and suppressor of zeste 12 (SUZ12), plays a key role in gene regulation, especially during embryonic development. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in a variety of cancer cells. EED is essential for the histone methyltransferase activity of PRC2 because EED directly binds to H3K27me3.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Efatutazone</VALIDVALUE>
          <VALUEMEANING>Efatutazone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma thus inducing cell differentiation and apoptosis, leading to a reduction in cellular proliferation. PPAR-gamma is a nuclear hormone receptor and a ligand-activated transcription factor that controls the expression of genes involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Efatutazone Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Efatutazone Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The dihydrochloride salt of efatutazone, an orally bioavailable agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma, a nuclear hormone receptor and a ligand-activated transcription factor controling gene expression involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eflornithine</VALIDVALUE>
          <VALUEMEANING>Eflornithine</VALUEMEANING>
          <MEANINGDESCRIPTION>A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7743034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eflornithine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Eflornithine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride form of eflornithine, a difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eftilagimod Alpha</VALIDVALUE>
          <VALUEMEANING>Eftilagimod Alpha</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell immunostimulatory factor, derived from the soluble form of the lymphocyte-activation gene 3 (LAG-3) protein, with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, eftilagimod alpha binds with high affinity to MHC class II molecules expressed by dendritic cells (DC), potentially resulting in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eftozanermin Alfa</VALIDVALUE>
          <VALUEMEANING>Eftozanermin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205</VALIDVALUE>
          <VALUEMEANING>Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of the human kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor 4SC-205 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein essential for the regulation of spindle dynamics, including assembly and maintenance, during mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Efizonerimod</VALIDVALUE>
          <VALUEMEANING>Efizonerimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621</VALIDVALUE>
          <VALUEMEANING>Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor ARQ 621 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein involved in the regulation of spindle dynamics, including assembly and maintenance, during mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGb761</VALIDVALUE>
          <VALUEMEANING>EGb761</VALUEMEANING>
          <MEANINGDESCRIPTION>A standardized ginkgo biloba extract with antioxidant and neuroprotective activities.  EGb761 has been shown to inhibit the proliferation of certain tumor cells in vitro. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Antagonist Hemay022</VALIDVALUE>
          <VALUEMEANING>EGFR Antagonist Hemay022</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, Hemay022 covalently binds to and inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Antisense DNA BB-401</VALIDVALUE>
          <VALUEMEANING>EGFR Antisense DNA BB-401</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, plasmid DNA expression vector encoding a 39 nucleotide (nt) short hairpin RNA (shRNA) specific for the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon intratumoral administration, the EGFR antisense DNA BB-401 is taken up by tumor cells and shRNA is transcribed. The shRNA is converted into small interfering RNA (siRNA) via the RNA interference (RNAi) pathway. The siRNA targets and binds to EGFR RNA expressed by tumor cells. This blocks EGFR mRNA translation and prevents EGFR protein expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Inhibitor TY-9591</VALIDVALUE>
          <VALUEMEANING>EGFR Inhibitor TY-9591</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of epidermal growth factor receptor (EGFR), including activating mutations, with potential antineoplastic activity. Upon administration, the EGFR inhibitor TY-9591 binds to and inhibits EGFR activating mutations, including the resistance mutation T790M, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Mutant-selective Inhibitor TQB3804</VALIDVALUE>
          <VALUEMEANING>EGFR Mutant-selective Inhibitor TQB3804</VALUEMEANING>
          <MEANINGDESCRIPTION>A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor TQB3804 binds to and inhibits the activity of mutant forms of EGFR, including the C797S EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. TQB3804 inhibits mutated forms of EGFR including C797S, which prevents covalent bond formation with third-generation EGFR inhibitor osimertinib leading to drug resistance. TQB3804 may have enhanced anti-tumor effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Mutant-specific Inhibitor CK-101</VALIDVALUE>
          <VALUEMEANING>EGFR Mutant-specific Inhibitor CK-101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor CK-101 specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CK-101 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132023</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Mutant-specific Inhibitor ZN-e4</VALIDVALUE>
          <VALUEMEANING>EGFR Mutant-specific Inhibitor ZN-e4</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR T790M Antagonist BPI-15086</VALIDVALUE>
          <VALUEMEANING>EGFR T790M Antagonist BPI-15086</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Inhibitor PD-168393</VALIDVALUE>
          <VALUEMEANING>EGFR Inhibitor PD-168393</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazolone compound with anti-tumor activity. PD-168393 is a cell-permeable, irreversible, and selective inhibitor of ligand-dependent epidermal growth factor (EGF) receptor (EGFR). This agent binds to the catalytic domain of EGFR with a 1:1 stoichiometry and inactivates the EGFR tyrosine kinase activity through alkylation of a cystine residue (Cys-773) within the ATP-binding pocket, thereby inhibiting proliferation of EGFR-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/EGFRvIII Inhibitor WSD0922-FU</VALIDVALUE>
          <VALUEMEANING>EGFR/EGFRvIII Inhibitor WSD0922-FU</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon administration of EGFR/EGFRvIII inhibitor WSD0922-FU, this agent is able to penetrate the BBB and specifically targets, binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors that are not able to penetrate the BBB, WSD0922-FU may have therapeutic benefits in brain tumors, such as glioblastoma (GBM) and metastatic CNS tumors. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/HER1/HER2 Inhibitor PKI166</VALIDVALUE>
          <VALUEMEANING>EGFR/HER1/HER2 Inhibitor PKI166</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolo-pyrimidine epidermal growth factor receptor (EGFR) protein kinase inhibitor with anti-tumor activity. PKI-166 reversibly inhibits HER1 and HER2 tyrosine kinases, belong to the epidermal growth factor receptor family, thereby inhibiting tumor growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/HER2 Inhibitor AV-412</VALIDVALUE>
          <VALUEMEANING>EGFR/HER2 Inhibitor AV-412</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/TGFb Fusion Monoclonal Antibody BCA101</VALIDVALUE>
          <VALUEMEANING>EGFR/TGFb Fusion Monoclonal Antibody BCA101</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration of EGFR/TGFb fusion monoclonal antibody BCA101, the anti-EGFR moiety targets, binds to and prevents activation of EGFR-mediated signaling. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. The anti-TGFb moiety targets and binds to TGFb, thereby preventing the activation of TGFb-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGFb is overactivated. EGFR and TGFb, mutated and/or overexpressed on the surfaces of various tumor cell types, play key roles in tumor cell proliferation and progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/VEGFR/RET Inhibitor HA121-28</VALIDVALUE>
          <VALUEMEANING>EGFR/VEGFR/RET Inhibitor HA121-28</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the epidermal growth factor receptor (EGFR), the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET) and vascular endothelial growth factor receptor (VEGFR), with potential anti-angiogenic and antineoplastic activities. Upon oral administration of HA121-28, this agent targets, binds to and inhibits the activity of EGFR, RET and VEGFR. This prevents EGFR-, RET- and VEGFR-mediated signaling, and may lead to the induction of apoptosis and inhibition of tumor growth in EGFR-, RET- and VEGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Dysregulation of RET activity plays a key role in the development and progression of a variety of cancers. Expression of VEGFR is upregulated in a variety of tumor cell types; it plays a key role in the migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eicosapentaenoic Acid</VALIDVALUE>
          <VALUEMEANING>Eicosapentaenoic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An essential, polyunsaturated, 20-carbon omega-3 fatty acid with anti-inflammatory and potential antineoplastic and chemopreventive activities. Eicosapentaenoic acid (EPA) may activate caspase 3, resulting in apoptosis in susceptible tumor cell populations. In addition, this agent may inhibit cyclooxygenase-2 (COX-2), resulting in inhibition of prostaglandin synthesis and prostaglandin-mediated inflammatory processes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3638077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eIF4E Antisense Oligonucleotide ISIS 183750</VALIDVALUE>
          <VALUEMEANING>eIF4E Antisense Oligonucleotide ISIS 183750</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation antisense oligonucleotide targeting the eukaryotic translation initiation factor 4E (eIF4E) with potential antitumor activity. Antisense oligonucleotide ISIS EIF4ERx suppresses the expression of eIF4E in fast dividing tumor cells. Blocking the expression of eIF4E results in inhibition of the synthesis of tumor angiogenic factors, thereby leading to the inhibition of cellular proliferation and apoptosis in tumor cells. eIF4E is overexpressed in a variety of cancers, is involved in the mRNA-ribosome binding step of eukaryotic protein synthesis and is the rate-limiting component of the eukaryotic translation apparatus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elacestrant</VALIDVALUE>
          <VALUEMEANING>Elacestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elacytarabine</VALIDVALUE>
          <VALUEMEANING>Elacytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>The lipophilic 5&#39;-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, elacytarabine is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, elacytarabine shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/HER2 Kinase Inhibitor TAK-285</VALIDVALUE>
          <VALUEMEANING>EGFR/HER2 Kinase Inhibitor TAK-285</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier (BBB) and does not appear to be a substrate for efflux pumps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elagolix</VALIDVALUE>
          <VALUEMEANING>Elagolix</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, second-generation, non-peptide based, small molecule compound and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, elagolix competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. In women, inhibition of FSH and LH prevents the production of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms of sex hormone-dependent disease states.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elesclomol</VALIDVALUE>
          <VALUEMEANING>Elesclomol</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elesclomol Sodium</VALIDVALUE>
          <VALUEMEANING>Elesclomol Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The water soluble sodium salt of a small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elinafide</VALIDVALUE>
          <VALUEMEANING>Elinafide</VALUEMEANING>
          <MEANINGDESCRIPTION>A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elisidepsin</VALIDVALUE>
          <VALUEMEANING>Elisidepsin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cyclic depsipeptide of the kahalalides family with potential antineoplastic activity. PM02734 is a derivative of a natural marine compound extracted from the sacoglossan sea slug, Elysia rufescens. Although the exact mechanism of action has yet to be elucidated, elisidepsin exhibits anti-proliferative activity in a wide variety of cancer types, such as breast, colon, pancreas, lung, and prostate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elliptinium</VALIDVALUE>
          <VALUEMEANING>Elliptinium</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elliptinium Acetate</VALIDVALUE>
          <VALUEMEANING>Elliptinium Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>Acetate salt of elliptinium, a derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elmustine</VALIDVALUE>
          <VALUEMEANING>Elmustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A (2-chloroethy1)nitrosourea derivative related to carmustine, with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elotuzumab</VALIDVALUE>
          <VALUEMEANING>Elotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elgemtumab</VALIDVALUE>
          <VALUEMEANING>Elgemtumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Elgemtumab binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elpamotide</VALIDVALUE>
          <VALUEMEANING>Elpamotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74090</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elsamitrucin</VALIDVALUE>
          <VALUEMEANING>Elsamitrucin</VALUEMEANING>
          <MEANINGDESCRIPTION>An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6153884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eltanexor</VALIDVALUE>
          <VALUEMEANING>Eltanexor</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic activity. Upon administration, eltanexor binds to the XPO1 cargo binding site, which prevents the XPO1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p73, BRCA1/2, pRB, FOXO, and other growth regulatory proteins and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), KPT-8602 restores the nuclear localization and function of tumor suppressing proteins which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The export of tumor suppressor proteins into the cytoplasm prevents them from initiating apoptosis and leads to uncontrolled tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emactuzumab</VALIDVALUE>
          <VALUEMEANING>Emactuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities. Upon administration, emactuzumab binds to CSF1R expressed on macrophages and inhibits the binding of colony-stimulating factor-1 (CSF-1) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells, which blocks the production of inflammatory mediators by macrophages and reduces inflammation. By blocking both the activity of CSF1R-dependent tumor-associated macrophages (TAMs) and the recruitment of TAMs to the tumor microenvironment, emactuzumab enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emibetuzumab</VALIDVALUE>
          <VALUEMEANING>Emibetuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Emibetuzumab binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emitefur</VALIDVALUE>
          <VALUEMEANING>Emitefur</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU&#39;s concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1022</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emofolin Sodium</VALIDVALUE>
          <VALUEMEANING>Emofolin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of a synthetic antimetabolite analogue of folate with antineoplastic activity.  Emfolin sodium competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, depletion of nucleotide pools, and inhibition of DNA, RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29019</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Empesertib</VALIDVALUE>
          <VALUEMEANING>Empesertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, empesertib binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116074</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enadenotucirev</VALIDVALUE>
          <VALUEMEANING>Enadenotucirev</VALUEMEANING>
          <MEANINGDESCRIPTION>A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain (E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes. Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches the tumor cells due to the leaky tumor vasculature and replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although the cancer-selectivity of enadenotucirev is not entirely understood, the virus does not efficiently infect normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113786</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emepepimut-S</VALIDVALUE>
          <VALUEMEANING>Emepepimut-S</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A</VALIDVALUE>
          <VALUEMEANING>Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic adenoviral vector, enadenotucirev (EnAd), that expresses a full-length agonistic anti-CD40 monoclonal antibody, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of NG-350A, enadenotucirev specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses the agonistic anti-CD40 antibody. The locally expressed anti-CD40 antibody targets and binds to CD40 on a variety of immune cells, including B-cells, T-cells and dendritic cells (DCs) in the tumor microenvironment (TME). This induces CD40-dependent signaling pathways, which activates these immune cells and induces a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response and leads to tumor cell death. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641</VALIDVALUE>
          <VALUEMEANING>Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic adenoviral vector, a transgene-modified variant of enadenotucirev (EnAd), that expresses a bi-specific T-cell activator molecule FAP-TAc together with immune enhancer molecules C-X-C motif chemokine 9 (CXCL9), C-X-C motif chemokine 10 (CXCL10) and interferon alpha (IFNalpha), with potential immunomodulating and antineoplastic activities. Upon administration of NG-641, EnAd specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses FAP-TAc. The locally expressed FAP-TAc targets and binds to both fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T-cells. This leads to T-cell activation and T-cell mediated killing of CAFs in tumor stroma. NG-641 also encodes the transgenes CXCL9, CXCL10 and IFNalpha. The production of CXCL9, CXCL10 and IFNalpha leads to the recruitment and further activation of T-cells, enhancing the overall immune response and cancer cell killing. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enasidenib</VALIDVALUE>
          <VALUEMEANING>Enasidenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encapsulated Rapamycin</VALIDVALUE>
          <VALUEMEANING>Encapsulated Rapamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable nanoparticle-based formulation composed of sub-micron particles of the macrolide antibiotic rapamycin incorporated into a pH-sensitive poly(methyl methacrylate) polymer, with potential immunomodulating and antineoplastic activities. Upon oral administration of the encapsulated rapamycin, the nanoparticle specifically delivers rapamycin at the tumor site. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR), a key regulatory kinase. This may suppress mTORC1 activity. In addition, inhibition of mTOR may modulate central memory CD8 T cells, CD3+/CD56+ natural killer (NK) cells and CD8 T-cell responses. This may kill tumor cells. Compared to the administration of rapamycin alone, this formulation improves oral bioavailability of rapamycin with more consistent rapamycin levels, thereby allowing for administration of lower rapamycin dosage, which improves and minimizes rapamycin&#39;s toxicity. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encelimab</VALIDVALUE>
          <VALUEMEANING>Encelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enclomiphene</VALIDVALUE>
          <VALUEMEANING>Enclomiphene</VALUEMEANING>
          <MEANINGDESCRIPTION>The trans-isomer of clomiphene citrate (CC).  Enclomiphene has a higher rate of clearance and is less active than the cis-isomer, cis-clomiphene.  Clomiphene citrate has been evaluated for antineoplastic activity against breast cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enclomiphene Citrate</VALIDVALUE>
          <VALUEMEANING>Enclomiphene Citrate (Androxal)</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12093850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Encorafenib</VALIDVALUE>
          <VALUEMEANING>Encorafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7679543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endothelin Receptor Type A Antagonist YM598</VALIDVALUE>
          <VALUEMEANING>Endothelin Receptor Type A Antagonist YM598</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enavatuzumab</VALIDVALUE>
          <VALUEMEANING>Enavatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. Enavatuzumab binds to TWEAKR and inhibits TWEAK ligand binding and activation of NF-kappaB-mediated cytokine release, which may result in tumor cell apoptosis. TWEAKR is a cell-surface receptor with homology to tumor necrosis factor receptors. Upon binding with its ligand, TWEAKR has been shown to stimulate cytokine release and cell proliferation, migration, and survival; it may also promote apoptosis under some conditions. This receptor may be overexpressed in a variety of tumors including those of the pancreas, colon, lung, kidney, and breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enfortumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Enfortumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7775224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240</VALIDVALUE>
          <VALUEMEANING>Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf (OTS) red blood cells (RBCs) engineered to express both the co-stimulatory molecule tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a fusion protein composed of the trans-presented cytokine interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) (IL-15TP) with potential modulating and antineoplastic activities. CD34+ hematopoietic precursor cells (HPC) are collected by apheresis from a healthy O negative donor, purified, and engineered with a lentiviral vector to express 4-1BBL and IL-15TP. The cells are then further expanded and differentiated until the nucleus is ejected, resulting in a mature reticulocyte. Upon administration of the engineered red blood cells co-expressing 4-1BBL and IL-15TP RTX-240, the RBCs express both 4-1BBL and IL-15TP on their cell surfaces. 4-1BBL and IL-15TP bind to and subsequently induce the proliferation and activation of natural killer (NK) cells and T-cells. This enhances the secretion of cytokine interferon-gamma (IFN-g) and results in the induction of an anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Engineered Toxin Body Targeting CD38 TAK-169</VALIDVALUE>
          <VALUEMEANING>Engineered Toxin Body Targeting CD38 TAK-169</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered toxin body (ETB) containing a single chain variable fragment (scFv) from an antibody targeting the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) that is fused to a cytotoxic payload composed of the enzymatically active, de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the anti-CD38 scFv moiety of TAK-169 specifically targets and binds to CD38-expressing tumor cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and removes an adenine nucleobase from the 28S RNA component of the 60S ribosomal subunit.of ribosomes This prevents ribosome activity,  This inhibits protein synthesis and leads to apoptosis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Engineered Toxin Body Targeting HER2 MT-5111</VALIDVALUE>
          <VALUEMEANING>Engineered Toxin Body Targeting HER2 MT-5111</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered toxin body (ETB) composed of a single chain variable fragment (scFv) from an antibody targeting the human epidermal growth factor receptor 2 (HER2; HER-2), fused to the enzymatically active de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the scFv moiety of MT-5111 specifically targets and binds to a distinct epitope on HER2-expressing cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and leads to apoptosis in HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enloplatin</VALIDVALUE>
          <VALUEMEANING>Enloplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A platinum-based alkylating agent with antineoplastic activity. Although its pharmacokinetic properties are similar to that of carboplatin, enloplatin appears to be non-cross resistant with other platinum-based agents, such as cisplatin and carboplatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enoblituzumab</VALIDVALUE>
          <VALUEMEANING>Enoblituzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enobosarm</VALIDVALUE>
          <VALUEMEANING>Enobosarm</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-steroidal agent with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone&#39;s action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enoticumab</VALIDVALUE>
          <VALUEMEANING>Enoticumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. Enoticumab specifically binds to human DLL4, preventing its binding to Notch receptors and inhibiting Notch signaling, which may result in defective tumor vascularization and, so, the inhibition of tumor cell growth. DLL4 is the only Notch ligand selectively expressed on endothelial cells; DLL4/Notch signaling is required for the development of functional tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enpromate</VALIDVALUE>
          <VALUEMEANING>Enpromate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic acetylenic carbamate, an alkylating agent, with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83689</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eniluracil/5-FU Combination Tablet</VALIDVALUE>
          <VALUEMEANING>Eniluracil/5-FU Combination Tablet</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C11252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ensartinib</VALIDVALUE>
          <VALUEMEANING>Ensartinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ensituximab</VALIDVALUE>
          <VALUEMEANING>Ensituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody against human colorectal and pancreatic carcinoma-associated antigens (CPAAs) with potential immunomodulating and anti-tumor activities. Anti-CPAA monoclonal antibody NPC-1C binds to CPAAs, which may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cellular cytotoxicity (ADCC) response against CPAA-expressing tumor cells. CPAAs, cell surface proteins, are upregulated on colon and pancreatic tumor cells. NPC-1C contains the variable region of the heavy and light chain of murine NPC-1 and linked in-frame to constant regions of a human IgG1 isotype.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An enteric-coated orally bioavailable formulation of the hydrochloride salt of a small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8) with potential antineoplastic activity. The active ingredient in enteric-coated TRPM8 agonist D-3263 hydrochloride binds to and activates TRPM8, which may result in an increase in calcium and sodium entry; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and BPH. TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in benign prostatic hyperplasia (BPH) and in prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Entinostat</VALIDVALUE>
          <VALUEMEANING>Entinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Entolimod</VALIDVALUE>
          <VALUEMEANING>Entolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A polypeptide derived from the Salmonella filament protein flagellin with potential radioprotective and anticancer activities. As a toll-like receptor 5 (TLR5) agonist, entolimod binds to and activates TLR5 thereby stimulating tumor necrosis factor production and activating nuclear factor kappa B (NF-kB). This induces NF-kB-mediated signaling pathways and inhibits the induction of apoptosis. This may prevent apoptosis in normal, healthy cells during radiotherapy of cancerous cells and may allow for increased doses of ionizing radiation. In addition, entolimod may inhibit radiation-independent proliferation in TLR5-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Entospletinib</VALIDVALUE>
          <VALUEMEANING>Entospletinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Entrectinib</VALIDVALUE>
          <VALUEMEANING>Entrectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6617876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Envafolimab</VALIDVALUE>
          <VALUEMEANING>Envafolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enzalutamide</VALIDVALUE>
          <VALUEMEANING>Enzalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5424693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enterococcus gallinarum Strain MRx0518</VALIDVALUE>
          <VALUEMEANING>Enterococcus gallinarum Strain MRx0518</VALUEMEANING>
          <MEANINGDESCRIPTION>A live strain of the flagellin-producing Gram-positive bacterium Enterococcus (E.) gallinarum that is isolated from a healthy human gut, with potential immunomodulating and antineoplastic activities. Upon oral administration, MRx0518 modulates the intestinal microbiota and targets both intestinal epithelial cells (IECs), and various immune cells, such as macrophages and dendritic cells (DCs)  and is able to induce the production of both pro- and anti-inflammatory mediators, such as interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-a), IL-1beta, IL-6, IL-23, in these cells and activates the innate immune system. The flagellin produced by MRx0518 interacts with and activates toll-like receptor 5 (TLR5), thereby activating the adaptive immune system and modulating the tumor microenvironment (TME). This activates the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enzastaurin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Enzastaurin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EP2/EP4 Antagonist TPST-1495</VALIDVALUE>
          <VALUEMEANING>EP2/EP4 Antagonist TPST-1495</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, dual antagonist of the human prostaglandin E2 receptor subtypes 2 (EP2) and 4 (EP4), with potential immunomodulating and antineoplastic activities. Upon oral administration, the EP2/EP4 antagonist TPST-1495 selectively targets and binds to EP2 and EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP2 and EP4. This prevents the activation of EP2 and EP4, and inhibits PGE2-EP2/EP4-mediated signaling. This inhibits PGE2-driven immune suppression by preventing the PGE2-mediated inhibition of anti-tumor immune effector cells in the tumor microenvironment (TME), such as natural killer (NK) cells, T-lymphocytes, dendritic cells (DCs) and M1 macrophages, and blocking the PGE2-mediated increase in suppressive immune cells, such as myeloid derived suppressor cells (MDSCs), M2 macrophages, and regulatory T cells (Tregs). This inhibits the proliferation of tumor cells in which the PGE2-EP2/4 signaling pathway is over-activated. EP2 and EP4, G protein-coupled receptors (GPCRs) that are overexpressed in certain types of cancers, promote tumor cell proliferation, invasion, survival, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EP4 Antagonist INV-1120</VALIDVALUE>
          <VALUEMEANING>EP4 Antagonist INV-1120</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist INV-1120 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EP4 Antagonist ONO-4578</VALIDVALUE>
          <VALUEMEANING>EP4 Antagonist ONO-4578</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist ONO-4578 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epcoritamab</VALIDVALUE>
          <VALUEMEANING>Epcoritamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163022</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EphA2-targeting Bicycle Toxin Conjugate BT5528</VALIDVALUE>
          <VALUEMEANING>EphA2-targeting Bicycle Toxin Conjugate BT5528</VALUEMEANING>
          <MEANINGDESCRIPTION>A bicyclic peptide targeting Ephrin receptor A2 (EphA2) and conjugated, through an inert sarcosine spacer chain and a valine-citrulline cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon administration of the EphA2-targeting bicycle toxin conjugate BT5528, this agent targets and binds to EphA2-expressing tumor cells. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAE binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epipodophyllotoxin Analog GL331</VALIDVALUE>
          <VALUEMEANING>Epipodophyllotoxin Analog GL331</VALUEMEANING>
          <MEANINGDESCRIPTION>An epipodophyllotoxin analogue possessing antineoplastic properties.  GL331 binds to and inhibits topoisomerase II, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epipropidine</VALIDVALUE>
          <VALUEMEANING>Epipropidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An epoxide and alkylating agent with antineoplastic activity. Epipropidone is not used clinically due to its unstable nature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epirubicin</VALIDVALUE>
          <VALUEMEANING>Epirubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A 4&#39;-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62028</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2757913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epacadostat</VALIDVALUE>
          <VALUEMEANING>Epacadostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6199773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epirubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Epirubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The 4&#39;-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epitinib Succinate</VALIDVALUE>
          <VALUEMEANING>Epitinib Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The succinate salt form of epitinib, an orally available epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon administration, epitinib inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may lead to induction of cell death and inhibition of tumor growth in EGFR-overexpressing tumor cells. EGFR is a receptor tyrosine kinase (RTK) that is overexpressed in certain tumor types and plays a key role in tumor cell proliferation and vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epitiostanol</VALIDVALUE>
          <VALUEMEANING>Epitiostanol</VALUEMEANING>
          <MEANINGDESCRIPTION>An androgenic anabolic steroid having potent anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers such as breast cancer. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epothilone KOS-1584</VALIDVALUE>
          <VALUEMEANING>Epothilone KOS-1584</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation epothilone with potential antineoplastic activity. Epothilone KOS-1584 binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and efficacy with an enhanced pharmaceutical profile, including enhanced water solubility and tumor penetration, and reduced CNS exposure. In addition, epothilone KOS-1584 is a poor substrate for the P-glycoprotein (P-gp) drug efflux pump.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epratuzumab-cys-tesirine</VALIDVALUE>
          <VALUEMEANING>Epratuzumab-cys-tesirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERa36 Modulator Icaritin</VALIDVALUE>
          <VALUEMEANING>ERa36 Modulator Icaritin</VALUEMEANING>
          <MEANINGDESCRIPTION>A metabolite of icariin, a principal flavonoid glycoside in Herba Epimedii (a traditional Chinese medicine herb used in treating osteoporosis) with potential antineoplastic activity. ERa36 modulator icaritin selectively binds to a novel variant of estrogen receptor alpha, a36, and mediates a membrane-initiated &quot;nongenomic&quot; signaling pathway, which is linked to activate signaling pathways like the MAPK/ERK and the PI3K/Akt pathways. This agent induces cell cycle arrest at G1, or G2/M arrest depending upon the dose. Consistently with G1 arrest, icaritin increases protein expressions of pRb, p27(Kip1) and p16(Ink4a), while decreasing phosphorylated pRb, Cyclin D1 and CDK4. 40% of ER-negative breast cancer tumors express high levels of ERa36, and this subset of patients is less likely to benefit from tamoxifen treatment compared with those with ERa66-positive/ERa36-negative tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erastin Analogue PRLX 93936</VALIDVALUE>
          <VALUEMEANING>Erastin Analogue PRLX 93936</VALUEMEANING>
          <MEANINGDESCRIPTION>A structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erbulozole</VALIDVALUE>
          <VALUEMEANING>Erbulozole</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble congener of tubulozole and a tubulin binding agent with potential antimitotic and antineoplastic activities. Erbulozole targets and binds to tubulin, thereby preventing the polymerization of tubulin. This may lead to an inhibition of cell division and induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erdafitinib</VALIDVALUE>
          <VALUEMEANING>Erdafitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7775226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epratuzumab</VALIDVALUE>
          <VALUEMEANING>Epratuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab&#39;s predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eribulin</VALIDVALUE>
          <VALUEMEANING>Eribulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4311896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eribulin Mesylate</VALIDVALUE>
          <VALUEMEANING>Eribulin Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK 1/2 Inhibitor ASTX029</VALIDVALUE>
          <VALUEMEANING>ERK 1/2 Inhibitor ASTX029</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, ASTX029 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK Inhibitor CC-90003</VALIDVALUE>
          <VALUEMEANING>ERK Inhibitor CC-90003</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK1/2 Inhibitor HH2710</VALIDVALUE>
          <VALUEMEANING>ERK1/2 Inhibitor HH2710</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor HH2710 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK1/2 Inhibitor JSI-1187</VALIDVALUE>
          <VALUEMEANING>ERK1/2 Inhibitor JSI-1187</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor JSI-1187 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK1/2 Inhibitor KO-947</VALIDVALUE>
          <VALUEMEANING>ERK1/2 Inhibitor KO-947</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141074</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erlotinib</VALIDVALUE>
          <VALUEMEANING>Erlotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erlotinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Erlotinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5709521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK Inhibitor MK-8353</VALIDVALUE>
          <VALUEMEANING>ERK Inhibitor MK-8353</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, MK-8353 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways; thereby, preventing ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ertumaxomab</VALIDVALUE>
          <VALUEMEANING>Ertumaxomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth.  Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esorubicin</VALIDVALUE>
          <VALUEMEANING>Esorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Esorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A hydrochloride salt of esorubicin, a derivative of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esperamicin A1</VALIDVALUE>
          <VALUEMEANING>Esperamicin A1</VALUEMEANING>
          <MEANINGDESCRIPTION>An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety.  Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora.  The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Essiac</VALIDVALUE>
          <VALUEMEANING>Essiac</VALUEMEANING>
          <MEANINGDESCRIPTION>An herbal formula containing burdock root (Arctium lappa), Turkey rhubarb root (Rheum palmatum), sheep sorrel (Rumex acetosella), and slippery elm bark (Ulmus fulva) with potential immunostimulating, anti-inflammatory and anti-tumor activities. The extract&#39;s chemical profile, their respective concentrations and the mechanism of action of Essiac are largely unknown due to the proprietary nature of the formula and product inconsistency. Several chemical classes in Essiac are consistently represented and may attribute to its therapeutic effect, including anthraquinone derivatives such as rhein and emodin, high molecular polysaccharides, and lignans such as arctigenin. However, all these chemicals are unlikely to occur in high concentrations in Essiac, and its potential therapeutic effect may be attributed to a potential synergistic effect of these various compounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Estradiol Valerate</VALIDVALUE>
          <VALUEMEANING>Estradiol Valerate</VALUEMEANING>
          <MEANINGDESCRIPTION>The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1090</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Estramustine</VALIDVALUE>
          <VALUEMEANING>Estramustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Estramustine Phosphate Sodium</VALIDVALUE>
          <VALUEMEANING>Estramustine Phosphate Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6153879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Estrogen Receptor Agonist GTx-758</VALIDVALUE>
          <VALUEMEANING>Estrogen Receptor Agonist GTx-758</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, nonsteroidal selective estrogen receptor (ER) alpha agonist with potential antineoplastic activity. Upon administration of GTx-758, this agent suppresses the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the pituitary gland through feedback inhibition. In males, the inhibition of LH secretion prevents the synthesis of androgens, including testosterone, by the testes. This may result in suppressed total serum testosterone to the levels observed in castration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etalocib</VALIDVALUE>
          <VALUEMEANING>Etalocib</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etanidazole</VALIDVALUE>
          <VALUEMEANING>Etanidazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etaracizumab</VALIDVALUE>
          <VALUEMEANING>Etaracizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Etaracizumab blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etarotene</VALIDVALUE>
          <VALUEMEANING>Etarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>An ethylsulfonyl derivative of arotinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, etarotene binds to and activates retinoic acid receptors (RARs), thereby inducing changes in the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethaselen</VALIDVALUE>
          <VALUEMEANING>Ethaselen</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable organoselenium inhibitor of thioredoxin reductase 1 (TrxR1), with potential antineoplastic activity. Upon oral administration, ethaselen specifically binds to the selenocysteine-cysteine redox pair in the C-terminal active site of TrxR1 and inhibits its activity, which may result in growth inhibition and the induction of apoptosis in TrxR1 overexpressing tumor cells. TrxR1, upregulated in many cancer cell types, plays a key role in various redox-dependent cellular pathways, regulates transcription factor activity, inhibits apoptosis, and promotes cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etanercept</VALIDVALUE>
          <VALUEMEANING>Anti-TNF (Etanercept, Embrel)</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5678501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethinyl Estradiol</VALIDVALUE>
          <VALUEMEANING>Ethinyl Estradiol</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576830</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethyleneimine</VALIDVALUE>
          <VALUEMEANING>Ethyleneimine</VALUEMEANING>
          <MEANINGDESCRIPTION>A monofunctional alkylating agent with potential antineoplastic activity.  Reacting with DNA mainly at guanine and adenine residues, ethylenimine alkylates DNA, thereby producing DNA interstrand crosslinks and DNA breaks, and interfering with DNA replication and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethylnitrosourea</VALIDVALUE>
          <VALUEMEANING>Ethylnitrosourea</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitrosourea with potential antineoplastic activity.  Used experimentally as a mutagen and carcinogen, ethylnitrosourea alkylates DNA and proteins, thereby damaging DNA and inducing point mutations. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etidronate-Cytarabine Conjugate MBC-11</VALIDVALUE>
          <VALUEMEANING>Etidronate-Cytarabine Conjugate MBC-11</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etirinotecan Pegol</VALIDVALUE>
          <VALUEMEANING>Etirinotecan Pegol</VALUEMEANING>
          <MEANINGDESCRIPTION>An extended-release (ER) formulation composed of irinotecan, which is a semisynthetic derivative of camptothecin and a topoisomerase I-inhibitor prodrug, that is conjugated, via a proprietary biodegradable ester-based linker, to polyethylene glycol (PEG), with antineoplastic activity. Upon administration of etirinotecan pegol (EP), the agent penetrates into the leaky tumor vasculature and accumulates in the tumor. The linker slowly hydrolyzes and releases irinotecan, which leads to sustained exposure of the tumor to irinotecan. In turn, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN38) by a carboxylesterase. SN38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA; this results in DNA breaks that inhibit DNA replication and trigger apoptosis. Pegylation provides improved systemic exposure, increases drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoglucid</VALIDVALUE>
          <VALUEMEANING>Etoglucid</VALUEMEANING>
          <MEANINGDESCRIPTION>An epoxide compound with potential antineoplastic alkylating activity. Etoglucid is able to crosslink DNA via its epoxide group, resulting in disruption of DNA function and cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoposide</VALIDVALUE>
          <VALUEMEANING>Etoposide</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoposide Phosphate</VALIDVALUE>
          <VALUEMEANING>Etoposide Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1093</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoposide Toniribate</VALIDVALUE>
          <VALUEMEANING>Etoposide Toniribate</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etigilimab</VALIDVALUE>
          <VALUEMEANING>Etigilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T-cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoprine</VALIDVALUE>
          <VALUEMEANING>Etoprine</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic, diaminopyrimidine folate antagonist with potential antineoplastic activity. Etoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism. This may eventually result in a reduction of cellular growth and the induction of apoptosis. In addition, this agent inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble etoprine is capable of crossing the blood-brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Etoricoxib</VALIDVALUE>
          <VALUEMEANING>Etoricoxib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ets-family Transcription Factor Inhibitor TK216</VALIDVALUE>
          <VALUEMEANING>Ets-family Transcription Factor Inhibitor TK216</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary biologic that inhibits the transcriptional-promoting activity of E26 transformation-specific (Ets, E-twenty-six) family transcription factors, with potential antineoplastic activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration, Ets-family transcription factor inhibitor TK216 inhibits transcriptional activation mediated by Ets family proteins, including the oncogenic Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 (EWSR1/FLI1; EWS/FLI1) fusion protein. This agent may both inhibit the malignant downstream effects mediated by genomic rearrangements that result in the overexpression of Ets family transcription factors and decrease tumor cell growth and proliferation. A chromosomal translocation t(11;22)(q24;q12) fuses the EWSR1 gene and the FLI1 gene and encodes the EWSR1/FLI1 fusion protein, which is an oncoprotein expressed by peripheral primitive neuroectodermal (pPNET) tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Everolimus</VALIDVALUE>
          <VALUEMEANING>Everolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Evofosfamide</VALIDVALUE>
          <VALUEMEANING>Evofosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ex Vivo-expanded Autologous T Cells IMA101</VALIDVALUE>
          <VALUEMEANING>Ex Vivo-expanded Autologous T Cells IMA101</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exatecan Mesylate</VALIDVALUE>
          <VALUEMEANING>Exatecan Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exatecan Mesylate Anhydrous</VALIDVALUE>
          <VALUEMEANING>Exatecan Mesylate Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous, mesylate salt form of exatecan, a semisynthetic, water-soluble derivative of camptothecin, with antineoplastic activity. Upon administration, exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting re-ligation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exemestane</VALIDVALUE>
          <VALUEMEANING>Exemestane</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3145843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Everolimus Tablets for Oral Suspension</VALIDVALUE>
          <VALUEMEANING>Everolimus Tablets for Oral Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR&#39;s cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exicorilant</VALIDVALUE>
          <VALUEMEANING>Exicorilant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exisulind</VALIDVALUE>
          <VALUEMEANING>Exisulind</VALUEMEANING>
          <MEANINGDESCRIPTION>An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac.  After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone.  Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extended Release Flucytosine</VALIDVALUE>
          <VALUEMEANING>Extended Release Flucytosine</VALUEMEANING>
          <MEANINGDESCRIPTION>An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extended Release Metformin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Extended Release Metformin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extended-release Onapristone</VALIDVALUE>
          <VALUEMEANING>Extended-release Onapristone</VALUEMEANING>
          <MEANINGDESCRIPTION>An extended-release (ER) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ezabenlimab</VALIDVALUE>
          <VALUEMEANING>Ezabenlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH1/2 Inhibitor HH2853</VALIDVALUE>
          <VALUEMEANING>EZH1/2 Inhibitor HH2853</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH1/2 inhibitor HH2853 inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH2 Inhibitor PF-06821497</VALIDVALUE>
          <VALUEMEANING>EZH2 Inhibitor PF-06821497</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor PF-06821497 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F16-IL2 Fusion Protein</VALIDVALUE>
          <VALUEMEANING>F16-IL2 Fusion Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FACT Complex-targeting Curaxin CBL0137</VALIDVALUE>
          <VALUEMEANING>FACT Complex-targeting Curaxin CBL0137</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity. Upon administration, CBL0137 binds to FACT and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa B and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. This causes an increase in tumor cell apoptosis and a decrease in tumor cell proliferation, in FACT-positive cancers. In addition, this agent is able to sensitize FACT-positive tumor cells to the cytotoxic effects of other chemotherapeutic agents. FACT, a transcription and replication factor composed of the Structure Specific Recognition Protein (SSRP1) and suppressor of Ty 16 (Spt16) proteins, is expressed in a variety of tumor cells while almost absent in normal cells; its expression is associated with increased tumor aggressiveness and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Factor VIIa Inhibitor PCI-27483</VALIDVALUE>
          <VALUEMEANING>Factor VIIa Inhibitor PCI-27483</VALUEMEANING>
          <MEANINGDESCRIPTION>A reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities.  FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Factor VII-targeting Immunoconjugate Protein ICON-1</VALIDVALUE>
          <VALUEMEANING>Factor VII-targeting Immunoconjugate Protein ICON-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoconjugate (ICON) fusion protein composed of a modified version of human factor VII (FVII) which targets tissue factor (TF) that is fused to the Fc domain of the human immunoglobulin G1, with potential anti-thrombotic and antineoplastic activities. Acting in a similar manner as plasma FVII, the natural ligand of TF, ICON-1 targets and binds to TF expressed on neovascular endothelia, thereby preventing TF-mediated signaling pathways, and leading to the initiation of an immune response and the destruction of neovascular tissue. This prevents angiogenesis, inflammation and blood coagulation. Upon intravitreal administration, ICON-1 may block TF-induced angiogenesis and treat wet age-related macular degeneration (AMD) and ocular melanoma. TF, a naturally occurring glycoprotein in humans, regulates blood clotting, angiogenesis, and inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fadraciclib</VALIDVALUE>
          <VALUEMEANING>Fadraciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH2 Inhibitor SHR2554</VALIDVALUE>
          <VALUEMEANING>EZH2 Inhibitor SHR2554</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor SHR2554 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fadrozole Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Fadrozole Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. Aromatase, a member of the cytochrome P-450 superfamily, is found in many tissues; overexpression has been linked to the development of preneoplastic and neoplastic changes in breast tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1044</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAK Inhibitor GSK2256098</VALIDVALUE>
          <VALUEMEANING>FAK Inhibitor GSK2256098</VALUEMEANING>
          <MEANINGDESCRIPTION>A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7070279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAK Inhibitor PF-00562271</VALIDVALUE>
          <VALUEMEANING>FAK Inhibitor PF-00562271</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. FAK inhibitor PF-00562271 inhibits the tyrosine kinase FAK, and to a lesser extent, proline-rich tyrosine kinase (PYK2), which may inhibit tumor cell migration, proliferation, and survival. As FAK is a signal transducer for integrins, inhibition of FAK by this agent may prevent integrin-mediated activation of several downstream signals including ERK, JNK/MAPK and PI3K/Akt. FAK and PYK2, upregulated in many tumor cell types, are involved in tumor cell invasion, migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAK Inhibitor VS-4718</VALIDVALUE>
          <VALUEMEANING>FAK Inhibitor VS-4718</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable focal adhesion kinase (FAK) inhibitor with potential antineoplastic activity. Upon administration, VS-4718 inhibits FAK, blocks fibronectin-stimulated FAK autophosphorylation of Tyr397, and may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt. This results in the reduction of the number of cancer stem cells (CSCs) and inhibits tumor cell migration, proliferation and survival. The cytoplasmic tyrosine kinase FAK is a signal transducer for integrins and is constitutively activated in various tumor cell types; it is involved in tumor cell invasion, migration and proliferation and plays a key role in the development, function and survival of CSCs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Falimarev</VALIDVALUE>
          <VALUEMEANING>Falimarev</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Famitinib</VALIDVALUE>
          <VALUEMEANING>Famitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAP/4-1BB-targeting DARPin MP0310</VALIDVALUE>
          <VALUEMEANING>FAP/4-1BB-targeting DARPin MP0310</VALUEMEANING>
          <MEANINGDESCRIPTION>A designed ankyrin repeat proteins (DARPin)-based agent targeting the tumor-associated protein fibroblast  activation protein (FAP) and the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting DARPin MP0310 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer associated fibroblasts in the majority of solid tumors. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAP/4-1BB-targeting Fusion Protein RO7122290</VALIDVALUE>
          <VALUEMEANING>FAP/4-1BB-targeting Fusion Protein RO7122290</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Farletuzumab</VALIDVALUE>
          <VALUEMEANING>Farletuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FAK/ALK/ROS1 Inhibitor APG-2449</VALIDVALUE>
          <VALUEMEANING>FAK/ALK/ROS1 Inhibitor APG-2449</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and the receptor tyrosine kinase C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon administration, ALK/FAK/ROS1 inhibitor APG-2449 selectively binds to and inhibits ALK, FAK and ROS1 kinases. The inhibition leads to disruption of ALK-, FAK- and ROS1-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and ROS1-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123</VALIDVALUE>
          <VALUEMEANING>Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzonitrile derivative capable of inhibiting some prenyltransferases. L-778,123 is a dual inhibitor of farnesyl:protein and geranylgeranyl:protein transferases; both enzymes catalyze prenylation of oncoprotein KRAS, a prerequisite step in activation of KRAS in signal transduction pathway of apoptosis. Although this agent was developed in part as an anti-KRAS agent, L-778,123 failed in a Phase I trial to inhibit KRAS, which is associated with many types of solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fas Receptor Agonist APO010</VALIDVALUE>
          <VALUEMEANING>Fas Receptor Agonist APO010</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, soluble, hexameric fusion protein consisting of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin with potential pro-apoptotic and antineoplastic activities. Assembled into a soluble hexameric structure mimicking the ligand clustering of endogenous active FasL, Fas receptor agonist APO010 activates the Fas receptor, resulting in caspase-dependent apoptosis in susceptible tumor cell populations. FasL is a transmembrane protein of the tumor necrosis factor (TNF) superfamily and a pro-apoptotic ligand for the death receptor Fas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fascin Inhibitor NP-G2-044</VALIDVALUE>
          <VALUEMEANING>Fascin Inhibitor NP-G2-044</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the protein fascin, with potential antineoplastic activity. Upon oral administration, NP-G2-044 targets and binds to fascin, thereby preventing the interaction of fascin with actin filaments, thereby preventing actin bundling and filopodia formation. By preventing actin cytoskeletal reorganization, the dynamic changes in cell shape that are necessary for tumor cell migration and invasion to occur are impaired, and tumor cell migration and metastasis are inhibited. Fascin, the main actin cross-linker protein in filopodia, is upregulated in many types of metastatic tumor cells while its expression is low or absent in normal adult epithelial cells; its expression is correlated with aggressive phenotypes, poor prognosis, and shorter survival. Filopodia, finger-like plasma membrane protrusions that are formed upon remodeling of the actin cytoskeleton, are found at a high frequency in metastatic tumor cells and their presence is correlated with tumor cell invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142086</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fazarabine</VALIDVALUE>
          <VALUEMEANING>Fazarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1096</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fc-engineered Anti-CD40 Agonist Antibody 2141-V11</VALIDVALUE>
          <VALUEMEANING>Fc-engineered Anti-CD40 Agonist Antibody 2141-V11</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-engineered agonistic antibody targeting the human B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, 2141-V11 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Febuxostat</VALIDVALUE>
          <VALUEMEANING>Febuxostat (Uloric, Adenuric)</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5727117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fedratinib</VALIDVALUE>
          <VALUEMEANING>Fedratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7134889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fedratinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Fedratinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162995</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Feladilimab</VALIDVALUE>
          <VALUEMEANING>Feladilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Favezelimab</VALIDVALUE>
          <VALUEMEANING>Favezelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Felzartamab</VALIDVALUE>
          <VALUEMEANING>Felzartamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fenebrutinib</VALIDVALUE>
          <VALUEMEANING>Fenebrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of Bruton&#39;s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fenretinide</VALIDVALUE>
          <VALUEMEANING> 4-HPR (Fenretinide)</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties.(NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1098</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fenretinide Lipid Matrix</VALIDVALUE>
          <VALUEMEANING>Fenretinide Lipid Matrix</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable powder formulation of a synthetic phenylretinamide analogue of retinol with potential chemopreventive and antineoplastic activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types, including those of the colon, breast, prostate, and neuroblastoma. Independent of RAR activation, this agent also modulates gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS). Compared to the capsule form, the powder contains a mixture of wheat flour, fats, and sugar that may contribute to the enhanced bioavailability of fenretinide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGF Receptor Antagonist HGS1036</VALIDVALUE>
          <VALUEMEANING>FGF Receptor Antagonist HGS1036</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble fusion protein consisting of the extracellular domain of human fibroblast growth factor receptor 1 (FGFR1) fused to the Fc portion of human immunoglobulin G1 (IgG1) with potential antineoplastic and anti-angiogenic activities. FGFR1 receptor antagonist FP-1039 prevents FGFR ligands, such as FGF1, FGF2, FGF4, from binding to their cognate receptors, thereby inhibiting the activation of the related FGFR tyrosine kinases. Inhibition of FGFR1 by this agent may retard tumor cell proliferation and induce tumor cell death. FP-1039 may also inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis. FGFR1 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cellular proliferation, differentiation, angiogenesis, and survival; most ligands that bind to FGFR1 also bind to the related receptors FGFR3 and FGFR4.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR Inhibitor ASP5878</VALIDVALUE>
          <VALUEMEANING>FGFR Inhibitor ASP5878</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor ASP5878 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR Inhibitor AZD4547</VALIDVALUE>
          <VALUEMEANING>FGFR Inhibitor AZD4547</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR Inhibitor CPL304110</VALIDVALUE>
          <VALUEMEANING>FGFR Inhibitor CPL304110</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor CPL304110 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR/CSF-1R Inhibitor 3D185</VALIDVALUE>
          <VALUEMEANING>FGFR/CSF-1R Inhibitor 3D185</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, FGFR/CSF-1R inhibitor 3D185 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-mediated signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. 3D185 also targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fenretinide Phospholipid Suspension ST-001</VALIDVALUE>
          <VALUEMEANING>Fenretinide Phospholipid Suspension ST-001</VALUEMEANING>
          <MEANINGDESCRIPTION>An intravenous formulation composed of a phospholipid suspension of nanoparticles containing the synthetic retinoid derivative fenretinide, with potential antineoplastic activity. Upon intravenous administration, fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in susceptible tumor cell types. Fenretinide also binds to and inhibits the activity of mammalian target of rapamycin (mTOR), which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Independent of RAR activation and mTOR inhibition, this agent may also modulate gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999</VALIDVALUE>
          <VALUEMEANING>FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR1/2/3 Inhibitor HMPL-453</VALIDVALUE>
          <VALUEMEANING>FGFR1/2/3 Inhibitor HMPL-453</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, FGFR inhibitor HMPL-453 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR4 Antagonist INCB062079</VALIDVALUE>
          <VALUEMEANING>FGFR4 Antagonist INCB062079</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist INCB062079 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR4 Inhibitor H3B-6527</VALIDVALUE>
          <VALUEMEANING>FGFR4 Inhibitor H3B-6527</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR4 Inhibitor ICP-105</VALIDVALUE>
          <VALUEMEANING>FGFR4 Inhibitor ICP-105</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fianlimab</VALIDVALUE>
          <VALUEMEANING>Fianlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ficlatuzumab</VALIDVALUE>
          <VALUEMEANING>Ficlatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Ficlatuzumab binds to the soluble ligand HGF, preventing the binding of HGF to its receptor c-Met and activation of the HGF/c-Met signaling pathway, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Figitumumab</VALIDVALUE>
          <VALUEMEANING>Figitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Filanesib</VALIDVALUE>
          <VALUEMEANING>KSP Inhibitor ARRY-520</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR4 Inhibitor BLU 9931</VALIDVALUE>
          <VALUEMEANING>FGFR4 Inhibitor BLU 9931</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist BLU 9931 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Filgotinib</VALIDVALUE>
          <VALUEMEANING>Filgotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6436748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fimaporfin A</VALIDVALUE>
          <VALUEMEANING>Fimaporfin A</VALUEMEANING>
          <MEANINGDESCRIPTION>The A isomer of fimaporfin, a synthetic light-activated compound, with potential photosensitizing activity. Upon administration, fimaporfin A incorporates into the cell&#39;s endosome and lysosome membranes. Subsequently, cytotoxic agents are administered and accumulate in endosomal and lysosomal compartments; upon local activation by light, fimaporfin A produces reactive oxygen species (ROS), such as singlet oxygen, damaging endo/lysosomal membranes and accumulated cytotoxic agents are released into the tumor cell cytosol. This photochemical internalization (PCI) method can enhance the efficacy and selectivity of cytotoxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fimepinostat</VALIDVALUE>
          <VALUEMEANING>Fimepinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104008</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Firtecan Pegol</VALIDVALUE>
          <VALUEMEANING>Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin</VALUEMEANING>
          <MEANINGDESCRIPTION>A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from polyethyleneglycol-7-ethyl-10-hydroxycamptothecin (PEG-SN38); 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flanvotumab</VALIDVALUE>
          <VALUEMEANING>Flanvotumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. Anti-gp75 monoclonal antibody IMC-20D7S targets and binds to gp75. This may lead to the induction of cytotoxic T cell immune and antibody-mediated immune responses against melanoma cells expressing gp75. gp75, a pigmentation-associated antigen, is expressed in melanosomes of human melanocytes and melanomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flotetuzumab</VALIDVALUE>
          <VALUEMEANING>Flotetuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Floxuridine</VALIDVALUE>
          <VALUEMEANING>Floxuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2&#39;-deoxyuridine-5&#39;-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3 Inhibitor FF-10101 Succinate</VALIDVALUE>
          <VALUEMEANING>FLT3 Inhibitor FF-10101 Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137988</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01</VALIDVALUE>
          <VALUEMEANING>Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic vaccinia virus (VV; VACV) genetically engineered to express an Fms-like tyrosine kinase 3 (Flt3) ligand, an antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the human pro-inflammatory cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon administration of the Flt3 ligand/anti-CTLA-4 antibody/IL-12 engineered oncolytic VV RIVAL-01, the virus preferentially targets, infects and replicates in tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. In addition, the Flt3 ligand, the anti-ctla-4 antibody and IL-12 are expressed by the VV in the cancer cells and may activate the immune system within the tumor microenvironment (TME), thereby stimulating both innate and adaptive immune responses. The anti-CTLA-4 antibody targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation, which promotes T-cell activation. Flt3 ligand binds to the Flt3 tyrosine kinase receptor and promotes Flt3 signaling which plays an important role in expanding the population of antigen-presenting dendritic cells (DCs). IL-12 activates natural killer cells (NKs), induces the secretion of interferon-gamma and promotes CD8 cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fisogatinib</VALIDVALUE>
          <VALUEMEANING>Fisogatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3 Tyrosine Kinase Inhibitor TTT-3002</VALIDVALUE>
          <VALUEMEANING>FLT3 Tyrosine Kinase Inhibitor TTT-3002</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with potential antineoplastic activity. Following administration, FLT3 tyrosine kinase inhibitor TTT-3002 binds to and inhibits ligand-dependent dimerization and autophosphorylation of mutant forms of FLT3 with constitutively activating mutations, including FLT3 internal tandem duplication (FLT3/ITD) and the activating point mutation D835Y. Prevention of autophosphorylation inhibits uncontrolled FLT3 signaling and may result in the inhibition of proliferation in tumor cells expressing constitutively active mutant forms of FLT3. The ability of TTT-3002 to inhibit FLT3 proteins with activating point mutations may result in increased efficacy because the activity of these mutants are resistant to other FLT3 kinase inhibitors. FLT3, a tyrosine kinase receptor, plays a role in the regulation of hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. Constitutively activating mutations of FLT3 are the most frequent genetic alterations in acute myeloid leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3/ABL/Aurora Kinase Inhibitor KW-2449</VALIDVALUE>
          <VALUEMEANING>FLT3/ABL/Aurora Kinase Inhibitor KW-2449</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3/CDK4/6 Inhibitor FLX925</VALIDVALUE>
          <VALUEMEANING>FLT3/CDK4/6 Inhibitor FLX925</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2) and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, FLT3/CDK4/6 inhibitor FLX925 specifically binds to and inhibits FLT3, which interferes with the activation of FLT3-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress FLT3. In addition FLX925 inhibits CDK4 and 6 and prevents the phosphorylation of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses DNA synthesis and inhibits cancer cell growth. FLT3, a class III tyrosine kinase receptor, is overexpressed in a variety of cancers. Overexpression of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3/FGFR Dual Kinase Inhibitor MAX-40279</VALIDVALUE>
          <VALUEMEANING>FLT3/FGFR Dual Kinase Inhibitor MAX-40279</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration of FLT3/FGFR dual kinase inhibitor MAX-40279, this agent binds to and inhibits both FGFR and FLT3, including FLT3 mutant forms, which results in the inhibition of FGFR/FLT3-mediated signal transduction pathways. This inhibits proliferation in FGFR/FLT3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases, is upregulated in many tumor cell types. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. They both play key roles in cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3/KIT Kinase Inhibitor AKN-028</VALIDVALUE>
          <VALUEMEANING>FLT3/KIT Kinase Inhibitor AKN-028</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3/KIT/CSF1R Inhibitor NMS-03592088</VALIDVALUE>
          <VALUEMEANING>FLT3/KIT/CSF1R Inhibitor NMS-03592088</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the receptor tyrosine kinases FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), the mast/stem cell factor receptor c-Kit (SCFR; KIT) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic and immunomodulating activities Upon administration, FLT3/KIT/CSF1R inhibitor NMS-03592088 binds to and inhibits the activity of FLT3, KIT and CSF1R. This prevents FLT3, KIT and CSF1R-mediated signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3, KIT and CSF1R. In addition, NMS-03592088 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), NMS-03592088 inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemia (AML), and plays a key role in tumor cell proliferation. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flt3/MerTK Inhibitor MRX-2843</VALIDVALUE>
          <VALUEMEANING>Flt3/MerTK Inhibitor MRX-2843</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of two receptor tyrosine kinases (RTKs), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2) and tyrosine-protein kinase Mer (MerTK; proto-oncogene c-Mer; Mer), with potential antineoplastic activity. Upon administration, MRX-2843 targets and binds to both Flt3 and MerTK. This prevents ligand-dependent phosphorylation and activation of Flt3 and MerTK, which inhibits the activation of their downstream signaling pathways. This induces apoptosis and inhibits proliferation of Flt3- and/or MerTK-overexpressing tumor cells. Flt3 and MerTK, are overexpressed in certain tumor cell types and play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fludarabine</VALIDVALUE>
          <VALUEMEANING>Fludarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1094</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fludarabine Phosphate</VALIDVALUE>
          <VALUEMEANING>Fludarabine Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5044412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluorodopan</VALIDVALUE>
          <VALUEMEANING>Fluorodopan</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating agent with potential antineoplastic activity.  Fluorodopan alkylates DNA at the N7 position of guanine.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluorouracil</VALIDVALUE>
          <VALUEMEANING>Fluorouracil</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2&#39;-deoxyuridine-5&#39;-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5567087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluorouracil Implant</VALIDVALUE>
          <VALUEMEANING>Fluorouracil Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>An implant containing a sustained release particle of fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine, with antineoplastic activity. Upon implantation and subsequent release, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with the pyrimidine uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2&#39;-deoxyuridine-5&#39;-O-monophosphate, inhibits thymidylate synthase and thus DNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluorouracil-E Therapeutic Implant</VALIDVALUE>
          <VALUEMEANING>Fluorouracil-E Therapeutic Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable collagen matrix gel containing the antimetabolite fluorouracil and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2&#39;-deoxyuridine-5&#39;-O-monophosphate, inhibits thymidylate synthase and, so, DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into tumor tissue and reduce dispersion to surrounding tissues, thus enhancing the local concentration of fluorouracil. Compared to systemic administration, the intratumoral injection of fluorouracil combined with epinephrine may increase fluorouracil&#39;s chemotherapeutic efficacy while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluoxymesterone</VALIDVALUE>
          <VALUEMEANING>Fluoxymesterone</VALUEMEANING>
          <MEANINGDESCRIPTION>An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flumatinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Flumatinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13637007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flutamide</VALIDVALUE>
          <VALUEMEANING>Flutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that belongs to the family of drugs called antiandrogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluvastatin</VALIDVALUE>
          <VALUEMEANING>Fluvastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluvastatin Sodium</VALIDVALUE>
          <VALUEMEANING>Fluvastatin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic lipid-lowering agent.  Formulated as as a sodium salt, fluvastatin sodium competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  Fluvastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate</VALIDVALUE>
          <VALUEMEANING>Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folate Receptor-Targeted Tubulysin Conjugate EC1456</VALIDVALUE>
          <VALUEMEANING>Folate Receptor-Targeted Tubulysin Conjugate EC1456</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folate Receptor-Targeted Vinca Alkaloid EC0489</VALIDVALUE>
          <VALUEMEANING>Folate Receptor-Targeted Vinca Alkaloid EC0489</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225</VALIDVALUE>
          <VALUEMEANING>Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate receptor-targeting cytotoxic agent with potential antineoplastic activity. Folate receptor-targeted vinca alkaloid/mitomycin C EC0225 contains two potent cytotoxic agents, a vinca alkaloid and mitomycin C, linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the cytotoxic agents directly into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. Mitomycin C alkylates DNA, producing DNA cross-links and inhibiting DNA replication. The relative tumor cell specificity of EC0225 reduces the toxicity profiles of its cytotoxic agent moieties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folate-FITC</VALIDVALUE>
          <VALUEMEANING>Folate-FITC</VALUEMEANING>
          <MEANINGDESCRIPTION>A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folitixorin</VALIDVALUE>
          <VALUEMEANING>Folitixorin</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2&#39;-deoxyuridine-5&#39;-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folate Receptor Targeted Epothilone BMS753493</VALIDVALUE>
          <VALUEMEANING>Folate Receptor Targeted Epothilone BMS753493</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate receptor-targeting antimitotic agent with potential antineoplastic activity. Folate receptor-targeted epothilone BMS753493 contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13643983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foretinib</VALIDVALUE>
          <VALUEMEANING>Multitargeted Tyrosine Kinase Inhibitor GSK1363089</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3124282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foritinib Succinate</VALIDVALUE>
          <VALUEMEANING>Foritinib Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The succinate salt form of foritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, foritinib targets, binds to and inhibits the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells. In addition, foritinib is able to cross the blood brain barrier. ALK and ROS1, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Formestane</VALIDVALUE>
          <VALUEMEANING>Formestane</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic steroidal substance with antineoplastic activity.  Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Forodesine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Forodesine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes. A transition state analogue is a substrate designed to mimic the properties or the geometry of the transition state of reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosbretabulin Disodium</VALIDVALUE>
          <VALUEMEANING>Fosbretabulin Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt of a water-soluble phosphate derivative of a natural stilbenoid phenol derived from the African bush willow (Combretum caffrum) with potential vascular disrupting and antineoplastic activities. Upon administration, the prodrug fosbretabulin is dephosphorylated to its active metabolite, the microtubule-depolymerizing agent combretastatin A4, which binds to tubulin dimers and prevents microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. In addition, this agent disrupts the engagement of the endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE-cadherin) and so the activity of the VE-cadherin/beta-catenin/Akt signaling pathway, which may result in the inhibition of endothelial cell migration and capillary tube formation. As a result of fosbretabulin&#39;s dual mechanism of action, the tumor vasculature collapses, resulting in reduced tumor blood flow and ischemic necrosis of tumor tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosbretabulin Tromethamine</VALIDVALUE>
          <VALUEMEANING>Fosbretabulin Tromethamine</VALUEMEANING>
          <MEANINGDESCRIPTION>The tromethamine salt form of prodrug fosbretabulin, a water-soluble phosphate derivative of a stilbenoid phenol derived from the African bush willow (Combretum caffrum) with antineoplastic activities. Upon administration, fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which targets and binds to tubulin dimers and prevents microtubule polymerization, thereby resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosgemcitabine Palabenamide</VALIDVALUE>
          <VALUEMEANING>Fosgemcitabine Palabenamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity. Upon intravenous administration and cellular uptake, fosgemcitabine palabenamide is converted into the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. With the phosphoramidate moiety on the gemcitabine monophosphate group, NUC-1031 has improved properties over its parent molecule: 1) is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, 2) as the agent is delivered in the monophosphate form, the first phosphorylation step by deoxycytidine kinase is not required, 3) this agent is not susceptible to deactivation by cytidine deaminase cleavage of the monophosphorylated form. Altogether, this may help overcome resistance to gemcitabine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosifloxuridine Nafalbenamide</VALIDVALUE>
          <VALUEMEANING>Fosifloxuridine Nafalbenamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2&#39;-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foslinanib</VALIDVALUE>
          <VALUEMEANING>Foslinanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosbretabulin</VALIDVALUE>
          <VALUEMEANING>Fosbretabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with antineoplastic activity. Fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13647660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foslinanib Disodium</VALIDVALUE>
          <VALUEMEANING>Foslinanib Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt form of foslinanib, an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosquidone</VALIDVALUE>
          <VALUEMEANING>Fosquidone</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechanism of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fostriecin</VALIDVALUE>
          <VALUEMEANING>Fostriecin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fotretamine</VALIDVALUE>
          <VALUEMEANING>Fotretamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentaethyleneimine derivative with antineoplastic alkylating activity. Fotretamine causes chromosomal breaks in lymphocytes which contributes to its immunosuppressive activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FPV Vaccine CV301</VALIDVALUE>
          <VALUEMEANING>FPV Vaccine CV301</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration following the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine MVA-BN-CV301, the FPV vaccine CV301, which is used as a booster vaccine, activates a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when FPV-CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. The TAAs CEA and MUC-1 are overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FPV-Brachyury-TRICOM Vaccine</VALIDVALUE>
          <VALUEMEANING>FPV-Brachyury-TRICOM Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fresolimumab</VALIDVALUE>
          <VALUEMEANING>Fresolimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fruquintinib</VALIDVALUE>
          <VALUEMEANING>Fruquintinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fulvestrant</VALIDVALUE>
          <VALUEMEANING>Fulvestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fotemustine</VALIDVALUE>
          <VALUEMEANING>Fotemustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1106</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13651293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fumagillin-Derived Polymer Conjugate XMT-1107</VALIDVALUE>
          <VALUEMEANING>Fumagillin-Derived Polymer Conjugate XMT-1107</VALUEMEANING>
          <MEANINGDESCRIPTION>A polymeric prodrug consisting of the fumagillol-derived small molecule XMT-1191 tethered to the hydrophilic, biodegradable70 kDa polymer poly[1-hydroxymethylethylene hydroxymethylformal] (PHF) with potential antiangiogenic and antineoplastic activities. Upon administration, fumagillin-derived polymer conjugate XMT-1107 releases XMT-1191, which may inhibit angiogenesis through the irreversible inhibition of the methionine aminopeptidase 2 (METAP2); although the exact mechanism of action has yet to be fully elucidated, this agent appears to induce cell cycle arrest in endothelial cells, inhibiting their proliferation and migration. Compared to an unconjugated fumagillin analog, XMT-1107 exhibits improved solubility and an extended half life due to its PHF backbone. METAP2, a member of the methionyl aminopeptidase family, binds two cobalt or manganese ions and protects the alpha subunit of eukaryotic initiation factor 2 (EIF2) from inhibitory phosphorylation by removing the amino-terminal methionine residue from nascent protein; this aminopeptidase may be overexpressed in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88321</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fursultiamine</VALIDVALUE>
          <VALUEMEANING>Fursultiamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Futibatinib</VALIDVALUE>
          <VALUEMEANING>Futibatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Futuximab/Modotuximab Mixture</VALIDVALUE>
          <VALUEMEANING>Futuximab/Modotuximab Mixture</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain III, with potential antineoplastic activity. Anti-EGFR monoclonal antibody mixture Sym004 binds to the extracellular domain of EGFR, thereby preventing ligand binding. This may prevent activation and subsequent dimerization of the receptor; the decrease in receptor activation may result in an inhibition of downstream ERK and JNK signaling pathways and thus inhibition of EGFR-dependent tumor cell proliferation and metastasis. In addition, binding of Sym004 to EGFRs causes EGFR internalization and degradation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G Protein-coupled Estrogen Receptor Agonist LNS8801</VALIDVALUE>
          <VALUEMEANING>G Protein-coupled Estrogen Receptor Agonist LNS8801</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective agonist of the G protein-coupled estrogen receptor (G protein-coupled estrogen receptor 1; GPER; GPER1; GPR30), with potential immunomodulating and antineoplastic activities. Upon oral administration, LNS8801 targets, binds to and activates GPER. This activates GPER-mediated signaling and suppresses the expression of various tumor-associated genes, such as c-Myc and programmed cell death-ligand 1 (PD-L1). This leads to an inhibition of tumor cell proliferation. GPER activation may also induce immune memory. GPER is a membrane protein and a member of the G-protein coupled receptors (GPCRs) that are widely distributed in various tissues. GPER is a tumor suppressor in a wide range of cell cancer types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galamustine</VALIDVALUE>
          <VALUEMEANING>Galamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A galactose mustard compound, an alkylating agent, with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galarubicin</VALIDVALUE>
          <VALUEMEANING>Galarubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline derivative with antineoplastic activity developed to circumvent doxorubicin resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galectin-1 Inhibitor OTX008</VALIDVALUE>
          <VALUEMEANING>Galectin-1 Inhibitor OTX008</VALUEMEANING>
          <MEANINGDESCRIPTION>A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galeterone</VALIDVALUE>
          <VALUEMEANING>Galeterone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5811373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Futuximab</VALIDVALUE>
          <VALUEMEANING>Futuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR; ErbB1; HER1), with potential antineoplastic activity. Upon administration, futuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13654924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galiximab</VALIDVALUE>
          <VALUEMEANING>Galiximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallium-based Bone Resorption Inhibitor AP-002</VALIDVALUE>
          <VALUEMEANING>Gallium-based Bone Resorption Inhibitor AP-002</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable gallium (Ga)-based small molecule agent with potential anti-bone resorption and antineoplastic activities. Upon oral administration, AP-002 selectively inhibits osteoclast differentiation and bone resorption, and may promote the growth of osteoblasts thereby improving the skeletal sequelae of bony metastases which include pain, spinal cord compression, fractures and hypercalcemia of malignancy. Additionally, AP-002 may, through an as of yet undescribed mechanism of action, directly target and kill bone tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galocitabine</VALIDVALUE>
          <VALUEMEANING>Galocitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5&#39;-deoxy-5-fluorocytidine, 5&#39;-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Galunisertib</VALIDVALUE>
          <VALUEMEANING>Galunisertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic activity. Upon administration, galunisertib specifically targets and binds to the kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells. Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is associated with increased cancer cell proliferation, migration, invasion and tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gamboge Resin Extract TSB-9-W1</VALIDVALUE>
          <VALUEMEANING>Gamboge Resin Extract TSB-9-W1</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable extract from the yellow to brown gum-resin of the gamboge tree (genus Garcinia) belonging to the Clusiaceae (or Guttiferae) family, with potential anti-inflammatory and antineoplastic activities. Gamboge resin extract TSB-9-W1 contains various active ingredients, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol and desoxymorellin. Upon oral administration, the various active components of the gamboge resin extract TSB-9-W1 may bind to and inhibit the activity of a variety of cancer-related proteins, may induce apoptosis, and may exert cytotoxic activity on tumor cells, thereby inhibiting tumor cell proliferation. TSB-9 is derived from TSB-14, which is the acetone-extract of gamboge resin, and pulverized into powder form; TSB-9 is 90% extract and 10% brown sugar. TSB-9-W1 is a milled form of TSB-9 with a particle size of 5 micrometers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gamma-delta Tocotrienol</VALIDVALUE>
          <VALUEMEANING>Gamma-delta Tocotrienol</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available nutritional supplement containing the gamma and delta forms of the vitamin E family member tocotrienol, with hypocholesterolemic, antithrombotic, antioxidant, and potential antineoplastic activity. Upon oral administration, gamma-delta tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Further, this agent prevents free radical formation and inhibits lipid peroxidation. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gamma-Secretase Inhibitor RO4929097</VALIDVALUE>
          <VALUEMEANING>Gamma-Secretase Inhibitor RO4929097</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor RO4929097 binds to GS and blocks activation of Notch receptors, which may inhibit tumor cell proliferation. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gandotinib</VALIDVALUE>
          <VALUEMEANING>Gandotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganetespib</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor STA-9090</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor STA-9090 binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of &quot;client&quot; proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3061618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganglioside GM2</VALIDVALUE>
          <VALUEMEANING>Ganglioside GM2</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in melanoma patients without deleterious effects associated with an immune response to GM2. Mutations in at least 1 of 3 recessive genes: HEXA, HEXB, and GM2A cause defects in GM2 catabolism, leading to lysosomal lipid storage disorders that manifest primarily as neurodegenerative diseases, including Tay-Sachs and Sandhoff Disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3685470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganitumab</VALIDVALUE>
          <VALUEMEANING>Ganitumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganoderma lucidum Spores Powder Capsule</VALIDVALUE>
          <VALUEMEANING>Ganoderma lucidum Spores Powder Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available powder-based nutritional supplement containing the spores of the mushroom Ganoderma lucidum (Ganoderma l.), a traditional Chinese medicine, with potential protective, sedative, anti-oxidant, immunomodulating, and antineoplastic activities. The spores contain various bioactive components including polysaccharides, triterpenoids, peptidoglycans, amino acids, fatty acids, vitamins, and minerals. Upon oral administration of the Ganoderma lucidum spores powder capsule, the active ingredients may modulate the immune system, may activate dendritic cells, natural killer cells, and macrophages and may modulate the production of certain cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin (IL) 1-beta (IL-1b), IL-2, IL-6 and IL-8. This supplement may improve cancer-related fatigue and may be used as a sleep aid; it may also have a beneficial effect on the heart, lung, liver, pancreas, kidney, and the central nervous system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118365</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Garlic</VALIDVALUE>
          <VALUEMEANING>Garlic</VALUEMEANING>
          <MEANINGDESCRIPTION>A bulbous herb isolated from the plant Allium sativum with potential antineoplastic activity. Garlic contains a number of different organosulfur compounds, some of which have displayed antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrin Immunotoxin</VALIDVALUE>
          <VALUEMEANING>Gastrin Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotoxin containing an epitope of human gastrin conjugated to diphtheria toxin, with antineoplastic activity. The gastrin epitope in this vaccine is chemically identical or similar to the endogenous gastrin-17 (G-17), a 17-amino acid peptide hormone that stimulates secretion of gastric acid by the stomach. Diphtheria toxin inhibits protein synthesis via modifying translation elongation factor 2 (EF-2). Vaccination with this immunotoxin may elicit production of antibodies against gastrinoma cells overexpressing gastrin, in addition to the toxic effects on protein synthesis exerted by the diphtheria toxin moiety.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganglioside GD2</VALIDVALUE>
          <VALUEMEANING>Ganglioside GD2</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD2, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. Due to its high level of expression in neuroblastoma, GD2 has the potential to be used as a component of anti-neuroblastoma vaccines, in addition to being used in polyvalent anti-melanoma vaccines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3270404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gataparsen Sodium</VALIDVALUE>
          <VALUEMEANING>Gataparsen Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation antisense oligonucleotide against survivin mRNA with potential antitumor activity. Gataparsen hybridizes to survivin mRNA, thereby blocking translation of survivin protein, a member of the inhibitor of apoptosis (IAP) family. Survivin, expressed during embryonal development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. Silencing expression of survivin potentially leads to restoration of the apoptotic process in cancer cells, thereby facilitating chemotherapeutic treatments.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gatipotuzumab</VALIDVALUE>
          <VALUEMEANING>Gatipotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), with potential antineoplastic activity. Gatipotuzumab targets and binds to the TA-MUC1 epitopes expressed on the cell surface of tumor cells, thereby potentially activating the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against the TA-MUC1-expressing tumor cells. TA-MUC1 is designated to MUC1 epitopes with O-glycosylated carbohydrate-induced conformational structures that are tumor-specific, thereby enabling gatipotuzumab to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GBM Antigens and Alloantigens Immunotherapeutic Vaccine</VALIDVALUE>
          <VALUEMEANING>GBM Antigens and Alloantigens Immunotherapeutic Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, immunotherapeutic vaccine composed of hydrolyzed and formulated glioblastoma multiforme (GBM) antigens and alloantigens derived from a pool of patients&#39; cancer cells in the blood and samples of tumor tissues, with potential immunomodulating and antineoplastic activities. Upon oral administration of the GBM antigens and alloantigens immunotherapeutic vaccine, the GBM antigens and alloantigens may stimulate the host immune system via antigen-presenting cells (APCs) lining the gut to mount an immune response against tumor cells expressing these antigens. This may lead to tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gefitinib</VALIDVALUE>
          <VALUEMEANING>Gefitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Geldanamycin</VALIDVALUE>
          <VALUEMEANING>Geldanamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Geldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gelonin</VALIDVALUE>
          <VALUEMEANING>Gelonin</VALUEMEANING>
          <MEANINGDESCRIPTION>A class I ribosome-inactivating protein (RIP) and toxin derived from the seeds of the plant Gelonium multiflorum. Gelonin (rGel) exerts N-glycosidase activity on the 28S ribosomal RNA (rRNA) unit of eukaryotic ribosomes by cleaving out adenine at the 4324 site, which depurinates rRNA, inactivates ribosomes, inhibits protein synthesis, and results in cell death. Used as the toxin moiety of certain immunotoxins and linked to antibodies specific for a tumor-associated antigen (TAA), gelonin can be targeted to and induce specific cytotoxicity in tumor cells expressing the TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133021</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine</VALIDVALUE>
          <VALUEMEANING>Gemcitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5242658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine Elaidate</VALIDVALUE>
          <VALUEMEANING>Gemcitabine Elaidate</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5&#39;-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Gemcitabine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite analog of the nucleoside pyrimidine with antineoplastic activity.  Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP).  dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gedatolisib</VALIDVALUE>
          <VALUEMEANING>Gedatolisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine Hydrochloride Emulsion</VALIDVALUE>
          <VALUEMEANING>Gemcitabine Hydrochloride Emulsion</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine Prodrug LY2334737</VALIDVALUE>
          <VALUEMEANING>Gemcitabine Prodrug LY2334737</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemcitabine-Releasing Intravesical System</VALIDVALUE>
          <VALUEMEANING>Gemcitabine-Releasing Intravesical System</VALUEMEANING>
          <MEANINGDESCRIPTION>A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemtuzumab Ozogamicin</VALIDVALUE>
          <VALUEMEANING>Gemtuzumab Ozogamicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2741177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genistein</VALIDVALUE>
          <VALUEMEANING>Genistein</VALUEMEANING>
          <MEANINGDESCRIPTION>A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation.  This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest.  Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gentuximab</VALIDVALUE>
          <VALUEMEANING>Gentuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Geranylgeranyltransferase I Inhibitor</VALIDVALUE>
          <VALUEMEANING>Geranylgeranyltransferase I Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that inhibits protein geranylgeranyltransferase type 1 (GGTase-I), with potential antineoplastic activity. GGTase-I is involved in the posttranslational modification of a number of oncogenic GTPases, including K-Ras, N-Ras, RhoA, RhoC, Cdc42, RalA, RalB and Rac1. Inhibition of the prenylation of these oncogenic proteins inhibits both their oncogenic activity and membrane localization. This may result in cell cycle arrest and apoptosis. Protein geranylgeranylation, catayzed by GGTase-I, plays a critical role in malignant transformation and cancer cell proliferation, migration and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GI-4000 Vaccine</VALIDVALUE>
          <VALUEMEANING>GI-4000 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity. Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Giloralimab</VALIDVALUE>
          <VALUEMEANING>Giloralimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum</VALIDVALUE>
          <VALUEMEANING>Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum</VALUEMEANING>
          <MEANINGDESCRIPTION>A live, genetically modified probiotic bacteria Bifidobacterium longum (B. longum) engineered to deliver genetic material encoding the human pro-inflammatory transgene interleukin-12 (IL-12), with potential immunoactivating activity. Upon administration of genetically modified IL-12 transgene-encoding B. longum, the bacteria selectively colonize hypoxic tumor tissues and deliver plasmid DNA encoding the IL-12 transgene within the tumor microenvironment (TME). IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gilteritinib</VALIDVALUE>
          <VALUEMEANING>Gilteritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gilteritinib Fumarate</VALIDVALUE>
          <VALUEMEANING>Gilteritinib Fumarate</VALUEMEANING>
          <MEANINGDESCRIPTION>The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gimatecan</VALIDVALUE>
          <VALUEMEANING>Gimatecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic and antiangiogenic activities. Gimatecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Although the mechanism of its antiangiogenic activity has yet to be full elucidated, this agent may inhibit endothelial cell migration, tumor neovascularization, and the expression of proangiogenic basic fibroblast growth factor (bFGF).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gimeracil</VALIDVALUE>
          <VALUEMEANING>Gimeracil</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Giredestrant</VALIDVALUE>
          <VALUEMEANING>Giredestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147030</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Girentuximab</VALIDVALUE>
          <VALUEMEANING>Girentuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, monoclonal antibody G250 (mAb G250) may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Girodazole</VALIDVALUE>
          <VALUEMEANING>Girodazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound isolated from the marine sponge Pseudaxinyssa cantharella exhibiting anti-tumor activity.  Studies indicate girodazole acts during the elongation/termination steps of protein synthesis, resulting in protein synthesis inhibition. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Givinostat</VALIDVALUE>
          <VALUEMEANING>Givinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Givinostat inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low, nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-6 and interferon-gamma. Givinostat has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and vascular endothelial cell growth factor (VEGF) by bone marrow stromal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glasdegib</VALIDVALUE>
          <VALUEMEANING>Glasdegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ginsenoside Rg3 Capsule</VALIDVALUE>
          <VALUEMEANING>Ginsenoside Rg3 Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule containing the steroidal saponin ginsenoside Rg3 isolated from the root of Panax ginseng, with potential cancer preventive and anti-angiogenic activities. Upon oral administration, ginsenoside Rg3 appears to inhibit endothelial cell proliferation, migration and tubular formation, and promotes cancer cell apoptosis. This agent also modulates the activities of certain growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs), on tumor angiogenesis. In addition, ginsenoside Rg3 may be able to sensitize cancer cells to some chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glasdegib Maleate</VALIDVALUE>
          <VALUEMEANING>Glasdegib Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glaucarubolone</VALIDVALUE>
          <VALUEMEANING>Glaucarubolone</VALUEMEANING>
          <MEANINGDESCRIPTION>A polycyclic lactone quassinoid phytochemical isolated from the seeds of Hannoa undulata and other plant species with potential antineoplastic activity.  This agent also has antiviral and antitumor properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1114</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glembatumumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Glembatumumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4925571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glesatinib</VALIDVALUE>
          <VALUEMEANING>Multitargeted Tyrosine Kinase Inhibitor MGCD265</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor MGCD265 binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3434560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glioblastoma Multiforme Multipeptide Vaccine IMA950</VALIDVALUE>
          <VALUEMEANING>Glioblastoma Multiforme Multipeptide Vaccine IMA950</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glioma Lysate Vaccine GBM6-AD</VALIDVALUE>
          <VALUEMEANING>Glioma Lysate Vaccine GBM6-AD</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701</VALIDVALUE>
          <VALUEMEANING>Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Globo H-DT Vaccine OBI-833</VALIDVALUE>
          <VALUEMEANING>Globo H-DT Vaccine OBI-833</VALUEMEANING>
          <MEANINGDESCRIPTION>A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glucarpidase</VALIDVALUE>
          <VALUEMEANING>Glucarpidase</VALUEMEANING>
          <MEANINGDESCRIPTION>A zinc-dependent enzyme isolated from a strain of the bacterium Pseudomonas. Because glucarpidase rapidly hydrolyzes methotrexate into inactive metabolites, it may be useful as a rescue agent for methotrexate-induced nephrotoxicity. In antibody-directed enzyme prodrug therapy (ADEPT), this agent is conjugated with an antibody that binds to a specific tumor cell type, allowing for glucarpidase-catalyzed activation of a co-administered prodrug at the site of the tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glioblastoma Cancer Vaccine ERC1671</VALIDVALUE>
          <VALUEMEANING>Glioblastoma Cancer Vaccine ERC1671</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glucocorticoid Receptor Antagonist ORIC-101</VALIDVALUE>
          <VALUEMEANING>Glucocorticoid Receptor Antagonist ORIC-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glufosfamide</VALIDVALUE>
          <VALUEMEANING>Glufosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by glucosidases in tumor cells and forms ifosforamide. In turn, ifosforamide alkylates and forms DNA crosslinks, thereby inhibiting DNA replication and subsequent cell growth. The glucose moiety may enhance this agent&#39;s uptake by tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101</VALIDVALUE>
          <VALUEMEANING>Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A glutathione (GSH) pegylated, liposome-encapsulated preparation of the hydrochloride salt form of the anthracycline antineoplastic antibiotic doxorubicin, with potential anetineoplastic activity. Upon administration, the glutathione pegylated liposomal formulation 2B3-101 specifically delivers doxorubicin into the brain. Doxorubicin intercalates between DNA base pairs and interferes with topoisomerase II activity, which inhibits both DNA replication and RNA synthesis, resulting in cancer cell death and tumor regression. Doxorubicin also generates reactive oxygen species, which causes cell membrane lipid peroxidation leading to cytotoxicity. The pegylated liposomal delivery of doxorubicin improves drug penetration into tumors and prolongs circulation time, thereby increasing doxorubicin&#39;s efficacy and decreasing its toxicity. Conjugation of GSH to the PEG molecules directs the liposomes to the GSH transporters on the blood brain barrier (BBB) and improves the delivery of doxorubicin into the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106121</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01</VALIDVALUE>
          <VALUEMEANING>Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01</VALUEMEANING>
          <MEANINGDESCRIPTION>A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GM-CSF-encoding Oncolytic Adenovirus CGTG-102</VALIDVALUE>
          <VALUEMEANING>GM-CSF-encoding Oncolytic Adenovirus CGTG-102</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gold Sodium Thiomalate</VALIDVALUE>
          <VALUEMEANING>Gold Sodium Thiomalate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of gold thiomalic acid, an organogold compound with antirheumatic and potential antineoplastic activities. Gold sodium thiomalate (GST) appears to inhibit the activity of atypical protein kinase C iota (PKCiota) by forming a cysteinyl-aurothiomalate adduct with the cysteine residue Cys-69 within the PB1 binding domain of PKCiota. This prevents the binding of Par6 (Partitioning defective protein 6) to PKCiota, thereby inhibiting PKCiota-mediated oncogenic signaling, which may result in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. Atypical PKCiota, a serine/threonine kinase overexpressed in numerous cancer cell types, plays an important role in cancer proliferation, invasion, and survival; Par6 is a scaffold protein that facilitates atypical PKC-mediated phosphorylation of cytoplasmic proteins involved in epithelial and neuronal cell polarization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Golnerminogene Pradenovec</VALIDVALUE>
          <VALUEMEANING>Golnerminogene Pradenovec</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Golotimod</VALIDVALUE>
          <VALUEMEANING>Golotimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and antineoplastic activities. Although the exact mechanism of action is unknown, golotimod appears to inhibit the expression of STAT-3, reversing immunosuppression and stimulating an anti-tumor immune response. This agent may stimulate the production of T-lymphocytes, in particular the helper T (Th1) cells, activate macrophages, and increase levels of interleukin 2 and interferon gamma. STAT-3, a transcription factor upregulated in many cancer cell types, is involved in tumor cell growth and survival and immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Golvatinib</VALIDVALUE>
          <VALUEMEANING>Golvatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glycooptimized Trastuzumab-GEX</VALIDVALUE>
          <VALUEMEANING>Glycooptimized Trastuzumab-GEX</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered form of a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. Glycooptimized trastuzumab-GEX specifically binds to the extracellular domain of HER2, thereby inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. This eventually results in apoptosis and growth inhibition of tumor cells. HER2, a member of the receptor tyrosine kinase EGFR superfamily, is overexpressed on the cell surfaces of various solid tumors. This agent has a specific glycosylation profile that may enhance its ADCC response against HER2-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gonadotropin-releasing Hormone Analog</VALIDVALUE>
          <VALUEMEANING>LHRH agonist</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1910</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Goserelin</VALIDVALUE>
          <VALUEMEANING>Goserelin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2921026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Goserelin Acetate</VALIDVALUE>
          <VALUEMEANING>Goserelin Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Goserelin Acetate Extended-release Microspheres LY01005</VALIDVALUE>
          <VALUEMEANING>Goserelin Acetate Extended-release Microspheres LY01005</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting, extended-release microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration, goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in an extended-release formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gossypol</VALIDVALUE>
          <VALUEMEANING>Gossypol</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active polyphenolic aldehyde with potential antineoplastic activity. Derived primarily from unrefined cottonseed oil, gossypol induces cell cycle arrest at the G0/G1 phase, thereby inhibiting DNA replication and inducing apoptosis. This agent also inhibits cell-signaling enzymes, resulting in inhibition of cell growth, and may act as a male contraceptive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G-Quadruplex Stabilizer BMVC</VALIDVALUE>
          <VALUEMEANING>G-Quadruplex Stabilizer BMVC</VALUEMEANING>
          <MEANINGDESCRIPTION>A carbazole derivative (3,6-bis[2-(1-methylpyridinium)vinyl]carbazole diiodide) that selectively targets to the G-quadruplex DNA structure, used as a fluorescent probe for cancer cytological diagnosis and with potential antitumor activity. G-quadruplex stabilizer BMVC, preferentially uptaken by cancer cells, binds to and stabilize the telomeric G-quadruplex structure at the end of DNA; when visualized with fluorescent imaging device, BMVC emits bright fluorescent light and can be used to differentiate tumor cells from normal cells. The BMVC/G-quadruplex complexes also interfere with the activity of telomerase, which is highly active in tumor cells and plays a key role in tumorigenesis while expressed at very low levels in most somatic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grapiprant</VALIDVALUE>
          <VALUEMEANING>Grapiprant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124131</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Green Tea Extract-based Antioxidant Supplement</VALIDVALUE>
          <VALUEMEANING>Green Tea Extract-based Antioxidant Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement containing a green tea extract including the catechin epigallocatechin gallate and other vitamins and antioxidants, with potential antineoplastic and chemopreventive activities. The polyphenols in green tea act as antioxidants and scavenge free radicals which may inhibit cellular oxidation and prevent free radical damage to cells. In addition, polyphenols may affect enzymes involved in cellular reproduction and tumor angiogenesis by modulating angiogenic factors. Other ingredients in green tea extract-based antioxidant supplement include dry cinnamon extract, germanium, zinc sulfate, manganese sulfate, arginine, cysteine, malic acid, ascorbic acid (vitamin c), glycyrrhizinic acid, glycine, glucosamine, pyridoxal (vitamin B6), calcium pantothenate (vitamin B5), folic acid, cyanocobalamin (vitamin B12).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GSK-3 Inhibitor LY2090314</VALIDVALUE>
          <VALUEMEANING>GSK-3 Inhibitor LY2090314</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gossypol Acetic Acid</VALIDVALUE>
          <VALUEMEANING>Gossypol Acetic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>The naturally occurring acetic acid form of gossypol, and an orally available polyphenolic aldehyde derived mostly from cottonseed with potential antineoplastic activity.  The biologic activities of gossypol acetic acid are similar to those of gossypol and include suppression of DNA replication, inhibition of tumor cell proliferation, and male contraceptive effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Guadecitabine</VALIDVALUE>
          <VALUEMEANING>Guadecitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. Following metabolic activation by phosphorylation and incorporation into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing genome-wide and non-specific hypomethylation, and inducing cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, hence may result in gradual release of decitabine both extra and intracellularly, leading to more prolonged exposures to decitabine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6753167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Guanabenz Acetate</VALIDVALUE>
          <VALUEMEANING>Guanabenz Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable, acetate salt form of guanabenz, a centrally-acting alpha-2 adrenergic receptor agonist, with anti-hypertensive and potential antineoplastic, cytoprotective and bone resorption inhibitory activities. Upon oral administration, guanabenz suppresses endoplasmic reticulum (ER) stress by inhibiting the stress-induced dephosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2a), thereby enhancing the phosphorylation level of eIF2a. This causes elF2a-mediated downregulation of the Rac1 pathway, upregulates the expression of activating transcription factor 4 (ATF4), which plays a key role in osteoblastogenesis, and downregulates the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), which is a transcription factor that plays a key role in osteoclastogenesis. This enhances osteoblastogenesis and suppresses osteoclastogenesis. Altogether, this promotes new bone formation and prevents bone degradation. In addition, guanabenz blocks the proliferation, survival, motility and invasiveness of tumor cells through the eIF2a-mediated downregulation of Rac1 signaling. Rac1, a Ras-related small GTPase belonging to the Rho family, plays a key role in tumor cell proliferation, survival and motility.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Guselkumab</VALIDVALUE>
          <VALUEMEANING>Guselkumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gusperimus Trihydrochloride</VALIDVALUE>
          <VALUEMEANING>Gusperimus Trihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the antitumor antibiotic spergualin with immunosuppressant activity.  Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H1299 Tumor Cell Lysate Vaccine</VALIDVALUE>
          <VALUEMEANING>H1299 Tumor Cell Lysate Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, the H1299 tumor cell lysate exposes the immune system to an undefined amount of tumor associated antigens (TAA), particularly cancer testis antigens (CTAs), which may result in the induction of both anti-tumoral cytotoxic T-lymphocytes (CTL) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. CTAs, such as MAGE, are selectively expressed in a variety of cancers but are not expressed in normal, healthy cells outside the testis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HAAH Lambda phage Vaccine SNS-301</VALIDVALUE>
          <VALUEMEANING>HAAH Lambda phage Vaccine SNS-301</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hafnium Oxide-containing Nanoparticles NBTXR3</VALIDVALUE>
          <VALUEMEANING>Hafnium Oxide-containing Nanoparticles NBTXR3</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 in the tumor, the hafnium oxide-containing nanoparticles accumulate into the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Halichondrin Analogue E7130</VALIDVALUE>
          <VALUEMEANING>Halichondrin Analogue E7130</VALUEMEANING>
          <MEANINGDESCRIPTION>A halichondrin analogue derived from a marine sponge with potential antineoplastic activity. Upon intravenous infusion, halichondrin analogue E7130 may bind to the vinca domain of tubulin and inhibit the polymerization of tubulin and the assembly of microtubules, thereby inhibiting mitotic spindle assembly and inducing cell cycle arrest at the G2/M phase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Halofuginone</VALIDVALUE>
          <VALUEMEANING>Halofuginone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1120</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gutolactone</VALIDVALUE>
          <VALUEMEANING>Gutolactone</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the plant Simaba guianensis with potential antineoplastic and antimalarial activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Halofuginone Hydrobromide</VALIDVALUE>
          <VALUEMEANING>Halofuginone Hydrobromide</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HCV DNA Vaccine INO-8000</VALIDVALUE>
          <VALUEMEANING>HCV DNA Vaccine INO-8000</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC Class I/IIb Inhibitor HG146</VALIDVALUE>
          <VALUEMEANING>HDAC Class I/IIb Inhibitor HG146</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of histone deacetylase (HDAC) classes I and IIb with potential antineoplastic activities. Upon oral administration, HDAC I/IIb inhibitor HG146 selectively inhibits the catalytic activity of class I and IIb HDACs, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Class I HDACs are located in the nucleus and include HDACs 1, 2, 3, and 8; class IIb HDACs include HDAC 6 and 10 and are located in both the nucleus and the cytoplasm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC Inhibitor CKD-581</VALIDVALUE>
          <VALUEMEANING>HDAC Inhibitor CKD-581</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, HDAC inhibitor CKD-581 targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC Inhibitor OBP-801</VALIDVALUE>
          <VALUEMEANING>HDAC Inhibitor OBP-801</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. This may inhibit proliferation of susceptible tumor cells. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC/EGFR/HER2 Inhibitor CUDC-101</VALIDVALUE>
          <VALUEMEANING>HDAC/EGFR/HER2 Inhibitor CUDC-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the activity of these three enzymes but the exact mechanism of action is presently unknown. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC6 Inhibitor KA2507</VALIDVALUE>
          <VALUEMEANING>HDAC6 Inhibitor KA2507</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of histone deacetylase (HDAC) type 6 (HDAC6; HDAC-6), with potential antineoplastic activity. Upon administration, KA2507 targets, binds to and inhibits the activity of HDAC6. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. Specifically, inhibition of HDAC6 prevents STAT3 activity, which leads to a reduction in programmed death-1 (PD-1) expression. Eventually, this results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC6. HDAC6, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC8 Inhibitor NBM-BMX</VALIDVALUE>
          <VALUEMEANING>HDAC8 Inhibitor NBM-BMX</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), with potential antineoplastic activity. Upon administration, NBM-BMX targets and inhibits the activity of HDAC8. This results in an accumulation of highly acetylated chromatin histones, chromatin remodeling, and selective transcription of tumor suppressor genes, ultimately promoting cell-cycle arrest and induction of tumor cell apoptosis. HDAC8, a class 1 histone deacetylase, plays a key role in transcriptional regulation and cell cycle progression. Aberrant expression of HDAC8 or deregulated interactions with transcription factors may contribute to tumorigenesis. Isotype-selective HDAC inhibitors may be associated with fewer adverse effects compared to pan-HDAC inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDM2 Inhibitor MK-8242</VALIDVALUE>
          <VALUEMEANING>HDM2 Inhibitor MK-8242</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human homolog of double minute 2 (HDM2), with potential antineoplastic activity. Upon oral administration, HDM2 inhibitor MK-8242 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the degradation of p53 is inhibited, which may result in the restoration of p53 signaling. This induces p53-mediated tumor cell apoptosis. HDM2 is a member of the RING finger-type family of E3 ubiquitin protein ligases and targets p53 for degradation; it is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC Inhibitor MPT0E028</VALIDVALUE>
          <VALUEMEANING>HDAC Inhibitor MPT0E028</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, HDAC inhibitor MPT0E028 selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, MPT0E028 inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematoporphyrin Derivative</VALIDVALUE>
          <VALUEMEANING>Hematoporphyrin Derivative</VALUEMEANING>
          <MEANINGDESCRIPTION>A complex mixture of monomeric and aggregated porphyrins with photosensitizing activity. Upon systemic administration, hematoporphyrin derivatives accumulate in tumor cells and, once activated by red laser light (630 nm), in the presence of oxygen, produce singlet oxygen and other reactive oxygen radicals, resulting in local radical-mediated tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemiasterlin Analog E7974</VALIDVALUE>
          <VALUEMEANING>Hemiasterlin Analog E7974</VALUEMEANING>
          <MEANINGDESCRIPTION>An analog of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analog E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of existing microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Henatinib Maleate</VALIDVALUE>
          <VALUEMEANING>Henatinib Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt form of henatinib, an orally bioavalable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901</VALIDVALUE>
          <VALUEMEANING>HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2 Inhibitor DZD1516</VALIDVALUE>
          <VALUEMEANING>HER2 Inhibitor DZD1516</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, blood brain barrier (BBB) penetrable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor DZD1516 selectively binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2 Inhibitor TAS0728</VALIDVALUE>
          <VALUEMEANING>HER2 Inhibitor TAS0728</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available covalent inhibitor of human epidermal growth factor receptor 2 (HER2; ERBB2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor TAS0728 specifically and irreversibly binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2- and HER3 (ErbB3)-expressing tumor cells. HER2, a receptor tyrosine kinase mutated or overexpressed in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. HER3 has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2 Tri-specific Natural Killer Cell Engager DF1001</VALIDVALUE>
          <VALUEMEANING>HER2 Tri-specific Natural Killer Cell Engager DF1001</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2 tri-specific NK cell engager DF1001 targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131</VALIDVALUE>
          <VALUEMEANING>HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a fusion peptide, composed of three peptides derived from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4, P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities. Upon administration, IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein. In turn, the antibodies bind to three separate binding sites on HER2 expressed on tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase receptor for epidermal growth factor (EGF) and is often overexpressed by a variety of tumor cell types. Montanide ISA 51, also known as incomplete Freund&#39;s adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in a specific order into a single 49 amino acid peptide antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2-targeted DARPin MP0274</VALIDVALUE>
          <VALUEMEANING>HER2-targeted DARPin MP0274</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, designed ankyrin repeat proteins (DARPin)-based agent targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the HER2-targeted DARPin MP0274 binds to two distinct non-overlapping epitopes on HER2, thereby inhibiting the activity of HER2 and promoting HER2 internalization. This prevents HER2-mediated signaling, induces apoptosis and inhibits the growth of HER2-overexpressing tumor cells. DARPin also binds to human serum albumin, which extends the half-life of MP0274. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2 Inhibitor CP-724,714</VALIDVALUE>
          <VALUEMEANING>HER2 Inhibitor CP-724,714</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable quinazoline with potential antineoplastic activity.  CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth.  HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302</VALIDVALUE>
          <VALUEMEANING>HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-targeted lipidic nano-carrier containing the antineoplastic anthracycline antibiotic doxorubicin encapsulated within liposomes, and conjugated to a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), with potential antitumor activity. Upon administration of HER2-targeted liposomal doxorubicin hydrochloride MM-302, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the HER2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted liposomal delivery of doxorubicin improves efficacy while lowering the toxicity profile. HER2, a tyrosine kinase receptor, is overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2-targeting Antibody Fc Fragment FS102</VALIDVALUE>
          <VALUEMEANING>HER2-targeting Antibody Fc Fragment FS102</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, antibody fragment composed of a constant (Fc) region that is engineered to bind to the tumor-associated antigen human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. HER2-targeted antibody Fc fragment FS102 specifically binds to its HER2 epitope, and causes downregulation of HER2-mediated signaling. This leads to tumor cell apoptosis. HER2, a member of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) superfamily, is overexpressed on the cell surface of various solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Herba Scutellaria Barbata</VALIDVALUE>
          <VALUEMEANING>Herba Scutellaria Barbata</VALUEMEANING>
          <MEANINGDESCRIPTION>A Chinese herb isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba Scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heterodimeric Interleukin-15</VALIDVALUE>
          <VALUEMEANING>Heterodimeric Interleukin-15</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T-cells. The T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hexamethylene Bisacetamide</VALIDVALUE>
          <VALUEMEANING>Hexamethylene Bisacetamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines.  Its precise mechanism of action is unknown. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1125</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hexaminolevulinate</VALIDVALUE>
          <VALUEMEANING>Hexaminolevulinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexyl 5-aminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hexylresorcinol</VALIDVALUE>
          <VALUEMEANING>Hexylresorcinol</VALUEMEANING>
          <MEANINGDESCRIPTION>A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIF-1alpha Inhibitor PX-478</VALIDVALUE>
          <VALUEMEANING>HIF-1alpha Inhibitor PX-478</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active small molecule with potential antineoplastic activity. Although its mechanism of action has yet to be fully elucidated, HIF1-alpha inhibitor PX-478 appears to inhibit hypoxia-inducible factor 1-alpha (HIF1A) expression, which may result in decreased expression of HIF1A downstream target genes important to tumor growth and survival, a reduction in tumor cell proliferation, and the induction of tumor cell apoptosis. The inhibitory effect of this agent is independent of the tumor suppressor genes VHL and p53 and may be related to derangements in glucose uptake and metabolism due to inhibition of glucose transporter-1 (Glut-1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIF-2alpha Inhibitor PT2385</VALIDVALUE>
          <VALUEMEANING>HIF-2alpha Inhibitor PT2385</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Herbimycin</VALIDVALUE>
          <VALUEMEANING>Herbimycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Herbimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126</VALIDVALUE>
          <VALUEMEANING>Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone-lysine N-methyltransferase EZH2, with potential antineoplastic activity. Upon administration, histone-lysine N-methyltransferase EZH2 inhibitor GSK2816126 inhibits the activity of EZH2 and specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in cancer cells that overexpress this enzyme. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancers and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histrelin Acetate</VALIDVALUE>
          <VALUEMEANING>Histrelin Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5989730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001</VALIDVALUE>
          <VALUEMEANING>HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111689</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HLA-A*2402-Restricted Multipeptide Vaccine S-488410</VALIDVALUE>
          <VALUEMEANING>HLA-A*2402-Restricted Multipeptide Vaccine S-488410</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HM2/MMAE Antibody-Drug Conjugate ALT-P7</VALIDVALUE>
          <VALUEMEANING>HM2/MMAE Antibody-Drug Conjugate ALT-P7</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hodgkin&#39;s Antigens-GM-CSF-Expressing Cell Vaccine</VALIDVALUE>
          <VALUEMEANING>Hodgkin&#39;s Antigens-GM-CSF-Expressing Cell Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. In addition, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Holmium Ho 166 Poly(L-Lactic Acid) Microspheres</VALIDVALUE>
          <VALUEMEANING>Holmium Ho 166 Poly(L-Lactic Acid) Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>Holmium Ho166 containing poly l-lactic acid (PLA) microspheres with potential antineoplastic actvity. Upon intra-arterial hepatic administration of holmium 166 microspheres, this agent is able to emit both beta particles direct killing cells and gamma photons for nuclear imaging. In addition, since holmium 166 is paramagnetic, this agent can be used for magnetic resonance imaging (MRI).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPPH</VALIDVALUE>
          <VALUEMEANING>HPPH</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202</VALIDVALUE>
          <VALUEMEANING>HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201</VALIDVALUE>
          <VALUEMEANING>HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c</VALIDVALUE>
          <VALUEMEANING>HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene pgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. The poly-glutamic acid synthetase PgsA from Bacillus subtilis acts as an anchoring motif that facilitates the expression of the HPV antigen protein on the surface of the bacteria. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in various viral-related cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV E6/E7 DNA Vaccine GX-188E</VALIDVALUE>
          <VALUEMEANING>HPV E6/E7 DNA Vaccine GX-188E</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV E6/E7-encoding Arenavirus Vaccine HB-201</VALIDVALUE>
          <VALUEMEANING>HPV E6/E7-encoding Arenavirus Vaccine HB-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C</VALIDVALUE>
          <VALUEMEANING>HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic vaccine composed of the immunoadjuvant alpha-galactosylceramide (a-GC) and autologous antigen presenting cells (APCs), specifically B-lymphocytes and monocytes transfected with an adenoviral vector that expresses the tumor-associated antigens (TAAs) E6 and E7 derived from human papillomavirus (HPV) types 16 and 18 (HPV-16/18 E6/E7), with potential immunostimulating and antineoplastic activities. Upon administration of BVAC-C, the APCs stimulate the immune system to mount a TAA-specific cytotoxic T-lymphocyte (CTL) response, as well as natural killer (NK) cell, NK T-cell (NKT), helper T-cell and antibody-mediated immune responses, against the tumor cells. This directly or indirectly kills the TAA-expressing tumor cells. HPV-16/18 E6/E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation. a-GC, an NKT cell ligand, is used to specifically stimulate NKT cells and to further stimulate an anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101</VALIDVALUE>
          <VALUEMEANING>HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T-cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN</VALIDVALUE>
          <VALUEMEANING>HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\E6\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV6/11-targeted DNA Plasmid Vaccine INO-3107</VALIDVALUE>
          <VALUEMEANING>HPV6/11-targeted DNA Plasmid Vaccine INO-3107</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of plasmids encoding E6 and E7 genes of human papilloma virus subtype 6 (HPV-6) and 11 (HPV-11), with potential immunostimulating and antineoplastic activities. Upon administration via intramuscular electroporation, the HPV-6/11-targeted DNA plasmid vaccine INO-3107 expresses the HPV-6/11 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing HPV6 and/or HPV11 E6 and E7 proteins, resulting in tumor cell lysis. HPV-6/11 infections are associated with aerodigestive malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV-6-targeting Immunotherapeutic Vaccine INO-3106</VALIDVALUE>
          <VALUEMEANING>HPV-6-targeting Immunotherapeutic Vaccine INO-3106</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H-ras Antisense Oligodeoxynucleotide ISIS 2503</VALIDVALUE>
          <VALUEMEANING>H-ras Antisense Oligodeoxynucleotide ISIS 2503</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic oligodeoxynucleotide.  Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras.  ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2024</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV-16 E6 Peptides Vaccine/Candida albicans Extract</VALIDVALUE>
          <VALUEMEANING>HPV-16 E6 Peptides Vaccine/Candida albicans Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with an extract of Candida albicans, with potential immunomodulating and antineoplastic activities. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the Candida albicans may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions, and HPV may be a cause of some head and neck squamous cell carcinomas (HNSCCs). Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Antagonist KW-2478</VALIDVALUE>
          <VALUEMEANING>Hsp90 Antagonist KW-2478</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 antagonist KW-2478 appears to inhibit Hsp90, resulting in impaired signal transduction, inhibition of cell proliferation, and the induction of apoptosis in tumor cells. HSP90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor AB-010</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor AB-010</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor BIIB021</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor BIIB021</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active inhibitor of heat shock protein 90 (HSP90) with potential antineoplastic activity. HSP90, a chaperon protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins. HSP90 inhibitor BIIB021 specifically blocks active HSP90, thereby inhibiting its chaperon function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. As a result, CNF2024 has the potential to inhibit the growth of a wide range of cancer cells in both solid tumors and blood-based cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor Debio 0932</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor Debio 0932</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Debio 0932 specifically blocks Hsp90, thereby inhibiting its chaperone function and promoting the degradation of its client proteins, many of which are oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stabilization and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor DS-2248</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor DS-2248</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor HSP990</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor HSP990</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Hsp990 binds to and inhibits the activity of Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90, upregulated in a variety of tumor cells, is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor SNX-5422 Mesylate</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor SNX-5422 Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor SNX-5542 Mesylate</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor SNX-5542 Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5542 is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor TQB3474</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor TQB3474</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration, Hsp90 inhibitor TQB3474 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor BIIB028</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor BIIB028</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78846</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor XL888</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor XL888</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor XL888 specifically binds to Hsp90, inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; inhibition of tumor cell proliferation may result. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins, including Her-2 and Met.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90-targeted Photosensitizer HS-201</VALIDVALUE>
          <VALUEMEANING>Hsp90-targeted Photosensitizer HS-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A conjugate consisting of a heat shock protein 90 (Hsp90) inhibitor connected via a linker to verteporfin, a photosensitizing agent, with potential imaging, photodynamic and antineoplastic activities. Upon administration, the Hsp90 inhibitor moiety of HS-201 selectively binds to the Hsp90 ATP binding domain in tumor cells and HS-201 accumulates in tumor cells. The verteporfin moiety of HS-201 allows for visualization and photodynamic therapy of the tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. Verteporfin is a synthetic photosensitizer with photodynamic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301</VALIDVALUE>
          <VALUEMEANING>hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund&#39;s adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119616</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>hTERT Vaccine V934/V935</VALIDVALUE>
          <VALUEMEANING>hTERT Vaccine V934/V935</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine directed against human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. Upon administration, hTERT vaccine V934/V935 may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase is involved in the restoration and maintenance of telomere length and so the functional lifespan of cells. Abnormally reactivated in tumorigenesis, telomerase is expressed in the majority of human cancer cells but is not expressed or is expressed at very low levels in normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HuaChanSu</VALIDVALUE>
          <VALUEMEANING>HuaChanSu</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) containing a water soluble Bufo toad skin extract that includes the cardiac glycosides bufalin, cinobufagin and resibufogenin with potential antineoplastic and antiangiogenic activities. Although the exact mechanism of action of this TCM has yet to be fully elucidated, huachansu, which may be administered in an injectable form, may induce cell cycle arrest and apoptosis by suppressing the expression of anti-apoptotic proteins, such as Bcl-2, while inducing the expression of pro-apoptotic proteins, such as BAX.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Huaier Extract Granule</VALIDVALUE>
          <VALUEMEANING>Huaier Extract Granule</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable traditional Chinese medicine (TCM) composed of a granule containing an aqueous extract of Trametes robiniophila murr (Huaier), a mushroom found on hardwood tree trunks, with potential antineoplastic and anti-angiogenic activities. Although the exact mechanism of action through which Huaier exerts its effects is largely unknown, upon administration, this agent induces cell cycle arrest and apoptosis, and inhibits proliferation and migration of susceptible cancer cells through the modulation of various signal transduction pathways involved in carcinogenesis and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Huang Lian</VALIDVALUE>
          <VALUEMEANING>Huang Lian</VALUEMEANING>
          <MEANINGDESCRIPTION>A Chinese herb of a desiccated root from the plant Coptis chinensis. Although the mechanism of action remains to be fully elucidated, Huang Lian has antibacterial, antifungal, and antiprotozoal activities. In addition, this herb exhibits antioxidant property that influences positively on lipid metabolism, cause dilation of blood vessels, and may slow the growth of tumor cells. This herb contains rich amount of phytogens, such as berberine, palmatine, jatrorrhizine, columbamine, geniposide, and anti-HIV compound baicalin, which might explain the broad effects of this herb. Huang Lian is commonly used to treat diarrhea or dysentery in Chinese medicine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>huBC1-huIL12 Fusion Protein AS1409</VALIDVALUE>
          <VALUEMEANING>huBC1-huIL12 Fusion Protein AS1409</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104</VALIDVALUE>
          <VALUEMEANING>Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic human cytotoxic T-lymphocyte cell line (TALL-104) with potential antineoplastic activity. TALL-104 is an IL-2-dependent human leukemic T cell line, expressing CD8 and T-cell receptor CD3, but not CD16. Because these cells are endowed with MHC-non-restricted killer activity, TALL-104 has destructive potential against a broad range of tumors, while sparing normal cells. Upon administration, TALL-104 targets and interacts with tumor cells and activates apoptotic and necrotic pathways, eventually leading to lysis of tumor cells. In addition, TALL-104 may induce secretion of various cytokines, such as interferon-gamma, thereby potentially enhancing the cytotoxic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>hTERT-encoding DNA Vaccine INVAC-1</VALIDVALUE>
          <VALUEMEANING>hTERT-encoding DNA Vaccine INVAC-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of a plasmid encoding a modified, inactive form of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase which synthesizes telomeric DNA at the chromosome ends, fused to ubiquitin, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INVAC-1 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. hTERT conjugation to ubiquitin, a 76 amino-acid peptide involved in the regulation of normal protein intracellular turnover in the cytoplasm, enhances proteasome-dependent degradation of the hTERT protein, increases hTERT presentation by major histocompatibility complex (MHC) class I molecules and results in an increased immune response against hTERT.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human MOAB LICO 28a32</VALIDVALUE>
          <VALUEMEANING>Human MOAB LICO 28a32</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal immunoglobulin M (IgM) antibody with potential antineoplastic activity.  Human MOAB LICO 28a32 binds to the colon tumor-associated antigen 28A32 (CTAA 28A32) found on the cell surface and in the cytoplasm of colon carcinoma cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human Monoclonal Antibody 216</VALIDVALUE>
          <VALUEMEANING>Human Monoclonal Antibody 216</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-dependent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75kD B-cell cell surface glycoprotein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307</VALIDVALUE>
          <VALUEMEANING>Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. Upon internalization and processing, APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. The tumor-associated antigen (TAA) hCG beta is selectively overexpressed by a number of tumors including breast, colorectal, pancreatic, bladder and ovarian tumors; its expression may correlate with the stage of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human Papillomavirus 16 E7 Peptide/Padre 965.10</VALIDVALUE>
          <VALUEMEANING>Human Papillomavirus 16 E7 Peptide/Padre 965.10</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms.  HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator.  This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas.  PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hycanthone</VALIDVALUE>
          <VALUEMEANING>Hycanthone</VALUEMEANING>
          <MEANINGDESCRIPTION>A thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. Hycanthone interferes with parasite nerve function, resulting in parasite paralysis and death.  This agent also intercalates into DNA and inhibits RNA synthesis in vitro. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydralazine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Hydralazine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A direct-acting vasodilator that is used as an antihypertensive agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydroxychloroquine</VALIDVALUE>
          <VALUEMEANING>Hydroxychloroquine</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydroxyprogesterone Caproate</VALIDVALUE>
          <VALUEMEANING>Hydroxyprogesterone Caproate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic progestational agent similar to the endogenous progesterone used in hormone therapy or as a female contraceptive. Mimicking the action of progesterone, hydroxyprogesterone caporate binds to and activates nuclear progesterone receptors in the reproductive system and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. Due to the negative feedback mechanism seen with progesterone, this agent also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impeding the growth of estrogen-sensitive tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydroxytyrosol</VALIDVALUE>
          <VALUEMEANING>Hydroxytyrosol</VALUEMEANING>
          <MEANINGDESCRIPTION>A phenolic phytochemical naturally occurring in extra virgin olive oil, with potential antioxidant, anti-inflammatory and cancer preventive activities. Although the mechanisms of action through which hydroxytyrosol exerts its effects have yet to be fully determined, this agent affects the expression of various components of the inflammatory response, possibly through the modulation of the nuclear factor-kappa B (NF-kB) pathway. The effects include the modulation of pro-inflammatory cytokines, such as the inhibition of interleukin-1alpha (IL-1a), IL-1beta, IL-6, IL-12, and tumor necrosis factor-alpha (TNF-a); increased secretion of the anti-inflammatory cytokine IL-10; inhibition of the production of certain chemokines, such as C-X-C motif chemokine ligand 10 (CXCL10/IP-10), C-C motif chemokine ligand 2 (CCL2/MCP-1), and macrophage inflammatory protein-1beta (CCL4/MIP-1b); and inhibition of the expression of the enzymes inducible nitric oxide synthase (iNOS/NOS2) and prostaglandin E2 synthase (PGES), which prevent the production of nitric oxide (NO) and prostaglandin E (PGE2), respectively. In addition, hydroxytyrosol is able to regulate the expression of other genes involved in the regulation of tumor cell proliferation, such as extracellular signal-regulated and cyclin-dependent kinases. Also, hydroxytyrosol scavenges free radicals and prevents oxidative DNA damage. This induces apoptosis and inhibits proliferation in susceptible cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydroxyurea</VALIDVALUE>
          <VALUEMEANING>Hydroxyurea</VALUEMEANING>
          <MEANINGDESCRIPTION>A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypoxia-activated Prodrug TH-4000</VALIDVALUE>
          <VALUEMEANING>Hypoxia-activated Prodrug TH-4000</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I 131 Antiferritin Immunoglobulin</VALIDVALUE>
          <VALUEMEANING>I 131 Antiferritin Immunoglobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a rabbit antihuman ferritin IgG labeled with iodine 131 (I-131). Using anti-ferritin IgG as a carrier for I-131 may result in the targeted imaging and/or destruction of cells expressing ferritin. Observed in 35% to 100% of patients with hepatocellular carcinoma, high serum ferritin levels may be due to ferritin production by the tumor cells, or related to the associated iron overload and/or cirrhosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I 131 Monoclonal Antibody A33</VALIDVALUE>
          <VALUEMEANING>I 131 Monoclonal Antibody A33</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 131 (I-131). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancers, with only restricted expression in normal colonic mucosa. Using MoAb A33 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressed A33 antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I 131 Monoclonal Antibody CC49</VALIDVALUE>
          <VALUEMEANING>I 131 Monoclonal Antibody CC49</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and gamma radiation-emitting I 131 radionuclide specifically to tumor cells that express tumor-associated glycoprotein (TAG)-72, allowing localization of TAG-72-expressing tumor cells with radioimaging devices in diagnostic applications or resulting in specific TAG-72-expressing tumor cell radiocytotoxicity in therapeutic applications. Monoclonal antibody CC49 binds to TAG-72, a pancarcinoma antigen, with high affinity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypericin</VALIDVALUE>
          <VALUEMEANING>Hypericin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John&#39;s wort) with antidepressant, potential antiviral, antineoplastic and immunostimulating activities. Hypericin appears to inhibit the neuronal uptake of serotonin, norepinephrine, dopamine, gamma-amino butyric acid (GABA) and L-glutamate, which may contribute to its antidepressant effect. Hypericin may also prevent the replication of encapsulated viruses probably due to inhibition of the assembly and shedding of virus particles in infected cells. This agent also exerts potent phototoxic effects by triggering apoptotic signaling that results in formation of reactive oxygen species.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I 131 Monoclonal Antibody F19</VALIDVALUE>
          <VALUEMEANING>I 131 Monoclonal Antibody F19</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a murine monoclonal antibody (MoAb) F19 labelled with Iodine 131 (I-131). MoAb F19 was raised against fibroblast activation protein (FAP), which is highly expressed by tumor stromal cells. Using MoAb F19 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed FAP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I 131 Monoclonal Antibody Lym-1</VALIDVALUE>
          <VALUEMEANING>I 131 Monoclonal Antibody Lym-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with iodine 131 (I-131). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. I-131 MoAb Lym-1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express HLA-DR, thereby allowing imaging and/or treatment of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iadademstat</VALIDVALUE>
          <VALUEMEANING>Iadademstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, iadademstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ianalumab</VALIDVALUE>
          <VALUEMEANING>Ianalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IAP Inhibitor APG-1387</VALIDVALUE>
          <VALUEMEANING>IAP Inhibitor APG-1387</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, IAP inhibitor APG-1387 selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, APG-1387 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IAP Inhibitor HGS1029</VALIDVALUE>
          <VALUEMEANING>IAP Inhibitor HGS1029</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a small-molecule inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins with potential antineoplastic activity. IAP inhibitor HGS1029 selectively inhibits the biological activity of IAP proteins, which may restore apoptotic signaling pathways; this agent may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ibandronate Sodium</VALIDVALUE>
          <VALUEMEANING>Ibandronate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4147715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iberdomide</VALIDVALUE>
          <VALUEMEANING>Iberdomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129048</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7554854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iboctadekin</VALIDVALUE>
          <VALUEMEANING>Recombinant Interleukin-18</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, IL-18 displays antitumor effects in vitro and in animal models. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3147595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ibritumomab Tiuxetan</VALIDVALUE>
          <VALUEMEANING>Ibritumomab Tiuxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan.  This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90.  The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes one infusion of Rituximab preceding In-111 ZEVALIN. Step 2 follows Step 1 by seven to nine days and consists of a second infusion of Rituximab followed by Y-90 ZEVALIN.  ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2741549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Icotinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Icotinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99160</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Icrucumab</VALIDVALUE>
          <VALUEMEANING>Icrucumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ICT-121 Dendritic Cell Vaccine</VALIDVALUE>
          <VALUEMEANING>ICT-121 Dendritic Cell Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idarubicin</VALIDVALUE>
          <VALUEMEANING>Idarubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2744955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ibrutinib</VALIDVALUE>
          <VALUEMEANING>Ibrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule inhibitor of Bruton&#39;s tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5588944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idarubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Idarubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idarubicin-Eluting Beads</VALIDVALUE>
          <VALUEMEANING>Idarubicin-Eluting Beads</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained-release drug delivery embolization system containing small polymeric beads impregnated with the anthracycline antibiotic idarubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with idarubicin. During transarterial chemoembolization (TACE) in the hepatic artery, idarubicin-eluting beads embolize to the tumor vasculature, occlude tumor blood vessels and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. Simultaneously, idarubicin-eluting beads release cytotoxic idarubicin locally and in a sustained manner. This may result in idarubicin-mediated inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90593</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idasanutlin</VALIDVALUE>
          <VALUEMEANING>Idasanutlin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule, antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), with potential antineoplastic activity. Idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99131</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idecabtagene Vicleucel</VALIDVALUE>
          <VALUEMEANING>Idecabtagene Vicleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6851615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idetrexed</VALIDVALUE>
          <VALUEMEANING>Idetrexed</VALUEMEANING>
          <MEANINGDESCRIPTION>An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDH1 Mutant Inhibitor LY3410738</VALIDVALUE>
          <VALUEMEANING>IDH1 Mutant Inhibitor LY3410738</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of mutant form of the isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including the substitution mutation at arginine (R) in position 132, IDH1(R132), with potential antineoplastic activity. Upon oral administration, IDH1 mutant inhibitor LY3410738 specifically and covalently binds to and modifies a single cysteine (Cys269) in the allosteric binding pocket of mutant forms of IDH1, thereby inactivating IDH1. This inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This depletes 2-HG levels, prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutant forms of IDH1. In addition, LY3410738 has the ability to cross the blood-brain barrier (BBB). IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDH1(R132) Inhibitor IDH305</VALIDVALUE>
          <VALUEMEANING>IDH1(R132) Inhibitor IDH305</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDH1R132H-Specific Peptide Vaccine PEPIDH1M</VALIDVALUE>
          <VALUEMEANING>IDH1R132H-Specific Peptide Vaccine PEPIDH1M</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020</VALIDVALUE>
          <VALUEMEANING>Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idelalisib</VALIDVALUE>
          <VALUEMEANING>Idelalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO Peptide Vaccine IO102</VALIDVALUE>
          <VALUEMEANING>IDO Peptide Vaccine IO102</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with IDO peptide vaccine IO102 may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO/TDO Inhibitor HTI-1090</VALIDVALUE>
          <VALUEMEANING>IDO/TDO Inhibitor HTI-1090</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor HTI-1090 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, HTI-1090 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO/TDO Inhibitor LY-01013</VALIDVALUE>
          <VALUEMEANING>IDO/TDO Inhibitor LY-01013</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor LY-01013 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, LY-01013 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO-1 Inhibitor LY3381916</VALIDVALUE>
          <VALUEMEANING>IDO-1 Inhibitor LY3381916</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO1 Inhibitor MK-7162</VALIDVALUE>
          <VALUEMEANING>IDO1 Inhibitor MK-7162</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor MK-7162 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, MK-7162 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This agent may also induce increased interferon (IFN) production, which may lead to a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against and inhibit the growth of the IDO1-expressing tumor cells. IDO1, an enzyme overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO1 Inhibitor PF-06840003</VALIDVALUE>
          <VALUEMEANING>IDO1 Inhibitor PF-06840003</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, PF-06840003 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes; PF-06840003 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO1/TDO2 Inhibitor DN1406131</VALIDVALUE>
          <VALUEMEANING>IDO1/TDO2 Inhibitor DN1406131</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor DN1406131 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (KYN). This inhibits the IDO1/TDO2-KYN-AhR pathway. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types, plays a key role in immunosuppression and its expression is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO1/TDO2 Inhibitor M4112</VALIDVALUE>
          <VALUEMEANING>IDO1/TDO2 Inhibitor M4112</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor M4112 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (Kyn). This inhibits the IDO1/TDO2-Kyn-AhR pathway and abrogates AhR activation. This prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME), and may restore the immune response by stimulating a cytotoxic T-lymphocyte (CTL) immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types and plays a key role in immunosuppression. Its expression is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idronoxil</VALIDVALUE>
          <VALUEMEANING>Idronoxil</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDO1 Inhibitor KHK2455</VALIDVALUE>
          <VALUEMEANING>IDO1 Inhibitor KHK2455</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, KHK2455 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes. KHK2455 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Idronoxil Suppository NOX66</VALIDVALUE>
          <VALUEMEANING>Idronoxil Suppository NOX66</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil&#39;s bioavailability as compared to idronoxil alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ieramilimab</VALIDVALUE>
          <VALUEMEANING>Ieramilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed on various immune cells, negatively regulates cellular proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ifabotuzumab</VALIDVALUE>
          <VALUEMEANING>Ifabotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-fucosylated monoclonal antibody directed against the ephrin receptor A3 (EphA3), with potential antineoplastic activity. Upon administration, ifabotuzumab selectively binds to tumor cells expressing EphA3. This blocks both EphA3 activation and EphA3-mediated signaling, and induces apoptosis in EphA3-expressing tumor cells. In addition, ifabotuzumab can stimulate antibody dependent cell-mediated cytotoxicity (ADCC) against EphA3-expressing tumor cells. This agent also prevents tumor cell proliferation by inhibiting both EphA3 signaling and proliferation of endothelial cells in the tumor vasculature. The cell-surface receptor EphA3, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of tumor types but is not expressed in normal healthy adult tissues. It plays an important role in tumor cell proliferation. Non-fucosylation of the antibody enhances its ADCC activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ifetroban</VALIDVALUE>
          <VALUEMEANING>Ifetroban</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable thromboxane (TxA2) and prostaglandin H2 (PGH2) (TP) receptor antagonist, with anti-thrombotic, anti-hypertensive, anti-asthmatic and potential anti-metastatic activities. Upon administration, ifetroban targets and binds to TxA2 and PGH2 receptors, thereby preventing the activity of both TxA2 and PGH2 and disrupting their downstream signaling pathways. This prevents platelet activation, aggregation and thrombosis. It also prevents vascular constriction and causes vasodilation. In addition, as cancer cells use platelets to metastasize to different parts of the body, ifetroban can reduce the stickiness of the platelets and prevent metastasis. TxA2 causes vascular contraction and platelet activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IGF-1R Inhibitor PL225B</VALIDVALUE>
          <VALUEMEANING>IGF-1R Inhibitor PL225B</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor PL225B selectively binds to and inhibits the activities of IGF-1R, which may result in both the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis in IGF-1R-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IGF-1R/IR Inhibitor KW-2450</VALIDVALUE>
          <VALUEMEANING>IGF-1R/IR Inhibitor KW-2450</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential antineoplastic activity. IGF-1R/IR inhibitor KW-2450 selectively binds to and inhibits the activities of IGF-1R and IR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-R1 and IR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IGF-methotrexate Conjugate</VALIDVALUE>
          <VALUEMEANING>IGF-methotrexate Conjugate</VALUEMEANING>
          <MEANINGDESCRIPTION>A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-10 Immunomodulator MK-1966</VALIDVALUE>
          <VALUEMEANING>IL-10 Immunomodulator MK-1966</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that downregulates the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), with potential immunomodulating and antineoplastic activities. Upon administration, IL-10 immunomodulator MK-1966 blocks the activity of IL-10 and may abrogate the IL-10-induced immunosuppressive tumor microenvironment. This activates cell-mediated immunity against cancer cells, increases cytokine production, including interferon-gamma (IFN-g), decreases T regulatory cell (Treg) activity, and induces a tumor-specific cytotoxic CD8+ T-cell-mediated immune response, which enhances tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-12-expressing HSV-1 NSC 733972</VALIDVALUE>
          <VALUEMEANING>IL-12-expressing HSV-1 NSC 733972</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically engineered, replication selective, infected cell protein (ICP) 34.5 gene-deleted, oncolytic human simplex virus type 1 (HSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12), with potential antineoplastic activity. Upon intratumoral administration of HSV-1 expressing IL-12 NSC 733972, the IL-12-expressing HSV-1 preferentially infects and replicates in tumor cells of neuronal origin causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. In addition, the IL-12-expressing HSV-1 promotes the secretion of IL-12 by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ifosfamide</VALIDVALUE>
          <VALUEMEANING>Ifosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051</VALIDVALUE>
          <VALUEMEANING>IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051</VALUEMEANING>
          <MEANINGDESCRIPTION>Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000</VALIDVALUE>
          <VALUEMEANING>IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic agent utilizing mRNA to encode the cytokines interleukin-12sc (IL-12sc), interleukin-15sushi (IL-15sushi), interferon alpha (IFNa) and granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based immunotherapeutic agent SAR441000, mRNA is picked up by nearby cells, translated and released into the local tumor microenvironment (TME). Secretion of these cytokines activate the immune system by promoting the activation of natural killer cells (NKs) and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in an immune-mediated destruction of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-2 Recombinant Fusion Protein ALT-801</VALIDVALUE>
          <VALUEMEANING>IL-2 Recombinant Fusion Protein ALT-801</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3896160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1</VALIDVALUE>
          <VALUEMEANING>IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ilixadencel</VALIDVALUE>
          <VALUEMEANING>Ilixadencel</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf immune primer consisting of allogeneic monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors to produce pro-inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-12, p70 (IL-12 p70), C-C motif chemokine 4 (CCL4; macrophage inflammatory protein 1-beta; MIP-1-beta), C-C motif chemokine 5 (CCL5; RANTES), and C-X-C motif chemokine 10 (CXCL10), with potential immunostimulating and antineoplastic activities. Upon intratumoral injection of ilixadencel, the dendritic cells (DCs) release type 1 T-helper cell (Th1)-associated chemokines, including CCL4, CCL5 and CXCL10, that may recruit natural killer (NK)-cells and pre-DCs into the tumor microenvironment (TME). The interaction between NK cells and ilixadencel DCs may induce NK-cell-mediated killing of tumor cells, resulting in release of tumor-associated-antigens (TAAs). The production of interferon-gamma (IFN-gamma) by activated NK-cells and TNF-alpha/beta released by ilixadencel DCs will induce maturation and promote cross-presentation of TAAs by recruited endogenous &quot;bystander&quot; DCs. Migration of these antigen-loaded and matured &quot;bystander&quot; DCs to the tumor-draining lymph node will lead to a Th1-polarized activation of tumor-specific T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iloprost</VALIDVALUE>
          <VALUEMEANING>Iloprost</VALUEMEANING>
          <MEANINGDESCRIPTION>A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ilorasertib</VALIDVALUE>
          <VALUEMEANING>Ilorasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imalumab</VALIDVALUE>
          <VALUEMEANING>Imalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, imalumab binds to MIF, blocking its activity and preventing the MIF-mediated secretion of certain cytokines, including interleukin-1 beta and tumor necrosis factor-alpha. This may lead to an inhibition of cancer cell proliferation in MIF-overexpressing tumor cells. MIF, a pro-inflammatory cytokine overexpressed in some cancers, plays a key role in inflammation, immune responses and cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaradenant</VALIDVALUE>
          <VALUEMEANING>Adenosine A2A Receptor Antagonist AZD4635</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist AZD4635 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6161765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ilginatinib</VALIDVALUE>
          <VALUEMEANING>Ilginatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. Ilginatinib competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, ilginatinib inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs); JAK2V617F is a constitutively activated kinase that activates the JAK/STAT signaling pathway and dysregulates cell growth and function, and its expression transforms hematopoietic cells to cytokine-independent growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98109</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imatinib</VALIDVALUE>
          <VALUEMEANING>Imatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imatinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Imatinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2737465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imetelstat</VALIDVALUE>
          <VALUEMEANING>Imetelstat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic lipid-conjugated, 13-mer oligonucleotide N3&#39;-P5&#39;-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49084</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imetelstat Sodium</VALIDVALUE>
          <VALUEMEANING>Imetelstat Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of imetelstat, a synthetic lipid-conjugated, 13-mer oligonucleotide N3&#39; P5&#39;-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase RNA (hTR), imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a &quot;telomerase template antagonist&quot;), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imexon</VALIDVALUE>
          <VALUEMEANING>Imexon</VALUEMEANING>
          <MEANINGDESCRIPTION>A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma.  Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8.  Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29115</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imidazole Mustard</VALIDVALUE>
          <VALUEMEANING>Imidazole Mustard</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of imidazole with potent antineoplastic properties.  Imidazole mustard alkylates DNA, preferentially at guanine residues, resulting in DNA interstrand crosslinks and inhibition of DNA replication and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imidazole-Pyrazole</VALIDVALUE>
          <VALUEMEANING>Imidazole-Pyrazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic agent, also known as IMPY, with antineoplastic properties.  IMPY inhibits ribonucleotide reductase, an enzyme that converts ribonucleotides to deoxyribonucleotides during DNA synthesis; this agent specifically binds the smaller, nonheme-iron subunit of the enzyme. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imifoplatin</VALIDVALUE>
          <VALUEMEANING>Imifoplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imipramine Blue</VALIDVALUE>
          <VALUEMEANING>Imipramine Blue</VALUEMEANING>
          <MEANINGDESCRIPTION>A triphenylmethane-based dye and an inhibitor of nicotinamide adenine dinucleotide phosphate (NADP+) oxidase 4 (NOX4), with potential anti-invasive and anti-oxidative activities. Upon administration, imipramine blue (IB) inhibits the activity of NOX4 and prevents NOX4-mediated cell signaling. This prevents the formation of NOX4-mediated reactive oxygen species (ROS), abrogates the ROS-induced inhibition of protein tyrosine phosphatase (PTP) activation, and induces both G2/M cell cycle arrest and apoptosis. NOX4, an enzyme belonging to the NOX family of proteins, promotes the production of ROS and plays a key role in the suppression of PTP activation; it is upregulated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imgatuzumab</VALIDVALUE>
          <VALUEMEANING>Imgatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Imgatuzumab binds to the extracellular domain of EGFR, preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition of downstream ERK and JNK signaling pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various solid tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imiquimod</VALIDVALUE>
          <VALUEMEANING>Imiquimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod&#39;s proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immediate-release Onapristone</VALIDVALUE>
          <VALUEMEANING>Immediate-release Onapristone</VALUEMEANING>
          <MEANINGDESCRIPTION>An immediate-release (IR) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immediate-release Tablet Afuresertib</VALIDVALUE>
          <VALUEMEANING>Immediate-release Tablet Afuresertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An immediate-release (IR) tablet formulation containing afuresertib, an inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Upon oral administration of the IR formulation, afuresertib binds to and inhibits the activity of Akt, which may result in the inhibition of PI3K/Akt signaling pathway, decreased tumor cell proliferation and the induction of tumor cell apoptosis in Akt-expressing tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunocytokine NHS-IL12</VALIDVALUE>
          <VALUEMEANING>Immunocytokine NHS-IL12</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3595594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunomodulator OHR/AVR118</VALIDVALUE>
          <VALUEMEANING>Immunomodulator OHR/AVR118</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad-spectrum peptide nucleic acid formulation comprised of breakdown products of casein, peptone, RNA and serum albumin, with potential anti-inflammatory, immunomodulatory, anti-anorectic and anti-cachexia activities. AVR118 mainly contains two peptides, peptide A and peptide B, in approximately a 1:1 ratio: peptide A (31 a. a.) is derived from bovine casein; peptide B (21 a. a.) is covalently linked via phosphodiester bond to a diadenosine unit. In addition, AVR118 contains nucleosides, nucleoside diphosphates and nucleoside monophosphates. Upon subcutaneous injection of AVR118, this agent affects the synthesis of many pro-inflammatory chemokines and cytokines, especially monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-8, IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha). In particular, AVR118 stimulates macrophages to produce these mediators while in highly activated macrophages this agent inhibits their synthesis. This way, AVR118 may prevent the excessive release of cytokines seen during chemotherapy. Controlling the release of pro-inflammatory mediators may ultimately improve appetite and mood, increase strength and weight gain, and decrease fatigue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunomodulatory Agent CC-11006</VALIDVALUE>
          <VALUEMEANING>Immunomodulatory Agent CC-11006</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunomodulatory Oligonucleotide HYB2055</VALIDVALUE>
          <VALUEMEANING>Immunomodulatory Oligonucleotide HYB2055</VALUEMEANING>
          <MEANINGDESCRIPTION>A second generation synthetic oligonucleotide with immunomodulatory and potential antineoplastic activities. HYB2055 consists of unmethylated CpG dinucleotide motifs that are present abundantly in bacterial and parasitic DNA, and a novel DNA structure, called an immunomer that contributes to metabolic stability of the agent. Upon infections, CpG-containing DNA released from pathogenic organisms triggers host immune responses, which are mediated by the action of intracellular toll-like receptor 9 (TLR9), a pattern recognition receptor. This agent mimics bacterial DNA and selectively activates TLR9, thereby initiating immune signaling pathways, and leading to activation of B-cells and dendritic cells and induction of Th1-type cytokine production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotherapeutic Combination Product CMB305</VALIDVALUE>
          <VALUEMEANING>Immunotherapeutic Combination Product CMB305</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic combination product composed of LV305, an engineered lentiviral vector that both targets dendritic cells (DCs) and contains nucleic acids encoding the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic activities. Upon intradermal administration of LV305, the DC-targeting lentiviral vector targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor cells, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122922</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotherapy Regimen MKC-1106-MT</VALIDVALUE>
          <VALUEMEANING>Immunotherapy Regimen MKC-1106-MT</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapy regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase.  After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a &quot;primed&quot; cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunocytokine NHS-IL2-LT</VALIDVALUE>
          <VALUEMEANING>Immunocytokine NHS-IL2-LT</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of a mouse-human chimeric antibody directed against DNA released by necrotic tumor cells fused to two molecules of a genetically modified human interleukin-2 (IL-2) with potential antineoplastic activity. Upon administration, the antibody moiety of immunocytokine NHS-IL2-LT binds to DNA released by necrotic tumor cells located primarily at the core of necrotic solid tumors, delivering the IL-2 moiety. In turn, the IL-2 moiety of this agent activates the immune system to mount a cytotoxic T lymphocyte response against nearby tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotoxin CMD-193</VALIDVALUE>
          <VALUEMEANING>Immunotoxin CMD-193</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunotoxin directed against the Lewis Y antigen conjugated with calicheamicin, a hydrophobic enediyne antibiotic, with potential antineoplastic activity. CMD193 binds to the Lewis Y antigen, a tetrasaccharide expressed on the cell surfaces of many tumor cell types. Upon binding, CMD-193 is internalized, thereby delivering the attached calicheamicin to Lewis Y antigen-expressing tumor cells. Calicheamicin binds non-covalently to the minor groove of DNA and prompts conformational changes and DNA oxidation, thereby inhibiting DNA synthesis and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IMT-1012 Immunotherapeutic Vaccine</VALIDVALUE>
          <VALUEMEANING>IMT-1012 Immunotherapeutic Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inactivated Oncolytic Virus Particle GEN0101</VALIDVALUE>
          <VALUEMEANING>Inactivated Oncolytic Virus Particle GEN0101</VALUEMEANING>
          <MEANINGDESCRIPTION>An inactivated, non-replicating particle of hemagglutinating virus of Japan (HVJ), an oncolytic virus of the paramyxovirus family, with potential immunostimulating and antineoplastic activities. Upon intracutaneous administration, GEN0101 targets and binds to the cytosolic nucleic acid receptor retinoic acid-inducible gene I (RIG-I). This induces RIG-I-mediated signaling and a potent innate immune response against tumor cells, leading to the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTL), and apoptosis in tumor cells. GEN0101 also activates dendritic cells (DCs) to produce cytokine interleukin-6 (IL-6), suppressing the function of regulatory T cells (Treg), a negative regulator of immune responses. The suppression of Treg activity helps maintain the induced immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inalimarev</VALIDVALUE>
          <VALUEMEANING>Inalimarev</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indatuximab Ravtansine</VALIDVALUE>
          <VALUEMEANING>Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a monoclonal antibody directed against a highly-expressed myeloma cell surface antigen covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-myeloma cell surface antigen immunoconjugate BT-062 binds to an unspecified cell surface antigen highly expressed on myeloma cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of myeloma tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indibulin</VALIDVALUE>
          <VALUEMEANING>Indibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule with antimitotic and potential antineoplastic activities. Indibulin binds to a site on tubulin that is different from taxane- or Vinca alkaloid-binding sites, destabilizing tubulin polymerization and inducing tumor cell cycle arrest and apoptosis. This agent has been shown to be active against multidrug-resistant (MDR) and taxane- resistant tumor cell lines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indicine-N-Oxide</VALIDVALUE>
          <VALUEMEANING>Indicine-N-Oxide</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural pyrrolizidine alkaloid with antineoplastic properties.  Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indisulam</VALIDVALUE>
          <VALUEMEANING>Indisulam</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel sulfonamide compound with potential antineoplastic activity. Indisulam inhibits cyclin-dependent kinases (CDK), which regulate cell cycle progression and are usually over-expressed in cancerous cells. Inhibition of CDK results in G1/S phase arrest of the cell cycle, and may lead to induction of apoptosis and inhibition of tumor cell proliferation. In addition, indisulam also inhibits carbonic anhydrases (CA), especially isoforms IX and XII that are involved in aqueous humor production and are highly overexpressed in some types of cancers. Inhibition of CA IX and XII results in interference with ion exchange and pH in hypoxic tumor tissue and preventing chemoresistance to weakly basic antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Individualized MVA-based Vaccine TG4050</VALIDVALUE>
          <VALUEMEANING>Individualized MVA-based Vaccine TG4050</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incyclinide</VALIDVALUE>
          <VALUEMEANING>Incyclinide</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indole-3-Carbinol</VALIDVALUE>
          <VALUEMEANING>Indole-3-Carbinol</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6847008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indomethacin</VALIDVALUE>
          <VALUEMEANING>Indomethacin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indoximod</VALIDVALUE>
          <VALUEMEANING>Indoximod</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indoximod Prodrug NLG802</VALIDVALUE>
          <VALUEMEANING>Indoximod Prodrug NLG802</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inebilizumab</VALIDVALUE>
          <VALUEMEANING>Inebilizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inecalcitol</VALIDVALUE>
          <VALUEMEANING>Inecalcitol</VALUEMEANING>
          <MEANINGDESCRIPTION>An analog of calcitriol and a vitamin D3 receptor (VDR) agonist, with potential antineoplastic activity. Upon administration, inecalcitol targets and binds to VDR. This activates VDR and VDR-mediated signal transduction pathways. This modulates the VDR-mediated expression of certain genes, including the expression of anti-cancer genes, enhances cellular differentiation, induces tumor cell apoptosis and inhibits tumor cell growth. VDR plays a central role in calcium homeostasis and in the growth of certain cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infigratinib</VALIDVALUE>
          <VALUEMEANING>Infigratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88302</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infigratinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Infigratinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Infliximab</VALIDVALUE>
          <VALUEMEANING>Anti-TNF (Infliximab, Remicade)</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5678502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indusatumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Indusatumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of indusatumab vedotin selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, but is also overexpressed on the surface of gastrointestinal cancers. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis in GCC-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ingenol Mebutate</VALIDVALUE>
          <VALUEMEANING>Ingenol Mebutate</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective small-molecule activator of protein kinase C (PKC) isolated from the plant Euphorbia peplus with potential antineoplastic activity. Ingenol mebutate activates various protein kinase C (PKC) isoforms, thereby inducing apoptosis in some tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes including proliferation, differentiation, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ingenol Mebutate Gel</VALIDVALUE>
          <VALUEMEANING>Ingenol Mebutate Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical, aqueous gel formulation containing the mebutate salt form of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with potential antineoplastic activity. Upon topical application of the ingenol mebutate gel, ingenol activates various PKC isoforms, which induces apoptosis in certain tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iniparib</VALIDVALUE>
          <VALUEMEANING>Iniparib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. Although the mechanism of action is unknown, iniparib appears to be cytotoxic in cells with DNA alterations or DNA damage, like that found in tumor cells with mutations in the ataxia telangiectasia mutated (ATM) gene. ATM encodes a serine/threonine protein kinase and mutations of the gene are associated with ataxia telangiectasia and contribute to certain cancers such as T-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>iNKT Cell Agonist ABX196</VALIDVALUE>
          <VALUEMEANING>iNKT Cell Agonist ABX196</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic glycolipid agonist for natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the iNKT cell agonist ABX196, this agent targets and binds to iNKTs, thereby activating iNKTs. In turn, iNKTs recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Innate Immunostimulator rBBX-01</VALIDVALUE>
          <VALUEMEANING>Innate Immunostimulator rBBX-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant 19 kDa protein derived from the Apicomplexa protozoan Eimeria with potential immunostimulating and antitumor activities. Upon administration, innate immunostimulator rBBX-01 activates dendritic cells (DCs), stimulates the Toll-like receptor 11 (TLR-11)-mediated release of interleukin-12 (Il-12) from DCs, and induces a T-helper 1 (Th1) type immune response, which may induce an immune response against tumor cells. Infection with Eimeria, a coccidian commonly infecting the intestine, may be negatively correlated with tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INO-1001</VALIDVALUE>
          <VALUEMEANING>INO-1001</VALUEMEANING>
          <MEANINGDESCRIPTION>A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inodiftagene Vixteplasmid</VALIDVALUE>
          <VALUEMEANING>Inodiftagene Vixteplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant DNA plasmid carrying the gene for diphtheria toxin-A (dT-A) chain under the regulation of the H19 promoter, with potential antineoplastic activity. Upon intravesical administration, dT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The dT-A chain binds to nicotinamide adenine dinucleotide (NAD) and inactivates the ADP-ribosylation of elongation factor 2 (EF2), resulting in the inhibition of protein synthesis and cell death leading to tumor cell destruction. Inodiftagene Vixteplasmid does not carry the gene for the diphtheria toxin-B (dT-B) chain, thereby preventing the transfer of the toxic dT-A chain between cells. H19, a paternally imprinted, oncofetal gene, is highly expressed in embryonic and certain malignant tissues, but minimally expressed in normal, adult tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inosine 5&#39;-monophosphate Dehydrogenase Inhibitor FF-10501-01</VALIDVALUE>
          <VALUEMEANING>Inosine 5&#39;-monophosphate Dehydrogenase Inhibitor FF-10501-01</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of inosine 5&#39;- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inosine Monophosphate Dehydrogenase Inhibitor AVN944</VALIDVALUE>
          <VALUEMEANING>Inosine Monophosphate Dehydrogenase Inhibitor AVN944</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis.  Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49181</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inositol</VALIDVALUE>
          <VALUEMEANING>Inositol</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inproquone</VALIDVALUE>
          <VALUEMEANING>Inproquone</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoquinone-based antineoplastic agent. Inproquone was never marketed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Integrin alpha-2 Inhibitor E7820</VALIDVALUE>
          <VALUEMEANING>Integrin alpha-2 Inhibitor E7820</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Integrin Receptor Antagonist GLPG0187</VALIDVALUE>
          <VALUEMEANING>Integrin Receptor Antagonist GLPG0187</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. Upon administration, GLPG0187 binds to and blocks the activity of 5 RGD-integrin receptor subtypes, including alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6 and alpha5beta1. This may result in the inhibition of endothelial cell-cell interactions and endothelial cell-matrix interactions, and the prevention of angiogenesis and metastasis in tumor cells expressing these integrin receptors. Integrin receptors are transmembrane glycoproteins expressed on the surface of tumor vessel endothelial cells and some types of cancer cells, and play a crucial role in endothelial cell adhesion and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Alfacon-1</VALIDVALUE>
          <VALUEMEANING>Interferon Alfacon-1</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of consensus interferon which contains an additional methionyl amino acid residue.  Consensus interferon (also known as interferon alfacon-1, rCon-IFN, and CIFN) is a genetically engineered synthetic interferon created from the most common amino acid sequences from the naturally occurring alpha interferons.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inotuzumab Ozogamicin</VALIDVALUE>
          <VALUEMEANING>Inotuzumab Ozogamicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5577157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Alfa-N1</VALIDVALUE>
          <VALUEMEANING>Interferon Alfa-N1</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Alfa-N3</VALIDVALUE>
          <VALUEMEANING>Interferon Alfa-N3</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulated therapeutic analog of the endogenous alpha interferon containing multiple interferon species with antiviral and antitumor properties.  Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with an interferon-specific response element, thereby inducing: antiviral effects (the most important being inhibition of viral protein synthesis); antiproliferative effects (including inhibition of cellular growth and alteration of cellular differentiation); anticancer effects (including interference with oncogene expression); and immune-modulating effects (including activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C30136</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Beta-1A</VALIDVALUE>
          <VALUEMEANING>Interferon Beta-1A</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities. Upon administration, interferon beta-1a targets and binds to specific type I IFN receptors, which eventually results in the transcription and translation of genes containing an interferon-specific response element and leads to the production of various anti-viral proteins and modulates the production of various immune-modulating proteins. This reduces the production of certain pro-inflammatory cytokines while upregulating the anti-inflammatory cytokine interleukin 10 (IL-10), upregulates the expression of major histocompatibility (MHC) I proteins which allows for increased presentation of peptides derived from viral antigens, and activates CD8+ T cells as well as other immune cells. Endogenous IFN-beta-1a is produced following viral infection and it plays a key role in innate immune response against viral pathogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Gamma-1b</VALIDVALUE>
          <VALUEMEANING>Interferon Gamma-1b</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin-12-Fc Fusion Protein DF6002</VALIDVALUE>
          <VALUEMEANING>Interleukin-12-Fc Fusion Protein DF6002</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of human interleukin-12 (IL-12) fused to a Fc fragment, with potential immunomodulatory and antineoplastic activities. Upon administration of IL-12-Fc fusion protein DF6002, the IL-12 moiety binds to the IL-12 receptor. This may activate the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin-15 Agonist Fusion Protein SHR1501</VALIDVALUE>
          <VALUEMEANING>Interleukin-15 Agonist Fusion Protein SHR1501</VALUEMEANING>
          <MEANINGDESCRIPTION>A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activity. Upon administration, SHR-1501 activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells without stimulating regulatory T-cells (Tregs). The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. SHR1501 is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action. The Fc moiety allows for an extended half-life of SHR-1501 while cross linking IL-15 with IL-15Ra sushi domain improves stability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin-15 Fusion Protein BJ-001</VALIDVALUE>
          <VALUEMEANING>Interleukin-15 Fusion Protein BJ-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A human fusion protein composed of the cytokine interleukin (IL)-15 linked with an integrins-targeting moiety, with potential antineoplastic activity. Upon subcutaneous administration, the integrins-targeting moiety of BJ-001 targets tumor cells that overexpress integrins such as alpha v beta 3 (avb3), alpha v beta 5 (avb5) and alpha v beta 6 (avb6) and the IL-15 moiety binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) cells and CD8+ T-lymphocytes. This activates and increases the levels of NK cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T- and NK cell development, activation and proliferation. Integrins are involved in tumor growth, angiogenesis, and metastasis and they are overexpressed in a variety of tumor cell types. The linkage of the two moieties may limit the effects of IL-15 to the local tumor microenvironment (TME), increasing efficacy while reducing systemic toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306</VALIDVALUE>
          <VALUEMEANING>Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306</VALUEMEANING>
          <MEANINGDESCRIPTION>An interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain, with potential antineoplastic activity. Upon administration, XmAb24306 stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. XmAb24306 does not require endogenous IL-15Ra for its activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin-2 Liposome</VALIDVALUE>
          <VALUEMEANING>Interleukin-2 Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation in which liposomes are loaded with the cytokine interleukin-2 (IL-2). By activating cytotoxic T-lymphocytes, such as lymphokine-activated killer cells, and increasing levels of the cytotoxic cytokines interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta), IL-2 may exhibit antitumoral activity.  Liposomal formulations of IL-2 may promote entry of the cytokine into target tumor cells and may be used as an immunoadjuvant in cancer vaccine therapy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon-gamma-expressing Adenovirus Vaccine ASN-002</VALIDVALUE>
          <VALUEMEANING>Interferon-gamma-expressing Adenovirus Vaccine ASN-002</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intetumumab</VALIDVALUE>
          <VALUEMEANING>Intetumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Intetumumab competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitate the adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases; and propagate signaling events that promote the survival and differentiation of cells in newly formed vasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intiquinatine</VALIDVALUE>
          <VALUEMEANING>Intiquinatine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intoplicine</VALIDVALUE>
          <VALUEMEANING>Intoplicine</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inulin</VALIDVALUE>
          <VALUEMEANING>Inulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring, indigestible and non-absorbable oligosaccharide produced by certain plants with prebiotic and potential anticancer activity. Inulin stimulates the growth of beneficial bacteria in the colon, including Bifidobacteria and Lactobacilli, thereby modulating the composition of microflora. This creates an environment that protects against pathogens, toxins and carcinogens, which can cause inflammation and cancer. In addition, fermentation of inulin leads to an increase in short-chain fatty acids and lactic acid production, thereby reducing colonic pH, which may further control pathogenic bacteria growth and may contribute to inulin&#39;s cancer protective properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 124 Monoclonal Antibody A33</VALIDVALUE>
          <VALUEMEANING>Iodine I 124 Monoclonal Antibody A33</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 124 (I-124). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancer metastases, with only restricted expression in normal colonic mucosa. I-124 MoAb A33 delivers beta particle emitting I-124 nuclide directly to metastatic colorectal tissues, thereby this agent could be used in kinetics studies or radioimmunotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 124 Monoclonal Antibody M5A</VALIDVALUE>
          <VALUEMEANING>Iodine I 124 Monoclonal Antibody M5A</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), labeled with iodine I 124 (I-124) with potential radiolocalization applications. Upon administration, the antibody moiety of iodine I 124 monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using positron-emission tomography (PET), thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 125-Anti-EGFR-425 Monoclonal Antibody</VALIDVALUE>
          <VALUEMEANING>Iodine I 125-Anti-EGFR-425 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of a murine IgG2a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR) labeled with iodine I 125 with potential antineoplastic activity. Iodine I 125 anti-EGFR-425 monoclonal antibody binds specifically to the epidermal growth factor receptor (EGFR). Upon binding to EGFR-expressing tumor cells, this agent is internalized, selectively delivering a potentially cytotoxic dose of gamma radiation. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74051</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP</VALUEMEANING>
          <MEANINGDESCRIPTION>An iodine 131 radioimmunoconjugate of a small immunoprotein (SIP), derived from the variable region fragment of human monoclonal antibody L19, that is directed against the extra-domain B (ED-B) of fibronectin, with potential radioimmunotherapeutic activity. The SIP moiety of iodine I 131 anti-fibronectin antibody fragment L19-SIP binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. Upon internalization, the I 131 radionuclide may selectively detect or deliver cytotoxic radiation to fibronectin-expressing tumor cells. ED-B of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is expressed in the majority of aggressive solid human tumors, whereas it is not detectable in normal vessels and tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Apamistamab</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Apamistamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iobenguane I-131</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Metaiodobenzylguanidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Meta-iodobenzylguanidine localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3585878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Derlotuximab Biotin</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Derlotuximab Biotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An iodine 131 labeled radioimmunoconjugate of monoclonal antibody (MOAB) TNT-1/B with radioimaging and antineoplastic properties. MOAB TNT-1/B was developed for radioimmunotherapy of solid tumors, designated as Tumor Necrosis Treatment (TNT). TNT exploits the presence of degenerating and necrotic cells within tumors by utilizing MOAbs directed against universal, intracellular nucleosomal determinants consisting of histone H1 and DNA. This MOAB was conjugated with biotin (B) molecules, which increase pharmacokinetic performance of the monoclonal antibody. Upon administration, iodine I 131 derlotuximab biotin delivers I 131 to tumor cells and results in the targeted imaging and/or destruction of cells with exposed necrotic antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Ethiodized Oil</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Ethiodized Oil</VALUEMEANING>
          <MEANINGDESCRIPTION>A cytotoxic radioconjugate consisting of lipiodol, an iodinated ethyl ester derived from poppy seed oil, labeled with iodine 131 (I-131).  I-131 Lipiodol accumulates in hepatocellular carcinoma and hepatoblastoma tumor cells, resulting in targeted cytotoxicity to tumor cells while sparing surrounding normal cells and tissues. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 IPA</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 IPA</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the tumor-specific amino acid derivative 4-iodo-L-phenylalanine labeled with iodine I 131, a beta emitting radionuclide, with potential antineoplastic activity. Upon administration, iodine I 131 IPA actively crosses the blood-brain barrier and accumulates specifically in gliomas, via the amino acid transport system l-amino acid transporter 1 (LAT1) over-expressed in malignant glioma cells. where it delivers a cytotoxic dose of beta radiation. Cells that are exposed to radiation may also release potent toxins into the intracellular environment, leading to radiation-induced biological bystander effects (RIBBE) and killing cells not directly exposed to the radiation. Iodine I 131 IPA may also act synergistically with external irradiation due to its radiosensitizing property.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 MIP-1095</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 MIP-1095</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody CC49-deltaCH2</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Monoclonal Antibody CC49-deltaCH2</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the humanized CH2 domain-deleted monoclonal antibody CC49 and iodine I 131 with antineoplastic activity. Monoclonal antibody CC49-deltaCH2 targets the tumor-associated glycoprotein 72 (TAG-72) that is expressed by a wide range of human neoplasms including colorectal, gastric, pancreatic, ovarian, endometrial, breast, non-small cell lung, and prostate cancers. Iodine I 131 monoclonal antibody CC49-deltaCH2 binds to tumor cells expressing TAG-72, selectively delivering a cytotoxic dose of beta and gamma radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody F16SIP</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Monoclonal Antibody F16SIP</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody (MoAb) against human A1 domain of tenascin-C, in small immunoprotein (SIP) format conjugated with iodine 131 with potential antineoplastic activity. Iodine I 131 MoAb F16SIP binds to tenascin-C on the vascular tissues and delivers cytotoxic radiation to the tumors, thereby minimizing systemic radiotoxicity. Tenascin-C is a glycoprotein of the extracellular matrix, and the large isoform of this matrix protein is expressed and restricted around vascular structures in the tumor stroma of a variety of different tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody G-250</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Monoclonal Antibody G-250</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 chimeric monoclonal antibody G-250 binds to G-250, a renal-cell carcinoma-associated antigen, delivering cytotoxic iodine I 131 specifically to renal carcinoma cells that express G-250.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody muJ591</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Monoclonal Antibody muJ591</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a mouse monoclonal antibody (MoAb) J591 labeled with Iodine 131 (I-131). MoAb muJ591 recognizes the extracellular domain of the prostate-specific membrane antigen (PSMA) and reacts with tumor vascular endothelium. Using MoAb muJ591 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed PSM.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2604</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Omburtamab</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Omburtamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immunomodulatory glycoprotein 4Ig-B7-H3 with potential radioimaging and radioimmunotherapeutic uses. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4Ig-B7-H3 inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). In vitro, it has been shown that monoclonal antibody-mediated masking of 4Ig-B7-H3 on neuroblastoma cells resulted in the enhancement of natural killer (NK)-mediated lysis of target cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody 81C6</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Monoclonal Antibody 81C6</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Rituximab</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Rituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Tenatumomab</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Tenatumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (TAA) tenascin-C (TNC), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to TNC, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing TNC. TNC, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 TM-601</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 TM-601</VALUEMEANING>
          <MEANINGDESCRIPTION>An iodine 131 (I 131) radioconjugate of the synthetic chlorotoxin (CTX) TM-601 with potential antiangiogenic and antineoplastic activities. CTX is a 36 amino acid neurotoxin found in the venom of the giant yellow scorpion Leiurus quinquestriatus that preferentially binds malignant cells of neuroectodermal origin. The recombinant version of this peptide, TM-601, is expressed in and purified from E. coli and then covalently linked to I 131 to produce 131I-TM-601. 131I-TM-601 binds to tumor cells of neuroectodermal origin and is internalized; administered once, it may be used as a radioimaging agent; repeated administration may result in a tumor-specific, cumulative radiocytotoxic dose of I 131. In addition, TM-601 alone, similar to native CTX, may inhibit angiogenesis due to its ability to bind to and inhibit matrix metalloproteinase 2 (MMP-2), an endopeptidase involved in tissue remodeling processes such as angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Tositumomab</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Tositumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ioflubenzamide I-131</VALIDVALUE>
          <VALUEMEANING>Ioflubenzamide I-131</VALUEMEANING>
          <MEANINGDESCRIPTION>An iodine 131-radiolabeled small-molecule benzamide compound with potential antineoplastic activity. The benzamide moiety of 131-I-MIP-1145 binds to melanin, selectively delivering a cyotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. Melanin pigments, polymer derivatives of the amino acid tyrosine, are over-expressed in approximately 40% of melanomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ionomycin</VALIDVALUE>
          <VALUEMEANING>Ionomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A polyether antibiotic isolated from Streptomyces conglobatus sp. nov. Trejo with antineoplastic activity.  Ionomycin is a calcium ionophore that increases intracellular Ca++ levels, possibly relating to endonuclease activation of lymphocytes and decreased ratio of Bcl-2 to Bax and ultimately apoptosis.  In addition, this agent is used to investigate the role of intracellular calcium in cellular processes. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C596</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipafricept</VALIDVALUE>
          <VALUEMEANING>Ipafricept</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6687980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipatasertib</VALIDVALUE>
          <VALUEMEANING>Ipatasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipilimumab</VALIDVALUE>
          <VALUEMEANING>Ipilimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3185135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I-131</VALIDVALUE>
          <VALUEMEANING>Iodine I 131</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipomeanol</VALIDVALUE>
          <VALUEMEANING>Ipomeanol</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural toxic furan isolated from a fungus-infected sweet potato (Ipomoea batatas) with potential antineoplastic activity.  Ipomeanol is activated by mixed function oxidases in vivo to its epoxide form, an alkylating agent that covalently binds cell macromolecules. This agent causes cell death by a p53-independent mechanism. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iproplatin</VALIDVALUE>
          <VALUEMEANING>Iproplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death.  Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596</VALIDVALUE>
          <VALUEMEANING>iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic, off-the-shelf, chimeric antigen receptor (CAR)-natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a NK cell-specific anti-CD19 CAR, a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF), with potential immunostimulatory and antineoplastic activities. Upon administration, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15RF enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. When used in combination with monoclonal antibodies, the hnCD16 Fc receptor of FT596 binds to the Fc portion of tumor cell-bound monoclonal antibodies, leading to NK cell activation, cytokine secretion and enhanced antibody-dependent cellular cytotoxicity (ADCC). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>iPSC-derived CD16-expressing Natural Killer Cells FT516</VALIDVALUE>
          <VALUEMEANING>iPSC-derived CD16-expressing Natural Killer Cells FT516</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic, off-the-shelf, natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived CD16-expressing NK cells FT516 bind to the Fc portion of tumor cell-bound monoclonal antibodies and activate NK cell activation, cytokine secretion and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. FT516 NK cells&#39; hnCD16 Fc receptor prevents downregulation and optimizes binding to tumor-targeting antibodies for enhanced ADCC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>iPSC-derived Natural Killer Cells FT500</VALIDVALUE>
          <VALUEMEANING>iPSC-derived Natural Killer Cells FT500</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of off-the-shelf, natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived natural killer cells FT500 bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. Additionally, iPSC-NK cells secrete inflammatory cytokines and chemokines including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokines 3, 4, and 22 (CCL3, CCL4, and CCL22), and C-X-C motif chemokine 10 (CXCL10), thereby enhancing T-cell activity and recruitment to the tumor site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iratumumab</VALIDVALUE>
          <VALUEMEANING>Iratumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody with potential antineoplastic activity.  MDX-060 is a fully humanized antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily found on activated lymphocytes.  CD30 is over-expressed in various lymphoproliferative disorders, Hodgkin disease and other lymphomas, and other cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iridium Ir 192</VALIDVALUE>
          <VALUEMEANING>Iridium Ir 192</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioactive isotope of iridium. Iridium-192 emits gamma rays and has a half-life of 74 days. A high dose rate of this radioisotope can be used in brachytherapy to treat tumors by selectively delivering a cytotoxic dose of radiation to the tumor site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irinotecan</VALIDVALUE>
          <VALUEMEANING>Irinotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62040</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3597791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irinotecan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Irinotecan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet</VALIDVALUE>
          <VALUEMEANING>Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable combination tablet containing the semisynthetic camptothecin derivative irinotecan and the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181AK, with potential antineoplastic activity. HM30181A binds to P-gp and prevents the P-gp-mediated efflux of irinotecan from tumor cells, which may result in greater intracellular concentrations of irinotecan and enhanced cytotoxicity. Retained intracellularly, the prodrug irinotecan is converted, by a carboxylesterase-converting enzyme, to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38). SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters and is overexpressed by some MDR tumors, preventing the intracellular accumulation of various cytotoxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irinotecan-Eluting Beads</VALIDVALUE>
          <VALUEMEANING>Irinotecan-Eluting Beads</VALUEMEANING>
          <MEANINGDESCRIPTION>Microporous hydrospheres of polyvinylalcohol (PVA) impregnated with irinotecan with potential antineoplastic activity. In transarterial chemoembolization (TACE), irinotecan-eluting beads are administered into blood vessels that feed the tumor, occluding tumor blood vessels and inducing ischemic tumor necrosis while simultaneously delivering high-dose chemotherapy locally. Irinotecan, a semisynthetic derivative of camptothecin, inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irofulven</VALIDVALUE>
          <VALUEMEANING>Irofulven</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iroplact</VALIDVALUE>
          <VALUEMEANING>Iroplact</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the endogenous chemokine platelet factor 4 with potential antiangiogenesis and antineoplastic activities. As a heparin-binding tetramer, iroplact inhibits growth factor-stimulated endothelial cell proliferation, migration, and angiogenesis; it has been shown that this agent inhibits fibroblast growth factor 2 (FGF2) angiogenic activity downstream from the FGF2 receptor. Its activity is antagonized by heparin. Recombinant platelet factor 4 may also directly inhibit the proliferation of some tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irosustat</VALIDVALUE>
          <VALUEMEANING>Irosustat</VALUEMEANING>
          <MEANINGDESCRIPTION>Steroid sulfatase inhibitor BN 83495 selectively binds to and inhibits steroid sulfatase (STS), which may inhibit the production of locally active estrogens and so inhibit estrogen-dependent cell growth in tumor cells, such as those of the breast, ovary, and endometrium. STS is a cytoplasmic enzyme responsible for the conversion of circulating inactive estrone sulfate and estradiol sulfate to biologically active unconjugated estrone and estradiol, respectively.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irinotecan Sucrosofate</VALIDVALUE>
          <VALUEMEANING>Liposomal Irinotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation of the hydrochloride salt of the semisynthetic camptothecin analogue irinotecan with potential antineoplastic activity. During the S phase of the cell cycle, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5831614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130</VALIDVALUE>
          <VALUEMEANING>Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic irradiated human lung cancer cell vaccine expressing a fusion protein composed of the OX40 ligand (OX40L) linked to an immunoglobulin (Ig) (OX40L-Ig), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130, the irradiated lung cancer cells continuously express OX40L-Ig. OX40L may then target, bind to and activate its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40; CD134), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, and induces the proliferation and activation of memory and effector T-lymphocytes against the human lung cancer cells. In turn, this promotes a CTL-mediated immune response against the endogenous lung cancer cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isatuximab</VALIDVALUE>
          <VALUEMEANING>Isatuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isobrucein B</VALIDVALUE>
          <VALUEMEANING>Isobrucein B</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from the tropical plant Cedronia granatensis with potential antineoplastic and chemopreventive activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iso-fludelone</VALIDVALUE>
          <VALUEMEANING>Iso-fludelone</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation epothilone B analogue with potential anti-mitotic and antineoplastic activites. Iso-fludelone binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to other generations of epothilones, iso-fludelone exhibits increased stability, water solubility, potency, duration of action, tumor penetration as well as reduced toxicity. In addition, this agent is a not a substrate of the P-glycoprotein (P-gp), a multidrug resistance pump often overexpressed in cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isotretinoin</VALIDVALUE>
          <VALUEMEANING>Isotretinoin</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ispinesib</VALIDVALUE>
          <VALUEMEANING>Ispinesib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38131</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ispinesib Mesylate</VALIDVALUE>
          <VALUEMEANING>Ispinesib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of ispinesib, a synthetic small molecule, derived from quinazolinone, and kinesin spindle protein (KSP) inhibitor, with antineoplastic activity. Ispinesib selectively inhibits KSP and prevents its binding to microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the M-phase, and cell death in tumor cells that are actively dividing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ISS 1018 CpG Oligodeoxynucleotide</VALIDVALUE>
          <VALUEMEANING>ISS 1018 CpG Oligodeoxynucleotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A short, synthetic, unmethylated CpG motif-based oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. As an immunostimulatory sequence (ISS) that signals through Toll-like receptor 9 (TLR9), ISS 1018 CpG ODN induces the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin (IL) -12, and tumor necrosis factor (TNF) -alpha by plasmacytoid dendritic cells (pDC). pDC, through cell-cell contact, and IFN-alpha and -beta, in turn, induce natural killer (NK) cell proliferation, NK cell production of IFN-gamma, and NK cell-mediated cytotoxicity; secreted IFNs also stimulate bystander T cell activation and differentiation of naive CD4+ T cells into T-helper 1 cells on specific antigen challenge. In addition, ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Istiratumab</VALIDVALUE>
          <VALUEMEANING>Istiratumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isocoumarin NM-3</VALIDVALUE>
          <VALUEMEANING>Isocoumarin NM-3</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antiangiogenic isocoumarin with potential antineoplastic activity.  NM-3 inhibits vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby inhibiting endothelial cell proliferation.  This agent also induces apoptosis by a mechanism involving reactive oxygen species. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Itacitinib</VALIDVALUE>
          <VALUEMEANING>Itacitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8123275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Itacitinib Adipate</VALIDVALUE>
          <VALUEMEANING>Itacitinib Adipate</VALUEMEANING>
          <MEANINGDESCRIPTION>The adipate salt form of itacitinib, an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ITK Inhibitor CPI-818</VALIDVALUE>
          <VALUEMEANING>ITK Inhibitor CPI-818</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) with potential immunomodulatory and antineoplastic activities. Upon oral administration, ITK inhibitor CPI-818 selectively and covalently binds to the cysteine residue at position 442 (CYS-442) of ITK, thereby disrupting ITK-mediated signal transduction, while sparing tyrosine-protein kinase TXK (resting lymphocyte kinase, RLK) activity. This may abrogate T-cell receptor (TCR) signaling through ITK and inhibit TCR-induced proliferation of malignant T-cells. Additionally, inhibiting ITK activation may prevent the upregulation of GATA-3, a transcription factor that drives T-helper 2 (Th2) cell differentiation and is overexpressed in certain T-cell lymphomas. Thus, selective inhibition of ITK may inhibit Th2 responses without affecting T-helper 1 (Th1)-dependent immunity. ITK, a member of the Tec family of non-receptor protein tyrosine kinases plays a significant role in the T-cell development, differentiation and production of pro-inflammatory cytokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Itraconazole Dispersion In Polymer Matrix</VALIDVALUE>
          <VALUEMEANING>Itraconazole Dispersion In Polymer Matrix</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104048</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ivaltinostat</VALIDVALUE>
          <VALUEMEANING>Ivaltinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Ivaltinosta tinhibits the catalytic activity of HDAC, resulting in an accumulation of highly acetylated chromatin histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. In particular, this agent enhances the histone acetylation of the tumor suppressor gene p53. This results in an accumulation of p53, p53-dependent transactivation and apoptosis in tumor cells. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK Inhibitor INCB047986</VALIDVALUE>
          <VALUEMEANING>JAK Inhibitor INCB047986</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK1 Inhibitor INCB052793</VALIDVALUE>
          <VALUEMEANING>JAK1 Inhibitor INCB052793</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK2 Inhibitor AZD1480</VALIDVALUE>
          <VALUEMEANING>JAK2 Inhibitor AZD1480</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK2 Inhibitor BMS-911543</VALIDVALUE>
          <VALUEMEANING>JAK2 Inhibitor BMS-911543</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-911543 selectively inhibits JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ivosidenib</VALIDVALUE>
          <VALUEMEANING>Ivosidenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ivuxolimab</VALIDVALUE>
          <VALUEMEANING>Ivuxolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ixabepilone</VALIDVALUE>
          <VALUEMEANING>Ixabepilone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ixazomib</VALIDVALUE>
          <VALUEMEANING>Ixazomib</VALUEMEANING>
          <MEANINGDESCRIPTION>An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5944043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ixazomib Citrate</VALIDVALUE>
          <VALUEMEANING>Ixazomib Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6025022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK Inhibitor</VALIDVALUE>
          <VALUEMEANING>JAK Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8062016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK2 Inhibitor XL019</VALIDVALUE>
          <VALUEMEANING>JAK2 Inhibitor XL019</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jin Fu Kang</VALIDVALUE>
          <VALUEMEANING>Jin Fu Kang</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese herbal medicine derived from the plant Astragalus membranaceus with potential immunopotentiation activity. Jin Fu Kang may stimulate anti-tumor macrophage and natural killer cell activity and may enhance immune recognition of tumor cells by inhibiting the production of T-helper cell type 2 (Th2) cytokines such as interleukin-4 (IL-4) and interleukin-10 (IL-10).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JNK Inhibitor CC-401</VALIDVALUE>
          <VALUEMEANING>JNK Inhibitor CC-401</VALUEMEANING>
          <MEANINGDESCRIPTION>A second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. Based on the chemistry of SP600125, another anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP binding site of JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun; decreased transcription activity of c-Jun; and a variety of cellular effects including decreased cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kanitinib</VALIDVALUE>
          <VALUEMEANING>Kanitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A tyrosine kinase inhibitor targeting the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR; MET) and vascular endothelial growth factor receptor 2 (VEGFR2), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, kanitinib targets and binds to c-Met and VEGFR2, thereby disrupting c-Met- and VEGFR2-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met and/or VEGFR2 protein. c-Met and VEGFR2 are both overexpressed in many tumor cell types and play key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ketoconazole</VALIDVALUE>
          <VALUEMEANING>Ketoconazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ketotrexate</VALIDVALUE>
          <VALUEMEANING>Ketotrexate</VALUEMEANING>
          <MEANINGDESCRIPTION>A folic acid antagonist and mammalian dihydrofolate reductase inhibitor with antineoplastic activity. Ketotrexate inhibits dihydrofolate reductase, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid which is essential for the synthesis of purine nucleotides and thymidylate. By depleting tetrahydrofolic acid availability, DNA synthesis is halted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRAS G12C Inhibitor LY3499446</VALIDVALUE>
          <VALUEMEANING>KRAS G12C Inhibitor LY3499446</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, LY3499446 targets and covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRASG12C Inhibitor JNJ-74699157</VALIDVALUE>
          <VALUEMEANING>KRASG12C Inhibitor JNJ-74699157</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRAS-MAPK Signaling Pathway Inhibitor JAB-3312</VALIDVALUE>
          <VALUEMEANING>KRAS-MAPK Signaling Pathway Inhibitor JAB-3312</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the KRAS-mitogen-activated protein kinase (MAPK) signaling pathway, with potential antineoplastic activity. Upon oral administration, JAB-3312 blocks signaling through the KRAS-MAPK pathway. This prevents proliferation of susceptible cancer cells in which the KRAS-MAPK signaling pathway is overactivated. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, such as those seen in KRAS-mutant cancer cells, and drives cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kanglaite</VALIDVALUE>
          <VALUEMEANING>Kanglaite</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable microemulsion of a purified oil extracted from the seeds of the traditional Chinese medicinal herb Coix lacryma-jobi (Job&#39;s tears), with potential antineoplastic activity. Although the exact mechanism of action is unknown, kanglaite exhibits an antineoplastic effect, potentially via interfering with the cell cycle and halting tumor cells in the G2/M phase, which may eventually inhibit mitosis and proliferation of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRN5500</VALIDVALUE>
          <VALUEMEANING>KRN5500</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus.  KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions.  This agent also induces cell differentiation and caspase-dependent apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KSP Inhibitor AZD4877</VALIDVALUE>
          <VALUEMEANING>KSP Inhibitor AZD4877</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis. Inhibition of KSP results in an inhibition of mitotic spindle assembly, activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, thereby causing cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, AZD4877 may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KSP Inhibitor SB-743921</VALIDVALUE>
          <VALUEMEANING>KSP Inhibitor SB-743921</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important protein involved in the early stages of mitosis that is expressed in proliferating cells. Inhibition of KSP results in inhibition of mitotic spindle assembly and interrupts cell division, thereby causing cell cycle arrest and induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Labetuzumab Govitecan</VALIDVALUE>
          <VALUEMEANING>Labetuzumab Govitecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity.  The monoclonal antibody moiety of labetuzumab govitecan selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lacutamab</VALIDVALUE>
          <VALUEMEANING>Lacutamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, lacutamab binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124999</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ladiratuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Ladiratuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ladirubicin</VALIDVALUE>
          <VALUEMEANING>Ladirubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A 4-demethoxydaunorubicin (idarubicin) analog with an aziridinyl group in position C-3&#39; and a methylsulphonyl on position C-4&#39;, with potential antineoplastic activity. Upon intravenous administration, ladirubicin alkylates guanine residues at the N7 position in the DNA major groove, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laetrile</VALIDVALUE>
          <VALUEMEANING>Laetrille</VALUEMEANING>
          <MEANINGDESCRIPTION>Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LAIR-2 Fusion Protein NC410</VALIDVALUE>
          <VALUEMEANING>LAIR-2 Fusion Protein NC410</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein of leukocyte-associated immunoglobulin (Ig)-like receptor (LAIR)-2, a high-affinity collagen receptor, with potential immunomodulatory and antineoplastic activities. Upon administration, LAIR-2 fusion protein NC410 binds to the ligand collagen of LAIR-1 (CD305), thereby blocking the binding of LAIR-1 to its ligand collagen and inhibiting LAIR-1-mediated immune suppression. This may result in enhanced T-cell and dendritic cell (DC) activities, and cytotoxic T-lymphocyte (CTL) and anti-tumor immune responses. LAIR-1, a collagen-receptor and an inhibitory immune receptor belonging to the Ig superfamily, is expressed on many peripheral blood mononuclear cells (PBMC) including T-cells and DCs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173559</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kunecatechins Ointment</VALIDVALUE>
          <VALUEMEANING>Kunecatechins Ointment</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical ointment containing a green tea polyphenol mixture (kunecatechins) with potential antiviral, antibacterial, antioxidant, and chemopreventive activities. Kunecatechins is a partially purified fraction of the aqueous extract of green tea leaves from Camellia sinensis and contains catechins and other green tea components. Catechins, polyphenolic antioxidant plant metabolites or flavonoids, comprise most of the drug substance in kunecatechins with epigallocatechin gallate (EGCG) present as the primary catechin. Catechins may inhibit basic functions of human papillomavirus (HPV), counteract specific changes in tumor cells, affect cell signaling, and stimulate the immune system. Topical application of kunecatechins ointment has been reported to reduce HPV-induced genital and anal warts through a not yet fully understood mechanism, which may involve anti-oxidative activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Landogrozumab</VALIDVALUE>
          <VALUEMEANING>Landogrozumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration,  landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laniquidar</VALIDVALUE>
          <VALUEMEANING>Laniquidar</VALUEMEANING>
          <MEANINGDESCRIPTION>A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lanreotide Acetate</VALIDVALUE>
          <VALUEMEANING>Lanreotide Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lapachone</VALIDVALUE>
          <VALUEMEANING>Lapachone</VALUEMEANING>
          <MEANINGDESCRIPTION>A poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. Beta-lapachone (b-lap) is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), creating a futile oxidoreduction that generates high levels of superoxide. In turn, the highly reactive oxygen species (ROS) interact with DNA, thereby causing single-strand DNA breaks and calcium release from endoplasmic reticulum (ER) stores. Eventually, the extensive DNA damage causes hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme facilitating DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and ER-stress induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. NQO1, a flavoprotein and two-electron oxidoreductase, is overexpressed in a variety of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lapatinib</VALIDVALUE>
          <VALUEMEANING>Lapatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4916291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lapatinib Ditosylate</VALIDVALUE>
          <VALUEMEANING>Lapatinib Ditosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5709520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laprituximab Emtansine</VALIDVALUE>
          <VALUEMEANING>Laprituximab Emtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>A targeted antibody payload (TAP)-based immunoconjugate consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of laprituximab emtansine binds to and inhibits EGFR on tumor cell surfaces. Inhibition of EGFR prevents EGFR-mediated signaling and may inhibit tumor cell proliferation. After internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival. Linkage of the antibody and drug, through a nonreducible linker, appears to contribute to the improved efficacy and reduced toxicity of this antibody-drug conjugate (ADC) compared to similar ADCs constructed with reducible linkers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lapuleucel-T</VALIDVALUE>
          <VALUEMEANING>Lapuleucel-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based vaccine targets tumors expressing the HER2/neu marker.  HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers.  APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient.  These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laromustine</VALIDVALUE>
          <VALUEMEANING>Laromustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larotaxel</VALIDVALUE>
          <VALUEMEANING>Larotaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larotrectinib</VALIDVALUE>
          <VALUEMEANING>Larotrectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larotrectinib Sulfate</VALIDVALUE>
          <VALUEMEANING>Larotrectinib Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lavendustin A</VALIDVALUE>
          <VALUEMEANING>Lavendustin A</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lazertinib</VALIDVALUE>
          <VALUEMEANING>Lazertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148147</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lead Pb 212 TCMC-trastuzumab</VALIDVALUE>
          <VALUEMEANING>Lead Pb 212 TCMC-trastuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larotinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Larotinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of larotinib, a reversible pan-ErbB inhibitor with potential antineoplastic activity. Upon administration, larotinib binds to and inhibits ErbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing ErbB. The ErbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13673411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lefitolimod</VALIDVALUE>
          <VALUEMEANING>Lefitolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic oligonucleotide based on a proprietary double stem-loop immunomodulator design with potential immunostimulating activity. Lefitolimod binds to and activates intracellular Toll-like receptor 9 (TLR9) in monocytes/macrophages, plasmacytoidal and myeloid dendritic cells (DCs), and natural killer (NK) cells, initiating immune signaling pathways and inducing T-helper 1 cell (Th1) production leading to the production of memory T cells and a Th1-mediated immune response. By activating the immune system, MGN1703 may attack tumor associated antigen (TAAs). TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leflunomide</VALIDVALUE>
          <VALUEMEANING>Leflunomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1128</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13368988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenalidomide</VALIDVALUE>
          <VALUEMEANING>Lenalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lentinan</VALIDVALUE>
          <VALUEMEANING>Lentinan</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenvatinib</VALIDVALUE>
          <VALUEMEANING>Lenvatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6682739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenvatinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Lenvatinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenzilumab</VALIDVALUE>
          <VALUEMEANING>Lenzilumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125081</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lerociclib</VALIDVALUE>
          <VALUEMEANING>Lerociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lestaurtinib</VALIDVALUE>
          <VALUEMEANING>Lestaurtinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lenalidomide Analog KPG-121</VALIDVALUE>
          <VALUEMEANING>Lenalidomide Analog KPG-121</VALUEMEANING>
          <MEANINGDESCRIPTION>A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Letetresgene Autoleucel</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794</VALUEMEANING>
          <MEANINGDESCRIPTION>Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the autologous anti-NY-ESO1/LAGE-1 TCR-transduced c259 T-lymphocytes GSK3377794 specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7479347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Letolizumab</VALIDVALUE>
          <VALUEMEANING>Letolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of letolizumab specifically targets and binds to CD40L expressed on T-lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B-lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B-cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B-cells and GPIIb/IIIa-dependent T-cell proliferation, letolizumab may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of letolizumab to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of letolizumab to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T-cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Letrozole</VALIDVALUE>
          <VALUEMEANING>Letrozole</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2921027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leucovorin Calcium</VALIDVALUE>
          <VALUEMEANING>Leucovorin Calcium</VALUEMEANING>
          <MEANINGDESCRIPTION>An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, &#39;rescuing&#39; the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug&#39;s metabolite to its target enzyme, thus prolonging drug activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leuprolide</VALIDVALUE>
          <VALUEMEANING>Leuprolide</VALUEMEANING>
          <MEANINGDESCRIPTION>The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2921029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leuprolide Mesylate Injectable Suspension</VALIDVALUE>
          <VALUEMEANING>Leuprolide Mesylate Injectable Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leurubicin</VALIDVALUE>
          <VALUEMEANING>Leurubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An N-L-leucyl prodrug of the anthracycline doxorubicin, with antineoplastic activity. Leurubicin is converted to its active form doxorubicin in or on tumor cells by hydrolytic enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lexatumumab</VALIDVALUE>
          <VALUEMEANING>HGS-ETR2 (Lexatumumab)</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64621</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lexibulin</VALIDVALUE>
          <VALUEMEANING>Lexibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Lexibulin inhibits tubulin polymerization in tumor blood vessel endothelial cells and tumor cells, blocking the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leuprolide Acetate</VALIDVALUE>
          <VALUEMEANING>Leuprolide Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L-Gossypol</VALIDVALUE>
          <VALUEMEANING>L-Gossypol</VALUEMEANING>
          <MEANINGDESCRIPTION>The levo-enantiomer of an orally bioavailable polyphenolic aldehyde, derived primarily from unrefined cottonseed oil, with potential antineoplastic activity. Mimicking the inhibitory BH3 (Bcl-2 homology 3) domain of endogenous antagonists of Bcl-2, L-gossypol binds to and inhibits various anti-apoptotic Bcl-2 proteins, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. This agent has greater affinity for Bcl-2 proteins than racemic gossypol.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liarozole</VALIDVALUE>
          <VALUEMEANING>Liarozole</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liarozole Fumarate</VALIDVALUE>
          <VALUEMEANING>Liarozole Fumarate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally active fumarate salt of the benzimidazole derivative liarozole with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liarozole Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Liarozole Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The fumarate salt of an orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Licorice</VALIDVALUE>
          <VALUEMEANING>Licorice</VALUEMEANING>
          <MEANINGDESCRIPTION>An herbal extract derived from the root of the plant Glycyrrhiza glabra with potential anti-inflammatory, antioxidant, and antineoplastic activities. Licorice root extract contains glycoside glycyrrhizinic acid and numerous flavonoids. Glycyrrhizinic acid in licorice root extract is hydrolyzed to glycyrrhetic acid (GA); GA inhibits 11 beta-hydroxysteroid dehydrogenase, resulting in inhibition of the conversion of cortisol to the inactive steroid cortisone and elevated cortisol levels. In addition, GA inhibits 17,20-lyase and 17 beta-hydroxysteroid dehydrogenase, resulting in decreased conversions of 17-hydroxyprogesterone to androstenedione and androstenedione to testosterone. The primary antioxidant found in licorice root, the flavonoid glabridin, may inactivate or inhibit the activities of some cytochrome P450 enzymes. In tumor cells, beta-hydroxy-DHP, another flavonoid, may induce Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lifastuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Lifastuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DNIB0600A binds to NaPi2b-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. NaPi2b, a tumor-associated antigen (TAA), overexpressed in a variety of cancer cell types, plays a key role in transport of inorganic phosphate and the maintenance of phosphate homeostasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lifileucel</VALIDVALUE>
          <VALUEMEANING>Lifileucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient&#39;s tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lifirafenib</VALIDVALUE>
          <VALUEMEANING>Lifirafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124995</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lilotomab</VALIDVALUE>
          <VALUEMEANING>Lilotomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. Upon administration, lilotomab both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Licartin</VALIDVALUE>
          <VALUEMEANING>Licartin</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Limonene, (+)-</VALIDVALUE>
          <VALUEMEANING>Limonene, (+)-</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral dietary supplement containing a natural cyclic monoterpene, and a major component of the oil extracted from citrus peels, with potential chemopreventive and antineoplastic activities. Upon oral administration, D-limonene activates aldehyde dehydrogenase 3A1 (ALDH3A1), thereby decreasing aldehyde level. This may protect salivary stem/progenitor cells (SSPCs) from toxic aldehydes and prevent or improve radiation-induced xerostomia. Limonene and its metabolites perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol may also inhibit tumor growth through inhibition of p21-dependent signaling and may induce apoptosis via the induction of the transforming growth factor beta-signaling pathway. In addition, they inhibit post-translational modification of signal transduction proteins, resulting in G1 cell cycle arrest as well as differential expression of cell cycle- and apoptosis-related genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Limonene, (+/-)-</VALIDVALUE>
          <VALUEMEANING>Limonene, (+/-)-</VALUEMEANING>
          <MEANINGDESCRIPTION>A racemic mixture of limonene, a natural cyclic monoterpene and major component of the oil extracted from citrus rind with chemo-preventive and antitumor activities. The metabolites of DL-limonene, perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol are suggested to inhibit tumor growth through inhibition of p21-dependent signaling, induce apoptosis via the induction of the transforming growth factor beta-signaling pathway, inhibit post-translational modification of signal transduction proteins, result in G1 cell cycle arrest as well as cause differential expression of cell cycle- and apoptosis-related genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linifanib</VALIDVALUE>
          <VALUEMEANING>Linifanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6423718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linoleyl Carbonate-Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Linoleyl Carbonate-Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the 6-omega fatty acid derivative 2&#39;-linoleyl carbonate (LOC) conjugated to paclitaxel, a taxane compound extracted from the Pacific yew tree Taxus brevifolia, with potential antineoplastic activity. Paclitaxel binds to and stabilizes tubulin, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. LOC enhances the uptake of paclitaxel by tumor cells, thereby concentrating this agent in tumor cells compared to normal cells, and may decrease its toxicity profile; fatty acids serve as energy sources and biochemical precursors for the fast growing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679582</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linrodostat</VALIDVALUE>
          <VALUEMEANING>Linrodostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, linrodostat specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, BMS-986205 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linsitinib</VALIDVALUE>
          <VALUEMEANING>Linsitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3444804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lintuzumab</VALIDVALUE>
          <VALUEMEANING>Lintuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liothyronine I-131</VALIDVALUE>
          <VALUEMEANING>Liothyronine I-131</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate of synthetic active thyroid hormone, liothyronine (T3), labeled with Iodine 131. Liothyronine involves many important metabolic functions and is essential to the proper development and differentiation of all cells. I131 liothyronine may be used in radiotherapy in thyroid cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1</VALIDVALUE>
          <VALUEMEANING>Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1</VALUEMEANING>
          <MEANINGDESCRIPTION>short interfering RNAs (siRNAs) directed against polo-like kinase 1 (PLK1, STPK13), with potential antineoplastic activity. Upon administration of lipid-encapsulated anti-PLK1 siRNA TKM-PLK1, siRNA binds to PLK1 mRNA, which results in the inhibition of both the translation and expression of the PLK1 protein. Blockage of PLK1 expression prevents proper tumor cell mitosis, causes cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis; its expression is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation. The pegylated lipid bilayer of SNALP provides stability and protects siRNA degradation; it facilitates uptake into the cell and release from endosomes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679587</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Linperlisib</VALIDVALUE>
          <VALUEMEANING>Linperlisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</VALIDVALUE>
          <VALUEMEANING>Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipid Nanoparticle Encapsulated OX40L mRNA-2416</VALIDVALUE>
          <VALUEMEANING>Lipid Nanoparticle Encapsulated OX40L mRNA-2416</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</VALIDVALUE>
          <VALUEMEANING>Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</VALUEMEANING>
          <MEANINGDESCRIPTION>A biodegradable, lyophilized lipid nanoparticle (LNP) encapsulating small interfering ribonucleic acid (siRNA) directed against glutathione S-transferase P (GSTP), with potential antineoplastic activity. Upon administration of LNP encapsulating GSTP siRNA NBF-006, the LNP formulation delivers the siRNA particles to the tumor cells where the GSTP siRNA targets and binds to GSTP mRNA. This results in the inhibition of the translation and expression of GSTP and may inhibit proliferation of KRAS-overexpressing tumor cells. GSTP, an enzyme overexpressed in many tumor cell types, is involved in modulating MAP kinase-related cell-signaling pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170753</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</VALIDVALUE>
          <VALUEMEANING>Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Bcl-2 Antisense Oligonucleotide BP1002</VALIDVALUE>
          <VALUEMEANING>Liposomal Bcl-2 Antisense Oligonucleotide BP1002</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal c-raf Antisense Oligonucleotide</VALIDVALUE>
          <VALUEMEANING>Liposomal c-raf Antisense Oligonucleotide</VALUEMEANING>
          <MEANINGDESCRIPTION>The liposomal formulation of a c-raf-1 antisense oligonucleotide, with potential antineoplastic activity. Liposomal c-raf antisense oligonucleotide targets the translation initiation site of human c-raf-1 mRNA, thereby blocking the expression and production of Raf-1 protein and thus inhibit tumor cell growth and development. Raf-1 plays a key role in the RAF/MEK/ERK signaling pathway, which regulates mammalian cell proliferation and growth. The liposomal formulation increases the solubility of the c-raf antisense oligonucleotide, thus improving its pharmacodynamic profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Curcumin</VALIDVALUE>
          <VALUEMEANING>Liposomal Curcumin</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation containing curcumin, a poorly water-soluble polylphenol pigment isolated from the plant Curcuma longa, with potential antineoplastic, chemopreventive, antioxidant, anti-angiogenic and anti-inflammatory activities. Upon intravenous administration of liposomal curcumin, this agent blocks the formation of reactive-oxygen species, neutralizes free radicals, and exhibits anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. In addition, curcumin disrupts various cell signal transduction pathways involved in carcinogenesis, inhibits the activity of nuclear factor-kappa B (NF-kB), SRC, and annexin A2 (ANXA2), and reduces the expression of both matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2). This prevents and/or inhibits tumor cell formation and proliferation. Liposome encapsulation of curcumin improves its efficacy, when compared to the administration of unencapsulated curcumin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Cytarabine</VALIDVALUE>
          <VALUEMEANING>Liposomal Cytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Daunorubicin Citrate</VALIDVALUE>
          <VALUEMEANING>Liposomal Daunorubicin Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Eribulin Mesylate</VALIDVALUE>
          <VALUEMEANING>Liposomal Eribulin Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</VALIDVALUE>
          <VALUEMEANING>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Mitoxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Liposomal Mitoxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in the rapidly dividing cancer cells. The liposomal delivery of mitoxantrone improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering the toxic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal MUC1/PET-lipid A Vaccine ONT-10</VALIDVALUE>
          <VALUEMEANING>Liposomal MUC1/PET-lipid A Vaccine ONT-10</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine ONT-10 results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal NDDP</VALIDVALUE>
          <VALUEMEANING>Liposomal NDDP</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Docetaxel</VALIDVALUE>
          <VALUEMEANING>Liposomal Docetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel encapsulated within liposomes, with antineoplastic activity.  Upon intravenous administration, docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  This liposomal formulation solubilizes docetaxel without the use of toxic solvents such as Tween 80, permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity, including hypersensitivity reactions. In addition, liposomal delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Rhenium Re 186</VALIDVALUE>
          <VALUEMEANING>Liposomal Rhenium Re 186</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal SN-38</VALIDVALUE>
          <VALUEMEANING>Liposomal SN-38</VALUEMEANING>
          <MEANINGDESCRIPTION>The liposomal formulation of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. The liposomal formulation of SN-38 increases the solubility of SN-38, which is a relatively insoluble compound, and improves the pharmacodynamic profile as compared to SN-38 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Topotecan FF-10850</VALIDVALUE>
          <VALUEMEANING>Liposomal Topotecan FF-10850</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome encapsulated formulation of the semisynthetic camptothecin analogue topotecan with potential antineoplastic activity. Upon administration, liposomal topotecan FF-10850 preferentially releases topotecan, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, into the tumor environment. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The novel liposome used in this agent prolongs its serum half-life while promoting efficient drug delivery into the cytosol from the endosome compartment of the tumor cell, which may minimize the adverse effect of bone marrow suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-encapsulated Daunorubicin-Cytarabine</VALIDVALUE>
          <VALUEMEANING>Liposome-encapsulated Daunorubicin-Cytarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7154914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-Encapsulated Doxorubicin Citrate</VALIDVALUE>
          <VALUEMEANING>Liposome-Encapsulated Doxorubicin Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2662264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-encapsulated miR-34 Mimic MRX34</VALIDVALUE>
          <VALUEMEANING>Liposome-encapsulated miR-34 Mimic MRX34</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-encapsulated OSI-7904</VALIDVALUE>
          <VALUEMEANING>Liposome-encapsulated OSI-7904</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94</VALIDVALUE>
          <VALUEMEANING>Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94</VALUEMEANING>
          <MEANINGDESCRIPTION>A systemic gene therapy anti-cancer agent composed of cationic liposomes, which encapsulates plasmid DNA encoding for the tumor suppressor gene RB94 and is complexed with anti-transferrin receptor single chain antibody fragment (TfRscFv), with potential antineoplastic activity. Upon systemic administration of liposome-encapsulated RB94 plasmid DNA gene therapy agent SGT-94, the TfRscFv portion of this agent selectively targets the tumor cells expressing transferrin receptors. TfRscFv binding to the transferrin receptor allows receptor-mediated endocytosis and transfection, followed by the expression of RB94 gene. This induces tumor cell apoptosis through an as of yet unknown pathway. RB94 is a modified, N-terminal truncated form of the full-length protein retinoblastoma gene RB110, and exerts enhanced antitumor activity. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin, and is overexpressed in a variety of tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome-encapsulated TAAs mRNA Vaccine W_ova1</VALIDVALUE>
          <VALUEMEANING>Liposome-encapsulated TAAs mRNA Vaccine W_ova1</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine consisting of messenger RNA (mRNA) encoding three tumor-associated antigens (TAAs) specific for ovarian cancer that are encapsulated in liposomes, with potential immunomodulating and antineoplastic activities. Upon administration of the liposome-encapsulated TAAs mRNA vaccine W_ova1, the liposomes bind to the plasma membrane of cells and release the mRNA into the cells. The mRNA is then translated by ribosomes to produce the TAAs. The TAAs are presented to the immune system which may activate both humoral and cellular immune responses against the ovarian cancer cells expressing these TAAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Vinorelbine</VALIDVALUE>
          <VALUEMEANING>Liposomal Vinorelbine</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the semisynthetic vinca alkaloid, vinorelbine, encapsulated within liposomes, with antineoplastic activity. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in cell cycle arrest in metaphase. Like other vinca alkaloids, vinorelbine may also interfere with the metabolism of nucleic acids, lipids, amino acids, cAMP, and glutathione, as well as other biological processes including calmodulin-dependent Ca2+-transport, ATPase activity, or cellular respiration. Liposomal delivery of vinorelbine improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lirilumab</VALIDVALUE>
          <VALUEMEANING>Lirilumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lisavanbulin</VALIDVALUE>
          <VALUEMEANING>Lisavanbulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of lisavanbulin and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lisocabtagene Maraleucel</VALIDVALUE>
          <VALUEMEANING>Lisocabtagene Maraleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6845581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142</VALIDVALUE>
          <VALUEMEANING>Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T-lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Litronesib</VALIDVALUE>
          <VALUEMEANING>Litronesib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein that plays an essential role during mitosis, particularly in the regulation of spindle dynamics, including assembly and maintenance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMP-2:340-349 Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>LMP-2:340-349 Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMP-2:419-427 Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>LMP-2:419-427 Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes</VALIDVALUE>
          <VALUEMEANING>LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207</VALIDVALUE>
          <VALUEMEANING>Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623</VALIDVALUE>
          <VALUEMEANING>Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623</VALUEMEANING>
          <MEANINGDESCRIPTION>A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13682331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMB-1 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>LMB-1 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMB-2 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>LMB-2 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMB-7 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>LMB-7 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMB-9 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>LMB-9 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L-methylfolate</VALIDVALUE>
          <VALUEMEANING>L-methylfolate</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5260858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LMP7 Inhibitor M3258</VALIDVALUE>
          <VALUEMEANING>LMP7 Inhibitor M3258</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, Beta5i, PSMB8), a chymotrypsin-like, proteolytic subunit of the immunoproteasome, with potential antineoplastic activity. Upon oral administration, LMP7 inhibitor M3258 targets and inhibits the proteolytic activity of the LMP7 subunit of immunoproteasome, thereby blocking its deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. Proteasomes are large multi-subunit protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated, thereby restoring protein homeostasis. Unlike the constitutive proteasome, which is expressed in most tissues, immunoproteasome is specifically present in normal and malignant hematopoietic cells, including multiple myeloma. Immunoproteasome degrades ubiquitinated proteins, generates peptides for presentation on MHC class I, and plays a key role in the adaptive immune response and inflammatory diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lm-tLLO-neoantigens Vaccine ADXS-NEO</VALIDVALUE>
          <VALUEMEANING>Lm-tLLO-neoantigens Vaccine ADXS-NEO</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed and presented to the immune system by both major histocompatibility complex (MHC) I and II molecules. This activates the immune system to exert both innate and adaptive immune responses involving the recruitment and activation of T-lymphocytes against the tumor-associated antigens (TAAs) specifically expressed by the patient&#39;s tumor cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). This results in tumor cell lysis. The various unique mutation-derived TAAs that are used in ADXS-NEO are identified from a biopsy of the patient&#39;s tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lobaplatin</VALIDVALUE>
          <VALUEMEANING>Lobaplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation, water-soluble platinum compound with potential antineoplastic activity. Lobaplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC- and AG-rich sites in DNA, inducing intrastrand DNA cross-links. These cross-links will ultimately result in induction of apoptosis and cell growth inhibition. Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lodapolimab</VALIDVALUE>
          <VALUEMEANING>Lodapolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lometrexol</VALIDVALUE>
          <VALUEMEANING>Lometrexol</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate analog antimetabolite with antineoplastic activity. As the 6R diastereomer of 5,10-dideazatetrahydrofolate, lometrexol inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C979</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lometrexol Sodium</VALIDVALUE>
          <VALUEMEANING>Lometrexol Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of lometrexol, a folate analogue antimetabolite with antineoplastic activity. As the stereoisomer of 5,10-dideazatetrahydrofolate, lometrexol selectively inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis and leading to an inhibition of tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate, but causes severe, dose-limiting toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lomustine</VALIDVALUE>
          <VALUEMEANING>Lomustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lonafarnib</VALIDVALUE>
          <VALUEMEANING>Lonafarnib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Loncastuximab Tesirine</VALIDVALUE>
          <VALUEMEANING>Loncastuximab Tesirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Long-acting Release Pasireotide</VALIDVALUE>
          <VALUEMEANING>Long-acting Release Pasireotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration of the LAR formulation of pasireotide, this somatostatin analog strongly binds to and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to an inhibition in the secretion of human growth hormone (hGH) and results in decreased production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated cell signaling pathways. This may lead to an inhibition in tumor cell growth and an increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which results in many unwanted symptoms. This agent may also block other key survival pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less frequent administration as compared to the original form of this agent. SSTRs are overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lontucirev</VALIDVALUE>
          <VALUEMEANING>Lontucirev</VALUEMEANING>
          <MEANINGDESCRIPTION>An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of lontucirev-mediated tumor cell cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2830</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lorlatinib</VALIDVALUE>
          <VALUEMEANING>Lorlatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6117830</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lorukafusp alfa</VALIDVALUE>
          <VALUEMEANING>Lorukafusp alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lorvotuzumab Mertansine</VALIDVALUE>
          <VALUEMEANING>Lorvotuzumab Mertansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Long Peptide Vaccine 7</VALIDVALUE>
          <VALUEMEANING>Long Peptide Vaccine 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Losatuxizumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Losatuxizumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of losatuxizumab vedotin selectively targets and binds to EGFR. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Losoxantrone</VALIDVALUE>
          <VALUEMEANING>Losoxantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Losoxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Losoxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of losoxantrone, an anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lovastatin</VALIDVALUE>
          <VALUEMEANING>Lovastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering activity and potential antineoplastic activity. Lovastatin is hydrolyszed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the cholesterol biosynthesis.  In addition, this agent may inhibit tumor cell proliferation and reduce tumor cell invasiveness, thereby decreasing tumor metastatic potential; induce tumor cell apoptosis, possibly by inhibiting protein geranylgeranylation and; arrest cells in the G1 phase of the cell cycle, an effect that sensitizes tumor cells to the cytotoxic effects of ionizing radiation.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LRP5/6 Antagonist BI 905677</VALIDVALUE>
          <VALUEMEANING>LRP5/6 Antagonist BI 905677</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized biparatopic nanobody composed of two blocking domains for the Wnt ligand co-receptors lipoprotein receptor-related proteins (LRP) 5 and 6, with potential antineoplastic and immunomodulating activities. Upon administration, BI 905677 targets and binds to LRP5 and LRP6, thereby blocking the binding of Wnt ligands to LRP5/6. This prevents the activation of the Frizzled (FZD)-Wnt-LRP5/6 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905677 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5/6 trimeric complex induces phosphorylation of LRP5 or LRP6 intracellular domains leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumorigenesis and resistance to immunotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LSD1 Inhibitor GSK2879552</VALIDVALUE>
          <VALUEMEANING>LSD1 Inhibitor GSK2879552</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LSD1 Inhibitor SYHA1807</VALIDVALUE>
          <VALUEMEANING>LSD1 Inhibitor SYHA1807</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of lysine-specific demethylase 1 (LSD1; KDM1A), with potential antineoplastic activity. Upon oral administration, LSD1 inhibitor SYHA1807 targets, binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1 is overexpressed in a number of tumor cell types. LSD1 acts on histone H3 as a transcription co-repressor through demethylation of lysine 4 (H3K4) or as a transcription co-activator through demethylation of lysine 9 (H3K9).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lucanthone</VALIDVALUE>
          <VALUEMEANING>Lucanthone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1 (APEX1 or APE1), with anti-schistosomal and potential antineoplastic activity. Lucanthone intercalates DNA and interferes with the activity of topoisomerases I and II during replication and transcription, thereby inhibiting the synthesis of macromolecules. In addition, this agent specifically inhibits the endonuclease activity of APE1, without affecting its redox activity, resulting in un-repaired DNA strand breaks which may induce apoptosis. Therefore, lucanthone may sensitize tumor cells to radiation and chemotherapy. Furthermore, lucanthone inhibits autophagy through the disruption of lysosomal function. The multifunctional nuclease APE1 is a key component for DNA repair; its expression is often correlated with tumor cell resistance to radio- and chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lucatumumab</VALIDVALUE>
          <VALUEMEANING>Lucatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Lucatumumab binds to and inhibits CD40, thereby inhibiting CD40 ligand-induced cell proliferation and triggering cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells overexpressing CD40. CD40, an integral membrane protein found on the surface of B lymphocytes, is a member of the tumor necrosis factor receptor superfamily and is highly expressed in a number of B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LRP5 Antagonist BI 905681</VALIDVALUE>
          <VALUEMEANING>LRP5 Antagonist BI 905681</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of the lipoprotein receptor-related protein (LRP) 5, with potential antineoplastic and immunomodulating activities. Upon administration, LRP5 antagonist BI 905681 targets and binds to LRP5, thereby blocking the binding of Wnt ligands to LRP5. This prevents the formation of the serpentine receptor Frizzled (FZD)-Wnt-LRP5 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt/beta-catenin-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905681 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5 trimeric complex induces phosphorylation of LRP5 intracellular domain leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumor cell proliferation and survival, and resistance to immunotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lucitanib</VALIDVALUE>
          <VALUEMEANING>Lucitanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Luminespib</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor AUY922</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or &quot;client&quot; proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3523218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Luminespib Mesylate</VALIDVALUE>
          <VALUEMEANING>Luminespib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of luminespib, a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Upon administration, luminespib binds with high affinity to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or &quot;client&quot; proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung-targeted Immunomodulator QBKPN</VALIDVALUE>
          <VALUEMEANING>Lung-targeted Immunomodulator QBKPN</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, lung-targeted, site specific immunomodulator (SSI), with potential immunostimulating and antineoplastic activities. Although the exact type and composition of the lung-targeted immunomodulator QBKPN has yet to be fully disclosed, upon subcutaneous administration, this agent is able to activate a local innate immune response in the lung tissue. This results in an increased number of M1 macrophages, which induces a shift from M2 to M1 macrophage dominance in the tumor microenvironment, and stimulates the recruitment of other immune cells. The M1 macrophages exert antitumor activity and eradicate lung cancer cells through phagocytosis. QBKPN does not induce a systemic immune response or affect other organs or tissues. Altogether, this SSI may decrease tumor cell growth in the lungs. SSIs contain specific, inactivated components of pathogens, such as bacteria and/or viruses, which normally cause an acute infection in the specific organ or tissue of interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lupartumab Amadotin</VALIDVALUE>
          <VALUEMEANING>Lupartumab Amadotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of an antibody against a structural homolog of the urokinase-type plasminogen activator receptor (uPAR) and tumor-associated antigen, C4.4a, and conjugated with a cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, lupartumab amadotin targets and binds to C4.4a-expressing tumor cells. Upon binding and cell entry, the cytotoxic agent kills the tumor cell. C4.4a, a glycolipid-anchored membrane protein and a member of the Ly-6 family, is overexpressed by a variety of cancer cell types whereas it is minimally expressed on healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lurbinectedin</VALIDVALUE>
          <VALUEMEANING>Lurbinectedin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7685533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lurtotecan</VALIDVALUE>
          <VALUEMEANING>Lurtotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lurtotecan Liposome</VALIDVALUE>
          <VALUEMEANING>Lurtotecan Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A&#39;&#39;-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumretuzumab</VALIDVALUE>
          <VALUEMEANING>Lumretuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration,  lumretuzumab binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 DOTA-biotin</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 DOTA-biotin</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 DOTA-N3-CTT1403</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 DOTA-N3-CTT1403</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158044</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Dotatate</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Dotatate</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Lilotomab-satetraxetan</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Lilotomab-satetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Monoclonal Antibody CC49</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Monoclonal Antibody CC49</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 PP-F11N</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 PP-F11N</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Satoreotide Tetraxetan</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Satoreotide Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177-DOTA-EB-TATE</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177-DOTA-EB-TATE</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177-DTPA-omburtamab</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177-DTPA-omburtamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin G1 (IgG1) antibody directed against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (DTPA), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium Lu 177-DTPA-omburtamab, the omburtamab moiety binds to B7-H3 expressed on certain tumor cells. Upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 DOTA-Tetulomab</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 DOTA-Tetulomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177-Edotreotide</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177-Edotreotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177-NeoB</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177-NeoB</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu-177 Capromab</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu-177 Capromab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA) with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA is a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu-177 Girentuximab</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu-177 Girentuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu-177 Rituximab</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu-177 Rituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1</VALIDVALUE>
          <VALUEMEANING>LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1</VALUEMEANING>
          <MEANINGDESCRIPTION>A whole-cell cancer vaccine, containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein encoded by a self-inactivating lentiviral vector (LV), with potential antineoplastic and immunomodulating activities. Upon administration, LV.IL-2/B7.1-transduced AML blast vaccine RFUSIN2-AML1 may stimulate a host cytotoxic T lymphocyte (CTL) response against AML cells.  The single fusion protein encoded by the LV is postsynthetically cleaved to produce biologically active membrane-anchored B7.1 and secreted IL-2 in AML blasts; combined expression of IL-2 and the co-stimulatory molecule B7.1 by AML blasts may increase stimulation of both allogeneic and autologous cytotoxic T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lyophilized Black Raspberry Lozenge</VALIDVALUE>
          <VALUEMEANING>Lyophilized Black Raspberry Lozenge</VALUEMEANING>
          <MEANINGDESCRIPTION>A lozenge containing lyophilized black raspberry with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, proanthocyanidins, and flavonoids. The anthocyanins appear to contribute significantly to this agent&#39;s effects. Anthocyanins inhibit both the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This inhibitory activity modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lyophilized Black Raspberry Saliva Substitute</VALIDVALUE>
          <VALUEMEANING>Lyophilized Black Raspberry Saliva Substitute</VALUEMEANING>
          <MEANINGDESCRIPTION>A saliva substitute (or artificial saliva) containing lyophilized black raspberry with potential antioxidant, pro-apoptotic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in flavonols of which the anthocyanins appear to contribute significantly to this agent&#39;s chemopreventive effects. Anthocyanins inhibit the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This in turn modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lysine-specific Demethylase 1 Inhibitor INCB059872</VALIDVALUE>
          <VALUEMEANING>Lysine-specific Demethylase 1 Inhibitor INCB059872</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression and in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu-177 PSMA-R2</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu-177 PSMA-R2</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lyso-Thermosensitive Liposome Doxorubicin</VALIDVALUE>
          <VALUEMEANING>Lyso-Thermosensitive Liposome Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A temperature-sensitive liposomal formulation of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Upon intravenous administration, circulating thermosensitive liposomes are activated locally by increasing the tumor temperature to 40-41 degrees Celsius using an external heat source. The elevated temperature causes compositional changes in the liposomes, creating openings that allow for the release of encapsulated doxorubicin. Compared to non-thermosensitive liposomes, lyso-thermosensitive liposomes deliver higher concentrations of a cytotoxic agent to a heat-treated tumor site while sparing normal tissues unexposed to heat treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Maackia amurensis Seed Lectin</VALIDVALUE>
          <VALUEMEANING>Maackia amurensis Seed Lectin</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of lectin extracted from the seeds of Maackia amurensis, with potential antineoplastic activity. Upon administration, Maackia amurensis seed lectin (MASL) may target and bind to podoplanin (PDPN), thereby blocking the activation of PDPN by endogenous ligands. This may inhibit tumor cell growth, migration and metastasis that result from PDPN activation. PDPN, a transmembrane receptor glycoprotein that is overexpressed in some cancer types, promotes tumor cell migration, invasion, and metastasis upon activation by various endogenous ligands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macimorelin</VALIDVALUE>
          <VALUEMEANING>Macimorelin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95123</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macrocycle-bridged STING Agonist E7766</VALIDVALUE>
          <VALUEMEANING>Macrocycle-bridged STING Agonist E7766</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Maekmoondong-tang</VALIDVALUE>
          <VALUEMEANING>Maekmoondong-tang</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and Oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mafosfamide</VALIDVALUE>
          <VALUEMEANING>Mafosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A form of cyclophosphamide that can be administered as an intrathecal infusion.  Mafosfamide is being studied as an anticancer drug.  It belongs to the family of drugs called alkylating agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1150</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2748755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-10.A2</VALIDVALUE>
          <VALUEMEANING>MAGE-10.A2</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells</VALIDVALUE>
          <VALUEMEANING>MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous CD4- and CD8-positive T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets the human melanoma-associated antigen A1 (MAGE-A1), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A1-specific TCR-transduced autologous T-cells bind to tumor cells expressing MAGE-A1, which may halt the growth of and kill MAGE-A1-expressing cancer cells. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-A3 Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>MAGE-A3 Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macitentan</VALIDVALUE>
          <VALUEMEANING>Macitentan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13689543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-A3-specific Immunotherapeutic GSK 2132231A</VALIDVALUE>
          <VALUEMEANING>MAGE-A3-specific Immunotherapeutic GSK 2132231A</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety of cancer cell types. This fusion protein may boost antitumoral immune responses. AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909, 3-O-desacyl-4&#39;-monophosphoryl lipid A (MPL), and QS-21, increases the immune response against MAGE-A3-expressing tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201</VALIDVALUE>
          <VALUEMEANING>MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Magnesium Valproate</VALIDVALUE>
          <VALUEMEANING>Magnesium Valproate</VALUEMEANING>
          <MEANINGDESCRIPTION>The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). The presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Magrolimab</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody Hu5F9-G4</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody Hu5F9-G4 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mannosulfan</VALIDVALUE>
          <VALUEMEANING>Mannosulfan</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkyl sulfonate with potential antineoplastic activity. Mannosulfan alkylates DNA, thereby producing DNA intra- or interstrand crosslinks, and ultimately results in inhibiting DNA replication and cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mannosylerythritol Lipid</VALIDVALUE>
          <VALUEMEANING>Mannosylerythritol Lipid</VALUEMEANING>
          <MEANINGDESCRIPTION>A yeast glycolipid biosurfactant with potential antineoplastic activity.  Mannosylerythritol lipid activates protein kinase signal cascades, resulting in cell differentiation, condensation of chromatin, DNA fragmentation, G1 phase cell-cycle arrest, and apoptosis of tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mapatumumab</VALIDVALUE>
          <VALUEMEANING>Mapatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Maraba Oncolytic Virus Expressing Mutant HPV E6/E7</VALIDVALUE>
          <VALUEMEANING>Maraba Oncolytic Virus Expressing Mutant HPV E6/E7</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Marcellomycin</VALIDVALUE>
          <VALUEMEANING>Marcellomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Manelimab</VALIDVALUE>
          <VALUEMEANING>Manelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MARCKS Protein Inhibitor BIO-11006</VALIDVALUE>
          <VALUEMEANING>MARCKS Protein Inhibitor BIO-11006</VALUEMEANING>
          <MEANINGDESCRIPTION>An aerosolized 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein, with potential immunomodulating and antineoplastic activities. Upon inhalation, the MARCKS protein inhibitor BIO-11006 targets, binds to and inhibits the phosphorylation of MARCKS (P-MARCKS). This prevents MARCKS-mediated signaling, thereby preventing the release of phosphatidylinositol 4,5-bisphosphate (PIP2) from the cell membrane upon MARCKS binding. This prevents the PIP2-mediated activation of focal adhesion kinase (FAK) and the FAK-mediated activation of the PI3K/AKT pathway and the activation of integrins, talin, vinculin and paxillin. This leads to an inhibition of tumor cell proliferation, migration, metastasis and survival. In addition, inhibition of MARCKS prevents mucin granule release and reduces the overproduction of mucus in the lungs. This may abrogate airway obstruction, impaired lung function, airway inflammation and bacterial infections associated with overproduction of mucus in the lungs. The MARCKS protein, a filamentous actin crosslinking protein and substrate for protein kinase C (PKC) is localized on the plasma membrane. Upon phosphorylation by PKC or binding to the calcium-calmodulin complex, the association of MARCKS with actin and with the plasma membrane is blocked, leading to its presence in the cytoplasm. The MARCKS protein plays a key role in the exocytosis of a number of vesicles and granules, cell movement, mitogenesis and membrane trafficking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Margetuximab</VALIDVALUE>
          <VALUEMEANING>Margetuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Marimastat</VALIDVALUE>
          <VALUEMEANING>Marimastat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Marizomib</VALIDVALUE>
          <VALUEMEANING>Marizomib</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Masoprocol</VALIDVALUE>
          <VALUEMEANING>Masoprocol</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Masoprocol directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, masoprocol inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished synthesis of inflammatory mediators such as prostaglandins and leukotrienes. It may prevent leukocyte infiltration into tissues and the release of reactive oxygen species.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAT2A Inhibitor AG-270</VALIDVALUE>
          <VALUEMEANING>MAT2A Inhibitor AG-270</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153180</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Matrix Metalloproteinase Inhibitor MMI270</VALIDVALUE>
          <VALUEMEANING>Matrix Metalloproteinase Inhibitor MMI270</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity.  MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Matuzumab</VALIDVALUE>
          <VALUEMEANING>Matuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and inhibiting receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mavelertinib</VALIDVALUE>
          <VALUEMEANING>Mavelertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Masitinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Masitinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mavorixafor</VALIDVALUE>
          <VALUEMEANING>Mavorixafor</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Maytansine</VALIDVALUE>
          <VALUEMEANING>Maytansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.  Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MCL-1 Inhibitor ABBV-467</VALIDVALUE>
          <VALUEMEANING>MCL-1 Inhibitor ABBV-467</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor ABBV-467 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mcl-1 Inhibitor AZD5991</VALIDVALUE>
          <VALUEMEANING>Mcl-1 Inhibitor AZD5991</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137989</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2 Antagonist ASTX295</VALIDVALUE>
          <VALUEMEANING>MDM2 Antagonist ASTX295</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2 Antagonist RO5045337</VALIDVALUE>
          <VALUEMEANING>MDM2 Antagonist RO5045337</VALUEMEANING>
          <MEANINGDESCRIPTION>An MDM2 (human homolog of double minutes-2; HDM2) antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2 Antagonist RO6839921</VALIDVALUE>
          <VALUEMEANING>MDM2 Antagonist RO6839921</VALUEMEANING>
          <MEANINGDESCRIPTION>An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2 Inhibitor AMGMDS3</VALIDVALUE>
          <VALUEMEANING>MDM2 Inhibitor AMGMDS3</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon administration, MDM2 inhibitor AMGMDS3 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171616</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2 Inhibitor BI 907828</VALIDVALUE>
          <VALUEMEANING>MDM2 Inhibitor BI 907828</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, BI 907828 binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mcl-1 Inhibitor MIK665</VALIDVALUE>
          <VALUEMEANING>Mcl-1 Inhibitor MIK665</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDM2/MDMX Inhibitor ALRN-6924</VALIDVALUE>
          <VALUEMEANING>MDM2/MDMX Inhibitor ALRN-6924</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, ALRN-6924 binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDR Modulator CBT-1</VALIDVALUE>
          <VALUEMEANING>MDR Modulator CBT-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring, orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mechlorethamine</VALIDVALUE>
          <VALUEMEANING>Mechlorethamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5044413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mechlorethamine Hydrochloride Gel</VALIDVALUE>
          <VALUEMEANING>Mechlorethamine Hydrochloride Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medorubicin</VALIDVALUE>
          <VALUEMEANING>Medorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A demethoxy derivative of doxorubicin with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medroxyprogesterone</VALIDVALUE>
          <VALUEMEANING>Medroxyprogesterone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medroxyprogesterone Acetate</VALIDVALUE>
          <VALUEMEANING>Medroxyprogesterone 17-Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Megestrol Acetate</VALIDVALUE>
          <VALUEMEANING>Megestrol Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK 1/2 Inhibitor AS703988/MSC2015103B</VALIDVALUE>
          <VALUEMEANING>MEK 1/2 Inhibitor AS703988/MSC2015103B</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic activity. MEK1/2 inhibitor AS703988/MSC2015103B selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth and are often upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mechlorethamine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Nitrogen Mustard</VALUEMEANING>
          <MEANINGDESCRIPTION>A vesicant and necrotizing irritant destructive to mucous membranes. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin&#39;s disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK 1/2 Inhibitor FCN-159</VALIDVALUE>
          <VALUEMEANING>MEK 1/2 Inhibitor FCN-159</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, MEK 1/2 Inhibitor FCN-159 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor AZD8330</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor AZD8330</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor CI-1040</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor CI-1040</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that inhibits both mitogen-activated protein kinase kinases 1 and 2 (MEK1 and MEK2), substrates of Raf and phosphorylates extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), preventing phosphorylation and activation of the Mitogen-Activated Protein Kinase (MAPK) pathways, involved with signal transduction pathways and tumor proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK inhibitor CS3006</VALIDVALUE>
          <VALUEMEANING>MEK inhibitor CS3006</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signal-regulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor RO4987655</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor RO4987655</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor SHR 7390</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor SHR 7390</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor WX-554</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor WX-554</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK/Aurora Kinase Inhibitor BI 847325</VALIDVALUE>
          <VALUEMEANING>MEK/Aurora Kinase Inhibitor BI 847325</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106126</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK-1/MEKK-1 Inhibitor E6201</VALIDVALUE>
          <VALUEMEANING>MEK-1/MEKK-1 Inhibitor E6201</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor GDC-0623</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor GDC-0623</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13694307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melanoma Monoclonal Antibody hIgG2A</VALIDVALUE>
          <VALUEMEANING>Melanoma Monoclonal Antibody hIgG2A</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a number human monoclonal antibodies of the immunoglobulin subclass IgG2a directed against melanoma antigens with potential antineoplastic activity.  A melanoma monoclonal antibody, subclass IgG2A, may have potential use as a diagnostic agent and, therapeutically, may induce macrophage-mediated cytotoxicity against antibody-bound melanoma cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melanoma TRP2 CTL Epitope Vaccine SCIB1</VALIDVALUE>
          <VALUEMEANING>Melanoma TRP2 CTL Epitope Vaccine SCIB1</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MELK Inhibitor OTS167</VALIDVALUE>
          <VALUEMEANING>MELK Inhibitor OTS167</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melphalan Flufenamide</VALIDVALUE>
          <VALUEMEANING>Melphalan Flufenamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melphalan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Melphalan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6592216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex</VALIDVALUE>
          <VALUEMEANING>Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex</VALUEMEANING>
          <MEANINGDESCRIPTION>A propylene glycol-free intravenous formulation containing the hydrochloride salt of the nitrogen mustard phenylalanine derivative melphalan complexed with polyanionic sulfobutyl ether beta-cyclodextrin (SBE-CD) with potential antineoplastic activity. Upon administration, melphalan is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA; RNA and proteins may also be alkylated. Subsequently, RNA transcription and protein synthesis are inhibited, resulting in cell growth arrest. The addition of sulfobutyl ether beta-cyclodextrin to the formulation improves the solubility, stability and ease of use of melphalan; cyclodextrins are cyclic dextrins derived from starch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Membrane-Disrupting Peptide EP-100</VALIDVALUE>
          <VALUEMEANING>Membrane-Disrupting Peptide EP-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, positively charged fusion protein consisting of a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of membrane-disrupting peptide EP-100 specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Menatetrenone</VALIDVALUE>
          <VALUEMEANING>Menatetrenone</VALUEMEANING>
          <MEANINGDESCRIPTION>A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13695532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Menogaril</VALIDVALUE>
          <VALUEMEANING>Menogaril</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melphalan</VALIDVALUE>
          <VALUEMEANING>Melphalan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Merbarone</VALIDVALUE>
          <VALUEMEANING>Merbarone</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsedating derivative of thiobarbituric acid and a novel catalytic topoisomerase II inhibitor with antineoplastic activity. Merbarone interferes with DNA replication via binding directly to topoisomerase II at a domain that maybe shared by other topoisomerase II cleavage-enhancing agents, ex., etoposide. Its mechanism of action appears to be a novel one, since merbarone does not intercalate DNA nor stabilize DNA-topoisomerase II cleavable complexes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mercaptopurine</VALIDVALUE>
          <VALUEMEANING>Mercaptopurine</VALUEMEANING>
          <MEANINGDESCRIPTION>A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mercaptopurine Anhydrous</VALIDVALUE>
          <VALUEMEANING>Mercaptopurine Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mercaptopurine Oral Suspension</VALIDVALUE>
          <VALUEMEANING>Mercaptopurine Oral Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536</VALIDVALUE>
          <VALUEMEANING>Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536</VALUEMEANING>
          <MEANINGDESCRIPTION>recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Kinase Inhibitor OMO-1</VALIDVALUE>
          <VALUEMEANING>MET Kinase Inhibitor OMO-1</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Tyrosine Kinase Inhibitor BMS-777607</VALIDVALUE>
          <VALUEMEANING>MET Tyrosine Kinase Inhibitor BMS-777607</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Tyrosine Kinase Inhibitor EMD 1204831</VALIDVALUE>
          <VALUEMEANING>MET Tyrosine Kinase Inhibitor EMD 1204831</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the receptor tyrosine kinase Met (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds to Met tyrosine kinase, thereby disrupting MET mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing this kinase. MET is overexpressed or mutated in many tumor cell types, and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Tyrosine Kinase Inhibitor PF-04217903</VALIDVALUE>
          <VALUEMEANING>MET Tyrosine Kinase Inhibitor PF-04217903</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78483</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Merestinib</VALIDVALUE>
          <VALUEMEANING>c-Met Inhibitor LY2801653</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the proto-oncogene c-Met (mesenchymal-epithelial transition, also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. c-Met inhibitor LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Tyrosine Kinase Inhibitor SAR125844</VALIDVALUE>
          <VALUEMEANING>MET Tyrosine Kinase Inhibitor SAR125844</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Upon intravenous administration, c-Met inhibitor SAR125844 binds to c-Met, thereby disrupting c-Met-mediated signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of cancers, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET Tyrosine Kinase Inhibitor SGX523</VALIDVALUE>
          <VALUEMEANING>MET Tyrosine Kinase Inhibitor SGX523</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metamelfalan</VALIDVALUE>
          <VALUEMEANING>Metamelfalan</VALUEMEANING>
          <MEANINGDESCRIPTION>The meta form of the levo isomer melphalan, an alkylating nitrogen mustard with potential antineoplastic activity. Metamelfalan causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MetAP2 Inhibitor APL-1202</VALIDVALUE>
          <VALUEMEANING>MetAP2 Inhibitor APL-1202</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metarrestin</VALIDVALUE>
          <VALUEMEANING>Metarrestin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metatinib Tromethamine</VALIDVALUE>
          <VALUEMEANING>Metatinib Tromethamine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metformin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Metformin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of metformin, a biguanide with antihyperglycemic activity. Metformin hydrochloride exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores. In addition, metformin hydrochloride increases the number and/or affinity of insulin receptors on cell surface membranes in muscle and adipose tissue, thereby increasing the sensitivity to insulin at receptor and post-receptor binding sites and increasing glucose uptake peripherally.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methanol Extraction Residue of BCG</VALIDVALUE>
          <VALUEMEANING>Methanol Extraction Residue of BCG</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methazolamide</VALIDVALUE>
          <VALUEMEANING>Methazolamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7460900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methionine Aminopeptidase 2 Inhibitor PPI-2458</VALIDVALUE>
          <VALUEMEANING>Methionine Aminopeptidase 2 Inhibitor PPI-2458</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties.  PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methotrexate</VALIDVALUE>
          <VALUEMEANING>Methotrexate</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methotrexate Sodium</VALIDVALUE>
          <VALUEMEANING>Methotrexate Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of methotrexate, an antimetabolite with antineoplastic and immunomodulating properties.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methotrexate-E Therapeutic Implant</VALIDVALUE>
          <VALUEMEANING>Methotrexate-E Therapeutic Implant</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles</VALIDVALUE>
          <VALUEMEANING>Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methionine Aminopeptidase 2 Inhibitor M8891</VALIDVALUE>
          <VALUEMEANING>Methionine Aminopeptidase 2 Inhibitor M8891</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13696509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methoxsalen</VALIDVALUE>
          <VALUEMEANING>Methoxsalen</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen&#39;s exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3944875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methoxyamine</VALIDVALUE>
          <VALUEMEANING>Methoxyamine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78084</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4255112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methoxyamine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Methoxyamine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of methoxyamine, an alkoxyamine with potential chemotherapeutic adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic DNA damage sites and thereby inhibits base excision repair (BER) process, which may prevent repair of DNA strand breaks and result in an induction of apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78085</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methyl-5-Aminolevulinate Hydrochloride Cream</VALIDVALUE>
          <VALUEMEANING>Methyl-5-Aminolevulinate Hydrochloride Cream</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical cream formulation containing the hydrochloride salt of methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic acid, with photosensitizer prodrug activity. Upon topical administration, methyl-5-aminolevulinate in the cream is selectively absorbed by tumor cells where it is converted to the photosensitizer protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and transfers energy to oxygen, generating singlet oxygen and superoxide and hydroxyl radicals, which may result in free-radical-mediated DNA damage and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylmercaptopurine Riboside</VALIDVALUE>
          <VALUEMEANING>Methylmercaptopurine Riboside</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine derivative with antineoplastic and anti-angiogenic properties.  6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylprednisolone</VALIDVALUE>
          <VALUEMEANING>Methylprednisolone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylselenocysteine</VALIDVALUE>
          <VALUEMEANING>Methylselenocysteine</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metoprine</VALIDVALUE>
          <VALUEMEANING>Metoprine</VALUEMEANING>
          <MEANINGDESCRIPTION>A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mevociclib</VALIDVALUE>
          <VALUEMEANING>Mevociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylcantharidimide</VALIDVALUE>
          <VALUEMEANING>Methylcantharidimide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable derivative of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, with potential antineoplastic activity. Although the exact mechanism of action through which methylcantharidimide exerts its effect has yet to be fully elucidated, this agent, upon oral administration, may exert a direct tumor cell killing effect in susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mezagitamab</VALIDVALUE>
          <VALUEMEANING>Mezagitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. Mezagitamab specifically binds to CD38 that is expressed on human plasmablasts, plasma cells, NK cells and activated T- and B-cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing cells. Additionally, TAK-079 does not induce CD38-dependent signaling and does not promote cytokine activation in peripheral blood mononuclear cells (PMBCs). CD38, a type II transmembrane glycoprotein, is overexpressed on cells associated with autoimmune diseases and hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mibefradil</VALIDVALUE>
          <VALUEMEANING>Mibefradil</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mibefradil Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Mibefradil Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Micro Needle Array-Doxorubicin</VALIDVALUE>
          <VALUEMEANING>Micro Needle Array-Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microbiome GEN-001</VALIDVALUE>
          <VALUEMEANING>Microbiome GEN-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A microbiome therapeutic composed of a single-strain bacterium, isolated from the gut of healthy donors, with potential anti-tumor and immunomodulating activities. Upon oral administration, the metabolites of GEN-001 may activate dendritic cells and macrophages in the gut and increase the expression of the cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15), which stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. GEN-001 may improve therapeutic responses to other therapies, such as anti-PD-1 therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microbiome-derived Peptide Vaccine EO2401</VALIDVALUE>
          <VALUEMEANING>Microbiome-derived Peptide Vaccine EO2401</VALUEMEANING>
          <MEANINGDESCRIPTION>A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T-cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300</VALIDVALUE>
          <VALUEMEANING>Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of a plasmid DNA encoding an inactivated form of the carcinogen activator cytochrome P450 1B1 (CYP1B1) encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles with potential antineoplastic activity. CYP1B1, an extrahepatic monooxygenase of the cytochrome P450 family, is overexpressed in many cancers with only restricted expression in normal tissues. Vaccination with ZYC300 may stimulate the immune system to elicit a cytotoxic T lymphocyte (CTL) response against the tumor associated antigen CYP1B1, thereby causing lysis of tumor cells expressing CYP1B1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microtubule Inhibitor SCB01A</VALIDVALUE>
          <VALUEMEANING>Microtubule Inhibitor SCB01A</VALUEMEANING>
          <MEANINGDESCRIPTION>An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent&#39;s effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Midostaurin</VALIDVALUE>
          <VALUEMEANING>Midostaurin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Micellar Nanoparticle-encapsulated Epirubicin</VALIDVALUE>
          <VALUEMEANING>Micellar Nanoparticle-encapsulated Epirubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mifamurtide</VALIDVALUE>
          <VALUEMEANING>Mifamurtide</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mifepristone</VALIDVALUE>
          <VALUEMEANING>Mifepristone</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milademetan Tosylate</VALIDVALUE>
          <VALUEMEANING>Milademetan Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milatuzumab</VALIDVALUE>
          <VALUEMEANING>Milatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110</VALIDVALUE>
          <VALUEMEANING>Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91086</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milciclib Maleate</VALIDVALUE>
          <VALUEMEANING>CDK2/TRKA Inhibitor PHA-848125 AC</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milk Thistle</VALIDVALUE>
          <VALUEMEANING>Milk Thistle</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle&#39;s active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Miltefosine</VALIDVALUE>
          <VALUEMEANING>Miltefosine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1170</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minretumomab</VALIDVALUE>
          <VALUEMEANING>Minretumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milataxel</VALIDVALUE>
          <VALUEMEANING>Milataxel</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mipsagargin</VALIDVALUE>
          <VALUEMEANING>Thapsigargin Prodrug G-202</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, the non-toxic prodrug targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. G-202 is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3461702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Miptenalimab</VALIDVALUE>
          <VALUEMEANING>Miptenalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mirabegron</VALIDVALUE>
          <VALUEMEANING>Mirabegron</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6046330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Miransertib</VALIDVALUE>
          <VALUEMEANING>Miransertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mirdametinib</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor PD0325901</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7348903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mirzotamab Clezutoclax</VALIDVALUE>
          <VALUEMEANING>Mirzotamab Clezutoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Misonidazole</VALIDVALUE>
          <VALUEMEANING>Misonidazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mistletoe Extract</VALIDVALUE>
          <VALUEMEANING>Mistletoe Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2703</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitazalimab</VALIDVALUE>
          <VALUEMEANING>Mitazalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mirvetuximab Soravtansine</VALIDVALUE>
          <VALUEMEANING>Mirvetuximab Soravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent&#39;s efficacy in multidrug resistant tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6199771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitindomide</VALIDVALUE>
          <VALUEMEANING>Mitindomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A bisdioxopiperazines analog with antineoplastic activity.  Mitinomide inhibits topoisomerase II and slowly promotes DNA-interstrand cross-linking, thereby inhibiting DNA repair, RNA and protein synthesis.  This agent acts without increasing topoisomerase II-DNA covalent cleavable complex formation, as do most topoisomerase inhibitors. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitobronitol</VALIDVALUE>
          <VALUEMEANING>Mitobronitol</VALUEMEANING>
          <MEANINGDESCRIPTION>A brominated analog of mannitol with potential antineoplastic activity. Mitobronitol most likely acts through alkylation via derived epoxide groups.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101</VALIDVALUE>
          <VALUEMEANING>Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitochondrial oxidative phosphorylation with potential antineoplastic activity. Upon administration, ATR-101 inhibits the activity of F1F0-ATP synthase, elevates the mitochondrial membrane potential and depletes ATP in adrenocortical cells. The mitochondrial dysfunction caused by the release of reactive oxygen and triggered cytochrome c release leads to caspase-mediated cell death. ATR-101 may be useful in treating certain types of adrenocortical carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoclomine</VALIDVALUE>
          <VALUEMEANING>Mitoclomine</VALUEMEANING>
          <MEANINGDESCRIPTION>An aromatic nitrogen mustard derivative with potential antineoplastic activity. Mitoclomine alkylates DNA and appears to concentrate primarily in the spleen and thymus where it causes lymphocyte depletion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoguazone</VALIDVALUE>
          <VALUEMEANING>Mitoguazone</VALUEMEANING>
          <MEANINGDESCRIPTION>A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoguazone Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Mitoguazone Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitolactol</VALIDVALUE>
          <VALUEMEANING>Mitolactol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties.  Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitomycin</VALIDVALUE>
          <VALUEMEANING>Mitomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4147714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitomycin A</VALIDVALUE>
          <VALUEMEANING>Mitomycin A</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin A generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Mitomycin A is more toxic than mitomycin C due to increased and nonselective DNA cross-linking in both aerobic and hypoxic cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoflaxone</VALIDVALUE>
          <VALUEMEANING>Mitoflaxone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159810</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitomycin B</VALIDVALUE>
          <VALUEMEANING>Mitomycin B</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin B generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitomycin C Analog KW-2149</VALIDVALUE>
          <VALUEMEANING>Mitomycin C Analog KW-2149</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C.  Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitotane</VALIDVALUE>
          <VALUEMEANING>Mitotane</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitotenamine</VALIDVALUE>
          <VALUEMEANING>Mitotenamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A nucleotoxic with potential antineoplastic activity. The mechanism of action through which mitotenamine exerts its effect has yet to be fully elucidated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoxantrone</VALIDVALUE>
          <VALUEMEANING>Mitoxantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3518877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitozolomide</VALIDVALUE>
          <VALUEMEANING>Mitozolomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of imidazotetrazine alkylating agent with antineoplastic property. Mitozolomide undergoes ring opening upon the nucleophilic attack at C-4 by an activated molecule of water within the major groove of DNA. The resulting bioactive mono-alkyltriazene species are capable of alkylating nucleophilic residues in the immediate vicinity such as N-7 and/or O-6 sites of guanine, thereby causes intra- or inter-stranded DNA cross-links and trigger apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mivavotinib</VALIDVALUE>
          <VALUEMEANING>Mivavotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mivebresib</VALIDVALUE>
          <VALUEMEANING>Mivebresib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of  BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mivobulin</VALIDVALUE>
          <VALUEMEANING>Mivobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, colchicine analogue with potential antineoplastic activity. Mivobulin targets and binds to colchicine-binding site on tubulin, thereby inhibiting microtubule polymerization, the assembly of the mitotic spindle and mitosis. This eventually results in cell cycle arrest, apoptosis and a reduction in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mitoxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Mitoxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mivobulin Isethionate</VALIDVALUE>
          <VALUEMEANING>Mivobulin Isethionate</VALUEMEANING>
          <MEANINGDESCRIPTION>The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mixed Bacteria Vaccine</VALIDVALUE>
          <VALUEMEANING>Mixed Bacteria Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley&#39;s toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MK0731</VALIDVALUE>
          <VALUEMEANING>MK0731</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MKNK1 Inhibitor BAY 1143269</VALIDVALUE>
          <VALUEMEANING>MKNK1 Inhibitor BAY 1143269</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MMP Inhibitor S-3304</VALIDVALUE>
          <VALUEMEANING>MMP Inhibitor S-3304</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-agent agent with potential antineoplastic activity.  S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MNK1/2 Inhibitor ETC-1907206</VALIDVALUE>
          <VALUEMEANING>MNK1/2 Inhibitor ETC-1907206</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, MNK1/2 inhibitor ETC-1907206 may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mobocertinib</VALIDVALUE>
          <VALUEMEANING>Mobocertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mocetinostat</VALIDVALUE>
          <VALUEMEANING>Mocetinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modakafusp Alfa</VALIDVALUE>
          <VALUEMEANING>Modakafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MKC-1</VALIDVALUE>
          <VALUEMEANING>MKC-1</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208</VALIDVALUE>
          <VALUEMEANING>Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208</VALUEMEANING>
          <MEANINGDESCRIPTION>A booster cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) Bavarian Nordic (MVA-BN) strain encoding the oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of MVA-vectored HPV16/18 vaccine JNJ-65195208, and after the administration of the prime vaccine(s) adenovirus serotype 26 (Ad26)-expressing HPV16 vaccine JNJ-63682918 and/or Ad26-expressing HPV18 vaccine JNJ-63682931, this vaccine further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16/18 proteins, resulting in tumor cell lysis. HPV16/18 infection plays a key role in the development of a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modified Vitamin D Binding Protein Macrophage Activator EF-022</VALIDVALUE>
          <VALUEMEANING>Modified Vitamin D Binding Protein Macrophage Activator EF-022</VALUEMEANING>
          <MEANINGDESCRIPTION>A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modotuximab</VALIDVALUE>
          <VALUEMEANING>Modotuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOF Compound RiMO-301</VALIDVALUE>
          <VALUEMEANING>MOF Compound RiMO-301</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mofarotene</VALIDVALUE>
          <VALUEMEANING>Mofarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>An arotinoic acid derivative with a morpholine structure in the polar end group with differentiation inducing and antineoplastic activity. Like other retinoic acid agents, mofarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells. In addition, this agent is able to inhibit melanoma cell motility.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mogamulizumab</VALIDVALUE>
          <VALUEMEANING>Mogamulizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5944042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molibresib</VALIDVALUE>
          <VALUEMEANING>Molibresib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molibresib Besylate</VALIDVALUE>
          <VALUEMEANING>Molibresib Besylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Momelotinib</VALIDVALUE>
          <VALUEMEANING>Momelotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monocarboxylate Transporter 1 Inhibitor AZD3965</VALIDVALUE>
          <VALUEMEANING>Monocarboxylate Transporter 1 Inhibitor AZD3965</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 105AD7 Anti-idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 105AD7 Anti-idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 11D10</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 11D10</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal anti-idiotype antibody (anti-Id). Anti-Id 11D10 mimics a specific epitope of the high molecular weight human milk fat globule (HMFG) glycoprotein primarily expressed by human breast and some other tumor cells at high density. This specific HMFG epitope is identified by mAb BrE1, which was used as the immunizing antibody, or Ab1 to generate the anti-Id (Ab2) 11D10. Anti-ID 11D10 reacts specifically with breast tumor cells and with minimal reactivity with normal tissues. Vaccination with anti-Id 11D10 induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 11D10 Anti-Idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 11D10 Anti-Idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope.  Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 14G2A</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 14G2A</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monalizumab</VALIDVALUE>
          <VALUEMEANING>Monalizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 1F5</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 1F5</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody directed against CD20, a cross-membrane ion channel phosphoprotein expressed by B cells, with potential antineoplastic activity.  MOAB 1F5 binds to CD20, thereby directly inhibiting B-cell proliferation and differentiation. When cross-linked by secondary anti-mouse antibodies or Fc receptor-bearing cells, MOAB 1F5 may induce activation of B-cell protein tyrosine kinases, increases in B-cell intracellular calcium ion concentrations, and B-cell caspase activation, resulting in apoptosis of B cells expressing CD20. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 3622W94</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 3622W94</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized murine monoclonal antibody (MoAb) against the 17-1A antigen, with potential adjuvant therapeutic properties in colorectal cancer. 17-1A antigen (EpCAM), a human epithelial cell adhesion molecule, expresses in a variety of carcinoma tissues, such as those of colon and breast carcinomas. Immunization with MoAb 3622W94 may elicit immune responses, which could result in eradicating tumor cells expressing 17-1A antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 3F8</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 3F8</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 3H1 Anti-Idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 3H1 Anti-Idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA).  This agent is used as a cancer vaccine against tumors that express CEA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 7C11</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 7C11</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgM monoclonal antibody against Fas antigen with antineoplastic property. Fas antigen is a member of tumor necrosis factor family that mediates antibody-triggered apoptosis. Upon binds to Fas, monoclonal antibody 7C11 (MoAb 7C11) induces apoptosis in Fas-expressing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody A1G4 Anti-Idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody A1G4 Anti-Idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody A27.15</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody A27.15</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody A33</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody A33</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human A33 antigen. Monoclonal antibody A33 recognizes the human A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, which is highly and homogenously expressed in 95% of colorectal cancer metastases with only restricted expression in normal colonic mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody AbGn-7</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody AbGn-7</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody against a Lewis-A-like glycotope (AbGn-7 antigen) with potential immunomodulating and antineoplastic activities. Monoclonal antibody AbGn-7 targets and binds to the carbohydrate AbGn-7 antigen on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing AbGn-7-epitope positive tumor cells. AbGn-7 antigen is expressed on a variety of tumor cell types, including human colorectal, pancreatic and gastric tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 4B5 Anti-Idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 4B5 Anti-Idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities.  Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody CAL</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody CAL</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody CC49-delta CH2</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody CC49-delta CH2</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody CEP-37250/KHK2804</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody CEP-37250/KHK2804</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting glycolipids, with potential immunomodulating and antineoplastic activity. Upon administration, monoclonal antibody CEP-37250/KHK2804 targets and binds to a specific tumor antigen, thereby stimulating the immune system to exert an antibody-dependent cellular cytotoxicity (ADCC) against the tumor associated antigen (TAA)-expressing cancer cells. This agent has shown to be active in both wild-type and mutant K-RAS-expressing colorectal cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98296</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody E2.3</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody E2.3</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody F19</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody F19</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby MoAb F19 has possible diagnostic and therapeutic applications in epithelial cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody GD2 Anti-Idiotype Vaccine</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody GD2 Anti-Idiotype Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody HeFi-1</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody HeFi-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody Hu3S193</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody Hu3S193</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody HuAFP31</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody HuAFP31</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31) binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody D6.12</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody D6.12</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody HuPAM4</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody HuPAM4</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody IMMU-14</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody IMMU-14</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-carcinoembryonic antigen (anti-CEA) murine monoclonal immunoglobulin G (IgG) with potential antineoplastic activity.  CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers.  MOAB IMMU-14 can be conjugated with a radioactive element for use in radioimmunotherapy (RIT), a regimen that uses a tumor-specific monoclonal antibody to deliver targeted radiation to cancer cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody L6</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody L6</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells.  This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody Lym-1</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody Lym-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1561</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody Me1-14 F(ab&#39;)2</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody Me1-14 F(ab&#39;)2</VALUEMEANING>
          <MEANINGDESCRIPTION>The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas.  By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab&#39;)2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody muJ591</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody muJ591</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG monoclonal antibody against the external domain of the prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Radiolabelled MoAb muJ591 may be used in prostate cancer diagnosis and therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody MX35 F(ab&#39;)2</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody MX35 F(ab&#39;)2</VALUEMEANING>
          <MEANINGDESCRIPTION>The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cells that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab&#39;)2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody NEO-201</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody NEO-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody R24</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody R24</VALUEMEANING>
          <MEANINGDESCRIPTION>An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells.  Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody m170</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody m170</VALUEMEANING>
          <MEANINGDESCRIPTION>A panadenocarcinoma murine monoclonal antibody (MoAb) with potential antineoplastic activity. MoAb m170 recognizes MUC-1 antigen present on the surface of many adenocarcinomas. It may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody RAV12</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody RAV12</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody SGN-14</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody SGN-14</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting the CD40 antigen with potential antineoplastic activity. CD-40, an integral membrane protein found on the surface of B lymphocytes and member of the tumor necrosis factor receptor super-family, is highly overexpressed on the cell surface of a number of B-cell malignancies. Monoclonal antibody SGN-14 specifically binds to and inhibits CD-40, thereby inhibiting cell proliferation and inducing cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody TRK-950</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody TRK-950</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monomethyl Auristatin E</VALIDVALUE>
          <VALUEMEANING>Monomethyl Auristatin E</VALUEMEANING>
          <MEANINGDESCRIPTION>A dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody that specifically targets a patient&#39;s tumor. The linker is stable in the extracellular milieu but is readily cleaved to release MMAE following binding and internalization of the ADC by the target cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morinda Citrifolia Fruit Extract</VALIDVALUE>
          <VALUEMEANING>Morinda Citrifolia Fruit Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations. Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morpholinodoxorubicin</VALIDVALUE>
          <VALUEMEANING>Morpholinodoxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1442</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mosedipimod</VALIDVALUE>
          <VALUEMEANING>Mosedipimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which EC-18 exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T-lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T- and B-lymphocytes, dendritic cells (DCs) and macrophages. Therefore, EC18 may stimulate the immune system to target cancer cells. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mosunetuzumab</VALIDVALUE>
          <VALUEMEANING>Mosunetuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motesanib</VALIDVALUE>
          <VALUEMEANING>Motesanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Microbial EDP1503</VALIDVALUE>
          <VALUEMEANING>Monoclonal Microbial EDP1503</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motesanib Diphosphate</VALIDVALUE>
          <VALUEMEANING>Motesanib Diphosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motexafin Gadolinium</VALIDVALUE>
          <VALUEMEANING>Motexafin Gadolinium</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motexafin Lutetium</VALIDVALUE>
          <VALUEMEANING>Motexafin Lutetium</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motixafortide</VALIDVALUE>
          <VALUEMEANING>Motixafortide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOv-gamma Chimeric Receptor Gene</VALIDVALUE>
          <VALUEMEANING>MOv-gamma Chimeric Receptor Gene</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moxetumomab Pasudotox</VALIDVALUE>
          <VALUEMEANING>Moxetumomab Pasudotox</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mps1 Inhibitor BAY 1217389</VALIDVALUE>
          <VALUEMEANING>Mps1 Inhibitor BAY 1217389</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mps1 Inhibitor BOS172722</VALIDVALUE>
          <VALUEMEANING>Mps1 Inhibitor BOS172722</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-based Personalized Cancer Vaccine mRNA-4157</VALIDVALUE>
          <VALUEMEANING>mRNA-based Personalized Cancer Vaccine mRNA-4157</VALUEMEANING>
          <MEANINGDESCRIPTION>An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient&#39;s cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient&#39;s tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient&#39;s cancer cells that express these neoantigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-based Personalized Cancer Vaccine NCI-4650</VALIDVALUE>
          <VALUEMEANING>mRNA-based Personalized Cancer Vaccine NCI-4650</VALUEMEANING>
          <MEANINGDESCRIPTION>An mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient&#39;s cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient&#39;s tumor are analyzed and subjected to RNA sequencing to identify mutant and immunogenic epitopes. The neoantigen epitopes are screened to select those that induce a strong immune response in tumor- infiltrating lymphocytes (TILs) isolated from the patient. The selected mRNA sequences encoding up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. Upon administration, the mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient&#39;s cancer cells that express these neoantigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Motolimod</VALIDVALUE>
          <VALUEMEANING>Motolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. Motolimod binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-based TriMix Melanoma Vaccine ECI-006</VALIDVALUE>
          <VALUEMEANING>mRNA-based TriMix Melanoma Vaccine ECI-006</VALUEMEANING>
          <MEANINGDESCRIPTION>A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T-cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902</VALIDVALUE>
          <VALUEMEANING>mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902</VALUEMEANING>
          <MEANINGDESCRIPTION>An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient&#39;s tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient&#39;s cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156926</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-derived KRAS-targeted Vaccine V941</VALIDVALUE>
          <VALUEMEANING>mRNA-derived KRAS-targeted Vaccine V941</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162186</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-Derived Prostate Cancer Vaccine CV9103</VALIDVALUE>
          <VALUEMEANING>mRNA-Derived Prostate Cancer Vaccine CV9103</VALUEMEANING>
          <MEANINGDESCRIPTION>A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-derived Prostate Cancer Vaccine CV9104</VALIDVALUE>
          <VALUEMEANING>mRNA-derived Prostate Cancer Vaccine CV9104</VALUEMEANING>
          <MEANINGDESCRIPTION>A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MTF-1 Inhibitor APTO-253 HCl</VALIDVALUE>
          <VALUEMEANING>MTF-1 Inhibitor APTO-253 HCl</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity. MTF-1 inhibitor APTO-253 inhibits MTF-1 activity and thereby induces the expression of MTF-1 dependent tumor suppressor factor Kruppel like factor 4 (KLF4). This subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation. This agent also causes decreased expression of genes involved in tumor hypoxia and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTOR Inhibitor GDC-0349</VALIDVALUE>
          <VALUEMEANING>mTOR Inhibitor GDC-0349</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTOR Kinase Inhibitor AZD8055</VALIDVALUE>
          <VALUEMEANING>mTOR Kinase Inhibitor AZD8055</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTOR Kinase Inhibitor OSI-027</VALIDVALUE>
          <VALUEMEANING>mTOR Kinase Inhibitor OSI-027</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mRNA-derived Lung Cancer Vaccine BI 1361849</VALIDVALUE>
          <VALUEMEANING>mRNA-derived Lung Cancer Vaccine BI 1361849</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTOR Kinase Inhibitor PP242</VALIDVALUE>
          <VALUEMEANING>mTOR Kinase Inhibitor PP242</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTOR1/2 Kinase Inhibitor ME-344</VALIDVALUE>
          <VALUEMEANING>mTOR1/2 Kinase Inhibitor ME-344</VALUEMEANING>
          <MEANINGDESCRIPTION>An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTORC 1/2 Inhibitor LXI-15029</VALIDVALUE>
          <VALUEMEANING>mTORC 1/2 Inhibitor LXI-15029</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTORC1/2 Kinase Inhibitor BI 860585</VALIDVALUE>
          <VALUEMEANING>mTORC1/2 Kinase Inhibitor BI 860585</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUC-1/WT1 Peptide-primed Autologous Dendritic Cells</VALIDVALUE>
          <VALUEMEANING>MUC-1/WT1 Peptide-primed Autologous Dendritic Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) loaded with the human tumor-associated antigens (TAAs) mucin-1 (MUC1) and Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, the MUC-1/WT1 peptide-primed autologous DCs expose the immune system to MUC1 and WT1 peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against MUC1 and WT1-expressing cancer cells, which could result in cancer cell lysis. MUC1 and WT1, are overexpressed in a variety of tumor types and play an important role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUC1-targeted Peptide GO-203-2C</VALIDVALUE>
          <VALUEMEANING>MUC1-targeted Peptide GO-203-2C</VALUEMEANING>
          <MEANINGDESCRIPTION>An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mucoadhesive Paclitaxel Formulation</VALIDVALUE>
          <VALUEMEANING>Mucoadhesive Paclitaxel Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-AGC Kinase Inhibitor AT13148</VALIDVALUE>
          <VALUEMEANING>Multi-AGC Kinase Inhibitor AT13148</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101786</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200</VALIDVALUE>
          <VALUEMEANING>Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mTORC1/mTORC2/DHFR Inhibitor ABTL0812</VALIDVALUE>
          <VALUEMEANING>mTORC1/mTORC2/DHFR Inhibitor ABTL0812</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, mTORC1/mTORC2/DHFR inhibitor ABTL0812 binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ABTL0812 inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-epitope HER2 Peptide Vaccine H2NVAC</VALIDVALUE>
          <VALUEMEANING>Multi-epitope HER2 Peptide Vaccine H2NVAC</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-epitope HER2 Peptide Vaccine TPIV100</VALIDVALUE>
          <VALUEMEANING>Multi-epitope HER2 Peptide Vaccine TPIV100</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer peptide vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. Upon administration of the multi-epitope HER2 peptide vaccine TPIV100, the four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. To enhance immunity, the peptides are admixed with the adjuvant granulocyte macrophage-colony-stimulating factor (GM-CSF).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multifunctional/Multitargeted Anticancer Agent OMN54</VALIDVALUE>
          <VALUEMEANING>Multifunctional/Multitargeted Anticancer Agent OMN54</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107</VALIDVALUE>
          <VALUEMEANING>Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multikinase Inhibitor 4SC-203</VALIDVALUE>
          <VALUEMEANING>Multikinase Inhibitor 4SC-203</VALUEMEANING>
          <MEANINGDESCRIPTION>A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multikinase Inhibitor AEE788</VALIDVALUE>
          <VALUEMEANING>AEE788</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multikinase Inhibitor AT9283</VALIDVALUE>
          <VALUEMEANING>Multikinase Inhibitor AT9283</VALUEMEANING>
          <MEANINGDESCRIPTION>A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multikinase Inhibitor SAR103168</VALIDVALUE>
          <VALUEMEANING>Multikinase Inhibitor SAR103168</VALUEMEANING>
          <MEANINGDESCRIPTION>A multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-mode Kinase Inhibitor EOC317</VALIDVALUE>
          <VALUEMEANING>Multi-mode Kinase Inhibitor EOC317</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multipeptide Vaccine S-588210</VALIDVALUE>
          <VALUEMEANING>Multipeptide Vaccine S-588210</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327</VALIDVALUE>
          <VALUEMEANING>Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muparfostat</VALIDVALUE>
          <VALUEMEANING>Muparfostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity. Muparfostat inhibits the endo-beta-D-glucuronidase heparanase, which may interfere with the heparanase-mediated degradation of heparan-sulfate proteoglycans in extracellular matrices, an important step in the metastatic process. This agent may also bind with high affinity to the heparan sulfate-binding domains of vascular endothelial growth factor (VEGF) and fibroblast growth factors 1 and 2, thereby reducing their functional activities and inhibiting VEGF and FGF stimulation of tumor angiogenesis. Increased heparanase activity has been implicated in tumor angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mureletecan</VALIDVALUE>
          <VALUEMEANING>Mureletecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces potentially lethal double-stranded DNA breaks when encountered by the DNA replication machinery, resulting in the inhibition of DNA replication and apoptosis. Compared to camtpothecin, this prodrug formulation increases camptothecin drug delivery to the tumor site while reducing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Murizatoclax</VALIDVALUE>
          <VALUEMEANING>Murizatoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-neo-epitope Vaccine OSE 2101</VALIDVALUE>
          <VALUEMEANING>Multi-neo-epitope Vaccine OSE 2101</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes.  This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscadine Grape Extract</VALIDVALUE>
          <VALUEMEANING>Muscadine Grape Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract derived from the Muscadine grape (Vitis rotundifolia), with potential anti-inflammatory, antioxidant, anti-lipidemic and chemopreventive activities. The muscadine grape extract (MGE) contains numerous phytochemicals including hydrolyzable tannins and flavonoids, such as resveratrol, anthocyanin 3,5-diglucosides, quercetin, ellagic acid, myricetin, and kaempferol glycosides. Upon administration, the active components in the MGE scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. MGE also inhibits enzymes involved in inflammation, cell replication and DNA synthesis, and induces the expression of anti-oxidant enzymes. The active ingredients may also inhibit certain signaling pathways upregulated in some tumor cell types, eventually leading to apoptosis and a reduction in tumor cell proliferation. MGE may also boost energy and prevent fatigue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175526</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mutant p53 Activator COTI-2</VALIDVALUE>
          <VALUEMEANING>Mutant p53 Activator COTI-2</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mutant-selective EGFR Inhibitor PF-06459988</VALIDVALUE>
          <VALUEMEANING>Mutant-selective EGFR Inhibitor PF-06459988</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119624</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP</VALIDVALUE>
          <VALUEMEANING>MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10457692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MVA-FCU1 TG4023</VALIDVALUE>
          <VALUEMEANING>MVA-FCU1 TG4023</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1</VALIDVALUE>
          <VALUEMEANING>MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient&#39;s tumor are co-localized in the patient&#39;s tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patient&#39;s own irradiated cancer cells as vaccine antigens, the patient&#39;s immune system is exposed to the entire repertoire of this individual&#39;s TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mycobacterium tuberculosis Arabinomannan Z-100</VALIDVALUE>
          <VALUEMEANING>Mycobacterium tuberculosis Arabinomannan Z-100</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mycobacterium w</VALIDVALUE>
          <VALUEMEANING>Mycobacterium w</VALUEMEANING>
          <MEANINGDESCRIPTION>An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mycophenolic Acid</VALIDVALUE>
          <VALUEMEANING>mycophenolic acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MVA-BN Smallpox Vaccine</VALIDVALUE>
          <VALUEMEANING>MVA-BN Smallpox Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MYC-targeting siRNA DCR-MYC</VALIDVALUE>
          <VALUEMEANING>MYC-targeting siRNA DCR-MYC</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea</VALIDVALUE>
          <VALUEMEANING>N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available isoxazole urea with potential anti-tumor activity.  In preclinical trials, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl)urea inhibited raf kinase, an enzyme capable of reversing the phenotype of ras-transformed cells and blocking tumor growth. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N,N-Dibenzyl Daunomycin</VALIDVALUE>
          <VALUEMEANING>N,N-Dibenzyl Daunomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>The N-alkylated analogue of the anthracycline antineoplastic antibiotic daunomycin.  N,N-Dibenzyl Daunomycin interacts with topoisomerase II, thereby inhibiting DNA replication and repair and promoting DNA fragmentation.  This agent is less cardiotoxic than daunomycin. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2084</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA17.A2 Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>NA17.A2 Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nab-paclitaxel</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Albumin-Stabilized Nanoparticle Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5567089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</VALIDVALUE>
          <VALUEMEANING>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nadofaragene Firadenovec</VALIDVALUE>
          <VALUEMEANING>Nadofaragene Firadenovec</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71011</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nagrestipen</VALIDVALUE>
          <VALUEMEANING>Nagrestipen</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of a human macrophage inflammatory protein-1 alpha (MIP1-alpha) with a substitution of aspartate to alanine at position 26, with potential immunomodulating and radiotherapy potentiating activity. Intravenous administration of nagrestipen after local tumor irradiation enhances the anti-tumor effect of ionizing radiation at the irradiated site as well as the antitumor effect at non-irradiated tumor sites (known as the abscopal effect). The abscopal effect appears to be attributed to this agent&#39;s ability to recruit and activate leukocytes, such as monocytes, dendritic cells, natural killer cells and T lymphocytes, thereby initiating an anti-tumor immune response against cancer cells. MIP1-alpha, also known as chemokine (C-C motif) ligand 3, is a ligand for the chemokine receptors CCR1, CCR4 and CCR5 that are involved in immune and inflammatory responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Namirotene</VALIDVALUE>
          <VALUEMEANING>Namirotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analogue of retinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, namirotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA17-A Antigen</VALIDVALUE>
          <VALUEMEANING>NA17-A Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3636108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Namodenoson</VALIDVALUE>
          <VALUEMEANING>Namodenoson</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NAMPT Inhibitor OT-82</VALIDVALUE>
          <VALUEMEANING>NAMPT Inhibitor OT-82</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon oral administration, NAMPT inhibitor OT-82 binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in cell death in NAMPT-overexpressing cancer cells. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is overexpressed in a variety of cancers and metabolic disorders; tumor cells rely on NAMPT activity for their NAD supply.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanafrocin</VALIDVALUE>
          <VALUEMEANING>Nanafrocin</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinone antibiotic isolated from Streptomyces rosa var. notoensis with activity against gram-positive bacteria, mycoplasmas and fungi. Within an organism, nanaomycin A is first reduced by flavin or NADH dehydrogenase then rapidly autooxidized leading to the production of singlet molecular oxygen (O2-). The increase in intracellular O2- results in inhibition of DNA, RNA and cell-wall peptidoglycan synthesis. Further, nanaomycin A may have antineoplastic properties resulting from a reduction in DNA methylation by inhibiting DNA methyltransferase 3B (DNMT3B) and reactivating the tumor suppressor gene RASSF1A.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanatinostat</VALIDVALUE>
          <VALUEMEANING>Nanatinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC), with potential antineoplastic activity. Nanatinostat targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle Albumin-Bound Docetaxel</VALIDVALUE>
          <VALUEMEANING>Nanoparticle Albumin-Bound Docetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle albumin-bound formulation of the taxane docetaxel with antineoplastic activity. Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. This nanoparticle albumin-bound formulation solubilizes docetaxel without the use of the nonionic solubilizer Cremophor ELP, permitting the administration of larger doses of docetaxel while avoiding Cremophor ELP-associated toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</VALIDVALUE>
          <VALUEMEANING>Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle Paclitaxel Ointment SOR007</VALIDVALUE>
          <VALUEMEANING>Nanoparticle Paclitaxel Ointment SOR007</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle-based Paclitaxel Suspension</VALIDVALUE>
          <VALUEMEANING>Nanoparticle-based Paclitaxel Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle-encapsulated Doxorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Nanoparticle-encapsulated Doxorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanocell-encapsulated miR-16-based microRNA Mimic</VALIDVALUE>
          <VALUEMEANING>Nanocell-encapsulated miR-16-based microRNA Mimic</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoscale Coordination Polymer Nanoparticles CPI-100</VALIDVALUE>
          <VALUEMEANING>Nanoscale Coordination Polymer Nanoparticles CPI-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanosomal Docetaxel Lipid Suspension</VALIDVALUE>
          <VALUEMEANING>Nanosomal Docetaxel Lipid Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug&#39;s safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel&#39;s therapeutic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Napabucasin</VALIDVALUE>
          <VALUEMEANING>Napabucasin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Naptumomab Estafenatox</VALIDVALUE>
          <VALUEMEANING>Naptumomab Estafenatox</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120), with immunomodulating and antineoplastic activities. The Fab moiety of naptumomab estafenatox binds to 5T4, an antigen expressed by various tumor cells. In turn, the superantigen binds to both major histocompatibility complex class II molecules and to the T-cell receptor beta chain, which results in a massive activation of T lymphocytes and induces a potent T-cell-mediated killing of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Naquotinib</VALIDVALUE>
          <VALUEMEANING>EGFR Inhibitor ASP8273</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Naratuximab Emtansine</VALIDVALUE>
          <VALUEMEANING>Naratuximab Emtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Narnatumab</VALIDVALUE>
          <VALUEMEANING>Narnatumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody against RON (recepteur d&#39;origine nantais; macrophage stimulating 1 receptor), with potential antineoplastic activity. Anti-RON monoclonal antibody IMC-RON8 binds to RON, thereby preventing binding of its ligand hepatocyte growth factor-like protein (HGFL or macrophage-stimulating protein (MSP)). This may prevent RON receptor-mediated signaling and may prevent cellular proliferation in tumor cells overexpressing RON. RON, a receptor tyrosine kinase, is overexpressed in a variety of epithelial cancer cell types and plays an important role in cellular proliferation, migration and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Natalizumab</VALIDVALUE>
          <VALUEMEANING>Natalizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8115531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Natural IFN-alpha OPC-18</VALIDVALUE>
          <VALUEMEANING>Natural IFN-alpha OPC-18</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation of natural human interferon alpha (IFN alpha) with potential immunomodulatory and antineoplastic activities. Natural human interferon alpha OPC-18 binds to cell-surface IFN alpha receptors (IFNARs), resulting in the transcription and translation of genes whose products mediate antiviral, antiproliferative, and immune-modulating effects. IFN alpha is a type I interferon produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products and is the primary interferon produced by virus-induced leukocyte cultures. In addition to its pronounced antiviral activity, it activates NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Naphthalimide Analogue UNBS5162</VALIDVALUE>
          <VALUEMEANING>Naphthalimide Analogue UNBS5162</VALUEMEANING>
          <MEANINGDESCRIPTION>An amonafide (naphthalimide) derivative and pan-antagonist of chemokine ligand (CXCL) expression, with potential anti-angiogenic activity. Although UNBS5162 is a derivative of amonafide, this agent appears to have a different profile to that of amonafide and its exact mechanism of action remains to be fully elucidated. This agent seems to decrease the expression of various proangiogenic CXCL chemokines in vitro and may have synergistic effects with radiotherapy or chemotherapy. CXCLs are small cytokines in the CXC chemokine family that are overexpressed in certain cancers; CXCL-mediated signaling plays a key role in angiogenesis and tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Natural Killer Cells ZRx101</VALIDVALUE>
          <VALUEMEANING>Natural Killer Cells ZRx101</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Navarixin</VALIDVALUE>
          <VALUEMEANING>Navarixin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Navicixizumab</VALIDVALUE>
          <VALUEMEANING>Navicixizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Navoximod</VALIDVALUE>
          <VALUEMEANING>Navoximod</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, navoximod targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Navy Bean Powder</VALIDVALUE>
          <VALUEMEANING>Navy Bean Powder</VALUEMEANING>
          <MEANINGDESCRIPTION>The powder form of the cooked navy bean with potential antioxidant and chemopreventive activities. Navy beans are rich in fiber, minerals, vitamins, and phytochemicals such as flavonoids and phytosterols. They appear to prevent carcinogenesis by inducing tumor cell apoptosis. Intake of navy bean powder may have a beneficial effect on intestinal microflora.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nazartinib</VALIDVALUE>
          <VALUEMEANING>Nazartinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115109</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N-dihydrogalactochitosan</VALIDVALUE>
          <VALUEMEANING>N-dihydrogalactochitosan</VALUEMEANING>
          <MEANINGDESCRIPTION>A carbohyrate polymer in which galactose molecules are attached to the amino groups of the glucosamine polymer chitosan, with potential imunostimulating activity. After a tumor ablation and upon intratumoral injection directly into the location of the ablated tumor, N-dihydrogalactochitosan may trigger a tumor-specific systemic immune response when exposed to tumor-associated neoantigens that are liberated by tumor ablation. This may kill tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Necitumumab</VALIDVALUE>
          <VALUEMEANING>Necitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nedaplatin</VALIDVALUE>
          <VALUEMEANING>Nedaplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61099</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Navitoclax</VALIDVALUE>
          <VALUEMEANING>Navitoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NEDD8 Activating Enzyme E1 Inhibitor TAS4464</VALIDVALUE>
          <VALUEMEANING>NEDD8 Activating Enzyme E1 Inhibitor TAS4464</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) activating enzyme E1 (NAE), with potential antineoplastic activity. Upon administration, TAS4464 selectively binds to and inhibits NAE, which prevents NAE/NEDD8-mediated signaling and prevents the NEDD8 conjugation of cullin-RING ligase complexes (CRLs). This inactivates the CRLs leading to an accumulation of CRL substrate proteins, such as CDT1, p27, p21 and phosphorylated IkappaB, and inactivates nuclear factor-kappaB (NF-kB) as well as downregulates anti-apoptotic proteins. This causes cell cycle dysregulation, induces apoptosis, and inhibits tumor cell proliferation and survival. NAE catalyzes the first step in the NEDD8 conjugation (neddylation) pathway which controls cancer cell growth and survival through activation of CRLs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nelarabine</VALIDVALUE>
          <VALUEMEANING>Nelarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nelipepimut-S</VALIDVALUE>
          <VALUEMEANING>Nelipepimut-S</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5399292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nelipepimut-S Plus GM-CSF Vaccine</VALIDVALUE>
          <VALUEMEANING>Nelipepimut-S Plus GM-CSF Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nemorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Nemorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of nemorubicin, a morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen Vaccine GEN-009</VALIDVALUE>
          <VALUEMEANING>Neoantigen Vaccine GEN-009</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based, personalized cancer vaccine consisting of patient-specific mutated synthetic long peptides (SLPs), which are immunogenic and unique to the patient&#39;s tumor, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination with the personalized neoantigen peptide vaccine GEN-009, and administration along with the immunoadjuvant poly-ICLC, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The Antigen Lead Acquisition System (ATLAS) will be used to identify neoantigens in each patient&#39;s tumor that are recognized by their CD4 and/or CD8 T-cells and will be incorporated into GEN-009 in the form of SLPs. Each personalized vaccine contains between four and twenty SLPs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-based Glioblastoma Vaccine</VALIDVALUE>
          <VALUEMEANING>Neoantigen-based Glioblastoma Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-based Melanoma-Poly-ICLC Vaccine</VALIDVALUE>
          <VALUEMEANING>Neoantigen-based Melanoma-Poly-ICLC Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine</VALIDVALUE>
          <VALUEMEANING>Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient&#39;s tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nemorubicin</VALIDVALUE>
          <VALUEMEANING>Nemorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83999</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-based Therapeutic Cancer Vaccine GRT-C903</VALIDVALUE>
          <VALUEMEANING>Neoantigen-based Therapeutic Cancer Vaccine GRT-C903</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-based Therapeutic Cancer Vaccine GRT-R904</VALIDVALUE>
          <VALUEMEANING>Neoantigen-based Therapeutic Cancer Vaccine GRT-R904</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017</VALIDVALUE>
          <VALUEMEANING>Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135018</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neratinib</VALIDVALUE>
          <VALUEMEANING>Neratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49094</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3720773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nesvacumab</VALIDVALUE>
          <VALUEMEANING>Nesvacumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NG-nitro-L-arginine</VALIDVALUE>
          <VALUEMEANING>NG-nitro-L-arginine</VALUEMEANING>
          <MEANINGDESCRIPTION>An amino acid derivative and nitric oxide synthase (NOS) inhibitor with potential antineoplastic and antiangiogenic activities. Upon administration, NG-nitro-L-arginine inhibits the enzyme nitric oxide synthase, thereby preventing the formation of nitric oxide (NO). By preventing NO generation, the vasodilatory effects of NO are abrogated leading to vasoconstriction, reduction in vascular permeability and an inhibition of angiogenesis. As blood flow to tumors is restricted, this may result in an inhibition of tumor cell proliferation. NO plays an important role in tumor blood flow and stimulation of angiogenesis, tumor progression, survival, migration and invasiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Niacinamide</VALIDVALUE>
          <VALUEMEANING>Niacinamide</VALUEMEANING>
          <MEANINGDESCRIPTION>The active form of vitamin B3 and a component of the coenzyme nicotinamide adenine dinucleotide (NAD). Niacinamide acts as a chemo- and radio-sensitizing agent by enhancing tumor blood flow, thereby reducing tumor hypoxia.  This agent also inhibits poly(ADP-ribose) polymerases, enzymes involved in the rejoining of DNA strand breaks induced by radiation or chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Niclosamide</VALIDVALUE>
          <VALUEMEANING>Niclosamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Upon oral administration, niclosamide specifically induces degradation of the androgen receptor (AR) variant V7 (AR-V7) through the proteasome-mediated pathway. This downregulates the expression of the AR variant, inhibits AR-V7-mediated transcriptional activity, and reduces AR-V7 recruitment to the prostate-specific antigen (PSA) gene promoter. Niclosamide also prevents AR-V7-mediated STAT3 phosphorylation and activation. This inhibits AR/STAT3-mediated signaling and prevents expression of STAT3 target genes. Altogether, this may inhibit growth of AR-V7-overexpressing cancer cells. The AR-V7 variant, which is encoded by contiguous splicing of AR exons 1/2/3/CE3, is upregulated in a variety of cancer cell types, and is associated with both cancer progression and resistance to AR-targeted therapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66240</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nicotinamide Riboside</VALIDVALUE>
          <VALUEMEANING>Nicotinamide Riboside</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neratinib Maleate</VALIDVALUE>
          <VALUEMEANING>Neratinib Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nidanilimab</VALIDVALUE>
          <VALUEMEANING>Nidanilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nifurtimox</VALIDVALUE>
          <VALUEMEANING>Nifurtimox</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitrofuran derivative with antiprotozoal and potential antineoplastic activities. Nifurtimox is reduced by cytosol enzymes or flavin-containing microsomal enzymes to a highly reactive nitro anion free radical; autooxidation of the nitro anion free radical generates cytotoxic superoxide anion (02-). In addition, nifurtimox-derived nitro anion free radicals may alkylate macromolecules such as nucleic acids and proteins, resulting in the disruption of their structure and function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nilotinib</VALIDVALUE>
          <VALUEMEANING>Nilotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nilotinib Hydrochloride Anhydrous</VALIDVALUE>
          <VALUEMEANING>Nilotinib Hydrochloride Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nilotinib Hydrochloride Monohydrate</VALIDVALUE>
          <VALUEMEANING>Nilotinib Hydrochloride Monohydrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimesulide-Hyaluronic Acid Conjugate CA102N</VALIDVALUE>
          <VALUEMEANING>Nimesulide-Hyaluronic Acid Conjugate CA102N</VALUEMEANING>
          <MEANINGDESCRIPTION>A covalently bound conjugate composed of the biological polymer sodium hyaluronate (NaHA) and the hydrophobic, cyclooxygenase 2 (COX-2) inhibitor and cytotoxic agent nimesulide (Nim), with potential antineoplastic activity. Upon intravenous administration of Nim-HA conjugate CA102N, the HA moiety targets and binds to CD44. Following endocytosis of CA102N and enzymatic degradation within the lysosomal compartment, Nim is released inside CD44-expressing tumor cells, causing Nim-mediated induction of cell cycle arrest tumor cell apoptosis and decreases tumor cell growth. In addition, Nim inhibits various tumor cell signaling pathways thereby further inhibiting tumor cell proliferation. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, plays a key role in cellular growth, survival, differentiation and motility. Overexpressed in a variety of cancer cell types, CD44 plays a key role in tumor cell proliferation, migration and survival. Conjugation of HA to Nim allows for increased solubility of Nim and for targeted delivery of Nim to CD44-expressing tumor cells, thereby increasing efficacy and safety of Nim.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimodipine</VALIDVALUE>
          <VALUEMEANING>Nimodipine</VALUEMEANING>
          <MEANINGDESCRIPTION>A dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity. Nimodipine inhibits the transmembrane influx of calcium ions in response to depolarization in smooth muscle cells, thereby inhibiting vascular smooth muscle contraction and inducing vasodilatation. Nimodipine has a greater effect on cerebral arteries than on peripheral smooth muscle cells and myocardial cells, probably because this agent can cross the blood brain barrier due to its lipophilic nature. Furthermore, this agent also inhibits the drug efflux pump P-glycoprotein, which is overexpressed in some multi-drug resistant tumors, and may improve the efficacy of some antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimotuzumab</VALIDVALUE>
          <VALUEMEANING>Nimotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimustine</VALIDVALUE>
          <VALUEMEANING>Nimustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nilutamide</VALIDVALUE>
          <VALUEMEANING>Nilutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug that blocks the effects of male hormones in the body.  It belongs to the family of drugs called antiandrogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3335142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimustine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Nimustine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of nimustine, a nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ningetinib Tosylate</VALIDVALUE>
          <VALUEMEANING>Ningetinib Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nintedanib</VALIDVALUE>
          <VALUEMEANING>Nintedanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Niraparib</VALIDVALUE>
          <VALUEMEANING>Niraparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nirogacestat</VALIDVALUE>
          <VALUEMEANING>Gamma Secretase Inhibitor PF-03084014</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors; Notch signaling pathway inhibition may follow, which may result in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nitric Oxide-Releasing Acetylsalicylic Acid Derivative</VALIDVALUE>
          <VALUEMEANING>Nitric Oxide-Releasing Acetylsalicylic Acid Derivative</VALUEMEANING>
          <MEANINGDESCRIPTION>A nitric oxide (NO) donating derivative of acetylsalicylic acid with anti-inflammatory, analgesic, antipyretic, antithrombotic, gastroprotective and potential antitumor activities. The acetylsalicylic acid derivative moiety of this agent inhibits the activities of cyclooxygenase (COX) I and II, preventing the formation of prostaglandins and thromboxanes. A reduction in prostaglandin synthesis accounts for this agent&#39;s anti-inflammatory, anti-pyretic and analgesic activities; a reduction in thromboxane A2 synthesis results in an irreversible inhibition of platelet aggregation. NO donation by this agent, after cleavage from the acetylsalicylic acid derivative in vivo, may protect the gastric mucosa against the damaging effects of the aspirin derivative by modulating prostaglandins. In tumor cells, the NO donating moiety may block the cell cycle in the G1 and G2 phases and may induce apoptosis through caspase-mediated mechanisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nitrogen Mustard Prodrug PR-104</VALIDVALUE>
          <VALUEMEANING>Nitrogen Mustard Prodrug PR-104</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A, which is reduced to form the active DNA-crosslinking mustard species hydroxylamine PR-104H intracellularly under hypoxic conditions. PR-104H specifically crosslinks hypoxic tumor cell DNA, resulting in the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis in susceptible hypoxic tumor cell populations while sparing normoxic tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nitroglycerin Transdermal Patch</VALIDVALUE>
          <VALUEMEANING>Nitroglycerin Transdermal Patch</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained release transdermal patch containing the organic nitrate nitroglycerin, with vasodilator and potential immunomodulating activities. Upon application to the skin, nitroglycerin is continuously released from the patch and absorbed. In turn, nitroglycerin is converted into nitric oxide (NO), which activates guanylyl cyclase, increasing cyclic guanosine monophosphate concentration thus resulting in smooth muscle relaxation. In addition, activation of NO-mediated signaling pathways may inhibit hypoxia-induced tumor cell invasiveness, chemoresistance, evasion of immune cell recognition and cancer cell progression. Particularly, reactivation of NO-mediated signaling appears to inhibit the increased tumor cell shedding of the major histocompatibility complex class I chain-related (MIC) molecules MICA and MICB as is seen in hypoxic tumor environments; MIC molecules play key roles in tumor cell immune surveillance through their interaction with the C-type lectin-like NKG2D receptor on natural killer, lymphokine-activated killer and effector T cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Niraparib Tosylate Monohydrate</VALIDVALUE>
          <VALUEMEANING>Niraparib Tosylate Monohydrate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nivolumab</VALIDVALUE>
          <VALUEMEANING>Nivolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NLRP3 Agonist BMS-986299</VALIDVALUE>
          <VALUEMEANING>NLRP3 Agonist BMS-986299</VALUEMEANING>
          <MEANINGDESCRIPTION>A nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD Containing Protein 3; NALP3) agonist with potential immunomodulatory and antineoplastic activities. Upon administration, NLRP3 agonist BMS-986299 binds to and activates NLRP3, potentially promoting NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may induce tumoricidal activity of natural killer (NK) cells against tumor cells. NLRP3, a sensor component of the NLRP3 inflammasome plays a significant role in immunity and inflammation, and may protect against tumorigenesis in some cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N-Methylformamide</VALIDVALUE>
          <VALUEMEANING>N-Methylformamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nocodazole</VALIDVALUE>
          <VALUEMEANING>Nocodazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tubulin-binding agent with antineoplastic activity. Nocodazole binds to beta-tubulin and disrupts microtubule assembly/disassembly dynamics. This prevents mitosis and induces apoptosis in tumor cells. Although nocodazole binding site overlaps with that of colchicine, the two agents are structurally quite different.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nogalamycin</VALIDVALUE>
          <VALUEMEANING>Nogalamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces nogalater.  Nogalamycin intercalates into DNA and interacts with topoisomerase I, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nolatrexed Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Nolatrexed Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1577</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201</VALIDVALUE>
          <VALUEMEANING>Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-small cell lung cancer (NSCLC) vaccine containing modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Upon subcutaneous administration, non-small cell lung cancer mRNA-derived vaccine CV9201 may stimulate the immune system to mount a cytotoxic, antigen-specific T lymphocyte response (CTL) against NSCLC cells. The modified mRNAs in this vaccine are taken up by cells after injection and exhibit enhanced translational potency. The five tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Norgestrel</VALIDVALUE>
          <VALUEMEANING>Norgestrel</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic progestin commonly used alone or in combination with an estrogen for contraception.  Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes.  This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C703</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>North American Ginseng Extract AFX-2</VALIDVALUE>
          <VALUEMEANING>North American Ginseng Extract AFX-2</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available proprietary aqueous extract from the North American ginseng (Panax quinquefolius) dried root, primarily containing poly-furanosyl-pyranosyl-saccharides, with potential immunostimulating activity. Upon administration, North American ginseng extract AFX-2 may stimulate the proliferation and activation of B-lymphocytes and stimulates IgG production by B cells. Also, this agent induces maturation of dendritic cells, induces T cell proliferation and activates peritoneal exudate macrophages leading to an increase in the production of the cytokines interleukin -1 and -6, tumor necrosis factor-alpha, interferon-gamma and nitric oxide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nogapendekin Alfa</VALIDVALUE>
          <VALUEMEANING>Nogapendekin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6004367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nortopixantrone</VALIDVALUE>
          <VALUEMEANING>Nortopixantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A 9-aza-anthrapyrazole-based antineoplastic antibiotic. Nortopixantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Nortopixantrone is less cardiotoxicity than anthracyclines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Noscapine</VALIDVALUE>
          <VALUEMEANING>Noscapine</VALUEMEANING>
          <MEANINGDESCRIPTION>A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3293803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Noscapine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Noscapine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally available hydrochloride salt of the opioid agonist noscapine, a phthalideisoquinoline alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine binds to tubulin and alters its conformation, resulting in a disruption of the dynamics of microtubule assembly (by increasing the time that microtubules spend idle in a paused state) and subsequently, the inhibition of mitosis and tumor cell death. Unlike other tubulin inhibitors such as the taxanes and vinca alkaloids, noscapine does not affect microtubule polymerization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Notch Signaling Inhibitor PF-06650808</VALIDVALUE>
          <VALUEMEANING>Notch Signaling Inhibitor PF-06650808</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nucleolin Antagonist IPP-204106N</VALIDVALUE>
          <VALUEMEANING>Nucleolin Antagonist IPP-204106N</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, multivalent, lysine-rich, pseudopeptide and nucleolin antagonist with potential anti-angiogenic, antineoplastic and pro-apoptotic activities. Upon administration, IPP-204106N antagonizes nucleolin leading to a downregulation of cell-surface nucleolin; preventing the binding of certain growth promoting ligands to nucleolin may suppress tumor cell proliferation and angiogenesis. In addition, IPP-204106N is able to translocate to the nucleolus and bind to nucleolar nucleolin. This prevents nucleolin from binding to and stabilizing mRNA of the anti-apoptotic Bcl2; destabilizing Bcl2 mRNA leads to a reduction in Bcl2 protein synthesis and induces apoptosis. Further, this agent can antagonize nucleophosmin. Nucleolin, a nucleolar phosphoprotein, is overexpressed on the cell surface of certain cancer cells and binds ligands involved in cell proliferation, adhesion and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nucleoside Analog DFP-10917</VALIDVALUE>
          <VALUEMEANING>Nucleoside Analog DFP-10917</VALUEMEANING>
          <MEANINGDESCRIPTION>A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nucleotide Analogue GS 9219</VALIDVALUE>
          <VALUEMEANING>Nucleotide Analogue GS 9219</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG) with potential antineoplastic activity. Formulated to selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is converted to its active metabolite, PMEG diphosphate (PMEGpp), via enzymatic hydrolysis, deamination, and phosphorylation; subsequently, PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which may result in the termination of DNA synthesis, S-phase cell cycle arrest, and the induction of apoptosis in susceptible lymphoma cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Numidargistat</VALIDVALUE>
          <VALUEMEANING>Numidargistat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nurulimab</VALIDVALUE>
          <VALUEMEANING>Nurulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Notch Signaling Pathway Inhibitor MK0752</VALIDVALUE>
          <VALUEMEANING>Notch Signaling Pathway Inhibitor MK0752</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated. The Notch signaling pathway plays an important role in cell-fate determination, cell survival, and cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nutraceutical TBL-12</VALIDVALUE>
          <VALUEMEANING>Nutraceutical TBL-12</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available nutritional supplement and proprietary formulation containing extracts from the sea cucumber, sea sponge, shark fin, sea urchin and the marine grass Sargassum, with potential antioxidant, antitumor, anti-angiogenic and immunomodulating activities. TBL-12 contains various amino acids, minerals, vitamins and omega-3 fatty acids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611</VALIDVALUE>
          <VALUEMEANING>NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine pPJV7611 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NY-ESO-1/GLA-SE Vaccine ID-G305</VALIDVALUE>
          <VALUEMEANING>NY-ESO-1/GLA-SE Vaccine ID-G305</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301</VALIDVALUE>
          <VALUEMEANING>NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301</VALUEMEANING>
          <MEANINGDESCRIPTION>Human peripheral blood T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and introduction into the patient, the NY-ESO-1-specific TCR gene-transduced T lymphocytes TBI-1301 bind to NY-ESO-1 on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NY-ESO-B</VALIDVALUE>
          <VALUEMEANING>NY-ESO-B</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O6-Benzylguanine</VALIDVALUE>
          <VALUEMEANING>O6-Benzylguanine</VALUEMEANING>
          <MEANINGDESCRIPTION>A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obatoclax Mesylate</VALIDVALUE>
          <VALUEMEANING>Obatoclax Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of obatoclax, a synthetic small-molecule inhibitor of the bcl-2 family of proteins with potential pro-apoptotic and antineoplastic activities. Obatoclax binds to members of the Bcl-2 protein family, preventing the binding of these anti-apoptotic proteins to the pro-apoptotic proteins Bax and Bak and so promoting the activation of the apoptotic pathway in Bcl-2-overexpressing cells. The Bcl-2 family of proteins (bcl-2, bcl-xl, bcl-w, and Mcl-1) are overexpressed in a wide variety of cancers, including those of the lymphatic system, breast, lung, prostate, and colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Obinutuzumab</VALIDVALUE>
          <VALUEMEANING>Obinutuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5096860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oblimersen Sodium</VALIDVALUE>
          <VALUEMEANING>Oblimersen Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ocaratuzumab</VALIDVALUE>
          <VALUEMEANING>Ocaratuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ocrelizumab</VALIDVALUE>
          <VALUEMEANING>Ocrelizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Octreotide</VALIDVALUE>
          <VALUEMEANING>Octreotide</VALUEMEANING>
          <MEANINGDESCRIPTION>The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Octreotide Pamoate</VALIDVALUE>
          <VALUEMEANING>Octreotide Pamoate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic long-acting octapeptide analogue of endogenous somatostatin.  Octreotide pamoate binds to somatostatin receptors expressed by some neuroendocrine and non-neuroendocrine tumor cells, thereby initiating somatostatin receptor-mediated apoptosis. Other possible antineoplastic activities of this agent include suppression of tumor angiogenesis and tumor growth-promoting insulin-like growth factor 1 (IGF-1).  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Odronextamab</VALIDVALUE>
          <VALUEMEANING>Odronextamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O-Chloroacetylcarbamoylfumagillol</VALIDVALUE>
          <VALUEMEANING>O-Chloroacetylcarbamoylfumagillol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ofatumumab</VALIDVALUE>
          <VALUEMEANING>Ofatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ofranergene Obadenovec</VALIDVALUE>
          <VALUEMEANING>Ofranergene Obadenovec</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature.  Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells.  Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oglufanide Disodium</VALIDVALUE>
          <VALUEMEANING>Oglufanide Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt of a synthetic form of a naturally-occurring dipeptide consisting of L-glutamic acid and L-tryptophan with potential antiangiogenic and potential immunomodulating activities. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitic C virus and intracellular bacterial infections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olaparib</VALIDVALUE>
          <VALUEMEANING>Olaparib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olaptesed Pegol</VALIDVALUE>
          <VALUEMEANING>Olaptesed Pegol</VALUEMEANING>
          <MEANINGDESCRIPTION>A 45-mer L-stereoisomer RNA oligonucleotide linked to a 40 kDa polyethyleneglycol that targets the small chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) with potential antineoplastic and hematopoietic stem cell-mobilization activities. SDF-1 targeted agent NOX-A12 specifically binds to SDF-1 thereby preventing the binding of SDF-1 to its receptors CXCR4 and CXCR7 blocking the subsequent receptor activation. This may prevent angiogenesis, tumor cell proliferation, invasion and metastasis and could sensitize tumor cells to chemotherapy. In addition, inhibition of SDF-1/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into blood. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and does not hybridize with native nucleic acids. Furthermore, this agent does not induce the innate immune response and has shown a favorable immunogenicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oleandrin</VALIDVALUE>
          <VALUEMEANING>Oleandrin</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid soluble cardiac glycoside with potential antineoplastic activity. Upon administration, oleandrin specifically binds to and inhibits the alpha3 subunit of the Na/K-ATPase pump in human cancer cells. This may inhibit the phosphorylation of Akt, upregulate MAPK, inhibit NF-kb activation and inhibit FGF-2 export and may downregulate mTOR thereby inhibiting p70S6K and S6 protein expression. All of this may lead to an induction of apoptosis. As cancer cells with relatively higher expression of the alpha3 subunit and with limited expression of the alpha1 subunit are more sensitive to oleandrin, one may predict the tumor response to treatment with lipid-soluble cardiac glycosides such as oleandrin based on the tumors Na/K-ATPase pump protein subunit expression. Overexpression of the alpha3 subunit in tumor cells correlates with tumor proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oleclumab</VALIDVALUE>
          <VALUEMEANING>Oleclumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5&#39;-nucleotidase (5&#39;-NT; ecto-5&#39;-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oligo-fucoidan</VALIDVALUE>
          <VALUEMEANING>Oligo-fucoidan</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfated polysaccharide low-molecular-weight fucoidan, with potential antioxidant, anti-inflammatory, antiproliferative, anti-angiogenic and pro-apoptotic activities. Upon administration of oligo-fucoidan, this agent seems to exert numerous effects through various mechanisms of action, some of which remain to be fully elucidated. Oligo-fucoidan induces cell cycle arrest, activates caspases, induces apoptosis, and inhibits tumor cell proliferation in susceptible tumor cells. It also increases the expression of tumor suppressors, such as p53, while decreasing levels of certain tumor promoters. Oligo-fucoidan also promotes the degradation of transforming growth factor-beta (TGFb) receptor and the inhibition of epithelial-mesenchymal transition (EMT). It prevents tumor progression, alters tumor microenvironment (TME) and decreases the tumor-promoting M2 macrophages in the TME. Oligo-fucoidan has anti-inflammatory effects that suppress the expression of nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and monocyte chemoattractant protein-1 (MCP-1/CCL2), and decrease the production of certain pro-inflammatory cytokines, such as interleukin-1beta (IL-1b) and tumor necrosis factor (TNF)-alpha (TNFa). This agent may also suppress angiogenic activity by inhibiting vascular endothelial growth factor (VEGF) receptor expression and VEGF-induced endothelial cell proliferation. As an antioxidant, this agent protects cells against oxidative stress by scavenging superoxide radicals and induces the expression of the anti-oxidant nuclear factor erythroid-2-related factor 2 and that of its target gene, superoxide dismutase; and prevents reactive oxidative species (ROS) generation in cancer cells and ROS release into the TME. Fucoidan also has immune-modulatory effects and enhances the proliferation of natural killer (NKs) cells and cytotoxic T-cells (CTLs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oligonucleotide SPC2996</VALIDVALUE>
          <VALUEMEANING>Oligonucleotide SPC2996</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic antisense oligonucleotide against Bcl-2 messenger RNA with potential antitumor activity. Oligonucleotide SPC2996 binds to and inactivates Bcl-2 mRNA, thereby inhibiting the expression of Bcl-2 protein, promoting tumor cell apoptosis, and potentially enhancing the efficacy of standard cytotoxic chemotherapy. Linked to tumor drug resistance, the antiapoptotic protein Bcl-2 is upregulated in several types of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olaratumab</VALIDVALUE>
          <VALUEMEANING>Anti-PDGFR alpha Monoclonal Antibody IMC-3G3</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olinvacimab</VALIDVALUE>
          <VALUEMEANING>Olinvacimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olivomycin</VALIDVALUE>
          <VALUEMEANING>Olivomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation containing a mixture of glycosidic antibiotics isolated from Streptomyces olivoreticuli with fluorescent microscopy applications and potential antineoplastic activities. Olivomycin preferentially binds to DNA and can be utilized as a fluorescent marker during the characterization of heterochromatin. Additionally, binding to DNA inhibits both RNA transcription and RNA elongation by RNA polymerase; therefore protein synthesis is inhibited. In addition, olivomycin antibiotics are able to induce apoptosis in tumor cells through a mechanism that has not yet been fully elucidated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olmutinib</VALIDVALUE>
          <VALUEMEANING>Olmutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor HM61713 binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olutasidenib</VALIDVALUE>
          <VALUEMEANING>Olutasidenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Olvimulogene Nanivacirepvec</VALIDVALUE>
          <VALUEMEANING>Olvimulogene Nanivacirepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omacetaxine Mepesuccinate</VALIDVALUE>
          <VALUEMEANING>Omacetaxine Mepesuccinate</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1127</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ombrabulin</VALIDVALUE>
          <VALUEMEANING>Ombrabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omipalisib</VALIDVALUE>
          <VALUEMEANING>Omipalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onalespib</VALIDVALUE>
          <VALUEMEANING>Hsp90 Inhibitor AT13387</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oltipraz</VALIDVALUE>
          <VALUEMEANING>Oltipraz</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onalespib Lactate</VALIDVALUE>
          <VALUEMEANING>Onalespib Lactate</VALUEMEANING>
          <MEANINGDESCRIPTION>The lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onartuzumab</VALIDVALUE>
          <VALUEMEANING>Onartuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Anti-MET monoclonal antibody MetMAb binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onatasertib</VALIDVALUE>
          <VALUEMEANING>Onatasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92575</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Adenovirus ORCA-010</VALIDVALUE>
          <VALUEMEANING>Oncolytic Adenovirus ORCA-010</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication competent, oncolytic adenovirus serotype 5 (Ad5) that has been modified with a delta24 (d24) deletion, an incorporation of an RGD-4C motif in the Ad fiber protein, and an insertion of the T1 mutation in E3/19K gene, with potential oncolytic activity. Upon administration, oncolytic adenovirus ORCA-010 binds to specific Ad3 receptors that are highly expressed on certain tumor cells. This results in the replication of oncolytic adenovirus Ad5/3-delta24 in tumor cells and induces tumor cell lysis which may potentially result in the activation of a systemic immune response against tumor-associated antigens (TAAs). The Ad5/3-delta24 has a 24 base pair deletion in constant region 2 of the E1A gene which allows for selective replication in cells that are defective in the retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (CDKN2A or p16INK4a). As most tumor cells are defective in the Rb/p16 pathway, this virus selectively replicates in these cells. The RGD-4C motif is a 9-amino acid peptide that binds to various and enhances viral-cell receptor binding by allowing for a Coxsackie-adenovirus receptor (CAR)-independent infection of tumor cells, which is the natural route of viral binding, as CAR expression is often deficient on cancer cells. As integrins are often overexpressed on tumor cell surfaces, integrin receptor binding enhances tumor cells binding and infection by the Ad. The T1 mutation enhances the Ad5 release from tumor cells and promotes spreading throughout the tumor, thereby enhancing anti-tumor activity. The T1 mutation, a single Adenine insertion at position 445 of the nucleotide sequence of the E3/19K gene of Adenovirus, creates a truncated E3/19K protein that is relocated to the plasma membrane due to the disruption of its ER retention signal. This increases plasma membrane permeability and enhances the release of Ad5.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 C134</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 C134</VALUEMEANING>
          <MEANINGDESCRIPTION>A neurovirulent, oncolytic second-generation, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1) where the gene for ICP34.5 has been deleted and the gene encoding the human cytomegalovirus (HCMV), protein kinase R (PKR) evasion protein IRS1, with potential oncolytic and immunostimulating activities. Upon intratumoral administration, oncolytic HSV-1 C134 specifically infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells. IRS1 expression allows the virus to replicate within tumors but limits viral spread.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12) and an antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intratumoral administration, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 infects and replicates in tumor cells causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In addition, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 promotes the secretion of IL-12 and anti-PD-1 antibody by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Anti-PD-1 antibody targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 G207</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 G207</VALUEMEANING>
          <MEANINGDESCRIPTION>A neuroattenuated, replication-competent, recombinant herpes simplex virus-1 (HSV-1) with potential oncolytic activity. Upon intracerebral administration, oncolytic HSV-1 G207 preferentially replicates within glioma cells, which may elicit tumor-specific systemic immune and cytotoxic T lymphocyte (CTL) responses in addition to direct cytopathic effects. Derived from wild-type HSV-1 strain F, this agent has been neuroattenuated by deletions in both copies of the gamma34.5 gene, the major determinant of HSV neurovirulence. In addition, the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), has been inactivated through the insertion of the Escherichia coli lacZ gene. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 NV1020</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 NV1020</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically engineered oncolytic virus with potential antineoplastic property. NV1020 is constructed from the herpes simplex virus 1 (HSV-1) by the deletion of a single copy of the gamma (1)34.5 gene and the substitution of the UL23 region of the thymidine kinase (tk) gene with a DNA fragment from HSV-2, thereby resulting in a replication-competent, attenuated virus. This modified virus preferentially transfects rapidly dividing cells, which causes cell lysis in tumor cells. NV1020 has shown reduced virulence against normal tissues and a decreased neurovirulence in comparison with some other modified HSV strains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 rQNestin34.5v.2</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 rQNestin34.5v.2</VALUEMEANING>
          <MEANINGDESCRIPTION>A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Herpes Simplex Virus-1 ONCR-177</VALIDVALUE>
          <VALUEMEANING>Oncolytic Herpes Simplex Virus-1 ONCR-177</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, genetically modified, microRNA (miRNA)-attenuated oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. In ONCR-177, a dual bidirectional promoter enables the expression of five different transgenes: the natural killer (NK) cell and T-cell activating cytokine interleuin-12 (IL-12), the chemokines C-C motif chemokine 4 (CCL4) and the extracellular domain of the Fms-related tyrosine kinase 3 ligand (FLT3LG), to allow for expansion and recruitment of classical dendritic cells (DCs), and antagonists to the immune checkpoints programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to counter T cell exhaustion. Upon intra-tumoral administration, the oncolytic HSV-1 ONCR-177 specifically targets, infects and selectively replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles then infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. In addition, the expressed transgenes that are released upon tumor cell lysis induce a systemic tumor-specific immune response and activate NKs, DCs and cytotoxic T-lymphocytes (CTLs) while inhibiting regulatory T-cells (Tregs). This further kills nearby non-infected tumor cells. In ONCR-177, the neurovirulence gene ICP34.5 allows for potent oncolysis, even in the presence of host cell antiviral responses. To ensure selective replication and oncolysis in cancer cells while attenuating replication in healthy tissue, tissue specific miRNA-binding cassettes (miR-T) are inserted into early genes essential for viral replication. In addition, UL37 mutation suppresses latent infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV-1 rRp450</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV-1 rRp450</VALUEMEANING>
          <MEANINGDESCRIPTION>A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain KOS with potential antineoplastic activity. Upon infusion into the hepatic artery, oncolytic HSV-1 rRp450 replicates in hepatocellular carcinoma (HCC) cells and exerts direct cytotoxic effects eventually disrupting cancer cell membranes and liberating progeny virions thereby infecting adjacent tumor cells. In addition, rRp450 expresses the cytochrome P450 transgene that activates oxazaphosphorines, such as cyclophosphamide (CPA). Therefore, CPA can become activated in the presence of rRp450 and exert its antineoplastic effect. rRp450 is deleted for the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), thereby disrupting the activity of viral ribonucleotide reductase and resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells. UL39 is replaced by the rat CYP2B1 gene, encoding a cytochrome P450 enzyme that activates oxazaphosphorines. rRp450 also expresses viral thymidine kinase, which activates the cancer prodrug ganciclovir.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic HSV1716</VALIDVALUE>
          <VALUEMEANING>Oncolytic HSV1716</VALUEMEANING>
          <MEANINGDESCRIPTION>A neuroattenuated, replication-restricted, ICP34.5 deleted (RL1 gene)-mutant herpes simplex virus (HSV) type I, constructed from wild-type strain 17, with potential oncolytic activity. Upon intratumoral injection, oncolytic HSV1716 transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. Because the RL1 gene is deleted, HSV1716 is unable to replicate in non-dividing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein</VALIDVALUE>
          <VALUEMEANING>Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>An attenuated oncolytic Edmonston (Ed) strain of measles virus (MV) encoding the N-terminus of the human lambda immunoglobulin light chain containing the Helicobacter pylori neutrophil-activating protein (NAP), with potential immunostimulating and antineoplastic activities. Upon administration, the oncolytic measles virus encoding H. pylori NAP selectively infects and replicates in tumor cells, leading to syncytia formation and tumor cell lysis. The expressed NAP, a toll-like receptor-2 (TLR2) agonist, may stimulate the secretion of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1 and IL-6, leading to local inflammatory reaction in the tumor microenvironment (TME). H. pylori NAP, a bacterial antigen and potent immunomodulator, may enhance the antitumor effect of oncolytic MV.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Newcastle Disease Virus MTH-68H</VALIDVALUE>
          <VALUEMEANING>Oncolytic Newcastle Disease Virus MTH-68H</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic viral agent containing the oncolytic, live-attenuated strain of the paramyxovirus Newcastle disease virus (NDV), with potential antineoplastic activity. Upon administration, NDV MTH-68H specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Newcastle Disease Virus Strain PV701</VALIDVALUE>
          <VALUEMEANING>Oncolytic Newcastle Disease Virus Strain PV701</VALUEMEANING>
          <MEANINGDESCRIPTION>An attenuated, replication-competent, oncolytic strain of Newcastle disease virus. PV701 selectively lyses tumor cells. The selectivity of this agent is related to defects in the interferon-mediated antiviral response found in tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Virus ASP9801</VALIDVALUE>
          <VALUEMEANING>Oncolytic Virus ASP9801</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered oncolytic virus with potential antineoplastic and immunomodulating activities. Upon intratumoral injection of ASP-9801, the oncolytic virus selectively targets and replicates in cancer cells without being able to infect and replicate in normal, healthy cells. This induces selective oncolytic virus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent tumor cells, which both induces further tumor cell oncolysis and may activate the immune system to exert an anti-tumor immune response against the tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161021</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ontorpacept</VALIDVALUE>
          <VALUEMEANING>Ontorpacept</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ontuxizumab</VALIDVALUE>
          <VALUEMEANING>Anti-Endosialin Monoclonal Antibody MORAb-004</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Anti-endosialin/TEM1 monoclonal antibody MORAb-004 binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3614158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onvansertib</VALIDVALUE>
          <VALUEMEANING>Onvansertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Newcastle Disease Virus MEDI5395</VALIDVALUE>
          <VALUEMEANING>Oncolytic Newcastle Disease Virus MEDI5395</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic viral agent containing the oncolytic, live-attenuated, replication-competent strain of the avian paramyxovirus Newcastle disease virus (NDV) that has been engineered to include a transgene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunostimulating activities. Upon administration, MEDI5395 specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation through the increased production and secretion of pro-inflammatory cytokines and chemokines which are able to recruit mediators of both the innate and adaptive immune responses. Additionally, the inclusion of the GM-CSF transgene in the viral construct leads to expression of GM-CSF, which may potentiate and strengthen the anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Onvatilimab</VALIDVALUE>
          <VALUEMEANING>Onvatilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against the protein V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative checkpoint regulatory and antineoplastic activities. Upon administration, onvatilimab targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth. VISTA, mainly expressed on hematopoietic cells, plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Opaganib</VALIDVALUE>
          <VALUEMEANING>Opaganib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, opaganib competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule</VALIDVALUE>
          <VALUEMEANING>OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule containing a fermented soymilk extract and oligomeric proanthocyanidins (OPCs), green tea, spirullina, curcumin and antrodia camphorate powder, with potential antioxidant, immunomodulating, anti-infective and anti-cancer activities. OPCs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule may boost the immune system and may alleviate fatigue and poor appetite in cancer chemotherapy patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Opioid Growth Factor</VALIDVALUE>
          <VALUEMEANING>Opioid Growth Factor</VALUEMEANING>
          <MEANINGDESCRIPTION>An endogenous pentapeptide with potential antineoplastic and antiangiogenic activities. Opioid growth factor (OGF) binds to and activates the OGF receptor, present on some tumor cells and vascular cells, thereby inhibiting tumor cell proliferation and angiogenesis. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Opolimogene Capmilisbac</VALIDVALUE>
          <VALUEMEANING>Opolimogene Capmilisbac</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, opolimogene capmilisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oportuzumab Monatox</VALIDVALUE>
          <VALUEMEANING>Oportuzumab Monatox (Vicinium)</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12187520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oprozomib</VALIDVALUE>
          <VALUEMEANING>Oprozomib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4740632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Opucolimab</VALIDVALUE>
          <VALUEMEANING>Opucolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Aminolevulinic Acid Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Oral Aminolevulinic Acid Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A powder for an oral solution comprised of the hydrochloride salt of 5-aminolevulinic acid (ALA) with a potential application for photodynamic therapy. After oral administration, ALA is converted intracellularly into the photosensitizer protoporphyrin IX (PpIX). Upon exposure to light of appropriate wavelength (violet to blue range), excited PpIX emits a characteristic red fluorescence which could facilitate guided resection, and generates excited singlet oxygen molecules that could kill cells when appropriate laser dosage is applied. ALA is preferentially taken up by and accumulates in many types of cancer cells compared to normal, healthy cells. Consequently, cancer cells can be visualized and can be distinguished from normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Cancer Vaccine V3-OVA</VALIDVALUE>
          <VALUEMEANING>Oral Cancer Vaccine V3-OVA</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. Upon oral administration of the oral cancer vaccine V3-OVA, the ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Docetaxel</VALIDVALUE>
          <VALUEMEANING>Oral Docetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral proprietary P-glycoprotein (P-gp) pump inhibitor-based formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, and a P-gp pump inhibitor, with potential antineoplastic activity. Upon administration of oral docetaxel, the P-gp pump inhibitor moiety, which is not absorbed, binds to the P-gp pump in the gastrointestinal (GI) tract and prevents the P-gp pump-mediated efflux of docetaxel from cells the docetaxel has been internalized by back into the GI tract. This decreases P-gp-mediated excretion and enhances absorption of docetaxel. Upon absorption, docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizes tubulin and inhibits microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. The P-gp pump inhibitor enhances the bioavailability of certain poorly bioavailable agents and thereby allows oral administration of those agents. P-gp, an efflux membrane transporter, plays a key role in active drug export, and prevents cellular uptake and accumulation of certain substances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Fludarabine Phosphate</VALIDVALUE>
          <VALUEMEANING>Oral Fludarabine Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported into malignant cells and metabolized by deoxycytidine kinase to its active form, 2-fluoro-ara-ATP; 2-fluoro-ara-ATP competes directly with deoxyadenosine triphosphate (dATP) and inhibits alpha DNA polymerase, RNA reductase, and DNA primase, which may result in inhibition of DNA synthesis and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Hsp90 Inhibitor IPI-493</VALIDVALUE>
          <VALUEMEANING>Oral Hsp90 Inhibitor IPI-493</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or &quot;client&quot; proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Ixabepilone</VALIDVALUE>
          <VALUEMEANING>Oral Ixabepilone</VALUEMEANING>
          <MEANINGDESCRIPTION>An enteric-coated formulation of ixabepilone, a semisynthetic analogue of epothilone B and a non-taxane tubulin inhibitor, with antineoplastic activity. Ixabepilone binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in cell cycle arrest at the G2-M phase and leads to apoptosis within fast growing tumor cells. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Compared to intravenously administered ixabepilone, the oral formulation provides a more manageable way to administer this agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Azacitidine</VALIDVALUE>
          <VALUEMEANING>Oral Azacitidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Microencapsulated Diindolylmethane</VALIDVALUE>
          <VALUEMEANING>Oral Microencapsulated Diindolylmethane</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable microencapsulated formulation of diindolylmethane, an indole phytonutrient found in cruciferous vegetables, with estrogen-modulating, antiandrogenic, and potential antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) modulates estrogen balance by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of beneficial 2-hydroxy estrogen metabolites. DIM also antagonizes androgen receptor activity, which may result in diminished cell proliferation and apoptosis in susceptible tumor cell populations. Pure DIM, which is relatively hydrophobic, is poorly absorbed after oral administration. This oral formulation, which consists of DIM, d-alpha-tocopheryl acid succinate, phosphatidylcholine, and silica microencapsulated in starch, significantly improves the gastrointestinal absorption of DIM.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Myoma Vaccine V3-myoma</VALIDVALUE>
          <VALUEMEANING>Oral Myoma Vaccine V3-myoma</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available therapeutic myoma vaccine containing pooled antigens derived from hydrolyzed, inactivated blood and tumor tissue samples from patients with uterine myoma, with potential antineoplastic and immunomodulatory activities. Upon oral administration, V3-myoma may stimulate the immune system to mount a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This may reduce the myoma growth and improve myoma-related symptoms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Pancreatic Cancer Vaccine V3-P</VALIDVALUE>
          <VALUEMEANING>Oral Pancreatic Cancer Vaccine V3-P</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Sodium Phenylbutyrate</VALIDVALUE>
          <VALUEMEANING>Oral Sodium Phenylbutyrate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Topotecan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Oral Topotecan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral formulation of the hydrochloride salt of topotecan, a semisynthetic derivative of the quinoline alkaloid camptothecin, with potential antineoplastic activity. Topotecan selectively inhibits topoisomerase I activity by stabilizing topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Orantinib</VALIDVALUE>
          <VALUEMEANING>Orantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable receptor tyrosine kinase inhibitor.  SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation.  SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oraxol</VALIDVALUE>
          <VALUEMEANING>Oraxol</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oregovomab</VALIDVALUE>
          <VALUEMEANING>Oregovomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Orelabrutinib</VALIDVALUE>
          <VALUEMEANING>Orelabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Picoplatin</VALIDVALUE>
          <VALUEMEANING>Oral Picoplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral preparation of picoplatin, a third generation platinum compound with antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and RNA transcription and the induction of apoptosis. Because of the increase in steric bulk around the platinum center, there is a relative reduction in the inactivation of picoplatin by thiol-containing species such as glutathione and metallothionein in comparison to cisplatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ormaplatin</VALIDVALUE>
          <VALUEMEANING>Ormaplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ortataxel</VALIDVALUE>
          <VALUEMEANING>Ortataxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Orteronel</VALIDVALUE>
          <VALUEMEANING>Steroid 17alpha-monooxygenase TAK-700</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Orvacabtagene Autoleucel</VALIDVALUE>
          <VALUEMEANING>Orvacabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7476584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osilodrostat</VALIDVALUE>
          <VALUEMEANING>Osilodrostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Otlertuzumab</VALIDVALUE>
          <VALUEMEANING>Otlertuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovapuldencel-T</VALIDVALUE>
          <VALUEMEANING>Ovapuldencel-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006</VALIDVALUE>
          <VALUEMEANING>Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovine Submaxillary Mucin</VALIDVALUE>
          <VALUEMEANING>Ovine Submaxillary Mucin</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring mucin glycoprotein. Ovine submaxillary mucin (OSM), extracted from an ovine submaxillary gland, provides a rich source of the sialylated Tn antigen (sTn), which is a carbohydrate antigen found on mucins of many epithelial tumors. Vaccination with OSM may result in the production of antibodies as well as elicitation of a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing sTn, thereby results in decreased tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osimertinib</VALIDVALUE>
          <VALUEMEANING>Osimertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5305951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxaliplatin</VALIDVALUE>
          <VALUEMEANING>Oxaliplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a &#39;leaving group.&#39; A &#39;leaving group&#39; is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1181</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxaliplatin Eluting Beads</VALIDVALUE>
          <VALUEMEANING>Oxaliplatin Eluting Beads</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of drug-eluting beads (DEB) consisting of polymeric microbeads impregnated with the organoplatinum complex and alkylating agent oxaliplatin, with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with oxaliplatin. During transarterial chemoembolization (TACE) in the hepatic artery, the oxaliplatin eluting beads occlude tumor blood vessels that feed the tumor and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. The beads release cytotoxic oxaliplatin locally, which may result in oxaliplatin-mediated inhibition of tumor cell proliferation through formation of both inter- and intra-strand platinum-DNA crosslinks, and the inhibition of DNA replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172098</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</VALIDVALUE>
          <VALUEMEANING>Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which results in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91074</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxeclosporin</VALIDVALUE>
          <VALUEMEANING>Oxeclosporin</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxidative Phosphorylation Inhibitor IM156</VALIDVALUE>
          <VALUEMEANING>Oxidative Phosphorylation Inhibitor IM156</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, IM156 inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxidopamine</VALIDVALUE>
          <VALUEMEANING>Oxidopamine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of the neurotransmitter dopamine with potential antineoplastic activity. 6-Hydroxydopamine (6-HOD) can be taken up by selective adrenergic terminals, thereby causing acute degeneration of adrenergic terminals that leads to depletion of norepinephrine, and of dopamine in the dopamine-sensitive sites. This agent is auto-oxidated at physiological pH that leads to the formation of reactive free radicals, thereby leading to cytotoxicity in neural cells.  6-Hydroxydopamine is often used to induce CNS and sympathetic neural lesions that model aging and various nervous disorders in animal systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OxPhos Inhibitor VLX600</VALIDVALUE>
          <VALUEMEANING>OxPhos Inhibitor VLX600</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic cation-based triazinoindolyl-hydrazone compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon infusion, in normal cells and proliferating tumor cells where glucose is readily available, inhibition of OxPhos by VLX600 induces a hypoxia-inducible factor 1-alpha (HIF-1alpha)-dependent shift to, and an increase in glycolysis. Glycolysis alone does not produce enough energy to support the growth of tumor cells in this environment, and the induction of autophagy occurs. In the metabolically compromised tumor microenvironment, the availability of oxygen and glucose is limited due to poor vascularization and perfusion of tumor micro-areas. Tumor cells growing in this environment are thus unable to compensate for decreased mitochondrial function by increasing glycolysis. This leads to nutrient depletion, decreased energy production, induction of autophagy, tumor cell death and an inhibition of cell proliferation in quiescent tumor cells. Mitochondrial OxPhos, which is hyperactivated in cancer cells, plays a key role in the promotion of cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ozarelix</VALIDVALUE>
          <VALUEMEANING>Ozarelix</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p38 MAPK Inhibitor LY3007113</VALIDVALUE>
          <VALUEMEANING>p38 MAPK Inhibitor LY3007113</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activity. Upon administration, LY3007113 inhibits the activity of p38, thereby preventing p38 MAPK-mediated signaling. This may result in the inhibition of the production of proinflammatory cytokines and the induction of tumor cell apoptosis. p38 MAPK, a serine/threonine protein kinase often upregulated in cancer cells, plays a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxidative Phosphorylation Inhibitor IACS-010759</VALIDVALUE>
          <VALUEMEANING>Oxidative Phosphorylation Inhibitor IACS-010759</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p53 Peptide Vaccine MPS-128</VALIDVALUE>
          <VALUEMEANING>p53 Peptide Vaccine MPS-128</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p53/HDM2 Interaction Inhibitor CGM097</VALIDVALUE>
          <VALUEMEANING>p53/HDM2 Interaction Inhibitor CGM097</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p53-HDM2 Interaction Inhibitor MI-773</VALIDVALUE>
          <VALUEMEANING>p53-HDM2 Interaction Inhibitor MI-773</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor MI-773 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106120</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p97 Inhibitor CB-5083</VALIDVALUE>
          <VALUEMEANING>p97 Inhibitor CB-5083</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p97 Inhibitor CB-5339</VALIDVALUE>
          <VALUEMEANING>p97 Inhibitor CB-5339</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including ER-associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p97 Inhibitor CB-5339 Tosylate</VALIDVALUE>
          <VALUEMEANING>p97 Inhibitor CB-5339 Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt of  CB-5339, an orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including endoplasmic reticulum associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Ceribate</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Ceribate</VALUEMEANING>
          <MEANINGDESCRIPTION>The ceribate ester form of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin thereby inhibiting the disassembly of microtubules, resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (BCL2).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Injection Concentrate for Nanodispersion</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Injection Concentrate for Nanodispersion</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity.  Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p70S6K Inhibitor LY2584702</VALIDVALUE>
          <VALUEMEANING>p70S6K Inhibitor LY2584702</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of p70S6K signaling, with potential antineoplastic activity. p70S6K inhibitor LY2584702 inhibits ribosomal protein S6 Kinase (p70S6K), and prevents phosphorylation of the S6 subunit of ribosomes, thereby inhibiting normal ribosomal function within tumor cells leading to a decrease in protein synthesis and in cellular proliferation. P70S6K, a serine/threonine kinase, acts downstream of PIP3 and phosphoinositide-dependent kinase-1 in the PI3 kinase pathway, is often upregulated in a variety of cancer cells, and is involved in the regulation of cell growth, proliferation, motility, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Liposome</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Poliglumex</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Poliglumex</VALUEMEANING>
          <MEANINGDESCRIPTION>The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Polymeric Micelle Formulation NANT-008</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Polymeric Micelle Formulation NANT-008</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Trevatide</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Trevatide</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-drug conjugate containing the taxane paclitaxel covalently linked to the proprietary 19 amino acid peptide angiopep-2, in a 3:1 ratio, with potential antineoplastic activity. Upon administration, paclitaxel trevatide, via angiopep-2 moiety, binds to LRP-1 (low density lipoprotein receptor-related protein 1), which is highly expressed in blood brain barrier (BBB) and glioma cells. This binding allows the transcytosis of the agent across the BBB and the delivery of the cytotoxic agent paclitaxel. Compared to paclitaxel alone, GRN1005 is able to increase the concentration of paclitaxel in the brain and is also able to specifically deliver paclitaxel to LRP-1-overexpressing tumor cells, both in the brain and in the periphery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel Vitamin E-Based Emulsion</VALIDVALUE>
          <VALUEMEANING>Paclitaxel Vitamin E-Based Emulsion</VALUEMEANING>
          <MEANINGDESCRIPTION>A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions. The tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel-Loaded Polymeric Micelle</VALIDVALUE>
          <VALUEMEANING>Paclitaxel-Loaded Polymeric Micelle</VALUEMEANING>
          <MEANINGDESCRIPTION>A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with antineoplastic activity. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pacmilimab</VALIDVALUE>
          <VALUEMEANING>Pacmilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pacritinib</VALIDVALUE>
          <VALUEMEANING>Pacritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor SB1518 competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Padeliporfin</VALIDVALUE>
          <VALUEMEANING>Padeliporfin</VALUEMEANING>
          <MEANINGDESCRIPTION>A vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with potential antineoplastic activity. Upon administration, paldeliporfin is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Vascular-targeted photodynamic therapy (VTP) with padeliporfin may allow tumor-site specific cytotoxicity while sparing adjacent normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paclitaxel PPE Microspheres</VALIDVALUE>
          <VALUEMEANING>Paclitaxel PPE Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>A paclitaxel formulation containing paclitaxel incorporated in biodegradable polyphosphoester (PPE) polymer form with potential antineoplastic activity. Upon intraperitoneal delivery, paclitaxel PPE microspheres slowly and continuously dissolve and deliver paclitaxel to the tumor site, where it binds to tubulin and inhibits the dynamics of disassembly-assembly of microtubules. As a result, this formulation induces cell cycle arrest and leads to cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Padoporfin</VALIDVALUE>
          <VALUEMEANING>Padoporfin</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel palladium-substituted bacteriochlorophyll derivative and photosensitizer with potential antitumor activity. Upon administration, inactive padoporfin is activated locally when the tumor bed is exposed to photoirradiation; the activated form induces local cytotoxic processes, resulting in local tissue damage, disruption of tumor vasculature, and tumor hypoxia and necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61321</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PAK4 Inhibitor PF-03758309</VALIDVALUE>
          <VALUEMEANING>PAK4 Inhibitor PF-03758309</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a variety of cancer cell types and plays an important role in cancer cell motility, proliferation, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palbociclib</VALIDVALUE>
          <VALUEMEANING>PD-0332991</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palbociclib Isethionate</VALIDVALUE>
          <VALUEMEANING>Palbociclib Isethionate</VALUEMEANING>
          <MEANINGDESCRIPTION>The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palifosfamide Tromethamine</VALIDVALUE>
          <VALUEMEANING>Palifosfamide Tromethamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic mustard compound of the tromethamine (tris) salt of palifosfamide (Isophosphamide mustard), with potential antineoplastic activity. As the stabilized active metabolite of ifosfamide, palifosfamide irreversibly alkylates and crosslinks DNA through GC base pairs, resulting in irreparable 7-atom interstrand crosslinks. This leads to an inhibition of DNA replication and ultimately cell death. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide. Stabilization with tris instead of lysine further increases stability and may further decrease nephrotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95703</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palladium Pd-103</VALIDVALUE>
          <VALUEMEANING>Palladium Pd-103</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioisotope of the metal palladium used in brachytherapy implants or &#39;seed&#39;. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pamidronate Disodium</VALIDVALUE>
          <VALUEMEANING>Pamidronate Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pamiparib</VALIDVALUE>
          <VALUEMEANING>Pamiparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pamrevlumab</VALIDVALUE>
          <VALUEMEANING>Pamrevlumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities. Pamrevlumab binds to CTGF thereby preventing the binding of the ligand to the receptor and subsequent receptor activation. As CTGF enhances the production of collagen and fibronectin, FG-319 may prevent and reverse fibrosis. In addition, FG-3019 may prevent tumor cell proliferation in CTGF-expressing tumor cells. CTGF, a member of the CCN family (CTGF, CYR61/CEF and NOV), is expressed in a variety of tumor cell types and is involved in processes such as cell proliferation, cell migration, cell adhesion, differentiation and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92577</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palifosfamide</VALIDVALUE>
          <VALUEMEANING>Palifosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lysine for stability, palifosfamide irreversibly alkylates and cross-links DNA through GC base pairs, resulting in irreparable 7-atom inter-strand cross-links; inhibition of DNA replication and cell death follow. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan FGFR Inhibitor PRN1371</VALIDVALUE>
          <VALUEMEANING>pan FGFR Inhibitor PRN1371</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514</VALIDVALUE>
          <VALUEMEANING>Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolotriazine-based compound and a pan inhibitor of receptor tyrosine kinases with potential antineoplastic activity. Pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690514 binds to human epidermal growth factor receptors (EGFR) 1, 2 and 4 (HER1, HER2 and HER4) and vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR-1, -2 and -3), all of which are frequently overexpressed by a variety of tumor types. Binding of this agent to these receptors may result in the inhibition of tumor cell proliferation; the inhibition of endothelial cell migration and proliferation and angiogenesis; and tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-AKT Inhibitor ARQ751</VALIDVALUE>
          <VALUEMEANING>Pan-AKT Inhibitor ARQ751</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, AKT inhibitor ARQ 751 selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-AKT Kinase Inhibitor GSK690693</VALIDVALUE>
          <VALUEMEANING>Pan-AKT Kinase Inhibitor GSK690693</VALUEMEANING>
          <MEANINGDESCRIPTION>An aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. Pan-AKT kinase inhibitor GSK-690693 binds to and inhibits Akt kinases 1, 2, and 3, which may result in the inhibition of protein phosphorylation events downstream from Akt kinases in the PI3K/Akt signaling pathway, and, subsequently, the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. In addition, this agent may inhibit other protein kinases including protein kinase C (PKC) and protein kinase A (PKA). As serine/threonine protein kinases which are involved in a number of biological processes, AKT kinases promote cell survival by inhibiting apoptosis and are required for glucose transport.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancratistatin</VALIDVALUE>
          <VALUEMEANING>Pancratistatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A isoquinoline alkaloid from amaryllis with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-FGFR Inhibitor LY2874455</VALIDVALUE>
          <VALUEMEANING>Pan-FGFR Inhibitor LY2874455</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-HER Kinase Inhibitor AC480</VALIDVALUE>
          <VALUEMEANING>pan-HER Kinase Inhibitor AC480</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3443990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Panitumumab</VALIDVALUE>
          <VALUEMEANING>Panitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-KRAS Inhibitor BI 1701963</VALIDVALUE>
          <VALUEMEANING>Pan-KRAS Inhibitor BI 1701963</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available protein-protein interaction (PPI) inhibitor that targets the guanine nucleotide exchange factor Son of sevenless homolog 1 (SOS1), with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BI 1701963 selectively targets and binds to SOS1, thereby preventing the interaction of SOS1 with Kirsten rat sarcoma viral oncogene homolog (KRAS) in the guanosine diphosphate (GDP)-bound &#39;off&#39; state, which is the inactivated state of KRAS. This abrogates the exchange of RAS-bound GDP for guanosine triphosphate (GTP) and prevents the formation of GTP-loaded KRAS, which is the activated &#39;on&#39; state of KRAS. This prevents activation of downstream RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway by GTP-loaded KRAS. This inhibits mutant KRAS-dependent signaling and may inhibit growth and survival of KRAS-expressing tumor cells. KRAS is a member of the RAS family of oncogenes that is mutated in many cancer cell types. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, survival, invasion, and metastasis. SOS1 regulates the KRAS GDP-GTP cycle and promotes nucleotide exchange and formation of &#39;active&#39; KRAS-GTP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-Mutant-IDH1 Inhibitor Bay-1436032</VALIDVALUE>
          <VALUEMEANING>Pan-Mutant-IDH1 Inhibitor Bay-1436032</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available pan-inhibitor of mutant forms of the metabolic enzyme isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including forms with mutations of arginine 132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, pan-mutant-IDH-1 inhibitor BAY-1436032 specifically inhibits the activity of IDH1 mutant forms, which prevents the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutant forms. IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Panobinostat Nanoparticle Formulation MTX110</VALIDVALUE>
          <VALUEMEANING>Panobinostat Nanoparticle Formulation MTX110</VALUEMEANING>
          <MEANINGDESCRIPTION>A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-PI3K Inhibitor CLR457</VALIDVALUE>
          <VALUEMEANING>pan-PI3K Inhibitor CLR457</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-PI3K/mTOR Inhibitor SF1126</VALIDVALUE>
          <VALUEMEANING>pan-PI3K/mTOR Inhibitor SF1126</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities. The targeting peptide SF1174 moiety of pan-PI3K/mTOR inhibitor SF1126 selectively binds to cell surface integrins and, upon cell entry, the agent is hydrolyzed to the active drug SF1101; SF1101 selectively inhibits all isoforms of phosphoinositide-3-kinase (PI3K) and other members of the PI3K superfamily, such as the mammalian target of rapamycin (mTOR) and DNA-PK. By inhibiting the PI3K signaling pathway, this agent may inhibit tumor cell and tumor endothelial cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-PIM Kinase Inhibitor AZD1208</VALIDVALUE>
          <VALUEMEANING>pan-PIM Kinase Inhibitor AZD1208</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, thereby causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs. The growth inhibition of several leukemia cell lines by this agent is correlated with the expression levels of PIM1, which is the substrate of STAT transcription factors. PIM kinases are downstream effectors of many cytokine and growth factor signaling pathways and are upregulated in various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Panobinostat</VALIDVALUE>
          <VALUEMEANING>Panobinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-PIM Kinase Inhibitor NVP-LGB-321</VALIDVALUE>
          <VALUEMEANING>pan-PIM Kinase Inhibitor NVP-LGB-321</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor NVP-LGB-321 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-RAF Inhibitor LY3009120</VALIDVALUE>
          <VALUEMEANING>Pan-RAF Inhibitor LY3009120</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-RAF Kinase Inhibitor CCT3833</VALIDVALUE>
          <VALUEMEANING>pan-RAF Kinase Inhibitor CCT3833</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the serine/threonine protein kinase family Raf, including A-Raf, B-Raf and C-Raf, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor CCT3833 inhibits Raf-mediated signal transduction pathways, which may inhibit the proliferation of Raf-overexpressing tumor cells. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-RAR Agonist/AP-1 Inhibitor LGD 1550</VALIDVALUE>
          <VALUEMEANING>Pan-RAR Agonist/AP-1 Inhibitor LGD 1550</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.  LGD 1550 selectively binds to all three retinoic acid receptors (RAR-alpha, RAR-beta, and RAR-gamma), resulting in alterations in the expression of genes responsible for cell differentiation and proliferation.  This agent also acts as an inhibitor of activator protein 1 (AP-1), a protein that mediates trophic responses and malignant transformation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-TRK Inhibitor ONO-7579</VALIDVALUE>
          <VALUEMEANING>Pan-TRK Inhibitor ONO-7579</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC).  This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes.The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Panulisib</VALIDVALUE>
          <VALUEMEANING>Panulisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981</VALIDVALUE>
          <VALUEMEANING>Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential antiangiogenic and antineoplastic activities. Pan-VEGFR/Tie2 tyrosine kinase inhibitor CEP-11981 selectively binds to VEGFR and Tie2 receptor tyrosine kinases, which may result in the inhibition of endothelial cell migration, proliferation and survival and the inhibition of tumor cell proliferation and tumor cell death. VEGFR and Tie2 are frequently overexpressed by a variety of tumor cell types and play crucial roles in the regulation of angiogenesis and the maintenance of tumor blood vessels. Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains) is activated by angiopoietin-1 (Ang-1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paricalcitol</VALIDVALUE>
          <VALUEMEANING>Paricalcitol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic noncalcemic, nonphosphatemic vitamin D analogue.  Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN (&#39;Phosphatase and Tensin homolog deleted on chromosome Ten&#39;), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP 1/2 Inhibitor NOV1401</VALIDVALUE>
          <VALUEMEANING>PARP 1/2 Inhibitor NOV1401</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, NOV1401 selectively binds to PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-TRK Inhibitor NOV1601</VALIDVALUE>
          <VALUEMEANING>Pan-TRK Inhibitor NOV1601</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, pan-TRK inhibitor NOV1601 specifically targets and binds to TRK, TRK mutations and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP Inhibitor AZD2461</VALIDVALUE>
          <VALUEMEANING>PARP Inhibitor AZD2461</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor AZD2461 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95201</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP Inhibitor CEP-9722</VALIDVALUE>
          <VALUEMEANING>PARP Inhibitor CEP-9722</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule prodrug of CEP-8983, a novel 4-methoxy-carbazole inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration and conversion from CEP-9722, CEP-8983 selectively binds to PARP 1 and 2, preventing repair of damaged DNA via base excision repair (BER). This agent enhances the accumulation of DNA strand breaks and promotes genomic instability and apoptosis. CEP-8983 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand breaks in DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP Inhibitor E7016</VALIDVALUE>
          <VALUEMEANING>PARP Inhibitor E7016</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemo- and/or radiosensitizing activity. PARP inhibitor E7016 selectively binds to PARP and prevents PARP mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. In addition, this agent may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP Inhibitor NMS-03305293</VALIDVALUE>
          <VALUEMEANING>PARP Inhibitor NMS-03305293</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, PARP inhibitor NMS-03305293 selectively binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parsaclisib</VALIDVALUE>
          <VALUEMEANING>Parsaclisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parsaclisib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Parsaclisib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of parsaclisib, an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parsatuzumab</VALIDVALUE>
          <VALUEMEANING>Parsatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parvovirus H-1</VALIDVALUE>
          <VALUEMEANING>Parvovirus H-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-competent oncolytic parvovirus with potential antineoplastic activity. Upon infection of host cells, parvovirus H-1 preferentially replicates in tumor cells compared to healthy normal cells, thereby potentially resulting in tumor cell lysis and leading to an inhibition of tumor cell proliferation. In addition, H1-infected tumor cells strongly induce the release of the inducible heat shock protein 72 (Hsp72i), which chaperone tumor associated antigens in the H1-mediated tumor lysates and may activate antigen presenting cells (APCs), thereby leading to antitumor immune responses. Parvovirus H-1 does not cause any pathogenic effect in normal, healthy cells and is able to cross the blood brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pasotuxizumab</VALIDVALUE>
          <VALUEMEANING>Pasotuxizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant T-cell engaging bispecific monoclonal antibody (BiTE) directed against human prostate specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex, with potential immunostimulating and antineoplastic activities.  Pasotuxizumab possesses two antigen-recognition sites, one for PSMA, and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings PSMA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) together, which may result in the CTL-mediated cell death of PSMA-expressing cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP-1/2 Inhibitor ABT-767</VALIDVALUE>
          <VALUEMEANING>PARP-1/2 Inhibitor ABT-767</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, ABT-767 selectively binds to PARP 1 and 2, thereby preventing repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of DNA strand breaks and promotes genomic instability eventually leading to apoptosis. ABT-767 may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patidegib</VALIDVALUE>
          <VALUEMEANING>Patidegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, patidegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patidegib Topical Gel</VALIDVALUE>
          <VALUEMEANING>Patidegib Topical Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical gel containing patidegib, a cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon topical application of the patidegib gel, patidegib binds to and inhibits the activity of the G-protein coupled receptor smoothened (SMO), thereby inhibiting Hh pathway signaling. This decreases proliferation and survival in tumor cells in which the Hh pathway is overactivated. Upregulated Hh signaling is associated with uncontrolled tumor cell proliferation. Topical application of patidegib allows for local anti-tumor activity while avoiding systemic exposure and unwanted systemic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patritumab</VALIDVALUE>
          <VALUEMEANING>Patritumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3 activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patritumab Deruxtecan</VALIDVALUE>
          <VALUEMEANING>Patritumab Deruxtecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patupilone</VALIDVALUE>
          <VALUEMEANING>Epothilone B</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, epothilone B induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Epothilone B may cause complete cell-cycle arrest. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1623</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3013195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paxalisib</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor GDC-0084</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6617877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pazopanib</VALIDVALUE>
          <VALUEMEANING>Pazopanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pazopanib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Pazopanib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pbi-shRNA STMN1 Lipoplex</VALIDVALUE>
          <VALUEMEANING>pbi-shRNA STMN1 Lipoplex</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary RNA interference construct consisting of bifunctional short hairpin RNAs (shRNA) against human stathmin 1 (STMN1) encapsulated in the cationic bilamellar invaginated vesicle lipoplex (LP) with potential antineoplastic activity. pbi-shRNA STMN1 LP contains 2 stem-loop structures encoded by a plasmid vector. Upon intratumoral administration, one shRNA unit with a perfectly matched sequence renders the suppression of STMN1 mRNA translation (mRNA sequestration and cleavage-independent degradation) while the other unit with an imperfectly matched sequence renders STMN1 mRNA degradation via RNase H-like cleavage (cleavage-dependent mRNA silencing). The suppression of STMN1 expression in tumor cells result in a reduction of tumor cell proliferation. STMN1, a ubiquitous cytosolic phosphoprotein and tubulin modulator that plays a key role in mitosis, is overexpressed in a variety of tumors and correlates with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P-cadherin Antagonist PF-03732010</VALIDVALUE>
          <VALUEMEANING>P-cadherin Antagonist PF-03732010</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that inhibits P-cadherin (cdh3), with potential antineoplastic activity. PF-03732010 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of solid tumors, and plays a role in cell adhesion, motility, invasion and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P-cadherin-targeting Agent PF-06671008</VALIDVALUE>
          <VALUEMEANING>P-cadherin-targeting Agent PF-06671008</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that targets p-cadherin (CDH3), with potential antineoplastic activity. Upon administration, PF-06671008 binds to and inhibits the activity of p-cadherin; this may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PCNU</VALIDVALUE>
          <VALUEMEANING>PCNU</VALUEMEANING>
          <MEANINGDESCRIPTION>A chloroethylnitrosourea compound and an alkylating agent with antineoplastic property. PCNU inhibits DNA synthesis by alkylating DNA and causing DNA cross links, thereby inducing apoptosis. In addition, this agent may be associated with pulmonary, hepatic, and hematologic toxicities. Unlike other nitrosoureas, PCNU has strong alkylating while weak carbamoylating activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1186</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-1 Directed Probody CX-188</VALIDVALUE>
          <VALUEMEANING>PD-1 Directed Probody CX-188</VALUEMEANING>
          <MEANINGDESCRIPTION>A probody composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a proprietary masking peptide that covers the active antigen binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of PD-1-directed probody CX-188, the masking peptide is cleaved by tumor-associated proteases within the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to PD-1, thereby disrupting PD-1 signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PDK1 Inhibitor AR-12</VALIDVALUE>
          <VALUEMEANING>PDK1 Inhibitor AR-12</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, celecoxib-derived inhibitor of phosphoinositide-dependent kinase-1 (PDK1) with potential antineoplastic activity. Devoid of any COX inhibiting activity, PDK1 inhibitor AR-12 binds to and inhibits the phosphorylation of 3-phosphoinositide-dependent kinase-1 (PDK-1).; subsequently, the phosphorylation and activation of the serine/threonine protein kinase Akt (protein kinase B or PKB) is inhibited, which may result in inhibition of the PI3K/Akt signaling pathway, inhibition of tumor cell proliferation, and the induction of tumor cell apoptosis.  In addition, this agent appears to induce the activity of protein kinase R-like endoplasmic reticulum kinase (PERK), which plays a key role in the endoplasmic reticulum stress pathway. Activation and dysregulation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P-cadherin Inhibitor PCA062</VALIDVALUE>
          <VALUEMEANING>P-cadherin Inhibitor PCA062</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent that inhibits p-cadherin, with potential antineoplastic activity. Upon intravenous infusion, PCA062 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-L1 Inhibitor GS-4224</VALIDVALUE>
          <VALUEMEANING>PD-L1 Inhibitor GS-4224</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, PD-L1 inhibitor GS-4224 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-L1 Inhibitor INCB086550</VALIDVALUE>
          <VALUEMEANING>PD-L1 Inhibitor INCB086550</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480</VALIDVALUE>
          <VALUEMEANING>PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, trispecific monovalent antibody-based molecule targeting the human programmed death-ligand 1 (PD-L1), 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and human serum albumin (HSA), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 consists of three monovalent antibody Fvs specific for PD-L1, HSA and 4-1BB fused in a single chain. Upon administration, PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 simultaneously targets and binds to a membrane-distal epitope of 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. The simultaneous binding to PD-L1 enables clustering of 4-1BB and thereby allows for conditional stimulation of 4-1BB signaling in the tumor microenvironment (TME) only upon binding to PD-L1 on tumor cells. 4-1BB activation results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, NM21-1480 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. HSA fusion prolongs the half-life of NM21-1480. The conditional activation of 4-1BB signaling prevents systemic T-cell activation and lowers toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-L1/PD-L2/VISTA Antagonist CA-170</VALIDVALUE>
          <VALUEMEANING>PD-L1/PD-L2/VISTA Antagonist CA-170</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0</VALIDVALUE>
          <VALUEMEANING>pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0</VALUEMEANING>
          <MEANINGDESCRIPTION>A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1</VALIDVALUE>
          <VALUEMEANING>PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent&#39;s potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegargiminase</VALIDVALUE>
          <VALUEMEANING>Pegargiminase</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent consisting of the arginine-degrading enzyme arginine deiminase combined with polyethylene glycol (20,000 MW) (ADI-PEG 20) with potential antineoplastic activity. Upon administration, pegargiminase breaks down the amino acid arginine into citrulline. Although arginine is a nonessential amino acid for normal human cells, certain cancer cells are autotrophic for arginine and need arginine in order to survive. Depletion of arginine may lead to an inhibition of cellular proliferation in those cancer cells. ADI is coupled to PEG in order to enhance this agent&#39;s half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegaspargase</VALIDVALUE>
          <VALUEMEANING>Pegaspargase</VALUEMEANING>
          <MEANINGDESCRIPTION>A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme&#39;s antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegdinetanib</VALIDVALUE>
          <VALUEMEANING>Pegdinetanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peginterferon Alfa-2a</VALIDVALUE>
          <VALUEMEANING>Peginterferon Alfa-2a</VALUEMEANING>
          <MEANINGDESCRIPTION>A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peginterferon Alfa-2b</VALIDVALUE>
          <VALUEMEANING>Peginterferon Alfa-2b</VALUEMEANING>
          <MEANINGDESCRIPTION>A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEG-interleukin-2</VALIDVALUE>
          <VALUEMEANING>PEG-interleukin-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1</VALIDVALUE>
          <VALUEMEANING>PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) encapsulated in a biodegradable, biocompatible lipoplex composed of polyethylene glycol (PEG), polyethylenimine (PEI), and cholesterol, with potential immunoactivating and antineoplastic activities. Upon intraperitoneal (IP) delivery of the PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, the lipoplex is endocytosed by nearby cells, and the plasmid DNA is transported into the nucleus, which leads to local expresssion of IL-12. In turn, the increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-cell responses against tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegvisomant</VALIDVALUE>
          <VALUEMEANING>Pegvisomant</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegilodecakin</VALIDVALUE>
          <VALUEMEANING>Pegilodecakin</VALUEMEANING>
          <MEANINGDESCRIPTION>A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory, immunomodulating and antineoplastic activities. Upon subcutaneous administration, pegilodecakin may activate cell-mediated immunity against cancer cells by stimulating the differentiation and expansion of tumor specific cytotoxic CD8+ T cells. This agent may also lower serum cholesterol levels and reduce atherosclerotic plaques by inhibiting the synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. The PEG moiety inhibits proteolytic breakdown and clearance of AM0010, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegvorhyaluronidase Alfa</VALIDVALUE>
          <VALUEMEANING>Pegvorhyaluronidase Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated formulation of a recombinant form of human hyaluronidase with potential antitumor activity. Upon intravenous administration, pegvorhyaluronidase alfa degrades hyaluronic acid (HA) coating tumor cells, which may result in the inhibition of tumor cell growth. In addition, the degradation of HA may result in a lowering of the interstitial fluid pressure (IFP), allowing better penetration of chemotherapeutic agents into the tumor bed. HA is a glycosaminoglycan found in the extracellular matrix (ECM) that is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increased tumor cell growth, metastatic potential, tumor progression, increased resistance to chemotherapeutic agents, and an elevation in tumor IFP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Deoxycytidine Analogue DFP-14927</VALIDVALUE>
          <VALUEMEANING>Pegylated Deoxycytidine Analogue DFP-14927</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated formulation containing DFP-10917, an analogue of the nucleoside deoxycytidine, with potential antineoplastic activity. Upon administration, the pegylated deoxycytidine analogue DFP-14927 is incorporated into the DNA of rapidly proliferating cells, such as tumor cells, and directly inhibits the activity of DNA polymerase, which results in the inhibition of DNA replication and cell cycle arrest, DNA fragmentation, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Interferon Alfa</VALIDVALUE>
          <VALUEMEANING>Pegylated Interferon Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Belotecan</VALIDVALUE>
          <VALUEMEANING>Pegylated Liposomal Belotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterically stabilized, pegylated liposomal formulation containing belotecan, a semi-synthetic analogue of campthotecin with potential antitumor activity. Belotecan inhibits the action of topoisomerase I, an enzyme that produces reversible single-strand breaks in DNA during DNA replication. This agent stabilizes the topoisomerase I and DNA complex, resulting in the inhibition of religation of DNA breaks, inhibition of DNA replication, and apoptotic cell death. The polyethylene glycol coating allows for greater plasma circulation time, thus enhancing the concentration of belotecan at the tumor site. Encapsulation of belotecan preserves the active lactone form, resulting in an increased cytotoxic effect of belotecan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Irinotecan</VALIDVALUE>
          <VALUEMEANING>Pegylated Liposomal Irinotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with antineoplastic activity. As a prodrug, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis. Pegylated liposomal delivery of irinotecan improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of exposure while lowering systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Mitomycin C Lipid-based Prodrug</VALIDVALUE>
          <VALUEMEANING>Pegylated Liposomal Mitomycin C Lipid-based Prodrug</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Mitoxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Pegylated Liposomal Mitoxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated liposomal mitoxantrone formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within pegylated small unilamellar vesicles (SUVs), with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in rapidly dividing cancer cells. The pegylated liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering toxic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</VALIDVALUE>
          <VALUEMEANING>Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor&#39;s vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel&#39;s efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116869</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Pegylated Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of polyethylene glycol (PEG) conjugated paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). Compared to paclitaxel alone, pegylated paclitaxel has an enhanced water solubility leading to an increase in bioavailability, and decreases its toxicity profile. Therefore, the pegylated formulation potentially supports delivery of higher doses of paclitaxel to the specific site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Liposomal Doxorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Doxorubicin Hydrochloride Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Recombinant Human Arginase I BCT-100</VALIDVALUE>
          <VALUEMEANING>Pegylated Recombinant Human Arginase I BCT-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human arginase I (liver arginase) covalently attached, via a succinamide propionic acid (SPA) linker, to a polyethylene glycol (PEG) of molecular weight 5,000 [rhArg-peg(5,000mw)] with potential antineoplastic activity. Upon intravenous administration of pegylated recombinant human arginase I BCT-100, arginase metabolizes the amino acid arginine to ornithine and urea, depleting intracellular arginine, which may inhibit proliferation of cells that are auxotrophic for arginine such as hepatocellular carcinoma (HCC) cells.  This agent may also work synergistically with various cytotoxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated SN-38 Conjugate PLX038</VALIDVALUE>
          <VALUEMEANING>Pegylated SN-38 Conjugate PLX038</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegzilarginase</VALIDVALUE>
          <VALUEMEANING>Pegzilarginase</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant modified form of the human enzyme arginase 1 (ARG1), in which cobalt is substituted for manganese as a cofactor, covalently attached to polyethylene glycol (PEG), with potential arginine degrading and antineoplastic activities. Upon intravenous administration of pegzilarginase, ARG1 metabolizes the amino acid arginine to ornithine and urea, thereby lowering blood arginine levels. This normalizes blood arginine levels in patients with ARG1 deficiency and prevents hyperargininemia. This also inhibits the proliferation of cancer cells that are dependent on extracellular arginine uptake for their proliferation. In normal, healthy cells, arginine is synthesized intracellularly by the enzymes ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL); thus they are not dependent on extracellular arginine for survival. In cancer cells these enzymes are disabled; therefore, this agent may inhibit proliferation and survival of these cells by depleting extracellular arginine. Pegylation improves blood circulation times and cobalt substitution increases the catalytic activity of ARG1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelareorep</VALIDVALUE>
          <VALUEMEANING>Reolysin</VALUEMEANING>
          <MEANINGDESCRIPTION>A serotype 3 Dearing strain (T3D) of reovirus (Respiratory Enteric Orphan VIRUS). Reovirus, a dsRNA virus, is able to replicate specifically in cancer cells bearing an activated Ras pathway. In contrast to normal cells, two-thirds of human cancer cells are Ras-activated, and are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR). In Ras-activated cancer cells, reovirus is able to freely replicate and subsequently cause apoptosis in the tumor cells. Cell lysis frees progeny viral particles to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until no more Ras-activated tumor cells are available. Because the reovirus kills Ras-activated cancer cells, this is a potential therapeutic for malignant glioma, pancreatic, colon and some lung cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3124280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peldesine</VALIDVALUE>
          <VALUEMEANING>Peldesine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrimidine analogue and purine nucleoside phosphorylase inhibitor with immunosuppressive and antineoplastic properties. Peldesine inhibits purine nucleoside phosphorylase (PNP) that plays a pivotal role in T-cell proliferation and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2&#39;-deoxyribonucleosides. Inhibition of PNP results in accumulation of dGTP and the subsequent failure of DNA synthesis. This agent maybe used in T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohn s disease and T-cell cancers</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelitinib</VALIDVALUE>
          <VALUEMEANING>Pelitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.  Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelitrexol</VALIDVALUE>
          <VALUEMEANING>Pelitrexol</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pemetrexed</VALIDVALUE>
          <VALUEMEANING>Pemetrexed</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2&#39;-deoxyuridine-5&#39;-monophosphate (dUMP) to 2&#39;-deoxythymidine-5&#39;-monophosphate (dTMP), an essential precursor in DNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelabresib</VALIDVALUE>
          <VALUEMEANING>Pelabresib</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrated form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pemetrexed Disodium</VALIDVALUE>
          <VALUEMEANING>Pemetrexed Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2&#39;-deoxyuridine-5&#39;-monophosphate (dUMP) to 2&#39;-deoxythymidine-5&#39;-monophosphate (dTMP), an essential precursor in DNA synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pemigatinib</VALIDVALUE>
          <VALUEMEANING>Pemigatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pemlimogene Merolisbac</VALIDVALUE>
          <VALUEMEANING>Pemlimogene Merolisbac</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding the tumor-associated antigens (TAAs) epidermal growth factor receptor mutant form EGFRvIII and human mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine Pemlimogene merolisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). EGFRvIII and mesothelin are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against EGFRvIII- and mesothelin-expressing tumor cells, eventually resulting in tumor cell lysis. EGFRvIII and mesothelin are overexpressed in many types of cancer. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penberol</VALIDVALUE>
          <VALUEMEANING>Penberol</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of bromoacrylic acid with cytostatic activity. Although the mechanism of action is unclear, penberol might inhibit tumor growth mediated through inhibition of the cell energetic metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penclomedine</VALIDVALUE>
          <VALUEMEANING>Penclomedine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penicillamine</VALIDVALUE>
          <VALUEMEANING>Penicillamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pentamethylmelamine</VALIDVALUE>
          <VALUEMEANING>Pentamethylmelamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A principal metabolite of hexamethylmelamine with antineoplastic activity.  Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pentamustine</VALIDVALUE>
          <VALUEMEANING>Pentamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A (2-chloroethy1)nitrosourea compound with antineoplastic activity. Petamustine was never marketed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pentostatin</VALIDVALUE>
          <VALUEMEANING>Pentostatin</VALUEMEANING>
          <MEANINGDESCRIPTION>The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEOX-based Polymer Encapsulated Paclitaxel FID-007</VALIDVALUE>
          <VALUEMEANING>PEOX-based Polymer Encapsulated Paclitaxel FID-007</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel&#39;s solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEP-3-KLH Conjugate Vaccine</VALIDVALUE>
          <VALUEMEANING>PEP-3-KLH Conjugate Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74070</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pepinemab</VALIDVALUE>
          <VALUEMEANING>Pepinemab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100) with potential immunomodulating and antineoplastic activities. Upon administration, pepinemab binds to and neutralizes SEMA4D, thereby preventing binding of SEMA4D to its receptor plexin-B1 (PLXNB1). By blocking the interaction of SEMA4D and PLXNB1, pepinemab may cause an inhibition of endothelial cell activation and migration, eventually leading to an inhibition of angiogenesis and tumor cell proliferation. Semaphorin 4D, a large cell surface antigen found on the resting T-cell and overexpressed in a variety of tumor cell types, plays an important role in vascular growth, tumor progression, invasion and immune cell regulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peplomycin</VALIDVALUE>
          <VALUEMEANING>Peplomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peplomycin Sulfate</VALIDVALUE>
          <VALUEMEANING>Peplomycin Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt of the bleomycin analogue peplomycin.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pentoxifylline</VALIDVALUE>
          <VALUEMEANING>Pentoxifylline</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peposertib</VALIDVALUE>
          <VALUEMEANING>Peposertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with potential antineoplastic activity, and potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, peposertib binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peptichemio</VALIDVALUE>
          <VALUEMEANING>Peptichemio</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of six synthetic oligopeptides in which the peptides are conjugated to metamelphalan, with alkylating and potential antineoplastic activity. Peptichemio causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peptide 946 Melanoma Vaccine</VALIDVALUE>
          <VALUEMEANING>Peptide 946 Melanoma Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A melanoma peptide vaccine with potential antineoplastic activity. Peptide 946 melanoma vaccine contains one of the peptide sequences for a melanoma-specific epitope that is recognized by melanoma-specific cytotoxic T lymphocytes (CTL). This vaccine contains a peptide sequence homologous to the native epitope and is often formulated with an adjuvant such as QS-21 or Montanide ISA-51 to boost its immune stimulation. Vaccination with peptide 946 vaccine may produce antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against cells expressing this antigen, resulting in decreased tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine</VALIDVALUE>
          <VALUEMEANING>Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A melanoma peptide vaccine complexed with tetanus toxoid with potential antineoplastic activity. Peptide 946 contains a melanoma-specific epitope recognized by melanoma-specific cytotoxic T lymphocytes (CTL). In addition to the peptide 946 sequence, this vaccine contains tetanus toxin, a protein known to stimulate the induction of CD4+ T lymphocytes; it thereby enhances antigen processing and presentation. Vaccination with the peptide 946-tetanus conjugate melanoma vaccine may produce antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response in tumor cells expressing the 946 epitope, thereby decreasing tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peretinoin</VALIDVALUE>
          <VALUEMEANING>Peretinoin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perflenapent Emulsion</VALIDVALUE>
          <VALUEMEANING>Perflenapent Emulsion</VALUEMEANING>
          <MEANINGDESCRIPTION>An oil-in-water nano-emulsion composed of the perfluorocarbon perflenapent, that has oxygen-carrying capacity, can be used as a contrast agent and has potential antihypoxic and radiosensitizing activities. Upon intravenous administration of the perflenapent emulsion, this agent increases the oxygen-carrying capacity of blood, enhances the transport of oxygen to hypoxic and ischemic tissues and increases the oxygen concentration in these tissues. Hypoxic tumors are correlated with increased resistance to radiation treatment; therefore, since perflenapent may increase tumor oxygenation, it may improve the tumor&#39;s sensitivity to radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perfosfamide</VALIDVALUE>
          <VALUEMEANING>Perfosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2748757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perifosine</VALIDVALUE>
          <VALUEMEANING>Perifosine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perillyl Alcohol</VALIDVALUE>
          <VALUEMEANING>Perillyl Alcohol</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring monoterpene related to limonene with antineoplastic activity. Perillyl alcohol inhibits farnesyl transferase and geranylgeranyl transferase, thereby preventing post-translational protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC</VALIDVALUE>
          <VALUEMEANING>Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based, personalized cancer therapeutic vaccine consisting of up to 8 patient-specific tumor peptides, which are immunogenic and unique to the patient&#39;s tumor and identified through DNA and RNA sequencing of a patient&#39;s tumor cells, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon administration, personalized and adjusted neoantigen peptide vaccine PANDA-VAC stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. The vaccine may be adjusted after initial therapy according to sequencing data.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Neoantigen DNA Vaccine GNOS-PV01</VALIDVALUE>
          <VALUEMEANING>Personalized Neoantigen DNA Vaccine GNOS-PV01</VALUEMEANING>
          <MEANINGDESCRIPTION>A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient&#39;s tumor, with potential immunomodulating and antineoplastic activities. Upon administration of GNOS-PV01, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Neoantigen DNA Vaccine GNOS-PVO2</VALIDVALUE>
          <VALUEMEANING>Personalized Neoantigen DNA Vaccine GNOS-PVO2</VALUEMEANING>
          <MEANINGDESCRIPTION>A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient&#39;s tumor, with potential immunomodulating and antineoplastic activities. Upon intradermal delivery by electroporation of GNOS-PVO2, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01</VALIDVALUE>
          <VALUEMEANING>Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide-based, personalized cancer vaccine consisting of patient-specific mutated long peptides, which are immunogenic and unique to the patient&#39;s tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized neoantigen peptide vaccine iNeo-Vac-P01, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Neoepitope Yeast Vaccine YE-NEO-001</VALIDVALUE>
          <VALUEMEANING>Personalized Neoepitope Yeast Vaccine YE-NEO-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a heat-killed yeast that has been genetically modified to express patient-specific neoantigen epitopes. Upon vaccination, neoepitope yeast vaccine YE-NEO-001 may elicit a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response against tumor cells expressing these specific epitopes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized ALL-specific Multi-HLA-binding Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>Personalized ALL-specific Multi-HLA-binding Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Peptide Cancer Vaccine NEO-PV-01</VALIDVALUE>
          <VALUEMEANING>Personalized Peptide Cancer Vaccine NEO-PV-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient&#39;s tumor, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pertuzumab</VALIDVALUE>
          <VALUEMEANING>Pertuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pevonedistat</VALIDVALUE>
          <VALUEMEANING>Pevonedistat</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pexastimogene Devacirepvec</VALIDVALUE>
          <VALUEMEANING>Pexastimogene Devacirepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pexmetinib</VALIDVALUE>
          <VALUEMEANING>Pexmetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic activities. Pexmetinib binds to and inhibits the activities of p38 and Tie2 kinases, which may inhibit the production of proinflammatory cytokines and may decrease tumor angiogenesis and tumor cell growth and survival. p38 is a MAP kinase that is often upregulated in cancer cells, playing a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6. Tie2 is an endothelial cell specific receptor that is activated by angiopoietins, growth factors required for angiogenesis. This agent has also been reported to inhibit other kinases including vascular endothelial growth factor receptor (VEGFR2) and Src tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PGLA/PEG Copolymer-Based Paclitaxel</VALIDVALUE>
          <VALUEMEANING>PGLA/PEG Copolymer-Based Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A controlled-release, intratumoral paclitaxel formulation in which paclitaxel is incorporated into a thermosensitive, biodegradable triblock copolymer consisting of poly(lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG). Upon intratumoral injection, paclitaxel is released slowly and continuously into tumor tissues from the gelled thermosensitive triblock copolymer over a period of 4 to 6 weeks; in tumor cells, paclitaxel binds to tubulin and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. The thermosensitive triblock copolymer component of this formulation transforms from a water-soluble polymer at room temperature to a water-insoluble, biodegradable gel depot at body temperature; intratumoral controlled-release of paclitaxel from the gel minimizes systemic exposure to paclitaxel and the paclitaxel toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PH20 Hyaluronidase-expressing Adenovirus VCN-01</VALIDVALUE>
          <VALUEMEANING>PH20 Hyaluronidase-expressing Adenovirus VCN-01</VALUEMEANING>
          <MEANINGDESCRIPTION>An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, PH20 hyaluronidase-expressing adenovirus VCN-01 selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor&#39;s interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phaleria macrocarpa Extract DLBS-1425</VALIDVALUE>
          <VALUEMEANING>Phaleria macrocarpa Extract DLBS-1425</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract of the flesh from the fruit of Phaleria macrocarpa, an Indonesian herbal medicine, with potential antineoplastic activity. Although the active ingredients and exact components are unclear, gallic acid and its derivatives in DLBS-1425 appear to inhibit the phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) signaling pathway by reducing PI3K transcription followed by a reduction in AKT phosphorylation. This extract also appears to induce apoptosis through induction of pro-apoptotic genes such as BAX, BAD and PUMA and inhibition of the apoptosis suppressor Bcl-2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharmacological Ascorbate</VALIDVALUE>
          <VALUEMEANING>Pharmacological Ascorbate</VALUEMEANING>
          <MEANINGDESCRIPTION>A high dose (HD) of ascorbic acid, a pro-oxidant agent, with potential antineoplastic and radio-chemo-sensitizing activities. Upon intravenous (IV) administration, pharmacological ascorbate is able to generate reactive oxygen species (ROS) by donating an electron to oxygen (O2) and forming hydrogen peroxide (H2O2), thereby causing oxidative stress and overwhelming the cell&#39;s anti-oxidant defense mechanisms. This induces DNA double-stranded breaks (DSBs) and cell death. Tumor cells are highly susceptible to ascorbate-mediated oxidative stress and cytotoxicity while normal, healthy cells are mostly unaffected. This induces the cell death of susceptible tumor cells and decreases tumor cell growth. Higher plasma ascorbate concentrations are achieved upon higher intravenous doses of ascorbate; oral administration of ascorbate is limited and uptake does not increase after a certain amount is administered. Only IV ascorbate produces plasma concentrations high enough to induce ascorbate-mediated cytotoxicity to susceptible tumor cells. In addition, HD parenteral ascorbate enhances radio- and chemo-sensitivity of susceptible cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pexidartinib</VALIDVALUE>
          <VALUEMEANING>Multitargeted Tyrosine Kinase Inhibitor PLX3397</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor PLX3397 binds to and inhibits phosphorylation of stem cell factor receptor (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), which may result in the inhibition of tumor cell proliferation and down-modulation of macrophages, osteoclasts and mast cells involved in the osteolytic metastatic disease. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5260856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phellodendron amurense Bark Extract</VALIDVALUE>
          <VALUEMEANING>Phellodendron amurense Bark Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary formulation consisting of a Phellodendron amurense (Amur cork tree) bark extract, often used in traditional Chinese medicine, with anti-inflammatory, anti-oxidant and potential chemopreventive and antineoplastic activities. Phellodendron amurense bark extract contains certain isoquinoline alkaloids, flavone glycosides and phenolic compounds. Upon administration of Phellodendron amurense bark extract, the various phytochemicals in this formulation modulate multiple signal transduction pathways. This agent appears to block the activation of the transcription factor cAMP response binding protein (CREB) and inhibits Akt signaling, thereby inhibiting tumor cell growth and inducing apoptosis in Akt- and CREB-overexpressing cancer cells. In addition, this agent inhibits cyclooxygenase type 2 (COX-2), nuclear factor kappa b (NF-kB) and tumor necrosis factor alpha (TNF-a)-mediated signaling; COX-2, NF-kB and TNF-a are upregulated in certain types of cancer and during inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phenesterin</VALIDVALUE>
          <VALUEMEANING>Phenesterin</VALUEMEANING>
          <MEANINGDESCRIPTION>A steroidal nitrogen mustard with antineoplastic and mutagenic activities. After attachment to cell-surface steroid receptors and uptake, phenesterin enters the nucleus where it alkylates macromolecules, resulting in decreased cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phenethyl Isothiocyanate</VALIDVALUE>
          <VALUEMEANING>Phenethyl Isothiocyanate</VALUEMEANING>
          <MEANINGDESCRIPTION>An isothiocyanate found in cruciferous vegetables with chemopreventive and potential antitumor activities. Although the mechanism of action is unclear, phenethyl Isothiocyanate (PEITC) was shown to induce apoptosis in tumor cells, possibly mediated through its metabolic intermediates, reactive oxygen species (ROS). PEITC also is able to activate ERK and JNK signal transduction, which in turn induces expression of stress-responsive genes. Specifically, this agent has been shown to reactivate gene expression of a detoxification enzyme, glutathione S-transferase that is silenced in prostate carcinoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phenethyl Isothiocyanate-containing Watercress Juice</VALIDVALUE>
          <VALUEMEANING>Phenethyl Isothiocyanate-containing Watercress Juice</VALUEMEANING>
          <MEANINGDESCRIPTION>A juice extracted from watercress containing high amounts of phenethyl isothiocyanate (PEITC), with potential chemopreventive and antitumor activities. Although the mechanism(s) of action through which PEITC exerts its effect(s) has yet to be fully elucidated, PEITC is able to induce apoptosis in tumor cells through the induction of reactive oxygen species (ROS). Additionally, PEITC is able to modulate extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signal transduction pathways, activating the expression of stress-responsive genes and eventually inducing apoptosis. PEITC also inhibits the expression of genes involved in tumor progression such as HIF, STAT-3, HER2, BCL-XL, and XIAP and induces the expression of genes involved in tumor suppression such as p53, ATF-2, and p57. Furthermore, this agent has been shown to reactivate the gene expression of certain detoxification enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phosphatidylcholine-Bound Silybin</VALIDVALUE>
          <VALUEMEANING>Phosphatidylcholine-Bound Silybin</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral preparation of the flavonoid silybin with potential antioxidant and chemopreventive activities. Silybin, also known as silibinin, is a mixture of two stereoisomers, denoted silybin A and silybin B, and is the major active constituent of silymarin, a mixture of flavonolignans extracted from blessed milk thistle (Silybum marianum). Silybin modulates P-glycoprotein (P-gp)-mediated cellular efflux; has oxygen radical-scavenging effects; inhibits the arachidonic acid pathway; and inhibits various cytochrome P450 enzymes. This agent may also exhibit anti-angiogenic activity, possibly by inducing endothelial cell apoptosis via modulation of the transcription factor NF-kB, the Bcl-2 family of proteins, and caspases. Complexing silybin with phosphatidylcholine increases its bioavailability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phosphoramide Mustard</VALIDVALUE>
          <VALUEMEANING>Phosphoramide Mustard</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a number of chemically-related alkylating agents with antineoplastic properties.  The prototype of this group of agents is cyclophosphamide.  Most phosphoramide mustards are administered as prodrugs that undergo reductive activation in hypoxic environments to yield cytotoxic metabolites. These agents alkylate and crosslink DNA, resulting in inhibition of DNA replication. Phosphoramide mustards are also immunosuppressants, mutagens and teratogens. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phosphorodiamidate Morpholino Oligomer AVI-4126</VALIDVALUE>
          <VALUEMEANING>Phosphorodiamidate Morpholino Oligomer AVI-4126</VALUEMEANING>
          <MEANINGDESCRIPTION>A c-Myc antisense phosphorodiamidate morpholino oligomer (PMO) with potential antineoplastic activity. Phosphorodiamidate morpholino oligomer AVI-4126 binds to c-Myc mRNA and blocks its translation, which may result in the death of tumor cells overexpressing c-Myc. Differing from traditional antisense oligodeoxynucleotides (ODNs), neutrally charged PMOs are composed of subunits of nucleic acid bases linked to a synthetic backbone and, so, are less prone to enzymatic degradation. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phosphorus P-32</VALIDVALUE>
          <VALUEMEANING>Phosphorus P-32</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Photodynamic Compound TLD-1433</VALIDVALUE>
          <VALUEMEANING>Photodynamic Compound TLD-1433</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-toxic ruthenium-based coordination-complex and photosensitizer, with potential antineoplastic activity upon photodynamic therapy (PDT). Upon intravesical administration, light-activated photodynamic compound (PDC) TLD-1433 targets and binds to transferrin (Tf) and is subsequently taken up by Tf receptors which are located on tumor cells. Upon exposure to green light (525nm), TLD-1433 becomes activated locally and induces the generation of reactive oxygen species (ROS) and singlet oxygen. The release of free radicals may induce apoptosis and destroy the tumor cells. Cancer cells have many more Tf receptors than normal cells,</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172822</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phenyl Acetate</VALIDVALUE>
          <VALUEMEANING>Phenylacetate</VALUEMEANING>
          <MEANINGDESCRIPTION>An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phytochlorin Sodium-Polyvinylpyrrolidone Complex</VALIDVALUE>
          <VALUEMEANING>Phytochlorin Sodium-Polyvinylpyrrolidone Complex</VALUEMEANING>
          <MEANINGDESCRIPTION>A photosensitizer composed of the sodium salt form of chlorin e6 and its derivatives complexed with a low-molecular weight polyvinylpyrrolidone (PVP) polymer component, with diagnostic and antineoplastic activities upon photodynamic therapy (PDT). Upon intravenous administration, the photosensitizer phytochlorin-PVP sodium complex preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of light with a certain wavelength to the tumor site results in the absorption of light by this agent leading to its photoactivation. This results in a photodynamic reaction between phytochlorin and oxygen, which causes the production of reactive oxygen species (ROS), including singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated oxidative DNA damage followed by apoptosis of tumor cells. Chlorin e6-PVP is able to penetrate deeply into tissues and is therefore able to treat hard-to-reach tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Alpha/Beta Inhibitor BAY1082439</VALIDVALUE>
          <VALUEMEANING>PI3K Alpha/Beta Inhibitor BAY1082439</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA, and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically targeting class I PI3K alpha and beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in increased tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate</VALIDVALUE>
          <VALUEMEANING>PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of PWT33597, an orally bioavailable dual inhibitor of phosphatidylinositide 3-kinase (PI3K) alpha and mammalian target of rapamycin (mTOR) kinase with potential antineoplastic activity. PI3K alpha/mTOR dual inhibitor PWT33597 selectively inhibits both PI3K alpha kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor GSK1059615</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor GSK1059615</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GSK1059615 inhibits PI3K in the PI3K/AKT kinase signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane and an increase in mitochondrial membrane permeability, followed by apoptosis. Bax is a member of the proapoptotic Bcl-2 family of proteins. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor WX-037</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor WX-037</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor ZSTK474</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor ZSTK474</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor ZSTK474 inhibits all four PI3K isoforms. Inhibiting the activation of the PI3K/AKT kinase (or protein kinase B) signaling pathway results in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. This agent does not induce apoptosis but rather induces strong G(0)/G(1) arrest, which might contribute to its favorable efficacy in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K p110beta/delta Inhibitor KA2237</VALIDVALUE>
          <VALUEMEANING>PI3K p110beta/delta Inhibitor KA2237</VALUEMEANING>
          <MEANINGDESCRIPTION>A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor KA2237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/BET Inhibitor LY294002</VALIDVALUE>
          <VALUEMEANING>PI3K/BET Inhibitor LY294002</VALUEMEANING>
          <MEANINGDESCRIPTION>A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6161756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTOR Kinase Inhibitor DS-7423</VALIDVALUE>
          <VALUEMEANING>PI3K/mTOR Kinase Inhibitor DS-7423</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor DS-7423 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor BGT226</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor BGT226</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BGT226 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTOR Kinase Inhibitor PF-04691502</VALIDVALUE>
          <VALUEMEANING>PI3K/mTOR Kinase Inhibitor PF-04691502</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor PF-04691502 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTOR Kinase Inhibitor VS-5584</VALIDVALUE>
          <VALUEMEANING>PI3K/mTOR Kinase Inhibitor VS-5584</VALUEMEANING>
          <MEANINGDESCRIPTION>A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTOR Kinase Inhibitor WXFL10030390</VALIDVALUE>
          <VALUEMEANING>PI3K/mTOR Kinase Inhibitor WXFL10030390</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon oral administration, PI3K/mTOR inhibitor WXFL10030390 (WX390) inhibits mTOR kinase and certain PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159499</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901</VALIDVALUE>
          <VALUEMEANING>PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity. Upon intravenous infusion, PI3K/mTORC1/mTORC2 inhibitor DCBCI0901 binds to and inhibits PI3K as well as both mTORC1 and mTORC2, which may result in both apoptosis and a decrease in cell proliferation in tumor cells overexpressing PI3K, mTORC1, and mTORC2. Activation of the PI3K/mTOR signaling pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3Kalpha Inhibitor AZD8835</VALIDVALUE>
          <VALUEMEANING>PI3Kalpha Inhibitor AZD8835</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118624</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3Kbeta Inhibitor AZD8186</VALIDVALUE>
          <VALUEMEANING>PI3Kbeta Inhibitor AZD8186</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-beta Inhibitor GSK2636771</VALIDVALUE>
          <VALUEMEANING>PI3K-beta Inhibitor GSK2636771</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-beta Inhibitor SAR260301</VALIDVALUE>
          <VALUEMEANING>PI3K-beta Inhibitor SAR260301</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor SAR260301 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in apoptosis and growth inhibition in PI3K beta-expressing and/or phosphatase and tensin homolog (PTEN)-deficient tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and contributes to increased tumor cell growth, tumor cell survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan-PI3K inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-delta Inhibitor AMG 319</VALIDVALUE>
          <VALUEMEANING>PI3K-delta Inhibitor AMG 319</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly selective, potent, and orally bioavailable small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.  PI3K-delta inhibitor AMG 319 prevents the activation of the PI3K signaling pathway through inhibition of the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), thus decreasing proliferation and inducing cell death.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3Ka/mTOR Inhibitor PKI-179</VALIDVALUE>
          <VALUEMEANING>PI3Ka/mTOR Inhibitor PKI-179</VALUEMEANING>
          <MEANINGDESCRIPTION>A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3Kdelta Inhibitor GS-9901</VALIDVALUE>
          <VALUEMEANING>PI3Kdelta Inhibitor GS-9901</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3Kdelta) with potential immunomodulating and antineoplastic activities. Upon oral administration, PI3Kdelta inhibitor GS-9901 selectively binds to the delta isoform of PI3K and inhibits its activity. This inhibits the activation of the PI3Kdelta-mediated signaling pathway and prevents proliferation of PI3Kdelta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is expressed primarily in certain tumor cell types and plays a key role in tumor cell proliferation, motility and survival. The targeted inhibition of PI3Kdelta is designed to preserve PI3K signaling in normal, non-neoplastic cells and thus reduces toxicity to normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-delta Inhibitor SHC014748M</VALIDVALUE>
          <VALUEMEANING>PI3K-delta Inhibitor SHC014748M</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K delta inhibitor SHC014748M selectively binds to and inhibits PI3K delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K delta over-expressing tumor cells. PI3K delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pibenzimol</VALIDVALUE>
          <VALUEMEANING>Pibenzimol</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorescent dye of benzimidazole derivative.  Pibenzimol binds to AT-specific sites in the minor groove of duplex DNA and inhibits topoisomerase I, and DNA polymerase, thereby preventing DNA replication. This agent prolongs the G2 phase of the cell cycle and initiates apoptosis in tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pibrozelesin Hydrobromide</VALIDVALUE>
          <VALUEMEANING>Pibrozelesin Hydrobromide</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrobromide salt form of pibrozelesin, a semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2, with antineoplastic activity. Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Picibanil</VALIDVALUE>
          <VALUEMEANING>Picibanil</VALUEMEANING>
          <MEANINGDESCRIPTION>A lyophilized formulation containing cultures of a low-virulent strain of Streptococcus pyogenes, treated and killed with penicillin G, with potential sclerosing, immunostimulating and antineoplastic activity. Besides from picibanil&#39;s direct damaging effect as a sclerosing agent, it seems to have multiple effects on the immune system as a non-specific immunostimulant.  Picibanil activates the host immune system by stimulating the activity of natural killer cells, macrophages and lymphocytes, and by enhancing the production of several key immune mediators, including interleukins and tumor necrosis factor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Picoplatin</VALIDVALUE>
          <VALUEMEANING>Picoplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Picrasinoside H</VALIDVALUE>
          <VALUEMEANING>Picrasinoside H</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid glycoside phytochemical isolated from the plant Picrasma ailanthoides with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Picropodophyllin</VALIDVALUE>
          <VALUEMEANING>Picropodophyllin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT). This agent shows potent activity in the suppression o f tumor cell proliferation and the induction of tumor cell apoptosis. IGF1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a critical role in the growth and survival of many types of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pictilisib</VALIDVALUE>
          <VALUEMEANING>Pictilisib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pibrozelesin</VALIDVALUE>
          <VALUEMEANING>Pibrozelesin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2.  Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pictilisib Bismesylate</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor GDC-0941 Bismesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway; inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations may result. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pidilizumab</VALIDVALUE>
          <VALUEMEANING>Pidilizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71014</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pilaralisib</VALIDVALUE>
          <VALUEMEANING>Pilaralisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PIM Kinase Inhibitor LGH447</VALIDVALUE>
          <VALUEMEANING>PIM Kinase Inhibitor LGH447</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor LGH447 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of the pro-apoptotic Bcl2 protein and tumor cell apoptosis in cells that overexpress PIMs. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PIM Kinase Inhibitor TP-3654</VALIDVALUE>
          <VALUEMEANING>PIM Kinase Inhibitor TP-3654</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, PIM kinase inhibitor TP-3654 selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PIM/FLT3 Kinase Inhibitor SEL24</VALIDVALUE>
          <VALUEMEANING>PIM/FLT3 Kinase Inhibitor SEL24</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. PIM/FLT3 kinase inhibitor SEL24 binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pimasertib</VALIDVALUE>
          <VALUEMEANING>Pimasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pimitespib</VALIDVALUE>
          <VALUEMEANING>Pimitespib</VALUEMEANING>
          <MEANINGDESCRIPTION>A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of &quot;client&quot; proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pimurutamab</VALIDVALUE>
          <VALUEMEANING>Pimurutamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PIM Kinase Inhibitor SGI-1776</VALIDVALUE>
          <VALUEMEANING>PIM Kinase Inhibitor SGI-1776</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor SGI-1776 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of pro-apoptotic Bcl2 proteins and tumor cell apoptosis. PIM kinases play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pinatuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Pinatuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of MCDT2219A, a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of pinatuzumab vedotin binds to B cell-specific CD22 receptors and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pingyangmycin</VALIDVALUE>
          <VALUEMEANING>Pingyangmycin</VALUEMEANING>
          <MEANINGDESCRIPTION>The naturally-occurring bleomycin antineoplastic antibiotic isolated from the bacterium Streptomyces pingyangensisn.  Pingyangmycin induces tumor cell apoptosis, possibly via a mechanism mediated by the mitogen-activated protein kinase (MAPK) pathway. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pinometostat</VALIDVALUE>
          <VALUEMEANING>Pinometostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103179</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pioglitazone</VALIDVALUE>
          <VALUEMEANING>Pioglitazone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3153632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pipendoxifene</VALIDVALUE>
          <VALUEMEANING>Pipendoxifene</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal 2-phenyl indole and a selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Pipendoxifene antagonizes binding of estradiol to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated gene expression, interfering with estrogen activity and inhibiting estrogen-stimulated growth in estrogen-dependent breast cancer. In addition, this agent also exerts intrinsic estrogenic activity depending on the tissue types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piperazinedione</VALIDVALUE>
          <VALUEMEANING>Piperazinedione</VALUEMEANING>
          <MEANINGDESCRIPTION>A crystalline antibiotic fermentation product isolated from the bacterium Streptomyces griseoluteus with antineoplastic activity. Piperazinedione alkylates DNA at the N-7 position of guanine, inhibiting DNA replication and inducing cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piperine Extract (Standardized)</VALIDVALUE>
          <VALUEMEANING>Piperine Extract (Standardized)</VALUEMEANING>
          <MEANINGDESCRIPTION>A standardized extract containing the active alkaloid piperine, derived from the fruit of the plant Piper nigrum (black pepper) and/or the plant Piper longum L. (long pepper), with thermogenic properties. Co-ingestion of piperidine enhances the bioavailability of various nutrients, including beta-carotene, curcumin, selenium, pyridoxine and coenzyme Q10. In addition, this agent may exert anti-inflammatory and anti-tumor activities and may enhance the production of serotonin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pipobroman</VALIDVALUE>
          <VALUEMEANING>Pipobroman</VALUEMEANING>
          <MEANINGDESCRIPTION>A piperazine derivative with potential antineoplastic alkyating activity. Although the exact mechanism of action of pipobroman has yet to be fully elucidated, this agent appears to act by alkylating DNA, leading to disruption of DNA replication and eventually cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piposulfan</VALIDVALUE>
          <VALUEMEANING>Piposulfan</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkyl sulfonate with potential antineoplastic activity.  Piposulfan alkylates DNA, thereby producing DNA interstrand crosslinks and DNA strand breaks and inhibiting DNA replication.  This agent has been shown to exhibit antitumor activity in an animal model of prostate cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pioglitazone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Pioglitazone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pirarubicin</VALIDVALUE>
          <VALUEMEANING>Pirarubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6029473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pirarubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Pirarubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of pirarubicin, an analogue of the anthracycline antineoplastic antibiotic doxorubicin with antineoplastic activity. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pirfenidone</VALIDVALUE>
          <VALUEMEANING>Pirfenidone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piritrexim</VALIDVALUE>
          <VALUEMEANING>Piritrexim</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piritrexim Isethionate</VALIDVALUE>
          <VALUEMEANING>Piritrexim Isethionate</VALUEMEANING>
          <MEANINGDESCRIPTION>The isethionate salt of piritrexim, a synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piroxantrone</VALIDVALUE>
          <VALUEMEANING>Piroxantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthrapyrazole antineoplastic antibiotic.  Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Piroxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Piroxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of piroxantrone, an anthrapyrazole antineoplastic antibiotic. Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pixantrone</VALIDVALUE>
          <VALUEMEANING>Pixantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pixantrone Dimaleate</VALIDVALUE>
          <VALUEMEANING>Pixantrone Dimaleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pirotinib</VALIDVALUE>
          <VALUEMEANING>Pirotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pixatimod</VALIDVALUE>
          <VALUEMEANING>Pixatimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic sugar modified heparan sulfate mimetic and agonist of toll-like receptor 9 (TLR9), with potential immunostimulating, antineoplastic and anti-viral activities. Upon administration, pixatimod binds to and activates TLR9 expressed by dendritic cells (DCs) and B-cells. This initiates cytokine release from DCs and activates innate immune signaling pathways, and leads to the activation of natural killer (NK) cells to destroy tumor cells. The combination of pixatimod with certain checkpoint inhibitors may enhance the activation of cytotoxic T-lymphocytes to further kill tumor cells. In addition, pixatimod inhibits the cleavage of heparan sulfate from cell surface proteoglycan by heparanase (HPSE) and inhibits the infiltration of tumor-associated macrophages (TAMs). TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231</VALIDVALUE>
          <VALUEMEANING>PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixed backbone oligonucleotide exhibiting antitumor activity.  GEM-231 is complementary to the RI alpha subunit of Protein Kinase A (PKA), resulting in downregulation of PKA expression and ultimately tumor growth. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PKC-beta Inhibitor MS-553</VALIDVALUE>
          <VALUEMEANING>PKC-beta Inhibitor MS-553</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the beta-isoform of protein kinase C (PKC), with potential immunosuppressive and antineoplastic activities. Upon oral administration, PKC-beta inhibitor MS-553 selectively binds to and inhibits PKC-beta, which prevents the activation of PKC-beta-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC-beta, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plamotamab</VALIDVALUE>
          <VALUEMEANING>Plamotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, plamotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plasmid DNA Vaccine pING-hHER3FL</VALIDVALUE>
          <VALUEMEANING>Plasmid DNA Vaccine pING-hHER3FL</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA cancer vaccine encoding the tumor-associated antigen (TAA) human epidermal growth factor receptor type-3 (HER-3; HER3), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the plasmid DNA vaccine pING-hHER3FL and after cellular uptake by muscle cells, the plasmid DNA expresses HER-3 which, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-3. HER-3 plays a key role in tumor cell proliferation and its overexpression is associated with poor prognosis. HER-3 is associated with tumor cell resistance to anti-HER-2 therapeutics.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</VALIDVALUE>
          <VALUEMEANING>Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plevitrexed</VALIDVALUE>
          <VALUEMEANING>Plevitrexed</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plicamycin</VALIDVALUE>
          <VALUEMEANING>Plicamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plinabulin</VALIDVALUE>
          <VALUEMEANING>Plinabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively targets and binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics. This disrupts mitotic spindle assembly leading to cell cycle arrest at M phase and blockage of cell division. In addition, plinabulin may also inhibit growth of proliferating vascular endothelial cells, thereby disrupting the function of tumor vasculature that further contributes to a decrease in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pladienolide Derivative E7107</VALIDVALUE>
          <VALUEMEANING>Pladienolide Derivative E7107</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic urethane derivative of pladienolide D with potential antineoplastic activity. Pladienolide derivative E7107 is generated from the 12-membered macrolide pladienolide D, one of several macrolides derived from the bacterium Streptomyces platensis Mer-11107. This agent appears to bind to the 130-kDa subunit 3 (spliceosome-associated protein 130; SAP130) of the splicing factor 3b (SF3b), resulting in inhibition of pre-messenger RNA splicing and the arrest of cell-cycle progression. The splicing factor SF3b is a multiprotein complex integral to the accurate excision of introns from pre-messenger RNA; the subunit SAP130 associates with U2 snRNP and is recruited to prespliceosomal complexes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plitidepsin</VALIDVALUE>
          <VALUEMEANING>Plitidepsin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1689</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plk1 Inhibitor BI 2536</VALIDVALUE>
          <VALUEMEANING>Plk1 Inhibitor BI 2536</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49091</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PLK1 Inhibitor TAK-960</VALIDVALUE>
          <VALUEMEANING>PLK1 Inhibitor TAK-960</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plocabulin</VALIDVALUE>
          <VALUEMEANING>Plocabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A marine-derived, synthetically produced compound with potential antineoplastic activity. Plocabulin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pNGVL4a-CRT-E6E7L2 DNA Vaccine</VALIDVALUE>
          <VALUEMEANING>pNGVL4a-CRT-E6E7L2 DNA Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic DNA vaccine encoding human calreticulin (CRT) linked to human papillomavirus (HPV) type 16 E6, E7, and L2 proteins, with potential immunomodulating and antineoplastic activities. Upon administration via intramuscular injection with electroporation, the pNGVL4a-CRT-E6E7L2 DNA vaccine expresses HPV16 E6, E7 and L2 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response and humoral immune responses against tumor cells expressing these proteins, resulting in tumor cell lysis and tumor cell death. In addition, HPV16 L2-specific neutralizing antibody may prevent a broad spectrum of HPV infections and HPV-associated cancers. The heat shock protein CRT may potentiate MHC class I presentation to antigen-specific CD8-positive T-cells, enhancing the induction of cellular immunity and the potency of the vaccine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2</VALIDVALUE>
          <VALUEMEANING>pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polatuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Polatuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7739453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polidocanol</VALIDVALUE>
          <VALUEMEANING>Polidocanol</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkyl polyglycol ether of lauryl alcohol with sclerosing and potential antineoplastic activities. Upon intralesional administration, polidocanol induces endothelial cell injury by disrupting calcium signaling and nitric oxide pathways. Following endothelial damage, platelets aggregate at the site of injury and attach to the venous wall, resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Inducing endothelial cell damage within melanoma metastases may incite an antitumor response in untreated bystander lesions and inhibit the growth of in transit metastases and other cutaneous lesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poliglusam</VALIDVALUE>
          <VALUEMEANING>Poliglusam</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally occurring polysaccharide composed of beta-1,4-linked glucosamine residues with potential antineoplastic activity. Upon administration, poliglusam may, through a not yet fully elucidated mechanism, reduce advanced glycation end product (AGE) levels. This may reduce the interaction between AGEs and the receptor for advanced glycation end products (RAGE, AGER), which is overexpressed in some tumor types and is associated with poor patient outcomes. AGE-RAGE interaction may induce the phosphorylation and subsequent degradation of retinoblastoma protein (Rb), a key cell cycle inhibitor and tumor suppressor, through the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) signaling pathway. Hyperphosphorylation of Rb leads to the dissociation of the Rb-E2F complex, which triggers the activation of genes required for G1/S transition and tumorigenesis. Reducing AGE levels may limit AGE-RAGE interaction and normalize the G1 to S-phase transition, potentially reducing the development and progression of certain cancers. AGEs are non-enzymatic protein modifications produced during the normal aging process that have been shown to play a role in the development and progression of some cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plozalizumab</VALIDVALUE>
          <VALUEMEANING>Plozalizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human chemokine receptor 2 (CCR2), with potential antiangiogenic, immunomodulating, antimetastatic, and antineoplastic activities. Plozalizumab binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and so inhibition of angiogenesis, tumor cell migration, and tumor cell proliferation. In addition, this agent may reduce levels of C-reactive protein (CRP). The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polo-like Kinase 1 Inhibitor GSK461364</VALIDVALUE>
          <VALUEMEANING>Polo-like Kinase 1 Inhibitor GSK461364</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polo-like Kinase 1 Inhibitor MK1496</VALIDVALUE>
          <VALUEMEANING>Polo-like Kinase 1 Inhibitor MK1496</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor MK1496 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poly-alendronate Dextran-Guanidine Conjugate</VALIDVALUE>
          <VALUEMEANING>Poly-alendronate Dextran-Guanidine Conjugate</VALUEMEANING>
          <MEANINGDESCRIPTION>A polybisphosphonate dextran-guanidine conjugate with potential anti-resorptive and antineoplastic activities. Alendronic acid and aminoguanidine were conjugated sequentially to oxidized dextran resulting in an average of 8 alendronate and 50 guanidine groups coupled to the dextran backbone. Upon administration, the poly-alendronate dextran-guanidine conjugate inhibits the mevalonate pathway by inhibiting farnesyl diphosphate synthase (FDPS) which leads to a reduction in protein prenylation and to the loss of downstream metabolites essential for osteoclast function. This eventually leads to the induction of apoptosis in osteoclasts. Also, by preventing osteoclast-mediated bone resorption, this agent decreases bone turnover and stabilizes the bone matrix. The guanidine moiety increases the nitrogen content and possibly the activity of the bisphosphonate and its ability to inhibit FDPS. In addition, the guanidine moiety facilitates cell internalization and may contribute to this agent&#39;s cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyamine Analog SL11093</VALIDVALUE>
          <VALUEMEANING>Polyamine Analog SL11093</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic compound of the polyamine class of chemicals with potential antineoplastic activity. Natural endogenous polyamines bind to DNA and are involved in a number of cellular processes such as cell division, differentiation, and membrane function. SL11093 displaces these polyamines from their DNA binding sites, resulting in cessation of cell growth and cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyamine Transport Inhibitor AMXT-1501 Dicaprate</VALIDVALUE>
          <VALUEMEANING>Polyamine Transport Inhibitor AMXT-1501 Dicaprate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dicaprate salt form of AMXT-1501, an orally bioavailable polyamine transport inhibitor, with immunostimulating and antineoplastic activities.  Upon administration, AMXT-1501 targets, binds to and blocks polyamine transport from the bloodstream into the tumor microenvironment (TME), thereby preventing cancer cell uptake. This decreases polyamine concentrations inside the TME and tumor cell, inhibits tumor cell proliferation and induces apoptosis. In addition, AMXT-1501 may abrogate polyamine-mediated immune suppression in the TME. Polyamines, naturally found in normal, heathy cells, are required for normal cell growth and division. In cancer cells, polyamines play key roles in tumor cell proliferation and tumor-induced suppression of the patient&#39;s immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyandrol</VALIDVALUE>
          <VALUEMEANING>Polyandrol</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from Castela polyandra and other plant species with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1628</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyethylene Glycol Recombinant Endostatin</VALIDVALUE>
          <VALUEMEANING>Polyethylene Glycol Recombinant Endostatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing recombinant endostatin attached to polyethylene glycol (PEG), with potential anti-angiogenic and antineoplastic activities. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction of tumor cell growth. Modification with PEG extends the circulation half-life of endostatin, improves stability and increases solubility in organic solvents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318</VALIDVALUE>
          <VALUEMEANING>Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting formulation composed of 7-ethyl-10-hydroxycamptothecin (SN38), a camptothecin derivative and active metabolite of irinotecan conjugated to polyethylene glycol (PEG), via a proprietary, cleavable linker, with potential antineoplastic activity. Upon administration, the proprietary linkage system allows for very slow release of SN38 from the formulation. Upon release, SN38 selectively stabilizes covalent topoisomerase I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to other PEG-SN38-based formulations, the linker system in DFP-13318 increases its half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs; this results in increased efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poly-gamma Glutamic Acid</VALIDVALUE>
          <VALUEMEANING>Poly-gamma Glutamic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble and biodegradable polymer naturally synthesized by various strains of Bacillus and composed of D- and L-glutamic acid polymerized via gamma-amide linkages, with potential antineoplastic activity. Upon administration, poly-gamma glutamic acid may augment the immune response by increasing the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and inducing the activation of macrophage and natural killer (NK) cells. IFN-gamma is a major mediator of innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. TNF-alpha is a cytokine involved in systemic inflammation, which is capable of inducing apoptotic cell death and exhibits anti-tumoral effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyamine Analogue PG11047</VALIDVALUE>
          <VALUEMEANING>Polyamine Analogue PG11047</VALUEMEANING>
          <MEANINGDESCRIPTION>A second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13723123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymer-conjugated IL-15 Receptor Agonist NKTR-255</VALIDVALUE>
          <VALUEMEANING>Polymer-conjugated IL-15 Receptor Agonist NKTR-255</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of polymer-conjugated IL-15 receptor agonist NKTR-255, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects. Compared to IL-15 alone, the polymer formulation allows for increased retention at the tumor site and reduced clearance, thereby increasing the effect of IL-15.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymer-encapsulated Luteolin Nanoparticle</VALIDVALUE>
          <VALUEMEANING>Polymer-encapsulated Luteolin Nanoparticle</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymeric Camptothecin Prodrug XMT-1001</VALIDVALUE>
          <VALUEMEANING>Polymeric Camptothecin Prodrug XMT-1001</VALUEMEANING>
          <MEANINGDESCRIPTION>A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polysaccharide-K</VALIDVALUE>
          <VALUEMEANING>Polysaccharide-K</VALUEMEANING>
          <MEANINGDESCRIPTION>A protein-bound polysaccharide derived from the mushroom Trametes versicolor (Turkey Tail) with immunoadjuvant and potential antitumor activities. Although its mechanism of action has yet to be fully elucidated, in vitro and in vivo studies indicate that polysaccharide-K induces peripheral blood monocyte secretion of IL-8 and TNF-alpha, induces T cell proliferation, and prevents cyclophosphamide-induced immunosuppression. This agent has also been reported to stimulate macrophages to produce reactive nitrogen intermediates and superoxide anions and to promote apoptosis in the promyelocytic leukemia cell line HL-60.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polysialic Acid</VALIDVALUE>
          <VALUEMEANING>Polysialic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly negative-charged carbohydrate composed of a linear polymer of alpha 2,8-linked sialic acid residue with potential immunotherapeutic activity. Polysialic acid (PSA) is mainly attached to the neural cell adhesion molecule (NCAM), a membrane-bound glycoprotein overexpressed in certain types of cancers. In embryonic tissue PSA-NCAM is abundantly expressed and PSA plays an important role in formation and remodeling of the neural system through modulation of the adhesive properties of NCAM, thereby reducing cell-cell interactions and promoting cellular mobility. In adult tissue however, the expression of PSA-NCAM is associated with a variety of malignant tumors, signifying its potential role in tumor metastasis. When administered in a vaccine formulation, PSA may stimulate a cytotoxic T cell response against tumors expressing PSA, thereby resulting in a reduction in tumor size.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1201</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyunsaturated Fatty Acid</VALIDVALUE>
          <VALUEMEANING>Polyunsaturated Fatty Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A fatty acid containing more than one double bond (C=C). The essential fatty acids omega-3 and omega-6 are polyunsaturated fatty acids (PUFAs) that contain 2 or more cis double bonds. Dietary intake of some PUFAs may have beneficial effects on blood pressure, serum lipds, and inflammation. Some PUFAs, such as omega-3 PUFAs, may have antineoplastic or chemopreventive activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6839549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyvalent Melanoma Vaccine</VALIDVALUE>
          <VALUEMEANING>Polyvalent Melanoma Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens.  Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pomalidomide</VALIDVALUE>
          <VALUEMEANING>Pomalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3944871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pomegranate Juice</VALIDVALUE>
          <VALUEMEANING>Pomegranate Juice</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural juice isolated from the fruit of the plant Punica granatum with antioxidant, potential antineoplastic, and chemopreventive activities.  Pomegranate juice contains flavonoids which promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thereby inhibiting angiogenesis. The flavonoids in pomegranate juice also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polypodium leucotomos Extract</VALIDVALUE>
          <VALUEMEANING>Polypodium leucotomos Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement composed of an aqueous extract derived from the leaves of the tropical fern belonging to the Polypodiaceae family, Polypodium leucotomos (PL; Phlebodium aureum), with potential photoprotective, skin protective, anti-inflammatory, immunomodulating and antioxidant activities. This extract contains many phenolic compounds, such as ferulic, caffeic, coumaric and vanillic acid, which are mainly responsible for this extract&#39;s effects. Upon administration, Polypodium leucotomos extract (PLE) exerts antioxidant activity by scavenging free radicals and inhibiting the generation and release of reactive oxygen species (ROS), thereby preventing ultraviolet (UV)-induced as well as ROS-induced DNA damage. In addition, the chemicals in this extract protect antioxidant enzymes and modulate expression of cancer and inflammation-related genes, including the induction of the expression of tumor suppressor genes and the inhibition of the expression of pro-inflammatory cytokines and inflammatory enzymes, thereby inhibiting the activation of signal transduction pathways involved in carcinogenesis and inflammation, respectively. PLE also stimulates tissue inhibitors of metalloproteinases (TIMPs) and inhibits matrix metalloproteinases (MMPs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pomegranate Liquid Extract</VALIDVALUE>
          <VALUEMEANING>Pomegranate Liquid Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid extract preparation derived from pomegranate (Punica granatum) seeds with antioxidant, and potential antineoplastic and chemopreventive activities. Pomegranate liquid extract contains flavonoids which may promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thus inhibiting angiogenesis. Pomegranate liquid extract flavanoids also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10571485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ponatinib</VALIDVALUE>
          <VALUEMEANING>Ponatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3776076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ponatinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Ponatinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porcupine Inhibitor CGX1321</VALIDVALUE>
          <VALUEMEANING>Porcupine Inhibitor CGX1321</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic, protective and regenerative activities. Upon oral administration, PORCN inhibitor CGX1321 specifically targets and binds to PORCN in the endoplasmic reticulum (ER), thereby inhibiting the post-translational palmitoylation and secretion of Wnt ligands, thus preventing the activation of Wnt-mediated signaling, and inhibiting cell growth in Wnt-driven tumors. In addition, by inhibiting the secretion of Wnt ligands and preventing Wnt-mediated signaling, CGX1321 may also limit fibrosis and promote regeneration of certain tissues upon cell injury. PORCN catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers and plays a key role in tumor cell proliferation. It also plays a key role in tissue regeneration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porcupine Inhibitor ETC-1922159</VALIDVALUE>
          <VALUEMEANING>Porcupine Inhibitor ETC-1922159</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-1922159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123830</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porcupine Inhibitor WNT974</VALIDVALUE>
          <VALUEMEANING>Porcupine Inhibitor WNT974</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porcupine Inhibitor XNW7201</VALIDVALUE>
          <VALUEMEANING>Porcupine Inhibitor XNW7201</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, PORCN inhibitor XNW7201 targets, binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. PORCN, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers and plays a key role in cancer cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porfimer Sodium</VALIDVALUE>
          <VALUEMEANING>Porfimer Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porfiromycin</VALIDVALUE>
          <VALUEMEANING>Porfiromycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species.  Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis.  Porfiromycin is preferentially toxic to hypoxic cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Porcupine Inhibitor RXC004</VALIDVALUE>
          <VALUEMEANING>Porcupine Inhibitor RXC004</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, RXC004 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poziotinib</VALIDVALUE>
          <VALUEMEANING>Poziotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P-p68 Inhibitor RX-5902</VALIDVALUE>
          <VALUEMEANING>P-p68 Inhibitor RX-5902</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PPAR Alpha Antagonist TPST-1120</VALIDVALUE>
          <VALUEMEANING>PPAR Alpha Antagonist TPST-1120</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule, selective and competitive antagonist of peroxisome proliferator activated receptor alpha (PPARa), with potential immunomodulating and antineoplastic activities. Upon oral administration, TPST-1120 targets, binds to and blocks the activity of PPARa, thereby blocking transcription of PPARa target genes leading to an intracellular metabolism shift from fatty acid oxidation (FAO) to glycolysis in FAO-dependent tumors and reducing the production of fatty acids in the tumor microenvironment (TME). As fatty acids are essential for tumor cell growth in FAO-dependent tumor cells and are needed for the metabolism of suppressive immune cells in the TME, including regulatory T-cells (Tregs), reducing the amount of fatty acids leads to a direct killing of FAO-dependent tumor cells. It also skews macrophages from the immune suppressive M2 phenotype to an effector M1 phenotype and facilitates the cytotoxicity of immune effector cells, thereby stimulating an anti-tumor immune response and further killing tumor cells. TPST-1120 also restores the natural inhibitor of angiogenesis thrombospondin-1 (TSP-1) and stimulator of interferon genes (STING) in the TME. PPARa, a ligand-activated nuclear transcription factor and metabolic checkpoint, regulates the expression of FAO genes and lipid metabolism. It plays a key role in immunosuppression in the TME. FAO is a metabolic pathway essential to tumor growth, survival and immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PR1 Leukemia Peptide Vaccine</VALIDVALUE>
          <VALUEMEANING>PR1 Leukemia Peptide Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pralatrexate</VALIDVALUE>
          <VALUEMEANING>10-Propargyl-10-Deazaaminopterin</VALUEMEANING>
          <MEANINGDESCRIPTION>A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pralsetinib</VALIDVALUE>
          <VALUEMEANING>Pralsetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Praluzatamab Ravtansine</VALIDVALUE>
          <VALUEMEANING>Praluzatamab Ravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>A probody drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity. Upon administration of praluzatamab ravtansine and migration to the tumor microenvironment (TME), the cleavable masking peptide, which prevent anti-CD166 antibody binding to the CD166 expressed on both normal cells and tumor cells, is proteolytically cleaved by tumor-associated proteases that are specifically present in the TME. This enables the anti-CD166 antibody moiety of CX-2009 to selectively bind to, be internalized by, and deliver DM4 into CD166-expressing tumor cells. Following internalization, DM4 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD166-expressing tumor cells. The masking peptide prevents binding of the anti-CD166 antibody to CD166 in normal tissues, thereby minimizing toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701</VALIDVALUE>
          <VALUEMEANING>PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701</VALUEMEANING>
          <MEANINGDESCRIPTION>Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted, preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903) can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701 T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated signaling, the induction of apoptosis and to selective and complete elimination of BPX-701 cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128029</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pravastatin Sodium</VALIDVALUE>
          <VALUEMEANING>Pravastatin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pracinostat</VALIDVALUE>
          <VALUEMEANING>Pracinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prednimustine</VALIDVALUE>
          <VALUEMEANING>Prednimustine</VALUEMEANING>
          <MEANINGDESCRIPTION>The prednisolone ester of chlorambucil and nitrogen mustard alkylating agent with antineoplastic activity. Prednimustine itself is not cytotoxic, however, it becomes cytotoxic upon hydrolysis by serum esterases to chlorambucil. Therefore, the increased potency of prednimustine is linked to the prolonged availability of free chlorambucil.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prednisolone</VALIDVALUE>
          <VALUEMEANING>Prednisolone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3305273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prednisone</VALIDVALUE>
          <VALUEMEANING>Prednisone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prexasertib</VALIDVALUE>
          <VALUEMEANING>Prexasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6199779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prexigebersen</VALIDVALUE>
          <VALUEMEANING>Prexigebersen</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation containing the antisense oligodeoxynucleotide (ODN) growth factor receptor-bound protein 2 (Grb2), with potential antineoplastic activity. Upon administration, liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of cancer cells overexpressing Grb2. Grb2, an adaptor protein involved in growth signaling pathways, is upregulated in certain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prinomastat</VALIDVALUE>
          <VALUEMEANING>Prinomastat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic hydroxamic acid derivative with potential antineoplastic activity.  Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  As a lipophilic agent, prinomastat crosses the blood-brain barrier. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRMT1 Inhibitor GSK3368715</VALIDVALUE>
          <VALUEMEANING>PRMT1 Inhibitor GSK3368715</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRMT5 Inhibitor PRT811</VALIDVALUE>
          <VALUEMEANING>PRMT5 Inhibitor PRT811</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration, PRMT5 inhibitor PRT811 selectively binds to PRMT5 and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proapoptotic Sulindac Analog CP-461</VALIDVALUE>
          <VALUEMEANING>Proapoptotic Sulindac Analog CP-461</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable second-generation selective apoptotic antineoplastic drug (SAAND) and analog of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, with potential pro-apoptotic and antineoplastic activities. Upon administration, CP-461 specifically binds to and blocks the activity of cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway. Inhibition of cGMP-PDE permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. cGMP-PDE is overexpressed in a variety of cancer cell types; therefore, CP-461 selectively induces apoptosis in cancer cells, with minimal or no effect in healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133019</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prime Cancer Vaccine MVA-BN-CV301</VALIDVALUE>
          <VALUEMEANING>Prime Cancer Vaccine MVA-BN-CV301</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301, a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Procarbazine</VALIDVALUE>
          <VALUEMEANING>Procarbazine</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Procarbazine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Procarbazine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Procaspase Activating Compound-1 VO-100</VALIDVALUE>
          <VALUEMEANING>Procaspase Activating Compound-1 VO-100</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable procaspase activating compound-1 (PAC-1), with potential proapoptotic and antineoplastic activities. Upon administration, VO-100 binds to and forms a chelating complex with zinc (Zn) ions inside cells, which prevents the binding of Zn ions to procaspase-3 (PC3) and abrogates the Zn-mediated inhibition of PC3. This allows for the proteolytic autoactivation of PC3 into the active form caspase-3. This results in the selective caspase-3-mediated induction of apoptosis and cell death in cancer cells. In addition, VO-100 is able to cross the blood-brain-barrier (BBB). PC3, a Zn-inhibited proenzyme, is upregulated in a variety of cancer cell types, while its expression is minimal in normal healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prohibitin-Targeting Peptide 1</VALIDVALUE>
          <VALUEMEANING>Prohibitin-Targeting Peptide 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric, 25-mer peptide that targets prohibitin, with potential antineoplastic activity. Prohibitin-targeting peptide 1 (prohibitin-TP01) consists of a fat-targeting motif (CKGGRAKDC), two repeats of a proapoptotic peptide motif (KLAKLAK) and a GG linker. This peptide binds specifically to prohibitin in the white adipose vasculature; upon receptor-mediated cell internalization, the ligand/receptor complex triggers apoptosis and results in ablation of white fat. Destruction of white fat may potentially have positive consequences for men with prostate cancer since a high level of white fat has been implicated as a critical contributing factor in poor prostate cancer outcome. Prohibitin, a multifunctional membrane-associated protein that is thought to regulate cell survival and growth, has been shown by immunohistochemical analysis to be expressed in the membrane of endothelial cells in white adipose tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostate Cancer Vaccine ONY-P1</VALIDVALUE>
          <VALUEMEANING>Prostate Cancer Vaccine ONY-P1</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostate Health Cocktail Dietary Supplement</VALIDVALUE>
          <VALUEMEANING>Prostate Health Cocktail Dietary Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement consisting of a blend of 8 natural ingredients with potential antineoplastic and chemopreventive activities. This dietary supplement contains vitamin D3 (as cholecalciferol), vitamin E (as d-alpha tocopherol), selenium (as L-selenomethionine), epigallocatechin (green tea extract), saw palmetto (berry extract), lycopene, and the isoflavonoids daidzein and genistein. This combination preparation may decrease prostate cell growth and inhibit prostate carcinogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77860</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024</VALIDVALUE>
          <VALUEMEANING>Prostatic Acid Phosphatase-Sargramostim Fusion Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4792058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Arginine Methyltransferase 5 Inhibitor PF-06939999</VALIDVALUE>
          <VALUEMEANING>Protein Arginine Methyltransferase 5 Inhibitor PF-06939999</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of protein arginine N-methyltransferase 5 (histone-arginine N-methyltransferase PRMT5; PRMT5) with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not yet been fully elucidated, orally administered PRMT5 inhibitor PF-06939999 inhibits the methyltransferase activity of PRMT5, thereby decreasing the levels of monomethylated and dimethylated arginine residues in histones H2A, H3, and H4, and modulating the expression of genes involved in several cellular processes including cell proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, and may decrease the growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Arginine Methyltransferase 5 Inhibitor PRT543</VALIDVALUE>
          <VALUEMEANING>Protein Arginine Methyltransferase 5 Inhibitor PRT543</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the exact mechanism of action has not been completely determined, upon oral administration, PRMT5 inhibitor PRT543 selectively binds to the substrate recognition site of PRMT5 and inhibits its methyltransferase activity. This decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cellular proliferation. As a result, PRT543 may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prolgolimab</VALIDVALUE>
          <VALUEMEANING>Prolgolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Phosphatase 2A Inhibitor LB-100</VALIDVALUE>
          <VALUEMEANING>Protein Phosphatase 2A Inhibitor LB-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Stabilized Liposomal Docetaxel Nanoparticles</VALIDVALUE>
          <VALUEMEANING>Protein Stabilized Liposomal Docetaxel Nanoparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel with antineoplastic activity. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Compared to the use of toxic carriers to increase solubilization of docetaxel, protein-stabilized liposomal docetaxel improves drug solubility while avoiding carrier-associated toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90534</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724986</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Tyrosine Kinase 2 Inhibitor IN10018</VALIDVALUE>
          <VALUEMEANING>Protein Tyrosine Kinase 2 Inhibitor IN10018</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, IN10018 targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proxalutamide</VALIDVALUE>
          <VALUEMEANING>Proxalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130036</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSA/PSMA DNA Plasmid INO-5150</VALIDVALUE>
          <VALUEMEANING>PSA/PSMA DNA Plasmid INO-5150</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pseudoisocytidine</VALIDVALUE>
          <VALUEMEANING>Pseudoisocytidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, pyrimidine C-5 nucleoside with antineoplastic activity. Pseudoisocytidine, after conversion into pseudoisocytidine triphosphate, is incorporated into DNA and RNA eventually halting tumor cell proliferation. Compared to 5-azacytidine and cytarabine, this agent shows enhanced stability and resistance to enzymatic deamination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSMA/CD3 Tri-specific T-cell Activating Construct HPN424</VALIDVALUE>
          <VALUEMEANING>PSMA/CD3 Tri-specific T-cell Activating Construct HPN424</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA; FOLH1) and the CD3 antigen found on T-lymphocytes and an albumin-binding domain, with potential immunostimulating and antineoplastic activities.  Upon administration, PSMA/CD3 tri-specific T-cell antibody construct HPN424 targets and binds PSMA on tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs), thereby bringing PSMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN424. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSMA-targeted Docetaxel Nanoparticles BIND-014</VALIDVALUE>
          <VALUEMEANING>PSMA-targeted Docetaxel Nanoparticles BIND-014</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane antigen (PSMA), with antineoplastic activity. PSMA-targeted docetaxel nanoparticles BIND-014 carry docetaxel within a matrix of polylactic acid covered with a coating of polyethylene glycol; embedded on the surface of the polyethylene glycol coating are ligands targeted to PSMA. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, and the PEG encapsulation escapes the host immune response while PSMA ligands on the surface restrict the cytotoxic effect to PSMA-expressing cells. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. PSMA is a cell-surface antigen that is abundantly present on the surface of cancer cells and on the neovasculature that feeds a wide variety of tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSMA-targeted Tubulysin B-containing Conjugate EC1169</VALIDVALUE>
          <VALUEMEANING>PSMA-targeted Tubulysin B-containing Conjugate EC1169</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable, water soluble, small molecule drug conjugate (SMDC) containing a ligand specific for prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to the cytotoxic agent tubulysin B hydrazide (TubBH), with potential antineoplastic activity. Upon administration of PSMA-targeted tubulysin B-containing conjugate EC1169, the PSMA ligand specifically targets and binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells as well as on the neovasculature of many solid tumors. This allows for the specific delivery of TubBH to PSMA-expressing cancer cells. Upon internalization and cleavage, tubulysin B binds to tubulin and inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in PSMA-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSA/IL-2/GM-CSF Vaccine</VALIDVALUE>
          <VALUEMEANING>PSA/IL-2/GM-CSF Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13724989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pterostilbene</VALIDVALUE>
          <VALUEMEANING>Pterostilbene</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-derived stilbenoid structurally related to resveratrol, with potential antioxidant, anti-inflammatory, pro-apoptotic, antineoplastic and cytoprotective activities. Upon administration, pterostilbene exerts its anti-oxidant activity by scavenging reactive oxygen species (ROS), thereby preventing oxidative stress and ROS-induced cell damage. It may also activate the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathway and increase the expression of various antioxidant enzymes, such as superoxide dismutase (SOD).  In addition, pterostilbene is able to inhibit inflammation by reducing the expression of various inflammatory mediators, such as interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-a), inducible nitric oxide synthase (iNOS), cyclooxygenases (COX), and nuclear factor kappa B (NF-kB). It also inhibits or prevents the activation of many signaling pathways involved in carcinogenesis, and increases expression of various tumor suppressor genes while decreasing expression of certain tumor promoting genes. It also directly induces apoptosis in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pumitepa</VALIDVALUE>
          <VALUEMEANING>Pumitepa</VALUEMEANING>
          <MEANINGDESCRIPTION>A thiotepa derivative with potential antineoplastic alkylating activity. Although the exact mechanism of action of pumitepa has yet to be fully elucidated, this agent appears to work through alkylation, thereby causing DNA damage and cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Puquitinib</VALIDVALUE>
          <VALUEMEANING>Puquitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Puquitinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Puquitinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of puquitinib, an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Puromycin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Puromycin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of puromycin, an aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger. Acting as an analog of the 3&#39; terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis. This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PVA Microporous Hydrospheres/Doxorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>PVA Microporous Hydrospheres/Doxorubicin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers loaded with doxorubicin hydrochloride with antineoplastic activity. Doxorubicin hydrochloride-loaded microspheres may be used as a drug delivery vehicle during embolization of tumor vasculature. Doxorubicin intercalates DNA, interferes with catalytic activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. When used in tumor vasculature embolization, this preparation may provide more tumor-specific treatment with doxorubicin compared to the systemic administration of doxorubicin, thereby reducing the systemic toxicity of doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyrazoloacridine</VALIDVALUE>
          <VALUEMEANING>Pyrazoloacridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A 9-methoxy acridine compound containing a reducible 5-nitro substituent.  Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyridyl Cyanoguanidine CHS 828</VALIDVALUE>
          <VALUEMEANING>Pyridyl Cyanoguanidine CHS 828</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyridyl cyanoguanidine that exhibits antitumor activity by an unknown mechanism. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyrotinib</VALIDVALUE>
          <VALUEMEANING>Pyrotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Puromycin</VALIDVALUE>
          <VALUEMEANING>Puromycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger.  Acting as an analog of the 3&#39; terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis.  This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyrotinib Dimaleate</VALIDVALUE>
          <VALUEMEANING>Pyrotinib Dimaleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimaleate ester of pyrotinib, an orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR, ErbB1 or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyroxamide</VALIDVALUE>
          <VALUEMEANING>Pyroxamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of hydroxamic acid with antineoplastic properties, Pyroxamide inhibits histone deacetylases involved in transcription; induces hyperacetylation of core histones, modulating chromatin structure and affecting transcription of some genes that inhibit tumor growth; and induces growth arrest and apoptosis. Pyroxamide is used in clinical studies for cancer chemotherapy. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyruvate Kinase Inhibitor TLN-232</VALIDVALUE>
          <VALUEMEANING>Pyruvate Kinase Inhibitor TLN-232</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cyclic heptapeptide with potential antineoplastic activity. Pyruvate kinase (PK) inhibitor TLN-232 targets pyruvate kinase M2 (M2PK), which may disrupt tumor cell anaerobic glycolysis. M2PK is a dimeric isoform of PK and the predominant PK isoform found in tumor cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Qilisheng Immunoregulatory Oral Solution</VALIDVALUE>
          <VALUEMEANING>Qilisheng Immunoregulatory Oral Solution</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral solution containing Spondias axillaris, Panax ginseng, schisandra berry, hawthorn, soybean and an as of yet not elucidated bacterium, with potential immunomodulating activity. Upon oral administration of the qilisheng immunoregulatory oral solution, the ingredients in qilisheng may modulate the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine</VALIDVALUE>
          <VALUEMEANING>Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3944880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quarfloxin</VALIDVALUE>
          <VALUEMEANING>Quarfloxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quinacrine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Quinacrine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The dihydrochloride salt of the 9-aminoacridine derivative quinacrine with potential antineoplastic and antiparasitic activities. Quinacrine may inhibit the transcription and activity of both basal and inducible nuclear factor-kappaB (NF-kappaB), which may result in the induction of tumor suppressor p53 transcription, the restoration of p53-dependent apoptotic pathways, and tumor cell apoptosis. Continuous NF-kappaB signaling, present in many tumors and in chronic inflammatory processes, promotes the expression of antiapoptotic proteins and cytokines while downregulating the expression of proapoptotic proteins, such as p53.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quinine</VALIDVALUE>
          <VALUEMEANING>Quinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinidine alkaloid isolated from the bark of the cinchona tree. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quisinostat</VALIDVALUE>
          <VALUEMEANING>Quisinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyruvate Kinase M2 Isoform Activator TP-1454</VALIDVALUE>
          <VALUEMEANING>Pyruvate Kinase M2 Isoform Activator TP-1454</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable activator of pyruvate kinase M2 isoform (PKM2), with potential immunomodulating and antineoplastic activities. Upon oral administration, PKM2 activator TP-1454 locks PKM2 into the active tetrameric form. This may prevent the production of glycolytic intermediates by the less active dimer form of PKM2, depleting the supply of glycolytic intermediates which are needed for tumor cell growth. This may also inhibit immune suppression mediated by the dimer form of PKM2. Altogether, this may slow tumor cell growth and enhance anti-tumor immune responses, thereby inhibiting tumor cell proliferation. PKM2, the predominant PK isoform found in tumor cells, is responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quizartinib</VALIDVALUE>
          <VALUEMEANING>Quizartinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R-(-)-Gossypol Acetic Acid</VALIDVALUE>
          <VALUEMEANING>R-(-)-Gossypol Acetic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable solvate of the R-(-) enantiomer of gossypol and acetic acid with potential antineoplastic activity. As a BH3 mimetic, R-(-)-gossypol binds to the hydrophobic surface binding groove BH3 of the anti-apoptotic proteins Bcl-2 and Bcl-xL, blocking their heterodimerization with pro-apoptotic members of the Bcl-2 family of proteins such as Bad, Bid, and Bim; this may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Racemic gossypol is a polyphenolic compound isolated from cottonseed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rabusertib</VALIDVALUE>
          <VALUEMEANING>Rabusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Racotumomab</VALIDVALUE>
          <VALUEMEANING>Racotumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95024</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radgocitabine</VALIDVALUE>
          <VALUEMEANING>Radgocitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radgocitabine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Radgocitabine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiolabeled CC49</VALIDVALUE>
          <VALUEMEANING>Radiolabeled CC49</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of a humanized monoclonal antibody with antitumor activity. The monoclonal antibody CC49 is developed from the murine monoclonal antibody B72.3 and is humanized by grafting the hypervariable regions onto the variable light (VL) and variable heavy (VH) frameworks of the monoclonal antibodies LEN and 21/28&#39; CL. The resultant antibody binds the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Furthermore, the antibody is commonly radiolabeled resulting in an effective agent for use in radioimmunotherapy for treatment of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radium Ra 223 Dichloride</VALIDVALUE>
          <VALUEMEANING>Radium Chloride Ra-223</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiopharmaceutic of short-lived radium-223 with potential anti-tumor activity. Radium preferentially binds to and accumulates in bone tissue. The radioisotope radium-223 may kill bone cancer cells through the local emission of high energy alpha particles, thereby potentially decreasing tumor progression in the skeleton.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radium Ra 224-labeled Calcium Carbonate Microparticles</VALIDVALUE>
          <VALUEMEANING>Radium Ra 224-labeled Calcium Carbonate Microparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiopharmaceutical composed of biodegradable calcium carbonate microspheres labeled with the alpha-emitting radioisotope radium Ra 224, with antineoplastic activity. Upon intraperitoneal (IP) administration of the radium Ra 224-labeled calcium carbonate microparticles, Ra 224 kills tumor cells through local emission of high energy alpha particles, causing DNA double-strand breaks. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RAD51 Inhibitor CYT-0851</VALIDVALUE>
          <VALUEMEANING>RAD51 Inhibitor CYT-0851</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the DNA damage repair protein RAD51, with potential antineoplastic and sensitizing activities. Upon oral administration, the RAD51 inhibitor CYT-0851 targets, binds to and inhibits the activity of RAD51. This prevents RAD51-mediated DNA damage repair in susceptible tumor cells and induces tumor cell apoptosis. RAD51, the central protein involved in homologous repair (HR) of DNA double-strand breaks (DSBs), is overexpressed in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radix Angelicae Sinensis/Radix Astragali Herbal Supplement</VALIDVALUE>
          <VALUEMEANING>Radix Angelicae Sinensis/Radix Astragali Herbal Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine comprising of Radix Angelicae Sinensis (RAS) and Radix Astragali (RA), with potential anti-inflammatory, immunostimulatory, neuroprotective, anti-hepatotoxic and antineoplastic activities. The main chemical constituents of RAS include ferulic acid, Z-ligustilide, butylidenephthalide and various polysaccharides. RA is the dried root of Astragalus membranaceus with primary constituents such polysaccharides, triterpenoids as well as isoflavones. Though their mechanisms of action remain largely elusive, Radix Angelicae Sinensis/Radix Astragali herbal supplements are commonly used for the treatment of various health conditions affecting women including premenstrual syndrome, dysmenorrhea, pelvic pain, recovery from childbirth and menopausal symptoms. These agents are also used for alleviating constipation, preventing and treating anemia and allergic attacks, and for the management of hypertension, joint pain and ulcers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radotinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Radotinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RAF Kinase Inhibitor L-779450</VALIDVALUE>
          <VALUEMEANING>RAF Kinase Inhibitor L-779450</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic triarylimidazole with potential antineoplastic activity.  As a Raf kinase inhibitor, L-779450 competes with ATP for binding to the Raf-1 and A-Raf catalytic sites, thus inhibiting their enzymatic activities and blocking various signal transduction pathways that depend on Raf-1 kinase (particularly the Ras-Raf-MEK-ERK cascade which is often up-regulated in neoplasms). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RAF Kinase Inhibitor XL281</VALIDVALUE>
          <VALUEMEANING>RAF Kinase Inhibitor XL281</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ragifilimab</VALIDVALUE>
          <VALUEMEANING>Ragifilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ralaniten Acetate</VALIDVALUE>
          <VALUEMEANING>Ralaniten Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the acetate form of ralaniten, a N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration of ralaniten acetate, ralaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ralimetinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Ralimetinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Raloxifene</VALIDVALUE>
          <VALUEMEANING>Raloxifene</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to and interacts with estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen&#39;s beneficial effects without producing its adverse effects.  In postmenopausal women, raloxifene may reduce the risk of strokes, osteoporosis and breast cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3190407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Raloxifene Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Raloxifene Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ramucirumab</VALIDVALUE>
          <VALUEMEANING>Ramucirumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3553252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ranibizumab</VALIDVALUE>
          <VALUEMEANING>Ranibizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3631684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ranimustine</VALIDVALUE>
          <VALUEMEANING>Ranimustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ranolazine</VALIDVALUE>
          <VALUEMEANING>Ranolazine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine&#39;s mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine&#39;s potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3631682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ranpirnase</VALIDVALUE>
          <VALUEMEANING>Ranpirnase</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens.  Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Raltitrexed</VALIDVALUE>
          <VALUEMEANING>Raltitrexed</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RARalpha Agonist IRX5183</VALIDVALUE>
          <VALUEMEANING>RARalpha Agonist IRX5183</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable retinoid acid receptor alpha (RARalpha) agonist and vitamin A derivative, with potential antineoplastic activity. Upon administration, RARalpha agonist IRX5183 binds to and activates RARalpha, which promotes RARalpha-mediated signaling. This results in the transcription of RARalpha-responsive genes, which are responsible for cellular differentiation and proliferation. This results in the induction of cellular differentiation and apoptosis, and leads to the inhibition of cellular proliferation and tumorigenesis. RARalpha is a nuclear receptor and a member of the steroid receptor superfamily; reduced RARalpha signaling is correlated with cancer development in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ras Peptide ASP</VALIDVALUE>
          <VALUEMEANING>Ras Peptide ASP</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of the ras peptide containing a point mutation at position 12 (glycine to aspartic acid) with potential antineoplastic activity.  Vaccination with ras peptide Asp may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this ras mutation, resulting in decreased tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ras Peptide CYS</VALIDVALUE>
          <VALUEMEANING>Ras Peptide CYS</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ras Peptide VAL</VALIDVALUE>
          <VALUEMEANING>Ras Peptide VAL</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to valine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Razoxane</VALIDVALUE>
          <VALUEMEANING>Razoxane</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Realgar-Indigo naturalis Formulation</VALIDVALUE>
          <VALUEMEANING>Realgar-Indigo naturalis Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) oncoprotein. In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. PML-RARalpha, an acute promyelocytic leukemia (APL)-specific fusion gene, inhibits differentiation and promotes survival of myeloid precursor cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rebastinib Tosylate</VALIDVALUE>
          <VALUEMEANING>Rebastinib Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt of rebastinib, an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rebeccamycin</VALIDVALUE>
          <VALUEMEANING>Rebeccamycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rebimastat</VALIDVALUE>
          <VALUEMEANING>Rebimastat</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Adenovirus-p53 SCH-58500</VALIDVALUE>
          <VALUEMEANING>Recombinant Adenovirus-p53 SCH-58500</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Anti-WT1 Immunotherapeutic GSK2302024A</VALIDVALUE>
          <VALUEMEANING>Recombinant Anti-WT1 Immunotherapeutic GSK2302024A</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system&#39;s response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Bacterial Minicells VAX014</VALIDVALUE>
          <VALUEMEANING>Recombinant Bacterial Minicells VAX014</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of recombinant bacterial minicells (rBMCs) engineered to express the alpha3beta1 (a3b1) and alpha5beta1 (a5b1) integrin-targeting invasion and that contain a bacterial protein toxin, perfringolysin O (PFO), with potential antineoplastic activity. Upon intravesical administration, VAX014 selectively targets and binds to tumor cells expressing un-ligated a3b1 and/or a5b1 integrins and delivers PFO, leading to destabilization of tumor cell membranes and tumor cell lysis. By targeting un-ligated a3b1 and/or a5b1 integrins, VAX014 selectively targets tumor cells over normal cells, with potentially less adverse effects in comparison with first generation integrin-targeted therapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Bispecific Single-Chain Antibody rM28</VALIDVALUE>
          <VALUEMEANING>Recombinant Bispecific Single-Chain Antibody rM28</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, bispecific, single-chain antibody directed against both the T-cell surface-associated costimulatory molecule CD28 and a melanoma-associated proteoglycan (MAPG) with potential antitumor activity. By targeting both CD28 and MAPG, recombinant bispecific single-chain antibody rM28 enhances cytotoxic T-cell recognition of melanoma cells, which may result in immune effector cell-mediated tumor cell death and a decrease in distant metastases. This agent appears to have a long serum half-life secondary to the formation of dimers. When activated, CD28 facilitates interactions between T-cells and other immune effector cells resulting in cytotoxic T-lymphocyte responses; MAPG is a surface antigen expressed on the majority of melanomas, including primary cutaneous, ocular, and metastatic melanomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant CD40-Ligand</VALIDVALUE>
          <VALUEMEANING>Recombinant CD40-Ligand</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Receptor Tyrosine Kinase Inhibitor R1530</VALIDVALUE>
          <VALUEMEANING>Receptor Tyrosine Kinase Inhibitor R1530</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. Mitosis-angiogenesis inhibitor (MAI) R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta, FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Erwinia asparaginase JZP-458</VALIDVALUE>
          <VALUEMEANING>Recombinant Erwinia asparaginase JZP-458</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167120</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12119549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Fas Ligand</VALIDVALUE>
          <VALUEMEANING>Recombinant Fas Ligand</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand, a protein related to tumor necrosis factor (TNF) with potential antineoplastic activity.  Fas ligand binds to the Fas receptor, thereby activating caspases and inducing apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Fractalkine</VALIDVALUE>
          <VALUEMEANING>Recombinant Fractalkine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pro-inflammatory delta chemokine with potential antineoplastic activity.  Fractalkine induces the adhesion and migration of T lymphocytes, monocytes and natural killer (NK) cells.  In lymphomas, this agent may promote cell-mediated lympholysis by recruiting activated NK cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human 6Ckine</VALIDVALUE>
          <VALUEMEANING>Recombinant Human 6Ckine</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic recombinant analogue of a member of the endogenous CC chemokines with potential antineoplastic activity. Expressed by various lymphoid tissues, endogenous 6Ckine is chemotactic for B and T lymphocytes and dendritic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Apolipoprotein(a) Kringle V MG1102</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Apolipoprotein(a) Kringle V MG1102</VALUEMEANING>
          <MEANINGDESCRIPTION>An 86 amino-acid long polypeptide fragment of a recombinant form of human apolipoprotein (a) (apo(a)) kringle V, with potential anti-angiogenic and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration, recombinant human apo(a) kringle V MG1102 inhibits the fibronectin-mediated migration of endothelial cells, binds to and blocks the activity of alpha 3 beta 1 integrin (a3b1 integrin), inhibits the activation of focal adhesion kinase (FAK) and FAK-mediated signaling, and leads to the inhibition of the p130 Crk-associated substrate (p130CAS)-c-Jun NH2-terminal kinase (JNK) pathway. This inhibits tumor angiogenesis, induces mitochondrial-mediated apoptosis of tumor cells and tumor-associated endothelial cells, and suppresses tumor growth and metastasis. Apo(a), a glycoprotein component of human lipoprotein(a), contains repeated kringle domains; certain kringle domains of apo(a), including the plasminogen kringle V homolog (KV), have anti-angiogenic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine</VALIDVALUE>
          <VALUEMEANING>Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Endostatin</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Endostatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden. This agent also may decrease hepatic metastasis by inhibiting proinflammatory cytokines and vascular cell adhesion molecule (VCAM)-dependent cell attachment to the hepatic microvasculature.  (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103830</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Papillomavirus 11-valent Vaccine</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Papillomavirus 11-valent Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, 11-valent, human papillomavirus (HPV) vaccine, produced in Hansenula polymorpha, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 11-valent vaccine may generate humoral and cellular immunity against the 11 undisclosed types of HPV antigens, thereby preventing cervical infection upon exposure to these 11 types of HPV. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Adenovirus Type 5 H101</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Adenovirus Type 5 H101</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Papillomavirus Bivalent Vaccine</VALIDVALUE>
          <VALUEMEANING>Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5041679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Papillomavirus Nonavalent Vaccine</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Papillomavirus Nonavalent Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7356947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human Plasminogen Kringle 5 Domain ABT 828</VALIDVALUE>
          <VALUEMEANING>Recombinant Human Plasminogen Kringle 5 Domain ABT 828</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human plasminogen kringle 5 domain with potential antiangiogenic and antineoplastic activities. Upon administration, recombinant human plasminogen kringle 5 domain ABT 828 may promote caspase activity and apoptosis in proliferating endothelial cells, thereby inhibiting migration. Kringle 5 (K5), an internal proteolytic fragment of plasminogen specifically inhibits endothelial cell growth via its interaction with endothelial cell surface ATP synthase, which sequentially triggers the activation of caspases -8, -9, and -3.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301</VALIDVALUE>
          <VALUEMEANING>Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301</VALUEMEANING>
          <MEANINGDESCRIPTION>A glyco-engineered heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization (ECD) domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, recombinant humanized anti-HER-2 bispecific monoclonal antibody MBS301 simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2. This prevents the activation of HER-2 signaling pathways. Also, by binding to HER-2, MBS301 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Alfa</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Alfa-1b</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alfa-1b</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-glycosylated recombinant interferon alpha, subtype 1b, with immunostimulatory and antineoplastic activities. Alpha interferon-1b binds to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Alfa-2a</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alfa-2a</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6428121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Alfa-2b</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alfa-2b</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Alpha 2b-like Protein</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alpha 2b-like Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary recombinant protein highly resembling human interferon alpha 2b (IFN-a2b), with potential anti-tumor, anti-inflammatory, immunomodulating and antiviral activities. Upon injection, recombinant IFN alpha 2b-like protein binds to specific IFN alpha cell surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs). This may activate the immune system, including the activation of natural killer cells (NKs) and may result in an inhibition of tumor cell proliferation, tumor angiogenesis, metastasis and an induction of apoptosis. Compared to human IFN-a2b (HuINF-a2b), this agent exhibits enhanced antiviral and antiproliferative activities. In addition, this agent exhibits antiviral activity against a variety of viruses, including hepatitis B and C viruses, human immunodeficiency virus (HIV) and Avian Influenza.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a group of recombinant therapeutic glycoprotein cytokines with antiviral, anti-proliferative, and immunomodulating activities. Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with interferon-specific response elements (ISREs). The resultant proteins mediate many complex effects, ultimately leading to inhibition of viral protein synthesis and cellular growth, alteration of cellular differentiation, interference with oncogene expression, activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity. The production of endogenous interferons is induced in response to foreign agents such as bacteria, viruses and parasites and to tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Beta</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Beta</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interferon Gamma</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Gamma</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous lymphokine interferon gamma (IFN-gamma) with antineoplastic, immunoregulatory, and antiviral activities. Therapeutic IFN-gamma binds to and activates the cell-surface IFN-gamma receptor, stimulating antibody-dependent cytotoxicity and enhances natural killer cell attachment to tumor cells. This agent also activates caspases, thereby inducing apoptosis in malignant cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interleukin-13</VALIDVALUE>
          <VALUEMEANING>Recombinant Interleukin-13</VALUEMEANING>
          <MEANINGDESCRIPTION>The recombinant analogue of an endogenous cytokine interleukin 13 with potential antineoplastic activity. Produced by lymphocytes and exhibiting a variety of functions, interleukin-13 (therapeutic) inhibits DNA synthesis and regulates inflammatory and immune responses. In animal models, this agent has been shown to kill tumor cells both directly and indirectly by activating the host immune system at the tumor site. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interleukin-6</VALIDVALUE>
          <VALUEMEANING>Recombinant Interleukin-6</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Leukocyte Interleukin</VALIDVALUE>
          <VALUEMEANING>Recombinant Leukocyte Interleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A cocktail preparation of synthetic interleukin (IL) -1, IL-2, IL-6, tumor necrosis factor (TNF)-alpha, interferon gamma and other cytokines that are chemically identical to or similar to signaling molecules secreted by leukocyte cells. Leukocyte interleukins are essential in many immune responses, such as antibodies production, modulating secretion of other cytokines, and activation of bone marrow stem cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Leukoregulin</VALIDVALUE>
          <VALUEMEANING>Recombinant Leukoregulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulated therapeutic analog of the endogenous lymphokine leukoregulin with potential antineoplastic activity.  Leukoregulin displays direct and indirect cytotoxicity through tumor cell lysis and enhancing tumor cell susceptibility to natural killer cell-mediated cytotoxicity.  This agent enhances membrane permeability and decreases p-glycoprotein expression, thereby promoting cytotoxic drug uptake into tumor cells.  Leukoregulin also induces the synthesis of collagenase and hyaluronan, expression and secretion of interleukin-8, and upregulates stromelysin-1 gene expression in human fibroblasts, thereby regulating extracellular matrix degradation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Macrophage Colony-Stimulating Factor</VALIDVALUE>
          <VALUEMEANING>Recombinant Macrophage Colony-Stimulating Factor</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine macrophage colony-stimulating factor (M-CSF). Synthesized endogenously by mesenchymal cells, M-CSF stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series and can reverse treatment-related neutropenias. Recombinant M-CSF may also enhance antigen presentation and activate antitumoral cytotoxic T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant MAGE-3.1 Antigen</VALIDVALUE>
          <VALUEMEANING>Recombinant MAGE-3.1 Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE-expressing cells, resulting in antitumoral T cell-mediated cytotoxicity. MAGE-expressing cells are found in melanoma, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, transitional cell carcinoma of the bladder, and esophageal carcinoma. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Modified Vaccinia Ankara-5T4 Vaccine</VALIDVALUE>
          <VALUEMEANING>Recombinant Modified Vaccinia Ankara-5T4 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant KSA Glycoprotein CO17-1A</VALIDVALUE>
          <VALUEMEANING>Recombinant KSA Glycoprotein CO17-1A</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant counterpart of tumor-associated KSA antigen (Ep-CAM), a type-I transmembrane glycoprotein cellular adhesion molecule with a molecular mass of 40 kDa, overexpressed on the majority of tumor cells of most human epithelia in a of variety of tumor tissues such as stomach, colon, pancreas, gall bladder, bile duct, mammary gland, breast, and lung carcinoma. It has been suggested to be involved in the differentiation, growth, and organization of epithelial cells within tissues under normal physiological conditions. The antigen has been used as a target for diagnosis and for passive and active immunotherapy of colorectal cancer. Immunization with KSA Glycoprotein elicits both humoral and Th1-associated cellular immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Oncolytic Poliovirus PVS-RIPO</VALIDVALUE>
          <VALUEMEANING>Recombinant Oncolytic Poliovirus PVS-RIPO</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon intratumoral administration of recombinant oncolytic poliovirus PVS-RIPO, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, PVS-RIPO only propagates in susceptible, nonneuronal cells (e.g., GBM).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A</VALIDVALUE>
          <VALUEMEANING>Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the human PRAME (Preferentially Expressed Antigen of Melanoma) protein combined with the AS15 adjuvant, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, GSK2302025A may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the PRAME protein, resulting in tumor cell lysis. The tumor-associated antigen PRAME is often overexpressed by a variety of tumor cell types. AS15 is an potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid, and QS-21.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207</VALIDVALUE>
          <VALUEMEANING>Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207</VALUEMEANING>
          <MEANINGDESCRIPTION>A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Thyroglobulin</VALIDVALUE>
          <VALUEMEANING>Recombinant Thyroglobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of thyroglobulin identical to or similar to the endogenous iodine-containing glycoprotein. Thyroglobulin is synthesized in the thyroid follicular cell, and is the precursor of thyroid hormones T3 and T4. Thyroglobulin levels can serve as a tumor marker for monitoring the status of differentiated thyroid carcinomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Thyrotropin Alfa</VALIDVALUE>
          <VALUEMEANING>Recombinant Thyrotropin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A form of thyroid-stimulating hormone (TSH) that is made in the laboratory. It is used to test for remaining or recurring cancer cells in patients who have been treated for thyroid cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Transforming Growth Factor-Beta</VALIDVALUE>
          <VALUEMEANING>Recombinant Transforming Growth Factor-Beta</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine transforming growth factor-beta (TGF-beta) with proapoptotic and antineoplastic properties. TGF-beta may suppress tumor cell growth by decreasing the expression of cyclin D1, a cell cycle regulatory protein, and downregulating the expression of the oncogene c-myc. This agent is also involved in T cell-mediated immunosuppression by CD4+CD25+ T cells, which permits cancer cells to evade immune surveillance. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Transforming Growth Factor-Beta-2</VALIDVALUE>
          <VALUEMEANING>Recombinant Transforming Growth Factor-Beta-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant polypeptide chemically identical to or similar to the endogenous cytokine transforming growth factor-beta-2 (TGF-beta-2). TGF-beta-2 modulates cell growth and immune function and may promote or inhibit tumor growth, depending on the tumor cell type. TGF-beta-2 may also suppress host immune system recognition of and/or response to tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Tumor Necrosis Factor-Alpha</VALIDVALUE>
          <VALUEMEANING>Recombinant Tumor Necrosis Factor-Alpha</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-alpha with antineoplastic properties.  Tumor necrosis factor-alpha binds to and activates &quot;death receptors&quot; on the cell surface, resulting in apoptosis and cell death by the p53-independent extrinsic pathway. This agent also disrupts tumor vascularization. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Tyrosinase-Related Protein-2</VALIDVALUE>
          <VALUEMEANING>Recombinant Tyrosinase-Related Protein-2</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to an endogenous non-mutated melanocyte differentiation antigen expressed by both normal and malignant melanocytes. Vaccinations with recombinant tyrosinase-related protein-2 may elicit an antitumoral cytotoxic T-cell response against tumor cells and some normal cells that express tyrosinase-related protein-2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Super-compound Interferon</VALIDVALUE>
          <VALUEMEANING>Recombinant Super-compound Interferon</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes less side effects compared to IFN-a.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter</VALIDVALUE>
          <VALUEMEANING>Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, replication competent form of the oncolytic RNA virus vesicular stomatitis virus (VSV), based on the Indiana strain of VSV, that is genetically engineered to express the genes for the human cytokine interferon beta (IFNbeta) and the human thyroidal sodium-iodide symporter (NIS), with potential oncolytic and imaging activities. Upon intravenous administration, VSV-hIFNbeta-NIS is preferentially taken up by tumor cells, resulting in tumor cell infection, viral replication and a direct virus-mediated cytolytic effect against the infected tumor cells. IFN-mediated signaling is defective in tumor cells and tumor cells are unable to exert an anti-viral response against VSV. As normal, healthy cells secrete and respond normally to IFNbeta and are able to activate IFN-mediated anti-viral pathways, the expressed IFNbeta from the VSV-infected tumor cells helps protect normal cells from VSV infection. Upon subsequent administration of certain isotope-containing imaging agents, NIS expression by the infected tumor cells allows visualization and tracking of VSV biodistribution, and analysis and quantification of VSV-infected tumor cells by positron emission tomography (PET). Also, upon subsequent administration of the radioisotope iodine I 131 (I131), I131 can be taken up by NIS and allows for a cytotoxic dose of radiation to accumulate in the NIS-expressing VSV-infected tumor cells, which also leads to tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Redaporfin</VALIDVALUE>
          <VALUEMEANING>Redaporfin</VALUEMEANING>
          <MEANINGDESCRIPTION>A bacteriochlorin-based photosensitizer, with antineoplastic activity upon photodynamic therapy (PDT). Following intravenous administration, redaporfin preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of laser light at the tumor site results in the absorption of light by this agent and a photodynamic reaction between LUZ 11 and oxygen. This results in the production of reactive oxygen species (ROS), which includes singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated DNA damage and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refametinib</VALIDVALUE>
          <VALUEMEANING>Refametinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regorafenib</VALIDVALUE>
          <VALUEMEANING>Regorafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3729312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relatlimab</VALIDVALUE>
          <VALUEMEANING>Relatlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111999</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relugolix</VALIDVALUE>
          <VALUEMEANING>Relugolix</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Remetinostat</VALIDVALUE>
          <VALUEMEANING>Remetinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal Cell Carcinoma Peptides Vaccine IMA901</VALIDVALUE>
          <VALUEMEANING>Renal Cell Carcinoma Peptides Vaccine IMA901</VALUEMEANING>
          <MEANINGDESCRIPTION>A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reparixin</VALIDVALUE>
          <VALUEMEANING>Reparixin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relacorilant</VALIDVALUE>
          <VALUEMEANING>Relacorilant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration,  relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Repotrectinib</VALIDVALUE>
          <VALUEMEANING>Repotrectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resiquimod</VALIDVALUE>
          <VALUEMEANING>Resiquimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of other transcription factors. This may lead to an increase in mRNA levels and subsequent production of cytokines, especially interferon-alpha (INF-a) and other cytokines, thereby enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans&#39; cells, leading to an enhanced activation of T-lymphocytes. Due to its immunostimulatory activity, this agent may potentially be useful as a vaccine adjuvant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resiquimod Topical Gel</VALIDVALUE>
          <VALUEMEANING>Resiquimod Topical Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical gel containing the Toll-like receptor (TLR) agonist resiquimod, an imidazoquinolinamine and with potential immunomodulating activity. Resiquimod binds toTLR7 and 8, mainly on dendritic cells, macrophages, and B-lymphocytes, and activates the TLR signaling pathway, resulting in the induction of the nuclear translocation of transcription activator NF-kB and activation of other transcription factors; subsequently, gene expression increases and the production of cytokines increases, especially interferon-alpha (INF-a), resulting in the enhancement of T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to an enhanced activation of T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resistant Starch</VALIDVALUE>
          <VALUEMEANING>Resistant Starch</VALUEMEANING>
          <MEANINGDESCRIPTION>A form of dietary fiber that resists degradation by gastrointestinal (GI) enzymes in the small intestine with potential chemopreventive and prebiotic activity. Upon consumption of resistant starch, the fiber is not metabolized or absorbed in the small intestine and enters the colon unaltered. Once in the colon, the starch is fermented by anaerobic colonic bacteria and produces short-chain fatty acids (SCFA), including butyrate, which has anti-inflammatory and immunoregulatory activities. In addition, butyrate appears to exert antitumor effects by inhibiting tumor cell proliferation, inducing tumor cell differentiation and promoting apoptosis in colorectal cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resminostat</VALIDVALUE>
          <VALUEMEANING>Resminostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resveratrol</VALIDVALUE>
          <VALUEMEANING>Resveratrol</VALUEMEANING>
          <MEANINGDESCRIPTION>A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resveratrol Formulation SRT501</VALIDVALUE>
          <VALUEMEANING>Resveratrol Formulation SRT501</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary formulation of resveratrol, a polyphenolic phytoalexin derived from grapes and other food products with potential antioxidant, anti-obesity, antidiabetic and chemopreventive activities. Resveratrol may activate sirtuin subtype 1 (SIRT-1). SIRT1 activation has been reported to inhibit tumorigenesis and tumor cell proliferation. SIRT-1 is a member of the silent information regulator 2 (SIR2) (or sirtuin) family of enzymes that plays an important role in mitochondrial activity and acts as a protein deacetylase. SIRT1 appears to be involved in the regulation of numerous transcription factors such as NF-kB and p53.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RET/SRC Inhibitor TPX-0046</VALIDVALUE>
          <VALUEMEANING>RET/SRC Inhibitor TPX-0046</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective dual inhibitor of fusions and mutations involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (ret) and the src family tyrosine kinases, with potential antineoplastic activity. Upon oral administration, the RET/SRC inhibitor TPX-0046 specifically targets and binds to ret mutants and ret-containing fusion products. This results in an inhibition of cell growth of tumor cells that exhibit increased ret activity. By inhibiting src kinase-mediated signaling and reducing the src-initiated recruitment of multiple receptor tyrosine kinases involved in bypass resistance, TPX-0046 may be able to overcome tumor resistance which may increase its therapeutic effect. Ret overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of ret tyrosine kinase activity in various cancer cell types; dysregulation of ret activity plays a key role in the development and progression of these cancers. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis. Src upregulation is seen in tumors with acquired resistance to RET inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retaspimycin</VALIDVALUE>
          <VALUEMEANING>Retaspimycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retelliptine</VALIDVALUE>
          <VALUEMEANING>Retelliptine</VALUEMEANING>
          <MEANINGDESCRIPTION>An ellipticine derivative and topoisomerase II inhibitor with antineoplastic activity. Retelliptine intercalates with DNA and inhibits topoisomerase II during DNA replication. In addition, this agent appears to induce cell cycle arrest at G2/M phase and apoptosis mediated through the Fas/Fas ligand death receptor and the mitochondrial pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73241</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retifanlimab</VALIDVALUE>
          <VALUEMEANING>Retifanlimab (Zynyz)</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13314837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinoic Acid Agent Ro 16-9100</VALIDVALUE>
          <VALUEMEANING>Retinoic Acid Agent Ro 16-9100</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, Ro 16-9100 binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinoid 9cUAB30</VALIDVALUE>
          <VALUEMEANING>Retinoid 9cUAB30</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic analogue of 9-cis retinoic acid with potential antineoplastic and chemopreventive activities. Retinoid 9cUAB30 binds to and activates retinoid X receptor (RXR) homodimers and/or and retinoic acid receptor (RAR)/RXR heterodimers, which may result in the dissociation of corepressor protein and the recruitment of coactivator protein, followed by transcription of downstream target genes into mRNAs and protein translation. Gene transcription regulated by these transcription factors may result in inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinol</VALIDVALUE>
          <VALUEMEANING>Retinol</VALUEMEANING>
          <MEANINGDESCRIPTION>The fat soluble vitamin retinol. Vitamin A binds to and activates retinoid receptors (RARs), thereby inducing cell differentiation and apoptosis of some cancer cell types and inhibiting carcinogenesis. Vitamin A plays an essential role in many physiologic processes, including proper functioning of the retina, growth and differentiation of target tissues, proper functioning of the reproductive organs, and modulation of immune function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68302</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retaspimycin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Retaspimycin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinyl Acetate</VALIDVALUE>
          <VALUEMEANING>Retinyl Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retinyl Palmitate</VALIDVALUE>
          <VALUEMEANING>Retinyl Palmitate</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring phenyl analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retrovector Encoding Mutant Anti-Cyclin G1</VALIDVALUE>
          <VALUEMEANING>Retrovector Encoding Mutant Anti-Cyclin G1</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Revdofilimab</VALIDVALUE>
          <VALUEMEANING>Revdofilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rezivertinib</VALIDVALUE>
          <VALUEMEANING>Rezivertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RFT5-dgA Immunotoxin IMTOX25</VALIDVALUE>
          <VALUEMEANING>RFT5-dgA Immunotoxin IMTOX25</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant immunotoxin consisting of the anti-CD25 monoclonal antibody RFT5 fused to the deglycosylated ricin A-chain (dgA) with potential antitumor activity.  The monoclonal antibody moiety of RFT5-dgA immunotoxin attaches to CD25 (the alpha chain of the IL-2 receptor complex) on the cell membrane; after internalization, the dgA moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death.  CD25 is expressed on activated normal T and B cells and macrophages and is frequently upregulated in many hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhenium Re 188 BMEDA-labeled Liposomes</VALIDVALUE>
          <VALUEMEANING>Rhenium Re 188 BMEDA-labeled Liposomes</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposome-based preparation consisting of the beta- and gamma-emitting radionuclide rhenium Re 188 (Re 188) linked to the chelator N,N-bis (2-mercaptoethyl)-N&#39;,N&#39;-diethylethylenediamine (BMEDA) and encapsulated in liposomes, with potential tumor imaging and antineoplastic activities. Upon intravenous infusion of rhenium Re 188 BMEDA-labeled liposomes, the liposomes selectively target tumor cells, facilitate the retention of the radioisotope by those cells, and cause localized antitumor radiocytotoxicity while sparing surrounding normal, healthy cells. In addition, Re 188 BMEDA-labeled liposomes can be used for imaging purposes. Re 188 has a short half-life and a short path length, which further contribute to limiting the radiotoxicity to the tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhenium Re-188 Ethiodized Oil</VALIDVALUE>
          <VALUEMEANING>Rhenium Re-188 Ethiodized Oil</VALUEMEANING>
          <MEANINGDESCRIPTION>A rhenium (Re) 188 conjugate of ethiodized oil (lipiodol), an iodinated ethyl ester derived from poppy seed oil, with potential antineoplastic activity. Upon hepatic intra-arterial injection rhenium Re 188 ethiodized oil accumulates in hepatocellular carcinoma (HCC) tumor cells, thereby delivering a cytotoxic dose of radiation through Re 188 directly to the tumor cells. This may kill tumor cells while sparing surrounding normal cells and tissues. Compared to iodine I 131, Re 188 has a shorter half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhenium Re-188 Etidronate</VALIDVALUE>
          <VALUEMEANING>Rhenium Re-188 Etidronate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rexinoid NRX 194204</VALIDVALUE>
          <VALUEMEANING>Rexinoid NRX 194204</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic and anti-inflammatory activities. Rexinoid NRX 194204 selectively binds to and activates RXRs. Because RXRs can form heterodimers with several nuclear receptors (NRs), RXR activation by this agent may result in a broad range of gene expression depending on the effector DNA response elements activated. Rexinoid NRX 194204 may inhibit the tumor-necrosis factor (TNF)-mediated release of nitric oxide (NO) and interleukin 6 (IL6) and may inhibit tumor cell proliferation. This agent appears to be less toxic than RAR-selective ligands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhizoxin</VALIDVALUE>
          <VALUEMEANING>Rhizoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribociclib</VALIDVALUE>
          <VALUEMEANING>Ribociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6072178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribociclib/Letrozole</VALIDVALUE>
          <VALUEMEANING>Ribociclib/Letrozole</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available co-packaged agent combination of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154675</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribonuclease QBI-139</VALIDVALUE>
          <VALUEMEANING>Ribonuclease QBI-139</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclease of mammalian origin that cleaves the phosphodiester bond between nucleotides of ribonucleic acids with potential antineoplastic activity. Ribonuclease QBI-139 catalyzes the hydrolysis and degradation of RNA leading to the inhibition of protein synthesis and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82689</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribozyme RPI.4610</VALIDVALUE>
          <VALUEMEANING>Ribozyme RPI.4610</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically recognizes the mRNA for FLT1 (vascular endothelial growth factor receptor 1; VEGFR1), and hydrolyzes the mRNA, thereby preventing VEGFR1 proteins from being made. This may prevent VEGF-stimulated angiogenesis in cancerous tissue and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rice Bran</VALIDVALUE>
          <VALUEMEANING>Rice Bran</VALUEMEANING>
          <MEANINGDESCRIPTION>The nutrient-rich hard outer layer of the rice cereal grain, with potential chemopreventive, antioxidant, iron chelating, anticholesterol and anti-inflammatory activities. Rice bran is rich in fiber, such as beta-glucan, pectin and gum; it also comprises vitamins and minerals, such as iron, magnesium and phosphorus, and essential fatty acids. In addition, Rice bran contains various bioactive components, including ferulic acid, tricin, beta-sitosterol, gamma-oryzanol, phytic acid, and inositol hexaphosphate (IP6). The potential anticancer activity of rice bran may be due to the synergistic effects of these phytochemicals on their ability to induce apoptosis, inhibit cell proliferation, and alter cell cycle progression in cancer cells. Rice bran&#39;s bioactive components also protect against tissue damage by scavenging free radicals and blocking chronic inflammatory responses. In addition, they are able to modulate the gut microflora and carcinogen-metabolizing enzymes, thereby further exerting a chemopreventive effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ricolinostat</VALIDVALUE>
          <VALUEMEANING>Ricolinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ridaforolimus</VALIDVALUE>
          <VALUEMEANING>Ridaforolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rilimogene Galvacirepvec</VALIDVALUE>
          <VALUEMEANING>Rilimogene Galvacirepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rilimogene Galvacirepvec/Rilimogene Glafolivec</VALIDVALUE>
          <VALUEMEANING>Rilimogene Galvacirepvec/Rilimogene Glafolivec</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7405923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rilimogene Glafolivec</VALIDVALUE>
          <VALUEMEANING>Rilimogene Glafolivec</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8024222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rilotumumab</VALIDVALUE>
          <VALUEMEANING>Rilotumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rindopepimut</VALIDVALUE>
          <VALUEMEANING>Rindopepimut</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with anti-EGFRvIII vaccine CDX-110 may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ripertamab</VALIDVALUE>
          <VALUEMEANING>Ripertamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rigosertib Sodium</VALIDVALUE>
          <VALUEMEANING>Polo-like kinase 1 Inhibitor ON 01910.Na</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like kinase1 (Plk1), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RIPK1 Inhibitor GSK3145095</VALIDVALUE>
          <VALUEMEANING>RIPK1 Inhibitor GSK3145095</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential antineoplastic and immunomodulatory activities.  Upon administration, GSK3145095 disrupts RIPK1-mediated signaling, which may reduce C-X-C motif chemokine ligand 1 (CXCL1)-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. RIPK1, a serine-threonine kinase that normally plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition, is overexpressed in certain cancer types and may be associated with oncogenesis and promotion of the immunosuppressive nature of the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ripretinib</VALIDVALUE>
          <VALUEMEANING>Ripretinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7685537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Risperidone Formulation in Rumenic Acid</VALIDVALUE>
          <VALUEMEANING>Risperidone Formulation in Rumenic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable capsule formulation containing the antipsychotic agent risperidone suspended in the lipid rumenic acid, with potential antineoplastic activity. Upon administration of VAL401, risperidone may, through an as of yet not elucidated mechanism of action, reduce cellular activity and tumor cell proliferation in multiple cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ritrosulfan</VALIDVALUE>
          <VALUEMEANING>Ritrosulfan</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfonate-based alkylation agent with potential antineoplastic activity. Ritrosulfan appears to alkylate DNA, thereby producing DNA crosslinks, resulting in cell cycle arrest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728684</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rituximab</VALIDVALUE>
          <VALUEMEANING>Anti-CD20 (Rituximab)</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5678505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rituximab Conjugate CON-4619</VALIDVALUE>
          <VALUEMEANING>Rituximab Conjugate CON-4619</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Riviciclib</VALIDVALUE>
          <VALUEMEANING>Riviciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rivoceranib Mesylate</VALIDVALUE>
          <VALUEMEANING>Rivoceranib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74012</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNR Inhibitor COH29</VALIDVALUE>
          <VALUEMEANING>RNR Inhibitor COH29</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis. RNR, an enzyme that catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, is essential for de novo DNA synthesis and plays an important role in cell growth; it is overexpressed in many cancer cell types and is associated with increased drug resistance, cancer cell growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rituximab and Hyaluronidase Human</VALIDVALUE>
          <VALUEMEANING>Rituximab and Hyaluronidase Human</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Robatumumab</VALIDVALUE>
          <VALUEMEANING>Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2958646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roblitinib</VALIDVALUE>
          <VALUEMEANING>Roblitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ROBO1-targeted BiCAR-NKT Cells</VALIDVALUE>
          <VALUEMEANING>ROBO1-targeted BiCAR-NKT Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of natural killer T (NKT) cells engineered to express a chimeric antigen receptor (CAR) specific for roundabout homolog 1 (ROBO1, Robo1), with potential immunostimulating and antineoplastic activities. Upon administration, the ROBO1-targeted BiCAR-NK/T cells target and bind to ROBO1 expressed on the surface of tumor cells. This induces selective toxicity in ROBO1-expressing tumor cells. ROBO1, a member of the axon guidance receptor family, is often overexpressed in a variety of tumor types. It is involved in axon guidance, cell proliferation, cell motility and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rocakinogene Sifuplasmid</VALIDVALUE>
          <VALUEMEANING>Rocakinogene Sifuplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rocapuldencel-T</VALIDVALUE>
          <VALUEMEANING>Rocapuldencel-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine in which autologous dendritic cells are transfected with patient-specific renal cell carcinoma (RCC) RNA and a synthetic, truncated human CD40 ligand (CD40L) RNA with potential immunostimulatory and antineoplastic activities. Individual RCC-specific RNA, encoding a unique repertoire of tumor-associated antigens (TAAs) (including telomerase reverse transcriptase, G250, and oncofetal antigen) is electroporated into autologous dendritic cells (DCs), transfected with synthetic RNA that encodes a truncated version of the T-cell protein CD40L; the transfected autologous DCs express and process both patient-specific RCC TAAs and the truncated CD40L protein. When reintroduced back to the patient, rocapuldencel-T may elicit a highly specific cytotoxic T-cell (CTL) response against RCC cells expressing the patient-specific RCC TAA repertoire. The signal cascade initiated by stimulation of the truncated, ectopically expressed co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12 downstream.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rociletinib</VALIDVALUE>
          <VALUEMEANING>Rociletinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6084997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rodorubicin</VALIDVALUE>
          <VALUEMEANING>Rodorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tetraglycosidic anthracycline antibiotic with antineoplastic activity. Rodorubicin appears to intercalate DNA and causes cell death. Due to its severe cardiotoxic effects, this agent was never marketed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roducitabine</VALIDVALUE>
          <VALUEMEANING>Roducitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rofecoxib</VALIDVALUE>
          <VALUEMEANING>Rofecoxib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7063354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rogaratinib</VALIDVALUE>
          <VALUEMEANING>Rogaratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Rogaratinib inhibits the activities of FGFRs, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rogletimide</VALIDVALUE>
          <VALUEMEANING>Rogletimide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a cytochrome P450 family enzyme found in many tissues and the key enzyme in the oxidative aromatization process of androgens to estrogens. In estrogen-dependent cancers, the inhibition of aromatase by this agent leads to a reduction in the synthesis of estrogen, thereby inhibiting estrogen-mediated signal transduction and consequently reducing tumor cell growth. In addition, rogletimide also inhibits enzymes that catalyzing conversion of cholesterol to corticosteroids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rolinsatamab Talirine</VALIDVALUE>
          <VALUEMEANING>Rolinsatamab Talirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against the prolactin receptor (PRLR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of rolinsatamab talirine, rolinsatamab targets and binds to PRLR expressed on tumor cells. Upon binding and internalization, talirine is released and kills the PRLR-expressing tumor cells, through an as of yet unknown mechanism of action. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Romidepsin</VALIDVALUE>
          <VALUEMEANING>Romidepsin</VALUEMEANING>
          <MEANINGDESCRIPTION>A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5342172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roneparstat</VALIDVALUE>
          <VALUEMEANING>Roneparstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An N-acetylated, glycol-split form of heparin that is devoid of anticoagulant activity and is an inhibitor of heparanase with antineoplastic and antiangiogenic activities. Upon subcutaneous administration, roneparstat inhibits the activity of heparanase. This prevents the heparanase-mediated cleavage of heparan sulfate (HS) proteoglycans on cell surfaces and within the extracellular matrix. In addition, this agent prevents the heparanase-induced production of a number of angiogenic growth factors, including matrix metalloproteinase-9, hepatocyte growth factor and vascular endothelial growth factor. Altogether, this leads to an inhibition of both tumor cell growth and angiogenesis. Heparanase, an enzyme that is responsible for the proteolytic cleavage of proteoglycans, is upregulated in a variety of tumor cell types and promotes tumor cell growth; it plays a key role in tumor cell invasion, metastasis and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roflumilast</VALIDVALUE>
          <VALUEMEANING>Roflumilast</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3&#39;,5&#39;-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3&#39;,5&#39;-cyclic guanosine monophosphate (cGMP) to their inactive 5&#39; monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roniciclib</VALIDVALUE>
          <VALUEMEANING>Roniciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ropeginterferon Alfa-2B</VALIDVALUE>
          <VALUEMEANING>Ropeginterferon Alfa-2B</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ropidoxuridine</VALIDVALUE>
          <VALUEMEANING>Ropidoxuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available thymidine analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Ropidoxuridine is efficiently converted to IUdR by a hepatic aldehyde oxidase. IUdR is incorporated into DNA during replication and sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4892033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ropocamptide</VALIDVALUE>
          <VALUEMEANING>Ropocamptide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rosabulin</VALIDVALUE>
          <VALUEMEANING>Rosabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule vascular disrupting agent, with potential antimitotic and antineoplastic activities. Rosabulin binds to tubulin in a similar manner as colchicine and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest and blockage of cell division. By destroying proliferating vascular cells, blood flow to the tumor is reduced and eventually leads to a decrease in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rose Bengal Solution PV-10</VALIDVALUE>
          <VALUEMEANING>Rose Bengal Solution PV-10</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rosiglitazone Maleate</VALIDVALUE>
          <VALUEMEANING>Rosiglitazone Maleate</VALUEMEANING>
          <MEANINGDESCRIPTION>The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.  Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rosmantuzumab</VALIDVALUE>
          <VALUEMEANING>Rosmantuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rosmantuzumab targets and binds to RSPO3 expressed on tumor cells. This prevents the activation of RSPO3, and inhibits both the binding of RSPO3 to leucine-rich repeat-containing G-coupled receptors (LGRs) and the activation of the RSPO-LGR pathway. This may result in an inhibition of both cancer stem cell (CSC) survival and the proliferation of cancer cells in which this pathway is overactivated. The RSPO-LGR pathway is a CSC pathway activated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rosopatamab</VALIDVALUE>
          <VALUEMEANING>Rosopatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Rosopatamab was generated by replacing murine Ig sequences with human ones, thereby MoAb huJ591can be administered to patients on multiple occasions over long time periods without inducing an immune response. Radiolabelled MoAb huJ591 may be used in immunotherapy of prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Roquinimex</VALIDVALUE>
          <VALUEMEANING>Roquinimex</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinoline-3-carboxamide with potential antineoplastic activity.  Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis.  This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rucaparib Phosphate</VALIDVALUE>
          <VALUEMEANING>Rucaparib Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>A tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP1 catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78186</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4273832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruthenium Ru-106</VALIDVALUE>
          <VALUEMEANING>Ruthenium Ru-106</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioactive isotope of the rare element ruthenium, a member of the light platinum group. A radioactive plaque containing ruthenium 106 may be inserted into the eye to irradiate ophthalmic tumors. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruthenium-based Small Molecule Therapeutic BOLD-100</VALIDVALUE>
          <VALUEMEANING>Ruthenium-based Small Molecule Therapeutic BOLD-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A ruthenium-based, small molecule that selectively inhibits stress-induced upregulation of GRP78, with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, BOLD-100 may selectively inhibit stress-induced upregulation of GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking GRP78-induced suppression of apoptotic pathways. This may lead to the induction of tumor cell apoptosis and slow tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types. Its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruthenium-based Transferrin Targeting Agent NKP-1339</VALIDVALUE>
          <VALUEMEANING>Ruthenium-based Transferrin Targeting Agent NKP-1339</VALUEMEANING>
          <MEANINGDESCRIPTION>A ruthenium-containing cancer agent targeting transferrin with potential antineoplastic activity. Upon intravenous administration, NKP-1339 (Ru3+) binds to transferrin (Tf) and is taken up via Tf receptors (TfR), which are overexpressed on cancer cells. Once inside the cell, NKP-1339 is released from Tf and is reduced, within the acidic environment of the endosomes, to its active form NKP-119 (Ru2+). In turn, the active form induces a redox reaction, thereby leading to the formation of reactive oxygen species (ROS) which inhibits GRP78 and SOD, endoplasmic reticulum-stress modulating molecules as well as BAG4 and ERK, program cell death regulating molecules. This eventually induces caspase-dependent apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rosuvastatin</VALIDVALUE>
          <VALUEMEANING>Rosuvastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rovalpituzumab Tesirine</VALIDVALUE>
          <VALUEMEANING>Rovalpituzumab Tesirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RSK1-4 Inhibitor PMD-026</VALIDVALUE>
          <VALUEMEANING>RSK1-4 Inhibitor PMD-026</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2 (RSK2), with potential antineoplastic activity. Upon administration of the RSK1-4 inhibitor PMD-026, this agent targets and inhibits the RSK subtypes, thereby inhibiting RSK-mediated signaling. This prevents the phosphorylation and activation of the transcription factor Y-box binding protein-1 (YB-1) and leads to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in RSK-expressing tumor cells. RSK is overexpressed in a variety of cancers, especially in triple negative breast cancer (TNBC). It plays a key role in tumor cell proliferation, differentiation, survival, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rubitecan</VALIDVALUE>
          <VALUEMEANING>Rubitecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rucaparib</VALIDVALUE>
          <VALUEMEANING>Rucaparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rucaparib Camsylate</VALIDVALUE>
          <VALUEMEANING>Rucaparib Camsylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruxolitinib</VALIDVALUE>
          <VALUEMEANING>Ruxolitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5125106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruxolitinib Phosphate</VALIDVALUE>
          <VALUEMEANING>Ruxolitinib Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ruxotemitide</VALIDVALUE>
          <VALUEMEANING>Ruxotemitide</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor. Human lactoferrin, a 692 amino acid glycoprotein, belongs to the transferrin family of metal-binding proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sabarubicin</VALIDVALUE>
          <VALUEMEANING>Sabarubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A disaccharide analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Sabarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces apoptosis through a p53-independent mechanism.  Sabarubicin is less cardiotoxic than doxorubicin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sabatolimab</VALIDVALUE>
          <VALUEMEANING>Sabatolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S-Adenosylmethionine</VALIDVALUE>
          <VALUEMEANING>S-Adenosylmethionine</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement that is synthesized from adenosine triphosphate (ATP) and the amino acid methionine by the endogenous essential enzyme methionine adenosyltransferase (MAT), with potential antineoplastic activity.  Upon administration, S-adenosylmethionine acts as a methyl donor for various transmethylation reactions. In cancer cells, this agent induces the methylation of tumor promoting genes, reverses DNA hypomethylation, and leads to the suppression of oncogene transcription. This induces apoptosis in and inhibits proliferation of susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Safingol</VALIDVALUE>
          <VALUEMEANING>Safingol</VALUEMEANING>
          <MEANINGDESCRIPTION>A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sagopilone</VALIDVALUE>
          <VALUEMEANING>Sagopilone</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully synthetic low-molecular-weight epothilone with potential antineoplastic activity. Sagopilone binds to tubulin and induces microtubule polymerization while stabilizing microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. The agent is not a substrate for the P-glycoprotein (P-gp) efflux pump and so may exhibit activity in multidrug-resistant (MDR) tumors. The epothilone class of metabolites was originally isolated from the myxobacterium Solangium cellulosum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salirasib</VALIDVALUE>
          <VALUEMEANING>Salirasib</VALUEMEANING>
          <MEANINGDESCRIPTION>A salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71146</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sacituzumab Govitecan</VALIDVALUE>
          <VALUEMEANING>Sacituzumab govitecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7651581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salmonella VNP20009</VALIDVALUE>
          <VALUEMEANING>Salmonella VNP20009</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sam68 Modulator CWP232291</VALIDVALUE>
          <VALUEMEANING>Sam68 Modulator CWP232291</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and prodrug of CWP232204 targeting Src associated in mitosis, of 68 kDa (Sam68 or KHDRBS1), with potential antineoplastic activity. CWP232291 is converted in serum into its active form CWP232204 which binds to Sam68, thereby resulting in the induction of apoptosis in selective cancer cells. Due to the multimodular structure of Sam68, the apoptosis mediated by CWP232204-Sam68 interaction can attribute from 1) activation of transcription factor NF-kB induced by tumor necrosis factor alpha signaling, 2) alternative splicing of BCL-2 apoptosis gene, driving the balance towards pro-apoptotic as opposed to anti-apoptotic isoforms, 3) down-regulation of the anti-apoptotic protein survivin via Wnt signaling. Sam68, a KH domain RNA-binding protein belonging to the signal transduction and activation of RNA (STAR) family, plays a key role in various cellular processes including cell cycle progression and apoptosis; it is upregulated in many types of cancer cells and its expression is associated with increased cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samalizumab</VALIDVALUE>
          <VALUEMEANING>Samalizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Samalizumab binds to CD200, blocking the binding of CD200 to its receptor, CD200R, present on cells of the macrophage lineage; inhibition of CD200 may augment the cytotoxic T-lymphocyte (CTL) mediated immune response against CD200-expressing tumor cells.  CD200 is a type 1a transmembrane protein, related to the B7 family of co-stimulatory receptors, and is upregulated on the surface of multiple hematologic malignant cells; this transmembrane protein appears to be involved in the downregulation of a Th1 (helper T cell) immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samarium Sm 153-DOTMP</VALIDVALUE>
          <VALUEMEANING>Samarium Sm 153-DOTMP</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of the phosphonic acid chelator DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid) conjugated to the beta- and gamma-emitting radioisotope samarium Sm 153, with potential antineoplastic activity. Upon administration of samarium Sm 153-DOTMP, the DOTMP moiety targets and binds to growing bone, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to bone tumor and metastases, which may help destroy bone metastases and mitigate pain from bone metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samrotamab Vedotin</VALIDVALUE>
          <VALUEMEANING>Samrotamab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-085 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7431041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samuraciclib</VALIDVALUE>
          <VALUEMEANING>Samuraciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sapacitabine</VALIDVALUE>
          <VALUEMEANING>Sapacitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the deoxycytosine analogue CNDAC (2&#39;-Cyano-2&#39;-deoxyarabinofuranosylcytosine), which is then phosphorylated into the active triphosphate form. As an analogue of deoxycytidine triphosphate, CNDAC triphosphate incorporates into DNA strands during replication, resulting in single-stranded DNA breaks during polymerization due to beta-elimination during the fidelity checkpoint process; cell cycle arrest in the G2 phase and apoptosis ensue. The unmetabolized prodrug may exhibit antineoplastic activity as well.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sapanisertib</VALIDVALUE>
          <VALUEMEANING>Sapanisertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Sapanisertib binds to and inhibits both TORC1 and TORC2 complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sapitinib</VALIDVALUE>
          <VALUEMEANING>Sapitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. erbB kinase inhibitor AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. The erbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samotolisib</VALIDVALUE>
          <VALUEMEANING>Samotolisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Saracatinib</VALIDVALUE>
          <VALUEMEANING>Saracatinib (AZD0530)</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Saracatinib Difumarate</VALIDVALUE>
          <VALUEMEANING>Saracatinib Difumarate</VALUEMEANING>
          <MEANINGDESCRIPTION>The difumarate salt of saracatinib, an orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SarCNU</VALIDVALUE>
          <VALUEMEANING>SarCNU</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C963</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sardomozide</VALIDVALUE>
          <VALUEMEANING>Sardomozide</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylglyoxal-bis(guanylhydrazone) (MGBG) derivative with potential antineoplastic and antiviral properties. Sardomozide selectively binds to and inhibits S-adenosylmethionine decarboxylase (SAMDC), an enzyme essential for the biosynthesis of polyamines, such as spermine and spermidine that bind to DNA and play critical roles in cell division, cell differentiation and membrane function. By inhibiting SAMDC, sardomozide reduces the intracellular polyamine concentration, thereby interfering with cell growth and differentiation. In addition, this agent also exhibits anti-HIV effect via suppressing expression of eukaryotic translation initiation factor 5A (eIF-5A), which is essential for retroviral replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sasanlimab</VALIDVALUE>
          <VALUEMEANING>Sasanlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Satraplatin</VALIDVALUE>
          <VALUEMEANING>Satraplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Savolitinib</VALIDVALUE>
          <VALUEMEANING>Volitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SBIL-2</VALIDVALUE>
          <VALUEMEANING>SBIL-2</VALUEMEANING>
          <MEANINGDESCRIPTION>An retroviral vector encoding human IL-2 with potential antineoplastic property. SBIL-2 (Surgery Branch IL-2) can be used to transfect tumor infiltrating lymphocytes, which can then be re-introduced back to cancer patients, thereby stimulate T cell activation and immunopotentiation responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scopoletin</VALIDVALUE>
          <VALUEMEANING>Scopoletin</VALUEMEANING>
          <MEANINGDESCRIPTION>A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5200035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SDF-1 Receptor Antagonist PTX-9908</VALIDVALUE>
          <VALUEMEANING>SDF-1 Receptor Antagonist PTX-9908</VALUEMEANING>
          <MEANINGDESCRIPTION>A stromal cell-derived factor 1 (SDF-1; CXCL12) analog and inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, PTX-9908 selectively targets and binds to CXCR4, thereby preventing the binding of CXCR4 to its ligand SDF-1. This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. The G protein-coupled receptor CXCR4, which is overexpressed in several tumor cell types, promotes tumor angiogenesis, tumor cell proliferation, survival, invasion and metastasis. SDF-1, a major chemotactic factor, plays a key role in mediating cell trafficking via selective binding to CXCR4.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sargramostim</VALIDVALUE>
          <VALUEMEANING>Sargramostim</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seclidemstat</VALIDVALUE>
          <VALUEMEANING>Seclidemstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sedoxantrone Trihydrochloride</VALIDVALUE>
          <VALUEMEANING>Sedoxantrone Trihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Sedoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selatinib Ditosilate</VALIDVALUE>
          <VALUEMEANING>Selatinib Ditosilate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Cytokine Inhibitory Drug CC-1088</VALIDVALUE>
          <VALUEMEANING>Selective Cytokine Inhibitory Drug CC-1088</VALUEMEANING>
          <MEANINGDESCRIPTION>An analog of thalidomide with potential antineoplastic activity that belongs to the functional class of agents called selective cytokine inhibitory drugs (SelCIDs).  SelCIDs inhibit phosphodiesterase-4 (PDE 4), an enzyme involved in tumor necrosis factor alpha (TNF alpha) production.  CC-1088 inhibits production of the cytokines vascular endothelial growth factor (VEGF) (a pro-angiogenic factor) and interleukin-6 (IL-6). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Degrader LSZ102</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Degrader LSZ102</VALUEMEANING>
          <MEANINGDESCRIPTION>An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Degrader LX-039</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Degrader LX-039</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD LX-039 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Degrader SRN-927</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Degrader SRN-927</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Modulator CC-8490</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Modulator CC-8490</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzopyran with potential antineoplastic activity.  CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.  This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Modulator TAS-108</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Modulator TAS-108</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, antiestrogenic steroidal compound with potential antitumor activity. TAS-108 binds to and inhibits estrogenic receptor alpha (ERa), mainly expressed in the mammary gland and uterus and upregulated in estrogen-dependent tumors. Blockage of ERa by TAS-108 prevents the binding and effects of estrogen and may lead to an inhibition of estrogen-dependent cancer cell proliferation. TAS-108 also is a partial agonist of the estrogenic receptor beta (ERb), expressed in many tissues including the central nervous system, urogenital tract, bone and cardiovascular system, thereby exerting a positive effect on these tissues. In addition, TAS-108 activates the co-repressor Silencing Mediator for Retinoid and Thyroid hormone receptor (SMRT), a protein that inhibits the activities of the estrogen receptors, which may contribute to the antitumor activity of TAS-108.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Degrader AZD9496</VALIDVALUE>
          <VALUEMEANING>Selective Estrogen Receptor Degrader AZD9496</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352</VALIDVALUE>
          <VALUEMEANING>Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seliciclib</VALIDVALUE>
          <VALUEMEANING>Seliciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Seliciclib primarily inhibits CDK 2, 7, and 9 by competing for the ATP binding sites on these kinases, leading to a disruption of cell cycle progression. In addition, this agent seems to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, thereby inhibiting RNA polymerase II-dependent transcription. This may lead to the down-regulation of anti-apoptotic factors, such as myeloid cell leukemia sequence 1 (Mcl-1), a protein crucial for the survival of a range of tumor cell types. The down-regulation of anti-apoptotic factors may lead to an induction of apoptosis, thereby further contributing to seliciclib&#39;s antiproliferative effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selicrelumab</VALIDVALUE>
          <VALUEMEANING>Selicrelumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selinexor</VALIDVALUE>
          <VALUEMEANING>Selinexor</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selonsertib</VALIDVALUE>
          <VALUEMEANING>Selonsertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selpercatinib</VALIDVALUE>
          <VALUEMEANING>Selpercatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selumetinib</VALIDVALUE>
          <VALUEMEANING>Selumetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3238481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selumetinib Sulfate</VALIDVALUE>
          <VALUEMEANING>Selumetinib Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Semaxanib</VALIDVALUE>
          <VALUEMEANING>Semaxanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1831</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selitrectinib</VALIDVALUE>
          <VALUEMEANING>Selitrectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, LOXO-195 specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3).  This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. LOXO-195 targets specific point mutations that occur after treatment with and result in acquired resistance to another TRK inhibitor; therefore, LOXO-195 is able to overcome acquired resistance to other TRK inhibitors. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of or fusion proteins involving NTRK family members results in uncontrolled TRK signaling and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138160</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Semuloparin</VALIDVALUE>
          <VALUEMEANING>Semuloparin</VALUEMEANING>
          <MEANINGDESCRIPTION>An ultralow-molecular-weight heparin (ULMWH) (Mw: 2000-3000 daltons)consisting of a polydisperse mixture of oligomeric heparin fragments with potential anticoagulant activity. Ultralow-molecular-weight heparin AVE5026 binds to and activates antithrombin III (ATIII), which may result in the inhibition of activated factor Xa and, to a much lesser extent, factor IIa (thrombin) and so the inhibition of fibrin formation. Compared to low-molecular-weight heparins (LMWHs), AVE5026 exhibits an even higher ratio of anti-Factor Xa to anti-Factor IIa activity (&gt;30:1). Compared to unfractionated heparins, the use of LMWHs is associated with lower incidences of major bleeding, osteoporosis and heparin-induced thrombocytopenia. Like LMWHs, this agent may inhibit tumor growth by regulating angiogenesis and apoptosis. AVE5026 is prepared by partial depolymerization of unfractionated porcine mucosal heparin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Semustine</VALIDVALUE>
          <VALUEMEANING>Semustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seneca Valley Virus-001</VALIDVALUE>
          <VALUEMEANING>Seneca Valley Virus-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-competent oncolytic picornavirus with potential antineoplastic activity. Administered systemically, Seneca Valley virus-001 specifically targets and infects tumor cells with neuroendocrine characteristics. Upon infection, this agent replicates intracellularly, resulting in tumor cell lysis and reduced tumor cell proliferation. The selective tropism of virus replication may involve receptor-mediated internalization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62524</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seocalcitol</VALIDVALUE>
          <VALUEMEANING>Seocalcitol</VALUEMEANING>
          <MEANINGDESCRIPTION>A vitamin D3 analogue with potential antineoplastic activity. Seocalcitol binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, seocalcitol may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743810</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S-equol</VALIDVALUE>
          <VALUEMEANING>S-equol</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serabelisib</VALIDVALUE>
          <VALUEMEANING>Serabelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity. Serabelisib selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K alpha-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy; PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serclutamab Talirine</VALIDVALUE>
          <VALUEMEANING>Serclutamab Talirine</VALUEMEANING>
          <MEANINGDESCRIPTION>A antibody drug conjugate (ADC) consisting of serclutamab, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to a talirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of serclutamab talirine, the serclutamab moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, talirine is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SERD SHR9549</VALIDVALUE>
          <VALUEMEANING>SERD SHR9549</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD SHR9549 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SERD ZN-c5</VALIDVALUE>
          <VALUEMEANING>SERD ZN-c5</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD ZN-c5 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sepantronium Bromide</VALIDVALUE>
          <VALUEMEANING>Survivin Inhibitor YM155</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61091</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serdemetan</VALIDVALUE>
          <VALUEMEANING>Serdemetan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable HDM2 antagonist with potential antineoplastic activity. Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sergiolide</VALIDVALUE>
          <VALUEMEANING>Sergiolide</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from Cedronia granatensis and other plant species with potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seribantumab</VALIDVALUE>
          <VALUEMEANING>Seribantumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Seribantumab binds to and inhibits ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78859</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serine/Threonine Kinase Inhibitor XL418</VALIDVALUE>
          <VALUEMEANING>Serine/Threonine Kinase Inhibitor XL418</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective, orally active small molecule, targeting protein kinase B (PKB or AKT) and ribosomal protein S6 Kinase (p70S6K), with potential antineoplastic activity. XL418 inhibits the activities of PKB and p70S6K, both acting downstream of phosphoinosotide-3 kinase (PI3K). These kinases are often upregulated in a variety of cancers. Inhibition of PKB by this agent will induce apoptosis, while inhibition of p70S6K will result in the inhibition of translation within tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68963</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743820</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serplulimab</VALIDVALUE>
          <VALUEMEANING>Serplulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sevacizumab</VALIDVALUE>
          <VALUEMEANING>Sevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, sevacizumab specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seviteronel</VALIDVALUE>
          <VALUEMEANING>Seviteronel</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shared Anti-Idiotype-AB-S006</VALIDVALUE>
          <VALUEMEANING>Shared Anti-Idiotype-AB-S006</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal anti-idiotype antibody that targets human B-cell lymphomas with potential antineoplastic activity.  Shared Anti-Id-Ab-S006 binds to antigens on neoplastic B cells, resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shared Anti-Idiotype-AB-S024A</VALIDVALUE>
          <VALUEMEANING>Shared Anti-Idiotype-AB-S024A</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal anti-idiotype antibody with potential antineoplastic activity. Shared anti-id-Ab-S024A binds to tumor-associated antigens (TAAs) on the surface of neoplastic cells resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serine/Threonine Kinase Inhibitor CBP501</VALIDVALUE>
          <VALUEMEANING>Serine/Threonine Kinase Inhibitor CBP501</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shark Cartilage</VALIDVALUE>
          <VALUEMEANING>Shark Cartilage</VALUEMEANING>
          <MEANINGDESCRIPTION>A nutritional supplement gleaned from the exoskeleton of the shark. Shark cartilage inhibits metalloproteinases (MMPs) and possesses antiangiogenic and antimetastatic properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shark Cartilage Extract AE-941</VALIDVALUE>
          <VALUEMEANING>Shark Cartilage Extract AE-941</VALUEMEANING>
          <MEANINGDESCRIPTION>A multifunctional antiangiogenic agent derived from shark cartilage with potential antineoplastic activity. Shark cartilage extract AE-941 competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cellular receptor, thereby inhibiting endothelial cell proliferation. This agent also inhibits matrix metalloproteinases (MMPs), stimulates tissue plasminogen activator (tPA), and activates caspase-mediated apoptotic pathways in endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shenqi Fuzheng Injection SQ001</VALIDVALUE>
          <VALUEMEANING>Shenqi Fuzheng Injection SQ001</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation composed of the two Chinese medicinal herbs Radix astragali, the root of astragalus membranaceus (huangqi) and Radix codonopsis, the root of Codonopsis pilosula (dangshen), with potential antineoplastic adjuvant and chemoprotective activities that may prevent cancer-related fatigue. Although the exact mechanisms by which shenqi fuzheng injection (SFI) have yet to be fully elucidated, the herbs may improve tumor response and/or reduce the toxicity of certain chemotherapeutics when administered together. It may also alleviate chemotherapy-associated immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sho-Saiko-To</VALIDVALUE>
          <VALUEMEANING>Sho-Saiko-To</VALUEMEANING>
          <MEANINGDESCRIPTION>A botanical formulation with potential chemopreventive activities. Sho-Saiko-to, an herbal mixture, contains seven herbal extracts whose mechanism of action if not fully understood. There is evidence of antiproliferative effects against hepatocellular carcinoma in vitro. Other effects of this agent described in animal models include the prevention of liver injury and hepatocyte-regenerating activity. Antitumor effects associated with this herbal product may include induction of apoptosis, cell cycle arrest at the G0/G1 phase, and activation of an immune response, characterized by the release of cytokines as well as activation of effector cells, such as macrophages and natural killer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHP-1 Agonist SC-43</VALIDVALUE>
          <VALUEMEANING>SHP-1 Agonist SC-43</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule agonist of Src homology region 2 domain-containing phosphatase-1 (SHP-1; tyrosine-protein phosphatase non-receptor type 6; PTPN6) with potential antineoplastic activity. Upon administration, SHP-1 agonist SC-43 enhances SHP-1 activity by impairing the association between the N-terminal Src homology 2 (N-SH2) domain and the protein tyrosine phosphatase (PTP) domain of SHP-1, triggering a conformational change of SHP-1 and relieving its autoinhibition. Activation of SHP-1 represses signal transducer and activator of transcription 3 (STAT3) signaling by inhibiting constitutive and interleukin-6 (IL-6)-induced STAT3 phosphorylation. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence, stemness, and resistance to conventional chemotherapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHP2 Inhibitor JAB-3068</VALIDVALUE>
          <VALUEMEANING>SHP2 Inhibitor JAB-3068</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHP2 Inhibitor RLY-1971</VALIDVALUE>
          <VALUEMEANING>SHP2 Inhibitor RLY-1971</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor RLY-1971 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172988</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shu Yu Wan Formula</VALIDVALUE>
          <VALUEMEANING>Shu Yu Wan Formula</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine comprising different herbs that may be used for a variety of medical purposes. Shu Yu Wan contains the following herbs: Da Zao (Fructus Jujubae), Shu Yu (Radix Dioscoreae Quinquelobae), Gan Cao (Radix Glycyrrhizae Uralensis), Shu Di Huang (Radix Rehmanniae Glutinosae Praeparata), Dang Gui (Radix Angelicae Sinensis), Shen Qu (Massa Medica Fermentata), Gui Zhi (Ramulus Cinnamomi Cassiae), Da Dou Juan (Semen Glycines Germinatum), E Jiao (Gelatinum Corii Asini), Ren Shen (Radix Ginseng), Bai Zhu (Rhizoma Atractylodis Macrocephalae), Fu Ling (Sclerotium Poriae Cocos), Chuan Xiong (Radix Ligustici Wallichii), Bai Shao Yao (Radix Paeoniae Lactiflorae), Mai Men Dong (Tuber Ophiopogonis Japonici), Chai Hu (Radix Bupleuri), Fang Feng (Radix Ledebouriellae Divaricatae), Jie Geng (Radix Platycodi Grandiflori), Xing Ren (Semen Pruni Armeniacae), Bai Lian (Radix Ampelopsis Japonicae) and Sheng Jiang (Rhizoma Zingiberis Officinalis Recens). This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sialyl Tn Antigen</VALIDVALUE>
          <VALUEMEANING>Sialyl Tn Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and a specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen may be co-administered with oral cyclophosphamide as an immune modulator.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3971432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sibrotuzumab</VALIDVALUE>
          <VALUEMEANING>Sibrotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>siG12D LODER</VALIDVALUE>
          <VALUEMEANING>siG12D LODER</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, miniature biodegradable polymeric matrix containing small-interfering RNAs for the mutated KRAS oncogene, KRASG12D, (siG12D), with potential antitumor activity. Upon intratumoral injection, this siG12D is released locally, thereby preventing translation of KRAS proteins and potentially inhibiting growth of tumor cells overexpressing KRAS. KRAS, a member of the small GTPase superfamily, is mutated in over 90% of human pancreatic ductal adenocarcinomas (PDAC) and is associated with tumor cell proliferation and reduced survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Silatecan AR-67</VALIDVALUE>
          <VALUEMEANING>Silatecan AR-67</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64618</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Silibinin</VALIDVALUE>
          <VALUEMEANING>Silibinin</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Silicon Phthalocyanine 4</VALIDVALUE>
          <VALUEMEANING>Silicon Phthalocyanine 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic photosensitizer agent containing a large macrocyclic ring chelated with silicon. Silicon phthalocyanine 4 localizes primarily in mitochondrial cytosolic membranes and, after photoexcitation, forms reactive oxygen species that induce apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sialyl Tn-KLH Vaccine</VALIDVALUE>
          <VALUEMEANING>Sialyl Tn-KLH Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vaccine composed of a substance that enhances immunity plus an antigen found on some tumors of the colon, breast, lung, ovary, pancreas, and stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1690</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Silmitasertib Sodium</VALIDVALUE>
          <VALUEMEANING>Silmitasertib Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of silmitasertib, an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Siltuximab</VALIDVALUE>
          <VALUEMEANING>Siltuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61084</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simalikalactone D</VALIDVALUE>
          <VALUEMEANING>Simalikalactone D</VALUEMEANING>
          <MEANINGDESCRIPTION>A quassinoid phytochemical isolated from Simaba multiflora, Quassia africana and other plant species with potential antineoplastic activity.  This agent also has antimalarial and antiviral properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simeprevir</VALIDVALUE>
          <VALUEMEANING>Simeprevir</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with activity against HCV genotype 1. Upon administration, simeprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simmitinib</VALIDVALUE>
          <VALUEMEANING>Simmitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), and colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antiangiogenic and antineoplastic activities. Upon oral administration, simmitinib binds to and inhibits the activities of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR2, and CSF1R are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simotaxel</VALIDVALUE>
          <VALUEMEANING>Simotaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic, orally bioavailable, third-generation taxane derivative and microtubule-stabilizing agent, with potential antineoplastic activity. Upon administration, simotaxel binds to tubulin, promotes microtubule assembly and stabilization, and prevents microtubule depolymerization. This results in G2/M arrest, apoptosis and the inhibition of cell proliferation in susceptible tumor cells. This agent is a poor substrate for P-glycoprotein-related drug resistance mechanisms; therefore, it may be useful for treating multi-drug resistant tumors. MST-997 is more potent than paclitaxel and docetaxel and overcomes paclitaxel and docetaxel resistance in certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simtuzumab</VALIDVALUE>
          <VALUEMEANING>Simtuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624 targets and specifically binds to the scavenger receptor cysteine rich domain 4 (SRCR-4) on LOXL2, thereby preventing the crosslinking of collagen and inhibiting the recruitment and activation of fibroblasts. Inhibiting fibroblast activation and the subsequent production of growth factors and chemokines may lead to an inhibition of tumor cell proliferation. LOXL2, a member of the lysyl oxidase (LO) gene family, is an extracellular, copper-dependent enzyme overexpressed in a variety of tumor cell types, and contributes to tumor cell invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simurosertib</VALIDVALUE>
          <VALUEMEANING>Simurosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126641</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sintilimab</VALIDVALUE>
          <VALUEMEANING>Sintilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Simlukafusp Alfa</VALIDVALUE>
          <VALUEMEANING>Simlukafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Siplizumab</VALIDVALUE>
          <VALUEMEANING>Siplizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sipuleucel-T</VALIDVALUE>
          <VALUEMEANING>APC8015 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3439565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Siremadlin</VALIDVALUE>
          <VALUEMEANING>Siremadlin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>siRNA-transfected Peripheral Blood Mononuclear Cells APN401</VALIDVALUE>
          <VALUEMEANING>siRNA-transfected Peripheral Blood Mononuclear Cells APN401</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous peripheral blood mononuclear cells (PBMCs) transfected ex vivo with small-interfering ribonucleic acid (siRNA) directed against the E3 ubiquitin ligase casitas B-lineage lymphoma-b gene (Cbl-b), with potential immunoactivating and antineoplastic activities. The Cbl-b gene is silenced ex vivo through the binding of Cbl-b siRNA to Cbl-b mRNA, which prevents the translation of the Cbl-b protein in T-lymphocytes. Upon infusion, the activated, Cbl-b-silenced T-lymphocytes are able to increase the production of cytokines, proliferate and activate the immune system, which leads to cancer cell eradication. Cbl-b, a negative regulator of the immune system, is mutated in a variety of cancer cell types. Its expression is inversely correlated with activation of T-lymphocytes and tumor cell eradication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIRPa-Fc-CD40L Fusion Protein SL-172154</VALIDVALUE>
          <VALUEMEANING>SIRPa-Fc-CD40L Fusion Protein SL-172154</VALUEMEANING>
          <MEANINGDESCRIPTION>A bi-functional fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) and CD40 ligand (CD40L; CD154; TRAP; TNFSF5) linked via a human Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the SIRPa-Fc-CD40L fusion protein SL-172154 selectively targets and binds to both CD47 expressed on tumor cells and CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family, expressed on antigen-presenting cells (APCs). Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of CD40L to CD40 activates CD40, increases CD40-mediated signaling and induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived dendritic cells (moDCs), and leads to the secretion of inflammatory cytokines. This activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. The crosslinking specifically enhances antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sitimagene Ceradenovec</VALIDVALUE>
          <VALUEMEANING>Sitimagene Ceradenovec</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-deficient adenovirus type 5 (Ad5) with E1 and partial E3 deletions containing cDNA for the herpes simplex virus thymidine kinase (HSV-Tk), which, when administered in combination with ganciclovir (GCV), possesses potential antineoplastic activity. Following administration, transgene-expressing cells produce thymidine kinase, which phosphorylates GCV to ganciclovir triphosphate, a cytotoxic nucleotide analog that is incorporated into DNA resulting in chain termination and induction of apoptosis in rapidly dividing cells. This process spares normal neurons as they do not proliferate and are therefore not susceptible to the toxic effects of GCV metabolites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sitravatinib</VALIDVALUE>
          <VALUEMEANING>Sitravatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sivifene</VALIDVALUE>
          <VALUEMEANING>Sivifene</VALUEMEANING>
          <MEANINGDESCRIPTION>The phenylhydrazone 4,4&#39;-dihydroxybenzophenone-2,4-dinitrophenylhydrazone formulated as a topical agent with immunomodulating and potential antineoplastic activities. Applied topically as a gel, sivifene may stimulate a local immune response against human papillomavirus (HPV)-induced cervical intraepithelial neoplasia (CIN).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sizofiran</VALIDVALUE>
          <VALUEMEANING>Sizofiran</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble beta-D-glucan produced by the Basidiomycetes fungus, Schizophyllum commune Fries, with potential immunomodulating and antitumor activities. Although sizofiran&#39;s exact mechanism of action has yet to be fully elucidated, this agent appears to stimulate the immune system by increasing cytokine production, activating macrophages and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIRPa-4-1BBL Fusion Protein DSP107</VALIDVALUE>
          <VALUEMEANING>SIRPa-4-1BBL Fusion Protein DSP107</VALUEMEANING>
          <MEANINGDESCRIPTION>A bi-functional, trimeric, fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) fused to a 4-1BB ligand (4-1BBL), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, the SIRPa-4-1BBL fusion protein DSP107 selectively targets and binds to both CD47 expressed on tumor cells and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) expressed on T-cells and natural killer (NK) cells. Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of 4-1BBL to 4-1BB activates 4-1BB-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as NK-mediated tumor cell killing. The crosslinking specifically enables the activation of 4-1BB-mediated signaling in T-cells and NK cells in the tumor microenvironment (TME), allowing targeted immune responses in the TME. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174171</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SMAC Mimetic BI 891065</VALIDVALUE>
          <VALUEMEANING>SMAC Mimetic BI 891065</VALUEMEANING>
          <MEANINGDESCRIPTION>A mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smac Mimetic GDC-0152</VALIDVALUE>
          <VALUEMEANING>Smac Mimetic GDC-0152</VALUEMEANING>
          <MEANINGDESCRIPTION>A second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0152 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2, which may inhibit their activities and promote the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Smac, the endogenous IAP antagonist, relies on its N-terminal four amino-acid motif for binding to IAPs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smac Mimetic GDC-0917</VALIDVALUE>
          <VALUEMEANING>Smac Mimetic GDC-0917</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0917 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smac Mimetic LCL161</VALIDVALUE>
          <VALUEMEANING>Smac Mimetic LCL161</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smoothened Antagonist BMS-833923</VALIDVALUE>
          <VALUEMEANING>Smoothened Antagonist BMS-833923</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smoothened Antagonist LDE225 Topical</VALIDVALUE>
          <VALUEMEANING>Smoothened Antagonist LDE225 Topical</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical formulation of the small-molecule Smoothened (Smo) antagonist LDE225 with potential antineoplastic activity. Upon topical application, smoothened antagonist LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smoothened Antagonist LEQ506</VALIDVALUE>
          <VALUEMEANING>Smoothened Antagonist LEQ506</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Dysregulated activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91089</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smoothened Antagonist TAK-441</VALIDVALUE>
          <VALUEMEANING>Smoothened Antagonist TAK-441</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441 selectively binds to and inhibits the activity Smo, which is a cell surface co-receptor for ligands in the Hedgehog (Hh) family. This may result in a suppression of Hh-mediated signaling pathways, thereby inhibiting the growth of tumor cells in which this pathway is aberrantly activated.  Smo is a G-protein coupled receptor that lies just downstream of the Hh cell surface receptor Patched-1 in the Hh pathway; in the absence of ligand, Patched-1 (Ptch1) inhibits Smo, and ligand binding to Ptch1 results in increased levels of Smo. The Hh-mediated signaling pathways play an important role in cellular growth and differentiation, and tissue repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SN-38-Loaded Polymeric Micelles NK012</VALIDVALUE>
          <VALUEMEANING>SN-38-Loaded Polymeric Micelles NK012</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation consisting of polymeric micelles loaded with the irinotecan metabolite SN-38 with potential antineoplastic activity. SN-38-loaded polymeric micelles NK012 is an SN-38-releasing nanodevice constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in an aqueous milieu. SN-38 (7-ethyl-10-hydroxy-camptothecin), a biological active metabolite of the prodrug irinotecan (CPT-11), binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. This formulation increases the water-solubility of SN-38 and allows the delivery of higher doses of SN-38 than those achievable with SN-38 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SMO Protein Inhibitor ZSP1602</VALIDVALUE>
          <VALUEMEANING>SMO Protein Inhibitor ZSP1602</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SNS01-T Nanoparticles</VALIDVALUE>
          <VALUEMEANING>SNS01-T Nanoparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>A colloidal mixture of nanoparticles consisting of small interfering RNA (siRNA) targeting the native eukaryotic translation initiation factor 5A (eIF5A), plasmids expressing a pro-apoptotic mutant of elF5A under the control of a B-cell specific promoter (B29), and a synthetic cationic polymer polyethylenimine (PEI) as a delivery vehicle, with potential antineoplastic activity. Upon administration, the siRNA component of SNS01-T suppresses elF5A expression, thereby interfering with translation of eIF5A and reducing levels of hypusinated elF5A in cancer cells. In turn, this inhibits activation of the transcription factor NF-kB and induces apoptosis. In addition, the B-cell specific plasmid component expresses an arginine substituted form of eIF5A, eIF5AK50R, which can not be hypusinated, thus leads to a selective induction of apoptosis in B-cells. The native unhypusinated form of eIF5A is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (DHS) and subsequently deoxyhypusine hydroxylase (DHH), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. The delivery vehicle protects the siRNA and plasmid from degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sobuzoxane</VALIDVALUE>
          <VALUEMEANING>Sobuzoxane</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally available active prodrug of ICRF-154, a bisdioxopiperazine derivative, with cardioprotective and antineoplastic activities. Like other ICRF compounds, sobuzoxane and its active metabolite ICRF-154 interfere with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition. Furthermore, sobuzoxane chelates metal cations thereby limiting the formation of free radical-generating anthracycline-metal complexes and may prevent anthracycline-induced oxidative damage to cardiac and soft tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Borocaptate</VALIDVALUE>
          <VALUEMEANING>Sodium Borocaptate</VALUEMEANING>
          <MEANINGDESCRIPTION>A boron-carrying compound. After parenteral administration, sodium borocaptate accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and &#39;recoil&#39; lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Butyrate</VALIDVALUE>
          <VALUEMEANING>Sodium Butyrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of butyrate with potential antineoplastic activity. Butyrate, a short chain fatty acid, competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This binding affects hyperacetylation of histones, resulting in a modified DNA conformation, which subsequently leads to the uncoiling or relaxing of chromatin. Enhanced accessibility of chromatin to transcription-regulatory complexes leads to increased transcriptional activation of various epigenetically suppressed genes. Butyrate, a HDAC inhibitor, induces cell cycle arrest in G1 or G2/M and also increases the expression of other genes and proteins involved in cellular differentiation and apoptotic signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Dichloroacetate</VALIDVALUE>
          <VALUEMEANING>Sodium Dichloroacetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of dichloroacetic acid with potential antineoplastic activity. Dichloroacetate ion inhibits pyruvate dehydrogenase kinase, resulting in the inhibition of glycolysis and a decrease in lactate production. This agent may stimulate apoptosis in cancer cells by restoring normal mitochondrial-induced apoptotic signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73591</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Iodide I-131</VALIDVALUE>
          <VALUEMEANING>Sodium Iodide I-131</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiopharmaceutical containing the beta- and gamma-emitting radioisotope I-131. After absorption, the iodide is distributed through the extracellular fluid of the body and accumulates in the thyroid gland, thereby allowing the imaging of the thyroid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Metaarsenite</VALIDVALUE>
          <VALUEMEANING>Sodium Metaarsenite</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91098</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Phenylbutyrate</VALIDVALUE>
          <VALUEMEANING>Sodium Phenylbutyrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Salicylate</VALIDVALUE>
          <VALUEMEANING>Sodium Salicylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of salicylic acid. As a nonsteroidal anti-inflammatory drug (NSAID), sodium salicylate irreversibly acetylates cyclooxygenases I and II, thereby inhibiting prostaglandin synthesis and associated inflammation and pain.  This agent may also activate mitogen-activated protein kinase (p38MAPK), thereby inducing apoptosis in cancer cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Stibogluconate</VALIDVALUE>
          <VALUEMEANING>Sodium Stibogluconate</VALUEMEANING>
          <MEANINGDESCRIPTION>Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108</VALIDVALUE>
          <VALUEMEANING>Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sofituzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Sofituzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of sofituzumab vedotin selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106119</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Solitomab</VALIDVALUE>
          <VALUEMEANING>Solitomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Solitomab attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sonepcizumab</VALIDVALUE>
          <VALUEMEANING>Sonepcizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Selenite</VALIDVALUE>
          <VALUEMEANING>Sodium Selenite</VALUEMEANING>
          <MEANINGDESCRIPTION>An inorganic form of the trace element selenium with potential antineoplastic activity. Selenium, administered in the form of sodium selenite, is reduced to hydrogen selenide (H2Se) in the presence of glutathione (GSH) and subsequently generates superoxide radicals upon reaction with oxygen. This may inhibit the expression and activity of the transcription factor Sp1; in turn Sp1 down-regulates androgen receptor (AR) expression and blocks AR signaling. Eventually, selenium may induce apoptosis in prostate cancer cells and inhibit tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sotorasib</VALIDVALUE>
          <VALUEMEANING>Sotorasib (AMG510)</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7656774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sotrastaurin</VALIDVALUE>
          <VALUEMEANING>Sotrastaurin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sotrastaurin Acetate</VALIDVALUE>
          <VALUEMEANING>Sotrastaurin Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt form of sotrastaurin, an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soy Isoflavones</VALIDVALUE>
          <VALUEMEANING>Soy Isoflavones</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary supplement isolated from soybeans containing phytoestrogen isoflavones. Although the mechanism of action is unclear, soy isoflavones mimic estrogen action mediated through estrogen receptors. In addition, this agent also modulates estrogen metabolism. As a result, soy isoflavones have been shown to reduce tumor cell proliferation and induce tumor cell apoptosis, as well as to be able to regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sonidegib</VALIDVALUE>
          <VALUEMEANING>Sonidegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6845944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sonolisib</VALIDVALUE>
          <VALUEMEANING>Sonolisib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sorafenib</VALIDVALUE>
          <VALUEMEANING>Sorafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sorafenib Tosylate</VALIDVALUE>
          <VALUEMEANING>Sorafenib Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sorghum bicolor Supplement</VALIDVALUE>
          <VALUEMEANING>Sorghum bicolor Supplement</VALUEMEANING>
          <MEANINGDESCRIPTION>An herbal-based nutritional supplement containing the leaf sheaths of the plant Sorghum bicolor, with potential antioxidant, anti-inflammatory, chemopreventive and immunomodulating activities. Sorghum bicolor supplement contains various phytochemicals, including phenolic acids and polyphenols such as proanthocyanidins. Sorghum bicolor supplement is particularly rich in 3-deoxyanthocyanins, such as luteolinidin and apigeninidin, and appears to induce apoptosis and inhibit cell proliferation in cancer cells through the stimulation of various apoptosis promoter genes and the downregulation of certain apoptosis inhibitor genes. In addition, due to the strong antioxidant nature of the phytochemicals, these compounds are able to scavenge free radicals and prevent tissue damage. Also, intake of this supplement modulates the immune system by both increasing the activity of natural killer (NK) cells and initiating the activation of macrophages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sotigalimab</VALIDVALUE>
          <VALUEMEANING>Sotigalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soy Protein Isolate</VALIDVALUE>
          <VALUEMEANING>Soy Protein Isolate</VALUEMEANING>
          <MEANINGDESCRIPTION>A dietary protein isolated from soybeans that contains isoflavone phytoestrogens.  Soy protein isolate has been shown to reduce tumor incidence and growth in some animal studies, possibly by modulating estrogen metabolism, reducing tumor cell proliferation, and inducing tumor cell apoptosis.  Soy protein isolate may also inhibit endothelial cell proliferation.  Isoflavone phytoestrogens display mild estrogen-like activities which may regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sparfosate Sodium</VALIDVALUE>
          <VALUEMEANING>Sparfosate Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The disodium salt form of N-phosphonacetyl-L-aspartate (PALA), a pyrimidine antimetabolite with antineoplastic activity.  PALA inhibits pyrimidine biosynthesis and increases the extent to which fluorouracil is incorporated into RNA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sparfosic Acid</VALIDVALUE>
          <VALUEMEANING>Sparfosic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spartalizumab</VALIDVALUE>
          <VALUEMEANING>Spartalizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spherical Nucleic Acid Nanoparticle NU-0129</VALIDVALUE>
          <VALUEMEANING>Spherical Nucleic Acid Nanoparticle NU-0129</VALUEMEANING>
          <MEANINGDESCRIPTION>A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spirogermanium</VALIDVALUE>
          <VALUEMEANING>Spirogermanium</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiromustine</VALIDVALUE>
          <VALUEMEANING>Spiromustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiroplatin</VALIDVALUE>
          <VALUEMEANING>Spiroplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of cyclohexane sulfatoplatinum with antineoplastic properties.  Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splicing Inhibitor H3B-8800</VALIDVALUE>
          <VALUEMEANING>Splicing Inhibitor H3B-8800</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spebrutinib</VALIDVALUE>
          <VALUEMEANING>Spebrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of Bruton&#39;s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spongistatin</VALIDVALUE>
          <VALUEMEANING>Spongistatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly cytotoxic macrocyclic lactone polyether with antitumor activity. Spongistatin, originally isolated from marine Spongia species, binds to the vinca domain of tubulin, thereby interferes with microtubule assembly and results in inhibition of mitosis. This agent does not affect the binding of colchicine to tubulin, but it was a potent inhibitor of the binding of vinblastine and GTP to tubulin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2051</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Squalamine Lactate</VALIDVALUE>
          <VALUEMEANING>Squalamine Lactate</VALUEMEANING>
          <MEANINGDESCRIPTION>The lactate salt form of squalamine, an aminosterol isolated from tissues of the dogfish shark Squalus acanthias.  Possessing anti-angiogenic properties, squalamine inhibits the sodium-hydrogen exchanger NHE3, resulting in suppression of endothelial cell proliferation and migration.  This agent also has broad-spectrum antimicrobial properties. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SR-BP1/HSI Inhibitor SR31747A</VALIDVALUE>
          <VALUEMEANING>SR-BP1/HSI Inhibitor SR31747A</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peripheral sigma receptor ligand with immunomodulatory and potential antitumor activities. Although the exact mechanism by which SR31747A exerts its antitumor effects has not been fully established, SR31747A binds to and inhibits the sigma1 receptor (SR31747A-binding protein-1 or SR-BP1), human sterol isomerase (HSI), also known as emopamil-binding protein (EBP), and the sigma2 receptor, which may result in a reduction in tumor cell proliferation and tumor cell apoptosis. In addition, this agent inhibits the production of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. Upregulated in various cancers, the sigma1 and sigma2 receptors and human sterol isomerase are proteins that are involved in the regulation of cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Src Kinase Inhibitor AP 23846</VALIDVALUE>
          <VALUEMEANING>Src Kinase Inhibitor AP 23846</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel small molecule Src family kinase inhibitor with potential antiangiogenic activity. Upon administration, Src kinase inhibitor AP23846 selectively binds to and stabilizes an inactive ATP-binding site conformation leading to reduced Src kinase activity. This may reduce the production of pro-angiogenic factors, vascular endothelial growth factor (VEGF) and interleukin (IL)-8. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Src/Abl Kinase Inhibitor AZD0424</VALIDVALUE>
          <VALUEMEANING>Src/Abl Kinase Inhibitor AZD0424</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SRPK1/ABCG2 Inhibitor SCO-101</VALIDVALUE>
          <VALUEMEANING>SRPK1/ABCG2 Inhibitor SCO-101</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/arginine-rich splicing factor protein kinase 1 (SRPK1) and the ATP-binding cassette sub-family G member 2 (ABCG2), with potential chemosensitizing and antineoplastic activities. Upon oral administration, SRPK1/ABCG2 inhibitor SCO-101 targets, binds to and inhibits the activity of SRPK1 and ABCG2. Inhibition of the cellular efflux pump ABCG2 by SCO-101 prevents the efflux of co-administered chemotherapeutic agents from cancer cells. This may abrogate cancer cell drug resistance and may re-sensitize cancer cells to the chemotherapeutic agents. Inhibition of SRPK1 kinase by SCO-101 inhibits the SRPK1-mediated phosphorylation of splicing factors rich in serine/arginine domains, thereby inhibiting the activation of proteins that are involved in the regulation of alternative splicing. This may inhibit cancer cell proliferation. SRPK1 is upregulated in various cancer cell types. Its upregulation is correlated with higher tumor staging, grading, and shorter survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SR-T100 Gel</VALIDVALUE>
          <VALUEMEANING>SR-T100 Gel</VALUEMEANING>
          <MEANINGDESCRIPTION>A cutaneous gel preparation containing an extract from Solanum incanum with potential antineoplastic activity. SR-T100 gel contains high amounts of the steroidal alkaloid glycoside solamargine. Solamargine is able to upregulate expression of tumor necrosis factor receptors 1 (TNFR1) and 6 (TNFRSF6 or Fas), and their signaling adaptors TNFR1-associated death domain, and Fas-associated death domain. In addition, this agent is able to upregulate expression of apoptosis promoter Bax, and suppress the expression of the anti-apoptotic proteins Bcl-xL and Bcl-2. Altogether, this induces apoptosis in tumor cells and may lead to an inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ssRNA-based Immunomodulator CV8102</VALIDVALUE>
          <VALUEMEANING>ssRNA-based Immunomodulator CV8102</VALUEMEANING>
          <MEANINGDESCRIPTION>A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>St. John&#39;s Wort</VALIDVALUE>
          <VALUEMEANING>St. John&#39;s Wort</VALUEMEANING>
          <MEANINGDESCRIPTION>An herbal extract prepared from the plant Hypericum perforatum (St. John&#39;s wort) with photodynamic, antineoplastic, and antidepressant activities. Hypericin, one of the active compounds found in Hypericum perforatum, is a photosensitizer that, when exposed to a particular wavelength and intensity of light, may induce tumor cell apoptosis. Another compound, hyperforin, induces caspase-dependent apoptosis in certain tumor cell lines. Hypericum perforatum preparations may also stimulate the activity of cytochrome P450 enzymes and P-glycoprotein drug transporters, resulting in increased metabolism and decreased efficacy of various chemotherapeutic agents and other drugs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Src Kinase Inhibitor M475271</VALIDVALUE>
          <VALUEMEANING>Src Kinase Inhibitor M475271</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stallimycin</VALIDVALUE>
          <VALUEMEANING>Stallimycin</VALUEMEANING>
          <MEANINGDESCRIPTION>An oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus.  Distamycin preferentially binds to adenine-thymine (A-T) rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and RNA transcription.  In addition to antitumor effects, distamycin also possesses antiviral and antiprotozoal activities and is used as a chromosome dye. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Staphylococcal Enterotoxin A</VALIDVALUE>
          <VALUEMEANING>Staphylococcal Enterotoxin A</VALUEMEANING>
          <MEANINGDESCRIPTION>A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin A (SEA), a gram positive bacterial superantigen (SAg), is a potent stimulator of T-cell activation. SEA superantigen binds directly to class II major histocompatibility complex (MHC) molecules and to the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEA, both CD4+ and CD8+ cells proliferate, secrete cytokines, and demonstrate enhanced cytotoxic activity against a broad range of antigens. Vaccination with the SEA protein, administered by direct transfection into tumor cells, may elicit a non-specific cytotoxic T-cell (CTL) response and result in decreased tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Staphylococcal Enterotoxin B</VALIDVALUE>
          <VALUEMEANING>Staphylococcal Enterotoxin B</VALUEMEANING>
          <MEANINGDESCRIPTION>A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin B (SEB), a gram positive superantigen produced by Staphylococcus aureus, is a potent stimulator of T-cell activation. SEB binds directly to class II major histocompatibility complex (MHC) molecules and the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEB, both CD4+ and CD8+ cells proliferate, secrete cytokines and demonstrate enhanced cytotoxic activity against a broad range of antigens. Co-administration of SEB with interleukin-2 (IL-2) by direct injection into tumor cells, may induce clonal T-cell expansion and potentiate apoptosis of tumor cells, resulting in decreased tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1084</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT Inhibitor OPB-111077</VALIDVALUE>
          <VALUEMEANING>STAT Inhibitor OPB-111077</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of one or more signal transducer and activator of transcription (STAT) protein(s), with potential antineoplastic activity. Upon oral administration, OPB-111077 binds to and inhibits the phosphorylation of STATs. This prevents binding of STATs to DNA sequences on a variety of STAT-responsive gene promoters, which may result in the inhibition of both STAT-mediated transcription and tumor cell proliferation. STATs are constitutively activated in a variety of cancers and play a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Inhibitor OPB-31121</VALIDVALUE>
          <VALUEMEANING>STAT3 Inhibitor OPB-31121</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. OPB-31121 inhibits the phosphorylation of STAT3, which prevents binding of STAT3 to DNA sequences on a variety of STAT3-responsive promoters and may result in the inhibition of STAT3-mediated transcription and, potentially, the inhibition of tumor cell proliferation. STAT3 is constitutively activated in a variety of cancers, contributing to the loss of cell growth control and neoplastic transformation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Inhibitor OPB-51602</VALIDVALUE>
          <VALUEMEANING>STAT3 Inhibitor OPB-51602</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. STAT3 inhibitor OPB-51602 inhibits the phosphorylation and thus the activation of STAT3 protein, impeding STAT3 protein from translocating from the cytoplasm to the nucleus and thereby blocking STAT3&#39;s regulation of gene expression through direct binding to the promoters of responsive genes. STAT3 regulates the cellular functions that lead to the cancer phenotype, and constitutive activation of STAT3 is observed in a wide range of human cancers, inducing uncontrolled proliferation and neoplastic transformation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Inhibitor WP1066</VALIDVALUE>
          <VALUEMEANING>STAT3 Inhibitor WP1066</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3), with potential antineoplastic and immunomodulatory activities. Upon administration, STAT3 inhibitor WP1066 blocks the intranuclear translocation of p-STAT, thereby suppressing STAT3 signaling and decreasing the levels of downstream products including c-Myc. Additionally, WP1066 may upregulate costimulatory molecules including CD80 and CD86 on human microglia, and reverse glioma cancer stem cell (gCSC)-mediated innate and adaptive immune suppression allowing for the restoration of antitumor effector immune responses. The STAT3 pathway is overly active in many cancer types and is implicated in CSC-mediated growth, recurrence and resistance to conventional chemotherapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Staurosporine</VALIDVALUE>
          <VALUEMEANING>Staurosporine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity.  Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.  This agent induces apoptosis by an undetermined mechanism. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist BMS-986301</VALIDVALUE>
          <VALUEMEANING>STING Agonist BMS-986301</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon administration, STING agonist BMS-986301 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Inhibitor DSP-0337</VALIDVALUE>
          <VALUEMEANING>STAT3 Inhibitor DSP-0337</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist GSK3745417</VALIDVALUE>
          <VALUEMEANING>STING Agonist GSK3745417</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist IMSA101</VALIDVALUE>
          <VALUEMEANING>STING Agonist IMSA101</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule analogue of cyclic GMP-AMP (cGAMP) that acts as an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173) with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING agonist IMSA101 binds to STING and activates STING-mediated pathways. This activates the immune response through the activation of certain immune cells which induces the expression of pro-inflammatory cytokines and chemokines, promotes tumor-associated antigen (TAA) processing and presentation by dendritic cells (DCs) and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist SB 11285</VALIDVALUE>
          <VALUEMEANING>STING Agonist SB 11285</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist SB 11285 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist TAK-676</VALIDVALUE>
          <VALUEMEANING>STING Agonist TAK-676</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist TAK-676 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING-activating Cyclic Dinucleotide Agonist MIW815</VALIDVALUE>
          <VALUEMEANING>STING-activating Cyclic Dinucleotide Agonist MIW815</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the STING agonist MIW815 binds to STING and stimulates STING-mediated pathways. This activates the immune response through the activation of certain immune cells, including dendritic cells (DCs), which induces the expression of cytokines and chemokines, and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING-expressing E. coli SYNB1891</VALIDVALUE>
          <VALUEMEANING>STING-expressing E. coli SYNB1891</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-pathogenic strain of Escherichia coli (E. coli) bacteria that has been engineered to express stimulator of interferon genes (STING; transmembrane protein 173; TMEM173) protein, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING-expressing E. coli SYNB1891 are engulfed by antigen presenting cells (APCs) within the tumor. STING-mediated pathways within the APCs are then activated resulting in a type I interferon (IFN) response which promotes initiation and propagation of tumor-specific T-cell responses. In addition, the bacterial component of SYNB1891 may further stimulate the innate immune system via Toll-like receptors (TLRs) which may enhance the magnitude of the overall immune response. STING, a transmembrane protein that activates immune cells in the tumor microenvironment (TME), plays a key role in the activation of the innate immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Streptonigrin</VALIDVALUE>
          <VALUEMEANING>Streptonigrin</VALUEMEANING>
          <MEANINGDESCRIPTION>An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus.  Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis.  This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Streptozocin</VALIDVALUE>
          <VALUEMEANING>Streptozocin</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strontium Chloride Sr-89</VALIDVALUE>
          <VALUEMEANING>Strontium Chloride Sr-89</VALUEMEANING>
          <MEANINGDESCRIPTION>The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5920617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sugemalimab</VALIDVALUE>
          <VALUEMEANING>Sugemalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sulfatinib</VALIDVALUE>
          <VALUEMEANING>Sulfatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sulforaphane</VALIDVALUE>
          <VALUEMEANING>Sulforaphane</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring phytochemical belonging to the class of isothiocyanates.  As the aglycone metabolite of glucosinolate glucoraphanin (sulforaphane glucosinolate), sulforaphane acts as an antioxidant and potent stimulator of endogenous detoxifying enzymes.  This agent displays anticarcinogenic properties due to its ability to induce phase II detoxification enzymes, such as glutathione S-transferase and quinone reductase, thereby providing protection against certain carcinogens and toxic, reactive oxygen species.  Broccoli sprouts contain large amounts of sulforaphane, which is also found in other cruciferous vegetables including cabbage and kale. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sulindac</VALIDVALUE>
          <VALUEMEANING>Sulindac</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3340618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sulofenur</VALIDVALUE>
          <VALUEMEANING>Sulofenur</VALUEMEANING>
          <MEANINGDESCRIPTION>A diarylsulfonylurea with potential antineoplastic activity. Sulofenur&#39;s antineoplastic mechanism of action is unknown. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Submicron Particle Paclitaxel Sterile Suspension</VALIDVALUE>
          <VALUEMEANING>Submicron Particle Paclitaxel Sterile Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sunitinib</VALIDVALUE>
          <VALUEMEANING>Sunitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3776074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sunitinib Malate</VALIDVALUE>
          <VALUEMEANING>Sunitinib Malate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2679054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Super Enhancer Inhibitor GZ17-6.02</VALIDVALUE>
          <VALUEMEANING>Super Enhancer Inhibitor GZ17-6.02</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic formulation of the Arum palaestinum plant that has been fortified with the already naturally occurring constituents of isovanillin, linolenic acid, and beta-sitosterol, with potential antineoplastic activity. Upon oral administration, GZ17-6.02 may induce apoptosis through caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, inhibit tumor cell progression by attenuating macrophage infiltration, and inhibit the phosphorylation of several mediators of tumor cell proliferation including Src kinase, extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), epidermal growth factor receptor (EGFR), serine/threonine protein kinase AKT (protein kinase B), signal transducer and activator of transcription 2 (STAT-2), and serine/threonine-protein kinase Chk2 (Chk-2). GZ17-6.02 may also inhibit certain super enhancers (SEs) that play an important role in the regulation of the sonic hedgehog (SHH) pathway and cancer stem cell activity. Super enhancers (SEs) are unique areas of the genome that are densely bound by numerous transcription factors and play a pivotal role in the cell, including tissue specification, identity and maintenance. SEs are known to regulate the expression of associated genes and often drive high-level transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suramin</VALIDVALUE>
          <VALUEMEANING>Suramin</VALUEMEANING>
          <MEANINGDESCRIPTION>A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suramin Sodium</VALIDVALUE>
          <VALUEMEANING>Suramin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Survivin mRNA Antagonist EZN-3042</VALIDVALUE>
          <VALUEMEANING>Survivin mRNA Antagonist EZN-3042</VALUEMEANING>
          <MEANINGDESCRIPTION>A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to survivin mRNA, thereby blocking translation of survivin protein and inhibiting survivin-induced anti-apoptotic activity and promoting tumor cell apoptosis in survivin-overexpressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. LNAs contain a methylene bridge linking 2&#39;-oxygen and 4&#39;-carbon of ribose sugar rings, thereby increasing their stability and decreasing degradation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sustained-release Lipid Inhaled Cisplatin</VALIDVALUE>
          <VALUEMEANING>Sustained-release Lipid Inhaled Cisplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained-release formulation for inhalation in which the inorganic platinum (Pt) agent cisplatin is encapsulated in lipids, with potential antineoplastic activity. Upon inhalation of the sustained-release lipid inhalation targeting (SLIT) cisplatin into the lungs, this agent forms highly reactive, positively charged, Pt complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. Pt complex binding introduces intrastrand and interstrand DNA cross-links, and DNA-Pt-protein cross-links. These cross-links result in apoptosis and cell growth inhibition of lung cancer cells. Encasement in liposomes prolongs cisplatin&#39;s efficacy when compared to intravenously administered cisplatin; inhalation of cisplatin improves its concentration at tumor sites in the lungs while minimizing its systemic toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sustained-release Mitomycin C Hydrogel Formulation UGN-101</VALIDVALUE>
          <VALUEMEANING>Sustained-release Mitomycin C Hydrogel Formulation UGN-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained-release (SR) hydrogel polymer-based formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon local administration of the SR MMC hydrogel formulation to the upper urinary tract via a ureteral catheter, the gel solidifies and deposits MMC locally to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures and solidifies at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for upper tract urothelial carcinoma (UTUC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126642</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sustained-release Mitomycin C Hydrogel Formulation UGN-102</VALIDVALUE>
          <VALUEMEANING>Sustained-release Mitomycin C Hydrogel Formulation UGN-102</VALUEMEANING>
          <MEANINGDESCRIPTION>A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-102, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in UGN-102 the strength of MMC is lower.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Survivin Antigen</VALIDVALUE>
          <VALUEMEANING>Survivin Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor-associated antigen. Vaccination with survivin antigen may result in a cytotoxic T-cell response against survivin antigen-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. Overexpressed in many tumors, endogenous survivin inhibits tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7485273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synchrotope TA2M Plasmid DNA Vaccine</VALIDVALUE>
          <VALUEMEANING>Synchrotope TA2M Plasmid DNA Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synchrovax SEM Plasmid DNA Vaccine</VALIDVALUE>
          <VALUEMEANING>Synchrovax SEM Plasmid DNA Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Alkaloid PM00104</VALIDVALUE>
          <VALUEMEANING>Synthetic Alkaloid PM00104</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alkaloid compound, related to natural alkaloid compounds, found in molluscs (jorumycin) and sponges (renieramycins), with potential antineoplastic activity. PM00104 reversibly binds to DNA, thereby inducing cytotoxicity due to its interference with DNA replication, transcription, and translation processes. DNA binding by this agent does not trigger DNA damage checkpoint responses, hence PM00104 demonstrates a manageable and reversible cytotoxicity as part of its antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2</VALIDVALUE>
          <VALUEMEANING>Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2</VALUEMEANING>
          <MEANINGDESCRIPTION>A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient&#39;s own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic hTERT DNA Vaccine INO-1400</VALIDVALUE>
          <VALUEMEANING>Synthetic hTERT DNA Vaccine INO-1400</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic hTERT DNA Vaccine INO-1401</VALIDVALUE>
          <VALUEMEANING>Synthetic hTERT DNA Vaccine INO-1401</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of a plasmid encoding a synthetic, full-length sequence of the tumor-associated antigen (TAA) telomerase reverse transcriptase (TERT), which was derived from the consensus sequence from humans and primates and contains two immunogenic mutations (SynCon TERT), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of INO-1401 in combination with electroporation, TERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. TERT is the catalytic subunit of telomerase and synthesizes telomeric DNA at the chromosome ends. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, TERT is expressed by many types of human cancer cells, but its expression is low or non-existent in normal cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Hypericin</VALIDVALUE>
          <VALUEMEANING>Synthetic Hypericin</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical ointment formulation containing a synthetic form of hypericin, an anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John&#39;s wort), with potential antineoplastic and photosensitizing activities. Upon topical administration of the ointment to the tumor site, hypericin becomes activated through the application of visible fluorescent light. During photoactivation, hypericin generates singlet oxygen, which induces DNA damage, necrosis and apoptosis, thereby inhibiting tumor cell growth. The use of visible light for activation avoids the risk of developing secondary malignancies, which are frequently associated with other photodynamic therapies that are dependent on ultraviolet A exposure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201</VALIDVALUE>
          <VALUEMEANING>Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2 (TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs. The processed viral epitopes are presented by DCs, which activate and stimulate the host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th) cell responses against HPV E6-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L improves antigen processing and presentation by, and activation of APCs, thereby improving the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Long E6/E7 Peptides Vaccine HPV-01</VALIDVALUE>
          <VALUEMEANING>Synthetic Long E6/E7 Peptides Vaccine HPV-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111037</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1</VALIDVALUE>
          <VALUEMEANING>Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1</VALUEMEANING>
          <MEANINGDESCRIPTION>A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient&#39;s expression of tumor-associated antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b</VALIDVALUE>
          <VALUEMEANING>Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic peptide vaccine consisting of nine overlapping synthetic long peptides (SLPs), 25 to 32 amino acids in size, derived from the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E6 and three SLPs, each 35 amino acids in size, derived from HPV16 E7, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the synthetic long HPV16 E6/E7 peptides vaccine ISA101b is taken up and the long peptides are proteolytically degraded to form shorter peptide epitopes by dendritic cells (DCs). The processed viral epitopes are presented by DCs, which stimulate the host immune system to mount helper T-cell and cytotoxic T-lymphocyte (CTL) responses against HPV16 E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The HPV16 E6 and E7 oncoproteins are implicated in the tumorigenesis of a variety of cancers. The SLPs allow optimal presentation by antigen-presenting cells (APCs). Compared to ISA101, the E6 SLPs in ISA101b are identical, overlap by ten to eighteen residues and cover the complete sequence of HPV16 E6. However, ISA101 has four overlapping SLPs E7 peptides while ISA101b has three E7 SLPs, which leaves seven amino acids of the E7 SLPs uncovered in ISA101b but this modification is not likely to alter the immunogenicity of ISA101b.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synthetic Plumbagin PCUR-101</VALIDVALUE>
          <VALUEMEANING>Synthetic Plumbagin PCUR-101</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of the plant-derived medicinal agent, plumbagin, with potential antineoplastic activity.  Plumbagin may act by inhibiting the expression of protein kinase C epsilon (PKCe), signal transducers and activators of transcription 3 phosphorylation (Stat3), protein kinase B (AKT), and certain epithelial-to-mesenchymal transition (EMT) markers, including vimentin and slug. This results in possible inhibition of proliferation in susceptible tumor cells.  PKCe, Stat3, AKT, and the EMT markers vimentin and slug have been linked to the induction and progression of prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T900607</VALIDVALUE>
          <VALUEMEANING>T900607</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tabalumab</VALIDVALUE>
          <VALUEMEANING>Tabalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgG4 monoclonal antibody against B-cell activating factor (BAFF), with potential immunomodulating and antineoplastic activities. Tabalumab binds to and inhibits the activity of both soluble and cell surface-bound BAFF. This may reduce the activity, proliferation and survival of B-cells. A dysregulated expression of BAFF, a member of the tumor necrosis factor (TNF) family of proteins, is often seen in certain autoimmune diseases and certain cancers, and may promote B lymphocyte activation, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tacedinaline</VALIDVALUE>
          <VALUEMEANING>Tacedinaline</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tafasitamab</VALIDVALUE>
          <VALUEMEANING>Tafasitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tagraxofusp-erzs</VALIDVALUE>
          <VALUEMEANING>Tagraxofusp-erzs</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration of tagraxofusp-erzs, the IL3 moiety binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. IL3 may be overexpressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talabostat</VALIDVALUE>
          <VALUEMEANING>Talabostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talabostat Mesylate</VALIDVALUE>
          <VALUEMEANING>Talabostat Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt of an orally active small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tabelecleucel</VALIDVALUE>
          <VALUEMEANING>Tabelecleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talacotuzumab</VALIDVALUE>
          <VALUEMEANING>Talacotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talactoferrin Alfa</VALIDVALUE>
          <VALUEMEANING>Talactoferrin</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug being studied in the treatment of kidney cancer that has spread. It is also being studied in the treatment of other types of cancer and other conditions. Talactoferrin increases the activity of dendritic cells (a type of immune cell) to help kill cancer cells. It is a form of human lactoferrin (a protein found in milk, tears, mucus, bile, and some white blood cells) that is made in the laboratory. Talactoferrin is a type of recombinant protein and a type of immunomodulatory protein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taladegib</VALIDVALUE>
          <VALUEMEANING>Taladegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talampanel</VALIDVALUE>
          <VALUEMEANING>Talampanel</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talazoparib</VALIDVALUE>
          <VALUEMEANING>Talazoparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taletrectinib</VALIDVALUE>
          <VALUEMEANING>Taletrectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talimogene Laherparepvec</VALIDVALUE>
          <VALUEMEANING>Talimogene Laherparepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6365953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tallimustine</VALIDVALUE>
          <VALUEMEANING>Tallimustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talmapimod</VALIDVALUE>
          <VALUEMEANING>Talmapimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activities. Talmapimod specifically binds to and inhibits the phosphorylation of p38 MAPK, which may result in the induction of tumor cell apoptosis, the inhibition of tumor cell proliferation, and the inhibition of tumor angiogenesis. This agent may also enhance proteasome inhibitor-induced apoptosis. p38 MAPK is a serine/threonine protein kinase involved in a MAPK signaling cascade that controls cellular responses to various environmental stresses, cytokines, and endotoxins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talaporfin Sodium</VALIDVALUE>
          <VALUEMEANING>Talaporfin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26675</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3977275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talotrexin</VALIDVALUE>
          <VALUEMEANING>Talotrexin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Talotrexin Ammonium</VALIDVALUE>
          <VALUEMEANING>Talotrexin Ammonium</VALUEMEANING>
          <MEANINGDESCRIPTION>An ammonium salt of tallotrexin, an analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taltobulin</VALIDVALUE>
          <VALUEMEANING>Taltobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the naturally occurring tripeptide hemiasterlin, with potential antimitotic and antineoplastic activities. Taltobulin binds tubulin in a similar manner as colchicine and inhibits tubulin polymerization. This results in the disruption of the cytoskeleton, ultimately leading to cell cycle arrest in G2/M phase, blockage of cell division and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TAM/c-Met Inhibitor RXDX-106</VALIDVALUE>
          <VALUEMEANING>TAM/c-Met Inhibitor RXDX-106</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tamibarotene</VALIDVALUE>
          <VALUEMEANING>Tamibarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taminadenant</VALIDVALUE>
          <VALUEMEANING>Taminadenant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This abrogates the adenosine/A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tamoxifen</VALIDVALUE>
          <VALUEMEANING>Tamoxifen</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12100425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tamoxifen Citrate</VALIDVALUE>
          <VALUEMEANING>Tamoxifen Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5294355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tamrintamab Pamozirine</VALIDVALUE>
          <VALUEMEANING>Tamrintamab Pamozirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124133</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tanespimycin</VALIDVALUE>
          <VALUEMEANING>Tanespimycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin.  Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tankyrase Inhibitor STP1002</VALIDVALUE>
          <VALUEMEANING>Tankyrase Inhibitor STP1002</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme tankyrase, with potential antineoplastic activity. Upon administration, tankyrase inhibitor STP1002 selectively binds to and inhibits the activity of tankyrase. This may block the tankyrase-mediated poly(ADP-ribosyl)ation of multiple target proteins including various tumor suppressors. This may include the blockage of the poly(ADP-ribosyl)ation and destabilization of AXIN, a negative regulator of beta-catenin, and prevents Wnt/beta-catenin signaling. This may inhibit the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. Tankyrase, a member of the PARP family, plays an important role in the regulation of the Wnt/beta-catenin signaling pathway, tumor suppressors, as well as telomere maintenance and mitosis regulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tanomastat</VALIDVALUE>
          <VALUEMEANING>Tanomastat</VALUEMEANING>
          <MEANINGDESCRIPTION>A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tapotoclax</VALIDVALUE>
          <VALUEMEANING>Tapotoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tarenflurbil</VALIDVALUE>
          <VALUEMEANING>Tarenflurbil</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active synthetic enantiomer of flurbiprofen.  Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tandutinib</VALIDVALUE>
          <VALUEMEANING>Tandutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tarextumab</VALIDVALUE>
          <VALUEMEANING>Tarextumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the Notch receptor with potential antineoplastic activity. Tarextumab binds to Notch on the cell surface, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Notch receptors are important for cell-cell communication, which involves gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life. Dysregulated Notch signaling is implicated in many diseases including T-ALL (T-cell acute lymphoblastic leukemia), CADASIL (Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy), MS (Multiple Sclerosis), and many other disease states.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tariquidar</VALIDVALUE>
          <VALUEMEANING>Tariquidar</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tasadenoturev</VALIDVALUE>
          <VALUEMEANING>Tasadenoturev</VALUEMEANING>
          <MEANINGDESCRIPTION>An adenovirus serotype 5 strain, selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential oncolytic activity. Tasadenoturev contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackie and adenovirus receptors (CARs). Selectively replication competent in cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16), active replication of oncolytic adenovirus Ad5-Delta 24RGD in tumor cells may induce oncolysis or cell lysis. As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle; ovarian cancer cells and non-small cell lung cancer cells may be defective in the Rb/p16 pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taselisib</VALIDVALUE>
          <VALUEMEANING>Taselisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tasisulam</VALIDVALUE>
          <VALUEMEANING>Tasisulam</VALUEMEANING>
          <MEANINGDESCRIPTION>An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tasisulam Sodium</VALIDVALUE>
          <VALUEMEANING>Tasisulam Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tasquinimod</VALIDVALUE>
          <VALUEMEANING>Tasquinimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3788418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taurolidine</VALIDVALUE>
          <VALUEMEANING>Taurolidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic broad-spectrum antimicrobial with antibacterial, antifungal, anticoagulant, and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent&#39;s anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tauromustine</VALIDVALUE>
          <VALUEMEANING>Tauromustine</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble taurine-based nitrosourea with potential antineoplastic activity. Tauromustine alkylates DNA and causes DNA cross links independent of cell cycle, thereby resulting in disruption of DNA function and induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tasidotin</VALIDVALUE>
          <VALUEMEANING>Tasidotin</VALUEMEANING>
          <MEANINGDESCRIPTION>A third generation, synthetic, water-soluble, pentapeptide analog of the marine depsipeptide dolastatin 15, with potential antimitotic and antineoplastic activities. Tasidotin and its metabolite, tasidotin C-carboxylate, suppress the dynamic instability behavior of the microtubules through a reduction of the shortening rate (disassembly); reduction of the switching frequency from growth to shortening; and by reducing microtubules growth time. This may eventually result in a reduction of cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taurultam</VALIDVALUE>
          <VALUEMEANING>Taurultam</VALUEMEANING>
          <MEANINGDESCRIPTION>A reversible metabolite of taurolidine and an amino acid taurine derivative, with antibacterial and antineoplastic activity. Taurultam, like its congener taurolidine, inhibits proliferation of microvascular endothelial cells, although to a lesser extent, by selectively inhibiting the adhesion of endothelial cells to laminin but not to collagen I and fibronectin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tavokinogene Telseplasmid</VALIDVALUE>
          <VALUEMEANING>Tavokinogene Telseplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA plasmid that encodes genes for both the p35 and p40 subunits of the heterodimeric human interleukin 12 (hIL-12) protein that are separated by an internal ribosome entry site (IRES) and under the control of a single cytomegalovirus (CMV) promoter, with potential immunomodulatory and antineoplastic activities. Upon administration via intratumoral injection and electroporation, the plasmid is introduced into human cells resulting in expression and highly-localized secretion of a functional IL-12 p70 protein into the tumor microenvironment (TME). IL-12 is a pro-inflammatory cytokine that plays a significant role in priming and maintaining T-helper (Th) cells, activating natural killer (NK) cells, and regulating the reactivation and survival of memory T-cells (Tm). Increased levels of IL-12 in the TME may augment host immune response against tumor cells by inhibiting regulatory T-cells (Tregs), T-helper 2 (Th2) responses, and myeloid-derived suppressor cells (MDSCs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tavolimab</VALIDVALUE>
          <VALUEMEANING>Tavolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taxane Analogue TPI 287</VALIDVALUE>
          <VALUEMEANING>Taxane Analogue TPI 287</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, third generation taxane with potential antineoplastic activity. TPI 287 binds to tubulin and stabilizes microtubules, resulting in inhibition of microtubule assembly/disassembly dynamics, cell cycle arrest at the G2/M phase, and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taxol Analogue SID 530</VALIDVALUE>
          <VALUEMEANING>Taxol Analogue SID 530</VALUEMEANING>
          <MEANINGDESCRIPTION>An intravenous formulation containing docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, with potential antineoplastic activity. Taxol analogue SID 530 binds to and stabilizes tubulin, inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tazarotene</VALIDVALUE>
          <VALUEMEANING>Tazarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tazemetostat</VALIDVALUE>
          <VALUEMEANING>Tazemetostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tebentafusp</VALIDVALUE>
          <VALUEMEANING>Tebentafusp</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teclistamab</VALIDVALUE>
          <VALUEMEANING>Teclistamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7554850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tefinostat</VALIDVALUE>
          <VALUEMEANING>Tefinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tegafur</VALIDVALUE>
          <VALUEMEANING>Tegafur</VALUEMEANING>
          <MEANINGDESCRIPTION>A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tegafur-gimeracil-oteracil Potassium</VALIDVALUE>
          <VALUEMEANING>Tegafur-gimeracil-oteracil Potassium</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation</VALIDVALUE>
          <VALUEMEANING>Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2&#39;-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby &#39;rescuing&#39; the patient while permitting the antitumor activity of 5-FU.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120099</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tegafur-Uracil</VALIDVALUE>
          <VALUEMEANING>Tegafur-Uracil</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tecogalan Sodium</VALIDVALUE>
          <VALUEMEANING>Tecogalan Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfated polysaccharide isolated from various Arthrobacter bacterial species.  Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors.  Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tegavivint</VALIDVALUE>
          <VALUEMEANING>Tegavivint</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teglarinad</VALIDVALUE>
          <VALUEMEANING>Teglarinad</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble prodrug of a pyridyl cyanoguanidine compound and an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential antineoplastic activity. Teglarinad is rapidly converted in the bloodstream into an active compound through hydrolytic cleavage of the carbonate ester bond. The activated form inhibits NAMPT, thereby inhibiting nicotinamide adenine dinucleotide (NAD+) biosynthesis and induces a rapid decline in intracellular NAD+ followed by ATP reduction. As NAD+ is essential for tumor cell growth, inhibition of NAMPT induces tumor cell death. NAMPT is an essential enzyme in the synthesis of NAD+ and is upregulated in some cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teglarinad Chloride</VALIDVALUE>
          <VALUEMEANING>Teglarinad Chloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3443983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telaglenastat</VALIDVALUE>
          <VALUEMEANING>Glutaminase Inhibitor CB-839</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telapristone</VALIDVALUE>
          <VALUEMEANING>Telapristone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telapristone Acetate</VALIDVALUE>
          <VALUEMEANING>Telapristone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104055</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telatinib Mesylate</VALIDVALUE>
          <VALUEMEANING>Telatinib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The orally bioavailable mesylate salt of the 17-allylaminogeldanamycin (17-AAG) small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activities. Telatinib binds to and inhibits the vascular endothelial growth factor receptors (VEGFRs) type 2 and 3, platelet-derived growth factor receptor beta (PDGFRb) and c-Kit, which may result in the inhibition of angiogenesis and cellular proliferation in tumors in which these receptors are upregulated. These telatinib-inhibited receptor protein tyrosine kinases are overexpressed or mutated in many tumor cell types and may play key roles in tumor angiogenesis and tumor cell proliferation. 17-AAG is a synthetic analogue of the benzoquinone ansamycin antibiotic geldanamycin and has also been found to inhibit the molecular chaperone Hsp90.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telisotuzumab</VALIDVALUE>
          <VALUEMEANING>Telisotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telisotuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Telisotuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telaglenastat Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Telaglenastat Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telomerase Inhibitor FJ5002</VALIDVALUE>
          <VALUEMEANING>Telomerase Inhibitor FJ5002</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of rhodacyanine with potential antineoplastic activity.  FJ5002 inhibits telomerase by interfering with holoenzyme assembly and telomere interaction, thus leading to replication-dependent shortening of telomeres with a concurrent increase in aneuploid metaphases and apoptotic cells.  Telomerase is active in most tumors cells, but is quiescent in adjacent normal cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teloxantrone</VALIDVALUE>
          <VALUEMEANING>Teloxantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teloxantrone Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Teloxantrone Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temarotene</VALIDVALUE>
          <VALUEMEANING>Temarotene</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic bioactive retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, temarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temoporfin</VALIDVALUE>
          <VALUEMEANING>Temoporfin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temozolomide</VALIDVALUE>
          <VALUEMEANING>Temozolomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1244</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temsirolimus</VALIDVALUE>
          <VALUEMEANING>Temsirolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tenalisib</VALIDVALUE>
          <VALUEMEANING>Tenalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, tenalisib inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms, including the inhibition of both the release of reactive oxygen species (ROS) from neutrophils and tumor necrosis factor (TNF)-alpha activity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and in inflammatory and autoimmune diseases. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tenifatecan</VALIDVALUE>
          <VALUEMEANING>Tenifatecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly lipophilic preparation of 7-Ethyl-10-hydroxycamptothecin (SN-38) with potential antineoplastic activity. SN2310 is an oil-in-water emulsion of tocopherol covalently linked, via a succinate linker, to SN-38, a synthetic derivative of the cytotoxic alkaloid camptothecin. After succinate linker is hydrolyzed in vivo, the active moiety SN-38 is released and selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks and inducing lethal double-stranded DNA breaks. This inhibits DNA replication and triggers programmed cell death. SN2310 emulsion provides longer circulation time and potentiates drug exposure as compared to the unconjugated SN-38.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telratolimod</VALIDVALUE>
          <VALUEMEANING>Telratolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teniposide</VALIDVALUE>
          <VALUEMEANING>Teniposide</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C857</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2739552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tepoditamab</VALIDVALUE>
          <VALUEMEANING>Tepoditamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tepotinib</VALIDVALUE>
          <VALUEMEANING>Tepotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teprotumumab</VALIDVALUE>
          <VALUEMEANING>Teprotumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Terfluranol</VALIDVALUE>
          <VALUEMEANING>Terfluranol</VALUEMEANING>
          <MEANINGDESCRIPTION>A trifluoroethyl derivative with antineoplastic agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tergenpumatucel-L</VALIDVALUE>
          <VALUEMEANING>Tergenpumatucel-L</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a &#39;xenograft&#39;. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Teroxirone</VALIDVALUE>
          <VALUEMEANING>Teroxirone</VALUEMEANING>
          <MEANINGDESCRIPTION>A triazene triepoxide with antineoplastic activity. Teroxine alkylates and cross-links DNA, thereby inhibiting DNA replication. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tertomotide</VALIDVALUE>
          <VALUEMEANING>Tertomotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tesetaxel</VALIDVALUE>
          <VALUEMEANING>Tesetaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and stabilizes tubulin, promoting microtubule assembly and thereby preventing microtubule depolymerization. This may lead to cell cycle arrest and an inhibition of cell proliferation. This agent may also inhibit pro-angiogenic factors such as vascular endothelial growth factor (VEGF). As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37451</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Terameprocol</VALIDVALUE>
          <VALUEMEANING>Terameprocol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tesevatinib</VALIDVALUE>
          <VALUEMEANING>Tesevatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tesidolumab</VALIDVALUE>
          <VALUEMEANING>Tesidolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. Upon administration, tesidolumab targets and binds to C5, thereby preventing both C5 convertase-mediated cleavage of C5 and the formation of C5a and C5b. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction. C5 plays a key role in the activation of the complement cascade.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testolactone</VALIDVALUE>
          <VALUEMEANING>Testolactone</VALUEMEANING>
          <MEANINGDESCRIPTION>A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tetanus Toxoid Vaccine</VALIDVALUE>
          <VALUEMEANING>Tetanus Toxoid</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that is derived from the toxin released by the bacterium that causes the disease tetanus.  It is used as a vaccine to prevent tetanus or to help boost the immune response to other vaccines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tetrahydrouridine</VALIDVALUE>
          <VALUEMEANING>Tetrahydrouridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2&#39;-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2&#39;-deoxycytidine monophosphate (CldCMP) to 5-chloro-2&#39;-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2&#39;-deoxyuridine). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tetrathiomolybdate</VALIDVALUE>
          <VALUEMEANING>Tetrathiomolybdate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tezacitabine</VALIDVALUE>
          <VALUEMEANING>Tezacitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5&#39;-diphosphates to deoxyribonucleoside 5&#39;-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tezacitabine Anhydrous</VALIDVALUE>
          <VALUEMEANING>Tezacitabine Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of tezacitabine, a synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and eventually tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, thereby further inhibiting DNA replication. RNR catalyzes the conversion of ribonucleoside 5&#39;-diphosphates to deoxyribonucleoside 5&#39;-diphosphates, a necessary step for DNA synthesis, and is overexpressed in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TGFa-PE38 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>TGFa-PE38 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29483</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tetradecanoylphorbol Acetate</VALIDVALUE>
          <VALUEMEANING>Tetradecanoylphorbol Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>A phorbol ester with potential antineoplastic effects.  Tetradecanoylphorbol acetate (TPA) induces maturation and differentiation of hematopoietic cell lines, including leukemic cells. This agent may induce gene expression and protein kinase C (PKC) activity.  In addition to potential antineoplastic effects, TPA may exhibit tumor promoting activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TGFbeta Inhibitor LY3200882</VALIDVALUE>
          <VALUEMEANING>TGFbeta Inhibitor LY3200882</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132013</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TGF-beta Receptor 1 Inhibitor PF-06952229</VALIDVALUE>
          <VALUEMEANING>TGF-beta Receptor 1 Inhibitor PF-06952229</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TGF-beta Receptor 1 Kinase Inhibitor SH3051</VALIDVALUE>
          <VALUEMEANING>TGF-beta Receptor 1 Kinase Inhibitor SH3051</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the serine/threonine kinase transforming growth factor-beta (TGF-beta) receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGFbR1 inhibitor SH3051 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of tumor cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thalicarpine</VALIDVALUE>
          <VALUEMEANING>Thalicarpine</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural aporphine benzylisoquinoline vinca alkaloid with antineoplastic activity. Thalicarpine binds to and inhibits p-glycoprotein, the multidrug resistance efflux pump. Thalicarpine also induces single-strand breaks in DNA and arrests cancer cells at the G2/M and G1 phase of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C869</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thalidomide</VALIDVALUE>
          <VALUEMEANING>Thalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  Thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3253641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Theramide</VALIDVALUE>
          <VALUEMEANING>Theramide</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic disaccharide derivative of muramyl dipeptide (MDP) with strong immunostimulating activity and used as a vaccine adjuvant. MDP, a component of bacterial cell wall, is the minimum chemical structure required for macrophage activation. Due to MDP&#39;s toxicity and short duration of action, theramide was developed with improved stability, and can be administered without a liposome carrier. Theramide stimulates macrophage activity, which in turn potentiates other immune responses, including the release of proinflammatory interleukins and tumor necrosis factor alpha (TNF alpha). The release of these cytokines further augments the activation of cellular and humoral immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Angiotensin-(1-7)</VALIDVALUE>
          <VALUEMEANING>Therapeutic Angiotensin-(1-7)</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. Therapeutic angiotensin 1-7 may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) receptor Mas, resulting in diminished tumor cell proliferation. Activation of the angiotensin-(1-7) receptor Mas, a G-protein coupled, seven transmembrane protein, may down-regulate the phosphorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 MAPK signaling pathway. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907</VALIDVALUE>
          <VALUEMEANING>Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Cancer Vaccine ATP128</VALIDVALUE>
          <VALUEMEANING>Therapeutic Cancer Vaccine ATP128</VALUEMEANING>
          <MEANINGDESCRIPTION>A self-adjuvanted chimeric recombinant protein vaccine, based on the self-adjuvanting KISIMA immunization platform, composed of three components: the 42 residue fragment Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo, a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed amount of major histocompatibility class (MHC)-restricted peptides derived from as of yet undisclosed tumor-associated antigens (TAAs) that are specific for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic activities. Upon administration of ATP128, the Z12 moiety targets, binds to and penetrates antigen-presenting cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments. Upon processing and antigen presentation by MHC II and I, the immune system is stimulated and activates specific CD4+ and CD8+ T-cells, respectively, against the multi-epitopes specific for the CRC cells, thereby killing the CRC cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165621</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TGF-beta Receptor 1 Kinase Inhibitor YL-13027</VALIDVALUE>
          <VALUEMEANING>TGF-beta Receptor 1 Kinase Inhibitor YL-13027</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine kinase transforming growth factor-beta receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGF-betaR1 inhibitor YL-13027 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Liver Cancer Peptide Vaccine IMA970A</VALIDVALUE>
          <VALUEMEANING>Therapeutic Liver Cancer Peptide Vaccine IMA970A</VALUEMEANING>
          <MEANINGDESCRIPTION>An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A*02), five to HLA-A*24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151942</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thiarabine</VALIDVALUE>
          <VALUEMEANING>Thiarabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thiodiglycol</VALIDVALUE>
          <VALUEMEANING>Thiodiglycol</VALUEMEANING>
          <MEANINGDESCRIPTION>A hydrolysis product of mustard gas, an alkylating agent, with antineoplastic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thioguanine</VALIDVALUE>
          <VALUEMEANING>Thioguanine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2744957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thioguanine Anhydrous</VALIDVALUE>
          <VALUEMEANING>Thioguanine Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous salt form of thioguanine, a synthetic guanosine analogue antimetabolite, with antineoplastic activity. Thioguanine is phosphorylated by hypoxanthine-guanine phosphoribosyltransferase to 6-thioguanylic acid (TGMP) and upon conversion to thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP), this agent is incorporated into DNA and RNA, resulting in inhibition of DNA and RNA synthesis and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine ribonulceotide synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thioinosine</VALIDVALUE>
          <VALUEMEANING>Thioinosine</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfhydryl analog of inosine and an antimetabolite with potential antineoplastic and immunosuppressive properties. Thioinosine interferes with de novo purine synthesis and perturbs the pool of nucleotides necessary for DNA replication. As a result, this agent inhibits DNA synthesis, blocks cellular proliferation and induces apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thioredoxin-1 Inhibitor PX-12</VALIDVALUE>
          <VALUEMEANING>Thioredoxin-1 Inhibitor PX-12</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. Thioredoxin-1 inhibitor PX-12 irreversibly binds to thioredoxin-1 (Trx-1) and inhibits its activity, which may result in growth inhibition and the induction of apoptosis. Overexpressed in many cancer cell types, the low molecular weight redox protein Trx-1 regulates transcription factor activity and inhibits apoptosis, promoting cell growth and survival; it also interacts with growth factors extracellularly to stimulate cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thiotepa</VALIDVALUE>
          <VALUEMEANING>Thiotepa</VALUEMEANING>
          <MEANINGDESCRIPTION>A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N&#39;,N&#39;&#39;-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5810420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>THL-P</VALIDVALUE>
          <VALUEMEANING>THL-P</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, oral Chinese medicinal herb preparation with potential antioxidant, immunomodulating, and antineoplastic activities. THL-P (Tien-Hsien Liquid-P) contains fourteen Chinese medicinal herbs including: Cordyceps sinensis, Oldenlandia diffusa, Indigo pulverata levis, Polyporus umbellatus, Radix astragali, Panax ginseng, Solanum nigrum L., Pogostemon cablin, Atractylodis macrocephalae rhizoma, Trichosanthes radix, Clematis radix, Margarite, Ligustrum lucidum Ait and Glycyrrhiza radix. Administered as an oral liquid, THL-P may modulate the activity of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs), macrophages and polymorphonuclear leukocytes, and enhance the secretion of interleukins (ILs) and interferon-gamma (IFN-gamma). This agent may also induce G2/M cell cycle arrest and downregulate several important oncogenic signaling pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thorium Th 227 Anetumab Corixetan</VALIDVALUE>
          <VALUEMEANING>Thorium Th 227 Anetumab Corixetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thymidylate Synthase Inhibitor CX1106</VALIDVALUE>
          <VALUEMEANING>Thymidylate Synthase Inhibitor CX1106</VALUEMEANING>
          <MEANINGDESCRIPTION>A thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon administration, TS inhibitor CX1106 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168609</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thymidylate Synthase Inhibitor DFP-11207</VALIDVALUE>
          <VALUEMEANING>Thymidylate Synthase Inhibitor DFP-11207</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thymopentin</VALIDVALUE>
          <VALUEMEANING>Thymopentin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thioureidobutyronitrile</VALIDVALUE>
          <VALUEMEANING>Thioureidobutyronitrile</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Upon intravenous administration, thioureidobutyronitrile activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Thioureidobutyronitrile may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tiazofurin</VALIDVALUE>
          <VALUEMEANING>Tiazofurin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tidutamab</VALIDVALUE>
          <VALUEMEANING>Tidutamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, tidutamab binds to both T-cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tigapotide</VALIDVALUE>
          <VALUEMEANING>PSP-94-Derived Peptide PCK3145</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tigatuzumab</VALIDVALUE>
          <VALUEMEANING>Tigatuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tilogotamab</VALIDVALUE>
          <VALUEMEANING>Tilogotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tilsotolimod Sodium</VALIDVALUE>
          <VALUEMEANING>Tilsotolimod Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of tilsotolimod, a proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Timonacic</VALIDVALUE>
          <VALUEMEANING>Timonacic</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclic sulfur amino acid derivative with potential antineoplastic and antioxidant activities. Acting on cellular membranes of malignant cells through an unknown mechanism, timonacic may induce malignant cells to revert back to an untransformed state. This agent may also restore contact inhibition, a phenomenon characterized by the paracrine inhibition of mitosis following the formation of a critical cell mass, presumably the result of cell-to-cell signal transfer. Timonacic may also produce antioxidant effects secondary to its release of cysteine and restoration of glutathione concentrations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tin Ethyl Etiopurpurin</VALIDVALUE>
          <VALUEMEANING>Tin Ethyl Etiopurpurin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic purpurin with photosensitizing activity.  Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tinostamustine</VALIDVALUE>
          <VALUEMEANING>Tinostamustine</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tilarginine</VALIDVALUE>
          <VALUEMEANING>Tilarginine</VALUEMEANING>
          <MEANINGDESCRIPTION>A pan-nitric oxide synthase (NOS) inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, tilarginine binds to and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis, and immunosuppression in the tumor microenvironment (TME). Reduction in NOS activity may abrogate the immunosuppressive TME, enhance tumor antigen-specific immune response and inhibit tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tinzaparin Sodium</VALIDVALUE>
          <VALUEMEANING>Tinzaparin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties.  Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tiomolibdate Choline</VALIDVALUE>
          <VALUEMEANING>Tiomolibdate Choline</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active second generation tetrathiomolybdate analog with anti-angiogenic and antineoplastic activities. Tiomolibdate choline selectively chelates the copper ion in superoxide dismutase 1 (SOD1) in endothelial cells, thereby depleting SOD1 of copper and inhibiting its activity. Inhibition of SOD1 interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis, including those mediated by ERK1/2 and FAK and Src kinases. This results in an inhibition of cell proliferation and angiogenesis as well as induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tiomolibdate Diammonium</VALIDVALUE>
          <VALUEMEANING>Ammonium Tetrathiomolybdate</VALUEMEANING>
          <MEANINGDESCRIPTION>An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tremelimumab</VALIDVALUE>
          <VALUEMEANING>Tremelimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49085</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3185137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tretazicar</VALIDVALUE>
          <VALUEMEANING>Tretazicar</VALUEMEANING>
          <MEANINGDESCRIPTION>A prodrug of a bifunctional alkylating, dinitrobenzamide derivative with antineoplastic activity. Tretazicar can be activated by the human enzyme quinone oxidoreductase 2 (NQO2) in the presence of the cosubstrate caricotamide, an analogue of the natural cosubstrate dihydronicotinamide riboside (NRH), which acts as an electron donor. The resulting active, but short-lived metabolite, dinitrobenzamide, leads to DNA replication inhibition and the induction of apoptosis in NQO2 expressing cancer cells. Due to the lack of the natural cosubstrate NRH, NQO2 expression is normally latent but is upregulated in certain types of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tretinoin</VALIDVALUE>
          <VALUEMEANING>Tretinoin</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5342173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tretinoin Liposome</VALIDVALUE>
          <VALUEMEANING>Tretinoin Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>An intravenous formulation of tretinoin (vitamin A acid or all-trans retinoic acid) encased in liposomes. Tretinoin is a naturally occurring retinoic acid agent that binds to and activates retinoic acid receptors (RAR), effecting changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis.  This agent also inhibits telomerase, leading to telomere shortening and eventual apoptosis of certain tumor cell types. Liposome encapsulation extends the half-life of intravenously administered tretinoin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triapine</VALIDVALUE>
          <VALUEMEANING>Triapine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triazene Derivative CB10-277</VALIDVALUE>
          <VALUEMEANING>Triazene Derivative CB10-277</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties.  Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treosulfan</VALIDVALUE>
          <VALUEMEANING>Treosulfan</VALUEMEANING>
          <MEANINGDESCRIPTION>The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3922372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triazene Derivative TriN2755</VALIDVALUE>
          <VALUEMEANING>Triazene Derivative TriN2755</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic triazene derivative with antineoplastic activity. Upon metabolic activation via N-demethylation, TriN2755 is converted into highly reactive carbocations that can alkylate DNA and other macromolecules, thereby resulting in DNA cross links, inhibiting DNA replication and repair, and subsequently inducing apoptosis. This agent has high hydrophilicity and photostability and shows a favorable toxicity profile over the other triazenes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triazinate</VALIDVALUE>
          <VALUEMEANING>Triazinate</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic dihydrotriazine derivative with antineoplastic properties.  As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis.  Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triaziquone</VALIDVALUE>
          <VALUEMEANING>Triaziquone</VALUEMEANING>
          <MEANINGDESCRIPTION>An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in triaziquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent&#39;s cytotoxic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tributyrin</VALIDVALUE>
          <VALUEMEANING>Tributyrin</VALUEMEANING>
          <MEANINGDESCRIPTION>A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triciribine Phosphate</VALIDVALUE>
          <VALUEMEANING>Triciribine Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/threonine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trientine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Trientine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triethylenemelamine</VALIDVALUE>
          <VALUEMEANING>Triethylenemelamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A trisaziridine alkylating agent with antineoplastic and carcinogenic properties.  Used to induce cancer in experimental animal models, triethylenemelamine ethylates DNA, resulting in inhibition of DNA replication, unscheduled DNA synthesis, chromosomal aberrations, and sister chromatid exchanges.  This agent also exhibits reproductive toxicities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trifluridine</VALIDVALUE>
          <VALUEMEANING>Trifluridine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trifluridine and Tipiracil Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2&#39;-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5831612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trimelamol</VALIDVALUE>
          <VALUEMEANING>Trimelamol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of trimethylmelamine with antineoplastic properties.  An analogue of siderophores (microbial iron chelators), trimelamol induces the formation of a reactive iminium species which may crosslink DNA. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trimeric GITRL-Fc OMP-336B11</VALIDVALUE>
          <VALUEMEANING>Trimeric GITRL-Fc OMP-336B11</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, trimeric GITRL-Fc OMP-336B11 targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trimethylcolchicinic Acid</VALIDVALUE>
          <VALUEMEANING>Trimethylcolchicinic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A colchicine analog with potential antineoplastic activity.  Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trimetrexate</VALIDVALUE>
          <VALUEMEANING>Trimetrexate</VALUEMEANING>
          <MEANINGDESCRIPTION>A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular Disrupting Agent BNC105</VALIDVALUE>
          <VALUEMEANING>Vascular Disrupting Agent BNC105</VALUEMEANING>
          <MEANINGDESCRIPTION>A vascular disrupting agent (VDA), with potential anti-vascular and antineoplastic activities. Upon administration, vascular disrupting agent BNC105 binds to tubulin and inhibits its polymerization, which results in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. This deprives tumor cells of nutrients and results in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trilaciclib</VALIDVALUE>
          <VALUEMEANING>Trilaciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities. Upon intravenous administration, trilaciclib binds to and inhibits the activity of CDK4/6, thereby blocking the phosphorylation of the retinoblastoma protein (Rb) in early G1. This prevents G1/S phase transition, causes cell cycle arrest in the G1 phase, induces apoptosis, and inhibits the proliferation of CDK4/6-overexpressing tumor cells. In patients with CDK4/6-independent tumor cells, G1T28 may protect against multi-lineage chemotherapy-induced myelosuppression (CIM) by transiently and reversibly inducing G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and preventing transition to the S phase. This protects all hematopoietic lineages, including red blood cells, platelets, neutrophils and lymphocytes, from the DNA-damaging effects of certain chemotherapeutics and preserves the function of the bone marrow and the immune system. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. HSPCs are dependent upon CDK4/6 for proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular Disrupting Agent BNC105P</VALIDVALUE>
          <VALUEMEANING>Vascular Disrupting Agent BNC105P</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vascular Disrupting Agent ZD6126</VALIDVALUE>
          <VALUEMEANING>Vascular Disrupting Agent ZD6126</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo into N-acetylcolchinol. N-acetylcolchinol binds to and destabilizes the tubulin cytoskeleton of endothelial cells in tumor blood vessels, which may result in tumor endothelial cell apoptosis, the selective occlusion of tumor blood vessels, cessation of tumor blood flow, and tumor necrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vatalanib</VALIDVALUE>
          <VALUEMEANING>Vatalanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vatalanib Succinate</VALIDVALUE>
          <VALUEMEANING>Vatalanib Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The succinate salt of vatalanib, an anilinophthalazine derivative, with antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector-peptide Conjugated Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Vector-peptide Conjugated Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary conjugate of paclitaxel with antineoplastic activity. Similar to the free drug, the paclitaxel moiety in vector-peptide conjugated paclitaxel binds to and stabilizes tubulin molecules, promoting assembly of microtubules and inhibiting tubulin disassembly which results in the inhibition of cell division. The Kunitz domain-derived vector-peptide carries the conjugated paclitaxel through the blood brain barrier (BBB), bypassing the transmembrane p-glycoprotein (P-gp) efflux pump, which may result in higher concentrations of paclitaxel in the brain parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vedolizumab</VALIDVALUE>
          <VALUEMEANING>Vedolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer&#39;s patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8115529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGF/HGF-targeting DARPin MP0250</VALIDVALUE>
          <VALUEMEANING>VEGF/HGF-targeting DARPin MP0250</VALUEMEANING>
          <MEANINGDESCRIPTION>A designed ankyrin repeat proteins (DARPin)-based agent targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), with potential antiangiogenic and antineoplastic activities. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the VEGF/HGF-targeting DARPin MP0250 binds to and inhibits both HGF and VEGF. This prevents HGF- and VEGF-mediated signaling, and inhibits the growth of HGF/VEGF-overexpressing tumor cells. This agent also prevents osteolysis, due to the inhibitory effect on HGF signaling. HGF and VEGF are overexpressed in a variety of cancer cell types and are associated with increased cell proliferation, migration and adhesion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR Inhibitor KRN951</VALIDVALUE>
          <VALUEMEANING>VEGFR Inhibitor KRN951</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable quinoline-urea derivative inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1 and 2 with potential antiangiogenesis and antineoplastic activities. VEGFR inhibitor KRN951 inhibits VEGF-induced phosphorylation of VEGFRs 1 and 2, which may result in inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR/FGFR Inhibitor ODM-203</VALIDVALUE>
          <VALUEMEANING>VEGFR/FGFR Inhibitor ODM-203</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), with potential antiangiogenic and antineoplastic activities. VEGFR/FGFR inhibitor ODM-203 inhibits both VEGFRs and FGFRs, which may result in the inhibition of VEGFR- and FGFR-mediated signaling. This leads to an inhibition of angiogenesis and cell proliferation in tumor cells overexpressing VEGFR and/or FGFR. Both VEGFRs and FGFRs belong to the superfamily of receptor tyrosine kinases and are upregulated in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118628</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vecabrutinib</VALIDVALUE>
          <VALUEMEANING>Vecabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available second-generation, reversible inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, vecabrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. Other irreversible BTK inhibitors covalently bind to the C481 site to inhibit BTK&#39;s activity; the C481S mutation prevents that binding. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593</VALIDVALUE>
          <VALUEMEANING>VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR-2 DNA Vaccine VXM01</VALIDVALUE>
          <VALUEMEANING>VEGFR-2 DNA Vaccine VXM01</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR2 Tyrosine Kinase Inhibitor PF-00337210</VALIDVALUE>
          <VALUEMEANING>VEGFR2 Tyrosine Kinase Inhibitor PF-00337210</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, the VEGFR2 tyrosine kinase inhibitor PF-00337210 selectively binds to VEGFR2 and prevents its phosphorylation which may result in an inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and may eventually cause tumor cell death. VEGFR2, a receptor tyrosine kinase, is frequently overexpressed by a variety of tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813</VALIDVALUE>
          <VALUEMEANING>VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active, tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-Kit and Fms-related tyrosine kinase 3 (Flt-3). This leads to an inhibition of cellular proliferation and angiogenesis and an induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Veliparib</VALIDVALUE>
          <VALUEMEANING>Veliparib</VALUEMEANING>
          <MEANINGDESCRIPTION>A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Veltuzumab</VALIDVALUE>
          <VALUEMEANING>Veltuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in cells that overexpress CD20. CD20 antigen is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vemurafenib</VALIDVALUE>
          <VALUEMEANING>Vemurafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3422122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Venetoclax</VALIDVALUE>
          <VALUEMEANING>Venetoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103147</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5944045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Verapamil</VALIDVALUE>
          <VALUEMEANING>Verapamil</VALUEMEANING>
          <MEANINGDESCRIPTION>A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3128735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Verpasep Caltespen</VALIDVALUE>
          <VALUEMEANING>Verpasep Caltespen</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7.  Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.  E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Basiliximab</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Basiliximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Colloid</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Colloid</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Daclizumab</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Daclizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity.  Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes.  As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y90 DOTA anti-CEA monoclonal antibody cT84.66 binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Glass Microspheres</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Glass Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Monoclonal Antibody B3</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Monoclonal Antibody B3</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Monoclonal Antibody BrE-3</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Monoclonal Antibody BrE-3</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Monoclonal Antibody Hu3S193</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Monoclonal Antibody Hu3S193</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Tabituximab Barzuxetan</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Tabituximab Barzuxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90-DOTA-Biotin</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90-DOTA-Biotin</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy property. Biotin is a water-soluble B-complex vitamin, present in minute amounts in every living cell, while its level in cancerous tissue is higher than that of normal tissue. Y 90-DOTA-Biotin could be used in 3-step pre-targeting radioimmunotherapy that employs a tumor targeting antibody conjugated with streptavidin, the natural ligand of biotin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90-DOTA-di-HSG Peptide IMP-288</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90-DOTA-di-HSG Peptide IMP-288</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90-Edotreotide</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90-Edotreotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y-90 Clivatuzumab Tetraxetan</VALIDVALUE>
          <VALUEMEANING>Yttrium Y-90 Clivatuzumab Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Monoclonal Antibody MN-14</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Monoclonal Antibody MN-14</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y-90 Epratuzumab Tetraxetan</VALIDVALUE>
          <VALUEMEANING>Yttrium Y-90 Epratuzumab Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y-90 Ibritumomab Tiuxetan</VALIDVALUE>
          <VALUEMEANING>Yttrium Y-90 Ibritumomab Tiuxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y-90 Tacatuzumab Tetraxetan</VALIDVALUE>
          <VALUEMEANING>Yttrium Y-90 Tacatuzumab Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium-90 Polycarbonate Brachytherapy Plaque</VALIDVALUE>
          <VALUEMEANING>Yttrium-90 Polycarbonate Brachytherapy Plaque</VALUEMEANING>
          <MEANINGDESCRIPTION>A polycarbonate-based semicylindrical plaque impregnated with yttrium Y 90 with radioisotopic and antineoplastic activities. An yttrium-90 polycarbonate brachytherapy plaque may be applied to a tumor site with a special brachytherapy applicator for a predetermined interval of time, selectively delivering a cytotoxic dose of beta-emitting yttrium Y 90.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zalifrelimab</VALIDVALUE>
          <VALUEMEANING>Zalifrelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zalutumumab</VALIDVALUE>
          <VALUEMEANING>Zalutumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells. Zalutumumab selectively binds to and blocks binding of EGF and transforming growth factor-alpha (TGF-a) to the EGFR receptor, thereby interfering with cellular signaling, leading to cell growth inhibition and apoptosis in tumor cells. In addition, zalutumumab also triggers cell lysis mediated through antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zandelisib</VALIDVALUE>
          <VALUEMEANING>Zandelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zanidatamab</VALIDVALUE>
          <VALUEMEANING>Zanidatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zanolimumab</VALIDVALUE>
          <VALUEMEANING>Zanolimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T-cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4 positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zalcitabine</VALIDVALUE>
          <VALUEMEANING>Zalcitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zanubrutinib</VALIDVALUE>
          <VALUEMEANING>Zanubrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of Bruton&#39;s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zebularine</VALIDVALUE>
          <VALUEMEANING>Zebularine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cytidine analogue and a cytidine deaminase inhibitor with anticancer activity. Following metabolic activation by phosphorylation and incorporation into DNA, zebularine inhibits DNA methyltransferase through covalent complex formation between the enzyme and zebularine-substituted DNA, hence resulting in non-specific, genome-wide induction of demethylation including the removal of aberrant methylation of promoter regions of genes critical for normal cellular functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zelavespib</VALIDVALUE>
          <VALUEMEANING>Zelavespib</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zinc Finger Nuclease ZFN-603</VALIDVALUE>
          <VALUEMEANING>Zinc Finger Nuclease ZFN-603</VALUEMEANING>
          <MEANINGDESCRIPTION>A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-603 into HPV16-positive cells, ZFN-603 targets, binds to and cleaves the HPV16 E7 oncogene in HPV16-infected cells. By cleaving the HPV16 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and inhibition of tumor cell proliferation in HPV16-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zinc Finger Nuclease ZFN-758</VALIDVALUE>
          <VALUEMEANING>Zinc Finger Nuclease ZFN-758</VALUEMEANING>
          <MEANINGDESCRIPTION>A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 18 (HPV18) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-758 into HPV18-positive cells, ZFN-758 targets, binds to and cleaves the HPV18 E7 oncogene in HPV18-infected cells. By cleaving the HPV18 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and an inhibition of tumor cell proliferation in HPV18-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zinostatin</VALIDVALUE>
          <VALUEMEANING>Zinostatin</VALUEMEANING>
          <MEANINGDESCRIPTION>An enediyne antineoplastic antibiotic hybrid containing an aminoglycoside chromophore.  Zinostatin is isolated from the bacterium Streptomyces carzinostaticus.  The aminoglycoside component of zinostatin intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-strand breaks in DNA and apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zinostatin Stimalamer</VALIDVALUE>
          <VALUEMEANING>Zinostatin Stimalamer</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly lipophilic conjugate protein comprised of the lipophilic antitumor protein, neocarzinostatin (NCS), conjugated with a water-soluble copolymer of styrene-maleic acid (SMA) with potential antineoplastic activity. Upon intra-hepatic arterial administration, zinostatin stimalamer is deposited within tumor tissues, where the NCS moiety induces sequence-specific single and double-stranded breaks via free-radical based mechanisms, resulting in tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zibotentan</VALIDVALUE>
          <VALUEMEANING>Zibotentan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tirbanibulin</VALIDVALUE>
          <VALUEMEANING>Tirbanibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tisagenlecleucel</VALIDVALUE>
          <VALUEMEANING>Tisagenlecleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13274846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tislelizumab</VALIDVALUE>
          <VALUEMEANING>Tislelizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tisotumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Tisotumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tivantinib</VALIDVALUE>
          <VALUEMEANING>Tivantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3377421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLC ELL-12</VALIDVALUE>
          <VALUEMEANING>TLC ELL-12</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation of the ether lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with potential antineoplastic activity.  TLC ELL-12 induces tumor cell apoptosis via mitochondria- and caspase-mediated mechanisms.  Liposomal encapsulation reduces the free agent&#39;s hemolytic toxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR Agonist BDB001</VALIDVALUE>
          <VALUEMEANING>TLR Agonist BDB001</VALUEMEANING>
          <MEANINGDESCRIPTION>A toll-like receptor (TLR) agonist with potential immunostimulating and antineoplastic activities. Upon administration, TLR agonist BDB001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha (IFNa); production of proinflammatory cytokines; upregulation of co-stimulatory molecules; enhanced T- and B-cell stimulatory responses; T-cell proliferation; and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR Agonist BSG-001</VALIDVALUE>
          <VALUEMEANING>TLR Agonist BSG-001</VALUEMEANING>
          <MEANINGDESCRIPTION>A toll-like receptor (TLR) agonist with potential immunomodulating and antineoplastic activities. Upon inhalation, TLR agonist BSG-001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation, secretion of interferon alpha (IFNa), production of proinflammatory cytokines, upregulation of co-stimulatory molecules, enhanced T- and B-cell stimulatory responses, T-cell proliferation and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others. Immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR Agonist CADI-05</VALIDVALUE>
          <VALUEMEANING>TLR Agonist CADI-05</VALUEMEANING>
          <MEANINGDESCRIPTION>A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tivozanib</VALIDVALUE>
          <VALUEMEANING>Tivozanib (AV-951)</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR7 Agonist 852A</VALIDVALUE>
          <VALUEMEANING>TLR7 Agonist 852A</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic imidazoquinoline Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. TLR7 agonist 852A binds to and activates TLR7, thereby stimulating plasmacytoid dendritic cells (pDC) through the TLR7-MyD88-dependent signaling pathway. Activation of pDC results in secretion of interferon alpha, the production of proimflammatory cytokines, the upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR7 agonist BNT411</VALIDVALUE>
          <VALUEMEANING>TLR7 agonist BNT411</VALUEMEANING>
          <MEANINGDESCRIPTION>A Toll-like receptor (TLR) 7 agonist with potential immunostimulating and antitumor activities. Upon administration, TLR7 agonist BNT411 binds to and activates TLR7. This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR7 Agonist LHC165</VALIDVALUE>
          <VALUEMEANING>TLR7 Agonist LHC165</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzonapthyridine Toll-like receptor (TLR) 7 agonist that is adsorbed to aluminum hydroxide with immunostimulating and potential antitumor activities. Upon intratumoral administration of TLR7 agonist LHC165, the agent is slowly released and targets, binds to and activates TLR7.  This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells, the blockage of the suppressive function of regulatory T cells (Tregs), and the production of interferon alpha (IFNa).  TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells</VALIDVALUE>
          <VALUEMEANING>TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixed preparation of allogeneic T-lymphocytes that have been genetically modified to express either a chimeric antigen receptor (CAR) specific for the antigen transmembrane 4 L six family member 1 (TM4SF1) (CART-TM4SF1) or a CAR specific for epithelial cell adhesion molecule (EpCAM) (CART-EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration of the TM4SF1-CAR/EpCAM-CAR-expressing autologous T cells, the TM4SF1-CAR-expressing autologous T-cells specifically recognize and bind to TM4SF1-expressing tumor cells and the EpCAM-CAR-expressing autologous T-cells specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. TM4SF1 and EpCAM are expressed by a variety of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tocilizumab</VALIDVALUE>
          <VALUEMEANING>Tocilizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4618052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tocladesine</VALIDVALUE>
          <VALUEMEANING>Tocladesine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a purine analogue and competes with ATP in transcription. In addition, generation of 8-chloro-ATP depletes endogenous ATP pool that is essential for many biological reactions in intracellular energy transfer. As a result, this agent causes RNA synthesis inhibition, blocks cellular proliferation, and induces apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tocotrienol</VALIDVALUE>
          <VALUEMEANING>Tocotrienol</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the four forms, alpha, beta, gamma and delta, of a member of the vitamin E family, with potential hypocholesterolemic, antithrombotic, antioxidant, immunomodulating and antineoplastic activities. Tocotrienol inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby lowering cholesterol levels. In addition, tocotrienol acts through multiple signal transduction pathways to induce cell cycle arrest and caspase-mediated apoptosis, and to decrease tumor cell proliferation. In addition, this agent may inhibit angiogenesis through the blockage of vascular endothelial growth factor receptor (VEGFR) and the subsequent inhibition of tumor cell-induced vessel formation. Also, this agent prevents free radical formation and inhibits lipid peroxidation, thereby preventing DNA cell damage. Tocotrienol farnesyl isoprenoid side chains contain 3 double bonds, which are absent in tocopherols, likely contribute to its anti-cancer activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tocotrienol-rich Fraction</VALIDVALUE>
          <VALUEMEANING>Tocotrienol-rich Fraction</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available nutritional supplement containing high amounts of the vitamin E family member tocotrienol with antioxidant, hypolipidemic and potential immunomodulating and antiproliferative activity. Upon oral administration, tocotrienol-rich fraction (TRF) accumulates in tumor cells and induces cell cycle arrest, programmed cell death, and inhibits tumor cell proliferation. In addition, this agent suppresses 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and inhibits angiogenesis. Rice bran oil, palm oil and annatto seed oil are common sources of TRF.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tolebrutinib</VALIDVALUE>
          <VALUEMEANING>Tolebrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, brain-penetrant, selective, small molecule inhibitor of Bruton&#39;s tyrosine kinase (BTK), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, tolebrutinib is able to cross the blood-brain barrier and inhibits the activity of BTK both peripherally and in the central nervous system (CNS). This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway, and the resulting immune activation and inflammation. The inhibition of BTK activity also prevents microglial inflammatory signaling in the CNS, and the resulting immune activation, neuroinflammation and neurodegeneration. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. In addition to B cells, BTK is also expressed in innate immune cells, including macrophages and microglia, and plays an important role in the regulation of microglial inflammatory signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR-Directed Cationic Lipid-DNA Complex JVRS-100</VALIDVALUE>
          <VALUEMEANING>TLR-Directed Cationic Lipid-DNA Complex JVRS-100</VALUEMEANING>
          <MEANINGDESCRIPTION>A cationic lipid DNA complex (CLDC) consisting of DOTIM/cholesterol liposomes and plasmid DNA, containing immunostimulatory CpG and non-CpG motifs, with potential immunostimulating and antineoplastic activities. Upon systemic administration, TLR-directed cationic lipid-DNA complex JVRS-100 enters dendritic cells (DCs) and macrophages; immunostimulatory DNA binds to and activates Toll-like receptors (TLRs), which may result in the generation of anti-tumor natural killer (NK) cell and T-cell responses by the innate immune system. In addition, as a vaccine adjuvant, this agent may induce a strong cytotoxic T-lymphocyte (CTL) response to co-administered antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tolnidamine</VALIDVALUE>
          <VALUEMEANING>Tolnidamine</VALUEMEANING>
          <MEANINGDESCRIPTION>An indazole carboxylic acid derivative with antispermatogenic and potential antineoplastic activity. As a male contraceptive, tolnidamine may irreversibly inhibit sperm production. This agent is less nephrotoxic than ionidamide, but it is just as effective in antispermatogenic action to ionidamide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tomaralimab</VALIDVALUE>
          <VALUEMEANING>Tomaralimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2), with potential anti-inflammatory and antineoplastic activities. Upon intravenous administration, tomaralimab binds to the ligand-binding site on the TLR2 receptor and blocks the activation of TLR2-mediated innate immunity signaling. This prevents the TLR2-mediated production of pro-inflammatory mediators and prevents inflammation. TLR2, a member of the TLR family primarily found on leukocytes, plays a key role in the activation of innate immunity; it is overexpressed in various inflammatory diseases and in certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tomato-Soy Juice</VALIDVALUE>
          <VALUEMEANING>Tomato-Soy Juice</VALUEMEANING>
          <MEANINGDESCRIPTION>A juice containing tomato extract and soy protein with potential chemopreventive and antiproliferative activities. Tomato-soy juice contains phytochemicals, including flavonoids, such as the soy isoflavone genistein, and carotenoids, including lycopene. These phytochemicals may exhibit antioxidative activity, antitumor activity by modulating certain tumor-associated signal transduction pathways, and apoptosis-inducing activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tomivosertib</VALIDVALUE>
          <VALUEMEANING>Tomivosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Celecoxib</VALIDVALUE>
          <VALUEMEANING>Topical Celecoxib</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical cream formulation containing celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory and potential keratolytic, chemopreventive and antineoplastic activities. Upon topical application to the affected area, celecoxib selectively binds to and inhibits cyclooxygenase-2 activity (COX-2), which may result in localized keratinocyte apoptosis. The breakdown of keratinocytes prevents their proliferation locally and may reduce tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Fluorouracil</VALIDVALUE>
          <VALUEMEANING>Topical Fluorouracil</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2&#39;-deoxyuridine-5&#39;-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Gemcitabine Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Topical Gemcitabine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical preparation of gemcitabine hydrochloride with antineoplastic activity. Gemcitabine, an analogue of the antimetabolite nucleoside deoxycytidine, is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74085</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Potassium Dobesilate</VALIDVALUE>
          <VALUEMEANING>Topical Potassium Dobesilate</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical formulation composed of an inhibitor of fibroblast growth factor (FGF), with potential antineoplastic activity. Upon topical administration potassium dobesilate selectively binds to and blocks the activity of FGF, interferes with the binding of FGF to FGFR and prevents FGFR-mediated signaling. This inhibits angiogenesis and tumor cell proliferation, and induces cell death in FGFR-overexpressing tumor cells. FGF plays a key role in angiogenesis, tumor cell proliferation, survival and invasiveness, and is upregulated in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Trichloroacetic Acid</VALIDVALUE>
          <VALUEMEANING>Topical Trichloroacetic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical solution containing the caustic agent trichloroacetic acid (TCA), with potential keratolytic, anti-viral and antineoplastic activities. Upon topical application to the affected area, TCA causes tissue necrosis through coagulation of proteins, leads to the destruction of human papilloma virus (HPV)-associated warts and inhibits HPV-driven proliferation of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Betulinic Acid</VALIDVALUE>
          <VALUEMEANING>Topical Betulinic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A topical formulation of a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial factors involved in apoptosis, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topixantrone</VALIDVALUE>
          <VALUEMEANING>Topixantrone</VALUEMEANING>
          <MEANINGDESCRIPTION>A 9-aza-anthrapyrazole antineoplastic antibiotic. Topixantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Compared to other DNA intercalators, this agent shows minimal cardiotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase I Inhibitor Genz-644282</VALIDVALUE>
          <VALUEMEANING>Topoisomerase I Inhibitor Genz-644282</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase I Inhibitor LMP400</VALIDVALUE>
          <VALUEMEANING>Topoisomerase I Inhibitor LMP400</VALUEMEANING>
          <MEANINGDESCRIPTION>An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3234540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase I Inhibitor LMP776</VALIDVALUE>
          <VALUEMEANING>Topoisomerase I Inhibitor LMP776</VALUEMEANING>
          <MEANINGDESCRIPTION>An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3234542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase-1 Inhibitor LMP744</VALIDVALUE>
          <VALUEMEANING>Topoisomerase-1 Inhibitor LMP744</VALUEMEANING>
          <MEANINGDESCRIPTION>An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase-II Inhibitor Racemic XK469</VALIDVALUE>
          <VALUEMEANING>Topoisomerase-II Inhibitor Racemic XK469</VALUEMEANING>
          <MEANINGDESCRIPTION>The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase-II-beta Inhibitor Racemic XK469</VALIDVALUE>
          <VALUEMEANING>Topoisomerase-II-beta Inhibitor Racemic XK469</VALUEMEANING>
          <MEANINGDESCRIPTION>The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topotecan</VALIDVALUE>
          <VALUEMEANING>Topotecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topotecan Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Topotecan Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the semisynthetic camptothecin analog topotecan with antineoplastic activity.  During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2744959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topoisomerase I/II Inhibitor NEV-801</VALIDVALUE>
          <VALUEMEANING>Topoisomerase I/II Inhibitor NEV-801</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topotecan Hydrochloride Liposomes</VALIDVALUE>
          <VALUEMEANING>Topotecan Hydrochloride Liposomes</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of a semisynthetic derivative of camptothecin mixed with sphingomyelin/cholesterol and sonicated to form small unilamellar vesicles containing topotecan, with potential antineoplastic activity. Topotecan hydrochloride liposomes mediates efficient drug delivery of topotecan into the cytosol from the endosome compartment. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80065</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topotecan Sustained-release Episcleral Plaque</VALIDVALUE>
          <VALUEMEANING>Topotecan Sustained-release Episcleral Plaque</VALUEMEANING>
          <MEANINGDESCRIPTION>An episcleral plaque containing sustained-release (SR) topotecan, a semisynthetic derivative of camptothecin and a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic activity. Upon local application of the topotecan SR episcleral plaque to the eye, topotecan is released in a sustained manner and inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The episcleral plaque allows for local delivery of topotecan for the potential treatment of retinoblastoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topsalysin</VALIDVALUE>
          <VALUEMEANING>Topsalysin</VALUEMEANING>
          <MEANINGDESCRIPTION>A targeted prodrug consisting of a recombinant modified form of the Aeromonas protoxin, proaerolysin (PA), bearing a prostate-specific protease cleavage site, with potential antineoplastic activity. When injected directly into the prostate, topsalysin is hydrolyzed to the active toxin aerolysin by the serine protease prostate specific antigen (PSA), a protein overexpressed by prostate cancers and prostate cells in hyperplastic prostatic tissue. Aerolysin molecules then oligomerize to form ring-like heptamers that are incorporated into the lipid bilayers of cell membranes, forming large membrane channels and resulting in the leakage of cellular contents and lysis of PSA-expressing prostate cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toremifene</VALIDVALUE>
          <VALUEMEANING>Toremifene</VALUEMEANING>
          <MEANINGDESCRIPTION>An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3145844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toremifene Citrate</VALIDVALUE>
          <VALUEMEANING>Toremifene Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4111916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toripalimab</VALIDVALUE>
          <VALUEMEANING>Toripalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tosedostat</VALIDVALUE>
          <VALUEMEANING>Tosedostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid deprivation, inhibition of protein synthesis due to a decrease in the intracellular free amino acid pool, an increase in the level of the proapoptotic protein Noxa, and cell death. Noxa is a member of the BH3 (Bcl-2 homology 3)-only subgroup of the proapoptotic Bcl-2 (B-cell CLL/lymphoma 2) protein family.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tositumomab</VALIDVALUE>
          <VALUEMEANING>Tositumomab</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2741550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tovetumab</VALIDVALUE>
          <VALUEMEANING>Tovetumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TORC1/2 Kinase Inhibitor DS-3078a</VALIDVALUE>
          <VALUEMEANING>TORC1/2 Kinase Inhibitor DS-3078a</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of raptor-mTOR protein complex (TORC1) and rictor-mTOR protein complex (TORC2) with potential antineoplastic activity. TORC1/2 inhibitor DS-3078a binds to and inhibits both TORC1 and TORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101795</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tozasertib Lactate</VALIDVALUE>
          <VALUEMEANING>Tozasertib Lactate</VALUEMEANING>
          <MEANINGDESCRIPTION>The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TP40 Immunotoxin</VALIDVALUE>
          <VALUEMEANING>TP40 Immunotoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric fusion protein containing human transforming growth factor alpha (TGF-a) covalently linked to a truncated form of the bacterial toxin Pseudomonas exotoxin A, PE40, with potential antitumor activity. PE40 lacks the cell-binding domain, but retains domains II and III that are involved in membrane translocation and inhibition of protein synthesis in eukaryotic cells. TGF-a moiety of the TP40 immunotoxin binds to and activates epidermal growth factor receptor (EGFR), a tyrosine kinase receptor overexpressed on certain cancer cells. After internalization, the endotoxin moiety of the immunotoxin-receptor complex causes protein synthesis inhibition via modifying translation elongation factor 2 (EF-2), thereby impedes tumor cell growth and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trabectedin</VALIDVALUE>
          <VALUEMEANING>Trabectedin</VALUEMEANING>
          <MEANINGDESCRIPTION>A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trabedersen</VALIDVALUE>
          <VALUEMEANING>Trabedersen</VALUEMEANING>
          <MEANINGDESCRIPTION>A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5&#39;-CGGCATGTCTATTTTGTA-3&#39;, with potential antineoplastic activity. Trebedersen binds to TGF-beta2 mRNA causing inhibition of protein translation, thereby decreasing TGF-beta2 protein levels; decreasing intratumoral TGF-beta2 levels may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trametinib</VALIDVALUE>
          <VALUEMEANING>Trametinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3523220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trans Sodium Crocetinate</VALIDVALUE>
          <VALUEMEANING>Trans Sodium Crocetinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of the trans-isomer of the carotenoid crocetin with potential antihypoxic and radiosensitizing activities. Trans sodium crocetinate (TSC) increases the diffusion rate of oxygen in aqueous solutions such as from plasma to body tissue. The agent has been shown to increase available oxygen during hypoxic and ischemic conditions that may occur in hemorrhage, vascular and neurological disorders, and in the tumor microenvionment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transdermal 17beta-Estradiol Gel BHR-200</VALIDVALUE>
          <VALUEMEANING>Transdermal 17beta-Estradiol Gel BHR-200</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, transdermal, hydroalcoholic gel formulation containing 17beta-estradiol, with potential antineoplastic activity. Upon topical administration, 17beta-estradiol exerts its antineoplastic effect(s) through as of yet not fully elucidated mechanism(s) of action(s). This formulation may induce feedback inhibition via the hypothalamic-pituitary-gonadal axis feedback loop, block the secretion of luteinizing hormone (LH) and prevent the release of testosterone from Leydig cells in the testes, thus suppressing testosterone secretion. In addition, 17beta-estradiol inhibits enzymes involved in steroidogenesis, thereby further inhibiting androgen production. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In addition, 17beta-estradiol prevents bone loss, and suppresses andropause symptoms, such as hot flashes, which appear during androgen-deprivation therapy (ADT) where the standard of care is the use of gonadotrophin releasing hormone (GnRH) analogs. Compared to oral estrogens, the topical gel formulation lowers the risk of cardiovascular side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transdermal 4-Hydroxytestosterone</VALIDVALUE>
          <VALUEMEANING>Transdermal 4-Hydroxytestosterone</VALUEMEANING>
          <MEANINGDESCRIPTION>A transdermal formulation containing 4-hydroxytestosterone (4-OHT), a steroidal aromatase inhibitor (AI) and androgen receptor (AR) antagonist, with potential antineoplastic activity. 4-OHT is largely converted into 4-hydroxyandrostenedione (4-OHA) and irreversibly binds to and inhibits aromatase, thereby blocking the conversion of androstenedione to estrone, and testosterone to estradiol. This may inhibit tumor cell proliferation in estrogen-dependent tumor cells. In addition, 4-OHT binds to the AR and may inhibit AR-mediated tumor cell growth. Aromatase, a cytochrome P-450 enzyme, is overexpressed in a variety of cancer cells; it plays a key role in estrogen biosynthesis. Compared to oral 4-OHT, the transdermal formulation allows for continuous release of 4-OHT into the bloodstream and prevents first pass metabolism by the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</VALIDVALUE>
          <VALUEMEANING>Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary transferrin receptor-targeted nanoparticle preparation of a non-chemically modified small-interfering RNA (siRNA) directed against the M2 subunit of ribonucleotide reductase (RRM2) with potential antineoplastic activity. Upon administration, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01 binds to transferrin receptors (TfRs), releasing anti-RRM2 siRNA after endocytosis; anti-RRM2 siRNA silences the expression of RRM2 via the RNAi pathway, impeding the assembly of the holoenzyme ribonucleotide reductase (RR) which catalyzes the production of deoxyribonucleotides. As a result, inhibition of cellular proliferation may occur in cells expressing TfR, a cell surface protein overexpressed on various cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trametinib Dimethyl Sulfoxide</VALIDVALUE>
          <VALUEMEANING>Trametinib Dimethyl Sulfoxide</VALUEMEANING>
          <MEANINGDESCRIPTION>A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12564909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transferrin Receptor-Targeted Liposomal p53 cDNA</VALIDVALUE>
          <VALUEMEANING>Transferrin Receptor-Targeted Liposomal p53 cDNA</VALUEMEANING>
          <MEANINGDESCRIPTION>A cationic liposomal, tumor-targeting p53 (TP53) gene delivery system with potential anti-tumor activity. Transferrin receptor-targeted liposomal p53 cDNA contains plasmid DNA encoding the tumor suppressor protein p53 packaged in membrane-like liposome capsules that are complexed with anti-transferrin receptor single-chain antibody (TfRscFv). Upon systemic administration, the anti-TfRscFv selectively binds to tumor cells expressing transferrin receptors. The p53 plasmid is delivered into the nucleus and as a result, p53 protein is produced in tumor cells that have altered p53 function. This results in the restoration of normal cell growth control mechanisms as well as normal response mechanisms to DNA damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transferrin-CRM107</VALIDVALUE>
          <VALUEMEANING>Transferrin-CRM107</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tranylcypromine Sulfate</VALIDVALUE>
          <VALUEMEANING>Tranylcypromine Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5118533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trapoxin</VALIDVALUE>
          <VALUEMEANING>Trapoxin</VALUEMEANING>
          <MEANINGDESCRIPTION>An epoxide-containing cyclotetrapeptide with antitumor activity.  It is an irreversible inhibitor of histone deacetylase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1665</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab Conjugate BI-CON-02</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Conjugate BI-CON-02</VALUEMEANING>
          <MEANINGDESCRIPTION>A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab Deruxtecan</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Deruxtecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab Duocarmazine</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Duocarmazine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab Emtansine</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Emtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4255113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab Monomethyl Auristatin F</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Monomethyl Auristatin F</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of trastuzumab monomethyl auristatin F, the trastuzumab moiety binds to HER2 on tumor cell surfaces; upon internalization, the MMAF moiety binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab</VALIDVALUE>
          <VALUEMEANING>Trastuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502</VALIDVALUE>
          <VALUEMEANING>Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of an engineered version of the humanized monoclonal anti-human epidermal growth factor receptor 2 (HER2) immunoglobulin G1 (IgG1) trastuzumab that is site-specifically conjugated, via a cleavable linker, to the cytotoxic, DNA cross-linking pyrrolobenzodiazepine (PBD) dimer-based drug tesirine, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the trastuzumab moiety of trastuzumab/tesirine ADC ADCT-502 targets the cell surface antigen HER2, which is expressed on various cancer cells. Upon antibody/antigen binding, internalization of the ADC and cleavage of the linker, the cytotoxic PBD moiety is released. The imine groups of tesirine bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of HER2-overexpressing tumor cells. The tumor-associated antigen (TAA) HER2 is expressed by various solid tumors and is associated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trebananib</VALIDVALUE>
          <VALUEMEANING>Angiopoietin 1/2-Neutralizing Peptibody AMG 386</VALUEMEANING>
          <MEANINGDESCRIPTION>An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3205720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trimetrexate Glucuronate</VALIDVALUE>
          <VALUEMEANING>Trimetrexate Glucuronate</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trioxifene</VALIDVALUE>
          <VALUEMEANING>Trioxifene</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal selective estrogen receptor modulator (SERM) with potential antineoplastic activity.  Trioxifene competes with estradiol in binding to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated signal transduction and gene expression. In addition, trioxifene exerts intrinsic estrogenic activity depending on the tissue. Clinical development of trioxifene has not been preceded due to its side effect profile and lack of increased efficacy over tamoxifen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triptolide Analog</VALIDVALUE>
          <VALUEMEANING>Triptolide Analog</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triptorelin</VALIDVALUE>
          <VALUEMEANING>Triptorelin</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triptorelin Pamoate</VALIDVALUE>
          <VALUEMEANING>Triptorelin Pamoate</VALUEMEANING>
          <MEANINGDESCRIPTION>The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6686955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tris-acryl Gelatin Microspheres</VALIDVALUE>
          <VALUEMEANING>Tris-acryl Gelatin Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>An embolic particle composed of water-soluble, compressible, nonabsorbable microspheres composed of tris-acryl gelatin, with potential use for embolization. Upon administration, the tris-acryl gelatin microspheres (TAGM) serve as an embolic agent before surgery for highly vascularized areas, such as those seen in certain tumors, by penetrating into the blood vessel system and blocking blood flow. These microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as drug delivery vehicles during embolization of tumor vasculature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tritylcysteine</VALIDVALUE>
          <VALUEMEANING>Tritylcysteine</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of cysteine with antimitotic activity and potential antineoplastic activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triplatin Tetranitrate</VALIDVALUE>
          <VALUEMEANING>Triplatin Tetranitrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A cationic tri-nuclear platinum complex related to cisplatin.  BBR 3464 binds to and forms DNA crosslinks and platinum-DNA adducts, preventing DNA replication and tumor cell division.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TRK Inhibitor AZD6918</VALIDVALUE>
          <VALUEMEANING>TRK Inhibitor AZD6918</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available liquid suspension containing the tropomyosin receptor kinase (Trk) inhibitor AZD6918 with potential antineoplastic activity. AZD6918 binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, and may eventually result in cell cycle arrest and apoptosis of tumor cells that express Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TRK Inhibitor TQB3558</VALIDVALUE>
          <VALUEMEANING>TRK Inhibitor TQB3558</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of tropomyosin receptor kinase (Trk), with potential antineoplastic activity. Upon oral administration, Trk inhibitor TQB3558 targets and binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation. This may lead to apoptosis of Trk-expressing tumor cells and the inhibition of tumor cell proliferation in Trk-expressing tumors. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TrkA Inhibitor VMD-928</VALIDVALUE>
          <VALUEMEANING>TrkA Inhibitor VMD-928</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trofosfamide</VALIDVALUE>
          <VALUEMEANING>Trofosfamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and ultimately lead to tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Troglitazone</VALIDVALUE>
          <VALUEMEANING>Troglitazone</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Troriluzole</VALIDVALUE>
          <VALUEMEANING>Troriluzole</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Troxacitabine</VALIDVALUE>
          <VALUEMEANING>Troxacitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TRPM8 Agonist D-3263</VALIDVALUE>
          <VALUEMEANING>TRPM8 Agonist D-3263</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8), with potential antineoplastic activity. Upon administration, TRPM8 agonist D-3263 targets, binds to and activates TRPM8, which may result in an increase in intracellular calcium and sodium influx; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and benign prostatic hyperplasia (BPH). TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in BPH and in prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TRPV6 Calcium Channel Inhibitor SOR-C13</VALIDVALUE>
          <VALUEMEANING>TRPV6 Calcium Channel Inhibitor SOR-C13</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trodusquemine</VALIDVALUE>
          <VALUEMEANING>Trodusquemine</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TSP-1 Mimetic ABT-510</VALIDVALUE>
          <VALUEMEANING>TSP-1 Mimetic ABT-510</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1).  ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TSP-1 Mimetic Fusion Protein CVX-045</VALIDVALUE>
          <VALUEMEANING>TSP-1 Mimetic Fusion Protein CVX-045</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein containing two thrombospondin (TSP-1)-derived nonamer peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic monoclonal aldolase monoclonal antibody with potential antiangiogenic and antineoplastic activities.  The TSP-1 mimetic peptide moieties of TSP-1 mimetic fusion protein CVX-045 bind to TSP-1 receptors, such as CD36, and inhibit tumor angiogenesis, which may result in the inhibition of tumor cell proliferation. The proprietary humanized catalytic monoclonal aldolase monoclonal antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the TSP-1 mimetic peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubercidin</VALIDVALUE>
          <VALUEMEANING>Tubercidin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibiotic and adenosine analog isolated from the bacterium Streptomyces tubercidicus with potential antineoplastic activity.  Tubercidin is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis.  This agent also exhibits antifungal and antiviral activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin Inhibitor ALB 109564 Dihydrochloride</VALIDVALUE>
          <VALUEMEANING>Tubulin Inhibitor ALB 109564 Dihydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB 109564 dihydrochloride binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78842</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin Polymerization Inhibitor AEZS 112</VALIDVALUE>
          <VALUEMEANING>Tubulin Polymerization Inhibitor AEZS 112</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Upon oral administration, tubulin polymerization inhibitor AEZS 112 binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin-Binding Agent SSR97225</VALIDVALUE>
          <VALUEMEANING>Tubulin-Binding Agent SSR97225</VALUEMEANING>
          <MEANINGDESCRIPTION>An antimitotic tubulin-binding agent with potential antineoplastic activity. Tubulin-binding agent SSR97225 binds to tubulin, arresting the cell cycle at the G2/M checkpoint and preventing mitosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tucatinib</VALIDVALUE>
          <VALUEMEANING>Tucatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tucidinostat</VALIDVALUE>
          <VALUEMEANING>Tucidinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Upon administration, tucidinostat binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tucotuzumab Celmoleukin</VALIDVALUE>
          <VALUEMEANING>Tucotuzumab Celmoleukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of a human monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM or KS) linked to an active interleukin-2 (IL2) molecule with potential antineoplastic activity. Tucotuzumab Celmoleukin recognizes and binds to EpCAM, a cell surface epithelial protein that is expressed on a wide variety of cancer cells, thereby concentrating IL2 in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of the fusion protein may stimulate a cytotoxic T-cell antitumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin Inhibitor ALB-109564</VALIDVALUE>
          <VALUEMEANING>Tubulin Inhibitor ALB-109564</VALUEMEANING>
          <MEANINGDESCRIPTION>A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB-109564 binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle. Check for active clinical trials using this agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyroserleutide</VALIDVALUE>
          <VALUEMEANING>Tyroserleutide</VALUEMEANING>
          <MEANINGDESCRIPTION>A tripeptide consisting of tyrosine, serine, and leucine with potential antineoplastic activity. Although the mechanism of its antitumor activity has yet to be fully elucidated, tyroserleutide appears to inhibit the expression of ICAM-1 (CD54), a cell adhesion factor of the immunoglobulin (Ig) superfamily that plays an important role in the invasion, adhesion, and metastasis of tumor cells. In addition, this agent may influence the Ca2+/calmodulin pathway, inhibiting phosphatidylinositol 3 kinase (PI3K); PI3K is upregulated in tumor cells and is involved in cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosinase Peptide</VALIDVALUE>
          <VALUEMEANING>Tyrosinase Peptide</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a number of recombinant peptides consisting of amino acid residues of the enzyme tyrosinase, a protein frequently expressed by melanoma cells.  Vaccination with tyrosinase peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosinase:146-156 Peptide</VALIDVALUE>
          <VALUEMEANING>Tyrosinase:146-156 Peptide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic peptide consisting of amino acid residues 146 through 156 of the enzyme tyrosinase, a protein frequently expressed by melanoma cells, with antitumor activity. Vaccination with tyrosinase:146-156 peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth and cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosinase-KLH</VALIDVALUE>
          <VALUEMEANING>Tyrosinase-KLH</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosine Kinase Inhibitor SU5402</VALIDVALUE>
          <VALUEMEANING>Tyrosine Kinase Inhibitor SU5402</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolinone-based small molecule selective tyrosine kinase inhibitor with potential antineoplastic activity. SU5402 blocks the activities of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor 1 (FGFR1) via competing with ATP for the specific binding site within the catalytic domain of these receptors. This agent was shown to inhibit cell growth, decrease cell viability in dose-dependent manner, and induce apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosine Kinase Inhibitor TL-895</VALIDVALUE>
          <VALUEMEANING>Tyrosine Kinase Inhibitor TL-895</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. In addition, they play important roles in the activation of leukocytes and in many immune-mediated inflammatory and autoimmune conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosine Kinase Inhibitor XL228</VALIDVALUE>
          <VALUEMEANING>Tyrosine Kinase Inhibitor XL228</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UAE Inhibitor TAK-243</VALIDVALUE>
          <VALUEMEANING>UAE Inhibitor TAK-243</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor TAK-243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome. This results in an excess of proteins in the cells and may lead to endoplasmic reticulum (ER) stress-mediated apoptosis. This inhibits tumor cell proliferation and survival. UAE, also called ubiquitin E1 enzyme (UBA1; E1), is more active in cancer cells than in normal, healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ubenimex</VALIDVALUE>
          <VALUEMEANING>Ubenimex</VALUEMEANING>
          <MEANINGDESCRIPTION>A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosine Kinase Inhibitor OSI-930</VALIDVALUE>
          <VALUEMEANING>Tyrosine Kinase Inhibitor OSI-930</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell factor receptor (c-Kit) and the vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of both tumor cell proliferation and tumor angiogenesis. Both c-Kit and VEGFR2 are overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ubidecarenone Nanodispersion BPM31510n</VALIDVALUE>
          <VALUEMEANING>Ubidecarenone Nanodispersion BPM31510n</VALUEMEANING>
          <MEANINGDESCRIPTION>A nanodispersion containing the benzoquinone ubidecarenone (coenzyme Q10), with potential protective, antioxidant and antineoplastic activities. Upon administration, ubidecarenone nanodispersion BPM31510 modulates tumor cell metabolism and causes an anti-Warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. This inhibits tumor cell proliferation. BPM 31510 also induces the activation and maturation of T-lymphocytes, and changes the surface expression of certain immune checkpoint modulators. In addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of LDL-cholesterol. Ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (ATP).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118621</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ublituximab</VALIDVALUE>
          <VALUEMEANING>Ublituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ulinastatin</VALIDVALUE>
          <VALUEMEANING>Ulinastatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A multivalent Kunitz-type serine protease inhibitor derived from human urine, with potential protective, anti-fibrinolytic and anticoagulant activities. Upon administration, ulinastatin (or urinary trypsinogen inhibitor) inhibits the activities of a variety of enzymes, including trypsin, chymotrypsin, thrombin, kallikrein, plasmin, elastase, cathepsin, lipase, hyaluronidase, factors IXa, Xa, XIa, and XlIa, and polymorphonuclear leukocyte elastase. In addition, ulinastatin inhibits the excessive release of proinflammatory mediators, such as tumor necrosis factor-alpha, interleukin-6 and -8, and chemokines. Altogether, this agent may improve the microcirculation, perfusion and function of tissues and may protect organ injury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ulixertinib</VALIDVALUE>
          <VALUEMEANING>Ulixertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Umbralisib</VALIDVALUE>
          <VALUEMEANING>Umbralisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  PI3K-delta inhibitor TGR-1202 inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uncaria tomentosa Extract</VALIDVALUE>
          <VALUEMEANING>Uncaria tomentosa Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An extract of Uncaria tomentosa (U. tomentosa), also called Cat&#39;s claw, a native Amazonian plant belonging to the Rubiaceae species, with potential anti-inflammatory, immunomodulating, antioxidant and antineoplastic activities. Although the exact mechanism(s) by which U. tomentosa extract exerts its effect(s) has yet to be fully elucidated, this extract may inhibit the proliferation of certain types of cancer cells. This extract may modulate inflammatory and immune responses through the stimulation of T- and B-lymphocytes and certain cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a). Components in U. tomentosa may both induce repair of chemically-induced DNA damage and scavenge free radicals, which may protect against reactive oxygen species (ROS)-mediated cellular damage. In addition, this extract stimulates myelopoiesis, which may prevent chemotherapy-induced neutropenia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upamostat</VALIDVALUE>
          <VALUEMEANING>Upamostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, upamostat is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upifitamab</VALIDVALUE>
          <VALUEMEANING>Upifitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upifitamab, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of XMT-1535 are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uproleselan</VALIDVALUE>
          <VALUEMEANING>Uproleselan</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ulocuplumab</VALIDVALUE>
          <VALUEMEANING>Ulocuplumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable monoclonal antibody against CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. Ulocuplumab binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uprosertib</VALIDVALUE>
          <VALUEMEANING>Uprosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Uprosertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urabrelimab</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody SRF231</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SRF231 selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uracil Ointment</VALIDVALUE>
          <VALUEMEANING>Uracil Ointment</VALUEMEANING>
          <MEANINGDESCRIPTION>A 0.1% topical formulation of uracil used potentially to lower the incidence of hand-foot syndrome (HFS) (or palmar-plantar erythrodysesthesia) during 5-fluorouracil (5-FU) or 5-FU prodrug capecitabine chemotherapy. Upon local administration of uracil ointment to the skin, uracil competes with capecitabine or 5-FU as substrates for the activating enzyme thymidine phosphorylase and the metabolizing enzyme dihydropyrimidine dehydrogenase. This may prevent the production of 5-FU as well as the breakdown of 5-FU into the toxic metabolites locally. As the 5-FU metabolites are responsible for the presentation of HFS, inhibiting their formation may prevent this adverse effect. By applying a high concentration of uracil locally, the skin toxicities of 5-FU may be countered while preserving the systemic anti-cancer activity of the 5FU.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urelumab</VALIDVALUE>
          <VALUEMEANING>Urelumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urokinase-Derived Peptide A6</VALIDVALUE>
          <VALUEMEANING>Urokinase-Derived Peptide A6</VALUEMEANING>
          <MEANINGDESCRIPTION>An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ursolic Acid</VALIDVALUE>
          <VALUEMEANING>Ursolic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A pentacyclic triterpenoid found in various fruits, vegetables and medicinal herbs, with a variety of potential pharmacologic activities including anti-inflammatory, antioxidative, antiviral, serum lipid-lowering, and antineoplastic activities. Upon administration, ursolic acid may promote apoptosis and inhibit cancer cell proliferation through multiple mechanisms. This may include the regulation of mitochondrial function through various pathways including the ROCK/PTEN and p53 pathways, the suppression of the nuclear factor-kappa B (NF-kB) pathways, and the increase in caspase-3, caspase-8 and caspase-9 activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>USP14/UCHL5 Inhibitor VLX1570</VALIDVALUE>
          <VALUEMEANING>USP14/UCHL5 Inhibitor VLX1570</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the 19S proteasome-specific deubiquitylating enzymes (DUBs) USP14 and UCHL5, with apoptosis-inducing and antineoplastic activities. Upon administration, VLX1570 specifically binds to both USP14 and UCHL5, thereby blocking their deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. USP14 and UCHL5, overexpressed in various tumor cell types, play a key role in the correct folding and deubiquitination of proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Utomilumab</VALIDVALUE>
          <VALUEMEANING>Utomilumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7154920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uzansertib</VALIDVALUE>
          <VALUEMEANING>Uzansertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uroacitides</VALIDVALUE>
          <VALUEMEANING>Uroacitides</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of peptides, organic acids, pigments, and phenylacetylglutamine isolated from healthy human urine with potential antineoplastic activity. Upon administration, uroacitides, also known as cell differentiation agent II (CDA-II) may inhibit telomerase activity in tumor cells. This may lead to an accumulation of tumor cells in G1 phase and inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>V930 Vaccine</VALIDVALUE>
          <VALUEMEANING>V930 Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel cancer vaccine designed to treat HER-2- and/or CEA-expressing cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaccine-Sensitized Draining Lymph Node Cells</VALIDVALUE>
          <VALUEMEANING>Vaccine-Sensitized Draining Lymph Node Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells isolated from lymph nodes from patients, and activated in vitro to generate tumor-specific effector T cells.  Lymph nodes in the lymphatics draining tumors often contain T cells that are immunologically sensitized but functionally deficient. Vaccine-sensitized draining lymph node cells are prepared by isolating these lymphocytes in vitro and stimulating them with cytokines to differentiate into mature effector cells.  Vaccine-draining lymph node cells may also be produced by pharmacological activation of lymph node-derived lymphocytes with drugs such as ionomycin or with bacterial toxin; these activated lymphocytes may be expanded in culture with cytokines such as interleukin-2 prior to infusion into the patient. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2542</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules</VALIDVALUE>
          <VALUEMEANING>Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary suspension formulation prepared from granules of standardized extracts from the fruits of Vaccinium myrtillus, the aerial parts of Macleaya cordata and the roots of Echinacea angustifolia, with potential anti-mucositis, anti-inflammatory, and analgesic activities. The main active ingredients of this formulation include anthocyanosides and procyanidins, benzophenanthridinic alkaloids, and alkylamides from V. myrtillus, M. cordata and E. angustifolia extracts, respectively. Upon administration in the mucosal cavity, the anthocyanosides scavenge free radicals, form a protective barrier on the mucosa, and protect the integrity of the capillary vessels; the benzophenanthridine alkaloids prevent the production of pro-inflammatory cytokines by inhibiting NF-kB and may halt the growth of microorganisms; the alkylamides inhibit cyclooxygenase and 5-lipoxygenase thereby blocking productions of prostaglandin and leukotriene. Furthermore, alkylamides modulate the expression of tumor necrosis factor alpha and other cytokines involved in inflammation processes through cannabinoid type 2 receptors and as cannabinomimetics they may also exert analgesic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vactosertib</VALIDVALUE>
          <VALUEMEANING>Vactosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vadacabtagene Leraleucel</VALIDVALUE>
          <VALUEMEANING>Vadacabtagene Leraleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vadastuximab Talirine</VALIDVALUE>
          <VALUEMEANING>Vadastuximab Talirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of SGN-CD33A, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vadimezan</VALIDVALUE>
          <VALUEMEANING>Vadimezan</VALUEMEANING>
          <MEANINGDESCRIPTION>A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3481458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Valecobulin</VALIDVALUE>
          <VALUEMEANING>Valecobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Valproic Acid</VALIDVALUE>
          <VALUEMEANING>Valproic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent&#39;s antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7460887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Valrubicin</VALIDVALUE>
          <VALUEMEANING>Valrubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4337185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Valspodar</VALIDVALUE>
          <VALUEMEANING>Valspodar</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vandetanib</VALIDVALUE>
          <VALUEMEANING>Vandetanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vandetanib-eluting Radiopaque Bead BTG-002814</VALIDVALUE>
          <VALUEMEANING>Vandetanib-eluting Radiopaque Bead BTG-002814</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiopaque drug-eluting beads (DEBs) that are loaded with vandetanib, a dual inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with potential antineoplastic, anti-angiogenic and imaging activities. Upon intra-arterial hepatic artery administration of vandetanib (VTB)-eluting Radiopaque beads (VERBs) BTG-002814, the DEBs occlude the tumor blood vessels and deprive tumor cells of oxygen and nutrients, thereby causing hepatic arterial embolization and direct tumor cell death. The VERBs release vandetanib from the beads in a sustained manner. Vandetanib selectively inhibits the tyrosine kinase activity of both VEGFR and EGFR, thereby blocking both VEGF/VEGFR- and EGF/EGFR-stimulated signaling and inhibiting cell proliferation, migration and angiogenesis in VEGFR/EGFR-expressing hepatic tumor cells. The DEBs, controlled release microspherical devices, cause low systemic exposure and prevent systemic toxicity of vandetanib. DEBs also deliver high concentrations of vandetanib in the tumor for a controlled and extended period of time. Use of radiopaque DEBs allows for visualization of both the bead location and the degree of embolization upon imaging.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vandortuzumab Vedotin</VALIDVALUE>
          <VALUEMEANING>Vandortuzumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed in a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Valemetostat</VALIDVALUE>
          <VALUEMEANING>Valemetostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127114</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vantictumab</VALIDVALUE>
          <VALUEMEANING>Vantictumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This may result in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. The Wnt signaling pathway is dysregulated in many cancer cell types and appears to play a major role in CSC regulation and activity; CSC are tumor initiating cells that are able to self-renew and are responsible for tumor growth and resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vanucizumab</VALIDVALUE>
          <VALUEMEANING>Vanucizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells. VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vapreotide</VALIDVALUE>
          <VALUEMEANING>Vapreotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Varlilumab</VALIDVALUE>
          <VALUEMEANING>Varlilumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99127</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6847011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Varlitinib Tosylate</VALIDVALUE>
          <VALUEMEANING>Varlitinib Tosylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The tosylate salt form of varlitinib, an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Verubulin</VALIDVALUE>
          <VALUEMEANING>Verubulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A quinazoline derivative with potential antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, and may be useful for treating multidrug resistant tumors. In addition, as a vascular disrupting agent, verubulin disrupts tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death. In addition, verubulin is able to cross the blood-brain barrier and accumulate in the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Verubulin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Verubulin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of verubulin, a quinazoline derivative with potential dual antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, such as P-glycoprotein, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1); therefore, it may be useful for treating multidrug resistant (MDR) tumors that express these transporters. In addition, as a vascular disrupting agent (VDA), verubulin appears to disrupt tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64782</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vesencumab</VALIDVALUE>
          <VALUEMEANING>Vesencumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous administration, vesencumab specifically targets and binds to NRP1; the antibody-NRP1 complex prevents the subsequent coupling of NRP1 to VEGFR2, thereby potentially inhibiting VEGF-mediated signaling and potentially preventing angiogenesis. In combination with other anti-VEGF therapies, vesencumab may enhance their anti-angiogenic effect. NRP1 is a membrane-bound co-receptor normally expressed by endothelial cells and overexpressed by certain tumor cells, and plays a role in angiogenesis, cell survival, migration, and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vesigenurtucel-L</VALIDVALUE>
          <VALUEMEANING>Vesigenurtucel-L</VALUEMEANING>
          <MEANINGDESCRIPTION>An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Varlitinib</VALIDVALUE>
          <VALUEMEANING>Varlitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220</VALIDVALUE>
          <VALUEMEANING>VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixed-backbone antisense oligonucleotide that is complementary to a pro-angiogenic vascular endothelial growth factor (VEGF) mRNA sequence.  Because of its antiangiogenic properties, GEM 220 has been studied as a potential antineoplastic agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2016</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820</VALIDVALUE>
          <VALUEMEANING>VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial growth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49090</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Viagenpumatucel-L</VALIDVALUE>
          <VALUEMEANING>Viagenpumatucel-L</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vibecotamab</VALIDVALUE>
          <VALUEMEANING>Vibecotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring Fc domain is maintained, with potential immunostimulatory and antineoplastic activities. Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of vibecotamab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell mediated tumor cell killing through its binding to the Fc receptors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127120</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vibostolimab</VALIDVALUE>
          <VALUEMEANING>Vibostolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vilaprisan</VALIDVALUE>
          <VALUEMEANING>Vilaprisan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, vilaprisan competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system and may inhibit PR-mediated proliferative effects in cells overexpressing PRs. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue or uterine fibroid formation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinblastine</VALIDVALUE>
          <VALUEMEANING>Vinblastine</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinblastine Sulfate</VALIDVALUE>
          <VALUEMEANING>Vinblastine Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vincristine Liposomal</VALIDVALUE>
          <VALUEMEANING>Vincristine Liposomal</VALUEMEANING>
          <MEANINGDESCRIPTION>A liposomal formulation of Vincristine designed to reduce toxicity and improve efficacy.  Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vincristine Sulfate</VALIDVALUE>
          <VALUEMEANING>Vincristine Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vincristine Sulfate Liposome</VALIDVALUE>
          <VALUEMEANING>Vincristine Sulfate Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vindesine</VALIDVALUE>
          <VALUEMEANING>Vindesine</VALUEMEANING>
          <MEANINGDESCRIPTION>Vinblastine derivative with antineoplastic activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus, head, and neck, and Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinepidine</VALIDVALUE>
          <VALUEMEANING>Vinepidine</VALUEMEANING>
          <MEANINGDESCRIPTION>A vinca alkaloid compound and semi-synthetic vincristine derivative with antineoplastic activity. Vinepidine binds to and stabilizes tubulin, thereby preventing tubulin polymerization and depolymerization, which result in microtubule assembly and disassembly, respectively. Treated cells are unable to complete mitosis process and are arrested in the metaphase, thereby leading to an inhibition of cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinflunine</VALIDVALUE>
          <VALUEMEANING>Vinflunine</VALUEMEANING>
          <MEANINGDESCRIPTION>A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5242660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vincristine</VALIDVALUE>
          <VALUEMEANING>Vincristine</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinflunine Ditartrate</VALIDVALUE>
          <VALUEMEANING>Vinflunine Ditartrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C76266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinfosiltine</VALIDVALUE>
          <VALUEMEANING>Vinfosiltine</VALUEMEANING>
          <MEANINGDESCRIPTION>An aminophosphonate derivative of a vinca alkaloid with potential antineoplastic activity. Vinfosiltine exerts its antineoplastic action just like its parent compound, vinblastine, by immobilizing tubulin molecules, thereby interrupting microtubule assembly/disassembly dynamics. As a result, vinfosiltine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinorelbine</VALIDVALUE>
          <VALUEMEANING>Vinorelbine</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinorelbine Tartrate</VALIDVALUE>
          <VALUEMEANING>Vinorelbine Tartrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine&#39;s neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7590019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinorelbine Tartrate Oral</VALIDVALUE>
          <VALUEMEANING>Vinorelbine Tartrate Oral</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tartrate salt of vinorelbine, a semisynthetic vinca alkaloid with potential antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine&#39;s neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vintafolide</VALIDVALUE>
          <VALUEMEANING>Vintafolide</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5808439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinzolidine</VALIDVALUE>
          <VALUEMEANING>Vinzolidine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinzolidine Sulfate</VALIDVALUE>
          <VALUEMEANING>Vinzolidine Sulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sulfate salt of vinzolidine, an orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Virulizin</VALIDVALUE>
          <VALUEMEANING>Virulizin</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural biological response modifier (BRM) isolated from bovine reticuloendothelial tissue. Viruzlin may enhance cell-mediated immune response to tumor cells by direct macrophage activation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vinorelbine Tartrate Emulsion</VALIDVALUE>
          <VALUEMEANING>Vinorelbine Tartrate Emulsion</VALUEMEANING>
          <MEANINGDESCRIPTION>An emulsion containing the tartrate salt of the semisynthetic vinca alkaloid vinorelbine with antineoplastic activity. Vinorelbine binds to tubulin, inhibiting tubulin polymerization into microtubules; cell division is prevented, the cell cycle is arrested metaphase and cell death ensues. In this formulation vinorelbine is emulsified in a homogeneous suspension of nanoparticles, which protects the venous endothelium from coming into direct contact with the active ingredient, potentially reducing vinorelbine-associated venous toxicity at the venous injection site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vismodegib</VALIDVALUE>
          <VALUEMEANING>Vismodegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vistusertib</VALIDVALUE>
          <VALUEMEANING>Vistusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vitamin D3 Analogue ILX23-7553</VALIDVALUE>
          <VALUEMEANING>Vitamin D3 Analogue ILX23-7553</VALUEMEANING>
          <MEANINGDESCRIPTION>A vitamin D3 analogue with potential antineoplastic activity.  ILX23-7553 binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, ILX23-7553 may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vitamin E Compound</VALIDVALUE>
          <VALUEMEANING>Vitamin E Compound</VALUEMEANING>
          <MEANINGDESCRIPTION>A fat-soluble vitamin which is primarily a chain-breaking antioxidant that prevents the propagation of lipid peroxidation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C942</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4804371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vitespen</VALIDVALUE>
          <VALUEMEANING>Vitespen</VALUEMEANING>
          <MEANINGDESCRIPTION>An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins.  Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vofatamab</VALIDVALUE>
          <VALUEMEANING>Vofatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon intravenous administration, vofatamab specifically binds to and inhibits both wild-type and mutated forms of FGFR3. This may result in the inhibition of FGFR3 phosphorylation, and thereby preventing its activation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Volasertib</VALIDVALUE>
          <VALUEMEANING>Volasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Volociximab</VALIDVALUE>
          <VALUEMEANING>Volociximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vonlerolizumab</VALIDVALUE>
          <VALUEMEANING>Vonlerolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, vonlerolizumab selectively binds to and activates OX40, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 activation induces proliferation of effector T-lymphocytes and inhibits the activity of regulatory T-cells. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vocimagene Amiretrorepvec</VALIDVALUE>
          <VALUEMEANING>Vocimagene Amiretrorepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication competent retroviral vector, derived from the Moloney murine leukemia virus (MoMLV), encoding a modified form of the yeast suicide gene cytosine deaminase (CD) (Toca 511) used as an antineoplastic adjuvant. Upon transcranial injection, vocimagene amiretrorepvec preferentially enters and transfects tumor cells, and expresses cytosine deaminase, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vopratelimab</VALIDVALUE>
          <VALUEMEANING>Vopratelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, anti-ICOS agonist monoclonal antibody JTX-2011 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vorasidenib</VALIDVALUE>
          <VALUEMEANING>Vorasidenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vorinostat</VALIDVALUE>
          <VALUEMEANING>Vorinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3380298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vorolanib</VALIDVALUE>
          <VALUEMEANING>Vorolanib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. Vorolanib inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. Vorolanib has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vosaroxin</VALIDVALUE>
          <VALUEMEANING>Vosaroxin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, hence reducing the risk of cardiotoxicity; it is not a P-glycoprotein (P-gp) substrate, and thereby evades the common mechanism for multidrug resistance; and it has limited distribution to normal tissues and a more chemically stable molecular structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vosilasarm</VALIDVALUE>
          <VALUEMEANING>Vosilasarm</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Voxtalisib</VALIDVALUE>
          <VALUEMEANING>Voxtalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vulinacimab</VALIDVALUE>
          <VALUEMEANING>Vulinacimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wee1 Kinase Inhibitor Debio 0123</VALIDVALUE>
          <VALUEMEANING>Wee1 Kinase Inhibitor Debio 0123</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the human tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu), with potential antineoplastic sensitizing activity. Upon oral administration of Debio 0123, this agent targets, binds to and inhibits Wee1. Inhibition of Wee1 inhibits Cdk1 (Cdc2) phosphorylation, promotes both premature mitosis and a prolonged mitotic arrest, which results in the accumulation of unrepaired DNA damage. This leads to apoptosis in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, especially in combination with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis. The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M and S cell cycle checkpoints.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vorsetzumab Mafodotin</VALIDVALUE>
          <VALUEMEANING>Vorsetzumab Mafodotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to the auristatin analogue monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. The anti-CD70 antibody moiety of vorsetuzumab mafodotin selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>White Carrot</VALIDVALUE>
          <VALUEMEANING>White Carrot</VALUEMEANING>
          <MEANINGDESCRIPTION>A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wnt Signaling Inhibitor SM04755</VALIDVALUE>
          <VALUEMEANING>Wnt Signaling Inhibitor SM04755</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor SM04755 targets and binds to an as of yet undisclosed target in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wnt Signaling Pathway Inhibitor SM08502</VALIDVALUE>
          <VALUEMEANING>Wnt Signaling Pathway Inhibitor SM08502</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, SM08502 inhibits the expression of genes involved in the Wnt signaling pathway through an as of yet not fully elucidated mechanism. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746545</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wnt-5a Mimic Hexapeptide Foxy-5</VALIDVALUE>
          <VALUEMEANING>Wnt-5a Mimic Hexapeptide Foxy-5</VALUEMEANING>
          <MEANINGDESCRIPTION>A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WT1 Peptide Vaccine OCV-501</VALIDVALUE>
          <VALUEMEANING>WT1 Peptide Vaccine OCV-501</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WT1 Peptide Vaccine WT2725</VALIDVALUE>
          <VALUEMEANING>WT1 Peptide Vaccine WT2725</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WT1 Protein-derived Peptide Vaccine DSP-7888</VALIDVALUE>
          <VALUEMEANING>WT1 Protein-derived Peptide Vaccine DSP-7888</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide cancer vaccine comprised of peptides derived from the Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT1 protein-derived peptide vaccine DSP-7888 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. In addition, DSP-7888 induces a helper T-lymphocyte-mediated immune response against WT1 expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121957</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401</VALIDVALUE>
          <VALUEMEANING>WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WT1-A10/AS01B Immunotherapeutic GSK2130579A</VALIDVALUE>
          <VALUEMEANING>WT1-A10/AS01B Immunotherapeutic GSK2130579A</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities.  Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wobe-Mugos E</VALIDVALUE>
          <VALUEMEANING>Wobe-Mugos E</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzymatic preparation containing proteolytic enzymes papain, trypsin and chymotrypsin with potential anti-inflammatory and anticarcinogenic activities. Papain can be extracted from the fruit of the papaya plant. Trypsin and chymotrypsin are serine proteases produced and secreted by the pancreas. Although its exact mechanisms has yet to be fully illustrated, Wobe-Mugos E appears to have the ability to modulate the immune system by degrading cytokines, and cytokine receptors and clearing circulating immune protein complexes, as well as disrupting adhesion molecules. This agent has been shown to reduce chemotherapy-induced toxicity, inhibit tumor cell proliferation and prolong survival rates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746547</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xanthohumol</VALIDVALUE>
          <VALUEMEANING>Xanthohumol</VALUEMEANING>
          <MEANINGDESCRIPTION>A prenylated flavonoid derived from the female flowers of the hops plant (Humulus lupulus L), with potential chemopreventive and antineoplastic activities. Upon administration, xanthohumol scavenges reactive oxygen species (ROS), thereby preventing DNA damage due to oxidative stress. In addition, xanthohumol is able to increase the expression of phase II cytoprotective enzymes, thereby inactivating carcinogens. This agent exerts anti-inflammatory activity, through the inhibition of inflammation-inducing enzymes, inhibits DNA synthesis, and induces apoptosis of susceptible cancer cells. Xanthohumol also decreases the expression of C-X-C chemokine receptor 4 (CXCR4), thereby preventing cancer cell invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410</VALIDVALUE>
          <VALUEMEANING>XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.  The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xentuzumab</VALIDVALUE>
          <VALUEMEANING>Xentuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106118</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xevinapant</VALIDVALUE>
          <VALUEMEANING>IAP Inhibitor AT-406</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins with potential apoptotic inducing and antineoplastic activity. IAP inhibitor AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). This may restore and promote the induction of apoptosis through apoptotic signaling pathways. AT-406 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3614156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XIAP Antisense Oligonucleotide AEG35156</VALIDVALUE>
          <VALUEMEANING>AEG35156</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49180</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xiliertinib</VALIDVALUE>
          <VALUEMEANING>Xiliertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, xiliertinib binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xisomab 3G3</VALIDVALUE>
          <VALUEMEANING>Xisomab 3G3</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, xisomab 3G3 targets and binds to the apple 2 domain of FXI, thereby preventing the binding of FXI to factor XIIa (FXIIa). This blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT), and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y 90 Monoclonal Antibody CC49</VALIDVALUE>
          <VALUEMEANING>Y 90 Monoclonal Antibody CC49</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with Yttrium 90 (Y-90). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Y-90 MoAb CC49 delivers beta particles emitting Y-90 radionuclide directly to tumor cells that express TAG-72, thereby this agent may be used in radioimmunotherapeutic treatment of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y 90 Monoclonal Antibody HMFG1</VALIDVALUE>
          <VALUEMEANING>Y 90 Monoclonal Antibody HMFG1</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of HMFG1, a humanized monoclonal antibody directed against the tumor associated antigen mucin-1 (MUC-1), labeled with the beta-emitting radioisotope yttrium 90 (Y-90), with potential antineoplastic activities. Upon administration, the monoclonal antibody moiety targets and binds to MUC-1 on the surface of certain tumor cells. Upon binding and internalization, pemtumomab and delivers a cytotoxic dose of beta radiation to MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xiaoai Jiedu Decoction</VALIDVALUE>
          <VALUEMEANING>Xiaoai Jiedu Decoction</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) decoction composed of Oldenlandia, Kuh-seng, Codonopsis pilosula, bighead atractylodes rhizome, smoked plum, the rhizome of Chinese goldthread, rhizome zingiberis preparata and semen Coicis, with potential chemopreventive and antineoplastic activities. Upon administration of Xiaoai Jiedu decoction, the active ingredients in this decoction may inhibit a variety of signal transduction pathways involved in carcinogenesis. This may induce cell cycle arrest and tumor cell apoptosis and inhibit tumor cell formation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y 90 Monoclonal Antibody Lym-1</VALIDVALUE>
          <VALUEMEANING>Y 90 Monoclonal Antibody Lym-1</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. Y-90 MoAb Lym-1 delivers Y-90 radionuclide directly to tumor cells that express HLA-DR antigen, thereby this agent may be used in radioimmunotherapy of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y 90 Monoclonal Antibody m170</VALIDVALUE>
          <VALUEMEANING>Y 90 Monoclonal Antibody m170</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of m170 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb m170 is a murine MoAb that recognizes MUC-1 antigen present on the surface of many adenocarcinomas. This radioimmunoconjugate emits beta particles that cause cytotoxicity in tumor cells and has both imaging and therapeutic uses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y 90 Monoclonal Antibody M195</VALIDVALUE>
          <VALUEMEANING>Y 90 Monoclonal Antibody M195</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yang Yin Fu Zheng</VALIDVALUE>
          <VALUEMEANING>Yang Yin Fu Zheng</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132024</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yiqi-yangyin-jiedu Herbal Decoction</VALIDVALUE>
          <VALUEMEANING>Yiqi-yangyin-jiedu Herbal Decoction</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132026</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities. Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74093</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y 90 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yangzheng Xiaoji Extract</VALIDVALUE>
          <VALUEMEANING>Yangzheng Xiaoji Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional Chinese medicine (TCM)-based formulation containing the Yangzheng Xiaoji (YZXJ) extract, consisting of various components, with potential antineoplastic and anti-angiogenic activities. Some of the main components in Yangzheng Xiaoji are Radix Astragali, Fructus Ligustri Lucidi, Radix Ginseng, Ganoderma, Rhizoma Curcumac, Fried Rhizoma Atractylodis, Macrocephalae and Herba Hedyotidis. Although the exact mechanism(s) through which Yangzheng Xiaoji exerts its effects have yet to be fully elucidated, this agent, upon administration, inhibits the activation of various signaling protein kinases, such as focal adhesion kinase (FAK) and paxillin. This prevents signal transduction pathways that are upregulated in cancer, prevents the adhesion and migration of tumor cells and inhibits tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ziv-Aflibercept</VALIDVALUE>
          <VALUEMEANING>Aflibercept</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2682</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3880514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zolbetuximab</VALIDVALUE>
          <VALUEMEANING>Zolbetuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zoledronic Acid</VALIDVALUE>
          <VALUEMEANING>Zoledronic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5709612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zoptarelin Doxorubicin</VALIDVALUE>
          <VALUEMEANING>Zoptarelin Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zorubicin</VALIDVALUE>
          <VALUEMEANING>Zorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91365</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zorubicin Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Zorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2829936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zotatifin</VALIDVALUE>
          <VALUEMEANING>Zotatifin</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective inhibitor of the eukaryotic translation initiation factor 4A (eIF4A), with potential antineoplastic activity. Upon administration of zotatifin, this agent targets and binds to elF4A, and promotes eIF4A binding to mRNA with specific polypurine motifs within their 5&#39;-untranslated region (5&#39;-UTR), leading to the formation of a stable sequence-specific ternary complex with eIF4A and mRNA (elF4A- zotatifin-mRNA). This results in the translational repression of key oncogenes and anti-apoptotic proteins involved in tumor cell proliferation, survival and metastasis, such as KRAS, Myc, myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase (CDK) 4 and 6, cyclin D, fibroblast growth factor receptor (FGFR) 1 and 2, human epidermal growth factor receptor 2 (HER2; ERBB2), and beta-catenin. The inhibition of the expression of these oncogenes leads to the inhibition of various oncogenic signal transduction pathways. This inhibits proliferation and induces apoptosis in tumor cells. eIF4A, a RNA helicase and the rate-limiting component of the eukaryotic translation initiation complex, catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5&#39;-UTR. elF4A is activated by various oncogenic signaling pathways, including RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)/AKT pathways, and regulates the translation of oncogenes and tumor survival factors with complex secondary structures within the 5&#39;-UTRs that are required for tumor cell proliferation, survival and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zotiraciclib Citrate</VALIDVALUE>
          <VALUEMEANING>Zotiraciclib Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zuclomiphene Citrate</VALIDVALUE>
          <VALUEMEANING>Zuclomiphene Citrate</VALUEMEANING>
          <MEANINGDESCRIPTION>The cis isomer of clomiphene which exhibits weak estrogen agonist activity evaluated for antineoplastic activity against breast cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zorifertinib</VALIDVALUE>
          <VALUEMEANING>Zorifertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration,  zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tipapkinogene Sovacivec</VALIDVALUE>
          <VALUEMEANING>Tipapkinogene Sovacivec</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with tipapkinogene sovacivec stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tipifarnib</VALIDVALUE>
          <VALUEMEANING>Tipifarnib</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1703</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tirabrutinib</VALIDVALUE>
          <VALUEMEANING>Tirabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tiragolumab</VALIDVALUE>
          <VALUEMEANING>Tiragolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tirapazamine</VALIDVALUE>
          <VALUEMEANING>Tirapazamine</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erythropoietin</VALIDVALUE>
          <VALUEMEANING>Erythropoietin</VALUEMEANING>
          <MEANINGDESCRIPTION>Glycoprotein hormone, secreted chiefly by the kidney in the adult and the liver in the fetus, that acts on erythroid stem cells of the bone marrow to stimulate proliferation and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2644085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gabapentin</VALIDVALUE>
          <VALUEMEANING>Gabapentin</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that is being studied as a treatment for relieving hot flashes in women with breast cancer.  It belongs to the family of drugs called anticonvulsants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glembatumumab</VALIDVALUE>
          <VALUEMEANING>Glembatumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer cells, but alone does not appear to inhibit cancer cell growth. However, this antibody could be utilized to deliver a conjugated cytotoxic agent to GPNMB-expressing tumor cells. GPNMB, overexpressed on the surface of various cancer cells, plays a key role in cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5073131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morphine</VALIDVALUE>
          <VALUEMEANING>Morphine</VALUEMEANING>
          <MEANINGDESCRIPTION>An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent exhibits widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62051</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5211114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Corticosteroid Immunosuppressive Agent</VALIDVALUE>
          <VALUEMEANING>Non-Corticosteroid Immunosuppressive Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunosuppressive agent that is not a corticosteroid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C185652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13818957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEG-filgrastim</VALIDVALUE>
          <VALUEMEANING>Pegfilgrastim</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2775105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plerixafor</VALIDVALUE>
          <VALUEMEANING>Plerixafor</VALUEMEANING>
          <MEANINGDESCRIPTION>A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3631680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sodium Thiosulfate</VALIDVALUE>
          <VALUEMEANING>Sodium Thiosulfate</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble salt and reducing agent that reacts with oxidizing agents.  Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13818958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Systemic Corticosteroid</VALIDVALUE>
          <VALUEMEANING>Systemic Corticosteroid Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroid Hormone Replacement</VALIDVALUE>
          <VALUEMEANING>Levothyroxine Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical Corticosteroid</VALIDVALUE>
          <VALUEMEANING>Topical Corticosteroids</VALUEMEANING>
          <MEANINGDESCRIPTION>Any synthetic steroid derivatives exhibiting the same function as the naturally occurring corticosteroid hormones, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3253644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GCSF</VALIDVALUE>
          <VALUEMEANING>Recombinant Granulocyte Colony Stimulating Factor</VALUEMEANING>
          <MEANINGDESCRIPTION>G-CSF. A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell).  It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called filgrastim.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2644084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GMCSF</VALIDVALUE>
          <VALUEMEANING>GM-CSF</VALUEMEANING>
          <MEANINGDESCRIPTION>Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-Hydroxyoleic Acid</VALIDVALUE>
          <VALUEMEANING>Idroxioleic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A2A Receptor Antagonist EOS100850</VALIDVALUE>
          <VALUEMEANING>Inupadenant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, inupadenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172109</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2A Receptor Antagonist AZD4635</VALIDVALUE>
          <VALUEMEANING>Adenosine A2A Receptor Antagonist AZD4635</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist AZD4635 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6161765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoviral PSA Vaccine ETBX-071</VALIDVALUE>
          <VALUEMEANING>Adenoviral PSA Vaccine ETBX-071</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEE788</VALIDVALUE>
          <VALUEMEANING>AEE788</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Akt/ERK Inhibitor ONC201</VALIDVALUE>
          <VALUEMEANING>Dordaviprone</VALUEMEANING>
          <MEANINGDESCRIPTION>A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor</VALIDVALUE>
          <VALUEMEANING>ALK Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C141136</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6010235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor WX-0593</VALIDVALUE>
          <VALUEMEANING>Iruplinalkib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenosine A2A/A2B Receptor Antagonist AB928</VALIDVALUE>
          <VALUEMEANING>Etrumadenant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon administration, etrumadenant competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of AB928 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK/c-Met Inhibitor TQ-B3139</VALIDVALUE>
          <VALUEMEANING>ALK/c-Met Inhibitor  TQ-B3139</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK/ROS1/Met Inhibitor TQ-B3101</VALIDVALUE>
          <VALUEMEANING>Unecritinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), C-ros oncogene 1 (ROS1) and Met (hepatocyte growth factor receptor; HGFR; c-Met), with potential antineoplastic activity. Upon oral administration,unecritinib targets, binds to and inhibits the activity of ALK, ROS1 and c-Met, which leads to the disruption of ALK-, ROS1- and c-Met-mediated signaling and the inhibition of cell growth in ALK-, ROS1- and c-Met-expressing tumor cells. ALK, ROS1 and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic Anti-CD19-CAR T-cells PBCAR0191</VALIDVALUE>
          <VALUEMEANING>Azercabtagene Zapreleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001</VALIDVALUE>
          <VALUEMEANING>Taniraleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of taniraleucel, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120</VALIDVALUE>
          <VALUEMEANING>Motacabtagene Lurevgedleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, motacabtagene lurevgedleucel recognize and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor for proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. The disruption of endogenous TCR prevents graft-versus-host disease (GvHD). The disruption of MHC class I molecules increases the persistence of the CAR T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allosteric ErbB Inhibitor BDTX-189</VALIDVALUE>
          <VALUEMEANING>Tuxobertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. Upon oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. EGFR and HER2, ErbB receptor tyrosine kinases mutated or overexpressed in many tumor cell types, play a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171059</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK-2 Inhibitor TP-0184</VALIDVALUE>
          <VALUEMEANING>Itacnosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACRV1), with potential antineoplastic activity. Upon oral administration,itacnosertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK-2-mediated signaling and inhibits cell growth in ALK-2-overexpressing tumor cells. In addition, in cancer and inflammatory conditions, ALK-2 is upregulated in response to increased signaling of pro-inflammatory cytokines, especially interleukin-6 (IL-6), and enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis. Blocking ALK-2-mediated pathways in inflammation and cancer leads to a decrease of hepcidin expression and restores plasma iron levels, thereby preventing low serum iron levels and anemia of chronic disease (ACD). ALK-2, a serine/threonine receptor kinase, is constitutively activated due to activating mutations or upregulated upstream signaling pathways in inflammatory conditions and certain types of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801</VALIDVALUE>
          <VALUEMEANING>Idetrexed</VALUEMEANING>
          <MEANINGDESCRIPTION>An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amino Acid Injection</VALIDVALUE>
          <VALUEMEANING>Amino Acid Injection</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentrated dietary supplement for injection containing the essential amino acids leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine and tryptophan as well as the non-essential amino acids alanine, arginine, glycine, proline, serine and tyrosine, with potential anabolic and anti-catabolic activities. Upon dilution and intravenous infusion of the amino acid nutritional supplement, the amino acids serve as protein building blocks, promote protein synthesis in muscle cells and prevent protein breakdown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Antagonist SHR3680</VALIDVALUE>
          <VALUEMEANING>Rezvilutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Androgen Receptor Degrader ARV-110</VALIDVALUE>
          <VALUEMEANING>Bavdegalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Bavdegalutamide is composed of an AR ligand attached to an E3 ligase recognition moiety. Upon oral administration, bavdegalutamide targets and binds to the AR ligand binding domain. E3 ligase is recruited to the AR by the E3 ligase recognition moiety and the AR target protein is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome. This prevents the expression of AR target genes and halts AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. In addition, the degradation of the AR protein releases the ARV-110 is released and can bind to additional AR target proteins. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anlotinib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Catequentinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-APRIL Monoclonal Antibody BION-1301</VALIDVALUE>
          <VALUEMEANING>Zigakibart</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142822</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AXL Fusion Protein AVB-S6-500</VALIDVALUE>
          <VALUEMEANING>Batiraxcept</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156017</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-AXL/PBD Antibody-drug Conjugate ADCT-601</VALIDVALUE>
          <VALUEMEANING>Mipasetamab Uzoptirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC), consisting of mipasetamab, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) that is site-specifically conjugated to uzoptitine (PL1601), which contains a valine-alanine cleavable linker and SG3199, a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of mipasetamab uzoptirine, mipasetamab binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, SG3199 is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing AXL-expressing cancer cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, is overexpressed by many tumor cell types, and plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-B7H3 Antibody-drug Conjugate MGC018</VALIDVALUE>
          <VALUEMEANING>Vobramitamab Duocarmazine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) comprised of vobamitamab, an anti-B7-homolog 3 (B7-H3, CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody, conjugated to the cleavable linker-duocarmycin payload duocarmazine (valine-citrulline-seco duocarmycin hydroxybenzamide azaindole; vc-seco-DUBA), with potential antineoplastic activity. Upon administration of vobramitamab duocarmazine, vobramitamab specifically targets and binds to the cell surface antigen B7-H3, leading to internalization of the ADC by B7-H3-expressing tumor cells. The vc linker is cleaved inside the tumor cell by proteases, thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a</VALIDVALUE>
          <VALUEMEANING>Ifinatamab Deruxtecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171577</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B</VALIDVALUE>
          <VALUEMEANING>Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities.  Upon administration, anti-BCMA/anti-CD3 T-cell engaging bispecific antibody ABBV-383 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-B7-H4 Monoclonal Antibody FPA150</VALIDVALUE>
          <VALUEMEANING>Alsevalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA Antibody-drug Conjugate CC-99712</VALIDVALUE>
          <VALUEMEANING>Ispectamab Debotansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member 17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid payload, with potential antineoplastic activity. Upon administration of ispectamab debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the maytansinoid payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic, and prevents cell division and reduces cell growth of BCMA-expressing cancer cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant plasma cells and plays a key role in plasma survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA/CD3 BiTE Antibody AMG 420</VALIDVALUE>
          <VALUEMEANING>Pacanalotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A short half-life bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pacanalotamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA/CD3 BiTE Antibody AMG 701</VALIDVALUE>
          <VALUEMEANING>Pavurutamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147028</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BCMA/CD3 BiTE Antibody REGN5458</VALIDVALUE>
          <VALUEMEANING>Linvoseltamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-BTLA Monoclonal Antibody TAB004</VALIDVALUE>
          <VALUEMEANING>Tifcemalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD117 Monoclonal Antibody JSP191</VALIDVALUE>
          <VALUEMEANING>Briquilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, briquilimab targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs.  As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. Briquilimab can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD123 ADC IMGN632</VALIDVALUE>
          <VALUEMEANING>Pivekimab Sunirine</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017</VALIDVALUE>
          <VALUEMEANING>Evunzekibart</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, evunzekibart targets and binds to CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells, and CD137 is activated upon crosslinking to Fc-gamma receptors (FcgRs) on macrophages. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. 4-1BB and FcgRs are both highly expressed in the tumor environment (TME) while their co-expression in non-tumor tissues is low. This may prevent systemic adverse effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antibody-drug Conjugate ABBV-155</VALIDVALUE>
          <VALUEMEANING>Mirzotamab Clezutoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD137 Agonistic Monoclonal Antibody LVGN6051</VALIDVALUE>
          <VALUEMEANING>Exlinkibart</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, exlinkibart targets and binds to CD137, thereby activating CD137 expressed on avariety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD19-DM4 Immunoconjugate SAR3419</VALIDVALUE>
          <VALUEMEANING>Coltuximab Ravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Coltuximab ravtansine targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody SCT400</VALIDVALUE>
          <VALUEMEANING>Ripertamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002</VALIDVALUE>
          <VALUEMEANING>Eramkafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD27 Agonistic Monoclonal Antibody MK-5890</VALIDVALUE>
          <VALUEMEANING>Boserolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, boserolimab targets and binds to CD27 on a variety of immune cell types, including most T-lymphocytes. This induces CD27-dependent signaling pathways and enhances T-cell-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation. It is overexpressed in certain tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564</VALIDVALUE>
          <VALUEMEANING>Talquetamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7554852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564</VALIDVALUE>
          <VALUEMEANING>Vixtimotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33/CD3 BiTE Antibody AMG 330</VALIDVALUE>
          <VALUEMEANING>Eluvixtamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323</VALIDVALUE>
          <VALUEMEANING>Imvotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Imvotamab contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of imvotamab may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD33/CD3 BiTE Antibody AMG 673</VALIDVALUE>
          <VALUEMEANING>Emerfetamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emerfetamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD37 Bispecific Monoclonal Antibody GEN3009</VALIDVALUE>
          <VALUEMEANING>Ivicentamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin (Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential immunomodulating and antineoplastic activities. Upon administration, ivicentamab specifically targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first component of complement, thereby triggering the complement cascade which activates the immune system to induce complement-dependent cytotoxicity (CDC). In addition, the binding of ivicentamab to the CD37-overexpressing tumor cells also causes antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular target binding, and enhances CDC.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38 Monoclonal Antibody MOR03087</VALIDVALUE>
          <VALUEMEANING>Felzartamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD38-targeted IgG4-attenuated IFNa TAK-573</VALIDVALUE>
          <VALUEMEANING>Modakafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD39 Monoclonal Antibody SRF617</VALIDVALUE>
          <VALUEMEANING>Perenostobart</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, perenostobart specifically binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy. Blocking its action may improve anti-tumor immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40 Monoclonal Antibody SEA-CD40</VALIDVALUE>
          <VALUEMEANING>Cifurtilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, cifurtilimab binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042</VALIDVALUE>
          <VALUEMEANING>Tecaginlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration,  tecaginlimab simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168604</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody IBI188</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody IBI188</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD47 monoclonal antibody IBI188 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody SRF231</VALIDVALUE>
          <VALUEMEANING>Anti-CD47 Monoclonal Antibody SRF231</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SRF231 selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6688528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47 Monoclonal Antibody TJC4</VALIDVALUE>
          <VALUEMEANING>Lemzoparlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, lemzoparlimab preferentially binds to a unique epitope of CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. TJC4, compared to other anti-CD47 monoclonal antibodies, is designed to minimize inherent binding to normal red blood cells (RBCs), which may results in a more advantageous hematologic safety profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801</VALIDVALUE>
          <VALUEMEANING>Zeripatamig</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of zeripatamig, the anti-CD19 moiety selectively targets and binds to CD19 on CD19-positive B-cells, thereby improving binding of the anti-CD47 moiety to the CD19+ malignant B-cells. The CD47 binding by TG-1801 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD19/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD19/CD47-expressing tumor cells. In addition, zeripatamig induces an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD19 is a membrane antigen that is widely expressed during B-cell development and in B-cell malignancies. By co-targeting CD47 and CD19, zeripatamig has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD40 Agonist Monoclonal Antibody ABBV-927</VALIDVALUE>
          <VALUEMEANING>Giloralimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD73 Monoclonal Antibody CPI-006</VALIDVALUE>
          <VALUEMEANING>Mupadolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5&#39;-ecto-nucleotidase (cluster of differentiation 73; CD73; 5&#39;-NT; ecto-5&#39;-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156061</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CD73 Monoclonal Antibody TJ4309</VALIDVALUE>
          <VALUEMEANING>Uliledlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody targeting the ectoenzyme 5&#39;-ecto-nucleotidase (cluster of differentiation 73; CD73; 5&#39;-NT; ecto-5&#39;-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, uliledlimab targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEACAM6 Antibody BAY1834942</VALIDVALUE>
          <VALUEMEANING>Tinurilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,tinurilimab targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Claudin18.2 Monoclonal Antibody TST001</VALIDVALUE>
          <VALUEMEANING>Osemitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. Osemitamab is produced with reduced fucosylation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-Met Monoclonal Antibody ABT-700</VALIDVALUE>
          <VALUEMEANING>Telisotuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-c-MET Monoclonal Antibody LY2875358</VALIDVALUE>
          <VALUEMEANING>Emibetuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Emibetuzumab binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody AGEN1181</VALIDVALUE>
          <VALUEMEANING>Botensilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody BCD-145</VALIDVALUE>
          <VALUEMEANING>Nurulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody HBM4003</VALIDVALUE>
          <VALUEMEANING>Porustobart</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, porustobart targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. In addition, porustobart induces an antibody-dependent cell cytotoxicity (ADCC). CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. Porustobart, being a HCAb, is smaller than conventional antibodies which may allow for increased tissue penetration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CEACAM5 Antibody-Drug Conjugate SAR408701</VALIDVALUE>
          <VALUEMEANING>Tusamitamab Ravtansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of tusamitamab ravtansine the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4 Monoclonal Antibody MK-1308</VALIDVALUE>
          <VALUEMEANING>Quavonlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841</VALIDVALUE>
          <VALUEMEANING>Pavunalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-DLL3/CD3 BiTE Antibody AMG 757</VALIDVALUE>
          <VALUEMEANING>Tarlatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR/c-Met Bispecific Antibody EMB-01</VALIDVALUE>
          <VALUEMEANING>Bafisontamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158085</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372</VALIDVALUE>
          <VALUEMEANING>Amivantamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFRvIII/CD3 BiTE Antibody AMG 596</VALIDVALUE>
          <VALUEMEANING>Etevritamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRvIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of etevritamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRvIII found on EGFRvIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRvIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRvIII-expressing tumor cells. EGFRvIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ErbB3 Antibody ISU104</VALIDVALUE>
          <VALUEMEANING>Barecetamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with potential antineoplastic activity. Upon intravenous administration, barecetamab targets and binds to domain 3 and weakly interacts with domain 1 of ErbB3. This prevents heregulin (HRG) binding and blocks dimerization of ErbB3, thereby inactivating ErbB3 downstream signaling. ISU104 may also elicit the internalization of ErbB3 from the plasma membrane and downregulate ErbB3 expression. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FAP/Interleukin-2 Fusion Protein RO6874281</VALIDVALUE>
          <VALUEMEANING>Simlukafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129383</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FCRH5/CD3 BiTE Antibody BFCR4350A</VALIDVALUE>
          <VALUEMEANING>Cevostamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633890</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-EGFR Monoclonal Antibody HLX-07</VALIDVALUE>
          <VALUEMEANING>Pimurutamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FLT3/CD3 BiTE Antibody AMG 427</VALIDVALUE>
          <VALUEMEANING>Emirodatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002</VALIDVALUE>
          <VALUEMEANING>Luveltamab Tazevibulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GARP Monoclonal Antibody ABBV-151</VALIDVALUE>
          <VALUEMEANING>Livmoniplimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs).  Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody</VALIDVALUE>
          <VALUEMEANING>Nivatrotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells and is required for signal transduction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-GITR Agonistic Monoclonal Antibody INCAGN01876</VALIDVALUE>
          <VALUEMEANING>Ragifilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-gremlin-1 Monoclonal Antibody UCB6114</VALIDVALUE>
          <VALUEMEANING>Ginisortamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration,ginisortamab specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate ARX788</VALIDVALUE>
          <VALUEMEANING>Anvatabart Opadotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER-2 Bispecific Antibody KN026</VALIDVALUE>
          <VALUEMEANING>Anbenitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anbenitamab simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162577</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343</VALIDVALUE>
          <VALUEMEANING>Cinrebafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A</VALIDVALUE>
          <VALUEMEANING>Runimotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128</VALIDVALUE>
          <VALUEMEANING>Zenocutuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER2 Antibody-drug Conjugate RC48</VALIDVALUE>
          <VALUEMEANING>Disitamab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC RC48, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202</VALIDVALUE>
          <VALUEMEANING>Farletuzumab Ecteribulin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) composed of farletuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the folate receptor alpha (FRA; FolRa; FOLR1), and conjugated, via a cathepsin B-cleavable linker, to the microtubule-targeting agent (MTA) eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, with potential antineoplastic activity. Upon administration of farletuzumab ecteribulin, the farletuzumab moiety targets and binds to FRA expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and the induction of tumor cell death in FRA-expressing cells. FRA is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-HER3 Antibody-drug Conjugate U3 1402</VALIDVALUE>
          <VALUEMEANING>Patritumab Deruxtecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ICOS Agonist Antibody GSK3359609</VALIDVALUE>
          <VALUEMEANING>Feladilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126804</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ICOS Monoclonal Antibody KY1044</VALIDVALUE>
          <VALUEMEANING>Alomfilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, alomfilimab selectively binds to dimeric ICOS expressed on certain T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Additionally, KY1044 may eliminate ICOS-positive T-cells via antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IL-1 alpha Monoclonal Antibody MABp1</VALIDVALUE>
          <VALUEMEANING>Bermekimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B-lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IL-15 Monoclonal Antibody AMG 714</VALIDVALUE>
          <VALUEMEANING>Ordesekimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human pro-inflammatory cytokine interleukin-15 (IL-15), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells. IL-15 plays a key role in inflammation and is associated with a variety of autoimmune and inflammatory disorders as well as with cell proliferation in certain cancer types, such as T-cell lymphomas. IL-15 is required for the proliferation of certain T-cells and NK cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126841</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ILDR2 Monoclonal Antibody BAY 1905254</VALIDVALUE>
          <VALUEMEANING>Bapotulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IRF4 Antisense Oligonucleotide ION251</VALIDVALUE>
          <VALUEMEANING>Frenlosirsen</VALUEMEANING>
          <MEANINGDESCRIPTION>An antisense oligonucleotide (ASO) targeting the interferon regulatory factor 4 (IRF4) mRNA, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, frenlosirsen hybridizes with IRF4 mRNA, which blocks translation of the IRF4 protein. Reduction of IRF4 levels prevents the expression of IRF4-controlled tumor promoter genes, and may enhance tumor cell apoptosis and prevent T-cell exhaustion. IRF4, a transcription factor expressed in lymphocytes and essential for plasma cell differentiation, is involved in immune cell development and plays a key role in T-cell functions. It is overexpressed in certain tumor cell types and is a key regulator of multiple genes controlling tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-IL-13 Humanized Monoclonal Antibody TNX-650</VALIDVALUE>
          <VALUEMEANING>Lebrikizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG3 Monoclonal Antibody BI 754111</VALIDVALUE>
          <VALUEMEANING>Miptenalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG-3 Monoclonal Antibody INCAGN02385</VALIDVALUE>
          <VALUEMEANING>Tuparstobart</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157127</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG3 Monoclonal Antibody MK-4280</VALIDVALUE>
          <VALUEMEANING>Favezelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LAG3 Monoclonal Antibody TSR-033</VALIDVALUE>
          <VALUEMEANING>Encelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-LIF Monoclonal Antibody MSC-1</VALIDVALUE>
          <VALUEMEANING>Falbikitug</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, falbikitug binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156176</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-MUC16/CD3 Bispecific Antibody REGN4018</VALIDVALUE>
          <VALUEMEANING>Ubamatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-MUC17/CD3 BiTE Antibody AMG 199</VALIDVALUE>
          <VALUEMEANING>Vepsitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165588</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062</VALIDVALUE>
          <VALUEMEANING>Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate consisting of a monoclonal antibody directed against a highly-expressed myeloma cell surface antigen covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-myeloma cell surface antigen immunoconjugate BT-062 binds to an unspecified cell surface antigen highly expressed on myeloma cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of myeloma tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181</VALIDVALUE>
          <VALUEMEANING>Linavonkibart</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, linavonkibart specifically targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-NaPi2b Monoclonal Antibody XMT-1535</VALIDVALUE>
          <VALUEMEANING>Upifitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upifitamab, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of XMT-1535 are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E</VALIDVALUE>
          <VALUEMEANING>Enfortumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7775224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antineoplastic Vaccine</VALIDVALUE>
          <VALUEMEANING>Antineoplastic Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of vaccine that prevents or treats cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Agonist Monoclonal Antibody ABBV-368</VALIDVALUE>
          <VALUEMEANING>Revdofilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Agonist Monoclonal Antibody PF-04518600</VALIDVALUE>
          <VALUEMEANING>Ivuxolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256</VALIDVALUE>
          <VALUEMEANING>Latikafusp</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of latikafusp, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody AK105</VALIDVALUE>
          <VALUEMEANING>Penpulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody AMG 404</VALIDVALUE>
          <VALUEMEANING>Zeluvalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zeluvalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-OX40 Monoclonal Antibody IBI101</VALIDVALUE>
          <VALUEMEANING>Cudarolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4; TNFRSF4; CD134; OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cudarolimab selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody BI 754091</VALIDVALUE>
          <VALUEMEANING>Ezabenlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13635738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody CS1003</VALIDVALUE>
          <VALUEMEANING>Nofazinlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody F520</VALIDVALUE>
          <VALUEMEANING>Rulonilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody GLS-010</VALIDVALUE>
          <VALUEMEANING>Zimberelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody HX008</VALIDVALUE>
          <VALUEMEANING>Pucotenlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pucotenlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody LZM009</VALIDVALUE>
          <VALUEMEANING>Lipustobart</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody SCT-I10A</VALIDVALUE>
          <VALUEMEANING>Finotonlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, finotonlimab targets, binds to, and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-CTLA4 DART Protein MGD019</VALIDVALUE>
          <VALUEMEANING>Lorigerlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315</VALIDVALUE>
          <VALUEMEANING>Fidasimtamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669</VALIDVALUE>
          <VALUEMEANING>Tobemstomig</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tobemstomig targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1 Monoclonal Antibody JTX-4014</VALIDVALUE>
          <VALUEMEANING>Pimivalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pimivalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-LAG-3 DART Protein MGD013</VALIDVALUE>
          <VALUEMEANING>Tebotelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143957</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172</VALIDVALUE>
          <VALUEMEANING>Reozalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160605</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/CTLA-4 Bispecific Antibody AK104</VALIDVALUE>
          <VALUEMEANING>Cadonilimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD1/CTLA4 Bispecific Antibody XmAb20717</VALIDVALUE>
          <VALUEMEANING>Vudalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/TIM-3 Bispecific Antibody RO7121661</VALIDVALUE>
          <VALUEMEANING>Lomvastomig</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody A167</VALIDVALUE>
          <VALUEMEANING>Tagitanlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody BGB-A333</VALIDVALUE>
          <VALUEMEANING>Garivulimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody CS1001</VALIDVALUE>
          <VALUEMEANING>Sugemalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody HLX20</VALIDVALUE>
          <VALUEMEANING>Opucolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody IMC-001</VALIDVALUE>
          <VALUEMEANING>Danburstotug</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, danburstotug specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, anti-PD-L1 monoclonal antibody IMC-001 also induces antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752</VALIDVALUE>
          <VALUEMEANING>Volrustomig</VALUEMEANING>
          <MEANINGDESCRIPTION>An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, volrustomig is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with volrustomig may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody LY3300054</VALIDVALUE>
          <VALUEMEANING>Lodapolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody MSB2311</VALIDVALUE>
          <VALUEMEANING>Betifisolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody TG-1501</VALIDVALUE>
          <VALUEMEANING>Cosibelimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1 Monoclonal Antibody ZKAB001</VALIDVALUE>
          <VALUEMEANING>Socazolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046</VALIDVALUE>
          <VALUEMEANING>Acasunlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081</VALIDVALUE>
          <VALUEMEANING>Voxalatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-ROR1 ADC VLS-101</VALIDVALUE>
          <VALUEMEANING>Zilovertamab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157772</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-sCLU Monoclonal Antibody AB-16B5</VALIDVALUE>
          <VALUEMEANING>Sotevtamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antisense Oligonucleotide QR-313</VALIDVALUE>
          <VALUEMEANING>Antisense Oligonucleotide QR-313</VALUEMEANING>
          <MEANINGDESCRIPTION>A twenty-one nucleotide-containing antisense oligonucleotide (AON) with potential use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene. Upon topical administration, QR-313 hybridizes to a specific sequence in COL7A1 pre-mRNA, resulting in exclusion of exon 73 from mRNA and translation of a functional type VII collagen protein. This may restore functionality of integument anchoring fibrils, prevent blistering, and improve wound healing in patients with DEB. Type VII collagen is a major component of anchoring fibrils, attachment structures that mediate dermal-epidermal adherence in human skin. DEB is an inherited mechano-bullous disorder caused by mutations in the COL7A1 gene, which lead to perturbations in anchoring fibrils.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-SIRPa Monoclonal Antibody CC-95251</VALIDVALUE>
          <VALUEMEANING>Anzurstobart</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-PGF Monoclonal Antibody RO5323441</VALIDVALUE>
          <VALUEMEANING>Anti-PLGF Monoclonal Antibody TB-403</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody TB-403 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13596969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E</VALIDVALUE>
          <VALUEMEANING>Sirtratumab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TGF-beta Monoclonal Antibody NIS793</VALIDVALUE>
          <VALUEMEANING>Nisevokitug</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIGIT Monoclonal Antibody BGB-A1217</VALIDVALUE>
          <VALUEMEANING>Ociperlimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, ociperlimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM-3 Monoclonal Antibody BGB-A425</VALIDVALUE>
          <VALUEMEANING>Surzebiclimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIM-3 Monoclonal Antibody MBG453</VALIDVALUE>
          <VALUEMEANING>Sabatolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a</VALIDVALUE>
          <VALUEMEANING>Datopotamab Deruxtecan</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based  linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-VEGFR2 Monoclonal Antibody HLX06</VALIDVALUE>
          <VALUEMEANING>Vulinacimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156172</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arginase Inhibitor INCB001158</VALIDVALUE>
          <VALUEMEANING>Numidargistat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142866</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13707073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATR Inhibitor RP-3500</VALIDVALUE>
          <VALUEMEANING>Camonsertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-TIGIT Monoclonal Antibody AB154</VALIDVALUE>
          <VALUEMEANING>Domvanalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, domvanalimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATR Kinase Inhibitor BAY1895344</VALIDVALUE>
          <VALUEMEANING>Elimusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, elimusertib selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATR Kinase Inhibitor M1774</VALIDVALUE>
          <VALUEMEANING>Tuvusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, tuvusertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aurora A Kinase Inhibitor TAS-119</VALIDVALUE>
          <VALUEMEANING>Aurora A Kinase Inhibitor VIC-1911</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon intravenous administration, aurora A kinase inhibitor VIC-1911 binds to and inhibits aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125</VALIDVALUE>
          <VALUEMEANING>Orvacabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7476584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053</VALIDVALUE>
          <VALUEMEANING>Zevorcabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a humanized single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, zevorcabtagene autoleucel specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1</VALIDVALUE>
          <VALUEMEANING>Obecabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794</VALIDVALUE>
          <VALUEMEANING>Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794</VALUEMEANING>
          <MEANINGDESCRIPTION>Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the autologous anti-NY-ESO1/LAGE-1 TCR-transduced c259 T-lymphocytes GSK3377794 specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7479347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATR Kinase Inhibitor VX-803</VALIDVALUE>
          <VALUEMEANING>Gartisertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528</VALIDVALUE>
          <VALUEMEANING>Ciltacabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7476588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous CD19-targeted CAR T Cells JWCAR029</VALIDVALUE>
          <VALUEMEANING>Relmacabtagene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Genetically-modified MAGE-A4 C1032 T Cells</VALIDVALUE>
          <VALUEMEANING>Afamitresgene Autoleucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175738</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13300999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous Tumor Infiltrating Lymphocytes LN-144</VALIDVALUE>
          <VALUEMEANING>Lifileucel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient&#39;s tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Azathioprine</VALIDVALUE>
          <VALUEMEANING>Azathioprine</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5&#39;-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3128751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bacillus Calmette-Guerin Substrain Connaught Live Antigen</VALIDVALUE>
          <VALUEMEANING>Bacillus Calmette-Guerin Substrain Connaught Live Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-2 Inhibitor S65487</VALIDVALUE>
          <VALUEMEANING>BCL2 Inhibitor VOB560</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcr-Abl Kinase Inhibitor K0706</VALIDVALUE>
          <VALUEMEANING>Vodobatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the &#39;gatekeeper&#39; resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcr-Abl Kinase Inhibitor PF-114</VALIDVALUE>
          <VALUEMEANING>Vamotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the &#39;gatekeeper&#39; resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph+) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130033</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351</VALIDVALUE>
          <VALUEMEANING>Olverembatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET inhibitor BI 894999</VALIDVALUE>
          <VALUEMEANING>Amredobresib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bcl-2 Inhibitor APG 2575</VALIDVALUE>
          <VALUEMEANING>Lisaftoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor CC-90010</VALIDVALUE>
          <VALUEMEANING>Trotabresib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BET Inhibitor CPI-0610</VALIDVALUE>
          <VALUEMEANING>Pelabresib Anhydrous</VALUEMEANING>
          <MEANINGDESCRIPTION>The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bi-functional Alkylating Agent VAL-083</VALIDVALUE>
          <VALUEMEANING>Dianhydrogalactitol</VALUEMEANING>
          <MEANINGDESCRIPTION>A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bis(choline)tetrathiomolybdate</VALIDVALUE>
          <VALUEMEANING>Tiomolibdate Choline</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active second generation tetrathiomolybdate analog with anti-angiogenic and antineoplastic activities. Tiomolibdate choline selectively chelates the copper ion in superoxide dismutase 1 (SOD1) in endothelial cells, thereby depleting SOD1 of copper and inhibiting its activity. Inhibition of SOD1 interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis, including those mediated by ERK1/2 and FAK and Src kinases. This results in an inhibition of cell proliferation and angiogenesis as well as induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BiTE Antibody AMG 910</VALIDVALUE>
          <VALUEMEANING>Gresonitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184829</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bozitinib</VALIDVALUE>
          <VALUEMEANING>Vebreltinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF Inhibitor</VALIDVALUE>
          <VALUEMEANING>BRAF Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6678120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BRAF Inhibitor PLX8394</VALIDVALUE>
          <VALUEMEANING>BRAF Inhibitor FORE8394</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, BRAF inhibitor FORE8394 selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bispecific Antibody GS-1423</VALIDVALUE>
          <VALUEMEANING>Dalutrafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific antibody that simultaneously binds two different as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brimonidine Tartrate Nanoemulsion OCU-300</VALIDVALUE>
          <VALUEMEANING>Brimonidine Tartrate Nanoemulsion OCU-300</VALUEMEANING>
          <MEANINGDESCRIPTION>An ophthalmic nanoemulsion consisting of the tartrate salt form of brimonidine, an imidazole derivative and selective alpha-2 adrenergic receptor agonist, with potential anti-inflammatory and vasoconstrictive activities. Upon ophthalmic instillation, brimonidine tartrate nanoemulsion OCU-300 reduces intraocular pressure by promoting the outflow and decreasing the production of aqueous humor and may reduce ocular erythema through direct vasoconstriction. Additionally, brimonidine may disrupt leukocyte extravasation into the ocular tissue, inhibit nociception and reduce inflammation associated with ocular graft-versus-host disease (oGvHD). The nanoemulsion formulation may enhance distribution of brimonidine to target tissues, thereby allowing more of the active drug to reach underlying ocular tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor ARQ 531</VALIDVALUE>
          <VALUEMEANING>Nemtabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available reversible inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, nemtabrutinib non-covalently binds to and inhibits the activity of both the wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, nemtabrutinib does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor ICP-022</VALIDVALUE>
          <VALUEMEANING>Orelabrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK inhibitor TG-1701</VALIDVALUE>
          <VALUEMEANING>Edralbrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available irreversible inhibitor of Bruton&#39;s tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAB-ROR2-ADC BA3021</VALIDVALUE>
          <VALUEMEANING>Ozuriftamab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calaspargase Pegol-mknl</VALIDVALUE>
          <VALUEMEANING>Calaspargase Pegol-mknl</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the anticancer drug PEG-asparaginase that stays in the body longer. EZN-2285 is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7533532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calcium Release-activated Channel Inhibitor CM4620</VALIDVALUE>
          <VALUEMEANING>Zegocractin</VALUEMEANING>
          <MEANINGDESCRIPTION>A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BTK Inhibitor LOXO-305</VALIDVALUE>
          <VALUEMEANING>Pirtobrutinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective, non-covalent Bruton&#39;s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Camptothecin Glycoconjugate BAY 38-3441</VALIDVALUE>
          <VALUEMEANING>BAY 56-3722</VALUEMEANING>
          <MEANINGDESCRIPTION>A water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. BAY 56-3722 stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cathelicidin LL-37</VALIDVALUE>
          <VALUEMEANING>Ropocamptide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CBP/beta-catenin Antagonist PRI-724</VALIDVALUE>
          <VALUEMEANING>Foscenvivint</VALUEMEANING>
          <MEANINGDESCRIPTION>A potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells with potential antineoplastic activity. Foscenvivint specifically inhibits the recruiting of beta-catenin with its coactivator CBP (the binding protein of the cAMP response element-binding protein CREB); together with other transcription factors beta-catenin/CBP binds to WRE (Wnt-responsive element) and activates transcription of a wide range of target genes of Wnt/beta-catenin signaling. Blocking the interaction of CBP and beta-catenin by this agent prevents gene expression of many proteins necessary for growth, thereby potentially suppressing cancer cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD28/ICOS Antagonist ALPN-101</VALIDVALUE>
          <VALUEMEANING>Acazicolcept</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc fusion protein comprised of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD) that binds to both inducible T-cell costimulator (ICOS; CD278) and cluster of differentiation 28 (CD28), with potential immunomodulating activity. Upon administration, acazicolcept targets and binds to both CD28 and ICOS expressed on certain T-cells. This prevents the activation of CD28 and ICOS by its ligands, thereby blocking the two T-cell costimulatory pathways and the resulting T-cell activation. CD28 is involved in initiation of the pathogenic process in graft versus host disease (GVHD). Following initial activation, CD28 is often downregulated while ICOS is upregulated, possibly sustaining GVHD. Dual blockade of CD28 and ICOS may be superior to individual blockade of CD28 or ICOS alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C179069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD40 Agonist Monoclonal Antibody CP-870,893</VALIDVALUE>
          <VALUEMEANING>Selicrelumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD40 Agonistic Monoclonal Antibody APX005M</VALIDVALUE>
          <VALUEMEANING>Sotigalimab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123734</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD47 Antagonist ALX148</VALIDVALUE>
          <VALUEMEANING>Evorpacept</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD73 Inhibitor AB680</VALIDVALUE>
          <VALUEMEANING>Quemliclustat</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5&#39;-ecto-nucleotidase; 5&#39;-NT; ecto-5&#39;-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon administration, quemliclustat targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5&#39;-nucleotidase (NTase) family, upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD80-Fc Fusion Protein ALPN-202</VALIDVALUE>
          <VALUEMEANING>Davoceticept</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of the N-terminal Ig variable-like (IgV) domain of CD80 fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, davoceticept targets and binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, which blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), and leads to PD-L1-dependent CD28 binding and co-stimulation in the local tumor microenvironment (TME). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells in the TME and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, davoceticept targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation. This further promotes T-cell activity. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK1 Inhibitor BEY1107</VALIDVALUE>
          <VALUEMEANING>Avotaciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor G1T38</VALIDVALUE>
          <VALUEMEANING>Lerociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13675273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK4/6 Inhibitor SHR6390</VALIDVALUE>
          <VALUEMEANING>CDK4/6 Inhibitor SHR6390</VALUEMEANING>
          <MEANINGDESCRIPTION>A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor SHR6390 selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6066733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK7 Inhibitor CT7001</VALIDVALUE>
          <VALUEMEANING>Samuraciclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CDK7 Inhibitor SY-1365</VALIDVALUE>
          <VALUEMEANING>Mevociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13697138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480</VALIDVALUE>
          <VALUEMEANING>Mezigdomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282</VALIDVALUE>
          <VALUEMEANING>Golcadomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cereblon Modulator CC-90009</VALIDVALUE>
          <VALUEMEANING>Eragidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cedazuridine/Decitabine Combination Agent ASTX727</VALIDVALUE>
          <VALUEMEANING>Decitabine and Cedazuridine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab Sarotalocan</VALIDVALUE>
          <VALUEMEANING>Cetuximab Sarotalocan</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C190488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab-IR700 Conjugate RM-1929</VALIDVALUE>
          <VALUEMEANING>Cetuximab Sarotalocan Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chemotherapy</VALIDVALUE>
          <VALUEMEANING>Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5102333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chiauranib</VALIDVALUE>
          <VALUEMEANING>Ibcasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, ibcasertib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chk1 Inhibitor CCT245737</VALIDVALUE>
          <VALUEMEANING>Chk1 Inhibitor SRA737</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ciclopirox Prodrug CPX-POM</VALIDVALUE>
          <VALUEMEANING>Fosciclopirox</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphoryloxymethyl (POM) ester-based prodrug of ciclopirox (CPX), a synthetic, broad-spectrum antifungal agent with antibacterial, anti-inflammatory and potential antineoplastic activities. Upon intravenous administration of fosciclopirox, the POM moiety is cleaved off by phosphatases and the active metabolite CPX is released. Although its exact anticancer mechanism is not yet fully elucidated, CPX has been shown to inhibit tumor cell proliferation, induce apoptosis, and reduce tumor cell mobility in certain cancer types. CPX inhibits Notch1 activation and inhibits the Notch1-mediated signaling pathway, which is upregulated in many cancer cell types. This inhibits Notch downstream target proteins, inhibits the expression of gamma-secretase complex proteins, and prevents proliferation in susceptible cancer cells. CPX inhibits the iron-containing enzymes, catalase and peroxidase, which facilitate the decomposition of hydrogen peroxide, a reactive oxygen species (ROS) involved in oxidative stress. CPX also inhibits the iron-dependent enzyme ribonucleotide reductase, which is essential in DNA synthesis. CPX downregulates protein expression of cyclin D1 and cyclin E1, as well as their enzymatic counterparts cyclin-dependent kinases 4 and 2 (CDK4 and CDK2), which may inhibit tumor cell proliferation by slowing cell cycle progression from G1/G0 to S phase. Further, CPX may induce apoptosis by downregulating the expression of anti-apoptotic proteins, Bcl-xL and survivin, and increasing cleavage of Bcl-2. Additionally, CPX may inhibit tumor cell proliferation, survival and motility by inhibiting the phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1). The CPX-POM prodrug improves the solubility of CPX and increases systemic efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175786</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cirmtuzumab</VALIDVALUE>
          <VALUEMEANING>Zilovertamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Kit Inhibitor PLX9486</VALIDVALUE>
          <VALUEMEANING>Bezuclastinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical Trial</VALIDVALUE>
          <VALUEMEANING>Clinical Trial</VALUEMEANING>
          <MEANINGDESCRIPTION>A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chimeric Monoclonal Antibody 81C6</VALIDVALUE>
          <VALUEMEANING>Chimeric Monoclonal Antibody 81C6</VALUEMEANING>
          <MEANINGDESCRIPTION>A chimeric, murine-human monoclonal antibody directed against the tumor-associated antigen (TAA) tenascin (hexabrachion) that may, when conjugated with a radioisotope, be useful in radiotherapy or radioimaging. Tenascin, an extracellular matrix glycoprotein is upregulated in certain pathological conditions such as infection, inflammation and tumor growth, and is highly expressed in the tumor microenvironment in some malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coxsackievirus V937</VALIDVALUE>
          <VALUEMEANING>Gebasaxturev</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coxsackievirus A21</VALIDVALUE>
          <VALUEMEANING>Gebasaxturev</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical Trial Agent</VALIDVALUE>
          <VALUEMEANING>Clinical Trial Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>The pharmacological substance that is being administered in the study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clodronate Disodium</VALIDVALUE>
          <VALUEMEANING>Clodronate Disodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used as treatment for hypercalcemia (abnormally high levels of calcium in the blood) and for cancer that has spread to the bone (bone metastases). It may decrease pain, the risk of fractures, and the development of new bone metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2597233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clodronic Acid</VALIDVALUE>
          <VALUEMEANING>Clodronate</VALUEMEANING>
          <MEANINGDESCRIPTION>A first-generation bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Clodronic acid adsorbs onto the surface of the hydroxyapatite crystals in bone matrix. Although the exact mechanism through which clodronic acid exerts its cytotoxic effect on osteoclasts has yet to be fully elucidated, this agent is metabolized intracellularly to a toxic beta-gamma-methylene analog of adenosine triphosphate (ATP), AppCCl2p. The ATP analog AppCCl2p competitively inhibits ADP/ATP translocase, thereby interfering with mitochondrial membrane potential and cellular energy metabolism. This may cause osteoclast apoptosis and, eventually, inhibiting osteoclast-mediated bone resorption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4147717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>c-Met Inhibitor MSC2156119J</VALIDVALUE>
          <VALUEMEANING>Tepotinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011</VALIDVALUE>
          <VALUEMEANING>Mecbotamab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copanlisib Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Copanlisib Hydrochloride (Aliqopa)</VALUEMEANING>
          <MEANINGDESCRIPTION>The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12117784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF-1R Inhibitor BLZ945</VALIDVALUE>
          <VALUEMEANING>Sotuletinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF1R Inhibitor DCC-3014</VALIDVALUE>
          <VALUEMEANING>Vimseltinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclodextrin-Based Polymer-Camptothecin CRLX101</VALIDVALUE>
          <VALUEMEANING>Cyclodextrin-Based Polymer-Camptothecin CRLX101</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5260854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cyclosporine</VALIDVALUE>
          <VALUEMEANING>Cyclosporine</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3253643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytidine Analog RX-3117</VALIDVALUE>
          <VALUEMEANING>Roducitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEC-205/NY-ESO-1 Fusion Protein CDX-1401</VALIDVALUE>
          <VALUEMEANING>Rasdegafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of a fully human monoclonal antibody directed against the endocytic dendritic cell (DC) receptor, DEC-205, linked to the tumor-associated antigen (TAA) NY-ESO-1 with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of rasdegafusp alfa1 binds to the endocytic DC receptor, which may result in DC endocytic internalization of this agent, specifically delivering the NY-ESO-1 moiety. DC processing of NY-ESO-1 may boost the immune system to mount a cytotoxic T-lymphocyte response (CTL) against cancer cells expressing NY-ESO-1. NY-ESO-1, a cell surface protein expressed in normal fetal and adult testes, is upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dendritic Cell Vaccine</VALIDVALUE>
          <VALUEMEANING>Dendritic Cell Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deoxycytidine Analogue TAS-109</VALIDVALUE>
          <VALUEMEANING>Radgocitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deoxycytidine Analogue TAS-109 Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Radgocitabine Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13725968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deuteporfin</VALIDVALUE>
          <VALUEMEANING>Deuteporfin</VALUEMEANING>
          <MEANINGDESCRIPTION>A photosensitizing agent composed of four sub-porphyrin derivatives, methoxyethy-hydroxyethyl-dipropionic, di-methoxyethyl-dipropionic, hydroxyethy-vinyl-dipropionic and methoxyethy-vinyl-dipropionic, with potential photosensitizing activity upon photodynamic therapy (PDT) and potential diagnostic imaging activity. Upon intravenous administration, deuteporfin preferentially targets and accumulates in cancer cells, especially those in the lymphatic system. Following photoactivation with an appropriate wavelength, deuteporfin generates highly cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cancer cells. In addition, deuteporfin could be used as a tracer in near-infrared (NIR) fluorescence lymph node mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deuterated Enzalutamide</VALIDVALUE>
          <VALUEMEANING>Deutenzalutamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Upon administration, deutenzalutamide competitively binds to and inhibits the activity of ARs expressed on prostate cancer cells, which impairs nuclear translocation and DNA binding, resulting in apoptosis of prostate cancer cells. This results in a reduction in prostate cancer cell growth. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide&#39;s metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can&#39;t cross the blood-brain barrier (BBB), the deutenzalutamide form also reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158096</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexamethasone Phosphate</VALIDVALUE>
          <VALUEMEANING>Dexamethasone Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dexamethasone Sodium Phosphate</VALIDVALUE>
          <VALUEMEANING>Dexamethasone Sodium Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>A sodium phosphate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Didox</VALIDVALUE>
          <VALUEMEANING>Didox</VALUEMEANING>
          <MEANINGDESCRIPTION>A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides obligatory for synthesis of the proviral DNA intermediate of retrovirus replication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13956480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti-myostatin Monoclonal Antibody LY2495655</VALIDVALUE>
          <VALUEMEANING>Landogrozumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration,  landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK Inhibitor RO5424802</VALIDVALUE>
          <VALUEMEANING>Alectinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4828189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dihydroorotate Dehydrogenase Inhibitor AG-636</VALIDVALUE>
          <VALUEMEANING>Dihydroorotate Dehydrogenase Inhibitor AG-636</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, AG-636 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dihydroorotate Dehydrogenase Inhibitor BAY2402234</VALIDVALUE>
          <VALUEMEANING>Orludodstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, orludodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) production, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diphencyprone</VALIDVALUE>
          <VALUEMEANING>Diphencyprone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DKK1-Neutralizing Monoclonal Antibody DKN-01</VALIDVALUE>
          <VALUEMEANING>Sirexatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99123</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DM-CHOC-PEN</VALIDVALUE>
          <VALUEMEANING>Mipicoledine</VALUEMEANING>
          <MEANINGDESCRIPTION>A cholesterol carbonate derivative of 4-demethylpenclomedine (DM-PEN) with potential antineoplastic alkylating activity. Upon intravenous administration of mipicoledine, the carbonium moiety binds to and alkylates DNA at the N7 guanine position, thereby causing DNA crosslinks. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. In addition, due to its lipophilic cholesteryl moiety this agent is able to cross the blood brain barrier (BBB) and therefore can be given intravenously compared to other alkylating agents that need to be given intra-cranially.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA Plasmid Encoding Interleukin-12 INO-9012</VALIDVALUE>
          <VALUEMEANING>Rocakinogene Sifuplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703</VALIDVALUE>
          <VALUEMEANING>Delolimogene Mupadenorepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DR5 HexaBody Agonist GEN1029</VALIDVALUE>
          <VALUEMEANING>Tilogotamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dual-affinity B7-H3/CD3-targeted Protein MGD009</VALIDVALUE>
          <VALUEMEANING>Obrindatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C136983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777</VALIDVALUE>
          <VALUEMEANING>Denileukin Diftitox</VALUEMEANING>
          <MEANINGDESCRIPTION>A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Inhibitor BIBX 1382</VALIDVALUE>
          <VALUEMEANING>Falnidamol</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR Mutant-specific Inhibitor BPI-7711</VALIDVALUE>
          <VALUEMEANING>Rezivertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/FLT3/Abl Inhibitor SKLB1028</VALIDVALUE>
          <VALUEMEANING>Ruserontinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, ruserontinib specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EGFR/HER2 Inhibitor DZD9008</VALIDVALUE>
          <VALUEMEANING>Sunvozertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), with potential antineoplastic activity. Upon oral administration,sunvozertinib binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. In contrast to other agents active against exon20ins mutations, sunvozertinib appears to be more selective against mutated EGFR than wild-type (wt) EGFR. This may lessen wtEGFR-related dose-limiting toxicity and may allow for the administration of the desired therapeutic dose of sunvozertinib.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Emapalumab</VALIDVALUE>
          <VALUEMEANING>Emapalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127123</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12151552</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enasidenib Mesylate</VALIDVALUE>
          <VALUEMEANING>Enasidenib Mesylate</VALUEMEANING>
          <MEANINGDESCRIPTION>The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6153882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endothelin B Receptor Blocker ENB 003</VALIDVALUE>
          <VALUEMEANING>Vodudeutentan Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonist of the immune checkpoint endothelin B receptor (ETBR; EDNRB), with potential immunomodulating and antineoplastic activities. Upon administration, the ETBR blocker ENB 003 selectively targets and binds to ETBR expressed on tumor cells. This prevents ETBR-mediated signaling and may abrogate the immunosuppressive tumor microenvironment (TME), may enhance a T-cell mediated anti-tumor immune response and may inhibit proliferation of ETBR-expressing tumor cells. ETBR, a G-protein coupled receptor, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. It also plays a role in tumor immunosuppression and blocks T-cell trafficking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Engineered Human Umbilical Vein Endothelial Cells AB-205</VALIDVALUE>
          <VALUEMEANING>Engineered Human Umbilical Vein Endothelial Cells AB-205</VALUEMEANING>
          <MEANINGDESCRIPTION>A population of ex vivo expanded, genetically engineered CD31 (platelet endothelial cell adhesion molecule; PECAM-1)-positive human umbilical vein endothelial cells (HUVECs) derived from human umbilical vein tissue, that can be used to enhance the hematopoietic stem and progenitor cells (HSPCs) transplantation potential and improve blood cell recovery. Following autologous stem cell transplantation (ASCT) and upon the administration of the engineered HUVEC AB-205, the endothelial cells secrete angiocrine growth factors and interact with the HSPCs, thereby forming endothelial cell network structures and improving engraftment potential. AB-205 also interacts with injured or damaged vascular niche cells, thereby promoting blood cell recovery and improving tissue regeneration. This enhances recovery from toxicities related to chemo/radiation regimens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enzastaurin</VALIDVALUE>
          <VALUEMEANING>Enzastaurin</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3378983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elbasvir/Grazoprevir</VALIDVALUE>
          <VALUEMEANING>Elbasvir/Grazoprevir</VALUEMEANING>
          <MEANINGDESCRIPTION>A fixed dose combination of elbasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A), and grazoprevir, a second-generation inhibitor of the HCV NS3/4A serine protease, with activity against certain HCV genotypes. Upon oral administration of elbasvir/grazoprevir, elbasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Grazoprevir inhibits the NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epothilone Analog UTD1</VALIDVALUE>
          <VALUEMEANING>Utidelone</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically engineered epothilone analog with potential antineoplastic activity. Upon administration, utidelone binds to tubulin, induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and enhanced activity against certain multidrug-resistant (MDR) tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471</VALIDVALUE>
          <VALUEMEANING>Vepdegestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK Inhibitor GDC-0994</VALIDVALUE>
          <VALUEMEANING>Ravoxertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, ravoxertinib inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK1/2 Inhibitor ASN007</VALIDVALUE>
          <VALUEMEANING>ERK1/2 Inhibitor ERAS-007</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK1/2 Inhibitor LY3214996</VALIDVALUE>
          <VALUEMEANING>Temuterkib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Erythrocyte-encapsulated L-asparaginase Suspension</VALIDVALUE>
          <VALUEMEANING>Eryaspase</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension of erythrocytes encapsulating L-asparaginase with potential antineoplastic activity. Upon administration of eryaspase, L-asparagine is hydrolyzed to L-aspartic acid and ammonia in plasma, thereby depleting tumor cells of asparagine. Due to low asparagine synthetase activity in tumor cells, de novo synthesis of asparagine is suppressed within tumor cells. Shortage of asparagine prevents synthesis of important proteins necessary for tumor cell growth. Encapsulation of asparaginase in erythrocytes decreases the immunogenicity of exogenous protein, enhances its circulation time and may limit toxicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esterified Estrogens</VALIDVALUE>
          <VALUEMEANING>Esterified Estrogens</VALUEMEANING>
          <MEANINGDESCRIPTION>A mixture of the sodium salts of the sulfate esters of estrogen including sodium estrone sulfate, sodium equilin sulfate and the concomitant component, 17 alpha-estradiol, that is used for estrogen replacement. Estrogens bind to nuclear receptors in estrogen-responsive tissues and modulate the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate skeletal growth, and have a widespread effect on metabolic processes including protein transport and electrolyte balance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ERK Inhibitor LTT462</VALIDVALUE>
          <VALUEMEANING>Rineterkib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, rineterkib binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Estrogens, Conjugated</VALIDVALUE>
          <VALUEMEANING>Estrogens, Conjugated</VALUEMEANING>
          <MEANINGDESCRIPTION>Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6148658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH1/2 Inhibitor DS-3201</VALIDVALUE>
          <VALUEMEANING>CYP11A1 inhibitor ODM-208</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor ODM-208 targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH2 inhibitor CPI-0209</VALIDVALUE>
          <VALUEMEANING>Tulmimetostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, tulmimetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells</VALIDVALUE>
          <VALUEMEANING>Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A donor graft derived from allogeneic filgrastim (granulocyte-colony stimulating factor; G-CSF)-mobilized peripheral blood cells (MPBC) that have been incubated with the recombinant human Fas ligand (FasL) APO010 ex vivo, and that can potentially be used for immune reconstitution purposes. The incubation of the hematopoietic stem cell graft with the apoptotic mediator Fas ligand (FasL) selectively induces apoptosis of mature T-cells which express high levels of Fas receptor, such as T stem cell memory (TSCM), T central memory (TCM), and T effector memory (TEM) cells and the pro-inflammatory T-helper cells (Th) Th1 and Th17 subsets while sparing CD34-positive stem and progenitor cells. Upon washing and further ex vivo preparations, and upon allogeneic hematopoietic stem cell transplantation (HSCT) with the FasL-treated allogeneic MPBCs, these cells provide hematopoietic cell recovery, preserve the graft-versus-leukemia (GvL) effects, and may prevent graft-versus-host disease (GvHD).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FASN Inhibitor TVB-2640</VALIDVALUE>
          <VALUEMEANING>Denifanstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGF/FGFR Pathway Inhibitor E7090</VALIDVALUE>
          <VALUEMEANING>Tasurgratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR Inhibitor Debio 1347</VALIDVALUE>
          <VALUEMEANING>Zoligratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. Zoligratinib binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EZH2 Inhibitor CPI-1205</VALIDVALUE>
          <VALUEMEANING>Lirametostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, lirametostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR2 Inhibitor RLY-4008</VALIDVALUE>
          <VALUEMEANING>Lirafugratinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FGFR4 Inhibitor FGF401</VALIDVALUE>
          <VALUEMEANING>Roblitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13728689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibromun</VALIDVALUE>
          <VALUEMEANING>Onfekafusp Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3 Inhibitor HM43239</VALIDVALUE>
          <VALUEMEANING>Tuspetinib</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration, tuspetinib reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3 Inhibitor SKI-G-801</VALIDVALUE>
          <VALUEMEANING>Denfivontinib Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of denfivontinib, an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flumatinib</VALIDVALUE>
          <VALUEMEANING>Flumbatinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C138991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluorine F 18 Ara-G</VALIDVALUE>
          <VALUEMEANING>Fluorine F 18 Ara-G</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Filgrastim</VALIDVALUE>
          <VALUEMEANING>Filgrastim</VALUEMEANING>
          <MEANINGDESCRIPTION>A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluzoparib</VALIDVALUE>
          <VALUEMEANING>Fuzuloparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Folic Acid</VALIDVALUE>
          <VALUEMEANING>Folic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fosaprepitant</VALIDVALUE>
          <VALUEMEANING>Fosaprepitant</VALUEMEANING>
          <MEANINGDESCRIPTION>No Value Exists</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3460078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gamma-Secretase Inhibitor LY3039478</VALIDVALUE>
          <VALUEMEANING>Crenigacestat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the integral membrane protein gamma-secretase (GS), with potential antineoplastic activity. Upon administration, crenigacestat binds to the GS protease complex, thereby blocking the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth in tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360</VALIDVALUE>
          <VALUEMEANING>Nastorazepide Calcium</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GITR Agonist MEDI1873</VALIDVALUE>
          <VALUEMEANING>Efgivanermin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C169931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glecaprevir/Pibrentasvir</VALIDVALUE>
          <VALUEMEANING>Glecaprevir/Pibrentasvir</VALUEMEANING>
          <MEANINGDESCRIPTION>A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glofitamab</VALIDVALUE>
          <VALUEMEANING>Glofitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glumetinib</VALIDVALUE>
          <VALUEMEANING>Gumarontinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glutamine Antagonist DRP-104</VALIDVALUE>
          <VALUEMEANING>Sirpiglenastat</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad acting glutamine antagonist, with potential immunomodulatory and antineoplastic activities. Upon administration, DON (6-Diazo-5-oxo-L-norleucine), the active moiety of sirpiglenastat, irreversibly inhibits multiple enzymes involved in glutamine metabolism. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors rely heavily on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, blocking glutamine metabolism leads to the accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon tumor cell death. As glutamine is essential for T-cell generation, DON may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells. The conversion of sirpiglenastat to the active moiety DON occurs primarily in tumor cells, allowing glutamine metabolism in healthy cells which may lessen adverse effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GS/pan-Notch Inhibitor AL101</VALIDVALUE>
          <VALUEMEANING>Osugacestat</VALUEMEANING>
          <MEANINGDESCRIPTION>A small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon intravenous administration, osugacestat binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overactivation of the Notch signaling pathway, often triggered by activating mutations, has been correlated with increased cellular proliferation and poor prognosis in certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961752</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GSK-3 Inhibitor 9-ING-41</VALIDVALUE>
          <VALUEMEANING>Elraglusib</VALUEMEANING>
          <MEANINGDESCRIPTION>A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Halichondrin B</VALIDVALUE>
          <VALUEMEANING>Halichondrin B</VALUEMEANING>
          <MEANINGDESCRIPTION>A complex macrolide polyether from marine sponge genera, such as Halichondria, Axinella, Phakellia, and Lissodendoryx that binds to tubulin, thereby inhibiting mitosis. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glutaminase Inhibitor CB-839 Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Telaglenastat Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC inhibitor CG200745</VALIDVALUE>
          <VALUEMEANING>Ivaltinostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Ivaltinosta tinhibits the catalytic activity of HDAC, resulting in an accumulation of highly acetylated chromatin histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. In particular, this agent enhances the histone acetylation of the tumor suppressor gene p53. This results in an accumulation of p53, p53-dependent transactivation and apoptosis in tumor cells. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HDAC Inhibitor CXD101</VALIDVALUE>
          <VALUEMEANING>HDAC Inhibitor CXD101</VALUEMEANING>
          <MEANINGDESCRIPTION>A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5621738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heparan Sulfate Glycosaminoglycan Mimetic M402</VALIDVALUE>
          <VALUEMEANING>Necuparanib</VALUEMEANING>
          <MEANINGDESCRIPTION>A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, necuparanib mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HER2-directed TLR8 Agonist SBT6050</VALIDVALUE>
          <VALUEMEANING>Pertuzumab Zuvotolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunotherapeutic composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a Toll-like receptor 8 (TLR8; CD288) agonist, with potential immunostimulating and antineoplastic activities. Upon intravenous administration pertuzumab zuvotolimod, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells, thereby localizing the TLR8 agonist directly to the tumor site. In turn, the TLR8 agonist moiety binds to TLR8 expressed on myeloid cells within the tumor microenvironment (TME). This activates myeloid cells, including tumor-associated macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional dendritic cells (cDCs). This may lead to the activation of nuclear factor NF-kappa-B, the production of pro-inflammatory cytokines and chemokines, macrophage-induced tumor cell killing, inflammasome activation, activation of cytolytic natural killer (NK) cells and neutrophils, and the induction of a Th1-weighted anti-tumor immune response. It also reverses the suppression of senescent naive and tumor-specific T-cells, and enhances the anti-tumor cytotoxic T-lymphocyte (CTL) immune response. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIF2a RNAi ARO-HIF2</VALIDVALUE>
          <VALUEMEANING>Zifcasiran</VALUEMEANING>
          <MEANINGDESCRIPTION>An RNA interference (RNAi) targeting hypoxia-inducible factor 2alpha (HIF-2a), with potential antineoplastic activity. Upon administration, zifcasiran binds to and neutralizes mRNA HIF2a, thereby preventing the production of HIF2a. This may lead to an inhibition of tumor cell proliferation. HIF2a, overexpressed in certain cell types, plays a key role in proliferation, progression and metastasis of tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HIF-2alpha Inhibitor PT2977</VALIDVALUE>
          <VALUEMEANING>Belzutifan</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hormone Therapy</VALIDVALUE>
          <VALUEMEANING>Endocrine Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4340414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPV DNA Plasmids Therapeutic Vaccine VGX-3100</VALIDVALUE>
          <VALUEMEANING>Bizalimogene Ralaplasmid</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, bizalimogene ralaplasmid expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13614591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hsp90 Inhibitor PU-H71</VALIDVALUE>
          <VALUEMEANING>Zelavespib</VALUEMEANING>
          <MEANINGDESCRIPTION>A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HSP90alpha/beta Inhibitor TAS-116</VALIDVALUE>
          <VALUEMEANING>Pimitespib</VALUEMEANING>
          <MEANINGDESCRIPTION>A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of &quot;client&quot; proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134448</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HSP90-targeted SN-38 Conjugate PEN-866</VALIDVALUE>
          <VALUEMEANING>Locnartecan</VALUEMEANING>
          <MEANINGDESCRIPTION>A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hu14.18-IL2 Fusion Protein EMD 273063</VALIDVALUE>
          <VALUEMEANING>Lorukafusp alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13684165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736</VALIDVALUE>
          <VALUEMEANING>Ianalumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hyaluronidase-zzxf/Pertuzumab/Trastuzumab</VALIDVALUE>
          <VALUEMEANING>Hyaluronidase-zzxf/Pertuzumab/Trastuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A ready-to-use fixed-dose combination of pertuzumab and trastuzumab, both recombinant humanized monoclonal antibodies directed against the tyrosine kinase receptor (TKR) human epidermal growth factor receptor 2 (HER2; HER-2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-zzxf, a biosimilar of the recombinant form of the naturally occurring endoglycosidase hyaluronidase, with antineoplastic activity that can be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-zzxf temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows both pertuzumab and trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of both antibodies into the bloodstream. Pertuzumab targets and binds to the extracellular dimerization domain (subdomain II) of HER2 and blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. This inhibits ligand-initiated intracellular signaling and prevents the activation of the mitogen-activated protein (MAP) kinase and the phosphoinositide 3-kinase (PI3K) signaling pathways, leading to growth arrest and apoptosis in HER2-overexpressing tumor cells, respectively. Trastuzumab targets and binds to subdomain IV of HER2 and inhibits ligand-independent, HER2 mediated cell proliferation and inhibits the PI3K signaling pathway in HER2-overexpressing tumor cells. Both antibodies induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173339</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hydrocortisone Sodium Succinate</VALIDVALUE>
          <VALUEMEANING>Hydrocortisone Sodium Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL4-Pseudomonas Exotoxin Fusion Protein MDNA55</VALIDVALUE>
          <VALUEMEANING>Bizaxofusp</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein consisting of the cytokine interleukin-4 (IL-4) linked to a truncated form of Pseudomonas exotoxin with potential antineoplastic activity. Upon specific, high-affinity binding to IL-4 receptors located on the tumor cell surface., bizaxofusp is internalized; the exotoxin moiety then binds to translation elongation factor 2 (EF-2), which may result in ADP ribosylation, deactivation of EF-2, inhibition of protein synthesis, and tumor cell apoptosis. The Pseudomonas exotoxin moiety of this agent has been engineered to reduce non-specific binding to cells expressing its receptor, the multiligand cell surface receptor alpha 2-macroglobulin receptor/low-density lipoprotein receptor-related protein (alpha 2MR/LRP). IL-4R is a type I transmembrane protein that binds IL-4 and IL-13 and may be overexpressed by cancers such as renal cell carcinoma and glioma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunotherapeutic GSK1572932A</VALIDVALUE>
          <VALUEMEANING>Astuprotimut-R</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indocyanine Green-labeled Polymeric Micelles ONM-100</VALIDVALUE>
          <VALUEMEANING>Pegsitacianine</VALUEMEANING>
          <MEANINGDESCRIPTION>A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>iNOS Dimerization Inhibitor ASP9853</VALIDVALUE>
          <VALUEMEANING>iNOS Dimerization Inhibitor FK-330</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule inhibitor of inducible nitric oxide synthase (iNOS) with potential antineoplastic activity. Upon administration, iNOS Dimerization Inhibitor FK-330 inhibits iNOS dimerization, which results in decreased nitric oxide (NO) production. iNOS expression is upregulated in certain cancers and may invoke a chronic inflammatory state in tumor cells that promotes metastatic growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon</VALIDVALUE>
          <VALUEMEANING>Interferon</VALUEMEANING>
          <MEANINGDESCRIPTION>Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3119698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interferon Alfa-2B</VALIDVALUE>
          <VALUEMEANING>Recombinant Interferon Alfa-2b</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13726786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interleukin Therapy</VALIDVALUE>
          <VALUEMEANING>Interleukin Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of interleukin in the treatment of any disease or disorder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230</VALIDVALUE>
          <VALUEMEANING>Nemvaleukin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, nemvaleukin alfa binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iodine I 131 Monoclonal Antibody BC8</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Apamistamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IRAK4 Inhibitor CA-4948</VALIDVALUE>
          <VALUEMEANING>Emavusertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, CA-4948 may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Itraconazole</VALIDVALUE>
          <VALUEMEANING>Itraconazole</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRAS G12C Inhibitor GDC-6036</VALIDVALUE>
          <VALUEMEANING>Divarasib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173995</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRAS G12C Inhibitor MRTX849</VALIDVALUE>
          <VALUEMEANING>Adagrasib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leucovorin</VALIDVALUE>
          <VALUEMEANING>Leucovorin</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil&#39;s converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6029475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Levetiracetam</VALIDVALUE>
          <VALUEMEANING>Levetiracetam</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Levoleucovorin Calcium</VALIDVALUE>
          <VALUEMEANING>Levoleucovorin Calcium</VALUEMEANING>
          <MEANINGDESCRIPTION>A levo isoform of leucovorin calcium with antineoplastic activity. Levoleucovorin is an active metabolite of folic acid, which does not require metabolism by dihydrofolate reductase. This agent counteracts the toxic effects of other folic acid derivative agents, rescuing the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug&#39;s metabolite to its target enzyme, thus prolonging drug activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JAK1 Inhibitor AZD4205</VALIDVALUE>
          <VALUEMEANING>Golidocitinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961766</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Levothyroxine</VALIDVALUE>
          <VALUEMEANING>Levothyroxine</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3305288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Levothyroxine Sodium</VALIDVALUE>
          <VALUEMEANING>Levothyroxine Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Light-activated AU-011</VALIDVALUE>
          <VALUEMEANING>Belzupacap Sarotalocan</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposomal Vinorelbine Tartrate</VALIDVALUE>
          <VALUEMEANING>Liposomal Vinorelbine Tartrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation of the tartrate salt form of vinorelbine, a semisynthetic vinca alkaloid, encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, vinorelbine binds to tubulin within tumor cells and prevents the formation of the mitotic spindle, resulting in cell cycle arrest, induction of apoptosis and an inhibition of tumor cell growth. Compared to the administration of vinorelbine alone, the liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing vinorelbine&#39;s efficacy while lowering the toxicity profile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liposome</VALIDVALUE>
          <VALUEMEANING>Liposome</VALUEMEANING>
          <MEANINGDESCRIPTION>Substances composed of layers of lipid that form hollow microscopic spheres within which drugs or agents could be contained for enhanced safety and efficacy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2612929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver X Receptor beta Agonist RGX-104</VALIDVALUE>
          <VALUEMEANING>Abequolixron</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131910</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164</VALIDVALUE>
          <VALUEMEANING>LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liothyronine Sodium</VALIDVALUE>
          <VALUEMEANING>Liothyronine Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of liothyronine, a synthetic thyroid hormone T3. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LSD1 Inhibitor CC-90011</VALIDVALUE>
          <VALUEMEANING>Pulrodemstat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, pulrodemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor (remove hyphen) suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family that is overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177 Monoclonal Antibody J591</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Rosopatamab Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lutetium Lu 177-PSMA-617</VALIDVALUE>
          <VALUEMEANING>Lutetium Lu 177 Vipivotide Tetraxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148145</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MAGE-A3 Multipeptide Vaccine GL-0817</VALIDVALUE>
          <VALUEMEANING>Biropepimut-S</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, biropepimut-S may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MALT1 Inhibitor JNJ-67856633</VALIDVALUE>
          <VALUEMEANING>Safimaltib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160147</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor HL-085</VALIDVALUE>
          <VALUEMEANING>Tunlametinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, tunlametinib selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MEK Inhibitor PD0325901</VALIDVALUE>
          <VALUEMEANING>MEK Inhibitor PD0325901</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C52195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7348903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Melapuldencel-T</VALIDVALUE>
          <VALUEMEANING>Eltrapuldencel-T</VALUEMEANING>
          <MEANINGDESCRIPTION>A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient&#39;s repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Menin-MLL Interaction Inhibitor SNDX-5613</VALIDVALUE>
          <VALUEMEANING>Revumenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165776</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesna</VALIDVALUE>
          <VALUEMEANING>Mesna</VALUEMEANING>
          <MEANINGDESCRIPTION>A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MCL-1 inhibitor AMG 397</VALIDVALUE>
          <VALUEMEANING>Murizatoclax</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13699305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MET x MET Bispecific Antibody REGN5093</VALIDVALUE>
          <VALUEMEANING>Davutamig</VALUEMEANING>
          <MEANINGDESCRIPTION>A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MetAP2 Inhibitor SDX-7320</VALIDVALUE>
          <VALUEMEANING>Evexomostat</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent&#39;s efficacy as compared to non-polymer conjugates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128030</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961786</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metformin</VALIDVALUE>
          <VALUEMEANING>Metformin</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3189685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylprednisolone Acetate</VALIDVALUE>
          <VALUEMEANING>Methylprednisolone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6606398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methylprednisolone Sodium Succinate</VALIDVALUE>
          <VALUEMEANING>Methylprednisolone Sodium Succinate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6159937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Methyltestosterone</VALIDVALUE>
          <VALUEMEANING>Methyltestosterone</VALUEMEANING>
          <MEANINGDESCRIPTION>A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody 81C6</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 81C6</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine IgG2 monoclonal antibody (MoAb) 81C6 raised against the extracellular matrix antigen tenascin (hexabrachion), up-regulated in gliomas and other cancers. Conjugated MoAb 81C6 may be used in diagnosis or treatment of cancers that over-express tenascin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal Antibody huJ591</VALIDVALUE>
          <VALUEMEANING>Rosopatamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Rosopatamab was generated by replacing murine Ig sequences with human ones, thereby MoAb huJ591can be administered to patients on multiple occasions over long time periods without inducing an immune response. Radiolabelled MoAb huJ591 may be used in immunotherapy of prostate cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100</VALIDVALUE>
          <VALUEMEANING>Tebentafusp</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-kinase Inhibitor TPX-0022</VALIDVALUE>
          <VALUEMEANING>Elzovantinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162676</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nanoparticle Albumin-Bound Rapamycin</VALIDVALUE>
          <VALUEMEANING>Sirolimus Albumin-bound Nanoparticles</VALUEMEANING>
          <MEANINGDESCRIPTION>The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74065</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Naxitamab</VALIDVALUE>
          <VALUEMEANING>Naxitamab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ncmtRNA Oligonucleotide Andes-1537</VALIDVALUE>
          <VALUEMEANING>Mulnitorsen</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5&#39; end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123825</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Otherwise Specified</VALIDVALUE>
          <VALUEMEANING>Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2853071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multi-kinase Inhibitor XL092</VALIDVALUE>
          <VALUEMEANING>Zanzalintinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2, AXL and MER, and prevents their RTK activity. This blocks c-Met/VEGFR2/AXL/MER-mediated signal transduction pathways, and inhibits the proliferation and migration of c-Met-, VEGFR2-, AXL- and MER-overexpressing tumor cells. c-Met, overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. VEGFR2, overexpressed in certain tumor types, plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. AXL and MER, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nutlin-3a</VALIDVALUE>
          <VALUEMEANING>Rebemadlin</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule and MDM2 (murine double minute 2) inhibitor, with potential antineoplastic activity. In cancer cells, rebemadlin antagonizes the binding of MDM2 to p53, thereby preventing MDM2-mediated p53 degradation. This results in stabilizing and activating p53-dependent cell cycle arrest and apoptosis. The protein MDM2, a negative regulator of p53 activity, is overexpressed in many cancer cell types; the tumor suppressor p53 is mutated or deleted in about 50% of all cancers but active in the other 50%.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Octreotide Acetate</VALIDVALUE>
          <VALUEMEANING>Octreotide Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3919466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Adenovirus Ad5-DNX-2401</VALIDVALUE>
          <VALUEMEANING>Tasadenoturev</VALUEMEANING>
          <MEANINGDESCRIPTION>An adenovirus serotype 5 strain, selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential oncolytic activity. Tasadenoturev contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackie and adenovirus receptors (CARs). Selectively replication competent in cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16), active replication of oncolytic adenovirus Ad5-Delta 24RGD in tumor cells may induce oncolysis or cell lysis. As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle; ovarian cancer cells and non-small cell lung cancer cells may be defective in the Rb/p16 pathway.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oncolytic Virus RP1</VALIDVALUE>
          <VALUEMEANING>Vusolimogene Oderparepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158074</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ondansetron Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Ondansetron Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist with antiemetic activity. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS, where the chemoreceptor trigger zone (CTZ) for vomiting is located, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6431768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OX40L-expressing Oncolytic Adenovirus DNX-2440</VALIDVALUE>
          <VALUEMEANING>Tezemlimogene Daxadenorepvec</VALUEMEANING>
          <MEANINGDESCRIPTION>A selectively replication competent oncolytic adenovirus that is engineered to express OX40 ligand (OX40L) with potential oncolytic and immunostimulatory activities. Upon administration, tezemlimogene daxadenorepvec, which contains an integrin binding RGD-4C motif, infects tumor cells in a Coxsackievirus-adenovirus receptor-independent manner and selectively replicates in tumor cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16). Tumor cell selectivity is achieved through a 24-base pair deletion in the E1A gene, which renders the oncolytic adenovirus unable to replicate in normal cells that maintain a functional Rb pathway, but fully replication competent in Rb/p16 defective tumor cells.  Active replication of the OX40L-expressing oncolytic adenovirus within tumor cells may induce oncolysis and release of OX40L. OX40L may then bind to and activate signaling pathways downstream of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes and promote the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. The Rb gene product and p16 are negative regulators of the cell cycle and are defective in certain tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oxcarbazepine</VALIDVALUE>
          <VALUEMEANING>Oxcarbazepine</VALUEMEANING>
          <MEANINGDESCRIPTION>A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5625815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p300/CBP Bromodomain Inhibitor CCS1477</VALIDVALUE>
          <VALUEMEANING>Inobrodib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160195</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p53-HDM2 Protein-protein Interaction Inhibitor APG-115</VALIDVALUE>
          <VALUEMEANING>Alrizomadlin</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PAK4/NAMPT Inhibitor KPT-9274</VALIDVALUE>
          <VALUEMEANING>Padnarsertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon administration, padnarsertib allosterically binds to, destabilizes and causes degradation of PAK4. This inhibits PAK4-mediated signaling, induces cell death in, and inhibits the proliferation of PAK4-overexpressing tumor cells. In addition, padnarsertib binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in tumor cell death in NAMPT-overexpressing cancer cells. PAK4, a serine/threonine kinase and member of the PAK family of proteins upregulated in various cancer cell types, regulates cell motility, proliferation and survival. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is often overexpressed in a variety of cancers and metabolic disorders and tumor cells rely on NAMPT activity for their NAD supply.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palonosetron Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Palonosetron Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7060538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pamidronic Acid</VALIDVALUE>
          <VALUEMEANING>Pamidronate</VALUEMEANING>
          <MEANINGDESCRIPTION>An amino- bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Pamidronic acid binds to and adsorbs onto hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also binds to and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis of osteoclasts. By preventing osteoclast-mediated bone resorption, pamidronic acid decreases bone turnover rate, stabilizes the bone matrix and reduces hypercalcemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4147713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-mutation-selective EGFR Inhibitor CLN-081</VALIDVALUE>
          <VALUEMEANING>Zipalertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), with potential antineoplastic activity. CLN-081 is also active against other EGFR mutations including exon 19 deletions (exon19del), L858R, and T790M, as well as the less common G719X, L861Q and S768I mutations. Upon administration, zipalertinib specifically and covalently binds to and inhibits a variety of EGFR mutations, with particularly high selectivity against EGFR Ex20ins, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CLN-081 may have therapeutic benefits in tumors with EGFR Ex20ins, as most EGFR mutant-selective inhibitors are not active against EGFR Ex20ins. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C165567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pan-PIM Inhibitor INCB053914</VALIDVALUE>
          <VALUEMEANING>Uzansertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>p70S6K/Akt Inhibitor MSC2363318A</VALIDVALUE>
          <VALUEMEANING>p70S6K/Akt Inhibitor M-2698</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, p70S6K/Akt inhibitor M-2698 binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pan-RAF Inhibitor LXH254</VALIDVALUE>
          <VALUEMEANING>Naporafenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP 1/2 Inhibitor IMP4297</VALIDVALUE>
          <VALUEMEANING>Senaparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, senaparib selectively binds to PARP 1 and 2 and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP7 Inhibitor RBN-2397</VALIDVALUE>
          <VALUEMEANING>Atamparib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration,atamparib selectively binds to PARP7 and restores interferon (type 1) signaling.  This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partially Engineered T-regulatory Cell Donor Graft TRGFT-201</VALIDVALUE>
          <VALUEMEANING>Partially Engineered T-regulatory Cell Donor Graft TRGFT-201</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-regulatory (Treg) cell donor graft that has been partially engineered by depleting all the T-cells and then enriching the graft with infusions of conventional T-cells, Tregs and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors, with potential immunomodulating activity. Upon administration of the partially engineered T-regulatory cell donor graft TRGFT-201 following myeloablation, the allograft may induce tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) as treatment for hematologic malignancies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pasireotide</VALIDVALUE>
          <VALUEMEANING>Pasireotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69131</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3564437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PBN Derivative OKN-007</VALIDVALUE>
          <VALUEMEANING>Disufenton Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PD-1 Inhibitor</VALIDVALUE>
          <VALUEMEANING>PD1 Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6059143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegfilgrastim</VALIDVALUE>
          <VALUEMEANING>Pegfilgrastim</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2775105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PARP/Tankyrase Inhibitor 2X-121</VALIDVALUE>
          <VALUEMEANING>PARP/Tankyrase Inhibitor 2X-121</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PEG-Proline-Interferon Alfa-2b</VALIDVALUE>
          <VALUEMEANING>Ropeginterferon Alfa-2B</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Recombinant Human Hyaluronidase PH20</VALIDVALUE>
          <VALUEMEANING>Pegvorhyaluronidase Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated formulation of a recombinant form of human hyaluronidase with potential antitumor activity. Upon intravenous administration, pegvorhyaluronidase alfa degrades hyaluronic acid (HA) coating tumor cells, which may result in the inhibition of tumor cell growth. In addition, the degradation of HA may result in a lowering of the interstitial fluid pressure (IFP), allowing better penetration of chemotherapeutic agents into the tumor bed. HA is a glycosaminoglycan found in the extracellular matrix (ECM) that is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increased tumor cell growth, metastatic potential, tumor progression, increased resistance to chemotherapeutic agents, and an elevation in tumor IFP.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82659</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Recombinant Interleukin-2 THOR-707</VALIDVALUE>
          <VALUEMEANING>Pegenzileukin</VALUEMEANING>
          <MEANINGDESCRIPTION>A pegylated recombinant, engineered variant of cytokine interleukin-2 (IL-2; IL2) where novel amino acid is encoded in the IL-2 gene that is leveraged for use in site-specific pegylation, with potential immunostimulating activity. Upon administration of pegenzileukin, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells, such as cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, thereby activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. The addition of the novel amino acid and the concurrent pegylation prevents the binding of the IL-2 moiety to the IL-2 receptor alpha chain (IL2Ra), thereby blocking the IL2Ra-mediated activation of CD4-positive regulatory and immunosuppressive T-cells (Tregs). Since it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, pegenzileukin prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of pegenzileukin. Compared to recombinant IL-2, pegenzileukin allows for increased IL-2Rbg binding and proliferation of CTLs without stimulating the toxicity caused by binding to IL-2Ra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Personalized Cancer Vaccine RO7198457</VALIDVALUE>
          <VALUEMEANING>Autogene Cevumeran</VALUEMEANING>
          <MEANINGDESCRIPTION>An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient&#39;s cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961810</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PGG Beta-Glucan</VALIDVALUE>
          <VALUEMEANING>Odetiglucan</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phenytoin Sodium</VALIDVALUE>
          <VALUEMEANING>Phenytoin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of phenytoin, a hydantoin derivate and non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin sodium promotes sodium efflux from neurons located in the motor cortex, thereby stabilizing the neuron and inhibiting synaptic transmission. This leads to a reduction in posttetanic potentiation at synapses, an inhibition of repetitive firing of action potentials and ultimately inhibits the spread of seizure activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48011</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phosphaplatin PT-112</VALIDVALUE>
          <VALUEMEANING>Imifoplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pegylated Recombinant L-asparaginase Erwinia chrysanthemi</VALIDVALUE>
          <VALUEMEANING>Pegcrisantaspase</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Recombinant Erwinia asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Recombinant Erwinia asparaginase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170297</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Phospholipid Ether-drug Conjugate CLR 131</VALIDVALUE>
          <VALUEMEANING>Iodine I 131 Iopofosine</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioconjugate composed of iopofosine, a phospholipid ether analog, labeled with the radioactive isotope iodine I 131, with potential antineoplastic activity. Upon administration, iodine I 131 iopofosine selectively accumulates in and retains within tumor cells for a prolonged period of time due to the decreased activity of a phospholipase D (PLD) in tumor cells compared to normal cells, thereby delivering cytotoxic radiation specifically to tumor cells.  PLD is an enzyme found in the cell membrane of normal cells that degrades phospholipids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84879</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor ACP-319</VALIDVALUE>
          <VALUEMEANING>PI3K-delta Inhibitor AMG 319</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly selective, potent, and orally bioavailable small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.  PI3K-delta inhibitor AMG 319 prevents the activation of the PI3K signaling pathway through inhibition of the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), thus decreasing proliferation and inducing cell death.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13722221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor GDC0077</VALIDVALUE>
          <VALUEMEANING>Inavolisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132166</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K Inhibitor GDC-0084</VALIDVALUE>
          <VALUEMEANING>PI3K Inhibitor GDC-0084</VALUEMEANING>
          <MEANINGDESCRIPTION>A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116877</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6617877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170</VALIDVALUE>
          <VALUEMEANING>Panulisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C104292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13715028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-alpha Inhibitor MEN1611</VALIDVALUE>
          <VALUEMEANING>Izorlisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. Upon administration, izorlisib selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, izorlisib may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, izorlisib also targets mutated forms of PI3K gamma (PI3Kg). It may also stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158603</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-delta Inhibitor HMPL 689</VALIDVALUE>
          <VALUEMEANING>Amdizalisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3&#39;-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-delta Inhibitor PWT143</VALIDVALUE>
          <VALUEMEANING>Zandelisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PI3K-delta Inhibitor YY-20394</VALIDVALUE>
          <VALUEMEANING>Linperlisib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13679583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Placebo</VALIDVALUE>
          <VALUEMEANING>Placebo</VALUEMEANING>
          <MEANINGDESCRIPTION>An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C753</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platinum</VALIDVALUE>
          <VALUEMEANING>Platinum</VALUEMEANING>
          <MEANINGDESCRIPTION>An element with atomic symbol Pt, atomic number 78, and atomic weight 195.09.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PLK1 Inhibitor CYC140</VALIDVALUE>
          <VALUEMEANING>Plogosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A competitive inhibitor for adenosine triphosphate (ATP) binding to polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, plogosertib selectively targets, binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation, transformation and invasion. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pol I Inhibitor CX5461</VALIDVALUE>
          <VALUEMEANING>Pidnarulex</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961820</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polo-like Kinase 1 Inhibitor NMS-1286937</VALIDVALUE>
          <VALUEMEANING>Onvansertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C143162</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate</VALIDVALUE>
          <VALUEMEANING>Ocifisertib Fumarate</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platinum Compound</VALIDVALUE>
          <VALUEMEANING>Platinum Compound</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961818</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polyamine Analogue SBP-101</VALIDVALUE>
          <VALUEMEANING>Ivospemin Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt form of ivospemin, an analogue of naturally occurring polyamine (PA), with potential antineoplastic activity. Upon subcutaneous administration,  ivospemin displaces endogenous PAs from PA-binding sites on the cell surface, which prevents internalization of PA. This inhibits PA-dependent cell cycle processes and results in cell cycle arrest, the induction of apoptosis, and inhibition of tumor cell proliferation. PA uptake is upregulated in various tumor types and increased levels of PA leads to enhanced tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prednisolone Acetate</VALIDVALUE>
          <VALUEMEANING>Prednisolone Acetate</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone acetate binds to specific intracellular glucocorticoid receptors, and causes the ligand-receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prednisolone Sodium Phosphate</VALIDVALUE>
          <VALUEMEANING>Prednisolone Sodium Phosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium phosphate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone sodium phosphate binds to specific intracellular glucocorticoid receptors, and causes the ligand- receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progestational IUD</VALIDVALUE>
          <VALUEMEANING>Progestational Intrauterine Device</VALUEMEANING>
          <MEANINGDESCRIPTION>An intrauterine device impregnated with progestin (synthetic progesterone) that can be inserted into the uterus to prevent conception.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostaglandin E2 EP4 Receptor Inhibitor AN0025</VALIDVALUE>
          <VALUEMEANING>Palupiprant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129689</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Arginine Methyltransferase 5 Inhibitor GSK3326595</VALIDVALUE>
          <VALUEMEANING>Pemrametostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not been completely determined, pemrametostat binds to the substrate recognition site of PRMT5 following oral administration and inhibits its methyltransferase activity, which decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cell proliferation. Therefore, this agent may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation and may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein Kinase C Inhibitor IDE196</VALIDVALUE>
          <VALUEMEANING>Darovasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PRMT5 Inhibitor JNJ-64619178</VALIDVALUE>
          <VALUEMEANING>Onametostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration,onametostat selectively targets and irreversibly binds to the S-adenosylmethionine (SAM)- and substrate-binding pockets of the PRMT5/methylosome protein 50 (MEP50) complex, and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961825</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PTEF-b/CDK9 Inhibitor BAY1251152</VALIDVALUE>
          <VALUEMEANING>Enitociclib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961830</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PV-10</VALIDVALUE>
          <VALUEMEANING>Rose Bengal Solution PV-10</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13743761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pyrazinamide</VALIDVALUE>
          <VALUEMEANING>Pyrazinamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radioactive Iodine</VALIDVALUE>
          <VALUEMEANING>Radioactive Iodine</VALUEMEANING>
          <MEANINGDESCRIPTION>(RAY-dee-o-AK-tiv EYE-uh-dine) A radioactive form of iodine, often used for imaging tests or as a treatment for cancer. For imaging tests, the patient takes a small amount of radioactive iodine by mouth, and it collects in the thyroid. A probe is used to scan the thyroid. For treatment, the patient takes a large dose of radioactive iodine, which kills thyroid cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3188245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ras Inhibitor</VALIDVALUE>
          <VALUEMEANING>Ras Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>An agent designed to inhibit the signal transduction process by interfering with the action of the ras family of proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Erythropoietin</VALIDVALUE>
          <VALUEMEANING>Recombinant Erythropoietin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2796011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Granulocyte-Macrophage Colony-Stimulating Factor</VALIDVALUE>
          <VALUEMEANING>GM-CSF</VALUEMEANING>
          <MEANINGDESCRIPTION>Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Human TRAIL-Trimer Fusion Protein SCB-313</VALIDVALUE>
          <VALUEMEANING>Rilunermin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L), with potential pro-apoptotic and antineoplastic activities. The binding of TRAIL to the Trimer-Tag allows TRAIL to form a stable covalently-linked homotrimer. Upon administration rilunermin alfa targets, binds to and trimerizes the TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby activating caspases and inducing apoptosis in TRAIL-R1/R2-expressing tumor cells. TRAIL, a homotrimeric type II transmembrane protein and member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types; The induction of receptor trimerization is needed for the initiation of the apoptotic signaling pathway. The TRAIL-Trimer retains similar bioactivity and receptor binding kinetics as native TRAIL but has more favorable pharmacokinetics and antitumor activity than native TRAIL.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interleukin-18</VALIDVALUE>
          <VALUEMEANING>Recombinant Interleukin-18</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, IL-18 displays antitumor effects in vitro and in animal models. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3147595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Interleukin-2</VALIDVALUE>
          <VALUEMEANING>Recombinant Interleukin-2</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-2 is made by a type of T lymphocyte. It increases the growth and activity of other T lymphocytes and B lymphocytes, and affects the development of the immune system. Aldesleukin (interleukin-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-2 is a type of cytokine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5799366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Luteinizing Hormone</VALIDVALUE>
          <VALUEMEANING>Recombinant Luteinizing Hormone</VALUEMEANING>
          <MEANINGDESCRIPTION>A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12326611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recombinant Platelet Factor 4</VALIDVALUE>
          <VALUEMEANING>Iroplact</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant form of the endogenous chemokine platelet factor 4 with potential antiangiogenesis and antineoplastic activities. As a heparin-binding tetramer, iroplact inhibits growth factor-stimulated endothelial cell proliferation, migration, and angiogenesis; it has been shown that this agent inhibits fibroblast growth factor 2 (FGF2) angiogenic activity downstream from the FGF2 receptor. Its activity is antagonized by heparin. Recombinant platelet factor 4 may also directly inhibit the proliferation of some tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13666533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RET Inhibitor DS-5010</VALIDVALUE>
          <VALUEMEANING>Zeteletinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, zeteletinib selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158093</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhenium Re-186 Hydroxyethylidene Diphosphonate</VALIDVALUE>
          <VALUEMEANING>Rhenium Re 186 Etidronate</VALUEMEANING>
          <MEANINGDESCRIPTION>An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RhoC Peptide Vaccine RV001V</VALIDVALUE>
          <VALUEMEANING>Onilcamotide</VALUEMEANING>
          <MEANINGDESCRIPTION>A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rigosertib</VALIDVALUE>
          <VALUEMEANING>Rigosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rivoceranib</VALIDVALUE>
          <VALUEMEANING>Rivoceranib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152237</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sacubitril/Valsartan</VALIDVALUE>
          <VALUEMEANING>Sacubitril/Valsartan</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Androgen Receptor Modulator RAD140</VALIDVALUE>
          <VALUEMEANING>Vosilasarm</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selective Estrogen Receptor Degrader LY3484356</VALIDVALUE>
          <VALUEMEANING>Imlunestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SERD D-0502</VALIDVALUE>
          <VALUEMEANING>Taragarestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156735</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SERD GDC-9545</VALIDVALUE>
          <VALUEMEANING>Giredestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147030</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13660231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Short Chain Fatty Acid HQK-1004</VALIDVALUE>
          <VALUEMEANING>Arginine Butyrate</VALUEMEANING>
          <MEANINGDESCRIPTION>A compound composed of the short chain fatty acid (SCFA) butyrate combined with the amino acid arginine, with potential Epstein-Barr virus thymidine kinase gene (EBV-TK)-inducing activity. Upon administration, arginine butyrate induces the expression of thymidine kinase (TK). This activates a co-administered antiviral, such as ganciclovir, and results in the destruction of EBV-infected cancer cells. In addition, butyrate inhibits histone deacetylase (HDAC), which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13597037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHP2 Inhibitor RMC-4630</VALIDVALUE>
          <VALUEMEANING>Vociprotafib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, vociprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHP2 Inhibitor TNO155</VALIDVALUE>
          <VALUEMEANING>Batoprotafib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration,batoprotafib binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139559</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sirolimus</VALIDVALUE>
          <VALUEMEANING>Sirolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIRPa-Fc Fusion Protein TTI-621</VALIDVALUE>
          <VALUEMEANING>Ontorpacept</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13714905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SERD G1T48</VALIDVALUE>
          <VALUEMEANING>Rintodestrant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SIRPa-IgG4-Fc Fusion Protein TTI-622</VALIDVALUE>
          <VALUEMEANING>SIRPa-IgG4-Fc Fusion Protein TTI-622</VALUEMEANING>
          <MEANINGDESCRIPTION>A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, the SIRPa-IgG4-Fc fusion protein TTI-622 selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7739455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SLC6A8 Inhibitor RGX-202</VALIDVALUE>
          <VALUEMEANING>Ompenaclid</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, ompenaclid inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961844</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SLCT Inhibitor GNS561</VALIDVALUE>
          <VALUEMEANING>Ezurpimtrostat</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spanlecortemlocel</VALIDVALUE>
          <VALUEMEANING>Spanlecortemlocel</VALUEMEANING>
          <MEANINGDESCRIPTION>A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of Spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SSTR2-targeting Protein/DM1 Conjugate PEN-221</VALIDVALUE>
          <VALUEMEANING>Nendratareotide Uzatansine</VALUEMEANING>
          <MEANINGDESCRIPTION>A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity. Upon administration, the peptide ligand moiety of nendratareotide uzatansine targets and binds to SSTR2, which is overexpressed on certain tumor cell types. Binding stimulates SSTR2-mediated endocytosis of the agent; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of SSTR2-expressing cancer cells. Compared to antibody-drug conjugates (ADCs), miniaturized drug conjugates are much smaller and can more easily penetrate and distribute in dense tumor tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STAT3 Inhibitor TTI-101</VALIDVALUE>
          <VALUEMEANING>STAT3 Inhibitor C-188-9</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151932</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STING Agonist MK-1454</VALIDVALUE>
          <VALUEMEANING>Ulevostinag</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803</VALIDVALUE>
          <VALUEMEANING>Nogapendekin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6004367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superoxide Dismutase Mimetic GC4711</VALIDVALUE>
          <VALUEMEANING>Rucosopasem Manganese</VALUEMEANING>
          <MEANINGDESCRIPTION>A mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). Upon administration, rucosopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation. As hydrogen peroxide is less toxic than superoxide to normal tissues, but more toxic to cancer cells, this may increase the anti-cancer efficacy of SBRT and decrease its damage to normal tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Src/tubulin Inhibitor KX02</VALIDVALUE>
          <VALUEMEANING>Src/tubulin Inhibitor KX2-361</VALUEMEANING>
          <MEANINGDESCRIPTION>A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120101</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Survivin-expressing CVD908ssb-TXSVN Vaccine</VALIDVALUE>
          <VALUEMEANING>Survivin-expressing CVD908ssb-TXSVN Vaccine</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable Salmonella-based survivin vaccine composed of a weakened form of a live strain of  Salmonella bacteria (CVD908ssb strain) that has been genetically modified to produce the tumor-associated antigen (TAA) survivin, with potential immunopotentiating and antineoplastic activities. Upon administration of the CVD908ssb-TXSVN vaccine, the expressed survivin stimulates the immune response to elicit a cytotoxic T-lymphocyte (CTL)-mediated immune response against survivin-expressing cancer cells, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158607</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syk Inhibitor HMPL-523</VALIDVALUE>
          <VALUEMEANING>Sovleplenib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taxane Compound</VALIDVALUE>
          <VALUEMEANING>Taxane Compound</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Telomerase-specific Type 5 Adenovirus OBP-301</VALIDVALUE>
          <VALUEMEANING>Suratadenoturev</VALUEMEANING>
          <MEANINGDESCRIPTION>A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testosterone Enanthate</VALIDVALUE>
          <VALUEMEANING>Testosterone Enanthate</VALUEMEANING>
          <MEANINGDESCRIPTION>A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tetraphenyl Chlorin Disulfonate</VALIDVALUE>
          <VALUEMEANING>Fimaporfin A</VALUEMEANING>
          <MEANINGDESCRIPTION>The A isomer of fimaporfin, a synthetic light-activated compound, with potential photosensitizing activity. Upon administration, fimaporfin A incorporates into the cell&#39;s endosome and lysosome membranes. Subsequently, cytotoxic agents are administered and accumulate in endosomal and lysosomal compartments; upon local activation by light, fimaporfin A produces reactive oxygen species (ROS), such as singlet oxygen, damaging endo/lysosomal membranes and accumulated cytotoxic agents are released into the tumor cell cytosol. This photochemical internalization (PCI) method can enhance the efficacy and selectivity of cytotoxic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13636985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Theliatinib</VALIDVALUE>
          <VALUEMEANING>Xiliertinib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally available, ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, xiliertinib binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13746557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Taurultam Analogue GP-2250</VALIDVALUE>
          <VALUEMEANING>Misetionamide</VALUEMEANING>
          <MEANINGDESCRIPTION>An oxathiazine-based structural analogue of taurultam (TRLT), which is the main derivative of the anti-infective agent taurolidine (TRD), with potential antineoplastic activity. Upon administration,misetionamide selectively induces reactive oxygen species (ROS)-mediated apoptosis in and inhibits proliferation of susceptible tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C159500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Estradiol</VALIDVALUE>
          <VALUEMEANING>Therapeutic Estradiol</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic form of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females, that may be used as hormone replacement therapy. Typically esterified, estradiol derivatives are formulated for oral, intravaginal, transdermal, or parenteral administration. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. It may play a role in immune and inflammatory processes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Therapeutic Hydrocortisone</VALIDVALUE>
          <VALUEMEANING>Therapeutic Hydrocortisone</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3305287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Threonine Tyrosine Kinase Inhibitor CFI-402257</VALIDVALUE>
          <VALUEMEANING>Luvixasertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroid Extract</VALIDVALUE>
          <VALUEMEANING>Thyroid Extract</VALUEMEANING>
          <MEANINGDESCRIPTION>An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7115554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TIGIT Inhibitor M6223</VALIDVALUE>
          <VALUEMEANING>Dargistotug</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), a co-inhibitory molecule and immune checkpoint inhibitor, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dargistotug targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C173891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TIGIT-targeting Agent MK-7684</VALIDVALUE>
          <VALUEMEANING>Vibostolimab</VALUEMEANING>
          <MEANINGDESCRIPTION>An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C140041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tipiracil</VALIDVALUE>
          <VALUEMEANING>Tipiracil</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439</VALIDVALUE>
          <VALUEMEANING>Thorium Th 227 Trastuzumab Corixetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C168996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tipiracil Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Tipiracil Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C152647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR8 Agonist DN1508052</VALIDVALUE>
          <VALUEMEANING>TLR8 Agonist DN1508052</VALUEMEANING>
          <MEANINGDESCRIPTION>A small molecule Toll-like receptor 8 (TLR8; CD288) agonist with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, TLR8 agonist DN1508052 binds to TLR8, which is expressed in myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells. This may lead to the activation of nuclear factor NF-kappa-B, the release of proinflammatory cytokines and a Th1-weighted anti-tumor immune response. Additionally, activation of TLR8 signaling in tumor cells may block the induction and reverse the suppression of senescent naive and tumor-specific T-cells, resulting in enhanced anti-tumor immunity. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toll-like Receptor 7 Agonist DSP-0509</VALIDVALUE>
          <VALUEMEANING>Guretolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Androgen Blockade</VALIDVALUE>
          <VALUEMEANING>Total Androgen Blockade</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TRAIL Receptor Agonist ABBV-621</VALIDVALUE>
          <VALUEMEANING>Eftozanermin Alfa</VALUEMEANING>
          <MEANINGDESCRIPTION>A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C146854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13634150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab/Hyaluronidase-oysk</VALIDVALUE>
          <VALUEMEANING>Trastuzumab/Hyaluronidase-oysk</VALUEMEANING>
          <MEANINGDESCRIPTION>A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. Trastuzumab binds to the extracellular ligand-binding domain of HER2 and mediates the activation of an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trastuzumab-TLR 7/8 Agonist BDC-1001</VALIDVALUE>
          <VALUEMEANING>Trastuzumab Imbotolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>An immune stimulating antibody conjugate (ISAC) consisting of trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, conjugated to a Toll-like receptor (TLR) 7/8 dual agonist, with potential immunostimulating and antineoplastic activities. Upon administration of trastuzumab imbotolimod, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells and, simultaneously, the TLR 7/8 dual agonist moiety targets, binds to and activates TLR7/8 expressed on antigen-presenting cells (APCs), specifically dendritic cells (DCs), in the tumor microenvironment (TME). The trastuzumab binding to the tumor cells causes the engulfment of the trastuzumab imbotolimod-bound tumor cells by tumor-associated myeloid (TAM) cells and the TAMs travel to the lymph nodes. The DCs activated by the TLR7/8 agonist causes the activation of TLR7/8-mediated pathways, and stimulates the maturation and activation of DCs, thereby re-activating the immune system against the tumor cells. Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses against tumor-associated antigens (TAAs), which lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation. HER2 is overexpressed by a variety of tumor cell types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TLR9 Agonist AST-008</VALIDVALUE>
          <VALUEMEANING>Cavrotolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triamcinolone Acetonide</VALIDVALUE>
          <VALUEMEANING>Triamcinolone Acetonide</VALUEMEANING>
          <MEANINGDESCRIPTION>The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48027</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Triamcinolone Hexacetonide</VALIDVALUE>
          <VALUEMEANING>Triamcinolone Hexacetonide</VALUEMEANING>
          <MEANINGDESCRIPTION>The hexacetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone hexacetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48026</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trigriluzole</VALIDVALUE>
          <VALUEMEANING>Troriluzole</VALUEMEANING>
          <MEANINGDESCRIPTION>A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142847</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tropomyosin Receptor Kinase Inhibitor AZD7451</VALIDVALUE>
          <VALUEMEANING>Tropomyosin Receptor Kinase Inhibitor AZD7451</VALUEMEANING>
          <MEANINGDESCRIPTION>A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. AZD7451 binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3444806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Troxacitabine Nucleotide Prodrug MIV-818</VALIDVALUE>
          <VALUEMEANING>Fostroxacitabine Bralpamide</VALUEMEANING>
          <MEANINGDESCRIPTION>A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C157496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin Binding Agent TTI-237</VALIDVALUE>
          <VALUEMEANING>Cevipabulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13633887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubulin Polymerization Inhibitor CKD-516</VALIDVALUE>
          <VALUEMEANING>Valecobulin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tyrosine Kinase Inhibitor</VALIDVALUE>
          <VALUEMEANING>Tyrosine Kinase Inhibitor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VLP-encapsulated TLR9 Agonist CMP-001</VALIDVALUE>
          <VALUEMEANING>Vidutolimod</VALUEMEANING>
          <MEANINGDESCRIPTION>A virus-like particle (VLP) composed of the Qbeta bacteriophage capsid encapsulating the toll-like receptor 9 (TLR9) agonist G10, an unmethylated CpG-A oligodeoxynucleotide (ODN), with potential immunostimulating and antineoplastic activities. Upon administration of vidutolimod, the VLPs are specifically taken up by and release the oligonucleotide into antigen-presenting cells (APCs), including dendritic cells (DCs). In turn, the oligonucleotide binds to and activates intracellular TLR9. This stimulates immune signaling pathways, induces the innate immune system and may promote the immune system to attack tumor cells. VLPs stimulate the immune system. TLR9, a member of the TLR family, plays a key role in both pathogen recognition and the activation of innate immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C175875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Warfarin Sodium</VALIDVALUE>
          <VALUEMEANING>Warfarin Sodium</VALUEMEANING>
          <MEANINGDESCRIPTION>The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3110880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wee1 Inhibitor ZN-c3</VALIDVALUE>
          <VALUEMEANING>Azenosertib</VALUEMEANING>
          <MEANINGDESCRIPTION>An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Although the exact mechanism of action by which this agent inhibits Wee1 has yet to be disclosed, upon administration of ZN-c3, this agent targets and inhibits Wee1. Inhibition of Wee1 promotes both premature mitosis and a prolonged mitotic arrest leading to cell death in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, upon treatment with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis; it negatively regulates the G2 checkpoint by disallowing entry into mitosis in response to DNA damage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C167064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Xeloda</VALIDVALUE>
          <VALUEMEANING>Capecitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XIAP/cIAP1 Antagonist ASTX660</VALIDVALUE>
          <VALUEMEANING>Tolinapant</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities. Upon administration, tolinapant selectively binds to and inhibits the activity of XIAP and cIAP1. This restores and promotes the induction of apoptotic signaling pathways in cancer cells, and inactivates the nuclear factor-kappa B (NF-kB)-mediated survival pathway. XIAP and cIAP1 are overexpressed by many cancer cell types and suppress apoptosis by inhibiting the activity of certain caspases; they promote both cancer cell survival and chemotherapy resistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XPO1 Inhibitor SL-801</VALIDVALUE>
          <VALUEMEANING>Felezonexor</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable inhibitor of the nuclear export protein exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic and pro-apoptotic activities. Upon administration, felezonexor reversibly binds to the cargo binding site of XPO1, and prevents the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins (TSPs), such as p53, FOXO, p21, and p27, and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), SL-801 restores the nuclear localization and function of TSPs, which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins and RNA from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The dysregulated export of TSPs into the cytoplasm prevents TSP-initiated apoptosis. XPO1 overexpression leads to uncontrolled tumor cell proliferation and is associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C171660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90 Resin Microspheres</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Resin Microspheres</VALUEMEANING>
          <MEANINGDESCRIPTION>An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101</VALIDVALUE>
          <VALUEMEANING>Yttrium Y 90 Tabituximab Barzuxetan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13744137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Z-Endoxifen Hydrochloride</VALIDVALUE>
          <VALUEMEANING>Z-Endoxifen Hydrochloride</VALUEMEANING>
          <MEANINGDESCRIPTION>The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3295775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zirconium Zr 89 Panitumumab</VALIDVALUE>
          <VALUEMEANING>Zirconium Zr 89 Panitumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This allows quantification of EGFR-expressing tumor cells and may allow selection of patients that would respond to panitumumab therapy. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156043</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13961877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Therapeutic Agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDS</Name>
        <OrganizationName/>
        <DocumentType>EXAMPLE</DocumentType>
        <DocumentText>13-Deoxydoxorubicin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ped Core Tier</Name>
        <OrganizationName/>
        <DocumentType>Tier</DocumentType>
        <DocumentText>Mandatory</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Name of ADT therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_02</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Name of ARPI therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173179</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>12173174</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>12173174v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Medications</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>12173201</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13574489</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCDI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Participant</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>13594092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13574489</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCDI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Therapeutic Procedure</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>13596242</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13954630</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>All Pediatric Core CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14599263</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MEDICATION</AlternateName>
        <AlternateNameType>PCDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>therapeutic_agent</AlternateName>
        <AlternateNameType>CCDI Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Therapeutic Agent</AlternateName>
        <AlternateNameType>Ped Cancer Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECTRT_ADT</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EC_ECTRT_ARPI</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>treatment</AlternateName>
        <AlternateNameType>CCDI Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="967">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>13714645</PUBLICID>
    <LONGNAME>Syringe Or Vial Lot Expiration Date Month Name</LONGNAME>
    <PREFERREDNAME>13714639v1.00:3259267v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The month that the syringe or vial lot expired.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>13714639</PublicId>
      <PreferredName>13714637v1.00:13714638v1.00</PreferredName>
      <PreferredDefinition>A device for the administration of drug products that consists of a rigid barrel fitted with septum with a plunger at one end and a seal or needle at the other end. The needle assembly may be part of the device or separate._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A small, often stoppered glass or plastic bottle for holding fluids._A defined quantity of manufactured material or product produced in a single manufacturing process or series of process steps so that it reasonably is expected to be homogeneous.:The date assigned by the manufacturer on which the product should no longer be used.</PreferredDefinition>
      <LongName>Syringe Or Vial Lot Expiration Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>13765536</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43202:C37998:C41275:C41396</PreferredName>
        <Version>1</Version>
        <LongName>Syringe Or Vial Lot</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43202</PREFERRED_NAME>
            <LONG_NAME>Syringe</LONG_NAME>
            <CON_ID>7164024</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41275</PREFERRED_NAME>
            <LONG_NAME>Vial</LONG_NAME>
            <CON_ID>2486072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41396</PREFERRED_NAME>
            <LONG_NAME>Lot</LONG_NAME>
            <CON_ID>2493175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>13714638</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C164516</PreferredName>
        <Version>1</Version>
        <LongName>Expiration Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C164516</PREFERRED_NAME>
            <LONG_NAME>Expiration Date</LONG_NAME>
            <CON_ID>10039065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3259267</PublicId>
      <PreferredName>3259267v1.0</PreferredName>
      <PreferredDefinition>One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Month Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>9</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3259266</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29846:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Month Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>December</VALIDVALUE>
          <VALUEMEANING>December</VALUEMEANING>
          <MEANINGDESCRIPTION>The twelfth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>November</VALIDVALUE>
          <VALUEMEANING>November</VALUEMEANING>
          <MEANINGDESCRIPTION>The eleventh month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>October</VALIDVALUE>
          <VALUEMEANING>October</VALUEMEANING>
          <MEANINGDESCRIPTION>The tenth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>September</VALIDVALUE>
          <VALUEMEANING>September</VALUEMEANING>
          <MEANINGDESCRIPTION>The ninth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>August</VALIDVALUE>
          <VALUEMEANING>August</VALUEMEANING>
          <MEANINGDESCRIPTION>The eighth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>July</VALIDVALUE>
          <VALUEMEANING>July</VALUEMEANING>
          <MEANINGDESCRIPTION>The seventh month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>June</VALIDVALUE>
          <VALUEMEANING>June</VALUEMEANING>
          <MEANINGDESCRIPTION>The sixth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>May</VALIDVALUE>
          <VALUEMEANING>May</VALUEMEANING>
          <MEANINGDESCRIPTION>The fifth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>April</VALIDVALUE>
          <VALUEMEANING>April</VALUEMEANING>
          <MEANINGDESCRIPTION>The fourth month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>March</VALIDVALUE>
          <VALUEMEANING>March</VALUEMEANING>
          <MEANINGDESCRIPTION>The third month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>February</VALIDVALUE>
          <VALUEMEANING>February</VALUEMEANING>
          <MEANINGDESCRIPTION>The second month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>January</VALIDVALUE>
          <VALUEMEANING>January</VALUEMEANING>
          <MEANINGDESCRIPTION>The first month of the year in the Julian and Gregorian calendars.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-07-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What month did the syringe or vial lot expire?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Lot expiration date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="968">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14035196</PUBLICID>
    <LONGNAME>Exposure Dose Form</LONGNAME>
    <PREFERREDNAME>EX_EXDOSFRM</PREFERREDNAME>
    <PREFERREDDEFINITION>The dosage form in which the EXTRT is physically presented.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CDISC:Clinical Data Interchange Standards Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>6384870</PublicId>
      <PreferredName>6384837v1.0:6384868v1.0</PreferredName>
      <PreferredDefinition>A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to exposure._The dosage form of the exposure.</PreferredDefinition>
      <LongName>Exposure Domain Exposure Dose Form</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6384837</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49587</PreferredName>
        <Version>1</Version>
        <LongName>Exposure Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49587</PREFERRED_NAME>
            <LONG_NAME>Exposure Domain</LONG_NAME>
            <CON_ID>2469061</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6384868</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83111</PreferredName>
        <Version>1</Version>
        <LongName>Exposure Dose Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83111</PREFERRED_NAME>
            <LONG_NAME>Exposure Dose Form</LONG_NAME>
            <CON_ID>6384867</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6607760</PublicId>
      <PreferredName>FRM</PreferredName>
      <PreferredDefinition>Terminology codelist used with Pharmaceutical Dosage Form within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>CDISC SDTM Pharmaceutical Dosage Form Terminology Type</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6607759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66726:C25284</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Pharmaceutical Dosage Form Terminology Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66726</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Dosage Form Terminology</LONG_NAME>
            <CON_ID>6230455</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TROCHE</VALIDVALUE>
          <VALUEMEANING>Troche Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A discoid-shaped solid containing the medicinal agent in a suitably flavored base; troches are placed in the mouth where they slowly dissolve, liberating the active ingredients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TINCTURE</VALIDVALUE>
          <VALUEMEANING>Tincture Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An alcoholic or hydroalcoholic solution prepared from vegetable materials or from chemical substances.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TAPE</VALIDVALUE>
          <VALUEMEANING>Tape Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A narrow woven fabric, or a narrow extruded synthetic (such as plastic), usually with an adhesive on one or both sides.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TAMPON</VALIDVALUE>
          <VALUEMEANING>Tampon Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A plug made of cotton, sponge, or oakum variously used in surgery to plug the nose, vagina, etc., for the control of hemorrhage or the absorption of secretions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, SUGAR COATED</VALIDVALUE>
          <VALUEMEANING>Sugar Coated Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a colored or an uncolored water-soluble sugar.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, SOLUBLE</VALIDVALUE>
          <VALUEMEANING>Soluble Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and possesses the ability to dissolve in fluids.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE</VALIDVALUE>
          <VALUEMEANING>Tablet Orally Disintegrating Delayed Release Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue, but which releases a drug (or drugs) at a time other than promptly after administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, ORALLY DISINTEGRATING</VALIDVALUE>
          <VALUEMEANING>Orally Disintegrating Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42999</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, MULTILAYER, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Multilayered Extended Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell, which, additionally, is covered in a designated coating; the tablet is formulated in such manner as to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42963</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, MULTILAYER</VALIDVALUE>
          <VALUEMEANING>Multilayered Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, IMMEDIATE RELEASE</VALIDVALUE>
          <VALUEMEANING>Immediate Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6619162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Tablet For Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet that forms a suspension when placed in a liquid (formerly referred to as a Dispersible Tablet).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Tablet For Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet that forms a solution when placed in a liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61004</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FILM COATED, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Film Coated Extended Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FILM COATED</VALIDVALUE>
          <VALUEMEANING>Film Coated Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, EFFERVESCENT</VALIDVALUE>
          <VALUEMEANING>Effervescent Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing, in addition to active ingredients, mixtures of acids (citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42910</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, DELAYED RELEASE PARTICLES</VALIDVALUE>
          <VALUEMEANING>Delayed Release Particles Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing a conglomerate of medicinal particles that have been covered with a coating which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, DELAYED RELEASE</VALIDVALUE>
          <VALUEMEANING>Delayed Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, COATED PARTICLES</VALIDVALUE>
          <VALUEMEANING>Tablet Coated Particles Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing a conglomerate of medicinal particles that have each been covered with a coating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, COATED</VALIDVALUE>
          <VALUEMEANING>Coated Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, CHEWABLE</VALIDVALUE>
          <VALUEMEANING>Chewable Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42893</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SYRUP</VALIDVALUE>
          <VALUEMEANING>Syrup Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An oral solution containing high concentrations of sucrose or other sugars; the term has also been used to include any other liquid dosage form prepared in a sweet and viscid vehicle, including oral suspensions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42996</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SWAB</VALIDVALUE>
          <VALUEMEANING>Swab Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small piece of relatively flat absorbent material that contains a drug. A swab may also be attached to one end of a small stick. A swab is typically used for applying medication or for cleansing. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUTURE</VALIDVALUE>
          <VALUEMEANING>Suture Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A strand or fiber used to hold wound edges in apposition during healing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUSPENSION/DROPS</VALIDVALUE>
          <VALUEMEANING>Drops Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension which is usually administered in a dropwise fashion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60995</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation consisting of solid particles dispersed throughout a liquid phase in which the particles are not soluble; the suspension has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUPPOSITORY, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Suppository Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system in the form of a suppository that allows at least a reduction in dosing frequency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STRIP</VALIDVALUE>
          <VALUEMEANING>Strip Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A long narrow piece of material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>STICK</VALIDVALUE>
          <VALUEMEANING>Stick Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosage form prepared in a relatively long and slender often cylindrical form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SPRAY, SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Spray Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation containing solid particles dispersed in a liquid vehicle and in the form of coarse droplets or as finely divided solids to be applied locally, most usually to the nasal-pharyngeal tract, or topically to the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SPRAY, METERED</VALIDVALUE>
          <VALUEMEANING>Metered Spray Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-pressurized dosage form consisting of valves which allow the dispensing of a specified quantity of spray upon each activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SPONGE</VALIDVALUE>
          <VALUEMEANING>Sponge Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An absorbent pad of folded gauze or cotton.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION/ DROPS</VALIDVALUE>
          <VALUEMEANING>Drops Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution which is usually administered in a drop-wise fashion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60992</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION, GEL FORMING, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Gel Forming Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution that forms a gel when it comes in contact with ocular fluid, and which allows at least a reduction in dosing frequency</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION, GEL FORMING / DROPS</VALIDVALUE>
          <VALUEMEANING>Gel Forming Drops Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution, which after usually being administered in a drop-wise fashion, forms a gel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IRRIGANT</VALIDVALUE>
          <VALUEMEANING>Irrigant Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile solution intended to bathe or flush open wounds or body cavities; they&#39;re used topically, never parenterally.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INTRAUTERINE DEVICE</VALIDVALUE>
          <VALUEMEANING>Intrauterine Device Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A device inserted and left in the uterus to prevent effective conception.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INSERT, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Insert Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A specially formulated and shaped solid preparation (e.g., ring, tablet, or stick) intended to be placed in the vagina by special inserters, where the medication is released, generally for localized effects; the extended release preparation is designed to allow a reduction in dosing frequency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42922</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INSERT</VALIDVALUE>
          <VALUEMEANING>Insert Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A specially formulated and shaped solid preparation (e.g. ring, tablet, or stick) intended to be placed in the body, where drug is released, generally for localized effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SUSPENSION, SONICATED</VALIDVALUE>
          <VALUEMEANING>Injectable Sonicated Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. In addition, the product is sonicated while a gas is bubbled through the suspension, and this results in the formation of microspheres by the solid particles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42988</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SUSPENSION, LIPOSOMAL</VALIDVALUE>
          <VALUEMEANING>Injectable Liposomal Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid parenteral pharmaceutical dosage form structured as a multilamellar composition of concentric phospholipid spheres that encapsulate the drug (drug delivery systems) separated by layers of water. Drug release is facilitated and controlled by in vivo erosion of the liposomes. To further increase the in vivo circulation time, liposomes in some preparations are covalently derivatized with PEG to produce PEGylated or stealth liposomes. Covalent attachment of drugs to the outer surface of liposomes can potentially serve as a delayed-release product.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Injectable Extended Release Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile preparation intended for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42926</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Injectable Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42995</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SOLUTION, CONCENTRATE</VALIDVALUE>
          <VALUEMEANING>Concentrate for Injectable Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, SOLUTION</VALIDVALUE>
          <VALUEMEANING>Injectable Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Lyophilized Powder For Extended Release Injectable Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42956</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION, FOR SLUSH</VALIDVALUE>
          <VALUEMEANING>Solution For Slush Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution for the preparation of an iced saline slush, which is administered by irrigation and used to induce regional hypothermia (in conditions such as certain open heart and kidney surgical procedures) by its direct application.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION, CONCENTRATE</VALIDVALUE>
          <VALUEMEANING>Concentrate for Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation (i.e., a substance that flows readily in its natural state) that contains a drug dissolved in a suitable solvent or mixture of mutually miscible solvents; the drug has been strengthened by the evaporation of its non-active parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLUTION</VALIDVALUE>
          <VALUEMEANING>Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A clear, homogeneous liquid dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOAP</VALIDVALUE>
          <VALUEMEANING>Soap Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Any compound of one or more fatty acids, or their equivalents, with an alkali; soap is detergent and is much employed in liniments, enemas, and in making pills. It is also a mild aperient, antacid and antiseptic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHAMPOO, SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Shampoo Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid soap or detergent containing one or more solid, insoluble substances dispersed in a liquid vehicle that is used to clean the hair and scalp and is often used as a vehicle for dermatologic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42982</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SHAMPOO</VALIDVALUE>
          <VALUEMEANING>Shampoo Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid soap or detergent used to clean the hair and scalp and is often used as a vehicle for dermatologic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42981</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SALVE</VALIDVALUE>
          <VALUEMEANING>Salve Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A thick ointment or cerate (a fat or wax based preparation with a consistency between an ointment and a plaster).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42980</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RINSE</VALIDVALUE>
          <VALUEMEANING>Rinse Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid used to cleanse by flushing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42979</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RING</VALIDVALUE>
          <VALUEMEANING>Ring Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small circular object with a vacant circular center that is usually intended to be placed in the body by special inserters, where the medication is released, generally for localized effects.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60988</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Lyophilized Powder For Injectable Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation, intended for parenteral use, that contains solids suspended in a suitable fluid medium and conforms in all respects to the requirements for Sterile Suspensions; the medicinal agents intended for the suspension are prepared by lyophilization (&quot;freeze drying&quot;), a process which involves the removal of water from products in the frozen state at extremely low pressures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Lyophilized Powder For Injectable Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosage form intended for the solution prepared by lyophilization (&#39;freeze drying&#39;), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42957</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Lyophilized Powder For Injectable Liposomal Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner that would allow liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance, either within a lipid bilayer or in an aqueous space) to be formed upon reconstitution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Powder For Injectable Extended Release Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile freeze dried preparation intended for reconstitution to form a suspension for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Powder For Injectable Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile preparation intended for reconstitution to form a suspension for parenteral use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, POWDER, FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Powder For Injectable Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sterile preparation intended for reconstitution to form a solution for parenteral use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, LIPID COMPLEX</VALIDVALUE>
          <VALUEMEANING>Injectable Lipid Complex Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>[definition pending]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION, EMULSION</VALIDVALUE>
          <VALUEMEANING>Emulsion for Injection Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An emulsion, a two-phase system in which one liquid is dispersed throughout another liquid in the form of small droplets, consisting of a sterile, pyrogen-free preparation intended to be administered parenterally.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTION</VALIDVALUE>
          <VALUEMEANING>Injectable Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a drug into a location within the body; this can be achieved either through an established access or via a needle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28160</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INJECTABLE, LIPOSOMAL</VALIDVALUE>
          <VALUEMEANING>Liposomal Injection Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An injection, which either consists of or forms liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INHALANT</VALIDVALUE>
          <VALUEMEANING>Inhalant Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A special class of inhalations consisting of a drug or combination of drugs, that by virtue of their high vapor pressure, can be carried by an air current into the nasal passage where they exert their effect; the container from which the inhalant generally is administered is known as an inhaler.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IMPLANT</VALIDVALUE>
          <VALUEMEANING>Implant Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A material containing drug intended to be inserted securely of deeply in a living site for growth, slow release, or formation of an organic union.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42942</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER, FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Powder for Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER, METERED</VALIDVALUE>
          <VALUEMEANING>Metered Powder Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A powder dosage form that is situated inside a container that has a mechanism to deliver a specified quantity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER, FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Powder for Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER, DENTIFRICE</VALIDVALUE>
          <VALUEMEANING>Dentifrice Powder Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A powder formulation intended to clean and/or polish the teeth, and which may contain certain additional agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POULTICE</VALIDVALUE>
          <VALUEMEANING>Poultice Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A soft, moist mass of meal, herbs, seed, etc., usually applied hot in cloth that consists of gruel-like consistency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PLASTER</VALIDVALUE>
          <VALUEMEANING>Plaster Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Substance intended for external application made of such materials and of such consistency as to adhere to the skin and attach to a dressing; plasters are intended to afford protection and support and/or to furnish an occlusion and macerating action and to bring medication into close contact with the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PILL</VALIDVALUE>
          <VALUEMEANING>Pill Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose of medicine in the form of a small pellet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PELLETS, COATED, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Coated Pellets Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug itself is in the form of granules to which varying amounts of coating have been applied, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PELLET, IMPLANTABLE</VALIDVALUE>
          <VALUEMEANING>Implantable Pellet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding; they are intended for implantation in the body (usually subcutaneously) for the purpose of providing continuous release of the drug over long periods of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PELLET</VALIDVALUE>
          <VALUEMEANING>Pellet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED</VALIDVALUE>
          <VALUEMEANING>Electrically Controlled Extended Release Patch Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system in the form of a patch which is controlled by an electric current that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATCH, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Patch Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system in the form of a patch that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PASTILLE</VALIDVALUE>
          <VALUEMEANING>Pastille Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An aromatic preparation, often with a pleasing flavor, usually intended to dissolve in the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PASTE, DENTIFRICE</VALIDVALUE>
          <VALUEMEANING>Dentifrice Paste Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A paste formulation intended to clean and/or polish the teeth, and which may contain certain additional agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PASTE</VALIDVALUE>
          <VALUEMEANING>Paste Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisolid dosage form, containing a large proportion (20 - 50%) of solids finely dispersed in a fatty vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PACKING</VALIDVALUE>
          <VALUEMEANING>Packing Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A material, usually covered by or impregnated with a drug, that is inserted into a body cavity or between the tooth enamel and the gingival margin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OINTMENT, AUGMENTED</VALIDVALUE>
          <VALUEMEANING>Augmented Ointment Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An ointment dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OIL</VALIDVALUE>
          <VALUEMEANING>Oil Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An unctuous, combustible substance which is liquid, or easily liquefiable, on warming, and is soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MOUTHWASH</VALIDVALUE>
          <VALUEMEANING>Mouthwash Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LOZENGE</VALIDVALUE>
          <VALUEMEANING>Lozenge Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid preparation containing one or more medicaments, usually in a flavored, sweetened base which is intended to dissolve or disintegrate slowly in the mouth. A lollipop is a lozenge on a stick.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42955</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LOTION/SHAMPOO</VALIDVALUE>
          <VALUEMEANING>Lotion Shampoo Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A lotion dosage form which has a soap or detergent that is usually used to clean the hair and scalp; it is often used as a vehicle for dermatologic agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LOTION, AUGMENTED</VALIDVALUE>
          <VALUEMEANING>Augmented Lotion Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A lotion dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60957</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LOTION</VALIDVALUE>
          <VALUEMEANING>Lotion Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation for bathing the skin, or an injured or diseased part, either for a medicinal purpose, or for improving its appearance. (On-line Medical Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2660009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LIQUID, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Liquid Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A state of a substance that is an intermediate one, and which is entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, but rather only pure chemicals in their liquid state); it delivers a drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LIQUID</VALIDVALUE>
          <VALUEMEANING>Liquid Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LIPSTICK</VALIDVALUE>
          <VALUEMEANING>Lipstick Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A waxy solid, usually colored cosmetic, in stick form for the lips.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LINIMENT</VALIDVALUE>
          <VALUEMEANING>Liniment Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution or mixture of various substances in oil, alcoholic solutions of soap, or emulsions intended for external application.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LINER, DENTAL</VALIDVALUE>
          <VALUEMEANING>Dental Liner Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A material applied to the inside of the dental cavity, for protection or insulation of the surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KIT</VALIDVALUE>
          <VALUEMEANING>Kit Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A packaged collection of related material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JELLY</VALIDVALUE>
          <VALUEMEANING>Jelly Gel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A class of gels--semisolid systems which consist of suspensions made up of either small inorganic particles or large organic molecules interpenetrated by a liquid--in which the structural coherent matrix contains a high portion of liquid, usually water.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42948</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEROSOL</VALIDVALUE>
          <VALUEMEANING>Aerosol Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system; it is intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual aerosols), or lungs (inhalation aerosols).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE</VALIDVALUE>
          <VALUEMEANING>Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid contained within either a hard or soft soluble shell, usually prepared from gelatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5796808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CREAM</VALIDVALUE>
          <VALUEMEANING>Cream Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisolid emulsion of either the oil-in-water or the water-in-oil type, ordinarily intended for topical use. (On-line Medical Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2660008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GAS</VALIDVALUE>
          <VALUEMEANING>Gas Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Any elastic aeriform fluid in which the molecules are separated from one another and have free paths.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GEL</VALIDVALUE>
          <VALUEMEANING>Gel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A semisolid (1) dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion (2). A gel may contain suspended particles. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: A colloidal dispersion is a system in which particles of colloidal dimension (i.e., typically between 1 nm and 1 micrometer) are distributed uniformly throughout a liquid. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OINTMENT</VALIDVALUE>
          <VALUEMEANING>Ointment Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A suspension or emulsion, semisolid (1) dosage form, usually containing &lt; 20% water and volatiles (2) and &gt; 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: Percent water and volatiles are measured by a loss on drying test in which the sample is heated at 105 degrees C until constant weight is achieved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42966</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PATCH</VALIDVALUE>
          <VALUEMEANING>Patch Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body. Its ingredients either passively diffuse from, or are actively transported from, some portion of the patch. Depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body. A patch is sometimes synonymous with the terms Extended Release Film and System.  </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER</VALIDVALUE>
          <VALUEMEANING>Powder Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SPRAY</VALIDVALUE>
          <VALUEMEANING>Spray Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid minutely divided as by a jet of air or steam.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42989</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUPPOSITORY</VALIDVALUE>
          <VALUEMEANING>Suppository Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid body of various weights and shapes, adapted for introduction into the rectal, vaginal, or urethral orifice of the human body; they usually melt, soften, or dissolve at body temperature.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42994</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET</VALIDVALUE>
          <VALUEMEANING>Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances with or without suitable diluents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WAFER</VALIDVALUE>
          <VALUEMEANING>Wafer Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A thin slice of material containing a medicinal agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNASSIGNED</VALIDVALUE>
          <VALUEMEANING>Unassigned Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosage form has yet to be assigned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, COATED, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Coated Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or &quot;shell&quot; made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, COATED PELLETS</VALIDVALUE>
          <VALUEMEANING>Coated Pellets in Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or &quot;shell&quot; made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEROSOL, SPRAY</VALIDVALUE>
          <VALUEMEANING>Aerosol Spray Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray; it is applicable to solutions of medicinal agents in aqueous solvents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEROSOL, POWDER</VALIDVALUE>
          <VALUEMEANING>Powder Aerosol Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEROSOL, METERED</VALIDVALUE>
          <VALUEMEANING>Metered Aerosol Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AEROSOL, FOAM</VALIDVALUE>
          <VALUEMEANING>Aerosol Foam Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An emulsion containing one or more active ingredients, surfactants, aqueous or non-aqueous liquids, and the propellants; if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GUM, RESIN</VALIDVALUE>
          <VALUEMEANING>Resin Gum Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural mixture of gum and resin, usually obtained as exudations from plants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GUM, CHEWING</VALIDVALUE>
          <VALUEMEANING>Chewing Gum Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A sweetened and flavored insoluble plastic material of various shapes which when chewed, releases a drug substance into the oral cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GUM</VALIDVALUE>
          <VALUEMEANING>Gum Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A mucilaginous excretion from various plants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42941</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, FOR SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Granule For Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the extended release system achieves slow release of the drug over an extended period of time and maintains constant drug levels in the blood or target tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Granule For Suspension Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Granule For Solution Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient. (Dorland&#39;s Illustrated Medical Dictionary, 24th Ed.; INTRODUCTION TO PHARMACEUTICAL DOSAGE FORMS, 4th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42939</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, EFFERVESCENT</VALIDVALUE>
          <VALUEMEANING>Effervescent Granule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small particle or grain containing a medicinal agent in a dry mixture usually composed of sodium bicarbonate, citric acid, and tartaric acid which, when in contact with water, has the capability to release gas, resulting in effervescence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, DELAYED RELEASE</VALIDVALUE>
          <VALUEMEANING>Delayed Release Granule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small medicinal particle or grain to which an enteric or other coating has been applied, thus delaying release of the drug until its passage into the intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE</VALIDVALUE>
          <VALUEMEANING>Granule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small particle or grain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRAFT</VALIDVALUE>
          <VALUEMEANING>Graft Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A slip of skin or of other tissue for implantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GLOBULE</VALIDVALUE>
          <VALUEMEANING>Globule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Also called pellets or pilules, are made of pure sucrose, lactose, or other polysaccharides. They are formed into small globular masses of various sizes, and are medicated by placing them in a vial and adding the liquid drug attenuation in the proportion not less than one percent (v/w). After shaking, the medicated globules are dried at temperatures not to exceed 40 degrees Centigrade.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GENERATOR</VALIDVALUE>
          <VALUEMEANING>Generator Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An apparatus for the formation of vapor or gas from a liquid or solid by heat or chemical action. The term GENERATOR also applies to radioactive columns from which radionuclides are provided.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GEL, METERED</VALIDVALUE>
          <VALUEMEANING>Metered Gel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A gel preparation, with metered dose valves, which allow for the delivery of a uniform quantity of gel upon each activation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GEL, DENTIFRICE</VALIDVALUE>
          <VALUEMEANING>Dentifrice Gel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A combination of a dentifrice (formulation intended to clean and/or polish the teeth, and which may contain certain additional agents), and a gel (a semisolid system which consists of suspensions made up of either small inorganic particles or large organic molecules interpenetrated by a liquid) and which is used with a toothbrush for the purpose of cleaning and polishing the teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GEL, CHEWABLE</VALIDVALUE>
          <VALUEMEANING>Chewable Gel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A formed or molded oral gel dosage form that maintains its shape, is elastic, and yields to mastication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C134876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6619154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FOR SUSPENSION, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Dosage Form For Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A product, usually a solid, intended for suspension prior to administration; once the suspension is administered, the drug will be released at a constant rate over a specified period.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FOR SUSPENSION</VALIDVALUE>
          <VALUEMEANING>Dosage Form For Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>A product, usually a solid, intended for suspension prior to administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FOR SOLUTION</VALIDVALUE>
          <VALUEMEANING>Dosage Form For Solution</VALUEMEANING>
          <MEANINGDESCRIPTION>A product, usually a solid, intended for solution prior to administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60927</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FILM, SOLUBLE</VALIDVALUE>
          <VALUEMEANING>Soluble Film Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A thin layer or coating which is susceptible to being dissolved when in contact with a liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FILM, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Film Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug delivery system in the form of a film that releases the drug over an extended period in such a way as to maintain constant drug levels in the blood or target tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42920</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FILM</VALIDVALUE>
          <VALUEMEANING>Film Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A thin layer or coating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42932</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FIBER, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Fiber Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A slender and elongated solid thread-like substance that delivers drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60926</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, COATED</VALIDVALUE>
          <VALUEMEANING>Coated Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or &quot;shell&quot; made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42895</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPLET</VALIDVALUE>
          <VALUEMEANING>Caplet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which a tablet has been compacted into capsule shape.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97197</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6619147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BLOCK</VALIDVALUE>
          <VALUEMEANING>Block Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Solid dosage form, usually in the shape of a square or rectangle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BEAD, IMPLANT, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Bead Implant Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A small sterile solid mass consisting of a highly purified drug intended for implantation in the body which would allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43451</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BEAD</VALIDVALUE>
          <VALUEMEANING>Bead Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in the shape of a small ball.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BAR, CHEWABLE</VALIDVALUE>
          <VALUEMEANING>Chewable Bar Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form usually in the form of a rectangle that is meant to be chewed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EXTRACT</VALIDVALUE>
          <VALUEMEANING>Extract Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentrated preparation of vegetable or animal drugs obtained by removal of the active constituents of the respective drugs with a suitable menstrua, evaporation of all or nearly all of the solvent, and adjustment of the residual masses or powders to the prescribed standards.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42929</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ENEMA</VALIDVALUE>
          <VALUEMEANING>Enema Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A rectal preparation for therapeutic, diagnostic, or nutritive purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EMULSION</VALIDVALUE>
          <VALUEMEANING>Emulsion Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosage form consisting of a two-phase system comprised of at least two immiscible liquids (1), one of which is dispersed as droplets (internal or dispersed phase) within the other liquid (external or continuous phase), generally stabilized with one or more emulsifying agents. Note 1: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. Note 2: Emulsion is used as a dosage form term unless a more specific term is applicable, e.g. cream, lotion, ointment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ELIXIR</VALIDVALUE>
          <VALUEMEANING>Elixir Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRUG DELIVERY SYSTEM</VALIDVALUE>
          <VALUEMEANING>Drug Delivery System</VALUEMEANING>
          <MEANINGDESCRIPTION>Modern technology, distributed with or as a part of a drug product that allows for the uniform release or targeting of drugs to the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRESSING</VALIDVALUE>
          <VALUEMEANING>Dressing Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>The application of various materials for protecting a wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DOUCHE</VALIDVALUE>
          <VALUEMEANING>Douche Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation, intended for the irrigative cleansing of the vagina, that is prepared from powders, liquid solutions, or liquid concentrates and contains one or more chemical substances dissolved in a suitable solvent or mutually miscible solvents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DISC</VALIDVALUE>
          <VALUEMEANING>Disc Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A circular plate-like organ or structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DIAPHRAGM</VALIDVALUE>
          <VALUEMEANING>Diaphragm Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A device usually dome-shaped, worn during copulation over the cervical mouth for prevention of conception or infection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47890</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CULTURE</VALIDVALUE>
          <VALUEMEANING>Culture Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>The propagation of microorganisms or of living tissue cells in special media conducive to their growth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CRYSTAL</VALIDVALUE>
          <VALUEMEANING>Crystal Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A naturally produced angular solid of definite form in which the ultimate units from which it is built up are systematically arranged; they are usually evenly spaced on a regular space lattice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CREAM, AUGMENTED</VALIDVALUE>
          <VALUEMEANING>Augmented Cream Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A cream dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CORE, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Core Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>An ocular system placed in the eye from which the drug diffuses through a membrane at a constant rate over a specified period.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CONE</VALIDVALUE>
          <VALUEMEANING>Cone Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form bounded by a circular base and the surface formed by line segments joining every point of the boundary of the base to a common vertex. A cone (usually containing antibiotics) is normally placed below the gingiva after a dental extraction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CONCENTRATE</VALIDVALUE>
          <VALUEMEANING>Concentrate Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid preparation of increased strength and reduced volume which is usually diluted prior to administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CLOTH</VALIDVALUE>
          <VALUEMEANING>Cloth Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A large piece of relatively flat, absorbent material that contains a drug. It is typically used for applying medication or for cleansing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CIGARETTE</VALIDVALUE>
          <VALUEMEANING>Cigarette Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A narrow tube of cut tobacco (or other similar material) enclosed in paper and designed for smoking.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42678</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEMENT</VALIDVALUE>
          <VALUEMEANING>Cement Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance that serves to produce solid union between two surfaces.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, LIQUID FILLED</VALIDVALUE>
          <VALUEMEANING>Liquid Filled Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within a soluble, gelatin shell which is plasticized by the addition of a polyol, such as sorbitol or glycerin, and is therefore of a somewhat thicker consistency than that of a hard shell capsule; typically, the active ingredients are dissolved or suspended in a liquid vehicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, IMMEDIATE RELEASE</VALIDVALUE>
          <VALUEMEANING>Immediate Release Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C142247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6619152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, GELATIN COATED</VALIDVALUE>
          <VALUEMEANING>Gelatin Coated Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin; through a banding process, the capsule is coated with additional layers of gelatin so as to form a complete seal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, FILM COATED, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Film Coated Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or &quot;shell&quot; made from a suitable form of gelatin; additionally, the capsule is covered in a designated film coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, DELAYED RELEASE PELLETS</VALIDVALUE>
          <VALUEMEANING>Delayed Release Pellets in Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or &quot;shell&quot; made from a suitable form of gelatin; the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, DELAYED RELEASE</VALIDVALUE>
          <VALUEMEANING>Delayed Release Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, SOFTGEL, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Capsule, Softgel Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule, covered with a soft gelatin shell and containing a liquid, suspension, or semisolid, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6774523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, HARD, EXTENDED RELEASE</VALIDVALUE>
          <VALUEMEANING>Extended Release Capsule, Hard Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule, covered with a rigid outer shell, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6774525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, IMMEDIATE RELEASE, SOLID DISPERSION</VALIDVALUE>
          <VALUEMEANING>Solid Dispersion Immediate Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing one or more active pharmaceutical ingredient which can be dispersed in a carrier at solid state, and immediately released upon administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6857102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, MODIFIED RELEASE, SHORT DURATION</VALIDVALUE>
          <VALUEMEANING>Short Modified Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s) that is classified as short.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7240276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, MODIFIED RELEASE, LONG DURATION</VALIDVALUE>
          <VALUEMEANING>Long Modified Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s) that is classified as long.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7240278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, MODIFIED RELEASE</VALIDVALUE>
          <VALUEMEANING>Modified Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7240280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SOLID</VALIDVALUE>
          <VALUEMEANING>Solid Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A substance having definite shape and volume manufactured for the administration of active and/or inert ingredient(s). Solids include tablets, capsules, powders, granules and certain suppositories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7236122</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VAGINAL RING</VALIDVALUE>
          <VALUEMEANING>Vaginal Ring Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A ring composed of active and/or inert ingredient(s), intended for administration in or around the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5205254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INHALATION VAPOR, CAPSULE</VALIDVALUE>
          <VALUEMEANING>Inhalation Vapor, Capsule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Solid preparation consisting of a capsule formulation intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the whole capsule or the capsule contents to hot water.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C149582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8070667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAPSULE, SOFTGEL</VALIDVALUE>
          <VALUEMEANING>Capsule Softgel Pharmaceutical Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A capsule, covered with a soft gelatin shell and containing a liquid, suspension, or semisolid, that is designed to release active and/or inert ingredient(s)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEPOT</VALIDVALUE>
          <VALUEMEANING>Extended Release Depot Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>Parenteral sustained-release systems of microparticles, implants, or biodegradable polymer-excipients designed to release their active pharmaceutical ingredient over a prolonged period of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6974996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GRANULE, COATED</VALIDVALUE>
          <VALUEMEANING>Coated Granule Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A granule whose outer shell is covered with a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C148551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13361709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>POWDER, LYOPHILIZED</VALIDVALUE>
          <VALUEMEANING>Lyophilized Powder Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A pharmaceutical dosage form comprised of lyophilized powder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13361710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NOT APPLICABLE</VALIDVALUE>
          <VALUEMEANING>Dosage Form Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that the dosage form is not relevant or appropriate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48624</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13361711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNKNOWN</VALIDVALUE>
          <VALUEMEANING>Unknown Dosage Form Category</VALUEMEANING>
          <MEANINGDESCRIPTION>The type of pharmaceutical dose form is unknown, or has unspecified or variable physical characteristics.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C150001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13361712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, CRUSHED</VALIDVALUE>
          <VALUEMEANING>Crushed Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form containing medicinal substances with or without suitable diluents that is crushed prior to administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202340</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14685870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FILM COATED, IMMEDIATE RELEASE, CRUSHED</VALIDVALUE>
          <VALUEMEANING>Film Coated Immediate Release Crushed Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer that is crushed prior to administration. The tablet is designed to release its active and/or inert ingredient(s) immediately upon administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14685871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TABLET, FILM COATED, IMMEDIATE RELEASE</VALIDVALUE>
          <VALUEMEANING>Film Coated Immediate Release Tablet Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is designed to release its active and/or inert ingredient(s) immediately upon administration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14685872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose form</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the dose form of the study treatment?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the dose form of the study treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the dose form of the [study treatment/dose]?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the dose form of the [study treatment/dose]?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="969">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14056141</PUBLICID>
    <LONGNAME>Punch Biopsy RNA Sequencing Bio-specimen Collection Indicator</LONGNAME>
    <PREFERREDNAME>PNCHBIO_RNA_SEQ_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether punch biopsy bio-specimen for RNA sequencing was collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14056140</PublicId>
      <PreferredName>5078761v1.00:14056139v1.00</PreferredName>
      <PreferredDefinition>Removal of a disk of skin tissue, for microscopic examination, using a punch.:An indicator that the RNA sequence test was performed._The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.</PreferredDefinition>
      <LongName>Punch Biopsy RNA Sequencing Performed Biospecimen Collection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5078761</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28743</PreferredName>
        <Version>1</Version>
        <LongName>Punch Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28743</PREFERRED_NAME>
            <LONG_NAME>Punch Biopsy</LONG_NAME>
            <CON_ID>2202918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14056139</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C182236:C70945</PreferredName>
        <Version>1</Version>
        <LongName>RNA Sequencing Performed Biospecimen Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C182236</PREFERRED_NAME>
            <LONG_NAME>RNA Sequencing Performed</LONG_NAME>
            <CON_ID>10052419</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70945</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Collection</LONG_NAME>
            <CON_ID>2714902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6343337</PublicId>
      <PreferredName>NY</PreferredName>
      <PreferredDefinition>Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6343336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66742:C25180</PreferredName>
        <Version>1</Version>
        <LongName>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66742</PREFERRED_NAME>
            <LONG_NAME>CDISC SDTM Yes No Unknown or Not Applicable Response Terminology</LONG_NAME>
            <CON_ID>4852475</CON_ID>
            <DEFINITION_SOURCE>CDISC</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5676138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was punch biopsy bio-specimen for RNA sequencing collected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was one punch biopsy collected for RNA sequencing on Day 21 of Cycle 1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was one punch biopsy collected for RNA sequencing within 28 days before starting study drug?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRETRT_RNASEQ_COLYN</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>D21C1_RNASEQ_COLYN</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="970">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14194463</PUBLICID>
    <LONGNAME>Six-Item Cognitive Impairment Test Score Greater Than 3 Indicator</LONGNAME>
    <PREFERREDNAME>6CIT_GRTR_3SCRE_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether the Six-Item Cognitive Impairment Test (6CIT) score is greater than 3.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NRG CRF:NRG Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14194434</PublicId>
      <PreferredName>14194432v1.00:14194433v1.00</PreferredName>
      <PreferredDefinition>: A brief cognitive function test. It contains a logical memory item, two attention items, and three orientation questions. It takes less than five minutes to administer and is widely used in primary care settings.:A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Six-Item Cognitive Impairment Test Greater Than Three Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14194432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C200567</PreferredName>
        <Version>1</Version>
        <LongName>Six-Item Cognitive Impairment Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C200567</PREFERRED_NAME>
            <LONG_NAME>Six-Item Cognitive Impairment Test</LONG_NAME>
            <CON_ID>14193209</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14194433</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61584:C66834:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Greater Than Three Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61584</PREFERRED_NAME>
            <LONG_NAME>Greater Than</LONG_NAME>
            <CON_ID>2620098</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66834</PREFERRED_NAME>
            <LONG_NAME>Three</LONG_NAME>
            <CON_ID>2635616</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the 6-Item Cognitive Impairment Test score greater than 3?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the participant have a score greater than 3 (4-6) on the 6-item cognitive screen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="971">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14429731</PUBLICID>
    <LONGNAME>Pulmonary or Extrapulmonary Mycobacterium tuberculosis Any Anatomic Site Present Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PLMY_EXTPLMY_MYC_TB_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No Indicator of whether pulmonary or extrapulmonary mycobacterium tuberculosis at any anatomic site is present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>AMC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14429618</PublicId>
      <PreferredName>14435923v1.00:14435924v1.00</PreferredName>
      <PreferredDefinition>Relating to the lungs as the intended site of administration, where the pharmaceutical product is administered, usually by inhalation, for local action in the lower respiratory tract or for systemic action after absorption via the lower respiratory tract._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Outside of or excluding the lungs._An obligate anaerobic, weakly Gram-positive species of mycobacterium that is the cause of most cases of tuberculosis.:One, some, every, or all without specification._Named locations of or within the body._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Pulmonary Or Extrapulmonary Mycobacterium tuberculosis Any Anatomic Site Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>AMC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14435923</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13304:C37998:C190829:C76370</PreferredName>
        <Version>1</Version>
        <LongName>Pulmonary Or Extrapulmonary Mycobacterium tuberculosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13304</PREFERRED_NAME>
            <LONG_NAME>Pulmonary</LONG_NAME>
            <CON_ID>2204862</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C190829</PREFERRED_NAME>
            <LONG_NAME>Extrapulmonary</LONG_NAME>
            <CON_ID>12062673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C76370</PREFERRED_NAME>
            <LONG_NAME>Mycobacterium tuberculosis</LONG_NAME>
            <CON_ID>2793571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14435924</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81168:C13717:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Any Anatomic Site Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81168</PREFERRED_NAME>
            <LONG_NAME>Any</LONG_NAME>
            <CON_ID>2981953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HXMYCOTB_MHOCCUR</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="972">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14599782</PUBLICID>
    <LONGNAME>Pediatric EAT-10 1 Child&#39;s Swallowing Problem Prevents Weight Gain Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PED_EAT10_1_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Parent&#39;s stated response about the problem severity of their child&#39;s swallowing problem preventing weight gain, using a 5-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14599713</PublicId>
      <PreferredName>14599711v1.00:14599712v1.00</PreferredName>
      <PreferredDefinition>A pediatric version of the Eating Assessment Tool-10, designed to allow a parent to report their child&#39;s swallowing difficulties.:A question about whether an individual&#39;s child does not gain weight due to swallowing problems._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Pediatric Eating Assessment Tool-10 Child&#39;s Swallowing Problem Prevents Weight Gain Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14599711</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C202103</PreferredName>
        <Version>1</Version>
        <LongName>Pediatric Eating Assessment Tool-10</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C202103</PREFERRED_NAME>
            <LONG_NAME>Pediatric Eating Assessment Tool-10</LONG_NAME>
            <CON_ID>14599667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14599712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C202104:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Child&#39;s Swallowing Problem Prevents Weight Gain Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C202104</PREFERRED_NAME>
            <LONG_NAME>Child&#39;s Swallowing Problem Prevents Weight Gain Question</LONG_NAME>
            <CON_ID>14599668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14599774</PublicId>
      <PreferredName>14599774v1.00</PreferredName>
      <PreferredDefinition>A ten question measure designed to assess swallowing difficulties._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Problem Severity Scale Eating Assessment Tool-10</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>14672710</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14672710v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Eating Assessment Tool-10 Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C202084</PREFERRED_NAME>
            <LONG_NAME>Eating Assessment Tool-10</LONG_NAME>
            <CON_ID>14599720</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 0 on a problem severity scale that ranges from 0: No problem to 4: Severe problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202096</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Mild Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 1 on a problem severity scale that ranges from 0: No problem to 4: Severe problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mild to Moderate Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 2 on a problem severity scale that ranges from 0: No problem to 4: Severe problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202098</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 3 on a problem severity scale that ranges from 0: No problem to 4: Severe problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202099</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Severe Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 4 on a problem severity scale that ranges from 0: No problem to 4: Severe problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>My child does not gain weight due to his/her swallowing problem.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pediatric Eating Assessment Tool (PEDI-EAT-10)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 1 of 10</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_WGHTMTN</AlternateName>
        <AlternateNameType>OID, COG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="973">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14600068</PUBLICID>
    <LONGNAME>Sequencing Library cDNA Length Text</LONGNAME>
    <PREFERREDNAME>14600067v1.00:2584117v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The length of the cDNA.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>Pediatric Cancer</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCDI:Childhood Cancer Data Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14600067</PublicId>
      <PreferredName>6273321v1.00:2223251v1.00</PreferredName>
      <PreferredDefinition>A collection of double stranded DNA fragments flanked by oligonucleotide sequence adapters to enable their analysis by high-throughput sequencing.:Single-stranded DNA that is complementary to messenger RNA or DNA that has been synthesized from messenger RNA by reverse transcriptase._The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.</PreferredDefinition>
      <LongName>Sequencing Library cDNA Length</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>Pediatric Cancer</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>6273321</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C148073</PreferredName>
        <Version>1</Version>
        <LongName>Sequencing Library</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C148073</PREFERRED_NAME>
            <LONG_NAME>Sequencing Library</LONG_NAME>
            <CON_ID>6144585</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223251</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C324:C25334</PreferredName>
        <Version>1</Version>
        <LongName>CDNA Length</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C324</PREFERRED_NAME>
            <LONG_NAME>cDNA</LONG_NAME>
            <CON_ID>2223187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25334</PREFERRED_NAME>
            <LONG_NAME>Length</LONG_NAME>
            <CON_ID>2203838</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCDI:Childhood Cancer Data Initiative</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2584117</PublicId>
      <PreferredName>2584117v1.0</PreferredName>
      <PreferredDefinition>LO: A 64-character string with leading or trailing spaces being non-significant; NO CONTROL characters. [Standard-based]</PreferredDefinition>
      <LongName>64 Character Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>64</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2637360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45253:C25704</PreferredName>
        <Version>1</Version>
        <LongName>String Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45253</PREFERRED_NAME>
            <LONG_NAME>String</LONG_NAME>
            <CON_ID>2539471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>cDNA Length</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13574489</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCDI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sequencing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>13594094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>13574489</PublicId>
          <ContextName>Pediatric Cancer</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCDI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Single Cell Sequencing File</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>13594225</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Pediatric Cancer</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cDNA_Length</AlternateName>
        <AlternateNameType>CCDI Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="974">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14643208</PUBLICID>
    <LONGNAME>Flow Cytometry Performed Bone Marrow Test Outcome</LONGNAME>
    <PREFERREDNAME>BM_FLOW_TEST_RSLT</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the bone marrow flow cytometry test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4119952</PublicId>
      <PreferredName>3910289v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Flow Cytometry Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3910289</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16585</PreferredName>
        <Version>1</Version>
        <LongName>Flow Cytometry</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16585</PREFERRED_NAME>
            <LONG_NAME>Flow Cytometry</LONG_NAME>
            <CON_ID>2202602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14640674</PublicId>
      <PreferredName>14640674v1.00</PreferredName>
      <PreferredDefinition>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._A procedure for critical evaluation; a means of determining the presence, quality, or truth of something._The result of an action.</PreferredDefinition>
      <LongName>Bone Marrow Test Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>14643206</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14643206v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Test Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47891</PREFERRED_NAME>
            <LONG_NAME>Test</LONG_NAME>
            <CON_ID>2427511</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4494160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal, specify</VALIDVALUE>
          <VALUEMEANING>Abnormal Specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.: Be specific about something; define clearly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3696619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4163021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the result of the bone marrow flow cytometry test?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Flow Cytometry Results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BMCM08</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="975">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14651973</PUBLICID>
    <LONGNAME>Healthcare Encounter Secondary Healthcare Payer Identifier Data Source Data Value Identifier</LONGNAME>
    <PREFERREDNAME>14635926v1.00:14961549v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Interactions between patients and providers within the context of healthcare delivery.:A health plan or payer not responsible for being the primary payer on a claim for medical services._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14635926</PublicId>
      <PreferredName>14596371v1.00:14660676v1.00</PreferredName>
      <PreferredDefinition>Interactions between patients and providers within the context of healthcare delivery.:A health plan or payer not responsible for being the primary payer on a claim for medical services._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.</PreferredDefinition>
      <LongName>Healthcare Encounter Secondary Healthcare Payer Identifier Data Source Data Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14596371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C154624</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C154624</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounter</LONG_NAME>
            <CON_ID>6424582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14660676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70690:C25364:C16493:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Secondary Healthcare Payer Identifier Data Source Data Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70690</PREFERRED_NAME>
            <LONG_NAME>Secondary Healthcare Payer</LONG_NAME>
            <CON_ID>10115013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16493</PREFERRED_NAME>
            <LONG_NAME>Data Source</LONG_NAME>
            <CON_ID>2223421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14961549</PublicId>
      <PreferredName>14961549v1.00</PreferredName>
      <PreferredDefinition>One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>SAS Char</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Raw Payer Identifier Secondary</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Encounter</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RAW_PAYER_ID_SECONDARY</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENCOUNTER</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="976">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14665534</PUBLICID>
    <LONGNAME>Person Ethnic Group Data Source Data Value Category</LONGNAME>
    <PREFERREDNAME>14522607v1.00:14665455v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A human being.:A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, &quot;Spanish origin&quot; can be used in addition to &quot;Hispanic or Latino&quot;. (OMB)_The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.:A grouping of items based on some commonality or by user defined characteristics.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14522607</PublicId>
      <PreferredName>2236731v1.00:14522606v1.00</PreferredName>
      <PreferredDefinition>A human being.:A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.</PreferredDefinition>
      <LongName>Person Ethnic Group Data Source Data Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14522606</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16564:C16493:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Ethnic Group Data Source Data Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16564</PREFERRED_NAME>
            <LONG_NAME>Ethnic Group</LONG_NAME>
            <CON_ID>2221860</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16493</PREFERRED_NAME>
            <LONG_NAME>Data Source</LONG_NAME>
            <CON_ID>2223421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14665455</PublicId>
      <PreferredName>14665455v1.00</PreferredName>
      <PreferredDefinition>A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>varchar</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ethnicity Source Value</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>userGuidance</Name>
        <OrganizationName/>
        <DocumentType>OMOP CDM User Guidance</DocumentType>
        <DocumentText>This field is used to store the ethnicity of the person from the source data. It is not intended for use in standard analytics but for reference only.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>etlConventions</Name>
        <OrganizationName/>
        <DocumentType>OMOP CDM ETL Conventions</DocumentType>
        <DocumentText>If the person has an ethnicity other than the OMB standard of &quot;Hispanic&quot; or &quot;Not Hispanic&quot; store that value from the source data here.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522466</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.4</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Person</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522469</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ethnicity_source_value</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PERSON</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="977">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14667268</PUBLICID>
    <LONGNAME>Address Use Start Date</LONGNAME>
    <PREFERREDNAME>14667123v1.00:14597071v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A standardized representation of the location of a person, business, building, or organization.:To put into action or service._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._The particular day, month and year an event has happened or will happen.:The particular day, month and year an event has happened or will happen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14667123</PublicId>
      <PreferredName>2341906v1.00:15030548v1.00</PreferredName>
      <PreferredDefinition>A standardized representation of the location of a person, business, building, or organization.:To put into action or service._The calendar date on which something is to start or did start.</PreferredDefinition>
      <LongName>Address Use Start Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2341906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25407</PreferredName>
        <Version>1</Version>
        <LongName>Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15030548</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95018:C68616</PreferredName>
        <Version>1</Version>
        <LongName>Use Start Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95018</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>3248409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68616</PREFERRED_NAME>
            <LONG_NAME>Start Date</LONG_NAME>
            <CON_ID>2712678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14597071</PublicId>
      <PreferredName>14597071v1.00</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>SAS Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Address Period Start</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LDS Address History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522576</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ADDRESS_PERIOD_START</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LDS_ADDRESS_HISTORY</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="978">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14675106</PUBLICID>
    <LONGNAME>External Estimated Exposure Dose Assessment Method Marrow Space Performed Type</LONGNAME>
    <PREFERREDNAME>14675105v1.00:4723942v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the assessment method used to estimate external dose exposure for marrow spaces.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14675105</PublicId>
      <PreferredName>14675103v1.00:14675104v1.00</PreferredName>
      <PreferredDefinition>Happening or arising or located outside or beyond some limits, or especially, some surface._To calculate approximately._The amount of exposure that a subject actually receives._The final result of a determination of the value, significance, or extent of._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:The hollow space in long bones that contains bone marrow._Executed and carried through to completion.</PreferredDefinition>
      <LongName>External Estimate Exposure Dose Assessment Method Marrow Space Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14675103</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14675103v1.00</PreferredName>
        <Version>1</Version>
        <LongName>External Estimate Exposure Dose Assessment Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44280</PREFERRED_NAME>
            <LONG_NAME>External</LONG_NAME>
            <CON_ID>2422632</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25498</PREFERRED_NAME>
            <LONG_NAME>Estimate</LONG_NAME>
            <CON_ID>2203929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83039</PREFERRED_NAME>
            <LONG_NAME>Exposure Dose</LONG_NAME>
            <CON_ID>4723754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14675104</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C203530:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Marrow Space Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C203530</PREFERRED_NAME>
            <LONG_NAME>Marrow Space</LONG_NAME>
            <CON_ID>14675083</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4723942</PublicId>
      <PreferredName>4723942v1.0</PreferredName>
      <PreferredDefinition>The amount of exposure that a subject actually receives._The final result of a determination of the value, significance, or extent of._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Exposure Dose Assessment Method Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>4723941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83039:C25217:C71460:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Exposure Dose Assessment Method Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83039</PREFERRED_NAME>
            <LONG_NAME>Exposure Dose</LONG_NAME>
            <CON_ID>4723754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other method</VALIDVALUE>
          <VALUEMEANING>Other Method</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71460, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chromosome analysis</VALIDVALUE>
          <VALUEMEANING>Cytogenetic Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2861225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prodromal symptoms</VALIDVALUE>
          <VALUEMEANING>Early Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>At or near the beginning of a period of time or course of events.: Subjective evidence of disease perceived by the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C61589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Time to onset of vomiting</VALIDVALUE>
          <VALUEMEANING>Time Onset Vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>the continuum of experience in which events pass from the future through the present to the past.: The start, beginning, or early stages.: Forceful ejection of the contents of the stomach through the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3442, C25279, C25207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocyte depletion kinetics</VALIDVALUE>
          <VALUEMEANING>Lymphocyte Depletion Kinetics</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for estimating the dose of an external radiation exposure following whole- or partial- body exposure. Serial CBCs are obtained and the absolute lymphocyte count is calculated and tracked over time. The dose absorbed is correlated with the rate of decline of peripheral blood lymphocytes and the lowest value for absolute lymphocyte depletion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4747334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What assessment method was used to estimate the external dose exposure for marrow spaces?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify method used to estimate external dose given for marrow spaces</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="979">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14706571</PUBLICID>
    <LONGNAME>Laboratory Procedure Result Data Source Data Value Result</LONGNAME>
    <PREFERREDNAME>14706364v1.00:14966726v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:The outcome of a laboratory test._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.:The result of an action.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14706364</PublicId>
      <PreferredName>2543047v1.00:14900712v1.00</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:The outcome of a laboratory test._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.</PreferredDefinition>
      <LongName>Laboratory Procedure Result Data Source Data Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14900712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C16493:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Data Source Data Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16493</PREFERRED_NAME>
            <LONG_NAME>Data Source</LONG_NAME>
            <CON_ID>2223421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14966726</PublicId>
      <PreferredName>14966726v1.00</PreferredName>
      <PreferredDefinition>The result of an action.</PreferredDefinition>
      <LongName>Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>SAS Char</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2476191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Raw Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lab Result CM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522565</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RAW_RESULT</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Lab Result CM</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="980">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14722989</PUBLICID>
    <LONGNAME>Healthcare Encounter Details Person Record Link Identifier</LONGNAME>
    <PREFERREDNAME>14722986v1.00:14527189v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Interactions between patients and providers within the context of healthcare delivery.:Particulars considered individually and in relation to a whole._A human being._A sequence of characters used as a linkage between related records.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14722986</PublicId>
      <PreferredName>14596371v1.00:14961176v1.00</PreferredName>
      <PreferredDefinition>Interactions between patients and providers within the context of healthcare delivery.:Particulars considered individually and in relation to a whole._A human being._A sequence of characters used as a linkage between related records.</PreferredDefinition>
      <LongName>Healthcare Encounter Details Person Record Link Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14596371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C154624</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C154624</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounter</LONG_NAME>
            <CON_ID>6424582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14961176</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25480:C25190:C117050</PreferredName>
        <Version>1</Version>
        <LongName>Details Person Record Link Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25480</PREFERRED_NAME>
            <LONG_NAME>Details</LONG_NAME>
            <CON_ID>2203578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117050</PREFERRED_NAME>
            <LONG_NAME>Record Link Identifier</LONG_NAME>
            <CON_ID>10012201</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14527189</PublicId>
      <PreferredName>14527189v1.00</PreferredName>
      <PreferredDefinition>One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Person Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522466</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.4</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Visit Detail</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522471</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>person_id</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VISIT_DETAIL</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="981">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14758486</PUBLICID>
    <LONGNAME>Intervention or Procedure Start Date</LONGNAME>
    <PREFERREDNAME>14758343v1.00:14597071v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The calendar date on which something is to start or did start.:The particular day, month and year an event has happened or will happen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14758343</PublicId>
      <PreferredName>2233215v1.00:2712679v1.00</PreferredName>
      <PreferredDefinition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:The calendar date on which something is to start or did start.</PreferredDefinition>
      <LongName>Intervention or Procedure Start Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218</PreferredName>
        <Version>1</Version>
        <LongName>Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2712679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68616</PreferredName>
        <Version>1</Version>
        <LongName>Start Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68616</PREFERRED_NAME>
            <LONG_NAME>Start Date</LONG_NAME>
            <CON_ID>2712678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14597071</PublicId>
      <PreferredName>14597071v1.00</PreferredName>
      <PreferredDefinition>The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>SAS Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Procedure Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Procedures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522560</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PX_DATE</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PROCEDURES</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="982">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14764832</PUBLICID>
    <LONGNAME>Health Status Assessment Unit of Measure OMOP Concept Identifier</LONGNAME>
    <PREFERREDNAME>14764187v1.00:14670377v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:The result of an action._A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._An identifier assigned to an external vocabulary item when it has been transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). It is an integer ID that is used to record data in the CDM event tables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14764187</PublicId>
      <PreferredName>14936166v1.00:2443551v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</PreferredDefinition>
      <LongName>Health Status Assessment Unit of Measure</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2443551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25709</PreferredName>
        <Version>1</Version>
        <LongName>Unit of Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14670377</PublicId>
      <PreferredName>14670377v1.00</PreferredName>
      <PreferredDefinition>A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._An identifier assigned to an external vocabulary item when it has been transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). It is an integer ID that is used to record data in the CDM event tables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Unit of Measure OMOP Concept Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Enumerated by Reference</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>15004633</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15004633v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Unit of Measure OMOP Concept Identifier Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205058</PREFERRED_NAME>
            <LONG_NAME>OMOP Concept Identifier</LONG_NAME>
            <CON_ID>14931547</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>https://athena.ohdsi.org/search-terms/terms?page=1&amp;pageSize=15&amp;query=</VALIDVALUE>
          <VALUEMEANING>Automated Terminology Harmonization, Extraction and Normalization for Analytics</VALUEMEANING>
          <MEANINGDESCRIPTION>A searchable database maintained by the Observational Health Data Sciences and Informatics (OHDSI) that is available to researchers to help identify codes and match them to their standard Observational Medical Outcomes Partnership (OMOP) equivalent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C201974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15329296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology>Automated Terminology Harmonization, Extraction and Normalization for Analytics|C201974</ReferenceTerminology>
      <ReferenceTerminologyDataValueSource>Code</ReferenceTerminologyDataValueSource>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Unit Concept Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>etlConventions</Name>
        <OrganizationName/>
        <DocumentType>OMOP CDM ETL Conventions</DocumentType>
        <DocumentText>There is no standardization requirement for units associated with OBSERVATION_CONCEPT_IDs, however, it is the responsibility of the ETL to choose the most plausible unit.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>userGuidance</Name>
        <OrganizationName/>
        <DocumentType>OMOP CDM User Guidance</DocumentType>
        <DocumentText>There is currently no recommended unit for individual observation concepts. UNIT_SOURCE_VALUES should be mapped to a Standard Concept in the Unit domain that best represents the unit as given in the source data.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522466</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.4</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Observation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522479</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>unit_concept_id</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OBSERVATION</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="983">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14764875</PUBLICID>
    <LONGNAME>Health Status Assessment Standard Result Unit Data Source Data Value PCORnet Common Data Model Code</LONGNAME>
    <PREFERREDNAME>14986672v1.00:14673387v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:The unit of measure for the standardized result of the measurement, test, or examination.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._A data model designed to standardize PCORnet data._A symbol or combination of symbols which is assigned to the members of a collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14986672</PublicId>
      <PreferredName>14936166v1.00:14986547v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:The unit of measure for the standardized result of the measurement, test, or examination.</PreferredDefinition>
      <LongName>Health Status Assessment Standard Result Unit Data Source Data Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14986547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82587</PreferredName>
        <Version>1</Version>
        <LongName>Standard Result Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82587</PREFERRED_NAME>
            <LONG_NAME>Standard Result Unit</LONG_NAME>
            <CON_ID>10098503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14673387</PublicId>
      <PreferredName>14673387v1.00</PreferredName>
      <PreferredDefinition>A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._A data model designed to standardize PCORnet data._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>Unit of Measure PCORnet Common Data Model Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <Datatype>SAS Char</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>14986640</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14986640v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Unit of Measure PCORnet Common Data Model Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C203939</PREFERRED_NAME>
            <LONG_NAME>PCORnet Common Data Model</LONG_NAME>
            <CON_ID>14741507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mol</VALIDVALUE>
          <VALUEMEANING>Nanomole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in nanomoles, to the amount of a different substance in the mixture, in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/d</VALIDVALUE>
          <VALUEMEANING>Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>Cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm and little else; biconcave, anucleate discs, 7nm diameter in mammals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3960061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/L</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/m2</VALIDVALUE>
          <VALUEMEANING>Microgram per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/m3</VALIDVALUE>
          <VALUEMEANING>Nanogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance per unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one nanogram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Gram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the number of milligrams per gram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mg</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/min</VALIDVALUE>
          <VALUEMEANING>Microgram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one minute. Microgram per minute is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6400548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass concentration defined as the  concentration of one gram of a substance in unit volume of the mixture  equal to one cubic meter. The concept also refers to the metric unit of  mass density (volumic mass) defined as the density of substance which  mass equal to one gram occupies the volume one cubic meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/L</VALIDVALUE>
          <VALUEMEANING>Liter Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume concentration expressed as the number of liters of a dissolved substance per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mmol</VALIDVALUE>
          <VALUEMEANING>Milligram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in milligram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{abnormal}</VALIDVALUE>
          <VALUEMEANING>Percent of Abnormal Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{OD_unit}</VALIDVALUE>
          <VALUEMEANING>Unit of Optical Density</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication of the type of unit of measure being used to express an optical density of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min/m2</VALIDVALUE>
          <VALUEMEANING>Liter Per Minute Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug</VALIDVALUE>
          <VALUEMEANING>Microgram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5656837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mPa</VALIDVALUE>
          <VALUEMEANING>Millipascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to one thousandth of one pascal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{activity}</VALIDVALUE>
          <VALUEMEANING>Percent Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>The rate of measured activity divided by the rate of total activity of a given object.  It is expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{percentile}</VALIDVALUE>
          <VALUEMEANING>Percentile</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the 99 numbered points that divide an ordered set of scores into 100 parts each of which contains one-hundredth of the total.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ukat</VALIDVALUE>
          <VALUEMEANING>Microkatal</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement equal to one millionth of katal (10E-6 katal).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min</VALIDVALUE>
          <VALUEMEANING>Liter per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/g</VALIDVALUE>
          <VALUEMEANING>Milliunit per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in milliunit(s) per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{inhibition}</VALIDVALUE>
          <VALUEMEANING>Percent Inhibition</VALUEMEANING>
          <MEANINGDESCRIPTION>The rate of measured normal activity minus inhibited activity, divided by the rate of normal activity of a given object. It is expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117963</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/s</VALIDVALUE>
          <VALUEMEANING>Liter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{ratio}</VALIDVALUE>
          <VALUEMEANING>Ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>Quotient of quantities of the same kind for different components within the same system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uL</VALIDVALUE>
          <VALUEMEANING>Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4272050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/L</VALIDVALUE>
          <VALUEMEANING>Microunit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one milliliter of mixture contains one millionth of a unit of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{vol}</VALIDVALUE>
          <VALUEMEANING>Percent Volume per Volume</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of percentage concentration expressed as a fraction of a component by volume s in the entire volume of a resulting mixture. The unit denotes a number of milliliters of a solute per 100 milliliters of solution. The standard conditions for temperature and pressure apply.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{titer}</VALIDVALUE>
          <VALUEMEANING>Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>Concentration of a substance in a solution as determined by the quantitative reaction with added measured volume(s) of a solution of the precisely known concentration(s) of a standard reagent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5656836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>um/s</VALIDVALUE>
          <VALUEMEANING>Micrometer per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of both speed (scalar) and velocity (vector), defined as the distance of one micrometer travelled per unit time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154858</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mV/s</VALIDVALUE>
          <VALUEMEANING>Millivolt per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived rate unit equal to one millivolt per unit of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405771</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{WBCs}</VALIDVALUE>
          <VALUEMEANING>Percent in White Blood Count Differential</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for percentage measurement of fraction of any type of white blood cells in the total white blood cell count differential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>lm</VALIDVALUE>
          <VALUEMEANING>Lumen</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of luminous flux. It is the amount of light that falls on a unit area at unit distance from a source of one candela.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>um</VALIDVALUE>
          <VALUEMEANING>Micron</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of length in metric system equal to 10E-6 meter, or micrometer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*12/L</VALIDVALUE>
          <VALUEMEANING>Million per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number of entities or quantity in millions per unit of volume equal to one microliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2732864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mV</VALIDVALUE>
          <VALUEMEANING>Millivolt</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of an electric potential and electromotive force equal to one thousandth of a volt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m/s</VALIDVALUE>
          <VALUEMEANING>Meter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of both speed (scalar) and velocity (vector), defined as the distance of one meter travelled per unit time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/(24.h)</VALIDVALUE>
          <VALUEMEANING>Micromole per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance flow rate equivalent to the rate at which one millionth of a mole of substance crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3/L</VALIDVALUE>
          <VALUEMEANING>Thousand Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m/s2</VALIDVALUE>
          <VALUEMEANING>Meter per Second Squared</VALUEMEANING>
          <MEANINGDESCRIPTION>Meter per second squared is a SI unit of acceleration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/[HPF]</VALIDVALUE>
          <VALUEMEANING>Per High Powered Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to the instances of an entity per visual field of a microscope set to its maximum magnification power.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96619</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406761</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>Newton</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of force. The force which, when applied in a vacuum to a body having a mass of one kilogram, causes an acceleration of one meter per second squared. It is equal to 10E5 dynes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3/mL</VALIDVALUE>
          <VALUEMEANING>Thousand per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one milliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m[IU]/L</VALIDVALUE>
          <VALUEMEANING>Microinternational Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one millionth of international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/d</VALIDVALUE>
          <VALUEMEANING>Nanogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/[LPF]</VALIDVALUE>
          <VALUEMEANING>Per Low Powered Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to the instances of an entity per visual field of a microscope set to its minimum magnification power.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/dL</VALIDVALUE>
          <VALUEMEANING>Micromole per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of concentration (molarity unit) equal to one millionth of mole of a solute in one deciliter of the solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3/uL</VALIDVALUE>
          <VALUEMEANING>Billion per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number or quantity of objects in billions per unit of volume equal to one liter, or the equivalent in milliliters or microliters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m[IU]/mL</VALIDVALUE>
          <VALUEMEANING>International Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*3{RBCs}</VALIDVALUE>
          <VALUEMEANING>Per Thousand Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit of measurement for a portion of a particular type of cell (excluding red blood cell subtypes) per one thousand red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12920300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/dL</VALIDVALUE>
          <VALUEMEANING>Nanogram per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one nanogram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one nanogram occupies the volume of one deciliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/g</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3{copies}/mL</VALIDVALUE>
          <VALUEMEANING>Thousand Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of concentration expressed as the number of 10 to the third power copies in unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m</VALIDVALUE>
          <VALUEMEANING>Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of linear measure in the metric system, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). Meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41139</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/g</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*3</VALIDVALUE>
          <VALUEMEANING>Per Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one thousand entities used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/h</VALIDVALUE>
          <VALUEMEANING>Micromole per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromoles per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6648900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m2/s</VALIDVALUE>
          <VALUEMEANING>Meter Squared per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of diffusion coefficient in SI system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14549125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/h</VALIDVALUE>
          <VALUEMEANING>Nanogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6644843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*6</VALIDVALUE>
          <VALUEMEANING>Per Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one million entities used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8002853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/kg</VALIDVALUE>
          <VALUEMEANING>Nanomole per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m2</VALIDVALUE>
          <VALUEMEANING>Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>Square meter is the SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 ares; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3</VALIDVALUE>
          <VALUEMEANING>Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/kg/min</VALIDVALUE>
          <VALUEMEANING>Nanogram per Kilogram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per kilogram per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6648930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/L/h</VALIDVALUE>
          <VALUEMEANING>Micromole per Liter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*9</VALIDVALUE>
          <VALUEMEANING>Part Per Billion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-9.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>m3/s</VALIDVALUE>
          <VALUEMEANING>Cubic Meter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of volumetric flow rate defined as the rate at which one cubic meter of matter crosses a given surface during the period of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6.[IU]</VALIDVALUE>
          <VALUEMEANING>Million International Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of biological activity equal to one million international units.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/kg</VALIDVALUE>
          <VALUEMEANING>Nanogram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass fraction expressed as a number of nanograms of a substance per kilogram of the mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100{cells}</VALIDVALUE>
          <VALUEMEANING>Per 100 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit of measurement for a portion of a particular type of entities per 100 total cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14688614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/L</VALIDVALUE>
          <VALUEMEANING>Micromole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4094774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mA</VALIDVALUE>
          <VALUEMEANING>Milliampere</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electric current equal to one thousandth of an ampere.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6/kg</VALIDVALUE>
          <VALUEMEANING>Million per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to 10 to the sixth power of the number of entities per unit of mass equal to one kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100{WBCs}</VALIDVALUE>
          <VALUEMEANING>Per 100 White Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit for measurement of portion of a particular type of blood cells (such as any type of white blood cells or nucleated red blood cells) in the total white blood cell count expressed per count of 100.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mg</VALIDVALUE>
          <VALUEMEANING>Mole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406543</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Nanogram per Milligram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per milligram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/min</VALIDVALUE>
          <VALUEMEANING>Micromole per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromoles per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406787</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/a</VALIDVALUE>
          <VALUEMEANING>Per Year</VALUEMEANING>
          <MEANINGDESCRIPTION>A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74924</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6401081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/(24.h)</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mg</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2918846</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mL</VALIDVALUE>
          <VALUEMEANING>Millimole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of concentration (molarity unit) equal to one one-thousandth of a mole of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2685301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/cm[H2O]</VALIDVALUE>
          <VALUEMEANING>Per Centimeter of Water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to one centimeter of water used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C135517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6</VALIDVALUE>
          <VALUEMEANING>Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/min</VALIDVALUE>
          <VALUEMEANING>Nanogram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6644845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mmol</VALIDVALUE>
          <VALUEMEANING>Millimole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of substance of solute in millimoles to the amount of substance of the mixture in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/d</VALIDVALUE>
          <VALUEMEANING>Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/dL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL/h</VALIDVALUE>
          <VALUEMEANING>Nanogram per Milliliter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to mass concentration of a substance expressed in nanograms per unit volume of one milliliter per time period of one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mol</VALIDVALUE>
          <VALUEMEANING>Micromole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/dL</VALIDVALUE>
          <VALUEMEANING>Per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/g{creat}</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Gram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance concentration defined as the concentration of milliequivalents per gram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*9/uL</VALIDVALUE>
          <VALUEMEANING>Billion per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to 10 to the ninth power of entities per unit of volume equal to one microliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol{BCE}/mol</VALIDVALUE>
          <VALUEMEANING>Nanomole Bone Collagen Equivalent per Millimole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of substance concentration equal to one millimole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g</VALIDVALUE>
          <VALUEMEANING>Per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/g</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance content equivalent to the content at which one gram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A/m</VALIDVALUE>
          <VALUEMEANING>Ampere per Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit used for linear electric current density, magnetic field strength, and magnetization. It is the magnetic auxiliary field strength created tangentially at a distance of one meter from a straight conductor of infinite length and with negligible cross section by a circulating current of one ampere, or linear electric current density when one ampere electric current is conducted in one meter wide conducting sheet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68830</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/s</VALIDVALUE>
          <VALUEMEANING>Nanogram per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85750</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol</VALIDVALUE>
          <VALUEMEANING>Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/h</VALIDVALUE>
          <VALUEMEANING>Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>Ampere</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electric current, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is that constant current which, if maintained in two straight parallel conductors of infinite length and zero diameter separated by one meter in a vacuum, would produce between these conductors a force equal to 2x10E7 newton per meter of length. This is dependent upon the definitions of the meter, kilogram, and second. One ampere represents 6.24 x 10E18 unit electric charge carriers, such as electrons, passing a specified fixed point in one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/h</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>us</VALIDVALUE>
          <VALUEMEANING>Microsecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one millionth of a second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng</VALIDVALUE>
          <VALUEMEANING>Nanogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to 10E-9 gram, or one millionth of a milligram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/kg</VALIDVALUE>
          <VALUEMEANING>Per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/kg/h</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Kilogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliequivalent(s) of substance per one kilogram of body mass administered per unit of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NI</VALIDVALUE>
          <VALUEMEANING>No Information Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3151989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uV</VALIDVALUE>
          <VALUEMEANING>Microvolt</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of an electric potential and electromotive force equal to one millionth of a volt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/L</VALIDVALUE>
          <VALUEMEANING>Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/kg</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance content equivalent to the content at which one kilogram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>atm</VALIDVALUE>
          <VALUEMEANING>Atmosphere</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-SI unit of pressure equal to 101 325 Pa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nkat</VALIDVALUE>
          <VALUEMEANING>Nanokatal</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement equal to one billionth of katal (10E-9 katal).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>V</VALIDVALUE>
          <VALUEMEANING>Volt</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of electric potential and electromotive force, equal to the difference of electric potential between two points on a conducting wire carrying a constant current of one ampere when the power dissipated between the points is one watt, equivalent to the potential difference across a resistance of one ohm when one ampere of current flows through it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/min</VALIDVALUE>
          <VALUEMEANING>Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/L</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bar</VALIDVALUE>
          <VALUEMEANING>Bar Dosing Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosing unit equal to the amount of active ingredient(s) contained in a bar.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48475</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nL</VALIDVALUE>
          <VALUEMEANING>Nanoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one billionth of a liter (10E-9 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wb</VALIDVALUE>
          <VALUEMEANING>Weber</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one volt, when the flux is uniformly reduced to zero within one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mL</VALIDVALUE>
          <VALUEMEANING>Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/mL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit expressed in milliequivalent(s) of solute per milliliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406888</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bq</VALIDVALUE>
          <VALUEMEANING>Becquerel</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of activity of a radionuclide, equal to one nuclear disintegration or other nuclear transition from a particular energy state occurring in an amount of a radionuclide during one second-long time interval.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nm</VALIDVALUE>
          <VALUEMEANING>Nanometer</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to to one billionth of a meter (10E-9 meter). Nanometer is used as a unit for light wavelength measurement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3648817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>wk</VALIDVALUE>
          <VALUEMEANING>Week</VALUEMEANING>
          <MEANINGDESCRIPTION>Any period of seven consecutive days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mm</VALIDVALUE>
          <VALUEMEANING>Per Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of length equal to one millimeter that is used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq</VALIDVALUE>
          <VALUEMEANING>Milliequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cal</VALIDVALUE>
          <VALUEMEANING>calorie</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of energy defined as the amount of heat required to raise the temperature of one gram of pure water by one degree Centigrade under standard conditions (the specific heat of the water at 3.98, 14.5, or 19.5 degrees Celcius and the constant pressure of 101.325 kPa or one atm being defined as unity), equal to approximately 4.184 J. According to the current national standard in the United States (IEEE/ASTM SI 10 TM-2002. American National Standard for Use of the International System of Units (SI): The Modern Metric System, New York: IEEE, 2002) the calorie in any form is not to be used. Joules should be used instead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/d</VALIDVALUE>
          <VALUEMEANING>Nanomole per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mo</VALIDVALUE>
          <VALUEMEANING>Monthly</VALUEMEANING>
          <MEANINGDESCRIPTION>Every month.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(24.h)</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cel</VALIDVALUE>
          <VALUEMEANING>Degree Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42559</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/dL</VALIDVALUE>
          <VALUEMEANING>Nanomole per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one nanomole of solute in one deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/s</VALIDVALUE>
          <VALUEMEANING>Per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of occurrences of something within a second of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66965</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cg</VALIDVALUE>
          <VALUEMEANING>Centigram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one hundredth of a gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/uL</VALIDVALUE>
          <VALUEMEANING>Per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL</VALIDVALUE>
          <VALUEMEANING>Milligram per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cL</VALIDVALUE>
          <VALUEMEANING>Centiliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/h/mL</VALIDVALUE>
          <VALUEMEANING>Hour Times Nanomole per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Hours times nanomoles per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6632347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/wk</VALIDVALUE>
          <VALUEMEANING>Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3277357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm/s</VALIDVALUE>
          <VALUEMEANING>Centimeter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[arb&#39;U]/mL</VALIDVALUE>
          <VALUEMEANING>Arbitrary Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit based on or subject to individual judgment, preference, or predetermined reference per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12920302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm[H2O]</VALIDVALUE>
          <VALUEMEANING>Centimeters of water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5477037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mg/h</VALIDVALUE>
          <VALUEMEANING>Nanomole per Milligram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in nanomole(s) per milligram per period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[arb&#39;U]</VALIDVALUE>
          <VALUEMEANING>Arbitrary Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/h</VALIDVALUE>
          <VALUEMEANING>Milligram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm[Hg]</VALIDVALUE>
          <VALUEMEANING>Centimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one centimeter rise of mercury in a barometer at the Earth&#39;s surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Milligram of Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration of amount of substance of a component measured in nanomoles of the component per milligram of protein of the mixture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[AU]/ml</VALIDVALUE>
          <VALUEMEANING>Allergy Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of measure of potency of allergenic product expressed as a number of allergy units per one milliliter of formulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg/d</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm</VALIDVALUE>
          <VALUEMEANING>Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[AU]</VALIDVALUE>
          <VALUEMEANING>Allergy Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A biological potency unit assigned to several standardized allergenic extracts, following in-vitro comparison of the test extract to an FDA CBER reference standard. The FDA CBER reference standard may be assigned a specific AU unitage based on quantitative skin testing in allergic individuals, or based on specific allergen content.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70503</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg/h</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm2</VALIDVALUE>
          <VALUEMEANING>Square Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A CGS unit of area measurement equal to a square measuring one centimeter on each side. One square centimeter is equal to 10E-4 square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795823</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min/mL</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute per minute per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[beth&#39;U]/ml</VALIDVALUE>
          <VALUEMEANING>Bethesda Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement for blood coagulation inhibitor activity, expressed as a Bethesda Unit per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg/min</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm3</VALIDVALUE>
          <VALUEMEANING>Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5035618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6646889</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[beth&#39;U]</VALIDVALUE>
          <VALUEMEANING>Bethesda Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement for blood coagulation inhibitor activity, expressed in the amount of an inhibitor neutralizing 50% of a coagulant during the incubation period per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117966</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cP</VALIDVALUE>
          <VALUEMEANING>Centipoise</VALUEMEANING>
          <MEANINGDESCRIPTION>A CGS unit of dynamic viscosity equal to 10E-3 pascal second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL/h</VALIDVALUE>
          <VALUEMEANING>Nanomole per Milliliter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per milliliter per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[CFU]/mL</VALIDVALUE>
          <VALUEMEANING>Colony Forming Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit of viable cell concentration defined as the number of colony forming units in one milliliter of substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68902</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406590</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>d/wk</VALIDVALUE>
          <VALUEMEANING>Days Per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to the number of days within a period of time equal to one week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7241645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[CFU]</VALIDVALUE>
          <VALUEMEANING>Colony Forming Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum number of separable cells which is able to produce a detectable colony of progeny. Examples of CFU usage include, but are not limited to, the measurement of the number of viable bacteria present in the environment, and the ability of stem cells to produce cells of single or multiple lineages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/m2</VALIDVALUE>
          <VALUEMEANING>Milligram per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67402</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>d</VALIDVALUE>
          <VALUEMEANING>Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3481386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[cin_i]</VALIDVALUE>
          <VALUEMEANING>Cubic Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of volume equal to 16.3871 cubic centimeters, or 0.5541 US fluid ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dB</VALIDVALUE>
          <VALUEMEANING>Decibel</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure representing the intensity of an electrical signal or sound which is equal to ten times the logarithm of the ratio of two signals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[degF]</VALIDVALUE>
          <VALUEMEANING>Fahrenheit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of temperature of the temperature scale designed so that the freezing point of water is 32 degrees and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. One degree Fahrenheit is 5/9ths of a kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5387072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mg</VALIDVALUE>
          <VALUEMEANING>Gram per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>deg/s</VALIDVALUE>
          <VALUEMEANING>Degrees Per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of angular velocity defined as the number of degrees per unit of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7236047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[diop]</VALIDVALUE>
          <VALUEMEANING>Diopter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement of the optical power of a curved mirror or lens represented by the inverse of the focal length in meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/min</VALIDVALUE>
          <VALUEMEANING>Milligram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation expressed in milligram(s) period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>deg</VALIDVALUE>
          <VALUEMEANING>Degree Unit of Plane Angle</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of plane angle measurement equal to the length of the arc cut out by the angle, divided by the circumference of the circle, and multiplied by 360. The symbol for degrees is a small superscript circle. One radian is about 57 degrees and one degree is pi/180 radians.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/s/L</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of dose concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute per one liter of solution per unit of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[dr_av]</VALIDVALUE>
          <VALUEMEANING>Dram Mass Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of mass equal to 1/16 Avoirdupois ounce or 1/256 Avoirdupois pound. One dram equals approximately 1.7718451953125 grams.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL</VALIDVALUE>
          <VALUEMEANING>Milligram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3130364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dg</VALIDVALUE>
          <VALUEMEANING>Decigram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one-tenth of a gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/s</VALIDVALUE>
          <VALUEMEANING>Nanomole per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[FEU]</VALIDVALUE>
          <VALUEMEANING>Fibrinogen Equivalent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6384481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Gram Per Mole of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the number of grams per mole quantity of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL</VALIDVALUE>
          <VALUEMEANING>Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/umol{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter per Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per liter per micromole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[foz_us]</VALIDVALUE>
          <VALUEMEANING>Fluid Ounce US</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of liquid volume equal in the US customary system to 1/16 pint, or 1.804 687 cubic inches or 29.573 531 milliliters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mmol</VALIDVALUE>
          <VALUEMEANING>Gram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dm</VALIDVALUE>
          <VALUEMEANING>Decimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of length equal to one tenth of a meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol{BCE}/L</VALIDVALUE>
          <VALUEMEANING>Nanomole Bone Collagen Equivalent per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ft_i]</VALIDVALUE>
          <VALUEMEANING>International Foot</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/wk</VALIDVALUE>
          <VALUEMEANING>Milligram per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eq</VALIDVALUE>
          <VALUEMEANING>Equivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or thing equal to another in value or measure or force or effect or significance etc; being essentially equal to something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol</VALIDVALUE>
          <VALUEMEANING>Nanomole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg{FEU}/L</VALIDVALUE>
          <VALUEMEANING>Milligram per Liter Fibrinogen Equivalent Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of equivalent concentration equal to the number of milligrams of fibrinogen per unit volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158291</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6775807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[gal_us]</VALIDVALUE>
          <VALUEMEANING>Gallon US</VALUEMEANING>
          <MEANINGDESCRIPTION>The US unit of liquid volume legally defined as 3785.411784 milliliters (3.785 411 784 liters), or 231 cubic inches. The US gallon holds 4 liquid quarts; the gallon of water gallon weighs approximately 8.33 pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>erg</VALIDVALUE>
          <VALUEMEANING>Erg</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy in the CGS system. One erg is the work done or energy expended by a force of one dyne acting through a distance of one centimeter. One erg equals to 10E-7 joule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ns</VALIDVALUE>
          <VALUEMEANING>Nanosecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one billionth of a second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg</VALIDVALUE>
          <VALUEMEANING>Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5035619</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[HPF]</VALIDVALUE>
          <VALUEMEANING>High Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>The area visible under the maximum magnification power of the objective being used in microscopy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nU/mL</VALIDVALUE>
          <VALUEMEANING>Nanounit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanounits per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eV</VALIDVALUE>
          <VALUEMEANING>Electronvolt</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy defined as the kinetic energy acquired by an electron in passing through a potential difference of one volt in a vacuum. Its value is experimentally determined as 1,602 177 x 10E-19 joule (approximately). The unit is accepted for use with SI units.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>min/d</VALIDVALUE>
          <VALUEMEANING>Minute per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to the number of minutes within a period of time equal to one day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7547111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[in_i]</VALIDVALUE>
          <VALUEMEANING>Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length equal to 1/12 of a foot or 2.54 centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ohm</VALIDVALUE>
          <VALUEMEANING>Ohm</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in siemens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>Farad</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of capacitance equal to the capacitance of a capacitor having an equal and opposite charge of one coulomb on each plate and a potential difference of one volt between the plates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>min</VALIDVALUE>
          <VALUEMEANING>Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit measure of time equal to 60 seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[in_us]</VALIDVALUE>
          <VALUEMEANING>Survey Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of length equal to international inch/0.999998 or approximately to 2.54000508001016002032004 centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>osm</VALIDVALUE>
          <VALUEMEANING>Osmole</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of osmotic pressure equal to that of an ideal solution of a nondissociating substance that has a concentration of one mole of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fg</VALIDVALUE>
          <VALUEMEANING>Femtogram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one quadrillionth of a gram (10E-15 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64552</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(24.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/d</VALIDVALUE>
          <VALUEMEANING>International Unit per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>International units per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OT</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14900756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fL</VALIDVALUE>
          <VALUEMEANING>Femtoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI equal to one quadrillionth of a liter (10E-15 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/dL</VALIDVALUE>
          <VALUEMEANING>International Unit per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one deciliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/{beat}</VALIDVALUE>
          <VALUEMEANING>Milliliter per Heartbeat</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure expressed as the number of milliliter(s) per heart beat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pa</VALIDVALUE>
          <VALUEMEANING>Pascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to one newton per square meter or 10 bars or to 1.45x10E-4 pounds per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/g{Hb}</VALIDVALUE>
          <VALUEMEANING>International Unit per Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (biologic activity) equal to one international unit of substance per gram of hemoglobin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fm</VALIDVALUE>
          <VALUEMEANING>Femtometer</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to one quadrillionth of a meter (10E-15 meter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69147</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/cm[H2O]</VALIDVALUE>
          <VALUEMEANING>Milliliter per Centimeter of Water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure expressed in milliliter(s) per centimeter of water.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/g</VALIDVALUE>
          <VALUEMEANING>Femtomole per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A molality unit that describes the amount of substance, expressed in femtomole(s) per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/g</VALIDVALUE>
          <VALUEMEANING>International Unit per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in grams. It is also used as a dose calculation unit expressed in International Units of biological activity per one gram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/{cell}</VALIDVALUE>
          <VALUEMEANING>Picogram Per Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration for the number of picograms of substance per cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7547119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/L</VALIDVALUE>
          <VALUEMEANING>Femtomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one quadrillionth of a mole (10E-15 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2685296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/h</VALIDVALUE>
          <VALUEMEANING>International Unit per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>International units per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6639392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/dL</VALIDVALUE>
          <VALUEMEANING>Milliliter per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume concentration expressed as the number of milliters of a dissolved substance per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/dL</VALIDVALUE>
          <VALUEMEANING>Picogram per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one picogram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of a substance which mass equal to one picogram occupies the volume of one deciliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/kg/h</VALIDVALUE>
          <VALUEMEANING>International Unit per Kilogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one international unit (an arbitrary unit of biological activity) of a product per one kilogram of body mass administered per unit of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/mL</VALIDVALUE>
          <VALUEMEANING>Picomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/h</VALIDVALUE>
          <VALUEMEANING>Milliliter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/L</VALIDVALUE>
          <VALUEMEANING>Femtogram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Femtograms per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/kg</VALIDVALUE>
          <VALUEMEANING>International Unit per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in international units of biological activity per one kilogram of mass of the system. It is also used as a dose calculation unit expressed in international units of biological activity per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol</VALIDVALUE>
          <VALUEMEANING>Femtomole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg/d</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliters per kilogram per day or milliliters per day (flow rate), divided by kilograms (weight).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Picogram per Milligram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>Picograms per milligram creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(24.h)</VALIDVALUE>
          <VALUEMEANING>Gram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg/h</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73759</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/mg{creat}</VALIDVALUE>
          <VALUEMEANING>International Unit per Milligram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration with biologic activity defined as the concentration of international unit(s) per milligram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/cm2</VALIDVALUE>
          <VALUEMEANING>Gram per Square Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71201</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg/min</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3652834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/min</VALIDVALUE>
          <VALUEMEANING>International Unit per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>International units per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6639390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/cm3</VALIDVALUE>
          <VALUEMEANING>Kilogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one milliliter of preparation per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg</VALIDVALUE>
          <VALUEMEANING>Picogram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/mL</VALIDVALUE>
          <VALUEMEANING>International Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/m2</VALIDVALUE>
          <VALUEMEANING>Milliliter per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pkat</VALIDVALUE>
          <VALUEMEANING>Picokatal</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement equal to trillionth of katal (10E-12 katal).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]</VALIDVALUE>
          <VALUEMEANING>International Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/dL</VALIDVALUE>
          <VALUEMEANING>Gram per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one gram of a substance in unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2685299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/{1.73_m2}</VALIDVALUE>
          <VALUEMEANING>Milliliter per Minute per 1.73 m2 of Body Surface Area</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one milliliter of preparation per 1.73 square meters of body surface area delivered during a period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pL</VALIDVALUE>
          <VALUEMEANING>Picoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one trillionth of a liter (10E-12 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[lb_av]</VALIDVALUE>
          <VALUEMEANING>Pound</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/g{creat}</VALIDVALUE>
          <VALUEMEANING>Gram Per Gram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the number of grams per gram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105485</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/m2</VALIDVALUE>
          <VALUEMEANING>Milliliter per Square Meter per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pm</VALIDVALUE>
          <VALUEMEANING>Picometer</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to one trillionth of a
meter (10E-12 meter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[LPF]</VALIDVALUE>
          <VALUEMEANING>Low Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>The area visible in one view field of the microscope under the low magnification of the objective being used in microscopy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min</VALIDVALUE>
          <VALUEMEANING>Milliliter per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/d</VALIDVALUE>
          <VALUEMEANING>Picomole per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance flow rate equivalent to the rate at which one picomole of substance travels to a given object or space over a period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[mi_i]</VALIDVALUE>
          <VALUEMEANING>Mile</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of distance equal to 5280 international feet, 1760 international yards, or 1609.344 meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6272184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/h</VALIDVALUE>
          <VALUEMEANING>Gram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Grams per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6632006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/dL</VALIDVALUE>
          <VALUEMEANING>Picomole per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one picomole of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/s</VALIDVALUE>
          <VALUEMEANING>Milliliter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[MPL&#39;U]/mL</VALIDVALUE>
          <VALUEMEANING>Immunoglobin M Phospholipid Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg/d</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose administration rate unit equal to the rate at which one gram of a product per kilogram of body mass is delivered or administered over the period of one day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/g</VALIDVALUE>
          <VALUEMEANING>Nanomole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[MPL&#39;U]</VALIDVALUE>
          <VALUEMEANING>IgM Phospholipid Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard. One IgM phospholipid unit is equivalent to one mg/mL of an affinity-purified standard IgM sample obtained from the specified individuals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm/h</VALIDVALUE>
          <VALUEMEANING>Millimeter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[oz_av]</VALIDVALUE>
          <VALUEMEANING>Ounce</VALUEMEANING>
          <MEANINGDESCRIPTION>The traditional unit of mass. The avoirdupois ounce is equal to 1/16 pound, or 28.3495 grams, or 0.911 457 troy ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm/min</VALIDVALUE>
          <VALUEMEANING>Millimeter Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter traveled per unit time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/m2</VALIDVALUE>
          <VALUEMEANING>Gram per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[oz_tr]</VALIDVALUE>
          <VALUEMEANING>Troy Ounce</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of mass equal to 31.103 grams, 20 pennyweight, or 480 grains, or 0.083 pound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol</VALIDVALUE>
          <VALUEMEANING>Picomole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm[H2O]</VALIDVALUE>
          <VALUEMEANING>Millimeter of Water Column</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI manometric unit of pressure defined by a column of water at 4 degrees Celsius with a height of one millimeter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/min</VALIDVALUE>
          <VALUEMEANING>Gram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Grams per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85602</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6632004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[pH]</VALIDVALUE>
          <VALUEMEANING>pH</VALUEMEANING>
          <MEANINGDESCRIPTION>Quantity of dimension one used to express on a scale from 0 to 14 the amount-of-substance concentration of hydrogen ion of dilute aqueous solution, calculated as the logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ps</VALIDVALUE>
          <VALUEMEANING>Picosecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one trillionth of a second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm[Hg]</VALIDVALUE>
          <VALUEMEANING>Millimeter of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth&#39;s surface. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>s</VALIDVALUE>
          <VALUEMEANING>Second</VALUEMEANING>
          <MEANINGDESCRIPTION>The second is the unit of time, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the ground state of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour. Abbreviation Sec. is acceptable in non-scientific usage only.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm</VALIDVALUE>
          <VALUEMEANING>Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ppm]</VALIDVALUE>
          <VALUEMEANING>Part Per Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-6.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48523</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/mmol</VALIDVALUE>
          <VALUEMEANING>Kilogram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in kilogram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm2</VALIDVALUE>
          <VALUEMEANING>Square Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ppth]</VALIDVALUE>
          <VALUEMEANING>Part per Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-3.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sv</VALIDVALUE>
          <VALUEMEANING>Sievert</VALUEMEANING>
          <MEANINGDESCRIPTION>The international system (SI) unit for radiation dose equivalent equal to 1 Joule/kilogram. 1 sievert = 100 rem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(24.h)</VALIDVALUE>
          <VALUEMEANING>Millimole per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance flow rate equivalent to the rate at which one thousandth of a mole of substance crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[pptr]</VALIDVALUE>
          <VALUEMEANING>Part Per Trillion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-12.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5035620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>t</VALIDVALUE>
          <VALUEMEANING>Ton</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to 1000 kilograms, or 2204.623 pounds avoirdupois.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[psi]</VALIDVALUE>
          <VALUEMEANING>Pound per Square Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of pressure equivalent to 6.894757 kilopascals, or 703.0696 kilograms per square meter, or 51.71507 millimeters of mercury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gy</VALIDVALUE>
          <VALUEMEANING>Gray</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter; one gray equals 100 rads. The unit is named for the British physician L. Harold Gray, an authority on the use of radiation in the treatment of cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[pt_us]</VALIDVALUE>
          <VALUEMEANING>Pint</VALUEMEANING>
          <MEANINGDESCRIPTION>A United States liquid unit equal to 16 fluid ounces; two pints equal one quart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/dL</VALIDVALUE>
          <VALUEMEANING>Centimole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one hundredth of a mole (10E-2 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>h/d</VALIDVALUE>
          <VALUEMEANING>Hour per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to the number of hours within a period of time equal to one day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C176380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7547113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Torr</VALIDVALUE>
          <VALUEMEANING>Torr</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of pressure equal to 1/760 of a standard atmosphere (a standard atmosphere being defined as equal to 101 325 pascals). One Torr is equal to 133.3223684 pascals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[qt_us]</VALIDVALUE>
          <VALUEMEANING>Quart</VALUEMEANING>
          <MEANINGDESCRIPTION>A United States liquid unit equal to 32 fluid ounces; four quarts equal one gallon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48534</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/g{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Gram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>h/wk</VALIDVALUE>
          <VALUEMEANING>Hours Per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to the number of hours within a period of time equal to one week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7241641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/(24.h)</VALIDVALUE>
          <VALUEMEANING>Unit per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of an activity rate expressed as a number of substance units which crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours. This unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[sft_i]</VALIDVALUE>
          <VALUEMEANING>Square Foot</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of area equal to 144 square inches, 929.0304 square centimeters, or 9.290304E-2 square meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H</VALIDVALUE>
          <VALUEMEANING>Henry</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of electric inductance. A coil with an inductance of one henry requires a flux of one weber for each ampere of induced current. If it is the current which changes, then the induced field will generate a potential difference within the coil: if the inductance is one henry a current change of one ampere per second generates a potential difference of one volt. The henry is a large unit; inductances in practical circuits are measured in millihenrys or microhenrys.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*12{RBCs}</VALIDVALUE>
          <VALUEMEANING>Unit per Trillion Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in units of biological activity per ten to the twelfth power red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[sin_i]</VALIDVALUE>
          <VALUEMEANING>Square Inch</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of area equal to the area of a square with sides of one inch. It is equal to 6.4516 square centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/h</VALIDVALUE>
          <VALUEMEANING>Millimole per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimoles per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85720</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6640558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[syd_i]</VALIDVALUE>
          <VALUEMEANING>Square Yard</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of area equal to 9 square feet, 1296 square inches, or 0.836 127 36 square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/dL</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one deciliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hz</VALIDVALUE>
          <VALUEMEANING>Hertz</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of frequency; equal to one oscillation per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42545</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[tbs_us]</VALIDVALUE>
          <VALUEMEANING>Tablespoon Dosing Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume informally used in pharmacy. Under the metric system the tablespoon has been standardized at 15 milliliters in the US, Britain, Canada, and New Zealand, and at 20 milliliters in Australia and some European countries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48541</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/g{Hb}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (biologic activity) equal to one enzyme unit of substance per gram of hemoglobin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/kg/min</VALIDVALUE>
          <VALUEMEANING>Nanomole per Milligram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in nanomole(s) per milligram per period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13433741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>J</VALIDVALUE>
          <VALUEMEANING>Joule</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electrical, mechanical, and thermal energy (as well as work and quantity of heat) in the SI system, equal to the work done when the point of application of a force of one newton is displaced through a distance of one meter in the direction of the force or the work done when a current of one ampere passes through a resistance of one ohm for one second. Joule is equal to 0.23889 gram-calorie (mean).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[tb&#39;U]</VALIDVALUE>
          <VALUEMEANING>Tuberculin Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of tuberculin dosage defined by comparison of clinical response to a preparation of the purified protein derivative standardized for use in humans for tuberculin skin test reaction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/g</VALIDVALUE>
          <VALUEMEANING>Unit per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in unit(s) per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[tsp_us]</VALIDVALUE>
          <VALUEMEANING>Teaspoon Dosing Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume used in pharmacy and equal to 5 milliliters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48544</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/h</VALIDVALUE>
          <VALUEMEANING>Unit per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance rate expressed in unit(s) per period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11483311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K</VALIDVALUE>
          <VALUEMEANING>Kelvin</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic unit of thermodynamic temperature, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is 1/273.16th of the thermodynamic temperature of the triple point of water, This sets the size of the kelvin unit for temperature differences and defines the thermodynamic temperature of an equilibrium mixture of waters ice-liquid-vapor as 273.16 K, where 0 K is the lowest possible temperature (&quot;absolute zero&quot;).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[yd_i]</VALIDVALUE>
          <VALUEMEANING>Yard</VALUEMEANING>
          <MEANINGDESCRIPTION>A traditional unit of length equal to 3 feet, or 36 inches, or 0.9144 meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/L</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one liter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C147130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kat</VALIDVALUE>
          <VALUEMEANING>Katal</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measuring catalytic (e.g. enzymatic) activity, the ability of the compound to accelerate the chemical reaction by providing a lower energy pathway between the reactants and the products. One katal is that catalytic activity which will raise the rate of reaction by one mole per second in a specified assay system. When the katal is used, the measurand should be specified by reference to the measurement procedure; the measurement procedure must identify the indicator reaction. The katal is not used to express a rate of reaction itself, which should be expressed in moles per second. Katal is coherent with the SI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/min</VALIDVALUE>
          <VALUEMEANING>Millimole per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimoles per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6644813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}</VALIDVALUE>
          <VALUEMEANING>Number</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3368980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/mL</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mL</VALIDVALUE>
          <VALUEMEANING>Molar</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one mole of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/d</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy equal to one kilocalorie per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{beats}/min</VALIDVALUE>
          <VALUEMEANING>Beats per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of heartbeats measured per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2659976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>u[IU]/L</VALIDVALUE>
          <VALUEMEANING>Micro-International Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (biologic activity) equal to one micro-international unit of substance per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mmol</VALIDVALUE>
          <VALUEMEANING>Mole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of substance of solute in moles to the amount of substance of the mixture in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal</VALIDVALUE>
          <VALUEMEANING>Calorie</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of energy defined as the amount of heat required to raise the temperature of one kilogram of pure water by one degree Centigrade under standard conditions (the specific heat of the water at 15 degrees Celsius and the constant pressure of 101.325 kPa or one atm being defined as unity), equal to approximately 4.1855 kJ. It is also is used by nutritionists in measuring the energy-producing potential of food as a unit of potential energy contained by a substance, which can be liberated when the material is oxidized, usually by combustion in the presence of oxygen. According to the current national standard in the United States (IEEE/ASTM SI 10 TM-2002. American National Standard for Use of the International System of Units (SI): The Modern Metric System, New York: IEEE, 2002) the calorie in any form is not to be used. Joules should be used instead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{breaths}/min</VALIDVALUE>
          <VALUEMEANING>Breaths per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of breaths (inhalation and exhalation) taken per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mol{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Mole of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the concentration of millimoles of solute per mole of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{CAE&#39;U}</VALIDVALUE>
          <VALUEMEANING>Complement Activity Enzyme Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measurement of enzymatic activity of plasma and membrane-bound proteins that comprise a complement system and their split products in functional assays indicative of the activity of the classical and alternative pathways designed to ward off invading pathogens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67270</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>u[IU]</VALIDVALUE>
          <VALUEMEANING>Microinternational Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one-millionth of an international unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{cells}/uL</VALIDVALUE>
          <VALUEMEANING>Cells per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell concentration expressed as a number of cells per unit volume equal to one microliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/m2</VALIDVALUE>
          <VALUEMEANING>Kilogram Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI derived unit of spread rate of a substance by mass, used also as a measure of area density.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol</VALIDVALUE>
          <VALUEMEANING>Millimole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{cells}</VALIDVALUE>
          <VALUEMEANING>Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3111299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ueq/L</VALIDVALUE>
          <VALUEMEANING>Microequivalent per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance concentration equal to one billionth of a gram of an equivalent weight per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mo</VALIDVALUE>
          <VALUEMEANING>Month</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{copies}/mL</VALIDVALUE>
          <VALUEMEANING>Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ueq</VALIDVALUE>
          <VALUEMEANING>Microequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one millionth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/s</VALIDVALUE>
          <VALUEMEANING>Kilogram per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate defined as the mass of matter equal to one kilogram which crosses a given surface during the period of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{copies}/ug</VALIDVALUE>
          <VALUEMEANING>Copies per Microgram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration expressed as a number of copies per unit mass equal to one microgram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/(24.h)</VALIDVALUE>
          <VALUEMEANING>Microgram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Microgram per 24 hours is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6132701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg</VALIDVALUE>
          <VALUEMEANING>Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{copies}</VALIDVALUE>
          <VALUEMEANING>Copy</VALUEMEANING>
          <MEANINGDESCRIPTION>A secondary representation, reproduction, or replica.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/{specimen}</VALIDVALUE>
          <VALUEMEANING>Microgram per Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as quantity in micrograms per specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>km</VALIDVALUE>
          <VALUEMEANING>Kilometer</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of distance equal to 1000 meters, 0.621 miles, 1094 yards, or 3281 feet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{count}</VALIDVALUE>
          <VALUEMEANING>Count</VALUEMEANING>
          <MEANINGDESCRIPTION>Determining the number or amount of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/mL</VALIDVALUE>
          <VALUEMEANING>Mole per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one mole of solute in one milliliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kPa</VALIDVALUE>
          <VALUEMEANING>Kilopascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to 1000 newtons per square meter or 10000 bars or to 0.145 pound per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{GPS&#39;U}</VALIDVALUE>
          <VALUEMEANING>Phosphatidylserine IgG Antibody Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/dL</VALIDVALUE>
          <VALUEMEANING>Microgram per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of  one microgram of a substance in unit volume of the mixture equal to one  deciliter. The concept also refers to the unit of mass density (volumic  mass) defined as the density of substance which mass equal to one  microgram occupies the volume one deciliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ks</VALIDVALUE>
          <VALUEMEANING>Kilosecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one thousand seconds (10E3 seconds).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{JDF&#39;U}</VALIDVALUE>
          <VALUEMEANING>Juvenile Diabetes Foundation Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure, defined by the Juvenile Diabetes Foundation, used to express the amount of islet cell antibodies in a biological sample; it is calculated by multiplying the titer by five.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7351479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/s</VALIDVALUE>
          <VALUEMEANING>Mole per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>Moles per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L</VALIDVALUE>
          <VALUEMEANING>Kilounit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one thousand units of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Log_copies}/mL</VALIDVALUE>
          <VALUEMEANING>Log10 Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{Hb}</VALIDVALUE>
          <VALUEMEANING>Unit Per Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105522</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol</VALIDVALUE>
          <VALUEMEANING>Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>The the basic unit of substance, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is the amount of substance that contains as many elementary units as there are atoms in 0.012 kg of carbon-12. When the mole is used, the elementary entities must be specified and may be atoms, molecules, ions, electrons, other particles, or specified groups of such particles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42539</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/mL</VALIDVALUE>
          <VALUEMEANING>Unit per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one microliter of mixture contains one unit of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Log_IU}/mL</VALIDVALUE>
          <VALUEMEANING>Log10 International Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5778792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosm/kg</VALIDVALUE>
          <VALUEMEANING>Milliosmole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic strength of solution as a measure of concentration of osmotically active particles expressed in a number of milliosmoles of solute per kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU</VALIDVALUE>
          <VALUEMEANING>Kilounit</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to one thousand units (10E3 units).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{M.o.M}</VALIDVALUE>
          <VALUEMEANING>Multiple of the Median</VALUEMEANING>
          <MEANINGDESCRIPTION>An individual test result&#39;s deviation from the median.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C179801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/h</VALIDVALUE>
          <VALUEMEANING>Microgram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosm/L</VALIDVALUE>
          <VALUEMEANING>Milliosmole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic pressure equal to one thousandth of an osmole per unit of volume equal to one Liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/(24.h)</VALIDVALUE>
          <VALUEMEANING>Liter per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{mm/dd/yyyy}</VALIDVALUE>
          <VALUEMEANING>Month-Day-Year</VALUEMEANING>
          <MEANINGDESCRIPTION>A format of a date in time, with the month followed by the date followed by the year.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/kg/d</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3059690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosm</VALIDVALUE>
          <VALUEMEANING>Milliosmole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic pressure equal to one thousandth of osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{MPS&#39;U}/mL</VALIDVALUE>
          <VALUEMEANING>Phosphatidylserine IgM Antibody Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of measure of potency of allergenic product expressed as a number of immunoglobin M phosphatidylserine units per one milliliter of formulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C186223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8167311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/kg/h</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{MPS&#39;U}</VALIDVALUE>
          <VALUEMEANING>Phosphatidylserine IgM Antibody Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/kg/min</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one millionth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/h</VALIDVALUE>
          <VALUEMEANING>Liter per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69160</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/kg</VALIDVALUE>
          <VALUEMEANING>Liter per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in liter(s) per kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*3{RBCs}</VALIDVALUE>
          <VALUEMEANING>Per Thousand Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit of measurement for a portion of a particular type of cell (excluding red blood cell subtypes) per one thousand red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12920300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/d</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>a</VALIDVALUE>
          <VALUEMEANING>Ampere</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electric current, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). It is that constant current which, if maintained in two straight parallel conductors of infinite length and zero diameter separated by one meter in a vacuum, would produce between these conductors a force equal to 2x10E7 newton per meter of length. This is dependent upon the definitions of the meter, kilogram, and second. One ampere represents 6.24 x 10E18 unit electric charge carriers, such as electrons, passing a specified fixed point in one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*9/L</VALIDVALUE>
          <VALUEMEANING>Billion per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number or quantity of objects in billions per unit of volume equal to one liter, or the equivalent in milliliters or microliters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/d</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6/uL</VALIDVALUE>
          <VALUEMEANING>Million per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number of entities or quantity in millions per unit of volume equal to one microliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6/L</VALIDVALUE>
          <VALUEMEANING>Thousand per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one milliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/L</VALIDVALUE>
          <VALUEMEANING>Nanogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance per unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one nanogram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mmol</VALIDVALUE>
          <VALUEMEANING>Micromole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/m3</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL</VALIDVALUE>
          <VALUEMEANING>Micromole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL/min</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute per minute per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/L</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mg</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g{creat}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Gram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the number of milligrams per gram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/g</VALIDVALUE>
          <VALUEMEANING>Nanomole per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per gram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/L</VALIDVALUE>
          <VALUEMEANING>Picomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/g</VALIDVALUE>
          <VALUEMEANING>Gram per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/d</VALIDVALUE>
          <VALUEMEANING>Gram per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mL</VALIDVALUE>
          <VALUEMEANING>Nanogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance per unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one nanogram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mg</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/L</VALIDVALUE>
          <VALUEMEANING>International Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/d</VALIDVALUE>
          <VALUEMEANING>Milliliter per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pA</VALIDVALUE>
          <VALUEMEANING>Pascal</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of pressure equivalent to one newton per square meter or 10 bars or to 1.45x10E-4 pounds per square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42547</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>h</VALIDVALUE>
          <VALUEMEANING>Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/g</VALIDVALUE>
          <VALUEMEANING>Mole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T</VALIDVALUE>
          <VALUEMEANING>Tesla</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of magnetic flux density equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/d</VALIDVALUE>
          <VALUEMEANING>Millimole per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance flow rate equivalent to the rate at which one thousandth of a mole of substance crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/mol{creat}</VALIDVALUE>
          <VALUEMEANING>Gram Per Mole of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the number of grams per mole quantity of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105486</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S</VALIDVALUE>
          <VALUEMEANING>Siemens</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electrical conductance, admittance, and susceptance. A conductor has a conductance of one siemens if an electrical potential difference of one volt produces a one ampere current in it. The conductance in siemens is the reciprocal of its resistance in ohms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/mL</VALIDVALUE>
          <VALUEMEANING>Kilogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ppb]</VALIDVALUE>
          <VALUEMEANING>Part Per Billion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-9.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/mL</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/L</VALIDVALUE>
          <VALUEMEANING>Billion per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived unit expressed as a number or quantity of objects in billions per unit of volume equal to one liter, or the equivalent in milliliters or microliters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/kg</VALIDVALUE>
          <VALUEMEANING>Mole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/mol</VALIDVALUE>
          <VALUEMEANING>Kilogram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in kilogram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122210</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/m3</VALIDVALUE>
          <VALUEMEANING>Kilogram per Cubic Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mol</VALIDVALUE>
          <VALUEMEANING>Millimole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of substance of solute in millimoles to the amount of substance of the mixture in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/L</VALIDVALUE>
          <VALUEMEANING>Kilogram per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>u[IU]/mL</VALIDVALUE>
          <VALUEMEANING>Microinternational Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one millionth of international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/L</VALIDVALUE>
          <VALUEMEANING>Millimole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>k[IU]/L</VALIDVALUE>
          <VALUEMEANING>International Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/kg</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/kg/h</VALIDVALUE>
          <VALUEMEANING>Nanomole per Milligram per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in nanomole(s) per milligram per period of time equal to one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/kg</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/d</VALIDVALUE>
          <VALUEMEANING>Liter per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mPa.s</VALIDVALUE>
          <VALUEMEANING>Centipoise</VALUEMEANING>
          <MEANINGDESCRIPTION>A CGS unit of dynamic viscosity equal to 10E-3 pascal second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69092</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/(min.m2)</VALIDVALUE>
          <VALUEMEANING>Liter Per Minute Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{creat}</VALIDVALUE>
          <VALUEMEANING>Nanogram per Milligram of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per milligram of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/mol</VALIDVALUE>
          <VALUEMEANING>Mole per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of substance of solute in moles to the amount of substance of the mixture in moles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/d</VALIDVALUE>
          <VALUEMEANING>Microgram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Microgram per 24 hours is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/m3</VALIDVALUE>
          <VALUEMEANING>Millimole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/L</VALIDVALUE>
          <VALUEMEANING>Mole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one mole of solute per one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48555</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/(12.h)</VALIDVALUE>
          <VALUEMEANING>Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(12.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(4.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Four Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66835, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(48.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Forty Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._The natural number greater than forty-seven and less than forty-nine and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C175678, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(5.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Five Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66836, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(6.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Six Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66837, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(72.h)</VALIDVALUE>
          <VALUEMEANING>Gram Per Seventy Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._The natural number greater than seventy-one and less than seventy-three and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C188334, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/(2.h)</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(10.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Ten Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C69122, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(12.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(2.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(6.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Six Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66837, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(72.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Seventy Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._The natural number greater than seventy-one and less than seventy-three and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C188334, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Milligram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(10.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Ten Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C69122, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(12.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(2.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(4.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Four Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66835, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(5.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Five Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66836, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912970</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(6.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Six Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66837, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(72.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Seventy Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._The natural number greater than seventy-one and less than seventy-three and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C188334, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(8.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(12.h)</VALIDVALUE>
          <VALUEMEANING>Millimole Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(2.h)</VALIDVALUE>
          <VALUEMEANING>Millimole Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(5.h)</VALIDVALUE>
          <VALUEMEANING>Millimole Per Five Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66836, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(6.h)</VALIDVALUE>
          <VALUEMEANING>Millimole Per Six Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66837, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/(8.h)</VALIDVALUE>
          <VALUEMEANING>Millimole Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/(8.h)</VALIDVALUE>
          <VALUEMEANING>Nanogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/(12.h)</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Twelve Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A natural number greater than 11 and less than 13 and the quantity that it denotes._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C113426, C65039, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/(2.h)</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/(8.h)</VALIDVALUE>
          <VALUEMEANING>Microgram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uL/(2.h)</VALIDVALUE>
          <VALUEMEANING>Microliter Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter)._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C48153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/(2.h)</VALIDVALUE>
          <VALUEMEANING>Micromole Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/(8.h)</VALIDVALUE>
          <VALUEMEANING>Micromole Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/(8.h)</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66839, C25529, C65039, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{total}</VALIDVALUE>
          <VALUEMEANING>Total Number Percent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the amount of total number of entities._A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570, C127787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{RBCs}</VALIDVALUE>
          <VALUEMEANING>Erythrocyte Count Percent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the number of erythrocytes in a biospecimen._A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570, C51946</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{cells}</VALIDVALUE>
          <VALUEMEANING>Cell Count Percent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure to determine the number of cells in a sample._A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570, C48938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/wk</VALIDVALUE>
          <VALUEMEANING>Number Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{reactive}</VALIDVALUE>
          <VALUEMEANING>Reaction Percent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response generated by a stimulus._A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570, C25637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/[HPF]</VALIDVALUE>
          <VALUEMEANING>Number Per High Powered Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A unit of measure equal to the instances of an entity per visual field of a microscope set to its maximum magnification power.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96619, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/[LPF]</VALIDVALUE>
          <VALUEMEANING>Number Per Low Powered Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A unit of measure equal to the instances of an entity per visual field of a microscope set to its minimum magnification power.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96620, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/a</VALIDVALUE>
          <VALUEMEANING>Number Per Year</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74924, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/d</VALIDVALUE>
          <VALUEMEANING>Number Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/g</VALIDVALUE>
          <VALUEMEANING>Number Per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198369, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/L</VALIDVALUE>
          <VALUEMEANING>Number Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/mL</VALIDVALUE>
          <VALUEMEANING>Number Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14912999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/uL</VALIDVALUE>
          <VALUEMEANING>Score Per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A number or range of numeric values measuring performance, function, quality, or ability._A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67254, C25338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10.L/(min.m2)</VALIDVALUE>
          <VALUEMEANING>Ten Liter Per Minute Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105496, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10.L/min</VALIDVALUE>
          <VALUEMEANING>Ten Liter per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(3.d)</VALIDVALUE>
          <VALUEMEANING>Gram Per Three Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66834, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/g{globulin}</VALIDVALUE>
          <VALUEMEANING>Gram per Gram Globulin Protein Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit._The determination of the amount of globulin protein present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74738, C70453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/g{tissue}</VALIDVALUE>
          <VALUEMEANING>Gram per Gram Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C70453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/g{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/g{Hb}</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/L{RBCs}</VALIDVALUE>
          <VALUEMEANING>Micromole per Liter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C48508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mol{creat}</VALIDVALUE>
          <VALUEMEANING>Micromole per Mole Creatinine Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles._A quantitative measurement of the amount of creatinine present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64547, C122231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mol{Hb}</VALIDVALUE>
          <VALUEMEANING>Micromole per Mole Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C122231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/mL{RBCs}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Milliliter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)_A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C103452, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Millimole Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C48513, C65039, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/s</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._The number of occurrences of something within a second of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66965, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ueq/mL</VALIDVALUE>
          <VALUEMEANING>Microequivalent Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one millionth of an equivalent weight._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C73726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/(100.g)</VALIDVALUE>
          <VALUEMEANING>Microgram Per One Hundred Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155, C105814, C65039, C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{feces}</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13234, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{hair}</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Hair</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._The filamentous outgrowth of the epidermis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32705, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{tissue}</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg.m/s</VALIDVALUE>
          <VALUEMEANING>Kilogram Meter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds._A SI derived unit of both speed (scalar) and velocity (vector), defined as the distance of one meter travelled per unit time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42571, C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{at_60_min}</VALIDVALUE>
          <VALUEMEANING>Percent Unit At Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Used to indicate position, location, or state._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C25427, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/(s.m2)</VALIDVALUE>
          <VALUEMEANING>Kilogram per Second Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate defined as the mass of matter equal to one kilogram which crosses a given surface during the period of time equal to one second._For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039, C70452</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{baseline}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Baseline</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A starting point to which things may be compared.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25213, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/d</VALIDVALUE>
          <VALUEMEANING>Kilogram Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/L/(24.h)</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter._For each, generally denoting a ratio._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C65039, C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{binding}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Binding</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._The action of attracting something and forming a bond with it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82888, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/h</VALIDVALUE>
          <VALUEMEANING>Kilogram Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/L{RBCs}</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{blockade}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Block</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Interrupt the normal function of; hinder or prevent the progress or accomplishment of; stop from happening or developing; interfere with or prevent the reception of signals; impede the movement of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61286, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kg/min</VALIDVALUE>
          <VALUEMEANING>Kilogram Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C28252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL{eqv}</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter Equivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter._A person or thing equal to another in value or measure or force or effect or significance etc.; being essentially equal to something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48793, C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/g</VALIDVALUE>
          <VALUEMEANING>Kilo Enzyme Unit Per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one thousand, 10E3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198369, C64778, C48436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Microgram Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{bound}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Fraction Bound</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._The ratio of bound drug concentration to the total concentration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154840, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/(8.h)</VALIDVALUE>
          <VALUEMEANING>Liter Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C48505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{dose}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Dose</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25488, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/ng</VALIDVALUE>
          <VALUEMEANING>Microgram Per Nanogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48516, C65039, C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>lm.m2</VALIDVALUE>
          <VALUEMEANING>Lumen Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of luminous flux. It is the amount of light that falls on a unit area at unit distance from a source of one candela._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C42560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{excretion}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Excretion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._THe process by which waste matter is discharged from the body</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94618, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug{FEU}/mL</VALIDVALUE>
          <VALUEMEANING>Microgram Fibrinogen Equivalent Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C96649, C48152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961342</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/{specimen}</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._For each, generally denoting a ratio._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19157, C65039, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{index}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uL/h</VALIDVALUE>
          <VALUEMEANING>Microliter Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter)._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C48153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{loss}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Loss</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A gradual decline in amount or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25559, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/{total_volume}</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Total Volume Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The determination of the volume of a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74720, C25304, C65039, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961347</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/dL{GF}</VALIDVALUE>
          <VALUEMEANING>Micromole per Deciliter Glomerular Filtration Rate</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of concentration (molarity unit) equal to one millionth of mole of a solute in one deciliter of the solution._A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman&#39;s capsule per unit of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90505, C67407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{lysis}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Tissue Lysis</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occurring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37889, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/m2</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/kg{feces}</VALIDVALUE>
          <VALUEMEANING>Micromole Per Kilogram Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio._The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13234, C120844, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{recovery}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Recovery</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A getting back or regaining.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70827, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>meq/min</VALIDVALUE>
          <VALUEMEANING>Milliequivalent Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Micromole Per Milligram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C28253, C65039, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{relative}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Relative Value</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Considered in comparison with something else; dependent on or interconnected with something else; not absolute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45830, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/{collection}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Collection</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._The act of gathering things together; having been brought together in one place.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25453, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{residual}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Residual</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Remaining or left behind.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37895, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/min/g{mucosa}</VALIDVALUE>
          <VALUEMEANING>Micromole per Minute Per Gram Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromoles per minute._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._Mucous membrane.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C198369, C85708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/{specimen}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19157, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{response}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Response</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25755, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/min/g{prot}</VALIDVALUE>
          <VALUEMEANING>Micromole per Minute Per Gram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromoles per minute._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C198369, C85708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{saturation}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Saturation</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Impregnation of one substance by another to the greatest possible extent; that concentration of a dissolved substance that cannot be exceeded.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61427, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/{total_output}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Total Output</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Anything coming out of a system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47906, C25304, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/min/g</VALIDVALUE>
          <VALUEMEANING>Micromole Per Minute Per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._The number of occurrences of something within a minute of time._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198369, C66967, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{uptake}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Uptake</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71688, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/{total_volume}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Total Volume Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The determination of the volume of a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74720, C25304, C65039, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/min/L</VALIDVALUE>
          <VALUEMEANING>Micromole Per Minute Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._The number of occurrences of something within a minute of time._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C66967, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/[arb&#39;U]</VALIDVALUE>
          <VALUEMEANING>Per Arbitrary Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75765, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mL/min</VALIDVALUE>
          <VALUEMEANING>Millimole per Liter Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL{RBCs}</VALIDVALUE>
          <VALUEMEANING>Milligram Per Deciliter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C105514, C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/[IU]/mL</VALIDVALUE>
          <VALUEMEANING>Per International Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g{feces}</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass._The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13234, C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/umol{creat}</VALIDVALUE>
          <VALUEMEANING>Micromole Per Micromole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._For each, generally denoting a ratio._A unit of amount of substance equal to a millionth of a mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48509, C65039, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/[IU]</VALIDVALUE>
          <VALUEMEANING>Per International Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48579, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g{tissue}</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/{entity}</VALIDVALUE>
          <VALUEMEANING>Per Entity</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._An independently existing thing (living or nonliving).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51070, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/umol</VALIDVALUE>
          <VALUEMEANING>Micromole Per Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a millionth of a mole._For each, generally denoting a ratio._A unit of amount of substance equal to a millionth of a mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48509, C65039, C48509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*4{RBCs}</VALIDVALUE>
          <VALUEMEANING>Per Ten Thousand Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C67234, C69122, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uOhm</VALIDVALUE>
          <VALUEMEANING>Micro Ohm</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-millionth, 10E-6._A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in siemens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42554, C48438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/L{RBCs}</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uU/g</VALIDVALUE>
          <VALUEMEANING>Micro Enzyme Unit Per Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-millionth, 10E-6._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198369, C64778, C48438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100{neutrophils}</VALIDVALUE>
          <VALUEMEANING>Per One Hundred Neutrophil</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12533, C105814, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Gram per Gram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C70453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{aggregation}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Aggregation</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._A process by which particles collect to form a cohesive mass or cluster. The resulting structure is called an aggregate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62344, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100{spermatozoa}</VALIDVALUE>
          <VALUEMEANING>Per One Hundred Spermatozoa Cell Count</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._The determination of the number of spermatozoa cells present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74663, C105814, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>min/wk</VALIDVALUE>
          <VALUEMEANING>Minute Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit measure of time equal to 60 seconds._Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069, C48154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{bacteria}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Bacterial Count</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._The quantitative determination of bacterial populations. The two most widely used methods for determining bacterial numbers are: 1) the standard, or viable, plate count method and 2) spectrophotometric (turbidimetric) analysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64469, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100</VALIDVALUE>
          <VALUEMEANING>Per One Hundred</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105814, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/(8.h)/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Eight Hour Per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120844, C25529, C66839, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Ten</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69122, C65039, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g{creat}</VALIDVALUE>
          <VALUEMEANING>Per Gram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C198369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one milliliter of preparation per one kilogram of body mass._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C67411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g{Hb}</VALIDVALUE>
          <VALUEMEANING>Per Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C198369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g{tot_nit}</VALIDVALUE>
          <VALUEMEANING>Per Gram Total Nitrogen</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._An element with atomic symbol N, atomic number 7, and atomic weight 14.01.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61863, C25304, C198369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/mm</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._A unit of length equal to one millimeter that is used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130188, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g{tot_prot}</VALIDVALUE>
          <VALUEMEANING>Per Gram Total Protein Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._A quantitative measurement of the amount of total protein present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64858, C198369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL{fetal_RBCs}</VALIDVALUE>
          <VALUEMEANING>Milliliter Fetus Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume._An unborn or unhatched vertebrate in the later stages of development showing the main recognizable features of the mature being._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C13235, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/kg{body_wt}</VALIDVALUE>
          <VALUEMEANING>Per Kilogram Body Weight</VALUEMEANING>
          <MEANINGDESCRIPTION>A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio._The weight of a subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81328, C120844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/{ejaculate}</VALIDVALUE>
          <VALUEMEANING>Millimole Per</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/m2</VALIDVALUE>
          <VALUEMEANING>Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/{specimen}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19157, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/m3</VALIDVALUE>
          <VALUEMEANING>Per Cubic Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A SI unit of volume or capacity equal to the volume of a cube with edges one meter in length. It is equal to 1,000 liters; 1,000 cubic decimeters; 10(e+6) cubic centimeters; 25.3 cubic feet; 6.29 barrels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42570, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/{total_vol}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Total Volume Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The determination of the volume of a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74720, C25304, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mg</VALIDVALUE>
          <VALUEMEANING>Per Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mm3</VALIDVALUE>
          <VALUEMEANING>Per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48153, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/h/mg{Hb}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Hour Per Milligram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C28253, C65039, C66966, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/h/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Hour Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C66966, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/U</VALIDVALUE>
          <VALUEMEANING>Per Enzyme Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>For each, generally denoting a ratio._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64778, C65039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[CFU]/L</VALIDVALUE>
          <VALUEMEANING>Colony Forming Unit Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>The minimum number of separable cells which is able to produce a detectable colony of progeny. Examples of CFU usage include, but are not limited to, the measurement of the number of viable bacteria present in the environment, and the ability of stem cells to produce cells of single or multiple lineages._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C68742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Per Integer Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._For each, generally denoting a ratio._A number with no fractional part, including the negative and positive numbers as well as zero._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C45255, C65039, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[GPL&#39;U]/mL</VALIDVALUE>
          <VALUEMEANING>Anticardiolipin IgG Antibody Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An IgG autoantibody directed against cardiolipin. It is associated with thrombosis, spontaneous abortion, and complications during labor._A single undivided thing occurring in the composition of something else._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C44278, C70990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/kg/d</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961414</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[GPL&#39;U]</VALIDVALUE>
          <VALUEMEANING>Anticardiolipin IgG Antibody Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>An IgG autoantibody directed against cardiolipin. It is associated with thrombosis, spontaneous abortion, and complications during labor._A single undivided thing occurring in the composition of something else.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278, C70990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/L{RBCs}</VALIDVALUE>
          <VALUEMEANING>Millimole per Liter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C64387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/(2.h)</VALIDVALUE>
          <VALUEMEANING>International Unit Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C48579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/m2</VALIDVALUE>
          <VALUEMEANING>Millimole Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/kg/d</VALIDVALUE>
          <VALUEMEANING>International Unit Per Kilogram Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C120844, C48579</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[MET].min/wk</VALIDVALUE>
          <VALUEMEANING>Metabolic Equivalent of Task Minute Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy expenditure equal to the number of metabolic equivalent units multiplied by the number of minutes of performed activity._Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069, C127807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/mmol{urea}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Millimole Urea</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 0.001 mole._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._A nitrogenous compound containing a carbonyl group attached to two amine groups with osmotic diuretic activity. In vivo, urea is formed in the liver via the urea cycle from ammonia and is the final end product of protein metabolism. Administration of urea elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain, cerebrospinal fluid and eye, into interstitial fluid and plasma, thereby decreasing pressure in those tissues and increasing urine outflow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29531, C48513, C65039, C48513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{binding_index}</VALIDVALUE>
          <VALUEMEANING>Binding Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>The action of attracting something and forming a bond with it._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C82888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{cells}/[HPF]</VALIDVALUE>
          <VALUEMEANING>Cell Count Per High Powered Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure to determine the number of cells in a sample._A unit of measure equal to the instances of an entity per visual field of a microscope set to its maximum magnification power.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96619, C48938</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961424</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/s/L</VALIDVALUE>
          <VALUEMEANING>Millimole per Second Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimoles per second._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C85723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{CH100&#39;U}</VALIDVALUE>
          <VALUEMEANING>Complement CH100 Measurement Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the amount of complement required to lyse 100 percent of red blood cells in a biological specimen._A single undivided thing occurring in the composition of something else.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278, C147317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mol/kg/s</VALIDVALUE>
          <VALUEMEANING>Mole per Kilogram Per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent._The number of occurrences of something within a second of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66965, C68740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{CPM}/10*3{cell}</VALIDVALUE>
          <VALUEMEANING>Count per Minute Per Thousand Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of frequency expressed as a number of events per minute._A unit of measure equal to the instances of an entity per 1000 cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116240, C73688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosm/dL</VALIDVALUE>
          <VALUEMEANING>Milliosmole Per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic pressure equal to one thousandth of osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate._A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105514, C67318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{delta_OD}</VALIDVALUE>
          <VALUEMEANING>Delta Optical Density Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in or difference between; usually represented by the 4th letter of the greek alphabet._A quantification of the amount of light that is absorbed by or transmitted through a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85776, C54126</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961430</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosm/mL</VALIDVALUE>
          <VALUEMEANING>Milliosmole Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of osmotic pressure equal to one thousandth of osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C67318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ms</VALIDVALUE>
          <VALUEMEANING>Millisecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to one thousandth of a second (10E-3 second).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ehrlich&#39;U}/(2.h)</VALIDVALUE>
          <VALUEMEANING>Ehrlich Unit Per Two Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to one milligram of urobilinogen per deciliter._For each, generally denoting a ratio._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66833, C65039, C96599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/g{Hb}</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C198369, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ehrlich&#39;U}/100.g</VALIDVALUE>
          <VALUEMEANING>Ehrlich Unit Per One Hundred Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to one milligram of urobilinogen per deciliter._For each, generally denoting a ratio._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155, C105814, C65039, C96599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/g{prot}</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Gram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C198369, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ehrlich&#39;U}/d</VALIDVALUE>
          <VALUEMEANING>Ehrlich Unit Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to one milligram of urobilinogen per deciliter._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C96599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Milligram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C28253, C65039, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ehrlich&#39;U}/dL</VALIDVALUE>
          <VALUEMEANING>Ehrlich Unit Per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to one milligram of urobilinogen per deciliter._A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105514, C96599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{EIA_index}</VALIDVALUE>
          <VALUEMEANING>Enzyme Immunoassay Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT)._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C17455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mg</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253, C65039, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{EIA_titer}</VALIDVALUE>
          <VALUEMEANING>Enzyme Immunoassay Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT)._Concentration of a substance in a solution as determined by the quantitative reaction with added measured volume(s) of a solution of the precisely known concentration(s) of a standard reagent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67454, C17455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mL/min</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Milliliter Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)_The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C103452, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{EIA&#39;U}/U</VALIDVALUE>
          <VALUEMEANING>Enzyme Immunoassay Per Enzyme Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT)._For each, generally denoting a ratio._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64778, C65039, C17455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{EV}</VALIDVALUE>
          <VALUEMEANING>Enzyme Immunoassay Value</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT)._A numerical quantity measured or assigned or computed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25712, C17455</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{GAA_repeats}</VALIDVALUE>
          <VALUEMEANING>Glioma-Associated Antigen Trinucleotide Repeat</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor associated antigen derived from the cell surface antigens expressed on glioma cells._No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94429, C129781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{genomes}/mL</VALIDVALUE>
          <VALUEMEANING>Genome Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The complete genomic content of an organism, and possibly the full DNA sequence of that organism. It is contained in a set of chromosomes in eukaryotes, a single chromosome in bacteria, or a DNA or RNA molecule in viruses._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C16629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961447</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mmol{RBCs}</VALIDVALUE>
          <VALUEMEANING>Milli Enzyme Unit Per Millimole Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A prefix indicating a quantity of one one-thousandth, 10E-3._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C48513, C65039, C64778, C48437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961448</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{IFA_index}</VALIDVALUE>
          <VALUEMEANING>Fluorescent Antibody Procedure Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunological procedure in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C17370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961449</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N.cm</VALIDVALUE>
          <VALUEMEANING>Newton Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of force. The force which, when applied in a vacuum to a body having a mass of one kilogram, causes an acceleration of one meter per second squared. It is equal to 10E5 dynes._A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49668, C42546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{IFA_titer}</VALIDVALUE>
          <VALUEMEANING>Fluorescent Antibody Procedure Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunological procedure in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells._Concentration of a substance in a solution as determined by the quantitative reaction with added measured volume(s) of a solution of the precisely known concentration(s) of a standard reagent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67454, C17370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N.s</VALIDVALUE>
          <VALUEMEANING>Newton Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of force. The force which, when applied in a vacuum to a body having a mass of one kilogram, causes an acceleration of one meter per second squared. It is equal to 10E5 dynes._A unit of time, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42535, C42546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{ImmuneComplex&#39;U}</VALIDVALUE>
          <VALUEMEANING>Immune Complex Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Protected against infectious disease by either specific or non-specific mechanisms._A molecular entity formed by loose association involving two or more component molecular entities. The bonding between the components is normally weaker than in a covalent bond._A single undivided thing occurring in the composition of something else.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278, C19398, C17997</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/10*6{RBCs}</VALIDVALUE>
          <VALUEMEANING>Nanogram Per Million Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._A unit equal to one million entities used as a denominator to build a derived unit expressed as a ratio._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C184719, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{JDF&#39;U}/L</VALIDVALUE>
          <VALUEMEANING>Juvenile Diabetes Foundation Unit Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure, defined by the Juvenile Diabetes Foundation, used to express the amount of islet cell antibodies in a biological sample; it is calculated by multiplying the titer by five._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C172606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/10*6</VALIDVALUE>
          <VALUEMEANING>Nanogram Per Million</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._A unit equal to one million entities used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184719, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Lyme_index_value}</VALIDVALUE>
          <VALUEMEANING>Borrelia Burgdorferi Antibody Measurement Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the amount of Borrelia burgdorferi antibody present in a sample._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C122098</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/g{creat}</VALIDVALUE>
          <VALUEMEANING>Microgram per Kilogram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C67396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{RBC}/uL</VALIDVALUE>
          <VALUEMEANING>Erythrocyte Per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans._A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67254, C12521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Nanogram per Kilogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass fraction expressed as a number of nanograms of a substance per kilogram of the mixture. The unit is also used as a dose calculation unit._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C67429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{spermatozoa}/mL</VALIDVALUE>
          <VALUEMEANING>Spermatozoa Cell Count Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the number of spermatozoa cells present in a sample._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C74663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961461</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/kg/h</VALIDVALUE>
          <VALUEMEANING>Nanogram per Kilogram Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass fraction expressed as a number of nanograms of a substance per kilogram of the mixture. The unit is also used as a dose calculation unit._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C67429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961462</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{TSI_index}</VALIDVALUE>
          <VALUEMEANING>Thyroid Stimulating Immunoglobulin Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoglobulin that can bind to thyrotropin receptors expressed on thyroid gland cells and stimulates excess secretion of the thyroid hormones thyroxine (T4) and triiodothyronine (T3)._A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368, C129780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*4/uL</VALIDVALUE>
          <VALUEMEANING>Ten Thousand Per Microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one._A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred._A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67254, C67234, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/m2</VALIDVALUE>
          <VALUEMEANING>Nanogram Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*5</VALIDVALUE>
          <VALUEMEANING>One Hundred Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234, C105814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mg/h</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6.[CFU]/L</VALIDVALUE>
          <VALUEMEANING>Million Colony Forming Units Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement of viable cell quantity equal to 10E6 colony forming units (10E6 CFU)._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C68896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Milligram per Kilogram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6/(24.h)</VALIDVALUE>
          <VALUEMEANING>Million Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 1000001 and the quantity that it denotes: one thousand thousands._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL{RBCs}</VALIDVALUE>
          <VALUEMEANING>Microgram per Liter Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*8</VALIDVALUE>
          <VALUEMEANING>One Hundred Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._A natural number following 999999 and preceding 1000001 and the quantity that it denotes: one thousand thousands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238, C105814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/U</VALIDVALUE>
          <VALUEMEANING>Nanogram Per Enzyme Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._For each, generally denoting a ratio._A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64778, C65039, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961473</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ag/{cell}</VALIDVALUE>
          <VALUEMEANING>Attogram Per Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one a quintillionth of a gram (10E-18 gram)._Natural number unit of measurement for a portion of a particular type of entities per one cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202454, C64553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng{FEU}/mL</VALIDVALUE>
          <VALUEMEANING>Nanogram Fibrinogen Equivalent Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram._A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C96649, C48516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm/m2</VALIDVALUE>
          <VALUEMEANING>Centimeter Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch._For each, generally denoting a ratio._A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42569, C65039, C49668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nm/s/L</VALIDVALUE>
          <VALUEMEANING>Nanometer Per Second Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of length equal to one billionth of a meter (10E-9 meter). Nanometer is used as a unit for light wavelength measurement._The number of occurrences of something within a second of time._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C66965, C67328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm[H2O]/s/m</VALIDVALUE>
          <VALUEMEANING>Centimeters of Water Per Second Per Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation._The number of occurrences of something within a second of time._For each, generally denoting a ratio._A unit of linear measure in the metric system, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). A meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41139, C65039, C66965, C91060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/dL{GF}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Deciliter Glomerular Filtration Rate</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one nanomole of solute in one deciliter of solution._A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman&#39;s capsule per unit of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90505, C198395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm2/s</VALIDVALUE>
          <VALUEMEANING>Square Centimeter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived metric unit of kinematic viscosity expressed as centimeters squared per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C204704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14920929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/g{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Gram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per gram._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C85752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL/day</VALIDVALUE>
          <VALUEMEANING>Deciliter Per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI._A frequency rate of occurrences of something within a period of time equal to twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66968, C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/h/L</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Hour Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C66966, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL/h</VALIDVALUE>
          <VALUEMEANING>Deciliter Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dL/min</VALIDVALUE>
          <VALUEMEANING>Deciliter Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The unit of volume equal to one tenth of a liter. Accepted for use with the SI._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C64697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/h/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Hour Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C66966, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eq/L</VALIDVALUE>
          <VALUEMEANING>Equivalent Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or thing equal to another in value or measure or force or effect or significance etc.; being essentially equal to something._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C48793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Liter Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C105515, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eq/mL</VALIDVALUE>
          <VALUEMEANING>Equivalent Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or thing equal to another in value or measure or force or effect or significance etc.; being essentially equal to something._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C48793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L{RBCs}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eq/mmol</VALIDVALUE>
          <VALUEMEANING>Equivalent Per Millimole</VALUEMEANING>
          <MEANINGDESCRIPTION>A person or thing equal to another in value or measure or force or effect or significance etc.; being essentially equal to something._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48513, C65039, C48793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/m/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Meter Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._For each, generally denoting a ratio._A unit of linear measure in the metric system, one of the seven base units of the International System of Units (Systeme International d&#39;Unites, SI). A meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C41139, C65039, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mg{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14913006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/mg{cyt_prot}</VALIDVALUE>
          <VALUEMEANING>Femtomole Per Milligram Cytosol Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole)._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._The aqueous part of the cytoplasm within which various particles and organelles are suspended._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C61554, C28253, C65039, C68854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mg{prot}/h</VALIDVALUE>
          <VALUEMEANING>Millimole per Kilogram Protein Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C17021, C68892</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Femtomole Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole)._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C68854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min/10*6{cells}</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Minute Per Million Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._The number of occurrences of something within a minute of time._For each, generally denoting a ratio._A unit of cell count expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67246, C65039, C66967, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fmol/mg</VALIDVALUE>
          <VALUEMEANING>Femtomole Per Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole)._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253, C65039, C68854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min/mg{Hb}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute Per Milligram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per minute._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C28253, C65039, C85758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(100.g)</VALIDVALUE>
          <VALUEMEANING>Gram Per Integer Gram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A number with no fractional part, including the negative and positive numbers as well as zero._The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155, C45255, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per minute._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C85758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/{specimen}</VALIDVALUE>
          <VALUEMEANING>Gram Per Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19157, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/{total_output}</VALIDVALUE>
          <VALUEMEANING>Gram Per Total Output</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Anything coming out of a system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47906, C25304, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/{total_weight}</VALIDVALUE>
          <VALUEMEANING>Gram Per Total Weight</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The vertical force exerted by a mass as a result of gravity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25208, C25304, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mol{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Mole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of fraction expressed as the ratio of the amount of a substance in solution, in nanomoles, to the amount of a different substance in the mixture, in moles._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C122220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg/(8.h)</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram Per Eight Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass._For each, generally denoting a ratio._A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one._A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529, C66839, C65039, C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/nmol</VALIDVALUE>
          <VALUEMEANING>Nanomole Per Nanomole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._For each, generally denoting a ratio._A unit of amount of substance equal to 10E-9 mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48517, C65039, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg/h</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram Per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass._A frequency rate of occurrences of something within a period of time equal to sixty minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66966, C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961507</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol{ATP}</VALIDVALUE>
          <VALUEMEANING>Nanomole Adenosine Triphosphate</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to 10E-9 mole._An adenine nucleotide comprised of three phosphate groups esterified to the sugar moiety, found in all living cells. Adenosine triphosphate is involved in energy production for metabolic processes and RNA synthesis.  In addition, this substance acts as a neurotransmitter.  In cancer studies, adenosine triphosphate is synthesized to examine its use to decrease weight loss and improve muscle strength.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209, C48517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg/min</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104, C66967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>osm/kg</VALIDVALUE>
          <VALUEMEANING>Osmole Per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of osmotic pressure equal to that of an ideal solution of a nondissociating substance that has a concentration of one mole of solute per liter of solution._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120844, C67330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/mg</VALIDVALUE>
          <VALUEMEANING>Gram Per Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253, C65039, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>osm/L</VALIDVALUE>
          <VALUEMEANING>Osmole Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-SI unit of osmotic pressure equal to that of an ideal solution of a nondissociating substance that has a concentration of one mole of solute per liter of solution._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C67330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g{creat}</VALIDVALUE>
          <VALUEMEANING>Gram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961513</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/{RBC}</VALIDVALUE>
          <VALUEMEANING>Picogram Per Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram)._For each, generally denoting a ratio._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C65039, C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g{Hb}</VALIDVALUE>
          <VALUEMEANING>Gram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mm</VALIDVALUE>
          <VALUEMEANING>Picogram Per Millimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram)._A unit of length equal to one millimeter that is used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C130188, C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961516</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g{total_nit}</VALIDVALUE>
          <VALUEMEANING>Gram Total Nitrogen</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._An element with atomic symbol N, atomic number 7, and atomic weight 14.01.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61863, C25304, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/{RBC}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Erythrocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._For each, generally denoting a ratio._A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12521, C65039, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g{total_prot}</VALIDVALUE>
          <VALUEMEANING>Gram Total Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C25304, C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/h/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Hour Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C66966, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>J/L</VALIDVALUE>
          <VALUEMEANING>Joule Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of electrical, mechanical, and thermal energy (as well as work and quantity of heat) in the SI system, equal to the work done when the point of application of a force of one newton is displaced through a distance of one meter in the direction of the force or the work done when a current of one ampere passes through a resistance of one ohm for one second. Joule is equal to 0.23889 gram-calorie (mean)._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C42548</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>k[IU]/mL</VALIDVALUE>
          <VALUEMEANING>Kilointernational Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one thousand international units._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C70492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kat/kg</VALIDVALUE>
          <VALUEMEANING>Katal Per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measuring catalytic (e.g. enzymatic) activity, the ability of the compound to accelerate the chemical reaction by providing a lower energy pathway between the reactants and the products. One katal is that catalytic activity which will raise the rate of reaction by one mole per second in a specified assay system. When the katal is used, the measurand should be specified by reference to the measurement procedure; the measurement procedure must identify the indicator reaction. The katal is not used to express a rate of reaction itself, which should be expressed in moles per second. Katal is coherent with the SI._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120844, C42566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961523</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/h/mL</VALIDVALUE>
          <VALUEMEANING>Picomole Per Hour Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C66966, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kat/L</VALIDVALUE>
          <VALUEMEANING>Katal Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measuring catalytic (e.g. enzymatic) activity, the ability of the compound to accelerate the chemical reaction by providing a lower energy pathway between the reactants and the products. One katal is that catalytic activity which will raise the rate of reaction by one mole per second in a specified assay system. When the katal is used, the measurand should be specified by reference to the measurement procedure; the measurement procedure must identify the indicator reaction. The katal is not used to express a rate of reaction itself, which should be expressed in moles per second. Katal is coherent with the SI._A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C42566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/min/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Minute Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._The number of occurrences of something within a minute of time._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C66967, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/min</VALIDVALUE>
          <VALUEMEANING>Picomole Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961528</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Millimole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._For each, generally denoting a ratio._A unit of amount of substance equal to 0.001 mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48513, C65039, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961529</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/umol{creat}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Micromole Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._For each, generally denoting a ratio._A unit of amount of substance equal to a millionth of a mole._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C48509, C65039, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961530</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/umol</VALIDVALUE>
          <VALUEMEANING>Picomole Per Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._For each, generally denoting a ratio._A unit of amount of substance equal to a millionth of a mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48509, C65039, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*6</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one million entities used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C184719, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/g{creat}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Gram Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C399, C198369, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/g{protein}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Gram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A unit equal to one gram used as a denominator to build a derived unit expressed as a ratio._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C198369, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/kg{Hb}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Kilogram Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio._The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16676, C120844, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/min</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals._The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967, C64778</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/H/mg{protein}</VALIDVALUE>
          <VALUEMEANING>Picomole Per Hour Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance equal to a trillionth (10E-12) of a mole._A frequency rate of occurrences of something within a period of time equal to sixty minutes._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C66966, C65045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{blocked}</VALIDVALUE>
          <VALUEMEANING>Percent Unit Block</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._Interrupt the normal function of; hinder or prevent the progress or accomplishment of; stop from happening or developing; interfere with or prevent the reception of signals; impede the movement of.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61286, C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/min/mg{protein}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Minute Per Milligram Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per minute._For each, generally denoting a ratio._A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021, C28253, C65039, C85758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14961499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{Hb}</VALIDVALUE>
          <VALUEMEANING>Percent of Total Hemoglobin</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for percentage measurement of any type or component of hemoglobin or its derivative such as methemoglobin; carboxyhemoglobin; sulfhemoglobin, etc. evaluated as fraction of total hemoglobin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{hemolysis}</VALIDVALUE>
          <VALUEMEANING>Percent Hemolysis</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{normal}</VALIDVALUE>
          <VALUEMEANING>Mean Percent of Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{positive}</VALIDVALUE>
          <VALUEMEANING>Percent of Positive Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantitative measurement of the proportion of cells that are positive for a given biomarker.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5338013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*12</VALIDVALUE>
          <VALUEMEANING>Part Per Trillion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-12.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[Ch]</VALIDVALUE>
          <VALUEMEANING>French Catheter Gauge</VALUEMEANING>
          <MEANINGDESCRIPTION>A number representing the outer diameter of a catheter where each integer represents 1/3 of a millimeter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5127065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[drp]</VALIDVALUE>
          <VALUEMEANING>Drop</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure of volume defined as the amount of liquid dispensed as one drop from a dropper dispenser. The volume of a drop depends on the physical properties of the liquid dispensed, the dispenser device, and the technique used to produce the drop.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/(24.h)</VALIDVALUE>
          <VALUEMEANING>International Unit per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>International units per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ppm]{v/v}</VALIDVALUE>
          <VALUEMEANING>Part per Million per Volume</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-6 per volumic unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92617</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/min</VALIDVALUE>
          <VALUEMEANING>Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of occurrences of something within a minute of time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{absorbance}</VALIDVALUE>
          <VALUEMEANING>Absorbance Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of optical density expressed as the absorbance of light transmitted through the medium on the logarithmic scale.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{activity}</VALIDVALUE>
          <VALUEMEANING>Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>An active process; excludes processes and mechanisms which fulfill biological functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4321086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{CPM}</VALIDVALUE>
          <VALUEMEANING>Count per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of frequency expressed as the detection rate of ionization events per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406728</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ct_value}</VALIDVALUE>
          <VALUEMEANING>Threshold Cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of signal amplification cycles at which the signal reaches an intensity above the background signal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{dilution}</VALIDVALUE>
          <VALUEMEANING>Dilute</VALUEMEANING>
          <MEANINGDESCRIPTION>To reduce in strength or concentration, especially by the addition of water.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3852202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Ehrlich&#39;U}</VALIDVALUE>
          <VALUEMEANING>Ehrlich Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to one milligram of urobilinogen per deciliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{EIA&#39;U}</VALIDVALUE>
          <VALUEMEANING>Enzyme Immunoassay Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme immunoassay method.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{ELISA&#39;U}</VALIDVALUE>
          <VALUEMEANING>Enzyme-Linked Immunosorbent Assay Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme-linked immunosorbent assay method. The enzyme-linked immunosorbent assay unit is used to express potency of immunologically active substances and products, e.g. vaccines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{FIU}</VALIDVALUE>
          <VALUEMEANING>Fluorescence Intensity Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure for the fluorescence intensity when the mathematic calculation is unspecified or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C163045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7241692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{fraction}</VALIDVALUE>
          <VALUEMEANING>Fraction</VALUEMEANING>
          <MEANINGDESCRIPTION>A part, a fragment of a whole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{index_val}</VALIDVALUE>
          <VALUEMEANING>Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{INR}</VALIDVALUE>
          <VALUEMEANING>International Normalized Ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2833109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Log}</VALIDVALUE>
          <VALUEMEANING>log10</VALUEMEANING>
          <MEANINGDESCRIPTION>The base 10 logarithmic value of argument X.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75941</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{mutation}</VALIDVALUE>
          <VALUEMEANING>Mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>A general term referring to single or multiple alterations in the genetic material of an organism that ranges from a single base change in a gene to the loss or addition of complete chromosomes. A mutation abnormality may be heritable or occur somatically.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3874311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{phenotype}</VALIDVALUE>
          <VALUEMEANING>Phenotype</VALUEMEANING>
          <MEANINGDESCRIPTION>The assemblage of traits or outward appearance of an individual. It is the product of interactions between genes and between genes and the environment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16977</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{risk}</VALIDVALUE>
          <VALUEMEANING>Risk</VALUEMEANING>
          <MEANINGDESCRIPTION>The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Rubella_virus}</VALIDVALUE>
          <VALUEMEANING>Rubella Virus</VALUEMEANING>
          <MEANINGDESCRIPTION>An enveloped, positive sense single-stranded RNA virus that is the causative agent of Rubella (German Measles).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{s_co_ratio}</VALIDVALUE>
          <VALUEMEANING>Signal to Cutoff Ratio Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>A relative measurement (ratio) of the signal strength of a pre-specified analyte in a specimen to the signal strength of an internal cutoff standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{saturation}</VALIDVALUE>
          <VALUEMEANING>Saturation</VALUEMEANING>
          <MEANINGDESCRIPTION>Impregnation of one substance by another to the greatest possible extent; that concentration of a dissolved substance that cannot be exceeded.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{score}</VALIDVALUE>
          <VALUEMEANING>Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3566833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{shift}</VALIDVALUE>
          <VALUEMEANING>Physical Shift</VALUEMEANING>
          <MEANINGDESCRIPTION>A physical movement from one place to another.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{STDV}</VALIDVALUE>
          <VALUEMEANING>Standard deviation</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the range of values in a set of numbers. Standard deviation is a statistic used as a measure of the dispersion or variation in a distribution, equal to the square root of the arithmetic mean of the squares of the deviations from the arithmetic mean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{TmStp}</VALIDVALUE>
          <VALUEMEANING>Computer Time Stamp</VALUEMEANING>
          <MEANINGDESCRIPTION>The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Tscore}</VALIDVALUE>
          <VALUEMEANING>T-Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14981884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{WBCs}</VALIDVALUE>
          <VALUEMEANING>Leukocyte</VALUEMEANING>
          <MEANINGDESCRIPTION>Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{yyyy}</VALIDVALUE>
          <VALUEMEANING>Year</VALUEMEANING>
          <MEANINGDESCRIPTION>The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29848</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2670939</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Zscore}</VALIDVALUE>
          <VALUEMEANING>Z-Score</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates how far and in what direction an item deviates from its distribution&#39;s mean, expressed in units of its distribution&#39;s standard deviation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2915866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*6/mL</VALIDVALUE>
          <VALUEMEANING>Million Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one milliliter of mixture contains one million units of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2721395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24.h</VALIDVALUE>
          <VALUEMEANING>Day</VALUEMEANING>
          <MEANINGDESCRIPTION>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>d/(7.d)</VALIDVALUE>
          <VALUEMEANING>Days Per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measurement equal to the number of days within a period of time equal to one week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C170633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/(24.h)</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy equal to one kilocalorie per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6352129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mL</VALIDVALUE>
          <VALUEMEANING>Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2724566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/(24.h)</VALIDVALUE>
          <VALUEMEANING>Nanogram per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanograms per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85741</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/(24.h)</VALIDVALUE>
          <VALUEMEANING>Nanomole per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomoles per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/(24.h)</VALIDVALUE>
          <VALUEMEANING>Picomole per Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of amount of substance flow rate equivalent to the rate at which one picomole of substance travels to a given object or space over a period of time equal to 24 hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/d</VALIDVALUE>
          <VALUEMEANING>Unit per 24 Hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of an activity rate expressed as a number of substance units which crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours. This unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Millimole Per Mole of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration defined as the concentration of millimoles of solute per mole of creatinine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UN</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uU/L</VALIDVALUE>
          <VALUEMEANING>Micro-Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in microunit(s) per liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>uU/mL</VALIDVALUE>
          <VALUEMEANING>Microunit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance concentration equal to the concentration at which one milliliter of mixture contains one millionth of a unit of a substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2719294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{index}</VALIDVALUE>
          <VALUEMEANING>Index Value</VALUEMEANING>
          <MEANINGDESCRIPTION>A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2718874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{basal_activity}</VALIDVALUE>
          <VALUEMEANING>Percent Basal Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>The rate of basal activity expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{breakdown}</VALIDVALUE>
          <VALUEMEANING>Percent Breakdown</VALUEMEANING>
          <MEANINGDESCRIPTION>The relative concentration of a substance in an initial state to the amount of substance that has undergone chemical or physical decomposition, expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207810</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{deficient}</VALIDVALUE>
          <VALUEMEANING>Percent Deficient</VALUEMEANING>
          <MEANINGDESCRIPTION>The measure of something compared to a standard or target amount, expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{loss_AChR}</VALIDVALUE>
          <VALUEMEANING>Percent Loss of Acetylcholine Receptor</VALUEMEANING>
          <MEANINGDESCRIPTION>The relative concentration of acetylcholine receptors in a sample to the amount of acetylcholine concentration from a standard sample, expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{penetration}</VALIDVALUE>
          <VALUEMEANING>Percent Penetration</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure dependent on the ratio of indicators in a sample to the number of indicators in the general population, expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{pooled_plasma}</VALIDVALUE>
          <VALUEMEANING>Percent Normal Pooled Plasma</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure dependent on the ratio of components in a sample to components in pooled normal plasma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{reference}</VALIDVALUE>
          <VALUEMEANING>Percent Reference</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure dependent on the ratio of a material in a sample compared to the amount in a reference sample, expressed as a percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207818</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%{viable}</VALIDVALUE>
          <VALUEMEANING>Percent Viable</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the number viable cells in a sample, expressed as a percentage of all cells in the sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/{OIF}</VALIDVALUE>
          <VALUEMEANING>Per Oil Immersion Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to the instances of an entity per visual field of a microscope using an oil-immersion lens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207865</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*10</VALIDVALUE>
          <VALUEMEANING>Part Per Billion</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of proportion equal to 10E-9.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/10*12{RBCs}</VALIDVALUE>
          <VALUEMEANING>Unit per Trillion Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in units of biological activity per ten to the twelfth power red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/g{wet_tis}</VALIDVALUE>
          <VALUEMEANING>Per Gram Of Wet Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>An expression with an unspecified numerator where the denominator is one gram of wet tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[APL&#39;U]/mL</VALIDVALUE>
          <VALUEMEANING>IgA Anticardiolipin Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of IgA anticardiolipin units per milliliter of liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ft_us]/[ft_us]</VALIDVALUE>
          <VALUEMEANING>Feet per Feet</VALUEMEANING>
          <MEANINGDESCRIPTION>An expression of length per length in US Feet, which can be used to express ratios of other values (e.g. numerical coefficients).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207941</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[in_i&#39;H2O]</VALIDVALUE>
          <VALUEMEANING>International Inch of Water</VALUEMEANING>
          <MEANINGDESCRIPTION>The measurement of the static pressure of a column of water under defined conditions, expressed in international inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/10*9{RBCs}</VALIDVALUE>
          <VALUEMEANING>International Unit per Billion Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio defined as the number of International Units of catalytic activity per billion red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207899</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[IU]/L{37Cel}</VALIDVALUE>
          <VALUEMEANING>International Unit per Liter at 37 Degrees Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio defined as the number of International Units of catalytic activity per liter at 37 degrees Celsius.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[mclg&#39;U]</VALIDVALUE>
          <VALUEMEANING>Maclagan Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure initially used in the determination of the degree of liver dysfunction based on the thymol turbidity test and relative optical densities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[PRU]</VALIDVALUE>
          <VALUEMEANING>Systemic Vascular Resistance Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure used to quantify the relationship between systemic vascular resistance, blood flow, and blood pressure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[todd&#39;U]</VALIDVALUE>
          <VALUEMEANING>Todd Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure used in the determination of the concentration of antibodies to streptolysin O.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{AHF&#39;U}</VALIDVALUE>
          <VALUEMEANING>American Hospital Formulary Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity defined by the American Hospital Formulary Service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207908</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{APS&#39;U}</VALIDVALUE>
          <VALUEMEANING>Phosphatidylserine IgA Antibody Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{ARU}</VALIDVALUE>
          <VALUEMEANING>Aspirin Response Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure used in the determination of the degree of platelet inhibition resulting from aspirin therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207907</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{CAG_repeats}</VALIDVALUE>
          <VALUEMEANING>Number of CAG Repeats</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantitative assessment of the number of repeating genetic sequences made up of cytosine, adenine, and guanine trinucleotides.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Globules}/[HPF]</VALIDVALUE>
          <VALUEMEANING>Globules per High Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of liquid globes in a sample that are contained in one field of a light microscope set to its maximum magnification.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{HA_titer}</VALIDVALUE>
          <VALUEMEANING>Influenza Hemagglutination Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>A canonical measurement expressed as a ratio that is dependent on the relative presence of influenza surface bound hemagglutinin glycoprotein and its ability to bind red blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{ISR}</VALIDVALUE>
          <VALUEMEANING>Immunological Status Ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio defined by the optical density of the tested sample to a predetermined cutoff value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{KCT&#39;U}</VALIDVALUE>
          <VALUEMEANING>Kaolin Clotting Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of activated partial thromboplastin time in which kaolin is the activator. It is often used in the detection of lupus anticoagulants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{KRONU&#39;U}/mL</VALIDVALUE>
          <VALUEMEANING>Kronus Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure expressed as one Kronus unit per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Log_IU}</VALIDVALUE>
          <VALUEMEANING>Log Base 10 International Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The base 10 logarithm of the International Unit (IU), a unit of measure of biologically active substances. The IU varies from substance to substance and is established by international agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{minidrop}/min</VALIDVALUE>
          <VALUEMEANING>Minidrop per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio of volume per unit time expressed as a minidrop per minute, which is dependent on the viscosity of the fluid and the resistance to flow, as well as the type of flow (laminar vs. turbulent flow).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207920</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{minidrop}/s</VALIDVALUE>
          <VALUEMEANING>Minidrop per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio of volume per unit time expressed as a minidrop per second. A minidrop is often understood to be 1/60 ml, though there are several ratios (volume/time) commercially available as intravenous infusion kits. The size of the minidrop is dependent on the viscosity of the fluid, resistance to flow, and the type of flow (laminar vs. turbulent flow).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207921</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{Pan_Bio&#39;U}</VALIDVALUE>
          <VALUEMEANING>Panbio Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary unit of measure trademarked by Abbott Laboratories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207922</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{rel_saturation}</VALIDVALUE>
          <VALUEMEANING>Relative Saturation</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the amount of water and hydrogen peroxide vapor in a gas, expressed as a ratio of the theoretical maximum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10*9/mL</VALIDVALUE>
          <VALUEMEANING>Billion per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A ratio of a number per unit volume expressed as billion per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207928</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10.uN.s/(cm5.m2)</VALIDVALUE>
          <VALUEMEANING>10 Micronewton Second Per Centimeter To The Fifth Power Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of kinematic viscosity expressed as micronewtons seconds per centimeter to the fifth power per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207930</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cSt</VALIDVALUE>
          <VALUEMEANING>Centistoke</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of kinematic viscosity that is equivalent to one hundredth of a stoke.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207931</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>daL/min/m2</VALIDVALUE>
          <VALUEMEANING>Dekaliter Per Minute Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of flow per area, equivalent to ten liters per minute per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207932</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>daL/min</VALIDVALUE>
          <VALUEMEANING>Dekaliter Per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of flow equivalent to ten liters per minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207934</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dm2/s2</VALIDVALUE>
          <VALUEMEANING>Square Decimeter Per Square Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of kinematic viscosity that is expressed as decimeters squared per second squared.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207935</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dyn.s/(cm.m2)</VALIDVALUE>
          <VALUEMEANING>Dyne Second Per Centimeter Per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived CGS unit of pressure/area, often used as a dynamic viscosity unit , expressed as dyne seconds per centimeter per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>dyn.s/cm</VALIDVALUE>
          <VALUEMEANING>Dyne Second Per Centimeter</VALUEMEANING>
          <MEANINGDESCRIPTION>A derived CGS unit of measurement equal to one dyne second per centimeter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207937</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[APL&#39;U]</VALIDVALUE>
          <VALUEMEANING>IgA Anticardiolipin Unit per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of IgA anticardiolipin units per milliliter of liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15017365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[bdsk&#39;U]</VALIDVALUE>
          <VALUEMEANING>Bodansky Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of alkaline phosphatase concentration in blood. It is defined as the quantity of alkaline phosphatase that releases 1 mg of phosphate ion during the first hour of incubation with a buffered substrate containing sodium beta-glycerophosphate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042348</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[ka&#39;U]</VALIDVALUE>
          <VALUEMEANING>King-Armstrong Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of alkaline phosphatase concentration in blood, defined as amount of phosphatase that releases 1 mg phenol from disodium phenylphosphate at pH 10 and 37 degrees Celsius in 15 minutes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208418</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>[knk&#39;U]</VALIDVALUE>
          <VALUEMEANING>Kunkel Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary biologic activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g.m/{beat}</VALIDVALUE>
          <VALUEMEANING>Gram-meter per Beat</VALUEMEANING>
          <MEANINGDESCRIPTION>An expression of the force (work) of a heart beat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g.m</VALIDVALUE>
          <VALUEMEANING>Gram-meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing cardiac ventricular work, equivalent to the force needed to lift one gram one meter vertically against gravity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/(8.h){shift}</VALIDVALUE>
          <VALUEMEANING>Gram per 8-hour Shift</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose administration rate unit equal to the rate at which one gram of a product is delivered or administered over an 8-hour period.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/kg/(8.h){shift}</VALIDVALUE>
          <VALUEMEANING>Gram per Kilogram per 8-hour Shift</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose administration rate unit equal to the rate at which one gram of a product per kilogram of body mass is delivered or administered over an 8-hour period.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042354</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g{wet_tissue}</VALIDVALUE>
          <VALUEMEANING>Gram of Wet Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the mass of a wet tissue sample in grams.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K/W</VALIDVALUE>
          <VALUEMEANING>Kelvin per Watt</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI unit of thermal resistance. It measures the opposition to the heat movement in a material or system. It is measured in units of degrees Kelvin per watt (K/W) and indicates how much temperature difference is required to transfer a unit of heat current through a material or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042356</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/[oz_av]</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Ounce</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the calorie content in an ounce of food.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/dL</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A measurement of the calorie content in a deciliter of food.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208437</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/h</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the amount of energy released in an hour, expressed in kilocalories.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/kg/(24.h)</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Kilogram per 24 Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the amount of energy added to a system in 24 hours, expressed as a ratio to the kilogram mass of the system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kcal/kg</VALIDVALUE>
          <VALUEMEANING>Kilocalorie per Kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of energy expressed as kilocalories per kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208435</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kL</VALIDVALUE>
          <VALUEMEANING>Cubic Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI unit of volume or capacity equal to the volume of a cube with edges one meter in length. It is equal to 1,000 liters; 1,000 cubic decimeters; 10(e+6) cubic centimeters; 25.3 cubic feet; 6.29 barrels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L{class}</VALIDVALUE>
          <VALUEMEANING>Kiloenzyme Unit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of catalytic activity expressed as 1000 enzyme units per liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/s/s2</VALIDVALUE>
          <VALUEMEANING>Liter per Second per Square Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of rate change expressed as liter per second per second squared.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042363</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mbar.s/L</VALIDVALUE>
          <VALUEMEANING>Millibar per Liter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of pressure change defined as a drop within a liter volume of 1 mbar per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mbar/L/s</VALIDVALUE>
          <VALUEMEANING>Millibar per Liter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of pressure change defined as a drop within a liter volume of 1 mbar per second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208454</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042364</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mbar</VALIDVALUE>
          <VALUEMEANING>Millibar</VALUEMEANING>
          <MEANINGDESCRIPTION>A centimeter-gram-second (cgs) unit of atmospheric pressure equivalent to 100 pascals.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/d/{1.73_m2}</VALIDVALUE>
          <VALUEMEANING>Milligram per Day per 1.73 Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milligram(s) per twenty-four hours per 1.73 square meters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g{dry_tissue}</VALIDVALUE>
          <VALUEMEANING>Milligram per Gram of Dry Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as the number of milligrams per gram of dry tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g{wet_tissue}</VALIDVALUE>
          <VALUEMEANING>Milligram per Gram of Wet Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as the number of milligrams per gram of wet tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/[sin_i]</VALIDVALUE>
          <VALUEMEANING>Milliliter per Square Inch (International)</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of measure equal to the number of milliliters per international square inch.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208456</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/{beat}/m2</VALIDVALUE>
          <VALUEMEANING>Milliliter per Heart Beat per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of ventricular stroke volume expressed as milliliter per heart beat per square meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/mbar</VALIDVALUE>
          <VALUEMEANING>Milliliter per Millibar</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of dynamic lung compliance expressed as milliliters per millibar.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ms</VALIDVALUE>
          <VALUEMEANING>Megasecond</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of time equal to 10E6 seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/g{dry_wt}</VALIDVALUE>
          <VALUEMEANING>Nanomole per Gram of Dry Weight</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as the number of nanomoles per gram of dry weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol{1/2cys}/mg{prot}</VALIDVALUE>
          <VALUEMEANING>Nanomole of 1/2 Cystine per Milligram of Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of 1/2 cystine concentration expressed as nanomole of 1/2 cystine per milligram of protein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol{BCE}/mmol{creat}</VALIDVALUE>
          <VALUEMEANING>Nanomole Bone Collagen Equivalent per Millimole of Creatinine</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the ratio of bone collagen equivalent, in nanomoles, compared to creatinine, in millimoles, present in a sample. The measurement may be expressed as a ratio or percentage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208476</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol{BCE}</VALIDVALUE>
          <VALUEMEANING>Nanomole Bone Collagen Equivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>The mass of bone collagen equivalent in a sample, expressed in nanomoles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042376</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nU/{RBC}</VALIDVALUE>
          <VALUEMEANING>Nanoenzyme Unit per Red Blood Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>The concentration of an enzyme activity expressed per red blood cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208462</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ohm.m</VALIDVALUE>
          <VALUEMEANING>Ohm Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>The SI unit of electrical resistivity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208479</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mL{sLT}</VALIDVALUE>
          <VALUEMEANING>Picogram per Milliliter Sulfidoleukotrienes</VALUEMEANING>
          <MEANINGDESCRIPTION>The concentration of sulfidoleukotrienes expressed as picograms per milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pT</VALIDVALUE>
          <VALUEMEANING>Picotesla</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of magnetic flux density equal to equal to 10E-12 tesla.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>s/{control}</VALIDVALUE>
          <VALUEMEANING>Second per Control</VALUEMEANING>
          <MEANINGDESCRIPTION>The time for something to happen expressed as a ratio to some control step.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/(10.g){feces}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per 10 Grams of Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per 10 grams of feces.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042382</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*10{cells}</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per 10 Billion Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per 10 billion cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*10</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per 10 Billion</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per 10 billion units of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*12</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Trillion</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per trillion units of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U/10*9</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Billion</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per billion units of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U{25Cel}/L</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Liter at 25 Degrees Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per liter at 25 degrees Celsius.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>U{37Cel}/L</VALIDVALUE>
          <VALUEMEANING>Enzyme Unit per Liter at 37 Degrees Celsius</VALUEMEANING>
          <MEANINGDESCRIPTION>An enzyme activity expressed per liter at 37 degrees Celsius.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/[sft_i]</VALIDVALUE>
          <VALUEMEANING>Microgram per Square Foot (International)</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as micrograms per international square foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{dry_tissue}</VALIDVALUE>
          <VALUEMEANING>Microgram per Gram of Dry Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as micrograms per gram of dry tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/g{dry_wt}</VALIDVALUE>
          <VALUEMEANING>Microgram per Gram of Dry Weight</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of substance concentration expressed as micrograms per gram dry weight of sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C208466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL{class}</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14902183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{#}/{platelet}</VALIDVALUE>
          <VALUEMEANING>Number Per Platelet</VALUEMEANING>
          <MEANINGDESCRIPTION>A numeral or string of numerals expressing value, quantity, or identification._For each, generally denoting a ratio._An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12520, C65039, C25337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15042422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>{clock_time}</VALIDVALUE>
          <VALUEMEANING>Clock Device Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A representation of time as measured by a clock device, e.g., 12:30PM.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C207913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm[H2O]/L/s</VALIDVALUE>
          <VALUEMEANING>Centimeter of Water per Liter per Second</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined as centimeters of water per unit of volume equal to one liter per unit of time equal to one second.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>eq/umol</VALIDVALUE>
          <VALUEMEANING>Equivalent per Micromole</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of an equivalent weight per micromole of substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/h/m2</VALIDVALUE>
          <VALUEMEANING>Gram per Hour per Square Meter</VALUEMEANING>
          <MEANINGDESCRIPTION>A representation of mass flux density in the International System of Units. It is the amount of fluid passing through the surface of one square meter at a rate of one gram per hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/dL{RBCs}</VALIDVALUE>
          <VALUEMEANING>Microgram per Deciliter of Red Blood Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A representation of the mass density of red blood cells, in micrograms, in one deciliter of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>umol/10*6{RBC}</VALIDVALUE>
          <VALUEMEANING>Micromole per Million Red Blood Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A representation of the molar concentration of one million red blood cells expressed in micromoles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Observation General Result Unit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Obs Gen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OBSGEN_RESULT_UNIT</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OBS_GEN</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="984">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14764924</PUBLICID>
    <LONGNAME>Health Status Assessment Clinical General Qualifier Data Source Data Value Type</LONGNAME>
    <PREFERREDNAME>14764264v1.00:14966730v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>An appraisal or evaluation of a patient&#39;s condition by a clinician that is based on a physical exam, medical history, and the patient&#39;s account of symptoms.:The act, by a healthcare worker, of monitoring an identified subject and recording signs, symptoms, or behavior._An outcome of observation represented as a text, qualitative, or quantitative parameter, code, image, graph, etc._A term that helps define and render a concept unique._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.:Something distinguishable as an identifiable class based on common qualities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCORNet CDM:The Patient-Centered Outcomes Research Network Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14764264</PublicId>
      <PreferredName>14936166v1.00:14986631v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._A term that helps define and render another concept unique._The person or authoritative body who provided the information._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.</PreferredDefinition>
      <LongName>Health Status Assessment Clinical General Qualifier Data Source Data Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14986631</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C27993:C16493:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Clinical General Qualifier Data Source Data Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27993</PREFERRED_NAME>
            <LONG_NAME>General Qualifier</LONG_NAME>
            <CON_ID>10061084</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16493</PREFERRED_NAME>
            <LONG_NAME>Data Source</LONG_NAME>
            <CON_ID>2223421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14966730</PublicId>
      <PreferredName>14966730v1.00</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>SAS Char</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Raw Observation Clinical Modifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522553</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PCORnet CDM 6.1</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Obs Clin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RAW_OBSCLIN_MODIFIER</AlternateName>
        <AlternateNameType>PCORNet Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OBS_CLIN</AlternateName>
        <AlternateNameType>PCORnet Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="985">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14846195</PUBLICID>
    <LONGNAME>Health Insurance Sponsor Data Source Data Value Code OMOP Concept Identifier</LONGNAME>
    <PREFERREDNAME>14846103v1.00:14986466v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A type of insurance designed to cover some of or all the cost of treating an insured person&#39;s illnesses or injuries. In some cases, it pays for preventive care, such as annual physicals and diagnostic tests.:A person or organization that supports or champions something._The person or authoritative body who provided the information._A character or string that represents the information contained in a data field.:An identifier assigned to an external vocabulary item when it has been transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). It is an integer ID that is used to record data in the CDM event tables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMOP CDM:The Observational Medical Outcomes Partnership (OMOP) Common Data Model</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14846103</PublicId>
      <PreferredName>14635915v1.00:14846102v1.00</PreferredName>
      <PreferredDefinition>A type of insurance designed to cover some of or all the cost of treating an insured person&#39;s illnesses or injuries. In some cases, it pays for preventive care, such as annual physicals and diagnostic tests.:A person or organization that supports or champions something._The person or authoritative body who provided the information._A character or string that represents the information contained in a data field.</PreferredDefinition>
      <LongName>Health Insurance Sponsor Data Source Data Value Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008540</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PYMT_METH</PreferredName>
        <Version>1</Version>
        <LongName>Payment Methods</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14635915</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C157356</PreferredName>
        <Version>1</Version>
        <LongName>Health Insurance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C157356</PREFERRED_NAME>
            <LONG_NAME>Health Insurance</LONG_NAME>
            <CON_ID>6618775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14846102</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48355:C16493:C117373</PreferredName>
        <Version>1</Version>
        <LongName>Sponsor Data Source Data Value Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48355</PREFERRED_NAME>
            <LONG_NAME>Sponsor</LONG_NAME>
            <CON_ID>2448403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16493</PREFERRED_NAME>
            <LONG_NAME>Data Source</LONG_NAME>
            <CON_ID>2223421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C117373</PREFERRED_NAME>
            <LONG_NAME>Data Value Code</LONG_NAME>
            <CON_ID>10012763</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14986466</PublicId>
      <PreferredName>14986466v1.00</PreferredName>
      <PreferredDefinition>An identifier assigned to an external vocabulary item when it has been transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). It is an integer ID that is used to record data in the CDM event tables._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>OMOP Concept Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>14986465</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14986465v1.00</PreferredName>
        <Version>1</Version>
        <LongName>OMOP Concept Identifier Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205058</PREFERRED_NAME>
            <LONG_NAME>OMOP Concept Identifier</LONG_NAME>
            <CON_ID>14931547</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sponsor Source Concept Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>etlConventions</Name>
        <OrganizationName/>
        <DocumentType>OMOP CDM ETL Conventions</DocumentType>
        <DocumentText>If the source data codes the sponsor in an OMOP supported vocabulary store the concept_id here.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>14522466</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMOP 5.4</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Payer Plan Period</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Table</ClassificationSchemeItemType>
        <CsiPublicId>14522490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>sponsor_source_concept_id</AlternateName>
        <AlternateNameType>OMOP Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PAYER_PLAN_PERIOD</AlternateName>
        <AlternateNameType>OMOP Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="986">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14846483</PUBLICID>
    <LONGNAME>T-Lymphocyte Harvest Procedure Sufficient Indicator</LONGNAME>
    <PREFERREDNAME>TCELL_HVST_SUFF_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the t-lymphocyte harvest procedure was sufficient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14846482</PublicId>
      <PreferredName>14846481v1.00:7992075v1.00</PreferredName>
      <PreferredDefinition>A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._Remove from a culture or a living or dead body, as for the purposes of transplantation.:Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation.</PreferredDefinition>
      <LongName>T-Lymphocyte Harvest Procedure Sufficient</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14846481</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12476:C37963</PreferredName>
        <Version>1</Version>
        <LongName>T-Lymphocyte Harvest Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12476</PREFERRED_NAME>
            <LONG_NAME>T-Lymphocyte</LONG_NAME>
            <CON_ID>2529672</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37963</PREFERRED_NAME>
            <LONG_NAME>Harvest Procedure</LONG_NAME>
            <CON_ID>2202648</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7992075</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63351</PreferredName>
        <Version>1</Version>
        <LongName>Sufficient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63351</PREFERRED_NAME>
            <LONG_NAME>Sufficient</LONG_NAME>
            <CON_ID>2538604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the t-lymphocyte harvest procedure sufficient?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was T-cell collection sufficient per local standard?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPPR_QVAL_TCELLCOLLSUFF</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="987">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>14951012</PUBLICID>
    <LONGNAME>SDoH Health Status Assessment Food Insecurity Questionnaire Past Year Hungry and Didn&#39;t Eat Because Couldn&#39;t Afford Food Yes No Don&#39;t Know Response Declined Indicator Code</LONGNAME>
    <PREFERREDNAME>14950986v1.00:14950948v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s indication within the last 12 months, whether they were hungry but didn&#39;t eat because they couldn&#39;t afford enough food.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14950986</PublicId>
      <PreferredName>14948144v1.00:14950985v1.00</PreferredName>
      <PreferredDefinition>The conditions in which people are born, grow, live, work and age. They include socioeconomic status, education, neighborhood and physical environment, employment, and social support networks, as well as access to health care._Assessments of health-related matters of interest, importance, or worry to a patient, patient’s family, or patient’s healthcare provider that could identify a need, problem, or condition.:An interviewer-administered six-item questionnaire designed to assess an individual&#39;s or family&#39;s access to food, ability to purchase food, and food quality and quantity. It is derived from the US Department of Agriculture (USDA) Economic Research Service&#39;s Food Security Module in the United States._A period of time consisting of the 12 months before the present._A question about whether an individual did not eat because they could not afford food.</PreferredDefinition>
      <LongName>Social Determinants of Health Health Status Assessment Food Insecurity Questionnaire Past Year Hungry and Didn&#39;t Eat Because Couldn&#39;t Afford Food</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14948144</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C171586:C205784</PreferredName>
        <Version>1</Version>
        <LongName>Social Determinants of Health Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C171586</PREFERRED_NAME>
            <LONG_NAME>Social Determinants of Health</LONG_NAME>
            <CON_ID>7277069</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>14950985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C206406:C125217:C205511</PreferredName>
        <Version>1</Version>
        <LongName>Food Insecurity Questionnaire Past Year Hungry and Didn&#39;t Eat Because Couldn&#39;t Afford Food</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C206406</PREFERRED_NAME>
            <LONG_NAME>Food Insecurity Questionnaire</LONG_NAME>
            <CON_ID>14948112</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125217</PREFERRED_NAME>
            <LONG_NAME>Past Year</LONG_NAME>
            <CON_ID>5108191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205511</PREFERRED_NAME>
            <LONG_NAME>Hungry and Didn&#39;t Eat Because Couldn&#39;t Afford Food Question</LONG_NAME>
            <CON_ID>14908769</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>14950948</PublicId>
      <PreferredName>14950948v1.00</PreferredName>
      <PreferredDefinition>The affirmative response to a question._The non-affirmative response to a question._The answer is not known by the person answering._Used to indicate when a respondent makes a decision to not answer a question._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>Yes No Does Not Know Response Declined Indicator Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>14943857</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14943857v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Does Not Know Response Declined Indicator Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67142</PREFERRED_NAME>
            <LONG_NAME>Does Not Know</LONG_NAME>
            <CON_ID>2653836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51024</PREFERRED_NAME>
            <LONG_NAME>Response Declined</LONG_NAME>
            <CON_ID>2435356</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refused</VALIDVALUE>
          <VALUEMEANING>Declined to answer</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate when a respondent makes a decision to not answer a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51024</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5936254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t Know</VALIDVALUE>
          <VALUEMEANING>Does Not Know</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12387697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14599624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6594241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DK</VALIDVALUE>
          <VALUEMEANING>Does Not Know</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12387697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In the last 12 months, were you ever hungry but didn&#39;t eat because there wasn&#39;t enough money for food?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Food Insecurity Protocol Question Number</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Q5</DocumentText>
        <URL>https://www.phenxtoolkit.org/protocols/view/270301?origin=subcollection</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Food Insecurity Protocol CDE</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>CDE represents a question appearing on the PhenX Toolkit Food Insecurity Protocol.</DocumentText>
        <URL>https://www.phenxtoolkit.org/protocols/view/270301?origin=subcollection</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Food Insecurity</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14946985</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="988">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15005632</PUBLICID>
    <LONGNAME>Person Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact Count</LONGNAME>
    <PREFERREDNAME>15005631v1.00:7069460v2.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A human being.:The number of days from the date of initial cancer diagnosis to the date of last contact.:To determine the number or amount of something; the result of this activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>TCIA:TheCancerImagingArchive</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15005631</PublicId>
      <PreferredName>2236731v1.00:6848744v1.00</PreferredName>
      <PreferredDefinition>A human being.:The number of days from the date of initial cancer diagnosis to the date of last contact.</PreferredDefinition>
      <LongName>Person Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>6848744</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156918</PreferredName>
        <Version>1</Version>
        <LongName>Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156918</PREFERRED_NAME>
            <LONG_NAME>Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact</LONG_NAME>
            <CON_ID>6848743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCIA:TheCancerImagingArchive</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7069460</PublicId>
      <PreferredName>7069460v2.00</PreferredName>
      <PreferredDefinition>To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>day</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Days from Initial Diagnosis to Last Contact</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6305258</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TCIA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Yale Glioma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14928803</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>Days from Initial Diagnosis to Last Contact</AlternateName>
        <AlternateNameType>TCIA Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="989">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15020128</PUBLICID>
    <LONGNAME>Cytogenetic Abnormality Present Number</LONGNAME>
    <PREFERREDNAME>2459197v1.00:15020125v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of cytogenetic abnormalities that were present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2459197</PublicId>
      <PreferredName>CYTOABNOR_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.</PreferredDefinition>
      <LongName>Cytogenetic Abnormality Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2459195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2950</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetic Abnormality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2950</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Abnormality</LONG_NAME>
            <CON_ID>2459194</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15020125</PublicId>
      <PreferredName>15020125v1.00</PreferredName>
      <PreferredDefinition>A finding indicating the presence of cytogenetic abnormalities in a sample._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Cytogenetic Abnormalities Present Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3910</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Abnormality</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>15020124</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15020124v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetic Abnormalities Present Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C186452</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Abnormalities Present</LONG_NAME>
            <CON_ID>10055561</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;5</VALIDVALUE>
          <VALUEMEANING>Greater Than Five</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3 - 5</VALIDVALUE>
          <VALUEMEANING>Three To Five</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._Used as a function word to indicate direction, purpose, or movement._A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65107, C66836, C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15020127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;3</VALIDVALUE>
          <VALUEMEANING>Less Than Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834, C61585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15020126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What were the number of cytogenetic abnormalities present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify number of cytogenetic abnormalities</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="990">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15022407</PUBLICID>
    <LONGNAME>Physical Activity Readiness Questionnaire Low Resting Blood Pressure Causing Dizziness Lightheadedness And/Or Fainting Present Yes No Indicator</LONGNAME>
    <PREFERREDNAME>LOW_BP_DIZNS_FAINT_PRSNT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Yes/No Response to indicate if the participant has low blood pressure causing dizziness, lightheadedness and/or fainting</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15022406</PublicId>
      <PreferredName>2739336v1.00:15022405v1.00</PreferredName>
      <PreferredDefinition>Any form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc._No value exists._A predetermined set of questions.:A minimum level or position or degree; less than normal in degree, intensity or amount._Freedom from activity._The pressure of the circulating blood against the walls of the blood vessels._No value exists._A sensation of lightheadedness, unsteadiness, turning, spinning or rocking._A feeling of faintness; a reeling sensation. Lightheadedness is medically distinct from dizziness, unsteadiness, and vertigo._Used to indicate that either or both of two items or options may be valid._Extremely weak; threatened with syncope._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Physical Activity Readiness Questionnaire Low Resting Blood Pressure Causing Dizziness Lightheadedness And/Or Fainting Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2739336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17708:CL315230:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Physical Activity Readiness Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17708</PREFERRED_NAME>
            <LONG_NAME>Physical Activity</LONG_NAME>
            <CON_ID>2202366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL315230</PREFERRED_NAME>
            <LONG_NAME>Readiness</LONG_NAME>
            <CON_ID>2203424</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15022405</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15022405v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Low Resting Blood Pressure Causing Dizziness Lightheadedness And/Or Fainting Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54722</PREFERRED_NAME>
            <LONG_NAME>Low</LONG_NAME>
            <CON_ID>2509528</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>8</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28185</PREFERRED_NAME>
            <LONG_NAME>Resting</LONG_NAME>
            <CON_ID>2494798</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54706</PREFERRED_NAME>
            <LONG_NAME>Blood Pressure</LONG_NAME>
            <CON_ID>2552352</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL267675</PREFERRED_NAME>
            <LONG_NAME>Causing</LONG_NAME>
            <CON_ID>2204543</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37943</PREFERRED_NAME>
            <LONG_NAME>Dizziness</LONG_NAME>
            <CON_ID>2203685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118255</PREFERRED_NAME>
            <LONG_NAME>Lightheadedness</LONG_NAME>
            <CON_ID>4488056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50857</PREFERRED_NAME>
            <LONG_NAME>Fainting</LONG_NAME>
            <CON_ID>4394423</CON_ID>
            <DEFINITION_SOURCE>FDA</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you have low resting blood pressure significant enough to cause dizziness, light-headedness, and/or fainting?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>8b. Do you commonly exhibit low resting blood pressure significant enough to cause dizziness, light-headedness, and/or fainting?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="991">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15024665</PUBLICID>
    <LONGNAME>Large Meal Taken Yes No Indicator</LONGNAME>
    <PREFERREDNAME>LG_MEAL_TK_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator on if a large meal is taken.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15024664</PublicId>
      <PreferredName>15024663v1.00:2185700v1.00</PreferredName>
      <PreferredDefinition>Of considerable or relatively great size, extent, or capacity._Any of the occasions for eating food that occur by custom or habit at more or less fixed times.:Having been accepted for some purpose; ingested as a medication.</PreferredDefinition>
      <LongName>Large Meal Taken</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>15024663</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49508:C80248</PreferredName>
        <Version>1</Version>
        <LongName>Large Meal</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49508</PREFERRED_NAME>
            <LONG_NAME>Large</LONG_NAME>
            <CON_ID>2470752</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80248</PREFERRED_NAME>
            <LONG_NAME>Meal</LONG_NAME>
            <CON_ID>3187011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2185700</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25701</PreferredName>
        <Version>1</Version>
        <LongName>Taken</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25701</PREFERRED_NAME>
            <LONG_NAME>Taken</LONG_NAME>
            <CON_ID>2203968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Do you have a large meal?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>A large meal?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="992">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15063764</PUBLICID>
    <LONGNAME>Health Status Assessment FAQLQ-Adult 25 Food Allergy How Frightened About Accidentally Eating Wrong Foods Score 7 Point Scale</LONGNAME>
    <PREFERREDNAME>FAQLQ_AF_25_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how frightened they are, because of their food allergy, of accidentally eating the wrong food, using a 7-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FAQLQ-AF: Food Allergy Quality of Life Questionnaire-Adult Form, Flokstra-de Blok BMJ, Van Der Meulen GN, et al., Dev and valid of the Food Allergy Quality of Life Questionnaire -Adult form,  Allergy, 2009</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15060050</PublicId>
      <PreferredName>14936166v1.00:15060086v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:A 29-item questionnaire designed to assess health-related quality of life in adults with food allergies._An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract._A question about how frightened an individual is or was of accidentally eating the wrong food._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Health Status Assessment Food Allergy Quality of Life Questionnaire - Adult Form Food Allergy How Frightened About Accidentally Eating Wrong Foods Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15060086</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15060086v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Quality of Life Questionnaire - Adult Form Food Allergy How Frightened About Accidentally Eating Wrong Foods Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209292</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Quality of Life Questionnaire - Adult Form</LONG_NAME>
            <CON_ID>15042281</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C172304</PREFERRED_NAME>
            <LONG_NAME>Food Allergy</LONG_NAME>
            <CON_ID>7465895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209333</PREFERRED_NAME>
            <LONG_NAME>How Frightened About Accidentally Eating Wrong Foods Question</LONG_NAME>
            <CON_ID>15042308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FAQLQ-AF: Food Allergy Quality of Life Questionnaire-Adult Form, Flokstra-de Blok BMJ, Van Der Meulen GN, et al., Dev and valid of the Food Allergy Quality of Life Questionnaire -Adult form,  Allergy, 2009</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15063229</PublicId>
      <PreferredName>FAQLQ_7PT_SCL</PreferredName>
      <PreferredDefinition>A questionnaire designed to assess health-related quality of life in individuals with food allergies._An ordered reference standard used to measure incremental changes with responses of 0-Not troublesome to 6-Extremely troublesome.</PreferredDefinition>
      <LongName>FAQLQ 7 PT Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>15063672</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15063672v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Quality of Life Questionnaire Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209870</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Quality of Life Questionnaire</LONG_NAME>
            <CON_ID>15063513</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Extremely Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was extremely troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was very troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Quite Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was quite troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderately Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was moderately troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209357</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Slightly Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was slightly troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Barely Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was barely troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not Troublesome</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was not troublesome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209354</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How frightened are you because of your food allergy of accidentally eating the wrong food?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How frightened are you because of your food allergy of accidentally eating the wrong food?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>of accidentally eating the wrong food?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Food Allergy Quality of Life Questionnaire (FAQLQ)-Adult</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 25 of 29</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15175021</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15099037</PublicId>
          <ContextName>NIAID</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>15099037v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15100800</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="993">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15081016</PUBLICID>
    <LONGNAME>PROMIS Pediatric Physical Health Physical Function PFA15 Able to Stand Up from Armless Straight Chair Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PROMISP_PFA15_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of the difficulty they have standing up from an armless straight chair, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PROMIS:Patient Reported Outcomes Measurement Information System, PROMIS Health Organization and PROMIS Cooperative Group</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15080991</PublicId>
      <PreferredName>15080987v1.00:15080990v1.00</PreferredName>
      <PreferredDefinition>The set of PROMIS measures that assess the physical health of pediatric subjects through self-report or parent proxy report._The collection of PROMIS item scales that assess an individual&#39;s ability to carry out activities that require physical actions including more complex activities that require a combination of skills, often within a social context.:A question about whether an individual is able to stand up from an armless straight chair._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>PROMIS Pediatric and Parent Proxy Physical Health Domain Physical Function Subordinate Domain Able to Stand Up from Armless Straight Chair Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>15080987</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C156219:C122356</PreferredName>
        <Version>1</Version>
        <LongName>PROMIS Pediatric and Parent Proxy Physical Health Domain Physical Function Subordinate Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C156219</PREFERRED_NAME>
            <LONG_NAME>PROMIS Pediatric and Parent Proxy Physical Health Domain</LONG_NAME>
            <CON_ID>6545291</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122356</PREFERRED_NAME>
            <LONG_NAME>Physical Function Subordinate Domain</LONG_NAME>
            <CON_ID>4860871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15080990</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C209980:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Able to Stand Up from Armless Straight Chair Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209980</PREFERRED_NAME>
            <LONG_NAME>Able to Stand Up from Armless Straight Chair Question</LONG_NAME>
            <CON_ID>15068073</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PROMIS:Patient Reported Outcomes Measurement Information System, PROMIS Health Organization and PROMIS Cooperative Group</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4809918</PublicId>
      <PreferredName>PROMIS_DIFFICULT_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard used with the PROMIS items that describes a range of subjective scores from 1: Unable to do, to 5: Without any difficulty.</PreferredDefinition>
      <LongName>PROMIS Ability Difficulty Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Without Any Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something without any difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>With a Little Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with a little difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>With Some Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with some difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>With Much Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with much difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Unable to Do</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is unable to do something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you able to stand up from an armless straight chair?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you able to stand up from an armless straight chair?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="994">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15081248</PUBLICID>
    <LONGNAME>Health Status Assessment FAQLQ-PF 4 Food Allergy Impact Child Feels Afraid to Try Unfamiliar Foods Score 7 Point Scale</LONGNAME>
    <PREFERREDNAME>FAQLQ_PF_4_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation, because of  the impact of their child&#39;s food allergy, whether their child feels afraid to try unfamiliar foods, using a 7-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15076522</PublicId>
      <PreferredName>14936166v1.00:15081218v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:A questionnaire designed to be completed by a parent to assess how much of an impact food allergies have on their child&#39;s quality of life. It is designed for children ages 0-12._An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract._The effect or consequence of an event or condition._A question about whether an individual&#39;s child feels afraid to try unfamiliar foods._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Health Status Assessment Food Allergy Quality of Life Questionnaire - Parent Form Food Allergy Impact Child Feels Afraid to Try Unfamiliar Foods Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15081218</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15081218v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Quality of Life Questionnaire - Parent Form Food Allergy Impact Child Feels Afraid to Try Unfamiliar Foods Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209941</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Quality of Life Questionnaire - Parent Form</LONG_NAME>
            <CON_ID>15063847</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C172304</PREFERRED_NAME>
            <LONG_NAME>Food Allergy</LONG_NAME>
            <CON_ID>7465895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122929</PREFERRED_NAME>
            <LONG_NAME>Impact</LONG_NAME>
            <CON_ID>4930073</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209945</PREFERRED_NAME>
            <LONG_NAME>Child Feels Afraid to Try Unfamiliar Foods Question</LONG_NAME>
            <CON_ID>15063851</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15081014</PublicId>
      <PreferredName>FAQLQPF_QUANT_7PT_SCL</PreferredName>
      <PreferredDefinition>A questionnaire designed to be completed by a parent to assess how much of an impact food allergies have on their child&#39;s quality of life. It is designed for children ages 0-12._An ordered reference standard used to measure incremental changes with responses from 0=not at all, 1=a little bit, 2=slightly, 3=moderately, 4=quite a bit, 5=very much, 6=extremely.</PreferredDefinition>
      <LongName>FAQLQ Parent Form Quantity 7 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>15081013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15081013v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Quality of Life Questionnaire - Parent Form Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C209941</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Quality of Life Questionnaire - Parent Form</LONG_NAME>
            <CON_ID>15063847</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Extremely Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7402703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>A lot</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3679493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Quite a lot</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate Response</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of a degree of agreement that is approximately halfway between the highest and lowest degrees of agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5576773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Slightly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in slight agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5119337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6730940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Because of food allergy, my child feels afraid to try unfamiliar foods</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Because of food allergy, my child feels afraid to try unfamiliar foods</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Afraid to try unfamiliar foods</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FAQLQ-Parent Form</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 4 of 30</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Parent Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15175023</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15099037</PublicId>
          <ContextName>NIAID</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>15099037v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Parent Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15100801</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="995">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15099102</PUBLICID>
    <LONGNAME>Ovary Within Radiation Field Present Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>OVRY_WTHN_RF_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indicator that specifies whether or not the ovary is present within the radiation field.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15099082</PublicId>
      <PreferredName>2677680v1.00:4745443v1.00</PreferredName>
      <PreferredDefinition>One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.:On the inside; contained in._The area of the body exposed to radiation during radiation therapy._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Ovary Within Radiation Field Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2677680</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12404</PreferredName>
        <Version>1</Version>
        <LongName>Ovary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12404</PREFERRED_NAME>
            <LONG_NAME>Ovary</LONG_NAME>
            <CON_ID>2202769</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4745443</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25282:C54648:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Within Radiation Field Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25282</PREFERRED_NAME>
            <LONG_NAME>Within</LONG_NAME>
            <CON_ID>2206273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54648</PREFERRED_NAME>
            <LONG_NAME>Radiation Field</LONG_NAME>
            <CON_ID>2479357</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ovary within radiation field?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the ovary in the treatment field?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes to Abdomen or Yes to Pelvis: Was the ovary in the treatment field?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OvaryTxFieldInd</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AbdPlvsOvaryTxFieldInd</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="996">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15101782</PUBLICID>
    <LONGNAME>Health Status Assessments FASE-P How Confident Able to Check Food Labels Score 11 Point Scale</LONGNAME>
    <PREFERREDNAME>FASEP_FD_LBL_CK_11PT_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person’s stated observation of how confident they are able to check food labels, using an 11-point linear scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FASE-P: Food Allergy Self-Efficacy Scale for Parents, Knibb RC, Barnes C, et al., Parental confidence in managing food allergy: dev and  valid of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). Clin Exp Allergy, 2015</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15101305</PublicId>
      <PreferredName>14936166v1.00:15101304v1.00</PreferredName>
      <PreferredDefinition>Assessments of health-related matters of interest, importance, or worry to a patient, patient&#39;s family, or patient&#39;s healthcare provider that could identify a need, problem, or condition.:A questionnaire design to measure parental confidence (self-efficacy) in managing food allergies in their child._A question about how confident an individual is about something._A question about whether an individual is or will be able to check food labels._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Health Status Assessment Food Allergy Self-Efficacy Scale for Parents How Confident Able to Check Food Labels Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14936166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C205784</PreferredName>
        <Version>1</Version>
        <LongName>Health Status Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C205784</PREFERRED_NAME>
            <LONG_NAME>Health Status Assessment</LONG_NAME>
            <CON_ID>14920961</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15101304</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15101304v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Self-Efficacy Scale for Parents How Confident Able to Check Food Labels Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C210155</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Self-Efficacy Scale for Parents</LONG_NAME>
            <CON_ID>15098743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C210156</PREFERRED_NAME>
            <LONG_NAME>How Confident Question</LONG_NAME>
            <CON_ID>15098744</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C210230</PREFERRED_NAME>
            <LONG_NAME>Able to Check Food Labels Question</LONG_NAME>
            <CON_ID>15098753</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FASE-P: Food Allergy Self-Efficacy Scale for Parents, Knibb RC, Barnes C, et al., Parental confidence in managing food allergy: dev and  valid of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). Clin Exp Allergy, 2015</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15099245</PublicId>
      <PreferredName>FASEP_11PT_SCL</PreferredName>
      <PreferredDefinition>A questionnaire design to measure parental confidence (self-efficacy) in managing food allergies in their child._An ordered reference standard used to measure incremental changes with ranges from 0 (Cannot do at all) to 100 (Highly certain can do).</PreferredDefinition>
      <LongName>FASE-P 11 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>FASE-P: Food Allergy Self-Efficacy Scale for Parents, Knibb RC, Barnes C, et al., Parental confidence in managing food allergy: dev and  valid of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). Clin Exp Allergy, 2015</Origin>
      <Representation>
        <PublicId>15099244</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15099244v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Food Allergy Self-Efficacy Scale for Parents Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C210155</PREFERRED_NAME>
            <LONG_NAME>Food Allergy Self-Efficacy Scale for Parents</LONG_NAME>
            <CON_ID>15098743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>90</VALIDVALUE>
          <VALUEMEANING>Ability Score 90</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 90 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>Ability Score 80</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 80 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>Ability Score 70</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 70 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>Ability Score 60</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 60 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>50</VALIDVALUE>
          <VALUEMEANING>Ability Score 50</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 50 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210251</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Ability Score 40</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 40 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Ability Score 30</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 30 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Ability Score 20</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 20 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Ability Score 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 10 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Ability Score 0</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 0 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100</VALIDVALUE>
          <VALUEMEANING>Ability Score 100</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 100 on an ability scale that goes from 0: Cannot do at all to 100: Highly certain can do.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C210256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15100785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I am confident that I will be able to check food labels</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I am confident that I will be able to check food labels</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FASE-P</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 9 of 21</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Check food labels</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Food Allergy Self-Efficacy Scale for Parents (FASE-P)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15175015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15099037</PublicId>
          <ContextName>NIAID</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>15099037v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Food Allergy Self-Efficacy Scale for Parents (FASE-P)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15100794</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="997">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15112163</PUBLICID>
    <LONGNAME>Person Lost To Follow-Up Indicator</LONGNAME>
    <PREFERREDNAME>15112162v1.00:3506034v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication as to whether or not communication with an individual was lost after a study has officially closed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CRDC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GDC:NCI Genomic Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15112162</PublicId>
      <PreferredName>2236731v1.00:7547295v1.00</PreferredName>
      <PreferredDefinition>A human being.:The loss or lack of continuation of subject participation after a study has officially closed.</PreferredDefinition>
      <LongName>Person Lost To Follow-Up</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>7547295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48227</PreferredName>
        <Version>1</Version>
        <LongName>Lost To Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48227</PREFERRED_NAME>
            <LONG_NAME>Lost To Follow-Up</LONG_NAME>
            <CON_ID>2470168</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GDC:NCI Genomic Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lost To Follow-Up</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>10429357</PublicId>
          <ContextName>CRDC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GDC (Genomic Data Commons)</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate New GDC CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14506028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15103644</PublicId>
          <ContextName>CRDC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>15103644v1.00</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15105437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lost_to_followup</AlternateName>
        <AlternateNameType>GDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lost_to_followup</AlternateName>
        <AlternateNameType>PDC Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lost_to_followup</AlternateName>
        <AlternateNameType>CRDC Model Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="998">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15113532</PUBLICID>
    <LONGNAME>Specimen Molecular RNA Integrity Number Integer</LONGNAME>
    <PREFERREDNAME>15113480v1.00:10540093v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>A numerical assessment of the integrity of RNA based on the entire electrophoretic trace of the RNA sample, including the presence or absence of degradation products.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CRDC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GDC:NCI Genomic Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15113480</PublicId>
      <PreferredName>2859635v1.00:15113479v1.00</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:A biological sample comprised of carbohydrates, protein, lipids, nucleic acids and/or cellular components that have been prepared for testing, diagnostic, propagation, treatment or research purposes._A numerical assessment of the integrity of RNA based on the entire electrophoretic trace of the RNA sample, including the presence or absence of degradation products.</PreferredDefinition>
      <LongName>Specimen Molecular RNA Integrity Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15113479</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C208038:C63637</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Biospecimen RNA Integrity Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C208038</PREFERRED_NAME>
            <LONG_NAME>Molecular Biospecimen</LONG_NAME>
            <CON_ID>15018690</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63637</PREFERRED_NAME>
            <LONG_NAME>RNA Integrity Number</LONG_NAME>
            <CON_ID>2673247</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GDC:NCI Genomic Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>10540093</PublicId>
      <PreferredName>10540093v1.00</PreferredName>
      <PreferredDefinition>A number with no fractional part, including the negative and positive numbers as well as zero.</PreferredDefinition>
      <LongName>Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CRDC:Cancer Research Data Commons</Origin>
      <Representation>
        <PublicId>2433737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255</PreferredName>
        <Version>1</Version>
        <LongName>Integer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RIN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="999">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15113688</PUBLICID>
    <LONGNAME>Maximum Serum Creatinine Less Than or Equal To Age Or Gender Normal Value Yes No Indicator</LONGNAME>
    <PREFERREDNAME>15113637v1.00:3506068v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to whether or not if the maximum serum creatinine is less than or equal to age or gender normal value.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15113637</PublicId>
      <PreferredName>15113635v1.00:15113636v1.00</PreferredName>
      <PreferredDefinition>The largest possible quantity or degree._The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins._The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.:A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways._How long something has existed; elapsed time since birth._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Characteristics of people that are socially constructed, including norms, behaviors, and roles based on sex. As a social construct, gender varies from society to society and can change over time. (Adapted from WHO.)_Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Maximum Serum Creatinine Less Than or Equal To Age Or Gender Normal Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>15113635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C13325:C399</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Serum Creatinine</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13325</PREFERRED_NAME>
            <LONG_NAME>Serum</LONG_NAME>
            <CON_ID>2203797</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C399</PREFERRED_NAME>
            <LONG_NAME>Creatinine</LONG_NAME>
            <CON_ID>2206188</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15113636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15113636v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Less Than or Equal To Age Or Gender Normal Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61586</PREFERRED_NAME>
            <LONG_NAME>Less Than or Equal To</LONG_NAME>
            <CON_ID>2790750</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17357</PREFERRED_NAME>
            <LONG_NAME>Gender</LONG_NAME>
            <CON_ID>2202402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Maximum serum creatinine &lt;= the age-gender-specific normal value</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximum serum creatinine &lt;= the below age-gender-specific norms?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1000">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15115498</PUBLICID>
    <LONGNAME>Specimen Type Code</LONGNAME>
    <PREFERREDNAME>15115476v1.00:15115491v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.:The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances._A symbol or combination of symbols which is assigned to the members of a collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CRDC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GDC:NCI Genomic Data Commons</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15115476</PublicId>
      <PreferredName>2859635v1.00:2715039v1.00</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.</PreferredDefinition>
      <LongName>Biospecimen Biospecimen Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715039</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70713</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70713</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Type</LONG_NAME>
            <CON_ID>2714914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GDC:NCI Genomic Data Commons</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15115491</PublicId>
      <PreferredName>15115491v1.00</PreferredName>
      <PreferredDefinition>The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>Specimen Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CRDC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>GDC:NCI Genomic Data Commons</Origin>
      <Representation>
        <PublicId>14670367</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>14670367v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Type Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70713</PREFERRED_NAME>
            <LONG_NAME>Biospecimen Type</LONG_NAME>
            <CON_ID>2714914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Type Code does not have Preferred Question Text.</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Type Code does not have Preferred Question Text.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>sample_type_id</AlternateName>
        <AlternateNameType>CRDC Model Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1001">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15176867</PUBLICID>
    <LONGNAME>Healthcare Encounter Patient Discharge Status Identifier CDISC Variable Terminology Text</LONGNAME>
    <PREFERREDNAME>14596442v1.00:6338238v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Interactions between patients and providers within the context of healthcare delivery.:The release of a patient from a course of care._A condition or state at a particular time._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.:The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FHIR US Core Profiles:Fast Healthcare Interoperability Resources US Core Profiles</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14596442</PublicId>
      <PreferredName>14596371v1.00:15082221v1.00</PreferredName>
      <PreferredDefinition>Interactions between patients and providers within the context of healthcare delivery.:The release of a patient from a course of care._A condition or state at a particular time._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Healthcare Encounter Patient Discharge Status Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>14596371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C154624</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C154624</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounter</LONG_NAME>
            <CON_ID>6424582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15082221</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25166:C25688:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Patient Discharge Status Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25166</PREFERRED_NAME>
            <LONG_NAME>Patient Discharge</LONG_NAME>
            <CON_ID>2203907</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6338238</PublicId>
      <PreferredName>CDISCTXT</PreferredName>
      <PreferredDefinition>The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables._The words of something written.</PreferredDefinition>
      <LongName>CDISC Variable Terminology Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDISC:Clinical Data Interchange Standards Consortium</Origin>
      <Representation>
        <PublicId>6396647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C83187:C25704</PreferredName>
        <Version>1</Version>
        <LongName>CDISC Variable Terminology Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C83187</PREFERRED_NAME>
            <LONG_NAME>CDISC Variable Terminology</LONG_NAME>
            <CON_ID>6396645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Discharge Disposition</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPHO</AlternateName>
        <AlternateNameType>CDISC SDTM Domain</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1002">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15180782</PUBLICID>
    <LONGNAME>Doxorubicin Total Cumulative Dose Administered 0 Decimal Place Milligram per Square Meter Value</LONGNAME>
    <PREFERREDNAME>15180578v1.00:7283690v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The 0 decimal place milligram per square meter numeric value related to the total cumulative dose of doxorubicin administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15180578</PublicId>
      <PreferredName>2867161v1.00:15180576v1.00</PreferredName>
      <PreferredDefinition>An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contri:Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Doxorubicin Total Cumulative Dose Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867161</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C456</PreferredName>
        <Version>1</Version>
        <LongName>Doxorubicin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C456</PREFERRED_NAME>
            <LONG_NAME>Doxorubicin</LONG_NAME>
            <CON_ID>2204905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15180576</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C94394:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Total Cumulative Dose Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94394</PREFERRED_NAME>
            <LONG_NAME>Cumulative Dose</LONG_NAME>
            <CON_ID>4887037</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7283690</PublicId>
      <PreferredName>7283690v1.0</PreferredName>
      <PreferredDefinition>A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Medication Dose 0 Decimal Place Milligram per Square Meter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/m2</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>7283689</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7283689v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Medication Dose Integer::0 Decimal Place Milligram per Square Meter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67402</PREFERRED_NAME>
            <LONG_NAME>Milligram per Square Meter</LONG_NAME>
            <CON_ID>2725140</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the total cumulative dose of doxorubicin administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Total cumulative dose of doxorubicin:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1003">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15180795</PUBLICID>
    <LONGNAME>Oxaliplatin Total Cumulative Dose Administered 0 Decimal Place Milligram per Square Meter Value</LONGNAME>
    <PREFERREDNAME>15180600v1.00:7283690v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The 0 decimal place milligram per square meter numeric value related to the total cumulative dose of oxaliplatin administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15180600</PublicId>
      <PreferredName>2867271v1.00:15180576v1.00</PreferredName>
      <PreferredDefinition>An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a &#39;leaving group.&#39; A &#39;leaving group&#39; is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04):Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Oxaliplatin Total Cumulative Dose Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1181</PreferredName>
        <Version>1</Version>
        <LongName>Oxaliplatin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1181</PREFERRED_NAME>
            <LONG_NAME>Oxaliplatin</LONG_NAME>
            <CON_ID>2321588</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15180576</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C94394:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Total Cumulative Dose Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94394</PREFERRED_NAME>
            <LONG_NAME>Cumulative Dose</LONG_NAME>
            <CON_ID>4887037</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>7283690</PublicId>
      <PreferredName>7283690v1.0</PreferredName>
      <PreferredDefinition>A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Medication Dose 0 Decimal Place Milligram per Square Meter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/m2</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>7283689</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>7283689v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Medication Dose Integer::0 Decimal Place Milligram per Square Meter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67402</PREFERRED_NAME>
            <LONG_NAME>Milligram per Square Meter</LONG_NAME>
            <CON_ID>2725140</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the total cumulative dose of oxaliplatin administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Total cumulative dose of oxaliplatin:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1004">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15242345</PUBLICID>
    <LONGNAME>Health Status Assessment IIEF-6 3 How Often Able to Maintain Erection After Penetrating Partner Score 6 Point Scale</LONGNAME>
    <PREFERREDNAME>IIEF6_3_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how often they were able to maintain their erection after penetrating their partner, using a 6 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>IIEF: International Index of Erectile Function, RC Rosen, A Riley, et al., Urology, 1997</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15240629</PublicId>
      <PreferredName>15393522v1.00:15393525v1.00</PreferredName>
      <PreferredDefinition>A standardized survey developed and published by Raymond C. Rosen and colleagues in 1997 which is used to assess erectile function. This instrument is a self-administered questionnaire with 15 items each with as set of 5 or 6 response options associated with a score of 1-5 or 1-6.:A question about how often an individual is or was able to maintain an erection after penetrating a partner during sexual intercourse._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>International Index of Erectile Function Questionnaire How Often Able to Maintain Erection After Penetrating Partner Question Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>15393522</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103521</PreferredName>
        <Version>1</Version>
        <LongName>International Index of Erectile Function Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103521</PREFERRED_NAME>
            <LONG_NAME>International Index of Erectile Function Questionnaire</LONG_NAME>
            <CON_ID>6643126</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15393525</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C211686:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Often Able to Maintain Erection After Penetrating Partner Question Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C211686</PREFERRED_NAME>
            <LONG_NAME>How Often Able to Maintain Erection After Penetrating Partner Question</LONG_NAME>
            <CON_ID>15237713</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>IIEF: International Index of Erectile Function, RC Rosen, A Riley, et al., Urology, 1997</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15230013</PublicId>
      <PreferredName>15230013v1.00</PreferredName>
      <PreferredDefinition>A standardized survey developed and published by Raymond C. Rosen and colleagues in 1997 which is used to assess erectile function. This instrument is a self-administered questionnaire with 15 items each with as set of 5 or 6 response options associated with a score of 1-5 or 1-6._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>IIEF Frequency 6 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>IIEF: International Index of Erectile Function, RC Rosen, A Riley, et al., Urology, 1997</Origin>
      <Representation>
        <PublicId>15240639</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15240639v1.00</PreferredName>
        <Version>1</Version>
        <LongName>International Index of Erectile Function Questionnaire Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103521</PREFERRED_NAME>
            <LONG_NAME>International Index of Erectile Function Questionnaire</LONG_NAME>
            <CON_ID>6643126</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Almost always or always</VALIDVALUE>
          <VALUEMEANING>Almost always or always</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happened always or almost always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Most times (much more than half the time)</VALIDVALUE>
          <VALUEMEANING>Most times (much more than half the time)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes (about half the time)</VALIDVALUE>
          <VALUEMEANING>Sometimes (about half the time)</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A few times (much less than half the time)</VALIDVALUE>
          <VALUEMEANING>A few times (much less than half the time)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happened less than half the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129349</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Almost never or never</VALIDVALUE>
          <VALUEMEANING>Almost never or never</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happened never or almost never.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable/Have not attempted intercourse</VALIDVALUE>
          <VALUEMEANING>Not Applicable Or Did Not Attempt Intercourse</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A response indicating that sexual intercourse was not attempted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129471, C37998, C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15231504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often were you able to maintain your erection after you had penetrated your partner?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>During sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1005">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15250313</PUBLICID>
    <LONGNAME>Disease or Disorder Code System Text</LONGNAME>
    <PREFERREDNAME>14596339v1.00:15102792v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A systematized collection of concepts that define corresponding codes.:The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FHIR US Core Profiles:Fast Healthcare Interoperability Resources US Core Profiles</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>14596339</PublicId>
      <PreferredName>2404658v1.00:2715138v1.00</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A systematized collection of concepts that define corresponding codes.</PreferredDefinition>
      <LongName>Disease or Disorder Code System</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT MOD</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715138</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70895</PreferredName>
        <Version>1</Version>
        <LongName>Code System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70895</PREFERRED_NAME>
            <LONG_NAME>Code System</LONG_NAME>
            <CON_ID>2715008</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15102792</PublicId>
      <PreferredName>15102792v1.00</PreferredName>
      <PreferredDefinition>The words of something written.</PreferredDefinition>
      <LongName>Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>string</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1048576</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>System</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15063879</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FHIR - US CORE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>US Core Condition Problems and Health Concerns Profile</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15250345</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Condition.code.coding[].system@value</AlternateName>
        <AlternateNameType>FHIR US CORE Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Condition</AlternateName>
        <AlternateNameType>FHIR US CORE Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1006">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15250340</PUBLICID>
    <LONGNAME>Disease or Disorder Healthcare Encounter Reason Identifier Health Level Seven Code</LONGNAME>
    <PREFERREDNAME>15250300v1.00:15083695v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Interactions between patients and providers within the context of healthcare delivery._An explanation of the cause of some phenomenon or action._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.:Interactions between patients and providers within the context of healthcare delivery._An explanation of the cause of some phenomenon or action._A Standards Developing Organization (SDO) operating in the healthcare arena with an emphasis on the domain of clinical and administrative data._A symbol or combination of symbols which is assigned to the members of a collection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>CDMH</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FHIR US Core Profiles:Fast Healthcare Interoperability Resources US Core Profiles</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15250300</PublicId>
      <PreferredName>2404658v1.00:15250299v1.00</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Interactions between patients and providers within the context of healthcare delivery._An explanation of the cause of some phenomenon or action._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Disease or Disorder Healthcare Encounter Reason Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15250299</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C154624:C25638:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounter Reason Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C154624</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounter</LONG_NAME>
            <CON_ID>6424582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15083695</PublicId>
      <PreferredName>15083695v1.00</PreferredName>
      <PreferredDefinition>Interactions between patients and providers within the context of healthcare delivery._An explanation of the cause of some phenomenon or action._A Standards Developing Organization (SDO) operating in the healthcare arena with an emphasis on the domain of clinical and administrative data._A symbol or combination of symbols which is assigned to the members of a collection.</PreferredDefinition>
      <LongName>Healthcare Encounter Reason Health Level Seven Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>CDMH</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1048576</MaximumLength>
      <MinimumLength>0</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>15083694</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15083694v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Encounter Reason Health Level Seven Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C154624</PREFERRED_NAME>
            <LONG_NAME>Healthcare Encounter</LONG_NAME>
            <CON_ID>6424582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80485</PREFERRED_NAME>
            <LONG_NAME>Health Level Seven</LONG_NAME>
            <CON_ID>2928160</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>https://hl7.org/fhir/R4/valueset-encounter-reason.html</VALIDVALUE>
          <VALUEMEANING>https://hl7.org/fhir/R4/valueset-encounter-reason.html</VALUEMEANING>
          <MEANINGDESCRIPTION>https://hl7.org/fhir/R4/valueset-encounter-reason.html</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-11-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15181770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Encounter Reason Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>15063879</PublicId>
          <ContextName>CDMH</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FHIR - US CORE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>US Core Condition Problems and Health Concerns Profile</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>15250345</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Condition.encounter.reference(http://hl7.org/fhir/us/core/StructureDefinition-us-core-encounter.html).reasonCode[].coding[].code@value</AlternateName>
        <AlternateNameType>FHIR US CORE Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CDMH</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Condition</AlternateName>
        <AlternateNameType>FHIR US CORE Table</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1007">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15334334</PUBLICID>
    <LONGNAME>Laboratory Procedure Other Positive Infectious Disease Marker Assessment Specify</LONGNAME>
    <PREFERREDNAME>15334301v1.00:2018806v1.00</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the other positive infectious disease marker and assessment performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>DRAFT NEW</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15334301</PublicId>
      <PreferredName>2543047v1.00:15334300v1.00</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:Different than the one(s) previously specified or mentioned._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact._Specific molecular signature of disease, physiological measurement, genotype structural or functional characteristic, metabolic changes, or other determinant that may simplify the diagnostic process, make diagnoses more accurate, distinguish different causes of disease, or enable physicians to make diagnoses before symptoms appear and to track disease progression.</PreferredDefinition>
      <LongName>Laboratory Procedure Other Positive Finding Infectious Disorder Disease Marker</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15334300</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C38758:C26726:C18329</PreferredName>
        <Version>1</Version>
        <LongName>Other Positive Finding Infectious Disorder Disease Marker</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38758</PREFERRED_NAME>
            <LONG_NAME>Positive Finding</LONG_NAME>
            <CON_ID>2516404</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26726</PREFERRED_NAME>
            <LONG_NAME>Infectious Disorder</LONG_NAME>
            <CON_ID>2203837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18329</PREFERRED_NAME>
            <LONG_NAME>Disease Marker</LONG_NAME>
            <CON_ID>2512695</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018806</PublicId>
      <PreferredName>ASSESS_SPEC</PreferredName>
      <PreferredDefinition>The free text field to specify the assessment performed.</PreferredDefinition>
      <LongName>Assessment Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify test and method for test performed on other positive infectious disease marker:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify test and method:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1008">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15334521</PUBLICID>
    <LONGNAME>OMWQ-HN 4e Past Week How Much Mouth and Throat Soreness Limit Talking Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>OMWQ_HN_4e_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation, during the past week, of how much mouth and throat soreness limited talking, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15334501</PublicId>
      <PreferredName>15334446v1.00:15354945v1.00</PreferredName>
      <PreferredDefinition>A patient-reported outcome questionnaire that measures the impact of mucositis in patients who are receiving radiation therapy, with or without chemotherapy, for head and neck cancer.:The most recent week. May include the present day._A question about how much mouth and throat soreness limits or limited an individual&#39;s talking._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Oral Mucositis Weekly Questionnaire-Head and Neck Cancer Past Week How Much Mouth and Throat Soreness Limits Talking Question Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>15334446</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C212003</PreferredName>
        <Version>1</Version>
        <LongName>Oral Mucositis Weekly Questionnaire-Head and Neck Cancer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C212003</PREFERRED_NAME>
            <LONG_NAME>Oral Mucositis Weekly Questionnaire-Head and Neck Cancer</LONG_NAME>
            <CON_ID>15334305</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15354945</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C212009:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Much Mouth and Throat Soreness Limits Talking Question Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C212009</PREFERRED_NAME>
            <LONG_NAME>How Much Mouth and Throat Soreness Limits Talking Question</LONG_NAME>
            <CON_ID>15334311</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15334461</PublicId>
      <PreferredName>15334461v1.00</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes with values 0=Not Limited at All, 1=Limited a Little, 2=Somewhat Limited, 3=Limited a Lot, 4=Unable to Do.</PreferredDefinition>
      <LongName>Patient Reported Outcome Measures Limited 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>DRAFT NEW</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>15382018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15382018v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcome Measures Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C177377</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcome Measures</LONG_NAME>
            <CON_ID>10049650</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Unable to Do</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is unable to do something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Limited a Lot</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual feels limited a lot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110983</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Somewhat Limited</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or feels somewhat limited.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C209415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15063643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Limited a Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual feels limited a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110984</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not Limited at All</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual does not feel limited at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110985</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5291035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How much did MOUTH AND THROAT SORENESS limit talking?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Talking</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OMWQ-HN</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 8 of 13</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1009">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15355217</PUBLICID>
    <LONGNAME>Disease or Disorder Classification Myeloid Neoplasm And Acute Leukemia 2022 WHO Category</LONGNAME>
    <PREFERREDNAME>MN_AL_2022_WHO_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>The classification of myeloid neoplasms and acute leukemia by the 2022 World Health Organization (WHO).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3945792</PublicId>
      <PreferredName>2404658v1.0:2321361v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Disease or Disorder Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2321361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25161</PreferredName>
        <Version>1</Version>
        <LongName>Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>15355174</PublicId>
      <PreferredName>MYE_AL_2022_WHO_CAT</PreferredName>
      <PreferredDefinition>Proliferation of myeloid cells originating from a primitive stem cell._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts)._A United Nations agency established to coordinate international health activities and to help governments improve health services._A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Myeloid Neoplasm And Acute Leukemia 2022 WHO Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>150</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>15355216</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15355216v1.00</PreferredName>
        <Version>1</Version>
        <LongName>Myeloid Neoplasm And Acute Leukemia World Health Organization Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9290</PREFERRED_NAME>
            <LONG_NAME>Myeloid Neoplasm</LONG_NAME>
            <CON_ID>2594569</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9300</PREFERRED_NAME>
            <LONG_NAME>Acute Leukemia</LONG_NAME>
            <CON_ID>2466873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75419</PREFERRED_NAME>
            <LONG_NAME>World Health Organization</LONG_NAME>
            <CON_ID>2774488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS-IB2</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome/Acute Myeloid Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7168</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15334605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS with fibrosis (MDS-f)</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome with Excess Blasts and Fibrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome with excess blasts associated with significant reticulin fibrosis of the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Childhood MDS with low blasts Hypocellular</VALIDVALUE>
          <VALUEMEANING>Childhood Myelodysplastic Syndrome with Low Blasts, Hypocellular</VALUEMEANING>
          <MEANINGDESCRIPTION>Childhood myelodysplastic syndrome with low blasts that is characterized by bone marrow hypocellularity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Childhood MDS with low blasts, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>Childhood Myelodysplastic Syndrome with Low Blasts, Not Otherwise Specified</VALUEMEANING>
          <MEANINGDESCRIPTION>Childhood myelodysplastic syndrome with low blasts in which further characterization is not available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Childhood MDS with increased blasts</VALIDVALUE>
          <VALUEMEANING>Childhood Myelodysplastic Syndrome with Excess Blasts</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome with excess blasts that occurs during childhood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic myelomonocytic leukemia</VALIDVALUE>
          <VALUEMEANING>CHRONIC MYELOMONOCYTIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelodysplastic/myeloproliferative neoplasm with neutrophilia</VALIDVALUE>
          <VALUEMEANING>ATYPICAL CHRONIC MYELOID LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS/MPN with SF3B1 mutation and thrombocytosis</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic/myeloproliferative neoplasm characterized by thrombocytosis, anemia, blasts less than 5% in bone marrow and less than 1% in peripheral blood, presence of SF3B1 gene mutation, absence of BCR/ABL fusion, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198581</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelodysplastic/myeloproliferative neoplasm, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES, UNCLASSIFIABLE</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute promyelocytic leukemia with PML::RARA fusion</VALIDVALUE>
          <VALUEMEANING>Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute promyelocytic leukemia characterized by the reciprocal balanced translocation t(15;17)(q24.1;q21.2) that results in the fusion of the promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARA) gene. The t(15;17)(q24.1;q21.2) with the resulting PML-RARA fusion gene occurs in over 95% of cases of acute promyelocytic leukemia. The remainder of the cases show variant RARA gene translocations with other genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with RUNX1::RUNX1T1 fusion</VALIDVALUE>
          <VALUEMEANING>ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22), (AML1/ETO)</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with CBFB::MYH11 fusion</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11</VALUEMEANING>
          <MEANINGDESCRIPTION>Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9018</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3257038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with DEK::NUP214 fusion</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with RBM15::MRTFA fusion</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with BCR::ABL1 fusion</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with BCR-ABL1</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5578258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with KMT2A rearrangement</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with KMT2A Rearrangement</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia characterized by rearrangement of the KMT2A gene. It affects infants, children and adults. It is usually associated with poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C174129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with MECOM rearrangement</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with MECOM Rearrangement</VALUEMEANING>
          <MEANINGDESCRIPTION>Acute myeloid leukemia characterized by rearrangement of the MECOM gene with various genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with NUP98 rearrangement</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with NUP98 Rearrangement</VALUEMEANING>
          <MEANINGDESCRIPTION>Acute myeloid leukemia characterized by rearrangement of the NUP98 gene with various genes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14673089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with NPM1 mutation</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with Mutated NPM1</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3257028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with CEBPA mutation</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with CEBPA Mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia with non-germline mutations of the CEBPA gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia, myelodysplasia-related</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia, Myelodysplasia-Related</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with other defined genetic alterations</VALIDVALUE>
          <VALUEMEANING>Acute Myeloid Leukemia with Recurrent Genetic Abnormalities</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of acute myeloid leukemias (AMLs) characterized by recurrent genetic abnormalities, mainly balanced translocations.  This group of AMLs often has a high rate of complete remission, and favorable prognosis.  (WHO, 2001) -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2836816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with minimal differentiation</VALIDVALUE>
          <VALUEMEANING>ACUTE MYELOID LEUKEMIA, MINIMALLY DIFFERENTIATED</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia without maturation</VALIDVALUE>
          <VALUEMEANING>ACUTE MYELOID LEUKEMIA WITHOUT MATURATION</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myeloid leukemia with maturation</VALIDVALUE>
          <VALUEMEANING>ACUTE MYELOID LEUKEMIA WITH MATURATION</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute basophilic leukemia</VALIDVALUE>
          <VALUEMEANING>ACUTE BASOPHILIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute myelomonocytic leukemia</VALIDVALUE>
          <VALUEMEANING>ACUTE MYELOMONOCYTIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7463</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute monocytic leukemia</VALIDVALUE>
          <VALUEMEANING>AML - 206.0; Leukemia-acute monocytic leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4861</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute erythroid leukemia</VALIDVALUE>
          <VALUEMEANING>ACUTE ERYTHROID LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute megakaryoblast leukemia</VALIDVALUE>
          <VALUEMEANING>Acute Megakaryoblastic Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3170</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic myeloid leukemia</VALIDVALUE>
          <VALUEMEANING>Chronic Myeloid Leukemia Pathway</VALUEMEANING>
          <MEANINGDESCRIPTION>Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91465</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7283671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polycythemia vera</VALIDVALUE>
          <VALUEMEANING>Polycythemia Vera</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001) -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Essential thrombocythemia</VALIDVALUE>
          <VALUEMEANING>ESSENTIAL THROMBOCYTHEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary myelofibrosis</VALIDVALUE>
          <VALUEMEANING>Primary Myelofibrosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2862</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic neutrophilic leukemia</VALIDVALUE>
          <VALUEMEANING>CHRONIC NEUTROPHILIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3179</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic eosinophilic leukemia</VALIDVALUE>
          <VALUEMEANING>Chronic Eosinophilic Pneumonia</VALUEMEANING>
          <MEANINGDESCRIPTION>Chronic inflammatory disorder of the lungs characterized by the presence of eosinophils in the interalveolar septa and alveolar spaces and peripheral blood eosinophilia.  Chest x-rays reveal peripheral infiltrates.  Approximately half of the patients have history of asthma or atopic disease.  Signs and symptoms include fever, dyspnea, cough, and weight loss.  Following treatment with corticosteroids, the eosinophilic infiltrates in the lungs disappear, resulting in dramatic clinical improvement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Juvenile myelomonocytic leukemia</VALIDVALUE>
          <VALUEMEANING>Juvenile Myelomonocytic Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myeloproliferative neoplasm, not otherwise specified</VALIDVALUE>
          <VALUEMEANING>CHRONIC MYELOPROLIFERATIVE DISEASE, UNCLASSIFIABLE</VALUEMEANING>
          <MEANINGDESCRIPTION>This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urticaria pigmentosa/Maculopapular cutaneous mastocytosis</VALIDVALUE>
          <VALUEMEANING>Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis, Polymorphic Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of urticaria pigmentosa/maculopapular cutaneous mastocytosis characterized by the presence of larger skin lesions of variable size compared to the monomorphic variant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C212103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monomorphic</VALIDVALUE>
          <VALUEMEANING>Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis, Monomorphic Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of urticaria pigmentosa/maculopapular cutaneous mastocytosis characterized by the presence of multiple small, roundish maculopapular skin lesions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C212102</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymorphic</VALIDVALUE>
          <VALUEMEANING>Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211509</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diffuse cutaneous mastocytosis</VALIDVALUE>
          <VALUEMEANING>Diffuse Cutaneous Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of cutaneous mastocytosis which is seen almost exclusively in children. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cutaneous mastocytoma</VALIDVALUE>
          <VALUEMEANING>Solitary Mastocytoma of the Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign, solitary, well-demarcated, yellow-brown or reddish-brown mast cell neoplasm that arises from the skin, most commonly in infants and children. The lesions are typically 2-5 cm in size, are characterized by infiltration of the dermis by neoplastic mast cells, and occasionally resolve spontaneously.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Isolated mastocytoma</VALIDVALUE>
          <VALUEMEANING>Solitary Mastocytoma of the Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>A benign, solitary, well-demarcated, yellow-brown or reddish-brown mast cell neoplasm that arises from the skin, most commonly in infants and children. The lesions are typically 2-5 cm in size, are characterized by infiltration of the dermis by neoplastic mast cells, and occasionally resolve spontaneously.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multilocalized mastocytoma</VALIDVALUE>
          <VALUEMEANING>Multiple Mastocytomas of the Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple distinct mastocytomas that arise from the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C212107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15355198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Systemic mastocytosis</VALIDVALUE>
          <VALUEMEANING>Systemic Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9235</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow mastocytosis</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of indolent systemic mastocytosis that affects predominantly older males. It is characterized by a limited degree of bone marrow infiltration by clonal mast cells and an absence of skin involvement. The serum tryptase levels are normal or slightly elevated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indolent systemic mastocytosis</VALIDVALUE>
          <VALUEMEANING>Indolent Systemic Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Smoldering systemic mastocytosis</VALIDVALUE>
          <VALUEMEANING>Smoldering Systemic Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>Slowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C115460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7150289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aggressive systemic mastocytosis</VALIDVALUE>
          <VALUEMEANING>Aggressive Systemic Mastocytosis</VALUEMEANING>
          <MEANINGDESCRIPTION>An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2836825</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Systemic mastocytosis with an associated hematologic neoplasm</VALIDVALUE>
          <VALUEMEANING>SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED CLONAL, HEMATOLOGICAL NON-MAST CELL LINEAGE DISEASE (SM-AHNMD)</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mast cell leukemia</VALIDVALUE>
          <VALUEMEANING>MAST CELL LEUKEMIA (MCL)</VALUEMEANING>
          <MEANINGDESCRIPTION>A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mast cell sarcoma</VALIDVALUE>
          <VALUEMEANING>MAST CELL SARCOMA (MCS)</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS with low blasts and isolated 5q deletion (MDS-5q)</VALIDVALUE>
          <VALUEMEANING>MYELODYSPLASTIC SYNDROME ASSOCIATED WITH ISOLATED DEL(5Q) CHROMOSOME ABNORMALITY</VALUEMEANING>
          <MEANINGDESCRIPTION>A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is &lt;5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS with low blasts and SF3B1 mutation (MDS-SF3B1)</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome with Mutated SF3B1</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome characterized by mutation of SF3B1 gene. There is bone marrow dysplasia typically in one or more hematopoietic cell lineages. There are less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C198587</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS with biallelic TP53 inactivation (MDS-biTP53)</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome with Biallelic TP53 Inactivation</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome characterized by the presence of biallelic TP53 inactivating alterations. They include biallelic TP53 gene mutations or one TP53 gene mutation and concurrent copy loss of TP53. There are less than 20% blasts in bone marrow and peripheral blood. It is associated with a poor prognosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS with low blasts (MDS-LB)</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome with Low Blasts</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome characterized by the presence of less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS, hypoplastic (MDS-h)</VALIDVALUE>
          <VALUEMEANING>Hypoplastic Myelodysplastic Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome characterized by decreased cellularity in the bone marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C122686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>14679046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDS-IB1</VALIDVALUE>
          <VALUEMEANING>Myelodysplastic Syndrome with Excess Blasts</VALUEMEANING>
          <MEANINGDESCRIPTION>Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>2022 World Health Organization classification of myeloid neoplasms and acute leukemia</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1010">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>15415779</PUBLICID>
    <LONGNAME>Patient High-Frequency Microsatellite Instability Or Mismatch Repair Protein Deficiency Carcinoma Clinical Trial Eligibility Criteria Code Indictor</LONGNAME>
    <PREFERREDNAME>PT_MSIH_DMMR_CA_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response to determine patient eligibility for clinical trial participation related to high-frequency microsatellite instability or DNA mismatch repair process and other types of carcinomas as outlined in the study protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>15415778</PublicId>
      <PreferredName>2233604v1.00:15415822v1.00</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The presence of genomic instability associated with defective DNA mismatch repair in greater than 30% of the microsatellite instability (MSI) biomarkers in a tumor sample._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A finding indicating that a cellular sample has a functional loss of a protein involved in the DNA mismatch repair process._A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient High-Frequency Microsatellite Instability Or Mismatch Repair Protein Deficiency Carcinoma Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>15415822</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>15415822v1.00</PreferredName>
        <Version>1</Version>
        <LongName>High-Frequency Microsatellite Instability Or Mismatch Repair Protein Deficiency Carcinoma Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36493</PREFERRED_NAME>
            <LONG_NAME>High-Frequency Microsatellite Instability</LONG_NAME>
            <CON_ID>4514753</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C137827</PREFERRED_NAME>
            <LONG_NAME>Mismatch Repair Protein Deficiency</LONG_NAME>
            <CON_ID>6144634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2916</PREFERRED_NAME>
            <LONG_NAME>Carcinoma</LONG_NAME>
            <CON_ID>2202711</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have MSI-H or deficient DNA mismatch repair (dMMR) colorectal cancer at pre-enrollment screening?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000703</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1011">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>792</PUBLICID>
    <LONGNAME>Prior Immunotherapy Administered Ind-3</LONGNAME>
    <PREFERREDNAME>PRIOR_ITX_ADM_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator that asks whether the patient previously had immunotherapy as treatment for cancer.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188716</PublicId>
      <PreferredName>PRIOR_ITX_ADM</PreferredName>
      <PreferredDefinition>information related to prior immunotherapy administered.</PreferredDefinition>
      <LongName>Prior Immunotherapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206560</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15262</PreferredName>
        <Version>1</Version>
        <LongName>Prior Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COMMENT_143</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction: If yes, provide treatment details in next module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Immunotherapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior Immunotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immmunologic therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immunological therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Drug and/or Immunotherapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Drug and/or Immunotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior investigational immunotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Immunotherapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive the last dose of immunotherapy at least 6 weeks of registration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive the last dose of immunotherapy at least 6 weeks of enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive the last dose of immunotherapy more than 28 days prior to enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive the last dose of immune modulating agents, including vaccine therapy, more than 28 days prior to enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Immunotherapy?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_TEXT4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient had immunotherapy after step 1 registration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received immunotherapy within 4 weeks prior to entry onto this study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immunotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immunotherapy for this tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Any prior Atezolizumab or other immunotherapy agent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have one course of immunotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>URCC21038</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have received prior immunotherapy for cancer, including checkpoint inhibitors, CAR-T therapy, and/or cytokine therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior immunotherapy for advanced NSCLC?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811789</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Esophageal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Amyloidosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Waldenstrom Macrogl</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811919</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Local-Reg Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000311</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Superficial Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000312</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Gastric</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2552643</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Training Class Examples</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3637837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000593</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0212</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000594</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6162769</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>URMC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>URCC Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6337044</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0001357</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0002430</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0002525</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0058385</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0061411</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0062922</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0064948</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065221</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0062680</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0061412</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PRIOR_ITX_ADM_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDUSIMM</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_ITX_ADM_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_ITX_ADM_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_ITX_ADM_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_ITX_ADM_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1012">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>1012</PUBLICID>
    <LONGNAME>Chronic Disease Present Ind-3</LONGNAME>
    <PREFERREDNAME>CHR_DZ_PRES_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if the patient has a chronic disease present.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188735</PublicId>
      <PreferredName>CHR_DZ_PRES</PreferredName>
      <PreferredDefinition>information related to a chronic disease being present.</PreferredDefinition>
      <LongName>Chronic Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206569</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14141:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Chronic Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14141</PREFERRED_NAME>
            <LONG_NAME>Chronic</LONG_NAME>
            <CON_ID>2206176</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a chron</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a chronic disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Chronic Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have serious uncontrolled infection, uncontrolled angina or serious peripheral neuropathy which would make protocol treatment unreasonably hazardous</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have serious uncontrolled infection, uncontrolled angina or serious peripheral neuropathy which would make protocol treatment unreasonably hazardous</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have any chronic disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Present</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have any other chronic disease that would preclude randomization into a lifestyle intervention trial?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have active or chronic infection requiring systemic therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have an underlying or documented history of a disease capable of causing lymphadenopathy (e.g., sarcoidosis or untreated mycobacterial infection)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have an active or chronic infection requiring systemic therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was there evidence of end organ disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SPOREs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2976812</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>GO Trial</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GO Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2976834</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0225</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPOREs</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CHR_DZ_PRES_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CHR_DZ_PRES_IND-3</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1013">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>1094</PUBLICID>
    <LONGNAME>Bronchoscopy Performed Date</LONGNAME>
    <PREFERREDNAME>BRONCHOSCOPY_PERF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date the Bronchoscopy was performed.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188753</PublicId>
      <PreferredName>BRONCHOSCOPY_PERF</PreferredName>
      <PreferredDefinition>information related to bronchoscopy being performed.</PreferredDefinition>
      <LongName>Bronchoscopy Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176974</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Bronchoscopy</PreferredName>
        <Version>1</Version>
        <LongName>Bronchoscopy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16366</PREFERRED_NAME>
            <LONG_NAME>Bronchoscopy</LONG_NAME>
            <CON_ID>2202694</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184322</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Performed</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Bronchoscopy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date the bronchoscopy was per</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date the bronchoscopy was performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of bronchoscopy/biopsy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1014">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>57797</PUBLICID>
    <LONGNAME>Contrast Agent Bolus Name Text</LONGNAME>
    <PREFERREDNAME>CONT_AGT_BOLUS_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name of contrast/bolus agent given to increase visualization of structures and tissues during medical imaging.</PREFERREDDEFINITION>
    <VERSION>2.31</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2008937</PublicId>
      <PreferredName>CONT_AGT_BOLUS_NM</PreferredName>
      <PreferredDefinition>Names of substances used in radiography that allow visualization of certain tissues.</PreferredDefinition>
      <LongName>Contrast Agent Bolus Name</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2413338</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C390</PreferredName>
        <Version>1</Version>
        <LongName>Contrast Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C390</PREFERRED_NAME>
            <LONG_NAME>Contrast Agent</LONG_NAME>
            <CON_ID>2202441</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2413340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15678:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Bolus Infusion Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15678</PREFERRED_NAME>
            <LONG_NAME>Bolus Infusion Procedure</LONG_NAME>
            <CON_ID>2413339</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015121</PublicId>
      <PreferredName>CONT_AGT_BOLUS_TXT</PreferredName>
      <PreferredDefinition>Text terms to capture the names of contrast/bolus agents given to increase visualization of structures and tissues during medical imaging.</PreferredDefinition>
      <LongName>Contrast Agent Bolus Name Text</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>64</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>e.g., Omnipaque</VALIDVALUE>
          <VALUEMEANING>e.g., Omnipaque</VALUEMEANING>
          <MEANINGDESCRIPTION>e.g., Omnipaque</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omnipaque</VALIDVALUE>
          <VALUEMEANING>Omnipaque</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0729203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Contrast/Bolus Agent</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Contrast/Bolus Agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180933</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>LIDC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rider Project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812022</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614828</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RIDER</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1015">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>61457</PUBLICID>
    <LONGNAME>Radiation Therapy Technique Type</LONGNAME>
    <PREFERREDNAME>RT_TECHNIQUE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the radiation therapy technique used to administer therapeutic doses for protocol treatment.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010486</PublicId>
      <PreferredName>RT_TECHNIQUE</PreferredName>
      <PreferredDefinition>information related to the practiced series of actions completed for therapeutic radiation using visible, laser, or ultraviolet light.</PreferredDefinition>
      <LongName>Radiation Therapy Technique</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231639</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16847</PREFERRED_NAME>
            <LONG_NAME>Technique</LONG_NAME>
            <CON_ID>2203854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015343</PublicId>
      <PreferredName>RT_TECHNIQUE_TP</PreferredName>
      <PreferredDefinition>a description of a practiced series of actions completed for therapeutic radiation using visible, laser, or ultraviolet light to treat cancer.</PreferredDefinition>
      <LongName>Radiation Therapy Technique Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTEP CDE Committee</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AP/PA</VALIDVALUE>
          <VALUEMEANING>AP/PA</VALUEMEANING>
          <MEANINGDESCRIPTION>AP/PA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combination of above</VALIDVALUE>
          <VALUEMEANING>COMBINATION OF ABOVE</VALUEMEANING>
          <MEANINGDESCRIPTION>COMBINATION OF ABOVE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Four-field box</VALIDVALUE>
          <VALUEMEANING>FOUR-FIELD BOX</VALUEMEANING>
          <MEANINGDESCRIPTION>FOUR-FIELD BOX</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lateral opposed</VALIDVALUE>
          <VALUEMEANING>LATERAL OPPOSED</VALUEMEANING>
          <MEANINGDESCRIPTION>LATERAL OPPOSED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>OTHER SPECIFY</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rotation</VALIDVALUE>
          <VALUEMEANING>ROTATION</VALUEMEANING>
          <MEANINGDESCRIPTION>ROTATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0035868</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3D conformal</VALIDVALUE>
          <VALUEMEANING>3D Conformal Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiation therapy that uses computers to create a 3-dimensional picture of the tumor so that multiple radiation beams can be shaped exactly (conform) to the contour of the treatment area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IMRT</VALIDVALUE>
          <VALUEMEANING>IMRT (intensity modulated RT)</VALUEMEANING>
          <MEANINGDESCRIPTION>An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3D-CRT</VALIDVALUE>
          <VALUEMEANING>3-Dimensional Conformal Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased. (from Varian Oncology web site)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>INRT</VALIDVALUE>
          <VALUEMEANING>Involved node radiation therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Involved node radiation therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-01-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3361328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electron Energy RT</VALIDVALUE>
          <VALUEMEANING>Electron Beam Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Radiation therapy using electron beam</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3D</VALIDVALUE>
          <VALUEMEANING>3D</VALUEMEANING>
          <MEANINGDESCRIPTION>The property of being measured and described using three orthogonal directions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Both</VALIDVALUE>
          <VALUEMEANING>Both</VALUEMEANING>
          <MEANINGDESCRIPTION>One and the other; relating to or being two in conjunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radiation Therapy Technique</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Radiation Therapy Technique</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RT Technique</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Planned radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiotherapy Technique</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>How was radiation therapy treated?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation therapy technique for boost</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0724</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171059</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>0065259</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_TECHNIQUE_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1016">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>62341</PUBLICID>
    <LONGNAME>Radiation Therapy Interruption Reason</LONGNAME>
    <PREFERREDNAME>RT_INTR_RSN</PREFERREDNAME>
    <PREFERREDDEFINITION>an explanation or reason for interruptions in the radiation treatment schedule.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014277</PublicId>
      <PreferredName>RT_INTR</PreferredName>
      <PreferredDefinition>an interruption of the planned schedule of radiation treatments.</PreferredDefinition>
      <LongName>Radiation Therapy Interruption</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2480308</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25542</PreferredName>
        <Version>1</Version>
        <LongName>Interruption</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25542</PREFERRED_NAME>
            <LONG_NAME>Interruption</LONG_NAME>
            <CON_ID>2203831</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015355</PublicId>
      <PreferredName>RT_INTR_RSN</PreferredName>
      <PreferredDefinition>an explanation for breaks in radiation treatment schedule.</PreferredDefinition>
      <LongName>RT Interruption Reason</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184326</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Reason</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>medical condition</VALIDVALUE>
          <VALUEMEANING>MEDICAL CONDITION, SPECIFY</VALUEMEANING>
          <MEANINGDESCRIPTION>MEDICAL CONDITION, SPECIFY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>non-medical reason</VALIDVALUE>
          <VALUEMEANING>NON-MEDICAL REASON</VALUEMEANING>
          <MEANINGDESCRIPTION>NON-MEDICAL REASON</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>other</VALIDVALUE>
          <VALUEMEANING>OTHER SPECIFY</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>scheduling problem</VALIDVALUE>
          <VALUEMEANING>Scheduling problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduling problem</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>technical problem</VALIDVALUE>
          <VALUEMEANING>TECHNICAL PROBLEM</VALUEMEANING>
          <MEANINGDESCRIPTION>A problem with some technical aspect of a clinical study, usually related to an instrument.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49633</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>toxicity</VALIDVALUE>
          <VALUEMEANING>Toxicity</VALUEMEANING>
          <MEANINGDESCRIPTION>Toxicity; the degree to which something is poisonous.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify reason</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>RT Interruptions Reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Cervical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Ovarian</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811938</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1017">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>62733</PUBLICID>
    <LONGNAME>Disease Respiratory Symptom Ind-3</LONGNAME>
    <PREFERREDNAME>DZ_RESP_SM_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if an individual is experiencing breathing or other respiratory difficulty as a sign or condition of disease.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010445</PublicId>
      <PreferredName>DZ_RESP_SM</PreferredName>
      <PreferredDefinition>related to breathing or other respiratory difficulty as an indication that a definite pathologic process is present.</PreferredDefinition>
      <LongName>Disease Respiratory Symptom</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2494738</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25656:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Respiratory Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25656</PREFERRED_NAME>
            <LONG_NAME>Respiratory</LONG_NAME>
            <CON_ID>2202469</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Respiratory symptoms</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Respiratory symptoms</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>1003</AlternateName>
        <AlternateNameType>HISTORICAL_CDE_ID</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1018">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64165</PUBLICID>
    <LONGNAME>Disease Extracapsular Extension Ind-3</LONGNAME>
    <PREFERREDNAME>DZ_EXTCP_EX_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator that asks whether or not there is extracapsular extension.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2015008</PublicId>
      <PreferredName>DZ_EX</PreferredName>
      <PreferredDefinition>the extension of a disease.</PreferredDefinition>
      <LongName>Disease Extension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177499</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Extension</PreferredName>
        <Version>1</Version>
        <LongName>Extension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25270</PREFERRED_NAME>
            <LONG_NAME>Extend</LONG_NAME>
            <CON_ID>2203922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COMMENT_389</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Add instruction to template form: If yes,</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Extracapsular Extension Ind</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Extracapsular Extension?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Extracapsular Extension?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG OPEN CheckList</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have evidence of extracapsular spread?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811932</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SPOREs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811942</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical blca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1005</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0815</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPOREs</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Disease Extracapsular Extension Ind-3</AlternateName>
        <AlternateNameType>TCGA_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>disease_extracapsular_extension_ind-3</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DZ_EXTCP_EX_IND-3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1019">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64560</PUBLICID>
    <LONGNAME>Laboratory Procedure Leukemic Cell Outcome Percentage Value</LONGNAME>
    <PREFERREDNAME>LAB_LEUK_OC_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the percentage of leukemic cells, malignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited, found in peripheral blood.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2191367</PublicId>
      <PreferredName>LAB_LEUKCL_OC</PreferredName>
      <PreferredDefinition>information related to the result from the medical procedure that involves testing a sample of blood for a leukemic cell, malignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited.</PreferredDefinition>
      <LongName>Laboratory Procedure Leukemic Cell Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2775986</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25553:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Leukemic Cell Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25553</PREFERRED_NAME>
            <LONG_NAME>Leukemic Cell</LONG_NAME>
            <CON_ID>2202338</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019101</PublicId>
      <PreferredName>HMT_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>a percentage for a hematologic laboratory value.</PreferredDefinition>
      <LongName>Blood Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lab, Hematology, Leukemic Cells, Cell Percentage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Peripheral Leukemic Cells (%)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Peripheral Leukemic Cells (%)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1020">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64699</PUBLICID>
    <LONGNAME>Tumor Marker Final Pathology Diagnosis Result Type</LONGNAME>
    <PREFERREDNAME>TMMK_FI_PA_DX_RES_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the last interpretation of outcome from pathologic tests to determine presence and nature of cancer by evaluating a sample of tissue for substances present in or produced by tumor.</PREFERREDDEFINITION>
    <VERSION>3.1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192071</PublicId>
      <PreferredName>TMMKR_FIN_PAT_DX_RES</PreferredName>
      <PreferredDefinition>related to the last outcome from tests by a specialist in cellular structure and function to evaluate tissue for substances present in or produced by tumor to determine presence and nature of cancer.</PreferredDefinition>
      <LongName>Tumor Marker Final Pathology Diagnosis Result</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443094</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17220</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Marker</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17220</PREFERRED_NAME>
            <LONG_NAME>Tumor Marker</LONG_NAME>
            <CON_ID>2202551</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2491434</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25508:C18189:C15220:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Final Pathology Diagnosis Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25508</PREFERRED_NAME>
            <LONG_NAME>Final</LONG_NAME>
            <CON_ID>2206213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019272</PublicId>
      <PreferredName>TMMKR_PATH_DX_RES_TP</PreferredName>
      <PreferredDefinition>the outcome reported from pathologic tests to determine presence and nature of cancer by evaluating a sample of tissue for substances present in or produced by tumor.</PreferredDefinition>
      <LongName>Tumor Marker Pathology Diagnosis Result Type</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Involving advantage or good.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER and PgR negative</VALIDVALUE>
          <VALUEMEANING>ER and PgR negative</VALUEMEANING>
          <MEANINGDESCRIPTION>ER and PgR negative</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER and PgR positive</VALIDVALUE>
          <VALUEMEANING>ER and PgR positive</VALUEMEANING>
          <MEANINGDESCRIPTION>ER and PgR positive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER or PgR positive</VALIDVALUE>
          <VALUEMEANING>ER or PgR positive</VALUEMEANING>
          <MEANINGDESCRIPTION>ER or PgR positive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER and/or PgR positive</VALIDVALUE>
          <VALUEMEANING>ER and/or PgR positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Estrogen and/or Progesterone positive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Final Interpretation of Resul</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Final Interpretation of Results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Final Result Marker</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>versioned due to improper ISO naming; corrected and released</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tumor Markers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811932</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>FINAL_RESULT_MARKER</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1021">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>64777</PUBLICID>
    <LONGNAME>Pathology Tissue Specimen Antibody Staining Method Type</LONGNAME>
    <PREFERREDNAME>PA_TI_SP_AB_ST_ME_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>a description for a process using protein from white blood cells to produce coloration in a sample of cells with similar characteristics for assessment by a specialist in tissue and cell function.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010652</PublicId>
      <PreferredName>PA_TIS_SPE_AB_ST_MET</PreferredName>
      <PreferredDefinition>related to the process using protein from certain white blood cells to produce coloration in sample of cells with similar characteristics that are assessed by a specialist in tissue and cell function.</PreferredDefinition>
      <LongName>Pathology Tissue Specimen Antibody Staining Method</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2488643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18189:C12801:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Pathology Tissue Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2488846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16295:C23010</PreferredName>
        <Version>1</Version>
        <LongName>Antibody Staining Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C23010</PREFERRED_NAME>
            <LONG_NAME>Staining Method</LONG_NAME>
            <CON_ID>2224007</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015537</PublicId>
      <PreferredName>PA_TI_SP_AB_ST_ME_TP</PreferredName>
      <PreferredDefinition>a description for a process using protein from white blood cells to produce coloration in a sample of cells with similar characteristics for assessment by a specialist in tissue and cell function.</PreferredDefinition>
      <LongName>Pathology Tissue Specimen Antibody Staining Method Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTEP CDE Committee</Origin>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IHC not done</VALIDVALUE>
          <VALUEMEANING>IHC not done</VALUEMEANING>
          <MEANINGDESCRIPTION>IHC not done</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-08-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CB-11 other</VALIDVALUE>
          <VALUEMEANING>CB-11 OTHER</VALUEMEANING>
          <MEANINGDESCRIPTION>CB-11 OTHER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CB-11/Ventana Kit</VALIDVALUE>
          <VALUEMEANING>CB-11/VENTANA KIT</VALUEMEANING>
          <MEANINGDESCRIPTION>CB-11/VENTANA KIT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DAKO Herceptest [TM]</VALIDVALUE>
          <VALUEMEANING>DAKO HERCEPTEST [TM]</VALUEMEANING>
          <MEANINGDESCRIPTION>DAKO HERCEPTEST [TM]</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>OTHER SPECIFY</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TAB-250</VALIDVALUE>
          <VALUEMEANING>TAB-250</VALUEMEANING>
          <MEANINGDESCRIPTION>TAB-250</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DAKO A0485</VALIDVALUE>
          <VALUEMEANING>DAKO A0485</VALUEMEANING>
          <MEANINGDESCRIPTION>DAKO A0485</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2647264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NCL-c-erbB2-316</VALIDVALUE>
          <VALUEMEANING>NCL-c-erbB2-316</VALUEMEANING>
          <MEANINGDESCRIPTION>NCL-c-erbB2-316</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2647265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Staining Antibody</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Staining Antibody</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunohistochemistry Kit or Test Type </DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812245</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tumor Markers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pathology Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811932</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer Data Mart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812624</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PA_TI_SP_AB_ST_ME_TP</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1022">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2001833</PUBLICID>
    <LONGNAME>Bone Fracture Date</LONGNAME>
    <PREFERREDNAME>BONE_FX_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>a date when fracture of a bone occurs.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2181274</PublicId>
      <PreferredName>BONE_FX</PreferredName>
      <PreferredDefinition>information related to bone fracture.</PreferredDefinition>
      <LongName>Bone Fracture</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176965</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Bone</PreferredName>
        <Version>1</Version>
        <LongName>Bone</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12366</PREFERRED_NAME>
            <LONG_NAME>Bone</LONG_NAME>
            <CON_ID>2202686</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Fracture</PreferredName>
        <Version>1</Version>
        <LongName>Fracture</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3046</PREFERRED_NAME>
            <LONG_NAME>Fracture</LONG_NAME>
            <CON_ID>2203813</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Fracture</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Bone Fracture</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of fracture</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1023">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2002422</PUBLICID>
    <LONGNAME>Tumor First Progression Begin Date</LONGNAME>
    <PREFERREDNAME>TUM_F_PROG_BEG_ DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date when the first onset of a sign of disease progression is noted</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014116</PublicId>
      <PreferredName>TUMOR_PROG</PreferredName>
      <PreferredDefinition>the progression of the tumor or disease.</PreferredDefinition>
      <LongName>Tumor Progression</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176931</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Tumor</PreferredName>
        <Version>1</Version>
        <LongName>Tumor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177380</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Progression</PreferredName>
        <Version>1</Version>
        <LongName>Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25331</PREFERRED_NAME>
            <LONG_NAME>Progression</LONG_NAME>
            <CON_ID>2202788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Suspected Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Suspected Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Progression Suspected Begin Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of last evaluation demonstrating free from progression</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1024">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2003325</PUBLICID>
    <LONGNAME>Prior Therapy Type Text Code</LONGNAME>
    <PREFERREDNAME>PRIOR_RX_TP_TXT_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>One or two character representation(s) for type(s) of prior therapy modality (Chemotherapy, Immunotherapy, others) received by a patient/participant.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012422</PublicId>
      <PreferredName>CDUS_PRIOR_TX_CD</PreferredName>
      <PreferredDefinition>Codes assigned by CDUS to represent types of prior therapy.</PreferredDefinition>
      <LongName>CDUS Prior Therapy Code</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660437</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19992:C16124</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Data Update System Prior Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19992</PREFERRED_NAME>
            <LONG_NAME>Clinical Data Update System</LONG_NAME>
            <CON_ID>2202434</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16124</PREFERRED_NAME>
            <LONG_NAME>Prior Therapy</LONG_NAME>
            <CON_ID>2202433</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016962</PublicId>
      <PreferredName>PRIOR_RX_TP_TXT_CD</PreferredName>
      <PreferredDefinition>One or two character representation(s) for types of prior therapy modality (Chemotherapy, Immunotherapy, others).</PreferredDefinition>
      <LongName>Prior Therapy Type Text Code</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234893</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Text Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BM</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>(trans-plan-TAY-shun) A procedure to replace bone marrow destroyed by treatment with high doses of anticancer drugs or radiation. Transplantation may be autologous (an individual&#39;s own marrow saved before treatment), allogeneic (marrow donated by someone else), or syngeneic (marrow donated by an identical twin).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15194</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CS</VALIDVALUE>
          <VALUEMEANING>Single Agent Systemic Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Systemic chemotherapy with a single agent regimen.  A regimen is described as a distinctive collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy.  All routes of administration are acceptable as long as the agent is intended for systemic therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S</VALIDVALUE>
          <VALUEMEANING>Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R</VALIDVALUE>
          <VALUEMEANING>Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>V</VALIDVALUE>
          <VALUEMEANING>Vaccine Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G</VALIDVALUE>
          <VALUEMEANING>Gene Transfer</VALUEMEANING>
          <MEANINGDESCRIPTION>Incorporation of new DNA into an organism&#39;s cells, usually by a vector such as a modified virus. Used in gene therapy.(From Human Genome Project Information).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER</VALIDVALUE>
          <VALUEMEANING>Extensive Radiation</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer therapy using ionizing radiation to a significant (&gt;50%) portion of the body, e.g. craniospinal, total body irradiation, or pelvic radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>Immunotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LR</VALIDVALUE>
          <VALUEMEANING>Limited Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer therapy using ionizing radiation to &lt; 50% of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H</VALIDVALUE>
          <VALUEMEANING>Hormone Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AS</VALIDVALUE>
          <VALUEMEANING>Antisense Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Antisense Oligonucleotide Therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OV</VALIDVALUE>
          <VALUEMEANING>Oncolytic Virotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment using an oncolytic virus (a virus that infects and breaks down cancer cells but not normal cells). Oncolytic virus therapy may make it easier to kill tumor cells with chemotherapy and radiation therapy. It is a type of targeted therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PT</VALIDVALUE>
          <VALUEMEANING>Prior Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Prior Therapy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No Prior Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>No prior cancer treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563824</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BP</VALIDVALUE>
          <VALUEMEANING>Biphosphonate Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A family of drugs used to treat osteoporosis and the bone pain caused by some types of cancer. Also called diphosphonates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-11-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AR</VALIDVALUE>
          <VALUEMEANING>Anti-retroviral Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug therapy which targets retrovirus function by multiple mechanisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939753</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>Chemotherapy, NOS</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04): Not characterized in any other way.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19594, C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939754</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CM</VALIDVALUE>
          <VALUEMEANING>Chemotherapy, multiple agents systemic</VALUEMEANING>
          <MEANINGDESCRIPTION>(sis-TEM-ik) Affecting the entire body.: many copies of or many forms: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI): The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632, C1708, C17648, C13310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939755</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HE</VALIDVALUE>
          <VALUEMEANING>Hematopoietic Stem Cell Transplantation</VALUEMEANING>
          <MEANINGDESCRIPTION>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.): The grafting of tissues from one individual to another or place to place within a single individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12551, C15342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ID</VALIDVALUE>
          <VALUEMEANING>Image Directed Local Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Tests that produce pictures of areas inside the body.: Treatment that affects cells in the tumor and the area close to it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15687, C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NC</VALIDVALUE>
          <VALUEMEANING>Chemotherapy, non-cytotoxic</VALUEMEANING>
          <MEANINGDESCRIPTION>Chemotherapy, non-cytotoxic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SY</VALIDVALUE>
          <VALUEMEANING>Systemic Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5028391</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RA</VALIDVALUE>
          <VALUEMEANING>Radiosensitizing Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5027911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DI</VALIDVALUE>
          <VALUEMEANING>Drug and/or Immunotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.: Used to indicate that either or both of two items or options may be valid.: Therapy designed to induce changes in a patient&#39;s immune status in order to treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15262, C48928, C1909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6945757</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Therapy Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Therapy Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Therapy Name Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radiation Therapy Code</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation Therapy Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Therapy Type Code</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Therapy Type Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior therapy type(s):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Radiation </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Therapy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248642</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatment Summary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248643</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oregon Health &amp; Sciences University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OHSU_288</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>THERAPY_TYPE_CODE</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_RX_TP_TXT_CD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1025">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2003945</PUBLICID>
    <LONGNAME>Packed Red Blood Cell Transfusion Received Most Recent Date</LONGNAME>
    <PREFERREDNAME>PRBC_TRA_RCVD_M_R_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the most recent date received transfusion of packed red blood cells.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012951</PublicId>
      <PreferredName>PRBC_TRANS_RCVD</PreferredName>
      <PreferredDefinition>information related to received transfusion of packed red blood cells.</PreferredDefinition>
      <LongName>Packed Red Blood Cell Transfusion Received</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2459088</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15409</PreferredName>
        <Version>1</Version>
        <LongName>Packed Red Blood Cell Transfusion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15409</PREFERRED_NAME>
            <LONG_NAME>Packed Red Blood Cell Transfusion</LONG_NAME>
            <CON_ID>2205021</CON_ID>
            <DEFINITION_SOURCE>N/A</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639</PreferredName>
        <Version>1</Version>
        <LongName>Received</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188928</PublicId>
      <PreferredName>MOSTRECENT_DT</PreferredName>
      <PreferredDefinition>the most recent date of an event, assessment, or treatment.</PreferredDefinition>
      <LongName>Most Recent Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yyyy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208021</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25577:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Most Recent Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25577</PREFERRED_NAME>
            <LONG_NAME>Most Recent</LONG_NAME>
            <CON_ID>2206311</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of most recent RBC transfusion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of most recent  PRBC tra</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of most recent  PRBC transfusion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1026">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2004100</PUBLICID>
    <LONGNAME>Response Note Text</LONGNAME>
    <PREFERREDNAME>RESP_NOTE_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Free text field to capture details and reason for a response call.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014027</PublicId>
      <PreferredName>DZ_RESP</PreferredName>
      <PreferredDefinition>The response of the patient&#39;s disease to treatment.</PreferredDefinition>
      <LongName>Disease Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177336</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Response</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25755</PREFERRED_NAME>
            <LONG_NAME>Response</LONG_NAME>
            <CON_ID>2202805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017364</PublicId>
      <PreferredName>CHAR_32_DESC_TXT</PreferredName>
      <PreferredDefinition>Free text field of 32 characters to capture a description.</PreferredDefinition>
      <LongName>Character 32 Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>32</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Response Note</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Response Note</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Response Note Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMSv3.02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811686</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR 2011 Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Course Assessment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3248623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Albert Einstein Medical Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 0404</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812578</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>P1_CPT_BCNU_RD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 02452</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812584</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 03058</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812585</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi 04251</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AE_104_085</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UNMC 284-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SJO_ERCC1_07035</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rembrandt</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2812349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857175</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Adopter CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS 3.12B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812490</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RESP_NOTE</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RESP_NOTE_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>RESP_NOTE_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1027">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005441</PUBLICID>
    <LONGNAME>CTC Adverse Event Bruising Description Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_BRUISING_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Dermatology/Skin, assessment of the severity of a bruising (in absence of grade 3 or 4 thrombocytopenia) adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192403</PublicId>
      <PreferredName>CTC_AE_BRUISING_DESC</PreferredName>
      <PreferredDefinition>information related to the grade or description of a CTC adverse event of bruising.</PreferredDefinition>
      <LongName>CTC Adverse Event Bruising Description</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660725</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37921:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Bruising Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37921</PREFERRED_NAME>
            <LONG_NAME>Bruise</LONG_NAME>
            <CON_ID>2615814</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017641</PublicId>
      <PreferredName>CTC_AE_BRUISING_GD</PreferredName>
      <PreferredDefinition>in CTC category Dermatology/Skin, assessment of the severity of a bruising (in absence of grade 3 or 4 thrombocytopenia) adverse event using a graded scale.</PreferredDefinition>
      <LongName>CTC Adverse Event Bruising Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>generalized</VALUEMEANING>
          <MEANINGDESCRIPTION>generalized</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>localized or in dependent area</VALUEMEANING>
          <MEANINGDESCRIPTION>localized or in dependent area</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bruising Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Bruising (i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Bruising (in absence of grade 3 or 4 thrombocytopenia) Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1028">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005466</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Impotence Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_IMPOTENCE_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Sexual/Reproductive Function, assessment of the severity of an erectile impotence adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192486</PublicId>
      <PreferredName>CTC_AE_IMPOTENCE</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of impotence.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Events Impotence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192484</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Impotence</PreferredName>
        <Version>1</Version>
        <LongName>Impotence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL106233</PREFERRED_NAME>
            <LONG_NAME>Impotence</LONG_NAME>
            <CON_ID>2204572</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017666</PublicId>
      <PreferredName>CTC_AE_IMPOTENCE_GD</PreferredName>
      <PreferredDefinition>in CTC category Sexual/Reproductive Function, assessment of the severity of an erectile impotence adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Impotence Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Decrease in erectile function (frequency/rigidity of erections) but erectile aids not indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Decrease in erectile function (frequency/rigidity of erections) but erectile aids not indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Decrease in erectile function (frequency/rigidity of erections), erectile aids indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Decrease in erectile function (frequency/rigidity of erections), erectile aids indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Decrease in erectile function (frequency/rigidity of erections) but erectile aids not helpful; penile prosthesis indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Decrease in erectile function (frequency/rigidity of erections) but erectile aids not helpful; penile prosthesis indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Erectile im</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Erectile impotence Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Erectile impotence Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1029">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005553</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Hypoxia Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_HYPOXIA_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Pulmonary/Upper Respiratory, assessment of the severity of a hypoxia adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2193082</PublicId>
      <PreferredName>CTC_AE_HYPOXIA</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of hypoxia.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Hypoxia</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2193080</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Hypoxia</PreferredName>
        <Version>1</Version>
        <LongName>Hypoxia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3890</PREFERRED_NAME>
            <LONG_NAME>Hypoxia</LONG_NAME>
            <CON_ID>2203764</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017753</PublicId>
      <PreferredName>CTC_AE_HYPOXIA_GD</PreferredName>
      <PreferredDefinition>in CTC category Pulmonary/Upper Respiratory, assessment of the severity of a hypoxia adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Hypoxia Grade</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTCAE:Common Terminology Criteria for Adverse Events v3.0</Origin>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Life-threatening; intubation or ventilation indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening; intubation or ventilation indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Decreased O\2 saturation with exercise (e.g., pulse oximeter &lt;88%); intermittent supplemental oxygen</VALUEMEANING>
          <MEANINGDESCRIPTION>Decreased O\2 saturation with exercise (e.g., pulse oximeter &lt;88%); intermittent supplemental oxygen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Decreased O\2 saturation at rest; continuous oxygen indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Decreased O\2 saturation at rest; continuous oxygen indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571486</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Hypoxia Gra</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Hypoxia Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Hypoxia Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1030">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2005718</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Other Arrhythmia Specify</LONGNAME>
    <PREFERREDNAME>CTC_AE_OTH_ARHY_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Cardiac Arrhythmia, text description of an unlisted adverse event type.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTCAE:Common Terminology Criteria for Adverse Events v3.0</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2193241</PublicId>
      <PreferredName>CTC_AE_O_ARRYTHMIA</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of other arrythmia.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Other Arrhythmia</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207070</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C2881</PreferredName>
        <Version>1</Version>
        <LongName>Other Arrhythmia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2881</PREFERRED_NAME>
            <LONG_NAME>Arrhythmia</LONG_NAME>
            <CON_ID>2202296</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018370</PublicId>
      <PreferredName>AE_SPEC</PreferredName>
      <PreferredDefinition>the free text field to specify an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTCAE_SOURCE</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDUS_SOURCE</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Use CTC v2.0 or CTCAE v3.0 (as determined by CTEP) for reporting to Clinical Data Update System (CDUS) v3.0 Release 2</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Cardiac Arr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Cardiac Arrhythmia-Other (Specify)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1031">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006108</PUBLICID>
    <LONGNAME>Laboratory Procedure Segmented Neutrophil Outcome Percentage Value</LONGNAME>
    <PREFERREDNAME>HMT_SEG_LAB_SPEC_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>a fraction or ratio with 100 understood as the denominator for a laboratory measure of results from a procedure that involves testing of blood for mature neutrophil with a nucleus having distinct lobes connected by filaments.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3245497</PublicId>
      <PreferredName>2543047v1.0:3245495v1.0</PreferredName>
      <PreferredDefinition>information related to outcome from a procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for mature neutrophil with a nucleus having distinct lobes connected by filaments.</PreferredDefinition>
      <LongName>Laboratory Procedure Segmented Neutrophil Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3245495</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36719:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Segmented Neutrophil Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36719</PREFERRED_NAME>
            <LONG_NAME>Segmented Neutrophil</LONG_NAME>
            <CON_ID>2876587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018341</PublicId>
      <PreferredName>SEGS_LAB_SPEC_VAL</PreferredName>
      <PreferredDefinition>a fraction or ratio with 100 understood as the denominator for a laboratory measure of segmented neutrophils.</PreferredDefinition>
      <LongName>Laboratory Procedure Segmented Neutrophil Result Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Segs</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Segs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Peripheral blood segs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Peripheral blood segmented neutrophils</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>HMT_SEG_LAB_SPEC_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HMT_SEG_LAB_SPEC_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1032">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006142</PUBLICID>
    <LONGNAME>Anticonvulsant Medication Received Ind-2</LONGNAME>
    <PREFERREDNAME>ACON_MEDS_RECD_IND-2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the patient is receiving enzyme-inducing anticonvulsant medication.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014035</PublicId>
      <PreferredName>MEDS_RECD</PreferredName>
      <PreferredDefinition>the medication received by the patient.</PreferredDefinition>
      <LongName>Medication Received</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177035</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Medication</PreferredName>
        <Version>1</Version>
        <LongName>Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184327</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Received</PreferredName>
        <Version>1</Version>
        <LongName>Received</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is patient receiving enzyme-i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is patient receiving enzyme-inducing anticonvulsant drugs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Currently on enzyme inducing anti-convulsants or other strong inducers (efavirenz, nevirapine, barbiturates, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, pioglitazone) or strong inhibitors of CYP3A4 (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, saquinavir, telithromycin).  (See http://medicine.iupui.edu/clinpharm/ddis/table.asp for an up-to-date list of strong inducers and inhibitors of CYP3A4.)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Will the patient receive treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine, primidone or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John&#39;s wort within 14 days prior to the first dose of MLN8237 or during the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient received treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine, primidone or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John&#39;s wort within 14 days prior to the first dose of MLN8237 or during the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient receiving non-enzyme inducing anticonvulsant drugs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient receiving anticonvulsant drugs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient require enzyme inducing anti-convulsants to control seizures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient receiving anticonvulsant drugs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient receiving non-enzyme inducing anticonvulsant drugs?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient require anti-convulsants to control seizures?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient received enzyme-inducing anticonvulsants within 14 days prior to enrollment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the uncontrolled seizure disorder stabilized with anti-convulsants?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0231D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104894</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PBTC-042</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4254119</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>10000103</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ACON_MEDS_RECD_IND-2</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ACON_MEDS_RECD_IND-2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ACON_MEDS_RECD_IND-2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ACON_MEDS_RECD_IND-2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ACON_MEDS_RECD</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1033">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006183</PUBLICID>
    <LONGNAME>Person Address Country Code</LONGNAME>
    <PREFERREDNAME>COUNTRY_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The two-letter code of values representing the countries of the world for the address of a person.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRDS</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDUS:Clinical Data Update System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014826</PublicId>
      <PreferredName>PERSON_ADDR</PreferredName>
      <PreferredDefinition>the address or postal information for a person.</PreferredDefinition>
      <LongName>Person Address</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177663</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Address</PreferredName>
        <Version>1</Version>
        <LongName>Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018396</PublicId>
      <PreferredName>CTRY_CD</PreferredName>
      <PreferredDefinition>two-letter coded values representing the countries of the world (CTEP, June 1999).</PreferredDefinition>
      <LongName>Country Code</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CH</VALIDVALUE>
          <VALUEMEANING>Switzerland</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, east of France, north of Italy. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17181</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CK</VALIDVALUE>
          <VALUEMEANING>Cook Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Cook Islands</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CM</VALIDVALUE>
          <VALUEMEANING>Cameroon</VALUEMEANING>
          <MEANINGDESCRIPTION>Cameroon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CN</VALIDVALUE>
          <VALUEMEANING>China</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, south of Kazakhstan, Mongolia and Russia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CO</VALIDVALUE>
          <VALUEMEANING>Colombia</VALUEMEANING>
          <MEANINGDESCRIPTION>Colombia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CR</VALIDVALUE>
          <VALUEMEANING>Costa Rica</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CU</VALIDVALUE>
          <VALUEMEANING>Cuba</VALUEMEANING>
          <MEANINGDESCRIPTION>An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CV</VALIDVALUE>
          <VALUEMEANING>Cape Verde</VALUEMEANING>
          <MEANINGDESCRIPTION>Cape Verde</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CX</VALIDVALUE>
          <VALUEMEANING>Christmas Island</VALUEMEANING>
          <MEANINGDESCRIPTION>An Australian-administered island in the eastern Indian Ocean south of Java, Indonesia. (American Heritage Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CY</VALIDVALUE>
          <VALUEMEANING>Cyprus</VALUEMEANING>
          <MEANINGDESCRIPTION>An island in the Mediterranean Sea, south of Turkey. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563948</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CZ</VALIDVALUE>
          <VALUEMEANING>Czech Republic</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, southeast of Germany. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DE</VALIDVALUE>
          <VALUEMEANING>Germany</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DK</VALIDVALUE>
          <VALUEMEANING>Denmark</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern Europe, bordering the Baltic Sea and the North Sea, on a peninsula north of Germany (Jutland); also includes two major islands (Sjaelland and Fyn). (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DM</VALIDVALUE>
          <VALUEMEANING>Dominica</VALUEMEANING>
          <MEANINGDESCRIPTION>Dominica</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DZ</VALIDVALUE>
          <VALUEMEANING>Algeria</VALUEMEANING>
          <MEANINGDESCRIPTION>Algeria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DO</VALIDVALUE>
          <VALUEMEANING>Dominican Republic</VALUEMEANING>
          <MEANINGDESCRIPTION>Dominican Republic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EC</VALIDVALUE>
          <VALUEMEANING>Ecuador</VALUEMEANING>
          <MEANINGDESCRIPTION>Ecuador</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EE</VALIDVALUE>
          <VALUEMEANING>Estonia</VALUEMEANING>
          <MEANINGDESCRIPTION>Estonia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EG</VALIDVALUE>
          <VALUEMEANING>Egypt</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EH</VALIDVALUE>
          <VALUEMEANING>Western Sahara</VALUEMEANING>
          <MEANINGDESCRIPTION>Western Sahara</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER</VALIDVALUE>
          <VALUEMEANING>Eritrea</VALUEMEANING>
          <MEANINGDESCRIPTION>Eritrea</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ES</VALIDVALUE>
          <VALUEMEANING>Spain</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, North Atlantic Ocean, and Pyrenees Mountains, southwest of France. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17152</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ET</VALIDVALUE>
          <VALUEMEANING>Ethiopia</VALUEMEANING>
          <MEANINGDESCRIPTION>Ethiopia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FI</VALIDVALUE>
          <VALUEMEANING>Finland</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FJ</VALIDVALUE>
          <VALUEMEANING>Fiji</VALUEMEANING>
          <MEANINGDESCRIPTION>Fiji</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FO</VALIDVALUE>
          <VALUEMEANING>Faroe Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Faroe Islands</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FR</VALIDVALUE>
          <VALUEMEANING>France</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Europe, bordering the Bay of Biscay and English Channel, between Belgium and Spain, southeast of the UK; bordering the Mediterranean Sea, between Italy and Spain. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SX</VALIDVALUE>
          <VALUEMEANING>Sint Maarten (Dutch Part)</VALUEMEANING>
          <MEANINGDESCRIPTION>A country comprising the southern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy, a constituent country of the Kingdom of the Netherlands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4667194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GA</VALIDVALUE>
          <VALUEMEANING>Gabon</VALUEMEANING>
          <MEANINGDESCRIPTION>Gabon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16596</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563967</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GD</VALIDVALUE>
          <VALUEMEANING>Grenada</VALUEMEANING>
          <MEANINGDESCRIPTION>Grenada</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GH</VALIDVALUE>
          <VALUEMEANING>Ghana</VALUEMEANING>
          <MEANINGDESCRIPTION>Ghana</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26330</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GI</VALIDVALUE>
          <VALUEMEANING>Gibraltar</VALUEMEANING>
          <MEANINGDESCRIPTION>Gibraltar</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16638</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GL</VALIDVALUE>
          <VALUEMEANING>Greenland</VALUEMEANING>
          <MEANINGDESCRIPTION>Greenland</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GM</VALIDVALUE>
          <VALUEMEANING>Gambia</VALUEMEANING>
          <MEANINGDESCRIPTION>Gambia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16598</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GN</VALIDVALUE>
          <VALUEMEANING>Guinea</VALUEMEANING>
          <MEANINGDESCRIPTION>Guinea</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16655</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GQ</VALIDVALUE>
          <VALUEMEANING>Equatorial Guinea</VALUEMEANING>
          <MEANINGDESCRIPTION>Equatorial Guinea</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16557</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GT</VALIDVALUE>
          <VALUEMEANING>Guatemala</VALUEMEANING>
          <MEANINGDESCRIPTION>Guatemala</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GY</VALIDVALUE>
          <VALUEMEANING>Guyana</VALUEMEANING>
          <MEANINGDESCRIPTION>Guyana</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16657</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HK</VALIDVALUE>
          <VALUEMEANING>Hong Kong</VALUEMEANING>
          <MEANINGDESCRIPTION>A special administrative region of China, bordering the South China Sea and China. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SS</VALIDVALUE>
          <VALUEMEANING>South Sudan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in east central Africa south of Sudan, north of Uganda and Kenya, and west of Ethiopia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4667192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AL</VALIDVALUE>
          <VALUEMEANING>Albania</VALUEMEANING>
          <MEANINGDESCRIPTION>Albania</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CL</VALIDVALUE>
          <VALUEMEANING>Chile</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern South America, bordering the South Atlantic Ocean and South Pacific Ocean, between Argentina and Peru. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GR</VALIDVALUE>
          <VALUEMEANING>Greece</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LS</VALIDVALUE>
          <VALUEMEANING>Lesotho</VALUEMEANING>
          <MEANINGDESCRIPTION>Lesotho</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PH</VALIDVALUE>
          <VALUEMEANING>Philippines</VALUEMEANING>
          <MEANINGDESCRIPTION>Philippines</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16978</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TO</VALIDVALUE>
          <VALUEMEANING>Tonga</VALUEMEANING>
          <MEANINGDESCRIPTION>Tonga</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ZA</VALIDVALUE>
          <VALUEMEANING>South Africa</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern Africa, at the southern tip of the continent of Africa. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17151</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TL</VALIDVALUE>
          <VALUEMEANING>Timor-Leste</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17200</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RS</VALIDVALUE>
          <VALUEMEANING>Serbia</VALUEMEANING>
          <MEANINGDESCRIPTION>A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3119206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PS</VALIDVALUE>
          <VALUEMEANING>State of Palestine</VALUEMEANING>
          <MEANINGDESCRIPTION>A sovereign state in western Africa consisting of the West Bank and the Gaza Strip. Its capital is Jerusalem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MF</VALIDVALUE>
          <VALUEMEANING>Saint Martin (French Part)</VALUEMEANING>
          <MEANINGDESCRIPTION>A country comprising the northern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ME</VALIDVALUE>
          <VALUEMEANING>Montenegro</VALUEMEANING>
          <MEANINGDESCRIPTION>A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CW</VALIDVALUE>
          <VALUEMEANING>Curacao</VALUEMEANING>
          <MEANINGDESCRIPTION>An island in the Caribbean Sea, north of Venezuela and east of Aruba, a constituent country of the Kingdom of the Netherlands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4667196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BQ</VALIDVALUE>
          <VALUEMEANING>Bonaire, Sint Eustatius and Saba</VALUEMEANING>
          <MEANINGDESCRIPTION>Three islands comprising the Caribbean portion of the Netherlands, north of Venezuela and east of Curacao.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4667198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BL</VALIDVALUE>
          <VALUEMEANING>Saint Barthelemy</VALUEMEANING>
          <MEANINGDESCRIPTION>An island in the Caribbean sea, between Saint Martin and Saint Kitts and Nevis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C83609</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AX</VALIDVALUE>
          <VALUEMEANING>Aland Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>An archipelago in the Baltic Sea at the entrance to the Gulf of Bothnia between Sweden and Finland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44481</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LV</VALIDVALUE>
          <VALUEMEANING>Latvia</VALUEMEANING>
          <MEANINGDESCRIPTION>Latvia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MA</VALIDVALUE>
          <VALUEMEANING>Morocco</VALUEMEANING>
          <MEANINGDESCRIPTION>Morocco</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16878</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MC</VALIDVALUE>
          <VALUEMEANING>Monaco</VALUEMEANING>
          <MEANINGDESCRIPTION>Monaco</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MD</VALIDVALUE>
          <VALUEMEANING>Moldova</VALUEMEANING>
          <MEANINGDESCRIPTION>Moldova</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16871</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MG</VALIDVALUE>
          <VALUEMEANING>Madagascar</VALUEMEANING>
          <MEANINGDESCRIPTION>Madagascar</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16808</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MH</VALIDVALUE>
          <VALUEMEANING>Marshall Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Marshall Islands</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16822</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ML</VALIDVALUE>
          <VALUEMEANING>Mali</VALUEMEANING>
          <MEANINGDESCRIPTION>Mali</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MM</VALIDVALUE>
          <VALUEMEANING>Myanmar</VALUEMEANING>
          <MEANINGDESCRIPTION>Myanmar</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MN</VALIDVALUE>
          <VALUEMEANING>Mongolia</VALUEMEANING>
          <MEANINGDESCRIPTION>Mongolia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MO</VALIDVALUE>
          <VALUEMEANING>Macau</VALUEMEANING>
          <MEANINGDESCRIPTION>Macau</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MR</VALIDVALUE>
          <VALUEMEANING>Mauritania</VALUEMEANING>
          <MEANINGDESCRIPTION>Mauritania</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16826</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MS</VALIDVALUE>
          <VALUEMEANING>Montserrat</VALUEMEANING>
          <MEANINGDESCRIPTION>Montserrat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16876</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MT</VALIDVALUE>
          <VALUEMEANING>Malta</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy). (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MU</VALIDVALUE>
          <VALUEMEANING>Mauritius</VALUEMEANING>
          <MEANINGDESCRIPTION>Mauritius</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16827</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MV</VALIDVALUE>
          <VALUEMEANING>Maldives</VALUEMEANING>
          <MEANINGDESCRIPTION>Maldives</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16815</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MW</VALIDVALUE>
          <VALUEMEANING>Malawi</VALUEMEANING>
          <MEANINGDESCRIPTION>Malawi</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MX</VALIDVALUE>
          <VALUEMEANING>Mexico</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southern North America, bordering the North Pacific Ocean and the Gulf of Mexico, south of the US.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MY</VALIDVALUE>
          <VALUEMEANING>Malaysia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Asia, occupying a peninsula and the northern one-third of the island of Borneo, bordering Indonesia and the South China Sea, south of Vietnam. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MZ</VALIDVALUE>
          <VALUEMEANING>Mozambique</VALUEMEANING>
          <MEANINGDESCRIPTION>Mozambique</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Namibia</VALUEMEANING>
          <MEANINGDESCRIPTION>Namibia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NE</VALIDVALUE>
          <VALUEMEANING>Niger</VALUEMEANING>
          <MEANINGDESCRIPTION>Niger</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NF</VALIDVALUE>
          <VALUEMEANING>Norfolk Island</VALUEMEANING>
          <MEANINGDESCRIPTION>Norfolk Island</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16919</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NG</VALIDVALUE>
          <VALUEMEANING>Nigeria</VALUEMEANING>
          <MEANINGDESCRIPTION>Nigeria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16917</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NI</VALIDVALUE>
          <VALUEMEANING>Nicaragua</VALUEMEANING>
          <MEANINGDESCRIPTION>Nicaragua</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NL</VALIDVALUE>
          <VALUEMEANING>Netherlands</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Europe, bordering the North Sea, between Belgium and Germany. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>Norway</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16920</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NP</VALIDVALUE>
          <VALUEMEANING>Nepal</VALUEMEANING>
          <MEANINGDESCRIPTION>Nepal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NR</VALIDVALUE>
          <VALUEMEANING>Nauru</VALUEMEANING>
          <MEANINGDESCRIPTION>Nauru</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NU</VALIDVALUE>
          <VALUEMEANING>Niue</VALUEMEANING>
          <MEANINGDESCRIPTION>Niue</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NZ</VALIDVALUE>
          <VALUEMEANING>New Zealand</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16914</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OM</VALIDVALUE>
          <VALUEMEANING>Oman</VALUEMEANING>
          <MEANINGDESCRIPTION>Oman</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PA</VALIDVALUE>
          <VALUEMEANING>Panama</VALUEMEANING>
          <MEANINGDESCRIPTION>Panama</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16951</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PE</VALIDVALUE>
          <VALUEMEANING>Peru</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western South America, bordering the South Pacific Ocean, between Chile and Ecuador. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HN</VALIDVALUE>
          <VALUEMEANING>Honduras</VALUEMEANING>
          <MEANINGDESCRIPTION>Honduras</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HR</VALIDVALUE>
          <VALUEMEANING>Croatia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HT</VALIDVALUE>
          <VALUEMEANING>Haiti</VALUEMEANING>
          <MEANINGDESCRIPTION>Haiti</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HU</VALIDVALUE>
          <VALUEMEANING>Hungary</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, northwest of Romania. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16699</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563988</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ID</VALIDVALUE>
          <VALUEMEANING>Indonesia</VALUEMEANING>
          <MEANINGDESCRIPTION>Indonesia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IE</VALIDVALUE>
          <VALUEMEANING>Ireland</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IL</VALIDVALUE>
          <VALUEMEANING>Israel</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IN</VALIDVALUE>
          <VALUEMEANING>India</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan.  (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IQ</VALIDVALUE>
          <VALUEMEANING>Iraq</VALUEMEANING>
          <MEANINGDESCRIPTION>Iraq</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IR</VALIDVALUE>
          <VALUEMEANING>Iran</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan.  (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IS</VALIDVALUE>
          <VALUEMEANING>Iceland</VALUEMEANING>
          <MEANINGDESCRIPTION>Iceland</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IT</VALIDVALUE>
          <VALUEMEANING>Italy</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JM</VALIDVALUE>
          <VALUEMEANING>Jamaica</VALUEMEANING>
          <MEANINGDESCRIPTION>Jamaica</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JO</VALIDVALUE>
          <VALUEMEANING>Jordan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Middle East, northwest of Saudi Arabia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JP</VALIDVALUE>
          <VALUEMEANING>Japan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KE</VALIDVALUE>
          <VALUEMEANING>Kenya</VALUEMEANING>
          <MEANINGDESCRIPTION>Kenya</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KH</VALIDVALUE>
          <VALUEMEANING>Cambodia</VALUEMEANING>
          <MEANINGDESCRIPTION>Cambodia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KI</VALIDVALUE>
          <VALUEMEANING>Kiribati</VALUEMEANING>
          <MEANINGDESCRIPTION>Kiribati</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KM</VALIDVALUE>
          <VALUEMEANING>Comoros</VALUEMEANING>
          <MEANINGDESCRIPTION>Comoros</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16458</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KW</VALIDVALUE>
          <VALUEMEANING>Kuwait</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KY</VALIDVALUE>
          <VALUEMEANING>Cayman Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Cayman Islands</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LB</VALIDVALUE>
          <VALUEMEANING>Lebanon</VALUEMEANING>
          <MEANINGDESCRIPTION>Lebanon</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574043</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LC</VALIDVALUE>
          <VALUEMEANING>Saint Lucia</VALUEMEANING>
          <MEANINGDESCRIPTION>Saint Lucia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LI</VALIDVALUE>
          <VALUEMEANING>Liechtenstein</VALUEMEANING>
          <MEANINGDESCRIPTION>Liechtenstein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16794</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LK</VALIDVALUE>
          <VALUEMEANING>Sri Lanka</VALUEMEANING>
          <MEANINGDESCRIPTION>Sri Lanka</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17163</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LR</VALIDVALUE>
          <VALUEMEANING>Liberia</VALUEMEANING>
          <MEANINGDESCRIPTION>Liberia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16791</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LT</VALIDVALUE>
          <VALUEMEANING>Lithuania</VALUEMEANING>
          <MEANINGDESCRIPTION>Lithuania</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LU</VALIDVALUE>
          <VALUEMEANING>Luxembourg</VALUEMEANING>
          <MEANINGDESCRIPTION>Luxembourg</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PG</VALIDVALUE>
          <VALUEMEANING>Papua New Guinea</VALUEMEANING>
          <MEANINGDESCRIPTION>Papua New Guinea</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16952</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PK</VALIDVALUE>
          <VALUEMEANING>Pakistan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PL</VALIDVALUE>
          <VALUEMEANING>Poland</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, east of Germany. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PN</VALIDVALUE>
          <VALUEMEANING>Pitcairn</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Pacific, comprised of islands in the South Pacific Ocean, about midway between Peru and New Zealand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16993</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PR</VALIDVALUE>
          <VALUEMEANING>Puerto Rico</VALUEMEANING>
          <MEANINGDESCRIPTION>Puerto Rico</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17043</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PT</VALIDVALUE>
          <VALUEMEANING>Portugal</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southwestern Europe, bordering the North Atlantic Ocean, west of Spain. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PW</VALIDVALUE>
          <VALUEMEANING>Palau</VALUEMEANING>
          <MEANINGDESCRIPTION>Palau</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PY</VALIDVALUE>
          <VALUEMEANING>Paraguay</VALUEMEANING>
          <MEANINGDESCRIPTION>Paraguay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16953</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>QA</VALIDVALUE>
          <VALUEMEANING>Qatar</VALUEMEANING>
          <MEANINGDESCRIPTION>Qatar</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RO</VALIDVALUE>
          <VALUEMEANING>Romania</VALUEMEANING>
          <MEANINGDESCRIPTION>Romania</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17108</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RW</VALIDVALUE>
          <VALUEMEANING>Rwanda</VALUEMEANING>
          <MEANINGDESCRIPTION>Rwanda</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SA</VALIDVALUE>
          <VALUEMEANING>Saudi Arabia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17117</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SB</VALIDVALUE>
          <VALUEMEANING>Solomon Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Solomon Islands</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17148</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SC</VALIDVALUE>
          <VALUEMEANING>Seychelles</VALUEMEANING>
          <MEANINGDESCRIPTION>Seychelles</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SD</VALIDVALUE>
          <VALUEMEANING>Sudan</VALUEMEANING>
          <MEANINGDESCRIPTION>Sudan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17170</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SE</VALIDVALUE>
          <VALUEMEANING>Sweden</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, Kattegat, and Skagerrak, between Finland and Norway. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17180</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SG</VALIDVALUE>
          <VALUEMEANING>Singapore</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Asia, comprised of islands between Malaysia and Indonesia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SI</VALIDVALUE>
          <VALUEMEANING>Slovenia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, bordering the Adriatic Sea, between Austria and Croatia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17138</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SK</VALIDVALUE>
          <VALUEMEANING>Slovakia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, south of Poland. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SL</VALIDVALUE>
          <VALUEMEANING>Sierra Leone</VALUEMEANING>
          <MEANINGDESCRIPTION>Sierra Leone</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17130</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SM</VALIDVALUE>
          <VALUEMEANING>San Marino</VALUEMEANING>
          <MEANINGDESCRIPTION>San Marino</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17115</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SN</VALIDVALUE>
          <VALUEMEANING>Senegal</VALUEMEANING>
          <MEANINGDESCRIPTION>Senegal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17121</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SO</VALIDVALUE>
          <VALUEMEANING>Somalia</VALUEMEANING>
          <MEANINGDESCRIPTION>Somalia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564054</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SV</VALIDVALUE>
          <VALUEMEANING>El Salvador</VALUEMEANING>
          <MEANINGDESCRIPTION>El Salvador</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SR</VALIDVALUE>
          <VALUEMEANING>Suriname</VALUEMEANING>
          <MEANINGDESCRIPTION>Suriname</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SY</VALIDVALUE>
          <VALUEMEANING>Syria</VALUEMEANING>
          <MEANINGDESCRIPTION>Syria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SZ</VALIDVALUE>
          <VALUEMEANING>Swaziland</VALUEMEANING>
          <MEANINGDESCRIPTION>Swaziland</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17179</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TD</VALIDVALUE>
          <VALUEMEANING>Chad</VALUEMEANING>
          <MEANINGDESCRIPTION>Chad</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TG</VALIDVALUE>
          <VALUEMEANING>Togo</VALUEMEANING>
          <MEANINGDESCRIPTION>Togo</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17202</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TH</VALIDVALUE>
          <VALUEMEANING>Thailand</VALUEMEANING>
          <MEANINGDESCRIPTION>Thailand</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TK</VALIDVALUE>
          <VALUEMEANING>Tokelau</VALUEMEANING>
          <MEANINGDESCRIPTION>Tokelau</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TM</VALIDVALUE>
          <VALUEMEANING>Turkmenistan</VALUEMEANING>
          <MEANINGDESCRIPTION>Turkmenistan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TN</VALIDVALUE>
          <VALUEMEANING>Tunisia</VALUEMEANING>
          <MEANINGDESCRIPTION>Tunisia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17221</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TR</VALIDVALUE>
          <VALUEMEANING>Turkey</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southeastern Europe and southwestern Asia (that portion of Turkey west of the Bosporus is geographically part of Europe), bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TV</VALIDVALUE>
          <VALUEMEANING>Tuvalu</VALUEMEANING>
          <MEANINGDESCRIPTION>Tuvalu</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17225</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TW</VALIDVALUE>
          <VALUEMEANING>Taiwan</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TZ</VALIDVALUE>
          <VALUEMEANING>Tanzania</VALUEMEANING>
          <MEANINGDESCRIPTION>Tanzania</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17185</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UA</VALIDVALUE>
          <VALUEMEANING>Ukraine</VALUEMEANING>
          <MEANINGDESCRIPTION>Ukraine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UG</VALIDVALUE>
          <VALUEMEANING>Uganda</VALUEMEANING>
          <MEANINGDESCRIPTION>Uganda</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>US</VALIDVALUE>
          <VALUEMEANING>USA</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in North America, between Canada and Mexico, bordering both the North Atlantic Ocean and the North Pacific Ocean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UY</VALIDVALUE>
          <VALUEMEANING>Uruguay</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17244</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UZ</VALIDVALUE>
          <VALUEMEANING>Uzbekistan</VALUEMEANING>
          <MEANINGDESCRIPTION>Uzbekistan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574070</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VE</VALIDVALUE>
          <VALUEMEANING>Venezuela</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VN</VALIDVALUE>
          <VALUEMEANING>Vietnam</VALUEMEANING>
          <MEANINGDESCRIPTION>Vietnam</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17252</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564088</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VU</VALIDVALUE>
          <VALUEMEANING>Vanuatu</VALUEMEANING>
          <MEANINGDESCRIPTION>Vanuatu</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YE</VALIDVALUE>
          <VALUEMEANING>Yemen</VALUEMEANING>
          <MEANINGDESCRIPTION>Yemen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YT</VALIDVALUE>
          <VALUEMEANING>Mayotte</VALUEMEANING>
          <MEANINGDESCRIPTION>Mayotte</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ZM</VALIDVALUE>
          <VALUEMEANING>Zambia</VALUEMEANING>
          <MEANINGDESCRIPTION>Zambia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ZW</VALIDVALUE>
          <VALUEMEANING>Zimbabwe</VALUEMEANING>
          <MEANINGDESCRIPTION>Zimbabwe</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AD</VALIDVALUE>
          <VALUEMEANING>Andorra</VALUEMEANING>
          <MEANINGDESCRIPTION>Andorra</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AE</VALIDVALUE>
          <VALUEMEANING>United Arab Emirates</VALUEMEANING>
          <MEANINGDESCRIPTION>United Arab Emirates</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AF</VALIDVALUE>
          <VALUEMEANING>Afghanistan</VALUEMEANING>
          <MEANINGDESCRIPTION>(Islamic St.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AG</VALIDVALUE>
          <VALUEMEANING>Antigua and Barbuda</VALUEMEANING>
          <MEANINGDESCRIPTION>Antigua and Barbuda</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AI</VALIDVALUE>
          <VALUEMEANING>Anguilla</VALUEMEANING>
          <MEANINGDESCRIPTION>Anguilla</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20133</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AM</VALIDVALUE>
          <VALUEMEANING>Armenia</VALUEMEANING>
          <MEANINGDESCRIPTION>Armenia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AO</VALIDVALUE>
          <VALUEMEANING>Angola</VALUEMEANING>
          <MEANINGDESCRIPTION>Angola</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AQ</VALIDVALUE>
          <VALUEMEANING>Antarctica</VALUEMEANING>
          <MEANINGDESCRIPTION>Antarctica</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AR</VALIDVALUE>
          <VALUEMEANING>Argentina</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AS</VALIDVALUE>
          <VALUEMEANING>American Samoa</VALUEMEANING>
          <MEANINGDESCRIPTION>American Samoa</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AT</VALIDVALUE>
          <VALUEMEANING>Austria</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Europe, north of Italy and Slovenia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AU</VALIDVALUE>
          <VALUEMEANING>Australia</VALUEMEANING>
          <MEANINGDESCRIPTION>The continent between the Indian Ocean and the South Pacific Ocean. The US State Department considers Ashmore and Cartier Islands and the Coral Sea Islands as a separate entities, each with its own code (AT and CR, respectively). (from CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AW</VALIDVALUE>
          <VALUEMEANING>Aruba</VALUEMEANING>
          <MEANINGDESCRIPTION>Aruba</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BA</VALIDVALUE>
          <VALUEMEANING>Bosnia-Herzegovina</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Europe, bordering the Adriatic Sea and Croatia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BB</VALIDVALUE>
          <VALUEMEANING>Barbados</VALUEMEANING>
          <MEANINGDESCRIPTION>Barbados</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BD</VALIDVALUE>
          <VALUEMEANING>Bangladesh</VALUEMEANING>
          <MEANINGDESCRIPTION>Bangladesh</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BE</VALIDVALUE>
          <VALUEMEANING>Belgium</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Europe, bordering the North Sea, between France and the Netherlands. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BF</VALIDVALUE>
          <VALUEMEANING>Burkina Faso</VALUEMEANING>
          <MEANINGDESCRIPTION>Burkina Faso</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BG</VALIDVALUE>
          <VALUEMEANING>Bulgaria</VALUEMEANING>
          <MEANINGDESCRIPTION>Bulgaria</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BH</VALIDVALUE>
          <VALUEMEANING>Bahrain</VALUEMEANING>
          <MEANINGDESCRIPTION>Bahrain</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BI</VALIDVALUE>
          <VALUEMEANING>Burundi</VALUEMEANING>
          <MEANINGDESCRIPTION>Burundi</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16371</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BM</VALIDVALUE>
          <VALUEMEANING>Bermuda</VALUEMEANING>
          <MEANINGDESCRIPTION>Bermuda</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BN</VALIDVALUE>
          <VALUEMEANING>Brunei Darussalam</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Asia, bordering the South China Sea and Malaysia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578965</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BO</VALIDVALUE>
          <VALUEMEANING>Bolivia</VALUEMEANING>
          <MEANINGDESCRIPTION>Bolivia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BR</VALIDVALUE>
          <VALUEMEANING>Brazil</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Eastern South America, bordering the Atlantic Ocean. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BS</VALIDVALUE>
          <VALUEMEANING>Bahamas</VALUEMEANING>
          <MEANINGDESCRIPTION>Bahamas</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16321</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BT</VALIDVALUE>
          <VALUEMEANING>Bhutan</VALUEMEANING>
          <MEANINGDESCRIPTION>Bhutan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BV</VALIDVALUE>
          <VALUEMEANING>Bouvet Island</VALUEMEANING>
          <MEANINGDESCRIPTION>Bouvet Island</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BW</VALIDVALUE>
          <VALUEMEANING>Botswana</VALUEMEANING>
          <MEANINGDESCRIPTION>Botswana</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BY</VALIDVALUE>
          <VALUEMEANING>Belarus</VALUEMEANING>
          <MEANINGDESCRIPTION>Belarus</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563936</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BZ</VALIDVALUE>
          <VALUEMEANING>Belize</VALUEMEANING>
          <MEANINGDESCRIPTION>Belize</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CA</VALIDVALUE>
          <VALUEMEANING>Canada</VALUEMEANING>
          <MEANINGDESCRIPTION>The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563937</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CG</VALIDVALUE>
          <VALUEMEANING>Congo</VALUEMEANING>
          <MEANINGDESCRIPTION>Congo</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AZ</VALIDVALUE>
          <VALUEMEANING>Azerbaijan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southwestern Asia, bordering the Caspian Sea, between Iran and Russia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GB</VALIDVALUE>
          <VALUEMEANING>United Kingdom</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Europe, comprising islands, including the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France. The US State Department considers Guernsey, Isle of Man, and Jersey as separate entities, each with its own code. (from CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2564079</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GE</VALIDVALUE>
          <VALUEMEANING>Georgia (Republic)</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southwestern Asia, bordering the Black Sea, between Turkey and Russia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16634</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BJ</VALIDVALUE>
          <VALUEMEANING>Benin</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CC</VALIDVALUE>
          <VALUEMEANING>Cocos (Keeling) Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the Indian Ocean, south of Indonesia, about halfway from Australia to Sri Lanka. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD</VALIDVALUE>
          <VALUEMEANING>Congo, the Democratic Republic of the</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Africa, northeast of Angola.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CF</VALIDVALUE>
          <VALUEMEANING>Central African Republic</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Africa, north of Democratic Republic of the Congo. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CI</VALIDVALUE>
          <VALUEMEANING>Cote d&#39;Ivoire</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578969</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DJ</VALIDVALUE>
          <VALUEMEANING>Djibouti</VALUEMEANING>
          <MEANINGDESCRIPTION>Djibouti</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16506</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FK</VALIDVALUE>
          <VALUEMEANING>Falkland Islands (Malvinas)</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the South Atlantic Ocean, east of southern Argentina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17954</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GF</VALIDVALUE>
          <VALUEMEANING>French Guiana</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16593</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GS</VALIDVALUE>
          <VALUEMEANING>South Georgia and the South Sandwich Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the South Atlantic Ocean, east of the tip of South America. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20111</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GU</VALIDVALUE>
          <VALUEMEANING>Guam</VALUEMEANING>
          <MEANINGDESCRIPTION>Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118551</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GW</VALIDVALUE>
          <VALUEMEANING>Guinea-Bissau</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578976</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HM</VALIDVALUE>
          <VALUEMEANING>Heard Island and McDonald Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Islands in the Indian Ocean, about two-thirds of the way from Madagascar to Antarctica. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20106</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IO</VALIDVALUE>
          <VALUEMEANING>British Indian Ocean Territory</VALUEMEANING>
          <MEANINGDESCRIPTION>An archipelago in the Indian Ocean, about one-half the way from Africa to Indonesia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16365</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JE</VALIDVALUE>
          <VALUEMEANING>Jersey</VALUEMEANING>
          <MEANINGDESCRIPTION>A British Crown dependency in the English Channel off the coast of Normandy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KG</VALIDVALUE>
          <VALUEMEANING>Kyrgyzstan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Asia, west of China. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578984</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KN</VALIDVALUE>
          <VALUEMEANING>Saint Kitts and Nevis</VALUEMEANING>
          <MEANINGDESCRIPTION>Islands in the Caribbean Sea, about one-third of the way from Puerto Rico to Trinidad and Tobago. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KP</VALIDVALUE>
          <VALUEMEANING>Korea, Democratic People&#39;s Republic of</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KR</VALIDVALUE>
          <VALUEMEANING>Korea, Republic of</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KZ</VALIDVALUE>
          <VALUEMEANING>Kazakhstan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Asia, northwest of China. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LA</VALIDVALUE>
          <VALUEMEANING>Lao People&#39;s Democratic Republic</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Southeastern Asia, northeast of Thailand, west of Vietnam.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LY</VALIDVALUE>
          <VALUEMEANING>Libya</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in northern Africa, bordering the Mediterranean Sea, between Egypt and Algeria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MP</VALIDVALUE>
          <VALUEMEANING>Northern Mariana Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MQ</VALIDVALUE>
          <VALUEMEANING>Martinique</VALUEMEANING>
          <MEANINGDESCRIPTION>An island in the Caribbean Sea, north of Trinidad and Tobago. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16823</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NC</VALIDVALUE>
          <VALUEMEANING>New Caledonia</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PF</VALIDVALUE>
          <VALUEMEANING>French Polynesia</VALUEMEANING>
          <MEANINGDESCRIPTION>An archipelago in the South Pacific Ocean, about one-half of the way from South America to Australia. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578973</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PM</VALIDVALUE>
          <VALUEMEANING>Saint Pierre and Miquelon</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada). (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RE</VALIDVALUE>
          <VALUEMEANING>Reunion</VALUEMEANING>
          <MEANINGDESCRIPTION>An Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17095</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RU</VALIDVALUE>
          <VALUEMEANING>Russian Federation</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in northern Asia, bordering the Arctic Ocean, between Europe and the North Pacific Ocean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17111</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SH</VALIDVALUE>
          <VALUEMEANING>Saint Helena, Ascension and Tristan da Cunha</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the South Atlantic Ocean, about midway between South America and Africa, west of Angola and South Africa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17164</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SJ</VALIDVALUE>
          <VALUEMEANING>Svalbard and Jan Mayen</VALUEMEANING>
          <MEANINGDESCRIPTION>Islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway.  (from CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ST</VALIDVALUE>
          <VALUEMEANING>Sao Tome and Principe</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TC</VALIDVALUE>
          <VALUEMEANING>Turks and Caicos Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>Two island groups in the North Atlantic Ocean, southeast of The Bahamas. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TF</VALIDVALUE>
          <VALUEMEANING>French Southern and Antarctic Lands</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the southern Indian Ocean, southeast of Africa, about equidistant between Africa, Antarctica, and Australia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TJ</VALIDVALUE>
          <VALUEMEANING>Tajikistan</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in Central Asia, west of China. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TT</VALIDVALUE>
          <VALUEMEANING>Trinidad and Tobago</VALUEMEANING>
          <MEANINGDESCRIPTION>Islands between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UM</VALIDVALUE>
          <VALUEMEANING>United States Minor Outlying Islands</VALUEMEANING>
          <MEANINGDESCRIPTION>The U.S. Minor Outlying Islands consist of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Island, Navassa Island, Palmyra Atoll, and Wake Island (Wake Atoll).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2959549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VA</VALIDVALUE>
          <VALUEMEANING>Holy See (Vatican City State)</VALUEMEANING>
          <MEANINGDESCRIPTION>An enclave of Rome (Italy).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17249</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VC</VALIDVALUE>
          <VALUEMEANING>Saint Vincent and the Grenadines</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Caribbean, comprised of islands in the Caribbean Sea, north of Trinidad and Tobago. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17114</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VG</VALIDVALUE>
          <VALUEMEANING>Virgin Islands, British</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of the US Virgin Islands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17653</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VI</VALIDVALUE>
          <VALUEMEANING>Virgin Islands, U.S.</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico and west of the British Virgin Islands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WF</VALIDVALUE>
          <VALUEMEANING>Wallis and Futuna</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, northeast of Fiji and west of American Samoa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WS</VALIDVALUE>
          <VALUEMEANING>Samoa</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FM</VALIDVALUE>
          <VALUEMEANING>Micronesia, Federated States of</VALUEMEANING>
          <MEANINGDESCRIPTION>An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia, west of the Marshall Islands and north of the Solomon Islands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17881</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GG</VALIDVALUE>
          <VALUEMEANING>Guernsey</VALUEMEANING>
          <MEANINGDESCRIPTION>A British Crown dependency in the English Channel off the coast of Normandy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IM</VALIDVALUE>
          <VALUEMEANING>Isle of Man</VALUEMEANING>
          <MEANINGDESCRIPTION>An island in the Irish Sea, between Great Britain and Ireland. (CIA World Factbook)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44480</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MK</VALIDVALUE>
          <VALUEMEANING>Macedonia, the Former Yugoslav Republic of</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in southeastern Europe, north of Greece, between Albania and Bulgaria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5109287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GP</VALIDVALUE>
          <VALUEMEANING>Guadeloupe</VALUEMEANING>
          <MEANINGDESCRIPTION>Islands in the eastern Caribbean Sea, southeast of Puerto Rico. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16651</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-01-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FX</VALIDVALUE>
          <VALUEMEANING>France (European Ter.)</VALUEMEANING>
          <MEANINGDESCRIPTION>France (European Territory)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AN</VALIDVALUE>
          <VALUEMEANING>Netherlands Antilles</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in the Caribbean, comprising two island groups in the Caribbean Sea - one includes Curacao and Bonaire north of Venezuela; the other is east of the Virgin Islands. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AC</VALIDVALUE>
          <VALUEMEANING>Ascension Island</VALUEMEANING>
          <MEANINGDESCRIPTION>Ascension Island</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Country of Residence (if not</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Country of Residence (if not USA)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2.</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>VALID_VALUE_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2; values are available at http://ctep.cancer.gov/forms/countrycodes.pdf (CTEP Country Codes - June 1999)</DocumentText>
        <URL>http://ctep.cancer.gov/forms/countrycodes.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient Country Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Country of residence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rave</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Country of Residence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Country of residence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Country of residence</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Country of residence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Demographic Items</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDUS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000130</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000524</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314482</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol Administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3314495</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3351909</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>OPEN to Rave Standard Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Demography</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813044</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1008</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1119</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4631580</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Exceptional Responder CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exceptional Responder CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OPEN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4861353</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RAVE Integrations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7434158</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CTEP CDISC Harmonization</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTEP CDISC Demography</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7473997</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SC_SCORRES_CNTRYRES</AlternateName>
        <AlternateNameType>OID, NRDS Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CNTRYRES</AlternateName>
        <AlternateNameType>NRDS Alternate Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SC_SCORRES_CNTRYRES</AlternateName>
        <AlternateNameType>CTEP CDISC CDE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1034">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2006280</PUBLICID>
    <LONGNAME>Prior Colorectal Treatment Combined Regimen Type</LONGNAME>
    <PREFERREDNAME>PR_COL_TX_COM_RGM_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>a description of agents, drugs and/or therapeutic procedures given previously as treatment for cancer of the large intestine.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2533518</PublicId>
      <PreferredName>PR_COLOR_TX_COMB_RGM</PreferredName>
      <PreferredDefinition>related to one or more agents, drugs and/or therapeutic procedures given previously as treatment for cancer of the large intestine.</PreferredDefinition>
      <LongName>Prior Colorectal Treatment Combined Regimen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2533515</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C13363:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Prior Colorectal Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13363</PREFERRED_NAME>
            <LONG_NAME>Colorectal</LONG_NAME>
            <CON_ID>2202379</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2533516</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25454:C15697</PreferredName>
        <Version>1</Version>
        <LongName>Combined Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25454</PREFERRED_NAME>
            <LONG_NAME>Combined</LONG_NAME>
            <CON_ID>2206179</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15697</PREFERRED_NAME>
            <LONG_NAME>Treatment Regimen</LONG_NAME>
            <CON_ID>2203773</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018568</PublicId>
      <PreferredName>PR_COL_TX_COM_RGM_TP</PreferredName>
      <PreferredDefinition>a description of agents, drugs and/or therapeutic procedures given previously as treatment for cancer of the large intestine.</PreferredDefinition>
      <LongName>Prior Colorectal Treatment Combined Regimen Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT + continuous infusion 5-FU</VALIDVALUE>
          <VALUEMEANING>RT + CONTINUOUS INFUSION 5-FU</VALUEMEANING>
          <MEANINGDESCRIPTION>RT + CONTINUOUS INFUSION 5-FU</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-02-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT + 5-FU/LU</VALIDVALUE>
          <VALUEMEANING>RT + 5-FU/LU</VALUEMEANING>
          <MEANINGDESCRIPTION>RT + 5-FU/LU</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-02-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT + capecitabine</VALIDVALUE>
          <VALUEMEANING>RT + CAPECITABINE</VALUEMEANING>
          <MEANINGDESCRIPTION>RT + CAPECITABINE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-02-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + 5-FU/LV</VALIDVALUE>
          <VALUEMEANING>XRT + 5-FU/LV (Leucovorin)</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT (external beam radiation therapy) + 5-FU/LV (Leucovorin)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + Capecitabine</VALIDVALUE>
          <VALUEMEANING>XRT + Capecitabine</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT (external beam radiation therapy) + Capecitabine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + Capecitabine + Oxaliplatin</VALIDVALUE>
          <VALUEMEANING>XRT + Capecitabine + Oxaliplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT (external beam radiation therapy) + Capecitabine + Oxaliplatin</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + CI 5-FU x 7d</VALIDVALUE>
          <VALUEMEANING>XRT + CI 5-FU x 7d</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT + CI 5-FU x 7d (5-FU 225 mg/m2 over 24 hours 7 days/week during XRT)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + CI 5-FU x 5d</VALIDVALUE>
          <VALUEMEANING>XRT + CI 5-FU x 5d</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT + CI 5-FU x 5d (5-FU 225 mg/m2/day by continuous IV infusion 5 days per week on days of planned XRT)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>XRT + CI 5-FU + Oxaliplatin</VALIDVALUE>
          <VALUEMEANING>XRT + CI 5-FU + Oxaliplatin</VALUEMEANING>
          <MEANINGDESCRIPTION>XRT + CI 5-FU + Oxaliplatin (5-FU 225 mg/m2/day by continuous IV infusion 5 days per week on days of planned XRT + Oxaliplatin 50 mg/m2 IV
weekly X 5)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Regimen Type Given</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Regimen Type Given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1035">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2007295</PUBLICID>
    <LONGNAME>Neurological Assessment Performed Date</LONGNAME>
    <PREFERREDNAME>NEURO_ASSESS_PERF_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on which the neurologic assessment of the patient was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195281</PublicId>
      <PreferredName>NEURO_ASSESS_PERF</PreferredName>
      <PreferredDefinition>information related to a neurological assessment being performed.</PreferredDefinition>
      <LongName>Neurological Assessment Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206859</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25262:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Neurologic Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25262</PREFERRED_NAME>
            <LONG_NAME>Neurologic</LONG_NAME>
            <CON_ID>2202770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184322</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Performed</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Neurologic Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Neurologic Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABTC CRF Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Neurologic Exam Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Neuro Exam Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Clinical Status Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of neurologic assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of neurologic examination</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rembrandt</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2812349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NEURO_ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NEURO_ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NEURO_ASSESS_PERF_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1036">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008365</PUBLICID>
    <LONGNAME>BIRAD Assessment Category Name</LONGNAME>
    <PREFERREDNAME>BIRAD_ASSESS_CAT_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name for assessment category using BI-RAD mammographic assessment, a system based on morphology and distributions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2015039</PublicId>
      <PreferredName>BIRAD_ASSESS</PreferredName>
      <PreferredDefinition>Mammographic assessment using Breast Imaging Reporting and Data System (BI-RADS) Atlas techniques. [Manually-curated]</PreferredDefinition>
      <LongName>Breast Imaging Reporting Data System Mammography Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2627581</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38071</PreferredName>
        <Version>1</Version>
        <LongName>Breast Imaging Reporting and Data System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38071</PREFERRED_NAME>
            <LONG_NAME>Breast Imaging Reporting and Data System</LONG_NAME>
            <CON_ID>2627580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019301</PublicId>
      <PreferredName>BIRAD_CAT_TXT_NM</PreferredName>
      <PreferredDefinition>Tet names for BIRAD mammographic assessment categories, based on morphologic changes and distributions.</PreferredDefinition>
      <LongName>BIRAD Category Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Text Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 1</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 2</VALIDVALUE>
          <VALUEMEANING>Benign Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Benign Finding</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 3</VALIDVALUE>
          <VALUEMEANING>Probably Benign Finding - Short interval follow-up suggested</VALUEMEANING>
          <MEANINGDESCRIPTION>Probably Benign Finding - Short interval follow-up suggested</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 5</VALIDVALUE>
          <VALUEMEANING>Highly Suggestive of Malignancy - Appropriate action should be taken</VALUEMEANING>
          <MEANINGDESCRIPTION>Highly Suggestive of Malignancy - Appropriate action should be taken</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567077</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 0</VALIDVALUE>
          <VALUEMEANING>Need additional imaging evaluation/prior mammograms</VALUEMEANING>
          <MEANINGDESCRIPTION>Need additional imaging evaluation and/or prior mammogram(s) for comparison</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574553</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 4</VALIDVALUE>
          <VALUEMEANING>Suspicious Abnormality</VALUEMEANING>
          <MEANINGDESCRIPTION>Suspicious Abnormality - biopsy should be considered</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Category 6</VALIDVALUE>
          <VALUEMEANING>Known Biopsy - Proven Malignancy</VALUEMEANING>
          <MEANINGDESCRIPTION>Known Biopsy - Proven Malignancy, appropriate action should be taken</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BIRAD Mammographic Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>BIRAD Mammographic Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Birad Assessment number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Overall BIRADS Assessment</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall BIRADS Assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180156</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>NEW CDEs PER STUDY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ACRIN_CALGB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811981</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000006</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1037">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2008417</PUBLICID>
    <LONGNAME>Attribution to Disease</LONGNAME>
    <PREFERREDNAME>ATTRIBN_DISEASE</PREFERREDNAME>
    <PREFERREDDEFINITION>Explains the likelihood of an adverse event being caused by the disease or condition under investigation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2015046</PublicId>
      <PreferredName>ATTRIBN_DISEASE</PreferredName>
      <PreferredDefinition>The likelihood of an event being caused by the disease under investigation.</PreferredDefinition>
      <LongName>Disease Attribution</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2493589</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25358</PreferredName>
        <Version>1</Version>
        <LongName>Attribution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25358</PREFERRED_NAME>
            <LONG_NAME>Attribution</LONG_NAME>
            <CON_ID>2202570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015190</PublicId>
      <PreferredName>ATTR_SCALE</PreferredName>
      <PreferredDefinition>scale of values to indicate the causal relation between the treatment modality and the specific adverse event.</PreferredDefinition>
      <LongName>Attribution Scale</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Definite</VALIDVALUE>
          <VALUEMEANING>DEFINITE</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of very strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Possible</VALIDVALUE>
          <VALUEMEANING>POSSIBLE</VALUEMEANING>
          <MEANINGDESCRIPTION>Capable of happening or occurring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82490</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Probable</VALIDVALUE>
          <VALUEMEANING>PROBABLE</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of the expectation of the occurrence of a particular event.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unlikely</VALIDVALUE>
          <VALUEMEANING>UNLIKELY</VALUEMEANING>
          <MEANINGDESCRIPTION>Having little chance of being the case or of coming about.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unrelated</VALIDVALUE>
          <VALUEMEANING>UNRELATED</VALUEMEANING>
          <MEANINGDESCRIPTION>Not connected or associated e.g. by kinship.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Attribution to Disease</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Attribution to Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180156</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>NEW CDEs PER STUDY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Iloprost 01279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811713</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1038">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179644</PUBLICID>
    <LONGNAME>Person Height Unit of Measure Code</LONGNAME>
    <PREFERREDNAME>PRSN_HGT_UOM_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>All codes used to represent the vertical distance from the base to the top of an individual.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012401</PublicId>
      <PreferredName>PRSN_HT</PreferredName>
      <PreferredDefinition>The vertical distance from the base to the top of an individual.</PreferredDefinition>
      <LongName>Person Height</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25347</PreferredName>
        <Version>1</Version>
        <LongName>Height</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25347</PREFERRED_NAME>
            <LONG_NAME>Height</LONG_NAME>
            <CON_ID>2202568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179484</PublicId>
      <PreferredName>HEIGHT_UOM_CD</PreferredName>
      <PreferredDefinition>All codes representing a height unit of measure.</PreferredDefinition>
      <LongName>Height Unit of Measure Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>in</VALIDVALUE>
          <VALUEMEANING>Inches</VALUEMEANING>
          <MEANINGDESCRIPTION>Inches</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0439204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm</VALIDVALUE>
          <VALUEMEANING>Centimeters</VALUEMEANING>
          <MEANINGDESCRIPTION>Centimeters</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>n/o</VALIDVALUE>
          <VALUEMEANING>Not Obtained</VALUEMEANING>
          <MEANINGDESCRIPTION>Not Obtained</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Units</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Units</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Height Unit of Measure Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Units</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Review Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SeriousAdverseEvents</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812325</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812969</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812731</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FES Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FMISO Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812733</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CIAF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imiquimod for Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exp. PK Formulations of SR13668</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett&#39;s Patients</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2813043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3152820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1039">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179686</PUBLICID>
    <LONGNAME>Therapy Interrupted Period Number</LONGNAME>
    <PREFERREDNAME>THERAPY_INTERR_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The number that represents the days the study agent dosage was interrupted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014062</PublicId>
      <PreferredName>TX_DELAY</PreferredName>
      <PreferredDefinition>the postponement of the patient&#39;s treatment.</PreferredDefinition>
      <LongName>Treatment Delay</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176930</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177613</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Delay</PreferredName>
        <Version>1</Version>
        <LongName>Delay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25476</PREFERRED_NAME>
            <LONG_NAME>Delay</LONG_NAME>
            <CON_ID>2203898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179472</PublicId>
      <PreferredName>THERAPY_INT_PER_NUM</PreferredName>
      <PreferredDefinition>The number that represents the number of days dosage of the study agent was interrupted.</PreferredDefinition>
      <LongName>Therapy Interrupted Period Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008565</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TEMPORAL_CONCEPTS</PreferredName>
        <Version>1</Version>
        <LongName>Temporal concepts</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If interrupted, specify total</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If interrupted, specify total number of days not given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF TEXT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Therapy Interrupted Period Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Review Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSAERS Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812969</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2190530</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Demonstration Applications</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CIAF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>THERAPY_INTERR_NUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1040">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2179846</PUBLICID>
    <LONGNAME>Non-Protocol Growth Factor Administered Text</LONGNAME>
    <PREFERREDNAME>NPROT_GFAC_ADM_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the description or name of any growth factor agents given to a patient that was not specified per protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195266</PublicId>
      <PreferredName>NPROT_GFAC_ADM</PreferredName>
      <PreferredDefinition>information related to the non-protocol growth factor administered.</PreferredDefinition>
      <LongName>Non-Protocol Growth Factor Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206858</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25590:C20424</PreferredName>
        <Version>1</Version>
        <LongName>Non-Protocol Growth Factor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25590</PREFERRED_NAME>
            <LONG_NAME>Non-Protocol</LONG_NAME>
            <CON_ID>2206325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20424</PREFERRED_NAME>
            <LONG_NAME>Growth Factor</LONG_NAME>
            <CON_ID>2202650</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180739</PublicId>
      <PreferredName>TX_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to treatment or therapy.</PreferredDefinition>
      <LongName>Therapy Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Yes specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Yes specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify growth factor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811810</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC 2nd Line</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811821</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Extensive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811822</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SCLC Limited</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811823</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000001</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000369</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Palliative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000614</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1041">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180015</PUBLICID>
    <LONGNAME>Necrotic Tumor Present Ind-3</LONGNAME>
    <PREFERREDNAME>NECR_TUMOR_PRES_IND-3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if necrotic tumor tissue was evident from the surgeon&#39;s observation during surgery on a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195383</PublicId>
      <PreferredName>NECR_TUMOR_PRES</PreferredName>
      <PreferredDefinition>information related to a necrotic tumor being present.</PreferredDefinition>
      <LongName>Necrotic Tumor Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206870</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25286:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Necrotic Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25286</PREFERRED_NAME>
            <LONG_NAME>Necrotic</LONG_NAME>
            <CON_ID>2206318</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is necrotic tumor present</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is necrotic tumor present</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1042">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180282</PUBLICID>
    <LONGNAME>Lymphoma First Recurrence Date</LONGNAME>
    <PREFERREDNAME>LYMPH_FIRST_RECUR_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on which the first return of disease symptoms is reported after receiving protocol therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195548</PublicId>
      <PreferredName>LYMPH_FIRST_RECUR</PreferredName>
      <PreferredDefinition>information related to the first recurrence of lymphoma.</PreferredDefinition>
      <LongName>Lymphoma First Recurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177031</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymphoma</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207403</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C3352</PreferredName>
        <Version>1</Version>
        <LongName>First Recurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3352</PREFERRED_NAME>
            <LONG_NAME>Recurrence</LONG_NAME>
            <CON_ID>2202848</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of First Recurrence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1043">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180395</PUBLICID>
    <LONGNAME>Medication Graft Versus Host Disease Administered Type</LONGNAME>
    <PREFERREDNAME>MEDS_GVHD_ADM_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the description or name for a medication or drug administered to systemically treat symptoms of graft versus host disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195768</PublicId>
      <PreferredName>MEDS_GVHD_ADM</PreferredName>
      <PreferredDefinition>information related to the medication administered for graft versus host disease.</PreferredDefinition>
      <LongName>Medication Graft Versus Host Disease Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206895</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C459:C0018133</PreferredName>
        <Version>1</Version>
        <LongName>Medication Graft Versus Host Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0018133</PREFERRED_NAME>
            <LONG_NAME>Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2203063</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180394</PublicId>
      <PreferredName>MEDS_GVHD_ADM_TP</PreferredName>
      <PreferredDefinition>the type of treatment administered to treat chronic graft-versus-host disease.</PreferredDefinition>
      <LongName>Medication Graft Versus Host Disease Administered Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>steroids</VALIDVALUE>
          <VALUEMEANING>Steroids</VALUEMEANING>
          <MEANINGDESCRIPTION>Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cyclosporine</VALIDVALUE>
          <VALUEMEANING>Cyclosporine</VALUEMEANING>
          <MEANINGDESCRIPTION>11-residue cyclic peptide produced by certain fungi which has antifungal and T cell specific immunosuppressive properties.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>imuran</VALIDVALUE>
          <VALUEMEANING>imuran</VALUEMEANING>
          <MEANINGDESCRIPTION>imuran</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0699279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mycophenolic acid</VALIDVALUE>
          <VALUEMEANING>mycophenolic acid</VALUEMEANING>
          <MEANINGDESCRIPTION>An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568114</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>puva</VALIDVALUE>
          <VALUEMEANING>PUVA</VALUEMEANING>
          <MEANINGDESCRIPTION>Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29973</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>thalidomide</VALIDVALUE>
          <VALUEMEANING>Thalidomide</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fk506</VALIDVALUE>
          <VALUEMEANING>fk506</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568118</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>clofaximine</VALIDVALUE>
          <VALUEMEANING>clofaximine</VALUEMEANING>
          <MEANINGDESCRIPTION>clofaximine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568115</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Corticosteroids</VALIDVALUE>
          <VALUEMEANING>Corticosteroid</VALUEMEANING>
          <MEANINGDESCRIPTION>Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2322</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mycophenolate Mofetil</VALIDVALUE>
          <VALUEMEANING>Mycophenolate Mofetil</VALUEMEANING>
          <MEANINGDESCRIPTION>The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5&#39;-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rapamycin</VALIDVALUE>
          <VALUEMEANING>Sirolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to help prevent rejection of organ and bone marrow transplants by the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2760061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daclizumab</VALIDVALUE>
          <VALUEMEANING>Daclizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1569</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tacrolimus</VALIDVALUE>
          <VALUEMEANING>Tacrolimus (Prograf, Protopic Ointment, Advagraf)</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2775673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other, specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sirolimus</VALIDVALUE>
          <VALUEMEANING>Sirolimus</VALUEMEANING>
          <MEANINGDESCRIPTION>A drug used to help prevent rejection of organ and bone marrow transplants by the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2760061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alemtuzumab</VALIDVALUE>
          <VALUEMEANING>Alemtuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: Be specific about something; define clearly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Drug/Agent Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Drug/Agent Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify therapy used to treat acute GVHD</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1044">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180411</PUBLICID>
    <LONGNAME>Vital Lung Capacity Test Percentage Value</LONGNAME>
    <PREFERREDNAME>VTL_LU_CP_TST_PC_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the value measuring the % predicted maximum volume of air that a patient can forcibly exhale from the lungs in one breath.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195781</PublicId>
      <PreferredName>VTL_LUNG_CAPAC_TST</PreferredName>
      <PreferredDefinition>information related to the vital lung capacity test.</PreferredDefinition>
      <LongName>Vital Lung Capacity Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206896</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18003:C12468</PreferredName>
        <Version>1</Version>
        <LongName>Vital Lung</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18003</PREFERRED_NAME>
            <LONG_NAME>Vital</LONG_NAME>
            <CON_ID>2206272</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207092</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25443:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Capacity Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25443</PREFERRED_NAME>
            <LONG_NAME>Capacity</LONG_NAME>
            <CON_ID>2203868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180234</PublicId>
      <PreferredName>LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the value as a percentage of 100.</PreferredDefinition>
      <LongName>Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Forced Vital Capacity (% pred</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Forced Vital Capacity (% predicted)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Forced Vital Capacity (% predicted FVC1)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FVC % predicted</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Lung-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FVC% PREDICTED</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SPOREs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811689</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2976812</PublicId>
          <ContextName>SPOREs</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>GO Trial</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GO Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2976834</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1306</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104937</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5271072</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung-Vanderbilt</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5152114</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506111</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung-Vanderbilt</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5506169</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506111</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Lung</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5506172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5506115</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vanderbilt Image Archive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5983666</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>5542682</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Reused-CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>5543567</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>SPOREs</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>VTL_LU_CP_TST_PC_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VTL_LU_CP_TST_PC_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EDRN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Reused-CDEs.Vital_Lung.PROC_LUNG_FVC-PREDICTED_VALUE_1251</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Vital_Lung:PROC_LUNG_FVC-PREDICTED_VALUE_1251</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1045">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180446</PUBLICID>
    <LONGNAME>Lymphoma Diagnosis Hematopoietic Type</LONGNAME>
    <PREFERREDNAME>LYMPHOMA_DX_HEMP_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the diagnosis of lymphoma based on clinical and pathologic data following guidelines from the World Health Organization (2001) with additional values from intergroup clinical trials.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014631</PublicId>
      <PreferredName>LYMPHOMA_DX</PreferredName>
      <PreferredDefinition>information related to the diagnosis of lymphoma.</PreferredDefinition>
      <LongName>Lymphoma Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177031</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymphoma</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Diagnosis</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180445</PublicId>
      <PreferredName>LYMPHOMA_DX_HEMP_TP</PreferredName>
      <PreferredDefinition>information regarding diagnosis type of lymphoma.</PreferredDefinition>
      <LongName>Lymphoma Diagnosis Hematopoietic Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>125</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13324:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13324</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic</LONG_NAME>
            <CON_ID>2206232</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Precursor B lymphoblastic leukemia/lymphoma</VALIDVALUE>
          <VALUEMEANING>PRECURSOR B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8936</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic lymphocytic leukemia/small lymphocytic lymphoma</VALIDVALUE>
          <VALUEMEANING>CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphoplasmacytic lymphoma</VALIDVALUE>
          <VALUEMEANING>LYMPHOPLASMACYTIC LYMPHOMA (WALDENSTROM MACROGLOBULINEMIA)</VALUEMEANING>
          <MEANINGDESCRIPTION>A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3212</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic marginal zone lymphoma</VALIDVALUE>
          <VALUEMEANING>SPLENIC MARGINAL ZONE LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4663</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</VALIDVALUE>
          <VALUEMEANING>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUSOSA-ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)</VALUEMEANING>
          <MEANINGDESCRIPTION>An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558767</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodal marginal zone B-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>NODAL MARGINAL ZONE B-CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8863</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma not further classifiable</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma not further classifiable</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma not further classifiable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma - grade I</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma grade I</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma grade I</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma - grade II</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma grade II</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma grade II</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568129</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma - grade III</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma grade III</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma grade III</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568130</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma - grade IIIa</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma grade IIIa</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma grade IIIa</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Follicular lymphoma - grade IIIb</VALIDVALUE>
          <VALUEMEANING>Follicular lymphoma grade IIIb</VALUEMEANING>
          <MEANINGDESCRIPTION>Follicular lymphoma grade IIIb</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mantle cell lymphoma</VALIDVALUE>
          <VALUEMEANING>MANTLE CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4337</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diffuse large B-cell lymphoma not further classifiable</VALIDVALUE>
          <VALUEMEANING>Diffuse large B-cell lymphoma not further classifiable</VALUEMEANING>
          <MEANINGDESCRIPTION>Diffuse large B-cell lymphoma not further classifiable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinal (thymic) large B-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary effusion lymphoma</VALIDVALUE>
          <VALUEMEANING>Primary Effusion Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intravascular large B-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>Intravascular large B-cell lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Intravascular large B-cell lymphoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burkitt lymphoma/leukemia</VALIDVALUE>
          <VALUEMEANING>BURKITT LYMPHOMA/LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>The leukemic counterpart of Burkitt&#39;s lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Burkitt-like lymphoma</VALIDVALUE>
          <VALUEMEANING>Burkitt-like lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Burkitt-like lymphoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite B-cell</VALIDVALUE>
          <VALUEMEANING>Composite B-cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Composite B-cell</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unclassifiable B-cell</VALIDVALUE>
          <VALUEMEANING>Unclassifiable B-cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Unclassifiable B-cell</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Precursor T lymphoblastic leukemia/lymphoma</VALIDVALUE>
          <VALUEMEANING>PRECURSOR T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blastic NK-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>BLASTIC NK-CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T-cell prolymphocytic leukemia</VALIDVALUE>
          <VALUEMEANING>T-CELL PROLYMPHOCYTIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T-cell large granular lymphocytic leukemia</VALIDVALUE>
          <VALUEMEANING>T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA</VALUEMEANING>
          <MEANINGDESCRIPTION>A T-cell peripheral neoplasm characterized by a persistent (&gt;6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aggressive NK-cell leukemia</VALIDVALUE>
          <VALUEMEANING>Aggressive NK-Cell Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adult T-cell leukemia/lymphoma</VALIDVALUE>
          <VALUEMEANING>ADULT T-CELL LEUKEMIA/LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extranodal NK/T cell lymphoma nasal type</VALIDVALUE>
          <VALUEMEANING>Extranodal NK/T cell lymphoma nasal type</VALUEMEANING>
          <MEANINGDESCRIPTION>Extranodal NK/T cell lymphoma nasal type</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enteropathy-type T-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>ENTEROPATHY-TYPE T-CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatosplenic T-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>HEPATOSPLENIC T-CELL LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subcutaneous panniculitis-like T-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>Subcutaneous Panniculitis-Like T-Cell </VALUEMEANING>
          <MEANINGDESCRIPTION>A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6918</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mycosis fungoides</VALIDVALUE>
          <VALUEMEANING>Mycosis Fungoides</VALUEMEANING>
          <MEANINGDESCRIPTION>A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sezary syndrome</VALIDVALUE>
          <VALUEMEANING>Sezary Syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral T-cell lymphoma unspecified</VALIDVALUE>
          <VALUEMEANING>Peripheral T-cell lymphoma unspecified</VALUEMEANING>
          <MEANINGDESCRIPTION>Peripheral T-cell lymphoma unspecified</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Angioimmunoblastic T-cell lymphoma</VALIDVALUE>
          <VALUEMEANING>Angioimmunoblastic T-Cell Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anaplastic large cell lymphoma - primary systemic</VALIDVALUE>
          <VALUEMEANING>Anaplastic large cell lymphoma - primary systemic</VALUEMEANING>
          <MEANINGDESCRIPTION>Anaplastic large cell lymphoma - primary systemic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anaplastic large cell lymphoma - primary cutaneous</VALIDVALUE>
          <VALUEMEANING>Anaplastic large cell lymphoma - primary cutaneous</VALUEMEANING>
          <MEANINGDESCRIPTION>Anaplastic large cell lymphoma - primary cutaneous</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphomatoid papulosis</VALIDVALUE>
          <VALUEMEANING>LYMPHOMATOID PAPULOSIS</VALUEMEANING>
          <MEANINGDESCRIPTION>A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unclassifiable CD30-positive cutaneous lymphoproliferative disorder</VALIDVALUE>
          <VALUEMEANING>Unclassifiable CD30-positive cutaneous lymphoproliferative disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Unclassifiable CD30-positive cutaneous lymphoproliferative disorder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite T-cell</VALIDVALUE>
          <VALUEMEANING>Composite T-cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Composite T-cell</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unclassifiable T-cell</VALIDVALUE>
          <VALUEMEANING>Unclassifiable T-cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Unclassifiable T-cell</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodular lymphocyte predominant Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>Composite Hodgkin lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Composite Hodgkin lymphoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodular sclerosis Classical Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocyte-rich Classical Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C6913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559128</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mixed cellularity Classical Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>MIXED CELLULARITY CLASSICAL HODGKIN LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphocyte-depleted Classical Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>LYMPHOCYTE-DEPLETED CLASSICAL HODGKIN LYMPHOMA</VALUEMEANING>
          <MEANINGDESCRIPTION>A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Classical Hodgkin lymphoma not further classifiable</VALIDVALUE>
          <VALUEMEANING>Classical Hodgkin lymphoma not further classifiable</VALUEMEANING>
          <MEANINGDESCRIPTION>Classical Hodgkin lymphoma not further classifiable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Hematopoietic Diagnosis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Hematopoietic Diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>WHO Diagnosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGCI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CGCI DLBCL </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179564</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMPHOMA_DX_HEMP_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1046">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180665</PUBLICID>
    <LONGNAME>Non-Protocol Treatment First Administered Specify</LONGNAME>
    <PREFERREDNAME>NPRO_TX_FIR_ADM_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to describe the first type of treatment that a patient received that was not part of the protocol treatment planned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188829</PublicId>
      <PreferredName>NPROT_TX_FIRS_ADM</PreferredName>
      <PreferredDefinition>information related to first non-protocol therapy administered.</PreferredDefinition>
      <LongName>Non-Protocol Therapy First Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206588</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25590:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Non-Protocol Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25590</PREFERRED_NAME>
            <LONG_NAME>Non-Protocol</LONG_NAME>
            <CON_ID>2206325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207814</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25382</PreferredName>
        <Version>1</Version>
        <LongName>First Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NonHodgkins Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811944</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1112</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1201</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104994</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0534</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171063</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0815</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0924</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171065</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NPRO_TX_FIR_ADM_SPEC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1047">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2180836</PUBLICID>
    <LONGNAME>Pediatric Lung Pulse Oximetry Test Ind-3</LONGNAME>
    <PREFERREDNAME>PED_LUN_PUL_TST_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if an oximetry test was performed to assess lung function in a pediatric patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195586</PublicId>
      <PreferredName>PEDS_LUNG_PULSE_TST</PreferredName>
      <PreferredDefinition>information related to the pediatric pulse oximetry lung test.</PreferredDefinition>
      <LongName>Pediatric Lung Pulse Oximetry Test</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39299:C12468</PreferredName>
        <Version>1</Version>
        <LongName>Pediatric Lung</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39299</PREFERRED_NAME>
            <LONG_NAME>Pediatric</LONG_NAME>
            <CON_ID>2206340</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38085:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Pulse Oximetry Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38085</PREFERRED_NAME>
            <LONG_NAME>Pulse Oximetry</LONG_NAME>
            <CON_ID>2615938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>1-COMMENT</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Instruction on template form: If yes,</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was oximetry done</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was oximetry done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1, inclusion</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient has a pulse oximetry &gt; 94% if there is clinical indication for determination?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient&#39;s oxygen saturation as measured by Pulse oximetry is &gt; 93% on room air?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hodgkin&#39;s Lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811943</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1048">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181277</PUBLICID>
    <LONGNAME>Bone Lesion Appearance Ind-3</LONGNAME>
    <PREFERREDNAME>BONE_LES_APR_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to ask if any new bone lytic lesions were identified following treatment that were not detected at study entry.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195986</PublicId>
      <PreferredName>BONE_LES_APR</PreferredName>
      <PreferredDefinition>information related to the appearance of a bone lesion.</PreferredDefinition>
      <LongName>Bone Lesion Appearance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206917</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12366:C3824</PreferredName>
        <Version>1</Version>
        <LongName>Bone Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12366</PREFERRED_NAME>
            <LONG_NAME>Bone</LONG_NAME>
            <CON_ID>2202686</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177628</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Appearance</PreferredName>
        <Version>1</Version>
        <LongName>Appearance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25377</PREFERRED_NAME>
            <LONG_NAME>Appearance</LONG_NAME>
            <CON_ID>2203581</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the appearance of any new</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the appearance of any new lesions documented</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1049">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2181439</PUBLICID>
    <LONGNAME>Peripheral Blood Cryoglobulin Result Type</LONGNAME>
    <PREFERREDNAME>PERI_BL_CRYO_RST_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>a laboratory test result to determine if cryoglobulin is present in blood serum.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2196123</PublicId>
      <PreferredName>PERI_BLOOD_CRYOG_RES</PreferredName>
      <PreferredDefinition>information related to the result of cryoglobulin in the peripheral blood.</PreferredDefinition>
      <LongName>Peripheral Blood Cryoglobulins Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25233:C12434</PreferredName>
        <Version>1</Version>
        <LongName>Peripheral Blood</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25233</PREFERRED_NAME>
            <LONG_NAME>Peripheral</LONG_NAME>
            <CON_ID>2206343</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660912</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0010404:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Cryoglobulins Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0010404</PREFERRED_NAME>
            <LONG_NAME>Cryoglobulins</LONG_NAME>
            <CON_ID>2615831</CON_ID>
            <DEFINITION_SOURCE>MSH2005_2004_10_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181434</PublicId>
      <PreferredName>BLOOD_RESULT_TP</PreferredName>
      <PreferredDefinition>information related to the type of blood result.</PreferredDefinition>
      <LongName>Blood Result Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cryoglobulin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cryoglobulin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Lung Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812017</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1050">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182014</PUBLICID>
    <LONGNAME>Total Agent Actual Course Dose</LONGNAME>
    <PREFERREDNAME>TTL_AGT_ACT_CRSE_DOS</PREFERREDNAME>
    <PREFERREDDEFINITION>the actual total dose of drugs for this cycle.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>Brain CDE Disease Committee</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188914</PublicId>
      <PreferredName>TTL_AGT_ACT_CRSE</PreferredName>
      <PreferredDefinition>information related to the actual total agent for a course.</PreferredDefinition>
      <LongName>Total Agent Actual Course</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206607</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Total Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207469</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Actual Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183281</PublicId>
      <PreferredName>AGT_ACTUAL_DOSE</PreferredName>
      <PreferredDefinition>information related to the actual dose administered for an agent.</PreferredDefinition>
      <LongName>Agent Actual Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207922</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Actual Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Actual Dose of Agents/D</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Actual Dose of Agents/Drugs for this cycle</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total actual dose of agent/drugs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812013</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain Recurr</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812015</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1051">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182156</PUBLICID>
    <LONGNAME>Upper Limb Assessment Emotional Scale</LONGNAME>
    <PREFERREDNAME>U_LIMB_ASSE_EMOT_SCA</PREFERREDNAME>
    <PREFERREDDEFINITION>the assessment of the patient&#39;s emotional acceptance of upper limb function and pain.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197672</PublicId>
      <PreferredName>U_LIMB_ASSESS</PreferredName>
      <PreferredDefinition>information related to an upper limb assessment.</PreferredDefinition>
      <LongName>Upper Limb Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25355:C0015385</PreferredName>
        <Version>1</Version>
        <LongName>Upper Limb</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25355</PREFERRED_NAME>
            <LONG_NAME>Upper</LONG_NAME>
            <CON_ID>2205320</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0015385</PREFERRED_NAME>
            <LONG_NAME>Limb</LONG_NAME>
            <CON_ID>2202972</CON_ID>
            <DEFINITION_SOURCE>UWDA155</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177637</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182149</PublicId>
      <PreferredName>LIMB_ASSE_EMOT_SCALE</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s limb assessment emotional scale.</PreferredDefinition>
      <LongName>Limb Assessment Emotional Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208113</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25495:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Emotional Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25495</PREFERRED_NAME>
            <LONG_NAME>Emotional</LONG_NAME>
            <CON_ID>2206201</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Satisfied</VALIDVALUE>
          <VALUEMEANING>Satisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is pleased and content.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568803</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intermediate</VALIDVALUE>
          <VALUEMEANING>INTERMEDIATE</VALUEMEANING>
          <MEANINGDESCRIPTION>Lying between two extremes in time or space or degree.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C73705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Accepts</VALIDVALUE>
          <VALUEMEANING>Accepts</VALUEMEANING>
          <MEANINGDESCRIPTION>Accepts</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568804</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dislikes</VALIDVALUE>
          <VALUEMEANING>Dislikes</VALUEMEANING>
          <MEANINGDESCRIPTION>Dislikes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Enthused</VALIDVALUE>
          <VALUEMEANING>Enthused</VALUEMEANING>
          <MEANINGDESCRIPTION>Enthused</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568801</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Likes</VALIDVALUE>
          <VALUEMEANING>Likes</VALUEMEANING>
          <MEANINGDESCRIPTION>Likes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Emotional Acceptance</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Emotional Acceptance</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1052">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182168</PUBLICID>
    <LONGNAME>Upper Limb Function Scale</LONGNAME>
    <PREFERREDNAME>U_LIMB_FUNC_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the assessment of upper limb function.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197677</PublicId>
      <PreferredName>U_LIMB_FUNC</PreferredName>
      <PreferredDefinition>information related to upper limb function.</PreferredDefinition>
      <LongName>Upper Limb Function</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25355:C0015385</PreferredName>
        <Version>1</Version>
        <LongName>Upper Limb</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25355</PREFERRED_NAME>
            <LONG_NAME>Upper</LONG_NAME>
            <CON_ID>2205320</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0015385</PREFERRED_NAME>
            <LONG_NAME>Limb</LONG_NAME>
            <CON_ID>2202972</CON_ID>
            <DEFINITION_SOURCE>UWDA155</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177519</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Function</PreferredName>
        <Version>1</Version>
        <LongName>Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182166</PublicId>
      <PreferredName>LIMB_FUNC_SCALE</PreferredName>
      <PreferredDefinition>information related to a patient&#39;s limb function.</PreferredDefinition>
      <LongName>Limb Function Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184332</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Scale</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No restriction</VALIDVALUE>
          <VALUEMEANING>No restriction</VALUEMEANING>
          <MEANINGDESCRIPTION>No restriction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial disability</VALIDVALUE>
          <VALUEMEANING>Partial disability</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial disability</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total disability</VALIDVALUE>
          <VALUEMEANING>Total disability</VALUEMEANING>
          <MEANINGDESCRIPTION>Total disability</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Recreational restriction</VALIDVALUE>
          <VALUEMEANING>Recreational restriction</VALUEMEANING>
          <MEANINGDESCRIPTION>Recreational restriction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Function</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Function</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811886</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000027</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bone Sarcoma Recur</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1053">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182276</PUBLICID>
    <LONGNAME>Disease Primary Relapse Ind-2</LONGNAME>
    <PREFERREDNAME>DZ_PRIM_REL_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the patient has had a relapse at the primary site of disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197718</PublicId>
      <PreferredName>DZ_PRIM_REL</PreferredName>
      <PreferredDefinition>information related to the relapse of disease at primary.</PreferredDefinition>
      <LongName>Disease Primary Relapse</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C18265</PreferredName>
        <Version>1</Version>
        <LongName>Primary Relapse</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18265</PREFERRED_NAME>
            <LONG_NAME>Relapse</LONG_NAME>
            <CON_ID>2202443</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Relapsed at primary site?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Relapsed at primary site?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did relapse occur at original tumor bed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did disease recur or progress at the site of original disease (local recurrence)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008588</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>USAGE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CLINICAL TRIALS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ped STS Recurrent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811889</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1054">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182481</PUBLICID>
    <LONGNAME>Equipment Station Name 16 Character Text</LONGNAME>
    <PREFERREDNAME>IMAGE_STATN_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>User defined name identifying the machine that produced the composite instances. [Standard-based]</PREFERREDDEFINITION>
    <VERSION>1.1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182479</PublicId>
      <PreferredName>EQUIP_STATION_NAME</PreferredName>
      <PreferredDefinition>The words to descibe the location equipped of supplies or apparatus used for cancer-related research, diagnosis or therapy.</PreferredDefinition>
      <LongName>Equipment Station Name</LongName>
      <Version>1.2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2681251</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43660</PreferredName>
        <Version>1</Version>
        <LongName>Equipment_Kind</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43660</PREFERRED_NAME>
            <LONG_NAME>Equipment_Kind</LONG_NAME>
            <CON_ID>2681250</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2681252</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67102:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Station Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67102</PREFERRED_NAME>
            <LONG_NAME>Station</LONG_NAME>
            <CON_ID>2677952</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2584116</PublicId>
      <PreferredName>16_CHAR_TXT</PreferredName>
      <PreferredDefinition>SH: A 16-character string that may be padded with leading or trailing spaces. [Standard-based]</PreferredDefinition>
      <LongName>16 Character Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>16</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2637360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45253:C25704</PreferredName>
        <Version>1</Version>
        <LongName>String Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45253</PREFERRED_NAME>
            <LONG_NAME>String</LONG_NAME>
            <CON_ID>2539471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Station Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Station Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Northwestern University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812693</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NU 0943_011</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812731</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FES Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FMISO Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812733</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Washington New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DICOM Tag CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review - NCIA DICOM CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812828</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2693115</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA_Model</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ncia.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000239</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Station Name</AlternateName>
        <AlternateNameType>DICOM Attribute Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>(0008,1010)</AlternateName>
        <AlternateNameType>DICOM_TAG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ncia.domain.Equipment.stationName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Equipment:stationName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1055">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182701</PUBLICID>
    <LONGNAME>Participant Randomization Number</LONGNAME>
    <PREFERREDNAME>PT_RNDM_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of participants who signed an informed consent, are registered to a study, and are randomized to a study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2186005</PublicId>
      <PreferredName>PERSON_RNDM</PreferredName>
      <PreferredDefinition>information related to randomization person.</PreferredDefinition>
      <LongName>Person Randomization</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2453144</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25196</PreferredName>
        <Version>1</Version>
        <LongName>Randomization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25196</PREFERRED_NAME>
            <LONG_NAME>Randomization</LONG_NAME>
            <CON_ID>2202624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182704</PublicId>
      <PreferredName>RANDOMIZATION_NUM</PreferredName>
      <PreferredDefinition>A free text field to enter the randomization numeric value.</PreferredDefinition>
      <LongName>Randomization Number</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Randomization Number</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Randomization Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Document Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Participant Randomization #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Effect of Finasteride - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812182</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261112</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280815</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5416571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2017-09-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2017-09-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5981652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1056">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182733</PUBLICID>
    <LONGNAME>Symptom Description Text</LONGNAME>
    <PREFERREDNAME>SM_DESCR_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The text that succinctly describes the symptom/adverse event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182731</PublicId>
      <PreferredName>SM_DESC</PreferredName>
      <PreferredDefinition>A description of the symptom.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.</PreferredDefinition>
      <LongName>Symptom Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008583</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>RESPONSE</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2181698</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Symptom</PreferredName>
        <Version>1</Version>
        <LongName>Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2182729</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Description</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Symptom Description</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Symptom Description</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text- 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Symptom Description (Verbatim Term)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event grade description</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-TEXT-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Symptom or Medical Event</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Budesonide Lung Nodules</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate - Lycopene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DIM - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812202</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PK and Safety - Novel Retinoid (9cUAB30)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Lung Pre-Surgical NSCLC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3152820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barrett&#39;s Esophagus Chemoprevention Metformin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3211792</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAB30 in NMSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3293737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pomegranate - Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3303133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2012-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3694151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280815</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2017-09-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889179</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-08-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6046252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1057">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2182857</PUBLICID>
    <LONGNAME>Off Follow-Up Date</LONGNAME>
    <PREFERREDNAME>OFF_FU_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date the participant completed follow-up.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2181682</PublicId>
      <PreferredName>OFF_FOLLOW-UP_DT</PreferredName>
      <PreferredDefinition>The DEC for Off Follow-up Date.</PreferredDefinition>
      <LongName>Off Follow-Up Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008565</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TEMPORAL_CONCEPTS</PreferredName>
        <Version>1</Version>
        <LongName>Temporal concepts</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660115</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40450:C16033</PreferredName>
        <Version>1</Version>
        <LongName>Off Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40450</PREFERRED_NAME>
            <LONG_NAME>Off</LONG_NAME>
            <CON_ID>2615912</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177607</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Off Follow-up</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Off Follow-up</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DESK Document Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>End Follow-Up Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of end of follow-up on A211601</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2811734</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2179692</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case Report Forms Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2957372</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAMe - Hepatitis C cirrhosis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812148</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic Mucinous Neoplasms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812149</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma Pathobiology - Lovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Hormone Receptor-Negative Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Study of Resiquimod for Atyical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Atrovastatin in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812183</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Spectral Markers in ASA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Se-Methyl-Seleno-L-Cystein (MSC) in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812188</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E - Pre-prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Acolbifene - High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812190</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALA PDT - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812194</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase II Resiquimod - Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Drug and Carcinogen Enzymes - Resveratrol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812258</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Aminolevulinic Acid - Barrett&#39;s Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812364</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812388</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Unconjugated Isoflavones in Women at High Risk for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Subclinical Neoplastic Lesions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>9cUAB30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EGF Receptor Signaling in ACF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>3, 3-Diindolylmethane Cervical Intraepithelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812735</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transdermal 4-OHT vs oral TAM DCIS of the Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812736</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Imiquimod for Atypical Nevi</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyethylene Glycol - Colon Carcinogenesis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812843</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac - Increased Risk of Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ursodeoxycholic Acid - Barrett&#39;s Patients</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2813043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Letrozole - Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2842768</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E in Women w/ Modulation of Arachidonic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2936518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MyoInositol Chemoprevention in Colitis-Assoc. Dysplasia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2979172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin Colorectal Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018781</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Resveratrol in Postmenopausal Women</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3018782</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSC and L SeMet in Adult Men</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3110219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cholecalciferol and Genistein</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3114163</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vitamin D - Bioactivity in the Skin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182878</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metformin - Pre-Prostatectomy Prostate Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3182879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Docosahexaenoic Acid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3528035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2487057</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DESK</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>E-Progress Report</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261112</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5416571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-08-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2017-09-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5981652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6046252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1058">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183239</PUBLICID>
    <LONGNAME>CTC Adverse Event Myelodysplasia Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_MYELOD_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Blood/Bone Marrow, assessment of the severity of a myelodysplasia adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197835</PublicId>
      <PreferredName>CTC_AE_MYELODYSPLAS</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of myelodysplasia.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Myelodysplasia</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2197833</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Myelodysplasia</PreferredName>
        <Version>1</Version>
        <LongName>Myelodysplasia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0026985</PREFERRED_NAME>
            <LONG_NAME>Myelodysplasia</LONG_NAME>
            <CON_ID>2204054</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183238</PublicId>
      <PreferredName>CTC_AE_MYELOD_GD</PreferredName>
      <PreferredDefinition>in CTC category Blood/Bone Marrow, assessment of the severity of a myelodysplasia adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Myelodysplasia Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Abnormal marrow cytogenetics (marrow blasts &lt;=5%)</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal marrow cytogenetics (marrow blasts &lt;=5%)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>RAEB or RAEB-T (marrow blasts &gt;5%)</VALUEMEANING>
          <MEANINGDESCRIPTION>RAEB or RAEB-T (marrow blasts &gt;5%)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Myelodyspla</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Myelodysplasia Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Myelodysplasia Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1059">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183245</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Spleen Function Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_SPLE_FUNC_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Blood/Bone Marrow, assessment of the severity of a splenic function adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2197836</PublicId>
      <PreferredName>CTC_AE_SPLEEN_FUNC</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of spleen function.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Spleen Function</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12432:C25518</PreferredName>
        <Version>1</Version>
        <LongName>Spleen Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12432</PREFERRED_NAME>
            <LONG_NAME>Spleen</LONG_NAME>
            <CON_ID>2202823</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183244</PublicId>
      <PreferredName>CTC_AE_SPLE_FUNC_GD</PreferredName>
      <PreferredDefinition>in CTC category Blood/Bone Marrow, assessment of the severity of a splenic function adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Spleen Function Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Incidental findings (e.g., Howell-Jolly bodies)</VALUEMEANING>
          <MEANINGDESCRIPTION>Incidental findings (e.g., Howell-Jolly bodies)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Prophylactic antibiotics indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Prophylactic antibiotics indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Life-threatening consequences</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening consequences</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of life or state of being dead.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Splenic function Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Splenic Fun</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Splenic Function Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1060">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2183853</PUBLICID>
    <LONGNAME>Supplement Dose Label Value</LONGNAME>
    <PREFERREDNAME>SUPP_DOSE_LABEL_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The dose of a supplement prescribed for a participant as recorded on the bottle/container label.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2183847</PublicId>
      <PreferredName>SUPP_DOSE_LABEL</PreferredName>
      <PreferredDefinition>The dose of a supplement prescribed for a participant as recorded on the bottle/container label.</PreferredDefinition>
      <LongName>Supplement Dose Label</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206500</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1505:C0719635</PreferredName>
        <Version>1</Version>
        <LongName>Supplements Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1505</PREFERRED_NAME>
            <LONG_NAME>Dietary Supplement</LONG_NAME>
            <CON_ID>2202835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0719635</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2203007</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2183845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0181496</PreferredName>
        <Version>1</Version>
        <LongName>Labels</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0181496</PREFERRED_NAME>
            <LONG_NAME>Labels</LONG_NAME>
            <CON_ID>2204101</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183849</PublicId>
      <PreferredName>DOSE_LABEL_VAL</PreferredName>
      <PreferredDefinition>Amount of an agent  prescribed for a person as identifed on the substance label.</PreferredDefinition>
      <LongName>Dose Label Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2478903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49100</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose recorded from Label</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose recorded from Label</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DFMO/Sul Colon III UCI 02_06</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCI 97_05</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1061">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2185852</PUBLICID>
    <LONGNAME>Dental Tooth Caries Description Specify</LONGNAME>
    <PREFERREDNAME>DEN_TOO_CAR_DES_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the specified dental tooth caries (cavities).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2240065</PublicId>
      <PreferredName>DENT_TOOTH_CAR_DESC</PreferredName>
      <PreferredDefinition>information related to the description of dental tooth caries.</PreferredDefinition>
      <LongName>Dental Tooth Caries Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2240058</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C12506</PreferredName>
        <Version>1</Version>
        <LongName>Dental Tooth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240063</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL159156:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Caries Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL159156</PREFERRED_NAME>
            <LONG_NAME>Caries</LONG_NAME>
            <CON_ID>2240062</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2226669</PublicId>
      <PreferredName>ANATSITE_SPEC</PreferredName>
      <PreferredDefinition>the free text field to specify an anatomic site.</PreferredDefinition>
      <LongName>Anatomic Site Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Deep caries</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Deep caries</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1062">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2185889</PUBLICID>
    <LONGNAME>Lesion Maxilla Site Type</LONGNAME>
    <PREFERREDNAME>LES_MAX_SITE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the anatomic location of a cancer lesion in the upper jawbone.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760401</PublicId>
      <PreferredName>LES_MAX_LCTN</PreferredName>
      <PreferredDefinition>the anatomic location of a cancer lesion in the upper jawbone.</PreferredDefinition>
      <LongName>Lesion Maxilla Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2465192</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2760399</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26470:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Maxilla Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26470</PREFERRED_NAME>
            <LONG_NAME>Maxilla</LONG_NAME>
            <CON_ID>2202586</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180581</PublicId>
      <PreferredName>LES_SITE_TP</PreferredName>
      <PreferredDefinition>information related to the type of lesion site for disease.</PreferredDefinition>
      <LongName>Lesion Site Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bone marrow only</VALIDVALUE>
          <VALUEMEANING>bone marrow only</VALUEMEANING>
          <MEANINGDESCRIPTION>bone marrow only</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bone marrow and other</VALIDVALUE>
          <VALUEMEANING>bone marrow and other</VALUEMEANING>
          <MEANINGDESCRIPTION>bone marrow and other</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anterior</VALIDVALUE>
          <VALUEMEANING>Anterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the front surface of the body; often used to indicate the position of one structure relative to another.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Posterior</VALIDVALUE>
          <VALUEMEANING>Posterior</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buccal</VALIDVALUE>
          <VALUEMEANING>Buccal</VALUEMEANING>
          <MEANINGDESCRIPTION>Buccal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lingual</VALIDVALUE>
          <VALUEMEANING>LINGUAL</VALUEMEANING>
          <MEANINGDESCRIPTION>LINGUAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alveolar ridge</VALIDVALUE>
          <VALUEMEANING>Alveolar ridge</VALUEMEANING>
          <MEANINGDESCRIPTION>Alveolar ridge</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palate</VALIDVALUE>
          <VALUEMEANING>Palate</VALUEMEANING>
          <MEANINGDESCRIPTION>(PAL-et) The roof of the mouth. The front portion is bony (hard palate), and the back portion is muscular (soft palate).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mylohyoid plate</VALIDVALUE>
          <VALUEMEANING>Mylohyoid plate</VALUEMEANING>
          <MEANINGDESCRIPTION>Mylohyoid plate</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Local</VALIDVALUE>
          <VALUEMEANING>Local</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or belonging to a restricted area or locality.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4567113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regional</VALIDVALUE>
          <VALUEMEANING>Regional</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or belonging to a broader area or region of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25643</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Distant</VALIDVALUE>
          <VALUEMEANING>Distant</VALUEMEANING>
          <MEANINGDESCRIPTION>Far apart in space, time, or relevance from a point of reference.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25321</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Maxilla</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Maxilla</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1063">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2186045</PUBLICID>
    <LONGNAME>Long-Term Adverse Event Follow-up Ind-3</LONGNAME>
    <PREFERREDNAME>LT_AE_FU_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator related to follow-up of an adverse event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2186046</PublicId>
      <PreferredName>AE_FU</PreferredName>
      <PreferredDefinition>information related to follow-up of an adverse event.</PreferredDefinition>
      <LongName>Long-Term Adverse Event Follow-up</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2856881</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25322:C41331</PreferredName>
        <Version>1</Version>
        <LongName>Long-Term Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25322</PREFERRED_NAME>
            <LONG_NAME>Long-Term</LONG_NAME>
            <CON_ID>2206295</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2682295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16033</PreferredName>
        <Version>1</Version>
        <LongName>Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient experienced a</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient experienced any grade 3 or greater, long term toxicity since the submission of the last follow-up form?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient experienced post diagnosis of progression or new primary, any severe (Grade &gt; 3), long-term toxicity that has not been previously reported</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NOS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811864</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1064">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188039</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Gastrointestinal Necrosis Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_GI_NECR_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Gastrointestinal, assessment of the severity of an adverse event for the supraordinate term gastrointestinal necrosis - select using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2198906</PublicId>
      <PreferredName>CTC_AE_GI_NECROSIS</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of gastrointestinal necrosis.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Gastrointestinal Necrosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207405</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13359:C16897</PreferredName>
        <Version>1</Version>
        <LongName>Gastrointestinal Necrosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13359</PREFERRED_NAME>
            <LONG_NAME>Gastrointestinal</LONG_NAME>
            <CON_ID>2202578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16897</PREFERRED_NAME>
            <LONG_NAME>Necrotic Process</LONG_NAME>
            <CON_ID>2202853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188038</PublicId>
      <PreferredName>CTC_AE_GI_NECR_GD</PreferredName>
      <PreferredDefinition>in CTC category Gastrointestinal, assessment of the severity of an adverse event for the supraordinate term gastrointestinal necrosis - select using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Gastrointestinal Necrosis Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Inability to aliment adequately by GI tract (e.g., requiring enteral or parenteral nutrition); interventional radiology, endoscopic, or operative intervention indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Inability to aliment adequately by GI tract (e.g., requiring enteral or parenteral nutrition); interventional radiology, endoscopic, or operative intervention indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Life-threatening consequences; operative intervention requiring complete organ resection (e.g., total colectomy)</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening consequences; operative intervention requiring complete organ resection (e.g., total colectomy)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Necrosis, G</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Necrosis, GI - Select Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Necrosis, GI - Select Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1065">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188607</PUBLICID>
    <LONGNAME>Image Slice Maximum Spacing Value</LONGNAME>
    <PREFERREDNAME>SLICE_MAX_SPAC_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Maximum spacing (distance) between cuts or exposures (slices) on a series of sequential medical images.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188605</PublicId>
      <PreferredName>IMAGE_SLICE_MAX_SPAC</PreferredName>
      <PreferredDefinition>Maximim spacing (distance) between cuts or exposures (slices) on a series of sequential medical images.</PreferredDefinition>
      <LongName>Image Slice Maximum Spacing</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206485</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19477:C25682</PreferredName>
        <Version>1</Version>
        <LongName>Medical Image Slice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25682</PREFERRED_NAME>
            <LONG_NAME>Slice</LONG_NAME>
            <CON_ID>2202619</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C0929962</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Anatomical space</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0929962</PREFERRED_NAME>
            <LONG_NAME>Anatomical space</LONG_NAME>
            <CON_ID>2211748</CON_ID>
            <DEFINITION_SOURCE>UWDA173</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016796</PublicId>
      <PreferredName>TMMKR_VAL</PreferredName>
      <PreferredDefinition>the value number for an assessment of tumor marker.</PreferredDefinition>
      <LongName>Tumor Marker Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008508</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CTEP</PreferredName>
        <Version>2.31</Version>
        <LongName>CTEP</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>99999.99</DisplayFormat>
      <MaximumLength>7</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184351</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Value</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Maximum spacing between Slice</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Maximum spacing between Slices in mm</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2180933</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>LIDC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Series</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812330</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614828</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIDC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812770</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614828</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Case-Study-Series</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812803</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614828</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCIA Collection</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Series</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812806</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1066">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188874</PUBLICID>
    <LONGNAME>Overall Lesion Response Status</LONGNAME>
    <PREFERREDNAME>OVERAL_LES_RESP_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>information about the overall response status for target, non-target, and new lesions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188872</PublicId>
      <PreferredName>OVERALL_LES_RESP</PreferredName>
      <PreferredDefinition>Information relating to the overall lesion response.</PreferredDefinition>
      <LongName>Overall Lesion Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25605:C3824</PreferredName>
        <Version>1</Version>
        <LongName>Overall Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25605</PREFERRED_NAME>
            <LONG_NAME>Overall</LONG_NAME>
            <CON_ID>2203597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177336</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Response</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25755</PREFERRED_NAME>
            <LONG_NAME>Response</LONG_NAME>
            <CON_ID>2202805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188873</PublicId>
      <PreferredName>OVERAL_LES_RESP_STAT</PreferredName>
      <PreferredDefinition>information about the overall response status for target, non-target, and new lesions.</PreferredDefinition>
      <LongName>Overall Lesion Response Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete Response</VALIDVALUE>
          <VALUEMEANING>Complete Response</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer in response to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial Response</VALIDVALUE>
          <VALUEMEANING>Partial Response</VALUEMEANING>
          <MEANINGDESCRIPTION>Partial Response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incomplete Response</VALIDVALUE>
          <VALUEMEANING>Incomplete Response</VALUEMEANING>
          <MEANINGDESCRIPTION>Incomplete Response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive Disease</VALIDVALUE>
          <VALUEMEANING>Progressive Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is increasing in scope or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Insufficient evaluation to determine response status</VALIDVALUE>
          <VALUEMEANING>insufficient evaluation to determine response status</VALUEMEANING>
          <MEANINGDESCRIPTION>insufficient evaluation to determine response status</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-10-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stable disease</VALIDVALUE>
          <VALUEMEANING>Stable Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is neither decreasing nor increasing in extent or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minor response</VALIDVALUE>
          <VALUEMEANING>minor response</VALUEMEANING>
          <MEANINGDESCRIPTION>minor response</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-02-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluable</VALIDVALUE>
          <VALUEMEANING>Not Evaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unable to be evaluated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progression</VALIDVALUE>
          <VALUEMEANING>PROGRESSION</VALUEMEANING>
          <MEANINGDESCRIPTION>The worsening of a disease over time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Regression</VALIDVALUE>
          <VALUEMEANING>Regression</VALUEMEANING>
          <MEANINGDESCRIPTION>A decrease in the size of a tumor or in the extent of cancer in the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2631957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metachronous</VALIDVALUE>
          <VALUEMEANING>Metachronous Malignant Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant tumor that arises at a site separate from another, primary malignant tumor in the same anatomic system.  It is not clear if metachronous malignant neoplasms represent new primary tumors or metastatic disease.  Examples include metachronous osteosarcoma of the bones that develops in patients with known primary bone osteosarcoma, and metachronous Wilms&#39; tumor that affects the opposite kidney in patients with a history of Wilms&#39; tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3357337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unevaluable</VALIDVALUE>
          <VALUEMEANING>Unevaluable</VALUEMEANING>
          <MEANINGDESCRIPTION>Unevaluable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treatment Failure (TF)</VALIDVALUE>
          <VALUEMEANING>Treatment Failure (TF)</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment Failure (TF)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4537076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapse</VALIDVALUE>
          <VALUEMEANING>RELAPSE</VALUEMEANING>
          <MEANINGDESCRIPTION>RELAPSE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial Response (PR)</VALIDVALUE>
          <VALUEMEANING>partial response (PR)</VALUEMEANING>
          <MEANINGDESCRIPTION>partial response (PR) -- 50% decrease in peripheral blood lymphocyte count from pretreatment value; at least 50% reduction in lymphodenopathy if present pretreatment; at least 50% reduction in level and spleen size if enlarged pretreatment; one or mor of the following: 1) neutrophils at least 1.5 x 10^9/L or 50% improvement over baseline 2) platelets &gt; 100 x 10^9/L or 50% improvement over baseline 3) hemoglobin &gt; 11.0 g/dL or 50% improvement over baseline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2626315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete Remission with Incomplete Blood Count Recovery (CRi)</VALIDVALUE>
          <VALUEMEANING>Complete Remission with Incomplete Blood Count Recovery (CRi)</VALUEMEANING>
          <MEANINGDESCRIPTION>Complete Remission with Incomplete Blood Count Recovery (CRi)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5072631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CR With Partial Recovery of Platelet Count (CRp)</VALIDVALUE>
          <VALUEMEANING>CR With Partial Recovery of Platelet Count (CRp)</VALUEMEANING>
          <MEANINGDESCRIPTION>CR With Partial Recovery of Platelet Count (CRp)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5072632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete Remission (CR)</VALIDVALUE>
          <VALUEMEANING>Complete remission (CR)</VALUEMEANING>
          <MEANINGDESCRIPTION>A treatment response where all of the following criteria are met for at least four weeks: &lt; 5% blasts in the bone marrow, normal maturation of all cellular components in the bone marrow (myeloid, erythroid, and megakaryocytic lineages), no blasts with Auer rods,  no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of &gt; 1,000/&amp;#956;L, Platelets &gt;= 100,000/ &amp;#956;L</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4602874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Response</VALIDVALUE>
          <VALUEMEANING>No Response</VALUEMEANING>
          <MEANINGDESCRIPTION>No apparent change or worsening in tumor staging classification.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5654573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morphologic Leukemia-Free State (MLFS)</VALIDVALUE>
          <VALUEMEANING>Morphologic Leukemia - Free State</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aplasia</VALIDVALUE>
          <VALUEMEANING>Agenesis</VALUEMEANING>
          <MEANINGDESCRIPTION>A congenital abnormality resulting in the absence of an anatomical structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120864</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7640819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapse/Refractory Disease</VALIDVALUE>
          <VALUEMEANING>Relapse/Refractory Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Relapse/Refractory Disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7652586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRD Negative</VALIDVALUE>
          <VALUEMEANING>Minimal Residual Disease Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757, C3896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8083085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRD Positive</VALIDVALUE>
          <VALUEMEANING>Minimal Residual Disease Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C3896</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6299956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET2 negative (RER)</VALIDVALUE>
          <VALUEMEANING>PET2 negative (RER)</VALUEMEANING>
          <MEANINGDESCRIPTION>PET2 negative (RER)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13313062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET2 positive (SER)</VALIDVALUE>
          <VALUEMEANING>PET2 positive (SER)</VALUEMEANING>
          <MEANINGDESCRIPTION>PET2 positive (SER)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2023-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13313063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive Disease / Relapse</VALIDVALUE>
          <VALUEMEANING>Progressive Disease Or Recurrent Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The reemergence of a neoplasm after a period of remission.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4798, C37998, C35571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13313064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Refractory Disease</VALIDVALUE>
          <VALUEMEANING>Refractory Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disease that resists treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C39752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4571271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Overall response</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Overall response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall response at this assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient&#39;s overall response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall response for the index lesions since baseline</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AECC TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target response at this assessment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Disease response:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion overall response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the patient&#39;s overall response?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient have a complete response?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall response:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall response assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Response assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathologic response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Pathologic evidence of response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Best disease response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>what was the response to non-protocol therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the disease status at the end of this cycle?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Current Status of Disease:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AMC Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Response assessment consensus</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Overall response status at this assessment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3298557</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3298577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7283431</PublicId>
          <ContextName>AMC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000342</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>OVERAL_LES_RESP_STAT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OVERAL_LES_RESP_STAT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AMC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OVRLRESP_RSORRES</AlternateName>
        <AlternateNameType>OID, AMC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OVERAL_TUMOR_RESP_TP</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1067">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2188983</PUBLICID>
    <LONGNAME>Unstained Specimen Frozen Sections Slide Number</LONGNAME>
    <PREFERREDNAME>UNSTA_FRZSC_SLID_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>the number of prepared slides of an unstatned frozen section, a thin slice of tissue cut from a frozen specimen without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2681168</PublicId>
      <PreferredName>UNST_FRZNSCT_SLIDE</PreferredName>
      <PreferredDefinition>information relating to prepared slides of an unstatned frozen section, a thin slice of tissue cut from a frozen specimen without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.</PreferredDefinition>
      <LongName>Unstained Specimen Frozen Sections Slide</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2681437</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62755:C67462</PreferredName>
        <Version>1</Version>
        <LongName>Unstained Specimen Frozen Section</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62755</PREFERRED_NAME>
            <LONG_NAME>Unstained Specimen</LONG_NAME>
            <CON_ID>2527993</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67462</PREFERRED_NAME>
            <LONG_NAME>Frozen Section</LONG_NAME>
            <CON_ID>2645107</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2645211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25325</PreferredName>
        <Version>1</Version>
        <LongName>Slide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25325</PREFERRED_NAME>
            <LONG_NAME>Slide</LONG_NAME>
            <CON_ID>2202820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188982</PublicId>
      <PreferredName>FROZENSECT_SLIDE_NUM</PreferredName>
      <PreferredDefinition>the number of unstained superfrost plus slides.</PreferredDefinition>
      <LongName>Frozen Sections Slide Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Unstained superfrost plus sli</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Unstained superfrost plus slides, specify number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1068">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2190246</PUBLICID>
    <LONGNAME>Other Thoracic Surgical Approach Descriptive Text</LONGNAME>
    <PREFERREDNAME>OTH_THOR_SURGAPP_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of a thoracic surgical approach that is type &#39;other&#39; in the Society of Thoracic Surgeons&#39; set of procedures.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Director&#39;s Challenge Lung Study</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014893</PublicId>
      <PreferredName>THOR_SURG_APPRCH</PreferredName>
      <PreferredDefinition>A way of entering or leaving for a surgical specialty concerned with diagnosis and treatment of disorders of the heart, lungs, and esophagus.</PreferredDefinition>
      <LongName>Thoracic Surgery Approach</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008578</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Surgery</PreferredName>
        <Version>1</Version>
        <LongName>Surgery</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177249</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Thoracic Surgery</PreferredName>
        <Version>1</Version>
        <LongName>Thoracic Surgery</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17195</PREFERRED_NAME>
            <LONG_NAME>Thoracic Surgery</LONG_NAME>
            <CON_ID>2202924</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177719</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Approach</PreferredName>
        <Version>1</Version>
        <LongName>Approach</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25424</PREFERRED_NAME>
            <LONG_NAME>Approach</LONG_NAME>
            <CON_ID>2203577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2190244</PublicId>
      <PreferredName>OTH_THOR_SURGAPP_TXT</PreferredName>
      <PreferredDefinition>Text description of a thoracic surgical approach that is type &#39;other&#39; in the Society of Thoracic Surgeons&#39; set of procedures.</PreferredDefinition>
      <LongName>Other Thoracic Surgical Approach Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008578</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Surgery</PreferredName>
        <Version>1</Version>
        <LongName>Surgery</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208096</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Description  Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other approach</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other approach</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183534</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Integrative Cancer Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Dir Chall Lung Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1069">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2190437</PUBLICID>
    <LONGNAME>Additional Dose Administered Specify</LONGNAME>
    <PREFERREDNAME>ADD_DOSE_ADM_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>a free text field to describe what additional doses were administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190435</PublicId>
      <PreferredName>ADD_DOSE_ADM</PreferredName>
      <PreferredDefinition>information relating to the administration of additional doses.</PreferredDefinition>
      <LongName>Additional Dose Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206742</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Additional Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182161</PublicId>
      <PreferredName>TX_DOSES_SPEC</PreferredName>
      <PreferredDefinition>the specified free-text field related to a treatment dose.</PreferredDefinition>
      <LongName>Treatment Dose Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, specify dose:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000609</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1070">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2190542</PUBLICID>
    <LONGNAME>Tissue Histology Concordance Description</LONGNAME>
    <PREFERREDNAME>TISS_HIST_CONCD_DESC</PREFERREDNAME>
    <PREFERREDDEFINITION>Text to describe the histologic disgreement (discordance)between methods of tissue sampling and preparation, such as frozen section and paraffin section.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Director&#39;s Challenge Lung Study</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190471</PublicId>
      <PreferredName>TISS_METH_HIST_CONCD</PreferredName>
      <PreferredDefinition>Histologic agreement between methods of tissue sampling and preparation, such as frozen section and paraffin section.</PreferredDefinition>
      <LongName>Tissue Methodology Histology Concordance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206745</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12801:CL025484</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Methodologies</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL025484</PREFERRED_NAME>
            <LONG_NAME>Methodologies</LONG_NAME>
            <CON_ID>2203499</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16681:C0680240</PreferredName>
        <Version>1</Version>
        <LongName>Histology Agreement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16681</PREFERRED_NAME>
            <LONG_NAME>Histology</LONG_NAME>
            <CON_ID>2202345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0680240</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If discordant, explain</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If discordant, explain</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183534</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Integrative Cancer Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Dir Chall Lung Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1071">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2192740</PUBLICID>
    <LONGNAME>Patient Off-Treatment Ind</LONGNAME>
    <PREFERREDNAME>PT_OTX_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether a patient was removed from protocol treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ADEERS:NCI/CTEP Adverse Event Expedited Report System</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014025</PublicId>
      <PreferredName>PT_OTX</PreferredName>
      <PreferredDefinition>information related to a patient being off-treatment.</PreferredDefinition>
      <LongName>Patient Off-treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2184318</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Off-Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Off-Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2192739</PublicId>
      <PreferredName>PT_OTX_IND</PreferredName>
      <PreferredDefinition>the yes/no indicator whether a patient was removed from protocol treatment.</PreferredDefinition>
      <LongName>Patient Off-Treatment Ind</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ADEERS:NCI/CTEP Adverse Event Expedited Report System</Origin>
      <Representation>
        <PublicId>2188676</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Decision Pending</VALIDVALUE>
          <VALUEMEANING>Decision Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Decision Pending</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-12-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Removed from Protocol Treatme</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Removed from Protocol Treatment (to date)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Alternate Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Removed from protocol treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Should patient be removed from protocol therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient removed from AHOD1331 therapy prior to completing the AHOD1331 protocol specified treatment plan?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AdEERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000210</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858965</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1072">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2194696</PUBLICID>
    <LONGNAME>Head and Neck Tumor Recurrence Present Count</LONGNAME>
    <PREFERREDNAME>HN_TUM_RECU_PRES_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the numeric count  of head and neck tumor recurrences or new primaries.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2194694</PublicId>
      <PreferredName>HN_TUMOR_RECUR_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of recurrence of head and neck tumor.</PreferredDefinition>
      <LongName>Head and Neck Tumor Recurrence Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12418:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Head and Neck Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12418</PREFERRED_NAME>
            <LONG_NAME>Head and Neck</LONG_NAME>
            <CON_ID>2203706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207558</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3352:C25626</PreferredName>
        <Version>1</Version>
        <LongName>Recurrence Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3352</PREFERRED_NAME>
            <LONG_NAME>Recurrence</LONG_NAME>
            <CON_ID>2202848</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018596</PublicId>
      <PreferredName>LES_CT</PreferredName>
      <PreferredDefinition>the quantity of specified lesions.</PreferredDefinition>
      <LongName>Lesion Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184284</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Count</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How many recurrences / new pr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How many recurrences / new primaries has the patient had since treatment of the original head and neck cancer?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1073">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2195049</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Lymphocele Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_LYMPHOCELE_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Lymphatics, assessment of the severity of a lymphocele adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195047</PublicId>
      <PreferredName>CTC_AE_LYMPHOCELE</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of lymphocele.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Lymphocele</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2195045</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lymphocele</PreferredName>
        <Version>1</Version>
        <LongName>Lymphocele</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0024248</PREFERRED_NAME>
            <LONG_NAME>Lymphocele</LONG_NAME>
            <CON_ID>2204367</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2195048</PublicId>
      <PreferredName>CTC_AE_LYMPHOCELE_GD</PreferredName>
      <PreferredDefinition>in CTC category Lymphatics, assessment of the severity of a lymphocele adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Lymphocele Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Asymptomatic, clinical or radiographic findings only</VALUEMEANING>
          <MEANINGDESCRIPTION>Asymptomatic, clinical or radiographic findings only</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Symptomatic; medical intervention indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Symptomatic; medical intervention indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Symptomatic and interventional radiology or operative intervention indicated</VALUEMEANING>
          <MEANINGDESCRIPTION>Symptomatic and interventional radiology or operative intervention indicated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Lymphocele</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Lymphocele Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lymphocele Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1074">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2195171</PUBLICID>
    <LONGNAME>Common Toxicity Criteria Adverse Event Connective Tissue Fibrosis Grade</LONGNAME>
    <PREFERREDNAME>CTC_AE_CONTIS_FIB_GD</PREFERREDNAME>
    <PREFERREDDEFINITION>in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of a deep connective tissue fibrosis adverse event using a graded scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195169</PublicId>
      <PreferredName>CTC_AE_CONTIS_FIB</PreferredName>
      <PreferredDefinition>information related to the CTC adverse event of deep connective tissue fibrosis.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Connective Tissue Fibrosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2480706</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12374:C3044</PreferredName>
        <Version>1</Version>
        <LongName>Connective Tissue Fibrosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12374</PREFERRED_NAME>
            <LONG_NAME>Connective Tissue</LONG_NAME>
            <CON_ID>2205929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3044</PREFERRED_NAME>
            <LONG_NAME>Fibrosis</LONG_NAME>
            <CON_ID>2203932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2195170</PublicId>
      <PreferredName>CTC_AE_CONTIS_FIB_GD</PreferredName>
      <PreferredDefinition>in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of a deep connective tissue fibrosis adverse event using a graded scale.</PreferredDefinition>
      <LongName>Common Toxicity Criteria Adverse Event Connective Tissue Fibrosis Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184299</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Grade</PreferredName>
        <Version>1</Version>
        <LongName>Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Increased density, &quot;spongy&quot; feel</VALUEMEANING>
          <MEANINGDESCRIPTION>Increased density, &quot;spongy&quot; feel</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Increased density with firmness or tethering</VALUEMEANING>
          <MEANINGDESCRIPTION>Increased density with firmness or tethering</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Increased density with fixation of tissue; operative intervention indicated; interfering with ADL</VALUEMEANING>
          <MEANINGDESCRIPTION>Increased density with fixation of tissue; operative intervention indicated; interfering with ADL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Life-threatening; disabling; loss of limb; interfering with vital organ function</VALUEMEANING>
          <MEANINGDESCRIPTION>Life-threatening; disabling; loss of limb; interfering with vital organ function</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Death</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTC Adverse Event Fibrosis-de</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CTC Adverse Event Fibrosis-deep connective tissue Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Fibrosis-deep connective tissue Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/ctc.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812032</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Terminology Criteria for Adverse Events v3.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000132</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1075">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2199984</PUBLICID>
    <LONGNAME>Additional Pathologic Findings None Identified Indicator</LONGNAME>
    <PREFERREDNAME>AD_PTHFNG_NO_ID_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/indeterminate indicator that asks whether no additional pathologic findings were identified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2199982</PublicId>
      <PreferredName>ADD_PATHFNDG_NONE_ID</PreferredName>
      <PreferredDefinition>information relating to no identified additional pathologic findings.</PreferredDefinition>
      <LongName>Additional Pathologic Findings None Identified</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2207003</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C1317598</PreferredName>
        <Version>1</Version>
        <LongName>Additional PATHOLOGIC FINDINGS</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1317598</PREFERRED_NAME>
            <LONG_NAME>PATHOLOGIC FINDINGS</LONG_NAME>
            <CON_ID>2203316</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2660709</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41132:C25737</PreferredName>
        <Version>1</Version>
        <LongName>None Identified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41132</PREFERRED_NAME>
            <LONG_NAME>None</LONG_NAME>
            <CON_ID>2433421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2199990</PublicId>
      <PreferredName>AD_PTHFNG_IND</PreferredName>
      <PreferredDefinition>the yes/no/indeterminate indicator that asks whether additional pathologic findings were identified.</PreferredDefinition>
      <LongName>Additional Pathologic Findings Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>225</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>None identified</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>None identified</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000189</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000104</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1076">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200286</PUBLICID>
    <LONGNAME>Centers for Disease Control and Prevention Race Unique Identifier Code</LONGNAME>
    <PREFERREDNAME>CDC_RACE_UNQ_ID_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The unique identifer code for reporting information about race based on the Center for Disease Control and Prevention (CDC) categories.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CDC:Center for Disease Control</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192191</PublicId>
      <PreferredName>RACE_CAT</PreferredName>
      <PreferredDefinition>The category describing the race of the individual.</PreferredDefinition>
      <LongName>Race Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2181708</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Race</PreferredName>
        <Version>1</Version>
        <LongName>Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Category</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200282</PublicId>
      <PreferredName>CDC_RACE_UNQ_ID_CD</PreferredName>
      <PreferredDefinition>All Centers for Disease Control and Prevention (CDC) unique identifiers codes for race.</PreferredDefinition>
      <LongName>Centers for Disease Control and Prevention Race Unique Identifier Codes</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CDC:Center for Disease Control</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDC Race &amp; Ethnicity Code Set</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Code set is available as a pdf file or an Excel spreadsheet.</DocumentText>
        <URL>http://www.cdc.gov/nedss/DataModels/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CDC Race Code</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CDC Race Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NIDA CTN Demographics</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What race does the participant consider him or herself to represent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NIDA CTN PhenX Demograhics for SAATier1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What race do you consider yourself to be</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Race CDC Code</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2822344</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Demography CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859967</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2718902</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ONS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multisite Research Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812728</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Demographics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3070841</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Core: Tier 1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3688551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Substance Abuse and Addiction Core Collection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3689959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mental Health Core Collection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4550917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Core: Tier 1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4550918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857184</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Potential CDEs for Reuse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PBRN</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812034</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3253737</PublicId>
          <ContextName>CDC/PHIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CSTE Position Statements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Possible CDEs for Reuse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3262077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Research</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952294</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Electronic Health Record</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952296</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Demography</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675695</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDE by Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Race CDC Code</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000029</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDA</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDA</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1077">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200314</PUBLICID>
    <LONGNAME>Brachtherapy Institution Name</LONGNAME>
    <PREFERREDNAME>BRT_INST_NAME</PREFERREDNAME>
    <PREFERREDDEFINITION>a name of a medical facility which specializes in the brachytherapy technique to administer radiation treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200102</PublicId>
      <PreferredName>BRT_INST_ID</PreferredName>
      <PreferredDefinition>identifying information about a medical facility which specializes in the brachytherapy technique to administer radiation treatment.</PreferredDefinition>
      <LongName>Brachytherapy Institution Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660491</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>CL054378:C21541</PreferredName>
        <Version>1</Version>
        <LongName>brachytherapy Institution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL054378</PREFERRED_NAME>
            <LONG_NAME>brachytherapy</LONG_NAME>
            <CON_ID>2204487</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21541</PREFERRED_NAME>
            <LONG_NAME>Healthcare Facility</LONG_NAME>
            <CON_ID>2202668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018256</PublicId>
      <PreferredName>INST_NAME</PreferredName>
      <PreferredDefinition>the name of the organization entering patients on a clinical trial.</PreferredDefinition>
      <LongName>Institution Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208039</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21541:C25191</PreferredName>
        <Version>1</Version>
        <LongName>Institution Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21541</PREFERRED_NAME>
            <LONG_NAME>Healthcare Facility</LONG_NAME>
            <CON_ID>2202668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Brachytherapy facility</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Brachytherapy facility</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Please enter radiation therapy facility code for brachytherapy boost</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BRT_INST_NAME</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1078">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200319</PUBLICID>
    <LONGNAME>Right Brachytherapy First Reference Point Dose</LONGNAME>
    <PREFERREDNAME>RT_BRT_FIR_REFPTDOSE</PREFERREDNAME>
    <PREFERREDDEFINITION>a quantity in Grays for radiation treatment administered to tissues at the standard cervical Point A anatomic location on the right side using a brachytherapy technique.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200124</PublicId>
      <PreferredName>RT_BRT_FIR_REFPTDOSE</PreferredName>
      <PreferredDefinition>the radiation treatment administered to tissues at the standard cervical Point A anatomic location on the right side using a brachytherapy technique.</PreferredDefinition>
      <LongName>Right Brachytherapy First Reference Point Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25228:C15195</PreferredName>
        <Version>1</Version>
        <LongName>Right Brachytherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15195</PREFERRED_NAME>
            <LONG_NAME>Brachytherapy</LONG_NAME>
            <CON_ID>2202699</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207894</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:CL220834</PreferredName>
        <Version>1</Version>
        <LongName>First Reference point dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL220834</PREFERRED_NAME>
            <LONG_NAME>Reference point dose</LONG_NAME>
            <CON_ID>2204485</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200298</PublicId>
      <PreferredName>BRT_LCTN_DOSE</PreferredName>
      <PreferredDefinition>a quantity in Grays for radiation treatment administered using the brachytherapy technique.</PreferredDefinition>
      <LongName>Brachytherapy Location Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>99.99</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184291</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Dose</PreferredName>
        <Version>1</Version>
        <LongName>Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Dose to point A - Right</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Dose to point A - Right</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Dose to point A - Rt</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RT_BRT_FIR_REFPTDOSE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1079">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200472</PUBLICID>
    <LONGNAME>Treatment Preparation Identifier Number</LONGNAME>
    <PREFERREDNAME>TX_PREP_ID_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>the treatment preparation ID number.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2200470</PublicId>
      <PreferredName>TX_PREP_ID</PreferredName>
      <PreferredDefinition>information related to the treatment preparation ID.</PreferredDefinition>
      <LongName>Treatment Preparation Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176930</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207198</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25625:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Preparation Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25625</PREFERRED_NAME>
            <LONG_NAME>Preparation</LONG_NAME>
            <CON_ID>2202599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200471</PublicId>
      <PreferredName>TX_PREP_ID_NUM</PreferredName>
      <PreferredDefinition>the treatment preparation ID number.</PreferredDefinition>
      <LongName>Treatment Preparation Identifier Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184315</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Number</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Treatment preparation ID numb</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Treatment preparation ID number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1080">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2200613</PUBLICID>
    <LONGNAME>Data Amended Text</LONGNAME>
    <PREFERREDNAME>DATA_AMD_TEXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to capture whether data on the form have been amended.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2008686</PublicId>
      <PreferredName>DATA_AMD</PreferredName>
      <PreferredDefinition>the field to identify data from a form that is changed after initial submission.</PreferredDefinition>
      <LongName>Data Amended</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177146</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Data</PreferredName>
        <Version>1</Version>
        <LongName>Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177623</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Amended</PreferredName>
        <Version>1</Version>
        <LongName>Amended</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25416</PREFERRED_NAME>
            <LONG_NAME>Amended</LONG_NAME>
            <CON_ID>2204036</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200608</PublicId>
      <PreferredName>DATA_UNKNOWN_TEXT</PreferredName>
      <PreferredDefinition>a single character text field to record data.</PreferredDefinition>
      <LongName>Data Unknown Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please mark an &#39;X&#39; if data ha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please mark an &#39;X&#39; if data have been amended.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811951</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1081">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201279</PUBLICID>
    <LONGNAME>Skin Surgical Incision End Time</LONGNAME>
    <PREFERREDNAME>SKIN_SURGINCI_END_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>the time a surgical skin incision stopped.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201275</PublicId>
      <PreferredName>SKIN_SURGINCISION</PreferredName>
      <PreferredDefinition>information related to the surgical incision of the skin.</PreferredDefinition>
      <LongName>Skin Surgical Incision</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177020</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Skin</PreferredName>
        <Version>1</Version>
        <LongName>Skin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2201273</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Surgical Incision</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Incision</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15384</PREFERRED_NAME>
            <LONG_NAME>Surgical Incision</LONG_NAME>
            <CON_ID>2203601</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201278</PublicId>
      <PreferredName>END_TM</PreferredName>
      <PreferredDefinition>the time a procedure or assessment ended.</PreferredDefinition>
      <LongName>End Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Skin incision stop time</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Skin incision stop time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SKIN_SURGINCI_END_TM</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1082">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201331</PUBLICID>
    <LONGNAME>Adverse Event Telephone Report Time</LONGNAME>
    <PREFERREDNAME>AE_PH_REPT_TM</PREFERREDNAME>
    <PREFERREDDEFINITION>The time at which an adverse event report was submitted via telephone call.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CIP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201327</PublicId>
      <PreferredName>AE_PH_REPT</PreferredName>
      <PreferredDefinition>Adverse event report submitted via telephone call.</PreferredDefinition>
      <LongName>Adverse Event Telephone Report</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CIP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2235992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207206</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25395:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Telephone Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25395</PREFERRED_NAME>
            <LONG_NAME>Telephone</LONG_NAME>
            <CON_ID>2202574</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019249</PublicId>
      <PreferredName>TM</PreferredName>
      <PreferredDefinition>the time at which an event was observed or occurred.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time called</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Time called</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2201295</PublicId>
          <ContextName>CIP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Adverse Events</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AE/SAE CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812387</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857169</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SAE Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE Reporting</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812370</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ENGLISH</AlternateName>
        <AlternateNameType>CONTEXT NAME</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1083">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2201705</PUBLICID>
    <LONGNAME>Prior Radiation Therapy Administered End Date</LONGNAME>
    <PREFERREDNAME>PRIOR_RT_ADM_END_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date that a prior radiation therapy ended.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188727</PublicId>
      <PreferredName>PRIOR_RT_ADM</PreferredName>
      <PreferredDefinition>information related to prior RT administered.</PreferredDefinition>
      <LongName>Prior RT Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206566</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Prior Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188674</PublicId>
      <PreferredName>END_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event ended.</PreferredDefinition>
      <LongName>End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184285</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior radiation therapy stop</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prior radiation therapy stop date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of radiotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last date of radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date completed</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last date of therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If yes, date of completion of prior RT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, date of completion of prior RT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of prior radiation therapy ended</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of last treatment received</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of last treatment received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date prior radiation therapy ended</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior radiation end date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If yes, date last received</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, date last received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, date completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>End Date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>End Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day of RT drug was taken</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Therapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior radiotherapy end date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior Therapies Form</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date (most recent) prior radiation therapy ended</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Last day drug was taken</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of radiation of bone lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of radiotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>last day of radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>date of last radiotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Text14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiotherapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stop date (dd MMM yyyy)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stop date (dd MMM yyyy)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text15</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation Therapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text16</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation End Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of last treatment:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF text17</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Conventional Fractionated Radiation Therapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text18</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stereotactic Ablative Radiation Therapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance A092105</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, Radiotherapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, radiation therapy completion date (≥ 12 weeks prior to registration)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text19</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, Radiation Therapy Completion Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2552643</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Training Class Examples</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3637837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Curative Head/Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811942</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SWOG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RTEDT</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRADIOEDT</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PRIOR_RT_ADM_END_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_RT_ADM_END_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIOR_RT_ADM_END_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>SWOG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RDLDT</AlternateName>
        <AlternateNameType>OID, SWOG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRSTDAT_PRIRT</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CMSTDAT_PRIRT</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRSTDAT_PRIRTEND</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1084">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2202031</PUBLICID>
    <LONGNAME>Fear Breath Shortness Assessment Scale</LONGNAME>
    <PREFERREDNAME>FEAR_BRSHRT_ASES_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>the assessment of how much fear of shortness of breath limits the patient&#39;s daily life.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2202030</PublicId>
      <PreferredName>FEAR_BRTHSHRT_ASSESS</PreferredName>
      <PreferredDefinition>information relating to an assessment of the fear of breath shortness.</PreferredDefinition>
      <LongName>Fear Breath Shortness Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0015726:C0392680</PreferredName>
        <Version>1</Version>
        <LongName>Fear, focus Breath shortness</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0015726</PREFERRED_NAME>
            <LONG_NAME>Fear, focus</LONG_NAME>
            <CON_ID>2615854</CON_ID>
            <DEFINITION_SOURCE>MDR-60</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0392680</PREFERRED_NAME>
            <LONG_NAME>Breath shortness</LONG_NAME>
            <CON_ID>2203361</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2261670</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20989</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2201889</PublicId>
      <PreferredName>BREATHSHORTNES_SCALE</PreferredName>
      <PreferredDefinition>the scale to determine the patient&#39;s shortness of breath.</PreferredDefinition>
      <LongName>Breath Shortness Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184332</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Scale</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-02-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Maximum</VALUEMEANING>
          <MEANINGDESCRIPTION>The largest possible quantity or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fear of shortness of breath</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Fear of shortness of breath</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1308</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104933</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FEAR_BRSHRT_ASES_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1085">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2220523</PUBLICID>
    <LONGNAME>Brachytherapy Implant Width Measurement</LONGNAME>
    <PREFERREDNAME>BRT_IMP_WIDTH_MSRMT</PREFERREDNAME>
    <PREFERREDDEFINITION>the width of brachytherapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2220521</PublicId>
      <PreferredName>BRACHYTX_IMP_WIDTH</PreferredName>
      <PreferredDefinition>information relating to mesh brachytherapy width.</PreferredDefinition>
      <LongName>Brachytherapy Implant Width</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2474533</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15195</PreferredName>
        <Version>1</Version>
        <LongName>Brachytherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15195</PREFERRED_NAME>
            <LONG_NAME>Brachytherapy</LONG_NAME>
            <CON_ID>2202699</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2688204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41075:C25345</PreferredName>
        <Version>1</Version>
        <LongName>Implant Width</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41075</PREFERRED_NAME>
            <LONG_NAME>Implant</LONG_NAME>
            <CON_ID>2686023</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25345</PREFERRED_NAME>
            <LONG_NAME>Width</LONG_NAME>
            <CON_ID>2203977</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2220522</PublicId>
      <PreferredName>BRT_LNG_WIDTH_MSRMT</PreferredName>
      <PreferredDefinition>the width of brachytherapy mesh.</PreferredDefinition>
      <LongName>Brachytherapy Implant Width Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2184312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mesh Width</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mesh Width</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Width</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Width</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation Therapy CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3028710</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000002</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NSCLC Stage I-III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000558</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation Therapy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3028706</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1086">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2220705</PUBLICID>
    <LONGNAME>Epidermal Growth Factor Receptor Allele Type</LONGNAME>
    <PREFERREDNAME>EGFR_ALLELE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>A designation of the specific EGFR allele being analyzed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2185950</PublicId>
      <PreferredName>EGFR_PRES</PreferredName>
      <PreferredDefinition>information related to Epidermal Growth Factor Receptor Tumor being present. </PreferredDefinition>
      <LongName>Epidermal Growth Factor Receptor Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2185949</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Epidermal Growth Factor Recept</PreferredName>
        <Version>1</Version>
        <LongName>Epidermal Growth Factor Receptor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17068</PREFERRED_NAME>
            <LONG_NAME>Epidermal Growth Factor Receptor</LONG_NAME>
            <CON_ID>2202420</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2220703</PublicId>
      <PreferredName>EGFR_ALLELE_TP</PreferredName>
      <PreferredDefinition>Designation of the specific allele being analyzed.</PreferredDefinition>
      <LongName>Epidermal Growth Factor Receptor Allele Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2201802</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allele 1</VALIDVALUE>
          <VALUEMEANING>Allele 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Allele 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574556</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allele 2</VALIDVALUE>
          <VALUEMEANING>Allele 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Allele 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Allele</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Allele</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812377</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1087">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223570</PUBLICID>
    <LONGNAME>Computer Application Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2223518v3.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A program that gives a computer instructions that provide the user with tools to accomplish a task._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223518</PublicId>
      <PreferredName>2223473v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A program that gives a computer instructions that provide the user with tools to accomplish a task._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Computer Application Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42608</PreferredName>
        <Version>1</Version>
        <LongName>Computer Application</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42608</PREFERRED_NAME>
            <LONG_NAME>Computer Application</LONG_NAME>
            <CON_ID>2223419</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Computer Application Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Computer Application Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.caBIG.caTIES.database.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caTIES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812488</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CSM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812253</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.security.authorization.domainobjects</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000217</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common Security Module (CSM)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812424</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.security.authorization.domainobjects</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812425</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.caBIG.caTIES.database.domain.Application.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Application:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.security.authorization.domainobjects.Application.applicationId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Application:applicationId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1088">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223755</PUBLICID>
    <LONGNAME>Vocabulary Object Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2223347v3.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The object describes the vocabulary._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Value Domain for java language Long datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223347</PublicId>
      <PreferredName>2223311v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The object describes the vocabulary._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Vocabulary Object Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43528</PreferredName>
        <Version>1</Version>
        <LongName>Vocabulary Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43528</PREFERRED_NAME>
            <LONG_NAME>Enterprise Vocabulary</LONG_NAME>
            <CON_ID>2223176</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Vocabulary Object Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Vocabulary Object Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Representation is Integer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>VD REFERENCE</DocumentType>
        <DocumentText>NCICB Database Primary Key</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Vocabulary.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Vocabulary:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@id</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1089">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223792</PUBLICID>
    <LONGNAME>Nucleotide Sequence Accession Number java.lang.String</LONGNAME>
    <PREFERREDNAME>2223634v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequence of nucleotide residues along an RNA or DNA chain._A control number unique to an object, used to identify it among the other objects in a collection._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223634</PublicId>
      <PreferredName>2223318v1.0:2223255v1.0</PreferredName>
      <PreferredDefinition>The sequence of nucleotide residues along an RNA or DNA chain._A control number unique to an object, used to identify it among the other objects in a collection.</PreferredDefinition>
      <LongName>Nucleotide Sequence Accession Number</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223318</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45374</PreferredName>
        <Version>1</Version>
        <LongName>Nucleotide Sequence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45374</PREFERRED_NAME>
            <LONG_NAME>Nucleotide Sequence</LONG_NAME>
            <CON_ID>2223191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223255</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25402</PreferredName>
        <Version>1</Version>
        <LongName>Accession Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Nucleotide Sequence Accession Number java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Nucleotide Sequence Accession Number java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>An alphanumeric code that indicates a specific sequence in the Genbank data repository maintained by NCBI.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.NucleicAcidSequence.accessionNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NucleicAcidSequence:accessionNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@accessionNumber</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1090">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223809</PUBLICID>
    <LONGNAME>Biochemical Pathway Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2223651v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An elaboration of the sequence of chemical reactions leading from one compound to another taking place in living tissue._The words or language units by which a thing is known._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223651</PublicId>
      <PreferredName>2223321v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>An elaboration of the sequence of chemical reactions leading from one compound to another taking place in living tissue._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Biochemical Pathway Name</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223321</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20633</PreferredName>
        <Version>1</Version>
        <LongName>Biochemical Pathway</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20633</PREFERRED_NAME>
            <LONG_NAME>Biochemical Pathway</LONG_NAME>
            <CON_ID>2211227</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biochemical Pathway Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biochemical Pathway Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Maintained by KEGG at kegg.com</DocumentText>
        <URL>http://www.kegg.com</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2638539</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Reactome Database Sharing</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.reactome.cabig.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.reactome.cabig.domain.Pathway.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Pathway.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Pathway:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@name</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1091">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223818</PUBLICID>
    <LONGNAME>Library Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2223660v3.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A collection of DNA molecules that have been cloned in vectors._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223660</PublicId>
      <PreferredName>2223324v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>A collection of DNA molecules that have been cloned in vectors._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Library Created Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223324</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16223</PreferredName>
        <Version>1</Version>
        <LongName>Library</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16223</PREFERRED_NAME>
            <LONG_NAME>DNA Library</LONG_NAME>
            <CON_ID>2223197</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Library Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Library Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Library.creationDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Library:creationDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1092">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2223838</PUBLICID>
    <LONGNAME>Gene Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2223680v3.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Value Domain for java language Long datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223680</PublicId>
      <PreferredName>2223326v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Gene Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223326</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16612</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2202483</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Representation is Integer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Comment</Name>
        <OrganizationName/>
        <DocumentType>VD REFERENCE</DocumentType>
        <DocumentText>NCICB Database Primary Key</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2496586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812496</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2544880</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GeneConnect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.geneconnect.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557869</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.samplecomposition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813026</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2629622</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TrAPSS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TrAPSS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2629622</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TrAPSS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.uiowa.clcg.trapss.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716603</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000647</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812742</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Bioinformatics Infrastructure Objects (caBIO)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857188</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server 1.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812071</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000649</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.function</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915887</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.uiowa.clcg.trapss.domain.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.geneconnect.domain.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Gene:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneIdentifier:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.array.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.samplecomposition.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.GeneIdentifier.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.function.Gene.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@id</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1093">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2226792</PUBLICID>
    <LONGNAME>Hormone Therapy Finasteride Prior Administered Ind-3</LONGNAME>
    <PREFERREDNAME>HORM_FIN_P_ADM_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator that asks whether finasteride was administered as a prior hormone therapy agent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2226791</PublicId>
      <PreferredName>HORM_FIN_P_ADM</PreferredName>
      <PreferredDefinition>information related to finasteride, a synthetic azasteroid compound that binds to and inhibits 5-alpha-reductase and interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone and ultimately interfering with prostate growth, administered as a prior hormone therapy.</PreferredDefinition>
      <LongName>Hormone Therapy Finasteride Prior Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2433915</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15445</PreferredName>
        <Version>1</Version>
        <LongName>Hormone Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15445</PREFERRED_NAME>
            <LONG_NAME>Hormone Therapy</LONG_NAME>
            <CON_ID>2202373</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2744042</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1099:C25629:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Finasteride Prior Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1099</PREFERRED_NAME>
            <LONG_NAME>Finasteride</LONG_NAME>
            <CON_ID>2226788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Finasteride</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Finasteride</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1094">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2230047</PUBLICID>
    <LONGNAME>Specimen Accession Number</LONGNAME>
    <PREFERREDNAME>SPEC_ACCNUM</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to a specimen accession number.:The alphanumeric identifier assigned to the specimen to uniquely identify it.</PREFERREDDEFINITION>
    <VERSION>4.1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2191580</PublicId>
      <PreferredName>SPEC_ACCNUM</PreferredName>
      <PreferredDefinition>information related to a specimen accession number.</PreferredDefinition>
      <LongName>Specimen Accession Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177659</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Accession Number</PreferredName>
        <Version>1</Version>
        <LongName>Accession Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2230045</PublicId>
      <PreferredName>SPEC_ACCNUM</PreferredName>
      <PreferredDefinition>The alphanumeric identifier assigned to the specimen to uniquely identify it.</PreferredDefinition>
      <LongName>Specimen Accession Number</LongName>
      <Version>4.1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specimen Accession #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Accession Number</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Accession Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Yes, Accession #(s)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specimen ID number or Pathology accession number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specimen ID</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Blood Sample ID #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Accession Number(s) and Number(s)/Letter(s) corresponding to slides</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Accession Number(s) and Number(s)/Letter(s) of FFPE Blocks</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FFPE Block Accession Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OPEN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the Specimen # from the Children&#39;s Hospital of Los Angeles MRD report?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Accession Number(s) and Block Number(s)/Letter(s)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Test/Results</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2864540</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Polyphenon E for Cervical Ca</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812399</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3194026</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>KAI Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812550</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3194026</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>KAI Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Tracking and Results Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3212386</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280815</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Test/Results</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000327</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Tests and Biospecimens/ Biomarkers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3151271</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Laboratory Tests and Tracking</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3152844</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Assessments and Examinations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000640</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_ACCNUM</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_ACCNUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Accession Number</AlternateName>
        <AlternateNameType>NINDS Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCTG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_ACCNUM</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CRDC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CRDC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>biosample_accession</AlternateName>
        <AlternateNameType>CDS Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BE_BEREFID</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1095">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2231200</PUBLICID>
    <LONGNAME>Immunohistochemistry Score Derived</LONGNAME>
    <PREFERREDNAME>IHC_SC_DERIV</PREFERREDNAME>
    <PREFERREDDEFINITION>The derived score of a immunohistochemistry analysis based on the determinants of Positive Cells (P) and Intensity (I).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2230162</PublicId>
      <PreferredName>IHC_SC</PreferredName>
      <PreferredDefinition>A numeric or range of numeric values measuring performance, function, or ability. Scores are used to aid in the diagnosis and treatment of a condition. In addition, scores may be part of the inclusion or exclusion criteria of a clinical trial protocol.  An assay that shows specific antigens by the use of markers that are either fluorescent dyes or enzymes. In these techniques an antibody is used to link a cellular antigen specifically to a stain that can be more readily seen with a microscope. Detection of antigens in tissues is known as immunohistochemistry, while detection in cultured cells is generally termed immunocytochemistry.</PreferredDefinition>
      <LongName>Immunohistochemistry Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177103</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Immunohistochemistry</PreferredName>
        <Version>1</Version>
        <LongName>Immunohistochemistry</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16722</PREFERRED_NAME>
            <LONG_NAME>Immunohistochemistry</LONG_NAME>
            <CON_ID>2202666</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177688</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Score</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0449820</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204090</CON_ID>
            <DEFINITION_SOURCE>NCI Thesaurus. Bethesda (MD): National Cancer Institute, National Institutes of Health, TDE version, August 2004. Contact: Sherri de Coronado, decorons@osp.nci.nih.gov, http://nci.nih.gov</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2231198</PublicId>
      <PreferredName>IHC_SC_DERIV</PreferredName>
      <PreferredDefinition>The derived score of a immunohistochemistry analysis_Having been determined by mathematical computation.</PreferredDefinition>
      <LongName>Immunohistochemistry Score Derived Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2480858</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42885:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Derived Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42885</PREFERRED_NAME>
            <LONG_NAME>Derivation</LONG_NAME>
            <CON_ID>2231196</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Score=PxI (0-12)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Score=PxI (0-12)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sulindac for Breast Cancer</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>CALCULATED</DerivationType>
      <DerivationTypeDescription>CALCULATED</DerivationTypeDescription>
      <Methods/>
      <Rule>Multiple the number of positive cells by the intensity score.</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>2230166</PublicId>
          <LongName>Immunohistochemistry Positive Cell Score</LongName>
          <PreferredName>IHC_POS_CELL_SC</PreferredName>
          <PreferredDefinition>The score assigned to a sample on the basis of immunohistochemistry analysis.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
          <ContextName>DCP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2007223</PublicId>
          <LongName>Immunohistochemistry Staining Intensity Number Score</LongName>
          <PreferredName>IHC_STAIN_INTS_SC</PreferredName>
          <PreferredDefinition>Numeric score to represent the strength of an immunohistochemistry (IHC) analysis result.</PreferredDefinition>
          <Version>2</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>SPOREs</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1096">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2230166</PUBLICID>
    <LONGNAME>Immunohistochemistry Positive Cell Score</LONGNAME>
    <PREFERREDNAME>IHC_POS_CELL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>The score assigned to a sample on the basis of immunohistochemistry analysis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1097">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2007223</PUBLICID>
    <LONGNAME>Immunohistochemistry Staining Intensity Number Score</LONGNAME>
    <PREFERREDNAME>IHC_STAIN_INTS_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric score to represent the strength of an immunohistochemistry (IHC) analysis result.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SPOREs</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1098">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232731</PUBLICID>
    <LONGNAME>Question Text Change Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2232130v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The actual text of the data element as specified on a Case Report Form of a Protocol. (NCICB)_An alteration or modification.:A statement or an account describing something. (Bartleby.com)_Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2232130</PublicId>
      <PreferredName>2231663v1.0:2231607v1.0</PreferredName>
      <PreferredDefinition>The actual text of the data element as specified on a Case Report Form of a Protocol. (NCICB)_An alteration or modification.:A statement or an account describing something. (Bartleby.com)</PreferredDefinition>
      <LongName>Question Text Change Description</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231663</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116</PreferredName>
        <Version>1</Version>
        <LongName>Question Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231607</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Change Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Question Text Change Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Question Text Change Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Question.changeNote</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Question:changeNote</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.changeNote</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:changeNote</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1099">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2232767</PUBLICID>
    <LONGNAME>Valid Value Administered Item End Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2232166v3.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The allowable values for a given question on a Case Report Form. (NCICB):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The point or place at which something terminates in time, space, or extent.:The particular day, month and year an event will happen or has happened._Java Date Type</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2232166</PublicId>
      <PreferredName>2231666v1.0:2231605v1.0</PreferredName>
      <PreferredDefinition>The allowable values for a given question on a Case Report Form. (NCICB):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The point or place at which something terminates in time, space, or extent.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Valid Value Administered Item End Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231666</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41124:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Valid Value Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41124</PREFERRED_NAME>
            <LONG_NAME>Valid Value</LONG_NAME>
            <CON_ID>2231578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496:C25164</PreferredName>
        <Version>1</Version>
        <LongName>End Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Valid Value Administered Item End Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Valid Value Administered Item End Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Data Standards Repository (caDSR)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857173</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812448</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ValidValue.endDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ValidValue:endDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponent.endDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponent:endDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1100">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2238012</PUBLICID>
    <LONGNAME>Cluster Node Value Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2237857v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An individual component of a clustering.  May contain other nodes.:A numerical quantity measured or assigned or computed._The words or language units by which a thing is known._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2237857</PublicId>
      <PreferredName>2236717v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>An individual component of a clustering.  May contain other nodes.:A numerical quantity measured or assigned or computed._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Cluster Node Value Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236717</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44475:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Cluster Node Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44475</PREFERRED_NAME>
            <LONG_NAME>Cluster Node</LONG_NAME>
            <CON_ID>2236543</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cluster Node Value Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cluster Node Value Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2321254</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Mage-OM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Higher Level Analysis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812458</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2321254</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Mage-OM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.HigherLevelAnalysis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812459</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>mageom 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812229</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534950</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray_1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.mageom.domain.HigherLevelAnalysis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000218</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.mageom.domain.HigherLevelAnalysis.NodeValue.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NodeValue:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1101">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2262034</PUBLICID>
    <LONGNAME>Laboratory Procedure Neutrophil Result Status</LONGNAME>
    <PREFERREDNAME>LAB_NEUTROP_RS_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>a qualitative result of the laboratory test for absolute neutrophil count.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188764</PublicId>
      <PreferredName>LAB_NEUTROPHIL_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of a medical procedure that involves testing a sample of blood for neutrophil, granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.</PreferredDefinition>
      <LongName>Laboratory Procedure Neutrophil Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2739333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12533:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Neutrophil Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12533</PREFERRED_NAME>
            <LONG_NAME>Neutrophil</LONG_NAME>
            <CON_ID>2206322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2225337</PublicId>
      <PreferredName>LAB_ASSESS_STAT</PreferredName>
      <PreferredDefinition>the status of a lab assessment.</PreferredDefinition>
      <LongName>Lab Assessment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength>6</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt; normal</VALIDVALUE>
          <VALUEMEANING>&gt; normal</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt; normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt; normal</VALIDVALUE>
          <VALUEMEANING>&lt; normal</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt; normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Within normal limits</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal, eligibility not affected</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal, not eligible</VALIDVALUE>
          <VALUEMEANING>ABNORMAL NOT ELIGIBLE</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal and no longer eligible</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal - Clinically significant</VALIDVALUE>
          <VALUEMEANING>Abnormal - Clinically significant</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal - Clinically significant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal - Not clinically significant</VALIDVALUE>
          <VALUEMEANING>Abnormal - Not clinically significant</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal - Not clinically significant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;= ULN</VALIDVALUE>
          <VALUEMEANING>&gt;= Upper limit of institutional normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Value is greater or equal to upper limit of institutional normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt; ULN</VALIDVALUE>
          <VALUEMEANING>Less than upper limit of institutional normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Value is less than upper limit of institutional normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trace</VALIDVALUE>
          <VALUEMEANING>Trace</VALUEMEANING>
          <MEANINGDESCRIPTION>A barely detectable amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2912071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Undetectable</VALIDVALUE>
          <VALUEMEANING>Undetectable</VALUEMEANING>
          <MEANINGDESCRIPTION>Undetectable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;</VALIDVALUE>
          <VALUEMEANING>Greater than (&gt;)</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than (&gt;)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;</VALIDVALUE>
          <VALUEMEANING>Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Less Than</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2840098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5042698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5178198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;= ULN</VALIDVALUE>
          <VALUEMEANING>Less Than or Equal To Upper Limit of Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.: The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25706, C61586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6013658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;ULN</VALIDVALUE>
          <VALUEMEANING>Greater Than Upper Limit of Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25706, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6013657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>=</VALIDVALUE>
          <VALUEMEANING>Equality</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being the same in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3423503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>ANC</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1102">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2321336</PUBLICID>
    <LONGNAME>Off-Treatment Chemotherapy Protocol Agent Dose</LONGNAME>
    <PREFERREDNAME>OTX_CT_PROT_AGT_DOSE</PREFERREDNAME>
    <PREFERREDDEFINITION>a dose amount for additional chemotherapy doses with the protocol-specified agent given after protocol-specified treatment ends but prior to completion of the follow-up period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2321308</PublicId>
      <PreferredName>OTX_CT_PROT_AGT</PreferredName>
      <PreferredDefinition>information related to additional chemotherapy doses with the protocol-specified agent given after protocol-specified treatment ends but prior to completion of the follow-up period.</PreferredDefinition>
      <LongName>Off-Treatment Chemotherapy Protocol Agent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206851</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25601:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Off-Treatment Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2321306</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25320:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018364</PublicId>
      <PreferredName>AGT_DOSE</PreferredName>
      <PreferredDefinition>the quantity of an agent or drug.</PreferredDefinition>
      <LongName>Agent Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>3</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Agent Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1103">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2322248</PUBLICID>
    <LONGNAME>Messenger RNA Ensembl Genomic Identifier</LONGNAME>
    <PREFERREDNAME>2322236v1.0:2425741v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Messenger RNA.  A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust.  The Ensembl Genome Brow:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier assigned to a transcript by EnsEMBL. It is used to uniquely identify a gene transcript in the EnsEMBL system. [Explanatory comment: The format is ENSTxxxxxxxxxxx for humans.  The one for mouse is ENSMUSTxxxxxxxxxxx.  So the general format is ENS Species (except human) T ? xxxxxxxxxxx.  There are always 11 digits in this identifier.There are some species that don&#39;t follow these rules. For instance, species such as Drosophila or Tetraodon were not annotated by Ensembl follow a different convention. This definition has been reviewed by Xose M. Fernandez and Bert Overduin representing the Ensembl Helpdesk.]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2322236</PublicId>
      <PreferredName>2322230v1.0:2322223v1.0</PreferredName>
      <PreferredDefinition>Messenger RNA.  A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust.  The Ensembl Genome Brow:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome.</PreferredDefinition>
      <LongName>Messenger RNA Ensembl Genomic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322230</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C813</PreferredName>
        <Version>1</Version>
        <LongName>Messenger RNA</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C813</PREFERRED_NAME>
            <LONG_NAME>Messenger RNA</LONG_NAME>
            <CON_ID>2322221</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2322223</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45763:C45766</PreferredName>
        <Version>1</Version>
        <LongName>Ensembl Genomic Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45763</PREFERRED_NAME>
            <LONG_NAME>Ensembl</LONG_NAME>
            <CON_ID>2322217</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45766</PREFERRED_NAME>
            <LONG_NAME>Genomic Identifier</LONG_NAME>
            <CON_ID>2322216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2425741</PublicId>
      <PreferredName>2425741v1</PreferredName>
      <PreferredDefinition>The unique identifier assigned to a transcript by EnsEMBL. It is used to uniquely identify a gene transcript in the EnsEMBL system. [Explanatory comment: The format is ENSTxxxxxxxxxxx for humans.  The one for mouse is ENSMUSTxxxxxxxxxxx.  So the general format is ENS Species (except human) T ? xxxxxxxxxxx.  There are always 11 digits in this identifier.There are some species that don&#39;t follow these rules. For instance, species such as Drosophila or Tetraodon were not annotated by Ensembl follow a different convention. This definition has been reviewed by Xose M. Fernandez and Bert Overduin representing the Ensembl Helpdesk.]</PreferredDefinition>
      <LongName>Messenger RNA Ensembl Genomic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genomic ID CDE documentation</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText/>
        <URL>http://cabigcvs.nci.nih.gov/viewcvs/viewcvs.cgi/pir/adopter_penn/month3/Documentation%20of%20Genomic%20Identifier%20CDEs.doc</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Information about Ensembl</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText/>
        <URL>http://www.ensembl.org/info/about/index.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EnsEMBL Identifier</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>EnsEMBL Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Genomic Identifers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812110</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2544880</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GeneConnect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.geneconnect.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857177</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Genomic Identifiers</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPenn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812494</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857177</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Genomic Identifiers</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upenn.med</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812495</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2954884</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GRANITE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.Granite</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2954885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675695</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDE by Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Genomic Identifers</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000133</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.geneconnect.domain.MessengerRNA.ensemblTranscriptId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MessengerRNA:ensemblTranscriptId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upenn.med.MessengerRNA.ensembltranscriptID</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MessengerRNA:ensembltranscriptID</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MessengerRNA:ensemblTranscriptID</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.Granite.MessengerRNA.ensemblTranscriptID</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1104">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2342516</PUBLICID>
    <LONGNAME>DNA Binding Domain Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2342339v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A region of a protein that interacts with DNA. Among the various recognized structural motifs present in DNA binding domains are the helix-loop-helix and the zinc-finger._A statement or an account describing something._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2342339</PublicId>
      <PreferredName>2342233v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A region of a protein that interacts with DNA. Among the various recognized structural motifs present in DNA binding domains are the helix-loop-helix and the zinc-finger._A statement or an account describing something.</PreferredDefinition>
      <LongName>DNA Binding Domain Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2342233</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13425</PreferredName>
        <Version>1</Version>
        <LongName>DNA Binding Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13425</PREFERRED_NAME>
            <LONG_NAME>DNA Binding Domain</LONG_NAME>
            <CON_ID>2342177</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element DNA Binding Domain Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element DNA Binding Domain Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2496586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812496</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716603</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.DNABindingRegion.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DNABindingRegion:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.ProteinFeature.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProteinFeature:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1105">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2342551</PUBLICID>
    <LONGNAME>Negation Consecutive Amino Acid End java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2342374v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Negation is an operation in which a term denies or inverts the meaning of another term or construction.:In regular succession without gaps.:Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins._The point or place at which something terminates in time or space._Value Domain for java language Integer datatype</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2342374</PublicId>
      <PreferredName>2342242v1.0:2236677v1.0</PreferredName>
      <PreferredDefinition>Negation is an operation in which a term denies or inverts the meaning of another term or construction.:In regular succession without gaps.:Organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins._The point or place at which something terminates in time or space.</PreferredDefinition>
      <LongName>Negation Consecutive Amino Acid End</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2342242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C47939:C231</PreferredName>
        <Version>1</Version>
        <LongName>Negation Consecutive Amino Acid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47939</PREFERRED_NAME>
            <LONG_NAME>Consecutive</LONG_NAME>
            <CON_ID>2342185</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C231</PREFERRED_NAME>
            <LONG_NAME>Amino Acid</LONG_NAME>
            <CON_ID>2342175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496</PreferredName>
        <Version>1</Version>
        <LongName>End</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Negation Consecutive Amino Acid End java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Negation Consecutive Amino Acid End java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2496586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812496</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2716603</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PIR 1.2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.georgetown.pir.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.NonConsecutiveResidues.end</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NonConsecutiveResidues:end</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.georgetown.pir.domain.ProteinFeature.end</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProteinFeature:end</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1106">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2399259</PUBLICID>
    <LONGNAME>Bladder Cancer Family History Type</LONGNAME>
    <PREFERREDNAME>BLAD_CA_FAM_HX_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the identification of the medical history of any family member with an occurrence of tumor affecting the urinary bladder.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2399251</PublicId>
      <PreferredName>BLAD_CA_FAM_HX</PreferredName>
      <PreferredDefinition>related to records of health and disease events of family members with specific regard to occurrences of tumor affecting the urinary bladder.</PreferredDefinition>
      <LongName>Bladder Cancer Family History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206697</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12414:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Bladder Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12414</PREFERRED_NAME>
            <LONG_NAME>Bladder</LONG_NAME>
            <CON_ID>2202678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2399249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17726</PreferredName>
        <Version>1</Version>
        <LongName>Family History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17726</PREFERRED_NAME>
            <LONG_NAME>Family Medical History</LONG_NAME>
            <CON_ID>2202638</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2399258</PublicId>
      <PreferredName>BLAD_CA_FAM_HX_TP</PreferredName>
      <PreferredDefinition>the identification of the medical history of any family member with an occurrence of tumor affecting the urinary bladder.</PreferredDefinition>
      <LongName>Bladder Cancer Family History Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2177853</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Type</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, first degree relative</VALIDVALUE>
          <VALUEMEANING>YES FIRST DEGREE RELATIVE</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes first degree relative (such as parent, sibling or child)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576065</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, but other relative</VALIDVALUE>
          <VALUEMEANING>YES BUT OTHER RELATIVE</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, but other relative</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Family history of bladder can</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Family history of bladder cancer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1107">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2404919</PUBLICID>
    <LONGNAME>Metastatic Bladder Cancer Diagnosis Ind-2</LONGNAME>
    <PREFERREDNAME>METC_BLAD_CA_DX_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if the spread of cancer has been identified by signs and symptoms for a tumor composed of atypical neoplastic cells of the urinary bladder.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2404913</PublicId>
      <PreferredName>METC_BLAD_CA_DX</PreferredName>
      <PreferredDefinition>related to the process of identifying the spread of cancer by the signs and symptoms for a tumor composed of atypical neoplastic cells of the urinary bladder.</PreferredDefinition>
      <LongName>Metastatic Bladder Cancer Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404911</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14174:C12414:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Metastatic Bladder Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12414</PREFERRED_NAME>
            <LONG_NAME>Bladder</LONG_NAME>
            <CON_ID>2202678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient been diagnose</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient been diagnosed with metastatic bladder cancer that has not been previously reported</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5242953</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Bladder Ca Advocacy Network</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC-GENOME</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5242975</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1108">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2405176</PUBLICID>
    <LONGNAME>Address Street/Thoroughfare Extension Name</LONGNAME>
    <PREFERREDNAME>ADDR_STRT_EXT_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>A component of an address that specifies a location by identification of an expanded part of road or public highway.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2405172</PublicId>
      <PreferredName>ADDR_STRT_EXT</PreferredName>
      <PreferredDefinition>The street/thoroughfare extension component of an address.</PreferredDefinition>
      <LongName>Address Street/Thoroughfare Extension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2341906</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25407</PreferredName>
        <Version>1</Version>
        <LongName>Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2452885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25270:C25690</PreferredName>
        <Version>1</Version>
        <LongName>Extension Street Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25270</PREFERRED_NAME>
            <LONG_NAME>Extend</LONG_NAME>
            <CON_ID>2203922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25690</PREFERRED_NAME>
            <LONG_NAME>Street Address</LONG_NAME>
            <CON_ID>2203802</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017348</PublicId>
      <PreferredName>STADDR_NAME</PreferredName>
      <PreferredDefinition>the street name component of an address.</PreferredDefinition>
      <LongName>Street Address Name</LongName>
      <Version>4</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184314</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Name</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Address Street/Thoroughfare E</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Address Street/Thoroughfare Extension Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Address</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812358</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3204728</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CBM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cbm.domain.LogicalModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3204729</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675695</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDE by Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Address</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cbm.domain.LogicalModel.Address.streetOrThoroughfareExtensionName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Address:streetOrThoroughfareExtensionName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1109">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2405253</PUBLICID>
    <LONGNAME>Immunotherapy Trastuzumab Received Ind-2</LONGNAME>
    <PREFERREDNAME>ITX_TRAS_RCVD_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to whether Trastuzumab immunotherapy was received.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2405250</PublicId>
      <PreferredName>IMMUNOTX_TRAS_RCVD</PreferredName>
      <PreferredDefinition>Information related to patient/participant having received Trastuzumab which is a humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.</PreferredDefinition>
      <LongName>Immunotherapy Trastuzumab Received</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2554222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15262</PreferredName>
        <Version>1</Version>
        <LongName>Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2743372</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1647:C25639</PreferredName>
        <Version>1</Version>
        <LongName>Trastuzumab Received</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1647</PREFERRED_NAME>
            <LONG_NAME>Trastuzumab</LONG_NAME>
            <CON_ID>2202865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient receive any H</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient receive any Herceptin treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive trastuzumab?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient ever take trastuzumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Trastuzumab</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Herceptin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Since the last follow-up, did the patient initiate COMMERCIAL Herceptin?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ITX_TRAS_RCVD_IND2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1110">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2414969</PUBLICID>
    <LONGNAME>Research Specimen Collected Tube Type</LONGNAME>
    <PREFERREDNAME>RSCH_SPEC_TUBE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Types of specimen tube(s) with specimen amounts collected for research purposes.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014993</PublicId>
      <PreferredName>SPEC_COLL</PreferredName>
      <PreferredDefinition>the sample collected from the patient for analysis or examination.</PreferredDefinition>
      <LongName>Specimen Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177590</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Collected</PreferredName>
        <Version>1</Version>
        <LongName>Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2414967</PublicId>
      <PreferredName>RSCH_SPEC_TUBE_TP</PreferredName>
      <PreferredDefinition>Types of specimen tubes with specimen amounts collected for research purposes.</PreferredDefinition>
      <LongName>Research Specimen Tube Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>10</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8 cc blood</VALIDVALUE>
          <VALUEMEANING>8 cc blood tube</VALUEMEANING>
          <MEANINGDESCRIPTION>8 cc blood tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8 cc blood 2nd tube</VALIDVALUE>
          <VALUEMEANING>8 cc blood 2nd tube</VALUEMEANING>
          <MEANINGDESCRIPTION>8 cc blood 2nd tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8 to 10 cc ACD</VALIDVALUE>
          <VALUEMEANING>8 to 10 cc ACD tube</VALUEMEANING>
          <MEANINGDESCRIPTION>8 to 10 cc ACD tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10 cc EDTA</VALIDVALUE>
          <VALUEMEANING>10 cc EDTA tube</VALUEMEANING>
          <MEANINGDESCRIPTION>10 cc EDTA tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10 cc Wildcard tube</VALIDVALUE>
          <VALUEMEANING>10 cc Wildcard tube</VALUEMEANING>
          <MEANINGDESCRIPTION>10 cc Wildcard tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100 cc urine</VALIDVALUE>
          <VALUEMEANING>100 cc urine tube</VALUEMEANING>
          <MEANINGDESCRIPTION>100 cc urine tube</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Research collection tubes/amo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Research collection tubes/amounts</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MediData Rave Use</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3308730</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Protocol 10C0052D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3331757</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1111">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2415055</PUBLICID>
    <LONGNAME>Daunorubicin Hydrochloride Agent Current Report Period Adminstered End Date</LONGNAME>
    <PREFERREDNAME>DN_AG_CU_R_P_AD_E_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date administration of daunorubicin hydrochloride ended during the current report period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2415040</PublicId>
      <PreferredName>DNR_AGT_CU_RE_PD_ADM</PreferredName>
      <PreferredDefinition>information related to the administration of daunorubicin hydrochloride, an anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces coeruleorubidus, during the current report period.</PreferredDefinition>
      <LongName>Daunorubicin Hydrochloride Agent Current Report Period Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2415038</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1583:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Daunorubicin Hydrochloride Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1583</PREFERRED_NAME>
            <LONG_NAME>Daunorubicin Hydrochloride</LONG_NAME>
            <CON_ID>2415037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2415030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25375:C25616:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Current Report Period Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25616</PREFERRED_NAME>
            <LONG_NAME>Period</LONG_NAME>
            <CON_ID>2202575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188674</PublicId>
      <PreferredName>END_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event ended.</PreferredDefinition>
      <LongName>End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184285</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>End date of daunorubicin duri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>End date of daunorubicin during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1112">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2422611</PUBLICID>
    <LONGNAME>Study Publication Author Order Name</LONGNAME>
    <PREFERREDNAME>ST_PUB_AUTH_ORD_NAME</PREFERREDNAME>
    <PREFERREDDEFINITION>Specify whether each author is the first author, second author, etc. (e.g., 1, 2, 3, etc.)</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2422236</PublicId>
      <PreferredName>ST_PUB_AUTHOR</PreferredName>
      <PreferredDefinition>The writer of the study related publication.</PreferredDefinition>
      <LongName>Study Publication Author</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008529</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RSCH_PROT</PreferredName>
        <Version>1</Version>
        <LongName>Research Protocols</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422076</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C48471</PreferredName>
        <Version>1</Version>
        <LongName>Study Publication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48471</PREFERRED_NAME>
            <LONG_NAME>Publication</LONG_NAME>
            <CON_ID>2422075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224057</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42781</PreferredName>
        <Version>1</Version>
        <LongName>Author</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42781</PREFERRED_NAME>
            <LONG_NAME>Author</LONG_NAME>
            <CON_ID>2223995</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2422609</PublicId>
      <PreferredName>AUTH_ORDER_NAME</PreferredName>
      <PreferredDefinition>Identification of a research protocol by the order number of the authors (e.g., first author, second author).</PreferredDefinition>
      <LongName>Author Order Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008529</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RSCH_PROT</PreferredName>
        <Version>1</Version>
        <LongName>Research Protocols</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2238450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25191</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25191</PREFERRED_NAME>
            <LONG_NAME>Person Name</LONG_NAME>
            <CON_ID>2203721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Author Order and Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Author Order and Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Source</Name>
        <OrganizationName/>
        <DocumentType>DATA_ELEMENT_SOURCE</DocumentType>
        <DocumentText>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2.</DocumentText>
        <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812446</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Publications</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812616</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data Update System</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000130</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1113">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2426130</PUBLICID>
    <LONGNAME>Other Chemotherapy Agent Administration Ind-3</LONGNAME>
    <PREFERREDNAME>O_CT_AGT_ADM_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator related to the administration of an unspecified chemotherapy agent as treatment to arrest or kill the growth and spread of cancer cells.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2426118</PublicId>
      <PreferredName>O_CT_AGT_ADM</PreferredName>
      <PreferredDefinition>information related to the administration of an unspecified chemotherapy agent as treatment to arrest or kill the growth and spread of cancer cells.</PreferredDefinition>
      <LongName>Other Chemotherapy Agent Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2426116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C15632:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Other Chemotherapy Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25409</PreferredName>
        <Version>1</Version>
        <LongName>Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Chemotherapy-Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Chemotherapy-Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2126r1: Neuroblastoma Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>neu_base_chm_oth_tx_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>neu_post_chemo_oth_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>neu_post_prg_chem_oth_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1114">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2426133</PUBLICID>
    <LONGNAME>Docetaxel Chemotherapy Agent Administration Ind-3</LONGNAME>
    <PREFERREDNAME>DOC_CT_AGT_ADM_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator related to the administration of docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, as treatment to arrest or kill the growth and spread of cancer cells.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2426115</PublicId>
      <PreferredName>DOC_CT_AGT_ADM</PreferredName>
      <PreferredDefinition>information related to the administration of docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, as treatment to arrest or kill the growth and spread of cancer cells.</PreferredDefinition>
      <LongName>Docetaxel Chemotherapy Agent Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2426113</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1526:C15632:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Docetaxel Chemotherapy Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1526</PREFERRED_NAME>
            <LONG_NAME>Docetaxel</LONG_NAME>
            <CON_ID>2421116</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25409</PreferredName>
        <Version>1</Version>
        <LongName>Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Chemotherapy-Docetaxel</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Chemotherapy-Docetaxel</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Docetaxel</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1115">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2428593</PUBLICID>
    <LONGNAME>Renal Cell Carcinoma Pathologic N Stage</LONGNAME>
    <PREFERREDNAME>RENAL_CELL_CA_P_N_ST</PREFERREDNAME>
    <PREFERREDDEFINITION>the pathologic N (the extent of lymph node involvement) stage of cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2428381</PublicId>
      <PreferredName>RENAL_CELL_CA_P_N_ST</PreferredName>
      <PreferredDefinition>information related to the pathologic N (the extent of lymph node involvement) stage of cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.</PreferredDefinition>
      <LongName>Renal Cell Carcinoma Pathologic N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2428360</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9385</PreferredName>
        <Version>1</Version>
        <LongName>Renal Cell Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9385</PREFERRED_NAME>
            <LONG_NAME>Renal Cell Carcinoma</LONG_NAME>
            <CON_ID>2428359</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2428379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25580</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic N Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2428504</PublicId>
      <PreferredName>RCC_N_STAGE</PreferredName>
      <PreferredDefinition>the N (nodal) stage of renal cell carcinoma.</PreferredDefinition>
      <LongName>Renal Cell Carcinoma N Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N0</VALIDVALUE>
          <VALUEMEANING>NO REGIONAL LYMPH NODE METASTASIS</VALUEMEANING>
          <MEANINGDESCRIPTION>Breast cancer with no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N1</VALIDVALUE>
          <VALUEMEANING>Metastasis in a single regional lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>Metastasis in a single regional lymph node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N2</VALIDVALUE>
          <VALUEMEANING>Metastasis in more than one regional lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>Metastasis in more than one regional lymph node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NX</VALIDVALUE>
          <VALUEMEANING>REGIONAL LYMPH NODE CANNOT BE ASSESSED</VALUEMEANING>
          <MEANINGDESCRIPTION>REGIONAL LYMPH NODE CANNOT BE ASSESSED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic N Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic N Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>N-stage:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1116">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2430142</PUBLICID>
    <LONGNAME>Specimen ICF Signed Ind-2</LONGNAME>
    <PREFERREDNAME>SPEC_ICF_SIGN_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether the informed consent form for the use of specimen was signed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190099</PublicId>
      <PreferredName>SPEC_ICF_SIG</PreferredName>
      <PreferredDefinition>information related to specimen informed consent formed signed.</PreferredDefinition>
      <LongName>Specimen ICF Signed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206704</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C16468</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Consent Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16468</PREFERRED_NAME>
            <LONG_NAME>Consent Form</LONG_NAME>
            <CON_ID>2202582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177360</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Signed</PreferredName>
        <Version>1</Version>
        <LongName>Signed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25679</PREFERRED_NAME>
            <LONG_NAME>Signed</LONG_NAME>
            <CON_ID>2203795</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Informed consent signed?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Informed consent signed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the Biological Material Consent been signed and dated by the patient and Investigator?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1117">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2430556</PUBLICID>
    <LONGNAME>Gynecologic Surgical Procedure Performed Type</LONGNAME>
    <PREFERREDNAME>GYN_SXPROC_PERF_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the surgical technique or operative procedure performed for cancer of the female reproductive tract.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2430553</PublicId>
      <PreferredName>GYN_SX_PROC_PERF</PreferredName>
      <PreferredDefinition>information related to the operative procedure performed on the female reproductive organs.</PreferredDefinition>
      <LongName>Gynecologic Surgical Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2430551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28016:C15329</PreferredName>
        <Version>1</Version>
        <LongName>Gynecologic Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28016</PREFERRED_NAME>
            <LONG_NAME>Gynecologic</LONG_NAME>
            <CON_ID>2202649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2430546</PublicId>
      <PreferredName>GYN_SXPRO_PER_TP</PreferredName>
      <PreferredDefinition>the type of the gynecologic surgical procedure performed.</PreferredDefinition>
      <LongName>Gynecologic Surgical Procedure Performed Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>55</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>bilateral salpingo-oophorectomy</VALIDVALUE>
          <VALUEMEANING>BILATERAL SALPINGO-OOPHORECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>BILATERAL SALPINGO-OOPHORECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cervical conization</VALIDVALUE>
          <VALUEMEANING>CERVICAL CONIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>CERVICAL CONIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omentectal biopsy</VALIDVALUE>
          <VALUEMEANING>OMENTECTAL BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>OMENTECTAL BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>omentectomy</VALIDVALUE>
          <VALUEMEANING>OMENTECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>OMENTECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0198614</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>other specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>para-aortic node sampling/dissection</VALIDVALUE>
          <VALUEMEANING>PARA-AORTIC NODE SAMPLING/DISSECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>PARA-AORTIC NODE SAMPLING/DISSECTION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>partial hysterectomy</VALIDVALUE>
          <VALUEMEANING>PARTIAL HYSTERECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>PARTIAL HYSTERECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C40961</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pelvic lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>PELVIC LYMPHADENECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>PELVIC LYMPHADENECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pelvic node sampling/dissection</VALIDVALUE>
          <VALUEMEANING>PELVIC NODE SAMPLING/DISSECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>PELVIC NODE SAMPLING/DISSECTION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneal sampling</VALIDVALUE>
          <VALUEMEANING>PERITONEAL SAMPLING</VALUEMEANING>
          <MEANINGDESCRIPTION>PERITONEAL SAMPLING</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>radical hysterectomy</VALIDVALUE>
          <VALUEMEANING>RADICAL HYSTERECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>RADICAL HYSTERECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>radical trachelectomy</VALIDVALUE>
          <VALUEMEANING>RADICAL TRACHELECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>RADICAL TRACHELECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>total hysterectomy</VALIDVALUE>
          <VALUEMEANING>TOTAL HYSTERECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>TOTAL HYSTERECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15701</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unilateral salpingo-oophorectomy</VALIDVALUE>
          <VALUEMEANING>UNILATERAL SALPINGO-OOPHORECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the fallopian tube(s) and ovary(ies).:Having to do with one side of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28012, C15323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total abdominal hysterectomy</VALIDVALUE>
          <VALUEMEANING>Total abdominal hysterectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of the uterus and cervix through the abdominal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total vaginal hysterectomy</VALIDVALUE>
          <VALUEMEANING>Total vaginal hysterectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of the uterus and cervix through the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radical vulvectomy</VALIDVALUE>
          <VALUEMEANING>Radical vulvectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Vulvectomy refers to a gynecological procedure in which the vulva is partly or completely removed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemi volvectomy</VALIDVALUE>
          <VALUEMEANING>Hemivolvectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of one of the halves, right or left sides, of the vulva</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superficial lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>Superficial lymphadenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Excision of one or more lymph nodes being near the skin surface.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Deep lymphadenectomy</VALIDVALUE>
          <VALUEMEANING>Deep lymphadenectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Excision of one or more lymph nodes located deep under the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577039</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exenteration</VALIDVALUE>
          <VALUEMEANING>Exenteration</VALUEMEANING>
          <MEANINGDESCRIPTION>The surgical removal of internal organs and tissues, usually the radical removal of the contents of a body cavity. Also called evisceration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary debulking</VALIDVALUE>
          <VALUEMEANING>Primary debulking</VALUEMEANING>
          <MEANINGDESCRIPTION>The first procedure to reduce the size of a tumor often through surgery but possibly through radiation therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interval debulking</VALIDVALUE>
          <VALUEMEANING>INTERVAL DEBULKING</VALUEMEANING>
          <MEANINGDESCRIPTION>Interval debulking of tumor using surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reassessment laparotomy</VALIDVALUE>
          <VALUEMEANING>Reassessment laparotomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A second or subsequent surgical incision into the abdominal cavity through the loin or flank.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577042</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hemi vulvectomy</VALIDVALUE>
          <VALUEMEANING>Hemivolvectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of one of the halves, right or left sides, of the vulva</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None Above</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.: In a place or position that is higher.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C75329, C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5293617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bilateral oophorectomy</VALIDVALUE>
          <VALUEMEANING>Bilateral Oophorectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to remove both ovaries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51590</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3289562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Single oophorectomy</VALIDVALUE>
          <VALUEMEANING>Single Oophorectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others; exclusive of anyone or anything else.: The surgical removal of one or both ovaries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15291, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5293618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tubal ligation</VALIDVALUE>
          <VALUEMEANING>Tubal Ligation</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of female sterilization where the fallopian tubes are surgically ligated to prevent conception.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C92901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3263735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hysterectomy</VALIDVALUE>
          <VALUEMEANING>Hysterectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5205637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Operative procedure performed</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Operative procedure performed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have you had any of the following?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0219</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104879</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0209</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104888</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GYN_SXPROC_PERF_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1118">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2431529</PUBLICID>
    <LONGNAME>Three Dimensional Size Additional Dimension Z Float</LONGNAME>
    <PREFERREDNAME>2431326v1.0:2434928v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Third dimension length in centimeters.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CAP PROTOCOLS:College of American Pathologists Cancer Protocols</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2431326</PublicId>
      <PreferredName>2431272v1.0:2431201v1.0</PreferredName>
      <PreferredDefinition>definition pending_Coming next after the first in position in space or time or degree or magnitude.:Added; extra.:The magnitude of something in a particular direction, especially length or width or height.</PreferredDefinition>
      <LongName>Three Dimensional Size Second Additional Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47866</PreferredName>
        <Version>1</Version>
        <LongName>Three Dimensional Size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47866</PREFERRED_NAME>
            <LONG_NAME>Three Dimensional Size</LONG_NAME>
            <CON_ID>2431148</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C25406:C25483</PreferredName>
        <Version>1</Version>
        <LongName>Second Additional Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2434928</PublicId>
      <PreferredName>2434928v1</PreferredName>
      <PreferredDefinition>A number that can have its decimal point in any position.</PreferredDefinition>
      <LongName>float cm</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CAP PROTOCOLS:College of American Pathologists Cancer Protocols</Origin>
      <Representation>
        <PublicId>2433735</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48150</PreferredName>
        <Version>1</Version>
        <LongName>Float</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48150</PREFERRED_NAME>
            <LONG_NAME>Float</LONG_NAME>
            <CON_ID>2433734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Additional dimension</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Additional dimension</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.general</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000135</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857187</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CAP Cancer Checklists</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.cabig.caties.cap.domain.general</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.general.ThreeDimensionalTumorSize.additionalDimensionZ</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ThreeDimensionalTumorSize:additionalDimensionZ</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ThreeDimensionalSize:additionalDimensionZ</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.cabig.caties.cap.domain.general.ThreeDimensionalSize.additionalDimensionZ</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1119">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2431591</PUBLICID>
    <LONGNAME>Cutaneous Melanoma Tumor Infiltrating Lymphocytes Quantity NCI Concept Code</LONGNAME>
    <PREFERREDNAME>2431383v1.0:2433676v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Description of degree of lymphocytic infiltration surrounding and disrupting tumor cells of the vertical growth phase in a cutaneous melanoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CAP PROTOCOLS:College of American Pathologists Cancer Protocols</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2431383</PublicId>
      <PreferredName>2431290v1.0:2431246v1.0</PreferredName>
      <PreferredDefinition>A malignant neoplasm derived from cells that are capable of forming melanin._A measurable amount of a substance:Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.</PreferredDefinition>
      <LongName>Cutaneous Melanoma Quantity Tumor Infiltrating Lymphocyte</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431290</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3510</PreferredName>
        <Version>1</Version>
        <LongName>Cutaneous Melanoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3510</PREFERRED_NAME>
            <LONG_NAME>Cutaneous Melanoma</LONG_NAME>
            <CON_ID>2431169</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431246</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25256:C12546</PreferredName>
        <Version>1</Version>
        <LongName>Quantity Tumor Infiltrating Lymphocyte</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12546</PREFERRED_NAME>
            <LONG_NAME>Tumor Infiltrating Lymphocyte</LONG_NAME>
            <CON_ID>2431176</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2433676</PublicId>
      <PreferredName>2433676v1.0</PreferredName>
      <PreferredDefinition>Description of the quantity of lymphocytes infiltrating the neoplasm._A concept unique identifier within the NCI Enterprise Vocabulary Service&#39;s NCI Thesaurus.</PreferredDefinition>
      <LongName>Cutaneous Melanoma Tumor Infiltrating Lymphocytes Quantity NCI Concept Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CAP PROTOCOLS:College of American Pathologists Cancer Protocols</Origin>
      <Representation>
        <PublicId>2433292</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43516</PreferredName>
        <Version>1</Version>
        <LongName>NCI Concept Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43516</PREFERRED_NAME>
            <LONG_NAME>NCI Concept Code</LONG_NAME>
            <CON_ID>2223221</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brisk</VALIDVALUE>
          <VALUEMEANING>Marked</VALUEMEANING>
          <MEANINGDESCRIPTION>A prominent or noticeable characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2568634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nonbrisk</VALIDVALUE>
          <VALUEMEANING>Not marked</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A prominent or noticeable characteristic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C48662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tumor-Infiltrating Lymphocytes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tumor-Infiltrating Lymphocytes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534075</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE CAE</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.pitt.cabig.cae.domain.cutaneousmelanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812219</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857187</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CAP Cancer Checklists</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.cabig.caties.cap.domain.cutaneousMelanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.pitt.cabig.cae.domain.cutaneousmelanoma.CutaneousMelanoma.tumorInfiltratingLymphocytesQuantity</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.cabig.caties.cap.domain.cutaneousMelanoma.CutaneousMelanoma.tumorInfiltratingLymphocytesQuantity</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CutaneousMelanoma:tumorInfiltratingLymphocytesQuantity</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1120">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2434155</PUBLICID>
    <LONGNAME>Radiation Therapy Whole Breast Administered Ind-2</LONGNAME>
    <PREFERREDNAME>RT_WH_BRST_ADM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator of whether radiation therapy, treatment of a disease by means of exposure of radiation to the entire breast, one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2434130</PublicId>
      <PreferredName>RT_WH_BRST_ADMIN</PreferredName>
      <PreferredDefinition>information related radiation therapy, treatment of a disease by means of exposure of radiation to the entire breast, one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</PreferredDefinition>
      <LongName>Radiation Therapy Whole Breast Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2736864</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25326:C12971:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Whole Breast Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25326</PREFERRED_NAME>
            <LONG_NAME>Whole</LONG_NAME>
            <CON_ID>2202484</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Whole Breast, no boost</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Whole Breast, no boost</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1121">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2436231</PUBLICID>
    <LONGNAME>Patient Ethnicity Subcategory Text Name</LONGNAME>
    <PREFERREDNAME>PRSN_ETHN_SUBCAT_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text terms to represent a patient&#39;s self-declared cultural, ancestral or ethnic origination subcategory.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014060</PublicId>
      <PreferredName>PT_ETHNGRP</PreferredName>
      <PreferredDefinition>the patient&#39;s self-declared cultural or ethnic origination.</PreferredDefinition>
      <LongName>Patient Ethnic Group</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222293</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>C16564</PreferredName>
        <Version>1</Version>
        <LongName>Ethnic Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16564</PREFERRED_NAME>
            <LONG_NAME>Ethnic Group</LONG_NAME>
            <CON_ID>2221860</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2436207</PublicId>
      <PreferredName>ETHN_SUBCAT_TXT_NM</PreferredName>
      <PreferredDefinition>Text terms to represent ancestral or ethnic subcategories for human beings.</PreferredDefinition>
      <LongName>Ethnicity Subcategory Text Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Text Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inuit</VALIDVALUE>
          <VALUEMEANING>Inuits</VALUEMEANING>
          <MEANINGDESCRIPTION>A general term for a group of culturally similar indigenous peoples inhabiting the Arctic regions of Canada, Greenland, Russia and the United States. In Alaska, the term Eskimo is commonly used, because it includes both Yupik and Inupiat, while Inuit is not accepted as a collective term. In Canada and Greenland, the term Eskimo has fallen out of favor, as it is considered pejorative by the natives and has been replaced by the term Inuit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86558</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African Caribbean</VALIDVALUE>
          <VALUEMEANING>African Caribbean</VALUEMEANING>
          <MEANINGDESCRIPTION>A person of African ancestral origins whose family settled in the Caribbean region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bangladeshi</VALIDVALUE>
          <VALUEMEANING>Bangladeshi</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Bangladesh or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other ethnic group</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned._A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16564, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chinese</VALIDVALUE>
          <VALUEMEANING>Chinese</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of China.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Japanese</VALIDVALUE>
          <VALUEMEANING>Japanese</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Japan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Korean</VALIDVALUE>
          <VALUEMEANING>Korean</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Korea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570995</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aleut</VALIDVALUE>
          <VALUEMEANING>Aleutian</VALUEMEANING>
          <MEANINGDESCRIPTION>Aleutian - a person having origins from the Aleut indigenous group of Alaska and their descendants and who maintains tribal affiliation, or community or cultural attachment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eskimo</VALIDVALUE>
          <VALUEMEANING>Eskimo</VALUEMEANING>
          <MEANINGDESCRIPTION>The native people inhabiting the Arctic of northern Canada, Greenland, Alaska, or eastern Siberia. The two main groups referred to as Eskimo are the Yupik and Inuit. A third group, the Aleut, is related. In Canada and Greenland, the term Eskimo has fallen out of favor, as it is considered pejorative by the natives and has been replaced by the term Inuit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asian Indian</VALIDVALUE>
          <VALUEMEANING>Asian Indian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in the original peoples of the Indian sub-continent. In North America the term is used to distinguish this population group from Native Americans. The concept is close to the term South Asian but several major South Asian populations such as Pakistani and Bangladeshi may not identify with it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cambodian</VALIDVALUE>
          <VALUEMEANING>Cambodian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Cambodia (formerly Kampuchea) or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Filipino</VALIDVALUE>
          <VALUEMEANING>Filipino</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in the Philippine Islands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hmong</VALIDVALUE>
          <VALUEMEANING>Hmong</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original Hmong people originating in China around the Yellow River or Hoang Ho.  Early in the 19th century, the Hmong migrated to French Indochina, which comprised Vietnam, Cambodia and Laos.  In 1947, Hmong officially became citizens of Loas.  Later a number of Hmong emigrated to Thailand and the United States.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laotian</VALIDVALUE>
          <VALUEMEANING>Laotian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Laos.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pakistani</VALIDVALUE>
          <VALUEMEANING>Pakistani</VALUEMEANING>
          <MEANINGDESCRIPTION>This primarily refers to a person having origins in the original peoples of the Indian sub-continent, a subset of which formed Pakistan.  The term also refers to a person from Pakistan, whether or not ancestors were from India.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thai</VALIDVALUE>
          <VALUEMEANING>Thai</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Thailand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vietnamese</VALIDVALUE>
          <VALUEMEANING>Vietnamese</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Vietnam.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43396</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fujian</VALIDVALUE>
          <VALUEMEANING>Fiji Islander</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Fiji or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Guamanian</VALIDVALUE>
          <VALUEMEANING>Guamanian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Guam or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Samoan</VALIDVALUE>
          <VALUEMEANING>Samoan</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Samoa or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tongan</VALIDVALUE>
          <VALUEMEANING>Tongan</VALUEMEANING>
          <MEANINGDESCRIPTION>A person from Tonga or of that ancestry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is your ethnicity (subca</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is your ethnicity (subcategory)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1122">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2438063</PUBLICID>
    <LONGNAME>Microarray Data Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2437860v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A microarray is a piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Value Domain for java language Long datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2437860</PublicId>
      <PreferredName>2437785v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A microarray is a piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Microarray Data Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437785</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C25474</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Data Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Data Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000546</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812744</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857162</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Models Database 2.0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000545</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000406</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000410</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.MicroArrayData.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MicroArrayData:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.MicroArrayData.microArrayDataId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MicroArrayData:microArrayDataId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.data.AbstractArrayData.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AbstractArrayData:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1123">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2448313</PUBLICID>
    <LONGNAME>Dental Professional Practice Week Treatment Performed Type</LONGNAME>
    <PREFERREDNAME>DENT_PP_W_TX_P_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of the procedure performed weekly for a health care professional business directed towards treatment and care of patients pertaining to a tooth or teeth, or to odontology.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2443539</PublicId>
      <PreferredName>DENT_PROF_WK_TX_PERF</PreferredName>
      <PreferredDefinition>information related to the procedure performed weekly for a health care professional business directed towards treatment and care of patients pertaining to a tooth or teeth, or to odontology.</PreferredDefinition>
      <LongName>Dental Professional Practice Week Treatment Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2443537</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29844:C0087111:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Week Treatment Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0087111</PREFERRED_NAME>
            <LONG_NAME>Treatment</LONG_NAME>
            <CON_ID>2203112</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2445975</PublicId>
      <PreferredName>PROFPRACT_PERF_TP</PreferredName>
      <PreferredDefinition>the type of performed (executed) professional practice.</PreferredDefinition>
      <LongName>Professional Practice Performed Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preventative</VALIDVALUE>
          <VALUEMEANING>Prevention</VALUEMEANING>
          <MEANINGDESCRIPTION>An attempt to prevent disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Implants</VALIDVALUE>
          <VALUEMEANING>Implants</VALUEMEANING>
          <MEANINGDESCRIPTION>Implants (a tooth, usually artificial, that is anchored in the gums or jawbone to replace a missing tooth)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Operative</VALIDVALUE>
          <VALUEMEANING>Operative</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring during or associated with a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54733</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Removable prosthodontics</VALIDVALUE>
          <VALUEMEANING>Removable prosthodontics</VALUEMEANING>
          <MEANINGDESCRIPTION>Removable prosthodontics (replacements for missing teeth and related mouth or jaw structures by artificial devices)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esthetic</VALIDVALUE>
          <VALUEMEANING>Esthetic</VALUEMEANING>
          <MEANINGDESCRIPTION>Esthetic (a guiding principle in matters of artistic beauty and taste)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Periodontics</VALIDVALUE>
          <VALUEMEANING>Periodontics</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty of dentistry that encompasses the prevention, diagnosis and treatment of diseases of the supporting and surrounding tissues of the teeth or their substitutes and the maintenance of the health, function and esthetics of these structures and tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577508</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fixed Prosthodontics</VALIDVALUE>
          <VALUEMEANING>Fixed Prosthodontics</VALUEMEANING>
          <MEANINGDESCRIPTION>Fixed replacement of missing teeth and related mouth or jaw structures by artificial devices</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Orthodontics</VALIDVALUE>
          <VALUEMEANING>Orthodontics</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental specialty concerned with the prevention and correction of dental and oral anomalies (malocclusion).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0029335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577505</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endodontics</VALIDVALUE>
          <VALUEMEANING>Endodontics</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental specialty concerned with the maintenance of the dental pulp in a state of health and the treatment of the pulp cavity (pulp chamber and pulp canal).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0014149</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577504</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Surgery</VALIDVALUE>
          <VALUEMEANING>Oral Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17174</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577506</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Which of these practice proce</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Which of these practice procedures do you perform on a weekly basis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1124">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2451594</PUBLICID>
    <LONGNAME>Ovarian Tumor Pathologic M Stage</LONGNAME>
    <PREFERREDNAME>OVARIAN_TUMOR_P_M_ST</PREFERREDNAME>
    <PREFERREDDEFINITION>the pathologically evaluated M (metastasis) stage for an ovarian tumor, as defined by the AJCC Cancer Staging Manual, 6th Ed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2451551</PublicId>
      <PreferredName>OVARIAN_TUMOR_P_M_S</PreferredName>
      <PreferredDefinition>information related to pathologic M stage of an ovarian tumor.</PreferredDefinition>
      <LongName>Ovarian Tumor Pathologic M Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2451523</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28047:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Ovarian Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28047</PREFERRED_NAME>
            <LONG_NAME>Ovarian</LONG_NAME>
            <CON_ID>2421152</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207807</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25727</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic M Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25727</PREFERRED_NAME>
            <LONG_NAME>M Category</LONG_NAME>
            <CON_ID>2204010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2451559</PublicId>
      <PreferredName>OVARIAN_TUMOR_M_ST</PreferredName>
      <PreferredDefinition>the M (metastasis) stage for an ovarian tumor, as defined by the AJCC Cancer Staging Manual, 6th Ed.</PreferredDefinition>
      <LongName>Ovarian Tumor M Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC:American Joint Committee on Cancer Cancer Staging Manual, 6th Ed., 2002</Origin>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M0</VALIDVALUE>
          <VALUEMEANING>No distant metastases</VALUEMEANING>
          <MEANINGDESCRIPTION>No clinical or radiographic evidence of distant metastases</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M1</VALIDVALUE>
          <VALUEMEANING>Distant metastasis (excludes peritoneal metastasis)</VALUEMEANING>
          <MEANINGDESCRIPTION>Distant metastasis (excludes peritoneal metastasis)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MX</VALIDVALUE>
          <VALUEMEANING>Distant metastasis cannot be assessed</VALUEMEANING>
          <MEANINGDESCRIPTION>DISTANT METASTASIS CANNOT BE ASSESSED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic M Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic M Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1125">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2452155</PUBLICID>
    <LONGNAME>Homologous Protein Alignment Homologous Protein Protein Sequence Alignment java.lang.String</LONGNAME>
    <PREFERREDNAME>2452017v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A protein similar in structure and evolutionary origin to a protein in another species.:The act of adjusting or aligning objects in relation to each other; the result of this activity._A protein similar in structure and evolutionary origin to a protein in another species.:The sequence of amino acids along a polypeptide chain.:The act of adjusting or aligning objects in relation to each other; the result of this activity._Value Domain for java language String datatype.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2452017</PublicId>
      <PreferredName>2451982v1.0:2451961v1.0</PreferredName>
      <PreferredDefinition>A protein similar in structure and evolutionary origin to a protein in another species.:The act of adjusting or aligning objects in relation to each other; the result of this activity._A protein similar in structure and evolutionary origin to a protein in another species.:The sequence of amino acids along a polypeptide chain.:The act of adjusting or aligning objects in relation to each other; the result of this activity.</PreferredDefinition>
      <LongName>Homologous Protein Alignment Homologous Protein Protein Sequence Alignment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2451982</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40992:C49033</PreferredName>
        <Version>1</Version>
        <LongName>Homologous Protein Alignment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40992</PREFERRED_NAME>
            <LONG_NAME>Homologous Protein</LONG_NAME>
            <CON_ID>2451925</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49033</PREFERRED_NAME>
            <LONG_NAME>Alignment</LONG_NAME>
            <CON_ID>2451927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2451961</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40992:C13187:C49033</PreferredName>
        <Version>1</Version>
        <LongName>Homologous Protein Protein Sequence Alignment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40992</PREFERRED_NAME>
            <LONG_NAME>Homologous Protein</LONG_NAME>
            <CON_ID>2451925</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13187</PREFERRED_NAME>
            <LONG_NAME>Amino Acid Sequence</LONG_NAME>
            <CON_ID>2223225</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49033</PREFERRED_NAME>
            <LONG_NAME>Alignment</LONG_NAME>
            <CON_ID>2451927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Homologous Protein Alignment Homologous Protein Protein Sequence Alignment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Homologous Protein Alignment Homologous Protein Protein Sequence Alignment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Molecular Pages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812107</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerMoleculePages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812108</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CancerMoleculePages.HomologAlignment.homologSequenceAlignment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HomologAlignment:homologSequenceAlignment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1126">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2452263</PUBLICID>
    <LONGNAME>RefSeq Length java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2452113v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The Reference Sequence (RefSeq) collection aims to provide a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms.  RefSeq standards serve as the basis for medical, functional, and diversity studies; they provide a stable reference for gene identification and characterization, mutation analysis, expression studies, polymorphism discovery, and comparative analyses. RefSeqs are used as a reagent for the functional annotation of some genome sequencing projects, including those of human and mouse._Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe._Value Domain for java language Integer datatype</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2452113</PublicId>
      <PreferredName>2451993v1.0:2223257v1.0</PreferredName>
      <PreferredDefinition>The Reference Sequence (RefSeq) collection aims to provide a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms.  RefSeq standards serve as the basis for medical, functional, and diversity studies; they provide a stable reference for gene identification and characterization, mutation analysis, expression studies, polymorphism discovery, and comparative analyses. RefSeqs are used as a reagent for the functional annotation of some genome sequencing projects, including those of human and mouse._Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe.</PreferredDefinition>
      <LongName>RefSeq Length</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2451993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45335</PreferredName>
        <Version>1</Version>
        <LongName>RefSeq</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45335</PREFERRED_NAME>
            <LONG_NAME>RefSeq</LONG_NAME>
            <CON_ID>2322222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25334</PreferredName>
        <Version>1</Version>
        <LongName>Length</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25334</PREFERRED_NAME>
            <LONG_NAME>Length</LONG_NAME>
            <CON_ID>2203838</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element RefSeq Length java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element RefSeq Length java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Molecular Pages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812107</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Cancer Molecular Pages</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerMoleculePages</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812108</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CancerMoleculePages.RefseqProtein.length</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RefseqProtein:length</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1127">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2453391</PUBLICID>
    <LONGNAME>Veterinary Patient Survival Status</LONGNAME>
    <PREFERREDNAME>VET_PT_SURV_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to represent the survival status of a veterinary patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2453389</PublicId>
      <PreferredName>VET_PT_STAT</PreferredName>
      <PreferredDefinition>Vital status of a veterinary patient in terms of survival.</PreferredDefinition>
      <LongName>Veterinary Patient Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2452699</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>VET_STUDY</PreferredName>
        <Version>1</Version>
        <LongName>Veterinary Study</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2479867</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53691</PreferredName>
        <Version>1</Version>
        <LongName>Veterinary Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53691</PREFERRED_NAME>
            <LONG_NAME>Veterinary Patient</LONG_NAME>
            <CON_ID>2479866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018765</PublicId>
      <PreferredName>SURV_STAT_CAT</PreferredName>
      <PreferredDefinition>Text terms to describe an individual&#39;s status in reference to the ability to maintain life.</PreferredDefinition>
      <LongName>Survival Status Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2735614</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17177:C25688:C25372</PreferredName>
        <Version>1</Version>
        <LongName>Survival Status Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17177</PREFERRED_NAME>
            <LONG_NAME>Survival</LONG_NAME>
            <CON_ID>2202477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alive with disease</VALIDVALUE>
          <VALUEMEANING>Alive with Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Alive with disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alive with no evidence of disease</VALIDVALUE>
          <VALUEMEANING>ALIVE WITH NO EVIDENCE OF DISEASE</VALUEMEANING>
          <MEANINGDESCRIPTION>ALIVE WITH NO EVIDENCE OF DISEASE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561841</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alive disease status unknown</VALIDVALUE>
          <VALUEMEANING>Alive Disease Status Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Alive but the status of disease is not known.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561842</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Died</VALIDVALUE>
          <VALUEMEANING>Died</VALUEMEANING>
          <MEANINGDESCRIPTION>The cessation of life.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28554</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1128">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2464252</PUBLICID>
    <LONGNAME>First Complete Response Observed Date</LONGNAME>
    <PREFERREDNAME>FRST_CR_OBS_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Date of first (temporal) disappearance of all study disease observed for a person.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2464250</PublicId>
      <PreferredName>FRST_CR_OBS</PreferredName>
      <PreferredDefinition>Information related to first (temporal) disappearance of all study disease observed.</PreferredDefinition>
      <LongName>First Complete Response Observed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2464248</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C4870</PreferredName>
        <Version>1</Version>
        <LongName>First CR</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4870</PREFERRED_NAME>
            <LONG_NAME>Complete Remission</LONG_NAME>
            <CON_ID>2202721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2419892</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25599</PreferredName>
        <Version>1</Version>
        <LongName>Observed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25599</PREFERRED_NAME>
            <LONG_NAME>Observed</LONG_NAME>
            <CON_ID>2203942</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of first complete respon</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of first complete response</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Pa Cancer Center New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812868</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4631580</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Exceptional Responder CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exceptional Responder CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FRST_CR_OBS_DT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1129">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2475243</PUBLICID>
    <LONGNAME>Heparin Regimen Treatment Plan Time Interval Text</LONGNAME>
    <PREFERREDNAME>HEP_TX_TM_INTVL_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>A text field to capture a time interval in reference to a prescribed heparin dosing plan.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2475240</PublicId>
      <PreferredName>HEP_RGM_SCHED</PreferredName>
      <PreferredDefinition>A prescribed outline for the administration of heparin using planned timepoints for dosing.</PreferredDefinition>
      <LongName>Heparin Treatment Regimen Schedule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475858</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C539:C15697</PreferredName>
        <Version>1</Version>
        <LongName>Heparin Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C539</PREFERRED_NAME>
            <LONG_NAME>Heparin</LONG_NAME>
            <CON_ID>2205347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15697</PREFERRED_NAME>
            <LONG_NAME>Treatment Regimen</LONG_NAME>
            <CON_ID>2203773</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25211</PreferredName>
        <Version>1</Version>
        <LongName>Schedule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2475241</PublicId>
      <PreferredName>TX_PLAN_TM_INTV_TXT</PreferredName>
      <PreferredDefinition>A text field to capture a set of time intervals in reference to a treatment plan.</PreferredDefinition>
      <LongName>Treatment Plan Time Interval Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Interval</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Interval</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1130">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2475568</PUBLICID>
    <LONGNAME>Concept Reference Object Pathology Report Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2475376v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A unit of knowledge created by a unique combination of characteristics. (ISO 1087):Something referred to; the object of a reference._A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2475376</PublicId>
      <PreferredName>2388857v1.0:2475272v1.0</PreferredName>
      <PreferredDefinition>A unit of knowledge created by a unique combination of characteristics. (ISO 1087):Something referred to; the object of a reference._A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Concept Reference Object Pathology Report Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2388857</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45728:C48294</PreferredName>
        <Version>1</Version>
        <LongName>Concept Reference Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45728</PREFERRED_NAME>
            <LONG_NAME>Concept</LONG_NAME>
            <CON_ID>2388821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2475272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28277:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Pathology Report Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28277</PREFERRED_NAME>
            <LONG_NAME>Pathology Report</LONG_NAME>
            <CON_ID>2202705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Concept Reference Object Pathology Report Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Concept Reference Object Pathology Report Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.caBIG.caTIES.database.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caTIES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812488</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.caBIG.caTIES.database.domain.ConceptReferent.pathologyReportId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ConceptReferent:pathologyReportId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1131">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2475582</PUBLICID>
    <LONGNAME>Identification Patient First Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2475390v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The procedure of having an identity established.:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A word or group of words indicating a person&#39;s first (personal) name. (NCI)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2475390</PublicId>
      <PreferredName>2475321v1.0:2223450v1.0</PreferredName>
      <PreferredDefinition>The procedure of having an identity established.:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A word or group of words indicating a person&#39;s first (personal) name. (NCI)</PreferredDefinition>
      <LongName>Identification Patient First Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475321</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25737:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Identification Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40974</PreferredName>
        <Version>1</Version>
        <LongName>First Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40974</PREFERRED_NAME>
            <LONG_NAME>First Name</LONG_NAME>
            <CON_ID>2203651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Identification Patient First Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Identification Patient First Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.caBIG.caTIES.database.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caTIES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812488</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.caBIG.caTIES.database.domain.IdentifiedPatient.firstName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IdentifiedPatient:firstName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1132">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2475703</PUBLICID>
    <LONGNAME>Identification Section End Offset java.lang.Long</LONGNAME>
    <PREFERREDNAME>2475507v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The procedure of having an identity established.:One of several parts or pieces that fit with others to constitute a whole object; a self-contained part of a larger composition (written or musical)._The point or place at which something terminates in time, space, or extent.:The distance between a point and a fixed reference point; difference between a set point and the actual reading._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2475507</PublicId>
      <PreferredName>2475330v1.0:2388850v1.0</PreferredName>
      <PreferredDefinition>The procedure of having an identity established.:One of several parts or pieces that fit with others to constitute a whole object; a self-contained part of a larger composition (written or musical)._The point or place at which something terminates in time, space, or extent.:The distance between a point and a fixed reference point; difference between a set point and the actual reading.</PreferredDefinition>
      <LongName>Identification Section End Offset</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475330</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25737:C54091</PreferredName>
        <Version>1</Version>
        <LongName>Identification Section</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54091</PREFERRED_NAME>
            <LONG_NAME>Section</LONG_NAME>
            <CON_ID>2475257</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388850</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496:C47923</PreferredName>
        <Version>1</Version>
        <LongName>End Offset</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47923</PREFERRED_NAME>
            <LONG_NAME>Offset</LONG_NAME>
            <CON_ID>2388823</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Identification Section End Offset java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Identification Section End Offset java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.upmc.opi.caBIG.caTIES.database.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2475251</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTIES 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caTIES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812488</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.upmc.opi.caBIG.caTIES.database.domain.IdentifiedSection.endOffset</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IdentifiedSection:endOffset</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1133">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2480554</PUBLICID>
    <LONGNAME>Sister Family Member Assessment Ind-2</LONGNAME>
    <PREFERREDNAME>SIS_FAM_M_ASES_IND_2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no response to a question that asks whether the participant has any full sisters.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2228984</PublicId>
      <PreferredName>SIST_PT_FMEMB_ASSESS</PreferredName>
      <PreferredDefinition>information relating to patient&#39;s sister family members assessment.</PreferredDefinition>
      <LongName>Sister Patient Family Members Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2228982</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25680:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Sister Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25680</PREFERRED_NAME>
            <LONG_NAME>Sister</LONG_NAME>
            <CON_ID>2202813</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2228969</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0086282:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Family Members Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0086282</PREFERRED_NAME>
            <LONG_NAME>Family Members</LONG_NAME>
            <CON_ID>2204255</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015873</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>A choice of Yes and No answer.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008509</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPORES</PreferredName>
        <Version>2.31</Version>
        <LongName>SPOREs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YES</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the participant have any</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the participant have any full sisters?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Barretts Esophagus - ASA-Esomeprazole</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Erlotinib - Lesions of Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2813064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1134">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2481103</PUBLICID>
    <LONGNAME>Patient Other Disposition Descriptive Text</LONGNAME>
    <PREFERREDNAME>PT_OTX_DISP_DESC_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of care continuation decision(s) of &#39;other type&#39; made for a patient..</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2481101</PublicId>
      <PreferredName>PT_OTX_DISPN</PreferredName>
      <PreferredDefinition>Care continuation decisions different from one(s) previously specified made for a patient at an administrative level.</PreferredDefinition>
      <LongName>Patient Other Disposition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404694</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0030705</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0030705</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2203388</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2481099</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C0743223</PreferredName>
        <Version>1</Version>
        <LongName>Other DISPOSITION</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0743223</PREFERRED_NAME>
            <LONG_NAME>DISPOSITION</LONG_NAME>
            <CON_ID>2204466</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1135">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2482150</PUBLICID>
    <LONGNAME>Specimen Biopsy Submitted Indicator</LONGNAME>
    <PREFERREDNAME>SPEC_BX_SUBM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator that asks whether a biopsy specimen was submitted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2014868</PublicId>
      <PreferredName>SPEC_BX</PreferredName>
      <PreferredDefinition>information regarding a biopsy of a pathologic specimen or tissue.</PreferredDefinition>
      <LongName>Specimen Biopsy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177647</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Biopsy</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015873</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>A choice of Yes and No answer.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008509</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPORES</PreferredName>
        <Version>2.31</Version>
        <LongName>SPOREs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YES</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a biopsy specimen submitt</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a biopsy specimen submitted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the biopsy specimen at recurrence been submitted according to protocol A151216?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sporadic Colorectal Neoplasia - Atrovastatin</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Myo-Inositol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2812876</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1136">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2494293</PUBLICID>
    <LONGNAME>Lung Carcinoma Disease-Free Survival Interval Year Number</LONGNAME>
    <PREFERREDNAME>LUNG_CA_DZ_FREE_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of years in the period of time after successful treatment of lung cancer in which there is no appearance of new lesions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2494291</PublicId>
      <PreferredName>LUNG_C_DZ_FR__INTVL</PreferredName>
      <PreferredDefinition>Period after successful treatment of lung cancer in which there is no appearance of new lesions.</PreferredDefinition>
      <LongName>Lung Carcinoma Disease-Free Survival Interval</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2190444</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4878</PreferredName>
        <Version>1</Version>
        <LongName>Lung Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4878</PREFERRED_NAME>
            <LONG_NAME>Lung Carcinoma</LONG_NAME>
            <CON_ID>2202892</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2494289</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17751:C25543</PreferredName>
        <Version>1</Version>
        <LongName>Disease-Free Survival Interval</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17751</PREFERRED_NAME>
            <LONG_NAME>Disease-Free Survival</LONG_NAME>
            <CON_ID>2494288</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25543</PREFERRED_NAME>
            <LONG_NAME>Interval</LONG_NAME>
            <CON_ID>2202600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2444367</PublicId>
      <PreferredName>YR_NUM</PreferredName>
      <PreferredDefinition>the number of years of an event or between events.</PreferredDefinition>
      <LongName>Year Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29848:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Year Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Interval between primary and</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Interval between primary and current lung lesion in years</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DC_0205</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812581</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1137">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2500834</PUBLICID>
    <LONGNAME>Treatment Group Identifier</LONGNAME>
    <PREFERREDNAME>TX_GP_ID</PREFERREDNAME>
    <PREFERREDDEFINITION>Numbers used to represent an Institution identifier for a common treatment group of patients; group is characterized by the administration of therapeutic agents at the same dose without modification for a contiguous number of cycles/courses of treatment, for the purpose of analysis.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2500831</PublicId>
      <PreferredName>TX_GP_ID</PreferredName>
      <PreferredDefinition>Institution identifer for a common treatment group of patients; group is characterized by the administration of therapeutic agents at the same dose without modification for a contiguous number of cycles/courses of treatment, for the purpose of anlysis.</PreferredDefinition>
      <LongName>Treatment Group Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2500829</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C17005</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17005</PREFERRED_NAME>
            <LONG_NAME>Population Group</LONG_NAME>
            <CON_ID>2202651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2500832</PublicId>
      <PreferredName>TWO_DEC_ID</PreferredName>
      <PreferredDefinition>One or more numbers used to identify an institution-identified common treatment group of patients.</PreferredDefinition>
      <LongName>Two Decimal Identifier</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength>3</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Treatment Group #</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Treatment Group #</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke 500</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812580</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1138">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2500953</PUBLICID>
    <LONGNAME>Laboratory Procedure Chromogranin A Tumor Marker Result Date</LONGNAME>
    <PREFERREDNAME>LAB_CHRM_TMK_RSL_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which a laboratory test was performed for Chromogranin A (CHGA, Secretory Protein I, Parathyroid Secretory Protein, PSP), a protein that is stored and released with catecholamines in the adrenal medulla, as well as with PTH from the parathyroid gland, and is also secreted by many endocrine neoplasms: pheochromocytoma, parathyroid adenoma, medullary thyroid carcinoma, carcinoids, oat-cell lung cancer, pancreatic islet-cell tumors, and aortic-body tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2500926</PublicId>
      <PreferredName>LAB_CGA_TMKR_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of the medical procedure that involves testing a sample of blood or tissue for Chromogranin A (CHGA, Secretory Protein I, Parathyroid Secretory Protein, PSP),  a protein that is stored and released with catecholamines in the adrenal medulla, as well as with PTH from the parathyroid gland, and is also secreted by many endocrine neoplasms: pheochromocytoma, parathyroid adenoma, medullary thyroid carcinoma, carcinoids, oat-cell lung cancer, pancreatic islet-cell tumors, and aortic-body tumor.</PreferredDefinition>
      <LongName>Laboratory Procedure Chromogranin A Tumor Marker Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17284:C17220:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Chromogranin A Tumor Marker Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17284</PREFERRED_NAME>
            <LONG_NAME>Chromogranin-A</LONG_NAME>
            <CON_ID>2500923</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17220</PREFERRED_NAME>
            <LONG_NAME>Tumor Marker</LONG_NAME>
            <CON_ID>2202551</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Chromogranin A assessment date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Chromogranin A assessment date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1139">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2505991</PUBLICID>
    <LONGNAME>Participant Health Care Provider Communication Sunscreen Use Date</LONGNAME>
    <PREFERREDNAME>HCP_COMM_SUNSC_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Date of an exchange of information with health care providers on the need to use chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2505987</PublicId>
      <PreferredName>HCP_COMM_SUNSC_USE</PreferredName>
      <PreferredDefinition>Exchange of information with health care providers on the need to use chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation.</PreferredDefinition>
      <LongName>Participant Health Care Provider Communication Sunscreen Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2505966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16666:C16452</PreferredName>
        <Version>1</Version>
        <LongName>Health Care Provider Communication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16666</PREFERRED_NAME>
            <LONG_NAME>Health Care Provider</LONG_NAME>
            <CON_ID>2479788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16452</PREFERRED_NAME>
            <LONG_NAME>Communication</LONG_NAME>
            <CON_ID>2435936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2505985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C851:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Sunscreen Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C851</PREFERRED_NAME>
            <LONG_NAME>Sunscreen</LONG_NAME>
            <CON_ID>2505984</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sunscreen usage date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Sunscreen usage date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1140">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513722</PUBLICID>
    <LONGNAME>Fluid Specimen Review Parameter Object Cell Count java.lang.Double</LONGNAME>
    <PREFERREDNAME>2513456v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of appraisal, evaluation, or analysis.:Any factor that defines a system and determines (or limits) its performance._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:To determine the number or amount of something; the result of this activity._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513456</PublicId>
      <PreferredName>2513362v1.0:2207098v1.0</PreferredName>
      <PreferredDefinition>A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.:A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of appraisal, evaluation, or analysis.:Any factor that defines a system and determines (or limits) its performance._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.:To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Fluid Specimen Review Parameter Object Cell Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513362</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25278:C19157:C42729:C44175</PreferredName>
        <Version>1</Version>
        <LongName>Fluid Specimen Review Parameter Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25278</PREFERRED_NAME>
            <LONG_NAME>Fluid</LONG_NAME>
            <CON_ID>2202644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42729</PREFERRED_NAME>
            <LONG_NAME>Review</LONG_NAME>
            <CON_ID>2202331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207098</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12508:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Cell Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Fluid Specimen Review Parameter Object Cell Count java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Fluid Specimen Review Parameter Object Cell Count java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.FluidSpecimenReviewEventParameters.cellCount</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FluidSpecimenReviewEventParameters:cellCount</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1141">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513735</PUBLICID>
    <LONGNAME>Storage Unit Type Default Degree Celsius Temperature java.lang.Double</LONGNAME>
    <PREFERREDNAME>2513469v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A physical structure or device capable of holding objects or samples.:A subdivision of a particular kind of thing._An option that is selected automatically unless an alternative is specified.:A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.:The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513469</PublicId>
      <PreferredName>2513365v1.0:2513312v1.0</PreferredName>
      <PreferredDefinition>A physical structure or device capable of holding objects or samples.:A subdivision of a particular kind of thing._An option that is selected automatically unless an alternative is specified.:A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.:The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit.</PreferredDefinition>
      <LongName>Storage Unit Type Default Degree Celsius Temperature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513365</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45322:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Storage Unit Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45322</PREFERRED_NAME>
            <LONG_NAME>Storage Unit</LONG_NAME>
            <CON_ID>2240763</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2513312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48156:C42559:C25206</PreferredName>
        <Version>1</Version>
        <LongName>Default Degree Celsius Temperature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48156</PREFERRED_NAME>
            <LONG_NAME>Default</LONG_NAME>
            <CON_ID>2422640</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42559</PREFERRED_NAME>
            <LONG_NAME>Degree Celsius</LONG_NAME>
            <CON_ID>2480765</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25206</PREFERRED_NAME>
            <LONG_NAME>Temperature</LONG_NAME>
            <CON_ID>2202772</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Storage Unit Type Default Degree Celsius Temperature java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Storage Unit Type Default Degree Celsius Temperature java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.StorageType.defaultTempratureInCentigrade</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StorageType:defaultTempratureInCentigrade</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1142">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2513856</PUBLICID>
    <LONGNAME>Distribution Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2513590v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of distributing or spreading or apportioning._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2513590</PublicId>
      <PreferredName>2513350v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The act of distributing or spreading or apportioning._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Distribution Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2513350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45273</PreferredName>
        <Version>1</Version>
        <LongName>Distribution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45273</PREFERRED_NAME>
            <LONG_NAME>Distribution</LONG_NAME>
            <CON_ID>2233218</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Distribution Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Distribution Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2513254</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTISSUE Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domainobject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.Distribution.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domainobject.Distribution.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Distribution:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1143">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2516193</PUBLICID>
    <LONGNAME>Gene Alias Collection java.lang.String</LONGNAME>
    <PREFERREDNAME>2516188v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>This object describes the gene alias. (NCICB)_The act of gathering things together; having been brought together in one place._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2516188</PublicId>
      <PreferredName>2223313v1.0:2413010v1.0</PreferredName>
      <PreferredDefinition>This object describes the gene alias. (NCICB)_The act of gathering things together; having been brought together in one place.</PreferredDefinition>
      <LongName>Gene Alias Collection</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41095</PreferredName>
        <Version>1</Version>
        <LongName>Gene Alias</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41095</PREFERRED_NAME>
            <LONG_NAME>Gene Alias</LONG_NAME>
            <CON_ID>2223185</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2413010</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25453</PreferredName>
        <Version>1</Version>
        <LongName>Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Alias Collection java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Alias Collection java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183534</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Integrative Cancer Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Gene Data Curation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812204</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneAliasCollection</AlternateName>
        <AlternateNameType>XML Tag</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1144">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2519430</PUBLICID>
    <LONGNAME>Data File Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2519341v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A set of related records (either written or electronic) kept together._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2519341</PublicId>
      <PreferredName>2422748v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A set of related records (either written or electronic) kept together._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Data File Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422748</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C42883</PreferredName>
        <Version>1</Version>
        <LongName>Data File</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42883</PREFERRED_NAME>
            <LONG_NAME>File</LONG_NAME>
            <CON_ID>2422612</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Data File Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Data File Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ProteomicsLIMS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.fccc.lims.protlims.domain.class.sampledata</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812035</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DataFile:identification</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.fccc.lims.protlims.domain.class.sampledata.DataFile.identification</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1145">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2519475</PUBLICID>
    <LONGNAME>Process Data File Association Class Input Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2519386v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sequence of events which produces some outcome.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A set of related records (either written or electronic) kept together.:In UML modeling, an association that is also a class.  It not only connects a set of classes, but also defines a set of features that belong to the relationship itself._Anything added into a sytem.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2519386</PublicId>
      <PreferredName>2519323v1.0:2422737v1.0</PreferredName>
      <PreferredDefinition>A sequence of events which produces some outcome.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:A set of related records (either written or electronic) kept together.:In UML modeling, an association that is also a class.  It not only connects a set of classes, but also defines a set of features that belong to the relationship itself._Anything added into a sytem.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Process Data File Association Class Input Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2519323</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29862:C25474:C42883:C45672</PreferredName>
        <Version>1</Version>
        <LongName>Process Data File Association Class</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29862</PREFERRED_NAME>
            <LONG_NAME>Process</LONG_NAME>
            <CON_ID>2202628</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42883</PREFERRED_NAME>
            <LONG_NAME>File</LONG_NAME>
            <CON_ID>2422612</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45672</PREFERRED_NAME>
            <LONG_NAME>Association Class</LONG_NAME>
            <CON_ID>2231583</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2422737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47905:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Input Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47905</PREFERRED_NAME>
            <LONG_NAME>Input</LONG_NAME>
            <CON_ID>2422639</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Process Data File Association Class Input Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Process Data File Association Class Input Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ProteomicsLIMS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.fccc.lims.protlims.domain.class.registry</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812038</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProcessDataFile:isInput</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.fccc.lims.protlims.domain.class.registry.ProcessDataFile.isInput</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1146">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2519488</PUBLICID>
    <LONGNAME>Procedure Data Type Association Class Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2519399v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A particular course of action intended to achieve a result.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Something distinguishable as an identifiable class based on common qualities.:In UML modeling, an association that is also a class.  It not only connects a set of classes, but also defines a set of features that belong to the relationship itself._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2519399</PublicId>
      <PreferredName>2519337v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>A particular course of action intended to achieve a result.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Something distinguishable as an identifiable class based on common qualities.:In UML modeling, an association that is also a class.  It not only connects a set of classes, but also defines a set of features that belong to the relationship itself._A statement or an account describing something.</PreferredDefinition>
      <LongName>Procedure Data Type Association Class Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2519337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218:C25474:C25284:C45672</PreferredName>
        <Version>1</Version>
        <LongName>Procedure Data Type Association Class</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45672</PREFERRED_NAME>
            <LONG_NAME>Association Class</LONG_NAME>
            <CON_ID>2231583</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Procedure Data Type Association Class Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Procedure Data Type Association Class Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ProteomicsLIMS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.fccc.lims.protlims.domain.class.registry</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812038</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProcedureDataType:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.fccc.lims.protlims.domain.class.registry.ProcedureDataType.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1147">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2520488</PUBLICID>
    <LONGNAME>Caries Periodontal Probe Assessment Longest Perpendicular Diameter Measurement</LONGNAME>
    <PREFERREDNAME>C_PDP_AS_LG_P_DI_MEA</PREFERREDNAME>
    <PREFERREDDEFINITION>the longest perpendicular diameter measurement of decay of a tooth, in which it becomes softened, discolored, and/or porous by a calibrated dental instrument used to measure periodontal pocket depth and/or clinical attachment level at various locations around the teeth.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2503706</PublicId>
      <PreferredName>CAR_PERPR_ASSESS</PreferredName>
      <PreferredDefinition>information related to the evaluation of decay of a tooth, in which it becomes softened, discolored, and/or porous by a calibrated dental instrument used to measure periodontal pocket depth and/or clinical attachment level at various locations around the teeth.</PreferredDefinition>
      <LongName>Caries Periodontal Probe Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52593</PreferredName>
        <Version>1</Version>
        <LongName>Caries</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52593</PREFERRED_NAME>
            <LONG_NAME>Caries</LONG_NAME>
            <CON_ID>2443118</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2503704</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62058:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Periodontal Probe Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62058</PREFERRED_NAME>
            <LONG_NAME>Periodontal Probe</LONG_NAME>
            <CON_ID>2500109</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2520476</PublicId>
      <PreferredName>CAR_LNG_PER_DIA_MEAS</PreferredName>
      <PreferredDefinition>the determination of the size or magnitude of the greatest length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference that is at right angles to a given line or plane of the decay of a tooth, in which it becomes softened, discolored, and/or porous.</PreferredDefinition>
      <LongName>Caries Longest Perpendicular Diameter Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2520480</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C25243:C25285:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Longest Vertical Diameter Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25243</PREFERRED_NAME>
            <LONG_NAME>Vertical</LONG_NAME>
            <CON_ID>2206270</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Greatest Cavity Width</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Greatest Cavity Width</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Restorative</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812086</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Oral Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1148">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2527138</PUBLICID>
    <LONGNAME>Disease Progression Bone First Observed Ind-3</LONGNAME>
    <PREFERREDNAME>DZPRO_BON_F_OBS_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if initial evidence is available to detect an increase in severity of disease indicated by presence of cancer in one or more bones.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188314</PublicId>
      <PreferredName>DZPROG_BONE_F_OBS</PreferredName>
      <PreferredDefinition>information related to the first observed bone disease progression.</PreferredDefinition>
      <LongName>Disease Progression Bone First Observed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660493</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17747:C12366</PreferredName>
        <Version>1</Version>
        <LongName>Disease Progression Bone</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17747</PREFERRED_NAME>
            <LONG_NAME>Disease Progression</LONG_NAME>
            <CON_ID>2202885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12366</PREFERRED_NAME>
            <LONG_NAME>Bone</LONG_NAME>
            <CON_ID>2202686</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25599</PreferredName>
        <Version>1</Version>
        <LongName>First Observed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25599</PREFERRED_NAME>
            <LONG_NAME>Observed</LONG_NAME>
            <CON_ID>2203942</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient been diagnosed wi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient been diagnosed with first bone progression</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1149">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2528475</PUBLICID>
    <LONGNAME>Research Activity Institution Source Department Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2528454v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization.:Where something is available or from where it originates._The name of the department that this user belongs to._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528454</PublicId>
      <PreferredName>2528442v1.0:2223453v1.0</PreferredName>
      <PreferredDefinition>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization.:Where something is available or from where it originates._The name of the department that this user belongs to.</PreferredDefinition>
      <LongName>Research Activity Institution Source Department Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528442</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15429:C41206:C25683</PreferredName>
        <Version>1</Version>
        <LongName>Research Activity Institution Source</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15429</PREFERRED_NAME>
            <LONG_NAME>Research Activity</LONG_NAME>
            <CON_ID>2528433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41206</PREFERRED_NAME>
            <LONG_NAME>Institution</LONG_NAME>
            <CON_ID>2228359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42671</PreferredName>
        <Version>1</Version>
        <LongName>Department Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42671</PREFERRED_NAME>
            <LONG_NAME>Department</LONG_NAME>
            <CON_ID>2223425</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Research Activity Institution Source Department Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Research Activity Institution Source Department Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000390</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000615</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000391</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000616</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000617</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000618</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000620</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.provenance.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000621</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ResearchInstitutionSource:institutionDepartment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.common.provenance.domain.ResearchInstitutionSource.institutionDepartment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@institutionDepartment</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1150">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2529131</PUBLICID>
    <LONGNAME>Gene Alias Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2223616v3.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>This object describes the gene alias. (NCICB)_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2223616</PublicId>
      <PreferredName>2223313v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>This object describes the gene alias. (NCICB)_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Gene Alias Identifier</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41095</PreferredName>
        <Version>1</Version>
        <LongName>Gene Alias</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41095</PREFERRED_NAME>
            <LONG_NAME>Gene Alias</LONG_NAME>
            <CON_ID>2223185</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Alias Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Alias Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528519</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.gene</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812314</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.annotation.gene.GeneAlias.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneAlias:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1151">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2529159</PUBLICID>
    <LONGNAME>Single Nucleotide Polymorphism Annotation Chromosome Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2528864v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:An explanatory or critical comment that has been added to a text._One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528864</PublicId>
      <PreferredName>2528732v1.0:2528630v1.0</PreferredName>
      <PreferredDefinition>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:An explanatory or critical comment that has been added to a text._One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Single Nucleotide Polymorphism Annotation Chromosome Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528732</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18279:C44272</PreferredName>
        <Version>1</Version>
        <LongName>Single Nucleotide Polymorphism Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18279</PREFERRED_NAME>
            <LONG_NAME>Single Nucleotide Polymorphism</LONG_NAME>
            <CON_ID>2433334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528630</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13202:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Chromosome Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13202</PREFERRED_NAME>
            <LONG_NAME>Chromosome</LONG_NAME>
            <CON_ID>2203872</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Single Nucleotide Polymorphism Annotation Chromosome Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Single Nucleotide Polymorphism Annotation Chromosome Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528519</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.snp</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812316</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.snp</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000401</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SNPAnnotation:chromosomeName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.annotation.snp.SNPAnnotation.chromosomeName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1152">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2529567</PUBLICID>
    <LONGNAME>Cancer Genome Anatomy Project Library Type Cloning Vector java.lang.String</LONGNAME>
    <PREFERREDNAME>2529514v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The Cancer Genome Anatomy Project (CGAP) is an interdisciplinary program to establish the information and technological tools needed to decipher the molecular anatomy of a cancer cell.  The Cancer Genome Anatomy Project (CGAP) will unite the newest techno:A collection of DNA molecules that have been cloned in vectors._Something distinguishable as an identifiable class based on common qualities.:Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2529514</PublicId>
      <PreferredName>2529487v1.0:2529476v1.0</PreferredName>
      <PreferredDefinition>The Cancer Genome Anatomy Project (CGAP) is an interdisciplinary program to establish the information and technological tools needed to decipher the molecular anatomy of a cancer cell.  The Cancer Genome Anatomy Project (CGAP) will unite the newest techno:A collection of DNA molecules that have been cloned in vectors._Something distinguishable as an identifiable class based on common qualities.:Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into</PreferredDefinition>
      <LongName>Cancer Genome Anatomy Project Library Type Cloning Vector</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2529487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15923:C16223</PreferredName>
        <Version>1</Version>
        <LongName>Cancer Genome Anatomy Project Library</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15923</PREFERRED_NAME>
            <LONG_NAME>Cancer Genome Anatomy Project</LONG_NAME>
            <CON_ID>2529469</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16223</PREFERRED_NAME>
            <LONG_NAME>DNA Library</LONG_NAME>
            <CON_ID>2223197</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2529476</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284:C1329</PreferredName>
        <Version>1</Version>
        <LongName>Type Cloning Vector</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1329</PREFERRED_NAME>
            <LONG_NAME>Cloning Vector</LONG_NAME>
            <CON_ID>2223199</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cancer Genome Anatomy Project Library Type Cloning Vector java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cancer Genome Anatomy Project Library Type Cloning Vector java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812556</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000402</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Library:cloneVectorType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.Library.cloneVectorType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@cloneVectorType</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1153">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2529678</PUBLICID>
    <LONGNAME>Transplant Chimerism Assessment Specify</LONGNAME>
    <PREFERREDNAME>TSPLT_CHIM_ASS_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify the type of test or evaluation for chimerism, the occurrence in an individual of two or more cell populations of different chromosomal constitutions derived from different individuals, as an evaluation for a transplant of healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body, was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Transplant CDE Committee</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2529659</PublicId>
      <PreferredName>TSPLT_CHIM_ASSESS</PreferredName>
      <PreferredDefinition>information related to chimerism, the occurrence in an individual of two or more cell populations of different chromosomal constitutions derived from different individuals, as an evaluation for a healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body.</PreferredDefinition>
      <LongName>Transplant Chimerism Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176929</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Transplant</PreferredName>
        <Version>1</Version>
        <LongName>Transplant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12981</PREFERRED_NAME>
            <LONG_NAME>Graft</LONG_NAME>
            <CON_ID>2202844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2529656</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62582:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Chimerism Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62582</PREFERRED_NAME>
            <LONG_NAME>Chimerism</LONG_NAME>
            <CON_ID>2521747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018806</PublicId>
      <PreferredName>ASSESS_SPEC</PreferredName>
      <PreferredDefinition>The free text field to specify the assessment performed.</PreferredDefinition>
      <LongName>Assessment Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1154">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2539771</PUBLICID>
    <LONGNAME>Contact Person Administered Item Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2539579v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person acting as a channel for communication between groups.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2539579</PublicId>
      <PreferredName>2539528v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>A person acting as a channel for communication between groups.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Contact Person Administered Item Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539528</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25461:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Contact Person Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25461</PREFERRED_NAME>
            <LONG_NAME>Contact Person</LONG_NAME>
            <CON_ID>2202621</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Contact Person Administered Item Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Contact Person Administered Item Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.AdministeredComponentContact.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdministeredComponentContact:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@modifiedBy</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1155">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2542384</PUBLICID>
    <LONGNAME>Positive Axillary Node Hematoxylin And Eosin Staining Assessment ind-2</LONGNAME>
    <PREFERREDNAME>P_AXNOD_HE_ASES_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether there were positive axillary nodes detected by hematoxylin &amp; eosin staining (H&amp;E).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2240701</PublicId>
      <PreferredName>POS_AXLNOD_HE_ASSESS</PreferredName>
      <PreferredDefinition>information relating to positive axillary node hematoxylin &amp; eosin staining (H&amp;E) assessment. hematoxylin-and-eosin, or H&amp;E, is a routine staining procedure of tissue sections that uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue; hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus; and eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.</PreferredDefinition>
      <LongName>Positive Axillary Node Hematoxylin and Eosin Staining Method Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206730</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25246:C12904</PreferredName>
        <Version>1</Version>
        <LongName>Positive Axillary Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25246</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2202905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12904</PREFERRED_NAME>
            <LONG_NAME>Axillary Lymph Node</LONG_NAME>
            <CON_ID>2202317</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2927853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C23011:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Hematoxylin and Eosin Staining Method Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C23011</PREFERRED_NAME>
            <LONG_NAME>Hematoxylin and Eosin Staining Method</LONG_NAME>
            <CON_ID>2480831</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Axillary nodes positive by H&amp;E</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Axillary nodes positive by H&amp;E</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the pathology report from the axillary staging procedure indicate on H&amp;E staining that residual axillary nodal metastasis was found in the surgical specimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer DataMart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2604617</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Submission and Reporting</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Cancer Data Mart</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812624</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>P_AXNOD_HE_ASES_IND</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1156">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2543425</PUBLICID>
    <LONGNAME>Erythrocyte Postoperative Transfusion Administered Ind-2</LONGNAME>
    <PREFERREDNAME>RBC_PO_TRNSF_ADM_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if an infusion of blood cells specialized for oxygen transport was given to an individual during the period immediately following a surgical operation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2543424</PublicId>
      <PreferredName>RBC_PO_TRNSF_ADM</PreferredName>
      <PreferredDefinition>related to the infusion of blood cells specialized for oxygen transport given to an individual during the period immediately following a surgical operation.</PreferredDefinition>
      <LongName>Erythrocyte Postoperative Transfusion Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543422</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12521:C28006:C15408</PreferredName>
        <Version>1</Version>
        <LongName>Erythrocyte Postoperative Transfusion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12521</PREFERRED_NAME>
            <LONG_NAME>Erythrocyte</LONG_NAME>
            <CON_ID>2203729</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28006</PREFERRED_NAME>
            <LONG_NAME>Postoperative</LONG_NAME>
            <CON_ID>2211921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15408</PREFERRED_NAME>
            <LONG_NAME>Transfusion</LONG_NAME>
            <CON_ID>2202846</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient require red b</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient require red blood cell (RBC) transfusion postoperatively</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have bleeding requiring 4 or more units of blood within 72 hours of surgery?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bleeding (transfusions &gt;5 U)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4471913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE2</ClassificationSchemeItemType>
        <CsiPublicId>4514847</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NRG-CC002</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RBC_PO_TRNSF_ADM_IND2</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1157">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2544971</PUBLICID>
    <LONGNAME>Protein UniProtKB Output java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2544925v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Proteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The UniProt Knowledgebase (UniProtKB), a product of the UniProt consortium, provides a central database of protein sequences with accurate, consistent, rich sequence and functional annotation.  The UniProt Knowledgebase consists of two sections: Swiss-Prot - a section containing manually-annotated records with information extracted from literature and curator-evaluated computational analysis, and TrEMBL - a section with computationally analyzed records that await full manual annotation.:Anything coming out of a system._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2544925</PublicId>
      <PreferredName>2223335v1.0:2544890v1.0</PreferredName>
      <PreferredDefinition>Proteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The UniProt Knowledgebase (UniProtKB), a product of the UniProt consortium, provides a central database of protein sequences with accurate, consistent, rich sequence and functional annotation.  The UniProt Knowledgebase consists of two sections: Swiss-Prot - a section containing manually-annotated records with information extracted from literature and curator-evaluated computational analysis, and TrEMBL - a section with computationally analyzed records that await full manual annotation.:Anything coming out of a system.</PreferredDefinition>
      <LongName>Protein UniProtKB Output</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223335</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17021</PreferredName>
        <Version>1</Version>
        <LongName>Protein</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2544890</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47851:C47906</PreferredName>
        <Version>1</Version>
        <LongName>UniProtKB Output</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47851</PREFERRED_NAME>
            <LONG_NAME>UniProtKB</LONG_NAME>
            <CON_ID>2342206</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47906</PREFERRED_NAME>
            <LONG_NAME>Output</LONG_NAME>
            <CON_ID>2425536</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein UniProtKB Output java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein UniProtKB Output java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2544880</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GeneConnect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.geneconnect.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.geneconnect.domain.Protein.uniprotkbAsOutput</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Protein:uniprotkbAsOutput</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1158">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2544978</PUBLICID>
    <LONGNAME>Protein Genomic Identifier Genomic Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2544932v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2544932</PublicId>
      <PreferredName>2544901v1.0:2514022v1.0</PreferredName>
      <PreferredDefinition>A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome</PreferredDefinition>
      <LongName>Protein Genomic Identifier Genomic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2544901</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17021:C45766</PreferredName>
        <Version>1</Version>
        <LongName>Protein Genomic Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45766</PREFERRED_NAME>
            <LONG_NAME>Genomic Identifier</LONG_NAME>
            <CON_ID>2322216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2514022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45766</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45766</PREFERRED_NAME>
            <LONG_NAME>Genomic Identifier</LONG_NAME>
            <CON_ID>2322216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Genomic Identifier Genomic Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Genomic Identifier Genomic Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2544880</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GeneConnect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.geneconnect.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.geneconnect.domain.ProteinGenomicIdentifier.genomicIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProteinGenomicIdentifier:genomicIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1159">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2545005</PUBLICID>
    <LONGNAME>Ensembl Transcript Genomic Identifier Genomic Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2544957v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust.  The Ensembl Genome Browser can be accessed through www.ensembl.org.:The initial RNA molecule produced by transcription.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2544957</PublicId>
      <PreferredName>2544912v1.0:2514022v1.0</PreferredName>
      <PreferredDefinition>Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust.  The Ensembl Genome Browser can be accessed through www.ensembl.org.:The initial RNA molecule produced by transcription.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome</PreferredDefinition>
      <LongName>Ensembl Transcript Genomic Identifier Genomic Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2544912</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45763:C1936:C45766</PreferredName>
        <Version>1</Version>
        <LongName>Ensembl Transcript Genomic Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45763</PREFERRED_NAME>
            <LONG_NAME>Ensembl</LONG_NAME>
            <CON_ID>2322217</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1936</PREFERRED_NAME>
            <LONG_NAME>Transcript</LONG_NAME>
            <CON_ID>2544881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45766</PREFERRED_NAME>
            <LONG_NAME>Genomic Identifier</LONG_NAME>
            <CON_ID>2322216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2514022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45766</PreferredName>
        <Version>1</Version>
        <LongName>Genomic Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45766</PREFERRED_NAME>
            <LONG_NAME>Genomic Identifier</LONG_NAME>
            <CON_ID>2322216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Ensembl Transcript Genomic Identifier Genomic Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Ensembl Transcript Genomic Identifier Genomic Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2544880</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GeneConnect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.geneconnect.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812247</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.geneconnect.domain.EnsemblTranscript.genomicIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EnsemblTranscript:genomicIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1160">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2548435</PUBLICID>
    <LONGNAME>Margin Ductal Carcinoma in Situ Status</LONGNAME>
    <PREFERREDNAME>MARG_DCIS_INVLT_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication of the status of a specimen&#39;s margins in reference to the diagnosis of ductal carcinoma in situ (DCIS) breast cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2413055</PublicId>
      <PreferredName>DCIS_EXCISION_MARGIN</PreferredName>
      <PreferredDefinition>information relating to the excision margin of DCIS.</PreferredDefinition>
      <LongName>DCIS Excision Margin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008574</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SURG_MARG_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Margin Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2413053</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2924</PreferredName>
        <Version>1</Version>
        <LongName>DCIS</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2924</PREFERRED_NAME>
            <LONG_NAME>Breast Ductal Carcinoma In Situ</LONG_NAME>
            <CON_ID>2202722</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2413047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15232:C25563</PreferredName>
        <Version>1</Version>
        <LongName>Resection Margin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25563</PREFERRED_NAME>
            <LONG_NAME>Margin</LONG_NAME>
            <CON_ID>2202676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2241251</PublicId>
      <PreferredName>BRESTCA_SX_MARG_STAT</PreferredName>
      <PreferredDefinition>the status of a breast cancer margin.</PreferredDefinition>
      <LongName>Breast Cancer Surgery Margin Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008574</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SURG_MARG_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Margin Measurements</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>70</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Involving advantage or good.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Close</VALIDVALUE>
          <VALUEMEANING>Close</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical margin which is in close proximity to the excised tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grossly negative and microscopically positive</VALIDVALUE>
          <VALUEMEANING>Grossly negative and microscopically positive</VALUEMEANING>
          <MEANINGDESCRIPTION>The presence of microscopically visible residual tumor at the edge of a surgically excised specimen that otherwise looks macroscopically normal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grossly negative and microscopically negative</VALIDVALUE>
          <VALUEMEANING>Grossly negative and microscopically negative</VALUEMEANING>
          <MEANINGDESCRIPTION>The absence of tumor cells at the edge of a surgically excised specimen, both macroscopically and microscopically.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grossly positive</VALIDVALUE>
          <VALUEMEANING>Grossly positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Visible to the naked eye.::1: An observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758, C43566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2854423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Focally positive resection margin</VALIDVALUE>
          <VALUEMEANING>Focally positive resection margin</VALUEMEANING>
          <MEANINGDESCRIPTION>In terms of cancer, limited to a specific area.::1: An observation confirming something, such as the presence of a disease, condition, or microorganism.::2: The act of cutting out; the surgical removal of part or all of a structure or organ.::3: One of the criteria for assessment of the effectiveness of given surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. It is defined by the tissue plane through which the dissection has been done and the actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient. There are four types of surgical margins: intracapsular or intralesional, marginal, wide, and radical.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41227, C15232, C38758, C28224</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3194045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Close resection margins; &gt; 0 mm to &lt;= 2 mm</VALIDVALUE>
          <VALUEMEANING>Narrow Surgical Margin </VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a surgical margin is in close proximity to the excised tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3194046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative margins defined as no tumor at the resected specimen edge</VALIDVALUE>
          <VALUEMEANING>Negative Surgical Margin</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates the absence of tumor cells at the edge of a surgically excised specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48621</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3194047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to access</VALIDVALUE>
          <VALUEMEANING>Unable to Assess Case or Control Status</VALUEMEANING>
          <MEANINGDESCRIPTION>The participant&#39;s case/control status could not be assessed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3334829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to Assess Case or Control Status</VALIDVALUE>
          <VALUEMEANING>Unable to Assess Case or Control Status</VALUEMEANING>
          <MEANINGDESCRIPTION>The participant&#39;s case/control status could not be assessed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3334829</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Margins - DCIS</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Margins - DCIS</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Margin Status</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Margin Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2548333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>I-SPY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C911/C1000</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1161">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2548442</PUBLICID>
    <LONGNAME>Separate Submission Specimen Margin Indicator</LONGNAME>
    <PREFERREDNAME>SEP_SUB_MARG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indication of whether specimen margins were submitted separately.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2548440</PublicId>
      <PreferredName>SEP_SUB_SPEC_MARG</PreferredName>
      <PreferredDefinition>Text terms to indicate if specimen margins were submitted separately.</PreferredDefinition>
      <LongName>Separate Submission Specimen Margin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2548438</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48440:C25694:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Single Submission Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48440</PREFERRED_NAME>
            <LONG_NAME>Single</LONG_NAME>
            <CON_ID>2413378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25694</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2202488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241248</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25563</PreferredName>
        <Version>1</Version>
        <LongName>Margin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25563</PREFERRED_NAME>
            <LONG_NAME>Margin</LONG_NAME>
            <CON_ID>2202676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Separately Submitted Margins?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Separately Submitted Margins?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UC Irvine</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811716</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2548333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>I-SPY</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C911/C1000</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812254</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1162">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2551776</PUBLICID>
    <LONGNAME>Patient Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2551708v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>One or more characters used to identify, name, or characterize the nature, properties, or contents of a person who requires medical care._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2521948</PublicId>
      <PreferredName>2233604v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>One or more characters used to identify, name, or characterize the nature, properties, or contents of a person who requires medical care.</PreferredDefinition>
      <LongName>Patient Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Patient Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Patient Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812255</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.c3pr.domain.PatientIdentifier.personIdentifierCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PatientIdentifier:personIdentifierCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1163">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2551980</PUBLICID>
    <LONGNAME>Anatomic Site Organ Number Code</LONGNAME>
    <PREFERREDNAME>ANAT_ORGAN_NUM_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to identify a named anatomic site(s)or organ withing the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012994</PublicId>
      <PreferredName>ANAT_SITE_ASSESS</PreferredName>
      <PreferredDefinition>Evaluations of named anatomic site(s) in the body.</PreferredDefinition>
      <LongName>Anatomic Site Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2429762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2551978</PublicId>
      <PreferredName>ANAT_ORGAN_NUM_CD</PreferredName>
      <PreferredDefinition>Numeric value to identify an organ or body site.</PreferredDefinition>
      <LongName>Anatomic Site Organ Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2551977</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717:C13018:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site Organ Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13018</PREFERRED_NAME>
            <LONG_NAME>Organ</LONG_NAME>
            <CON_ID>2202464</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>00</VALIDVALUE>
          <VALUEMEANING>Chest Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.: The muscles, bones, and joints that make up the area of the body between the neck and the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL035093, C62484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>01</VALIDVALUE>
          <VALUEMEANING>CNS/spinal</VALUEMEANING>
          <MEANINGDESCRIPTION>CNS/spinal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>02</VALIDVALUE>
          <VALUEMEANING>Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>03</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>04</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>05</VALIDVALUE>
          <VALUEMEANING>Spleen</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that produces lymphocytes, filters the blood, stores blood cells, and destroys those that are aging. It is located on the left side of the abdomen near the stomach. (OCC)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>06</VALIDVALUE>
          <VALUEMEANING>Lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>07</VALIDVALUE>
          <VALUEMEANING>Oopharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>Oopharynx</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>08</VALIDVALUE>
          <VALUEMEANING>Esophagus</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>09</VALIDVALUE>
          <VALUEMEANING>Stomach</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ located between the esophagus and the small intestine where digestion of food occurs before passing to the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Ovary</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>COLORECTAL</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the colon and rectum, or to the entire large bowel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Adrenal Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Heart</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow muscular organ which receives the blood from the veins and propels it into the arteries. It is divided by a musculomembranous septum into two halves -- right or venous and left or arterial -- each of which consists of a receiving chamber (atrium) and an ejecting chamber (ventricle). SYN cor, coeur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Pleural effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Pleural effusion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Area/Organ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Area/Organ</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ThermoDox Study</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812723</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1164">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552027</PUBLICID>
    <LONGNAME>Lesion Target Site</LONGNAME>
    <PREFERREDNAME>LES_TARGET_SITE</PREFERREDNAME>
    <PREFERREDDEFINITION>an anatomic location of a cancer lesion which is being followed as a target (or indicator) lesion for response to study treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192328</PublicId>
      <PreferredName>LES_TGT_LCTN</PreferredName>
      <PreferredDefinition>information related to target lesion location.</PreferredDefinition>
      <LongName>Lesion Target Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177112</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lesion</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207160</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25702:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Target Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2552028</PublicId>
      <PreferredName>LES_ANATOMIC_SITE</PreferredName>
      <PreferredDefinition>an anatomic location of a cancer lesion which is being followed for response to study treatment.</PreferredDefinition>
      <LongName>Lesion Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2261687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37901</PreferredName>
        <Version>1</Version>
        <LongName>Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37901</PREFERRED_NAME>
            <LONG_NAME>Site</LONG_NAME>
            <CON_ID>2202394</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary tumor</VALIDVALUE>
          <VALUEMEANING>Primary Tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor at the original site of origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow</VALIDVALUE>
          <VALUEMEANING>Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brain</VALIDVALUE>
          <VALUEMEANING>Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest wall</VALIDVALUE>
          <VALUEMEANING>Chest Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.: The muscles, bones, and joints that make up the area of the body between the neck and the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL035093, C62484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal tract</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Tract</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gynecologic other</VALIDVALUE>
          <VALUEMEANING>Gynecologic other</VALUEMEANING>
          <MEANINGDESCRIPTION>Gynecologic other</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582388</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodes distant</VALIDVALUE>
          <VALUEMEANING>Distant Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>Distant Nodes</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodes local</VALIDVALUE>
          <VALUEMEANING>Nodes local</VALUEMEANING>
          <MEANINGDESCRIPTION>Nodes local</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582389</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneum</VALIDVALUE>
          <VALUEMEANING>Peritoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>(PAIR-ih-toe-NEE-um) The tissue that lines the abdominal wall and covers most of the organs in the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleura</VALIDVALUE>
          <VALUEMEANING>Pleura</VALUEMEANING>
          <MEANINGDESCRIPTION>(PLOOR-a) A thin layer of tissue covering the lungs and the wall of the chest cavity to protect and cushion the lungs. A small amount of fluid that acts as a lubricant allows the lungs to move smoothly in the chest cavity during breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovary</VALIDVALUE>
          <VALUEMEANING>Ovary</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin subcutaneous</VALIDVALUE>
          <VALUEMEANING>Skin / subcutaneous tissue involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>Skin / subcutaneous tissue involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node</VALIDVALUE>
          <VALUEMEANING>Lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-nodal</VALIDVALUE>
          <VALUEMEANING>Non-nodal</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-nodal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2947209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adrenal Gland</VALIDVALUE>
          <VALUEMEANING>Adrenal Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284845</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast</VALIDVALUE>
          <VALUEMEANING>Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon</VALIDVALUE>
          <VALUEMEANING>Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney</VALIDVALUE>
          <VALUEMEANING>Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the two organs that excrete the urine. The kidneys are bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae. SYN ren, nephros.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinum</VALIDVALUE>
          <VALUEMEANING>Mediastinum</VALUEMEANING>
          <MEANINGDESCRIPTION>(mee-dee-a-STYE-num) The area between the lungs. The organs in this area include the heart and its large blood vessels, the trachea, the esophagus, the bronchi, and lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreas</VALIDVALUE>
          <VALUEMEANING>Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvis</VALIDVALUE>
          <VALUEMEANING>Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural effusion</VALIDVALUE>
          <VALUEMEANING>Pleural effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Pleural effusion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostate Gland</VALIDVALUE>
          <VALUEMEANING>Prostate Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>A gland in males that surrounds the neck of the BLADDER and the URETHRA. It secretes a substance that liquifies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectum</VALIDVALUE>
          <VALUEMEANING>Rectum</VALUEMEANING>
          <MEANINGDESCRIPTION>The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2990372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stomach</VALIDVALUE>
          <VALUEMEANING>Stomach</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine. The stomach is the primary organ of food digestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder</VALIDVALUE>
          <VALUEMEANING>Bladder</VALUEMEANING>
          <MEANINGDESCRIPTION>A distensible musculomembranous organ serving as a receptacle for fluid, as the gallbladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterus</VALIDVALUE>
          <VALUEMEANING>Uterus</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-nodal/non-osseous</VALIDVALUE>
          <VALUEMEANING>Non-nodal/non-osseous</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-nodal/non-osseous</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracic lymph node</VALIDVALUE>
          <VALUEMEANING>Thoracic Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Lymph node located in the thoracic cavity. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3916274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral lung</VALIDVALUE>
          <VALUEMEANING>Ipsilateral lung</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the same side of the body._One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468, C25308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Distant Metastasis</VALIDVALUE>
          <VALUEMEANING>Distant Metastasis</VALUEMEANING>
          <MEANINGDESCRIPTION>A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18206</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5627051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oropharynx</VALIDVALUE>
          <VALUEMEANING>Oropharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the pharynx between the soft palate and the upper portion of the epiglottis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3625361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Cavity</VALIDVALUE>
          <VALUEMEANING>Oral Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Target Lesion Site</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Target Lesion Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Lesion type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion 3 Location (organ type)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion 4 Location (organ type)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion 5 Location (organ type)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion1 (Primary tumor) Location (organ type)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Target lesion 2 Location (organ type)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3298557</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3298577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LES_TARGET_SITE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1165">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552623</PUBLICID>
    <LONGNAME>Object Class Relationship Administered Item Long Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2552461v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of ideas, abstractions, or things in the real world that can be identified with explicit boundaries and meaning and whose properties and behavior follow the same rules.:A state of connectedness between people, objects, or events; to be associated or connected with something.:A registry item for which administrative information is recorded in an Administration Record._Of relatively great or greater than average spatial extension or temporal duration.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552461</PublicId>
      <PreferredName>2539526v1.0:2231601v1.0</PreferredName>
      <PreferredDefinition>A set of ideas, abstractions, or things in the real world that can be identified with explicit boundaries and meaning and whose properties and behavior follow the same rules.:A state of connectedness between people, objects, or events; to be associated or connected with something.:A registry item for which administrative information is recorded in an Administration Record._Of relatively great or greater than average spatial extension or temporal duration.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Object Class Relationship Administered Item Long Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539526</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41106:C25648:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Object Class Relationship Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41106</PREFERRED_NAME>
            <LONG_NAME>Object Class</LONG_NAME>
            <CON_ID>2223438</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25248:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Long Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25248</PREFERRED_NAME>
            <LONG_NAME>Long</LONG_NAME>
            <CON_ID>2206292</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Object Class Relationship Administered Item Long Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Object Class Relationship Administered Item Long Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ObjectClassRelationship.longName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ObjectClassRelationship:longName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1166">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552766</PUBLICID>
    <LONGNAME>Question Repeat Administered Item Long Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2552569v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Of relatively great or greater than average spatial extension or temporal duration.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552569</PublicId>
      <PreferredName>2539534v1.0:2231601v1.0</PreferredName>
      <PreferredDefinition>A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Make or do or perform again.:A registry item for which administrative information is recorded in an Administration Record._Of relatively great or greater than average spatial extension or temporal duration.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Question Repeat Administered Item Long Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C47886:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Question Repeat Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25248:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Long Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25248</PREFERRED_NAME>
            <LONG_NAME>Long</LONG_NAME>
            <CON_ID>2206292</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Question Repeat Administered Item Long Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Question Repeat Administered Item Long Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.QuestionRepetition.longName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QuestionRepetition:longName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1167">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2552806</PUBLICID>
    <LONGNAME>Form Administered Item Workflow Status Name Administered Component Workflow Status Name</LONGNAME>
    <PREFERREDNAME>2552606v1.0:2463565v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A printed or electronic document with spaces to be filled out.:A registry item for which administrative information is recorded in an Administration Record._Workflow is the operational aspect of a work procedure: how tasks are structured, who performs them, what their relative order is, how they are synchronized, how information flows to support the tasks and how tasks are being tracked. (from Wikipedia):A condition or state at a particular time.:Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc._A name of a designation of the status in the administrative life-cycle of a Context Owner for handling new administered items.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2552606</PublicId>
      <PreferredName>2539536v1.0:2442892v1.0</PreferredName>
      <PreferredDefinition>A printed or electronic document with spaces to be filled out.:A registry item for which administrative information is recorded in an Administration Record._Workflow is the operational aspect of a work procedure: how tasks are structured, who performs them, what their relative order is, how they are synchronized, how information flows to support the tasks and how tasks are being tracked. (from Wikipedia):A condition or state at a particular time.:Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc.</PreferredDefinition>
      <LongName>Form Administered Item Workflow Status Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2539536</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19464:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Form Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2463565</PublicId>
      <PreferredName>2463565v1.0</PreferredName>
      <PreferredDefinition>A name of a designation of the status in the administrative life-cycle of a Context Owner for handling new administered items.</PreferredDefinition>
      <LongName>Administered Component Workflow Status Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2422682</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42753:C25688:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Workflow Status Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42753</PREFERRED_NAME>
            <LONG_NAME>Workflow</LONG_NAME>
            <CON_ID>2231547</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>APPRVD FOR TRIAL USE</VALIDVALUE>
          <VALUEMEANING>Approved for trial use</VALUEMEANING>
          <MEANINGDESCRIPTION>Status assigned to Draft New Data Elements included on Common Data Element-compliant forms, as well as their associated Administered Components.  Promotion to this status occurs when the Administered Component has been fully specified and Case Report Forms with which the Data Element is associated are deemed Common Data Element-compliant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE APPROVED</VALIDVALUE>
          <VALUEMEANING>Committee Approved</VALUEMEANING>
          <MEANINGDESCRIPTION>Admistered component approved by a committee.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE SUBMTD</VALIDVALUE>
          <VALUEMEANING>Committee Submitted</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component submitted to a review committee</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CMTE SUBMTD USED</VALIDVALUE>
          <VALUEMEANING>Committee Submitted Used</VALUEMEANING>
          <MEANINGDESCRIPTION>Trial use approved, committee submitted administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRAFT MOD</VALIDVALUE>
          <VALUEMEANING>Draft Modified</VALUEMEANING>
          <MEANINGDESCRIPTION>New version of an existing administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DRAFT NEW</VALIDVALUE>
          <VALUEMEANING>Draft New</VALUEMEANING>
          <MEANINGDESCRIPTION>Newly created administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RELEASED</VALIDVALUE>
          <VALUEMEANING>Released</VALUEMEANING>
          <MEANINGDESCRIPTION>Reviewed and approved administered component</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RELEASED-NON-CMPLNT</VALIDVALUE>
          <VALUEMEANING>Released Non-Compliant</VALUEMEANING>
          <MEANINGDESCRIPTION>Status for short-term use only, to be replaced long term</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED ARCHIVED</VALIDVALUE>
          <VALUEMEANING>Retired Archived</VALUEMEANING>
          <MEANINGDESCRIPTION>Old version administered component replaced with new version</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED DELETED</VALIDVALUE>
          <VALUEMEANING>Retired Deleted</VALUEMEANING>
          <MEANINGDESCRIPTION>Erroneous administered component to be removed from database</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED PHASED OUT</VALIDVALUE>
          <VALUEMEANING>Retired Phased Out</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component rejected for general release</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RETIRED WITHDRAWN</VALIDVALUE>
          <VALUEMEANING>Retired Withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Administered component removed from general release</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576710</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Form Administered Item Workflow Status Name Administered Component Workflow Status Name does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Form Administered Item Workflow Status Name Administered Component Workflow Status Name does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812554</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE</PreferredName>
          <Version>3.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.Form.workflowStatusName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Form:workflowStatusName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1168">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2553030</PUBLICID>
    <LONGNAME>Support Treatment Agent Current Course Administered Specify</LONGNAME>
    <PREFERREDNAME>S_TX_AGT_C_C_AD_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field to specify the other type of support agent administered during the current course.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2222036</PublicId>
      <PreferredName>SU_TX_AGT_CU_CRS_ADM</PreferredName>
      <PreferredDefinition>information related to the support treatment agent administered during current course.</PreferredDefinition>
      <LongName>Support Treatment Agent Current Course Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2222028</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>C37902:C15368:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Support Therapy Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37902</PREFERRED_NAME>
            <LONG_NAME>Support</LONG_NAME>
            <CON_ID>2202834</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222029</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>C25471:C25379:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Current Course Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If other than the above, please provide antibiotic name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1169">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2553290</PUBLICID>
    <LONGNAME>Audit Event Question Log Question Details java.lang.String</LONGNAME>
    <PREFERREDNAME>2553169v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A methodical examination or review of a condition or situation.:Something that happens at a given place and time.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A written record of events._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Particulars considered individually and in relation to a whole._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2553169</PublicId>
      <PreferredName>2553152v1.0:2553136v1.0</PreferredName>
      <PreferredDefinition>A methodical examination or review of a condition or situation.:Something that happens at a given place and time.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A written record of events._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:Particulars considered individually and in relation to a whole.</PreferredDefinition>
      <LongName>Audit Event Question Log Question Details</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2553152</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45269:C25499:C41116:C45279</PreferredName>
        <Version>1</Version>
        <LongName>Audit Event Question Log</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45269</PREFERRED_NAME>
            <LONG_NAME>Audit</LONG_NAME>
            <CON_ID>2513261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45279</PREFERRED_NAME>
            <LONG_NAME>Log</LONG_NAME>
            <CON_ID>2422634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553136</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C25480</PreferredName>
        <Version>1</Version>
        <LongName>Question Details</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25480</PREFERRED_NAME>
            <LONG_NAME>Details</LONG_NAME>
            <CON_ID>2203578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Audit Event Question Log Question Details java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Audit Event Question Log Question Details java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2553133</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661745</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_caArray</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2680967</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Core_1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000633</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AuditEventQueryLog:queryDetails</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.AuditEventQueryLog.queryDetails</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1170">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2555559</PUBLICID>
    <LONGNAME>Organization Professional Organization or Group Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2555484v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A formal group of people with one or more shared goals._A formal group of people with one or more shared goals.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2555484</PublicId>
      <PreferredName>2407006v1.0:2475269v1.0</PreferredName>
      <PreferredDefinition>A formal group of people with one or more shared goals._A formal group of people with one or more shared goals.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Organization Professional Organization or Group Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19711</PreferredName>
        <Version>1</Version>
        <LongName>Organization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19711</PREFERRED_NAME>
            <LONG_NAME>Professional Organization or Group</LONG_NAME>
            <CON_ID>2202773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2475269</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19711:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Professional Organization or Group Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19711</PREFERRED_NAME>
            <LONG_NAME>Professional Organization or Group</LONG_NAME>
            <CON_ID>2202773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Organization Professional Organization or Group Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Organization Professional Organization or Group Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2555333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trials Lab Model</PreferredName>
          <Version>0.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lab Hub Model</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2555333</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trials Lab Model</PreferredName>
          <Version>0.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.labhub.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.labhub.domain.Organization.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.Organization.identifierNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:identifierNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1171">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2557834</PUBLICID>
    <LONGNAME>ARACNE Algorithm Programming Parameter Mutual Information Value Bin java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2557796v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An information-theoretic algorithm for reverse engineering of transcriptional networks using microarray data, specifically designed to scale up to the complexity of regulatory networks in mammalian cells, yet general enough to address a wider range of network deconvolution problems, while eliminating the majority of indirect interactions inferred by co-expression methods.:A value that is passed to a routine._Expresses the extent to which the observed frequency of co-occurrence differs from that expected under the null hypothesis.:An interval into which a given data point does or does not fall._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2557796</PublicId>
      <PreferredName>2557779v1.0:2557761v1.0</PreferredName>
      <PreferredDefinition>An information-theoretic algorithm for reverse engineering of transcriptional networks using microarray data, specifically designed to scale up to the complexity of regulatory networks in mammalian cells, yet general enough to address a wider range of network deconvolution problems, while eliminating the majority of indirect interactions inferred by co-expression methods.:A value that is passed to a routine._Expresses the extent to which the observed frequency of co-occurrence differs from that expected under the null hypothesis.:An interval into which a given data point does or does not fall.</PreferredDefinition>
      <LongName>ARACNE Algorithm Programming Parameter Mutual Information Value Bin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2557779</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63899:C48913</PreferredName>
        <Version>1</Version>
        <LongName>ARACNE Algorithm Programming Parameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63899</PREFERRED_NAME>
            <LONG_NAME>ARACNE Algorithm</LONG_NAME>
            <CON_ID>2557744</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48913</PREFERRED_NAME>
            <LONG_NAME>Programming Parameter</LONG_NAME>
            <CON_ID>2451932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2557761</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63898:C63902</PreferredName>
        <Version>1</Version>
        <LongName>Mutual Information Value Bin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63898</PREFERRED_NAME>
            <LONG_NAME>Mutual Information Value</LONG_NAME>
            <CON_ID>2557743</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63902</PREFERRED_NAME>
            <LONG_NAME>Bin</LONG_NAME>
            <CON_ID>2557746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element ARACNE Algorithm Programming Parameter Mutual Information Value Bin java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element ARACNE Algorithm Programming Parameter Mutual Information Value Bin java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.columbia.geworkbench.cagrid.aracne</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000471</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>geworkbench</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.columbia.geworkbench.cagrid.aracne</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812534</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.columbia.geworkbench.cagrid.aracne.AracneParameter.mutualInformationSteps</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AracneParameter:mutualInformationSteps</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1172">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2557987</PUBLICID>
    <LONGNAME>UniGene Tissue Source Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2433377v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information such as the tissue types in which the gene has been expressed and map location.  It is provided as a web application from the National Center for Biotechnology Information (NCBI).:An aggregate of cells with similar or identical specialized characteristics, contributing to the performance of a specific function.  Tissues are parts of organs.:Where something is available or from where it originates._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2433377</PublicId>
      <PreferredName>2433354v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>An experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information such as the tissue types in which the gene has been expressed and map location.  It is provided as a web application from the National Center for Biotechnology Information (NCBI).:An aggregate of cells with similar or identical specialized characteristics, contributing to the performance of a specific function.  Tissues are parts of organs.:Where something is available or from where it originates._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>UniGene Tissue Source Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2433354</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43563:C12801:C25683</PreferredName>
        <Version>1</Version>
        <LongName>UniGene Tissue Source</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43563</PREFERRED_NAME>
            <LONG_NAME>UniGene</LONG_NAME>
            <CON_ID>2223200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element UniGene Tissue Source Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element UniGene Tissue Source Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2557869</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UnigeneTissueSource:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.UnigeneTissueSource.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1173">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2585765</PUBLICID>
    <LONGNAME>Radical Prostate Therapy Participating Ind-2</LONGNAME>
    <PREFERREDNAME>RAD_PRS_TX_PART_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no indicator to ask if a subject will take part in therapy to completely remove or stop the function of the prostate gland in the male reproductive system in order to alter the course of cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCIC CRF:National Cancer Institute of Canada Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2585761</PublicId>
      <PreferredName>RAD_PRS_TX_PARTIC</PreferredName>
      <PreferredDefinition>related to taking part in administering therapy to completely remove or stop the function of the prostate gland in the male reproductive system in order to alter the course of malignant disease.</PreferredDefinition>
      <LongName>Radical Prostate Therapy Participating</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2585757</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0439807:C12410:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Radical Prostate Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0439807</PREFERRED_NAME>
            <LONG_NAME>Radical</LONG_NAME>
            <CON_ID>2474326</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2585758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25608</PreferredName>
        <Version>1</Version>
        <LongName>Participating</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25608</PREFERRED_NAME>
            <LONG_NAME>Participation</LONG_NAME>
            <CON_ID>2206339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Will the patient receive radi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Will the patient receive radical prostatectomy or radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient is a suitable candidate for radical prostatectomy or radiotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Robotic-assisted laparoscopic radical prostatectomy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Laparoscopic radical prostatectomy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radical prostatectomy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1174">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2593116</PUBLICID>
    <LONGNAME>Provider Communication Participant Family Member Skin Exam Date</LONGNAME>
    <PREFERREDNAME>HCP_COMM_FAM_EXAM_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Date of exchange of information between health care provider and participant about his/her family members&#39; skin examinations.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2593105</PublicId>
      <PreferredName>HCP_COMM_FAM_EXAM</PreferredName>
      <PreferredDefinition>Exchange of information between health care provider and participant about his/her family members&#39; skin examinations.</PreferredDefinition>
      <LongName>Participant Provider Communication Participant Family Member Skin Exam</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2505966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16666:C16452</PreferredName>
        <Version>1</Version>
        <LongName>Health Care Provider Communication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16666</PREFERRED_NAME>
            <LONG_NAME>Health Care Provider</LONG_NAME>
            <CON_ID>2479788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16452</PREFERRED_NAME>
            <LONG_NAME>Communication</LONG_NAME>
            <CON_ID>2435936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2593103</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867:C41256:C12470:C25305</PreferredName>
        <Version>1</Version>
        <LongName>Participant Family Member Skin Exam</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41256</PREFERRED_NAME>
            <LONG_NAME>Family Member</LONG_NAME>
            <CON_ID>2426000</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017121</PublicId>
      <PreferredName>CTMS_DT</PreferredName>
      <PreferredDefinition>Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).</PreferredDefinition>
      <LongName>CTMS Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CCR:Center for Cancer Research</Origin>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Participant&#39;s family members&#39;</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Participant&#39;s family members&#39; skin examinations</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812205</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AZCC 0210</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Arizona New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812607</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1175">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2595990</PUBLICID>
    <LONGNAME>Surgical Procedure Periodontal Treatment Left Mandible Performed Year Date</LONGNAME>
    <PREFERREDNAME>SP_PERD_LM_PER_YDT</PREFERREDNAME>
    <PREFERREDDEFINITION>the year date of treatment of the gums, soft tissues, and bones that support the teeth with an operation to the left lower jaw.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2595982</PublicId>
      <PreferredName>SP_PERTX_LM_PERF</PreferredName>
      <PreferredDefinition>information related to treatment of the gums, soft tissues, and bones that support the teeth with an operation to the left lower jaw.</PreferredDefinition>
      <LongName>Surgical Procedure Periodontal Treatment Left Mandible Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2595980</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329:C63747</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure Periodontal Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63747</PREFERRED_NAME>
            <LONG_NAME>Periodontal Treatment</LONG_NAME>
            <CON_ID>2547897</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2595904</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25229:C12290:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Left Mandible Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25229</PREFERRED_NAME>
            <LONG_NAME>Left</LONG_NAME>
            <CON_ID>2204810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12290</PREFERRED_NAME>
            <LONG_NAME>Mandible</LONG_NAME>
            <CON_ID>2202585</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2195353</PublicId>
      <PreferredName>YR_DT</PreferredName>
      <PreferredDefinition>the numeric representation of the calendar year. </PreferredDefinition>
      <LongName>Year Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208026</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29848:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Year Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Year</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Year</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1176">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2595995</PUBLICID>
    <LONGNAME>Surgical Procedure Periodontal Treatment Left Maxilla Performed Type</LONGNAME>
    <PREFERREDNAME>SP_PERD_LMA_PE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of treatment of the gums, soft tissues, and bones that support the teeth with an operation to the left upper jaw.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2595986</PublicId>
      <PreferredName>SP_PERTX_LMA_PERF</PreferredName>
      <PreferredDefinition>information related to treatment of the gums, soft tissues, and bones that support the teeth with an operation in the left upper jaw.</PreferredDefinition>
      <LongName>Surgical Procedure Periodontal Treatment Left Maxilla Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2595980</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329:C63747</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure Periodontal Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63747</PREFERRED_NAME>
            <LONG_NAME>Periodontal Treatment</LONG_NAME>
            <CON_ID>2547897</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2595920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25229:C26470:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Left Maxilla Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25229</PREFERRED_NAME>
            <LONG_NAME>Left</LONG_NAME>
            <CON_ID>2204810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26470</PREFERRED_NAME>
            <LONG_NAME>Maxilla</LONG_NAME>
            <CON_ID>2202586</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2595933</PublicId>
      <PreferredName>SURG_PERTX_TP</PreferredName>
      <PreferredDefinition>the type of invasive treatment to the gums, soft tissues, and bones that support the teeth.</PreferredDefinition>
      <LongName>Surgical Periodontal Treatment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4220: Gingival curettage</VALIDVALUE>
          <VALUEMEANING>4220: Gingival curettage</VALUEMEANING>
          <MEANINGDESCRIPTION>Gingival curettage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2595997</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4210: Gingivectomy or gingivoplasty</VALIDVALUE>
          <VALUEMEANING>4210: Gingivectomy or gingivoplasty</VALUEMEANING>
          <MEANINGDESCRIPTION>Gingivectomy or gingivoplasty</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2595996</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4240: Gingival flap procedure</VALIDVALUE>
          <VALUEMEANING>4240: Gingival flap procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Gingival flap procedure</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2595998</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4249: Crown lengthening</VALIDVALUE>
          <VALUEMEANING>4249: Crown lengthening</VALUEMEANING>
          <MEANINGDESCRIPTION>Crown lengthening</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2595999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4250: Mucogingival surgery</VALIDVALUE>
          <VALUEMEANING>4250: Mucogingival surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Mucogingival surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4260:  Osseous surgery</VALIDVALUE>
          <VALUEMEANING>4260:  Osseous surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Osseous surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4245:  Apically positioned flap</VALIDVALUE>
          <VALUEMEANING>4245:  Apically positioned flap</VALUEMEANING>
          <MEANINGDESCRIPTION>Apically positioned flap</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4266:  Guided tissue regeneration</VALIDVALUE>
          <VALUEMEANING>4266:  Guided tissue regeneration</VALUEMEANING>
          <MEANINGDESCRIPTION>Guided tissue regeneration</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4263:  Bone replacement graft</VALIDVALUE>
          <VALUEMEANING>4263:  Bone replacement graft</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone replacement graft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4664:  Bone replacement graft</VALIDVALUE>
          <VALUEMEANING>4664:  Bone replacement graft</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone replacement graft</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2596005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Surgical periodontal procedur</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Surgical periodontal procedures (UL)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1177">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2596218</PUBLICID>
    <LONGNAME>Patient Tooth Gingiva Health Assessment Scale</LONGNAME>
    <PREFERREDNAME>PT_T_G_HLT_AS_SCAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale related to the assessment of a patient&#39;s/participant&#39;s health of the teeth and the mucous membrane-covered tissue of the jaws that surrounds the bases of the teeth.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2585125</PublicId>
      <PreferredName>PT_T_GIN_HLTH_ASSESS</PreferredName>
      <PreferredDefinition>information related to the assessment of a patient&#39;s/participant&#39;s health of the teeth and the mucous membrane-covered tissue of the jaws that surrounds the bases of the teeth.</PreferredDefinition>
      <LongName>Patient Tooth Gingiva Health Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2585123</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12506:C32677:C25178:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Tooth Gingiva Health Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32677</PREFERRED_NAME>
            <LONG_NAME>Gingiva</LONG_NAME>
            <CON_ID>2203989</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25178</PREFERRED_NAME>
            <LONG_NAME>Health</LONG_NAME>
            <CON_ID>2202325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2596219</PublicId>
      <PreferredName>PT_TO_HLTH_ASSE_STAT</PreferredName>
      <PreferredDefinition>a condition or state at a particular time of the patient&#39;s tooth.</PreferredDefinition>
      <LongName>Patient Tooth Health Assessment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excellent</VALIDVALUE>
          <VALUEMEANING>Excellent</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to the highest quality or standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Good</VALIDVALUE>
          <VALUEMEANING>GOOD</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing._The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poor</VALIDVALUE>
          <VALUEMEANING>POOR</VALUEMEANING>
          <MEANINGDESCRIPTION>Of low value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very Good</VALIDVALUE>
          <VALUEMEANING>Very good</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something has a high degree of quality, value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fair</VALIDVALUE>
          <VALUEMEANING>Fair</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no exceptional quality or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How would you describe the he</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How would you describe the health of your teeth and gums today</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1178">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2596254</PUBLICID>
    <LONGNAME>Dentist Identifier Name</LONGNAME>
    <PREFERREDNAME>DENT_ID_NAM</PREFERREDNAME>
    <PREFERREDDEFINITION>the name of the inidividual dentist.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2443310</PublicId>
      <PreferredName>DENT_ID</PreferredName>
      <PreferredDefinition>information related to the identification using one or more characters used to identify an individual licensed for the prevention, diagnosis, and treatment of diseases in the oral cavity, adjacent tissues, and related structures.</PreferredDefinition>
      <LongName>Dentist Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443308</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654</PreferredName>
        <Version>1</Version>
        <LongName>Dentist</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018284</PublicId>
      <PreferredName>INDS_NAME</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Individuals Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Provider Name</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Provider Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1179">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2596601</PUBLICID>
    <LONGNAME>Orthodontic Treatment Patient Self-Report Prior Osteonecrosis of Jaw Performed Begin Date</LONGNAME>
    <PREFERREDNAME>OT_PSR_P_ONJ_P_B_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date on which an observation or an event began related to dental treatment to correct malocclusions of the teeth and their surrounding structures prior to self-reported area of necrotic bone in the mandible or maxilla.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2589975</PublicId>
      <PreferredName>O_TX_PSR_P_ONJ_PERF</PreferredName>
      <PreferredDefinition>information related to dental treatment to correct malocclusions of the teeth and their surrounding structures prior to self-reported area of necrotic bone in the mandible or maxilla.</PreferredDefinition>
      <LongName>Orthodontic Treatment Patient Self-Report Prior Osteonecrosis of Jaw Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2589973</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64248</PreferredName>
        <Version>1</Version>
        <LongName>Orthodontic Treatment
</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64248</PREFERRED_NAME>
            <LONG_NAME>Orthodontic Treatment</LONG_NAME>
            <CON_ID>2558017</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2589929</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C25629:C63924:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Prior Osteonecrosis of Jaw Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63924</PREFERRED_NAME>
            <LONG_NAME>Osteonecrosis of Jaw</LONG_NAME>
            <CON_ID>2549643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188673</PublicId>
      <PreferredName>BEG_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event began.</PreferredDefinition>
      <LongName>Begin Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yyyy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208020</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Begin Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Start Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Start Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1180">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2597104</PUBLICID>
    <LONGNAME>Laboratory Procedure Uric Acid Result Unspecified Upper Limit of Normal Value</LONGNAME>
    <PREFERREDNAME>LAB_UR_RS_U_ULN_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the top value, units of measure not specified, of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern renal lab for uric acid, a white tasteless odorless crystalline product of protein metabolism, found in the blood and urine,  as well as trace amounts found in the various organs of the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2195946</PublicId>
      <PreferredName>LAB_URICACID_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of the medical procedure that involves testing a sample of blood or urine for uric acid, a white tasteless odorless crystalline product of protein metabolism.</PreferredDefinition>
      <LongName>Laboratory Procedure Uric Acid Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738929</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62652:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Uric Acid Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62652</PREFERRED_NAME>
            <LONG_NAME>Uric Acid</LONG_NAME>
            <CON_ID>2525583</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2597102</PublicId>
      <PreferredName>URA_LAB_UNS_ULN_VAL</PreferredName>
      <PreferredDefinition>the top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for uric acid (units not specified).</PreferredDefinition>
      <LongName>Uric Acid Lab Unspecified Upper Limit of Normal Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mg/dL</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2597101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C25706:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Upper Limit of Normal Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25706</PREFERRED_NAME>
            <LONG_NAME>Upper Limit of Normal</LONG_NAME>
            <CON_ID>2203609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Uric Acid ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1181">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608081</PUBLICID>
    <LONGNAME>Staging Value TNM Staging System java.lang.String</LONGNAME>
    <PREFERREDNAME>2607706v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made._A numerical quantity measured or assigned or computed.:A system of clinicopathologic evaluation of tumors based on the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion), and lymph node involvement (N) and metastasis (M) each followed by a number starting at 0 for no evident metastasis; numbers used depend on the organ involved and influence the prognosis and choice of treatment._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607706</PublicId>
      <PreferredName>2607679v1.0:2607512v1.0</PreferredName>
      <PreferredDefinition>The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made._A numerical quantity measured or assigned or computed.:A system of clinicopathologic evaluation of tumors based on the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion), and lymph node involvement (N) and metastasis (M) each followed by a number starting at 0 for no evident metastasis; numbers used depend on the organ involved and influence the prognosis and choice of treatment.</PreferredDefinition>
      <LongName>Staging Value TNM Staging System</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607679</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15608</PreferredName>
        <Version>1</Version>
        <LongName>Staging</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15608</PREFERRED_NAME>
            <LONG_NAME>Staging</LONG_NAME>
            <CON_ID>2204881</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607512</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712:C25384</PreferredName>
        <Version>1</Version>
        <LongName>Value TNM Staging System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25384</PREFERRED_NAME>
            <LONG_NAME>TNM Staging System</LONG_NAME>
            <CON_ID>2206263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Staging Value TNM Staging System java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Staging Value TNM Staging System java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CancerStage:tnmStage</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.CancerStage.tnmStage</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1182">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608179</PUBLICID>
    <LONGNAME>Diagnosis Other Source java.lang.String</LONGNAME>
    <PREFERREDNAME>2607803v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The process of identifying a disease by the signs and symptoms._Different than the one(s) previously specified or mentioned.:Where something is available or from where it originates._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607803</PublicId>
      <PreferredName>2442484v1.0:2607586v1.0</PreferredName>
      <PreferredDefinition>The process of identifying a disease by the signs and symptoms._Different than the one(s) previously specified or mentioned.:Where something is available or from where it originates.</PreferredDefinition>
      <LongName>Diagnosis Other Source</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2442484</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607586</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25683</PreferredName>
        <Version>1</Version>
        <LongName>Other Source</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Diagnosis Other Source java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Diagnosis Other Source java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.Diagnosis.sourceOther</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Diagnosis:sourceOther</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1183">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608266</PUBLICID>
    <LONGNAME>Adverse Event Common Terminology Criteria for Adverse Events Grade Code System java.lang.String</LONGNAME>
    <PREFERREDNAME>2607889v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.:A position on a scale of intensity or amount or quality.:A system, often of numbered categories, for representation of data.:A group of independent but interrelated elements comprising a unified whole._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607889</PublicId>
      <PreferredName>2235992v1.0:2607634v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.:A position on a scale of intensity or amount or quality.:A system, often of numbered categories, for representation of data.:A group of independent but interrelated elements comprising a unified whole.</PreferredDefinition>
      <LongName>Adverse Event Common Terminology Criteria for Adverse Events Grade Code System</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2235992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607634</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49704:C48309:C25162:C25700</PreferredName>
        <Version>1</Version>
        <LongName>Common Terminology Criteria for Adverse Events Grade Code System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49704</PREFERRED_NAME>
            <LONG_NAME>Common Terminology Criteria for Adverse Events</LONG_NAME>
            <CON_ID>2480705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Common Terminology Criteria for Adverse Events Grade Code System java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Common Terminology Criteria for Adverse Events Grade Code System java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent:ctcGradeCodeSystem</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.AdverseEvent.ctcGradeCodeSystem</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1184">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608290</PUBLICID>
    <LONGNAME>Lesion Description Anatomic Site Code System java.lang.String</LONGNAME>
    <PREFERREDNAME>2607912v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any visible abnormal structural change in a bodily part.:A written or verbal account, representation, statement, or explanation of something._Named locations of or within the body.:A system, often of numbered categories, for representation of data.:A group of independent but interrelated elements comprising a unified whole._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607912</PublicId>
      <PreferredName>2607699v1.0:2607552v1.0</PreferredName>
      <PreferredDefinition>Any visible abnormal structural change in a bodily part.:A written or verbal account, representation, statement, or explanation of something._Named locations of or within the body.:A system, often of numbered categories, for representation of data.:A group of independent but interrelated elements comprising a unified whole.</PreferredDefinition>
      <LongName>Lesion Description Anatomic Site Code System</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Lesion Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717:C25162:C25700</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site Code System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Lesion Description Anatomic Site Code System java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Lesion Description Anatomic Site Code System java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LesionDescription:anatomicSiteCodeSystem</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.LesionDescription.anatomicSiteCodeSystem</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1185">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608321</PUBLICID>
    <LONGNAME>Observation Confidentiality Level Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2607942v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Observation; watching something and taking note of what happens._The ethical principle or legal right that a physician or other health professional will hold secret all information relating to a patient, unless the patient gives consent permitting disclosure.:A position on a scale measuring intensity, quality, or amount.:A system, often of numbered categories, for representation of data._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2607942</PublicId>
      <PreferredName>2482069v1.0:2607672v1.0</PreferredName>
      <PreferredDefinition>Observation; watching something and taking note of what happens._The ethical principle or legal right that a physician or other health professional will hold secret all information relating to a patient, unless the patient gives consent permitting disclosure.:A position on a scale measuring intensity, quality, or amount.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Observation Confidentiality Level Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2482069</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598</PreferredName>
        <Version>1</Version>
        <LongName>Observation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607672</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16466:C25554:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Confidentiality Level Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16466</PREFERRED_NAME>
            <LONG_NAME>Confidentiality</LONG_NAME>
            <CON_ID>2493174</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Confidentiality Level Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Confidentiality Level Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.Observation.confidentialityCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Observation:confidentialityCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1186">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2608414</PUBLICID>
    <LONGNAME>Death Summary Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2608031v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The absence of life or state of being dead.:A shortened version of a speech or written text, containing only the main points._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2608031</PublicId>
      <PreferredName>2607702v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The absence of life or state of being dead.:A shortened version of a speech or written text, containing only the main points._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Death Summary Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607702</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28554:C42581</PreferredName>
        <Version>1</Version>
        <LongName>Death Summary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28554</PREFERRED_NAME>
            <LONG_NAME>Dead</LONG_NAME>
            <CON_ID>2202731</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42581</PREFERRED_NAME>
            <LONG_NAME>Summary</LONG_NAME>
            <CON_ID>2203701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Death Summary Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Death Summary Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000403</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.DeathSummary.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DeathSummary:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1187">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2611892</PUBLICID>
    <LONGNAME>Oligonucleotide Primer Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2611803v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2611803</PublicId>
      <PreferredName>2611786v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Oligonucleotide Primer Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1451</PreferredName>
        <Version>1</Version>
        <LongName>Oligonucleotide Primer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1451</PREFERRED_NAME>
            <LONG_NAME>Oligonucleotide Primer</LONG_NAME>
            <CON_ID>2611725</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Oligonucleotide Primer Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Oligonucleotide Primer Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812759</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.Primer.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Primer:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Primer.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1188">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2613102</PUBLICID>
    <LONGNAME>Shape Minimum Dimension java.lang.Float</LONGNAME>
    <PREFERREDNAME>2612454v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial arrangement of something as distinct from its substance._The smallest possible quantity.:The magnitude of something in a particular direction, especially length or width or height._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2612454</PublicId>
      <PreferredName>2612281v1.0:2612225v1.0</PreferredName>
      <PreferredDefinition>The spatial arrangement of something as distinct from its substance._The smallest possible quantity.:The magnitude of something in a particular direction, especially length or width or height.</PreferredDefinition>
      <LongName>Shape Minimum Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612281</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25677</PreferredName>
        <Version>1</Version>
        <LongName>Shape</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25677</PREFERRED_NAME>
            <LONG_NAME>Shape</LONG_NAME>
            <CON_ID>2203587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2612225</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25570:C25483</PreferredName>
        <Version>1</Version>
        <LongName>Minimum Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Shape Minimum Dimension java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Shape Minimum Dimension java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calab.domain.nano.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812764</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813021</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Shape:minDimension</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calab.domain.nano.characterization.physical.Shape.minDimension</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.characterization.physical.Shape.minDimension</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.physical.Shape.minDimension</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1189">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2613980</PUBLICID>
    <LONGNAME>Image Device Transducer Frequency Text</LONGNAME>
    <PREFERREDNAME>2613944v1.0:2613952v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Textual representation of the transducer frequency used to obtain images as reported in MHz. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>IVI:caBIG In Vivo Imaging Workspace</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2613944</PublicId>
      <PreferredName>2613942v1.00:2234899v1.00</PreferredName>
      <PreferredDefinition>Any record of an imaging event whether physical or electronic._An electrical device that converts one form of energy into another.:A manner, or usual, or accepted practice of using something.</PreferredDefinition>
      <LongName>Image Device Transducer Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2613942</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179:C50226</PreferredName>
        <Version>1</Version>
        <LongName>Image Device Transducer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50226</PREFERRED_NAME>
            <LONG_NAME>Transducer Device</LONG_NAME>
            <CON_ID>2613941</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>IVI:caBIG In Vivo Imaging Workspace</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2613952</PublicId>
      <PreferredName>2613952v1.0</PreferredName>
      <PreferredDefinition>The textual representation of the transducer center frequency used to obtain images as reported in MHz.</PreferredDefinition>
      <LongName>Device Transducer Frequency Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>IVI:caBIG In Vivo Imaging Workspace</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low frequency</VALIDVALUE>
          <VALUEMEANING>Center frequency range (low end)</VALUEMEANING>
          <MEANINGDESCRIPTION>Transducer low end center frequency range used to obtain images reported MHz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2613953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High frequency</VALIDVALUE>
          <VALUEMEANING>Center frequency range (high end)</VALUEMEANING>
          <MEANINGDESCRIPTION>Transducer high end center frequency range used to obtain images reported MHz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2613954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Center frequency</VALIDVALUE>
          <VALUEMEANING>Center frequency</VALUEMEANING>
          <MEANINGDESCRIPTION>Transducer center  frequency used to obtain images reported in MHz.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2613955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Transducer frequency</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Transducer frequency</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314439</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Imaging Modality</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ultrasound (US)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3314454</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314514</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Under Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Old ACRIN Content</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3625158</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1190">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2620033</PUBLICID>
    <LONGNAME>Mouse Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2619726v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2619726</PublicId>
      <PreferredName>2619598v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Mouse Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2619598</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14238</PreferredName>
        <Version>1</Version>
        <LongName>Mouse</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14238</PREFERRED_NAME>
            <LONG_NAME>Mouse</LONG_NAME>
            <CON_ID>2437670</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Mouse Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Mouse Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.ucdavis.caelmir.domain.subject</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812793</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Mouse:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.ucdavis.caelmir.domain.subject.Mouse.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.Mouse.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1191">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2620276</PUBLICID>
    <LONGNAME>Biomarker Outcome First State Mean java.lang.Double</LONGNAME>
    <PREFERREDNAME>2620194v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Objectively measurable phenotypic parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype, presence of biological substances) that characterize an organism&#39;s state of health or disease, likelihood of developing a disease, or response to a particular therapeutic intervention.:A phenomenon that follows and is caused by some previous phenomenon._Preceding all others in time or space or degree.:The way something is with respect to its main attributes.:The sum of a set of values divided by the number of values in the set._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2620194</PublicId>
      <PreferredName>2620164v1.0:2620138v1.0</PreferredName>
      <PreferredDefinition>Objectively measurable phenotypic parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype, presence of biological substances) that characterize an organism&#39;s state of health or disease, likelihood of developing a disease, or response to a particular therapeutic intervention.:A phenomenon that follows and is caused by some previous phenomenon._Preceding all others in time or space or degree.:The way something is with respect to its main attributes.:The sum of a set of values divided by the number of values in the set.</PreferredDefinition>
      <LongName>Biomarker Outcome First State Mean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2620164</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16342:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Biomarker Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2620138</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25687:C53319</PreferredName>
        <Version>1</Version>
        <LongName>First State Mean</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25687</PREFERRED_NAME>
            <LONG_NAME>State</LONG_NAME>
            <CON_ID>2203805</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53319</PREFERRED_NAME>
            <LONG_NAME>Arithmetic Mean</LONG_NAME>
            <CON_ID>2528578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biomarker Outcome First State Mean java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biomarker Outcome First State Mean java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gridExtensions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812798</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.genepattern.caGrid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812799</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.genepattern.caGrid.MarkerResult.class0Mean</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MarkerResult:class0Mean</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1192">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2620282</PUBLICID>
    <LONGNAME>Biomarker Outcome Characteristics java.lang.String</LONGNAME>
    <PREFERREDNAME>2620200v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Objectively measurable phenotypic parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype, presence of biological substances) that characterize an organism&#39;s state of health or disease, likelihood of developing a disease, or response to a particular therapeutic intervention.:A phenomenon that follows and is caused by some previous phenomenon._Characteristics; distinguishing qualities of a person, object, or substance._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2620200</PublicId>
      <PreferredName>2620164v1.0:2548312v1.0</PreferredName>
      <PreferredDefinition>Objectively measurable phenotypic parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype, presence of biological substances) that characterize an organism&#39;s state of health or disease, likelihood of developing a disease, or response to a particular therapeutic intervention.:A phenomenon that follows and is caused by some previous phenomenon._Characteristics; distinguishing qualities of a person, object, or substance.</PreferredDefinition>
      <LongName>Biomarker Outcome Characteristics</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2620164</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16342:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Biomarker Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2548312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25447</PreferredName>
        <Version>1</Version>
        <LongName>Characteristics</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biomarker Outcome Characteristics java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biomarker Outcome Characteristics java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gridExtensions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812798</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2620091</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GenePattern</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.genepattern.caGrid</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812799</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.genepattern.caGrid.MarkerResult.feature</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MarkerResult:feature</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1193">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2630716</PUBLICID>
    <LONGNAME>Laboratory Procedure Calcium Electrolytes Outcome Unspecified Value</LONGNAME>
    <PREFERREDNAME>LAB_CA_EL_OC_SPE_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the laboratory value related to the quantity of calcium present in peripheral blood serum measured by laboratory test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2189860</PublicId>
      <PreferredName>LAB_CA_ELECT_OC</PreferredName>
      <PreferredDefinition>information related to the medical procedure that involves testing a sample of blood for calcium electrolytes, substances that break up into ions (electrically charged particles) when they are dissolved in body fluids and are primarily responsible for the movement of nutrients into cells and the movement of wastes out of cells.</PreferredDefinition>
      <LongName>Laboratory Procedure Calcium Electrolytes Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2766644</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C331:C464:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Calcium Electrolytes Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C331</PREFERRED_NAME>
            <LONG_NAME>Calcium</LONG_NAME>
            <CON_ID>2204986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C464</PREFERRED_NAME>
            <LONG_NAME>Electrolytes</LONG_NAME>
            <CON_ID>2202615</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2630714</PublicId>
      <PreferredName>CA_LAB_UNSPEC_VAL</PreferredName>
      <PreferredDefinition>the laboratory value for the blood content of calcium.</PreferredDefinition>
      <LongName>Calcium Lab Unspecified Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2586710</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Calcium</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Corrected calcium</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2670694</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Relapse</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Chronic Myelogenous Leukemia Relapse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1194">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2632154</PUBLICID>
    <LONGNAME>Dental Post Replacement Performed Specify</LONGNAME>
    <PREFERREDNAME>DNTLP_REPL_PER_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field related to replacement of a rod that a dentist has positioned and then cemented in the canal space in a tooth&#39;s root.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2624989</PublicId>
      <PreferredName>DNTLPOST_REPL_PERF</PreferredName>
      <PreferredDefinition>information related to replacement of a rod that a dentist has positioned and then cemented in the canal space in a tooth&#39;s root.</PreferredDefinition>
      <LongName>Dental Post Replacement Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2624987</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66863</PreferredName>
        <Version>1</Version>
        <LongName>Dental Post</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66863</PREFERRED_NAME>
            <LONG_NAME>Dental Post</LONG_NAME>
            <CON_ID>2614400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2519832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53610:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Replacement Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53610</PREFERRED_NAME>
            <LONG_NAME>Replacement</LONG_NAME>
            <CON_ID>2504929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Endodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812087</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1195">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2638642</PUBLICID>
    <LONGNAME>Reference Object External Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2638580v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Something referred to; the object of a reference._Happening or arising or located outside or beyond some limits, or especially, some surface.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2638580</PublicId>
      <PreferredName>2638557v1.0:2422660v1.0</PreferredName>
      <PreferredDefinition>Something referred to; the object of a reference._Happening or arising or located outside or beyond some limits, or especially, some surface.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Reference Object External Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2638557</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48294</PreferredName>
        <Version>1</Version>
        <LongName>Reference Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2422660</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44280:C25364</PreferredName>
        <Version>1</Version>
        <LongName>External Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44280</PREFERRED_NAME>
            <LONG_NAME>External</LONG_NAME>
            <CON_ID>2422632</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Reference Object External Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Reference Object External Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2638539</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Reactome Database Sharing</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.reactome.cabig.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.reactome.cabig.domain.ReferenceEntity.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReferenceEntity:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1196">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2641819</PUBLICID>
    <LONGNAME>Experiment Run Identifier java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2640442v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:The act of testing or performing something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640442</PublicId>
      <PreferredName>2640415v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:The act of testing or performing something._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Experiment Run Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640415</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42790:C47911</PreferredName>
        <Version>1</Version>
        <LongName>Experiment Run</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47911</PREFERRED_NAME>
            <LONG_NAME>Run</LONG_NAME>
            <CON_ID>2422617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Experiment Run Identifier java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Experiment Run Identifier java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.ExperimentRun.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExperimentRun:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1197">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2641829</PUBLICID>
    <LONGNAME>Object Property Description Container Object Domain Uniform Resource Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2640451v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A named data value associated with an object.:A written or verbal account, representation, statement, or explanation of something.:An object that holds the values or locations of other objects._An area of knowledge considered as a discreet unit for some purpose.:A character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640451</PublicId>
      <PreferredName>2640417v1.0:2640392v1.0</PreferredName>
      <PreferredDefinition>A named data value associated with an object.:A written or verbal account, representation, statement, or explanation of something.:An object that holds the values or locations of other objects._An area of knowledge considered as a discreet unit for some purpose.:A character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL.</PreferredDefinition>
      <LongName>Object Property Description Container Object Domain Uniform Resource Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640417</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62498:C25365:C43446</PreferredName>
        <Version>1</Version>
        <LongName>Object Property Description Container Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62498</PREFERRED_NAME>
            <LONG_NAME>Computer Programming Object Property</LONG_NAME>
            <CON_ID>2640374</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43446</PREFERRED_NAME>
            <LONG_NAME>Container Object</LONG_NAME>
            <CON_ID>2236557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2640392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62289:C42778</PreferredName>
        <Version>1</Version>
        <LongName>Domain Uniform Resource Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62289</PREFERRED_NAME>
            <LONG_NAME>Domain</LONG_NAME>
            <CON_ID>2553135</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42778</PREFERRED_NAME>
            <LONG_NAME>Uniform Resource Identifier</LONG_NAME>
            <CON_ID>2236546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Object Property Description Container Object Domain Uniform Resource Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Object Property Description Container Object Domain Uniform Resource Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2640373</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LabKey CPAS Client API</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.labkey.cpas.client</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.labkey.cpas.client.DomainDescriptor.domainUri</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DomainDescriptor:domainUri</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1198">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2646311</PUBLICID>
    <LONGNAME>Kaposi Sarcoma Malignant Neoplasm Elevated Count</LONGNAME>
    <PREFERREDNAME>KS_MALIGNEO_ELEV_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the total number of raised or elevated malignant neoplasms (lesions) identified in Kaposi Sarcoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2640026</PublicId>
      <PreferredName>KS_MLIGNEO_ELEV_QTY</PreferredName>
      <PreferredDefinition>information relating to the quantity or number of elevated (raised) malignant neoplasms (lesions) in Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells).</PreferredDefinition>
      <LongName>Kaposi Sarcoma Malignant Neoplasm Elevated Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640017</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9087:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Kaposi Sarcoma Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9087</PREFERRED_NAME>
            <LONG_NAME>Kaposi Sarcoma</LONG_NAME>
            <CON_ID>2637488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2640024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25493:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Elevated Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25493</PREFERRED_NAME>
            <LONG_NAME>Elevated</LONG_NAME>
            <CON_ID>2203913</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018392</PublicId>
      <PreferredName>CT</PreferredName>
      <PreferredDefinition>The quantity of the specified item.</PreferredDefinition>
      <LongName>Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Number Raised Lesions</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Number Raised Lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1199">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2658084</PUBLICID>
    <LONGNAME>Biomarker Positively Stained Cell Result Code</LONGNAME>
    <PREFERREDNAME>BIOM_P_STN_C_RSLT_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The code used to represent the percentage value of positively staining cells value of the biomarker.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2186590</PublicId>
      <PreferredName>BIOM_TST_RSL</PreferredName>
      <PreferredDefinition>Reported result of testing to determine the presence or absence of a definite disease or of some substance in any of the fluids, tissues, or excretions of the body, or to determine the presence or degree of a psychological or behavioral trait. (from STED26)</PreferredDefinition>
      <LongName>Biomarker Test Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16342:C0039593</PreferredName>
        <Version>1</Version>
        <LongName>Biomarker Testing</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0039593</PREFERRED_NAME>
            <LONG_NAME>Testing</LONG_NAME>
            <CON_ID>2202956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177339</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Result</PreferredName>
        <Version>1</Version>
        <LongName>Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2658082</PublicId>
      <PreferredName>BIOM_P_STN_C_RSLT_CD</PreferredName>
      <PreferredDefinition>The code used to represent the percentage value of positively staining cells value of the biomarker.</PreferredDefinition>
      <LongName>Biomarker Positively Stained Cell Result Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2658081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16342:C25246:C841:C12508:C202</PreferredName>
        <Version>1</Version>
        <LongName>Biomarker Positive Stain Cell Result Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25246</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2202905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C841</PREFERRED_NAME>
            <LONG_NAME>Stain</LONG_NAME>
            <CON_ID>2202830</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>5-50%</VALUEMEANING>
          <MEANINGDESCRIPTION>5 to 50 percent postively stained cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2658217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>II</VALIDVALUE>
          <VALUEMEANING>Greater than 50.</VALUEMEANING>
          <MEANINGDESCRIPTION>Participated greater than 50 times.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>LESS THAN 5% OF CELLS OBSCURED</VALUEMEANING>
          <MEANINGDESCRIPTION>LESS THAN 5% OF CELLS OBSCURED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Result (Positively staining c</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Result (Positively staining cells)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1200">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2659313</PUBLICID>
    <LONGNAME>Lytic Lesion Present Count</LONGNAME>
    <PREFERREDNAME>LYT_LES_PRES_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>the number of bone lytic lesions identified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2196037</PublicId>
      <PreferredName>LYTIC_LES_PRES</PreferredName>
      <PreferredDefinition>information related to a lytic lesion being present.</PreferredDefinition>
      <LongName>Lytic Lesion Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640390</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C27963:C3824</PreferredName>
        <Version>1</Version>
        <LongName>Lytic Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27963</PREFERRED_NAME>
            <LONG_NAME>Lytic</LONG_NAME>
            <CON_ID>2615896</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2659314</PublicId>
      <PreferredName>LYT_LES_CT</PreferredName>
      <PreferredDefinition>To determine the number or amount of lytic lesions.</PreferredDefinition>
      <LongName>Lytic Lesion Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>18</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1-3</VALIDVALUE>
          <VALUEMEANING>1-3 lesions</VALUEMEANING>
          <MEANINGDESCRIPTION>1-3 lesions</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4-5</VALIDVALUE>
          <VALUEMEANING>4-5</VALUEMEANING>
          <MEANINGDESCRIPTION>4-5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2658173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6+</VALIDVALUE>
          <VALUEMEANING>6+</VALUEMEANING>
          <MEANINGDESCRIPTION>6 or more</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2658174</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>none</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteoporosis</VALIDVALUE>
          <VALUEMEANING>Osteoporosis</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of lytic lesions</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of lytic lesions</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811955</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1201">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2659867</PUBLICID>
    <LONGNAME>Breast Assessment Complete Indicator</LONGNAME>
    <PREFERREDNAME>BRST_ASSESS_COMP_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to signify whether or not a breast exam was done. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2659865</PublicId>
      <PreferredName>BRST_ASSESS_COMP</PreferredName>
      <PreferredDefinition>Final result of an evalution of the breast(s). [Manually-curated]</PreferredDefinition>
      <LongName>Breast Assessment Complete</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2659863</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Breast Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2405014</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25250</PreferredName>
        <Version>1</Version>
        <LongName>Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017177</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2179965</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Indicator</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Breast Exam Done?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Breast Exam Done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1202">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2661688</PUBLICID>
    <LONGNAME>Composite Sequence Summary Composite Sequence Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2661665v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A collection of Reporter or CompositeSequence Design Elements, annotated through the association to BioSequence. (caMAGE):A shortened version of a speech or written text, containing only the main points._A collection of Reporter or CompositeSequence Design Elements, annotated through the association to BioSequence. (caMAGE):A written or verbal account, representation, statement, or explanation of something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2661665</PublicId>
      <PreferredName>2661641v1.0:2661639v1.0</PreferredName>
      <PreferredDefinition>A collection of Reporter or CompositeSequence Design Elements, annotated through the association to BioSequence. (caMAGE):A shortened version of a speech or written text, containing only the main points._A collection of Reporter or CompositeSequence Design Elements, annotated through the association to BioSequence. (caMAGE):A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Composite Sequence Summary Composite Sequence Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2661641</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43435:C42581</PreferredName>
        <Version>1</Version>
        <LongName>Composite Sequence Summary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43435</PREFERRED_NAME>
            <LONG_NAME>Composite Sequence</LONG_NAME>
            <CON_ID>2236615</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42581</PREFERRED_NAME>
            <LONG_NAME>Summary</LONG_NAME>
            <CON_ID>2203701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2661639</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43435:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Composite Sequence Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43435</PREFERRED_NAME>
            <LONG_NAME>Composite Sequence</LONG_NAME>
            <CON_ID>2236615</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Composite Sequence Summary Composite Sequence Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Composite Sequence Summary Composite Sequence Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2661628</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caFE Server</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.fe</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000308</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CompositeSequenceSummary:compositeSequenceDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.fe.CompositeSequenceSummary.compositeSequenceDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1203">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2663019</PUBLICID>
    <LONGNAME>Bronchoscopy Biopsy Reviewer Result Number Code</LONGNAME>
    <PREFERREDNAME>BRON_BX_R_RST_NUM_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>The numberical code used to represent the findings of a bronchoscopy biopsy recorded from a person with a responsibility for examining the specimens.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2662995</PublicId>
      <PreferredName>BROCH_BX_RVWR</PreferredName>
      <PreferredDefinition>Information related to a person with a responsibility for examining specimens from a procedure in which a thin, lighted tube is inserted through the nose or mouth. This allows examination of the inside of the trachea and bronchi (air passages that lead to the lung), as well as the lung and making sure that it is adequate, accurate, or correct.</PreferredDefinition>
      <LongName>Bronchoscopy Biopsy Reviewer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2662992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16366</PreferredName>
        <Version>1</Version>
        <LongName>Bronchoscopy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16366</PREFERRED_NAME>
            <LONG_NAME>Bronchoscopy</LONG_NAME>
            <CON_ID>2202694</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2662993</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15189:C54634</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy Reviewer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54634</PREFERRED_NAME>
            <LONG_NAME>Reviewer</LONG_NAME>
            <CON_ID>2626289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2663004</PublicId>
      <PreferredName>BRON_BX_RSLT_NUM_CD</PreferredName>
      <PreferredDefinition>The number code used to represent the findings of a bronchoscopy biopsy.</PreferredDefinition>
      <LongName>Bronchoscopy Biopsy Result Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208104</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Not applicable (Reviewer 3 Use Only)</VALUEMEANING>
          <MEANINGDESCRIPTION>Not applicable (Reviewer 3 Use Only)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Invasive carcinoma (not eligible) (grade 5)</VALUEMEANING>
          <MEANINGDESCRIPTION>Invasive carcinoma (not eligible) (grade 5)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663006</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Carcinoma in situ (not eligible) (grade 4)</VALUEMEANING>
          <MEANINGDESCRIPTION>Carcinoma in situ (not eligible) (grade 4)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663007</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Severe dysplasia (grade 3)</VALUEMEANING>
          <MEANINGDESCRIPTION>Severe dysplasia (grade 3)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663008</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate dysplasia (grade 2)</VALUEMEANING>
          <MEANINGDESCRIPTION>Moderate dysplasia (grade 2)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mild dysplasia (grade 1)</VALUEMEANING>
          <MEANINGDESCRIPTION>Mild dysplasia (grade 1)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2663010</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Normal, basal cell hyperplasia, or metaplasia</VALUEMEANING>
          <MEANINGDESCRIPTION>Normal, basal cell hyperplasia, or metaplasia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579308</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bronchoscopy Biopsy Result: R</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bronchoscopy Biopsy Result: Reviewer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1204">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2668607</PUBLICID>
    <LONGNAME>Anxiety Acute Distress Person Quality of Life Assessment Scale</LONGNAME>
    <PREFERREDNAME>A_A_D_PRS_QOLA_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale relating to whether a person has sudden feelings of panic or is easily startled.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2668571</PublicId>
      <PreferredName>ANX_AC_DIS_PERS_QOLA</PreferredName>
      <PreferredDefinition>information relating to the anxiety (apprehension of danger and dread) and acute distress (extreme physical pain or psychological suffering having a rapid onset of symptoms with short duration) experienced by a person in a quality of life assessment (the subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life).</PreferredDefinition>
      <LongName>Anxiety Acute Distress Person Quality of Life Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2668569</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26696:C14140:C37942:C25190</PreferredName>
        <Version>1</Version>
        <LongName>Anxiety Acute Distress Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26696</PREFERRED_NAME>
            <LONG_NAME>Anxiety</LONG_NAME>
            <CON_ID>2206376</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14140</PREFERRED_NAME>
            <LONG_NAME>Acute</LONG_NAME>
            <CON_ID>2206371</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37942</PREFERRED_NAME>
            <LONG_NAME>Distress</LONG_NAME>
            <CON_ID>2667531</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2667463</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2668559</PublicId>
      <PreferredName>PERS_QOL_SCALE</PreferredName>
      <PreferredDefinition>the scale relating to the quality of life assessment of a person.</PreferredDefinition>
      <LongName>Person Quality of Life Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A great deal of the time</VALIDVALUE>
          <VALUEMEANING>A GREAT DEAL OF THE TIME</VALUEMEANING>
          <MEANINGDESCRIPTION>A GREAT DEAL OF THE TIME</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little, but it doesn&#39;t worry me</VALIDVALUE>
          <VALUEMEANING>A LITTLE, BUT IT DOESN&#39;T WORRY ME</VALUEMEANING>
          <MEANINGDESCRIPTION>A LITTLE, BUT IT DOESN&#39;T WORRY ME</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A lot of the time</VALIDVALUE>
          <VALUEMEANING>A LOT OF THE TIME</VALUEMEANING>
          <MEANINGDESCRIPTION>A LOT OF THE TIME</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>As much as I always could</VALIDVALUE>
          <VALUEMEANING>AS MUCH AS I ALWAYS COULD</VALUEMEANING>
          <MEANINGDESCRIPTION>AS MUCH AS I ALWAYS COULD</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>As much as I ever did</VALIDVALUE>
          <VALUEMEANING>AS MUCH AS I EVER DID</VALUEMEANING>
          <MEANINGDESCRIPTION>AS MUCH AS I EVER DID</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Definitely</VALIDVALUE>
          <VALUEMEANING>Definitely</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitely</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Definitely as much</VALIDVALUE>
          <VALUEMEANING>DEFINITELY AS MUCH</VALUEMEANING>
          <MEANINGDESCRIPTION>DEFINITELY AS MUCH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Definitely less than I used to</VALIDVALUE>
          <VALUEMEANING>DEFINITELY LESS THAN I USED TO</VALUEMEANING>
          <MEANINGDESCRIPTION>DEFINITELY LESS THAN I USED TO</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561678</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Definitely not so much now</VALIDVALUE>
          <VALUEMEANING>DEFINITELY NOT SO MUCH NOW</VALUEMEANING>
          <MEANINGDESCRIPTION>DEFINITELY NOT SO MUCH NOW</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>From time to time but not too often</VALIDVALUE>
          <VALUEMEANING>FROM TIME TO TIME BUT NOT TOO OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>FROM TIME TO TIME BUT NOT TOO OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>From time to time, occasionally</VALIDVALUE>
          <VALUEMEANING>FROM TIME TO TIME, OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>FROM TIME TO TIME, OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hardly at all</VALIDVALUE>
          <VALUEMEANING>HARDLY AT ALL</VALUEMEANING>
          <MEANINGDESCRIPTION>HARDLY AT ALL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I don&#39;t take so much care as I should</VALIDVALUE>
          <VALUEMEANING>I DON&#39;T TAKE SO MUCH CARE AS I SHOULD</VALUEMEANING>
          <MEANINGDESCRIPTION>I DON&#39;T TAKE SO MUCH CARE AS I SHOULD</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I may not take quite as much care</VALIDVALUE>
          <VALUEMEANING>I MAY NOT TAKE QUITE AS MUCH CARE</VALUEMEANING>
          <MEANINGDESCRIPTION>I MAY NOT TAKE QUITE AS MUCH CARE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561671</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I take just as much care as ever</VALIDVALUE>
          <VALUEMEANING>I TAKE JUST AS MUCH CARE AS EVER</VALUEMEANING>
          <MEANINGDESCRIPTION>I TAKE JUST AS MUCH CARE AS EVER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Most of the time</VALIDVALUE>
          <VALUEMEANING>Most of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nearly all the time</VALIDVALUE>
          <VALUEMEANING>NEARLY ALL THE TIME</VALUEMEANING>
          <MEANINGDESCRIPTION>NEARLY ALL THE TIME</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not often</VALIDVALUE>
          <VALUEMEANING>NOT OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not quite so much</VALIDVALUE>
          <VALUEMEANING>NOT QUITE SO MUCH</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT QUITE SO MUCH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561661</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not quite so much now</VALIDVALUE>
          <VALUEMEANING>NOT QUITE SO MUCH NOW</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT QUITE SO MUCH NOW</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not very much</VALIDVALUE>
          <VALUEMEANING>NOT VERY MUCH</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT VERY MUCH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not very often</VALIDVALUE>
          <VALUEMEANING>NOT VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Often</VALIDVALUE>
          <VALUEMEANING>OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Only a little</VALIDVALUE>
          <VALUEMEANING>ONLY A LITTLE</VALUEMEANING>
          <MEANINGDESCRIPTION>ONLY A LITTLE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Only occasionally</VALIDVALUE>
          <VALUEMEANING>ONLY OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>ONLY OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite often</VALIDVALUE>
          <VALUEMEANING>QUITE OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>QUITE OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rather less than I used to</VALIDVALUE>
          <VALUEMEANING>RATHER LESS THAN I USED TO</VALUEMEANING>
          <MEANINGDESCRIPTION>RATHER LESS THAN I USED TO</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561677</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>SOMETIMES</VALUEMEANING>
          <MEANINGDESCRIPTION>SOMETIMES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Usually</VALIDVALUE>
          <VALUEMEANING>Usually</VALUEMEANING>
          <MEANINGDESCRIPTION>That which is considered customary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102843</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very definitely and quite badly</VALIDVALUE>
          <VALUEMEANING>VERY DEFINITELY AND QUITE BADLY</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY DEFINITELY AND QUITE BADLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much indeed</VALIDVALUE>
          <VALUEMEANING>VERY MUCH INDEED</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY MUCH INDEED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very often</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very often indeed</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN INDEED</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN INDEED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very seldom</VALIDVALUE>
          <VALUEMEANING>VERY SELDOM</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY SELDOM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, but not too badly</VALIDVALUE>
          <VALUEMEANING>YES, BUT NOT TOO BADLY</VALUEMEANING>
          <MEANINGDESCRIPTION>YES, BUT NOT TOO BADLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a lot</VALIDVALUE>
          <VALUEMEANING>QUITE A LOT</VALUEMEANING>
          <MEANINGDESCRIPTION>QUITE A LOT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the time</VALIDVALUE>
          <VALUEMEANING>None of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>None of the time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little of the time</VALIDVALUE>
          <VALUEMEANING>A little of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>A little of the time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>All of the time</VALIDVALUE>
          <VALUEMEANING>All of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>All of the time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Some of the time</VALIDVALUE>
          <VALUEMEANING>Some of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>Some of the time</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to do</VALIDVALUE>
          <VALUEMEANING>UNABLE To Do</VALUEMEANING>
          <MEANINGDESCRIPTION>UNABLE To Do (Health Activity Questionnaire)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very difficult</VALIDVALUE>
          <VALUEMEANING>Very difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Very difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat difficult</VALIDVALUE>
          <VALUEMEANING>Somewhat difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little difficult</VALIDVALUE>
          <VALUEMEANING>A little difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A little difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not difficult at all</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not difficult at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Once in a while</VALIDVALUE>
          <VALUEMEANING>Once in a while</VALUEMEANING>
          <MEANINGDESCRIPTION>Once in a while</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4325606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never/Rarely</VALIDVALUE>
          <VALUEMEANING>Never/Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Never/Rarely</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4325607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I was jumpy and easily startled</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I get sudden feelings of panic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I get sudden feelings of panic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1205">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669663</PUBLICID>
    <LONGNAME>Image Unique Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2669508v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any record of an imaging event whether physical or electronic._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669508</PublicId>
      <PreferredName>2423453v1.0:2231610v1.0</PreferredName>
      <PreferredDefinition>Any record of an imaging event whether physical or electronic._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Image Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2423453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179</PreferredName>
        <Version>1</Version>
        <LongName>Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45282:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45282</PREFERRED_NAME>
            <LONG_NAME>Unique</LONG_NAME>
            <CON_ID>2231550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Unique Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Unique Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614836</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Generic Image</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ivi.genericimage</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Image:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ivi.genericimage.Image.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1206">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669676</PUBLICID>
    <LONGNAME>Time Series Image Data Maximum Y-Dimension java.lang.Double</LONGNAME>
    <PREFERREDNAME>2669521v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points.:A group or succession of objects, substances, or events arranged in regular order in space or time, connected by a like relation, or forming a kind of chain.:Any record of an imaging event whether physical or electronic.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._The largest possible quantity or degree.:The magnitude of something in a vertical direction._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669521</PublicId>
      <PreferredName>2669392v1.0:2669371v1.0</PreferredName>
      <PreferredDefinition>The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points.:A group or succession of objects, substances, or events arranged in regular order in space or time, connected by a like relation, or forming a kind of chain.:Any record of an imaging event whether physical or electronic.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._The largest possible quantity or degree.:The magnitude of something in a vertical direction.</PreferredDefinition>
      <LongName>Time Series Image Data Maximum Y-Dimension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2669392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207:C25674:C48179:C25474</PreferredName>
        <Version>1</Version>
        <LongName>Time Series Image Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25674</PREFERRED_NAME>
            <LONG_NAME>Series</LONG_NAME>
            <CON_ID>2202620</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2669371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C45785</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Y-Dimension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45785</PREFERRED_NAME>
            <LONG_NAME>Y-Dimension</LONG_NAME>
            <CON_ID>2236518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Time Series Image Data Maximum Y-Dimension java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Time Series Image Data Maximum Y-Dimension java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614836</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Generic Image</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ivi.genericimage</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ivi.genericimage.TimeSeries.maximumY</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TimeSeries:maximumY</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1207">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669681</PUBLICID>
    <LONGNAME>Time Series Image Data Minimum Time java.lang.Double</LONGNAME>
    <PREFERREDNAME>2669526v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points.:A group or succession of objects, substances, or events arranged in regular order in space or time, connected by a like relation, or forming a kind of chain.:Any record of an imaging event whether physical or electronic.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._The smallest possible quantity.:The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669526</PublicId>
      <PreferredName>2669392v1.0:2669376v1.0</PreferredName>
      <PreferredDefinition>The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points.:A group or succession of objects, substances, or events arranged in regular order in space or time, connected by a like relation, or forming a kind of chain.:Any record of an imaging event whether physical or electronic.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._The smallest possible quantity.:The continuum of experience in which events pass from the future through the present to the past; a specific point in this continuum or the interval separating two points.</PreferredDefinition>
      <LongName>Time Series Image Data Minimum Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2669392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207:C25674:C48179:C25474</PreferredName>
        <Version>1</Version>
        <LongName>Time Series Image Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25674</PREFERRED_NAME>
            <LONG_NAME>Series</LONG_NAME>
            <CON_ID>2202620</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2669376</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25570:C25207</PreferredName>
        <Version>1</Version>
        <LongName>Minimum Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Time Series Image Data Minimum Time java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Time Series Image Data Minimum Time java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614836</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Generic Image</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ivi.genericimage</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TimeSeries:minimumT</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ivi.genericimage.TimeSeries.minimumT</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1208">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669704</PUBLICID>
    <LONGNAME>Region Index java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2669549v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An area or portion of something with more or less definite boundaries designed or specified according to some established biological, administrative, economic, demographic, etc. criteria._A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669549</PublicId>
      <PreferredName>2669394v1.0:2669356v1.0</PreferredName>
      <PreferredDefinition>An area or portion of something with more or less definite boundaries designed or specified according to some established biological, administrative, economic, demographic, etc. criteria._A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.</PreferredDefinition>
      <LongName>Region Index</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2669394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41129</PreferredName>
        <Version>1</Version>
        <LongName>Region</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41129</PREFERRED_NAME>
            <LONG_NAME>Region</LONG_NAME>
            <CON_ID>2422333</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2669356</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25390</PreferredName>
        <Version>1</Version>
        <LongName>Index</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25390</PREFERRED_NAME>
            <LONG_NAME>Index</LONG_NAME>
            <CON_ID>2203825</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Region Index java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Region Index java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614836</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Generic Image</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ivi.genericimage</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Tile:index</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ivi.genericimage.Tile.index</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1209">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2669796</PUBLICID>
    <LONGNAME>Laboratory Procedure Reticulocyte Result Percentage Value</LONGNAME>
    <PREFERREDNAME>LAB_RET_RSL_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the percentage value related to a reticulocyte (immature erythrocytes that have just undergone extrusion of their cell nucleus) hematology laboratory procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2669312</PublicId>
      <PreferredName>LAB_RETIC_RSLT</PreferredName>
      <PreferredDefinition>information relating to the result of the medical procedure that involves testing a sample of blood for reticulocytes, immature erythrocytes that have just undergone extrusion of their cell nucleus.</PreferredDefinition>
      <LongName>Laboratory Procedure Reticulocyte Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738918</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12528:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Reticulocyte Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12528</PREFERRED_NAME>
            <LONG_NAME>Reticulocyte</LONG_NAME>
            <CON_ID>2632390</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019101</PublicId>
      <PreferredName>HMT_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>a percentage for a hematologic laboratory value.</PreferredDefinition>
      <LongName>Blood Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Peripheral reticulocytes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Peripheral reticulocytes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Reticulocyte:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LAB_DIFF_reticulo_2dec_pct</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1210">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2674599</PUBLICID>
    <LONGNAME>Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder Transplantation Timepoint Remission Status</LONGNAME>
    <PREFERREDNAME>MDS_MPS_CMML_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the disease status of myelodysplastic syndrome, chronic myeloproliferative disorder or chronic myelomonocytic leukemia at the time of transplant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2676474</PublicId>
      <PreferredName>MDS_MPS_CMML_TRN_TM</PreferredName>
      <PreferredDefinition>A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The grafting of tissues from one individual to another or place to place within a single individual._A specific point in the time continuum, including those established relative to an event.</PreferredDefinition>
      <LongName>Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder Transplantation Timepoint</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2760526</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3247:C4345:C3178:C2991</PreferredName>
        <Version>1</Version>
        <LongName>MDS Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3247</PREFERRED_NAME>
            <LONG_NAME>Myelodysplastic Syndrome</LONG_NAME>
            <CON_ID>2202745</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4345</PREFERRED_NAME>
            <LONG_NAME>Myeloproliferative Neoplasm</LONG_NAME>
            <CON_ID>2590869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3178</PREFERRED_NAME>
            <LONG_NAME>Chronic Myelomonocytic Leukemia</LONG_NAME>
            <CON_ID>2204758</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2716694</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15342:C68568</PreferredName>
        <Version>1</Version>
        <LongName>Transplantation Timepoint</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68568</PREFERRED_NAME>
            <LONG_NAME>Timepoint</LONG_NAME>
            <CON_ID>2656619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2672741</PublicId>
      <PreferredName>MDS_MPS_CMML_STAT</PreferredName>
      <PreferredDefinition>A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001)_An abatement in intensity or degree (as in the manifestations of a disease)._A condition or state at a particular time.</PreferredDefinition>
      <LongName>Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Remission Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>51</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2760528</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3247:C4345:C3178:C18246:C2568</PreferredName>
        <Version>1</Version>
        <LongName>MDS Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Remission Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3247</PREFERRED_NAME>
            <LONG_NAME>Myelodysplastic Syndrome</LONG_NAME>
            <CON_ID>2202745</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4345</PREFERRED_NAME>
            <LONG_NAME>Myeloproliferative Neoplasm</LONG_NAME>
            <CON_ID>2590869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3178</PREFERRED_NAME>
            <LONG_NAME>Chronic Myelomonocytic Leukemia</LONG_NAME>
            <CON_ID>2204758</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18246</PREFERRED_NAME>
            <LONG_NAME>Remission</LONG_NAME>
            <CON_ID>2203779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prog / worse</VALIDVALUE>
          <VALUEMEANING>Progressive Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer that is increasing in scope or severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C35571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NR - no response</VALIDVALUE>
          <VALUEMEANING>Without Response</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): In medicine, an improvement related to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C50995, C25718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2683158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CR</VALIDVALUE>
          <VALUEMEANING>Complete Remission</VALUEMEANING>
          <MEANINGDESCRIPTION>The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treated with chemotherapy</VALIDVALUE>
          <VALUEMEANING>Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapse after complete response</VALIDVALUE>
          <VALUEMEANING>Relapse CR</VALUEMEANING>
          <MEANINGDESCRIPTION>The return of signs and symptoms of cancer after a period of improvement.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870, C18265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Supportive care or treatment without chemotherapy</VALIDVALUE>
          <VALUEMEANING>Supportive Care Without Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximise the benefits of treatment and to live as well as possible with the effects of the disease. There is considerable overlap between supportive and palliative care in terms of need.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15632, C25718, C15747</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2683161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improvement but no CR</VALIDVALUE>
          <VALUEMEANING>No CR Better</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.: In an improved condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71685, C4870, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2761979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the status of MDS/MP</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the status of MDS/MPS/CMML at transplantation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2674599</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = &quot;Myelodysplastic Syndrome&quot; AND PerformedDiagnosis &gt; PerformedSubstanceAdministration &gt; DefinedSubstranceAdministration.nameCode = &quot;Administer Hematopoietic Stem Cell Product {Transplantation}&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_mds_mps_cmml_stat</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:diseaseStatusCode</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1211">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2677434</PUBLICID>
    <LONGNAME>Trastuzumab Agent Second Dose Administered Ind-2</LONGNAME>
    <PREFERREDNAME>TRA_AGT_S_DO_ADM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether the second dose or amount of trastuzumab, a humanized recombinant monoclonal antibody directed against the HER2- receptor protein, was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2677412</PublicId>
      <PreferredName>TRAST_AGT_S_DOS_ADM</PreferredName>
      <PreferredDefinition>information related to the second dose or amount of trastuzumab, a humanized recombinant monoclonal antibody directed against the HER2- receptor protein, being administered.</PreferredDefinition>
      <LongName>Trastuzumab Agent Second Dose Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322168</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1647:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Trastuzumab Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1647</PREFERRED_NAME>
            <LONG_NAME>Trastuzumab</LONG_NAME>
            <CON_ID>2202865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2677410</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C25488:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Second Dose Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was dose 2 of trastuzumab adm</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was dose 2 of trastuzumab administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811835</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colorectal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811908</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1212">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2677704</PUBLICID>
    <LONGNAME>Value Domain Administered Item Data Type Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2677455v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of permissible values for a data element.:A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_An indication of the form that a value will have.  Examples include string, integer, and character.:A written or verbal account, representation, statement, or explanation of something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2677455</PublicId>
      <PreferredName>2231653v1.0:2677371v1.0</PreferredName>
      <PreferredDefinition>A set of permissible values for a data element.:A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_An indication of the form that a value will have.  Examples include string, integer, and character.:A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Value Domain Administered Item Data Type Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231653</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42748:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Value Domain Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42748</PREFERRED_NAME>
            <LONG_NAME>Value Domain</LONG_NAME>
            <CON_ID>2231559</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2677371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42645:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Data Type Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42645</PREFERRED_NAME>
            <LONG_NAME>Data Type</LONG_NAME>
            <CON_ID>2231560</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Value Domain Administered Item Data Type Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Value Domain Administered Item Data Type Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ValueDomain.datatypeDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ValueDomain:datatypeDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@datatypeDescription</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1213">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2677789</PUBLICID>
    <LONGNAME>Data Element Concept Administered Item Registration Status Administered Component Registration Status Name</LONGNAME>
    <PREFERREDNAME>2231948v3.0:2463561v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A concept that can be represented in the form of a data element, described independently of any particular representation. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The act of enrolling.:A condition or state at a particular time._A designation of the status in the registration life-cycle of an Administered Item.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>caCORE</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2231948</PublicId>
      <PreferredName>2231650v1.0:2231613v1.0</PreferredName>
      <PreferredDefinition>A concept that can be represented in the form of a data element, described independently of any particular representation. (ISO 11179):A registry item for which administrative information is recorded in an Administration Record. (ISO 11179)_The act of enrolling.:A condition or state at a particular time.</PreferredDefinition>
      <LongName>Data Element Concept Administered Item Registration Status</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2231650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41087:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Data Element Concept Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41087</PREFERRED_NAME>
            <LONG_NAME>Data Element Concept</LONG_NAME>
            <CON_ID>2231555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25646:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Registration Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2463561</PublicId>
      <PreferredName>AC_REG_STAT_NAME</PreferredName>
      <PreferredDefinition>A designation of the status in the registration life-cycle of an Administered Item.</PreferredDefinition>
      <LongName>Administered Component Registration Status Name</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2638254</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Status Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Application</VALIDVALUE>
          <VALUEMEANING>Application</VALUEMEANING>
          <MEANINGDESCRIPTION>A dosing measurement based on the application unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Candidate</VALIDVALUE>
          <VALUEMEANING>Candidate</VALUEMEANING>
          <MEANINGDESCRIPTION>Candidate</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proposed</VALIDVALUE>
          <VALUEMEANING>Proposed</VALUEMEANING>
          <MEANINGDESCRIPTION>Being reviewed for promotion to Candidate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Qualified</VALIDVALUE>
          <VALUEMEANING>Qualified</VALUEMEANING>
          <MEANINGDESCRIPTION>Met quality requirements, ready to be reviewed for Proposed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579367</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Standard</VALIDVALUE>
          <VALUEMEANING>Standard</VALUEMEANING>
          <MEANINGDESCRIPTION>Recommended for usage by all contexts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Standardized Elsewhere</VALIDVALUE>
          <VALUEMEANING>Standardized Elsewhere</VALUEMEANING>
          <MEANINGDESCRIPTION>The Administered Component has been adopted for standard usage by a community outside of NCI.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Superceded</VALIDVALUE>
          <VALUEMEANING>Superceded</VALUEMEANING>
          <MEANINGDESCRIPTION>The Administered Component is no longer recommended for usage because it has been replaced by another Administered Component.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suspended</VALIDVALUE>
          <VALUEMEANING>Suspended status</VALUEMEANING>
          <MEANINGDESCRIPTION>The Administered Component has been considered for standard status in the past and was not selected for promotion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retired</VALIDVALUE>
          <VALUEMEANING>RETIRED</VALUEMEANING>
          <MEANINGDESCRIPTION>RETIRED</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-05-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Data Element Concept Administered Item Registration Status Administered Component Registration Status Name does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Data Element Concept Administered Item Registration Status Administered Component Registration Status Name does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000552</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2528431</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORE 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caDSR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>10000645</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DataElementConcept:registrationStatus</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.DataElementConcept.registrationStatus</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1214">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2678414</PUBLICID>
    <LONGNAME>Recurrent Disease Preoperative Chemotherapy Response java.lang.String</LONGNAME>
    <PREFERREDNAME>2678178v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The return of a disease after a period of remission._Relating to or occurring during the period immediately before a surgical operation.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, particularly, it refers to the variety of chemical-based agents employed to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.:In medicine, an improvement related to treatment._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2678178</PublicId>
      <PreferredName>2678101v1.0:2677961v1.0</PreferredName>
      <PreferredDefinition>The return of a disease after a period of remission._Relating to or occurring during the period immediately before a surgical operation.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, particularly, it refers to the variety of chemical-based agents employed to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.:In medicine, an improvement related to treatment.</PreferredDefinition>
      <LongName>Recurrent Disease Preoperative Chemotherapy Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2678101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38155</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2677961</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C15632:C50995</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Chemotherapy Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50995</PREFERRED_NAME>
            <LONG_NAME>Disease Response</LONG_NAME>
            <CON_ID>2459436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Recurrent Disease Preoperative Chemotherapy Response java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Recurrent Disease Preoperative Chemotherapy Response java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2677906</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CoCaNUT</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.princeton.cocanut.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.princeton.cocanut.domain.Recurrence.preOperationChemoResponse</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Recurrence:preOperationChemoResponse</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1215">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2678630</PUBLICID>
    <LONGNAME>Ribonucleic Acid Microarray Analysis Experiment Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2678387v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A nucleic acid molecule similar to DNA but containing ribose rather than deoxyribose. RNA is formed upon a DNA template. There are several classes of RNA molecules. They play crucial roles in protein synthesis and other cell activities. (MedicineNet.com):Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2678387</PublicId>
      <PreferredName>2678118v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>A nucleic acid molecule similar to DNA but containing ribose rather than deoxyribose. RNA is formed upon a DNA template. There are several classes of RNA molecules. They play crucial roles in protein synthesis and other cell activities. (MedicineNet.com):Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Ribonucleic Acid Microarray Analysis Experiment Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2678118</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C812:C18477:C42790</PreferredName>
        <Version>1</Version>
        <LongName>Ribonucleic Acid Microarray Analysis Experiment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C812</PREFERRED_NAME>
            <LONG_NAME>Ribonucleic Acid</LONG_NAME>
            <CON_ID>2222294</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18477</PREFERRED_NAME>
            <LONG_NAME>Microarray Analysis</LONG_NAME>
            <CON_ID>2557754</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Ribonucleic Acid Microarray Analysis Experiment Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Ribonucleic Acid Microarray Analysis Experiment Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2677906</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CoCaNUT</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.princeton.cocanut.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812737</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.princeton.cocanut.domain.RnaExperiment.comments</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RnaExperiment:comments</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1216">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2680980</PUBLICID>
    <LONGNAME>Post Donor Cellular Infusion Acute Graft Versus Host Disease Maximum Overall Grade</LONGNAME>
    <PREFERREDNAME>PO_DCI_AGVHD_OV_GR</PREFERREDNAME>
    <PREFERREDDEFINITION>Post; occuring after._A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The largest possible quantity or degree._Including everything._A position on a scale of intensity or amount or quality.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2680976</PublicId>
      <PreferredName>PO_DCI_AC_GVHD_MA_GR</PreferredName>
      <PreferredDefinition>Post; occuring after._A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The largest possible quantity or degree._A position on a scale of intensity or amount or quality.</PreferredDefinition>
      <LongName>Post Donor Cellular Infusion Acute Graft Versus Host Disease Maximum Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2793672</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C77273:C4980</PreferredName>
        <Version>1</Version>
        <LongName>Post Donor Cellular Infusion Acute Graft Versus Host Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77273</PREFERRED_NAME>
            <LONG_NAME>Donor Cellular Infusion</LONG_NAME>
            <CON_ID>2793536</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4980</PREFERRED_NAME>
            <LONG_NAME>Acute Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202363</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2512722</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C48309</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2680968</PublicId>
      <PreferredName>AGVHD_OVALL_GD</PreferredName>
      <PreferredDefinition>A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._Including everything._A position on a scale of intensity or amount or quality.</PreferredDefinition>
      <LongName>Acute Graft Versus Host Disease Overall Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>22</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2785783</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4980:C25605:C48309</PreferredName>
        <Version>1</Version>
        <LongName>Acute Graft Versus Host Disease Overall Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4980</PREFERRED_NAME>
            <LONG_NAME>Acute Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202363</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25605</PREFERRED_NAME>
            <LONG_NAME>Overall</LONG_NAME>
            <CON_ID>2203597</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Present, grade unknown</VALIDVALUE>
          <VALUEMEANING>AGVHD present, Grade unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>AGVHD present, severity unknown</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2685126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Severity unknown</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2685127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade 0</VALUEMEANING>
          <MEANINGDESCRIPTION>NO Degree of Organ Involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793630</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade  I</VALUEMEANING>
          <MEANINGDESCRIPTION>At least stage 1-2 skin, with no liver and no gut involvement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>II</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade  II</VALUEMEANING>
          <MEANINGDESCRIPTION>At least stage 3 skin OR stage 1 liver OR stage 1 gut.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>III</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade  III</VALUEMEANING>
          <MEANINGDESCRIPTION>At least stage 2-3 for liver or stage 2-4 for gut.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793633</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IV</VALIDVALUE>
          <VALUEMEANING>AGVHD Grade  IV</VALUEMEANING>
          <MEANINGDESCRIPTION>At least stage 4 skin, or stage 4 liver or lessor organ involvement with an extreme decrease in performance status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2793634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5035616</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Maximum grade of Acute Graft</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Maximum grade of Acute Graft Versus Host Disease after this DCI?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Maximum grade of acute graft versus host disease:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximum grade of acute graft versus host disease:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Journal article with Acute GVHD grades &quot;Bone Marrow Transplant 1995 Jun;15(6):825-8&quot;.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Journal article with Acute GVHD grades &quot;Bone Marrow Transplant 1995 Jun;15(6):825-8&quot;.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2680980</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedObservation &gt; PerformedClinicalInterpretation.value WHERE PerformedObservation &gt; AssessedResultRelationship &gt; PerformedDiagnosis.value = &quot;GVHD&quot; AND PerformedDiagnosis.diseaseStatusCode = &quot;Acute&quot; AND  PerformedObservation &gt; DefinedObservation.nameCode = &quot;assess grade&quot; AND PerformedClinicalInterpretation.value IS MAXIMUM AND PerformedObservation.dateRange IS GREATER THAN {infusion date}  {infusion date} is determined by: Subject &gt; PerformedSubstanceAdministration.dateRange WHERE PerformedSubstanceAdministration &gt; DefinedSubstanceAdministration.nameCode = &quot;Administer donor cellular infusion(DCI)&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2681516</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>New Content T Joshua</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Post_TED Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2681516</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>New Content T Joshua</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Data Element</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812950</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2450r1: Post-TED</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964925</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>post_ted_dci_agvhd_grd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalInterpretation:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1217">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2682052</PUBLICID>
    <LONGNAME>Neoadjuvant Therapy Follow-up Endocrine Therapy Administration End Date</LONGNAME>
    <PREFERREDNAME>NEO_J_FU_END_AD_E_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the end date of  endocrine therapy, treatment that adds, blocks, or removes hormones, was administered as treatment during follow-up to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2682019</PublicId>
      <PreferredName>FU_NEOADJ_ENDOTX_ADM</PreferredName>
      <PreferredDefinition>information related to the administration of endocrine therapy, treatment that adds, blocks, or removes hormones,  as treatment during follow-up to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.</PreferredDefinition>
      <LongName>Neoadjuvant Therapy Follow-up Endocrine Therapy Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2681997</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665:C16033</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539213</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15445:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Hormone Therapy Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15445</PREFERRED_NAME>
            <LONG_NAME>Hormone Therapy</LONG_NAME>
            <CON_ID>2202373</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188674</PublicId>
      <PreferredName>END_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event ended.</PreferredDefinition>
      <LongName>End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184285</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Treatment end date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Treatment end date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1218">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2685350</PUBLICID>
    <LONGNAME>Hospital Specific National Provider Identifier Facility Number Code</LONGNAME>
    <PREFERREDNAME>2685343v1.0:2645015v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>This field identifies the facility that originally accessioned the tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2685343</PublicId>
      <PreferredName>2685312v1.0:2685341v1.0</PreferredName>
      <PreferredDefinition>The field that identifies the facility that originally accessioned the tumor.</PreferredDefinition>
      <LongName>Hospital Specific National Provider Identifier Facility</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008527</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>RES_ORGS</PreferredName>
        <Version>1</Version>
        <LongName>Research Organizations</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16696:C38024</PreferredName>
        <Version>1</Version>
        <LongName>Hospital Specified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16696</PREFERRED_NAME>
            <LONG_NAME>Hospital</LONG_NAME>
            <CON_ID>2202656</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38024</PREFERRED_NAME>
            <LONG_NAME>Specified</LONG_NAME>
            <CON_ID>2211671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2685341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54633:C62574</PreferredName>
        <Version>1</Version>
        <LongName>National Provider Identifier Facility</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54633</PREFERRED_NAME>
            <LONG_NAME>National Provider Identifier</LONG_NAME>
            <CON_ID>2542148</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62574</PREFERRED_NAME>
            <LONG_NAME>Facility</LONG_NAME>
            <CON_ID>2542035</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2645015</PublicId>
      <PreferredName>2645015v1.0</PreferredName>
      <PreferredDefinition>A system for uniquely identifying all providers of health care services, supplies, and equipment. NPIs are assigned by the National Plan and Provider Enumeration System (NPPES) and are 10-position, all-numeric identification numbers that will identify a health care provider in standard transactions, such as health care claims._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>National Provider Identifier Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>10</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2661793</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54633:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>National Provider Identifier Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54633</PREFERRED_NAME>
            <LONG_NAME>National Provider Identifier</LONG_NAME>
            <CON_ID>2542148</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Archive FIN</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Archive FIN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Archive FIN Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>NPI, a unique identification number for health care providers, is scheduled for 2007 implementation by the Centers for Medicare &amp; Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). When a facility starts to use the NPI codes, that information should be transmitted in the data item NPI--Archive FIN [3105].</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Note</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>CoC maintains the codes, including those for non-hospital sources of reporting.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103526</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103542</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HospitalSpecific11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242104</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3100</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ARCHIVE FIN</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1219">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2686163</PUBLICID>
    <LONGNAME>Neurologic Autoimmune Disease Other Classification Disease Diagnosis Other Specify</LONGNAME>
    <PREFERREDNAME>NEURO_AUTO_O_CLS_SPC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe another neurological autoimmune disorder classification.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2686161</PublicId>
      <PreferredName>NEURO_AUTO_O_CLS</PreferredName>
      <PreferredDefinition>Pertaining to nerves or the nervous system._A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.  It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). -- 2003_Different than the one(s) previously specified or mentioned._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Neurologic Autoimmune Disease Other Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2686159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25262:C2889</PreferredName>
        <Version>1</Version>
        <LongName>Neurologic Autoimmune Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25262</PREFERRED_NAME>
            <LONG_NAME>Neurologic</LONG_NAME>
            <CON_ID>2202770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2889</PREFERRED_NAME>
            <LONG_NAME>Autoimmune Disease</LONG_NAME>
            <CON_ID>2486854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2685062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Other Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019199</PublicId>
      <PreferredName>DZ_DX_O_SPEC</PreferredName>
      <PreferredDefinition>the text field to describe a disease diagnosis not otherwise listed. </PreferredDefinition>
      <LongName>Disease Diagnosis Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other autoimmune</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the other autoimmune neurological disorder:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2686163</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>&quot;PerformedDiagnosis.value(ANY=&gt;CD).originalText WHERE  PerformedDiagnosis.value(ANY=&gt;CD).nullFlavor = &quot;&quot;OTH&quot;&quot;&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other autoimmune neurological disorder:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other autoimmune neurological disorder:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other autoimmune neurological disorder:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other autoimmune neurological disorder:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pre_ted_neuro_oth_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1220">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2689925</PUBLICID>
    <LONGNAME>Condition Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2689871v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A state of being, such as a state of health or physical being._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2689871</PublicId>
      <PreferredName>2444517v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A state of being, such as a state of health or physical being._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Condition Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2444517</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25457</PreferredName>
        <Version>1</Version>
        <LongName>Condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Condition Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Condition Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2689825</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PathwayInteractionDatabase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PID</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812660</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000687</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2860261</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Condition:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PID.Condition.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.pathways.Condition.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1221">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2691126</PUBLICID>
    <LONGNAME>Treatment First Course Diagnostic Surgery Number Code</LONGNAME>
    <PREFERREDNAME>2691124v1.0:2653782v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2691124</PublicId>
      <PreferredName>2691043v1.0:2688042v1.0</PreferredName>
      <PreferredDefinition>Surgical procedure(s) performed in an effort to diagnose and/or stage disease.</PreferredDefinition>
      <LongName>Treatment First Course Diagnostic Surgery</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2691043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25509:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure First Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2688042</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25482:C17173</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Surgery</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25482</PREFERRED_NAME>
            <LONG_NAME>Diagnostic</LONG_NAME>
            <CON_ID>2202397</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17173</PREFERRED_NAME>
            <LONG_NAME>Surgery</LONG_NAME>
            <CON_ID>2203602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2653782</PublicId>
      <PreferredName>2653782v1.0</PreferredName>
      <PreferredDefinition>Characteristic or indicative of (e.g., a disease)._A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data. [Explanatory Comment:  See NAACCR Data Dicionary, Eleventh Edition, for coding instructions.]</PreferredDefinition>
      <LongName>Diagnostic Surgery Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2661648</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25482:C17173:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Surgery Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25482</PREFERRED_NAME>
            <LONG_NAME>Diagnostic</LONG_NAME>
            <CON_ID>2202397</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17173</PREFERRED_NAME>
            <LONG_NAME>Surgery</LONG_NAME>
            <CON_ID>2203602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>07</VALIDVALUE>
          <VALUEMEANING>A procedure was done, but the type of procedure is unknown.</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure was done, but the type of procedure is unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>06</VALIDVALUE>
          <VALUEMEANING>A bypass procedure was performed, and a biopsy of either the primary site or another site was done.</VALUEMEANING>
          <MEANINGDESCRIPTION>A bypass procedure was performed, and a biopsy of either the primary site or another site was done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3010112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>09</VALIDVALUE>
          <VALUEMEANING>No information about whether a diagnostic or staging procedure was performed.</VALUEMEANING>
          <MEANINGDESCRIPTION>No information about whether a diagnostic or staging procedure was performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>05</VALIDVALUE>
          <VALUEMEANING>An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.</VALUEMEANING>
          <MEANINGDESCRIPTION>An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>04</VALIDVALUE>
          <VALUEMEANING>A surgical procedure with a bypass was performed, but no biopsy was done.</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure with a bypass was performed, but no biopsy was done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>03</VALIDVALUE>
          <VALUEMEANING>A surgical exploratory only. The patient was not biopsied or treated.</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical exploratory only. The patient was not biopsied or treated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>02</VALIDVALUE>
          <VALUEMEANING>A biopsy (incisional, needle, or aspiration) was done of the primary site.</VALUEMEANING>
          <MEANINGDESCRIPTION>A biopsy (incisional, needle, or aspiration) was done of the primary site.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>01</VALIDVALUE>
          <VALUEMEANING>A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.</VALUEMEANING>
          <MEANINGDESCRIPTION>A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>00</VALIDVALUE>
          <VALUEMEANING>No surgical diagnostic or staging procedure was performed.</VALUEMEANING>
          <MEANINGDESCRIPTION>No surgical diagnostic or staging procedure was performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Summary Diagnostic/Staging</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RX Summary Diagnostic/Staging Procedure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Summ--DX\STG Proc Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>COC recommends this item for tumors diagnosed 1996 and forward. For tumors diagnosed before 1996, this item may have been converted, and tumors with surgery would have been converted to 09 in this field.  See also RX Summ--Surg Prim Site [1290] and RX Summ--Reconstruct 1st [1330].  For SEER and pre-1996 COC, see RX Summ--Surgery Type [1640].</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FORDS Manual, Revised 2009</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>See FORDS Manual for specifications of codes and data entry rules.</DocumentText>
        <URL>http://www.facs.org/cancer/coc/fords/2009/fords2009.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103535</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242111</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>1350</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Non Cancer-Directed Surgery (COC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX SUMM--DX/STG PROC </AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Summ--DX/Stg/Pall Proc</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Surgical Diagnostic and Staging Procedure (1996-2002)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1222">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2693363</PUBLICID>
    <LONGNAME>Radiation Therapy Radiation Field Administration Axis Measurement</LONGNAME>
    <PREFERREDNAME>RT_RTF_ADM_A_MSRMT</PREFERREDNAME>
    <PREFERREDDEFINITION>the measurement of the length of the axis of the radiation field.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2693304</PublicId>
      <PreferredName>RT_RADFIELD_ADM</PreferredName>
      <PreferredDefinition>information related to the radiation field or treatment area administered to an area of the body exposed to treatment of a disease by means of exposure of the target or the whole body to radiation.</PreferredDefinition>
      <LongName>Radiation Therapy Radiation Field Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2479684</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54648:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Field Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54648</PREFERRED_NAME>
            <LONG_NAME>Radiation Field</LONG_NAME>
            <CON_ID>2479357</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2470389</PublicId>
      <PreferredName>RADFIELD_AXIS_MSRMT</PreferredName>
      <PreferredDefinition>the first measurement used to calculate the longest dimensional measurement of a radiation field.</PreferredDefinition>
      <LongName>Radiation Field Axis Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2470388</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25154:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Axis Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25154</PREFERRED_NAME>
            <LONG_NAME>Axis</LONG_NAME>
            <CON_ID>2203858</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Field size</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Field size</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Metastatic Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000632</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1223">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2694987</PUBLICID>
    <LONGNAME>Treatment First Course Chemotherapy Intervention or Procedure Date</LONGNAME>
    <PREFERREDNAME>2694985v1.0:3027968v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Date of initiation of chemotherapy that is part of the first course of treatment.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2694985</PublicId>
      <PreferredName>2691043v1.0:2694983v1.0</PreferredName>
      <PreferredDefinition>Chemotherapy that is part of the first course of treatment.</PreferredDefinition>
      <LongName>Treatment First Course Chemotherapy Intervention or Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2691043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25509:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure First Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2694983</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C25218</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3027968</PublicId>
      <PreferredName>3027968v1.1</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population.  This is a general term that encompasses the medical, social, behavioral, and environmnetal acts that can have preventive, therapeutic, or palliative effects._a particular day specified as the time something has, or will, happen._</PreferredDefinition>
      <LongName>Chemotherapy Intervention or Procedure Date</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYYMMDD</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>3027967</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C25218:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Intervention or Procedure Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Date Chemotherapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>RX Date Chemotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RX Date--Chemo Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>See also RX Summ--Chemo [1390]. See page 97 for date format.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899849</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment1stCourse18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX DATE--CHEMO</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TX_FRS_CHEMO_DT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>1220</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Date Chemotherapy Started (COC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Date--Chemo</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Date Chemotherapy Started (CoC)</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RX Date Chemo</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1224">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2698009</PUBLICID>
    <LONGNAME>Edit Over-ride Case Completed Date</LONGNAME>
    <PREFERREDNAME>2698007v1.0:3017432v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>The date that the tumor report was complete and the case passed all edits that were applied.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2698007</PublicId>
      <PreferredName>2695315v1.0:2698005v1.0</PreferredName>
      <PreferredDefinition>The tumor report was complete and the case passed all edits that were applied.</PreferredDefinition>
      <LongName>Edit Over-ride Case Completed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DATA_SOURCE</PreferredName>
        <Version>1</Version>
        <LongName>Data Source</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2695315</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42682:C67529</PreferredName>
        <Version>1</Version>
        <LongName>Edit Action Override</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42682</PREFERRED_NAME>
            <LONG_NAME>Edit Action</LONG_NAME>
            <CON_ID>2222833</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67529</PREFERRED_NAME>
            <LONG_NAME>Override</LONG_NAME>
            <CON_ID>2653013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2698005</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49152:C25250</PreferredName>
        <Version>1</Version>
        <LongName>Case Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49152</PREFERRED_NAME>
            <LONG_NAME>Case</LONG_NAME>
            <CON_ID>2491895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3017432</PublicId>
      <PreferredName>3017432v1.1</PreferredName>
      <PreferredDefinition>A problem requiring investigation._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._a particular day specified as the time something has, or will, happen.</PreferredDefinition>
      <LongName>Case Completed Date</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DATA_SOURCE</PreferredName>
        <Version>1</Version>
        <LongName>Data Source</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYYMMDD</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3263558</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49152:C25250:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Case Complete Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49152</PREFERRED_NAME>
            <LONG_NAME>Case</LONG_NAME>
            <CON_ID>2491895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Case Completed</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date Case Completed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date Case Completed Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Definitions may vary among registries and software providers. This is a local use field. See page 97 for date format. Standard edits check that no dates are later than the current date.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EditOverrides16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EditOverrides18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464309</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2090</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DATE CASE COMPLETED</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Date Case Completed</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1225">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2698029</PUBLICID>
    <LONGNAME>Edit Over-ride Surveillance, Epidemiology, and End Results Program Coding System Original Number Code</LONGNAME>
    <PREFERREDNAME>2698027v1.0:2656693v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>This shows the SEER coding system best describing the way the majority of SEER items in the record were originally coded.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2698027</PublicId>
      <PreferredName>2695315v1.0:2698025v1.0</PreferredName>
      <PreferredDefinition>The SEER coding system best describing the way the majority of SEER items in the record were originally coded.</PreferredDefinition>
      <LongName>Edit Over-ride Surveillance, Epidemiology, and End Results Program Coding System Original</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DATA_SOURCE</PreferredName>
        <Version>1</Version>
        <LongName>Data Source</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2695315</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42682:C67529</PreferredName>
        <Version>1</Version>
        <LongName>Edit Action Override</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42682</PREFERRED_NAME>
            <LONG_NAME>Edit Action</LONG_NAME>
            <CON_ID>2222833</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67529</PREFERRED_NAME>
            <LONG_NAME>Override</LONG_NAME>
            <CON_ID>2653013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2698025</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15432:C45971:C25700:C25604</PreferredName>
        <Version>1</Version>
        <LongName>Surveillance, Epidemiology, and End Results Program Coding System Original</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15432</PREFERRED_NAME>
            <LONG_NAME>Surveillance, Epidemiology, and End Results Program</LONG_NAME>
            <CON_ID>2554150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45971</PREFERRED_NAME>
            <LONG_NAME>Coding</LONG_NAME>
            <CON_ID>2492757</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25604</PREFERRED_NAME>
            <LONG_NAME>Original</LONG_NAME>
            <CON_ID>2206332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2656693</PublicId>
      <PreferredName>2656693v3.0</PreferredName>
      <PreferredDefinition>A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From a brochure of the National Cancer Institute, NIH Publication No. 91-3074, October 1990)_The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis. (from Wikipedia)_a group of independent but interrelated elements comprising a unified whole._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Surveillance, Epidemiology, and End Results Program Coding System Number Code</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2662953</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15432:C45971:C25700:C25337:C2</PreferredName>
        <Version>1</Version>
        <LongName>Surveillance, Epidemiology, and End Results Program Coding System Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15432</PREFERRED_NAME>
            <LONG_NAME>Surveillance, Epidemiology, and End Results Program</LONG_NAME>
            <CON_ID>2554150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45971</PREFERRED_NAME>
            <LONG_NAME>Coding</LONG_NAME>
            <CON_ID>2492757</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>2004 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>2004 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>2003 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>2003 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>2007 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>2007 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>1998 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>1998 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>1992 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>1992 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>1989 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>1989 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Pre-1988 SEER Coding Manuals</VALUEMEANING>
          <MEANINGDESCRIPTION>Pre-1988 SEER Coding Manuals</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2656700</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No SEER coding</VALUEMEANING>
          <MEANINGDESCRIPTION>No SEER coding</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-06-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2656701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>1988 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>1988 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>January 2010 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>January 2010 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3281852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>January 2008 SEER Coding Manual</VALUEMEANING>
          <MEANINGDESCRIPTION>January 2008 SEER Coding Manual</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3281853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SEER Coding System Original</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>SEER Coding System Original</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SEER Coding and Staging Manuals</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Coding and Staging Manuals for the Surivellance Epidemiology and End Results Program</DocumentText>
        <URL>http://seer.cancer.gov/tools/codingmanuals/index.html</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EditOverrides16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899836</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EditOverrides18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464309</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2130</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SEER CODING SYS--ORIGINAL</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SEER Coding Sys--Original</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1226">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2698334</PUBLICID>
    <LONGNAME>Protocol Agent Dose Adverse Event Modification Dose Modification Status</LONGNAME>
    <PREFERREDNAME>PROT_DOS_AE_MOD_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to dose modification of a therapeutic agent (drug, intervention therapy) used in a clinical trial protocol due to any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding temporally associated with the use of synthetic or naturally-occurring chemicals for the treatment of diseases that may or may not be considered related to that medical treatment or procedure.:the dose modification status.</PREFERREDDEFINITION>
    <VERSION>4</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2698336</PublicId>
      <PreferredName>PROT_DOSE_AE_MOD</PreferredName>
      <PreferredDefinition>information related to dose modification of a therapeutic agent (drug, intervention therapy) used in a clinical trial protocol due to any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding temporally associated with the use of synthetic or naturally-occurring chemicals for the treatment of diseases that may or may not be considered related to that medical treatment or procedure.</PreferredDefinition>
      <LongName>Protocol Agent Dose Adverse Event Modification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2698333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41161:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41161</PREFERRED_NAME>
            <LONG_NAME>Protocol Agent</LONG_NAME>
            <CON_ID>2390873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2517432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331:C25572</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Modification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25572</PREFERRED_NAME>
            <LONG_NAME>Modification</LONG_NAME>
            <CON_ID>2203850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188246</PublicId>
      <PreferredName>DOSE_MOD_STAT</PreferredName>
      <PreferredDefinition>the dose modification status.</PreferredDefinition>
      <LongName>Dose Modification Status</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No dose modification</VALIDVALUE>
          <VALUEMEANING>No dose modification</VALUEMEANING>
          <MEANINGDESCRIPTION>No dose modification</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed</VALIDVALUE>
          <VALUEMEANING>Dose Delayed</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose of agent given later than scheduled.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed and reduced</VALIDVALUE>
          <VALUEMEANING>Dose delayed and reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._Made less in size or amount or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25640, C37912, C25476, C25488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-09-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571808</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug discontinued</VALIDVALUE>
          <VALUEMEANING>Drug discontinued</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug discontinued</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-09-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose escalated</VALIDVALUE>
          <VALUEMEANING>Dose escalated</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose escalated</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579542</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dosing error</VALIDVALUE>
          <VALUEMEANING>DOSING ERROR</VALUEMEANING>
          <MEANINGDESCRIPTION>DOSING ERROR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose held and reduced</VALIDVALUE>
          <VALUEMEANING>Dose Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose stopped</VALIDVALUE>
          <VALUEMEANING>Agent Stopped</VALUEMEANING>
          <MEANINGDESCRIPTION>Agent Stopped</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose or INR modfication</VALIDVALUE>
          <VALUEMEANING>Dose or INR modfication</VALUEMEANING>
          <MEANINGDESCRIPTION>A modification in the dose or international normalized ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2588573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose missed</VALIDVALUE>
          <VALUEMEANING>Dose missed</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose missed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2588574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug changed</VALIDVALUE>
          <VALUEMEANING>Drug changed</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug changed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2588575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IV rate decreased</VALIDVALUE>
          <VALUEMEANING>IV rate decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>the rate of intravenous administration of an agent was reduced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2698338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed/omitted</VALIDVALUE>
          <VALUEMEANING>Dose delayed/omitted</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose delayed/omitted</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2698341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug interrupted</VALIDVALUE>
          <VALUEMEANING>Drug Interrupted</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a medication schedule was modified by temporarily terminating a prescribed regimen of medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49501</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug permanently discontinued prior to completion</VALIDVALUE>
          <VALUEMEANING>Drug permanently discontinued prior to completion</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug permanently discontinued prior to completion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-02-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2833612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose omitted</VALIDVALUE>
          <VALUEMEANING>Dose Omitted</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a scheduled dose was not given.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C202338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2879744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Change of route</VALIDVALUE>
          <VALUEMEANING>Change of route</VALUEMEANING>
          <MEANINGDESCRIPTION>Change of route</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2879745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose increased (since last report)</VALIDVALUE>
          <VALUEMEANING>Dose increased (since last report)</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose increased (since last report)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3017658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose reduced (since last report)</VALIDVALUE>
          <VALUEMEANING>Dose reduced (since last report)</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose reduced (since last report)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3017659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agent not scheduled for this cycle</VALIDVALUE>
          <VALUEMEANING>Agent not scheduled for this cycle</VALUEMEANING>
          <MEANINGDESCRIPTION>Agent not scheduled for this cycle</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3017605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dosing not indicated per protocol</VALIDVALUE>
          <VALUEMEANING>Dosing not indicated per protocol</VALUEMEANING>
          <MEANINGDESCRIPTION>Dosing not indicated per protocol</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Re-escalated</VALIDVALUE>
          <VALUEMEANING>Dose re-escalated</VALUEMEANING>
          <MEANINGDESCRIPTION>A re-escalation in the prescribed amount of an agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Permanent Reduction</VALIDVALUE>
          <VALUEMEANING>Non-Permanent Reduction</VALUEMEANING>
          <MEANINGDESCRIPTION>A temporary reduction in the prescribed amount of an agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Permanent Reduction</VALIDVALUE>
          <VALUEMEANING>Permanent Reduction</VALUEMEANING>
          <MEANINGDESCRIPTION>A permanent reduction in the prescribed amount of an agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug re-escalation</VALIDVALUE>
          <VALUEMEANING>Drug re-escalation</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug re-escalation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug given too early</VALIDVALUE>
          <VALUEMEANING>Drug given too early</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug given too early</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug increased (error)</VALIDVALUE>
          <VALUEMEANING>Drug increased (error)</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug increased (error)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed and escalated</VALIDVALUE>
          <VALUEMEANING>Dose Escalation Delay</VALUEMEANING>
          <MEANINGDESCRIPTION>A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.: Delay; time during which some action is awaited; inactivity resulting in something being put off until a later time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25476, C107213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3946420</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treatment interrupted and reduced</VALIDVALUE>
          <VALUEMEANING>Treatment interrupted and reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment interrupted and reduced</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4187634</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2838911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Drug withdrawn</VALIDVALUE>
          <VALUEMEANING>Drug Withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a medication schedule was modified through termination of a prescribed regimen of medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2659978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed and drug discontinued</VALIDVALUE>
          <VALUEMEANING>Discontinued Delay</VALUEMEANING>
          <MEANINGDESCRIPTION>Discontinued; stopped permanently or temporarily.: Delay; time during which some action is awaited; inactivity resulting in something being put off until a later time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25476, C25484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3946421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose reduced and drug discontinued</VALIDVALUE>
          <VALUEMEANING>Discontinued Dose Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>Discontinued; stopped permanently or temporarily.: An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49505, C25484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3946422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose modified</VALIDVALUE>
          <VALUEMEANING>Dose modified</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose modified</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-04-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose discontinued</VALIDVALUE>
          <VALUEMEANING>Dose Discontinued</VALUEMEANING>
          <MEANINGDESCRIPTION>The amount of medicine taken, or radiation given, at one time.: Discontinued; stopped permanently or temporarily.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25484, C25488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2871585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treatment interrupted</VALIDVALUE>
          <VALUEMEANING>Treatment interrupted</VALUEMEANING>
          <MEANINGDESCRIPTION>Treatment interrupted</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4187635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose not changed</VALIDVALUE>
          <VALUEMEANING>Dose Not Changed</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a medication schedule was continued without modification.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2660003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose not given</VALIDVALUE>
          <VALUEMEANING>Dose not given</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose not given</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4415411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose interruption</VALIDVALUE>
          <VALUEMEANING>Dose interruption</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose interruption</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4470066</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed, reduced, and then permanently withdrawn</VALIDVALUE>
          <VALUEMEANING>Dose delayed, reduced, and then permanently withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose delayed, reduced, and then permanently withdrawn</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4470067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose delayed and then permanently withdrawn</VALIDVALUE>
          <VALUEMEANING>Dose delayed and then permanently withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose delayed and then permanently withdrawn</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4470068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Permanently withdrawn</VALIDVALUE>
          <VALUEMEANING>Permanently withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Permanently withdrawn</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4470069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose reduced, and then permanently withdrawn</VALIDVALUE>
          <VALUEMEANING>Dose reduced, and then permanently withdrawn</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose reduced, and then permanently withdrawn</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4484491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose is stable</VALIDVALUE>
          <VALUEMEANING>Stable Dose</VALUEMEANING>
          <MEANINGDESCRIPTION>Subject to little fluctuation; showing little if any change.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25488, C30103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4273135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT given BID</VALIDVALUE>
          <VALUEMEANING>Twice Daily Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times per day, at unspecified times.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15313, C64496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7760026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose Held</VALIDVALUE>
          <VALUEMEANING>Dose Held</VALUEMEANING>
          <MEANINGDESCRIPTION>Dose Held</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7765241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dose Reduced</VALIDVALUE>
          <VALUEMEANING>Dose Reduced</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Action taken regarding study therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Action taken for study drug</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000005</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pilot</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Localized Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000455</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adjuvant Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000523</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multiple Myeloma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000608</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced Melanoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000609</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1227">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708009</PUBLICID>
    <LONGNAME>Comparison Group Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2528962v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The examination of two or more people or things in order to detect similarities and differences.:Any number of entities (members) considered as a unit._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528962</PublicId>
      <PreferredName>2528758v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The examination of two or more people or things in order to detect similarities and differences.:Any number of entities (members) considered as a unit._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Comparison Group Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49156:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Comparison Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49156</PREFERRED_NAME>
            <LONG_NAME>Comparison</LONG_NAME>
            <CON_ID>2528577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Comparison Group Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Comparison Group Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.analysis</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000046</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.analysis.AnalysisGroup.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnalysisGroup:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1228">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2708062</PUBLICID>
    <LONGNAME>Variation Reporter Type java.lang.String</LONGNAME>
    <PREFERREDNAME>2707977v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An alteration or difference from a norm or standard.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._A subdivision of a particular kind of thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2707977</PublicId>
      <PreferredName>2528729v1.0:2223243v1.0</PreferredName>
      <PreferredDefinition>An alteration or difference from a norm or standard.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._A subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Variation Reporter Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528729</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25713:C44255</PreferredName>
        <Version>1</Version>
        <LongName>Variation Reporter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44255</PREFERRED_NAME>
            <LONG_NAME>Reporter Substance</LONG_NAME>
            <CON_ID>2236612</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Variation Reporter Type java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Variation Reporter Type java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2707890</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caIntegrator 2.1</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caintegrator.domain.annotation.snp</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000401</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caintegrator.domain.annotation.snp.VariationReporter.type</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VariationReporter:type</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1229">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711631</PUBLICID>
    <LONGNAME>Analysis Record Background Edit java.lang.Double</LONGNAME>
    <PREFERREDNAME>2710874v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:Anything (e.g., a document) providing permanent evidence of or information about past events._Existing conditions, especially those that would be confused with the phenomenon to be observed or measured.:The act of preparing by correcting, revising, or adapting._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2710874</PublicId>
      <PreferredName>2710717v1.0:2710337v1.0</PreferredName>
      <PreferredDefinition>Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:Anything (e.g., a document) providing permanent evidence of or information about past events._Existing conditions, especially those that would be confused with the phenomenon to be observed or measured.:The act of preparing by correcting, revising, or adapting.</PreferredDefinition>
      <LongName>Analysis Record Background Edit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710717</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25391:C25198</PreferredName>
        <Version>1</Version>
        <LongName>Analysis Record</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25198</PREFERRED_NAME>
            <LONG_NAME>Record</LONG_NAME>
            <CON_ID>2203775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45782:C70595</PreferredName>
        <Version>1</Version>
        <LongName>Background Edit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45782</PREFERRED_NAME>
            <LONG_NAME>Background</LONG_NAME>
            <CON_ID>2236603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70595</PREFERRED_NAME>
            <LONG_NAME>Edit</LONG_NAME>
            <CON_ID>2710232</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Analysis Record Background Edit java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Analysis Record Background Edit java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.AnalysisRecord.backgroundEdit</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnalysisRecord:backgroundEdit</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1230">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711768</PUBLICID>
    <LONGNAME>Specimen Experiment Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711011v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._In the scientific method, an experiment is a set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena. The experiment is a cornerstone of the empirical approach to knowledge. (from Wikipedia):One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711011</PublicId>
      <PreferredName>2241613v1.0:2224061v1.0</PreferredName>
      <PreferredDefinition>Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._In the scientific method, an experiment is a set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena. The experiment is a cornerstone of the empirical approach to knowledge. (from Wikipedia):One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Specimen Experiment Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42790:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Experiment Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Experiment Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Experiment Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Sample.experimentIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Sample:experimentIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1231">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711776</PUBLICID>
    <LONGNAME>Protein Microarray Microplate Reader Programming Parameter Protein Microarray Microplate Reader Experiment Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711019v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A value that is passed to a routine._A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711019</PublicId>
      <PreferredName>2710734v1.0:2710420v1.0</PreferredName>
      <PreferredDefinition>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A value that is passed to a routine._A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Protein Microarray Microplate Reader Programming Parameter Protein Microarray Microplate Reader Experiment Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710734</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25867:C70661:C48913</PreferredName>
        <Version>1</Version>
        <LongName>Protein Microarray Microplate Reader Programming Parameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25867</PREFERRED_NAME>
            <LONG_NAME>Protein Microarray</LONG_NAME>
            <CON_ID>2710229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70661</PREFERRED_NAME>
            <LONG_NAME>Microplate Reader</LONG_NAME>
            <CON_ID>2710228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48913</PREFERRED_NAME>
            <LONG_NAME>Programming Parameter</LONG_NAME>
            <CON_ID>2451932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25867:C70661:C42790:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Protein Microarray Microplate Reader Experiment Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25867</PREFERRED_NAME>
            <LONG_NAME>Protein Microarray</LONG_NAME>
            <CON_ID>2710229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70661</PREFERRED_NAME>
            <LONG_NAME>Microplate Reader</LONG_NAME>
            <CON_ID>2710228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Microarray Microplate Reader Programming Parameter Protein Microarray Microplate Reader Experiment Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Microarray Microplate Reader Programming Parameter Protein Microarray Microplate Reader Experiment Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.A2LP4Parameters.a2ExperimentIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>A2LP4Parameters:a2ExperimentIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1232">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711802</PUBLICID>
    <LONGNAME>Protein Microarray Microplate Reader Specimen Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711045v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711045</PublicId>
      <PreferredName>2710736v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.:An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Protein Microarray Microplate Reader Specimen Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710736</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25867:C70661:C19157</PreferredName>
        <Version>1</Version>
        <LongName>Protein Microarray Microplate Reader Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25867</PREFERRED_NAME>
            <LONG_NAME>Protein Microarray</LONG_NAME>
            <CON_ID>2710229</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70661</PREFERRED_NAME>
            <LONG_NAME>Microplate Reader</LONG_NAME>
            <CON_ID>2710228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protein Microarray Microplate Reader Specimen Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protein Microarray Microplate Reader Specimen Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.A2Sample.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>A2Sample:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1233">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2711890</PUBLICID>
    <LONGNAME>Contour Chain Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2711135v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outline of a part; the surface configuration._A series of objects linked, connected, or associated together in linear fashion (e.g., the assemblage of atoms, radicals and chemical groups in a chemical compound, or an assemblage of individual microorganisms).:A system, often of numbered categories, for representation of data._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711135</PublicId>
      <PreferredName>2710757v1.0:2710485v1.0</PreferredName>
      <PreferredDefinition>The outline of a part; the surface configuration._A series of objects linked, connected, or associated together in linear fashion (e.g., the assemblage of atoms, radicals and chemical groups in a chemical compound, or an assemblage of individual microorganisms).:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Contour Chain Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710757</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70749</PreferredName>
        <Version>1</Version>
        <LongName>Contour</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70749</PREFERRED_NAME>
            <LONG_NAME>Contour</LONG_NAME>
            <CON_ID>2710269</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710485</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41207:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Chain Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41207</PREFERRED_NAME>
            <LONG_NAME>Chain</LONG_NAME>
            <CON_ID>2203993</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Contour Chain Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Contour Chain Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Contour.chainCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Contour:chainCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1234">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2712135</PUBLICID>
    <LONGNAME>Differential In-Gel Electrophoresis Protein Protein Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2711380v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A form of gel electrophoresis where up to three different protein samples can be labeled with fluorescent dyes prior to two-dimensional electrophoresis in the same gel. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye and the imges are superimposed, allowing detection of changes in protein abundance between samples.:A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711380</PublicId>
      <PreferredName>2710786v1.0:2671580v1.0</PreferredName>
      <PreferredDefinition>A form of gel electrophoresis where up to three different protein samples can be labeled with fluorescent dyes prior to two-dimensional electrophoresis in the same gel. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye and the imges are superimposed, allowing detection of changes in protein abundance between samples.:A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Differential In-Gel Electrophoresis Protein Protein Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70654:C17021</PreferredName>
        <Version>1</Version>
        <LongName>Differential In-Gel Electrophoresis Protein</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70654</PREFERRED_NAME>
            <LONG_NAME>Differential In-Gel Electrophoresis</LONG_NAME>
            <CON_ID>2710244</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2671580</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17021:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Protein Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17021</PREFERRED_NAME>
            <LONG_NAME>Protein</LONG_NAME>
            <CON_ID>2202792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Differential In-Gel Electrophoresis Protein Protein Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Differential In-Gel Electrophoresis Protein Protein Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.ProteinDige.proteinName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ProteinDige:proteinName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1235">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2712210</PUBLICID>
    <LONGNAME>Experiment Second Dimension Liquid Chromatography Protocol First Dimension Liquid Chromatography Protocol Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2711455v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:Coming next after the first in position in space or time or degree or magnitude.:The magnitude of something in a particular direction, especially length or width or height.:A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.:A rule which guides how an activity should be performed._Preceding all others in time or space or degree.:The magnitude of something in a particular direction, especially length or width or height.:A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.:A rule which guides how an activity should be performed.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2711455</PublicId>
      <PreferredName>2710796v1.0:2710664v1.0</PreferredName>
      <PreferredDefinition>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena.:Coming next after the first in position in space or time or degree or magnitude.:The magnitude of something in a particular direction, especially length or width or height.:A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.:A rule which guides how an activity should be performed._Preceding all others in time or space or degree.:The magnitude of something in a particular direction, especially length or width or height.:A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.:A rule which guides how an activity should be performed.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Experiment Second Dimension Liquid Chromatography Protocol First Dimension Liquid Chromatography Protocol Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2710796</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2710796v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Experiment Second Dimension Liquid Chromatography Protocol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16435</PREFERRED_NAME>
            <LONG_NAME>Liquid Chromatography</LONG_NAME>
            <CON_ID>2710236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2710664</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2710664v1.0</PreferredName>
        <Version>1</Version>
        <LongName>First Dimension Liquid Chromatography Protocol Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16435</PREFERRED_NAME>
            <LONG_NAME>Liquid Chromatography</LONG_NAME>
            <CON_ID>2710236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Experiment Second Dimension Liquid Chromatography Protocol First Dimension Liquid Chromatography Protocol Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Experiment Second Dimension Liquid Chromatography Protocol First Dimension Liquid Chromatography Protocol Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ProteinDB</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812696</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2710221</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NHLBI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.jhu.icm.proteindb</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.jhu.icm.proteindb.Experiment2DLiquidChromatography2ndSetup.twoDimensionalLiquidChromatography1stSetupIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Experiment2DLiquidChromatography2ndSetup:twoDimensionalLiquidChromatography1stSetupIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1236">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2713352</PUBLICID>
    <LONGNAME>Diagnosis Text Imaging Examination Diagnostic Procedure Text</LONGNAME>
    <PREFERREDNAME>2713350v1.0:2644975v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text area for manual documentation from all X-rays, scan, and/or other imaging examinations that provide information about staging.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2713350</PublicId>
      <PreferredName>2704295v1.0:2713348v1.0</PreferredName>
      <PreferredDefinition>Manual documentation from all X-rays, scan, and/or other imaging examinations that provide information about staging.</PreferredDefinition>
      <LongName>Diagnosis Text Imaging Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2704295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2713348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17369:C25305</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technique Exam</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17369</PREFERRED_NAME>
            <LONG_NAME>Imaging Procedure</LONG_NAME>
            <CON_ID>2713347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2644975</PublicId>
      <PreferredName>2644975v1.0</PreferredName>
      <PreferredDefinition>Methods, procedures, and tests performed to diagnose disease, disordered function, or disability._Text; the words of something written.</PreferredDefinition>
      <LongName>Diagnostic Procedure Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>250</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3015291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18020:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Procedure Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18020</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Procedure</LONG_NAME>
            <CON_ID>2488312</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Text Diagnosis Xray Scan</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Text Diagnosis Xray Scan</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR, V 11.1 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.1 Data Standards and Data Dictionary (5/4/06)</DocumentText>
        <URL>http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103532</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3103548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TextDiagnosis11.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3242106</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2530</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TEXT--DX PROC--X-RAY/SCAN</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1237">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2714543</PUBLICID>
    <LONGNAME>Gynecologic Malignant Neoplasm Staging Anatomic Location</LONGNAME>
    <PREFERREDNAME>GYN_MALN_STAG_ANA_SIT</PREFERREDNAME>
    <PREFERREDDEFINITION>A structure or organ within the body in which cancer (atypical neoplastic cells) of the female reproductive organs might originate or to which cancer of the female reproductive organs might spread. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>caBIG:Cancer Biomedical Informatics Grid</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2010313</PublicId>
      <PreferredName>GYN_MALN_PROG_ANATLC</PreferredName>
      <PreferredDefinition>related to the spread of cancer (atypical neoplastic cells) originating in the female reproductive organs to other structures or organs within the body indicating advancement of disease.</PreferredDefinition>
      <LongName>Gynecologic Malignant Neoplasm Progression Anatomic Location</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2481123</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28016:C9305:C25331</PreferredName>
        <Version>1</Version>
        <LongName>Gynecologic Malignant Neoplasm Progression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28016</PREFERRED_NAME>
            <LONG_NAME>Gynecologic</LONG_NAME>
            <CON_ID>2202649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25331</PREFERRED_NAME>
            <LONG_NAME>Progression</LONG_NAME>
            <CON_ID>2202788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2442487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25421:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25421</PREFERRED_NAME>
            <LONG_NAME>Anatomic</LONG_NAME>
            <CON_ID>2202601</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2712496</PublicId>
      <PreferredName>GY_MALN_STAG_ANA_SIT</PreferredName>
      <PreferredDefinition>Text terms to represent site of cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina. [Manually-curated]</PreferredDefinition>
      <LongName>Gynecologic Malignant Neoplasm Staging Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>caBIG:Cancer Biomedical Informatics Grid</Origin>
      <Representation>
        <PublicId>2714628</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4913:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Female Reproductive System Neoplasm Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4913</PREFERRED_NAME>
            <LONG_NAME>Malignant Female Reproductive System Neoplasm</LONG_NAME>
            <CON_ID>2714627</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Other, specify</VALIDVALUE>
          <VALUEMEANING>Other Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Not otherwise specified.: A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph glands filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels. Also called a lymph node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2720403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Inguinal</VALIDVALUE>
          <VALUEMEANING>Inguinal lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>Inguinal lymph node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Paraaortic</VALIDVALUE>
          <VALUEMEANING>Paraaortic lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>Group of lymph nodes that lie in front of the lumbar vertebral bodies near the aorta.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2712497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Pelvic</VALIDVALUE>
          <VALUEMEANING>Pelvic lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>Pelvic lymph node</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Supraclavicular</VALIDVALUE>
          <VALUEMEANING>Supraclavicular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Lymph nodes located above the clavicle (collarbone).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fallopian tube</VALIDVALUE>
          <VALUEMEANING>Fallopian tube</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562643</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder</VALIDVALUE>
          <VALUEMEANING>Bladder</VALUEMEANING>
          <MEANINGDESCRIPTION>The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervix</VALIDVALUE>
          <VALUEMEANING>Cervix Uteri</VALUEMEANING>
          <MEANINGDESCRIPTION>(SER-viks) The lower, narrow end of the uterus that forms a canal between the uterus and vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571117</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CNS/Brain</VALIDVALUE>
          <VALUEMEANING>CNS/BRAIN</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the nervous system that consists of the brain, spinal cord, and meninges.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439, C37998, C12438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon</VALIDVALUE>
          <VALUEMEANING>Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endometrium</VALIDVALUE>
          <VALUEMEANING>Endometrium</VALUEMEANING>
          <MEANINGDESCRIPTION>The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovary</VALIDVALUE>
          <VALUEMEANING>Ovary</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parametrial Involvement</VALIDVALUE>
          <VALUEMEANING>PARAMETRIAL INVOLVEMENT</VALUEMEANING>
          <MEANINGDESCRIPTION>PARAMETRIAL INVOLVEMENT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneum</VALIDVALUE>
          <VALUEMEANING>Peritoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>(PAIR-ih-toe-NEE-um) The tissue that lines the abdominal wall and covers most of the organs in the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleura</VALIDVALUE>
          <VALUEMEANING>Pleura</VALUEMEANING>
          <MEANINGDESCRIPTION>(PLOOR-a) A thin layer of tissue covering the lungs and the wall of the chest cavity to protect and cushion the lungs. A small amount of fluid that acts as a lubricant allows the lungs to move smoothly in the chest cavity during breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleural Effusion</VALIDVALUE>
          <VALUEMEANING>Pleural effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Pleural effusion</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin</VALIDVALUE>
          <VALUEMEANING>Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterus</VALIDVALUE>
          <VALUEMEANING>Uterus</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - External iliac</VALIDVALUE>
          <VALUEMEANING>External Iliac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located along the external iliac artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) - Parenchymal</VALIDVALUE>
          <VALUEMEANING>Parenchyma Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C74601</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3536189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Site of Involvement</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Site of Involvement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1238">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2716088</PUBLICID>
    <LONGNAME>Diseases and Disorders Patient Self-Report Arthritis Diagnosis Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>DZ_PS_ARTH_DX_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no/unknown indicator for the person self-report of a diagnosis by a physician of arthritis, inflammation of a joint or a state characterized by inflammation of joints., as an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2716015</PublicId>
      <PreferredName>DAD_PSR_ARTH_DX</PreferredName>
      <PreferredDefinition>information related to the self-reported diagnosis by a physician of arthritis, inflammation of a joint or a state characterized by inflammation of joints., as an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PreferredDefinition>
      <LongName>Diseases and Disorders Patient Self-Report Arthritis Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2716013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C2883:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Arthritis Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2883</PREFERRED_NAME>
            <LONG_NAME>Arthritis</LONG_NAME>
            <CON_ID>2206374</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you ever been diagnosed</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you ever been diagnosed by your doctor with Arthritis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1239">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2716327</PUBLICID>
    <LONGNAME>Exon Microarray Reporter Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2716246v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2716246</PublicId>
      <PreferredName>2716122v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.:A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Exon Microarray Reporter Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2716122</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13231:C44282:C44255</PreferredName>
        <Version>1</Version>
        <LongName>Exon Microarray Reporter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13231</PREFERRED_NAME>
            <LONG_NAME>Exon</LONG_NAME>
            <CON_ID>2240634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44255</PREFERRED_NAME>
            <LONG_NAME>Reporter Substance</LONG_NAME>
            <CON_ID>2236612</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exon Microarray Reporter Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exon Microarray Reporter Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000536</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000541</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000542</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.ExonArrayReporter.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ExonArrayReporter:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1240">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2724866</PUBLICID>
    <LONGNAME>Participant Employment Status Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2724764v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Someone who takes part in an activity._The state of being engaged in an activity or service for wages or salary; the occupation for which you are paid.:A condition or state at a particular time.:A system, often of numbered categories, for representation of data._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2724764</PublicId>
      <PreferredName>2407061v1.0:2607591v1.0</PreferredName>
      <PreferredDefinition>Someone who takes part in an activity._The state of being engaged in an activity or service for wages or salary; the occupation for which you are paid.:A condition or state at a particular time.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Participant Employment Status Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867</PreferredName>
        <Version>1</Version>
        <LongName>Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607591</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25172:C25688:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Employment Status Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25172</PREFERRED_NAME>
            <LONG_NAME>Employed</LONG_NAME>
            <CON_ID>2202381</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Participant Employment Status Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Participant Employment Status Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2724612</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CTODS</PreferredName>
          <Version>0.53</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.ctom.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000404</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.ctom.domain.Participant.employmentStatusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant:employmentStatusCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1241">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2727140</PUBLICID>
    <LONGNAME>Experiment Study Design Description java.lang.String</LONGNAME>
    <PREFERREDNAME>2726796v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._A plan detailing how a study will be performed in order to represent the phenomenon under examination, to answer the research questions that have been asked, and defining the methods of data analysis. Study design is driven by research hypothesis being posed, study subject/population/sample available, logistics/resources: technology, support, networking, collaborative support, etc.:A written or verbal account, representation, statement, or explanation of something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2726796</PublicId>
      <PreferredName>2619601v1.0:2726685v1.0</PreferredName>
      <PreferredDefinition>A set of actions and observations, performed to verify or falsify a hypothesis or research a causal relationship between phenomena._A plan detailing how a study will be performed in order to represent the phenomenon under examination, to answer the research questions that have been asked, and defining the methods of data analysis. Study design is driven by research hypothesis being posed, study subject/population/sample available, logistics/resources: technology, support, networking, collaborative support, etc.:A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Experiment Study Design Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2619601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42790</PreferredName>
        <Version>1</Version>
        <LongName>Experiment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42790</PREFERRED_NAME>
            <LONG_NAME>Experiment</LONG_NAME>
            <CON_ID>2223979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2726685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15320:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Study Design Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15320</PREFERRED_NAME>
            <LONG_NAME>Study Design</LONG_NAME>
            <CON_ID>2203985</CON_ID>
            <DEFINITION_SOURCE>MSH2001</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Experiment Study Design Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Experiment Study Design Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2812740</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000572</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2812747</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2726654</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray 2.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2813048</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2831137</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORRECT</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caCORRECT Grid Services 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2832871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2831137</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caCORRECT</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000575</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2839153</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>omniBiomarker</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>omniBiomarker Grid Services 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2839155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2839153</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>omniBiomarker</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000576</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.project.Experiment.experimentDesignDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Experiment:experimentDesignDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.project.Experiment.designDescription</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Experiment:designDescription</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1242">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2730798</PUBLICID>
    <LONGNAME>Laboratory Procedure Post  Thaw Colony Forming Unit  Outcome Total Colony Count</LONGNAME>
    <PREFERREDNAME>CFU_PST_THW_LB_TL_CT</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric value related to the total number of colony-forming unit colonies counted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2729207</PublicId>
      <PreferredName>LAB_P_SP_TH_CFU_RSLT</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Happening at a time subsequent to a reference time; later in time or order._The process whereby heat changes something from a solid to a liquid._A unit of measurement of viable bacterial numbers. Colony forming unit (CFU) is the minimum number of separable cells, which is able to produce a visible colony of progeny. The examples of CFU usage include but not limited to the measurement of the number of bacteria present in the environment, and the ability of stem cells to produce cells of single or multiple lineages._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure Post  Thaw Colony Forming Unit  Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2785802</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C48165:C68742:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Post Thaw Colony Forming Unit Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48165</PREFERRED_NAME>
            <LONG_NAME>Thaw</LONG_NAME>
            <CON_ID>2513278</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68742</PREFERRED_NAME>
            <LONG_NAME>Colony Forming Unit</LONG_NAME>
            <CON_ID>2729203</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2730796</PublicId>
      <PreferredName>TL_CLN_CNT</PreferredName>
      <PreferredDefinition>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A group of cells or organisms grown from a single progenitor._To determine the number or amount of something; the result of this activity x 10E5 . [manual entered]</PreferredDefinition>
      <LongName>Total Colony Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>9999.9</DisplayFormat>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2730795</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C61515:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Total Colony Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61515</PREFERRED_NAME>
            <LONG_NAME>Colony</LONG_NAME>
            <CON_ID>2619565</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>When the colony-forming units</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>When the colony-forming units (CFU) were assessed, what was the total number of colonies counted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total colonies per product</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Total colonies per product:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2730798</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value(ANY=&gt;REAL) WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Count  Total Colony Forming Unit&quot; AND DefinedObservation [total colony count] &gt; DefinedCompositionRelationship &gt; DefinedActivity [composite thaw process] &gt; DefinedCompositionRelationship &gt;DefinedActivity [composite product analysis process] &gt; DefinedCompositionRelationship &gt; DefinedActivity [overall composite HCT process]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2006r1: HSCT Infusion</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_an_cfu_ttl_rst</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1243">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2737364</PUBLICID>
    <LONGNAME>Lesion Lymph Node Recurrence Anatomic Site</LONGNAME>
    <PREFERREDNAME>LES_LN_RECUR_SITE</PREFERREDNAME>
    <PREFERREDDEFINITION>the anatomic site of the lymph node, lymphatic tissue that is surrounded by a capsule of connective tissue, that had a recurrence, return of signs or symptoms of a disease following a period of remission, of an area of abnormal tissue change.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2737363</PublicId>
      <PreferredName>LES_LN_RECUR</PreferredName>
      <PreferredDefinition>information related to the recurrence, return of signs or symptoms of a disease following a period of remission, of an area of abnormal tissue change in lymphatic tissue that is surrounded by a capsule of connective tissue.</PreferredDefinition>
      <LongName>Lesion Lymph Node Recurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2465192</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2737361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12745:C3352</PreferredName>
        <Version>1</Version>
        <LongName>Lymph Node Recurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3352</PREFERRED_NAME>
            <LONG_NAME>Recurrence</LONG_NAME>
            <CON_ID>2202848</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180752</PublicId>
      <PreferredName>LN_PROG_SITE</PreferredName>
      <PreferredDefinition>the site of lymph node progression.</PreferredDefinition>
      <LongName>Lymph Node Progression Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Intranodal recurrence</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811911</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Response</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Upper GI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1244">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2739077</PUBLICID>
    <LONGNAME>Third Cycle Consolidation Therapy Off Treatment Specify</LONGNAME>
    <PREFERREDNAME>TH_CYC_CON_OTX_SP</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify the reason a patient is not receiving cycle 3 or 4 consolidation therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2739064</PublicId>
      <PreferredName>TH_CYC_CONSTX_OTX</PreferredName>
      <PreferredDefinition>information related to the third cycle of consolidation therapy, chemotherapy treatments given after induction chemotherapy to further reduce the number of cancer cells, not being administered.</PreferredDefinition>
      <LongName>Third Cycle Consolidation Therapy Off Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2466082</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25260:C25472:C15679</PreferredName>
        <Version>1</Version>
        <LongName>Third Cycle Consolidation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25260</PREFERRED_NAME>
            <LONG_NAME>Third</LONG_NAME>
            <CON_ID>2206262</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15679</PREFERRED_NAME>
            <LONG_NAME>Consolidation Therapy</LONG_NAME>
            <CON_ID>2466081</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2679219</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25601</PreferredName>
        <Version>1</Version>
        <LongName>Off-Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019106</PublicId>
      <PreferredName>TX_OTX_RSN_SPEC</PreferredName>
      <PreferredDefinition>the free text field to specify a reason or event that caused a patient to be removed from a clinical protocol.</PreferredDefinition>
      <LongName>Treatment Off-Treatment Reason Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008554</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_OTX_RSNS</PreferredName>
        <Version>1</Version>
        <LongName>Treatment/Off-treatment Reasons</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other reason, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other reason, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1245">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2739418</PUBLICID>
    <LONGNAME>Specimen Not Collected Not Collected Reason</LONGNAME>
    <PREFERREDNAME>SPEC_N_COLL_RSN</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to a specimen not being collected._the explanation something was not collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2547631</PublicId>
      <PreferredName>SPEC_NOT_COLL</PreferredName>
      <PreferredDefinition>Information related to a specimen not being collected.</PreferredDefinition>
      <LongName>Specimen Not Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2480188</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25452</PreferredName>
        <Version>1</Version>
        <LongName>Not Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2739420</PublicId>
      <PreferredName>N_COLL_RSN</PreferredName>
      <PreferredDefinition>the explanation something was not collected.</PreferredDefinition>
      <LongName>Not Collected Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Institutional error</VALIDVALUE>
          <VALUEMEANING>INSTITUTION ERROR</VALUEMEANING>
          <MEANINGDESCRIPTION>INSTITUTION ERROR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient refusal</VALIDVALUE>
          <VALUEMEANING>PATIENT REFUSAL</VALUEMEANING>
          <MEANINGDESCRIPTION>PATIENT REFUSAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Administrative error</VALIDVALUE>
          <VALUEMEANING>Administration Error</VALUEMEANING>
          <MEANINGDESCRIPTION>Performing or possessing executive duties; acting as a supervisor or manager.: A discrepancy between a computed, observed, or measured value or condition and the true, specified, or theoretically correct value or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43369, C48905</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3536034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Selection error</VALIDVALUE>
          <VALUEMEANING>Choose Error</VALUEMEANING>
          <MEANINGDESCRIPTION>Select from a group.: A discrepancy between a computed, observed, or measured value or condition and the true, specified, or theoretically correct value or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43369, C48912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3536035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Can only obtain uncharged slides</VALIDVALUE>
          <VALUEMEANING>Can only obtain uncharged slides</VALUEMEANING>
          <MEANINGDESCRIPTION>Can only obtain uncharged slides</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Can only obtain charged slides</VALIDVALUE>
          <VALUEMEANING>Can only obtain charged slides</VALUEMEANING>
          <MEANINGDESCRIPTION>Can only obtain charged slides</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Form Q0 completed</VALIDVALUE>
          <VALUEMEANING>Form Therapeutic Procedure Complete</VALUEMEANING>
          <MEANINGDESCRIPTION>A printed or electronic document with spaces to be filled out.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25250, C49236, C19464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE>2015-05-18</PVENDDATE>
          <VMPUBLICID>3813713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient off-study</VALIDVALUE>
          <VALUEMEANING>Patient Off Study</VALUEMEANING>
          <MEANINGDESCRIPTION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: No longer participating in a study; not being followed and will not be retreated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29851, C16960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cannot obtain from outside site</VALIDVALUE>
          <VALUEMEANING>Cannot obtain from outside site</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot obtain from outside site</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Can only obtain OCT</VALIDVALUE>
          <VALUEMEANING>Single Tissue-Tek OCT Acquisition</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others; exclusive of anyone or anything else. : A solution of water soluble glycols and resins that provide a specimen support matrix for cryostat sectioning at temperatures of -10 degrees C and below.: The process by which something is acquired or obtained.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43384, C63523, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Submitted for other GOG study</VALIDVALUE>
          <VALUEMEANING>Submission Other Gynecologic Oncology Group Clinical Study</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of referring for judgment or consideration by others; the act of handing over something.: Different than the one(s) previously specified or mentioned.: The Gynecologic Oncology Group (GOG) is a non-profit NCI-supported organization headquartered in Philadelphia, PA, with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15206, C25521, C17649, C25695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE>2015-05-18</PVENDDATE>
          <VMPUBLICID>3813717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tried but could not collect</VALIDVALUE>
          <VALUEMEANING>Negation Success Collection</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Success; an event that accomplishes its intended purpose.: The act of gathering things together; having been brought together in one place.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25453, C25362, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-US site</VALIDVALUE>
          <VALUEMEANING>Negation United States Clinical Study Site</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (CIA World Factbook 2002): A healthcare organization, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70777, C17234, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient died</VALIDVALUE>
          <VALUEMEANING>Patient Death</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient Death</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Collected in wrong tube</VALIDVALUE>
          <VALUEMEANING>Negation Correct Tube Collection</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Free from error; especially conforming to fact or truth.: A hollow cylinder, especially one for holding or conveying liquids; anything shaped like such a hollow cylinder, e.g. an organic structure having the shape or function of a tube such as channel within a plant or animal body (e.g. fallopian tube).: The act of gathering things together; having been brought together in one place.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25453, C41277, C68815, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Insufficient tissue</VALIDVALUE>
          <VALUEMEANING>Inadequate tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Inadequate tissue</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2734581</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathology department will not release</VALIDVALUE>
          <VALUEMEANING>Laboratory or Pathology Department Negation Release</VALUEMEANING>
          <MEANINGDESCRIPTION>A facility responsible for various analyses on tissue samples.: An operation in which a term denies or inverts the meaning of another term or construction.: Having been made available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42882, C25594, C53551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Time point missed</VALIDVALUE>
          <VALUEMEANING>Missing Timepoint</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing; not able to be found.: A specific point in the time continuum, including those established relative to an event.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68568, C54031</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3813722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Submitted for legacy GOG study</VALIDVALUE>
          <VALUEMEANING>Submitted for legacy GOG study</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of referring for judgment or consideration by others; the act of handing over something.::1: A non-profit NCI-supported organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG.::2: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15206, C25521, C25695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-26</PVBEGINDATE>
          <PVENDDATE>2015-05-18</PVENDDATE>
          <VMPUBLICID>4178475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No recurrent metastatic disease</VALIDVALUE>
          <VALUEMEANING>No recurrent metastatic disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.::1: The return of a disease after a period of remission.::2: A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3261, C38155, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4178476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No recurrent primary disease</VALIDVALUE>
          <VALUEMEANING>No recurrent primary disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.::1: The return of a disease after a period of remission.::2: A tumor at the original site of origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8509, C38155, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4178477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No metastatic disease</VALIDVALUE>
          <VALUEMEANING>No metastatic disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.::1: A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3261, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4178478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No storage facility</VALIDVALUE>
          <VALUEMEANING>No storage facility</VALUEMEANING>
          <MEANINGDESCRIPTION>No storage facility</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4155046</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Specimen lost</VALIDVALUE>
          <VALUEMEANING>Specimen lost</VALUEMEANING>
          <MEANINGDESCRIPTION>Specimen lost</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2990419</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient withdrew consent</VALIDVALUE>
          <VALUEMEANING>Patient withdrew consent</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient withdrew consent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lost to follow-up</VALIDVALUE>
          <VALUEMEANING>Lost to follow-up</VALUEMEANING>
          <MEANINGDESCRIPTION>The loss or lack of continuation of subject participation after a study has officially closed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subject refused</VALIDVALUE>
          <VALUEMEANING>Subject refused</VALUEMEANING>
          <MEANINGDESCRIPTION>Subject refused</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4155047</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Specimen damaged</VALIDVALUE>
          <VALUEMEANING>Specimen damaged</VALUEMEANING>
          <MEANINGDESCRIPTION>Specimen damaged</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4155327</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Technical problems</VALIDVALUE>
          <VALUEMEANING>Technical problems</VALUEMEANING>
          <MEANINGDESCRIPTION>Technical problems</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4155328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patient did not consent</VALIDVALUE>
          <VALUEMEANING>Patient did not consent</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient did not consent</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4290617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Treatment Completion form completed</VALIDVALUE>
          <VALUEMEANING>Therapeutic Procedure Form Complete</VALUEMEANING>
          <MEANINGDESCRIPTION>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: A printed or electronic document with spaces to be filled out.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25250, C19464, C49236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4827305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Submitted for legacy study</VALIDVALUE>
          <VALUEMEANING>Submission Clinical Study</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of referring for judgment or consideration by others; the act of handing over something.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15206, C25695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4827306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Submission for other study</VALIDVALUE>
          <VALUEMEANING>Other Clinical Study Submission</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of referring for judgment or consideration by others; the act of handing over something.: Different than the one(s) previously specified or mentioned.: Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15206, C17649, C25695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4827307</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other tumor type submitted</VALIDVALUE>
          <VALUEMEANING>Other tumor type submitted</VALUEMEANING>
          <MEANINGDESCRIPTION>Other tumor type submitted</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-09-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6436722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If not collected, specify rea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If not collected, specify reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Reason not obtained</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Reason specimen not available</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Not collected reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If consented but not collected, specify reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF_Text_4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Reason sample not collected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If No, please specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If not obtained, why?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AML Prev Untreated</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811784</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PBTC-042</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4254119</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>10000103</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_N_COLL_RSN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SPEC_N_COLL_RSN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1246">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2742647</PUBLICID>
    <LONGNAME>Stoma Quality of Life Olfaction Assessment Scale</LONGNAME>
    <PREFERREDNAME>ST_QOL_OLF_ASS_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale to evaluate a person&#39;s odor, the sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form, as part of the subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life following a surgical procedure that created an opening from an area inside the body to the outside.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2741815</PublicId>
      <PreferredName>ST_QOL_OLF_ASS</PreferredName>
      <PreferredDefinition>information related to the evaluation of a person&#39;s odor, the sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form, as part of the subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life following a surgical procedure that created an opening from an area inside the body to the outside.</PreferredDefinition>
      <LongName>Stoma Quality of Life Olfaction Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2741553</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13345:C17047</PreferredName>
        <Version>1</Version>
        <LongName>Stoma Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13345</PREFERRED_NAME>
            <LONG_NAME>Stoma</LONG_NAME>
            <CON_ID>2719328</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2741813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17139:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Olfaction Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17139</PREFERRED_NAME>
            <LONG_NAME>Olfaction</LONG_NAME>
            <CON_ID>2741812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2742555</PublicId>
      <PreferredName>ST_QOL_SC</PreferredName>
      <PreferredDefinition>an ordered reference for the quality of life measure.</PreferredDefinition>
      <LongName>Stoma Quality of Life Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>45</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly agree</VALIDVALUE>
          <VALUEMEANING>STRONGLY AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disagree</VALIDVALUE>
          <VALUEMEANING>DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561597</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly disagree</VALIDVALUE>
          <VALUEMEANING>STRONGLY DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Agree</VALIDVALUE>
          <VALUEMEANING>AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neither</VALIDVALUE>
          <VALUEMEANING>Neither</VALUEMEANING>
          <MEANINGDESCRIPTION>Neither</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>I NEVER had an erection when I wanted one </VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seldom</VALIDVALUE>
          <VALUEMEANING>Seldom</VALUEMEANING>
          <MEANINGDESCRIPTION>Seldom</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2734612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frequently</VALIDVALUE>
          <VALUEMEANING>Frequently</VALUEMEANING>
          <MEANINGDESCRIPTION>Frequently</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Improved my quality of life</VALIDVALUE>
          <VALUEMEANING>Improved my quality of life</VALUEMEANING>
          <MEANINGDESCRIPTION>Improved my quality of life</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2742720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Made my quality of life worse</VALIDVALUE>
          <VALUEMEANING>Made my quality of life worse</VALUEMEANING>
          <MEANINGDESCRIPTION>Made my quality of life worse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2742721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No effect on my quality of life</VALIDVALUE>
          <VALUEMEANING>No effect on my quality of life</VALUEMEANING>
          <MEANINGDESCRIPTION>No effect on my quality of life</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2742722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-04-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have problems with odor</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have problems with odor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were you afraid that other people would be able to smell your stools</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1247">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2744993</PUBLICID>
    <LONGNAME>Adverse Event Onset Date</LONGNAME>
    <PREFERREDNAME>AE_ONSET_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which the adverse event was first evident.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>caBIG:Cancer Biomedical Informatics Grid</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012524</PublicId>
      <PreferredName>AE_ONSET_DT</PreferredName>
      <PreferredDefinition>Start or onset date of an adverse event.</PreferredDefinition>
      <LongName>Adverse Event Onset Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2184272</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Adverse Event</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207409</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25279:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Onset Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25279</PREFERRED_NAME>
            <LONG_NAME>Onset</LONG_NAME>
            <CON_ID>2202391</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183138</PublicId>
      <PreferredName>ALPHA_DVG_DT</PreferredName>
      <PreferredDefinition>Oracle&#39;s Alpha Discrete Value Group for a date field.</PreferredDefinition>
      <LongName>Alpha DVG Date</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>Date Alpha DVG</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AE Start Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>AE Start Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Conditional NCI Standard CRF Question</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>There are business rules to indicate situations under which this element should be used on a CRF.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCI Standard CRF Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse Event Onset Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Event Onset Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OHSU Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of Onset</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event onset date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse Event Onset Date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Onset Date</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Onset Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Ticket number:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Start Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Reaction onset date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Adverse event onset date:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Adverse event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Adverse event onset date:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Adverse event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Ocular toxicity adverse event onset date:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate Reuse</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2992453</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859992</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3194026</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>KAI Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812550</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3194026</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>KAI Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000679</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2012-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3694151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896537</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3896538</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2013-00-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4111771</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4188651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261112</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-01-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280811</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-04</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280815</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2014-03-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2013-02-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5416571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5441476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5592146</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5612586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-07-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889176</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889177</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2017-09-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889178</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2016-08-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889179</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889180</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-08-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889185</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5889187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2017-09-02</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5981652</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2017-09-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>6005698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229O</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104892</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0286B</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4272090</PublicId>
          <ContextName>ONC SDC Project</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MedWatch Form FDA 3500A</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Event or Product Problem</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4382694</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000681</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4861354</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RAVE Integrations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Safety Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3135097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000678</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adverse Events</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000680</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>ONSETXX</AlternateName>
        <AlternateNameType>OID, Alliance</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_ONSET_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ONC SDC Project</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SDC Pilot Project</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_ONSET_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_ONSET_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AE_ONSET_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Adverse Event Start Date</AlternateName>
        <AlternateNameType>NINDS Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1248">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2746466</PUBLICID>
    <LONGNAME>Participant Prior Clinical Study Participation Ind-3</LONGNAME>
    <PREFERREDNAME>PART_PR_CL_ST_PT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown indicator that asks whether the participant was on a prior protocol with this group.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2746462</PublicId>
      <PreferredName>2407061v1.0:2746460v1.0</PreferredName>
      <PreferredDefinition>Information related to an individual who has taken part in an earlier clinical study with the registering group.</PreferredDefinition>
      <LongName>Participant Prior Clinical Study Participation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407061</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867</PreferredName>
        <Version>1</Version>
        <LongName>Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2746460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15206:C25608</PreferredName>
        <Version>1</Version>
        <LongName>Prior Clinical Study Participating</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25608</PREFERRED_NAME>
            <LONG_NAME>Participation</LONG_NAME>
            <CON_ID>2206339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2746464</PublicId>
      <PreferredName>2746464v1.0</PreferredName>
      <PreferredDefinition>The yes/no/unknown indicator that describes the response to a question about taking part in an activity.</PreferredDefinition>
      <LongName>Participation Ind-3</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2746463</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25608:C38148</PreferredName>
        <Version>1</Version>
        <LongName>Participating Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25608</PREFERRED_NAME>
            <LONG_NAME>Participation</LONG_NAME>
            <CON_ID>2206339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the participant on a prio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the participant on a prior study with this group?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient previously enrolled in a ECOG study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was patient previously enrolled and randomized on POG Study 9404, 9425 or 9426?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient previously enrolled on ANBL00B1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CALGB CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient previously enrolled in a CALGB study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the subject been previously enrolled in a Caris Biorepository collection?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the subject been previously enrolled in a Caris Biorepository collection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient previously enrolled in an ECOG study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient previously randomized to the present study</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EA1141 EC</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient previously enrolled in an ECOG-ACRIN study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CL</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient previously enrolled in an ECOG-ACRIN study (including EAY131)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCORP Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was patient previously enrolled?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient enrolled prior to starting study medication on A011502?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient enrolled on a sub-study associated with this protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient Previously Registered to A151216?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>OPEN Checklist</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was patient enrolled on EA4181?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the patient previously enrolled in A011502?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was patient previously enrolled on a COG ALL frontline therapeutic trial?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If the patient was enrolled on ANBL1531, did the patient undergo arm assignment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EAQ201</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient previously enrolled in ECOG-ACRIN study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient enroll in this study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EAQ201_2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Participant previously enrolled in ECOG-ACRIN study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient previously enrolled on the ComboMATCH Registration Protocol EAY191?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was patient enrolled on APEC14B1 prior to enrollment on this study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183712</PublicId>
          <ContextName>caCORE</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR Training</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Admin Training</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7067812</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Registration CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2552643</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Training Class Examples</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3637837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000006</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Registration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635325</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6921971</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDISC Aligned Collection CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Registration - CDISC Aligned</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>7318365</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>Has the patient previously enrolled in a CALGB study?</AlternateName>
        <AlternateNameType>Synonym</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PART_PR_CL_ST_PT_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PART_PR_CL_ST_PT_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPMH_QVAL_MHENROLL_ALL</AlternateName>
        <AlternateNameType>COG Form Element</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1249">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2746935</PUBLICID>
    <LONGNAME>Concomitant Medication Levetiracetam Administered Ind-2</LONGNAME>
    <PREFERREDNAME>CONMED_LEVET_AD_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to the concomitant medication levetriacetam (keppra), a long pyrrolidine with antiepileptic activity, being administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2746354</PublicId>
      <PreferredName>CONCOM_MEDS_LEV_ADM</PreferredName>
      <PreferredDefinition>information related to the concomitant medication levetriacetam (keppra), a long pyrrolidine with antiepileptic activity, being administered.</PreferredDefinition>
      <LongName>Concomitant Medication Levetiracetam Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206481</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C459</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2746352</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47581:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Levetiracetam Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47581</PREFERRED_NAME>
            <LONG_NAME>Levetiracetam</LONG_NAME>
            <CON_ID>2458019</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Keppra</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Keppra</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was Keppra (Levetiracetam) used as anti-seizure prophylaxis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1250">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2750394</PUBLICID>
    <LONGNAME>Text Annotation Font Opacity java.lang.String</LONGNAME>
    <PREFERREDNAME>2750254v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The words of something written.:An explanatory or critical comment that has been added to a text._A specific size and style of type within a type family.:The quality of being opaque to a degree; the degree to which something reduces the passage of light._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750254</PublicId>
      <PreferredName>2750191v1.0:2750160v1.0</PreferredName>
      <PreferredDefinition>The words of something written.:An explanatory or critical comment that has been added to a text._A specific size and style of type within a type family.:The quality of being opaque to a degree; the degree to which something reduces the passage of light.</PreferredDefinition>
      <LongName>Text Annotation Font Opacity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C44272</PreferredName>
        <Version>1</Version>
        <LongName>Text Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750160</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71594:C71596</PreferredName>
        <Version>1</Version>
        <LongName>Font Opacity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71594</PREFERRED_NAME>
            <LONG_NAME>Font</LONG_NAME>
            <CON_ID>2750133</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71596</PREFERRED_NAME>
            <LONG_NAME>Opacity</LONG_NAME>
            <CON_ID>2750136</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Text Annotation Font Opacity java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Text Annotation Font Opacity java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813012</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3079208</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 1.5</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.TextAnnotation.fontOpacity</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TextAnnotation:fontOpacity</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1251">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2750420</PUBLICID>
    <LONGNAME>Medical Image Description Characteristic Coding Scheme Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2750279v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any record of a medical imaging event whether physical or electronic.:A written or verbal account, representation, statement, or explanation of something.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis.:An elaborate and systematic plan of action.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750279</PublicId>
      <PreferredName>2750196v1.0:2750147v1.0</PreferredName>
      <PreferredDefinition>Any record of a medical imaging event whether physical or electronic.:A written or verbal account, representation, statement, or explanation of something.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis.:An elaborate and systematic plan of action.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Medical Image Description Characteristic Coding Scheme Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750196</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19477:C25365:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Medical Image Description Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750147</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45971:C25665:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Coding Scheme Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45971</PREFERRED_NAME>
            <LONG_NAME>Coding</LONG_NAME>
            <CON_ID>2492757</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25665</PREFERRED_NAME>
            <LONG_NAME>Scheme</LONG_NAME>
            <CON_ID>2203791</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Medical Image Description Characteristic Coding Scheme Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Medical Image Description Characteristic Coding Scheme Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813012</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3079208</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 1.5</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ImagingObservationCharacteristic.codingSchemeDesignator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagingObservationCharacteristic:codingSchemeDesignator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1252">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2750421</PUBLICID>
    <LONGNAME>Medical Image Description Characteristic Code Value java.lang.String</LONGNAME>
    <PREFERREDNAME>2750280v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any record of a medical imaging event whether physical or electronic.:A written or verbal account, representation, statement, or explanation of something.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._A system, often of numbered categories, used for representation of data.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750280</PublicId>
      <PreferredName>2750196v1.0:2750148v1.0</PreferredName>
      <PreferredDefinition>Any record of a medical imaging event whether physical or electronic.:A written or verbal account, representation, statement, or explanation of something.:The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._A system, often of numbered categories, used for representation of data.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.</PreferredDefinition>
      <LongName>Medical Image Description Characteristic Code Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750196</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19477:C25365:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Medical Image Description Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750148</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Code Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Medical Image Description Characteristic Code Value java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Medical Image Description Characteristic Code Value java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813012</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3079208</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 1.5</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ImagingObservationCharacteristic.codeValue</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagingObservationCharacteristic:codeValue</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1253">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2750644</PUBLICID>
    <LONGNAME>Electrocardiogram Report Sign Cardiac Dysrhythmia Indicator</LONGNAME>
    <PREFERREDNAME>EKG_REP_CARD_DYS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response to a question that asks whether the electrocardiogram report showed signs of cardiac dysrhythmia.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750642</PublicId>
      <PreferredName>EKG_REP_SGN_CARD_DYS</PreferredName>
      <PreferredDefinition>Information pertaining to a report of a domain utilized for the submission of information encompassing and representing data, vocabulary or records related to electrocardiogram and the evidence of disease having to do with the heart and any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation).</PreferredDefinition>
      <LongName>Electrocardiogram Report Sign Cardiac Dysrhythmia</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750638</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49626:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Electrocardiogram Domain Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49626</PREFERRED_NAME>
            <LONG_NAME>Electrocardiogram Domain</LONG_NAME>
            <CON_ID>2469059</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750640</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53458:C13306:C2881</PreferredName>
        <Version>1</Version>
        <LongName>Sign Cardiac Arrhythmia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53458</PREFERRED_NAME>
            <LONG_NAME>Sign</LONG_NAME>
            <CON_ID>2750639</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13306</PREFERRED_NAME>
            <LONG_NAME>Cardiac</LONG_NAME>
            <CON_ID>2204960</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2881</PREFERRED_NAME>
            <LONG_NAME>Arrhythmia</LONG_NAME>
            <CON_ID>2202296</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015873</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>A choice of Yes and No answer.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008509</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPORES</PreferredName>
        <Version>2.31</Version>
        <LongName>SPOREs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YES</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the EKG report show signs</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the EKG report show signs of cardiac dysrhythmia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pioglitazone - Oral Leukoplakia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812998</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1254">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2751609</PUBLICID>
    <LONGNAME>Measure Identifier Number</LONGNAME>
    <PREFERREDNAME>2528954v1.0:2815300v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The unique identifier for the measure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2528954</PublicId>
      <PreferredName>2236773v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Measurement is the determination of the size or magnitude of something.  It is also used ro refer to the result of this act._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Measurement Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236773</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2815300</PublicId>
      <PreferredName>2815300v1.0</PreferredName>
      <PreferredDefinition>Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Measure Identifier Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2815299</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209:C25364:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Measurement Identifier Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Measure Identifier</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Measure Identifier</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2983752</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>GEM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>com.westat.cagrid.gem.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000270</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PS&amp;CC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BehavioralMeasure:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>com.westat.cagrid.brpmeasures.domain.BehavioralMeasure.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>com.westat.cagrid.gem.domain.Measure.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Measure:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1255">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752679</PUBLICID>
    <LONGNAME>Generalized Laboratory Procedure Therapeutic Procedure Absolute Neutrophil Count Relationship java.lang.Character</LONGNAME>
    <PREFERREDNAME>2752163v1.0:2467195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Widespread, broadly dispersed, common.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The real number of white blood cells (WBCs) that are neutrophils. The ANC is derived by multiplying the WBC count times the percent of neutrophils in the differential WBC count; the percent of neutrophils consists of the segmented (fully mature neutrophils) + the bands (almost mature neutrophils). The normal range for the ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).:A state of connectedness between people, objects, or events; to be associated or connected with something._Generic value domain for a primitive java dataype that is a single character (16-bit Unicode character).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752163</PublicId>
      <PreferredName>2751998v1.0:2751807v1.0</PreferredName>
      <PreferredDefinition>Widespread, broadly dispersed, common.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The real number of white blood cells (WBCs) that are neutrophils. The ANC is derived by multiplying the WBC count times the percent of neutrophils in the differential WBC count; the percent of neutrophils consists of the segmented (fully mature neutrophils) + the bands (almost mature neutrophils). The normal range for the ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).:A state of connectedness between people, objects, or events; to be associated or connected with something.</PreferredDefinition>
      <LongName>Generalized Laboratory Procedure Therapeutic Procedure Absolute Neutrophil Count Relationship</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2751998</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63764:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Generalized Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63764</PREFERRED_NAME>
            <LONG_NAME>Generalized</LONG_NAME>
            <CON_ID>2547905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751807</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C63321:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Absolute Neutrophil Count Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63321</PREFERRED_NAME>
            <LONG_NAME>Absolute Neutrophil Count</LONG_NAME>
            <CON_ID>2531941</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2467195</PublicId>
      <PreferredName>java.lang.Character</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a single character (16-bit Unicode character).</PreferredDefinition>
      <LongName>java.lang.Character</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Character</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Generalized Laboratory Procedure Therapeutic Procedure Absolute Neutrophil Count Relationship java.lang.Character does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Generalized Laboratory Procedure Therapeutic Procedure Absolute Neutrophil Count Relationship java.lang.Character does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.LabGeneral.ANCTreatmentRelation</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LabGeneral:ANCTreatmentRelation</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1256">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752695</PUBLICID>
    <LONGNAME>Generalized Laboratory Procedure Hematocrit Grade java.lang.Character</LONGNAME>
    <PREFERREDNAME>2752179v1.0:2467195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Widespread, broadly dispersed, common.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.:A position on a scale of intensity or amount or quality._Generic value domain for a primitive java dataype that is a single character (16-bit Unicode character).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752179</PublicId>
      <PreferredName>2751998v1.0:2751820v1.0</PreferredName>
      <PreferredDefinition>Widespread, broadly dispersed, common.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.:A position on a scale of intensity or amount or quality.</PreferredDefinition>
      <LongName>Generalized Laboratory Procedure Hematocrit Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2751998</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63764:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Generalized Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63764</PREFERRED_NAME>
            <LONG_NAME>Generalized</LONG_NAME>
            <CON_ID>2547905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751820</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C64796:C48309</PreferredName>
        <Version>1</Version>
        <LongName>Hematocrit Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64796</PREFERRED_NAME>
            <LONG_NAME>Hematocrit Measurement</LONG_NAME>
            <CON_ID>2660103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2467195</PublicId>
      <PreferredName>java.lang.Character</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a single character (16-bit Unicode character).</PreferredDefinition>
      <LongName>java.lang.Character</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Character</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Generalized Laboratory Procedure Hematocrit Grade java.lang.Character does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Generalized Laboratory Procedure Hematocrit Grade java.lang.Character does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.LabGeneral.hematocritGrade</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LabGeneral:hematocritGrade</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1257">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752727</PUBLICID>
    <LONGNAME>Adverse Event Amended By Last Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2752211v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._Indicates the person or authoritative body who made an amendment.:A word or group of words indicating a person&#39;s last (family) name._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752211</PublicId>
      <PreferredName>2235992v1.0:2751722v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._Indicates the person or authoritative body who made an amendment.:A word or group of words indicating a person&#39;s last (family) name.</PreferredDefinition>
      <LongName>Adverse Event Amended By Last Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2235992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751722</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73460:C40975</PreferredName>
        <Version>1</Version>
        <LongName>Amended By Last Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73460</PREFERRED_NAME>
            <LONG_NAME>Amended By</LONG_NAME>
            <CON_ID>2751671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40975</PREFERRED_NAME>
            <LONG_NAME>Last Name</LONG_NAME>
            <CON_ID>2222026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Amended By Last Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Amended By Last Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.AdverseEvent.lastNameAmended</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent:lastNameAmended</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1258">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752751</PUBLICID>
    <LONGNAME>Concomitant Medication Details Resolution Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2752235v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.:A drug or medicine that treats or prevents or alleviates the symptoms of disease.:Particulars considered individually and in relation to a whole._Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752235</PublicId>
      <PreferredName>2752000v1.0:2607640v1.0</PreferredName>
      <PreferredDefinition>Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.:A drug or medicine that treats or prevents or alleviates the symptoms of disease.:Particulars considered individually and in relation to a whole._Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Concomitant Medication Details Resolution Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2752000</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25730:C459:C25480</PreferredName>
        <Version>1</Version>
        <LongName>Concomitant Medication Details</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25730</PREFERRED_NAME>
            <LONG_NAME>Concomitant</LONG_NAME>
            <CON_ID>2202429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25480</PREFERRED_NAME>
            <LONG_NAME>Details</LONG_NAME>
            <CON_ID>2203578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607640</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25655:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Resolution Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25655</PREFERRED_NAME>
            <LONG_NAME>Physiologic Resolution</LONG_NAME>
            <CON_ID>2202897</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Concomitant Medication Details Resolution Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Concomitant Medication Details Resolution Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.ConcomitantMedicationDetail.dateResolution</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ConcomitantMedicationDetail:dateResolution</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1259">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752979</PUBLICID>
    <LONGNAME>Or Pharmacologic Substance Surgical Procedure Data Completed By Last Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2752462v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b)).:A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._Indicates the person or authoritative body who made completed something.:A word or group of words indicating a person&#39;s last (family) name._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752462</PublicId>
      <PreferredName>2752012v1.0:2751744v1.0</PreferredName>
      <PreferredDefinition>An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b)).:A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._Indicates the person or authoritative body who made completed something.:A word or group of words indicating a person&#39;s last (family) name.</PreferredDefinition>
      <LongName>Or Pharmacologic Substance Surgical Procedure Data Completed By Last Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2752012</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37998:C1909:C15329:C25474</PreferredName>
        <Version>1</Version>
        <LongName>Or Pharmacologic Substance Surgical Procedure Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2751744</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73470:C40975</PreferredName>
        <Version>1</Version>
        <LongName>Completed By Last Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73470</PREFERRED_NAME>
            <LONG_NAME>Completed By</LONG_NAME>
            <CON_ID>2751675</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40975</PREFERRED_NAME>
            <LONG_NAME>Last Name</LONG_NAME>
            <CON_ID>2222026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Or Pharmacologic Substance Surgical Procedure Data Completed By Last Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Or Pharmacologic Substance Surgical Procedure Data Completed By Last Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.DrugSurgeryData.lastNameComplete</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DrugSurgeryData:lastNameComplete</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1260">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2752995</PUBLICID>
    <LONGNAME>Hematology Test Chemistry Test Collection Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2752478v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A laboratory test that has blood as its specimen.:A laboratory test designed for the quantification of a simple organic or inorganic chemical within a biological specimen._The act of gathering things together; having been brought together in one place.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2752478</PublicId>
      <PreferredName>2752013v1.0:2512765v1.0</PreferredName>
      <PreferredDefinition>A laboratory test that has blood as its specimen.:A laboratory test designed for the quantification of a simple organic or inorganic chemical within a biological specimen._The act of gathering things together; having been brought together in one place.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Hematology Test Chemistry Test Collection Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2752013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49286:C49237</PreferredName>
        <Version>1</Version>
        <LongName>Hematology Test Chemistry Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49286</PREFERRED_NAME>
            <LONG_NAME>Hematology Test</LONG_NAME>
            <CON_ID>2751689</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49237</PREFERRED_NAME>
            <LONG_NAME>Chemistry Test</LONG_NAME>
            <CON_ID>2751688</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2512765</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25453:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Collection Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Hematology Test Chemistry Test Collection Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Hematology Test Chemistry Test Collection Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2751669</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LEADS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.emory.wci.lymphoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.emory.wci.lymphoma.HematologyChemistry.dateAssessment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HematologyChemistry:dateAssessment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1261">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2753195</PUBLICID>
    <LONGNAME>Calculation Outcome Type Result Identifier</LONGNAME>
    <PREFERREDNAME>2750283v1.0:2753188v2.1</PREFERREDNAME>
    <PREFERREDDEFINITION>The procedure or activity of determining something by mathematical or logical methods.:The result of an action._A subdivision of a particular kind of thing._The type of result, for example, scalar, vector, histogram, array</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>IVI:caBIG In Vivo Imaging Workspace</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2750283</PublicId>
      <PreferredName>2750199v1.0:2223243v1.0</PreferredName>
      <PreferredDefinition>The procedure or activity of determining something by mathematical or logical methods.:The result of an action._A subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Calculation Outcome Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750199</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54125:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Calculation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54125</PREFERRED_NAME>
            <LONG_NAME>Calculation</LONG_NAME>
            <CON_ID>2654477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2753188</PublicId>
      <PreferredName>2753188v1.0</PreferredName>
      <PreferredDefinition>The type of result, for example, scalar, vector, histogram, array</PreferredDefinition>
      <LongName>CalculationResultIdentifier</LongName>
      <Version>2.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435019</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20181</PreferredName>
        <Version>1</Version>
        <LongName>Conceptual Entity</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scalar</VALIDVALUE>
          <VALUEMEANING>Scalar</VALUEMEANING>
          <MEANINGDESCRIPTION>Any data type that stores a single value (e.g. a number or Boolean), as opposed to an aggregate data type that has many elements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector</VALIDVALUE>
          <VALUEMEANING>Vector</VALUEMEANING>
          <MEANINGDESCRIPTION>A single dimensional array.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2572249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histogram</VALIDVALUE>
          <VALUEMEANING>Histogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A bar chart representing a frequency distribution where the heights of the bars represent observed frequencies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71615</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Matrix</VALIDVALUE>
          <VALUEMEANING>Matrix</VALUEMEANING>
          <MEANINGDESCRIPTION>A rectangular array of elements (or entries) set out by rows and columns.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Array</VALIDVALUE>
          <VALUEMEANING>Array</VALUEMEANING>
          <MEANINGDESCRIPTION>An orderly arrangement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26358</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2753192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Binary</VALIDVALUE>
          <VALUEMEANING>Binary Object</VALUEMEANING>
          <MEANINGDESCRIPTION>An object that includes binary encoding of a picture, photo, image, graphic, sound, or video.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60708</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2968598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Calculation Outcome Type Result Identifier does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Calculation Outcome Type Result Identifier does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CalculationResult:type</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.CalculationResult.type</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1262">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2755975</PUBLICID>
    <LONGNAME>Shape Maximum Dimension Unit of Measure java.lang.String</LONGNAME>
    <PREFERREDNAME>2753867v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial arrangement of something as distinct from its substance._The largest possible quantity or degree.:The magnitude of something in a particular direction, especially length or width or height.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2753867</PublicId>
      <PreferredName>2612281v1.0:2753748v1.0</PreferredName>
      <PreferredDefinition>The spatial arrangement of something as distinct from its substance._The largest possible quantity or degree.:The magnitude of something in a particular direction, especially length or width or height.:A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</PreferredDefinition>
      <LongName>Shape Maximum Dimension Unit of Measure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612281</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25677</PreferredName>
        <Version>1</Version>
        <LongName>Shape</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25677</PREFERRED_NAME>
            <LONG_NAME>Shape</LONG_NAME>
            <CON_ID>2203587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2753748</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25564:C25483:C25709</PreferredName>
        <Version>1</Version>
        <LongName>Maximum Dimension Unit of Measure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25564</PREFERRED_NAME>
            <LONG_NAME>Maximum</LONG_NAME>
            <CON_ID>2202550</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25709</PREFERRED_NAME>
            <LONG_NAME>Unit of Measure</LONG_NAME>
            <CON_ID>2203864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Shape Maximum Dimension Unit of Measure java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Shape Maximum Dimension Unit of Measure java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813021</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.physical</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.characterization.physical.Shape.maxDimensionUnit</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Shape:maxDimensionUnit</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.physical.Shape.maxDimensionUnit</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1263">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756110</PUBLICID>
    <LONGNAME>Cytotoxicity Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2754000v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells.  In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed._The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2754000</PublicId>
      <PreferredName>2612273v1.0:2192971v1.0</PreferredName>
      <PreferredDefinition>The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells.  In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed._The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Cytotoxicity Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612273</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C27988</PreferredName>
        <Version>1</Version>
        <LongName>Cytotoxicity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27988</PREFERRED_NAME>
            <LONG_NAME>Cytotoxicity</LONG_NAME>
            <CON_ID>2612109</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Cytotoxicity Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Cytotoxicity Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.characterization.invitro</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813020</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.invitro</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.characterization.invitro.Cytotoxicity.date</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Cytotoxicity:date</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.invitro.Cytotoxicity.date</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1264">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756261</PUBLICID>
    <LONGNAME>Antibody Value java.lang.Float</LONGNAME>
    <PREFERREDNAME>2754151v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An antibody is a type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen._A numerical quantity measured or assigned or computed._Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2754151</PublicId>
      <PreferredName>2612310v1.0:2186636v1.0</PreferredName>
      <PreferredDefinition>An antibody is a type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Antibody Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612310</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16295</PreferredName>
        <Version>1</Version>
        <LongName>Antibody</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2186636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Antibody Value java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Antibody Value java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.particle.samplecomposition.functionalization</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813025</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.agentmaterial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915882</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.particle.samplecomposition.functionalization.Antibody.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Antibody:value</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.agentmaterial.Antibody.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1265">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2756521</PUBLICID>
    <LONGNAME>Gene Function Relationship Role Entity Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2756439v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product.:The normal action performed by a structure or device.:A state of connectedness between people, objects, or events; to be associated or connected with something._A non-hierarchical, named relationship between concepts.  They are binary relationships pointing from one concept to another concept.  Roles are unidirectional and each role has a Domain and a Range; the role points from one kind, the domain, to another (or same) kind, the range.  The specific concept pointed to is considered the Role Value.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2756439</PublicId>
      <PreferredName>2756420v1.0:2756408v1.0</PreferredName>
      <PreferredDefinition>A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product.:The normal action performed by a structure or device.:A state of connectedness between people, objects, or events; to be associated or connected with something._A non-hierarchical, named relationship between concepts.  They are binary relationships pointing from one concept to another concept.  Roles are unidirectional and each role has a Domain and a Range; the role points from one kind, the domain, to another (or same) kind, the range.  The specific concept pointed to is considered the Role Value.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Gene Function Relationship Role Entity Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2756420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612:C25518:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Gene Function Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16612</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2202483</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2756408</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42754:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Role Entity Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42754</PREFERRED_NAME>
            <LONG_NAME>Role Entity</LONG_NAME>
            <CON_ID>2222828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Gene Function Relationship Role Entity Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Gene Function Relationship Role Entity Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000539</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000544</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.domain.GeneFunctionAssociation.role</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GeneFunctionAssociation:role</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@role</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1266">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2759169</PUBLICID>
    <LONGNAME>Adjuvant Radiation Therapy Begin Date</LONGNAME>
    <PREFERREDNAME>ADJ_RT_STT_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>Date that adjuvant radiation therapy began. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2008638</PublicId>
      <PreferredName>ADJ_RT_BEG_OCUR</PreferredName>
      <PreferredDefinition>information related to the begin date or occurrence of adjuvant radiation therapy.</PreferredDefinition>
      <LongName>Adjuvant Radiation Therapy Begin Occurrence</LongName>
      <Version>6</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206630</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2140:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Adjuvant Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2140</PREFERRED_NAME>
            <LONG_NAME>Adjuvant</LONG_NAME>
            <CON_ID>2204993</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207746</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Begin Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016970</PublicId>
      <PreferredName>START_DT</PreferredName>
      <PreferredDefinition>A particular calendar day specified as when an event or activity began or was initiated.  Exchange format is YYYYMMDD.</PreferredDefinition>
      <LongName>Start Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>DD/MON/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Start Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Start Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1267">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2759176</PUBLICID>
    <LONGNAME>Adjuvant Immunotherapy Agent Name</LONGNAME>
    <PREFERREDNAME>ADJ_IMMU_AGT_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Name of a adjuvant immunotherapy agent administered to an individual.[Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2759174</PublicId>
      <PreferredName>ADJ_IMMU_AGT</PreferredName>
      <PreferredDefinition>Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_(AD-joo-vant) Treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.</PreferredDefinition>
      <LongName>Adjuvant Therapy Immunotherapy Agent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2759172</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15675:C15262</PreferredName>
        <Version>1</Version>
        <LongName>Adjuvant Therapy Immunotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15675</PREFERRED_NAME>
            <LONG_NAME>Adjuvant Therapy</LONG_NAME>
            <CON_ID>2205339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15262</PREFERRED_NAME>
            <LONG_NAME>Immunotherapy</LONG_NAME>
            <CON_ID>2202664</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2514627</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018334</PublicId>
      <PreferredName>AGT_NAME</PreferredName>
      <PreferredDefinition>the name of the agent or drug that has been administered to the patient.</PreferredDefinition>
      <LongName>Agent Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2738661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Agent Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Drug(s) used</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Drug(s) used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1268">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2760869</PUBLICID>
    <LONGNAME>Laboratory Procedure Tumor Marker Biomarker Outcome Date</LONGNAME>
    <PREFERREDNAME>LP_TM_BIOMRK_OUTC_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date that the outcome of a laboratory test measuring a biomarker is determined.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760865</PublicId>
      <PreferredName>LAB_BIMKR_TMMKR_OUTC</PreferredName>
      <PreferredDefinition>information relating to the outcome of a laboratory procedure that involves testing for a biomarker (measurable and quantifiable biological parameters which serve as indices for health-related and physiology-related assessments, such as disease risk).</PreferredDefinition>
      <LongName>Laboratory Procedure Tumor Marker Biomarker Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2760863</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17220:C16342:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Marker Biomarker Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17220</PREFERRED_NAME>
            <LONG_NAME>Tumor Marker</LONG_NAME>
            <CON_ID>2202551</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of Biomarker Assessment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of Biomarker Assessment Result</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000366</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurr Gynecologic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811830</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Endometrial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000187</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Recurrent Gyn</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000233</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0249</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104896</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0261</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104914</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104930</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000275</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0283</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000276</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000589</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0252</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0281</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000705</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LP_TM_BIOMRK_OUTC_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1269">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2768571</PUBLICID>
    <LONGNAME>Mini Mental Status Exam Scale Score</LONGNAME>
    <PREFERREDNAME>NNSE_SCL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the total score on the Mini-Mental Status Exam (MMSE).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2768464</PublicId>
      <PreferredName>MMSE_OUTC</PreferredName>
      <PreferredDefinition>Conceptual functions or thinking in all its forms. (NCI)_A condition or state at a particular time._An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s)_Outcome; a phenomenon that follows and is caused by some previous phenomenon._A brief quantitative test used for assessing cognitive function in adults.</PreferredDefinition>
      <LongName>Mini-Mental Status Exam Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2774533</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74982</PreferredName>
        <Version>1</Version>
        <LongName>Mini-Mental Status Exam</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74982</PREFERRED_NAME>
            <LONG_NAME>Mini-Mental Status Exam</LONG_NAME>
            <CON_ID>2768589</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224045</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2768565</PublicId>
      <PreferredName>MMSE_SCL_SC</PreferredName>
      <PreferredDefinition>Conceptual functions or thinking in all its forms. (NCI)_A condition or state at a particular time._An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s)_an ordered reference standard._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Mental Process Status Exam Scale Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>30</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2768564</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16840:C25688:C25305:C25664:C2</PreferredName>
        <Version>1</Version>
        <LongName>Mental Process Status Exam Scale Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16840</PREFERRED_NAME>
            <LONG_NAME>Mental Process</LONG_NAME>
            <CON_ID>2463509</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MMSE total score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>MMSE total score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 0904</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3335732</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ABTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ABTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NNSE_SCL_SC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1270">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771502</PUBLICID>
    <LONGNAME>Next Hematopoietic Cell Transplantation Other Indication Specify Text</LONGNAME>
    <PREFERREDNAME>2771498v2.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the other indication for the subsequent hematopoietic cell transplantation.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771498</PublicId>
      <PreferredName>2770827v1.0:2593350v1.0</PreferredName>
      <PreferredDefinition>Subsequent; immediately following in time or order._Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_The replacement of tissue with tissue from the person&#39;s own body or from another person._Different than the one(s) previously specified or mentioned._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).</PreferredDefinition>
      <LongName>Next Hematopoietic Cell Transplantation Other Indication</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2770827</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C53286:C12551:C15342</PreferredName>
        <Version>1</Version>
        <LongName>Next Hematopoietic Stem Cell Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C53286</PREFERRED_NAME>
            <LONG_NAME>Next</LONG_NAME>
            <CON_ID>2443959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2593350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C41184</PreferredName>
        <Version>1</Version>
        <LongName>Other Indication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41184</PREFERRED_NAME>
            <LONG_NAME>Indication</LONG_NAME>
            <CON_ID>2203766</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other indication</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the other indication for the subsequent hematopoietic cell transplantation:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other indication</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other indication</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2771502</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedProcedure &gt; DefinedProcedure.reasonCode(CD).originalText WHERE DefinedProcedure.nameCode = &quot;Perform Overall Hematopoietic Stem Cell Transplantation&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other indication:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other indication:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other indication:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other indication:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedProcedure:reasonCode</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_SH_sub_hct_indic_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_STX_sub_hct_indic_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1271">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771613</PUBLICID>
    <LONGNAME>Scientific Publication Research Activity Subject java.lang.String</LONGNAME>
    <PREFERREDNAME>2771596v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:Some matter, situation, or event that is thought about, written about, or discussed._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771596</PublicId>
      <PreferredName>2224105v1.0:2771588v1.0</PreferredName>
      <PreferredDefinition>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:Some matter, situation, or event that is thought about, written about, or discussed.</PreferredDefinition>
      <LongName>Scientific Publication Research Activity Subject</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19026</PreferredName>
        <Version>1</Version>
        <LongName>Scientific Publication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19026</PREFERRED_NAME>
            <LONG_NAME>Scientific Publication</LONG_NAME>
            <CON_ID>2223990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2771588</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15429:C48910</PreferredName>
        <Version>1</Version>
        <LongName>Research Activity Subject</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15429</PREFERRED_NAME>
            <LONG_NAME>Research Activity</LONG_NAME>
            <CON_ID>2528433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48910</PREFERRED_NAME>
            <LONG_NAME>Subject</LONG_NAME>
            <CON_ID>2553605</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Scientific Publication Research Activity Subject java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Scientific Publication Research Activity Subject java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813019</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.common.Publication.researchArea</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Publication:researchArea</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1272">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2771617</PUBLICID>
    <LONGNAME>Scientific Publication Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2771599v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2771599</PublicId>
      <PreferredName>2224105v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>A class of publication in which original scientific work is described.  The format usually includes an introduction in which relevant concepts are identified and the experimental system under study is presented, a section describing the experiments that were performed to test a specific hypothesis and the results and observations that were obtained, a section in which the results are discussed relative to findings by other investigators and the current state of knowledge in the field, and a section describing the experimental methods and procedures in sufficient detail to enable the reproduction of the work by independent investigators._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Scientific Publication Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2224105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19026</PreferredName>
        <Version>1</Version>
        <LongName>Scientific Publication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19026</PREFERRED_NAME>
            <LONG_NAME>Scientific Publication</LONG_NAME>
            <CON_ID>2223990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Scientific Publication Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Scientific Publication Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2612100</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813019</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000157</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.common.Publication.createdDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Publication:createdDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1273">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2772967</PUBLICID>
    <LONGNAME>Contact Information Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2772322v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information regarding the means of contacting a person or group._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772322</PublicId>
      <PreferredName>2772232v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>Information regarding the means of contacting a person or group._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Contact Information Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772232</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60776</PreferredName>
        <Version>1</Version>
        <LongName>Contact Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60776</PREFERRED_NAME>
            <LONG_NAME>Contact Information</LONG_NAME>
            <CON_ID>2751571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Contact Information Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Contact Information Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.ContactInformation.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ContactInformation:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1274">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2772977</PUBLICID>
    <LONGNAME>Contact Information Uniform Resource Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2772332v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information regarding the means of contacting a person or group._A Uniform Resource Identifier is a character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL. (from http://www.computeruser.com)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772332</PublicId>
      <PreferredName>2772232v1.0:2236656v1.0</PreferredName>
      <PreferredDefinition>Information regarding the means of contacting a person or group._A Uniform Resource Identifier is a character string that can identify any kind of resource on the Internet, including images, text, video, audio and programs.  The most commom type of a URI is a URL. (from http://www.computeruser.com)</PreferredDefinition>
      <LongName>Contact Information Uniform Resource Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772232</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60776</PreferredName>
        <Version>1</Version>
        <LongName>Contact Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60776</PREFERRED_NAME>
            <LONG_NAME>Contact Information</LONG_NAME>
            <CON_ID>2751571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236656</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42778</PreferredName>
        <Version>1</Version>
        <LongName>Uniform Resource Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42778</PREFERRED_NAME>
            <LONG_NAME>Uniform Resource Identifier</LONG_NAME>
            <CON_ID>2236546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Contact Information Uniform Resource Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Contact Information Uniform Resource Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.ContactInformation.URI</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ContactInformation:URI</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1275">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773048</PUBLICID>
    <LONGNAME>Application Adapter Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2772399v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A software layer that converts data from an application into a form that will allow integration with other applications._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772399</PublicId>
      <PreferredName>2772238v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>A software layer that converts data from an application into a form that will allow integration with other applications._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Application Adapter Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772238</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73536</PreferredName>
        <Version>1</Version>
        <LongName>Application Adapter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73536</PREFERRED_NAME>
            <LONG_NAME>Application Adapter</LONG_NAME>
            <CON_ID>2772176</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Application Adapter Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Application Adapter Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.Adapter.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Adapter:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1276">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773194</PUBLICID>
    <LONGNAME>Fill Pattern Display Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2772544v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Execute or satisfy a request or order; supply or furnish.:A distinctive style or form of something, the characteristic set of traits or actions or qualities of a group, person, or thing, as behavior patterns; in molecular biology: a nucleic acid or protein motif that is computationally detectable within aligned sequences._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772544</PublicId>
      <PreferredName>2772254v1.0:2231629v1.0</PreferredName>
      <PreferredDefinition>Execute or satisfy a request or order; supply or furnish.:A distinctive style or form of something, the characteristic set of traits or actions or qualities of a group, person, or thing, as behavior patterns; in molecular biology: a nucleic acid or protein motif that is computationally detectable within aligned sequences._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Fill Pattern Display Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772254</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54093:C25336</PreferredName>
        <Version>1</Version>
        <LongName>Fill Pattern</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54093</PREFERRED_NAME>
            <LONG_NAME>Fill</LONG_NAME>
            <CON_ID>2475259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25336</PREFERRED_NAME>
            <LONG_NAME>Pattern</LONG_NAME>
            <CON_ID>2203946</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25485:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Display Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25485</PREFERRED_NAME>
            <LONG_NAME>Display</LONG_NAME>
            <CON_ID>2203905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Fill Pattern Display Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Fill Pattern Display Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FillPattern:displayName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.FillPattern.displayName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1277">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773294</PUBLICID>
    <LONGNAME>Type Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2772644v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Something distinguishable as an identifiable class based on common qualities._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772644</PublicId>
      <PreferredName>2772264v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Type Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772264</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Type Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Type Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.Type.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Type:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1278">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773466</PUBLICID>
    <LONGNAME>Polymerase Chain Reaction Product Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2772811v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.:The end result of a manufacturing process; anything that is produced._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772811</PublicId>
      <PreferredName>2772256v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.:The end result of a manufacturing process; anything that is produced._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Polymerase Chain Reaction Product Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772256</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17003:C51980</PreferredName>
        <Version>1</Version>
        <LongName>Polymerase Chain Reaction Product</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17003</PREFERRED_NAME>
            <LONG_NAME>Polymerase Chain Reaction</LONG_NAME>
            <CON_ID>2202449</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Polymerase Chain Reaction Product Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Polymerase Chain Reaction Product Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCRProduct:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.PCRProduct.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1279">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2773533</PUBLICID>
    <LONGNAME>Oligonucleotide Primer Created Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2772872v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._Brought into existence.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772872</PublicId>
      <PreferredName>2611786v1.0:2222853v1.0</PreferredName>
      <PreferredDefinition>Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis._Brought into existence.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Oligonucleotide Primer Created Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2611786</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1451</PreferredName>
        <Version>1</Version>
        <LongName>Oligonucleotide Primer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1451</PREFERRED_NAME>
            <LONG_NAME>Oligonucleotide Primer</LONG_NAME>
            <CON_ID>2611725</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222853</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42620:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Created Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Oligonucleotide Primer Created Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Oligonucleotide Primer Created Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Primer:dateCreated</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Primer.dateCreated</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1280">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2774677</PUBLICID>
    <LONGNAME>T-Cell Depletion Method Cell Sorting Immunomagnetic Column Performed Indicator</LONGNAME>
    <PREFERREDNAME>TCP_M_CLS_IMC_PR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft from a donor may reduce the chance of an immune reaction against the recipient&#39;s tissues._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Techniques and methods for separating cells (usually viable) based on a variety of criteria for separation, such as size or density, non-specific surface properties, or specific surface properties.  Examples include cell affinity chromatography and centrifugation using density gradients._A separation column that when placed in proximity to a magnet creates a high gradient magnetic field strong enough to retain cells labeled with antibodies complexed to magnetic particles._Executed and carried through to completion._Indicator of Yes, No, Unknown, Not Done, or Not Applicable to a question.[manually curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2774675</PublicId>
      <PreferredName>TCD_M_CL_SRT_IM_C_PR</PreferredName>
      <PreferredDefinition>Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft from a donor may reduce the chance of an immune reaction against the recipient&#39;s tissues._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Techniques and methods for separating cells (usually viable) based on a variety of criteria for separation, such as size or density, non-specific surface properties, or specific surface properties.  Examples include cell affinity chromatography and centrifugation using density gradients._A separation column that when placed in proximity to a magnet creates a high gradient magnetic field strong enough to retain cells labeled with antibodies complexed to magnetic particles._Executed and carried through to completion.</PreferredDefinition>
      <LongName>T-Cell Depletion Method Cell Sorting Immunomagnetic Column Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2774065</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15699:C71460</PreferredName>
        <Version>1</Version>
        <LongName>T-Cell Depletion Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15699</PREFERRED_NAME>
            <LONG_NAME>T-Cell Depletion Therapy</LONG_NAME>
            <CON_ID>2205412</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2774673</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16406:C71606:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Cell Sorting Immunomagnetic Column Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16406</PREFERRED_NAME>
            <LONG_NAME>Cell Sorting</LONG_NAME>
            <CON_ID>2742799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71606</PREFERRED_NAME>
            <LONG_NAME>Immunomagnetic Column</LONG_NAME>
            <CON_ID>2719441</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was immunomagnetic beads used</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was immunomagnetic beads used to manipulate the product?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>immunomagnetic beads</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>immunomagnetic beads</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Immunomagnetic beads</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Immunomagnetic beads</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2006r1: HSCT Infusion</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_proc_tcell_beads_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>dci_manip_tcell_beads_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1281">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2778515</PUBLICID>
    <LONGNAME>Organ NCI Concept Code AnatomicalTermCode</LONGNAME>
    <PREFERREDNAME>2437934v1.0:2778460v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A unique macroscopic (gross) anatomic structure that performs specific functions.  It is composed of various tissues.  An organ is part of an anatomic system or a body region.  Representative examples include the heart, lung, liver, spleen, and uterus._A concept unique identifier within the NCI Enterprise Vocabulary Service&#39;s NCI Thesaurus._EVS Concept code for zebrafish, rat, mouse and human anatomy</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2437934</PublicId>
      <PreferredName>2437800v1.0:2223296v1.0</PreferredName>
      <PreferredDefinition>A unique macroscopic (gross) anatomic structure that performs specific functions.  It is composed of various tissues.  An organ is part of an anatomic system or a body region.  Representative examples include the heart, lung, liver, spleen, and uterus._A concept unique identifier within the NCI Enterprise Vocabulary Service&#39;s NCI Thesaurus.</PreferredDefinition>
      <LongName>Organ NCI Concept Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2437800</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13018</PreferredName>
        <Version>1</Version>
        <LongName>Organ</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13018</PREFERRED_NAME>
            <LONG_NAME>Organ</LONG_NAME>
            <CON_ID>2202464</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223296</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43516</PreferredName>
        <Version>1</Version>
        <LongName>NCI Concept Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43516</PREFERRED_NAME>
            <LONG_NAME>NCI Concept Code</LONG_NAME>
            <CON_ID>2223221</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2778460</PublicId>
      <PreferredName>2778460v1.0</PreferredName>
      <PreferredDefinition>EVS Concept code for zebrafish, rat, mouse and human anatomy</PreferredDefinition>
      <LongName>AnatomicalTermCode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Organ NCI Concept Code AnatomicalTermCode does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Organ NCI Concept Code AnatomicalTermCode does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Organ.conceptCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organ:conceptCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1282">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2778955</PUBLICID>
    <LONGNAME>Patient Prior Registration Diagnostic Imaging Eligibility Determination End Date</LONGNAME>
    <PREFERREDNAME>PT_P_RE_DX_ELG_E_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the last or end date of any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation prior to the act of enrolling on a clinical trial as a determination of the suitable for enrollment in a study according specific protocol criteria and procedures.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2778954</PublicId>
      <PreferredName>PT_P_REG_DXIMG_ELIG</PreferredName>
      <PreferredDefinition>information related to any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation prior to the act of enrolling on a clinical trial as a determination of the suitable for enrollment in a study according specific protocol criteria and procedures.</PreferredDefinition>
      <LongName>Patient Prior Registration Diagnostic Imaging Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2778951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C25646:C16502:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Prior Registration Diagnostic Imaging Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16502</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Imaging</LONG_NAME>
            <CON_ID>2321519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188674</PublicId>
      <PreferredName>END_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event ended.</PreferredDefinition>
      <LongName>End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184285</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Date</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>latest exception test date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>latest exception test date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1283">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2782602</PUBLICID>
    <LONGNAME>Optional Research Blood Sample Not Submitted Reason Text</LONGNAME>
    <PREFERREDNAME>O_R_B_SAM_NS_RSN_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>A free text field used to describe the reason an optional research blood sample was not submitted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2782598</PublicId>
      <PreferredName>O_RSCH_B_SAMP_N_SUBM</PreferredName>
      <PreferredDefinition>Information pertaining to a optional systematic investigation into a subject in order to discover facts, to establish or revise a theory, or to develop a plan of action based on the facts discovered liquid tissue taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis not submitted; referred for judgment or consideration.</PreferredDefinition>
      <LongName>Optional Research Blood Sample Not Submitted</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782590</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25603:C15319</PreferredName>
        <Version>1</Version>
        <LongName>Optional Research</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25603</PREFERRED_NAME>
            <LONG_NAME>Optional</LONG_NAME>
            <CON_ID>2206331</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15319</PREFERRED_NAME>
            <LONG_NAME>Research</LONG_NAME>
            <CON_ID>2202802</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2782596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12434:C19157:C25594:C25695</PreferredName>
        <Version>1</Version>
        <LongName>Blood Specimen Negation Submission</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25695</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2203811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2480204</PublicId>
      <PreferredName>BLD_SAMP_NS_RSN_TXT</PreferredName>
      <PreferredDefinition>A free text field used to describe the reason a blood sample was not submitted.</PreferredDefinition>
      <LongName>Blood Sample Not Submitted Reason Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2403868</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Reason Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bronchial Dysplasia - Sulindac</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2194255</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Condition</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast Sulindac DFMO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2859628</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1284">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783879</PUBLICID>
    <LONGNAME>Specimen Base Tissue Pathology Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2783114v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The most important or necessary part of something.:An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783114</PublicId>
      <PreferredName>2782829v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The most important or necessary part of something.:An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Specimen Base Tissue Pathology Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782829</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C48055:C12801:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Base Tissue Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48055</PREFERRED_NAME>
            <LONG_NAME>Base</LONG_NAME>
            <CON_ID>2547991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen Base Tissue Pathology Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen Base Tissue Pathology Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen.SpecimenBaseSolidTissuePathologyAnnotation.comments</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenBaseSolidTissuePathologyAnnotation:comments</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1285">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783910</PUBLICID>
    <LONGNAME>New Specimen Order Object Specimen Type Specimen Type Collection Text Type</LONGNAME>
    <PREFERREDNAME>2783143v1.0:2624019v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Having no previous example or precedent or parallel; of a kind not seen before.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of requesting that person, business, or organization supply something in return for payment.:Something perceptible by one or more of the senses, especially by vision or touch; a material thing. (dictionary.com)_A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:A subdivision of a particular kind of thing._Specimen; a bit of tissue or blood or urine that is taken or used for research purposes.:Type; a subdivision of a particular kind of thing:several things grouped together.__Text; the words of something written._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783143</PublicId>
      <PreferredName>2782845v1.0:2553148v1.0</PreferredName>
      <PreferredDefinition>Having no previous example or precedent or parallel; of a kind not seen before.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The act of requesting that person, business, or organization supply something in return for payment.:Something perceptible by one or more of the senses, especially by vision or touch; a material thing. (dictionary.com)_A sample or part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:A subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>New Specimen Order Object Specimen Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25586:C19157:C48906:C45281</PreferredName>
        <Version>1</Version>
        <LongName>New Specimen Order Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48906</PREFERRED_NAME>
            <LONG_NAME>Order</LONG_NAME>
            <CON_ID>2534953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45281</PREFERRED_NAME>
            <LONG_NAME>Object</LONG_NAME>
            <CON_ID>2233226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2553148</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2624019</PublicId>
      <PreferredName>2624019v1.1</PreferredName>
      <PreferredDefinition>Specimen; a bit of tissue or blood or urine that is taken or used for research purposes.:Type; a subdivision of a particular kind of thing:several things grouped together.__Text; the words of something written._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Specimen Type Collection Text Type</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2207966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Text Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frozen Tissue</VALIDVALUE>
          <VALUEMEANING>Frozen Section Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C49338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fresh Tissue</VALIDVALUE>
          <VALUEMEANING>Tissue, Fresh</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue that is not frozen or embedded in preservatives</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fixed Tissue Slide</VALIDVALUE>
          <VALUEMEANING>Fix Tissue Slide</VALUEMEANING>
          <MEANINGDESCRIPTION>Cause to be firmly attached; stick or hold together and resist separation.: An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25325, C12801, C52253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fixed Tissue</VALIDVALUE>
          <VALUEMEANING>Fix Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Cause to be firmly attached; stick or hold together and resist separation.: An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C52253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frozen Cell Pellet</VALIDVALUE>
          <VALUEMEANING>Frozen Section Cell Pellet Formation</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._Formation by cetrifugation of a tightly packed sample in the bottom of a tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45813, C12508, C49338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2624026</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slide</VALIDVALUE>
          <VALUEMEANING>Slide</VALUEMEANING>
          <MEANINGDESCRIPTION>A flat rectangular piece of glass on which specimens can be mounted for microscopic study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frozen Cell Block</VALIDVALUE>
          <VALUEMEANING>Frozen Section Cell Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25436, C12508, C49338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2624025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fixed Cell Block</VALIDVALUE>
          <VALUEMEANING>Fix Cell Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>Cause to be firmly attached; stick or hold together and resist separation.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. Cells are highly variable and specialized in both structure and function, though all must at some stage replicate proteins and nucleic acids, utilize energy, and reproduce themselves.: Blocks; refers to preserved specimens embedded in support material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25436, C12508, C52253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2624024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fixed Tissue Block</VALIDVALUE>
          <VALUEMEANING>Fix Tissue Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>Cause to be firmly attached; stick or hold together and resist separation.: An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.: Blocks; refers to preserved specimens embedded in support material.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25436, C12801, C52253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2622785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DNA</VALIDVALUE>
          <VALUEMEANING>DNA</VALUEMEANING>
          <MEANINGDESCRIPTION>A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cDNA</VALIDVALUE>
          <VALUEMEANING>cDNA</VALUEMEANING>
          <MEANINGDESCRIPTION>Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C324</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cryopreserved Cells</VALIDVALUE>
          <VALUEMEANING>Cryopreserved Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells which are indefinitely maintained in a viable state at extremely low temperatures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amniotic Fluid</VALIDVALUE>
          <VALUEMEANING>Amniotic Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid within the amniotic cavity which surrounds and protects the developing embryo.  It is initially produced by the amnion and then later by the lungs and kidneys.  The amount at term normally varies from 500 to 2000 ml.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bile</VALIDVALUE>
          <VALUEMEANING>Bile</VALUEMEANING>
          <MEANINGDESCRIPTION>An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS, CHOLESTEROL, and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Body Cavity Fluid</VALIDVALUE>
          <VALUEMEANING>Body Cavity Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural hollow or sinus within the body.: Fluid; a continuous amorphous substance that tends to flow and to conform to the outline of its container: a liquid or a gas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25278, C25444</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Plasma</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Plasma</VALUEMEANING>
          <MEANINGDESCRIPTION>The soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets.: Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13356, C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrospinal Fluid</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Feces</VALIDVALUE>
          <VALUEMEANING>Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric Fluid</VALIDVALUE>
          <VALUEMEANING>Gastric Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the stomach.: Fluid; a continuous amorphous substance that tends to flow and to conform to the outline of its container: a liquid or a gas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25278, C13307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lavage</VALIDVALUE>
          <VALUEMEANING>Lavage</VALUEMEANING>
          <MEANINGDESCRIPTION>Washing out a hollow organ (especially the stomach) by flushing with a fluid. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Milk</VALIDVALUE>
          <VALUEMEANING>Breast Milk</VALUEMEANING>
          <MEANINGDESCRIPTION>Milk produced by female humans for the purpose of feeding their young.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13257</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Specified</VALIDVALUE>
          <VALUEMEANING>Unspecified</VALUEMEANING>
          <MEANINGDESCRIPTION>Not stated explicitly or in detail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericardial Fluid</VALIDVALUE>
          <VALUEMEANING>Pericardial Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Located around the heart or relating to or affecting the pericardium.: Fluid; a continuous amorphous substance that tends to flow and to conform to the outline of its container: a liquid or a gas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25278, C38001</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581989</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plasma</VALIDVALUE>
          <VALUEMEANING>Plasma</VALUEMEANING>
          <MEANINGDESCRIPTION>Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13356</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Saliva</VALIDVALUE>
          <VALUEMEANING>Saliva</VALUEMEANING>
          <MEANINGDESCRIPTION>A clear liquid secreted into the mouth by the salivary glands and mucous glands of the mouth; moistens the mouth and starts the digestion of starches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581985</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum</VALIDVALUE>
          <VALUEMEANING>Serum</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sputum</VALIDVALUE>
          <VALUEMEANING>Sputum</VALUEMEANING>
          <MEANINGDESCRIPTION>Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sweat</VALIDVALUE>
          <VALUEMEANING>Sweat</VALUEMEANING>
          <MEANINGDESCRIPTION>The liquid secreted by the sweat glands, having a salty taste and a pH that varies from 4.5 to 7.5. Sweat produced by the eccrine sweat glands is clear with a faint characteristic odor, and contains water, sodium chloride, and traces of albumin, urea, and other compounds. Its composition varies with many factors, e.g., fluid intake, external temperature and humidity, and some hormonal activity. Sweat produced by the larger, deeper, apocrine sweat glands of the axillae contains, in addition, organic material which on bacterial decomposition produces an offensive odor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synovial Fluid</VALIDVALUE>
          <VALUEMEANING>Synovial Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>A viscid fluid secreted by the synovial membrane, serving as a lubricant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine</VALIDVALUE>
          <VALUEMEANING>Urine</VALUEMEANING>
          <MEANINGDESCRIPTION>Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vitreous Fluid</VALIDVALUE>
          <VALUEMEANING>Vitreous Humor</VALUEMEANING>
          <MEANINGDESCRIPTION>A clear, avascular, gelatinous body that occupies the posterior chamber of the eye. It is bounded by the retina except anteriorly where it lies adjacent to the lens and iris.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13323</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2590876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Whole Blood</VALIDVALUE>
          <VALUEMEANING>Whole Blood: C41067</VALUEMEANING>
          <MEANINGDESCRIPTION>Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41067</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Whole Bone Marrow</VALIDVALUE>
          <VALUEMEANING>Whole Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>Whole; including all components without exception; being one unit or constituting the full amount or extent or duration; complete.: The soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12431, C25326</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA, poly-A enriched</VALIDVALUE>
          <VALUEMEANING>RNA Polyadenylation</VALUEMEANING>
          <MEANINGDESCRIPTION>1. The process of formation of poly(adenylic acid). 2. The covalent modification of a macromolecule (e.g., mRNA) by the formation of a polyadenylyl moiety covalently linked to the macromolecule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18947</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA, nuclear</VALIDVALUE>
          <VALUEMEANING>Nuclear Ribonucleic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to the nucleus.: A nucleic acid molecule similar to DNA but containing ribose rather than deoxyribose. RNA is formed upon a DNA template. There are several classes of RNA molecules. They play crucial roles in protein synthesis and other cell activities. (MedicineNet.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C812, C13361</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2590874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA, cytoplasmic</VALIDVALUE>
          <VALUEMEANING>Cytoplasm Ribonucleic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>That portion of the cell contained within the plasma membrane but excluding the nucleus.: A nucleic acid molecule similar to DNA but containing ribose rather than deoxyribose. RNA is formed upon a DNA template. There are several classes of RNA molecules. They play crucial roles in protein synthesis and other cell activities. (MedicineNet.com)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C812, C13226</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2590873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA</VALIDVALUE>
          <VALUEMEANING>Ribonucleic Acid</VALUEMEANING>
          <MEANINGDESCRIPTION>Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protein</VALIDVALUE>
          <VALUEMEANING>Protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of a group of complex organic macromolecules that contain carbon, hydrogen, oxygen, nitrogen, and usually sulfur and are composed of one or more chains of amino acids. Proteins are fundamental components of all living cells and include many substances, such as enzymes, hormones, and antibodies, that are necessary for the proper functioning of an organism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17021</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microsessected</VALIDVALUE>
          <VALUEMEANING>Microdissection</VALUEMEANING>
          <MEANINGDESCRIPTION>A laboratory method in which the tissue from a histology slide is dissected under a microscope to procure specific cells or cell populations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frozen Tissue Slide</VALIDVALUE>
          <VALUEMEANING>Frozen Section Tissue Slide</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C49338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frozen Tissue Block</VALIDVALUE>
          <VALUEMEANING>Frozen Section Tissue Blocks</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25436, C12801, C49338</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2622788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stem Cells</VALIDVALUE>
          <VALUEMEANING>Stem Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Relatively undifferentiated cells of the same lineage (family type) that retain the ability to divide throughout postnatal life to reproduce themselves and to give rise to other more specialized types of cells to take the place of those that die or are lost. (MeSH)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12662</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3781715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buffy Coat</VALIDVALUE>
          <VALUEMEANING>Buffy Coat</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper clear layer of fluid which is separated from a blood clot following density gradient centrifugation. It contains most of the white blood cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical/Vaginal</VALIDVALUE>
          <VALUEMEANING>Cervical/Vaginal</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.: Of or relating to the vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13309, C12311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5720349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood</VALIDVALUE>
          <VALUEMEANING>Blood</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eyebrow Hair</VALIDVALUE>
          <VALUEMEANING>Eyebrow Hair</VALUEMEANING>
          <MEANINGDESCRIPTION>The arched strip of hair on the bony ridge above each eye socket.: The filamentous outgrowth of the epidermis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32705, C32575</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5720350</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral</VALIDVALUE>
          <VALUEMEANING>Oral</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or relating to, or affecting, or for use in the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5711127</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreatic Fluid</VALIDVALUE>
          <VALUEMEANING>Pancreatic Exocrine Secretion</VALUEMEANING>
          <MEANINGDESCRIPTION>Secretion from the pancreas that contains digestive enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical Tissue</VALIDVALUE>
          <VALUEMEANING>Tissue Surgical</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.: of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25698, C12801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5990031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Core Biopsy Tissue</VALIDVALUE>
          <VALUEMEANING>Tissue Core Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.: The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15680, C12801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5990032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ctDNA</VALIDVALUE>
          <VALUEMEANING>Circulating Tumor-Derived DNA</VALUEMEANING>
          <MEANINGDESCRIPTION>Neoplasm-derived DNA found in blood plasma and other bodily fluids that is not associated with cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4061103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cfDNA</VALIDVALUE>
          <VALUEMEANING>Circulating cell-free DNA</VALUEMEANING>
          <MEANINGDESCRIPTION>DNA found in blood plasma and other bodily fluids that is not associated with cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stained slides (bone marrow clot)</VALIDVALUE>
          <VALUEMEANING>Stained Slide Bone Marrow Clot</VALUEMEANING>
          <MEANINGDESCRIPTION>Marked or discolored by foreign material.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.: The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: A specimen that has become coagulated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78724, C12431, C25325, C94578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Aspirate Slides</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Aspirate Slide</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: Fluid withdrawn from a lump, often a cyst, or a nipple.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25325, C13347, C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Touch Prep Biopsy Slides</VALIDVALUE>
          <VALUEMEANING>Bone Marrow Touch Prep Biopsy Slides</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: The faculty of touch, the sensation produced by pressure receptors in the skin.: The act or process of making something ready.: The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25325, C15189, C25625, C38535, C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor Tissue Touch Prep Slides</VALIDVALUE>
          <VALUEMEANING>Tumor Tissue Touch Prep Slides</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor sample, or entire tumor that is removed for microscopic examination.: The faculty of touch, the sensation produced by pressure receptors in the skin.: The act or process of making something ready.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25325, C25625, C38535, C18009</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stained slides (bone marrow biopsy)</VALIDVALUE>
          <VALUEMEANING>Stained Slide Bone Marrow Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Marked or discolored by foreign material.: A flat rectangular piece of glass on which specimens can be mounted for microscopic study.: A biopsy involving the removal of a core tissue containing bone spicules and hematopoietic elements embedded in the marrow stroma.  This procedure is done in the hip area mainly for the diagnosis and evaluation of neoplastic and non-neoplastic hematopoietic disorders (e.g. anemias, leukemias, lymphomas) and the evaluation of the spread of solid tumors (e.g. carcinomas, sarcomas) and lymphomas for therapeutic purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15193, C25325, C94578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unstained slides (bone marrow clot)</VALIDVALUE>
          <VALUEMEANING>Unstained Slide Bone Marrow Clot</VALUEMEANING>
          <MEANINGDESCRIPTION>A specimen that is mounted for microscopic study but without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.: The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: A specimen that has become coagulated.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C78724, C12431, C62755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6562603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unstained slides (bone marrow biopsy)</VALIDVALUE>
          <VALUEMEANING>Unstained Slide Bone Marrow Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A specimen that is mounted for microscopic study but without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.: A biopsy involving the removal of a core tissue containing bone spicules and hematopoietic elements embedded in the marrow stroma.  This procedure is done in the hip area mainly for the diagnosis and evaluation of neoplastic and non-neoplastic hematopoietic disorders (e.g. anemias, leukemias, lymphomas) and the evaluation of the spread of solid tumors (e.g. carcinomas, sarcomas) and lymphomas for therapeutic purposes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15193, C62755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5573204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stained slides (bone marrow aspirate)</VALIDVALUE>
          <VALUEMEANING>Stained slides (bone marrow aspirate)</VALUEMEANING>
          <MEANINGDESCRIPTION>Aspirate from bone marrow._A stained specimen that has been thinly sectioned and adhered to a slide for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C200360, C133261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6571149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unstained slides (bone marrow aspirate)</VALIDVALUE>
          <VALUEMEANING>Unstained slides (bone marrow aspirate)</VALUEMEANING>
          <MEANINGDESCRIPTION>Aspirate from bone marrow._A specimen that is mounted for microscopic study but without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62755, C133261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6571150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tissue</VALIDVALUE>
          <VALUEMEANING>Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Archival Tissue</VALIDVALUE>
          <VALUEMEANING>Archival Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue stored in a biospecimen repository for future study use.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C160656</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6769261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aliquot</VALIDVALUE>
          <VALUEMEANING>Aliquot</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to a portion of the whole; any one of two or more samples of something, of the same volume or weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2584020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Analyte</VALIDVALUE>
          <VALUEMEANING>Analyte</VALUEMEANING>
          <MEANINGDESCRIPTION>The sample or material being subjected to analysis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128639</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7979294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5446318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells</VALIDVALUE>
          <VALUEMEANING>Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3111299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stool</VALIDVALUE>
          <VALUEMEANING>Feces</VALUEMEANING>
          <MEANINGDESCRIPTION>The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mouth rinse</VALIDVALUE>
          <VALUEMEANING>Mouthwash Dosage Form</VALUEMEANING>
          <MEANINGDESCRIPTION>A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579085</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluids</VALIDVALUE>
          <VALUEMEANING>Body Fluid or Substance</VALUEMEANING>
          <MEANINGDESCRIPTION>Liquid and semi liquid substances produced by living organisms to fulfill specific functions or excreted as waste; does not include hormones or enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3212369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow</VALIDVALUE>
          <VALUEMEANING>Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flash Frozen Tissue</VALIDVALUE>
          <VALUEMEANING>Quick Freeze Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>To freeze rapidly so as to preserve structure and prevent ice crystal formation._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C63521</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5573212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Luminal Fluid</VALIDVALUE>
          <VALUEMEANING>Luminal Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Fluid contained within the lumen of a vessel or other tubular structure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188058</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10467533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal-Appearing Duodenal Mucosa</VALIDVALUE>
          <VALUEMEANING>Normal Appearance Duodenal Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no anomalies or unexpected findings on visual inspection._The inner lining of the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C188062, C188060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10467534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cell Pellet</VALIDVALUE>
          <VALUEMEANING>Cell Pellet</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell sample collected and compacted by centrifugation of a liquid suspension.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C113745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-11-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6618600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Whole Blood (RNA Stabilizer)</VALIDVALUE>
          <VALUEMEANING>Ribonucleic Acid Stabilizing Excipient Whole Blood</VALUEMEANING>
          <MEANINGDESCRIPTION>Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis._A substance within a formulation that is used to preserve its integrity and prevent its degradation._Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41067, C176636, C812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12435865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surveillance Mucosal Biopsies</VALIDVALUE>
          <VALUEMEANING>Surveillance Biopsy of Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The systematic collection, analysis, and interpretation of health data on an ongoing basis._Removal of mucosal tissue for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51922, C15719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12571717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopic Research Biopsies</VALIDVALUE>
          <VALUEMEANING>Research Activity Endoscopic Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered._The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. In the case of an endoscopic biopsy, an endoscope is used to obtain the sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15389, C15429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12571718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal Cytology Brushings</VALIDVALUE>
          <VALUEMEANING>Esophageal Endoscopic Brush Cytology</VALUEMEANING>
          <MEANINGDESCRIPTION>Cytologic evaluation of esophageal cells collected by an endoscopic brush.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C192845</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12931368</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2990372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resected Polyp</VALIDVALUE>
          <VALUEMEANING>Resected Polyp</VALUEMEANING>
          <MEANINGDESCRIPTION>Having been removed by surgery._A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3340, C25654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15022289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal Tissue</VALIDVALUE>
          <VALUEMEANING>NORMAL TISSUE</VALUEMEANING>
          <MEANINGDESCRIPTION>An anatomical structure, which consists of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships. Examples: epithelium, muscle tissue, connective tissue, neural tissue, lymphoid tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33177</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559584</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoma</VALIDVALUE>
          <VALUEMEANING>Adenoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-08-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574990</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element New Specimen Order Object Specimen Type Specimen Type Collection Text Type does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element New Specimen Order Object Specimen Type Specimen Type Collection Text Type does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NewSpecimenOrderItem:specimenType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.NewSpecimenOrderItem.specimenType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1286">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783923</PUBLICID>
    <LONGNAME>Order Object Status OrderItemStatus</LONGNAME>
    <PREFERREDNAME>2783156v1.0:2783451v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of requesting that person, business, or organization supply something in return for payment.:Something perceptible by one or more of the senses, especially by vision or touch; a material thing. (dictionary.com)_A condition or state at a particular time._A single unit of information or material within an order</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783156</PublicId>
      <PreferredName>2782851v1.0:2320064v1.0</PreferredName>
      <PreferredDefinition>The act of requesting that person, business, or organization supply something in return for payment.:Something perceptible by one or more of the senses, especially by vision or touch; a material thing. (dictionary.com)_A condition or state at a particular time.</PreferredDefinition>
      <LongName>Order Object Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782851</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48906:C45281</PreferredName>
        <Version>1</Version>
        <LongName>Order Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48906</PREFERRED_NAME>
            <LONG_NAME>Order</LONG_NAME>
            <CON_ID>2534953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45281</PREFERRED_NAME>
            <LONG_NAME>Object</LONG_NAME>
            <CON_ID>2233226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320064</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2783451</PublicId>
      <PreferredName>2783451v1.0</PreferredName>
      <PreferredDefinition>A single unit of information or material within an order</PreferredDefinition>
      <LongName>OrderItemStatus</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>distributed</VALIDVALUE>
          <VALUEMEANING>Distribution</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of distributing or spreading or apportioning.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>new</VALIDVALUE>
          <VALUEMEANING>NEW</VALUEMEANING>
          <MEANINGDESCRIPTION>New; having no previous example or precedent or parallel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2574013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pendingForDistribution</VALIDVALUE>
          <VALUEMEANING>Pending Distribution</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of distributing or spreading or apportioning.:Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470, C45273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pendingProtocolReview</VALIDVALUE>
          <VALUEMEANING>Pending Protocol Review</VALUEMEANING>
          <MEANINGDESCRIPTION>The act of appraisal, evaluation, or analysis.:A rule which guides how an activity should be performed.:Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470, C42651, C42729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pendingSpecimenPreparation</VALIDVALUE>
          <VALUEMEANING>Pending Specimen Preparation</VALUEMEANING>
          <MEANINGDESCRIPTION>The act or process of making something ready; also an anatomic or pathologic specimen made ready and preserved for study.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470, C19157, C25625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783455</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>readyForArrayPreparation</VALIDVALUE>
          <VALUEMEANING>Approval Array Preparation</VALUEMEANING>
          <MEANINGDESCRIPTION>The act or process of making something ready; also an anatomic or pathologic specimen made ready and preserved for study.:An orderly arrangement.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25425, C26358, C25625</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>rejectedInappropriateRequest</VALIDVALUE>
          <VALUEMEANING>Rejected Inappropriate Request</VALUEMEANING>
          <MEANINGDESCRIPTION>Express the need or desire for; ask for.:Not in keeping with what is correct or proper.:Having been judged unacceptable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69304, C74958, C48312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>rejectedSpecimenUnavailable</VALIDVALUE>
          <VALUEMEANING>Rejected Negation Availability Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The quality of being obtainable or accessible and ready for use or service.:An operation in which a term denies or inverts the meaning of another term or construction.:Having been judged unacceptable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69304, C25594, C25429, C19157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>3, 2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>rejectedUnableToCreate</VALIDVALUE>
          <VALUEMEANING>Rejected Negation Creation</VALUEMEANING>
          <MEANINGDESCRIPTION>The process by which something is brought into existence; having been brought into existence.:An operation in which a term denies or inverts the meaning of another term or construction.:Having been judged unacceptable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69304, C25594, C42620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Order Object Status OrderItemStatus does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Order Object Status OrderItemStatus does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OrderItem:status</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.OrderItem.status</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1287">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2783997</PUBLICID>
    <LONGNAME>Recurrent Disease Medical Examination Summary Other Intervention or Procedure java.lang.String</LONGNAME>
    <PREFERREDNAME>2783229v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The return of a disease after a period of remission.:An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.:A shortened version of a speech or written text, containing only the main points._Different than the one(s) previously specified or mentioned.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783229</PublicId>
      <PreferredName>2782741v1.0:2782658v1.0</PreferredName>
      <PreferredDefinition>The return of a disease after a period of remission.:An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.:A shortened version of a speech or written text, containing only the main points._Different than the one(s) previously specified or mentioned.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.</PreferredDefinition>
      <LongName>Recurrent Disease Medical Examination Summary Other Intervention or Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782741</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38155:C25305:C42581</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Disease Medical Examination Summary</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25305</PREFERRED_NAME>
            <LONG_NAME>Medical Examination</LONG_NAME>
            <CON_ID>2202633</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42581</PREFERRED_NAME>
            <LONG_NAME>Summary</LONG_NAME>
            <CON_ID>2203701</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2782658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25218</PreferredName>
        <Version>1</Version>
        <LongName>Other Intervention or Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Recurrent Disease Medical Examination Summary Other Intervention or Procedure java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Recurrent Disease Medical Examination Summary Other Intervention or Procedure java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813059</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.ClinicalAnnotation.RecurrenceHealthExaminationAnnotation.otherProcedure</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RecurrenceHealthExaminationAnnotation:otherProcedure</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1288">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784012</PUBLICID>
    <LONGNAME>Breast Specimen Pathology Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2783244v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783244</PublicId>
      <PreferredName>2782832v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Breast Specimen Pathology Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C19157:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Breast Specimen Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Breast Specimen Pathology Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Breast Specimen Pathology Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813061</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BreastSpecimenPathologyAnnotation:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_Specimen.BreastSpecimenPathologyAnnotation.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1289">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784048</PUBLICID>
    <LONGNAME>Kidney Pathology Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2783280v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>One of the two organs that excrete the urine. The kidneys are bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._A written explanation or criticism or illustration that is added to a book or other textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783280</PublicId>
      <PreferredName>2782811v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>One of the two organs that excrete the urine. The kidneys are bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Kidney Pathology Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782811</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12415:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Kidney Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12415</PREFERRED_NAME>
            <LONG_NAME>Kidney</LONG_NAME>
            <CON_ID>2204911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Kidney Pathology Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Kidney Pathology Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000322</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_SCG.KidneyPathologyAnnotation.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>KidneyPathologyAnnotation:comment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1290">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784121</PUBLICID>
    <LONGNAME>Binary Content Data java.lang.String</LONGNAME>
    <PREFERREDNAME>2783352v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Consisting of two (e.g., units, components, elements, terms, possibilities) or based on two.:Everything that is included in a collection, container, or communication._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783352</PublicId>
      <PreferredName>2782842v1.0:2423441v1.0</PreferredName>
      <PreferredDefinition>Consisting of two (e.g., units, components, elements, terms, possibilities) or based on two.:Everything that is included in a collection, container, or communication._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.</PreferredDefinition>
      <LongName>Binary Content Data</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782842</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45969:C44476</PreferredName>
        <Version>1</Version>
        <LongName>Binary Content</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45969</PREFERRED_NAME>
            <LONG_NAME>Binary</LONG_NAME>
            <CON_ID>2388827</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44476</PREFERRED_NAME>
            <LONG_NAME>Content</LONG_NAME>
            <CON_ID>2236544</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423441</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474</PreferredName>
        <Version>1</Version>
        <LongName>Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Binary Content Data java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Binary Content Data java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813062</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000671</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.pathology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000670</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BinaryContent:data</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.pathology.BinaryContent.data</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1291">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784161</PUBLICID>
    <LONGNAME>Retropubic Enucleation Pathology Seminal Vesicle Tumor Cell Invasion SeminalVesicleInvasion</LONGNAME>
    <PREFERREDNAME>2783392v1.0:2783524v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Denoting the area posterior to the pubic bone.:A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Glands that help produce semen.:Tumor Cell Invasion is the local spread of tumor cells of a malignant neoplasm through infiltration or destruction of adjacent tissue; for epithelial neoplasms, invasion signifies infiltration beneath the epithelial basement membrane._Spreading of cancer cells</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783392</PublicId>
      <PreferredName>2782787v1.0:2431253v1.0</PreferredName>
      <PreferredDefinition>Denoting the area posterior to the pubic bone.:A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Glands that help produce semen.:Tumor Cell Invasion is the local spread of tumor cells of a malignant neoplasm through infiltration or destruction of adjacent tissue; for epithelial neoplasms, invasion signifies infiltration beneath the epithelial basement membrane.</PreferredDefinition>
      <LongName>Retropubic Enucleation Pathology Seminal Vesicle Tumor Cell Invasion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782787</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71904:C48601:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Retropubic Enucleation Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71904</PREFERRED_NAME>
            <LONG_NAME>Retropubic</LONG_NAME>
            <CON_ID>2730270</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48601</PREFERRED_NAME>
            <LONG_NAME>Enucleation</LONG_NAME>
            <CON_ID>2431185</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431253</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12787:C20625</PreferredName>
        <Version>1</Version>
        <LongName>Seminal Vesicle Tumor Cell Invasion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12787</PREFERRED_NAME>
            <LONG_NAME>Seminal Vesicle</LONG_NAME>
            <CON_ID>2204870</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20625</PREFERRED_NAME>
            <LONG_NAME>Tumor Cell Invasion</LONG_NAME>
            <CON_ID>2203828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2783524</PublicId>
      <PreferredName>2783524v1.0</PreferredName>
      <PreferredDefinition>Spreading of cancer cells</PreferredDefinition>
      <LongName>SeminalVesicleInvasion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28389</PreferredName>
        <Version>1</Version>
        <LongName>NCI Administrative Concept</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>noSeminalVesiclePresent</VALIDVALUE>
          <VALUEMEANING>Seminal Vesicle Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.:One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12787, C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2783525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>notIdentified</VALIDVALUE>
          <VALUEMEANING>Not Identified</VALUEMEANING>
          <MEANINGDESCRIPTION>The finding is not present, but a value of &#39;none&#39; cannot be unequivocally established absence in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48661</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2581153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>notSpecified</VALIDVALUE>
          <VALUEMEANING>Unspecified</VALUEMEANING>
          <MEANINGDESCRIPTION>Not stated explicitly or in detail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2573360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>present</VALIDVALUE>
          <VALUEMEANING>Present</VALUEMEANING>
          <MEANINGDESCRIPTION>Being or existing in a specified place or at the specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25626</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>absent</VALIDVALUE>
          <VALUEMEANING>Absent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Retropubic Enucleation Pathology Seminal Vesicle Tumor Cell Invasion SeminalVesicleInvasion does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Retropubic Enucleation Pathology Seminal Vesicle Tumor Cell Invasion SeminalVesicleInvasion does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000322</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.PathAnnotation_SCG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.PathAnnotation_SCG.RetropubicEnucleationPathologyAnnotation.seminalVesicleInvasion</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RetropubicEnucleationPathologyAnnotation:seminalVesicleInvasion</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1292">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2784176</PUBLICID>
    <LONGNAME>Negation Disease or Disorder History Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2783407v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An operation in which a term denies or inverts the meaning of another term or construction.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2783407</PublicId>
      <PreferredName>2782747v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>An operation in which a term denies or inverts the meaning of another term or construction.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Negation Disease or Disorder History Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782747</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C2991:C54625</PreferredName>
        <Version>1</Version>
        <LongName>Negation Disease or Disorder History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Negation Disease or Disorder History Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Negation Disease or Disorder History Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2782636</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813059</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.ClinicalAnnotation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.ClinicalAnnotation.NoEvidentDiseaseHealthAnnotation.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NoEvidentDiseaseHealthAnnotation:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1293">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2787872</PUBLICID>
    <LONGNAME>Blinded Clinical Study And Randomized Trial Pharmacologic Substance Administered Specify Text</LONGNAME>
    <PREFERREDNAME>BLND_RAND_PS_ADM_SPC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe the blinded and randomized trial agent that was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2787850</PublicId>
      <PreferredName>BLND_RAND_TRL_PS_ADM</PreferredName>
      <PreferredDefinition>A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s)._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group.  Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively.  At the time of the trial, it is not known which treatment is best. It is the patient&#39;s choice to be in a randomized trial._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Blinded Clinical Study And Randomized Trial Pharmacologic Substance Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2955173</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70840:C37912:C15417:C1909</PreferredName>
        <Version>1</Version>
        <LongName>Blinded Clinical Study And Randomized Clinical Trial Pharmacologic Substance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70840</PREFERRED_NAME>
            <LONG_NAME>Blinded Clinical Study</LONG_NAME>
            <CON_ID>2714973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15417</PREFERRED_NAME>
            <LONG_NAME>Randomized Clinical Trial</LONG_NAME>
            <CON_ID>2607500</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the blinded randomize</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the blinded randomized trial agent administered:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify agent:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify trial agent</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify trial agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2787872</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedProcedure &gt; DefinedActivity &gt; Product &gt; MaterialName.name WHERE MaterialName.typeCode = &quot;blinded&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify trial agent:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify trial agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify trial agent:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify trial agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify study agent:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify study agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify blinded randomized trial agent:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify blinded randomized trial agent:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2300r1: Greater Than 2 Years Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842912</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapy</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2842918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cgvhd_trt_blinded_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>agvhd_trt_blinded_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>agvhd_prevent_blind_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MaterialName:name</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_AGHD_blind_trial_agent_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_AGHD_p_blind_trl_agt_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_CGHD_blind_trial_agent_sp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1294">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2789933</PUBLICID>
    <LONGNAME>Father Geographic Birth Place Text</LONGNAME>
    <PREFERREDNAME>FAT_GEOG_BIRT_PLAC_T</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that identifies the geographical location where the father was born. [Manually curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACS:American Community Survey 2008 Questionnaire</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2789892</PublicId>
      <PreferredName>FATH_GEOG_BIRT_PLAC</PreferredName>
      <PreferredDefinition>Text that identify the geographical location where the father was born [Manually curated]</PreferredDefinition>
      <LongName>Father Geographic Birth Place</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2595729</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25174</PreferredName>
        <Version>1</Version>
        <LongName>Father</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25174</PREFERRED_NAME>
            <LONG_NAME>Father</LONG_NAME>
            <CON_ID>2202637</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2789888</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37957:C25155:C25319</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Birth Place</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37957</PREFERRED_NAME>
            <LONG_NAME>Geographic</LONG_NAME>
            <CON_ID>2434959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2682007</PublicId>
      <PreferredName>BRTH_PLC_TXT</PreferredName>
      <PreferredDefinition>The words that describe the geographic location where a person was born.</PreferredDefinition>
      <LongName>Birth Place Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2682006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25155:C25319:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Birth Place Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was your biological fat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Where was your biological father born?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Demographics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3070841</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1295">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2794427</PUBLICID>
    <LONGNAME>Laboratory Procedure Viable Cell Specimen Outcome Percentage Value</LONGNAME>
    <PREFERREDNAME>LAB_VIA_CEL_SPE_PCTG</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric laboratory percentage value measured, assigned or computed related to the assessment of viable cells in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2763998</PublicId>
      <PreferredName>LAB_VIA_CEL_SPEC_OC</PreferredName>
      <PreferredDefinition>information related to the medical procedure that involves testing a sample of blood, urine, or other substance from the body to determine the viability, capable of life or normal growth and development, of the cells, the smallest units of living structure capable of independent existence, from a bit of tissue or blood or urine that is taken or used for research purposes.</PreferredDefinition>
      <LongName>Laboratory Procedure Viable Cell Specimen Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2763996</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25324:C12508:C19157:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Viable Cell Specimen Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25324</PREFERRED_NAME>
            <LONG_NAME>Viable</LONG_NAME>
            <CON_ID>2206271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12508</PREFERRED_NAME>
            <LONG_NAME>Cell</LONG_NAME>
            <CON_ID>2202900</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019202</PublicId>
      <PreferredName>SPEC_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the percentage value for a specimen laboratory finding.</PreferredDefinition>
      <LongName>Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Percent Cells Viable:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Percent Cells Viable:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Viability of cells</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Viability of cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cell viability: (post-processing)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cell viability: (post-processing)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2794427</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.value(ANY=&gt;PQ) WHERE PerformedObservation &gt; DefinedObservation.nameCode = &quot;Determine Cell Viability&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2006r1: HSCT Infusion</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964920</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2007r1:Cord Blood Unit -SCTOD Data Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3191905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_an_viab_rst</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1296">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2799095</PUBLICID>
    <LONGNAME>Laboratory Procedure Platelet Result Missing Value Reason Indicator</LONGNAME>
    <PREFERREDNAME>2188766v1.0:2756825v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the result of a medical procedure that involves testing a sample of blood for platelets, irregular, disc-shaped fragments of large bone marrow cells called megakaryocytes in the blood that assist in blood clotting._A specific reason explaining why a meaningful value is not available.  A meaningful value answers the question posed by a Data Element Concept.  In contrast, a Missing Value Reason answers the implicit question &quot;Why is there no &#39;meaningful&#39; value?&quot;, when there is none._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188766</PublicId>
      <PreferredName>LAB_PLATE_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of a medical procedure that involves testing a sample of blood for platelets, irregular, disc-shaped fragments of large bone marrow cells called megakaryocytes in the blood that assist in blood clotting.</PreferredDefinition>
      <LongName>Laboratory Procedure Platelet Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738534</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12520:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Platelet Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12520</PREFERRED_NAME>
            <LONG_NAME>Platelet</LONG_NAME>
            <CON_ID>2202377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2756825</PublicId>
      <PreferredName>MISS_IND</PreferredName>
      <PreferredDefinition>A specific reason explaining why a meaningful value is not available.  A meaningful value answers the question posed by a Data Element Concept.  In contrast, a Missing Value Reason answers the implicit question &quot;Why is there no &#39;meaningful&#39; value?&quot;, when there is none._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Missing Value Reason Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2756824</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48655:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Missing Value Reason Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48655</PREFERRED_NAME>
            <LONG_NAME>Missing Value Reason</LONG_NAME>
            <CON_ID>2431146</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-quantitative</VALIDVALUE>
          <VALUEMEANING>Negation Quantitative</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of being estimated or expressed with numeric values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70766, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2777712</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested</VALIDVALUE>
          <VALUEMEANING>Negation Test</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47891, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown/not applicable</VALIDVALUE>
          <VALUEMEANING>Unknown Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.: Determination that a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660, C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2756827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not tested / unknown</VALIDVALUE>
          <VALUEMEANING>Negation Test Or Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998, C37998, C47891, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3262968</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not measurable</VALIDVALUE>
          <VALUEMEANING>Non-Measurable</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-Measurable; not possible to be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2678954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the reason for the pl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the reason for the platelets missing value?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Not tested</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Not tested</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:2799095</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedClinicalResult.valueNullFlavorReason WHERE PerformedClinicalResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Measure Platelet&quot; AND PerformedObservation.negationIndicator = &quot;true&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2000r1: Recipient Baseline Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964872</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2100r1: 100 Days Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964902</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2200r1: 6 Month to 2 Year Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964922</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2131r2: Immune Deficiencies Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3234637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r2: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3638517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>prep_plts_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>current_plt_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_diag_plts_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_mrecent_plt_nt</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1297">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2802268</PUBLICID>
    <LONGNAME>Patient Distress Symptom Scale</LONGNAME>
    <PREFERREDNAME>PT_DYS_SYM_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the person&#39;s symptom scale as related to extreme physical pain or psychological suffering as an indication that a person has a condition or disease.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2801982</PublicId>
      <PreferredName>PT_DISTRE_SYMPT</PreferredName>
      <PreferredDefinition>information related to extreme physical pain or psychological suffering as an indication that a person has a condition or disease.</PreferredDefinition>
      <LongName>Patient Distress Symptom</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2801980</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37942:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Distress Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37942</PREFERRED_NAME>
            <LONG_NAME>Distress</LONG_NAME>
            <CON_ID>2667531</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2801776</PublicId>
      <PreferredName>PERSON_SM_SCALE</PreferredName>
      <PreferredDefinition>the person&#39;s symptom scale.</PreferredDefinition>
      <LongName>Person Symptom Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Your feeling of being distres</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Your feeling of being distressed at its worst</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Your feeling of being distressed (upset) at its WORST?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_DYS_SYM_SCALE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1298">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2802997</PUBLICID>
    <LONGNAME>Trail Making Test Second Part Not Complete Reason Specify</LONGNAME>
    <PREFERREDNAME>TRAIL_MK_TST_PT_B_N_COMP_SPC</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field related to neurocognitive evaluation of Trail Making Test Part B not being done.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2802993</PublicId>
      <PreferredName>5573224v1.0:5590806v1.0</PreferredName>
      <PreferredDefinition>A neuropsychological test of visual attention and task switching that requires a subject to connect a sequence of 25 consecutive targets. It provides an easy to administer and reliable assessment of attention, sequencing, cognition, visual search, and motor function._Coming next after the first in position in space or time or degree or magnitude._One of the portions into which something is regarded as divided and which together constitute a whole._An operation in which a term denies or inverts the meaning of another term or construction._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Trail Making Test Second Part Not Complete Reason</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5573224</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C92205</PreferredName>
        <Version>1</Version>
        <LongName>Trail Making Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C92205</PREFERRED_NAME>
            <LONG_NAME>Trail Making Test</LONG_NAME>
            <CON_ID>3139607</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5590806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5590806v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Second Part Negation Complete Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45313</PREFERRED_NAME>
            <LONG_NAME>Part</LONG_NAME>
            <CON_ID>2405237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018806</PublicId>
      <PreferredName>ASSESS_SPEC</PreferredName>
      <PreferredDefinition>The free text field to specify the assessment performed.</PreferredDefinition>
      <LongName>Assessment Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Not tested, other reason spec</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Not tested, other reason specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1299">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2807564</PUBLICID>
    <LONGNAME>Person Integer::2 Minute Walking Distance International Foot Value</LONGNAME>
    <PREFERREDNAME>PERS_2_MIN_DIST_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the number of feet walked by an individual in 2 minutes.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2807562</PublicId>
      <PreferredName>PERS_2_MIN_WLK_DIST</PreferredName>
      <PreferredDefinition>Person; a human being._A number with no fractional part, including the negative and positive numbers as well as zero.::2_A unit measure of time equal to 60 seconds._The act of traveling by foot._The space separating two objects or points._A unit measure of time equal to 60 seconds.</PreferredDefinition>
      <LongName>Person Integer::2 Minute Walking Distance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2807560</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C45255::2:C48154:C73554</PreferredName>
        <Version>1</Version>
        <LongName>Person Integer::2 Minute Walking</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::2</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48154</PREFERRED_NAME>
            <LONG_NAME>Minute</LONG_NAME>
            <CON_ID>2513263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73554</PREFERRED_NAME>
            <LONG_NAME>Walking</LONG_NAME>
            <CON_ID>2743260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2436194</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25167</PreferredName>
        <Version>1</Version>
        <LongName>Distance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25167</PREFERRED_NAME>
            <LONG_NAME>Distance</LONG_NAME>
            <CON_ID>2203902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2807557</PublicId>
      <PreferredName>DIST_FT_VAL</PreferredName>
      <PreferredDefinition>The space separating two objects or points._A unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.(NCI)_A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Distance International Foot Value</LongName>
      <Version>2.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2807556</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25167:C71253:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Distance International Foot Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25167</PREFERRED_NAME>
            <LONG_NAME>Distance</LONG_NAME>
            <CON_ID>2203902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71253</PREFERRED_NAME>
            <LONG_NAME>International Foot</LONG_NAME>
            <CON_ID>2807555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name># Feet walked in 2 minutes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText># Feet walked in 2 minutes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1300">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2807848</PUBLICID>
    <LONGNAME>Reference Object Calculation Unique Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2807836v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Something referred to; the object of a reference.:The procedure or activity of determining something by mathematical or logical methods._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2807836</PublicId>
      <PreferredName>2750177v1.0:2231610v1.0</PreferredName>
      <PreferredDefinition>Something referred to; the object of a reference.:The procedure or activity of determining something by mathematical or logical methods._The single one of its kind.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Reference Object Calculation Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750177</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48294:C54125</PreferredName>
        <Version>1</Version>
        <LongName>Reference Object Calculation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54125</PREFERRED_NAME>
            <LONG_NAME>Calculation</LONG_NAME>
            <CON_ID>2654477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45282:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45282</PREFERRED_NAME>
            <LONG_NAME>Unique</LONG_NAME>
            <CON_ID>2231550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Reference Object Calculation Unique Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Reference Object Calculation Unique Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813012</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 2.0</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 3.0</PreferredName>
          <Version>3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3079208</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 1.5</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ReferencedCalculation.uniqueIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ReferencedCalculation:uniqueIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1301">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2816788</PUBLICID>
    <LONGNAME>Patient Pulmonary Fibrosis Personal Medical History Ind-3</LONGNAME>
    <PREFERREDNAME>PT_PULMFIB_PMH_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator that asks whether the patient/participant has pulmonary fibrosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2816786</PublicId>
      <PreferredName>PT_PULMFIBROSIS_PMH</PreferredName>
      <PreferredDefinition>information relating to the personal medical history (an account of all medical events and problems a person has experienced) of pulmonary fibrosis (chronic inflammation and progressive fibrosis of the pulmonary alveolar walls, with steadily progressive dyspnea, resulting finally in death from oxygen lack or right heart failure).</PreferredDefinition>
      <LongName>Patient Pulmonary Fibrosis Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2816784</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26869:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Pulmonary Fibrosis Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26869</PREFERRED_NAME>
            <LONG_NAME>Pulmonary Fibrosis</LONG_NAME>
            <CON_ID>2203697</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pulmonary fibrosis</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pulmonary fibrosis</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a history of pulmonary fibrosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or known active pneumonitis, excluding history of radiation pneumonitis in the radiation field?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1216</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104934</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_PULMFIB_PMH_IND3</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1302">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2819873</PUBLICID>
    <LONGNAME>Copy Number Analysis Programming Parameter Expectation Maximization Algorithm Iteration Number java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2819825v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:A value that is passed to a routine._Algorithm used in statistics for finding maximum likelihood estimates of parameters in probabilistic models, where the model depends on unobserved latent (inferred) variables.:Doing or saying again; a repeated performance.:A numeral or string of numerals expressing value, quantity, or identification._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2819825</PublicId>
      <PreferredName>2819800v1.0:2819779v1.0</PreferredName>
      <PreferredDefinition>The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.:Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:A value that is passed to a routine._Algorithm used in statistics for finding maximum likelihood estimates of parameters in probabilistic models, where the model depends on unobserved latent (inferred) variables.:Doing or saying again; a repeated performance.:A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Copy Number Analysis Programming Parameter Expectation Maximization Algorithm Iteration Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2819800</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49142:C25391:C48913</PreferredName>
        <Version>1</Version>
        <LongName>Copy Number Analysis Programming Parameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49142</PREFERRED_NAME>
            <LONG_NAME>Copy Number</LONG_NAME>
            <CON_ID>2528506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48913</PREFERRED_NAME>
            <LONG_NAME>Programming Parameter</LONG_NAME>
            <CON_ID>2451932</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2819779</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75945:C63922:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Expectation Maximization Algorithm Iteration Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75945</PREFERRED_NAME>
            <LONG_NAME>Expectation Maximization Algorithm</LONG_NAME>
            <CON_ID>2819758</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63922</PREFERRED_NAME>
            <LONG_NAME>Iteration</LONG_NAME>
            <CON_ID>2557753</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Copy Number Analysis Programming Parameter Expectation Maximization Algorithm Iteration Number java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Copy Number Analysis Programming Parameter Expectation Maximization Algorithm Iteration Number java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2819751</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Copy Number Analysis Tool</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.icr.asrv1.cnat</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2819753</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.icr.asrv1.cnat.CnatParameters.eMIterations</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CnatParameters:eMIterations</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1303">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2820739</PUBLICID>
    <LONGNAME>Transplantation Alternative Entry Anatomic Site java.lang.String</LONGNAME>
    <PREFERREDNAME>2820719v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The grafting of tissues from one individual to another or place to place within a single individual._Available in place of something else.:An item inserted in a written or electronic record.:Named locations of or within the body._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2820719</PublicId>
      <PreferredName>2820715v1.0:2778340v1.0</PreferredName>
      <PreferredDefinition>The grafting of tissues from one individual to another or place to place within a single individual._Available in place of something else.:An item inserted in a written or electronic record.:Named locations of or within the body.</PreferredDefinition>
      <LongName>Transplantation Alternative Entry Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2820715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15342</PreferredName>
        <Version>1</Version>
        <LongName>Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2778340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25415:C43381:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Alternative Entry Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25415</PREFERRED_NAME>
            <LONG_NAME>Alternative</LONG_NAME>
            <CON_ID>2206155</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43381</PREFERRED_NAME>
            <LONG_NAME>Entry</LONG_NAME>
            <CON_ID>2236576</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Transplantation Alternative Entry Anatomic Site java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Transplantation Alternative Entry Anatomic Site java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Transplantation.adminSiteAlternEntry</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Transplantation:adminSiteAlternEntry</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1304">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2820745</PUBLICID>
    <LONGNAME>Transplantation Transplantation Harvest Procedure Time java.lang.String</LONGNAME>
    <PREFERREDNAME>2820725v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The grafting of tissues from one individual to another or place to place within a single individual._The grafting of tissues from one individual to another or place to place within a single individual.:Remove from a culture or a living or dead body, as for the purposes of transplantation.:The continuum of experience in which events pass from the future through the present to the past._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2820725</PublicId>
      <PreferredName>2820715v1.0:2778345v1.0</PreferredName>
      <PreferredDefinition>The grafting of tissues from one individual to another or place to place within a single individual._The grafting of tissues from one individual to another or place to place within a single individual.:Remove from a culture or a living or dead body, as for the purposes of transplantation.:The continuum of experience in which events pass from the future through the present to the past.</PreferredDefinition>
      <LongName>Transplantation Transplantation Harvest Procedure Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2820715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15342</PreferredName>
        <Version>1</Version>
        <LongName>Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2778345</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15342:C37963:C25207</PreferredName>
        <Version>1</Version>
        <LongName>Transplantation Harvest Procedure Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37963</PREFERRED_NAME>
            <LONG_NAME>Harvest Procedure</LONG_NAME>
            <CON_ID>2202648</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Transplantation Transplantation Harvest Procedure Time java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Transplantation Transplantation Harvest Procedure Time java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2534690</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMOD_2.5</PreferredName>
          <Version>2.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.camod.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000547</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.camod.domain.Transplantation.growthPeriod</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Transplantation:growthPeriod</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1305">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2821178</PUBLICID>
    <LONGNAME>Agent Reduced Percentage Quantity Ind-2</LONGNAME>
    <PREFERREDNAME>AGT_RED_PTG_QTY_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the dose was reduced more than 20%.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2821176</PublicId>
      <PreferredName>AGT_REDUC_PTG_QTY</PreferredName>
      <PreferredDefinition>information relating to a decrease in the percentage (a fraction or ratio with 100 understood as the denominator) amount taken of an agent (a substance, physical or biological factor, etc., that produces a specific effect).</PreferredDefinition>
      <LongName>Agent Reduced Percentage Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2821174</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25640:C25613:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Reduced Percentage Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was dose reduced more than 20%</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was dose reduced more than 20%</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811949</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Brain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000134</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Primary Brain New</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000561</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1306">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2822298</PUBLICID>
    <LONGNAME>Patient Lung Pathologic T Stage Clinical Trial Eligibility Criteria Status</LONGNAME>
    <PREFERREDNAME>PT_L_P_TST_CTEC_STAT</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of a patient&#39;s lung pathologic T stage in relation to clinical trial eligibility.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2822289</PublicId>
      <PreferredName>PT_L_PATH_TSTG_CTEC</PreferredName>
      <PreferredDefinition>information relating to lung (the organs of respiration in which aeration of the blood takes place) pathologic (caused by or altered by or manifesting disease or pathology) T stage (T refers to the extent of tumor involvement at the primary site) and determining whether a patient/participant is suitable for enrollment in a study according to protocol criteria and procedures.</PreferredDefinition>
      <LongName>Patient Lung Pathologic T Stage Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2822287</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C25610:C25728:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Lung Pathologic T Stage Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2822294</PublicId>
      <PreferredName>L_PTH_TSTG_ELIG_STAT</PreferredName>
      <PreferredDefinition>the status of a patient&#39;s lung pathologic T stage in relation to clinical trial eligibility.</PreferredDefinition>
      <LongName>Lung Pathologic T Stage Eligibility Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T3-4</VALIDVALUE>
          <VALUEMEANING>T3-4</VALUEMEANING>
          <MEANINGDESCRIPTION>A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures._Used as a function word to indicate direction, purpose, or movement._A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48732, C65107, C48728</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2822295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2</VALIDVALUE>
          <VALUEMEANING>T2</VALUEMEANING>
          <MEANINGDESCRIPTION>A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48724</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1</VALIDVALUE>
          <VALUEMEANING>T1</VALUEMEANING>
          <MEANINGDESCRIPTION>T1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>T stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>T stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Criteria</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811954</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1307">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2823307</PUBLICID>
    <LONGNAME>FACT-L Questionnaire Total Score</LONGNAME>
    <PREFERREDNAME>FACTL_TTL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Questionnaire to assess cancer subject functionality through the use of Likert scale questions; a core instrument is the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, with a lung cancer-specific subscale to complement the FACT-G. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2823303</PublicId>
      <PreferredName>FACTL_QUEST_ASSESS</PreferredName>
      <PreferredDefinition>Questionnaire to assess cancer subject functionality through the use of Likert scale questions._A general quality of life instrument intended for use with a variety of chronic illness conditions. A core instrument in the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, a system which has multiple disease-, treatment-, and condition-specific subscales to complement the FACT-G._One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border. SYN pulmo._An ordered reference standard used to measure incremental changes._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>FACT-L Questionnaire Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2823301</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45899:C12468:C25664</PreferredName>
        <Version>1</Version>
        <LongName>FACT-G Questionnaire Lung Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45899</PREFERRED_NAME>
            <LONG_NAME>FACT-G Questionnaire</LONG_NAME>
            <CON_ID>2552004</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2823305</PublicId>
      <PreferredName>FACTL_TTL_SC</PreferredName>
      <PreferredDefinition>A core instrument in the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, a system which has multiple disease-, treatment-, and condition-specific subscales to complement the FACT-G._A general quality of life instrument intended for use with a variety of chronic illness conditions. One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border. SYN pulmo._An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>FACT-L Questionnaire Lung Scale Total Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>144</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2823304</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45899:C12468:C25664:C25338</PreferredName>
        <Version>1</Version>
        <LongName>FACT-G Questionnaire Lung Scale Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45899</PREFERRED_NAME>
            <LONG_NAME>FACT-G Questionnaire</LONG_NAME>
            <CON_ID>2552004</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-L Questionnaire Total Sc</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>FACT-L Questionnaire Total Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Nebraska Med Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812726</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UNMC New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812870</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1308">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2825151</PUBLICID>
    <LONGNAME>Lab Test Panel Coagulation Name</LONGNAME>
    <PREFERREDNAME>LAB_TST_PNL_COAG_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name that describes the procedure that invloves the process of clot formation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2186110</PublicId>
      <PreferredName>LAB_TST_PANEL</PreferredName>
      <PreferredDefinition>A group or panel of lab tests, often logically grouped according to type of testing (Hematology, Chemistry, Coagulation) or specimen type (Blood, Urine, CSF).</PreferredDefinition>
      <LongName>Lab Test Panel</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2180899</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>laboratory test</PreferredName>
        <Version>1</Version>
        <LongName>laboratory test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0022885</PREFERRED_NAME>
            <LONG_NAME>laboratory test</LONG_NAME>
            <CON_ID>2203066</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192091</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Grouping</PreferredName>
        <Version>1</Version>
        <LongName>Grouping</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL052214</PREFERRED_NAME>
            <LONG_NAME>Grouping</LONG_NAME>
            <CON_ID>2204557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2825147</PublicId>
      <PreferredName>COAG_LAB_PROC_NM</PreferredName>
      <PreferredDefinition>The name that describes the procedure that invloves the process of clot formation.</PreferredDefinition>
      <LongName>Coagulation Laboratory Procedure Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>2825146</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20812:C25294:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Coagulation Laboratory Procedure Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20812</PREFERRED_NAME>
            <LONG_NAME>Coagulation</LONG_NAME>
            <CON_ID>2203681</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total Protein S</VALIDVALUE>
          <VALUEMEANING>Total Protein S</VALUEMEANING>
          <MEANINGDESCRIPTION>Total Protein S</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825148</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Von Willebrand</VALIDVALUE>
          <VALUEMEANING>Von Willebrand</VALUEMEANING>
          <MEANINGDESCRIPTION>Von Willebrand</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825149</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Factor VIII</VALIDVALUE>
          <VALUEMEANING>Factor VIII</VALUEMEANING>
          <MEANINGDESCRIPTION>Factor VIII</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Factor IX</VALIDVALUE>
          <VALUEMEANING>Factor IX</VALUEMEANING>
          <MEANINGDESCRIPTION>Factor IX</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Test</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Test</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1309">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2826927</PUBLICID>
    <LONGNAME>Skin Quality of Life Work Activity Problem Assessment Scale</LONGNAME>
    <PREFERREDNAME>S_QOL_W_A_P_AS_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the quality of life assessment scale to evaluate how much a patient/participant&#39;s skin has been a problem at work or during studying over the last week.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2826898</PublicId>
      <PreferredName>SKN_QOL_W_A_P_ASSESS</PreferredName>
      <PreferredDefinition>information relating to skin (the external surface of the body, including in addition to the epidermis and dermis, all of the derivatives of the epidermis) and a problem (a state of difficulty that needs to be resolved) with work (exertion or effort directed to produce or accomplish something) activity (the state of being active), as part of the subjective measurement of an individual&#39;s sense of well-being and ability to enjoy life.</PreferredDefinition>
      <LongName>Skin Quality of Life Work Activity Problem Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2826881</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12470:C17047</PreferredName>
        <Version>1</Version>
        <LongName>Skin Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2826896</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74299:C43431:C28020:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Work Activity Problem Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74299</PREFERRED_NAME>
            <LONG_NAME>Work</LONG_NAME>
            <CON_ID>2758919</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2194224</PublicId>
      <PreferredName>PT_ASSESS_SCALE</PreferredName>
      <PreferredDefinition>the scale of patient assessment.</PreferredDefinition>
      <LongName>Patient Assessment Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>75</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not relevant</VALIDVALUE>
          <VALUEMEANING>Not relevant</VALUEMEANING>
          <MEANINGDESCRIPTION>Not relevant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A lot</VALIDVALUE>
          <VALUEMEANING>A LOT</VALUEMEANING>
          <MEANINGDESCRIPTION>A LOT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, more than once</VALIDVALUE>
          <VALUEMEANING>Yes, more than once</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, more than once</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, once</VALIDVALUE>
          <VALUEMEANING>Yes, once</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, once</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily</VALIDVALUE>
          <VALUEMEANING>About once a day</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Several times a week</VALIDVALUE>
          <VALUEMEANING>Several times a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Several times a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3203325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>About once a week</VALIDVALUE>
          <VALUEMEANING>ABOUT ONCE A WEEK</VALUEMEANING>
          <MEANINGDESCRIPTION>About once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than once a week</VALIDVALUE>
          <VALUEMEANING>Less than once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than once a week</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3120272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, not limited at all</VALIDVALUE>
          <VALUEMEANING>No, not limited at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No, not limited at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a little</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Little</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a lot</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Lot</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Lot</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>Slightly</VALUEMEANING>
          <MEANINGDESCRIPTION>Slightly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered somewhat</VALIDVALUE>
          <VALUEMEANING>Bothered somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered somewhat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little</VALIDVALUE>
          <VALUEMEANING>Bothered a little</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered a little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not bothered at all</VALIDVALUE>
          <VALUEMEANING>Not bothered at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not bothered at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not well</VALIDVALUE>
          <VALUEMEANING>Not well</VALUEMEANING>
          <MEANINGDESCRIPTION>Not well</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5290195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very well</VALIDVALUE>
          <VALUEMEANING>Very Well</VALUEMEANING>
          <MEANINGDESCRIPTION>Existing to a great degree.: A cavity or vessel used to contain liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70592, C116076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5290196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Well</VALIDVALUE>
          <VALUEMEANING>Well</VALUEMEANING>
          <MEANINGDESCRIPTION>Well</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-06-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4975879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable to me</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5805854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Very Much</VALIDVALUE>
          <VALUEMEANING>Not Very Much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of disagreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5806311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prefer not to answer</VALIDVALUE>
          <VALUEMEANING>Prefer Not to Answer</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual prefers or preferred not to answer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C132222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5684650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Over the last week how much h</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Over the last week how much has your skin been a problem at work or studying</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Head and Neck</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811912</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0920</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>S_QOL_W_A_P_AS_SCALE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1310">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2827605</PUBLICID>
    <LONGNAME>Magnetic Resonance Spectroscopy Lactate Creatine Metabolite Ratio Value</LONGNAME>
    <PREFERREDNAME>MRS_LACCRE_RATIO_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value for the ratio of brain metabolites Lactate and Creatine as a measure of function in an individual undergoing an MR imaging scan. [Manually-curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2827603</PublicId>
      <PreferredName>MRS_LAC_CRE_RATIO</PreferredName>
      <PreferredDefinition>Detection and measurement of the resonant spectra of molecular species in a tissue or sample._The sodium salt of the dextro isomer of lactic acid with alkalinizing and electrolyte replenishing property. Upon metabolism, sodium lactate D is converted to bicarbonate, thereby increasing plasma bicarbonate, which facilitates removal of hydrogen ion and lactate from blood stream and leads to raised blood pH._An endogenous amino acid derivative produced by vertebrate animals and occurring primarily in muscle cells.  Creatine is important for energy storage; it is phosphorylated to creatine phosphate, which serves as a phosphate donor in the conversion of ADP to ATP and supplies energy necessary for muscle contraction.  Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases._Quotient of quantities of the same kind for different components within the same system.</PreferredDefinition>
      <LongName>Magnetic Resonance Spectroscopy Lactate Creatine Ratio</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2827585</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16810</PreferredName>
        <Version>1</Version>
        <LongName>Magnetic Resonance Spectroscopy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16810</PREFERRED_NAME>
            <LONG_NAME>Magnetic Resonance Spectroscopy</LONG_NAME>
            <CON_ID>2827584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2827601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61718:C37937:C44256</PreferredName>
        <Version>1</Version>
        <LongName>Sodium Lactate, D- Creatine Ratio</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61718</PREFERRED_NAME>
            <LONG_NAME>Sodium Lactate, D-</LONG_NAME>
            <CON_ID>2827600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37937</PREFERRED_NAME>
            <LONG_NAME>Creatine</LONG_NAME>
            <CON_ID>2827594</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2827591</PublicId>
      <PreferredName>MET_RATIO_VAL</PreferredName>
      <PreferredDefinition>Any substance involved in metabolism, either as a product of metabolism or as necessary for metabolism._Quotient of quantities of the same kind for different components within the same system._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Metabolite Ratio Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2827590</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61154:C44256:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Metabolite Ratio Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61154</PREFERRED_NAME>
            <LONG_NAME>Metabolite</LONG_NAME>
            <CON_ID>2486651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lac/Cre</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lac/Cre</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mass General Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MGH New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813098</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1311">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2829904</PUBLICID>
    <LONGNAME>Tooth Therapy Other Administered Specify</LONGNAME>
    <PREFERREDNAME>TOO_TX_O_ADMIN_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field related to other treatment for the tooth being administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2829888</PublicId>
      <PreferredName>TOOTH_TX_O_ADMIN</PreferredName>
      <PreferredDefinition>information related to other treatment for tooth being administered.</PreferredDefinition>
      <LongName>Tooth Therapy Other Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443548</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12506:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Tooth Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207818</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Other Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1312">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2830251</PUBLICID>
    <LONGNAME>Animal Participant Organism Strain java.lang.String</LONGNAME>
    <PREFERREDNAME>2830141v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A living organism that has membranous cell walls, requires oxygen and organic foods, and is capable of voluntary movement, as distinguished from a plant or mineral.:Someone who takes part in an activity._A population or type of organisms that is geneticaly different from others of the same species and possessing a set of defined characteristics._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2830141</PublicId>
      <PreferredName>2830101v1.0:2437759v1.0</PreferredName>
      <PreferredDefinition>A living organism that has membranous cell walls, requires oxygen and organic foods, and is capable of voluntary movement, as distinguished from a plant or mineral.:Someone who takes part in an activity._A population or type of organisms that is geneticaly different from others of the same species and possessing a set of defined characteristics.</PreferredDefinition>
      <LongName>Animal Participant Organism Strain</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2830101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14182:C29867</PreferredName>
        <Version>1</Version>
        <LongName>Animal Participant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14182</PREFERRED_NAME>
            <LONG_NAME>Animal</LONG_NAME>
            <CON_ID>2210812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2437759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14419</PreferredName>
        <Version>1</Version>
        <LongName>Organism Strain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14419</PREFERRED_NAME>
            <LONG_NAME>Organism Strain</LONG_NAME>
            <CON_ID>2422627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Animal Participant Organism Strain java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Animal Participant Organism Strain java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2619399</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caElmir</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.AnimalParticipant.strain</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnimalParticipant:strain</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1313">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2842562</PUBLICID>
    <LONGNAME>Specimen Primary Malignant Neoplasm Prostate Gland Submission Type</LONGNAME>
    <PREFERREDNAME>2841448v1.0:2842556v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of submission of a tissue specimen taken from the prostate, walnut shaped accessory sex gland of the male reproductive system that secretes a fluid which is part of the semen, containing a sample of the primary malignant neoplasm, a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2841448</PublicId>
      <PreferredName>2241613v1.0:2841445v1.0</PreferredName>
      <PreferredDefinition>information related to submission of a tissue specimen taken from the prostate, walnut shaped accessory sex gland of the male reproductive system that secretes a fluid which is part of the semen, containing a sample of the primary malignant neoplasm, a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.</PreferredDefinition>
      <LongName>Specimen Primary Malignant Neoplasm Prostate Gland Submission</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2841445</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C9305:C12410:C25695</PreferredName>
        <Version>1</Version>
        <LongName>Primary Malignant Neoplasm Prostate Gland Submission</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25695</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2203811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2842556</PublicId>
      <PreferredName>2842556v1.0</PreferredName>
      <PreferredDefinition>the type of submission of a primary maligant neoplasm specimen.</PreferredDefinition>
      <LongName>Specimen Primary Malignant Neoplasm Submission Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paraffin block</VALIDVALUE>
          <VALUEMEANING>Tissue, Paraffin</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue that is preserved and embedded in paraffin</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842557</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unstained slide</VALIDVALUE>
          <VALUEMEANING>Unstained Specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A specimen that is mounted for microscopic study but without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slides</VALIDVALUE>
          <VALUEMEANING>Slides</VALUEMEANING>
          <MEANINGDESCRIPTION>Slides</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Block</VALIDVALUE>
          <VALUEMEANING>Block</VALUEMEANING>
          <MEANINGDESCRIPTION>Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25436</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4721104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Representative primary tumor</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Representative primary tumor from prostate</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Labs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811957</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1314">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2848506</PUBLICID>
    <LONGNAME>Single Nucleotide Polymorphism External Uniform Resource Locator External Database Name java.lang.String</LONGNAME>
    <PREFERREDNAME>2848357v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:Happening or arising or located outside or beyond some limits, or especially, some surface.:The global address of documents and other resources on the World Wide Web. The first part of the address indicates what protocol to use, and the second part specifies the IP address or the domain name where the resource is located._Happening or arising or located outside or beyond some limits, or especially, some surface.:An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.:The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2848357</PublicId>
      <PreferredName>2848335v1.0:2848265v1.0</PreferredName>
      <PreferredDefinition>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:Happening or arising or located outside or beyond some limits, or especially, some surface.:The global address of documents and other resources on the World Wide Web. The first part of the address indicates what protocol to use, and the second part specifies the IP address or the domain name where the resource is located._Happening or arising or located outside or beyond some limits, or especially, some surface.:An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Single Nucleotide Polymorphism External Uniform Resource Locator External Database Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2848335</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18279:C44280:C42743</PreferredName>
        <Version>1</Version>
        <LongName>Single Nucleotide Polymorphism External Uniform Resource Locator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18279</PREFERRED_NAME>
            <LONG_NAME>Single Nucleotide Polymorphism</LONG_NAME>
            <CON_ID>2433334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44280</PREFERRED_NAME>
            <LONG_NAME>External</LONG_NAME>
            <CON_ID>2422632</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42743</PREFERRED_NAME>
            <LONG_NAME>Uniform Resource Locator</LONG_NAME>
            <CON_ID>2224026</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2848265</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44280:C15426:C42614</PreferredName>
        <Version>1</Version>
        <LongName>External Database Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44280</PREFERRED_NAME>
            <LONG_NAME>External</LONG_NAME>
            <CON_ID>2422632</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15426</PREFERRED_NAME>
            <LONG_NAME>Database</LONG_NAME>
            <CON_ID>2228339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Single Nucleotide Polymorphism External Uniform Resource Locator External Database Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Single Nucleotide Polymorphism External Uniform Resource Locator External Database Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2611721</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CGWB</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cgwb.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000139</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cgwb.domain.SNPExternalLink.extSNPDatabase</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SNPExternalLink:extSNPDatabase</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1315">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2852193</PUBLICID>
    <LONGNAME>Quality of Life Fatigue Wash Evaluation Scale</LONGNAME>
    <PREFERREDNAME>QOL_FAT_W_EVAL_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the scale to determine how much, in the past week, fatigue interfered with the patient&#39;s ability to bathe and dress themselves.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2787222</PublicId>
      <PreferredName>QOL_FAT_WAH_EVA</PreferredName>
      <PreferredDefinition>information related to fatigue, the state, following a period of mental or bodily activity, causing an inability to cleanse with a cleaning agent, such as soap and water, as a measure of well-being and ability to enjoy life.</PreferredDefinition>
      <LongName>Quality of Life Fatigue Wash Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2736450</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17047</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2787220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3036:C65077:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Fatigue Wash Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3036</PREFERRED_NAME>
            <LONG_NAME>Fatigue</LONG_NAME>
            <CON_ID>2202444</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65077</PREFERRED_NAME>
            <LONG_NAME>Wash</LONG_NAME>
            <CON_ID>2673223</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2801776</PublicId>
      <PreferredName>PERSON_SM_SCALE</PreferredName>
      <PreferredDefinition>the person&#39;s symptom scale.</PreferredDefinition>
      <LongName>Person Symptom Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>WHOLE NUMBER</VALUEMEANING>
          <MEANINGDESCRIPTION>WHOLE NUMBER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560444</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rate how much, in the past we</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Rate how much, in the past week, fatigue interfered with your ability to bathe and dress yourself</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Char.</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811959</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1316">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2860322</PUBLICID>
    <LONGNAME>Physical Participant Object Location java.lang.String</LONGNAME>
    <PREFERREDNAME>2860283v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:Something that takes part in an activity._A position, site, or point in space where something can be found._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2860283</PublicId>
      <PreferredName>2860268v1.0:2240715v1.0</PreferredName>
      <PreferredDefinition>Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:Something that takes part in an activity._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Physical Participant Object Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2860268</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25618:C79269</PreferredName>
        <Version>1</Version>
        <LongName>Physical Participant Object</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25618</PREFERRED_NAME>
            <LONG_NAME>Physical</LONG_NAME>
            <CON_ID>2203948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79269</PREFERRED_NAME>
            <LONG_NAME>Participant Object</LONG_NAME>
            <CON_ID>2860263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2240715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25341</PreferredName>
        <Version>1</Version>
        <LongName>Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Physical Participant Object Location java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Physical Participant Object Location java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714661</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000687</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabio.pathways</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2860261</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabio.pathways.PhysicalParticipant.location</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PhysicalParticipant:location</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@location</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1317">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2860862</PUBLICID>
    <LONGNAME>Absolute Monocyte Laboratory Procedure Performed  Outcome Integer::1 Decimal Place Value</LONGNAME>
    <PREFERREDNAME>2860451v1.0:2784509v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The 1 decimal place numeric laboratory value measured, assigned or computed related to the assessment of absolute monocytes in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2860451</PublicId>
      <PreferredName>AB_MONO_LAB_PROC_PFC</PreferredName>
      <PreferredDefinition>Complete and without restriction or qualification; something that does not depends on anything else; not relative._Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Absolute Monocyte Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2863882</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45829:C12547:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Absolute Monocyte Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45829</PREFERRED_NAME>
            <LONG_NAME>Absolute</LONG_NAME>
            <CON_ID>2483455</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12547</PREFERRED_NAME>
            <LONG_NAME>Monocyte</LONG_NAME>
            <CON_ID>2206308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784509</PublicId>
      <PreferredName>2784509v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Outcome; a phenomenon that follows and is caused by some previous phenomenon._A number with no fractional part, including the negative and positive numbers as well as zero.::1_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Laboratory Procedure Outcome Integer::1 Decimal Place Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784508</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294:C20200:C45255::1:C42646</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Outcome Integer::1 Decimal Place Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the value of the abso</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the value of the absolute monocyte count?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Absolute monocyte count</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Absolute monocyte count</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Absolute monocyte count</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Absolute monocyte count</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>jmml_base_diag_amc_val</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JMMLpre_lab_diag_absolute_monocyte_value</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JMMLpre_lab_prep_absolute_monocyte_value</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1318">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2860918</PUBLICID>
    <LONGNAME>Absolute Monocyte Laboratory Procedure Performed Lab Unit of Measure Name</LONGNAME>
    <PREFERREDNAME>2860451v1.0:2017137v3.2</PREFERREDNAME>
    <PREFERREDDEFINITION>The unit of measure that represents a determinate amount or quantity of absolute monocytes in a laboratory specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2860451</PublicId>
      <PreferredName>AB_MONO_LAB_PROC_PFC</PreferredName>
      <PreferredDefinition>Complete and without restriction or qualification; something that does not depends on anything else; not relative._Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Absolute Monocyte Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2863882</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45829:C12547:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Absolute Monocyte Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45829</PREFERRED_NAME>
            <LONG_NAME>Absolute</LONG_NAME>
            <CON_ID>2483455</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12547</PREFERRED_NAME>
            <LONG_NAME>Monocyte</LONG_NAME>
            <CON_ID>2206308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017137</PublicId>
      <PreferredName>LAB_UOM_NM</PreferredName>
      <PreferredDefinition>Unit of measure standard values to describe a lab test result.</PreferredDefinition>
      <LongName>Lab Unit of Measure Name</LongName>
      <Version>3.2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>LITER</VALUEMEANING>
          <MEANINGDESCRIPTION>LITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol</VALIDVALUE>
          <VALUEMEANING>MILLIMOLE</VALUEMEANING>
          <MEANINGDESCRIPTION>MILLIMOLE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/L</VALIDVALUE>
          <VALUEMEANING>millimole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>millimole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/kg</VALIDVALUE>
          <VALUEMEANING>milligram per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Any division of quantity accepted as a standard of measurement or exchange.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C44278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL</VALIDVALUE>
          <VALUEMEANING>Nanograms per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%</VALIDVALUE>
          <VALUEMEANING>Percent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48570</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g</VALIDVALUE>
          <VALUEMEANING>Grams (g)</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass equal to one one thousandth of a kilogram.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/L</VALIDVALUE>
          <VALUEMEANING>International unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq</VALIDVALUE>
          <VALUEMEANING>Milliequivalent</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of a substance equal to one thousandth of an equivalent weight.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/24hr</VALIDVALUE>
          <VALUEMEANING>Milliequivalents per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/dL</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/L</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A concentration unit measured as a number of milliequivalents of solute per liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67474</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/dL</VALIDVALUE>
          <VALUEMEANING>Milligram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67015</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million</VALIDVALUE>
          <VALUEMEANING>Million</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit equal to one-thousandth of an international unit.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/m2</VALIDVALUE>
          <VALUEMEANING>Milliinternational units per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to one-thousandth (10E-3) of an arbitrary unit of biological activity (International Unit) of substance per square meter of body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg</VALIDVALUE>
          <VALUEMEANING>Picograms</VALUEMEANING>
          <MEANINGDESCRIPTION>The metric unit of mass equal to one trillionth of a gram (10E-12 gram).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64551</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand</VALIDVALUE>
          <VALUEMEANING>Thousand</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg</VALIDVALUE>
          <VALUEMEANING>Milligram</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28253</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>Thousand per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thousand per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E12 Cells per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell concentration expressed as a number of cells in trillions per unit volume equal to one liter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E3 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E3 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mill PFU</VALIDVALUE>
          <VALUEMEANING>Million Plaque Forming Units</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of viable infectious entities expressed in millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No Srce</VALIDVALUE>
          <VALUEMEANING>No Source Data</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-07-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>kU/L</VALIDVALUE>
          <VALUEMEANING>Kilounit per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>Cubic microns</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU</VALIDVALUE>
          <VALUEMEANING>Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>The property used in conjunction with a nutrient or food component, typically expressed in gram (g), milligram (mg), microgram (mcg), joule, or kilojoule.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573870</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/dL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EU/mL</VALIDVALUE>
          <VALUEMEANING>Enzyme Units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Enzyme Units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>fL</VALIDVALUE>
          <VALUEMEANING>Femtoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-SI unit of volume accepted for use with the SI equal to one quadrillionth of a liter (10E-15 liter).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/24hr</VALIDVALUE>
          <VALUEMEANING>Gram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/dL</VALIDVALUE>
          <VALUEMEANING>Gram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/L</VALIDVALUE>
          <VALUEMEANING>Gram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>g/microL</VALIDVALUE>
          <VALUEMEANING>Gram per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Gram per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HPF</VALIDVALUE>
          <VALUEMEANING>Per High Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per High Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573877</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iunit</VALIDVALUE>
          <VALUEMEANING>INTERNATIONAL UNIT</VALUEMEANING>
          <MEANINGDESCRIPTION>INTERNATIONAL UNIT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28255</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/m2</VALIDVALUE>
          <VALUEMEANING>International unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>International unit per meter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573878</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>International unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573879</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUnit/mL</VALIDVALUE>
          <VALUEMEANING>IU/mL</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE>2019-04-30</PVENDDATE>
          <VMPUBLICID>2573880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LPF</VALIDVALUE>
          <VALUEMEANING>Per Low Power Field</VALUEMEANING>
          <MEANINGDESCRIPTION>Per Low Power Field</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/24hr</VALIDVALUE>
          <VALUEMEANING>Microgram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/dL</VALIDVALUE>
          <VALUEMEANING>Microgram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/L</VALIDVALUE>
          <VALUEMEANING>microgram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>microgram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/mL</VALIDVALUE>
          <VALUEMEANING>Microgram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mcg/spec</VALIDVALUE>
          <VALUEMEANING>Microgram per specimen</VALUEMEANING>
          <MEANINGDESCRIPTION>Microgram per specimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mEq/kg</VALIDVALUE>
          <VALUEMEANING>Milliequivalent per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliequivalent per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/L</VALIDVALUE>
          <VALUEMEANING>Milligram per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mL/min</VALIDVALUE>
          <VALUEMEANING>Milligram per milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milligram per milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microIU/mL</VALIDVALUE>
          <VALUEMEANING>Micro International Unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micro International Unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microL</VALIDVALUE>
          <VALUEMEANING>MICROLITER</VALUEMEANING>
          <MEANINGDESCRIPTION>MICROLITER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/24hr</VALIDVALUE>
          <VALUEMEANING>Micromole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/dL</VALIDVALUE>
          <VALUEMEANING>Micromole per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>micromol/L</VALIDVALUE>
          <VALUEMEANING>Micromole per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Micromole per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Million per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>miu/mL</VALIDVALUE>
          <VALUEMEANING>Milliinternational unit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliinternational unit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573897</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL</VALIDVALUE>
          <VALUEMEANING>Milliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/1.73/BSA</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute times 1.73 times BSA</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute times 1.73 times BSA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573900</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg</VALIDVALUE>
          <VALUEMEANING>Milliter per minute per millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliter per minute per millimeters of Mercury</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm/hr</VALIDVALUE>
          <VALUEMEANING>Millimeter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter per hour</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573902</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mm3</VALIDVALUE>
          <VALUEMEANING>Millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmHg</VALIDVALUE>
          <VALUEMEANING>Millimeter of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth&#39;s surface. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573904</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/24hr</VALIDVALUE>
          <VALUEMEANING>Millimole per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mosmol/kg</VALIDVALUE>
          <VALUEMEANING>Milliosmole per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliosmole per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567615</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MU/mL</VALIDVALUE>
          <VALUEMEANING>Million units per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Million units per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not applicable; no UOM required</VALUEMEANING>
          <MEANINGDESCRIPTION>Not applicable; no UOM required</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/mL/hr</VALIDVALUE>
          <VALUEMEANING>Nanogram per milliliter per hour</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit equal to mass concentration of a substance expressed in nanograms per unit volume of one milliliter per time period of one hour.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/L</VALIDVALUE>
          <VALUEMEANING>Nanomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nMol/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573910</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/mL</VALIDVALUE>
          <VALUEMEANING>Nanomole per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573911</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/dL</VALIDVALUE>
          <VALUEMEANING>Picogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573912</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pgPGE2/mg protein</VALIDVALUE>
          <VALUEMEANING>pgPGE2/mg protein</VALUEMEANING>
          <MEANINGDESCRIPTION>pgPGE2/mg protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/L</VALIDVALUE>
          <VALUEMEANING>Picomole per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) in one liter of solution.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ratio</VALIDVALUE>
          <VALUEMEANING>ratio</VALUEMEANING>
          <MEANINGDESCRIPTION>ratio</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>sec</VALIDVALUE>
          <VALUEMEANING>seconds</VALUEMEANING>
          <MEANINGDESCRIPTION>seconds</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C0457385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567080</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/24hr</VALIDVALUE>
          <VALUEMEANING>Unit per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per 24 hours</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/L</VALIDVALUE>
          <VALUEMEANING>Unit per liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mL</VALIDVALUE>
          <VALUEMEANING>Unit per millilliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millilliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/mm3</VALIDVALUE>
          <VALUEMEANING>Unit per millimeters cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit per millimeters cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7 Cells/kg</VALIDVALUE>
          <VALUEMEANING>10E7 Cells per kilogram</VALUEMEANING>
          <MEANINGDESCRIPTION>10E7 Cells per kilogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/min</VALIDVALUE>
          <VALUEMEANING>Liters per minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/24hr</VALIDVALUE>
          <VALUEMEANING>Milligram per 24 hours</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unit/m2</VALIDVALUE>
          <VALUEMEANING>Unit per meter squared</VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed as a number of arbitrary units of substance per one square meter of a body surface area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>%/100 WBC</VALIDVALUE>
          <VALUEMEANING>Percent Per 100 WBC</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit for percentage measurement of fraction of any type of white blood cells in the total white blood cell count differential.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573856</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/mm3</VALIDVALUE>
          <VALUEMEANING>Per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells</VALIDVALUE>
          <VALUEMEANING>10E6 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of cell count expressed in millions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per microLiter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per microLiter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6 Cells/mm3</VALIDVALUE>
          <VALUEMEANING>10E6 Cells per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 Cells per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8 Cells</VALIDVALUE>
          <VALUEMEANING>10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E8 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells</VALIDVALUE>
          <VALUEMEANING>10E9 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/L</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573863</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/microL</VALIDVALUE>
          <VALUEMEANING>Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573864</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies</VALIDVALUE>
          <VALUEMEANING>Copies</VALUEMEANING>
          <MEANINGDESCRIPTION>Copies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573865</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ng/dL</VALIDVALUE>
          <VALUEMEANING>nanogram per deciliter</VALUEMEANING>
          <MEANINGDESCRIPTION>nanogram per deciliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pg/mL</VALIDVALUE>
          <VALUEMEANING>Picrogram per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Picrogram per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/100 WBC</VALIDVALUE>
          <VALUEMEANING>Per 100 identifiable White blood cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Natural number unit for measurement of portion of a particular type of blood cells (such as any type of white blood cells or nucleated red blood cells) in the total white blood cell count expressed per count of 100.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAE Unit</VALIDVALUE>
          <VALUEMEANING>Complement activity enzyme unit</VALUEMEANING>
          <MEANINGDESCRIPTION>Complement activity enzyme unit</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574303</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Titer</VALIDVALUE>
          <VALUEMEANING>Titer</VALUEMEANING>
          <MEANINGDESCRIPTION>Titer</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RNA copies/mL</VALIDVALUE>
          <VALUEMEANING>RNA copies per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>RNA copies per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-04-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>Million per millimeter cubed</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MIC</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic Microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICR</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573869</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cubic microns</VALIDVALUE>
          <VALUEMEANING>CU MICRON</VALUEMEANING>
          <MEANINGDESCRIPTION>Cubic microns</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GPL</VALIDVALUE>
          <VALUEMEANING>IgG anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgG anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Index value</VALIDVALUE>
          <VALUEMEANING>Index value</VALUEMEANING>
          <MEANINGDESCRIPTION>Index value</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576475</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>microU/mL</VALIDVALUE>
          <VALUEMEANING>Microunit per milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>Microunit per milliliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/mcL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>MILL/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576480</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>Mil/UI</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>MILL/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>MILL/CMM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/mm3</VALIDVALUE>
          <VALUEMEANING>M/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/minute/mmHg/L</VALIDVALUE>
          <VALUEMEANING>Milliliter per minute per millimeter Hg per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Milliliter per minute per millimeter Hg per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576487</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol/min/kPa/L</VALIDVALUE>
          <VALUEMEANING>Millimole per minute per thousand Pascal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Millimole per minute per thousand Pascal per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MPL</VALIDVALUE>
          <VALUEMEANING>IgM anti-cardiolipin antibodies</VALUEMEANING>
          <MEANINGDESCRIPTION>IgM anti-cardiolipin antibodies</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576489</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOU/UL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576491</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>THOUS/MCL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576492</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576493</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>K/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>K/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm2</VALIDVALUE>
          <VALUEMEANING>1000/mm2</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter squared</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>THOU/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>K/cmm</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>1000/mm3</VALUEMEANING>
          <MEANINGDESCRIPTION>1000/mm3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/mm3</VALIDVALUE>
          <VALUEMEANING>Thous/CMM</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per millimeter cubed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L/sec</VALIDVALUE>
          <VALUEMEANING>Liter per second</VALUEMEANING>
          <MEANINGDESCRIPTION>Liter per second</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Million/microL</VALIDVALUE>
          <VALUEMEANING>M/uL</VALUEMEANING>
          <MEANINGDESCRIPTION>Million per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thousand/microL</VALIDVALUE>
          <VALUEMEANING>1000/microL</VALUEMEANING>
          <MEANINGDESCRIPTION>Thousand per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Threshold</VALIDVALUE>
          <VALUEMEANING>Threshold</VALUEMEANING>
          <MEANINGDESCRIPTION>The lowest limit at which something becomes detectable or relevant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6/L</VALIDVALUE>
          <VALUEMEANING>10E6 per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E6 per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2755857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ukat/L</VALIDVALUE>
          <VALUEMEANING>Microkatal per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67397</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Picomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Picomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>nmol/hr/mg protein</VALIDVALUE>
          <VALUEMEANING>Nanomole per hour per milligram of protein</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanomole per hour per milligram of protein</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3004124</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trillion/L</VALIDVALUE>
          <VALUEMEANING>Trillion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Trillion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161477</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Billion/L</VALIDVALUE>
          <VALUEMEANING>Billion/Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>Billion per Liter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161478</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/g</VALIDVALUE>
          <VALUEMEANING>milligram per gram</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69104</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3170018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minutes</VALIDVALUE>
          <VALUEMEANING>Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit measure of time equal to 60 seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48154</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/24hr</VALIDVALUE>
          <VALUEMEANING>Milliliter Per Integer::24 Hour Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: For each, generally denoting a ratio.: A number with no fractional part, including the negative and positive numbers as well as zero.::24: In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C25529, C45255::24, C65039, C28254</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mU/mL</VALIDVALUE>
          <VALUEMEANING>Milliunit Per Milliliter Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity equivalent to the one thousandth unit (10E-3 unit).: For each, generally denoting a ratio.: A measure of volume for a liquid.  A milliliter is approximately 950 times smaller than a quart and 30 times smaller than a fluid ounce.  A milliliter of liquid and a cubic centimeter (cc) of liquid are the same.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28254, C65039, C67315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hours</VALIDVALUE>
          <VALUEMEANING>Hour</VALUEMEANING>
          <MEANINGDESCRIPTION>In modern usage, an hour is defined as a unit of time 60 minutes, or 3600 seconds in length. It is approximately 1/24 of a median day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cells/kg</VALIDVALUE>
          <VALUEMEANING>Cell Per Kilogram Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>Any small compartment.: For each, generally denoting a ratio.: A basic SI unit of mass. It is definied as the mass of an  international prototype in the form of a platinum-iridium cylinder kept at Sevres in france.   A kilogram is equal to 1,000 grams and 2.2046226 pounds.: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C28252, C65039, C48694</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3402651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies/mL</VALIDVALUE>
          <VALUEMEANING>Copy per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration of RNA copies expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2725041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E6 Cells</VALIDVALUE>
          <VALUEMEANING>Integer::2 Multiplication Million Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::2: An arithmetic operation by which the product of two numbers is computed; the inverse of division.: A natural number following 999999 and preceding 100001 and the quantity that it denotes: one thousand thousand.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12508, C67238, C65000, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E10</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 10 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::10: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::10, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624685</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E2</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 2 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::2: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::2, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E3</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 3 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::3: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45255::3, C95157, C25709, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 2, 0, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E5</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 5 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::5: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::5, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624688</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E4</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 4 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::4: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::4, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624689</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E7</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 7 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::7: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::7, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624690</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E6</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 6 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::6: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::6, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 9 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::9: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::9, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E8</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 8 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::8: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::8, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E12</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 12 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::12: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::12, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E11</VALIDVALUE>
          <VALUEMEANING>Ten Exponent:11 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::11: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::11, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E14</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 14 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::14: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::14, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E13</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 13 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::13: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::13, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624697</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E16</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 16 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::16: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::16, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E15</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 15 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E18</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 18 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::18: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::18, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E17</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 17 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::17: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::17, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E20</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 20 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::20: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::20, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624749</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E19</VALIDVALUE>
          <VALUEMEANING>Ten Exponent 19 Unit of Measure</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A mathematical expression that results when e(=2.71828) is raised to it argument&#39;s power.: A number with no fractional part, including the negative and positive numbers as well as zero.::19: A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25709, C45255::19, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3624750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E8 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E8 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 8 (one hundred million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2X10E7 Cells</VALIDVALUE>
          <VALUEMEANING>Two times 10E7 Cells</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times 10 exponential value 7 (ten million) cells</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3463260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mL/min/kg</VALIDVALUE>
          <VALUEMEANING>Milliliter per Kilogram per Minute </VALUEMEANING>
          <MEANINGDESCRIPTION>A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty seconds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73760</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3652827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log</VALIDVALUE>
          <VALUEMEANING>Logarithm</VALUEMEANING>
          <MEANINGDESCRIPTION>For a specified base b, a function such that its argument results when b is raised to the power given by this function&#39;s value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94925</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3703164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mmol CO/min/kPa</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Millimoles per Minute per Kilopascal</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit of gas diffusion capacity equal to one millimole per minute per kilopascal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116242, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ml CO/min/mm Hg</VALIDVALUE>
          <VALUEMEANING>Carbon Monoxide Milliliter per Minute per Millimeters of Mercury</VALUEMEANING>
          <MEANINGDESCRIPTION>An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.: A unit for measuring a pulmonary diffusing capacity expressed in units of gas flow rate (in milliliters per minute) per a unit of pressure (in torrs).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67417, C76742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5037093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>cm H2O</VALIDVALUE>
          <VALUEMEANING>Centimeters of water</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91060</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5477037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>copies/L</VALIDVALUE>
          <VALUEMEANING>Copy Per Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A secondary representation, reproduction, or replica.: A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105515, C67336</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5637481</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log10 IU/mL</VALIDVALUE>
          <VALUEMEANING>Log10 International Units per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5778792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ug/mL FEU</VALIDVALUE>
          <VALUEMEANING>Microgram per Milliliter Fibrinogen Equivalent Unit</VALUEMEANING>
          <MEANINGDESCRIPTION>A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.: A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96649, C64572</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6479361</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>mg/mmol</VALIDVALUE>
          <VALUEMEANING>Gram per Mole</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73721</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-07-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6406905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E-15L (fL)</VALIDVALUE>
          <VALUEMEANING>Ten Exponential Function 15 Liter</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: A function of the form f(x) = ab^x, characterized by the fact that the growth rate of such a function is directly proportional to the value of the function.: A number with no fractional part, including the negative and positive numbers as well as zero.::15: The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48505, C45255::15, C95157, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8057682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100900</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6404378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Log copies per milliliter</VALIDVALUE>
          <VALUEMEANING>Log10 Copies per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6405652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arbitrary unit per milliliter</VALIDVALUE>
          <VALUEMEANING>Arbitrary Unit Per Milliliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle._A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103452, C75765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10631416</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10E9 Cells/microL</VALIDVALUE>
          <VALUEMEANING>10E9 Cells per microliter</VALUEMEANING>
          <MEANINGDESCRIPTION>10E9 Cells per microliter</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2024-09-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15128242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/nL</VALIDVALUE>
          <VALUEMEANING>Per Nanoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one nanoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116243</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>/pL</VALIDVALUE>
          <VALUEMEANING>Per Picoliter</VALUEMEANING>
          <MEANINGDESCRIPTION>A volume unit equal to one picoliter used as a denominator to build a derived unit expressed as a ratio.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117964</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>15424812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the unit of measure f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the unit of measure for absolute monocytes?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the unit of measure for absolute monocytes?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>What is the unit of measure for absolute monocytes?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842777</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Labs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>jmml_base_diag_amc_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JMMLpre_lab_diag_absolute_monocyte_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>JMMLpre_lab_prep_absolute_monocyte_uom</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1319">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2861451</PUBLICID>
    <LONGNAME>Kit Ligand Administered Indicator</LONGNAME>
    <PREFERREDNAME>2861449v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not kit ligand was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2861449</PublicId>
      <PreferredName>2861447v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Stem Cell Factor is a hematopoietic growth factor, a key signal in mast cell differentiation and function, and a ligand for the KIT tyrosine kinase receptor CD117.  In the mouse, this growth factor is encoded by Sl (&#39;steel&#39;), a gene critical to the development of several cell lineages as well as to hematopoiesis in the adult.  SCF augments proliferation of myeloid and lymphoid progenitors.  (from OMIM 184745 and NCI)_The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Kit Ligand Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2861447</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20440</PreferredName>
        <Version>1</Version>
        <LongName>Kit Ligand</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20440</PREFERRED_NAME>
            <LONG_NAME>Kit Ligand</LONG_NAME>
            <CON_ID>2861446</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was kit ligand administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was kit ligand administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stem cell factor</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stem cell factor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964895</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2014r1: MDS Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842912</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapy</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Systemic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2842916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mds_base_tx_scf_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>fan_base_gf_scfactor_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1320">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2866744</PUBLICID>
    <LONGNAME>Bleomycin Administered Indicator</LONGNAME>
    <PREFERREDNAME>BLEOMY_ADM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not bleomycin was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2866742</PublicId>
      <PreferredName>BLEOMY_ADM</PreferredName>
      <PreferredDefinition>A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Bleomycin Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2866740</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C313</PreferredName>
        <Version>1</Version>
        <LongName>Bleomycin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C313</PREFERRED_NAME>
            <LONG_NAME>Bleomycin</LONG_NAME>
            <CON_ID>2521201</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was bleomycin administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was bleomycin administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bleomycin</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bleomycin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient previously received Bleomycin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bleomycin (BLM, Blenoxane)</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Bleomycin (BLM, Blenoxane)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the last chemotherapy agent bleomycin?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2018r1: Lymphoma Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2025r1: Central Nervous System Tumor Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964893</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2122r1: Testicular / Germ Cell Cancer Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2125r1: Central Nervous System Tumor Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2842912</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Therapy</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Systemic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2842916</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>lym_base_tx_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_post_tx_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_tx_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>tc_post_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>tc_base_tx_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>BLEOMY_ADM_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LYMpre_therapy_multi_bleomycin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1321">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2867373</PUBLICID>
    <LONGNAME>Bladder Tumor Histologic WHO 1973 Grade</LONGNAME>
    <PREFERREDNAME>BLAD_TUMOR_HIST_73GD</PREFERREDNAME>
    <PREFERREDDEFINITION>the histologic grade of the bladder tumor based on the 1973 World Health Organization classification.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190095</PublicId>
      <PreferredName>BLAD_TUMOR_HIST_DESC</PreferredName>
      <PreferredDefinition>information related to histologic description of a bladder tumor.</PreferredDefinition>
      <LongName>Bladder Tumor Histologic Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206698</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12414:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Bladder Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12414</PREFERRED_NAME>
            <LONG_NAME>Bladder</LONG_NAME>
            <CON_ID>2202678</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2867367</PublicId>
      <PreferredName>BLAD_TU_WHO_73_H_GD</PreferredName>
      <PreferredDefinition>the histologic grade of the bladder tumor base on the 1973 World Health Organization classification.</PreferredDefinition>
      <LongName>Bladder Tumor WHO 1973 Histologic Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2208071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C18000</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 3</VALIDVALUE>
          <VALUEMEANING>Grade 3</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 2</VALIDVALUE>
          <VALUEMEANING>Grade 2</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade 1</VALIDVALUE>
          <VALUEMEANING>Grade 1</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Papilloma</VALIDVALUE>
          <VALUEMEANING>Papilloma</VALUEMEANING>
          <MEANINGDESCRIPTION>Papilloma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histologic Grade</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Histologic Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Description</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Muscle Invasive Blad</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>10000462</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Bladder</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Met/Urothelial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811929</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1322">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869711</PUBLICID>
    <LONGNAME>Intervention or Procedure Performed Study Activity Method Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868040v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the technique that is used to perform the procedure. EXAMPLE(S): Finger stick, veni puncture, Abdominal/ ascites effusion, Biopsy, Bronchial alveolar lavage (BAL) (for specimen collection). Open, laparoscopic (for cholecystectomy).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868040</PublicId>
      <PreferredName>2867610v1.0:2839671v1.0</PreferredName>
      <PreferredDefinition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Intervention or Procedure Performed Study Activity Method Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218:C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Intervention or Procedure Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2839671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Method Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Intervention or Procedure Performed Study Activity Method Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Intervention or Procedure Performed Study Activity Method Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedProcedure.methodCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure:methodCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedProcedure.methodCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2789998:Tissue Banking.What method was used to thaw the product?</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenAcquisition.methodCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure.methodCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2748813:Therapies.Specify the other malignant cell removal method:</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure.methodCode</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenCollection.type</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenCollection.method</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RadiationIntervention.administration</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Lab_Result_CM.specimen_source</AlternateName>
        <AlternateNameType>Map:PCORNetv4.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2790003:Tissue Banking.Specify other thaw method:</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Laboratory Result.Specimen_Source</AlternateName>
        <AlternateNameType>Map:Sentinelv6.0.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedSpecimenFixed.fixationType</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure.methodCode</AlternateName>
        <AlternateNameType>Map:CDMHv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Lab_Result_CM.specimen_source</AlternateName>
        <AlternateNameType>Map:PCORNetv3.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenCollection.method</AlternateName>
        <AlternateNameType>Map:Lab</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InvitroCharacterization.assayType</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1323">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869765</PUBLICID>
    <LONGNAME>Clinical Performed Observation Outcome Reference Object Range Comment ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>2868092v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._Something referred to; the object of a reference.:The difference between the lowest and highest numerical values.:A written explanation or criticism or illustration that is added to a book or other textual material._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868092</PublicId>
      <PreferredName>2867629v1.0:2555356v1.0</PreferredName>
      <PreferredDefinition>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._Something referred to; the object of a reference.:The difference between the lowest and highest numerical values.:A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Clinical Performed Observation Outcome Reference Object Range Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25398:C38000:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2555356</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48294:C38013:C25393</PreferredName>
        <Version>1</Version>
        <LongName>Reference Object Range Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48294</PREFERRED_NAME>
            <LONG_NAME>Reference Object</LONG_NAME>
            <CON_ID>2388820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Performed Observation Outcome Reference Object Range Comment ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Performed Observation Outcome Reference Object Range Comment ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedClinicalResult.referenceRangeComment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedClinicalResult:referenceRangeComment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1324">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2869919</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Observation Performed Study Activity Not Applicable Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>2868244v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies whether the specific eligibility criterion is not applicable to this participant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868244</PublicId>
      <PreferredName>2867671v1.0:2867886v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._Determination of a value is not relevant in the current context.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Observation Performed Study Activity Not Applicable Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867671v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867886</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48660:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Not Applicable Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Trial Eligibility Criteria Observation Performed Study Activity Not Applicable Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Trial Eligibility Criteria Observation Performed Study Activity Not Applicable Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedEligibilityCriterion.notApplicableIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedEligibilityCriterion:notApplicableIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedEligibilityCriterion.notApplicableIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EligbilityCriterion.notApplicableIndicator</AlternateName>
        <AlternateNameType>Map:C3PR</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedEligibilityCriterion.notApplicableIndicator</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1325">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2870050</PUBLICID>
    <LONGNAME>Adverse Event Performed Observation Outcome Grade Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>2868373v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the level of injury suffered by the subject for whom the event is reported. EXAMPLE(S): The gradeCode could be 3 if the CTCAE coding system is being used.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868373</PublicId>
      <PreferredName>2867728v1.0:2512774v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.  Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).:Executed and carried through to completion.:Watching something and taking note of what happens.:The result of an action._A position on a scale of intensity or amount or quality.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Adverse Event Performed Observation Outcome Grade Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331:C38000:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Performed Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2512774</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48309:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Grade Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48309</PREFERRED_NAME>
            <LONG_NAME>Grade</LONG_NAME>
            <CON_ID>2434105</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Performed Observation Outcome Grade Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Performed Observation Outcome Grade Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEvent.gradeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent:gradeCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain.AdverseEvent.gradeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2944515v1.0:  Adverse Event Severity Grade</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.gradeOrSeverity</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.ctcGradeCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.ctcGradeCodeSystem</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2201188v1.0:  Common Toxicity Criteria Adverse Event Reporting Grade</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.description</AlternateName>
        <AlternateNameType>Map:PSCv2.6</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.gradeCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent.grade</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1326">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2870387</PUBLICID>
    <LONGNAME>Administration, Management Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>2868712v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed activity within the context of a given study that is not directly related to the study&#39;s overarching hypothesis evaluation or testing, but is nonetheless essential to the efficient and/or effective coordination and execution of the study. EXAMPLE(S): assignment to a treatment arm, registration to a study, start of on-study period, end of on-study period, obtain informed consent, verify eligibility criteria, enroll, randomize, complete study visits, exit trial, break treatment blind, protocol violation, premature withdrawal. Specifies whether an activity did not occur. EXAMPLE(S): &quot;Y&quot; designates that the PerformedActivity is missed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868712</PublicId>
      <PreferredName>2867692v1.0:2867944v1.0</PreferredName>
      <PreferredDefinition>Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._An operation in which a term denies or inverts the meaning of another term or construction.:An instance of something happening, such as an event or incident.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Administration, Management Performed Study Activity Negation Occurrence Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48905:C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Administration, Management Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867944</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25275:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Negation Occurrence Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Administration, Management Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Administration, Management Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedAdministrativeActivity.missedIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedAdministrativeActivity:missedIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1327">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2870399</PUBLICID>
    <LONGNAME>Study Protocol Document Public Title ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>2868724v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._Not private; open to or concerning the people as a whole.:An official descriptive name of a document, e.g. the long name of a study protocol provided by the study sponsor._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868724</PublicId>
      <PreferredName>2867648v1.0:2867931v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._Not private; open to or concerning the people as a whole.:An official descriptive name of a document, e.g. the long name of a study protocol provided by the study sponsor.</PreferredDefinition>
      <LongName>Study Protocol Document Public Title</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867648</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536:C42651:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Study Protocol Document</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867931</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49060:C42774</PreferredName>
        <Version>1</Version>
        <LongName>Public Title</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49060</PREFERRED_NAME>
            <LONG_NAME>Public</LONG_NAME>
            <CON_ID>2475263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42774</PREFERRED_NAME>
            <LONG_NAME>Title</LONG_NAME>
            <CON_ID>2223215</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Protocol Document Public Title ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Protocol Document Public Title ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>2.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000473</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyProtocol.publicTitle</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyProtocol:publicTitle</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.StudyProtocol.publicTitle</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1328">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2896963</PUBLICID>
    <LONGNAME>Month Surgical Resection Number</LONGNAME>
    <PREFERREDNAME>MON_SURG_RESC_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the month of an individual&#39;s surgical resection procedure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012993</PublicId>
      <PreferredName>SURG_DT</PreferredName>
      <PreferredDefinition>Date that a surgical procedure was done.</PreferredDefinition>
      <LongName>Surgery Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2192971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2895904</PublicId>
      <PreferredName>EVT_MON_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Event Month Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2895903</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29846:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Month Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>One of ten equal parts; a quantity corresponding to one tenth of the whole.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C81010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896395</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>12th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::12: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>11th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::11: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>9th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::9: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896396</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>8th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896397</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>7th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::7: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>6th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54568</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>5th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4th month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the third position in an ordering or series; coming next after the third and just before the fifth in position.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C54566</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896401</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3rd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Following the second position in an ordering or series.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896402</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Coming next after the first in position in space or time or degree or magnitude.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-06-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2896403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1st month of a calendar year</VALUEMEANING>
          <MEANINGDESCRIPTION>Preceding all others in time or space or degree.: A list or register of events; a tabular array of the days.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C19459, C25509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2896404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Month of surgical resection</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Month of surgical resection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Month of Tissue Procurement</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Month of Tissue Procurement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TCGA Other Malignancy Question</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Month of Surgical Resection for the Other Malignancy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5589063</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDDP/CTSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDDP/CTSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5589068</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1329">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898744</PUBLICID>
    <LONGNAME>Variable Value Life Sciences Identifier Entity Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2898578v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any characteristic or attribute that can be measured.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898578</PublicId>
      <PreferredName>2726722v1.0:2898546v1.0</PreferredName>
      <PreferredDefinition>Any characteristic or attribute that can be measured.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Variable Value Life Sciences Identifier Entity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2726722</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43371:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Variable Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43371</PREFERRED_NAME>
            <LONG_NAME>Variable Characteristic</LONG_NAME>
            <CON_ID>2236568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898546</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C51070:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Entity Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Variable Value Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Variable Value Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000576</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.project.AbstractFactorValue.lsidObjectId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AbstractFactorValue:lsidObjectId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1330">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898745</PUBLICID>
    <LONGNAME>Publication Life Sciences Identifier Organizational Unit java.lang.String</LONGNAME>
    <PREFERREDNAME>2898579v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A printed or electronic work offered for distribution._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898579</PublicId>
      <PreferredName>2523473v1.0:2898544v1.0</PreferredName>
      <PreferredDefinition>A printed or electronic work offered for distribution._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:Organizational unit like a laboratory, institute or consortium.</PreferredDefinition>
      <LongName>Publication Life Sciences Identifier Organizational Unit</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2523473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48471</PreferredName>
        <Version>1</Version>
        <LongName>Publication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48471</PREFERRED_NAME>
            <LONG_NAME>Publication</LONG_NAME>
            <CON_ID>2422075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C41167</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Organizational Unit</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41167</PREFERRED_NAME>
            <LONG_NAME>Organizational Unit</LONG_NAME>
            <CON_ID>2223214</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Publication Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Publication Life Sciences Identifier Organizational Unit java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.publication</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000578</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.publication</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000579</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.publication.Publication.lsidAuthority</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Publication:lsidAuthority</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1331">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898790</PUBLICID>
    <LONGNAME>Protocol Life Sciences Identifier Namespace java.lang.String</LONGNAME>
    <PREFERREDNAME>2898624v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898624</PublicId>
      <PreferredName>2236759v1.0:2898545v1.0</PreferredName>
      <PreferredDefinition>A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)</PreferredDefinition>
      <LongName>Protocol Life Sciences Identifier Namespace</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651</PreferredName>
        <Version>1</Version>
        <LongName>Protocol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898545</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C42699</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Namespace</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42699</PREFERRED_NAME>
            <LONG_NAME>Namespace</LONG_NAME>
            <CON_ID>2222837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protocol Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protocol Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.protocol.Protocol.lsidNamespace</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Protocol:lsidNamespace</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1332">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898805</PUBLICID>
    <LONGNAME>Variable Life Sciences Identifier Entity Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2898639v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any characteristic or attribute that can be measured. (CDC)_A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898639</PublicId>
      <PreferredName>2236761v1.0:2898546v1.0</PreferredName>
      <PreferredDefinition>Any characteristic or attribute that can be measured. (CDC)_A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:An independently existing thing (living or nonliving).:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Variable Life Sciences Identifier Entity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236761</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43371</PreferredName>
        <Version>1</Version>
        <LongName>Variable</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43371</PREFERRED_NAME>
            <LONG_NAME>Variable Characteristic</LONG_NAME>
            <CON_ID>2236568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898546</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C51070:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Entity Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Variable Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Variable Life Sciences Identifier Entity Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.project</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000576</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.project.Factor.lsidObjectId</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Factor:lsidObjectId</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1333">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2898856</PUBLICID>
    <LONGNAME>Controlled Vocabulary Term Parameter Value Life Sciences Identifier Namespace java.lang.String</LONGNAME>
    <PREFERREDNAME>2898690v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A specified list of terms with a fixed and unalterable meaning, and from which a selection is made when cataloging, indexing, or searching books, journals, and other documents. The control is intended to avoid the scattering of related subjects under different headings.:A word or expression used for some particular thing.:Any factor that defines a system and determines (or limits) its performance.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2898690</PublicId>
      <PreferredName>2898540v1.0:2898545v1.0</PreferredName>
      <PreferredDefinition>A specified list of terms with a fixed and unalterable meaning, and from which a selection is made when cataloging, indexing, or searching books, journals, and other documents. The control is intended to avoid the scattering of related subjects under different headings.:A word or expression used for some particular thing.:Any factor that defines a system and determines (or limits) its performance.:The information contained in a data field.  It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute._A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.:In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)</PreferredDefinition>
      <LongName>Controlled Vocabulary Term Parameter Value Life Sciences Identifier Namespace</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2898540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48697:C45559:C44175:C49100</PreferredName>
        <Version>1</Version>
        <LongName>Controlled Vocabulary Term Parameter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48697</PREFERRED_NAME>
            <LONG_NAME>Controlled Vocabulary</LONG_NAME>
            <CON_ID>2519067</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44175</PREFERRED_NAME>
            <LONG_NAME>Parameter</LONG_NAME>
            <CON_ID>2236569</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2898545</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47841:C42699</PreferredName>
        <Version>1</Version>
        <LongName>Life Sciences Identifier Namespace</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47841</PREFERRED_NAME>
            <LONG_NAME>Life Sciences Identifier</LONG_NAME>
            <CON_ID>2423426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42699</PREFERRED_NAME>
            <LONG_NAME>Namespace</LONG_NAME>
            <CON_ID>2222837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Controlled Vocabulary Term Parameter Value Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Controlled Vocabulary Term Parameter Value Life Sciences Identifier Namespace java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2898533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000256</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Internal 2.4</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3120357</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2898532</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Internal</PreferredName>
          <Version>2.4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.domain.protocol</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.domain.protocol.TermBasedParameterValue.lsidNamespace</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TermBasedParameterValue:lsidNamespace</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1334">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900015</PUBLICID>
    <LONGNAME>Shape Unique Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2899757v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial arrangement of something as distinct from its substance._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899757</PublicId>
      <PreferredName>2612281v1.0:2715029v1.0</PreferredName>
      <PreferredDefinition>The spatial arrangement of something as distinct from its substance._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data.</PreferredDefinition>
      <LongName>Shape Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2612281</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25677</PreferredName>
        <Version>1</Version>
        <LongName>Shape</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25677</PREFERRED_NAME>
            <LONG_NAME>Shape</LONG_NAME>
            <CON_ID>2203587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70663</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70663</PREFERRED_NAME>
            <LONG_NAME>Unique Identifier</LONG_NAME>
            <CON_ID>2714899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Shape Unique Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Shape Unique Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.analysis.segmentation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899627</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Shape:uid</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.analysis.segmentation.Shape.uid</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1335">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900070</PUBLICID>
    <LONGNAME>Imaging Technology System Unique Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2899812v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any of a number of technologies that permits the visualization and acquisition of images into a physical or electronic record.:A group of independent but interrelated elements comprising a unified whole._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899812</PublicId>
      <PreferredName>2899667v1.0:2715029v1.0</PreferredName>
      <PreferredDefinition>Any of a number of technologies that permits the visualization and acquisition of images into a physical or electronic record.:A group of independent but interrelated elements comprising a unified whole._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data.</PreferredDefinition>
      <LongName>Imaging Technology System Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899667</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18843:C25700</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Technology System</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18843</PREFERRED_NAME>
            <LONG_NAME>Imaging Technology</LONG_NAME>
            <CON_ID>2615877</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70663</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70663</PREFERRED_NAME>
            <LONG_NAME>Unique Identifier</LONG_NAME>
            <CON_ID>2714899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Imaging Technology System Unique Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Imaging Technology System Unique Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.image</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899632</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.image.ImagingSystem.uid</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagingSystem:uid</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1336">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900117</PUBLICID>
    <LONGNAME>Malignant Neoplasm Clinical Information Group Nuclear Grade java.lang.String</LONGNAME>
    <PREFERREDNAME>2899859v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:Any number of entities (members) considered as a unit._An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899859</PublicId>
      <PreferredName>2899675v1.0:2673287v1.0</PreferredName>
      <PreferredDefinition>A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:Any number of entities (members) considered as a unit._An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.</PreferredDefinition>
      <LongName>Malignant Neoplasm Clinical Information Group Nuclear Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899675</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305:C25398:C48191:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Clinical Information Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25398</PREFERRED_NAME>
            <LONG_NAME>Clinical</LONG_NAME>
            <CON_ID>2203600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2673287</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18513</PreferredName>
        <Version>1</Version>
        <LongName>Nuclear Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18513</PREFERRED_NAME>
            <LONG_NAME>Nuclear Grade</LONG_NAME>
            <CON_ID>2673248</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Malignant Neoplasm Clinical Information Group Nuclear Grade java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Malignant Neoplasm Clinical Information Group Nuclear Grade java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma.dynamic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899635</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CancerClinicalPanel:nuclearGrade</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.dynamic.CancerClinicalPanel.nuclearGrade</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1337">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900126</PUBLICID>
    <LONGNAME>Tissue Microarray Data Field Group Data Table java.lang.String</LONGNAME>
    <PREFERREDNAME>2899868v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:An area of database record, or graphical user interface form, into which a particular item of data is entered.:Any number of entities (members) considered as a unit._A set of data arranged in rows and columns._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899868</PublicId>
      <PreferredName>2899676v1.0:2899724v1.0</PreferredName>
      <PreferredDefinition>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:An area of database record, or graphical user interface form, into which a particular item of data is entered.:Any number of entities (members) considered as a unit._A set of data arranged in rows and columns.</PreferredDefinition>
      <LongName>Tissue Microarray Data Field Group Data Table</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19922:C25507:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Microarray Data Field Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19922</PREFERRED_NAME>
            <LONG_NAME>Tissue Microarray</LONG_NAME>
            <CON_ID>2842644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25507</PREFERRED_NAME>
            <LONG_NAME>Data Field</LONG_NAME>
            <CON_ID>2202635</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48693</PreferredName>
        <Version>1</Version>
        <LongName>Data Table</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48693</PREFERRED_NAME>
            <LONG_NAME>Data Table</LONG_NAME>
            <CON_ID>2519064</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tissue Microarray Data Field Group Data Table java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tissue Microarray Data Field Group Data Table java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma.dynamic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899635</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TmaDataPanel:template</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.dynamic.TmaDataPanel.template</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1338">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900145</PUBLICID>
    <LONGNAME>Evaluation Question Set Question Index java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2899887v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A group of things of the same kind that belong together and are so used._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899887</PublicId>
      <PreferredName>2899681v1.0:2899730v1.0</PreferredName>
      <PreferredDefinition>Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A group of things of the same kind that belong together and are so used._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.</PreferredDefinition>
      <LongName>Evaluation Question Set Question Index</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899681</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25214:C41116:C47894</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation Question Set</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47894</PREFERRED_NAME>
            <LONG_NAME>Set</LONG_NAME>
            <CON_ID>2425537</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899730</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C25390</PreferredName>
        <Version>1</Version>
        <LongName>Question Index</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25390</PREFERRED_NAME>
            <LONG_NAME>Index</LONG_NAME>
            <CON_ID>2203825</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Evaluation Question Set Question Index java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Evaluation Question Set Question Index java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma.evaluation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899636</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.evaluation.Question.questionIndex</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Question:questionIndex</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1339">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900178</PUBLICID>
    <LONGNAME>Tissue Microarray Disc Shape Unique Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2899920v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:A flat circular plate or anything with a similar shape._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899920</PublicId>
      <PreferredName>2899685v1.0:2715029v1.0</PreferredName>
      <PreferredDefinition>A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.:A flat circular plate or anything with a similar shape._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data.</PreferredDefinition>
      <LongName>Tissue Microarray Disc Shape Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19922:C73648</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Microarray Disc Shape</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19922</PREFERRED_NAME>
            <LONG_NAME>Tissue Microarray</LONG_NAME>
            <CON_ID>2842644</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73648</PREFERRED_NAME>
            <LONG_NAME>Disk Shape</LONG_NAME>
            <CON_ID>2748433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70663</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70663</PREFERRED_NAME>
            <LONG_NAME>Unique Identifier</LONG_NAME>
            <CON_ID>2714899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tissue Microarray Disc Shape Unique Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tissue Microarray Disc Shape Unique Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TMAMiner</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899634</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.tma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.tma.TmaDisc.uid</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TmaDisc:uid</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1340">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900210</PUBLICID>
    <LONGNAME>Medical Image Image Feature Set Primary Source Image java.lang.Long</LONGNAME>
    <PREFERREDNAME>2899952v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any record of a medical imaging event whether physical or electronic.:In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A group of things of the same kind that belong together and are so used._Occurring first in time or sequence; original; of greatest rank or importance or value.:Where something is available or from where it originates.:Any record of an imaging event whether physical or electronic._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899952</PublicId>
      <PreferredName>2899647v1.0:2899696v1.0</PreferredName>
      <PreferredDefinition>Any record of a medical imaging event whether physical or electronic.:In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A group of things of the same kind that belong together and are so used._Occurring first in time or sequence; original; of greatest rank or importance or value.:Where something is available or from where it originates.:Any record of an imaging event whether physical or electronic.</PreferredDefinition>
      <LongName>Medical Image Image Feature Set Primary Source Image</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19477:C70838:C47894</PreferredName>
        <Version>1</Version>
        <LongName>Medical Image Image Feature Set</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19477</PREFERRED_NAME>
            <LONG_NAME>Medical Image</LONG_NAME>
            <CON_ID>2202344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70838</PREFERRED_NAME>
            <LONG_NAME>Image Feature</LONG_NAME>
            <CON_ID>2710233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47894</PREFERRED_NAME>
            <LONG_NAME>Set</LONG_NAME>
            <CON_ID>2425537</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C25683:C48179</PreferredName>
        <Version>1</Version>
        <LongName>Primary Source Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Medical Image Image Feature Set Primary Source Image java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Medical Image Image Feature Set Primary Source Image java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.analysis.featureextraction</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GenericImageFeatureSet:primarySourceImage</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.analysis.featureextraction.GenericImageFeatureSet.primarySourceImage</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1341">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2900233</PUBLICID>
    <LONGNAME>Image Feature Data Extraction Algorithm Version Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2899975v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A process whereby specific data is taken out of a larger set of data and presented in a usable format.:A defined procedure for solving a problem.  Applied to a problem-solving procedure implemented in software to be executed by a computer._A form or variant of a type or original.:The particular day, month and year an event will happen or has happened._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2899975</PublicId>
      <PreferredName>2899646v1.0:2431199v1.0</PreferredName>
      <PreferredDefinition>In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.:A process whereby specific data is taken out of a larger set of data and presented in a usable format.:A defined procedure for solving a problem.  Applied to a problem-solving procedure implemented in software to be executed by a computer._A form or variant of a type or original.:The particular day, month and year an event will happen or has happened.</PreferredDefinition>
      <LongName>Image Feature Data Extraction Algorithm Version Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2899646</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70838:C44285:C16275</PreferredName>
        <Version>1</Version>
        <LongName>Image Feature Data Extraction Algorithm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70838</PREFERRED_NAME>
            <LONG_NAME>Image Feature</LONG_NAME>
            <CON_ID>2710233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44285</PREFERRED_NAME>
            <LONG_NAME>Data Extraction</LONG_NAME>
            <CON_ID>2236550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16275</PREFERRED_NAME>
            <LONG_NAME>Algorithm</LONG_NAME>
            <CON_ID>2553061</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2431199</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25714:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Version Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Feature Data Extraction Algorithm Version Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Feature Data Extraction Algorithm Version Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ImageMinerCore</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2899622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2899621</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ImageMiner</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>org.imageminer.domain.analysis.featureextraction</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2899623</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FeatureExtraction:versionDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>org.imageminer.domain.analysis.featureextraction.FeatureExtraction.versionDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1342">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2902189</PUBLICID>
    <LONGNAME>Additional Pathology Pancreatic Intraepithelial Neoplasia Finding Text</LONGNAME>
    <PREFERREDNAME>AD_P_PANIN_FIN_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field for the additional pathologic findings related to pancreatic intraepithelial neoplasia (PanIN) is a recently adopted term to describe precancerous pancreatic duct lesions.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2902144</PublicId>
      <PreferredName>ADD_PATH_PIN_FIND</PreferredName>
      <PreferredDefinition>information relating to additional pathologic findings related to pancreatic intraepithelial neoplasia (PanIN) is a recently adopted term to describe precancerous pancreatic duct lesions.</PreferredDefinition>
      <LongName>Additional Pathology Pancreatic Intraepithelial Neoplasia Finding</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2902141</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C18189</PreferredName>
        <Version>1</Version>
        <LongName>Additional Pathology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2902142</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4845:C3367</PreferredName>
        <Version>1</Version>
        <LongName>Pancreatic Intraepithelial Neoplasia Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4845</PREFERRED_NAME>
            <LONG_NAME>Pancreatic Intraepithelial Neoplasia</LONG_NAME>
            <CON_ID>2838909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2902170</PublicId>
      <PreferredName>HIST_GRAD_TXT</PreferredName>
      <PreferredDefinition>the free-text field for the histologic grade.</PreferredDefinition>
      <LongName>Histologic Grade Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify highest grade</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify highest grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0848</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171060</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AD_P_PANIN_FIN_TXT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1343">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2902595</PUBLICID>
    <LONGNAME>Single Nucleotide Polymorphism Probe Unpaired Analysis Outcome Raw Copy Number java.lang.Double</LONGNAME>
    <PREFERREDNAME>2902566v1.0:2200948v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:Data obtained from observations where there is a no link between an observation in one set of measurements and a particular observation in the other set of measurements.:The result of an action._Not processed or refined.:The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium._Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2902566</PublicId>
      <PreferredName>2902530v1.0:2804621v1.0</PreferredName>
      <PreferredDefinition>A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.:General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.:Data obtained from observations where there is a no link between an observation in one set of measurements and a particular observation in the other set of measurements.:The result of an action._Not processed or refined.:The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.</PreferredDefinition>
      <LongName>Single Nucleotide Polymorphism Probe Unpaired Analysis Outcome Raw Copy Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2902530</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18279:C43523:C81020:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Single Nucleotide Polymorphism Probe Unpaired Analysis Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18279</PREFERRED_NAME>
            <LONG_NAME>Single Nucleotide Polymorphism</LONG_NAME>
            <CON_ID>2433334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43523</PREFERRED_NAME>
            <LONG_NAME>Probe</LONG_NAME>
            <CON_ID>2433326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81020</PREFERRED_NAME>
            <LONG_NAME>Unpaired Data</LONG_NAME>
            <CON_ID>2880144</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2804621</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48188:C49142</PreferredName>
        <Version>1</Version>
        <LongName>Raw Copy Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48188</PREFERRED_NAME>
            <LONG_NAME>Raw</LONG_NAME>
            <CON_ID>2422622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49142</PREFERRED_NAME>
            <LONG_NAME>Copy Number</LONG_NAME>
            <CON_ID>2528506</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200948</PublicId>
      <PreferredName>java.lang.Double</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Double-precision floating point number (64-bit IEEE 7540).</PreferredDefinition>
      <LongName>java.lang.Double</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Double</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Single Nucleotide Polymorphism Probe Unpaired Analysis Outcome Raw Copy Number java.lang.Double does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Single Nucleotide Polymorphism Probe Unpaired Analysis Outcome Raw Copy Number java.lang.Double does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2819751</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Copy Number Analysis Tool</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.icr.asrv1.cnat.ext</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2819752</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.icr.asrv1.cnat.ext.CnatUnpairedAnalysisProbesetOutput.copyNumberState</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CnatUnpairedAnalysisProbesetOutput:copyNumberState</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1344">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2903675</PUBLICID>
    <LONGNAME>Temporomandibular Joint Disorder Pain Treatment Other Intraoral Appliance Administered Specify</LONGNAME>
    <PREFERREDNAME>TMJD_P_TX_O_IA_A_SP</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field related to the splint or mouthguard treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint that is different than the one(s) previously specified or mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2903370</PublicId>
      <PreferredName>TMJD_PAI_TX_IO_AP_AD</PreferredName>
      <PreferredDefinition>information related to the splint or mouthguard treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint that is different than the one(s) previously specified or mentioned.</PreferredDefinition>
      <LongName>Temporomandibular Joint Disorder Pain Treatment Other Intraoral Appliance Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2862211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63709:C3303:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Temporomandibular Joint Disorder Pain Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63709</PREFERRED_NAME>
            <LONG_NAME>Temporomandibular Joint Disorder</LONG_NAME>
            <CON_ID>2547865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2903368</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C62543:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Other Intraoral Appliance Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62543</PREFERRED_NAME>
            <LONG_NAME>Intraoral Appliance</LONG_NAME>
            <CON_ID>2518906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Diagnostic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Preventive</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812085</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Orthodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812041</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1345">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2912194</PUBLICID>
    <LONGNAME>Lesion Alteration Diffusion MRI Type</LONGNAME>
    <PREFERREDNAME>2912192v1.0:2912185v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Predominantly facilitated or restricted diffusion in the enhancing or nCET portion of the tumor based on ADC map. Rate CET alone when present, otherwise use nCET.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>VASARI:Visually AccesSAble Rembrandt Images</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2912192</PublicId>
      <PreferredName>2904053v1.0:2912190v1.0</PreferredName>
      <PreferredDefinition>(LEE-zhun) An area of abnormal tissue change._A change resulting in something that is different from the original._MRI method that measure the diffusion of water in the tissue, rather than the content of water as measured in conventional MRI.</PreferredDefinition>
      <LongName>Lesion Alteration Diffusion MRI</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2904053</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3824:C28344</PreferredName>
        <Version>1</Version>
        <LongName>Lesion Alteration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28344</PREFERRED_NAME>
            <LONG_NAME>Alteration</LONG_NAME>
            <CON_ID>2204020</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2912190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20117</PreferredName>
        <Version>1</Version>
        <LongName>Diffusion MRI</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20117</PREFERRED_NAME>
            <LONG_NAME>Diffusion MRI</LONG_NAME>
            <CON_ID>2827013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>VASARI:Visually AccesSAble Rembrandt Images</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2912185</PublicId>
      <PreferredName>2912185v1.0</PreferredName>
      <PreferredDefinition>MRI method that measure the diffusion of water in the tissue, rather than the content of water as measured in conventional MRI._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Diffusion MRI Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>VASARI:Visually AccesSAble Rembrandt Images</Origin>
      <Representation>
        <PublicId>2912184</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20117:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Diffusion MRI Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20117</PREFERRED_NAME>
            <LONG_NAME>Diffusion MRI</LONG_NAME>
            <CON_ID>2827013</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cannot determine</VALIDVALUE>
          <VALUEMEANING>Cannot determine</VALUEMEANING>
          <MEANINGDESCRIPTION>When findings are equivocal or mixed</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No ADC images</VALIDVALUE>
          <VALUEMEANING>No ADC Image</VALUEMEANING>
          <MEANINGDESCRIPTION>ADC Images not provided.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2912188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Restricted</VALIDVALUE>
          <VALUEMEANING>Restricted Diffusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Enhancing (when present) or nCET portion of the tumor is predominantly low signal to normal tissue on ADC maps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Facilitated</VALIDVALUE>
          <VALUEMEANING>Facilitated Diffusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Enhancing (when present) or nCET portion of the tumor is predominantly hyperintense to normal tissue on ADC maps.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>VASARI 3.0</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>F17 Diffusion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Diffusion</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Diffusion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2880281</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>VASARI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>VASARI Feature List</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2890970</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1346">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2916113</PUBLICID>
    <LONGNAME>Transfection Analysis Conclusion java.lang.String</LONGNAME>
    <PREFERREDNAME>2915991v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The process of introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cell&#39;s chromosomal DNA, so that the cells or progeny may express the integrated donor gene._Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:A position or opinion or judgment reached after consideration._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2915991</PublicId>
      <PreferredName>2915894v1.0:2915588v1.0</PreferredName>
      <PreferredDefinition>The process of introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cell&#39;s chromosomal DNA, so that the cells or progeny may express the integrated donor gene._Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.:A position or opinion or judgment reached after consideration.</PreferredDefinition>
      <LongName>Transfection Analysis Conclusion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2915894</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17209</PreferredName>
        <Version>1</Version>
        <LongName>Transfection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17209</PREFERRED_NAME>
            <LONG_NAME>Transfection</LONG_NAME>
            <CON_ID>2673222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2915588</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25391:C54033</PreferredName>
        <Version>1</Version>
        <LongName>Analysis Conclusion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25391</PREFERRED_NAME>
            <LONG_NAME>Analysis</LONG_NAME>
            <CON_ID>2202310</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54033</PREFERRED_NAME>
            <LONG_NAME>Conclusion</LONG_NAME>
            <CON_ID>2787001</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Transfection Analysis Conclusion java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Transfection Analysis Conclusion java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2915522</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caNanoLab</PreferredName>
          <Version>1.5</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cananolab.domain.characterization.invitro</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2915883</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cananolab.domain.characterization.invitro.Transfection.analysisConclusion</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Transfection:analysisConclusion</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1347">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919641</PUBLICID>
    <LONGNAME>Shipping Sender Comment java.lang.String</LONGNAME>
    <PREFERREDNAME>2919493v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act or business of transporting goods._Somebody or something that sends or transmits something.:A written explanation, observation or criticism added to textual material._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919493</PublicId>
      <PreferredName>2919351v1.0:2919364v1.0</PreferredName>
      <PreferredDefinition>The act or business of transporting goods._Somebody or something that sends or transmits something.:A written explanation, observation or criticism added to textual material.</PreferredDefinition>
      <LongName>Shipping Sender Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2919351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40353</PreferredName>
        <Version>1</Version>
        <LongName>Shipping</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40353</PREFERRED_NAME>
            <LONG_NAME>Shipping</LONG_NAME>
            <CON_ID>2204003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2919364</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71895:C25393</PreferredName>
        <Version>1</Version>
        <LongName>Sender Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71895</PREFERRED_NAME>
            <LONG_NAME>Sender</LONG_NAME>
            <CON_ID>2747443</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Shipping Sender Comment java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Shipping Sender Comment java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.shippingtracking</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2919342</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain.shippingtracking</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000333</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.shippingtracking.Shipment.senderComments</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Shipment:senderComments</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1348">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2919657</PUBLICID>
    <LONGNAME>Specimen 2-Dimensional Position Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>2919507v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The property of being measured and described using two orthogonal directions.:The particular portion of space occupied by a physical object._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919507</PublicId>
      <PreferredName>2919355v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:The property of being measured and described using two orthogonal directions.:The particular portion of space occupied by a physical object._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Specimen 2-Dimensional Position Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2919355</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C48282:C25339</PreferredName>
        <Version>1</Version>
        <LongName>Specimen 2-Dimensional Position</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48282</PREFERRED_NAME>
            <LONG_NAME>2-Dimensional</LONG_NAME>
            <CON_ID>2422614</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25339</PREFERRED_NAME>
            <LONG_NAME>Position</LONG_NAME>
            <CON_ID>2203955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Specimen 2-Dimensional Position Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Specimen 2-Dimensional Position Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_1</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000638</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2919341</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caTissue_Suite1_2</PreferredName>
          <Version>1.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.wustl.catissuecore.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000639</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.wustl.catissuecore.domain.SpecimenPosition.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SpecimenPosition:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1349">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2930020</PUBLICID>
    <LONGNAME>Boolean Value xsd.boolean</LONGNAME>
    <PREFERREDNAME>2928519v1.0:2861811v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of an expression with two possible values, &quot;true&quot; and &quot;false&quot;. Also, a variable of Boolean type or a function with Boolean arguments or result. The most common Boolean functions are AND, OR and NOT._The information contained in a data field._Binary-valued logic.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2928519</PublicId>
      <PreferredName>2737835v1.0:2528693v1.0</PreferredName>
      <PreferredDefinition>The type of an expression with two possible values, &quot;true&quot; and &quot;false&quot;. Also, a variable of Boolean type or a function with Boolean arguments or result. The most common Boolean functions are AND, OR and NOT._The information contained in a data field.</PreferredDefinition>
      <LongName>Boolean Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2737835</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45254</PreferredName>
        <Version>1</Version>
        <LongName>Boolean</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45254</PREFERRED_NAME>
            <LONG_NAME>Boolean</LONG_NAME>
            <CON_ID>2229262</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49100</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2861811</PublicId>
      <PreferredName>2861811v1.0</PreferredName>
      <PreferredDefinition>Binary-valued logic.</PreferredDefinition>
      <LongName>xsd.boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2861806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>W3C XML DATATYPES</PreferredName>
        <Version>1</Version>
        <LongName>W3C XML Datatypes</LongName>
      </ConceptualDomain>
      <Datatype>xsd:boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Boolean Value xsd.boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Boolean Value xsd.boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2928087</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ISO21090v1_0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISO21090v1_0.ISODatatypes</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2928092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>coppa_datatypes.iso21090.isodatatype</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958967</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coppa_datatypes.iso21090.isodatatype.BL.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BL:value</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ISO21090v1_0.ISODatatypes.BL.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1350">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2930143</PUBLICID>
    <LONGNAME>Concept Identifier Display Name ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>2928642v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A unit of knowledge created by a unique combination of characteristics.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2928642</PublicId>
      <PreferredName>2928348v1.0:2231629v1.0</PreferredName>
      <PreferredDefinition>A unit of knowledge created by a unique combination of characteristics.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Exhibit, present, or demonstrate for viewing.:The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Concept Identifier Display Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2928348</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45728:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Concept Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45728</PREFERRED_NAME>
            <LONG_NAME>Concept</LONG_NAME>
            <CON_ID>2388821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25485:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Display Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25485</PREFERRED_NAME>
            <LONG_NAME>Display</LONG_NAME>
            <CON_ID>2203905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Concept Identifier Display Name ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Concept Identifier Display Name ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2928087</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ISO21090v1_0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISO21090v1_0.ISODatatypes</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2928092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>coppa_datatypes.iso21090.coppaflavor</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958966</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ISO21090v1_0.ISODatatypes.CD.displayName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CD:displayName</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coppa_datatypes.iso21090.coppaflavor.CD.displayName</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1351">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2930883</PUBLICID>
    <LONGNAME>Delivery Address Text Line Address Part Code xsd.string</LONGNAME>
    <PREFERREDNAME>2929383v1.0:2861810v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of conveying or transporting from one place to another.:A standardized representation of the location of a person, business, building, or organization.:Text consisting of a row of words written across a page or computer screen.:A standardized representation of the location of a person, business, building, or organization.:One of the portions into which something is regarded as divided and which together constitute a whole._A system of numbered categories for representation of data._Character strings in XML.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2929383</PublicId>
      <PreferredName>2928383v1.0:2222855v1.0</PreferredName>
      <PreferredDefinition>The act of conveying or transporting from one place to another.:A standardized representation of the location of a person, business, building, or organization.:Text consisting of a row of words written across a page or computer screen.:A standardized representation of the location of a person, business, building, or organization.:One of the portions into which something is regarded as divided and which together constitute a whole._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Delivery Address Text Line Address Part Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2928383</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2928383v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Delivery Address Text Line Address Part</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61560</PREFERRED_NAME>
            <LONG_NAME>Delivery</LONG_NAME>
            <CON_ID>2660099</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49259</PREFERRED_NAME>
            <LONG_NAME>Text Line</LONG_NAME>
            <CON_ID>2516224</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45313</PREFERRED_NAME>
            <LONG_NAME>Part</LONG_NAME>
            <CON_ID>2405237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2861810</PublicId>
      <PreferredName>2861810v1.0</PreferredName>
      <PreferredDefinition>Character strings in XML.</PreferredDefinition>
      <LongName>xsd.string</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2861806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>W3C XML DATATYPES</PreferredName>
        <Version>1</Version>
        <LongName>W3C XML Datatypes</LongName>
      </ConceptualDomain>
      <Datatype>xsd:string</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Delivery Address Text Line Address Part Code xsd.string does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Delivery Address Text Line Address Part Code xsd.string does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2928087</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ISO21090v1_0</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISO21090v1_0.ISODatatypes</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2928092</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>coppa_datatypes.iso21090.isodatatype</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958967</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ADXPDAL:code</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ISO21090v1_0.ISODatatypes.ADXPDAL.code</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>coppa_datatypes.iso21090.isodatatype.ADXPDAL.code</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1352">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2932824</PUBLICID>
    <LONGNAME>Disease or Disorder Therapeutic Procedure Indicator</LONGNAME>
    <PREFERREDNAME>DE_OR_DR_TC_PE_YN_IN</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not therapy was used to treat the disease or disorder.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2932815</PublicId>
      <PreferredName>DSE_DRDR_THC_PRDE</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.</PreferredDefinition>
      <LongName>Disease or Disorder Therapeutic Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2554155</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the treatment used?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the treatment used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the therapy used?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the therapy used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Systemic therapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Systemic therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radiation</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Radiation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other therapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was therapy to treat disease given prior to the DLI?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2010r1: Acute Myelogenous Leukemia Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964927</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2014r1: MDS Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3279271</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_base_pri_dx_chemo_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_base_pri_dx_oth_tx_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_base_pri_dx_radiat_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mds_base_pri_dx_chemo_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mds_base_pri_dx_oth_tx_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mds_base_pri_dx_radiat_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpre_assess_diag_oth_therapy_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpre_assess_diag_rad_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpre_assess_diag_systemic_therapy_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MDSpre_assess_diag_oth_therapy_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MDSpre_assess_diag_rad_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MDSpre_assess_diag_systemic_therapy_ynu</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1353">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2932891</PUBLICID>
    <LONGNAME>Past Month Urinary Frequency Occurrence AUA Symptom Assessment Score</LONGNAME>
    <PREFERREDNAME>P_MON_UR_FREQ_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to signify how often over the past month a person had to urinate again less than 2 hours after he/she finished urinating.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AUA:American Urological Association</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2928064</PublicId>
      <PreferredName>P_MON_UR_FREQ_OCC</PreferredName>
      <PreferredDefinition>Past; before the present time._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._urination at short intervals; it may result from increased urine formation, decreased bladder capacity, or lower urinary tract irritation._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Past Month Urinary Frequency Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2928062</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25609:C29846:C26906</PreferredName>
        <Version>1</Version>
        <LongName>Past Month Urinary Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26906</PREFERRED_NAME>
            <LONG_NAME>Urinary Frequency</LONG_NAME>
            <CON_ID>2203691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2932881</PublicId>
      <PreferredName>AUA_SX_SC</PreferredName>
      <PreferredDefinition>a number or range of numeric values measuring performance, function, quality, or ability for the American Urological Association Symptom Score._Subjective evidence of disease perceived by the patient._Having determined the value, significance, or extent of.</PreferredDefinition>
      <LongName>American Urological Association Symptom Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AUA:American Urological Association</Origin>
      <Representation>
        <PublicId>2932882</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4876:C25217:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Symptom Assessment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Five</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Four</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932885</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932886</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>One</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932887</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2740377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Over the past month, how ofte</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1354">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2935349</PUBLICID>
    <LONGNAME>Person Hypertension During Pregnancy Indicator</LONGNAME>
    <PREFERREDNAME>HYPTENS_DUR_PRG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A human being._Abnormally high blood pressure._At some point in a given period of time. (NCI)_Pregnancy is the state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI)_Indicator of Yes or No to a question.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CARDIA:Coronary Artery Risk Development in Young Adults Study</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2935347</PublicId>
      <PreferredName>PERS_HYPT_DUR_PREG</PreferredName>
      <PreferredDefinition>A human being._At some point in a given period of time. (NCI)_Pregnancy is the state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI)_Abnormally high blood pressure.</PreferredDefinition>
      <LongName>Person During Pregnancy Hypertension</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183452</PublicId>
        <ContextName>TEST</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ASSESSMENTS</PreferredName>
        <Version>6</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2936243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25490:C25742:C3117</PreferredName>
        <Version>1</Version>
        <LongName>During Pregnancy Hypertension</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3117</PREFERRED_NAME>
            <LONG_NAME>Hypertension</LONG_NAME>
            <CON_ID>2202655</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CARDIA:Coronary Artery Risk Development in Young Adults Study</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you have High blood press</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you have High blood pressure without toxemia during this pregnancy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cardiovascular</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2936662</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1355">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2935376</PUBLICID>
    <LONGNAME>Persistent Recurrent Or Progressive Disease Therapeutic Procedure Administered Indicator</LONGNAME>
    <PREFERREDNAME>2935368v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not persistent, recurrent or progressive disease therapy was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2935368</PublicId>
      <PreferredName>3113203v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A disease that does not go to remission despite treatment._The return of a disease after a period of remission._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A disease process that is increasing in scope or severity._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.__The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Persistent Recurrent Or Progressive Disease Therapeutic Procedure Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3113203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C90169:C38155:C37998:C35571:C4</PreferredName>
        <Version>1</Version>
        <LongName>Persistent Disease Recurrent Disease Or PD Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C90169</PREFERRED_NAME>
            <LONG_NAME>Persistent Disease</LONG_NAME>
            <CON_ID>3111550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35571</PREFERRED_NAME>
            <LONG_NAME>Progressive Disease</LONG_NAME>
            <CON_ID>2202776</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was ?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was ?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was any treatment given in response to a disease assessment?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was any treatment given in response to a disease assessment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was treatment given for persistent, progressive or recurrent CNS disease?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was treatment given for persistent, progressive or recurrent CNS disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was any treatment given for relapsed, persistent, or progressive disease?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was any treatment given for relapsed, persistent, or progressive disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2110r1: Acute Myelogenous Leukemia Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964903</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2111r1: All Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2112r1: CML Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_post_tx_rlps_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cml_post_hsct_trt_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>all_post_rlps_tx_lrpt_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>aml_post_rlps_rx_l_rpt_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1356">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2936033</PUBLICID>
    <LONGNAME>Dental Professional Practice Periodontium Physical Examination Type</LONGNAME>
    <PREFERREDNAME>D_PP_PERD_PE_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of assessment of the fibrous connective tissue surrounding the root of a tooth that separates it from and attaches it to the alveolar bone in a dental practice.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2936028</PublicId>
      <PreferredName>D_PP_PERIO_PE</PreferredName>
      <PreferredDefinition>information related to assessment of the fibrous connective tissue surrounding the root of a tooth that separates it from and attaches it to the alveolar bone in a dental practice.</PreferredDefinition>
      <LongName>Dental Professional Practice Periodontium Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2936026</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C33304:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Periodontium Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C33304</PREFERRED_NAME>
            <LONG_NAME>Periodontium</LONG_NAME>
            <CON_ID>2203988</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2936029</PublicId>
      <PreferredName>PERIO_PE_TP</PreferredName>
      <PreferredDefinition>the type of periodontium examination.</PreferredDefinition>
      <LongName>Periodontium Physical Examination Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A recorded periodontal charting</VALIDVALUE>
          <VALUEMEANING>A recorded periodontal charting</VALUEMEANING>
          <MEANINGDESCRIPTION>A recorded periodontal charting</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A screening, non-recorded examination</VALIDVALUE>
          <VALUEMEANING>A screening, non-recorded examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A screening, non-recorded examination</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2936031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Type of periodontal exam</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Type of periodontal exam</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Periodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1357">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2936596</PUBLICID>
    <LONGNAME>Dental Professional Practice Gingival Margin Location Physical Examination Yes No Indicator</LONGNAME>
    <PREFERREDNAME>D_PP_GM_L_PE_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to assessment in a dental practice of location of the crest of the gingiva surrounding a tooth.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2936523</PublicId>
      <PreferredName>D_PRPR_GM_LOC_PE</PreferredName>
      <PreferredDefinition>information related to assessment in a dental practice of location of the crest of the gingiva surrounding a tooth.</PreferredDefinition>
      <LongName>Dental Professional Practice Gingival Margin Location Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2936521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60722:C25341:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Gingival Margin Location Physical Examination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60722</PREFERRED_NAME>
            <LONG_NAME>Gingival Margin</LONG_NAME>
            <CON_ID>2481618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Location of the free gingival</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Location of the free gingival margin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Periodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1358">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2936701</PUBLICID>
    <LONGNAME>Dental Professional Practice Other Health Care Provider Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>D_PP_O_HCP_PERF_IND2</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to other care provider being utilized to carry out a task in the dental practice.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2935380</PublicId>
      <PreferredName>D_PP_O_HCP_PERF</PreferredName>
      <PreferredDefinition>information related to other care provider being utilized to carry out a task in the dental practice.</PreferredDefinition>
      <LongName>Dental Professional Practice Other Health Care Provider Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2935378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C16666:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Other Health Care Provider Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16666</PREFERRED_NAME>
            <LONG_NAME>Health Care Provider</LONG_NAME>
            <CON_ID>2479788</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other care providers</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other care providers</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Periodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1359">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2939288</PUBLICID>
    <LONGNAME>Search Term Value java.lang.String</LONGNAME>
    <PREFERREDNAME>2939242v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The activity of looking thoroughly in order to find something or someone; an operation that determines whether one or more of a set of items has a specified property.:A word or expression used for some particular thing._The information contained in a data field._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2939242</PublicId>
      <PreferredName>2939201v1.0:2528693v1.0</PreferredName>
      <PreferredDefinition>The activity of looking thoroughly in order to find something or someone; an operation that determines whether one or more of a set of items has a specified property.:A word or expression used for some particular thing._The information contained in a data field.</PreferredDefinition>
      <LongName>Search Term Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2939201</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54117:C45559</PreferredName>
        <Version>1</Version>
        <LongName>Search Term</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54117</PREFERRED_NAME>
            <LONG_NAME>Search</LONG_NAME>
            <CON_ID>2505702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49100</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49100</PREFERRED_NAME>
            <LONG_NAME>Data Value</LONG_NAME>
            <CON_ID>2463853</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Search Term Value java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Search Term Value java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939183</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caBIO</PreferredName>
          <Version>4.3</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.common.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000036</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.common.domain.Keyword.value</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>@value</AlternateName>
        <AlternateNameType>GME_XMLLocReference</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Keyword:value</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1360">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2939398</PUBLICID>
    <LONGNAME>Bioassay Purpose Other Specify Text</LONGNAME>
    <PREFERREDNAME>ASSAY_PUR_O_SPEC_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field used to describe the reason or intent of the assay when other is chosen from a list of values.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2939391</PublicId>
      <PreferredName>ASSAY_PURPS</PreferredName>
      <PreferredDefinition>Information pertaining to the reason or intention of the method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions.</PreferredDefinition>
      <LongName>Bioassay Purpose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17828 </PreferredName>
        <Version>1</Version>
        <LongName>Biological Process</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176953</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assay</PreferredName>
        <Version>1</Version>
        <LongName>Assay</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16341</PREFERRED_NAME>
            <LONG_NAME>Bioassay</LONG_NAME>
            <CON_ID>2202922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177388</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Purpose</PreferredName>
        <Version>1</Version>
        <LongName>Purpose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25634</PREFERRED_NAME>
            <LONG_NAME>Purpose</LONG_NAME>
            <CON_ID>2202870</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Assay Purpose Other Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Assay Purpose Other Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If Other, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939361</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCTD</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Assay Development</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2939362</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939361</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCTD</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>In Situ Hybridization Biomarker Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3232302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1361">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2945940</PUBLICID>
    <LONGNAME>Nucleotide Sequence FASTA Format Value java.lang.String</LONGNAME>
    <PREFERREDNAME>2945924v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The sequence of nucleotide residues along an RNA or DNA chain._A sequence in FASTA format consists of a single-line description, followed by lines of sequence data. The first character of the description line is a greater-than (&quot;&gt;&quot;) symbol in the first column.  Sequences are represented in the standard IUB/IUPAC single letter amino acid and nucleic acid codes, with a single hyphen or dash being used to represent a gap of indeterminate length; in amino acid sequences asterix (&quot;*&quot;) can represent a translation stop.:A numerical quantity measured or assigned or computed._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2945924</PublicId>
      <PreferredName>2223318v1.0:2945920v1.0</PreferredName>
      <PreferredDefinition>The sequence of nucleotide residues along an RNA or DNA chain._A sequence in FASTA format consists of a single-line description, followed by lines of sequence data. The first character of the description line is a greater-than (&quot;&gt;&quot;) symbol in the first column.  Sequences are represented in the standard IUB/IUPAC single letter amino acid and nucleic acid codes, with a single hyphen or dash being used to represent a gap of indeterminate length; in amino acid sequences asterix (&quot;*&quot;) can represent a translation stop.:A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Nucleotide Sequence FASTA Format Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223318</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45374</PreferredName>
        <Version>1</Version>
        <LongName>Nucleotide Sequence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45374</PREFERRED_NAME>
            <LONG_NAME>Nucleotide Sequence</LONG_NAME>
            <CON_ID>2223191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2945920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47845:C25712</PreferredName>
        <Version>1</Version>
        <LongName>FASTA Format Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47845</PREFERRED_NAME>
            <LONG_NAME>FASTA Format</LONG_NAME>
            <CON_ID>2342208</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Nucleotide Sequence FASTA Format Value java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Nucleotide Sequence FASTA Format Value java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2858220</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Taverna-caGrid</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>IRWG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2945917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IRWG.NucleicAcidSequence.valueInFastaFormat</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NucleicAcidSequence:valueInFastaFormat</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1362">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2947036</PUBLICID>
    <LONGNAME>Colony Stimulating Factor Use Dose Start Date</LONGNAME>
    <PREFERREDNAME>CSF_USE_D_S_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>the date the treatment began for the use of colony stimulating factor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2182378</PublicId>
      <PreferredName>CSF_USE</PreferredName>
      <PreferredDefinition>information related to the use of colony stimulating factor.</PreferredDefinition>
      <LongName>Colony Stimulating Factor Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Colony Stimulating Factor</PreferredName>
        <Version>1</Version>
        <LongName>Colony Stimulating Factor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20586</PREFERRED_NAME>
            <LONG_NAME>Colony Stimulating Factor</LONG_NAME>
            <CON_ID>2202603</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177321</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Use</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179424</PublicId>
      <PreferredName>DOSE_START_DT</PreferredName>
      <PreferredDefinition>The date the treatment began.</PreferredDefinition>
      <LongName>Dose Start Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008565</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TEMPORAL_CONCEPTS</PreferredName>
        <Version>1</Version>
        <LongName>Temporal concepts</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>10</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of first dose of G-CSF/G</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of first dose of G-CSF/GM-CSF during this reporting period</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Start date of GCSF administration</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3298557</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008594</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hepatobiliary</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>3298577</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857166</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_TTU</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Advanced</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>2811791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CSF_USE_D_S_DT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1363">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2953122</PUBLICID>
    <LONGNAME>Laboratory Procedure Cytogenetic Analysis Chimerism Outcome Percentage Value</LONGNAME>
    <PREFERREDNAME>LP_CGA_CH_OC_PTG_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>the value in percentage estimating the portion of chimeric cells present in a donor sample.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2953120</PublicId>
      <PreferredName>LP_CGA_CHIM_OUTCOME</PreferredName>
      <PreferredDefinition>information relating to a laboratory procedure that involves chimerism (the occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals) using techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.</PreferredDefinition>
      <LongName>Laboratory Procedure Cytogenetic Analysis Chimerism Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2953118</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18280:C62582:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Cytogenetic Analysis Chimerism Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18280</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Analysis</LONG_NAME>
            <CON_ID>2528326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62582</PREFERRED_NAME>
            <LONG_NAME>Chimerism</LONG_NAME>
            <CON_ID>2521747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180234</PublicId>
      <PreferredName>LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the value as a percentage of 100.</PreferredDefinition>
      <LongName>Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Donor Chimerism percentage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Donor Chimerism percentage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bone chimerism result:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Chimerism result:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Leukemia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811909</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1364">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2953671</PUBLICID>
    <LONGNAME>Microarray Provider Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2953588v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:One that makes something available._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2953588</PublicId>
      <PreferredName>2953497v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.:One that makes something available._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Microarray Provider Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2953497</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44282:C37900</PreferredName>
        <Version>1</Version>
        <LongName>Microarray Provider</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44282</PREFERRED_NAME>
            <LONG_NAME>Microarray</LONG_NAME>
            <CON_ID>2223237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37900</PREFERRED_NAME>
            <LONG_NAME>Provider</LONG_NAME>
            <CON_ID>2202411</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Microarray Provider Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Microarray Provider Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2953481</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Service</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caArray Service 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2953482</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2953481</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caArray Service</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.caarray.external.v1_0.array</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2953484</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.caarray.external.v1_0.array.ArrayProvider.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ArrayProvider:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1365">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2955476</PUBLICID>
    <LONGNAME>Hyperglycemia Present Ind-3</LONGNAME>
    <PREFERREDNAME>HYPGLY_PRES_IND3</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown question related to the presence of a high level of blood sugar.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2955474</PublicId>
      <PreferredName>HYPERGL_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of a high level of blood sugar.</PreferredDefinition>
      <LongName>Hyperglycemia Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2955472</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C26797</PreferredName>
        <Version>1</Version>
        <LongName>Hyperglycemia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26797</PREFERRED_NAME>
            <LONG_NAME>Hyperglycemia</LONG_NAME>
            <CON_ID>2203768</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fasting AM glucose &gt; 110 mg/dl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Fasting AM glucose &gt; 110 mg/dl</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled hyperglycemia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have hyperglycemia (fasting) greater than or equal to Grade 2?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have known hyperglycemia (fasting) greater than or equal to Grade 2?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008608</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase III</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>2811890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857165</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CRF_DISEASE</PreferredName>
          <Version>2.31</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prostate</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000010</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1366">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2957396</PUBLICID>
    <LONGNAME>Prior Hematopoietic Cell Graft Source Name</LONGNAME>
    <PREFERREDNAME>2957394v2.0:2730897v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the prior hematopoietic cell product (graft) source or origin.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2957394</PublicId>
      <PreferredName>2957392v1.0:2223297v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body._Where something is available or from where it originates.</PreferredDefinition>
      <LongName>Prior Hematopoietic Cell Graft Source</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12219</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Structure, System, or Substance</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2957392</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C12551:C12981</PreferredName>
        <Version>1</Version>
        <LongName>Prior Hematopoietic Stem Cell Graft</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12981</PREFERRED_NAME>
            <LONG_NAME>Graft</LONG_NAME>
            <CON_ID>2202844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223297</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25683</PreferredName>
        <Version>1</Version>
        <LongName>Source</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2730897</PublicId>
      <PreferredName>2730897v2.0</PreferredName>
      <PreferredDefinition>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Where something is available or from where it originates._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Hematopoietic Cell Source Name</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2730896</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12551:C25683:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Stem Cell Source Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25683</PREFERRED_NAME>
            <LONG_NAME>Source</LONG_NAME>
            <CON_ID>2202479</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syngeneic (identical twin)</VALIDVALUE>
          <VALUEMEANING>syngeneic</VALUEMEANING>
          <MEANINGDESCRIPTION>syngeneic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-02-21</PVBEGINDATE>
          <PVENDDATE>2013-10-07</PVENDDATE>
          <VMPUBLICID>2568338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic, unrelated</VALIDVALUE>
          <VALUEMEANING>Unrelated Allogenic</VALUEMEANING>
          <MEANINGDESCRIPTION>Unrelated; not connected or associated e.g. by kinship.: Taken from different individuals of the same species.  Also called allogeneic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28343, C25328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2730898</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autologous</VALIDVALUE>
          <VALUEMEANING>autologous</VALUEMEANING>
          <MEANINGDESCRIPTION>Taken from an individual&#39;s own tissues, cells, or DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28000</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allogeneic, related</VALIDVALUE>
          <VALUEMEANING>Related Allogenic</VALUEMEANING>
          <MEANINGDESCRIPTION>Related; connected or associated.: Taken from different individuals of the same species.  Also called allogeneic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28343, C25648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2730899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Syngeneic</VALIDVALUE>
          <VALUEMEANING>Syngeneic</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting individuals or tissues that are genetically identical.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71901</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3829171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was (were) the prior hem</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was (were) the prior hematopoietic cell source(s)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2957396</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>SubstanceExtractionAdministrationRelationship.relationCode WHERE SubstanceExtractionAdministrationRelationship &gt; PerformedSubstanceAdministration [prior HSCT]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the HSC source(s) for the prior HCT</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify the HSC source(s) for the prior HCT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the HSC source(s) for the prior HCT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the HSC source(s) for the prior HCT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the HSC source(s) for all prior HCTs</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the HSC source(s) for all prior HCTs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the HPC source for the prior HCT?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the HPC source for the prior HCT?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the donor source(s) for the prior HCT?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2000r1: Recipient Baseline Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964872</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Prior Hematopoietic Stem Cell Source Name</AlternateName>
        <AlternateNameType>System-Generated</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SubstanceExtractionAdministrationRelationship:relationCode</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_PHM_pr_HCT_cell_source</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_PH_pr_HCT_cell_source</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1367">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2958205</PUBLICID>
    <LONGNAME>Patient National Heart, Lung, and Blood Institute Identifier Code</LONGNAME>
    <PREFERREDNAME>PT_NHLBI_ID_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>a system for representation of patient identifier for the NHLBI (an institute within the National Institutes of Health that provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2958190</PublicId>
      <PreferredName>PT_NHLBI_ID</PreferredName>
      <PreferredDefinition>information related to NHLBI (an institute within the National Institutes of Health that provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives) patient ID.</PreferredDefinition>
      <LongName>Patient National Heart, Lung, and Blood Institute Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2958188</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82613:C25364</PreferredName>
        <Version>1</Version>
        <LongName>National Heart, Lung, and Blood Institute Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82613</PREFERRED_NAME>
            <LONG_NAME>National Heart, Lung, and Blood Institute</LONG_NAME>
            <CON_ID>2958187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2958203</PublicId>
      <PreferredName>2958203v1.0</PreferredName>
      <PreferredDefinition>a system of numbered categories for representation of data for patient identifier.</PreferredDefinition>
      <LongName>Patient Identifier Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Name Code</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Name Code</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1368">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2958573</PUBLICID>
    <LONGNAME>Risk Factor Deceased Sibling Cause of Death java.lang.String</LONGNAME>
    <PREFERREDNAME>2958467v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any aspect of an individual&quot;s life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury._The historical fact that a legal or consanguineous brother or sister has died.:The circumstance or condition that results in the death of a living being._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NICHD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2958467</PublicId>
      <PreferredName>2958324v1.0:2958377v1.0</PreferredName>
      <PreferredDefinition>Any aspect of an individual&#39;s life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury._The historical fact that a legal or consanguineous brother or sister has died.:The circumstance or condition that results in the death of a living being.</PreferredDefinition>
      <LongName>Risk Factor Deceased Sibling Cause of Death</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2958324</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17103</PreferredName>
        <Version>1</Version>
        <LongName>Risk Factor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17103</PREFERRED_NAME>
            <LONG_NAME>Risk Factor</LONG_NAME>
            <CON_ID>2217585</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2958377</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81244:C81239</PreferredName>
        <Version>1</Version>
        <LongName>Deceased Sibling Cause of Death</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81244</PREFERRED_NAME>
            <LONG_NAME>Deceased Sibling</LONG_NAME>
            <CON_ID>2958298</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81239</PREFERRED_NAME>
            <LONG_NAME>Cause of Death</LONG_NAME>
            <CON_ID>2958299</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Risk Factor Deceased Sibling Cause of Death java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Risk Factor Deceased Sibling Cause of Death java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958247</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Newborn Examination</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NewbornExamClasses</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000463</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958652</PublicId>
          <ContextName>NICHD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NewbornExamination</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NewbornExamClasses</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958253</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NewbornExamClasses.RiskFactor.deceasedSiblingCauseofDeath</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RiskFactor:deceasedSiblingCauseofDeath</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1369">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2960056</PUBLICID>
    <LONGNAME>Observation Study Protocol Document Data Monitoring Committee Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>2959322v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Watching something and taking note of what happens.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:The act of observing something (and sometimes keeping a record of it).:A group delegated to consider some matter; a self-constituted organization to promote something.:An indicator that can be set or unset in order to signal whether a particular condition is true._Values of two-valued logic.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2959322</PublicId>
      <PreferredName>2867687v1.0:2959163v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:The act of observing something (and sometimes keeping a record of it).:A group delegated to consider some matter; a self-constituted organization to promote something.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Observation Study Protocol Document Data Monitoring Committee Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598:C63536:C42651:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Observation Study Protocol Document</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2959163</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C61256:C78508:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Data Monitoring Committee Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61256</PREFERRED_NAME>
            <LONG_NAME>Monitoring</LONG_NAME>
            <CON_ID>2691603</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78508</PREFERRED_NAME>
            <LONG_NAME>Study Related Committee</LONG_NAME>
            <CON_ID>2867572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Study Protocol Document Data Monitoring Committee Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Study Protocol Document Data Monitoring Committee Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ObservationalStudyProtocol:dataMonitoringCommitteeAppointedIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.ObservationalStudyProtocol.dataMonitoringCommitteeAppointedIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1370">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2960130</PUBLICID>
    <LONGNAME>Intervention Trial Study Protocol Document Institutional Review Board Approval Required Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>2959374v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A specially constituted independent review body comprised of medical, scientific and non-scientific members established and designated by an entity to ensure the protection of the rights, safety and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38, part 16 (same as Title 45, part 46 and Title 21, part 56) of the U.S. Code of Federal Regulations. IRB responsibility include but not limited to the reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material(s) to be used in obtaining and documenting informed consent of the trial. Other equivalent committees with the same or similar functions are also considered to be IRBs.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.:Necessary, not optional.:An indicator that can be set or unset in order to signal whether a particular condition is true._Values of two-valued logic.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2959374</PublicId>
      <PreferredName>2867669v1.0:2959174v1.0</PreferredName>
      <PreferredDefinition>A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A specially constituted independent review body comprised of medical, scientific and non-scientific members established and designated by an entity to ensure the protection of the rights, safety and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38, part 16 (same as Title 45, part 46 and Title 21, part 56) of the U.S. Code of Federal Regulations. IRB responsibility include but not limited to the reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material(s) to be used in obtaining and documenting informed consent of the trial. Other equivalent committees with the same or similar functions are also considered to be IRBs.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.:Necessary, not optional.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Intervention Trial Study Protocol Document Institutional Review Board Approval Required Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867669</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16140:C63536:C42651:C19498</PreferredName>
        <Version>1</Version>
        <LongName>Intervention Trial Study Protocol Document</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16140</PREFERRED_NAME>
            <LONG_NAME>Intervention Trial</LONG_NAME>
            <CON_ID>2867568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2959174</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16741:C25425:C25652:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Institutional Review Board Approval Required Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16741</PREFERRED_NAME>
            <LONG_NAME>Institutional Review Board</LONG_NAME>
            <CON_ID>2202674</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25425</PREFERRED_NAME>
            <LONG_NAME>Approval</LONG_NAME>
            <CON_ID>2203580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25652</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2204014</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Intervention Trial Study Protocol Document Institutional Review Board Approval Required Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Intervention Trial Study Protocol Document Institutional Review Board Approval Required Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.InterventionalStudyProtocol.reviewBoardApprovalRequiredIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>InterventionalStudyProtocol:reviewBoardApprovalRequiredIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1371">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2960143</PUBLICID>
    <LONGNAME>Research Activity Consortium or Network Or Professional Organization or Group Status Code RoleStatus</LONGNAME>
    <PREFERREDNAME>2868252v1.0:2959613v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:Groups of scientists who link their expertise and resources in collaborative efforts to address important questions of shared interest.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A formal group of people that that exists to further a particular profession._A condition or state at a particular time.:A system, often of numbered categories, for representation of data._The code that represents the responsibility of the investigator on a particular study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868252</PublicId>
      <PreferredName>2867678v1.0:2607549v1.0</PreferredName>
      <PreferredDefinition>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.:Groups of scientists who link their expertise and resources in collaborative efforts to address important questions of shared interest.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A formal group of people that that exists to further a particular profession._A condition or state at a particular time.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Research Activity Consortium or Network Or Professional Organization or Group Status Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867678</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15429:C19975:C37998:C19711</PreferredName>
        <Version>1</Version>
        <LongName>Research Activity Consortium or Network Or Professional Organization or Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15429</PREFERRED_NAME>
            <LONG_NAME>Research Activity</LONG_NAME>
            <CON_ID>2528433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19975</PREFERRED_NAME>
            <LONG_NAME>Consortium or Network</LONG_NAME>
            <CON_ID>2867561</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19711</PREFERRED_NAME>
            <LONG_NAME>Professional Organization or Group</LONG_NAME>
            <CON_ID>2202773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Status Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2959613</PublicId>
      <PreferredName>2959613v1.0</PreferredName>
      <PreferredDefinition>The code that represents the value for the state of a structural role.</PreferredDefinition>
      <LongName>RoleStatus</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nullified</VALIDVALUE>
          <VALUEMEANING>Negation Valid</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.:Allowable, usable, or acceptable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25594, C71756</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2959484</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Suspended</VALIDVALUE>
          <VALUEMEANING>Suspension</VALUEMEANING>
          <MEANINGDESCRIPTION>To stop a process by imposing a freeze on it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49134</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2959485</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Active</VALIDVALUE>
          <VALUEMEANING>Active</VALUEMEANING>
          <MEANINGDESCRIPTION>Exerting influence or producing an effect; taking part in an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Research Activity Consortium or Network Or Professional Organization or Group Status Code RoleStatus does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Research Activity Consortium or Network Or Professional Organization or Group Status Code RoleStatus does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2958963</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COPPA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.COPPA.InformationModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2958964</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.COPPA.InformationModel.ResearchOrganization.statusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ResearchOrganization:statusCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1372">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2960431</PUBLICID>
    <LONGNAME>Lineage Biomarker Occurrence Name</LONGNAME>
    <PREFERREDNAME>LING_MKR_OCC_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name for a biomarker that is objectively measured and evaluated as an indicator of an individual&#39;s descent in a line from a common progenitor or source.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2960422</PublicId>
      <PreferredName>LING_MKR_OCC</PreferredName>
      <PreferredDefinition>Descent in a line from a common progenitor or source._A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. (From: FDA Guidance for Industry: Pharmacogenomic Data Submissions.)_An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Lineage Biomarker Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2960420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60792:C16342</PreferredName>
        <Version>1</Version>
        <LongName>Lineage Biomarker</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60792</PREFERRED_NAME>
            <LONG_NAME>Lineage</LONG_NAME>
            <CON_ID>2496587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2960424</PublicId>
      <PreferredName>LING_MKR_NM</PreferredName>
      <PreferredDefinition>Descent in a line from a common progenitor or source._Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc_The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Lineage Biomarker Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2960423</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60792:C16342:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Lineage Biomarker Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60792</PREFERRED_NAME>
            <LONG_NAME>Lineage</LONG_NAME>
            <CON_ID>2496587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DC marker (CD 11c)</VALIDVALUE>
          <VALUEMEANING>DC marker (CD 11c)</VALUEMEANING>
          <MEANINGDESCRIPTION>DC marker (CD 11c)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HLA-DR</VALIDVALUE>
          <VALUEMEANING>HLA-DR Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2829707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NK Cells (CD 56+)</VALIDVALUE>
          <VALUEMEANING>NK Cells (CD 56+)</VALUEMEANING>
          <MEANINGDESCRIPTION>NK Cells (CD 56+)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960426</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monocytes (CD 14+)</VALIDVALUE>
          <VALUEMEANING>Monocytes (CD 14+)</VALUEMEANING>
          <MEANINGDESCRIPTION>Monocytes (CD 14+)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B Lymphocytes (CD 19+)</VALIDVALUE>
          <VALUEMEANING>B Lymphocytes (CD 19+)</VALUEMEANING>
          <MEANINGDESCRIPTION>B Lymphocytes (CD 19+)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960428</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T Lymphocytes (CD 3+)</VALIDVALUE>
          <VALUEMEANING>T Lymphocytes (CD 3+)</VALUEMEANING>
          <MEANINGDESCRIPTION>T Lymphocytes (CD 3+)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-11-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lineage Markers</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lineage Markers</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1373">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2963347</PUBLICID>
    <LONGNAME>Diagnostic Imaging Method Indicator</LONGNAME>
    <PREFERREDNAME>DIAG_IMG_METHOD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not a diagnostic imaging method was used.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2201766</PublicId>
      <PreferredName>2321520v1.0:2231639v1.0</PreferredName>
      <PreferredDefinition>information relate to the method or technique used to create a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.</PreferredDefinition>
      <LongName>Diagnostic Imaging Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2321520</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16502</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Imaging</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16502</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Imaging</LONG_NAME>
            <CON_ID>2321519</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231639</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16847</PREFERRED_NAME>
            <LONG_NAME>Technique</LONG_NAME>
            <CON_ID>2203854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was a diagnostic imaging meth</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was a diagnostic imaging method used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the test used to determine involvement?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the test used to determine involvement?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CT (scan performed)?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CT (scan performed)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MRI (scan performed)?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>MRI (scan performed)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify type of scan performed:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify type of scan performed:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the scan performed?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the scan performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2025r1: Central Nervous System Tumor Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964893</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2026r1: Neuroblastoma Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964894</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2039r1: Hemophagocytic Lymphohistiocytosis Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3279244</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_dx_bone_scan_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>cns_base_dx_bone_mri_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>felh_base_cns_abn_mri_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>felh_base_cns_abn_ct_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1374">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2964993</PUBLICID>
    <LONGNAME>Plan Activity Label Label java.lang.String</LONGNAME>
    <PREFERREDNAME>2964962v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>To devise, contrive, or formed in design.:An action taken in pursuit of an objective; the state of being active.:A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object._A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2964962</PublicId>
      <PreferredName>2964950v1.0:2422649v1.0</PreferredName>
      <PreferredDefinition>To devise, contrive, or formed in design.:An action taken in pursuit of an objective; the state of being active.:A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object._A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object.</PreferredDefinition>
      <LongName>Plan Activity Label Label</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2964950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25619:C43431:C45561</PreferredName>
        <Version>1</Version>
        <LongName>Plan Activity Label</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45561</PREFERRED_NAME>
            <LONG_NAME>Label</LONG_NAME>
            <CON_ID>2422619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2422649</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45561</PreferredName>
        <Version>1</Version>
        <LongName>Label</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45561</PREFERRED_NAME>
            <LONG_NAME>Label</LONG_NAME>
            <CON_ID>2422619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Plan Activity Label Label java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Plan Activity Label Label java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2672769</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PSC</PreferredName>
          <Version>2.6</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.bioinformatics.studycalendar.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000049</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.bioinformatics.studycalendar.domain.PlannedActivityLabel.label</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PlannedActivityLabel:label</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1375">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2968091</PUBLICID>
    <LONGNAME>Form Element Administered Item Modified By java.lang.String</LONGNAME>
    <PREFERREDNAME>2967609v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who changed an item._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967609</PublicId>
      <PreferredName>2967422v1.0:2231612v1.0</PreferredName>
      <PreferredDefinition>A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who changed an item.</PreferredDefinition>
      <LongName>Form Element Administered Item Modified By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2967422</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19464:C48792:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Form Element Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48792</PREFERRED_NAME>
            <LONG_NAME>Element</LONG_NAME>
            <CON_ID>2513271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42629</PreferredName>
        <Version>1</Version>
        <LongName>Modified By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42629</PREFERRED_NAME>
            <LONG_NAME>Modified By</LONG_NAME>
            <CON_ID>2231552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Form Element Administered Item Modified By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Form Element Administered Item Modified By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FormElement:modifiedBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.FormElement.modifiedBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1376">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2968176</PUBLICID>
    <LONGNAME>Valid Value Form Element Administered Item Created By java.lang.String</LONGNAME>
    <PREFERREDNAME>2967687v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The allowable values for a given data element (question) on a Case Report Form.:A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who brought the item into existence._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2967687</PublicId>
      <PreferredName>2967421v1.0:2231611v1.0</PreferredName>
      <PreferredDefinition>The allowable values for a given data element (question) on a Case Report Form.:A printed or electronic document with spaces to be filled out.:An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.:A registry item for which administrative information is recorded in an Administration Record._Indicates the person or authoritative body who brought the item into existence.</PreferredDefinition>
      <LongName>Valid Value Form Element Administered Item Created By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2967421</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41124:C19464:C48792:C42613</PreferredName>
        <Version>1</Version>
        <LongName>Valid Value Form Element Administered Item</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41124</PREFERRED_NAME>
            <LONG_NAME>Valid Value</LONG_NAME>
            <CON_ID>2231578</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48792</PREFERRED_NAME>
            <LONG_NAME>Element</LONG_NAME>
            <CON_ID>2513271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42613</PREFERRED_NAME>
            <LONG_NAME>Administered Item</LONG_NAME>
            <CON_ID>2231545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231611</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42628</PreferredName>
        <Version>1</Version>
        <LongName>Created By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42628</PREFERRED_NAME>
            <LONG_NAME>Created By</LONG_NAME>
            <CON_ID>2231551</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Valid Value Form Element Administered Item Created By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Valid Value Form Element Administered Item Created By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2967376</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caDSR</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cadsr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000553</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ValidValue:createdBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cadsr.domain.ValidValue.createdBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1377">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2974934</PUBLICID>
    <LONGNAME>Dental Professional Practice Periodontist Other Referral Specify</LONGNAME>
    <PREFERREDNAME>2974914v1.0:2018810v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the free text field related to the dental practice referral to a dentist who specializes in the prevention, diagnosis and treatment of the hard and soft tissue supporting the teeth for other treatment not otherwise specified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2974914</PublicId>
      <PreferredName>2443314v1.0:2974912v1.0</PreferredName>
      <PreferredDefinition>information related to the dental practice referral to a dentist who specializes in the prevention, diagnosis and treatment of the hard and soft tissue supporting the teeth for other treatment not otherwise specified.</PreferredDefinition>
      <LongName>Dental Professional Practice Periodontist Other Referral</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2974912</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63736:C17649:C52582</PreferredName>
        <Version>1</Version>
        <LongName>Periodontist Other Referral</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63736</PREFERRED_NAME>
            <LONG_NAME>Periodontist</LONG_NAME>
            <CON_ID>2547884</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52582</PREFERRED_NAME>
            <LONG_NAME>Referral</LONG_NAME>
            <CON_ID>2443156</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857180</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Periodontics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2857182</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Forms</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PEARL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1378">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2975227</PUBLICID>
    <LONGNAME>Multiple Spectrum Picture Estimate Material Imaging Signal Channel Profile Identifier java.lang.String</LONGNAME>
    <PREFERREDNAME>2975217v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold. (dictionary.com):An array of entities, as light waves or particles, ordered in accordance with the magnitudes of a common physical property, as wavelength or mass.:A visual representation of an object, scene, person or abstraction.:To calculate approximately.:The tangible substance that goes into the makeup of a physical object.:The measured value of a response in a recorded image produced by the intensity, abundance, or concentration of source materials.:An independent acquisition scheme, i.e., a route or conduit through which flows data consisting of one particular measurement using one particular parameter.:An analysis (often in graphical form) representing the extent to which something exhibits various characteristics._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2975217</PublicId>
      <PreferredName>2975202v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold. (dictionary.com):An array of entities, as light waves or particles, ordered in accordance with the magnitudes of a common physical property, as wavelength or mass.:A visual representation of an object, scene, person or abstraction.:To calculate approximately.:The tangible substance that goes into the makeup of a physical object.:The measured value of a response in a recorded image produced by the intensity, abundance, or concentration of source materials.:An independent acquisition scheme, i.e., a route or conduit through which flows data consisting of one particular measurement using one particular parameter.:An analysis (often in graphical form) representing the extent to which something exhibits various characteristics._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Multiple Spectrum Picture Estimate Material Imaging Signal Channel Profile Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2975202</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2975202v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Multiple Spectrum Picture Estimate Material Imaging Signal Channel Profile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17648</PREFERRED_NAME>
            <LONG_NAME>Multiple</LONG_NAME>
            <CON_ID>2202577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84383</PREFERRED_NAME>
            <LONG_NAME>Spectrum</LONG_NAME>
            <CON_ID>2971816</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54273</PREFERRED_NAME>
            <LONG_NAME>Picture</LONG_NAME>
            <CON_ID>2464663</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25498</PREFERRED_NAME>
            <LONG_NAME>Estimate</LONG_NAME>
            <CON_ID>2203929</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84384</PREFERRED_NAME>
            <LONG_NAME>Imaging Signal</LONG_NAME>
            <CON_ID>2975200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44170</PREFERRED_NAME>
            <LONG_NAME>Channel</LONG_NAME>
            <CON_ID>2236547</CON_ID>
            <DEFINITION_SOURCE>NCICB</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84385</PREFERRED_NAME>
            <LONG_NAME>Profile</LONG_NAME>
            <CON_ID>2975199</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Multiple Spectrum Picture Estimate Material Imaging Signal Channel Profile Identifier java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Multiple Spectrum Picture Estimate Material Imaging Signal Channel Profile Identifier java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2975196</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>omniSpect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>omniSpect Grid Services 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>2975197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2975196</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>omniSpect</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.gatech.bme.biomiblab.omnispect</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2975198</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ChannelMaterialProfile:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.gatech.bme.biomiblab.omnispect.ChannelMaterialProfile.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1379">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2975858</PUBLICID>
    <LONGNAME>Imaging Agent Net Radioactivity Administered Float 16 Character Number</LONGNAME>
    <PREFERREDNAME>2975819v1.0:2585012v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>Imaging Agent Net Radioactivity Administered (0018,1074) is the radiopharmaceutical net dose administered to the patient measured in MegaBecquerels (Mbq) at the Radiopharmaceutical Start Time (0018,1072).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DICOM:Digital Imaging and Communications in Medicine</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2975819</PublicId>
      <PreferredName>2986612v1.0:2986632v1.0</PreferredName>
      <PreferredDefinition>The imaging agent (radiopharmaceutical) net dose administered to the patient measured at the Radiopharmaceutical Start Time (0018,1072).</PreferredDefinition>
      <LongName>Imaging Agent Net Radioactivity Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2986612</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16831:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16831</PREFERRED_NAME>
            <LONG_NAME>Medical Imaging</LONG_NAME>
            <CON_ID>2224877</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2986632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70842:C17054:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Net Radioactivity Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70842</PREFERRED_NAME>
            <LONG_NAME>Net</LONG_NAME>
            <CON_ID>2710306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17054</PREFERRED_NAME>
            <LONG_NAME>Radioactivity</LONG_NAME>
            <CON_ID>2915572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2585012</PublicId>
      <PreferredName>FLOAT_16_CHAR_NUM</PreferredName>
      <PreferredDefinition>DS: A string of characters representing either a fixed point number or a floating point number. A fixed point number shall contain only the characters 0-9 with an optional leading &quot;+&quot; or &quot;-&quot; and an optional &quot;.&quot; to mark the decimal point. A floating point number shall be conveyed as defined in ANSI X3.9, with an &quot;E&quot; or &quot;e&quot; to indicate the start of the exponent. Decimal Strings may be padded with leading or trailing spaces. Embedded spaces are not allowed.  (valid characters 0-9, +,-, E,e,&quot;.&quot;) [Standard-based]</PreferredDefinition>
      <LongName>Float 16 Character Number</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>16</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DICOM:Digital Imaging and Communications in Medicine</Origin>
      <Representation>
        <PublicId>2585011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45253:C25337</PreferredName>
        <Version>1</Version>
        <LongName>String Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45253</PREFERRED_NAME>
            <LONG_NAME>String</LONG_NAME>
            <CON_ID>2539471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Imaging Agent Net Activity Ad</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Imaging Agent Net Activity Administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>6671-TA</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Administered activity (net injected dose)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PET Imaging Agent NCI Standard Template Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Net activity administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Isotope</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812712</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614826</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DICOM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>DICOM Tag CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812790</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>(0018,1074)</AlternateName>
        <AlternateNameType>DICOM_TAG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Radionuclide Total Dose</AlternateName>
        <AlternateNameType>DICOM Attribute Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1380">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2986153</PUBLICID>
    <LONGNAME>Extragonadal Germ Cell Tumor Present Anatomic Site Name</LONGNAME>
    <PREFERREDNAME>2986094v1.0:2017282v1.3</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the extra-gonadal germ cell tumor site.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2986094</PublicId>
      <PreferredName>2986092v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum). _Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Extragonadal Germ Cell Tumor Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2986092</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3918</PreferredName>
        <Version>1</Version>
        <LongName>Extragonadal Germ Cell Tumor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3918</PREFERRED_NAME>
            <LONG_NAME>Extragonadal Germ Cell Tumor</LONG_NAME>
            <CON_ID>2593142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2017282</PublicId>
      <PreferredName>ANAT_SITE_NM</PreferredName>
      <PreferredDefinition>Name of the organ site (single) within the body; may be referenced in primary site of disease, surgical intervention, or extent of disease documentation.</PreferredDefinition>
      <LongName>Anatomic Site Name</LongName>
      <Version>1.3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>120</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261898</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Text Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brow</VALIDVALUE>
          <VALUEMEANING>Eyebrow</VALUEMEANING>
          <MEANINGDESCRIPTION>The arched strip of hair on the bony ridge above each eye socket.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32575</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buccal mucosa</VALIDVALUE>
          <VALUEMEANING>Buccal Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The mucosal membranes located on the inside of the cheek, in the buccal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12505</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3522966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cecum</VALIDVALUE>
          <VALUEMEANING>Cecum</VALUEMEANING>
          <MEANINGDESCRIPTION>A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12381</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613621</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Finger</VALIDVALUE>
          <VALUEMEANING>Fingers (Phalanges)</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the digits of the hand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frontal lobe</VALIDVALUE>
          <VALUEMEANING>Frontal Lobe</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2688392</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hard palate</VALIDVALUE>
          <VALUEMEANING>Hard Palate</VALUEMEANING>
          <MEANINGDESCRIPTION>The bony anterior part of the roof of the mouth separating the nose from the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12230</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3522964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Humerus</VALIDVALUE>
          <VALUEMEANING>Humerus</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper arm bone between the shoulder and elbow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12731</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ilium</VALIDVALUE>
          <VALUEMEANING>Ilium</VALUEMEANING>
          <MEANINGDESCRIPTION>The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jejunum</VALIDVALUE>
          <VALUEMEANING>Jejunum</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the small intestine that extends from the duodenum to the ileum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12388</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parotid gland</VALIDVALUE>
          <VALUEMEANING>Parotid Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>The largest of the three paired salivary glands, located in front of the ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12427</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ampulla of Vater</VALIDVALUE>
          <VALUEMEANING>Ampulla of Vater</VALUEMEANING>
          <MEANINGDESCRIPTION>The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla. The flow of bile and pancreatic juices into the duodenum through the Ampulla of Vater is controlled by the sphincter of Oddi.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13011</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adipose</VALIDVALUE>
          <VALUEMEANING>Adipose Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue composed of fat cells lodged in the meshes of areolar tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skeletal Muscle</VALIDVALUE>
          <VALUEMEANING>Skeletal Muscle Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Striated muscles that are under voluntary control of the organism. They are connected at either or both ends to a bone and are utilized for locomotion and other movements. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13050</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremities</VALIDVALUE>
          <VALUEMEANING>Extremities</VALUEMEANING>
          <MEANINGDESCRIPTION>Body limbs, consisting of right upper and lower (arm and leg) and left upper and lower (arm and leg).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C30140</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lacrimal Gland</VALIDVALUE>
          <VALUEMEANING>Lacrimal Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ligament</VALIDVALUE>
          <VALUEMEANING>Ligament</VALUEMEANING>
          <MEANINGDESCRIPTION>Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211576</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ganglia</VALIDVALUE>
          <VALUEMEANING>Ganglion</VALUEMEANING>
          <MEANINGDESCRIPTION>A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid</VALIDVALUE>
          <VALUEMEANING>Body Fluid or Substance</VALUEMEANING>
          <MEANINGDESCRIPTION>Liquid and semi liquid substances produced by living organisms to fulfill specific functions or excreted as waste; does not include hormones or enzymes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13236</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3212369</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophagus, Mucosa only</VALIDVALUE>
          <VALUEMEANING>Esophageal Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or relating to the esophagus.: The moist tissue that lines some organs and body cavities (such as the nose, mouth, lungs) and makes mucus (a thick, slippery fluid).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C37950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242560</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Effusion</VALIDVALUE>
          <VALUEMEANING>Effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>A collection of fluid in a body cavity.  It may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung). -- 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242561</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Placenta</VALIDVALUE>
          <VALUEMEANING>Placenta</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ present in some vertebrates during embryonic gestation that surrounds the fetus and provides it with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother, and provides parasitic cloaking from the mother&#39;s immune system by excretion of neurokinin B.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parathyroid</VALIDVALUE>
          <VALUEMEANING>Parathyroid Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12765</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral Cavity, Mucosa only</VALIDVALUE>
          <VALUEMEANING>Oral Cavity Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The cavity lying at the upper end of the alimentary canal, bounded on the outside by the lips and inside by the oropharynx and containing in humans the tongue, gums, and teeth.: The moist tissue that lines some organs and body cavities (such as the nose, mouth, lungs) and makes mucus (a thick, slippery fluid).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C12421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nails</VALIDVALUE>
          <VALUEMEANING>Nail</VALUEMEANING>
          <MEANINGDESCRIPTION>The cutaneous plate on the dorsal surface of the distal end of a finger or toe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211554</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesothelium</VALIDVALUE>
          <VALUEMEANING>Mesothelium</VALUEMEANING>
          <MEANINGDESCRIPTION>A simple layer of cells, derived from the mesoderm that lines the coelom or body cavity of the embryo. In the adult, it covers all true serous membranes (peritoneum, pericardium, pleura).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33105</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vas Deferens</VALIDVALUE>
          <VALUEMEANING>Vas Deferens</VALUEMEANING>
          <MEANINGDESCRIPTION>Duct carrying spermatozoa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12813</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urethra</VALIDVALUE>
          <VALUEMEANING>Urethra</VALUEMEANING>
          <MEANINGDESCRIPTION>(yoo-REE-thra) The tube through which urine leaves the body. It empties urine from the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12417</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3181637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Umbilical Cord</VALIDVALUE>
          <VALUEMEANING>Umbilical Cord</VALUEMEANING>
          <MEANINGDESCRIPTION>Extraembryonic structure that connects the fetus to the placenta. It contains two arteries and one vein.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211588</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wrist</VALIDVALUE>
          <VALUEMEANING>Wrist</VALUEMEANING>
          <MEANINGDESCRIPTION>A joint between the distal end of the radius and the proximal row of carpal bones. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33894</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest</VALIDVALUE>
          <VALUEMEANING>Chest</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vulva</VALIDVALUE>
          <VALUEMEANING>Vulva</VALUEMEANING>
          <MEANINGDESCRIPTION>The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12408</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562490</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertebra</VALIDVALUE>
          <VALUEMEANING>Vertebra</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the ring-shaped bony structures that constitute the spinal column and surround the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12933</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563638</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebellum</VALIDVALUE>
          <VALUEMEANING>Cerebellum</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central nervous system</VALIDVALUE>
          <VALUEMEANING>Central Nervous System</VALUEMEANING>
          <MEANINGDESCRIPTION>The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558476</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tonsil</VALIDVALUE>
          <VALUEMEANING>Tonsil</VALUEMEANING>
          <MEANINGDESCRIPTION>The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12802</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567150</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spleen</VALIDVALUE>
          <VALUEMEANING>Spleen</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that produces lymphocytes, filters the blood, stores blood cells, and destroys those that are aging. It is located on the left side of the abdomen near the stomach. (OCC)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567549</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thymus</VALIDVALUE>
          <VALUEMEANING>Thymus</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that is part of the lymphatic system, in which T lymphocytes grow and multiply. The thymus is in the chest behind the breastbone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stomach</VALIDVALUE>
          <VALUEMEANING>Stomach</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ located between the esophagus and the small intestine where digestion of food occurs before passing to the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thorax</VALIDVALUE>
          <VALUEMEANING>Thorax</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper part of the trunk between the neck and the abdomen. It contains the chief organs of the circulatory and respiratory systems. (From Stedman, 25th ed)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12799</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Genitourinary</VALIDVALUE>
          <VALUEMEANING>Genitourinary</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or related to the genital and urinary organs or their functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25350</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retroperitoneum</VALIDVALUE>
          <VALUEMEANING>Retroperitoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>The back of the abdomen where the kidneys lie and the great blood vessels run.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skull</VALIDVALUE>
          <VALUEMEANING>Skull</VALUEMEANING>
          <MEANINGDESCRIPTION>The skeleton of the head including the bones of the face and the bones enclosing the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mandible</VALIDVALUE>
          <VALUEMEANING>Mandible</VALUEMEANING>
          <MEANINGDESCRIPTION>The largest and strongest bone of the FACE constituting the lower jaw. It supports the lower teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Maxilla</VALIDVALUE>
          <VALUEMEANING>Maxilla</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper jawbone in vertebrates: it is fused to the cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ribs</VALIDVALUE>
          <VALUEMEANING>Ribs</VALUEMEANING>
          <MEANINGDESCRIPTION>Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum&#39; by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12782</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568925</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clavicle</VALIDVALUE>
          <VALUEMEANING>Clavicle</VALUEMEANING>
          <MEANINGDESCRIPTION>A bone of the upper extremity that articulates with the acromion process of the scapula on one end and the sternum on the other.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12695</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Femur</VALIDVALUE>
          <VALUEMEANING>Femur</VALUEMEANING>
          <MEANINGDESCRIPTION>The longest and largest bone of the skeleton, it is situated between the hip and the knee.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibula</VALIDVALUE>
          <VALUEMEANING>Fibula</VALUEMEANING>
          <MEANINGDESCRIPTION>The bone of the lower leg lateral to and smaller than the tibia. In proportion to its length, it is the most slender of the long bones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anus</VALIDVALUE>
          <VALUEMEANING>Anus</VALUEMEANING>
          <MEANINGDESCRIPTION>(AY-nus) The opening of the rectum to the outside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvis</VALIDVALUE>
          <VALUEMEANING>Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pancreas</VALIDVALUE>
          <VALUEMEANING>Pancreas</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adrenal gland</VALIDVALUE>
          <VALUEMEANING>Adrenal Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12666</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal sphincter</VALIDVALUE>
          <VALUEMEANING>Anal Sphincter</VALUEMEANING>
          <MEANINGDESCRIPTION>The area that includes the anus and the perianal skin.: A ring-shaped muscle that relaxes or tightens to open or close a passage or opening in the body. Examples are the anal sphincter (around the opening of the anus) and the pyloric sphincter (at the lower opening of the stomach).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28381, C32069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569665</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood</VALIDVALUE>
          <VALUEMEANING>Blood</VALUEMEANING>
          <MEANINGDESCRIPTION>A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12434</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567366</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aorta</VALIDVALUE>
          <VALUEMEANING>Aorta</VALUEMEANING>
          <MEANINGDESCRIPTION>The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12669</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Artery</VALIDVALUE>
          <VALUEMEANING>Artery</VALUEMEANING>
          <MEANINGDESCRIPTION>The vessels carrying blood away from the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12372</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569764</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Back</VALIDVALUE>
          <VALUEMEANING>Back</VALUEMEANING>
          <MEANINGDESCRIPTION>The dorsal area between the base of the neck and the sacrum. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13062</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buttock</VALIDVALUE>
          <VALUEMEANING>Buttock</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchus</VALIDVALUE>
          <VALUEMEANING>Bronchus</VALUEMEANING>
          <MEANINGDESCRIPTION>Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Conjunctiva</VALIDVALUE>
          <VALUEMEANING>Conjunctiva</VALUEMEANING>
          <MEANINGDESCRIPTION>A thin, transparent mucous membrane that covers the posterior surface of lids (palpebral conjunctiva) and the outer surface of the sclera (bulbar conjunctiva).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12341</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569843</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Salivary gland</VALIDVALUE>
          <VALUEMEANING>Salivary Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>An exocrine gland that secretes saliva.  Salivary glands are mostly located in and around the oral cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12426</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scalp</VALIDVALUE>
          <VALUEMEANING>Scalp</VALUEMEANING>
          <MEANINGDESCRIPTION>The skin which covers the top of the head and which is usually covered by hair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lip</VALIDVALUE>
          <VALUEMEANING>Lip</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two fleshy, full-blooded margins of the mouth. (MeSH)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12220</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trachea/Major Bronchi</VALIDVALUE>
          <VALUEMEANING>Trachea and Main Bronchus</VALUEMEANING>
          <MEANINGDESCRIPTION>The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi.: The left and right main bronchi considered as a group.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12284, C12428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242565</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tonsil, Pharyngeal</VALIDVALUE>
          <VALUEMEANING>Tonsillar Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2761349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tendon</VALIDVALUE>
          <VALUEMEANING>Tendon</VALUEMEANING>
          <MEANINGDESCRIPTION>A band of fibrous connective tissue that joins bone to muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13045</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Synovium</VALIDVALUE>
          <VALUEMEANING>Synovial Membrane</VALUEMEANING>
          <MEANINGDESCRIPTION>The inner layer of the connective tissue that seals the joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small Bowel, Mucosa only</VALIDVALUE>
          <VALUEMEANING>Small Bowel Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the digestive tube between the stomach and the cecum or beginning of the large intestine; it consists of three portions: duodenum, jejunum, and ileum. SYN intestinum tenue.: The moist tissue that lines some organs and body cavities (such as the nose, mouth, lungs) and makes mucus (a thick, slippery fluid).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C12386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spinal Cord</VALIDVALUE>
          <VALUEMEANING>Spinal Cord</VALUEMEANING>
          <MEANINGDESCRIPTION>The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge.|On-line Medical Dictionary</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12464</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stomach, Mucosa only</VALIDVALUE>
          <VALUEMEANING>Stomach Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ located between the esophagus and the small intestine where digestion of food occurs before passing to the small intestine.: The moist tissue that lines some organs and body cavities (such as the nose, mouth, lungs) and makes mucus (a thick, slippery fluid).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C12391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antrum</VALIDVALUE>
          <VALUEMEANING>Antrum Pylori</VALUEMEANING>
          <MEANINGDESCRIPTION>The initial part of the pyloric canal of the stomach.  This site contains endocrine cells that produce gastrin and somatostatin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastroesophageal Junction</VALIDVALUE>
          <VALUEMEANING>Gastroesophageal Junction</VALUEMEANING>
          <MEANINGDESCRIPTION>The anatomical location where the esophagus joins to the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardia</VALIDVALUE>
          <VALUEMEANING>Gastric Cardia</VALUEMEANING>
          <MEANINGDESCRIPTION>The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12256</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peri-orbital Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Periorbital Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring in, or located in the area around the orbit of the eye.: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471, C98190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasal Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Nasal Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>By or having to do with the nose.: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471, C27958</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinal Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Mediastinal Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Mediastinal; related to the mediastinum.: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471, C25310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Retroperitoneal</VALIDVALUE>
          <VALUEMEANING>Retroperitoneal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the retroperitoneal space.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Submandibular</VALIDVALUE>
          <VALUEMEANING>Submandibular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located beneath the floor of the oral cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77650</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Splenic</VALIDVALUE>
          <VALUEMEANING>Splenic Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the hilar region of the spleen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Popliteal</VALIDVALUE>
          <VALUEMEANING>Popliteal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Lymph node located within the fat layer of the knee joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53146</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Parotid</VALIDVALUE>
          <VALUEMEANING>Parotid Gland Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located close to, on, or within the parotid gland. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280099</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Occipital</VALIDVALUE>
          <VALUEMEANING>Occipital Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the back of the head adjacent to the trapezius muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Mesenteric</VALIDVALUE>
          <VALUEMEANING>Mesenteric Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the mesentery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77641</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Iliac-external</VALIDVALUE>
          <VALUEMEANING>External Iliac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located along the external iliac artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Iliac-common</VALIDVALUE>
          <VALUEMEANING>Common Iliac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Widely known or encountered.: One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32761, C43461</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3354957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Femoral</VALIDVALUE>
          <VALUEMEANING>Femoral Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the upper inner portion of the thigh.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98183</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Epitrochlear</VALIDVALUE>
          <VALUEMEANING>Epitrochlear Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located above and adjacent to the elbow.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98182</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284847</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hepatic duct</VALIDVALUE>
          <VALUEMEANING>Hepatic Duct</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the three ducts associated with the liver including the right hepatic duct, left hepatic duct and common hepatic duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32730</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Popliteal fossa</VALIDVALUE>
          <VALUEMEANING>Popliteal Fossa</VALUEMEANING>
          <MEANINGDESCRIPTION>A diamond-shaped depression located in the back of the knee joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Round ligament</VALIDVALUE>
          <VALUEMEANING>Round Ligament</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the round ligaments including the round ligament of the liver and the round ligament of the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12319</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leptomeninges</VALIDVALUE>
          <VALUEMEANING>Leptomeninges</VALUEMEANING>
          <MEANINGDESCRIPTION>The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32979</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578457</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>Abdomen and Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the body that lies between the thorax and the pelvis.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C37912, C12664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3393975</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alveolar Ridge</VALIDVALUE>
          <VALUEMEANING>Alveolar Ridge</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or relating to the alveoli.: Any long raised border or margin of a bone or tooth or membrane.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61549, C14155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3393977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anorectum</VALIDVALUE>
          <VALUEMEANING>Anorectum</VALUEMEANING>
          <MEANINGDESCRIPTION>(AY-nus) The opening of the rectum to the outside of the body.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12390, C37912, C43362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3393978</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antecubital fossa</VALIDVALUE>
          <VALUEMEANING>Antecubital Fossa</VALUEMEANING>
          <MEANINGDESCRIPTION>The hinge joint between the forearm and upper arm or the corresponding joint in the forelimb of a quadruped.: A concavity in a surface, especially an anatomical depression.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34007, C32497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3393979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aortic Body</VALIDVALUE>
          <VALUEMEANING>Aortic Body</VALUEMEANING>
          <MEANINGDESCRIPTION>A small mass that is located in the inferior surface of the aortic arch.  It functions as a peripheral chemoreceptor and is composed of glomus cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C97112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3259520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Testicle</VALIDVALUE>
          <VALUEMEANING>Testicle</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the paired male reproductive glands that produce the male germ cells and the male hormones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Duodenum</VALIDVALUE>
          <VALUEMEANING>Duodenum</VALUEMEANING>
          <MEANINGDESCRIPTION>(doo-ah-DEE-num) The first part of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eye</VALIDVALUE>
          <VALUEMEANING>Eye</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ of sight or vision. (On-line Medical Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallbladder</VALIDVALUE>
          <VALUEMEANING>Gallbladder</VALUEMEANING>
          <MEANINGDESCRIPTION>A pear-shaped organ just below the liver that stores the bile secreted by the liver, delivering the bile through the bile ducts into the intestines to help with digestion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12377</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intestine</VALIDVALUE>
          <VALUEMEANING>Intestine</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581494</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Larynx</VALIDVALUE>
          <VALUEMEANING>Larynx</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ of voice production; the part of the respiratory tract between the pharynx and the trachea; it consists of a framework of cartilages and elastic membranes housing the vocal folds and the muscles which control the position and tension of these elements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12420</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Penis</VALIDVALUE>
          <VALUEMEANING>Penis</VALUEMEANING>
          <MEANINGDESCRIPTION>The male organ of urination and copulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12409</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tongue</VALIDVALUE>
          <VALUEMEANING>Tongue</VALUEMEANING>
          <MEANINGDESCRIPTION>The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Muscle</VALIDVALUE>
          <VALUEMEANING>Muscle</VALUEMEANING>
          <MEANINGDESCRIPTION>Muscle; one of the contractile organs of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retina</VALIDVALUE>
          <VALUEMEANING>Retina</VALUEMEANING>
          <MEANINGDESCRIPTION>A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trachea</VALIDVALUE>
          <VALUEMEANING>Trachea</VALUEMEANING>
          <MEANINGDESCRIPTION>The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12428</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneal cavity</VALIDVALUE>
          <VALUEMEANING>Peritoneal Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the abdomen that contains the intestines (the last part of the digestive tract), the stomach, and the liver. It is bound by thin membranes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569907</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pharynx</VALIDVALUE>
          <VALUEMEANING>Pharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>(FAIR-inks) The hollow tube about 5 inches long that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12425</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569909</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scrotum</VALIDVALUE>
          <VALUEMEANING>Scrotum</VALUEMEANING>
          <MEANINGDESCRIPTION>The musculocutaneous pouch that encloses the testicles. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Arm</VALIDVALUE>
          <VALUEMEANING>Arm</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32141</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leg</VALIDVALUE>
          <VALUEMEANING>Leg</VALUEMEANING>
          <MEANINGDESCRIPTION>Commonly used to refer to the whole lower limb but technically only the part between the knee and ankle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571023</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ankle</VALIDVALUE>
          <VALUEMEANING>Ankle</VALUEMEANING>
          <MEANINGDESCRIPTION>A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palate</VALIDVALUE>
          <VALUEMEANING>Palate</VALUEMEANING>
          <MEANINGDESCRIPTION>(PAL-et) The roof of the mouth. The front portion is bony (hard palate), and the back portion is muscular (soft palate).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12229</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acetabulum</VALIDVALUE>
          <VALUEMEANING>Acetabulum</VALUEMEANING>
          <MEANINGDESCRIPTION>Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32042</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anal canal</VALIDVALUE>
          <VALUEMEANING>Anal Canal</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12375</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bile duct</VALIDVALUE>
          <VALUEMEANING>Bile Duct</VALUEMEANING>
          <MEANINGDESCRIPTION>A tube through which bile passes in and out of the liver.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571102</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood vessel</VALIDVALUE>
          <VALUEMEANING>Blood Vessel</VALUEMEANING>
          <MEANINGDESCRIPTION>A tube through which the blood circulates in the body. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brain stem</VALIDVALUE>
          <VALUEMEANING>Brain Stem</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the brain that is connected to the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12441</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchiole</VALIDVALUE>
          <VALUEMEANING>Bronchiole</VALUEMEANING>
          <MEANINGDESCRIPTION>(BRON-kee-olz) The tiny branches of air tubes in the lungs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12684</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Buccal cavity</VALIDVALUE>
          <VALUEMEANING>Buccal Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The region consisting of the vestibulum oris, the narrow cleft between the lips and cheeks, and the teeth and gums, and the cavitas oris propria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carotid artery</VALIDVALUE>
          <VALUEMEANING>Carotid Artery</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two principal arteries on both sides of the neck that supply blood to the head and neck; each divides into two branches, the internal carotid artery and the external carotid artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Connective tissue</VALIDVALUE>
          <VALUEMEANING>Connective Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>The supporting or framework tissue of the animal body, formed of fibrous and ground substance with more or less numerous cells of various kinds; it is derived from the mesenchyme, and this in turn from the mesoderm; the varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; and lymphoid tissue; cartilage; and bone; the blood and lymph may be regarded as connective tissues the ground substance of which is a liquid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12374</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ear</VALIDVALUE>
          <VALUEMEANING>Ear</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ of hearing: composed of the external ear, which includes the auricle and the external acoustic, or auditory, meatus; the middle ear, or the tympanic cavity with its ossicles; and the internal ear or inner ear, or labyrinth, which includes the semicircular canals, vestibule, and cochlea. SEE ALSO auricle. SYN auris.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571121</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endocrine gland</VALIDVALUE>
          <VALUEMEANING>Endocrine Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12704</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571123</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foot</VALIDVALUE>
          <VALUEMEANING>Foot</VALUEMEANING>
          <MEANINGDESCRIPTION>The structure found below the ankle joint required for locomotion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571126</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Forearm</VALIDVALUE>
          <VALUEMEANING>Forearm</VALUEMEANING>
          <MEANINGDESCRIPTION>The structure on the upper limb, between the elbow and the wrist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32628</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577687</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrointestinal tract</VALIDVALUE>
          <VALUEMEANING>Gastrointestinal Tract</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568045</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hand</VALIDVALUE>
          <VALUEMEANING>Hand</VALUEMEANING>
          <MEANINGDESCRIPTION>The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypopharynx</VALIDVALUE>
          <VALUEMEANING>Hypopharynx (Laryngopharynx)</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the pharynx between the inferior portion of the oropharynx and the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphoma</VALIDVALUE>
          <VALUEMEANING>Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567355</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasopharynx</VALIDVALUE>
          <VALUEMEANING>Nasopharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>The nasal part of the pharynx, lying above the level of the soft palate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571143</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral cavity</VALIDVALUE>
          <VALUEMEANING>Oral Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The cavity lying at the upper end of the alimentary canal, bounded on the outside by the lips and inside by the oropharynx and containing in humans the tongue, gums, and teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE>2018-02-28</PVENDDATE>
          <VMPUBLICID>2571144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patella</VALIDVALUE>
          <VALUEMEANING>Patella</VALUEMEANING>
          <MEANINGDESCRIPTION>A small flat triangular bone in front of the knee that articulates with the femur and protects the knee joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pituitary gland</VALIDVALUE>
          <VALUEMEANING>Pituitary Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>A small, unpaired gland situated in the sella turcica tissue. It is connected to the hypothalamus by a short stalk.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12399</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571146</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sacrum</VALIDVALUE>
          <VALUEMEANING>Sacrum</VALUEMEANING>
          <MEANINGDESCRIPTION>The wedge-shaped bone consisting of five fused vertebrae, S1-S5 in man, forming the posterior part of the pelvis; its base connects with the lowest lumbar vertebra and its tip with the coccyx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shoulder</VALIDVALUE>
          <VALUEMEANING>Shoulder Joint</VALUEMEANING>
          <MEANINGDESCRIPTION>The region of the body between the neck and the upper arm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25203</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sigmoid colon</VALIDVALUE>
          <VALUEMEANING>Sigmoid Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the colon that connects to the descending colon above and the rectum below.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581640</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Periportal</VALIDVALUE>
          <VALUEMEANING>Periportal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Extending on all sides of simultaneously; encircling.: Of or pertaining to a porta, especially the porta of the liver; as, the portal vein, which enters the liver at the porta, and divides into capillaries after the manner of an artery. Portal is applied to other veins which break up into capillaries; as, the renal portal veins in the frog. (On-line Medical Dictionary): A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C38007, C52247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3526806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Paracaval</VALIDVALUE>
          <VALUEMEANING>Paracaval Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Extending on all sides of simultaneously; encircling.: A large vein which returns blood from the head, neck and extremeties to the heart.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C12817, C52247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3526807</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Iliac</VALIDVALUE>
          <VALUEMEANING>Iliac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32761</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hilum</VALIDVALUE>
          <VALUEMEANING>Hilum</VALUEMEANING>
          <MEANINGDESCRIPTION>A depression or fissure where vessels or nerves or ducts enter a bodily organ.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73467</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scapula</VALIDVALUE>
          <VALUEMEANING>Scapula</VALUEMEANING>
          <MEANINGDESCRIPTION>The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascites</VALIDVALUE>
          <VALUEMEANING>Ascites</VALUEMEANING>
          <MEANINGDESCRIPTION>Accumulation of fluid in the peritoneal cavity.  The fluid may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2944432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Groin</VALIDVALUE>
          <VALUEMEANING>Inguinal Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower region of the anterior abdominal wall located laterally to the pubic region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sternum</VALIDVALUE>
          <VALUEMEANING>Sternum</VALUEMEANING>
          <MEANINGDESCRIPTION>The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12793</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper extremity</VALIDVALUE>
          <VALUEMEANING>Upper Extremity</VALUEMEANING>
          <MEANINGDESCRIPTION>The region of the body that includes the arm, the forearm, and hand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12671</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasal Cavity</VALIDVALUE>
          <VALUEMEANING>Nasal Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12424</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613635</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vena Cava, Inferior/Superior</VALIDVALUE>
          <VALUEMEANING>Vena Cava</VALUEMEANING>
          <MEANINGDESCRIPTION>A large vein which returns blood from the head, neck and extremities to the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3613667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CNS + Systemic</VALIDVALUE>
          <VALUEMEANING>Central Nervous System And Systemic Anatomic Site</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the nervous system that consists of the brain, spinal cord, and meninges. : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: (sis-TEM-ik) Affecting the entire body.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C13310, C37912, C12438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3623717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Systemic</VALIDVALUE>
          <VALUEMEANING>Systemic</VALUEMEANING>
          <MEANINGDESCRIPTION>(sis-TEM-ik) Affecting the entire body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3178352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Floor of Mouth</VALIDVALUE>
          <VALUEMEANING>Floor of Mouth</VALUEMEANING>
          <MEANINGDESCRIPTION>The area of the mouth under the ventral surface of the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Forehead</VALIDVALUE>
          <VALUEMEANING>Forehead</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the face between the eyebrows and the normal hairline.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89803</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foreskin</VALIDVALUE>
          <VALUEMEANING>Male Prepuce</VALUEMEANING>
          <MEANINGDESCRIPTION>A fold of skin covering the tip of the penis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33049</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fundus of stomach</VALIDVALUE>
          <VALUEMEANING>Fundus</VALUEMEANING>
          <MEANINGDESCRIPTION>The larger part of a hollow organ that is farthest away from the organ&#39;s opening. The bladder, gallbladder, stomach, uterus, eye, and cavity of the middle ear all have a fundus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gum</VALIDVALUE>
          <VALUEMEANING>Gingiva</VALUEMEANING>
          <MEANINGDESCRIPTION>The mucous membrane-covered tissue of the jaws that surrounds the bases of the teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Head - face or neck, NOS</VALIDVALUE>
          <VALUEMEANING>Head (Face Or Neck , Not otherwise specified)</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior or superior part of an animal, containing the brain, or chief ganglia of the nervous system, the mouth, and in the higher animals, the chief sensory organs. (On-line Medical Dictionary): The anterior portion of the head extending from the forehead to the chin and ear to ear. The facial structures contain the eyes, nose and mouth, cheeks and jaws.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The region that connects the head to the rest of the body.: Not characterized in any other way.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C19594, C13063, C37998, C13071, C12419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Head/Neck</VALIDVALUE>
          <VALUEMEANING>Head and Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior or superior part of an animal, containing the brain, or chief ganglia of the nervous system, the mouth, and in the higher animals, the chief sensory organs. (On-line Medical Dictionary): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The region that connects the head to the rest of the body.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C13063, C37912, C12419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paraspinal Ganglion</VALIDVALUE>
          <VALUEMEANING>Spinal Ganglion</VALUEMEANING>
          <MEANINGDESCRIPTION>Spinal; of or relating to the spine or spinal cord.: A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12719, C38026</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perianus</VALIDVALUE>
          <VALUEMEANING>Anal Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The area that includes the anus and the perianal skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396648</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pylorus</VALIDVALUE>
          <VALUEMEANING>Pylorus</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the stomach that connects to the duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242769</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectosigmoid Junction</VALIDVALUE>
          <VALUEMEANING>Rectosigmoid Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The area where the sigmoid colon joins the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396649</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retro-orbital Area</VALIDVALUE>
          <VALUEMEANING>Retro-Orbital Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The area of the body behind the orbit of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54155</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3268518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus(es)</VALIDVALUE>
          <VALUEMEANING>Sinus</VALUEMEANING>
          <MEANINGDESCRIPTION>A recess, cavity, or channel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33556</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3071180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sinus(es), Maxillary</VALIDVALUE>
          <VALUEMEANING>Maxillary Sinus</VALUEMEANING>
          <MEANINGDESCRIPTION>A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12275</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spine</VALIDVALUE>
          <VALUEMEANING>Vertebral Column</VALUEMEANING>
          <MEANINGDESCRIPTION>The spinal or vertebral column.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spine/Femur</VALIDVALUE>
          <VALUEMEANING>Vertebral Column and Femur</VALUEMEANING>
          <MEANINGDESCRIPTION>The spinal or vertebral column.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The longest and largest bone of the skeleton, it is situated between the hip and the knee.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12717, C37912, C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spine/Femur/Radius</VALIDVALUE>
          <VALUEMEANING>Vertebral Column and Femur Radius</VALUEMEANING>
          <MEANINGDESCRIPTION>The spinal or vertebral column.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The longest and largest bone of the skeleton, it is situated between the hip and the knee.: A straight line from the center to the perimeter of a circle or from the center to the surface of a sphere.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63921, C12717, C37912, C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396654</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carina</VALIDVALUE>
          <VALUEMEANING>Carina</VALUEMEANING>
          <MEANINGDESCRIPTION>A ridge or ridge-like structure.  In humans it usually refers to the trachea.  The carina of trachea is part of the lowest tracheal cartilage which is placed between the orifices of the two bronchi.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394021</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrum</VALIDVALUE>
          <VALUEMEANING>Cerebral Hemisphere</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical/Thoracic/Lumbar spine</VALIDVALUE>
          <VALUEMEANING>Cervical and Thoracic and Lumbar Spine </VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to a neck, or cervix, in any sense.: (thor-ASS-ik) Having to do with the chest.: Those vertebrae between the ribs and the pelvis, L1-L5 in man.: The spinal or vertebral column.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12998, C69314, C13360, C12844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394022</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vertebral column</VALIDVALUE>
          <VALUEMEANING>Vertebral Column</VALUEMEANING>
          <MEANINGDESCRIPTION>A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Jaw</VALIDVALUE>
          <VALUEMEANING>Jaw</VALUEMEANING>
          <MEANINGDESCRIPTION>The bones of the skull that frame the mouth and serve to open it; the bones that hold the teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48821</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574422</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumbar spine</VALIDVALUE>
          <VALUEMEANING>Lumbar spine</VALUEMEANING>
          <MEANINGDESCRIPTION>Those vertebrae between the ribs and the pelvis, L1-L5 in man.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nerve</VALIDVALUE>
          <VALUEMEANING>nerve</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12466</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small intestine</VALIDVALUE>
          <VALUEMEANING>Small Intestine</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the digestive tube between the stomach and the cecum or beginning of the large intestine; it consists of three portions: duodenum, jejunum, and ileum. SYN intestinum tenue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracic spine</VALIDVALUE>
          <VALUEMEANING>Thoracic spine</VALUEMEANING>
          <MEANINGDESCRIPTION>Those vertebrae of the thoracic region, T1-T12 in man.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thyroid gland</VALIDVALUE>
          <VALUEMEANING>Thyroid Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>(THIGH-royd) A gland located beneath the voice box (larynx) that produces thyroid hormone. The thyroid helps regulate growth and metabolism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12400</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal wall</VALIDVALUE>
          <VALUEMEANING>Abdominal wall</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77608</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autonomic nervous system</VALIDVALUE>
          <VALUEMEANING>Autonomic Nervous System</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the nervous system of vertebrates that controls involuntary actions of the smooth muscles and heart and glands.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12673</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571101</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck/Chest/Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>Neck and Chest and Abdomen and Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The region that connects the head to the rest of the body.: The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.: The portion of the body that lies between the thorax and the pelvis.: The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C12664, C25389, C13063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ocular Orbits</VALIDVALUE>
          <VALUEMEANING>Orbit</VALUEMEANING>
          <MEANINGDESCRIPTION>The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa.  Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12347</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PA/Lat</VALIDVALUE>
          <VALUEMEANING>Posterior Anterior Lateral Chest</VALUEMEANING>
          <MEANINGDESCRIPTION>Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.: Denoting the front surface of the body; often used to indicate the position of one structure relative to another.: Lateral; situated at or extending to the side.: The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25389, C25230, C25231, C25622</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ileum</VALIDVALUE>
          <VALUEMEANING>Ileum</VALUEMEANING>
          <MEANINGDESCRIPTION>The final section of the small intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12387</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242838</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ischium</VALIDVALUE>
          <VALUEMEANING>Ischium</VALUEMEANING>
          <MEANINGDESCRIPTION>The most posterior and ventral bone making up the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Joints</VALIDVALUE>
          <VALUEMEANING>Joint</VALUEMEANING>
          <MEANINGDESCRIPTION>The connection point between two bones or skeletal elements. The joint may be fixed or movable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13044</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3305580</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Knee</VALIDVALUE>
          <VALUEMEANING>Knee Joint</VALUEMEANING>
          <MEANINGDESCRIPTION>A hinge joint in the human leg connecting the tibia and fibula with the femur and protected in front by the patella.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32898</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2675067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Large bowel</VALIDVALUE>
          <VALUEMEANING>Large Intestine</VALUEMEANING>
          <MEANINGDESCRIPTION>A muscular tube that extends from the end of the small intestine to the anus. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2873884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngopharynx</VALIDVALUE>
          <VALUEMEANING>Hypopharynx (Laryngopharynx)</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the pharynx between the inferior portion of the oropharynx and the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12246</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE>2018-02-28</PVENDDATE>
          <VMPUBLICID>2571134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver and intrahepatic duct</VALIDVALUE>
          <VALUEMEANING>Liver and Intrahepatic Duct</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: Refers to the liver.: A tube that carries various secretions from one part of the body to another.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12948, C13308, C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver/Spleen</VALIDVALUE>
          <VALUEMEANING>Liver and Spleen</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37912, C12392, C13717, C12432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 3, 0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395721</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Axilla</VALIDVALUE>
          <VALUEMEANING>Axillary Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Cervical</VALIDVALUE>
          <VALUEMEANING>Cervical Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the lymph nodes located in the neck.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Hilar</VALIDVALUE>
          <VALUEMEANING>Hilar Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the hilum of the lung.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98187</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Inguinal</VALIDVALUE>
          <VALUEMEANING>Inguinal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A superficial or deep lymph node located in the inguinal area.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Int Mammary</VALIDVALUE>
          <VALUEMEANING>Internal Mammary Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the lymph nodes of the breast located under the ribcage, near the sternum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Mammary</VALIDVALUE>
          <VALUEMEANING>Mammary Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the breast.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C43595</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Pelvic</VALIDVALUE>
          <VALUEMEANING>Pelvic Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Any lymph node within the pelvic region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12363</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3137525</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) Scalene</VALIDVALUE>
          <VALUEMEANING>Scalene Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in proximity to any of the scalene muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3395734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Subclavicular</VALIDVALUE>
          <VALUEMEANING>Infraclavicular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the area below the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2969629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Supraclav</VALIDVALUE>
          <VALUEMEANING>Supraclavicular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node which is located above the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3284855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mesentery</VALIDVALUE>
          <VALUEMEANING>Mesentery</VALUEMEANING>
          <MEANINGDESCRIPTION>A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mini Mantle</VALIDVALUE>
          <VALUEMEANING>Minimantle Radiation Field</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiation field that includes the bilateral cervical, supraclavicular, and axillary lymph nodes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53632</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mouth</VALIDVALUE>
          <VALUEMEANING>Oral Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The cavity lying at the upper end of the alimentary canal, bounded on the outside by the lips and inside by the oropharynx and containing in humans the tongue, gums, and teeth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12421</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571144</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Head/Neck/Chest/Abd/Pelvis</VALIDVALUE>
          <VALUEMEANING>Head and Neck and Chest and Abdomen and Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior or superior part of an animal, containing the brain, or chief ganglia of the nervous system, the mouth, and in the higher animals, the chief sensory organs. (On-line Medical Dictionary): The region that connects the head to the rest of the body.: The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.: The portion of the body that lies between the thorax and the pelvis.: The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C12664, C25389, C13063, C12419</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aqueous Fluid</VALIDVALUE>
          <VALUEMEANING>Aqueous Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear, watery fluid which fills the anterior and posterior chambers of the eye. It has a refractive index lower than the crystalline lens, which it surrounds, and is involved in the metabolism of the cornea and the crystalline lens. (Cline et al., Dictionary of Visual Science, 4th ed, p319)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascending Colon Hepatic Flexure</VALIDVALUE>
          <VALUEMEANING>Ascending Colon Hepatic Flexure</VALUEMEANING>
          <MEANINGDESCRIPTION>The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.: The bend of the colon at the juncture of its ascending and transverse portions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12266, C12265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Auditory canal</VALIDVALUE>
          <VALUEMEANING>Auditory Canal</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or relating to the process of hearing.: A bodily passage or tube lined with epithelial cells and conveying a secretion or other substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61487, C37915</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bowel</VALIDVALUE>
          <VALUEMEANING>Bowel</VALUEMEANING>
          <MEANINGDESCRIPTION>(in-TES-tin) The long, tube-shaped organ in the abdomen that completes the process of digestion. There is both a large intestine and a small intestine. Also called the bowel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394015</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Broad ligament</VALIDVALUE>
          <VALUEMEANING>Broad Ligament</VALUEMEANING>
          <MEANINGDESCRIPTION>A broad fold of peritoneum that extends from the side of the uterus to the wall of the pelvis. (MeSH)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394017</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchus and Lung</VALIDVALUE>
          <VALUEMEANING>Bronchus And Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12468, C37912, C12683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394018</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calf</VALIDVALUE>
          <VALUEMEANING>Calf</VALUEMEANING>
          <MEANINGDESCRIPTION>The posterior aspect of the lower extremity that extends from the knee to the foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93027</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central Line Catheter</VALIDVALUE>
          <VALUEMEANING>Central Venous Access Catheter</VALUEMEANING>
          <MEANINGDESCRIPTION>A venous catheter positioned with the tip in the proximal third of the superior vena cava, the right atrium, or the inferior vena cava.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17612</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394019</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebral cortex</VALIDVALUE>
          <VALUEMEANING>Cerebral Cortex</VALUEMEANING>
          <MEANINGDESCRIPTION>The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers.  It is responsible for memory, attention, consciousness and other high mental functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12443</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3134756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subcutaneous tissue</VALIDVALUE>
          <VALUEMEANING>Subcutaneous Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Beneath the skin.: An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12801, C13353</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3187285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thigh</VALIDVALUE>
          <VALUEMEANING>Thigh</VALUEMEANING>
          <MEANINGDESCRIPTION>A part of the lower limb, located between hip and knee.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33763</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracic/Lumbar spine</VALIDVALUE>
          <VALUEMEANING>Thoracic And Lumbar Spine</VALUEMEANING>
          <MEANINGDESCRIPTION>(thor-ASS-ik) Having to do with the chest.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Those vertebrae between the ribs and the pelvis, L1-L5 in man.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69314, C37912, C13360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396656</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Throat</VALIDVALUE>
          <VALUEMEANING>Throat</VALUEMEANING>
          <MEANINGDESCRIPTION>The narrow passage from the mouth to the cavity at the back of the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tongue, Base of tongue</VALIDVALUE>
          <VALUEMEANING>Base of the Tongue</VALUEMEANING>
          <MEANINGDESCRIPTION>The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx responsible for swallowing and modification of the voice in speech.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12228</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3108187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trunk, Superficial</VALIDVALUE>
          <VALUEMEANING>Superficial Trunk</VALUEMEANING>
          <MEANINGDESCRIPTION>Of little substance or significance; involving only a surface.: The body excluding the head and neck and limbs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33816, C25239</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary tract</VALIDVALUE>
          <VALUEMEANING>Urinary System</VALUEMEANING>
          <MEANINGDESCRIPTION>The organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12413</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396659</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uvula</VALIDVALUE>
          <VALUEMEANING>Uvula</VALUEMEANING>
          <MEANINGDESCRIPTION>The fleshy lobe that hangs at the back of the soft palate.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3396660</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Whole body</VALIDVALUE>
          <VALUEMEANING>Body</VALUEMEANING>
          <MEANINGDESCRIPTION>The entire physical structure of an organism.  It is composed of anatomic systems, regions, cavities, and spaces.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13041</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Mediastinal</VALIDVALUE>
          <VALUEMEANING>Mediastinal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s)</VALIDVALUE>
          <VALUEMEANING>Lymph node</VALUEMEANING>
          <MEANINGDESCRIPTION>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical spine</VALIDVALUE>
          <VALUEMEANING>Cervical spine</VALUEMEANING>
          <MEANINGDESCRIPTION>Those vertebrae immediately behind (caudal to) the skull, C1-C7 in man.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C69313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdomen</VALIDVALUE>
          <VALUEMEANING>Abdominal Cavity</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the body that lies between the thorax and the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12664</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412474</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tibia</VALIDVALUE>
          <VALUEMEANING>Tibia</VALUEMEANING>
          <MEANINGDESCRIPTION>The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12800</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Soft tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mammary Gland</VALIDVALUE>
          <VALUEMEANING>Mammary Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12367</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ear, Pinna (External)</VALIDVALUE>
          <VALUEMEANING>External Ear</VALUEMEANING>
          <MEANINGDESCRIPTION>The external part of the ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck/Chest</VALIDVALUE>
          <VALUEMEANING>Neck and Chest</VALUEMEANING>
          <MEANINGDESCRIPTION>The region that connects the head to the rest of the body.: The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25389, C13063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2757726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vein</VALIDVALUE>
          <VALUEMEANING>Vein</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood vessel that carries blood toward the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2757727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Appendix</VALIDVALUE>
          <VALUEMEANING>Appendix</VALUEMEANING>
          <MEANINGDESCRIPTION>Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12380</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ascending colon</VALIDVALUE>
          <VALUEMEANING>Ascending Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12265</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bladder</VALIDVALUE>
          <VALUEMEANING>Bladder</VALUEMEANING>
          <MEANINGDESCRIPTION>The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12414</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone</VALIDVALUE>
          <VALUEMEANING>Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue that forms the skeletal components of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow</VALIDVALUE>
          <VALUEMEANING>Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12431</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brain</VALIDVALUE>
          <VALUEMEANING>Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cerebrospinal fluid</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervix</VALIDVALUE>
          <VALUEMEANING>Cervix</VALUEMEANING>
          <MEANINGDESCRIPTION>(SER-viks) The lower, narrow end of the uterus that forms a canal between the uterus and vagina.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon</VALIDVALUE>
          <VALUEMEANING>Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uterus</VALIDVALUE>
          <VALUEMEANING>Uterus</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ureter</VALIDVALUE>
          <VALUEMEANING>Ureter</VALUEMEANING>
          <MEANINGDESCRIPTION>The thick-walled tube that carries urine from each kidney to the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12416</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vagina</VALIDVALUE>
          <VALUEMEANING>Vagina</VALUEMEANING>
          <MEANINGDESCRIPTION>The female genital canal, extending from the uterus to the vulva.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12407</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574082</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axilla</VALIDVALUE>
          <VALUEMEANING>Axilla</VALUEMEANING>
          <MEANINGDESCRIPTION>Axilla; the hollow under the arm where it is joined to the shoulder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12674</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560981</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast</VALIDVALUE>
          <VALUEMEANING>Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561089</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heart</VALIDVALUE>
          <VALUEMEANING>Heart</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow muscular organ which receives the blood from the veins and propels it into the arteries. It is divided by a musculomembranous septum into two halves -- right or venous and left or arterial -- each of which consists of a receiving chamber (atrium) and an ejecting chamber (ventricle). SYN cor, coeur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561096</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney</VALIDVALUE>
          <VALUEMEANING>Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12415</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561100</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hip</VALIDVALUE>
          <VALUEMEANING>Hip</VALUEMEANING>
          <MEANINGDESCRIPTION>The lateral prominence of the pelvis from the waist to the thigh.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adenoid</VALIDVALUE>
          <VALUEMEANING>Tonsillar Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33318</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-27</PVBEGINDATE>
          <PVENDDATE>2018-02-28</PVENDDATE>
          <VMPUBLICID>2761349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) Para aortic</VALIDVALUE>
          <VALUEMEANING>Paraaortic Region Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Regions near to the aorta.: A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph glands filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels. Also called a lymph node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25316, C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) Regional</VALIDVALUE>
          <VALUEMEANING>Regional Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or belonging to a broader area or region of the body.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25643, C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2963866</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) Distant</VALIDVALUE>
          <VALUEMEANING>Distant Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Far apart in space from a point of origin on the body.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25321, C12745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2963867</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epidural space</VALIDVALUE>
          <VALUEMEANING>Epidural Spinal Canal Space</VALUEMEANING>
          <MEANINGDESCRIPTION>Space between the dura mater and the walls of the vertebral canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41449</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-10-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2954131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nerve(s) Cranial</VALIDVALUE>
          <VALUEMEANING>Cranial Nerve</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the 12 paired nerves that originate in the brain stem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-22</PVBEGINDATE>
          <PVENDDATE>2018-02-28</PVENDDATE>
          <VMPUBLICID>2798874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic Flexure</VALIDVALUE>
          <VALUEMEANING>Splenic Flexure</VALUEMEANING>
          <MEANINGDESCRIPTION>The bend at the junction of the transverse and descending colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088304</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transverse Colon</VALIDVALUE>
          <VALUEMEANING>Transverse Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3088305</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oropharynx</VALIDVALUE>
          <VALUEMEANING>Oropharynx</VALUEMEANING>
          <MEANINGDESCRIPTION>(or-o-FAIR-inks) The middle part of the throat that includes the soft palate, the base of the tongue, and the tonsils.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12762</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peritoneum</VALIDVALUE>
          <VALUEMEANING>Peritoneum</VALUEMEANING>
          <MEANINGDESCRIPTION>(PAIR-ih-toe-NEE-um) The tissue that lines the abdominal wall and covers most of the organs in the abdomen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pineal Gland</VALIDVALUE>
          <VALUEMEANING>Pineal Gland</VALUEMEANING>
          <MEANINGDESCRIPTION>A small endocrine gland in the brain, situated beneath the back part of the corpus callosum, that secretes melatonin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581527</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon, mucosa only</VALIDVALUE>
          <VALUEMEANING>Colon Mucosa</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.: The moist tissue that lines some organs and body cavities (such as the nose, mouth, lungs) and makes mucus (a thick, slippery fluid).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13166, C12382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clitoris</VALIDVALUE>
          <VALUEMEANING>Clitoris</VALUEMEANING>
          <MEANINGDESCRIPTION>The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carotid body</VALIDVALUE>
          <VALUEMEANING>Carotid Body</VALUEMEANING>
          <MEANINGDESCRIPTION>A cluster of cells that function as chemo-receptors, located at the bifurcation of the carotid artery. Its main purpose is to detect changes in the composition of arterial blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capillary</VALIDVALUE>
          <VALUEMEANING>Capillary</VALUEMEANING>
          <MEANINGDESCRIPTION>Tiny blood vessels that connect the arterioles with the venules.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211566</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cartilage</VALIDVALUE>
          <VALUEMEANING>Cartilage</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12373</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211567</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amniotic Fluid</VALIDVALUE>
          <VALUEMEANING>Amniotic Fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid within the amniotic cavity which surrounds and protects the developing embryo.  It is initially produced by the amnion and then later by the lungs and kidneys.  The amount at term normally varies from 500 to 2000 ml.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13188</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest wall</VALIDVALUE>
          <VALUEMEANING>Chest Wall</VALUEMEANING>
          <MEANINGDESCRIPTION>The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2816310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest/Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>Chest and Abdomen and Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.: The portion of the body that lies between the thorax and the pelvis.: The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C12664, C25389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest/Pelvis</VALIDVALUE>
          <VALUEMEANING>Chest and Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C37912, C25389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394028</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chin</VALIDVALUE>
          <VALUEMEANING>Mentum</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the face below the lower lip and including the protruding part of the lower jaw.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C81169</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colon and rectum</VALIDVALUE>
          <VALUEMEANING>Colon and Rectum</VALUEMEANING>
          <MEANINGDESCRIPTION>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.: Named locations of, or within, the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12390, C37912, C12382</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Common duct</VALIDVALUE>
          <VALUEMEANING>Common Bile Duct</VALUEMEANING>
          <MEANINGDESCRIPTION>Bile ducts are passageways that carry bile. Two major bile ducts come together into a &quot;trunk&quot;-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12698</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ear canal</VALIDVALUE>
          <VALUEMEANING>Ear Canal</VALUEMEANING>
          <MEANINGDESCRIPTION>The organ of hearing: composed of the external ear, which includes the auricle and the external acoustic, or auditory, meatus; the middle ear, or the tympanic cavity with its ossicles; and the internal ear or inner ear, or labyrinth, which includes the semicircular canals, vestibule, and cochlea. SEE ALSO auricle. SYN auris.: A bodily passage or tube lined with epithelial cells and conveying a secretion or other substance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61487, C12394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3394035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Elbow</VALIDVALUE>
          <VALUEMEANING>Elbow Joint</VALUEMEANING>
          <MEANINGDESCRIPTION>The hinge joint between the forearm and upper arm or the corresponding joint in the forelimb of a quadruped.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32497</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2675064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epididymis</VALIDVALUE>
          <VALUEMEANING>Epididymis</VALUEMEANING>
          <MEANINGDESCRIPTION>A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12328</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3211571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophagogastric junction</VALIDVALUE>
          <VALUEMEANING>Gastroesophageal Junction</VALUEMEANING>
          <MEANINGDESCRIPTION>The anatomical location where the esophagus joins to the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32668</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE>2018-02-28</PVENDDATE>
          <VMPUBLICID>3131339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Descending colon</VALIDVALUE>
          <VALUEMEANING>Descending Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diaphragm</VALIDVALUE>
          <VALUEMEANING>Diaphragm</VALUEMEANING>
          <MEANINGDESCRIPTION>Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trunk</VALIDVALUE>
          <VALUEMEANING>Trunk</VALUEMEANING>
          <MEANINGDESCRIPTION>The body excluding the head and neck and limbs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophagus</VALIDVALUE>
          <VALUEMEANING>Esophagus</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12389</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fallopian tube</VALIDVALUE>
          <VALUEMEANING>Fallopian tube</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12403</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver</VALIDVALUE>
          <VALUEMEANING>Liver</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung</VALIDVALUE>
          <VALUEMEANING>Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediastinum</VALIDVALUE>
          <VALUEMEANING>Mediastinum</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12748</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck</VALIDVALUE>
          <VALUEMEANING>Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>The region that connects the head to the rest of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Omentum</VALIDVALUE>
          <VALUEMEANING>Omentum</VALUEMEANING>
          <MEANINGDESCRIPTION>A fold of peritoneum originating at the stomach and supporting the viscera. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33209</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574087</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ovary</VALIDVALUE>
          <VALUEMEANING>Ovary</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12404</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574083</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pericardium</VALIDVALUE>
          <VALUEMEANING>Pericardium</VALUEMEANING>
          <MEANINGDESCRIPTION>A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13005</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pleura</VALIDVALUE>
          <VALUEMEANING>Pleura</VALUEMEANING>
          <MEANINGDESCRIPTION>(PLOOR-a) A thin layer of tissue covering the lungs and the wall of the chest cavity to protect and cushion the lungs. A small amount of fluid that acts as a lubricant allows the lungs to move smoothly in the chest cavity during breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12469</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prostate</VALIDVALUE>
          <VALUEMEANING>Prostate</VALUEMEANING>
          <MEANINGDESCRIPTION>A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12410</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectum</VALIDVALUE>
          <VALUEMEANING>Rectum</VALUEMEANING>
          <MEANINGDESCRIPTION>The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin</VALIDVALUE>
          <VALUEMEANING>Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extra-adrenal</VALIDVALUE>
          <VALUEMEANING>Extra-adrenal</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to tissues outside the adrenal gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3641057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cranial Nerve</VALIDVALUE>
          <VALUEMEANING>Cranial Nerve</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the 12 paired nerves that originate in the brain stem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12700</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2798874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Seminal Vesicle</VALIDVALUE>
          <VALUEMEANING>Seminal Vesicle</VALUEMEANING>
          <MEANINGDESCRIPTION>(SEM-in-al VES-ih-kulz) Glands that help produce semen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2932862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Subcarinal</VALIDVALUE>
          <VALUEMEANING>Subcarinal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Aortocaval</VALIDVALUE>
          <VALUEMEANING>Aortocaval Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the area between the abdominal aorta and inferior vena cava.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118775</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4594051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Anterior mediastinal</VALIDVALUE>
          <VALUEMEANING>Anterior Mediastinal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the superior mediastinum that collects lymph from the thymus, the pericardium, and the right side of the heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32097</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3916261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Diaphragmatic</VALIDVALUE>
          <VALUEMEANING>Diaphragm Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Fibromuscular tissue that separates the thoracic from the abdominal cavity.  It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C12702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Inguinal/Femoral</VALIDVALUE>
          <VALUEMEANING>Inguinal Lymph Node Femoral Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A superficial or deep lymph node located in the inguinal area.: A lymph node located in the upper inner portion of the thigh.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98183, C32801</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575851</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Internal iliac</VALIDVALUE>
          <VALUEMEANING>Internal Iliac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located along the internal iliac artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C88142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3280095</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Lower cervical/Supraclavicular</VALIDVALUE>
          <VALUEMEANING>Lower Cervical Lymph Node Supraclavicular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>The bottom one of two.: Any of the lymph nodes located in the neck.: A lymph node which is located above the clavicle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12903, C32298, C25309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Lower paratracheal/precarinal</VALIDVALUE>
          <VALUEMEANING>Precarinal Paratracheal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or pertaining to the area in front of the bifurcation of the trachea.: A lymph node located adjacent to the trachea within the mediastinum. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103426, C118773</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4594053</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Prevascular</VALIDVALUE>
          <VALUEMEANING>Prior Vascular Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Earlier in time or order.: Relating to or containing blood vessels.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C13311, C25629</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4594071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frontal bone</VALIDVALUE>
          <VALUEMEANING>Frontal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>A bone of the skull forming the forehead, root of the nose and the roof of both orbits.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32635</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ethmoid bone</VALIDVALUE>
          <VALUEMEANING>Ethmoid Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>A light and spongy bone that is cubical in shape. This bone is positioned at the anterior part of the cranium, sitting between the two orbits, at the roof of the nose. It consists of four parts: a horizontal or cribriform plate; a perpendicular plate; and two lateral masses or labyrinths.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Zygomatic bone</VALIDVALUE>
          <VALUEMEANING>Zygomatic Buttress</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the maxillary jaw bone and other facial bones that form the most lateral mid face skeletal structure known as the cheekbone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94592</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Temporal bone</VALIDVALUE>
          <VALUEMEANING>Temporal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>A large irregular bone situated at the base and side of the skull, connected with the mandible via the temporomandibular joint. The temporal bone consists of the squamous, tympanic and petrous parts. The petrous portion of the temporal bone contains the vestibulocochlear organ of the inner ear. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12797</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204324</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sphenoid bone</VALIDVALUE>
          <VALUEMEANING>Sphenoid Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>The butterfly-shaped bone located at the base of the skull that helps to form the orbit of the eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12790</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Parietal bone</VALIDVALUE>
          <VALUEMEANING>Parietal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two cranial bones that by their union form the sides and roof of the skull.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204328</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occipital bone</VALIDVALUE>
          <VALUEMEANING>Occipital Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>The trapezoidal-shaped bone that forms the back and part of the base of the skull.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204330</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasal bone</VALIDVALUE>
          <VALUEMEANING>Nasal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>One of two small oblong bones placed side by side at the middle and upper part of the face.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33157</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lacrimal bone</VALIDVALUE>
          <VALUEMEANING>Lacrimal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>A small rectangular thin plate forming part of the medial orbit wall. It is located posterior to the frontal process of the maxilla and articulates with the inferior nasal concha, ethmoid, frontal, and maxillary bones.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32906</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4204334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Toe</VALIDVALUE>
          <VALUEMEANING>Toes (Phalanges)</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the terminal digits of the foot.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33788</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4207651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pulmonary system</VALIDVALUE>
          <VALUEMEANING>Respiratory System</VALUEMEANING>
          <MEANINGDESCRIPTION>(RES-pih-ra-tor-ee) The organs that are involved in breathing. These include the nose, throat, larynx, trachea, bronchi, and lungs.Also known as the respiratory tract.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12779</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracic vertebra</VALIDVALUE>
          <VALUEMEANING>Thoracic Vertebra</VALUEMEANING>
          <MEANINGDESCRIPTION>One of 12 vertebrae in the human vertebral column. The thoracic vertebrae are situated between the seventh cervical vertebra down to the first lumbar vertebra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12798</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ulna</VALIDVALUE>
          <VALUEMEANING>Ulna</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the bones that comprise the forearm. The largest aspect articulates with the humerus at the elbow joint and the smallest portion of the ulna articulates with the carpal bones in the wrist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tarsus</VALIDVALUE>
          <VALUEMEANING>Tarsal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Any one of the seven bones forming the instep of the foot. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radius</VALIDVALUE>
          <VALUEMEANING>Radius Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>The long bone of the forearm that extends from the lateral aspect of the elbow to the thumb-side of the wrist.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12777</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metatarsus</VALIDVALUE>
          <VALUEMEANING>Metatarsal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>A bone belonging to the middle part of the foot located between toes and ankle. There are 5 metatarsal bones and they are numbered from the medial side.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2957626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metacarpus</VALIDVALUE>
          <VALUEMEANING>Metacarpal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of the five bones between the wrist and the fingers that form the skeleton of the palm.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3155320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumbar vertebra</VALIDVALUE>
          <VALUEMEANING>Lumbar Vertebra</VALUEMEANING>
          <MEANINGDESCRIPTION>One of the five bones situated between the thoracic vertebrae and the sacrum in the lower part of the spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fibula head</VALIDVALUE>
          <VALUEMEANING>Head of the Fibula</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest portion of the fibula that articulates with the patella.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32719</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical vertebra</VALIDVALUE>
          <VALUEMEANING>Cervical Vertebra</VALUEMEANING>
          <MEANINGDESCRIPTION>Any one of the seven vertebrae that start with C1, connecting the skull to the spine, and ends with C7, which joins the cervical with the thoracic spine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12693</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Coccyx</VALIDVALUE>
          <VALUEMEANING>Coccyx</VALUEMEANING>
          <MEANINGDESCRIPTION>The last portion of the vertebral column just below the sacrum consisting of 3-5 rudimentary vertebrae.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carpus</VALIDVALUE>
          <VALUEMEANING>Carpal Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>The eight bones of the wrist: capitate bone, hamate bone, lunate bone (SEMILUNAR BONE), pisiform bone, SCAPHOID BONE, trapezium bone, trapezoid bone and triquetral bone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12688</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199815</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Calcaneus</VALIDVALUE>
          <VALUEMEANING>Calcaneum</VALUEMEANING>
          <MEANINGDESCRIPTION>The irregular and largest tarsal bone that forms the heel.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199816</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pubis</VALIDVALUE>
          <VALUEMEANING>Pubic Bone</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two bones (left and right) that form the front of the pelvis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33423</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4199817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cervical</VALIDVALUE>
          <VALUEMEANING>Cervical</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to a neck, or cervix, in any sense.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2966750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thoracic</VALIDVALUE>
          <VALUEMEANING>Thoracic</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13360</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Celiac/Gastrohepatic</VALIDVALUE>
          <VALUEMEANING>Gastrohepatic Lymph Node Celiac Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the gastrohepatic ligament.: A lymph node at the base of the celiac artery.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65166, C118774</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4594052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extra-adrenal</VALIDVALUE>
          <VALUEMEANING>Extra-Adrenal</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to tissues outside the adrenal gland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103852</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4132071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Iris</VALIDVALUE>
          <VALUEMEANING>Iris</VALUEMEANING>
          <MEANINGDESCRIPTION>The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12737</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4503817</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ciliary body</VALIDVALUE>
          <VALUEMEANING>Ciliary Body</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Choroid</VALIDVALUE>
          <VALUEMEANING>Choroid</VALUEMEANING>
          <MEANINGDESCRIPTION>A blood vessel-containing membrane of the eye that lies between the retina and the sclera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Upper cervical</VALIDVALUE>
          <VALUEMEANING>Upper Cervical Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: Any of the lymph nodes located in the neck.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32298, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575852</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Upper paratracheal</VALIDVALUE>
          <VALUEMEANING>Upper Paratracheal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: A lymph node located adjacent to the trachea within the mediastinum. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103426, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4575859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clivus</VALIDVALUE>
          <VALUEMEANING>Clivus</VALUEMEANING>
          <MEANINGDESCRIPTION>A sloped depression between the dorsum sellae and foramen magnum at the base of the skull.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12494</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4860891</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extraabdominal Lymph Nodes</VALIDVALUE>
          <VALUEMEANING>Extraabdominal Lymph Nodes</VALUEMEANING>
          <MEANINGDESCRIPTION>Happening or arising or located outside or beyond some limits, or especially, some surface.: Of, or related to, the abdomen.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C25342, C44280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4903774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardiothoracic</VALIDVALUE>
          <VALUEMEANING>Cardiothoracic</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the heart and chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4731639</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower gastrointestinal (GI)</VALIDVALUE>
          <VALUEMEANING>Lower Gastrointestinal Tract</VALUEMEANING>
          <MEANINGDESCRIPTION>The lower part of the gastrointestinal tract that includes the jejunum and ileum of the small intestine and the large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33010</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3143267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper gastrointestinal (GI)</VALIDVALUE>
          <VALUEMEANING>Upper Gastrointestinal Tract</VALUEMEANING>
          <MEANINGDESCRIPTION>The upper part of the gastrointestinal tract that includes the esophagus, stomach, and duodenum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3143268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF/Leptomeningeal</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid and Leptomeninges </VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that flows in and around the hollow spaces of the brain and spinal cord, and between two of the meninges (the thin layers of tissue that cover and protect the brain and spinal cord). CSF is made by tissue called the choroid plexus in the ventricles (hollow spaces) in the brain.: The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.: Named locations of or within the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C32979, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5189531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Renal Pelvis</VALIDVALUE>
          <VALUEMEANING>Renal Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The area at the center of the kidney. Urine collects here and is funneled into the ureter, the tube that connects the kidney to the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3138163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left lung</VALIDVALUE>
          <VALUEMEANING>Left Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>The 2-lobed lung located on the left side of the body. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32967</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5481958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal-pelvic</VALIDVALUE>
          <VALUEMEANING>Abdominal Pelvis Anatomic Site</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or related to, the abdomen.: The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.: Named locations of or within the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13717, C12767, C25342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5524271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Mediastinal/Cervical</VALIDVALUE>
          <VALUEMEANING>Mediastinal-Cervical Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Related to the mediastinum.: Relating to a neck, or cervix, in any sense.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C12844, C25310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5524272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary Tumor</VALIDVALUE>
          <VALUEMEANING>Primary Neoplasm</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor at the original site of origin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8509</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2938142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Central</VALIDVALUE>
          <VALUEMEANING>Central Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>A point or area that is approximately central within some larger region or structure.: One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468, C25445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139458</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lung Peripheral</VALIDVALUE>
          <VALUEMEANING>Peripheral Lung</VALUEMEANING>
          <MEANINGDESCRIPTION>On or near an edge or constituting an outer boundary; the outer area.: One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border. SYN pulmo.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12468, C25233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3139459</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extranodal</VALIDVALUE>
          <VALUEMEANING>Extranodal</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated outside of a node.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25504</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5509577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oropharyngeal Soft Tissue</VALIDVALUE>
          <VALUEMEANING>Oropharyngeal Tissue Soft Tissue</VALUEMEANING>
          <MEANINGDESCRIPTION>Tissue that occupies the area between the soft palate and upper portion of the epiglottis.: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12471, C92600</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5727044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraocular</VALIDVALUE>
          <VALUEMEANING>Intraocular</VALUEMEANING>
          <MEANINGDESCRIPTION>Within the eyeball.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96904</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3282263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver parenchyma</VALIDVALUE>
          <VALUEMEANING>Liver Parenchyma</VALUEMEANING>
          <MEANINGDESCRIPTION>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.: The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74601, C12392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2986892</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contralateral ovary</VALIDVALUE>
          <VALUEMEANING>Contralateral Ovary</VALUEMEANING>
          <MEANINGDESCRIPTION>On or relating to the opposite side of the body.: One of the paired female reproductive glands containing the ova or germ cells; the ovary&#39;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12404, C25307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5646651</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Meninges</VALIDVALUE>
          <VALUEMEANING>Meninges</VALUEMEANING>
          <MEANINGDESCRIPTION>Any one of three membranes that surround the brain and spinal cord.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3242719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Adnexa</VALIDVALUE>
          <VALUEMEANING>Adnexa</VALUEMEANING>
          <MEANINGDESCRIPTION>An appendage or accessory structure of an adjacent or related organ.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5936331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heart/myocardium</VALIDVALUE>
          <VALUEMEANING>Heart And/Or Myocardium</VALUEMEANING>
          <MEANINGDESCRIPTION>A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).: Used to indicate that either or both of two items or options may be valid.: The striated muscle tissue of the heart enveloped by the epicardium and the endocardium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12371, C48928, C12727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6003946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s), non-regional</VALIDVALUE>
          <VALUEMEANING>Lymph node(s), non-regional</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Of or belonging to a broader area or region of the body.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C25643, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6065880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph node(s) Non-regional</VALIDVALUE>
          <VALUEMEANING>Lymph node(s), non-regional</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Of or belonging to a broader area or region of the body.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C25643, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-22</PVBEGINDATE>
          <PVENDDATE>2021-04-06</PVENDDATE>
          <VMPUBLICID>6065880</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin/subcutaneous</VALIDVALUE>
          <VALUEMEANING>Subcutaneous Skin</VALUEMEANING>
          <MEANINGDESCRIPTION>Beneath the skin.: An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13353, C12470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-09-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6429927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extrahepatic Bile Duct</VALIDVALUE>
          <VALUEMEANING>Extrahepatic Bile Duct</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C32573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3689469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nodule(s) Pleural</VALIDVALUE>
          <VALUEMEANING>Pleural Nodule</VALUEMEANING>
          <MEANINGDESCRIPTION>Of or pertaining to the pleura.: A small lump, swelling or collection of tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3280, C25223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6161750</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Effusion(s) pleural</VALIDVALUE>
          <VALUEMEANING>Pleural Effusion</VALUEMEANING>
          <MEANINGDESCRIPTION>Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4264940</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node(s) Peritoneal</VALIDVALUE>
          <VALUEMEANING>Peritoneal Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymph node located in the peritoneum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6659691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney(s), Inter Pole</VALIDVALUE>
          <VALUEMEANING>Kidney(s) - Inter Pole</VALUEMEANING>
          <MEANINGDESCRIPTION>The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C186124</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6776784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney(s), Lower Pole</VALIDVALUE>
          <VALUEMEANING>Lower Pole of Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>The pole of the kidney located in the lowest region of the kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93180</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6403393</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Kidney(s), Upper Pole</VALIDVALUE>
          <VALUEMEANING>Upper Pole of Kidney</VALUEMEANING>
          <MEANINGDESCRIPTION>The pole of the kidney located in the uppermost region of the kidney.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C93179</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6403325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glottis, posterior commissure</VALIDVALUE>
          <VALUEMEANING>Posterior commissure of glottis</VALUEMEANING>
          <MEANINGDESCRIPTION>The posterior surface of the glottic opening at the level of the vocal cords.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C164282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6943245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Glottis, anterior commissure</VALIDVALUE>
          <VALUEMEANING>Anterior commissure of glottis</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior-most portion of the vocal cord, located within the larynx, that constitutes the junction of the conus elasticus and the thyroepiglottic, vestibular, and vocal ligaments.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128630</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6943246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sacroiliac</VALIDVALUE>
          <VALUEMEANING>Sacroiliac Joint</VALUEMEANING>
          <MEANINGDESCRIPTION>The joint located between the sacrum and the ilium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6402604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Periumbilical</VALIDVALUE>
          <VALUEMEANING>Periumbilical Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The region of the body that surrounds the umbilicus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139205</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6408785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lumbosacral Spine</VALIDVALUE>
          <VALUEMEANING>Lumbosacral Region</VALUEMEANING>
          <MEANINGDESCRIPTION>The region of the spine in the lower back that consists of the five lumbar vertebrae and the sacrum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48824</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3417617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nerve(s), Sural</VALIDVALUE>
          <VALUEMEANING>Sural Nerve</VALUEMEANING>
          <MEANINGDESCRIPTION>A peripheral nerve that runs close to the small saphenous vein. It supplies innervation to the skin of the lower back of the leg and sends a branch to the lateral side of the foot and little toe.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77675</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6943313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MSK</VALIDVALUE>
          <VALUEMEANING>Musculoskeletal System</VALUEMEANING>
          <MEANINGDESCRIPTION>The system of muscles, tendons, ligaments, bones, joints and associated tissues that move the body and maintain its form.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-11-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192585</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymph Node, Extrapelvic</VALIDVALUE>
          <VALUEMEANING>Extrapelvic Lymph Node</VALUEMEANING>
          <MEANINGDESCRIPTION>Situated outside of the pelvis.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12745, C172875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7691658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cardio-pulmonary</VALIDVALUE>
          <VALUEMEANING>Cardiopulmonary</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the heart and lungs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10597961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectum/Sigmoid Colon</VALIDVALUE>
          <VALUEMEANING>Rectosigmoid Colon</VALUEMEANING>
          <MEANINGDESCRIPTION>A portion of the large intestine that includes the descending colon, sigmoid colon and rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103438</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6403756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastric</VALIDVALUE>
          <VALUEMEANING>Gastric</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the stomach.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-09-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4975987</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Face</VALIDVALUE>
          <VALUEMEANING>Face</VALUEMEANING>
          <MEANINGDESCRIPTION>The anterior portion of the head extending from the forehead to the chin and ear to ear. The facial structures contain the eyes, nose and mouth, cheeks and jaws.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3412479</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Musculoskeletal</VALIDVALUE>
          <VALUEMEANING>Musculoskeletal</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with muscles, bones, and cartilage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25348</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paracolic gutter</VALIDVALUE>
          <VALUEMEANING>Paracolic Gutter</VALUEMEANING>
          <MEANINGDESCRIPTION>Either of the two naturally ocurring spaces between the colon and the abdominal wall, lateral to the ascending and descending colons.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C89787</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5630081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify site of extra-gonadal</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify site of extra-gonadal germ cell tumor:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Extra-gonadal germ cell tumor</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Extra-gonadal germ cell tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:2986153</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis &gt; TargetAnatomicSite.code WHERE PerformedDiagnosis.value = &quot;extra-gonadal metastases&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964899</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TargetAnatomicSite:code</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1381">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2990794</PUBLICID>
    <LONGNAME>Research Personnel Status Code StatusType</LONGNAME>
    <PREFERREDNAME>2990583v1.0:2990755v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>People engaged in research._A condition or state at a particular time.:A system, often of numbered categories, for representation of data._The state of the status.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2990583</PublicId>
      <PreferredName>2422792v1.0:2607549v1.0</PreferredName>
      <PreferredDefinition>People engaged in research._A condition or state at a particular time.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Research Personnel Status Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422792</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17089</PreferredName>
        <Version>1</Version>
        <LongName>Research Personnel</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17089</PREFERRED_NAME>
            <LONG_NAME>Research Personnel</LONG_NAME>
            <CON_ID>2202675</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2607549</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Status Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2990755</PublicId>
      <PreferredName>2990755v1.0</PreferredName>
      <PreferredDefinition>The state of the status.</PreferredDefinition>
      <LongName>StatusType</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Active</VALIDVALUE>
          <VALUEMEANING>Active</VALUEMEANING>
          <MEANINGDESCRIPTION>Exerting influence or producing an effect; taking part in an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2571510</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inactive</VALIDVALUE>
          <VALUEMEANING>Inactive</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates an absence of a measurable amount of a specific function or role performed by a biological entity in a Biophysical Process, Biochemical Reaction, or Biochemical Process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>2959578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Research Personnel Status Code StatusType does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Research Personnel Status Code StatusType does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.ResearchStaff.statusCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ResearchStaff:statusCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1382">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2991573</PUBLICID>
    <LONGNAME>Vial Volume Size Type</LONGNAME>
    <PREFERREDNAME>VIAL_VOL_SZ_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text identifier for a vial based on the volume capacity (in millilters) of the container.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2991555</PublicId>
      <PreferredName>VIAL_VOL_SZ</PreferredName>
      <PreferredDefinition>A small, often stoppered glass or plastic bottle for holding medicines and chemicals._Volume; the amount of 3-dimensional space occupied by an object._Size; the physical magnitude of something.</PreferredDefinition>
      <LongName>Vial Volume Size</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2991552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41275</PreferredName>
        <Version>1</Version>
        <LongName>Vial</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41275</PREFERRED_NAME>
            <LONG_NAME>Vial</LONG_NAME>
            <CON_ID>2486072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2991553</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25335:C25681</PreferredName>
        <Version>1</Version>
        <LongName>Volume Size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25681</PREFERRED_NAME>
            <LONG_NAME>Size</LONG_NAME>
            <CON_ID>2203799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2991557</PublicId>
      <PreferredName>VIAL_VOL_TP</PreferredName>
      <PreferredDefinition>A small, often stoppered glass or plastic bottle for holding medicines and chemicals._Volume; the amount of 3-dimensional space occupied by an object._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Vial Volume Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2991556</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41275:C25335:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Vial Volume Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41275</PREFERRED_NAME>
            <LONG_NAME>Vial</LONG_NAME>
            <CON_ID>2486072</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5 mL</VALIDVALUE>
          <VALUEMEANING>5 milliliter vial</VALUEMEANING>
          <MEANINGDESCRIPTION>5 milliliter vial</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991558</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1 mL</VALIDVALUE>
          <VALUEMEANING>1 milliliter vial</VALUEMEANING>
          <MEANINGDESCRIPTION>1 milliliter vial</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1.6 mL</VALIDVALUE>
          <VALUEMEANING>1.6 milliliter vial</VALUEMEANING>
          <MEANINGDESCRIPTION>1.6 milliliter vial</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-01-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5633385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Vial size</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Vial size</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1383">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998001</PUBLICID>
    <LONGNAME>Password Policy Computer Configuration Number Required Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2992688v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A secret set of characters, numbers, or symbols used as a form of authentication.:A plan of action adopted by an individual or social group.:Refers to 1) the way a computer&#39;s operating system is set up, 2) the total combination of hardware components that make up the computer system, or 3) the specific software settings that have been established for the system._A numeral or string of numerals expressing value, quantity, or identification.:Necessary, not optional.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992688</PublicId>
      <PreferredName>2992544v1.0:2992605v1.0</PreferredName>
      <PreferredDefinition>A secret set of characters, numbers, or symbols used as a form of authentication.:A plan of action adopted by an individual or social group.:Refers to 1) the way a computer&#39;s operating system is set up, 2) the total combination of hardware components that make up the computer system, or 3) the specific software settings that have been established for the system._A numeral or string of numerals expressing value, quantity, or identification.:Necessary, not optional.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Password Policy Computer Configuration Number Required Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2992544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42710:C17735:C85235</PreferredName>
        <Version>1</Version>
        <LongName>Password Policy Computer Configuration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42710</PREFERRED_NAME>
            <LONG_NAME>Password</LONG_NAME>
            <CON_ID>2223427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17735</PREFERRED_NAME>
            <LONG_NAME>Policy</LONG_NAME>
            <CON_ID>2790012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85235</PREFERRED_NAME>
            <LONG_NAME>Computer Configuration</LONG_NAME>
            <CON_ID>2992523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337:C25652:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Number Required Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25652</PREFERRED_NAME>
            <LONG_NAME>Requirement</LONG_NAME>
            <CON_ID>2204014</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Password Policy Computer Configuration Number Required Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Password Policy Computer Configuration Number Required Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.security.passwordpolicy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2992521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.security.passwordpolicy.CombinationPolicy.baseTenDigitRequired</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CombinationPolicy:baseTenDigitRequired</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1384">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998014</PUBLICID>
    <LONGNAME>Password Creation Policy Password History Size java.lang.Integer</LONGNAME>
    <PREFERREDNAME>2992701v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A secret set of characters, numbers, or symbols used as a form of authentication.:The process by which something is brought into existence; having been brought into existence.:A plan of action adopted by an individual or social group._A secret set of characters, numbers, or symbols used as a form of authentication.:The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.:The physical magnitude of something._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992701</PublicId>
      <PreferredName>2992547v1.0:2992618v1.0</PreferredName>
      <PreferredDefinition>A secret set of characters, numbers, or symbols used as a form of authentication.:The process by which something is brought into existence; having been brought into existence.:A plan of action adopted by an individual or social group._A secret set of characters, numbers, or symbols used as a form of authentication.:The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.:The physical magnitude of something.</PreferredDefinition>
      <LongName>Password Creation Policy Password History Size</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2992547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42710:C42620:C17735</PreferredName>
        <Version>1</Version>
        <LongName>Password Creation Policy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42710</PREFERRED_NAME>
            <LONG_NAME>Password</LONG_NAME>
            <CON_ID>2223427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42620</PREFERRED_NAME>
            <LONG_NAME>Creation</LONG_NAME>
            <CON_ID>2222835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17735</PREFERRED_NAME>
            <LONG_NAME>Policy</LONG_NAME>
            <CON_ID>2790012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42710:C54625:C25681</PreferredName>
        <Version>1</Version>
        <LongName>Password History Size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42710</PREFERRED_NAME>
            <LONG_NAME>Password</LONG_NAME>
            <CON_ID>2223427</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25681</PREFERRED_NAME>
            <LONG_NAME>Size</LONG_NAME>
            <CON_ID>2203799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Password Creation Policy Password History Size java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Password Creation Policy Password History Size java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain.security.passwordpolicy</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2992521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.security.passwordpolicy.PasswordCreationPolicy.passwordHistorySize</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PasswordCreationPolicy:passwordHistorySize</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1385">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998056</PUBLICID>
    <LONGNAME>Investigator Access Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>2992739v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a researcher in a clinical trial or clinical study._The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992739</PublicId>
      <PreferredName>2528490v1.0:2992631v1.0</PreferredName>
      <PreferredDefinition>a researcher in a clinical trial or clinical study._The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Investigator Access Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528490</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25936</PreferredName>
        <Version>1</Version>
        <LongName>Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25936</PREFERRED_NAME>
            <LONG_NAME>Investigator</LONG_NAME>
            <CON_ID>2202869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2992631</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25396:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Access Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25396</PREFERRED_NAME>
            <LONG_NAME>Access</LONG_NAME>
            <CON_ID>2203568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Investigator Access Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Investigator Access Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Investigator:allowedToLogin</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.Investigator.allowedToLogin</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1386">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998089</PUBLICID>
    <LONGNAME>Adverse Event End Date java.util.Date</LONGNAME>
    <PREFERREDNAME>2192228v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date the unwanted effect caused by a drug or therapy. Such effects can be drug related, dose related, route related, patient related, caused by an interaction with another drug, or caused by opioid initiation or dose escalation ceased._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192228</PublicId>
      <PreferredName>AE_END_DT</PreferredName>
      <PreferredDefinition>The date the unwanted effect caused by a drug or therapy. Such effects can be drug related, dose related, route related, patient related, caused by an interaction with another drug, or caused by opioid initiation or dose escalation ceased.</PreferredDefinition>
      <LongName>Adverse Event End Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2235992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25496:C25164</PreferredName>
        <Version>1</Version>
        <LongName>End Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25496</PREFERRED_NAME>
            <LONG_NAME>End</LONG_NAME>
            <CON_ID>2223233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event End Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event End Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.AdverseEvent.endDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEvent:endDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1387">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2998222</PUBLICID>
    <LONGNAME>Distant Research Personnel Staff Email Address java.lang.String</LONGNAME>
    <PREFERREDNAME>2992896v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Far apart in space, time, or relevance from a point of origin.:People engaged in research.:The employees of an organization; personnel who assist their superior in carrying out an assigned task._An e-mail address identifies a location to which e-mail can be delivered. A modern Internet e-mail address (using SMTP) is a string of the form jsmith@domain.example. (from Wikipedia)_Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2992896</PublicId>
      <PreferredName>2992561v1.0:2223457v1.0</PreferredName>
      <PreferredDefinition>Far apart in space, time, or relevance from a point of origin.:People engaged in research.:The employees of an organization; personnel who assist their superior in carrying out an assigned task._An e-mail address identifies a location to which e-mail can be delivered. A modern Internet e-mail address (using SMTP) is a string of the form jsmith@domain.example. (from Wikipedia)</PreferredDefinition>
      <LongName>Distant Research Personnel Staff Email Address</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2992561</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25321:C17089:C63612</PreferredName>
        <Version>1</Version>
        <LongName>Distant Research Personnel Staff</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25321</PREFERRED_NAME>
            <LONG_NAME>Distant</LONG_NAME>
            <CON_ID>2204917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17089</PREFERRED_NAME>
            <LONG_NAME>Research Personnel</LONG_NAME>
            <CON_ID>2202675</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63612</PREFERRED_NAME>
            <LONG_NAME>Staff</LONG_NAME>
            <CON_ID>2667911</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223457</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42775</PreferredName>
        <Version>1</Version>
        <LongName>Email Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42775</PREFERRED_NAME>
            <LONG_NAME>E-mail Address</LONG_NAME>
            <CON_ID>2223429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Distant Research Personnel Staff Email Address java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Distant Research Personnel Staff Email Address java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cabig.caaers.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000413</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RemoteResearchStaff:emailAddress</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cabig.caaers.domain.RemoteResearchStaff.emailAddress</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1388">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3005054</PUBLICID>
    <LONGNAME>Regional Lymph Node Pathologic N Stage Clinical Trial Eligibility Criteria Type</LONGNAME>
    <PREFERREDNAME>RN_PATH_N_ST_CTEC_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>the type or extent of the pathologic N stage for regional lymph nodes, used to determine whether an individual can participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3004073</PublicId>
      <PreferredName>RLN_PATH_N_ST_CTEC</PreferredName>
      <PreferredDefinition>information relating to clinical trial eligibility criteria (elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial) and the pathologic (manifesting disease or pathology) N stage (one criteria of the TMN staging system, N refers to the extent of lymph node involvement) of a regional lymph node (a lymph node that drains lymph from a region of interest).</PreferredDefinition>
      <LongName>Regional Lymph Node Pathologic N Stage Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2782784</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49018</PreferredName>
        <Version>1</Version>
        <LongName>Regional Lymph Node</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49018</PREFERRED_NAME>
            <LONG_NAME>Regional Lymph Node</LONG_NAME>
            <CON_ID>2486807</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3004071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25580:CL008804</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic N Stage Clinical Trials Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25580</PREFERRED_NAME>
            <LONG_NAME>N Category</LONG_NAME>
            <CON_ID>2204625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL008804</PREFERRED_NAME>
            <LONG_NAME>Clinical Trials Eligibility Criteria</LONG_NAME>
            <CON_ID>2203513</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3005050</PublicId>
      <PreferredName>RLN_P_N_STAGE_ELG_TP</PreferredName>
      <PreferredDefinition>the type or extent of the pathologic N stage for regional lymph nodes, used to determine whether an individual can participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Regional Lymph Node Pathologic N Stage Eligibility Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN+ (fully resected)</VALIDVALUE>
          <VALUEMEANING>pN+ (fully resected)</VALUEMEANING>
          <MEANINGDESCRIPTION>pN+ (fully resected)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3005051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pNX (where clinically N0)</VALIDVALUE>
          <VALUEMEANING>pNX (where clinically N0)</VALUEMEANING>
          <MEANINGDESCRIPTION>pNX (where clinically N0)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3005052</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pN0</VALIDVALUE>
          <VALUEMEANING>pN0</VALUEMEANING>
          <MEANINGDESCRIPTION>pN0</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Regional lymph nodes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Regional lymph nodes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1389">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3008433</PUBLICID>
    <LONGNAME>Therapeutic Procedure Pregnancy Associated Performed Status</LONGNAME>
    <PREFERREDNAME>3008414v1.0:2225337v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the status or outcome ofan action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process that could have an impact on pregnancy, the state or condition of having a developing embryo or fetus in the body, that was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3008414</PublicId>
      <PreferredName>2512834v1.0:3008412v1.0</PreferredName>
      <PreferredDefinition>information related to an action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process that could have an impact on pregnancy, the state or condition of having a developing embryo or fetus in the body, having been performed.</PreferredDefinition>
      <LongName>Therapeutic Procedure Pregnancy Associated Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3008412</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25742:C25281:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Pregnancy Associated Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25281</PREFERRED_NAME>
            <LONG_NAME>Associated</LONG_NAME>
            <CON_ID>2202442</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2225337</PublicId>
      <PreferredName>LAB_ASSESS_STAT</PreferredName>
      <PreferredDefinition>the status of a lab assessment.</PreferredDefinition>
      <LongName>Lab Assessment Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength>6</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Normal</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt; normal</VALIDVALUE>
          <VALUEMEANING>&gt; normal</VALUEMEANING>
          <MEANINGDESCRIPTION>&gt; normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt; normal</VALIDVALUE>
          <VALUEMEANING>&lt; normal</VALUEMEANING>
          <MEANINGDESCRIPTION>&lt; normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Within normal limits</VALIDVALUE>
          <VALUEMEANING>Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14165</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal, eligibility not affected</VALIDVALUE>
          <VALUEMEANING>Abnormal</VALUEMEANING>
          <MEANINGDESCRIPTION>Deviating from the norm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25401</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562119</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal, not eligible</VALIDVALUE>
          <VALUEMEANING>ABNORMAL NOT ELIGIBLE</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal and no longer eligible</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal - Clinically significant</VALIDVALUE>
          <VALUEMEANING>Abnormal - Clinically significant</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal - Clinically significant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abnormal - Not clinically significant</VALIDVALUE>
          <VALUEMEANING>Abnormal - Not clinically significant</VALUEMEANING>
          <MEANINGDESCRIPTION>Abnormal - Not clinically significant</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2645498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;= ULN</VALIDVALUE>
          <VALUEMEANING>&gt;= Upper limit of institutional normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Value is greater or equal to upper limit of institutional normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt; ULN</VALIDVALUE>
          <VALUEMEANING>Less than upper limit of institutional normal</VALUEMEANING>
          <MEANINGDESCRIPTION>Value is less than upper limit of institutional normal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Trace</VALIDVALUE>
          <VALUEMEANING>Trace</VALUEMEANING>
          <MEANINGDESCRIPTION>A barely detectable amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80218</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2912071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Undetectable</VALIDVALUE>
          <VALUEMEANING>Undetectable</VALUEMEANING>
          <MEANINGDESCRIPTION>Undetectable</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;</VALIDVALUE>
          <VALUEMEANING>Greater than (&gt;)</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than (&gt;)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;</VALIDVALUE>
          <VALUEMEANING>Less Than</VALUEMEANING>
          <MEANINGDESCRIPTION>Less Than</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-05-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571450</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2840098</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-02-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5042698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Equivocal</VALIDVALUE>
          <VALUEMEANING>Equivocal</VALUEMEANING>
          <MEANINGDESCRIPTION>Open to question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C86071</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5178198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt;= ULN</VALIDVALUE>
          <VALUEMEANING>Less Than or Equal To Upper Limit of Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.: The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25706, C61586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6013658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;ULN</VALIDVALUE>
          <VALUEMEANING>Greater Than Upper Limit of Normal</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25706, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6013657</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>=</VALIDVALUE>
          <VALUEMEANING>Equality</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being the same in quantity or measure or value or status.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61582</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-07-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3423503</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Result of test</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Result of test</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1390">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3009205</PUBLICID>
    <LONGNAME>Disease or Disorder Best Outcome of Therapy Amyloidosis Hematologic Status Type</LONGNAME>
    <PREFERREDNAME>2946463v1.0:3009199v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the best hematologic response to therapy for amyloidosis.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2946463</PublicId>
      <PreferredName>2404658v1.0:3194600v1.0</PreferredName>
      <PreferredDefinition>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.</PreferredDefinition>
      <LongName>Disease or Disorder Best Outcome of Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404658</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2991</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3194600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25432:C18919</PreferredName>
        <Version>1</Version>
        <LongName>Best Outcome of Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25432</PREFERRED_NAME>
            <LONG_NAME>Best</LONG_NAME>
            <CON_ID>2206164</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18919</PREFERRED_NAME>
            <LONG_NAME>Outcome of Therapy</LONG_NAME>
            <CON_ID>3194599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3009199</PublicId>
      <PreferredName>3009199v1.1</PreferredName>
      <PreferredDefinition>A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Pertaining to or related to the blood and blood-forming organs._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Amyloidosis Hematologic Status Type</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3009198</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2868:C62780:C25688:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Amyloidosis Hematologic Status Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2868</PREFERRED_NAME>
            <LONG_NAME>Amyloidosis</LONG_NAME>
            <CON_ID>2443944</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62780</PREFERRED_NAME>
            <LONG_NAME>Hematologic</LONG_NAME>
            <CON_ID>2528497</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Continued complete response (CCR)</VALIDVALUE>
          <VALUEMEANING>Continued complete response</VALUEMEANING>
          <MEANINGDESCRIPTION>For recipients already in CR prior to the start of the preparative regimen</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6769541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Partial response (PR)</VALIDVALUE>
          <VALUEMEANING>Partial response</VALUEMEANING>
          <MEANINGDESCRIPTION>A greater than 50% reduction in the dFLC (difference between serum involved free light and uninvolved serum free light chain)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4241993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No response (NR) / stable disease (SD)</VALIDVALUE>
          <VALUEMEANING>No response/stable disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than a PR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4241991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682944</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapse from CR (Rel) (untreated)</VALIDVALUE>
          <VALUEMEANING>Relapse from CR</VALUEMEANING>
          <MEANINGDESCRIPTION>From CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6757623</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very good partial response (VGPR)</VALIDVALUE>
          <VALUEMEANING>Very good partial response</VALUEMEANING>
          <MEANINGDESCRIPTION>Reduction in the dFLC (difference between involved serum free light and uninvolved serum free light chain) to &lt; 40 mg/l</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-05-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6757624</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete response (CR)</VALIDVALUE>
          <VALUEMEANING>Complete response</VALUEMEANING>
          <MEANINGDESCRIPTION>Normalization of the free serum light chain level and ratio, negative serum and urine immunofixation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-11-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4241992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progressive disease (PD)</VALIDVALUE>
          <VALUEMEANING>Progressive disease</VALUEMEANING>
          <MEANINGDESCRIPTION>From PR, 50% increase in serum M protein to &gt; 0.5 g/dl or 50% increase in urine M protein to &gt;200 mg/day (a visible peak must be present) and free light chain increase of 50% to &gt; 100 mg</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4871971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the best hematologic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the best hematologic outcome of therapy for amyloidosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the best response to  HSCT?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the best response to  HSCT?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the best hematologic response to therapy?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the best hematologic response to therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the best hematologic response:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the best hematologic response:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping path for CDE:3009205</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis &gt; AssessedResultRelationship &gt; PerformedObservation &gt; PerformedClinicalinterpretation.value = &quot;best result&quot; AND PerformedDiagnosis.value = &quot;hematologic disorder&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the recipient&#39;s best hematologic response to the HCT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the recipient&#39;s best hematologic response to the HCT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the recipient&#39;s best hematologic response to the HCT</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify the recipient&#39;s best hematologic response to the HCT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the recipient&#39;s best hematologic response to the HSCT</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the recipient&#39;s best hematologic response to the HSCT</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Best hematologic response to line of therapy</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Best hematologic response to line of therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>For recipients with primary disease or concurrent / history of Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>For recipients with primary disease or concurrent / history of Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2117r1: Amyloidosis Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964910</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3279271</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCDpost_amy_hema_organ_hema_best_resp</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:diseaseStatusCode </AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1391">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3009539</PUBLICID>
    <LONGNAME>Other Asian Race Category Specify</LONGNAME>
    <PREFERREDNAME>3009534v1.0:2016311v5.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of a person&#39;s self-described Asian racial origination that is different from the choices previously identified.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3009534</PublicId>
      <PreferredName>3009532v1.0:2236665v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including Cambodia, China, India, Japan, Korea, Malaysia, Mongolia, Pakistan, the Philippine Islands, Thailand, and Vietnam. The concept refers also to individuals who classify themselves as described below.</PreferredDefinition>
      <LongName>Other Asian Race Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3009532</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C41260:C17049</PreferredName>
        <Version>1</Version>
        <LongName>Other Asian Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41260</PREFERRED_NAME>
            <LONG_NAME>Asian</LONG_NAME>
            <CON_ID>2389382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016311</PublicId>
      <PreferredName>RACE_SPEC</PreferredName>
      <PreferredDefinition>the free text description of the patient&#39;s/participant&#39;s racial orgination.</PreferredDefinition>
      <LongName>Race Specify</LongName>
      <Version>5</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Asian</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Asian</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NIDA CTN Demographics</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other Asian specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HOW Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2988352</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>About Me</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Research</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952294</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Electronic Health Record</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952296</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDA</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDA</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1392">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3013115</PUBLICID>
    <LONGNAME>Tumor Histologic Stratification Code</LONGNAME>
    <PREFERREDNAME>TUMOR_HIST_STRAT_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>the coded value used to classify patients into strata by tumor histology as part of the randomization process or for purposes of data analysis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2186002</PublicId>
      <PreferredName>TUMOR_HIST_STRAT</PreferredName>
      <PreferredDefinition>information related to tumor histologic stratification.</PreferredDefinition>
      <LongName>Tumor Histologic Stratification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404687</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2688600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C25689</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Stratification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25689</PREFERRED_NAME>
            <LONG_NAME>Stratification</LONG_NAME>
            <CON_ID>2203803</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3013113</PublicId>
      <PreferredName>TUMOR_HIST_STRAT_CD</PreferredName>
      <PreferredDefinition>the coded value used to classify patients into strata by tumor histology as part of the randomization process or for purposes of data analysis.</PreferredDefinition>
      <LongName>Tumor Histologic Stratification Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Non-clear cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell that does not have an empty-appearing cytoplasm when viewed with a light microscope</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3198848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Clear Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell with empty-appearing cytoplasm when viewed with a light microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12478</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3198849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histology</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Histology</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NCIP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>STRATIFICATION VAR 2</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>stratification_var_2</AlternateName>
        <AlternateNameType>VM Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1393">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3014242</PUBLICID>
    <LONGNAME>Strenuous Exercise Physical Activity Assessment Scale</LONGNAME>
    <PREFERREDNAME>3014238v1.0:3014236v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Response to an inquiry about a person&#39;s level of activity on a typical day and health limits in vigorous activities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3014238</PublicId>
      <PreferredName>2230341v1.0:2233077v1.0</PreferredName>
      <PreferredDefinition>information relating to a physical activity assessment involving moderate exercise._Strenuous exercise is defined as 20-60 minutes of exercise which elevates your heart rate to 80-90% of your maximum heart rate performed at least 3-4 times per week.  Your maximum heart rate is approximately 220 minus your age.  Strenuous exercises include jogging, swimming, bicycling, and brisk walking._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Strenuous Exercise Physical Activity Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2230341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39773:C0221187</PreferredName>
        <Version>1</Version>
        <LongName>Strenuous Exercise Physical Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39773</PREFERRED_NAME>
            <LONG_NAME>Strenuous Exercise</LONG_NAME>
            <CON_ID>2202478</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0221187</PREFERRED_NAME>
            <LONG_NAME>Physical Activity</LONG_NAME>
            <CON_ID>2203293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3014236</PublicId>
      <PreferredName>3014236v1.0</PreferredName>
      <PreferredDefinition>the scale to determine the patient&#39;s physical activity._Any form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc.</PreferredDefinition>
      <LongName>Physical Activity Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3014235</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17708:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Physical Activity Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17708</PREFERRED_NAME>
            <LONG_NAME>Physical Activity</LONG_NAME>
            <CON_ID>2202366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Stated</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-02-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2964573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, not limited at all</VALIDVALUE>
          <VALUEMEANING>NO, NOT LIMITED AT ALL</VALUEMEANING>
          <MEANINGDESCRIPTION>NO, NOT LIMITED AT ALL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a little</VALIDVALUE>
          <VALUEMEANING>YES, LIMITED A LITTLE</VALUEMEANING>
          <MEANINGDESCRIPTION>YES, LIMITED A LITTLE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a lot</VALIDVALUE>
          <VALUEMEANING>YES, LIMITED A LOT</VALUEMEANING>
          <MEANINGDESCRIPTION>YES, LIMITED A LOT</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Vigorous activities, such as</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Vigorous activities, such as runing, lifting heavy objects, participating in strenuous sports</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HOW Trial</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2988352</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2760132</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caMatch</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>My Health as of Today</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009818</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1394">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3019955</PUBLICID>
    <LONGNAME>Person Biospecimen Angiogenesis Biomarker Research Consent Status</LONGNAME>
    <PREFERREDNAME>3019928v1.0:3019961v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the status of consent from a person for the use of biologic samples for research on blood vessel formation and/or biomarkers, measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3019928</PublicId>
      <PreferredName>2236731v1.0:3019926v1.0</PreferredName>
      <PreferredDefinition>information related to consent from a person for the use of biologic samples for research on blood vessel formation and/or biomarkers, measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments.</PreferredDefinition>
      <LongName>Person Biospecimen Angiogenesis Biomarker Research Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3019926</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699:C17932:C16342:C15319:C2</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Angiogenesis Biomarker Research Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17932</PREFERRED_NAME>
            <LONG_NAME>Angiogenic Process</LONG_NAME>
            <CON_ID>2677110</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16342</PREFERRED_NAME>
            <LONG_NAME>Biomarker</LONG_NAME>
            <CON_ID>2202308</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15319</PREFERRED_NAME>
            <LONG_NAME>Research</LONG_NAME>
            <CON_ID>2202802</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3019961</PublicId>
      <PreferredName>3019961v1.0</PreferredName>
      <PreferredDefinition>the status of consent of a person to allow biologic specimens to be used for research on angiogensis or biomarkers.</PreferredDefinition>
      <LongName>Person Biospecimen Angiogenesis Biomarker Research Consent Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post chemo specimens only</VALIDVALUE>
          <VALUEMEANING>Post chemo specimens only</VALUEMEANING>
          <MEANINGDESCRIPTION>Post chemo specimens only</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3019962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Week 9 specimens only</VALIDVALUE>
          <VALUEMEANING>Week 9 specimens only</VALUEMEANING>
          <MEANINGDESCRIPTION>Week 9 specimens only</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3019963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I agree to submit my tissue f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I agree to submit my tissue for additional follow-up angiogenic and other biomarker studies to see what role the treatment is having on my disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1395">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3025120</PUBLICID>
    <LONGNAME>Person Race Number Code</LONGNAME>
    <PREFERREDNAME>2512963v2.0:3025067v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Coded value representing a person&#39;s self-identified racial category as defined in the Health Information National Trends Survey.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2512963</PublicId>
      <PreferredName>2236731v1.0:2388842v1.0</PreferredName>
      <PreferredDefinition>A human being._An arbitrary classification of taxonomic group that is a division of a species; usually arise as a consequence of geographical isolation within a species and characterised by shared heredity, physical attributes and behavior, and in case of humans, by common history, nationality, or geographic distribution.</PreferredDefinition>
      <LongName>Person Race</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388842</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17049</PreferredName>
        <Version>1</Version>
        <LongName>Race</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17049</PREFERRED_NAME>
            <LONG_NAME>Race</LONG_NAME>
            <CON_ID>2202465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3025067</PublicId>
      <PreferredName>3025067v1.0</PreferredName>
      <PreferredDefinition>code representing racial origination based on OMB approved categories.</PreferredDefinition>
      <LongName>Race Number Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008552</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PHYS_DESC_OF_INDS</PreferredName>
        <Version>1</Version>
        <LongName>Physical Description of Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Native Hawaiian or Other Pacific Islander</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025068</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>American Indian or Alaska Native</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41259</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including Cambodia, China, India, Japan, Korea, Malaysia, Mongolia, Pakistan, the Philippine Islands, Thailand, and Vietnam. The concept refers also to individuals who classify themselves as described below.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3009515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>African American</VALUEMEANING>
          <MEANINGDESCRIPTION>African American; term used in the United States to categorize a population group comprised of persons having origins in any of the black racial groups of Africa, most of whose ancestors were brought from Africa to the Americas as slaves between the sixteenth and nineteenth centuries. Includes population subgroups, e.g. Kenyan, Nigerian, or Haitian. The concept refers also to individuals who classify themselves as described.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>White (including Hispanic)</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41261</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3009517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Person Race Number Code does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Person Race Number Code does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3028392</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HINTS2005</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.dccps.hints2005.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3024953</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person:race</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PS&amp;CC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.dccps.hints2005.domain.Person.race</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1396">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3028617</PUBLICID>
    <LONGNAME>T-Lymphocyte Messenger RNA Response Integer Count</LONGNAME>
    <PREFERREDNAME>TcellRpndmRNAsurvI0U76</PREFERREDNAME>
    <PREFERREDDEFINITION>Human BIRC5 wild-type allele is located in the vicinity of 17q25 and is approximately 10 kb in length. This allele, which encodes baculoviral IAP repeat-containing protein 5, is involved in the prevention of apoptotic cell death._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._A numeral or string of numerals expressing value, quantity, or identification. (NCI)_Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent._To determine the number or amount of something; the result of this activity._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent._A number with no fractional part._To determine the number or amount of something; the result of this activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3028530</PublicId>
      <PreferredName>TcellRpndmRNA</PreferredName>
      <PreferredDefinition>Human BIRC5 wild-type allele is located in the vicinity of 17q25 and is approximately 10 kb in length. This allele, which encodes baculoviral IAP repeat-containing protein 5, is involved in the prevention of apoptotic cell death._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._A numeral or string of numerals expressing value, quantity, or identification. (NCI)_Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent._To determine the number or amount of something; the result of this activity._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.</PreferredDefinition>
      <LongName>T-Lymphocyte Messenger RNA Response Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2964747</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12476</PreferredName>
        <Version>1</Version>
        <LongName>T-Lymphocyte</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12476</PREFERRED_NAME>
            <LONG_NAME>T-Lymphocyte</LONG_NAME>
            <CON_ID>2529672</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2423583</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2433291</PublicId>
      <PreferredName>2433291v1.0</PreferredName>
      <PreferredDefinition>A number with no fractional part._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Integer Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue>0</MinimumValue>
      <Origin>CAP PROTOCOLS:College of American Pathologists Cancer Protocols</Origin>
      <Representation>
        <PublicId>2434150</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463:C45255</PreferredName>
        <Version>1</Version>
        <LongName>Count Integer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element T-Lymphocyte Messenger RNA Response Integer Count does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element T-Lymphocyte Messenger RNA Response Integer Count does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1397">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3059901</PUBLICID>
    <LONGNAME>Infertility Treatment Type</LONGNAME>
    <PREFERREDNAME>INFERT_TX_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to describe an action or administration of therapeutic agents to produce an effect that is intended to alter a woman&#39;s inability to produce children.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2436694</PublicId>
      <PreferredName>INFTL_TX</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter a woman&#39;s inability to produce children.</PreferredDefinition>
      <LongName>Infertility Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2436692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3836</PreferredName>
        <Version>1</Version>
        <LongName>Infertility</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3836</PREFERRED_NAME>
            <LONG_NAME>Infertility</LONG_NAME>
            <CON_ID>2203765</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2324753</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3059894</PublicId>
      <PreferredName>INFER_TX_TP</PreferredName>
      <PreferredDefinition>Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Infertility Treatment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>32</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3059893</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3836:C15368:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Infertility Therapy Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3836</PREFERRED_NAME>
            <LONG_NAME>Infertility</LONG_NAME>
            <CON_ID>2203765</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVF</VALIDVALUE>
          <VALUEMEANING>In vitro fertilization</VALUEMEANING>
          <MEANINGDESCRIPTION>Fertilization of an egg outside the body when the egg is normally fertilized in the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16580</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2698310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Letrozole</VALIDVALUE>
          <VALUEMEANING>Letrozole</VALUEMEANING>
          <MEANINGDESCRIPTION>A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2921027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clomid</VALIDVALUE>
          <VALUEMEANING>Clomid</VALUEMEANING>
          <MEANINGDESCRIPTION>A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C379</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577819</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IUI</VALIDVALUE>
          <VALUEMEANING>Intrauterine Insemination</VALUEMEANING>
          <MEANINGDESCRIPTION>Intrauterine Insemination</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3059896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Injectable Fertility Medication</VALIDVALUE>
          <VALUEMEANING>Injectable Fertility Medication</VALUEMEANING>
          <MEANINGDESCRIPTION>Injectable Fertility Medication</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-04-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3059899</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Fertility Treatment Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Fertility Treatment Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UPCC 07403</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U of Pa Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812727</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>U Pa Cancer Center New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812868</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1398">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3076108</PUBLICID>
    <LONGNAME>Person Stroke Symptom Assessment Description Text</LONGNAME>
    <PREFERREDNAME>3076106v1.0:2954078v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Person; a human being._A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event._Subjective evidence of disease perceived by the patient._The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3076106</PublicId>
      <PreferredName>2236731v1.0:3076104v1.0</PreferredName>
      <PreferredDefinition>Person; a human being._A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event._Subjective evidence of disease perceived by the patient.</PreferredDefinition>
      <LongName>Person Stroke Symptom</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3076104</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3390:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Cerebrovascular Accident Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3390</PREFERRED_NAME>
            <LONG_NAME>Stroke</LONG_NAME>
            <CON_ID>2444514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>A questionnaire to determine</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>A questionnaire to determine if the respondent has had an ischemic infarction (i.e. stroke) and/or any symptoms related to this event.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neurology</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009616</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1399">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3078760</PUBLICID>
    <LONGNAME>Primary Tumor Dominant Histologic Subtype Type</LONGNAME>
    <PREFERREDNAME>3076539v1.0:3076543v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to identify the predominant histologic subtype for a primary tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3076539</PublicId>
      <PreferredName>2206557v1.0:3076537v1.0</PreferredName>
      <PreferredDefinition>information related to a tumor&#39;s histologic subtype._Occurring first in time or sequence; original; of greatest rank or importance or value._Occurring first in time or sequence; original; of greatest rank or importance or value._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Exercising influence or control._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.</PreferredDefinition>
      <LongName>Primary Tumor Dominant Histologic Subtype</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206557</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Primary Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3076537</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25487:C25526:C25696</PreferredName>
        <Version>1</Version>
        <LongName>Dominant Histologic Subtype</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25487</PREFERRED_NAME>
            <LONG_NAME>Dominant</LONG_NAME>
            <CON_ID>2206199</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25696</PREFERRED_NAME>
            <LONG_NAME>Subtype</LONG_NAME>
            <CON_ID>2203810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3076543</PublicId>
      <PreferredName>3076543v1.0</PreferredName>
      <PreferredDefinition>An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._A group forming a type within a larger type._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Wilms Tumor Histologic Subtype Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3076542</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3267:C25526:C25696:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Wilms Tumor Histologic Subtype Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3267</PREFERRED_NAME>
            <LONG_NAME>Wilms Tumor</LONG_NAME>
            <CON_ID>2593187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25696</PREFERRED_NAME>
            <LONG_NAME>Subtype</LONG_NAME>
            <CON_ID>2203810</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epithelial</VALIDVALUE>
          <VALUEMEANING>Epithelial Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Cells that cover the surface of the body and line its cavities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12578</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3076544</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stromal</VALIDVALUE>
          <VALUEMEANING>Stromal Predominant Wilms Tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.: Exercising influence or control.: An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3267, C25487, C12571</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3143371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mixed</VALIDVALUE>
          <VALUEMEANING>Mixed Cell Type Wilms Tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Mixed; being composed of a combination of normal and tumor cells.: An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3267, C26457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3143372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blastemal</VALIDVALUE>
          <VALUEMEANING>Blastemal Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>An embryonic undifferentiated cell that can grow and differentiate into organs or body parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4615992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Predominant histologic subtyp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Predominant histologic subtype of primary tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET Wilms Tumor</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3165863</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179562</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5650570</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Kidney Tumors</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5650573</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1400">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3078929</PUBLICID>
    <LONGNAME>Dental Implant Patient Oral Cavity Pain Oral Health Impact Profile Physical Examination Oral Health Impact Profile Scale</LONGNAME>
    <PREFERREDNAME>3078927v1.0:2504090v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>a scaled index related to the Oral Health Impact Profile assessment, a measure of a person&#39;s perceptions of the social impact of oral disorders on their well-being, of a patient&#39;s sensation of discomfort of cavity lying at the upper end of the alimentary canal from the materials placed into (endosseous) or onto (subperiosteal) the jawbone.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3078927</PublicId>
      <PreferredName>3078858v1.0:2516909v1.0</PreferredName>
      <PreferredDefinition>information related to the Oral Health Impact Profile assessment, a measure of a person&#39;s perceptions of the social impact of oral disorders on their well-being, of a patient&#39;s sensation of discomfort of cavity lying at the upper end of the alimentary canal from the materials placed into (endosseous) or onto (subperiosteal) the jawbone.</PreferredDefinition>
      <LongName>Dental Implant Patient Oral Cavity Pain Oral Health Impact Profile Physical Examination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3078858</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63718:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Dental Implant Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63718</PREFERRED_NAME>
            <LONG_NAME>Dental Implant</LONG_NAME>
            <CON_ID>2547874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2516909</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12421:C3303:C62359:C20989</PreferredName>
        <Version>1</Version>
        <LongName>Mouth Pain Oral Health Impact Profile Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12421</PREFERRED_NAME>
            <LONG_NAME>Oral Cavity</LONG_NAME>
            <CON_ID>2202746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62359</PREFERRED_NAME>
            <LONG_NAME>Oral Health Impact Profile</LONG_NAME>
            <CON_ID>2511485</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2504090</PublicId>
      <PreferredName>OHIP_SCALE</PreferredName>
      <PreferredDefinition>a scaled index of the social impact of oral disorders which draws on a theoretical heirarchy of  oral health outcomes (Oral Health Impact Profile).</PreferredDefinition>
      <LongName>Oral Health Impact Profile Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-05-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hardly ever</VALIDVALUE>
          <VALUEMEANING>Hardly ever</VALUEMEANING>
          <MEANINGDESCRIPTION>Hardly ever</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fairly often</VALIDVALUE>
          <VALUEMEANING>Fairly often</VALUEMEANING>
          <MEANINGDESCRIPTION>Fairly often</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very often</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you had painful aching i</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you had painful aching in your mouth due to the implant placement</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1401">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3090688</PUBLICID>
    <LONGNAME>Hematopoietic Stem Cell Transplantation Performed Ind-3</LONGNAME>
    <PREFERREDNAME>2644275v1.0:2018278v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/unknown indicator related to having primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.) being grafted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2644275</PublicId>
      <PreferredName>HSCT_PRFRMD</PreferredName>
      <PreferredDefinition>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_The grafting of tissues from one individual to another or place to place within a single individual._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Hematopoietic Stem Cell Transplantation Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2531883</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12551:C15342</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Stem Cell Transplantation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was stem cell transplant done</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was stem cell transplant done</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have a stem cell transplant</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Transplant or Stem Cell Infusion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Transplant or Infusion without TBI</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Stem Cell Infusion without TBI</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was stem cell infusion performed this cycle?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text_4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has Patient had any prior autologous or allogeneic Stem Cell Transplant?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Transplant without TBI</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text_6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Infusion with or without TBI</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive a stem cell transplant treatment during this reporting interval?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive a stem cell infusion during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Transplant with or without TBI</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 09</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient previously received a hematopoietic stem cell transplantation (HSCT)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text  001</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was a peripheral blood stem cell (PBSC) infusion performed during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Stem Cell Transplant or Infusion (with or without TBI)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient had prior Stem Cell Transplant or Infusion (with or without TBI)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient had prior stem cell transplant?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the patient previously had prior stem cell infusions (with or without TBI as treatment)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>2644275v1.0:2018278v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PrRcvStclXptITp</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>2644275v1.0:2018278v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1402">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101024</PUBLICID>
    <LONGNAME>Postal Address Street Address Prior Direction Type java.lang.String</LONGNAME>
    <PREFERREDNAME>3099798v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A physical location used by a person or organization for the purpose of receiving postal mail deliveries._The street name and building number where a person or organization can be found.:Earlier in time or order.:The spatial relation between something and the course along which it points or moves.:Something distinguishable as an identifiable class based on common qualities._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099798</PublicId>
      <PreferredName>3099530v1.0:3099620v1.0</PreferredName>
      <PreferredDefinition>A physical location used by a person or organization for the purpose of receiving postal mail deliveries._The street name and building number where a person or organization can be found.:Earlier in time or order.:The spatial relation between something and the course along which it points or moves.:Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Postal Address Street Address Prior Direction Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099530</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70946</PreferredName>
        <Version>1</Version>
        <LongName>Postal Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70946</PREFERRED_NAME>
            <LONG_NAME>Postal Address</LONG_NAME>
            <CON_ID>2714916</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3099620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25690:C25629:C42677:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Street Address Prior Direction Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25690</PREFERRED_NAME>
            <LONG_NAME>Street Address</LONG_NAME>
            <CON_ID>2203802</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42677</PREFERRED_NAME>
            <LONG_NAME>Direction</LONG_NAME>
            <CON_ID>2231593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Postal Address Street Address Prior Direction Type java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Postal Address Street Address Prior Direction Type java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PostalAddress:addressStreetPreDirectonalType</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.PostalAddress.addressStreetPreDirectonalType</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1403">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101228</PUBLICID>
    <LONGNAME>Carbon Dioxide Percentage Carbon Dioxide Minimum Percentage java.lang.Float</LONGNAME>
    <PREFERREDNAME>3099995v1.0:2178535v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Carbon Dioxide:A fraction or ratio with 100 understood as the denominator. (NCI)_Carbon Dioxide:The smallest possible quantity.:A fraction or ratio with 100 understood as the denominator. (NCI)_Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3099995</PublicId>
      <PreferredName>3099600v1.0:3099648v1.0</PreferredName>
      <PreferredDefinition>Carbon Dioxide:A fraction or ratio with 100 understood as the denominator. (NCI)_Carbon Dioxide:The smallest possible quantity.:A fraction or ratio with 100 understood as the denominator. (NCI)</PreferredDefinition>
      <LongName>Carbon Dioxide Percentage Carbon Dioxide Minimum Percentage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C65288:C25613</PreferredName>
        <Version>1</Version>
        <LongName>Carbon Dioxide Percentage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65288</PREFERRED_NAME>
            <LONG_NAME>Carbon Dioxide</LONG_NAME>
            <CON_ID>2922837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3099648</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C65288:C25570:C25613</PreferredName>
        <Version>1</Version>
        <LongName>Carbon Dioxide Minimum Percentage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65288</PREFERRED_NAME>
            <LONG_NAME>Carbon Dioxide</LONG_NAME>
            <CON_ID>2922837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178535</PublicId>
      <PreferredName>java.lang.Float</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is Single-precision floating point number (32-bit IEEE 754).</PreferredDefinition>
      <LongName>java.lang.Float</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Float</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Carbon Dioxide Percentage Carbon Dioxide Minimum Percentage java.lang.Float does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Carbon Dioxide Percentage Carbon Dioxide Minimum Percentage java.lang.Float does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common.environmentalcondition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>percentCO2:minimumPercentCO2</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.environmentalcondition.percentCO2.minimumPercentCO2</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1404">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101244</PUBLICID>
    <LONGNAME>Document Keyword Code java.lang.String</LONGNAME>
    <PREFERREDNAME>2868353v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An organized collection of records that describe a particular body of data._A small set of words designed to convey the subject of a technical article.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868353</PublicId>
      <PreferredName>2772265v1.0:2867935v1.0</PreferredName>
      <PreferredDefinition>An organized collection of records that describe a particular body of data._A small set of words designed to convey the subject of a technical article.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Document Keyword Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2772265</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19498</PreferredName>
        <Version>1</Version>
        <LongName>Document</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867935</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43513:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Keyword Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43513</PREFERRED_NAME>
            <LONG_NAME>Keyword</LONG_NAME>
            <CON_ID>2223202</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Document Keyword Code java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Document Keyword Code java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.Document.keywordCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Document:keywordCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1405">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101296</PUBLICID>
    <LONGNAME>Development Stage Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100055v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100055</PublicId>
      <PreferredName>3099579v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>Development is the act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.:Any distinct time period in a sequence of events._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Development Stage Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17770:C48308</PreferredName>
        <Version>1</Version>
        <LongName>Development Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17770</PREFERRED_NAME>
            <LONG_NAME>Maturation</LONG_NAME>
            <CON_ID>2237044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48308</PREFERRED_NAME>
            <LONG_NAME>Stage</LONG_NAME>
            <CON_ID>2676538</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Development Stage Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Development Stage Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.DevelopmentalStage.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DevelopmentalStage:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1406">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101337</PUBLICID>
    <LONGNAME>Quick Freeze Event Description java.lang.String</LONGNAME>
    <PREFERREDNAME>3100094v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>To freeze rapidly so as to preserve structure and prevent ice crystal formation.:Something that happens at a given place and time._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100094</PublicId>
      <PreferredName>3099544v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>To freeze rapidly so as to preserve structure and prevent ice crystal formation.:Something that happens at a given place and time._A statement or an account describing something.</PreferredDefinition>
      <LongName>Quick Freeze Event Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099544</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63521:C25499</PreferredName>
        <Version>1</Version>
        <LongName>Quick Freeze Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63521</PREFERRED_NAME>
            <LONG_NAME>Quick Freeze</LONG_NAME>
            <CON_ID>2536983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Quick Freeze Event Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Quick Freeze Event Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory.event</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.event.FreezeEvent.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FreezeEvent:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1407">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101446</PUBLICID>
    <LONGNAME>Humidity Created By java.lang.String</LONGNAME>
    <PREFERREDNAME>3100203v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A measure of the water vapor content of air._Indicates the person or authoritative body who brought the item into existence._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100203</PublicId>
      <PreferredName>3099608v1.0:2231611v1.0</PreferredName>
      <PreferredDefinition>A measure of the water vapor content of air._Indicates the person or authoritative body who brought the item into existence.</PreferredDefinition>
      <LongName>Humidity Created By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099608</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88206</PreferredName>
        <Version>1</Version>
        <LongName>Humidity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88206</PREFERRED_NAME>
            <LONG_NAME>Humidity</LONG_NAME>
            <CON_ID>3099517</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231611</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42628</PreferredName>
        <Version>1</Version>
        <LongName>Created By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42628</PREFERRED_NAME>
            <LONG_NAME>Created By</LONG_NAME>
            <CON_ID>2231551</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Humidity Created By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Humidity Created By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common.environmentalcondition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.environmentalcondition.Humidity.createdBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Humidity:createdBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1408">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101480</PUBLICID>
    <LONGNAME>Carbohydrate Condition java.lang.String</LONGNAME>
    <PREFERREDNAME>3100237v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The largest class of organic compounds, including starches, glycogens, cellulose, gums, and simple sugars. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. (MeSH)_A state of being, such as a state of health or physical being._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100237</PublicId>
      <PreferredName>3099582v1.0:2239841v1.0</PreferredName>
      <PreferredDefinition>The largest class of organic compounds, including starches, glycogens, cellulose, gums, and simple sugars. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. (MeSH)_A state of being, such as a state of health or physical being.</PreferredDefinition>
      <LongName>Carbohydrate Condition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099582</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C344</PreferredName>
        <Version>1</Version>
        <LongName>Carbohydrate</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C344</PREFERRED_NAME>
            <LONG_NAME>Carbohydrate</LONG_NAME>
            <CON_ID>3099505</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25457</PreferredName>
        <Version>1</Version>
        <LongName>Condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Carbohydrate Condition java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Carbohydrate Condition java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Carbohydrate:condition</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Carbohydrate.condition</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1409">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101622</PUBLICID>
    <LONGNAME>Neonatal Hearing Impairment Description java.lang.String</LONGNAME>
    <PREFERREDNAME>3100382v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Partial or complete loss of the ability to detect or understand sounds present in an infant within its first month after birth._A statement or an account describing something._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100382</PublicId>
      <PreferredName>3099576v1.0:2222846v1.0</PreferredName>
      <PreferredDefinition>Partial or complete loss of the ability to detect or understand sounds present in an infant within its first month after birth._A statement or an account describing something.</PreferredDefinition>
      <LongName>Neonatal Hearing Impairment Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099576</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C50667</PreferredName>
        <Version>1</Version>
        <LongName>Neonatal Hearing Impairment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50667</PREFERRED_NAME>
            <LONG_NAME>Neonatal Hearing Impairment</LONG_NAME>
            <CON_ID>3099500</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Neonatal Hearing Impairment Description java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Neonatal Hearing Impairment Description java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NeonatalHearingImpairment:description</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.NeonatalHearingImpairment.description</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1410">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101654</PUBLICID>
    <LONGNAME>Ventilation Name java.lang.String</LONGNAME>
    <PREFERREDNAME>3100414v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of moving air into and out of a space._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100414</PublicId>
      <PreferredName>3099604v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>The act of moving air into and out of a space._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Ventilation Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88203</PreferredName>
        <Version>1</Version>
        <LongName>Ventilation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88203</PREFERRED_NAME>
            <LONG_NAME>Ventilation</LONG_NAME>
            <CON_ID>3099515</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Ventilation Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Ventilation Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common.environmentalcondition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Ventilation:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.environmentalcondition.Ventilation.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1411">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101672</PUBLICID>
    <LONGNAME>Air Filtration Identifier java.lang.Long</LONGNAME>
    <PREFERREDNAME>3100432v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A mixture of gases making up the earth&#39;s atmosphere, consisting mainly of nitrogen, oxygen, argon, and carbon dioxide.:The process of passing a liquid or gas through a filter._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100432</PublicId>
      <PreferredName>3099603v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>A mixture of gases making up the earth&#39;s atmosphere, consisting mainly of nitrogen, oxygen, argon, and carbon dioxide.:The process of passing a liquid or gas through a filter._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Air Filtration Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099603</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73434:C16583</PreferredName>
        <Version>1</Version>
        <LongName>Air Filtration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73434</PREFERRED_NAME>
            <LONG_NAME>Air</LONG_NAME>
            <CON_ID>2737316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16583</PREFERRED_NAME>
            <LONG_NAME>Filtration</LONG_NAME>
            <CON_ID>3099514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Air Filtration Identifier java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Air Filtration Identifier java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common.environmentalcondition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.environmentalcondition.AirFiltration.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AirFiltration:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1412">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101695</PUBLICID>
    <LONGNAME>Audiometric Test Clinical Test Result Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100455v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss.:The result of a laboratory, radiologic, or other clinical test performed to determine the presence, absence, or degree of a condition._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100455</PublicId>
      <PreferredName>3099580v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss.:The result of a laboratory, radiologic, or other clinical test performed to determine the presence, absence, or degree of a condition._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Audiometric Test Clinical Test Result Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099580</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38036:C77140</PreferredName>
        <Version>1</Version>
        <LongName>Audiometric Test Clinical Test Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38036</PREFERRED_NAME>
            <LONG_NAME>Audiometric Test</LONG_NAME>
            <CON_ID>2660092</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77140</PREFERRED_NAME>
            <LONG_NAME>Clinical Test Result</LONG_NAME>
            <CON_ID>3005938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Audiometric Test Clinical Test Result Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Audiometric Test Clinical Test Result Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.HearingTestResult.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HearingTestResult:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1413">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101717</PUBLICID>
    <LONGNAME>Lipid Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100477v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Lipids are fatty acid esters, an oily organic compound insoluble in water but soluble in organic solvents._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100477</PublicId>
      <PreferredName>2495304v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>Lipids are fatty acid esters, an oily organic compound insoluble in water but soluble in organic solvents._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Lipid Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2495304</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C616</PreferredName>
        <Version>1</Version>
        <LongName>Lipid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C616</PREFERRED_NAME>
            <LONG_NAME>Lipid</LONG_NAME>
            <CON_ID>2202375</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Lipid Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Lipid Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Lipid:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.Lipid.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1414">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101834</PUBLICID>
    <LONGNAME>Minimum Reservation Quantity Name java.lang.String</LONGNAME>
    <PREFERREDNAME>3100594v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The smallest possible quantity.:The act of keeping back or setting aside for some future occasion.:How much there is of something that you can measure; the total amount or number._The words or language units by which a thing is known._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100594</PublicId>
      <PreferredName>3099529v1.0:2222841v1.0</PreferredName>
      <PreferredDefinition>The smallest possible quantity.:The act of keeping back or setting aside for some future occasion.:How much there is of something that you can measure; the total amount or number._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Minimum Reservation Quantity Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099529</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25570:C71729:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Minimum Reservation Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71729</PREFERRED_NAME>
            <LONG_NAME>Reservation</LONG_NAME>
            <CON_ID>2734796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Minimum Reservation Quantity Name java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Minimum Reservation Quantity Name java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2813050</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MinimumReserveQuantity:name</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.administration.MinimumReserveQuantity.name</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1415">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3101967</PUBLICID>
    <LONGNAME>Visible Light Exposure Created By java.lang.String</LONGNAME>
    <PREFERREDNAME>3100727v1.0:2178533v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Electromagnetic radiation in the portion of the spectrum from about 380 nm (violet) to 800 nm (red).:The act of subjecting someone or something to an influencing experience._Indicates the person or authoritative body who brought the item into existence._Generic value domain for a java datatype that is a class that represents character strings.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100727</PublicId>
      <PreferredName>3099601v1.0:2231611v1.0</PreferredName>
      <PreferredDefinition>Electromagnetic radiation in the portion of the spectrum from about 380 nm (violet) to 800 nm (red).:The act of subjecting someone or something to an influencing experience._Indicates the person or authoritative body who brought the item into existence.</PreferredDefinition>
      <LongName>Visible Light Exposure Created By</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17732:C17941</PreferredName>
        <Version>1</Version>
        <LongName>Visible Light Exposure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17732</PREFERRED_NAME>
            <LONG_NAME>Visible Light</LONG_NAME>
            <CON_ID>3099513</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17941</PREFERRED_NAME>
            <LONG_NAME>Exposure</LONG_NAME>
            <CON_ID>2203924</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231611</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42628</PreferredName>
        <Version>1</Version>
        <LongName>Created By</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42628</PREFERRED_NAME>
            <LONG_NAME>Created By</LONG_NAME>
            <CON_ID>2231551</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178533</PublicId>
      <PreferredName>java.lang.String</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that is a class that represents character strings.</PreferredDefinition>
      <LongName>java.lang.String</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.String</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Visible Light Exposure Created By java.lang.String does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Visible Light Exposure Created By java.lang.String does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.common.environmentalcondition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LightExposure:createdBy</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.common.environmentalcondition.LightExposure.createdBy</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1416">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102048</PUBLICID>
    <LONGNAME>Mating Event Change Date java.util.Date</LONGNAME>
    <PREFERREDNAME>3100807v1.0:2222504v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of pairing individuals for sexual reproduction.:Something that happens at a given place and time._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen._Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3100807</PublicId>
      <PreferredName>3099533v1.0:2539482v1.0</PreferredName>
      <PreferredDefinition>The act of pairing individuals for sexual reproduction.:Something that happens at a given place and time._The act of alteration or modification; changed or altered in form or character.:The particular day, month and year an event has happened or will happen.</PreferredDefinition>
      <LongName>Mating Event Change Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3099533</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C88194:C25499</PreferredName>
        <Version>1</Version>
        <LongName>Mating Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88194</PREFERRED_NAME>
            <LONG_NAME>Mating</LONG_NAME>
            <CON_ID>3099491</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2539482</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25446:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Change Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2222504</PublicId>
      <PreferredName>java.util.Date</PreferredName>
      <PreferredDefinition>Generic value domain for a java datatype that represents a specific instant in time, with millisecond precision.</PreferredDefinition>
      <LongName>java.util.Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.util.Date</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Mating Event Change Date java.util.Date does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Mating Event Change Date java.util.Date does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2772168</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caLIMS2</PreferredName>
          <Version>1.1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.calims2.domain.inventory.event</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3099476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.calims2.domain.inventory.event.MatingEvent.dateModified</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MatingEvent:dateModified</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1417">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3102944</PUBLICID>
    <LONGNAME>Hepatic Disorder Medication Use Ind-2</LONGNAME>
    <PREFERREDNAME>3102932v1.0:2018279v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to medication use for any disease or dysfunction of the liver and the intrahepatic bile ducts.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3102932</PublicId>
      <PreferredName>3102930v1.0:2234899v1.0</PreferredName>
      <PreferredDefinition>information related to medication use for any disease or dysfunction of the liver and the intrahepatic bile ducts.</PreferredDefinition>
      <LongName>Hepatic Disorder Medication Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3102930</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3196:C459</PreferredName>
        <Version>1</Version>
        <LongName>Hepatic Disorder Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3196</PREFERRED_NAME>
            <LONG_NAME>Liver and Intrahepatic Bile Duct Disorder</LONG_NAME>
            <CON_ID>2516836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Liver disease</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Liver disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1418">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3104081</PUBLICID>
    <LONGNAME>Follow-up Metastasis Assessment Outcome Success Margin Status</LONGNAME>
    <PREFERREDNAME>3104079v1.0:2608700v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to describe the status of tissue margin following surgical resection for a metastatic progression procedure.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3104079</PublicId>
      <PreferredName>3104077v1.0:2786715v1.0</PreferredName>
      <PreferredDefinition>_The final result of a determination of the value, significance, or extent of.__Cancer that has spread from the organ in which it first appeared to another organ. For example, breast cancer cells may spread (metastasize) to the lungs and cause the growth of a new tumor. When this happens, the disease is called metastatic breast cancer._The process by which information about the health status of an individual is obtained after a study has officially closed._The result of an action._An event that accomplishes its intended purpose.</PreferredDefinition>
      <LongName>Follow-up Metastasis Assessment Outcome Success</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3104077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16033:C19151:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Follow-up Metastasis Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16033</PREFERRED_NAME>
            <LONG_NAME>Follow-Up</LONG_NAME>
            <CON_ID>2202303</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19151</PREFERRED_NAME>
            <LONG_NAME>Metastasis</LONG_NAME>
            <CON_ID>2202751</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2786715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200:C25362</PreferredName>
        <Version>1</Version>
        <LongName>Outcome Success</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25362</PREFERRED_NAME>
            <LONG_NAME>Success</LONG_NAME>
            <CON_ID>2203809</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2608700</PublicId>
      <PreferredName>MARG_STAT</PreferredName>
      <PreferredDefinition>Text terms to describe the status of a tissue margin.</PreferredDefinition>
      <LongName>Margin Status</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2608699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25563:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Margin Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25563</PREFERRED_NAME>
            <LONG_NAME>Margin</LONG_NAME>
            <CON_ID>2202676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No source documentation</VALIDVALUE>
          <VALUEMEANING>No/Not in source document</VALUEMEANING>
          <MEANINGDESCRIPTION>Data from an original source is not present, accessible or ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-03-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2604857</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R0</VALIDVALUE>
          <VALUEMEANING>All Margins Pathologically Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates the absence of tumor cells at the edge of a surgically excised specimen.: Cancer cells that remain after attempts to remove the cancer have been made.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4809, C48621</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R1</VALIDVALUE>
          <VALUEMEANING>Microscopically Positive Margins or Microscopic Residual Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates the presence of tumor cells at the edge of a surgically excised specimen.: A finding resulting from the examination of a tissue sample under light or electron microscopy.: Cancer cells that remain after attempts to remove the cancer have been made.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4809, C83490, C48620</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R2</VALIDVALUE>
          <VALUEMEANING>Macroscopically Positive Margins or Gross Residual Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The presence of macroscopically visible residual tumor at the edge of a surgically excised specimen.: Visible to the naked eye.: Cancer cells that remain after attempts to remove the cancer have been made.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4809, C43566, C120274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-04-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559141</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RX</VALIDVALUE>
          <VALUEMEANING>Presence of Residual Disease Cannot Be Assessed</VALUEMEANING>
          <MEANINGDESCRIPTION>Cancer cells that remain after attempts to remove the cancer have been made.: Being or existing in a specified place or at the specified time.: Aspects of the context prevent the evaluation needed to determine a value.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48657, C25626, C4809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559858</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5607983</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Residual tumor after Surgery</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Residual tumor after Surgery for New Tumor Event Metastatic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5589063</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CDDP/CTSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDDP/CTSP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5589068</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1419">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3107324</PUBLICID>
    <LONGNAME>Adult Physical Activity Self-Efficacy Assessment Score</LONGNAME>
    <PREFERREDNAME>3107322v1.0:3076086v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A human who has reached reproductive age._Any form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc._A person&#39;s subjective assessment of their ability to succeed at a task or challenge._The final result of a determination of the value, significance, or extent of._The final result of a determination of the value, significance, or extent of._A number or range of numeric values measuring performance, function, quality, or ability.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3107322</PublicId>
      <PreferredName>2944354v1.0:3107316v1.0</PreferredName>
      <PreferredDefinition>A human who has reached reproductive age._Any form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc._A person&#39;s subjective assessment of their ability to succeed at a task or challenge._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Adult Physical Activity Self-Efficacy Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2944354</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17600</PreferredName>
        <Version>1</Version>
        <LongName>Adult</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17600</PREFERRED_NAME>
            <LONG_NAME>Adult</LONG_NAME>
            <CON_ID>2204022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3107316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17708:C88184:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Physical Activity Self-Efficacy Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17708</PREFERRED_NAME>
            <LONG_NAME>Physical Activity</LONG_NAME>
            <CON_ID>2202366</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C88184</PREFERRED_NAME>
            <LONG_NAME>Self-Efficacy</LONG_NAME>
            <CON_ID>3060696</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3076086</PublicId>
      <PreferredName>ASSES_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>A measure of a person&#39;s confi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>A measure of a person&#39;s confidence in their ability to exercise on a regular basis.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1420">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3109631</PUBLICID>
    <LONGNAME>Medication Osteoporosis Administered Indicator</LONGNAME>
    <PREFERREDNAME>M_OSTEOPO_ADMIN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>the indicator relating to whether the patient has received bone active medication during this follow-up period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>IBCSG CRF:International Breast Cancer Study Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2495785</PublicId>
      <PreferredName>MED_OSTEO_ADMIN</PreferredName>
      <PreferredDefinition>information related to the administration of a biologically active substance to reverse or slow the condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.</PreferredDefinition>
      <LongName>Medication Osteoporosis Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411879</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C459</PreferredName>
        <Version>1</Version>
        <LongName>Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2732414</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3298:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Osteoporosis Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3298</PREFERRED_NAME>
            <LONG_NAME>Osteoporosis</LONG_NAME>
            <CON_ID>2202545</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2753450</PublicId>
      <PreferredName>TX_INDIC</PreferredName>
      <PreferredDefinition>The indicator whether an event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Therapy Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N/A</VALIDVALUE>
          <VALUEMEANING>Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Information regarding the subject is unknown or inaccessible at this time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-12-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Continuing</VALIDVALUE>
          <VALUEMEANING>Continuing</VALUEMEANING>
          <MEANINGDESCRIPTION>Existing in time or space without stop or interruption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53279</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569325</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient receive bone</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient receive bone active medication other than calcium or vitamin D during this follow-up period</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008587</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>DISEASE</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811831</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1421">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3109974</PUBLICID>
    <LONGNAME>Breast Carcinoma Combined Histologic Grade Category</LONGNAME>
    <PREFERREDNAME>2550739v1.0:3109965v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Tumor grade according Scarff and Bloom grading modified by Eltson and Ellis (SBR/Elston), which yields a classification for histopathologic grading of breast cancer that determines a grade for a specimen based on tubule formation, nuclear pleomorphism, and mitotic count.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2550739</PublicId>
      <PreferredName>BRSTCA_COMB_HIST_GD</PreferredName>
      <PreferredDefinition>Reference to the Scarff and Bloom grading modified by Eltson and Ellis (SBR/Elston), which yields a classification for histopathologic grading of breast cancer that determines a grade for a specimen based on tubule formation, nuclear pleomorphism, and mitotic count.</PreferredDefinition>
      <LongName>Breast Carcinoma Combined Histologic Grade</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4872</PreferredName>
        <Version>1</Version>
        <LongName>Breast Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4872</PREFERRED_NAME>
            <LONG_NAME>Breast Carcinoma</LONG_NAME>
            <CON_ID>2475940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2550737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25454:C18000</PreferredName>
        <Version>1</Version>
        <LongName>Combined Histologic Grade</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25454</PREFERRED_NAME>
            <LONG_NAME>Combined</LONG_NAME>
            <CON_ID>2206179</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3109965</PublicId>
      <PreferredName>BRST_TM_NUC_GRAD_CAT</PreferredName>
      <PreferredDefinition>the nuclear grade category for the breast tumor in the patient.</PreferredDefinition>
      <LongName>Breast Neoplasm Nuclear Grade Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>40</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indeterminate</VALIDVALUE>
          <VALUEMEANING>Indeterminate</VALUEMEANING>
          <MEANINGDESCRIPTION>Cannot distinguish between two or more possible values in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Stated</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2964573</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade III (High)</VALIDVALUE>
          <VALUEMEANING>High </VALUEMEANING>
          <MEANINGDESCRIPTION>An elevated level or position or degree; greater than normal in degree or intensity or amount.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915788</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade II (Intermediate)</VALIDVALUE>
          <VALUEMEANING>Intermediate </VALUEMEANING>
          <MEANINGDESCRIPTION>Lying between two extremes in time or space or degree.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C73705</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915789</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Grade I (Low)</VALIDVALUE>
          <VALUEMEANING>Low </VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree or intensity or amount.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18000, C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915790</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No residual invasive breast cancer</VALIDVALUE>
          <VALUEMEANING>No residual invasive breast cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Remaining or left behind.: A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9245, C37895, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3109966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Combined Histologic Grade Pos</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Combined Histologic Grade Post-Surgery</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histologic Grade</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Histologic Grade</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2956164</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Transcend</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Transcend CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2956165</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461588</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886753</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>General Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902138</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BOLD</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BOLD</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1422">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3110125</PUBLICID>
    <LONGNAME>Emphysema Patient Self-Report Personal Medical History Yes or No Response</LONGNAME>
    <PREFERREDNAME>3110123v1.0:3108967v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A subcategory of chronic obstructive pulmonary disease (COPD).  It occurs in people who smoke and suffer from chronic bronchitis.  It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.  Alveoli are the vital lung structures where the transfer of oxygen and carbon dioxide takes place. Subjective reports made by the patient. An account of all medical events and problems a person has experienced. A caDSR representation term that is used to indicate a question with permissible values of yes/no</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3110123</PublicId>
      <PreferredName>3110121v1.0:2793065v1.0</PreferredName>
      <PreferredDefinition>A subcategory of chronic obstructive pulmonary disease (COPD).  It occurs in people who smoke and suffer from chronic bronchitis.  It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.  Alveoli are the vital lung structures where the transfer of oxygen and carbon dioxide takes place. Subjective reports made by the patient. An account of all medical events and problems a person has experienced.</PreferredDefinition>
      <LongName>Emphysema Patient Self-Report Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3110121</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3348</PreferredName>
        <Version>1</Version>
        <LongName>Emphysema</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3348</PREFERRED_NAME>
            <LONG_NAME>Pulmonary Emphysema</LONG_NAME>
            <CON_ID>2202614</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2793065</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3108967</PublicId>
      <PreferredName>C49487:C49488:3108967v1.0</PreferredName>
      <PreferredDefinition>A caDSR representation term that is used to indicate a question with permissible values of yes/no</PreferredDefinition>
      <LongName>Yes or No Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No [0]</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes [0]</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Emphysema</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Emphysema</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1423">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3110199</PUBLICID>
    <LONGNAME>Tongue Patient Self-Report Personal Medical History Yes or No Response</LONGNAME>
    <PREFERREDNAME>3110197v1.0:3108967v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech. Subjective reports made by the patient. An account of all medical events and problems a person has experienced. A caDSR representation term that is used to indicate a question with permissible values of yes/no</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3110197</PublicId>
      <PreferredName>3110195v1.0:2793065v1.0</PreferredName>
      <PreferredDefinition>The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech. Subjective reports made by the patient. An account of all medical events and problems a person has experienced.</PreferredDefinition>
      <LongName>Tongue Patient Self-Report Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3110195</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12422</PreferredName>
        <Version>1</Version>
        <LongName>Tongue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12422</PREFERRED_NAME>
            <LONG_NAME>Tongue</LONG_NAME>
            <CON_ID>2451477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2793065</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C18772</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3108967</PublicId>
      <PreferredName>C49487:C49488:3108967v1.0</PreferredName>
      <PreferredDefinition>A caDSR representation term that is used to indicate a question with permissible values of yes/no</PreferredDefinition>
      <LongName>Yes or No Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No [0]</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes [0]</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Burning sensation on tongue</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Burning sensation on tongue</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1424">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3113351</PUBLICID>
    <LONGNAME>Cancer Identification Multiple Tumor Multiple Neoplasm Number Code</LONGNAME>
    <PREFERREDNAME>2684627v1.0:3113331v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>This data item is used to identify the type of multiple tumors in cases with multiple tumors that are abstracted and reported as a single primary using the SEER, IARC, or Canadian Cancer Registry multiple primary rules.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PS-CC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NAACCR:North American Association of Central Cancer Registries</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2684627</PublicId>
      <PreferredName>2666870v1.0:2684625v1.0</PreferredName>
      <PreferredDefinition>The identification of cases with multiple tumors that are abstracted and reported as a single primary using the SEER, IARC, or Canadian Cancer Registry multiple primary rules.</PreferredDefinition>
      <LongName>Cancer Identification Multiple Tumor</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2666870</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305:C25737</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Identified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2684625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17648:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Multiple Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17648</PREFERRED_NAME>
            <LONG_NAME>Multiple</LONG_NAME>
            <CON_ID>2202577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3113331</PublicId>
      <PreferredName>3113331v1.1</PreferredName>
      <PreferredDefinition>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold. (dictionary.com)_(TOO-mer) An abnormal mass of tissue that results from excessive cell division. Tumors perform no useful body function. They may be benign (not cancerous) or malignant (cancerous)._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Multiple Neoplasm Number Code</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PS-CC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NAACCR:North American Association of Central Cancer Registries</Origin>
      <Representation>
        <PublicId>2661602</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17648:C3262:C25337:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Multiple Neoplasm Number Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17648</PREFERRED_NAME>
            <LONG_NAME>Multiple</LONG_NAME>
            <CON_ID>2202577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>NA</VALUEMEANING>
          <MEANINGDESCRIPTION>NA</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Multiple invasive</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple invasive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113334</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>FAP with carcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>FAP with carcinoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>Polyp and adenocarcinoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Polyp and adenocarcinoma</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>In situ and invasive</VALUEMEANING>
          <MEANINGDESCRIPTION>In situ and invasive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113337</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Multiple in situ</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple in situ</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Benign and borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Benign and borderline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113339</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Multiple borderline</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple borderline</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Multiple benign</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiple benign</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3113341</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>00</VALIDVALUE>
          <VALUEMEANING>Single tumor</VALUEMEANING>
          <MEANINGDESCRIPTION>Single tumor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2644895</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>Unknown in situ or invasive</VALUEMEANING>
          <MEANINGDESCRIPTION>Unknown in situ or invasive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-09-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3269802</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Multiple Tumors Reported as Single Primary Description</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Multiple tumors may individually exhibit in situ, invasive, or any combination of in situ and invasive behaviors. Multiple intracranial and central nervous system tumors may individually exhibit benign, borderline, malignant, or any combination of these behaviors. Multiple tumors found in the same organ or in a single primary site may occur at the time of initial diagnosis or within one year of the initial diagnosis. The data item does not apply to metastatic tumors. Data will be collected at the time of initial case abstract or within one year of the initial diagnosis. This data item is also used when a physician states that there are two or more primaries, but for surveillance purposes, the case is reported as a single primary.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Multiple Tumors Reported as S</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Multiple Tumors Reported as Single Primary</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.3 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.3 Data Standards and Data Dictionary (4/2008)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=xSH32ZzIzGI%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR V11.2 Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 11.2 Data Standards and Data Dictionary (5/30/2007)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=PQdlAnykU1U%3d</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 12.1, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)</DocumentText>
        <URL>http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&amp;tabid=133&amp;mid=473</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NAACCR 16, Data Stds/Dict.</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)</DocumentText>
        <URL>https://www.naaccr.org/data-standards-data-dictionary/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134707</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerID12.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134731</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899833</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerID16</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5899834</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NAACCR 18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464305</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2193114</PublicId>
          <ContextName>PS-CC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCCPS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CancerID18</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7464307</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Multiple Tumors Reported as Single Primary</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Type of Multiple Tumors Reported as One Primary</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>444</AlternateName>
        <AlternateNameType>NAACCR Item #</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MULT TUM RPT AS ONE PRIM</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Mult Tum Rpt as One Prim</AlternateName>
        <AlternateNameType>NAACCR Item Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PS-CC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Type of Multiple Tumors Reported As One Primary</AlternateName>
        <AlternateNameType>NAACCR Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1425">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3120054</PUBLICID>
    <LONGNAME>External System Clinical Study Protocol Stratification Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>3119942v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Happening or arising or located outside or beyond some limits, or especially, some surface.:A group of independent but interrelated elements comprising a unified whole.:A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3119942</PublicId>
      <PreferredName>3119832v1.0:2990531v1.0</PreferredName>
      <PreferredDefinition>Happening or arising or located outside or beyond some limits, or especially, some surface.:A group of independent but interrelated elements comprising a unified whole.:A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>External System Clinical Study Protocol Stratification Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3119832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44280:C25700:C25320</PreferredName>
        <Version>1</Version>
        <LongName>External System Clinical Study Protocol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44280</PREFERRED_NAME>
            <LONG_NAME>External</LONG_NAME>
            <CON_ID>2422632</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2990531</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25689:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Stratification Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25689</PREFERRED_NAME>
            <LONG_NAME>Stratification</LONG_NAME>
            <CON_ID>2203803</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element External System Clinical Study Protocol Stratification Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element External System Clinical Study Protocol Stratification Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RemoteStudy:stratificationIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.RemoteStudy.stratificationIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1426">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3120067</PUBLICID>
    <LONGNAME>Clinical Study Coordination Center Negation System Communication Mode java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>3119953v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:The act of bringing into common action, movement, or condition.:A point or area that is approximately central within some larger region or structure._An operation in which a term denies or inverts the meaning of another term or construction.:A group of independent but interrelated elements comprising a unified whole.:The exchange of information between objects, people, or groups.:A particular functioning condition or arrangement._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Superceded</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3119953</PublicId>
      <PreferredName>2734860v1.0:3119850v1.0</PreferredName>
      <PreferredDefinition>Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research.:The act of bringing into common action, movement, or condition.:A point or area that is approximately central within some larger region or structure._An operation in which a term denies or inverts the meaning of another term or construction.:A group of independent but interrelated elements comprising a unified whole.:The exchange of information between objects, people, or groups.:A particular functioning condition or arrangement.</PreferredDefinition>
      <LongName>Clinical Study Coordination Center Negation System Communication Mode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2734860</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15206:C25462:C25445</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Coordination Center</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25462</PREFERRED_NAME>
            <LONG_NAME>Coordination</LONG_NAME>
            <CON_ID>2206184</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25445</PREFERRED_NAME>
            <LONG_NAME>Center</LONG_NAME>
            <CON_ID>2206174</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3119850</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25700:C16452:C25571</PreferredName>
        <Version>1</Version>
        <LongName>Negation System Communication Mode</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25700</PREFERRED_NAME>
            <LONG_NAME>System</LONG_NAME>
            <CON_ID>2202584</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16452</PREFERRED_NAME>
            <LONG_NAME>Communication</LONG_NAME>
            <CON_ID>2435936</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25571</PREFERRED_NAME>
            <LONG_NAME>Mode</LONG_NAME>
            <CON_ID>2203852</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Clinical Study Coordination Center Negation System Communication Mode java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Clinical Study Coordination Center Negation System Communication Mode java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2551427</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3PR</PreferredName>
          <Version>2.8</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.duke.cabig.c3pr.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000481</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.duke.cabig.c3pr.domain.StudyCoordinatingCenter.hostedMode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyCoordinatingCenter:hostedMode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1427">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3131188</PUBLICID>
    <LONGNAME>Person History Leukemogenic Agent Other Exposure Text</LONGNAME>
    <PREFERREDNAME>3131187v1.0:2181231v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text description of a potentially leukemogenic nonmedical agent to which a person has been exposed that is different from an identified set of agents/sources.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3131187</PublicId>
      <PreferredName>3123157v1.0:3131185v1.0</PreferredName>
      <PreferredDefinition>Person; a human being._The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events._Leading to or causing leukemia._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_Different than the one(s) previously specified or mentioned._Contact with infectious agents (bacteria or viruses) in a manner that promotes transmission and increases the likelihood of disease. (CDC)</PreferredDefinition>
      <LongName>Person History Leukemogenic Agent Other Exposure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3123157</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C54625:C90605:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Person History Leukemogenic Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54625</PREFERRED_NAME>
            <LONG_NAME>History</LONG_NAME>
            <CON_ID>2519676</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C90605</PREFERRED_NAME>
            <LONG_NAME>Leukemogenic</LONG_NAME>
            <CON_ID>3121507</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3131185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C17941</PreferredName>
        <Version>1</Version>
        <LongName>Other Exposure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17941</PREFERRED_NAME>
            <LONG_NAME>Exposure</LONG_NAME>
            <CON_ID>2203924</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Chemical Exposure</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Chemical Exposure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical laml</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787540</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>person_history_leukemogenic_agent_other_exposure_text</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1428">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3133946</PUBLICID>
    <LONGNAME>Dental Implant Gingiva Health Appearance Indicator</LONGNAME>
    <PREFERREDNAME>3124683v1.0:3133944v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the indicator related to the mucous membrane-covered tissue of the jaws that surround the bases of teeth appearance in the dental implant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3124683</PublicId>
      <PreferredName>2597304v1.0:3124681v1.0</PreferredName>
      <PreferredDefinition>information related to the mucous membrane-covered tissue of the jaws that surround the bases of teeth appearance in the dental implant.</PreferredDefinition>
      <LongName>Dental Implant Gingiva Health Appearance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2597304</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63718</PreferredName>
        <Version>1</Version>
        <LongName>Dental Implant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63718</PREFERRED_NAME>
            <LONG_NAME>Dental Implant</LONG_NAME>
            <CON_ID>2547874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3124681</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C32677:C25178:C25377</PreferredName>
        <Version>1</Version>
        <LongName>Gingiva Health Appearance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C32677</PREFERRED_NAME>
            <LONG_NAME>Gingiva</LONG_NAME>
            <CON_ID>2203989</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25178</PREFERRED_NAME>
            <LONG_NAME>Health</LONG_NAME>
            <CON_ID>2202325</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25377</PREFERRED_NAME>
            <LONG_NAME>Appearance</LONG_NAME>
            <CON_ID>2203581</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3133944</PublicId>
      <PreferredName>3133944v1.0</PreferredName>
      <PreferredDefinition>an event, entity or condition that typically characterizes a prescribed environment or situation for appearance of dental implant.</PreferredDefinition>
      <LongName>Dental Implant Appearance Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Minor</VALIDVALUE>
          <VALUEMEANING>Minor</VALUEMEANING>
          <MEANINGDESCRIPTION>Minor</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Major</VALIDVALUE>
          <VALUEMEANING>Major</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater or bigger in amount, extent, or size.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Gingival health around implant</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Gingival health around implant</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1429">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3139202</PUBLICID>
    <LONGNAME>Transplantation Facility Identifier Name</LONGNAME>
    <PREFERREDNAME>3139201v1.0:3014787v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the free-text field to specify the transplant center.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>SWOG CRF:Southwest Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3139201</PublicId>
      <PreferredName>3139199v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>information related to identifying the transplant center.</PreferredDefinition>
      <LongName>Transplantation Facility Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3139199</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15342:C62574</PreferredName>
        <Version>1</Version>
        <LongName>Transplantation Facility</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62574</PREFERRED_NAME>
            <LONG_NAME>Facility</LONG_NAME>
            <CON_ID>2542035</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3014787</PublicId>
      <PreferredName>3014787v1.0</PreferredName>
      <PreferredDefinition>the free-text field to specify the name related to a geographic location.</PreferredDefinition>
      <LongName>Geographic Location Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Which approved Transplant Cen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Which approved Transplant Center will be used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Allogeneic Transplant Center</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Autologous Transplant Center</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1430">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3139260</PUBLICID>
    <LONGNAME>Speech Stutter Assessment Description Text</LONGNAME>
    <PREFERREDNAME>STUTTER_ASSE_DESC_T</PREFERREDNAME>
    <PREFERREDDEFINITION>Speech; the exchange of spoken words._A disturbance in the normal fluency and time patterning of speech that is inappropriate for the individual&#39;s age. This disturbance is characterized by frequent repetitions or prolongations of sounds or syllables. Various other types of speech dysfluencies may also be involved including interjections, broken words, audible or silent blocking, circumlocutions, words produced with an excess of physical tension, and monosyllabic whole word repetitions. Stuttering may occur as a developmental condition in childhood or as an acquired disorder which may be associated with BRAIN INFARCTIONS and other BRAIN DISEASES. (From DSM-IV, 1994)_The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3139259</PublicId>
      <PreferredName>STUTTER</PreferredName>
      <PreferredDefinition>Speech; the exchange of spoken words._A disturbance in the normal fluency and time patterning of speech that is inappropriate for the individual&#39;s age. This disturbance is characterized by frequent repetitions or prolongations of sounds or syllables. Various other types of speech dysfluencies may also be involved including interjections, broken words, audible or silent blocking, circumlocutions, words produced with an excess of physical tension, and monosyllabic whole word repetitions. Stuttering may occur as a developmental condition in childhood or as an acquired disorder which may be associated with BRAIN INFARCTIONS and other BRAIN DISEASES. (From DSM-IV, 1994)</PreferredDefinition>
      <LongName>Speech Stutter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187661</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Speech</PreferredName>
        <Version>1</Version>
        <LongName>Speech</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38025</PREFERRED_NAME>
            <LONG_NAME>Speech</LONG_NAME>
            <CON_ID>2202857</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3139257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C35043</PreferredName>
        <Version>1</Version>
        <LongName>Stutter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35043</PREFERRED_NAME>
            <LONG_NAME>Stutter</LONG_NAME>
            <CON_ID>3139256</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>This measure assesses the sev</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>This measure assesses the severity of the respondent&#39;s stuttering.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Speech and Hearing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1431">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3139289</PUBLICID>
    <LONGNAME>Personal Medical History Hearing Loss Assessment Description Text</LONGNAME>
    <PREFERREDNAME>3139288v1.0:2954078v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.:A partial or complete loss of hearing in one or both ears. It is classified as conductive, sensory, or central._The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3139288</PublicId>
      <PreferredName>2431097v1.00:3139283v1.00</PreferredName>
      <PreferredDefinition>A record of a patient&#39;s background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.:A partial or complete loss of hearing in one or both ears. It is classified as conductive, sensory, or central.</PreferredDefinition>
      <LongName>Personal Medical History Hearing Loss</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2431097</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3139283</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C35731</PreferredName>
        <Version>1</Version>
        <LongName>Hearing Loss</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35731</PREFERRED_NAME>
            <LONG_NAME>Hearing Loss</LONG_NAME>
            <CON_ID>3057334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>This measure is a questionnai</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>This measure is a questionnaire to assess risk factors related to hearing loss.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Speech and Hearing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3009622</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1432">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3143551</PUBLICID>
    <LONGNAME>Chest Wall Malignant Neoplasm Invasion Skin Mastectomy Present Longest Dimension Value</LONGNAME>
    <PREFERREDNAME>3143319v1.0:3143406v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the measured or computed greater length of two measurements, especially length or width or height of a tumor composed of atypical neoplastic, often pleomorphic cells invading the skin situated on either side of the chest following surgery to remove the breast (or as much of the breast tissue as possible).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3143319</PublicId>
      <PreferredName>3143316v1.0:3143317v1.0</PreferredName>
      <PreferredDefinition>information related to the presence of a tumor composed of atypical neoplastic, often pleomorphic cells invading the skin situated on either side of the chest following surgery to remove the breast (or as much of the breast tissue as possible).</PreferredDefinition>
      <LongName>Chest Wall Malignant Neoplasm Invasion Skin Mastectomy Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3143316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62484</PreferredName>
        <Version>1</Version>
        <LongName>Chest Wall</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62484</PREFERRED_NAME>
            <LONG_NAME>Chest Wall</LONG_NAME>
            <CON_ID>2516459</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3143317</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3143317v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Invasion Skin Mastectomy Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75004</PREFERRED_NAME>
            <LONG_NAME>Invasion</LONG_NAME>
            <CON_ID>2769688</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12470</PREFERRED_NAME>
            <LONG_NAME>Skin</LONG_NAME>
            <CON_ID>2202821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15277</PREFERRED_NAME>
            <LONG_NAME>Mastectomy</LONG_NAME>
            <CON_ID>2204820</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3143406</PublicId>
      <PreferredName>3143406v1.0</PreferredName>
      <PreferredDefinition>the measured or computed greater length of two measurements, especially length or width or height.</PreferredDefinition>
      <LongName>Longest Dimension Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat>99.9</DisplayFormat>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3143405</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C25483:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Longest Dimension Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Longest dimension of skin inv</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Longest dimension of skin invasion</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1433">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3161944</PUBLICID>
    <LONGNAME>Patient Self-Report Tooth Spontaneous Pain Type</LONGNAME>
    <PREFERREDNAME>3161940v1.0:3161941v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Subjective reports made by the patient_is an organ, the organ parts of which primarily consist of dentine and dental enamel; together with other teeth it constitutes a subdivision of the facial skeleton. Example(s): incisor, molar._Happening or arising without apparent external cause._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3161940</PublicId>
      <PreferredName>3161938v1.0:3115841v1.0</PreferredName>
      <PreferredDefinition>Subjective reports made by the patient_is an organ, the organ parts of which primarily consist of dentine and dental enamel; together with other teeth it constitutes a subdivision of the facial skeleton. Example(s): incisor, molar._Happening or arising without apparent external cause._The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.</PreferredDefinition>
      <LongName>Patient Self-Report Tooth Spontaneous Pain</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3161938</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C12506</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Tooth</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3115841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48307:C3303</PreferredName>
        <Version>1</Version>
        <LongName>Spontaneous Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48307</PREFERRED_NAME>
            <LONG_NAME>Spontaneous</LONG_NAME>
            <CON_ID>2437694</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3161941</PublicId>
      <PreferredName>3161941v1.0</PreferredName>
      <PreferredDefinition>The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Tooth Pain Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3134649</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Pain Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Throbbing</VALIDVALUE>
          <VALUEMEANING>Throbbing</VALUEMEANING>
          <MEANINGDESCRIPTION>Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; throbbing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C100317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2582445</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sharp</VALIDVALUE>
          <VALUEMEANING>Sharp</VALUEMEANING>
          <MEANINGDESCRIPTION>Sharp</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dull</VALIDVALUE>
          <VALUEMEANING>Dull</VALUEMEANING>
          <MEANINGDESCRIPTION>Dull</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-11-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3161943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the study tooth exhibiting</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the study tooth exhibiting spontaneous pain(pain in the absence of stimuli). If yes, Quality of pain:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1434">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3171222</PUBLICID>
    <LONGNAME>Single Agent Protocol Therapy Modified Type</LONGNAME>
    <PREFERREDNAME>2012878v3.0:2733847v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of reason related to a change or deviation from standard administration of one therapeutic agent (substance given to alter course of disease) from that described by documented procedures for a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2012878</PublicId>
      <PreferredName>SING_AGT_PROT_TX_MOD</PreferredName>
      <PreferredDefinition>related to a change or deviation from standard administration of one therapeutic agent (substance given to alter course of disease) from that described by documented procedures for a clinical trial.</PreferredDefinition>
      <LongName>Single Agent Protocol Therapy Modified</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2598274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48440:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Single Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48440</PREFERRED_NAME>
            <LONG_NAME>Single</LONG_NAME>
            <CON_ID>2413378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2598275</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42651:C15368:C25573</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Therapy Modified</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42651</PREFERRED_NAME>
            <LONG_NAME>Protocol</LONG_NAME>
            <CON_ID>2211236</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25573</PREFERRED_NAME>
            <LONG_NAME>Modified</LONG_NAME>
            <CON_ID>2203849</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2733847</PublicId>
      <PreferredName>TX_CUR_CRSE_DXD_TP</PreferredName>
      <PreferredDefinition>the type of reason the current course or cycle of treatment was discontinued or held.</PreferredDefinition>
      <LongName>Therapy Current Course Discontinued Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other nonhematologic adverse events</VALIDVALUE>
          <VALUEMEANING>Other nonhematologic adverse events</VALUEMEANING>
          <MEANINGDESCRIPTION>Other nonhematologic adverse events</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2733839</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ocular/visual</VALIDVALUE>
          <VALUEMEANING>OCULAR/VISUAL</VALUEMEANING>
          <MEANINGDESCRIPTION>OCULAR/VISUAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561541</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Metabolic/laboratory</VALIDVALUE>
          <VALUEMEANING>METABOLIC/LABORATORY</VALUEMEANING>
          <MEANINGDESCRIPTION>METABOLIC/LABORATORY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mucositis/stomatitis</VALIDVALUE>
          <VALUEMEANING>Mucositis/stomatitis</VALUEMEANING>
          <MEANINGDESCRIPTION>Mucositis/stomatitis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2733840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diarrhea</VALIDVALUE>
          <VALUEMEANING>diarrhea</VALUEMEANING>
          <MEANINGDESCRIPTION>A condition of frequent and watery bowel movements.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2987</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568499</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematologic</VALIDVALUE>
          <VALUEMEANING>Hematologic System</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to or related to the blood and blood-forming organs.: The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12909, C62780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pain</VALIDVALUE>
          <VALUEMEANING>Pain</VALUEMEANING>
          <MEANINGDESCRIPTION>An unpleasant sensation induced by noxious stimuli and generally received by specialized nerve endings.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3303</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thromboembolic event (Venous)</VALIDVALUE>
          <VALUEMEANING>Thromboembolic event (Venous)</VALUEMEANING>
          <MEANINGDESCRIPTION>Thromboembolic event (Venous)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hypertension</VALIDVALUE>
          <VALUEMEANING>Hypertension</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13785</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dyspnea</VALIDVALUE>
          <VALUEMEANING>Dyspnea</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by an uncomfortable sensation of difficulty breathing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13368</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchopulmonary hemorrhage</VALIDVALUE>
          <VALUEMEANING>Bronchopulmonary hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118310</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proteinuria</VALIDVALUE>
          <VALUEMEANING>Proteinuria</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13008</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3122589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intracranial hemorrhage</VALIDVALUE>
          <VALUEMEANING>Intracranial hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by bleeding from the cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Platelet count decreased</VALIDVALUE>
          <VALUEMEANING>Platelet count decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12207</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123784</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutrophil count decreased</VALIDVALUE>
          <VALUEMEANING>Neutrophil count decreased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12198</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3117934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood bilirubin increased</VALIDVALUE>
          <VALUEMEANING>Blood bilirubin increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12096</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspartate aminotransferase increased (AST)</VALIDVALUE>
          <VALUEMEANING>Aspartate aminotransferase increased (AST)</VALUEMEANING>
          <MEANINGDESCRIPTION>Aspartate aminotransferase increased (AST)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alanine aminotranserase increased (ALT)</VALIDVALUE>
          <VALUEMEANING>Alanine aminotranserase increased (ALT)</VALUEMEANING>
          <MEANINGDESCRIPTION>Alanine aminotranserase increased (ALT)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alkaline phosphatase increased</VALIDVALUE>
          <VALUEMEANING>Alkaline phosphatase increased</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3117896</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound dehiscence</VALIDVALUE>
          <VALUEMEANING>Wound dehiscence</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of separation of the approximated margins of a surgical wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12063</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118092</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Wound complication</VALIDVALUE>
          <VALUEMEANING>Wound complication</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of development of a new problem at the site of an existing wound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E12057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biliary, esophageal, gastric, large intestinal, small intestinal anastomotic leak</VALIDVALUE>
          <VALUEMEANING>Biliary, esophageal, gastric, large intestinal, small intestinal anastomotic leak</VALUEMEANING>
          <MEANINGDESCRIPTION>Biliary, esophageal, gastric, large intestinal, small intestinal anastomotic leak</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epistaxis, esophageal, gastric, lower gastrointestinal, intra-abdominal and retroperitoneal hemorrhage</VALIDVALUE>
          <VALUEMEANING>Epistaxis, esophageal, gastric, lower gastrointestinal, intra-abdominal and retroperitoneal hemorrhage</VALUEMEANING>
          <MEANINGDESCRIPTION>Epistaxis, esophageal, gastric, lower gastrointestinal, intra-abdominal and retroperitoneal hemorrhage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Esophageal, gastric, colonic, and small intestinal obstruction</VALIDVALUE>
          <VALUEMEANING>Esophageal, gastric, colonic, and small intestinal obstruction</VALUEMEANING>
          <MEANINGDESCRIPTION>Esophageal, gastric, colonic, and small intestinal obstruction</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vomiting</VALIDVALUE>
          <VALUEMEANING>Vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E11068</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mucositis oral</VALIDVALUE>
          <VALUEMEANING>Mucositis oral</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by inflammation of the oral mucosal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E10872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3117559</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Febrile neutropenia</VALIDVALUE>
          <VALUEMEANING>Febrile neutropenia</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by a decrease in neutrophils associated with fever.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E10033</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3117323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palmar-plantar erythrodysesthesia syndrome</VALIDVALUE>
          <VALUEMEANING>Palmar-plantar erythrodysesthesia syndrome</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3118386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cough</VALIDVALUE>
          <VALUEMEANING>Cough</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>E13364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>CTCAE</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paresthesias/dysethesias</VALIDVALUE>
          <VALUEMEANING>Paresthesias/dysethesias</VALUEMEANING>
          <MEANINGDESCRIPTION>Paresthesias/dysethesias</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-12-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neurologic</VALIDVALUE>
          <VALUEMEANING>Neurologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Neurologic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blood/bone marrow</VALIDVALUE>
          <VALUEMEANING>BLOOD/BONE MARROW</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL324677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561526</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason Modified</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason Modified</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1435">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3171537</PUBLICID>
    <LONGNAME>Standardize Assay Condition Minimize Variance Assessment Description Text</LONGNAME>
    <PREFERREDNAME>STD_AS_CND_MN_VR_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The text used to describe who the assay conditions are standardized to minimize variance.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3170420</PublicId>
      <PreferredName>STD_AS_CND_MIN_VAR</PreferredName>
      <PreferredDefinition>The standardization of assay conditions to minimize variance.</PreferredDefinition>
      <LongName>Standardize Assay Condition Minimize Variance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3170417</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44275:C16341:C25457</PreferredName>
        <Version>1</Version>
        <LongName>Standard Bioassay Condition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44275</PREFERRED_NAME>
            <LONG_NAME>Standard</LONG_NAME>
            <CON_ID>2230968</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16341</PREFERRED_NAME>
            <LONG_NAME>Bioassay</LONG_NAME>
            <CON_ID>2202922</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3170418</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25570:C48918</PreferredName>
        <Version>1</Version>
        <LongName>Minimum Variance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25570</PREFERRED_NAME>
            <LONG_NAME>Minimum</LONG_NAME>
            <CON_ID>2206306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48918</PREFERRED_NAME>
            <LONG_NAME>Variance</LONG_NAME>
            <CON_ID>2423424</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2954078</PublicId>
      <PreferredName>ASSE_DESC_TEXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._A written or verbal account, representation, statement, or explanation of something._The words of something written.</PreferredDefinition>
      <LongName>Assessment Description Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2954077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0679207:C25365:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Description Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0679207</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2204079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How were assay conditions sta</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How were assay conditions standardized to minimize variance?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1436">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3171578</PUBLICID>
    <LONGNAME>Alcohol Use History Prior Last Year Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>ALCHL_HIST_B_LST_YR</PREFERREDNAME>
    <PREFERREDDEFINITION>Past experience with alcoholic beverage consumption prior to last year.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3171569</PublicId>
      <PreferredName>ALCHL_HIST_B_LST_YR</PreferredName>
      <PreferredDefinition>Past experience with alcoholic beverage consumption prior to last year.</PreferredDefinition>
      <LongName>Alcohol Use History Prior Last Year</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3171567</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81229</PreferredName>
        <Version>1</Version>
        <LongName>Alcohol Use History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81229</PREFERRED_NAME>
            <LONG_NAME>Alcohol Use History</LONG_NAME>
            <CON_ID>2958267</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3170077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C25551:C29848</PreferredName>
        <Version>1</Version>
        <LongName>Prior Last Year</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25551</PREFERRED_NAME>
            <LONG_NAME>Last</LONG_NAME>
            <CON_ID>2206286</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018691</PublicId>
      <PreferredName>YES_NO_U_IND</PreferredName>
      <PreferredDefinition>Text terms to determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Past consumption of alcohol b</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Past consumption of alcohol but NOT in last year?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NINDS CDE Project</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>NINDS CDE Project</DocumentText>
        <URL>http://www.commondataelements.ninds.nih.gov/</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Participant/Subject History and Family History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Behavioral History at Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3145522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6272292</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NINDS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General Health History</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000274</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1437">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3173111</PUBLICID>
    <LONGNAME>Therapeutic Procedure First Course Identifier Number java.lang.Long</LONGNAME>
    <PREFERREDNAME>3173073v1.0:2178534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Preceding all others in time or space or degree.:A period of protocol-prescribed activity or intervention._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.:A numeral or string of numerals expressing value, quantity, or identification._Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3173073</PublicId>
      <PreferredName>2691043v1.0:3173044v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Preceding all others in time or space or degree.:A period of protocol-prescribed activity or intervention._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.:A numeral or string of numerals expressing value, quantity, or identification.</PreferredDefinition>
      <LongName>Therapeutic Procedure First Course Identifier Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2691043</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25509:C25379</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure First Course</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25379</PREFERRED_NAME>
            <LONG_NAME>Course</LONG_NAME>
            <CON_ID>2202898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3173044</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Identifier Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178534</PublicId>
      <PreferredName>java.lang.Long</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is a long integer (64-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Long</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Long</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Therapeutic Procedure First Course Identifier Number java.lang.Long does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Therapeutic Procedure First Course Identifier Number java.lang.Long does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3173038</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>gridTCR</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.tmu.cabig.TaiwanCancerRegistry.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3173039</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FirstCourseTreatment:idno</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.tmu.cabig.TaiwanCancerRegistry.domain.FirstCourseTreatment.idno</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1438">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3173961</PUBLICID>
    <LONGNAME>Additional Embolization Or Ablation Therapeutic Procedure Post Recurrent Disease Performed Indicator</LONGNAME>
    <PREFERREDNAME>3173960v1.0:2182115v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify whether or not additional ablation or embolization was performed to treat the new tumor event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3173960</PublicId>
      <PreferredName>3173957v1.0:3173958v1.0</PreferredName>
      <PreferredDefinition>Added; extra. (from American Heritage Dictionary)_(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor._Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Removal of a part, pathway, or function by surgery, chemical destruction, electrocautery, or radiofrequency. (Taber&#39;s)_An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Post; occuring after._the return of a sign, symptom, or disease after a remission._Performed; carried out.</PreferredDefinition>
      <LongName>Additional Embolization Or Ablation Therapeutic Procedure Post Recurrent Disease Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3173957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3173957v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Additional Embolization Therapy Or Ablation Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15230</PREFERRED_NAME>
            <LONG_NAME>Embolization Therapy</LONG_NAME>
            <CON_ID>2541727</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20985</PREFERRED_NAME>
            <LONG_NAME>Ablation Therapy</LONG_NAME>
            <CON_ID>2202276</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3173958</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C38155:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Post Recurrent Disease Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Additional Treatment of New T</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Additional Treatment of New Tumor Event Ablation/Embolization Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TCGA Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>If yes, complete ablation/embolization therapy supplemental form</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical lihc </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>additional_embolization_or_ablation_therapeutic_procedure_post_recurrent_disease_performed_indicator</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>adjacent_hepatic_tissue_inflammation_extent_type</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1439">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175803</PUBLICID>
    <LONGNAME>Biological Entity Or Sex Gender Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3174696v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the physical or societal properties by which male is distinguished from female. NOTE(S): For humans, identification of sex is usually based upon self-report and may come from a form, questionnaire, interview, etc.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174696</PublicId>
      <PreferredName>2867707v1.0:3174519v1.0</PreferredName>
      <PreferredDefinition>Pertaining to biology or to life and living things.:An independently existing thing (living or nonliving)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.:The assemblage of properties that distinguish people on the basis of their societal roles.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Biological Entity Or Sex Gender Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867707</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28226:C51070</PreferredName>
        <Version>1</Version>
        <LongName>Biological Entity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28226</PREFERRED_NAME>
            <LONG_NAME>Biological</LONG_NAME>
            <CON_ID>2206378</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174519</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37998:C28421:C17357:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Or Sex Gender Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28421</PREFERRED_NAME>
            <LONG_NAME>Sex</LONG_NAME>
            <CON_ID>2403944</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17357</PREFERRED_NAME>
            <LONG_NAME>Gender</LONG_NAME>
            <CON_ID>2202402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biological Entity Or Sex Gender Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biological Entity Or Sex Gender Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.CommonSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.BiologicEntity.administrativeGenderCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BiologicEntity:administrativeGenderCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.CommonSubDomain.BiologicEntity.administrativeGenderCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:C3PRv2.9</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ParticipantSex.codeSystemName</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ParticipantSex.displayName</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Subject.gender</AlternateName>
        <AlternateNameType>Map:PSCv2.6</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ParticipantSex.codeSystemVersion</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:C3PR</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organism.sex</AlternateName>
        <AlternateNameType>Map:AE</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Animal.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:HL7SP</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ParticipantSex.code</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Investigator.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Patient Module - Patient&#39;s Sex (0010,0040)</AlternateName>
        <AlternateNameType>Map:DICOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person.sex</AlternateName>
        <AlternateNameType>Map:AIM v4 rv48</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SECTION III DEMOGRAPHIC INFORMATION - SEX</AlternateName>
        <AlternateNameType>Map:SEER 2015</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 3171628:Physical Description of Individuals.Person Gender:</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Patient Level Attributes for the Patient Root Query/Retrieve Information Model - Patient&#39;s Sex (0010,0040)</AlternateName>
        <AlternateNameType>Map:DICOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2180389:Physical Description of Individuals.Donor Gender</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person.sexCode</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BiologicEntity.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BiologicEntity.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:CDMHv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2200604:Recipient Identification.Gender</AlternateName>
        <AlternateNameType>Map:HCTv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Provider.provider_sex</AlternateName>
        <AlternateNameType>Map:PCORNetv4.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person.sexCode</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant.gender</AlternateName>
        <AlternateNameType>Map:caAERSv2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TID 1007 SubjectContext,Patient &gt; Subject Sex</AlternateName>
        <AlternateNameType>Map:DICOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PROVIDER.gender_concept_id</AlternateName>
        <AlternateNameType>Map:OMOPv5.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2200604v3.0:  Person Gender Text Type</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ParticipantSex.codeSystem</AlternateName>
        <AlternateNameType>Map:LabViewer2.2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Animal.administrativeGenderCode (in IndividualCaseSafetyReport)</AlternateName>
        <AlternateNameType>Map:ICSRr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:CTOM</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Participant.gender</AlternateName>
        <AlternateNameType>Map:PSC</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Person2.administrativeGenderCode (in IndividualCaseSafetyReport)</AlternateName>
        <AlternateNameType>Map:ICSRr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BiologicEntity.administrativeGenderCode</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Subject.Subject Sex</AlternateName>
        <AlternateNameType>Map:CDISCLabv1.0.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Subject.Subject Sex Code List ID</AlternateName>
        <AlternateNameType>Map:CDISCLabv1.0.1</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1440">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175835</PUBLICID>
    <LONGNAME>Plan Options Relationship Delay Quantity ISO21090.URG.PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>3174725v1.0:3152486v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A quantity of time that should elapse between when an activity is ready for execution and the actual beginning of the execution. EXAMPLE(S): Take a blood sample 15 minutes after administration of study drug or measure blood glucose 2 hours after each meal, the pauseQuantity would be 15 minutes and 2 hours respectively. NOTE(S): The pauseQuantity defines the amount of time between two points in time: (1) the point when all preceding steps (in sequence) and preconditions of an activity have been completed, and (2) the actual start of the activity. The completion of all pre-conditions and preceding steps (based on sequence number) indicates that an activity is &quot;ready for execution&quot; according to the definition above. The pauseQuantity counter or timeclock starts then, and when the full amount of time is reached, the activity begins. A pauseQuantity with a negative value means that the activity starts some amount of time prior to the estimated time that the activity is &quot;ready for execution&quot;, i.e. prior to the estimated time that the pre-conditions and preceding steps will be completed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174725</PublicId>
      <PreferredName>3174172v1.0:2867895v1.0</PreferredName>
      <PreferredDefinition>To devise, contrive, or formed in design.:Alternative choices or actions.:A state of connectedness between people, objects, or events; to be associated or connected with something._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.:How much there is of something that you can measure; the total amount or number.</PreferredDefinition>
      <LongName>Plan Options Relationship Delay Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174172</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25619:C25374:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Plan Options Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25374</PREFERRED_NAME>
            <LONG_NAME>Options</LONG_NAME>
            <CON_ID>2203938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867895</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25476:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Delay Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25476</PREFERRED_NAME>
            <LONG_NAME>Delay</LONG_NAME>
            <CON_ID>2203898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152486</PublicId>
      <PreferredName>3152486v1.0</PreferredName>
      <PreferredDefinition>Constrains URG so that the values are PQ.TIME.</PreferredDefinition>
      <LongName>ISO21090.URG.PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090URGv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Plan Options Relationship Delay Quantity ISO21090.URG.PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Plan Options Relationship Delay Quantity ISO21090.URG.PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PlannedOptionRelationship.pauseQuantity</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PlannedOptionRelationship:pauseQuantity</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1441">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175856</PUBLICID>
    <LONGNAME>Reuse Template Observation Outcome Outcome ISO21090.ANY.v1.0</LONGNAME>
    <PREFERREDNAME>3174747v1.0:2846959v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Data or information that is determined by an act of observation. EXAMPLE(S): The result of a lab test, physical finding, self-reported symptom; The adverse event term code.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174747</PublicId>
      <PreferredName>3174182v1.0:2224045v1.0</PreferredName>
      <PreferredDefinition>To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:Watching something and taking note of what happens.:The result of an action._A phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Reuse Template Observation Outcome Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174182</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C79891:C45677:C25598:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Reuse Template Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2224045</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200</PreferredName>
        <Version>1</Version>
        <LongName>Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2846959</PublicId>
      <PreferredName>2846959v1.0</PreferredName>
      <PreferredDefinition>Defines the basic properties of every data value.</PreferredDefinition>
      <LongName>ISO21090.ANY.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090ANYv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Reuse Template Observation Outcome Outcome ISO21090.ANY.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Reuse Template Observation Outcome Outcome ISO21090.ANY.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedObservationResult.result</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedObservationResult:result</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1442">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175891</PUBLICID>
    <LONGNAME>Study Legal Or Preclinical Sponsor Clinical Study Sponsor Primary Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3174782v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specifies whether this is the main or principal study legal sponsor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174782</PublicId>
      <PreferredName>3174194v1.0:2231647v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:To meet the requirements under law; not in violation of law or anything related to the law.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Refers to in vitro testing or in vivo animal testing before clinical trials in humans are to be carried out.:A person or organization that supports or champions something.:An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Occurring first in time or sequence; original; of greatest rank or importance or value.:An indicator that can be set or unset in order to signal whether a particular condition is true. The indicator usually takes the form of a single binary digit, or bit (either 0 or 1). (from Dictionary of Computers)</PreferredDefinition>
      <LongName>Study Legal Or Preclinical Sponsor Clinical Study Sponsor Primary Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174194</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174194v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Study Legal Or Preclinical Sponsor Clinical Study Sponsor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54074</PREFERRED_NAME>
            <LONG_NAME>Legal</LONG_NAME>
            <CON_ID>2493182</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48674</PREFERRED_NAME>
            <LONG_NAME>Preclinical</LONG_NAME>
            <CON_ID>2867563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48355</PREFERRED_NAME>
            <LONG_NAME>Sponsor</LONG_NAME>
            <CON_ID>2448403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70793</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Sponsor</LONG_NAME>
            <CON_ID>2715021</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2231647</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Primary Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Legal Or Preclinical Sponsor Clinical Study Sponsor Primary Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Legal Or Preclinical Sponsor Clinical Study Sponsor Primary Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyLegalSponsor.primaryIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyLegalSponsor:primaryIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.StudyLegalSponsor.primaryIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Primary Sponsor</AlternateName>
        <AlternateNameType>Map:WHO</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Sponsor</AlternateName>
        <AlternateNameType>Map:CTRR</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyLegalSponsor.primaryIndicator</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Secondary Sponsor</AlternateName>
        <AlternateNameType>Map:WHO</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1443">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175986</PUBLICID>
    <LONGNAME>Submission Document Collection Group Received Date and Time ISO21090.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>2868305v1.0:3148148v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date (and time) on which the first submission unit is received by the regulatory authority.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2868305</PublicId>
      <PreferredName>2867699v1.0:2388832v1.0</PreferredName>
      <PreferredDefinition>Something submitted for the judgment or consideration of others.:An organized collection of records that describe a particular body of data.:The act of gathering things together; having been brought together in one place.:Any number of entities (members) considered as a unit._To have taken, accepted, or gotten something offered.:An expression of both date and time that an event has happened or will happened.</PreferredDefinition>
      <LongName>Submission Document Collection Group Received Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25694:C19498:C25453:C43359</PreferredName>
        <Version>1</Version>
        <LongName>Submission Document Collection Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25694</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2202488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19498</PREFERRED_NAME>
            <LONG_NAME>Document</LONG_NAME>
            <CON_ID>2223216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43359</PREFERRED_NAME>
            <LONG_NAME>Group</LONG_NAME>
            <CON_ID>2236516</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2388832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639:C37939</PreferredName>
        <Version>1</Version>
        <LongName>Received Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3148148</PublicId>
      <PreferredName>3148148v1.0</PreferredName>
      <PreferredDefinition>Constrains TS so that it&#39;s precision can not be more precise than seconds.</PreferredDefinition>
      <LongName>ISO21090.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSDTTIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Submission Document Collection Group Received Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Submission Document Collection Group Received Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.Submission.receiptDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submission:receiptDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain.Submission.receiptDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IEC Submission Date</AlternateName>
        <AlternateNameType>Map:CTR&amp;Rr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCA Submission Date</AlternateName>
        <AlternateNameType>Map:CTR&amp;Rr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submission.receiptDate</AlternateName>
        <AlternateNameType>Map:CTRRr3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Submission.receiptDate</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1444">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3175994</PUBLICID>
    <LONGNAME>Government Funding Research Resource Serial Number Text ISO21090.ST.SIMPLE.v1.0</LONGNAME>
    <PREFERREDNAME>3174877v1.0:3165771v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A character string that represents the six-digit number generally assigned sequentially to a funding mechanism within an institute, center, or division.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3174877</PublicId>
      <PreferredName>3174225v1.0:3174577v1.0</PreferredName>
      <PreferredDefinition>The political organization by which a state or nation is ruled.:A sum of money or other resources set aside for a specific purpose.:The funding, research facilities, and materials available for research_A unique identifier assigned to a member of a series of similar items.:The words of something written.</PreferredDefinition>
      <LongName>Government Funding Research Resource Serial Number Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174225</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78315:C17769:C15321</PreferredName>
        <Version>1</Version>
        <LongName>Government Funding Research Resource</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78315</PREFERRED_NAME>
            <LONG_NAME>Government</LONG_NAME>
            <CON_ID>2867550</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17769</PREFERRED_NAME>
            <LONG_NAME>Funding</LONG_NAME>
            <CON_ID>2514003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15321</PREFERRED_NAME>
            <LONG_NAME>Research Resource</LONG_NAME>
            <CON_ID>2867549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174577</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73518:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Serial Number Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73518</PREFERRED_NAME>
            <LONG_NAME>Serial Number</LONG_NAME>
            <CON_ID>2771050</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3165771</PublicId>
      <PreferredName>3165771v1.0</PreferredName>
      <PreferredDefinition>Constrains ST.NT so that it has no language.</PreferredDefinition>
      <LongName>ISO21090.ST.SIMPLE.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STSIMv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Government Funding Research Resource Serial Number Text ISO21090.ST.SIMPLE.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Government Funding Research Resource Serial Number Text ISO21090.ST.SIMPLE.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.GovernmentFunding.serialNumberText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GovernmentFunding:serialNumberText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.GovernmentFunding.serialNumberText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyResourcing.serialNumber</AlternateName>
        <AlternateNameType>Map:CTRPv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>[NIH Grant].Serial Number</AlternateName>
        <AlternateNameType>Map:HSDBv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyResourcing.serialNumber</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1445">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176783</PUBLICID>
    <LONGNAME>Notification Schedule Study Activity Comment ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3175297v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity that represents the communication of a message to a recipient that is anticipated to occur at some time in the future and has been assigned a time or date when that activity is to be performed. Additional description of the activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175297</PublicId>
      <PreferredName>3174244v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>Informing by words.:An ordered list of times at which things are planned to occur.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Notification Schedule Study Activity Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174244</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25297:C25211:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Notification Schedule Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Notification Schedule Study Activity Comment ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Notification Schedule Study Activity Comment ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ScheduledNotification.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ScheduledNotification:comment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.ScheduledNotification.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1446">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176881</PUBLICID>
    <LONGNAME>Negation Study Subject Administration, Management Performed Study Activity Variance Type Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175382v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed study level administrative activity that is independent of a study subject. EXAMPLE(S): IRB Approval, site enrollment, FDA audit. A coded value specifying the kind of variance. EXAMPLE(S): early / late occurrence of an act, higher / lower amount transferred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175382</PublicId>
      <PreferredName>2867640v1.0:3174589v1.0</PreferredName>
      <PreferredDefinition>An operation in which a term denies or inverts the meaning of another term or construction.:A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._A statistical computation dervied by using the expected value and averaging the squared distance of all viable values.:Something distinguishable as an identifiable class based on common qualities.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Negation Study Subject Administration, Management Performed Study Activity Variance Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867640</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867640v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Negation Study Subject Administration, Management Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41189</PREFERRED_NAME>
            <LONG_NAME>Study Subject</LONG_NAME>
            <CON_ID>2202706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174589</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48918:C25284:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Variance Type Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48918</PREFERRED_NAME>
            <LONG_NAME>Variance</LONG_NAME>
            <CON_ID>2423424</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Negation Study Subject Administration, Management Performed Study Activity Variance Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Negation Study Subject Administration, Management Performed Study Activity Variance Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedStudyAdministrativeActivity.varianceTypeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedStudyAdministrativeActivity:varianceTypeCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedStudyAdministrativeActivity.varianceTypeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1447">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176897</PUBLICID>
    <LONGNAME>Product Investigation Observation Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3175395v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed process of evaluating a product after it has been returned to the manufacturer or reprocessor. Specifies whether an activity did not occur. EXAMPLE(S): &quot;Y&quot; designates that the PerformedActivity is missed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175395</PublicId>
      <PreferredName>3174133v1.0:2867944v1.0</PreferredName>
      <PreferredDefinition>The end result of a manufacturing process; anything that is produced.:The act or process of a systematic and thorough examination; research, study; the process of inquiring into or following up, intended to develop facts.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._An operation in which a term denies or inverts the meaning of another term or construction.:An instance of something happening, such as an event or incident.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Product Investigation Observation Performed Study Activity Negation Occurrence Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174133</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174133v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Product Investigation Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41198</PREFERRED_NAME>
            <LONG_NAME>Investigation</LONG_NAME>
            <CON_ID>2469351</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867944</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25275:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Negation Occurrence Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Product Investigation Observation Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Product Investigation Observation Performed Study Activity Negation Occurrence Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedProductInvestigation.missedIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProductInvestigation:missedIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1448">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176990</PUBLICID>
    <LONGNAME>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Method Code ISO21090.DSET.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175487v1.0:2803321v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that identifies a characteristic or requirement intended to be applied to a potential study subject to determine whether they may participate in a study. EXAMPLE(S): Must be over the age of 18. A coded value specifying the technique that is used for the observation. EXAMPLE(S): Arterial puncture, sphygmomanometry (for blood pressure measurement); Global introspection, algorithm, bayesian (for Adverse Event causality); Estrogen Receptor Assay, Progesterone Receptor Assay, p53 Assay (for clinical result assay)</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175487</PublicId>
      <PreferredName>3174215v1.0:2839671v1.0</PreferredName>
      <PreferredDefinition>Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Method Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174215v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25370</PREFERRED_NAME>
            <LONG_NAME>Exclusion Criteria</LONG_NAME>
            <CON_ID>2203927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2839671</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Method Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803321</PublicId>
      <PreferredName>2803321v1.0</PreferredName>
      <PreferredDefinition>A collection containing unordered distinct/discrete values of the type CD.</PreferredDefinition>
      <LongName>ISO21090.DSET.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090DSETv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Method Code ISO21090.DSET.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Method Code ISO21090.DSET.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedExclusionCriterion.methodCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedExclusionCriterion:methodCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1449">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3176994</PUBLICID>
    <LONGNAME>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Duration ISO21090.PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>3175491v1.0:2848092v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that identifies a characteristic or requirement intended to be applied to a potential study subject to determine whether they may participate in a study. EXAMPLE(S): Must be over the age of 18. A quantity of time in which the observation result is held to be true. EXAMPLE(S): 2 months is the focalDuration for the question, &quot;Have you smoked in the last 2 months?&quot;</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175491</PublicId>
      <PreferredName>3174215v1.0:3174558v1.0</PreferredName>
      <PreferredDefinition>Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._Area of greatest concentration, attention, or activity; a central point or locus, especially of an infection.:The period of time during which something continues.</PreferredDefinition>
      <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174215v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25370</PREFERRED_NAME>
            <LONG_NAME>Exclusion Criteria</LONG_NAME>
            <CON_ID>2203927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174558</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25511:C25330</PreferredName>
        <Version>1</Version>
        <LongName>Foci Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25511</PREFERRED_NAME>
            <LONG_NAME>Focus</LONG_NAME>
            <CON_ID>2203817</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2848092</PublicId>
      <PreferredName>2848092v1.0</PreferredName>
      <PreferredDefinition>Constrains PQ to have units that describe a period of time.</PreferredDefinition>
      <LongName>ISO21090.PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090PQTIMEv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Reuse Template Study Activity Foci Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedExclusionCriterion.focalDuration</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedExclusionCriterion:focalDuration</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedExclusionCriterion.focalDuration</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1450">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177042</PUBLICID>
    <LONGNAME>Adverse Event Outcome Assessment Observation Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0</LONGNAME>
    <PREFERREDNAME>3175539v1.0:3148148v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A judgment of the final state of a person who experienced an adverse event, which takes place after the adverse event occurs. The date (and time) on which the status is assigned to the activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175539</PublicId>
      <PreferredName>3174129v1.0:2867759v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.  Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).:The result of an action.:The final result of a determination of the value, significance, or extent of.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._A condition or state at a particular time.:An expression of both date and time that an event has happened or will happen.</PreferredDefinition>
      <LongName>Adverse Event Outcome Assessment Observation Performed Study Activity Status Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174129</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174129v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Outcome Assessment Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867759</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688:C37939</PreferredName>
        <Version>1</Version>
        <LongName>Status Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3148148</PublicId>
      <PreferredName>3148148v1.0</PreferredName>
      <PreferredDefinition>Constrains TS so that it&#39;s precision can not be more precise than seconds.</PreferredDefinition>
      <LongName>ISO21090.TS.DATETIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSDTTIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Outcome Assessment Observation Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Outcome Assessment Observation Performed Study Activity Status Date and Time ISO21090.TS.DATETIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757152</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventOutcomeAssessment.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AdverseEventOutcomeAssessment:statusDate</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.AdverseEventSubDomain.AdverseEventOutcomeAssessment.statusDate</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1451">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177046</PUBLICID>
    <LONGNAME>Protocol Agent Transfer Reuse Template Study Activity Name Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175543v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An administrative activity defined at a global library level that is an action in which an authorized party at a designated study site dispenses or receives a study agent to/from a study subject, though as a defined activity, no actual study subject is identified. EXAMPLE(S): Dispensing a bottle of pills A coded value specifying the non-unique textual identifier for the activity. EXAMPLE(S): A surgical procedure might be described with CPT4 or SNOMED term. In a lab test, this coded value would be associated with a single analytic procedure. The code and text of an individual question on the eligibility checklist of a protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175543</PublicId>
      <PreferredName>3174212v1.0:2867793v1.0</PreferredName>
      <PreferredDefinition>A medical product, practice, or application that is tested in a clinical trial.:The act of conveying or transporting from one place to another.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._The words or language units by which a thing is known.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Protocol Agent Transfer Reuse Template Study Activity Name Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174212v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Agent Transfer Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41161</PREFERRED_NAME>
            <LONG_NAME>Protocol Agent</LONG_NAME>
            <CON_ID>2390873</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48167</PREFERRED_NAME>
            <LONG_NAME>Transfer</LONG_NAME>
            <CON_ID>2422624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867793</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Name Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Protocol Agent Transfer Reuse Template Study Activity Name Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Protocol Agent Transfer Reuse Template Study Activity Name Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedStudyAgentTransfer.nameCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedStudyAgentTransfer:nameCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedStudyAgentTransfer.nameCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1452">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177148</PUBLICID>
    <LONGNAME>Substance Administration Intervention or Procedure Performed Study Activity Target Anatomic Site Condition Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3175644v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action of applying, dispensing or otherwise giving medications or other substances to experimental units. EXAMPLE(S): An experimental unit who receives methotrexate as part of chemotherapy, radiation therapy. For a SubstanceAdministration, targetAnatomicSiteCode = &quot;coronary artery&quot;, approachAnatomicSiteCode = &quot;groin&quot;, routeOfAdministrationCode = &quot;intra-arterial&quot;. A coded value specifying the state of the target anatomic site. EXAMPLE(S): The subject&#39;s left arm was bruised where the IV was inserted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175644</PublicId>
      <PreferredName>3174249v1.0:2867758v1.0</PreferredName>
      <PreferredDefinition>A material with particular features.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._An object fixed as a goal or point of examination; something to point at; a destination.:Named locations of or within the body.:A state of being, such as a state of health.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Substance Administration Intervention or Procedure Performed Study Activity Target Anatomic Site Condition Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174249v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Substance Administration Intervention or Procedure Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45306</PREFERRED_NAME>
            <LONG_NAME>Substance</LONG_NAME>
            <CON_ID>2523396</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867758</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25702:C13717:C25457:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Target Anatomic Site Condition Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25702</PREFERRED_NAME>
            <LONG_NAME>Target</LONG_NAME>
            <CON_ID>2206261</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25457</PREFERRED_NAME>
            <LONG_NAME>Condition</LONG_NAME>
            <CON_ID>2202899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Substance Administration Intervention or Procedure Performed Study Activity Target Anatomic Site Condition Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Substance Administration Intervention or Procedure Performed Study Activity Target Anatomic Site Condition Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.PerformedSubstanceAdministration.targetAnatomicSiteConditionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedSubstanceAdministration:targetAnatomicSiteConditionCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedSubstanceAdministration.targetAnatomicSiteConditionCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1453">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177189</PUBLICID>
    <LONGNAME>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Repeat Frequency Ratio ISO21090.RTO.INT,PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>3175684v1.0:3152481v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that is an action of gathering samples that may be used for subsequent analysis. EXAMPLE(S): blood draw A ratio representing the number of occurrences of an activity within a given time period. EXAMPLE(S): Once per 12 hours; 2 times per day</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175684</PublicId>
      <PreferredName>3174208v1.0:3174538v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:The act of gathering things together; having been brought together in one place.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._Make or do or perform again.:The number of occurrences of something within a given time period.:Quotient of quantities of the same kind for different components within the same system.</PreferredDefinition>
      <LongName>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Repeat Frequency Ratio</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174208</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174208v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174538</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47886:C25515:C44256</PreferredName>
        <Version>1</Version>
        <LongName>Repeat Frequency Ratio</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3152481</PublicId>
      <PreferredName>3152481v1.0</PreferredName>
      <PreferredDefinition>Quantity quotient of a numerator of type INT divided by a denominator of type PQ.TIME.</PreferredDefinition>
      <LongName>ISO21090.RTO.INT,PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090RTOv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Repeat Frequency Ratio ISO21090.RTO.INT,PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Repeat Frequency Ratio ISO21090.RTO.INT,PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedSpecimenCollection.repeatFrequencyRatio</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedSpecimenCollection:repeatFrequencyRatio</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1454">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3177195</PUBLICID>
    <LONGNAME>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Identifier ISO21090.II.v1.0</LONGNAME>
    <PREFERREDNAME>3175690v1.0:2803193v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An activity defined at a global library level that is an action of gathering samples that may be used for subsequent analysis. EXAMPLE(S): blood draw A unique symbol that establishes identity of an activity. EXAMPLE(S): 12345 is the identifier for a substance administration</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3175690</PublicId>
      <PreferredName>3174208v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.:The act of gathering things together; having been brought together in one place.:An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174208</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3174208v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen Collection Intervention or Procedure Reuse Template Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803193</PublicId>
      <PreferredName>2803193v1.0</PreferredName>
      <PreferredDefinition>Identifier that uniquely identifies a thing or object.</PreferredDefinition>
      <LongName>ISO21090.II.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Identifier ISO21090.II.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biospecimen Collection Intervention or Procedure Reuse Template Study Activity Identifier ISO21090.II.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2714898</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.0.2</PreferredName>
          <Version>3.02</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>2867548</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.DefinedSpecimenCollection.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedSpecimenCollection:identifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedSpecimenCollection.identifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1455">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3182372</PUBLICID>
    <LONGNAME>Tooth Pain Percussion Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3120185v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator related to pain in tooth from a diagnostic test performed on a tooth by tapping on the crown with a dental instrument.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3120185</PublicId>
      <PreferredName>3119746v1.0:3120179v1.0</PreferredName>
      <PreferredDefinition>is an organ, the organ parts of which primarily consist of dentine and dental enamel; together with other teeth it constitutes a subdivision of the facial skeleton. Example(s): incisor, molar. The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings. A diagnostic test performed on a tooth by tapping on the crown with a dental instrument.</PreferredDefinition>
      <LongName>Tooth Pain Percussion</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3119746</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12506:C3303</PreferredName>
        <Version>1</Version>
        <LongName>Tooth Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3120179</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62298</PreferredName>
        <Version>1</Version>
        <LongName>Percussion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62298</PREFERRED_NAME>
            <LONG_NAME>Dental Percussion</LONG_NAME>
            <CON_ID>2509291</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is pain on percussion present?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is pain on percussion present?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4442461</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDCR CDEs with Retired VDs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CDEs for Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4442571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1456">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3187622</PUBLICID>
    <LONGNAME>Microwave Ablation Size Centimeter Value</LONGNAME>
    <PREFERREDNAME>MCW_ABL_SZ_CM_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value representing the size of the area ablated in the liver, measured in centimeters.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3187619</PublicId>
      <PreferredName>MCW_ABL_SZ</PreferredName>
      <PreferredDefinition>A type of treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs._Removal of a part, pathway, or function by surgery, chemical destruction, electrocautery, or radiofrequency. (Taber&#39;s)_Size; the physical magnitude of something.</PreferredDefinition>
      <LongName>Microwave Ablation Size</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3187579</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93351</PreferredName>
        <Version>1</Version>
        <LongName>Microwave Thermotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93351</PREFERRED_NAME>
            <LONG_NAME>Microwave Thermotherapy</LONG_NAME>
            <CON_ID>3187578</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3187617</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20985:C25681</PreferredName>
        <Version>1</Version>
        <LongName>Ablation Size</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20985</PREFERRED_NAME>
            <LONG_NAME>Ablation Therapy</LONG_NAME>
            <CON_ID>2202276</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25681</PREFERRED_NAME>
            <LONG_NAME>Size</LONG_NAME>
            <CON_ID>2203799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3187621</PublicId>
      <PreferredName>MSRMT_CM_VAL</PreferredName>
      <PreferredDefinition>Measurement; the size or magnitude of something._A centimeter is a basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Measurement Centimeter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008546</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ORGAN_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Organ Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>cm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3187620</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209:C49668:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Measurement Centimeter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49668</PREFERRED_NAME>
            <LONG_NAME>Centimeter</LONG_NAME>
            <CON_ID>2475085</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Ablation size (cm)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Ablation size (cm)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph Hospital</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813054</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>St. Joseph New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2813056</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1457">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3188372</PUBLICID>
    <LONGNAME>Patient Self-Report Dry Skin Assessment Status</LONGNAME>
    <PREFERREDNAME>3188352v1.0:2018076v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the condition of the severity related to subjective reports made by the patient regarding pores that are generally fine with a papery thin texture that feels dry to the touch.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3188352</PublicId>
      <PreferredName>3188309v1.0:3188350v1.0</PreferredName>
      <PreferredDefinition>information related to subjective reports made by the patient regarding pores that are generally fine with a papery thin texture that feels dry to the touch.</PreferredDefinition>
      <LongName>Patient Self-Report Dry Skin Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3188309</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3188350</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74592:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Dry Skin Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74592</PREFERRED_NAME>
            <LONG_NAME>Dry Skin</LONG_NAME>
            <CON_ID>2919161</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018076</PublicId>
      <PreferredName>QOL_SEVER_STAT</PreferredName>
      <PreferredDefinition>the condition of the severity of QOL question.</PreferredDefinition>
      <LongName>QOL Severity Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>none</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>severe</VALIDVALUE>
          <VALUEMEANING>SEVERE</VALUEMEANING>
          <MEANINGDESCRIPTION>Toxicity grade- SEVERE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Mild</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very severe</VALIDVALUE>
          <VALUEMEANING>Very severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Very severe</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the SEVERITY of your</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the SEVERITY of your DRY SKIN at its WORST</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3188352v1.0:2018076v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1458">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3188482</PUBLICID>
    <LONGNAME>CyberKnife And IMRT Therapy Actual Dose Value</LONGNAME>
    <PREFERREDNAME>CK_IMRT_ACT_DOSE_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value representing the total planned dose for a Cyberknife plus IMRT treatment, expressed as a number of Gy (gray) units.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3188475</PublicId>
      <PreferredName>CK_IMRT_ACT_DOSE</PreferredName>
      <PreferredDefinition>A proprietary, robotic radiosurgery system designed to deliver precise beams of high does radiation to tumors with extreme accuracy._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An advanced form of 3-Dimensional Conformal Radiation Therapy_Existing in fact; real._The amount of medicine taken, or radiation given, at one time.</PreferredDefinition>
      <LongName>CyberKnife And IMRT Therapy Actual Dose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3188468</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95484:C37912:C16135:C15368</PreferredName>
        <Version>1</Version>
        <LongName>CyberKnife And IMRT Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95484</PREFERRED_NAME>
            <LONG_NAME>CyberKnife</LONG_NAME>
            <CON_ID>3187682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16135</PREFERRED_NAME>
            <LONG_NAME>Intensity-Modulated Radiation Therapy</LONG_NAME>
            <CON_ID>2202663</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3188473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25274:C25488</PreferredName>
        <Version>1</Version>
        <LongName>Actual Dose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25274</PREFERRED_NAME>
            <LONG_NAME>Actual</LONG_NAME>
            <CON_ID>2206152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3188477</PublicId>
      <PreferredName>CK_IMRT_DOSE_VAL</PreferredName>
      <PreferredDefinition>A proprietary, robotic radiosurgery system designed to deliver precise beams of high does radiation to tumors with extreme accuracy._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An advanced form of 3-Dimensional Conformal Radiation Therapy_The amount of medicine taken, or radiation given, at one time._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>CyberKnife And IMRT Dose Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>Gray</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3188476</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3188476v1.0</PreferredName>
        <Version>1</Version>
        <LongName>CyberKnife And IMRT Dose Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95484</PREFERRED_NAME>
            <LONG_NAME>CyberKnife</LONG_NAME>
            <CON_ID>3187682</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16135</PREFERRED_NAME>
            <LONG_NAME>Intensity-Modulated Radiation Therapy</LONG_NAME>
            <CON_ID>2202663</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Gray - Actual</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Gray - Actual</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1459">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3188491</PUBLICID>
    <LONGNAME>Patient Self-Report Sadness Assessment Status</LONGNAME>
    <PREFERREDNAME>3188324v1.0:2018076v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the condition of the severity related to subjective reports made by the patient regarding feelings of grief or unhappiness.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3188324</PublicId>
      <PreferredName>3188309v1.0:3188322v1.0</PreferredName>
      <PreferredDefinition>information related to subjective reports made by the patient regarding feelings of grief or unhappiness.</PreferredDefinition>
      <LongName>Patient Self-Report Sadness Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3188309</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3188322</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74534:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Sadness Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74534</PREFERRED_NAME>
            <LONG_NAME>Sadness</LONG_NAME>
            <CON_ID>2760587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018076</PublicId>
      <PreferredName>QOL_SEVER_STAT</PreferredName>
      <PreferredDefinition>the condition of the severity of QOL question.</PreferredDefinition>
      <LongName>QOL Severity Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>none</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>severe</VALIDVALUE>
          <VALUEMEANING>SEVERE</VALUEMEANING>
          <MEANINGDESCRIPTION>Toxicity grade- SEVERE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561849</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mild</VALIDVALUE>
          <VALUEMEANING>Mild</VALUEMEANING>
          <MEANINGDESCRIPTION>Mild</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3141244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very severe</VALIDVALUE>
          <VALUEMEANING>Very severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Very severe</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563415</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the SEVERITY of your</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the SEVERITY of your SAD OR UNHAPPY FEELINGS at their WORST</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171051</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3188324v1.0:2018076v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1460">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3189705</PUBLICID>
    <LONGNAME>Person Bone Marrow Specimen Consent Ind-2</LONGNAME>
    <PREFERREDNAME>3189704v1.0:2018303v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator whether a person has consent to use of a bone marrow specimen (soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets) for testing, examination, or study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3189704</PublicId>
      <PreferredName>2236731v1.0:3189702v1.0</PreferredName>
      <PreferredDefinition>information relating to consent of a person to use of a bone marrow specimen (soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets) for testing, examination, or study.</PreferredDefinition>
      <LongName>Person Bone Marrow Specimen Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3189702</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12431:C19157:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Specimen Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Willing to provide bone marrow aspirate for correlative research purposes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I agree to have my bone marro</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I agree to have my bone marrow submitted for this testing.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to having bone marrow sample studied to see how much of the protein CRLF2 is present on the leukemia cells?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient agree to have bone marrow  collected, sent to a COG laboratory, and studied to see how well MRD testing can predict outcomes in T-LLy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient agree to allow bone marrow and blood to be sent to a COG laboratory and tested for minimal residual disease (MRD), changes in genes, and evaluation of blood clotting factors?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient agree to allow extra bone marrow to be sent to a COG laboratory for the optional biology studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient agree to allow extra bone marrow to be obtained and sent to a COG laboratory for the optional biology studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to extra bone marrow to be sent to a COG laboratory for the optional biology studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Bone marrow aspirate for LDA assay will be submitted to University of New Mexico for central LDA analysis.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have their bone marrow or blood samples studied to see how much CD22 is present on the leukemia cells?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have bone marrow and/or blood studied to see if genetic changes can be used to predict how a subject will respond to therapy, and to learn more about different testing methods used to monitor how well their leukemia is responding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient agree to their bone marrow being studied to learn more about different testing methods used to monitor how well their  leukemia is responding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have their bone marrow and/or blood samples studied for MRD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have their bone marrow and/or blood samples studied for resistance to InO therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have bone marrow samples collected and studied for Minimal Marrow Disease study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SWOG - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I agree that my bone marrow aspirate samples and related health information may be used for the laboratory MRD study and optional sample collections for known future studies and/or storage for possible future studies described above.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>SWOG - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I agree that my bone marrow aspirate samples and related health information may be used for the laboratory MRD study described above.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent to have samples and related health information used for the bone marrow assessment study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BMCsntTest</AlternateName>
        <AlternateNameType>VM Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CsntBmPtnCl</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1461">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3192382</PUBLICID>
    <LONGNAME>Person Malignant Neoplasm Measurable_Disease Detection Present Clinical Trial Eligibility Criteria Type</LONGNAME>
    <PREFERREDNAME>3192278v1.0:3192379v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type of malignant neoplastic tumor present as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3192278</PublicId>
      <PreferredName>2236731v1.0:3192276v1.0</PreferredName>
      <PreferredDefinition>information related to the presence of malignant neoplastic tumor as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Person Malignant Neoplasm Measurable_Disease Detection Present Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3192276</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3192276v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Measurable_Disease Detection Present Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C8507</PREFERRED_NAME>
            <LONG_NAME>Measurable Disease</LONG_NAME>
            <CON_ID>2202920</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3192379</PublicId>
      <PreferredName>3192379v1.0</PreferredName>
      <PreferredDefinition>the types of malignant neoplasm, detectable or measurable.</PreferredDefinition>
      <LongName>Malignant Neoplasm Measurable Disease Detection Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Detectable</VALIDVALUE>
          <VALUEMEANING>Detectable</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant neoplasm that is detectable but not measurable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192380</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Measurable</VALIDVALUE>
          <VALUEMEANING>Measurable_Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor that can be accurately measured in size. This information can be used to judge response to treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C8507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-02-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192381</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Measurable</VALIDVALUE>
          <VALUEMEANING>Non-Measurable</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-Measurable; not possible to be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562329</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have measura</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have measurable disease or detectable disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have measurable disease or non-measurable disease?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Measurable/Non-Measurable disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104904</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104905</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104906</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104907</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000077</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186H</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000078</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000081</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186J</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000082</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000345</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186K</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000346</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0186I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000430</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3192278v1.0:3192379v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1462">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3193902</PUBLICID>
    <LONGNAME>Patient Reported Outcome Problem Nervousness Or Tension Or Anxiety Past Week Severity Score_11 Point Scale</LONGNAME>
    <PREFERREDNAME>3193892v1.0:3186243v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of how bad, if at all, being nervous, tense or anxious has been a problem during the past week, including today, using an 11-point Likert scale where 0 is not a problem and 10 is as bad as possible.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PCM:Patient Care Monitor</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3193892</PublicId>
      <PreferredName>3191919v1.0:3193885v1.0</PreferredName>
      <PreferredDefinition>Information collected directly from a patient that typically includes subjective feelings regarding symptons, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.:A difficulty, disorder, or condition needing resolution._An uneasy psychological state; the anxious feeling you have when you have the jitters.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A feeling of mental or emotional strain or suspense.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.:The most recent week, including today.:Severity; used of the degree of something undesirable e.g. pain or weather.:A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Patient Reported Outcome Problem Nervousness Or Tension Or Anxiety Past Week Severity Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3191919</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95401:C28020</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcome Problem</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95401</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcome</LONG_NAME>
            <CON_ID>3185129</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3193885</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3193885v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Nervousness Or Tension Or Anxiety Past Week Severity Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74532</PREFERRED_NAME>
            <LONG_NAME>Nervousness</LONG_NAME>
            <CON_ID>2760585</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95502</PREFERRED_NAME>
            <LONG_NAME>Tension</LONG_NAME>
            <CON_ID>3187702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26696</PREFERRED_NAME>
            <LONG_NAME>Anxiety</LONG_NAME>
            <CON_ID>2206376</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PCM:Patient Care Monitor</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3186243</PublicId>
      <PreferredName>3186243v1.0</PreferredName>
      <PreferredDefinition>The most recent week, including today._Severity; used of the degree of something undesirable e.g. pain or weather._A number or range of numeric values measuring performance, function, quality, or ability._A number with no fractional part.::11_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Past Week Severity Score_11 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ePRO:ePRO Data Dictionary</Origin>
      <Representation>
        <PublicId>3186242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3186242v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Severity Score Integer::11 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>A score of 10 on an 11 point scale meaning As Bad as Possible.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 10 on an 11 point scale meaning As Bad as Possible.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>A score of 9 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 9 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>A score of 8 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 8 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>A score of 7 on an 11 point scale meaning Severe Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 7 on an 11 point scale meaning Severe Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>A score of 6 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 6 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>A score of 5 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 5 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186318</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>A score of 4 on an 11 point scale meaning Moderate Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 4 on an 11 point scale meaning Moderate Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>A score of 3 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 3 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186320</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A score of 2 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 2 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186321</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A score of 1 on an 11 point scale meaning Mild Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 1 on an 11 point scale meaning Mild Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>A score of 0 on an 11 point scale meaning Not a Problem.</VALUEMEANING>
          <MEANINGDESCRIPTION>A score of 0 on an 11 point scale meaning Not a Problem.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-01-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3186323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Nervous, tense, anxious</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Nervous, tense, anxious</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Touch the red dot below that best describes how bad, if at all, being nervous, tense or anxious has been a problem for you during the past week, including today.</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Touch the red dot below that best describes how bad, if at all, being nervous, tense or anxious has been a problem for you during the past week, including today.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Instrument Creator</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>ACORN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3185645</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BIGHealth ePRO Data Dictionary</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Care Monitor_PCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3185646</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PCM79</AlternateName>
        <AlternateNameType>ePRO Field Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1463">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3211590</PUBLICID>
    <LONGNAME>Organization Data Table java.lang.Integer</LONGNAME>
    <PREFERREDNAME>3210630v1.0:2178537v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A formal group of people with one or more shared goals._A set of data arranged in rows and columns._Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3210630</PublicId>
      <PreferredName>2407006v1.0:2899724v1.0</PreferredName>
      <PreferredDefinition>A formal group of people with one or more shared goals._A set of data arranged in rows and columns.</PreferredDefinition>
      <LongName>Organization Data Table</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2407006</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19711</PreferredName>
        <Version>1</Version>
        <LongName>Organization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19711</PREFERRED_NAME>
            <LONG_NAME>Professional Organization or Group</LONG_NAME>
            <CON_ID>2202773</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48693</PreferredName>
        <Version>1</Version>
        <LongName>Data Table</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48693</PREFERRED_NAME>
            <LONG_NAME>Data Table</LONG_NAME>
            <CON_ID>2519064</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178537</PublicId>
      <PreferredName>java.lang.Integer</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java dataype that is an Integer (32-bit two&#39;s complement).</PreferredDefinition>
      <LongName>java.lang.Integer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Organization Data Table java.lang.Integer does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Organization Data Table java.lang.Integer does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3204728</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CBM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cbm.domain.LogicalModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3204729</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cbm.domain.LogicalModel.Organization.id</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Organization:id</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1464">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3211611</PUBLICID>
    <LONGNAME>Information Availability Metadata Information Data Longitudinal Study Flag java.lang.Boolean</LONGNAME>
    <PREFERREDNAME>3210651v1.0:2178538v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:The quality of being obtainable or accessible and ready for use or service.:Data about data; information that describes another set of data._Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:In medicine, a study or clinical trial in which participants are identified and then followed forward in time.:An indicator that can be set or unset in order to signal whether a particular condition is true._Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3210651</PublicId>
      <PreferredName>3210605v1.0:3210618v1.0</PreferredName>
      <PreferredDefinition>Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:The quality of being obtainable or accessible and ready for use or service.:Data about data; information that describes another set of data._Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:In medicine, a study or clinical trial in which participants are identified and then followed forward in time.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Information Availability Metadata Information Data Longitudinal Study Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3210605</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48191:C25429:C52095</PreferredName>
        <Version>1</Version>
        <LongName>Information Availability Metadata</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25429</PREFERRED_NAME>
            <LONG_NAME>Availability</LONG_NAME>
            <CON_ID>2204038</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52095</PREFERRED_NAME>
            <LONG_NAME>Metadata</LONG_NAME>
            <CON_ID>2521487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3210618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48191:C25474:C15273:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Information Data Longitudinal Study Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15273</PREFERRED_NAME>
            <LONG_NAME>Longitudinal Study</LONG_NAME>
            <CON_ID>2959061</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178538</PublicId>
      <PreferredName>java.lang.Boolean</PreferredName>
      <PreferredDefinition>Generic value domain for a primitive java datatype that is a Boolean value (true or false).</PreferredDefinition>
      <LongName>java.lang.Boolean</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>caCORE</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2178532</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>BIOINFORMATICS</PreferredName>
        <Version>1</Version>
        <LongName>Bioinformatics</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Boolean</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Information Availability Metadata Information Data Longitudinal Study Flag java.lang.Boolean does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Information Availability Metadata Information Data Longitudinal Study Flag java.lang.Boolean does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3204728</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CBM</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.cbm.domain.LogicalModel</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3204729</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnnotationAvailabilityProfile:hasLongitudinalSpecimens</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.cbm.domain.LogicalModel.AnnotationAvailabilityProfile.hasLongitudinalSpecimens</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1465">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3212317</PUBLICID>
    <LONGNAME>Past 4 Week Urinary Problem Severity Code</LONGNAME>
    <PREFERREDNAME>PST4_WK_HMTUR_SEV_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code response to a question about the severity of bleeding with urination for a person during the previous four weeks.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EPIC:Expanded Prostate Cancer Index Composite</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3210474</PublicId>
      <PreferredName>HEMUR_PROB_SEV</PreferredName>
      <PreferredDefinition>A disorder characterized by laboratory test results that indicate blood in the urine_Problem; a state of difficulty that needs to be resolved._Severity; used of the degree of something undesirable e.g. pain or weather.</PreferredDefinition>
      <LongName>Hematuria Problem Severity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3210472</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3090</PreferredName>
        <Version>1</Version>
        <LongName>Hematuria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3090</PREFERRED_NAME>
            <LONG_NAME>Hematuria</LONG_NAME>
            <CON_ID>2206233</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3210466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28020:C25676</PreferredName>
        <Version>1</Version>
        <LongName>Problem Severity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3210590</PublicId>
      <PreferredName>PST4WK_PRB_SEV_CD</PreferredName>
      <PreferredDefinition>Past; before the present time._A number with no fractional part.::4_Any period of seven consecutive days._A difficulty, disorder, or condition needing resolution._Severity; used of the degree of something undesirable e.g. pain or weather._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Past 4 Week Problem Severity Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3210596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3210596v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::4 Week Urinary Problem Severity Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25711</PREFERRED_NAME>
            <LONG_NAME>Urinary</LONG_NAME>
            <CON_ID>2202482</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Small Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: Limited in number or quantity or magnitude or extent.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C25376, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Small Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Limited in number or quantity or magnitude or extent.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C25376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Big Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Of considerable or relatively great size, extent, or capacity.
: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bleeding with urination</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bleeding with urination</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1466">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3212324</PUBLICID>
    <LONGNAME>Past 4 Week Bloody Feces Severity Code</LONGNAME>
    <PREFERREDNAME>PST4_WK_BLD_FEC_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code response to a question about the severity of blood stools for a person during the previous four weeks.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EPIC:Expanded Prostate Cancer Index Composite</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3210495</PublicId>
      <PreferredName>BLD_STL_PROB_SEV</PreferredName>
      <PreferredDefinition>A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.__Problem; a state of difficulty that needs to be resolved._Severity; used of the degree of something undesirable e.g. pain or weather._Abnormally dark tarry feces containing blood (usually from gastrointestinal bleeding).</PreferredDefinition>
      <LongName>Bloody Feces Problem Severity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3210493</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12434:C13234</PreferredName>
        <Version>1</Version>
        <LongName>Blood Feces</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13234</PREFERRED_NAME>
            <LONG_NAME>Feces</LONG_NAME>
            <CON_ID>2202536</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3210466</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28020:C25676</PreferredName>
        <Version>1</Version>
        <LongName>Problem Severity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3210590</PublicId>
      <PreferredName>PST4WK_PRB_SEV_CD</PreferredName>
      <PreferredDefinition>Past; before the present time._A number with no fractional part.::4_Any period of seven consecutive days._A difficulty, disorder, or condition needing resolution._Severity; used of the degree of something undesirable e.g. pain or weather._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Past 4 Week Problem Severity Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3210596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3210596v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::4 Week Urinary Problem Severity Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25711</PREFERRED_NAME>
            <LONG_NAME>Urinary</LONG_NAME>
            <CON_ID>2202482</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25676</PREFERRED_NAME>
            <LONG_NAME>Severity</LONG_NAME>
            <CON_ID>2202697</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderate Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210594</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Small Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: Limited in number or quantity or magnitude or extent.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C25376, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210592</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Small Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Limited in number or quantity or magnitude or extent.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C25376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Big Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>Of considerable or relatively great size, extent, or capacity.
: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49508</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3210595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No Problem</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: A difficulty, disorder, or condition needing resolution. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28020, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561679</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bloody stools</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bloody stools</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1467">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3219375</PUBLICID>
    <LONGNAME>Pain Medication First Tooth Dentition Code</LONGNAME>
    <PREFERREDNAME>3219351v1.0:2404907v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the values and value meanings for tooth designation related to the pain medicaiton for a tooth.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3219351</PublicId>
      <PreferredName>2207030v1.0:3219349v1.0</PreferredName>
      <PreferredDefinition>information related to the pain medicaiton for a tooth in the teeth collection in the dental arch.</PreferredDefinition>
      <LongName>Pain Medication First Tooth Dentition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2207030</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3303:C459</PreferredName>
        <Version>1</Version>
        <LongName>Pain Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3219349</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C12506:C13072</PreferredName>
        <Version>1</Version>
        <LongName>First Tooth Dentition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2404907</PublicId>
      <PreferredName>NLT_DNTN_CD</PreferredName>
      <PreferredDefinition>The values and value meanings for tooth designation.</PreferredDefinition>
      <LongName>National Dentition Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2407197</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13072:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Dentition Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch  lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch  lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>J</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Q</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ES</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>QS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tooth Number A</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tooth Number A</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1468">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3227103</PUBLICID>
    <LONGNAME>Patient Bad Breath Ind-3</LONGNAME>
    <PREFERREDNAME>3227102v1.0:2548257v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having undesirable or negative qualities._The air that is inhaled and exhaled during respiration._A term that is used to indicate a question with permissible values of yes/no/unknown.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3227102</PublicId>
      <PreferredName>2233604v1.0:3227100v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having undesirable or negative qualities._The air that is inhaled and exhaled during respiration.</PreferredDefinition>
      <LongName>Patient Bad Breath</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3227100</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80228:C94552</PreferredName>
        <Version>1</Version>
        <LongName>Bad Breath</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80228</PREFERRED_NAME>
            <LONG_NAME>Bad</LONG_NAME>
            <CON_ID>2928119</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94552</PREFERRED_NAME>
            <LONG_NAME>Breath</LONG_NAME>
            <CON_ID>3163115</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2548257</PublicId>
      <PreferredName>2548257v1.0</PreferredName>
      <PreferredDefinition>A term that is used to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Ind-3</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-11-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Bad breath</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Bad breath</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1469">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3227319</PUBLICID>
    <LONGNAME>Malignant Neoplasm Mitosis Assessment Mitotic Count</LONGNAME>
    <PREFERREDNAME>2749719v1.0:3227318v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the mitoses counted microscopically in ten fields using the high power lens.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2749719</PublicId>
      <PreferredName>MALIG_NUC_MIT_ASS</PreferredName>
      <PreferredDefinition>information related to tumor having usual process of somatic reproduction of cells assessment.</PreferredDefinition>
      <LongName>Malignant Neoplasm Mitosis Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2186369</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2749717</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16864:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Mitosis Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16864</PREFERRED_NAME>
            <LONG_NAME>Mitosis</LONG_NAME>
            <CON_ID>2494671</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3227318</PublicId>
      <PreferredName>3227318v1.0</PreferredName>
      <PreferredDefinition>The number of mitoses identified under the microscope in tumors. It is one of the parameters that determine the grade of malignant tumors. The method of counting varies, according to the specific tumor examined. Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Mitotic Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>Mitosis/10 HPF</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>30</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>3227317</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47864:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Mitotic Count Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47864</PREFERRED_NAME>
            <LONG_NAME>Mitotic Count</LONG_NAME>
            <CON_ID>2431166</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mitoses per 10 HPF</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mitoses per 10 HPF</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical sarc shared</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793091</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NEOP_MIT_ASSESS_CT</AlternateName>
        <AlternateNameType>C3D Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>mitotic_count</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1470">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3229394</PUBLICID>
    <LONGNAME>ETV6 RUNX1 Fusion Molecular Genetic Technique Or Cytogenetic Analysis Detection Status Type</LONGNAME>
    <PREFERREDNAME>3229393v1.0:5042697v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The text term that describes the presence or absence of ETV6-RUNX1 (TEL-AML1) fusion detected by FISH.</PREFERREDDEFINITION>
    <VERSION>3</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3229393</PublicId>
      <PreferredName>3229389v1.0:3229391v1.0</PreferredName>
      <PreferredDefinition>Expression of a fusion protein containing the helix-loop-helix domain encoded by the human ETV6 gene and the DNA-binding and transactivation domains encoded by the human RUNX1 gene as a result of a t(12;21)(p13; q22) translocation._The methods and tools used for DNA analysis and manipulation._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._The activity of perceiving, discerning, discovering or identifying._A condition or state at a particular time.</PreferredDefinition>
      <LongName>TEL-AML1 Fusion Protein Expression Molecular Genetic Technique Or Cytogenetic Analysis Detection Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3910</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Abnormality</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3229389</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37227</PreferredName>
        <Version>1</Version>
        <LongName>TEL-AML1 Fusion Protein Expression</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37227</PREFERRED_NAME>
            <LONG_NAME>ETV6-RUNX1 Fusion Protein Expression</LONG_NAME>
            <CON_ID>2500166</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3229391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3229391v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Molecular Genetic Technique Or Cytogenetic Analysis Detection Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19235</PREFERRED_NAME>
            <LONG_NAME>Molecular Genetic Technique</LONG_NAME>
            <CON_ID>3229390</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18280</PREFERRED_NAME>
            <LONG_NAME>Cytogenetic Analysis</LONG_NAME>
            <CON_ID>2528326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16210</PREFERRED_NAME>
            <LONG_NAME>Detection</LONG_NAME>
            <CON_ID>2203866</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5042697</PublicId>
      <PreferredName>POS_NEG_UNK_FNG</PreferredName>
      <PreferredDefinition>The preferred Value Domain to capture a list of findings following an examination or observation.</PreferredDefinition>
      <LongName>Positive Negative Unknown Finding Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>5042696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5042696v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Positive Finding Negative Finding Unknown Finding Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38758</PREFERRED_NAME>
            <LONG_NAME>Positive Finding</LONG_NAME>
            <CON_ID>2516404</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38757</PREFERRED_NAME>
            <LONG_NAME>Negative Finding</LONG_NAME>
            <CON_ID>2203934</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Positive</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5042698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Negative</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pending</VALIDVALUE>
          <VALUEMEANING>Pending</VALUEMEANING>
          <MEANINGDESCRIPTION>Not yet decided or settled; awaiting conclusion or confirmation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C53470</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2784518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Data not available</VALIDVALUE>
          <VALUEMEANING>Source Data Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Data from an original source is not present, accessible or ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4842575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Tested</VALIDVALUE>
          <VALUEMEANING>Not Tested</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that a test was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3918247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Presence or absence of ETV6-R</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Presence or absence of ETV6-RUNX1 (TEL-AML1) fusion detected by FISH</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Presence or absence of ETV6-RUNX1 (TEL-AML1) fusion detected by FISH:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET ALL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3165862</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179562</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5650570</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ALL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5650571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1471">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3233218</PUBLICID>
    <LONGNAME>In Situ Hybridization DNA Probe Label Type</LONGNAME>
    <PREFERREDNAME>ISH_DNA_PROB_LAB_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>A brief description given for purposes of identification of a piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3229496</PublicId>
      <PreferredName>3229493v1.0:3229494v1.0</PreferredName>
      <PreferredDefinition>Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues_A piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.  Applications include Northern and Southern blots, in situ hybridization techniques, and diagnostic tests.  DNA probes can be highly specific or degenerate.</PreferredDefinition>
      <LongName>in situ Hybridization DNA Probe</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3229493</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17562</PreferredName>
        <Version>1</Version>
        <LongName>in situ Hybridization</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17562</PREFERRED_NAME>
            <LONG_NAME>In Situ Hybridization</LONG_NAME>
            <CON_ID>2202909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3229494</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C451</PreferredName>
        <Version>1</Version>
        <LongName>DNA Probes</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C451</PREFERRED_NAME>
            <LONG_NAME>DNA Probes</LONG_NAME>
            <CON_ID>2203991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3233211</PublicId>
      <PreferredName>DNA_PRB_LAB_TP</PreferredName>
      <PreferredDefinition>A brief description given for purposes of identification of a piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.</PreferredDefinition>
      <LongName>DNA Probes Label Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3233210</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C451:C45561:C25284</PreferredName>
        <Version>1</Version>
        <LongName>DNA Probes Label Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C451</PREFERRED_NAME>
            <LONG_NAME>DNA Probes</LONG_NAME>
            <CON_ID>2203991</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45561</PREFERRED_NAME>
            <LONG_NAME>Label</LONG_NAME>
            <CON_ID>2422619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quantum Dots</VALIDVALUE>
          <VALUEMEANING>Quantum Dot</VALUEMEANING>
          <MEANINGDESCRIPTION>Nanometer-sized semiconductor particles, made of cadmium selenide (CdSe), cadmium sulfide (CdS) or cadmium telluride (CdTe) with an inert polymer coating. The semiconductor material used for the core is chosen based upon the emission wavelength range being targeted: CdS for UV-blue, CdSe for the bulk of the visible spectrum, and CdTe for far red and near-infrared. The size of the particle determines the exact color of a given quantum dot. The polymer coating protects cells from cadmium toxicity but also facilitates the attachment of a variety of targeting molecules, including monoclonal antibodies directed to tumor-specific biomarkers. Because of their small size, quantum dots can function as cell- and even molecule-specific markers that will not interfere with the normal cellular functions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62378</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2612926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alexa Fluor</VALIDVALUE>
          <VALUEMEANING>Alexa Fluor</VALUEMEANING>
          <MEANINGDESCRIPTION>Any of series of proprietary fluorescent dyes that span the visible spectrum. They are typically used as cell and tissue labels in fluorescence microscopy and cell biology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C96647</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3233682</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FITC</VALIDVALUE>
          <VALUEMEANING>Fluorescein Isothiocyanate</VALUEMEANING>
          <MEANINGDESCRIPTION>An organic compound that has wide use as a synthetic coloring agent. It is prepared by heating phthalic anhydride and resorcinol over a zinc catalyst, and it crystallizes as a deep red powder. This agent emits an intense green fluorescence in the presence of alkaline solutions and therefore is used as a label when conjugated to antibodies or as a contrast agent for ophthalmic angiography.: A chemical group containing the monovalent -N=C=S group. Isothiocyanate is the fundamental structure in many synthetic and biological active compounds.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45711, C61766</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3233216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: Be specific about something; define clearly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the probe label?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the probe label?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2939361</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>DCTD</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>In Situ Hybridization Biomarker Template</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3232302</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1472">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3244808</PUBLICID>
    <LONGNAME>Extraction Therapy Use Use Frequency</LONGNAME>
    <PREFERREDNAME>3244794v1.0:3244807v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The act of pulling out, including the process of obtaining something from a mixture or compound by chemical or physical or mechanical means._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The number of occurrences of something within a given time period. (NCI)</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3244794</PublicId>
      <PreferredName>3244792v1.0:2234899v1.0</PreferredName>
      <PreferredDefinition>The act of pulling out, including the process of obtaining something from a mixture or compound by chemical or physical or mechanical means._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Extraction Therapy Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3244792</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61575:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Extraction Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61575</PREFERRED_NAME>
            <LONG_NAME>Extraction</LONG_NAME>
            <CON_ID>2528525</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234899</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340</PreferredName>
        <Version>1</Version>
        <LongName>Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3244807</PublicId>
      <PreferredName>3244807v1.0</PreferredName>
      <PreferredDefinition>Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The number of occurrences of something within a given time period. (NCI)</PreferredDefinition>
      <LongName>Dental Therapy Use Frequency</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3244806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340:C25515</PreferredName>
        <Version>1</Version>
        <LongName>Use Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frequently</VALIDVALUE>
          <VALUEMEANING>Frequently</VALUEMEANING>
          <MEANINGDESCRIPTION>Frequently</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>(Please indicate with what fr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>(Please indicate with what frequency you use the following): Extraction Treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1473">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3245249</PUBLICID>
    <LONGNAME>Person Endometrial Metastatic Malignant Neoplasm Pelvic Lymph Node Eligibility Determination Ind-3b</LONGNAME>
    <PREFERREDNAME>3245186v1.0:2958018v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no/not applicable indicator whether there is an atypical neoplastic relating to or composed of endometrium having spread to any lymph node within the abdominal pelvic region as part of the eligibility criteria for participation on a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3245186</PublicId>
      <PreferredName>2236731v1.0:3245184v1.0</PreferredName>
      <PreferredDefinition>information related to criteria to determine eligibility of patients based on atypical neoplastic relating to or composed of endometrium having spread to any lymph node within the abdominal pelvic region.</PreferredDefinition>
      <LongName>Person Endometrial Metastatic Malignant Neoplasm Pelvic Lymph Node</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3245184</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13322:C36263:C12363:C25171</PreferredName>
        <Version>1</Version>
        <LongName>Endometrial Metastatic Malignant Neoplasm Pelvic Lymph Node Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13322</PREFERRED_NAME>
            <LONG_NAME>Endometrial</LONG_NAME>
            <CON_ID>2206203</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36263</PREFERRED_NAME>
            <LONG_NAME>Metastatic Malignant Neoplasm</LONG_NAME>
            <CON_ID>2554141</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12363</PREFERRED_NAME>
            <LONG_NAME>Pelvic Lymph Node</LONG_NAME>
            <CON_ID>2205344</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Positive pelvic nodes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Positive pelvic nodes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0258</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104898</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3245186v1.0:2958018v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1474">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3245392</PUBLICID>
    <LONGNAME>Orthodontist Dental Impression Use Use Frequency</LONGNAME>
    <PREFERREDNAME>3245391v1.0:3244807v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A dentist specializing in the prevention, diagnosis, and treatment of malocclusions of the teeth and their surrounding structures._A procedure used to acquire a negative reproduction of an oral structure for the purpose of producing a positive model or cast of the structure upon which restorations, prostheses, and dentures are fabricated._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The number of occurrences of something within a given time period. (NCI)</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3245391</PublicId>
      <PreferredName>3243774v1.0:3245389v1.0</PreferredName>
      <PreferredDefinition>A dentist specializing in the prevention, diagnosis, and treatment of malocclusions of the teeth and their surrounding structures._A procedure used to acquire a negative reproduction of an oral structure for the purpose of producing a positive model or cast of the structure upon which restorations, prostheses, and dentures are fabricated._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.</PreferredDefinition>
      <LongName>Orthodontist Dental Impression Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3243774</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63737</PreferredName>
        <Version>1</Version>
        <LongName>Orthodontist</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63737</PREFERRED_NAME>
            <LONG_NAME>Orthodontist</LONG_NAME>
            <CON_ID>2547885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3245389</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73514:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Dental Impression Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73514</PREFERRED_NAME>
            <LONG_NAME>Dental Impression</LONG_NAME>
            <CON_ID>2740976</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3244807</PublicId>
      <PreferredName>3244807v1.0</PreferredName>
      <PreferredDefinition>Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._The number of occurrences of something within a given time period. (NCI)</PreferredDefinition>
      <LongName>Dental Therapy Use Frequency</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3244806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25340:C25515</PreferredName>
        <Version>1</Version>
        <LongName>Use Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Frequently</VALIDVALUE>
          <VALUEMEANING>Frequently</VALUEMEANING>
          <MEANINGDESCRIPTION>Frequently</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What diagnosis guidance do yo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What diagnosis guidance do you use or request for placement of the miniscrew TAD? Clinical impression or photos</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1475">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3246295</PUBLICID>
    <LONGNAME>Adult Patient Dental Disease or Disorder Level Child/Disabled Patient Level Scale</LONGNAME>
    <PREFERREDNAME>3246279v1.0:3246263v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A human who has reached reproductive age._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Pertaining to a tooth or teeth, or to odontology._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A position on a scale measuring intensity, quality, or amount.  (NCI)_an ordered reference standard.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3246279</PublicId>
      <PreferredName>3246228v1.0:3246277v1.0</PreferredName>
      <PreferredDefinition>A human who has reached reproductive age._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Pertaining to a tooth or teeth, or to odontology._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A position on a scale measuring intensity, quality, or amount.  (NCI)</PreferredDefinition>
      <LongName>Adult Patient Dental Disease or Disorder Level</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3246228</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17600:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Adult Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17600</PREFERRED_NAME>
            <LONG_NAME>Adult</LONG_NAME>
            <CON_ID>2204022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3246277</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C2991:C25554</PreferredName>
        <Version>1</Version>
        <LongName>Dental Disease or Disorder Level</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3247404</PublicId>
      <PreferredName>3247404v1.0</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>Child/Disabled Patient Level Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No effect</VALIDVALUE>
          <VALUEMEANING>No effect</VALUEMEANING>
          <MEANINGDESCRIPTION>No effect</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3246264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low</VALIDVALUE>
          <VALUEMEANING>Low</VALUEMEANING>
          <MEANINGDESCRIPTION>Low</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Medium</VALIDVALUE>
          <VALUEMEANING>Medium</VALUEMEANING>
          <MEANINGDESCRIPTION>Mid-way between small and large in number, quantity, magnitude or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49507</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High</VALIDVALUE>
          <VALUEMEANING>High</VALUEMEANING>
          <MEANINGDESCRIPTION>High</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please identify to what degre</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please identify to what degree a patient&#39;s level of dental disease may be a barrier to your willingness to see disabled adult patients.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1476">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3247331</PUBLICID>
    <LONGNAME>Disabled Adult Medicaid Patient Treatment Reason</LONGNAME>
    <PREFERREDNAME>3247301v1.0:2546566v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>No longer able to be activated or utilized._A human who has reached reproductive age._A jointly funded program of the United States federal and state governments that provides hospital expense and medical expense coverage to some people with low-income and certain aged and disabled individuals._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._An explanation of the cause of some phenomenon or action.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3247301</PublicId>
      <PreferredName>3247295v1.0:2187763v1.0</PreferredName>
      <PreferredDefinition>No longer able to be activated or utilized._A human who has reached reproductive age._A jointly funded program of the United States federal and state governments that provides hospital expense and medical expense coverage to some people with low-income and certain aged and disabled individuals._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.</PreferredDefinition>
      <LongName>Disabled Adult Medicaid Patient Treatment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3247295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63367:C17600:C68633:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Disabled Adult Medicaid Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63367</PREFERRED_NAME>
            <LONG_NAME>Disabled</LONG_NAME>
            <CON_ID>2538596</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17600</PREFERRED_NAME>
            <LONG_NAME>Adult</LONG_NAME>
            <CON_ID>2204022</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68633</PREFERRED_NAME>
            <LONG_NAME>Medicaid</LONG_NAME>
            <CON_ID>2660079</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2187763</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Treatment</PreferredName>
        <Version>1</Version>
        <LongName>Treatment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0087111</PREFERRED_NAME>
            <LONG_NAME>Treatment</LONG_NAME>
            <CON_ID>2203112</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2546566</PublicId>
      <PreferredName>2546566v1.0</PreferredName>
      <PreferredDefinition>An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Medicaid Therapy Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2240632</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25638</PreferredName>
        <Version>1</Version>
        <LongName>Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If no, what would increase yo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If no, what would increase your willingness to see Medicaid patients?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1477">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3247466</PUBLICID>
    <LONGNAME>Miniscrew Temporary Anchorage Device Manufacturer Name</LONGNAME>
    <PREFERREDNAME>3247460v1.0:3247465v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Manufacturer Name; the name of a business engaged in manufacturing some product_The words or language units by which a thing is known.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3247460</PublicId>
      <PreferredName>3244920v1.0:2236661v1.0</PreferredName>
      <PreferredDefinition>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._Manufacturer Name; the name of a business engaged in manufacturing some product</PreferredDefinition>
      <LongName>Miniscrew Temporary Anchorage Device Manufacturer</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3244920</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82082</PreferredName>
        <Version>1</Version>
        <LongName>Miniscrew Temporary Anchorage Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82082</PREFERRED_NAME>
            <LONG_NAME>Miniscrew Temporary Anchorage Device</LONG_NAME>
            <CON_ID>2904796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2236661</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25392</PreferredName>
        <Version>1</Version>
        <LongName>Manufacturer Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25392</PREFERRED_NAME>
            <LONG_NAME>Manufacturer</LONG_NAME>
            <CON_ID>2203842</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3247465</PublicId>
      <PreferredName>3247465v1.0</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Miniscrew Temporary Ancorage Device Manufacturer Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tomas (Dentaurum)</VALIDVALUE>
          <VALUEMEANING>Tomas (Dentaurum)</VALUEMEANING>
          <MEANINGDESCRIPTION>Tomas (Dentaurum)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AbsoAnchor, Dentos (Daegu City, Korea)</VALIDVALUE>
          <VALUEMEANING>AbsoAnchor, Dentos (Daegu City, Korea)</VALUEMEANING>
          <MEANINGDESCRIPTION>AbsoAnchor, Dentos (Daegu City, Korea)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245405</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Osteomed (Dallas, TX)</VALIDVALUE>
          <VALUEMEANING>Osteomed (Dallas, TX)</VALUEMEANING>
          <MEANINGDESCRIPTION>Osteomed (Dallas, TX)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Straumann</VALIDVALUE>
          <VALUEMEANING>Straumann</VALUEMEANING>
          <MEANINGDESCRIPTION>Straumann</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DualTop (RMO)</VALIDVALUE>
          <VALUEMEANING>DualTop (RMO)</VALUEMEANING>
          <MEANINGDESCRIPTION>DualTop (RMO)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gebruder, Martin (Tuttlingen, Ger)</VALIDVALUE>
          <VALUEMEANING>Gebruder, Martin (Tuttlingen, Ger)</VALUEMEANING>
          <MEANINGDESCRIPTION>Gebruder, Martin (Tuttlingen, Ger)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245409</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imtec</VALIDVALUE>
          <VALUEMEANING>Imtec</VALUEMEANING>
          <MEANINGDESCRIPTION>Imtec</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245410</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M.A.S. (Jazi Dental)</VALIDVALUE>
          <VALUEMEANING>M.A.S. (Jazi Dental)</VALUEMEANING>
          <MEANINGDESCRIPTION>M.A.S. (Jazi Dental)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ACR</VALIDVALUE>
          <VALUEMEANING>ACR</VALUEMEANING>
          <MEANINGDESCRIPTION>ACR</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245412</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector TAS (Ormco)</VALIDVALUE>
          <VALUEMEANING>Vector TAS (Ormco)</VALUEMEANING>
          <MEANINGDESCRIPTION>Vector TAS (Ormco)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245413</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Miniscrew TAD Manufacturer</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Miniscrew TAD Manufacturer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1478">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3248052</PUBLICID>
    <LONGNAME>Dental Professional Practice Alcohol Illicit Substance Use Counseling Indicator</LONGNAME>
    <PREFERREDNAME>3247989v1.0:3248047v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>an indicator related to counseling by the dental professional business directed towards treatment and care of patients for alcohol or illicit drug use.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3248015</PublicId>
      <PreferredName>2443314v1.0:3248013v1.0</PreferredName>
      <PreferredDefinition>information related to counseling by the dental professional business directed towards treatment and care of patients for alcohol or illicit drug use.</PreferredDefinition>
      <LongName>Dental Professional Practice Alcohol Illicit Substance Use Counseling</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443314</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C52673</PreferredName>
        <Version>1</Version>
        <LongName>Dental Professional Practice</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52673</PREFERRED_NAME>
            <LONG_NAME>Professional Practice</LONG_NAME>
            <CON_ID>2443152</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3248013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2190:C79097:C25340:C61547</PreferredName>
        <Version>1</Version>
        <LongName>Alcohol Illicit Substance Use Counseling</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2190</PREFERRED_NAME>
            <LONG_NAME>Alcohol</LONG_NAME>
            <CON_ID>2202315</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79097</PREFERRED_NAME>
            <LONG_NAME>Illicit Substance</LONG_NAME>
            <CON_ID>2820624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61547</PREFERRED_NAME>
            <LONG_NAME>Counseling</LONG_NAME>
            <CON_ID>2833533</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3248047</PublicId>
      <PreferredName>3248047v1.0</PreferredName>
      <PreferredDefinition>an indicator related to counseling in the dental professional practice.</PreferredDefinition>
      <LongName>Dental Professional Practice Counseling Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, with OTHER</VALIDVALUE>
          <VALUEMEANING>Yes, with OTHER</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, with OTHER</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248048</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, with appropriate reimbursement</VALIDVALUE>
          <VALUEMEANING>Yes, with appropriate reimbursement</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, with appropriate reimbursement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248049</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, with proper training</VALIDVALUE>
          <VALUEMEANING>Yes, with proper training</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, with proper training</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248050</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, I would be willing to start now</VALIDVALUE>
          <VALUEMEANING>Yes, I would be willing to start now</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, I would be willing to start now</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3248051</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If it was to be offered in yo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If it was to be offered in your practice, who would be primarily engaged in counseling patients on alcohol and illicit drug use</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1479">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3248956</PUBLICID>
    <LONGNAME>Miniscrew Temporary Anchorage Device Orthodontic Treatment Difficulty Specify Text</LONGNAME>
    <PREFERREDNAME>3248949v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._A dental treatment to correct malocclusions of the teeth and their surrounding structures._Something not easily done, accomplished, comprehended, or solved._Be specific about something; define clearly._Text; the words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3248949</PublicId>
      <PreferredName>3248947v1.0:2724990v1.0</PreferredName>
      <PreferredDefinition>A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodonic treatment._A dental treatment to correct malocclusions of the teeth and their surrounding structures._Something not easily done, accomplished, comprehended, or solved.</PreferredDefinition>
      <LongName>Miniscrew Temporary Anchorage Device Orthodontic Treatment Difficulty</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3248947</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82082:C64248</PreferredName>
        <Version>1</Version>
        <LongName>Miniscrew Temporary Anchorage Device Orthodontic Treatment </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82082</PREFERRED_NAME>
            <LONG_NAME>Miniscrew Temporary Anchorage Device</LONG_NAME>
            <CON_ID>2904796</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64248</PREFERRED_NAME>
            <LONG_NAME>Orthodontic Treatment</LONG_NAME>
            <CON_ID>2558017</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2724990</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62189</PreferredName>
        <Version>1</Version>
        <LongName>Difficulty</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62189</PREFERRED_NAME>
            <LONG_NAME>Difficulty</LONG_NAME>
            <CON_ID>2503546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1480">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3249303</PUBLICID>
    <LONGNAME>Alcohol Substance Abuse Problem Inappropriate Therapy Type</LONGNAME>
    <PREFERREDNAME>3249287v1.0:2489013v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the text that describes the strength of agreement related to problems with not being correct therapy for maladaptive pattern of alcohol use that may lead to social, occupational, psychological, or physical problems.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3249287</PublicId>
      <PreferredName>3249025v1.0:3249259v1.0</PreferredName>
      <PreferredDefinition>information related to problems with not being correct therapy for maladaptive pattern of alcohol use that may lead to social, occupational, psychological, or physical problems.</PreferredDefinition>
      <LongName>Alcohol Substance Abuse Problem Inappropriate Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3249025</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2190:C18272</PreferredName>
        <Version>1</Version>
        <LongName>Alcohol Substance Abuse</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2190</PREFERRED_NAME>
            <LONG_NAME>Alcohol</LONG_NAME>
            <CON_ID>2202315</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18272</PREFERRED_NAME>
            <LONG_NAME>Substance Abuse</LONG_NAME>
            <CON_ID>2585790</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3249259</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28020:C74958:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Problem Inappropriate Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74958</PREFERRED_NAME>
            <LONG_NAME>Inappropriate</LONG_NAME>
            <CON_ID>2782641</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2489013</PublicId>
      <PreferredName>2489013v1.0</PreferredName>
      <PreferredDefinition>The text that describes the strength of agreement.</PreferredDefinition>
      <LongName>Agreement Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Agree</VALIDVALUE>
          <VALUEMEANING>STRONGLY AGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY AGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat Agree</VALIDVALUE>
          <VALUEMEANING>Somewhat Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat Agree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neither agree nor disagree</VALIDVALUE>
          <VALUEMEANING>NEITHER AGREE NOR DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>NEITHER AGREE NOR DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat Disagree</VALIDVALUE>
          <VALUEMEANING>somewhat disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>somewhat disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580091</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Strongly Disagree</VALIDVALUE>
          <VALUEMEANING>STRONGLY DISAGREE</VALUEMEANING>
          <MEANINGDESCRIPTION>STRONGLY DISAGREE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neutral</VALIDVALUE>
          <VALUEMEANING>Neutral</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person has a neutral opinion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C154573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2902512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uncertain</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I don&#39;t think dental practice</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I don&#39;t think dental practices are an appropriate setting to address alcohol</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1481">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3250736</PUBLICID>
    <LONGNAME>Prior Dental Restoration Buildup Material Type</LONGNAME>
    <PREFERREDNAME>3250731v1.0:3250735v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Earlier in time or order._Replacement or reconstruction of a lost tooth structure._Material that has accumulated gradually._The tangible substance that goes into the makeup of a physical object._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3250731</PublicId>
      <PreferredName>3250724v1.0:3250729v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._Replacement or reconstruction of a lost tooth structure._Material that has accumulated gradually._The tangible substance that goes into the makeup of a physical object.</PreferredDefinition>
      <LongName>Prior Dental Restoration Buildup Material</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3250724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C60718</PreferredName>
        <Version>1</Version>
        <LongName>Prior Dental Restoration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60718</PREFERRED_NAME>
            <LONG_NAME>Dental Restoration</LONG_NAME>
            <CON_ID>2481613</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3250729</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94553:C48187</PreferredName>
        <Version>1</Version>
        <LongName>Buildup Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94553</PREFERRED_NAME>
            <LONG_NAME>Buildup</LONG_NAME>
            <CON_ID>3163116</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3250735</PublicId>
      <PreferredName>3250735v1.0</PreferredName>
      <PreferredDefinition>Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Prior Dental Restoration Buildup Material Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ceramic</VALIDVALUE>
          <VALUEMEANING>Ceramic</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental restorative material made from fired porcelain.  This may include restorations that are both metal and ceramic such as porcelain bonded to metal crowns.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gold</VALIDVALUE>
          <VALUEMEANING>Gold</VALUEMEANING>
          <MEANINGDESCRIPTION>Gold</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243751</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Composite</VALIDVALUE>
          <VALUEMEANING>Composite</VALUEMEANING>
          <MEANINGDESCRIPTION>Consisting of separate interconnected parts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Amalgam</VALIDVALUE>
          <VALUEMEANING>Amalgam</VALUEMEANING>
          <MEANINGDESCRIPTION>A dental restorative material consisting primarily of an analgamation of silver, tin and mercury.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If yes, type of buildup mater</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If yes, type of buildup material used?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1482">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3251130</PUBLICID>
    <LONGNAME>Dentist Dental Specialty Specify Text</LONGNAME>
    <PREFERREDNAME>2443344v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the specialized area of dentistry, prevention, diagnosis, and treatment of specific oral and craniofacial diseases and disorders, of an individual licensed for the prevention, diagnosis, and treatment of diseases in the oral cavity, adjacent tissues, and related structures._Be specific about something; define clearly._Text; the words of something written.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2443344</PublicId>
      <PreferredName>DENT_DENTSPEC</PreferredName>
      <PreferredDefinition>information related to the specialized area of dentistry, prevention, diagnosis, and treatment of specific oral and craniofacial diseases and disorders, of an individual licensed for the prevention, diagnosis, and treatment of diseases in the oral cavity, adjacent tissues, and related structures.</PreferredDefinition>
      <LongName>Dentist Dental Specialty</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008545</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>JOBS</PreferredName>
        <Version>1</Version>
        <LongName>Jobs</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2443308</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52654</PreferredName>
        <Version>1</Version>
        <LongName>Dentist</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52654</PREFERRED_NAME>
            <LONG_NAME>Dentist</LONG_NAME>
            <CON_ID>2443130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2443340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C52653</PreferredName>
        <Version>1</Version>
        <LongName>Dental Specialty</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52653</PREFERRED_NAME>
            <LONG_NAME>Dental Specialty</LONG_NAME>
            <CON_ID>2443129</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1483">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3253537</PUBLICID>
    <LONGNAME>Finding Present Specify Text</LONGNAME>
    <PREFERREDNAME>2943226v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field to describe clinical, laboratory or molecular evidence of disease that was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2943226</PublicId>
      <PreferredName>2528734v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>Clinical, laboratory or molecular evidence, or absence of evidence of disease._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Finding Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528734</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3367</PreferredName>
        <Version>1</Version>
        <LongName>Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3367</PREFERRED_NAME>
            <LONG_NAME>Finding</LONG_NAME>
            <CON_ID>2202448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other finding:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify the other finding:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other clinical feature:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other clinical feature:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other features:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other features:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other clinical finding:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the other clinical finding:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the other radiologic finding:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the other radiologic finding:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the clinical finding:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the clinical finding:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify the radiologic finding:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify the radiologic finding:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other symptom:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other symptom:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2131r2: Immune Deficiencies Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3234637</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2036r1: Osteopetrosis Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3279243</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2136r1: Osteopetrosis Post-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3279261</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3279271</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2031r2: Immune Deficiencies Pre-HSCT Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3638517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ost_post_othr_hema_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ost_post_othr_clin_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_post_othr_feat_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>id_prep_othr_feat_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MACpre_clin_features_diag_oth_symptom_spec</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1484">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3257620</PUBLICID>
    <LONGNAME>Current Pain Anatomic Site Specify</LONGNAME>
    <PREFERREDNAME>CUR_PAIN_ANTLC_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>Free text description of anatomic site(s) of current pain.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3257619</PublicId>
      <PreferredName>CUR_PAIN_ANATLOC</PreferredName>
      <PreferredDefinition>Occurring in or belonging to the present time._information relating to the anatomic location of pain present._A position, site, or point in space where something can be found._Relating to anatomy.</PreferredDefinition>
      <LongName>Current Pain Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3257617</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C3303</PreferredName>
        <Version>1</Version>
        <LongName>Current Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2442487</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25421:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25421</PREFERRED_NAME>
            <LONG_NAME>Anatomic</LONG_NAME>
            <CON_ID>2202601</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2226669</PublicId>
      <PreferredName>ANATSITE_SPEC</PreferredName>
      <PreferredDefinition>the free text field to specify an anatomic site.</PreferredDefinition>
      <LongName>Anatomic Site Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anatomic Site of Current Pain</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Anatomic Site of Current Pain</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1485">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3261266</PUBLICID>
    <LONGNAME>Dental Occlusion Evaluation Ind-2</LONGNAME>
    <PREFERREDNAME>3261265v1.0:2018320v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to assessment of the spatial relation of the upper and lower teeth when the jaws are closed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3261265</PublicId>
      <PreferredName>3261263v1.0:2177570v1.0</PreferredName>
      <PreferredDefinition>information related to assessment of the spatial relation of the upper and lower teeth when the jaws are closed.</PreferredDefinition>
      <LongName>Dental Occlusion Evaluation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3261263</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62301</PreferredName>
        <Version>1</Version>
        <LongName>Dental Occlusion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62301</PREFERRED_NAME>
            <LONG_NAME>Dental Occlusion</LONG_NAME>
            <CON_ID>2509293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177570</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Evaluation</PreferredName>
        <Version>1</Version>
        <LongName>Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you check the occlusion o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you check the occlusion on the treated tooth</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1486">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3262961</PUBLICID>
    <LONGNAME>Laboratory Procedure Pharmacologic Substance Third Level Integer::0 Decimal Place Microgram per Milliliter Value</LONGNAME>
    <PREFERREDNAME>3262949v1.0:3181243v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The 0 decimal place numeric laboratory third level value measured, assigned or computed related to the assessment of the pharmacologic substance in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3262949</PublicId>
      <PreferredName>3262897v1.0:3262947v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._Following the second position in an ordering or series; coming next after the second and just before the fourth in position._A position on a scale measuring intensity, quality, or amount.</PreferredDefinition>
      <LongName>Laboratory Procedure Pharmacologic Substance Third Level</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3262897</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294:C1909</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Pharmacologic Substance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3262947</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25260:C25554</PreferredName>
        <Version>1</Version>
        <LongName>Third Level</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25260</PREFERRED_NAME>
            <LONG_NAME>Third</LONG_NAME>
            <CON_ID>2206262</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25554</PREFERRED_NAME>
            <LONG_NAME>Level</LONG_NAME>
            <CON_ID>2202440</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3181243</PublicId>
      <PreferredName>3181243v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A number with no fractional part, including the negative and positive numbers as well as zero.::0_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Laboratory Procedure 0 Decimal Place Microgram per Milliliter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>ug/mL</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3264685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3264685v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Integer::0 Decimal Place Microgram per Milliliter Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64572</PREFERRED_NAME>
            <LONG_NAME>Microgram per Milliliter</LONG_NAME>
            <CON_ID>2685402</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the third level for t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the third level for the drug?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2046r1: Fungal Infection Supplemental Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964901</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>fng_inf_voricon3_lvl</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1487">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3264249</PUBLICID>
    <LONGNAME>Dental Restoration Patient Second Tooth Dentition Code</LONGNAME>
    <PREFERREDNAME>3264248v1.0:2404907v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the values and value meanings for tooth designation related to the dental restoration patient&#39;s second tooth being assessed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3264248</PublicId>
      <PreferredName>2500511v1.0:3219352v1.0</PreferredName>
      <PreferredDefinition>information related to the dental restoration patient&#39;s second tooth being assessed.</PreferredDefinition>
      <LongName>Dental Restoration Patient Second Tooth Dentition</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2500511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60718:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Dental Restoration Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60718</PREFERRED_NAME>
            <LONG_NAME>Dental Restoration</LONG_NAME>
            <CON_ID>2481613</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3219352</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25666:C12506:C13072</PreferredName>
        <Version>1</Version>
        <LongName>Second Tooth Dentition</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25666</PREFERRED_NAME>
            <LONG_NAME>Second</LONG_NAME>
            <CON_ID>2202591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2404907</PublicId>
      <PreferredName>NLT_DNTN_CD</PreferredName>
      <PreferredDefinition>The values and value meanings for tooth designation.</PreferredDefinition>
      <LongName>National Dentition Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2407197</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13072:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Dentition Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13072</PREFERRED_NAME>
            <LONG_NAME>Dentition</LONG_NAME>
            <CON_ID>2404901</CON_ID>
            <DEFINITION_SOURCE>MeSH</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576175</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576178</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>central incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576194</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576195</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576196</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576197</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576200</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576204</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor permanent arch  lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor permanent arch  lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>supernumerary cuspid (canine/eye tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary cuspid (canine/eye tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st bicuspid (1st premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd bicuspid (2nd premolar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>supernumerary 1st molar (6-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 1st molar (6-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 2nd molar (12-yr. molar) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary 3rd molar (wisdom tooth) permanent arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>D</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576230</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>E</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>H</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I</VALIDVALUE>
          <VALUEMEANING>first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>J</VALIDVALUE>
          <VALUEMEANING>second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>K</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>L</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>O</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P</VALIDVALUE>
          <VALUEMEANING>central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Q</VALIDVALUE>
          <VALUEMEANING>lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R</VALIDVALUE>
          <VALUEMEANING>canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>S</VALIDVALUE>
          <VALUEMEANING>first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T</VALIDVALUE>
          <VALUEMEANING>second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine(cuspid) primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine(cuspid) primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ES</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>JS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch upper left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch upper left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>OS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower left</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower left</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PS</VALIDVALUE>
          <VALUEMEANING>supernumerary central incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary central incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>QS</VALIDVALUE>
          <VALUEMEANING>supernumerary lateral incisor primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary lateral incisor primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RS</VALIDVALUE>
          <VALUEMEANING>supernumerary canine (cuspid) primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary canine (cuspid) primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SS</VALIDVALUE>
          <VALUEMEANING>supernumerary first molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary first molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TS</VALIDVALUE>
          <VALUEMEANING>supernumerary second molar primary arch lower right</VALUEMEANING>
          <MEANINGDESCRIPTION>supernumerary second molar primary arch lower right</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-09-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Tooth Number B</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Tooth Number B</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3232580</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRL0602</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Data</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>3232568</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3232580</PublicId>
          <ContextName>NIDCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRL0602</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.nidcr.prl0602</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3232569</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.nidcr.prl0602.DentalRestorationPatient.tooth_Number_B</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DentalRestorationPatient:tooth_Number_B</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1488">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3264678</PUBLICID>
    <LONGNAME>Personal Medical History Total Pregnancy Count</LONGNAME>
    <PREFERREDNAME>3263763v1.0:3263737v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Value to describe the number of total pregnancies experienced.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3263763</PublicId>
      <PreferredName>2607692v1.0:3263761v1.0</PreferredName>
      <PreferredDefinition>A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both._Reproduction is the creation of one thing as a copy of, product of, or replacement for a similar thing.  It is commonly used in the context of biological reproduction and sex. (from Wikipedia)_Characteristics; distinguishing qualities of a person, object, or substance._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)</PreferredDefinition>
      <LongName>Female Reproduction Characteristic Total Pregnancy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16576:C17087:C25447</PreferredName>
        <Version>1</Version>
        <LongName>Female Reproduction Characteristic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16576</PREFERRED_NAME>
            <LONG_NAME>Female</LONG_NAME>
            <CON_ID>2204935</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17087</PREFERRED_NAME>
            <LONG_NAME>Reproduction</LONG_NAME>
            <CON_ID>2203777</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25447</PREFERRED_NAME>
            <LONG_NAME>Characteristic</LONG_NAME>
            <CON_ID>2203874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3263761</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25742</PreferredName>
        <Version>1</Version>
        <LongName>Total Pregnancy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3263737</PublicId>
      <PreferredName>3263737v1.0</PreferredName>
      <PreferredDefinition>an account of all medical events and problems a person has experienced._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Personal Medical History Pregnancy Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>35</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3263736</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18772:C25742:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History Pregnancy Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25742</PREFERRED_NAME>
            <LONG_NAME>Pregnancy</LONG_NAME>
            <CON_ID>2202906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5 or more</VALIDVALUE>
          <VALUEMEANING>5 or more</VALUEMEANING>
          <MEANINGDESCRIPTION>5 or more</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568894</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Four</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3218929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>One</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How many total pregnancies ha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How many total pregnancies have you had?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Gravida-Total number of pregnancies including current</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Womens Health</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259225</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UWI2016-07-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280817</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1489">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3287353</PUBLICID>
    <LONGNAME>Partial Breast Radiation Therapy Administration Method Type</LONGNAME>
    <PREFERREDNAME>PART_BR_RT_METH_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>Text name for a partial breast irradiation modality/method used to deliver irradiation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BOLD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BOLD:Breast Oncology Local Disease Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3287346</PublicId>
      <PreferredName>PART_BR_RT_ADM_METH</PreferredName>
      <PreferredDefinition>Partial; being or affecting only a part; not total_One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Boost; increase or raise._Performing or possessing executive duties; acting as a supervisor or manager._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._</PreferredDefinition>
      <LongName>Partial Breast Radiation Therapy Administration Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3287282</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25378:C12971:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Partial Breast Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25378</PREFERRED_NAME>
            <LONG_NAME>Partial</LONG_NAME>
            <CON_ID>2202690</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3287204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48905:C71460</PreferredName>
        <Version>1</Version>
        <LongName>Administration Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3287348</PublicId>
      <PreferredName>PART_BR_RT_METH_TP</PreferredName>
      <PreferredDefinition>Partial; being or affecting only a part; not total_A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter&#39;s syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Partial Breast Carcinoma Radiation Therapy Method Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>80</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3287347</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3287347v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Partial Breast Carcinoma Radiation Therapy Method Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25378</PREFERRED_NAME>
            <LONG_NAME>Partial</LONG_NAME>
            <CON_ID>2202690</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4872</PREFERRED_NAME>
            <LONG_NAME>Breast Carcinoma</LONG_NAME>
            <CON_ID>2475940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C15313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Protons</VALIDVALUE>
          <VALUEMEANING>Proton Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66897</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IMRT</VALIDVALUE>
          <VALUEMEANING>Intensity-Modulated Radiation Therapy </VALUEMEANING>
          <MEANINGDESCRIPTION>An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16135</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3D CRT</VALIDVALUE>
          <VALUEMEANING>3-Dimensional Conformal Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16035</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraop</VALIDVALUE>
          <VALUEMEANING>Intraoperative</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring during the course of a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intracavitary Brachytherapy Device (MammoSite, Contour, ClearPath, etc.)</VALIDVALUE>
          <VALUEMEANING>Intracavitary Brachytherapy Device</VALUEMEANING>
          <MEANINGDESCRIPTION>Within a cavity or space, such as the abdomen, pelvis, or chest.: (ray-dee-AY-shun) A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor. Also called brachytherapy, internal radiation, or interstitial radiation.: An object contrived for a specific purpose.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62103, C15195, C28364</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287351</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interstitial Brachytherapy</VALIDVALUE>
          <VALUEMEANING>Interstitial Radiation Therapy Brachytherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue. (Cancer.gov): (ray-dee-AY-shun) A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor. Also called brachytherapy, internal radiation, or interstitial radiation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15195, C66891</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3287352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post-op external beam</VALIDVALUE>
          <VALUEMEANING>Postoperative External Beam Radiation Therapy</VALUEMEANING>
          <MEANINGDESCRIPTION>After surgery.: Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15751, C28006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5230191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Post-op brachytherapy device</VALIDVALUE>
          <VALUEMEANING>Postoperative Brachytherapy Device</VALUEMEANING>
          <MEANINGDESCRIPTION>After surgery.: A type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor.: Any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16830, C15195, C28006</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5230192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Partial Breast Irradiation Me</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Partial Breast Irradiation Method</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461591</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886758</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Radiation Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Radiation</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902141</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PART_BR_RT_METH_TP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1490">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3287957</PUBLICID>
    <LONGNAME>Clinical Study Protocol Other Stratification Factors Type</LONGNAME>
    <PREFERREDNAME>3287956v1.0:2200969v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the type as related to the other protocol stratification factors.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3287956</PublicId>
      <PreferredName>2176994v1.0:3287954v1.0</PreferredName>
      <PreferredDefinition>information related to the other protocol stratification factors.</PreferredDefinition>
      <LongName>Clinical Study Protocol Other Stratification Factors</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176994</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Protocol</PreferredName>
        <Version>1</Version>
        <LongName>Protocol</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3287954</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C16153</PreferredName>
        <Version>1</Version>
        <LongName>Other Stratification Factors</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16153</PREFERRED_NAME>
            <LONG_NAME>Stratification Factors</LONG_NAME>
            <CON_ID>2203599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2200969</PublicId>
      <PreferredName>PROT_STRATFACTOR_TP</PreferredName>
      <PreferredDefinition>the protocol stratification factors.</PreferredDefinition>
      <LongName>Protocol Stratification Factors Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>150</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Progression of measurable or evaluable disease</VALIDVALUE>
          <VALUEMEANING>Progression of measurable or evaluable disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Progression of measurable or evaluable disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSA progression only</VALIDVALUE>
          <VALUEMEANING>PSA progression only</VALUEMEANING>
          <MEANINGDESCRIPTION>PSA progression only</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small bowel</VALIDVALUE>
          <VALUEMEANING>SMALL BOWEL</VALUEMEANING>
          <MEANINGDESCRIPTION>The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560057</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-small bowel</VALIDVALUE>
          <VALUEMEANING>Non-small bowel</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-small bowel</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578323</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Small bowel, cecum, appendix</VALIDVALUE>
          <VALUEMEANING>Small bowel, cecum, appendix</VALUEMEANING>
          <MEANINGDESCRIPTION>Small bowel, cecum, appendix</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2674227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other sites</VALIDVALUE>
          <VALUEMEANING>Other sites</VALUEMEANING>
          <MEANINGDESCRIPTION>Other sites</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2674228</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stage II</VALIDVALUE>
          <VALUEMEANING>Stage II Breast Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, MO); (T3,NO,MO).  T0: No evidence of primary tumor.  T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th Ed.) - 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676548</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stage I</VALIDVALUE>
          <VALUEMEANING>Stage I Breast Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7767</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676546</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER and/or PGR positive</VALIDVALUE>
          <VALUEMEANING>ER and/or PgR positive</VALUEMEANING>
          <MEANINGDESCRIPTION>Estrogen and/or Progesterone positive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580876</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ER and PGR negative</VALIDVALUE>
          <VALUEMEANING>ER and PgR negative</VALUEMEANING>
          <MEANINGDESCRIPTION>ER and PgR negative</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gleason 8 and PSA &lt; 20 and &gt;=T2</VALIDVALUE>
          <VALUEMEANING>Gleason score 8 and PSA value &lt; 20 and &gt;=T2</VALUEMEANING>
          <MEANINGDESCRIPTION>Gleason score 8 and PSA value &lt; 20 and &gt;=T2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2770793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gleason 8 and PSA &gt;=20-150 and any T-stage</VALIDVALUE>
          <VALUEMEANING>Gleason score 8 and PSA value &gt;=20-150 and any T-stage</VALUEMEANING>
          <MEANINGDESCRIPTION>Gleason score 8 and PSA value &gt;=20-150 and any T-stage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2770794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gleason 7 and PSA &gt;=20-150 and any T-stage</VALIDVALUE>
          <VALUEMEANING>Gleason score 7 and PSA value &gt;=20-150 and any T-stage</VALUEMEANING>
          <MEANINGDESCRIPTION>Gleason score 7 and PSA value &gt;=20-150 and any T-stage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2770795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stratum 1 - The patient has either measurable or recurrent disease</VALIDVALUE>
          <VALUEMEANING>The patient has either measurable or recurrent disease</VALUEMEANING>
          <MEANINGDESCRIPTION>The patient has either measurable or recurrent disease</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2771792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stratum 2 - The patient has non-measurable Stage III or IV disease and HAS received radiation to the pelvis</VALIDVALUE>
          <VALUEMEANING>The patient has non-measurable Stage III or IV disease and has received radiation to the pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The patient has non-measurable Stage III or IV disease and has received radiation to the pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2771793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stratum 3 - The patient has non-measurable Stage III or IV disease with NO previous radiation to the pelvis</VALIDVALUE>
          <VALUEMEANING>The patient has non-measurable Stage III or IV disease with no previous radiation to the pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>The patient has non-measurable Stage III or IV disease with no previous radiation to the pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2771794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gleason 8 and PSA &lt;20 and &gt;=T2</VALIDVALUE>
          <VALUEMEANING>Gleason 8 and PSA &lt;20 and &gt;=T2</VALUEMEANING>
          <MEANINGDESCRIPTION>Gleason 8 and PSA &lt;20 and &gt;=T2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2825181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gleason &gt;=9 and PSA &lt;=150 and any T-stage</VALIDVALUE>
          <VALUEMEANING>Gleason score &gt;=9, PSA value &lt;=150, and any T-stage</VALUEMEANING>
          <MEANINGDESCRIPTION>Gleason score &gt;=9, PSA value &lt;=150, and any T-stage</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2852431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ITD Allelic ratio &gt;= 0.7 (with or without FLT3 TKD)</VALIDVALUE>
          <VALUEMEANING>ITD Allelic ratio &gt;= 0.7 (with or without FLT3 TKD)</VALUEMEANING>
          <MEANINGDESCRIPTION>Internal tandem duplications of allelic ratio &gt;= 0.7 (with or without FLT3 point mutation or on tyrosin kinase domain)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2945370</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ITD Allelic ratio &lt; 0.7 (with or without FLT3 TKD)</VALIDVALUE>
          <VALUEMEANING>ITD Allelic ratio &lt; 0.7 (with or without FLT3 TKD)</VALUEMEANING>
          <MEANINGDESCRIPTION>Internal tandem duplications allelic ratio &lt; 0.7 (with or without FLT3 point mutation or on tyrosine kinase domain)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2945371</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLT3 TKD (No ITD)</VALIDVALUE>
          <VALUEMEANING>FLT3 TKD (No ITD)</VALUEMEANING>
          <MEANINGDESCRIPTION>FLT3 point mutation or on the tyrosin kinase domain (no internal tandem duplications)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2945372</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Down Syndrome Patient</VALIDVALUE>
          <VALUEMEANING>Down Syndrome Patient</VALUEMEANING>
          <MEANINGDESCRIPTION>Down Syndrome Patient</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Down Syndrome Patient</VALIDVALUE>
          <VALUEMEANING>Non-Down Syndrome Patient</VALUEMEANING>
          <MEANINGDESCRIPTION>Non-Down Syndrome Patient</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192578</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>All Patients</VALIDVALUE>
          <VALUEMEANING>All Patients</VALUEMEANING>
          <MEANINGDESCRIPTION>All Patients</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3192579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stage III</VALIDVALUE>
          <VALUEMEANING>Stage III Breast Cancer</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.) - 2003</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C7769</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676550</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A1 or A2 or cannot enroll on Part A1 because of stratum suspension or lack of available slots</VALIDVALUE>
          <VALUEMEANING>Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A1 or A2 or cannot enroll on Part A1 because of stratum suspension or lack of available slots</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A1 or A2 or cannot enroll on Part A1 because of stratum suspension or lack of available slots</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243644</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients with recurrent/refractory malignancies that have confirmed ALK fusion proteins or ALK mutations or ALK amplification</VALIDVALUE>
          <VALUEMEANING>Patients with recurrent/refractory malignancies that have confirmed ALK fusion proteins or ALK mutations or ALK amplification</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with recurrent/refractory malignancies that have confirmed ALK fusion proteins or ALK mutations or ALK amplification</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243645</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITH OR WITHOUT bone marrow involvement</VALIDVALUE>
          <VALUEMEANING>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITH OR WITHOUT bone marrow involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITH OR WITHOUT bone marrow involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243646</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITHOUT bone marrow involvement</VALIDVALUE>
          <VALUEMEANING>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITHOUT bone marrow involvement</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITHOUT bone marrow involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3243647</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Age &gt;= 51 years and KPS &lt; 70</VALIDVALUE>
          <VALUEMEANING>Age &gt;= 51 years and Karnofsky Performance Status score &lt; 70</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is 51 years or older with a Karnofsky Performance Status score below 70.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Age &gt;= 51 years and KPS &gt;=70</VALIDVALUE>
          <VALUEMEANING>Age &gt;= 51 years and KPS score &gt;=70</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is 51 years or older with a Karnofsky Performance Status score equal to 70 or higher</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Age &lt; 51 years</VALIDVALUE>
          <VALUEMEANING>Age &lt; 51 years</VALUEMEANING>
          <MEANINGDESCRIPTION>Patient is less than 51 years of age</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neuroblastoma WITH OR WITHOUT BM</VALIDVALUE>
          <VALUEMEANING>Neuroblastoma WITH OR WITHOUT BM</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A1 or A2 or cannot enroll on Part A1 because of stratum suspension or lack of available slots</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3418439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapsed, refractory solid WITHOUT BM</VALIDVALUE>
          <VALUEMEANING>Relapsed, refractory solid WITHOUT BM</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITHOUT bone marrow involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3418441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Relapsed, refractory solid WITH OR WITHOUT BM</VALIDVALUE>
          <VALUEMEANING>Relapsed, refractory solid WITH OR WITHOUT BM</VALUEMEANING>
          <MEANINGDESCRIPTION>Patients with relapsed/refractory solid tumors (including CNS tumors), and anaplastic large cell lymphoma (ALCL) WITH OR WITHOUT bone marrow involvement</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-03-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3418440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ADVL0912 stratum</VALIDVALUE>
          <VALUEMEANING>ADVL0912 stratum</VALUEMEANING>
          <MEANINGDESCRIPTION>ADVL0912 stratum</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3343188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AALL08B1 stratum</VALIDVALUE>
          <VALUEMEANING>AALL08B1 stratum</VALUEMEANING>
          <MEANINGDESCRIPTION>AALL08B1 stratum</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3343189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Age 60-69 years</VALIDVALUE>
          <VALUEMEANING>Age 60-69 years</VALUEMEANING>
          <MEANINGDESCRIPTION>Participant is &gt;= 60 years of age but &lt; 70 years of age.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3553884</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Age &gt;= 70 years</VALIDVALUE>
          <VALUEMEANING>Age &gt;= 70 years</VALUEMEANING>
          <MEANINGDESCRIPTION>Participant is 70 years or older</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-08-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3553883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderate or severe neurologic symptoms</VALIDVALUE>
          <VALUEMEANING>Moderate Or Severe Neurologic Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Intensely bad or unpleasant in degree, quality or extent.: (noor-uh-LOJ-ik) Having to do with nerves or the nervous system.: Subjective evidence of disease perceived by the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C25262, C70667, C37998, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4255432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No or minor neurologic symptoms</VALIDVALUE>
          <VALUEMEANING>No Or Minor Neurologic Symptom</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Lesser or smaller in amount, extent, or size.: (noor-uh-LOJ-ik) Having to do with nerves or the nervous system.: Subjective evidence of disease perceived by the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4876, C25262, C45367, C37998, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4255431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class III</VALIDVALUE>
          <VALUEMEANING>Class Three</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class IV</VALIDVALUE>
          <VALUEMEANING>Class Four</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class V</VALIDVALUE>
          <VALUEMEANING>Class Five</VALUEMEANING>
          <MEANINGDESCRIPTION>A grouping of things based on shared common attributes.: A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4336915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&lt; 25 kg/m2 (normal/underweight)</VALIDVALUE>
          <VALUEMEANING>&lt; 25 kg/m2 (normal/underweight)</VALUEMEANING>
          <MEANINGDESCRIPTION>Less than 25 kilograms per meter squared (normal/underweight).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4554281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>&gt;/= 25 kg/m2 (overweight/obese)</VALIDVALUE>
          <VALUEMEANING>&gt;/= 25 kg/m2 (overweight/obese)</VALUEMEANING>
          <MEANINGDESCRIPTION>Greater than or equal to 25 kilograms per meter squared (overweight/obese)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4554316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Controlled</VALIDVALUE>
          <VALUEMEANING>Disease Controlled</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication or description that a particular disorder is being managed successfully.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82500</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4538963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Uncontrolled</VALIDVALUE>
          <VALUEMEANING>Disease or Disorder Uncontrolled</VALUEMEANING>
          <MEANINGDESCRIPTION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL124380, C2991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4538964</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class I</VALIDVALUE>
          <VALUEMEANING>Class One</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class II</VALIDVALUE>
          <VALUEMEANING>Class Two</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stratum 2 - No PN related morbidity present at enrollment</VALIDVALUE>
          <VALUEMEANING>No Plexiform Neurofibroma (PN) related morbidity present at enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>No Plexiform Neurofibroma (PN) related morbidity present at enrollment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-11-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5047271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stratum 1 - PN related morbidity present at enrollment</VALIDVALUE>
          <VALUEMEANING>Plexiform Neurofibroma (PN) related morbidity present at enrollment</VALUEMEANING>
          <MEANINGDESCRIPTION>Plexiform Neurofibroma (PN) related morbidity present at enrollment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-11-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5047272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High bowel and urinary scores</VALIDVALUE>
          <VALUEMEANING>High Intestine And Urinary Score</VALUEMEANING>
          <MEANINGDESCRIPTION>An elevated level or position or degree; greater than normal in degree or intensity or amount.: The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Having to do with urine or the organs of the body that produce and get rid of urine.: A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338, C25711, C37912, C12736, C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589189</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High bowel and low urinary scores</VALIDVALUE>
          <VALUEMEANING>High Intestine And Low Urinary Score</VALUEMEANING>
          <MEANINGDESCRIPTION>An elevated level or position or degree; greater than normal in degree or intensity or amount.: The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A minimum level or position or degree; less than normal in degree, intensity or amount.: Having to do with urine or the organs of the body that produce and get rid of urine.: A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338, C25711, C54722, C37912, C12736, C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589190</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low bowel and high urinary scores</VALIDVALUE>
          <VALUEMEANING>Low Intestine And High Urinary Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree, intensity or amount.: The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An elevated level or position or degree; greater than normal in degree or intensity or amount.: Having to do with urine or the organs of the body that produce and get rid of urine.: A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338, C25711, C25227, C37912, C12736, C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589191</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Low bowel and urinary scores</VALIDVALUE>
          <VALUEMEANING>Low Intestine And Urinary Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A minimum level or position or degree; less than normal in degree, intensity or amount.: The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Having to do with urine or the organs of the body that produce and get rid of urine.: A number or range of numeric values measuring performance, function, quality, or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25338, C25711, C37912, C12736, C54722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No not impaired greater than or equal to  -0.5</VALIDVALUE>
          <VALUEMEANING>No not impaired greater than or equal to  -0.5</VALUEMEANING>
          <MEANINGDESCRIPTION>No not impaired greater than or equal to  -0.5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5840137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes impaired  less than -0.5</VALIDVALUE>
          <VALUEMEANING>Yes impaired  less than -0.5</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes impaired  less than -0.5</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5840138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modified CCI greater than 0</VALIDVALUE>
          <VALUEMEANING>Modified Charlson Comorbidity Index Chart Review Version Greater Than Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>Modified; changed in form or character.: A method of predicting mortality by weighting comorbid conditions calculated by reviewing an individual&#39;s chart.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70430, C61584, C106374, C25573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Modified CCI equals 0</VALIDVALUE>
          <VALUEMEANING>Modified Charlson Comorbidity Index Chart Review Version Equality Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>Modified; changed in form or character.: A method of predicting mortality by weighting comorbid conditions calculated by reviewing an individual&#39;s chart.: The quality of being the same in quantity or measure or value or status.: A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70430, C61582, C106374, C25573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6024349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stage III-IVa</VALIDVALUE>
          <VALUEMEANING>Stage III-IVa</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage III-IVa</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6401153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Stage I-II</VALIDVALUE>
          <VALUEMEANING>Stage I-II</VALUEMEANING>
          <MEANINGDESCRIPTION>Stage I-II</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2018-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6401154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BID (3 weeks)</VALIDVALUE>
          <VALUEMEANING>Twice Daily</VALUEMEANING>
          <MEANINGDESCRIPTION>Two times per day, at unspecified times.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64496</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3162686</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily (6.5 weeks)</VALIDVALUE>
          <VALUEMEANING>Daily</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3269963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Undetectable after surgery and then rising</VALIDVALUE>
          <VALUEMEANING>Undetectable after surgery and then rising</VALUEMEANING>
          <MEANINGDESCRIPTION>Undetectable after surgery and then rising</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6865695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never undetectable after surgery</VALIDVALUE>
          <VALUEMEANING>Never undetectable after surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Never undetectable after surgery</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-08-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6865696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Undetectable (0.0)</VALIDVALUE>
          <VALUEMEANING>Undetectable (0.0)</VALUEMEANING>
          <MEANINGDESCRIPTION>Undetectable (0.0)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7604248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Detectable (Greater than 0)</VALIDVALUE>
          <VALUEMEANING>Detectable (Greater than 0)</VALUEMEANING>
          <MEANINGDESCRIPTION>Detectable (Greater than 0)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2021-03-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7604249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clear Cell</VALIDVALUE>
          <VALUEMEANING>Clear Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Clear Cell</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Clear Cell</VALIDVALUE>
          <VALUEMEANING>Non-clear cell</VALUEMEANING>
          <MEANINGDESCRIPTION>A cell that does not have an empty-appearing cytoplasm when viewed with a light microscope</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3198848</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Stratification factors</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Stratification factors</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ADVL0912 Stratum</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ANBL12P1 STRATUM</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ALTE11C1 Stratum</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Primary disease status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ALTE1621 Stratum:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>Stratum</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PRIM_DIS_STATUS</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1491">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3288137</PUBLICID>
    <LONGNAME>Tissue Storage Vessel Other Specify Text</LONGNAME>
    <PREFERREDNAME>3081874v2.0:2857322v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Free text field for another type of container utilized to store and ship tissue that is not previously mentioned or specified.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3081874</PublicId>
      <PreferredName>2192778v1.0:5118572v1.0</PreferredName>
      <PreferredDefinition>An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The act of safekeeping goods in a depository._An object that can be used to hold things.</PreferredDefinition>
      <LongName>Tissue Storage Container</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2192778</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12801</PreferredName>
        <Version>1</Version>
        <LongName>Tissue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5118572</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60824:C43186</PreferredName>
        <Version>1</Version>
        <LongName>Storage Container</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60824</PREFERRED_NAME>
            <LONG_NAME>Storage</LONG_NAME>
            <CON_ID>2547381</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43186</PREFERRED_NAME>
            <LONG_NAME>Container</LONG_NAME>
            <CON_ID>2513272</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other Vessel Used</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other Vessel Used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BRCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CESC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>COAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787503</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KICH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787508</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787513</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PAAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>READ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SKCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787519</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>STAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787520</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>THCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCEC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical cqcf</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787533</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>other_vessel_used</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1492">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3290619</PUBLICID>
    <LONGNAME>Preoperative Neoadjuvant Therapy Occurrence Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>3290618v1.0:2181608v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to signify whether an individual received any preoperative neoadjuvant therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BOLD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BOLD:Breast Oncology Local Disease Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3290618</PublicId>
      <PreferredName>2759145v1.0:2234856v1.0</PreferredName>
      <PreferredDefinition>neoadjuvant therapy, as treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents._An instance of something happening, such as an event or incident._Relating to or occurring during the period immediately before a surgical operation.</PreferredDefinition>
      <LongName>Preoperative Neoadjuvant Therapy Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2759145</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54732:C15665</PreferredName>
        <Version>1</Version>
        <LongName>Preoperative Neoadjuvant Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54732</PREFERRED_NAME>
            <LONG_NAME>Preoperative</LONG_NAME>
            <CON_ID>2512567</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pre-Operative Therapy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pre-Operative Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461586</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BOLD </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Surgery Elements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461590</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886759</PublicId>
          <ContextName>BOLD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Surgery Elements</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Surgery</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3902142</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1493">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3293647</PUBLICID>
    <LONGNAME>Subject Malignant Neoplasm Stage Sponsor Assessment Indicator</LONGNAME>
    <PREFERREDNAME>S_CA_ST_SPON_ASS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator to signify that the site defers to the sponsor for determination of the subject&#39;s stage of cancer at diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3293646</PublicId>
      <PreferredName>S_CA_ST_SPON_ASSESS</PreferredName>
      <PreferredDefinition>Information pertaining to the extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body and the final determiniation of the value, significance, or extent of by the sponsor.</PreferredDefinition>
      <LongName>Subject Malignant Neoplasm Stage Sponsor Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3293643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48910:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Subject Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48910</PREFERRED_NAME>
            <LONG_NAME>Subject</LONG_NAME>
            <CON_ID>2553605</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3293644</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899:C48355:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Stage Sponsor Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48355</PREFERRED_NAME>
            <LONG_NAME>Sponsor</LONG_NAME>
            <CON_ID>2448403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015873</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>A choice of Yes and No answer.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>2.31</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SPOREs</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008509</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPORES</PreferredName>
        <Version>2.31</Version>
        <LongName>SPOREs</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>YES</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-03-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NO</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Defer to Sponsor for Staging</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Defer to Sponsor for Staging</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen Repository</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3060675</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3021954</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Caris Life Sciences</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Breast</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000006</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1494">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3294419</PUBLICID>
    <LONGNAME>Sufficient Sleep Feelings Past 30 Day Count</LONGNAME>
    <PREFERREDNAME>3294315v1.0:3290597v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Number that represents how many days in the past month a person has felt that they did not get enough sleep.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3294315</PublicId>
      <PreferredName>3294313v1.0:3294307v1.0</PreferredName>
      <PreferredDefinition>Meeting a quantitative measure necessary for a requirement; enough to meet the needs of a situation._A natural and periodic state of rest during which  consciousness of the world is suspended._Past; before the present time._A number with no fractional part.::30_The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._Emotional sensations.</PreferredDefinition>
      <LongName>Sufficient Sleep Past 30 Day Feelings</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3294313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63351:C73425</PreferredName>
        <Version>1</Version>
        <LongName>Sufficient Sleep</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63351</PREFERRED_NAME>
            <LONG_NAME>Sufficient</LONG_NAME>
            <CON_ID>2538604</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73425</PREFERRED_NAME>
            <LONG_NAME>Sleep</LONG_NAME>
            <CON_ID>2736838</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3294307</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3294307v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::30 Day Feelings</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::30</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77965</PREFERRED_NAME>
            <LONG_NAME>Feelings</LONG_NAME>
            <CON_ID>2802554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3290597</PublicId>
      <PreferredName>3290597v1.0</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._Quantity; how much there is of something that you can measure._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>30 Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>30</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>3290609</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25256:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Day Quantity Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>Day 28</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::28: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::28</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>Day 27</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::27: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::27</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>Day 26</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::26: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::26</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>Day 25</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::25: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::25</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>Day 24</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::24: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::24</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>Day 23</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::23: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::23</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>Day 22</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::22: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::22</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>Day 21</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Day 19</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::19: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::19</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Day 18</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::18: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::18</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Day 20</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::20: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::20</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Day 17</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::17: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::17</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Day 16</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::16: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::16</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Day 15</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::15: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::15</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>Day 14</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::14</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Day 30</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::30: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::30</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>Day 29</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::29: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::29</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Day 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C69122</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Day 9</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66840</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Day 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66839</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290600</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Day 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66838</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290601</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Day 6</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66837</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290602</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Day 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290603</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Day 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290604</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Day 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Day 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Day 1</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Day 0</VALUEMEANING>
          <MEANINGDESCRIPTION>A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C70430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3290608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Day 13</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::13: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::13</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Day 12</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::12: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Day 11</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::11: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>Don&#39;t know/Not sure</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>To decline to do, accept, give, or allow something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2639691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577064</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>During the past 30 days, for</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>During the past 30 days, for about how many days have you felt you did not get enough rest or sleep?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Health Survey </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259220</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3259219</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>University of Michigan</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Quality of Life</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3259230</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1495">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3332528</PUBLICID>
    <LONGNAME>Tobacco Brief Wisconsin Inventory of Smoking Dependence Motive (Brief WISDM) Questionnaire Assessment Score</LONGNAME>
    <PREFERREDNAME>Toba_Brie_Wisc_Inve_Smok_Depe_</PREFERREDNAME>
    <PREFERREDDEFINITION>The leaves of the tobacco plant, Nicotiana tabacum, dried and prepared for smoking or ingestion._Of short duration, extent, or distance._A state in the northern midwest United States. Its capital is Madison._The goods and materials held by a business._The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe._The psychological or physiological need to take a substance in oder to experience its effects or to avoid the effects of its absence._The psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._The final result of a determination of the value, significance, or extent of._A number or range of numeric values measuring performance, function, quality, or ability.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3332527</PublicId>
      <PreferredName>Toba_Brie_Wisc_Inve_Smok_Depe_</PreferredName>
      <PreferredDefinition>The leaves of the tobacco plant, Nicotiana tabacum, dried and prepared for smoking or ingestion._Of short duration, extent, or distance._A state in the northern midwest United States. Its capital is Madison._The goods and materials held by a business._The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe._The psychological or physiological need to take a substance in oder to experience its effects or to avoid the effects of its absence._The psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.</PreferredDefinition>
      <LongName>Tobacco Brief Wisconsin Inventory of Smoking Dependence Motive (Brief WISDM) Questionnaire</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2662193</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C891</PreferredName>
        <Version>1</Version>
        <LongName>Tobacco</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C891</PREFERRED_NAME>
            <LONG_NAME>Tobacco</LONG_NAME>
            <CON_ID>2202548</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3346665</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3346665v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Brief Wisconsin Inventory Smoking Dependence Motivation Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61484</PREFERRED_NAME>
            <LONG_NAME>Brief</LONG_NAME>
            <CON_ID>2727634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43485</PREFERRED_NAME>
            <LONG_NAME>Wisconsin</LONG_NAME>
            <CON_ID>2553504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86559</PREFERRED_NAME>
            <LONG_NAME>Inventory</LONG_NAME>
            <CON_ID>3070657</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17934</PREFERRED_NAME>
            <LONG_NAME>Tobacco Smoking</LONG_NAME>
            <CON_ID>2202827</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35458</PREFERRED_NAME>
            <LONG_NAME>Dependence</LONG_NAME>
            <CON_ID>2442256</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28495</PREFERRED_NAME>
            <LONG_NAME>Motivation</LONG_NAME>
            <CON_ID>2714465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3076086</PublicId>
      <PreferredName>ASSES_SC</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Assessment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Tobacco Brief Wisconsin Inventory of Smoking Dependence Motive (Brief WISDM) Questionnaire Assessment Score does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Tobacco Brief Wisconsin Inventory of Smoking Dependence Motive (Brief WISDM) Questionnaire Assessment Score does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Substance Abuse and Addiction Specialty Collection</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3689612</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Substance-specific Intermediate Phenotypes</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3689960</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NIDA</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NIDA</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1496">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3335774</PUBLICID>
    <LONGNAME>Human Herpes Virus 8 Result Indicator</LONGNAME>
    <PREFERREDNAME>HHV8_KSHV_RSL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text indicator to respresent whether a serological herpes human virus 8 (HHV8) test was completed for an individual.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3335765</PublicId>
      <PreferredName>3335762v1.00:3335763v1.00</PreferredName>
      <PreferredDefinition>An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.:The outcome of an experiment or set of experiments, including observations and primary, processed, and analyzed data.</PreferredDefinition>
      <LongName>Human Herpes Virus 8 Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3335762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C39291</PreferredName>
        <Version>1</Version>
        <LongName>Human Herpes Virus 8 Infection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39291</PREFERRED_NAME>
            <LONG_NAME>HHV8 Infection</LONG_NAME>
            <CON_ID>3335761</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3335763</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C76125</PreferredName>
        <Version>1</Version>
        <LongName>Experimental Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C76125</PREFERRED_NAME>
            <LONG_NAME>Experimental Result</LONG_NAME>
            <CON_ID>3099511</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>KSHV</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>KSHV</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335152</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HTMCP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HTMCP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3257277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655968</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HTMCP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HTMCP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000067</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1497">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3349536</PUBLICID>
    <LONGNAME>Eastern Cooperative Oncology Group And Karnofsky Performance Status Score</LONGNAME>
    <PREFERREDNAME>ECOG_K_PERF_STAT_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>The number or value that determines the value, significance, or extent of how well a patient is able to perform ordinary tasks and to carry out daily activities based on the Eastern Cooperative Oncology Group (ECOG) and the Karnofsky Performance Statuses.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RETIRED ARCHIVED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2486204</PublicId>
      <PreferredName>PERFORSTAT_ASSESS</PreferredName>
      <PreferredDefinition>information related to the final result of a determination of the value, significance, or extent of how well a patient is able to perform ordinary tasks and carry out daily activities.</PreferredDefinition>
      <LongName>Performance Status Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2486202</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20641</PreferredName>
        <Version>1</Version>
        <LongName>Performance Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20641</PREFERRED_NAME>
            <LONG_NAME>Performance Status</LONG_NAME>
            <CON_ID>2202910</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3349519</PublicId>
      <PreferredName>ECOG_K_PERF_STAT_SC</PreferredName>
      <PreferredDefinition>The number or range of numeric values measuring performance, function, quality, or ability for the Eastern Cooperative Oncology Group (ECOG) and the Karnofsky Performance Status.</PreferredDefinition>
      <LongName>Eastern Cooperative Oncology Group And Karnofsky Performance Status Score</LongName>
      <Version>1.2</Version>
      <WorkflowStatus>RETIRED ARCHIVED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
      <Representation>
        <PublicId>3349518</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25491:C37912:C28013:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Eastern Cooperative Oncology Group And Karnofsky Performance Status Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25491</PREFERRED_NAME>
            <LONG_NAME>Eastern Cooperative Oncology Group</LONG_NAME>
            <CON_ID>2205050</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28013</PREFERRED_NAME>
            <LONG_NAME>Karnofsky Performance Status</LONG_NAME>
            <CON_ID>2202463</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>0=Asymptomatic and fully active (ECOG)</VALUEMEANING>
          <MEANINGDESCRIPTION>Fully active, able to carry on all pre-disease performance without restriction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105722</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350729</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>10=Moribund, fatal processes progressing rapidly</VALUEMEANING>
          <MEANINGDESCRIPTION>Moribund; fatal processes progressing rapidly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105718</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350730</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100</VALIDVALUE>
          <VALUEMEANING>100=Normal, no complaints, no evidence of disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Normal; no complaints; no evidence of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105707</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350731</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>1=Symptomatic; fully ambulatory; restricted in physically strenuous activity</VALUEMEANING>
          <MEANINGDESCRIPTION>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3349534</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>20=Very sick, hospitalization indicated. Death not imminent</VALUEMEANING>
          <MEANINGDESCRIPTION>Very sick; hospitalization necessary; active support treatment is necessary.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105716</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>30=Severely disabled, hospitalization indicated. Death not imminent</VALUEMEANING>
          <MEANINGDESCRIPTION>Severely disabled; hospitalization is indicated, although death not imminent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105715</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>40=Disabled, requires special care and assistance</VALUEMEANING>
          <MEANINGDESCRIPTION>Disabled; requires special care and assistance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>4=Completely disabled; no self-care; bedridden</VALUEMEANING>
          <MEANINGDESCRIPTION>Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3349531</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>50</VALIDVALUE>
          <VALUEMEANING>50=Requires considerable assistance and frequent medical care</VALUEMEANING>
          <MEANINGDESCRIPTION>Requires considerable assistance and frequent medical care.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105713</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>60=Requires occasional assistance, but is able to care for most of his/her needs</VALUEMEANING>
          <MEANINGDESCRIPTION>Requires occasional assistance, but is able to care for most personal needs.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105712</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>70=Cares for self, unable to carry on normal activity or to do active work</VALUEMEANING>
          <MEANINGDESCRIPTION>Cares for self; unable to carry on normal activity or do active work.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105711</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>80=Normal activity with effort; some signs or symptoms of disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Normal activity with effort; some sign or symptoms of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105710</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>90</VALIDVALUE>
          <VALUEMEANING>90=Able to carry on normal activity; minor signs or symptoms of disease</VALUEMEANING>
          <MEANINGDESCRIPTION>Able to carry on normal activity; minor signs or symptoms of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105709</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3350739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>2=Symptomatic; ambulatory; capable of self-care; greater than 50% waking hours out of bed</VALUEMEANING>
          <MEANINGDESCRIPTION>Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105725</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3349533</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>3=Symptomatic; limited self-care; greater than 50% waking hours in bed</VALUEMEANING>
          <MEANINGDESCRIPTION>Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C105726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3349532</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Performance Status</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Performance Status</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>On-Study KPS</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG_K_PERF_STAT_SCv2</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>COMPOUND</DerivationType>
      <DerivationTypeDescription>COMPOUND</DerivationTypeDescription>
      <Methods/>
      <Rule>Composite of the ECOG and Karnofsky Performance Statuses.</Rule>
      <ConcatenationCharacter>;</ConcatenationCharacter>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>88</PublicId>
          <LongName>Performance Status Assessment Eastern Cooperative Oncology Group Scale</LongName>
          <PreferredName>PERF_ASS_ECOG_SCALE</PreferredName>
          <PreferredDefinition>the ECOG functional performance status of the patient/participant.</PreferredDefinition>
          <Version>5.1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>CTEP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2003853</PublicId>
          <LongName>Karnofsky Performance Status Score</LongName>
          <PreferredName>KARN_PERF_STAT_SC</PreferredName>
          <PreferredDefinition>Score from the Karnofsky Performance status scale, representing the functional capabilities of a person.</PreferredDefinition>
          <Version>4.2</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>CCR</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1498">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>88</PUBLICID>
    <LONGNAME>Performance Status Assessment Eastern Cooperative Oncology Group Scale</LONGNAME>
    <PREFERREDNAME>PERF_ASS_ECOG_SCALE</PREFERREDNAME>
    <PREFERREDDEFINITION>the ECOG functional performance status of the patient/participant.</PREFERREDDEFINITION>
    <VERSION>5.1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1499">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2003853</PUBLICID>
    <LONGNAME>Karnofsky Performance Status Score</LONGNAME>
    <PREFERREDNAME>KARN_PERF_STAT_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Score from the Karnofsky Performance status scale, representing the functional capabilities of a person.</PREFERREDDEFINITION>
    <VERSION>4.2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1500">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3359766</PUBLICID>
    <LONGNAME>Creatinine Isotope Dilute Mass Spectrometry Method Type</LONGNAME>
    <PREFERREDNAME>Isot_Dilu_Mass_Type</PREFERREDNAME>
    <PREFERREDDEFINITION>The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.(NCI)_Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._Type; a subdivision of a particular kind of thing.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3359759</PublicId>
      <PreferredName>3359757v1.0:2730351v1.0</PreferredName>
      <PreferredDefinition>The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.(NCI)_Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</PreferredDefinition>
      <LongName>Creatinine Isotope Dilute Mass Spectrometry Method</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3359757</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C399:C47933:C64657:C17156</PreferredName>
        <Version>1</Version>
        <LongName>Creatinine Isotope Dilute Mass Spectrometry</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C399</PREFERRED_NAME>
            <LONG_NAME>Creatinine</LONG_NAME>
            <CON_ID>2206188</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47933</PREFERRED_NAME>
            <LONG_NAME>Isotope</LONG_NAME>
            <CON_ID>2688011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64657</PREFERRED_NAME>
            <LONG_NAME>Dilute</LONG_NAME>
            <CON_ID>2710230</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17156</PREFERRED_NAME>
            <LONG_NAME>Mass Spectrometry</LONG_NAME>
            <CON_ID>2710222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2730351</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71460</PreferredName>
        <Version>1</Version>
        <LongName>Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71460</PREFERRED_NAME>
            <LONG_NAME>Method</LONG_NAME>
            <CON_ID>2730350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3359761</PublicId>
      <PreferredName>Isot_Dilu_Mass_Type</PreferredName>
      <PreferredDefinition>Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Isotope Dilute Mass Spectrometry Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3359760</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47933:C64657:C17156:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Isotope Dilute Mass Spectrometry Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47933</PREFERRED_NAME>
            <LONG_NAME>Isotope</LONG_NAME>
            <CON_ID>2688011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64657</PREFERRED_NAME>
            <LONG_NAME>Dilute</LONG_NAME>
            <CON_ID>2710230</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17156</PREFERRED_NAME>
            <LONG_NAME>Mass Spectrometry</LONG_NAME>
            <CON_ID>2710222</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-IDMS</VALIDVALUE>
          <VALUEMEANING>Not Isotope dilution mass spectrometry (IDMS)</VALUEMEANING>
          <MEANINGDESCRIPTION>Any other method of obtaining Creatinine value</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3359762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IDMS</VALIDVALUE>
          <VALUEMEANING>Isotope dilution mass spectrometry (IDMS)</VALUEMEANING>
          <MEANINGDESCRIPTION>An assay that measures the amount of serum creatinine. The NKDEP program in the United States is trying to get all laboratories to calibrate their measures of creatinine to a &quot;gold standard&quot;, which is isotope dilution mass spectrometry (IDMS).  On December 1, 2008, Lakeland Laboratory will change the creatinine method used for testing and move to a method of creatinine testing which is calibrated to a traceable reference method (Isotope Dilution Mass Spectrophotometry or IDMS), resulting in more accurate and standardized creatinine results</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3359763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Method used to obtain Creatin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Method used to obtain Creatinine value</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0263</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104885</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229L</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104890</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0277</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104900</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0275</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104991</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0241</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000172</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000174</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0262</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000175</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Isot_Dilu_Mass_Type</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1501">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3366758</PUBLICID>
    <LONGNAME>Lymphoma Treatment Administered Combination Pharmaceutical Agent Name</LONGNAME>
    <PREFERREDNAME>3284249v1.0:3366679v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term or code to represent the name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3284249</PublicId>
      <PreferredName>2475110v1.0:3284230v1.0</PreferredName>
      <PreferredDefinition>A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Lymphoma Treatment Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2475110</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3208</PreferredName>
        <Version>1</Version>
        <LongName>Lymphoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3208</PREFERRED_NAME>
            <LONG_NAME>Lymphoma</LONG_NAME>
            <CON_ID>2202736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3284230</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3366679</PublicId>
      <PreferredName>3366679v1.0</PreferredName>
      <PreferredDefinition>A collection of things that have been assembled together to form a new whole._A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Combination Pharmaceutical Agent Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435016</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12218</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Regimen</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3366678</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61517:C1909:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Combination Pharmacologic Substance Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61517</PREFERRED_NAME>
            <LONG_NAME>Combination</LONG_NAME>
            <CON_ID>2673231</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP-14</VALIDVALUE>
          <VALUEMEANING>14 Day CHOP Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9549, C25301, C45255::14</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366680</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAP-BOP</VALIDVALUE>
          <VALUEMEANING>CAP-BOP</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, procarbazine, and vincristine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9564</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366681</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BACOP</VALIDVALUE>
          <VALUEMEANING>Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, and vincristine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9550</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Single Agent Therapy (please specify)</VALIDVALUE>
          <VALUEMEANING>Single Agent</VALUEMEANING>
          <MEANINGDESCRIPTION>Not accompanied by another or others.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1708, C48440</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366701</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Pharmaceutical Regimen (please specify)</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241404</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>VACOP-B</VALIDVALUE>
          <VALUEMEANING>VACOP-B</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C11343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366702</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ProMace-MOPP</VALIDVALUE>
          <VALUEMEANING>ProMace-MOPP</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of cyclophosphamide, doxorubicin, etoposide, mechlorethamine, methotrexate, prednisone, procarbazine, and vincristine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9679</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366703</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ProMace-CytaBOM</VALIDVALUE>
          <VALUEMEANING>ProMace-CytaBOM Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin&#39;s lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63460</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366704</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MACOP-B</VALIDVALUE>
          <VALUEMEANING>MACOP-B Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin&#39;s lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LNH-87</VALIDVALUE>
          <VALUEMEANING>LNH-87</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin&#39;s lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63446</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366707</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>LNH-84</VALIDVALUE>
          <VALUEMEANING>LNH-84</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C10783</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366708</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ICE + Rituxumab</VALIDVALUE>
          <VALUEMEANING>ICE Plus Rituxumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702, C37912, C10345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366709</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ICE</VALIDVALUE>
          <VALUEMEANING>ICE Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C10345</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366711</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>High Dose Methotrexate w/Leucovorin</VALIDVALUE>
          <VALUEMEANING>High Dose Leucovorin Calcium/Methotrexate</VALUEMEANING>
          <MEANINGDESCRIPTION>High; greater than normal in degree or intensity or amount.: The amount of medicine taken, or radiation given, at one time.: No Value Exists</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C11823, C25488, C25227</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DA-EPOCH + Rituxumab</VALIDVALUE>
          <VALUEMEANING>Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin plus Rituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time. : The act of making necessary corrections or modifications.: A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702, C37912, C405, C63779, C49157, C25488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366714</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DA-EPOCH</VALIDVALUE>
          <VALUEMEANING>Dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time. : The act of making necessary corrections or modifications.: A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63779, C49157, C25488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>F-MACHOP</VALIDVALUE>
          <VALUEMEANING>5-Fluorouracil, Methotrexate with Leucovorin Rescue, Cytarabine, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99697</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366716</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CVP</VALIDVALUE>
          <VALUEMEANING>CVP Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of cyclophosphamide, vincristine and prednisone used to treat indolent forms of non-Hodgkin&#39;s lymphoma; also used for the treatment of chronic lymphocytic leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9573</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CNOP</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin&#39;s lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63453</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366722</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP-21 + Rituximab</VALIDVALUE>
          <VALUEMEANING>CHOP Regimen 21 Day And Rituximab </VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702, C37912, C25301, C45255::21, C9549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP-14 + Rituximab</VALIDVALUE>
          <VALUEMEANING>CHOP Regimen 14 Day And Rituximab </VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702, C37912, C25301, C45255::14, C9549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP + Etoposide</VALIDVALUE>
          <VALUEMEANING>CHOP Regimen And Etoposide</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C491, C37912, C9549</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP + Bleomycin</VALIDVALUE>
          <VALUEMEANING>CHOP Regimen And Bleomycin</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9549, C313, C37912</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>2, 0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366726</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CHOP-21</VALIDVALUE>
          <VALUEMEANING>21 Day CHOP Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       : A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9549, C25301, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366727</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>M-BACOP</VALIDVALUE>
          <VALUEMEANING>M-BACOP</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy regimen consisting of methotre xate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C99696</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3366706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C-MOPP</VALIDVALUE>
          <VALUEMEANING>COPP Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin&#39;s lymphoma. Also used for the treatment of non-Hodgkin&#39;s lymphoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9567</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3368104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vanderbilt regimen + Rituximab</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide Etoposide Vincristine Bleomycin Methotrexate Doxorubicin Rituximab Treatment Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04): An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15697, C1702, C456, C642, C313, C933, C491, C405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3590031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>HyperCVAD-Mtx/AraC + Rituximab</VALIDVALUE>
          <VALUEMEANING>HyperCVAD/HD MTX AraC Regimen Rituximab Treatment Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) administered on a hyperfractionated schedule, followed by high dose methotrexate and cytarabine, and used to treat Burkitt&#39;s lymphoma.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15697, C1702, C63472</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3590033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CODOX + Rituximab</VALIDVALUE>
          <VALUEMEANING>Cyclophosphamide/Doxorubicin/Vincristine Rituximab Treatment Regimen</VALUEMEANING>
          <MEANINGDESCRIPTION>A chemotherapy combination consisting of cyclophosphamide, doxorubicin, and vincristine.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15697, C1702, C9540</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-09-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3590034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CE (Cisplatin and Etoposide)</VALIDVALUE>
          <VALUEMEANING>Cisplatin and Etoposide</VALUEMEANING>
          <MEANINGDESCRIPTION>An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C491, C37912, C376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3645446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CAV (Cyclophosphamide, Adriamycin and Vincristin)</VALIDVALUE>
          <VALUEMEANING>CAV (Cyclophosphamide, Adriamycin and Vincristin)</VALUEMEANING>
          <MEANINGDESCRIPTION>CAV (Cyclophosphamide, Adriamycin and Vincristin)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-10-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5544377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Carboplatin + Paclitaxel</VALIDVALUE>
          <VALUEMEANING>Carboplatin And Paclitaxel</VALUEMEANING>
          <MEANINGDESCRIPTION>A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1411, C37912, C1282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5544378</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pharmaceutical Regimen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pharmaceutical Regimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3590028</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Initial Treatment and Followup Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3590029</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5655939</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BLGSP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Initial Treatment and Followup Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000268</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1502">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3369255</PUBLICID>
    <LONGNAME>Specimen Anus Collected Ind-2</LONGNAME>
    <PREFERREDNAME>3369241v1.0:2018362v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no question related to the sample collected from the patient for analysis or examination from the lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>AMC CRF:AIDS Malignancy Consortium Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3369241</PublicId>
      <PreferredName>2177026v1.0:3369239v1.0</PreferredName>
      <PreferredDefinition>the sample collected from the patient for analysis or examination from the lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.</PreferredDefinition>
      <LongName>Specimen Anus Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3369239</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43362:C25452</PreferredName>
        <Version>1</Version>
        <LongName>Anus Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43362</PREFERRED_NAME>
            <LONG_NAME>Anus</LONG_NAME>
            <CON_ID>2494283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>AMC CRF:AIDS Malignancy Consortium Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the anal specimen collect</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the anal specimen collected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1503">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3377292</PUBLICID>
    <LONGNAME>Injection Site Erythema Occurrence Indicator</LONGNAME>
    <PREFERREDNAME>INJECT_ERYTH_OCC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to signify whether redness or erythema occurred at the site of an injection.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3377290</PublicId>
      <PreferredName>INJECT_ERYTH_OCC</PreferredName>
      <PreferredDefinition>The anatomic site at which a medication or a vaccine is injected._Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Injection Site Erythema Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3377288</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3508:C77680:C26901</PreferredName>
        <Version>1</Version>
        <LongName>Injection Site Reaction Injection Site Erythema</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3508</PREFERRED_NAME>
            <LONG_NAME>Injection Site Reaction</LONG_NAME>
            <CON_ID>2203670</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C77680</PREFERRED_NAME>
            <LONG_NAME>Injection Site</LONG_NAME>
            <CON_ID>3377282</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C26901</PREFERRED_NAME>
            <LONG_NAME>Erythema</LONG_NAME>
            <CON_ID>2482163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181608</PublicId>
      <PreferredName>Y_N_CHAR_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes or No to a question.</PreferredDefinition>
      <LongName>Yes No Character Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Redness or erythema</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Redness or erythema</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>For Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3891931</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-02-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4528052</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1504">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3395746</PUBLICID>
    <LONGNAME>Pills Remaining Eflornithine Count</LONGNAME>
    <PREFERREDNAME>3395745v1.0:2188893v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Total number of Eflornithine/placebo pills remaining.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3395745</PublicId>
      <PreferredName>3395728v1.0:2433945v1.0</PreferredName>
      <PreferredDefinition>Eflornithine/placebo pills remaining.</PreferredDefinition>
      <LongName>Pills Remaining Eflornithine</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3395728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C226:C25394</PreferredName>
        <Version>1</Version>
        <LongName>Eflornithine Pills</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C226</PREFERRED_NAME>
            <LONG_NAME>Eflornithine</LONG_NAME>
            <CON_ID>3395727</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25394</PREFERRED_NAME>
            <LONG_NAME>Pill Dosage Form</LONG_NAME>
            <CON_ID>2202784</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2433945</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25649</PreferredName>
        <Version>1</Version>
        <LongName>Remaining</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25649</PREFERRED_NAME>
            <LONG_NAME>Remaining</LONG_NAME>
            <CON_ID>2203780</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188893</PublicId>
      <PreferredName>PILLS_RMNG_NUM</PreferredName>
      <PreferredDefinition>the numeric count of tablets remaining.</PreferredDefinition>
      <LongName>Pills Remaining Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CALGB CRF:Cancer and Leukemia Group B Case Report Form</Origin>
      <Representation>
        <PublicId>2261845</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25463</PreferredName>
        <Version>1</Version>
        <LongName>Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total number of eflornithine/</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total number of eflornithine/placebo pills participant brought in to the current visit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008589</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>CATEGORY</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Treatment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1505">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3397375</PUBLICID>
    <LONGNAME>Toxicity Hematologic Report Ind-2</LONGNAME>
    <PREFERREDNAME>HmlDsLimTxyIND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the report of toxicity pertaining to or related to the blood and blood-forming organs, hematologic toxicity.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3397373</PublicId>
      <PreferredName>2500847v1.0:3397371v1.0</PreferredName>
      <PreferredDefinition>information related to the report of toxicity pertaining to or related to the blood and blood-forming organs, hematologic toxicity</PreferredDefinition>
      <LongName>Toxicity Hematologic Report</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008508</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CTEP</PreferredName>
        <Version>5</Version>
        <LongName>CTEP</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2500847</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C27990</PreferredName>
        <Version>1</Version>
        <LongName>Toxicity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27990</PREFERRED_NAME>
            <LONG_NAME>Toxicity</LONG_NAME>
            <CON_ID>2202546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3397371</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62780:C25375</PreferredName>
        <Version>1</Version>
        <LongName>Hematologic Report</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62780</PREFERRED_NAME>
            <LONG_NAME>Hematologic</LONG_NAME>
            <CON_ID>2528497</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Grade 4 hematologic toxicity lasting more than 7 days</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient experience an</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient experience any hematologic toxicity per the indicated criteria</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient experience any hematologic dose-limiting toxicity per the indicated criteria</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did a hematologic dose limiting toxicity occur</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Grade 4 hematologic toxicity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient have a grade 4 hematologic toxicity?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other grade 4 hematologic toxicity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient experience any hematologic toxicity per the indicated criteria?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 05</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient experience any hematologic dose-limiting toxicity per the indicated criteria during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>HmlDsLimTxyIND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HmlDsLimTxyIND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1506">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3419053</PUBLICID>
    <LONGNAME>Tooth Pain Participant Description Participant Pain Scale</LONGNAME>
    <PREFERREDNAME>3419048v1.0:3419033v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the participant&#39;s description of tooth pain measured on the pain scale</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3419048</PublicId>
      <PreferredName>3119746v1.0:3419046v1.0</PreferredName>
      <PreferredDefinition>the participant&#39;s description of tooth pain</PreferredDefinition>
      <LongName>Tooth Pain Participant Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3119746</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12506:C3303</PreferredName>
        <Version>1</Version>
        <LongName>Tooth Pain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12506</PREFERRED_NAME>
            <LONG_NAME>Tooth</LONG_NAME>
            <CON_ID>2202581</CON_ID>
            <DEFINITION_SOURCE>UWDA142</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3303</PREFERRED_NAME>
            <LONG_NAME>Pain</LONG_NAME>
            <CON_ID>2202326</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3419046</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29867:C25365</PreferredName>
        <Version>1</Version>
        <LongName>Participant Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29867</PREFERRED_NAME>
            <LONG_NAME>Participant</LONG_NAME>
            <CON_ID>2202627</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3419033</PublicId>
      <PreferredName>3419033v1.0</PreferredName>
      <PreferredDefinition>an ordered reference standerd for the amount of pain/discomfort the patient feels</PreferredDefinition>
      <LongName>Participant Pain Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Please indicate how you would</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Please indicate how you would DESCRIBE the tooth pain you felt just now</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1507">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3420848</PUBLICID>
    <LONGNAME>Dental Patient  Retainer Device Component  Bad Gustation Oral Cavity Assessment  Scale</LONGNAME>
    <PREFERREDNAME>3420791v1.0:2596220v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>When the participant is wearing the oral device that holds their teeth in position, how frequently do they have an unpleasant taste in their mouth as rated on the Oral Health Quality of Life Scale</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3420791</PublicId>
      <PreferredName>2714778v1.0:3420789v1.0</PreferredName>
      <PreferredDefinition>When the participant is wearing the oral device that holds their teeth in position, how frequently do they have an unpleasant taste in their mouth</PreferredDefinition>
      <LongName>Dental Patient  Retainer Device Component  Bad Gustation Oral Cavity Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2714778</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C16960</PreferredName>
        <Version>1</Version>
        <LongName>Dental Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3420789</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3420789v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Retainer Device Component Bad Gustation Oral Cavity Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50144</PREFERRED_NAME>
            <LONG_NAME>Retainer Device</LONG_NAME>
            <CON_ID>3420764</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80228</PREFERRED_NAME>
            <LONG_NAME>Bad</LONG_NAME>
            <CON_ID>2928119</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20620</PREFERRED_NAME>
            <LONG_NAME>Gustation</LONG_NAME>
            <CON_ID>2500851</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12421</PREFERRED_NAME>
            <LONG_NAME>Oral Cavity</LONG_NAME>
            <CON_ID>2202746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2596220</PublicId>
      <PreferredName>OH_QOL_SCALE</PreferredName>
      <PreferredDefinition>a scaled index of the feelings about teeth, mouth and gums.</PreferredDefinition>
      <LongName>Oral Health Quality of Life Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fairly often</VALIDVALUE>
          <VALUEMEANING>Fairly often</VALUEMEANING>
          <MEANINGDESCRIPTION>Fairly often</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hardly ever</VALIDVALUE>
          <VALUEMEANING>Hardly ever</VALUEMEANING>
          <MEANINGDESCRIPTION>Hardly ever</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>OCCASIONALLY</VALUEMEANING>
          <MEANINGDESCRIPTION>OCCASIONALLY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561574</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very often</VALIDVALUE>
          <VALUEMEANING>VERY OFTEN</VALUEMEANING>
          <MEANINGDESCRIPTION>VERY OFTEN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-08-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561572</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>I NEVER had an erection when I wanted one </VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-02-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561555</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>When you ARE wearing your ret</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>When you ARE wearing your retainer, how often do you have a bad taste in your mouth?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1508">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3421485</PUBLICID>
    <LONGNAME>Dental  Removable  Retainer Device Component  Lower Oral Cavity Negation Satisfaction Use  Text</LONGNAME>
    <PREFERREDNAME>3421330v1.0:2018321v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the reason of the participant&#39;s dissatisfaction with the removable retainer in the lower parts of the mouth</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3421330</PublicId>
      <PreferredName>3421317v1.0:3421328v1.0</PreferredName>
      <PreferredDefinition>The participant&#39;s dissatisfaction with the removable retainer in the lower parts of the mouth</PreferredDefinition>
      <LongName>Dental  Removable  Retainer Device Component  Lower Oral Cavity Negation Satisfaction Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3421317</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41136:C64250:C50144</PreferredName>
        <Version>1</Version>
        <LongName>Dental Removable Retainer Device Component</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41136</PREFERRED_NAME>
            <LONG_NAME>Dental</LONG_NAME>
            <CON_ID>2240057</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64250</PREFERRED_NAME>
            <LONG_NAME>Removable</LONG_NAME>
            <CON_ID>2558027</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50144</PREFERRED_NAME>
            <LONG_NAME>Retainer Device</LONG_NAME>
            <CON_ID>3420764</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3421328</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3421328v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Lower Oral Cavity Negation Satisfaction Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25309</PREFERRED_NAME>
            <LONG_NAME>Lower</LONG_NAME>
            <CON_ID>2205319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12421</PREFERRED_NAME>
            <LONG_NAME>Oral Cavity</LONG_NAME>
            <CON_ID>2202746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62185</PREFERRED_NAME>
            <LONG_NAME>Satisfaction</LONG_NAME>
            <CON_ID>2585226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PRECEDENT CRF:Practice-based Research Collaborative in Evidence-Based Dentistry Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Why are you not satisfied</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Why are you not satisfied</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1509">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3427615</PUBLICID>
    <LONGNAME>New Neoplasm Event Additional Radiation Therapy Indicator</LONGNAME>
    <PREFERREDNAME>3427415v1.0:2182115v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify whether or not additional radiation therapy was administered for the new tumor event.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3427415</PublicId>
      <PreferredName>3108264v1.0:3427413v1.0</PreferredName>
      <PreferredDefinition>New; having no previous example or precedent or parallel._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Something that happens at a given place and time._Added; extra; further._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</PreferredDefinition>
      <LongName>New Neoplasm Event Additional Radiation Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3108264</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25586:C3262</PreferredName>
        <Version>1</Version>
        <LongName>New Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3427413</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C49236:C15313:C25499</PreferredName>
        <Version>1</Version>
        <LongName>Additional Therapeutic Procedure Radiation Therapy Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182115</PublicId>
      <PreferredName>Y_N_U_IND</PreferredName>
      <PreferredDefinition>Indicator of Yes, No, or Unknown to represent a condition.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-03-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Additional treatment for New</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Additional treatment for New Tumor Event: Radiation Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BLCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787499</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BRCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CESC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787502</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>COAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787503</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GBM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787504</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HNSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787505</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KICH</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787507</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>KIRP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787508</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LAML</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787509</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LGG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787510</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LIHC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787512</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LUSC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787513</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OV</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787514</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PAAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787515</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787516</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>READ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787517</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SARC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SKCM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787519</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>STAD</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787520</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>THCA</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787521</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787498</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Disease</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UCEC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787522</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3787524</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TCGA 2.6 by Namespace</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>clinical shared</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3787543</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>new_tumor_additional_rad_tx</AlternateName>
        <AlternateNameType>TCGA_XML_Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1510">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3434524</PUBLICID>
    <LONGNAME>Material Data File Identification Term Accession Number</LONGNAME>
    <PREFERREDNAME>3434410v1.0:3377626v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Identification number of a term selected from an ontology or a controlled vocabulary, if the term is entered as a value for Material File Type</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3434410</PublicId>
      <PreferredName>2640427v1.0:3631756v1.0</PreferredName>
      <PreferredDefinition>The tangible substance that goes into the makeup of a physical object._A set of related records (either written or electronic) kept together._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn._The procedure of having an identity established.</PreferredDefinition>
      <LongName>Material Data File Identification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2640427</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48187</PreferredName>
        <Version>1</Version>
        <LongName>Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3631756</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C42883:C25737</PreferredName>
        <Version>1</Version>
        <LongName>Data File Identification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42883</PREFERRED_NAME>
            <LONG_NAME>File</LONG_NAME>
            <CON_ID>2422612</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3377626</PublicId>
      <PreferredName>3377626v1.0</PreferredName>
      <PreferredDefinition>A word or expression used for some particular thing._A control number unique to an object, used to identify it among the other objects in a collection._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Term Accession Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</Origin>
      <Representation>
        <PublicId>3377625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45559:C25402:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Term Accession Number Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Material Data File Type Term</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Material Data File Type Term Accession</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Material V1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286097</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Material V1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286102</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Material  File Type Term Accession Number</AlternateName>
        <AlternateNameType>ISA-TAB-Nano Col Nm</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Term Accession Number</AlternateName>
        <AlternateNameType>ISA-TAB-Nano Col Nm</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1511">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3436058</PUBLICID>
    <LONGNAME>Surgical Procedure Gynecologic Excision Performed Anatomic Site</LONGNAME>
    <PREFERREDNAME>GYN_EXC_PERF_ANAT_STE</PREFERREDNAME>
    <PREFERREDDEFINITION>Anatomical site of gynecologic excision performed.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3436047</PublicId>
      <PreferredName>Surg_Gyne_Exci_Perf</PreferredName>
      <PreferredDefinition>information regarding the surgical removal of part or all of a structure or organ pertaining to the health issues of women for a diagnostic or treatment procedure.</PreferredDefinition>
      <LongName>Surgical Procedure Gynecologic Excision Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3442435</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28016:C15232:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Gynecologic Excision Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28016</PREFERRED_NAME>
            <LONG_NAME>Gynecologic</LONG_NAME>
            <CON_ID>2202649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436054</PublicId>
      <PreferredName>Gyne_Anat</PreferredName>
      <PreferredDefinition>Named locations within the body that pertains to the health issues of women.</PreferredDefinition>
      <LongName>Gynecologic Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3436053</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15232:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Excision Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right labium majus</VALIDVALUE>
          <VALUEMEANING>Labium major - rt.</VALUEMEANING>
          <MEANINGDESCRIPTION>Labium major - rt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left labium majus</VALIDVALUE>
          <VALUEMEANING>Labium major - lt.</VALUEMEANING>
          <MEANINGDESCRIPTION>Labium major - lt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569537</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Distant: upper urethra, rectal, etc.</VALIDVALUE>
          <VALUEMEANING>Upper Urethra Rectal</VALUEMEANING>
          <MEANINGDESCRIPTION>Higher in place or position; the topmost one of two.: (yoo-REE-thra) The tube through which urine leaves the body. It empties urine from the bladder.: Rectal; of, or pertaining to, the rectum.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25224, C12417, C25355</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3436055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perineum</VALIDVALUE>
          <VALUEMEANING>PERINEUM</VALUEMEANING>
          <MEANINGDESCRIPTION>The area located between the anus and vulva in females, and anus and scrotum in males.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C33301</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565650</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right Labium minus</VALIDVALUE>
          <VALUEMEANING>Labium minor - rt.</VALUEMEANING>
          <MEANINGDESCRIPTION>Labium minor - rt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Left labium minus</VALIDVALUE>
          <VALUEMEANING>Labium minor - lt.</VALUEMEANING>
          <MEANINGDESCRIPTION>Labium minor - lt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569539</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Local: vaginal, anus, lower urethra</VALIDVALUE>
          <VALUEMEANING>Anus Urethra Vaginal</VALUEMEANING>
          <MEANINGDESCRIPTION>(AY-nus) The opening of the rectum to the outside of the body.: (yoo-REE-thra) The tube through which urine leaves the body. It empties urine from the bladder.: Relating to the vagina or to any sheath.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13309, C12417, C43362</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3436056</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clitoris</VALIDVALUE>
          <VALUEMEANING>Clitoris</VALUEMEANING>
          <MEANINGDESCRIPTION>The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12308</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3123670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lesion site</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lesion site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0279</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104996</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Surg_Gyne_Exci_Perf_Gyne_Anat</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1512">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3436609</PUBLICID>
    <LONGNAME>Surgical Procedure Subcutaneous Drainage Use Specify</LONGNAME>
    <PREFERREDNAME>Surg_Subc_Drai_Use_TX_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin during a diagnostic or treatment procedure performed by manual and/or instrumental means</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3436380</PublicId>
      <PreferredName>Surg_Subc_Drai_Use</PreferredName>
      <PreferredDefinition>information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin during a diagnostic or treatment procedure performed by manual and/or instrumental means</PreferredDefinition>
      <LongName>Surgical Procedure Subcutaneous Drainage Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3436378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13353:C50434:C95018</PreferredName>
        <Version>1</Version>
        <LongName>Subcutaneous Drainage Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13353</PREFERRED_NAME>
            <LONG_NAME>Subcutaneous</LONG_NAME>
            <CON_ID>2204970</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50434</PREFERRED_NAME>
            <LONG_NAME>Drainage</LONG_NAME>
            <CON_ID>2521941</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95018</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>3248409</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018810</PublicId>
      <PreferredName>TX_SPEC</PreferredName>
      <PreferredDefinition>the free text field related to therapy.</PreferredDefinition>
      <LongName>Therapies Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104884</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000340</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0244</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000341</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Surg_Subc_Drai_Use_TX_SPEC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1513">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3438620</PUBLICID>
    <LONGNAME>Therapeutic Procedure Monoclonal Antibody Performed COG Monoclonal Antibody Type</LONGNAME>
    <PREFERREDNAME>MonoclonalAntibody</PREFERREDNAME>
    <PREFERREDDEFINITION>Monoclonal antibody or other agent administered as prior anti-cancer therapy with a known half life._Type of Monoclonal antibody or other agent received by the patient</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3438603</PublicId>
      <PreferredName>2512834v1.0:3438601v1.0</PreferredName>
      <PreferredDefinition>Monoclonal antibody or other agent administered as prior anti-cancer therapy with a known half life.</PreferredDefinition>
      <LongName>Therapeutic Procedure Monoclonal Antibody Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3438601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20401:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Monoclonal Antibody Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20401</PREFERRED_NAME>
            <LONG_NAME>Monoclonal Antibody</LONG_NAME>
            <CON_ID>2205426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3438591</PublicId>
      <PreferredName>3438591v1.0</PreferredName>
      <PreferredDefinition>Type of Monoclonal antibody or other agent received by the patient</PreferredDefinition>
      <LongName>COG Monoclonal Antibody Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>55</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Specify</VALIDVALUE>
          <VALUEMEANING>OTHER THERAPY</VALUEMEANING>
          <MEANINGDESCRIPTION>OTHER THERAPY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563822</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GDC-0449</VALIDVALUE>
          <VALUEMEANING>Vismodegib</VALUEMEANING>
          <MEANINGDESCRIPTION>An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74038</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438593</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SGN-35</VALIDVALUE>
          <VALUEMEANING>Brentuximab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SGN-30</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody SGN-30</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438595</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nimotuzimab</VALIDVALUE>
          <VALUEMEANING>Nimotuzimab</VALUEMEANING>
          <MEANINGDESCRIPTION>Nimotuzimab</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rituximab</VALIDVALUE>
          <VALUEMEANING>Rituximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1702</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2738482</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IMC-A12</VALIDVALUE>
          <VALUEMEANING>Cixutumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gemtuzumab</VALIDVALUE>
          <VALUEMEANING>Gemtuzumab Ozogamicin</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1806</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2741177</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Epratuzumab</VALIDVALUE>
          <VALUEMEANING>Epratuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab&#39;s predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cetuximab</VALIDVALUE>
          <VALUEMEANING>Cetuximab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1723</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574309</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ch 14.18</VALIDVALUE>
          <VALUEMEANING>Ch 14.18</VALUEMEANING>
          <MEANINGDESCRIPTION>Ch 14.18</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3438599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bevacizumab</VALIDVALUE>
          <VALUEMEANING>Bevacizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2039</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574306</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alemtuzumab</VALIDVALUE>
          <VALUEMEANING>Alemtuzumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577772</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pembrolizumab</VALIDVALUE>
          <VALUEMEANING>Pembrolizumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106432</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ramucirumab</VALIDVALUE>
          <VALUEMEANING>Ramucirumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70792</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3553252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ontuxizumab</VALIDVALUE>
          <VALUEMEANING>Anti-Endosialin Monoclonal Antibody MORAb-004</VALUEMEANING>
          <MEANINGDESCRIPTION>A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Anti-endosialin/TEM1 monoclonal antibody MORAb-004 binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82406</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3614158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nivolumab</VALIDVALUE>
          <VALUEMEANING>Nivolumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lorvotuzumab</VALIDVALUE>
          <VALUEMEANING>Lorvotuzumab Mertansine</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38714</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipilimumab</VALIDVALUE>
          <VALUEMEANING>Ipilimumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2654</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3185135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I-3F8</VALIDVALUE>
          <VALUEMEANING>Monoclonal Antibody 3F8</VALUEMEANING>
          <MEANINGDESCRIPTION>A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5076698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cixutumumab</VALIDVALUE>
          <VALUEMEANING>Cixutumumab</VALUEMEANING>
          <MEANINGDESCRIPTION>A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brentuximab Vedotin</VALIDVALUE>
          <VALUEMEANING>Brentuximab Vedotin</VALUEMEANING>
          <MEANINGDESCRIPTION>An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3228385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complement C5 inhibitor (Eculizumab, Ravalizumab)</VALIDVALUE>
          <VALUEMEANING>Complement C5 inhibitor (Eculizumab, Ravalizumab)</VALUEMEANING>
          <MEANINGDESCRIPTION>Complement C5 inhibitor (Eculizumab, Ravalizumab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD52 target (Alemtuzumab)</VALIDVALUE>
          <VALUEMEANING>CD52 target (Alemtuzumab)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD52 target (Alemtuzumab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067796</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD38 target (Daratumumab)</VALIDVALUE>
          <VALUEMEANING>CD38 target (Daratumumab)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD38 target (Daratumumab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD30 target (Brentuximab)</VALIDVALUE>
          <VALUEMEANING>CD30 target (Brentuximab)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD30 target (Brentuximab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)</VALIDVALUE>
          <VALUEMEANING>CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067799</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CD19 CD3 target (Blinatumomab)</VALIDVALUE>
          <VALUEMEANING>CD19 CD3 target (Blinatumomab)</VALUEMEANING>
          <MEANINGDESCRIPTION>CD19 CD3 target (Blinatumomab)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8067800</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Select the patient&#39;s most rec</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Select the patient&#39;s most recent monoclonal antibody received</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Monoclonal Antibody Type:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>MonoclonalAntibody</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MonoclonalAntibody</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MONO_ANT_TYP</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1514">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3443484</PUBLICID>
    <LONGNAME>Study Publication Identification Term Accession Number</LONGNAME>
    <PREFERREDNAME>3443464v1.0:3377626v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The identification number of a term selected from an ontology or a controlled vocabulary, if the term is entered as a value for study publication status.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3443464</PublicId>
      <PreferredName>2619600v1.0:3380113v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it; the activities undertaken during a study._A copy of a printed work offered for distribution._The procedure of having an identity established</PreferredDefinition>
      <LongName>Study Publication Identification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2619600</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536</PreferredName>
        <Version>1</Version>
        <LongName>Study</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3380113</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48471:C25737</PreferredName>
        <Version>1</Version>
        <LongName>Publication Identification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48471</PREFERRED_NAME>
            <LONG_NAME>Publication</LONG_NAME>
            <CON_ID>2422075</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25737</PREFERRED_NAME>
            <LONG_NAME>Identification</LONG_NAME>
            <CON_ID>2203822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3377626</PublicId>
      <PreferredName>3377626v1.0</PreferredName>
      <PreferredDefinition>A word or expression used for some particular thing._A control number unique to an object, used to identify it among the other objects in a collection._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Term Accession Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISA-TAB-Nano:Investigation Study Assay Excel Table Format for Nanotechnology</Origin>
      <Representation>
        <PublicId>3377625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45559:C25402:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Term Accession Number Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45559</PREFERRED_NAME>
            <LONG_NAME>Term</LONG_NAME>
            <CON_ID>2417435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25402</PREFERRED_NAME>
            <LONG_NAME>Accession Number</LONG_NAME>
            <CON_ID>2203569</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Study Publication Status Term</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Study Publication Status Term Accession Number</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286084</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Investigation V1.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286088</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ISA-TAB-Nano Version 1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286095</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3354861</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>nano-TAB</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Investigation V1.1</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4286100</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Study Publication Status Term Accession Number</AlternateName>
        <AlternateNameType>ISA-TAB-Nano Col Nm</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1515">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3452491</PUBLICID>
    <LONGNAME>Pancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T Stage</LONGNAME>
    <PREFERREDNAME>3452372v1.0:3452421v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Extent of the primary exocrine and endocrine pancreatic cancer based on evidence obtained from pathologic examination through completion of definitive surgery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</ORIGIN>
    <REGISTRATIONSTATUS>Preferred Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3452372</PublicId>
      <PreferredName>3452357v1.0:2207099v1.0</PreferredName>
      <PreferredDefinition>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon)._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).</PreferredDefinition>
      <LongName>Pancreas Neoplasm Pathologic T Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3452357</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12393:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Pancreas Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12393</PREFERRED_NAME>
            <LONG_NAME>Pancreas</LONG_NAME>
            <CON_ID>2205345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207099</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25610:C25728</PreferredName>
        <Version>1</Version>
        <LongName>Pathologic T Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3452421</PublicId>
      <PreferredName>3452421v1.0</PreferredName>
      <PreferredDefinition>A finding about one or more characteristics of exocrine or endocrine pancreatic cancer, following the rules of the TNM AJCC v7 classification system.  Pancreatic neuroendocrine tumors (including carcinoid tumors) are now staged by a single pancreatic staging system. (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Exocrine and Endocrine Pancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 T Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System</Origin>
      <Representation>
        <PublicId>3452420</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C90284:C39315:C25728:C16899</PreferredName>
        <Version>1</Version>
        <LongName>Exocrine and Endocrine Pancreatic Cancer TNM Finding v7 American Joint Committee on Cancer T Stage Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C90284</PREFERRED_NAME>
            <LONG_NAME>Exocrine and Endocrine Pancreatic Cancer TNM Finding v7</LONG_NAME>
            <CON_ID>3452419</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C39315</PREFERRED_NAME>
            <LONG_NAME>American Joint Committee on Cancer</LONG_NAME>
            <CON_ID>2554142</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T0</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pT0 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with no evidence of primary tumor. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T1</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pT1 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with tumor limited to the pancreas, measuring 2 cm or less in greatest dimension.. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452425</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pT2 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with tumor limited to the pancreas, measuring more than 2 cm in greatest dimension. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90292</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T3</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pT3 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with tumor extending beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452429</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T4</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pT4 TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with tumor involving the celiac axis or the superior mesenteric artery (unresectable primary tumor). (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452431</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tis</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pTis TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer with a finding of carcinoma in situ.  This also includes the PanIn III classification.  (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90289</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TX</VALIDVALUE>
          <VALUEMEANING>Exocrine and Endocrine Pancreatic Cancer pTX TNM Finding v7</VALUEMEANING>
          <MEANINGDESCRIPTION>Exocrine or endocrine pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3452435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pathologic T Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pathologic T Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>TNM Staging: T Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Staging/Extent of Disease (by Disease)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3434437</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreas</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3451697</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3461150</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3461151</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>AJCC Edition 7</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000596</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574838</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Staging</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Pancreatic</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000602</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>AECC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AECC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CITN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OHSU Knight</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OHSU Knight</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3452372v1.0:3452421v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PANC_TUMOR_P_T_STG</AlternateName>
        <AlternateNameType>Synonym</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1516">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3462784</PUBLICID>
    <LONGNAME>Non Cancer Tissue Excision To Freezing Time Duration Range</LONGNAME>
    <PREFERREDNAME>3462783v1.0:3462746v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the amount of time in minutes between the removal of the submitted tissue from the patient, to the time it was frozen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3462783</PublicId>
      <PreferredName>3462697v1.0:3462781v1.0</PreferredName>
      <PreferredDefinition>An operation in which a term denies or inverts the meaning of another term or construction._Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The act of cutting out; the surgical removal of part or all of a structure or organ._Used as a function word to indicate direction, purpose, or movement._The act or event which causes the transition from a liquid to solid matter phase._the continuum of experience in which events pass from the future through the present to the past._The period of time during which something continues.</PreferredDefinition>
      <LongName>Non Cancer Tissue Excision To Freezing Time Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3462697</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C14143:C12801</PreferredName>
        <Version>1</Version>
        <LongName>Negation Malignant Tissue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14143</PREFERRED_NAME>
            <LONG_NAME>Malignant</LONG_NAME>
            <CON_ID>2203843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3462781</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3462781v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Excision To Freezing Time Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48160</PREFERRED_NAME>
            <LONG_NAME>Freezing</LONG_NAME>
            <CON_ID>2513273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3462746</PublicId>
      <PreferredName>3462746v1.0</PreferredName>
      <PreferredDefinition>the continuum of experience in which events pass from the future through the present to the past._The difference between the lowest and highest numerical values; the limits or scale of variation.</PreferredDefinition>
      <LongName>Time Range</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>min</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3462747</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207:C38013</PreferredName>
        <Version>1</Version>
        <LongName>Time Range</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Warm ischemic time (in minute</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Warm ischemic time (in minutes)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Inactive CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1517">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3523161</PUBLICID>
    <LONGNAME>Diagnostic Procedure Cerebrospinal Fluid Cytology Positive Finding Assessment Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3523156v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether positive cerebrospinal fluid cytology was used in diagnosis.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CALGB CRF:Cancer and Leukemia Group B Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3523156</PublicId>
      <PreferredName>2639063v1.0:3523154v1.0</PreferredName>
      <PreferredDefinition>information related to a diagnostic procedure (methods, procedures, and tests performed to diagnose disease, disordered function, or disability) and a positive finding (an observation confirming something, such as the presence of a disease or condition) in an assessment of cerebrospinal fluid (the fluid flowing around the brain and spinal cord) cytology (the branch of biology that studies the structure and function of cells).</PreferredDefinition>
      <LongName>Diagnostic Procedure Cerebrospinal Fluid Cytology Positive Finding Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2639063</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18020</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18020</PREFERRED_NAME>
            <LONG_NAME>Diagnostic Procedure</LONG_NAME>
            <CON_ID>2488312</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3523154</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12692:C16491:C38758:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Cerebrospinal Fluid Cytology Positive Finding Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12692</PREFERRED_NAME>
            <LONG_NAME>Cerebrospinal Fluid</LONG_NAME>
            <CON_ID>2202710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16491</PREFERRED_NAME>
            <LONG_NAME>Cytology</LONG_NAME>
            <CON_ID>2202726</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38758</PREFERRED_NAME>
            <LONG_NAME>Positive Finding</LONG_NAME>
            <CON_ID>2516404</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Positive cerebrospinal fluid</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Positive cerebrospinal fluid</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1518">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3534743</PUBLICID>
    <LONGNAME>Patient Pregnancy Complication Specify</LONGNAME>
    <PREFERREDNAME>Pati_Preg_ASSESS_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>Description of a pregnancy complication (the co-occurrence of pregnancy and a medical problem that occurs during a disease or disorder).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>GOG CRF:Gynecologic Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3534706</PublicId>
      <PreferredName>Pati_Preg</PreferredName>
      <PreferredDefinition>information relating to a  pregnancy complication (the co-occurrence of pregnancy and a medical problem that occurs during a disease or disorder).</PreferredDefinition>
      <LongName>Patient Pregnancy Complication</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008542</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>REPRODUCTION</PreferredName>
        <Version>1</Version>
        <LongName>Reproduction</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3534704</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C34941</PreferredName>
        <Version>1</Version>
        <LongName>Pregnancy Complication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C34941</PREFERRED_NAME>
            <LONG_NAME>Pregnancy Complication</LONG_NAME>
            <CON_ID>3233220</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>GOG CRF:Gynecologic Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018806</PublicId>
      <PreferredName>ASSESS_SPEC</PreferredName>
      <PreferredDefinition>The free text field to specify the assessment performed.</PreferredDefinition>
      <LongName>Assessment Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184338</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specify</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If yes, specify:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If yes, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0278</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4058120</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Pati_Preg_ASSESS_SPEC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1519">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3534934</PUBLICID>
    <LONGNAME>Person Urine Protein Measurement Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>ApprUrPtn</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to urine protein measurement as a criterion to determine clinical trial eligibility for a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3534924</PublicId>
      <PreferredName>2236731v1.0:3534922v1.0</PreferredName>
      <PreferredDefinition>Urine protein measurement as a criterion to determine clinical trial eligibility for a patient.</PreferredDefinition>
      <LongName>Person Urine Protein Measurement Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3534922</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C74760:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Urine Protein Measurement Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C74760</PREFERRED_NAME>
            <LONG_NAME>Urine Protein Measurement</LONG_NAME>
            <CON_ID>3178972</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have appropriate</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have appropriate urine protein</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1520">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3536720</PUBLICID>
    <LONGNAME>Inappropriate Antidiuretic Hormone Secretion Syndrome Personal Medical History Yes No Indicator</LONGNAME>
    <PREFERREDNAME>Inap_Dise_Pers_YES_NO_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>indication of yes/no regarding an account of the medical events and problems related to a syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body._The preferred Value Domain to</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3536719</PublicId>
      <PreferredName>Inap_Dise_Pers</PreferredName>
      <PreferredDefinition>an account of the medical events and problems related to a syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body.</PreferredDefinition>
      <LongName>Inappropriate Antidiuretic Hormone Secretion Syndrome Personal Medical History</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3536717</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3988:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Inappropriate Antidiuretic Hormone Secretion Syndrome Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3988</PREFERRED_NAME>
            <LONG_NAME>Syndrome of Inappropriate Antidiuretic Hormone Secretion</LONG_NAME>
            <CON_ID>2922967</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2195639</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Personal Medical History</PreferredName>
        <Version>1</Version>
        <LongName>Personal Medical History</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18772</PREFERRED_NAME>
            <LONG_NAME>Personal Medical History</LONG_NAME>
            <CON_ID>2202879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a histo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a history of syndrome of inappropriate antidiuretic hormone secretion (SIADH)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0229N</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104903</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000426</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>GOG-0170R</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000427</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Inap_Dise_Pers_YES_NO_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1521">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3544444</PUBLICID>
    <LONGNAME>Specimen Alpha-Gal Glycosphingolipid Antibodies Collected Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3544438v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether a specimen was collected relating to antiglycan antibodies.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3544438</PublicId>
      <PreferredName>2177026v1.0:3544436v1.0</PreferredName>
      <PreferredDefinition>information related to a specimen (a preparation of tissue or bodily fluid taken for examination or diagnosis) and alpha-gal glycosphingolipid (a preparation of glycosphingolipids containing the disaccharide epitope galactose-alpha-1,3-galactose--alpha-Gal) antibodies (a type of protein made by certain white blood cells in response to a foreign substance).</PreferredDefinition>
      <LongName>Specimen Alpha-Gal Glycosphingolipid Antibodies Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177026</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3544436</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78200:C16295:C25452</PreferredName>
        <Version>1</Version>
        <LongName>Alpha-Gal Glycosphingolipids Antibody Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78200</PREFERRED_NAME>
            <LONG_NAME>Alpha-Gal Glycosphingolipids</LONG_NAME>
            <CON_ID>3544435</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was specimen collected-Antigl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was specimen collected-Antiglycan antibodies</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1522">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3553435</PUBLICID>
    <LONGNAME>Lesion Longest Diameter Measurement</LONGNAME>
    <PREFERREDNAME>LES_LGST_DIAM_MSRM</PREFERREDNAME>
    <PREFERREDDEFINITION>the primary or longest diameter measurement in millimeters used to calculate the longest bidimensional measurement for a lesion or tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2188775</PublicId>
      <PreferredName>LES_LGST_DIAM</PreferredName>
      <PreferredDefinition>information related to the longest lesion diameter.</PreferredDefinition>
      <LongName>Lesion Longest Diameter</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177112</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lesion</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207732</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C25285</PreferredName>
        <Version>1</Version>
        <LongName>Longest Diameter</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25285</PREFERRED_NAME>
            <LONG_NAME>Diameter</LONG_NAME>
            <CON_ID>2203909</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2722798</PublicId>
      <PreferredName>DIM_LG_MSRM</PreferredName>
      <PreferredDefinition>the primary or longest diameter measurement in millimeters used to calculate the longest bidimensional measurement for a lesion or tumor.</PreferredDefinition>
      <LongName>Dimension Longest Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2722797</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25558:C25209</PreferredName>
        <Version>1</Version>
        <LongName>Longest Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25558</PREFERRED_NAME>
            <LONG_NAME>Longest</LONG_NAME>
            <CON_ID>2206293</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Longest Diameter of Lesion(s)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Longest Diameter of Lesion(s) (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximal diameter - first dimension (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximal diameter - second dimension (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximal diameter - third dimension (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest diameter of lesion(s) (cm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest diameter of lesion(s) (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest diameter of primary tumor (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest diameter of lesion (cm) measurement:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 50</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Longest diameter of lesion (mm):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Maximal diameter:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1523">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3575527</PUBLICID>
    <LONGNAME>Other Malignant Neoplasm Response Evaluation Criteria in Solid Tumors Indicator</LONGNAME>
    <PREFERREDNAME>2685111v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not RECIST criteria was used for the evaluation of the other malignancy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2685111</PublicId>
      <PreferredName>MLGNCY_RECIST</PreferredName>
      <PreferredDefinition>Not otherwise specified._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (&quot;respond&quot;), stay the same (&quot;stable&quot;), or worsen (&quot;progression&quot;) during treatments. (from www.recist.com)</PreferredDefinition>
      <LongName>Other Malignant Neoplasm Response Evaluation Criteria in Solid Tumors</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2660471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Other Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2685109</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49164</PreferredName>
        <Version>1</Version>
        <LongName>Response Evaluation Criteria in Solid Tumors</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49164</PREFERRED_NAME>
            <LONG_NAME>Response Evaluation Criteria in Solid Tumors</LONG_NAME>
            <CON_ID>2426966</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was RECIST criteria used for</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was RECIST criteria used for evaluation of the status of the other malignancy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1524">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3588476</PUBLICID>
    <LONGNAME>Patient Data Send Indicator dataSendIndicatorCode</LONGNAME>
    <PREFERREDNAME>3588423v1.0:3588450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who requires medical care._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Cause or enable to go or be conveyed or transmitted.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied._Flag indicating whether data have been transferred to the DCC</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NICHD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3588423</PublicId>
      <PreferredName>2233604v1.0:3588401v1.0</PreferredName>
      <PreferredDefinition>A person who requires medical care._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:Cause or enable to go or be conveyed or transmitted.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Patient Data Send Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NICHD</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3588401</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C25672:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Data Send Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25672</PREFERRED_NAME>
            <LONG_NAME>Send</LONG_NAME>
            <CON_ID>2206250</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3588450</PublicId>
      <PreferredName>3588450v1.0</PreferredName>
      <PreferredDefinition>Flag indicating whether data have been transferred to the DCC</PreferredDefinition>
      <LongName>dataSendIndicatorCode</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NICHD</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008528</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PROT_ADM</PreferredName>
        <Version>1</Version>
        <LongName>Protocol Administration</LongName>
      </ConceptualDomain>
      <Datatype>java.lang.Integer</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Send</VALUEMEANING>
          <MEANINGDESCRIPTION>Cause or enable to go or be conveyed or transmitted.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25672</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3588451</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>New</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no previous example or precedent or parallel; of a kind not seen before.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID>3588517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Patient Data Send Indicator dataSendIndicatorCode does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Patient Data Send Indicator dataSendIndicatorCode does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3588382</PublicId>
          <ContextName>NICHD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PICUgrid</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.utah.bmi.picugrid.domain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3588383</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NICHD</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Patient:sendIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NICHD</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.utah.bmi.picugrid.domain.Patient.sendIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1525">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3589810</PUBLICID>
    <LONGNAME>List of Threatening Experiences Questionnaire Problem Friend Assessment Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3589808v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no indicator designed to assess weather the following stressful life event occurred: A difficulty, with a close friend, neighbor, relative</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3589808</PublicId>
      <PreferredName>3589772v1.0:3589806v1.0</PreferredName>
      <PreferredDefinition>A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following a difficulty with a friend.</PreferredDefinition>
      <LongName>List of Threatening Experiences Questionnaire Problem Friend Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3589772</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102991</PreferredName>
        <Version>1</Version>
        <LongName>List of Threatening Experiences Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102991</PREFERRED_NAME>
            <LONG_NAME>List of Threatening Experiences Questionnaire</LONG_NAME>
            <CON_ID>3589465</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3589806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28020:C72884:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Problem Friend Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72884</PREFERRED_NAME>
            <LONG_NAME>Friend</LONG_NAME>
            <CON_ID>2734005</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serious problem with a close</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Serious problem with a close friend, neighbor, or relative</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1526">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3590117</PUBLICID>
    <LONGNAME>Genus Identifier Result Text</LONGNAME>
    <PREFERREDNAME>2772456v1.0:2322154v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text field to identify the genus as determined by a lab test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2772456</PublicId>
      <PreferredName>2342266v1.0:2523426v1.0</PreferredName>
      <PreferredDefinition>A group or category, at any level, in a system for classifying plants or animals. (On-line Medical Dictionary)_A taxonomic category ranking below a family (or Subfamily) and above a species and generally consisting of a group of species exhibiting similar characteristics.</PreferredDefinition>
      <LongName>Taxon Genus</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2342266</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40098</PreferredName>
        <Version>1</Version>
        <LongName>Taxon</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40098</PREFERRED_NAME>
            <LONG_NAME>Taxon</LONG_NAME>
            <CON_ID>2342211</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2523426</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45292</PreferredName>
        <Version>1</Version>
        <LongName>Genus</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45292</PREFERRED_NAME>
            <LONG_NAME>Genus</LONG_NAME>
            <CON_ID>2523386</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2322154</PublicId>
      <PreferredName>LAB_RSLT_TXT</PreferredName>
      <PreferredDefinition>the text field related to a lab result.</PreferredDefinition>
      <LongName>Lab Results Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2322153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Result Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Genus</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Genus</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1527">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600300</PUBLICID>
    <LONGNAME>Image Physical Entity Question Index ISO21090.INT.v1.0</LONGNAME>
    <PREFERREDNAME>3599757v1.0:2803195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Any record of an imaging event whether physical or electronic.:Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:An independently existing thing (living or nonliving)._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence._Number results from counting and enumerating.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599757</PublicId>
      <PreferredName>3599583v1.0:2899730v1.0</PreferredName>
      <PreferredDefinition>Any record of an imaging event whether physical or electronic.:Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.:An independently existing thing (living or nonliving)._A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).:A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.</PreferredDefinition>
      <LongName>Image Physical Entity Question Index</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599583</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179:C25618:C51070</PreferredName>
        <Version>1</Version>
        <LongName>Image Physical Entity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25618</PREFERRED_NAME>
            <LONG_NAME>Physical</LONG_NAME>
            <CON_ID>2203948</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2899730</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41116:C25390</PreferredName>
        <Version>1</Version>
        <LongName>Question Index</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41116</PREFERRED_NAME>
            <LONG_NAME>Question</LONG_NAME>
            <CON_ID>2231575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25390</PREFERRED_NAME>
            <LONG_NAME>Index</LONG_NAME>
            <CON_ID>2203825</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803195</PublicId>
      <PreferredName>2803195v1.0</PreferredName>
      <PreferredDefinition>Number results from counting and enumerating.</PreferredDefinition>
      <LongName>ISO21090.INT.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Image Physical Entity Question Index ISO21090.INT.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Image Physical Entity Question Index ISO21090.INT.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ImagingPhysicalEntity.questionIndex</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ImagingPhysicalEntity:questionIndex</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1528">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600423</PUBLICID>
    <LONGNAME>Dimension Point Shape Identifier ISO21090.INT.v1.0</LONGNAME>
    <PREFERREDNAME>3599885v1.0:2803195v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial outline of an object as described by the configuration of straight or curved lines.:The precise location of something; a spatially limited location._The spatial arrangement of something as distinct from its substance.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Number results from counting and enumerating.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599885</PublicId>
      <PreferredName>3599542v1.0:2750166v1.0</PreferredName>
      <PreferredDefinition>The spatial outline of an object as described by the configuration of straight or curved lines.:The precise location of something; a spatially limited location._The spatial arrangement of something as distinct from its substance.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Dimension Point Shape Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599542</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25483:C70656</PreferredName>
        <Version>1</Version>
        <LongName>Dimension Point</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2750166</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25677:C25364</PreferredName>
        <Version>1</Version>
        <LongName>Shape Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25677</PREFERRED_NAME>
            <LONG_NAME>Shape</LONG_NAME>
            <CON_ID>2203587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803195</PublicId>
      <PreferredName>2803195v1.0</PreferredName>
      <PreferredDefinition>Number results from counting and enumerating.</PreferredDefinition>
      <LongName>ISO21090.INT.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Dimension Point Shape Identifier ISO21090.INT.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Dimension Point Shape Identifier ISO21090.INT.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ThreeDimensionPoint.shapeIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ThreeDimensionPoint:shapeIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1529">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600507</PUBLICID>
    <LONGNAME>Text Annotation Unique Identifier ISO21090.II.v1.0</LONGNAME>
    <PREFERREDNAME>3599968v1.0:2803193v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The words of something written.:An explanatory or critical comment that has been added to a text._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data._Identifier that uniquely identifies a thing or object.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599968</PublicId>
      <PreferredName>2750191v1.0:2715029v1.0</PreferredName>
      <PreferredDefinition>The words of something written.:An explanatory or critical comment that has been added to a text._A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or a body of data.</PreferredDefinition>
      <LongName>Text Annotation Unique Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2750191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704:C44272</PreferredName>
        <Version>1</Version>
        <LongName>Text Annotation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2715029</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70663</PreferredName>
        <Version>1</Version>
        <LongName>Unique Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70663</PREFERRED_NAME>
            <LONG_NAME>Unique Identifier</LONG_NAME>
            <CON_ID>2714899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803193</PublicId>
      <PreferredName>2803193v1.0</PreferredName>
      <PreferredDefinition>Identifier that uniquely identifies a thing or object.</PreferredDefinition>
      <LongName>ISO21090.II.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090IIv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2405190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Text Annotation Unique Identifier ISO21090.II.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Text Annotation Unique Identifier ISO21090.II.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TextAnnotationEntity:uniqueIdentifier</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.TextAnnotationEntity.uniqueIdentifier</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1530">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3600528</PUBLICID>
    <LONGNAME>Annotation Annotation Collection Date and Time ISO21090.TS.v1.0</LONGNAME>
    <PREFERREDNAME>3599989v1.0:2803209v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An explanatory or critical comment, or other in-context information (e.g., pattern, motif, link), that has been associated with data or other types of information.:A set of annotations, or comments about an idea, subject or item._An expression of both date and time that an event has happened or will happened._Quantity specifying a point on the axis of natural time.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3599989</PublicId>
      <PreferredName>3599573v1.0:2437776v1.0</PreferredName>
      <PreferredDefinition>An explanatory or critical comment, or other in-context information (e.g., pattern, motif, link), that has been associated with data or other types of information.:A set of annotations, or comments about an idea, subject or item._An expression of both date and time that an event has happened or will happened.</PreferredDefinition>
      <LongName>Annotation Annotation Collection Date and Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599573</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C44272:C101123</PreferredName>
        <Version>1</Version>
        <LongName>Annotation Annotation Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44272</PREFERRED_NAME>
            <LONG_NAME>Annotation</LONG_NAME>
            <CON_ID>2519066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C101123</PREFERRED_NAME>
            <LONG_NAME>Annotation Collection</LONG_NAME>
            <CON_ID>3419458</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2437776</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803209</PublicId>
      <PreferredName>2803209v1.0</PreferredName>
      <PreferredDefinition>Quantity specifying a point on the axis of natural time.</PreferredDefinition>
      <LongName>ISO21090.TS.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090TSv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYYMMDD</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue>19000101</MinimumValue>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Annotation Annotation Collection Date and Time ISO21090.TS.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Annotation Annotation Collection Date and Time ISO21090.TS.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AnnotationOfAnnotationCollection:dateTime</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.AnnotationOfAnnotationCollection.dateTime</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1531">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3601073</PUBLICID>
    <LONGNAME>Graft Versus Host Disease Preventive Intervention Administration Indicator</LONGNAME>
    <PREFERREDNAME>2681983v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not graft versus host disease prophylaxis was administered.</PREFERREDDEFINITION>
    <VERSION>1.1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2681983</PublicId>
      <PreferredName>GVHD_PRV_ADMN</PreferredName>
      <PreferredDefinition>An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</PreferredDefinition>
      <LongName>Graft Versus Host Disease Preventive Intervention Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2681981</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3063:C15843</PreferredName>
        <Version>1</Version>
        <LongName>Graft Versus Host Disease Preventive Intervention</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3063</PREFERRED_NAME>
            <LONG_NAME>Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2206367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15843</PREFERRED_NAME>
            <LONG_NAME>Preventive Intervention</LONG_NAME>
            <CON_ID>2488996</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25409</PreferredName>
        <Version>1</Version>
        <LongName>Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was graft versus host disease</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was graft versus host disease prophylaxis administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Corticosteroids (systemic)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Corticosteroids (systemic)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ALG, ALS, ATG, ATS</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>ALG, ALS, ATG, ATS</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cyclosporine (CSA, Neoral, Sandimmune)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cyclosporine (CSA, Neoral, Sandimmune)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cyclophosphamide (Cytoxan)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cyclophosphamide (Cytoxan)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Extra-corporeal photopheresis (ECP)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Extra-corporeal photopheresis (ECP)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FK 506 (Tacrolimus, Prograf)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>FK 506 (Tacrolimus, Prograf)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In vivo monoclonal antibody</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In vivo monoclonal antibody</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In vivo immunotoxin</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In vivo immunotoxin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Methotrexate (MTX) (Amethopterin)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Methotrexate (MTX) (Amethopterin)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mycophenolate mofetil (MMF) (CellCept)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mycophenolate mofetil (MMF) (CellCept)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Sirolimus (Rapamycin, Rapamune)</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Sirolimus (Rapamycin, Rapamune)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Blinded randomized trial</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Blinded randomized trial</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other agent</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive GVHD Prophylaxis and/or treatment during the Study period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG mapping for CDE:3601073</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>PerformedObservationResult.value(ANY=&gt;BL) WHERE PerformedObservationResult &gt; PerformedObservation &gt; DefinedObservation.nameCode = &quot;Adminsiter GVHD prophylaxis&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was GVHD prophylaxis administered per protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the recipient receive GVHD prophylaxis?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the recipient receive GVHD prophylaxis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was specific therapy used after the start of the preparative regimen to prevent acute GVHD?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was specific therapy used after the start of the preparative regimen to prevent acute GVHD?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive GVHD prophylaxis or treatment this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive aGvHD prophylaxis OR treatment during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive GvHD prophylaxis during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was GVHD prophylaxis administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Methotrexate</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Tacrolimus</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Cyclosporine</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Mycophenylate mofetil</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Post-transplant cyclophosphamide</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive GVHD prophylaxis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient off medications to treat or prevent either GVHD post BM transplant or organ rejection post-transplant for at least 14 days prior to start of protocol treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were GVHD prophylaxis agent/s administered during this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HPST_AGHD_agvhd_prev_thrpy_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult:value</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GVHD_PVT_INVT_ADM_IND</AlternateName>
        <AlternateNameType>COG GDE Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1532">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3610177</PUBLICID>
    <LONGNAME>Unspecified Endocrine Disease Present Indicator</LONGNAME>
    <PREFERREDNAME>2527007v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not any unspecified endocrine disease was present.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527007</PublicId>
      <PreferredName>UNS_ENDO_DZ_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of any unspecified or unlisted abnormal condition of the endocrine system, those tissues capable of secreting hormones, that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PreferredDefinition>
      <LongName>Unspecified Endocrine Disease Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008571</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CHR_O_ASS_DZ_AND_EXP</PreferredName>
        <Version>1</Version>
        <LongName>Chronic or Associated Diseases and Exposures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2527257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38046:C41064:C2991</PreferredName>
        <Version>1</Version>
        <LongName>Unspecified Endocrine Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38046</PREFERRED_NAME>
            <LONG_NAME>Unspecified</LONG_NAME>
            <CON_ID>2230154</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41064</PREFERRED_NAME>
            <LONG_NAME>Endocrine</LONG_NAME>
            <CON_ID>2225340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did a significant endocrine a</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did a significant endocrine abnormality occur that was not listed above</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1533">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3629986</PUBLICID>
    <LONGNAME>Laboratory Procedure Serum Mesothelin Result Lower Limit of Normal Value</LONGNAME>
    <PREFERREDNAME>3629949v1.0:3628764v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numerical quantity measured that is the bottom value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for serum mesothelin result.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3629949</PublicId>
      <PreferredName>2543047v1.0:3629947v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed._Mesothelin (630 aa, ~69 kDa) is encoded by the human MSLN gene. This protein may play a role in cellular adhesion._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure Serum Mesothelin Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3629947</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13325:C20887:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Serum Mesothelin Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13325</PREFERRED_NAME>
            <LONG_NAME>Serum</LONG_NAME>
            <CON_ID>2203797</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20887</PREFERRED_NAME>
            <LONG_NAME>Mesothelin</LONG_NAME>
            <CON_ID>2986772</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>RADLEX_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3628764</PublicId>
      <PreferredName>3628764v1.0</PreferredName>
      <PreferredDefinition>The bottom of the normal range for a particular laboratory result._A number with no fractional part, including the negative and positive numbers as well as zero.::2_An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Lower Limit of Normal 2 Decimal Place Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3628763</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25555:C45255::2:C42646:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Lower Limit of Normal Integer::2 Decimal Place Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25555</PREFERRED_NAME>
            <LONG_NAME>Lower Limit of Normal</LONG_NAME>
            <CON_ID>2204652</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42646</PREFERRED_NAME>
            <LONG_NAME>Decimal Place</LONG_NAME>
            <CON_ID>2555336</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Serum mesothelin (SM) Lower L</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Serum mesothelin (SM) Lower Limit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1534">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3630334</PUBLICID>
    <LONGNAME>MBSRQ Appearance Orientation Use Very Few Grooming Products Agreement Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>3628886v1.0:3630261v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of their agreement to a statement about using very few grooming products, using a five point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3628886</PublicId>
      <PreferredName>3628865v1.0:3629807v1.0</PreferredName>
      <PreferredDefinition>A well-validated, self-report inventory for the assessment of body image._A person&#39;s stated observation about using very few grooming products._1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)_A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Multidimensional Body-Self Relations Questionnaire Appearance Orientation Use Very Few Grooming Products Agreement Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3628865</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103316</PreferredName>
        <Version>1</Version>
        <LongName>Multidimensional Body-Self Relations Questionnaire Appearance Orientation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103316</PREFERRED_NAME>
            <LONG_NAME>Multidimensional Body-Self Relations Questionnaire Appearance Orientation</LONG_NAME>
            <CON_ID>3626503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3629807</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103322:C25369:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Use Very Few Grooming Products Agreement Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103322</PREFERRED_NAME>
            <LONG_NAME>Use Very Few Grooming Products Question</LONG_NAME>
            <CON_ID>3626522</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3630261</PublicId>
      <PreferredName>3630261v1.0</PreferredName>
      <PreferredDefinition>The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number or range of numeric values measuring performance, function, quality, or ability._A number with no fractional part, including the negative and positive numbers as well as zero.::5_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Agreement Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>3630260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3630260v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Agreement Score Integer::5 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Definitely Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitely Agree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Mostly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Mostly Agree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Neither Agree or Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Neither Agree or Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2940116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mostly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Mostly Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Definitely Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitely Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I use very few grooming produ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I use very few grooming products.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3626264</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MBSRQ Appearance</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MBSRQ-Appearance</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3626267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multidimensional Body-Self Relations Questionnaire-Appearance Scale (MBSRQ Appearance)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900324</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1535">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3630336</PUBLICID>
    <LONGNAME>MBSRQ Appearance Orientation Wear Whatever Is Handy Without Care Agreement Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>3628893v1.0:3630261v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of their agreement to a statement about usually wearing whatever is handy without caring how it looks, using a five point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3628893</PublicId>
      <PreferredName>3628865v1.0:3629809v1.0</PreferredName>
      <PreferredDefinition>A well-validated, self-report inventory for the assessment of body image._A person&#39;s stated observation about usually wearing whatever is handy without caring how it looks._The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Multidimensional Body-Self Relations Questionnaire Appearance Orientation Wear Whatever Is Handy Without Care Agreement Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3628865</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103316</PreferredName>
        <Version>1</Version>
        <LongName>Multidimensional Body-Self Relations Questionnaire Appearance Orientation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103316</PREFERRED_NAME>
            <LONG_NAME>Multidimensional Body-Self Relations Questionnaire Appearance Orientation</LONG_NAME>
            <CON_ID>3626503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3629809</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103324:C25369:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Wear Whatever is Handy Without Care Agreement Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103324</PREFERRED_NAME>
            <LONG_NAME>Wear Whatever is Handy Without Care Question</LONG_NAME>
            <CON_ID>3626524</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3630261</PublicId>
      <PreferredName>3630261v1.0</PreferredName>
      <PreferredDefinition>The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion._A number or range of numeric values measuring performance, function, quality, or ability._A number with no fractional part, including the negative and positive numbers as well as zero.::5_The precise location of something; a spatially limited location._an ordered reference standard.</PreferredDefinition>
      <LongName>Agreement Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>3630260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3630260v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Agreement Score Integer::5 Point Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25369</PREFERRED_NAME>
            <LONG_NAME>Agreement</LONG_NAME>
            <CON_ID>2204037</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70656</PREFERRED_NAME>
            <LONG_NAME>Point</LONG_NAME>
            <CON_ID>2710246</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Definitely Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitely Agree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Mostly Agree</VALUEMEANING>
          <MEANINGDESCRIPTION>Mostly Agree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630263</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Neither Agree or Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Neither Agree or Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2940116</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Mostly Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Mostly Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630264</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Definitely Disagree</VALUEMEANING>
          <MEANINGDESCRIPTION>Definitely Disagree</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-11-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3630265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I usually wear whatever is ha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I usually wear whatever is handy without caring how it looks.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3626264</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MBSRQ Appearance</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MBSRQ-Appearance</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3626267</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Multidimensional Body-Self Relations Questionnaire-Appearance Scale (MBSRQ Appearance)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900324</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1536">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3630771</PUBLICID>
    <LONGNAME>Biospecimen Oncocytic Variant Thyroid Gland Papillary Carcinoma Confirmed Diagnosis Indicator</LONGNAME>
    <PREFERREDNAME>3630764v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify whether or not the confirmed diagnosis of the thyroid papillary tumor contained oncocytic variant features.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3630764</PublicId>
      <PreferredName>2859635v1.0:3630762v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of papillary or follicular structures, containing malignant follicular cells with abundant granular eosinophilic cytoplasm.  These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland._Confirmed; having been established or verified._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Biospecimen Oncocytic Variant Thyroid Gland Papillary Carcinoma Confirmed Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3630762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C46093:C25458:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Oncocytic Variant Thyroid Gland Papillary Carcinoma Confirmed Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C46093</PREFERRED_NAME>
            <LONG_NAME>Oncocytic Variant Thyroid Gland Papillary Carcinoma</LONG_NAME>
            <CON_ID>3630761</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does this specimen have oncoc</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does this specimen have oncocytic variant features?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2756809</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>The Cancer Genome Atlas</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Active CDEs as of March 2017</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6044923</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1537">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3638867</PUBLICID>
    <LONGNAME>Person Resting Systolic Blood Pressure Assessment Value</LONGNAME>
    <PREFERREDNAME>REST_SYST_BP_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The blood pressure during the contraction of the left ventricle of the heart for a person at rest.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3638863</PublicId>
      <PreferredName>REST_SYS_BP</PreferredName>
      <PreferredDefinition>Person; a human being._Freedom from activity._The blood pressure during the contraction of the left ventricle of the heart.</PreferredDefinition>
      <LongName>Person Resting Systolic Blood Pressure Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3638861</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C28185:C25298</PreferredName>
        <Version>1</Version>
        <LongName>Person Resting Systolic Blood Pressure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28185</PREFERRED_NAME>
            <LONG_NAME>Resting</LONG_NAME>
            <CON_ID>2494798</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25298</PREFERRED_NAME>
            <LONG_NAME>Systolic Blood Pressure</LONG_NAME>
            <CON_ID>2206259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2182880</PublicId>
      <PreferredName>BLOOD_PRESSURE_SYSTOLIC</PreferredName>
      <PreferredDefinition>Indicating the maximum arterial pressure occurring during contraction of the left ventricle of the heart.</PreferredDefinition>
      <LongName>Blood Pressure, Systolic</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008514</PublicId>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DCP</PreferredName>
        <Version>1</Version>
        <LongName>DCP Conceptual Domain</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mmHg</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Resting Systolic BP</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Resting Systolic BP</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>REST_SYST_BP_VAL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1538">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3647985</PUBLICID>
    <LONGNAME>Neoadjuvant Chemotherapy Docetaxel Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3647289v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel) was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647289</PublicId>
      <PreferredName>2206713v1.0:3647287v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel).</PreferredDefinition>
      <LongName>Neoadjuvant Chemotherapy Docetaxel Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647287</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1526:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Docetaxel Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1526</PREFERRED_NAME>
            <LONG_NAME>Docetaxel</LONG_NAME>
            <CON_ID>2421116</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Taxotere (docetaxel)</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Taxotere (docetaxel)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1539">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3651292</PUBLICID>
    <LONGNAME>Hot Flash Related Daily Interference Past Week Relations With Others Score Likert Scale Text</LONGNAME>
    <PREFERREDNAME>3651238v1.0:3626258v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how much in the past week hot flashes have interfered with their relations with others, using a Likert scale value captured as a non-enumerated text field.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HFRDIS Based:Based on Hot Flash Related Daily Interference Scale</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3651238</PublicId>
      <PreferredName>3651220v1.0:3651279v1.0</PreferredName>
      <PreferredDefinition>A tool designed to measure the impact of hot flashes on overall quality of life as well as nine specific activities using a 10 point Likert scale._The most recent week, including today._A short or long-term association between two or more people, including kinship relations, romantic, business, and social interactions._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Hot Flash Related Daily Interference Past Week Relations With Others Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3651220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C104044</PreferredName>
        <Version>1</Version>
        <LongName>Hot Flash Related Daily Interference Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104044</PREFERRED_NAME>
            <LONG_NAME>Hot Flash Related Daily Inference Scale</LONG_NAME>
            <CON_ID>3651219</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3651279</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C92454:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Interpersonal Relationship Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C92454</PREFERRED_NAME>
            <LONG_NAME>Interpersonal Relationship</LONG_NAME>
            <CON_ID>3143347</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HFRDIS:Hot Flash Related Daily Interference Scale</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3626258</PublicId>
      <PreferredName>3626258v1.0</PreferredName>
      <PreferredDefinition>A psychometric scale commonly used in questionnaires where a respondent is asked to evaluate an opinion according to subjective or objective criteria, by rating their level of agreement or disagreement with a statement._Text; the words of something written.</PreferredDefinition>
      <LongName>Likert Scale Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3626257</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85429:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Likert Scale Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85429</PREFERRED_NAME>
            <LONG_NAME>Likert Scale</LONG_NAME>
            <CON_ID>2971959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Nonenumerated Value Domain Use</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>Based on need of NCI Alliance LPO and approved by Dr. Jeff Sloan.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Relations with others</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Relations with others</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3638606</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HFRDIS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HFRDIS Text Format</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3651248</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Hot Flash Related Daily Interference Scale (HFRDIS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900313</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1540">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3651861</PUBLICID>
    <LONGNAME>Father Geographic Birth Place Specify</LONGNAME>
    <PREFERREDNAME>2789892v1.0:3651855v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Specification of birthplace within the US or outside the US</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2789892</PublicId>
      <PreferredName>FATH_GEOG_BIRT_PLAC</PreferredName>
      <PreferredDefinition>Text that identify the geographical location where the father was born [Manually curated]</PreferredDefinition>
      <LongName>Father Geographic Birth Place</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2595729</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25174</PreferredName>
        <Version>1</Version>
        <LongName>Father</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25174</PREFERRED_NAME>
            <LONG_NAME>Father</LONG_NAME>
            <CON_ID>2202637</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2789888</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37957:C25155:C25319</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Birth Place</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37957</PREFERRED_NAME>
            <LONG_NAME>Geographic</LONG_NAME>
            <CON_ID>2434959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3651855</PublicId>
      <PreferredName>3651855v1.0</PreferredName>
      <PreferredDefinition>The words that specify the geographic location where a person was born.</PreferredDefinition>
      <LongName>Birth Place Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20189</PreferredName>
        <Version>1</Version>
        <LongName>Property or Attribute</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>50</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3651854</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25155:C25319:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Birth Place Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25155</PREFERRED_NAME>
            <LONG_NAME>Birth</LONG_NAME>
            <CON_ID>2202896</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25319</PREFERRED_NAME>
            <LONG_NAME>Place</LONG_NAME>
            <CON_ID>2202682</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Outside the United States</VALIDVALUE>
          <VALUEMEANING>Other country</VALUEMEANING>
          <MEANINGDESCRIPTION>Other country of birth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>In the United States</VALIDVALUE>
          <VALUEMEANING>United States</VALUEMEANING>
          <MEANINGDESCRIPTION>A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (CIA World Factbook 2002)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579004</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>In the State of Arkansas</VALIDVALUE>
          <VALUEMEANING>Arkansas</VALUEMEANING>
          <MEANINGDESCRIPTION>A state in the southern midwest United States. Its capital is Little Rock.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577229</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Where was your father born?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Where was your father born?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1541">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3652863</PUBLICID>
    <LONGNAME>Medication Ibuprofen Use Twice Weekly Month or more Frequency Indicator</LONGNAME>
    <PREFERREDNAME>3379222v1.0:3651379v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify whether Ibuprofen was taken twice weekly for a month or more</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3379222</PublicId>
      <PreferredName>2411879v1.0:3379220v1.0</PreferredName>
      <PreferredDefinition>A manner, or usual, or accepted practice of using a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects (Ibuprofen).</PreferredDefinition>
      <LongName>Medication Ibuprofen Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008558</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>UOM</PreferredName>
        <Version>1</Version>
        <LongName>Units of Measure</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2411879</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C459</PreferredName>
        <Version>1</Version>
        <LongName>Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3379220</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C561:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Ibuprofen Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C561</PREFERRED_NAME>
            <LONG_NAME>Ibuprofen</LONG_NAME>
            <CON_ID>2443592</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3651379</PublicId>
      <PreferredName>3651379v1.0</PreferredName>
      <PreferredDefinition>Two times per week._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways._One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._The number of occurrences of something within a given time period. (NCI)_An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Twice Weekly Month or more Frequency Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2513925</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43431</PreferredName>
        <Version>1</Version>
        <LongName>Activity</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3651378</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3651378v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Twice Weekly Greater Than or Equal To Month Frequency Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64497</PREFERRED_NAME>
            <LONG_NAME>Twice Weekly</LONG_NAME>
            <CON_ID>3651377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61583</PREFERRED_NAME>
            <LONG_NAME>Greater Than or Equal To</LONG_NAME>
            <CON_ID>2673224</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Don&#39;t Know/Refused</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-01-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you ever taken Ibuprofen</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you ever taken Ibuprofen-based medications, at least 2 times a week for a month or more? Examples are Advil, Aleve, Motrin, Nuprin, Indocin, Naprosy, Medipren and NSAIDS.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1542">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3656011</PUBLICID>
    <LONGNAME>Dimension Ellipsoid Comment ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3655977v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The spatial outline of an object as described by the configuration of straight or curved lines.:A surface whose plane sections are all ellipses or circles._A written explanation or criticism or illustration that is added to a book or other textual material._Character string datatype stands for text data.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3655977</PublicId>
      <PreferredName>3599588v1.0:2223274v1.0</PreferredName>
      <PreferredDefinition>The spatial outline of an object as described by the configuration of straight or curved lines.:A surface whose plane sections are all ellipses or circles._A written explanation or criticism or illustration that is added to a book or other textual material.</PreferredDefinition>
      <LongName>Dimension Ellipsoid Comment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3599588</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25483:C64363</PreferredName>
        <Version>1</Version>
        <LongName>Dimension Ellipsoid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25483</PREFERRED_NAME>
            <LONG_NAME>Dimension</LONG_NAME>
            <CON_ID>2203908</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64363</PREFERRED_NAME>
            <LONG_NAME>Ellipsoid</LONG_NAME>
            <CON_ID>2612180</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223274</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25393</PreferredName>
        <Version>1</Version>
        <LongName>Comment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25393</PREFERRED_NAME>
            <LONG_NAME>Comment</LONG_NAME>
            <CON_ID>2202716</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Dimension Ellipsoid Comment ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Dimension Ellipsoid Comment ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2614824</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM 4.0</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000057</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3599505</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>AIM FM</PreferredName>
          <Version>4</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>edu.northwestern.radiology.AIM</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000053</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>edu.northwestern.radiology.AIM.ThreeDimensionEllipsoid.comment</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ThreeDimensionEllipsoid:comment</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1543">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3691281</PUBLICID>
    <LONGNAME>Person Allele Testing Variation Code</LONGNAME>
    <PREFERREDNAME>ALL_VARIANT_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Coded representation for the genotype variant identified during testing of an individual.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2867509</PublicId>
      <PreferredName>PERS_ALL_TEST_RSL</PreferredName>
      <PreferredDefinition>Person; a human being._one of a series of possible alternative forms of a given gene, differing in DNA sequence, and affecting the functioning of a single product._A procedure for critical evaluation._Outcome; a phenomenon that follows and is caused by some previous phenomenon.</PreferredDefinition>
      <LongName>Person Allele Testing Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867507</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190:C16277</PreferredName>
        <Version>1</Version>
        <LongName>Person Allele</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16277</PREFERRED_NAME>
            <LONG_NAME>Allele</LONG_NAME>
            <CON_ID>2223183</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2527278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15336:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Testing Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15336</PREFERRED_NAME>
            <LONG_NAME>Testing</LONG_NAME>
            <CON_ID>2204718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3691277</PublicId>
      <PreferredName>ALL_VAR_CD</PreferredName>
      <PreferredDefinition>Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in DNA sequence and governing the same biochemical and developmental process._An alteration or difference from a norm or standard._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Allele Variation Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2939340</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16277:C25713:C47891:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Allele Variation Test Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16277</PREFERRED_NAME>
            <LONG_NAME>Allele</LONG_NAME>
            <CON_ID>2223183</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47891</PREFERRED_NAME>
            <LONG_NAME>Test</LONG_NAME>
            <CON_ID>2427511</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Variant/Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>The phenotypic differences among individuals in a population: The phenotypic differences among individuals in a population</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17248, C17248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3691278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Wildtype/Variant</VALUEMEANING>
          <MEANINGDESCRIPTION>The naturally-occuring, normal, non-mutated version of a gene or genome.: The phenotypic differences among individuals in a population</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17248, C62492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3691279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Wildtype/Wildtype</VALUEMEANING>
          <MEANINGDESCRIPTION>The naturally-occuring, normal, non-mutated version of a gene or genome.: The naturally-occuring, normal, non-mutated version of a gene or genome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62492, C62492</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3691280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Variant Genotype</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Variant Genotype</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812605</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6545315</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SI Workshop Query Categories</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Genetic Variants/Genotype/Mutations</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>SemanticCategory</ClassificationSchemeItemType>
        <CsiPublicId>6545447</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>LCC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LCC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1544">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3701085</PUBLICID>
    <LONGNAME>APGAR Test Heart Rate Score</LONGNAME>
    <PREFERREDNAME>2958402v1.0:3698825v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numerical value that represents the assessment of the circulatory status of a neonate, as a component of the APGAR test.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NICHD</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>APGAR:APGAR Score, Dr. Virginia Apgar, 1953</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2958402</PublicId>
      <PreferredName>2958312v1.0:2958337v1.0</PreferredName>
      <PreferredDefinition>A test devised by Dr. Virginia Apgar to assess the overall health of a newborn upon birth. The test is administered at one and five minutes after birth and allows for the assignation of numerical values between zero and two for specific observations regarding skin color, pulse rate, reflex irritability, muscle tone and breathing._A component of the APGAR score, it is the numerical value assigned to an assessment of the circulatory status of a neonate. 0 = no pulse; 1 = rate less than 100 beats per minute; 2 = rate greater than 100 beats per minute.</PreferredDefinition>
      <LongName>APGAR Test Heart Rate Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2958312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81230</PreferredName>
        <Version>1</Version>
        <LongName>APGAR Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81230</PREFERRED_NAME>
            <LONG_NAME>Apgar Test</LONG_NAME>
            <CON_ID>2958260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2958337</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81309</PreferredName>
        <Version>1</Version>
        <LongName>Heart Rate Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81309</PREFERRED_NAME>
            <LONG_NAME>Heart Rate Score</LONG_NAME>
            <CON_ID>2958263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3698825</PublicId>
      <PreferredName>3698825v1.0</PreferredName>
      <PreferredDefinition>A test devised by Dr. Virginia Apgar to assess the overall health of a newborn upon birth. The test is administered at one and five minutes after birth and allows for the assignation of numerical values between zero and two for specific observations regarding skin color, pulse rate, reflex irritability, muscle tone and breathing._The number of heartbeats per unit of time, usually expressed as beats per minute._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>APGAR Test Heart Rate Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NICHD</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>2</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>APGAR:APGAR Score, Dr. Virginia Apgar, 1953</Origin>
      <Representation>
        <PublicId>3698824</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C81230:C49677:C25338</PreferredName>
        <Version>1</Version>
        <LongName>APGAR Test Heart Rate Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81230</PREFERRED_NAME>
            <LONG_NAME>Apgar Test</LONG_NAME>
            <CON_ID>2958260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49677</PREFERRED_NAME>
            <LONG_NAME>Heart Rate</LONG_NAME>
            <CON_ID>2451566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>No Pulse</VALUEMEANING>
          <MEANINGDESCRIPTION>Not existing in a specified place at a specified time.: The rhythmic wave within the arteries occurring with each contraction of the left ventricle. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25749, C48190</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Rate Less Than 100 Beats per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::100: The number of heartbeats measured per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49673, C45255::100, C61585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698827</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Rate Greater Than 100 Beats per Minute</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::100: The number of heartbeats measured per minute time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49673, C45255::100, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Heart Rate Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Heart Rate Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3685569</PublicId>
          <ContextName>NICHD</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Newborn Examination</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical Examination</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000329</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1545">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3703192</PUBLICID>
    <LONGNAME>Timeline Followback Method Illicit Substance Heroin Assessment Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3703171v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator that asks whether the participant had used heroin as part of the Timeline Followback Method assessment, a calendar-based measure for assessing self-reported retrospective daily estimates of alcohol, tobacco and/or illicit substance use.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDA</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3703171</PublicId>
      <PreferredName>3703092v1.0:3703169v1.0</PreferredName>
      <PreferredDefinition>information related to a Timeline Followback Method assessment (a calendar-based measure for assessing self-reported retrospective daily estimates of alcohol, tobacco and/or illicit substance use) of illicit substance use (drugs or alcoholic beverages deemed harmful and usually subject to legal restriction) of heroin (a substance made from morphine that is very addictive and is a type of opiate).</PreferredDefinition>
      <LongName>Timeline Followback Method Illicit Substance Heroin Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDA</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3703092</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105552</PreferredName>
        <Version>1</Version>
        <LongName>Timeline Followback Method</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105552</PREFERRED_NAME>
            <LONG_NAME>Timeline Followback Method</LONG_NAME>
            <CON_ID>3703041</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3703169</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C79097:C424:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Illicit Substance Heroin Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79097</PREFERRED_NAME>
            <LONG_NAME>Illicit Substance</LONG_NAME>
            <CON_ID>2820624</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C424</PREFERRED_NAME>
            <LONG_NAME>Diacetylmorphine</LONG_NAME>
            <CON_ID>2728916</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Heroin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Heroin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3696642</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Instrument</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NIDA CTN TimeLine FollowBack</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3696701</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3902628</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Legacy HRQOL/PRO CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Legacy HRQOL/PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104451</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1546">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3718876</PUBLICID>
    <LONGNAME>Patient Endotracheal Intubation Procedure Clinical Trial Eligibility Criteria Category</LONGNAME>
    <PREFERREDNAME>PT_ENDO_INT_PR_CL_TR_EC_CATE</PREFERREDNAME>
    <PREFERREDDEFINITION>the Mallampatti category based on the visualization of four anatomical structures found in the oropharynx.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3694794</PublicId>
      <PreferredName>Pati_Endo_Intu_Proc_Clin</PreferredName>
      <PreferredDefinition>information related to an endotracheal intubation procedure which is required to allow an individual to participate in a specific clinical trial.</PreferredDefinition>
      <LongName>Patient Endotracheal Intubation Procedure Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3694792</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C84984:C37981:C79751:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Endotracheal Intubation Procedure Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84984</PREFERRED_NAME>
            <LONG_NAME>Endotracheal</LONG_NAME>
            <CON_ID>2969637</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37981</PREFERRED_NAME>
            <LONG_NAME>Intubation Procedure</LONG_NAME>
            <CON_ID>2203648</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79751</PREFERRED_NAME>
            <LONG_NAME>Procedure</LONG_NAME>
            <CON_ID>2833027</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3718871</PublicId>
      <PreferredName>PT_ENDO_INT_PR_CATE</PreferredName>
      <PreferredDefinition>the category or classification related to the Mallampatti scoring system.</PreferredDefinition>
      <LongName>Patient Endotracheal Intubation Procedure Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class 1</VALIDVALUE>
          <VALUEMEANING>Class One</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718872</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class 2</VALIDVALUE>
          <VALUEMEANING>Class Two</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class 3</VALIDVALUE>
          <VALUEMEANING>Class Three</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718874</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Class 4</VALIDVALUE>
          <VALUEMEANING>Class Four</VALUEMEANING>
          <MEANINGDESCRIPTION>Class; a collection of things sharing a common attribute.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835, C25346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3718875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Modified Mallampatti assessme</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Modified Mallampatti assessment score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>PT_ENDO_IN_PR_CATE</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_ENDO_INT_PR_CL_TR_EC_CATE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1547">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3725072</PUBLICID>
    <LONGNAME>Lymphedema and Breast Cancer Questionnaire During Past Year Have Numbness Experience Indicator</LONGNAME>
    <PREFERREDNAME>3722549v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of whether or not during the past year they have or had numbness in their arm, breast, or chest, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3722549</PublicId>
      <PreferredName>3718831v1.0:3722547v1.0</PreferredName>
      <PreferredDefinition>A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer._At some point in a given period of time._Past; before the present time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._A question about whether an individual has or had numbness._The accumulation of knowledge or skill that results from direct participation in events or activities.</PreferredDefinition>
      <LongName>Lymphedema and Breast Cancer Questionnaire During Past Year Have Numbness Experience</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3718831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105763</PreferredName>
        <Version>1</Version>
        <LongName>Lymphedema and Breast Cancer Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105763</PREFERRED_NAME>
            <LONG_NAME>Lymphedema and Breast Cancer Questionnaire</LONG_NAME>
            <CON_ID>3715997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3722547</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3722547v1.0</PreferredName>
        <Version>1</Version>
        <LongName>During Past Year Have Numbness Experience</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105777</PREFERRED_NAME>
            <LONG_NAME>Have Numbness Question</LONG_NAME>
            <CON_ID>3715983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54627</PREFERRED_NAME>
            <LONG_NAME>Experience</LONG_NAME>
            <CON_ID>2731931</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>LBCQ: Lymphedema and Breast Cancer Questionnaire, Jane M. Armer</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you experienced numbness</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you experienced numbness during the past year?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>LBCQ Comment</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>Pitting is when you press firmly on your skin and the dent stays long enough to feel it when you slide the pad of your finger across it.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3704455</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LBCQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LBCQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3704456</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lymphedema and Breast Cancer Questionnaire (LBCQ)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1548">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3755942</PUBLICID>
    <LONGNAME>Plan Hematopoietic Cell Graft Peripheral Blood Stem Cell Type Indicator</LONGNAME>
    <PREFERREDNAME>3755928v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the planned hematopoietic cell graft (product) were peripheral blood stem cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3755928</PublicId>
      <PreferredName>3767211v1.0:2728548v1.0</PreferredName>
      <PreferredDefinition>To devise, contrive, or form in design._Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body._An immature (progenitor) cell circulating in the peripheral blood.  It has the capacity for replication and differentiation to mature blood cells._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Plan Hematopoietic Cell Graft Peripheral Blood Stem Cell Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3767211</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25619:C12551:C12981</PreferredName>
        <Version>1</Version>
        <LongName>Plan Hematopoietic Stem Cell Graft</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25619</PREFERRED_NAME>
            <LONG_NAME>Plan</LONG_NAME>
            <CON_ID>2203947</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12981</PREFERRED_NAME>
            <LONG_NAME>Graft</LONG_NAME>
            <CON_ID>2202844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2728548</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12946:C25284</PreferredName>
        <Version>1</Version>
        <LongName>PBSC Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12946</PREFERRED_NAME>
            <LONG_NAME>Peripheral Blood Stem Cell</LONG_NAME>
            <CON_ID>2202777</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the planned hematopoietic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the planned hematopoietic cell graft peripheral blood stem cells?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Peripheral blood stem cells</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Peripheral blood stem cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Peripheral blood stem cells</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Peripheral blood stem cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2804r4: Unique ID Assignment Form</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3755941</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1549">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760888</PUBLICID>
    <LONGNAME>Regulation Submission Assessment Outcome Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760105v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the regulatory designation made by the regulatory authority. EXAMPLE(S): (1) For regular submissions the code can be: approved, not approvable, approvable, complete response or cleared. (2) For expanded access submissions the code can be: Available, No longer available, Temporarily not available, or Approved for marketing. NOTE(S): For some submissions, there are business processes that will make &quot;default&quot; action based on timelines --i.e., if no action is taken, then the submission is &quot;approved&quot;. For a submission, there may be multiple regulatory assessments that correspond to the state transitions for a submission, but only one regulatory assessment is true at a given time. A submission can first be &quot;approveable&quot; and then when the data is complete, a new regulatory assessment can be made that is &quot;approved&quot;.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760105</PublicId>
      <PreferredName>3757254v1.0:2528599v1.0</PreferredName>
      <PreferredDefinition>A rule or order issued by an authority stating what may or may not be done or how something must be done.:Something submitted for the judgment or consideration of others.:The final result of a determination of the value, significance, or extent of._A phenomenon that follows and is caused by some previous phenomenon.:A system, often of numbered categories, for representation of data.</PreferredDefinition>
      <LongName>Regulation Submission Assessment Outcome Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757254</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68821:C25694:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Regulation Submission Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68821</PREFERRED_NAME>
            <LONG_NAME>Regulation</LONG_NAME>
            <CON_ID>2867554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25694</PREFERRED_NAME>
            <LONG_NAME>Submission</LONG_NAME>
            <CON_ID>2202488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2528599</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20200:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Outcome Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Regulation Submission Assessment Outcome Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Regulation Submission Assessment Outcome Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757155</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.RegulatorySubDomain.RegulatoryAssessment.resultCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RegulatoryAssessment:resultCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GMP MP Auth granted</AlternateName>
        <AlternateNameType>Map:CTR&amp;Rr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyAgent.expandedAccessStatusCode</AlternateName>
        <AlternateNameType>Map:CTRRr3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RegulatoryAssessment.resultCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Expanded access indicator</AlternateName>
        <AlternateNameType>Map:CTRR</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Expanded Access Status</AlternateName>
        <AlternateNameType>Map:CTGOV</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>IEC Opinion Given</AlternateName>
        <AlternateNameType>Map:CTR&amp;Rr2</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyIndIde.expandedAccessStatusCode</AlternateName>
        <AlternateNameType>Map:CTRPv3.8</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RegulatoryAssessment.assessmentCode</AlternateName>
        <AlternateNameType>Map:CTRRr3</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1550">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760953</PUBLICID>
    <LONGNAME>Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760177v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded value specifying the anatomical structure that consists of organs and organ subclasses responsible for certain body functions. EXAMPLE(S): gastrointestinal system, urinary system, hematopoietic system.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760177</PublicId>
      <PreferredName>2867717v1.0:3174586v1.0</PreferredName>
      <PreferredDefinition>Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._An anatomical structure that consists of organs and organ subclasses responsible for certain body functions.  Representative examples are the gastrointestinal system, urinary system, and hematopoietic system.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Observation Performed Study Activity Organ System Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867717</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25598:C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174586</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12919:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Organ System Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12919</PREFERRED_NAME>
            <LONG_NAME>Organ System</LONG_NAME>
            <CON_ID>2589988</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Observation Performed Study Activity Organ System Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservation:bodySystemCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedObservation.bodySystemCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult.bodySystemCode</AlternateName>
        <AlternateNameType>Map:CTRv1.0</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedObservationResult.bodySystemCode</AlternateName>
        <AlternateNameType>Map:LSDAMv2.2.3Plus</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 2182671v1.0:  Other Body System/Site Text</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 3192450v1.0: Physical Examination Criteria Category</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CDE 3192540v1.0: Medical History Review of Systems Criteria Category</AlternateName>
        <AlternateNameType>Map:NCI CRF Standard</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1551">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760964</PUBLICID>
    <LONGNAME>Study Execution Registration Study Subject Quantity ISO21090.INT.POS.v1.0</LONGNAME>
    <PREFERREDNAME>3760187v1.0:2848082v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An integer specifying the quantity of study subjects enrolled in the study at the current time.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760187</PublicId>
      <PreferredName>3174254v1.0:3759970v1.0</PreferredName>
      <PreferredDefinition>A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:The act of carrying out some order or instruction to accomplish an aim._The act of listing or recording officially; officially qualified or enrolled.:A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.:How much there is of something that you can measure; the total amount or number.</PreferredDefinition>
      <LongName>Study Execution Registration Study Subject Quantity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3174254</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63536:C48293</PreferredName>
        <Version>1</Version>
        <LongName>Study Execution</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48293</PREFERRED_NAME>
            <LONG_NAME>Execution</LONG_NAME>
            <CON_ID>2388829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3759970</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25646:C41189:C25256</PreferredName>
        <Version>1</Version>
        <LongName>Registration Study Subject Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25646</PREFERRED_NAME>
            <LONG_NAME>Registration</LONG_NAME>
            <CON_ID>2202799</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41189</PREFERRED_NAME>
            <LONG_NAME>Study Subject</LONG_NAME>
            <CON_ID>2202706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2848082</PublicId>
      <PreferredName>2848082v1.0</PreferredName>
      <PreferredDefinition>Constrains INT to a value of greater than 0.</PreferredDefinition>
      <LongName>ISO21090.INT.POS.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090INTPOSv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2433737</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45255</PreferredName>
        <Version>1</Version>
        <LongName>Integer</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Execution Registration Study Subject Quantity ISO21090.INT.POS.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Execution Registration Study Subject Quantity ISO21090.INT.POS.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.StudyExecution.enrolledStudySubjectNumber</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>StudyExecution:enrolledStudySubjectNumber</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1552">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3760979</PUBLICID>
    <LONGNAME>Intervention or Procedure Performed Study Activity Fasting Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3760202v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action whose immediate and primary intention is the alteration of the physical or mental condition of the subject, study subject or experimental unit. EXAMPLE(S): Procedures may involve the disruption of some body surface (e.g. an incision in a surgical procedure) conservative procedures such as reduction of a luxated joint, including physiotherapy such as chiropractic treatment, massage, balneotherapy, acupuncture, shiatsu, counseling, etc. Specifies whether the participant had abstained from eating when the specimen is obtained.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760202</PublicId>
      <PreferredName>2867610v1.0:2867741v1.0</PreferredName>
      <PreferredDefinition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._Abstaining from food.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Intervention or Procedure Performed Study Activity Fasting Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25218:C38000:C63536:C43431</PreferredName>
        <Version>1</Version>
        <LongName>Intervention or Procedure Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2867741</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63663:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Fasting Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63663</PREFERRED_NAME>
            <LONG_NAME>Fasting</LONG_NAME>
            <CON_ID>2555334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Intervention or Procedure Performed Study Activity Fasting Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Intervention or Procedure Performed Study Activity Fasting Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedProcedure:fastingStatusIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedProcedure.fastingStatusIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1553">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761009</PUBLICID>
    <LONGNAME>Adverse Event Reuse Template Observation Outcome Data Negation Flag ISO21090.BL.v1.0</LONGNAME>
    <PREFERREDNAME>3760227v1.0:2803169v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A reusable, template description of any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship. EXAMPLE(S): death, back pain, headache, pulmonary embolism, heart attack Specifies whether, when the observation event occurred, the finding communicated by the value attribute was NOT found. NOTE(S): This attribute should only be used when the terminology used for the defined observation result value is not itself capable of expressing negated findings (e.g., ICD9).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760227</PublicId>
      <PreferredName>3757224v1.0:3759075v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.  Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).:To use again.:Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.:Watching something and taking note of what happens.:The result of an action._A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.:An operation in which a term denies or inverts the meaning of another term or construction.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Adverse Event Reuse Template Observation Outcome Data Negation Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757224</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757224v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Reuse Template Observation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C79891</PREFERRED_NAME>
            <LONG_NAME>Reuse</LONG_NAME>
            <CON_ID>2839821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45677</PREFERRED_NAME>
            <LONG_NAME>Template</LONG_NAME>
            <CON_ID>2231570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3759075</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25474:C25594:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Data Negation Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25474</PREFERRED_NAME>
            <LONG_NAME>Data</LONG_NAME>
            <CON_ID>2202724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803169</PublicId>
      <PreferredName>2803169v1.0</PreferredName>
      <PreferredDefinition>Values of two-valued logic.</PreferredDefinition>
      <LongName>ISO21090.BL.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090BLv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Adverse Event Reuse Template Observation Outcome Data Negation Flag ISO21090.BL.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Adverse Event Reuse Template Observation Outcome Data Negation Flag ISO21090.BL.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757154</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.ProtocolRepresentationSubDomain.DefinedAdverseEvent.valueNegationIndicator</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DefinedAdverseEvent:valueNegationIndicator</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1554">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761047</PUBLICID>
    <LONGNAME>Medical Device Product Material Code Change Text ISO21090.ST.v1.0</LONGNAME>
    <PREFERREDNAME>3760264v1.0:2803207v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>An object intended for use whether alone or in combination for diagnostic, prevention, monitoring, therapeutic, scientific, and/or experimental purposes. EXAMPLE(S): tongue depressor, pacemaker, insulin pump, EKG machine, x-ray machine, mass spectrometer, polymerase chain reaction (PCR) machine, microscope, pH meter A character string that is a revision of the original text of the product to enable the coding of the text. EXAMPLE(S): If the original text is &quot;aspriin&quot;, the code modified text could be set to &quot;aspirin&quot;, so that the text can be successfully coded. NOTE(S): In the context of BRIDG, text modification occurs a single time for a given instance of original text.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760264</PublicId>
      <PreferredName>2867666v1.0:3174585v1.0</PreferredName>
      <PreferredDefinition>Any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions.:The end result of a manufacturing process; anything that is produced.:The tangible substance that goes into the makeup of a physical object._A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.:The act of alteration or modification; changed or altered in form or character.:The words of something written.</PreferredDefinition>
      <LongName>Medical Device Product Material Code Change Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867666</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16830:C51980:C48187</PreferredName>
        <Version>1</Version>
        <LongName>Medical Device Product Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16830</PREFERRED_NAME>
            <LONG_NAME>Medical Device</LONG_NAME>
            <CON_ID>2240760</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174585</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162:C25446:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Code Change Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25446</PREFERRED_NAME>
            <LONG_NAME>Change</LONG_NAME>
            <CON_ID>2202307</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803207</PublicId>
      <PreferredName>2803207v1.0</PreferredName>
      <PreferredDefinition>Character string datatype stands for text data.</PreferredDefinition>
      <LongName>ISO21090.ST.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090STv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Medical Device Product Material Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Medical Device Product Material Code Change Text ISO21090.ST.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.CommonSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Device:codeModifiedText</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.CommonSubDomain.Device.codeModifiedText</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1555">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761182</PUBLICID>
    <LONGNAME>Study Subject Milestone Administration, Management Performed Study Activity Duration ISO21090.PQ.TIME.v1.0</LONGNAME>
    <PREFERREDNAME>3760392v1.0:2848092v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action which marks a common administrative landmark for a study subject in the course of a study. EXAMPLE(S): obtain informed consent, verify eligibility criteria, enroll, registration to a study, randomize, assignment to a treatment arm, start of on-study period, complete study visits, end of on-study period, exit study, break treatment blind, premature withdrawal The period of time over which the activity is performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760392</PublicId>
      <PreferredName>2867636v1.0:2234809v1.0</PreferredName>
      <PreferredDefinition>A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.:An important event in the progress, development, or history of something or in someone&#39;s life.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._The period of time during which something continues.</PreferredDefinition>
      <LongName>Study Subject Milestone Administration, Management Performed Study Activity Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867636v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Study Subject Milestone Administration, Management Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41189</PREFERRED_NAME>
            <LONG_NAME>Study Subject</LONG_NAME>
            <CON_ID>2202706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70743</PREFERRED_NAME>
            <LONG_NAME>Milestone</LONG_NAME>
            <CON_ID>2691049</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234809</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25330</PreferredName>
        <Version>1</Version>
        <LongName>Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2848092</PublicId>
      <PreferredName>2848092v1.0</PreferredName>
      <PreferredDefinition>Constrains PQ to have units that describe a period of time.</PreferredDefinition>
      <LongName>ISO21090.PQ.TIME.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090PQTIMEv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2423394</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939</PreferredName>
        <Version>1</Version>
        <LongName>Date/Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Study Subject Milestone Administration, Management Performed Study Activity Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Study Subject Milestone Administration, Management Performed Study Activity Duration ISO21090.PQ.TIME.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedStudySubjectMilestone:duration</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedStudySubjectMilestone.duration</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1556">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761320</PUBLICID>
    <LONGNAME>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760521v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A characteristic or requirement that disqualifies a subject from participation in a study. EXAMPLE(S): pregnancy A coded value specifying the degree of authoritativeness or certiitude of the date of the activity. EXAMPLE(S): date estimated, date greater than 100 days - day is correct, date known, date less than 100 days - date is correct, date previously reported NOTE(S): The concept of &quot;date unknown&quot; is captured by a null flavor of &quot;UNK&quot; on the date range attribute, rather than a code in this attribute.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760521</PublicId>
      <PreferredName>2867643v1.0:3759969v1.0</PreferredName>
      <PreferredDefinition>Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.:Watching something and taking note of what happens.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An action taken in pursuit of an objective; the state of being active._An expression of both date and time that an event has happened or will happen.:The act of validating; finding or testing the truth of something.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Date and Time Validation Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867643</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>2867643v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Exclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25370</PREFERRED_NAME>
            <LONG_NAME>Exclusion Criteria</LONG_NAME>
            <CON_ID>2203927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25598</PREFERRED_NAME>
            <LONG_NAME>Observation</LONG_NAME>
            <CON_ID>2224011</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3759969</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939:C16237:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time Validation Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16237</PREFERRED_NAME>
            <LONG_NAME>Validation</LONG_NAME>
            <CON_ID>2203726</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Exclusion Criteria Clinical Trial Eligibility Criteria Observation Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedExclusionCriterion:dateRangeValidationCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedExclusionCriterion.dateRangeValidationCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1557">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761354</PUBLICID>
    <LONGNAME>Biologically-Derived Material Product Material Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760554v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A substance made from a living organism or thing it produces. EXAMPLE(S): virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, analogous product A coded value specifying the non-unique textual identifier for the material. EXAMPLE(S): aspirin, tobacco, caffeine NOTE(S): The granularity of the code may vary depending on the specificity of the material. For example, acetaminophen, Tylenol, Tylenol 250 mg gel cap.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760554</PublicId>
      <PreferredName>2867618v1.0:2222855v1.0</PreferredName>
      <PreferredDefinition>Natural substances derived from living organisms such as cells, tissues, proteins, and DNA.:The end result of a manufacturing process; anything that is produced.:The tangible substance that goes into the makeup of a physical object._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Biologically-Derived Material Product Material Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867618</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C43376:C51980:C48187</PreferredName>
        <Version>1</Version>
        <LongName>Biologically-Derived Material Product Material</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43376</PREFERRED_NAME>
            <LONG_NAME>Biologically-Derived Material</LONG_NAME>
            <CON_ID>2236534</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51980</PREFERRED_NAME>
            <LONG_NAME>Product</LONG_NAME>
            <CON_ID>2527882</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48187</PREFERRED_NAME>
            <LONG_NAME>Material</LONG_NAME>
            <CON_ID>2514541</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222855</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Biologically-Derived Material Product Material Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Biologically-Derived Material Product Material Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.CommonSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757153</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.CommonSubDomain.Biologic.code</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Biologic:code</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1558">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761455</PUBLICID>
    <LONGNAME>Notification Administration Performed Study Activity Variance Type Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760651v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action within the context of a given study that represents the communication of a message to a recipient. A coded value specifying the kind of variance. EXAMPLE(S): early / late occurrence of an act, higher / lower amount transferred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760651</PublicId>
      <PreferredName>3757293v1.0:3174589v1.0</PreferredName>
      <PreferredDefinition>Informing by words.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._A statistical computation dervied by using the expected value and averaging the squared distance of all viable values.:Something distinguishable as an identifiable class based on common qualities.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Notification Administration Performed Study Activity Variance Type Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757293v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Notification Administration Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25297</PREFERRED_NAME>
            <LONG_NAME>Notification</LONG_NAME>
            <CON_ID>2202895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3174589</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48918:C25284:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Variance Type Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48918</PREFERRED_NAME>
            <LONG_NAME>Variance</LONG_NAME>
            <CON_ID>2423424</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Notification Administration Performed Study Activity Variance Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Notification Administration Performed Study Activity Variance Type Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedNotification:varianceTypeCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedNotification.varianceTypeCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1559">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761503</PUBLICID>
    <LONGNAME>Investigational Entity Allocation Administration Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0</LONGNAME>
    <PREFERREDNAME>3760699v1.0:2803170v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The completed action that is the assignment of an experimental unit to a portion of the study, such as an arm or a portion of an arm (when secondary allocations may occur). EXAMPLE(S): Mrs. Smith is assigned to Arm A. A coded value specifying the degree of authoritativeness or certiitude of the date of the activity. EXAMPLE(S): date estimated, date greater than 100 days - day is correct, date known, date less than 100 days - date is correct, date previously reported NOTE(S): The concept of &quot;date unknown&quot; is captured by a null flavor of &quot;UNK&quot; on the date range attribute, rather than a code in this attribute.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3760699</PublicId>
      <PreferredName>3757327v1.0:3759969v1.0</PreferredName>
      <PreferredDefinition>In the process of being studied; experimental.:An independently existing thing (living or nonliving).:The distribution of resources over various time periods, products, operations, or investments.:Performing or possessing executive duties; acting as a supervisor or manager.:Executed and carried through to completion.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:An active process; excludes processes and mechanisms which fulfill biological functions._An expression of both date and time that an event has happened or will happen.:The act of validating; finding or testing the truth of something.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.</PreferredDefinition>
      <LongName>Investigational Entity Allocation Administration Performed Study Activity Date and Time Validation Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3757327</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3757327v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Investigational Entity Allocation Administration Performed Study Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28041</PREFERRED_NAME>
            <LONG_NAME>Investigational</LONG_NAME>
            <CON_ID>2422346</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51070</PREFERRED_NAME>
            <LONG_NAME>Entity</LONG_NAME>
            <CON_ID>2452881</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C52580</PREFERRED_NAME>
            <LONG_NAME>Allocation</LONG_NAME>
            <CON_ID>2443113</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48905</PREFERRED_NAME>
            <LONG_NAME>Administration, Management</LONG_NAME>
            <CON_ID>2528523</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63536</PREFERRED_NAME>
            <LONG_NAME>Study</LONG_NAME>
            <CON_ID>2553063</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43431</PREFERRED_NAME>
            <LONG_NAME>Activity</LONG_NAME>
            <CON_ID>2222740</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3759969</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37939:C16237:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Date and Time Validation Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37939</PREFERRED_NAME>
            <LONG_NAME>Date and Time</LONG_NAME>
            <CON_ID>2202495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16237</PREFERRED_NAME>
            <LONG_NAME>Validation</LONG_NAME>
            <CON_ID>2203726</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2803170</PublicId>
      <PreferredName>2803170v1.0</PreferredName>
      <PreferredDefinition>Reference concept defined by a referenced code system.</PreferredDefinition>
      <LongName>ISO21090.CD.v1.0</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2846956</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ISO21090 DATA TYPES</PreferredName>
        <Version>1</Version>
        <LongName>ISO21090 Data Types</LongName>
      </ConceptualDomain>
      <Datatype>ISO21090CDv1.0</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>ISO:International Organization for Standardization</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Investigational Entity Allocation Administration Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0 does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Investigational Entity Allocation Administration Performed Study Activity Date and Time Validation Code ISO21090.CD.v1.0 does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3757111</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG 3.2</PreferredName>
          <Version>3.2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>3757156</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedExperimentalUnitAllocation:dateRangeValidationCode</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>gov.nih.nci.BRIDG.domain.StudyConductSubDomain.PerformedExperimentalUnitAllocation.dateRangeValidationCode</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1560">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3761974</PUBLICID>
    <LONGNAME>Anticoagulant Agent Not Low Molecular Weight Heparin Administered Indicator</LONGNAME>
    <PREFERREDNAME>3761951v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify whether or not the patient is receiving anti-coagulants other than low-molecular weight heparin.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3761951</PublicId>
      <PreferredName>2647695v1.0:3761949v1.0</PreferredName>
      <PreferredDefinition>Any agent capable of preventing blood clot formation._An operation in which a term denies or inverts the meaning of another term or construction._Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.(NCI)_The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Anticoagulant Agent Not Low Molecular Weight Heparin Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2647695</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C263</PreferredName>
        <Version>1</Version>
        <LongName>Anticoagulant Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C263</PREFERRED_NAME>
            <LONG_NAME>Anticoagulant Agent</LONG_NAME>
            <CON_ID>2202376</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3761949</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C2578:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Negation Low Molecular Weight Heparin Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2578</PREFERRED_NAME>
            <LONG_NAME>Low Molecular Weight Heparin</LONG_NAME>
            <CON_ID>2431520</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the patient receiving anti</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the patient receiving anti-coagulants other than low-molecular weight heparin?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Period/Therapy 1</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>12 weeks - radiation therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Period/Therapy 2</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>6 weeks - nitrosourea chemotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Period/Therapy 3</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>3 weeks - non-nitrosourea chemotherapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Period/Therapy 4</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>4 weeks - any investigational (not FDA-approved) agents</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Period/Therapy 5</Name>
        <OrganizationName/>
        <DocumentType>COMMENT</DocumentType>
        <DocumentText>2 weeks - non-cytoxic, FDA-approved agent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ABTC-1602 Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient taking warfarin, factor Xa inhibitors, and direct thrombin inhibitors? (Low molecular weight heparin and prophylactic low dose warfarin are permitted)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 1202</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3761917</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1561">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3776046</PUBLICID>
    <LONGNAME>Charlson Comorbidity Index Chart Review Version Has Any Rheumatic or Connective Tissue Disease Indicator</LONGNAME>
    <PREFERREDNAME>CCI_ RHEUMATIC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator to signify whether or not an individual have rheumatologic disease including systemic lupus erythematous, polymyositis, mixed connective tissue disease, rheumatoid arthritis, polymyalgia rheumatica, vasculitis, sarcoidosis, Sjogrens syndrome or any other systemicvasculitis, determined by reviewing information from the medical record.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCI:Charlson Comorbidity Index, Charlson, ME, 1987</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3775878</PublicId>
      <PreferredName>3775629v1.0:3775876v1.0</PreferredName>
      <PreferredDefinition>A method of predicting mortality by weighting comorbid conditions calculated by reviewing an individual&#39;s chart._A question about whether an individual has or had any rheumatic or connective tissue disease.</PreferredDefinition>
      <LongName>Charlson Comorbidity Index Chart Review Version Has Any Rheumatic or Connective Tissue Disease</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435021</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20047</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic or Prognostic Factor</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3775629</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106374</PreferredName>
        <Version>1</Version>
        <LongName>Charlson Comorbidity Index Chart Review Version</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106374</PREFERRED_NAME>
            <LONG_NAME>Charlson Comorbidity Index Derived from Chart Review</LONG_NAME>
            <CON_ID>3774596</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3775876</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106390</PreferredName>
        <Version>1</Version>
        <LongName>Has any Rheumatic or Connective Tissue Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106390</PREFERRED_NAME>
            <LONG_NAME>Has any Rheumatic or Connective Tissue Disease Question</LONG_NAME>
            <CON_ID>3774617</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CCI:Charlson Comorbidity Index, Charlson, ME, 1987</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have any rhe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have any rheumatic or connective tissue disease? (RHEUMATIC)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCI Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Connective Tissue Disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Alliance Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Connective tissue disease</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3775608</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCI</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3775609</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3835419</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Pharmacovigilance</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Baseline</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3835421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-1221</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4104935</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Charlson Comorbidity Index (CCI)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14888184</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCI_ RHEUMATIC_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1562">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3778530</PUBLICID>
    <LONGNAME>Prior RT Systemic Radiopharmaceutical Compound Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>Prio_Radi_Syst_Radi_Admi_YES_N</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator related to prior systemic radiation therapy administered using a radiopharmaceutical compound.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3785728</PublicId>
      <PreferredName>Prio_Radi_Syst_Radi_Admi</PreferredName>
      <PreferredDefinition>information related to prior systemic RT administered using a radiopharmaceutical compound (agents that contain a radioactive isotope and are used for diagnostic or therapeutic purposes that affect the entire body).</PreferredDefinition>
      <LongName>Prior RT Systemic Radiopharmaceutical Compound Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206566</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Prior Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3785726</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13310:C1446:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Systemic Radiopharmaceutical Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13310</PREFERRED_NAME>
            <LONG_NAME>Systemic</LONG_NAME>
            <CON_ID>2204930</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1446</PREFERRED_NAME>
            <LONG_NAME>Radiopharmaceutical Compound</LONG_NAME>
            <CON_ID>2684134</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>At least 8 weeks of prior &quot;sy</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>At least 8 weeks of prior &quot;systemic&quot; radiopharmaceuticals (strontium, samarium).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>At least 8 weeks from prior &quot;systemic&quot; radiopharmaceuticals (strontium, samarium, radium 223 dichloride ).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG_CRF_TEXT_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior Radiopharmaceutical Therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Prio_Radi_Syst_Radi_Admi_YES_N</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1563">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3781476</PUBLICID>
    <LONGNAME>Adverse Event Reporting Rules Validation Value</LONGNAME>
    <PREFERREDNAME>3781471v1.0:3781472v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indication of whether an adverse event will be passed to caAERS (cancer Adverse Event Expedited Reporting System) for rules validation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3781471</PublicId>
      <PreferredName>3781468v1.0:3781469v1.0</PreferredName>
      <PreferredDefinition>Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._The act of providing a short account._A prescribed guide for conduct or action._Validation; the act of validating; finding or testing the truth of something.</PreferredDefinition>
      <LongName>Adverse Event Reporting Rule Validation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3781468</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331:C25651</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Reporting</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25651</PREFERRED_NAME>
            <LONG_NAME>Reporting</LONG_NAME>
            <CON_ID>2206359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3781469</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C78269:C16237</PreferredName>
        <Version>1</Version>
        <LongName>Rule Validation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C78269</PREFERRED_NAME>
            <LONG_NAME>Rule</LONG_NAME>
            <CON_ID>2867555</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16237</PREFERRED_NAME>
            <LONG_NAME>Validation</LONG_NAME>
            <CON_ID>2203726</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3781472</PublicId>
      <PreferredName>3781472v1.0</PreferredName>
      <PreferredDefinition>A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Rules Validation Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rules Validation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Rules Validation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1564">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3781763</PUBLICID>
    <LONGNAME>Investigator Withdrawal by Subject Knowledge Confirmation Yes No Indicator</LONGNAME>
    <PREFERREDNAME>3781762v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Term to signify confirmation of the Investigator&#39;s understanding of the study participant&#39;s decision to withdraw informed consent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCISTD: NCI CRF Harmonization and Standards Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3781762</PublicId>
      <PreferredName>2528490v1.0:3781760v1.0</PreferredName>
      <PreferredDefinition>An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements._An indication that a study participant has removed itself from the study._The body of truths or facts accumulated in the course of time, the cumulated sum of information, its volume and nature, in any civilization, period, or country._Having been established or verified.</PreferredDefinition>
      <LongName>Investigator Withdrawal by Subject Knowledge Confirmation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2528490</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25936</PreferredName>
        <Version>1</Version>
        <LongName>Investigator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25936</PREFERRED_NAME>
            <LONG_NAME>Investigator</LONG_NAME>
            <CON_ID>2202869</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3781760</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49634:C0376554:C25458</PreferredName>
        <Version>1</Version>
        <LongName>Withdrawal by Subject Knowledge Confirmed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49634</PREFERRED_NAME>
            <LONG_NAME>Withdrawal by Subject</LONG_NAME>
            <CON_ID>2470175</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0376554</PREFERRED_NAME>
            <LONG_NAME>Knowledge</LONG_NAME>
            <CON_ID>2229561</CON_ID>
            <DEFINITION_SOURCE>MSH2004_2003_12_12</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Investigator Attestation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Investigator Attestation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Investigator confirms that the patient has withdrawn their consent to participate on this trial, as per the criteria listed in this form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CCTG_02</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>I confirm the patient has withdrawn their consent to participate on trial, as per the criteria listed in this form:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consent Withdrawal CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Template Type</ClassificationSchemeItemType>
        <CsiPublicId>3914852</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consent Withdrawal</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635303</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>INV_WD_SUB_KNW_CON_IND</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3781762v1.0:3506068v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3781762v1.0:3506068v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SUPPDS_QVAL_WITHDRAW</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1565">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3794634</PUBLICID>
    <LONGNAME>Image Interpretation Date</LONGNAME>
    <PREFERREDNAME>IMG_INTRPN_DT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date on which the results of human logic is applied to an acquired image are recorded.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACRIN:American College of Radiology Imaging Network</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3794633</PublicId>
      <PreferredName>2423453v1.0:2670035v1.0</PreferredName>
      <PreferredDefinition>Any record of an imaging event whether physical or electronic._An act or process of elucidation; explication, or explanation of the meaning of the event or thing via the assignment of objects from the domain to the constants of a formal language, truth-values to the proposition symbols, truth-functions to the connectives, other functions to the function symbols, and extensions to the predicates, if any. The assignments are result of human logic application and are not native to the symbols of the formal language.</PreferredDefinition>
      <LongName>Image Interpretation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2423453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48179</PreferredName>
        <Version>1</Version>
        <LongName>Image</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48179</PREFERRED_NAME>
            <LONG_NAME>Image</LONG_NAME>
            <CON_ID>2422618</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2670035</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41255</PreferredName>
        <Version>1</Version>
        <LongName>Interpretation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41255</PREFERRED_NAME>
            <LONG_NAME>Interpretation</LONG_NAME>
            <CON_ID>2230185</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date of interpretation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date of interpretation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Interpretation Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PET-CT Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of PET/CT reading</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Image Administration CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3079059</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Image Administration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635317</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3794633v1.0:2018550v1.0</AlternateName>
        <AlternateNameType>System-Generated</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1566">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3808619</PUBLICID>
    <LONGNAME>NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool Past Week Distress over Practical Problem with Transportation Indicator</LONGNAME>
    <PREFERREDNAME>NCCN_DSTMG_TRANS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how distressed they have been during the past week over practical problems with transportation, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCN 1.2011 Distress Management Guidelines, 10/12/2010</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3799963</PublicId>
      <PreferredName>3799951v1.0:3799961v1.0</PreferredName>
      <PreferredDefinition>A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient problems in five categories._The most recent week, including today._A question about an individual&#39;s distress related to their practical problems with transportation.</PreferredDefinition>
      <LongName>NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool Past Week Distress over Practical Problem with Transportation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3799951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107157</PreferredName>
        <Version>1</Version>
        <LongName>NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107157</PREFERRED_NAME>
            <LONG_NAME>NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011</LONG_NAME>
            <CON_ID>3794690</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3799961</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C107172</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Distress over Practical Problem with Transportation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107172</PREFERRED_NAME>
            <LONG_NAME>Distress over Practical Problem with Transportation Question</LONG_NAME>
            <CON_ID>3794695</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCN 1.2011 Distress Management Guidelines, 10/12/2010</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Transportation</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Transportation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3793272</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCN Guidelines</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Distress Management v1.2011</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3793273</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1567">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3808791</PUBLICID>
    <LONGNAME>Surgical Procedure Other Prior Benign Ipsilateral Breast Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>OTHPRIBRSTSURG</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to a prior surgical procedure involving a benign malignant neoplasm in the ipsilateral breast, different than the one(s) previously specified or mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3808783</PublicId>
      <PreferredName>OTHPRIBRSTSURG</PreferredName>
      <PreferredDefinition>Information related to a prior surgical procedure involving a benign malignant neoplasm in the ipsilateral breast, different than the one(s) previously specified or mentioned.</PreferredDefinition>
      <LongName>Surgical Procedure Other Prior Benign Ipsilateral Breast Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3808781</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3808781v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Other Prior Benign Ipsilateral Breast Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14172</PREFERRED_NAME>
            <LONG_NAME>Benign</LONG_NAME>
            <CON_ID>2204745</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25308</PREFERRED_NAME>
            <LONG_NAME>Ipsilateral</LONG_NAME>
            <CON_ID>2206283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other prior benign ipsilatera</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other prior benign ipsilateral breast surgery</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OTHPRIBRSTSURG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1568">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3809551</PUBLICID>
    <LONGNAME>Person Age Known Unknown Indicator</LONGNAME>
    <PREFERREDNAME>2634443v1.0:2935542v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes if the person&#39;s age was known or unknown.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2634443</PublicId>
      <PreferredName>2236731v1.0:2239916v1.0</PreferredName>
      <PreferredDefinition>The length of time a person has been living since birth.</PreferredDefinition>
      <LongName>Person Age</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2239916</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25150</PreferredName>
        <Version>1</Version>
        <LongName>Age</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NHLBI FBPP:Family Blood Pressure Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2935542</PublicId>
      <PreferredName>2935542v1.0</PreferredName>
      <PreferredDefinition>Recognized, familiar, or within the scope of knowledge._Not known, not observed, not recorded, or refused._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Known Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2935541</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C80137:C17998:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Known Unknown Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C80137</PREFERRED_NAME>
            <LONG_NAME>Known</LONG_NAME>
            <CON_ID>2858228</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-25</PVBEGINDATE>
          <PVENDDATE>2013-09-04</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the person&#39;s age known or</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the person&#39;s age known or unknown?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Age</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Age</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Age</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Age</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Donor age</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Donor age</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>hla_donor_cbu_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>idm_donor_cbu_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_donor_multi_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_donor_cbu_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CTPI_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTP_CTPI_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedMedicalConditionResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_DIM_age_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1569">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3809569</PUBLICID>
    <LONGNAME>Palpable Tumor Present Measurements Performed Indicator</LONGNAME>
    <PREFERREDNAME>LESPALPPE</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator related to a palpable tumor being present and measurements being performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2011459</PublicId>
      <PreferredName>TUMOR_PALP_PRES</PreferredName>
      <PreferredDefinition>information related to palpable tumor being present.</PreferredDefinition>
      <LongName>Palpable Tumor Present</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2225630</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>C25606:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Palpable Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25606</PREFERRED_NAME>
            <LONG_NAME>Palpable</LONG_NAME>
            <CON_ID>2206335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177376</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Present</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3809519</PublicId>
      <PreferredName>MXIND</PreferredName>
      <PreferredDefinition>The indicator related to measurements being performed.</PreferredDefinition>
      <LongName>Measurements Performed Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exam not done</VALIDVALUE>
          <VALUEMEANING>Exam not done</VALUEMEANING>
          <MEANINGDESCRIPTION>An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s): Indicates a task, process or examination that has either not been initiated or completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484, C25305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, size not noted</VALIDVALUE>
          <VALUEMEANING>Yes Size Negation Documented</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: Size; the physical magnitude of something.: An operation in which a term denies or inverts the meaning of another term or construction.: Documented; furnished with or supported by documents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25356, C25594, C25681, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, size noted</VALIDVALUE>
          <VALUEMEANING>Yes Size Documented</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: Size; the physical magnitude of something.: Documented; furnished with or supported by documents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25356, C25681, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging not done</VALIDVALUE>
          <VALUEMEANING>Imaging Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484, C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3810903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was lesion palpable by physic</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was lesion palpable by physical exam?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LESPALPPE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1570">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3809570</PUBLICID>
    <LONGNAME>Breast Neoplasm Mammogram Detected Measurements Performed Indicator</LONGNAME>
    <PREFERREDNAME>LESVISMAMMO</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator related to measurements being performed and lesions being perceived, discerned, discovered or identified in the breast detected by a low voltage X-ray photograph.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2432574</PublicId>
      <PreferredName>BRST_TUMOR_MAMM_DET</PreferredName>
      <PreferredDefinition>information related to perceived, discerned, discovered or identified abnormal and uncontrolled cell growth in the breast detected by a low voltage X-ray photograph.</PreferredDefinition>
      <LongName>Breast Neoplasm Mammogram Detected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2432571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12971:C3262:C20178</PreferredName>
        <Version>1</Version>
        <LongName>Breast Neoplasm Mammogram</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12971</PREFERRED_NAME>
            <LONG_NAME>Breast</LONG_NAME>
            <CON_ID>2202571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20178</PREFERRED_NAME>
            <LONG_NAME>Mammogram</LONG_NAME>
            <CON_ID>2202867</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2432572</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25481</PreferredName>
        <Version>1</Version>
        <LongName>Detected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25481</PREFERRED_NAME>
            <LONG_NAME>Detected</LONG_NAME>
            <CON_ID>2203891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3809519</PublicId>
      <PreferredName>MXIND</PreferredName>
      <PreferredDefinition>The indicator related to measurements being performed.</PreferredDefinition>
      <LongName>Measurements Performed Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exam not done</VALIDVALUE>
          <VALUEMEANING>Exam not done</VALUEMEANING>
          <MEANINGDESCRIPTION>An appraisal or evaluation of a patient&#39;s condition by a physician or registered nurse, based on clinical and laboratory data, medical history, and the patient&#39;s account of symptoms.  2. The process by which a patient&#39;s condition is appraised or evaluated. (Taber&#39;s): Indicates a task, process or examination that has either not been initiated or completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484, C25305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809520</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, size not noted</VALIDVALUE>
          <VALUEMEANING>Yes Size Negation Documented</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: Size; the physical magnitude of something.: An operation in which a term denies or inverts the meaning of another term or construction.: Documented; furnished with or supported by documents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25356, C25594, C25681, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809521</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, size noted</VALIDVALUE>
          <VALUEMEANING>Yes Size Documented</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.: Size; the physical magnitude of something.: Documented; furnished with or supported by documents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25356, C25681, C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3809522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging not done</VALIDVALUE>
          <VALUEMEANING>Imaging Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484, C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-07-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3810903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was lesion visible on mammogr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was lesion visible on mammogram?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LESVISMAMMO</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1571">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3810874</PUBLICID>
    <LONGNAME>Therapy HER2/neu Other Administered Specify</LONGNAME>
    <PREFERREDNAME>ANTIHER2TXOTHSP</PREFERREDNAME>
    <PREFERREDDEFINITION>The free text field to specify information related to the administration of an anti-HER2 therapy different than the one(s) previously specified or mentioned.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3810872</PublicId>
      <PreferredName>ANTIHER2TXOTH</PreferredName>
      <PreferredDefinition>Information related to the administration of an anti-HER2 therapy different than the one(s) previously specified or mentioned.</PreferredDefinition>
      <LongName>Therapy HER2/neu Other Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3810870</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17756:C17649:C25382</PreferredName>
        <Version>1</Version>
        <LongName>HER2/neu Other Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17756</PREFERRED_NAME>
            <LONG_NAME>ERBB2 Gene</LONG_NAME>
            <CON_ID>2202658</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179878</PublicId>
      <PreferredName>TX_ADM_SPEC</PreferredName>
      <PreferredDefinition>the free-text field to specify the therapy administered.</PreferredDefinition>
      <LongName>Therapy Administered Specify</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208052</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Administered Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ANTIHER2TXOTHSP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1572">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3829053</PUBLICID>
    <LONGNAME>Patient Reported Lost To Follow-up Ind</LONGNAME>
    <PREFERREDNAME>PT_REP_LTFU_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A response to indicate if the patient was reported lost to follow-up.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCISTD: NCI CRF Harmonization and Standards Initiative</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3829052</PublicId>
      <PreferredName>2233604v1.0:3829050v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A short textual account; having provided a short account._The loss or lack of continuation of follow-up after a study has officially closed.  See Follow-up.</PreferredDefinition>
      <LongName>Patient Reported Lost To Follow-up</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3829050</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25375:C48227</PreferredName>
        <Version>1</Version>
        <LongName>Report Lost To Follow-up</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25375</PREFERRED_NAME>
            <LONG_NAME>Report</LONG_NAME>
            <CON_ID>2202481</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48227</PREFERRED_NAME>
            <LONG_NAME>Lost To Follow-Up</LONG_NAME>
            <CON_ID>2470168</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you reporting the partici</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you reporting the participant lost to follow-up?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lost To Follow-Up</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the study participant unable to be contacted for follow-up per defined criteria?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lost to Follow-up CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3828993</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635298</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>All Mandatory CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Mandatory CRF CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635299</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lost to Follow-up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635319</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1573">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3852733</PUBLICID>
    <LONGNAME>Preparative Regimen Planned Occurrence Administered Classification Type</LONGNAME>
    <PREFERREDNAME>3919295v1.0:2875716v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the planned preparative regimen administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3919295</PublicId>
      <PreferredName>2685191v1.0:3919293v1.0</PreferredName>
      <PreferredDefinition>The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._An instance of an event or incident that is intended to take place._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Preparative Regimen Planned Occurrence Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2685191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61155</PreferredName>
        <Version>1</Version>
        <LongName>Preparative Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61155</PREFERRED_NAME>
            <LONG_NAME>Preparative Regimen</LONG_NAME>
            <CON_ID>2486806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3919293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102557:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Planned Occurrence Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102557</PREFERRED_NAME>
            <LONG_NAME>Planned Occurrence</LONG_NAME>
            <CON_ID>3915747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2875716</PublicId>
      <PreferredName>PR_RG_CL_TYP</PreferredName>
      <PreferredDefinition>The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Preparative Regimen Classification Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2875715</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61155:C25161:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Preparative Regimen Classification Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61155</PREFERRED_NAME>
            <LONG_NAME>Preparative Regimen</LONG_NAME>
            <CON_ID>2486806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-myeloablative</VALIDVALUE>
          <VALUEMEANING>Nonmyeloablative therapy (NMA)</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16231, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2875718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myeloablative</VALIDVALUE>
          <VALUEMEANING>Myeloablative Chemotherapy</VALUEMEANING>
          <MEANINGDESCRIPTION>The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2875719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Reduced intensity</VALIDVALUE>
          <VALUEMEANING>Reduced Intensity</VALUEMEANING>
          <MEANINGDESCRIPTION>Reduced; made less in size or amount or degree.: The degree or magnitude of strength, energy, or feeling.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25539, C25640</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2875717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the planned preparati</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the planned preparative regimen administered type?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Classify the recipient&#39;s prescribed preparative regimen</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Classify the recipient&#39;s prescribed preparative regimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Classify the recipient&#39;s prescribed preparative regimen</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Classify the recipient&#39;s prescribed preparative regimen</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_pre_hct_prep_prescribe_class_type</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1574">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3863388</PUBLICID>
    <LONGNAME>Nucleated Red Blood Cell Laboratory Procedure Assessment Performed Status</LONGNAME>
    <PREFERREDNAME>2760273v1.0:2528343v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The outcome of the laboratory procedure related to the assessment of nucleated red blood cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2760273</PublicId>
      <PreferredName>NUCL_RBC_LAB_PRO</PreferredName>
      <PreferredDefinition>Red blood cells that are at the last stage of development, still containing a nucleus, that are found in the bone marrow and occasionally in the peripheral blood._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.</PreferredDefinition>
      <LongName>Nucleated Red Blood Cell Laboratory Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2760271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C73125</PreferredName>
        <Version>1</Version>
        <LongName>Nucleated Red Blood Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C73125</PREFERRED_NAME>
            <LONG_NAME>Nucleated Red Blood Cell</LONG_NAME>
            <CON_ID>2735706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2486250</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2528343</PublicId>
      <PreferredName>ASSESS_PERFM_STAT</PreferredName>
      <PreferredDefinition>The condition or state of an evaluation being performed at a particular time.</PreferredDefinition>
      <LongName>Assessment Performed Status</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3863379</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217:C38000:C25688</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Performed Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Done</VALIDVALUE>
          <VALUEMEANING>Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has been performed and completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111784</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3954417</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the nucleated red bl</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the nucleated red blood cells assessment status?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Nucleated red blood cells</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Nucleated red blood cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Nucleated red blood cells</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Nucleated red blood cells</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_nucleated_red_cell_dnd</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1575">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3863425</PUBLICID>
    <LONGNAME>CD3 Complex CD4 Antigen Laboratory Procedure Performed Exponent Value</LONGNAME>
    <PREFERREDNAME>3863422v1.0:2644807v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric exponent laboratory value of CD3+ CD4+ cells in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3863422</PublicId>
      <PreferredName>3955951v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Consisting of cell surface type I membrane Delta, Epsilon, Gamma, Zeta, and Eta protein subunits with ITAM domains and noncovalently associated with the disulfide bound heterodimeric alpha/beta and gamma/delta TCR, the CD3 complex couples receptor antigen recognition to signal transduction pathways during T-cell activation. During TCR engagement with MHC-associated antigen on host cell surfaces and synapse formation, CD3 activity leads to Tyr-phosphorylated CD3 subunits, Tyr phosphorylation of LAT colocalized in lipid rafts, and MAPK activation. CD3 signal transduction appears to involve LCK, ZAP70, Nck, SLA, SLA2, and DOCK2. CD3 subunits may also associate with the cytoskeleton. CD3 also mediates TCR signal transduction during the developmental transition through positive selection of immature thymocytes to mature CD4+ or CD8+ T cells. (NCI)_CD4 Antigen, encoded by the CD4 gene, is a T-cell surface glycoprotein. CD4 has a role in cell-cell interactions and may act in signal transduction. CD4 is a accessory protein for MHC class-II antigen/T-cell receptor interaction and functions to initiate or augment the early phase of T-cell activation. CD4 enhances T-cell sensitivity to antigen and binds to LCK, which phosphorylates CD3-zeta. CD4 Antigen also serves as an HIV receptor, binding directly to the envelope protein gp120 on HIV. (From LocusLink, OMIM and NCI)_Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>CD3 Complex CD4 Antigen Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3955951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38897:C16300:C25294</PreferredName>
        <Version>1</Version>
        <LongName>CD3 Complex CD4 Antigen Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38897</PREFERRED_NAME>
            <LONG_NAME>CD3 Complex</LONG_NAME>
            <CON_ID>2593496</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16300</PREFERRED_NAME>
            <LONG_NAME>T-Cell Surface Glycoprotein CD4</LONG_NAME>
            <CON_ID>2593503</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2644807</PublicId>
      <PreferredName>EXP_VAL</PreferredName>
      <PreferredDefinition>The number of times a quantity is multiplied by itself._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Exponent Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2644806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48923:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Coefficient Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48923</PREFERRED_NAME>
            <LONG_NAME>Exponent</LONG_NAME>
            <CON_ID>2423437</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD3+CD4+ cells exponent value:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CD3+CD4+ cells exponent value:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>x 10</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>x 10</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>x 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>x 10</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_cd3_cd4_cell_exponent_value</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1576">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3865377</PUBLICID>
    <LONGNAME>Total Erythroid Stem Cell Laboratory Procedure Exponent Value</LONGNAME>
    <PREFERREDNAME>3865374v1.0:2644807v2.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric exponent laboratory value of total erythroid stem cells (BFU-E) in a specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3865374</PublicId>
      <PreferredName>3865372v1.0:2486250v1.0</PreferredName>
      <PreferredDefinition>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Committed, erythroid stem cells derived from myeloid stem cells. The progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E). BFU-E differentiate into CFU-E on stimulation by erythropoietin, and then further differentiate into erythroblasts when stimulated by other factors. (MeSH)._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.</PreferredDefinition>
      <LongName>Total Erythroid Stem Cell Laboratory Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3865372</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C12526</PreferredName>
        <Version>1</Version>
        <LongName>Total Erythroid Stem Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12526</PREFERRED_NAME>
            <LONG_NAME>Erythroid Stem Cell</LONG_NAME>
            <CON_ID>2669297</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2486250</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2644807</PublicId>
      <PreferredName>EXP_VAL</PreferredName>
      <PreferredDefinition>The number of times a quantity is multiplied by itself._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Exponent Value</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2644806</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48923:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Coefficient Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48923</PREFERRED_NAME>
            <LONG_NAME>Exponent</LONG_NAME>
            <CON_ID>2423437</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total erythroid stem cell exp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total erythroid stem cell exponent value:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>x 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>x 10</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>x 10</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>x 10</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_prod_analysis_bfu_e_exponent_value</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1577">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3865385</PUBLICID>
    <LONGNAME>6-Item Orientation-Memory-Concentration Test What Year Is It Number</LONGNAME>
    <PREFERREDNAME>3865237v1.0:2896906v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s response to a request to state the current year.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>OMC:6-Item Orientation-Memory-Concentration Test, Katzman, R., 1983</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3865237</PublicId>
      <PreferredName>3865234v1.0:3865235v1.0</PreferredName>
      <PreferredDefinition>A screening test for cognitive impairment that is administered by a non-physician. This test is designed to discriminate between mild, moderate, and severe cognitive deficits._A question asking an individual to state the current year.</PreferredDefinition>
      <LongName>6-Item Orientation-Memory-Concentration Test What Year Is It</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3865234</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110928</PreferredName>
        <Version>1</Version>
        <LongName>6-Item Orientation-Memory-Concentration Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110928</PREFERRED_NAME>
            <LONG_NAME>6-Item Orientation-Memory-Concentration Test</LONG_NAME>
            <CON_ID>3863091</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3865235</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110929</PreferredName>
        <Version>1</Version>
        <LongName>What Year is it</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110929</PREFERRED_NAME>
            <LONG_NAME>What Year is It Question</LONG_NAME>
            <CON_ID>3863092</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>OMC:6-Item Orientation-Memory-Concentration Test, Katzman, R., 1983</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2896906</PublicId>
      <PreferredName>EVT_YR_NUM</PreferredName>
      <PreferredDefinition>Event; something that happens at a given place and time._The period of time that it takes for Earth to make a complete revolution around the sun; a period of time containing 365 days._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Event Year Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>YYYY </DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2896905</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25499:C29848:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Event Year Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What year is it now?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What year is it now?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>6-Item Orientation-Memory-Concentration Test (OMCT)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 1 of 9</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863411</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>OMC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>OMC</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3863412</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Orientation-Memory-Concentration Test [6-Item] (OMCT)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900334</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <AlternateName>CTEP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>3865237v1.0:2896906v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1578">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3872817</PUBLICID>
    <LONGNAME>Liver PET Test Result Code</LONGNAME>
    <PREFERREDNAME>LV_PET_RES_CD</PREFERREDNAME>
    <PREFERREDDEFINITION>Code to represent the outcome of a liver Positron Emission Tomography (PET) scan.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3856206</PublicId>
      <PreferredName>3856204v1.0:2207606v1.0</PreferredName>
      <PreferredDefinition>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The result of an action.</PreferredDefinition>
      <LongName>Liver Positron Emission Tomography Test Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3856204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C17007</PreferredName>
        <Version>1</Version>
        <LongName>Liver Positron Emission Tomography</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17007</PREFERRED_NAME>
            <LONG_NAME>Positron Emission Tomography</LONG_NAME>
            <CON_ID>2224887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207606</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Test Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3856200</PublicId>
      <PreferredName>POS_NEG_ND_CD</PreferredName>
      <PreferredDefinition>Involving advantage or good._Negative; not indicating the presence of microorganisms or disease or a specific condition._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Positive Negative Not Done Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2721414</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25246:C38757:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Positive Negative Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25246</PREFERRED_NAME>
            <LONG_NAME>Positive</LONG_NAME>
            <CON_ID>2202905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38757</PREFERRED_NAME>
            <LONG_NAME>Negative Finding</LONG_NAME>
            <CON_ID>2203934</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>Negative Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2617835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>P</VALIDVALUE>
          <VALUEMEANING>Positive Finding</VALUEMEANING>
          <MEANINGDESCRIPTION>An observation confirming something, such as the presence of a disease, condition, or microorganism.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38758</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2840097</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Liver PET results</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Liver PET results</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1579">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3902282</PUBLICID>
    <LONGNAME>Total Body Surface Plaque Involvement Sum Percentage</LONGNAME>
    <PREFERREDNAME>TLBDY_PLQ_SUBTTL_PCT</PREFERREDNAME>
    <PREFERREDDEFINITION>Percentage value to describe the percent of an individual&#39;s total body affected by plaque as a sum of individual body sites (head, trunk, arms, legs).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3902205</PublicId>
      <PreferredName>3902202v1.0:3902203v1.0</PreferredName>
      <PreferredDefinition>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete._The surface of an external body region._Abnormal tissue that results from the progressive accumulation or deposit of certain substances in a body cavity, surface, or lumen._To have a connection by participation or association or use; sharing in an activity or process._Sum; the final aggregate amount.</PreferredDefinition>
      <LongName>Total Body Surface Plaque Involvement Sum</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3902202</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C29667:C95603</PreferredName>
        <Version>1</Version>
        <LongName>Total Body Surface Plaque</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29667</PREFERRED_NAME>
            <LONG_NAME>Body Surface</LONG_NAME>
            <CON_ID>2598059</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95603</PREFERRED_NAME>
            <LONG_NAME>Plaque</LONG_NAME>
            <CON_ID>3902150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3902203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25548:C25697</PreferredName>
        <Version>1</Version>
        <LongName>Involvement Sum</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25697</PREFERRED_NAME>
            <LONG_NAME>Sum</LONG_NAME>
            <CON_ID>2203808</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3902220</PublicId>
      <PreferredName>PLAQ_INVLT_PTG</PreferredName>
      <PreferredDefinition>A measure of skin involvement (BSA) with skin plaque(s).</PreferredDefinition>
      <LongName>Plaque Involvement Percentage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>100.00</MaximumValue>
      <MinimumValue>0.00</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2239955</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613</PreferredName>
        <Version>1</Version>
        <LongName>Percentage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total % affected area</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total % affected area</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1580">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3909275</PUBLICID>
    <LONGNAME>Arsenic Administered Indicator</LONGNAME>
    <PREFERREDNAME>3909274v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not arsenic was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3909274</PublicId>
      <PreferredName>3909272v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A poisonous chemical used to kill weeds and pests. Also used in cancer therapy._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Arsenic Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3909272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28131</PreferredName>
        <Version>1</Version>
        <LongName>Arsenic</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28131</PREFERRED_NAME>
            <LONG_NAME>Arsenic</LONG_NAME>
            <CON_ID>3909271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was arsenic administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was arsenic administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Arsenic</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Arsenic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Arsenic</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Arsenic</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpost_rel_arsenic_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpost_therapy_arsenic_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>AMLpre_therapy_multi_arsenic_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1581">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3910309</PUBLICID>
    <LONGNAME>Laboratory Procedure CD38+ cell Performed Lab Percentage Value</LONGNAME>
    <PREFERREDNAME>CD38PERCENT</PREFERREDNAME>
    <PREFERREDDEFINITION>The value as a percentage of 100 for information related to a laboratory procedure on CD38+ expression.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3910304</PublicId>
      <PreferredName>CD38</PreferredName>
      <PreferredDefinition>Information related to a laboratory procedure on CD38+ expression.</PreferredDefinition>
      <LongName>Laboratory Procedure CD38+ cell Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3910302</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C0945928:C38000</PreferredName>
        <Version>1</Version>
        <LongName>CD38+ cell Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0945928</PREFERRED_NAME>
            <LONG_NAME>CD38+ cell</LONG_NAME>
            <CON_ID>2543453</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCTG CRF:North Central Cancer Treatment Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180234</PublicId>
      <PreferredName>LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the value as a percentage of 100.</PreferredDefinition>
      <LongName>Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD38+ expression</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CD38+ expression</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CD38PERCENT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1582">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3911832</PUBLICID>
    <LONGNAME>Palpable Liver Present Category</LONGNAME>
    <PREFERREDNAME>PALP_LV_PRES_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Code to signify whether an enlarged liver is palpable during a patient&#39;s examination.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3856196</PublicId>
      <PreferredName>3856194v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>Capable of being handled or touched or felt._A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>Palpable Liver Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3856194</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25606:C12392</PreferredName>
        <Version>1</Version>
        <LongName>Palpable Liver</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25606</PREFERRED_NAME>
            <LONG_NAME>Palpable</LONG_NAME>
            <CON_ID>2206335</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3911831</PublicId>
      <PreferredName>PALP_CAT</PreferredName>
      <PreferredDefinition>Category; used informally to mean a class of things.</PreferredDefinition>
      <LongName>Palpability Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Palpable</VALIDVALUE>
          <VALUEMEANING>Not Palpable</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of being handled or touched or felt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25606, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3856198</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palpable</VALIDVALUE>
          <VALUEMEANING>Palpable</VALUEMEANING>
          <MEANINGDESCRIPTION>Capable of being handled or touched or felt.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25606</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3856199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or not been completed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3104692</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Palpable Liver</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Palpable Liver</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1583">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3912796</PUBLICID>
    <LONGNAME>Patient Prostate Gland Malignant Neoplasm Pathology T Stage Clinical Trial Eligibility Criteria Stage</LONGNAME>
    <PREFERREDNAME>Pt_Pros_MN_CTEC_St</PREFERREDNAME>
    <PREFERREDDEFINITION>A pathologic finding about one or more characteristics of prostate cancer for eligibility and stratification</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3912776</PublicId>
      <PreferredName>Pati_Pros_Mali_Path_T St_Clin</PreferredName>
      <PreferredDefinition>Information related to pathologic T stage for prostate tumor for eligibility criteria</PreferredDefinition>
      <LongName>Patient Prostate Gland Malignant Neoplasm Pathology T Stage Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3912774</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3912774v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Gland Malignant Neoplasm Pathology T Stage Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18189</PREFERRED_NAME>
            <LONG_NAME>Pathology</LONG_NAME>
            <CON_ID>2202779</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25728</PREFERRED_NAME>
            <LONG_NAME>T Category</LONG_NAME>
            <CON_ID>2202382</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3912792</PublicId>
      <PreferredName>Pt_Pros_Mal_Neo_Cl_Tr_El_Ct_St</PreferredName>
      <PreferredDefinition>A pathologic finding about one or more characteristics of prostate cancer for eligibility and stratification</PreferredDefinition>
      <LongName>Patient Protstate Malignant Neoplasm Clinical Trial Eligibility Criteria Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>RTOG CRF:Radiation Therapy Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>pT2 and margin negative</VALIDVALUE>
          <VALUEMEANING>pT2 Stage Finding And Margin Negative</VALUEMEANING>
          <MEANINGDESCRIPTION>A pathologic primary tumor TNM finding. The definition of pT2 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT2 finding is defined as follows: cancer with tumor size more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for colorectal cancer, pT2 finding is defined as follows: cancer with invasion into the muscularis propria. (from AJCC 6th and 7th Eds.)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A boundary line or the area immediately inside the boundary._Involving disadvantage or harm.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25247, C25563, C37912, C48764</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3912794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>All Others</VALIDVALUE>
          <VALUEMEANING>All Other</VALUEMEANING>
          <MEANINGDESCRIPTION>To a complete degree or to the full or entire extent.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C64916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3912795</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify Pathology Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify Pathology Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4057943</PublicId>
          <ContextName>NRG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Disease Site</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RTOG-0534</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4171063</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Pt_Pros_MN_CTEC_St</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1584">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3913874</PUBLICID>
    <LONGNAME>Radiation Therapy Radioembolization Performed Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PRIOR_LVR_RX_EMBOL</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator to whether radioembolization was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3913873</PublicId>
      <PreferredName>2403872v1.0:3913871v1.0</PreferredName>
      <PreferredDefinition>Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._A type of radiation therapy used to treat liver cancer that is advanced or has come back. Tiny beads that hold the radioisotope yttrium Y 90 are injected into the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the yttrium Y 90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the cancer cells. Radioembolization is a type of selective internal radiation therapy (SIRT)._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Radiation Therapy Radioembolization Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3913871</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93340:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Radioembolization Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93340</PREFERRED_NAME>
            <LONG_NAME>Radioembolization</LONG_NAME>
            <CON_ID>3225719</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Radioembolization?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Radioembolization?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1585">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3914815</PUBLICID>
    <LONGNAME>ACNS1221 Reporting Period Code</LONGNAME>
    <PREFERREDNAME>ACNS1221ReportingPeriod</PREFERREDNAME>
    <PREFERREDDEFINITION>the code for the ACNS1221 reporting evaluation period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190169</PublicId>
      <PreferredName>REP_EVAL_PD</PreferredName>
      <PreferredDefinition>information related to the reporting evaluation period.</PreferredDefinition>
      <LongName>Reporting Evaluation Period</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206724</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25651:C25214</PreferredName>
        <Version>1</Version>
        <LongName>Reporting Evaluation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25651</PREFERRED_NAME>
            <LONG_NAME>Reporting</LONG_NAME>
            <CON_ID>2206359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25214</PREFERRED_NAME>
            <LONG_NAME>Evaluation</LONG_NAME>
            <CON_ID>2202634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177446</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Period</PreferredName>
        <Version>1</Version>
        <LongName>Period</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25616</PREFERRED_NAME>
            <LONG_NAME>Period</LONG_NAME>
            <CON_ID>2202575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3914808</PublicId>
      <PreferredName>ACNS1221_RP_Code</PreferredName>
      <PreferredDefinition>A numbered categories represent ACNS1221 reporting period.</PreferredDefinition>
      <LongName>ACNS1221 Reporting Period Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008508</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>CTEP</PreferredName>
        <Version>5</Version>
        <LongName>CTEP</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2261841</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25162</PreferredName>
        <Version>1</Version>
        <LongName>Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Follow Up 10 (60 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 10 (60 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379605</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Follow Up 9 (48 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 9 (48 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379606</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>Follow Up 8 (36 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 8 (36 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379607</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Follow Up 4 (12 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 4 (12 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379611</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Follow Up 3 (9 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 3 (9 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379612</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Follow Up 2 (6 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 2 (6 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379613</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Follow Up 1 (3 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 1 (3 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379614</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Continuation Cycle 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Continuation Cycle 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Continuation Cycle 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Continuation Cycle 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914810</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Second-Look Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery performed after primary treatment to determine whether tumor cells remain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15317</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Induction Cycle 3</VALUEMEANING>
          <MEANINGDESCRIPTION>Induction Cycle 3</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914812</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Induction Cycle 2</VALUEMEANING>
          <MEANINGDESCRIPTION>Induction Cycle 2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914813</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Induction Cycle 1</VALUEMEANING>
          <MEANINGDESCRIPTION>Induction Cycle 1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3914814</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Follow Up 11 (72 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 11 (72 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3915920</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Follow Up 5 (16 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 5 (16 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379610</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Follow Up 6 (20 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 6 (20 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379609</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Follow Up 7 (24 months)</VALUEMEANING>
          <MEANINGDESCRIPTION>Follow Up 7 (24 months)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-10-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3379608</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ACNS1221 Reporting Period:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>ACNS1221 Reporting Period:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1586">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3923101</PUBLICID>
    <LONGNAME>Chronic Myelogenous Leukemia Prior Therapeutic Procedure Complete Remission Phase Category</LONGNAME>
    <PREFERREDNAME>3923096v1.0:2675138v1.1</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the disease status of chronic myelogenous leukemia prior to treatment that achieved a complete remission.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3923096</PublicId>
      <PreferredName>2500393v1.0:3923094v1.0</PreferredName>
      <PreferredDefinition>The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.</PreferredDefinition>
      <LongName>Chronic Myelogenous Leukemia Prior Therapeutic Procedure Complete Remission</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2500393</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3174</PreferredName>
        <Version>1</Version>
        <LongName>CML</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3174</PREFERRED_NAME>
            <LONG_NAME>Chronic Myeloid Leukemia, BCR-ABL1 Positive</LONG_NAME>
            <CON_ID>2202712</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3923094</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C49236:C4870</PreferredName>
        <Version>1</Version>
        <LongName>Prior Therapeutic Procedure Complete Remission</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4870</PREFERRED_NAME>
            <LONG_NAME>Complete Remission</LONG_NAME>
            <CON_ID>2202721</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2675138</PublicId>
      <PreferredName>2675138v1.1</PreferredName>
      <PreferredDefinition>The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle._This term is used informally to mean a class of things.</PreferredDefinition>
      <LongName>CML Phase Category</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2677055</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3174:C25257:C25372</PreferredName>
        <Version>1</Version>
        <LongName>CML Phase Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3174</PREFERRED_NAME>
            <LONG_NAME>Chronic Myeloid Leukemia, BCR-ABL1 Positive</LONG_NAME>
            <CON_ID>2202712</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25257</PREFERRED_NAME>
            <LONG_NAME>Phase</LONG_NAME>
            <CON_ID>2203949</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chronic phase</VALIDVALUE>
          <VALUEMEANING>Chronic Phase Chronic Myelogenous Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A phase of chronic myelogenous leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3175</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2675140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Blast phase</VALIDVALUE>
          <VALUEMEANING>Blast Phase Chronic Myelogenous Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>An advanced phase of chronic myelogenous leukemia.  It is characterized a. by the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or b. an extramedullary proliferation of blasts, and/or c. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C9110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2675142</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hematologic complete remission</VALIDVALUE>
          <VALUEMEANING>Hematologic CR</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to or related to the blood and blood-forming
organs.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C4870, C62780</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2675145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Accelerated Phase</VALIDVALUE>
          <VALUEMEANING>Accelerated Phase Chronic Myelogenous Leukemia</VALUEMEANING>
          <MEANINGDESCRIPTION>A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3304774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the disease status p</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the disease status prior to treatment for this complete remission?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CML disease status before treatment that achieved this CR</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>CML disease status before treatment that achieved this CR</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CML disease status before treatment that achieved this CR</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CML disease status before treatment that achieved this CR</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BRIDG Mapping for CDE:3923101</Name>
        <OrganizationName/>
        <DocumentType>BRIDG Mapping Path</DocumentType>
        <DocumentText>&quot;PerformedDiagnosis.diseaseStatusCode [pre] WHERE PerformedDiagnosis.value [pre] = &quot;&quot;Chronic Myelogenous Leukemia(CML)&quot;&quot; AND PerformedDiagnosis [pre] &gt; PerformedObservation.methodCode = &quot;&quot;hematologic&quot;&quot; AND PerformedDiagnosis [pre] &gt; PerformedSubstanceAdministration &gt; DefinedSubstranceAdministration.nameCode = &quot;&quot;Administer Hematopoietic Cell Product{ Transplantation}&quot;&quot; AND PerformedDiagnosis [pre] &gt; Subject &gt;  PerformedDiagnosis.diseaseStatusCode [post] = &quot;&quot;complete remission&quot;&quot; AND PerformedDiagnosis [post] &gt; PerformedObservation.dateRange IS GREATER THAN PerformedSubstanceAdministration.dateRange&quot;</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2695319</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NMDP: CDEs to review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>2400r1: Pre-TED</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>2964924</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3553940</PublicId>
          <ContextName>NHLBI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Version 3.2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4133055</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Training Set</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PerformedDiagnosis:diseaseStatusCode</AlternateName>
        <AlternateNameType>HCT_BRIDG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PreTed_prime_dis_hct_prior_treat_cml_dis_stat</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1587">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3923831</PUBLICID>
    <LONGNAME>Right Palmar Region Plaque Desquamation Pustular Scale</LONGNAME>
    <PREFERREDNAME>RPLM_PLQ_DSQ_PUS_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the desquamation/scaling associated with plaque occurring in the right palm.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CCR:Center for Cancer Research</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3923452</PublicId>
      <PreferredName>3923432v1.0:3914831v1.0</PreferredName>
      <PreferredDefinition>Being or located on or directed toward the side of the body to the east when facing north._The undersurface of the hand._Abnormal tissue that results from the progressive accumulation or deposit of certain substances in a body cavity, surface, or lumen._Shedding of the outer layer of skin or mucosal tissue.</PreferredDefinition>
      <LongName>Right Palmar Region Plaque Desquamation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3923432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25228:C33252:C95603</PreferredName>
        <Version>1</Version>
        <LongName>Right Palmar Region Plaque</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C33252</PREFERRED_NAME>
            <LONG_NAME>Palmar Region</LONG_NAME>
            <CON_ID>3923431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95603</PREFERRED_NAME>
            <LONG_NAME>Plaque</LONG_NAME>
            <CON_ID>3902150</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3914831</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111657</PreferredName>
        <Version>1</Version>
        <LongName>Desquamation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111657</PREFERRED_NAME>
            <LONG_NAME>Desquamation</LONG_NAME>
            <CON_ID>3909505</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3906432</PublicId>
      <PreferredName>PPASI_SCL</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>Pustular Plaque Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Exceedingly intense or unpleasant in degree, quality or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely or extremely bad or unpleasant in degree, quality, or extent; life threatening.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2842706</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Slight</VALUEMEANING>
          <MEANINGDESCRIPTION>Small or little in size, quantity, or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Right Palm Desquamation/Scali</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Right Palm Desquamation/Scaling</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1588">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3930171</PUBLICID>
    <LONGNAME>Imaging Agent Radionuclide Specific Activity Value</LONGNAME>
    <PREFERREDNAME>3930161v1.0:3930112v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A numerical quantity defined as the ratio of radioisotope activity to total mass of the element present, used as a measure of radio-purity for the radioactive imaging agent.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3930161</PublicId>
      <PreferredName>3165840v1.0:3930159v1.0</PreferredName>
      <PreferredDefinition>A compound that enables or improves the visualization of body structures or functions for medical imaging._The radioactivity per unit mass of a stated element or compound.</PreferredDefinition>
      <LongName>Imaging Agent Radionuclide Specific Activity</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3165840</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1966</PreferredName>
        <Version>1</Version>
        <LongName>Imaging Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1966</PREFERRED_NAME>
            <LONG_NAME>Imaging Agent</LONG_NAME>
            <CON_ID>3162377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3930159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111699</PreferredName>
        <Version>1</Version>
        <LongName>Radionuclide Specific Activity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111699</PREFERRED_NAME>
            <LONG_NAME>Radionuclide Specific Activity</LONG_NAME>
            <CON_ID>3925891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3930112</PublicId>
      <PreferredName>3930112v1.0</PreferredName>
      <PreferredDefinition>The radioactivity per unit mass of a stated element or compound._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Radionuclide Specific Activity Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mCi/g </UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>16</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>4</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>3930111</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C111699:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Radionuclide Specific Activity Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C111699</PREFERRED_NAME>
            <LONG_NAME>Radionuclide Specific Activity</LONG_NAME>
            <CON_ID>3925891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specific Activity</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specific Activity</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Imaging Agent CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3165849</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PET Imaging Agent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5635321</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1589">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3976711</PUBLICID>
    <LONGNAME>Hematopoietic Cell Graft Alteration Antibody Administered Type</LONGNAME>
    <PREFERREDNAME>3952433v1.0:3976692v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the antibodies administered during the hematopoietic cell product (graft) manipulation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3952433</PublicId>
      <PreferredName>3952431v1.0:2744937v1.0</PreferredName>
      <PreferredDefinition>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body._A change resulting in something that is different from the original._A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Hematopoietic Cell Graft Alteration Antibody Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3952435</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12551:C12981:C28344:C16295</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Stem Cell Graft Alteration Antibody</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12981</PREFERRED_NAME>
            <LONG_NAME>Graft</LONG_NAME>
            <CON_ID>2202844</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28344</PREFERRED_NAME>
            <LONG_NAME>Alteration</LONG_NAME>
            <CON_ID>2204020</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3976692</PublicId>
      <PreferredName>3976692v1.0</PreferredName>
      <PreferredDefinition>(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Antibody Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3976691</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16295:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Antibody Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16295</PREFERRED_NAME>
            <LONG_NAME>Antibody</LONG_NAME>
            <CON_ID>2202301</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other antibody</VALIDVALUE>
          <VALUEMEANING>Other Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16295, C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3976693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD52</VALIDVALUE>
          <VALUEMEANING>Anti-CD52</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD52, regardless of the antibody type (e.g., rat, mouse, humanized).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C72960</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD8</VALIDVALUE>
          <VALUEMEANING>Anti-CD8 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD8, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112888</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD7</VALIDVALUE>
          <VALUEMEANING>Anti-CD7 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD7, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112887</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD6</VALIDVALUE>
          <VALUEMEANING>Anti-CD6 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD6, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112886</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD5</VALIDVALUE>
          <VALUEMEANING>Anti-CD5 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD5, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112885</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000134</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD4</VALIDVALUE>
          <VALUEMEANING>Anti-CD4 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD4, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112884</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000135</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD3</VALIDVALUE>
          <VALUEMEANING>Anti-CD3 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD3, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112883</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000136</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD2</VALIDVALUE>
          <VALUEMEANING>Anti-CD2 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD2, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112882</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000137</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD19</VALIDVALUE>
          <VALUEMEANING>Anti-CD19 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against the cell surface glycoprotein CD19, regardless of the antibody type.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000140</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Alpha/beta antibody</VALIDVALUE>
          <VALUEMEANING>Alpha-Beta T-Cell Receptor Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody directed against an alpha-beta T-Cell receptor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C112909</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4000139</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD45RA</VALIDVALUE>
          <VALUEMEANING>Anti-CD45RA Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody that recognizes receptor-type tyrosine-protein phosphatase C isoform CD45RA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158687</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6681825</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anti CD34</VALIDVALUE>
          <VALUEMEANING>Anti-CD34 Monoclonal Antibody</VALUEMEANING>
          <MEANINGDESCRIPTION>Any monoclonal antibody that recognizes hematopoietic progenitor cell antigen CD34.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C158686</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6681826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What antibodies were administ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What antibodies were administered during the graft alteration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What antibodies were used during product manipulation?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What antibodies were used during product manipulation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify antibodies used</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify antibodies used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify antibodies used</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify antibodies used</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>inf_proc_prod_manip_ab_type</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1590">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>3983795</PUBLICID>
    <LONGNAME>Genital Odor Duration Day Count</LONGNAME>
    <PREFERREDNAME>3983378v1.0:3294157v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis._The sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form._The period of time during which something continues._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3983378</PublicId>
      <PreferredName>3983376v1.0:2234809v1.0</PreferredName>
      <PreferredDefinition>The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis._The sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form._The period of time during which something continues.</PreferredDefinition>
      <LongName>Genital Odor Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3983376</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13348:C86573</PreferredName>
        <Version>1</Version>
        <LongName>Genital Odor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13348</PREFERRED_NAME>
            <LONG_NAME>Genital</LONG_NAME>
            <CON_ID>2203629</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86573</PREFERRED_NAME>
            <LONG_NAME>Odor</LONG_NAME>
            <CON_ID>3125064</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234809</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25330</PreferredName>
        <Version>1</Version>
        <LongName>Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3294157</PublicId>
      <PreferredName>3294157v1.0</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.</PreferredDefinition>
      <LongName>Day Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>100</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2207941</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Day Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Day -2</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::2: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::2</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>20</VALIDVALUE>
          <VALUEMEANING>Day 20</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::20: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::20</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>21</VALIDVALUE>
          <VALUEMEANING>Day 21</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::21: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::21</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>22</VALIDVALUE>
          <VALUEMEANING>Day 22</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::22: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::22</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>23</VALIDVALUE>
          <VALUEMEANING>Day 23</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::23: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::23</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>24</VALIDVALUE>
          <VALUEMEANING>Day 24</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::24: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::24</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>25</VALIDVALUE>
          <VALUEMEANING>Day 25</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::25: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::25</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>26</VALIDVALUE>
          <VALUEMEANING>Day 26</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::26: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::26</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>27</VALIDVALUE>
          <VALUEMEANING>Day 27</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::27: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::27</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>28</VALIDVALUE>
          <VALUEMEANING>Day 28</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::28: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::28</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>29</VALIDVALUE>
          <VALUEMEANING>Day 29</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::29: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::29</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Day 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::3: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::3</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>30</VALIDVALUE>
          <VALUEMEANING>Day 30</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::30: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::30</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>31</VALIDVALUE>
          <VALUEMEANING>Integer::31 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::31: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::31</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>32</VALIDVALUE>
          <VALUEMEANING>Integer::32 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::32: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::32</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294206</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>33</VALIDVALUE>
          <VALUEMEANING>Integer::33 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::33: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::33</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294207</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>34</VALIDVALUE>
          <VALUEMEANING>Integer::34 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::34: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::34</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294208</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>35</VALIDVALUE>
          <VALUEMEANING>Integer::35 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::35: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::35</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294209</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>36</VALIDVALUE>
          <VALUEMEANING>Integer::36 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::36: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::36</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>37</VALIDVALUE>
          <VALUEMEANING>Integer::37 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::37: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::37</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>38</VALIDVALUE>
          <VALUEMEANING>Integer::38 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::38: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::38</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>39</VALIDVALUE>
          <VALUEMEANING>Integer::39 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::39: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::39</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Integer::4 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::4: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::4</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>40</VALIDVALUE>
          <VALUEMEANING>Integer::40 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::40: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::40</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>41</VALIDVALUE>
          <VALUEMEANING>Integer::41 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::41: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::41</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>42</VALIDVALUE>
          <VALUEMEANING>Integer::42 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::42: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::42</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>43</VALIDVALUE>
          <VALUEMEANING>Integer::43 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::43: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::43</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>44</VALIDVALUE>
          <VALUEMEANING>Integer::44 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::44: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::44</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>45</VALIDVALUE>
          <VALUEMEANING>Integer::45 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::45: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::45</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>46</VALIDVALUE>
          <VALUEMEANING>Integer::46 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::46: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::46</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>47</VALIDVALUE>
          <VALUEMEANING>Integer::47 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::47: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::47</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>48</VALIDVALUE>
          <VALUEMEANING>Integer::48 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::48: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::48</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>49</VALIDVALUE>
          <VALUEMEANING>Integer::49 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::49: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::49</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Day 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::5: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::5</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>50</VALIDVALUE>
          <VALUEMEANING>Integer::50 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::50: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::50</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>51</VALIDVALUE>
          <VALUEMEANING>Integer::51 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::51: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::51</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294234</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>52</VALIDVALUE>
          <VALUEMEANING>Integer::52 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::52: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::52</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294235</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>53</VALIDVALUE>
          <VALUEMEANING>Integer::53 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::53: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::53</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294236</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>54</VALIDVALUE>
          <VALUEMEANING>Integer::54 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::54: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::54</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>55</VALIDVALUE>
          <VALUEMEANING>Integer::55 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::55: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::55</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>56</VALIDVALUE>
          <VALUEMEANING>Integer::56 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::56: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::56</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294239</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>57</VALIDVALUE>
          <VALUEMEANING>Integer::57 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::57: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::57</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294240</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>58</VALIDVALUE>
          <VALUEMEANING>Integer::58 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::58: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::58</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294241</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>59</VALIDVALUE>
          <VALUEMEANING>Integer::59 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::59: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::59</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294242</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Integer::6 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::6: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::6</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>60</VALIDVALUE>
          <VALUEMEANING>Integer::60 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::60: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::60</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294244</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>61</VALIDVALUE>
          <VALUEMEANING>Integer::61 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::61: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::61</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294245</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>62</VALIDVALUE>
          <VALUEMEANING>Integer::62 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::62: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::62</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294246</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>63</VALIDVALUE>
          <VALUEMEANING>Integer::63 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::63: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::63</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>64</VALIDVALUE>
          <VALUEMEANING>Integer::64 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::64: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::64</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>65</VALIDVALUE>
          <VALUEMEANING>Integer::65 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::65: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::65</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294249</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>66</VALIDVALUE>
          <VALUEMEANING>Integer::66 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::66: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::66</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294250</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>67</VALIDVALUE>
          <VALUEMEANING>Integer::67 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::67: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::67</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>68</VALIDVALUE>
          <VALUEMEANING>Integer::68 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::68: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::68</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294252</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>69</VALIDVALUE>
          <VALUEMEANING>Integer::69 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::69: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::69</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Integer::7 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::7: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::7</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294254</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>70</VALIDVALUE>
          <VALUEMEANING>Integer::70 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::70: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::70</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294255</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>71</VALIDVALUE>
          <VALUEMEANING>Integer::71 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::71: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::71</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>72</VALIDVALUE>
          <VALUEMEANING>Integer::72 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::72: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::72</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294257</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>73</VALIDVALUE>
          <VALUEMEANING>Integer::73 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::73: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::73</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294258</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>74</VALIDVALUE>
          <VALUEMEANING>Integer::74 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::74: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::74</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294259</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>75</VALIDVALUE>
          <VALUEMEANING>Integer::75 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::75: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::75</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294260</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>76</VALIDVALUE>
          <VALUEMEANING>Integer::76 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::76: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::76</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>77</VALIDVALUE>
          <VALUEMEANING>Integer::77 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::77: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::77</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>78</VALIDVALUE>
          <VALUEMEANING>Integer::78 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::78: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::78</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294267</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>79</VALIDVALUE>
          <VALUEMEANING>Integer::79 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::79: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::79</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294268</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Day 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::8: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::8</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294261</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>80</VALIDVALUE>
          <VALUEMEANING>Integer::80 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::80: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::80</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>81</VALIDVALUE>
          <VALUEMEANING>Integer::81 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::81: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::81</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294270</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>82</VALIDVALUE>
          <VALUEMEANING>Integer::82 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::82: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::82</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294271</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>83</VALIDVALUE>
          <VALUEMEANING>Integer::83 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::83: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::83</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294272</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>84</VALIDVALUE>
          <VALUEMEANING>Integer::84 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::84: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::84</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>85</VALIDVALUE>
          <VALUEMEANING>Integer::85 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::85: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::85</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294274</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>86</VALIDVALUE>
          <VALUEMEANING>Integer::86 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::86: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::86</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294275</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>87</VALIDVALUE>
          <VALUEMEANING>Integer::87 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::87: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::87</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>88</VALIDVALUE>
          <VALUEMEANING>Integer::88 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::88: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::88</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>89</VALIDVALUE>
          <VALUEMEANING>Integer::89 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::89: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::89</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Integer::9 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::9: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::9</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294262</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>90</VALIDVALUE>
          <VALUEMEANING>Integer::90 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::90: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::90</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>91</VALIDVALUE>
          <VALUEMEANING>Integer::91 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::91: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::91</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294280</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>92</VALIDVALUE>
          <VALUEMEANING>Integer::92 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::92: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::92</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294281</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>93</VALIDVALUE>
          <VALUEMEANING>Integer::93 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::93: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::93</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294282</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>94</VALIDVALUE>
          <VALUEMEANING>Integer::94 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::94: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::94</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294283</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>95</VALIDVALUE>
          <VALUEMEANING>Integer::95 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::95: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::95</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294284</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>96</VALIDVALUE>
          <VALUEMEANING>Integer::96 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::96: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::96</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>97</VALIDVALUE>
          <VALUEMEANING>Integer::97 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::97: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::97</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>98</VALIDVALUE>
          <VALUEMEANING>Integer::98 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::98: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::98</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Integer::99 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::99: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::99</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>100</VALIDVALUE>
          <VALUEMEANING>Integer::100 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::100: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::100</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2787406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Integer::1 Day</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::1: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::1</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Day 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::10: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::10</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3294159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>11</VALIDVALUE>
          <VALUEMEANING>Day 11</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::11: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::11</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>12</VALIDVALUE>
          <VALUEMEANING>Day 12</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::12: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::12</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>13</VALIDVALUE>
          <VALUEMEANING>Day 13</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::13: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::13</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291285</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>14</VALIDVALUE>
          <VALUEMEANING>Day 14</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::14: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::14</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291302</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>15</VALIDVALUE>
          <VALUEMEANING>Day 15</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part, including the negative and positive numbers as well as zero.::15: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::15</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291301</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>16</VALIDVALUE>
          <VALUEMEANING>Day 16</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::16: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::16</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291300</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>17</VALIDVALUE>
          <VALUEMEANING>Day 17</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::17: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::17</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291299</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>18</VALIDVALUE>
          <VALUEMEANING>Day 18</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::18: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::18</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291298</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>19</VALIDVALUE>
          <VALUEMEANING>Day 19</VALUEMEANING>
          <MEANINGDESCRIPTION>A number with no fractional part.::19: The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.       </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25301, C45255::19</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3291297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Odor/smell</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Odor/smell</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1591">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4024778</PUBLICID>
    <LONGNAME>Symptom Assessment Questionnaire Total Score</LONGNAME>
    <PREFERREDNAME>SX_ASSMT_TTL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>The mean of all responses by an individual to the symptom assessment tool.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4024756</PublicId>
      <PreferredName>4024754v1.0:2714576v1.0</PreferredName>
      <PreferredDefinition>Subjective evidence of disease perceived by the patient._The final result of a determination of the value, significance, or extent of._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Symptom Assessment Questionnaire Total Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4024754</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4876:C25217:C17048</PreferredName>
        <Version>1</Version>
        <LongName>Symptom Assessment Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2714576</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Total Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4006271</PublicId>
      <PreferredName>SYMPT_INV_TTL_SCR</PreferredName>
      <PreferredDefinition>The number that represents the average of all scores collected to assess symptoms.</PreferredDefinition>
      <LongName>Symptom Inventory Total Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>10</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Score</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1592">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4076163</PUBLICID>
    <LONGNAME>Prostate Erection Function Sexual Activity Problem Scale</LONGNAME>
    <PREFERREDNAME>epic_57</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent changes in the ability of the penis to function for hardening, enlarging and rising indicating arousal in males due to interference from symptoms of prostate cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527845</PublicId>
      <PreferredName>PRS_QOL_EREC_FUNC</PreferredName>
      <PreferredDefinition>related to changes in the ability of the penis to function for hardening, enlarging and rising indicating arousal in males due to interference from symptoms of prostate cancer.</PreferredDefinition>
      <LongName>Prostate Quality of Life Erection Function</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2527736</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12410:C17047</PreferredName>
        <Version>1</Version>
        <LongName>Prostate Quality of Life</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12410</PREFERRED_NAME>
            <LONG_NAME>Prostate Gland</LONG_NAME>
            <CON_ID>2202794</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2527843</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25740:C25518</PreferredName>
        <Version>1</Version>
        <LongName>Erection Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25740</PREFERRED_NAME>
            <LONG_NAME>Erection</LONG_NAME>
            <CON_ID>2203916</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4076057</PublicId>
      <PreferredName>PROS_SEX_PROB_SCL</PreferredName>
      <PreferredDefinition>a scaled set of values rating interference of prostate cancer symptoms with activities of daily living._an ordered reference standard.</PreferredDefinition>
      <LongName>Prostate Sexual Activity Problem Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Poor to None</VALUEMEANING>
          <MEANINGDESCRIPTION>Of especially low value or worth.: No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132, C104315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4076058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very good</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something has a high degree of quality, value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3639406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Good</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Fair</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no exceptional quality or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Poor</VALUEMEANING>
          <MEANINGDESCRIPTION>Of low value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Your ability to have an erect</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Your ability to have an erection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3886752</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>For Review</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EPIC CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4030518</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1593">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4118037</PUBLICID>
    <LONGNAME>Lesion Assessment Yes No Indicator</LONGNAME>
    <PREFERREDNAME>4118036v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the outcome of a disease assessment</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4118036</PublicId>
      <PreferredName>2177112v1.0:2177636v1.0</PreferredName>
      <PreferredDefinition>A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Lesion Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177112</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Lesion</PreferredName>
        <Version>1</Version>
        <LongName>Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3824</PREFERRED_NAME>
            <LONG_NAME>Lesion</LONG_NAME>
            <CON_ID>2202339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177636</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessed</PreferredName>
        <Version>1</Version>
        <LongName>Assessed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other lesions were not assess</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other lesions were not assessed</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Multiple lesions that don&#39;t meet the criteria as satellite lesions?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Multiple lesions that don&#39;t meet the criteria as satellite lesions?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have less than or equal to 3 satellite lesions?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>MULT_LES_NOT_SATLITE_IND</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>4118036v1.0:3506068v1.0</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1594">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4126017</PUBLICID>
    <LONGNAME>Adjuvant Therapy Zoledronate Administered Yes No Indicator</LONGNAME>
    <PREFERREDNAME>4125851v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the administration of Zoledronic Acid</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4125851</PublicId>
      <PreferredName>2739022v1.0:4125849v1.0</PreferredName>
      <PreferredDefinition>Information related to the administration of Zoledronic Acid.</PreferredDefinition>
      <LongName>Adjuvant Therapy Zoledronate Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2739022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15675</PreferredName>
        <Version>1</Version>
        <LongName>Adjuvant Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15675</PREFERRED_NAME>
            <LONG_NAME>Adjuvant Therapy</LONG_NAME>
            <CON_ID>2205339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4125849</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1699:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Zoledronate Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1699</PREFERRED_NAME>
            <LONG_NAME>Zoledronic Acid</LONG_NAME>
            <CON_ID>2421131</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Zoledronic Acid</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Zoledronic Acid</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1595">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4179271</PUBLICID>
    <LONGNAME>Multiple Polyp Fragment Specimen Storage Indicator</LONGNAME>
    <PREFERREDNAME>MUL_PLYP_FRAG_STO_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response regarding whether multiple pieces/fragments of a polyp or multiple polyps were stored in a single specimen container.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4179262</PublicId>
      <PreferredName>4179259v1.0:4179260v1.0</PreferredName>
      <PreferredDefinition>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold. (dictionary.com)_A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations._A part of a larger entity._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The act of safekeeping goods in a depository.</PreferredDefinition>
      <LongName>Multiple Polyp Fragment Specimen Storage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4179259</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17648:C3340:C48295</PreferredName>
        <Version>1</Version>
        <LongName>Multiple Polyp Fragment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17648</PREFERRED_NAME>
            <LONG_NAME>Multiple</LONG_NAME>
            <CON_ID>2202577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3340</PREFERRED_NAME>
            <LONG_NAME>Polyp</LONG_NAME>
            <CON_ID>2202781</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48295</PREFERRED_NAME>
            <LONG_NAME>Fragment</LONG_NAME>
            <CON_ID>2388822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4179260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157:C60824</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Storage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60824</PREFERRED_NAME>
            <LONG_NAME>Storage</LONG_NAME>
            <CON_ID>2547381</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Were multiple polyps/fragment</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Were multiple polyps/fragments placed in one specimen container?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1596">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4180740</PUBLICID>
    <LONGNAME>Patient Alcohol Consumption Past Year Morning Drink Frequency</LONGNAME>
    <PREFERREDNAME>PT_ALCCONS_P_YR_MORN_DRNK_FRQ</PREFERREDNAME>
    <PREFERREDDEFINITION>The semi-quantitative description for rate of occurrence of an event for a perceived need or craving at a time the past calendar year to consume a drink containing alcohol when waking in the morning after a prior day drinking beverages or other liquids containing ethanol or other alcohols as reported by a person receiving medical care or treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NIDA</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4180013</PublicId>
      <PreferredName>PT_ALCCONS_P_YR_MORN_DRNK</PreferredName>
      <PreferredDefinition>The perceived need at a time the past calendar year to consume a drink containing alcohol when waking in the morning after a prior day drinking beverages or other liquids containing ethanol or other alcohols as reported by a person receiving medical care or treatment.</PreferredDefinition>
      <LongName>Patient Alcohol Consumption Past Year Morning Drink</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDA</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4179983</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C16273</PreferredName>
        <Version>1</Version>
        <LongName>Patient Alcohol Consumption</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16273</PREFERRED_NAME>
            <LONG_NAME>Alcohol Consumption</LONG_NAME>
            <CON_ID>2204017</CON_ID>
            <DEFINITION_SOURCE>NCIt</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4180011</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25609:C29848:C64934:C86036</PreferredName>
        <Version>1</Version>
        <LongName>Past Year Morning Drink</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64934</PREFERRED_NAME>
            <LONG_NAME>Morning</LONG_NAME>
            <CON_ID>2738653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86036</PREFERRED_NAME>
            <LONG_NAME>Drink</LONG_NAME>
            <CON_ID>3121377</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3277356</PublicId>
      <PreferredName>3277356v1.0</PreferredName>
      <PreferredDefinition>A list or register of events; a tabular array of the days._The number of occurrences of something within a given time period. (NCI)</PreferredDefinition>
      <LongName>Calendar Frequency</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008566</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>BEHAVIOR</PreferredName>
        <Version>1</Version>
        <LongName>Behavior</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3277355</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19459:C25515</PreferredName>
        <Version>1</Version>
        <LongName>Calendar Frequency</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19459</PREFERRED_NAME>
            <LONG_NAME>Calendar</LONG_NAME>
            <CON_ID>2615818</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Daily or almost daily</VALIDVALUE>
          <VALUEMEANING>Daily</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring or done each day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25473</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3269963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Weekly</VALIDVALUE>
          <VALUEMEANING>Weekly</VALUEMEANING>
          <MEANINGDESCRIPTION>Every week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67069</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3277357</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4 or more times a week</VALIDVALUE>
          <VALUEMEANING>Four Or Greater Than Integer::4 Instance Per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A number with no fractional part.::4: An occurrence of something.: For each, generally denoting a ratio.: Any period of seven consecutive days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29844, C65039, C48364, C45255::4, C61584, C37998, C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3277358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 to 3 times a week</VALIDVALUE>
          <VALUEMEANING>Two To Three Instance Per Week</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: An occurrence of something.: For each, generally denoting a ratio.: Any period of seven consecutive days.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29844, C65039, C48364, C66834, C65107, C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3277359</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Monthly</VALIDVALUE>
          <VALUEMEANING>Monthly</VALUEMEANING>
          <MEANINGDESCRIPTION>Every month.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64498</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991205</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2 to 4 times a month</VALIDVALUE>
          <VALUEMEANING>Two To Four Instance Per Month</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: An occurrence of something.: For each, generally denoting a ratio.: One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C29846, C65039, C48364, C66835, C65107, C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3277360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Less than monthly</VALIDVALUE>
          <VALUEMEANING>Less Than Monthly</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: Every month.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64498, C61585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3171658</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-09-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often during the last yea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3952293</PublicId>
          <ContextName>NIDA</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NIDA CTN Usage</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Research</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3952294</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1597">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4182612</PUBLICID>
    <LONGNAME>Recurrent Polyp Colonoscopy Identified Location Indicator</LONGNAME>
    <PREFERREDNAME>REC_POL_COL_LOC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown/not specified response regarding whether the recurrent polyp is located at the same site as a polyp identified by colonoscopy performed at baseline.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4182594</PublicId>
      <PreferredName>4182591v1.0:4182592v1.0</PreferredName>
      <PreferredDefinition>occurring again._A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations._Endoscopic examination of the luminal surface of the colon._process by which an individual unconsciously endeavors to pattern himself after another; this process is also important in the development of the personality, particularly the superego or conscience, which is modeled largely on the behavior of adult significant others._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Recurrent Polyp Colonoscopy Identified Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435022</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C7057</PreferredName>
        <Version>1</Version>
        <LongName>Disease, Disorder or Finding</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4182591</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C14173:C3340</PreferredName>
        <Version>1</Version>
        <LongName>Recurrent Polyp</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14173</PREFERRED_NAME>
            <LONG_NAME>Recurrent</LONG_NAME>
            <CON_ID>2204863</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3340</PREFERRED_NAME>
            <LONG_NAME>Polyp</LONG_NAME>
            <CON_ID>2202781</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4182592</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16450:C0020792:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Colonoscopy Identified Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16450</PREFERRED_NAME>
            <LONG_NAME>Colonoscopy</LONG_NAME>
            <CON_ID>2528526</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0020792</PREFERRED_NAME>
            <LONG_NAME>Identified</LONG_NAME>
            <CON_ID>2204266</CON_ID>
            <DEFINITION_SOURCE>CSP2003</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4182611</PublicId>
      <PreferredName>YN_UNK_NOSPEC_IND</PreferredName>
      <PreferredDefinition>An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Yes No Unknown Not Specified Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not specified</VALIDVALUE>
          <VALUEMEANING>Unspecified</VALUEMEANING>
          <MEANINGDESCRIPTION>Not stated explicitly or in detail.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38046</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3945562</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is this recurrent polyp in th</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is this recurrent polyp in the same location as a polyp identified on the baseline colonoscopy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MAY2013-01-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4261411</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1598">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4187537</PUBLICID>
    <LONGNAME>Special Interest Adverse Event Occurrence Adverse Event Yes or No Response</LONGNAME>
    <PREFERREDNAME>3729294v1.0:4187534v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the occurrence of an adverse event of special interest.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3729294</PublicId>
      <PreferredName>SPEC_INT_AE_OCC</PreferredName>
      <PreferredDefinition>Surpassing what is common or usual or expected._A state of curiosity or concern about or attention to something_Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._Occurrence; an instance of something happening.</PreferredDefinition>
      <LongName>Special Interest Adverse Event Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3729292</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25684:C60730:C41331</PreferredName>
        <Version>1</Version>
        <LongName>Special Interest Adverse Event</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25684</PREFERRED_NAME>
            <LONG_NAME>Special</LONG_NAME>
            <CON_ID>2206254</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60730</PREFERRED_NAME>
            <LONG_NAME>Interest</LONG_NAME>
            <CON_ID>2481625</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>C3D:Central Cancer Clinical Database</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4187534</PublicId>
      <PreferredName>4187534v1.0</PreferredName>
      <PreferredDefinition>The yes or no response related to a specific adverse event of special interest.</PreferredDefinition>
      <LongName>Adverse Event Yes or No Response</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008559</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE_OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2390878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331:C38147</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, vomiting</VALIDVALUE>
          <VALUEMEANING>Yes, vomiting</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, vomiting</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4187535</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, nausea</VALIDVALUE>
          <VALUEMEANING>Yes, nausea</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, nausea</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4187536</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3216924</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the AE of special interest</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the AE of special interest</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1599">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4188601</PUBLICID>
    <LONGNAME>Liver Symptom Intermittent Yes No Indicator</LONGNAME>
    <PREFERREDNAME>4188600v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to the occurrence of liver symptoms</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4188600</PublicId>
      <PreferredName>4188597v1.0:4188598v1.0</PreferredName>
      <PreferredDefinition>Information related to liver symptoms occurring intermittently.</PreferredDefinition>
      <LongName>Liver Symptom Intermittent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008575</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SM</PreferredName>
        <Version>1</Version>
        <LongName>Symptoms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4188597</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12392:C4876</PreferredName>
        <Version>1</Version>
        <LongName>Liver Symptom</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4876</PREFERRED_NAME>
            <LONG_NAME>Symptom</LONG_NAME>
            <CON_ID>2202622</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4188598</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C71325</PreferredName>
        <Version>1</Version>
        <LongName>Intermittent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C71325</PREFERRED_NAME>
            <LONG_NAME>Intermittent</LONG_NAME>
            <CON_ID>2855044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Intermittent</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Intermittent</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1600">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4192296</PUBLICID>
    <LONGNAME>Liver Diagnostic Investigation Date</LONGNAME>
    <PREFERREDNAME>4192273v1.0:2018550v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date of the liver diagnostic investigation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4192273</PublicId>
      <PreferredName>2177203v1.0:4192271v1.0</PreferredName>
      <PreferredDefinition>Information related to the diagnostic information resulting from the investigation of the liver.</PreferredDefinition>
      <LongName>Liver Diagnostic Investigation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177203</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Liver</PreferredName>
        <Version>1</Version>
        <LongName>Liver</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12392</PREFERRED_NAME>
            <LONG_NAME>Liver</LONG_NAME>
            <CON_ID>2202332</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4192271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25482:C41198</PreferredName>
        <Version>1</Version>
        <LongName>Diagnostic Investigation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25482</PREFERRED_NAME>
            <LONG_NAME>Diagnostic</LONG_NAME>
            <CON_ID>2202397</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41198</PREFERRED_NAME>
            <LONG_NAME>Investigation</LONG_NAME>
            <CON_ID>2469351</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018550</PublicId>
      <PreferredName>DT</PreferredName>
      <PreferredDefinition>The date on which an observation was made or an event occurred.</PreferredDefinition>
      <LongName>Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Liver diagnostic investigatio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Liver diagnostic investigation date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP CRF Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date of cirrhosis diagnostic procedure</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NWU2015-06-03</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5280814</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1601">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4207549</PUBLICID>
    <LONGNAME>Lung Cancer Diagnosis Age Year Count</LONGNAME>
    <PREFERREDNAME>LUNGCANCERAGE</PREFERREDNAME>
    <PREFERREDDEFINITION>The person&#39;s age in years at diagnosis of lung cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3284194</PublicId>
      <PreferredName>2206442v1.0:2554159v1.0</PreferredName>
      <PreferredDefinition>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas, leukemias, melanomas, and sarcomas. -- 2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._How long something has existed; elapsed time since birth.</PreferredDefinition>
      <LongName>Lung Cancer Diagnosis Age</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206442</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12468:C9305</PreferredName>
        <Version>1</Version>
        <LongName>Lung Malignant Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12468</PREFERRED_NAME>
            <LONG_NAME>Lung</LONG_NAME>
            <CON_ID>2202738</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2554159</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15220:C25150</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis Age</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25150</PREFERRED_NAME>
            <LONG_NAME>Age</LONG_NAME>
            <CON_ID>2202837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2185961</PublicId>
      <PreferredName>AGE_YR_CT</PreferredName>
      <PreferredDefinition>the age in years.</PreferredDefinition>
      <LongName>Age Year Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2524762</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29848:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Year Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29848</PREFERRED_NAME>
            <LONG_NAME>Year</LONG_NAME>
            <CON_ID>2203986</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Age at the first diagnosis of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Age at the first diagnosis of lung cancer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>LUNGCANCERAGE</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1602">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4240392</PUBLICID>
    <LONGNAME>Past 4 Week Reduced Careful Emotion Problem Reason Yes No Coded Indicator</LONGNAME>
    <PREFERREDNAME>SF36_19</PREFERREDNAME>
    <PREFERREDDEFINITION>Coded indicator to signify whether a person reported either not working or doing activities as carefully as usual as a result of emotional problems during the past four weeks.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4240379</PublicId>
      <PreferredName>4240377v1.0:4240362v1.0</PreferredName>
      <PreferredDefinition>Before the present time._A number with no fractional part, including the negative and positive numbers as well as zero.::4_Any period of seven consecutive days._Made less in size or amount or degree._The act or process of concentrating, focusing the attention and mental energy on a single object to the exclusion of others._That aspect of consciousness devoted to affect or feeling; a strong feeling, aroused mental state, or intense state of drive or unrest directed toward a definite object, with physiological, somatic, and behavioral components._A difficulty, disorder, or condition needing resolution._An explanation of the cause of some phenomenon or action.</PreferredDefinition>
      <LongName>Past 4 Week Reduced Careful Emotion Problem Reason</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4240377</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4240377v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Past Integer::4 Week Reduced Attention Concentration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::4</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25640</PREFERRED_NAME>
            <LONG_NAME>Reduced</LONG_NAME>
            <CON_ID>2204920</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41209</PREFERRED_NAME>
            <LONG_NAME>Attention Concentration</LONG_NAME>
            <CON_ID>2650781</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4240362</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54266:C28020:C25638</PreferredName>
        <Version>1</Version>
        <LongName>Emotion Problem Reason</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54266</PREFERRED_NAME>
            <LONG_NAME>Emotion</LONG_NAME>
            <CON_ID>2464659</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28020</PREFERRED_NAME>
            <LONG_NAME>Problem</LONG_NAME>
            <CON_ID>2203953</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183836</PublicId>
      <PreferredName>YES_NO_CD_IND</PreferredName>
      <PreferredDefinition>Yes or No response to a question coded as 1 (Yes) or 2 (No).</PreferredDefinition>
      <LongName>Yes No Coded Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Didn&#39;t do work or other activ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Didn&#39;t do work or other activities as carefully as usual</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Princess Margaret TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did work or activities less carefully than usual.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke University</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811715</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Duke U New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1603">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4265442</PUBLICID>
    <LONGNAME>Distance From Ventricle to Tumor Millimeter Value</LONGNAME>
    <PREFERREDNAME>VENT_TUM_DIST_MM_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value representing the neuro anatomy distance from any ventricle in the brain to a specified primary tumor measured in millimeters (mm).</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4265438</PublicId>
      <PreferredName>BR_VENT_TUM_DIST</PreferredName>
      <PreferredDefinition>The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord._Used as a function word to indicate direction, purpose, or movement._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The space separating two objects or points.</PreferredDefinition>
      <LongName>Brain Ventricle To Neoplasm Distance</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4265436</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12356:C65107:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Brain Ventricle To Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12356</PREFERRED_NAME>
            <LONG_NAME>Brain Ventricle</LONG_NAME>
            <CON_ID>2534106</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2436194</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25167</PreferredName>
        <Version>1</Version>
        <LongName>Distance</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25167</PREFERRED_NAME>
            <LONG_NAME>Distance</LONG_NAME>
            <CON_ID>2203902</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4265435</PublicId>
      <PreferredName>DIST_MM_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Distance in Millimeter Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>mm</UnitOfMeasure>
      <DisplayFormat>99.9</DisplayFormat>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Distance from ventricle to tu</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Distance from ventricle to tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1604">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4265611</PUBLICID>
    <LONGNAME>Surgical Procedure Greater Than or Equal To 500 Milligrams Enhancing Lesion and 100 Milligrams Non Enhancing Lesion Excision Indicator</LONGNAME>
    <PREFERREDNAME>RSC_500_ENH_TMR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not the surgeon expects to resect at least 500 mg of tumor from enhancing tumor and at least 100 mg from non-enhancing tumor with low risk of inducing neurological injury.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4265377</PublicId>
      <PreferredName>2322305v1.0:4265375v1.0</PreferredName>
      <PreferredDefinition>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::500_A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce._A well-demarcated area of unequivocally increased signal intensity on MRI or CT scan images compared with normal-appearing, surrounding tissue following intravenous injection of an enhancing agent._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes._A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce._An operation in which a term denies or inverts the meaning of another term or construction._A well-demarcated area of unequivocally increased signal intensity on MRI or CT scan images compared with normal-appearing, surrounding tissue following intravenous injection of an enhancing agent._The act of cutting out; the surgical removal of part or all of a structure or organ.</PreferredDefinition>
      <LongName>Surgical Procedure Greater Than or Equal To 500 Milligrams Enhancing Lesion And 100 Milligrams Non Enhancing Lesion Excision</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2322305</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15329</PreferredName>
        <Version>1</Version>
        <LongName>Surgical Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4265375</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4265375v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Greater Than or Equal To Integer::500 Milligram Enhancing Lesion And One Hundred Milligram Negation Enhancing Lesion Excision</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61583</PREFERRED_NAME>
            <LONG_NAME>Greater Than or Equal To</LONG_NAME>
            <CON_ID>2673224</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>9</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::500</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>8</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28253</PREFERRED_NAME>
            <LONG_NAME>Milligram</LONG_NAME>
            <CON_ID>2204828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113842</PREFERRED_NAME>
            <LONG_NAME>Enhancing Lesion</LONG_NAME>
            <CON_ID>4188621</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105814</PREFERRED_NAME>
            <LONG_NAME>One Hundred</LONG_NAME>
            <CON_ID>4265374</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28253</PREFERRED_NAME>
            <LONG_NAME>Milligram</LONG_NAME>
            <CON_ID>2204828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113842</PREFERRED_NAME>
            <LONG_NAME>Enhancing Lesion</LONG_NAME>
            <CON_ID>4188621</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the surgeon expect to be</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the surgeon expect to be able to resect at least 500 mg of tumor from the enhancing tumor and 100 mg for the non-enhancing tumor with low risk of inducing neurological injury?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3335728</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocols</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>ABTC 1302</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4264871</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1605">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4267095</PUBLICID>
    <LONGNAME>Cyclin-Dependent Kinase Inhibitor Administered Indicator</LONGNAME>
    <PREFERREDNAME>CDK_IHBT_ADM_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response indicating whether or not a person has been previously treated with a CDK inhibitor.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PBTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4267094</PublicId>
      <PreferredName>4271511v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>An indicator that a person has been previously treated with cyclin dependent kinase (CDK) inhibitor.</PreferredDefinition>
      <LongName>Cyclin-Dependent Kinase Inhibitor Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PBTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4271511</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18492</PreferredName>
        <Version>1</Version>
        <LongName>Cyclin-Dependent Kinase Inhibitor</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18492</PREFERRED_NAME>
            <LONG_NAME>Cyclin-Dependent Kinase Inhibitor Protein</LONG_NAME>
            <CON_ID>3009665</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received prior tr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient received prior treatment with a CDK inhibitor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prior CDK inhibitor</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Prior CDK inhibitor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>CDK 4/6 inhibitors</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PBTC-042</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4254119</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4254096</PublicId>
          <ContextName>PBTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Protocol Phase</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase I</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Phase Type</ClassificationSchemeItemType>
        <CsiPublicId>10000103</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1606">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4281551</PUBLICID>
    <LONGNAME>SF-36v2 Health Survey In General Would You Say Your Health Is Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>SF36_GEN_HEALTH_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated perception of their general health, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>SF-36v2:Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire, Sherbourne Cathy D; Ware John E., 1998</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4281297</PublicId>
      <PreferredName>4281291v1.0:4281295v1.0</PreferredName>
      <PreferredDefinition>A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Quality Metric Inc. and the Medical Outcomes Trust in 1996 and 2000 which is used to assess the patient&#39;s functional health and overall well-being. This second version contains 36 questions that refer to the patient&#39;s symptoms or status within the past four weeks and can be completed by the patient. For each question the patient must choose from five different responses._Widespread, broadly dispersed, common._The state of a subject&#39;s mental or physical condition._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Short Form 36 Health Survey Standard US Version 2.0 Questionnaire Generalized Health Status Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4281291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102122</PreferredName>
        <Version>1</Version>
        <LongName>Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102122</PREFERRED_NAME>
            <LONG_NAME>Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire</LONG_NAME>
            <CON_ID>4276451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4281295</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C63764:C16669:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Generalized Health Status Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C63764</PREFERRED_NAME>
            <LONG_NAME>Generalized</LONG_NAME>
            <CON_ID>2547905</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16669</PREFERRED_NAME>
            <LONG_NAME>Health Status</LONG_NAME>
            <CON_ID>2457012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SF-36v2:Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire, Sherbourne Cathy D; Ware John E., 1998</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4281211</PublicId>
      <PreferredName>RATE_5PT_SCL</PreferredName>
      <PreferredDefinition>Likert scale used for rating something from excellent (1) to poor (5).</PreferredDefinition>
      <LongName>Rating Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>SF-36v2:Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire, Sherbourne Cathy D; Ware John E., 1998</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Poor</VALUEMEANING>
          <MEANINGDESCRIPTION>Of low value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Fair</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no exceptional quality or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Good</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Very good</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something has a high degree of quality, value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3639406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Excellent</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to the highest quality or standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In general, would you say you</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In general, would you say your health is</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3863415</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MOS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SF-36v2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4281631</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4280881</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>SF-36v2</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SF-36v2</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4281200</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>SF36_GEN_HEALTH_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1607">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4321776</PUBLICID>
    <LONGNAME>QOL Assessment Time</LONGNAME>
    <PREFERREDNAME>ASSESSTIME</PREFERREDNAME>
    <PREFERREDDEFINITION>The time related to a Quality of Life assessment for a protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2013971</PublicId>
      <PreferredName>QOL_ASSESS</PreferredName>
      <PreferredDefinition>information related to a Quality of Life assessment for a protocol.</PreferredDefinition>
      <LongName>QOL Assessment</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008553</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>Quality of Life</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2176997</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>QOL</PreferredName>
        <Version>1</Version>
        <LongName>QOL</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17047</PREFERRED_NAME>
            <LONG_NAME>Quality of Life</LONG_NAME>
            <CON_ID>2202504</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177637</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019249</PublicId>
      <PreferredName>TM</PreferredName>
      <PreferredDefinition>the time at which an event was observed or occurred.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Current time</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Current time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Actual time</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ASSESSTIME</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1608">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4331011</PUBLICID>
    <LONGNAME>Medical Device Description Text</LONGNAME>
    <PREFERREDNAME>MED_DEVICE_DESC_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>Text that describes the name, functional category, manufacturer name, or associated information about a medical device.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2192890</PublicId>
      <PreferredName>MEDDEV_DESC</PreferredName>
      <PreferredDefinition>information related to the decription medical device.</PreferredDefinition>
      <LongName>Medical Device Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2541698</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16830</PreferredName>
        <Version>1</Version>
        <LongName>Medical_Device</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16830</PREFERRED_NAME>
            <LONG_NAME>Medical Device</LONG_NAME>
            <CON_ID>2240760</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177536</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Description</PreferredName>
        <Version>1</Version>
        <LongName>Description </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Study device[Brand name][Comm</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Study device[Brand name][Common name][Device type]</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRDS Alternate Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Study device</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5858960</PublicId>
          <ContextName>NRDS</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Adopted</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>SAE</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5858965</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRDS</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRDS</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1609">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4339030</PUBLICID>
    <LONGNAME>Patient Version Prognosis Treatment and Perceptions Questionnaire Quality of the Information Received from Oncologist About Cancer Prognosis 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PT_RATE_INF_ONC_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated rating of the quality of the information they have been given by their oncologist about the likely outcome of their cancer over time, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PTPQ:Prognosis and Treatment Perceptions Questionnaire as referenced in Associations Among Prognostic Understanding, Quality of Life, El-Jawahri A, et.al., 2014</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4337000</PublicId>
      <PreferredName>4336902v1.0:4336998v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._A 13-item questionnaire used to assess information preferences, perceptions of prognosis and goal of therapy, and communication about end-of-life care._A question about a person&#39;s rating of the quality of information they have received from an oncologist about treatment and treatment choices available.</PreferredDefinition>
      <LongName>Patient Version Prognosis Treatment and Perceptions Questionnaire Quality of the Information Received About Cancer Prognosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4336902</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C25714:C115446</PreferredName>
        <Version>1</Version>
        <LongName>Patient Version Prognosis Treatment and Perceptions Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C115446</PREFERRED_NAME>
            <LONG_NAME>Prognosis Treatment and Perceptions Questionnaire</LONG_NAME>
            <CON_ID>4336889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4336998</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C115454</PreferredName>
        <Version>1</Version>
        <LongName>Quality of the Information Received About Cancer Prognosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C115454</PREFERRED_NAME>
            <LONG_NAME>Quality of the Information Received About Cancer Prognosis Question</LONG_NAME>
            <CON_ID>4336897</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PTPQ:Prognosis and Treatment Perceptions Questionnaire as referenced in Associations Among Prognostic Understanding, Quality of Life, El-Jawahri A, et.al., 2014</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4337191</PublicId>
      <PreferredName>QUAL_RATE_5PT_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard with five text responses related to a rating of quality from excellent to poor.</PreferredDefinition>
      <LongName>Quality Rating 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>PTPQ:Prognosis and Treatment Perceptions Questionnaire as referenced in Associations Among Prognostic Understanding, Quality of Life, El-Jawahri A, et.al., 2014</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Poor</VALIDVALUE>
          <VALUEMEANING>Poor</VALUEMEANING>
          <MEANINGDESCRIPTION>Of low value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fair</VALIDVALUE>
          <VALUEMEANING>Fair</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no exceptional quality or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Satisfactory</VALIDVALUE>
          <VALUEMEANING>Satisfactory</VALUEMEANING>
          <MEANINGDESCRIPTION>Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4337192</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Good</VALIDVALUE>
          <VALUEMEANING>Good</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excellent</VALIDVALUE>
          <VALUEMEANING>Excellent</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to the highest quality or standard.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-05-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206717</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very good</VALIDVALUE>
          <VALUEMEANING>Very good</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something has a high degree of quality, value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-11-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4840980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How would you rate the qualit</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How would you rate the quality of the information you have been given by your oncologist about the likely outcome of your cancer over time (i.e. your prognosis)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4320453</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PTPQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Version PTPQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4320455</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Patient Version PTPQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900390</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1610">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4358319</PUBLICID>
    <LONGNAME>Serious Adverse Event Laboratory Test Result Relationship Current Reporting Period Occurrence Yes No Coded Indicator</LONGNAME>
    <PREFERREDNAME>SAE_LAB_RPT_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to signify whether any laboratory test results were associated with any serious adverse events occurring in the current reporting period.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4358318</PublicId>
      <PreferredName>4358316v1.0:4358312v1.0</PreferredName>
      <PreferredDefinition>Any expected or unexpected adverse event, related or unrelated to the intervention, occurring at any agent dose, any phase of product or procedure testing, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect. Important medical events that may not result in the listed outcomes may be considered as serious when, based upon appropriate medical judgment, they represent significant hazards or potentially serious harm to the research subject or others and may require medical intervention to prevent one of the outcomes listed in this definition._The outcome of a laboratory test._A state of connectedness between people, objects, or events; to be associated or connected with something._Occurring in or belonging to the present time._The act of providing a short account._An interval of time._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Serious Adverse Event Laboratory Test Result Relationship Current Reporting Period Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4358316</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41335:C36292:C25648</PreferredName>
        <Version>1</Version>
        <LongName>Serious Adverse Event Laboratory Test Result Relationship</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41335</PREFERRED_NAME>
            <LONG_NAME>Serious Adverse Event</LONG_NAME>
            <CON_ID>2202356</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25648</PREFERRED_NAME>
            <LONG_NAME>Relationship</LONG_NAME>
            <CON_ID>2203770</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4358312</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25651:C25616:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Current Reporting Period Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25651</PREFERRED_NAME>
            <LONG_NAME>Reporting</LONG_NAME>
            <CON_ID>2206359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25616</PREFERRED_NAME>
            <LONG_NAME>Period</LONG_NAME>
            <CON_ID>2202575</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183836</PublicId>
      <PreferredName>YES_NO_CD_IND</PreferredName>
      <PreferredDefinition>Yes or No response to a question coded as 1 (Yes) or 2 (No).</PreferredDefinition>
      <LongName>Yes No Coded Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are there laboratory results</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are there laboratory results associated with any serious adverse events occurring this reporting period?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1611">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4358803</PUBLICID>
    <LONGNAME>Patient Primary Neoplasm Volume Assessment Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>PtPmyTmrVolAssIND4</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/unknown/not applicable indicator related to the amount of three dimensional space occupied by a tissue growth resulting from uncontrolled cell proliferation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4358802</PublicId>
      <PreferredName>PtPmyTmrVolAss</PreferredName>
      <PreferredDefinition>Information related to the amount of three dimensional space occupied by a tissue growth resulting from uncontrolled cell proliferation.</PreferredDefinition>
      <LongName>Patient Primary Neoplasm Volume Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008548</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TUMOR_MSRMTS</PreferredName>
        <Version>1</Version>
        <LongName>Tumor Measurements</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4358800</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C3262:C25335:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Primary Neoplasm Volume Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25335</PREFERRED_NAME>
            <LONG_NAME>Volume</LONG_NAME>
            <CON_ID>2203979</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did patient have greater than</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did patient have greater than 25% increase in the primary tumor volume?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient have at least 50% reduction in the primary tumor volume?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient have greater than 50% increase in the primary tumor volume?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1612">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4358961</PUBLICID>
    <LONGNAME>Additional Information Progress Note Flag Yes No Coded Indicator</LONGNAME>
    <PREFERREDNAME>PROG_SAE_RPT_CK_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to signify whether progress notes were added to an expedited adverse event report.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2919233</PublicId>
      <PreferredName>2747619v1.0:2919204v1.0</PreferredName>
      <PreferredDefinition>Added; extra; further.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication._The act of moving forward toward a goal.:A brief written record.:An indicator that can be set or unset in order to signal whether a particular condition is true.</PreferredDefinition>
      <LongName>Additional Information Progress Note Flag</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2222502</PublicId>
        <ContextName>caCORE</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>UML DEFAULT CD</PreferredName>
        <Version>1</Version>
        <LongName>UML DEFAULT CD</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2747619</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25406:C48191</PreferredName>
        <Version>1</Version>
        <LongName>Additional Information</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25406</PREFERRED_NAME>
            <LONG_NAME>Additional</LONG_NAME>
            <CON_ID>2206153</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48191</PREFERRED_NAME>
            <LONG_NAME>Information</LONG_NAME>
            <CON_ID>2422630</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2919204</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25630:C42619:C43578</PreferredName>
        <Version>1</Version>
        <LongName>Progress Note Flag</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25630</PREFERRED_NAME>
            <LONG_NAME>Progress</LONG_NAME>
            <CON_ID>2202789</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42619</PREFERRED_NAME>
            <LONG_NAME>Note</LONG_NAME>
            <CON_ID>2223997</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43578</PREFERRED_NAME>
            <LONG_NAME>Flag</LONG_NAME>
            <CON_ID>2223213</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183836</PublicId>
      <PreferredName>YES_NO_CD_IND</PreferredName>
      <PreferredDefinition>Yes or No response to a question coded as 1 (Yes) or 2 (No).</PreferredDefinition>
      <LongName>Yes No Coded Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Progress notes</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Progress notes</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1613">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4359169</PUBLICID>
    <LONGNAME>Radiation Therapy Adverse Event Morbidity Criterion Assessment Score</LONGNAME>
    <PREFERREDNAME>RTOGRTMORBID</PREFERREDNAME>
    <PREFERREDDEFINITION>The score related to the Acute Radiation Morbidity Scoring Criteria, the acute morbidity criteria are used to score/grade toxicity from radiation therapy. The criteria are relevant from day 1, the commencement of therapy, through day 90. Thereafter, the EORTC/RTOG Criteria of Late Effects are to be utilized.  [Reference http://www.rtog.org/researchassociates/adverseeventreporting/acuteradiationmorbidityscoringcriteria.aspx for more details.]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4359155</PublicId>
      <PreferredName>RTOGRTMORBID</PreferredName>
      <PreferredDefinition>Information related to the Acute Radiation Morbidity Scoring Criteria, the acute morbidity criteria are used to score/grade toxicity from radiation therapy. The criteria are relevant from day 1, the commencement of therapy, through day 90. Thereafter, the EORTC/RTOG Criteria of Late Effects are to be utilized.  [Reference http://www.rtog.org/researchassociates/adverseeventreporting/acuteradiationmorbidityscoringcriteria.aspx for more details.]</PreferredDefinition>
      <LongName>Radiation Therapy Adverse Event Morbidity Criterion Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2403872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15313</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4359153</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C41331:C16877:C25466:C25217</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Event Morbidity Criterion Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C41331</PREFERRED_NAME>
            <LONG_NAME>Adverse Event</LONG_NAME>
            <CON_ID>2202353</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16877</PREFERRED_NAME>
            <LONG_NAME>Morbidity</LONG_NAME>
            <CON_ID>4359012</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25466</PREFERRED_NAME>
            <LONG_NAME>Criterion</LONG_NAME>
            <CON_ID>2203889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4359166</PublicId>
      <PreferredName>RTOGRTMORBIDSCORE</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Acute Radiation Therapy Morbidity Scoring Criteria Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008517</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>AE</PreferredName>
        <Version>1</Version>
        <LongName>Adverse Events</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>20</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3 or more</VALIDVALUE>
          <VALUEMEANING>Greater Than or Equal To Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834, C61583</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3163496</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Four</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577599</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Three</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3218929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572564</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>One</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572563</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Zero</VALUEMEANING>
          <MEANINGDESCRIPTION>A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70430</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-06-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2683226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Acute Radiation Morbidity Sco</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Acute Radiation Morbidity Scoring Criteria score</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1614">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4360051</PUBLICID>
    <LONGNAME>Agent Intervention or Procedure Clinical Study Protocol Administration Yes No Coded Indicator</LONGNAME>
    <PREFERREDNAME>AGT_INTN_PROT_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric code to signify whether an agent intervention was administered within a specific protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4359980</PublicId>
      <PreferredName>4359978v1.0:4359913v1.0</PreferredName>
      <PreferredDefinition>An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine</PreferredDefinition>
      <LongName>Agent Intervention or Procedure Clinical Study Protocol Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4359978</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708:C25218</PreferredName>
        <Version>1</Version>
        <LongName>Agent Intervention or Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25218</PREFERRED_NAME>
            <LONG_NAME>Clinical Intervention or Procedure</LONG_NAME>
            <CON_ID>2202893</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4359913</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25320:C25409</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Study Protocol Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183836</PublicId>
      <PreferredName>YES_NO_CD_IND</PreferredName>
      <PreferredDefinition>Yes or No response to a question coded as 1 (Yes) or 2 (No).</PreferredDefinition>
      <LongName>Yes No Coded Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was there an agent interventi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was there an agent intervention administered on this protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG CRF_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were any therapies given or procedures done?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2747429</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>caAERS</PreferredName>
          <Version>2</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caAERS Rave Integration</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4358257</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1615">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4364011</PUBLICID>
    <LONGNAME>Prior First Clinical Study Pharmacologic Substance Administration Received Radiation Therapy Code Indicator</LONGNAME>
    <PREFERREDNAME>PT_EC_1006</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/not applicable indicator that describes if patient received radiotherapy prior to first study drug administration.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4363974</PublicId>
      <PreferredName>4363919v1.0:4363972v1.0</PreferredName>
      <PreferredDefinition>Earlier in time or order._Preceding all others in time or space or degree._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._To take, accept, or get something offered._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.</PreferredDefinition>
      <LongName>Prior First Clinical Study Pharmacologic Substance Administration Received Radiation Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4363919</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4363919v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Prior First Clinical Study Pharmacologic Substance Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1909</PREFERRED_NAME>
            <LONG_NAME>Pharmacologic Substance</LONG_NAME>
            <CON_ID>2437691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4363972</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25639:C15313</PreferredName>
        <Version>1</Version>
        <LongName>Receive Radiation Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received prior full field radiotherapy less than or equal to 4 weeks or limited field radiotherapy less than or equal to 2 weeks prior to first study drug administration?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior full field radiotherapy less than or equal to 4 weeks or limited field radiotherapy less than or equal to 2 weeks prior to first study drug administration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received radiothe</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient received radiotherapy prior to first study drug administration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior radiation therapy within 2 weeks prior to the first dose of the study regimen?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior WBRT?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior WBRT or has SRS/SRT/fractionated boost or neurosurgery after WBRT has been planned upfront?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient receiving radiation therapy during the screening and treatment phases (including retreatment for post-complete response relapse) of this trial?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior radiation therapy within 3 weeks prior to initiation of study treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received or is scheduled to receive radiation therapy within 7 days or less from gemcitabine administration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have at least 14 days elapsed from local radiotherapy to initiation of protocol therapy or at least 150 days from total body irradiation (TBI), craniospinal radiotherapy, or radiation to greater than or equal to 50% of the pelvis or at least 42 days from other substantial bone marrow radiation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatments</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876424</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876594</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Theradex</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Theradex - CTMS 3.14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3876603</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_EC_1006</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1616">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4379958</PUBLICID>
    <LONGNAME>Person Uncontrolled Concurrent Disease or Disorder Exclusion Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>UNCTL_DZ_CRT_COD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded yes/no/unknown indicator whether a person has an uncontrolled, concurrent disease, any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person, that would restrict entrance or bar from participation in a clinical trial.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3160245</PublicId>
      <PreferredName>2236731v1.0:2778872v1.0</PreferredName>
      <PreferredDefinition>information related to a person having an uncontrolled, concurrent disease, any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person, that would restrict entrance or bar from participation in a clinical trial.</PreferredDefinition>
      <LongName>Person Uncontrolled Concurrent Disease or Disorder Exclusion Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2778872</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48932:C25456:C2991:C25370</PreferredName>
        <Version>1</Version>
        <LongName>Uncontrolled Concurrent Disease or Disorder Exclusion Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48932</PREFERRED_NAME>
            <LONG_NAME>Uncontrolled</LONG_NAME>
            <CON_ID>2437662</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25456</PREFERRED_NAME>
            <LONG_NAME>Concurrent</LONG_NAME>
            <CON_ID>2206181</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25370</PREFERRED_NAME>
            <LONG_NAME>Exclusion Criteria</LONG_NAME>
            <CON_ID>2203927</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have uncontrolle</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris (Canadian Cardiovascular Society grade II-IV despite medical therapy), cardiac arrhythmia, active bleeding diatheses, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, diabetes mellitus, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in the protocol that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in protocol section 3.2.3 noted below, that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in protocol in Section 3.4.4 as noted below, that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 12</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have active and/or uncontrolled infections or is still recovering from an infection or actively febrile patients with uncertain etiology of febrile episode?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 13</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 14</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any serious intercurrent or psychiatric illness that could, in the investigator&#39;s opinion, potentially interfere with the completion of treatment according to this protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 16</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 18</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, previous cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 15</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, the following:  ongoing or active infection; history of significant bleeding disorder, including congenital (von Willebrand&#39;s disease) or acquired (anti-factor VIII antibodies) disorders; large pleural effusions; or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 20</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (including sinus bradycardia), or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 19</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any serious medical condition, uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, cardiac arrhythmias, laboratory abnormalities, or psychiatric illness and/or biopsychosocial conditions that may limit compliance)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 22</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 21</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, pneumonitis, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 24</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, congestive heart failure NYHA grade greater than or equal to 3, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 25</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 23</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorder in the opinion of the investigator?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 27</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, myocardial infarction within 6 months, congestive heart failure, symptomatic congestive heart failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, active liver disease or cerebrovascular disease with previous stroke, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 28</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements, including but not limited to, ongoing uncontrolled serious infection requiring IV antibiotics,  symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 36</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 26</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 32</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cognitive impairment, active substance abuse, or psychiatric illness/social situations that, in the view of the Investigator, would preclude safe treatment or the ability to give informed consent and limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 31</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known HIV infection requiring protease inhibitor therapy, known Hepatitis B, known Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 35</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, uncontrolled seizures, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 34</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, active tuberculosis (TB), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 30</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known HIV infection requiring protease inhibitor therapy, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 37</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 39</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness if it would increase the risk of toxicity or limit compliance with study requirements including but not limited to,   ongoing uncontrolled serious infection requiring i.v. antibiotics, progressive congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 38</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 41</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 44</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any evidence of severe or uncontrolled systemic diseases, including, but not limited to, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations which in the investigator&#39;s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 42</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection,   including but not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent and would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 47</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have clinically significant illnesses which would compromise participation in the study, including but not limited to active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, active tuberculosis, uncontrolled asthma, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, myocardial infarction within the past 6 months, cerebral vascular accident/stroke within the past 6 months, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 48</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, active tuberculosis (TB), symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 49</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection including but not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression, superior vena cava syndrome, symptomatic congestive heart failure, unstable angina pectoris, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent and would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 46</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (including symptomatic sinus bradycardia), or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 53</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness if it would increase the risk of toxicity or limit compliance with study requirements including but not limited to,   ongoing uncontrolled serious infection requiring i.v. antibiotics, progressive congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 52</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, active, non-colorectal malignancies requiring systemic therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 45</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding rate controlled atrial fibrillation/flutter), or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 50</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled concurrent disease or illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, unstable or untreated cardiac conditions or ejection fraction of less than 50% as determined by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA), uncontrolled diabetes mellitus or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 51</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness, including but not limited to, symptomatic congestive heart failure (greater than NYHA class 2), unstable angina pectoris, new-onset angina, cardiac arrhythmia, uncontrolled hypertension despite optimal medical management, seizure disorder requiring medication, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 54</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, active tuberculosis (TB), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 43</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring need for intravenous anti-microbials, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 55</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months), or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 57</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled or clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 58</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have an uncontrolled inter-current illness?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 11</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to: ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation, symptomatic congestive heart failure (requiring hospital stay within the last 6 months), myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 59</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness, including but not limited to, psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 60</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the past 6 months, invasive fungal infections, or active (acute or chronic) or uncontrolled severe infection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 61</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator&#39;s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 63</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have active and/or uncontrolled bacterial, fungal or viral infections or is still recovering from an infection or is actively febrile with uncertain etiology of febrile episode?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 64</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection including but not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent and would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 62</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 66</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness, including but not limited to, symptomatic congestive heart failure (greater than NYHA class 2), unstable angina pectoris, new-onset angina, uncontrolled hypertension despite optimal medical management, seizure disorder requiring medication, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 68</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing uncontrolled serious infection requiring IV antibiotics at the time of registration, symptomatic congestive heart failure, unstable angina pectoris, symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 65</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 67</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 69</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to,  ongoing or active infection requiring systemic treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 70</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection, including but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 17</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements, including but not limited to, ongoing uncontrolled serious infection requiring i.v. antibiotics at the time of registration or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 71</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, active infection (patients receiving an anti-microbial agent may be eligible if the patient remains afebrile and hemodynamically stable for 72 hours)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 72</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have significant (uncontrolled) cardiac conduction abnormalities?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 74</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 73</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness requiring antibiotics?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 75</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have an uncontrolled intercurrent illness, including but not limited to any uncontrolled infection or grade 2 or greater motor or sensory neuropathy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 76</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have severe uncontrolled inter-current illness?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 77</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, active and uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 78</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, active infection (patients receiving an anti-microbial agent may be eligible if the patient remains hemodynamically stable for 72 hours)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 80</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have a history of or current uncontrolled cardiovascular disease including: unstable angina, myocardial infarction, or known congestive heart failure Class II-IV within the preceding 12 months; cerebrovascular accident or transient ischemic attack within the preceding 3 months; any of the following: sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, cardiac arrest, Mobitz II second degree heart block or third degree heart block; known presence of dilated, hypertrophic, or restrictive cardiomyopathy; Left ventricular ejection fraction (LVEF) less than 50% as assessed by echocardiography (or multi-gated acquisition scan [MUGA]) performed at screening; QTc prolongation as confirmed by triplicate assessment at screening (Fridericia QTc greater than 480 milliseconds)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 81</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring need for intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 56</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, non-healing wound or ulcer, or bone fracture, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, known history of atrial fibrillation except those with 1 event that has resolved more than 1 year ago without recurrence, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 82</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 79</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to:  ongoing or active serious or systemic infection (within 14 days prior to study enrollment), active hepatitis B or C virus infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or myocardial infarction (within the past 6 months)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 83</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, serious untreated infection, symptomatic respiratory failure/congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 84</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness, including active infection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 85</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness, including but not limited to: ongoing or active infection requiring systemic therapy, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment (e.g. estimated creatinine clearance less than30ml/min), history of major surgical resection involving the stomach or small bowel, or preexisting Crohn&#39;s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea that, in the judgment of the investigator, would preclude participation in this study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 86</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness (febrile within 48 hours, or on antibiotics, if applicable), including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or serious chronic gastrointestinal conditions associated with diarrhea, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 87</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness (e.g. requiring intravenous therapy) at the discretion of the investigator?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 88</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or chronic indwelling drains?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 29</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other significant condition(s) that would make this protocol unreasonably hazardous?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 40</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 89</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of initiation of study drug, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion etc.)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 90</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have an uncontrolled inter-current illness, acute liver disease, poorly controlled liver disease, or cirrhosis?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 91</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have serious and/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance less than 30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn&#39;s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 92</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 93</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have an uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical &amp; Concomitant Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000083</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876594</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Theradex</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Theradex - CTMS 3.14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3876603</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UNCTL_DZ_CRT_COD_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>UNCTL_DZ_CRT_CD_IND</AlternateName>
        <AlternateNameType>OID, Theradex</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1617">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4380953</PUBLICID>
    <LONGNAME>Blood Sample Inadequate For WES Shipping Due To Normal DNA Yield Indicator</LONGNAME>
    <PREFERREDNAME>4380666v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator response regarding whether a blood specimen did not meet the requirements for shipping for the purpose of whole exome sequencing due to the normal specimen DNA yield.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4380666</PublicId>
      <PreferredName>2187712v1.0:4380664v1.0</PreferredName>
      <PreferredDefinition>The yes/no response regarding whether a blood specimen meets the requirements for shipping for the purpose of whole exome sequencing due to the normal specimen DNA yield.</PreferredDefinition>
      <LongName>Blood Sample Inadequate For Whole Exome Sequencing Shipping Due To Normal DNA Yield</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2187712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17610</PreferredName>
        <Version>1</Version>
        <LongName>Blood Sample</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17610</PREFERRED_NAME>
            <LONG_NAME>Blood Sample</LONG_NAME>
            <CON_ID>2202864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4380934</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4380934v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Inadequate For Whole Exome Sequencing Shipping Due To Normal DNA Extraction</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C69177</PREFERRED_NAME>
            <LONG_NAME>Inadequate</LONG_NAME>
            <CON_ID>2672206</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C64956</PREFERRED_NAME>
            <LONG_NAME>For</LONG_NAME>
            <CON_ID>2689723</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C101295</PREFERRED_NAME>
            <LONG_NAME>Whole Exome Sequencing</LONG_NAME>
            <CON_ID>4380933</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40353</PREFERRED_NAME>
            <LONG_NAME>Shipping</LONG_NAME>
            <CON_ID>2204003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C89272</PREFERRED_NAME>
            <LONG_NAME>Due To</LONG_NAME>
            <CON_ID>3111313</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14165</PREFERRED_NAME>
            <LONG_NAME>Normal</LONG_NAME>
            <CON_ID>2204843</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C449</PREFERRED_NAME>
            <LONG_NAME>DNA</LONG_NAME>
            <CON_ID>2202485</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61575</PREFERRED_NAME>
            <LONG_NAME>Extraction</LONG_NAME>
            <CON_ID>2528525</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Normal not adequate for shipp</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Normal not adequate for shipping for WES due to normal DNA yield:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4631580</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Exceptional Responder CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exceptional Responder CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1618">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4385893</PUBLICID>
    <LONGNAME>Post Radiation Therapy Fatigue Assessment Response Type</LONGNAME>
    <PREFERREDNAME>4360304v1.0:2178127v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Assessment of fatigue post treatment</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4360304</PublicId>
      <PreferredName>4360302v1.0:2233077v1.0</PreferredName>
      <PreferredDefinition>Happening at a time subsequent to a reference time; later in time or order._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Overall tiredness and lack of energy._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Post Radiation Therapy Fatigue Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4360302</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38008:C15313:C3036</PreferredName>
        <Version>1</Version>
        <LongName>Post Radiation Therapy Fatigue</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15313</PREFERRED_NAME>
            <LONG_NAME>Radiation Therapy</LONG_NAME>
            <CON_ID>2202467</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3036</PREFERRED_NAME>
            <LONG_NAME>Fatigue</LONG_NAME>
            <CON_ID>2202444</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233077</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25367</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2178127</PublicId>
      <PreferredName>ASSESS_RESP_TP</PreferredName>
      <PreferredDefinition>the response type or report regarding an assessment.</PreferredDefinition>
      <LongName>Assessment Response Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little bit</VALIDVALUE>
          <VALUEMEANING>2</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66833</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat</VALIDVALUE>
          <VALUEMEANING>3</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66834</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558081</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quite a bit</VALIDVALUE>
          <VALUEMEANING>4</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very much</VALIDVALUE>
          <VALUEMEANING>5</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66836</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558086</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all</VALIDVALUE>
          <VALUEMEANING>1</VALUEMEANING>
          <MEANINGDESCRIPTION>The smallest natural number and quantity it denotes: a single entity, unit, or object.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C66832</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558069</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-07-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561586</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately</VALIDVALUE>
          <VALUEMEANING>Moderately</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely</VALIDVALUE>
          <VALUEMEANING>EXTREMELY</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is in extreme agreement with something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561184</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered very much</VALIDVALUE>
          <VALUEMEANING>Bothered very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was very bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111751</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered quite a bit</VALIDVALUE>
          <VALUEMEANING>Bothered quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was quite a bit bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111752</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851440</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat bothered</VALIDVALUE>
          <VALUEMEANING>Somewhat bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was somewhat bothered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C125683</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851441</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little bit</VALIDVALUE>
          <VALUEMEANING>Bothered a little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was bothered just a little.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111754</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all bothered</VALIDVALUE>
          <VALUEMEANING>Not at all bothered</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is or was not bothered at all.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111755</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2851443</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2927955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No, not limited at all</VALIDVALUE>
          <VALUEMEANING>No, not limited at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No, not limited at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3442202</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a little</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Little</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115762</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes, limited a lot</VALIDVALUE>
          <VALUEMEANING>Yes, Limited a Lot</VALUEMEANING>
          <MEANINGDESCRIPTION>Yes, Limited a Lot</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-04-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly</VALIDVALUE>
          <VALUEMEANING>Slightly</VALUEMEANING>
          <MEANINGDESCRIPTION>Slightly</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not bothered at all</VALIDVALUE>
          <VALUEMEANING>Not bothered at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not bothered at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653278</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered somewhat</VALIDVALUE>
          <VALUEMEANING>Bothered somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered somewhat</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653277</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bothered a little</VALIDVALUE>
          <VALUEMEANING>Bothered a little</VALUEMEANING>
          <MEANINGDESCRIPTION>Bothered a little</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653276</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat difficult</VALIDVALUE>
          <VALUEMEANING>Somewhat difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unable to do</VALIDVALUE>
          <VALUEMEANING>UNABLE To Do</VALUEMEANING>
          <MEANINGDESCRIPTION>UNABLE To Do (Health Activity Questionnaire)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568199</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Very difficult</VALIDVALUE>
          <VALUEMEANING>Very difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>Very difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2935515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A little difficult</VALIDVALUE>
          <VALUEMEANING>A little difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A little difficult</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not difficult at all</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>Not difficult at all</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3653181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>More than twice</VALIDVALUE>
          <VALUEMEANING>Greater Than Twice</VALUEMEANING>
          <MEANINGDESCRIPTION>A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._Two times.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65134, C61584</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3983131</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Twice</VALIDVALUE>
          <VALUEMEANING>Twice</VALUEMEANING>
          <MEANINGDESCRIPTION>Twice</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2013-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Once</VALIDVALUE>
          <VALUEMEANING>Once</VALUEMEANING>
          <MEANINGDESCRIPTION>One time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2965297</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None at all</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-12-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574138</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sometimes</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Always</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A great deal</VALIDVALUE>
          <VALUEMEANING>A great deal of the time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened much of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114706</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4270273</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Most of the Time</VALIDVALUE>
          <VALUEMEANING>Most of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5731765</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To a large extent</VALIDVALUE>
          <VALUEMEANING>To Large Extent</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: Of considerable or relatively great size, extent, or capacity.: The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25332, C49508, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5731758</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To some extent</VALIDVALUE>
          <VALUEMEANING>To Some Extent</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: At least a small amount or number of, but not a large amount of, or often.: The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25332, C65099, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5731759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To a slight extent</VALIDVALUE>
          <VALUEMEANING>To Slight Extent</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: Small or little in size, quantity, or degree.: The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25332, C103807, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5731760</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Halfway between Jesse and Alex</VALIDVALUE>
          <VALUEMEANING>Halfway between Jesse and Alex</VALUEMEANING>
          <MEANINGDESCRIPTION>Halfway between Jesse and Alex</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777072</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat like Alex</VALIDVALUE>
          <VALUEMEANING>Somewhat like Alex</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat like Alex</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777073</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat like Jesse</VALIDVALUE>
          <VALUEMEANING>Somewhat like Jesse</VALUEMEANING>
          <MEANINGDESCRIPTION>Somewhat like Jesse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exactly or a lot like Alex</VALIDVALUE>
          <VALUEMEANING>Exactly or a lot like Alex</VALUEMEANING>
          <MEANINGDESCRIPTION>Exactly or a lot like Alex</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Exactly or a lot like Jesse</VALIDVALUE>
          <VALUEMEANING>Exactly or a lot like Jesse</VALUEMEANING>
          <MEANINGDESCRIPTION>Exactly or a lot like Jesse</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-04-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5777076</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely sure</VALIDVALUE>
          <VALUEMEANING>Extreme Certain</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: Having no doubts; definitely true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107561, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5801949</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moderately sure</VALIDVALUE>
          <VALUEMEANING>Moderate Certain</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: Having no doubts; definitely true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107561, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5801950</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly sure</VALIDVALUE>
          <VALUEMEANING>Slight Certain</VALUEMEANING>
          <MEANINGDESCRIPTION>Small or little in size, quantity, or degree.: Having no doubts; definitely true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107561, C103807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5801951</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not at all sure</VALIDVALUE>
          <VALUEMEANING>Not at All Certain</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.: Having no doubts; definitely true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C107561, C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3852903</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Extremely concerned</VALIDVALUE>
          <VALUEMEANING>Extreme Concern</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: A matter of interest or importance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79892, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5734744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Somewhat concerned</VALIDVALUE>
          <VALUEMEANING>Somewhat Concern</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.: A matter of interest or importance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79892, C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5734745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Slightly concerned</VALIDVALUE>
          <VALUEMEANING>Slight Concern</VALUEMEANING>
          <MEANINGDESCRIPTION>Small or little in size, quantity, or degree.: A matter of interest or importance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79892, C103807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5734746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not concerned</VALIDVALUE>
          <VALUEMEANING>Negation Concern</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: A matter of interest or importance.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79892, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5734747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Often</VALIDVALUE>
          <VALUEMEANING>Often</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something occurs frequently.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91247</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4271632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Occasionally</VALIDVALUE>
          <VALUEMEANING>Occasionally</VALUEMEANING>
          <MEANINGDESCRIPTION>Not frequently or regularly.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C151974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6341147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rarely</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you had fatigue since st</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you had fatigue since starting radiation treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1619">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4442735</PUBLICID>
    <LONGNAME>Intravaginal Medication Administered Other Specify Text</LONGNAME>
    <PREFERREDNAME>4442492v1.0:2857322v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Related to the use of Intravaginal medication_The free text field that describes another response when other is chosen from a list of values.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4442492</PublicId>
      <PreferredName>4024732v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Related to the use of Intravaginal medication</PreferredDefinition>
      <LongName>Intravaginal Medication Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4024732</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94327:C459</PreferredName>
        <Version>1</Version>
        <LongName>Intravaginal Medication</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94327</PREFERRED_NAME>
            <LONG_NAME>Intravaginal</LONG_NAME>
            <CON_ID>4024731</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C459</PREFERRED_NAME>
            <LONG_NAME>Medication</LONG_NAME>
            <CON_ID>2202423</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2857322</PublicId>
      <PreferredName>OTHR_SPEC_TXT</PreferredName>
      <PreferredDefinition>The free text field that describes another response when other is chosen from a list of values.</PreferredDefinition>
      <LongName>Other Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2857047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other, specify</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other, specify</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3029677</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>UAMS Clinical Research</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAMS New CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812848</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1620">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4456131</PUBLICID>
    <LONGNAME>Anthracycline Therapy Administration Yes No Indicator</LONGNAME>
    <PREFERREDNAME>ANTHRACYCLINE</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for information relating to the administration of an anthracycline (a member of a family of anticancer drugs that are also antibiotics) treatment regimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2845360</PublicId>
      <PreferredName>ANTH_TX_ADMIN</PreferredName>
      <PreferredDefinition>information relating to a prior anthracycline (a member of a family of anticancer drugs that are also antibiotics) treatment regimen._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</PreferredDefinition>
      <LongName>Anthracycline Therapy Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2845358</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1594:C15368</PreferredName>
        <Version>1</Version>
        <LongName>Anthracycline Antibiotic Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1594</PREFERRED_NAME>
            <LONG_NAME>Anthracycline Antineoplastic Antibiotic</LONG_NAME>
            <CON_ID>2521216</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2320521</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25409</PreferredName>
        <Version>1</Version>
        <LongName>Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anthracycline</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Anthracycline</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Anthracycline-based therapies</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Was the anthracycline dose threshold  met as part of the treatment of a cancer that was diagnosed at &lt; 22 years of age?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient receive an anthracycline other than CPX during this cycle?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1621">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4474271</PUBLICID>
    <LONGNAME>Patient Correlative Study Tissue Specimen Consent Code Indicator</LONGNAME>
    <PREFERREDNAME>COR_SDY_TIS_SPEC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/not applicable coded response regarding the patient&#39;s consent for the use of tissue samples in a correlative study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2759850</PublicId>
      <PreferredName>PT_CORS_TIS_SPE_CONS</PreferredName>
      <PreferredDefinition>information related to the patient&#39;s/participant&#39;s consent for the use of tissue samples for correlative study use.</PreferredDefinition>
      <LongName>Patient Correlative Study Tissue Specimen Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2759848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16100:C12801:C19157:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Correlative Study Tissue Specimen Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16100</PREFERRED_NAME>
            <LONG_NAME>Correlative Study</LONG_NAME>
            <CON_ID>2206187</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12801</PREFERRED_NAME>
            <LONG_NAME>Tissue</LONG_NAME>
            <CON_ID>2202489</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>SWOG CRF:Southwest Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the patient willing to pro</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the patient willing to provide tissue specimen for a correlative study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide tissue as required per protocol for central BRAF V600X mutation testing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide the biologic specimens (peripheral blood) required by protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide mandatory tissue and blood samples for correlative studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide mandatory blood samples and tissue samples for correlative studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to undergo extra blood sampling for correlative studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 7</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to undergo extra blood sampling for correlative studies?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 8</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide blood for research purposes?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 9</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide tissue and blood samples for correlative research?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to undergo mandatory biopsies (day -14, approximately 4 hours post end of irinotecan infusion and Day 1, approximately 4 hours post end of irinotecan infusion (= 3 hours post end of M6620)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 10</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is patient willing to provide mandatory blood and tissue samples for correlative studies and central pathology confirmation of surgical specimens during study participation?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Consents &amp; Contraceptive Guidelines</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876423</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1622">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4536072</PUBLICID>
    <LONGNAME>FGFR1 Gene Rearrangement Present Indicator</LONGNAME>
    <PREFERREDNAME>FGFR1_GENE_REARRANG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no response that indicates the rearrangement of the FGFR1 gene resulting in translocations with an 8p11 breakpoint. It has been described in hematologic malignancies presenting as myeloproliferative neoplasms or acute leukemias.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4534803</PublicId>
      <PreferredName>4534801v1.0:2233878v1.0</PreferredName>
      <PreferredDefinition>Rearrangement of the FGFR1 gene resulting in translocations with an 8p11 breakpoint. It has been described in hematologic malignancies presenting as myeloproliferative neoplasms or acute leukemias._Being or existing in a specified place or at the specified time.</PreferredDefinition>
      <LongName>FGFR1 Gene Rearrangement Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OHSU Knight</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4534801</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C84273</PreferredName>
        <Version>1</Version>
        <LongName>FGFR1 Gene Rearrangement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C84273</PREFERRED_NAME>
            <LONG_NAME>FGFR1 Gene Rearrangement</LONG_NAME>
            <CON_ID>4534800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Rearrangement of FGFR1</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Rearrangement of FGFR1</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1623">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4549871</PUBLICID>
    <LONGNAME>Bone Marrow Biopsy Myeloid Erythroid Ratio Character Value</LONGNAME>
    <PREFERREDNAME>BM_BX_MYL_ERY_RT_CHAR_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Ratio of myeloid to erythroid precursors in the bone marrow.  Usually 3-4:1 in a normal marrow.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3322315</PublicId>
      <PreferredName>BM_BX_MYL_ERY_RTO</PreferredName>
      <PreferredDefinition>The soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets._Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body._(MYE-eh-loyd) Pertaining to, derived from, or manifesting certain features of the bone marrow. In some cases also pertains to certain types of non-lymphocyte white blood cells found in the bone marrow, including granulocyte, monocyte, and platelet lineages. Also called myelogenous._1) Reddish in color. 2) relating to erythrocytes or their precursors._The ratio of two or more signals, typically between two channels.  Of type float. (caMAGE)_The result of an action.</PreferredDefinition>
      <LongName>Bone Marrow Biopsy Myeloid Erythroid Ratio Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206880</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12431:C15189</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3322313</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13349:C13805:C44256:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Myeloid Erythroid Ratio Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13349</PREFERRED_NAME>
            <LONG_NAME>Myeloid</LONG_NAME>
            <CON_ID>2459024</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13805</PREFERRED_NAME>
            <LONG_NAME>Erythroid</LONG_NAME>
            <CON_ID>2693267</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44256</PREFERRED_NAME>
            <LONG_NAME>Ratio</LONG_NAME>
            <CON_ID>2230969</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3241063</PublicId>
      <PreferredName>LAB_TST_RSL_VAL</PreferredName>
      <PreferredDefinition>The outcome of a laboratory test._Any single letter, number, or symbol._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Laboratory Test Result Character Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>3241003</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C36292:C68805:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Test Result Character Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C36292</PREFERRED_NAME>
            <LONG_NAME>Laboratory Test Result</LONG_NAME>
            <CON_ID>2451822</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68805</PREFERRED_NAME>
            <LONG_NAME>Character</LONG_NAME>
            <CON_ID>2671499</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Myeloid:Erythroid ratio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Myeloid:Erythroid ratio</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1624">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4551738</PUBLICID>
    <LONGNAME>Thymoma World Health Organization Stage</LONGNAME>
    <PREFERREDNAME>THYMOMA_WHO_STG</PREFERREDNAME>
    <PREFERREDDEFINITION>Code to represent the extent of a thymoma involvement in the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4551713</PublicId>
      <PreferredName>3952785v1.0:4551711v1.0</PreferredName>
      <PreferredDefinition>A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant and probably not neoplastic. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin&#39;s disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (Stedman, 25th ed)_A United Nations agency established to coordinate international health activities and to help governments improve health services._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Thymoma World Health Organization Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>LCC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3952785</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3411</PreferredName>
        <Version>1</Version>
        <LongName>Thymoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3411</PREFERRED_NAME>
            <LONG_NAME>Thymoma</LONG_NAME>
            <CON_ID>2593190</CON_ID>
            <DEFINITION_SOURCE>MSH2003_2003_05_12</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4551711</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C75419:C16899</PreferredName>
        <Version>1</Version>
        <LongName>World Health Organization Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C75419</PREFERRED_NAME>
            <LONG_NAME>World Health Organization</LONG_NAME>
            <CON_ID>2774488</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4551731</PublicId>
      <PreferredName>4551731v1.0</PreferredName>
      <PreferredDefinition>The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.</PreferredDefinition>
      <LongName>Thymoma WHO Stage</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2428501</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16899</PreferredName>
        <Version>1</Version>
        <LongName>Stage</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16899</PREFERRED_NAME>
            <LONG_NAME>Neoplasm Stage</LONG_NAME>
            <CON_ID>2202831</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>C</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage C</VALUEMEANING>
          <MEANINGDESCRIPTION>A thymic tumor exhibiting clear-cut cytologic atypia and a set of cytoarchitectural features no longer specific to the thymus, but rather analogous to those seen in carcinomas of other organs. Type C thymomas lack immature lymphocytes; whatever lymphocytes may be present are mature and usually admixed with plasma cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B3</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage B3</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of thymoma predominantly composed of epithelial cells having a round or polygonal shape and exhibiting no or mild atypia. They are admixed with a minor component of lymphocytes, resulting in a sheet-like growth of the neoplastic epithelial cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B2</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage B2</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor in which the neoplastic epithelial component appears as scattered plump cells with vesicular nuclei and distinct nucleoli among a heavy population of lymphocytes. Perivascular spaces are common and sometimes very prominent. A perivascular arrangement of tumor cells resulting in a palisading effect may be seen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>B1</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage B1</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor that resembles the normal functional thymus in that it combines large expanses having an appearance practically indistinguishable from normal thymic cortex with areas resembling thymic medulla.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>AB</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage AB</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor in which foci having the features of type A thymoma are admixed with foci rich in lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A</VALIDVALUE>
          <VALUEMEANING>Thymoma Stage A</VALUEMEANING>
          <MEANINGDESCRIPTION>A tumor composed of a population of neoplastic thymic epithelial cells having spindle/oval shape, lacking nuclear atypia, and accompanied by few or no non-neoplastic lymphocytes.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4551737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Disease Stage</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Disease Stage</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1625">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4566694</PUBLICID>
    <LONGNAME>Other Mutation Abnormality Allele Burden Percentage Value</LONGNAME>
    <PREFERREDNAME>OT_MU_AL_BUR_PER_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric response regarding the measurement of the percentage ratio between mutant and wild type genes, other than those previously specified, in hematopoietic cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4566679</PublicId>
      <PreferredName>4566677v1.0:4566670v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._one of a series of possible alternative forms of a given gene, differing in DNA sequence, and affecting the functioning of a single product._The quantity of something that is borne or carried by an individual or population.</PreferredDefinition>
      <LongName>Other Mutation Abnormality Allele Burden</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OHSU Knight</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4566677</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C45576</PreferredName>
        <Version>1</Version>
        <LongName>Other Mutation Abnormality</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45576</PREFERRED_NAME>
            <LONG_NAME>Mutation Abnormality</LONG_NAME>
            <CON_ID>2532673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4566670</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16277:C85883</PreferredName>
        <Version>1</Version>
        <LongName>Allele Burden</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16277</PREFERRED_NAME>
            <LONG_NAME>Allele</LONG_NAME>
            <CON_ID>2223183</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85883</PREFERRED_NAME>
            <LONG_NAME>Burden</LONG_NAME>
            <CON_ID>3811426</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4566691</PublicId>
      <PreferredName>4566691v1.0</PreferredName>
      <PreferredDefinition>Measurement of the ratio between mutant and wild type genes in hematopoietic cells.</PreferredDefinition>
      <LongName>Allele Burden Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OHSU Knight</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Other mutations allele burden:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Other mutations allele burden:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Variant allele fraction %</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>variant allele fraction %</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1626">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4572455</PUBLICID>
    <LONGNAME>Biopsy Specimen Pair Pretreatment Post-Treatment Availability Code Indicator</LONGNAME>
    <PREFERREDNAME>BX_PRE_POS_AV_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/not applicable coded response regarding whether a paired set of pre-treatment and post-treatment biopsy specimens are available for diagnostic examination.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4572450</PublicId>
      <PreferredName>2422833v1.0:4572448v1.0</PreferredName>
      <PreferredDefinition>A specimen obtained by biopsy, which is a process of removing tissue from living patients for diagnostic examination._A set of two similar things considered as a unit._Any relevant actions that were performed or occurred prior to a specific treatment._Definition not available._The quality of being obtainable or accessible and ready for use or service.</PreferredDefinition>
      <LongName>Biopsy Specimen Pair Pretreatment Post-Treatment Availability</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2422833</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C18202</PreferredName>
        <Version>1</Version>
        <LongName>Biopsy Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18202</PREFERRED_NAME>
            <LONG_NAME>Biopsy Specimen</LONG_NAME>
            <CON_ID>2422832</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4572448</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48046:C103339:CL024863:C25429</PreferredName>
        <Version>1</Version>
        <LongName>Pair Pretreatment Post-Treatment Availability</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48046</PREFERRED_NAME>
            <LONG_NAME>Pair</LONG_NAME>
            <CON_ID>2414570</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103339</PREFERRED_NAME>
            <LONG_NAME>Pretreatment</LONG_NAME>
            <CON_ID>3860691</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL024863</PREFERRED_NAME>
            <LONG_NAME>Post-Treatment</LONG_NAME>
            <CON_ID>2205710</CON_ID>
            <DEFINITION_SOURCE>N/A</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25429</PREFERRED_NAME>
            <LONG_NAME>Availability</LONG_NAME>
            <CON_ID>2204038</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are paired pre-treatment and</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are paired pre-treatment and post-treatment biopsies available?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical &amp; Concomitant Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876426</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1627">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4572679</PUBLICID>
    <LONGNAME>Measured Less Than or Equal 1.5 Times Upper Limit of Normal Prothrombin Time Within Anticoagulant Agent Therapeutic Range Occurrence Yes No Indicator</LONGNAME>
    <PREFERREDNAME>PT_1.5ULN_COAG_YNIND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to signify whether the result of the Prothrombin Time (PT) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CITN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4572678</PublicId>
      <PreferredName>4572676v1.0:4572672v1.0</PreferredName>
      <PreferredDefinition>Having been determined by measurement._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::1.5_The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter._A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation._On the inside; contained in._Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs._Relating to or involved in therapy._The difference between the lowest and highest numerical values; the limits or scale of variation._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Measured Less Than or Equal 1.5 Times Upper Limit of Normal Prothrombin Time Within Anticoagulant Agent Therapeutic Range Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4572676</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4572676v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Measured Less Than or Equal To Integer::1.5 Upper Limit of Normal Prothrombin Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44473</PREFERRED_NAME>
            <LONG_NAME>Measured</LONG_NAME>
            <CON_ID>2236606</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61586</PREFERRED_NAME>
            <LONG_NAME>Less Than or Equal To</LONG_NAME>
            <CON_ID>2790750</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::1.5</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25706</PREFERRED_NAME>
            <LONG_NAME>Upper Limit of Normal</LONG_NAME>
            <CON_ID>2203609</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62656</PREFERRED_NAME>
            <LONG_NAME>Prothrombin Time</LONG_NAME>
            <CON_ID>2525591</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4572672</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4572672v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Within Anticoagulant Agent Therapeutic Range Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25282</PREFERRED_NAME>
            <LONG_NAME>Within</LONG_NAME>
            <CON_ID>2206273</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C263</PREFERRED_NAME>
            <LONG_NAME>Anticoagulant Agent</LONG_NAME>
            <CON_ID>2202376</CON_ID>
            <DEFINITION_SOURCE>MSH2002_06_01</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25277</PREFERRED_NAME>
            <LONG_NAME>Therapeutic</LONG_NAME>
            <CON_ID>2204955</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38013</PREFERRED_NAME>
            <LONG_NAME>Range</LONG_NAME>
            <CON_ID>2204649</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Prothrombin Time (PT) &lt;=1.5 x</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Prothrombin Time (PT) &lt;=1.5 x institutional ULN unless patient is receiving anticoagulant therapy in which case the INR must be within the therapeutic range of intended use for the anticoagulant</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PT_1.5ULN_COAG_YNIND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1628">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4609707</PUBLICID>
    <LONGNAME>FACT-Cog Questionnaire Version 3 CogC33a How Often Past Seven Days Have to Work Harder to Express Myself Clearly Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FACTCOG_V3_COGC33A_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A persons&#39; stated observation of how often in the past 7 days they have had to work harder than usual to express themselves clearly, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4609622</PublicId>
      <PreferredName>4609571v1.0:4621693v1.0</PreferredName>
      <PreferredDefinition>The FACT-Cognitive Function questionnaire is a 37 item measure developed by Dr. David Cella to evaluate knowledge and information processing._A question about the frequency of an event or behavior._The most recent week, including today._A question about whether an individual has or had to work harder than usual to express themselves clearly._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-Cognitive Function How Often Past Week Have to Work Harder to Express Myself Clearly Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4609571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103850</PreferredName>
        <Version>1</Version>
        <LongName>FACT-Cognitive Function</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103850</PREFERRED_NAME>
            <LONG_NAME>FACT-Cognitive Function</LONG_NAME>
            <CON_ID>3640861</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4621693</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C118873:C95402:C118703:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Often Past Week Have to Work Harder to Express Myself Clearly Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118873</PREFERRED_NAME>
            <LONG_NAME>How Often Question</LONG_NAME>
            <CON_ID>4615091</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118703</PREFERRED_NAME>
            <LONG_NAME>Have to Work Harder to Express Myself Clearly Question</LONG_NAME>
            <CON_ID>4601471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4614311</PublicId>
      <PreferredName>FACT_FREQ_5PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Never) to 4 (Several Times Daily) on a Likert scale used for FACT questionnaires.</PreferredDefinition>
      <LongName>FACT Day Week Frequency Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACT-Cog:Functional Assessment of Cancer Therapy - Cognitive Function, David Cella, Ph.D., Version 3, Feb. 2008</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>About once a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of approximately once per week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118853</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Two to three times a week</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of two or three times per week.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118854</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Nearly every day</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency bordering on daily.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118855</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Several times a day</VALUEMEANING>
          <MEANINGDESCRIPTION>Scheduled or occurring at a frequency of several times per day.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118856</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-12-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4614315</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have had to work harder tha</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have had to work harder than usual to express myself clearly</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-Cognitive Function</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>I have had to work harder than usual to express myself clearly (17)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Link to Scoring and Interpretation Materials</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cog </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4718476</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000349</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cog (Functional Assessment of Cancer Therapy - Cognitive Function)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4551753</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT/FACT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Cognitive Function (Version 3)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918034</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCI Standards</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1629">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4616372</PUBLICID>
    <LONGNAME>International Neuroblastoma Pathology Classification Histology Score Category</LONGNAME>
    <PREFERREDNAME>3521379v1.0:4616371v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term that represents the International Neuroblastoma Pathology Classification (INPC) histology score category based on age, mitosis-karyorhexis index, stromal content and degree of tumor cell differentiation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3521379</PublicId>
      <PreferredName>2961432v1.0:3521377v1.0</PreferredName>
      <PreferredDefinition>Neuroblastoma is a specific type of neuroblastic tumor which is characterized by the presense of neuroblastic cells forming groups or nests separated by delicate stromal septa without prominent Schwannian stroma. (Adapted from WHO.)_A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.</PreferredDefinition>
      <LongName>Neuroblastoma International Neuroblastoma Pathology Classification Histology</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2961432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3270</PreferredName>
        <Version>1</Version>
        <LongName>Neuroblastoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3270</PREFERRED_NAME>
            <LONG_NAME>Neuroblastoma</LONG_NAME>
            <CON_ID>2479017</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3521377</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102562:C16681</PreferredName>
        <Version>1</Version>
        <LongName>International Neuroblastoma Pathology Classification Histology</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102562</PREFERRED_NAME>
            <LONG_NAME>International Neuroblastoma Pathology Classification</LONG_NAME>
            <CON_ID>3519781</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16681</PREFERRED_NAME>
            <LONG_NAME>Histology</LONG_NAME>
            <CON_ID>2202345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4616371</PublicId>
      <PreferredName>4616371v1.0</PreferredName>
      <PreferredDefinition>A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>International Neuroblastoma Pathology Classification Histologic Score Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>15</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Favorable</VALIDVALUE>
          <VALUEMEANING>Favorable</VALUEMEANING>
          <MEANINGDESCRIPTION>Expressing something as positive, advantageous or desired.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102560</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3521336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unfavorable</VALIDVALUE>
          <VALUEMEANING>Unfavorable</VALUEMEANING>
          <MEANINGDESCRIPTION>Expressing something as negative, undesired or adverse.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102561</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3521335</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Revised INPC prognostic group</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Revised INPC prognostic group (Cancer 2003)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>TARGET Instruction</Name>
        <OrganizationName/>
        <DocumentType>NOTE</DocumentType>
        <DocumentText>If INPC is missing, this is Shimada classification (JNCI 1984).</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>HCMI Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>International Neuroblastoma Pathology Classification Histology</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 01</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What is the INPC histology category of the patient&#39;s tumor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET NBL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3165864</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3070837</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET/CGCI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>TARGET</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3179562</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5650570</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>TARGET</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>NBL</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5650574</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Neuroblastoma</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5806867</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>INPC_Histology</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1630">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4617794</PUBLICID>
    <LONGNAME>Patient Histological Procedure Or Cytological Procedure Confirmation Metastatic Solid Neoplasm Diagnosis Code Indicator</LONGNAME>
    <PREFERREDNAME>CNF_MT_SOL_DX_CD_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded indicator response regarding whether a patient has histologic or cytologic confirmation of metastatic disease from a solid tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4617627</PublicId>
      <PreferredName>2233604v1.0:4617625v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Technique or procedure used for the study of the microanatomy of tissues and their cellular structure; usually involves microscopic examination of tissue slices._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Technique or procedure for manipulation of cells and analysis of cell properties and subcellular features._Having been established or verified._Having to do with metastasis, which is the spread of cancer from the primary site (place where it started) to other places in the body._An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Patient Histological Procedure Or Cytological Procedure Confirmation Metastatic Solid Neoplasm Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4617625</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4617625v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Histological Procedure Or Cytological Procedure Confirmation Metastatic Solid Neoplasm Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16680</PREFERRED_NAME>
            <LONG_NAME>Histological Procedure</LONG_NAME>
            <CON_ID>3914981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16490</PREFERRED_NAME>
            <LONG_NAME>Cytological Procedure</LONG_NAME>
            <CON_ID>3352362</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25458</PREFERRED_NAME>
            <LONG_NAME>Confirmation</LONG_NAME>
            <CON_ID>2203883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C14174</PREFERRED_NAME>
            <LONG_NAME>Metastatic</LONG_NAME>
            <CON_ID>2204914</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9292</PREFERRED_NAME>
            <LONG_NAME>Solid Neoplasm</LONG_NAME>
            <CON_ID>2593120</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have histologica</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have histologically or cytologically confirmed metastatic disease from any solid tumor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>In dose escalation, does patient have histologically or cytologically confirmed metastatic disease from any solid tumor (NOS 10029000)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If patient is in the six-patient safety cohort, does patient have histologically or cytologically confirmed advanced solid tumors that are metastatic or recurrent, and require palliative systemic treatment, for which there are either FDA approved indications for XL184 (cabozantinib) or nivolumab or have at least phase 2 data clearly indicating activity (such as RCC, HCC, MTC, melanoma, NSCLC, Head and neck cancer, Urothelial Carcinoma, SCLC, radioiodine-refractory differentiated thyroid cancer, ovarian cancer, CRPC, and TNBC)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>For the Dose-escalation phase: Does patient have histologically confirmed advanced solid tumor including but not restricted to breast cancer, gastric or gastroesophageal cancer, colon cancer, endometrial cancer, salivary gland tumors, and hepatobiliary tumors?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have histologically confirmed solid tumors with metastatic disease that has progressed after greater than or equal to 1 line of prior therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1631">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4681457</PUBLICID>
    <LONGNAME>Computed Tomography Simulation Successful Occurrence Yes No Indicator</LONGNAME>
    <PREFERREDNAME>CT_SIMUL_SUC_OCC_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Text term to signify whether a plan for radiation therapy that insures the target area is precisely located and marked using computed tomography (CT)  was successfully completed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4681456</PublicId>
      <PreferredName>CT_SIMUL_SUC_OCC</PreferredName>
      <PreferredDefinition>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._In cancer treatment, a process used to plan radiation therapy so that the target area is precisely located and marked._An event that accomplishes its intended purpose._An instance of something happening, such as an event or incident.</PreferredDefinition>
      <LongName>Computed Tomography Simulation Successful Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4681453</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17204:C16461</PreferredName>
        <Version>1</Version>
        <LongName>Computed Tomography Computer Modeling</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17204</PREFERRED_NAME>
            <LONG_NAME>Computed Tomography</LONG_NAME>
            <CON_ID>2202436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16461</PREFERRED_NAME>
            <LONG_NAME>Computer Modeling</LONG_NAME>
            <CON_ID>4681452</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4681454</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25362:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Success Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25362</PREFERRED_NAME>
            <LONG_NAME>Success</LONG_NAME>
            <CON_ID>2203809</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CT simulation success</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CT simulation success</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>caBIG</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812367</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lombardi Cancer Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812571</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2183535</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Clinical Trial Mgmt Systems</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CTMS C3D Adopter Sites</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2812625</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1632">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4682134</PUBLICID>
    <LONGNAME>Disease Assessment Type</LONGNAME>
    <PREFERREDNAME>2178332v2.0:4682131v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the examination of the body by auscultation, palpation, percussion, inspection, and olfaction for any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person._Something distinguishable as an identifiable class based on common qualities.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>SWOG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2178332</PublicId>
      <PreferredName>DZ_ASSESS</PreferredName>
      <PreferredDefinition>information related to the examination of the body by auscultation, palpation, percussion, inspection, and olfaction for any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.</PreferredDefinition>
      <LongName>Disease Assessment</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008583</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>RESPONSE</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177151</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Disease</PreferredName>
        <Version>1</Version>
        <LongName>Diseases and Disorders</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2178813</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4682131</PublicId>
      <PreferredName>4682131v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Disease Assessment Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>SWOG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT (not included in any of the above)</VALIDVALUE>
          <VALUEMEANING>CT Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other imaging studies</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2946060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI (not included in any of the above)</VALIDVALUE>
          <VALUEMEANING>MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Brain MRI/CT</VALIDVALUE>
          <VALUEMEANING>Brain CT or MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Brain CT or MRI</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572104</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total body PET-CT (without brain)</VALIDVALUE>
          <VALUEMEANING>Total Body Length Positron Emission Tomography and Computed Tomography Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>The total linear extent of the body.: An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103512, C81298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4682132</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Total body PET-CT (with brain)</VALIDVALUE>
          <VALUEMEANING>Total Body Length Positron Emission Tomography and Computed Tomography Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>The total linear extent of the body.: An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103512, C81298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4682133</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical Examination</VALIDVALUE>
          <VALUEMEANING>Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581620</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Disease assessment (indicate</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Disease assessment (indicate all methods used to document that the patient was disease-free)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1633">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4723837</PUBLICID>
    <LONGNAME>Distant New Site Description</LONGNAME>
    <PREFERREDNAME>4723822v1.0:4723835v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>the text field to describe a distant new site.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4723822</PublicId>
      <PreferredName>NEW_DIST_PD_SP</PreferredName>
      <PreferredDefinition>Far apart in space, time, or relevance from a point of origin._Having no previous example or precedent or parallel; of a kind not seen before._Named locations of or within the body._A written or verbal account, representation, statement, or explanation of something.</PreferredDefinition>
      <LongName>Distant New Anatomic Site Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4723820</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25321:C25586:C13717</PreferredName>
        <Version>1</Version>
        <LongName>Distant New Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25321</PREFERRED_NAME>
            <LONG_NAME>Distant</LONG_NAME>
            <CON_ID>2204917</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25586</PREFERRED_NAME>
            <LONG_NAME>New</LONG_NAME>
            <CON_ID>2204982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222846</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25365</PreferredName>
        <Version>1</Version>
        <LongName>Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4723835</PublicId>
      <PreferredName>NEW_DIST_PD_SP</PreferredName>
      <PreferredDefinition>the free-text field to describe a distant new site.</PreferredDefinition>
      <LongName>Specify distant new site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008549</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INV_AND_EXT_OF_DZ</PreferredName>
        <Version>1</Version>
        <LongName>Involvement and Extent of Disease</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2390957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685</PreferredName>
        <Version>1</Version>
        <LongName>Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify distant new site</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify distant new site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1634">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4723971</PUBLICID>
    <LONGNAME>Radiation Exposure Event Injury Occurrence Indicator</LONGNAME>
    <PREFERREDNAME>4723951v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not an injury due to a radiation exposure event occurred.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4723951</PublicId>
      <PreferredName>4588711v1.0:2234856v1.0</PreferredName>
      <PreferredDefinition>Exposure to radioactive materials or ionizing radiation, whether by external irradiation, contact or contamination with radioactive material, or incorporation of radioactive materials, as in the case of certain diagnostic procedures._An instance of something happening, such as an event or incident._Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity._Something that happens at a given place and time.</PreferredDefinition>
      <LongName>Radiation Exposure Event Injury Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4763651</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61398:C25499:C3671</PreferredName>
        <Version>1</Version>
        <LongName>Radiation Exposure Event Injury</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61398</PREFERRED_NAME>
            <LONG_NAME>Radiation Exposure</LONG_NAME>
            <CON_ID>2922951</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25499</PREFERRED_NAME>
            <LONG_NAME>Event</LONG_NAME>
            <CON_ID>2202572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3671</PREFERRED_NAME>
            <LONG_NAME>Injury</LONG_NAME>
            <CON_ID>2202560</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234856</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25275</PreferredName>
        <Version>1</Version>
        <LongName>Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did an injury due to a radiat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did an injury due to a radiation exposure event occur?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient experience any trauma / injuries as a result of the radiation incident?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the patient experience any trauma / injuries as a result of the radiation incident?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient experience any trauma / injuries as a result of the radiation incident?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Did the patient experience any trauma / injuries as a result of the radiation incident?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>RITNb_trma_rad_exp_inj_occ_ind</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1635">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4725504</PUBLICID>
    <LONGNAME>Wechsler Adult Intelligence Scale - Fourth Edition Coding Scaled Score Value</LONGNAME>
    <PREFERREDNAME>WAISIV_CODING_SSCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric representation of the scaled score for the Coding subtest in the Wechsler Adult Intelligence Scale, Fourth Edition.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>WAIS-IV:Wechsler Adult Intelligence Scale-Fourth Edition. Pearson, San Antonio, TX, 2008</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4725401</PublicId>
      <PreferredName>4725395v1.0:4725399v1.0</PreferredName>
      <PreferredDefinition>The fourth version of the Wechsler Adult Intelligence Scale that was published in 2008. It is a test designed to measure intelligence in individuals ranging in age from 16 to 90 years._A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that is sensitive to brain damage, dementia, age and depression. Using a paper key, the subject copies symbols that are paired with numbers within a specified time limit._Conversion of a raw score on a test to a common scale that allows for a numerical comparison.</PreferredDefinition>
      <LongName>Wechsler Adult Intelligence Scale - Fourth Edition Coding Scaled Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4725395</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120254</PreferredName>
        <Version>1</Version>
        <LongName>Wechsler Adult Intelligence Scale - Fourth Edition </LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120254</PREFERRED_NAME>
            <LONG_NAME>Wechsler Adult Intelligence Scale - Fourth Edition</LONG_NAME>
            <CON_ID>4711078</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4725399</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120363:C120341</PreferredName>
        <Version>1</Version>
        <LongName>Coding Subtest (WAIS-IV) Scaled Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120363</PREFERRED_NAME>
            <LONG_NAME>Coding Subtest (WAIS-IV)</LONG_NAME>
            <CON_ID>4724051</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120341</PREFERRED_NAME>
            <LONG_NAME>Scaled Score</LONG_NAME>
            <CON_ID>4723451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>WAIS-IV:Wechsler Adult Intelligence Scale-Fourth Edition. Pearson, San Antonio, TX, 2008</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4725335</PublicId>
      <PreferredName>WAISIV_SSCR_VAL</PreferredName>
      <PreferredDefinition>A numerical quantity that represents the conversion of a raw score on a test to a common scale in the Wechsler Adult Intelligence Scale - Fourth Edition.</PreferredDefinition>
      <LongName>WAIS-IV Scaled Score Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>WAIS-IV:Wechsler Adult Intelligence Scale-Fourth Edition. Pearson, San Antonio, TX, 2008</Origin>
      <Representation>
        <PublicId>2414933</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25712</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Wechsler Adult Intelligence S</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) - Coding scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NMDP Text 1</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Coding scaled score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1636">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4742995</PUBLICID>
    <LONGNAME>Specimen Repeat Assessment Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>SpcRptAssmtIND</PREFERREDNAME>
    <PREFERREDDEFINITION>The  yes/no/unknown/not applicable indicator related to the final result of a part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis that was perform again.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4742994</PublicId>
      <PreferredName>SpcRptAssmt</PreferredName>
      <PreferredDefinition>Information related to the final result of a part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis that was perform again.</PreferredDefinition>
      <LongName>Specimen Repeat Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177198</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Specimen</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4742992</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C47886:C25367</PreferredName>
        <Version>1</Version>
        <LongName>Repeat Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C47886</PREFERRED_NAME>
            <LONG_NAME>Repeat</LONG_NAME>
            <CON_ID>2415563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25367</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2203593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was repeat sample tested?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was repeat sample tested?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF TEXT 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is this a repeat sample?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1637">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4746666</PUBLICID>
    <LONGNAME>EORTC QLQ-C30 Version 3.0 26 Past Week Interference with Family Life due to Physical Condition or Medical Treatment Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>EORTCQLQ30_TRMTIF_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception of how often in the past week their physical condition or medical treatment interfered with family life, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3679790</PublicId>
      <PreferredName>3679696v1.0:3679788v1.0</PreferredName>
      <PreferredDefinition>A 30-item questionnaire about patient ability to function, symptoms related to the cancer and its treatment, overall health and quality of life, and perceived financial impact of cancer and its treatment._A question about whether an individual&#39;s physical condition or medical treatment interferes or has interfered with their family life._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>EORTC QLQ-C30 Past Week Interference with Family Life due to Physical Condition or Medical Treatment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3679696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C104355</PreferredName>
        <Version>1</Version>
        <LongName>The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104355</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30</LONG_NAME>
            <CON_ID>3673437</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3679788</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C104310:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Interference with Family Life due to Physical Condition or Medical Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104310</PREFERRED_NAME>
            <LONG_NAME>Interference with Family Life due to Physical Condition or Medical Treatment Question</LONG_NAME>
            <CON_ID>3673417</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EORTC QLQ-C30 Version 3</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #26 of 30</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure.  The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents.  Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has your physical condition o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has your physical condition or medical treatment interfered with your family life?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How to Use EORTC QLQ-C30</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring Manual for EORTC QLQ-C30</DocumentText>
        <URL>http://groups.eortc.be/qol/manuals</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medidata ePRO CDE</Name>
        <OrganizationName/>
        <DocumentType>ePRO Compliant</DocumentType>
        <DocumentText>This CDE has been validated for use with the Medidata Rave ePRO module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-C30 </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4997311</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000708</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-C30 Version 3</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3654500</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551586</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-C30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4728551</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711251</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-C30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000093</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6051063</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Electronic PROs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-C30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000094</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EORTCQLQ30_TRMTIF_SC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CCR</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_QSORRES_QLQC30_26</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1638">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4753703</PUBLICID>
    <LONGNAME>Outcome Satisfaction Questionnaire Current Ability to do Self-Care After Treatment Score 5 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>CS_SELF_CARE_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation after treatment of their satisfaction now with their ability to do self care activities such as washing and dressing after treatment.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCI CRF:  Duke Cancer Institute Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4751035</PublicId>
      <PreferredName>4751032v1.0:4751033v1.0</PreferredName>
      <PreferredDefinition>A set of questions and responses designed to evaluate an individual&#39;s self-reported satisfaction with the outcome of treatment._Occurring in or belonging to the present time._A question about an individual&#39;s ability to do self-care since treatment._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Outcome Satisfaction Questionnaire Current Ability to do Self-Care After Treatment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4751032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120952</PreferredName>
        <Version>1</Version>
        <LongName>Outcome Satisfaction Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120952</PREFERRED_NAME>
            <LONG_NAME>Outcome Satisfaction Questionnaire</LONG_NAME>
            <CON_ID>4743065</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4751033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C120956:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Current Ability to do Self-Care After Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120956</PREFERRED_NAME>
            <LONG_NAME>Ability to do Self-Care After Treatment Question</LONG_NAME>
            <CON_ID>4743066</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4753671</PublicId>
      <PreferredName>OS_SATISF_5_LIK_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Extremely satisfied) to 5 (Extremely dissatisfied) on a Likert scale used on Outcome Satisfaction Questionnaire.</PreferredDefinition>
      <LongName>Outcome Satisfaction Questionnaire How Satisfied Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Extremely dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is extremely dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753672</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Somewhat Dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is somewhat dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120974</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753673</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Neutral, Neither Satisfied Nor Dissatisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indication that an individual is neither satisfied nor dissatisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120972</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753674</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Somewhat Satisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is somewhat satisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120971</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753675</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Extremely satisfied</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that an individual is extremely satisfied.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120970</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4753676</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Self-care, such as washing an</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Self-care, such as washing and dressing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4748831</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prospective Sarcoma PRO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4748832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1639">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4761381</PUBLICID>
    <LONGNAME>Toronto Extremity Salvage Score, Upper Extremity Past Week Difficulty Ability to Lift a Box to an Overhead Shelf Score 5 Point Likert Scale</LONGNAME>
    <PREFERREDNAME>TESSUE_LIFTBOX_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of the difficulty in the past week lifting a box to an overhead shelf, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Toronto Extremity Salvage Score (TESS); 1996</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4761216</PublicId>
      <PreferredName>4761155v1.0:4762911v1.0</PreferredName>
      <PreferredDefinition>A self-administered questionnaire designed to assess physical disability for patients undergoing upper limb salvage surgery for musculoskeletal tumors._The most recent week, including today._Something not easily done, accomplished, comprehended, or solved._A question about an individual&#39;s ability to lift a box to an overhead shelf._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Toronto Extremity Salvage Score, Upper Extremity Past Week Difficulty Ability to Lift a Box to an Overhead Shelf Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4761155</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121219</PreferredName>
        <Version>1</Version>
        <LongName>Toronto Extremity Salvage Score, Upper Extremity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121219</PREFERRED_NAME>
            <LONG_NAME>Toronto Extremity Salvage Score, Upper Extremity</LONG_NAME>
            <CON_ID>4747400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4762911</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C62189:C121257:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Difficulty Ability to Lift a Box to an Overhead Shelf Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62189</PREFERRED_NAME>
            <LONG_NAME>Difficulty</LONG_NAME>
            <CON_ID>2503546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121257</PREFERRED_NAME>
            <LONG_NAME>Ability to Lift a Box to an Overhead Shelf Question</LONG_NAME>
            <CON_ID>4747452</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Toronto Extremity Salvage Score (TESS); 1996</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4744189</PublicId>
      <PreferredName>TESS_DIFFICULTY_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Impossible to do) to 5 (Not at all difficult) on a Likert scale used on the Toronto Extremity Salvage Score questionnaires.</PreferredDefinition>
      <LongName>Toronto Extremity Salvage Score Difficulty 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue>888</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>Toronto Extremity Salvage Score (TESS); 1996</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>888</VALIDVALUE>
          <VALUEMEANING>This task is not applicable to me</VALUEMEANING>
          <MEANINGDESCRIPTION>An assigned piece of work, usually with a time allotment.: Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660, C101129</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Not difficult at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3811316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>A little bit Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Moderately Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4761314</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Extremely Difficult</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.: Something not easily done, accomplished, comprehended, or solved.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62189, C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3811313</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Impossible to do</VALUEMEANING>
          <MEANINGDESCRIPTION>An operation in which a term denies or inverts the meaning of another term or construction.: Capable of happening or occurring.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82490, C25594</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4744212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Lifting a box to an overhead</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Lifting a box to an overhead shelf is:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4748831</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prospective Sarcoma PRO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4748832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1640">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4767361</PUBLICID>
    <LONGNAME>Musculoskeletal Tumor Society Rating Scale Lower Extremity Pain Score 6 Point Scale</LONGNAME>
    <PREFERREDNAME>MSTS_LOW_PAIN_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of lower extremity pain, using a six-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Musculoskeletal Tumor Society Rating Scale; 1993</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4767153</PublicId>
      <PreferredName>4764032v1.0:4767151v1.0</PreferredName>
      <PreferredDefinition>A physician-completed measure used to assess extremity function in patients undergoing surgery for musculoskeletal cancer. The scale scores for function and acceptance by 6 variables for upper extremities and 6 variables for lower extremities._The bottom one of two._A question about the pain in a person&#39;s extremity._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Musculoskeletal Tumor Society Rating Scale Lower Extremity Pain Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4764032</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121380</PreferredName>
        <Version>1</Version>
        <LongName>Musculoskeletal Tumor Society Rating Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121380</PREFERRED_NAME>
            <LONG_NAME>Musculoskeletal Tumor Society Rating Scale</LONG_NAME>
            <CON_ID>4763811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4767151</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25309:C121381:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Lower Extremity Pain Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25309</PREFERRED_NAME>
            <LONG_NAME>Lower</LONG_NAME>
            <CON_ID>2205319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121381</PREFERRED_NAME>
            <LONG_NAME>Extremity Pain Question</LONG_NAME>
            <CON_ID>4763812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Musculoskeletal Tumor Society Rating Scale; 1993</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4767211</PublicId>
      <PreferredName>MSTS_EX_PAIN_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Severe) to 5 (None) on a Likert scale used on the Musculoskeletal Tumor Rating Scale questionnaire.</PreferredDefinition>
      <LongName>MSTS Extremity Pain Score 6 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>Musculoskeletal Tumor Society Rating Scale; 1993</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Severe (continuous disabling pain; continuous use of narcotic or equivalent medication)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person&#39;s extremity pain is severe: continuous and disabling and requiring continuous use of narcotic (or equivalent) medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121395</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Moderate (pain is not continuous but is disabling when present; occasional or intermittent use of narcotic or equivalent medication)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person&#39;s extremity pain is at a moderate level: not continuous but disabling when present and requiring occasional or intermittent use of narcotic (or equivalent) medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121394</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Intermediate - Extremity Pain Between Modest and Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person&#39;s extremity pain is at an intermediate level between modest and moderate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121393</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Modest (intermittent pain that is not disabling; intermittent use of anti-inflammatory or non-narcotic)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person&#39;s extremity pain is modest: intermittent but not disabling and requiring intermittent use of anti-inflammatory or non-narcotic medication for pain relief.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Intermediate - Extremity Pain Between None and Modest</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person&#39;s extremity pain is at an intermediate level: between none and modest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>None (no use of medication)</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that a person has no extremity pain and is using no medication.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4767217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pain Score:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pain Score:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4748831</PublicId>
          <ContextName>DCI</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Prospective Sarcoma PRO</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sarcoma PRO</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4748832</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1641">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4770577</PUBLICID>
    <LONGNAME>Person Body Mass Index Percentile Meet Clinical Trial Eligibility Criteria Number</LONGNAME>
    <PREFERREDNAME>PtBMIPct</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric value related to a persons BMI percentile for the purpose of eligibility on a clinical trial</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4770550</PublicId>
      <PreferredName>Pers_Body_Perc_Clin</PreferredName>
      <PreferredDefinition>A human being.:An individual&#39;s weight in kilograms divided by the square of the height in meters._Any of the 99 numbered points that divide an ordered set of scores into 100 parts each of which contains one-hundredth of the total._Satisfy the requirements or expectations of._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person Body Mass Index Percentile Meet Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>11518293</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16358:C48919:C87531:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Body Mass Index Percentile Fulfill Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16358</PREFERRED_NAME>
            <LONG_NAME>Body Mass Index</LONG_NAME>
            <CON_ID>2202323</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48919</PREFERRED_NAME>
            <LONG_NAME>Percentile</LONG_NAME>
            <CON_ID>2423425</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C87531</PREFERRED_NAME>
            <LONG_NAME>Fulfill</LONG_NAME>
            <CON_ID>3017448</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3247302</PublicId>
      <PreferredName>3247302v1.0</PreferredName>
      <PreferredDefinition>Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NIDCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233101</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25337</PreferredName>
        <Version>1</Version>
        <LongName>Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, observed, recorded; or reported as unknown by the data contributor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570901</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2991873</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2.5 mm</VALIDVALUE>
          <VALUEMEANING>2.5 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>2.5 mm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2.0 mm</VALIDVALUE>
          <VALUEMEANING>2.0 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>2.0 mm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1.8 mm</VALIDVALUE>
          <VALUEMEANING>1.8 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>1.8 mm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1.6 mm</VALIDVALUE>
          <VALUEMEANING>1.6 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>1.6 mm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1.4 mm</VALIDVALUE>
          <VALUEMEANING>1.4 mm</VALUEMEANING>
          <MEANINGDESCRIPTION>1.4 mm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2011-06-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3245437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BMI percentile for age</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>BMI percentile for age</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Phase 1/Pilot Consortium</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3303197</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1642">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4785672</PUBLICID>
    <LONGNAME>Route of Administration Performed Type</LONGNAME>
    <PREFERREDNAME>ROA_PERF_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>The path or method through which a product is administered into the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCI CRF Standards</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4783887</PublicId>
      <PreferredName>2452897v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Designation of the part of the body through which or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Route of Administration Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2452897</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38114</PreferredName>
        <Version>1</Version>
        <LongName>Route of Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38114</PREFERRED_NAME>
            <LONG_NAME>Route of Administration</LONG_NAME>
            <CON_ID>2437663</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCI CRF Standards</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4784372</PublicId>
      <PreferredName>ROA_TP</PreferredName>
      <PreferredDefinition>Designation of the part of the body through which or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration._Something distinguishable as an identifiable class based on common qualities.</PreferredDefinition>
      <LongName>Route of Administration Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2486825</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38114:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Route of Administration Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38114</PREFERRED_NAME>
            <LONG_NAME>Route of Administration</LONG_NAME>
            <CON_ID>2437663</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraperitoneal</VALIDVALUE>
          <VALUEMEANING>Intraperitoneal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within the peritoneal cavity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38258</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578020</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Oral</VALIDVALUE>
          <VALUEMEANING>Oral</VALUEMEANING>
          <MEANINGDESCRIPTION>The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38288</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562296</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rectal</VALIDVALUE>
          <VALUEMEANING>Rectal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-12-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581011</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Subcutaneous</VALIDVALUE>
          <VALUEMEANING>Subcutaneous Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38299</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sublingual</VALIDVALUE>
          <VALUEMEANING>Sublingual Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration beneath the tongue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577977</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Topical</VALIDVALUE>
          <VALUEMEANING>Topical Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>The application of a drug to a certain area of the skin or mucous membrane (including the intra-organ application), or other tissue locally, so that the agent will take effect on the surface and/or on the underlying tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38304</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577941</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transdermal</VALIDVALUE>
          <VALUEMEANING>Transdermal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a substance through the dermal layer of the skin into the systemic circulation by diffusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>The route of drug administration is unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4633411</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intrauterine</VALIDVALUE>
          <VALUEMEANING>Intrauterine Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within the uterus.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4784374</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraurethral</VALIDVALUE>
          <VALUEMEANING>Intraurethral Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a drug directly into the urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38271</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Route of drug administration not specified on this list.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38290</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3698078</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraarticular</VALIDVALUE>
          <VALUEMEANING>Intraarticular Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within a joint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38223</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intrathecal</VALIDVALUE>
          <VALUEMEANING>Intrathecal</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38267</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574002</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intravenous</VALIDVALUE>
          <VALUEMEANING>Intravenous Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within or into a vein or veins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38276</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasal</VALIDVALUE>
          <VALUEMEANING>Nasal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38284</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2660005</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nasogastric</VALIDVALUE>
          <VALUEMEANING>Nasogastric</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration through the nose and into the stomach, usually by means of a tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38285</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568390</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ophthalmic</VALIDVALUE>
          <VALUEMEANING>Ophthalmic Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a drug to the external eye.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577938</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Dermal</VALIDVALUE>
          <VALUEMEANING>Cutaneous Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration to the skin.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38675</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endotracheal</VALIDVALUE>
          <VALUEMEANING>Endotracheal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Endotracheal drug administration involves the introduction of the agent directly through the endotracheal tube in an intubated patient. Generally this route is considered as a last resort for drug administration, and provides a fast, effective means of drug delivery in a patient who requires immediate medication. Plasma levels obtained via endotracheal administration are considerably less than those obtained with an equal dosage administered intravenously or intraosseously. Endotracheal administration must be followed by hyper-insufflation of the lungs to promote optimal drug absorption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38208</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-11-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577075</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gastrostomy</VALIDVALUE>
          <VALUEMEANING>Gastrostomy Tube</VALUEMEANING>
          <MEANINGDESCRIPTION>Drug administration through a gastric fistula or a surgically created artificial opening into the stomach through the abdominal wall with insertion of a tube.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38199</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-06-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraarterial</VALIDVALUE>
          <VALUEMEANING>Intraarterial Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within an artery or arteries.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38222</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578037</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intradermal</VALIDVALUE>
          <VALUEMEANING>Intradermal Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within the dermis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38238</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578084</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intrahepatic</VALIDVALUE>
          <VALUEMEANING>Intrahepatic Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Intrahepatic route of drug administration is a method of drug delivery within the liver, predominantly via hepatic vein or artery. Regimen might be more beneficial then systemic one by delivering a higher dose of drug to the liver and reducing overall systemic exposure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38248</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3629942</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intramuscular</VALIDVALUE>
          <VALUEMEANING>Intramuscular Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within a muscle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578009</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inhalation</VALIDVALUE>
          <VALUEMEANING>Inhalation Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577932</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Interstitial</VALIDVALUE>
          <VALUEMEANING>Interstitial Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration to or in the interstices of a tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38219</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4784373</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraventricular</VALIDVALUE>
          <VALUEMEANING>Intraventricular Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within a ventricle.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-07-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578016</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intravesical</VALIDVALUE>
          <VALUEMEANING>Intravesical Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration within the bladder.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38278</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-07-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577982</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intratumoral</VALIDVALUE>
          <VALUEMEANING>Intratumoral Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>The administration of a drug within or introduced directly into a tumor. Method allows to achieve high concentration of the agent in the tumor and delay drug release in systemic circulation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38269</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-01-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578029</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Otic</VALIDVALUE>
          <VALUEMEANING>Auricular Route of Administration</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration to or by way of the ear.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38192</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transmucosal</VALIDVALUE>
          <VALUEMEANING>Transmucosal Route</VALUEMEANING>
          <MEANINGDESCRIPTION>Administration of a substance to the mucosa; often resulting in systemic action due to absorption.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38283</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2635256</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vaginal</VALIDVALUE>
          <VALUEMEANING>Vaginal Route</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the vagina or to any sheath.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575266</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Route</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Route</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1643">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4786749</PUBLICID>
    <LONGNAME>Research Biospecimen Collection Schedule Interval</LONGNAME>
    <PREFERREDNAME>RSCH_COLL_SCHED_ITVL</PREFERREDNAME>
    <PREFERREDDEFINITION>Time point during or at which a research specimen was collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4786685</PublicId>
      <PreferredName>4786683v1.0:2233116v1.0</PreferredName>
      <PreferredDefinition>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered._Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The act of gathering things together; having been brought together in one place._Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The act of gathering things together; having been brought together in one place._An ordered list of times at which things are planned to occur.</PreferredDefinition>
      <LongName>Research Biospecimen Collection Schedule</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4786683</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15429:C70699:C25453</PreferredName>
        <Version>1</Version>
        <LongName>Research Activity Biospecimen Collection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15429</PREFERRED_NAME>
            <LONG_NAME>Research Activity</LONG_NAME>
            <CON_ID>2528433</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233116</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25211</PreferredName>
        <Version>1</Version>
        <LongName>Schedule</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25211</PREFERRED_NAME>
            <LONG_NAME>Schedule</LONG_NAME>
            <CON_ID>2203792</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4786731</PublicId>
      <PreferredName>COLL_SCHED_ITVL</PreferredName>
      <PreferredDefinition>The period of time or the distance separating two instances, events, or occurrences.</PreferredDefinition>
      <LongName>Collection Schedule Interval</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>30</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>C3D:Central Cancer Clinical Database</Origin>
      <Representation>
        <PublicId>2525196</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25543</PreferredName>
        <Version>1</Version>
        <LongName>Interval</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25543</PREFERRED_NAME>
            <LONG_NAME>Interval</LONG_NAME>
            <CON_ID>2202600</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 15 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 15 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 15 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786732</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 14 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 14 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 14 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786733</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 13 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 13 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 13 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786734</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 12 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 12 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 12 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786735</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 11 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 11 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 11 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786736</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr 10 Archive</VALIDVALUE>
          <VALUEMEANING>Yr 10 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr 10 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786737</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  9 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  9 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  9 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  8 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  8 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  8 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786739</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  7 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  7 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  7 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  6 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  6 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  6 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  5 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  5 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  5 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  4 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  4 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  4 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  3 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  3 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  3 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786744</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yr  2 Archive</VALIDVALUE>
          <VALUEMEANING>Yr  2 Archive</VALUEMEANING>
          <MEANINGDESCRIPTION>Yr  2 Archive</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mo 12 RCR Assay</VALIDVALUE>
          <VALUEMEANING>Mo 12 RCR Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>Mo 12 RCR Assay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mo  6 RCR Assay</VALIDVALUE>
          <VALUEMEANING>Mo  6 RCR Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>Mo  6 RCR Assay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786747</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mo  3 RCR Assay</VALIDVALUE>
          <VALUEMEANING>Mo  3 RCR Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>Mo  3 RCR Assay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-04-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4786748</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scheduled Collection</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Scheduled Collection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1644">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4788351</PUBLICID>
    <LONGNAME>Linear Analogue Self-Assessment 6 3 Past Week Overall Physical Well Being Score 11 Point Scale</LONGNAME>
    <PREFERREDNAME>LASA6_PHYSICAL_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception of their overall physical well being during the past week, using an eleven point Linear Analogue scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>LASA:Linear Analogue Self Assessment, Mayo Foundation for Medical Research, 1996.</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4783232</PublicId>
      <PreferredName>4783223v1.0:3690957v1.0</PreferredName>
      <PreferredDefinition>A six-item, self-reported questionnaire  designed to measure general well-being and the major domains of quality of life (mental, physical, emotional, social, and spiritual well-being) using a linear analogue scale to describe the assessment responses._The most recent week, including today._A question about an individual&#39;s overall physical well being._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Linear Analogue Self-Assessment-6 Past Week Overall Physical Well Being Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4783223</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C121507</PreferredName>
        <Version>1</Version>
        <LongName>Linear Analogue Self-Assessment-6</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121507</PREFERRED_NAME>
            <LONG_NAME>Linear Analogue Self-Assessment-6</LONG_NAME>
            <CON_ID>4770971</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3690957</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C104596:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Overall Physical Well Being Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104596</PREFERRED_NAME>
            <LONG_NAME>Overall Physical Well-Being Question</LONG_NAME>
            <CON_ID>3690129</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4783211</PublicId>
      <PreferredName>4783211v1.0</PreferredName>
      <PreferredDefinition>A scale for the subjective scoring of the intensity of a person&#39;s feelings that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</PreferredDefinition>
      <LongName>LASA-6 Feeling Intensity Score 11 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>10</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>LASA:Linear Analogue Self Assessment, Mayo Foundation for Medical Research, 1996.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 10 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121520</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783212</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 9</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 9 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121519</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 8 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121518</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783214</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 7 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121517</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 6</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 6 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121516</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 5 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121515</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783217</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 4 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121514</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 3 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121513</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783219</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 2 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783220</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 1 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121511</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Feeling Intensity Score 0</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 0 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121510</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4783222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How would you describe your o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How would you describe your overall physical well being?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these elements. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>LASA 6</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #3 of 6</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medidata ePRO CDE</Name>
        <OrganizationName/>
        <DocumentType>ePRO Compliant</DocumentType>
        <DocumentText>This CDE has been validated for use with the Medidata Rave ePRO module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Standard CRFs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2859963</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Generic Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551591</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measure CRF</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718286</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2192345</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Data Standards</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LASA-6</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4997331</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3690872</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>LASA</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LASA Questionnaire</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3690873</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LASA 6 (Linear Analogue Self Assessment 6)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4779114</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Generic Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000428</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Generic Core Domains</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711235</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LASA-6</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000297</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6051063</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Electronic PROs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>LASA-6</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918049</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>caBIG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1645">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4788391</PUBLICID>
    <LONGNAME>Patient Current Clinical Study Protocol Enrollment Consent Yes No Unknown Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>PtCurPrtEnrCsnt</PREFERREDNAME>
    <PREFERREDDEFINITION>a yes/no/unknown/not applicable indicator related to the registration of a patient to the current research activity of a clinical study is permitted.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4788377</PublicId>
      <PreferredName>2177068v1.0:4788375v1.0</PreferredName>
      <PreferredDefinition>information related to the registration of a patient to the current research activity of a clinical study is permitted.</PreferredDefinition>
      <LongName>Patient Current Clinical Study Protocol Enrollment Consent</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4788375</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25320:C37948:C25460</PreferredName>
        <Version>1</Version>
        <LongName>Current Clinical Study Protocol Enrollment Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25320</PREFERRED_NAME>
            <LONG_NAME>Clinical Study Protocol</LONG_NAME>
            <CON_ID>2202702</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37948</PREFERRED_NAME>
            <LONG_NAME>Enrollment</LONG_NAME>
            <CON_ID>2203918</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was patient consented to and</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was patient consented to and enrolled on the most current version of protocol?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient consent on Amendment #1 or later?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1646">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4798219</PUBLICID>
    <LONGNAME>Genetic Variation Nomenclature Standard</LONGNAME>
    <PREFERREDNAME>Gene_Nome_Gene_Nome_Stan</PREFERREDNAME>
    <PREFERREDDEFINITION>Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents._A system of words used in a particular discipline._Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents._A system of words used in a particular discipline._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4798218</PublicId>
      <PreferredName>Gene_Nome</PreferredName>
      <PreferredDefinition>Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents._A system of words used in a particular discipline.</PreferredDefinition>
      <LongName>Genetic Variation Nomenclature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4798215</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17248</PreferredName>
        <Version>1</Version>
        <LongName>Genetic Variation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17248</PREFERRED_NAME>
            <LONG_NAME>Genetic Variation</LONG_NAME>
            <CON_ID>2223975</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4798216</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48298</PreferredName>
        <Version>1</Version>
        <LongName>Nomenclature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48298</PREFERRED_NAME>
            <LONG_NAME>Nomenclature</LONG_NAME>
            <CON_ID>2684619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4797986</PublicId>
      <PreferredName>Gene_Nome_Stan</PreferredName>
      <PreferredDefinition>Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents._A system of words used in a particular discipline._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.</PreferredDefinition>
      <LongName>Genetic Variation Nomenclature Standard</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>4797985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17248:C48298:C81893</PreferredName>
        <Version>1</Version>
        <LongName>Genetic Variation Nomenclature Standard</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17248</PREFERRED_NAME>
            <LONG_NAME>Genetic Variation</LONG_NAME>
            <CON_ID>2223975</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48298</PREFERRED_NAME>
            <LONG_NAME>Nomenclature</LONG_NAME>
            <CON_ID>2684619</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C81893</PREFERRED_NAME>
            <LONG_NAME>Standard</LONG_NAME>
            <CON_ID>3170302</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Genetic Variation Nomenclature Standard does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Genetic Variation Nomenclature Standard does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Rare Genetic Conditions</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4809611</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1647">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4798592</PUBLICID>
    <LONGNAME>Patient RECIST Metastatic Disease Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>RECIST_MET_DZ_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response indicating that a patient meets the criteria with regards to a diagnosis of progressive metastatic disease as defined by RECIST criteria.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4794122</PublicId>
      <PreferredName>2233604v1.0:4794120v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (&quot;respond&quot;), stay the same (&quot;stable&quot;), or worsen (&quot;progression&quot;) during treatments. (from www.recist.com)_A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient RECIST Metastatic Disease Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4794120</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49164:C3261:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Response Evaluation Criteria in Solid Tumors Metastatic Neoplasm Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49164</PREFERRED_NAME>
            <LONG_NAME>Response Evaluation Criteria in Solid Tumors</LONG_NAME>
            <CON_ID>2426966</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3261</PREFERRED_NAME>
            <LONG_NAME>Metastatic Neoplasm</LONG_NAME>
            <CON_ID>2443854</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does patient have progressive</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does patient have progressive metastatic disease defined as new or progressive lesions on cross-sectional imaging, including one measurable site of disease (according to RECIST criteria)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If patient has locally recurrent, unresectable disease, is at least one lymph node metastasis either regional or non-regional that is measurable by RECIST v1.1?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient have unresectable or metastatic measurable disease on imaging for RECIST 1.1 determination within 28 days of registration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876352</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Inclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Disease Status &amp; Genetics</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876422</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1648">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4821858</PUBLICID>
    <LONGNAME>EORTC QLQ-BN20 49 Past Week Feel Unsteady on Feet Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>BN20_UNSTEADY_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception of how often in the past week they felt unsteady on their feet, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-BN20:European Organization for Research and Treatment of Cancer Quality of Life Group, Quality of Life Questionnaire-Brain Neoplasm BN20, 1994</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4821522</PublicId>
      <PreferredName>4821451v1.0:4821520v1.0</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._A question about whether an individual feels or felt unsteady on their feet._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Neoplasm 20 Past Week Feel Unsteady on Feet Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4821451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C121794</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Neoplasm 20</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121794</PREFERRED_NAME>
            <LONG_NAME>Quality of Life Questionnaire-Brain Neoplasm 20</LONG_NAME>
            <CON_ID>4812411</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4821520</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C121811:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Feel Unsteady on Feet Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C121811</PREFERRED_NAME>
            <LONG_NAME>Feel Unsteady on Feet Question</LONG_NAME>
            <CON_ID>4812424</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EORTC QLQ-BN20:European Organization for Research and Treatment of Cancer Quality of Life Group, Quality of Life Questionnaire-Brain Neoplasm BN20, 1994</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you feel unsteady on your</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you feel unsteady on your feet?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How to Use EORTC QLQ-BN20</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring Manual</DocumentText>
        <URL>http://groups.eortc.be/qol/manuals</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Question Sequence including QLQ-30</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #49 of 50</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-BN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4811891</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-BN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000513</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BN20_UNSTEADY_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1649">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4824311</PUBLICID>
    <LONGNAME>Somatic Oncogene Mutation Type</LONGNAME>
    <PREFERREDNAME>SOM_ONCOG_MUT_TP</PREFERREDNAME>
    <PREFERREDDEFINITION>A list of genetic mutation.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4812074</PublicId>
      <PreferredName>SmtcMtnTp</PreferredName>
      <PreferredDefinition>Information related to genetic alterations found in the neoplastic lesions of the human body.</PreferredDefinition>
      <LongName>Somatic Mutation Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4812072</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C94322:C16885</PreferredName>
        <Version>1</Version>
        <LongName>Somatic Mutation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C94322</PREFERRED_NAME>
            <LONG_NAME>Somatic</LONG_NAME>
            <CON_ID>4812071</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16885</PREFERRED_NAME>
            <LONG_NAME>Mutation</LONG_NAME>
            <CON_ID>2224010</CON_ID>
            <DEFINITION_SOURCE>CABIO</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2223243</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4824292</PublicId>
      <PreferredName>OncgMutTp</PreferredName>
      <PreferredDefinition>A list of genes that normally direct cell growth, but if mutated or overexpressed in a dominant fashion, it can release the cell from normal restraints on growth causing detectable and heritable changes in the genetic material that triggering a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.</PreferredDefinition>
      <LongName>Oncogene Mutation Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>4824291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16936:C0026882:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Oncogene Mutation Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16936</PREFERRED_NAME>
            <LONG_NAME>Oncogene</LONG_NAME>
            <CON_ID>2680068</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C0026882</PREFERRED_NAME>
            <LONG_NAME>Mutation</LONG_NAME>
            <CON_ID>3448538</CON_ID>
            <DEFINITION_SOURCE>MSH</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>UMLS_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PTPN11</VALIDVALUE>
          <VALUEMEANING>PTPN11</VALUEMEANING>
          <MEANINGDESCRIPTION>PTPN11</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4824293</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KRAS</VALIDVALUE>
          <VALUEMEANING>KRAS</VALUEMEANING>
          <MEANINGDESCRIPTION>KRAS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4824294</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NRAS</VALIDVALUE>
          <VALUEMEANING>NRAS</VALUEMEANING>
          <MEANINGDESCRIPTION>NRAS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4824295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NF1</VALIDVALUE>
          <VALUEMEANING>NF1</VALUEMEANING>
          <MEANINGDESCRIPTION>NF1</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4830960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CBL</VALIDVALUE>
          <VALUEMEANING>CBL</VALUEMEANING>
          <MEANINGDESCRIPTION>CBL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4830961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None</VALIDVALUE>
          <VALUEMEANING>None</VALUEMEANING>
          <MEANINGDESCRIPTION>No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6149013</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2960664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ALK</VALIDVALUE>
          <VALUEMEANING>ALK Gene</VALUEMEANING>
          <MEANINGDESCRIPTION>This gene is involved in brain development and neuronal specificity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3234670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>TP53</VALIDVALUE>
          <VALUEMEANING>TP53 Gene</VALUEMEANING>
          <MEANINGDESCRIPTION>This gene plays a critical role in cell cycle regulation and has tumor suppressor activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5438715</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ATRX</VALIDVALUE>
          <VALUEMEANING>ATRX Gene</VALUEMEANING>
          <MEANINGDESCRIPTION>This gene plays a role in the regulation of both chromatin remodeling and transcription.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74976</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3772156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mutation Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Mutation Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Mutation Type COG 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have any of the following genetic mutations?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CFR Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did the tumor have any of the following genetic mutations?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1650">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4826369</PUBLICID>
    <LONGNAME>Etoposide And/Or Teniposide Administered Indicator</LONGNAME>
    <PREFERREDNAME>4826365v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not etoposide and/or teniposide was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4826365</PublicId>
      <PreferredName>4826363v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)_Used to indicate that either or both of two items or options may be valid._An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Etoposide And/Or Teniposide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4826363</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C491:C48928:C857</PreferredName>
        <Version>1</Version>
        <LongName>Etoposide And/Or Teniposide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C491</PREFERRED_NAME>
            <LONG_NAME>Etoposide</LONG_NAME>
            <CON_ID>2521226</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C857</PREFERRED_NAME>
            <LONG_NAME>Teniposide</LONG_NAME>
            <CON_ID>2521284</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was etoposide and/or teniposi</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was etoposide and/or teniposide administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>VP-16 / VM-26</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>VP-16 / VM-26</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1651">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4841991</PUBLICID>
    <LONGNAME>Stage I Stage II Stage III Stage IV Refractory Progressive Disease Recurrent Disease Mycosis Fungoides Sezary Syndrome Post Greater Than or Equal To One Systemic Treatment Regimen Progressive Disease Yes No Indicator</LONGNAME>
    <PREFERREDNAME>S1_4_MF_PRG_DZ_YN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes/no response to indicate if a patient with Stage I, II, III or IV refractory, relapsed or progressive Sezary Syndrome or Mycosis Fungoides after at least one standard systemic therapy regimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CITN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4841973</PublicId>
      <PreferredName>STG1_4_REL_MF_SZ_PS_REG</PreferredName>
      <PreferredDefinition>Invasive cancer confined to the original anatomic site of growth without lymph node involvement._Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites._Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites._Cancer that has spread to distant anatomic sites beyond its original site of growth._Not responding to treatment._A disease process that is increasing in scope or severity._The return of a disease after a period of remission._A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)_Happening at a time subsequent to a reference time; later in time or order._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways_Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._The smallest natural number and quantity it denotes: a single entity, unit, or object._A treatment plan that specifies the dosage, the schedule, and the duration of treatment.</PreferredDefinition>
      <LongName>Stage I Stage II Stage III Stage IV Refractory Progressive Disease Recurrent Disease Mycosis Fungoides Sezary Syndrome Post Greater Than or Equal To One Systemic Treatment Regimen Progressive Disease</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CITN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4842071</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4842071v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Stage I Stage II Stage III Stage IV Refractory Progressive Disease Recurrent Disease Mycosis Fungoides</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27966</PREFERRED_NAME>
            <LONG_NAME>Stage I</LONG_NAME>
            <CON_ID>2205259</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>7</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28054</PREFERRED_NAME>
            <LONG_NAME>Stage II</LONG_NAME>
            <CON_ID>2205262</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27970</PREFERRED_NAME>
            <LONG_NAME>Stage III</LONG_NAME>
            <CON_ID>2205263</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C27971</PREFERRED_NAME>
            <LONG_NAME>Stage IV</LONG_NAME>
            <CON_ID>2205264</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38014</PREFERRED_NAME>
            <LONG_NAME>Refractory</LONG_NAME>
            <CON_ID>2205322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C35571</PREFERRED_NAME>
            <LONG_NAME>Progressive Disease</LONG_NAME>
            <CON_ID>2202776</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38155</PREFERRED_NAME>
            <LONG_NAME>Recurrent Disease</LONG_NAME>
            <CON_ID>2202887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3246</PREFERRED_NAME>
            <LONG_NAME>Mycosis Fungoides</LONG_NAME>
            <CON_ID>2204836</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4571552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4571552v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Post Greater Than or Equal To Integer::1 Systemic Therapy Treatment Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38008</PREFERRED_NAME>
            <LONG_NAME>Post</LONG_NAME>
            <CON_ID>2204992</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61583</PREFERRED_NAME>
            <LONG_NAME>Greater Than or Equal To</LONG_NAME>
            <CON_ID>2673224</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45255::1</PREFERRED_NAME>
            <LONG_NAME>Integer</LONG_NAME>
            <CON_ID>2433736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15698</PREFERRED_NAME>
            <LONG_NAME>Systemic Therapy</LONG_NAME>
            <CON_ID>2202843</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15697</PREFERRED_NAME>
            <LONG_NAME>Treatment Regimen</LONG_NAME>
            <CON_ID>2203773</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patients must have Stage IB-I</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patients must have Stage IB-IVB MF/SS (maximal stage since diagnosis), and have relapsed, are refractory, or progressed after at least one standard systemic therapy</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CITN-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient has Stage IB-IVB MF/SS, which has relapsed, is refractory or has progressed after at least one standard systemic therapy. Maximal stage since diagnosis will determine eligibility</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5999742</PublicId>
          <ContextName>CITN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5999747</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CITN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>S1_4_MF_PRG_DZ_YN_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1652">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4845129</PUBLICID>
    <LONGNAME>Bioelectrical Impedance Dual X-ray Absorptometry Total Body Fat Measurement Percentage Value</LONGNAME>
    <PREFERREDNAME>DXA_FAT_PERC_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>The numeric response that represents the percent of total body fat content calculated using measurements using a Dual X-ray Absorptometry.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCI CRF:  Duke Cancer Institute Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2199528</PublicId>
      <PreferredName>BIA_BDY_FAT</PreferredName>
      <PreferredDefinition>Measurement of total body fat as determined by either dual xray absorptometry or bioelectrical impedence. [Manually-curated]</PreferredDefinition>
      <LongName>Bioelectrical Impedance Dual X-ray Absorptometry Total body fat Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2697721</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48789:C43545:CL196773</PreferredName>
        <Version>1</Version>
        <LongName>Dual X-ray Absorptometry Bioelectric Impedance Analysis Total body fat</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48789</PREFERRED_NAME>
            <LONG_NAME>Dual X-ray Absorptiometry</LONG_NAME>
            <CON_ID>2435014</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C43545</PREFERRED_NAME>
            <LONG_NAME>Bioelectric Impedance Analysis</LONG_NAME>
            <CON_ID>2693108</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL196773</PREFERRED_NAME>
            <LONG_NAME>Total body fat</LONG_NAME>
            <CON_ID>2204603</CON_ID>
            <DEFINITION_SOURCE>No value exists.</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2697685</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37990</PreferredName>
        <Version>1</Version>
        <LongName>Measurement - Retired</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37990</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2534954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4842774</PublicId>
      <PreferredName>ADIPOSE_TIS_PERC_VAL</PreferredName>
      <PreferredDefinition>Connective tissue composed of fat cells lodged in the meshes of areolar tissue._A fraction or ratio with 100 understood as the denominator._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Adipose Tissue Percentage Value</LongName>
      <Version>1.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
      <Representation>
        <PublicId>4842773</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12472:C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Adipose Tissue Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12472</PREFERRED_NAME>
            <LONG_NAME>Adipose Tissue</LONG_NAME>
            <CON_ID>2202563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>% Fat</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>% Fat</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1653">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4845351</PUBLICID>
    <LONGNAME>Circulating Plasma Cell Assessment Method Type</LONGNAME>
    <PREFERREDNAME>4845272v1.0:2015230v3.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The circulating plasma cell method of evaluation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4845272</PublicId>
      <PreferredName>4770555v1.0:2465182v1.0</PreferredName>
      <PreferredDefinition>information related to circulating plasma cell assessment</PreferredDefinition>
      <LongName>Circulating Plasma Cell Assessment</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4770555</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C114278</PreferredName>
        <Version>1</Version>
        <LongName>Circulating Plasma Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C114278</PREFERRED_NAME>
            <LONG_NAME>Circulating Plasma Cell</LONG_NAME>
            <CON_ID>4232668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2465182</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217</PreferredName>
        <Version>1</Version>
        <LongName>Assessed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2015230</PublicId>
      <PreferredName>ASSESS_METH_TP</PreferredName>
      <PreferredDefinition>the enumerated list of methods of conducting diagnostic evaluation.</PreferredDefinition>
      <LongName>Assessment Method Type</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone scan</VALIDVALUE>
          <VALUEMEANING>Bone Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A nuclear imaging method used to evaluate pathological bone metabolism. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17646</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558319</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT scan</VALIDVALUE>
          <VALUEMEANING>CT Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest x-ray</VALIDVALUE>
          <VALUEMEANING>Chest X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>Chest X-Ray</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570173</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical examination</VALIDVALUE>
          <VALUEMEANING>CLINICAL EXAMINATION (PE)</VALUEMEANING>
          <MEANINGDESCRIPTION>CLINICAL EXAMINATION (PE)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558517</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytology</VALIDVALUE>
          <VALUEMEANING>Cytology</VALUEMEANING>
          <MEANINGDESCRIPTION>Cytology; the branch of biology that studies the structure and function of cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16491</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558589</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine needle aspiration biopsy</VALIDVALUE>
          <VALUEMEANING>FINE NEEDLE ASPIRATION BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy by a fine needle aspiration technique</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2005-04-13</PVENDDATE>
          <VMPUBLICID>2574518</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fine needle aspiration biopsy, with wire localization</VALIDVALUE>
          <VALUEMEANING>FINE NEEDLE ASPIRATION BIOPSY WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>Biopsy by a fine needle aspiration technique using wire localization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2005-04-13</PVENDDATE>
          <VMPUBLICID>2574519</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histology</VALIDVALUE>
          <VALUEMEANING>HISTOLOGY</VALUEMEANING>
          <MEANINGDESCRIPTION>HISTOLOGY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16681</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558883</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incisional biopsy</VALIDVALUE>
          <VALUEMEANING>INCISIONAL BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which part of a lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15386</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558933</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Incisional biopsy, with wire localization</VALIDVALUE>
          <VALUEMEANING>INCISIONAL BIOPSY, WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>INCISIONAL BIOPSY, WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558934</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI (NMR)</VALIDVALUE>
          <VALUEMEANING>MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE>2015-10-29</PVENDDATE>
          <VMPUBLICID>2559279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mastectomy</VALIDVALUE>
          <VALUEMEANING>Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgical removal of the breast.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15277</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Needle biopsy (tru-cut or core)</VALIDVALUE>
          <VALUEMEANING>NEEDLE BIOPSY (TRU-CUT OR CORE)</VALUEMEANING>
          <MEANINGDESCRIPTION>NEEDLE BIOPSY (TRU-CUT OR CORE)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559497</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Needle biopsy (tru-cut or core), with wire localization)</VALIDVALUE>
          <VALUEMEANING>NEEDLE BIOPSY (TRU-CUT OR CORE), WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>NEEDLE BIOPSY (TRU-CUT OR CORE), WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559498</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not evaluated</VALIDVALUE>
          <VALUEMEANING>Not Evaluated</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25214, C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570488</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Resection/re-excision of lumpectomy margins</VALIDVALUE>
          <VALUEMEANING>RESECTION/RE-EXCISION OF LUMPECTOMY MARGINS</VALUEMEANING>
          <MEANINGDESCRIPTION>RESECTION/RE-EXCISION OF LUMPECTOMY MARGINS</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiral CT scan</VALIDVALUE>
          <VALUEMEANING>SPIRAL CT SCAN</VALUEMEANING>
          <MEANINGDESCRIPTION>SPIRAL CT SCAN</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560090</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor markers</VALIDVALUE>
          <VALUEMEANING>Tumor Markers</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor Markers</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570768</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>Very high frequency sound. </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64384</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570770</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autopsy</VALIDVALUE>
          <VALUEMEANING>Autopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Autopsy; an examination and dissection of a dead body to determine cause of death or the changes produced by disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25153</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567287</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axillary dissection</VALIDVALUE>
          <VALUEMEANING>AXILLARY DISSECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to the armpit area, including the lymph nodes that are located there.: The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15227, C13351</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558265</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ductal lavage</VALIDVALUE>
          <VALUEMEANING>DUCTAL LAVAGE</VALUEMEANING>
          <MEANINGDESCRIPTION>DUCTAL LAVAGE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL054589</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ductoscopic biopsy</VALIDVALUE>
          <VALUEMEANING>DUCTOSCOPIC BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>DUCTOSCOPIC BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558694</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy or lumpectomy</VALIDVALUE>
          <VALUEMEANING>EXCISIONAL BIOPSY OR LUMPECTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>EXCISIONAL BIOPSY OR LUMPECTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558745</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy or lumpectomy, with wire localization</VALIDVALUE>
          <VALUEMEANING>LUMPECTOMY, WITH WIRE LOCALIZATION</VALUEMEANING>
          <MEANINGDESCRIPTION>LUMPECTOMY, WITH WIRE LOCALIZATION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559103</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, ascites</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, ASCITES</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, ASCITES</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558792</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, cerebrospinal fluid</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, CEREBROSPINAL FLUID</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, CEREBROSPINAL FLUID</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558793</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fluid cytology, pleural</VALIDVALUE>
          <VALUEMEANING>FLUID CYTOLOGY, PLEURAL</VALUEMEANING>
          <MEANINGDESCRIPTION>FLUID CYTOLOGY, PLEURAL</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558794</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Nipple fluid</VALIDVALUE>
          <VALUEMEANING>NIPPLE FLUID</VALUEMEANING>
          <MEANINGDESCRIPTION>NIPPLE FLUID</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559514</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other, specify</VALIDVALUE>
          <VALUEMEANING>Other specify</VALUEMEANING>
          <MEANINGDESCRIPTION>Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C25685</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570538</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Prophalactic mastectomy</VALIDVALUE>
          <VALUEMEANING>Prophylactic Mastectomy</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery to reduce the risk of developing breast cancer by removing one or both breasts before disease develops.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C94445</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559913</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sentinel node biopsy</VALIDVALUE>
          <VALUEMEANING>SENTINEL NODE BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>SENTINEL NODE BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560027</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparotomy</VALIDVALUE>
          <VALUEMEANING>LAPAROTOMY</VALUEMEANING>
          <MEANINGDESCRIPTION>LAPAROTOMY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15266</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559025</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laparoscopy</VALIDVALUE>
          <VALUEMEANING>Laparoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(lap-a-RAHS-ko-pee) The insertion of a thin, lighted tube (called a laparoscope) through the abdominal wall to inspect the inside of the abdomen and remove tissue samples.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16969</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559024</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy other</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE>2012-07-10</PVENDDATE>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preoperative CT scan</VALIDVALUE>
          <VALUEMEANING>CT Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE>2018-06-06</PVENDDATE>
          <VMPUBLICID>2570151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EKG</VALIDVALUE>
          <VALUEMEANING>EKG</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure to assess heart function using an electrocardiogram (EKG) device</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-08-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Biopsy</VALIDVALUE>
          <VALUEMEANING>Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15189</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574093</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathologic</VALIDVALUE>
          <VALUEMEANING>Pathologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or altered by or manifesting disease or pathology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559724</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical exam</VALIDVALUE>
          <VALUEMEANING>PHYSICAL EXAM</VALUEMEANING>
          <MEANINGDESCRIPTION>PHYSICAL EXAM</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559805</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiograph</VALIDVALUE>
          <VALUEMEANING>RADIOGRAPH</VALUEMEANING>
          <MEANINGDESCRIPTION>RADIOGRAPH</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559945</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bilateral mammogram</VALIDVALUE>
          <VALUEMEANING>Bilateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Affecting both sides of the body or a matched pair of organs.: A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C13332, C20178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-11-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2563569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bimanual examination</VALIDVALUE>
          <VALUEMEANING>BIMANUAL EXAMINATION</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to, or performed by, both hands.: A formal or careful inspection of an object or subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131902, C25433</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558295</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection</VALIDVALUE>
          <VALUEMEANING>DIRECT INSPECTION</VALUEMEANING>
          <MEANINGDESCRIPTION>DIRECT INSPECTION</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraoperative ultrasound</VALIDVALUE>
          <VALUEMEANING>INTRAOPERATIVE ULTRASOUND</VALUEMEANING>
          <MEANINGDESCRIPTION>INTRAOPERATIVE ULTRASOUND</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558991</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgery</VALIDVALUE>
          <VALUEMEANING>Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17173</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560125</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Primary surgery</VALIDVALUE>
          <VALUEMEANING>PRIMARY SURGERY</VALUEMEANING>
          <MEANINGDESCRIPTION>Surgery of curative intent to remove tumor or malignant tissue</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-10-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X-ray</VALIDVALUE>
          <VALUEMEANING>X-RAY </VALUEMEANING>
          <MEANINGDESCRIPTION>X-RAY </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2002-12-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562460</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET scan</VALIDVALUE>
          <VALUEMEANING>PET Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Positron Emission Tomography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2003-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565860</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gallium scan</VALIDVALUE>
          <VALUEMEANING>Gallium Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Gallium Scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38087</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2003-05-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not done</VALIDVALUE>
          <VALUEMEANING>NOT DONE</VALUEMEANING>
          <MEANINGDESCRIPTION>NOT DONE</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>CL281691</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Differential</VALIDVALUE>
          <VALUEMEANING>DIFFERENTIAL</VALUEMEANING>
          <MEANINGDESCRIPTION>evaluation by differential</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visual assessment</VALIDVALUE>
          <VALUEMEANING>VISUAL ASSESSMENT</VALUEMEANING>
          <MEANINGDESCRIPTION>evaluation by visual assessment</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical</VALIDVALUE>
          <VALUEMEANING>Clinical</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the examination and treatment of patients.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-02-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568063</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytologic confirmation</VALIDVALUE>
          <VALUEMEANING>Cytologic confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Cytologic confirmation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569470</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytoscopy</VALIDVALUE>
          <VALUEMEANING>Cytoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination of the bladder and urethra using a cystoscope, inserted into the urethra. A cystoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569472</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cystoscopy</VALIDVALUE>
          <VALUEMEANING>Cystoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the urinary bladder or urethra.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16482</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-06-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569349</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Palpation</VALIDVALUE>
          <VALUEMEANING>Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient&#39;s body to examine the size, consistency, texture, location and tenderness of an organ or body part.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569463</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Visualization</VALIDVALUE>
          <VALUEMEANING>Visualization</VALUEMEANING>
          <MEANINGDESCRIPTION>Visualization</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569464</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colposcopy</VALIDVALUE>
          <VALUEMEANING>Colposcopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Colposcopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569465</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy</VALIDVALUE>
          <VALUEMEANING>Endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>(en-DAHS-ko-pee) The use of a thin, lighted tube (called an endoscope) to examine the inside of the body.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16546</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2558723</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI scan</VALIDVALUE>
          <VALUEMEANING>MRI scan</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569466</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain film/X-ray without contrast</VALIDVALUE>
          <VALUEMEANING>Plain film/X-ray without contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Plain film/X-ray without contrast</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain film/X-ray with contrast</VALIDVALUE>
          <VALUEMEANING>Plain film/X-ray with contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Plain film/X-ray with contrast</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radioisotope scan</VALIDVALUE>
          <VALUEMEANING>Radioisotope scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Radioisotope scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569467</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histologic confirmation</VALIDVALUE>
          <VALUEMEANING>Histologic confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Histologic confirmation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-05-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569471</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histologic</VALIDVALUE>
          <VALUEMEANING>histologic</VALUEMEANING>
          <MEANINGDESCRIPTION>histologic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570861</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic</VALIDVALUE>
          <VALUEMEANING>Radiographic</VALUEMEANING>
          <MEANINGDESCRIPTION>The use of Radiographic methodology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-01-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568067</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tumor Marker</VALIDVALUE>
          <VALUEMEANING>Tumor Marker</VALUEMEANING>
          <MEANINGDESCRIPTION>Tumor Marker</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2004-11-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572218</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mammogram</VALIDVALUE>
          <VALUEMEANING>Mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20178</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Echocardiogram</VALIDVALUE>
          <VALUEMEANING>Echocardiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An image of the heart produced by ultrasonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37945</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566540</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUGA scan</VALIDVALUE>
          <VALUEMEANING>MUGA Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A multi-gated acquisition (MUGA) scan and a form of radionuclide imaging that provides a comprehensive look at blood flow and the function of the lower chambers of the heart ventricles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2005-10-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2571740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contrast enhanced CT scan/CT perfusion exam</VALIDVALUE>
          <VALUEMEANING>CONTRAST ENHANCED CT SCAN</VALUEMEANING>
          <MEANINGDESCRIPTION>Contrast enhanced computed tomography scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2005-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2575809</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MSK Nomogram</VALIDVALUE>
          <VALUEMEANING>Nomograms</VALUEMEANING>
          <MEANINGDESCRIPTION>Graphical representation of a statistical model containing scales for calculating the prognostic weight of a value for each individual variable. Nomograms are instruments that can be used to predict outcomes using specific clinical parameters. They use ALGORITHMS that incorporate several variables to calculate the predicted probability that a patient will achieve a particular clinical endpoint.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C1450294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN></MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-03-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2578375</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/CT scan</VALIDVALUE>
          <VALUEMEANING>Positron Emission Tomography and Computed Tomography Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103512</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-09-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580798</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSA Assessment</VALIDVALUE>
          <VALUEMEANING>Prostate-Specific Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Alternate isoforms of the single-chain 261-aa 30-kD Kallikrein 3 (Prostate Specific Antigen) glycoprotein precursor are encoded by human KLK3 Gene (Kallikrein Family). Frameshifted isoform 2 has a shorter distinct C-terminus. A serine protease in seminal plasma, PSA may function in liquefaction of seminal coagulum by (preferential Tyr-X) cleavage of seminal vesicle protein. Kallikrein proteases have diverse functions. Mounting evidence implicates kallikreins in carcinogenesis; some have potential as cancer biomarkers. The serum level of PSA is useful in diagnosis and monitoring of prostatic carcinoma. (from LocusLink, Swiss-Prot, OMIM, and NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17525</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580427</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Digital rectal exam</VALIDVALUE>
          <VALUEMEANING>Digital Rectal Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>Digital rectal examination.  An examination in which a doctor inserts a lubricated, gloved finger into the rectum to feel for abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17631</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-10-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581179</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral Axilla Ultrasound</VALIDVALUE>
          <VALUEMEANING>Ipsilateral Axilla Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>Ipsilateral Axilla Ultrasound</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2006-10-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581522</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT/MRI scan</VALIDVALUE>
          <VALUEMEANING>CT/MRI scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Computed tomographic and magnetic image resonance scan</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2604641</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Endoscopy with biopsy</VALIDVALUE>
          <VALUEMEANING>Endoscopy with biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopy with biopsy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-03-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2604642</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiological</VALIDVALUE>
          <VALUEMEANING>Radiologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.: The use of radiation (such as x-rays) or other imaging technologies (such as ultrasound and magnetic resonance imaging) to diagnose or treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17059, C118849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2640362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchoscopy</VALIDVALUE>
          <VALUEMEANING>Bronchoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which a thin, lighted tube is inserted through the nose or mouth. NCI Concept Code C16366</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16366</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2566854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper endoscopy</VALIDVALUE>
          <VALUEMEANING>Upper Endoscopy Esophagogastroduodenoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Upper Endoscopy Esophagogastroduodenoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574269</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonoscopy</VALIDVALUE>
          <VALUEMEANING>Colonoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the luminal surface of the colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16450</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2569094</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Sigmoidoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-05-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Proctoscopy/sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Proctoscopy/sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Examination of the anus or sigmoid colon using a flexible tube enclosing a light and camera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2672935</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal MRI</VALIDVALUE>
          <VALUEMEANING>Abdominal MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or related to, the abdomen.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C25342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2673036</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transrectal ultrasound</VALIDVALUE>
          <VALUEMEANING>Transrectal Ultrasound</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure that uses sound waves to create a video image of the prostate gland. A small, lubricated probe placed into the rectum releases sound waves, which create echoes as they enter the prostate. Prostate tumors sometimes create echoes that are different from normal prostate tissue. The echoes that bounce back are sent to a computer that translates the pattern of echoes into a picture of the prostate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581622</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chest CT</VALIDVALUE>
          <VALUEMEANING>Chest Radiography</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray examination of the chest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38103</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580421</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal CT</VALIDVALUE>
          <VALUEMEANING>Abdominal CT-scan</VALUEMEANING>
          <MEANINGDESCRIPTION>Of, or related to, the abdomen.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25342, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2667062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic CT</VALIDVALUE>
          <VALUEMEANING>Pelvic CT</VALUEMEANING>
          <MEANINGDESCRIPTION>Pelvic computed tomography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-08-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2671035</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Evaluated but no disease found</VALIDVALUE>
          <VALUEMEANING>Evaluated but no disease found</VALUEMEANING>
          <MEANINGDESCRIPTION>Evaluated but no disease found</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2738850</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Core biopsy</VALIDVALUE>
          <VALUEMEANING>Core Needle Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15680</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Excisional biopsy with frozen section</VALIDVALUE>
          <VALUEMEANING>Excisional biopsy with frozen section</VALUEMEANING>
          <MEANINGDESCRIPTION>Excisional biopsy with frozen section</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2722512</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Skin biopsy</VALIDVALUE>
          <VALUEMEANING>Skin biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>the removal of a piece of skin to diagnose or rule out an illness.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2722511</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Contralateral mammogram</VALIDVALUE>
          <VALUEMEANING>Contralateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray picture of the breast not involved with the primary tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2697040</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ipsilateral mammogram</VALIDVALUE>
          <VALUEMEANING>Ipsilateral mammogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray picture of the breast with the primary tumor.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2007-11-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2697041</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CEA</VALIDVALUE>
          <VALUEMEANING>Carcinoembryonic Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Carcinoembryonic antigen. A substance that is sometimes found in an increased amount in the blood of people with certain cancers.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25159</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2633456</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvic MRI</VALIDVALUE>
          <VALUEMEANING>Pelvic Magnetic Resonance imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A procedure in which a magnet linked to a computer is used to create detailed pictures of areas inside the pelivs. Also called nuclear magnetic resonance </MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Colonscopy/proctoscopy</VALIDVALUE>
          <VALUEMEANING>Colonscopy/proctoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>An examination of the rectum using a thin, lighted tube called a proctoscope or An examination of the inside of the colon using a thin, lighted tube (called a colonoscope).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-01-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2717947</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>CT of Abdomen/Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>CT of Abdomen/Pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2765399</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Abdomen/Pelvis</VALIDVALUE>
          <VALUEMEANING>MRI of Abdomen/Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Abdomen/Pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2008-07-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2765400</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Diagnostic Imaging</VALIDVALUE>
          <VALUEMEANING>Diagnostic Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation..</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16502</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573670</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow cytometry, cerebrospinal fluid</VALIDVALUE>
          <VALUEMEANING>Flow cytometry, cerebrospinal fluid</VALUEMEANING>
          <MEANINGDESCRIPTION>Flow cytometry, cerebrospinal fluid</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2824966</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IVP</VALIDVALUE>
          <VALUEMEANING>Intravenous Pyelogram</VALUEMEANING>
          <MEANINGDESCRIPTION>Intravenous Pyelogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573974</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lymphangiogram</VALIDVALUE>
          <VALUEMEANING>Lymphangiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An x-ray image of the lymphatic system using a radiopaque imaging agent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-01-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573980</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiologic</VALIDVALUE>
          <VALUEMEANING>Radiologic</VALUEMEANING>
          <MEANINGDESCRIPTION>Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.: The use of radiation (such as x-rays) or other imaging technologies (such as ultrasound and magnetic resonance imaging) to diagnose or treat disease.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17059, C118849</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-10-07</PVBEGINDATE>
          <PVENDDATE>2016-01-05</PVENDDATE>
          <VMPUBLICID>2640362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2-D Echocardiogram</VALIDVALUE>
          <VALUEMEANING>2-D Echocardiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>The property of being measured and described using two orthogonal directions.: An image of the heart produced by ultrasonography.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C37945, C48282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-03-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2847201</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serological</VALIDVALUE>
          <VALUEMEANING>Serology</VALUEMEANING>
          <MEANINGDESCRIPTION>Pertaining to the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41264</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-02-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562238</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT w/contrast</VALIDVALUE>
          <VALUEMEANING>CT w/contrast</VALUEMEANING>
          <MEANINGDESCRIPTION>Computed tomography that uses a contrast agent to visualize anatomic structures.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137805</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-05-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2876591</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ECHO</VALIDVALUE>
          <VALUEMEANING>ECHO</VALUEMEANING>
          <MEANINGDESCRIPTION>Echocardiogram</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2009-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2951058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET</VALIDVALUE>
          <VALUEMEANING>Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2919109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Biopsy</VALIDVALUE>
          <VALUEMEANING>BONE MARROW BIOPSY</VALUEMEANING>
          <MEANINGDESCRIPTION>BONE MARROW BIOPSY</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15193</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2562182</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone Marrow Aspirate</VALIDVALUE>
          <VALUEMEANING>Aspirate, Bone Marrow</VALUEMEANING>
          <MEANINGDESCRIPTION>(as-per-AY-shun) The removal of a small sample of bone marrow (usually from the hip) through a needle for examination under a microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15644</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-08-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573943</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral Blood Counts</VALIDVALUE>
          <VALUEMEANING>Peripheral Blood Counts</VALUEMEANING>
          <MEANINGDESCRIPTION>Peripheral Blood Counts</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2010-01-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2978652</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Spiral CT</VALIDVALUE>
          <VALUEMEANING>Spiral CT</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970362</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Plain X-Ray</VALIDVALUE>
          <VALUEMEANING>X-Ray</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-energy radiation.  In low doses, x-rays are used to diagnose diseases by making pictures of the inside of the body.  In high doses, x-rays are used to treat cancer.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2009-12-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2970340</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunophenotyping (4 Color flow cytometry)</VALIDVALUE>
          <VALUEMEANING>Four Color Flow Cytometry Immunophenotype</VALUEMEANING>
          <MEANINGDESCRIPTION>A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation.: A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.: Immunophenotype is the characterization of a set of cells according to the antigens expressed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20072, C16585, C37927, C66835</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3027791</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Heavy chain gene rearrangement</VALIDVALUE>
          <VALUEMEANING>Immunoglobulin Heavy Chain Gene Rearrangement</VALUEMEANING>
          <MEANINGDESCRIPTION>A protein complex that consists of two heavy chains (gamma, alpha, delta, epsilon or mu). The larger of the two immunoglobulin chain types determines the immunoglobulin class (G, A, D, E or M, respectively). The heavy chain molecules exhibit the same structure and composition, which consists of constant, variable, and hypervariable regions._Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16611, C16717</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3027713</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytogenetic analysis by FISH</VALIDVALUE>
          <VALUEMEANING>Cytogenetic Analysis Fluorescence in situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563, C18280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028332</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical and/or hematologic analysis</VALIDVALUE>
          <VALUEMEANING>Clinical And/Or Hematologic Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Having to do with the examination and treatment of patients.: Used to indicate that either or both of two items or options: Pertaining to or related to the blood and blood-forming organs.: Analysis; examination and interpretation.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25391, C62780, C48928, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3028333</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Cytogenetic Analysis</VALIDVALUE>
          <VALUEMEANING>Cytogenetic Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18280</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2861225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular Analysis</VALIDVALUE>
          <VALUEMEANING>Molecular Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C19770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-04-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2861224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DEXA scan</VALIDVALUE>
          <VALUEMEANING>Scan, Dual-Energy X-ray Absorpitometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for scanning bone and measuring bone mineral density (BMD). A DXA scanner produces 2 X-ray beams, each with different energy levels. One beam is high energy while the other is low energy. The amount of x-rays that pass through the bone is measured for each beam. This will vary depending on the thickness of the bone. Based on the difference between the 2 beams, the bone density can be measured.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48789</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-06-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574279</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caliper measurement by clinical exam</VALIDVALUE>
          <VALUEMEANING>Vernier Caliper Measurement Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>A medical device that is a combination of ruler and caliper that can measure the distance between two points. The configuration of this device permits the measurement of internal dimensions.: Measurement; the size or magnitude of something.: A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989, C25209, C81184</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2010-08-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3131893</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Culture</VALIDVALUE>
          <VALUEMEANING>Culture Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Any laboratory procedure for growing microorganisms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25300</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577346</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Aspergillus galactomannan assay</VALIDVALUE>
          <VALUEMEANING>ELISA</VALUEMEANING>
          <MEANINGDESCRIPTION>A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attatched, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16553</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3173905</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>KOH / calcofluor stain</VALIDVALUE>
          <VALUEMEANING>Calcofluor White Stain</VALUEMEANING>
          <MEANINGDESCRIPTION>A fluorescent stain that binds to the cell wall.  It is used for the detection of fungi, parasites, and yeasts, using fluorescent microscopy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C85880</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-01-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3181377</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/Conventional CT</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. : A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237468</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PET/Spiral CT</VALIDVALUE>
          <VALUEMEANING>Spiral CT Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44): A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C20645</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2011-05-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3237469</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Spine</VALIDVALUE>
          <VALUEMEANING>MRI of Spine</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Spine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of Brain</VALIDVALUE>
          <VALUEMEANING>MRI of Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of Brain</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-02-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3392216</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urine catecholamines</VALIDVALUE>
          <VALUEMEANING>Urine catecholamines</VALUEMEANING>
          <MEANINGDESCRIPTION>Urine catecholamines</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3566835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bone marrow morphology</VALIDVALUE>
          <VALUEMEANING>Bone marrow morphology</VALUEMEANING>
          <MEANINGDESCRIPTION>Bone marrow morphology</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565826</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIBG scintiscan</VALIDVALUE>
          <VALUEMEANING>MIBG scintiscan</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging test that uses a radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine) tracer and a special scanner to find or confirm the presence of pheochromocytoma and neuroblastoma, which are tumors of specific types of nervous tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-05-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3458598</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CA-125 assay</VALIDVALUE>
          <VALUEMEANING>CA-125 assay</VALUEMEANING>
          <MEANINGDESCRIPTION>CA-125 assay</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2012-06-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3485237</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic Imaging</VALIDVALUE>
          <VALUEMEANING>Radiograph Imaging Technique</VALUEMEANING>
          <MEANINGDESCRIPTION>An image produced on a radiosensitive surface by x-ray radiation that has penetrated and passed through a structure.: Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17369, C60727</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-11-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3626193</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymerase Chain Reaction</VALIDVALUE>
          <VALUEMEANING>Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3234683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>in situ hybridization</VALIDVALUE>
          <VALUEMEANING>in situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17562</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-10-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2939763</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flow Cytometry</VALIDVALUE>
          <VALUEMEANING>Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2974014</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Physical examination with imaging</VALIDVALUE>
          <VALUEMEANING>Imaging With Physical Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.: Used to indicate the presence of something or someone.: A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual&#39;s health assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20989, C62355, CL024911</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-09-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906854</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Microscopic evaluation</VALIDVALUE>
          <VALUEMEANING>Microscopic evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>Microscopic evaluation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Macroscopic evaluation</VALIDVALUE>
          <VALUEMEANING>Macroscopic evaluation</VALUEMEANING>
          <MEANINGDESCRIPTION>Macroscopic evaluation</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-01-30</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4120632</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Antigen</VALIDVALUE>
          <VALUEMEANING>Antigen</VALUEMEANING>
          <MEANINGDESCRIPTION>Any substance that appears foreign or potentially adverse to the body and elicits immune response.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C268</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3167779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI + DWI</VALIDVALUE>
          <VALUEMEANING>MRI DWI</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.: A diffusion MRI technique in which diffusion-sensitizing gradients are applied to the imaging sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C111116, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4253231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shell Vial Culture</VALIDVALUE>
          <VALUEMEANING>Shell Vial Culture</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for virus culture and detection in which a virus sample is mixed with a susceptible cell type and then centrifuged into a single layer of cells. Following a short incubation, viral growth is determined using immunological detection techniques.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114597</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4262871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T2</VALIDVALUE>
          <VALUEMEANING>MRI T2</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the transverse relaxation of a tissue&#39;s net magnetization vector; it measures the time taken for spinning protons to lose phase coherence among the nuclei spinning perpendicular to the main field. This MRI sequence is produced by using a longer time to echo (TE) and repetition time (TR) than a T1-weighted sequence.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180729</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4231311</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T1gad</VALIDVALUE>
          <VALUEMEANING>MRI T1gad</VALUEMEANING>
          <MEANINGDESCRIPTION>Magnetic resonance imaging (MRI) of the T1gad signal intensity ratio (SIR)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-03-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4231312</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI T1gad and MRI T2</VALIDVALUE>
          <VALUEMEANING>MRI T1gad and MRI T2</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI T1gad and MRI T2</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-07-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4377743</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Neck</VALIDVALUE>
          <VALUEMEANING>CT of Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>CT of Neck</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2014-10-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4512871</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Combination of these methods</VALIDVALUE>
          <VALUEMEANING>Combination of these methods</VALUEMEANING>
          <MEANINGDESCRIPTION>Combination of these methods</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669452</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection / endoscopy under anesthesia</VALIDVALUE>
          <VALUEMEANING>Direct inspection / endoscopy under anesthesia</VALUEMEANING>
          <MEANINGDESCRIPTION>Direct inspection / endoscopy under anesthesia</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Direct inspection / in office endoscopy</VALIDVALUE>
          <VALUEMEANING>Direct inspection / in office endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Direct inspection / in office endoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-01-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4669454</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Fiberoptic nasopharyngolaryngoscopy</VALIDVALUE>
          <VALUEMEANING>Fiberoptic nasopharyngolaryngoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Fiberoptic nasopharyngolaryngoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4726691</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Laryngoscopy</VALIDVALUE>
          <VALUEMEANING>Laryngoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Endoscopic examination of the larynx.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16781</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2832055</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WBC differential</VALIDVALUE>
          <VALUEMEANING>WBC differential</VALUEMEANING>
          <MEANINGDESCRIPTION>A hematologic procedure for the evaluation of the qualitative and quantitative characteristics of the white cells in peripheral blood smears and bone marrow aspirates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C98493</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4845352</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Peripheral smear</VALIDVALUE>
          <VALUEMEANING>Peripheral smear</VALUEMEANING>
          <MEANINGDESCRIPTION>A sample of blood applied in a thin film to a microscope slide for study under a microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C79903</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4845353</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Myelin-Associated Glycoprotein</VALIDVALUE>
          <VALUEMEANING>Myelin-Associated Glycoprotein</VALUEMEANING>
          <MEANINGDESCRIPTION>An autoantibody directed against myelin-associated glycoprotein (MAG). It is associated with active demyelination in peripheral neuropathy and is detected in about 50% of patients with IgM&amp;#8200;paraproteinemia and may occur in some patients with multiple sclerosis, Guillain-Barre syndrome, chronic polyneuropathy, or myasthenia gravis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121771</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4811579</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MIBG</VALIDVALUE>
          <VALUEMEANING>MIBG</VALUEMEANING>
          <MEANINGDESCRIPTION>A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C87757</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565821</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRV</VALIDVALUE>
          <VALUEMEANING>MRV</VALUEMEANING>
          <MEANINGDESCRIPTION>Magnetic resonance venography</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723853</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRA</VALIDVALUE>
          <VALUEMEANING>MRI-Based Angiogram</VALUEMEANING>
          <MEANINGDESCRIPTION>An image of blood vessels constructed using magnetic resonance imaging.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C114867</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-24</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4723855</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>None of the above</VALIDVALUE>
          <VALUEMEANING>None of the above</VALUEMEANING>
          <MEANINGDESCRIPTION>None of the choices above are suitable.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C133298</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-06-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577583</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary cytology with mass visualized during upper tract endoscopy</VALIDVALUE>
          <VALUEMEANING>Urinary cytology with mass visualized during upper tract endoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Urinary cytology with mass visualized during upper tract endoscopy</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</VALIDVALUE>
          <VALUEMEANING>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Urinary cytology with 3-D upper urinary tract mass on Cross-Sectional Imaging</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Image-guided Biopsy</VALIDVALUE>
          <VALUEMEANING>Image-guided Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis, using imaging technology.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15652</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4719251</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Electromyography</VALIDVALUE>
          <VALUEMEANING>Electromyography</VALUEMEANING>
          <MEANINGDESCRIPTION>An assessment of skeletal muscle function and nerve control, obtained by recording and studying the intrinsic electrical properties of the muscles.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C38056</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4821875</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SQUID</VALIDVALUE>
          <VALUEMEANING>Superconducting Quantum Interference Device</VALUEMEANING>
          <MEANINGDESCRIPTION>A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C124066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5039992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver Biopsy</VALIDVALUE>
          <VALUEMEANING>Liver Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue from the liver for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51677</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2831213</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI</VALIDVALUE>
          <VALUEMEANING>Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-10-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5039993</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Disease specific molecular marker</VALIDVALUE>
          <VALUEMEANING>Disease specific molecular marker</VALUEMEANING>
          <MEANINGDESCRIPTION>Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.::2: Clearly and explicitly stated.::2: A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16342, C38024, C2991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5084231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chimerism testing</VALIDVALUE>
          <VALUEMEANING>Chimerism testing</VALUEMEANING>
          <MEANINGDESCRIPTION>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C62582, C25294</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-11-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043868</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET + MRI</VALIDVALUE>
          <VALUEMEANING>FDG-PET + MRI</VALUEMEANING>
          <MEANINGDESCRIPTION>FDG-PET + MRI</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5170915</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FDG-PET + CT</VALIDVALUE>
          <VALUEMEANING>FDG-PET + CT</VALUEMEANING>
          <MEANINGDESCRIPTION>An imaging procedure that combines FDG PET with a CT scan to overlay activity data onto detailed anatomic images.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C137817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5170916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical Palpation</VALIDVALUE>
          <VALUEMEANING>Clinical Palpation</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.: A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient&#39;s body to examine the size, consistency, texture, location and tenderness of an organ or body part.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16950, C25398</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5283971</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Imaging</VALIDVALUE>
          <VALUEMEANING>Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17369</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-05-31</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5283972</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sokal</VALIDVALUE>
          <VALUEMEANING>Sokal Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. The numerical value is calculated at diagnosis from the percentage of blast cells in peripheral blood, the platelet count, the spleen size, and the age of the patient.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127875</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485916</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hasford</VALIDVALUE>
          <VALUEMEANING>Hasford Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high, medium, or low risk on the basis of age, spleen size, and eosinophil, basophil, and platelet counts.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485917</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EUTOS</VALIDVALUE>
          <VALUEMEANING>European Treatment Outcome Study Score</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high or low risk on the basis of the percentage of basophils in the peripheral blood and spleen size at diagnosis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127872</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-09-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5485918</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>IgH/TCR PCR</VALIDVALUE>
          <VALUEMEANING>Immunoglobulin Heavy Locus T-Cell Receptor Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink): Heterodimeric antigen receptors present on the surface of T-cells.  Two T-cell antigen receptors have been identified, consisting of heterodimeric 40-55 kD Ig-like alpha/beta or gamma/delta integral membrane glycoproteins.  Genes for TCR alpha, beta, gamma, and delta subunits are assembled during T-cell development by somatic rearrangement of germline gene segments, resembling B-cell Ig genes in their mechanisms of diversity generation and activation of expression.  Alpha/beta heterodimers are found on helper and cytotoxic T-cells and are specific for antigenic peptides presented by MHC gene products.  T-cells expressing gamma/delta heterodimers directly recognize proteins and non-proteinacious phospho-ligands.  T-cell receptors are non-covalently associated with CD3, forming the TCR-CD3 complex.  TCRs activate MAPKs and JNK1 through the CD3 antigens, the adaptor protein LAT, and tyrosine kinases LCK and ZAP70.  (from OMIM and NCI): A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly s</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003, C17065, C26422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5664683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>BCR-ABL1/FISH</VALIDVALUE>
          <VALUEMEANING>BCR Protein Fluorescence in Situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>The 160 kD BCR phosphoprotein exhibits a unique serine/threonine kinase activity, at least two SH2 binding sites, and a C-terminal GTPase activating domain for p21(rac).  The Philadelphia translocation produces a BCR-ABL1 chimeric product required for induction and maintenance of leukemia.  (from OMIM 151410 and NCI): A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563, C17477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5664705</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Morphology</VALIDVALUE>
          <VALUEMEANING>Morphology</VALUEMEANING>
          <MEANINGDESCRIPTION>The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17943</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4661331</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunohistochemistry</VALIDVALUE>
          <VALUEMEANING>Immunohistochemistry Staining Method</VALUEMEANING>
          <MEANINGDESCRIPTION>Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C23020</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-05-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3031358</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Radiographic confirmation only</VALIDVALUE>
          <VALUEMEANING>Radiographic Examination Confirmation Only</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiographic procedure using the emission of penetrating energy waves to form an image of the structure penetrated by the radiation._Having been established or verified._Not accompanied by another or others; exclusive of anyone or anything else.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48440, C25458, C128940</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5977653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pathologic confirmation</VALIDVALUE>
          <VALUEMEANING>Pathologic Confirmation</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or altered by or manifesting disease or pathology.: Having been established or verified.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25458, C25610</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-09-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5633738</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gene expression profile</VALIDVALUE>
          <VALUEMEANING>Microarray Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18477</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-11-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3600806</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CT of Brain</VALIDVALUE>
          <VALUEMEANING>Computed Tomography Brain</VALUEMEANING>
          <MEANINGDESCRIPTION>A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.: An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12439, C17204</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-01-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6058859</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FLAIR</VALIDVALUE>
          <VALUEMEANING>Fluid Attenuated Inversion Recovery</VALUEMEANING>
          <MEANINGDESCRIPTION>A magnetic resonance imaging (MRI) pulse sequence that uses an inversion recovery technique to null fluids present in the imaging area, improving clarity of the object of interest.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-03-23</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6147291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Both</VALIDVALUE>
          <VALUEMEANING>Both</VALUEMEANING>
          <MEANINGDESCRIPTION>One and the other; relating to or being two in conjunction.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49636</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-05-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612442</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Axumin PET Scan</VALIDVALUE>
          <VALUEMEANING>Fluciclovine F18 Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C74002</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6399698</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>PSMA PET Scan</VALIDVALUE>
          <VALUEMEANING>Glutamate Carboxypeptidase 2 Positron Emission Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Glutamate carboxypeptidase 2 (750 aa, ~84 kDa) is encoded by the human FOLH1 gene. This protein plays a role in the mediation of folate metabolism.: A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17007, C17796</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-08-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6399696</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Preoperative CT Scan</VALIDVALUE>
          <VALUEMEANING>Preoperative Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or occurring during the period immediately before a surgical operation.: A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17204, C54732</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6332631</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS)</VALIDVALUE>
          <VALUEMEANING>Next Generation Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>Technologies that facilitate the rapid determination of the DNA sequence of large numbers of strands or segments of DNA.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C101293</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-06-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4448577</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Liver MRI</VALIDVALUE>
          <VALUEMEANING>Liver Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C12392, C16809</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>1, 0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147344</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Capillary electrophoresis</VALIDVALUE>
          <VALUEMEANING>Capillary Electrophoresis</VALUEMEANING>
          <MEANINGDESCRIPTION>An electrophoresis procedure, in which a sample is introduced into a capillary tube and the components are separated by the application of high voltage. Due to the large surface to volume ratio, cooling is more efficient, allowing use of higher voltages.  As a result, separation occurs more quickly and sensitivity is increased. The technique allows for separation of proteins, nucleic acids, and carbohydrates.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17637</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-10-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2915741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>SQUID MRI</VALIDVALUE>
          <VALUEMEANING>Superconducting Quantum Interference Device Magnetic Resonance Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.: Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16809, C124066</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>T2 MRI</VALIDVALUE>
          <VALUEMEANING>T2 (Observed)-Weighted Imaging</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI imaging based on the observed T2 relaxation time of tissues.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156447</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FerriScan</VALIDVALUE>
          <VALUEMEANING>FerriScan</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary method to determine liver iron concentration through an MRI-based imaging technology that uses R2-MRI relaxometry.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153820 </MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-12-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6576931</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Polymerase Chain Reaction (PCR)</VALIDVALUE>
          <VALUEMEANING>Polymerase Chain Reaction</VALUEMEANING>
          <MEANINGDESCRIPTION>A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17003</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE>2019-07-15</PVENDDATE>
          <VMPUBLICID>3234683</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>FISH</VALIDVALUE>
          <VALUEMEANING>Fluorescence in Situ Hybridization</VALUEMEANING>
          <MEANINGDESCRIPTION>A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17563</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5622317</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Karyotype</VALIDVALUE>
          <VALUEMEANING>Karyotype</VALUEMEANING>
          <MEANINGDESCRIPTION>The assessment of the chromosomal morphology and number in somatic cells of an individual.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5255756</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MRI of the Brain with orbital cuts</VALIDVALUE>
          <VALUEMEANING>MRI of the Brain with orbital cuts</VALUEMEANING>
          <MEANINGDESCRIPTION>MRI of the Brain with orbital cuts</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2019-02-19</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6649483</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Immunofluorescence</VALIDVALUE>
          <VALUEMEANING>Fluorescent Antibody Technique</VALUEMEANING>
          <MEANINGDESCRIPTION>An immunological technique in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17370</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2978232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mass spectrometry</VALIDVALUE>
          <VALUEMEANING>Mass Spectrometry</VALUEMEANING>
          <MEANINGDESCRIPTION>An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17156</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3339145</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ICE</VALIDVALUE>
          <VALUEMEANING>Immune Effector Encephalopathy - ICE Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>A grading system for Immune Effector Cell Associated Neurotoxicity Syndrome that includes: orientation to year, month, city, hospital; ability to name objects; ability to follow simple commands; ability to write a standard sentence; and ability to count backwards from 100 by 10. Grading ranges from 10: no impairment to 0: patient unarousable and unable to perform ICE assessment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C162916</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6927187</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CARTOX</VALIDVALUE>
          <VALUEMEANING>CARTOX 10 Point Neurological Assessment</VALUEMEANING>
          <MEANINGDESCRIPTION>A test to monitor for neurotoxicity related to CAR T therapy: orientation to year, month, city, hospital, and President; ability to name 3 specified objects; ability to write a standard sentence; ability to count backwards from 100 by 10.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C155295</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6927188</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Serum ferritin</VALIDVALUE>
          <VALUEMEANING>Serum Ferritin Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.: The determination of the amount of ferritin present in a sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C74737, C13325</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-01-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7147345</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multicolor flow cytometry</VALIDVALUE>
          <VALUEMEANING>Multiple Color Flow Cytometry</VALUEMEANING>
          <MEANINGDESCRIPTION>Having, relating to, or consisting of more than one individual, element, part, or other component; manifold.: The appearance of objects (or light sources) described in terms of a person&#39;s perception of their hue and lightness (or brightness) and saturation.: A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16585, C37927, C17648</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7246031</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular assay</VALIDVALUE>
          <VALUEMEANING>Molecular Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>Relating to or produced by or consisting of molecules.: A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C60819, C25574</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7246030</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Right Heart Catheterization</VALIDVALUE>
          <VALUEMEANING>Right Heart Catheterization</VALUEMEANING>
          <MEANINGDESCRIPTION>A diagnostic procedure in which a catheter is guided into the right heart, where pressures may be measured and radiocontrast material may be injected to visualize blood flow in and around the right heart.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80411</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-04-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7244953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clinical exam</VALIDVALUE>
          <VALUEMEANING>Clinical exam</VALUEMEANING>
          <MEANINGDESCRIPTION>Clinical exam</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2020-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7340571</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Complete red blood cell count</VALIDVALUE>
          <VALUEMEANING>Complete Erythrocyte Count</VALUEMEANING>
          <MEANINGDESCRIPTION>To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: The determination of the number of erythrocytes in a blood sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51946, C25250</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7320617</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pitted Erythrocyte Count</VALIDVALUE>
          <VALUEMEANING>Pitted Erythrocyte Count</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of pitted erythrocytes in a blood sample, expressed as a percentage. It is used as an indicator of splenic function.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172658</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7320618</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS) by Guardant360</VALIDVALUE>
          <VALUEMEANING>Guardant360 Genomic Profiling</VALUEMEANING>
          <MEANINGDESCRIPTION>A proprietary genomic profiling system that utilizes a proprietary next generation Digital Sequencing technology on samples obtain from blood. It is designed to detect alterations in over 70 genes relevant to multiple solid tumor types.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172874</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7334407</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Next generation sequencing (NGS) by FoundationOne</VALIDVALUE>
          <VALUEMEANING>FoundationOne Genomic Profiling</VALUEMEANING>
          <MEANINGDESCRIPTION>A set of proprietary genomic profiling techniques that utilize next generation sequencing. FoundationOne CDX is optimized for PPFE samples from solid tumors; FoundationOne Liquid is optimized for peripheral whole blood, targeting solid tumors; FoundationOne Heme is optimized for leukemias, lymphomas, sarcomas, and solid tumors using RNA sequencing on samples obtained from FFPE, peripheral whole blood, or bone marrow aspirate.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172873</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-17</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7334408</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Splenic Scan</VALIDVALUE>
          <VALUEMEANING>Splenic Scan</VALUEMEANING>
          <MEANINGDESCRIPTION>A radionuclide imaging technique that is used to evaluate the size and shape of the spleen, and to detect and evaluate lesions, rupture, and hematomas.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C172726</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-06-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7331906</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Research Flexible Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Research Activity Flexible Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.: Able to be adjusted readily to different conditions.: Endoscopic examination of the luminal surface of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17131, C80495, C15429</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7536999</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Flexible Sigmoidoscopy</VALIDVALUE>
          <VALUEMEANING>Flexible Sigmoidoscopy</VALUEMEANING>
          <MEANINGDESCRIPTION>Able to be adjusted readily to different conditions.: Endoscopic examination of the luminal surface of the sigmoid colon.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17131, C80495</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2020-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7537000</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Open / thorascopic (VATS) lung biopsy</VALIDVALUE>
          <VALUEMEANING>Open Lung Biopsy Or Video-assisted Thoracic Surgery</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue from the lung, for microscopic examination, obtained during an open surgical procedure.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Thoracic surgery that is aided by the use of a video camera.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63704, C37998, C51923</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7715759</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Bronchoalveolar Lavage</VALIDVALUE>
          <VALUEMEANING>Bronchoalveolar Lavage</VALUEMEANING>
          <MEANINGDESCRIPTION>Washing out the bronchi and alveoli by flushing with a fluid.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51913</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transbronchial Biopsy</VALIDVALUE>
          <VALUEMEANING>Transbronchial Lung Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>Removal of tissue through the bronchial wall, for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51749</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-06-29</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2795720</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multiplex ligation-dependent probe amplification (MLPA)</VALIDVALUE>
          <VALUEMEANING>Multiplex Ligation-dependent Probe Amplification</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of high-throughput, multiplex PCR method used to determine abnormal DNA copy number changes of up to 50 genomic DNA or RNA sequences with a single pair of PCR primers. It is frequently used in the detection of genetic aberrations in tumors, and can distinguish sequences differing in only a single nucleotide.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C116161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6413914</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Loss of heterozygosity (LOH)</VALIDVALUE>
          <VALUEMEANING>Loss of Heterozygosity</VALUEMEANING>
          <MEANINGDESCRIPTION>genetic phenomenon due to deletion or mutation in one allele of a polymorphic gene, as detected by expression after cell fusion; used as a test for tumor-promoting mutations; do not confuse with &quot;loss of heterogeneity&quot; which applies to diverse cell populations within a tissue.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18016</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3082343</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>RT-PCR amplification (e.g., MethyLight)</VALIDVALUE>
          <VALUEMEANING>RT-PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>RT-PCR is short for reverse transcriptase-polymerase chain reaction. It is a technique in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase. (from Wikipedia)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C18136</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3121570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Sequencing (e.g., bisulfite sequencing)</VALIDVALUE>
          <VALUEMEANING>Bisulfite Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C106054</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-09</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7736012</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Quantitative CT</VALIDVALUE>
          <VALUEMEANING>Quantitative Computed Tomography</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of computed tomography in which a calibration standard correlates radiodensity values to quantitative tissue density values.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C161405</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-02-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6859111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CSF examination</VALIDVALUE>
          <VALUEMEANING>Cerebrospinal Fluid Examination</VALUEMEANING>
          <MEANINGDESCRIPTION>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.: A formal or careful inspection of an object or subject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131902, C12692</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-03-10</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8078596</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not assessed</VALIDVALUE>
          <VALUEMEANING>Not Assessed</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates that an assessment was not performed.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C139527</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5189423</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Karyotyping</VALIDVALUE>
          <VALUEMEANING>Karyotyping</VALUEMEANING>
          <MEANINGDESCRIPTION>The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16768</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5095203</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clonality Analysis</VALIDVALUE>
          <VALUEMEANING>Clonality Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>No value exists.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C63327</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>10382636</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mutation Abnormality</VALIDVALUE>
          <VALUEMEANING>Mutation Abnormality</VALUEMEANING>
          <MEANINGDESCRIPTION>A general term referring to single or multiple alterations in the genetic material of an organism that ranges from a single base change in a gene to the loss or addition of complete chromosomes. A mutation abnormality may be heritable or occur somatically.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C45576</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-05-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3219495</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Surgical biopsy</VALIDVALUE>
          <VALUEMEANING>Excisional Biopsy</VALUEMEANING>
          <MEANINGDESCRIPTION>A surgical procedure in which an entire lesion is removed for microscopic examination.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C15385</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-07-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2576316</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Molecular testing / NextGen sequencing</VALIDVALUE>
          <VALUEMEANING>Molecular Analysis And/Or Next Generation Sequencing Method</VALUEMEANING>
          <MEANINGDESCRIPTION>A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._Used to indicate that either or both of two items or options may be valid._Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C71460, C101293, C48928, C19770</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12134398</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Allelic editing frequency</VALIDVALUE>
          <VALUEMEANING>Allelic Editing Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of allele editing detected after a subject is exposed to gene editing agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137221</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Clonal expansion</VALIDVALUE>
          <VALUEMEANING>Clonal Expansion</VALUEMEANING>
          <MEANINGDESCRIPTION>Multiplication or reproduction by cell division of a population of identical cells descended from a single progenitor. In immunology, may refer to the clonal proliferation of cells responsive to a specific antigen as part of an immune response. (NCI)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C20613</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137222</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Homology directed DNA repair (HDR) frequency</VALIDVALUE>
          <VALUEMEANING>Homology-Directed DNA Repair Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of directed gene modification or DNA repair occurring after a subject is exposed to homology-directed DNA repair promoting agents.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191744</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137224</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indel mutations frequency</VALIDVALUE>
          <VALUEMEANING>Indel Mutation Frequency Measurement</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the frequency of indel mutations in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191745</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137225</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Transgene expression</VALIDVALUE>
          <VALUEMEANING>Transgene Expression Level Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the level of expression of a transgene in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191746</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Vector copy number</VALIDVALUE>
          <VALUEMEANING>Vector Copy Number</VALUEMEANING>
          <MEANINGDESCRIPTION>The number of vector molecules present in a cell or sub-cellular location, sometimes stated as copies per diploid genome.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C180599</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137227</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Gene therapy globin expression</VALIDVALUE>
          <VALUEMEANING>Therapeutic Globin Gene Level Expression Analysis</VALUEMEANING>
          <MEANINGDESCRIPTION>The determination of the level of expression of a therapeutic globin gene in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C191743</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-12-13</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>12137223</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ddPCR</VALIDVALUE>
          <VALUEMEANING>Droplet Digital PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>A type of digital polymerase chain reaction technique in which the sample is fractionated into thousands of tiny droplets using a water-oil emulsion droplet technology, within which individual PCR reactions occur in each droplet.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C166064</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7167105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MicroRNA Sequencing</VALIDVALUE>
          <VALUEMEANING>MicroRNA Sequencing</VALUEMEANING>
          <MEANINGDESCRIPTION>A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C156057</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>13331403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>qPCR</VALIDVALUE>
          <VALUEMEANING>Real Time PCR</VALUEMEANING>
          <MEANINGDESCRIPTION>A modified polymerase chain reaction (PCR) technique in which DNA amplification is detected and quantified as the PCR reaction progresses, through the use of fluorescent DNA probes in the reaction mixture.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C51962</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3727155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2023-04-07</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5612322</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>ClonoSEQ</VALIDVALUE>
          <VALUEMEANING>clonoSEQ Assay</VALUEMEANING>
          <MEANINGDESCRIPTION>A next generation sequencing-based proprietary immunogenetic assay that identifies and quantitates the expression of the B-cell receptor (BCR) and T-cell receptor (TCR) variable, diversity and joining segments in a peripheral blood sample from subject. This assay can establish a genetic barcode for clonal lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (B-ALL), and can be leveraged to monitor clonal recurrence and/or measurable residual disease during and after treatment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C189828</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-10-16</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>11509111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Circulating plasma cell metho</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Circulating plasma cell method of evaluation</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1654">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4851595</PUBLICID>
    <LONGNAME>Cyclophosphamide Administered Checkbox Ind</LONGNAME>
    <PREFERREDNAME>2867138v1.0:2185839v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator determining whether or not Cyclophosphamide was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2867138</PublicId>
      <PreferredName>2867136v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>information related to act of having given a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.</PreferredDefinition>
      <LongName>Cyclophosphamide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2867136</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C405</PreferredName>
        <Version>1</Version>
        <LongName>Cyclophosphamide</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C405</PREFERRED_NAME>
            <LONG_NAME>Cyclophosphamide</LONG_NAME>
            <CON_ID>2204906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2185839</PublicId>
      <PreferredName>CHECKBOX_IND</PreferredName>
      <PreferredDefinition>Indicator determining determining whether or not certain stated circumstances exist._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Checkbox Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2183782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>NCIP</PreferredName>
        <Version>1</Version>
        <LongName>NCIP</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Cyclophosphamide</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Cyclophosphamide</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1655">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4872539</PUBLICID>
    <LONGNAME>FACT-BRM Questionnaire Version 4 BRM9 How True Past Seven Days Have Emotional Ups and Downs Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>FACTBRM_V4_BRM9_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how true in the past 7 days they had emotional ups and downs, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>FACT-BRM:Functional Assessment of Cancer Therapy - Biologic Response Modifiers, David Cella, Ph.D., Version 4, Nov. 2007</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4872041</PublicId>
      <PreferredName>4496814v1.0:4872051v1.0</PreferredName>
      <PreferredDefinition>A subscale complement to the FACT-G developed specifically for evaluating the potential side effects of biological response modifiers on cancer patients._A question about an individual&#39;s agreement with a statement._The most recent week, including today._A question about whether an individual has or had emotional ups and downs_A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>FACT-BRM Questionnaire How True Past Week Have Emotional Ups and Downs Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4496814</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C118267</PreferredName>
        <Version>1</Version>
        <LongName>FACT-BRM Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118267</PREFERRED_NAME>
            <LONG_NAME>FACT-BRM Questionnaire</LONG_NAME>
            <CON_ID>4488400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4872051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C91781:C95402:C122570:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How True Past Week Have Emotional Ups and Downs Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122570</PREFERRED_NAME>
            <LONG_NAME>Have Emotional Ups and Downs Question</LONG_NAME>
            <CON_ID>4870495</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>FACT-BRM:Functional Assessment of Cancer Therapy - Biologic Response Modifiers, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4552765</PublicId>
      <PreferredName>4552765v1.0</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Not at all) to 4 (Very Much) on a Likert scale used on FACT questionnaires.</PreferredDefinition>
      <LongName>FACT Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>FACT-G:Functional Assessment of Cancer Therapy - General, David Cella, Ph.D., Version 4, Nov. 2007</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144289</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Some-what</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144290</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144291</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-10-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-MM</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>I have emotional ups and downs (37)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have emotional ups and downs</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have emotional ups and downs</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Link to Scoring and Interpretation Materials</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Scoring and Interpretation materials are accessible after registration on the FACIT website.</DocumentText>
        <URL>http://www.facit.org/FACITOrg/Questionnaires</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>FACT-Leu</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>I have emotional ups and downs (44)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4811884</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>FACIT System Scales</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-MM (Functional Assessment of Cancer Therapy-Multiple Myeloma)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>4860918</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACIT/FACT</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5918014</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-MM (Version 4)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918028</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-L (Version 4)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>5918043</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FACT-Leu (Version 4)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Form Type</ClassificationSchemeItemType>
        <CsiPublicId>6409621</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FACTBRM_V4_BRM9_SCL</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ECOG-ACRIN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1656">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4883558</PUBLICID>
    <LONGNAME>Smoke Cigarettes or Other Tobacco Products Laboratory Procedure Nicotine Content Nicotine Quantity Microgram Per Gram</LONGNAME>
    <PREFERREDNAME>Smok_Labo_Nico_Cont_Nico_Micr_</PREFERREDNAME>
    <PREFERREDDEFINITION>cigarettes or other tobacco products._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain._Everything that is included in a collection, container, or communication._A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine&#39;s CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting._How much there is of something that you can measure; the total amount or number._A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._The metric unit of mass equal to one thousandth of a kilogram.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4883555</PublicId>
      <PreferredName>Smok_Labo_Nico_Cont</PreferredName>
      <PreferredDefinition>A question about whether an individual smokes cigarettes or other tobacco products._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine&#39;s CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting._Everything that is included in a collection, container, or communication.</PreferredDefinition>
      <LongName>Smoke Cigarettes or Other Tobacco Products Laboratory Procedure Nicotine Content</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4883552</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C105050</PreferredName>
        <Version>1</Version>
        <LongName>Smoke Cigarettes or Other Tobacco Products</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C105050</PREFERRED_NAME>
            <LONG_NAME>Smoke Cigarettes or Other Tobacco Products Question</LONG_NAME>
            <CON_ID>3693459</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4883553</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294:C691:C44476</PreferredName>
        <Version>1</Version>
        <LongName>Laboratory Procedure Nicotine Content</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C691</PREFERRED_NAME>
            <LONG_NAME>Nicotine</LONG_NAME>
            <CON_ID>2435400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C44476</PREFERRED_NAME>
            <LONG_NAME>Content</LONG_NAME>
            <CON_ID>2236544</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4883550</PublicId>
      <PreferredName>Nico_Micr_Per_Gram_Quan</PreferredName>
      <PreferredDefinition>A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine&#39;s CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting._How much there is of something that you can measure; the total amount or number._A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram._For each, generally denoting a ratio._The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.</PreferredDefinition>
      <LongName>Nicotine Quantity Microgram Per Gram</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>4883551</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4883551v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Nicotine Microgram Per Gram Quantity</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C691</PREFERRED_NAME>
            <LONG_NAME>Nicotine</LONG_NAME>
            <CON_ID>2435400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48152</PREFERRED_NAME>
            <LONG_NAME>Microgram</LONG_NAME>
            <CON_ID>2513257</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65039</PREFERRED_NAME>
            <LONG_NAME>Per</LONG_NAME>
            <CON_ID>2679568</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48155</PREFERRED_NAME>
            <LONG_NAME>Gram</LONG_NAME>
            <CON_ID>2480768</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Smoke Cigarettes or Other Tobacco Products Laboratory Procedure Nicotine Content Nicotine Quantity Microgram Per Gram does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Smoke Cigarettes or Other Tobacco Products Laboratory Procedure Nicotine Content Nicotine Quantity Microgram Per Gram does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tobacco Regulatory Research Specialty Collections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Agent</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745819</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1657">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4884767</PUBLICID>
    <LONGNAME>Pipe Purchase Location Purchase Assessment Text</LONGNAME>
    <PREFERREDNAME>Pipe_Purc_Loca_ASSESS_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>A tube with a small bowl at one end, especially one used for smoking tobacco._The action of obtaining something by payment._A position, site, or point in space where something can be found._a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PhenX</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4884766</PublicId>
      <PreferredName>Pipe_Purc_Loca</PreferredName>
      <PreferredDefinition>A tube with a small bowl at one end, especially one used for smoking tobacco._The action of obtaining something by payment._A position, site, or point in space where something can be found.</PreferredDefinition>
      <LongName>Pipe Purchase Location Purchase</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PhenX</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4884764</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C86044</PreferredName>
        <Version>1</Version>
        <LongName>Pipe</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86044</PREFERRED_NAME>
            <LONG_NAME>Pipe</LONG_NAME>
            <CON_ID>3014411</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4921712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C122672:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Purchase Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122672</PREFERRED_NAME>
            <LONG_NAME>Purchase</LONG_NAME>
            <CON_ID>4887572</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2018321</PublicId>
      <PreferredName>ASSESS_TXT</PreferredName>
      <PreferredDefinition>a free text field to specify information on the evaluations of the patient and the patient&#39;s disease</PreferredDefinition>
      <LongName>Assessment Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184342</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Text</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Data Element Pipe Purchase Location Purchase Assessment Text does not have Preferred Question Text</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Data Element Pipe Purchase Location Purchase Assessment Text does not have Preferred Question Text</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>0</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tobacco Regulatory Research Specialty Collections</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745816</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2793652</PublicId>
          <ContextName>PhenX</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PhenX </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Vector</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4745820</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1658">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4888035</PUBLICID>
    <LONGNAME>Right Lymph Nodes Vs Initial Injection Dendritic Cell Measurement Percent Value</LONGNAME>
    <PREFERREDNAME>RLN_STE_DEND_PCT_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Percentage value of dendritic cells in lymph nodes right of the initial injection as compared to the dendritic cell count at the initial injection site.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCI CRF:  Duke Cancer Institute Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4888000</PublicId>
      <PreferredName>4887998v1.0:2188090v1.0</PreferredName>
      <PreferredDefinition>Being or located on or directed toward the side of the body to the east when facing north._A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._The examination of two or more people or things in order to detect similarities and differences._occurring at the beginning._Administration of a drug into a location within the body; this can be achieved either through an established access or via a needle._The anatomic site at which a medication or a vaccine is injected._Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._</PreferredDefinition>
      <LongName>Right Lymph Nodes Vs Initial Injection Dendritic Cell Measurement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2233241</PublicId>
        <ContextName>CIP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MEDICAL IMAGING</PreferredName>
        <Version>1</Version>
        <LongName>Medical Imaging</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4887998</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4887998v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Right Lymph Node Comparison Initial Injection Procedure Dendritic Cell</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25228</PREFERRED_NAME>
            <LONG_NAME>Right</LONG_NAME>
            <CON_ID>2204868</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12745</PREFERRED_NAME>
            <LONG_NAME>Lymph Node</LONG_NAME>
            <CON_ID>2202290</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49156</PREFERRED_NAME>
            <LONG_NAME>Comparison</LONG_NAME>
            <CON_ID>2528577</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>CL052284</PREFERRED_NAME>
            <LONG_NAME>Initial</LONG_NAME>
            <CON_ID>2205861</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE>NCI_META_CUI</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28160</PREFERRED_NAME>
            <LONG_NAME>Injection Route of Administration</LONG_NAME>
            <CON_ID>2202407</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12583</PREFERRED_NAME>
            <LONG_NAME>Dendritic Cell</LONG_NAME>
            <CON_ID>2615837</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2188090</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25209</PreferredName>
        <Version>1</Version>
        <LongName>Measurement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019325</PublicId>
      <PreferredName>PCT_VAL</PreferredName>
      <PreferredDefinition>the numerical quantity measured or assigned or computed as a fraction or ratio with 100 understood as the denominator.</PreferredDefinition>
      <LongName>Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>%</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>1</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>% Right Lymph Nodes vs Initia</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>% Right Lymph Nodes vs Initial Injection</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1659">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4896091</PUBLICID>
    <LONGNAME>Clinical Data Form Document Identifier Version Number</LONGNAME>
    <PREFERREDNAME>2527787v1.0:4896041v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A unique document identifier version number assigned to a clinical data form.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2527787</PublicId>
      <PreferredName>CLNCL_DATA_FRM</PreferredName>
      <PreferredDefinition>Data obtained through patient examination or treatment._A printed or electronic document with spaces to be filled out.</PreferredDefinition>
      <LongName>Clinical Data Form</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008555</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MED_RCD_AND_FORMS</PreferredName>
        <Version>1</Version>
        <LongName>Medical Records and Forms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2732185</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15783</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Data</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15783</PREFERRED_NAME>
            <LONG_NAME>Clinical Data</LONG_NAME>
            <CON_ID>2714989</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2440310</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19464</PreferredName>
        <Version>1</Version>
        <LongName>Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19464</PREFERRED_NAME>
            <LONG_NAME>Form</LONG_NAME>
            <CON_ID>2202476</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4896041</PublicId>
      <PreferredName>4896041v1.0</PreferredName>
      <PreferredDefinition>The unique identification of a document in a specified context._A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.</PreferredDefinition>
      <LongName>Document Identifier Version Number</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008555</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MED_RCD_AND_FORMS</PreferredName>
        <Version>1</Version>
        <LongName>Medical Records and Forms</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>4</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>4896040</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C93399:C25714:C25337</PreferredName>
        <Version>1</Version>
        <LongName>Document Identifier Version Number</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C93399</PREFERRED_NAME>
            <LONG_NAME>Document Identifier</LONG_NAME>
            <CON_ID>4896039</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25714</PREFERRED_NAME>
            <LONG_NAME>Version</LONG_NAME>
            <CON_ID>2203981</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25337</PREFERRED_NAME>
            <LONG_NAME>Number</LONG_NAME>
            <CON_ID>2202701</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>AGNIS Form Version:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>AGNIS Form Version:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the the clinical data</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the the clinical data form identifier version number?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FrmDue_param_agnis_frm_version</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>FrmDue_rs_mt_agnis_frm_version</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1660">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4900595</PUBLICID>
    <LONGNAME>Injection Negation Administered Name</LONGNAME>
    <PREFERREDNAME>INJECT_NOT_ADMIN_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the injection not given to the participant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4900592</PublicId>
      <PreferredName>2482141v1.0:2207837v1.0</PreferredName>
      <PreferredDefinition>Use of a syringe and needle to push fluids or drugs into the body; often called a &quot;shot.&quot;_An operation in which a term denies or inverts the meaning of another term or construction._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Injection Procedure Negation Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2831222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15347</PreferredName>
        <Version>1</Version>
        <LongName>Vaccine Therapy</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2482141</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28160</PreferredName>
        <Version>1</Version>
        <LongName>Injection</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28160</PREFERRED_NAME>
            <LONG_NAME>Injection Route of Administration</LONG_NAME>
            <CON_ID>2202407</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207837</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25594:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Not Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4900594</PublicId>
      <PreferredName>4900594v1.0</PreferredName>
      <PreferredDefinition>Use of a syringe and needle to push fluids or drugs into the body; often called a &quot;shot.&quot;_The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Injection Procedure Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2831222</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15347</PreferredName>
        <Version>1</Version>
        <LongName>Vaccine Therapy</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>4900593</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C28160:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Injection Procedure Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C28160</PREFERRED_NAME>
            <LONG_NAME>Injection Route of Administration</LONG_NAME>
            <CON_ID>2202407</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If Yes, indicate which inject</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If Yes, indicate which injection(s) was not given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>UAZ2015-05-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>4915511</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1661">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4909029</PUBLICID>
    <LONGNAME>Primary Hepatic Neoplasm Histology Diagnosis Type</LONGNAME>
    <PREFERREDNAME>PmyHepSarcDxTp</PREFERREDNAME>
    <PREFERREDDEFINITION>An identifiable class which describes the original aggressive malignant liver neoplasm identified by analysis of the tissue and cell structure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5288293</PublicId>
      <PreferredName>PmyHepSarcomaDx</PreferredName>
      <PreferredDefinition>Occurring first in time or sequence; original; of greatest rank or importance or value._Pertaining to, affecting, or associated with the liver._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.</PreferredDefinition>
      <LongName>Primary Hepatic Neoplasm Histology Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5288291</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C13308:C3262</PreferredName>
        <Version>1</Version>
        <LongName>Primary Hepatic Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13308</PREFERRED_NAME>
            <LONG_NAME>Hepatic</LONG_NAME>
            <CON_ID>2202660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4916365</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16681:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Histology Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16681</PREFERRED_NAME>
            <LONG_NAME>Histology</LONG_NAME>
            <CON_ID>2202345</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4909020</PublicId>
      <PreferredName>PmyHepSarcTp</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities of the original liver aggressive malignant neoplasm.</PreferredDefinition>
      <LongName>Primary Hepatic Sarcoma Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234813</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25284</PreferredName>
        <Version>1</Version>
        <LongName>Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Rhabdomyosarcoma</VALIDVALUE>
          <VALUEMEANING>Rhabdomyosarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3359</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4265253</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Angiosarcoma</VALIDVALUE>
          <VALUEMEANING>Angiosarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma. -- 2004</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3088</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568840</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Undifferentiated embryonal sarcoma</VALIDVALUE>
          <VALUEMEANING>Undifferentiated (Embryonal) Sarcoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A rare malignant tumor of the liver, the incidence of which is highest in children between 6 and 10 years of age.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C27096</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-07-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3251862</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If Primary Hepatic Sarcoma, s</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If Primary Hepatic Sarcoma, specify:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1662">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4928931</PUBLICID>
    <LONGNAME>Non-Rhabdomyosarcoma Soft Tissue Sarcoma Primary Location Anatomic Site</LONGNAME>
    <PREFERREDNAME>NRSTSPmyLocAnaSt</PREFERREDNAME>
    <PREFERREDDEFINITION>A list of non-rhabdomyosarcoma soft tissue sarcoma sites to indicate the site of a primary tumor classified as a soft tissue sarcoma not related to rhabdomyosarcoma.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4928854</PublicId>
      <PreferredName>NRSTSPrmLoc</PreferredName>
      <PreferredDefinition>Information indicating the site of a primary tumor classified as a soft tissue sarcoma not related to rhabdomyosarcoma.</PreferredDefinition>
      <LongName>Non-Rhabdomyosarcoma Soft Tissue Sarcoma Neoplasm Primary Location</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4928852</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103117:C3262</PreferredName>
        <Version>1</Version>
        <LongName>NCI CTEP SDC Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103117</PREFERRED_NAME>
            <LONG_NAME>NCI CTEP SDC Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology</LONG_NAME>
            <CON_ID>4928851</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2207144</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C25341</PreferredName>
        <Version>1</Version>
        <LongName>Primary Location</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25341</PREFERRED_NAME>
            <LONG_NAME>Location</LONG_NAME>
            <CON_ID>2202456</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4928857</PublicId>
      <PreferredName>NRSTSStTp</PreferredName>
      <PreferredDefinition>A list of non-rhabdomyosarcoma soft tissue sarcoma sites.</PreferredDefinition>
      <LongName>Anatomic Site</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008526</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ANAT_SITES</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Sites</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
      <Representation>
        <PublicId>2519596</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13717</PreferredName>
        <Version>1</Version>
        <LongName>Anatomic Site</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13717</PREFERRED_NAME>
            <LONG_NAME>Anatomic Site</LONG_NAME>
            <CON_ID>2202400</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Foot</VALIDVALUE>
          <VALUEMEANING>19: Foot</VALUEMEANING>
          <MEANINGDESCRIPTION>19: Foot</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929152</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>9995: Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>9995: Unknown</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Leg</VALIDVALUE>
          <VALUEMEANING>18: Leg</VALUEMEANING>
          <MEANINGDESCRIPTION>18: Leg</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Thigh</VALIDVALUE>
          <VALUEMEANING>17: Thigh</VALUEMEANING>
          <MEANINGDESCRIPTION>17: Thigh</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hip</VALIDVALUE>
          <VALUEMEANING>16: Hip</VALUEMEANING>
          <MEANINGDESCRIPTION>16: Hip</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929155</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hand</VALIDVALUE>
          <VALUEMEANING>15: Hand</VALUEMEANING>
          <MEANINGDESCRIPTION>15: Hand</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929156</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Lower arm</VALIDVALUE>
          <VALUEMEANING>14: Lower arm</VALUEMEANING>
          <MEANINGDESCRIPTION>14: Lower arm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929157</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Upper arm</VALIDVALUE>
          <VALUEMEANING>13: Upper arm</VALUEMEANING>
          <MEANINGDESCRIPTION>13: Upper arm</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Shoulder</VALIDVALUE>
          <VALUEMEANING>12: Shoulder</VALUEMEANING>
          <MEANINGDESCRIPTION>12: Shoulder</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929159</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Perineum</VALIDVALUE>
          <VALUEMEANING>11: Perineum</VALUEMEANING>
          <MEANINGDESCRIPTION>11: Perineum</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929160</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Pelvis</VALIDVALUE>
          <VALUEMEANING>10: Pelvis</VALUEMEANING>
          <MEANINGDESCRIPTION>10: Pelvis</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929161</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Retroperitoneal</VALIDVALUE>
          <VALUEMEANING>9: Retroperitoneal</VALUEMEANING>
          <MEANINGDESCRIPTION>9: Retroperitoneal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929162</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraperitoneal</VALIDVALUE>
          <VALUEMEANING>8: Intraperitoneal</VALUEMEANING>
          <MEANINGDESCRIPTION>8: Intraperitoneal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929163</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intrathoracic</VALIDVALUE>
          <VALUEMEANING>7: Intrathoracic</VALUEMEANING>
          <MEANINGDESCRIPTION>7: Intrathoracic</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929164</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Breast</VALIDVALUE>
          <VALUEMEANING>20: Breast</VALUEMEANING>
          <MEANINGDESCRIPTION>20: Breast</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929165</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Abdominal wall</VALIDVALUE>
          <VALUEMEANING>6: Abdominal wall</VALUEMEANING>
          <MEANINGDESCRIPTION>6: Abdominal wall</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929166</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intraspinal</VALIDVALUE>
          <VALUEMEANING>21: Intraspinal</VALUEMEANING>
          <MEANINGDESCRIPTION>21: Intraspinal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929167</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Paraspinal</VALIDVALUE>
          <VALUEMEANING>5: Paraspinal</VALUEMEANING>
          <MEANINGDESCRIPTION>5: Paraspinal</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Posterior chest wall</VALIDVALUE>
          <VALUEMEANING>4: Posterior chest wall</VALUEMEANING>
          <MEANINGDESCRIPTION>4: Posterior chest wall</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929169</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Anterior chest wall</VALIDVALUE>
          <VALUEMEANING>3: Anterior chest wall</VALUEMEANING>
          <MEANINGDESCRIPTION>3: Anterior chest wall</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Neck</VALIDVALUE>
          <VALUEMEANING>2: Neck</VALUEMEANING>
          <MEANINGDESCRIPTION>2: Neck</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929171</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Head</VALIDVALUE>
          <VALUEMEANING>1: Head</VALUEMEANING>
          <MEANINGDESCRIPTION>1: Head</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2015-08-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4929172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRSTS Primary site:</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>NRSTS Primary site:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1663">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4970971</PUBLICID>
    <LONGNAME>Specimen Other Non-Germ Cell Tumor Percentage Value</LONGNAME>
    <PREFERREDNAME>OthNonGCTPctVal</PREFERREDNAME>
    <PREFERREDDEFINITION>The percentage of different kind of a benign or malignant pathologic structure tumor not in the category of germ cell.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4970773</PublicId>
      <PreferredName>2241613v1.0:4970972v1.0</PreferredName>
      <PreferredDefinition>Information related to the explanation of different kind of a benign or malignant pathologic structure tumor not in the category of germ cell.</PreferredDefinition>
      <LongName>Specimen Other Non-Germ Cell Tumor Description</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008547</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>SPEC_CHAR</PreferredName>
        <Version>1</Version>
        <LongName>Specimen Characteristics</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2241613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19157</PreferredName>
        <Version>1</Version>
        <LongName>Specimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19157</PREFERRED_NAME>
            <LONG_NAME>Specimen</LONG_NAME>
            <CON_ID>2202566</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4970972</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4970972v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Other Negation Germ Cell Tumor Mass Description</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25594</PREFERRED_NAME>
            <LONG_NAME>Negation</LONG_NAME>
            <CON_ID>2204956</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12597</PREFERRED_NAME>
            <LONG_NAME>Germ Cell</LONG_NAME>
            <CON_ID>2615864</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C98275</PREFERRED_NAME>
            <LONG_NAME>Tumor Mass</LONG_NAME>
            <CON_ID>3741976</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25365</PREFERRED_NAME>
            <LONG_NAME>Description</LONG_NAME>
            <CON_ID>2202730</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180234</PublicId>
      <PreferredName>LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>the value as a percentage of 100.</PreferredDefinition>
      <LongName>Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Percent other non-germ cell t</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Percent other non-germ cell tumor</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1664">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4976258</PUBLICID>
    <LONGNAME>Disease Response Other Criterion Use Reason Text</LONGNAME>
    <PREFERREDNAME>RES_OTH_CRIT_RSN_TXT</PREFERREDNAME>
    <PREFERREDDEFINITION>The response that describes the reason why a response criterion not previously mentioned was selected for the technique used to evaluate disease response.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CTEP</CONTEXTNAME>
    <CONTEXTVERSION>2.31</CONTEXTVERSION>
    <ORIGIN>CTEP:Cancer Therapy Evaluation Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4975933</PublicId>
      <PreferredName>2607696v1.0:4975931v1.0</PreferredName>
      <PreferredDefinition>The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Different than the one(s) previously specified or mentioned._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison._A manner, or usual, or accepted practice of using something.</PreferredDefinition>
      <LongName>Disease Response Other Criterion Use</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2607696</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C50995</PreferredName>
        <Version>1</Version>
        <LongName>Response</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C50995</PREFERRED_NAME>
            <LONG_NAME>Disease Response</LONG_NAME>
            <CON_ID>2459436</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4975931</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25466:C25340</PreferredName>
        <Version>1</Version>
        <LongName>Other Criterion Use</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25466</PREFERRED_NAME>
            <LONG_NAME>Criterion</LONG_NAME>
            <CON_ID>2203889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CTEP:Cancer Therapy Evaluation Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4975910</PublicId>
      <PreferredName>ASMT_CRIT_USE_RSN_TXT</PreferredName>
      <PreferredDefinition>The final result of a determination of the value, significance, or extent of._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison._A manner, or usual, or accepted practice of using something._An explanation of the cause of some phenomenon or action._Text; the words of something written.</PreferredDefinition>
      <LongName>Assessment Criterion Use Reason Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008550</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DZ_RESP</PreferredName>
        <Version>1</Version>
        <LongName>Disease Response</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>500</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTEP:Cancer Therapy Evaluation Program</Origin>
      <Representation>
        <PublicId>4975909</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>4975909v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Criterion Use Reason Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25466</PREFERRED_NAME>
            <LONG_NAME>Criterion</LONG_NAME>
            <CON_ID>2203889</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25340</PREFERRED_NAME>
            <LONG_NAME>Use</LONG_NAME>
            <CON_ID>2203973</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25638</PREFERRED_NAME>
            <LONG_NAME>Reason</LONG_NAME>
            <CON_ID>2202901</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Why is the &#39;Other&#39; Imaging Re</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Why is the &#39;Other&#39; Imaging Review being conducted?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4631580</PublicId>
          <ContextName>CTEP</ContextName>
          <ContextVersion>2.31</ContextVersion>
          <PreferredName>Exceptional Responder CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Exceptional Responder CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4631582</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1665">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>4987875</PUBLICID>
    <LONGNAME>Work Productivity and Activity Impairment General Health V2.0 Questionnaire Past Seven Days Health Problems Affect Ability to do Regular Daily Activities Other than Work at Job Score 11 Point Scale</LONGNAME>
    <PREFERREDNAME>WAPI_GH_DAYACTIV_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how much their health problems affected their ability to do regular daily activities, other than work at a job, in the past seven days, using an 11 point visual analogue scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>WPAI-GH:Work Productivity and Activity Impairment Questionnaire-General Health V2.0. Reilly MC, Zbrozek AS, Dukes EM., 1993.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4987869</PublicId>
      <PreferredName>4987851v1.0:4987867v1.0</PreferredName>
      <PreferredDefinition>The second version of a standardized survey originally developed by Margaret C. Reilly in 1993 which is used to evaluate the extent to which a patient&#39;s general health problems effects their ability to work and perform daily activities. This instrument consists of 6 questions which can be completed by the patient or in an interview format._The most recent week, including today._A question about how much an individual&#39;s health problems affects or affected their ability to do regular daily activities other than work at a job._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Work Productivity and Activity Impairment General Health V2.0 Questionnaire Past Week Health Problems Affect Ability to do Regular Daily Activities other than Work at Job Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>4987851</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C123285</PreferredName>
        <Version>1</Version>
        <LongName>Work Productivity and Activity Impairment General Health V2.0 Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123285</PREFERRED_NAME>
            <LONG_NAME>Work Productivity and Activity Impairment General Health V2.0 Questionnaire</LONG_NAME>
            <CON_ID>4980680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4987867</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C123291:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Health Problems Affect Ability to do Regular Daily Activities other than Work at Job Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C123291</PREFERRED_NAME>
            <LONG_NAME>Health Problems Affect Ability to do Regular Daily Activities other than Work at Job Question</LONG_NAME>
            <CON_ID>4980693</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>WPAI-GH:Work Productivity and Activity Impairment Questionnaire-General Health V2.0. Reilly MC, Zbrozek AS, Dukes EM., 1993.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4987772</PublicId>
      <PreferredName>WPAI_ACTIV_SCALE</PreferredName>
      <PreferredDefinition>An ordered reference standard used in the Work Productivity and Activity Impairment General Health V2.0 Questionnaire with values ranging from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</PreferredDefinition>
      <LongName>WPAI Effect of Health Problems on Daily Activities 11 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>10</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>WPAI-GH:Work Productivity and Activity Impairment Questionnaire-General Health V2.0. Reilly MC, Zbrozek AS, Dukes EM., 1993.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 0</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 0 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123305</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987773</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 1 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123306</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987774</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 2 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123307</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987775</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 3 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123309</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987776</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 4 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123310</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987777</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 5 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987778</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 6</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 6 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123312</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987779</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 7 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123313</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987780</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 8 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123314</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987781</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 9</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 9 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987782</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Health Problems Effect on Daily Activities Score 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 10 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C123316</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-08-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4987783</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>During the past seven days, h</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>During the past seven days, how much did your health problems affect your ability to do your regular daily activities, other than work at a job?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>During the past seven days how much did your stem cell donation process affect your ability to do your regular daily activities, other than work at a job?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>During the past seven days how much did your stem cell donation process affect your ability to do your regular daily activities, other than work at a job?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4986873</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>WPAI:GH</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>WPAI:GH V2.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4986915</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Work Productivity and Activity Impairment Questionnaire: General Health v2.0 (WPAI:GH)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900361</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NHLBI</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1666">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5023705</PUBLICID>
    <LONGNAME>Patient Controlled Thyroid Gland Function Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>THYROIDFX</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for eligibility criteria related to controlled thyroid gland function.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>4900747</PublicId>
      <PreferredName>2233604v1.0:3178985v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another._An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control._The normal action performed by a structure or device._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Controlled Thyroid Gland Function Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3178985</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61299:C12400:C25518:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Control Thyroid Gland Function Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61299</PREFERRED_NAME>
            <LONG_NAME>Control</LONG_NAME>
            <CON_ID>2527789</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12400</PREFERRED_NAME>
            <LONG_NAME>Thyroid Gland</LONG_NAME>
            <CON_ID>2202526</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25518</PREFERRED_NAME>
            <LONG_NAME>Function</LONG_NAME>
            <CON_ID>2202643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Does the patient have a norma</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Does the patient have a normal Free T4 and Free Thyroxine Index and clinically euthyroid?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>does the patient have a normal Free T4 and clinically euthyroid?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the patient euthyroid on thyroid replacement therapy with TSH &lt; ULN</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is free T4 within normal limits?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text3</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is Free T4 normal and is patient clinically euthyroid?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text4</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does the patient have a normal Free T4 and clinically euthyroid?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 5</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Is the free T4 level normal with no symptoms of thyroid dysfunction?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_eCRF_Text_1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Does patient show no symptoms of thyroid dysfunction and is Free T4 within normal range?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1667">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5038394</PUBLICID>
    <LONGNAME>Gene Mutation Abnormality Variant Descriptive Text</LONGNAME>
    <PREFERREDNAME>Gene_Variant</PREFERREDNAME>
    <PREFERREDDEFINITION>A text term that describes the gene mutation variant.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5038393</PublicId>
      <PreferredName>2223326v1.0:5038391v1.0</PreferredName>
      <PreferredDefinition>A functional unit of heredity which occupies a specific position on a particular chromosome and serves as the template for a product that contributes to a phenotype or a biological function._Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer._An alteration or difference from a norm or standard._A variation in the nucleic acid sequence of a specific gene.</PreferredDefinition>
      <LongName>Gene Mutation Abnormality Variation Gene Mutant</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OHSU Knight</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223326</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16612</PREFERRED_NAME>
            <LONG_NAME>Gene</LONG_NAME>
            <CON_ID>2202483</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5038391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C45576:C25713:C97927</PreferredName>
        <Version>1</Version>
        <LongName>Mutation Abnormality Variation Gene Mutant</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45576</PREFERRED_NAME>
            <LONG_NAME>Mutation Abnormality</LONG_NAME>
            <CON_ID>2532673</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C97927</PREFERRED_NAME>
            <LONG_NAME>Gene Variant</LONG_NAME>
            <CON_ID>3343010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2181231</PublicId>
      <PreferredName>DESCR_TXT</PreferredName>
      <PreferredDefinition>The text that provides a description of a topic.</PreferredDefinition>
      <LongName>Descriptive Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>ALPHANUMERIC</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Gene variant description</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Gene variant description</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Variant (if actionable marker)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Which gene in the report has a potentially actionable alteration?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Gene- Which gene in the report has a potentially actionable alteration</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Theradex</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Theradex</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1668">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5045116</PUBLICID>
    <LONGNAME>Chest X-ray Assessment Indicator</LONGNAME>
    <PREFERREDNAME>CHEST_XR_ASSESS_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A yes, no, unknown or not applicable indicator of whether a chest x-ray was assessed. [manually curated]</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2008872</PublicId>
      <PreferredName>CHEST_XR_ASSESS</PreferredName>
      <PreferredDefinition>information related to a chest X-ray assessment.</PreferredDefinition>
      <LongName>Chest X-ray Assessment</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206657</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25389:C17261</PreferredName>
        <Version>1</Version>
        <LongName>Chest X-Ray</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25389</PREFERRED_NAME>
            <LONG_NAME>Chest</LONG_NAME>
            <CON_ID>2202707</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17261</PREFERRED_NAME>
            <LONG_NAME>X-Ray</LONG_NAME>
            <CON_ID>2202559</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177637</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Assessment</PreferredName>
        <Version>1</Version>
        <LongName>Assessment</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20989</PREFERRED_NAME>
            <LONG_NAME>Physical Examination</LONG_NAME>
            <CON_ID>2202921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Chest X-Ray?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Chest X-Ray?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7409079</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CS for Training Gwen</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Level 2 Training 2 Gwen CSI Level </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409397</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1669">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5045730</PUBLICID>
    <LONGNAME>Laboratory Procedure Total Bilirubin Result Yes No Indicator</LONGNAME>
    <PREFERREDNAME>2199563v2.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator related to a patient&#39;s total bilirubin result</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2199563</PublicId>
      <PreferredName>LAB_TTLBIL_RSLT</PreferredName>
      <PreferredDefinition>information related to the results of the procedure that involves testing or manipulating a sample of blood in a laboratory setting for total bilirubin, a breakdown product of hemoglobin in the liver.</PreferredDefinition>
      <LongName>Laboratory Procedure Total Bilirubin Result</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738928</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38037:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Total Bilirubin Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38037</PREFERRED_NAME>
            <LONG_NAME>Total Bilirubin Measurement</LONG_NAME>
            <CON_ID>2202370</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total bilirubin (must be less</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total bilirubin (must be less than 2.0 mg/dL)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1670">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5046711</PUBLICID>
    <LONGNAME>Patient Consent Brief Steroid Therapy Inflammatory Response Clinical Trial Eligibility Criteria Yes No Indicator</LONGNAME>
    <PREFERREDNAME>5046434v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Permission to do something._Of short duration, extent, or distance._Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation._A part of innate immunity, the Inflammatory Response occurs when injured tissues induce release of vasodilatory, opsonizing, and chemotactic mediators that attract macrophages and leukocytes to phagocytize and destroy foreign substances; dilate local blood vessels increasing local blood flow; increase capillary permeability; produce edematous swelling; and induce pain. Plasma- and cell-derived inflammatory mediators include Prostaglandins, Leukotrines, Cytokines, Lymphokines, Monokines, PAF, Histamine, Bradykinin, Complement, and Interferons._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PBTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5046434</PublicId>
      <PreferredName>2233604v1.0:5046432v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Permission to do something._Of short duration, extent, or distance._Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation._A part of innate immunity, the Inflammatory Response occurs when injured tissues induce release of vasodilatory, opsonizing, and chemotactic mediators that attract macrophages and leukocytes to phagocytize and destroy foreign substances; dilate local blood vessels increasing local blood flow; increase capillary permeability; produce edematous swelling; and induce pain. Plasma- and cell-derived inflammatory mediators include Prostaglandins, Leukotrines, Cytokines, Lymphokines, Monokines, PAF, Histamine, Bradykinin, Complement, and Interferons._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Patient Consent Brief Steroid Therapy Inflammatory Response Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PBTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16203</PreferredName>
        <Version>1</Version>
        <LongName>Clinical or Research Activity</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5046432</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5046432v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Consent Brief Steroid Therapy Inflammatory Response Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61484</PREFERRED_NAME>
            <LONG_NAME>Brief</LONG_NAME>
            <CON_ID>2727634</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15370</PREFERRED_NAME>
            <LONG_NAME>Steroid Therapy</LONG_NAME>
            <CON_ID>2220360</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20151</PREFERRED_NAME>
            <LONG_NAME>Inflammatory Response</LONG_NAME>
            <CON_ID>5046431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Patient is willing to use bri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Patient is willing to use brief courses  (at least 72 hours) of steroids as directed for potential inflammatory side effects of MK-3475, if recommended?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PBTC_Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Patient is willing to use brief courses  (at least 72 hours) of steroids as directed for potential inflammatory side effects of Pembrolizumab, if recommended?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>PBTC</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>PBTC</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1671">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5083699</PUBLICID>
    <LONGNAME>Midostaurin Administered Indicator</LONGNAME>
    <PREFERREDNAME>5083697v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not midostaurin was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5083697</PublicId>
      <PreferredName>5083695v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Midostaurin Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5083695</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1872</PreferredName>
        <Version>1</Version>
        <LongName>Midostaurin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1872</PREFERRED_NAME>
            <LONG_NAME>Midostaurin</LONG_NAME>
            <CON_ID>2723084</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was midostaurin administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was midostaurin administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Midostaurin</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Midostaurin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Midostaurin</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Midostaurin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_PHCT_midostaurin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_RP_midostaurin_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1672">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5083731</PUBLICID>
    <LONGNAME>Quizartinib Administered Indicator</LONGNAME>
    <PREFERREDNAME>5083714v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not quizartinib was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5083714</PublicId>
      <PreferredName>5083712v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Quizartinib Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5083712</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C68936</PreferredName>
        <Version>1</Version>
        <LongName>Quizartinib</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C68936</PREFERRED_NAME>
            <LONG_NAME>Quizartinib</LONG_NAME>
            <CON_ID>5083711</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Quizartinib</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Quizartinib</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was quizartinib administered?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was quizartinib administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Quizartinib</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Quizartinib</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_PHCT_quizartinib_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TPST_RP_quizartinib_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1673">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5102411</PUBLICID>
    <LONGNAME>Treatment Start Subtract First Pathologic Diagnosis Time Day Calculation Value</LONGNAME>
    <PREFERREDNAME>5102343v1.0:3008213v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Time interval from the date of the initial pathologic diagnosis to the start of treatment, represented as a calculated number of days.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5102343</PublicId>
      <PreferredName>5102341v1.0:2234809v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._The act of removing a part from the whole._Preceding all others in time or space or degree._Caused by or altered by or manifesting disease or pathology._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._The continuum of experience in which events pass from the future through the present to the past._The period of time during which something continues.</PreferredDefinition>
      <LongName>Therapeutic Procedure Begin Subtraction First Pathologic Diagnosis Time Duration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5102341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5102341v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Begin Subtraction First Pathologic Diagnosis Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70590</PREFERRED_NAME>
            <LONG_NAME>Subtraction</LONG_NAME>
            <CON_ID>2710223</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25610</PREFERRED_NAME>
            <LONG_NAME>Pathologic</LONG_NAME>
            <CON_ID>2204850</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2234809</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25330</PreferredName>
        <Version>1</Version>
        <LongName>Duration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25330</PREFERRED_NAME>
            <LONG_NAME>Duration</LONG_NAME>
            <CON_ID>2202512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3008213</PublicId>
      <PreferredName>DAY_CALC_VAL</PreferredName>
      <PreferredDefinition>The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours._The procedure or activity of determining something by mathematical or logical methods._A numerical quantity measured or assigned or computed.</PreferredDefinition>
      <LongName>Day Calculation Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008541</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>NUMS</PreferredName>
        <Version>1</Version>
        <LongName>Numbers</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
      <Representation>
        <PublicId>3008212</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25301:C54125:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Day Calculation Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25301</PREFERRED_NAME>
            <LONG_NAME>Day</LONG_NAME>
            <CON_ID>2202680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54125</PREFERRED_NAME>
            <LONG_NAME>Calculation</LONG_NAME>
            <CON_ID>2654477</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Number of Days from Date of I</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Number of Days from Date of Initial Pathologic Diagnosis to Start Date of Treatment</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CTSP Question</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Number of days from Date of Initial Pathologic Diagnosis to the Date the Agent used to Treat the Patient was First Administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5806857</PublicId>
          <ContextName>OCG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HCMI</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>General CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3134869</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>pharmaceutical_therapy_start_subtract_initial_pathologic_diagnosis_time_duration</AlternateName>
        <AlternateNameType>HCMI Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>OCG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>OCG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType>CALCULATED</DerivationType>
      <DerivationTypeDescription>CALCULATED</DerivationTypeDescription>
      <Methods>Date 1 is the concatenation of the component CDE1 to CDE2 to CDE3 to form a date in the format of DDMMYYYY. Date 2 is the concatenation of the component CDE4 to CDE5 to CDE6 to form a date in the format of DDMMYYYY.</Methods>
      <Rule>Calculation is as follows: 1. CDES 1,2,3 are concatenated to create one calendar date for the event referenced (Date1). 2. CDES 4,5,6 are concatenated to create one calendar date for the event referenced (Date2). 3. Values of both dates are converted to milliseconds since the epoch (January 1, 1970) 4. The values of Date2 are subtracted from the value of Date1. 5. The remainder of the subtraction will be divided by the number of milliseconds in a day (86,400,000).</Rule>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId>5102385</PublicId>
          <LongName>Treatment Start Day Number</LongName>
          <PreferredName>2190058v1.0:2896868v1.0</PreferredName>
          <PreferredDefinition>Numeric value that represents the day the treatment started.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>1</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>5102384</PublicId>
          <LongName>Treatment Start Month Number</LongName>
          <PreferredName>2190058v1.0:2895904v1.0</PreferredName>
          <PreferredDefinition>Numeric value that represents the month the treatment was started.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>2</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>5102386</PublicId>
          <LongName>Treatment Start Year Number</LongName>
          <PreferredName>2190058v1.0:2896906v1.0</PreferredName>
          <PreferredDefinition>Numeric value that represents the year the treatment started.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>3</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2896958</PublicId>
          <LongName>Day Cancer Initial Diagnosis Number</LongName>
          <PreferredName>DAY_CA_INIT_DX_NUM</PreferredName>
          <PreferredDefinition>Numeric value to represent the day of an individual&#39;s initial pathologic diagnosis of cancer.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>4</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2896956</PublicId>
          <LongName>Month Cancer Initial Diagnosis Number</LongName>
          <PreferredName>MON_CA_INIT_DX_NUM</PreferredName>
          <PreferredDefinition>Numeric value to represent the month of an individual&#39;s initial pathologic diagnosis of cancer.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>5</DisplayOrder>
        </ComponentDataElementList_ITEM>
        <ComponentDataElementList_ITEM>
          <PublicId>2896960</PublicId>
          <LongName>Year Cancer Initial Diagnosis Number</LongName>
          <PreferredName>YR_CA_INIT_DX_NUM</PreferredName>
          <PreferredDefinition>Numeric value to represent the year of an individual&#39;s initial pathologic diagnosis of cancer.</PreferredDefinition>
          <Version>1</Version>
          <WorkflowStatus>RELEASED</WorkflowStatus>
          <ContextName>NCIP</ContextName>
          <DisplayOrder>6</DisplayOrder>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1674">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5102385</PUBLICID>
    <LONGNAME>Treatment Start Day Number</LONGNAME>
    <PREFERREDNAME>2190058v1.0:2896868v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the day the treatment started.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1675">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5102384</PUBLICID>
    <LONGNAME>Treatment Start Month Number</LONGNAME>
    <PREFERREDNAME>2190058v1.0:2895904v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the month the treatment was started.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1676">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5102386</PUBLICID>
    <LONGNAME>Treatment Start Year Number</LONGNAME>
    <PREFERREDNAME>2190058v1.0:2896906v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value that represents the year the treatment started.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1677">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2896958</PUBLICID>
    <LONGNAME>Day Cancer Initial Diagnosis Number</LONGNAME>
    <PREFERREDNAME>DAY_CA_INIT_DX_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the day of an individual&#39;s initial pathologic diagnosis of cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1678">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2896956</PUBLICID>
    <LONGNAME>Month Cancer Initial Diagnosis Number</LONGNAME>
    <PREFERREDNAME>MON_CA_INIT_DX_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the month of an individual&#39;s initial pathologic diagnosis of cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1679">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>2896960</PUBLICID>
    <LONGNAME>Year Cancer Initial Diagnosis Number</LONGNAME>
    <PREFERREDNAME>YR_CA_INIT_DX_NUM</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the year of an individual&#39;s initial pathologic diagnosis of cancer.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>TCGA:The Cancer Genome Atlas</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId/>
      <PreferredName/>
      <PreferredDefinition/>
      <LongName/>
      <Version/>
      <WorkflowStatus/>
      <ContextName/>
      <ContextVersion/>
      <ConceptualDomain>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
      </ConceptualDomain>
      <Datatype/>
      <ValueDomainType/>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId/>
        <ContextName/>
        <ContextVersion/>
        <PreferredName/>
        <Version/>
        <LongName/>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME/>
            <LONG_NAME/>
            <CON_ID/>
            <DEFINITION_SOURCE/>
            <ORIGIN/>
            <EVS_SOURCE/>
            <PRIMARY_FLAG_IND/>
            <DISPLAY_ORDER/>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name/>
        <OrganizationName/>
        <DocumentType/>
        <DocumentText/>
        <URL/>
        <Language/>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1680">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5105731</PUBLICID>
    <LONGNAME>Expanded Prostate Cancer Index Composite 17A Past 4 Weeks Level of Sexual Desire Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>EPIC_LEVEL_SEX_DESIRE_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation in the past 4 weeks their level of sexual desire, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EPIC:Expanded Prostate Cancer Index Composite</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5105104</PublicId>
      <PreferredName>5105021v1.0:5105102v1.0</PreferredName>
      <PreferredDefinition>A self-administered questionnaire designed to evaluate patient function and bother after prostate cancer treatment._A period of time consisting of the 28 days before the present._A question about an individual&#39;s level of sexual desire._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Expanded Prostate Cancer Index Composite Past 4 Weeks Level of Sexual Desire Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5105021</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C107630</PreferredName>
        <Version>1</Version>
        <LongName>Expanded Prostate Cancer Index Composite</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107630</PREFERRED_NAME>
            <LONG_NAME>Expanded Prostate Cancer Index Composite</LONG_NAME>
            <CON_ID>3854580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5105102</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C110986:C125037:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past 4 Weeks Level of Sexual Desire Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110986</PREFERRED_NAME>
            <LONG_NAME>Past 4 Weeks</LONG_NAME>
            <CON_ID>3871096</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125037</PREFERRED_NAME>
            <LONG_NAME>Level of Sexual Desire Question</LONG_NAME>
            <CON_ID>5100459</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EPIC:Expanded Prostate Cancer Index Composite</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5094792</PublicId>
      <PreferredName>EPIC_LEVEL_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard related to the level or ability of an individual associated with the EPIC measure.</PreferredDefinition>
      <LongName>EPIC Level or Ability 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very good</VALUEMEANING>
          <MEANINGDESCRIPTION>An indication that something has a high degree of quality, value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3639406</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Very Poor to None</VALUEMEANING>
          <MEANINGDESCRIPTION>Of especially low value or worth.: No person or thing, nobody, not any.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41132, C104315</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4076058</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Poor</VALUEMEANING>
          <MEANINGDESCRIPTION>Of low value or worth.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77959</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3115746</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Fair</VALUEMEANING>
          <MEANINGDESCRIPTION>Having no exceptional quality or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C82489</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206719</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Good</VALUEMEANING>
          <MEANINGDESCRIPTION>Valuable or useful or agreeable or pleasing.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C64975</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-01-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3206718</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Your level of sexual desire?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Your level of sexual desire?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3855897</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EPIC</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sexual Function</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5090657</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1681">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5118216</PUBLICID>
    <LONGNAME>Laboratory Procedure C-Reactive Protein Result Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>2196250v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory results for C-reactive protein.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2196250</PublicId>
      <PreferredName>LAB_CRP_RSLT</PreferredName>
      <PreferredDefinition>information related to the result of the medical procedure that involves testing a sample of blood for C-reactive protein, encoded by the CRP gene this protein is cleaved during biological activation and is associated with host defense mechanisms and inflammatory responses.</PreferredDefinition>
      <LongName>Laboratory Procedure C-Reactive Protein Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2738843</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C60651:C20200</PreferredName>
        <Version>1</Version>
        <LongName>C-Reactive Protein Result</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C60651</PREFERRED_NAME>
            <LONG_NAME>C-Reactive Protein</LONG_NAME>
            <CON_ID>2514638</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the C-r</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the C-reactive protein finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>C-reactive protein</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>C-reactive protein</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>C-reactive protein</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>C-reactive protein</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_CRS_c_react_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_c_react_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>performedClinicalResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPRE_HFPL_c_react_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CBSE_HFPL_c_react_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1682">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5118274</PUBLICID>
    <LONGNAME>IL-6 Laboratory Procedure Performed Finding Status Indicator</LONGNAME>
    <PREFERREDNAME>5118273v1.0:3436461v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the status of the laboratory results for IL-6.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5118273</PublicId>
      <PreferredName>5118271v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.</PreferredDefinition>
      <LongName>IL-6 Laboratory Procedure Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5118271</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C20451:C25294</PreferredName>
        <Version>1</Version>
        <LongName>Interleukin-6 Laboratory Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20451</PREFERRED_NAME>
            <LONG_NAME>Interleukin-6</LONG_NAME>
            <CON_ID>2457977</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3436461</PublicId>
      <PreferredName>3436461v1.0</PreferredName>
      <PreferredDefinition>The result of an examination or inquiry._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.</PreferredDefinition>
      <LongName>Finding Status Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>3436460</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C61036:C25688:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Finding Status Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61036</PREFERRED_NAME>
            <LONG_NAME>Investigation Finding</LONG_NAME>
            <CON_ID>2528540</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not known</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE>2013-03-12</PVENDDATE>
          <VMPUBLICID>2575365</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Known</VALIDVALUE>
          <VALUEMEANING>Known</VALUEMEANING>
          <MEANINGDESCRIPTION>Recognized, familiar, or within the scope of knowledge.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C80137</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-04-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2934435</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2013-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3371379</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2014-03-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Previously reported</VALIDVALUE>
          <VALUEMEANING>Previous Report</VALUEMEANING>
          <MEANINGDESCRIPTION>Occurring prior to something else.: Report; a short account.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C25375, C25627</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2024-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2676338</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is the status of the IL-</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is the status of the IL-6 finding?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Interleukin-6</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Interleukin-6</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Interleukin-6</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Interleukin-6</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6685474</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>ANNA for BRIDG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Testing Set – Moderately Different</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6685478</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_CRS_IL6_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CPST_TOX_IL6_kn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>performedClinicalResult:valueNullFlavorReason</AlternateName>
        <AlternateNameType>HCT_BRIDG_5</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1683">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5120346</PUBLICID>
    <LONGNAME>Adjuvant Chemotherapy Administered First Date</LONGNAME>
    <PREFERREDNAME>ADJCHEMOSTRTDT</PREFERREDNAME>
    <PREFERREDDEFINITION>The date adjuvant chemotherapy was first administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2190188</PublicId>
      <PreferredName>ADJ_CT_ADM</PreferredName>
      <PreferredDefinition>information related to adjuvant chemotherapy administered.</PreferredDefinition>
      <LongName>Adjuvant Chemotherapy Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2140:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Adjuvant Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2140</PREFERRED_NAME>
            <LONG_NAME>Adjuvant</LONG_NAME>
            <CON_ID>2204993</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177665</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Administered</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2016734</PublicId>
      <PreferredName>FIRST_DT</PreferredName>
      <PreferredDefinition>the first date of an assessment, test, or treatment.</PreferredDefinition>
      <LongName>First Date</LongName>
      <Version>3</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yyyy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208018</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25509:C25164</PreferredName>
        <Version>1</Version>
        <LongName>First Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25509</PREFERRED_NAME>
            <LONG_NAME>First</LONG_NAME>
            <CON_ID>2206214</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>First date adjuvant chemother</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>First date adjuvant chemotherapy given</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Date adjuvant chemotherapy first administered</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1684">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5120394</PUBLICID>
    <LONGNAME>Adjuvant Chemotherapy Complete Yes No Not Applicable Indicator</LONGNAME>
    <PREFERREDNAME>ADJCHEMODONE</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no/not applicable indicator for information related to the completion of adjuvant chemotherapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5120393</PublicId>
      <PreferredName>ADJCHEMODONE</PreferredName>
      <PreferredDefinition>Information related to the completion of adjuvant chemotherapy.</PreferredDefinition>
      <LongName>Adjuvant Chemotherapy Complete</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2404910</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5120391</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2140:C25250</PreferredName>
        <Version>1</Version>
        <LongName>Adjuvant Complete</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2140</PREFERRED_NAME>
            <LONG_NAME>Adjuvant</LONG_NAME>
            <CON_ID>2204993</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25250</PREFERRED_NAME>
            <LONG_NAME>Complete</LONG_NAME>
            <CON_ID>2203885</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506036</PublicId>
      <PreferredName>YES_NO_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.</PreferredDefinition>
      <LongName>Yes No Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694966</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49797</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3b</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49797</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Not Applicable Response</LONG_NAME>
            <CON_ID>2694965</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient complete all</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient complete all adjuvant chemotherapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1685">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5126916</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale S8 Past Week Usual Severity Feeling of Drowsiness Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MSAS_S_DROWSY_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation in the past week the severity of their drowsy feelings, using a four-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS:Memorial Symptom Assessment Scale. Portenoy, RK, et.al. Eur J Cancer. 1994;30A(9):1326-36.</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5114774</PublicId>
      <PreferredName>5114473v1.0:5114772v1.0</PreferredName>
      <PreferredDefinition>A patient-rated instrument developed to provide multidimensional information about a diverse group of common symptoms. This 32-question, self-rated questionnaire evaluates the prevalence, characteristics, and distress associated with each of the symptoms._The most recent week, including today._A question about the usual severity of an individual&#39;s drowsiness._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale Past Week Usual Severity Feeling of Drowsiness Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5114473</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C125238</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125238</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale</LONG_NAME>
            <CON_ID>5109052</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5114772</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C125305:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Usual Severity Feeling of Drowsiness Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125305</PREFERRED_NAME>
            <LONG_NAME>Usual Severity Feeling of Drowsiness Question</LONG_NAME>
            <CON_ID>5109124</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS-SF:Memorial Symptom Assessment Scale Short Form.Chang VT, et.al., Cancer. 2000 Sep 1;89(5):1162-71.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5114471</PublicId>
      <PreferredName>MSAS_SEVERE_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Slight) to 4 (Very Severe) on a Likert scale used on the Memorial Symptom Assessment Scale questionnaire.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale Severity Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>MSAS-SF:Memorial Symptom Assessment Scale Short Form.Chang VT, et.al., Cancer. 2000 Sep 1;89(5):1162-71.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Exceedingly intense or unpleasant in degree, quality or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906433</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Severe</VALUEMEANING>
          <MEANINGDESCRIPTION>Intensely bad or unpleasant in degree, quality or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70667</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4633034</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Moderate</VALUEMEANING>
          <MEANINGDESCRIPTION>The quality of being within reasonable or average limits; not excessive or extreme.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C61376</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3225979</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Slight</VALUEMEANING>
          <MEANINGDESCRIPTION>Small or little in size, quantity, or degree.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C103807</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-01-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3906434</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure.  The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents.  Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MSAS</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #56 of 126</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How SEVERE was your feeling d</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How SEVERE was your feeling drowsy usually?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4551587</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4551585</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS (Memorial Symptom Assessment Scale)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5115651</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-HRQoL Measures</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4718285</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5635300</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Case Report Form (CRF) Modules</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Cancer and/or Treatment Related Symptoms</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5711252</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840828</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS (Memorial Symptom Assessment Scale)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840837</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCI Standards</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1686">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5143961</PUBLICID>
    <LONGNAME>Gene Variant Detected Indicator</LONGNAME>
    <PREFERREDNAME>VARIANT_DETECTED</PREFERREDNAME>
    <PREFERREDDEFINITION>An indicator of whether a protocol specified genetic variant was detected [manually curated].</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>OHSU Knight</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5143960</PublicId>
      <PreferredName>5143958v1.0:2177539v1.0</PreferredName>
      <PreferredDefinition>A variation in the nucleic acid sequence of a specific gene._An alteration or difference from a norm or standard._Detected; perceived or discerned.</PreferredDefinition>
      <LongName>Gene Mutant Variation Detected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>OHSU Knight</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5143958</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C97927:C25713</PreferredName>
        <Version>1</Version>
        <LongName>Gene Mutant Variation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C97927</PREFERRED_NAME>
            <LONG_NAME>Gene Variant</LONG_NAME>
            <CON_ID>3343010</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25713</PREFERRED_NAME>
            <LONG_NAME>Variation</LONG_NAME>
            <CON_ID>2203982</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177539</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Detected</PreferredName>
        <Version>1</Version>
        <LongName>Detected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25481</PREFERRED_NAME>
            <LONG_NAME>Detected</LONG_NAME>
            <CON_ID>2203891</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506035</PublicId>
      <PreferredName>YES_NO_UNKNOWN_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.</PreferredDefinition>
      <LongName>Yes No Unknown Not Applicable Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>14</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2694968</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49486</PreferredName>
        <Version>1</Version>
        <LongName>Ind-4</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49486</PREFERRED_NAME>
            <LONG_NAME>Yes, No, Unknown, or Not Applicable Response</LONG_NAME>
            <CON_ID>2475171</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3261243</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Variant detected?</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Variant detected?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Were there additional variants in the report not  annotated here?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7409079</PublicId>
          <ContextName>Training</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CS for Training Gwen</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Level 2 Training 2 Gwen CSI Level </ClassificationSchemeItemName>
        <ClassificationSchemeItemType>DISEASE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7409397</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>COG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>COG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1687">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5151268</PUBLICID>
    <LONGNAME>EORTC QLQ-CIPN20 35 Extent During Past Week Have Shooting or Burning Pain in Fingers or Hands Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>EORTC_CIPN_Q35_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception during the past week of the extent to which they have shooting or burning pain in their fingers or hands, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-CIPN20:European Organization for Research and Treatment of Cancer, Study Group on Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Module, 1999.</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5148782</PublicId>
      <PreferredName>5148751v1.0:5148780v1.0</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life related to symptoms and functional limitations in patients with  Chemotherapy-Induced Peripheral Neuropathy (CIPN)._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time._At some point in a given period of time._The most recent week, including today._A question about whether an individual has or had shooting or burning pain in their fingers or hands._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Extent During Past Week Have Shooting or Burning Pain in Fingers or Hands Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5148751</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C125719</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125719</PREFERRED_NAME>
            <LONG_NAME>Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20</LONG_NAME>
            <CON_ID>5145277</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5148780</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5148780v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Extent During Past Week Have Shooting or Burning Pain in Fingers or Hands Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25332</PREFERRED_NAME>
            <LONG_NAME>Extent</LONG_NAME>
            <CON_ID>2203921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125724</PREFERRED_NAME>
            <LONG_NAME>Have Shooting or Burning Pain in Fingers or Hands Question</LONG_NAME>
            <CON_ID>5145282</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EORTC QLQ-CIPN20:European Organization for Research and Treatment of Cancer, Study Group on Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Module, 1999.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you have shooting or burn</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you have shooting or burning pain in your fingers or hands?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Question Sequence including QLQ-30</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #35 of 50</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure.</DocumentText>
        <URL>http://groups.eortc.be/qol/chemotherapy-induced-peripheral-neuropathy-eortc-qlq-cipn20</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-CIPN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5151352</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-CIPN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000295</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_QSORRES_CIPN20_35</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1688">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5151272</PUBLICID>
    <LONGNAME>EORTC QLQ-CIPN20 36 Extent During Past Week Have Shooting or Burning Pain in Toes or Feet Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>EORTC_CIPN_Q36_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception during the past week of the extent to which they have shooting or burning pain in their toes or feet, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-CIPN20:European Organization for Research and Treatment of Cancer, Study Group on Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Module, 1999.</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5148785</PublicId>
      <PreferredName>5148751v1.0:5148783v1.0</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life related to symptoms and functional limitations in patients with  Chemotherapy-Induced Peripheral Neuropathy (CIPN)._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time._At some point in a given period of time._The most recent week, including today._A question about whether an individual has or had shooting or burning pain in their toes or feet._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Extent During Past Week Have Shooting or Burning Pain in Toes or Feet Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5148751</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C125719</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125719</PREFERRED_NAME>
            <LONG_NAME>Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20</LONG_NAME>
            <CON_ID>5145277</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5148783</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5148783v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Extent During Past Week Have Shooting or Burning Pain in Toes or Feet Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25332</PREFERRED_NAME>
            <LONG_NAME>Extent</LONG_NAME>
            <CON_ID>2203921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125725</PREFERRED_NAME>
            <LONG_NAME>Have Shooting or Burning Pain in Toes or Feet Question</LONG_NAME>
            <CON_ID>5145283</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EORTC QLQ-CIPN20:European Organization for Research and Treatment of Cancer, Study Group on Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Module, 1999.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did you have shooting or burn</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did you have shooting or burning pain in your toes or feet?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Question Sequence including QLQ-30</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #36 of 50</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure.</DocumentText>
        <URL>http://groups.eortc.be/qol/chemotherapy-induced-peripheral-neuropathy-eortc-qlq-cipn20</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-CIPN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5151352</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-CIPN20</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000295</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>CCTG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>QS_QSORRES_CIPN20_36</AlternateName>
        <AlternateNameType>OID, CCTG</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1689">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5152079</PUBLICID>
    <LONGNAME>Other Genetic Modification Performed Specify Text</LONGNAME>
    <PREFERREDNAME>5152077v1.0:2799057v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The free-text field that describes other genetic modifications that were performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5152077</PublicId>
      <PreferredName>5152075v1.0:2241241v1.0</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Techniques used for deliberately altering the genetic material of an organism in order to make them capable of making new substances or performing new or different functions._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Other Genetic Modification Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435033</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16847</PreferredName>
        <Version>1</Version>
        <LongName>Techniques</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5152075</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C22489</PreferredName>
        <Version>1</Version>
        <LongName>Other Organism Modification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C22489</PREFERRED_NAME>
            <LONG_NAME>Organism Modification</LONG_NAME>
            <CON_ID>2673209</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2241241</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38000</PreferredName>
        <Version>1</Version>
        <LongName>Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2799057</PublicId>
      <PreferredName>SPC_TXT</PreferredName>
      <PreferredDefinition>Be specific about something; define clearly._Text; the words of something written.</PreferredDefinition>
      <LongName>Specify Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2799056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25685:C25704</PreferredName>
        <Version>1</Version>
        <LongName>Specify Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What was the other genetic mo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What was the other genetic modification performed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other genetic manipulation:</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify other genetic manipulation:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify other genetic manipulation:</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Specify other genetic manipulation:</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTI_CPM_oth_gene_manip_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CTP_CPM_oth_gene_manip_spe</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1690">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5153329</PUBLICID>
    <LONGNAME>EORTC QLQ-PAN26 50 Extent During Past Week Troubled With Side-Effects from Treatment Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>EORTC_PAN_Q50_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception during the past week of the extent to which they have been troubled with side-effects from your treatment, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-Pan26: EORTC Quality of Life Questionnaire Pancreas 26</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5152921</PublicId>
      <PreferredName>5152614v1.0:5152919v1.0</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 26 questions designed to assess pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes)._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time._At some point in a given period of time._The most recent week, including today._A question about the extent to which an individual is or was troubled with side effects from their treatment._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer 26 Extent During Past Week Troubled with Side Effects from Treatment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5152614</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C125906</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer 26</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125906</PREFERRED_NAME>
            <LONG_NAME>Quality of Life Questionnaire - Pancreatic Cancer 26</LONG_NAME>
            <CON_ID>5152254</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5152919</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5152919v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Extent During Past Week Troubled with Side Effects from Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25332</PREFERRED_NAME>
            <LONG_NAME>Extent</LONG_NAME>
            <CON_ID>2203921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125918</PREFERRED_NAME>
            <LONG_NAME>Extent Troubled with Side Effects from Treatment Question</LONG_NAME>
            <CON_ID>5152265</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EORTC QLQ-Pan26: EORTC Quality of Life Questionnaire Pancreas 26</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>To what extent have you been</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>To what extent have you been troubled with side-effects from your treatment?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-PAN26</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5138855</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-PAN26</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000506</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCI Standards</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCI Standards</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1691">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5155536</PUBLICID>
    <LONGNAME>Perceived Stress Scale - 14 Questionnaire How Often Able to Control the Way You Spend Your Time in the Last Month Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PSS14_CTRL_TIME_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation of how often in the past month they had been able to control the way they spent their time, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PSS-14:Perceived Stress Scale-14. Cohen, S., Kamarck, T., &amp; Mermelstein, R., Journal of Health and Social Behavior, 24, 385-396, 1983.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5154765</PublicId>
      <PreferredName>5154451v1.0:5154763v1.0</PreferredName>
      <PreferredDefinition>A 14 item self-report questionnaire that utilizes a 5-point Likert Scale rating system to assess an individual&#39;s perception of the stressfulness of life situations in the past month._A question about the frequency an individual has been able to control the way they spent their time in the last month._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Perceived Stress Scale - 14 Questionnaire How Often Able to Control the Way You Spend Your Time in the Last Month Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5154451</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126095</PreferredName>
        <Version>1</Version>
        <LongName>Perceived Stress Scale - 14 Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126095</PREFERRED_NAME>
            <LONG_NAME>Perceived Stress Scale - 14 Questionnaire</LONG_NAME>
            <CON_ID>5153111</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5154763</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126099:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Often Able to Control the Way You Spend Your Time in the Last Month Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126099</PREFERRED_NAME>
            <LONG_NAME>How Often Able to Control the Way You Spend Your Time in the Last Month Question</LONG_NAME>
            <CON_ID>5153115</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5154431</PublicId>
      <PreferredName>5154431v1.0</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (Never) to 4 (Very often) on a Likert scale used on the Perceived Stress Scale Questionnaire.</PreferredDefinition>
      <LongName>Perceived Stress Scale Questionnaire Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Fairly Often</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something occurs relatively frequently.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95144</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232438</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Almost Never</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something rarely happens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very Often</VALUEMEANING>
          <MEANINGDESCRIPTION>On most occasions, or in most situations.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91245</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3165908</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In the last month, how often</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In the last month, how often have you been able to control the way you spend your time?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Perceived Stress Scale - 14 (PSS-14)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 2 of 14</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5151329</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PSS-14</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PSS-14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5151342</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Perceived Stress Scale-14 (PSS-14)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900344</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1692">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5189620</PUBLICID>
    <LONGNAME>Human Activity Profile 20 Using Public Transport or Driving a Car 100 Miles or More 3 Point Scale</LONGNAME>
    <PREFERREDNAME>HAP_Q20_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of their ability to use public transport or drive a car (100 miles or more), using a three point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5188854</PublicId>
      <PreferredName>5188571v1.0:5188852v1.0</PreferredName>
      <PreferredDefinition>A self-administered instrument designed to measure energy expenditure or physical fitness. It was originally developed to measure quality of life achieved by patients in rehabilitation programs for chronic obstructive pulmonary disease, but has also been used as a measure of physical activity in both healthy and impaired populations. The profile consists of 94 common daily activities listed in ascending order according to the energy required to perform them. Activities including self-care tasks, personal/household work, entertainment/social activities, and independent exercise pursuits and respondents are requested to indicate if they are currently able to perform the activity (unassisted), they have stopped performing the activity, or they have never performed the activity._A question about an individual&#39;s ability to use public transport or drive a car for 100 miles or more.</PreferredDefinition>
      <LongName>Human Activity Profile Using Public Transport or Driving a Car, 100 Miles or More</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5188571</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C48948</PreferredName>
        <Version>1</Version>
        <LongName>Human Activity Profile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48948</PREFERRED_NAME>
            <LONG_NAME>Human Activity Profile</LONG_NAME>
            <CON_ID>5168044</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5188852</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126157</PreferredName>
        <Version>1</Version>
        <LongName>Using Public Transport or Driving a Car, 100 Miles or More</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126157</PREFERRED_NAME>
            <LONG_NAME>Using Public Transport or Driving a Car, 100 Miles or More Question</LONG_NAME>
            <CON_ID>5168090</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5188567</PublicId>
      <PreferredName>HAP_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>HAP Activity 3 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>32</MaximumLength>
      <MinimumLength>23</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HAP:Human Activity Profile. Daughton, DM and Fix, James, J Rehabil Res Dev. 41(4): 621-630, 1980.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Never Did This Activity</VALIDVALUE>
          <VALUEMEANING>Never Did This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is never did an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126233</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188568</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Have Stopped Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Have Stopped Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual has stopped doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126232</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188569</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Still Doing This Activity</VALIDVALUE>
          <VALUEMEANING>Still Doing This Activity</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is still doing an activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126231</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5188570</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using public transport or dri</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Using public transport or driving a car (100 miles or more)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Human Activity Profile (HAP)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 20 of 94</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5187973</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>HAP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>HAP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5187974</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Human Activity Profile (HAP)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900309</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1693">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5189904</PUBLICID>
    <LONGNAME>CAncer Rehabilitation Evaluation System for Research 26 How Much Past Month Difficulty Finding Clothes to Fit Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>CARES_Q26_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated observation of how much in the past month, including today, they had difficulty finding clothes to fit, using a five point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CARES:CAncer Rehabilitation Evaluation System for Research. Schag and Heinrich, CARES Consultants, 1988.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5189892</PublicId>
      <PreferredName>5189883v1.0:5189890v1.0</PreferredName>
      <PreferredDefinition>A self-reported, clinically relevant instrument designed to assess the rehabilitation needs and daily problems of patients with cancer._How much there is of something that you can measure; the total amount or number._Before the present time._One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon&#39;s phases, about 30 days or 4 weeks._A question about whether an individual has difficulty finding clothes to fit._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Cancer Rehabilitation Evaluation System for Research Quantity Past Month Difficulty Finding Clothes to Fit Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5189883</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C126278</PreferredName>
        <Version>1</Version>
        <LongName>Cancer Rehabilitation Evaluation System for Research</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126278</PREFERRED_NAME>
            <LONG_NAME>Cancer Rehabilitation Evaluation System for Research</LONG_NAME>
            <CON_ID>5189871</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5189890</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5189890v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Quantity Past Month Difficulty Finding Clothes to Fit Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25256</PREFERRED_NAME>
            <LONG_NAME>Quantity</LONG_NAME>
            <CON_ID>2202797</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25609</PREFERRED_NAME>
            <LONG_NAME>Past</LONG_NAME>
            <CON_ID>2203983</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29846</PREFERRED_NAME>
            <LONG_NAME>Month</LONG_NAME>
            <CON_ID>2202580</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126282</PREFERRED_NAME>
            <LONG_NAME>Difficulty Finding Clothes to Fit Question</LONG_NAME>
            <CON_ID>5189874</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>CARES:CAncer Rehabilitation Evaluation System for Research. Schag and Heinrich, CARES Consultants, 1988.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5189880</PublicId>
      <PreferredName>CARES_SCALE</PreferredName>
      <PreferredDefinition>an ordered reference standard.</PreferredDefinition>
      <LongName>CARES 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>CARES:CAncer Rehabilitation Evaluation System for Research. Schag and Heinrich, CARES Consultants, 1988.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Fair Amount</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was a fair amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126286</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5189882</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective response indicating that something is or was a large amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126287</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5189881</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-03-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I have difficulty finding clo</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I have difficulty finding clothes to fit</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5187972</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CARES</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CARES</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5187976</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1694">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5207118</PUBLICID>
    <LONGNAME>Antithrombin-III Administered Indicator</LONGNAME>
    <PREFERREDNAME>5207117v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not antithrombin-III was administered.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5207117</PublicId>
      <PreferredName>5207115v1.0:2233610v1.0</PreferredName>
      <PreferredDefinition>Antithrombin-III (464 aa, ~53 kDa) is encoded by the human SERPINC1 gene. This protein is involved in the negative regulation of serine proteinase activity during blood coagulation._The act of having given something (e.g., a medication or test).</PreferredDefinition>
      <LongName>Antithrombin-III Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5207115</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C104683</PreferredName>
        <Version>1</Version>
        <LongName>Antithrombin-III</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C104683</PREFERRED_NAME>
            <LONG_NAME>Antithrombin-III</LONG_NAME>
            <CON_ID>5207114</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233610</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25382</PreferredName>
        <Version>1</Version>
        <LongName>Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was antithrombin-III administ</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was antithrombin-III administered?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anti-thrombin III</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Anti-thrombin III</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Anti-thrombin III</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Anti-thrombin III</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VOD_THPY_antithrom_III_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>VOD_CS_antithrom_III_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1695">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5207134</PUBLICID>
    <LONGNAME>Person High Risk Seizure Disorder Clinical Trial Eligibility Criteria Code Indicator</LONGNAME>
    <PREFERREDNAME>HIRSK_SZRDR_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A coded response for questions related to the high risk of seizures as outlined in the study protocol to allow clinical trial participation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5207133</PublicId>
      <PreferredName>2236731v1.0:5207131v1.0</PreferredName>
      <PreferredDefinition>A human being._The potential future harm that may arise from some present action or attribute or condition is almost certain._A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Person High Risk Seizure Disorder Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2236731</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25190</PreferredName>
        <Version>1</Version>
        <LongName>Person</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25190</PREFERRED_NAME>
            <LONG_NAME>Person</LONG_NAME>
            <CON_ID>2202486</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5207131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C102401:C3020:C16112</PreferredName>
        <Version>1</Version>
        <LongName>High Risk Seizure Disorder Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C102401</PREFERRED_NAME>
            <LONG_NAME>High Risk</LONG_NAME>
            <CON_ID>3637811</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3020</PREFERRED_NAME>
            <LONG_NAME>Seizure Disorder</LONG_NAME>
            <CON_ID>2971316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is patient at high risk of se</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is patient at high risk of seizures (e.g. those patients with an uncontrolled seizure disorder, and/or patients who have had a focal or generalized seizure within the last 12 months)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Physical &amp; Concomitant Requirements</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000083</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1696">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5211063</PUBLICID>
    <LONGNAME>Ovarian Carcinoma Histologic Primary Classification Other Specify</LONGNAME>
    <PREFERREDNAME>OVR_CRC_HX_PRI_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The type of tumor submitted/identified upon slide review that has not been previously listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5210572</PublicId>
      <PreferredName>3304105v1.0:2430074v1.0</PreferredName>
      <PreferredDefinition>information relating to the histologic primary classification of ovarian carcinoma._</PreferredDefinition>
      <LongName>Ovarian Carcinoma Histologic Primary Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3304105</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4908</PreferredName>
        <Version>1</Version>
        <LongName>Ovarian Carcinoma</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4908</PREFERRED_NAME>
            <LONG_NAME>Ovarian Carcinoma</LONG_NAME>
            <CON_ID>2593146</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2430074</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25526:C25251:C25161</PreferredName>
        <Version>1</Version>
        <LongName>Histologic Primary Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25526</PREFERRED_NAME>
            <LONG_NAME>Histologic</LONG_NAME>
            <CON_ID>2206234</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Histologic Type - other</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Histologic Type - other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>BPV - Specify Other histologic type or histologic type details</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Specify Other histologic type or histologic type details</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovary Local Path Review</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736426</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1697">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5215271</PUBLICID>
    <LONGNAME>Therapeutic Insulin During Surgical Procedure Administration Other Specify</LONGNAME>
    <PREFERREDNAME>INSULIN_SURG_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the insulin agent that was administered during surgery.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5211164</PublicId>
      <PreferredName>5211161v1.0:5211162v1.0</PreferredName>
      <PreferredDefinition>A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues._At some point in a given period of time._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.</PreferredDefinition>
      <LongName>Therapeutic Insulin During Surgical Procedure Administration</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435024</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1908</PreferredName>
        <Version>1</Version>
        <LongName>Drug or Chemical</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5211161</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C581</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Insulin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C581</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Insulin</LONG_NAME>
            <CON_ID>5211160</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5211162</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25490:C15329:C25409</PreferredName>
        <Version>1</Version>
        <LongName>During Surgical Procedure Administration</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15329</PREFERRED_NAME>
            <LONG_NAME>Surgical Procedure</LONG_NAME>
            <CON_ID>2202399</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25409</PREFERRED_NAME>
            <LONG_NAME>Administration</LONG_NAME>
            <CON_ID>2202552</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify insulin</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify insulin</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Colon Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736432</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Kidney Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736433</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Lung Surgery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736434</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovary Sugery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736435</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1698">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5215515</PUBLICID>
    <LONGNAME>Pelvis Lavage Fluid Collected Indicator</LONGNAME>
    <PREFERREDNAME>PELVIS_LAVG_COLL_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>An indication of whether pelvic washings were collected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5212015</PublicId>
      <PreferredName>2177069v1.0:5212013v1.0</PreferredName>
      <PreferredDefinition>The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans._Fluid introduced into, and collected from, a body cavity by lavage procedure._Collected; brought together in one place.</PreferredDefinition>
      <LongName>Pelvis Lavage Fluid Collected</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177069</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Pelvis</PreferredName>
        <Version>1</Version>
        <LongName>Pelvis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12767</PREFERRED_NAME>
            <LONG_NAME>Pelvis</LONG_NAME>
            <CON_ID>2202775</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5212013</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103411:C25452</PreferredName>
        <Version>1</Version>
        <LongName>Lavage Fluid Collected</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103411</PREFERRED_NAME>
            <LONG_NAME>Lavage Fluid</LONG_NAME>
            <CON_ID>5212012</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25452</PREFERRED_NAME>
            <LONG_NAME>Collected</LONG_NAME>
            <CON_ID>2203888</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Record Pelvic washing collect</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Record Pelvic washing collection?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Ovary Sugery-Anesthesia</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736435</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1699">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5215743</PUBLICID>
    <LONGNAME>Patient Refractory Blood Transfusion Eligibility Indicator</LONGNAME>
    <PREFERREDNAME>2233604v1.0:3438700v1.0_YES_NO</PREFERREDNAME>
    <PREFERREDDEFINITION>the yes/no indicator of patient being refractory to transfusions (red blood cell, platelet, or both) to determine clinical trial eligibility for a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NRG CRF:NRG Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3438702</PublicId>
      <PreferredName>2233604v1.0:3438700v1.0</PreferredName>
      <PreferredDefinition>Indicator of patient being refractory to transfusions (red blood cell, platelet, or both) to determine clinical trial eligibility for a patient.</PreferredDefinition>
      <LongName>Patient Refractory Blood Transfusion Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3438700</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38014:C15192:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Refractory Blood Transfusion Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38014</PREFERRED_NAME>
            <LONG_NAME>Refractory</LONG_NAME>
            <CON_ID>2205322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15192</PREFERRED_NAME>
            <LONG_NAME>Blood Transfusion</LONG_NAME>
            <CON_ID>2615251</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is the patient unwilling to b</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is the patient unwilling to be transfused with blood components?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1700">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5216258</PUBLICID>
    <LONGNAME>Consent Not Obtained Other Specify</LONGNAME>
    <PREFERREDNAME>CONSENT_NOT_OBT_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>The response that indicates the reason that consent was not obtained that has not previously been listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5215899</PublicId>
      <PreferredName>2647056v1.0:5215897v1.0</PreferredName>
      <PreferredDefinition>Permission to do something._Not acquired, gained or come to the possession.</PreferredDefinition>
      <LongName>Consent Not Obtained</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2647056</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25460</PreferredName>
        <Version>1</Version>
        <LongName>Consent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25460</PREFERRED_NAME>
            <LONG_NAME>Consent</LONG_NAME>
            <CON_ID>2203590</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5215897</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C67325</PreferredName>
        <Version>1</Version>
        <LongName>Not Obtained</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67325</PREFERRED_NAME>
            <LONG_NAME>Not Obtained</LONG_NAME>
            <CON_ID>4888054</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Reason consent not obtained -</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Reason consent not obtained - other</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate Screening</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736417</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1701">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5216271</PUBLICID>
    <LONGNAME>Patient Geographic Ethnic Group Category</LONGNAME>
    <PREFERREDNAME>GEOGRAPH_ETHNIC_CAT</PREFERREDNAME>
    <PREFERREDDEFINITION>Classification categories the participant either identifies with or is identified with by others as a result of geographical factors.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5215933</PublicId>
      <PreferredName>2177068v1.0:5215931v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Of or relating to the science of geography; determined by geography._A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.</PreferredDefinition>
      <LongName>Patient Geographic Ethnic Group</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2177068</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Patient</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5215931</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C37957:C16564</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Ethnic Group</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37957</PREFERRED_NAME>
            <LONG_NAME>Geographic</LONG_NAME>
            <CON_ID>2434959</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16564</PREFERRED_NAME>
            <LONG_NAME>Ethnic Group</LONG_NAME>
            <CON_ID>2221860</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5215951</PublicId>
      <PreferredName>5215951v1.0</PreferredName>
      <PreferredDefinition>A grouping of items based on some commonality or by user defined characteristics.</PreferredDefinition>
      <LongName>Geographical Ethnic Group Category</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>75</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
      <Representation>
        <PublicId>2433877</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25372</PreferredName>
        <Version>1</Version>
        <LongName>Category</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25372</PREFERRED_NAME>
            <LONG_NAME>Category</LONG_NAME>
            <CON_ID>2203876</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Australian</VALIDVALUE>
          <VALUEMEANING>Australian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the country or continent of Australia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126535</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5230637</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Europe </VALIDVALUE>
          <VALUEMEANING>Europe</VALUEMEANING>
          <MEANINGDESCRIPTION>The continent whose boundaries are the Atlantic Ocean in the west, the Arctic Ocean to the north, the Ural Mountains and Ural River in the east, the Caspian Sea, Caucasus mountains and Black Sea in the southeast and the Mediterranean Sea in the south.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26274</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4512828</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asia </VALIDVALUE>
          <VALUEMEANING>Asia</VALUEMEANING>
          <MEANINGDESCRIPTION>The world&#39;s largest continent; it occupies the eastern part of the Eurasian landmass and its adjacent islands and is separated from Europe by the Ural Mountains.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26273</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5356418</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Africa </VALIDVALUE>
          <VALUEMEANING>Africa</VALUEMEANING>
          <MEANINGDESCRIPTION>The continent located south of Europe and bordered to the west by the South Atlantic and to the east by the India Ocean.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-07-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570074</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Middle Eastern</VALIDVALUE>
          <VALUEMEANING>Middle Eastern</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person having origins in the region of southwest Asia, between the India subcontinent and Europe, including Kuwait, Turkey, Lebanon, Israel, Iraq, Iran, Jordan, Saudi Arabia, lands east of Pakistan or the other countries of the Arabian Peninsula.  Also includes people of Jewish ethnicity including Sephardic and Ashkenazic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77820</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579664</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hispanic or Latino</VALIDVALUE>
          <VALUEMEANING>Hispanic or Latino</VALUEMEANING>
          <MEANINGDESCRIPTION>A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, &quot;Spanish origin,&quot; can be used in addition to &quot;Hispanic or Latino.&quot; (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581176</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Western European</VALIDVALUE>
          <VALUEMEANING>Western European</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person having origins in any of the countries of Western Europe such as Spain, Portugal, or France.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77817</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579668</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Scandinavian</VALIDVALUE>
          <VALUEMEANING>Scandinavian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the countries of Scandinavia: Denmark, Norway and Sweden. Finland and Iceland are generally included as part of the Scandinavian region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126538</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215952</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Mediterranean</VALIDVALUE>
          <VALUEMEANING>Mediterranean</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person having origins in a country such as  Italy, Greece, Romania, Turkey, and Bulgaria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77811</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579663</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Icelandic</VALIDVALUE>
          <VALUEMEANING>Icelandic</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the country of Iceland.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126537</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2630336</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eastern European</VALIDVALUE>
          <VALUEMEANING>Eastern European</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person having origins in any of the countries of Eastern Europe such as Czechoslovakia, Poland, Croatia, Hungary, Slovenia, Former Soviet Union, or Finland. It also includes persons who call themselves Gypsies from this region.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77819</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579662</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>New Zealander</VALIDVALUE>
          <VALUEMEANING>New Zealander</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the country of New Zealand.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126536</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Indian</VALIDVALUE>
          <VALUEMEANING>Asian Indian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in the original peoples of the Indian sub-continent. In North America the term is used to distinguish this population group from Native Americans. The concept is close to the term South Asian but several major South Asian populations such as Pakistani and Bangladeshi may not identify with it.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41262</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577286</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Japanese</VALIDVALUE>
          <VALUEMEANING>Japanese</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of Japan.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43392</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570994</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Chinese</VALIDVALUE>
          <VALUEMEANING>Chinese</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of China.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43391</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570992</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central Asian</VALIDVALUE>
          <VALUEMEANING>Central Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the Asian countries between the Caspian Sea in the west, China in the east, Afghanistan in the south, and Russia in the north.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126534</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>South American</VALIDVALUE>
          <VALUEMEANING>South American</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the countries of South America.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126532</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Caribbean</VALIDVALUE>
          <VALUEMEANING>Caribbean</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of islands in the Caribbean Sea. These islands curve southward from the bottom tip of Florida to the Northwest of Venezuela in South America. There are at least 7,000 islands, islets, reefs and cayes in the region. There exist twenty-five territories, including sovereign states, overseas departments and dependencies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26320</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Latin American</VALIDVALUE>
          <VALUEMEANING>Latin American</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the countries of the Americas or the Caribbean where Spanish or Portuguese is spoken.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126531</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2654033</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>North American</VALIDVALUE>
          <VALUEMEANING>North American</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person of European, Middle Eastern, or North African ancestral origins whose family settled in a North American country such as the United States of America or Canada.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77812</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579666</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African American</VALIDVALUE>
          <VALUEMEANING>Black or African American</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the Black racial groups of Africa. Terms such as &quot;Haitian&quot; or &quot;Negro&quot; can be used in addition to &quot;Black or African American&quot;. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16352</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5021394</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>South African</VALIDVALUE>
          <VALUEMEANING>South African</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the country of South Africa.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126530</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>North African</VALIDVALUE>
          <VALUEMEANING>North African</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the countries of the northern part of the African continent: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, and Western Sahara.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126529</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Central African</VALIDVALUE>
          <VALUEMEANING>Central African</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the countries of the central part of the African continent: Burundi, the Central African Republic, Chad, the Democratic Republic of the Congo, and Rwanda.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126528</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Australia/New Zealand</VALIDVALUE>
          <VALUEMEANING>Australia And/Or New Zealand</VALUEMEANING>
          <MEANINGDESCRIPTION>The continent and country between the Indian Ocean and the South Pacific Ocean, south of Asia.: Used to indicate that either or both of two items or options may be valid.: A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C16914, C48928, C16311</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5377232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other Ethnic Background, specify</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Intercontinental</VALIDVALUE>
          <VALUEMEANING>Intercontinental Ethnicity</VALUEMEANING>
          <MEANINGDESCRIPTION>A collection of ethnic geographical categories including Middle Eastern and Hispanic.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128459</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5377231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Americas</VALIDVALUE>
          <VALUEMEANING>American Ethnicity</VALUEMEANING>
          <MEANINGDESCRIPTION>A collection of ethnic geographical categories including African American, North American, Latin American, Caribbean, and South American.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128457</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-08-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5377233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown/Don&#39;t know</VALIDVALUE>
          <VALUEMEANING>Unknown Does Not Know</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.: The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142, C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378831</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Southeastern European</VALIDVALUE>
          <VALUEMEANING>Southeastern European</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the European countries of the Balkan peninsula: Turkey, Albania, Bosnia and Herzegovina, Bulgaria, Republic of Macedonia, Romania, Serbia, Greece, Croatia, Moldova and Montenegro.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153344</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378832</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Northern European</VALIDVALUE>
          <VALUEMEANING>Northern European</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person having origins in any of the countries of northern Europe such as Belgium, Denmark, Austria, Switzerland, Norway, Sweden, or Great Britain.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C77814</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579667</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African Descent/Other</VALIDVALUE>
          <VALUEMEANING>African Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person with African ancestral origins who self identifies, or is identified, as African. The concept does not refer to those of other ancestry, for example, European and South Asian. In practice, the term mainly refers to people originated from forty-eight sub-Saharan Africa nations; and excludes individuals from North Africa countries, e.g. such as Algeria, Morocco, Egypt, Tunisia with Arab and Berber ethnicity.: Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649, C42331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378833</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African Descent/Sub-Saharan</VALIDVALUE>
          <VALUEMEANING>Sub-Saharan African</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestral origins are in any of the African countries that are fully or partially located south of the Sahara desert.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153346</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378834</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African Descent/Caribbean</VALIDVALUE>
          <VALUEMEANING>African Caribbean</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person with African ancestral origins who self identifies, or is identified, as African. The concept does not refer to those of other ancestry, for example, European and South Asian. In practice, the term mainly refers to people originated from forty-eight sub-Saharan Africa nations; and excludes individuals from North Africa countries, e.g. such as Algeria, Morocco, Egypt, Tunisia with Arab and Berber ethnicity.: A group of islands in the Caribbean Sea. These islands curve southward from the bottom tip of Florida to the Northwest of Venezuela in South America. There are at least 7,000 islands, islets, reefs and cayes in the region. There exist twenty-five territories, including sovereign states, overseas departments and dependencies.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C26320, C42331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378835</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Western Asian</VALIDVALUE>
          <VALUEMEANING>Western Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the Asian countries bordering Africa, such as Afghanistan, Armenia, Azerbaijan, Bahrain, Cyprus, Gaza Strip, Georgia, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Turkey, United Arab Emirates, West Bank, and Yemen.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153343</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378836</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Northeastern Asian</VALIDVALUE>
          <VALUEMEANING>Northeastern Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the Asian countries bordering the Pacific Ocean: China, Japan, Mongolia, North Korea, and South Korea.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C153342</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2018-07-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6378837</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Southern Asian</VALIDVALUE>
          <VALUEMEANING>South Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in the countries of the Indian sub-continent, including India, Pakistan, Bangladesh, and Sri Lanka.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41263</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579669</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Southeastern Asian</VALIDVALUE>
          <VALUEMEANING>Southeast Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person whose ancestry is in any of the Asian countries south of China, east of India, west of New Guinea and north of Australia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126533</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5215956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>European</VALIDVALUE>
          <VALUEMEANING>European</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes the inhabitants of any of the countries of Europe, a person from there, or their descendants elsewhere.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>6411001</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>African Descent</VALIDVALUE>
          <VALUEMEANING>African</VALUEMEANING>
          <MEANINGDESCRIPTION>Denotes a person with African ancestral origins who self identifies, or is identified, as African. The concept does not refer to those of other ancestry, for example, European and South Asian. In practice, the term mainly refers to people originated from forty-eight sub-Saharan Africa nations; and excudes individuals from North Africa countries, e.g. such as Algeria, Morocco, Egypt, Tunisia with Arab and Berber ethnicity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C42331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2794439</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Asian</VALIDVALUE>
          <VALUEMEANING>Asian</VALUEMEANING>
          <MEANINGDESCRIPTION>A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C41260</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-07-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572233</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>NA</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2022-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5682946</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Choose not to disclose</VALIDVALUE>
          <VALUEMEANING>Choose not to disclose</VALUEMEANING>
          <MEANINGDESCRIPTION>Choose not to disclose</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2022-04-15</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>8169226</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Candidate Ethnic Background (</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Candidate Ethnic Background (geographic)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-001 Question Text</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Geographic Ethnic Group</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3533741</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCORP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Trial Screening Tool</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5023691</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Candidate Consent and Enrollment</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736416</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>GEOGRAPH_ETHNIC_CAT</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1702">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5222597</PUBLICID>
    <LONGNAME>Case Eligibility Determination Status</LONGNAME>
    <PREFERREDNAME>CASE_ELIG_STATUS</PREFERREDNAME>
    <PREFERREDDEFINITION>The response that indicates a patient&#39;s eligibility status for participation in a clinical trial or research study.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5219512</PublicId>
      <PreferredName>3310760v1.0:2177563v1.0</PreferredName>
      <PreferredDefinition>A problem requiring investigation._Criteria to determine eligibility of patients for medical care programs and services.</PreferredDefinition>
      <LongName>Case Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3310760</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49152</PreferredName>
        <Version>1</Version>
        <LongName>Case</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49152</PREFERRED_NAME>
            <LONG_NAME>Case</LONG_NAME>
            <CON_ID>2491895</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177563</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Eligibility</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5219513</PublicId>
      <PreferredName>5219513v1.0</PreferredName>
      <PreferredDefinition>A condition or state at a particular time.</PreferredDefinition>
      <LongName>Eligibility Determination Status</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
      <Representation>
        <PublicId>2404650</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25688</PreferredName>
        <Version>1</Version>
        <LongName>Status</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25688</PREFERRED_NAME>
            <LONG_NAME>Status</LONG_NAME>
            <CON_ID>2202322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Eligible</VALIDVALUE>
          <VALUEMEANING>Eligible</VALUEMEANING>
          <MEANINGDESCRIPTION>Satisfying the appropriate conditions for inclusion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C126586</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5227215</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Ineligible</VALIDVALUE>
          <VALUEMEANING>Ineligible</VALUEMEANING>
          <MEANINGDESCRIPTION>The state or quality of being disqualified by law, rule, or provision.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C40412</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-04-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3785693</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>This case was</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>This case was</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG-ACRIN - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>What was the eligibility status reported in the confirmation email from the central Gleason Score and %Ki67 Expression review?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>6 Month Follow-Up</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736414</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1703">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5227600</PUBLICID>
    <LONGNAME>Faced Block Surface Section Preparation Other Specify</LONGNAME>
    <PREFERREDNAME>FACD_BLOCK_FACE_PREP_SPEC</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the preparation on the faced block prior to sectioning that has not been previously listed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5219694</PublicId>
      <PreferredName>5407631v1.0:5219692v1.0</PreferredName>
      <PreferredDefinition>A block that has been cut down to the desired tissue plane, with the overlaying support material removed._The extended two-dimensional outer boundary of a three-dimensional object._A very thin slice (of tissue or mineral or other substance) for examination under a microscope._The act or process of making something ready.</PreferredDefinition>
      <LongName>Faced Block Surface Section Preparation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5407631</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C128636</PreferredName>
        <Version>1</Version>
        <LongName>Faced Block</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128636</PREFERRED_NAME>
            <LONG_NAME>Faced Block</LONG_NAME>
            <CON_ID>5407595</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5219692</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25245:C25668:C25625</PreferredName>
        <Version>1</Version>
        <LongName>Surface Section Preparation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25245</PREFERRED_NAME>
            <LONG_NAME>Surface</LONG_NAME>
            <CON_ID>2203807</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25668</PREFERRED_NAME>
            <LONG_NAME>Section</LONG_NAME>
            <CON_ID>2202808</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25625</PREFERRED_NAME>
            <LONG_NAME>Preparation</LONG_NAME>
            <CON_ID>2202599</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2666713</PublicId>
      <PreferredName>OTH_SPEC</PreferredName>
      <PreferredDefinition>Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.</PreferredDefinition>
      <LongName>Other Specify</LongName>
      <Version>2</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NCI CRF Standards</Origin>
      <Representation>
        <PublicId>2208051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C17649:C25685</PreferredName>
        <Version>1</Version>
        <LongName>Other Specify</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25685</PREFERRED_NAME>
            <LONG_NAME>Specify</LONG_NAME>
            <CON_ID>2203800</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Specify Other faced block prep</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Specify Other faced block prep</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>FFPE Section-Stain</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736421</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1704">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5227840</PUBLICID>
    <LONGNAME>Biospecimen Blood Collection Laboratory Receive Person Name</LONGNAME>
    <PREFERREDNAME>BLD_COL_LAB_RCV_NAM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the person who received the blood in the lab in the format first initial last name.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5369113</PublicId>
      <PreferredName>2859635v1.0:5408891v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._The act of gathering things together; having been brought together in one place._A facility equipped and competent to conduct scientific experiments, observations, tests, investigations, and/or to manufacture chemicals or medical products._To take, accept, or get something offered.</PreferredDefinition>
      <LongName>Biospecimen Blood Collection Laboratory Receive</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5408892</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12434:C25453:C37984:C25639</PreferredName>
        <Version>1</Version>
        <LongName>Blood Collection Laboratory Receive</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37984</PREFERRED_NAME>
            <LONG_NAME>Laboratory</LONG_NAME>
            <CON_ID>2202883</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2746719</PublicId>
      <PreferredName>PERS_NM</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Person Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008532</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>INDS</PreferredName>
        <Version>1</Version>
        <LongName>Individuals</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Blood tube(s) received in lab</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Blood tube(s) received in lab by</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Blood Collection and Processing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1705">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5227858</PUBLICID>
    <LONGNAME>Biospecimen Blood Collection Plasma Processing Begin Time</LONGNAME>
    <PREFERREDNAME>PLASMA_PROC_BEG_TIME</PREFERREDNAME>
    <PREFERREDDEFINITION>The time in which specimen processing began.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5226696</PublicId>
      <PreferredName>5226693v1.0:5226694v1.0</PreferredName>
      <PreferredDefinition>Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._The act of gathering things together; having been brought together in one place._Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation._The act of preparing or putting through a prescribed procedure._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.</PreferredDefinition>
      <LongName>Biospecimen Blood Collection Plasma Processing Begin</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2859635</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70699</PreferredName>
        <Version>1</Version>
        <LongName>Biospecimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70699</PREFERRED_NAME>
            <LONG_NAME>Biospecimen</LONG_NAME>
            <CON_ID>2726660</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5409131</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5409131v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Blood Collection Plasma Processing Begin</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12434</PREFERRED_NAME>
            <LONG_NAME>Blood</LONG_NAME>
            <CON_ID>2202587</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25453</PREFERRED_NAME>
            <LONG_NAME>Collection</LONG_NAME>
            <CON_ID>2203887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13356</PREFERRED_NAME>
            <LONG_NAME>Plasma</LONG_NAME>
            <CON_ID>2204980</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48177</PREFERRED_NAME>
            <LONG_NAME>Processing</LONG_NAME>
            <CON_ID>2422623</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019249</PublicId>
      <PreferredName>TM</PreferredName>
      <PreferredDefinition>the time at which an event was observed or occurred.</PreferredDefinition>
      <LongName>Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>TIME</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>TIME (HR(24):MN)</DisplayFormat>
      <MaximumLength>4</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2184344</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Time</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Time Plasma processing began</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Time Plasma processing began</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Blood Collection and Processing</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736415</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1706">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5230144</PUBLICID>
    <LONGNAME>Histology Cassette Tissue Processor Fixation Minute Duration Time</LONGNAME>
    <PREFERREDNAME>CASS_FIX_MIN_DUR_TIM</PREFERREDNAME>
    <PREFERREDDEFINITION>The length of time, from beginning to end, required to process or preserve biospecimens in fixative.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>BBRB</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>BPV: Biospecimen Pre-analytical Variables (BPV) Program</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5408533</PublicId>
      <PreferredName>5408491v1.0:5408531v1.0</PreferredName>
      <PreferredDefinition>A device designed to hold tissue specimens during processing, embedding and storage._An automated system used to process tissue specimens for examination through fixation, dehydration, and infiltration._The chemical preservation of a substance to maintain structural and/or molecular features of that substance as they exist in the living entity.</PreferredDefinition>
      <LongName>Histology Cassette Tissue Processor Fixation</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>BBRB</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2230266</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TISSUE BANKING</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Banking</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5408491</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C128638</PreferredName>
        <Version>1</Version>
        <LongName>Histology Cassette</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128638</PREFERRED_NAME>
            <LONG_NAME>Histology Cassette</LONG_NAME>
            <CON_ID>5408471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5408531</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C62219:C25219</PreferredName>
        <Version>1</Version>
        <LongName>Tissue Processor Fixation</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62219</PREFERRED_NAME>
            <LONG_NAME>Tissue Processor</LONG_NAME>
            <CON_ID>2503747</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25219</PREFERRED_NAME>
            <LONG_NAME>Fixation</LONG_NAME>
            <CON_ID>2206216</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>BPV: Biospecimen Pre-analytical Variables (BPV) Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3812462</PublicId>
      <PreferredName>3812462v1.0</PreferredName>
      <PreferredDefinition>The time in minutes (nnnn.nn) that it takes for an event or activity to take place from beginning to end.</PreferredDefinition>
      <LongName>Minute Duration Time</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>min</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2193249</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25207</PreferredName>
        <Version>1</Version>
        <LongName>Time</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25207</PREFERRED_NAME>
            <LONG_NAME>Time</LONG_NAME>
            <CON_ID>2202306</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Actual Time in Fixative (minu</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Actual Time in Fixative (minutes)</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>BPV - Tumor Biospecimen Acquisition</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>5405791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5188870</PublicId>
          <ContextName>BBRB</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>BPV - Tumor Biospecimen Acquis</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tissue Processing Wksht</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>6736429</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>BBRB</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>BBRB</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1707">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5230733</PUBLICID>
    <LONGNAME>Chronic Graft Versus Host Disease Patient Self-Report Last 7 Days Mouth Sensitivity at its Worst Score 11 Point Scale</LONGNAME>
    <PREFERREDNAME>CGVHD_SLFRP_SENS_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of the severity of mouth sensitivity at it&#39;s worst in the last 7 days, using an 11 point scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5230640</PublicId>
      <PreferredName>2512832v1.0:5230638v1.0</PreferredName>
      <PreferredDefinition>A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._Report coming directly from patients or subjects through interviews or self-completed questionnaires or other data capture tools such as diaries about their life, health condition(s) and treatment. NOTE: PROs are used to assess outcomes involving the patients&#39;/subjects&#39; perceptions, symptoms, satisfaction with treatment, adherence to prescribed regimens. PROs include outcomes recorded by interviewers transcribing the views expressed by the patient, but the term does not apply to outcomes recorded by observers who rely on their own judgment. A PRO is usually distinguished from a self-reported objective measurement such as a PEF score or body weight [from PRO Draft Guidance, Gordon Guyatt and Holger Schuneman - personal communication; Patrick, D.L., 2003. After Acquardo C., Berzon C., et al., 2001] See also outcome, subject, patient._The most recent week, including today._A question about an individual&#39;s mouth sensitivity at its worst._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Chronic Graft Versus Host Disease Patient Self-Report Past Week Mouth Sensitivity at its Worst Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2512832</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4981</PreferredName>
        <Version>1</Version>
        <LongName>Chronic Graft Versus Host Disease</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4981</PREFERRED_NAME>
            <LONG_NAME>Chronic Graft Versus Host Disease</LONG_NAME>
            <CON_ID>2202365</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5230638</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21089:C95402:C126664:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Patient Self-Report Past Week Mouth Sensitivity at its Worst Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21089</PREFERRED_NAME>
            <LONG_NAME>Patient Self-Report</LONG_NAME>
            <CON_ID>2234887</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126664</PREFERRED_NAME>
            <LONG_NAME>Mouth Sensitivity at its Worst Question</LONG_NAME>
            <CON_ID>5230593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4680952</PublicId>
      <PreferredName>4680952v1.0</PreferredName>
      <PreferredDefinition>An ordered reference standard for the subjective scoring of symptoms that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</PreferredDefinition>
      <LongName>MDASI Severity of Symptom Score 11 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>2</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>10</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>MDASI-Core:M.D. Anderson Symptom Inventory - Core, Cleeland CS, 1999</Origin>
      <Representation>
        <PublicId>4680951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C120071:C25664</PreferredName>
        <Version>1</Version>
        <LongName>Severity of Symptom Likert Scale Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C120071</PREFERRED_NAME>
            <LONG_NAME>Severity of Symptom Likert Scale</LONG_NAME>
            <CON_ID>4674046</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>10</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 10</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 10 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120082</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680953</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>9</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 9</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 9 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120081</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680954</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>8</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 8</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 8 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120080</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680955</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>7</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 7</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 7 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120079</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680956</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>6</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 6</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 6 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120078</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680957</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 5 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120077</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680958</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 4 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120076</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680959</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 3 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120075</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680960</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 2 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120074</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680961</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 1 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120073</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680962</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Severity of Symptom Score 0</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 0 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C120072</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-01-26</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4680963</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Your mouth sensitivity at its</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Your mouth sensitivity at its WORST?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1708">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5260267</PUBLICID>
    <LONGNAME>First Degree Relative Cancer Diagnosis Indicator</LONGNAME>
    <PREFERREDNAME>2436701v1.0:6682528v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>A response to indicate if there is an immediate family member (i.e., biological parents, siblings, children) with a history of cancer other than basal/squamous cell skin cancer.</PREFERREDDEFINITION>
    <VERSION>2</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>MCL</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MCL:Molecular and Cellular Characterization of Screened Lesions</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2436701</PublicId>
      <PreferredName>FT_DEG_RELTV_CA_DX</PreferredName>
      <PreferredDefinition>Report or record of a cancer diagnosis in any relative with whom one half of an individual&#39;s genes is shared (i.e., parent, sibling, offspring).</PreferredDefinition>
      <LongName>First Degree Relative Cancer Diagnosis</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2400272</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21481</PreferredName>
        <Version>1</Version>
        <LongName>First Degree Relative</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21481</PREFERRED_NAME>
            <LONG_NAME>First Degree Relative</LONG_NAME>
            <CON_ID>2400271</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2436699</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C9305:C15220</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Neoplasm Diagnosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C9305</PREFERRED_NAME>
            <LONG_NAME>Malignant Neoplasm</LONG_NAME>
            <CON_ID>2202593</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15220</PREFERRED_NAME>
            <LONG_NAME>Diagnosis</LONG_NAME>
            <CON_ID>2202734</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>6682528</PublicId>
      <PreferredName>YES_NO_UNK_DATA_NA_IND</PreferredName>
      <PreferredDefinition>A response or indicator that can have a value of yes, no, unknown, not applicable, or that the data is not present in the original source.</PreferredDefinition>
      <LongName>Yes No Unknown Data Not Available Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>MCL</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>18</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MCL:Molecular and Cellular Characterization of Screened Lesions</Origin>
      <Representation>
        <PublicId>6763099</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148:C67329:C25180</PreferredName>
        <Version>1</Version>
        <LongName>Yes, No, or Unknown Response Source Data Not Available Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C67329</PREFERRED_NAME>
            <LONG_NAME>Source Data Not Available</LONG_NAME>
            <CON_ID>2724563</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Data not available</VALIDVALUE>
          <VALUEMEANING>Source Data Not Available</VALUEMEANING>
          <MEANINGDESCRIPTION>Data from an original source is not present, accessible or ready for use or service.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67329</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-04-01</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4842575</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not applicable</VALIDVALUE>
          <VALUEMEANING>Not Applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-05-20</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5043360</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not reported</VALIDVALUE>
          <VALUEMEANING>Not Reported</VALUEMEANING>
          <MEANINGDESCRIPTION>Not provided or available.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C43234</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2021-01-03</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2572231</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have any of your living and d</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have any of your living and deceased first degree blood relatives been diagnosed with cancer</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL Core</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have any of your living and deceased first degree blood relatives (biological parents, siblings, children) been diagnosed with cancer [other than basal/squamous cell skin cancer]? [Not including half-siblings, step-siblings, step-parents, or step-children].</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-PCA-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have any of your living and deceased first degree blood relatives (biological parents, siblings, children) been diagnosed with cancer [other than basal/squamous cell skin cancer]?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Core-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Have any of your living and deceased first degree blood relatives (biological parents, siblings, children) been diagnosed with cancer [other than basal/squamous cell skin cancer]?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-Template Name</Name>
        <OrganizationName/>
        <DocumentType>Data Collection Template</DocumentType>
        <DocumentText>clinicalcore_v0-1_template-1</DocumentText>
        <URL>https://mcl.nci.nih.gov/resources/standards/mcl-cdes</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MCL-1</Name>
        <OrganizationName/>
        <DocumentType>Coding Instructions</DocumentType>
        <DocumentText>First degree relatives only: not including half-siblings, step-siblings, step-parents, or step-children.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5271073</PublicId>
          <ContextName>MCL</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MCL Core</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Clinical Core</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7537143</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>MCL</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>relative_with_cancer_history</AlternateName>
        <AlternateNameType>MCL Alt Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1709">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5260833</PUBLICID>
    <LONGNAME>Treatment Regimen Text</LONGNAME>
    <PREFERREDNAME>5260832v1.0:2180739v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Text field that describes a drug regimen or type of treatment given to a patient.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>CTSP/CDDP: Clinical Trial Sequencing and Cancer Driver Discovery Projects</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5260832</PublicId>
      <PreferredName>2416951v1.0:2177402v1.0</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._ A treatment plan that specifies the dosage, the schedule, and the duration of treatment.</PreferredDefinition>
      <LongName>Treatment Regimen</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2416951</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15368</PreferredName>
        <Version>1</Version>
        <LongName>Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15368</PREFERRED_NAME>
            <LONG_NAME>Therapy</LONG_NAME>
            <CON_ID>2202841</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2177402</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>Regimen</PreferredName>
        <Version>1</Version>
        <LongName>Regimen</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15697</PREFERRED_NAME>
            <LONG_NAME>Treatment Regimen</LONG_NAME>
            <CON_ID>2203773</CON_ID>
            <DEFINITION_SOURCE>NCI-GLOSS</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>TCGA:The Cancer Genome Atlas</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180739</PublicId>
      <PreferredName>TX_TXT</PreferredName>
      <PreferredDefinition>the free-text field related to treatment or therapy.</PreferredDefinition>
      <LongName>Therapy Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Treatment Regimen Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Treatment Regimen Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>NRG_CRF_TEXT1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Treatment Name</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NRG</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NRG</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>TREATMENT_REG</AlternateName>
        <AlternateNameType>Context Short Name</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1710">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5289039</PUBLICID>
    <LONGNAME>MBSImP Component 16 Pharyngeal Residue Score</LONGNAME>
    <PREFERREDNAME>MBSImP_16_SCR</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric score for the assessment of pharyngeal residue in the pharyngeal impairment section of the Modified Barium Swallow Impairment Profile.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MBSImP:Modified Barium Swallow Impairment Profile, Martin-Harris et al., 2008</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5288392</PublicId>
      <PreferredName>5288336v1.0:5288390v1.0</PreferredName>
      <PreferredDefinition>An evidence-based, standardization of the Modified Barium Swallow Study in adults. The protocol assesses 17 critical components of swallowing and provides an objective profile of the physiologic impairment affecting adult swallowing function._An assessment of an individual&#39;s pharyngeal impairment during swallowing._An observation of the pharyngeal residue remaining after an individual swallows.</PreferredDefinition>
      <LongName>Modified Barium Swallow Impairment Profile Pharyngeal Impairment During Swallowing Pharyngeal Residue Following Swallowing</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5288336</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C127178</PreferredName>
        <Version>1</Version>
        <LongName>Modified Barium Swallow Impairment Profile</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C127178</PREFERRED_NAME>
            <LONG_NAME>Modified Barium Swallow Impairment Profile</LONG_NAME>
            <CON_ID>5286714</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5288390</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C127180:C127330</PreferredName>
        <Version>1</Version>
        <LongName>Pharyngeal Impairment During Swallowing Pharyngeal Residue Following Swallowing</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C127180</PREFERRED_NAME>
            <LONG_NAME>Pharyngeal Impairment During Swallowing</LONG_NAME>
            <CON_ID>5286756</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C127330</PREFERRED_NAME>
            <LONG_NAME>Pharyngeal Residue Following Swallowing</LONG_NAME>
            <CON_ID>5286812</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MBSImP:Modified Barium Swallow Impairment Profile, Martin-Harris et al., 2008</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5288925</PublicId>
      <PreferredName>PHRYN_RESD_SCR</PreferredName>
      <PreferredDefinition>A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Pharyngeal Residue Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>MBSImP:Modified Barium Swallow Impairment Profile, Martin-Harris et al., 2008</Origin>
      <Representation>
        <PublicId>2193207</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25338</PreferredName>
        <Version>1</Version>
        <LongName>Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Minimal to no pharyngeal clearance</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of minimal to no pharyngeal clearance following swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127335</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5288926</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Majority of contrast within or on pharyngeal structures</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of the majority of contrast within or on pharyngeal structures following swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127334</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5288927</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Collection of residue within or on pharyngeal structures</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of collection of residue within or on pharyngeal structures following swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127333</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5288928</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Trace residue within or on pharyngeal structures</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of trace residue within or on pharyngeal structures following swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127332</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5288929</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Complete pharyngeal clearance</VALUEMEANING>
          <MEANINGDESCRIPTION>A finding of complete pharyngeal clearance following swallowing.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C127331</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-06-08</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5288930</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Pharyngeal Residue</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Pharyngeal Residue</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Modified Barium Swallow Impairment Profile (MBSImP)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question 16 of 17</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>1</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions. Questions used in this manner do not represent the original measure and should not be referenced by the measure’s name.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>2</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Copyrighted/Trademarked/Licensed PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Proprietary Measure Permission</DocumentType>
        <DocumentText>This data element is part of a set of items that comprise a proprietary PRO/HRQoL measure. Permission from the owning organization/entity must be acquired prior to use.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder>3</DisplayOrder>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5288334</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>MBSImP</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MBSImP</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5288335</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Modified Barium Swallow Impairment Profile (MBSImP)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900323</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1711">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5315135</PUBLICID>
    <LONGNAME>Voice Handicap Index Functional F10 Frequency Voice Problem Causes Loss of Income Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>VHI_F10_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how frequently their voice problem causes them to lose income, using a 5 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>VHI-10:Voice Handicap Index, 10 Items. Rosen, C, Lee, A, Osborne, J, Zullo, T, and Murry, T.,Development and Validation of the Voice Handicap Index- 10.</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5315106</PublicId>
      <PreferredName>5315091v1.0:5315104v1.0</PreferredName>
      <PreferredDefinition>A subscale of the Voice Handicap Index that measures an individual&#39;s perception of the effect of their voice handicap on their daily activity._The number of occurrences of something within a given time period._A question about how frequently an individual&#39;s voice problem causes them to lose income._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Voice Handicap Index Functional Subscale Temporal Frequency Voice Problem Causes Loss of Income Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5315091</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C128065</PreferredName>
        <Version>1</Version>
        <LongName>Voice Handicap Index Functional Subscale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128065</PREFERRED_NAME>
            <LONG_NAME>Voice Handicap Index Functional Subscale</LONG_NAME>
            <CON_ID>5313571</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5315104</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25515:C128072:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Temporal Frequency Voice Problem Causes Loss of Income Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25515</PREFERRED_NAME>
            <LONG_NAME>Temporal Frequency</LONG_NAME>
            <CON_ID>2202418</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128072</PREFERRED_NAME>
            <LONG_NAME>Voice Problem Causes Loss of Income Question</LONG_NAME>
            <CON_ID>5313654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>VHI-10:Voice Handicap Index, 10 Items. Rosen, C, Lee, A, Osborne, J, Zullo, T, and Murry, T.,Development and Validation of the Voice Handicap Index- 10.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4735831</PublicId>
      <PreferredName>VHI_SCALE</PreferredName>
      <PreferredDefinition>Numeric scores from 0 (never) to 4 (always) on a Likert scale used with the Voice Handicap Index.</PreferredDefinition>
      <LongName>VHI-10 Score 5 Point Likert Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>VHI-10:Voice Handicap Index, 10 Items. Rosen, C, Lee, A, Osborne, J, Zullo, T, and Murry, T.,Development and Validation of the Voice Handicap Index- 10.</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Always</VALUEMEANING>
          <MEANINGDESCRIPTION>At all times; on every occasion.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70670</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581797</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Almost Always</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4633044</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Almost Never</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something rarely happens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>My voice problem causes me to</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>My voice problem causes me to lose income.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4735811</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>VHI-10</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>VHI-10</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4735813</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Voice Handicap Index-10 (VHI-10)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900359</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1712">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5401011</PUBLICID>
    <LONGNAME>Derkay Recurrent Papillomatosis Assessment Total Score</LONGNAME>
    <PREFERREDNAME>DERKAY_PAP_TL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value representing the sum of scores from all anatomic sites assessed for recurrent papillomatosis using the Derkay staging measure.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5400982</PublicId>
      <PreferredName>5525613v1.0:2972008v1.0</PreferredName>
      <PreferredDefinition>A staging system for assessment of recurrent respiratory papillomatosis (RRP). The staging system includes a functional assessment of severity as well as an anatomic assessment of disease distribution. The anatomic score can then be used in combination with the functional assessment to measure an individual patient&#39;s clinical course and response to therapy over time._Glandular or squamous cell neoplastic proliferations characterized by the formation of multiple papillary structures diffusely involving a specific anatomic site._The result of an action._The final result of a determination of the value, significance, or extent of.</PreferredDefinition>
      <LongName>Derkay Staging System Papillomatosis Assessment Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5525613</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C128932:C3713</PreferredName>
        <Version>1</Version>
        <LongName>Derkay Staging System Papillomatosis</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128932</PREFERRED_NAME>
            <LONG_NAME>Derkay Staging System</LONG_NAME>
            <CON_ID>5448651</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3713</PREFERRED_NAME>
            <LONG_NAME>Papillomatosis</LONG_NAME>
            <CON_ID>4264945</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2972008</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25217:C20200</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25217</PREFERRED_NAME>
            <LONG_NAME>Assessment</LONG_NAME>
            <CON_ID>2202457</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>C3D:Central Cancer Clinical Database</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3727197</PublicId>
      <PreferredName>3727197v1.0</PreferredName>
      <PreferredDefinition>Pertaining to an entirety or whole, also constituting the full quantity or extent; complete._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Total Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>200</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2495121</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25304:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Total Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25304</PREFERRED_NAME>
            <LONG_NAME>Total</LONG_NAME>
            <CON_ID>2204938</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Total Score all Sites</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Total Score all Sites</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1713">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5408213</PUBLICID>
    <LONGNAME>Parent Off Treatment Survey Yes No Indicator</LONGNAME>
    <PREFERREDNAME>5408193v1.0:3506068v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The survey for parent when the pediatric patient is off treatment. A mother or a father; an immediate progenitor._When a patient is not receiving therapy they are considered off treatment.  In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off._A document used in a method of data collection that involves interviewing (or giving questionnaires to) a representative and often large group of people._The preferred Value Domain to indicate a question with permissible values of yes/no.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>PBTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5408193</PublicId>
      <PreferredName>3111322v1.0:5408191v1.0</PreferredName>
      <PreferredDefinition>A mother or a father; an immediate progenitor._When a patient is not receiving therapy they are considered off treatment.  In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off._A document used in a method of data collection that involves interviewing (or giving questionnaires to) a representative and often large group of people.</PreferredDefinition>
      <LongName>Parent Off Treatment Survey</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>PBTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3111322</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42709</PreferredName>
        <Version>1</Version>
        <LongName>Parent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42709</PREFERRED_NAME>
            <LONG_NAME>Parent</LONG_NAME>
            <CON_ID>2222173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5408191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25601:C17176</PreferredName>
        <Version>1</Version>
        <LongName>Off Treatment Survey</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25601</PREFERRED_NAME>
            <LONG_NAME>Off Treatment</LONG_NAME>
            <CON_ID>2202767</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17176</PREFERRED_NAME>
            <LONG_NAME>Survey</LONG_NAME>
            <CON_ID>2614081</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Is exit survey completed by p</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Is exit survey completed by parent or proxy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1714">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5419064</PUBLICID>
    <LONGNAME>Clinics and Hospitals Facility Name</LONGNAME>
    <PREFERREDNAME>CLN_HOSP_FAC_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>The name of the organizations where healthcare services are provided.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCP:Division of Cancer Prevention</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3115628</PublicId>
      <PreferredName>3120927v1.0:2222848v1.0</PreferredName>
      <PreferredDefinition>Institutions with an organized medical staff for the medical care, treatment, and cure of the sick and wounded, for the study of disease, and for the training of physicians, nurses, and allied health personnel._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.</PreferredDefinition>
      <LongName>Clinics and Hospitals Identifier</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008555</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>MED_RCD_AND_FORMS</PreferredName>
        <Version>1</Version>
        <LongName>Medical Records and Forms</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3120927</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19326</PreferredName>
        <Version>1</Version>
        <LongName>Clinics and Hospitals</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19326</PREFERRED_NAME>
            <LONG_NAME>Clinics and Hospitals</LONG_NAME>
            <CON_ID>3120923</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>CTCAE_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2222848</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25364</PreferredName>
        <Version>1</Version>
        <LongName>Identifier</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25364</PREFERRED_NAME>
            <LONG_NAME>Identifier</LONG_NAME>
            <CON_ID>2202473</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5419052</PublicId>
      <PreferredName>5419052v1.0</PreferredName>
      <PreferredDefinition>The buildings and organizations where healthcare services are provided._The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>Healthcare Facility Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008576</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DATA_SOURCE</PreferredName>
        <Version>1</Version>
        <LongName>Data Source</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>10</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCP:Division of Cancer Prevention</Origin>
      <Representation>
        <PublicId>5419051</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C21541:C42614</PreferredName>
        <Version>1</Version>
        <LongName>Healthcare Facility Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C21541</PREFERRED_NAME>
            <LONG_NAME>Healthcare Facility</LONG_NAME>
            <CON_ID>2202668</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Moffitt</VALIDVALUE>
          <VALUEMEANING>Moffitt Cancer Center</VALUEMEANING>
          <MEANINGDESCRIPTION>Moffitt Cancer Center</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5419059</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MDACC</VALIDVALUE>
          <VALUEMEANING>MD Anderson Cancer Center</VALUEMEANING>
          <MEANINGDESCRIPTION>MD Anderson Cancer Center</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2570432</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>CUMC</VALIDVALUE>
          <VALUEMEANING>Columbia University Medical Center</VALUEMEANING>
          <MEANINGDESCRIPTION>Columbia University Medical Center - NY024</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5419060</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>GALLIERA</VALIDVALUE>
          <VALUEMEANING>GALLIERA Hospital</VALUEMEANING>
          <MEANINGDESCRIPTION>GALLIERA Hospital - Italy 41062</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5419061</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>EIO</VALIDVALUE>
          <VALUEMEANING>European Institute of Oncology</VALUEMEANING>
          <MEANINGDESCRIPTION>European Institute of Oncology - Italy 41058</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-08-18</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5419062</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Tel Aviv</VALIDVALUE>
          <VALUEMEANING>Tel Aviv Sourasky Medical Center</VALUEMEANING>
          <MEANINGDESCRIPTION>Tel Aviv Sourasky Medical Center</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5911741</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Weill Cornell</VALIDVALUE>
          <VALUEMEANING>Weill Medical College of Cornell University</VALUEMEANING>
          <MEANINGDESCRIPTION>Weill Medical College of Cornell University</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5911740</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>DFCI</VALIDVALUE>
          <VALUEMEANING>Dana  Farber Cancer Institute</VALUEMEANING>
          <MEANINGDESCRIPTION>Dana  Farber Cancer Institute</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2017-07-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5911742</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Site</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Site</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>SITE</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Site Stratification</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3896529</PublicId>
          <ContextName>DCP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Consortia 2012 Studies</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MDA2014-04-01</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>TRIAL_TYPE_USAGE</ClassificationSchemeItemType>
        <CsiPublicId>5598962</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1715">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5431251</PUBLICID>
    <LONGNAME>Patient Voucher Shipping Address Text</LONGNAME>
    <PREFERREDNAME>5431215v1.0:2192759v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The location for where to ship the patient related documents exchanged for particular goods or services.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5431215</PublicId>
      <PreferredName>5434132v1.0:5434171v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A document that can be exchanged for particular goods or services or one serving as a record of money paid._The act or business of transporting goods._A standardized representation of the location of a person, business, building, or organization.</PreferredDefinition>
      <LongName>Patient Voucher Shipping Address</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2861581</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>ADDRESS</PreferredName>
        <Version>1</Version>
        <LongName>Address</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5434132</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C128456</PreferredName>
        <Version>1</Version>
        <LongName>Patient Voucher</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C128456</PREFERRED_NAME>
            <LONG_NAME>Voucher</LONG_NAME>
            <CON_ID>5362071</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5434171</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C40353:C25407</PreferredName>
        <Version>1</Version>
        <LongName>Shipping Address</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C40353</PREFERRED_NAME>
            <LONG_NAME>Shipping</LONG_NAME>
            <CON_ID>2204003</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25407</PREFERRED_NAME>
            <LONG_NAME>Address</LONG_NAME>
            <CON_ID>2202289</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ECOG CRF:Eastern Cooperative Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2192759</PublicId>
      <PreferredName>ADDR_ID_TEXT</PreferredName>
      <PreferredDefinition>the street location or other designation, such as the name of the street for the address.  This can be for either a person or an organization.</PreferredDefinition>
      <LongName>Address Identifier Text</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008543</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>GEO_LCTNS</PreferredName>
        <Version>1</Version>
        <LongName>Geographic Locations</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>200</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2234203</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25704</PreferredName>
        <Version>1</Version>
        <LongName>Text</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25704</PREFERRED_NAME>
            <LONG_NAME>Text</LONG_NAME>
            <CON_ID>2203863</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Shipping Address for Patient</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Shipping Address for Patient Voucher</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ECOG OPEN CheckList</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Shipping Address for Patient Vouchers for PK study.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1716">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5505264</PUBLICID>
    <LONGNAME>Withdrawal Opioid Current Cycle Occurrence Yes No Indicator</LONGNAME>
    <PREFERREDNAME>With_Opio_Curr_Cycl_Occu_Ind</PREFERREDNAME>
    <PREFERREDDEFINITION>The yes/no indicator for a current cycle occurrence of withdrawal from a class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5505221</PublicId>
      <PreferredName>With_Opio_Curr_Cycl_Occu</PreferredName>
      <PreferredDefinition>A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.  Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)_To cease active participation in; remove from active use._An instance of something happening, such as an event or incident._Occurring in or belonging to the present time._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.</PreferredDefinition>
      <LongName>Withdrawal Opioid Current Cycle Occurrence</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5505219</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38061:C1506</PreferredName>
        <Version>1</Version>
        <LongName>Withdraw Opioid</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38061</PREFERRED_NAME>
            <LONG_NAME>Withdraw</LONG_NAME>
            <CON_ID>2434706</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1506</PREFERRED_NAME>
            <LONG_NAME>Opioid</LONG_NAME>
            <CON_ID>2718835</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>4358251</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25471:C25472:C25275</PreferredName>
        <Version>1</Version>
        <LongName>Current Cycle Occurrence</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25471</PREFERRED_NAME>
            <LONG_NAME>Current</LONG_NAME>
            <CON_ID>2202334</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25275</PREFERRED_NAME>
            <LONG_NAME>Occurrence</LONG_NAME>
            <CON_ID>2203940</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Did the patient experience op</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did the patient experience opioid withdrawal during this cycle?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1717">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5542591</PUBLICID>
    <LONGNAME>Bone Marrow Biopsy Erythroid Precursor Involvement Specimen Percentage Value</LONGNAME>
    <PREFERREDNAME>BM_BX_ERY_PRC_PC_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric value to represent the percentage of erythroid precursors in a bone marrow specimen.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5542589</PublicId>
      <PreferredName>BM_BX_ERY_PRECR_INVL</PreferredName>
      <PreferredDefinition>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis._1) Reddish in color. 2) relating to erythrocytes or their precursors._A substance from which another substance is formed._To have a connection by participation or association or use; sharing in an activity or process.</PreferredDefinition>
      <LongName>Bone Marrow Biopsy Erythroid Precursor Involvement</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206880</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C12431:C15189</PreferredName>
        <Version>1</Version>
        <LongName>Bone Marrow Biopsy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15189</PREFERRED_NAME>
            <LONG_NAME>Biopsy</LONG_NAME>
            <CON_ID>2202502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5542587</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13805:C48044:C25548</PreferredName>
        <Version>1</Version>
        <LongName>Erythroid Precursor Involvement</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13805</PREFERRED_NAME>
            <LONG_NAME>Erythroid</LONG_NAME>
            <CON_ID>2693267</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48044</PREFERRED_NAME>
            <LONG_NAME>Precursor</LONG_NAME>
            <CON_ID>2671512</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25548</PREFERRED_NAME>
            <LONG_NAME>Involvement</LONG_NAME>
            <CON_ID>2203737</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2019101</PublicId>
      <PreferredName>HMT_LAB_PTG_VAL</PreferredName>
      <PreferredDefinition>a percentage for a hematologic laboratory value.</PreferredDefinition>
      <LongName>Blood Specimen Lab Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure>%</UnitOfMeasure>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Percent Erythroid Precursors</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Percent Erythroid Precursors</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1718">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5543188</PUBLICID>
    <LONGNAME>Dysplasia Present Neoplasm Histologic Grade Code</LONGNAME>
    <PREFERREDNAME>2459193v1.0:5542895v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the presence of cells that look abnormal under a microscope but are not cancer._Records the degree of dysplasia for the cyst or lesion under consideration.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>EDRN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>2459193</PublicId>
      <PreferredName>DYSPLASIA_PRES</PreferredName>
      <PreferredDefinition>information related to the presence of cells that look abnormal under a microscope but are not cancer.</PreferredDefinition>
      <LongName>Dysplasia Present</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2459191</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C4086</PreferredName>
        <Version>1</Version>
        <LongName>Dysplasia</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C4086</PREFERRED_NAME>
            <LONG_NAME>Dysplasia</LONG_NAME>
            <CON_ID>2202401</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2233878</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25626</PreferredName>
        <Version>1</Version>
        <LongName>Present</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25626</PREFERRED_NAME>
            <LONG_NAME>Present</LONG_NAME>
            <CON_ID>2203654</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5542895</PublicId>
      <PreferredName>5542895v1.0</PreferredName>
      <PreferredDefinition>Records the degree of dysplasia for the cyst or lesion under consideration.</PreferredDefinition>
      <LongName>Neoplasm Histologic Grade Code</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>EDRN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength/>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>5654311</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262:C18000:C25162</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm Histologic Grade Code</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C18000</PREFERRED_NAME>
            <LONG_NAME>Histologic Grade</LONG_NAME>
            <CON_ID>2203821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>99</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>High Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14158</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288211</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Intermediate Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C28083</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3335158</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Low Grade</VALUEMEANING>
          <MEANINGDESCRIPTION>Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C14161</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-02-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3288210</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Degree of dysplasia (cyst):</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Degree of dysplasia (cyst):</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Biospecimen CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_ALIAS</ClassificationSchemeItemType>
        <CsiPublicId>5542682</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5542681</PublicId>
          <ContextName>EDRN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EDRN_CDE_Project</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EDRN-CDEs</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>UML_PACKAGE_NAME</ClassificationSchemeItemType>
        <CsiPublicId>10000601</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>7576399</PublicId>
          <ContextName>HTAN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Biospecimen CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Tier 2 Assay-specific</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>7577840</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>HTAN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>HTAN</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Dysplasia:SPECIMEN_RESULT_CYSTDYSPLASIA_CODE_3306</AlternateName>
        <AlternateNameType>UML Class:UML Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>EDRN-CDEs.Dysplasia.SPECIMEN_RESULT_CYSTDYSPLASIA_CODE_3306</AlternateName>
        <AlternateNameType>UML Qualified Attr</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1719">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5543639</PUBLICID>
    <LONGNAME>RDAS 8 How Often Quarrel with Partner Score 6 Point Scale</LONGNAME>
    <PREFERREDNAME>RDAS_8_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how often they and their partner quarrel, using a 6 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>RDAS (Revised Dyadic Adjustment Scale)</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5542114</PublicId>
      <PreferredName>5540399v1.0:5542112v1.0</PreferredName>
      <PreferredDefinition>A 14 item self report questionnaire that assess seven dimensions of couple relationship satisfaction. This revised version of the Dyadic Adjustment Scale is shorter and offers improved psychometric properties._A question about how often an individual quarrels with their partner._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Revised Dyadic Adjustment Scale How Often Quarrel with Partner Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5540399</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C129539</PreferredName>
        <Version>1</Version>
        <LongName>Revised Dyadic Adjustment Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129539</PREFERRED_NAME>
            <LONG_NAME>Revised Dyadic Adjustment Scale</LONG_NAME>
            <CON_ID>5527605</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5542112</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C129550:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How Often Quarrel with Partner Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129550</PREFERRED_NAME>
            <LONG_NAME>How Often Quarrel with Partner Question</LONG_NAME>
            <CON_ID>5527613</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>RDAS (Revised Dyadic Adjustment Scale)</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5543523</PublicId>
      <PreferredName>RDAS_FRQNCY_6_PT_SCL</PreferredName>
      <PreferredDefinition>6 point scale.</PreferredDefinition>
      <LongName>RDAS Frequency 6 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>0</MinimumValue>
      <Origin>RDAS (Revised Dyadic Adjustment Scale)</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Never</VALUEMEANING>
          <MEANINGDESCRIPTION>Not ever; at no time in the past (or future).</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C70543</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3025032</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Rarely</VALUEMEANING>
          <MEANINGDESCRIPTION>Not often.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C73116</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2577922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232437</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>More Often than Not</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something occurs more than half the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C129565</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5543524</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Most of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened most of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110991</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561186</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>0</VALIDVALUE>
          <VALUEMEANING>All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C110990</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-10-25</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561185</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often do you and your par</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often do you and your partner quarrel?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>RDAS (Revised Dyadic Adjustment Scale)</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #8 of 14.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5529781</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>RDAS</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>RDAS (Revised Dyadic Adjustment Scale)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5529791</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Revised Dyadic Adjustment Scale (RDAS)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>14900348</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1720">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5557039</PUBLICID>
    <LONGNAME>Bone Marrow CD19 Count Flow Cytometry Result Value</LONGNAME>
    <PREFERREDNAME>BM_CD19_FC_AB_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Numeric result of the evaluation of a bone marrow specimen for CD19 cells using flow cytometry.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5546603</PublicId>
      <PreferredName>5543716v1.0:5546601v1.0</PreferredName>
      <PreferredDefinition>A procedure for critical evaluation._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._Indicates that CD19 expression has been detected in a sample._A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid._The result of an action.</PreferredDefinition>
      <LongName>Testing Bone Marrow CD19 Count Flow Cytometry Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5543716</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15336:C12431</PreferredName>
        <Version>1</Version>
        <LongName>Testing Bone Marrow</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15336</PREFERRED_NAME>
            <LONG_NAME>Testing</LONG_NAME>
            <CON_ID>2204718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5546601</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C129255:C16585:C20200</PreferredName>
        <Version>1</Version>
        <LongName>CD19 Positive Flow Cytometry Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129255</PREFERRED_NAME>
            <LONG_NAME>CD19 Positive</LONG_NAME>
            <CON_ID>5476717</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16585</PREFERRED_NAME>
            <LONG_NAME>Flow Cytometry</LONG_NAME>
            <CON_ID>2202602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>C3D:Central Cancer Clinical Database</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2183369</PublicId>
      <PreferredName>LAB_STD_VAL</PreferredName>
      <PreferredDefinition>Lab test values as entered by a user irrespective of the unit of measure (UOM) required to perform adverse event grading.  </PreferredDefinition>
      <LongName>Labs Standard Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>5</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2183095</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>Value</PreferredName>
        <Version>1</Version>
        <LongName>Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD19, Absolute count, Bone Ma</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CD19, Absolute count, Bone Marrow</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1721">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5557268</PUBLICID>
    <LONGNAME>Bone Marrow CD45 Count Chimeric Antigen Receptor Flow Cytometry Result Percentage Value</LONGNAME>
    <PREFERREDNAME>BM_CD45CAR_FC_PC_VAL</PREFERREDNAME>
    <PREFERREDDEFINITION>Percentage result of the evaluation of a bone marrow specimen for CD45 chimeric antigen receptor (CAR) cells using flow cytometry.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>C3D:Central Cancer Clinical Database</ORIGIN>
    <REGISTRATIONSTATUS>Qualified</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5547137</PublicId>
      <PreferredName>5543716v1.00:5547135v1.00</PreferredName>
      <PreferredDefinition>A procedure for critical evaluation._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.:An immunophenotypic finding indicating that expression of CD45 has been detected in a sample of neoplastic cells._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid._The result of an action.</PreferredDefinition>
      <LongName>Testing Bone Marrow CD45 Count Chimeric Antigen Receptor Flow Cytometry Result</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5543716</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15336:C12431</PreferredName>
        <Version>1</Version>
        <LongName>Testing Bone Marrow</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15336</PREFERRED_NAME>
            <LONG_NAME>Testing</LONG_NAME>
            <CON_ID>2204718</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12431</PREFERRED_NAME>
            <LONG_NAME>Bone Marrow</LONG_NAME>
            <CON_ID>2202685</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5547135</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C72561:C126108:C16585:C20200</PreferredName>
        <Version>1</Version>
        <LongName>CD45-Positive Neoplastic Cells Present Chimeric Antigen Receptor Flow Cytometry Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C72561</PREFERRED_NAME>
            <LONG_NAME>CD45-Positive Neoplastic Cells Present</LONG_NAME>
            <CON_ID>5547131</CON_ID>
            <DEFINITION_SOURCE/>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C126108</PREFERRED_NAME>
            <LONG_NAME>Chimeric Antigen Receptor</LONG_NAME>
            <CON_ID>5153954</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16585</PREFERRED_NAME>
            <LONG_NAME>Flow Cytometry</LONG_NAME>
            <CON_ID>2202602</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>C3D:Central Cancer Clinical Database</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2180903</PublicId>
      <PreferredName>BM_PTG_VAL</PreferredName>
      <PreferredDefinition>the numeric value in percentage for a test on a bone marrow specimen.</PreferredDefinition>
      <LongName>Bone Marrow Percentage Value</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>5</MaximumLength>
      <MinimumLength/>
      <DecimalPlace>2</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208119</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25613:C25712</PreferredName>
        <Version>1</Version>
        <LongName>Percentage Value</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25613</PREFERRED_NAME>
            <LONG_NAME>Percentage</LONG_NAME>
            <CON_ID>2203724</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25712</PREFERRED_NAME>
            <LONG_NAME>Value</LONG_NAME>
            <CON_ID>2203990</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CD45 CAR Cells, Percent count</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>CD45 CAR Cells, Percent count, Bone Marrow</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1722">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5581281</PUBLICID>
    <LONGNAME>EORTC QLQ-BLM30 Version 1.0 58 Extent During Past 4 Weeks Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>EORTC_BLM30_58_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>Persons&#39; stated perception during the past 4 weeks of the extent to which they worried that they may contaminate their partner during sexual contact with the bladder treatment they have been receiving, using a four point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>EORTC QLQ-BLM30:European Organization for Research and Treatment of Cancer Quality of Life Group, Quality of Life Questionnaire-Muscle Invasive Bladder Cancer (BLM30), 1994</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5573428</PublicId>
      <PreferredName>5573345v1.0:5573426v1.0</PreferredName>
      <PreferredDefinition>A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients&#39; quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London._A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 30 questions designed to assess quality of life in patients with muscle-invasive bladder cancer (BLM)._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time._At some point in a given period of time._A period of time consisting of the 28 days before the present._A question about the extent to which an individual worries or worried that they may contaminate their partner during sexual contact with the bladder treatment they have been receiving._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>European Organization for Research and Treatment of Cancer Bladder Cancer Muscle-Invasive 30 Questionnaire Extent During Past 4 Weeks Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5573345</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C19741:C129791</PreferredName>
        <Version>1</Version>
        <LongName>European Organization for Research and Treatment of Cancer Bladder Cancer Muscle-Invasive 30 Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C19741</PREFERRED_NAME>
            <LONG_NAME>European Organization for Research and Treatment of Cancer</LONG_NAME>
            <CON_ID>2205056</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129791</PREFERRED_NAME>
            <LONG_NAME>Bladder Cancer Muscle-Invasive 30 Questionnaire</LONG_NAME>
            <CON_ID>5573322</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5573426</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5573426v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Extent During Past 4 Weeks Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25332</PREFERRED_NAME>
            <LONG_NAME>Extent</LONG_NAME>
            <CON_ID>2203921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25490</PREFERRED_NAME>
            <LONG_NAME>During</LONG_NAME>
            <CON_ID>2206200</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C110986</PREFERRED_NAME>
            <LONG_NAME>Past 4 Weeks</LONG_NAME>
            <CON_ID>3871096</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129813</PREFERRED_NAME>
            <LONG_NAME>Extent of Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment Question</LONG_NAME>
            <CON_ID>5573342</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>EORTC QLQ-BLM30:European Organization for Research and Treatment of Cancer Quality of Life Group, Quality of Life Questionnaire-Muscle Invasive Bladder Cancer (BLM30), 1994</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4728552</PublicId>
      <PreferredName>EORTC_4PT_SCL</PreferredName>
      <PreferredDefinition>Numeric scores from 1 (Not at All) to 4 (Very Much) on a Likert scale used on EORTC questionnaires.</PreferredDefinition>
      <LongName>EORTC Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>4</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin>EORTC QLQ-C30:European Organization for Research and Treatment of Cancer Quality of Life Group, Questionnaire C30, Version 3. 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A Little</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-03-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4733151</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of no agreement or ability.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144288</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Extremely</VALUEMEANING>
          <MEANINGDESCRIPTION>The highest degree of severity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C102844</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-02-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3144292</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure.</DocumentText>
        <URL>http://groups.eortc.be/qol/bladder-cancer-eortc-qlq-nmibc24-eortc-qlq-blm30</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Have you worried that you may</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Have you worried that you may contaminate your partner during sexual contact with the bladder treatment you have been receiving?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>EORTC QLQ-BLM30 Version 1.0</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #58 of 60</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3654497</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>EORTC QLQ</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-BLM30 Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5573344</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5778773</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>EORTC QLQ-BLM30</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5881762</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>Alliance</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>Alliance</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1723">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5589280</PUBLICID>
    <LONGNAME>Institutional Review Board Approval Consent Form Participation Clinical Study Signature Indicator</LONGNAME>
    <PREFERREDNAME>5589237v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not an IRB-approved consent form for participating in a clinical study was signed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5589237</PublicId>
      <PreferredName>3852265v1.0:5589235v1.0</PreferredName>
      <PreferredDefinition>A document containing the determination of the Institutional Review Board (IRB) that the clinical study with human subject participation has been reviewed and may be conducted at a particular study site within the constraints set forth by the IRB and other institutional and federal requirements. The regulations require that an IRB conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once a year._A document explaining all the relevant information to assist an individual in understanding the expectations and risks in making a decision about a procedure. This document is presented to and signed by the individual or guardian._The act of taking part in an activity._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._Individual&#39;s name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions; having a handwritten signature.</PreferredDefinition>
      <LongName>Institutional Review Board Approval Consent Form Participation Clinical Study Signature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008530</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>PT_CONSENT</PreferredName>
        <Version>1</Version>
        <LongName>Patient Consent</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3852265</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C70800:C16468</PreferredName>
        <Version>1</Version>
        <LongName>Institutional Review Board Approval Consent Form</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70800</PREFERRED_NAME>
            <LONG_NAME>Institutional Review Board Approval</LONG_NAME>
            <CON_ID>3852264</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16468</PREFERRED_NAME>
            <LONG_NAME>Consent Form</LONG_NAME>
            <CON_ID>2202582</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5589235</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25608:C15206:C25678</PreferredName>
        <Version>1</Version>
        <LongName>Participation Clinical Study Signature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25608</PREFERRED_NAME>
            <LONG_NAME>Participation</LONG_NAME>
            <CON_ID>2206339</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15206</PREFERRED_NAME>
            <LONG_NAME>Clinical Study</LONG_NAME>
            <CON_ID>2202828</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was an IRB-approved consent f</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was an IRB-approved consent form for participating in a clinical study signed?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the recipient signed an IRB / Ethics Committee-approved consent form for participation in the study?</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has the recipient signed an IRB / Ethics Committee-approved consent form for participation in the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the recipient signed an IRB / Ethics Committee-approved consent form for participation in the study?</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Has the recipient signed an IRB / Ethics Committee-approved consent form for participation in the study?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NHLBI</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>CMSR_RC_irb_cn_rs_yn</AlternateName>
        <AlternateNameType>NMDP_FN</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1724">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5596088</PUBLICID>
    <LONGNAME>Health Assessment Questionnaire Disability Index Past Week Difficulty Ability to Stand Up From a Straight Chair 4 Point Scale</LONGNAME>
    <PREFERREDNAME>HAQDI_PWD_STND_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of the difficulty they had standing up from a straight chair over the past week, using a 4 point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5592192</PublicId>
      <PreferredName>5590830v1.0:5592190v1.0</PreferredName>
      <PreferredDefinition>A standardized questionnaire developed by James F. Fries in 1983, which is originally used to measure outcome in patients with Rheumatoid Arthritis. It has also been applied to patients with HIV/AIDS and in studies of normal aging. The HAQ-DI is a generic instrument which focuses on self-reported, patient-oriented outcome measures. The questionnaire contains 8 categories of 46 items; dressing and grooming, arising, eating, walking, hygiene, reaching, grip, and activities. A 0-3 grade scale is used, where grade 0 represents category performed without any difficulty and grade 3 represents category performed with the greatest difficulty (unable to do)._The most recent week, including today._Something not easily done, accomplished, comprehended, or solved._A question about the ability of an individual to stand up from a chair.</PreferredDefinition>
      <LongName>Health Assessment Questionnaire Disability Index Questionnaire Past Week Difficulty Ability to Stand Up From Chair</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5590830</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C106699</PreferredName>
        <Version>1</Version>
        <LongName>Health Assessment Questionnaire Disability Index Questionnaire</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C106699</PREFERRED_NAME>
            <LONG_NAME>Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire</LONG_NAME>
            <CON_ID>5590829</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5592190</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C62189:C129992</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Difficulty Ability to Stand Up From Chair</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62189</PREFERRED_NAME>
            <LONG_NAME>Difficulty</LONG_NAME>
            <CON_ID>2503546</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129992</PREFERRED_NAME>
            <LONG_NAME>Ability to Stand Up From Chair</LONG_NAME>
            <CON_ID>5586806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5589436</PublicId>
      <PreferredName>ACT_DIFF_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard used to measure incremental changes.</PreferredDefinition>
      <LongName>Activity Difficulty 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>22</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>HAQ-DI:Health Assessment Questionnaire Disability Index, James F. Fries, MD. 1978</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>UNABLE TO DO</VALIDVALUE>
          <VALUEMEANING>Unable to Do</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is unable to do something.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121742</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809923</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITH MUCH DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>With Much Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with much difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121740</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809922</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITH SOME DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>With Some Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something with some difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121739</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809921</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>WITHOUT ANY DIFFICULTY</VALIDVALUE>
          <VALUEMEANING>Without Any Difficulty</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that an individual is able to do something without any difficulty.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C121736</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-05</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>4809919</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Are you able to stand up from</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Are you able to stand up from a straight chair?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1725">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5596119</PUBLICID>
    <LONGNAME>Multidimensional Fatigue Inventory 4 How True Feel Like Doing All Sorts of Nice Things Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>MFI_4_SCL</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated agreement with how true a statement of I feel like doing all sorts of nice things is, using a 5 point visual analogue scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>CCR</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MFI:Multi-dimensional Fatigue Inventory, Smets EM, Garssen B, Bonke B, De Haes JC. J Psychosom Res., April 1995</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5595166</PublicId>
      <PreferredName>5594996v1.0:5595164v1.0</PreferredName>
      <PreferredDefinition>A 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity._A question about an individual&#39;s agreement with a statement._A question about whether an individual feels or felt like doing all sorts of nice things._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Multidimensional Fatigue Inventory How True Feel Like Doing All Sorts of Nice Things Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5594996</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C54719</PreferredName>
        <Version>1</Version>
        <LongName>Multidimensional Fatigue Inventory</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C54719</PREFERRED_NAME>
            <LONG_NAME>Multidimensional Fatigue Inventory</LONG_NAME>
            <CON_ID>5594995</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5595164</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C91781:C130017:C25338</PreferredName>
        <Version>1</Version>
        <LongName>How True Feel Like Doing All Sorts of Nice Things Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C91781</PREFERRED_NAME>
            <LONG_NAME>How True Question</LONG_NAME>
            <CON_ID>3133350</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C130017</PREFERRED_NAME>
            <LONG_NAME>Feel Like Doing All Sorts of Nice Things Question</LONG_NAME>
            <CON_ID>5586826</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MFI:Multi-dimensional Fatigue Inventory, Smets EM, Garssen B, Bonke B, De Haes JC. J Psychosom Res., April 1995</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5589624</PublicId>
      <PreferredName>TRU_AGRMT_5PT_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard of five responses from 1 (yes, that is true) to 5 (no, that is not true).</PreferredDefinition>
      <LongName>Truth Agreement 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>MFI:Multi-dimensional Fatigue Inventory, Smets EM, Garssen B, Bonke B, De Haes JC. J Psychosom Res., April 1995</Origin>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Truth Agreement Score 5</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 5 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589625</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Truth Agreement Score 4</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 4 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589626</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Truth Agreement Score 3</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 3 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589627</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Truth Agreement Score 2</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 2 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589628</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Truth Agreement Score 1</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective score of 1 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE>2016-12-06</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5589629</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>I feel like doing all sorts o</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>I feel like doing all sorts of nice things.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2008601</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>C3D Domain</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>CCR</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>C3D</ClassificationSchemeItemType>
        <CsiPublicId>2811685</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2182125</PublicId>
          <ContextName>CCR</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CCR Implementation</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>C3D</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>USAGE_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2811673</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1726">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5604119</PUBLICID>
    <LONGNAME>IDH2 Mutation Gene Name</LONGNAME>
    <PREFERREDNAME>IDH2_MUT_GENE_NM</PREFERREDNAME>
    <PREFERREDDEFINITION>Name that describes the gene related to IDH2 mutation.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>DCI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>DCI CRF:  Duke Cancer Institute Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5603994</PublicId>
      <PreferredName>2543047v1.0:5604044v1.0</PreferredName>
      <PreferredDefinition>Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A change in the nucleotide sequence of the IDH2 gene._The result of an action.</PreferredDefinition>
      <LongName>Laboratory Procedure IDH2 Gene Mutation Outcome</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2543047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25294</PreferredName>
        <Version>1</Version>
        <LongName>Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25294</PREFERRED_NAME>
            <LONG_NAME>Laboratory Procedure</LONG_NAME>
            <CON_ID>2202340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5604044</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C118390:C20200</PreferredName>
        <Version>1</Version>
        <LongName>IDH2 Gene Mutation Outcome</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C118390</PREFERRED_NAME>
            <LONG_NAME>IDH2 Gene Mutation</LONG_NAME>
            <CON_ID>4529327</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C20200</PREFERRED_NAME>
            <LONG_NAME>Outcome</LONG_NAME>
            <CON_ID>2203785</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5604104</PublicId>
      <PreferredName>IDH2_GENE_NM</PreferredName>
      <PreferredDefinition>The words or language units by which a thing is known.</PreferredDefinition>
      <LongName>IDH2 Mutation Gene Name</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2435027</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16612</PreferredName>
        <Version>1</Version>
        <LongName>Gene</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>12</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>DCI CRF:  Duke Cancer Institute Case Report Form</Origin>
      <Representation>
        <PublicId>2229718</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C42614</PreferredName>
        <Version>1</Version>
        <LongName>Name</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42614</PREFERRED_NAME>
            <LONG_NAME>Name</LONG_NAME>
            <CON_ID>2222821</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G515A</VALIDVALUE>
          <VALUEMEANING>IDH2 NM_002168.3:c.515G&gt;A</VALUEMEANING>
          <MEANINGDESCRIPTION>A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to adenine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131110</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604113</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G515T(R172M)</VALIDVALUE>
          <VALUEMEANING>IDH2 NP_002159.2:p.R172M</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by methionine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131114</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604105</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>A514G(R172G)</VALIDVALUE>
          <VALUEMEANING>IDH2 NP_002159.2:p.R172G</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131109</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604106</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>172R&gt;R/M</VALIDVALUE>
          <VALUEMEANING>172R&gt;R/M</VALUEMEANING>
          <MEANINGDESCRIPTION>Human IDH2 wt allele is located in the vicinity of 15q26.1 and is approximately 18 kb in length. This allele, which encodes isocitrate dehydrogenase 2 (NADP+) mitochondrial protein, plays a role in intermediary metabolism. Mutations in this gene are associated with astrocytoma, oligodendroglioma and secondary glioblastoma.: A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by methionine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131114, C84949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604107</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>172R&gt;R/K</VALIDVALUE>
          <VALUEMEANING>172R&gt;R/K</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by lysine.: Human IDH2 wt allele is located in the vicinity of 15q26.1 and is approximately 18 kb in length. This allele, which encodes isocitrate dehydrogenase 2 (NADP+) mitochondrial protein, plays a role in intermediary metabolism. Mutations in this gene are associated with astrocytoma, oligodendroglioma and secondary glioblastoma.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C84949, C131112</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604108</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>172R&gt;R/G</VALIDVALUE>
          <VALUEMEANING>172R&gt;R/G</VALUEMEANING>
          <MEANINGDESCRIPTION>Human IDH2 wt allele is located in the vicinity of 15q26.1 and is approximately 18 kb in length. This allele, which encodes isocitrate dehydrogenase 2 (NADP+) mitochondrial protein, plays a role in intermediary metabolism. Mutations in this gene are associated with astrocytoma, oligodendroglioma and secondary glioblastoma.: A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131109, C84949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604109</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>172R&gt;K/R</VALIDVALUE>
          <VALUEMEANING>172R&gt;K/R</VALUEMEANING>
          <MEANINGDESCRIPTION>Human IDH2 wt allele is located in the vicinity of 15q26.1 and is approximately 18 kb in length. This allele, which encodes isocitrate dehydrogenase 2 (NADP+) mitochondrial protein, plays a role in intermediary metabolism. Mutations in this gene are associated with astrocytoma, oligodendroglioma and secondary glioblastoma.: A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by lysine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131112, C84949</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604110</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>MUT</VALIDVALUE>
          <VALUEMEANING>IDH2 Gene Mutation</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the nucleotide sequence of the IDH2 gene.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C118390</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604111</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>G515T</VALIDVALUE>
          <VALUEMEANING>IDH2 NM_002168.3:c.515G&gt;T</VALUEMEANING>
          <MEANINGDESCRIPTION>A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C131113</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2016-12-14</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5604112</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R140</VALIDVALUE>
          <VALUEMEANING>IDH2 NP_002159.2:p.R140X</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117281</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7092248</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>R172</VALIDVALUE>
          <VALUEMEANING>IDH2 NP_002159.2:p.R172X</VALUEMEANING>
          <MEANINGDESCRIPTION>A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C117282</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2019-12-12</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>7092247</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>IDH2 Mutation Type</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>IDH2 Mutation Type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Princess Marg 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>IDH2 mutation type</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>NCIP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1727">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5611337</PUBLICID>
    <LONGNAME>PRO-CTCAE Version 1.0 12a. Past Seven Days Any Increased Passing of Gas Indicator</LONGNAME>
    <PREFERREDNAME>PROCTCAE_12A_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of whether or not they had any increased passing of gas (flatulence) over the past seven days.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PRO-CTCAE TM:Patient-Reported Outcomes version of the CTCAE, Item Library Version 1.0, 3/24/2016</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5611323</PublicId>
      <PreferredName>3645995v1.0:5611321v1.0</PreferredName>
      <PreferredDefinition>A library of items for patient self-reporting of symptoms and side effects associated with cancer treatment trials._A question about whether or not an individual had any increased passing of gas (flatulence) over the past seven days.</PreferredDefinition>
      <LongName>Patient Reported Outcomes Version of CTCAE Past Seven Days Increased Passing of Gas</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3645995</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103843</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcomes Version of CTCAE</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103843</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcomes Version of CTCAE</LONG_NAME>
            <CON_ID>3640502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5611321</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C129276</PreferredName>
        <Version>1</Version>
        <LongName>Past Seven Days Increased Passing of Gas</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129276</PREFERRED_NAME>
            <LONG_NAME>Past Seven Days Increased Passing of Gas Question</LONG_NAME>
            <CON_ID>5477025</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PRO-CTCAE TM:Patient-Reported Outcomes version of the CTCAE, Item Library Version 1.0, 3/24/2016</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In the last 7 days, did you h</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In the last 7 days, did you have any INCREASED PASSING OF GAS (FLATULENCE)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PRO-CTCAE Spanish Translation</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>En los últimos 7 días, ¿tuvo una MAYOR EXPULSIÓN DE GASES INTESTINALES (FLATULENCIA)?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medidata ePRO CDE</Name>
        <OrganizationName/>
        <DocumentType>ePRO Compliant</DocumentType>
        <DocumentText>This CDE has been validated for use with the Medidata Rave ePRO module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3638608</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-CTCAE </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5675450</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574822</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-CTCAE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Item Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6051090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Item Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000711</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6051063</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Electronic PROs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6051064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1728">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5611342</PUBLICID>
    <LONGNAME>PRO-CTCAE Version 1.0 33a. Past Seven Days Any Color Change of Fingernails or Toenails Indicator</LONGNAME>
    <PREFERREDNAME>PROCTCAE_33A_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of whether or not they had any color change of fingernails or toenails over the past seven days.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PRO-CTCAE TM:Patient-Reported Outcomes version of the CTCAE, Item Library Version 1.0, 3/24/2016</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5611332</PublicId>
      <PreferredName>3645995v1.0:5611330v1.0</PreferredName>
      <PreferredDefinition>A library of items for patient self-reporting of symptoms and side effects associated with cancer treatment trials._A question about whether or not an individual had any change in color of their fingernails or toenails over the past seven days.</PreferredDefinition>
      <LongName>Patient Reported Outcomes Version of CTCAE Past Seven Days Color Change of Fingernails or Toenails</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>3645995</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C103843</PreferredName>
        <Version>1</Version>
        <LongName>Patient Reported Outcomes Version of CTCAE</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C103843</PREFERRED_NAME>
            <LONG_NAME>Patient Reported Outcomes Version of CTCAE</LONG_NAME>
            <CON_ID>3640502</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5611330</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C129281</PreferredName>
        <Version>1</Version>
        <LongName>Past Seven Days Color Change of Fingernails or Toenails</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C129281</PREFERRED_NAME>
            <LONG_NAME>Past Seven Days Color Change of Fingernails or Toenails Question</LONG_NAME>
            <CON_ID>5477029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PRO-CTCAE TM:Patient-Reported Outcomes version of the CTCAE, Item Library Version 1.0, 3/24/2016</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>In the last 7 days, did you h</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>In the last 7 days, did you have any CHANGE IN THE COLOR OF YOUR FINGERNAILS OR TOENAILS?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PRO-CTCAE Spanish Translation</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>En los últimos 7 días, ¿tuvo algún CAMBIO EN EL COLOR DE LAS UÑAS DE LAS MANOS O DE LOS PIES?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Medidata ePRO CDE</Name>
        <OrganizationName/>
        <DocumentType>ePRO Compliant</DocumentType>
        <DocumentText>This CDE has been validated for use with the Medidata Rave ePRO module.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3638608</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-CTCAE </PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5675450</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5574822</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO-CTCAE</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Item Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6051090</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Item Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000711</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>6051063</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Electronic PROs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>PRO-CTCAE Library Version 1.0</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>6051064</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1729">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5622021</PUBLICID>
    <LONGNAME>Eligibility Criteria Received Prior Therapy for Brain Tumor Indicator</LONGNAME>
    <PREFERREDNAME>PR_THERP_BRAIN_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>Indicator of whether or not the patient received any kind of prior therapy for their brain tumor.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ABTC</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ABTC: Adult Brain Tumor Consortium</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5621980</PublicId>
      <PreferredName>2767728v1.0:5621984v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._A benign or malignant neoplasm that arises from or metastasizes to the brain._To take, accept, or get something offered._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Brain Neoplasm Receive Prior Therapeutic Procedure</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ABTC</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2767728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16112</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5621984</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C2907:C25639:C25629:C49236</PreferredName>
        <Version>1</Version>
        <LongName>Brain Neoplasm Receive Prior Therapeutic Procedure</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2907</PREFERRED_NAME>
            <LONG_NAME>Brain Neoplasm</LONG_NAME>
            <CON_ID>2740429</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25639</PREFERRED_NAME>
            <LONG_NAME>Receive</LONG_NAME>
            <CON_ID>2203960</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has the patient received prio</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has the patient received prior radiation, chemo, hormonal, or immuno therapy, or therapy with a biologic agent for their brain tumor?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4280691</PublicId>
          <ContextName>ABTC</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>CRF CDEs</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility Checklist</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>4280724</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1730">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5622639</PUBLICID>
    <LONGNAME>PROMIS Version 1.0 Adult Physical Health Domain Global Satisfaction with Sex Life SFSAT101 Past 30 Days How Satisfied with Sex Life Score 5 Point Scale</LONGNAME>
    <PREFERREDNAME>PROMISV1_SFSAT101_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how satisfied in the past 30 days they have been with their sex life, using a five-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>PROMIS:Patient Reported Outcomes Measurement Information System, PROMIS Health Organization and PROMIS Cooperative Group, 2008-2012</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5621974</PublicId>
      <PreferredName>5621971v1.0:5621972v1.0</PreferredName>
      <PreferredDefinition>A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual&#39;s physical health._The collection of PROMIS item scales that assess self-reported perceptions of overall sexual satisfaction in men and women._A period of time consisting of the 30 days before the present._A question about how satisfied an individual is or was with their sex life._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>PROMIS Adult Physical Health Domain Global Satisfaction with Sex Life Past 30 Days How Satisfied with Sex Life Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5621971</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C122346:C131155</PreferredName>
        <Version>1</Version>
        <LongName>PROMIS Adult Physical Health Domain Global Satisfaction with Sex Life Subordinate Domain</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C122346</PREFERRED_NAME>
            <LONG_NAME>PROMIS Adult Physical Health Domain</LONG_NAME>
            <CON_ID>4860856</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131155</PREFERRED_NAME>
            <LONG_NAME>Global Satisfaction with Sex Life Subordinate Domain</LONG_NAME>
            <CON_ID>5609898</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5621972</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C131330:C131158:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past 30 Days How Satisfied with Sex Life Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131330</PREFERRED_NAME>
            <LONG_NAME>Past 30 days</LONG_NAME>
            <CON_ID>5615928</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C131158</PREFERRED_NAME>
            <LONG_NAME>How Satisfied with Sex Life Question</LONG_NAME>
            <CON_ID>5609899</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>PROMIS:Patient Reported Outcomes Measurement Information System, PROMIS Health Organization and PROMIS Cooperative Group, 2008-2012</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>4810013</PublicId>
      <PreferredName>PROMIS_HOW_MUCH_SCL</PreferredName>
      <PreferredDefinition>An ordered reference standard used with the PROMIS items that describes a range of subjective scores for representing how much of something an individual experiences from 1: Not at all, to 5: Very much.</PreferredDefinition>
      <LongName>PROMIS Quantity Score 5 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace>0</DecimalPlace>
      <CharacterSetName/>
      <MaximumValue>5</MaximumValue>
      <MinimumValue>1</MinimumValue>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Not at all</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of non-agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91213</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561180</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>A little bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of weak agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91214</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561181</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Somewhat</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of partial agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91215</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561500</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Quite a bit</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer describing a fairly large amount or extent.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91216</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561183</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>5</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-05-04</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. In cases where retaining the question set intact to preserve the validity and reliability are not as important as advancing the science, questions may be used individually or in combination with other measure questions.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Scoring Manual Link</Name>
        <OrganizationName/>
        <DocumentType>REFERENCE</DocumentType>
        <DocumentText>Link to PROMIS Assessment Center manual for scoring and additional information.</DocumentText>
        <URL>http://assessmentcenter.net/documents/Sexual%20Function%20Manual.pdf</URL>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How satisfied have you been w</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How satisfied have you been with your sex life?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4857911</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PROMIS Item Banks</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Adult Physical Health</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>4857913</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>4857911</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PROMIS Item Banks</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Sexual Function and Satisfaction</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5606698</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1731">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5622785</PUBLICID>
    <LONGNAME>Enhancing Lesion Neoplasm Measurement Clinical Trial Eligibility Criteria Indicator</LONGNAME>
    <PREFERREDNAME>ENHLES_NPM_MSRMT_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A response to determine patient eligibility for clinical trial participation for questions related to the measurements of contrast-enhancing lesions (tumors) as outlined in the protocol.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>ECOG-ACRIN</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>ACRIN:American College of Radiology Imaging Network</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5622784</PublicId>
      <PreferredName>5622781v1.0:5622782v1.0</PreferredName>
      <PreferredDefinition>A well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, following intravenous injection of an enhancing agent._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.</PreferredDefinition>
      <LongName>Enhancing Lesion Neoplasm Measurement Clinical Trial Eligibility Criteria</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>ECOG-ACRIN</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5622781</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C113842</PreferredName>
        <Version>1</Version>
        <LongName>Enhancing Lesion</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C113842</PREFERRED_NAME>
            <LONG_NAME>Enhancing Lesion</LONG_NAME>
            <CON_ID>4188621</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5622782</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C3262:C25209:C16112</PreferredName>
        <Version>1</Version>
        <LongName>Neoplasm Measurement Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C3262</PREFERRED_NAME>
            <LONG_NAME>Neoplasm</LONG_NAME>
            <CON_ID>2202518</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25209</PREFERRED_NAME>
            <LONG_NAME>Measurement</LONG_NAME>
            <CON_ID>2203848</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>ACRIN:American College of Radiology Imaging Network</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>If yes, does the region of en</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>If yes, does the region of enhancing tumor not affected by the blooming artifact on the hemosiderin-sensitive images meet the 10x10x10 mm measurement enhancement threshold?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>ACRIN - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>If yes, is there at least a 10x10x10mm &quot;measurable enhancement&quot; that is not obscured or distorted by magnetic susceptibility blooming artifact?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3314482</PublicId>
          <ContextName>ECOG-ACRIN</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Type of Category</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Eligibility</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>10000277</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>ECOG-ACRIN</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>ENHLES_NPM_MSRMT_IND</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1732">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5629832</PUBLICID>
    <LONGNAME>Agent T-DM1 Administered Agent Start Date</LONGNAME>
    <PREFERREDNAME>3645343v1.0:2179512v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The date T-DM1 therapy started</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3645343</PublicId>
      <PreferredName>2223333v1.0:3645341v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of the agent T-DM1 (Trastuzumab emtansine; an antibody-drug conjugate consisting of the recombinant anti-epidermal growth factor receptor 2 HER2 monoclonal antibody trastuzumab conjugated to the maytansinoid DM1) to a patient.</PreferredDefinition>
      <LongName>Agent T-DM1 Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2223333</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1708</PreferredName>
        <Version>1</Version>
        <LongName>Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3645341</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C82492:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Trastuzumab Emtansine Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C82492</PREFERRED_NAME>
            <LONG_NAME>Trastuzumab Emtansine</LONG_NAME>
            <CON_ID>3645340</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2179512</PublicId>
      <PreferredName>AGT_START_DT</PreferredName>
      <PreferredDefinition>The date an agent dosage begin.</PreferredDefinition>
      <LongName>Agent Start Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008565</PublicId>
        <ContextName>SPOREs</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TEMPORAL_CONCEPTS</PreferredName>
        <Version>1</Version>
        <LongName>Temporal concepts</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>MM/DD/YYYY</DisplayFormat>
      <MaximumLength>10</MaximumLength>
      <MinimumLength>10</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2233081</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25164</PreferredName>
        <Version>1</Version>
        <LongName>Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Start Date</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Start Date</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1733">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5629884</PUBLICID>
    <LONGNAME>Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Begin Date</LONGNAME>
    <PREFERREDNAME>3647989v1.0:2188673v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>information related to the administration of a dose-dense neoadjuvant chemotherapy regimen consisting of AC (or CA): adriamycin (doxorubicin) and cyclophosphamide._the date on which an observation or an event began.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647989</PublicId>
      <PreferredName>2206713v1.0:3647987v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of a dose-dense neoadjuvant chemotherapy regimen consisting of AC (or CA): adriamycin (doxorubicin) and cyclophosphamide.</PreferredDefinition>
      <LongName>Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647987</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3647987v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25488</PREFERRED_NAME>
            <LONG_NAME>Dose</LONG_NAME>
            <CON_ID>2202287</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61562</PREFERRED_NAME>
            <LONG_NAME>Dense</LONG_NAME>
            <CON_ID>2903351</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1326</PREFERRED_NAME>
            <LONG_NAME>Doxorubicin Hydrochloride</LONG_NAME>
            <CON_ID>2751680</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C405</PREFERRED_NAME>
            <LONG_NAME>Cyclophosphamide</LONG_NAME>
            <CON_ID>2204906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2188673</PublicId>
      <PreferredName>BEG_DT</PreferredName>
      <PreferredDefinition>The date on which an observation or an event began.</PreferredDefinition>
      <LongName>Begin Date</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008561</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>OCURS</PreferredName>
        <Version>1</Version>
        <LongName>Occurrences</LongName>
      </ConceptualDomain>
      <Datatype>DATE</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat>mm/dd/yyyy</DisplayFormat>
      <MaximumLength>8</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2208020</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25431:C25164</PreferredName>
        <Version>1</Version>
        <LongName>Begin Date</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25431</PREFERRED_NAME>
            <LONG_NAME>Begin</LONG_NAME>
            <CON_ID>2206163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25164</PREFERRED_NAME>
            <LONG_NAME>Date</LONG_NAME>
            <CON_ID>2202880</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Date First Dose</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Date First Dose</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1734">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5629943</PUBLICID>
    <LONGNAME>Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Agent Administration Week Count</LONGNAME>
    <PREFERREDNAME>3647280v1.0:2538637v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Intended length of taxotere and cyclophosphamide cycles</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>3647280</PublicId>
      <PreferredName>2206713v1.0:3647278v1.0</PreferredName>
      <PreferredDefinition>information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel) and cyclophosphamide.</PreferredDefinition>
      <LongName>Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2206713</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15665:C15632</PreferredName>
        <Version>1</Version>
        <LongName>Neoadjuvant Therapy Chemotherapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15665</PREFERRED_NAME>
            <LONG_NAME>Neoadjuvant Therapy</LONG_NAME>
            <CON_ID>2206319</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3647278</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C1526:C405:C25382</PreferredName>
        <Version>1</Version>
        <LongName>Docetaxel Cyclophosphamide Administered</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1526</PREFERRED_NAME>
            <LONG_NAME>Docetaxel</LONG_NAME>
            <CON_ID>2421116</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C405</PREFERRED_NAME>
            <LONG_NAME>Cyclophosphamide</LONG_NAME>
            <CON_ID>2204906</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25382</PREFERRED_NAME>
            <LONG_NAME>Administered</LONG_NAME>
            <CON_ID>2204029</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2538637</PublicId>
      <PreferredName>AGT_ADM_WK_CT</PreferredName>
      <PreferredDefinition>the number of weeks an agent was administered.</PreferredDefinition>
      <LongName>Agent Administration Week Count</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CTEP</ContextName>
      <ContextVersion>2.31</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008560</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX_DOSES</PreferredName>
        <Version>1</Version>
        <LongName>Therapy Doses</LongName>
      </ConceptualDomain>
      <Datatype>NUMBER</Datatype>
      <ValueDomainType>Non-enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2538636</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C29844:C25463</PreferredName>
        <Version>1</Version>
        <LongName>Week Count</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C29844</PREFERRED_NAME>
            <LONG_NAME>Week</LONG_NAME>
            <CON_ID>2203710</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25463</PREFERRED_NAME>
            <LONG_NAME>Count</LONG_NAME>
            <CON_ID>2202368</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE/>
          <VALUEMEANING/>
          <MEANINGDESCRIPTION/>
          <MEANINGCONCEPTS/>
          <MEANINGCONCEPTORIGIN/>
          <MEANINGCONCEPTDISPLAYORDER/>
          <PVBEGINDATE/>
          <PVENDDATE/>
          <VMPUBLICID/>
          <VMVERSION/>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Intended Length of Cycles</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Intended Length of Cycles</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>CRF Text 2</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Intended length of each cycle</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1735">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5630730</PUBLICID>
    <LONGNAME>Aspergillus Galactomannan Antigen Test Positive Finding Indicator</LONGNAME>
    <PREFERREDNAME>5630729v1.0:2784450v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>The indicator that describes whether or not the aspergillus galactomannan antigen test was positive.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5630729</PublicId>
      <PreferredName>5630727v1.0:2639100v1.0</PreferredName>
      <PreferredDefinition>An enzyme-linked serum immunoassay used for the detection of aspergillosis._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.</PreferredDefinition>
      <LongName>Aspergillus Galactomannan Antigen Test Positive Finding</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008557</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>LAB_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Lab Results</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5630727</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C85875</PreferredName>
        <Version>1</Version>
        <LongName>Aspergillus Galactomannan Antigen Test</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C85875</PREFERRED_NAME>
            <LONG_NAME>Aspergillus Galactomannan Antigen Test</LONG_NAME>
            <CON_ID>2992466</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2639100</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38758</PreferredName>
        <Version>1</Version>
        <LongName>Positive Finding</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38758</PREFERRED_NAME>
            <LONG_NAME>Positive Finding</LONG_NAME>
            <CON_ID>2516404</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2784450</PublicId>
      <PreferredName>Y_N_U_ND_NA_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.</PreferredDefinition>
      <LongName>Yes No Unk ND NA Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008556</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS_RESULTS</PreferredName>
        <Version>1</Version>
        <LongName>Assessment Results</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2784449</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49488:C49487:C17998:C49484:C4</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Unknown Not Done Not Applicable Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17998</PREFERRED_NAME>
            <LONG_NAME>Unknown</LONG_NAME>
            <CON_ID>2202475</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49484</PREFERRED_NAME>
            <LONG_NAME>Not Done</LONG_NAME>
            <CON_ID>2480549</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567168</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2567170</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2565695</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Applicable</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Not Done</VALIDVALUE>
          <VALUEMEANING>Not Done: C49484</VALUEMEANING>
          <MEANINGDESCRIPTION>Indicates a task, process or examination that has either not been initiated or completed.
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49484</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-09-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2579172</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the aspergillus galactoma</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the aspergillus galactomannan antigen test positive?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Galactomannan assay</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Galactomannan assay</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Galactomannan assay</Name>
        <OrganizationName/>
        <DocumentType>Application Standard Question Text</DocumentType>
        <DocumentText>Galactomannan assay</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1736">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5675520</PUBLICID>
    <LONGNAME>Patient Parent Or Guardian Informed Consent Signature Code Indicator</LONGNAME>
    <PREFERREDNAME>PPG_CONS_SIG</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response indicating whether the patient, parent, or guardian signed a written consent document.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5675519</PublicId>
      <PreferredName>5675516v1.0:5675528v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A mother or a father; an immediate progenitor._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research._Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved._Individual&#39;s name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one&#39;s wishes and intentions; having a handwritten signature.</PreferredDefinition>
      <LongName>Patient Parent Or Guardian Informed Consent Signature</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5675516</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960:C42709:C37998:C51828</PreferredName>
        <Version>1</Version>
        <LongName>Patient Parent Or Guardian</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C42709</PREFERRED_NAME>
            <LONG_NAME>Parent</LONG_NAME>
            <CON_ID>2222173</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37998</PREFERRED_NAME>
            <LONG_NAME>Or</LONG_NAME>
            <CON_ID>2233137</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C51828</PREFERRED_NAME>
            <LONG_NAME>Guardian</LONG_NAME>
            <CON_ID>2479783</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5675528</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16735:C25678</PreferredName>
        <Version>1</Version>
        <LongName>Informed Consent Signature</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16735</PREFERRED_NAME>
            <LONG_NAME>Informed Consent</LONG_NAME>
            <CON_ID>2202451</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25678</PREFERRED_NAME>
            <LONG_NAME>Signature</LONG_NAME>
            <CON_ID>2202359</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient and, or their par</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient and, or their parent or legal guardian signed a written informed consent?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3292694</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Theradex</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Theradex-CTMS 3.14</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>Case Report Form</ClassificationSchemeItemType>
        <CsiPublicId>3292695</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1737">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5718292</PUBLICID>
    <LONGNAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Physical Problem with Diarrhea Indicator</LONGNAME>
    <PREFERREDNAME>NCCN_DTPL_DRRHEA_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>A person&#39;s stated observation of how distressed they have been during the past week over physical problems with diarrhea, using a yes or no indicator.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCIP</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5717519</PublicId>
      <PreferredName>5717471v1.0:3807950v1.0</PreferredName>
      <PreferredDefinition>A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source and patient problems in five categories._The most recent week, including today._A question about an individual&#39;s distress related to their physical problems with diarrhea.</PreferredDefinition>
      <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016 Past Week Distress over Physical Problem with Diarrhea</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCIP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5717471</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C132492</PreferredName>
        <Version>1</Version>
        <LongName>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C132492</PREFERRED_NAME>
            <LONG_NAME>NCCN Distress Thermometer and Problem List for Patients Version 2.2016</LONG_NAME>
            <CON_ID>5709921</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>3807950</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C107194</PreferredName>
        <Version>1</Version>
        <LongName>Past Week Distress over Physical Problem with Diarrhea</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C107194</PREFERRED_NAME>
            <LONG_NAME>Distress over Physical Problem with Diarrhea Question</LONG_NAME>
            <CON_ID>3794753</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NCCN Distress Management Guidelines, Version 2.2016, 07/25/16.</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Diarrhea</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Diarrhea</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>DCP-Text-1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Physical Problems - Diarrhea</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3793272</PublicId>
          <ContextName>NCIP</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>NCCN Guidelines</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Distress Thermometer and Problem List for Patients Version 2.2016</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5717470</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName>DCP</ContextName>
        <ContextVersion>1</ContextVersion>
        <AlternateName>DCP</AlternateName>
        <AlternateNameType>USED_BY</AlternateNameType>
        <Language>ENGLISH</Language>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1738">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5727038</PUBLICID>
    <LONGNAME>Prostate Cancer Treatment Questionnaire Prostate Cancer Spreads To Other Parts Of The Body True False Unsure Indicator</LONGNAME>
    <PREFERREDNAME>PR_CA_TX_QST_SPRD_OT_PT_TFUNS_</PREFERREDNAME>
    <PREFERREDDEFINITION>A true, false, or unsure response indicator related to prostate cancer spreading to other parts of the body.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5727037</PublicId>
      <PreferredName>PR_CA_TX_QST_SPRD_OT_PART</PreferredName>
      <PreferredDefinition>An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._A primary or metastatic malignant tumor involving the prostate gland.  The vast majority are carcinomas._The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces._A primary or metastatic malignant tumor involving the prostate gland.  The vast majority are carcinomas._The act of extending over a wider scope or expanse of space or time._Used as a function word to indicate direction, purpose, or movement._Different than the one(s) previously specified or mentioned._One of the portions into which something is regarded as divided and which together constitute a whole.</PreferredDefinition>
      <LongName>Prostate Cancer Treatment Questionnaire Prostate Cancer Spreads To Other Parts Of The Body</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5727034</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C49236:C17048:C7378</PreferredName>
        <Version>1</Version>
        <LongName>Therapeutic Procedure Questionnaire Malignant Prostate Neoplasm</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49236</PREFERRED_NAME>
            <LONG_NAME>Therapeutic Procedure</LONG_NAME>
            <CON_ID>2467309</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17048</PREFERRED_NAME>
            <LONG_NAME>Questionnaire</LONG_NAME>
            <CON_ID>2202367</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C7378</PREFERRED_NAME>
            <LONG_NAME>Malignant Prostate Neoplasm</LONG_NAME>
            <CON_ID>2923045</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5727035</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5727035v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Malignant Prostate Neoplasm Spread To Other Part Body</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C7378</PREFERRED_NAME>
            <LONG_NAME>Malignant Prostate Neoplasm</LONG_NAME>
            <CON_ID>2923045</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C61404</PREFERRED_NAME>
            <LONG_NAME>Spread</LONG_NAME>
            <CON_ID>2742514</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65107</PREFERRED_NAME>
            <LONG_NAME>To</LONG_NAME>
            <CON_ID>2672667</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C17649</PREFERRED_NAME>
            <LONG_NAME>Other</LONG_NAME>
            <CON_ID>2202691</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45313</PREFERRED_NAME>
            <LONG_NAME>Part</LONG_NAME>
            <CON_ID>2405237</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13041</PREFERRED_NAME>
            <LONG_NAME>Body</LONG_NAME>
            <CON_ID>2202687</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5725734</PublicId>
      <PreferredName>TRUE_FALSE_UNSURE_IND</PreferredName>
      <PreferredDefinition>A response of true, false or unsure.</PreferredDefinition>
      <LongName>True False Unsure Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>6</MaximumLength>
      <MinimumLength>4</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>2320047</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25180</PreferredName>
        <Version>1</Version>
        <LongName>Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unsure</VALIDVALUE>
          <VALUEMEANING>Uncertain</VALUEMEANING>
          <MEANINGDESCRIPTION>Not established beyond doubt; still undecided or unknown.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C47944</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-03-28</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2749725</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>False</VALIDVALUE>
          <VALUEMEANING>False</VALUEMEANING>
          <MEANINGDESCRIPTION>Not in accordance with the fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68851</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>True</VALIDVALUE>
          <VALUEMEANING>True</VALUEMEANING>
          <MEANINGDESCRIPTION>Conforming to fact or reality or definitive criteria.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C68850</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2015-12-21</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2574502</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Most prostate cancer spreads</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Most prostate cancer spreads quickly to other parts of the body</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1739">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5727118</PUBLICID>
    <LONGNAME>Patient First-Line Therapy Recurrent Disease One Cycle Eligibility Determination Indicator</LONGNAME>
    <PREFERREDNAME>FST_LN_TX_CY_ELIG_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The response indicating the patient meets the eligibility requirements for participation in a clinical trial with regards to receiving at least one cycle of first-line therapy.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>COG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>COG CRF:Children&#39;s Oncology Group Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5717824</PublicId>
      <PreferredName>2183985v1.0:5717822v1.0</PreferredName>
      <PreferredDefinition>A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The smallest natural number and quantity it denotes: a single entity, unit, or object._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._The preferred standard treatment for a particular condition._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.</PreferredDefinition>
      <LongName>Patient One Cycle First-Line Therapy Eligibility Determination</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>COG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2233604</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16960</PreferredName>
        <Version>1</Version>
        <LongName>Patient</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16960</PREFERRED_NAME>
            <LONG_NAME>Patient</LONG_NAME>
            <CON_ID>2202778</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>12108242</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C66832:C25472:C45792:C25171</PreferredName>
        <Version>1</Version>
        <LongName>One Cycle First-Line Therapy Eligibility Determination</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66832</PREFERRED_NAME>
            <LONG_NAME>One</LONG_NAME>
            <CON_ID>2636736</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25472</PREFERRED_NAME>
            <LONG_NAME>Cycle</LONG_NAME>
            <CON_ID>2202487</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C45792</PREFERRED_NAME>
            <LONG_NAME>First-Line Therapy</LONG_NAME>
            <CON_ID>2229260</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25171</PREFERRED_NAME>
            <LONG_NAME>Eligibility Determination</LONG_NAME>
            <CON_ID>2202422</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>COG CRF:Children&#39;s Oncology Group Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506068</PublicId>
      <PreferredName>YES_NO_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no.</PreferredDefinition>
      <LongName>Yes No Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>3</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2421125</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38147</PreferredName>
        <Version>1</Version>
        <LongName>Ind-2</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38147</PREFERRED_NAME>
            <LONG_NAME>Yes or No Response</LONG_NAME>
            <CON_ID>2204645</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>PQT</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Did patient receive at least one cycle of first-line therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>COG CRF Text 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Did patient receive at least one cycle of intensive frontline therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>2961451</PublicId>
          <ContextName>COG</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>COG</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Statistics and Data Center</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>2961452</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1740">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5727815</PUBLICID>
    <LONGNAME>Clinical Trial Eligibility Criteria Prior Oncolytic Virus Therapy Code Indicator</LONGNAME>
    <PREFERREDNAME>PRR_OVTX_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to prior targeted therapy that uses viral infection to cause the lysis of tumor cells.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Theradex</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>THERADEX:Theradex Systems Inc</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5727814</PublicId>
      <PreferredName>2767728v1.0:5727812v1.0</PreferredName>
      <PreferredDefinition>Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._Earlier in time or order._A targeted therapy that uses viral infection to cause the lysis of tumor cells.</PreferredDefinition>
      <LongName>Clinical Trial Eligibility Criteria Prior Oncolytic Virus Therapy</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Theradex</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008525</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ELIG</PreferredName>
        <Version>1</Version>
        <LongName>Eligibility</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>2767728</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C16112</PreferredName>
        <Version>1</Version>
        <LongName>Clinical Trial Eligibility Criteria</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C16112</PREFERRED_NAME>
            <LONG_NAME>Clinical Trial Eligibility Criteria</LONG_NAME>
            <CON_ID>2202439</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5727812</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25629:C62713</PreferredName>
        <Version>1</Version>
        <LongName>Prior Oncolytic Virus Therapy</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25629</PREFERRED_NAME>
            <LONG_NAME>Prior</LONG_NAME>
            <CON_ID>2204016</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C62713</PREFERRED_NAME>
            <LONG_NAME>Oncolytic Virus Therapy</LONG_NAME>
            <CON_ID>4536191</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>THERADEX:Theradex Systems Inc</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3298541</PublicId>
      <PreferredName>YES_NO_NA_CD_IND</PreferredName>
      <PreferredDefinition>Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.</PreferredDefinition>
      <LongName>Yes No Not Applicable Code Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>CCR</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008551</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>ASSESS</PreferredName>
        <Version>1</Version>
        <LongName>Assessments</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>1</MaximumLength>
      <MinimumLength>1</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>CTMS:Clinical Trials Monitoring Service</Origin>
      <Representation>
        <PublicId>3298540</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>3298540v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Not Applicable Code Indicator</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49488</PREFERRED_NAME>
            <LONG_NAME>Yes</LONG_NAME>
            <CON_ID>2451557</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C49487</PREFERRED_NAME>
            <LONG_NAME>No</LONG_NAME>
            <CON_ID>2451556</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48660</PREFERRED_NAME>
            <LONG_NAME>Not Applicable</LONG_NAME>
            <CON_ID>2428103</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25162</PREFERRED_NAME>
            <LONG_NAME>Code</LONG_NAME>
            <CON_ID>2203865</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25180</PREFERRED_NAME>
            <LONG_NAME>Indicator</LONG_NAME>
            <CON_ID>2202683</CON_ID>
            <DEFINITION_SOURCE>Source =&gt; Name: NCI, </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>X</VALIDVALUE>
          <VALUEMEANING>Not applicable</VALUEMEANING>
          <MEANINGDESCRIPTION>Determination of a value is not relevant in the current context.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48660</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-02-11</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2581003</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>N</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559515</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Y</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question or activity.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2002-08-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2560453</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Has patient received prior tr</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Has patient received prior treatment with talimogene laherparepvec (T-VEC) or any other oncolytic virus?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Theradex - 1</Name>
        <OrganizationName/>
        <DocumentType>Alternate Question Text</DocumentType>
        <DocumentText>Has patient received prior treatment with talimogene laherparepvec (T-VEC), or other herpes virus based therapy?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>3876359</PublicId>
          <ContextName>Theradex</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>Exclusion Criteria</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>Prior Treatments</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>3876424</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1741">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5783388</PUBLICID>
    <LONGNAME>Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose Six Mercaptopurine And Methotrexate Take Purpose Type</LONGNAME>
    <PREFERREDNAME>5782837v1.0:5783382v1.0</PREFERREDNAME>
    <PREFERREDDEFINITION>Information related to the understanding of the purpose of taking 6MP and Methotrexate.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>Alliance</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>Alliance Case Report Form</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5782837</PublicId>
      <PreferredName>5782078v1.0:5782835v1.0</PreferredName>
      <PreferredDefinition>The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._What something is used for; reason or intention._An ability to understand the meaning or importance of something (or the knowledge acquired as a result)._As pertains to a medication: ingest, inhale, instill, or inject.</PreferredDefinition>
      <LongName>Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5782078</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15632:C195:C642:C1708</PreferredName>
        <Version>1</Version>
        <LongName>Chemotherapy Mercaptopurine Methotrexate Agent</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15632</PREFERRED_NAME>
            <LONG_NAME>Chemotherapy</LONG_NAME>
            <CON_ID>2202708</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C195</PREFERRED_NAME>
            <LONG_NAME>Mercaptopurine</LONG_NAME>
            <CON_ID>2416389</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C642</PREFERRED_NAME>
            <LONG_NAME>Methotrexate</LONG_NAME>
            <CON_ID>2204926</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C1708</PREFERRED_NAME>
            <LONG_NAME>Agent</LONG_NAME>
            <CON_ID>2202316</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5782835</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C86022:C65105:C25634</PreferredName>
        <Version>1</Version>
        <LongName>Comprehension Take Purpose</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C86022</PREFERRED_NAME>
            <LONG_NAME>Comprehension</LONG_NAME>
            <CON_ID>3124863</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65105</PREFERRED_NAME>
            <LONG_NAME>Take</LONG_NAME>
            <CON_ID>3303127</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25634</PREFERRED_NAME>
            <LONG_NAME>Purpose</LONG_NAME>
            <CON_ID>2202870</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>Alliance Case Report Form</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5783382</PublicId>
      <PreferredName>5783382v1.0</PreferredName>
      <PreferredDefinition>Something distinguishable as an identifiable class based on common qualities._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5&#39;-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._What something is used for; reason or intention._As pertains to a medication: ingest, inhale, instill, or inject._What something is used for; reason or intention.</PreferredDefinition>
      <LongName>Six Mercaptopurine And Methotrexate Take Purpose Type</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>Alliance</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008538</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>TX</PreferredName>
        <Version>1</Version>
        <LongName>Therapies</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>60</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>Alliance Case Report Form</Origin>
      <Representation>
        <PublicId>5783381</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5783381v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Six Mercaptopurine And Methotrexate Take Purpose Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C66837</PREFERRED_NAME>
            <LONG_NAME>Six</LONG_NAME>
            <CON_ID>2647606</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>6</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C195</PREFERRED_NAME>
            <LONG_NAME>Mercaptopurine</LONG_NAME>
            <CON_ID>2416389</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C37912</PREFERRED_NAME>
            <LONG_NAME>And</LONG_NAME>
            <CON_ID>2528554</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C642</PREFERRED_NAME>
            <LONG_NAME>Methotrexate</LONG_NAME>
            <CON_ID>2204926</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C65105</PREFERRED_NAME>
            <LONG_NAME>Take</LONG_NAME>
            <CON_ID>3303127</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25634</PREFERRED_NAME>
            <LONG_NAME>Purpose</LONG_NAME>
            <CON_ID>2202870</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Other</VALIDVALUE>
          <VALUEMEANING>Other</VALUEMEANING>
          <MEANINGDESCRIPTION>Different than the one(s) previously specified or mentioned.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17649</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559653</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>I don&#39;t really know</VALIDVALUE>
          <VALUEMEANING>Does Not Know</VALUEMEANING>
          <MEANINGDESCRIPTION>The answer is not known by the person answering.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C67142</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3247120</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Because the doctor/nurse tells me to take it</VALIDVALUE>
          <VALUEMEANING>Due To Doctor Nurse Statement To Take</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or resulting from.: A courtesy title for a person who has received a doctorate degree or who practices medicine.: A professional healthcare provider who has graduated from an accredited nursing program, has passed the state exam for licensure, and been registered or licensed to practice by a state authority.  Nurses are educationally prepared as functional (LPN/LVN) or professional (RN).: A verbal and/or written message that asserts, affirms, or declares something.: Used as a function word to indicate direction, purpose, or movement.: As pertains to a medication: ingest, inhale, instill, or inject.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C65105, C65107, C49154, C20821, C69164, C89272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5783383</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To fight or destroy cancer or leukemia cells</VALIDVALUE>
          <VALUEMEANING>To Resistance Process Or Destruction Malignant Neoplasm Or Leukemia Cell</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The act of destroying; demolition or annihilation.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Any small compartment.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C48694, C3161, C37998, C9305, C62100, C37998, C41546, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4, 5, 6, 7</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5783384</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Because it is part of my treatment</VALIDVALUE>
          <VALUEMEANING>Due To Part Therapeutic Procedure</VALUEMEANING>
          <MEANINGDESCRIPTION>Caused by or resulting from.: One of the portions into which something is regarded as divided and which together constitute a whole.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49236, C45313, C89272</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5783385</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To fight or prevent infection</VALIDVALUE>
          <VALUEMEANING>To Resistance Process Or Preventive Infection</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to prevent disease.: The invasion of an organism&#39;s body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C128320, C28005, C37998, C41546, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3, 4</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5783386</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>To keep the blood counts low</VALIDVALUE>
          <VALUEMEANING>To Retain Blood Cell Count Low</VALUEMEANING>
          <MEANINGDESCRIPTION>Used as a function word to indicate direction, purpose, or movement.: To maintain possession of something.: A test to check the number of red blood cells, white blood cells, and platelets in a sample of blood.: A minimum level or position or degree; less than normal in degree, intensity or amount.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C54722, C28133, C99569, C65107</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus, NCI Thesaurus, NCI Thesaurus, NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0, 1, 2, 3</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-04-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5783387</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>What is your understanding of</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>What is your understanding of purpose of taking 6MP and Methotrexate?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1742">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5836939</PUBLICID>
    <LONGNAME>Periosteum Excision Performed Yes No Unknown Indicator</LONGNAME>
    <PREFERREDNAME>PERIOSTEUM_RESECTION_IND</PREFERREDNAME>
    <PREFERREDDEFINITION>The Yes/No/Unknown indicator that indicates whether the periosteum was resected.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NRG</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN/>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5836938</PublicId>
      <PreferredName>5836936v1.0:2687982v1.0</PreferredName>
      <PreferredDefinition>The outer membrane that surrounds a bone. It contains connective tissue, capillaries, nerves, and a number of types of cell, including osteoclasts. The periosteum plays an important role in bone repair and growth._The act of cutting out; the surgical removal of part or all of a structure or organ._Executed and carried through to completion.</PreferredDefinition>
      <LongName>Periosteum Excision Performed</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NRG</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2182370</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>PROCEDURES</PreferredName>
        <Version>1</Version>
        <LongName>Procedures</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5836936</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C13184</PreferredName>
        <Version>1</Version>
        <LongName>Periosteum</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C13184</PREFERRED_NAME>
            <LONG_NAME>Periosteum</LONG_NAME>
            <CON_ID>4264943</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2687982</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C15232:C38000</PreferredName>
        <Version>1</Version>
        <LongName>Excision Performed</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15232</PREFERRED_NAME>
            <LONG_NAME>Excision</LONG_NAME>
            <CON_ID>2202806</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38000</PREFERRED_NAME>
            <LONG_NAME>Performed</LONG_NAME>
            <CON_ID>2203950</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin/>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>3506034</PublicId>
      <PreferredName>YES_NO_UNKNOWN_IND</PreferredName>
      <PreferredDefinition>The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.</PreferredDefinition>
      <LongName>Yes No Unknown Indicator</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>3502157</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>YES_NO_IND_VD</PreferredName>
        <Version>1</Version>
        <LongName>Yes No Indicator Value Domains</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>7</MaximumLength>
      <MinimumLength>2</MinimumLength>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2548260</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C38148</PreferredName>
        <Version>1</Version>
        <LongName>Ind-3</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C38148</PREFERRED_NAME>
            <LONG_NAME>Yes, No, or Unknown Response</LONG_NAME>
            <CON_ID>2204653</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Yes</VALIDVALUE>
          <VALUEMEANING>Yes</VALUEMEANING>
          <MEANINGDESCRIPTION>The affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49488</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197153</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>No</VALIDVALUE>
          <VALUEMEANING>No</VALUEMEANING>
          <MEANINGDESCRIPTION>The non-affirmative response to a question.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C49487</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3197154</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Unknown</VALIDVALUE>
          <VALUEMEANING>Unknown</VALUEMEANING>
          <MEANINGDESCRIPTION>Not known, not observed, not recorded, or refused.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C17998</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2012-06-27</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3241403</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Was the periosteum resected</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>Was the periosteum resected</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId/>
          <ContextName/>
          <ContextVersion/>
          <PreferredName/>
          <Version/>
        </ClassificationScheme>
        <ClassificationSchemeItemName/>
        <ClassificationSchemeItemType/>
        <CsiPublicId/>
        <CsiVersion/>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1743">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5854582</PUBLICID>
    <LONGNAME>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week How Often Difficulty Swallowing Score 4 Point Scale</LONGNAME>
    <PREFERREDNAME>MSAS10_18_F_SWALL_SC</PREFERREDNAME>
    <PREFERREDDEFINITION>Person&#39;s stated observation in the past week of how often they had difficulty swallowing, using a four-point Likert scale.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NCI Standards</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</ORIGIN>
    <REGISTRATIONSTATUS>Standard</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5844950</PublicId>
      <PreferredName>5840805v1.0:5114539v1.0</PreferredName>
      <PreferredDefinition>A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to children with cancer aged 10-18. This 30-question instrument was adapted from a previously-validated adult version._The most recent week, including today._A question about how often an individual has or had difficulty swallowing._A number or range of numeric values measuring performance, function, quality, or ability.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18 Past Week How Often Difficulty Swallowing Score</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NCI Standards</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5840805</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C134965</PreferredName>
        <Version>1</Version>
        <LongName>Memorial Symptom Assessment Scale (MSAS) 10-18</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C134965</PREFERRED_NAME>
            <LONG_NAME>Memorial Symptom Assessment Scale (MSAS) 10-18</LONG_NAME>
            <CON_ID>5840197</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>5114539</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C95402:C125288:C25338</PreferredName>
        <Version>1</Version>
        <LongName>Past Week How Often Difficulty Swallowing Score</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C95402</PREFERRED_NAME>
            <LONG_NAME>Past Week</LONG_NAME>
            <CON_ID>3185130</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C125288</PREFERRED_NAME>
            <LONG_NAME>How Often Difficulty Swallowing Question</LONG_NAME>
            <CON_ID>5109107</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25338</PREFERRED_NAME>
            <LONG_NAME>Score</LONG_NAME>
            <CON_ID>2204643</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>MSAS 10-18:  Memorial Symptom Assessment Scale (10-18). J. Collins, et al. Journal of Pain and Symptom Management. 2000 May; 19(5): 363-377</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>5840804</PublicId>
      <PreferredName>MSAS10_18_FREQ_SC</PreferredName>
      <PreferredDefinition>A scale for the subjective scoring of event frequency that ranges from 1: Almost Never to 4: Almost Always designed for use with the Memorial Symptom Assessment Scale (MSAS) 10-18.</PreferredDefinition>
      <LongName>Memorial Symptom Assessment Scale (10-18) Frequency Score 4 Point Scale</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>DCP</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2524082</PublicId>
        <ContextName>CCR</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>MEASURE/INSTRUMENT TESTING</PreferredName>
        <Version>1</Version>
        <LongName>Person Measure/Instrument Testing</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>25</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin/>
      <Representation>
        <PublicId>2452834</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25664</PreferredName>
        <Version>1</Version>
        <LongName>Scale</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25664</PREFERRED_NAME>
            <LONG_NAME>Scale</LONG_NAME>
            <CON_ID>2203964</CON_ID>
            <DEFINITION_SOURCE>NCI </DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>4</VALIDVALUE>
          <VALUEMEANING>Almost All of the Time</VALUEMEANING>
          <MEANINGDESCRIPTION>A response indicating that something happens or happened almost all of the time.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C119986</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>5273232</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>3</VALIDVALUE>
          <VALUEMEANING>Very much</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer of strong agreement.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C91217</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2561501</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>2</VALIDVALUE>
          <VALUEMEANING>Sometimes</VALUEMEANING>
          <MEANINGDESCRIPTION>From time to time, but not continually or always.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C90025</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2889147</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>1</VALIDVALUE>
          <VALUEMEANING>Almost Never</VALUEMEANING>
          <MEANINGDESCRIPTION>A subjective answer that something rarely happens.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C95143</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2017-06-02</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>3232436</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
      </PermissibleValues>
      <ValueDomainConcepts/>
      <ReferenceTerminology/>
      <ReferenceTerminologyDataValueSource/>
    </VALUEDOMAIN>
    <REFERENCEDOCUMENTSLIST>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>How often did you have the di</Name>
        <OrganizationName/>
        <DocumentType>Preferred Question Text</DocumentType>
        <DocumentText>How often did you have the difficulty swallowing?</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>MSAS 10-18</Name>
        <OrganizationName/>
        <DocumentType>Measure Sequence Number</DocumentType>
        <DocumentText>Question #82 of 112</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
      <REFERENCEDOCUMENTSLIST_ITEM>
        <Name>Using PRO/HRQoL Measures</Name>
        <OrganizationName/>
        <DocumentType>Outcome Measure Implementation</DocumentType>
        <DocumentText>This data element is part of a full set of items that comprise a PRO/HRQoL measure. The full set must be used without any changes to the questions or value set in order to retain the validity and reliability associated with the measure. The URL citation is provided so that caDSR users can obtain materials related to instructions for administering and/or scoring the measure. Changes may not be made to these documents. Where an investigator wants to use single Patient Reported Outcome items that are integrated into a study, DCP review is required prior to inclusion of the item on a case report form.</DocumentText>
        <URL/>
        <Language>ENGLISH</Language>
        <DisplayOrder/>
      </REFERENCEDOCUMENTSLIST_ITEM>
    </REFERENCEDOCUMENTSLIST>
    <CLASSIFICATIONSLIST>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>GROUP_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840828</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
      <CLASSIFICATIONSLIST_ITEM>
        <ClassificationScheme>
          <PublicId>5675693</PublicId>
          <ContextName>NCI Standards</ContextName>
          <ContextVersion>1</ContextVersion>
          <PreferredName>PRO HRQoL</PreferredName>
          <Version>1</Version>
        </ClassificationScheme>
        <ClassificationSchemeItemName>MSAS 10-18 (Memorial Symptom Assessment Scale 10-18)</ClassificationSchemeItemName>
        <ClassificationSchemeItemType>CATEGORY_TYPE</ClassificationSchemeItemType>
        <CsiPublicId>5840838</CsiPublicId>
        <CsiVersion>1</CsiVersion>
      </CLASSIFICATIONSLIST_ITEM>
    </CLASSIFICATIONSLIST>
    <ALTERNATENAMELIST>
      <ALTERNATENAMELIST_ITEM>
        <ContextName/>
        <ContextVersion/>
        <AlternateName/>
        <AlternateNameType/>
        <Language/>
      </ALTERNATENAMELIST_ITEM>
    </ALTERNATENAMELIST>
    <DATAELEMENTDERIVATION>
      <DerivationType/>
      <DerivationTypeDescription/>
      <Methods/>
      <Rule/>
      <ConcatenationCharacter/>
      <ComponentDataElementList>
        <ComponentDataElementList_ITEM>
          <PublicId/>
          <LongName/>
          <PreferredName/>
          <PreferredDefinition/>
          <Version/>
          <WorkflowStatus/>
          <ContextName/>
          <DisplayOrder/>
        </ComponentDataElementList_ITEM>
      </ComponentDataElementList>
    </DATAELEMENTDERIVATION>
  </DataElement>
  <DataElement num="1744">
    <RAI>2.16.840.1.113883.3.26.2</RAI>
    <PUBLICID>5863895</PUBLICID>
    <LONGNAME>Hematopoietic Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder Classification Type</LONGNAME>
    <PREFERREDNAME>5863894v1.0:2488348v2.1</PREFERREDNAME>
    <PREFERREDDEFINITION>A description of the primary disease classification for which the hematopoietic cell transplantation and/or cellular therapy was performed.</PREFERREDDEFINITION>
    <VERSION>1</VERSION>
    <WORKFLOWSTATUS>RELEASED</WORKFLOWSTATUS>
    <CONTEXTNAME>NHLBI</CONTEXTNAME>
    <CONTEXTVERSION>1</CONTEXTVERSION>
    <ORIGIN>NMDP:National Marrow Donor Program</ORIGIN>
    <REGISTRATIONSTATUS>Application</REGISTRATIONSTATUS>
    <DATAELEMENTCONCEPT>
      <PublicId>5863894</PublicId>
      <PreferredName>5863892v1.0:2321361v1.0</PreferredName>
      <PreferredDefinition>Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species._Used to indicate that either or both of two items or options may be valid._Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._Occurring first in time or sequence; original; of greatest rank or importance or value._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.</PreferredDefinition>
      <LongName>Hematopoietic Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder Classification</LongName>
      <Version>1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008537</PublicId>
        <ContextName>CTEP</ContextName>
        <ContextVersion>2.31</ContextVersion>
        <PreferredName>DX</PreferredName>
        <Version>1</Version>
        <LongName>Diagnosis</LongName>
      </ConceptualDomain>
      <ObjectClass>
        <PublicId>5863892</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>5863892v1.0</PreferredName>
        <Version>1</Version>
        <LongName>Hematopoietic Stem Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C12551</PREFERRED_NAME>
            <LONG_NAME>Hematopoietic Stem Cell</LONG_NAME>
            <CON_ID>2486421</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>5</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C15342</PREFERRED_NAME>
            <LONG_NAME>Transplantation</LONG_NAME>
            <CON_ID>2205403</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>4</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C48928</PREFERRED_NAME>
            <LONG_NAME>And/Or</LONG_NAME>
            <CON_ID>2431163</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>3</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C70601</PREFERRED_NAME>
            <LONG_NAME>Cellular Therapy</LONG_NAME>
            <CON_ID>2688746</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </ObjectClass>
      <Property>
        <PublicId>2321361</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25161</PreferredName>
        <Version>1</Version>
        <LongName>Classification</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25161</PREFERRED_NAME>
            <LONG_NAME>Classification</LONG_NAME>
            <CON_ID>2203879</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Property>
      <ObjectClassQualifier/>
      <PropertyQualifier/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
    </DATAELEMENTCONCEPT>
    <VALUEDOMAIN>
      <PublicId>2488348</PublicId>
      <PreferredName>PRMRY_DS_TYP</PreferredName>
      <PreferredDefinition>Occurring first in time or sequence; original; of greatest rank or importance or value._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Type; a subdivision of a particular kind of thing.</PreferredDefinition>
      <LongName>Primary Disease or Disorder Type</LongName>
      <Version>2.1</Version>
      <WorkflowStatus>RELEASED</WorkflowStatus>
      <ContextName>NHLBI</ContextName>
      <ContextVersion>1</ContextVersion>
      <ConceptualDomain>
        <PublicId>2008584</PublicId>
        <ContextName>EDRN</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>DZ_DISORDER_CLASS</PreferredName>
        <Version>1</Version>
        <LongName>Disease-Disorder Classification</LongName>
      </ConceptualDomain>
      <Datatype>CHARACTER</Datatype>
      <ValueDomainType>Enumerated</ValueDomainType>
      <UnitOfMeasure/>
      <DisplayFormat/>
      <MaximumLength>100</MaximumLength>
      <MinimumLength/>
      <DecimalPlace/>
      <CharacterSetName/>
      <MaximumValue/>
      <MinimumValue/>
      <Origin>NMDP:National Marrow Donor Program</Origin>
      <Representation>
        <PublicId>2724510</PublicId>
        <ContextName>NCIP</ContextName>
        <ContextVersion>1</ContextVersion>
        <PreferredName>C25251:C2991:C25284</PreferredName>
        <Version>1</Version>
        <LongName>Primary Diseases and Disorders Type</LongName>
        <ConceptDetails>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25251</PREFERRED_NAME>
            <LONG_NAME>Primary</LONG_NAME>
            <CON_ID>2203705</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>2</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C2991</PREFERRED_NAME>
            <LONG_NAME>Disease or Disorder</LONG_NAME>
            <CON_ID>2202471</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>No</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>1</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
          <ConceptDetails_ITEM>
            <PREFERRED_NAME>C25284</PREFERRED_NAME>
            <LONG_NAME>Type</LONG_NAME>
            <CON_ID>2202431</CON_ID>
            <DEFINITION_SOURCE>NCI</DEFINITION_SOURCE>
            <ORIGIN>NCI Thesaurus</ORIGIN>
            <EVS_SOURCE>NCI_CONCEPT_CODE</EVS_SOURCE>
            <PRIMARY_FLAG_IND>Yes</PRIMARY_FLAG_IND>
            <DISPLAY_ORDER>0</DISPLAY_ORDER>
          </ConceptDetails_ITEM>
        </ConceptDetails>
      </Representation>
      <PermissibleValues>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Histiocytic disorders</VALIDVALUE>
          <VALUEMEANING>Histiocytic disorders</VALUEMEANING>
          <MEANINGDESCRIPTION>A group of non-neoplastic and neoplastic disorders characterized by the proliferation of histiocytes. This category includes hemophagocytic lymphohistiocytosis and histiocytic and dendritic cell neoplasms.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C203422</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2580038</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Autoimmune diseases</VALIDVALUE>
          <VALUEMEANING>Autoimmune Disease</VALUEMEANING>
          <MEANINGDESCRIPTION>A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). 
</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C2889</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2008-01-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2585785</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Acute lymphoblastic leukemia (ALL)</VALIDVALUE>
          <VALUEMEANING>ALL</VALUEMEANING>
          <MEANINGDESCRIPTION>A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt&#39;s leukemia.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3167</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2573071</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Inherited disorders of metabolism</VALIDVALUE>
          <VALUEMEANING>Congenital Metabolic Disorder</VALUEMEANING>
          <MEANINGDESCRIPTION>Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C34816</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2593446</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Multiple myeloma / plasma cell disorder (PCD)</VALIDVALUE>
          <VALUEMEANING>Plasma Cell Myeloma</VALUEMEANING>
          <MEANINGDESCRIPTION>A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3242</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2559811</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Non-Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>Non-Hodgkin lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.</MEANINGDESCRIPTION>
          <MEANINGCONCEPTS>C3211</MEANINGCONCEPTS>
          <MEANINGCONCEPTORIGIN>NCI Thesaurus</MEANINGCONCEPTORIGIN>
          <MEANINGCONCEPTDISPLAYORDER>0</MEANINGCONCEPTDISPLAYORDER>
          <PVBEGINDATE>2006-06-22</PVBEGINDATE>
          <PVENDDATE/>
          <VMPUBLICID>2568326</VMPUBLICID>
          <VMVERSION>1</VMVERSION>
        </PermissibleValues_ITEM>
        <PermissibleValues_ITEM>
          <VALIDVALUE>Hodgkin lymphoma</VALIDVALUE>
          <VALUEMEANING>Hodgkin&#39;s Lymphoma</VALUEMEANING>
          <MEANINGDESCRIPTION>A lymphoma, previously known as Hodgkin&#39;s disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin&#39;s lymp